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1 A Refresher of Immunoglobulin and Fc-Receptor Biology
and Advances Related to Therapeutic Antibody
Development.
T. W. Salcedo. Bristol-Myers Squibb Company, New Brunswick, NJ.
The presentation will review the immunobiology of antibodies and Fc receptors
and explore the field of therapeutic antibody development and advances in “anti-
body engineering” leading to the development of improved therapeutics. A basic
overview will be provided on the structure and function of antibodies, as well as the
various types and formats of antibody therapeutics and technological methods of
production. In addition, the immunobiology of human leukocyte Fc receptors will
be discussed. These receptors serve to link humoral immune responses to cellular
activities within the immune system, and generally function as either antibody-
binding receptors that trigger immune cell effector functions, or as transport recep-
tors (FcRn). Highlights will include how immunoglobulin Fc sequences are now
being tailored to trigger specific Fc receptors to improve therapeutic outcomes by
introducing amino acid mutations, glycoengineering, or other approaches leading
to next generation formats. Known species differences in immunoglobulins and Fc
receptors that may be important for pharmacologic and toxicologic evaluations will
be explored, as well as other challenges in assessing the nonclinical toxicities of new
antibody formats. Building upon these basic themes, the presentation will explore
the current landscape of approved therapeutics and forecasts for future develop-
ments in the field. The course will provide something for those seeking basic
knowledge in the field of immunology and therapeutic antibody development, as
well as those seeking to refresh and enhance their knowledge of recent advances.
2 Basic Principles of Human Risk Assessment.
Q. Zhao1 and M. Meek2. 1US EPA, Cincinnati, OH; 2University of Ottawa,
Ottawa, ON, Canada.
An overview of the fundamental, evolving guiding principles, and general methods
used in chemical risk assessment will be provided. These principles and methods are
addressed in presentations and discussions organized by the four components iden-
tified by the National Research Council in the Risk Assessment Paradigm: Hazard
Identification and Characterization; Dose-Response Assessment; Exposure
Assessment; and Risk Characterization. Guiding principles and key concepts in risk
assessment will be illustrated by examples from the literature and sample calcula-
tions for dose-response assessment, exposure assessment, and risk characterization
will presented.
3 Recent Developments in Cardiovascular Physiology-Based
Toxicology.
T. L. Knuckles1 and W. McGuinn2. 1West Virginia University, Morgantown, WV;
2US FDA-CDER, Columbia, MD.
Contemporary drug development and toxicity assessments are focused on exploit-
ing specific molecular targets that can improve disease outcomes with minimal un-
toward effects. Unfortunately, modern training in toxicology and pharmacology is
directed primarily at specific ligand-receptor interactions at the expense of systems
physiology. An overview of cardiovascular physiology, with a thematic focus on tox-
icology, will be provided. The presentations will include: overall physiological
changes that manifest at the whole-animal level following toxicant exposure; in
vivo, in vitro and ex vivo cardiac testing protocols in the regulatory environment,
and how current testing strategies may potentially miss cardiac effects that manifest
chronically; vascular and microvascular effects that result from toxicity initiated in
other tissues; and microvascular physiology and toxicology in the context of model
development, application, and underlying pathology. The course will be of interest
to a broad scope of scientists that are increasingly being requested to consider the
impact of novel compounds and toxicants on the physiology of the entire cardio-
vascular system.
4 Approval of Biosimilar Monoclonal Antibodies: Scientific,
Regulatory, and Legal Challenges.
L. LeSauteur2 and J. D. Urban1. 1ToxStrategies, Inc., Austin, TX; 2Charles River
Laboratories, Senneville, QC, Canada.
Technological advances have resulted in the development of a wide range of inno-
vative monoclonal antibodies (mAb). As the patents for these monoclonal antibod-
ies expire, there has been a growing interest in the market of “generic” follow-on
products, or biosimilars. These biosimilar drugs, however, are not generic in the
same sense as small molecule drugs since they do not have identical active compo-
nent(s) as the innovative drug product due to the differences in production. While
established standard analytical methodologies enable manufacturers of generic
small molecule drugs to demonstrate pharmaceutical equivalence, the complex and
sensitive nature of even the most similar biological manufacturing systems (e.g.,
commercial cell lines) makes producing identical copies of the innovative mono-
clonal antibody products impossible. Therefore, the scientific and regulatory para-
digm for demonstrating that the products are highly similar and that there are no
clinically meaningful differences between a biosimilar product and an innovative
therapeutic in order to obtain drug approval is necessarily much more complex.
Adding to this complexity is the regulatory environment that impacts on the
biosimilar approval process. Case studies will compare and contrast the scientific
and regulatory approaches used for mAb biosimilar drug development. These ex-
amples will cover the GMP to clinical strategies in broad scope but focus on the
preclinical breadth of studies conducted based on the extent of GMP and clinical
similarity data available. Within these presentations the scientific rational for simi-
larity with the innovator drug will be highlighted. The basic concepts of the legal
challenges and recent Biologics Price Competition and Innovation Act (BPCIA),
which creates an abbreviated approval framework for biological products that are
demonstrated to be “biosimilar” to or “interchangeable” with a US FDA-licensed
biological product, along with the role the patent and data exclusivity provisions
will play in biosimilar drug development, will also be discussed.
5 The What, When, and How of Nonclinical Support for an
IND Submission.
P. Nugent1 and D. Colagiovanni2. 1Pfizer Worldwide Research and Development,
Groton, CT; 2N30 Pharmaceuticals, LLC, Boulder, CO.
The initiation of dosing of human subjects in a Phase 1 clinical trial represents the
culmination of years of drug development, and immediately preceding the start of
dosing, months of work to prepare and submit the Investigational New Drug
(IND) application (or Clinical Trial Application (CTA)). A critical part of the sub-
mission dossier is the sections that describe the nonclinical data and interpretation
that underwrite the clinical plan; specifically, the results of studies in pharmacology,
pharmacokinetics, and toxicology, and their integration into a coherent argument
that justifies the clinical starting dose, escalation of dose, and “stopping criteria” to
be used in the clinical trial. The objective of the course is to elucidate the path to a
successful IND/CTA submission by outlining what needs to be done (concentrat-
ing principally on the toxicology and safety pharmacology studies), the timeline
and order of activities, and the presentation of the data and its integration into a co-
herent risk assessment to support introduction of the investigational compound
into the clinic. The focus will be the content of the Nonclinical Overview (NCO),
which represents an integrated detailed summary of the nonclinical studies con-
ducted to support the clinical plan for first-in-human (FIH) dosing. The course will
address the expectations of the two main “customers” for the NCO: the FDA phar-
macology/toxicology reviewer evaluating the data to determine if it supports the
safety considerations of the clinical plan, and the clinician designing the clinical
protocol and conducting the FIH trial.
6 The Practice and Implementation of Neural Stem Cell-Based
Approaches to Neurotoxicology.
T. J. Shafer1 and A. B. Bowman2. 1US EPA, Research Triangle Park, NC;
2Vanderbilt University Medical Center, Nashville, TN.
The availability and use of human pluripotent stem cells (hPSC) and human neural
stem cells (hNSC) for toxicology has dramatically increased in the past decade.
hNSC are powerful tools for toxicologists and can provide tissue that would other-
wise be unobtainable. This includes a renewable source of neural tissue from the
same genetic stock that is not transformed or derived from a tumor, a source of nor-
mal human nervous system tissue, and sources of nervous system tissue from pa-
tients with clinical disease. However, culture and differentiation of hNSC are
unique from culture of primary or transformed neural tissue. The course will bring
together experts in the culture of various types of neural stem cells, including em-
bryonic human derived neural stem cells, neurospheres, and neural cells derived
from hPSC. Each expert will discuss the basic approaches to culturing different
types of hNSC, including propagation of the cells in a progenitor status, as well as
protocols for differentiation of the cells into different types of neurons. Pitfalls that
are both common to the different models as well as unique ones will be described.
The goal of the course is to provide the student with knowledge regarding different
types of neural stem cell cultures, the techniques to successfully culture and differ-
entiate these models, and application of these model systems to neurotoxicology.
The course will conclude with an examination of appropriate outcome measures
and discuss the possibility of personalized neurotoxicological assessment.
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7 Toxic Effects of Metals.
M. F. Hughes2 and M. P. Waalkes1. 1NIEHS, Research Triangle Park, NC; 2US
EPA, Research Triangle Park, NC.
Human exposures to metals are a daily occurrence because of their natural presence
in the environment— their uses in production of many commercial products—are
byproducts of energy production and are found in many hazardous waste sites. The
objective of the course is to highlight the fundamentals of metals toxicology. Metals
have unique chemical and physical properties that distinguish them from organic-
based chemicals. Even though some metals are essential to life, overexposure to
these and other metals may result in a toxic effect in one or more organ systems.
Upon exposure, metals may be absorbed, distributed throughout the systemic cir-
culation, metabolized, and eliminated. The response of an organism following ex-
posure to metals may be protective (e.g., induction of the metal-binding protein
metallothionein), or toxicological by several mechanisms including oxidative stress.
Key organ systems such as the central nervous system, the vascular system, as well as
the skeleton system are affected by metals including manganese, lead, aluminum,
and others. Accumulation of metals in bone has recently gained renewed interest as
an eventual source of internal exposure. Noninvasive methods such as neutron acti-
vation are now being used to quantitate bone metal levels. Metals can influence
gene expression, signal transduction, and epigenetics. Various toxic and carcino-
genic metals such as arsenic and chromium alter the epigenetic program in cells;
these effects on DNA methylation, histone tail modifications, and microRNA may
be involved in metal-induced toxicity. Metals are known to cause cancer by several
proposed mechanisms, including oxidative stress and the cancer stem cell hypothe-
sis. Recent evidence suggests that developmental exposure to metals may affect stem
cell population dynamics, which could result in adult onset of cancer. Overall, this
is intended to be a basic course on metals toxicology, and is ideal to those who de-
sire knowledge on the health effects of metals and useful tools used in metals toxi-
cology research.
8 Advances in Nanotoxicology—Challenges.
S. M. Hussain1 and S. F. Ali2. 1US Air Force, Wright-Patterson AFB, OH; 2US
FDA-NCTR, Jefferson, AR.
Recent developments in nanotechnology have generated a degree of apprehension
concerning the potential risk to human health and the environment from manufac-
tured nanomaterials (MN). The unique chemical and physical properties of MN,
coupled with their high surface area per unit mass, require an extensive suite of
characterization tools to effectively assess the toxicity of MN. Not only must the
size and surface area of the MN be characterized prior to cellular exposure, but also
a number of other specific features must be additionally evaluated, such as the size
distribution, chemical composition, crystallinity, surface structure, shape, and solu-
bility. The ionic strength of biological fluids may produce MN instability, resulting
in environmental-specific aggregation tendencies that may impact toxicological re-
sults. Since aggregation of MN can modify uptake rates, transport properties, and
clearance by the cell model or organ system, it is critical to interpret the data from
MN toxicity experiments with a detailed knowledge of the physicochemical prop-
erties of the MN at all experimental time points. Due to the lack of standardized
methods to determine the physicochemical behavior of MN in biological systems,
the mechanisms and nature of acute or chronic toxicity of engineered MN cannot
be fully understood at this time. An understanding of a proper manner by which
MN should be introduced to a biological environment has yet to be established,
and consistency between cellular assay techniques has not been verified—both situ-
ations presenting clear challenges that must be addressed. This course raises issues
to consider for the toxicity assessment of MN, and addresses recent advances and
technical obstructions associated with conducting or interpreting in vitro or in vivo
toxicity studies. The goal is to provide a comprehensive understanding of MN char-
acterization, as well as facilitate valuable discussions of key challenges and advance-
ments in the newly emerging field of nanotoxicology.
9 Gonadal Development, Function, and Toxicology.
B. McIntyre1 and J. A. Flaws2. 1NIEHS, Research Triangle Park, NC; 2University of
Illinois Urbana-Champaign, Urbana, IL.
The course objectives are to provide the basic tools for toxicologists who desire a
better understanding of how to assess the effects of toxicants on the male and fe-
male gonads from development through adulthood. A focus on reproductive biol-
ogy, study design considerations, reproductive endpoints, data interpretation, and
use of data in risk assessment will be highlighted. Reproductive toxicity studies are
among the most complex and challenging studies in the field of toxicology. The
studies assess multiple interrelated endpoints of male and female reproductive de-
velopment and function. To properly design, conduct, and interpret these studies, a
fundamental knowledge of male and female gonadal development, anatomy, physi-
ology, and endocrinology are required. Individual lectures will discuss the anatomy
and physiology of the male and female gonads, as well as endocrine regulation of
these systems. Evaluation of toxicity endpoints to assess male and female reproduc-
tive function will also be discussed, including folliculogenesis, spermatogenesis,
hormone analysis, cyclicity, fertility, histopathology, and proper use of statistical
analysis. The regulatory expectations related to reproductive toxicity testing, inter-
pretation of results, and how these results are ultimately used to assess potential
risks to human reproduction, will be presented. The course will conclude with
methodologies for in vitro reproductive toxicity assessments for screening and in-
vestigation of mode of action. In summary, key information required for the design
of reproductive toxicity studies and interpretation of reproductive toxicity data, and
provide guidance for use of the data for risk assessment of reproduction, will be pre-
sented.
10 The Reach Regulation and Safety Assessment Approaches for
Chemicals That Come in Contact with the Skin.
J. Mortensen1 and J. Heylings2. 1CiToxLAB Scantox, Lille Skensved, Denmark;
2Dermal Technology Laboratory Ltd., Keele University Science Park, United Kingdom.
REACH (Registration, Evaluation, Authorization, and Restriction of Chemical
substances) is the European Union regulation on chemicals and their safe use,
which came into force on June 1, 2007. The aim of REACH is to improve the pro-
tection of human health and the environment through better and earlier identifica-
tion of the intrinsic properties of chemical substances. REACH places greater re-
sponsibility on the industry to manage the risks from chemicals, and to provide
safety information on their substances. The regulation will come gradually into
force in the period up to 2018. Under REACH, 30-40,000 new and existing chem-
icals will have to be (re)classified and registered. The regulation requires companies
to conduct risk assessment and safety classification, with a minimal use of experi-
mental animals, and to share information via databases managed by the European
Chemicals Agency (ECHA). The skin (together with the respiratory system) is im-
portant as a route of chemical exposure, and as a target organ for toxicity induced
by chemicals. Since under REACH so many chemicals need to be evaluated, it is
important to use and develop testing methods that reliably predict human exposure
and safety, while minimizing the use of experimental animals. An overview of the
REACH regulation, and its practical implications for toxicological safety evaluation
of chemicals marketed in Europe, will be given. Efforts to develop new methods
and validation status of alternative methods that will limit the number of experi-
mental animals to be used will be highlighted. Specifically, state-of-the art investi-
gational methods within dermal toxicology will be discussed since the skin is very
important, both as a barrier to exposure and as a target organ. Practical examples of
the use of the collected dermal safety data in the risk assessment of chemicals under
REACH will be presented.
11 T4: Tools and Technologies in Translational Toxicology.
D. L. Mendrick2 and V. S. Vaidya1. 1Harvard Medical School, Boston, MA; 2US
FDA-NCTR, Jefferson, AR.
The last decade has seen revolutionary advances in the tools and technologies avail-
able for biomedical scientists such that researchers can now conduct transformative
experiments to solve unmet medical needs moving from a single cell to whole or-
ganism, and vice versa. Novel tools and innovative technologies have facilitated the
development of sophisticated molecular diagnostics, enabled the use of new ap-
proaches in safety evaluation and risk assessment, and led to the development of
targeted therapeutics. The development and utilization of novel technologies and
tools requires interaction between scientists of differing backgrounds and talents
(e.g., biologists, chemists and programmers). Only with this shared effort can med-
icine transform itself to meet the needs of the 21st century.  The panel of experts
will decode and demystify the potential of these translational and transformative
technologies over a wide variety of applications, including safety/efficacy screening
of compounds, imaging, ‘omics, and in silico modeling. The key goals are to enable
you to understand how recent advances in “T4”: 1) help in solving important prob-
lems that have been critical barriers to progress in the field and, 2) transform the
field by generating foundational resources that will be widely used throughout bio-
medical science for safety evaluation and risk assessment.
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12 Understanding Toxic Neuropathy in Drug Development:
Both Clinical and Nonclinical Perspectives.
M. Kallman1 and J. Benitez2. 1Covance Research Laboratories, Greenfield, IN;
2Vanderbilt University, Nashville, TN.
The topic of risk assessment of peripheral neuropathies is timely due to the in-
creased clinical incidence of challenges related to multiple antecedents for the clin-
ical presentation of neuropathies. The integration of both nonclinical and clinical
dialogue on peripheral neuropathies will provide greater possibilities for successful
drug development and improved patient outcomes. Peripheral nervous system tox-
icity is a common complication of exposure to industrial chemicals and drugs such
as chemotherapeutics. Neuropathy can be caused by either limited or long-term ex-
posure to drugs or chemicals, and toxic neuropathies can be classified by their pres-
entation (e.g. motor vs. sensory), their electrodiagnostic features or their neu-
roanatomical location within the peripheral nerve. Identification of toxic
neuropathology prior to human exposure in the drug development process requires
a multidisciplinary approach. Presentations will include information on the pre-
clinical and clinical syndromes that have been characterized and the specific tech-
niques for assessment. The preclinical presenters will focus on the application of
preclinical data to provide risk assessment and to direct clinical assessment possibil-
ities. The clinical presenters will emphasize the clinical situation and current treat-
ment approaches. The course will conclude with open discussion between the pre-
senters and the audience about opportunities for future risk assessment and the
application to clinical management.
13 Weighing in on Nutrition—Essential Concepts for
Toxicologists.
D. M. Wilson1 and A. L. Slitt2. 1The Dow Chemical Company, Midland, MI;
2University of Rhode Island, Kingston, RI.
There has been an exponential increase in the attention focused on the potential
role of nutrition in reducing the risk for numerous health complications, ranging
from birth defects to age-associated vascular disease. Underscoring the above is the
increasing number of presentations and publications related to this subject, and
hallmarks such as the recently revamped Food Pyramid into a Plate Icon. Chronic
nutritional diseases are accepted to be a current crisis in our society; three nutrition-
related diseases alone, obesity, Metabolic Syndrome, and Type 2 Diabetes, afflict
over one-third of the American population. To better understand the components
and etiology of nutritional diseases, it’s essential for toxicologists to be well versed in
the science of nutrition. A comprehensive understanding of nutrition has broad ap-
plications in toxicology, especially considering that many of us have roles in investi-
gating the safety of nutrients, food additives or food ingredients, studying nutri-
tional disease, or designing and interpreting preclinical or clinical studies wherein
the need to consider and understand nutritional homeostasis is essential. The po-
tential for intersection of normal nutritional metabolic pathways with adverse out-
come pathways is becoming even more important to delineate. This course on gen-
eral nutrition, the biochemistry of nutritional pathways, the essential role of
vitamins, the channeling of nutrients such as carbohydrates, proteins and fats, cel-
lular and molecular details of nutrition, and nutritional aspects of development and
reproduction, will heighten awareness of their importance in human and animal
health at multiple levels. The focus will be on relevant information, starting with an
introduction to nutrition, followed by a review of biochemical and metabolic reac-
tions in nutrition, with an emphasis on their relation to toxicology. How the nutri-
tional status of a woman can modulate the developmental toxicity of a number of
diverse toxicants, including alcohol, will be presented.
14 Genetic and Epigenetic Determinants of Susceptibility to
Environmental and Occupational Toxicants.
V. J. Johnson1 and B. Yucesoy2. 1BRT-Burleson Research Technologies, Morrisville,
NC; 2Toxicology and Molecular Biology Branch, NIOSH/CDC, Morgantown, WV.
The most common chronic disorders are multifactorial in nature, influenced by
complex sequences of gene-gene and gene-environment interactions. While gene
expression is a dynamic process that varies in response to a myriad of internal and
external triggers and the surrounding microenvironment, the epigenetic mecha-
nisms play a key role in mediating environmental influences on gene expression and
epistatic interactions. In this respect, the expression of complex phenotypes should
be assessed in a functional context that would look at the interplay between envi-
ronmental, genetic, and epigenetic factors. Recent advances in genetic and epige-
netic research offer new opportunities to integrate experimental approaches, in-
cluding animal models and in vitro/in vivo translational research, with
computational strategies to predict such interactions at multiple levels of complex-
ity. The focus of this session will be on current research investigating the role of ge-
netic factors, epigenetic factors, and gene-environment interactions in the develop-
ment and outcomes of complex diseases caused by environmental and occupational
toxicants.
15 Genetic Susceptibility to Occupational and Environmental
Exposures.
D. C. Christiani. School of Public Health, Harvard Medical School, Boston, MA.
Due to their high prevalence in the general population, genetic polymorphisms in
the susceptibility genes may predispose community members exposed to toxicants.
Studies in genetic susceptibilities can eventually provide the following benefits: (1)
to provide mechanistic insight of the etiology of disease; (2) to identify the more
susceptible subpopulations with respect to exposure; (3) to provide valuable input
in setting exposure limits by taking into account individual susceptibility. Research
in this area has provided promising insights to occupational medicine, such as those
illustrated by the NAT2 polymorphisms-aniline dyes and bladder cancer, and the
HLA-DPB1Glu69 in chronic beryllium disease, a hypersensitivity-mediated in-
flammatory disorder. Nonetheless, even for the genetic susceptibility markers that
have been shown scientifically to have a clear role in disease risk, the value of wide-
scale genetic screening in occupational settings remains limited. In the general en-
vironmental setting, there are limited, but growing data on the role of common
gene polymorphisms in predisposing children and adults to inflammation-related
respiratory disorders induced by air pollution, and to heavy metal toxicity. The pur-
pose of this presentation is to discuss state of knowledge with regard to gene vari-
ants interacting with environmental exposures in causing cancer and inflammatory
disorders.
16 Toxicogenomic and Systems Biology Approaches in the
Understanding of Toxicity and Leukemogenesis Induced by
Benzene.
C. McHale1,  L. Zhang1,  Q. Lan2,  R. Thomas1,  A. E. Hubbard1,
R. Vermeulen3,  G. Li4,  S. M. Rappaport1,  S. Yin4,  M. T. Smith1 and
N. Rothman2. 1School of Public Health, University of California Berkeley, Berkeley,
CA; 2Division of Cancer Epidemiology and Genetics, National Cancer Institute,
Bethesda, MD; 3Institute of Risk Assessment Sciences, Utrecht University, Utrecht,
Netherlands; 4Institute of Occupational Health and Poison Control, Chinese Center
for Disease Control and Prevention, Beijing, China.
Benzene is an established cause of acute myeloid leukemia (AML) and may cause
one or more lymphoid malignancies in humans. Occupational exposure to ben-
zene, even at levels below the current U.S. occupational standard of 1 ppm, causes
hematotoxicity. Toxicogenomics (e.g. genomics, transcriptomics and epigenomics)
and systems biology (study of the interactions among toxicogenomic endpoints
using bioinformatics) approaches in human populations, animals, and in vitro
models, exposed to a range of benzene levels, are key to understanding gene-envi-
ronment interactions in benzene toxicity and can identify biomarkers of exposure,
early effect and susceptibility. Through analysis of the peripheral blood mononu-
clear cell (PBMC) transcriptomes of 125 workers exposed to a wide range of ben-
zene levels, we recently reported highly significant widespread perturbation of gene
expression at all exposure levels, as well as alterations in AML and immune response
pathways. Sequencing of the PBMC transcriptomes from a subset of the study sub-
jects revealed additional alterations in gene expression. From preliminary epige-
nomic data in the human subjects, we have identified benzene-induced alterations
in the DNA methylome and miRNome. Using genomic screens in yeast, with sub-
sequent confirmation in human cells, we have identified potential biomarkers of
susceptibility. We are developing bioinformatic methods to integrate these and fu-
ture toxicogenomic datasets, in a systems biology approach, to further understand
pathways of benzene toxicity and to reveal potential biomarkers associated with a
range of exposures.
Supported by NIH grant P42ES04705.
17 Integrated Genetic and Genomic Approaches to Understand
Susceptibility to Toxicant-Induced Lung Disease.
S. R. Kleeberger. Laboratory of Respiratory Biology, NIEHS, Research Triangle Park,
NC. Sponsor: V. Johnson.
Genetic background has an important role in susceptibility to complex lung dis-
eases, and the genetic contribution to disease phenotypes varies between popula-
tions. Understanding the mechanisms of interactions between genetic background
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and exposures to environmental stimuli are critical to disease prevention. Animal
models, particularly inbred mice, provide important insight to understand human
disease etiologies because genetic background and environmental exposures can be
controlled. Tools including in silico haplotyping, collaborative cross and diversity
outcross mouse panels, bioinformatic applications, and -omics technologies have
enhanced our ability to identify disease genes and pathways to guide translational
investigations that apply these discoveries to human populations. Combined ge-
netic and genomic approaches have yielded important insight to mechanisms of
susceptibility to many complex traits and diseases. We have integrated inbred
mouse and cell-based models with haplotype association mapping (genetic), global
gene expression analyses (genomic), and expression quantitative trait locus map-
ping (eQTL or genetical genomics) to identify candidate susceptibility genes and
associated gene networks important in toxicant-induced lung injury. The overarch-
ing goal of these investigations is to determine whether human homologues of these
susceptibility genes associate with disease risk in human populations. Efforts to
identify and validate susceptibility genes in mouse models of environmental disease
with a goal towards translational application have enabled identification of individ-
uals who are susceptible to disease. For example, epidemiological and clinical inves-
tigations have associated functional polymorphisms in human NRF2 (NF-E2 re-
lated factor 2) and TNF (tumor necrosis factor alpha) with susceptibility to acute
lung injury and ozone-induced changes in lung function, respectively. Importantly,
these discoveries may also lead to novel intervention or therapeutic strategies to pre-
vent disease.
18 Developmental Exposure to Bisphenol A and Lead: Effects
on Metabolic Homeostasis and the Epigenome.
D. Dolinoy. University of Michigan, Ann Arbor, MI.
Environmental exposures during early development and other critical life stages
may induce changes to the epigenome resulting in potentially deleterious pheno-
typic effects including metabolic disease, cancer, and neurological disorders. The
field of epigenetics is experiencing a rapid advancement in technology, methodol-
ogy, and data acquisition that now allows for the identification of the constellation
of genomic loci with altered epigenetic status following dose-dependent exposures.
Thus, epigenomic profiling facilitates the identification of biomarkers of exposure,
enabling clinicians to identify at-risk individuals prior to disease onset. Utilizing a
multi-pronged approach with an in vivo mouse model, human clinical samples, and
an ongoing 15-year longitudinal epidemiological study, the overall goal of this pres-
entation is to elucidate the impact of perinatal bisphenol A (BPA) and lead (Pb) ex-
posure on metabolic homeostasis and DNA methylation, and the interplay between
the two. Developmental exposure to environmentally relevant levels of BPA has
been shown to affect both global and gene-specific DNA methylation patterns in
rodents. We now draw upon data from multiple whole-epigenome platforms to
show that multiple dose levels of BPA affect DNA methylation in mice and humans
and that these epigenetic effects are non-monotonic in dose response. Preliminary
studies also indicate that Pb exhibits epigenetic effects that may contribute to its
known neurotoxic and obesogenic activities.
19 Predictive Toxicology Paradigms for Understanding Carbon
Nanotube Toxicity in the Lung.
J. C. Bonner1,  A. Nel2,  D. W. Porter3,  V. Castranova3 and K. E. Pinkerton4.
1NCSU, Raleigh, NC; 2UCLA, Los Angeles, CA; 3NIOSH, Morgantown, WV; 4UC
Davis, Davis, CA.
Nanotechnology is rapidly developing, resulting in the production of a variety of
engineered nanoparticles. Carbon nanotubes (CNTs) represent an important fam-
ily of nanoparticles because they have many potential uses in engineering, electron-
ics, and medicine due to their ease of functionalization, unusual strength, and elec-
trical conductivity. However, these novel nanostructures also represent a potential
human health risk, due to the possibility of inhalation exposure and evidence that
the lung and cardiovascular systems are targets for hazardous effects. Inhalation
studies in rodents show that CNTs deposit within the distal regions in the lungs
and migrate to the pleura to cause inflammatory and/or fibrotic effects.
Presentations in this session are aimed at elucidating the pulmonary and cardiovas-
cular effects of CNTs, and how an increasing variety of functionalized CNTs can be
evaluated via high-content screening. Because functionalized CNTs vary in toxico-
logical activity, we will address high-content screening for the development of
structure-activity relationships relevant to inhalation toxicity and safer design of
nanoparticles. This will include exploration of factors that mediate toxic effects
such as high aspect ratio, durability, and residual metal content and discuss how re-
moving metal catalysts or changing surface properties alters the pattern and timing
of toxicity. While the lung is a major target organ, another goal is to determine the
potential for inhaled CNTs to have toxic effects that reach beyond the lung to in-
fluence the cardiovascular system. Finally, we will discuss how susceptibility factors,
both genetic and environmental, determine pulmonary and cardiovascular toxicity
to CNTs. The outcome of this session is to gain a better understanding of the struc-
ture-activity relationships, target organs, and susceptibility factors that will aid the
development of predictive toxicology paradigms for understanding CNT toxicity.
20 Time Course of Pulmonary Responses to Inhaled
Multiwalled Carbon Nanotubes.
D. W. Porter1,  A. F. Hubbs1,  R. R. Mercer1,  N. Wu2,  W. McKinney1,
B. T. Chen1,  M. G. Wolfarth1,  L. A. Battelli1,  J. F. Scabilloni1,  D. Schwegler-
Berry1,  S. Friend1,  S. Tsuruoka3,  M. Endo3,  D. Frazer1 and V. Castranova1.
1NIOSH, Morgantown, WV; 2Department of Mechanical & Aerospace Engineering,
West Virginia University, Morgantown, WV; 3Research Center for Exotic Nanocarbons,
Shinshu University, Nagano, Japan.
In the present study, an aerosol of multi-walled carbon nanotubes (MWCNT) was
produced with an acoustical generator, and airborne concentration and size distri-
bution was determined. Mice were exposed by whole body inhalation to MWCNT
(5 mg/m3, 5 hours/day, 12 days) and pulmonary responses were monitored at 1 day,
2, 4, 12, 24 and 48 weeks post-exposure. Pulmonary responses were investigated
using whole lung lavage, histopathology, morphometry, and enhanced darkfield
light microscopy studies. MWCNT lung burden was also measured to assess
MWCNT clearance. Data indicate that the lung burdens of MWCNT in this study
represent lung burdens relevant to estimated human occupational exposures and
caused time-dependent pulmonary inflammation, damage and pulmonary fibrosis.
Using enhanced darkfield microscopy, MWCNT fibers were found in lavage of the
pleural space, parietal pleura, and respiratory muscles of the diaphragm and chest
wall. The time course of pulmonary responses and their relationship to MWCNT
lung burden and clearance will be discussed.
21 Establishment of Carbon Nanotube Structure-Activity
Relationships (SARs) That Can Be Used to Understand
Pulmonary Toxicity and Safer Design.
A. Nel. UCLA, Los Angeles, CA.
There is a fundamental gap in understanding how the physicochemical properties
of carbon nanotubes (CNTs) contribute to hazard generation in the lung. Without
this knowledge, it is difficult to evaluate CNT safety in a predictive manner. Our
goal is to develop a predictive toxicological paradigm for CNT safety assessment in
which we define the structure-activity relationships (SARS) leading to hazard gen-
eration at the nano/bio interface, including ways to design safer materials that do
not induce chronic inflammation and fibrosis. To achieve this goal, we are develop-
ing a series of single-wall and multi-wall CNT test materials that can be screened by
robust cellular assays to perform hazard ranking and SAR analysis. We are looking
at the role of CNT dimensions (including length, diameter and aspect ratio), dis-
persability, catalytic surface chemistry, electronic properties and purity in initiating
cooperative cellular interactions in macrophages and cells of the epithelial-mes-
enchymal trophic (EMT), which are involved in the pathogenesis of pulmonary in-
flammation and fibrosis. The above physicochemical characteristics impact the
lysosomal stability in macrophages in a hierarchical fashion, leading to cathepsin B
release and assembly of the subunits of the NALP3 inflammasome. This leads to
IL-1 beta release, which primes the EMT unit and initiates a march of events lead-
ing to TGF-beta and PDGF production and subsequent induction of chronic in-
flammation and fibrosis in the lung. Utilizing myeloid and epithelial cell lines, it is
possible to study the induction of these biomarkers in relation to the property vari-
ations of the CNT materials, predicting the SARs that are associated with pul-
monary inflammation and fibrosis. Moreover, we have also implemented surface
coating and functionalization approaches that can change the hazardous character-
istics, leading to the design of safer CNTs. The overall utility of this research explo-
ration is to establish a predictive and quantitative toxicological paradigm for the
safety assessment of CNTs and their safe implementation in the marketplace.
22 Surface and Chemical Modification of Single-Walled Carbon
Nanotubes Does Not Necessarily Create a Safer
Nanomaterial.
K. E. Pinkerton. University of California Davis, Davis, CA.
We hypothesized iron (Fe) content and morphology of inhaled single-walled car-
bon nanotubes (SWCNTs) would influence the extent of cellular injury and alters
homeostasis in the lung. Rats (SD) were exposed (1 mg/m3) to either aerosolized
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SWCNTs (raw FeSWCNT or purified cSWCNT), carbon black (CB), crocidolite
asbestos, or fresh air via nose-only inhalation for 6 hr/d for 10 d. SWCNTs con-
taining varied amounts of iron. Depending on the endpoint of interest, pulmonary
responses of SWCNTs sometimes followed that of CB while in other circumstances
matched that of crocidolite. Notably, animals exposed to FeSWCNTs were unable
to respond to an additional oxidant challenge and cSWCNTs exposed animals had
a latent and persistent development of mucous cells in the distal airways. In sum-
mary, while some toxicity endpoints follow patterns comparable to CB or crocido-
lite, the respiratory effects of inhaled FeSWCNTs and cSWCNTs appear to be
unique. These changes could be suggestive of precursor events to pathologic
changes that could develop under more prolonged exposure conditions.
23 Cardiovascular Responses to Pulmonary Inhalation of
Nanoparticles.
V. Castranova. Pathology & Physiology Research Branch, NIOSH, Morgantown, WV.
Pulmonary exposure to various nanoparticles has been reported to cause lung in-
flammation and in some cases fibrosis. This presentation describes cardiovascular
responses which occur following inhalation of titanium dioxide nanospheres or
multi-walled carbon nanotubes in rats. Pulmonary exposure to nano titanium diox-
ide inhibits the ability of systemic and coronary arterioles to respond normally to
dilators and affects heart rate and blood pressure in response to adenergic agonists
24 hours post-exposure. This microvascular dysfunction is associated with adher-
ence of polymorphonuclear leukocytes and generation of reactive species at the ves-
sel walls, and resultant scavenging of nitric oxide secreted from dilator-stimulated
endothelial cells. Neutrophil depletion or antioxidants partially reverse this vascular
dysfunction.There also appears to be a neurogenic component to these cardiovascu-
lar changes, since inhibition of pulmonary sensory neurons or neuronal input to
the arteriolar smooth muscle partially reverses these effects. Inhalation of multi-
walled carbon nanotubes also inhibits coronary arterial responsiveness to dilators.
This dysfunction occurs 24 hours after exposure and declines over several days
thereafter. Human relevance of these rat data will be discussed.
24 Genetic and Environmental Factors That Determine
Susceptibility to Inhaled Carbon Nanotubes.
J. C. Bonner. Toxicology, NC State University, Raleigh, NC.
While studies with rodents suggest that inhaled carbon nanotubes could represent a
human health risk for the development of pulmonary diseases, it is likely that indi-
viduals with pre-existing disease or those with specific genetic deficiency would be
most susceptible to exposure and lung injury. The goal of this presentation is to em-
phasize genetic and environmental factors that determine susceptibility to inflam-
matory, immune, and fibroproliferative responses in the lungs of mice exposed to
carbon nanotubes. Evidence will be presented showing that pre-existing non-aller-
gic lung inflammation induced by bacterial lipopolysaccharide (LPS) or allergic air-
way disease induced by ovalbumin sensitization alters the immune response and fi-
broproliferative effects of carbon nanotubes as well as modulates other aspects of
airway remodeling such as inflammatory cell infiltration and mucus hypersecretion.
In addition, transgenic mouse studies show that susceptibility or resistance to car-
bon nanotubes is determined by the relative abundance or expression of specific
genes that encode transcription factors involved in the innate immune response.
Finally, the consequence of enhancing the physical or chemical properties of carbon
nanotubes by atomic layer deposition will be addressed to better understand how
post-synthesis engineering affects toxicity and disease pathogenesis.
25 Translatable Indicators of Testicular Toxicity: Inhibin B,
microRNAs, and Sperm Signatures.
K. Boekelheide1,  B. McIntyre3,  M. Coulson4 and R. E. Chapin2. 1Brown
University, Providence, RI; 2Pfizer Drug Safety, DART Group, Groton, CT;
3National Toxicology Program, NIEHS, NIH, Research Triangle Park, NC;
4AstraZeneca R&D, Alderley Park, United Kingdom.
The typical endpoints used in preclinical animal models for reproductive toxicity
testing, such as histopathology, are not translatable for human clinical assessment,
which typically focuses on the analyses of semen and serum hormones. Therefore,
when testicular toxicity arises in preclinical toxicity testing, the methods currently
available to monitor this liability in clinical trials are limited. Because of these limi-
tations, there is a need to develop sensitive and translatable indicators that reliably
reflect testicular function. In this symposium, an introductory talk will set the stage
by describing testicular physiology, preclinical tests of male reproductive toxicity,
and current methods for assessing testicular function in men in clinical trials. The
following three talks will discuss currently active efforts to develop improved trans-
latable indicators of testicular toxicity in men. Serum inhibin B is a product of the
testicular Sertoli cell and levels fall in response to testicular injury. Testis-specific
miRNAs may be released upon testicular injury, and their measurement in serum
may be a measure of effect. Sperm mRNA transcripts and DNA methylation may
be indicators of testicular toxicity because they are easily measured and persistently
altered after testicular injury. Developing reliable and predictive translatable indica-
tors of testicular toxicity would be valuable for drug development in the pharma-
ceutical industry, and for monitoring men in occupational settings where exposure
to potential testicular toxicants is a concern.
26 Biomarkers of Testicular Injury: Where Have We Been.
B. McIntyre. NIEHS/NTP, Research Triangle Park, NC.
Toxicological findings in the male reproductive system are one of the most chal-
lenging events to put into perspective during nonclinical drug toxicity testing.
These findings in animal models often consist of adverse changes in testicular
histopathology and decreases in male fertility. Understanding the toxicological rele-
vance of these findings to men enrolled in clinical trials is necessary for patient
safety and is often paramount for continued development of the drug candidate.
The mammalian testis is a complex tissue consisting specialized cell types that sup-
port spermatogenesis and reproduction. Although rodents, canines and non-
human primates exhibit anatomical and physiological similarities, there are distinct
differences that make extrapolation to human males challenging. Historically, alter-
ations in non-invasive biomarkers such as hormone levels (e.g. testosterone and fol-
licle stimulating hormone) and semen parameters (motility, morphology, count)
have been used as indicators of altered testicular function. However, these changes
are often insensitive and may require significant and potentially irreversible damage
to the testes before biologically significant alterations in levels are evident in either
animal models or humans. This has led to pragmatic nonclinical approaches where
the pathogenesis of testicular toxicity is characterized with respect to both the po-
tential for recovery/reversibility, and the margin of safety between the preclinical
toxic exposure and the expected clinical exposure. Noninvasive (and often insensi-
tive) biomarkers are often benchmarked against these exposures. This presentation
with review the benefits of this sometimes challenging and inferential paradigm,
but will also underscore that new tools and methodologies would be of value in un-
derstanding the human relevance of drug-induced testicular findings observed in
animals.
27 Industry Efforts to Evaluate Inhibin B As Potential
Biomarker for Testicular Toxicity.
M. Coulson. Safety Assessment, AstraZeneca, Macclesfield, United Kingdom.
Sponsor: K. Boekelheide.
Serum inhibin B is a hormone product of the seminiferous epithelium that has long
been considered as The Next Great Biomarker. A HESI-sponsored effort in the
early 2000’s failed due to poor antibody behavior. A new antibody and a new assay
kit have revived interest in this protein, and HESI has again sponsored a multi-
company analysis of the analytic method and the protein’s response to toxicity. This
talk will introduce the biology, and the results of the consortium in evaluating the
robustness of the analytic method, and the correlation between changes in inhibin
B blood levels and the histologic state of the testis.
28 Circulating microRNAs As Biomarkers of Testicular
Damage?
R. E. Chapin. DART, Drug Safety R&D, Pfizer, Inc, Groton, CT.
MicroRNAs released into the blood following injury of specific tissues are emerging
as promising biomarkers of toxicity, and the testis is no exception. A large multi-
company effort under the auspices of the Predictive Safety Testing Consortium has
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been working to define which miRNAs are testis-specific or -enriched, and to de-
fine their changes in the blood during testicular toxicant-induced injury. This pres-
entation will briefly review the underlying biology and present an update of the
work in this fast-moving area.
29 Sperm mRNA Transcripts and DNA Methylation Marks As
Indicators of Testicular Injury.
K. Boekelheide. Brown University, Providence, RI.
As a pure population of cells that have matured and differentiated within the semi-
niferous epithelium, sperm carry all of the information needed to fertilize an oocyte
and initiate embryogenesis. Sperm deliver small and large RNAs and DNA to the
oocyte. Using high throughput array technology, a panel of altered sperm mRNAs
has been identified after exposure of rats to testicular toxicants. In men, the extent
of sperm DNA methylation is related to sperm motility. The ultimate goal is to
identify translatable sperm molecular signatures that will allow the rapid assessment
of sperm effects in preclinical test species and exposed men.
30 Biology of Low-Dose Response for DNA-Reactive Chemicals.
J. Klapacz1 and B. P. Engelward2. 1TERC, The Dow Chemical Company, Midland,
MI; 2Department of Biological Engineering, Massachusetts Institute of Technology,
Cambridge, MA.
In the risk assessment process, DNA-reactive agents are generally considered to
have no thresholds for their biological effects and this assumption formed the basis
for linear low-dose extrapolation of any carcinogenic effects induced by these
agents. On the other hand, cells have evolved to handle DNA lesions from endoge-
nous and many exogenous DNA-reactive agents. In fact, DNA-repair processes are
strictly conserved from bacteria to humans underlying their importance in protec-
tion against the effects of these agents, such as disease and aging. In recent years,
low-dose response for DNA-reactive agents has been an active domain for research
in toxicology, with publication of several datasets with large numbers of doses fo-
cused on the determination of no-observed-genotoxic-effect-level (NOGEL) val-
ues. This effort has included dose-response modelling to identify the best fit be-
tween linear and nonlinear models, such as bilinear (hockey-stick) and the
benchmark dose (BMD) suite of models, and most datasets have supported a bilin-
ear or nonlinear/threshold dose response as providing best fit based on statistical
criteria. However, empirical demonstration of statistically-supported
nonlinear/threshold dose response alone is not sufficient to achieve a paradigm shift
in risk assessment. A clear understanding of the biological processes behind the
shape of the low-dose response curve is similarly a critical piece of this journey, and
one where less effort has been focused to date within toxicology. This workshop will
explore some of the questions that need to be addressed to understand and bridge
DNA-repair processes and cellular responses with the mode-of-action driving these
nonlinear/threshold dose responses for genotoxic effects. The workshop will exam-
ine existing knowledge from the field of DNA repair and link it with response to
low doses of DNA-reactive agents, in order to draw specific recommendations on a
path forward.
31 Genotoxic Effects and Dose Response: What Do We Know
So Far?
L. H. Pottenger. TERC, The Dow Chemical Company, Midland, MI.
Low-dose genotoxic response for DNA-reactive alkylating agents has been actively
investigated recently, with large datasets focused on low-dose response and determi-
nation of no-observed-genotoxic-effect-level (NOGEL) values. Most of these re-
cent datasets include dose-response modelling analyses and have demonstrated a bi-
linear or non-linear/threshold dose-response as the statistically supported best fit,
including datasets for directly DNA-reactive chemicals such as MMS, MNU, EMS,
and ENU. Recent data have demonstrated the ubiquitous presence of endoge-
nously-derived DNA adducts, some of which are identical to ones induced by ex-
ogenous exposure to DNA-reactive chemicals. Use of stable isotopes has permitted
differentiation between the identical endogenously- and exogenously-induced
DNA adducts, demonstrating that the exogenously-induced DNA adducts can
have non-linear dose-responses at low doses; examples include formaldehyde and
EO, both of which show that endogenous adduct levels can swamp the exoge-
nously-induced ones at low exposures. Thus the available empirical evidence sup-
porting the existence of non-linear/threshold dose-response for mutagenic effects
from DNA-reactive agents is already compelling, while a growing body of evidence
is demonstrating similar non-linear/threshold dose-responses for exogenously-in-
duced DNA adducts. However, statistically supported demonstration of non-lin-
ear/threshold dose-response alone is inadequate to achieve a paradigm shift in risk
assessment. A clear understanding of the biology behind the shape of the dose-re-
sponse is a critical piece for this journey, especially at low doses, although consider-
ably less effort has transpired on this aspect to date. Addressing the biology and bi-
ologically plausible modes-of-action driving these non-linear/threshold
dose-responses for genotoxic effects is the next task, one in which DNA repair
mechanisms are likely to play a key role, both for adducts and for impact on dose-
response for any resulting mutagenic effects.
32 CometChip and Recombomice Shed Light on Gene-
Exposure Interactions That Impact Genomic Stability.
B. P. Engelward. Department of Biological Engineering, Massachusetts Institute of
Technology, Cambridge, MA.
We are interested in homologous recombination (HR) and base excision repair
(BER) and the interaction between these DNA repair pathways. To explore HR in
mammals, we created mice with recombination reporter systems (Recombomice) in
which cells that have undergone an HR event fluoresce by combining tandem re-
peat of truncated copies of EYFP or EGFP gene. Here, we explore genetic and en-
vironmental factors that modulate susceptibility to HR in vivo. In particular, the
impact of inflammation, producing endogenous oxidative and alkylating DNA
damage, as both a modulator and an inducer of HR is presented. Exposure to low
dose and high dose radiation causes many of the same changes to DNA as exposure
to inflammation and can lead to severe inflammatory responses. Consequently, our
inflammation studies have broad relevance. In addition, we have developed Comet
assay called ‘CometChip’ for DNA damage analysis in single cells in an automated
fashion. The approach increases throughput and improves reproducibility. Here, we
show proof of principle of the technology as well as several applications of the
CometChip for studies of gene-environment interactions. Together, this work and
the technologies generated new biological insights.
HR has emerged as an important driver of carcinogenic sequence rearrangements.
HR repairs double strand breaks in the S/G2 phases of the cell cycle resulting from
endogenous and exogenous processes. While usually error free, errors in homolo-
gous recombination may result in sequence rearrangements and loss of heterozygos-
ity, both of which are prominent features of cancer cells. BER is also a key DNA re-
pair pathway. In this case, damaged bases are removed, the DNA backbone is
cleaved, the ends are processed and the resulting gap is filled from the opposite
strand. Both pathways are usually error-free, but there are still rare events where
there are misalignments during HR, and misinsertions during BER. Also, both
pathways are active in response to spontaneous DNA damage, and thus would be
expected to be active in response to low dose radiation.
33 Role of Mismatch Repair in Mutagenesis, Cancer, and DNA-
Damage Signaling.
W. Edelmann. Department of Cell Biology, Albert Einstein College of Medicine,
Bronx, NY. Sponsor: J. Klapacz.
The DNA mismatch repair (MMR) system is essential for maintaining the integrity
of mammalian genomes by removing misincorporated nucleotides that result from
erroneous replication. In addition, MMR participates in the early steps of check-
point activation and apoptosis during the cellular response to alkylation induced
O6MeG:T mismatches and many other DNA lesions, particularly relevant at low-
dose, clinically-relevant exposures. Mutations in mammalian MMR genes result in
increased spontaneous mutation rates and strong predisposition to colorectal can-
cers and other cancers. Eukaryotic MMR is a complex system that requires the in-
teraction of several MutS and MutL proteins for the initiation of the repair reac-
tion. Subsequent to mismatch recognition, downstream events are activated that
lead to the excision of misincorporated or damaged nucleotides and the signaling of
DNA damage-induced cell cycle arrest and apoptosis. The loss of the MMR-de-
pendent DNA damage response is of significant clinical relevance as it results in in-
creased resistance to many alkylating and chemotherapeutic agents. Our research
program focuses on elucidating the functions of the individual MutS and MutL ho-
mologs in mammalian MMR and on assessing their importance for tumor suppres-
sion and the DNA damage response. Our results show that the DNA damage sig-
naling by MMR is important for the suppression of tumorigenesis in the initial
stages of the process. In addition, we found that MMR missense mutations can ef-
fectively separate the DNA repair and damage response functions and result in
more heterogeneous cancer phenotypes than those caused by complete loss of func-
tion mutations.
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34 Computational Systems Biology Modeling of DNA-Damage
Stress Pathways for Assessing Mutation Rates at Low Doses.
M. E. Andersen. The Hamner Institutes for Health Sciences, Research Triangle Park,
NC.
Homeostasis with cellular stress response pathways involves negative feedback act-
ing through a series of steps to reduce stressor concentrations. Many stress response
pathways have rapid response, post-translational signaling and slower signaling
through transcriptional upregulation of gene families. Our laboratory, in close col-
laboration with scientists from Unilever Safety and Environment Assurance Centre
(SEAC), UK, has examined multiple biological read-outs in cells treated with sev-
eral DNA-damaging compounds in order to create mechanistic computational
models for micronuclei (MN) formation across wide dose ranges.  The readouts in
several cell types – AHH-1, HT-1080 and TK6 - included dose and time-depend-
ent examination of whole genome gene expression, high content imaging of DNA-
damage markers (γH2AX and p53), semi-quantitative measures of key phospho-
proteins (ATM, ATR, p38, Chk2, and p53), and MN as a measure of
DNA-damage. Transcriptional upregulation only occurred in the regions of dose-
response with clear increases in MN formation. Post-translational activation of rate
constants for DNA-repair processes acting through activation of specific kinases ap-
pears to be the main contributor to regulation of DNA-damage at lower doses of
these compounds. This talk describes stress pathway homeostatic feedback loops,
shows our steps to populate high- and low-dose models for DNA-damage response
pathways with etoposide, quercitin and methylmethansulfonate, notes our progress
in creating mechanistically-based low dose threshold models and discusses the value
of these computational models in guiding new experimental approaches for assess-
ing thresholds.
35 Do Alkylating Agents Cause Genotoxic Thresholds through a
DNA Repair Mode of Action?
G. E. Johnson,  S. H. Doak,  B. J. Rees,  A. D. Thomas,  J. R. Verma,  Z. M. Zair
and G. J. Jenkins. College of Medicine, Swansea University, Swansea, United
Kingdom.
The long standing theory that linear dose responses exist for all DNA reactive geno-
toxic agents has recently been challenged. This paradigm shift towards accepting
thresholds has been initiated by the scientific and regulatory community. High
power non-linear dose responses are being produced in robust test systems.
However, for the scientific community to accept a range of low doses as biologically
irrelevant, a plausible mechanism of action must be shown experimentally. Many
different research groups are tackling this issue for methyl- and ethyl-methane
sulphonate (EMS and MMS) and methyl- and ethyl- nitrosourea (MNU and
ENU) which have all been shown to exhibit non-linear dose responses for both mu-
tagenicity and clastogenicity in vitro and in vivo. These alkylating agents induce
specific DNA adducts (O6-alkylG, N7-alkyl-G and N3-alkyl-A), and recent work
has been to investigate the roles of DNA repair in relation to their genotoxic thresh-
olds. Specific DNA repair enzymes (N-methyl DNA purine glycosylase [MPG] and
O6- alkyl guanine transferase [AGT]) have been shown to be up-regulated by low
dose alkylating agents, and knocking down these specific DNA repair enzymes in
vitro alters the shape of the dose response e.g. to EMS and MNU. Therefore,
mono-functional alkylating agents have threshold dose responses through a DNA
repair mode of action.
36 Incorporation of Exposure Data and Chemical Properties
into Early In Vitro Screening Studies: Putting Early Hazard
Identification into Appropriate Context.
R. T. Dunn1 and Y. Will2. 1Discovery Toxicology, Amgen Inc, Thousand Oaks, CA;
2Compound Safety Prediction, Pfizer R&D, Groton, CT.
Over the past several years, a multiplicity of innovative early-screening assays have
been adopted to improve our ability to select drug candidates with the maximal op-
portunity to eventually succeed in later development. Examples of medium and
high-throughput assays that can enable early hazard identification include ion
channels related to cardiovascular safety (hERG, NaV1.5, and others), assays to un-
derstand CNS permeability and hepatobiliary transport (PgP, BSEP, etc.), and re-
ceptor and kinase screens, as well as screening ADME assays. These assays are typi-
cally employed early in the drug discovery process when little other data are
available to help contextualize the early-screening result. Data output from these
early screens is often produced, then utilized by project teams to select molecules
for advancement, deprioritization, or to accumulate the knowledge base around a
compound. In this model, the early-screening data may become a static entity, such
as an IC50 value, which is then stored in a database often without further consider-
ation or re-evaluation. There is a possibility that early-screening data in such a
model is underutilized or potentially misleading. An inherent problem with gener-
ating early-screening data is that it is often produced in the absence of accompany-
ing data (e.g., in vivo exposure), which is information that can be leveraged to place
these data into better context and enable more accurate predictions. In this work-
shop, several use case examples will be presented where in vivo exposure informa-
tion and chemical compound properties have been weaved into early in vitro toxic-
ity screening data enabling the discovery toxicologist to conduct a more robust
assessment of the hazard identification assay data.
37 Inclusion of Exposure Data to Early Toxicity Screening:
Using the Bile Salt Export Pump (BSEP) Screen As an
Illustrative Example.
R. T. Dunn,  R. E. Morgan and H. K. Hamadeh. Discovery Toxicology, Amgen Inc,
Thousand Oaks, CA.
Inhibition of the bile salt export pump (BSEP) is a recognized risk factor in the de-
velopment of drug induced hepatic toxicity. To date there has not been an animal
model that can be reliably used to predict toxicity arising from inhibition of bile salt
transport. Thus, in order to provide project teams with an early hazard identifica-
tion tool for BSEP inhibition, a vesicle-based BSEP assay was developed. Guidance
for decision making or prioritization was initially based on a series of cutoff values,
where potency on BSEP was used as a singular criterion for hazard flagging. As part
of an effort to refine how early screening data are used, BSEP inhibition data was
obtained from a compendium of approved and withdrawn drugs. The available
human exposure data was then applied in a ratio calculation (BSEP
IC50/Exposure) in order to provide an estimate of the safety multiple. Using the
ratio-based data, a more robust evaluation of the IC50 data is now possible and the
decision making power is enhanced. In addition, both false positive and false nega-
tive compounds were further analyzed and hypotheses generated to refine judgment
around the hazard for individual molecules.
38 High-Content Mechanistic Screening (HCMS) Technology to
Impact Safety in the Context of Efficacy, Exposure, and
Toxicity.
K. Tsaioun. Apredica, Watertown, MA.
High content mechanism screening (HCMS) is a powerful platform that images
numerous mechanistic toxicity endpoints in full dose response at various time
points in cells of choice to generate IC50 based toxicity profiles presented as
heatmaps. This allows to compare toxicity profiles of compounds across chemical
series or within a series, with the goal to only take compounds forward that meet an
acceptable safety profile and minimize the probability of attrition in later stages of
development. We have successfully applied this approach to retrospective analysis
for organ toxicity prediction as well as within our own portfolio. This work demon-
strated that accurate prediction of clinical safety outcome depended on the avail-
ability of accurate information on clinical exposure levels. Rank ordering of com-
pounds should be done in the context of exposure to most accurately define the
safety window. When adjusted for clinical Cmax, retrospectively, the rank ordering
of compounds fell in line with the FDA status and known clinical adverse events
observations. This information was available to us for retrospective validation of the
HCMS technology, but is not available for discovery compounds. To address this
problem, as part of retrospective validation, we used industry-standard approach of
using pharmacologically-based pharmacokinetic (PBPK) model and predicted
human Cmax to normalize HCMS toxicity data. We demonstrated that when
HCMS data were adjusted for predicted Cmax, that was calculated using PBPK
model CloePK, rank order of the compounds fell in the same range as when we
used clinical Cmax. In order to generate PBPK predictions a set of standard ADME
data is used as an input.
39 Lead Optimization Against Toxicological End Points in Drug
Discovery: Recognition of Structural Determinants of Small
Molecule Target Organ Exposure and Toxicity.
D. P. Hartley. Array Biopharma, Boulder, CO.
Target organ toxicity is a leading cause of attrition for novel small molecules in non-
clinical drug discovery and early clinical development. Given the demands on drug
discovery teams to produce molecules devoid of toxicity concerns, a paradigm shift
has occurred such that toxicologists are now integral members of these teams with
new responsibilities geared toward lead optimization. As such, it is no longer suffi-
cient for the toxicologist to simply describe the observed organ toxicities of a new
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compound, it is expected that we assess risk for toxicity in a predictive manner, or
ascribe a mechanism to early toxicity findings, link the findings to an offending
moiety within the structure, and assist in defining the chemical lead optimization
path. In many instances, simple modifications to structural or physical chemical
properties to molecules with insufficient safety profiles can quickly lead to new can-
didates with improved exposure and target organ toxicity profiles. Examples will be
presented where recognition and subsequent modification of structural and physi-
cal chemical features were employed to reduce attrition of small molecules due to
undesirable safety pharmacology or target-organ toxicity.
40 The Challenges of Putting In Vitro Safety Assays into
Context with In Vivo Data.
N. Greene. Compound Safety Prediction, Pfizer, Inc., Groton, CT.
In the quest for higher-throughput, lower cost assays for safety assessment, many ef-
forts have focused on cell based in vitro assays that generate a effect at a certain con-
centration level readout such as an LC50 etc. However, most of the efforts on cor-
relating these in vitro concentration responses to in vivo effects have looked at the
simple presence or absence of a phenotypic response in the in vivo study resulting
in the potential misinterpretation of a result. In this presentation, we will describe
efforts to more fully describe the in vivo responses in the context of compound ex-
posure to enhance the interpretation and correlation of in vitro assays. We will
highlight some of the issues in working with in vivo data such as the loosely con-
trolled vocabularies used in describing the findings observed in a study and ap-
proaches we have taken to overcome these. Finally, we will show how this may then
enhance the predictive value of an in vitro assay such as a simple ATP depletion
assay.
41 Relating Molecular Properties and In Vitro ADME/Tox
Surrogate Assay Results to In Vivo Outcomes.
D. E. Watson. Lilly Research Laboratories, Indianapolis, IN.
A primary goal of lead generation and lead optimization is to identify compounds
with good pharmacological properties and optimal absorption, distribution, metab-
olism, excretion and toxicological (ADMET) characteristics. Chemists routinely
consider molecular properties in designing compounds and utilize in vitro
ADMET surrogate assays to select promising compounds for in vivo studies. A
number of recent reports have investigated the relationship between computed mo-
lecular properties and in vivo ADMET outcomes. Although there is consensus that
compound properties are important, one limitation of these analyses is a lack of
controls for possible covariates (i.e. correlation vs. causation). We have examined
the relationship between molecular properties and in vitro ADMET surrogate as-
says vs. in vivo properties within 175 chemical series identified from a database of
3792 compounds for which short term rodent pharmacokinetic and toxicology
data are available. The role of confounding covariates was minimized by focusing
on those variable associated with large differences in outcomes between compound
pairs within chemically similar series of molecules. The analysis identified the fol-
lowing pairs of surrogates as most predictive among those examined: rat primary
hepatocyte (RPH) cytolethality / volume of distribution (Vd) for in vivo toxicology
outcomes, scaled microsome metabolism / calculated logP for in vivo unbound
clearance, and calculated logD / kinetic aqueous solubility for thermodynamic sol-
ubility. An important practical outcome of the analysis is a set of guidelines defin-
ing the utility of specific surrogates for several in vivo ADMET endpoint and the
magnitude of change required in a surrogate endpoint to achieve a desired in vivo
result for novel drug candidates.
42 Inhaled Mixtures: A Mode-of-Action Framework Applied to
the Criteria Air Pollutants.
E. O. Owens and C. C. Bowman. National Center for Environmental Assessment,
US EPA, Durham, NC.
Although regulated individually, the criteria air pollutants, NOx, Sox, CO, PM,
Pb, and O3, exist as a complex mixture in the atmosphere. Thus, the interactions
and cumulative effects of multiple pollutants are important to consider when as-
sessing the impact of ambient air exposures on health. The criteria air pollutants act
through complex biological pathways to elicit health effects, but many share com-
mon modes of action, including oxidative stress and inflammation. Mode of action
for a given toxic agent is defined as the set of key events involved in a given toxic ef-
fect. Key events are measurable endpoints along a continuum from exposure to ef-
fect, and are consistent with emerging concepts of how to use biomarkers, surrogate
endpoints, and toxicity pathways to characterize health risks. Recent discussions
have proposed the use of mode of action to develop a unifying framework for the
evaluation of mixtures containing multiple pollutants. This session convenes ex-
perts in the modes of action of criteria air pollutants to examine how this informa-
tion can be organized, beginning with a description of an emerging framework for
integrating mechanistic and biological plausibility information regarding the crite-
ria air pollutants and a subset of ambient air toxics. Attendees will gain knowledge
of how a mode-of-action framework can be used to consider mixtures, as well as
emerging and established mechanisms of toxicity of air pollutants, focusing on po-
tential interactions between pollutants encountered in a multipollutant context.
43 Assessing Health Effects of Air Pollution Mixtures: Mode-of-
Action Framework.
B. Buckley. National Center for Environmental Assessment, US EPA, Durham, NC.
Sponsor: C. Bowman.
To better understand the health effects resulting from exposures to mixtures of cri-
teria pollutants (PM, particulate matter; sulfur oxides, SOx; nitrogen oxides, NOx;
ozone, O3; lead, Pb and carbon monoxide, CO) that actually occur in ambient air,
we are developing a framework for integrating information provided by toxicologi-
cal, epidemiologic, and controlled human exposure studies based on mode of ac-
tion. Mode of action for a given agent is defined as the set of key events which re-
sult in a toxic effect. Key events are measurable endpoints along the continuum
from exposure to effect, and are consistent with emerging concepts of how to use
biomarkers, surrogate endpoints, and toxicity pathways to characterize health risks.
The approach elucidates commonalities in key events and pathways triggered by ex-
posure to multiple pollutants. Available literature regarding the respiratory health
effects of PM, SOx, NOx and O3 indicates that all four pollutants activate neural
reflexes, increase bronchial reactivity, initiate inflammation and modulate immune
responses which may lead to the exacerbation of allergic responses, asthma and al-
tered host defenses. Emerging evidence also demonstrates that exposure to either
PM or O3 may result in systemic inflammation, oxidative stress and impaired vaso-
motor function while exposure to NOx may result in pro-inflammatory circulating
factors; all of which may lead to cardiovascular health effects. Exposure to CO may
impair vasomotor function or lead to myocardial ischemia, while exposure to Pb
may result in hypertension. Incorporation of important considerations for extrapo-
lation in risk assessment such as adaptive responses, susceptibility factors, dose and
duration of exposure, toxicokinetics, toxicodynamics and endogenous species into
this framework is explored.
44 The Effects of Criteria Pollutants in the Brain.
M. L. Block. Anatomy and Neurobiology, Medical College of Virginia, Richmond,
VA.
Increasing evidence links air pollution to central nervous system (CNS) disease, but
the mechanisms remain poorly understood. Experimental studies and human case
reports reveal that neuroinflammation and oxidative stress have emerged as a com-
mon deleterious pathway triggered by exposures to diverse criteria pollutants, in-
cluding ozone and particulate matter. Thus, evidence indicates that not only does
the brain’s innate immune system respond to criteria pollutants, but that this has
been linked to neurodegenerative-disease-like pathology in cell culture, rodent
models, and humans. This presentation will focus on the cellular and peripheral
mechanisms that may be driving the CNS effects of air pollution, as our work with
diesel exhaust shows that both the peripheral immune system and microglia, the
brain’s resident innate immune cell, may be key to this process. In addition to pro-
viding new information on specific mechanisms of CNS disease development re-
lated to criteria air pollutant exposure, a mode of action framework will be used to
describe the pathways leading to emerging health effects with uncertain mecha-
nisms.
45 Air Pollution and Pattern Recognition Receptors: Like a Wee
LCMS in Every Mouse.
M. J. Campen. College of Pharmacy, University of New Mexico, Albuquerque, NC.
Distinguishing among the toxicities of the numerous criteria pollutants and other
unregulated air hazards that exist in the multipollutant environment challenges the
most sophisticated human and animal studies. To adopt a more refined approach to
assessing the effects of multipollutant exposures, it will be essential to better under-
stand the shared mechanisms driving toxicity. One common pathway that several
labs have recently elucidated relates to a class of receptors known as pattern recog-
nition receptors (PRR). Research will be presented looking at the role of PRR in
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driving allergic airway response, cardio-metabolic response, and the systemic vascu-
lar inflammatory response to combustion-source mixtures, such as gasoline and
diesel emissions. These findings, combined with results from other laboratories, in-
dicate a role for PRRs that may help refine our understanding of the link between
the chemistry of pollutant interactions at the lung surface and the ultimate patho-
physiological outcome.
46 Differential Effects of PM Components: Toward a Better
Understanding of Underlying Mechanisms.
A. Rohr. Air Quality, Electric Power Research Institute, Palo Alto, CA.
Multiple epidemiological and toxicological studies have reported differential re-
sponses to fine particulate matter components, such as elemental carbon, organic
carbon, sulfate, nitrate, and individual elements. While different PM components
likely invoke unique pathophysiological pathways, it is also likely that there is over-
lap between mechanisms of action. For example, oxidative stress is a likely pathway
for both organic PM components as well as trace elements. In a multipollutant set-
ting, it is critical to understand the underlying mechanisms of adverse biological re-
sponses to these materials. This presentation will review what is currently known
about pathophysiological pathways of response to PM components, with an em-
phasis on shared pathways.
47 Toxicological Challenges in Food Production in Texas and
the Gulf Coast.
L. M. Plunkett. Integrative Biostrategies LLC, Houston, TX.
With recent media attention on episodes of food contamination and the impact of
chemicals in the environment on the food supply (i.e., bacterial contamination of
food, as well as the 2010 BP oil spill), public awareness of food safety issues has
grown. This symposium will explore the topic of food safety as it relates to unique
features of food production in Texas and the Gulf Coast. Texas is a major source of
fresh fruit and vegetable production for both regional and countrywide consump-
tion, while the Gulf Coast is a major source of fresh fish and seafood for many parts
of the United States. Topics covered in the symposium will include recent legislative
initiatives such as the Food Safety and Modernization Act of 2010, current regula-
tory oversight of food safety in the Gulf Coast region, and key public and/or worker
health issues associated with food production in the region. The goal of the sympo-
sium is to describe the strengths and weaknesses of current regulations and practices
to ensure a safe food supply as well as worker safety, and provide dialog for ways to
address unique concerns related to food production in Texas and the Gulf Coast.
Symposium speakers work in academia, for the United States government (US
FDA), and an organization representing the interests of the public (Center for
Science in the Public Interest), which will allow for discussion of the topics from a
variety of perspectives.
48 Multiagency Response to Seafood Safety Concerns following
the 2010 Deepwater Horizon Oil Spill.
R. W. Dickey. US FDA, Dauphine Island, AL. Sponsor: L. Plunkett.
The April 20, 2010 explosion and sinking of the Deepwater Horizon oil drilling
platform (DWH) resulted in the largest oil spill in U.S. history. For a period of 87
days roughly 53 thousand barrels of oil per day flowed into the Gulf of Mexico
(GOM). The U.S. Coast Guard estimated 4.9 million barrels of crude oil escaped
before the damaged wellhead was sealed on July 15. The DWH spill threatened all
States bordering the GOM, and crossed Federal and State jurisdictional bound-
aries. Agencies responded to the spill in a coordinated manner to execute a unified
seafood safety risk assessment and protocol for testing and re-opening GOM fish-
eries. 
Polycyclic aromatic hydrocarbons (PAH) are internationally recognized as the most
appropriate indicators of potential human health risk from crude oil residues in
seafood. A representative subset of 13 PAH and their alkylated homologues was se-
lected for critical analysis of oil-impacted seafood. A standard set of calculations was
used to determine seafood PAH tissue concentrations above which a 10-5 upper-
bound risk for low dose, life-time cancer is exceeded. Levels of concern for non-
cancer risks were also adopted from EPA IRIS reference dose values. Values for
other event-specific variables were selected from the most recent and reliable infor-
mation available.
FDA and NOAA tested more than 10,000 seafood specimens from state territorial
and federal waters that were impacted by the oil spill. Waters were not reopened for
fisheries harvest until oil had dissipated and testing showed that seafood was safe for
consumption. The duration of fishery closures in the oil-impacted region ranged
from 16 days for areas receiving little to no impact to greater than 24 months for
areas more heavily oiled. 
Most seafood samples that were tested after the oil spill had dissipated, and before
waters were reopened for fishing, did not contain measurable levels of oil or disper-
sant residues. The samples that did contain measurable residues were consistently
100 to 1000-fold below levels of concern established in the unified seafood safety
protocol.
49 Seafood Safety Challenges for the Texas Gulf Coast.
D. W. Plunkett. Center for Science in the Public Interest, Washington DC. Sponsor:
L. Plunkett.
Potentially toxic chemistry from the 2010 BP oil spill and clean-up efforts gener-
ated widespread public concern over the safety of seafood harvested from the Gulf
of Mexico. Government agencies moved swiftly to contain the threat and reassure
consumers. The effort, though, masked a larger truth. While contamination events
caused by human activities draw public attention, naturally occurring toxins and
deadly bacteria in Gulf waters sicken, maim and kill far more people than oil and
chemical dispersants. Rare cases of neurotoxic shellfish poisoning occur in Texas.
Much more common are illnesses and deaths from naturally occurring vibrios.
Oysters harvested from Texas coastal waters have killed 53 people since 1995 and
resulted in 45 serious illnesses from Vibrio vulnificus contamination. The presenta-
tion will cover the risks to human health from human and naturally occurring con-
taminants, focusing on shellfish. It will also cover responses, adequate and inade-
quate, by governmental food safety agencies and the fishing industry.
50 Occupational Hazards in Texas Food Production.
E. Shipp. Epidemiology and Biostatistics, Texas A&M School of Rural Public Health,
College Station, TX. Sponsor: E. Bruce.
A substantial number of hired farmworkers help Americans to put food on their ta-
bles. This largely foreign-born (>75%) workforce makes a huge contribution to the
agricultural economy, yet the average family income ranges from $15,000 to
$17,499 and less than a quarter are covered by health insurance. The agricultural
industry also is among the most hazardous in the United States in terms of fatal and
nonfatal injury. Common occupational hazards include: prolonged time in awk-
ward postures, sun and heat stress, sharp implements, motorized farm equipment,
inadequate safety training and field sanitation, and pesticides. Pesticides are espe-
cially a concern for farmworkers given the potential for long-term consequences
such as skin problems, neurologic and motor problems, birth defects, and cancer.
There are an estimated 10,000-20,000 cases of physician diagnosed pesticide poi-
soning among agricultural workers each year in the U.S. Many more cases likely go
undiagnosed because symptoms can be flu-like and non-specific or the farmworkers
lack access to healthcare. Worker training can reduce this exposure, but employers
often do not provide training even when required to do so by law. In a study of ado-
lescent farmworkers from Texas, only 21% had ever received any training in pesti-
cide safety. This is troubling because adolescents are still developing both physically
and mentally and may be especially vulnerable to chemical exposures. A recent pilot
study showed that adolescent farmworkers who reported 5+ symptoms of neuro-
toxicity were nearly nine times as likely to report an acute injury compared to those
reporting a lower number of symptoms (Whitworth et al., 2010). This presentation
provides an overview of the occupational health and safety issues impacting farm-
workers with a focus on pesticides and a current research study designed to examine
this issue further in adolescents.
51 Occupational Heat Stress in Agricultural Settings.
J. L. Levin. Occupational Health Sciences, The University of Texas Health Science
Center at Tyler, Tyler, TX. Sponsor: E. Bruce.
Occupational heat stress and heat illness disproportionately affect agricultural
workers compared with other occupations, including migrant and seasonal farm-
workers. From 1992 to 2006, there were 423 occupational heat-related deaths in
the United States. The mortality rate from occupational heat-related illness among
crop workers was nearly twenty times as high as for all industries during that time
frame. This presentation will review underlying causes and risk factors for occupa-
tional heat stress, recognition of the continuum of heat illness, and recommenda-
tions for monitoring and prevention. Presently, there is no federal occupational reg-
ulatory standard specifically regarding heat exposure. This presentation will also
review fundamental differences between OSHA and NIOSH and emphasize the
complexities of understanding recommended exposure limits. Case examples from
outdoor work environments will be presented including one which culminated in
adjudication before the Occupational Safety and Health Review Commission.
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52 Developmental Toxicity and Neurobehavioral Effects of
Dietary Flavonoids.
S. M. Bugel and R. L. Tanguay. Department of Environmental and Molecular
Toxicology, Environmental Health Sciences Center, Oregon State University, Corvallis,
OR.
Flavonoids are a structurally diverse group of phytochemicals that are known hor-
mone mimics (phytoestrogens), and are thought to have therapeutic properties.
Humans are exposed to flavonoids through consumption of fruits, vegetables, and
dietary supplements. These ubiquitous chemicals are found in baby formulas and
foods, and are detected in human urine, plasma, and breast milk. Therefore, the po-
tential for developmental effects should be explored. Using zebrafish (Danio rerio)
as a model vertebrate, we tested the hypothesis that flavonoids exhibit structure-de-
pendent effects on development. Embryos were treated with 5 representative
flavonoids (apigenin, biochanin A, S-equol, galangin and kaempferol), 1-50 μM,
from 6 hours post fertilization (hpf ) to 120 hpf. At 120 hpf, effects included yolk-
sac and pericardial edemas, axis curvature, fin dysmorphogenesis and craniofacial
abnormalities. For all 5 compounds, we also observed spastic pectoral fin and cau-
dal tail movements at 72 hpf, suggestive of neurotoxicity. To test the hypothesis that
flavonoids are stimulants, we assessed acute effects on neurobehavior in naïve 120
hpf larvae challenged with 16 flavonoids: apigenin, biochanin A, chrysin, daidzein,
S-equol, fisetin, formononetin, galangin, genistein, kaempferol, luteolin, myricetin,
naringenin, puerarin, quercetin and resveratrol. With the exception of puerarin, all
induced hyperactive swimming behavior suggesting that flavonoids have psychoac-
tive and stimulant properties. This zebrafish larval bioassay is amenable to rapid
throughput screening for anxiogenic and anxiolytic properties, which we validate
using neurotoxicants chosen to represent diverse mechanisms (e.g. nicotine, chlor-
pyrifos, picrotoxin, etc.). Using pharmacological intervention with receptor specific
chemicals, this screen will be valuable for identifying interaction of dietary
flavonoids and other chemicals of interest with neuro-receptors to identify the
mechanism of toxicity in vivo. This research is supported by NIEHS grants P30
ES00210, RC4ES019764 and T32 ES07060.
53 Perinatal Toxicity and Carcinogenicity Studies of Styrene
Acrylonitrile Trimer, a Ground Water Contaminant.
M. Behl1, 2,  S. A. Elmore1,  M. R. Hejtmancik3,  D. K. Gerken3 and
R. S. Chhabra1. 1Division of the National Toxicology Program, NIEHS, Research
Triangle Park, NC; 2Kelly Government Solutions, Research Triangle Park, NC;
3Battelle Memorial Institute, Columbus, OH.
Styrene Acrylonitrile (SAN) Trimer is a by-product of the production of acryloni-
trile styrene plastics. Following the report of a childhood cancer cluster in the Toms
River section of Dover Township, New Jersey, SAN Trimer was identified as one of
the groundwater contaminants at Reich Farm Superfund site in the township. The
contaminants from the Reich Farm site’s ground water plume impacted two wells at
the Parkway well field. The National Toxicology Program (NTP) studied the toxic-
ity and carcinogenicity of SAN Trimer in F344/N rats exposed during their perina-
tal developmental period and adulthood. The chronic toxicity and carcinogenicity
studies in rats were preceded by 7 and 18-week perinatal toxicity studies to deter-
mine exposure concentrations for the 2 year studies Pregnant dams were exposed to
SAN-Trimer in the diet at 400, 800, or 1600 ppm during gestation, nursing and
weaning periods of offspring followed by two years of adult exposure to both male
and female pups. There was no statistically significant evidence of carcinogenic ac-
tivity following SAN-Trimer exposure; however, rare neoplasms in the brain and
spinal cord were noted in males and to lesser extent in female rats. These incidences
were considered within the range of historical control background in the animal
model used in the current studies. The major finding was a dose-related peripheral
neuropathy associated with the sciatic nerves in females and spinal nerve roots in
males and females, thereby suggesting that SAN-Trimer is a potential nervous sys-
tem toxicant. Other non-neoplastic lesions included increased incidences of some
lesions in the bone marrow and liver in males and females, and in the urinary blad-
der in females.
54 Does Developmental Hypothyroidism Produce Lasting
Effects on Adult Neurogenesis?
J. Nance1,  R. C. Switzer2,  A. Tennant1,  A. F. Johnstone1 and M. E. Gilbert1. 1US
EPA, Research Triangle Park, NC; 2NeuroScience Associates, Knoxville, TN.
The subgranular zone of the dentate gyrus (DG) of the adult hippocampus gener-
ates new neurons throughout life. Thyroid hormones (TH) are essential for brain
development, but impaired neurogenesis with adult hypothyroidism has also been
reported. We investigated the role of milder degrees of TH disruption on adult neu-
rogenesis following hypothyroidism induced during development, in adulthood, or
both. Pregnant dams were administered the TH synthesis inhibitor, propylth-
iouracil (PTU, 0 or 3ppm in drinking water) from gestational day 6 and pups were
weaned to control water on postnatal day (PN)21. On PN60, offspring from con-
trol or PTU dams were either re-exposed to PTU (3ppm) for 1 month or main-
tained on control. Bromodeoxyuridine (BrdU 50 mg/kg, ip, twice daily) was ad-
ministered to all animals on the last 5 days of the re-exposure period, and animals
sacrificed 28 d later. Animals were perfused intracardially, the brains removed and
embedded in a MultiBrain (NSA) array and freeze sectioned. Every 8th section
throughout the hippocampus stained with an antibody against BrdU to mark ac-
tively dividing cells. The volume of the DG and the number of BrdU-positive cells
were assessed from images captured on a Nikon microscope (400X) and Nikon
Elements software. Preliminary findings indicate that developmental exposure to
PTU produced a persistent reduction in the volume of the adult DG. BrdU cell
counts were reduced similarly in all PTU-exposed groups. These data suggest that
moderate levels of hypothyroidism decrease cell survival in the adult brain and that
transient developmental hypothyroidism leads to persistent decreases in DG vol-
ume and cell survival. The degree to which these findings are determined by reduc-
tions in cell proliferation is currently under investigation. As neurogenesis in the
adult recapitulates developmental processes of proliferation, differentiation, and
migration, study of this neurogenic niche in the adult may provide a simpler means
to assess the consequences of TH insufficiency on neurodevelopment. (Does not re-
flect EPA policy).
55 Dietary Administration of Paraquat for 13 Weeks Does Not
Result in a Loss of Dopaminergic Neurones from the
Substantia Nigra of Mice.
N. Sturgess1,  P. Botham1,  M. Butt3,  D. Minnema2,  L. Smith1 and J. Wolf4.
1Syngenta, Bracknell, United Kingdom; 2Syngenta, Greensboro, NC; 3Tox Path
Specialists, Frederick, MD; 4EPL, Sterling, VA.
A number of publications have reported that i.p. administration of paraquat (PQ)
to rodents (e.g. C57Bl6J mouse) at high doses results in a loss of dopaminergic neu-
rones from the substantia nigra pars compacta (SNpc), the primary area of neu-
ropathological damage in Parkinson’s disease (PD). Such studies have been used to
indicate mechanistic plausibility for epidemiological claims of a link between PQ
exposure and PD. A major criticism of the i.p. mouse model is that it uses a route
of administration and duration of exposure which is not relevant to human expo-
sure. To better understand the relevance of the reported findings from the i.p.
mouse model we have conducted a study where male C57Bl6J mice were exposed
to PQ in the diet for 13 weeks, and the brains examined for evidence of dopamin-
ergic neuronal cell loss using stereology, changes in striatal neurochemistry and
pathological changes using stains to detect neuronal cell damage and inflammatory
responses. Dietary concentrations of 10 & 50 ppm paraquat dichloride salt were
used which resulted in achieved doses of 2.4 & 14.1 mg/kg/day. A low dose of N-
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP; 10 mg/kg administered
i.p. to a separate group of male mice 4 times in a single day at 2 hr intervals, 7 days
prior to the end of the dietary study) served as a positive control. PQ at either dose
level did not induce a loss of tyrosine hydroxylase positive (TH+) dopaminergic
neurones in the SNpc, alter the concentration of striatal dopamine and its metabo-
lites or result in evidence of neuronal cell damage or astrocyte/microglial activation
in the SNpc. In the MPTP group the number of TH+ neurones in the SNpc and
striatal dopamine was reduced and there were significant pathological changes in-
cluding neuronal necrosis and astrocyte/microglial activation. This study further
brings into question the relevance of the findings from previous i.p. mouse studies
as evidence for a link between PQ exposure and PD/parkinsonism.
56 Neurodevelopmental Effects of Inhaled Vapors of Gasoline
and Ethanol in Rats.
P. J. Bushnell1,  T. E. Beasley1,  W. M. Oshiro1,  P. A. Evansky1,  S. A. Martin1,
V. C. Moser1,  K. L. McDaniel1,  P. M. Phillips1,  J. Norwood1,  M. E. Gilbert1,
M. M. Taylor2,  C. J. Gordon1,  C. E. Grace1 and J. M. Rogers1. 1NHEERL/ORD,
US EPA, Research Triangle Park, NC; 2MMT Inc, Durham, NC.
Gasoline-ethanol blends comprise the major fraction of the fuel used in the US au-
tomotive fleet. To address uncertainties regarding the health risks associated with
exposure to gasoline with more than 10% ethanol, we are assessing the effects of
prenatal exposure to inhaled vapors of gasoline-ethanol blends. Pregnant Long-
Evans rats are exposed to fuel vapors, 6.5 hr/day, on days 9–20 of gestation, and
their offspring are assessed for a variety of neurodevelopmental effects. This report
compares effects of inhaled gasoline vapor lacking ethanol (E0) at concentrations of
0, 3000, 6000, or 9000 ppm with previously-reported effects of inhaled ethanol
(E100) at concentrations of 0, 5000, 10000 or 21000 ppm. Maximum concentra-
tions were limited by the lower explosive limits of the vapors. As observed with
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E100, E0 vapors caused no overt maternal toxicity, changes in litter size or weight,
or weight gain of the pups. In contrast to E100, E0 did not alter locomotor activity
of adults. Both E0 and E100 produced a few minor, unsystematic changes in the
functional observational battery. In water maze tests, E100 altered search strategies
(not dose-related) and impaired memory in females (no-platform probe trials, all
doses); in contrast, E0 was essentially ineffective. No treatment affected working
memory, as assessed in operant delayed-matching-to-position tests. In an operant
reaction-time test, 21000 ppm E100 and 9000 ppm E0 increased hold failures, a
measure of impulsivity, and increased decision times at the lower doses. Responses
to a conditioned audiovisual cue were reduced in females at all doses of E100, but
were not affected by E0; neither agent affected conditioning to context.
Telemetered mean blood pressure (BP) was increased in male offspring by 9000
ppm E0 at PND 90 and 180; tail cuff tests corroborated these results at PND 180
only. E100 increased BP (tail cuff ) in males at all doses on PND90 only. This ab-
stract does not reflect EPA policy.
57 Postnatal Trichloroethylene Exposure Is Associated with
Abnormal Behavior and Alterations Global DNA
Methylation Patterns in Mouse Cerebellum.
S. Blossom1,  J. L. Rau1,  S. B. Melnyk1,  C. A. Cooney1,  S. J. James1 and
W. D. Wessinger2. 1Pediatrics, Arkansas Children’s Hospital Research Institute, Little
Rock, AR; 2Pharmacology and Toxicology, University of Arkansas for Medical
Scieinces, Little Rock, AR.
Previous studies have shown that continuous exposure throughout gestation until
the juvenile period to environmentally-relevant doses of trichloroethylene (TCE) in
the drinking water of MRL+/+ mice promoted adverse behavior associated with
glutathione (GSH)depletion in the cerebellum indicating increased sensitivity to
oxidative stress. Here we extend these findings to further characterize the impact of
TCE exposure on redox homeostasis, biomarkers of oxidative stress, transmethyla-
tion metabolites and global DNA methylation patterns in mice exposed to water
only or two doses of TCE in the drinking water postnatally from birth until 6 weeks
of age. The mice were subjected to a variety of open field behavioral tests in order to
correlate behaviors with metabolic and methylation patterns observed in our
model. Our results show that the cerebellum from male mice exposed to TCE have
lower GSH and increased biomarkers of oxidative stress compared with controls.
Methionine levels were also significantly reduced in the TCE-exposed mice which
suggested compromised cellular methylation. Global DNA methylation, including
hydroxymethylation patterns, were signiifcantly lower in the cerebellum of TCE ex-
posed mice, compared to controls. Mice exposed to TCE exhibited increased loco-
motor and exploratory activity compared to control mice suggesting increased nov-
elty seeking behavior similar to that observed in humans with attendion deficit
disorder. Understanding the mechanisms of TCE neurotoxicity during sensitive
windows of exposure is important in order to enhance mechanistic understanding
of environmentally-related neurologic disorders in susceptible populations.
58 Perfluorohexane Sulfonate (PFHxS) Causes Adult Behavioral
Disturbances in Male and Female Mice, after Neonatal
Exposure.
H. Viberg,  I. Lee,  A. Fredriksson and P. Eriksson. Environmental Toxicology,
Uppsala University, Uppsala, Sweden.
Perfluorohexane sulfonate (PFHxS) is a perfluorinated compound (PFC) used as an
industrial additive. PFC chemical properties make them suitable as surfactants and
oil -and water repellents, which are frequently used in products for packaging and
as protective coatings. However, the same properties also account for their extreme
physic-chemical stability, making them practically non-biodegradable, accumulat-
ing in the global environment, causing concern, since little is known about the tox-
icity of the compound. We recently have seen that other PFCs, like perfluorooctane
sulfonate (PFOS) and perfluorooctanoic acid (PFOA), can induce developmental
neurotoxic effects and the purpose of the present study was to explore if neonatal
exposure to PFHxS can affect behavior and cognitive function. In the present study
we exposed male and female mouse pups to a single dose of PFHxS (0.61-9.2
mg/kg bw) during the defined critical period of brain development, on postnatal
day 10. At two months of age male and female mice showed altered spontaneous
behavior in a novel home environment, affecting cognitive function. Furthermore,
these functional behavioral effects were long-lasting or irreversible since they were
once again seen at four month of age. The nicotine-induced behavior test revealed
that male and female mice neonatally exposed to PFHxS responded differently
compared to control animals, when challenged with a dose of nicotine. The present
findings show that PFHxS can cause developmental neurotoxicity, effects similar
with effects earlier reported after neonatal exposure to PFOS and PFOA and other
persistent pollutants, such as PBDEs and PCBs.
59 Acute Ozone-Induced Impairment of Glucose Regulation:
Age-Related and Temporal Changes.
V. L. Bass1,  R. C. MacPhail1,  D. L. Andrews1,  B. Vallanat1,  W. O. Ward1,
M. C. Schladweiler1,  A. D. Ledbetter1,  D. B. Johnson2,  K. A. Jarema1,
C. J. Gordon1 and U. P. Kodavanti1. 1EPHD/NHEERL/ORD, US EPA, Research
Triangle Park, NC; 2Curriculum in Toxicology, University of North Carolina at
Chapel Hill, Chapel Hill, NC.
Ozone (O3) is associated with adverse cardiopulmonary effects in humans and
thought to produce metabolic effects, such as insulin resistance. We showed that
episodic O3 exposure increased insulin levels in aged rats. We hypothesized that O3
could impair glucose homeostasis by altering insulin signaling and/or causing an
unfolded protein response (UPR) in the liver. Brown Norway rats, 1, 4, 12, 21, and
24mo old, (a model of non-obese aging) were exposed to O3 at 0, 0.25 or 1ppm,
6h/day for 2 consecutive days. As a follow-up study, 4mo old rats were exposed to 0
or 1ppm O3 over 2 days to examine the time course of response. Glucose tolerance
tests (GTT) directly followed exposure in all studies and additionally at 24h post-
exposure in the time-course experiment. Liver gene expression was examined using
Affymetrix RG-230PM Array strips. Liver and adipose tissues were also analyzed
using RT-PCR for metabolic and UPR markers. Phospho-protein analysis to assess
insulin signaling was done in the liver, adipose tissue, and muscle. GTT showed a
marked impairment of glucose clearance among 1ppm O3 exposed rats of all ages.
The reduction in glucose regulation after O3 exposure was most apparent in 1mo
rats, who exhibited no baseline glucose intolerance. The 24mo rats exhibited glu-
cose intolerance at baseline. Analyses of metabolic and acute phase response (APR)
biomarkers show that the insulin signaling pathway is altered by O3 in all three tis-
sues and serum APR proteins were increased. Selected UPR genes were upregulated
in the liver. Serum leptin increased acutely following 1 day (6h) O3 exposure.
Maximum effects of O3 on insulin signaling and APR were seen directly following
the second day of exposure. Our results suggest that glucose intolerance is a result
of metabolic changes in response to O3. These findings raise concern about ambi-
ent O3’s potential to cause predisposition towards metabolic impairment. (Does
not reflect US EPA policy).
60 Fine Particulate Matter (PM2.5) Exposure Impairs Vascular
Insulin Signaling and Exacerbates Diet-Induced Systemic
Insulin Resistance in Mice.
P. Haberzettl,  J. McCracken,  J. Lee,  A. Bhatnagar and D. J. Conklin. University
of Louisville, Louisville, KY.
Recent epidemiological studies suggest that increases in fine particulate matter
(PM2.5) air pollution contribute to the rapidly evolving epidemics of obesity and di-
abetes. Because metabolic syndrome, diabetes and air pollution all induce endothe-
lial dysfunction, and because we recently showed that short-term exposure to con-
centrated ambient PM2.5 (CAP) impairs endothelial VEGF signaling and decreases
circulating endothelial progenitor cells (EPCs), we examined the effects of CAP ex-
posure (9-30 consecutive days, 6h/d) on endothelial and systemic insulin resistance
and inflammation, adiposity and vascular function in mice fed normal chow or
high fat-diet (HFD). Surprisingly, CAP exposure impaired vascular insulin signal-
ing after only 9 or 30 days, and exacerbated HFD-induced systemic insulin resist-
ance after 30 days without increasing adiposity. Insulin sensitivity and inflamma-
tion in adipose and liver were unaltered by CAP or HFD. In contrast, CAP
exposure (30 days) impaired endothelial insulin signaling diet-independent in heart
and aorta, but HFD-dependent skeletal muscle. Changes in insulin sensitivity were
accompanied by organ-specific but not systemic inflammation and a decrease in
circulating EPCs. Collectively, our results suggest that short-term CAP exposure
provokes HFD-induced systemic insulin resistance by inducing inflammation and
endothelial insulin resistance accompanied by decreased circulating EPC levels.
Impaired vascular maintenance due to EPC suppression could contribute to vascu-
lar insulin resistance (or vice versa) thereby increasing systemic insulin resistance
and the risk for the development of T2D and CVD by PM2.5.
61 Ozone (O3): A Potential Contributor to Metabolic
Syndrome through Altered Insulin Signaling.
D. B. Johnson3,  D. L. Andrews2,  V. L. Bass1,  M. C. Schladweiler1,
A. D. Ledbetter1 and U. P. Kodavanti1. 1EPHD/NHEERL/ORD, US EPA, Research
Triangle Park, NC; 2RCU/NHEERL/ORD, US EPA, Research Triangle Park, NC;
3Curriculum in Toxicology, University of North Carolina at Chapel Hill, Chapel Hill,
NC.
Air pollutants have been associated with diabetes and metabolic syndrome, but the
mechanisms remain to be elucidated. We hypothesized that acute O3 exposure will
produce metabolic impairments through endoplasmic reticular stress (ER) stress
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and altered insulin signaling in liver, muscle and adipose tissues in the Wistar Kyoto
rats. Rats were exposed to air or 1ppm O3, 6hr/day for 1 or 2 days. Glucose toler-
ance tests were conducted immediately following each day or one day after 2-day
exposure. Tissues were analyzed for insulin and ER stress signaling and serum for
inflammation and metabolic biomarkers. O3 produced severe hyperglycemia and
glucose intolerance that was reversible following 1 day recovery. Phosphorylation of
insulin receptor substrate (pIRS) decreased after 2nd day O3 in all three organs.
Downstream mediators, phospho-serine/threonine kinase and phospho-glycogen
synthase kinase also decreased but only in adipose tissue. Serum insulin changes
were correlated with tissue levels of pIRS. Serum IL-6, thought to link ozone-in-
duced inflammation and metabolic alterations, did not increase at any time; how-
ever lipocalin and acute phase proteins increased after O3. Serum leptin was also in-
creased sharply after 1-day O3 exposure and it was correlated with O3-induced
hyperglycemia, but not glucose intolerance. Genes downstream of unfolded protein
response were changed in the liver indicating ER stress. To examine the role of liver
ER stress in O3 induced impairment of metabolism, we treated rats with ER-stress
inhibitor, salubrinal prior to air or 1ppm O3. Salubrinal did not diminish O3 in-
duced hyperglycemia and glucose intolerance, suggesting that hyperglycemia likely
did not result from ER stress. In conclusion, acute O3 exposure alters insulin sig-
naling in metabolic organs causing hyperglycemia and glucose intolerance, which
might contribute to increased incidences of diabetes and metabolic syndrome.
(Does not reflect USEPA policy).
62 Inhaled Ozone Induces Metabolic Abnormalities in Mice Fed
a High-Fructose Diet.
K. M. Allen1, 2,  P. Brooks1,  M. Dereski1,  R. Lewandowski1, 2,  I. Hotchkiss1,
D. Jackson-Humbles1,  C. Brandenberger1,  L. Bramble1, 2,  J. G. Wagner1, 2 and
J. Harkema1, 2. 1Pathobiology, Michigan State University, East Lansing, MI; 2Great
Lakes Air Center for Integrated Environmental Research, Michigan State University,
East Lansing, MI.
Results of recent inhalation toxicology studies have indicated that long-term expo-
sure of mice to concentrated ambient particulate matter induces insulin resistance
and potentiates other adverse metabolic effects brought on by consumption of a
high fat diet. Similar adverse metabolic effects on insulin signaling and glucose
homeostasis caused by gaseous air pollutants, such as ozone (O3), have not been in-
vestigated. In the present study, we tested the hypothesis that subacute inhalation
exposure to O3 enhances metabolic abnormalities, caused by a high fructose diet
(HFrD), in mice.  C57/Bl6 male mice were maintained on either a normal chow
(NC) or a HFrD (from which 60% of the calories were derived from fructose) for
the duration of the study. Mice were exposed to 0 (filtered air controls; FA) or 0.5
ppm O3, 4 h/day for 24 consecutive weekdays. No combination of exposure or diet
caused changes in glucose metabolism, as measured by oral glucose tolerance test-
ing. In contrast, mice fed the HFrD and exposed to O3 had an increased fasting in-
sulin (1519+128 ρg/mL) as compared to all other groups (NC/FA: 646+62.73,
HFrD/FA: 841+87.17, NC/O3: 535+48.32). Similarly, plasma leptin levels were
markedly increased in the HF/O3 group. HOMA-IR, an indicator of insulin resist-
ance, was also increased in the HFr/O3 (16.61+2.23) mice as compared to the
NC/FA, HFr/FA or NC/O3 mice (7.64+0.91, 7.98+0.7 and 5.23+0.44, respec-
tively). In addition, O3 exposure enhanced the severity of HFrD-induced hepatic
steatosis. Overall these data in mice suggest that subacute inhalation exposure to
O3 may induce or enhance some adverse metabolic effects caused by a HFrD. The
interaction of diet and air pollution exposure on human health requires further
study. Funded by USEPA RD83479701
63 Suppressed Responses in Heart Rate Variability during
Inhalation Exposure to Ozone and Ambient Fine Particles in
Rats on a High-Fructose Diet.
J. G. Wagner1,  H. Yang2,  K. M. Allen1,  M. Morishita2,  B. Nan2,
B. Mukherjee2,  G. Fink1 and J. Harkema1. 1Michigan State University, East
Lansing, MI; 2University of Michigan, Ann Arbor, MI.
People with diet-induced cardiometabolic disorders (diabetes, hypertension) may
be more susceptible to the adverse cardiovascular effects of air pollution. The pres-
ent study was designed to determine if a high-fructose diet affects cardiovascular re-
sponses to inhaled air pollutants. We used a mobile air research laboratory located
in an industrial area of Dearborn, MI, to expose male Sprague Dawley rats, to fil-
tered air (FA), ozone (O3; 0.5 ppm), concentrated ambient fine particles (CAPs;
400 μg/m3) or the combination of O3 & CAPs. Rats were fed a normal (ND) or
high-fructose diet (HFD) for 8 weeks prior to exposure and during exposure.
Inhalation exposures were 8h/day for 9 days (4-5 days/week). Heart rate (HR) and
ECG waveforms were collected by radiotelemetry every 5 minutes during expo-
sures, and measures of heart rate variability (HRV, indicated as SDNN and
rMSSD) were calculated and analyzed by a linear mixed model. Compared to FA-
exposed rats fed ND, rats fed HFD had significantly greater HR (328 + 27.5 vs 299
+ 35 bpm, respectively) and lower SDNN (44.6 + 78.8 vs 64.4 + 86 ms). All expo-
sures caused decreases in HR that were greater in HFD rats (25-40 bpm) than in
ND rats (6-15 bpm). However responses in HRV were dependent on the specific
exposure and diet. Exposure to O3&CAPs induced significant decreases in HRV in
ND- but not HFD-fed rats, with a 55% decrease in SDNN over the nine days of
exposure. By comparison exposure to O3 alone had the opposite effect on HRV,
with a 48% increase in SDNN, but with no effect in HFD rats. Lastly, ND-fed rats
exposed to CAPs alone had a modest decrease in SDNN (23%), while similarly ex-
posed HFD-fed rats again had no change. In summary, while HR was decreased in
all experimental groups, the degree and direction in change of HRV depends on the
specific exposure and diet. The mechanism(s) underlying altered autonomic re-
sponses in HFD rats to single- or multi-pollutant exposures requires further study.
US EPA RD83479701
64 Oxidative Stress and the Acceleration of Atherosclerosis in
Susceptible Mice after Exposure to Semivolatile Components
of Ultrafine Particulate Matter.
A. J. Keebaugh1,  P. Pakbin2,  L. B. Mendez1,  Z. Ning2,  G. Gookin1,  C. Sioutas2
and M. T. Kleinman1. 1Community and Environmental Medicine, University of
California Irvine, Irvine, CA; 2Environmental Engineering, University of Southern
California, Los Angeles, CA.
Exposure to ultrafine particulate matter (UF-PM) has been associated with adverse
cardiovascular health effects. UF-PM contains semi-volatile organics (SVOCs) that
are bound to particles but can partition to the vapor phase after emission. SVOCs
contain species such as polycyclic aromatic hydrocarbons and quinones that can in-
duce oxidative stress and may be responsible for the exacerbation of cardiovascular
disease by UF-PM. Therefore, we hypothesized that the removal of SVOCs from an
aerosol should decrease the ability of the particle to cause oxidative damage and
consequently the acceleration of atherosclerotic plaque formation. ApoE -/- mice,
which are prone to developing atherosclerosis, were exposed to UF concentrated
ambient particles (CAPs), CAPs with the SVOC components removed, or SVOC
components without the particle core. A control group was exposed to purified, fil-
tered air. Particles were concentrated using a VACES, and SVOCs were separated
from the particle core using a thermal denuder. The exposures took place 5
hours/day, 4 days/week for 8 weeks in downtown Los Angeles, 100m downwind of
a major freeway. Plaque formation in the aortic arch and total and LDL cholesterol
in the serum were measured to evaluate the progression of atherosclerosis. Serum
concentrations of lipid peroxidation, protein carbonyl content, and glutathione
were assessed to determine systemic oxidative stress. Aortic plaque formation in
mice exposed to unmodified CAPs was higher than in those exposed to CAPs with
no SVOCs. Similarly, higher levels of lipid peroxidation were measured in mice ex-
posed to unmodified CAPs and SVOC components of CAPs compared to those ex-
posed to CAPs without SVOCs. The corresponding trends in plaque formation and
lipid peroxidation support the notion that exposure to SVOCs may contribute to
the acceleration of atherosclerosis via an oxidative stress pathway.
65 Acrolein-Induced Increases in Blood Pressure and Heart Rate
Are Coupled with Decreased Blood Oxygen Levels during
Exposure in Hypertensive Rats.
C. M. Perez1,  A. D. Ledbetter2,  M. S. Hazari2,  N. Haykal-Coates2,  A. P. Carll1,
D. W. Winsett2,  D. L. Costa3 and A. K. Farraj2. 1University of North Carolina at
Chapel Hill, Chapel Hill, NC; 2Environmental Public Health Division, US EPA,
Research Triangle Park, NC; 3ORD, US EPA, Research Triangle Park, NC.
Exposure to air pollution increases the risk of cardiovascular morbidity and mortal-
ity, especially in individuals with pre-existing cardiovascular disease. Recent studies
link exposure to air pollution with reduced blood oxygen saturation suggesting that
hypoxia is a potential mechanism that mediates the adverse cardiovascular effects of
air pollution. The purpose of this study was to characterize the cardiovascular ef-
fects of exposure to acrolein, a potent irritant and component of cigarette smoke
and diesel exhaust and determine if acrolein exposure causes decreased blood oxy-
gen levels. We hypothesized that hypertensive rats would be more sensitive to the
adverse cardiovascular effects of acrolein and that the cardiovascular effects of
acrolein would be coupled with decreased arterial blood oxygen levels during expo-
sure. Spontaneously hypertensive (SH) and Wistar Kyoto (WKY; rats with normal
blood pressure) rats implanted with biopotential radiotelemetry transmitters were
exposed once for 3 hours to 3 parts per million acrolein gas or filtered air (control)
in whole body plethysmograph chambers while cardiovascular and ventilatory pa-
rameters were monitored. In a separate cohort of rats, arterial blood samples were
drawn before, during, and after exposure to acrolein to monitor blood oxygen satu-
ration. We found that hypertensive, but not normal rats, had significant increases
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in heart rate, blood pressure, breathing frequency, and minute volume during
acrolein exposure. These effects were coupled with significant decreases in arterial
blood pO2 and K+ levels and significant increases in pCO2. The data suggest that
hypertension predisposes to the adverse health effects of air pollution exposure and
that hypoxia may have an important role in mediating these physiologic responses
(This abstract does not reflect EPA policy).
66 PM2.5 Exposure and Rage: Insight into an Emerging Risk
for Diabetes.
J. M. Vaughan,  J. T. Zelikoff,  B. Narayanan,  A. Schmidt and L. Chen.
Environmental Health Science, New York University, Tuxedo, NY.
Diabetics are a particularly vulnerable population to the adverse cardiopulmonary
effects of particulate air pollution (PM)-often attributed to enhanced inflammation
and endothelial dysfunction. Recent reports have implicated activated receptors for
advanced glycation end-products (RAGE) as an integral factor in the inflammatory
processes of cardiovascular dysfunction and diabetes; nonetheless, it is unclear
whether ambient PM alone/or in combination w/ other endogenous factors may
contribute to RAGE activation. Levels of soluble RAGE (sRAGE) were measured
in human serum samples (n=60) from two cities in Gansu, China (Jinchang (JC)
and Zhangye (ZH)-albeit similar ambient levels of PM; Ni, Cu, As, and Se in JC
were 76, 25, 17, and 7 fold higher than ZH, respectively). In addition, human pul-
monary endothelial cells were exposed to PM (collected from the same region) to
investigate RAGE-mediated vascular dysfunction. Lastly, to examine the link be-
tween PM and overt diabetic endpoints, B6C3/F2 mice were exposed to concen-
trated ambient PM (CAPS). Results: sRAGE was significantly higher (p=0.04) in
residents of JC (538.7±37.5ng/ml) than that measured in ZH (452.6±29.1ng/ml).
Multiple regression analyses revealed PM2.5 concentration as a significant (p=0.03)
predictor of RAGE outcome. In the in vitro work, after 48h of PM2.5 exposure, a
dose dependent increase in cell proliferation and small increases in sRAGE activity
at higher doses of PM was evident. Immunofluorescence detection showed an ele-
vation in cells positive for membranous RAGE expression; accompanied w/ a 2-fold
increase in mRNA for RAGE & NF-κB and >2 fold increase of ATF4 & NF-κB in
cells treated w/ PM+BSA. These findings suggest plausible interaction between PM
& RAGE resulting in enhanced expression of NF-κB, ATF4 and RAGE. Finally,
preliminary mouse exposures have yielded supportive findings: progeny of CAPs
exposed pregnant mice have shown significantly decreased glucose tolerance com-
pared to controls (p=0.03). Collectively, these data offer valuable insight into PM-
mediated RAGE activation / its influence on diabetes.
67 Integration of Jacketed Telemetric Hemodynamics in a
Toxicology Study Design: Assessment of Sensitivity and
Distribution and Impact of Erroneous Values.
H. Holzgrefe,  S. Tichenor,  R. Kaiser and D. Meyer. Toxicology, Charles River
Laboratories, Reno, NV.
Integration of telemetered hemodynamics in toxicology studies is an emerging
trend which offers detailed information on potential cardiovascular safety issues
that are only identified with repeat dosing. Jacketed external telemetry (JET) is an
enabling technology for which the intrinsic variability of the associated minimally
invasive blood pressure (BP) device (PA-C10, DSI, St. Paul, Minn.) has not been
extensively characterized. Accordingly, we evaluated the intrinsic and extrinsic beat-
to-beat pressure measurement errors of JET BP in 10 male cynomolgus monkeys
(2.7-3.7 yrs, 3.0±0.2 kg). BP catheters were advanced to the descending aorta via
the femoral artery. BP (24 h) was continuously digitized (500 Hz) in a quiet radio
frequency environment and retrospectively analyzed in beat-to-beat increments
(Life Sciences Suite, ver. 5.0, DSI). Data are presented as mean±std. Sham dosing
occurred at 2.5 h post acquisition start to mimic a typical toxicology study design.
Erroneous values were categorized as beats where either systolic pressure, pulse
height, and/or +dP/dt were 60<>240, 20<>80, or 600<>4000 native units, respec-
tively. Transducer stability was assessed as the beat-to-beat change (Δ) in systolic
pressure. Over 24 h, systolic pressure was 130.6±8.5 mmHg and Δ was 0.0±2.67
mmHg. During a quiescent nocturnal period (10 h) systolic pressure was
131.9±8.5 mmHg and Δ was 0.0±2.42 mmHg. Erroneous values (8874/2428462
beats, 0.36%) were infrequent and temporally random. These data confirm that the
JET BP device conformed to, or exceeded, design sensitivity (± 3 mmHg) at all
times. Systolic pressures exhibited stable diurnal variances of ± 8.5 mmHg yielding
~ 80% power to detect a 10 mmHg change (p<0.05) with n=6. The sparse, spo-
radic incidence of non-physiologic hemodynamic values was insufficient to influ-
ence mean BP values aggregated over times ≥ 5 min. Consequently, resources de-
voted to the beat-to-beat filtering of JET BP values will not improve the accuracy,
precision, or power of these data.
68 Evaluation of an in Line Filter for Reducing Noise in
Subcutaneous Telemetered ECGs.
C. M. Kelly1,  M. Miyamoto1,  M. Brockway2 and B. Brockway2. 1Huntingdon
Life Sciences, East Millstone, NJ; 2VivaQuant, St. Paul, MN.
EMG noise and movement artifact are barriers to obtaining accurate interval meas-
urements in ambulatory subjects in preclinical studies. Herein we report the results
of testing of a new device, an In Line Filter (ILF) that employs Multi-Domain
Signal Processing™ (MDSP) technology, for real-time noise and artifact suppres-
sion in telemetered subcutaneous ECG recordings. Prior evaluations of MDSP
technology using ECGs already acquired by the Dataquest™ system showed that it
reduces the amplitude of in-band noise by > 95% without distorting ECG mor-
phology and provides a corresponding increase in the number of analyzable beats.
In this work, studies of ILF performance were conducted using freely moving sub-
jects instrumented with DSI™ D70-PCT telemetry transmitters. An ILF was in-
serted between the telemetry receiver and the Dataquest system to filter out noise.
Raw and filtered ECG signals were collected from multiple species commonly used
in safety studies and were analyzed with emka ECGauto using standard methods.
Results obtained from filtered and unfiltered recordings were evaluated to assess the
impact of filtering on parameter measurement accuracy, the increase in beats avail-
able for analysis, and the amount of labor required to perform interval analysis.
Results show that, on average in all species tested, filtering the ECGs using the ILF
prior to analysis increased the analyzable portion of the data to roughly that re-
ported in the literature for telemetered epicardial and intravenous ECG sensors and
significantly reduced the amount of labor required to perform interval analysis.
There was no degradation in the accuracy of parameter measurements as a result of
filtering the signal. Use of the ILF could make routine beat-to-beat analysis of 24-
hour subcutaneous ECG recordings practical and cost-effective without the com-
plications and complexities associated with epicardial, endocardial, and intravenous
ECG sensing leads.
69 The Application of Telemetry EEG and EMG in Conscious
Dogs and Monkeys for Safety Assessment and Translational
Science.
X. Cheng,  C. Cao,  N. N. Niu,  K. H. Chen,  S. L. Sun and A. Hu. Toxicology
and Safety Pharmacology, Pharmaron, Beijing, China.
The species differences are the common and major concerns in safety assessment
and translational science, particular in situations where results from CV and CNS
safety studies in the same species are required or the receptor subunits expression
are significantly difference cross species etc. In this study, we have used the radio-
telemetry technique to record EEG and EMG form conscious, non-sedated dogs
and monkeys and validated the model with a proconvulsant, pentylenetetrazole
(PTZ).
Beagle dogs and cynomolgus monkeys were implanted with four electrodes
epidural over the motor cortex and connected to the radio-transmitter (DSI) placed
subcutaneously in the lateral neck region. Two additional electrodes were inserted
into the ridge cervical muscle for EMG recording simultaneously. The signals cap-
tured by the receiver were routed via a data matrix board to a PC and sampled at a
rate of 500Hz.
Subcutaneous (s.c) administration of PTZ dose-dependently (10, 20 and 50 mg/kg
s.c) induced paroxysmal activity, clonic convulsion and tonic convulsion in both
dogs and monkeys, indicating a remarkable CNS safety issue of PTZ as positive
control article. When PTZ administrated i.v at 1.5mg/kg/min and 1.5mL/min,
both dogs and monkey showed similar level of paroxysmal spike-and-wave activity
associated with clonic convulsions occurred between 17 and 36 min after the start
of infusion at 4-5Hz. 
The data indicate that the electroencephalogram (EEG) and electromyogram
(EMG) are the most sensitive and valuable biomarkers in identifying pathologic
CNS activity, in particular for safety pharmacology evaluation and translational ap-
plication.
70 Established Method to Assess Cardiorespiratory Parameters
in Inhalation Safety Pharmacology Studies in Conscious
Beagle Dogs.
T. Ziegelhofer,  J. Sheehan,  J. Sentz,  M. Miyamoto and A. Curran. Safety
Pharmacology, Huntingdon Life Sciences, East Millstone, NJ.
A critical aspect of cardiorespiratory safety pharmacology studies is the collection of
good quality cardiovascular and respiratory data immediately prior to dose, during
dose and immediately after dose to be able to recognize any acute effects of the test
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article. This is especially challenging when the test article is administered via in-
halation. This poster describes the method for achieving a successful outcome in
these types of studies, including the factors that must be considered in the design
and execution. Effects of proper habituation to equipment and carefully scheduled
study activities were assessed based on the overall character of cardiorespiratory re-
sponse from 3 different studies.
Prior to the first data collection, all animals were surgically implanted with DSI
telemetry transmitters and habituated to the exposure/data collection system.
Respiratory parameters were collected using respiratory inductance plethysmogra-
phy (RIP). Telemetry data were collected continuously while animals were in their
home cage, after transfer to the exposure suite but prior to either air or the vehicle,
during the exposure period, and for 24 hours post dose in 3 different studies. Each
study used a different vehicle and an air (sham) control was administered to assess
the vehicle effect.
Administration of the vehicle produced no effects on blood pressure, heart rate,
body temperature, respiratory rate, tidal volume and minute volume during pre-
dose, exposure period and for the 24 hour post dose recording period when com-
pared to air (sham) control in all 3 studies. Very similar patterns in blood pressure
and heart rate were noted in all 3 studies; however, each study has a specific pattern
for body temperature and respiratory parameters, which was attributed to individ-
ual variation in these parameters. This poster presents a consistent and reliable
method of collecting cardiorespiratory data from conscious beagle dogs prior to,
during and after inhalation exposure in our Testing Facility.
71 Assessment of QT-Interval Prolongation in Nonclinical
Safety Study Using External Telemetric Device in Conscious
Beagle Dogs: Application of QT Shift and Probabilistic
Methods.
L. Renaud1,  P. Champeroux2,  S. Ruillon1,  N. Velasquez1,  P. Desbois1,
O. Wattrelos1 and N. Claude1. 1Drug Safety, Servier, Gidy, France; 2Centre de
Recherches Biologiques, CERB, Baugy, France.
The detection of delayed ventricular repolarization, characterized by a QT interval
prolongation, is one of the main issues for the preclinical evaluation of potential
risk of pro-arrythmia for a new drug candidate. This study was designed to compare
different methods of QT interval prolongation assessment in conscious beagle dogs
using external telemetric device. The same 6 dogs (3/sex) were given vehicle or ref-
erence compounds known to induce QT interval prolongation using a sequential
design (single oral dosing of Sotalol at 30 mg/kg and Moxifloxacin at 30 then 90
mg/kg or repeated oral dosing for 6 days of Thioridazine at 20 mg/kg/d and
Terfenadine at 30 mg/kg/d). Electrocardiograms were recorded during a treatment-
free period and on day 1 and/or day 6 for approximately 20 h post dosing. QT in-
tervals were measured from a beat to beat analysis over 10-min periods centred on
selected timeslots and corrected according to the Van de Waters formula (QTvdw).
QT shift calculations and an analysis based on the principles of the Holzgrefe’s
probabilistic method (QTh, using a minimum 250 beats/timeslot) were also per-
formed. All methods allowed an accurate evidence of QT effect for Sotalol and
Moxifloxacin. The QT shift and QTh methods gave more evidences for
Terfenadine effect than QTvdw. As expected, the marked increase in heart rate
(HR) induced by Thioridazine resulted in no apparent effect on QT and a statisti-
cally significant overcorrection for QTvdw whereas QT shift and QTh gave more
accurate and reliable results. The statistical sensitivity threshold detection of QT
prolongation was low, i.e. 10 to 15 ms for QT shift and QTh methods. Thus, ex-
ternal telemetry in non-clinical safety dog studies allows new perspectives for a bet-
ter assessment of QT prolongation when associated to QT shift and Holzgrefe’s
probabilistic methods, especially in case of slight drug-induced QT effect or
marked changes in HR.
72 Integration of Automated Patch Clamp Systems and Logistic
Models in the Cardiochannelgramtm (CCGTM) for Better
Prediction of Cardiac Risk.
J. W. Kramer1,  G. J. Myatt2,  C. A. Obejero-Paz1,  A. Bruening-Wright1,
Y. A. Kuryshev1 and A. M. Brown1. 1ChanTest Corporation, Cleveland, OH;
2Leadscope Inc., Columbus, OH.
Drug-induced inhibition of the cardiac hERG potassium channel is recommended
by ICH and FDA to predict delayed cardiac repolarization (DR) and cardiac risk.
The consequent QTc prolongation is a surrogate marker of Torsade de Pointes
(TdP), a rare but potentially lethal iatrogenic outcome. Drugs with effective thera-
peutic plasma concentrations (ETPC) within 30-fold of their hERG IC50s are
thought to be dangerous despite the fact that multiple ion channel effects (MICE)
can mitigate DR. Here we demonstrate that logistic regression models, which inte-
grate MICE, predict TdP with much greater certainty than the hERG safety ratio
(hERG IC50/ETPC or safety margin (SM)) alone. To this end we measured hERG,
Nav1.5,Cav1.2, Kir2.1 and KvLQT1/minK IC50 values of 56 drugs (33 +TdP and
23 -TdP) from multiple classes using automated patch clamp systems including
Qpatch and PatchXpress. The sensitivity of the automated patch clamp platforms
was evaluated in a comparison to manual patch clamp. ETPC values and the tor-
sadogenic liability of drugs was obtained from the literature, package inserts and
Arizona CERT. Eleven logistic regression models were constructed; one using the
hERG SM alone, the others integrating hERG SM, Nav1.5 SM and/or Cav1.2 SM
data. The predictive power of each model was evaluated using the likelihood ratio
test. Leave-one-out cross validations were performed and each model’s accuracy was
determined by comparing receiver–operating characteristics (ROC, sensitivity vs.
1-specificity). Models that include Nav1.5, Cav1.2 or both variables are statistically
significant better predictors of TdP liability than the model that contains only
hERG (Model 1). Model 1 had a ROC area under the curve (AUC) of 0.80 and
Model 11, that includes hERG, Nav and Cav1.2 SMs, significantly improved accu-
racy showing a ROC AUC of 0.94. Thus, Model 11 that incorporates the concept
of MICE in the CardioChannelGramTM (CCGTM) is a robust nonclinical pre-
dictor of cardiac risk.
73 Characterization of Jacketed External Telemetry with Blood
Pressure in Conscious Nonhuman Primates in Pen-Style
Housing Administered Etilefrine, Sotalol, or Hydralazine.
L. Kreckler,  J. Kopshinsky,  J. Schneider,  G. Hanson,  D. Morris and C. Foley.
Covance Laboratories, Inc., Madison, WI.
An important component of nonclinical safety assessment is the evaluation of elec-
trocardiography (ECG) and hemodynamic parameters. Jacketed external telemetry
with an implanted telemetry blood pressure transmitter (JET-BP) is a minimally in-
vasive technology being utilized in general toxicology studies to assess ECG and
blood pressure measurements in conscious, unrestrained animals. We characterized
JET-BP in nonhuman primates (NHPs) housed in pen-style caging with three ref-
erence compounds with known effects on blood pressure or ECG parameters.
Thirty-six male NHPs were implanted with a telemetry blood pressure device and
group-housed in pen-style caging (3 animals/pen). Four animals per group were
given reference material or a concurrent control article. Etilefrine, a sympath-
omimetic, was given at 1 or 10 mg/kg; hydralazine, a vasodilator, at 1 or 10 mg/kg;
and sotalol, a non-specific β-blocker, at 3 or 30 mg/kg. JET-BP measurements were
recorded for at least 90 minutes prior to dosing and continuously for at least 20
hours postdose. The following ECG and hemodynamic parameters were deter-
mined as one (light phase) or two-hour (dark phase) averages: PR, QT and rate-cor-
rected QT; systolic, diastolic, and mean arterial pressures; heart rate; and arterial
pulse pressure. In addition, blood was collected at seven postdose timepoints for
each test article for pharmacokinetic analysis. Etilefrine significantly increased
mean arterial pressure, systolic blood pressure and pulse height, while diastolic
blood pressure remained unchanged. Sotalol significantly prolonged QT with no
significant change in blood pressure. Administration of hydralazine did not signifi-
cantly change blood pressure at the dose levels administered. In summary, ECG
and blood pressure changes caused by three different reference compounds were de-
tectable using JET-BP technology in group-housed NHPs.
74 Differential Cardiovascular Physiology and Pathology in
Selected Lineages of Miniature Swine.
A. Stricker-Krongrad1,  T. J. Madsen1,  B. C. Hanks1, 2,  D. Brocksmith2,  J. Liu1,
L. D. Brown1, 2 and G. F. Bouchard1, 2. 1Sinclair Research Center, LLC, Columbia,
MO; 2Sinclair BioResources LLC, Auxvasse, MO.
The miniature swine has been increasingly recognized as a valid alternative to ca-
nine and non-human primates in regulatory toxicity. This poster presents the re-
sults of cardiovascular assessments in the Yucatan, Hanford, and Sinclair miniature
swine conducted during clinical investigations and control toxicity testing.
Anatomic parameters were obtained at necropsy. Blood vessels diameter, velocity,
and flow were obtained by Doppler ultrasonography. Cardiac electrophysiology was
obtained using clinical ECG and surgical monitor units. Macroscopic lesions and
histopathology assessments were conducted on heart and kidneys. Data were com-
pared to published measurements of adult human illustrating similarities or differ-
ences (for practicality, male data are reported here). Across the three lineages, heart-
to-body weights ratio ranged from 0.41 to 0.50 and were higher than human
(0.42). The geometric corrections for heart rate adjustment to body size ranged
from 215 to 297 and were comparable to human (241), indicating that heart vol-
ume and function were well adjusted to the reduction in body size. The miniswine
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hearts showed a coronary artery distribution comparable to human. The right coro-
nary internal diameters ranged from 1.44 to 1.79 mm and were comparable to
human (3.9 mm) when adjusted to body surface area (weight range: 10-30 kg).
External femoral blood flows at rest averaged 93 mL/min and were slightly lower
than human (260 mL/min) when adjusted to body size. Electrophysiological heart
segments duration (e.g. RR ranged from 360 to 662 msec) and their ratio (QT/RR)
were proportional to human and well-adjusted to body size. Macroscopic lesions
were nonexistent. Histopathology findings were rare and limited to sub-level my-
ocardial inflammation with low incidence in the Hanford lineage. In conclusion,
the similarities between the cardiovascular systems make these three lineages of
miniature swine suitable animals to model the human counterpart.
75 Whole Heart Energetics and Stress Test As an Indicator of
Drug-Induced Cardiac Toxicity.
K. A. Henderson1,  R. Borders1,  J. Ross1,  A. Jalil2,  W. Brandon1,  J. Ma1 and
R. M. Brian1. 1Battelle Memorial Institute, Columbus, OH; 2Ohio State University,
Columbus, OH.
Cardiac toxicity, manifested as compromised contractility or ischemic heart disease,
comprises 26.9% of post-approval drug failures. The heart has a high demand for a
constant energy supply which can be affected by many sources of stress and thus
may be a good indicator of potential toxicity. The purpose of this research was to
utilize the ex vivo heart model to assess contractility and whole heart energetics in
response to drugs with known/unknown mechanisms of toxicity. We used FCCP
and verapamil as positive and negative controls and doxorubicin (dox), doxoru-
bicin-ol, sunitinib, and sorafanib as the chemotherapies associated with latent toxi-
city. Rat hearts were removed, perfused with Modified Henseliet Krebs, and LVP
was monitored via insertion of a fluid-filled balloon. The perfused heart was in-
serted into an 11.7 NMR magnet. Whole heart phosphogen content was assessed
before and during 60 min of drug exposure and then during 20 min of 0.1μM iso-
proterenol (iso) with drug to assess energy reserve. Control heart contractility and
energetics were stable throughout the experiment until the iso challenge, where
contractility increased as expected and PCr and ATP decreased and Pi increased.
FCCP treated hearts showed a decline in contractility and PCr and reduced reserve
during the iso challenge. Verapamil treated hearts did not change in energetics dur-
ing treatment or during the iso challenge. Dox increased contractility, while the
other chemotherapies showed very little change in contractility during drug treat-
ment. Dox treated hearts demonstrated a drop in Pi, PCr, and ATP. In addition,
during the iso challenge contractility increased compared to control and PCr de-
creased. Dox and sorafanib may be enhancing part of the beta–agonist pathway,
causing a more pronounced response to iso and thus resulting in an increased work
load for the heart. This may be a possible pathway to investigate as a mechanism for
latent toxicity, as well as an early indicator of potential drug induced cardiac issues
after treatment.
76 Simultaneous Recording of Action Potentials and Calcium
Transients from Stem-Cell Derived Cardiomyocytes:
Applications for Cardiotoxicity Testing.
R. Whittaker1,  F. Cerignoli1,  R. Vega1,  R. Ingermanson1,  R. Towart2,
D. Gallacher2,  M. Mercola3 and J. Price1, 3. 1Vala Sciences Inc, San Diego, CA;
2Center of Excellence for Cardiovascular Safety Research, Janssen Pharmaceuticals,
Beerse, Belgium; 3Sanford-Burnham Medical Research Institute, La Jolla, CA.
Current methods for preclinical cardiotoxicity testing generally examine the effects
of candidate compounds on the activity of single ion channels using manual or pla-
nar patch clamp methods. Limitations in these assays require that the tests be per-
formed with cell lines which stably express the ion channel of interest. This reduc-
tionist approach grossly underestimates the complexity of cardiomyocyte
excitability and physiology. We have developed a new automated image cytometer
and associated software which facilitates a more physiologically relevant test of
compound effects on cardiomyocyte excitation-contraction coupling. This new ap-
proach utilizes a dual channel automated Image cytometer that allows for simulta-
neous measurement of the cardiomyocyte action potential and calcium transient
using voltage and calcium sensitive dyes. By using these advanced imaging tech-
niques this system frees the need for the assay apparatus to interact physically with
the cells, allowing the use of a wide array of cell types including more clinically rel-
evant models such as cardiomyocytes derived from human induced pluripotent
stem cells (hIPSC). Here we demonstrate the application of this system to a small
scale screen of known cardioactive compounds in hIPSC derived cardiomyocytes.
Our results suggest that the ability to identify perturbations in the cardiomyocyte
action potential and/or calcium transient due to exposure to cardioactive com-
pounds is on par with existing technologies. However, this system demonstrates a
much higher throughput than existing systems and provides a more complete
analysis of compound effects on exicitation-contraction coupling in the cardiomy-
ocyte.
77 Effect of Cell Culture Media on the Growth and Viability of
Neonatal Rat Cardiomyocytes.
L. Baeva,  D. Chan,  H. Dinesdurage,  M. W. Betz and R. P. Brown. CDRH, US
FDA, Silver Spring, MD.
We studied the suitability of serum-free medium, reduced serum medium, and
chemically defined medium with serum replacement for growing rat neonatal car-
diomyocytes. The cardiac cells were grown for up to 48 hours under six different
culture conditions: the base make up (Dulbecco’s Modified Eagle Medium (
DMEM) containing 100 μM BrdU, 10 mM HEPES, 50 U/mL penicillin and
50μg/mL streptomycin) with 10% Fetal Bovine Serum (FBS)-(A), or 10% Goat
Serum- (C), or 10% Knockout Serum Replacement (KRS)- (D) or no serum – (B);
Knockout DMEM(Gibco) (E) and Advanced DMEM(Gibco) (F) were supple-
mented by 15%
KSR and 2% FBS, respectively. The beating rates and viabilities of the cells were
evaluated by counting the beats of cells under a phase contrast microscope and
Neutral Red Assay method, respectively. The cell damage and cytotoxicity were de-
termined by measuring lactate dehydrogenase (LDH) activity and the troponin I
release from the cardiomyocytes were examined by rat cardiac Troponin ELISA.
The results indicate poor cell beating and viability for medium C without serum.
The media D, E, and F had relatively low background troponin level, provided
good viability and morphology and low cytotoxicity, and may be used for the car-
diotoxicity study.
78 Understanding the Relationship of PI3K Inhibition to
HERG Liabilities and QT Prolongation.
D. Puppala1,  H. Cheng3,  A. Rosado2,  K. McKiernan2,  S. Sun2,  B. Fermini2 and
K. Leach1. 1Compound Safety Prediction, Pfizer Inc, Groton, CT; 2Global Safety
Pharmacology, Pfizer Inc, Groton, CT; 3Oncology Medicinal Chemistry, Pfizer Inc,
Groton, CT.
Off target promiscuity is one of the biggest issues that kinase targeting drug discov-
ery teams have to overcome in order to achieve efficacy with limited toxicity. In a
recent paper, Zhongju Lu et al (Science Translational Medicine 25 April 2012 Vol 4
Issue 131) showed that suppression of Phosphoinositide 3-Kinase(PI3K) signaling
directly or indirectly via tyrosine kinase inhibition prolongs the QT interval by af-
fecting multiple ion channels, including HERG. In an effort to understand the role
of PI3K inhibitors and HERG channels, we investigated the effects of Pfizer PI3Ka
inhibitors both in a Dofetilide binding assay that determines their affinity for
HERG channels as well as in a patch clamp assay that assesses their functional ac-
tivity on these channels. Out of 48 PI3K inhibitors selected from four structurally
distinct series and with PI3Ka Ki less than 1 nM, 47 exhibited Dofetilide Ki values
> 10 uM, and one demonstrated a Ki value of ≈ 2.0 uM, a concentration > 2000-
fold above its kinase activity. 8 compounds, including the one with a Dofetilide Ki
of 2.0 uM, were tested in the HERG functional assay and all showed IC50 values >
30 uM.
In addition, 16 marketed drugs, which are known HERG blockers and that have
been shown to induce QTc prolongation (14/16) and/or cause Torsades de Pointes
in the clinic (8/14), were tested in a PI3Ka enzyme assay. Only Verapamil, a cal-
cium channel blocker that inhibits HERG current (IC50: 0.2 uM) but does not
prolong the QTc interval or cause TdP in the clinic exhibited activity on PI3Ka
(IC50: 33 uM), while the rest showed IC50 > 100 uM. 
In summary, the data obtained from both Pfizer potent PI3Ka inhibitors and mar-
keted drugs demonstrate the absence of the correlation between PI3Ka inhibition
and HERG activity. 
Furthermore, our results support the notion that HERG inhibition, in the absence
of PI3K inhibition, is sufficient to prolong the QT interval.
79 Characterization of Cell Signaling Events in Human
Cardiomyocytes.
S. Eldridge1,  M. Davis1,  J. Mussio2 and R. Parchment2. 1DCTD, NCI, Bethesda,
MD; 2SAIC-Frederick, Frederick National Laboratory for Cancer Research, Frederick,
MD.
Cardiotoxicity is a significant concern for anticancer therapeutics. “On-target” tox-
icity may result when a drug target that regulates cancer growth also serves an im-
portant role in normal cardiac function. To explore mechanisms of cardiac toxicity
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associated with anti-cancer agents, in vitro approaches are key investigative tools.
iCell® cardiomyocytes (Cellular Dynamics International, Madison, WI) are highly
purified human cardiomyocytes derived from induced pluripotent stem cells
through reprogramming adult cells, and are becoming widely used for the assess-
ment of cardiac toxicity. To begin to inform the utility of these cells to monitor cel-
lular events involved in critical cardiac myocyte signaling, we measured expression
and activity of ErbB receptors, Erk1, Erk2, AKT, troponins, and endothelin-1 (ET-
1) receptors A and B. Untreated iCell® cardiomyocytes expressed ErbB2 and
ErbB4 receptors, Erk1, Erk2, AKT, cardiac troponin I, cardiac troponin T and ET-
1 receptors A and B, but not ErbB1 or ErbB3 receptors. Furthermore, treatment
with neuregulin-1 (a natural ligand for ErbB4) activated ERK1/2 and AKT as
demonstrated by increased levels of phosphorylated proteins measured by western
blotting with phospho-specific antibodies. Ligand-activated ErbB2/ErbB4 signal-
ing was both dose and time dependent. We also examined the effect of tyrosine ki-
nase inhibitors (lapatinib, sorafanib and staurosporine) and anthracyclines (doxoru-
bicin) on cell death and mitochondrial membrane potential (MMP) using a high
content multiplexed imaging system, and on troponin release into the cell culture
media using the Meso Scale Discovery® platform. All of these anticancer agents in-
duced a dose-dependent release of cardiac troponins I and T and caused a reduction
in MMP. Based on these results, this model may present an opportunity to explore
and “back-translate” mechanisms of cardiotoxicity using human cardiomyocytes in
vitro. Funded by NCI Contract No HHSN261200800001E.
80 Mitochondria and Intrinsic Apoptotic Pathway Mediate
Cardiac Toxicity of Environmentally Persistent Free Radicals
(EPFR).
G. C. Chuang1,  B. Dellinger2 and K. J. Varner1. 1Pharmacology, Louisiana State
University Health Sciences Center, New Orleans, LA; 2Chemistry, Louisiana State
University and A&M College, Baton Rouge, LA.
Epidemiology studies have linked combustion-derived particulate matter to in-
creased cardiac morbidity and mortality. To conduct prospective controlled-expo-
sure studies, we synthesized the model EPFR, DCB230, by chemisorption of 1,2-
dichlorobenzene to 0.2 μm silica particles containing 5% Cu(II)O at 230°C.
Electron paramagnetic resonance showed that DCB230 generates radicals in solu-
tion similar to those produced by EPFRs found in environmental samples. We have
shown that DCB230 inhalation produces inflammation and oxidative stress in
both lung and heart. Since oxidative stress and apoptosis are mechanisms impli-
cated in cardiac injury, we hypothesized that DCB230 exposure exerts cardiotoxic-
ity by activating apoptotic pathways. HL-1 cardiomyocytes were dosed with 0-200
μg/mL DCB230 for 8 h and assessed for cytotoxicity and apoptotic markers.
DCB230 dose-dependently increased lactate dehydrogenase (LDH) release, a
marker of late cell death. Caspase 3, caspase 9, and poly (ADP-ribose) polymerase 1
cleavage also increased concomitant with DCB230 concentration, indicating apop-
totic signaling activation. Next, HL-1 cardiomyocytes were treated with 0-200
μg/mL DCB230 for 2 h to examine early signaling events. While neither LDH re-
lease nor caspase 3 cleavage were detected after 2 h, increased caspase 9 cleavage
suggests that mitochondrial dysfunction initiated early intrinsic apoptotic signal-
ing. Confocal microscopy showed that mitochondrial membrane potential de-
creased after 2 h treatment with DCB230. Lastly, fluorescence data was validated as
mitochondrial via FRET and co-localization with MitoTracker Green. Taken to-
gether, DCB230 exposure depolarized mitochondria in cardiomyocytes, leading to
the activation of canonical intrinsic apoptotic signaling and resulting in cell death.
Future studies will assess mitochondrial permeability transition and autophagy as
contributing mechanisms. Supported by NIH P42-ES013648, sub-award 61365.
81 Evaluation of Cellular Impedance Assays for Drug Screening
in Cardiomyocytes.
M. Peters,  C. W. Scott,  S. D. Lamore and Y. P. Dragan. Safety Assessment,
AstraZeneca, Waltham, MA.
Cardiovascular (CV) toxicity is a leading contributor to drug withdrawal and late-
stage attrition. Earlier screening is a validated approach to build-in CV safety, as
demonstrated for hERG screening to reduce arrhythmia. There is an urgent need
for novel in vitro assays to extend this success to contractility, heart rate, hypertro-
phy, structural damage, and non-hERG arrhythmia. Advances in cellular imped-
ance technology enables label-free tracking of spontaneous synchronized beating of
cultured cardiomyocytes (CM). To validate and translate CM impedance assays, we
tested a set of drugs with established CV effects in humans- 22 neg. inotropes, 8
pos. inotropes, and 21 inactives (previously tested in canine CM Tox Appl Pharm
260(2):162). The data clearly indicate that beat rate and amplitude are independ-
ent variables, capable of providing robust potency data. Consistent with the balance
of negative inotropes, the most frequent response was a dose-dependent decrease in
amplitude until beating stopped. The cessation of beating was not linked to cyto-
toxicity (judged by ATP and cell index) indicating specific changes in CM func-
tion. Since rat neonatal (and stem cell-derived) CMs have a negative frequency-
force relationship, it is not surprising that the decrease in amplitude was linked to a
concomitant increase in rate. However, for another subset of validation com-
pounds, rate initially decreased, whereas amplitude showed no associated change
until higher drug concentrations. Moreover, for a test compound not in the valida-
tion set (that was selected for inducing myocarditis in 2 days), beat rate increased
with no change in amplitude or cytotoxicity. Together this data demonstrates that
impedance assays can detect and differentiated functional changes in CMs. The
changes are sensitive to electrical and mechanical aspects of contraction, yield ro-
bust data, and offer a versatile format with moderate throughput making this plat-
form a candidate for addressing gaps in early phase screening for CV toxicity.
82 Cellular Impedance Assays for Predictive Preclinical Drug
Screening of Kinase Inhibitors in Cardiovascular Toxicity.
S. D. Lamore,  C. W. Scott,  Y. P. Dragan and M. Peters. Safety Assessment,
AstraZeneca, Waltham, MA.
Cardiotoxicity is the leading cause for late stage drug attrition and withdrawals
from the market. Serious adverse cardiac events have emerged as a prevalent risk for
kinase inhibitors (KI). Although current in vivo screens can reduce known risks due
to arrhythmia, there is urgent need for novel in vitro assays with sufficient through-
put to identify risks and support the development of SAR against other prevalent
cardiovascular (CV) toxicities. Recently, cellular impedance technology has been
adapted for detecting spontaneous, synchronized beating of cultures of cardiomy-
ocytes (CM) in a real-time, label-free format. Impedance technology is a good can-
didate for detecting the pleiotropic cellular effects of kinases since it detects mor-
phological changes thereby giving a readout that is downstream of key toxicity
targets in the contraction cascade (i.e. cardiac action potential, calcium flux, me-
chanical elements of contraction). We evaluated the application of impedance-
based assays for screening KI effects on rat neonatal CM. We selected compounds
from a MAP-microtubule affinity-regulating kinase (MARK) inhibitor program
that failed in late-stage preclinical development with dramatically decreased blood
pressure in anesthetized dogs as an example for the earlier detection of CV toxicity.
Two MARK inhibitors were tested and both dose-dependently influenced CM beat
rate and amplitude without causing cell death as judged by cell index, cellular ATP
levels, or cardiac troponin release assays. The relative potency of the two com-
pounds on reducing beat amplitude in impedance assays (EC50= 4.31μM and 0.55
μM; 20 min exposure) aligned with the ~10-fold difference in affinity for MARK
isoforms 1-4. Knockdown of pan-MARK expression reduced beat amplitude by
40%. These MARK data indicate that impedance assays can specifically detect non-
cytotoxic functional effects of KIs on CM. Our data support the validation of cel-
lular impedance-based assays for an early preclinical CV toxicity screening of KIs.
83 Activation of Human Monocytic NADPH Oxidase by
Chlorinated Cyclodiene Insecticides.
L. C. Mangum,  J. E. Chambers and M. K. Ross. CVM Basic Sciences, Mississippi
State University, Mississippi State, MS.
Although the mechanistic relationship between bioaccumulative organochlorine
(OC) insecticide exposure and increased atherosclerosis risk is poorly defined, ele-
vated systemic oxidative stress stemming from OC-mediated induction of NADPH
oxidase activity may play a significant role in disease development. Activation of
phagocytic Nox2-containing NADPH oxidase can result in a rapid intracellular ac-
cumulation of superoxide-derived reactive oxygen species (ROS) that may be di-
rectly linked to the progression of atherosclerosis. This study measured the ability of
two legacy OC compounds to induce Nox2-containing NADPH oxidase activity in
vitro, in addition to providing evidence for a possible mechanism of action. Human
THP-1 monocytes exposed to micromolar amounts (1-20 μM) of the cyclodiene
OC insecticides trans-nonachlor and dieldrin exhibited increased levels of serine
phosphorylation of the p47phox regulatory subunit of NADPH oxidase, a neces-
sary process for enzyme assembly and translocation, with trans-nonachlor demon-
strating several fold greater potency than dieldrin. OC treatment also induced ele-
vated levels of intracellular ROS, as shown by 2’,7’- dichlorofluorescein-diacetate
fluorescence assay, suggesting increased superoxide anion production. Pretreatment
of monocytes with arachidonyl trifluoromethyl ketone, a specific inhibitor of cy-
tosolic phospholipase A2, prior to cyclodiene treatment abrogated p47phox serine
phosphorylation and blocked the induction of arachidonic acid and prostanoid lib-
eration, as determined by UPLC-ESI MS/MS, suggesting that this enzyme may
play a crucial role in the induction of NADPH oxidase activity by cyclodienes via
the modulation of intracellular arachidonic acid levels. The results suggest that
trans-nonachlor and dieldrin are capable of altering intracellular ROS levels via an
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inducible NADPH oxidase dependent mechanism that may be significant in the
etiology of atherosclerosis associated with exposure to bioaccumulative cyclodiene
insecticides. (NIH R15ES015348)
84 Mechanistic Studies of Drug-Induced Cardiac Hypertrophy
in H9c2 Cell.
Z. Lin and Y. Will. Compound Safety Prediction, Pfizer Global Research &
Development, Groton, CT.
Drug induced cardiotoxicity can manifest itself through a variety of mechanisms in-
cluding mitochondrial toxicity, apoptosis, oxidative stress and ion channel distur-
bance. However, cardiac hypertrophy is the most common safety finding. Here, we
aimed at established an in vitro platform which could reliably characterize hyper-
trophic responses. Fifty drugs reported to cause hypertrophy in vivo were utilized in
this study and consistent of a variety of drug classes such as anthracylines, statins,
kinase inhibitors and catecholamines. Compounds were characterized in H9c2 cell
assessing the following endpoints: cell size, protein synthesis, fetal gene expression
(ANP, BNP, MYH7), cell viability and reactive oxygen species (ROS). 
Our results indicate that unlike the traditional cardiac hypertrophy which is driven
by ventricular wall stress and hormonal factors including angiotensin II, endothe-
lin-1, and catecholamine, compound-induced cardiac hypertrophy (increase in pro-
tein and cell size) may be initiated by the same mechanisms that drive cytotoxicity.
In contrast, fetal gene expression is different from the mechanisms that drive cell
size and protein increase. 
Specifically, our results demonstrate that: 1) all protein synthesis-inducing com-
pounds (23) caused significant cytotoxicity; 2) all compounds causing increase in
cell size also induced protein synthesis; 3) both protein and cell size increase were
compound-concentration dependent with protein increase occurring always ahead
of cell size increase; 4) of the total of 50 drugs known to cause hypertrophy in vivo,
28 compounds induced fetal gene expression; 5) Oxidative stress was associated
with the hypertrophic response (25%). 
In summary, our data suggest the initial trigger(s) of compound-induced hyper-
trophic response are multi-factorial; one of which shares the same mechanism that
induces cytotoxicity. Not all compounds known to cause hypertrophy in vivo were
accurately characterized by our in vitro approach. Whether stem cells and addi-
tional mechanistic parameters can improve our assay is subject to future studies.
85 Optical Measurements of Electrical Activity from hiPSC-
Derived Cardiomyocytes Is a Robust and High-Throughput
Method for Measuring NCE-Effects on the Cardiac Action
Potential.
G. Smith2,  B. D. Anson1,  M. A. Craig3 and I. Ghouri2. 1Cellular Dynamics
International, Madison, WI; 2University of Glasgow, Glasgow, United Kingdom;
3Clyde Biosciences, Glasgow, United Kingdom. Sponsor: K. Kolaja.
Pro-arrhythmic assessment of new chemical entities (NCEs) is a vital component of
toxicological and safety profiling.  Manual patch clamp interrogation of the cardiac
action potential (AP) is a gold standard for proarrhythmia assessment; however this
technique is laborious, requires highly skilled scientists, and neither the technique
nor traditional tissue cells have been readily amenable to higher throughput tech-
niques. Optical measurements of electrical activity with human cardiomyocytes
may offer a solution. We present data here characterizing and demonstrating the
suitability of a novel optical platform used in conjunction with hiPSC-derived car-
diomyocytes to assess NCE-mediated pro-arrhythmogenicity. 
Cardiac electrical activity was monitored from spontaneously beating hiPSC-car-
diomyocyte synctia with di-4-ANEPPS at a 10kHz over 60 second time windows
from 2-3 areas per well over 3 wells for both experimental and control values. Small
molecule effects on Na+, hERG, and Ca2+ channels were assessed and compared
with time matched controls. Ion channel block by all agents produced dose-de-
pendent changes in the expected AP parameters relative to controls. Na+ channel
block by 3μM mexelitine produced a 244±86% (n=3) increase in AP rise time,
hERG channel block by 30nM E4031 produced a 39±14% (n=3) increase in
APD90, and Ca2+ channel block by 300nM nifedipine produced an approximate
50% shortening in APD90. Experimental measurements for a single compound
were completed in less than 3 hours. Similar data was obtained across cellular man-
ufacturing batches and experimental days. This dataset demonstrate that optical
measurements of electrical activity on hIPSC-derived cardiomyocytes is a suitable
methodology for assessing NCE arrhythmogenic potential with a robustness that
approaches that of manual patch clamp and throughput that is an order of magni-
tude greater.
86 Multiparameter In Vitro Assessment of Drug Effects on
Cardiomyocyte Physiology Using iPSCells.
O. Sirenko1,  C. Crittenden1,  A. Blake2,  I. Rusyn3 and E. F. Cromwell1.
1Molecular Devices LLC, Sunnyvale, CA; 2Cellular Dynamics International, Madison,
WI; 3University of North Carolina at Chapel Hill, Chapel Hill, NC.
Highly predictive in vitro assays suitable for high throughput screening (HTS) for
potential cardiotoxicity are critical to drug safety testing. Adult human stem cell de-
rived cadiomyocytes show promise for screening compounds during early drug de-
velopment.  We developed methods for measuring the impact of drug candidates
on the beating rate of human iPSC derived cardiomyocytes using fast kinetic fluo-
rescence imaging. Cardiomyocyte contraction rate and pattern are characterized by
monitoring changes in intracellular Ca2+ measured using calcium sensitive dyes.
The assay was optimised for HTS and allows characterization of beating profiles by
using multi-parameter analysis outputs such as beating rate, peak frequency and
width, or waveform irregularities. The assay is suitable for assessment of short-term
(minutes) and delayed (days) effects. Next, we tested known cardiotoxic com-
pounds including alpha and beta blockers, hERG inhibitors, ion channel blockers,
etc., as well as control drugs. IC50 values showed a significant rank correlation with
published values determined by other cardiotoxicity models as well as good concor-
dance with reported human plasma Cmax values. The assay was further tested using
commercially available cardiotoxicity library representing different classes of com-
pounds including receptor antagonists, ion channel blockers, anti-cancer and anti-
inflammatory drugs, and kinase inhibitors. The estimated balanced prediction ac-
curacy of the assay was greater than 80%, and multi-parameter characterization of
beating profiles allowed identification of specific patterns defining hERG or Na
channel blockers. We conclude that this assay shows utility for screening com-
pounds for potential to cause arrhythmic and non-arrhythmic cardiotoxicity.
87 Nucleoside Reverse Transcriptase Inhibitors Induced
Premature Senescence in Aortic Endothelial Cells.
V. Y. Hebert,  K. Slaybaugh,  C. N. Robinson,  S. Xue,  D. Hayes,  M. C. Glover
and T. R. Dugas. Pharmacology, LSU Health Sciences Center, Shreveport, LA.
HIV patients undergoing antiretroviral therapy exhibit an increased incidence of
cardiovascular events and their associated diseases. Though HIV therapy generally
involves a combination drug approach, nucleoside reverse transcriptase inhibitors
(NRTI) are considered a backbone of this therapy. Prior studies in rodents sug-
gested that NRTI promote HIV-associated endothelial dysfunction, an initiating
factor in atherosclerosis. Further, this cellular dysfunction was associated with mi-
tochondrial injury. In cultured endothelial cells, NRTI treatment increased mito-
chondrial ROS production, while decreasing ATP production and the activities of
mitochondrial electron transport chain (ETC) complexes I-IV. While these effects
were observed for acute treatment, in other studies, we noted that when the mito-
chondria were exposed to low doses of NRTI, damaged mitochondria were re-
moved through a process known as mitophagy. Thus, our hypothesis was that with
chronic treatment, this repair mechanism may be overwhelmed, so as to promote
premature endothelial senescence. In these studies, human aortic endothelial cells
(HAEC) were exposed to chronic NRTI treatment. ROS production, cell prolifera-
tion rate and levels of senescence were determined. Our findings were that NRTI
treatment increased ROS production, at least initially. Also, the rate of cell prolifer-
ation decreased from passage 1 to passage 8, and the level of NRTI-induced senes-
cence increased. In addition, co-treatment with the mitochondrial antioxidant
coenzyme (Q10) resulted in a delayed onset of senescence. In conclusion, long term
NRTI treatment resulted in ROS production, reduced cell proliferation rate and
premature endothelial senescence. Moreover, our findings may suggest approaches
for reducing the cardiovascular side effects of NRTI therapy.
88 Fluoride Prevents Ectopic Calcification of Vascular Cells
through Inhibition of Crystal Nucleation.
A. Martin-Pardillos1,  A. Millan2 and V. Sorribas1. 1Laboratory of Molecular
Toxicology, University of Zaragoza, Zaragoza, Spain; 2Institute of Materials Science,
CSIC, Zaragoza, Spain. Sponsor: A. Anadon.
Fluoridation of public water to improve dental and bone health can involve a risk
during degenerative processes such as ectopic calcification. 
We have analysed the effect of fluoride (F) on the calcification of rat aortic vascular
smooth muscle cells. Cytotoxicity in vitro was determined by a lactate dehydroge-
nase (LDH) assay. F did not affect cell viability at the normal plasma concentra-
tions of fluoridation (2.5-10 μM), but surprisingly, it reduced the cell death gener-
ated during calcification conditions. 5 and 10 μM fluoride also decreased the
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calcification caused by 2 mM Pi by 25 and 59% in VSCMs, respectively. A dose-re-
sponse relationship of calcification inhibition with increasing concentrations of py-
rophosphate (PPi) revealed that the IC50 shifted from 4.26 μM to 2.14 in the pres-
ence of 5 μM NaF, therefore indicating that less PPi is necessary to prevent
calcification when F is present in the calcification medium. Similar effect was ob-
tained with phosphonoformic acid. 
Electron microscopy (TEM, SEM, ED and EDS) observations have revealed that
the calcification deposits consist of spherollites of intergrowth particles that had an
amorphous character, a low density, and a laminar particle shape, in the absence of
F-. With increasing F- concentration, the deposits turn more dense and compacted,
while the particle shape becomes clearly fibrillar. F is not incorporated in the de-
posits, therefore suggesting a modification of crystallization process and inhibition
of nucleation, which could explain the prevention of calcification. This effect was
similar both in living and dead (fixed) cells, which indicates an intrinsic effect of F-
ions on the calcification process independent of cellular activity. Furthermore, F-
decreases the Pi-induced expression of osteogenes, most likely as the consequence of
the reduced calcium phosphate deposits. 
In conclusion, F addition to drinking water can have a beneficial effect in prevent-
ing vascular calcification originated during hyperphosphatemic conditions.
89 Development of an In Vitro Multiwell Cardiovascular
Microelectrode Array (MEA) Toxicity Assay with Human
IPS-Derived Cardiomyocytes.
S. Qin1,  J. Ross2,  M. Brock2,  J. Bradley1,  H. Luithardt1,  J. Gilbert1 and
C. Strock1. 1Cyprotex, Watertown, MA; 2Axion Biosystems, Atlanta, GA.
Cardiotoxicity represents the most common reason for attrition of compounds due
to toxicity. Current in vitro assays fail to predict the many causes of cardiac toxicity.
Cytotoxicity assays only identify the most overtly toxic compounds, while assays to
measure more specific liabilities such as hERG or other ion channels measure only
a specific risk target, potentially missing the overall physiological response a com-
pound elicits in cardiac cells. Additionally, in vivo animal studies rely on determi-
nation of compound activity in a different species, which does not always model
human responses. Therefore, an ideal assay would screen compounds in human car-
diomyocytes and provide a comprehensive assessment of their effects on electro-
physiology. Here we demonstrate the successful use of multiwell MEAs to screen
for cardiotoxic liabilities in human IPS derived cardiomyocytes (hsCM). MEAs
measure the electrical activity in cells and therefore can be used to capture the field
potential of the cardiomyocytes, producing a virtual EKG. This data can then be
extracted to report effects of test compounds on the different phases of the heart-
beat. Response endpoints that can be reported include: field potential duration
(“QT”), conduction velocity, beat rate, as well as field potential metrics
(Amplitude, Slope, etc.).  The recent development of the multiwell MEA has al-
lowed for an increased throughput for cardiotoxicity screening as well as the ability
to generate dose curve responses for each compound. Here we demonstrate the dif-
ferent electrophysiological responses observed when we test compounds with differ-
ent targets and liabilities (hERG, other ion channels, etc.). The compounds tested
are E4031, Nifedipine, Sotalol, isoproterenol, Ouabain, Mexiletine, ZD7288,
Amitryptiline, Cisapride, Terfenadine, and Verapamil. In summary, we show that
use of multiwell MEAs with hsCM is highly effective for screening test compounds
for toxic liabilities.
90 Development of Improved hESCH-Based High-Throughput
Screening Assays for Cardiotoxicity Assessment.
H. Xian,  C. Blanco,  J. Lam and R. Snodgrass. VistaGen Therapeutics Inc., South
San Francisco, CA.
The limitations of current pre-clinical drug testing systems contribute to the high
failure rate of drugs. Unexpected human cardiotoxicity is one of the two major rea-
sons for failure of drugs and drug candidates due to safety concerns. Incorporating
human embryonic stem cell-derived cardiomyocytes (hESC-CMs) assays into the
pre-clinical drug development offers the potential to improve the predictability of
toxicity and efficacy testing and to decrease drug development costs. Our goal is to
utilize hESC-CMs to develop reproducible and predictive assays for cardiac func-
tion and toxicity prediction. We have developed protocols that, without selection,
reproducibly yield >80% hESC-CMs that function reliably in various established,
and newly developed, assays relevant to cardiac drug effects. In addition, the
CD172a cell surface marker enables the production of substantially pure (>95%)
hESC-CMs. Here we expand our previous electrophysiological assessments, and
describe the development of a series of fluorescence or luminescence based high-
throughput assays that were used to assess drug-induced necrosis, apoptosis, mito-
chondrial toxicity and oxidative stress of hESC-CMs. These assays were validated
using well-known cardiotoxic compounds. These compounds include inhibitors of
various kinases, DNA intercalating agents, hERG trafficking blockers and K+ chan-
nel blockers. These assays were able to measure drug effects, with high sensitivity,
consistent with known biology of the compounds. In addition, a medium through-
put multi-electrode array (MEA) system was used to evaluate electrophysiological
functions of the hESC-CMs. The effects of selective ion channel blockers and com-
pounds associated with QT prolongation on field potentials and beat rates were as-
sessed. The observed cardiac electrophysiology was reproducible and consistent
with the known effects of the compounds. Our data suggest that these hESC-CM
based screening systems are valuable tools for preclinical cardiac safety screening,
which we believe will contribute to the efficient and rapid identification of safer
drugs.
91 Vascular Effects Induced by 15nm Gold Nanoparticles in
Isolated Rat Aortic Rings.
M. Gonzalez Castillo1, 2,  S. Salazar-García1,  D. Maldonado Ortega1,
G. Palestino Escobedo1,  M. Ramirez Lee1,  A. Mendez Mancilla1 and S. F. Ali2.
1Universidad Autonoma de San Luis Potosi, San Luis Potosi, Mexico; 2National
Center for Toxicological Research, US FDA, Jefferson, AR.
Gold nanoparticles (AuNPs) have been used in biomedicine as therapeutic tool.
However, their role on the vascular physiology, have not been fully studied. The
purpose of the present work was to evaluate the effects of 15 nm AuNPs on the vas-
culature, using a rat aortic rings model, pre-contracted with phenylephrine, a well
known contractile agent. Adult male Sprague Dawley rats were sacrificed; aorta was
excised, and maintained in an organic bath chamber with physiological solution.
Each individual aorta rings were treated under isometric conditions, in presence
and absence of endothelium (E), along with increasing concentrations (0.1-100
ug/mL) of AuNPs. AuNPs exerted a vasodilator effect independent on E, the relax-
ation was exerted in the same magnitude that was found in presence of E.
Relaxation induced by the Au-NPs were not dependent on nitric oxide (NO),
since, L-Nitro-arginine methyl ester (L-NAME), an inhibitor of the NO produc-
tion and a potent vasodilator mediator, did not block this effect. However, a pre-
treatment with indomethacin, an inhibitor of prostanoids synthesis, blocked par-
tially the vasodilation induced by AuNPs, suggesting that prostanoids could be, at
least in part, mediators of these actions. Further studies are underway to evaluate
the mechanisms of action which are underlying the relaxation induced by AuNPs,
and the implications that they could confer in the cardiovascular physiology.
92 Nano-Cerium Dioxide Exposure and Arteriolar Dysfunction:
Exposure Route Dependency.
T. R. Nurkiewicz1,  P. A. Stapleton1,  E. M. Sabolsky2 and V. C. Minarchick1.
1Center for Cardiovascular and Respiratory Sciences, West Virginia University,
Morgantown, WV; 2Mechanical Engineering, West Virginia University, Morgantown,
WV.
Nano-cerium dioxide (CeO2) is being used or developed as a fuel catalyst (diesel), a
protective drug (radiation and ischemia) and as a contrast agent (medical imaging).
These diverse uses possess the potential for human exposures that are beyond the
well studied pulmonary route. Our laboratory has assessed the arteriolar effect of
nano-CeO2 24hrs post-pulmonary exposure; however, other routes of exposure
such as systemic and gastrointestinal have not been investigated. Therefore, our aim
was to analyze the microvascular effects of nano-CeO2 via instillation, injection,
and gavage. Sprague-Dawley rats were intratraceally instilled (100 μg), intra-
venously injected (100 or 900μg), or gavaged (100 or 600μg) with nano-CeO2 sus-
pended in Normosol (5% serum). 24hrs later the mesentery was harvested, and 4th
or 5th order arterioles were dissected and prepared for isolated vessel experiments.
Arteriolar reactivity was evaluated by determining endothelium-dependent (acetyl-
choline, 10-9-10-4M), and -independent dilation (spermine NONOate, 10-9-10-
4M), vasoconstriction [phenylephrine (PE), 10-9-10-4M], and mechanotransduc-
tion [myogenic responsiveness (0-105 mmHg) and shear stress (0-30μl/min].
Endothelium-dependent and -independent dilation for all three exposure routes
(instillation: 30% and 50%, injection: 45% and 55% and gavage: 36% and 64% vs
sham arterioles, respectively) was significantly impaired. Arteriolar responsiveness
to PE or pressure was unaltered for the exposure routes. There was an impaired di-
lation in response to flow for the rats injected or gavaged (53% and 35% vs sham,
respectively). This arteriolar dysfunction was exposure route dependent because lit-
tle to no arteriolar dysfunction was observed in rats injected or gavaged with 100μg
of nano-CeO2 as compared in instilled rats. These results provide evidence that mi-
crovascular dysfunction is present 24hrs after nano-CeO2 exposure and is depend-
ent on the exposure route.
NIH-RO1-ES015022, RC1-ES018274(TRN) and NSF-1003907(VCM)
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93 Simulated Metabolism in the Langendorff Isolated Rat
Heart: A Comparison of Novel and Traditional Dosing
Techniques for 5-Fluorouracil and Doxorubicin.
J. B. Ross,  K. A. Henderson,  R. Borders,  P. S. Hong,  W. M. Black and
B. M. Roche. Battelle, Columbus, OH.
There is a clear need for more predictive and translatable assays in early drug dis-
covery. It is important to take a multi-scale approach to translate data to pre-clini-
cal and clinical trials. The Langendorff isolated heart model provides a tool to assess
cardiotoxicity in the whole organ in the absence of in-vivo variables. We used the
Langendorff to assess both acute and latent cardiotoxicity of 5-fluorouracil (5-FU)
and doxorubicin. Physiologically Based Pharmacokinetic (PBPK) models were de-
veloped to determine clinically relevant doses. A reverse extrapolation from human
physiological and physiochemical parameters to rat was performed. The resulting
pharmacokinetic (PK) curves led to some challenging dose considerations; both 5-
FU and doxorubicin are rapidly cleared in humans and rats, never reaching a steady
state. Other PK parameters such as Area Under the Curve (AUC) and the maxi-
mum concentration (Cmax) pose problems as well. AUC will accurately represent
the total amount of drug over a given period of time; however, a single concentra-
tion derived from the AUC could potentially underestimate a biological response.
In contrast, Cmax would greatly overestimate the total amount of drug, potentially
leading to false toxicity. Computer generated dosing schemes were developed and
characterized in an effort to fit the modeled PBPK curves. Initial concentrations
(Cmax) were diluted with deionized water and perfused though the Langendorff
system in the absence of a heart. Perfusate was collected at various time points, an-
alyzed with HPLC, and concentration curves were generated for proof of concept.
An acceptable fit was observed between the computer generated and the tested
curves. This dosing technique was applied to an isolated rat heart; multiple end-
points were collected and compared to previous data collected at constant perfusion
concentrations. The novel dose schemes proved to be a better representation of in-
vivo concentrations in our ex-vivo model.
94 Oxidative Stress Uncovers fM β2-Adrenergic Mediated
Dilation to Curcumin Mimicked by Preventing Clathrin
Endosome Formation.
M. Frame1, 2,  B. Calizo2,  A. M. Dewar1 and S. Scarlata2. 1Biomedical Engineering,
Stony Brook University, Stony Brook, NY; 2Physiology/Biophysics, Stony Brook
University, Stony Brook, NY. Sponsor: T. Nurkiewicz.
The nutraceutical, curcumin, has anti-oxidative properties, but also is a potent
adrenergic receptor (AR) agonist, with an EC50 for dilation in the nM range (beta,
bAR). Our goal was to determine how oxidative stress impacted vasoactive re-
sponses to curcumin. Intravital microscopy of small arterioles in the hamster cheek
pouch was performed (N=10; pentobarbital 70mg/kg i.p.). Oxidative stress (OX)
was induced by applying exogenous nitric oxide for 2 minutes in the tissue bath.
Before OX, dilation to micropipette applied curcumin was dose dependent, with a
maximum from 10-9 to 10-6M. After OX, dilation was eliminated in the nM and
higher range, and significantly left shifted to a narrow peak from 10-15 to 10-10M,
which was inhibited by the b2-adrenergic receptor inverse agonist, carazolol (1nM).
We next tested whether preventing clathrin endosome formation with dynasore al-
tered dilation to curcumin. Dynasore (80uM) alone eliminated dilation to cur-
cumin in the uM range, and uncovered a dilation in the pM range. Dynasore with
OX further increased the potency, and increased the efficacy of dilation to cur-
cumin over the range 10-15 to 10-10M. To understand the mechanism of this OX
induced narrow potency range, we tested whether curcumin and the bAR were in-
ternalized and co-localized using FRET in HEK cells. Before OX, curcumin was
rapidly internalized (seconds), and co-localized with bAR. After OX (1mM
CoCl2), curcumin was internalized, but bAR remained at the plasma membrane.
Thus, in cells, OX prevented internalization of curcumin with bAR. In situ, inhibi-
tion of clathrin endosome formation mimicked and enhanced the vasoactive re-
sponses after OX. (AHA 0655908T)
95 Diminished Oxygen Supply in Microvessels following
Inflammatory Oxidative Stress.
A. M. Dewar,  M. Frame,  N. Zhou and C. Du. Biomedical Engineering, Stony
Brook University, Stony Brook, NY. Sponsor: T. Nurkiewicz.
Increased heterogeneity of flow accompanies many inflammatory states, including
oxidative stress (OX) with toxicant exposure or thermal injury. Red blood cell
(RBC) flux along nutrient flow paths is an indicator of oxygen delivery; many in-
flammatory mediators result in a specifically located arteriole-venule RBC shunt
pathway. Our goal was to directly measure oxy- vs deoxy-hemoglobin (HbO v
HbR) to determine whether OX induced shunt paths resulted in heterogeneity of
oxygen supply. A controlled thermal burn model in the hamster cheek pouch tissue
localized OX so that unequivocal control vs OX spatial locations could be observed.
Adult male hamsters (N=10, isoflurane) were prepared for intravital microscopy of
the cheek pouch tissue. Fluorescently labeled RBC flow markers confirmed shunt
pathways after a thermocouple controlled 50 degree C 300um spot burn (same lo-
cation before vs 15m-1hr after, within 500um of burn rim). Multi-wavelength laser
speckle contrast imaging was used (1-2h after burn) to determine HbO and HbR at
630 and 570nm at locations within 500um of the burn rim (near) vs. locations
>1mm from the burn rim (far); values of changes in HbO and HbR were obtained
in [Hb] mM. Total Hb in the large vessels was consistent with a local tube hemat-
ocrit of 5-40%, as is typically found using fluorescent RBC. HbO was 30% less in
perfused large arterioles near vs far from the burn, and 24% less in perfused large
venules near vs far from the burn. Within the terminal arteriolar networks far from
the burn, HbO is 7% higher along the shunt pathway vs the non-shunt pathway,
consistent with RBC flux values. Near the burn, HbO is 71% greater along the
shunt pathway vs the non-shunt pathway, also consistent with RBC flux values.
Comparing HbO along shunt pathways, HbO is decreased 52% near vs far from
the burn rim. Thus, in this model of inflammation, RBC flux and HbO values to-
gether suggest that a diminished oxygen shunt pathway is initiated by inflamma-
tion and maintained for several hours after the inflammatory event. (NIH
HL55492; AHA 0655908T)
96 Validation of the Amphibian Metamorphosis Assay for
Potential Endocrine Disrupting Chemicals with Xenopus
Laevis.
J. J. Burlingham,  C. A. Jenkins,  J. Pawsey,  I. Taylor and L. Haynes. Aquatic
Ecotoxicology and Biodegradation, HLS, Eye, United Kingdom. Sponsor: C. Auletta.
The new European Union Plant Protection Products Regulation (PPPR
1107/2009) identifies the need to consider whether a substance is a potential en-
docrine disrupter in aquatic non-target organisms and the current draft of the PPP
data requirements refers to three screening assays for ecotoxicological endocrine-
disrupting potential. Of these, we describe in detail our experience in the establish-
ment and validation of the amphibian metamorphosis assay (OECD 231; OPPTS
890.1100) with the African Clawed Frog. 
In this method, in order to satisfy validity criteria in the rearing phase, conditions
necessary to allow tadpoles to develop from fertilisation to development stage 51 as
defined by Nieuwkoop and Faber (1994) were established, and individuals selected
for the exposure phase and transferred to test vessels. To establish the assay, 400 tad-
poles were exposed to a range of levels of the three reference substances, thyroxine
(T4) which produces stimulatory effects on the normal function of the hypothala-
mic-pituitary-thyroid (HPT) axis, sodium perchlorate (which retards development)
and iopanoic acid (which affects hind limb development) and levels of each were
verified using an appropriate analytical method. At Day 7, 80 randomly selected in-
dividuals at each exposure level were removed and assessed (body weight, develop-
mental stage, hind limb and snout to vent length). Exposure continued for a further
two weeks and the study terminated on Day 21 when all the remaining individuals
were assessed as on Day 7. Following developmental stage matching, 80 individuals
were selected for thyroid removal and histopathological analysis. 
We found that our results were similar to the ring test results published by the
OECD (Series on Testing and Assessment Document Number 77) and make a
number of observations on methodology that may improve the reproducibility of
these assays.
97 Mammary Gland Morphology and Gene Expression
Signature of Prepubertal Male and Female Rats following
Exposure to Exogenous Estradiol.
M. Ronis1, 2,  I. R. Miousse1, 2,  N. Sharma2,  J. Vantrease2,  L. Hennings1,
K. Shankar1, 2,  H. Gomez-Acevedo1, 2,  M. Cleves1, 2 and T. M. Badger1, 2.
1UAMS, Little Rock, AR; 2Arkansas Children’s Nutrition Center, Little Rock, AR.
In order to properly understand whether xenoestrogens act as true estrogen ago-
nists, it is essential to possess a solid portrait of the physiological effects of exoge-
nous 17β-estradiol (E2). Because the estrogen-dependent gene expression is one of
the primary indicators of estrogenic action, we have assessed effects of three doses of
exogenous E2 (0.1, 1.0 and 10 μg/kg of body weight/day) on the mammary gland
morphology and gene expression profiles of prepubertal male and female rats of
both sexes compared to untreated controls. The mammary gland was more respon-
sive to E2 treatment in males than in females with 1392 genes modulated >1.5-fold
up or down relative to controls at the higest E2 dose compared to 463 genes. There
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was an increase in the number of terminal end buds in males (P<0.05), and a corre-
sponding increase in the expression of the gene encoding amphiregulin (P<0.05), a
protein known to drive the differentiation of terminal end buds. In intact females,
the highest dose of E2 tested induced an increase in the expression of genes encod-
ing milk components, as well as muscle proteins. Lower doses had limited effects on
gene expression. Therefore, the prepubertal rat male mammary gland is a very sen-
sitive tissue to evaluate estrogenicity using morphological changes coupled to mi-
croarray-analysis of gene expression. Intact prepubertal females were comparatively
poorly responsive to exogenous E2, although many modulated genes were common
to both sexes. Supported by USDA CRIS-6251-51999-007-04S.
98 Potential Endocrine Disruption of a Drinking Water Sample
from the State of São Paulo, Brazil.
M. M. Solano1,  C. M. Raimundo2,  I. C. Pescara2,  W. F. Jardim2,  D. D. França3,
G. A. Quinaglia3,  J. A. Anselmo-Franci4,  R. G. Carolino4,  J. L. Luvizutto1,
G. A. Umbuzeiro5 and J. V. de Camargo1. 1Botucatu Medical School, Department
of Pathology, São Paulo State University- UNESP, Botucatu, Brazil; 2Institute of
Chemistry, University of Campinas- UNICAMP, Campinas, Brazil; 3Environmental
Toxicology, Genotoxicity and Microbiology Division - CETESB, São Paulo, Brazil;
4School of Dentistry, Department of Morphology, Stomatology and Physiology,
University of São Paulo- USP, Ribeirão Preto, Brazil; 5Faculty of Technology,
University of Campinas- UNICAMP, Limeira, Brazil.
Many xenoestrogens, natural and synthetic estrogens may end up in the water bod-
ies through sewage discharges. Contaminated rivers are conventionally treated by
Water Treatment Plants (WTP) to produce drinking water, but emerging contami-
nants may remain. This study investigated the potential for endocrine disruption of
a drinking water sample from a São Paulo State WTP, using two harmonized bioas-
says. Female rats 21 days old were exposed by gavage to drinking water extracts dur-
ing 03 days (uterotrophic assay; OECD 440) or 20 days (pubertal development fe-
male rat assay, EPA 890.1450) at 33.3, 166.5, and 333.0 mL equivalent of water/kg
body weight, modeling a daily ingestion of 2 L, 5 L and 10 L of drinking water by
a 60 kg human being. Traces of caffeine (5.8 ug/L), estrone (1 ng/L) and atrazine
(11.2 ng/L) were detected in the extracts by LC-MS/MS. Androgen or estrogen ag-
onistic activity of the water extract resulted negative by the bioluminescent yeast
assay (BLYES, BLYAS). Accordingly, both in vivo assays were negative: there was no
significant increase of the uterus wet weight in the uterotrophic assay and no alter-
ation of the moment for vaginal opening in the pubertal assay. However, the serum
levels of LH, FHS, PRL and 17β-estradiol were altered, with a significant dose-re-
sponse increase. Therefore, it has to be assumed that the tested drinking water sam-
ple induced steroidogenic dysregulation in vivo.
99 Development of Medium-Throughput Thyroperoxidase
Inhibition Assays for Screening.
K. B. Paul1, 2,  J. M. Hedge2,  K. M. Crofton2,  M. W. Hornung3 and
S. O. Simmons2. 1ORISE, US EPA, Research Triangle Park, NC; 2Integrated Systems
Toxicology Division, NHEERL, ORD, US EPA, Research Triangle Park, NC; 3Mid-
Continent Ecology Division, NHEERL, ORD, US EPA, Duluth, MN.
Thyroperoxidase (TPO), the catalyst for thyroid hormone (TH) synthesis, is a tar-
get for thyroid-disruptors, including methimazole (MMI), isoflavones, benzophe-
none-2, and malachite green; however, no medium- to high-throughput screening
methods for TPO inhibition are available. To adapt the low-throughput guaiacol
oxidation assay for TPO inhibition to chemical screening, we replaced guaiacol
with a fluorescent peroxidase substrate in a rat thyroid-based assay and developed
an in vitro human TPO model. We tested the hypothesis that use of a peroxidase
substrate (Amplex UltraRed, AUR, LifeTech) in 96- or 384-well plate formats with
automated reagent delivery could increase the TPO assay throughput with thyroid
microsomes. The IC50 of MMI-induced TPO inhibition was reduced with AUR
compared to the guaiacol assay, with average IC50s of 0.15 μM and 5 μM, respec-
tively. AUR signal was stable from 30-120 min after initiation. The dynamic range
of the assay with MMI was 6- to 10-fold using 96- or 384-well formats, with Z’
scores of 0.75 to 0.9. A 21 chemical training set is being used to validate the assay
for screening. One limitation of this model is the availability of human thyroid mi-
crosomes. Preliminary work demonstrated that lentiviral-transduction of a human
cell line (HEK293T) with recombinant TPO could also be used to test for human
TPO inhibition. TPO activity measured by the AUR assay in cell fractions was
maximally inhibited by MMI at 100 μM. This approach to improving and devel-
oping medium-throughput assays for thyroid-disruptor screening demonstrates the
feasibility of screening 100s to 1000s of chemicals for TPO inhibition, and drasti-
cally reduces the need for animal tissue. This abstract does not necessarily reflect the
policy of the US EPA.
100 High-Throughput Detection of Estrogenic Compounds
Using Autonomously Bioluminescent Human Breast Cancer
Cells.
T. Xu1,  D. Close2,  S. L. Price1 and G. S. Sayler1, 2. 1The University of Tennessee,
Knoxville, TN; 2490 BioTech Inc., Knoxville, TN. Sponsor: S. Ripp.
Substantial public health concerns exist over the potential endocrine disrupting ca-
pabilities of a wide variety of untested or under-tested natural and industrial chem-
icals. It is clear that the development of accurate, high-throughput, and inexpensive
testing regimens will be key to mitigating public concern. Here we report on the
development of a novel screening assay for estrogenic activity that utilizes an au-
tonomously bioluminescent human cell line to provide direct bioavailability data.
To construct this cell line, estrogen-responsive human breast carcinoma cells (T-
47D) were genetically engineered to express the full bacterial bioluminescence gene
cassette (luxCDABEfrp), generating an autonomously bioluminescent cell line (T-
47D/Lux) capable of maintaining bioluminescent output independent of substrate
addition. Bioluminescence emitted from T-47D/Lux cells was correlated tightly (R2
> 0.99) to the number of cells present in a population, permitting the use of light
production dynamics as an indicator of cell proliferation. Additionally, the sub-
strate-free nature of the lux system allowed for continuous, near real-time monitor-
ing of the same cell population throughout exposure to the tested compounds. A
significant change in bioluminescent production (p < 0.05) compared with unex-
posed control was observed 3 days after exposure to concentrations of 17β-estradiol
(E2) as low as 1 pM. The EC50 for E2 in this assay was determined to be approxi-
mately 10 pM. These results are similar to those obtained using a traditional cell
proliferation assay, but offer the advantage that data acquisition can be performed
in a fully automated fashion since the need for sample destruction or substrate ad-
dition is removed, making it an ideal candidate for high-throughput analysis.
101 Cryopreserved Rainbow Trout Hepatocytes Model Endocrine
Disruption As Detected by Protein and Gene Expression of
Vitellogenin.
L. K. Markell,  R. T. Mingoia,  H. M. Peterson,  J. P. Finn,  D. L. Nabb and
X. Han. DuPont Haskell Global Centers for Health and Environmental Sciences,
Newark, DE.
The toxicity of environmental pollutants may occur through modes of action that
alter normal endocrine functions, resulting in altered development, growth and re-
production of aquatic species. Consequently, there is a need to develop assay end-
points capable of identifying endocrine disruption in fish. Our lab has previously
shown the utility of cryopreserved trout hepatocytes. Here we use this cell culture
method to identify the potential estrogenicity of chemicals through vitellogenin
(VTG) expression. This biomarker indicates an estrogenic effect when the protein
is expressed by male trout hepatocytes, both in vivo in plasma and in vitro in cell
culture media. To test the performance of cryopreserved trout hepatocytes, refer-
ence chemicals estradiol (E2), estrone (E1) and diethylstilbestrol (DES) were used
and culture media was collected for ELISA 96-hrs post-treatment. Our results show
that the levels of protein detected with cryopreserved trout hepatocytes are similar
to results previously published using fresh trout hepatocytes, ranking the com-
pounds E2 ≥ DES > E1. To determine whether transcriptional regulation of VTG
correlated with protein expression, quantitative real-time PCR was performed.
mRNA was collected from cryopreserved hepatocytes treated for 24 hours with the
same doses of reference chemicals. VTG gene expression correlated well with pro-
tein expression, ranking the compounds similarly. In addition, the negative control
corticosterone showed no increase in gene expression at any dose, indicating that
this is a sensitive, yet specific endpoint. These studies demonstrate both ELISA and
transcription-based methods can be used with cryopreserved trout hepatocytes for
screening chemicals for potential estrogenic effects, enabling greater access to this
model system and potentially improving the turn-around time for generating re-
sults through detection of VTG mRNA levels.
102 Permethrin Does Not Have Endocrine Disrupting Properties
As Evaluated by the US EPA’s Endocrine Disruptor Screening
Program (EDSP) In Vivo Assays.
L. Zorrilla1,  S. J. Borghoff1 and T. G. Osimitz2. 1Integrated Laboratory Systems,
Inc, Durham, NC; 2Science Strategies, Charlottesville, VA.
Permethrin, a pyrethroid insecticide, was evaluated for potential endocrine activity
in 3 of 4 in vivo US EPA EDSP assays. The maximum tolerated dose (MTD) of
permethrin used in these assays was selected based on the results of dose range find-
ing studies. Sprague Dawley rats were administered permethrin in corn oil by oral
gavage for 10 (Hershberger Bioassay, OPPTS 890.1400, castrated model), 21/22
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(female pubertal assay, OPPTS 890.1450), or 31/32 (male pubertal assay, OPPTS
890.1500) days based on daily body weights. The Hershberger Bioassay, which
evaluated agonist and antagonist androgenic activity, was negative; no significant
changes in any androgen-dependent tissue weights up to the MTD of 120
mg/kg/day were observed. The male pubertal assay, administered a MTD of 120
mg/kg/day, showed no effects on male pubertal development with no differences
observed in reproductive organ weights, the day of preputial separation, or serum
testosterone levels compared to controls. Liver weight was significantly increased,
with a decrease in thyroxine (T4) and a corresponding increase in thyroid stimulat-
ing hormone (TSH) compared to controls. No changes were observed in thyroid
gland weights or histopathology. The female pubertal assay, administered a MTD
of 150 mg/kg/day, showed no effects on female pubertal development with no dif-
ferences observed in the day of vaginal opening, estrus onset, cyclicity, or reproduc-
tive organ weights. The liver and thyroid gland weights were significantly increased,
and serum TSH concentrations were increased with a corresponding decrease in
serum T4 following administration permethrin, however, the thyroid gland showed
no histopathological changes. In summary, permethrin did not show androgen or
estrogen activity in these assays, and the effects observed in the thyroid likely are
secondary to liver enzyme induction, a phenomenon known to occur following re-
peated dosing with permethrin, and not a reflection of a direct effect on the thy-
roid.
103 Linking In Vitro Enzyme Activity To In Vivo Effects:
Thyroperoxidase Inhibition in Methimazole-Exposed Rats.
J. M. Hedge1,  K. M. Crofton1,  S. O. Simmons1,  M. W. Hornung2 and
K. B. Paul1, 3. 1Integrated Systems Toxicology Division, NHEERL, ORD, US EPA,
Research Triangle Park, NC; 2Mid-Continent Ecology Division, NHEERL, ORD, US
EPA, Duluth, MN; 3Oak Ridge Institute for Science Education, US EPA, Research
Triangle Park, NC.
The anti-thyroid drug methimazole (MMI) inhibits thyroperoxidase (TPO), the
enzymatic catalyst for thyroid hormone (TH) production and a target for thyroid-
disrupting chemicals. Our development of a medium-throughput screening assay
for TPO inhibitors using a fluorescent peroxidase substrate (Amplex UltraRed) has
instigated characterization of the relationship between in vitro TPO inhibition
using thyroid microsomes and in vivo TH status. This work tested the hypothesis
that TPO activity would be decreased in thyroids from rats exposed in vivo to MMI
doses that decreased serum THs. Weanling female Long-Evans rats received MMI
in corn oil (0, 0.1, 0.3, 1, 10, 20, 30 mg/kg/day po) for 4 days and were sacrificed
24 hr later. Pooled thyroid microsomes (n=8/pooled treatment) were used in the
TPO inhibition assay. As a positive control, the vehicle control microsomes were
exposed in vitro to MMI (0.015 – 200 μM), which yielded an assay dynamic range
of 6-fold, an IC50 = 0.14 μM, and Z’ = 0.9. TPO was inhibited in a dose-depend-
ent manner, up to 53% of vehicle control at 30 mg/kg/day, which corresponded to
significant serum thyroxine (T4) decreases of 60% and thyroid gland weight in-
creases of 64% (p<0.05). TPO inhibition in the 10-30 mg/kg/day MMI corre-
sponded to in vitro MMI concentrations of 0.14-0.44 μM. These results suggest
that MMI-induced serum T4 decreases in vivo correspond to significant TPO ac-
tivity decreases in vitro. Continued work will aim to strengthen understanding of
the association between the degree of TH perturbation in vivo and the magnitude
of TPO inhibition in the AUR screening assay. This abstract does not necessarily re-
flect the policy of the US EPA.
104 Endocrine Disruption Potential of Benefin: Weight of
Evidence Evaluation.
S. Papineni1,  K. K. Coady2,  S. Marty2,  V. J. Kramer1 and S. C. Gehen1. 1Dow
AgroSciences, Indianapolis, IN; 2The Dow Chemical Company, Midland, MI.
Benefin, a pre-emergent herbicide, was included on List 1 of chemicals to be
screened under US EPA’s Endocrine Disruptor Screening Program (EDSP).
Following completion of 11 Tier 1 EDSP assays, a Weight of Evidence (WoE) eval-
uation was conducted using all available data to determine if benefin has potential
to interact with the estrogen, androgen or thyroid (EAT) systems following the five
(5) – tiered OECD conceptual framework. For the in vitro assays, benefin was neg-
ative for androgen and estrogen receptor binding, and negative in the aromatase
and steroidogenesis assays but induced a weak positive response in the estrogen re-
ceptor transactivation assay (ERTA). However, this slight positive response in the
ERTA assay was not corroborated in other estrogen sensitive assays estrogen recep-
tor (ER) binding, uterotrophic, estrogen-sensitive endpoints in the female pubertal,
and vitellogenin levels in the fish short-term reproduction assay (FSTRA) that were
negative. Anti-androgenic and anti-estrogenic effects were observed in the pubertal
assays and in the Hershberger assay only at the high dose levels. However, the WoE
evaluation of the data does not support a direct interaction; rather, an indirect
mode-of-action (MoA) due to enhanced liver enzyme induction and hormone
clearance appears evident. Similarly, results for thyroid effects in the pubertal assays
were consistent with previously demonstrated MoA data which support an indirect
MOA due to enhanced thyroxine clearance not relevant to humans. Furthermore,
benefin was negative in the amphibian metamorphosis assay designed to detect thy-
roid agonists and antagonists. A high-degree of coherence and consistency is ob-
served in results from the higher-tiered data and previous toxicity studies showing
no direct interaction with the endocrine system. In conclusion, the vast majority of
Tier 1 studies/endpoints were clearly negative and those few positive responses were
seen only at high-dose levels and were either isolated (e.g., ERTA) in nature or sec-
ondary to other effects.
105 Endocrine Exposure at Environmentally-Relevant
Concentrations.
K. C. Fussel1,  S. Schneider1,  S. Melching-Kolmuss2,  S. Gröters1,  V. Strauss1,
B. Siddeek3,  M. Benahmed3,  M. Frericks2 and B. van Ravenzwaay1.
1Experimental Toxicology and Ecology, BASF SE, Ludwigshafen am Rhein, Germany;
2Product Safety, BASF SE, Ludwigshafen am Rhein, Germany; 3U895, équipe 5,
Centre Hospitalier l’Archet 2, Inserm, Nice, France.
Endocrine disruption has become an important topic of public concern. Despite an
increasing amount of attention, little is understood about how doses of endocrine
disrupting chemicals (EDCs) at environmental concentrations affect homeostasis.
To address these concerns, we performed a pre-/post-natal reproductive toxicity
study to measure the developmental toxicity of low doses of three anti-androgenic
compounds: vinclozolin, flutamide, and prochloraz. The tested doses were selected
to mimic low-effect levels, the no observed adverse effect levels (NOAEL) for en-
docrine effects, and the acceptable daily intake (ADI).
Despite mild maternal toxicity in parental females treated with the top dose of
prochloraz, sufficient offspring were produced to evaluate the developmental effects
of the three EDCs. While female offspring developed normally, the male offspring
showed effects known for anti-androgens. One sensitive clinical parameter was the
retention of nipples and/or areolas by male animals on PND 12. This effect was
largely transient, as all had regressed by PND 21, with the exception of the off-
spring exposed to the flutamide top dose. The young adult male offspring displayed
additional anti-androgen effects including, delayed sexual maturation and reduced
male sex organ weights. These alterations were observed at the effect doses of all
three anti-androgens, and at the putative flutamide NOAEL. Offspring from the
flutamide top dose group had an increased incidence of developmental sexual de-
fects including hypospadias, short penis, and cryptorchidism. No effects at all were
noted at the low doses, as expected for the ADI. Assessment of sexual steroid hor-
mones and their precursors revealed no effects at any of the dose levels. Taken to-
gether, the weight of evidence of the clinical and pathological findings suggests a
lack of a non-monotonic dose-response curve.
106 Assessment of Estrogenic and Androgenic Impairment of
Iowa Surface Water by Chemical Analysis and Bioassays.
S. Flor1,  J. Vargo2 and G. Ludewig1. 1University of Iowa, Iowa City, IA; 2Iowa State
Hygienic Lab, Coralville, IA.
Limited data are available regarding the presence of hormones and steroids in Iowa
surface water. To obtain more information about the hormonal impairment, river
water samples were collected in October 2011 up- and downstream of Iowa City
and Des Moines. Chemical analysis of water extracts was performed by LCMSMS
using drinking water method EPA 539 that assesses equilin, estriol, 17α- and 17β-
estradiol, estrone, 17α-ethynylestradiol, androstenedione, testosterone, proges-
terone, and 17β-trenbolone concentrations. For endocrine disrupting activity of
the water extracts the E- and A-screen with human MCF-7 breast cancer cells (es-
trogenic and androgenic activity) and the H295R assay with adrenal cancer cells
(interference with steroid hormone synthesis) were used. A goal of this study was to
determine how well chemical testing for targeted hormones and steroids reflects the
total androgenic and estrogenic activity determined by bioassay tests. Preliminary
evaluation revealed that the added preservative 2-mercaptopyridine-1-oxide or a de-
rivative that was formed during the extraction procedure was highly cytotoxic to
the cells. However, extracts preserved with sulfuric acid could be used in the bioas-
says. The chemical analysis detected only a few hormones and those that were de-
tected were found at low- or sub-ng/L concentrations in the Iowa surface waters.
The Iowa River up- and downstream extracts showed an estrogenic activity in the
E- and A-screen and the Des Moines River extracts had a small androgenic and
antiestrogenic activity. The H295R hormone concentration tests revealed no obvi-
ous changes in testosterone and cortisol levels in the medium but the extracts
tended to increase the estradiol levels. Additional tests with synthetic samples pre-
pared according to the analytical test results are needed to examine whether the de-
tected hormones alone caused these biological effects or whether other, still unde-
termined endocrine disrupting chemicals were involved. (Funded by ES05605
from NIEHS)
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107 Endocrine Disruption: Weight of the Evidence for Low-Dose
Effects of TCDD on Sperm Counts.
K. L. Hentz,  A. L. Williams and J. C. Lamb. Exponent, Alexandria, VA.
Considerable debate is ongoing regarding the potential for endocrine-mediated
low-dose effects. One of the examples that has been presented as evidence for low
dose effects is exposure to 2,3,7,8-tetrachlodibenzodioxin (TCDD) and the impact
on sperm counts in the male offspring. Although one epidemiological study has re-
ported reduced sperm counts in males exposed to TCDD, the results of this study
are limited by the small number of subjects, evaluation of a single sperm sample,
potential differences in sexual activity, and lack of control in the collection/trans-
port of the sperm sample. We have conducted a weight-of-the-evidence review of
the toxicological studies investigating the impact of maternal TCDD exposure on
sperm counts in their offspring and the results have been highly variable.
Epididymal sperm counts have been reported to be reduced at doses as low as 64 ng
TCDD/kg, but other studies have failed to show effects at doses of 800 ng
TCDD/kg or higher. Several other animal studies have not reported effects on
sperm counts at doses between 10 and 50 ng TCDD/kg, suggesting a potential
threshold. While sperm effects have been reported in experimental animal studies at
64 ng TCDD/kg, this dose should not be considered a low dose because human ex-
posures are much lower. This dose is not relevant to current human exposures to
TCDD based on estimated intakes that are 100-fold lower for all dioxins and fu-
rans combined based on TEQ (toxic equivalents). Thus, discussions regarding the
potential endocrine disruptive effects of TCDD on sperm counts are misleading
and do not occur at the low doses experienced by general American public.
108 Effects of Pesticides on Cytochrome P450 17 (CYP17) and
Androgen Receptor (AR) Function in Human H295R
Adrenocortical and LNCaP Prostate Cancer Cells.
C. Robitaille,  P. Rivest and T. Sanderson. INRS-Institut Armand-Frappier, Laval,
QC, Canada.
Exposures to endocrine disrupting chemicals, including pesticides, are thought to
be contributing to the increased incidence of certain endocrine-related cancers in
the human population, such as prostate cancer. Prostate cancer growth is initially
androgen-dependent and under control of the nuclear androgen receptor (AR),
which increases the gene transcription of proteins involved in cell proliferation,
such as prostate specific antigen (PSA). CYP17 is a key enzyme in the biosynthesis
of androgens and increased expression is associated with increased prostate cancer
risk. We evaluated the effects of several pesticides suspected or known to modulate
hormonal function in androgen-dependent LNCaP human prostate cancer cells
and in an in vitro steroidogenesis model, the H295R human adrenocortical carci-
noma cell line. Benomyl, vinclozolin and prochloraz reduced dihydrotestosterone-
(DHT)-stimulated LNCaP cell proliferation and nuclear AR protein accumulation
concentration-dependently (0.1-30 μM). Levels of an active phosphorylated form
of AR, pAR-Ser81, were increased by 10 nM DHT, whereas benomyl, vinclozolin
and prochloraz decreased these stimulated levels (after a 1 or 6 h exposure). All
three pesticides reduced DHT-stimulated PSA secretion by LNCaP cells. We found
AR to be expressed in H295R cells but levels of AR and pAR-Ser81 were not af-
fected by DHT, although they were increased by 30 μM atrazine. Benomyl and vin-
clozolin (10 and 30 μM) and prochloraz (1 and 3 μM) decreased CYP17 mRNA
expression in H295R cells at sub-cytotoxic concentrations and prochloraz strongly
inhibited CYP17-catalyzed conversion of pregnenolone to DHEA (24h exposure).
In H295R and LNCaP cells, CYP17 protein expression was increased by atrazine
(30 μM). In conclusion, certain pesticides exert combined antiandrogenic effects in
androgen-dependent prostate cancer cells at the level of CYP17 and AR, the latter
by reducing AR phosphorylation at serine 81.
109 Metabolomics Characterization of the Effects of Estradiol in
Human Breast Cancer Cell Lines.
L. Zhao1,  S. Odwin-DaCosta1,  M. M. Vantangoli2,  H. T. Hogberg1,
M. Bouhifd1,  A. Kleensang1,  L. Smirnova1,  K. Boekelheide2,  J. D. Yager1 and
T. Hartung1. 1Department of Environmental Health Sciences, Johns Hopkins
University, Bloomberg School of Public Health, Baltimore, MD; 2Department of
Pathology and Laboratory Medicine, Brown University, Providence, RI.
Estradiol (E2 or 17β-estradiol) is the most potent naturally occurring estrogen. Its
effects on cell function during development and in adults in a variety of tissues are
mediated through estrogen receptors located in the nucleus, cytoplasm, mitochon-
dria and at the cell membrane. Our objective is to employ high-throughput liquid
chromatography mass spectrometry based metabolomics analysis to map pathways
affected by estradiol in MCF-7 and T47D cells and then compare them with path-
ways affected by endocrine disrupting compounds (e.g. BPA and others).
Concurrent cell growth and gene expression studies are also being carried out. Cells
were exposed to estradiol at different concentrations and times. Stimulation of cell
growth was observed at 0.1nM in association with changes in the metabolome at 6
and 24hrs. A time course study at 100nM estradiol revealed that some metabolites
were significantly altered at various time points. The metabolites and pathways
most affected included metabolites from cellular energy-related pathways (e.g.
Malate, Fumarate, Pyruvate) and amino acid synthesis pathways (e.g. Arginine,
Valine, Ornithine, Leucine/Isoleucine, 2-Methylmalate). Further investigation is
underway and should give more insight into the identification of metabolism path-
ways affected by estradiol and endocrine disruptors.
110 Creating In Vitro Test Methods for Endocrine Disruptor
Risk Assessment: Assay Development.
C. Le Sommer,  S. M. Ross,  P. D. McMullen,  M. E. Andersen and R. A. Clewell.
The Hamner Institutes, Research Triangle Park, NC.
Endocrine disruptor test programs in the US are moving forward to identify active
compounds and prioritize them for subsequent in-life toxicity studies. Our focus is
on developing in vitro tests for cellular responses to endocrine active substances that
will be sufficient for health risk assessment without moving on to in-life toxicity
tests. We have begun a research effort for the estrogen receptor (ER) pathway to: 1)
map signaling pathways for estrogen mediated proliferation, 2) define the dose-re-
sponse for perturbation of estrogen signaling by xenobiotics and 3) develop com-
putational models to predict chemical effect on uterine epithelium. The first phase
develops a cell-based assay in human Ishikawa endometrial cell line expressing the
three major ERs: ESR1, ESR2 and G-protein coupled receptor GPER. The dose-
response for 17β-estradiol (E2) and 17α-ethynyl estradiol (EE) (0.001 – 10 nM)
were examined at 1, 2, 3, 4, 5, and 6 days of exposure for proliferation and induc-
tion of protein and gene targets of ESR1, including alkaline phosphatase (ALP),
proliferation associated gene GREB1 and progesterone receptor (PGR). E2 and EE
increased proliferation and ALP activity by day 3 at 0.01 nM, while gene induction
(GREB1, ALP, PGR) occurred earlier (day 1). Cells were also treated with selective
receptor agonists PPT, DPN, and G1 targeting ESR1, ESR2 and GPER. PPT in-
creased proliferation, ALP activity and gene expression similar to EE. DPN in-
duced proliferation and ALP only at higher doses associated with cross-reactivity
with ESR1. GPER plays a role in regulating uterine proliferative response; however,
we saw no change in proliferation upon treatment with G1 alone. This may result
from low GPER expression in our cells. We also conducted expression analysis of
studies with Ishikawa cells from our laboratory and published sources to evaluate
dose-response of GO-categories by these receptor specific ligands. In vitro responses
have been analyzed in light of in vivo rodent uterotrophic assay transcriptomic data
to show consistency between in vitro and in vivo assays.
111 Leaching of Chemicals with Estrogenic Activity from
Packaging into Popular Lab Animal Feeds.
D. Klein1,  C. Z. Yang2,  G. J. Kollessery2 and G. D. Bittner1, 2, 3. 1PlastiPure, Inc.,
Austin, TX; 2CertiChem, Austin, TX; 3University of Texas, Austin, TX. Sponsor: M.
Stoner.
A robotized MCF-7 cell proliferation assay currently undergoing validation by IC-
CVAM/NICEATM was used to quantify the total estrogenic activity (EA) of chem-
ical mixtures leaching from lab animal feed bags into feed over time. A standard
open-formula (low phytoestrogen AIN-93G) feed was purchased from Harlan®,
Research Diets™, and TestDiet®. The TestDiet® feed was packaged in EA-Free
bags recently developed by PlastiPure for PMI® LabDiet® and other customers.
All diets were analyzed 0, 2, and 4 weeks after purchase. All leachates were quanti-
fied relative to the percentage of the maximum DNA produced per well induced by
a test chemical with respect to the maximum DNA produced per well induced by
the 17beta-estradiol positive control (%RME2) and corrected by the cell response
to the vehicle (negative) control. The significance level (p < 0.01) to detect EA was
a %RME2 value 3 standard deviations more than the VC. According to this con-
servative criterion, EA levels in 72 hour ethanol extracts of commercial bags for
TestDiet®, Harlan®, and Research Diets™ were non-detectable (ND), signifi-
cantly positive, and significantly positive, respectively. In the feed study, there was
no detectable EA activity in TestDiet® feed at any time point. Feed samples from
Harlan® and Research Diets™ were ND at week 0 but significantly positive fol-
lowing storage for 2 and 4 weeks after purchase. EA readings for Harlan® and
Research Diets™ increased from week 0 to week 2 and again from week 2 to week
4. These data suggest that leaching of chemicals having EA from the non-EA free
plastic packaging can alter the hormonal activity of semi-purified animal feeds.
Such leaching of chemicals having EA from plastic packaging into animal feeds may
impact research protocols that examine hormonally- responsive end-points.
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112 Endocrine Disruption Potential of Trifluralin: Weight of
Evidence Evaluation.
S. Marty1,  S. Papineni2,  V. J. Kramer2,  S. C. Gehen2 and K. K. Coady1. 1The
Dow Chemical Company, Midland, MI; 2Dow AgroSciences LLC, Indianapolis, IN.
Trifluralin was included on List 1 for the EPA’s Endocrine Disruptor Screening
Program (EDSP). EDSP screens chemicals for their potential to interact with the
estrogen, androgen, or thyroid pathways. A battery of 11 Tier 1 EDSP assays was
completed for trifluralin and a Weight of Evidence (WoE) evaluation was con-
ducted. Estrogen pathway: Trifluralin was weakly positive in the estrogen receptor
(ER) transactivation assay, but it did not affect other estrogen-sensitive assays (i.e.,
ER binding, uterotrophic, estrogen-sensitive endpoints in the female pubertal, and
vitellogenin levels in the fish short-term reproduction assay (FSTRA)). Androgen
pathway: Trifluralin was negative for androgen receptor binding and while positive
in the Hershberger assay, this result was due to enhanced testosterone metabolism.
The male pubertal assay showed some indications of antiandrogenicity; however,
we believe these effects were indirect. In a previous two-generation study,
mating/reproductive indices, litter size/survival and reproductive organ
histopathology were unaffected. The FSTRA was potentially positive; however, in-
terpretation was complicated by overt toxicity and the absence of a cohesive link be-
tween study observations and known endocrine modes-of-action (MoA). Thyroid
pathway: The female pubertal assay was positive for thyroid changes due to liver en-
zyme induction and enhanced thyroxine clearance. Thyroxine levels were decreased
in the male pubertal assay, but other thyroid-related endpoints were not altered.
Trifluralin increased thyroid tumors in a previous carcinogenicity study via a mode-
of-action that is understood to be not relevant to humans. The amphibian meta-
morphosis assay was negative. Thus, there was no consistent evidence of effects on
the estrogen pathway and effects on the androgen pathway did not fit a mode-of-
action fingerprint for antiandrogenicity. Trifluralin alters the rodent thyroid system
via an indirect effect on the liver; these effects are not expected in humans, who are
quantitatively less sensitive than rats.
113 Cosmetics Products Have Detectable Estrogenic and
Antiestrogenic Activity.
C. Z. Yang1,  G. J. Kollessery1,  M. Stoner1,  A. W. Wong1 and G. D. Bittner1, 2.
1CertiChem, Inc., Ausin, TX; 2The University of Texas, Austin, TX.
We have used a roboticized MCF-7 cell proliferation assay and a BG1-Luc assay
undergoing validation by ICCVAM/NICEATM to quantify estrogenic activity
(EA) and anti-estrogenic activity (AEA) in saline (hydrophilic), ethanol (hydropho-
bic), and DMSO extracts of over 50 commercially available cosmetic products.
These included lipsticks, colognes, shampoos, hair conditioners and skin lotions
sent to CertiChem for testing by the National Toxicology Program and the Breast
Cancer Fund or purchased for testing by CertiChem from local stores. The total EA
in extracts was quantified relative to the maximum response of 17β-estradiol
(%RME2) and defined as the percentage of the maximum DNA/well produced by
an extract with respect to the maximum DNA/well produced by E2 at any dilution
and corrected by the cell response to the vehicle (negative) control (VC). The total
AEA in extracts was quantified relative to the AEA of ICI 182,780 (%RMICI). As
previously reported (see Yang et al, 2011, EHP 119:989-998), %RME2 and %
RMICI values >15% are significantly (P<0.01) greater than the VC, i.e. are de-
tectable for EA or AEA. In both MCF-7 and BG1-Luc assays, over 60% of the cos-
metics products tested had easily detectable EA in either saline, ethanol or DMSO
extracts. Some products exhibited AEA. When multiple extracts and tests were
done on eight cosmetic samples, 7 out of 8 had detectable EA or AEA in at least one
extract. Our results indicate that many cosmetics products contain components
that exhibit easily detectable EA when tested on two human cell lines in vitro. EA
or AEA in widely used cosmetics may account for some epidemiological data sug-
gesting hormonal perturbations in the early onset of puberty in girls, development
of uterine fibroids in adult females, and other adverse health effects (e.g., breast
cancer). The study was supported by NTP and Breast cancer Fund.
114 Use of Novel Assays to Screen Large Chemical Inventories for
Functional Estrogen Receptor (ER) Activity.
K. Houck1,  M. Martin1,  R. Judson1,  D. Rotroff1,  J. Melnick2,  J. Lamedin2 and
J. Weswick2. 1NCCT, US EPA, Research Triangle Park, NC; 2Odyssey Thera, San
Ramon, CA.
Rapid, efficient screening assays are important for providing the means to prioritize
large inventories of environmental chemicals for potential endocrine disrupting ef-
fects. Past efforts focused on transcriptional activation (TA) assays for estrogen, an-
drogen and thyroid receptors. The complexities of nuclear receptor (NR) biology,
however, limit this approach as a comprehensive strategy to identify all NR modu-
lators. For example, selective ER modulators can have cell type-specific activity de-
pendent on the particular coregulator proteins expressed. We thus examined alter-
native, complimentary assay methodologies that provide unique functional
information for chemical modulation of the ER pathway. We measured the ability
of 1848 chemicals to induce ER dimerization and nuclear translocation, initial and
required steps in ligand-induced activation of the ER pathway, using fluorescent
imaging in intact cells at multiple time points. We also determined receptor selec-
tivity using distinctly tagged ERα and ERβ receptors and found the great majority
of compounds to have similar potency for both receptors. Secondly, we determined
the activity of these 1848 chemicals in an ER/chromatin assay that visualizes active
ER transcriptional loci and provides functional information as to the level of ago-
nist versus antagonist activity of the ligand. Overall assay results showed chemicals
could be categorized into several groups. First, there were unequivocal ER agonists
active under virtually all testing conditions. Second, antagonists and partial agonists
with weak or no activity in TA assays run in agonist mode were readily detected by
these assays. Finally, there are spurious or artifactual results for each assay that must
be taken in to account when performing large scale assays such as this and are ap-
parent by looking at data across multiple assays and formats. These results demon-
strate the value of multiple, complimentary assay approaches in understanding
complex biological responses with in vitro systems.
115 Effect of Technical Variation and Bioinformatics on the
Biological Discovery in a Mechanistic Toxicogenomics Study.
B. Gong1,  J. Xu1,  Z. Su1,  H. Hong1,  J. Meehan1,  H. Fang1,  W. Ge1,
S. S. Auerbach2,  C. Wang3,  L. Shi1 and W. Tong1. 1Division for Bioinformatics
and Biostatistics, National Center for Toxicological Research, US FDA, Jefferson, AR;
2National Toxicology Program, NIEHS, Durham, NC; 3Department of Molecular
Medicine, City of Hope National Medical Center and Beckman Research Institute,
Duarte, CA.
Whole-transcriptome sequencing using next-generation sequencing technologies,
i.e., RNA-Seq, has drawn a significant attention as a ground-breaking tool for clin-
ical application and safety assessment. However, critical assessment of RNA-seq to
toxicology needs to be carefully conducted to understand whether the technology is
robust and reproducible and how the choice of the bioinformatics approaches im-
pacts study of the toxicity mechanisms and predictive toxicology. In this study, we
conducted a specific study design to evaluate the impact of sequencing platforms
and library preparation to the differentially expressed genes (DEGs) obtained, as
well as the impact of different methods for DEG identification. Specifically, RNA
samples from six rats’ livers were collected, three of them were treated with aflatoxin
(AFL) and the other three were matched controls. Two libraries were separately pre-
pared for the samples and two sequencing platforms (Illumina HiScanSQ and
HiSeq2000 systems) were used. The investigation was based on the results derived
from 6 different bioinformatics pipelines; each pipeline consists of a workflow in-
cluding a specific genome template, mapping algorithm, quantification and nor-
malization. Several methods for DEG identification were compared. The prelimi-
nary results show that library preparation introduces more variance than
sequencing platform on gene expression quantification. Additionally, more variance
has been observed for the low-expressed genes and thus increases the false positive
rate in DEG identification among those genes. We proposed two filters for data re-
liability control prior to DEG analysis, one on the low expression level and another
on high variance. Comparison was also carried out at functional module and path-
way levels.
116 Structural Classification of 1848 Chemicals Evaluated for
Estrogenic Activity in 13 HTS Assays.
R. Judson1,  D. Rotroff1,  M. Martin1,  D. Reif1,  K. Houck1,  P. Kothia1,
N. S. Sipes1,  T. B. Knudsen1,  M. Xia2 and R. Huang2. 1US EPA, Research
Triangle Park, NC; 2NCGC, Rockville, MD.
High-throughput screening (HTS) assays are seeing increasing use for identifying
chemicals that can cause toxicity via key biological pathways. However, biological
complexities often mean that a single assay will fail to correctly classify all com-
pounds for pathway activity. Here we use multiple orthogonal HTS assays to clas-
sify chemicals for their ability to interact with the estrogen receptor (ER) pathway
among a structurally diverse library of 1848 chemicals, including pesticidal actives
and inerts, industrial chemicals, food additives, cosmetics and drugs. The assays are:
reporter gene assays in HepG2 cells selected to maximize metabolic activity,
HEK293 cells, BG1 cells, CHO-K1 cells; cell-free binding assays (human, mouse,
bovine); assays for ER dimerization (ERa-ERa, ERa-ERb, ERb-ERb) in HEK293
cells; a transcription-factor/DNA binding assay in HeLa cells; and an ER-sensitive
cell proliferation assay in T47D cells. Multiple assay readouts used (fluorescence,
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luminescence, sequencing, electronic impedance) allowed determination of possi-
ble assay interference. Non-ER related assays (cytotoxicity, cell stress, chemical flu-
orescence, unrelated endpoints) in the same engineered cells were also included.
Assay data were compared with chemical structure clusters. A total of 237/1848
chemicals were active in at least 4 assays. (Note: the library was enriched in chemi-
cal classes expected to be estrogenic). This survey identified well known structural
classes of estrogenic compounds including steroids, phenols, chlorobenzenes, ani-
lines and perfluorinated alkanes. In metabolically competent assays, we also ob-
served bioactivation in classes of compounds including permethrins and anthracine
derivatives. In addition, we confirmed classes of compounds that consistently cause
false activity in certain assays, including surfactants. Finally, there were novel com-
pounds active in many assays that will require more analysis and follow-up studies
to confirm their activity. This abstract does not necessarily reflect Agency policy.
117 Categorizing Tobacco Related Documents by Salient Topics
for Regulatory Examination with Topic Modeling.
K. Yu1,  Y. Ding1,  R. Perkins1,  W. Aaaronson2,  D. Sholtes2,  Y. Tian2,
G. Rochester2,  X. Xu1, 3 and W. Tong1. 1Division of Bioinformatics and Biostatistics,
National Center for Toxicological Research, US FDA, Jefferson, AR; 2Center for
Tobacco Products, US FDA, Rockville, MD; 3Department of Information Science,
University of Arkansas at Little Rock, Little Rock, AR.
The FDA’s Center for Tobacco Products (CTP) has received a large volume of doc-
uments from its regulated industries, and even more documents are forthcoming.
The documents are unstructured and in various formats, including email,
PowerPoint slides, memoranda and others. These documents contain diverse infor-
mation related to such areas as marketing, safety and risk. The language is free text
often containing ambiguous semantic descriptions, posing difficulty in retrieving
useful information in a consistent and accurate fashion that is needed for regulatory
review. Moreover, the shear volume makes manual reading of the entire corpus im-
practical. To increase the review efficiency, the FDA requires submitters to include
key word tags corresponding to FDA supplied question areas. The goal of this study
is to identify the hidden topics or concepts from the submitted documents using
topic modeling, and to assess whether the extracted topics reflect the FDA defined
questions and thus facilitate review. As a pilot study, more than three thousand
menthol-related tobacco documents were used to develop a topic model with latent
Dirichlet allocation (LDA). The number of topics was optimized based on an in-
formation-loss approach. After generating the topics, a cosine similarity based ap-
proach was used to map FDA questions to the extracted topics. The results demon-
strated that the extracted topics reflect the concepts of regulatory questions. The
majority of documents clustered by topic modeling coincided with those grouped
by FDA defined requests. This study demonstrates the potential utility of topic
modeling as an unsupervised machine learning technique to classify the submitted
documents based on the hidden topics, and thus provides an alternative means to
support the review process.
118 Gene Expression Analysis to Predict the Dermal
Carcinogenic Potential of Petroleum Streams.
K. Mathijs1,  J. van Delft1,  M. van Steensel2,  K. Goyak3,  H. Ketelslegers3,
J. Freeman3 and R. Phillips3. 1Department of Toxicogenomics, Maastricht University,
Maastricht, Netherlands; 2Department of Dermatology, Maastricht University,
Maastricht, Netherlands; 3ExxonMobil Biomedical Sciences Inc., Annandale, NJ.
Certain poorly refined petroleum streams that contain high levels of polycyclic aro-
matic compounds have been shown to cause skin cancer in mice, as determined by
the appearance of skin tumors after chronic dermal administration, which has cost
and time constraints. We wish to identify biomarkers for petroleum-induced skin
tumorigenesis, based on toxicogenomic responses in treated mouse skin from which
predictive short-term tests can be developed. C3H/HeNCrl mice were treated der-
mally three times for one week with carcinogenic (C) or non-carcinogenic (NC) pe-
troleum streams or with the solvent control. 24 h after the last treatment, sections
of dorsal skin from sacrificed mice were used for immunohistochemistry (IHC),
RNA and DNA isolation. Gene expression profiling using Agilent microarrays was
done to select altered genes and molecular pathways related to individual test sub-
stances and substance classes for use in class prediction analyses to discriminate C
from NC. No clear differences in IHC markers for hyper-proliferation, differentia-
tion, or apoptosis were found between control, C and NC. Increased γH2AX, a
DNA damage marker, was found in C vs control and NC. Clear differences in gene
expression profiles occurred between C and NC. Based on the gene expression pro-
files, correct prediction occurred; the top 10 classifier genes (which included
Cyp1a1, Cyp1b1, Nqo1, Ahrr, Artn) are mainly involved in xenobiotic metabolism
and oxidoreductase reactions. Classification based on pathway expression changes
correctly predicted only NC and the highest concentrations of C; the top classifier
in the pathway analysis was the KEGG pathway “xenobiotic metabolism by cy-
tochrome P450”. Our results indicate that gene expression responses from a short-
term dermal mouse study can predict C and NC petroleum streams, and that the
AhR receptor pathway warrants further evaluation as a biomarker of exposure for
petroleum-induced skin tumorigenesis.
119 Structure-Based Virtual Screening: Identification of New
Targets for Triclosan.
D. Montes-Grajales and J. Olivero-Verbel. Environmental and Computational
Chemistry Group Pharmaceutical Sciences, University of Cartagena, Cartagena,
Colombia.
Triclosan (TCS; 2,4,4′-trichloro-2′-hydroxy-diphenylether) is a broad-spectrum
antimicrobial agent used in personal care products. It has cytotoxic and endocrine-
disrupting properties, and may be bioaccumulated from daily use. However, its im-
pact on human health is largely unexplored with little evidence for deleterious ef-
fects in humans. A total of 248 proteins involved in different pathological processes
were evaluated by in sílico virtual screening to find new possible human protein tar-
gets for TCS. The 3D-structures of the proteins were downloaded from PDB, pre-
pared and optimized by Sybyl X-2.0. The TCS structure was optimized by DFT at
the B3LYP/6-31G level in Gaussian 0.9. Docking studies were performed in
AutoDockVina 2.0 using a blind docking strategy, exhaustiveness of 25 and 10
runs. Calculated binding affinities were then employed for ranking proteins. A re-
docking step of 100 runs and exhaustiveness of 100, as well as the interaction analy-
sis with Ligand Scout, LigPlot and MMV were carried out on the complexes pre-
senting the best docking results. The greatest affinity scores were found for
CDC2-like kinase 4 (CLK4, -8.4±0.0 kcal/mol), oligomeric death domain com-
plex (CRADD/PIDD, -8.3±0.1 kcal/mol); progesterone receptor (PGR, -8.1±0.0
kcal/mol); and estradiol 17-beta-dehydrogenase 1 (17-beta-HSD 1, -8.1±0.1
kcal/mol), proteins involved in endocrine disruption and breast cancer-related
processes. Validation showed our protocol predicted the binding site for the 17-
beta-HSD and PGR native ligands, in agreement with crystallographic data.
Moreover, TCS interacts in the same binding site occupied by the 17-beta-HSD 1
native ligand, but in a different one from that used by progesterone in PGR.
Protein-ligand binding included hydrophobic and hydrogen bonding interactions.
These results suggest TCS may target different proteins, probably altering pathways
involved in pathophysiological disorders. Vice-Rectory for Research.
UniCartagena. 2011-2012. Colciencias-UniCartagena: Grants 110745921616
(2009) and 110751929058 (2010).
120 Generation of In Vitro Margin of Exposure (MOE) Values to
Support the Postulated Mode of Action (MOA) for Selected
Tobacco Smoke Toxicants.
S. A. Fiebelkorn,  F. H. Cunningham,  E. L. Bishop,  D. M. Dillon and
C. Meredith. Group R&D, British American Tobacco, Southampton, United
Kingdom.
Over the last ten years there has been increasing interest in the identification and
characterisation of tobacco smoke toxicants. We propose the use of a biologically
relevant risk assessment framework incorporating both in vivo and in vitro data for
the prioritisation of such toxicants. We have previously described the use of in vivo
data in the generation of Margin of Exposure (MOE) values alongside Mode of
Action (MOA) reviews. We have also proposed that individual toxicants are tested
for activity in a battery of in vitro assays including in vitro micronucleus, Ames and
mouse lymphoma assays. 
MOE assessments are used as an initial tool to segregate tobacco smoke toxicants
into high or low priority for risk reduction research. As recommended by EFSA,
MOE values above 10,000 can be considered a low priority for risk management
actions. We have generated in vitro MOEs for a number of tobacco smoke toxicants
in conjunction with MOA reviews and in vivo MOEs (where suitable data is avail-
able). Where the in vivo MOEs generated for individual toxicants do not provide a
conclusive evaluation and are split across the critical value of 10,000 (e.g. NNK and
arsenic) or where the available in vivo data is unsuitable for MOE generation (e.g.
hydroquinone and catechol), the use of in vitro data can provide an alternative
source of information. We present here MOE data for five different tobacco smoke
toxicants:
Benzo[a]pyrene: in vitro: 42,469–3.0 x 107; in vivo: 16,805–2.4 x 106.
NNK: in vitro: 1.0 x 106–3.7 x 108; in vivo: 338–3.7 x 105.
Arsenic: in vitro: 2.95 x 107; in vivo: 13–4.9 x 105.
Catechol: in vitro 938–12,094; in vivo: No data.
Hydroquinone: in vitro: 1651–10,304; in vivo: No data.
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The incorporation of in vitro data into our suite of assessment methods allows us to
generate additional MOEs to support the MOAs and provide further mechanistic
understanding of individual toxicants. There is also the potential to incorporate
such in vitro data into the future development of PBPK models for individual toxi-
cants.
121 Developing a Gene-Gene Interaction Network for
Nonsyndromic Orofacial Clefts Using Computational
Analysis.
J. McKone,  A. N. Van,  E. Lachenauer and D. Johnson. University of California
Berkeley, Berkeley, CA.
Orofacial clefts (OFCs) are caused by malformations in the closing of the lip or the
soft palate. Although OFCs are considered to be one of the most common congen-
ital birth defects, the underlying mechanisms of its etiology have yet to be clearly
elucidated. This study sought to systematically determine how candidate genes pre-
viously identified in the literature interact, potentially implicating specific pathways
for nonsyndromic OFC formation. OFC gene candidates were derived from
genome-wide association studies (GWAS), the Comparative Toxicology Database,
and Thomson Reuter’s GeneGo. The compiled OFC genes were analyzed in con-
junction with genes associated with the metabolic pathways of vitamin A and folic
acid, factors shown to be implicated in OFC formation. Utilizing GeneGo and the
candidate gene list, a gene-gene interaction network was constructed. Analysis of
the network led to the identification of the TCF/LEF gene family, members of
which regulate several downstream targets identified in the GWAS and/or are asso-
ciated with vitamin A or folic acid metabolism. The TCF/LEF genes were shown in
the network to be regulated by genes involved with the WNT signaling pathway,
suggesting a mechanistic relationship between WNT signaling and orofacial cleft
formation. Through computational analysis, this study proposes a potential gene-
gene interaction mechanism for OFC formation via the WNT signaling pathway
and ultimately identifies the TCF/LEF family as possible target gene candidates for
future studies.
122 Role of Beta-Methylamino-L-Alanine in GRIK1-Mediated
Amyotrophic Lateral Sclerosis Disease Pathway.
S. Firouzbakht,  Y. Iizuka and D. Johnson. University of California Berkeley,
Berkeley, CA.
Amyotrophic Lateral Sclerosis (ALS) is a debilitating neurodegenerative disease that
affects about 30,000 people in the United States alone. Only a small fraction of
cases are linked to genetics, making it likely that the overwhelming majority are in-
duced by environmental factors. Therefore, the elucidation of a toxicity pathway is
critical to the understanding of the vast majority of the ALS disease population.
Amongst potential environmental exposures, neurotoxin beta-N-Methylamino-L-
alanine (BMAA) has shown strong association with ALS in a small disease cluster in
Guam. However, the several proposed mechanisms are insufficient in explaining
the entire disease pathway. In this study, we utilized computational predictions with
GeneGo, STITCH, BLAST, PubChem, and KEGG to generate the most feasible
pathway for BMAA toxicity. The results from PubChem structure clustering be-
tween a highly kainate-specific ligand and BMAA-β-carbamate revealed a statisti-
cally significant 3D Tanimoto score, implicating a comparable receptor repertoire.
BLAST sequencing comparisons between GRIK1-5 and GLUL, an ALS associated
gene, showed significant overlap between the two nucleotide sequences, further
suggesting that kainate receptors are crucial to the ALS disease pathway.
Incorporating these computational studies with current knowledge, there is com-
pelling evidence suggesting a primary disease pathway in which BMAA-β-carba-
mate binds to the kainate receptor GRIK1 at the presynaptic motor neuron, lead-
ing to increased glutamate release and subsequent neurodegeneration.
123 Computational Analysis of a Potential Mechanistic
Relationship between Depleted Uranium (DU) Exposure and
Risk of Spina Bifida Cystica.
S. Aghaee,  H. Ngo and D. Johnson. University of California Berkeley, Berkeley, CA.
Prolonged weapon use in war zones increases the environmental levels of potentially
teratogenic metals which may have a direct relationship to increased incidences of
birth defects. In Fallujah, Iraq since 2003, high levels of depleted uranium (DU) in
the environment and in hair samples of residents suggests that constant exposure to
DU may play a role in the alarming rates of congenital defects found in Iraqi chil-
dren. One particular birth defect, Spina bifida, is a congenital defect of the spinal
column with two major subclasses: spina bifida occulta and spina bifida cystica.
Cystica is the most severe form of the disease but also the least prevalent. However,
this has not been the case in Fallujah, Iraq where from 2003 cystica has been found
to be the most prevalent form of spina bifida. The purpose of this study was to
search for any commonalities between the genes and biological pathways associated
with exposure to uranium and development of spina bifida cystica. Computational
methods and tools utilized included the Comparative Toxicogenomics Database
(CTD), PubChem, ToxNet, Pathway Commons, and unpublished exposure/defect
data from Iraq. Out of the 292 genes reportedly affected by uranium exposure, 155
were also associated with spina bifida cystica. Biological pathway analysis revealed
three genes, NT5E, PED, and TALDO1, associated with uranium are also involved
in upstream pathways of folic acid synthesis. Research has shown that a lack of fo-
late is known to be related to spina bifida. This study provides a broad look at the
genetic and molecular similarities between response to uranium exposure and spina
bifida cystica, and may offer options for preventive therapeutic interventions.
Further studies examining gene ontologies of populations exposed and not exposed
to depleted uranium would offer a clearer picture of the relationship between ura-
nium and spina bifida.
124 Computational Analysis of Catechins in Teas and Potential
Relationship to Cardiovascular Health.
C. Lei,  M. Nhan,  C. Ha and D. Johnson. University of California Berkeley,
Berkeley, CA.
Consumption of green tea has been reported to have beneficial effects on a variety
of health-related issues. Of interest is the beneficial differences between green, oo-
long, and black teas, all produced from the leaves of Camillia senesis. Of the five
main groups of bioactive compounds in the Camillia sinensis plant, catechins were
found to be the most bioactive. Of the six main catechins in tea, epigallocatechin-
3-gallate (EGCG), the most abundant and bioactive of the catechins was found to
be in the highest concentration in green tea as compared to oolong and black teas
and subsequently was considered to be the most health-relevant component. The
potential health benefits of tea depend on their level of fermentation, which is cor-
related to the amount of oxidation the catechins undergo during processing.
EGCG is most abundant in green tea, which is not fermented, and highest in fresh
unprocessed leaves from Camillia senesis. Green tea extract has also been reported
to have increased biological activities. EGCG and pro-drugs have also been shown
to be potential epigenetic modulators. DNA methylation is catalyzed by DNA
methyltransferase (DNMT) with S-adenosyl-methione (SAM) as the methyl
donor. EGCG has been shown to reduce DNMT indirectly by reducing SAM and
increasing S-adenosyl homocysteine (SAH) and homocysteine levels in the MCF-7
breast cancer cell line. In this study, primarily utilizing Genego Metadrug and
MetaCore we report a proposed overlap between EGCG affected pathways and the
atherosclerosis disease pathway. EGCG was found to competitively block hydroxy-
3-methyl-glutaryl-CoA, and non-competitively inhibit squalene epoxidase, two
rate limiting enzymes in the cholesterol biosynthesis pathway. In addition, previous
animal studies have reported a decrease in LDL levels in rats given the three teas
with the highest response coming from green tea treatment. This study provides an
analysis of antioxidant compound levels found in tea and their relation to its effect
on cardiovascular health, providing a possible explanation to the differences in ben-
eficial effects found in different types of teas.
125 Computational Analysis of Environmental Factors
Potentially Associated with Multiple Sclerosis Susceptibility.
F. Su,  M. Gooding,  G. Anderson and D. Johnson. University of California
Berkeley, Berkeley, CA.
Multiple Sclerosis (MS), an autoimmune disease of the CNS, may have associated
environmental risk factors. A relationship between distance from the equator and
MS risk reinforces the belief that UVB radiation and subsequent Vitamin D syn-
thesis act protectively. The Human Leukocyte Antigen b chain, HLA-DRB1 is ac-
tivated by Vitamin D and its receptor, and a polymorphism, HLA-DRB1*15.01,
has been associated with MS susceptibility. Computational methods utilized to ex-
plore environmental factors beyond UVB radiation that might influence MS dis-
ease pathways included the Comparative Toxicogenomics Database (CTD),
STITCH, GWAS data, Genego, and the EPA Toxic Release Inventory (TRI).
Historical MS clusters in the US were identified and toxic release data obtained
through TRI. Lead (Pb 2+), was found as a top contaminant among the MS clus-
ters. Although lead has been proposed as a risk factor for MS, no previous pub-
lished studies have clearly linked lead and MS. To identify and investigate genes,
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cellular pathways and disease interactions, CTD was utilized with STITCH to gen-
erate association networks between genes and proteins and to identify another in-
termediate protein, ALAD. Binding assays show that a polymorphism of ALAD,
ALAD2, causes red blood cells to bind lead more tightly and previous research has
implicated ALAD as an important factor in lead susceptibility. VDR polymor-
phisms are also associated with lead susceptibility. Although a correlation between
VDR B and higher blood, urine, and plasma lead levels has been reported, the
mechanism and systemic effect of the allele are not well understood. Maps of the
frequency of haplotypes in different populations for VDR B, ALAD2 and HLA-
DRB1 were obtained from GWAS and correlating biological pathways involving
MHCII, ALAD, and VDR were constructed with Genego. In combination, the re-
lationships identified suggest that ALAD2 and VDR B haplotypes confer an indi-
vidual with heightened lead susceptibility. Furthermore, the results suggest that ele-
vated levels of lead are associated with decreased expression of HLA-DRB1 and
greater risk of MS.
126 Profiling the Activity of Environmental Chemicals in
Causing Testicular Dysgenesis Syndrome Using the US EPA
Toxicity Reference Database (ToxRefDB).
M. C. Leung1,  K. W. McLaurin1,  J. Phuong1,  N. S. Sipes1,  N. C. Baker1,
N. Kleinstreuer1,  A. M. Frame1,  R. Judson1,  G. R. Klinefelter2,  M. T. Martin1
and T. B. Knudsen1. 1National Center of Computational Toxicology, US EPA,
Research Triangle Park, NC; 2Reproductive Toxicology Division, US EPA, Research
Triangle Park, NC.
Hypogonadism, cryptorchidism, hypospadias, and testicular cancer are increasingly
common male reproductive defects. Clinical and experimental evidence suggest
that these defects are associated with testicular dysgenesis syndrome (TDS). We hy-
pothesize an Adverse Outcome Pathway (AOP) framework for TDS starting with
disruption of cell signaling and structural targets of the fetal testis during embryo-
genesis, followed by a series of key events that lead to male reproductive defects.
Since understanding chemical-endpoint associations is an approach in building the
AOP conceptual models, we mined 4209 guideline animal studies in EPA’s
ToxRefDB, which included 963 compounds tested in rats, mice, and rabbits.
Testicular neoplasia was an outcome for 60 (6.2 %) chemicals. Sperm abnormalities
were an outcome for 72 (9.8 %) chemicals tested in chronic and subchronic toxic-
ity studies and 44 (5.7 %) chemicals tested in prenatal developmental and/or multi-
generational fertility studies. Reductions in anogenital distance were recorded for
15 (3.5 %) chemicals tested in multigenerational studies, and 11 (1.5 %) chemicals
tested caused hypospadias or cryptorchidism in developmental or multigenera-
tional studies. The chemical classes showing the broadest activity across different
TDS endpoints were pesticides (amdro, benomyl, primisulfuron-methyl, tetra-
chlorobenzene, and vinclozolin) and phthalates (butyl benzyl phthalate, dibutyl ph-
thalate, and diethylhexyl phthalate) with a lowest effect level on the order of ~300
mg/kg/day. The most potent TDS-actives (17β-estradiol, fluazinam, and tebupir-
imfos) produced testicular effects below 0.1 mg/kg/day. These results suggest a hi-
erarchical pattern of male reproductive defects in ToxRefDB which can be used as
an AOP anchor for TDS. [This work does not reflect EPA policy].
127 Compound Toxicity Profiling and Prioritization Using Tox21
Phase I Quantitative High-Throughput Screening (qHTS)
Cytotoxicity Data.
J. Hsieh1,  A. Sedykh2,  R. Huang3,  M. Xia3 and R. R. Tice1. 1Division of the
National Toxicology Program, NIEHS, NIH, Research Triangle Park, NC; 2University
of North Carolina at Chapel Hill, Chapel Hill, NC; 3National Center for Advancing
Translational Sciences, Bethesda, MD.
Using in vitro data to prioritize compounds for in vivo toxicity testing is a goal of
Tox21. Phase I profiled 1408 NTP compounds against 126 cell-based qHTS as-
says; those that measured cytotoxicity record the ability of a chemical to adversely
perturb multiple cellular pathways in a concentration-response fashion. The curves
from 39 cytotoxicity assays (9 human cell types, 4 rodent cell types, 13 sets of iden-
tical twin lymphoblastoid cell lines) were curated to filter noise and remove arti-
facts. To quantify the activity of each compound in these assays, we calculated a
weighted version of Area Under the Curve (wAUC) intended to capture potency
and efficacy simultaneously, as well as the conventional half-maximal activity con-
centration (AC50) value. The average wAUC or AC50 values across the 39 cyto-
toxicity assays were used to rank compounds and the rankings were compared, for
880 compounds, with available rat acute oral toxicity data. The compounds were
categorized as toxic or non-toxic based on various “Globally Harmonized System of
Classification and Labelling of Chemicals” (GHS) acute toxicity thresholds (50,
300, 500, 2000 mg/kg). The wAUC approach consistently prioritized more toxic
compounds at the early stage (up 1% non-toxic compounds of dataset) at all
thresholds. The best receiver operating characteristic (ROC) enrichment value at
1% and AUC value are 14.3 [95% CI=1.8-26.8] and 0.73 [95% CI=0.65-0.80],
respectively, at a threshold of 50 mg/kg. Also, some toxic compounds (e.g., actino-
mycin D, colchicine, daunomycin) had higher ranks based on wAUC due to their
ill-fitted curves in some of the cell lines, resulting in missing AC50 values. We con-
clude that the wAUC provides an additional and useful metric to estimate the toxi-
city potential of compounds for Tox21 qHTS assays. Based on this metric, com-
pounds screened in Tox21 can be prioritized for more extensive testing.
128 Predicting Cellular Dynamics and Key Events in
Developmental Toxicity with a Multicellular Systems Model.
T. B. Knudsen1,  M. R. Rountree1,  S. Hunter2,  N. C. Baker3,  R. Spencer3,
R. S. DeWoskin4 and W. Setzer1. 1NCCT, US EPA, Research Triangle Park, NC;
2NHEERL, US EPA, Research Triangle Park, NC; 3Lockheed Martin, Research
Triangle Park, NC; 4NCEA, US EPA, Research Triangle Park, NC.
Computer simulation of cellular networks is one possible solution for modeling key
events in developmental toxicology. We constructed a multicellular agent-based
model (ABM) of early limb-bud development in CompuCell3D (www.compu-
cell3d.org/). The model simulates key cellular behaviors (mitosis, apoptosis, adhe-
sion, migration, chemotaxis, shape, secretion), organizing centers (AER, ZPA) and
signals (FGFs, SHH, BMPs, RA). It effectively emulates hindlimb-bud develop-
ment during a 42h period in mouse (Theiler stages 16-19) and 160h in human
(Carnegie stages 13-16). The ABM reflects biological variability across parallel sim-
ulations for spatio-temporal expression of biochemical gradients and cell behaviors,
ultimately manifesting in trajectories of outgrowth. To evaluate the model as a tool
for predictive toxicology, we selected 5-Fluorouracil (5FU) as a prototype. 5FU per-
turbed 13 of 650 ToxCast assays based on AC50s (or LECs) at or below 15 uM.
5FU effects observed in the assays were disruption of stem cell (mES) growth and
differentiation, suppression of TGFb1 signaling and mitochondrial density, p53-in-
duction, mitotic arrest, reduced cell proliferation and increased cell death.
Challenging the ABM with concentration-response data derived from mES cell
number produced a dose-dependent wave of mitotic arrest and apoptosis, disrupt-
ing outgrowth. Varying the dose and time of exposure localized the primary key
event to arrest of SHH-expressing cells and their geometric relationships to cells ex-
pressing GREM1, a BMP antagonist maintained by SHH signals. Different out-
comes emerged when perturbation of the SHH/GREM1/BMP loop was switched
between mitotic arrest and excessive apoptosis, indicating the importance of con-
sidering both cellular consequences together. These findings support the applica-
tion of multi-cellular ABMs as tools to translate cellular dynamics into simulation
of emergent (higher order) tissue effects for predictive toxicology. [This abstract
does not necessarily reflect EPA policy.]
129 Chemical Structure-Based In Silico Phototoxicity Prediction:
An Approach from a Combination of Photochemical
Properties.
Y. Haranosono,  S. Nemoto,  M. Kurata and H. Sakaki. Senju Pharmaceutical Co.,
Ltd., Kobe, Japan.
Some photochemical properties are essential factor for prediction of phototoxicity,
since phototoxicity is caused by photo-activation of the compounds. Highest
Occupied Molecular Orbital – Lowest Unoccupied Molecular Orbital Gap (HLG)
is a photochemical property of needful energy for photo-activation, and HLG was
reported to be related with phototoxicity based on in vitro 3T3 Neutral Red Uptake
assay (3T3 NRU assay). However there are few reports to predict of phototoxicity
using photochemical property including HLG. In this research, we established the
stepwise approach using Maximum-Conjugated-π-Electron- Number (PENMC) of
the compounds in addition to HLG for in vitro phototoxicity prediction. HLG and
PENMC were calculated by ChemDraw
® and Chem3D® for total 64 compounds
which were known the results of 3T3 NRU assay (32 positive and 32 negative). As
step 1, we set the cut lines of HLG as follows; the compounds that have over 8.0 of
HLG were determined as negative, and the compounds that have less than 5.2 of
HLG were determined as positive. On the other side, the compounds that have
HLG from 5.2 to 8.0 showed no predicting performance to phototoxicity, and then
we defined this range of HLG as gray zone. As step 2, we employed PENMC for the
gray zone compounds. We found that PENMC also indicated correlation to in vitro
phototoxicity, and therefore set the cut lines as follows; the compounds that have
12 and more than of PENMC were determined as positive, and 11 or less of PENMC
were determined as negative. This stepwise approach for phototoxicity prediction
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was validated by the following results; sensitivity (84.4%), specificity (81.3%), pos-
itive rate (81.8%), negative rate (83.9%) and concordance (82.8%). We concluded
that the stepwise approach with combination of HLG and PENMC for prediction of
phototoxicity is adaptable and useful for drug development as in silico screening,
because it showed high sensitivity and negative rate from only chemical structure.
130 High-Content Screening of ToxCast Compounds for
Developmental Endpoints Related to Adipogenesis and
Angiogenesis.
D. L. Filer,  N. Kleinstreuer,  M. Martin,  K. Houck and D. Reif. National Center
for Computational Toxicology, US EPA, Research Triangle Park, NC.
The US EPA’s ToxCast research program gathers toxicity information for over 1000
chemicals utilizing high-throughput toxicity screening (HTS) assays with human
gene and protein targets to inform prioritization of chemicals with little or no toxi-
city information for further testing. Vala Sciences provides high content multi-
plexed assays utilizing quantitative digital imaging of cultured cells, tissues and
small model organisms. We measured the ToxCast Phase I_v2 chemical library,
(293 unique compounds, primarily food-use pesticides with associated in vivo tox-
icity data), with 12 Vala Sciences assays in six-point concentration response from
0.013 μM to 100 μM. Assays examined chemical effects on embryonic stem cell
differentiation, neuronal function, pancreatic β cell differentiation, germ layer pro-
liferation, adipogenesis, adipocyte lypolysis, hepatic steatosis, and junctional pro-
teins critical to developmental angiogenic processes and tumor progression. We
subjected concentration response data to automated curve-fitting using modified
Hill functions, outlier detection algorithms, and uncertainty analysis to determine
the half-maximal activity concentration (AC50) and Lowest Effective
Concentration (LEC) for each chemical/assay combination. Assays showed high re-
producibility, both within triplicate replicate sets and in blinded compound repli-
cate sets. Across the entire Phase I chemical set, 5% of chemical/assay combinations
demonstrated significant (> 50% change over control baseline) activity. Early re-
sponse targets in this data set provide toxicological and mechanistic insight to com-
plement other ToxCast assays and lead to stronger predictive toxicity models.
Collectively, these results add important data to ToxCastDB that will help identify
and prioritize possible developmental toxicants, endocrine disruptors, liver toxi-
cants, and carcinogens to inform targeted testing strategies. This abstract does not
necessarily reflect U.S. EPA policy.
131 In Silico Models for Dermal Absorption from Complex
Formulations.
K. Guth1,  J. E. Riviere2, 3,  J. Brooks2,  M. Schäfer-Korting4,  M. Dammann1,
E. Fabian1,  B. van Ravenzwaay1 and R. Landsiedel1. 1Experimental Toxicology and
Ecology, BASF SE, Ludwigshafen am Rhein, Germany; 2Toxicology Research and
Pharmacokinetics, North Carolina State University, Center for Chemical, Raleigh,
NC; 3Institute of Computational Comparative Medicine, Kansas State University,
Manhattan, KS; 4Institut für Pharmazie, Freie Universität, Berlin, Germany.
Dermal exposure is a relevant parameter for risk assessment of chemicals, cosmetics
and pesticides. Here, we present potential in silico models for prediction of dermal
absorption based on realistic exposure scenarios in complex mixtures.
The calculations were based on 342 individual dermal absorption in vitro experi-
ments using human or rat skin samples for 56 chemicals (mainly pesticides) in
more than 150 different mixtures containing up to 20 ingredients like water, or-
ganic solvents, surfactants or thickeners. The first approach was based on the
Abraham solute descriptors, mixture factors (MFs) as suggested by Riviere and
Brooks and the logarithmic maximal permeability coefficient (logmaxKp) as re-
sponse1,2. Additionally, an indicator variable for the species (SpI) was introduced.
In a second approach class variables – which bundled substance-specific informa-
tion – were used in combination with mixture factors. Validation was performed in
accordance with the OECD Guidance document for QSAR models.
The final validated Abraham-based model comprised the solute excess molar refrac-
tivity of the penetrant, SpI and topological polar surface area of the mixture
(R2:0.38, Q2Ext: 0.41). Despite the low correlation, the model was suitable to es-
timate Marzulli classes of penetration for unknown penetrants in specific mix-
tures3. Furthermore, precise prediction of mixture effects on well-known sub-
stances was possible with the substance-based approach (R2:0.75, Q2Ext: 0.73).
Taken together, both applications are suitable screening tools in early stages of
product development.
1 Abraham et al. 1999. Pesticide Science 55, 78-88
2 Riviere and Brooks 2005. Toxicology and Applied Pharmacology 208, 99-110
3 Marzulli and Brown 1969. Toxicology and Applied Pharmacology 3, 76-83
132 Development of Improved Salmonella Mutagenicity QSAR
Models Using Structural Fingerprints of Known
Toxicophores.
L. Stavitskaya1,  B. L. Minnier2,  R. Benz1 and N. L. Kruhlak1. 1US FDA, Silver
Spring, MD; 2GlobalNet Services, Inc., Rockville, MD.
The current draft of the International Conference on Harmonisation (ICH) M7
guidance describes the use of in silico models to qualify genotoxic impurities during
the drug safety evaluation and approval process. In order to attain the highest accu-
racy and improve the domain of applicability of the current Salmonella mutagenic-
ity quantitative structure-activity prediction models, continuous updates to the
training set must be made to accommodate new genotoxic findings. In this study,
we first assessed our current Salmonella mutagenicity training set using fingerprints
of known genotoxic structural alerts to determine the domain of applicability and
performance characteristics of several commercial (Q)SAR models. We then en-
hanced the previous version of our non-proprietary training database for
Salmonella mutagenicity with data for 431 new compounds harvested from FDA
approval packages and the published literature, to give a total of 3965 compounds.
Of the 431 chemicals, 247 are drug molecules marketed between 1970 and 2011.
Data gaps within the training set were identified and, using structural features de-
rived from known toxicophores, 141 examples containing functional groups such
as azides, amine oxides, hindered epoxides, propriolactones, quinones, amine
halides, diazines, azo compounds, diazoniums, sulfates, aziridine chlorides, nitrites,
hydrazines, nitriles, isocyanates, and sulfur mustards were added. Moreover, the
new training set was expanded to include over 40 compounds containing previ-
ously unmodeled atoms such as boron, silicon, selenium, and tin. A hierarchical
clustering analysis of the final training set showed representation of an additional
44 structural clusters over which the model can make a prediction.
133 Evaluation of QSPR Models to Predict Evaporation Rates of
Hazardous Chemicals from the Skin Surface.
T. Liu,  M. Rauma and G. Johanson. Institute of Environmental Medicine,
Karolinska Institutet, Stockholm, Sweden.
The skin serves as a barrier against hazardous agents in the environment. However,
the barrier is incomplete in that chemicals may penetrate the skin and cause toxic-
ity. The absorbed dose depends not only on the absorption rate but also the evapo-
ration rate (assuming a fixed dose and skin area). The limited data available suggest
that rates vary by several orders of magnitude between chemicals. However, there is
a huge lack of data and new approaches are needed. One attractive possibility is to
use quantitative structure-permeability relationship (QSPR) models. The aim of
the present study was to examine different QSPR models addressing evaporation
rate. We calculated evaporation rates for nine volatiles (methanol, n-propanol, ace-
tone, methyl ethyl ketone, hexane, n-heptane, octane, benzene and toluene) at
three air velocities and three air temperatures, using four semi-empirical models;
McCready & Saghir, EPA, Mackay & Matsugu, and BAU. The predictions were
compared with experimental data published by the EPA1. None of the four models
were able to predict the evaporation rate at all wind speeds. For comparison, we also
developed linear solvation energy relationships (LSER) and partial least squares
projections to latent structures (PLS) models. Seven solvents were used for calibra-
tion and two to test predictive performance. The LSER and PLS models showed
good correlation (R2 0.95 and 0.92) and predictive performance (Q2 0.86 and
0.95) and seem more suitable than the semi-empirical models to predict evapora-
tion rate. The semi-empirical models, EPA and Mackay &Matsugu at higher air ve-
locity (5.08 m/s) and lower temperature (280.35 K), showed a fair agreement be-
tween predictive and experimental values. As a result, evaporation rates can be
adequately predicted from available physicochemical properties of the volatile or-
ganic compounds (VOCs).
Reference
1. Braun, K.O. and Caplan, K.J. (1989) Evaporation rate of volatile liquids, final
report, 2nd edition. EPA/744-R-92-001, NTIS PB92-232305, Springfield.
134 Regulatory Targets of CDKN2A in Lung Epithelial Cells.
J. Mehta and G. Acquaah-Mensah. Massachusetts College of Pharmacy and Health
Sciences, Worcester, MA.
Cyclin Dependent Kinase Inhibitor 2A (CDKN2A) is a tumor suppressor protein
in humans. It is capable of inducing cell cycle arrest in the G1 and G2 phases.
p16INK4a is a major component of the RB pathway. p14ARF is part of an ARF-
MDM2-TP53 system that exercises a negative control on hyper-proliferative sig-
nals originating from oncogenic stimuli. ARF binds to MDM2 and blocks its cyto-
plasmic transfer and thereby sequesters it in the nucleolus. This hinders the MDM2
action, thereby blocking degradation of p53 and thus enhancing transactivation
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and apoptosis. The purpose of this study was to identify additional regulatory tar-
gets of CDKN2A in lung epithelial cells, using Bayesian networks. Using the
Robust Multi-Array Average procedure, a compendium of lung epithelial cell mi-
croarray data was generated based on Gene Expression Omnibus datasets GSE
19027 and GSE 994. The best-scoring regulatory networks, given the gene expres-
sion data, were then learned using the Bayesian Network Inference with Java
Objects toolkit (BANJO) for static Bayesian Network inference. A set of known
regulatory relationships involving CDKN2A was used as the initial network to
focus the search space. Two proposers concurred in predicting IL1RN, IL6ST,
IL1RAPL1, IGFALS, and WNT10B as regulatory targets for CDKN2A. These
genes are known to interact with a range of chemicals, including certain environ-
mental toxicants. Furthermore, CDKN2A was predicted to be a direct regulator of
RB1. These hypotheses warrant additional study as they lend valuable insights into
the functions of CDKN2A in Chronic Obstructive Pulmonary Disease (COPD)
and cancer. E2F3 was predicted, and validated in the literature, to be a regulator of
MDM2 and TP53. Thus, Bayesian networks are a valuable tool for drawing signal-
ing insights from gene expression data.
135 Irreversible Inhibition of Acetylcholinesterase by Soman.
G. S. Sirin1, 2 and Y. Zhang2. 1ATSDR, Atlanta, GA; 2New York University, New
York, NY. Sponsor: P. Ruiz.
Acetylcholinesterase (AChE) is a key enzyme in the cholinergic nervous system that
hydrolyses acetylcholine and terminates synaptic signals. Organophosphate com-
pounds, such as nerve agents, can covalently inhibit AChE by phosphorylating the
enyzme’s catalytic serine residue. The phosphonylated adducts can either be reacti-
vated to some limited extent by nucleophilic compounds with oxime functional
unit or undergo an aging reaction. Phosphonylation and subsequent aging leads to
irreversible AChE inhibition, resulting in overstimulation of the nervous system. By
employing ab initio QM/MM molecular dynamics simulations with umbrella sam-
pling, we characterized the phosphonylation reaction mechanism between AChE
and the nerve agent soman (GD), as well as the aging mechanism of GD phospho-
nylated AChE. The phosphonylation reaction between AChE and GD follows an
associative nucleophilic substitution mechanism that is initiated when the nucle-
ophilic Ser200 attacks GD’s phosphorus atom, with His440 acting as a general
base. In the elimination step, Try121 of the catalytic gorge forms hydrogen bonds
with the leaving fluorine atom prior to its dissociation from the active site. Once a
stable covalent adduct is formed, the aging reaction begins with excision of the
alkoxyl covalent bond connecting the bound GD’s alkyl group to the phosphonate
moiety. This cleavage is swiftly followed with a methyl group rearrangement of the
alkyl group resulting in a stable tertiary carbenium, which is hydrated to an alcohol
by a reactive water molecule facilitated by Tyr121. The characterized mechanisms
and simulation results provide new detailed insights into this important process.
Such mechanistic details are of significant interest for the development of novel
strategies to reduce the toxic effects of GD poisoning by facilitating the search and
design of novel compounds capable of slowing the aging of nerve-agent-inhibited
AChEs as well as effective reactivators for the aged conjugates. Lastly, this work may
also facilitate the design of aging-resistant pseudo-catalytic scavengers capable of se-
questering nerve agents.
136 Computational Elucidation of Energetic Trends for DNA
Intercalation.
H. W. German and M. J. Novak. Chemistry, Florida Institute of Technology, W.
Melbourne, FL. Sponsor: L. Valerio.
The prediction of general energetic trends from intercalation of polycyclic aromatic
compounds with DNA can provide insight into these pertinent interactions from a
pharmacological and toxicological perspective. Compounds chosen for this study
are nucleotide base pairs (AT, GC, AA) and two novel intercalating agents (4-aza-
tryptanthrin and coralyne). Unfortunately, neither of these compounds have an es-
tablished crystal structure when intercalated into DNA. The absence of this com-
putational starting place gives rise to the need for a strong alternative
computational method.
Since dispersion forces have been shown to drive optimal orientation based on π-
stacking, this method utilizes the electrostatic potential (ESP) maps of both inter-
acting species. Presented herein is our improved method that uses more pertinent
variables, overcomes the weakness of a center of mass method, and improves the ef-
ficiency with which computational studies can provide insight to experimental de-
sign by relying primarily on visual intuition of the ESP alignments. The simplicity
of this study leads to the decrease in the time cost and the consideration of disper-
sion forces increases confidence in our results. 
Our computational methods utilize SPARTAN and GAUSSIAN software, a
Ground State Density Functional Theory (DFT), Local Spin-Density
Approximation (LSDA) method, and a 6-311++G(d,p) basis set. Initial results in-
dicate a preferential intercalation of 4-azatryptanthrin with the GC base pair over
an AT base pair based on energetic stabilization due to π-stacking. Identification of
trends such as this can be valuable in designing future experimental studies target-
ing GC or AT rich regions associated with genetic disorders such as Myotonic
Dystrophies, Fragile X, and Freidrich’s Ataxia.
137 Efficient In Vivo Developmental and Neurotoxicity Screen of
ToxCast Phase I and II Compounds in Zebrafish.
L. Truong1, 2, 3,  C. Miller1, 2, 3,  D. Haggard1, 2, 3,  G. Gonnerman1, 2, 3,
L. Chalker1, 2, 3,  K. Nhan1, 2, 3 and R. L. Tanguay1, 2, 3. 1Environmental and
Molecular Toxicology, Oregon State University, Corvallis, OR; 2Environmental Health
Sciences Center, Corvallis, OR; 3Sinnhuber Aquatic Research Laboratory, Corvallis,
OR.
The United States Environmental Protection Agency launched the Toxcast program
to begin to predict the potential chemical toxicity of 1,078 compounds made up of
pesticides, pharmaceuticals, “green” chemicals, chemicals in cosmetics and other
consumer products. Early life stages are often sensitive to chemical insult, which
make embryonic zebrafish an ideal platform to investigate the developmental and
neurotoxicity of these compounds. We developed an efficient in vivo phenotypic
screen using embryonic zebrafish to assess all 1,078 compounds. Using a wide
range of concentrations (0.0064 to 64 μM, 10 fold serial dilution); all compounds
were assessed for developmental toxicity beginning at 6 hours post fertilization
(hpf ). We kept exposed embryos completely in the dark until 24 hpf, and assessed
photo-motor responses using the Photo-motor Response Assessment Tool (PRAT)
that we developed. PRAT quantifies individual embryonic photo-motor response
following two pulses of bright light. The initial pulse normally results in pro-
nounced movement, and the second light pulse usually produces no activity. At 120
hpf, using Viewpoint Zebrabox, we assessed photo-induced larval locomotor activ-
ity. The locomotor activity is tracked for 25 minutes (10 in the light, 10 in the dark,
and 5 in the light). Afterwards, each larva was assessed for changes in a suite of 20
morphological endpoints. We have successfully conducted the phenotypic screen
on all 1,078 compounds, and a summary of the results will be discussed.
Collectively, we have demonstrated the efficiency of the zebrafish model as a phe-
notypic screening platform to identify hazardous chemicals. This research is sup-
ported by NIEHS grants P30 ES00210 and RC4ES019764.
138 In Silico and In Vitro Analyses of the Hormonal Activity of
Hydroxylated Polychlorinated Biphenyl on Human Thyroid
Receptor.
C. Dassuncao,  O. Faroon,  J. Wheeler and P. Ruiz. DTHHS, ATSDR/CDC,
Chamblee, GA.
Hydroxylated polychlorinated biphenyl (OH-PCBs) may disrupt thyroid hormone
status because of their structural similarity to thyroid hormone. However, the mo-
lecular mechanisms of interactions with thyroid hormone receptors (TRs) are not
fully understood. The integrated application of omics studies, bioinformatics, and
computational modeling can provide to biological systems an enhanced under-
standing of the mechanisms underlying the toxicity of endocrine disruptor chemi-
cals and support the study of disease etiology and prevention. In the present study,
we examined the interactions between OH-PCBs and TRs to identify critical struc-
tural features and molecular properties of OH-PCBs related to their hormonal ac-
tivity and to develop quantitative structure–activity relationship (QSAR) models
for the thyroid hormone activity of OH-PCBs. Molecular descriptors were com-
puted, selected, and used to characterize the ligand-receptor binding, and subse-
quently develop an in silico model. The in silico model had good robustness, pre-
dictive ability, and mechanism interpretability. Lipophilic distribution,
hydrophobic and electrostatic interactions between OH-PCBs and TRs are impor-
tant factors governing thyroid hormone activities. The OH-PCBs with higher abil-
ity to accept electrons, ortho position of the hydroxyl group, low dipole-dipole in-
teractions tend to have weak binding with TRs and subsequently lower thyroid
hormone activities. Hence, this in silico model can be used as a screening tool for
further targeted toxicity testing and risk assessment, generate hypotheses about po-
tential mechanistic pathways leading to adverse outcomes, and reduce time and
cost of OH-PCBs testing.
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139 A Systematic Analysis of ToxCast In Vitro Assays Associated
with In Vivo Hepatic Outcomes.
J. Liu1, 2,  M. T. Martin1,  C. Corton3,  C. Wood3 and I. Shah1. 1NCCT/EPA,
Durham, NC; 2University of Arkansas, Little Rock, AR; 3NHEERL/EPA, Durham,
NC.
The U.S. EPA’s ToxCastTM program uses hundreds of high-throughput, in vitro
assays to screen chemicals for bioactivity. The EPA Virtual Liver project combines
ToxCastDB data with guideline rodent toxicology data to map hepatic adverse out-
come pathways (AOPs). Here our objective is to reveal meaningful relationships be-
tween in vitro assays and in vivo liver outcomes. 289 ToxCast phase Ι chemicals
were organized into 15 categories based on 272 histopathological lesions reported
in guideline testing studies from ToxRefDB. Based on lesions reported at the study
end, 242(83.7%) chemicals produced hypertrophy, 39(13.5%) chemicals resulted
in hyperplasia, and neoplastic lesions were found for 79(24.9%). We compared the
AC50 concentrations of chemicals for each of the 973 ToxCast assays and identified
assays with at least 10 chemicals per category and the mean potency was signifi-
cantly different (p<0.05). Out of the 973 assays, 28/147(19%) of the high-content
imaging assays (APR) had associations with 7 liver injury categories. 6/83(7.2%)
multiplexed transcription reporter assays (ATG) and 15/112(13.4%) protein com-
plementation (OT) assays were also significant for liver injury. A number of the as-
says such as, cell loss, enzyme induction and enzyme inhibition, were generally sig-
nificant across most categories. On the other hand, some assays were quite specific
to certain categories. For instance, APR_StressKinase_72hr_pos (stress kinase path-
way activation) and ATG_CRE_CIS (transcription factor DNA binding activity)
were significant for chemicals that showed regeneration vs ATG_VDRE_CIS(nu-
clear receptor transcription activity) for hypertrophy. The results suggest the utility
of HTS assays for screening hepatotoxicity, and for linking biological events in the
pathways to specific adverse outcomes. Such assays are not only mechanistically rel-
evant but also aid in defining cell-based toxicity signatures for rapidly screening
thousands of environmental chemicals. Abstract does not represent EPA policy.
140 Interpreting QSAR Toxicity Predictions in Hazard
Assessments: An Acrylamide Case Study.
R. S. DeWoskin,  L. D. Burgoon and G. M. Woodall. US EPA, Research Triangle
Park, NC.
Toxicity predictions based on QSAR are used to screen large numbers of chemicals
with little to no toxicity data into prioritized categories for further toxicity testing,
development as “green” chemicals, or candidates for efficacious drug therapy. As
databases incorporate more information on adverse pathways and potential targets,
QSAR results may also contribute to hazard assessment for chemicals considered
“data rich” (based on the availability of a full suite of traditional animal bioassays),
but which are often “data poor” when it comes to characterizing the mode of action
(MOA), severity progression, or potential adverse human clinical effects not moni-
tored in animal bioassays. Presented here is an exercise to evaluate QSAR results
within the context of extant hazard assessments on a data rich chemical, in this case,
acrylamide (AA), and its less well studied active metabolite, glycidamide (GA).
Results from four QSAR programs – two freeware programs (VEGA and OECD’s
QSAR) and two proprietary programs (MetaCore™ and Discovery
Studio/TopKat™) provided considerable new information in the areas mentioned
above. Potential AA and GA induced adverse effects of clinical relevance to humans
were identified as well as likely biological targets for AA, GA, and analogous chem-
icals. The results further supported the qualitative characterization of the MOAs,
potential endpoints to consider in dose-response arrays, and identification of po-
tentially important early biomarkers to aid future bioassay or human study design.
Conversely, extant AA and GA ADME data and PBPK models helped assess the
likelihood of AA or GA reaching biological targets predicted by the QSAR pro-
grams. This exercise demonstrated the value of integrating QSAR results into tradi-
tional hazard assessment for improved qualitative information. The next step is to
integrate high throughput screening /content (HTS/HTC) assay results into the as-
sessment to further quantitate dose-response for a wider array of effects. [The views
expressed are those of the authors and do not necessarily reflect the views or policies
of the U.S. EPA]
141 Health-Related Effects Reported by Electronic Cigarette
Users in Online Forums.
M. Hua,  M. Alfi and P. Talbot. Cell Biology and Neuroscience, University of
California. Riverside, Riverside, CA.
Electronic cigarettes (e-cigarettes) are battery-operated devices that deliver
aerosolized nicotine to users without burning tobacco. Because little data exists on
their health effects, we explored the symptoms that e-cigarette use has on humans
by analyzing online user posts from three e-cigarette forums with “health and
safety” sections. Basic information (location, age, and gender) and health (symp-
toms and doctor diagnosed signs) information were collected. A total of 405 symp-
toms (78 positive, 326 negative and 1 neutral) were reported in three forums. Most
data analysis was performed on Electronic Cigarette Forum (ECF) posts. A total of
12 systems/anatomical regions were affected in e-cigarette users. Systems most
often affected include: mouth and throat, respiratory, neurological, sensory, and di-
gestive. The majority of negative health effects occurred in the respiratory system.
We further consolidated reported symptoms into categories to determine which
anatomical regions/physiological processes were most affected for each system. For
consolidated data, symptoms were most frequently reported for: bronchi/lungs
(e.g., wheezing, shortness of breath, difficulty breathing), throat; neurological
(headaches), intestine/digestion, and sight. To analyze interactions between sys-
tems, interactomes were created with Cytoscape software. Interactions were most
frequently seen between circulatory/neurological; respiratory/mouth and throat;
respiratory/chest, and digestive/neurological systems. Increased blood pressure was
the most frequently reported sign diagnosed by physicians treating e-cigarette users.
While some positive health effects were reported, a significant proportion of the
data showed a correlation with e-cigarette use and onset of adverse health effects.
This study is the first to compile and quantitatively assess health data associated
with e-cigarette use from online forums.
142 The Relationship Between T-Box Transcription Factors
CAMK2B and PITX2 in the Expression of Collagen Protein
COL4A3 in COPD.
B. Nguyen,  G. Acquaah-Mensah and C. Ngo. Pharmaceutical Sciences, MCPHS,
Worcester, MA.
The T-Box transcriptions factors are known have recently been highlighted for their
expression role in epithelial cells in Chronic Obstructive Pulmonary Disease
(COPD), which genes, including COL4A3, TBX2, TBX3, TBX5, PML, CFLAR,
GULP1, CASP10, PAX3, BOK, and PITX2 are connected in transcriptional regu-
latory networks of lung epithelial cells. The type IV, alpha 3, collagen gene
(COL4A3) involves into extracellular matrix construction as the major structural
component of basement membrane. COL4A3 is known to have suppressed expres-
sion in COPD3. The A polymorphism of the COL4A3 is also indicated of associ-
ated with the risk of developing COPD. COL4A3’s C terminus binds to autoanti-
bodies at basement membranes in Goodpasture syndrome and is phosphorylated
by calcium/calmodulin-dependent protein kinase II beta (CAMK2B), which is ac-
tivated by the promyelocytic leukemia protein (PML). The paired-like home-
odomain 2 (PITX2) regulates the expression of N-cadherin. N-cadherin changes
the adhesion of extracellular matrix (ECM) by interacting with collagen proteins.
PITX2 gene is regulated by different kinase pathways, such as MAPK and Akt.
However, the relationship between these factors is still not well studied. Thus, we
have come up with the question that if is PITX2 gene also regulated by CAMK2B.
We conducted the study in focus on exploring the relationship between PITX2 and
CAMK2B genes by applying Bayesian Network Structural Learning (BNSL).
Version 2.2 of Bayesian Network Inference with Java Objects (Banjo) was employed
in the study. The result was used to compare to the known interactions between
COL4A3, CAMK2B, PITX2 and PML. The study has shown the possible novel
phosphorylation of PITX2 by CAMK2B.
143 Validation of a Systems Toxicology Based Adverse Outcome
Pathway Prediction with Functional Outcome: Effect of
Exposure to 2, 4-Dinitrotoluene on Energy Metabolism and
Exercise Endurance.
M. S. Wilbanks1,  K. Gust1,  S. Atwa2,  I. Sunesara3,  S. A. Meyer2 and
E. J. Perkins1. 1Engineer R & D Center, US Army Corps of Engineers, Vicksburg,
MS; 2Department of Toxicology, University of LA-Monroe, Monroe, LA; 3Center of
Biostatistics and Bioinformatics, University of MS Medical Center, Jackson, MS.
2,4-dinitrotoluene (2,4DNT), commonly used in industrial and explosive manu-
facturing processes, is known to contaminate artillery ranges, demilitarization areas
and munitions manufacturing facilities leading to its listing on US EPA’s
Contaminant Candidate List. Previous transcriptomic and lipidomic studies identi-
fied energy metabolism as a potential target of DNT toxicity. The impact of such
perturbations of energy metabolism on exercise endurance is largely unknown. We
hypothesized that organism-level impacts of 2,4DNT dosing were the result of en-
ergy metabolism deficits, especially lipid metabolism, from involving interference
with PPARα signaling and its downstream pathways. To validate this adverse out-
come pathway, we linked molecular changes caused by 2,4DNT exposure to effects
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on whole animals. PPARα (-/-) and wild-type (WT) mice exposed to a sublethal
2,4DNT dose (134 mg/kg/day for 14 days) or vehicle were given an exercise chal-
lenge (a forced swim) 1 day after the last dose to determine how 2,4DNT and/or
PPARα impairment affected overall performance. Observations were collected at
multiple levels of biological organization including genes involved in fatty acid and
glucose metabolism, PPAR activation and response, biochemistry (serum triglyc-
erides and glucose), and swimming endurance. Decreased swim times were ob-
served with DNT in WT and PPARα (-/-) mice, but DNT effect was significantly
less in knock-down mice indicating that knock down of PPARα expression par-
tially rescued mice from DNT-induced energy metabolism deficits. Our results
support the proposed hypothesis by demonstrating that 2,4DNT’s impact on en-
ergy metabolism, especially lipid metabolism, occurs via perturbation of PPARα
signaling resulting in reduced exercise endurance at the individual level. 
(Support: US Army Corps of Engineers)
144 Modelability of ToxCast Phase I Datasets.
A. Golbraikh1, 2,  A. Sedykh1,  E. Muratov1,  R. Shah2, 3,  W. A. Boyd4,
M. Smith4,  G. Zhao5,  H. Zhu6,  J. H. Freedman4 and A. Tropsha1, 2. 1University
of North Carolina at Chapel Hill, Chapel Hill, NC; 2Sciome LLC, Research Triangle
Park, NC; 3SRA International, Durham, NC; 4NIEHS, Research Triangle Park, NC;
5AstraZeneca, Shanghai, China; 6Rutgers University, Camden, NJ.
One of the problems in Quantitative Structure-Activity Relationships (QSAR)
analysis is to establish, whether it is possible to build a predictive model for a given
dataset. For some datasets, all attempts to build a predictive model using different
sets of descriptors and QSAR/QSTR methodologies fail raising a question, whether
it is possible to evaluate the dataset modelability prior to modeling. We have de-
vised several modelability criteria such as dataset diversity, new activity cliff indices,
correct classification rate (CCR) for similarity search models (ssCCR),
CCR=0.5*(sensitivity+specificity), etc. These criteria were applied to 40 binary
datasets, for which QSAR models were built using Dragon 5.5 descriptors and/or
ToxCast in vitro assays treated as biological descriptors, and kNN, Random Forest
and SVM methods. The best modelability criterion was found to be the ssCCR,
which had the correlation coefficient of 0.73 with the QSAR/QSTR model CCR.
We consider a model predictive, if its CCR as well as both sensitivity and specificity
are at least 0.70. We found that to satisfy this condition, ssCCR should be at least
0.68. ssCCR values were obtained for ToxCast datasets with 24 ToxRefDB in vivo
assays as end points, which had at least 30 toxic compounds among 212 com-
pounds of the curated ToxCast dataset. None of the ssCCR for these datasets was as
high as 0.60 except for the rat cholinesterase inhibition assay, for which it was 0.85,
and sensitivity and specificity were 0.83 and 0.88, respectively. We conclude that
with the latter exception, ToxCast Phase I datasets with ToxRefDB in vivo assays as
end points do not appear to be modelable using QSAR approaches. This conclu-
sion agrees with the recent empirical observations of Thomas et al (Toxicol Sci.
2012, 128:398-417).
145 Celastrol Decreases Specificity Proteins (Sp) and Fibroblast
Growth Factor Receptor-3 (FGFR3) in Bladder Cancer Cells.
G. Chadalapaka1,  I. D. Jutooru1 and S. H. Safe1, 2. 1Department of Veterinary
Physiology and Pharmacology, Texas A&M University, College Station, TX; 2CEGM,
Institute of Biosciences & Technology, Houston, TX.
Bladder cancer is the ninth most common cancer worldwide and ranks 13th as a
cause of cancer deaths. MVAC (methotrexate, vinblastine, adriamycin and cis-
platin) chemotherapy has been extensively used for treatment of advanced bladder
cancer and is accompanied by toxic side effects and, thus, it is important to develop
less toxic alternate chemotherapeutic therapies and dietary management strategies
for prevention of this disease. Celastrol (CSL) is a naturally occurring triterpenoid
acid that exhibits anticancer activity, and in KU7 and 253JB-V bladder cells, 0.5 to
2.5 μM CSL induced apoptosis, inhibited growth, colony formation and migration
and CSL decreased bladder tumor growth in vivo. CSL also decreased expression of
specificity protein (Sp) transcription factors Sp1, Sp3 and Sp4 and several Sp-regu-
lated genes/proteins including vascular endothelial growth factor, survivin and cy-
clin D1. CSL also decreased fibroblast growth factor receptor-3 (FGFR3), a poten-
tial drug target for bladder cancer therapy. Results of RNA interference and
knockdown of Sp proteins show that FGFR3 is a Sp-regulated gene downregulated
by CSL. The mechanism of Sp downregulation by CSL was cell context-dependent
due to activation of proteosome-dependent (KU7) and -independent (253JB-V)
pathways. In 253JB-V cells, CSL induced reactive oxygen species (ROS) and in-
hibitors of ROS such as glutathione blocked CSL-induced growth inhibition and
repression of Sp1, Sp3 and Sp4. This response was due to induction of the Sp re-
pressors ZBTB10 and ZBTB4 and downregulation of miR-27a and miR-20a/17-
5p, respectively, which regulate expression of these transcriptional repressors. Thus,
the anticancer activity of CSL in 253JB-V cells is due to induction of ROS and
ROS-mediated induction of Sp repressors (ZBTB4/ZBTB10) through downregu-
lation of miR-27a and miR-20a/17-5p and this is emerging as a characteristic path-
way observed for many ROS inducers in cancer cells.
146 Raloxifene Potentiates the Cytotoxicity-Induced by RL91, a
Second Generation Curcumin Analog, in PC3 Prostate
Cancer Cells.
A. Mazumder1,  M. Gould2,  S. Taurin1,  H. D. Nicholson2 and R. J. Rosengren1.
1Pharmacology & Toxicology, University of Otago, Dunedin, New Zealand; 2Anatomy,
University of Otago, Dunedin, New Zealand.
The survival rate for men with hormone refractory prostate cancer has not changed
significantly in the last 30 years. Thus there is a need for new drug treatments for
this aggressive cancer. Our lab has had success with second generation curcumin de-
rivatives as novel therapies for aggressive breast cancer. In this study we examined
the combination of raloxifene and 2,6-bis(pyridin-4-ylmethylene)-cyclohexanone
(RL91), a potent 2nd generation curcumin derivative as a novel treatment for hor-
mone refractory prostate cancer (HRPC). The combination treatment showed
highly potent cytotoxicity toward PC3 prostate cancer cells compared to individual
treatments. Specifically, EC50 values of 2 μM and 10 μM were produced by RL91
and raloxifene, respectively. Moreover, this combination decreased cell number by
85% compared to control after 96 h of treatment, as determined by the sulforho-
damine B assay. Raloxifene is known to modulate the activity of estrogen receptor
alpha (ERα) and beta (ERβ). The activation of these receptors as well as the epi-
dermal growth factor receptor (EGFR), is crucial for the proliferation of HRPC. To
determine how raloxifene potentiates the cytotoxic effect of RL91, the localization
of these receptors was examined by fluorescent microscopy. The results showed that
ERα, ERβ, the androgen receptor (AR) and EGFR were expressed in PC3 cells.
However, raloxifene treatment (10 μM for 48 h) promoted EGFR internalization
in the cytoplasm. A similar effect was also seen for ERβ where raloxifene promoted
a translocation from the nucleus to the cytoplasm. However, no change was ob-
served for either ERα or the AR. These results suggest that raloxifene-mediated
changes in the localization of ERβ and the EGFR provide a mechanism by which
raloxifene enhances the cytotoxicity of RL91 toward PC3 cells. This novel mecha-
nism should be explored further in order to develop new therapies for HRPC.
147 Evaluation of Wild Yam (Dioscorea Villosa) Root Extract As
a Potential Epigenetic Agent in Breast Cancer Cells.
P. Aumsuwan1, 2,  S. I. Khan1, 3,  I. A. Khan1, 3,  L. A. Walker1, 2 and
A. K. Dasmahapatra1, 2. 1National Center for Natural Product Research, University
of Mississippi, University, MS; 2Department of Pharmacology, University of
Mississippi, University, MS; 3Department of Pharcognosy, University of Mississippi,
University, MS.
Aberrant epigenetic alterations in the genome, is believed to be a potential cause of
some forms of cancer. Due to their reversibility, epigenetic modifications are con-
sidered potentially useful in drug development approaches (epi-drugs). The current
available synthetic epi-drugs are non-specific and induce adverse effects. Natural
products might offer advantages and find utility for cancer treatment. The present
study was designed to evaluate the efficacy of wild yam root extract as a potential
demethylating agent using two breast cancer cell lines, MCF-7 (Estrogen receptor
positive, ER+) and MDA-MB-231 (ER negative, ER-), and a gene, GATA-3, a po-
tential marker of breast cancer development. Moreover, GATA-3 expression is
methylation-specific, being higher in ER+ cells with promoter hypomethylation
and insignificant in ER- with promoter hypermethylation. In this study, cells, ap-
proximately at 70 % confluency, were treated with wild yam root extract (0-50
μg/ml) for 72h and then used for viability, mRNA, and methylation analyses. It
was observed that wild yam significantly reduced viability of both cell lines and en-
hanced the mRNA contents of DNMTs (DNMT1, 3A, and 3B) and GATA-3 in a
dose-dependent manner. Global DNA methylation, analyzed as 5’-methyl-2’-de-
oxycytidine (mC) and 5-hydroxymethylcytosine (hmC), showed that mC was in-
creased only in MCF-7 cells, whereas hmC level was reduced in both cell lines.
Since hmC is generated from mC by ten-eleven-translocation (TET) enzymes, the
present data suggest that enhanced expression of GATA-3 and DNMT enzyme
mRNAs followed by a reduction in hmC in MCF-7 and MDA-MB-231 cells are
the result of interruption of TET enzyme functions in the epigenome by wild yam
root extract. This plant with a long history of traditional use should be further ex-
plored with regard to its potential as an epigenetic agent in breast cancer therapy.
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148 Mucosa-Associated Enteropathogenic Escherichia coli As an
Internal Exposome Triggers Tumor Cell Dissemination via
Macrophage Inhibitory Cytokine 1.
H. Choi,  J. Kim,  S. Park,  K. Do,  C. Oh and Y. Moon. Laboratory of Mucosal
Exposome and Biomodulation, Department Microbiology and Immunology, Pusan
National University School of Medicine and Medical Research Institute, Yangsan,
Republic of Korea.
Commensal bacterial community shifts in the pathogenic colonic environment and
chronic colonization of mucosa-associated Escherichia coli (MAEC) has been
linked to colonic tumourigenesis. Enteropathogenic Escherichia coli (EPEC) is one
of commonly identified MAEC in colorectal cancer patients. The aim of this study
is to address the contribution of MAEC colonization to human carcinogenesis.
EPEC infection of cancer cell caused alterations in affect locomotion-related behav-
iors of cancer cell including detachment, migration, cytoskeleton rearrangement,
dissemination and survival via induction of macrophage inhibitory cytokine 1
(MIC-1). Mechanistically, MIC-1 induced RhoA GTPase which mediated survival
of the detached cancer cells. In terms of signaling pathway, MIC-1 triggered TGF-
beta-activated kinase 1 (TAK-1), which enhanced expression of RhoA GTPase. In
conclusion, mucosal EPEC enhanced MIC-1 gene expression in the human intes-
tinal cancer cells, which was associated with enhanced tumor cell resistance to
anoikis and subsequent survival via enhanced TAK-1 and RhoA GTPase (This
work was supported by the Basic Science Research Program through the National
Research Foundation of Korea, funded by Ministry of Education, Science, and
Technology Grant 2012R1A1A2005837).
149 Ring-Substituted Analogs of 3, 3’-Diindolylmethane (DLM)
Induce Apoptosis and Necrosis in Androgen-Dependent and
-Independent Prostate Cancer Cells.
A. Goldberg1,  V. I. Titorenko2,  A. Beach2,  S. H. Safe3, 4 and T. Sanderson1.
1Toxicology, INRS, Laval, QC, Canada; 2Biology, Concordia University, Montréal,
QC, Canada; 3Veterinary Physiology and Pharmacology, Texas A&M University,
College Station, TX; 4Institute for Bioscience and Technology, Houston, TX.
We have recently reported that novel ring-substituted analogs of 3,3’-diindolyl-
methane (ring-DIMs), exhibit anti-androgenic and anti-proliferative activities in
androgen-dependent prostate cancer cells. We hypothesized that the anti-prolifera-
tive effects of ring-DIMs may be due to their ability to induce cell death. Ring-
DIMs inhibited androgen-stimulated LNCaP cell proliferation and induced apop-
tosis and necrosis in LNCaP and PC-3 prostate cancer cells with 2-4 fold greater
potencies than DIM. DIM and the ring-DIMs increased caspases-3, -8 and -9 ac-
tivity and induced PARP cleavage in both cell lines. The cytotoxicity of the most
potent ring-DIM, 4,4’-dibromoDIM, but not the other ring-DIMs, was decreased
by caspase-3 inhibition. The 4-4’-dibromoDIM was primarily found in the extra-
cellular media, whereas the ring-DIMs were located intracellularly in both cell lines.
Ring-DIMs were more potent inhibitors of cell growth and survival in LNCaP and
PC-3 cells than DIM and the differential structure-dependent cell death mecha-
nisms indicates ring-DIMs have clinical potential as chemopreventive and
chemotherapeutic agents in prostate cancer, regardless of hormone-dependency.
150 Ellagitannins and Anthocyanins Constituents of
Pomegranate Suppress Colorectal Aberrant Crypt Foci (ACF)
and Inflammation: Possible Role of miR126.
N. Banerjee1, 2,  H. Kim2 and S. U. Mertens-Talcott1, 2, 3. 1Toxicology, Texas A&M
University, College Station, TX; 2Nutrition and Food Science, Texas A&M University,
College Station, TX; 3Veterinary Physiology & Pharmacology, Texas A&M University,
College Station, TX.
The antitumorigenic efficacy of polyphenols ellagitannins and anthocyanins ex-
tracted from pomegranate (Punica granatum L.) has been extensively studied where
cytotoxic, anti-inflammatory and antioxidant effects were demonstrated in various
cancer models. The objective of this study was to investigate the role of post-tran-
scriptional regulation of apoptotic and inflammatory biomarkers by specific
microRNAs in cells treated with pomegranate polyphenols (PP). 
mRNA, microRNA expression were measured by RT-PCR, protein by western
blotting and multiplex bead assay. In vivo studies were performed with Sprague
Dawley rats (10rats/group) that received PP (2504.74mg/L GAE) for 10 weeks and
were injected with azoxymethane (AOM) subcutaneously (15 mg/kg) at weeks 3
and 4. 
PP juice suppressed the number of high multiplicity aberrant crypts foci (HMACF
〉4 ACF) by 42% (P<0.05) and lowered Ki67 (proliferation marker) antigen.
Correspondingly, cell proliferation was also inhibited by PP (5 -25 μg/mL) in colon
cancer cells HT-29. In vitro and vivo results were accompanied by a downregula-
tion of expression including NF-κB, inducible nitric oxide synthase (iNOS), cy-
clooxygenase-2 (COX-2), vascular adhesion molecule-1 (VCAM-1) and insulin
growth factor (IGF). PP also inhibited phosphorylation of PI3K/Akt, and mTOR
signaling pathways. miRNA 126 is frequently lost in colon cancer and targets
VCAM-1 and PI3K that are involved in inflammation and cell survival. PP in-
creased miR126 expression in both in vitro and vivo, corresponding to the observed
decrease in VCAM-1 and PI3K. In vitro, the involvement of miR-126 was con-
firmed using the antagomir for miR-126, where PP reversed the effects of the an-
tagomir.
In summary Pg inhibited HT29 cell proliferation, suppressed number of HMACF
formation and colon tumorgenesis through the involvement of microRNA 126-
regulated pathways.
151 Dichloroacetate (DCA) Increases Radiation Sensitivity of
A549 and H1299 Lung Cancer Cells.
J. B. Watkins1,  K. T. Allen1,  H. Chin-Sinex2,  J. D. Sherer2,  J. M. Jesseph1,
J. G. Foley1 and M. S. Mendoca2. 1Medical Sciences Program, Indiana University
School of Medicine, Bloomington, IN; 2Department of Medical and Molecular
Genetics, Indiana University School of Medicine, Indianapolis, IN.
Dichloroacetate (DCA) is a synthetic small molecule inhibitor of pyruvate dehy-
drogenase kinase used to treat metabolic diseases with low toxicity in human pa-
tients for decades. Recent reports suggest that DCA is cytotoxic to several cancer
cell types including non-small-cell lung cancers (NSCLC). The cytotoxicity to can-
cer cells appears to be a result of a reversal of the Warburg effect through partial
restoration of mitochondrial glucose oxidation away from cytoplasmic aerobic gly-
colysis. With the increase in glucose oxidation, ROS production is augmented lead-
ing to the opening of the mitochondrial transition pore to release cytochrome c and
apoptosis inducing-factor (AIF) into the cytoplasm. The consequence is mitochon-
dria membrane depolarization and induction of cell death in a caspase-dependent
or -independent manner. Given the potential therapeutic translation of DCA to
human cancer treatment, we investigated the efficacy of DCA to sensitize NSCLC
to X-ray induced killing in vitro after both single and fractionated X-ray exposure.
Treatment with DCA decreased plating efficiency (PE) and enhanced radiation-in-
duced cell killing by dose modification factors of 1.5 in A549 and 1.4 in H1299.
The decrease in PE was not due to induction of apoptosis or necrosis. X-ray frac-
tionation showed that DCA inhibited split-dose recovery/repair by 3.5 fold in
A549 and 1.5 fold in H1299. Flow cytometry analysis with propidium iodide indi-
cated significant cell cycle arrest at G1/S in A549 and at G2/M in H1299. The data
suggest that DCA enhances X-ray-induced NSCLC cell killing through inhibition
of DSB repair and/or alteration of cell cycle distribution.
152 Mango Polyphenolics Reduce Inflammation in Intestinal
Colitis—Potential Involvement of the miR-
126/PI3K/AKT/mTOR Pathway In Vitro and In Vivo.
H. Kim1,  N. Banerjee1, 2,  S. Talcott1 and S. U. Mertens-Talcott1, 2. 1Department
of Nutrition and Food Science, Texas A&M University, College Station, TX;
2Interdisciplinary Program of Toxicology, Texas A&M University, College Station, TX.
Mango polyphenolics including gallic acid, mangiferin and gallotannins, have
shown antioxidant, anti-inflammatory and anticarcinogenic properties in several
studies. However, anti-inflammatory mechanisms relevant to the prevention of
colon cancer have not been well investigated.
This study investigates the potential role of the miRNA-126/PI3K/AKT/mTOR
signaling pathway in the anti-inflammatory effects of mango polyphenolics in
human CCD-18Co colon-myofibroblastic cells and on DSS-induced colitis in rats.
Animals were administered control juice (15.7g sugar and 0.05g citric acid/100ml)
or mango juice (total phenolic content of 475.80mg/L GAE), and exposed three
cycles of 3% DSS. The mRNA and protein levels were measured by RT-PCR, west-
ern blot analysis and multiplex bead assay.
In vitro mango extract and gallic acid suppressed the expressions of inflammatory
mediators such as NF-κB (p65) and IL-1β and reduced the expressions of AKT and
HIF1α involved in AKT/mTOR pathway at mRNA and protein level in a dose de-
pendent manner. Correspondingly, miRNA-126, which negatively regulates the
Akt/mTOR pathway, was induced by mango extract and gallic acid. In the rat coli-
tis model, mango juice intake suppressed cell proliferation as measured by Ki-67
staining, and resulted in protection against DSS-induced colon inflammation dur-
ing chronic colitis compared to control juice. The juice significantly attenuated the
expressions of pro-inflammatory cytokines such as TNF-α, IL-1β, IL-6, and IL-10
at protein and mRNA level. Moreover, the phosphorylation of AKT and mTOR
were suppressed, and the expression of PI3K was reduced while miRNA-126 that
has a target site in the mRNA of PI3K was upregulated by the juice.
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These results suggest that mango polyphenols attenuated inflammatory response by
modulating the miR-126/PI3K/AKT/mTOR pathway both in vitro and in vivo,
and is a potential therapeutic for colitis and colon cancer.
153 Loss of the Tumor Suppressor Protein PTEN Contributes to
Increased Nrf2 Signaling.
P. M. Shelton1,  M. I. Vitolo2,  S. S. Martin2 and A. K. Jaiswal1. 1Pharmacology,
University of Maryland, Baltimore, Baltimore, MD; 2Marlene and Stewart
Greenebaum Cancer Center, University of Maryland, Baltimore, Baltimore, MD.
Nrf2 is a master regulator of cyto-protective genes involved in the maintenance of
cellular redox balance. In recent studies, the PI3K/Akt pathway is reported to posi-
tively regulate the Nrf2 pathway. The protein phosphatase PTEN counteracts the
action of PI3K by removing the phosphate from PIP3. This led us to hypothesize
that loss or mutation of PTEN, an event that occurs frequently in cancers, might
increase Nrf2 activity that promotes the survival and proliferation of cancer cells. In
our study we investigated the role of PTEN in prostate and breast cancer, com-
monly reported to have either loss of heterozygosity or mutations in PTEN. Using
the PTEN-null human prostate cancer cell line PC3, we found that expression of
wild-type but not mutant PTEN decreased the basal and anti-oxidant induced ex-
pression of Nrf2 target genes. More common clinically, patients have loss of a sin-
gle allele of PTEN. Therefore, we also investigated the Nrf2 pathway in cells het-
erozygosity for the PTEN gene. Using a murine prostate tumor cell line with a
spontaneous loss of a single allele in PTEN (PTEN-P8, +/-) and an isogenic cell
line that had deletion of the second allele (PTEN-CaP8, -/-) we found that com-
plete loss of PTEN resulted in higher expression of the Nrf2 target genes. In order
to fully address the role of PTEN haploinsufficiency that could mimic the cellular
progression from benign to malignant we also looked at Nrf2 activity in the im-
mortalized breast epithelial cell line MCF-10a that had both alleles intact (+/+),
deletion of a single allele (+/-), or deletion of both alleles (-/-) of PTEN. As ex-
pected, we found that both the basal and inducible expression of the prototypical
Nrf2 target gene NQO1 inversely correlated with PTEN status. Together this sug-
gests that the loss of PTEN contributes to increased Nrf2 transcriptional activity,
which likely provides cells with an altered proteome that favors oncogenesis.
154 Formaldehyde-Induced Replication Stress Causes Activation
of ATR Kinase Leading to p53-Mediated Apoptosis and
Senescence in Human Lung Cells.
J. Morse,  V. Wong and A. Zhitkovich. Brown University, Providence, RI.
Formaldehyde (FA) is a recognized human carcinogen with documented inhalation
exposures in many occupational groups. Here we examined stress signaling path-
ways and cell fate decisions triggered by FA in human lung cells (normal lung fi-
broblasts, H460 lung epithelial cells and primary bronchial epithelial cells). We
found that FA induced a rapid activation of the DNA damage-responsive ATR ki-
nase that preferentially targeted the p53 transcription factor at low and moderate
damage levels. Activation of p53 was evidenced by its strong Ser-15 phosphoryla-
tion, protein stabilization and upregulation of its target genes, such as MDM2 and
CDKN1A (p21). Knockdown experiments with shRNA confirmed the p53 de-
pendence of the gene expression responses. FA also caused a depletion of the p53
inhibitor MDM4 via its enhanced proteolysis. The use of biochemical markers of
individual cell cycle phases and replication status manipulations showed that acti-
vation of ATR-p53 signaling by FA occurred exclusively in the S phase. The p53
played a major role in FA-induced apoptosis in lung epithelial cells, which was as-
sociated with upregulation of the proapoptotic gene BBC3 (PUMA). The presence
of p53 was also required for permanent growth arrest (senescence) in FA-treated
lung fibroblasts. Overall, our results indicate that replication stress and ATR-acti-
vated p53 are responsible for cytotoxic responses in FA-exposed human lung cells.
Acknowledgements. This work was supported by grant ES020689 from NIEHS.
155 Down-Regulation of Telomerase Activity and Shortening of
Telomere Length by Polychlorinated Biphenyls (PCBs) in
HL-60 Cells.
X. Xin1,  S. Pk1,  J. L. Schnoor1, 2 and G. Ludewig1. 1Interdisciplinary Graduate
Program in Human Toxicology, The University of Iowa, Iowa City, IA; 2Department
of Civil and Environmental Engineering, The University of Iowa, Iowa City, IA.
We reported that PCBs, environmental persistent organic pollutants and probable
human carcinogens, can down-regulate telomerase activity in vitro in immortal
human keratinocytes (HaCaT). The most efficacious congener was the dioxin-like
PCB126, a potent arylhydrocarbon receptor (AhR) agonist. To analyze whether this
effect of PCB126 is tissue specific and to gain insight into the mode of action
(MOA) we exposed another cell type, human promyelocytic leukemia (HL-60)
cells, to PCB126 and also to PCB153, not an AhR activating congener. Both com-
pounds reduced telomerase activity, visible after 6 days of exposure, and telomere
length, to about 50% within 30 days of exposure, PCB126 more so than PCB153.
This reduction in telomerase activity and telomere length was seen in both cell
lines, but only HaCaT also showed a strong increase in cytochrome P450 1A1
mRNA and activity, the hallmark of AhR activation. This suggests that AhR activa-
tion may be one, but not the only mechanism for this effect of PCBs. HL-60 can
differentiate which is accompanied by a reduction in telomerase activity. However,
the continuous proliferation of the PCB-exposed cells makes this mechanism less
likely. Telomeric repeat binding factors (TRF1, TRF2) are involved in the stabiliza-
tion of telomeres. Up-regulation of TRF1/2 was seen in PCB126-exposed HaCaT,
pointing to a possible mechanism. Experiments with both cell lines, representing
different target tissues of PCB toxicity, are under way to elucidate the MOA of
PCBs on telomeres and the possible significance of this effect on precursor cells of
the hematopoietic pathway. (Supported by NIEHS P42 ES013661)
156 Chronic Exposure to Particulate Hexavalent Chromium
Disrupts Shugoshin1 Localization in Human Lung Cells.
C. Falank1 and J. Wise1, 2, 3. 1Wise Laboratory of Environmental and Genetic
Toxicology, University of Southern Maine, Portland, ME; 2Maine Center for
Toxicology and Environmental Health, University of Southern Maine, Portland, ME;
3Department of Applied Medical Science, University of Southern Maine, Portland,
ME.
Chromosomal instability (CIN) is a hallmark of cancer and can be caused by
spindle assembly checkpoint disruption or chromosome missegregation during mi-
tosis. Hexavalent chromium (Cr(VI)) is a well-known human lung carcinogen, and
has shown to induce numerical CIN, however its mechanisms for inducing aneu-
ploidy remain unknown. In this study we are investigating whether Cr(VI) affects a
key centromeric cohesion protein, Shugoshin 1 (Sgo1). Sgo1 maintains and pro-
tects centromeric cohesion in G2 and continues to maintain proper sister-chro-
matid cohesion during mitosis. This protection mechanism prevents sister-chro-
matids from prematurely separating during mitosis. Disruption of Sgo1 localization
has been shown to lead to chromosome missegregation. We have found that
chronic exposure to particulate Cr(VI) disrupts the localization of Sgo1 in G2 cells.
Specifically, after a 24 h exposure to 0.1, 0.2, or 0.3 ug/cm2 lead chromate we did
not observe any changes in the percent of G2 cells with Sgo1 localization at the
kinetochores. However, a 120 h exposure to the same concentrations showed a con-
centration-dependent decrease in the percent of G2 cells with Sgo1 localization at
the kinetochores. Specifically 0.1, 0.2 or 0.3 ug/cm2 disrupted localization in 36,
88, and 90% of G2 cells, respectively. Our findings suggest that particulate Cr(VI)-
induced CIN is mediated through disrupting Sgo1 localization to the kinetochores
during G2 cells, thus leading to chromosome missegregation and ultimately aneu-
ploidy. This work was supported by NIEHS grant ES016893 (J.P.W.).
157 Ultraviolet B-Irradiated L-Tryptophan Induces Human
UDP-Glucuronosyltransferase 1A1 and 1A8 Expressed in the
Human Skin.
R. Fujiwara,  M. Kawana,  E. Kouno,  S. Takano,  T. Narawa and T. Itoh. School
of Pharmacy, Kitasato University, Tokyo, Japan.
Benzo[a]pyrene is a widespread environmental contaminant and its active metabo-
lite, benzo[a]pyrene-7,8-dihydrodiol-9,10-epoxide, is associated with the develop-
ment of ultraviolet (UV) B-induced skin cancer. While UDP-glucuronosyltrans-
ferase (UGT) is involved in the detoxification of benzo[a]pyrene, the protective role
of UGT in the defensive mechanism against UVB-induced skin cancer has not
been elucidated yet . Here, we investigated the effects of UVB irradiation on the ex-
pression of human UGT1A enzymes as well as on cytochrome P450 (CYP) 1A1 in
HaCaT cells. Multiple UGT1A isoforms such as UGT1A1, UGT1A3, UGT1A4,
and UGT1A8 were expressed in human skin and HaCaT cells. When HaCaT cells
were treated with 6-formylindolo[3,2-b]carbazole (FICZ), which is one of the tryp-
tophan derivatives formed by UVB, UGT1A1 and UGT1A8 along with CYP1A1
were significantly induced. While UVB-irradiated tryptophan also induced those
enzymes, the formation of FICZ was not detected in the irradiated tryptophan so-
lution, indicating that tryptophan derivatives other than FICZ formed by UVB
might have the potential to activate the aryl hydrocarbon receptor. While UVB in-
duces CYP1A1, increasing the bioformation of benzo[a]pyrene-7,8-dihydrodiol-
9,10-epoxide from benzo[a]pyrene, it also induces UGTs, accelerating the detoxifi-
cation of benzo[a]pyrene. Specific induction of skin UGT1A1 and UGT1A8
without inducing CYP1A1 might protect individuals from developing skin cancer.
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158 The Cannabinoid WIN 55, 212-2 Decreases Specificity
Protein (Sp) Transcription Factor and the CaP Protein eIF4E
in Colon Cancer Cells.
S. Sreevalsan1 and S. H. Safe1, 2. 1VTPP, Texas A&M University, College Station,
TX; 2Institute of Biosciences and Technology, Texas A&M Health Science Center,
Houston, TX.
The eukaryotic translational initiation factor (eIF4E) is an essential component of
the cellular translational machinery and is responsible for binding ribosomes to the
cap structure of mRNAs. The phosphorylated form (serine-209) of eIF4E plays a
critical role in cancer cell growth and transformation. Treatment of colon cancer
cells with a synthetic cannabinoid WIN 55,212-2 (WIN) inhibited cancer cell
growth, induced apoptosis and downregulated specificity protein (Sp) transcription
factors and Sp-regulated gene products associated with cancer cell growth (EGFR
and Cyclin D1), angiogenesis (VEGF and VEGFR) and survival (survivin and bcl-
2). The anticancer activity of WIN is accompanied by induction of multiple phos-
phatases and some of the effects of WIN are blocked by the phosphatase inhibitor
sodium orthovanadate (SOV). Treatment of SW480 cells with 7.5 μM WIN alone
also decreased levels of eIF4E and co-treatment with 0.35 mM SOV blocked WIN-
induced downregulation of eIF4E and knockdown of Sp proteins confirmed that
eIF4E was an Sp-regulated gene. Protein phosphatase 2A (PP2A) catalyzes dephos-
phorylation of both eIF4E and Mnk-1, an upstream kinase that phosphorylates
eIF4E. Treatment of SW480 cells with 7.5 μM WIN and knockdown of PP2A by
RNA interference blocked downregulation of eIF4E, Sp proteins and some Sp-de-
pendent genes. Several anticancer agents inhibit Sp transcription factors by induc-
ing zinc finger binding protein ZBTB10 and by suppressing microRNA-27a
(miR27a). Treatment of SW480 cells with 7.5uM WIN induced ZBTB10 protein
and decreased miR27a expression and knockdown of PP2A reversed these re-
sponses demonstrating that WIN-induced downregulation of Sp and eIF4E was
due to PP2A-mediated disruption of miR27a:ZBTB10 axis.
159 HOTTIP, a lncRNA, Exhibits Pro-Oncogenic Activity in
Pancreatic Cancer.
I. D. Jutooru1,  G. Chadalapaka1,  K. Kim2 and S. H. Safe1, 2. 1TAMU, College
Station, TX; 2IBT, Texas A&M Health Science Center, Houston, TX.
Recent studies have demonstrated that non-coding RNAs (ncRNAs) are differen-
tially expressed and play an important role in gene regulation and influence normal
and cancer cell phenotypes. About 3000 lncRNAs have been identified and some of
these act as scaffolds regulating molecular (protein, RNA and DNA) interactions
required for various signaling networks and this is accomplished, in part, by associ-
ation with chromatin-modifying complexes. HOXA transcript at the distal tip
(HOTTIP) is a 3,764-bp lncRNA transcribed from 5’ tip of HOXA gene cluster
and is expressed in anatomically distal cells such as hand and foot fibroblasts.
Previous studies in our laboratory showed that HOTAIR is a negative prognostic
marker in pancreatic cancer and this is due, in part, to interaction of HOTAIR with
Polycomb Repressive Complex 2. In contrast, HOTTIP was reported to interact
with MLL complexes by specifically binding to WDR5 adapter protein leading to
broad loss of H3K4me3 across HOXA locus. In this study, we investigated the
functional role of HOTTIP in Panc1 and L3.6pL pancreatic cancer cell lines.
Knockdown of HOTTIP by RNA interference studies (iHOTTIP) resulted in
~50% reduction in cell survival within 72 hr after transfection and iHOTTIP also
decreased pancreatic cancer cell migration which was determined in a Boyden
chamber assay. iHOTTIP enhanced Annexin V staining and PARP cleavage associ-
ated with induction of apoptosis in both Panc1 and L3.6pL cells. Knockdown of
HOTTIP also decreased expression of cyclin D1, VEGF and survivin which play
an important role in cell proliferation, angiogenesis and survival. An in vivo study
was performed using L3.6pL cells transfected with iHOTTIP in a mouse xenograft
model and after 15 days of knockdown there was a significant reduction in tumor
volumes and weights (≥70%). RNASeq analysis of HOTTIP knockdown in Panc1
cells resulted in significant (>1.5 fold) changes in expression of ~1467 genes and
analysis of data suggest that HOTTIP mediated gene regulation has a critical role in
pancreatic cancer progression.
160 Metformin Causes Degradation of Fatty Acid Synthase and
PI3 Kinase Signaling Proteins in Pancreatic Cancer Cells
through Downregulation of Specificity Protein (Sp)
Transcription Factors.
V. Vasanthakumari1 and S. H. Safe1, 2. 1VTPP, Texas A&M University, College
Station, TX; 2IBT, TAMHSC, Houston, TX.
Metformin or N,N’-dimethyl biguanide is an oral hypoglycemic drug with a re-
markable record of safety that has been prescribed worldwide for treatment of Type
II diabetes. In addition to its antidiabetic property it also exhibits antineoplastic ef-
fects which include inhibition of angiogenesis through decreased levels of vascular
endothelial growth factor (VEGF) and blocks cell cycle progression through de-
creased expression of cyclin D1. Fatty Acid Synthase (FAS) a key enzyme in lipid
metabolism is overexpressed in cancer cells, which is one of the phenotypic alter-
ations in cancer progression. Here we show that expression of FAS was significantly
decreased when pancreatic cancer cells were treated with metformin. FAS expres-
sion is stimulated by growth factors and their receptors, like EGFR and IGFR.
Effects of these receptors on FAS complex involve cross talk between various signal
transduction pathways. One such signaling pathway include PI3kinase/ mTOR
pathway. Specificity protein (Sp) transcription factors - Sp1, Sp3 and Sp4 play a
complex role in malignant transformation of pancreatic cancer cells. We report for
the first time that metformin downregulates specificity protein (Sp) transcription
factors (Sp1, Sp3, Sp4) in cancer cells. Furthermore metformin downregulates the
expression of growth factor receptors like EGFR, IGFR and phosphorylation/ex-
pression of major PI3K effectors like AKT and mTOR. Knockdown of Sp1, Sp3,
and Sp4 proteins by RNA interference decreased the expression of FAS, pmTOR
and pAKT indicating that FAS and these signaling proteins are regulated by Sp pro-
teins. However when cells were pretreated with SOV (Sodium Ortho Vanadate), a
phosphatase inhibitor, there was a reversal of Sp downregulation and phosphoryla-
tion of mTOR by metformin. The effects of metformin on downstream targets of
PI3 kinase pathway and the specific phosphatases which play a major role in the an-
tineoplastic effects of metformin are currently being investigated.
161 Overexpression of STAT-3 Induces Anoikis Resistance,
Promotes Cell Migration, and Metastatic Potential in Cancer
Cells.
N. M. Fofaria and S. K. Srivastava. Biomedical Sciences and Cancer Biology Center,
Texas Tech University Health Sciences Center, Amarillo, TX.
Anoikis is an anchorage independent cell death. Resistance to anoikis is one of the
key features of the metastatic cells. In the current study, we have shown the role of
STAT-3 in anoikis resistance in various melanoma and pancreatic cancer cells.
Marked anoikis was induced as such in the cells that were grown in anchorage-in-
dependent conditions. The melanoma and pancreatic cancer cells that resisted
anoikis were observed to have higher rate of migration as compared to the cells that
were exposed to anchorage dependent growth, as observed in cell migration and in-
vasion assays. These anoikis resistant cells also had significantly higher expression
and phosphorylation of STAT-3 at Tyr 705, than the cells that were attached to the
basement membrane. Treatment of these cells with IL-6, a cytokine which phos-
phorylates STAT-3, prevented the induction of anoikis. STAT-3 inhibitors AG490
and piplartine induced anoikis in a concentration-dependent manner, whereas IL-6
blocked anoikis. Over-expression of STAT-3 by transfection, not only increased the
anoikis resistance but also protected cancer cells from piplartine-induced anoikis,
confirming the role of STAT-3 in anoikis resistance. On the other hand, silencing
STAT-3 decreased the potential of cancer cells to resist anoikis. Furthermore,
STAT-3 (-/-) cancer cells were more sensitive to anoikis as well as to the effect of pi-
plartine as compared to STAT-3 (+/+) cells. The STAT-3 (+/+) cells also had en-
hanced migration potential as compared to STAT-3 (-/-) cells. In summary, our re-
sults establish STAT-3 as a critical player that renders anoikis resistance to the
cancer cells and enhance their metastasis potential. The role of STAT-3 in anoikis in
breast and ovarian cancer is currently under investigation. The outcome of this
study has great clinical implications as it will serve as a platform to devise rational
therapeutic approaches to treat metastatic cancers. [Supported in part by R01
grants CA106953 and CA129038 (to S.K.S) awarded by the National Cancer
Institute].
162 Indole and Related Compounds Exhibit AhR
Antagonist/Agonist Activities.
S. H. Safe1,  A. Jayaraman2,  R. Alaniz2 and U. Jin2. 1Texas A&M University,
College Station, TX; 2IBT, Texas A&M University System, Houston, TX.
Indole-derived compounds including diindolylmethane (DIM), indole-3-carbinol,
tryptophan photoproducts and metabolites have been identified as agonists of the
aryl hydrocarbon receptor (AHR). Indole and tryptophan metabolites tryptamine
(TA) and indole 3-actetate (IAA) are produced by gut microflora and there is evi-
dence that AHR ligands modulate gut inflammatory pathways. We therefore inves-
tigated the AHR agonist/antagonist activities of indole, TA and IAA using Ah-re-
sponsive breast and colon cancer cells as in vitro models. In MDA-MB-468 breast
cancer cells TA (0-500 uM) induced CYP1A1 mRNA and protein with an EC50 <
500 μM; IAA and indole also induced CYP1A1 mRNA (only IAA induced
CYP1A1 protein) however < 30 and < 10% of the maximal induction responses
were observed at 1000 μM concentrations of IAA and indole respectively. The ef-
fects of these compounds as inhibitors of 2,3,7,8-tetrachlorodibenzo-p-dioxin
34 SOT 2013 ANNUAL MEETING
(TCDD) induced responses were also investigated in cells treated with the indole
compound alone or in combination with TCDD. Indole (500 and 1000 μM) sig-
nificantly inhibited TCDD-induced CYP1A1 mRNA and protein levels and simi-
lar results were observed for 500 μM TA however the former compound was a sig-
nificantly more potent AHR antagonist. In contrast IAA did not exhibit AHR
antagonist activity. These results were somewhat variable among different cell lines
however, it was evident that the major gut microbiome product, indole, was an
AHR antagonist and this may impact AHR-dependent gut inflammatory path-
ways.
163 Tolfenamic Acid Inhibits Colon Cancer Cell and Tumor
Growth and Downregulates Specificity Protein (Sp)
Transcription Factors.
S. Pathi1 and S. H. Safe1, 2. 1Veterinary Physiology and Pharmacology, Texas A&M
University, College Station, TX; 2Institute of Bioscience and Technology, Houston, TX.
Introduction: Tolfenamic acid (TA) is a nonsteroidal anti-inflammatory drug
(NSAID) and is a potential chemotherapeutic agent for treatment of colon cancer;
however, the mechanism of action of TA is unknown and was investigated in this
study.
Methods: Inhibition of colon cancer cell growth and induction of apoptosis by TA
was investigated using cell counting and Annexin V staining, and modulation of
specificity protein (Sp) transcription factors Sp1, Sp3, Sp4 and Sp-regulated gene
products was determined by western blot analysis of whole cell lysates. Mechanisms
of TA-induced Sp downregulation were investigated using specific pathway in-
hibitors and the in vivo anticancer activity of TA was determined in athymic nude
xenograft studies using RKO cells as xenografts.
Results: TA induced apoptosis and decreased colon cancer cell growth and this was
accompanied by caspase-dependent proteolysis of Sp1, Sp3 and Sp4 and decreased
expression of Sp-regulated gene products including bcl-2, survivin, VEGF,
VEGFR1, cyclin D1 and c-MET. TA also inhibited colon tumor growth and de-
creased Sp1, Sp3, Sp4 and Sp-dependent gene product expression in tumors.
Conclusion: TA-induced repression of Sp transcription factors and Sp-regulated
genes play a role in the cancer chemotherapeutic effects of TA. Since TA acts as an-
ticancer agent in several tumor types, results of this study suggest for the first time
that TA is a potential chemotherapeutic agent for treatment of colon cancer.
Clinical applications of TA alone or in combined treatment of colon cancer are en-
hanced since this agent is relatively non-toxic and has previously been used as a
non-steroidal anti-inflammatory drug. The prior use of TA, as an NSAID will also
facilitate approval of the drug for application as a cancer therapeutic agent.
164 Ni+2-Induced Chromosome Aberrations/Gene
Amplification/Gene Silencing Alter Cytoskeleton, Ca+2
Distribution, and Global Gene Expression, Causing
Morphol./Neoplast. Transformation of 10T1/2 Mouse
Embryo Cells.
J. R. Landolph1, 3, 2,  A. DaSilva Pehl2, 3,  P. Samala1, 3,  S. Keliipaakaua2, 3 and
K. Akinwumi1, 3. 1Department of Molecular Microbiology and Immunology,
University of Southern California, Los Angeles, CA; 2Department of Pathology,
University of Southern California, Los Angeles, CA; 3USC Cancer Center, University
of Southern California, Los Angeles, CA.
Ni refinery workers inhaling Ni sulfidic ore dusts/smoking cigarettes contracted
lung/nasal cancers. Inhaled Ni3S2/green NiO induced lung cancer in rats.
Ni3S2/green-black NiOs induced chromosome aberrations/morph-neoplas trans-
formation (Tx) in 10T1/2 mouse cells. Ni/MCA-Tx cell lines showed a) ect-2 gene
amplification/higher ect-2 mRNA/protein, b) no DRIP80 c) no β-centaurin-2
mRNA. We hypothesized Ni+2 1) amplified ect-2 gene, causing higher levels of mi-
crotubules (MTs); 2) silenced β-centaurin-2 gene, causing higher levels of microfil-
aments (MFs); and 3) silenced DRIP gene, altering Ca+2 distribution/Tx 10T1/2
cells. We tested these hypotheses by staining cells with fluor. phalloidin to decorate
MFs; fluor. Ab to α-tubulin to decorate MTs; Fluo 3AM to stain Ca+2; DAPI to
decorate nuclei; then examined cells by confocal microscopy. In non-Tx 10T1/2
cells, MFs/MTs were arranged in long fibers. In NiS/green NiO-Tx cell lines,
MFs/MTs were over-expressed, aggregated in areas, absent/other areas, changing
cell shapes. Low density non-Tx cells had high nuclear/low cytoplasmic Ca+2 con-
centrations (State I); high density near-confluent cells had low nucl./high cyto.
Ca+2 (State II). Ni/MCA-Tx cell lines were largely in State II. We conclude Ni+2
ions 1) amplified ect-2/silenced β-centaurin-2 genes, causing over-expression of
MTs/MFs, altering cell shapes, changing global gene expression; 2) silenced
DRIP80 gene, altering Ca+2 distributions in Tx cells; and 3) induced muta-
tions/methylations in 15 genes, causing differential expression of 130 genes, con-
tributing to induction/maintenance of Tx phenotypes in Ni+2/MCA-Tx cell lines.
Support: R01 ES03341/NIEHS (PI JRL); Cancer Center Core Grant 5 P30
CA09320/NCI; MS Program/Discret. Funding (JRL).
165 Benzoquinone-Induced Topoisomerase Modifications:
Linking Benzene Myelotoxicity and Leukemia.
C. L. Kuhlman,  G. Tsaprailis,  T. J. Monks and S. S. Lau. Southwest
Environmental Health Sciences Center, Department of Pharmacology and Toxicology,
University of Arizona, Tucson, AZ.
Protein adduction by reactive electrophiles can induce structural and functional
changes that contribute to toxicity and disease progression. Such electrophiles are
often products of xenobiotic metabolism or generated endogenously via oxidative
stress and lipid peroxidation. Relevant to this phenomenon are the redox-active and
electrophilic metabolites of benzene, which are believed to contribute to its myelo-
toxic effects. When the benzene metabolites hydroquinone (HQ) and phenol
(PHE) are administered to rats, HQ oxidizes to 1,4-benzoquinone (BQ) and in the
presence of GSH gives rise to multi-GSH conjugates detectible in bone marrow.
These HQ-GSH conjugates retain the ability to adduct proteins and to redox cycle.
Here we report that bone marrow malondialdehyde levels in PHE/HQ treated rats
are significantly elevated, indicative of lipid peroxidation and the consequent gen-
eration of other reactive electrophilic aldehydes, such as 4-hydroxy-2-nonenal
(4HNE). Indeed, proteomics profiling revealed bone marrow proteins targeted by
benzene metabolites and 4HNE, including 14-3-3 protein zeta/delta, protein disul-
fide isomerase A3, peroxiredoxin 2, and calreticulin. Adduction of topoisomerase II
α (topo IIα) has been implicated in benzene-induced leukemia, and cancer
chemotherapeutic topo IIα inhibitors are a leading cause of therapy-induced
leukemia. We next reacted purified topo IIα (6 units) with BQ (0.5 μM) or 4HNE
(1.3 μM). A marked reduction in the ability of topo IIα to decatenate the kDNA
substrate was observed. Proteomic analysis of 4HNE-reacted topo IIα revealed
multiple amino acid sites of adduction, including K893 and K1480 adducts.
Adduction of these lysine residues could impair topo IIα-DNA binding, or inhibit
topo IIα’s ATP-dependent formation and annealing of DNA strand breaks. The
consequences of BQ- and 4HNE-induced functional alterations in topo IIα are
currently under investigation.
166 Overexpression of CRM1 in Normal Human Lung Epithelial
Cells Changes Cellular Morphology and Cytotoxic
Responses to Tobacco-Specific Carcinogen NNK.
C. Lu,  W. Zhu and W. Gao. The Institute of Environmental and Human Health,
Texas Tech University, Lubbock, TX.
Chromosome region maintenance 1 (CRM1), the major nuclear export receptor
with a broad substrate range, is not only required for transport of many RNAs and
proteins but also involved in various modulations within the cell such as mitosis,
cell arrest, and apoptosis. Our recently published study showed that CRM1 played
critical roles in response to tobacco-specific carcinogen, 4-(methylnitrosamino)-1-
(3-pyridyl)-1-butanone (NNK), in BEAS-2B cells (a normal human lung epithelial
cell line). The objective of the present study was to further examine the significance
of CRM1 in lung cancer development using BEAS-2B cells stably overexpressing
CRM1 (BEAS-2BCRM1+ cells). The overexpression of CRM1 in BEAS-
2BCRM1+ cells was confirmed by real-time PCR and western blot. As compared to
BEAS-2B cells, BEAS-2BCRM1+ cells were prone to form colonies. Soft-agar assay
further demonstrated increased colony formation and larger colony size in BEAS-
2BCRM1+ cells in comparison with BEAS-2B cells. In addition, the cytotoxic ef-
fects in response to NNK was measured by 3-(4,5-dimethylthiazol-2-yl)-5-(3-car-
boxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay in both cells.
Cells were treated with 0-500 μM NNK for 24, 48, and 72 h. The inhibitory ef-
fects were dose and time dependent in both cells (p<0.05). However, BEAS-
2BCRM1+ cells showed different sensitivity to NNK as compared to BEAS-2B
cells. Taken together, our results indicate that CRM1 overexpression changes cellu-
lar morphology and cytotoxic response to tobacco carcinogen in human lung ep-
ithelial cells. The potential molecular mechanisms involving these changes are
being evaluated to better understand the critical role of CRM1 in chemical car-
cinogenesis after NNK exposure.
167 ARNT Isoforms Mediate Opposing Effects on NF-κB
Signaling.
K. Gardella1, 2,  I. Muro1, 2 and C. Wright1, 2. 1Divison of Pharmacology and
Toxicology, The University of Texas at Austin, Austin, TX; 2The Center for Molecular
and Cellular Toxicology, The University of Texas at Austin, Austin, TX.
We have previously shown that the arylhydrocarbon receptor nuclear translocator
(ARNT) regulates the chromatin binding activity of the RelB NF-κB subunit.
ARNT is a transcription factor that is integral in the regulation of xenobiotic and
hypoxic responses but our studies suggest that ARNT also participates in NF-κB
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signaling. ARNT is expressed as two isoforms, isoform 1 and 3, but whether these
isoforms differentially regulate NF-κB activity is unclear. Isoform 1 is identical to
isoform 3 except for an additional 15 amino acids near the N-terminus. The extra
amino acids in isoform 1 provide a phosphorylation site, which has been shown to
inhibit its DNA binding. Interestingly, we have observed in lymphoid malignancies
that ARNT isoform 1 is expressed at much higher levels than isoform 3 as com-
pared to normal lymphocytes where the ARNT isoforms are expressed at equal lev-
els. We find that ARNT isoform 1 potentiates while ARNT isoform 3 abrogates
NF-κB activity. In light of our previous ARNT-RelB model, these opposing effects
of the ARNT isoforms in NF-κB signaling appear to hinge on their ability to asso-
ciate with RelB as ARNT isoform 3 binds much more strongly than isoform 1.
Lastly, we found that the co-expression of a GFP-tagged p100 in combination with
the ARNT isoforms promoted p100 nuclear translocation, possibly through a RelB
bridge, resulting in diminished transactivation of NF-κB responsive genes. Thus,
our current working model is one in which lymphoid malignancies shift toward the
production of ARNT isoform 1, which in turn enhances NF-κB activity, as a con-
tributing factor to their growth and survival.
168 Co-Exposure to Arsenic and Estrogen Leads to Enhanced
Transformation of Normal Human Prostate Epithelial Cells.
J. Treas,  T. Tyagi and K. P. Singh. The Institute of Environmental and Human
Health, Texas Tech, Lubbock, TX.
Exposure to both arsenic and estrogen are known risk factors for prostate cancer,
however the carcinogenic effect of their co-exposure is not known. Therefore, the
objective of this study was to evaluate the transformation potential and its mecha-
nism in human prostate epithelial cells by co-exposure to these two chemicals. To
achieve this objective, the human prostate epithelial cells, RWPE-1 were treated for
6 months with sodium-meta arsenite and 17β-estradiol, both alone and in combi-
nation, at concentrations of 100 pg/mL and 100 ng/mL. Cell counts and MTT
assay was performed to determine the effects on growth, and soft agar assay was per-
formed to evaluate the cell transformation by exposure to arsenic and estrogen.
Potential role of estrogen receptors and aromatase in mediating the cellular re-
sponse to these chemicals was evaluated by measuring their expression at transcript
level. The result of this study revealed that the growth and transformation of
RWPE-1 cells were significantly greater in arsenic and estrogen co-exposed cells as
compared to cells individually exposed to these two chemicals. The data of quanti-
tative real time PCR revealed that expression of estrogen receptor beta was signifi-
cantly increased whereas aromatase was significantly decreased in arsenic and estro-
gen co-exposed cells. These findings together with our recently published data on
aberrant expression of epigenetic regulatory genes, such as, DNMTs, HDACs and
MBDs in arsenic and estrogen co-exposed cells suggest that co-exposure to these
two chemicals enhances carcinogenicity through epigenetic mechanisms.
169 Effects of Polycyclic Aromatic Hydrocarbons with Estrogen
Receptors α and β in Breast Cancer Cells.
T. T. James1, 2,  C. K. Sievers2,  E. Shanle1, 2,  S. S. Hecht3,  C. A. Bradfield1, 2 and
W. Xu1, 2. 1Molecular and Environmental Toxicology Center, University of Wisconsin-
Madison, Madison, WI; 2Oncology, University of Wisconsin-Madison, Madison, WI;
3Masonic Cancer Center, University of Minnesota, Minneapolis, MN.
Polycyclic aromatic hydrocarbons (PAHs) are widespread environmental pollutants
found in cigarette smoke, contaminated soil, vehicle exhaust, among others, known
to cause adverse health effects including carcinogenesis and endocrine disruption.
The metabolites of PAHs have been implicated in endocrine disruption. Some
PAHs are known to have estrogenic effects by interacting with estrogen receptors
(ERs). Estrogens have diverse roles including regulation of mammary gland devel-
opment and morphogenesis, and maturation of uterus and ovaries. These functions
are mediated by two subtypes of estrogen receptors, ERα and ERβ, which function
in dimer forms (i.e. ER α,β homodimers and ERα/β heterodimers).ERα is known
to be proliferative while ERβ is known to be antiproliferative in the mammary
gland. The estrogenic effects of PAHs have been mostly focused on their effects on
ERα. Recently our lab reported that the monohydroxylated metabolites of naph-
thalene, phenanthrene and pyrene showed differential effects with ERα and ERβ.
These PAHs were selected because they are found at high levels in contaminated
environments. The ability of the PAH compounds to promote estrogenic effects
were revealed by luciferase assays in isogenic reporter cell lines, competitive binding
assays and bioluminescent resonance transfer (BRET) assays. The PAHs metabo-
lites were more selective for ERβ and were able to activate ERβ target genes sug-
gesting that these compounds can interfere with ERβ signaling in human breast
cancer cells. In this study we screened additional PAHs and their monohydroxy-
lated metabolites to determine their estrogenic effects. These studies demonstrate
the impact of monohydroxylated PAHs on ER signaling and provide basis for the
determination of the effects of other environmental compounds on ER. Supported
by NIEHS Predoctoral Training Grant T32 ES007015
170 Alternative Splicing of ATG5 in DU145 Human Prostate
Cancer Cells Inactivates Autophagy and Promotes Xenograft
Tumor Growth.
D. J. Wible1, 2,  T. M. Calhoun-Davis2,  D. G. Tang2 and S. B. Bratton2. 1Institute
for Cellular and Molecular Biology, The University of Texas at Austin, Austin, TX;
2Molecular Carcinogenesis, Virginia Harris Cockrell Cancer Research Center at The
University of Texas MD Anderson Cancer Center Science Park, Smithville, TX.
Autophagy is a highly conserved pathway that targets cytoplasmic cargo to the lyso-
some for degradation. Excess or aberrant organelles, large protein aggregates and
non-selective portions of the cytosol can be targeted by the autophagosome and de-
livered to the lysosome in order to maintain cellular homeostasis or survival in re-
sponse to stress. In this study, we show that DU145 human prostate cancer cells al-
ternatively splice Autophagy-related protein 5 (ATG5), an essential protein for
autophagosome formation. These novel ATG5 splice forms are unable to conjugate
normally to ATG12 and instead are rapidly ubiquitinated and turned over by the
proteasome. The absence of ATG5-ATG12 conjugate in DU145 cells prevents au-
tophagosome formation and autophagic degradation. Stable expression of full-
length ATG5 using lentiviral infection rescued both ATG5-ATG12 conjugation
and autophagy. Autophagy is currently thought to be tumor suppressive by elimi-
nating potentially genotoxic protein aggregates and damaged organelles. However,
the role it plays in tumor progression and metastasis remains unclear. To address
this question, we performed subcutaneous injections of autophagy-deficient and
autophagy-proficient DU145 cells into immunodeficient mice and monitored
tumor formation and growth. In initial experiments, autophagy deficient tumors
had a significantly longer latency period, yet grew at a faster rate than autophagy
competent tumors. This suggests that autophagy can promote initial tumor estab-
lishment, while suppressing later tumor growth. Currently there are numerous clin-
ical trials investigating the therapeutic potential of drugs that inhibit autophagy.
Since it’s not yet clear how these opposing aspects affect cancer metastasis, further
study is essential to ensure effective therapy.
171 The Aryl Hydrocarbon Receptor Regulation during
Epithelial-to-Mesenchymal Transition.
S. S. Kishinhi and S. E. Eltom. Biochemistry & Cancer Biology, Meharry Medical
College, Nashville, TN.
The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor that
plays a role as a mediator of the xenobiotic signaling pathways. Recently, the AhR
emerged as a major player in breast carcinogenesis. We have shown previously that
ectopic overexpression of AhR in immortalized normal human mammary epithelial
cells (HMEC) resulted in the development of malignant phenotypes, most notably
the epithelial-to-mesenchymal transition (EMT). This EMT phenotype however, is
not rigid but is in a dynamic state; with cells moving back and forth between ep-
ithelial and mesenchymal states. We asked the question whether this flux of pheno-
types is due to changes in AhR levels or activity. A clone of HMEC overexpressing
AhR, with either epithelial (E) or fibroblastic (F) phenotypes was compared to an
empty vector (EV) control cells. We employed Western blotting, immunocytofluo-
rescence (ICF) staining and RT-PCR techniques to assess the AhR expression as
well as the epithelial and mesenchymal markers, E-Cadherin and vimentin, respec-
tively. Our results showed that although at the mRNA levels AhR expression was
similar, the AhR protein was higher in E- than in F-type cells. The AhR protein lev-
els were always higher when cells were grown at higher density. Nuclear localization
as assessed by ICF and CYP1A1 expression as assessed by RT-real time PCR, were
used as surrogates for AhR activation. Our analysis showed that AhR activation was
much higher in F-type cells and is more pronounced at higher cell density. In con-
trast, a 3h treatment with TCDD, a potent AhR agonist resulted in a steeper in-
duction of CYP1A1 in E-type than the F-type cells, which is further enhanced at
higher density. The observed difference in AhR protein levels and activity may be
due to a differential stability of the protein associated with the two morphological
forms, which is under investigation.
172 Expression and Role of ALDH1B1 in Pancreatic Cancer.
S. Singh1,  K. Quackenbush2,  A. Purkey2,  J. Arcaroli2,  Y. Chen1,  D. J. Orlicky3,
W. Messersmith2 and V. Vasiliou1. 1Department of Pharmaceutical Sciences,
University of Colorado, Aurora, CO; 2Division of Medical Oncology, University of
Colorado, Aurora, CO; 3Department of Pathology, University of Colorado, Aurora,
CO.
Recent studies show that ALDH activity selectively defines an enhanced tumor-ini-
tiating cell population in human pancreatic adenocarcinoma. The specific ALDH
isozyme(s) contributing to the high ALDH activity in these cells are unknown. We
have recently shown that the mitochondrial aldehyde dehydrogenase 1B1
36 SOT 2013 ANNUAL MEETING
(ALDH1B1) is a potential biomarker for colon cancer. The aim of the current
study was to examine expression and the role, if any, of ALDH1B1 in pancreatic
adenocarcinoma. In normal pancreas, ALDH1B1 is abundantly expressed in glan-
dular cells, but sparsely in the ducts (ALDH1B1 immunopositivity = 16.7 ± 1.7).
In pancreatic ductal carcinoma, we found a rather high ALDH1B1 expression in
ductal cancerous tissues (ALDH1B1 immunopositivity = 197.2 ± 29.4). Our data
were also confirmed by analyzing human pancreatic adenocarcinoma tissue mi-
croarrays. Furthermore, ALDH1B1 appears to be contributing to ALDH activity
in some, but not all, human pancreatic cancer explants examined. The variation of
ALDH1B1 expression was also observed in 16 human pancreatic cancer cell lines.
Two high and two low ALDH1B1 expressing cell lines were subjected to siRNA
ALDH1B1 knockdown and cell proliferation was evaluated. High ALDH1B1 cell
lines showed a 35% reduction in cell growth whereas proliferation was not affected
in low ALDH1B1 cell lines. Treatment of high ALDH1B1 cells with gemcitabine
resulted in greater ALDH1B1 mRNA levels and enzyme activity. In contrast low
ALDH1B1 cells showed no such effect. Collectively our data show for the first time
that ALDH1B1 is expressed at very high levels in pancreatic cancer and it con-
tributes to proliferation of these tumor cells. These data suggest a potential role of
ALDH1B1 in pancreatic cancer.
173 Gene Expression Changes in Human Endometrial and
Mammary Cells Exposed to Tamoxifen.
E. Hernandez Ramon1,  E. Asaki2,  O. Olivero1 and M. C. Poirier1. 1LCBG, NCI,
NIH, Bethesda, MD; 2Division of Computational Bioscience, CIT, NIH, Bethesda,
MD.
Tamoxifen (TAM), a selective estrogen receptor modulator used for adjuvant ther-
apy and chemoprevention of breast cancer, also increases the risk of endometrial
and myometrial cancer. We hypothesized that comparison of gene expression pat-
terns in cultured normal breast and endometrial cells may elucidate TAM-induced
mechanisms. Gene expression studies in normal human mammary epithelial cells
(NHMECs) exposed to 10 μM TAM for 48 hr, using NIH DNA-oligonucleotide
microarrays (Schild et al., 2003), demonstrated up-regulation of genes active in the
interferon and immune-response pathways. Here we used the same NHMECs and
TAM exposure conditions, and evaluated gene expression by Human Gene 1.0 ST
Affymetrix expression array. Results using the Affymetrix array confirmed TAM-in-
duced up-regulation of interferon signaling and complement pathways. Genes sig-
nificantly overexpressed include some reported before (IFI27, IFIT1, IFIT3,
IFI44L, IFITM1 and OAS3), and new genes involved in the same pathway (IFI44,
IFI35, and IFIH1), as well as genes in the complement system (C1S, C1R and
SERPING1). To contrast breast with endometrium, we used human endometrial
stromal cells (HESC cells), also exposed to 10 μM TAM for 48 hr. The primary
genes up-regulated included some involved with biosynthesis of steroids (DHCR7,
FDPS and MVD), and SREBF2, a sterol transcription factor. In addition, there was
up-regulation of PPARG, a gene involved in cell proliferation and cancer, and
down-regulation of CC1, a gene with anti-tumor activity. Expression changes of
the most highly altered genes have been confirmed by qRT-PCR, and the microar-
ray data are being subjected to extensive pathway analysis. However, these prelimi-
nary data show induction of different gene expression patterns in normal human
mammary and endometrial cells exposed to TAM, confirming that immune-re-
sponse pathways are induced in the breast, and showing that steroidal and prolifer-
ative pathways are induced in the endometrium.
174 Revealing the Role of Cancer Testes Antigens in Hif
Signaling.
C. Okechukwu1,  A. Whitehurst2,  J. Wooten2 and K. Corcoran2. 1Chemistry and
Pharmaceutical Sciences, North Carolina Central University, Durham, NC;
2Pharmacology, University of North Carolina Chapel Hill, Chapel Hill, NC.
Sponsor: A. Baines.
The hypoxia –inducible factor-1 (HIF-1), is a transcription factor that responds to
changes in oxygen homeostasis. Furthermore, the HIF pathway has been observed
to contribute to tumor aggressiveness. The overexpression of HIF proteins has been
observed to increase malignancy in tumor cells. Identifying the mechanisms that
regulate HIF is essential to developing therapeutic strategies to inhibit its function.
Here, we asked whether any members of the cancer-testes (CT)-antigen (CTA)
family support HIF signaling. We combined an siRNA mediated loss of function
approach with a luciferase reporter fused to a HIF Response Element (HRE) to de-
termine consequences on HIF signaling following individual depletion of 120
CTAs. This screen revealed a subset of CT-antigens that positively support HIF in-
duced transcription. This regulation appears to be at the level of the HIF1a protein
as depletion of a subset of these CTAs, MAGEA3/6 and IGF2BP3 reduced induc-
tion of HIF1a protein. These findings suggest that CTAs may support stress signal-
ing, particularly under hypoxic conditions and further demonstrate that CTAs may
be playing functional roles in supporting tumor cell survival.
175 Aryl Hydrocarbon Receptor (AhR)-Active Pharmaceuticals
Are Selective AhR Modulators in Triple Negative Breast
Cancer Cell Lines.
U. Jin1,  S. Lee1 and S. H. Safe1, 2. 1CEGM, Institute of Biosciences & Technology,
Houston, TX; 2VTPP, Texas A&M University, College Station, TX.
The aryl hydrocarbon receptor (AHR) plays an important role in multiple biologi-
cal processes including regulation of drug-metabolizing enzymes, inflammatory
pathways, immune responses and modulation of tumor cell formation and growth.
Activation of the AHR by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) or the se-
lective AHR modulator 6-methyl-1,3,8-trichlorodibenzofuran (MCDF) inhibited
metastasis/invasion of triple negative MDA-MB-231 breast cancer cells in vitro and
in vivo and identification of other antimetastatic AHR ligands was further investi-
gated among a group of previously identified  AHR-active pharmaceuticals.
Treatment of BT474, MDA-MB-468 and MDA-MB-231 breast cancer cells with
4-hydroxytamoxifen, flutamide, leflunomide, mexiletine-HCl, nimodipine,
omeprazole, sulindac, or tranilast gave highly variable results for their AHR agonist
activity which was structure and cell context-dependent. The most striking data
were observed in MDA-MB-468 cells where tranilast exhibited partial AHR ago-
nist/antagonist activities and mexiletine inhibited TCDD-induced CYP1A1 gene
expression and was a full AHR antagonist in this cell line. We also investigated the
potential AHR-mediated inhibition of MDA-MB-231 cancer cell migration and
invasion by this panel of pharmaceuticals using scratch and Boyden Chamber inva-
sion assays. Only omeprazole blocked cell migration and invasion in this cell line
and these responses were inhibited by knockdown of the AHR by RNA interfer-
ence or co-treatment with the AHR antagonists, 3’-methoxy-4’-nitroflavone or 3,4-
methoxy-α -naphthoflavone. These in vitro antimetastatic responses were accom-
panied down-regulation of the prometastatic gene CXCR4, previously been
reported as an AHR ligand-inducible gene. Omeprazole and related benzimidazole
analogs also exhibited anti-invasion activities in vitro suggesting that this AHR-
pharmaceutical class may have clinical importance for treating advanced basal-type
breast cancer that metastasizes to other tissues. (Supported by NIH-R01-CA-
136571).
176 A Retrospective Analysis of Vehicle-Related Effects on Body
Weight Gain and Survival from Two-Year Sprague-Dawley
Rat Carcinogenicity Studies.
R. Yeager1,  C. Papagiannis2,  D. Poage2,  R. Pimentel2,  T. Henriques1,  C. Lin3
and L. Shu3. 1Preclinical Safety Toxicology, Abbott Laboratories, Abbott Park, IL;
2MPI Research, Inc., Mattawan, MI; 3Non-Clinical Statistics, Abbott Laboratories,
Abbott Park, IL.
Depending on the proposed clinical indication, two-year rat carcinogenicity (CA)
studies are conducted in support of the marketing application for new chemical en-
tities (NCEs). The vehicle(s) used to formulate NCEs for the preclinical GLP rat
toxicology studies are often utilized in the CA studies. Therefore, the objective of
this study was to conduct a retrospective analysis of vehicle-related effects on body
weight gain and survival from rat CA studies. The data set consisted of 30 individ-
ual vehicle groups, which included the following vehicles: water, methylcellulose,
ad libitum diet/feed, and a lipid mixture. Survival was analyzed by the proportional
hazard model and body weight gain was analyzed by the Gompertz non-linear
mixed model. For males and females, there was higher variability in survival with
diet compared to other vehicles. In males, there was a marginally significant (p =
0.069) increase in survival with diet compared to water. In addition, there was a sig-
nificant decrease in survival with the lipid mixture vehicle compared to all other ve-
hicles. This significant decrease in survival with the lipid mixture vehicle corre-
sponded with a decrease in body weight gain in this group compared to all other
vehicles. In females, there was a significant increase in survival with methylcellulose
compared to diet; however, there were no other significant differences in survival
among other vehicle groups in females. Moreover, there was not as profound of an
effect on body weight gain in females administered the lipid mixture vehicle, com-
pared to other vehicles, as was observed in males. In conclusion, this analysis
demonstrates that complex vehicle formulations, such as lipid mixtures, may affect
body weight gain and survival on two-year rat carcinogenicity studies.
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177 Modifying Effect of Glycidol Fatty Acid Esters on N-Methyl-
N-Nitrosourea Induced Mammary Carcinogenesis in Rats.
Y. Cho1,  T. Toyoda1,  S. Onami1,  Y. Mizuta1,  A. Nishikawa2 and K. Ogawa1.
1Division of Pathology, NIHS, Tokyo, Japan; 2Biological Safety Research Center,
NIHS, Tokyo, Japan.
Glycidol fatty acid esters (GEs), trace contaminants in edible oils which are possibly
formed during refining processes, have recently been detected in vegetable fat-con-
taining products, including infant formulas. The level of GEs was ten times higher
in enzymatically processed diacylglycerol-rich oil than that in the regular cooking
oil containing triacylglycerols as major components. Although there is no toxico-
logical data available yet on the GEs, the primary toxicological concern is based on
the potential release of genotoxic carcinogen, glycidol from the parent esters. In the
present study, to detect the modifying effects of GEs on the mammary gland, one
of the carcinogenic target organs of glycidol, we pretreated 7-week-old SD rats with
N-methyl-N-nitrosourea (50 mg/kg i.p.) and then administered glycidol (800
ppm) or GEs (3600 ppm, glycidol oleate (GO) or glycidol linoleate (GL)) in the
drinking water for 26 weeks. The dose levels being selected on the basis of carcino-
genic dose levels in rat carcinogenicity study of glycidol (37.5 and 75 mg/kg/day)
and on the equal moles of the esters. In body weights, significant decrease was
noted in the glycidol group compared to control group from week 2 through ex-
perimental period due to obvious decrease of water consumption. The calculated
glycidol intake was 43 mg/kg per day and on the assumption that all treated GEs
would be completely metabolized to glycidol, intake of glycidol in GO and GL
groups was 93 and 74 mg/kg per day, respectively. The multiplicity and volume of
histopathologically diagnosed mammary tumors, in particular poorly differentiated
mammary carcinomas were significantly increased in the glycidol group as com-
pared with the control. In the GO group, the multiplicity and volume of mammary
tumors showed a slight tendency to increase, but no change was noted in the GL
group. These results provide evidence of a mammary tumor promoting activity of
glycidol, but not GEs in the present model.
178 Spontaneous Thymoma Observed in Carcinogenicity Study
of Wistar Han Rats.
C. Maraschiello1,  W. Henderson1,  H. Iwata1, 2,  K. Weber1, 2,  S. Gaehle1 and
T. Anzai1. 1Harlan Laboratories, Inc., Indianapolis, IN; 2AnaPath GmbH,
Oberbuchsiten, Switzerland.
Wistar Han rats are an appropriate model for toxicity and carcinogenicity studies in
rodents and spontaneous thymoma is sometimes recorded in carcinogenicity stud-
ies of this strain of rats. The incidence of thymoma in historical control data of
Harlan Laboratories is as follows: benign thymoma 0.64% for males, 2.39% for fe-
males; malignant thymoma 0.50% for males, 0.63% for females. The incidence of
benign thymoma is higher in females with a range of 0% to 17.02% in these data.
Histologically, these tumors commonly appear as solitary lesions with expansive
growth, consisting of a mixture of thymic epithelial cells and lymphocytes with
medullary differentiation. It was not always clear and requires careful consideration
to distinguish between hyperplastic lesions and benign thymoma, and also between
benign and malignant thymoma for many cases. In this report, we introduce typi-
cal hyperplastic lesions, thymoma and also the rarer epithelial cell type thymoma
observed in Wistar Han rats.
179 Mechanisms of Acetyleugenol Nanocapsules on Melanoma
Development: In Vitro andIn Vivo Assays.
C. C. Drewes1,  C. G. Bexiga1,  L. A. Fiel2,  V. F. de Paula1,  A. R. Pohlmann2, 3,
S. S. Guterres2 and S. P. Farsky1. 1Department of Clinical and Toxicological Analyses,
Universidade de São Paulo, São Paulo, Brazil; 2Department of Pharmacy, UFRGS,
Porto Alegre, Brazil; 3Department of Organic Chemistry, UFRGS, Porto Alegre,
Brazil. Sponsor: S. Barros.
Eugenol displays antiproliferative and pro-apoptotic activities in different types of
cancer cells, although effects of Acetyleugenol (AC) and Acetyleugenol
Nanocapsules (NCAC) have not been elucidated. Here the role of NCAC on in
vivo melanoma model and their actions on in vitro melanoma and endothelial cell
cultures were investigated. Murine melanoma cells (B16F10, 8X105/100μL) were
s.c. injected in the dorsal region of C57BL6 mice. Animals were i.p. or p.o. treated
with Saline, AC, NCAC (50 mg/kg/day) or with their respective controls during 7
days. In vitro human endothelial cells (HUVEC) and melanoma cells (SK-Mel-28)
were incubated with RPMI, DMSO, NC, AC or NCAC. Cell viability, nitric oxide
(NO), clonogenic survival and cell adherence were monitored. Only NCAC
(100μM and 300μM), treatment reduced the endothelial and melanoma cell via-
bility. NC and NCAC (60μM) treatments reduced the clonogenic survival only in
melanoma cells and AC (30 and 60μM) treatment reduced clonogenic survival in
both endothelial and melanoma cells. AC and NCAC (60μM) treatments inhibited
endothelial and melanoma cells adherence. Both NC and NCAC (10, 30 and
60μM), but not AC, treatments increases the NO production by endothelial and
melanoma cells. I.p. injection of NC or NCAC reduced melanoma growth, never-
theless they caused loss of weight, due to lower food intake and reduced the num-
ber of platelets. These in vivo toxic effects may be caused by accumulation of NC or
NCAC in the peritoneum. P.o administration of NC or NCAC reduced melanoma
growth more than AC, and NC, AC or NCAC treatments decreased the number of
circulating leukocytes. Together, data obtained show that i.p route is not feasible to
NC treatments, and the efficiency of NCs on tumor cell growth detected by p.o.
may be due to their higher activity on clonogenic survival and adherence of
melanoma cells.
180 Natural Compounds As Chemopreventive Agents for the
Inhibition of Protein Targets Involved in Cancer Induced by
UV Radiation.
W. Maldonado-Rojas,  M. Ojeda-Cuello and J. Olivero-Verbel. Environmental
and Computational Chemistry Group Pharmaceutical Sciences, University of
Cartagena, Cartagena, Colombia.
Skin cancer is one of the most common worldwide, with an increasing incidence in
recent years. This disease is mainly caused by excessive exposure to solar ultraviolet
(UV) radiation. Currently, there is a high demand for natural chemopreventive
compounds that may work on the biochemical mechanisms involved in the devel-
opment of the disease. In this study, in silico molecular protein-ligand docking was
performed with Autodock Vina to assess the interaction of 44 natural bioactive
compounds with protein kinases (ERK/1TVO, p38/2YIX, and JNK/2ZDT) and
cyclooxygenase-2 (3LN1), widely recognized protein targets in the signaling cas-
cades of skin tumor formation induced by UV radiation. The results showed these
compounds presented theoretical binding affinity scores of similar magnitude to
those recorded for known inhibitors of these proteins. The best binding affinity val-
ues were registered for cyaniding-3-rutinoside docked to ERK and JNK (-10.3±0.1
kcal/mol), and to cyclooxygenase-2 (9.7±0.1 kcal/mol). In the case of p38, the
greatest affinity was found for epigallocatechin-3-gallate (-9.2±0.0 kcal/mol). The
affinities obtained for the inhibitors of 1TVO, 2YIX, 2ZDT and 3LN1 were -
9.4±0.0 (FR-180204), -7.0±0.0 (CE-159167), -7.3±0.0 (C46), and -10.3±0.0
kcal/mol (celecoxib), respectively. These theoretical results are good indicators that
natural bioactive compounds may work as potential chemopreventive agents
against skin cancer induced by UV exposure, probably by a mechanism involving
their direct binding on key protein targets associated with the disease. Vice-Rectory
for Research. UniCartagena. 2011-2012. Colciencias-UniCartagena, Colombia:
Grants 110745921616 (2009) and 110751929058 (2010).
181 Genetic Polymorphism of Human Microsomal Epoxide
Hydrolase As a Determinant of Polyaromatic Hydrocarbon
Metabolism and Toxicity.
X. Cai1,  W. D. Hedrich1,  E. M. Laurenzana1,  B. E. Sell1,  K. John1,
A. K. Sharma2,  S. G. Amin2 and C. J. Omiecinski1. 1Center for Molecular
Toxicology and Carcinogenesis, The Pennsylvania State University, University Park,
PA; 2Department of Pharmacology, Hershey College of Medicine, Hershey, PA.
Microsomal epoxide hydrolase (mEH, EPHX1) is a key catalytic determinant in
the formation of diol-epoxide metabolites of certain polyaromatic hydrocarbons
(PAHs), noted as potent and ultimate mutagenic moieties. Epidemiological associ-
ations between EPHX1 genetic status and the incidence of certain diseases, includ-
ing lung cancer, have been reported, yet the mechanistic bases for these associations
remain unclear. Further, PAH diol-epoxides have never been evaluated as substrates
for human EPXH1. Using enzymatic analyses, we evaluated substrate selectivity of
the most common mEH genetic variants in the hydrolysis of planar vs. the highly
tumorigenic non-planar fjord region PAH epoxides, together with their respective
abilities to metabolize bay region and fjord region PAH diol-epoxide intermediates.
Among the mEH variants, Y113/H139 wild type allele displayed highest capacity
for hydrolysis of the bay region benzo[a]pyrene (BaP)-4,5-epoxide. The
H113/H139 variant exhibited lowest affinity for the bioactivation of the fjord re-
gion dibenzo[a]pyrene-8,9-epoxide (~11-fold higher Km vs. wild type).
Surprisingly, all of the human mEH variant enzymes were capable of hydrolyzing
the bay region BaP-7,8-diol-9,10-epoxide, although displaying differential activity
toward the fjord region dibenzo[a,l]pyrene-11,12-diol-13,14-epoxides. Results
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from Comet assays and in situ DNA damage assays conducted in COS1 cells trans-
fected with the mEH variants and treated with the corresponding epoxides gener-
ally corroborated the enzymatic activity data. Overall, these findings demonstrate
marked substrate selectivity among the mEH variants with respect to PAH epoxide
metabolism and provide mechanistic support for published epidemiology data sug-
gesting that the H113 mEH allele is associated with a reduced risk of lung cancer.
182 Cotinine Levels and Gene Polymorphisms in Asthmatic
Children Exposed to Tobacco Smoke in Northern Mexico.
A. Albores1,  B. S. Barron-Vivanco1, 2,  V. M. Davila-Borja3,  E. Juárez-Pérez4,
A. E. Rojas-García2,  C. López-Campos4,  B. Muñoz5 and I. Poblete-Naredo1.
1Toxicology, Cinvestav, Mexico City, Mexico; 2Laboratorio de Contaminacón y
Toxicologia Ambiental, UAN, Tepic, Mexico; 3Laboratorio de Toxicologia Genetica,
Instituto Nacional de Pediatría, Mexico City, Mexico; 4Departamento de Pediatría,
UMAE 71, IMSS, Torreon, Mexico; 5Escuela de Ciencias de la Vida, ITESM-Ciudad
de Mexico, Mexico City, Mexico.
Tobacco smoke (TS) represents a serious health threat to consumers and passively
exposed individuals. However, passive exposure receives much less attention than
smokers. In addition, more than 700 million children worldwide are passively ex-
posed to TS, meaning an increased risk to develop tobacco related diseases later in
life; among them children with respiratory impairments, like asthmatics, are a par-
ticularly vulnerable group since the lung is the main route of TS entrance. Asthma
is a multifactorial disease and the environment quality is a relevant etiology factor.
We investigated children exposure to tobacco smoke in an asthmatic population
(n=100 individuals; 6.98 ± 0.85 years), and non-asthmatic children (n=100, 7.1 ±
0.82 years) living in Región Lagunera, Northern Mexico. There was a statistically
significant difference in urinary cotinine between the exposed and non-exposed
groups. Urinary cotinine levels showed a small positive correlation between chil-
dren and smoking adults (r= 0.1205 and p= 0.244). Although, cotinine levels were
higher in asthmatic children compared to non-asthmatic, such difference was not
statistically significant. In addition, no association between cotinine levels and
asthma severity was observed in this study. As for the allelic frequencies of GSTT1
null and CYP2A6*2 (1799 T-A) polymorphisms, were significantly different com-
paring TS exposed asthmatic and non-asthmatic children. This study suggests chil-
dren response to passive TS exposure may be affected by asthma and GSTT1 or
CYP2A6 polymorphisms (Supported by the grant SEP-Conacyt (60463) and a
BBV scholarship (Conacyt-6544).
183 Identification of Genomic Regions Linked to
Epigallochatechin Gallate Induced Liver Toxicity Using the
Diversity Outbred Stock.
R. J. Church1,  D. M. Gatti2,  J. Eaddy1,  P. B. Watkins1,  D. Threadgill3 and
A. H. Harrill1. 1The Hamner-UNC Institute for Drug Safety Sciences, The Hamner
Institutes, Research Triangle Park, NC; 2The Jackson Laboratories, Bar Harbor, ME;
3North Carolina State University, Raleigh, NC.
Epigallochatechin gallate (EGCG), an abundant polyphenol in green tea, has
caused idiosyncratic liver toxicity when taken as an herbal supplement. The identi-
fication of genetic risk factors utilizing mouse population-based approaches, and
validated in patient cohorts, could improve clinical management of EGCG-in-
duced liver injury. In order to map genomic loci related to EGCG induced hepato-
toxicity, we utilized the Diversity Outbred (DO) stock. DO mice are derived from
eight inbred founder strains and have high genetic diversity, enabling high resolu-
tion mapping in this population. We hypothesized that Quantitative Trait Locus
(QTL) mapping in DO mice exposed to EGCG would allow us to identify candi-
date genomic regions influencing the hepatotoxicity of EGCG. Male DO mice
were treated once daily, for 3 days, with EGCG (50 mg/kg i.g.) or vehicle. Twenty
four hours after the final dose, animals were sacrificed and serum and liver tissue
were collected. Similar to humans, EGCG treatment in DO mice precipitates wide
variation in hepatotoxic response. In treated animals, serum alanine aminotrans-
ferase (ALT) fold changes (terminal compared to pre-dose) ranged from 0.46-495.5
(mean: 24.8 ± 65.4) and percent liver necrosis ranged from 0-86.8% (mean: 6.3 ±
14.1). QTL mapping in treated animals identified two suggestive loci– one on
chromosome 12 and one on chromosome X. In a follow-up study, we will genotype
suspected risk alleles in DNA collected by the Drug Induced Livery Injury Network
(DILIN) from patients with suspected EGCG-induced liver toxicity. We have
demonstrated the first application of the DO mice to the detection of xenobiotic
risk alleles of toxicity responses. While further validation is needed, our data suggest
that QTL mapping in DO mice may aid in identification of pharmacogenetic risk
alleles for compounds causing liver injury.
184 Pharmaco-Genomics and -Genetics of 5-Fluorouracil in
Koreans.
M. Yang and M. Bae. Sookmyung Women’s University, Seoul, Republic of Korea.
Genetic polymorphisms of several enzymes such as dehydropyrimidine degydroge-
nase (DPYD), methyltetrahydrofolate reductase (MTHFR) and thymidylate syn-
thase (TS) have been emphasized for pharmaco-genomics and -genetics of 5-FU,
which has been used for half century as a representative therapy for various cancers,
however, shown individual variations in its various toxicities including life-threat-
ening toxicity. Focusing on the three genes, we performed a pharmaco-genomic and
-genetic study of 5-FU in a Korean population. Most of genotypes and gene ex-
pression were analyzed with 7500 Realtime PCR System (ABI).  As results, we
found genetic polymorphisms in DPYD-85, -1627, and -1896 sites, 5’-ER, and 3’-
UTR at TS, and MTHFR-222, and -429 sites among the Korean subjects (N=133;
normal, N=105; head and neck patients, N=28). There was a significant association
between 3’-UTR genetic polymorphism at TS and its genetic expression (p<0.05).
From 5-FU pharmacokinetic (PK) analyses, each genotype did not show any effect
on PK parameters. However, the combination of genetic polymorphisms in
MTHFR -222T/C, DPYD- 1896T/C and 3’-UTR at TS showed significant differ-
ences in AUC of 5-FU and 5-FU/5-FUH2 ratios (p<0.01). Therefore, this study
provides association between TS expression and its 3’-UTR polymorphism.
Moreover, combination of the three genetic polymorphisms of the three genes can
affect PK of 5-FU in Koreans.
185 PON1 Genotypes of Black Females from the Mississippi
Delta Are Different from Those in the Rest of the State and
Country.
M. Dail,  P. Eden,  C. McDaniel,  E. C. Meek and J. E. Chambers. Center for
Environmental Health Sciences, Mississippi State University, Mississippi State, MS.
Paraoxonase (PON1) is named for its ability to hydrolyze paraoxon, the active
metabolite of the insecticide parathion. It is implicated in cardiovascular and meta-
bolic diseases, such as Type 2 diabetes as well as tolerance of organophosphate in-
secticides. The human PON1 gene has several single nucleotide polymorphisms
(SNPs). The SNP of an arginine (R) to glutamine (Q) substitution at codon 192 is
associated with catalytic efficiency while the SNP of a methionine (M) to leucine
(L) substitution at codon 55 is linked with serum levels. Since the Mississippi Delta
has the highest rate of metabolic disease in the country, and a historically high use
of pesticides, we compared the PON1 genotypes of black female Mississippi Delta
clinic patients to those of black females from northeastern Mississippi and military
populations. Genomic DNA was isolated from whole blood and the SNP codon
areas were amplified by PCR. Since there is a native Alw I restriction site at codon
192, the QQ, RR, and QR SNPs yield different digest patterns. A native NlaIII re-
striction site at codon 55 generates different digest patterns for the LL, MM, and
LM allozymes. Genotypic frequencies were different for the Q192R SNP. QR was
most frequent in the military (45%) and northeastern Mississippians (50%), but
RR was most frequent in the Delta group (54%). Similarly, the most common
combination of polymorphisms was QRLL in the military (24%) and northeastern
Mississippi groups (36%), but in the Delta group it was RRLL (48%). Using
Fisher’s exact test to analyze genotypic frequencies, the largest differences were be-
tween the Delta and military groups with Q192R P=0.0024 and L55M
P=0.000176. When all three groups were compared, Q192R ratios were signifi-
cantly different at P=0.00007 and L55M ratios at P= 0.00001. The significant dif-
ferences seen in the Delta population may be associated with the region’s health dis-
parities.
186 In Vitro Toxicogenomic Screen Developed Using Genetically-
Diverse Mouse Inbred Cell Lines: Developing In Vivo
Validations.
T. Wiltshire1,  O. Suzuki1,  B. B. Parks2,  O. Trask2,  C. Benton1,  A. Frick1,
N. Butz1,  E. Chan1,  E. Healy2 and R. S. Thomas1. 1Eshelman School of Pharmacy,
University of North Carolina at Chapel Hill, Chapel Hill, NC; 2The Hamner
Institute for Health Sciences, Durham, NC.
Cell-based assays provide unprecedented means to globally and systematically
screen for drugs and chemicals likely to display high inter subject toxicity variabil-
ity. Genetic determinants of toxicity identified in these screens can guide clinical
trial design or identify susceptible subpopulations. Here, we developed an innova-
tive in vitro genetic screen using mouse embryonic fibroblast (MEFs) cells isolated
from 32 inbred strains and screened them against 69 different drugs and chemicals.
Using high-content imaging, we measured multiplexed cell health parameters, in-
cluding cell loss, mitochondrial membrane potential, and cytochrome c release at
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24 and 72 hours post treatment. We looked for genetic loci significantly linked to
inter-strain cellular responses to treatment and found a 1.2 Mb locus on Chr X that
was significantly linked to variable cytotoxic responses to a known mitochondrial
toxicant, rotenone (-logP >4.0). Within this putative locus is cytochrome b-245,
beta polypeptide (Cybb) gene, which encodes for a voltage-gated H(+) channel that
mediates pH in the mitochondria. We conducted a series of experiments to exam-
ine the role of Cybb in mediating toxic responses to rotenone in vivo, given that
mitochondrial dysfunction has been shown to underlie idiosyncratic adverse drug
reactions. We found that strains belonging to different Cybb haplotypes scored dif-
ferently in the treadmill exercise stress test for aerobic endurance after chronic treat-
ment with rotenone. Our study demonstrates that cell-based genetic assays using
MEFs are an effective tool for identifying genes underlying drug and chemical tox-
icity. Importantly, mouse strains that exhibit differential in vitro sensitivity, from a
cell-based screen, also display a differential in vivo phenotype. This in vitro-to-in
vivo validation is difficult, but a fundamental step toward recognition of cell-based
toxicity screens.
187 P-Glycoprotein Transport in the Disposition of
Neurotoxicants.
S. Lacher,  K. Skagen,  R. Dalton,  F. Cardozo-Pelaez and E. Woodahl.
CEHS/BMED, The University of Montana, Missoula, MT.
Background: P-glycoprotein (P-gp), encoded by the ABCB1 (or MDR1) gene, is an
efflux xenobiotic transporter expressed in many tissues important in xenobiotic dis-
position. P-gp is highly expressed at the blood-brain-barrier and protects the brain
from substances circulating in the blood. Although the importance of P-gp in drug
disposition is clear, its role in disposition of environmental neurotoxicants is not
well understood. Our goal is to investigate the role of P-glycoprotein in neurotoxi-
cant accumulation in the brain, particularly pesticides that have been associated
with Parkinson’s disease such as rotenone, maneb, paraquat, and MPP+. Methods:
We used polarized kidney epithelial control cells, LLC-PK1, and ABCB1-trans-
fected cells, LLC-MDR1, to characterize pesticides as substrates or inhibitors of P-
gp using flow cytometry, cytotoxicity, and transepithelial permeability assays. P-gp-
stimulated ATPase activity was also measured to evaluate compounds as P-gp
substrates in a membrane-based system. Results: We observed weak inhibition of
rhodamine-123 (R123) efflux in ABCB1-expressing cells by flow cytometry in the
presence of 100 μM rotenone or maneb, 16.2 ± 1.53 and 11.6 ± 4.53%, respec-
tively. Paraquat and MPP+ showed no R123 inhibition. ATPase assays showed that
rotenone is a P-gp substrate with a Km = 26.7 ± 12.9 μM and Vmax = 35.8 ± 6.5
nmol Pi/mg protein/min. This compares to the known P-gp substrate verapamil
with kinetic constants of Km = 8.22 ± 3.79 μM and Vmax = 42.9 ± 5.5 nmol
Pi/mg protein/min. Paraquat, maneb, and MPP+ showed no ATPase stimulation.
Conclusions: In combination these data suggest that rotenone acts both as a sub-
strate and a weak inhibitor of P-gp, whereas maneb acts only as a weak inhibitor.
MPP+ and paraquat are neither substrates nor inhibitors of P-gp. We will further
confirm these results using cytotoxicity and transepithelial permeability studies.
Our studies will provide data to show the role of P-gp in the disposition of pesti-
cides associated with Parkinson’s disease.
188 Polymorphic Enzymes, Urinary Bladder Cancer Risk, and
Structural Change in the Local Industry.
K. Golka1,  D. Ovsiannikov2,  S. Selinski1,  M. Lehmann1,  M. Blaszkewicz1,
O. Moormann2,  M. W. Haenel3 and J. G. Hengstler1. 1Leibniz Research Centre for
Working Environment and Human Factors, Dortmund, Germany; 2Department of
Urology, St.-Josefs-Hospital Dortmund-Hörde, Dortmund, Germany; 3Max-Planck-
Institut für Kohlenforschung, Mülheim an der Ruhr, Germany.
In the 1990s, the highest percentage of glutathione S-transferase M1 (GSTM1)
negative urinary bladder cancer cases (70%) ever reported was observed in the
greater Dortmund area. The question arose whether this uncommonly high per-
centage of GSTM1 negative urinary bladder cancer cases was due to environmental
and/or occupational exposure decades ago. Thus, 15 years later, another study on
urinary bladder cancer was performed in the same area after the coal, iron and steel
industries had finally closed in the 1990s. In total 196 bladder cancer patients from
a local department of urology and 235 controls with benign urological diseases were
investigated by a questionnaire and genotyped for GSTM1, GSTT1 and the N-
acetyltransferase 2 (NAT2) tag SNP rs1495741. The frequency of the GSTM1 neg-
ative genotype was 52% in bladder cancer cases and in the controls as well and thus
much lower, compared to a previous study performed from 1992-95 in the same
area (70%). NAT2 genotypes were distributed equally among cases and controls
(63% slow acetylators). Less GSTT1 negative genotypes were present in cases
(17%) than in controls (20%). The normal frequency of the GSTM1 negative
genotype in bladder cancer cases in the present study supports the assumption that
the highly increased percentage of GSTM1 negative bladder cancer patients ob-
served in the preceding study may be related to past occupational and environmen-
tal exposures decades ago.
189 CTNNA3 (α-Catenin) Gene Variants Are Associated with
Diisocyanate Asthma in Occupationally-Exposed Workers.
B. Yucesoy1,  M. L. Kashon1,  Z. L. Lummus2,  V. J. Johnson3,  K. L. Fluharty1,
D. Gautrin4,  J. Malo4,  A. Cartier4,  D. R. Germolec5,  M. I. Luster1 and
D. I. Bernstein2. 1Health Effects Laboratory Division, CDC/NIOSH, Morgantown,
WV; 2Division of Immunology, Allergy and Rheumatology, University of Cincinnati,
Cincinnati, OH; 3BRT-Burleson Research Technologies, Morrisville, NC; 4Hôpital du
Sacré-Coeur de Montréal, Université de Montréal, Montréal, QC, Canada;
5Toxicology Branch, DNTP/NIEHS, Research Triangle Park, NC.
A genome-wide association study conducted recently in Korean subjects identified
three CTNNA3 (alpha-T catenin) single nucleotide polymorphisms (SNPs)
(rs10762058, rs7088181, and rs4378283) associated with diisocyanate induced oc-
cupational asthma (DA). We conducted a candidate gene association study to repli-
cate these findings in Caucasian workers. Genotyping was performed on genomic
DNA, using a 5’ nuclease PCR assay. Genotyping of these SNPs was performed in
410 diisocyanate-exposed and predominantly Canadian workers including: 132
workers with DA confirmed by a specific inhalation challenge (DA+); 131 sympto-
matic workers in whom DA was excluded by a negative challenge (DA-); and 147
HDI-exposed asymptomatic workers (AWs). CTNNA3 rs7088181 and
rs10762058 SNPs were significantly associated with DA+ when compared to AWs
(p≤0.05) but not in comparison to DA- workers. After adjusting for potentially
confounding variables of age, smoking status and duration of exposure, minor allele
homozygotes of rs7088181 and rs10762058 SNPs were at increased risk for DA
compared with AWs [OR= 9.05 (95% CI:1.69, 48.54) and OR = 6.82 (95%
CI:1.65, 28.24), respectively]. In conclusion, we replicated association between two
closely linked CTNNA3 gene SNPs and DA in Caucasian workers. These findings
suggest that genetically altered expression of CTNNA3 might influence cellular ad-
herence and epithelial barrier function in the airways and play a role in the patho-
genesis of DA.
This work was supported in part by an NIEHS IAG (Y1-ES-0001) and
NIOSH/CDC R01 OH 008795.
190 Prevalence and Functional Characterization of the NADH
Cytochrome b5 Reductase I1M
+6C>T Intronic Variant.
K. L. Blanke1, 2,  J. Sacco1 and L. Trepanier1, 2. 1Department of Medical Sciences,
School of Veterinary Medicine, University of Wisconsin - Madison, Madison, WI;
2Molecular & Environmental Toxicology Center, University of Wisconsin - Madison,
Madison, WI.
Women exposed to cigarette smoke may have an increased risk of breast cancer, al-
though this is controversial. In addition, African American, but not Caucasian,
women showed an association with smoking and breast cancer in the Carolina
Breast Cancer Study (CBCS) population. We hypothesized that this could be due
to race-associated genetic variability in the pathways that detoxify tobacco carcino-
gens such as 4-aminobiphenyl (4-ABP) and 2-amino-1-methyl-6-phenylimidazo
[4,5-b] pyridine (PhIP). Both are mammary procarcinogens that are bioactivated to
hydroxylamine metabolites, which form DNA adducts and are thought to initiate
cancer. Cytochrome b5 (CYB5A) and NADH cytochrome b5 reductase (CYB5R3)
comprise a detoxification pathway that reduces 4-ABP and PhIP hydroxylamine
metabolites back to their parent compounds. The purpose of this study was to de-
termine whether CYB5A and CYB5R3 polymorphisms were over-represented in
African American women in the CBCS, and to evaluate their role in the association
with smoking and breast cancer risk. Several CYB5A and CYB5R3 single nucleotide
polymorphisms (SNPs) were more prevalent in African Americans than in non-
African Americans in the CBCS population. One intronic SNP in CYB5R3,
I1M+6C>T, previously found in tissue samples with low b5 reductase protein ex-
pression, was found with a minor allele frequency that was 100-fold higher in
African American subjects (MAF = 0.0428, P < 0.0001). Among smokers, this vari-
ant was significantly over-represented in African American women with breast can-
cer compared to same-race controls (OR 2.10, 95% CI, 1.08-4.06). The
I1M+6C>T CYB5R3 variant is being functionally characterized for promoter and
repressor function using a dual-luciferase reporter assay. These studies suggest that
the I1M+6C>T intronic variant in CYB5R3 may increase the risk of breast cancer
among African American women that smoke.
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191 Influence of Genetics on Paraoxonase 1 Activity in
Monozygotic and Dizygotic Twins.
L. Podolefsky1,  K. M. Kelly2,  J. C. Murray3,  T. J. Raife4 and G. Ludewig1, 2.
1Grad Program in Human Toxicology, University of Iowa, Iowa City, IA;
2Occupational and Environmental Health, University of Iowa, Iowa City, IA;
3Pediatrics, University of Iowa, Iowa City, IA; 4Pathology, University of Iowa, Iowa
City, IA.
Paraoxonase 1 (PON1) is an important HDL-associated endogenous antioxidant
found to play a major role in susceptibility to health effects from pesticides and ox-
idative stress. A number of gene polymorphisms influence both protein concentra-
tion and substrate specificity, as do certain lifestyle factors. However, reports about
the influence of PON1 genetics have varied widely in the literature. The goal of this
study was to examine the influence of genes and health data in a group of monozy-
gotic and dizygotic twins to better understand the effect of genetics on PON1 ac-
tivity levels. DNA, serum, and standard blood donation information was obtained
from 6 sets of dizygotic twins and 13 sets of monozygotic twins. DNA was geno-
typed for polymorphisms within PON1, PON2, C-reactive protein (CRP), and
tumor necrosis factor (TNF). PON1 activity was determined using phenyl acetate
(PA) and CMPA [4-(Chloromethyl)phenyl acetate] as substrates, and genotyping
was performed using the TaqMan-Applied Biosystems 7900 HT System. Using a
general linear model, PON1 Q192R, L55M and C-108T were significantly associ-
ated with both PA and CMPA activity, with CMPA activity showing a stronger as-
sociation with genetic variants. PON2 S311C was significantly associated with PA
activity, but not CMPA. Activity for either substrate was not found to be associated
with CRP or TNF polymorphisms. BMI was found to significantly correlate with
CMPA activity, but not PA activity (correlation = -.34), while gender did not corre-
late with either substrate. Pair-wise analysis of all twins with identical PON geno-
types showed no difference in PON activity variance between siblings, regardless of
zygosity. Though other shared or variant genetic and lifestyle factors may influence
PON1 activity, the findings in this twin population suggest a strong link between
PON activity and specific PON polymorphisms.
192 Contribution of Environmental and Genetic Factors to
Pancreatic Cancer.
S. Chittiboyina,  A. A. Bond,  L. M. Kamendulis and B. A. Hocevar.
Environmental Health, Indiana University School of Public Health, Bloomington, IN.
Pancreatic cancer is the fourth leading cause of cancer deaths in the United States
with a five year survival rate of less than 6%. Several environmental risk factors have
been identified for pancreatic cancer, including dietary factors. In particular, high
dietary intake of folate has been associated with a decreased incidence of pancreatic
cancer, while low plasma folate levels are associated with an increased cancer risk. In
conjunction with diet and lifestyle determinants, an individual’s folate pathway sta-
tus is determined by their genetic makeup. In the present study, we determined the
expression of selected SNPs in the folate metabolic pathway in a cohort of pancre-
atic cancer patients and healthy related and unrelated control groups. In agreement
with other cancer studies, we show that cancer cases were more likely to express the
TT allele of the methylene tetrahydrofolate reductase (MTHFR) C677T polymor-
phism compared to controls. Expression of this allele has been associated with low
folate levels and elevated homocysteine (Hcy) levels. In support of this, we found
that pancreatic cancer patients display elevated serum Hcy levels in comparison to
both control groups. In addition, 48% of the pancreatic cancer patients exhibited
hyperhomocysteinemia, as defined by a value >15 μM/L, (range 11.15 - 26.17
μM/L), while no subjects in either control group exhibited hyperhomocysteinemia.
In addition, we found that SNPs in betaine hydroxymethyltransferase (BHMT; rs
3733890) and serine hydroxymethyl transferase (SHMT; rs 1979277) exhibited
significantly different distributions between the case and control groups (p < 0.05).
While a clear association was not seen between cancer risk and alcohol or smoking
use in our population, self reported environmental exposure data suggested an asso-
ciation between pancreatic cancer and exposure to welding fumes. These findings
underlie the necessity to investigate further the interaction between environmental
exposures and genetic factors which could provide further insight into the etiology
of pancreatic cancer.
193 The Impact of CYP2S1 Single Nucleotide Polymorphisms on
the Metabolic Activation of the Anticancer Prodrug, AQ4N.
N. Bajaj,  N. M. Singh and A. M. Rowland. Chemistry and Biochemistry, NMSU,
Las Cruces, NM.
Cytochrome P450 2S1 (CYP2S1) is one of the most recent additions to the P450
superfamily of enzymes. Although its physiological role has not yet been defined, it
has been shown to influence metabolism of bioactive lipids, including
prostaglandins and retinoids. CYP2S1 is predominantly expressed in extra-hepatic
epithelial cells. Its expression is elevated in cancer and catalyzes the metabolic acti-
vation of the anticancer prodrug, AQ4N, under hypoxic conditions. Interestingly
our lab has also demonstrated that increased CYP2S1 expression may protect
against AQ4 cytotoxicity under normoxic (21% O2) conditions. The main objec-
tive of this study is to determine whether individual variability in the CYP2S1 en-
zyme alters sensitivity of human lung cells to AQ4N and AQ4-mediated cytotoxic-
ity. Five published CYP2S1 allelic variants have been published: CYP2S1*2
(R380C), CYP2S1*3 (P466L), CYP2S1*4 (S61N), CYP2S1*5 (L230R).
According to the NCBI database, two additional non-synonymous variants have
been identified in cancer (A205T and L189F) and L189F is restricted to African
American populations. We generate each of the polymorphisms in a CYP2S1-Flag
mammalian expression vector, using site directed mutagenesis. Thus far, two stable
lines (S61N and L189F) in bronchial epithelial cells (BEAS-2B) and four stable
(S61N, R166H, A205T, and P466L) alveolar carcinoma cell lines (A549) have
been made. Examination of AQ4N and AQ4 cytotoxicity in BEAS-2B cells re-
vealed that both mutants (S61N and L189F) exhibit significantly increased cyto-
toxicity in response to AQ4N compared with wild type CYP2S1-Flag and
pcDNA3.1 controls. Interestingly, the S61N polymorphism was significantly more
sensitive to AQ4 than any of the other cell lines. This effect appears to be selective
because cytotoxicity is not altered in response to a similar topoisomerase II in-
hibitor, mitoxantrone. We are currently testing the effects of these polymorphisms
on AQ4N and AQ4 levels, using HPLC. Research funded by NIH NIGMS Grant
# R25GM061222.
194 The Remarkable Genotoxic Effect of Exposure to Ethyl
Tertiary Butyl Ether in ALDH2 Knockout Mice.
R. Wang,  Z. Weng,  K. Ohtani,  M. Suda,  Y. Yanagiba and T. Suzuki. Japan
National Institute of Occupational Safety and Health, Kawasaki, Japan.
Ethyl Tertiary Butyl Ether (ETBE) is used in gasoline for vehicles as a biofuel.
ETBE exposure induced liver damage and other health effects only at high concen-
trations in our previous studies, and its No Observed Adverse Effect Level
(NOAEL) was calculated to be 500 ppm. However, in mice without ALDH2 en-
zyme activity, ETBE could induce DNA damage even at the NOAEL. To find out
how low concentration at which ETBE shows its genotoxic effect, we did the expo-
sure experiment with mice at low range of ETBE concentrations. METHODS:
Male Aldh2-/- (KO), Aldh2+/- (HT) as well as C57BL/6 strain (WT), at 8 weeks
old were exposed to ETBE at 0, 50, 200 and 500 ppm, 6 hr/day and 5 days/week,
for 9 weeks. Blood, liver, epididymides were sampled 20 hr after the last exposure,
and DNA damages were analyzed with comet assay in these tissues. RESULTS: The
tail intensity (TI) was used to evaluate the degree of DNA damage. In the leuko-
cytes of WT mice, the TI value was not affected in any exposure group as compared
to the control. However, the TI was significantly increased in 200 and 500 ppm
groups of KO mice. Similar results were also obtained in HT mice, but there was
no difference between the two types of mice. In liver cells and sperm, ETBE also in-
duced DNA damage, but this effect was only observed in KO and HT mice as in
the leukocytes. The NOAEL was 50 ppm in these types of mice. These results sug-
gest that ALDH2 deficiency may increase the susceptibility to the health effect of
ETBE exposure. We thank Ms. S. Watanabe for her assistance in the manipulation
of the animals.
195 MGMT Haplotypes Alter MGMT Expression and Can Thus
Affect Response to Alkylating Agents.
M. Xu,  I. Nekhayeva,  C. E. Cross,  C. M. Rondelli and S. Z. Abdel-Rahman.
OB/Gyn, UTMB, Galveston, TX.
Glioblastoma (GB) is rapidly fatal. However, treatment with temozolomide (TMZ)
and radiation is beneficial, but only for some patients. TMZ alkylates tumor DNA
to form O6-alkylguanine (O6-AG) DNA adducts, inducing apoptosis. Because
O6-AG is repaired by O6-methylguanine-DNA methyltransferase (MGMT), levels
of MGMT are critical in determining tumor response to TMZ. Single nucleotide
polymorphisms (SNPs) in the promoter/enhancer (P/E) region of the MGMT gene
can alter its transcription and thus alter MGMT protein levels. Genetic variants are
not arrayed as individual SNPs but as combinations forming specific “haplotypes”.
To date, no studies have determined the haplotypes structure of the P/E region of
MGMT or their effect on its transcription. We sequenced 104 DNA samples from
healthy individuals and identified 8 SNPS in this region (7/Y, 135/K, 290 /R,
485/M, 575/M, 666/R, 777/M and 1099/Y). Using bioinformatics, we inferred
the haplotypes encompassing these SNPs. We identified 21 potential haplotypes
ranging in frequency from 0.39 to 0.00005, of which 10 were identified in our
sample population as 20 paired haplotype combinations. We hypothesized that
these haplotypes alter the regulation of MGMT transcription. Luciferase-reporter
constructs containing different MGMT haplotypes were transfected into a GB cell
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line and the effects of the haplotypes on MGMT transcription were determined
using a Dual-Luciferase Reporter Assay. Compared with the most common (refer-
ence) haplotype, haplotypes 7 and 18 induced a significant 60% and 65% reduc-
tion in expression, respectively (P<0.001). However, haplotype 11 significantly in-
creased expression by 70% (P<0.001). These data indicate that MGMT haplotypes
regulate MGMT transcription and thus could play a major role in tumor response
to TMZ treatment. Work is in progress to define the underlying mechanisms and
to develop sensitive and specific markers that can distinguish those patients who
would most be likely responsive to chemotherapy from those who would not (sup-
ported by P30 ES006676; T32-07454; 1 R03 NS065392-01 grants).
196 Associations between Genetic Polymorphisms of the Genes
Mediating Inflammatory Response and Acute Pancreatitis
Risk.
B. Alpertunga and G. Ozhan. Pharmaceutical Toxicology, Istanbul University,
Faculty of Pharmacy, Istanbul, Turkey.
Acute pancreatitis is a common inflammatory disease. The reported incidence is ap-
proximately 30 to 40 per 100.000 population per year and 25% will develop severe
or life-threatening complications. Inflammation is typified by the activation of im-
munocytes such as monocytes and macrophages, and the secretion of inflammatory
mediators such as nitric oxide, prostaglandin E2, and tumour necrosis factor-α
(TNF-α). Nitric oxide is especially controlled by the inducible nitric oxide syn-
thases (iNOS). Prostaglandin E2 is produced from arachidonic acid metabolites by
the catalysis of cyclooxygenase-2 (COX-2). TNF-α, thought to be the first cytokine
released, is a principal mediator of immune responses. Genetic factors may play im-
portant roles in susceptibility to pancreatic injury, as well as in the severity and evo-
lution of the inflammatory process. The aim of our study was to determine if poly-
morphisms in iNOS, COX-2, TNF-α genes were associated with acute
pancreatitis. For that, three iNOS (Ser608Leu, 1173C/T, 954G/C), seven COX-2
(rs5275, rs2206593, rs4648262, rs4648261, rs2066826, rs5277, rs2745557) and
two TNF-α (308G/A, 238 G/A) variants were determined using polymerase chain
reaction-restriction fragment length polymorphism analysis in patients with acute
pancreatitis and healthy controls. Odds ratios (ORs) and 95% confidence intervals
(CI) were estimated. In conclusion; the association was seen with COX-2 rs5275
(P=0.03); specifically, patients carrying the TT genotype in comparison to patients
carrying the CC genotype had a significantly lower risk of disease (OR=1.88;
95%CI:1.06-3.34). Both SNPs of TNF-α were not genetic risk factor for acute
pancreatitis susceptibility. It was also found that iNOS Ser608Leu polymorphism
was more frequent among cases with acute pancreatitis compared to controls
(OR=2.88; 95%CI:1.49-5.57; P=0.002). We believe that the findings may be ben-
eficial to the development of efficacious preventive strategies and therapies for in-
flammation-associated diseases.
197 In Vitro Toxicity of Antibacterial Silver Ions Released by Low
Intensity Direct Electric Current (LIDC) Stimulation.
R. A. Shirwaiker1, 2,  M. E. Samberg2,  Z. Tan1 and N. A. Monteiro-Riviere2, 3. 1E.
P. Fitts Department of Industrial and Systems Engineering, North Carolina State
University, Raleigh, NC; 2Joint Department of Biomedical Engineering, University of
North Carolina at Chapel Hill and North Carolina State University, North Carolina
State University, Raleigh, NC; 3Nanotechnology Innovation Center of Kansas State,
Kansas State University, Manhattan, KS.
Medical devices related surgical site infections and their treatment are a major cause
of concern in the global healthcare system. The problem is compounded by the
presence of antibiotic-resistant bacteria such as methicillin-resistant Staphylococcus
aureus (MRSA) in healthcare environments, because infections caused by these bac-
teria are difficult to treat with conventional antibiotics. To prevent transmission of
such infections, a prophylactic surface system that provides protracted release of an-
tibacterial silver ions from interdigitated silver electrodes using low intensity direct
electric current (LIDC) stimulation was developed and successfully validated
against four pathogenic bacterial strains including S. aureus, Escherichia coli,
Enterococcus faecalis and Pseudomonas aeruginosa. The objective of this study was to
evaluate the toxicity of the LIDC system to human epidermal keratinocytes (HEK)
and human dermal fibroblasts (HDF) with alamarBlue, using parameters proven to
be antibacterial (28μA at 6V). It was found that 1.5h exposure to the silver ion-re-
leasing surface system was not toxic to HEK or HDF, which suggests that the ap-
plications of the antibacterial system for surfaces that come into contact with skin
epithelial cells or connective tissue for less than 1.5h are not expected to cause tox-
icity in vivo. The application of this technology is particularly relevant for high con-
tact surface areas in medical devices such as stethoscopes, scalpel handles, endo-
scopes, and forceps that are prone to microbial contamination. In conclusion, the
lack of toxicity in vitro provides support for future in vivo or clinical studies.
(Supported by ArgentumCidalElectrics, Inc.)
198 Safety Assessment of Colorants Used in a Short Term Blood
Contacting Medical Device—Challenges in Color Extraction
Testing.
F. K. Hsia1,  H. J. Beckord1,  M. P. Beauchane1,  C. J. Anderson2,  D. R. Kent3
and E. E. Reverdy1. 1Corporate Toxicology and Biocompatibility Services, Boston
Scientific Corporation, Maple Grove, MN; 2Materials, Testing, Analysis, and
Characterization, Boston Scientific Corporation, Maple Grove, MN; 3Product Safety
and Validation, NAMSA, Northwood, OH.
Use of colorants in medical devices continues to be scrutinized by the FDA. In re-
sponse to the FDA questions on a recent PMA submission and to be compliant
with ISO 10993 Biological Evaluation of Medical Devices - Part 1: Evaluation and
Testing within a Risk Management Process, Boston Scientific completed extraction
studies on colorants as part of the safety assessment. The challenges and successes in
demonstrating the safety of the colorants used in a short-term blood-contacting
catheter are presented here. A color elution study was conducted to demonstrate
the potential bioavailability of four colorants. Devices were extracted at 37οC for 24
hours in acetone. These aggressive extraction conditions maximized the potential to
extract colorant and were not intended to represent clinical use. Non-volatile
residue (NVR) portions of the extracts were microwave digested and then analyzed
using ICP-OES against control colorant samples of known concentration. The esti-
mated maximum amounts of extracted colorant ranged from <LOQ - 2.4 mg/de-
vice. These values together with the NVR value (0.1 mg/device) from the USP
Physicochemical test were used as “worst case” estimates in the safety assessment.
Variable process spike recovery results and device degradation during extraction
contributed to uncertainty in the reported results. The safety assessment was con-
ducted following ISO 10993-17: Establishment of Allowable Limits for Leachable
Substances. The existing toxicological and biological safety data were included in the
risk assessment. The threshold of toxicological concern (TTC) approach was ap-
plied for colorants with insufficient toxicological data. We concluded that the col-
orants used in this short-term catheter are eluted from the device at toxicologically
insignificant amounts when extrapolated to the clinical exposure.
199 Comparison of Results from 2 In Vitro Cytotoxicity Tests
Used in the Evaluation of Medical Devices.
D. E. Malek1 and R. T. Przygoda2. 1Malek Toxicology Delaware LLC, Greenville,
DE; 2Life Cycle Materials, Johnson & Johnson, Cincinnati, OH.
ISO 10993-1 includes an in vitro cytotoxicity test as part of a biological evaluation
of medical devices.  Two cytotoxicity tests commonly used in this evaluation are the
MEM elution (ME) and Colony Formation (CF).  The results from 43 samples
used in medical devices were analyzed to evaluate the utility of both tests. Twenty-
eight test samples also were evaluated for in vivo irritation, sensitization and sys-
temic toxicity. The ME test was performed according to ISO 10993-5, section 8.2
including serial dilution of the extract, and CF test was performed according to
ISO 10993-5, Annex B. The in vivo tests were performed according to the appro-
priate ISO 10993 standard. The ME and CF test results from 36 test samples
showed agreement (84% agreement). Seven test samples were non – toxic in ME
but toxic in the CF test (16% disagreement).  Toxicity was not observed in any of
the in vivo tests on the 12 samples that were toxic in either the ME, CF, or both cy-
totoxicity tests. When compared to the results of the 28 sets of in vivo tests, the ME
test was 71 % in agreement and the CF test was 46% in agreement. Cytotoxicity
was not observed in ME or CF tests for the 3 samples that failed for irritation.  The
results from this comparison demonstrate that in vitro cytotoxicity is not predictive
of in vivo irritation, sensitization or systemic toxicity; and the lack of cytotoxicity
does not guarantee acceptable in vivo test results. The ME test with serial dilutions
is more in agreement with results from in vivo tests, and when toxicity is observed
provides comparable results to CF test.
200 Evaluation of Sample Preparation Methods in the ISO
10993-12 Standard: Implications for the Biocompatibility
Assessment of Medical Devices.
R. P. Brown,  H. Dinesdurage,  J. Goode and M. Ghosh. US FDA, Silver Spring,
MD.
The ISO 10993-12 standard outlines suitable extraction conditions for the prepa-
ration of test samples for the biological evaluation of medical devices. The standard
provides a list of temperature, time, and solvent conditions recommended for the
preparation of extracts for toxicity testing, but no guidance is offered on which spe-
cific extraction conditions are optimal for various types of materials. The goal of
this study is to identify extraction conditions that can be used to differentiate toxic
from nontoxic polymeric materials in an indirect hemolysis assay without resulting
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in the degradation of the material. A “toxic” material is defined in this study as one
that produces a positive response in a modified MEM Elution cytotoxicity test. A
wide range of polymeric materials (e.g., BUNA, nitrile, butyl, neoprene, latex, sili-
cone rubbers; polyurethane, polyethylene, PVC) was extracted in a closed glass vial
in phosphate buffered saline (PBS) using the default conditions outlined in the ISO
10993-12 standard (37oC x 24 hrs, 37oC x 72 hr, 50oC x 72 hr, 70oC x 24 hr,
121oC x 1 hr). In addition, the polymers were extracted in 5% or 50% ethanol
(EtOH) or acetone at 37oC for 24 hours. The 50% EtOH extracts were diluted to
5% with PBS for the hemolysis assay. The acetone extracts were evaporated under a
nitrogen stream, then reconstituted with PBS. Our results show that rigorous ex-
traction conditions (acetone, 50% EtOH) are necessary to correctly differentiate
toxic from nontoxic materials. For example, latex and BUNA were positive in the
cytotoxicity assay, positive when 50% EtOH extracts were used in the hemolysis
assay, but negative when extracted in PBS using the standard extraction conditions
in the ISO 10993-12 standard (e.g., 50oC x 72 hrs).  Since the use of acetone as an
extraction vehicle resulted in the degradation of some materials, such as PVC, the
use of EtOH:PBS solvent mixture represents a promising approach for preparing
samples for the biological evaluation of medical device materials.
201 Can There Be a Universal Extraction Solvent for Medical
Device Biocompatibility Testing? Comparison of Extraction
Efficiencies among Five Solvents Used to Extract Polymeric
Dental Devices.
L. H. Moilanen1,  J. K. Dahms2,  B. D. Bagley1 and E. F. Hope1. 1Medical
Department, 3M, St. Paul, MN; 23M ESPE, 3M, St. Paul, MN.
The biocompatibility of medical devices is often evaluated using extracts prepared
from the final product. The selection of the most appropriate extraction solvent(s)
for product chemical characterization and biocompatibility assessment remains a
subject of active discussion within the medical device standards community. For
this study, we examined extraction data obtained for nine experimental dental
product prototypes extracted using five solvents of varying polarity to address both
clinical use and exaggerated extraction scenarios. The extracted prototypes included
four composite restoratives, a resin-modified glass ionomer, a polymeric polishing
brush, a temporary cement, a self-etch adhesive, and a dental sealant. ISO 10993-
12 compliant samples of each product were extracted in aqueous 5% ethanol solu-
tion, acetone, methanol, heptane, and 50:50 cyclohexane:isopropanol at 37°C with
a target sample:solvent extraction ratio of 0.2 g/mL. Extraction time intervals
ranged from 24 hours to 28 days. Gravimetric and HPLC analyses of the extracts
show that in most cases use of methanol either resulted in the highest concentration
of extractables or gave results similar to acetone. In the remaining cases, either ace-
tone or water extracted the largest amount of residue. These results confirm the
utility of methanol as an exaggerated solvent for many polymeric dental products,
but also highlight the importance of proper solvent selection based on detailed
knowledge of product chemistry.
202 Determination of Total Leachable Bisphenol A from
Polysulfone Membranes in Hemodialyzers and
Hemoconcentrators.
S. M. Cho,  Y. Choi,  H. Luu and J. Guo. US FDA, Silver Spring, MD.
Bisphenol A (BPA) is a high-production-volume chemical widely used to manufac-
ture polysulfone (PS), polycarbonate, epoxy resin, etc. Over the past ten years, BPA
has been the subject of numerous risk assessment reviews and research worldwide
because of its potential to produce adverse health effects through endocrine disrup-
tion. Although there is a significant body of literature focused on the adverse effects
of BPA at low doses, there are discrepancies in the relevance and reliability of the
published results. These make it difficult to properly evaluate the hazards of BPA.
To reduce discrepancies and variation in research results, it is essential to establish
reproducible/accurate analytical methods. In this study, we evaluated the BPA levels
eluted from porous PS membranes used in hemodialyzers and hemoconcentrators
using single and multiple consecutive extractions under clinically relevant extrac-
tion condition. The levels of BPA release were determined using solid phase extrac-
tion (SPE) coupled with high performance liquid chromatography-mass spectrom-
etry (HPLC-MS). We demonstrated that it was difficult to determine the total
amount of BPA released from the PS membranes using a single extraction method
with finite solvent volume because of the chemical equilibrium between the extrac-
tion solution and the polymer phase. A general equation was derived to fit the BPA
elution data and deepen our understanding on the equilibrium phenomenon dur-
ing the extraction. The results revealed that repeated consecutive extractions of the
PS membranes are needed to accurately determine the total leachable BPA in
porous membranes.
203 Bisphenol A Content in Polycarbonate from Medical,
Automotive and Consumer Suppliers.
R. T. Przygoda1,  J. A. Anim1,  D. E. Malek2 and D. J. Caldwell3. 1Life Cycle
Materials, Johnson & Johnson, Cincinnati, OH; 2Malek Toxicology Delaware, LLC,
Greenville, DE; 3Worldwide Environment, Health, and Safety, Johnson & Johnson,
New Brunswick, NJ.
Bisphenol A (BPA) is an organic compound used to make polycarbonate (PC) poly-
mers and epoxy resins. The presence of BPA has the potential to produce human re-
productive and developmental effects. Three sources of PC’s were utilized in this
study: from medical, automotive, and consumer suppliers (cups). Sterilized and un-
sterilized samples were extracted using ethanol (ETOH) or isopropanol (IPA) and
incubated at 37 degrees C for 24 hours. Extracts were analyzed by high perform-
ance liquid chromatography (HPLC). In addition, exhaustive extraction by Soxhlet
with IPA was performed on a medical grade PC. BPA was below the level of detec-
tion (0.5μg/g) in ETOH and IPA extracts with the exception of the cups. In ex-
tracts from cups, between 4 to 5.8μg BPA/g of test sample was detected, however
BPA was not detected in the non-sterilized sample extracted with ETOH (limit of
detection was 0.51μg). Assuming a 10g cup and the worst-case of 5.8μg BPA/g, an
adult male (70kg) would be exposed to 0.829μg BPA/kg/day. Using exhaustive
Soxhlet extraction with IPA, BPA was below the limit of detection (0. 51μg/g) for
automotive PC. Assuming a 10g sample and the worst-case of 0.5μg/g, an adult
male would be exposed to 0.071μg/kg/day. The average BPA amount found in
medical grade PC by exhaustive Soxhlet extraction with IPA was 0.25μg/g. For a
10g medical device, the calculated exposure for an adult male is 0.036μg/kg/day.
The US FDA acceptable Daily Intake (ADI) and/or EU Tolerable Daily Intake
(TDI) for BPA is 50μg/kg/day. The adult male exposures to BPA from consumer,
automotive, and medical grade PC are 58, 704, and 1300 times less than US FDA
ADI or EU TDI. The extractable BPA from automotive and medical grade PC was
significantly less than that observed from the consumer PC.
204 Local Effects of Microelectrode Implantation in Rabbit
Muscles.
J. Yoon1,  E. Cho1,  S. Kim1,  J. You1,  Y. Kim1,  E. Kwon1,  B. Kang1, 2 and
J. Che1. 1Biomedical Research Institute, Seoul National University Hospital, Seoul,
Republic of Korea; 2Graduate School of Immunology, Seoul National University, Seoul,
Republic of Korea. Sponsor: K. Lim.
The purpose of this study was to evaluate the biocompatibility of various polymer-
based microelectrodes (PBMs) after implantation in rabbit muscle tissues following
a standardized method. Three types of PBMs were examined: silicone-based plat-
inum, polyimide-based gold, and liquid crystal polymer-based gold microelec-
trodes. All experimental procedures followed the International Organization for
Standardization (ISO) 10993-6:2007(E). Six female rabbits were used for this
study. The PBMs were implanted into the left paravertebral muscle of the dorsal re-
gion of the rabbits for 12 weeks, each type being implanted into two rabbits.
Control article (high density polyethylene, HDPE) was implanted in the equivalent
site on the right side of each rabbit. No changes in the clinical signs, mortality, body
weight, and gross findings related to the PBMs were noted. The results of
histopathological evaluation suggest that the PBMs did not induce any cellular
changes. Thus it could be concluded that the three types of PBMs are all non-toxic,
non-irritating, and biocompatible.
205 Subchronic Systemic Toxicity of Subcutaneous Implantation
of Microelectrodes in Rats.
E. Cho1,  S. Kim1,  J. You1,  Y. Kim1,  E. Kwon1,  B. Kang1,  J. Che1, 2 and
J. Yoon1. 1Biomedical Research Institute, Seoul National University Hospital, Seoul,
Republic of Korea; 2Graduate School of Immunology, Seoul National University, Seoul,
Republic of Korea. Sponsor: K. Lim.
The purpose of this study was to evaluate the biocompatibility of various polymer-
based microelectrodes (PBMs) through the subchronic systemic toxicity of subcuta-
neous microelectrode implantation in rats following a standardized method. Three
types of PBMs were examined: silicone-based platinum, polyimide-based gold, and
liquid crystal polymer-based gold microelectrodes. All experimental procedures fol-
lowed the International Organization for Standardization (ISO) 10993-6:2007(E)
and ISO 10993-11:2006(E). Ten female rats were used for four each groups.
Control article (high density polyethylene, HDPE) and three types of PBMs were
implanted subcutaneously in the same site in each group and were left in place for
13 weeks. No effects related to the microelectrodes were observed in any tested cri-
teria, included mortality, clinical signs, body weight, food and water consumption,
hematology and serum biochemistry parameters, urinalysis and ophthalmoscopy,
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organ weight, gross findings, or histopathological findings. These results suggest
that no subchronic systemic toxicity is induced by subcutaneous implantation of
these three types of PBMs under the conditions used in this study.
206 Comprehensive Health-Based Risk Assessment of Material
from an Ingestible Medical Device.
M. A. Nascarella1,  G. M. Savage2,  G. Moon2 and B. D. Beck1. 1Gradient,
Cambridge, MA; 2Proteus Biomedical, Inc., Redwood City, CA.
We present an analysis of the potential toxicity of an ingestible medical device. The
primary toxicological concern is an 8 μM layer of copper (Cu), with an area of ap-
proximately 1.0 mm2, that is a component of the device’s battery. The Cu content
is approximately 20-33.1 μg/device. We calculated the potential toxicological risks
of Cu leached from the device, assuming a maximum use of 30 devices/event.
Depending upon fluid in the stomach, an individual could have a stomach dose of
approximately 219 μg Cu, resulting in a stomach concentration ranging from 0.25-
2.73 μg Cu/mL. These concentrations may be compared to a threshold Cu concen-
tration for gastrointestinal (GI) toxicity of 1.4 μg/mL. In the most plausible sce-
nario, the predicted concentration of Cu in the stomach is below the concentration
associated with GI symptoms in humans, consisting of mild, reversible effects and
no associated systemic toxicity. The higher potential stomach concentrations some-
what exceed the threshold concentration, but potential GI symptoms could be mit-
igated by ingesting the devices with food. We also estimated the potential total in-
take of Cu from all sources, including the device. Ingestion of the device, combined
with the ingestion of median levels of Cu in food, water, and multivitamins, is esti-
mated to be well below the 10 mg/day IOM determined level of safe daily intake
for the general population. We also evaluated the cytotoxicity of the extractable ma-
terial from this device, based on ISO-compliant tests of device extractions using
simulated gastric fluid. Using open-source software, we calculated the number of
devices that would be associated with a cytotoxic effect according to ISO standards.
This analysis indicated that plausible use of the devices would not lead to cytotoxic
effects. Overall, we conclude that ingestion of the medical device under plausible
use conditions is unlikely to present a toxicological concern for Cu.
207 Comparative Pulmonary Response to Aerosolized
Humidifier Disinfectants by Intratracheal Instillation and
Inhalation Exposure.
Y. Kim1,  S. Choi2,  Y. Yang2,  Y. Kim1,  C. Song1,  J. Cho1,  C. Ha2 and K. Lee2.
1Korea Institute of Toxicology, Daejeon, Republic of Korea; 2Jeonbuk Department of
Non-Human Primate, Korea Institute of Toxicology, Jeongup, Republic of Korea.
Sponsor: S. Park.
Mice intratracheal instillation (IT) and rat inhalation exposure (IH) were con-
ducted to identify the toxicity of 3 representative humidifier disinfectants (products
A, B, and C containing polyhexamethylene guanidine (PHMG), 5-chloro-2-
methylisothiazol-3-(2H)-one/2-methylisothiazol-3(2H)-one (CMIT/MIT), and
oligo(2-(2-ethoxy)ethoxyl guanidinium chloride (PGH), respectively). In mice ad-
ministered by multiple 7-9 IT at 0.05 ml for 2 wk, severe necrotic obliterative
bronchiolitis (OB) was found in product A and C. But no adverse treatment effect
was observed in product B. In rat inhalation study (IH), necrotizing inflammation
was observed in nasal cavity, larynx, trachea, and lung airways at repeated IH with
product A at 0.4 mg/m3 and product C at 1.75 mg/m3. However, necrotizing in-
flammatory lesions in the upper airways were not present in the IT due to direct ad-
ministration of test substance to the lung via trachea. Granulomatous OB, bronchi-
tis, collagenized fibrosis, alveolar bronchiolarization, and extensive squamous
metaplasia were observed in product A at 10 wk IH, and product C at 7 wk IH. No
treatment-related adverse effects were observed in 13 wk IH with product B at 1.80
mg/m3. Lung lesions induced by IT and IH with product A and C were compara-
ble and no treatment-related lesions were present with product B in both IT and IH
exposure. It was difficult to evaluate dose-related toxicity by IT dosing. However,
IT with low dose was a useful methodology to screen and identify toxicity of test
substances in this study.
208 Effect of Fuel Composition on Chemistry and Pulmonary
Toxicity in Mice Exposed to Biomass Pyrolysis Vapor.
I. Gilmour1,  E. Mutlu3,  B. Elizabeth1,  D. Mary1,  L. Copeland1,  C. King1,
T. Krantz1,  I. George2,  M. Hays2,  J. Dye1,  M. Higuchi1 and C. Lee2.
1NHEERL, US EPA, Durham, NC; 2NRMRL, US EPA, Durham, NC; 3CEMALB,
University of North Carolina at Chapel Hill, Chapel Hill, NC.
Biomass pyrolysis is a method to form oil through the thermal degradation of or-
ganic material in the absence of oxygen. The process results in a mix of gaseous ox-
ides, organic vapors and particulate matter that could pose an inhalation hazard. In
this study, we characterized aerosol emissions from three different fuels (corn, pine,
maple) pyrolyzed under similar conditions, and compared pulmonary and systemic
toxicity endpoints in CD-1 mice after a 4h inhalation exposure. Particle number
counts/cc were 37000, 48000 and 34000 for corn cob, pine and maple respectively,
with median count diameters of 221, 254 and 225 nm. Particle mass was 409, 689
and 362 μg/m3 for the three fuels, and CO measurements were 37, 39 and 45
ppm. Volatile organic analysis by GC-MS showed acrolein being 1.3, 1.7 and 2.3
ppm, with lower levels of propylene, acetone and vinyl acetate. Pulmonary re-
sponses were assessed in a plethysmograph immediately before and after exposure,
as well as 4 and 24h post-exposure, when mice were euthanized. ll fuels altered
breathing parameters immediately following exposure, and this effect persisted at
the 4h time-point for the corn cob and maple atmospheres before returning to con-
trol levels at 24h. Total protein was increased in the BALF of animals exposed to
corn cob (4h and 24h post), pine (24h post), and maple (4h post), with corn hav-
ing the highest effect. No other indices were affected except BALF LDH for pine,
and increased hematocrits for corn cob at 24h. Because these atmospheres were
considered to have high irritant characteristics, nasal lavage was also performed and
although some increases in inflammatory cells were seen for the corn cob and maple
atmospheres, the effects were variable. We conclude that corn cob and maple pyrol-
ysis products seemed to have a more potent effect on pulmonary function and tox-
icity parameters than pine emissions. (This abstract does not reflect EPA policy).
209 Gene Expression in Bronchiolitis Obliterans-Like Lesions in
Rats Exposed to 2, 3-Pentanedione.
D. L. Morgan1,  B. A. Merrick1,  K. E. Gerrish2,  P. S. Stockton1,  J. F. Foley1,
W. M. Gwinn1 and G. P. Flake1. 1Division of the National Toxicology Program,
NIEHS, Research Triangle Park, NC; 2Division of Intramural Research, NIEHS,
Research Triangle Park, NC.
Obliterative bronchiolitis (OB) is an irreversible lung disease characterized by pro-
gressive fibrosis in the small airways with eventual obliteration of the airway lu-
mens. OB is most commonly associated with lung transplant rejection; however,
OB has also been diagnosed in workers exposed to artificial butter flavoring (ABF)
vapors. Research has been limited by the lack of an adequate animal model of OB,
and as a result the mechanism is unclear and there are no effective treatments for
this condition. A rat model of chemical-induced OB using the ABF component,
2,3-pentanedione (PD), was found to cause airway lesions histopathologically sim-
ilar to OB lesions in humans. We used this model to evaluate changes in gene ex-
pression in the distal bronchi of rats with OB. Male Wistar Han rats were exposed
to 200 ppm PD or air (controls) 6hr/d, 5d/wk for 2-wks. Distal bronchial tissues
were laser microdissected from serial sections of frozen lung. In exposed lungs, both
fibrotic and nonfibrotic airways were collected. Following RNA extraction and mi-
croarray analysis, differential gene expression was evaluated. In exposed nonfibrotic
bronchi, 1548 genes were significantly altered relative to air-exposed controls with
notable downregulation of many inflammatory cytokines and chemokines. In con-
trast, in PD-exposed fibrotic bronchi, 2504 genes were significantly altered with a
majority of genes being upregulated in affected pathways. TGF-beta2 and down-
stream genes implicated in fibrosis were significantly upregulated in fibrotic lesions.
Genes for collagens and extracellular matrix proteins were highly upregulated. In
addition, expression of genes for peptidases and for peptidase inhibitors were sig-
nificantly altered suggesting tissue remodeling that may contribute to fibrosis.
These data will be used to gain a better understanding of the molecular mechanisms
of OB and to identify potential therapeutic targets.
210 Polyhexamethyleneguanidine Phosphate Induces Severe
Lung Inflammation, Fibrosis, and Thymic Atrophy.
J. Song1,  H. Park1,  H. Yang1,  M. Yang1,  C. Song2 and K. Lee1. 1Inhalation
Toxicology Center, Jeonbuk Department of Nonhuman Primate, Koeran Institute of
Toxicology, Jeongeup, Republic of Korea; 2Korean Institute of Toxicology, Daejeon,
Republic of Korea. Sponsor: S. Park.
Polyhexamethyleneguanidine phosphate (PHMG-ph) has been widely used as a
disinfectant due to its strong bactericidal activity. But The Korea Centers for
Disease Control and Prevention (KCDC) and Ministry of Health and Welfare re-
ported that humidifier disinfectants might cause of the unknown pulmonary dis-
ease in 2011. The purpose of this study was to assess the potential adverse effect of
PHMG-Ph, a ingredient of humidifier disinfectant, exposed to lung directly.
0.0125%, 0.0375%, and 0.0625% PHMG-Ph was instilled intratracheally into
mice. Seven and fourteen days after instillation, lungs were collected and proin-
flammatory cytokines, chemokines and fibrotic markers were measured from lung
lysates. We also performed flow cytometry to evaluate the cell distribution of thy-
mus and RT-PCR to measure the mRNA expression associated with T cell develop-
ment.
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As a result, single exposure of 0.0125%, 0.0375%, and 0.0625% PHMG-Ph in-
duced inflammatory response with increased proinflammatory cytokines and im-
mune cell infiltration to the lungs, and interestingly, this inflammation did not re-
solved till the end of the experiments (14 days after instillation). The
histopathology showed the both inflammation and pulmonary fibrosis exacerbated
at day 14 after exposure in dose-dependent manner. Also PHMG-Ph decreased the
total cell number and the CD4+/CD8+ cell proportion in thymus and induced se-
vere medulla reduction based on histopathology data. 
These observations demonstrated that PHMG-Ph exposed to lung lead to pul-
monary inflammation and fibrosis as well as to thymic atrophy.
211 Inhalation of a Spot Welding Aerosol Using an Adhesive
Increased Airway Resistance but Not Lung Inflammation.
J. M. Antonini,  A. Afshari,  J. A. Thompson,  J. S. Fedan,  W. McKinney,
T. G. Meighan,  M. C. Jackson,  B. T. Chen,  D. Schwegler-Berry,  A. Erdely,
D. Frazer and P. C. Zeidler-Erdely. NIOSH, Morgantown, WV.
Spot welding (SW) is used in the automotive and aircraft industries where high
speed repetitive welding is needed and relatively thin metal sections are welded.
Epoxy adhesives are applied as sealers to the seams of the metals that are joined. SW
produces complex aerosols composed of both metal and volatile compounds which
may cause bronchitis and asthma in workers. The goal was to assess the effect of SW
fumes on lung function and toxicity. Male Sprague-Dawley rats were exposed by in-
halation to 20 mg/m3 of SW aerosol in the presence of an adhesive for 4 hr/d x 8 d.
Controls were exposed to air. Size distribution of the aerosol as determined by a
MOUDI particle impactor was tri-modal with a MMAD of 1.66 μm in the large-
fine mode, 0.30 μm in the small-fine mode, and 0.01-0.05 μm in the ultrafine
mode. Two distinct particle morphologies were observed- a brownish metal particle
that predominated in the small-fine particle fraction and a black, glue-like particle
that was in the large-fine fraction. The metal fraction was found to be >90% Fe.
Significant amounts of volatiles (e.g., benzene, toluene, others) were present, likely
produced from the vaporization of the adhesive. At different times after exposure,
bronchoalveolar lavage (BAL) was performed to assess lung toxicity. Lung resistance
(RL) was evaluated in a separate set of animals before and after challenge with in-
haled methacholine (MCh). Immediately after exposure, baseline RL was signifi-
cantly elevated in the group exposed to the SW fumes. Basal RL returned to control
level by 1 d after exposure. Reactivity to MCh was not affected at any time point
after fume exposure. No significant increase in lung inflammation (neutrophil in-
flux) or injury (cytotoxicity and lung epithelial permeability) was observed in BAL
fluid at 1 and 5 d after exposure to SW fume. Acute inhalation of SW fumes at oc-
cupationally-relevant concentrations may act as an irritant as evidenced by the in-
creased RL but had little effect on toxicity.
212 Cardiopulmonary Health Effects of Traffic-Related Air
Pollutants in a Healthy Population.
J. E. Mirowsky1,  R. Peltier2,  M. Lippmann1,  L. Griffith1,  J. Carter3,  D. Diaz-
Sanchez3,  W. Cascio3 and T. Gordon1. 1Environmental Medicine, New York
University, Tuxedo, NY; 2Environmental Health Science, University of Massachusetts,
Amherst, MA; 3US EPA, Research Triangle Park, NC.
There is emerging evidence that inhaling certain components of ambient particu-
late matter, specifically traffic pollutants, is associated with adverse health effects.
We hypothesized that exposure to air pollution components of diesel exhaust-rich
traffic, compared to cars-only traffic, produces greater adverse cardiopulmonary ef-
fects. In this case-crossover study, 23 participants were recruited to measure pul-
monary function, exhaled NO, blood cytokines, heart rate variability, and blood
pressure prior to, immediately after, and 24 hours after intermittent walking along
3 diverse roadways. Exposures lasted for 1.5 hours between June and September in
2011 and 2012, and personal exposures to pollutants were collected. The 3 loca-
tions differed by traffic type: the George Washington Bridge (GWB) carries truck
and car traffic, the Garden State Parkway (GSP) carries only car traffic, and Sterling
Forest, NY (SF) acted as a control location. Levels of PM2.5, PM10, black carbon,
elemental carbon, and organic carbon were found to be highest at GWB and lowest
at SF for all pollutants measured. The traffic count was similar between GSP and
GWB. Using a repeated measures 2-way ANOVA, p-values were generated for
time, location, and interactions between time and location. Location was a signifi-
cant factor for FVC (p = 0.04) and FEV1 (p = 0.05); a significant interaction term
for pulse pressure was also observed (p < 0.01). Upon further analysis, systolic and
pulse pressures varied significantly amongst locations when comparing the baseline
and 24 hr-post measurement, while IL-1β varied amongst locations between the
baseline and immediately after exposure. A trend of increasing eNO at the GWB
was seen immediately after exposure, but did not reach significance (p = 0.06).
These results suggest that acute effects of traffic-related pollution are observed in a
small, healthy population; these effects differed by traffic type.
213 Ventricular Transcriptional Data Provide Mechanistic
Insights into Diesel Exhaust-Induced Attenuation of Cardiac
Contractile Response and Blood Pressure.
U. P. Kodavanti,  V. L. Bass,  J. Crooks,  B. Vallanat,  H. Ren,
M. C. Schladweiler,  R. F. Thomas,  T. Krantz,  C. King,  C. J. Gordon and
A. D. Ledbetter. EPHD/NHEERL/ORD, US EPA, Research Triangle Park, NC.
Human exposure to diesel exhaust (DE) has been associated with cardiovascular
impairments however the mechanisms and the role of hypertension are not well un-
derstood. We have shown that DE reduces blood pressure (BP) and cardiac con-
tractility in healthy normotensive Wistar Kyoto (WKY) rats. We hypothesized that
DE would induce differential myocardial gene expression changes that modulate
contractility in WKY and spontaneously hypertensive (SH) rats, and that lowering
BP in WKY and SH with hydralazine (HYD) would increase this effect of DE.
Male WKY and SH rats were treated with HYD (150 mg/L) in drinking water for
10 days prior to exposure and until necropsy. All rats were exposed to clean air or
freshly-generated whole DE (1500 μg/m3), 5-hrs/day for 2-days. Systolic BP was
monitored using the tail-cuff method on days -10, 0, and 2. Left ventricular
genome-wide expression was analyzed using Illumina RatRef-12 BeadChips. As ex-
pected, WKY and SH rat’s ventricular gene expression patterns differed markedly.
Surprisingly, DE exposure caused differential expression of 256 genes in WKY but
none in SH rats. In WKY rats, the effect of HYD on expression patterns were
nearly identical to changes induced by DE (same genes with same directional
change); while HYD was without effect on expression changes in SH rats despite
lowering BP. Genes inhibited by DE or HYD in WKY were induced at baseline in
SH and vice versa. These genes inhibited by DE and HYD were related to seques-
tration of oxidants, inhibition of proteases, and membrane stability. The genes up-
regulated by DE and HYD in WKY included those involved in decreasing BP and
muscle contraction as well as calcium homeostasis and apoptosis. In conclusion,
acute DE exposure caused gene expression changes only in normotensive WKY
rats; these changes mimicked those induced by HYD and are associated with de-
creased cardiac contractility and BP in healthy rats. (Abstract does not reflect
USEPA policy)
214 Comparative Cardiopulmonary Toxicity of Soy Biofuel and
Diesel Exhausts in Healthy and Hypertensive Rats.
M. C. Schladweiler1,  V. L. Bass1,  R. F. Thomas1,  J. E. Richards1,  D. Johnson2,
D. L. Andrews4,  A. Nyska3,  T. Krantz1,  C. King1 and U. P. Kodavanti1.
1EPHD/NHEERL/ORD, US EPA, Research Triangle Park, NC; 2Curriculum in
Toxicology, University of North Carolina at Chapel Hill, Chapel Hill, NC; 3Tel Aviv
University, Tel Aviv, Israel; 4RCU/NHEERL/ORD, US EPA, Research Triangle Park,
NC.
Increased use of renewable energy sources raise concerns about health effects of
emissions from such sources. We conducted a comprehensive analysis of relative
cardiopulmonary health effects of exhausts from 1) 100% soy biofuel (B100), 2)
20% soy biofuel + 80% low sulfur petroleum diesel (B20), and 3) 100% petroleum
diesel (B0) in rats. Normotensive Wistar Kyoto and spontaneously hypertensive
rats were exposed to these 3 exhausts at 0, 50, 150 and 500 μg/m3, 4 h/day for ei-
ther 2d or 4 wk (5 d/wk) to mimic near environmental concentrations.
Additionally, WKY rats were exposed for 1d and responses were analyzed 0 hr, 1d
or 4d later for time course analysis. Hematological parameters, in vitro platelet ag-
gregation, bronchoalveolar lavage fluid (BALF) markers of pulmonary injury and
inflammation, ex-vivo aortic ring constriction, heart and aorta mRNA markers of
atherogenesis, and serum biomarkers of acute cardiac injury as well as cytokines
were analyzed. The presence of pigmented macrophages in the lung alveoli was
clearly evident with all 3 exhaust exposures. Overall, exposure to all 3 exhausts pro-
duced only modest effects in most endpoints analyzed in both rat strains. BALF γ-
glutamyl transferase (GGT) activity was the most consistent marker shown to be
increased in both strains with all 3 fuels (B0>B100>B20) without increases in
BALF neutrophils. Small inconsistent changes in aorta mRNA markers of inflam-
mation, vasoconstriction and thrombosis, and those of serum biomarkers need to
be interpreted cautiously. Our comparative evaluations show modest cardiovascular
and pulmonary effects at low concentrations of all exhausts. Additionally, our study
highlights the value of BALF levels of GGT activity as the most sensitive biomarker
in low level inhalation studies. (This abstract does not represent USEPA policy).
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215 Acute and Delayed Effects of Intermittant Ozone on
Cardiovascular and Thermoregulatory Responses of Young
and Aged Rats.
A. F. Johnstone1,  R. C. MacPhail1,  C. Aydin2 and C. J. Gordon1. 1TAD,
NHEERL, US EPA, Research Triangle Park, NC; 2Physiology, University of Uludag,
Bursa, Turkey.
Ozone (O3) is associated with cardiovascular and respiratory diseases. The aged
population is considered to be more sensitive to air pollutants but relatively few
studies have demonstrated increased susceptibility in animal models of aging. To
study the acute and delayed physiological responses to O3, core temperature (Tc)
and heart rate (HR) monitored by telemetry in adult (12 m) and senescent (24 m)
Brown Norway rats exposed to intermittent O3 (1.0 ppm, 6 hr/d for 2 consecutive
d for 12 wk). Tc and HR dropped precipitously in both age groups during the 1st
bout of O3 exposure; Tc decreased from ~38 to ~35 °C while HR decreased from
~300 to ~175 b/min. These acute responses were attenuated during the 2nd day of
O3. As O3 exposures continued, the acute Tc and HR responses abated but the
aged animals were consistently less affected than the young adults throughout the
12 wk exposure period. During 5 d of recovery in home cages, both young and
senescent rats displayed a fever-like ~0.5 °C elevation in daytime Tc. HR was also
elevated in the young adults during recovery. The rise in Tc persisted for 2-3 d after
O3. The O3-induced fever was marked following the 1st exposure, abated by the
3rd exposure week but then gained in magnitude throughout the remainder of the
study. We postulate that inflammatory responses of the respiratory system to O3 are
exacerbated in younger animals, leading to accentuated acute physiological re-
sponses compared to that of senescent rats. This is an abstract of a proposed pres-
entation and does not reflect US EPA policy.
216 Dose and Effect of Inhaled Ozone in Resting versus
Exercising Human Subjects: Comparison with Resting Rats.
G. E. Hatch,  J. McKee,  J. S. Brown,  B. McDonnell,  E. Seal,  J. Soukup,
R. Slade,  K. Crissman and R. B. Devlin. Environmental Public Health Division,
US EPA, Research Triangle Park, NC.
Rationale: Human controlled exposure studies have generally focused on subjects
exposed to ozone (O3) while exercising. We exposed resting subjects to labeled O3
(18O3, 0.4 ppm, for 2 hr) and compared O3 dose and effects with our previously
published study of exercising subjects.
Methods: We measured O3 dose as the concentration of 
18O in cells and extracel-
lular material of nasal, bronchial and bronchoalveolar lavage fluid (BALF) immedi-
ately post exposure and related these measurements to O3 effects on inflammation,
epithelial permeability and phagocytosis in the same fluids and to breathing param-
eters measured during the 18O3 exposure. A parallel study of resting subjects exam-
ined FEV1 changes during and immediately following a 2 hr exposure to 0.18,
0.25, 0.3 and 0.4 ppm O3. 
Results: Subjects exposed while resting had 18O concentrations in BALF and nasal
lavage that were proportional to the amount of air breathed during exposure.
Significant but small changes were observed in BALF total cells and neutrophils
and in BALF cell phagocytosis following resting O3, however, most indicators of O3
effects that were observable in exercising subjects (including increased BALF super-
natant protein, lactate dehydrogenase, interleukin-6 and low molecular weight an-
tioxidants) were not observed in resting subjects. The 18O incorporation into BALF
of resting humans was similar to that of similarly exposed resting F344 rats. FEV1
changes in resting human subjects showed a much attenuated response compared
to exercising subjects. 
Conclusions: Quantitative measures of alveolar O3 dose and toxicity that were ob-
served previously in exercising subjects were greatly reduced or non-observable in
O3 exposed resting subjects. Resting rats and resting humans have similar alveolar
O3 dose.  Disclaimer: This abstract does not represent E.P.A. policy.
217 Biological Responses in Rats Exposed to Mainstream Smoke
from a Heated Cigarette Compared to a Conventional
Reference Cigarette.
H. Fujimoto1,  H. Tsuji1,  I. Fukuda1,  T. Nishino1,  M. K. Lee2,  R. Renne3 and
H. Yoshimura1. 1R&D Group, Japan Tobacco Inc., Yokohama, Japan; 2Scientific and
Regulatory Affairs, Japan Tobacco International S.A, Geneva, Swaziland; 3Roger
Renne ToxPath Consulting, Sumner, WA.
The heated cigarette (HC) generates mainstream smoke (MS) primarily by vaporiz-
ing the components of the tobacco rod using a carbon heat source at the cigarette
tip. Consequently, MS of HC contains markedly less chemical constituents com-
pared to conventional (combusted) cigarettes. In this study, MS from a non-venti-
lated HC (nvHC) was generated under a modified Canadian Intense Regimen
(CIR) and its biological activities were compared to those of Reference (3R4F) cig-
arettes, using nose-only inhalation studies. In a 5-week inhalation study, female SD
rats were exposed to MS of either cigarette at 600 or 1000 μg wet total particulate
matter (WTPM) /L for 1 hr, 2 times/day, 7 days/week for 5 weeks. Pulmonary in-
flammation was significantly weaker in nvHC groups compared to 3R4F groups,
based on the neutrophil counts and deviation enzyme levels in bronchoalveolar
lavage fluid (BALF). After a 4-week recovery, BALF parameters of nvHC groups
were similar to the air-exposed Sham group, while those of 3R4F groups remained
elevated. In a 13-week inhalation study, male and female SD rats were exposed to
MS from each cigarette at 200, 600, or 1000 WTPM μg/L for 1 hr/day, 7
days/week for 13 weeks. Histopathological changes in the respiratory tract were sig-
nificantly lower in incidence/severity for nvHC groups, especially in respiratory ep-
ithelial hyperplasia and accumulation of pigmented macrophages in alveoli. After a
13-week recovery, the lesions were completely or partially regressed, except for ac-
cumulation of pigmented macrophages in alveoli, in both nvHC and 3R4F groups.
In conclusion, nvHC demonstrated clearly and significantly lower biological activ-
ities compared to 3R4F, based on the BALF parameters and histopathology.
218 A Cross-Regulatory T Cell Response in Pulmonary
Hypertension.
G. Grunig,  W. Chen,  C. Hoffman,  T. Gordon and S. Park. NYU Medical
Center, Tuxedo, NY.
Exposure to urban air pollution (fuel emissions, particulate matter) has been associ-
ated with the exacerbation of autoimmune diseases. Our studies are focused on the
mechanism of immune response induced pulmonary hypertension. We have shown
that co-exposure of mice to inhaled antigen and urban particulate matter (PM) ex-
acerbates pulmonary arterial remodeling and induces pulmonary hypertension. The
current studies were performed with neutralizing anti-cytokine antibodies to iden-
tify the critical mediators for pulmonary hypertension and the interactions in the
mediator-network.
Sensitized mice were intranasally challenged with either antigen (Ovalbumin)
combined with urban PM2.5 (collected in New York City), or given saline. Groups
of mice were injected with neutralizing anti-Interleukin (IL)-13, or anti-IL-17A/F
antibodies alone or in combination, or control antibody. Right ventricular systolic
pressures and immune response markers in the lungs were measured.
Intranasal challenge with antigen and urban PM significantly increased right ven-
tricular systolic pressures. Only combined, but not single, injections with IL-13-
and IL-17A/F-blockers significantly reduced this outcome. Surprisingly, injections
with single neutralizing antibodies not only significantly reduced the inflammatory
markers known to be regulated by IL-13 or IL-17A/F, but also revealed cross-inhi-
bition of these markers. For example, the increased expression of the antigen pres-
entation molecule, major histocompatibility class II (MHCII), by airway dendritic
cells was inhibited by the IL-13 blocker given alone or in combination, while the
IL-17A/F blocker lead to an increase in MHCII expression. Conversely, infiltration
of the airways with neutrophils was inhibited by the administration of the IL-
17A/F blocker given alone or in combination, while injections with the IL-13
blocker increased neutrophil influx.
In conclusion, exposure to antigen and urban PM induced pulmonary
hypertension by elaborating a mixed immune response that has at least two, cross-
regulatory arms that are controlled by IL-13 and IL-17A/F, respectively.
219 Capsule-Based Aerosol Generator (CBAG)—Validation in a
Rat Model of LPS-Induced Nonallergic Pulmonary
Inflammation.
S. Jordan,  S. Moore and R. Armstrong. Huntingdon Life Sciences, Huntingdon,
United Kingdom. Sponsor: E. Moore.
Intratracheal (IT) insufflation is the principal method of delivery of inhaled drug
substances to conscious non-clinical species in early drug development; however,
this achieves particulate deposition dissimilar to conscious inhaled delivery and can
produce artefactual toxicological and pharmacological results. The CBAG was de-
veloped(1) as an alternative to IT insufflation whilst providing representative in-
halation exposure by demonstrating the effectiveness of the CBAG in the rat model
of LPS-induced non-allergic airway inflammation. Rats were exposed to 0.01, 0.1
or 1.0 mg/kg of inhaled fluticasone propionate (FP) over a 20-minute period using
nominally 1 mg filled hydroxypropyl methyl cellulose size 2 capsules at blend
strengths of 1, 10 and 100% w/w of FP respectively. Two concurrent control groups
were exposed to lactose only using the same regime. Twenty minutes after the end
of the inhalation exposure the animals were challenged with either aerosolised LPS
(0.1 mg/mL) for the FP groups and one control group or 0.9% w/v saline (second
control group) for 30 minutes. Rats were euthanized 4hrs following the challenge
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and a bronchoalveolar lavage (BAL) investigation performed. A BAL total and dif-
ferential cell count was used to evaluate the efficacy of FP. Delivered doses of
0.0103, 0.117 and 0.863 mg/kg were achieved, which were within 14% of target.
This resulted in a dose dependent inhibition of BAL neutrophils of 40%, 79% and
98% respectively compared with the lactose/LPS control group. In conclusion, the
results give confidence that the CBAG is a viable alternative to IT methodology for
studies in early drug development and has the added advantage of producing results
representative of inhaled exposures.
(1) Paul G, Somers G, Moore S and Goodway R, Respiratory Drug Delivery 2012,
Vol. 2, 525-530.
220 Distinct Inflammatory Macrophage Subpopulations and
Myeloid-Derived Suppressor Cells Accumulate in the Lung
and Spleen following Exposure of Mice to Inhaled Ozone.
D. L. Laskin1,  H. M. Choi1,  J. D. Laskin2 and M. Mandal1. Pharmacology and
Toxicology, University of Arizona, Tucson, AZ.
Ozone is an ubiquitous urban air pollutant known to damage the lung. Activated
macrophages (MP) and inflammatory mediators they produce have been impli-
cated in ozone toxicity. However, the phenotype and origin of these cells have not
been established. In these studies, techniques in flow cytometry were used to assess
macrophage subpopulations in the lung, spleen and bone marrow following ozone
inhalation. Exposure of C57Bl/6 male mice to ozone (0.8 ppm, 3 h) resulted in in-
creased bronchoalveolar lavage (BAL) protein levels after 24-72 h, indicative of
alveolar epithelial injury. This was correlated with a rapid and persistent increase in
the percentage of CD11b+F4/80+ inflammatory macrophages in BAL. An increase
in F4/80 negative CD11b+Ly6C+Ly6G+ myeloid-derived suppressor cells
(MDSCs) was also observed in BAL, a response most prominent 24 h post ozone
exposure. Conversely, F4/80 positive CD11b+Ly6C+Ly6G+ MDSCs decreased in
BAL after ozone exposure.  We also found that ozone exposure resulted in a persist-
ent decrease in CD11b+F4/80+ inflammatory macrophages, and a transient in-
crease in CD11b-F4/80+Ly6C+Ly6G+ MDSCs in the spleen. In contrast, there
were no changes in bone marrow cell subpopulations after ozone inhalation. Taken
together, these results suggest that the spleen is a source of inflammatory MP in the
lung following ozone exposure; moreover, subpopulations of MDSCs originating in
the lung and the spleen may contribute to early inflammatory responses in the lung
and to processes of injury and repair. Supported by NIH grants GM034310,
ES004738, CA132624, AR055073, ES007148, ES005022.
221 Compare In Vitro Endothelial Cell Release of Endothelium
Derived Vasodilators in Response to Diesel, Biodiesel Blend
and Biodiesel Neat Combustion Extract.
L. Bhavaraju1,  A. Williams2,  T. Kormos3 and M. Madden4. 1Toxicology,
University of North Carolina at Chapel Hill, Chapel Hill, NC; 2National Renewable
Energy Laboratory, Golden, CO; 3NERL, ORD, US EPA, Research Triangle Park,
NC; 4EPHD, NHEERL, US EPA, Chapel Hill, NC.
Diesel exhaust exposure in controlled human chamber studies found exposure in-
duced inhibition of vasodilation. Particles emitted in exhaust can translocate into
the vascular system however when particles are disolved in solvents of various po-
larity the insoluble fraction separates from the soluble fraction. We collected the
soluble fraction of combusted particles dissolved in DMSO for evaluation of the
extract to interfere with the release of endothelium derived vasodilators.
Endothelium dependent vasodilation is dependent on 6-keto PGF1alpha (6keto) a
vaso-active metabolite of arachidonic acid. We have investigated the effects of
diesel, biodiesel blend and biodiesel neat for a change in 6 keto release from three
cell lines: endothelial hybrid cell line (EA hy 926 cells), primary human umbilical
vein endothelial cells (HUVEC) and primary human coronary artery endothelial
cells (HCAEC). ELISA results of EA hy 926 cells with extract exposure for 24hrs
indicate a statistically significant (p≤0.009) increase in 6keto from control and
100μg/mL of biodiesel neat (B100). However ELISA results from HUVEC and
HCAEC exposed to extract for 6, 8 and 24hrs indicate no statistically significant
change in 6keto release. QPCR data from extract exposure indicates there is no in-
crease in markers of inflammation. However there is a measureable increase in
heme oxygenase-1(HO-1) gene expression. HUVEC and HCAEC with 8hr extract
exposure to B100 at 100ug/mL have over two fold increase in HO-1. The B100
particle composition analysis indicates high levels of Zn and Fe compared to
biodiesel blend and diesel. In our work we address a possible mechanism for atten-
uation of vaso-active arachidonic acid metabolites in endothelial cells exposed to
diesel, biodiesel blend and biodiesel neat particle extracts. [This is an abstract of a
proposed presentation and may not necessarily reflect official US EPA Policy.]
222 Role of CD36 in Ozone (O3)-Induced Lung Injury,
Inflammation, and Vascular Dysfunction.
S. Robertson,  S. N. Lucas,  P. Hall,  M. Paffett and M. J. Campen. University of
New Mexico, Albuquerque, NM.
Ground level O3 can damage the cardiovascular system. A lack of a clear mecha-
nism explaining O3-induced vascular health effects hinders the effectiveness of poli-
cies for achieving better health. Evidence suggests that inhaled pollutants evoke a
systemic inflammatory response that causes endothelial injury and dysfunction.
Using serum from O3-exposed mice, we found that circulating components im-
paired acetylcholine (ACh) vasorelaxation in aortas from naïve wild type (WT)
mice. However, the mechanistic interaction(s) between circulating factors and en-
dothelial cells is unknown. To address this issue we turned our attention to pattern
recognition receptors (PRRs), such as CD36 (cluster of differentiation 36), as me-
diators of vascular abnormalities following O3 exposure. PRRs are capable of de-
tecting danger signals released by stressed or injured cells. We hypothesized that ac-
tivation of endothelial CD36 following acute O3 exposure mediates cross-talk
between lung-derived circulating factors and vascular endothelium, culminating in
endothelial dysfunction.  
Female C57 wild type (WT) and CD36 knockout (KO) mice were exposed to fil-
tered air (FA) or 1 ppm O3 for 4 h. Indices of pulmonary (quantified by lavage in-
flammatory cells) inflammation was assessed 24 h later. The effects of exposure on
ACh-induced vasorelaxation were studied using the aortic ring preparation. Parallel
experiments were performed in aortas from naïve WT mice incubated with serum
from exposed mice. 
O3-induced infiltration of macrophages and neutrophils into the airspace in WT
mice were absent in CD36 KO mice. ACh-evoked vasorelaxation of thoracic aorta
of WT mice, but not CD36 KO mice, was significantly reduced after inhalation of
O3. Ex vivo assays utilizing homologous serum demonstrated that the vascular dam-
age caused by O3-induced circulating factors was dependent on vascular CD36 re-
ceptor expression.
Collectively, our data demonstrate that an as yet unidentified circulating factor, or
factors, induced by O3 exposure leads to vascular dysfunction mediated, in part, by
CD36 binding in the vascular tissue.
223 In Vitro Endothelial Cell Model to Assess the Impact of
Systemic Inflammation on Vascular Health.
M. Aragon,  E. S. Colombo,  M. J. Campen and S. Lucas. Department of
Pharmaceutical Sciences, University of New Mexico, Albuquerque, NM.
Assessing the adverse vascular health effects of systemic inflammation caused by in-
haled toxins has presented a substantial research challenge. Current models rely on
anatomically disputable direct application of xenobiotics, especially airborne partic-
ulate matter, on cultured endothelial cells. Such assay systems fail to account for the
complex interactions and toxicokinetics that occur in vivo. We have developed a
model that takes these factors into account to better elucidate the mechanisms in-
volved in a living system. This approach utilizes plasma or serum from exposed an-
imals as the endothelial stimulus, as this is the component in direct contact with en-
dothelial cells. Briefly, the serum/plasma isolated from exposed animals is incubated
on endothelial cells and canonical activation pathways are assessed. In this way the
endothelial cells act as a “biosensor”, expressing markers of inflammation, especially
cell surface adhesion molecules. In addition, nitric oxide (NO) bioavailability via
electron paramagnetic resonance can be directly measured in the supernatant. We
have characterized this model paradigm using primary endothelial cells from rats
and mice, using known mediators (IL-6, TNF-α) to assess the range of response in
order to compare endothelial cell responses to serum obtained from ozone-exposed
rodents. Serum obtained 24h following exposure to 1ppm ozone for 4h caused a 2-
fold increase in vascular cell adhesion molecule-1 cell surface expression on rat aor-
tic endothelial cells, as compared to serum from filtered air-exposed rats. Similarly,
we observe reductions in NO generation and elevated mRNA expression of specific
markers of endothelial cell activation. The potential for this assay extends beyond
the toxic effects of air pollution, with potential applications to drug safety and effi-
cacy, as well as having prognostic value for vascular disease.
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224 Interaction of Human Bronchial Epithelial Cells and
Alveolar Macrophages Modifies the Innate Immune
Response to Ozone.
R. N. Bauer1,  L. Mueller2,  L. Brighton2 and I. Jaspers1, 2. 1Curriculum in
Toxicology, University of North Carolina at Chapel Hill, Chapel Hill, NC; 2Center
for Environmental Medicine, Asthma, and Lung Biology, University of North
Carolina at Chapel Hill, Chapel Hill, NC.
The lining of the airway consists of airway epithelial cells and resident immune
cells, which together coordinate the innate immune response to oxidant pollutants.
Oxidant pollutants can damage airway epithelial cells and induce the production of
soluble mediators that attract nearby immune cells, such as alveolar macrophages,
and activate innate immune pathways. Using ozone (O3) as a model oxidant pollu-
tant, we developed a human bronchial epithelial cell (HBE) and alveolar
macrophage (AM) co-culture model to assess how the interaction between HBE
and AM modifies the innate immune response to oxidant air pollutants. AM de-
rived from the bronchoalveolar lavage of healthy volunteers were co-cultured with
the HBE cell line 16HBEo- on transwell cell culture inserts or on transwells alone.
Co-cultures, AM alone, and HBE alone were exposed to 0.4 ppm O3 or clean air
for 4 hours and analyzed 1 and 24 hours after O3 exposure. O3-induced secretion of
interleukin(IL)-1β and IL-8 was compared between the cultures to determine the
specific cellular sources and whether the interaction between AM and HBE modi-
fies the inflammatory response. Using flow cytometry, co-cultures or AM alone
were examined for AM surface receptor expression, particularly CD44, Toll-like
Receptor 4 (TLR4) and its co-receptor CD14, which recognize soluble mediators
produced in response to oxidative damage. Our results suggest that co-culture of
AM and HBE modifies O3-induced secretion of IL-1β, but not IL-8. Whereas the
co-cultures had robust O3-induced IL-1β production, this response was blunted in
both AM and HBE cultured alone. Both O3-exposed AM had altered CD14,
TLR4, and CD44 expression, and co-culture further modified surface marker ex-
pression. These results suggest that HBE and AM coordinate the inflammatory re-
sponse to O3, and that the interaction between HBE and AM is an important de-
terminate of the innate immune response to inhaled oxidant pollutants.
225 Behaviour of Lactose Blends in Nonclinical Respiratory
Safety Assessment Studies.
S. Moore1 and S. Cracknell2. 1Huntingdon Life Sciences, Huntingdon, United
Kingdom; 2Huntingdon Life Sciences, East Millstone, NJ. Sponsor: D. Mitchell.
Drug/lactose powder blend range and complexity has also grown proportionally as
the potency of drug molecules has increased. This review, therefore, addresses the
relationship between the active drug moieties and total particulate over a range of
lactose powder blend formulations before and after aerosolisation to ensure en-
hanced study control. Test atmosphere concentration data from studies were chem-
ical or gravimetric analysed for drug:total particulate (TP) ratios and compared
with the original blend strength (BS). Results for unmicronised blends indicated up
to a 13-fold increase in drug:TP ratio for lower drug blend strengths (0.25% w/w)
for non-rodent exposure systems and 9-fold for rodent systems. The fold change
(FC) decreased exponentially with increasing drug BS for unmicronised blends and
by 40% w/w; the FC was only 2-fold. Greater variation between different drug ac-
tives was also evident at lower blend strengths. Using stabilisers or additives resulted
in a slight increase (between 0.25 and 0.50 w/w) in the drug:TP ratio over the same
BS range. Comparison of 3 different lactose types indicated varying proportions of
FC depending on the particle size of the lactose. Micronised Lactohale LH301 gave
marginal increase in FC between BS of 0.25 and 40% w/w (1.02 to 1.11) but the
FC exhibited for unmicronised Respitose SV008 gave a much greatest change over
the same BS range. The FC using the same BS with different size inhalation cham-
bers showed no difference with chamber level implying that the animals receive the
same drug:lactose ratio irrespective of their position within the chamber.
Comparison between the Flow-Through and Flow past chambers with different
blend strengths gave a greater FC for the latter chamber type (up to 67%) due to in-
creased lactose sedimentation related to internal geometry of the chamber. In con-
clusion, this approach will allow greater prediction and confidence that the gravi-
metric aerosol concentrations will be an accurate representation of the active drug
moiety when the frequency of chemical analysis is reduced.
226 An In Vitro Cell-Based Assay to Measure the Solubilization
of Indium-Containing Particles by Macrophages.
W. M. Gwinn1,  W. Qu1,  R. W. Bousquet2,  M. P. Waalkes1 and D. L. Morgan1.
1NTP Laboratory, NIEHS, Research Triangle Park, NC; 2Alion Science and
Technology, Research Triangle Park, NC.
Inhaled or airway-delivered indium-containing particles (ICPs) such as indium
phosphide (InP) and indium tin oxide (ITO) exhibit pulmonary toxicity and are
carcinogenic. Many ICPs are highly insoluble compounds which are engulfed by
alveolar macrophages; however, the mechanism(s) of ICP-induced pathogenesis
within the lung is unclear. We have previously shown that ICPs are cytotoxic to
macrophages in vitro which is dependent upon phagolysosome acidification. In the
current study, we hypothesized that macrophages phagocytose and solubilize ICPs
which generates free indium ions- likely the cytotoxic constituent of ICPs.
Adherent RAW 264.7 macrophages were treated with 200 μg/ml InP particles for
24 hrs. In some groups, macrophages were pre-treated for 30 min with 5 μg/ml cy-
tochalasin D (cytoD), an inhibitor of phagocytosis, and then co-treated with InP +
cytoD for 24 hrs. CytoD treatment blocked both the phagocytic uptake and cyto-
toxicity of InP particles. Cell culture supernatants were collected after 24 hrs of
treatment and centrifuged to pellet any residual cells and InP particles. Cell and
particle-free supernatants were then acid digested overnight and the concentration
of total indium was measured using atomic absorption spectroscopy. The concen-
tration of extracellular indium in cell culture supernatants from macrophages
treated with InP particles in the absence of cytoD (91.2 μg/L) was significantly in-
creased and approximately 3-fold greater compared to macrophages treated with
InP in the presence of cytoD (29.8 μg/L). These data indicate that macrophages
phagocytose and solubilize InP particles within lysosomes resulting in cell death
and the extracellular release of free indium metal species. This cell-based assay can
potentially be applied to other ICPs to determine if the in vitro macrophage solu-
bility of different ICPs correlates with in vivo pulmonary toxicity.
227 Acute Pulmonary Heme Oxygenase-1 Protein Response to
Particulate Matter in Naïve Animals As an Indicator of
Allergic Adjuvant Potential.
C. Carosino,  A. Castaneda,  L. E. Plummer,  K. Green,  Y. Zhao,  K. J. Bein,
A. S. Wexler and K. E. Pinkerton. Center for Health and the Environment,
University of California Davis, Davis, CA.
The San Joaquin Valley (SJV) of California is home to high PM pollution and
asthma symptom prevalence. Recently, source oriented sampling (SOS) approaches
have been employed in the SJV to collect commonly occurring particle source com-
binations in the normal milieu of PM typical to the region to allow for the evalua-
tion of their differential toxicities. Acute toxicity studies to assess differential pul-
monary inflammation were performed. Additional studies were performed in an
acute model of allergic airway inflammation. Studies utilized BALB/c mice, 8-10
weeks old and re-suspended particles collected and extracted by SOS methods.
Naïve studies utilized dosing via oropharyngeal aspiration of 50μg SOS PM with
tissues examined for pulmonary inflammation 24-hours post dosing. Allergic stud-
ies utilized intranasal aspiration dosing on day 1, 3, and 5 of a) vehicle control, b)
25μg endotoxin purified D. Farinae house dust mite allergen, HDM (allergic con-
trol), or c) HDM and 15μg SOS PM (45μg total dose). Animals were challenged
on day 11, 12, and 13 with allergen alone and tissues collected on day 14. All aller-
gen-treated animals exhibited cellular profiles indicative of an allergic response with
elevations in leukocytes characterized by neutrophils, lymphocytes and eosinophils.
Heme oxygenase-1 (HO-1) protein levels in homogenized pulmonary tissue of
acutely exposed naïve mice were quantified as a biomarker of oxidative stress.
Analysis of correlations revealed large associations between total cell, lymphocytic,
eosinophilic and neutrophilic pulmonary inflammation in allergic animals in con-
trast to HO-1 protein levels in the tissue of acutely exposed naïve animals. Cellular
inflammation in naïve acute studies did not correlate with HO-1 protein and did
not accurately predict adjuvant potential. These studies suggest that pulmonary
HO-1 levels in naïve acute studies and existing archived tissue may be a valuable in-
dicator of particle adjuvant potential. Support: CARB/EPRI
228 Toxic and Mutagenic Effects of World Trade Center Dust on
Cultured Human Lung Cells.
A. M. DiLorenzo,  C. Lambroussis,  S. Choi and P. Rivera. Montclair State
University, Montclair, NJ.
The terrible events of the September 11, 2001 World Trade Center (WTC) tragedy
left many dead, injured, devastated and emotionally scarred. The effect of this
tragic event was noticed even a decade later in many upper -respiratory complica-
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tions resulting from the exposure to the toxic dust. The purpose of these experi-
ments was to investigate the extent of cellular damage resulting from WTC dust ex-
posure. This research project was conducted with cultured human lung fibroblast
cells exposed to WTC dust. To determine if cell proliferation levels were affected,
cultured cells were exposed to WTC dust at various concentrations ranging from
2.5 to 250 parts per million (ppm) in simulated physiological stress environments.
LD 50 had previously been determined in choosing sample concentrations.
Decreased serum levels were also utilized to mimic stress conditions which were to
be correlated to the stress levels experienced in the exposed human population. The
cultures under the various conditions were studied using both Cell Titer 96
Aqueous Non-radioactive Assay and Caspase Glo 3/7 Assay (Promega). Results in-
dicated that cell proliferation levels decreased as WTC dust concentrations in-
creased reaching a peak at 250ppm. This pattern persisted regardless of stress in-
duced serum level. The serum concentrations used were 10% Fetal Bovine Serum
(FBS), which represented a non-stressed system, with 2.5 and 1% FBS concentra-
tions used to simulate stressed environments. Assessment for apoptosis, pro-
grammed cell death, resulted in higher than baseline levels in cells exposed to WTC
dust in both MRC-5 (male) and WI-38 (female) human lung fibroblasts. In sum-
mary, results determined that exposure to WTC dust led to decreased cell prolifera-
tion and increased apoptosis levels. These findings evidence need for future research
regarding possible mutagenic properties of World Trade Center dust. Further clari-
fication of the small differences seen relative to gender of the exposed sample lung
cells is also needed.
229 Dose Response to Sacramento Particulate Matter.
L. S. Van Winkle,  D. Anderson,  K. E. Pinkerton,  F. Tablin,  D. Wilson,
K. J. Bein and A. S. Wexler. University of California Davis, Davis, CA.
Particulate matter (PM) exposure contributes to respiratory diseases and cardiopul-
monary mortality. The toxicity of PM could be related to sources, such as vehicle
exhaust, and composition, such as abundance of polycyclic aromatic hydrocarbons
(PAHs). We exposed adult male balb/c mice, via oropharyngeal aspiration, to a
range of doses of PM2.5 collected during the winter in downtown Sacramento near
a major freeway interchange (SacPM). Because the relative contribution of PAHs in
SacPM might be important, and since filter extraction may alter PM biological ef-
fects, we tested two PM preparation methods (sonication/spin-down and sonica-
tion/lyophilization) at 10, 50 and 100 μg doses and analyzed the lung tissue re-
sponse at 24 hrs after dosing. We analyzed 1) leukocytes and total protein in BALF,
2) airway-specific and whole lobe expression of PAH sensitive genes (CYP1B1 and
CYP1A1) and IL-1b and 3) lung histology. We found both PM extraction methods
stimulated similar biological responses, but the spin-down method was more robust
at producing IL-1b and CYP1B1 gene responses and the lyophilization method in-
duced whole lung CYP1A1. Neutrophils in the BALF were increased 5-fold at 50
μg and 10-fold at 100 μg. Total protein in the BALF was significantly increased at
both the 50 and 100 μg doses. Histopathology scores were dose responsive and
more robust in mice treated with spin-down derived PM. CYP1B1 gene expression
in whole lung increased 3-fold at the 50 and 100 μg dose for this method as well,
but was increased less than 1.5-fold for the lyophilization method. In microdis-
sected airways all doses of the spin-down PM increased CYP1B1 gene expression
significantly, but the lyophilized PM did not change CYP1B1. We conclude 1) the
method of filter extraction can influence the degree of biological response at a given
dose, 2) for SacPM the minimal effective dose for this strain of mouse and route of
exposure is 50μg and 3) P450s in airways and the lung parenchyma have differen-
tial ability to be upregulated in response to PAH-containing PM. (Supported by
California Air Resources Board)
230 Subchronic Inhalation Exposure of Rats to Libby Amphibole
and Amosite Asbestos: Effects at 1 and 3 Months
Postexposure.
G. A. Willson1,  D. E. Dodd2,  K. Roberts2,  H. G. Wall1,  J. M. Cyphert3,
A. M. Jarabek4 and S. H. Gavett4. 1Experimental Pathology Laboratories, Inc.,
Research Triangle Park, NC; 2The Hamner Institutes for Health Sciences, Research
Triangle Park, NC; 3Curriculum in Toxicology, University of North Carolina School
of Medicine Chapel Hill, Chapel Hill, NC; 4US EPA, Research Triangle Park, NC.
Increased asbestosis, lung cancer, and mesothelioma rates are evident after expo-
sures to Libby amphibole (LA). To support dosimetry model development and
compare potency, a subchronic nose-only inhalation study (6 hr/d, 5 d/wk, 13 wk)
was conducted in male F344 rats. Rats were exposed to air (control), LA (LO,
MED, HI; 1.01, 3.33, 10.08 mg/m3; 300, 701, 4050 fibers/cc), or amosite (AM;
3.35 mg/m3; 1035 f/cc). Toxicity endpoints, pathology, and fiber burden evaluation
were determined 1 d and 1, 3, and 18 mo post-exposure. Previously reported results
(Dodd, SOT 2012) showed comparable inflammatory and fibrogenic responses 1 d
after exposure to MED LA and AM. Here we report BAL neutrophils were in-
creased in HI LA and AM groups at 1 mo, but only in HI and MED LA groups at
3 mo. Macrophages were decreased in the HI and MED LA groups at 3 mo. AM
and MED LA groups had comparable increases in BAL LDH and protein at 1 and
3 mo. Lung tissue cytokine production and activation of pro-fibrotic and cellular
growth signaling pathways were also comparable between AM and MED LA.
Histopathological examination of the lung found a minimal increase in alveolus in-
flammation, interstitial fibrosis, bronchiolization, and foreign body presence in
both AM and LA groups compared to controls. Alveolus inflammation was most
severe in HI LA rats at 1 and 3 mo compared to all other exposure groups. Only HI
LA rats had bronchiole epithelial hyperplasia, but only 1 mo after exposure. These
results show comparable fibrogenic responses 1 and 3 mo after subchronic exposure
of rats to LA and AM asbestos. Tissue fiber burdens are being measured to support
dosimetry model development of deposition and clearance (Asgharian, SOT 2012:
Jarabek, SOT 2013); comparison of responses between fibers may change based on
dosimetry modeling. (This abstract does not represent US EPA policy)
231 Exposure to Sumas Mountain Chrysotile Induces Similar
Gene Expression Changes As Libby Amphibole but Has
Greater Effect on Long-Term Pathology and Lung Function.
J. M. Cyphert1, 2,  A. Nyska3,  R. K. Mahoney4,  M. C. Schladweiler2,
U. P. Kodavanti2 and S. H. Gavett2. 1Curriculum in Toxicology, UNC School of
Medicine, Chapel Hill, NC; 2EPHD, NHEERL, US EPA, Research Triangle Park,
NC; 3Sackler School of Medicine, Tel Aviv University, Timrat, Israel; 4EMSL
Analytical, Inc., Libby, MT.
This study was designed to provide understanding of the toxicity of naturally oc-
curring asbestos (NOA) including Libby amphibole (LA), Sumas Mountain
chrysotile (SM), El Dorado Hills tremolite (ED) and Ontario ferroactinolite cleav-
age fragments (ON). Rat-respirable fractions (aerodynamic diameter ≤ 2.5 μm)
were prepared by water elutriation and a dose of 1.5 mg/rat delivered via a single in-
tratracheal (IT) instillation. Bronchoalveolar lavage (BAL), gene expression,
histopathology, and lung function were analyzed 1 d, 3 mo, or 15 mo post-instilla-
tion.
One day after exposure, although inducing less acute inflammation than other sam-
ples, LA and SM induced a greater degree of lung injury. A similar trend was also
observed in gene expression profiles, as both LA- and SM-exposed rats differed sig-
nificantly from dispersion media (DM) controls. Changes were suggestive of dys-
regulation of both extracellular matrix and fibrosis pathways. By three months,
most BAL parameters had returned to DM control levels. However, significant
time-dependent fibrosis was evident in rats exposed to LA or SM. By 15 months,
the greatest fibrotic changes were observed in SM-exposed rats; while no fibrosis
was noted in the cleavage-fragment or DM control group
(SM>LA>ED>ON=DM). Consistent with the greatest degree of fibrosis, only SM-
exposed rats exhibited persistent, long-term changes in lung function parameters.
These data demonstrate that, in the rat, SM resulted in more significant long-term
effects after a single IT exposure than LA. This study suggests that there may be
cause for concern for people at risk of being exposed to NOA from the Sumas
Mountain landslide, and highlights the need for further study of sites where NOA
is present. (This abstract does not represent U.S. EPA policy).
232 Lack of Sex Difference in Nasal Glutathione Response to
Naphthalene.
J. A. Cichocki1,  L. S. Van Winkle2,  G. J. Smith1 and J. B. Morris1. 1Toxicology,
University of Connecticut, Storrs, CT; 2Veterinary Medicine, University of California
Davis, Davis, CA.
At concentrations of 10 ppm or greater, naphthalene (NA) is a nasal carcinogen in-
ducing respiratory adenomas in male and olfactory neuroblastomas in female rats,
respectively. The proposed carcinogenic mode of action includes metabolic activa-
tion via CYP450 to an electrophile with subsequent glutathione depletion, escape
of electrophile, and covalent binding. Respiratory and olfactory mucosa are tumor
target sites and both contain NA CYP450 activating capacity; the activity in olfac-
tory exceeds that in respiratory mucosa by 3-fold. To fully define the effect of NA
on nasal glutathione, male and female F344 rats were exposed to 0, 10, or 30 ppm
NA for 1, 4, or 6 hours. Following exposure, nasal olfactory and respiratory tissues
were analyzed for reduced/oxidized glutathione levels (GSH/GSSG). Female con-
trol rats had twice the levels of GSH compared to male controls, but NA exerted
similar effects on GSH in both genders. GSH was depleted at all times; in females,
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respiratory and olfactory mucosal levels were ~45 and 70% of control levels (re-
spectively) after 10 or 30 ppm, an effect that did not correlate with local CYP450
activation rates. Similar trends were seen for male rats. To fully define the concen-
tration response, rats were exposed to 0, 0.5, 1, 3, 10, or 30 ppm NA for 4 hours.
Significant GSH depletion occurred at all exposure levels in respiratory and olfac-
tory mucosa with maximal depletion (about 30 and 60% of control levels, respec-
tively) occurring at or above 1 ppm. Similar trends were seen in both males and fe-
males. NA, at concentrations well below those shown to be carcinogenic, causes
significant depletion of GSH in the nose. The degree of GSH depletion in different
nasal regions does not correlate with activation rates, suggesting that other factors
contribute to the GSH response. No sex difference was observed in GSH response,
suggesting that the sex difference in tumor response cannot be attributed to this
step in the carcinogenic mode of action. (Supported by the Naphthalene Research
Council)
233 Acetaminophen at Low Doses Depletes Airway Glutathione
and Alters Respiratory Reflex Responses.
G. J. Smith,  J. A. Cichocki,  J. E. Manautou and J. B. Morris. Toxicology Program,
University of Connecticut, Storrs, CT.
In the past three decades the prevalence of asthma has more than doubled. The rea-
sons for this increase are unknown. Several hypothetical mechanisms have been
proposed, but none have been proven. The “acetaminophen (APAP) hypothesis”,
first derived from epidemiological data, postulates that pediatric use of acetamino-
phen, by decreasing lung antioxidant defenses, increases asthma risk. APAP (N-
acetyl-para-aminophenol, is an analgesic thought to be safe at therapeutic doses.
APAP is activated by CYP450 to a reactive intermediate that conjugates with, and
depletes, the important antioxidant, glutathione (GSH). To determine if this occurs
in the airways, female C57Bl/6J mice were administered APAP (ip) at non-hepato-
toxic doses (30, 60, or 100 mg/kg) followed by measurement of tissue non-protein
sulfhydryl (NPSH) (~ 90% of which is GSH). A dose and time dependent reduc-
tion in NPSH levels occurred with maximal depletion to ~60% of control at 1hr in
the liver, and at 2hrs in the lung, trachea, and nose. Inhalation exposure to reactive
electrophilic vapors, such as acrolein, stimulates the trigeminal nerve Transient
Receptor Potential A1 (TRPA1) receptor and elicits the sensory irritation response.
(The role of TRPA1 has been confirmed in our model via use of TRPA1 knockout
mice.) Acrolein acts at intracellular N-terminal cysteines of the TRPA1 receptor; we
reasoned that APAP, by decreasing GSH would increase the amount of acrolein
available to interact with TRPA1. APAP (100 mg/kg 1 hr prior to acrolein expo-
sure) increased the irritation response by 75% over that of acrolein alone. Nasal
NPSH levels in acrolein/APAP exposed mice were reduced to 88, 69, and 59% of
control at 30, 60, and 100 mg/kg, respectively. These results suggest that APAP, at
near therapeutic doses, causes depletion of airway GSH to levels sufficient to mod-
ulate acute respiratory responses. These findings lend support to the APAP hypoth-
esis. (Supported by the UConn Presidents Research Award)
234 Upper Respiratory Lesions in Rats Administered
Amiodarone Hydrochloride Solution Orally for 4 Days by
Intraesophageal Dosing: Absence of the Lesion by
Intragastric Dosing.
S. Ogata,  Y. Nezu,  T. Watanabe,  S. Takada,  Y. Tani and W. Takasaki. Medicinal
Safety Research Laboratories, Daiichi-Sankyo, Tokyo, Japan.
Upper respiratory (UR) tract can be damaged by compounds administered orally.
Retrograde exposure of nasal passage to dose formulation from the esophagus has
been suggested as one of the toxicological mechanisms (Damsch et al. Toxicol
Pathol, 2011). However, literatures are limited with this toxicity of orally adminis-
tered drugs in clinical use and the toxicological significance remains unclear.
Amiodarone hydrochloride (AM) is an antiarrhythmic agent administered orally
and intravenously in clinical use. We demonstrated AM induces UR lesions in rats
by gavage dosing for 4 days with a metallic tube. Retrograde exposure of the nasal
passage to dose formulation was suggested because incidence of the lesion was
higher in the posterior nasal passage than the anterior one (Ogata et al., JSTP
Annual Meeting, 2011). Furthermore, irritability of the dose formulation to nasal
epithelium was confirmed based on induction of UR lesions after single intranasal
dosing (Ogata et al., JSOT Annual Meeting, 2012). To examine the effect of the
dosing procedure on the lesions, rats were administered 150 mg/kg AM by a
catheter instead of a metallic tube and the UR lesions were compared histopatho-
logically with those obtained in the former study with a metallic tube. In this study,
no UR lesions were observed in rats given AM with a catheter. Cmax and AUC was
equivalent between dosing procedures with the catheter and metallic tube after a
single dose. The results suggest that the UR lesions in rats given AM by a metallic
tube is not attributable to systemic exposure alone. Dependence on metallic tube
dosing may suggest low toxicological relevance of the UR lesions. Furthermore,
catheter dosing would be an option to evaluate toxicological significance of gavage-
related UR lesion, with equivalent Cmax and AUC obtained by metallic tube dos-
ing, and without possible concern specific to dosing from parenteral or feeding
routes.
235 A High-Fructose Diet Attenuates Adaptation of Nasal
Epithelium to Subacute Ozone Exposure in Mice.
J. Harkema1, 2,  P. Brooks1,  K. M. Allen1, 2,  M. Dereski1,  R. Lewandowski1, 2,
D. Jackson1,  L. Bramble1, 2 and J. G. Wagner1, 2. 1Michigan State University, East
Lansing, MI; 2US EPA Great Lakes Air Center for Integrated Environmental
Research, East Lansing, MI.
INTRODUCTION: Ozone (O3) is a common oxidant air pollutant and inhaled
respiratory toxicant. Repeated inhalation exposures to high ambient concentrations
of O3 cause an adaptive epithelial change, mucous cell metaplasia (MCM), in the
nasal airways of laboratory rodents and nonhuman primates. Since airway mucus is
a known anti-oxidant, MCM with increases in mucus-secreting cells, is a defensive
response of airway epithelium to minimize further oxidant injury caused by inhaled
irritants. Unhealthy diets associated with the metabolic syndrome may adversely af-
fect the host’s normal response to inhaled pollutants. The present study was de-
signed to determine the effect of a high fructose diet (HFD) on the adaptive MCM
response of nasal epithelium to O3. METHODS: C57/Bl6 male mice were ex-
posed to 0 (controls) or 0.5 ppm O3, 4h/day, for 24 consecutive week days. Half of
the mice were fed a normal diet (ND) and the other half were fed a HFD. Mice
were sacrificed 24h after the last day of O3 exposure. Nasal tissues were processed
for light microscopy and morphometric analysis. RESULTS: No exposure-related
nasal lesions were found in filtered air-exposed control mice fed either diet. ND-fed
mice exposed to O3 developed marked MCM in nasal transitional epithelium that
was accompanied by a mucosal influx of eosinophils. In contrast, HFD-fed mice
had minimal nasal MCM and few mucosal eosinophils (85 and 60% less, respec-
tively, compared to ND mice) after O3 exposure. CONCLUSIONS: In mice, a
HFD significantly altered the MCM adaptation of nasal epithelium to O3 expo-
sure. Underlying mechanism(s) responsible for this diet-induced alteration in host
response and its possible human health implications are yet to be determined.
Funded by USEPA RD83479701.
236 Morphometric Assessment of Concentration- and Time-
Dependent Injury in the Nasal Airways of Rats Exposed to
Chlorine Gas.
A. M. Jarabek2,  A. Watkins1 and J. Harkema1. 1Michigan State University, East
Lansing, MI; 2US EPA, Research Triangle Park, NC.
Chlorine (Cl2) is an oxidizing chemical used in industrial processes and as a house-
hold disinfectant. It is also an inhaled toxicant that causes airway injury, ranging
from minor irritation to death, depending on exposure conditions. Due to its toxi-
city and availability, Cl2 is considered a chemical threat agent. Understanding the
airway pathology of inhaled Cl2 is critical to both preventing and treating its toxic-
ity. In rodents, the nose is a primary target organ for inhaled Cl2. Risk assessment
approaches rely on the daily concentration times time (C x t) product for extrapo-
lation of effect levels across studies of different duration (Haber’s Rule). This Cl2
inhalation study in rats was designed to determine the contribution of daily C x t
product and exposure duration to the severity of nasal injury. Cl2 was one of the
gases on which Haber’s Rule was based, but emerging understanding of its pathobi-
ology suggests that the relationship does not hold. We hypothesized that the daily C
x t product does not capture the occurrence and magnitude of Cl2-induced toxic-
ity. Rats were exposed to equivalent combinations of daily C x t inhaled Cl2 for
acute (6 ppm for 1 h; 1 ppm for 6 h; 0.25 ppm for 24 h) or subacute and sub-
chronic (1 ppm, 6h/d for 5d, 10d or 90d) durations. The amount of histochemi-
cally stained mucosubstances in nasal transitional epithelium was morphometri-
cally determined as a quantitative measure of the severity of Cl2-induced mucous
cell metaplasia (MCM). Only rats subacutely or subchronically exposed to Cl2 de-
veloped this lesion and the magnitude of MCM markedly increased with duration.
Our results indicate that daily C x t product alone is not a good estimator of Cl2-
induced MCM and exposure duration is an important determinant of the risk to
Cl2-induced nasal toxicity. Funded by EP-12-C-000052. (The views expressed in
this abstract are those of the authors and do not necessarily represent the views or
policies of the U.S. Environmental Protection Agency.)
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237 Diacetyl-Induced Respiratory and Olfactory Toxicity in
Mice: Influence of Ubiquitination, Gender, and
Dicarbonyl/L-Xylulose Reductase Gene Knockout.
A. F. Hubbs1,  K. L. Fluharty1,  M. P. Goravanahally2, 1,  R. J. Edwards2, 1,
M. L. Kashon1,  L. Sargent1,  R. R. Mercer1,  M. C. Jackson1,  A. M. Cumpston1,
W. T. Goldsmith1,  J. S. Fedan1,  R. D. Dey2,  L. A. Battelli1,  T. Munro1,
W. B. Moyers1,  P. A. Willard1,  K. McKinstry1,  S. Friend1 and K. Sriram1.
1HELD, NIOSH, Morgantown, WV; 2West Virginia University, Morgantown, WV.
The α-dicarbonyl butter flavoring, diacetyl (2,3-butanedione), is associated with
flavorings-related constrictive bronchiolitis in workers who make or use flavorings.
Diacetyl causes protein damage in a process believed to be dependent upon the α-
dicarbonyl structure. A protective response to damaged protein is ubiquitination
with subsequent proteasomal processing. Diacetyl is also metabolized to the less re-
active α-hydroxyketone, acetoin, by dicarbonyl/L-xylulose reductase (Dcxr). We
examined the role of Dcxr and gender on acute toxicity of inhaled diacetyl by ex-
posing Dcxr knockout and wildtype mice of both sexes to diacetyl at target concen-
trations of 0, 100, 200 or 300 ppm for 6 hr. At 1 day post-exposure, endpoints were
semi-quantitative histopathology and morphometric measurement of ubiquitin im-
munofluorescence in nose and lung sections. Ubiquitin was principally localized to
nasal and intrapulmonary airways, increased in large bronchioles at concentrations
≥ 100 ppm, and in the nose at 300 ppm. Diacetyl-induced ubiquitin in the nose
and lung was modified by both gender and Dcxr. In lung histopathology, diacetyl
caused vacuolation of airway epithelium of large bronchioles at concentrations ≥
100 ppm. In olfactory bulb (OB) of male mice inhaling 300 ppm diacetyl, mRNA
expression of inflammatory mediators and olfactory marker protein (Omp), a
marker of olfactory neuron axons, were assayed by real-time PCR. Diacetyl elevated
Il6, Cxcl2, and Tnfa and decreased Omp in OB. The data suggest that ubiquitin
expression is a sensitive biomarker of diacetyl-induced protein damage in airway
epithelium. Further, diacetyl causes neuroinflammation and potential loss of axons
of olfactory neurons in OB, suggestive of neurotoxicity.
238 Subchronic Exposure to Ambient Particulate Matter Induces
Oxidative Stress Responses in Brain Tissue of ApoE-/- Mice.
L. B. Mendez1,  A. J. Keebaugh1,  L. Chen2,  M. Lippmann2 and
M. T. Kleinman1. 1University of California Irvine Irvine, CA; 2New York University,
New York, NY.
Exposure to particulate matter (PM), present in urban environments, has been
shown to induce pro-inflammatory and oxidative stress responses in the central
nervous system (CNS) of apopoliprotein E knockout (ApoE-/-) and Balb/c mice.
In this study oxidative stress responses in different subcellular fractions of the
ApoE-/- mouse brains were evaluated after a subchronic exposure to fine (≤2.5 μm)
concentrated ambient particles (CAPs). Apo E-/- mice were exposed to either CAPs
or particle-free air for 5 hours a day, 5 days per week, for a period of 6 months. The
whole-body inhalation exposures were conducted in two urban cities (Seattle, WA
and Detroit, MI) with distinct sources and chemical composition of PM. Brain tis-
sue was collected after the exposures were completed and analyzed for biomarkers
of oxidative stress. The antioxidant glutathione was reduced in the brains of mice
exposed to CAPs in Michigan but not in Washington. In contrast the lipid peroxi-
dation product 4-hydroxyalkenal (HNE) was significantly increased in the mem-
brane fraction of brain tissue of mice exposed to CAPs in Washington but not in
Michigan. No significant differences were observed in protein carbonyl levels, a
biomarker of protein oxidation, although the levels were slightly higher in the cyto-
plasmic fraction of brain tissue from animals exposed to CAPs when compared to
controls regardless of exposure site. The results suggest that PM from different
sources can modulate oxidative stress responses in a distinct fashion and that differ-
ent subcellular fractions in the brain can be more susceptible to the effects of PM.
239 Co-Exposure to Ultrafine Particulate Matter and Ozone
Causes Electrocardiogram Changes Indicative of Increased
Arrhythmia Risk in Mice.
N. Kurhanewicz1,  R. McIntosh-Kastrinsky1,  L. Walsh2,  A. K. Farraj2 and
M. S. Hazari2. 1University of North Carolina at Chapel Hill, Chapel Hill, NC;
2Environmental Public Health Division, US EPA, Research Triangle Park, NC.
Numerous studies have shown a relationship between acute air pollution exposure
and increased risk for cardiovascular morbidity and mortality. Due to the inherent
complexity of air pollution, recent studies have focused on co-exposures to better
understand potential interactions. This study was designed to evaluate the cardiac
effects of concentrated ambient fine (PM2.5) and ultrafine (UFP) particles with
and without ozone (O3) co-exposure. We hypothesized that ozone co-exposure
would enhance the acute effects of particles, particularly UFP. Conscious unre-
strained C57BL/6 mice implanted with radiotelemeters were exposed by whole-
body inhalation to either 250 ug/m3 PM2.5 or 100 ug/m3 UFP with or without
0.3 ppm O3 (4hrs); separate groups were exposed to either filtered air or O3 only.
Heart rate (HR) and electrocardiogram (ECG) were recorded continuously before,
during and after exposure. Control animals experienced a decrease in HR during
exposure. Neither PM2.5 nor UFP alone caused any HR change; however with O3
co-exposure, HR remained transiently elevated above control levels. Exposure to
UFP+O3 caused decreased PR-interval, a transient increase in QRS, and increased
QTc. PM2.5 alone caused QRS to decrease and O3 alone caused a decrease in QRS
interval and QTc. There were no other significant differences in the ECG parame-
ters measured of any groups. Lastly, only animals exposed to UFP+O3 had an in-
crease in the number of non-conductive P-waves; there were no differences in other
arrhythmia counts. These data suggest that O3 co-exposure might worsen the stress
response to PM, especially UFP, and cause repolarization heterogeneity in the heart,
which increases the risk for arrhythmogenesis. As such, this indicates that the car-
diovascular effects of particle and gas co-exposures are not easily characterized, po-
tentially increasing the complexity of risk assessment. (This abstract does not reflect
EPA policy)
240 An Air-Liquid Interface In Vitro Approach for Studying
Toxic Effects of Exhaust Emissions Using a Heavy Duty
Truck.
I. M. Kooter1,  M. Alblas1,  J. van Triel2,  A. Jedynska1,  M. Steenhof1,
M. Houtzager1 and M. van Ras1. 1EELS, TNO, Utrecht, Netherlands; 2TAP, TNO
Triskelion, Zeist, Netherlands. Sponsor: R. Woutersen.
Classically in vitro diesel exhaust (DE) studies have been performed with sub-
merged cell cultures which are exposed to collected DE particles. Major drawback
of this exposure method is that cells are not exposed to the whole complex and dy-
namic mixture of compounds DE is composed of. In recent years, air-liquid inter-
face exposures have become more widely used, enabling in vitro exposures to mix-
tures of gases and particles. The main objective of this study was to investigate the
feasibility of exposing human lung epithelial cells at the air-liquid interface to com-
plete DE generated by a heavy-duty truck in the state-of-the-art TNO power train
facilities.
Human epithelial lung cells (A549) were directly exposed at the air liquid interface
to DE generated by a heavy-duty Euro III truck (turbo diesel model 2002). The
truck was tested at a steady-state cycle at a speed of ~70 kmh-1 to simulate free-
flowing traffic at a motorway on a transient engine dynamometer. Cells were ex-
posed to DE for 1.5 hours. After a 24 hours post-incubation period, cells were
analysed for markers of oxidative stress (glutathione levels, GSH; heme oxygenase 1
protein levels, HO-1), cytotoxicity (lactate dehydrogenase release, LDH; Alamar
Blue assay) and inflammation (interleukine-8 protein levels, IL-8).
DE exposure resulted in a decreased cell viability (significantly decreased Alamar
Blue levels in the incubation medium and slightly increased LDH levels), and an
increased oxidative stress response (significantly increased HO-1 levels and reduced
GSH/GSSH ratio). However, the pro-inflammatory response seemed to decrease
(non-significant decrease in IL-8).
The results presented here demonstrate that our in vitro exposure approach is in-
deed well suited for testing complex particulate and gaseous pollutant mixtures
from diesel trucks. Our results confirm previous in vitro studies showing cytotoxic-
ity and oxidative stress responses due to DE exposure.
241 Comparative Toxicity of Soy Biodiesel and Diesel Emissions
in Healthy and Allergic Mice.
S. H. Gavett1,  M. A. Williams1,  J. M. Cyphert2, 1,  E. H. Boykin1,
M. E. Daniels1,  L. B. Copeland1,  D. L. Andrews3,  J. H. Richards1 and
I. Gilmour1. 1EPHD, NHEERL, US EPA, Research Triangle Park, NC; 2Curriculum
in Toxicology, UNC School of Medicine, Chapel Hill, NC; 3Research Cores Unit,
Proteomic Research Core, US EPA, Research Triangle Park, NC.
Toxicity from combustion of 100% soy-based biodiesel (B100) was compared to
that of petrodiesel (B0) or a 20% biodiesel / 80% petrodiesel mix (B20) in healthy
and house dust mite (HDM)-allergic Balb/cJ mice. Exhaust from combustion of
B0, B20, or B100 was diluted to target concentrations of 50, 150, or 500 μg/m3 as
determined by real-time Tapered Element Oscillating Microbalance. Studies in
healthy mice showed greater levels of MIP-2 and neutrophils in bronchoalveolar
lavage (BAL) fluid 2 hr after a single 4 hr exposure to B0 compared with exposure
to biodiesel emissions (air control neutrophils = 1x, B0 = 11.9x, B20 = 4.4x, B100
= 2.1x). However these differences were attenuated 24 hr after exposure and no
consistent differences were observed 2 or 24 hr after 5 d (4 hr/d) or 4 wk (5 d/wk)
exposures. Mice sensitized and challenged intranasally with HDM and exposed to
B0, B20, or B100 for 4 wk (5 d/wk) had no emissions-related differences in airway
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hyperresponsiveness to MCh aerosol (determined by total lung resistance in anes-
thetized, paralyzed and ventilated mice). Non-significant trends of decreased
eosinophils and IL-5 in BAL fluid were found after exposure to the 500 μg/m3
concentration of all 3 fuels. Proliferative responses of peribronchiolar lymph node
cells in response to HDM antigens in vitro were not significantly affected by expo-
sure to fuel emissions. We conclude that alternative soy biofuel emissions have com-
parable or reduced adverse effects relative to diesel emissions in healthy mice or a
mouse model of allergic asthma. (This abstract does not represent U.S. EPA policy.)
242 Mechanisms Underlying Anti-Inflammatory Effects of
Selective Diindolylmethane Compounds Using RAW264.7
Cells.
M. F. Afzali1,  G. P. Dooley1,  S. H. Safe2,  W. H. Hanneman1 and M. E. Legare1.
1Center for Environmental Medicine, Environmental and Radiological Health
Sciences, Colorado State University, Fort Collins, CO; 2Center for Environmental and
Genetic Medicine, Institute of Biosciences and Technology, Texas A&M Health
Sciences, Houston, TX.
Chronic inflammation has been associated as the root cause of many serious ill-
nesses including heart disease, Alzheimer’s disease and many cancers. Tolfenamic
Acid (TA) a non-steroidal anti-inflammatory (NSAID) drug has been shown to
have multiple anti-inflammatory effects in RAW264.7 murine macrophages. This
study compares the anti-inflammatory effects of selected diindolylmethane (DIM)
compounds in activated RAW264.7 cells. Results indicate a significant decrease in
production of prostaglandin E (2), D (2) and F (2). In addition, there was a de-
crease expression of mediators of inflammation including cyclooxygenase-2 (COX-
2) in LPS-induced RAW 264.7 cells. These results underscore the potential use for
these DIM compounds in ameliorating inflammation in disease processes and ther-
apeutic regimens.
243 Fyn Kinase Inhibitors Attenuate Manganese Nanoparticles
Induced Neuroinflammatory Signaling in BV2 Microglial
Cells and Primary Microglia.
K. Kanthasamy,  N. Panicker,  A. Ngwa,  C. Jeffery,  M. Neal,  A. Kanthasamy
and V. Anantharam. Iowa State University, Ames, IA.
Manganese (Mn) nanoparticles are currently used in a multitude of industrial and
biomedical applications, including magnetic resonance imaging, high capacity bat-
teries, industrial coatings, biosensors, plastics, ultrahigh density storage devices,
nanofibers, and catalysts. Yet, the potential impacts of these particles on human
health and the environment are not well understood. Notably, the cellular mecha-
nisms underlying Mn nanoparticle induced neurotoxicity are yet to be identified.
Because nanoparticles are similar in size to microbes, we hypothesize that Mn
nanoparticles exposure may activate phagocytic microglial cells to induce a neuro-
toxic response. We exposed BV2 microglia and primary microglial cultures to vari-
ous doses of Mn nanoparticles and then measured inflammatory markers. Exposure
of 0-50 μg/mL Mn nanoparticles to BV2 microglia over 24 hr period resulted in a
dose-dependent increase in iNOS, ROS, TNFα, IL-6, IL-12, and RANTES levels.
Additionally, Mn nanoparticles induced over a threefold increase in ROS genera-
tion in primary microglial cells. Interestingly, Mn nanoparticles also activated the
non-receptor tyrosine kinase Fyn in BV2 microglia. In order to determine whether
Fyn kinase plays a role in the Mn induced inflammatory response, we tested a series
of Fyn kinase inhibitors, including rosmarinic acid, dinitro-rosmarinic acid and caf-
feic acids. Rosmarinic and caffeic acids showed EC50s of 33 and 32 μM, respec-
tively, against Mn induced iNOS activation. In addition, Fyn kinase inhibitors sig-
nificantly blocked Mn-nanoparticle induced TNFα, IL-6, IL-12 release and ROS
generation, indicating that Fyn kinase may play a central role in the Mn nanoparti-
cle neuroinflammation and oxidative stress. Taken together, our results demonstrate
that Mn nanoparticles activate microglial cells via a Fyn kinase dependent mecha-
nism and that Fyn kinase inhibitors may serve as efficacious therapeutic agents
against the metal nanoparticle induced neuroinflammatory insult (supported by
NIH grants ES10586 and NS65167).
244 Proinflammatory Cytokines Present in the Tumour
Microenvironment Induce Phenotypic Change in Colorectal
Cancer Cell Lines.
S. Patel and N. J. Gooderham. Surgery and Cancer, Imperial College London,
London, United Kingdom.
Colorectal cancer (CRC) is the third most common cancer worldwide with
metastatic disease responsible for high mortality rates. The cellular microenviron-
ment is modified during malignancy to support tumor development and metasta-
sis, however mechanisms by which this occurs remain unclear. Previous data from
our laboratory has shown an overexpression of cytochrome P450 (CYP) drug me-
tabolizing enzymes 1B1 and 2E1 and pro-inflammatory cytokines interleukin (IL)
1β and IL6 in neoplastic tissue resected from colorectal cancer patients compared
to matched non-neoplastic controls. In the current study, the presence of these cy-
tokines in the tumour microenvironment was investigated in vitro using two CRC
cell lines HCT116 and SW480, differing in metastatic potential. Treatment with
conditioned media from activated THP1 monocytes, known to secrete an array of
cytokines (including IL6, IL1β and TNFα), was able to induce the invasive proper-
ties of the metastatic cell line HCT116 as measured using wound and migration
chamber assays. Treatment with IL6 alone (0-1000 pg/ml) was also shown to pro-
mote cell motility and invasion in a bell-shaped dose response, characteristic of cy-
tokine function. The non-metastatic cell line SW480 did not respond to the condi-
tioned media and was more resistant to IL6, generating a response only at the
higher doses. Additionally, CYP 1B1 and 2E1 expression were increased following
treatment with the conditioned media as well as with IL6 on its own. Taken to-
gether, these data indicate that pro-inflammatory cytokines, in particular IL6, are
able to cause phenotypic change in CRC cells by inducing CYP expression and pro-
moting ability for the cells to migrate and invade surrounding tissue, thus demon-
strating the important role of tumor microenvironment in disease progression.
245 A Novel Anti-Inflammatory Peptide: Potential Therapy of
Sepsis Induced by Bacterial Endotoxin.
U. Wormser1,  M. Aschner2,  Y. Finkelstein3,  E. Proscura1,  B. Brodsky1 and
E. Shapira1. 1Institute of Drug Research, The Hebrew University, Jerusalem, Israel;
2Department of Pharmacology, Center for Molecular Toxicology, and the Kennedy
Center for Research on Human Development, Vanderbilt University School of
Medicine, Nashville, TN; 3Neurology and Toxicology Service and Unit, Shaare Zedek
Medical Center, Jerusalem, Israel.
Sepsis is a syndrome of infection complicated by vital organ dysfunction and con-
sidered one of the leading causes of mortality in intensive care units. It is character-
ized by a generalized inflammatory response caused by systemic activation of
macrophages and other immune and microvascular endothelidal cells. The present
study demonstrates the efficacy of a novel anti-inflammatory peptide termed
IIIIM1 in ameliorating sepsis induced by the bacterial endotoxin lipopolysaccha-
ride (LPS). A single injection of the peptide 3 days prior to lethal dose of LPS in-
creased animal survival by 60%. Shorter or longer intervals between IIIM1 and LPS
administration reduced peptide efficacy. LPS-induced increase in liver, kidney and
spleen mass was reverted by peptide treatment. Thioglycolate-induced peritonitis,
expressed by increased number of macrophages in the peritoneal cavity, was re-
duced by 38% in IIIM1-treated mice. A bell-shape dose-response effect was ob-
served in both peritonitis and sepsis models reaching maximal effect at 1mg/kg.
Chemical modifications such as omission of the C- or N-terminal residues weak-
ened the anti-inflammatory activities of the peptide. Serum levels of interleukin 6
and tumor necrosis factor alpha were reduced by 32% and 53%, respectively, in
IIIM1-treated mice intoxicated by LPS. Similar cytokine profile was observed in
LPS-activated peritoneal macrophages treated in vitro with the peptide. In view of
these data IIIM1 is a promising drug candidate for treatment of sepsis induced by
bacterial endotoxin.
246 S-Adenosylhomocysteine Inhibits NF-κB Activity in the
Nucleus of Hepatocytes and Confers Sensitivity to TNF
Cytotoxicity.
W. Watson1,  T. Burke1 and C. McClain1, 2. 1Department of Medicine/GI,
University of Louisville, Louisville, KY; 2Louisville VAMC, Louisville, KY.
Chronic alcohol exposure results in liver injury that is largely driven by inflamma-
tory cytokines such as tumor necrosis factor-α (TNF). Hepatocytes are normally
resistant to the cytotoxic effects of TNF, but they become sensitized to TNF by
chronic alcohol exposure. Recently we reported that the decrease in the ratio of S-
adenosylmethionine (SAM) to S-adenosylhomocysteine (SAH) that occurs with al-
coholic liver injury renders hepatocytes sensitive to TNF cytotoxicity. The purpose
of the present study was to determine whether inhibition of the transcription factor
NF-κB contributed to TNF-induced cell death in hepatocytes with high levels of
SAH. HepG2 cells were pre-incubated with a combination of adenosine plus ho-
mocysteine to increase SAH levels. Following stimulation with TNF, viability was
determined by the MTT assay, and activation of the NF-κB pathway was assessed
by measuring degradation of cytosolic IκB, translocation of NF-κB to the nucleus,
and expression of an NF-κB -dependent reporter gene as well as endogenous targets
of NF-κB related to cell death. The results showed that NF-κB was indeed inhib-
ited in cells with high SAH, and that this inhibition occurred at the level of the nu-
cleus; the cytoplasmic inhibitor IkB-α was degraded and NF-κB translocated to the
nucleus in response to TNF stimulation of HepG2 cells in both control cells and in
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cells with high SAH levels. Nuclear NF-κB was not transcriptionally active, how-
ever, when SAH levels were high. As a result, IκB-α was not re-synthesized and NF-
κB remained in the nucleus. It is likely that cross-talk with other transcription fac-
tors is perturbed under these conditions, resulting in still other changes in gene
expression.
247 Cyanobacterium Anabaena sp. Lipopolysaccharide (LPS)
Elicits Release of MIP-α, Interleukin-6, and Matrix
Metalloproteinase-9 from Rat Brain Microglia In Vitro.
D. Macadam1,  M. L. Hall1,  D. Feher2,  P. Williams2 and A. M. Mayer1.
1Pharmacology, Midwestern University, Downers Grove, IL; 2Chemistry and
Biochemistry, University of Hawaii at Manoa, Honolulu, HI.
We recently reported that freshwater cyanobacterium AnabaenaLPS (AnaLPS)
elicited release of superoxide anion (O2
-), thromboxane B2 (TXB2), and tumor
necrosis alpha (TNF-α) by rat microglia (BMG) in vitro (The Toxicologist CD 126
(S-1), 2012). We hypothesized that AnaLPS-activated BMG might additionally re-
lease the cytokine interleukin-6 (IL-6), the chemokine MIP-1α (MIP-1α), and the
matrix metalloproteinase-9 (MMP-9) in vitro. Methods: AnaLPS was prepared by
hot phenol/water extraction. BMG were isolated from neonatal rats, and treated in
vitro with 0.1-105 ng/mL AnaLPS at 35.9 °C for 17 hours. TNF-α, MIP-1α and
IL-6 were determined by Milliplex® MAP rat cytokine/chemokine immunoassays,
and MMP-9 by zymography. Results: MIP-1α, TNF-α, and IL-6 generation were
observed at AnaLPS >10 ng/mL(MIP-1α), and > 1,000 ng/mL, respectively. In
contrast, MMP-9 release was significant at AnaLPS 10,000 ng/mL. Conclusions:
Treatment of BMG with AnaLPS confirmed previously reported TNF-α release,
and futhermore demonstrated for the first time the release of MIP-1α, IL-6 and
MMP-9. Taken together, our results suggest that in vitro proinflammatory media-
tor release by cyanobacterial AnaLPS-treated BMG is complex, including lipids
(TXB2), free radicals (O2
-), cytokines (TNF-α & IL-6), chemokines (MIP-1α) and
enzymes (MMP-9), all of which might play a yet unknown role in the putative im-
munotoxicity of AnaLPS in vivo. Continued investigation of AnaLPS chemistry
and immunotoxicology are currently ongoing in our laboratories. Supported by
Midwestern University and the University of Hawaii at Manoa.
248 Spleen As a Source of Inflammatory Macrophages: Role in
Acetaminophen-Induced Hepatotoxicity.
M. Mandal1,  A. Dragomir1,  H. M. Choi1,  J. D. Laskin2 and D. L. Laskin1.
1Pharmacolgy & Toxicology, Rutgers University, Piscataway, NJ; 2Environmental &
Occupational Medicine, UMDNJ-RWJMS, Piscataway, NJ.
Activated macrophages (MP) have been implicated in the hepatotoxicity of aceta-
minophen (APAP). However, the origin of these cells has not been established.
Splenic monocytes (mono)/MP have been shown to accumulate at inflammatory
sites following tissue injury. In the present studies, we analyzed the contribution of
splenic mono/MP to liver inflammation and injury induced by APAP. Mice were
fasted overnight prior to administration of APAP (300 mg/kg, i.p.) or PBS. Spleen,
bone marrow (BM) and liver were collected 24-96 h later and analyzed by flow cy-
tometry and immunofluorescence for the presence of activated mono/MP. APAP
intoxication was associated with a time-dependent increase in CD11b+Ly6C+
proinflammatory MP, and a decrease in F4/80+ resident MP in the liver; this was
correlated with a significant decrease in CD11b+F4/80+Ly6C-Ly6G- resident
mono/MP in the spleen at 24 and 48 h post APAP, with no effect on BM
mono/MP. Conversely, CD11b+F4/80+Ly6C+ inflammatory mono/MP increased
in the spleen after 48–96 h, but decreased in the BM. To assess the role of splenic
mono/MP in APAP hepatotoxicity, we used splenectomized (spx) mice. APAP-in-
duced hepatotoxicity was significantly decreased in spx mice, as measured by de-
creases in serum transaminases. Histologic evidence of hepatic necrosis was also re-
duced. This was associated with a significant decrease in inflammatory mono/MP
subsets (CD11b+F4/80-Ly6C+ and CD11b+F4/80+Ly6C+) in the BM at 24 h
post APAP when compared to sham control mice. In addition, in spx mice, a de-
crease in CD11b+F4/80+Ly6C+Ly6G+ myeloid derived suppressor cells (MDSCs)
was observed in BM at 96 h post-APAP. Taken together, these results indicate that
splenic mono/MP contribute to early inflammation and hepatotoxicity induced by
APAP. Moreover, removal of the splenic reservoir of mono/MP results in emigration
of MDSCs out of the BM following APAP administration and this may contribute
to tissue repair. Supported by NIH GM034310, ES004738, CA132624,
AR055073, ES007148, ES005022.
249 Exaggerated Hepatotoxicity of Acetaminophen (APAP)
following Administration of Clodronate Liposomes Is
Associated with the Persistence of Classically-Activated
Macrophages in the Liver.
A. Dragomir,  R. Sun,  M. Mili,  J. D. Laskin and D. L. Laskin. Joint Graduate
Program in Toxicology, Rutgers University/UMDNJ-Robert Wood Johnson Medical
School, Piscataway, NJ.
Toxic doses of APAP are known to cause centrilobular hepatic necrosis. Evidence
suggests that classically and alternatively activated macrophages play distinct roles
in APAP-induced hepatotoxicity. In the present studies, we investigated the effects
of macrophage depletion using clodronate liposomes (CL) on activated
macrophage subpopulations accumulating in the liver in response to APAP intoxi-
cation. Mice were administered empty liposomes (EL) or CL (100 μl, i.v.) 48 h be-
fore APAP (300 mg/kg, i.p.) or PBS control. In mice pretreated with EL, increases
in serum transaminases and hepatic necrosis were observed within 24 h; this was
correlated with hepatic accumulation of CD11b+/Ly6C+ classically activated
macrophages in the liver and increased expression of galectin-3, a marker for these
cells. These effects were significantly increased in mice pretreated with CL at 72 and
96 h post APAP, and were associated with increases in CD11b+Ly6C+F4/80-/in-
flammatory monocytes in the bone marrow, suggesting a potential origin of these
cells. In contrast, APAP-induced expression of the alternative macrophage activa-
tion markers Fizz-1 and Ym1, and the anti-inflammatory cytokine IL-10, were sig-
nificantly reduced in livers of mice treated with CL when compared to EL.
Expression of TNF-alpha, the chemokine CCL2, and its receptor CCR2, cytokines
critical for repair of APAP-induced injury, were also decreased in CL-pretreated
mice relative to EL-treated mice. Taken together, these results suggest that increased
APAP-induced hepatotoxicity following macrophage depletion using CL is due, in
part, to persistent accumulation of classically activated macrophages in the liver.
Supported by NIH GM034310, ES004738, CA132624, AR055073 and
ES005022.
250 Bone Marrow Inflammation Precedes Delayed
Myelosuppression from Hexahydro-1-Nitroso-3, 5-Dinitro-1,
3, 5-Triazine (MNX) Induced in Rats.
S. Jaligama1,  V. M. Kale2,  M. S. Wilbanks3,  E. J. Perkins3 and S. A. Meyer1.
1Toxicology, University of Los Angeles Monroe, Monroe, LA; 2College Pharmacy,
Roseman University Health Science South Jordan, UT; 3US Army Engineer Research
& Development Center, Vicksburg, MS.
MNX (hexahydro-1-nitroso-3, 5-dinitro-1, 3, 5-triazine), an environmental ni-
troreduced product of munitions RDX, contaminates military sites. Our previous
studies identified bone marrow (BM) and spleen as hematological targets of acute
oral exposure to MNX in rats in the form of splenic hemosiderosis and loss of BM
Granulocyte Macrophage Colony Forming Cells (GM-CFCs). To address whether
delayed loss of GM-CFCs and blood granulocytes (NOAELs 24, 47 mg/kg resp) at
14 days after exposure to MNX is due to persistence of early hematological effects
or is late-onset due to required expression period, female Sprague-Dawley rats were
orally gavaged with MNX from 0 to 94 mg/kg and different toxicological end-
points were evaluated over a time course at 2, 7, 10, 12, and 14d. Significant de-
crease in relative spleen weight and increased macrophage activity in splenic red
pulp at 2d (≥ 47 mg/kg); and persistent splenic hemosiderosis at 2d (≥ 47 mg/kg),
7d (NOAEL 24 mg/kg) and 14d were observed. A significant increase in blood
granulocytes and circulating levels of RANTES, a leukocyte chemokine, indicate
that an acute inflammatory response occurs at 2d after exposure to MNX. Also,
persistent BM macrophage infiltration was observed in MNX (94 mg/kg) treated
rat iliums (24h, 2d and 10d) and activation of NFkB signaling pathway in BM cells
was evident at 10d. Further, significant increase in adherent BM mesenchymal stro-
mal cell colonies constituting macrophages, endothelial cells and fibroblasts was ob-
served in MNX (94 mg/kg) treated rats. Collectively, these data suggest that while
splenic effects are early onset and persist for at least 14d, myelosuppression is de-
layed until 10d presumably due to development of inhibitory effects of preceding
BM inflammation on myelopoiesis. (Support: DoD/CDMRP, US Army Corps of
Engineers)
251 Reversibility of Prostate Fibrosis in Response to Bacterial-
Induced Chronic Inflammation.
L. Wong,  P. Hutson and W. A. Bushman. University of Wisconsin-Madison,
Madison, WI.
Introduction: Benign prostatic hyperplasia (BPH) and its associated lower urinary
tract symptoms (LUTS) are common in aging men. Chronic inflammation and in-
creased stromal collagen are common features observed in BPH. Recent study has
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shown that the collagen content is correlated with the degree of LUTS and tissues
stiffness, suggesting a role of prostate fibrosis in BPH/LUTS. Using the bacterial-
prostatic inflammation mouse model, we have shown that prostatic inflammation
induces collagen content. The goal of this study is to investigate the reversibility of
prostate fibrosis during bacterial-induced chronic inflammation.
Methods: We transurethrally instilled uropathogenic E-coli into adult
C3H/HeOuJ male mice to induce chronic inflammation in the prostate. Naïve,
saline and E-coli instilled animals were sacrificed after 1 month. Other animals
were treated with Baytril in drinking water to resolve the infection and underwent
an additional 2-month resolution. The prostate tissues were used for bacterial cul-
ture and measurement of hydroxyproline level as collagen content using high-pres-
sure liquid chromatography.
Results: The uropathogenic E-coli was present in the prostates of all E-coli infected
animals after 1-month post-instillation and treatment of Baytril completely re-
solved the bacterial infection. We further found that hydroxyproline content in the
prostates was significantly increased in the E-coli infected mice compared to the
saline. Infected mice treated with Baytril with an additional 2-month resolution
had a significant increase in hydroxyproline level in the prostates compared to the
saline, but the level was significantly lowered to the E-coli infected prostates. 
Conclusion: This study suggests that prostate fibrosis in response to bacterial-in-
duced chronic inflammation is only partially reversed. Given that prostate fibrosis
is suggested to strongly associate with the loss of prostate compliance and the de-
velopment and progression of BPH/LUTS, an understanding on the mechanisms
of the irreversible collagen deposition is required for improvement of therapeutic
treatment.
252 Topical Application of TRPV1 Antagonist Effectively
Inhibits PTD-Induced Sensitization in Murine Skin.
K. Lim,  K. Jung,  W. Jang and Y. Park. AMOREPACIFIC.Co. R&D Center,
Gyeonggi-do, Republic of Korea.
Transient receptor potential vanilloid type 1 (TRPV1) is expressed in the skin and
plays a role in migration of dendritic cells to lymph nodes in allergic diseases.
However, it has been unaddressed if TRPV1 blockade can suppress chemical-in-
duced contact dermatitis. 1,4-toluenediamine (PTD) and 1,4-phenylenediamine
(PPD) are widely used as permanent hair dye but repeated use of PTD can induce
contact hypersensitivity by the induction of regulatory T cells in the draining
lymph node and of inflammation in the exposed skin. In this study, the inhibitory
effect TRPV1 antagonist, PAC-14028 on PTD-induced dermatitis and dendritic
cell (DC) function was explored. This study was performed according to the
method of nonradioactive local lymph node assay using flow cytometry. Groups of
mice (N=4~5) were treated with 25 ul of the PTD alone, PAC-14028 alone, PTD
and PAC-14028 or vehicle alone on the dorsal area of both ears daily for 3 consec-
utive days (Day 1, 2 and 3) and were sacrificed at Day 6. The local response was
measured by ear swelling and by histological examinations (H&E staining). We also
used immunohistochemistry staining and western blot assays to evaluate the activa-
tion of specific inflammation makers and key mediators of signaling pathway in the
mouse skin. The DCs migration markers in the draining lymph nodes were
analysed by flow cytometry. TRPV1 antagonist suppressed PTD-induced edema in
skin and proliferation of lymphocyte and inhibits the migration of CD11c+ DC
and CD207+ Langerhans cells (LC) to the draining lymph nodes (LNs).
253 Comparative Inflammatory Effects of Differential Particulate
Matter Species in an OVA-Sensitization and Challenge
Model.
M. A. Williams1,  M. J. Daniels1,  E. H. Boykin1,  T. Smith1,  N. Hykal-Coates2,
L. B. Copeland1,  D. L. Andrews2,  J. H. Richards1 and I. Gilmour1.
1Environmental Public Health Division, US EPA, Research Triangle Park, NC;
2Research Core Unit, US EPA, Research Triangle Park, NC.
Exposure to respirable ambient particulate matter (APM) provokes allergic immu-
nity that may also occur on exposure to environmental diesel exhaust particles
(eDEP) or emission source DEP (cDEP). Our hypothesis tested whether APM,
eDEP or cDEP provide immune adjuvancy in an antigen (OVA) sensitization and
challenge model. We assayed for oxidative stress, inflammatory and cytokine ana-
lytes in BALF,assay of lung infiltrating cells, assay of serological analytes (total IgE,
IgG1, IgG2a), and antigen-specific recall responses of primary lymph node cells
(pLNC). All PM species increased markers of airway or allergic inflammation.
However, eDEP or cDEP sensitized mice had lower levels of superoxide dismutase
as compared APM, without affecting other oxidative stress markers (p<0.005). By
contrast, all PM species enhanced eosinophil and neutrophil infiltration to the lung
as compared saline or OVA alone (p<0.001). These effects for APM (p<0.005) and
cDEP (p<0.05) were concordant with enhanced levels of pro-Th2 cytokines like
IL-5 in BALF. Assay of isotype class-switching was less informative. All PM species
partially augmented total IgE as compared saline, but not when compared to LPS
control or each other, and dampened secretion of IgG2a (p=0.07) and IgG1
(p=0.059) as compared low-dose LPS/OVA. In OVA-specific recall responses,
pLNC proliferation was enhanced in mice sensitized with eDEP and particularly
cDEP, which provoked robust IL-5 and IL-13 secretion (p<0.01). We conclude that
all PM species provoked airway and allergic inflammation. However diesel PM, and
particularly cDEP were most effective in sensitizing mice and driving Th2-type cy-
tokine and OVA-specific responses ex vivo. This study supports the realization that
respirable PM differentially provoke allergic inflammation, and provides new in-
sights on signaling changes contributing to these effects. This abstract does not re-
flect US EPA policy.
254 Role of Ortho-Phthalaldehyde in IgE-Induced Airway
Hyperresponsiveness As a Hapten and an IgE-Selective
Adjuvant-Like Activity in Mice Treated with Ovalbumin.
Y. Ishihara1,  M. Nakao1,  T. Morinaga1,  G. Hasegawa1,  M. Yamaguchi1,
T. Nishikawa2 and H. Kawashima3. 1Public Health, Kurume University, Kurume,
Japan; 2Surgical Pathology, Tokyo Women’s Medical University, Tokyo, Japan;
3Microbiology & Immunology, University of Shizuoka, Shizuoka, Japan.
[Purpose] We previously reported that ortho-phthalaldehyde (OPA) disinfectant
induces acute inflammation and enhances allergen-specific IgE production without
allergen-specific IgG in ovalbumin (OVA)-sensitized mice. However, etiology of
this disorder is not fully understood. The purpose of this study is to explore rela-
tionship between airway hyperresponsiveness and host immunity in OPA-treated
OVA sensitized mice. [Methods] Female ICR mice were divided into five groups;
OPA + OVA group, aluminum hydroxide (Alum) +OVA group, OPA group, OVA
group, and Control group. The mice were sensitized twice with OVA and chal-
lenged with OVA inhalation one day prior to testing airway responsiveness to
acetylcholine (Ach) under anesthesia. [Results] Airway hyperresponsiveness to Ach
was observed in the OPA + OVA and Alum +OVA groups compared with the re-
sponses observed in the OPA, OVA and control groups. OPA-specific IgE and IgG
antibodies and OVA-specific IgE antibody increased markedly, whereas OVA-spe-
cific IgG antibody did not increase in the OPA + OVA group due to the masking of
OVA’s antigenicity for IgG production by the aldehyde group of OPA.
[Conclusion] These results strongly suggest that OPA functions as both a hapten
and an allergen-specific, IgE-selective adjuvant, leading to significant airway in-
flammation and hyperresponsiveness to Ach.
255 Dual Oxidase Modulates Airway Neutrophil Recruitment in
Allergic Airways.
S. Chang1, 2,  A. L. Linderholem2,  H. Grasberger3 and R. W. Harper2.
1Pharmacology Toxicology, University of California Davis, Davis, CA; 2Internal
Medicine, University of California Davis, Davis, CA; 3Internal Medicine, University
of Michigan, Ann Arbor, MI.
Introduction/Rationale: Reactive oxygen species (ROS) plays an important role in
maintaining lung homeostasis. However disregulation of ROS, specifically hydro-
gen peroxide, has been linked to respiratory diseases such as chronic obstructive
pulmonary disease, cystic fibrosis and asthma. Dual Oxidase (DUOX) is an
NADPH oxidase, whose function is regulated production of hydrogen peroxide, lo-
calized to the lung epithelium. DUOX activity and expression are upregulated by
IL-4 and IL-13 which are key cytokines in allergic airways. Interestingly, the role of
DUOX in asthma has never been evaluated in vivo. The objective of this study was
to determine the role of DUOX derived hydrogen peroxide in asthmatic airways,
using a DUOX system knock out mouse. Methods: Wild-type and dual DUOX
A1/DUOX A2 knockout mice were sensitized with ovalbumin (day 0 and 14) and
subsequently exposed to aerosolized ovalbumin for a period of 2 weeks to evaluate
the role of DUOX in allergic asthma. Measurement of forced expiratory nitric
oxide concentrations, airway compliance, live cell counts, brochoalveolar lavage
fluid (BALF) cell differentials and histology were performed and compared be-
tween the two groups. Results: Wild-type mice with functional DUOX had a
greater influx of neutrophils than knockout mice when subjected to ovalbumin as
observed in BALF as well as semi quantitative counts in lung tissue. Conclusion:
These findings suggest that DUOX derived hydrogen peroxide has an important
role in signaling neutrophils into allergic airways. 
This research was supported by NIH(R01 HL 085311& R01 HL085311-S1).
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256 Epithelial-Derived Hypoxia Inducible Factor-1/2α Plays a
Role in Programming the Innate Immune Response of the
Lung.
K. Greenwood,  S. P. Proper,  Y. Saini,  D. Jackson-Humbles,  J. G. Wagner,
J. Harkema and J. J. LaPres. Michigan State University, East Lansing, MI.
Allergic airway disease (AAD) involves a complex interaction between various cell
types within the lung, including inflammatory and epithelial cells. The inherent in-
flammation of AAD also leads to localized hypoxia. Communication between in-
flammatory cells, such as macrophages and T cells, and the epithelia in these hy-
poxic conditions is hypothesized to be critical to the progression of AAD. To
characterize the role of epithelial-mediated hypoxia-induced signaling in AAD, ep-
ithelial and lung-specific conditional hypoxia inducible factor-1α (HIF1α),
HIF2α, and HIF1α and HIF2α (HIF1/2α) knockout mouse models were created.
Previous research in our lab has shown that the HIF1α-deficient (HIF1αΔ/Δ) mice
exhibit an exacerbated response to the ovalbumin (OVA) model of AAD. To deter-
mine the role of HIF2α in AAD and characterize possible compensation between
the two HIFs following OVA challenge, recombination was induced early in post-
natal development and control and HIF-deficient mice were then sensitized/chal-
lenged with OVA via a standard paradigm. In contrast to the HIF1αΔ/Δ model,
the HIF2αΔ/Δ mice displayed no increase in eosinophil infiltration, T helper 2 cy-
tokines, or airway resistance following OVA treatment. The HIF2αΔ/Δ mice ap-
pear phenotypically identical to OVA-treated littermate controls. Interestingly,
when HIF1/2αΔ/Δ mice were sensitized/challenged with OVA, these animals ap-
peared similar to HIF2αΔ/Δ and littermate controls, suggesting that HIF2α plays
a role in the exacerbated inflammation observed in the HIF1αΔ/Δ model. These
data suggests that epithelial-derived HIF signaling plays an important role in estab-
lishing the immunity of the lung and that a proper balance between the two HIFs
is required for a normal inflammatory response. The observed changes in the in-
flammatory response of the various models also suggest that early life exposures that
alter the expression or function of HIF1α and/or HIF2α might have profound ef-
fects on the lung’s response to toxicant challenge upon reaching adulthood.
257 ODSH Improves Survival in PA Pneumonia by Increased
Bacterial Clearance and Reduced Lung Injury.
L. Sharma1,  J. Wu1,  V. Patel1,  R. Sitapara1,  N. Rao3,  T. P. Kennedy4 and
L. L. Mantell1, 2. 1St. John’s University, New York, NY; 2The Feinstein Institute for
Medical Research, Manhasset, New York, NY; 3University of Utah, Salt Lake City,
UT; 4Pulmonary and Critical Care Medicine, Georgia Health Sciences University,
Augusta, GA.
Nosocomial Pneumonia (NP) or Hospital Acquired Pneumonia (HAP) is associ-
ated with infections originated from the hospital borne pathogens. Resistance
against antimicrobial agents is the most common feature of these infections which
results in persistent infection leading to high mortality rates and therapeutic costs.
Due to the involvement of multidrug resistant bacteria, alternative or supportive
therapies are required. Pseudomonas aeruginosa (PA), gram negative pathogen, is
one of the prominent pathogens associated with NP. PA pneumonia increases the
secretion of inflammatory cytokines, neutrophil infiltration and subsequent lung
damage. HMGB1, one of the inflammatory cytokines, has been shown to play im-
portant roles in PA lung infections. HMGB1 can compromise innate immunity by
impairing phagocyte function mediated by its receptors TLR2 and TLR4. Heparin,
a well-known anticoagulant, exhibits anti-inflammatory properties that are inde-
pendent of anticoagulant property. 2-O, 3-O –desulfated heparin (ODSH), he-
parin, has been proven to have anti-inflammatory properties with minimal antico-
agulation effect. ODSH has been shown to reduce lung injury in sterile
inflammation and reducing inflammatory lung damage. In this study, we examined
the effect of ODSH on PA pneumonia. Here we demonstrate that ODSH not only
reduces PA-induced lung injury, illustrated by reduced total protein content in lung
lavage fluids, it also significantly increases bacterial clearance. This improved lung
injury and bacterial clearance resulted in marked improvement in overall survival of
the mice with PA infection. The attenuation in lung injury and improved bacterial
clearance was associated with reduced airway HMGB1. In addition, ODSH in-
hibits binding of HMGB1 with receptors TLR2 and TLR4. These data indicate a
novel role of ODSH in the treatment of PA pneumonia.
258 Role of Mannose-Binding Lectin in the Pulmonary Response
to Ozone.
J. Ciencewicki,  K. E. Gerrish,  P. Bushel and S. R. Kleeberger. NIEHS, Research
Triangle Park, NC. Sponsor: D. Harbourt.
Ozone is a common pollutant and a potent oxidant in many areas of the country.
Inhalation causes airway hyperreactivity, lung hyperpermeability, inflammation and
cell damage in humans and laboratory animals, and exposure to ozone has been as-
sociated with exacerbation of asthma, altered lung function, and mortality.
Currently the mechanisms of ozone-induced lung injury and differential suscepti-
bility are not fully understood. Ozone exposure induces a number of pro-inflam-
matory events in the lung, some of which are mediated by the innate immune sys-
tem. We hypothesized that mannose binding lectin (MBL), which plays a central
role in the activation of the complement pathway of innate immunity, is needed to
elicit some of the pro-inflammatory events caused by ozone-mediated activation of
the innate immune system. Wild-type (Mbl+/+) and MBL deficient (Mbl-/-) mice
were exposed to ozone (0.3 ppm) for 24, 48, and 72 hours. Compared to Mbl+/+
mice, significantly less neutrophilic infiltration and the neutrophil attractants
CXCL2 (MIP-2) and CXCL5 (LIX) were found in the lungs of Mbl-/- mice ex-
posed to ozone. We then used mRNA microarray analyses to gain additional mech-
anistic insight to the role of MBL in this model. We identified significant differ-
ences in expression response profiles and networks at baseline and after exposure
between Mbl+/+ (WT) and Mbl-/- (KO) mice, providing potential roles for MBL
at steady-state and in the innate immune pulmonary response to ozone inhalation.
For example, we found gene enrichment for lipid metabolism and hematological
disease at baseline, and innate immunity and cell morphology after ozone exposure.
These novel findings demonstrate that MBL function contributes to ozone-in-
duced pulmonary inflammation and may be mediated through the activation of the
complement cascade. 
Research supported by intramural research program at NIEHS.
259 Anti-Inflammatory Effect of Imipramine in Silica-Induced
Inflammation.
R. Biswas,  R. Hamilton and A. Holian. Center for Environmental Health Sciences,
University of Montana, Missoula, MT.
Environmental or occupational exposure to silica particles over an extended period
of time is associated with the development of progressive inflammation and silico-
sis. Silicosis remains a prevalent health problem throughout the world. Currently,
treatment choices for silicosis are limited and at present there is no cure for the dis-
ease. Therefore, it is essential to investigate potential therapeutic agents in silicosis
treatment. Imipramine (IMP) is an approved tricyclic antidepressant, and a lysoso-
motropic agent. The aim of this study was to determine the protective effect of IMP
on silica-induced inflammation and determine the mechanism by which IMP in-
hibits inflammation. C57BL/6 wild-type (WT) mice were used throughout the
study. The protective effect of IMP was evaluated in vitro and 24 hours and 42 days
following silica exposure in vivo. Silica was administered once a week for 4 weeks
and IMP was delivered for 42 days via osmotic pumps implanted subcutaneously.
Collagen levels were determined by hydroxproline content. IMP treatment de-
creased collagen levels compared to the silica-exposed group. Lung histopathology
improved on IMP treatment. WT mice were pretreated with IMP 25 mg/kg, and
subsequently exposed to silica 1mg/kg during the in vivo acute study. IMP inhib-
ited silica-exposed neutrophil infiltration, IL-1β and IL-6 in the lavage fluid. For in
vitro experiments, WT alveolar macrophages (AM) were pretreated with 25 μM
IMP and subsequently exposed to LPS (20 ng/ml) and silica (100 μg/ml). IMP was
highly effective in blocking silica-induced inflammasome activation without any
toxic effects on AM. The effect of IMP on acid sphingomylinase (A-SMase) was de-
termined since A-SMase has been associated with acute lung injury. A-SMase was
significantly inhibited by IMP treatment. The results demonstrate that IMP in-
hibits silica-induced inflammation and IMP may be exhibiting anti-inflammatory
properties through its effect on lysosomes. The work was supported by NIH grants
P20 RR017670 and R01 ES 15294
260 Higher Susceptibility of Male Mice to Diesel Exhaust
Neurotoxicity.
L. G. Costa1, 2,  G. Giordano1,  A. Engstrom1,  C. S. Weldy3,  F. Farin1 and
T. J. Kavanagh1. 1Department Environmental Occupational Health Sciences,
University of Washington, Seattle, WA; 2Department of Neuroscience, University of
Parma, Parma, Italy; 3Division of Cardiology, University of Washington, Seattle, WA.
In addition to increased morbidity and mortality caused by respiratory and cardio-
vascular diseases, air pollution may also contribute to CNS diseases. Traffic-related
air pollution is a major contributor to global air pollution, and diesel exhaust (DE)
is its most important component. DE contains more than 40 toxic air pollutants
and is a major constituent of ambient particulate matter (PM), particularly of ul-
trafine-PM. Limited information suggest that exposure to DE may cause oxidative
stress and neuroinflammation in the CNS. We hypothesized that males may be
more susceptible than females to DE neurotoxicity, because a lower level of expres-
sion of paraoxonase 2 (PON2), an anti-oxidant mitochondrial enzyme. Acute ex-
posure to DE (250 ug/m3 for 6h) causes significant oxidative stress (lipid peroxida-
tion as determined by the malonyldialdehyde assay) in several brain regions
(particularly the olfactory bulb, the hippocampus and the cerebellum) and the ef-
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fect is consistently higher in male mice than in females. A number of pro-inflam-
matory cytokines (IL-1 alpha, IL-1 beta, IL-3, IL-6, TNF-alpha) were also meas-
ured in olfactory bulb and hippocampus by the Luminex xMAP® technology.
Levels of all cytokines increased significantly in both brain regions upon acute DE
exposure, and in most cases gender differences were present. For example, in the
hippocampus, levels of IL-6 increased by 18-fold and 8-fold in male and female
mice, respectively. Such differences may also be due to a gender-dependent, differ-
ential expression of PON2, which has been shown to have anti-inflammatory ac-
tions in the periphery, and may have similar effects in the CNS. These findings in-
dicate that acute exposure to DE causes oxidative stress and neuroinflammation in
several brain regions, and suggests that gender plays an important role in modulat-
ing susceptibility to DE neurotoxicity, with male mice being more sensitive (Supp.
in part by DEOHS).
261 Pilot Study Using an Alzheimer’s Disease Animal Model to
Assess the Role of Particulate Matter Exposure in
Neuroinflammation and Amyloid Production.
S. Lung1,  L. B. Mendez2 and A. Campbell1. 1Pharmaceutical Science, Western
University of Health Science, Pomona, CA; 2Medicine, University of California Irvine,
Irvine, CA.
Alzheimer’s Disease (AD) is a neurodegenerative disease that is associated with se-
vere memory loss and dementia. One of the major pathological markers for AD is
formation of senile plaques, which are composed of amyloid beta peptides derived
from amyloid precursor protein (APP). In this pilot study, we examined the effect
of exposure to fine particulate matter (PM2.5) on proinflammatory markers and
potential association with enhanced amyloid levels. Mice with the human Swedish
mutation (Tg2576) in the APP gene and wild-type control animals were exposed to
filtered air or PM2.5. Brain APP levels, NF-κB activation, and IL-1β levels were
determined. Microglia and TLR2 activation in hippocampus were demonstrated.
Brain levels of Aβ40 and Aβ42 were also assessed. Results showed APP levels were
expressed only in brains of Tg2576 mice and not in wild type animals. The Aβ40
and Aβ42 brain level after PM2.5 exposure showed upregulation. NF-κB activa-
tion was also increased in the brain of both wild type and transgenic animals after
PM2.5 exposure. IL-1β increased only in transgenic mice exposed to PM2.5. In
transgenic animals, the hippocampus region showed enhanced staining for both
TLR-2 and microglia after PM2.5 exposure compared to filtered air. The results of
our pilot study suggest PM2.5 exposure may lead to the activation of innate im-
mune response mediated by NF-κB pathway. The upregulation of Aβ levels in the
brain of PM2.5 exposed animals suggest that there could be a link between PM2.5
exposure and enhancement of amyloid production. The results of this pilot project
justify the need for a more extensive study assessing the effect of particulate matter
on potentiating amyloid pathology in AD.
262 Subchronic Exposure to Deltamethrin Causes Hippocampal
Neuroinflammation and Deficits in Learning and Memory.
M. M. Hossain and J. Richardson. Environmental and Occupational Medicine,
Robert Wood Johnson Medical School, Piscataway, NJ.
Previously, we have reported that in vitro exposure of neuroblastoma cells to
deltamethrin causes apoptosis through the ER stress pathway, leading to calpain
and caspase-3 activation (Hossain and Richardson, 2011). Others have found that
acute high-dose deltamethrin (12.5 mg/kg) exposure causes hippocampal apoptosis
in adult rats (Wu and Liu, 2000). However, little is known about the effects of
longer-term lower level exposure that does not result in acute poisoning. Here, we
investigated the effects of deltamethrin at a dose of 3mg/kg every 3 days for 2
months on hippocampal ER stress, neuroinflammation, and learning and memory
in adult mice. Deltamethrin treatment did not result in over toxicity. However, we
observed increased spectrin cleavage in the hippocampus of deltamethrin-treated
mice, indicating activation of calpain. Deltamethrin also significantly increased the
hippocampal mRNA expression of glial fibrillary acidic protein (GFAP; 23%) and
the pro-inflammatory cytokines tumor necrosis factor-alpha (121%) and
Interleukin-1 alpha (96%), indicating an ongoing neuroinflammatory process.
Finally, we found that subchronic deltamethrin exposure causes profound deficits
in hippocampal-dependent learning and memory in the Morris water maze, which
was accompanied by a decreased mRNA expression (30%) and protein level (39%)
of nerve growth factor (NGF), respectively. Together, these data suggest activation
of the ER stress pathway and neuroinflammation by repeated exposure to
deltamethrin may contribute to the down-regulation of NGF in the hippocampus,
which may result in subsequent impairment in learning and memory in mice.
Supported by NIH ES015991 and ES005022.
263 Ambient Endotoxins Possible Links to Toll-Like Receptors
Gene Polymorphisms in Puerto Rican Asthmatics.
M. G. Ortiz-Martínez1, 2 and B. D. Jiménez-Vélez1, 2. 1Biochemistry, University of
Puerto Rico-Medical Sciences Campus, San Juan, Puerto Rico; 2Center for
Environmental and Toxicological Research, University of Puerto Rico-Medical Sciences
Campus, San Juan, Puerto Rico.
African Dust Storms also referred as Events (ADE) are believed to be associated to
high prevalence of respiratory diseases such as asthma in Puerto Rico (PR).
Endotoxins (ENX) have been previously reported as constituents associated with
ADE particulate matter (PM). These ENX and related compounds are known to
promote pro-inflammatory responses in lung cells and in susceptible individuals.
Since ENX have been shown to work through the following receptors, we have
evaluated a number of Toll-like receptors (TLR2/4) as well as the co-receptor,
Cluster of Differentiation 14 (CD14) single nucleotide polymorphisms (SNPs) in
the Puerto Rican population. Contradictory results exist, which link SNPs to in-
creased asthma prevalence and/or risk in some populations. A total of 6 SNPs have
been evaluated in the Puerto Rican asthmatic population. TLR2 (+596C/T,
+6686T/A, +399A/G), TLR4 (+896A/G, +1196C/T) and CD14 (+1188C/G)
SNPs were measured in 62 asthmatics and 59 non-asthmatic controls using
Taqman® probes through a genotyping assay (Real Time PCR). Minor allele fre-
quencies (n=121) were determined for those variants as 0.35, 0.37, 0.32, 0.07, 0.06
and 0.09, respectively. Two (+596C/T and +399A/G) TLR2 SNPs showed to be
more represented in the asthmatic group (89% and 65%), combining C/T plus
T/T and A/G plus G/G genotypes, respectively. TLR4 SNP +896A/G analysis re-
vealed only 1 G/G genotype (2%) on the asthmatic group. The CD14 SNP was
similarly represented in both groups. The identification of specific TLR SNPs will
be valuable to understand action mechanisms of environmental ENX, which have
been associated with the triggering of asthma in PR. Moreover, it will help to reveal
the relevance of TLR pathway genes as potential candidates for gene-environment
interactions in Puerto Ricans. Study approved by the UPR-MSC-IRB
(#A8570111) and supported by MBRS-RISE Grant R25GMO61838.
264 Cytotoxicity Effect and Utilization of Mytilus edulis Shell in
the Diet of Clarias gariepinus.
A. A. Idowu1 and S. O. Ayoola2. 1Aquaculture and Fisheries Management, Federal
University of Agriculture, Abeokuta, Abeokuta, Nigeria; 2Marine Sciences, University
of Lagos Akoka, Lagos, Lagos, Nigeria.
Five isonitrogenous diets (100% DCP compounded feed,75% DCP Compounded
feed and 25% Mytilus edulis shell, 50% DCP Compounded feed and 50% Mytilus
edulis shell,25% DCP compounded feed and 75% Mytilus edulis shell,100%
Mytilus edulis shell were formulated. The Mytilus edulis shell was washed, sun
dried for 5 days and later grinded and added to the feed and were fed to 150 juve-
niles of Clarias gariepinus which were distributed into 15 different plastic bowls.
Ten specimens were stocked in each of the plastic bowls and they were fed twice
daily for an experimental period of 12 weeks. In the cytotoxicity, five fishes were
picked randomly from each triplicate and their blood collected carefully with sy-
ringe from the anal region and kept in sample bottles. The blood was smeared on
slides and were air-dried for 24 hours, fixed in ethanol for 20 minutes and followed
by 10% Giemsa staining. Each fish had 2000 erythrocytes examined and to detect
micronuclei in erythrocytes, the slides were analysed using a 1000X oil-immersion
lens. This implies that Mytilus edulis shell can be utilized best with compounded
feed at a ratio of 50 to 100%. Therefore, this ratio should be adopted by fish farm-
ers whose intention is to increase the calcium mineral level of their fishes. The ob-
tained results for micronucleus reveals that T1 (25% MES) had the highest number
of micronucleated cells while the rest (T2, T3, and T4 ) including the control had
no significant differences. Results for BN reveal that T1 having the highest number
of BN and T0 (control) having the least number of BN. While in LB, BL, and NT
there were no significant differences in all the treatments. From the results it
showed that Mytilus edulis shell (MES) has no toxins since there are less micronu-
cleus and other aberrations in the haematopoietic cells. Hence, Mytilus edulis shell
can be included from 50 – 100%.
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265 Using a Sequence Homology-Based Predictive Strategy to
Address Current Demands for Focused Toxicity Testing in
Ecological Risk Assessment.
C. LaLone1,  D. L. Villeneuve1,  L. D. Burgoon2,  C. Russom1,  H. Helgen4,
J. Berninger3,  J. Tietge1,  M. Severson1,  J. Cavallin5 and G. T. Ankley1. 1US EPA,
Duluth, MN; 2US EPA, Research Triangle Park, NC; 3National Research Council,
Duluth, MN; 4Computer Sciences Corporation, Duluth, MN; 5ORISE Research
Participation Program, Duluth, MN.
The lack of resources available for comprehensive toxicity testing, international in-
terest in limiting the quantity of animals used in testing, and a mounting list of an-
thropogenic chemicals produced world-wide have led to the exploration of innova-
tive means for identifying chemicals that are potentially hazardous to the
environment and its inhabitants. Predictive toxicological approaches, which utilize
publically available, a priori, knowledge of a chemical and its known molecular, cel-
lular, or whole organism interactions, show promise for focusing current toxicity
testing strategies. Using modern bioinformatic techniques, we have created a com-
putational tool, which mines the extensive genomic and proteomic sequence repos-
itories available through the National Center for Biotechnology Information and
strategically compares homology metrics associated with primary and secondary
protein sequences/structural domains across taxa. These comparisons are used to
identify and rank species most likely to be susceptible to a chemical acting through
a known molecular initiating event and can therefore aid in designing toxicity stud-
ies for species of concern. This presentation will identify the domains of applicabil-
ity for this tool and describe examples related to predicting species sensitivities to
pharmaceuticals and pesticides. An assessment of honey bee sensitivity to various
pesticides will demonstrate the applicability of this tool for existing questions in
risk assessment. The contents of this abstract neither constitute nor reflect official
US EPA policy.
266 Alteration in Behaviour, Histoarchitecture of Liver, Lung,
and Kidney of Male Wistar Rats Exposed to Open Refuse
Dump.
P. U. Nwoha1, 2, 3,  G. E. Waritimi2,  A. D. Atoni2,  F. Onyije2 and
O. M. Ijomone1. 1Anatomy and Cell Biology, Obafemi Awolowo University, Ile-Ife,
Nigeria; 2Human Anatomy, Niger Delta University, Wilberforce Island, Nigeria;
3Environmental Neurobiology and Toxicology, Centre for Scientific Investigations and
Training, Owerri, Nigeria.
Household wastes are disposed in the open in Nigeria, and most third world coun-
tries. These could have serious consequences on the health of humans and animals
in the vicinity. Yet not much is known on the effects of such exposure on behaviour,
and organs of the body. The present work exposed weaned male Wistar rats to open
refuse dump continuously for five months. During this period the rats were housed
in a building on the dump, kept in clean plastic cages,fed normal rat chow, and pro-
vided clean drinking water. Control rats were housed in Niger Delta University
Animal Holding. At the end of the period, behavour of the rats was tested on Open,
and Elevated plus maze, for exploratory activity and for anxiety respectively. The
animals were sacrificed, liver, lung, kidney dissected, examined macroscopically,
and prepared for histological examination with H & E staining. Data obtained and
analysed with student t-test showed that rats exposed to refuse dump spent signifi-
cantly less time in open arms of the elevated plus maze than their unexposed con-
trols (p < 0.05). Organs showed massive infiltration with fat, while the histology
showed destruction of the radial liver architecture, thinning and collapse of alveolar
wall of lung, and tubular wall of the kidney. Thus indicating that such exposure
could induce anxiety, and massive destruction of organs of the body, leading to se-
rious health consequences. 
Key words: refuse exposure, anxiety, destruction, liver, lung, kidney
267 In Vitro Fish Metabolism Using Rainbow Trout Liver S9
Fractions to Evaluate the Bioaccumulation Potential of
Fragrance Ingredients.
G. Adamson1,  H. Laue2,  K. J. Jenner3,  H. Gfeller2,  S. Kern2,  J. W. Nichols4
and A. Natsch2. 1Givaudan US, East Hanover, NJ; 2Givaudan Schweiz AG,
Duebendorf, Switzerland; 3Givaudan UK Ltd., Ashford, United Kingdom; 4US EPA,
Duluth, MN.
Bioaccumulation in aquatic species is a critical endpoint in the evaluation of novel
chemicals as part of PBT assessment (persistent, bioaccumulative, and toxic) by the
U.S. EPA. In vivo determination of the bioconcentration factor (BCF) requires the
use of large numbers of animals. Predictive models are commonly used if no in vivo
BCF data are available. These models generally acknowledge the possibility that
biotransformation can reduce the extent of accumulation. Lacking measured data,
however, modeled biotransformation rates are commonly set equal to zero. In vitro
systems have been proposed as alternative methods that can be used to provide
metabolic data needed to refine BCF computer model estimates.
The goal of our study was to determine the in vitro metabolic stability of common
chemical classes of fragrance ingredients (esters, alcohols and ketones) using rain-
bow trout liver S9 fractions and to use in vitro clearance rate to model the bioaccu-
mulation potential. Metabolic stability was determined by monitoring the disap-
pearance of the parent molecule by GC MS and metabolite formation by GC-MS
and LC-MS. 
Slow enzymatic turnover was found with isolongifolanone (CAS 23787-90-8). The
ester serenolide (477218-42-1) was transformed rapidly. Alcohols like Ambermax
(929625-08-1) and ketones like spirogalbanone (224031-70-3) were transformed
moderately to rapidly. Metabolic routes, identified by selective use of cofactors and
metabolite identification, involve ester cleavage, hydroxylations, reductions and
conjugation with glucuronic acid and glutathione. When clearance rates measured
in vitro were used as inputs to the BCF model a good correlation was observed be-
tween predicted BCFs and measured in vivo values. In vitro S9 metabolism data in
combination with new refined BCF models are a valuable tool to assess bioaccumu-
lation potential as part of a weight-of-evidence approach for chemical registrations.
268 The Role of Aquaporin 3 in the Uptake of Arsenite through
the Intestine of the Atlantic Killifish (Fundulus heteroclitus).
D. Jung1, 2,  M. A. Adamo2,  R. M. Lehman2,  R. Barnaby1,  B. P. Jackson3,
J. R. Shaw4, 2 and B. A. Stanton1, 2. 1Microbiology and Immunology, Geisel School of
Medicine at Dartmouth, Hanover, NH; 2Mount Desert Island Biological Laboratory,
Salisbury Cove, ME; 3Earth Sciences and Chemistry, Dartmouth College, Hanover,
NH; 4School of Public and Environmental Affairs, Indiana University, Bloomington,
IN.
Aquaglyceroporins (AQPs) are proteins that mediate movement of water and small
solutes across cellular membrane. Previously, we cloned kfAQP3a from the gill of
the killifish (Fundulus heteroclitus), an environmental sentinel species. kfAQP3a,
the only AQP expressed in gill, is the first AQP3 described that does not transport
arsenite. This finding accounts for the low levels of cellular arsenite in gill of killi-
fish exposed to environmental arsenite. Another homolog of AQP3 (kfAQP3b),
which transports arsenic, was identified as the consensus from a transcriptome data-
base. In this study, we sought to identify the AQP3s in the intestine, a major route
of arsenite uptake. First, we examined AQP mRNA expression by qRT-PCR in the
killifish intestine. Among the AQPs examined, only AQP3 was significantly ex-
pressed above background levels. Western blot studies with a polyclonal antibody
that did not discriminate among kfAQP3 variants, revealed that kfAQP3 abun-
dance was higher in killifish acclimated to FW compared to SW. Intriguingly,
whereas only kfAQP3a was expressed in the intestine of FW killifish, both
kfAQP3a and a new variant, kfAQP3c, were expressed in the intestine of SW fish.
When kfAQP3c was transfected into HEK293T cells, cells took up arsenic as effec-
tively as cells transfected with kfAQP3b. When we examined arsenic levels in the
intestine of FW fish and SW fish exposed to 1000 μg/L arsenite for 72h, the
amount of arsenic detected in the intestine of SW fish was higher than the amount
detected in FW fish. Results indicate that arsenite uptake in the killifish mostly
likely occurs via ingestion, and that killifish acclimated to SW take up more arsen-
ite than FW acclimated fish, because kfAQP3c expression is up-regulated in SW
fish and because SW fish drink more water than FW fish.
269 Characterization of DCOIT Bioaccumulation Mechanism via
In Vitro Incubation with Rainbow Trout Liver S9.
F. Zhang,  D. L. Rick,  M. Bartels and G. A. Hazelton. 1Global Environmental
Health Sciences, Tulane University, New Orleans, LA; 2Tulane Cancer Center, Tulane
University, New Orleans, LA; 3Department of Biomedical Sciences, Tulane University,
New Orleans, LA; 4Department of Sociology, Washington State University, Pullman,
WA; 5Mary Queen of Vietnam Community Development Corporation, New Orleans,
LA.
4, 5-Dichloro-2-(n-Octyl)-4-Isothiazolin-3-one (DCOIT) is an important biocide
widely used in a variety of industrial processes. In supporting DCOIT regulatory
registration, a bioaccumulation study in bluegill sunfish was conducted with 14C-
DCOIT and indicated the bioconcentration factor (BCF) was 750 ml/g with less
than 1 % of radioactivity in tissues attributed to DCOIT. To understand the find-
ings in the in vivo fish bioaccumulation study, the in vitro metabolism of DCOIT
was examined by using rainbow trout liver S9 (Fish S9) and glutathione (as protein
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surrogate) in the presence or absence of NADPH. The potential metabolites in-
cluding glutathione conjugates were identified and quantified via LC/MS-MS
methodologies and radioactivity counting, and the protein binding activity of
DCOIT was also quantified. Overall, more than nineteen metabolites (all chlorine-
free) were identified with a majority of these metabolites conjugated to glutathione
or cysteine. Incubations containing Fish S9 and DCOIT in the absence of glu-
tathione resulted in much higher protein binding than those incubations contain-
ing glutathione. This demonstrated that glutathione present in the incubation
medium acts as a useful surrogate of endogenous Fish S9 proteins to competitively
react with DCOIT (or DCOIT active metabolites). The results from the present
study provide evidence that the BCF value measured in vivo can be attributed to
ring-opened metabolites binding high molecular weight tissue fractions- likely the
sulfhydryl moieties in proteins. These data confirm that parent DCOIT does not
bioaccumulate in fish, but the parent molecule is extensively metabolized to
metabolites which were bond to high molecular weight components of the fish tis-
sue (i.e., proteins).
270 Zinc Content Determines the Toxicity of Tire Leachate in
Girardia tigrina.
R. Sneed,  E. Coleman and E. Rice. Biology, Chemistry, and Physics, University of
the District of Columbia, Washington DC. Sponsor: P. Ganey.
The practice of recycling old tires into various outdoor structures such as play-
ground surfaces and landfill liners poses the risk of tire components moving into
local watersheds and possibly affecting aquatic organisms. In this study we tested
the hypothesis that the zinc content of tire leachate is a significant factor in its tox-
icity to Girardia tigrina (Girard, 1850), a freshwater planarian common to North
American waterways. Planarians were cultured in tire leachate containing either
49.5 mg/L of zinc (BALT) or 0.13 mg/L (FRESH) of zinc or a control of extraction
medium (EM) over a time period of 24 hours. All planarians in the BALT group
died within 24 hours while no planarians died in either the FRESH or EM groups.
To verify that zinc was the causative agent in the observed toxicity, planarians were
maintained in a solution containing an equivalent amount of zinc (from zinc sul-
fate) for 24 hours. The survival rate of planarians in this group was not significantly
different from the survival rate observed in the BALT group. These data strongly in-
dicate zinc as the toxic agent. In addition to the lethality demonstrated by both
high-zinc solutions, planarians displayed signs of distress indicated by increased ac-
tivity, writhing, and loss of motor coordination prior to death when compared to
controls, suggesting that neurotoxicity may be the mechanism of action. Future
studies will examine the dose-response relationship of zinc toxicity in G. tigrina as
well as evidence of neurotoxicity. (Support: NSF Award 0928444.)
271 Harmonizing Use of the 3Rs in Fish Toxicity Testing.
C. Willett1,  S. Belanger2,  M. Embry3,  T. Iguchi4,  M. Halder5,  A. Lillicrap6,
H. Rufli7,  L. Touart8 and S. Zok9. 1The Humane Society of the United States,
Gaithersburg, MD; 2Procter & Gamble, Cincinnati, OH; 3Health and
Environmental Sciences Institute, Washington DC; 4National Institute for Basic
Biology, Okazaki, Japan; 5ECVAM, Joint Research Centre, Ispra, Italy; 6Norwegian
Institute for Water Research, Ecotoxicology and Risk Assessment, Oslo, Norway;
7Ecotoxsolutions, Basel, Switzerland; 8Office of Science Coordination and Policy, US
EPA, Washington DC; 9BASF, Ludwigshafen, Germany.
Pursuit of methods that refine, reduce or replace animals is often discussed in the
context of human health hazard and risk assessment; however, several approaches
that are in common use for human health are more frequently being applied in eco-
logical hazard and risk assessment as well. Organized testing frameworks such as
tiered frameworks or integrated strategies can be used to prioritize information
needs and focus testing on tests that would be the most informative for a given reg-
ulatory need. Specific application of integrated strategies has been used to minimize
fish used for acute toxicity testing, for example the limit and threshold approaches.
There are principles that can be applied to specific test protocols that minimize an-
imal use, for example the use of historical controls where appropriate or using sta-
tistical analyses to define the minimum individuals needed to obtain statistically
significant results. Computer modeling can assist in extrapolating information
from one species to another or in predicting acute toxicity, bioaccumulation and
other biological activity in fish. While limited embryo, ex-vivo, and in vitro ap-
proaches are currently used in fish toxicity testing, opportunities exist for expand-
ing the repertoire, particularly in the area of ‘omics technologies. This presentation
will describe these approaches as currently applied and present recommendations
for improving the application and harmonization of 3Rs approaches to fish toxicity
testing, as presented in Chapter 5 of the Fish Toxicity Testing Framework Guidance
Document prepared by the Organization of Economic Cooperation and
Development (August 2012).
272 Concentrations of Metals Associated with Crude Oil from
the BP Macondo Well in Sediments and Fish from the
Northeastern Gulf of Mexico.
A. C. Nichols,  D. A. Steffy and L. J. Morgan. Physical and Earth Sciences,
Jacksonville State University, Jacksonville, AL.
To investigate if metals associated with crude oil from the BP Macondo Well were
entering the marine food chain, sediment and scad mackerel (TRACHURUS
LATHAMI) samples were analyzed by ICP for five of these metals: chromium,
nickel, lead, thallium and vanadium. Samples were collected from the carbonate
shelf along the west coast of Florida in fall, 2010. A subset of these samples was col-
lected from the western Florida Panhandle. This area was south of the Florida
beaches where tar balls washed ashore during the summer of 2010. Nickel levels in
samples from this subset ranged from 2.85 to 11.18 micrograms/g in dry sedi-
ments, and 0.00 to 0.86 micrograms/g in dry fish tissues. Chromium levels in sam-
ples from this area ranged from 7.08 to 12.43 micrograms/g in sediments, and from
0.00 to 0.76 micrograms/g in scad. Vanadium levels ranged from 3.32 to 10.07 mi-
crograms/g in sediments. Vanadium was the only one of these metals not detected
in any of the fish. Lead levels ranged from 1.13 to 5.89 micrograms/g in sdeiments,
and 0.00 to 0.36 micrograms/g in scad. Thallium appears to be biomagnified in
scad, as concentrations in fish ranged from 0.72 to 1.42 micrograms/g, while sedi-
ment levels ranged from 0.00 to 0.30 micrograms/g.
273 The Effect of Tributyltin (TBT) on Zebrafish Sexual
Differentiation.
C. L. McGinnis. Quinnipiac University, Hamden, CT.
Tributyltin (TBT), an antifouling agent, has been implicated in the masculinization
of fish species worldwide, however the molecular mechanism is not fully under-
stood. Our lab has previously examined the actions of TBT as an endocrine disrup-
tor in zebrafish (Danio rerio) and determined, in vitro, that TBT inhibits zfER spe-
cific activity in a dose dependent manner and may potentially act through the RXR
portion of the PPAR-RXR (peroxisome proliferator-activated receptor gamma -
retinoid X receptor alpha) heterodimer. Additionally, zebrafish were exposed to in-
creasing concentrations of TBT and sexual differentiation genes were analyzed via
qPCR. Results from qPCR focused our experimental efforts on the candidate gene,
SRY-box containing gene 9a (Sox9a). Sox9a is a key regulator in mammalian testis
differentiation, where it is shuttled to the nucleus upon differentiation; this appears
to be a conserved mechanism across fish, marsupials and placental mammals.
Developing zebrafish embryos were exposed to 1pM and 2.5pM TBT from 10 days
post hatch (dph) to 90 dph and sampling was done at 25, 35, 40, 45, 60 and 90
dph. Fish were treated three times per week with either TBT, estrogen or vehicle.
Following treatments, immunohistochemical (IHC) analysis was performed to as-
sess Sox9a nuclear or cytoplasmic localization.
274 Heavy Metal Response in Daphnia magna: An Ecologically-
Relevant Nonmodel Organism.
S. Roy and M. E. Pfrender. Biology, University of Notre Dame, Notre Dame, IN.
Environmental health issues have become a major focus of ecotoxicology research
over the last decade. Due to rapid industrialization and urbanization, ecosystems
are currently, and into the foreseeable future, under the threat of potential damage.
In order to mitigate these risks, environmental scientists build predictive models to
gauge the impact of pollutants, perform risk assessment studies to measure water
quality, and protect organisms from potential damage due to the effects of pollu-
tants. 
One major pollutant is heavy metal. Since aquatic systems are the major sinks of
industrial effluents they are often more highly impacted by heavy metals than area
terrestrial ecosystems. Numerous studies on individual organisms and populations
have demonstrated the effects of acute exposure to metal pollutants, but few studies
are available that show the consequences of long-term low dose metal exposure to
aquatic organisms.
In regular risk assessment practice, acute and high dose/concentration exposure is
a common approach to predict which metal/chemical has potentially harmful ef-
fects on a particular organism. This approach is informative, but not predictive of
the long-term low dose/concentration scenario that is more likely happening in our
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day-to-day life. Further, aquatic toxicity tests have historically been largely limited
to model organisms. However, not all organisms show the same physiological re-
sponse to a particular metal/chemical making these assessments species specific.
Our approach is to use quantitative genetics/genomics tools applied in a ecological
relevant non-model organism to determine the genetic basis and mechanisms of re-
sponse to a common, toxic metal pollutant. . We use Daphnia magna, a widespread
freshwater invertebrate, as a model organism to understand and interpret the ge-
netic mechanisms of response to cadmium.
275 Characterization of the Hepatic Metabolome of Migrating
Sockeye Salmon in British Columbia, Canada.
J. P. Benskin1, 2,  M. G. Ikonomou2,  N. Veldhoen3,  C. Dubetz2,  C. C. Helbing3
and J. R. Cosgrove1. 1Product Development, AXYS Analytical Services Ltd., Sidney,
BC, Canada; 2Fisheries and Oceans Canada, Institute of Ocean Sciences, Sidney, BC,
Canada; 3Biochemistry and Microbiology, University of Victoria, Victoria, BC,
Canada.
The health of British Columbia wild sockeye salmon (Onchorhychus nerka) is of
increasing concern due to recent extreme variation in the number of fish returning
to spawn annually. Causes of this variability are unclear but may be related to to
contaminant or viral exposures, climate change, or food shortages. Two key migra-
tory routes for Pacific sockeye are the Fraser and Skeena River watersheds. These
watersheds represent highly contrasting environments for spawning salmon; the
former flows through populous and industrialized regions of Vancouver, while the
latter flows through fairly remote regions with little industrial input. A recent com-
parison of hepatic mRNA profiles between Fraser and Skeena sockeye revealed stark
differences in estrogen-associated signaling in Skeena fish, despite these fish spawn
in a relatively pristine environment. In contrast, the status of hepatic gene tran-
scripts for Fraser River sockeye showed normal reproduction-related changes in es-
trogen-associated signaling. To expand upon available toxicological endpoints and
further define potential sources of exposure resulting in the observed hepatic
mRNA profiles in Skeena River salmon, we compared aspects of the hepatic
metabolome of fish from both populations. A total of 186 metabolites from 6 dif-
ferent metabolite classes were measured using a recently developed assay. Molecular
targets included acylcarnitines (n=40), amino acids (n=21), glycerophospholipids
(n=90), ∑hexose, sphingolipids (n=15), and biogenic amines (n=19). Major
metabolites quantified in Sockeye salmon liver included glycine, carnitine, phos-
phatidylcholine acyl-alkyl C38:6, and sphingomyeline C24:1. The combined tran-
scriptomic and metabolomic data provides a comprehensive molecular profile of
fish health, and sheds light on the biochemical changes arising from alteration of es-
trogen-associated signaling.
276 Elevated Metals and Organic Concentrations Linked to
Biomarkers’ Alterations in Organisms Exposed to Mining
Effluent.
O. T. Olubambi and V. Wepener. Centre for Aquatic Research, Department of
Zoology, University of Joburg, Johannesburg, South Africa.
The Blesbokspruit wetland, South Africa, continuously receives diffuse and point
source releases of mining effluent till date. Results are presented from a first time
study conducted in the system on metals and organic bio-accumulation in sedi-
ments, residents and transplanted organisms. A suite of biomarkers assay was also
carried out in bio-indicators. During the 2008 low and high flow periods, resident
catfish, Clarias gariepinus and tilapia, Tilapia sparrmanii species were collected
from 5 sites in a field survey. During the 2009 high flow, a transplantation study
(active bio-monitoring - ABM) was conducted using laboratory reared Tilapia spp.
at four of the five sites in cages for four weeks. Biomarkers of exposure: cytocrome
P-450 (CYT-P450) and acetylcholine esterase (AChE) and biomarkers of effect:
catalase (CAT) and superoxide dismutase (SOD) responses were determined in all
samples. Metal and organic concentrations measured varied among sites and were
elevated (p<0.05) during the field survey high flow than the low flow in most cases.
This was always high for both periods in Site 1 which is upstream and close to mine
dumps. Biomarkers were found altered both in resident and transplanted organisms
at all sites. For example, triggered CAT activity and inhibition of SOD both in-
dicative of oxidative stress was observed. CYT-P450 and AChE activities inhibition,
which indicates organometallic and pesticides exposure was also observed.
Biomarker responses were similar for both resident and transplanted fishes for the
high flow periods (p<0.05). Site 5 (reference site) generally showed the least altered
responses during the field survey low flow but not during the high flow and ABM.
Biomarkers were able to successfully demonstrate biological effects from toxicants
in the system. It was possible to link these effects to observed elevated metal and or-
ganic concentrations found in bio-indicators. This approach can be applied within
the proposed integrated management plan for the Blesbokspruit as well as other
catchments.
277 Effects of Two Progestins, Norethindrone and
Levonorgestrel, on Reproduction in a Marine Fish,
Tautogolabrus adspersus.
L. Mills1,  D. Borsay Horowitz1,  G. Zaroogian1,  B. Rashleigh1,  B. W. Riffle2 and
S. C. Laws2. 1Atlantic Ecology Division, US EPA, ORD, NHEERL, Narragansett,
RI; 2Toxicology Assessment Division, US EPA, ORD, NHEERL, Research Triangle
Park, NC.
Endocrine-active pharmaceuticals that enter the aquatic environment through
sewage effluent may have unintended impacts on reproduction in fish, which in
turn may affect the sustainability of exposed populations. Laboratory experiments
were conducted with the marine fish cunner (Tautogolabrus adspersus) to evaluate
whether norethindrone (NOR) and levonorgestrel (LNG) affected reproduction in
spawning adults. Both progestins are used in human contraceptive formulations
and have been detected in low (ng/L) concentrations in aquatic environments.
Synthetic progestins in aquatic environments are of special concern because some
fish use natural progesterones as pheromones to coordinate reproduction, and evi-
dence suggests progestins may be selectively taken up through the gills in some
species. Reproductive endpoints of egg production, viability and fertility were as-
sessed daily in spawning cunner treated with NOR or LNG (nominal concentra-
tions of 0, 0.075 or 0.75 mg/kg) by oral gavage on days 0, 4, 8, 12 and 16 of the ex-
periment. All fish were sacrificed on day 17 and gonadosomatic index (GSI) was
determined. In NOR-treated fish, egg production per gram female was significantly
reduced relative to controls at both concentrations, while egg fertility and viability
was notably decreased, although not significantly, only in the 0.75 mg/kg treat-
ment. GSI was significantly reduced in both males and females from the 0.75
mg/kg treatment. Female mortality in this treatment group was more than twice
that in controls, indicating an increase in male aggression. In LNG-treated cunner,
no significant effect was seen on egg production, fertility, viability, or GSI com-
pared to control fish. Results indicate some progestins can impact fish reproduc-
tion, even in short-term exposures. Research is planned to determine if these fish se-
lectively take up progestins from the aquatic environment. This abstract does not
reflect U.S. EPA policy.
278 Effects of Fungicides on Honey Bee Development and
Behavior.
L. A. Hooven. Oregon State University, Corvallis, OR.
Pesticides may contribute to the health challenges facing honey bees. Bees experi-
ence chronic exposures through contaminated beeswax and stored pollen and
honey. There is a need to study possible sublethal or delayed effects from such ex-
posures, which may ultimately result in the collapse of the colony. Fungicides are
thought to have little effect on insects, and are routinely sprayed while bees are pol-
linating crops. Multiple fungicides are transported with pollen into the colony, and
some are known to persist in beeswax. Beekeepers suspect that fungicides may have
an effect on honey bee development, and some laboratory tests have demonstrated
adverse effects of fungicides on bee larvae. We have developed laboratory methods
to chronically expose young adult bees to pesticide-contaminated beeswax, in con-
centrations similar to those found in hives. By using Noldus Ethovision to track the
behavior of bees on video, we have found that the major contaminants of beeswax,
including the fungicide chlorothalonil, delay behavioral development as measured
by the initiation of circadian activity rhythms. Young adult bees consume pollen
and secrete proteinaceous brood food and royal jelly to feed developing larva and
the queen. In semi-field experiments, we fed pollen spiked with fungicides to
colonies of bees, similar to field concentrations. By evaluating colonies weekly, we
found that chlorothalonil and iprodione affect larval development, and ziram af-
fects queen health several weeks after initial exposure. These results suggest that
chronic contact exposure through wax and ingestion of fungicides through pollen
may target the development and social function of young worker bees, and may
have detrimental effects on the colony.
279 The Mediterranean Gecko, Hemidactylus turcicus
(Gekkonidae : Squamata)—An Alternative Model for the
Study of Redox Potential.
M. Y. Farooqui and R. Bloom. Biology, University of Texas Pan American, Edinburg,
TX.
Glutathione and similar sulfhydryl groups play an important role in redox cycling
in mammals. In this study we have investigated the role of sulfhydryls in the
Mediterranean Gecko, Hemidactylus turcicus (Gekkonidae : Squamata).
Concentrations of hepatic sulfhydryls were determined in the field controls and the
geckos maintained at various temperatures. Concentrations of sulfhydryls in livers
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of field controls were 46.3 ± 5 μmoles / g and were significantly elevated (141 and
151 % of controls) in geckos maintained at 15 and 10oC, respectively. Female
geckos had significantly higher (139 %) concentrations of sulfhydryls than did the
males. This study indicates that this oxidative biochemical pathway is operative in
geckos. Geckos may provide a very inexpensive alternative animal model for redox
studies.
280 Recent Emergence of Perfluorohexanoate in Tap, River, and
Sea Water in Japan.
N. Saito,  K. Sasaki and S. Tsuda. Iwate Institute of Environmental Health Sciences,
Morioka, Japan.
Environmental waters such as river water (RW) and sea water (SW) are expected to
be the major exposure sources of Perfluoroalkyl acids (PFAA) to humans via tap
water (TW) and food fish. At the 2012 Annual Meeting of SOT, we reported the
trend in PFAA contaminations in Japanese RW and TW from 2003 to 2010, based
on the results of measurement of Perfluorocarboxylates (from C5 to C12 carbon
backbone) and perfluorosulfonates (CS4, CS6, CS8 and CS10). The major PFAA
(C6, C8, C9 and CS8) concentrations in both RW and TW were always highest in
Kinki area. In 2010 extremely high RW C6 concentrations (46 and 24 μg/L) were
detected in the lower reaches at the foot of a fluorochemical plant, where extremely
high concentrations of C8 (67 and 24μg/L) had been detected in 2003. From 2003
to 2010, Kinki showed drastic reduction of RW C8 concentration to one tenth. C6
concentration in TW in 2007 showed as low as 2.3 % of RW in 2010 compared to
42.3% for that of C8. The conclusion there was that the release of C6 to the envi-
ronment had begun recently from the source in Kinki. In the present study, we
measured PFAA (from C4 to C16; and CS4, CS6, CS8 and CS10) in RW (12 lo-
cations) and TW (6 locations) in the Kinki area and costal SW around Japan (31 lo-
cations) collected in 2011 using LC-MS/MS. The highest RW
Perfluorocarboxylates (from C4 to C10) were detected in the lower reaches at the
foot of the fluorochemical plant (for C6: 49 and 43μg/L) . The highest TW C6
concentration in the 2011 samples was 2.85 ng/L, which was greater than the high-
est C6 concentration (1.51 ng/L) in the 2007 samples. The highest SW C6 con-
centration in Kinki was far greater than the samples from the other areas and was
129 ng/L. From these results it was concluded that C6 release from the source to
the river of resent onset is rapidly contaminating surrounding SW and gradually
contaminating TW in the nearby areas.
281 Distributions of Metals (Cadmium, Lead, Iron, Manganese,
Zinc, and Copper) in Water, Aquatic Plant, and Fish.
K. A. Abdou1,  A. S. Mahmoud2,  M. S. Housen1 and K. I. Ahmed1. 1Department
of Toxicology and Forensic, Medicine, Faculty of Veterinary Medicine, Beni Suef
University, Beni Suef, Egypt; 2Department of Toxicology and Forensic Medicine,
Faculty of Veterinary Medicine, Assiut University, Assiut, Egypt. Sponsor: A. Kadry.
Concentrations of cadmium (Cd), lead (Pb), iron (Fe), manganese (Mn), zinc (Zn)
and copper (Cu ) were measured in water, Ceratophillyum demersum (C. demer-
sum) aquatic plant, Claries lazera fish (C. lazera) collected from nine sampling sta-
tions along El Ebrahimia canal and two districts located at the east bank of the Nile
in the province of Beni Suef, Egypt during 2009-2010. 
Atomic Absorption analysis revealed that the studied metals were higher than the
limit of detection (LOD) in all the examined samples. In water, Pb had the highest
concentration among the metals detected in seven of the nine tested locations ( 0.3
- 0.9 ppm ). The concentrations of Pb, Fe, and Mn were above the maximum
Egyptian permitted limits in all tested sites, while Zn and Cu concentrations were
below the permitted limits (4 mg/l and 2 mg/l) in the nine districts. Comparisons
were made of the metal concentrations in water and aquatic plants with those in the
catfish tissues obtained from water. The metal concentrations found in the C. de-
mersum aquatic plant samples taken in the nine studied districts were distributed in
this order; Mn > Zn > Cu >Pb >Fe > Cd. and were higher than the water In fish,
metals accumulated in the various examined tissues at several levels, but the metal
concentrations in muscles (edible part) were below the metal levels in the other or-
gans (nonedible) in the fish samples. The concentrations of Cd, Pb and Fe in fish
tissues were above the international standard, while the concentrations of Mn, Zn
and Cu were below this standard. The high concentrations of these metals in water,
aquatic plants and fish in El Ebrahimia canal may be the result of both anthro-
pogenic activities producing industrial, agricultural and domestic waste and acci-
dental pollution incidents.
282 Cytochrome P450 Monooxygenases Expression in Human
Epithelial Lung Cell Lines.
M. Niehof and T. Hansen. Fraunhofer ITEM, Hannover, Germany. Sponsor: C.
Dasenbrock.
The pulmonary epithelium is the first barrier for airborne xenobiotics and inhaled
drugs. Cytochrome P450 monooxygenases (CYP) participate in metabolic inactiva-
tion of xenobiotics. Beyond that some compounds require enzymatic activation to
exert their toxic effects or their desirable functions. The bronchiale epithelial cell
line Calu-3 and the type II-like pulmonary epithelial cell line A549 serve as cell cul-
ture models for the human respiratory epithelium. So far, there is little information
regarding their metabolic properties especially for Calu-3 cells. The goal of this
study was to further characterize both cell lines regarding their basal and inducible
CYP isoform expression. 
CYP expression was determined using real-time reverse transcription quantitative
polymerase chain reaction (RT-qPCR). Basal expression of CYP1B1, CYP1A1,
CYP2D6, CYP2B6/7, CYP3A5, and CYP2J2, and slight amounts of further CYPs
were detected in both cell lines, which is consistent with expression in the human
lung. 
Furthermore, potential CYP inducers were analyzed. Omeprazole acts on aryl hy-
drocarbon receptor (AhR) activation and induced CYP1A1 and CYP1B1 in both
cell lines. Rifampicin acts on pregnane x receptor (PXR) and phenobarbitale acts
predominantly on constitutive androstane receptor (CAR), however, both receptors
are not expressed in the lung. Accordingly, both agents did not induce any CYP in
these cells. Besides PXR, dexamethasone acts on glucocorticoid receptors and we
found induction of members of the CYP3A family, mainly CYP3A7 in Calu-3
cells, and CYP3A5 and CYP3A7 in A549 cells. CITCO is known to act as a CAR
agonist and is normally used to induce CYP2B6/7. However, it is a potent inducer
of CYP1B1 in Calu-3 cells, and of CYP1A1 and CYP1B1 in A549 cells. 
Thus, Calu-3 cells and A549 cells express a broad range of CYPs with preserved in-
ducibility and are valuable models of the airway epithelial barrier for metabolic in
vitro experiments.
283 Role of Renal Proximal Tubule P450 Enzymes in
Chloroform-Induced Nephrotoxicity.
S. Liu1, 2,  Y. Yao1,  S. Lu1,  X. Ding1,  C. Mei1 and J. Gu1. 1Wadsworth Center,
Albany, NY; 2Changzheng Hospital, Shanghai, China.
The kidney is a primary target for numerous toxicants. Cytochrome P450 enzymes
(P450s), responsible for the metabolic activation of various chemical compounds,
are predominantly expressed in proximal tubules in the kidney. However, the spe-
cific role of proximal tubule P450s in chemical-induced nephrotoxicity is unclear.
The aim of this study was to test the hypothesis that renal proximal tubule P450s
are critical for the metabolic activation and nephrotoxicity of chloroform. To test
this hypothesis, we have developed two new mouse models, one having proximal
tubule-specific deletion of the cytochrome P450 reductase (Cpr) gene (the enzyme
required for all microsomal P450 activities), named kidney-Cpr-null, and the other
with proximal tubule-specific rescue of CPR activity in a model with global sup-
pression of CPR activity in all extra-renal tissues, named extra-renal Cpr-low. The
kidney-Cpr-null, extra-renal-Cpr-low, Cpr-low, and wild-type (WT) control mice
were treated with a single oral dose of chloroform at 200 mg/kg. Blood, liver and
kidney samples were obtained at 24 h after the treatment. Kidney toxicity was as-
sessed by measuring serum levels of BUN and creatinine, and by pathological ex-
amination. The blood and tissue levels of chloroform were also determined.
Chloroform-induced proximal tubular lesions and increases in BUN and creatinine
levels were observed in all four genotypes, but the severity of toxicity was less in kid-
ney-Cpr-null and Cpr-low mice, compared to WT and extra-renal-Cpr low mice,
respectively. There was no significant difference in chloroform levels in the blood,
liver, or kidney, between kidney-Cpr-null and WT mice, or between extra-renal-
Cpr-low and Cpr-low mice. These findings indicate that local P450 dependent
metabolic activation plays an important role in renal toxicity induced by chloro-
form. Our results also demonstrate the utility of these novel mouse models for stud-
ies on the renal toxicity of other chemicals.
284 Green Tea Epigallocatechin Gallate Inhibits Drug
Metabolizing Enzymes by Covalent-Binding to the Proteins
and Formation of Protein Aggregates.
Z. Weng and Q. Shi. Division of Systems Biology, US FDA, NCTR, Jefferson, AR.
Sponsor: X. Yang.
Green tea supplements have been reported to cause hepatotoxicity but the mecha-
nisms of the toxic metabolite, epigallocatechin gallate (EGCG), are unknown. In
this study, the rat liver microsomes were treated with 1 - 100 μM EGCG for 30
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min, and the EGCG-binding proteins were affinity purified and probed with anti-
bodies against glyceraldehyde-3-phosphate dehydrogenase (GAPDH), actin, cy-
tochrome P450 (CYP) 1A1, CYP1A2, CYP2B1/2, CYP2E1, CYP3A, catechol-O-
methyltransferase (COMT) and microsomal glutathione transferase 1 (MGST1).
All but actin and soluble COMT were positively detected at ≥1 μM EGCG, indi-
cating EGCG selectively bound to a subset of proteins including membrane-bound
COMT. The binding correlated well with inhibition of CYP activities, except for
CYP2E1 whose activity was unaffected despite evident binding. When microsomes
were probed on Western Blots, all but the actin and CYP2E1 antibodies showed a
significant reduction in binding at ≥1 μM EGCG, suggesting that a fraction of the
indicated proteins formed aggregates that were not recognizable by antibodies
against the intact proteins. Protein aggregate formation was also observed in
Coomassie Blue-stained SDS-PAGE gels. EGCG effects were partially abolished in
the presence of 1 mM glutathione. We conclude that EGCG inhibits drug metabo-
lizing enzymes by covalent-binding to the target proteins and formation of protein
aggregates.
285 Metabolism of Rutaecarpine in Freshly Isolated Hepatocytes
from Rats and Mice.
T. Jeong,  D. Lee,  D. Oh,  J. Kim,  Y. Jahng and M. Kang. Pharmacy, Yeungnam
University, Gyeongsan, Republic of Korea.
Rutaecarpine is an alkaloid originally isolated from Evodia rutaecarpa that has been
used for the treatment of gastrointestinal disorders in Asia. In the present study,
Phase I and Phase II metabolisms of rutaecarpine were investigated in freshly iso-
lated hepatocytes from rats and mice. The results indicated that the metabolism of
rutaecarpine in rats and mice was different. When rutaecarpine was incubated with
fresh hepatocytes isolated from either rats or mice for 2 hr, 5 major Phase I metabo-
lites were observed in both hepatocytes with different extents. Likewise, the pro-
duction of sulfate conjugates also showed difference. In rat hepatocytes, 4 sulfate
conjugates were observed, whereas only two conjugates were observed in murine
hepatocytes. The results indicated that the species selection would be concerned in
the process of preclinical investigation Supported by a grant from National
Research Foundation of Korea (2010-00266220).
286 Effects of Intestinal Microflora on Oral Pharmacokinetics of
Baicalin in Normal and Antibiotic-Treated Mice.
D. Oh,  M. Kong,  J. Kim,  M. Kang,  W. Kang and T. Jeong. Pharmacy,
Yeungnam University, Gyeongsan, Republic of Korea.
Baicalin (baicalein-7-glucuronide) is an ingredient of Scutellaria baicalensis Georgi
that has been used as one of the most popular herbs in Korea for treatment of in-
flammation, cardiovascular diseases, hypertension, and microbial infections. In the
present study, effects of intestinal microflora on oral pharmacokinetics of baicalin
were investigated in normal SPF and antibiotic-treated mice. To control the num-
ber of intestinal bacteria, mice were pre-treated orally with erythromycin, oxytetra-
cyclin and cefadroxil for 3 consecutive days, followed by an oral administration
with 100 mg/kg baicalin. Then baicalin and its possible metabolites in serum were
determined by using liquid chromatography/electrospray ionization mass spec-
trometry. By the pre-treatment with antibiotics, the number of intestinal microflora
was significantly reduced. In addition, serum concentrations of baicalin and its
metabolite, baicalein-6-glucuronide, were remarkably changed by treatment with
antibiotics when compared with control mice. These results indicated that the in-
testinal microflora might have a critical role in modulating oral pharmacokinetics
of baicalin. Supported by the grant from KFDA (09172KFDA996) and from
National Research Foundation of Korea (2010-00266220) .
287 Role of Intestinal Microflora in Oral Pharmacokinetics of
Baicalin in a Germ-Free Mouse Model.
J. Kim1,  D. Oh1,  M. Kang1,  W. Yun2,  H. Kim2 and T. Jeong1. 1Pharmacy,
Yeungnam University, Gyeongsan, Republic of Korea; 2Biomedical Mouse Resource
Center, KRIBB, Ochang, Republic of Korea.
Baicalin and its aglycone baicalein are bioactive flavonoids originally isolated from
the root of Scutellaria baicalensis Georgi, a medicinal plant that has been used for
the treatment of inflammation, hypertension, cardiovascular and allergic diseases.
In the present study, role of intestinal microflora in baicalin metabolism was inves-
tigated following a single oral administration with 100 mg/kg baicalin in germ-free
and control mice. Baicalin and its metabolites were determined by HPLC coupled
with a tandem mass spectrometry. Serum concentrations of baicalin and its
metabolite in germ-free animals were significantly lower than those in control mice
having normal intestinal microflora. Likewise, transient hepatotoxicity induced by
baicalin in germ-free mice was significantly different from that in control mice.
These results indicated that the intestinal microflora might play a key role in me-
tabolism of baicalin orally ingested. Supported by the grant from KFDA
(09172KFDA996) and from National Research Foundation of Korea (2010-
00266220).
288 Importance of Chirality Considerations in Risk Assessments:
Enantiomer-Specific Pharmaceutical Metabolism with
Rainbow Trout (Oncorhynchus mykiss) S9.
K. Connors1,  B. Du1,  P. N. Fitzsimmons2,  C. K. Chambliss1,  J. W. Nichols2
and B. W. Brooks1. 1Baylor University, Waco, TX; 2US EPA, Duluth, MN.
Enantiomers are capable of having significantly different biological effects, selectiv-
ity for receptors/transporters/enzymes, potency, and biodegradation rates.
Differences in environmental fate, bioavailability and toxicity have also been re-
ported. Despite this knowledge, enantiomers are often treated as a single chemical
entity in environmental monitoring and risk assessment. Enantiomer-specific dif-
ferences in pharmaceuticals are especially well documented within mammalian lit-
erature. Finding a way to leverage existing pharmaceutical safety data and pharma-
cology information through biological “read-across” may aid our ability to perform
more accurate environmental assessments. In this study, we examined the compara-
tive metabolism of R, S and the racemate of three pharmaceuticals (propranolol,
ibuprofen and fluoxetine) in rainbow trout liver S9 using a substrate depletion ap-
proach.  An isotope dilution liquid chromatography tandem mass spectrometry
(LC-MS/MS) method was employed for quantitation of parent chemical concen-
trations. Differential substrate depletion rates were observed for propranolol enan-
tiomers. The fastest clearances rates were observed with rac-propranolol, followed
by S and R-propranolol, respectively. Ibuprofen appeared to undergo limited me-
tabolism; however, the resulting depletion curves did not differ statistically from
those obtained for denatured controls. No substrate depletion was observed for rac,
R or S fluoxetine. Mammalian clearance rates will be compared and risk assessment
implications discussed.
289 The Role of Interstrain Differences in Trichloroethylene
Metabolism in Kidney Effects in Mice.
H. Yoo,  B. U. Bradford,  L. B. Collins,  O. Kosyk,  S. Shymonyak,
W. M. Bodnar,  L. M. Ball,  A. Gold and I. Rusyn. Department of Environmental
Sciences and Engineering, University of North Carolina at Chapel Hill, Chapel Hill,
NC.
Trichloroethylene (TCE) is a well-known environmental and occupational toxicant
contaminating air, water, and soil. The U.S. EPA recently issued the final IRIS as-
sessment of TCE and classified TCE as carcinogenic to humans. Still, several issues
critical for assessing human health risks from TCE remain unresolved, such as (1)
the amount of glutathione (GSH)-conjugated metabolites formed in various tis-
sues, and possible inter-individual and inter-species differences; and (2) the mode
of action involved in kidney toxicity/carcinogenesis. The aim of this study was to
use a panel of inbred mouse strains to investigate the relationship between inter-
strain differences in TCE metabolism and kidney toxicity. TCE (600 mg/kg/day, in
5% Alkamuls EL-620 in saline) was administered by gavage to male mice (6-8
weeks old) from 7 inbred strains (129S1/SvImJ, A/J, BTBR T+tf/J, C57BL/6J,
CAST/EiJ, NOD/ShiLtJ, NZW/LacJ) for 5 days. Liver, kidney, and serum were
collected at 2 and 8 hrs after the last dose. Quantification of S-(1,2-
dichlorovinyl)glutathione (DCVG), S-(1,2-dichlorovinyl)-L-cysteine (DCVC),
and trichloroethanol (TCOH) was performed. In addition, blood urea nitrogen,
kidney-to-body weight ratio, proximal tubular cell proliferation, expression of per-
oxisome proliferator marker genes (Ppara, Acox1, and Cyp4a10), kidney injury
molecule-1 in kidney were evaluated. Inter-strain variability in the levels of DCVG,
DCVC, and TCOH in liver, serum, and kidney were observed. Overall, the level of
TCOH was 10,000-fold greater than that of DCVG and DCVC in both liver and
kidney. In conclusion, the inter-strain differences in TCE metabolism provide a
mechanistic basis for examining the inter-strain differences in TCE organ-specific
toxicity. This work was supported by the Superfund Basic Research Program grant
P42 ES005948.
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290 Interpretation of Multiroute Data for Chloroform-Induced
Renal Toxicity in Rats and Mice Using an Updated
Physiologically-Based Pharmacokinetic Model.
A. F. Sasso1,  P. M. Schlosser2,  G. L. Kedderis6,  M. Genter3,  J. E. Snawder4,
Z. Li1,  S. Rieth1 and J. C. Lipscomb5. 1National Center for Environmental
Assessment, US EPA, Washington DC; 2National Center for Environmental
Assessment, US EPA, Research Triangle Park, NC; 3Department of Environmental
Health and Center for Environmental Genetics, University of Cincinnati, Cincinnati,
OH; 4NIODH, CDC, Cincinnati, OH; 5National Center for Environmental
Assessment, US EPA, Cincinnati, OH; 6Independent Consultant, Chapel Hill, NC.
Chloroform (CF) is a trihalomethane present in drinking water as a byproduct of
disinfection, and the kidney is one of the targets of toxicity in experimental ani-
mals. Since CF induces toxic effects via production of reactive metabolites, proper
characterization of metabolism is essential for risk assessment. A revised physiolog-
ically-based pharmacokinetic (PBPK) model, in conjunction with benchmark dose
(BMD) modeling, was used to interpret rat and mouse renal toxicity markers in
three oral and inhalation studies. Large species differences in potency as a function
of external dose became minimal when expressed in terms of a renal dose metric
(daily mg CF metabolized per L cortex), indicating that species differences in sus-
ceptibility may be primarily mediated by toxicokinetics, rather than differences in
toxicodynamics. The external BMD result for nuclear enlargement was 6 ppm for
the mouse, but 40 ppm for the rat—a 7-fold difference. When the measure of dose
was changed from inhaled concentration to the renal dose metric, the BMD result
becomes 62 mg/L in the mouse, and 47 mg/L in the rat—a difference of 30%.
Since results derived from drinking water data were also consistent with inhalation
data, the work presented here increases confidence in the PBPK model, and the use
of site-specific chloroform metabolism as the internal dose-metric. The views ex-
pressed in this publication are those of the authors and do not represent the views
and policies of their respective Agencies
291 The Use of Cytochrome P450-Embedded Nanodisks to
Enhance Metabolism and Elimination of Chemical
Toxicants.
M. Malfatti1,  E. Kuhn1,  A. Kohlgruber1,  Y. Li2,  K. Lam2 and M. Coleman1.
1Lawrence Livermore National Laboratory, Livermore, CA; 2University of California
Davis, Davis, CA.
Exposure to toxic chemicals and how to eliminate them from the body is a topic of
great concern. Developing safe and effective methods that can mitigate exposures is
critical for responding to many different exposure scenarios. In this study we are
capitalizing on the body’s endogenous detoxification capabilities by supplementing
existing metabolic enzymes to increase the natural capacity for transforming toxic
agents into less harmful constituents. We are developing a novel system that pack-
ages cytochrome P450 proteins, liposomes, and telodendrimers into nanodisks, in
an effort to enhance the metabolism of toxic chemicals into inactive compounds.
Microsomes expressing human cytochrome P4503A4 (CYP3A4) were combined
with POPC lipid and 1% telodendrimer, comprised of an octamer of cholic acid
linked to the terminal end of a linear 5kDa PEG molecule. Assembly of CYP3A4
teledendrimer nanodisks (TND) was achieved after overnight incubation at 4° C.
Activity of CYP3A4 in the TND was assessed by fluorescent intensity, using the
P450-Glo assay (Promega), and determined to be 57.0 FU. This was comparable to
the CYP3A4 positive control of 64.8 FU, indicating successful incorporation of
functional CYP3A4 into the TND. Functional stability was assessed by monitoring
TND-CYP3A4 activity over time at 4° C. TND-CYP3A4 activity was stable for 7
days post assembly. After 7 days, activity decreased by 42% and remained at that
level for the 24-day study duration. In vitro metabolism tests demonstrated that the
TND was able to metabolize the model substrate testosterone to 6β-OH-testos-
terone at rates comparable to the CYP3A4 microsomal control incubations. These
results indicate that this system has the potential to improve ones ability to detoxify
chemicals. Further studies are needed to determine the capability of the TNDs to
metabolize chemicals in vivo.  
This work was performed under the auspices of the U.S. DOE by LLNL under
Contract DE-AC52-07NA27344 and supported by LLNL LDRD 11-ERD-012.
292 Sulfonation of 1-Methyl-Phenanthrene and 9-Ethyl-
Phenanthrene in Human Hepatoma (HepG2) Cells.
M. Huang,  I. A. Blair and T. M. Penning. Centers of Excellence in Environmental
Toxicology and Cancer Pharmacology, Department of Pharmacology, University of
Pennsylvania, Philadelphia, PA.
Exposure to petrogenic polycyclic aromatic hydrocarbons (PAHs) in the food-chain
is the major human health hazard associated with the Deepwater Horizon gulf-oil
spill. Risk assessment is based on the assumption that petrogenic and pyrogenic
PAHs have similar toxicological profiles yet information on the metabolism of pet-
rogenic PAHs is lacking. We report the metabolic fate of 1-methyl-phenanthrene
and 9-ethyl-phenanthrene as representative alkylated petrogenic PAHs in human
hepatoma (HepG2) cells. The structures of the metabolites were identified by
HPLC-UV-fluorescence detection and LC-MS/MS. Both 1-methyl-phenanthrene
and 9-ethyl-phenanthrene showed the formation of O-sulfated mono-phenols, O-
sulfated bis-phenols, O-sulfated dihydrodiols, and O-sulfated catechols. The iden-
tification of these sulfate conjugates supports metabolic activation of 1-methyl-
phenanthrene and 9-ethyl-phenanthrene by P450 and AKR isozymes followed by
metabolic detoxification by SULT isozymes. (Supported by U19ES020676-01 to
TMP)
293 N-Acetyltransferase 1 (NAT1) Expression and Activity during
Keratinocyte Differentiation and Cell Cycle Progression.
J. Bonifas and B. Blömeke. Environmental Toxicology, University of Trier, Trier,
Germany.
N-acetyltransferase 1 (NAT1) dependent N-acetylation is an important detoxifica-
tion pathway for arylamines including certain dyes. Proliferating keratinocytes have
high N-acetylation capacities, but the influence of differentiation on NAT1 is not
clear. 
Keratinocyte differentiation is associated with an arrest of cells in the G0/G1 phase
of the cell cycle. In order to analyze NAT1 regulation in the different cell cycle
phases we synchronized HaCaT keratinocytes by serum starvation (83±4%
G0/G1) and re-addition for 20hrs (66±1.7% S-phase) as well as by double thymi-
dine block (68±2% G0/G1, 72±6% S-Phase) and analyzed NAT1 activity, protein
and mRNA expression. In line with the high N-acetylation capacity of the skin,
NAT1 activity was, compared to S-phase, elevated (about 40±2%) in the G0/G1
phase, which is the predominant state of keratinocytes in the epidermis. NAT1 pro-
tein levels were also higher in G0/G1 phase, while NAT1 promoter P1 dependent
steady state mRNA levels were not enhanced.
In the next step, we differentiated the keratinocyte cell line HaCaT and primary
keratinocytes in vitro and analyzed NAT1 mRNA expression and NAT1 activity.
With increasing differentiation we found no NAT1 variation after in vitro differen-
tiation and detected NAT1 protein staining throughout the entire epidermis using
human skin slices. 
These results indicate that in vitro differentiated keratinocytes do not loose N-
acetylation capacity, although cell proliferation is terminated, possibly due to high
NAT1 activities in G0/G1 phase arrested cells. However, variations of the ker-
atinocyte cell cycle phase distribution may influence NAT1 activity and thereby
detoxification capacities.
294 Characterization of Peroxidase Activity in SkinethicTm
Reconstructed Skin Models Compared with Ex Vivo Human
Skin Samples.
J. Eilstein,  G. Lereaux,  A. Garrigues-Mazert,  J. Meunier and D. Duché. L’Oréal
Research & Innovation - Advanced Research, Aulnay-sous-Bois, France. Sponsor: E.
Dufour.
Skin metabolism is becoming a major consideration in the development of new
cosmetic ingredients, skin being the first organ exposed to them. Consequently, the
use of ex vivo samples of normal human skin (NHS) or reconstructed human skin
models (skin models) as alternative tools to animal testing requires to characterize
and compare their abilities to metabolize xenobiotics. In this work, we determined
if they possessed a functional peroxidase activity. Previous studies showed that NHS
and skin models from SkinEthicTM Laboratories such as EpiskinTM, SkinEthic-
RHETM and the full thickness model of EpiskinTM expressed the mRNAs of several
peroxidase isoforms (mainly in GPx and COX families). The catalytic activity of
these enzymes was measured from dose-response studies using cumene hydroperox-
ide as substrate. Apparent Vmax, Km and ratio Vmax/Km (assessing metabolic
clearance) were calculated for each biological model from 2-phenyl-2-propanol
quantification. Results showed that in NHS and skin models, a peroxidase activity
was demonstrated to be functional and that the obtained enzymatic parameters
could be influenced by the lack of the glutathione co-factor. To conclude, a peroxi-
dase activity is present and functional in NHS and skin models which can be easily
used for studying the biotransformation process of peroxides and assessing their im-
pact on cellular biomarkers.
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295 Covalent Thiol Adducts Arising from Cocaine and Morphine
Biotransformation.
K. J. Schneider and A. P. DeCaprio. Department of Chemistry & Biochemistry and
International Forensic Research Institute, Florida International University, Miami,
FL.
Covalent protein adduction, which can underlie drug toxicity and/or reflect expo-
sure, is largely unstudied in the case of illicit drugs of abuse. This research investi-
gates the formation of protein adducts resulting from cocaine and morphine bio-
transformation using in vitro assay systems. Human liver microsomal preparations
were incubated for 1.5 or 6 h with cocaine or morphine in the presence of thiol-
containing trapping agents at 37°C, pH 7.4. Thiols included N-acetylcysteine
(NAC), glutathione (GSH), and a synthetic hexapeptide (AcPAACAA).
Microsomes were removed by centrifugation and supernatants were subjected to
LC-MS/MS analysis for characterization of metabolites and adducts. Isomeric hy-
droxycocaine adducts from thiol adduction on the arene ring were the major prod-
ucts with all three model thiols. Eight isomers of cocaine-adducted NAC were sep-
arated and characterized. While the structural complexity of adducted GSH and
model peptide diminished the ability to separate isomers, MS/MS data supported
adduct structures analogous to those with NAC. With morphine, two distinct
metabolites were identified as the likely species responsible for thiol adduction, the
known reactive metabolite morphinone and a novel metabolite, morphine quinone
methide. Reaction between morphinone and NAC formed two isomeric products
which underwent secondary reduction to form three additional stereoisomeric
products. Likewise, morphine quinone methide formed two structural isomers, al-
though no secondary reduction was noted. Individual structural isomers of mor-
phine adducts with GSH and AcPAACAA could not be isolated; however, mor-
phine-derived adduction products were nevertheless present. Analysis using
recombinant cytochrome P450s determined that formation of cocaine adduction
products was mediated by CYPs 1A2, 2C19, and 2D6, while those from morphine
were produced by CYP3A4. Results obtained from this study enhance the existing
knowledge of illicit drug metabolism and demonstrate novel mechanisms for cova-
lent protein modification by these compounds.
296 The Enantioselective Oxidation of 2, 2’, 3, 3’, 6, 6’-
Hexachlorobiphenyl (PCB136) by Liver Microsomes Is
Species Dependent.
H. Lehmler,  X. Wu and A. Kammerer. Department of Occupational and
Environmental Health, College of Public Health, The University of Iowa, Iowa City,
IA.
The adverse neurodevelopmental effects of chiral PCBs, such as PCB 136, are me-
diated by the enantiospecific sensitization of Ryanodine receptors and may be in-
fluenced by enantioselective PCB metabolism. Since the enantioselective disposi-
tion of PCBs is only poorly investigated, we tested the hypothesis that the
enantioselective oxidation of PCB 136 to hydroxylated metabolites by liver micro-
somes is species dependent. Racemic PCB 136 was incubated with liver micro-
somes obtained from different species (i.e., male guinea pig, hamster, monkey,
mouse, and rabbit; female dog) or pooled human liver microsomes. According to
gas chromatographic analysis, 2,2’,3,3’,6,6’-hexachlorobiphenyl-4-ol (4-136) was
the major metabolite in incubations with monkey, rabbit and human microsomes.
2,2’,3,3’,6,6’-Hexachlorobiphenyl-5-ol (5-136) was the major metabolite in incu-
bations using dog, guinea pig, hamster and mouse microsomes. 4-136 to 5-136 ra-
tios were 0.1, 0.1, 0.1, 13, 0.6, 1.7 and 1.8 for dog, guinea pig, hamster, monkey,
mouse, rabbit and human microsomes, respectively. Furthermore, enantioselective
analyses showed species-dependent difference in the enrichment pattern of atropi-
somers of 4-136 and 5-136. Taken together, these observations suggest that species-
dependent enantioselective metabolism needs to be considered in studies investigat-
ing the developmental neurotoxicity of PCBs and other chiral pollutants.
297 CYP2F1 Expression and Activity Toward Naphthalene in a
CYP2A13/2F1-Humanized Mouse Model.
L. Li1,  K. Jia1,  Y. Wei1,  L. V. Winkle2 and X. Ding1. 1Health Research Inc.,
Albany, NY; 2Center for Health and the Environment, University of California Davis,
Davis, CA.
The aim of this study is to characterize the expression and activity of CYP2F1, a
human P450 expressed preferentially in the respiratory tract, using a recently gen-
erated CYP2A13/2B6/2F1-transgenic (TG) mouse model. CYP2F1 has been pro-
posed to metabolize several lung toxicants, including naphthalene. However, con-
clusive data on how efficient CYP2F1 is in the bioactivation of these compounds
are still unavailable, as it has been difficult to obtain functional CYP2F1 protein
through heterologous expression. Both CYP2F1 and CYP2A13, but not CYP2B6,
are expressed in the lung and nasal mucosa (NM) of the TG mice. The level of
CYP2A13 protein was 100 and 0.2 pmol/mg protein in nasal and lung micro-
somes, respectively, of the TG mice. The level of CYP2F1 protein was not deter-
mined previously, for lack of a suitable CYP2F1 standard. Here, using a newly de-
veloped LC-MS/MS method, we have determined that the level of CYP2F1 was 8
and 2 pmol/mg protein in nasal and lung microsomes, respectively, of the TG mice.
To determine the activity of CYP2F1, we further crossed the TG mouse to a newly
generated Cyp2abfgs-null (null) mouse, in which all mouse Cyp2abfgs genes are
deleted, and the naphthalene bioactivating activities of nasal and lung microsomes
were substantially decreased. In the resultant CYP2A13/2B6/2F1-humanized mice
(TG/null), nasal and lung microsomal activity toward naphthalene was significant
higher than in the null mice (2-fold for lung and 8-fold for NM). Thus, CYP2A13
and/or CYP2F1 are active toward naphthalene in the humanized mouse. Further
analysis of the activities in the humanized mice provided evidence that, while the
activity in the NM was primarily contributed by CYP2A13, the activity in the lung
was mainly contributed by CYP2F1.
298 Effect of Vinclozolin Exposure during Pregnancy on In Vitro
Testosterone Metabolism.
F. G. García-Montes de Oca,  M. L. Lopez-Gonzalez,  D. C. Escobar-Wilches and
A. Sierra-Santoyo. Toxicology, CINVESTAV-IPN, Mexico City, Mexico.
Vinclozolin (V) is a fungicide used for agricultural settings. V is classified as an en-
docrine disruptor by inhibiting competitively the androgen receptor. V exposure
during pregnancy alters morphogenesis of the masculine reproductive system. V
regulates liver cytochrome P450 (CYP) expression and may affect the biotransfor-
mation of endogenous substances, such as testosterone (T) which is an important
hormone during pregnancy. There is no information about the effect of V exposure
during pregnancy on testosterone metabolism. The objective of this study was to
evaluate the effect of V exposure during the pregnancy on in vitro testosterone me-
tabolism. Pregnant Wistar rats were orally administered with V at the dose of 150
mg/kg/d from gestational days 14 to 21 suspended in corn oil. Two control groups
were included, pregnant and non-pregnant rats in oestrus phase and received only
vehicle. Animals were sacrificed at 2 h after last dose by asphyxia with CO2. Liver
was removed and processed to obtain microsomes to carry out in vitro enzyme as-
says using T as substrate. T and its metabolites were analyzed by HPLC. The preg-
nancy decreased 50% the liver total CYP content as well as the formation of
metabolites 7α-hydroxytestosterone (-OHT), 16β-OHT, androstenedione (AD)
and 6β-OHT, 78, 40, 97 and 28%, respect to non-pregnant rats. V exposure sig-
nificantly decreased the weight gain during pregnancy and increased 27% the con-
tent of total CYP, respect to the non-treated pregnant group. Moreover, V increased
the formation of 7α-OHT, 2β-OHT, 16β-OHT, AD, 6β-OHT and 16α-OHT,
1.7-, 1.7-, 3.0-, 1.5-, 4.3- and 1.7-fold, respectively. These results suggest that V af-
fects the pregnancy by reducing weight gain and modulates liver CYP expression.
In addition, they also suggest that V exposure during pregnancy may alter the bio-
transformation of testosterone and affecting physiological processes regulated by
this hormone. These effects may represent another mechanism of action associated
to V exposure during the pregnancy.
299 In Vitro Metabolism of Benzo[a]pyrene and Dibenzo[Def,
P]Chrysene in Rodents and Humans.
S. Hanson-Drury1,  S. R. Crowell1,  J. Soelberg1,  R. A. Corley1 and
D. E. Williams2. 1Systems Toxicology, Pacific Northwest National Laboratory,
Richland, WA; 2Oregon State University, Corvallis, OR.
Polycyclic aromatic hydrocarbons (PAHs) are ubiquitous and often carcinogenic
contaminants released into the environment during natural and anthropogenic
combustion processes. Benzo[a]pyrene (BaP) is the prototypical carcinogenic PAH,
and dibenzo[def,p]chrysene (DBC) is a less prevalent, but highly potent transpla-
cental carcinogenic PAH. Both are metabolically activated by isoforms of the cy-
tochrome P450 (CYP450) enzyme superfamily to form reactive carcinogenic and
cytotoxic metabolites. Metabolism of BaP and DBC was studied in hepatic micro-
somes of male Sprague Dawley rats, naïve and pregnant female B6129SF1/J mice,
and female humans, corresponding to available pharmacokinetic data. Michaelis
Menten saturation kinetic parameters were calculated from substrate depletion
data. Maximum rates of metabolism (VMAX, nmol/min/mg microsomal protein)
and rates of intrinsic clearance (CLINT, ml/min/kg body weight) were higher for
BaP than DBC, regardless of species. Clearance for both BaP and DBC was highest
in naïve female mice (1705 and 182 ml/min/kg) and lowest in female humans
(27.2 and 7.5 ml/min/kg). Clearance rates of BaP and DBC in male rat (52.2 and
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18.8 ml/min/kg) were more similar to female human than to female mice.
Clearance of DBC in pregnant mice (136 ml/min/kg) was reduced compared to
naïve mice, possibly contributing to elevated tissue concentrations and residence
times observed in pharmacokinetic data. These parameters have been used in the
development of physiologically based pharmacokinetic (PBPK) models of PAH ex-
posure and dosimetry for rodents and humans, which accurately describe available
pharmacokinetic data. Supported by Award Number P42 ES016465 from the
National Institute of Environmental Health Sciences.
300 Hyperoxia Attenuates Cytochrome CYP1B1 Expression in
Human Bronchial Epithelial Cell BEAS-2B: Implications for
Oxygen-Mediated Lung Injury.
D. Dinu,  C. Chu,  W. Jiang,  B. Shivanna,  X. Couroucli and B. Moorthy.
Pediatrics, Baylor College of Medicine, Houston, TX.
Supplemental oxygen, used to treat premature infants with pulmonary insuffi-
ciency, contributes to the development of bronchopulmonary dysplasia (BPD) in
animal models and infants by mechanisms that are not entirely known. We recently
observed that cyp1b1-null mice are less susceptible to hyperoxic lung injury, sug-
gesting a pro-oxidant role for CYP1B1. Hyperoxia inhibits the growth of the cells,
and β-naphthoflavone (BNF) was reported to protect cells from hyperoxic injury.
This study tested the hypotheses: 1. hyperoxia attenuates endogenous and BNF in-
ducible CYP1B1 expression in human lung cell line, BEAS-2B; 2. downregulation
of CYP1B1 protects cells from hyperoxic injury while overexpression augments the
damage.
BEAS-2B cells treated with DMSO (control) or BNF were maintained in room air
or hyperoxia for 24, 48, and 72 h. CYP1B1 promoter activity, mRNA and protein
expression were evaluated. Cell proliferation, cell viability, apoptotic markers and
reactive oxygen species were assessed.
BEAS-2B cells expressed endogenous CYP1B1 protein, which was diminished by
about 50% by 24 or 48 h of hyperoxia. BNF induced CYP1B1 mRNA and protein
expression. Hyperoxia attenuated endogenous and BNF inducible CYP1B1 protein
expression and mRNA expression. Also, hyperoxia attenuated luciferase driven
CYP1B1 promoter activity. BNF had minimal improvement in cell viability.
Downregulation of CYP1B1 using siRNA improved cell viability in hyperoxia, and
overexpression of CYP1B1 was associated with a significant decrease in viability.
Our finding that hyperoxia decreases CYP1B1 protein, mRNA and promoter ex-
pression suggests transcriptional or post-transcriptional mechanisms. The finding
that downregulation of CYP1B1 improves cell viability, while the overexpression
decreases the cells viability supports the role of CYP1B1 as pro-oxidant in hyper-
oxic injury. As CYP1B1 appears to contribute to lung injury mediated by hyper-
oxia, understanding the mechanisms of regulation of CYP1B1 may lead to new
strategies to prevent or treat BPD.
301 Metabolism of Deltamethrin (DLM) and Trans-Permethrin
(TPM) by Human Hepatic and Intestinal Preparations.
B. G. Lake1,  R. J. Price1,  B. Ing1,  M. Scott1,  R. N. Hines2,  H. J. Clewell4,
D. W. Gammon5,  N. Assaf3,  M. Yoon4,  S. S. Anand6 and T. G. Osimitz7. 1LFR
Molecular Sciences, Leatherhead, United Kingdom; 2Medical College of Wisconsin,
Milwaukee, WI; 3Valent Biosciences, Libertyville, IL; 4The Hamner Institutes for
Health Sciences, Research Triangle Park, NC; 5FMC, Ewing, NJ; 6DuPont Haskell,
Newark, DE; 7Science Strategies LLC, Charlottesville, VA.
Pyrethroids can be metabolised by both cytochrome P450 (CYP) and car-
boxylesterase (CES) enzymes. DLM and TPM metabolism was studied using the
substrate depletion approach in pooled human hepatic S9, microsomes and cytosol
and intestinal S9 fractions. Studies with liver S9 in the presence and absence of
NADPH indicated that DLM was metabolised mainly by CES enzymes, whereas
TPM was metabolised by both CES and CYP enzymes. Rates of DLM and TPM
clearance in liver microsomes were 22.3 and 11.9 ml/min/mg protein, respectively,
and in liver cytosol were 2.6 and 5.3 ml/min/mg protein, respectively. The hepatic
clearance of both pyrethroids is thus due to both microsomal and cytosolic en-
zymes. Addition of cofactors for glucuronidation and sulfation did not enhance the
metabolism of DLM and TPM by hepatic S9, suggesting that the rate limiting step
for hepatic clearance of both pyrethroids is predominantly due to phase I enzymes
and not to phase II enzymes. Rates of DLM and TPM clearance by intestinal S9
were 0.6 and 0.8 ml/min/mg protein, respectively. Rates of pyrethroid metabolism
were not reduced in the absence of NADPH, suggesting that both compounds are
largely metabolised by only intestinal CES enzymes. The metabolic data obtained
with human tissue fractions will be used to develop PBPK models for DLM and
TPM (Supported by CAPHRA).
302 Biological Impact of a Dysfunctional CYP1/AhR Auto-
Regulatory Feedback Loop.
E. Wincent1, 2,  A. Kubota2,  A. R. Timme-Laragy2,  M. E. Hahn2,  A. Rannug1
and J. Stegeman2. 1Institute of Environmental Medicine, Karolinska Institutet,
Stockholm, Sweden; 2Biology Department, Woods Hole Oceanographic Institution,
Woods Hole, MA.
The toxicity of slowly metabolized AHR agonists (e.g., dioxins) can be explained by
their persistent activation of the receptor, whereas transient AHR activation by
readily metabolized chemicals leads to toxicity through cytochrome P4501
(CYP1)-dependent bioactivation of PAHs to toxic products. Still, CYP1A inhibi-
tion has been shown to amplify carcinogenic and teratogenic effects of PAHs, em-
phasizing the complex relationship between CYP1 induction and toxicity. The en-
dogenous and proposed physiological ligand 6-formylindolo[3,2-b]carbazole
(FICZ) has the highest AHR affinity found to date and is an almost perfect sub-
strate for CYP1A, resulting in an efficient auto-regulatory feedback of its actions.
The importance of CYP1/AHR feedback regulation to in vivo responses to FICZ
are unknown. 
We tested the hypothesis that blocking CYP1A expression would result in FICZ be-
coming toxic in vivo. Studies were performed using zebrafish (zf; Danio rerio) em-
bryos with morpholino knockdown of CYP1A (CYP1A-KD) or AHR2 (AHR2-
KD). Zf embryos were exposed to vehicle (DMSO) or FICZ (10 or 100nM)
starting at 24 hr post fertilization (hpf ), and morphology was monitored from 54
to 96 hpf. In the CYP1A-KD embryos FICZ caused a dose-dependent increase in
the incidence and severity of pericardial edema and circulation failure, and in-
creased lethality. Hatching frequency was reduced and swimbladder inflation abol-
ished. In control-KD and AHR2-KD embryos, FICZ (100nM) had no significant
morphological effects. 
The results show that a functioning CYP1/AHR feedback loop is crucial for regula-
tion of AHR signaling by a potential physiological ligand. Considering the large
number of chemicals and drugs known to inhibit CYP1s, we suggest a novel mech-
anism of toxicity whereby chemicals inhibit the metabolism of FICZ, resulting in
prolonged activation of the AHR. [FORMAS grant 2011-963; NIH grants
R01ES015912, F32ES017585, and R01ES006272; JSPS Postdoctoral Fellowship
for Research Abroad 820]
303 Metabolism and Disposition of 2-Ethylhexyl-P-
Methoxycinnamate in Male and Female Harlan Sprague-
Dawley Rats and B6C3F1/N Mice After Gavage and
Intravenous Administration.
S. Waidyanatha1,  R. Snyder2,  Y. Hong2,  S. Watson2,  S. Black2,  B. McIntyre1
and J. Mathews2. 1Division of National Toxicology Program, NIEHS, Research
Triangle Park, NC; 2RTI International, Research Triangle Park, NC.
2-Ethylhexyl-p-methoxycinnamate (EHMC) was nominated to the National
Toxicology Program for toxicological evaluation based on its presence as one of the
most common active ingredients in sunscreens. Therefore, the current study was
undertaken to investigate the metabolism and disposition of [14C]EHMC in male
and female Harlan Sprague Dawley rats and B6C3F1/N mice 24 h or 72 h follow-
ing gavage and intravenous administration. Intravenous doses to male rats and mice
were 8 mg/kg. Gavage doses of 8, 80 or 800 mg/kg to rats were mostly excreted in
urine (73-80% in 72 h), with 3-8% of the radioactivity recovered in feces and 1-4%
as CO2; volatiles accounted for less than 0.25% of the radioactivity for the 800
mg/kg dose. Radioactive residues in tissues were <1% of the dose. There were no
sex or route differences in disposition in rats. In male and female mice administered
8 mg/kg gavage and intravenous doses of EHMC, radioactivity was excreted mostly
in urine (57-73% in 72 h), recovery in CO2 and volatiles traps was only 2-4% and
1%, respectively, and tissues contained <0.3% of the radioactivity 72 h post dosing
without any apparent sex- or route-related differences in disposition. Urinary
metabolites following gavage administration of 800 mg/kg EHMC were associated
with hydrolysis of the ester and hydroxylation of the ring; no parent EHMC was
detected in urine. The metabolites 2-ethylhexanol and 2-ethylhexanoic acid, which
are developmental toxicants, were identified by GC-MS in plasma from rats 1 and
2 h following a gavage dose of 800 mg/kg EHMC. These data indicate that oral
doses of EHMC are well absorbed, completely metabolized and excreted chiefly in
urine with no species or sex difference. [Supported by NIH, N01ES75563]
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304 Immunochemical Characterization of Xenobiotic-
Metabolizing Enzyme Expression in Adult Rat Testis.
R. R. Gilibili1,  W. A. Vogl2,  T. K. Chang1 and S. M. Bandiera1. 1Faculty of
Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada;
2Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.
Relatively little is known about the protein expression of xenobiotic-metabolizing
enzymes, such as cytochrome P450 (CYP) and epoxide hydrolase (EH) in rat testis.
These enzymes are expressed in liver and many other organs, and are known to play
an important role in the oxidative biotransformation of various endogenous and ex-
ogenous compounds. Some xenobiotics such as benzo[a]pyrene are bioactivated to
form genotoxic and/or carcinogenic metabolites. Formation of reactive metabolites
in the testis could cause severe adverse effects on steroidogenesis and germ cell de-
velopment. In the present study, we characterized the expression of various xenobi-
otic-metabolizing enzymes in adult rat testis using immunoblot and immunohisto-
chemical analyses. Testicular microsomes prepared from adult male
Sprague-Dawley rats were separated using SDS-PAGE and electrophoretically
transferred onto membranes and probed with different antibodies. Immunoblot re-
sults indicated that CYP1B1, CYP2A1, NADPH-cytochrome P450 reductase, and
EH were expressed in testicular microsomes isolated from adult rats. By compari-
son, CYP1A1, CYP1A2, CYP2B1, CYP2E1, CYP2D1, CYP2D2, CYP2C6,
CYP2C7, CYP2C11, CYP2C12, CYP2C13, CYP3A1, CYP3A2, CYP4A1,
CYP4A2 and CYP4A3 were not detected in the testicular microsomal samples. In
addition, tissue sections were prepared from frozen adult rat testis and probed with
antibodies to CYP1B1, CYP2A1, NADPH-cytochrome P450 reductase, and EH.
Fluorescent staining indicated that CYP1B1 and CYP2A1 were expressed in inter-
stitial cells, which are comprised mainly of Leydig cells, but not in seminiferous
tubules. In contrast, EH and NADPH-cytochrome P450 reductase were expressed
in both interstitial cells and in seminiferous tubules. In summary, among the CYP
enzymes studied, only CYP1B1 and CYP2A1 were detected in testicular micro-
somes and appeared to be confined to interstitial cells.
305 Demographic Differences by Age, BMI, Gender, and Disease
States of Phase I and Phase II Enzyme Activities in
Cryopreserved Human Hepatocytes.
T. Moeller,  C. Six,  S. Dennell,  T. Rose and C. Watt. Celsis In Vitro Technologies,
Halethorpe, MD. Sponsor: M. Xia.
Human hepatocytes are a key in vitro reagent for making predictions of in vivo
drug metabolism, interactions and intrinsic clearance in drug discovery and devel-
opment. However, inter- individual differences in drug metabolizing enzyme activ-
ities complicate pharmacokinetics, leading to varying efficacy and drug-drug inter-
actions.  To delineate the potential influences, we have reviewed phase I (CYP1A2,
2A6, 2C9, 2C19, 2E1 and 3A4) and phase II (UGT and SULT) enzymatic activi-
ties as they relate to age, BMI, gender and ethnicity. The data was generated using
cryosuspension hepatocytes with specific substrates (CYP1A2: phenacetin, 2A6:
coumarin, 2C9: tolbutamide, 2C19: mephenytoin, 2E1:chlorzoxazone, 3A4:testos-
terone, UGT:7-hydroxycoumarin and SULT:7-hydroxycoumarin) near Km con-
centrations, as well as with multiple enzyme substrate 7-ethoxycoumarin (ECOD).
From a minimum of 180 donors, several statistically significant trends were ob-
served. For age-dependent differences, a loss of activity was observed for ECOD
and CYP2C19, and an increase in CYP1A2 activity as the age increased from 1 to
89 years old. As BMI increased, ECOD, CYP1A2 and CYP2C19 decreased be-
tween the range of 14 and 53. As for gender-related differences, men showed higher
activities in ECOD and CYP2E1. Diabetic donors had lower CYP2C9, CYP2C19
and CYP3A4 activities compared to non-diabetics. Overall, choosing appropriate
hepatocyte preparations for metabolism studies as a reflection of “average” are de-
pendent upon gender, age, BMI and disease states in many drug metabolizing en-
zymes.
306 Metabolism of Benzo(a)pyrene (BAP) and Fluoranthene
(FLA) in Gastrointestinal Tract Subcellular Fractions of the
APCMin Mouse.
K. L. Harris,  P. V. Rekhadevi,  D. L. Diggs,  A. C. Huderson,  J. A. Mantey,
L. D. Banks,  M. S. Niaz and A. Ramesh. Biochemistry & Cancer Biology, Meharry
Medical College, Nashville, TN.
The objective of the present study was to investigate whether subcellular fractions
(nuclear, cytosolic, mitochondrial, and microsomal) from the gastrointestinal (GI)
tract of a colon cancer mouse model were capable of metabolizing BaP, a combus-
tion byproduct, which is released into the environment from automobile exhausts,
cigarette smoke, and industrial emissions. A significant intake of BaP is also ex-
pected in people who consume barbecued foods, and diet rich in saturated fat. In
this study, subcellular fractions (SCF) were isolated by differential centrifugation
from a tumor-bearing ApcMin mouse induced by subchronic doses of 50μg/kg BaP
and incubated with either BaP or FLA (3μM each) alone or in combination and ap-
propriate control groups. Subsequent to incubation, samples were extracted with
ethyl acetate and analyzed for BaP and FLA metabolites by reverse-phase HPLC
with fluorescence detection. The SCF from tumor tissues metabolized BaP to a
greater extent than those from the non-tumor tissues. The rate of BaP metabolism
(pmol of metabolite/min/mg protein) was found to be more when fractions from
BaP-pretreated mice were exposed to BaP alone. The SCF from BaP-pre-exposed
mice generated greater proportion of BaP 7,8-diol, BaP 3,6- and 6,12-diones com-
pared to other experimental groups. Furthermore, SCF from BaP-pretreated mice
produced greater proportion of FLA 2, 3-diol, and 2, 3 D FLA when fractions were
incubated with FLA alone or a combination of BaP and FLA. Our studies revealed
that the tumor SCF were competent to metabolize BaP and FLA either individually
or as a binary mixture. The metabolism of BaP and FLA as a consequence of prior
or simultaneous exposure to BaP may influence the growth of tumors. Our findings
are of relevance to long-term dietary intake of these toxicants and the consequent
acceleration of the GI tract carcinogenesis process in humans (supported by
5R01CA142845-02, 1F31ES017391-01, 1F31ES019432-01A1,
5R25GM059994-11 and SREB grants).
307 Studies of Styrene, Styrene Oxide and 4-Hydroxystyrene
Toxicity in CYP2F2 Knockout and CYP2F1 Humanized
Mice Support Lack of Human Relevance for Mouse Lung
Tumors.
G. Cruzan1,  J. Bus2,  J. A. Hotchkiss2,  R. Sura2,  M. Banton3 and S. Sarang4.
1ToxWorks, Bridgeton, NJ; 2Dow Chemical Company, Midland, MI; 3LyondellBasell
Company, Houston, TX; 4Shell International, Houston, TX.
Styrene (S) is lung tumorigenic in mice but not in rats. In previous mode of action
(MOA) studies, S and its alkene-oxidized metabolite styrene oxide (SO) were not
lung toxic in CYP2F2(-/-) [knockout] mice, indicating S-induced mouse lung tu-
mors are mediated through mouse-specific CYP2F2-generated cytotoxic ring-oxi-
dized metabolite(s) producing repeated localized cytotoxicity in Clara cells and as-
sociated cumulative cell proliferation in lung bronchioles. This conclusion is
consistent with the observation that 4-hydroxystyrene (4HS) is toxic to Clara cells
in mice at doses lower than S or SO. The human relevance of the CYP2F MOA was
assessed by insertion of a human CYP2F1,2A13,2B6 transgene into CYP2F2(-/-)
mice; CYP2F1 expression and activity were confirmed in the transgenic (TG) mice.
No evidence of cytotoxicity or increased cell proliferation (BrdU labeling) was seen
in TG mice treated with either S or SO (200 mg/kg/day ip for 5 days), while cyto-
toxicity was apparent and BrdU labeling was increased ~10-fold in wild-type (WT)
mice. Consistent with the hypothesis, 4HS (60 or 105 mg/kg ip for 5 days) in-
creased BrdU labeling 5-10 fold in WT mice, and was attenuated to less than a 3
fold increase in KO mice and a 2-4 fold increase in TG mice. The limited response
of 4HS in both KO and TG mice suggests that direct administration of high doses
of 4HS are either intrinsically lung toxic or are capable of limited metabolism by ei-
ther CYP2F1 and/or other lung CYPs in KO and TG mice to lung toxic metabo-
lite(s). Regardless of the MOA of the limited 4HS toxicity in KO or TG mice, these
findings indicate that the CYP2F-mediated tumorigenic MOA in WT mice is not
operative for S, SO, or for 4HS putatively derived from metabolism of S by
CYP2F1 in humans, and thus S-induced mouse lung tumors are unlikely to be rel-
evant to human risk. 
Sponsor: Styrene Information and Research Center
308 Metabolism and Disposition of Bisphenol AF in Male and
Female Harlan Sprague-Dawley Rats following Gavage and
Intravenous Administration.
T. Fennell1,  R. Snyder1,  P. Patel1,  S. Black1,  J. Mathews1,  M. Mercado-
Feliciano2 and S. Waidyanatha2. 1Pharmacology and Toxicology, RTI International,
Research Triangle Park, NC; 2Division of National Toxicology Program, NIEHS,
Research Triangle Park, NC.
Bisphenol AF (BPAF) is used as a cross linking agent in polymers. BPAF was nom-
inated to the National Toxicology Program for toxicological evaluation based on its
moderate production levels, structural similarity to bisphenol A, and lack of ade-
quate toxicity data. The current study was undertaken to investigate the metabo-
lism and disposition of [14C]BPAF in male and female Harlan Sprague Dawley
(HSD) rats. Following gavage administration of 3.4, 34 or 340 mg/kg to male rats,
the administered dose was mostly excreted in feces (73-80%) with < 6% of the dose
recovered in urine and cage rinse at 72 h. Radioactivity in tissues was 0.2-1.5% of
the dose 72 h post dosing compared to 7% at 24 h following a dose of 34 mg/kg.
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Urinary excretion at 72 h post administration was higher in females (~15%) com-
pared to males (~4%) following a 34 mg/kg dose. Distribution of an intravenous
dose of 34 mg/kg was similar to that following gavage, but with less excreted in
urine in both males (0.62% for intravenous vs. 4.32% for gavage) and in females
(7% for intravenous vs. 15% for gavage). About 52% of a 340 mg/kg gavage dose
was excreted in bile by 24 h, indicating that high excretion in feces is not due
mostly to unabsorbed BPAF. BPAF glucuronide (major metabolite), diglucuronide,
glucuronide-sulfate, and sulfate were identified in bile using LC/MS/MS. This
study demonstrated that BPAF is well absorbed following gavage administration in
rats, metabolized by glucuronidation and sulfation, and excreted mainly in feces.
[Supported by NIH, N01ES75563].
309 Absorption, Distribution, Metabolism, and Excretion Studies
of n -Butylbenzenesulfonamide in Harlan Sprague-Dawley
Rats following Gavage Administration.
S. Black1,  S. Watson1,  J. Mathews1,  C. Rider2 and S. Waidyanatha2.
1Pharmacology and Toxicology, RTI International, Research Triangle Park, NC;
2Division of National Toxicology Program, NIEHS, Research Triangle Park, NC.
n – Butylbenzenesulfonamide (NBBS) is used as a plasticizer and an antifungal
agent. There is high potential for human exposure to NBBS due to its likely occur-
rence in drinking water and leaching from NBBS-containing products. The limited
toxicity data in rodents suggests that NBBS can cause toxicity to the hematopoietic,
nervous, and male reproductive systems. The present studies were conducted to in-
vestigate the clearance of NBBS in male Harlan Sprague Dawley (HSD) rat and
B6C3F1/N mouse hepatocytes in vitro and metabolism and disposition of NBBS
following gavage administration in HSD rats in vivo. The half-lives of disappear-
ance of NBBS (1 μM) in rat and mouse hepatocytes were 136 ± 24 and 320 ± 41
min, respectively. Following gavage administration of ring-labeled [14C]NBBS to
male HSD rats at 2 and 200 mg/kg and sacrificed at 72h, NBBS was excreted pri-
marily in urine (70-76%) with feces accounting for about 12% of the administered
dose. Retention in tissues was 5-7% at 72 h, with no tissue exhibiting high concen-
trations of radioactivity relative to blood. Profiling of urine showed presence of nu-
merous metabolites; however, the parent NBBS was not observed. Some of the
polar metabolites were diminished upon treatment with β–glucuronidase or acy-
lase, indicative of glucuronides and mercapturates, but minimal changes were ob-
served after sulfatase treatment. In conclusion, NBBS is well absorbed following
gavage administration and metabolized to products including glucuronides and
mercapturates. [Supported by NIH, N01ES75563].
310 Biotransformation of BDE-47 to Potentially Toxic
Metabolites Is Predominantly Mediated by Human CYP2B6:
Implications for Interindividual Variability in Metabolism
and Retention of BDEs.
J. R. Olson1,  M. S. Gross2,  M. L. Feo3,  S. T. Singleton1,  A. L. Crane1,
B. P. McGarrigle1,  E. Eljarrat3,  D. Barcelo3 and D. S. Aga2. 1Pharmacology and
Toxicology, University at Buffalo, Buffalo, NY; 2Chemistry, University at Buffalo,
Buffalo, NY; 3Environmental Chemistry, IDAEA CSIC, Barcelona, Spain.
Recent studies suggest that bioactivation by oxidative metabolism may add consid-
erably to the neurotoxic potential of polybrominated diphenyl ethers (PBDEs), but
critical data are lacking on PBDE metabolism in humans. The purpose of this study
was to characterize the in vitro metabolism of 2,2′,4,4′-BDE (BDE-47), the most
abundant PBDE detected in human serum, by human liver microsomes (HLMs)
and recombinant human cytochrome P450s (CYPs), and to identify the CYP(s)
that are active in the oxidative metabolism of BDE-47. Human CYPs (CYP1A1,
1A2, 1B1, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, 3A4) were incubated with
BDE-47 (20 μM) and metabolites were measured and characterized using
GC/MS/MS. For kinetic studies, CYP2B6 and pooled HLMs were incubated with
BDE-47 (0-60 μM). CYP2B6 was the predominant CYP capable of forming six
different OH-BDEs, including 3-OH-BDE-47, 5-OH-BDE-47, 6-OH-BDE-47,
2′-OH-BDE-66, 4-OH-BDE-42, and 4′-OH-BDE-49. GC/MS analysis also re-
vealed formation of novel metabolites, di-OH-BDE-47 and di-OH-dioxin. Kinetic
studies of BDE-47 metabolism by CYP2B6 and pooled HLMs found Km values
ranging from 4.1-6.9 μM and 7.8-13 μM, respectively, indicating the high affinity
towards the formation of OH-BDEs. Interindividual variability in the in vitro me-
tabolism of BDE-47 will be assessed utilizing CYP2B6 genotyped HLMs, with up
to a 100-fold range in the level of CYP2B6 activity, and recombinant polymorphic
variants of human CYP2B6 (*4, *5, *6, *7, *18). Our findings support the pre-
dominant role of CYP2B6 in the metabolism of BDE-47 and suggest that in addi-
tion to variable exposures to PBDEs, genetic variability in CYP2B6-specific metab-
olism may contribute to interindividual variability in the body burden of PBDEs
and the formation of potentially toxic metabolites. (NIEHS, grant # ES021554)
311 Coculture of Antigen-Presenting Cells and Keratinocytes
Increases Responsiveness to Prohaptens.
J. Hennen1,  C. Cohrs1,  A. John2,  A. Seidel2 and B. Blömeke1. 1Department of
Environmental Toxicology, University Trier, Trier, Germany; 2Biochemical Institute for
Environmental Carcinogens, Prof. Dr. Gernot Grimmer Foundation, Grosshansdorf,
Germany.
Small chemical compounds can induce sensitization to humans that results in tol-
erance or allergic contact dermatitis after repeated skin exposure. A subgroup of
chemicals (prohaptens) can induce an immune response only following metabolic
activation, e.g. by cytochrome P450 (CYP). Related in vitro assays currently consist
of either skin cells or dendritic cells (DC) but importance of cross talk between
these two cell types including xenobiotic metabolism is becoming even more evi-
dent (Modi et al., 2012). To study this cross talk in more detail we established a co-
culture model consisting of THP-1 cells as DC-like cells and HaCaT keratinocytes
(Hennen et al., 2011). Upregulated expression of costimulatory molecule CD86
was clearly increased in coculture after incubation with prohaptens and depended
on phase I/II enzyme activity. It is not known whether proximate or ultimate
metabolites are transported between these two cell types or whether coculture en-
hances THP-1 responsiveness towards prohaptens. As relevant metabolites have not
been identified for most prohaptens, we used the strong sensitizer benzo[a]pyrene
(B[a]P) as model prohapten. In single cultured THP-1 cells, B[a]P neither induces
CYP1 enzymes nor CD86 expression, whereas in coculture with HaCaTs CYP1A1
(>100-fold) and CYP1B1 (13-fold) as well as CD86 are clearly induced. In prelim-
inary experiments, we could detect several B[a]P metabolites in both HaCaT and
THP-1 supernatants, but the suspected ultimate metabolite was only formed in
HaCaT cells and in coculture as indicated by the presence of B[a]P tetrol in the su-
pernatants. Whether and how metabolites are transported needs further investiga-
tion, but results indicate that both cell types are needed for the activation of anti-
gen-presenting cells and likely sensitization.
312 Early Vertebrate Origin of ALDH1B1 from ALDH2 Gene
and Inactivation of ALDH1B1 by Heteromerization with
ALDH2*2.
B. C. Jackson1,  R. S. Holmes3,  D. S. Backos1,  P. Reigan1,  D. C. Thompson2
and V. Vasiliou1. 1Department of Pharmaceutical Sciences, University of Colorado
Anschutz Medical Campus, Aurora, CO; 2Department of Clinical Pharmacy,
University of Colorado Anschutz Medical Campus, Aurora, CO; 3School of
Biomolecular and Physical Sciences, Griffith University, Nathan, QLD, Australia.
Vertebrate ALDH2 genes encode mitochondrial enzymes capable of metabolizing
acetaldehyde and other biological aldehydes in the body. Mammalian ALDH1B1,
another mitochondrial enzyme sharing 72% identity with ALDH2, is also capable
of metabolizing acetaldehyde but has a tissue distribution and pattern of activity
distinct from that of ALDH2. Bioinformatic analyses of several vertebrate genomes
were undertaken using known ALDH2 and ALDH1B1 amino acid sequences.
Phylogenetic analysis of many representative vertebrate species (including fish, am-
phibians, birds and mammals) indicated the presence of ALDH1B1 in many mam-
malian species and in frogs (Xenopus tropicalis); no evidence was found for
ALDH1B1 in the genomes of birds, reptiles or fish. Predicted vertebrate ALDH2
and ALDH1B1 subunit sequences and structures were highly conserved, including
residues previously shown to be involved in catalysis and coenzyme binding for
human ALDH2. Studies of ALDH1B1 sequences supported the hypothesis that
the ALDH1B1 gene originated in early vertebrates from a retrotransposition of the
vertebrate ALDH2 gene. Given the high degree of similarity between ALDH2 and
ALDH1B1, it is surprising that individuals with an inactivating mutation in
ALDH2 (ALDH2*2) do not exhibit a compensatory increase in ALDH1B1 activ-
ity. We hypothesized that the similarity between the two ALDHs would allow for
dominant negative heterotetramerization between the inactive ALDH2 mutants
and ALDH1B1. Computational-based molecular modeling studies examining pre-
dicted protein-protein interactions indicated that heterotetramerization between
ALDH2 and ALDH1B1 subunits was highly probable and may partially explain a
lack of compensation by ALDH1B1 in ALDH2*2 individuals.
313 Epigallocatechin-3-Gallate Abrogates Cytotoxicity and DNA
Damage Induced by Benzo[a]pyrene in Lung Epithelial
Cells.
W. Zhu,  W. Gao and Q. Cai. The Institute of Environmental and Human Health,
Lubbock, TX.
Epigallocatechin-3-gallate (EGCG) is an active component isolated from green tea
which has chemopreventive and anticancer properties. However, the molecular
mechanisms of EGCG in these processes are still not very clear. The objective of the
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present study is to evaluate the potential protective effects of EGCG on
benzo[a]pyrene (BaP)-induced cytotoxicity and DNA damage in BEAS-2B, a
human normal lung epithelial cell. BEAS-2B cells were treated with vehicle control
(0.1% DMSO), BaP or BaP+EGCG for 24 hours. The cytotoxicity, cell cycle,
benzo[a]pyrene diol epoxidation (BPDE)-DNA adducts, and mRNA expression
levels of cytochrome P450 (CYPs) were determined by MTT assay, flow cytometry,
high performance liquid chromatography (HPLC), and quantitative real-time PCR
(qRT-PCR), respectively. BaP induced cell growth inhibition in a dose-dependent
manner; while EGCG dose- dependently reversed this inhibition (P<0.05). The
flow cytometry analysis showed that BaP caused significant G2/M phase arrest
compared to controls, however, increased S phase and decreased G2/M phase were
observed in cells co-treated with BaP and EGCG compared to BaP group (P<0.05).
BEAS-2B cells exposed to BaP had a significant induction of BPDE-DNA adducts
when compared with controls (P<0.01). Moreover, these adducts were diminished
significantly by EGCG treatment with an 80% reduction. CYP1A1 and CYP1B1
expression levels analyzed by qRT-PCR dramatically increased after BaP exposure
compared to controls (CYP1A1: 130.2-folds; CYP1B1: 6.0-folds; P<0.001).
EGCG significantly reduced BaP-induced CYP1A1 and CYP1B1 expression
(CYP1A1: 1.6-folds; CYP1B1: 1.2-folds; BaP vs. BaP+EGCG, P<0.05). On the
other hand, CYP1A2 and CYP3A4 did not show any changes among the control,
BaP-treated, and BaP and EGCG co-treated groups. In summary, BaP-induced ad-
verse effects could be prevented by EGCG, suggesting a possible chemopreventive
role for this natural polyphenol against the development of lung cancer.
314 17β-Estradiol Benzoate and Bisphenol A Suppress
Xenobiotic-Metabolizing Enzyme Expression in Adult Rat
Testis.
S. M. Bandiera,  R. R. Gilibili and T. K. Chang. Faculty of Pharmaceutical Sciences,
University of British Columbia, Vancouver, BC, Canada.
Previous studies showed that 17β-estradiol benzoate (EB) (at 4 μmol/kg) decreased
testicular expression of cytochrome P450 1B1 (CYP1B1) in adult male rats.
Bisphenol A (BPA) is an endocrine disrupting chemical that has been reported to
exert estrogenic activity in vitro and in vivo. In the present study, we investigated
the effect of treatment with EB and BPA at varying dosages on the expression of
CYP and other xenobiotic-metabolizing enzymes in rat testis. In Experiment 1, five
groups of adult male Sprague-Dawley rats (n = 4 per group, except for control, n =
5) were injected sc with EB (0.004, 0.04, 0.4 or 4 μmol/kg) or vehicle (propylene
glycol, 1ml/kg), once daily for 14 days. Immunoblot analysis indicated that treat-
ment with EB at 0.004, 0.04, 0.4 or 4 μmol/kg decreased testicular CYP1B1 (by
15, 56, 70 and 80 %), CYP2A1 (by 48, 79, 97 and 95%) and CYP17A1 (by 15,
44, 94 and 98 %) protein levels, respectively, when compared with vehicle-treated
rats. The constitutive expression of EH and NADPH-cytochrome P450 reductase
was not affected by EB at 0.004 μmol/kg, but EH (by 56, 70 and 80 %) and
NADPH-cytochrome P450 reductase (by 53, 58 and 48 %) protein levels were de-
creased following EB treatment at 0.04, 0.4 and 4 μmol/kg, respectively. In
Experiment 2, adult male rats (n = 4 per group) were injected sc with saline, vehicle
(propylene glycol, 1ml/kg) or BPA at 400, 800 or 1600 μmol/kg, once daily for 14
days. Treatment with BPA at 400, 800 or 1600 μmol/kg decreased CYP1B1 (by 51,
87 and 89%), CYP2A1 (by 79, 92 and 92%), EH (by 50, 67 and 67%) and
NADPH-cytochrome P450 reductase (by 43, 67 and 67%) protein levels, respec-
tively, when compared with saline- or vehicle-treated rats. CYP17A1 protein levels
were decreased by 49% by BPA at 400 μmol/kg dose and were not detectable at
other BPA doses. In conclusion, testicular expression of CYP1B1, CYP2A1,
CYP17A1, EH and NADPH-cytochrome P450 reductase was down-regulated by
exogenous estradiol and BPA, at higher dosages, produced a similar effect.
315 Acute Lead Exposure Induces Cardiotoxicity In Vivo and In
Vitro Rat Model through the Cytochrome P450 1A1
Signaling Pathway.
H. M. Korashy,  M. A. Ansari and Z. H. Maayah. Pharmacology & Toxicology,
King Saud University, Riyadh, Saudi Arabia. Sponsor: S. Al-Bakheet.
Lead (Pb2+) is a naturally occurring systemic toxicant heavy metal that has been re-
ported to affects several organs in the body including the kidneys, liver, central
nervous system, and the cardiovascular system. However, Pb2+-induced cardiotox-
icity has never been investigated yet and the exact mechanism of Pb2+ associated
cardiotoxicity has not been studied. Therefore, the current study was designed to
investigate the potential effect of Pb2+ to induce cardiotoxicity in vivo and in vitro
rat model and explore the molecular mechanisms and the role of cytochrome
P4501A1 (CYP1A1) in Pb2+-mediated cardiotoxicity. For these purposes, Wistar
albino rats were treated with Pb2+ (25, 50 and 100 mg/kg, i.p.) for three days to
study its effect on physiological and histopathological parameters of cardiotoxicity.
On the other hand, rat cardiomyocye H9c2 cell line, which was utilized as an in
vitro model, were incubated with increasing concentration of Pb2+ (25, 50, and
100 μM) and the expression of hypertrophic genes, α- and β-myocin (α-MHC and
β-MHC) and CYP1A1 were determined at the mRNA and protein levels using
real-time PCR and Western blot analysis, respectively. Our results showed that
Pb2+ significantly induced cardiotoxicity and heart failure as evidence by increase
cardiac enzymes, lactate dehydrogenese and creatine kinase-MB) and changes in
histopathology in vivo. In addition, Pb2+ treatment induced β-MHC whereas in-
hibited α-MHC mRNA levels in a time- and dose-dependent manner in vivo and
in vitro. Importantly, these changes were accompanied with a proportional increase
in the expression of CYP1A1 mRNA and protein expression levels, suggesting a
role for the CYP1A1. The direct evidence for the involvement of CYP1A1 in the
induction of cardiotoxicity by Pb2+ was evidenced by the ability of CYP1A1
blocker, resveratrol, to significantly inhibit the Pb2+-modulated β-MHC and α-
MHC mRNAs. It was concluded that acute lead exposure induced cardiotoxicity
through CYP1A1 mediated mechanism.
316 Reciprocal Roles of Cytochromes P4501a1 and 1A2 in Lung
Carcinogenesis Mediated by Polycyclic Aromatic
Hydrocarbons (PAHs) in Mice.
W. Jiang1,  L. Wang1,  G. Zhou2,  X. Couroucli1 and B. Moorthy1. 1Pediatrics,
Baylor College of Medicine, Houston, TX; 2Institute of Biosciences and Technology,
Texas A&M University Health Science Center, Houston, TX.
Humans are constantly exposed to polycyclic aromatic hydrocarbons (PAHs).
Cytochrome P4501A (CYP1A) enzymes play important roles in the activation of
PAHs such as 3-methylcholanthrene (MC) to DNA-binding metabolites, which in
turn mediate carcinogenesis in target organs such as lung. In this study, we tested
the hypothesis that CYP1A1 and 1A2 have reciprocal roles in PAH-mediated tu-
morigenesis. Eight week-old female wild type (WT) (A/J) mice or mice lacking the
gene for CYP1A1 or CYP1A2 on the A/J background were treated with a single
dose of MC (40 μmol/kg), or vehicle (corn oil), and liver and lung tumors were
studied after 28 weeks. While 100% of WT or Cyp1a2-null mice exposed to MC
showed lung tumors after 28 weeks, about 80% of the Cyp1a1-null mice showed
lung tumors. However, there were striking differences in the Cyp1a1-null and
Cyp1a2-null mice in regard to lung tumor multiplicities. The WT mice treated
with MC had about 15 lung tumors/animal. On the other hand, the Cyp1a2-null
mice displayed about 40 lung tumors/animal, while the Cyp1a1-null mice showed
about 2-3 tumors/mouse. DNA adduct studies at early time points (8 days) showed
increased MC-DNA adducts in lungs of Cyp1a2-null mice compared to WT mice,
and decreased adduct formation in the Cyp1a1-null mice, supporting the hypothe-
sis that DNA adducts are early biomarkers of PAH-mediated carcinogenesis.
Overall, our results suggest that CYP1A1 contributes to the formation of tumorige-
nesis by PAHs, while CYP1A2 protects against carcinogenesis mediated by PAHs,
presumably through it role in PAH detoxification. In conclusion, our results
strongly suggest that CYP1A1 and 1A2 could be novel candidates for cancer pre-
vention and therapy though either inhibition of CYP1A1 or induction of CYP1A2.
(Supported by NIH grant ES009132.)
317 Activity-Based Protein Profiling of Metabolizing Enzyme
Ontogeny and Response to PAH Exposure in Rodents and
Humans.
N. Sadler1,  S. R. Crowell1,  A. Wright1,  D. E. Williams2 and R. A. Corley1.
1Systems Toxicology, Pacific Northwest National Laboratory, Richland, WA; 2Oregon
State University, Corvallis, OR.
Activity-based protein profiling (ABPP) has recently emerged as a post-genomic
technology for characterizing functional proteins in complex biological systems.
This approach applies chemical activity-based probes that monitor the functional
activity of enzymes under physiological conditions, thereby providing high-content
proteomic information beyond the reach of standard gene- and protein-expression
profiling. We have previously developed a suite of activity based probes that display
broad coverage across mouse and human phase I and II metabolizing enzymes.
Each probe contains three moieties: (1) a reactive group that forms a covalent bond
to a functional P450 through a mechanism-based reaction, (2) a binding group that
targets a probe towards P450s, and (3) an alkyne (C2) handle to exploit the bio-
compatible click chemistry reaction for attachment of an enrichment moiety or flu-
orescent reporter. In this study, we measured enzyme activity at key life stages in
mouse, including fetal development, normal adulthood, and pregnancy, as well as
in human fetal tissues. Additionally, we compared the effects of exposure to the
transplacental carcinogenic polycyclic aromatic hydrocarbon (PAH)
dibenzo[def,p]chrysene (DBC) on enzyme activity in the mouse. We have deter-
mined that the activity of most hepatic phase I enzymes associated with PAH me-
tabolism (e.g., CYP 1A1, CYP2E1, epoxide hydrolase) was reduced by 2-10 fold
during pregnancy in mice. By incorporating these reductions in enzyme activity
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into a physiologically based pharmacokinetic (PBPK) model, along with normal
changes in anatomy and physiology, we were able to describe the significantly ele-
vated concentrations of DBC in blood and tissues of pregnant mice versus naïve
mice, following equivalent exposures. We additionally report, for the first time, de-
velopmentally driven changes in enzyme activity in both mice and humans.
Supported by Award Number P42 ES016465 from the NIEHS, and DOE
Laboratory Directed R&D Project 90001.
318 Elucidating the Catalytic Mechanisms of the Novel Styrene
Detoxification System in Pseudomonas Bacteria.
N. Okonkwo and G. T. Gassner. Chemistry and Biochemistry, San Francisco State
University, San Francisco, CA. Sponsor: F. Bayliss.
As the world becomes more polluted with styrene-based polymers, it is essential to
consider how the 28 million tons of Styrofoam and commercial plastics produced
in the United States impact human health. Styrene and its metabolites act as bio-
logical membrane disrupters and intracellularly where they are transformed by cy-
tochrome p450 isofroms to styrene oxide and vinylphenol, which have biological
activity as pulmonary and hepatic poisons. This toxic vinyl benzene is a danger to
living systems and for this reason we focused our research on the styrene detoxifica-
tion pathway in Pseudomonas bacteria. The first enzyme, styrene monooxygenase
(SMO), a two component flavoenzyme with an NADH specific reductase, SMOB,
and a FAD specific epoxidase, SMOA, catalyzes the epoxidation of styrene to yield
styrene oxide. Here, SMOB binds NADH and oxidized FAD as substrates and cat-
alyzes the reduction of FAD by a hydride-transfer mechanism. Many details of the
SMOB catalyzed flavin reduction and transfer still need to be explained. This re-
search evaluates the catalytic mechanism of N-terminally histidine-tagged styrene
monooxygenase reductase (N-SMOB) from Pseudomonas putida S12 bacteria.
Over expression of N-SMOB in E.coli BL21(DE3) cells produces high amounts of
the enzyme, which we purified using nickel affinity chromatography. A
Spectromax190 microplate reader was used to measure the rate at which the hy-
dride ion is transferred from NADH to FAD at 340nm. Previous data showed the
native SMOB enzyme follows a sequential mechanism under identical conditions.
However, preliminary data of N-SMOB at 10 °C suggests that a double displace-
ment reaction with NADH as the leading substrate could be prevalent mechanism.
These studies of N-SMOB at 10°C provided estimates of the Km of NADH, Km
of FAD and Vmax of N-SMOB at 5.0 uM, 3.7 uM, and 38.0 uMs-1, respectively.
Through the use of high resolution kinetic analysis at 30°C, we confirm that the
double displacement mechanism is the preferred reaction for N-SMOB and these
findings will be used to elucidate the flavin-transfer reaction.
319 Impact of Liver-Specific Loss of Cytochrome P450 Reductase
on the Expression and Function of Intestinal P450 Enzymes.
Y. Zhu1,  X. Ding1,  C. Fang2 and Q. Zhang1. 1Wadsworth Center, Albany, NY;
2American Clinical Solutions, Tampa, FL.
Tissue-specific deletion of the cytochrome P450 reductase (CPR) gene in either
liver or intestine leads to upregulation of many P450 genes in the tissue with the
Cpr deletion. The aim of this study was to test whether a loss of hepatic CPR would
also lead to upregulation of P450 expression in the small intestine (SI). We found
that in the liver-specific Cpr-null (LCN) mouse, SI expression of CYP2B, 2C and
3A proteins was increased, by 2- to 3-fold, relative to that in wild-type (WT) mice.
This increase was accompanied by increases in rates of SI microsomal metabolism
of lovastatin (LVS), a CYP3A substrate (by 2.1-fold). The overall impact of the loss
of hepatic P450 function and the increase in SI P450 expression on systemic clear-
ance of orally administered LVS was dependent on LVS dose: the rates of clearance
were increased at an LVS dose of 5 mg/kg, unchanged at 25 mg/kg, but decreased
at 50 mg/kg, in the LCN mice, compared to WT mice. Thus, we show for the first
time that hepatic CPR/P450 deficiency leads to compensatory increases in SI P450
expression and capacity of first-pass metabolism of oral drugs; this finding may aid
in the prediction of drug exposure in patients with compromised hepatic P450
function. We also found that SI FGF15 and IBABP mRNA levels were significantly
lower (by 15- and 5-fold, respectively) in LCN than in WT mice, while the levels of
PXR and FXR mRNAs were unchanged. Furthermore, treatment of mice with
FGF19 (the human counterpart of mouse FGF15) abolished the difference be-
tween WT and LCN mice in SI CYP3A levels. Thus, SI FGF15 may play a previ-
ously unrecognized, direct role in the regulation of SI P450 expression. Overall, our
results not only provide the basis for further mechanistic studies of physiological
regulation of SI P450 expression, but will also help with data interpretation for nu-
merous studies utilizing the LCN mouse model to determine roles of hepatic P450s
in the disposition of orally administered drugs.
320 Organ-Specific Ugt1 Locus Profiling in Defining the Toxic
Response Towards Irinotecan Anticancer Drug Therapy.
S. Chen,  V. Devaraj,  M. Fagan and R. H. Tukey. Laboratory of Environmental
Toxicology, Departments of Chemistry & Biochemistry and Pharmacology, University
of California San Diego, La Jolla, CA.
Irinotecan (CPT-11) has been used as a first line drug in the treatment of colorectal
cancer. However, its efficacy and safety is compromised because of severe late onset
diarrhea, a result of enterocyte toxicity from the active metabolite SN-38. SN-38 is
inactivated primarily by hepatic UGT1A1 catalyzed glucuronidation to form SN-
38 glucuronide, which is excreted via the biliary ducts into the gastrointestinal (GI)
tract, where it serves as a substrate for bacterial β-glucuronidase. Free SN-38 is then
re-absorbed by entry through the GI tract. Since an abundance of the UGT1 pro-
teins are rich in the GI tract, it was important to examine the association between
SN-38 glucuronidation and the pending intestinal tissue damage resulting from
CPT-11 therapy. To carry out these experiments, we have generated mouse models
targeting deletion of the Ugt1 locus specifically in liver (Ugt1ΔHep) and the intestines
(Ugt1ΔGI). Wild type (Ugt1F/F), Ugt1ΔHep, and Ugt1ΔGI adult male mice were treated
by the intraperitoneal route with CPT-11 daily for four constitutive days. At a daily
dose of 75 mg/kg, survival curves of the Ugt1ΔHep mice showed a 50% lethality rate,
comparable to the LD50 values of CPT-11 treated Ugt1F/F mice. Deletion of the
Ugt1 locus in hepatic tissue had no impact on liver or GI toxicity when compared
to wild type mice. Alternatively, Ugt1ΔGI mice were highly susceptible to CPT-11-
induced diarrhea, developing severe ileocolitus. At a CPT-11 dose of 25 mg/kg,
bloody diarrhea was observed in all Ugt1ΔGI mice and was associated with 100%
lethality, while no diarrhea or lethality was observed in Ugt1ΔHep or Ugt1F/F mice at
that dose. Thus, intestinal expression of the UGT1A proteins is critical towards the
detoxification of SN-38. Regulation of the intestinal UGT1A1 gene may serve as a
target for improving the therapeutic index and efficacy associated with CPT-11
treatment. (Supported by USPHS grants ES010337 and CA171008)
321 Selective Criteria for Determining Catalytic Competency in
CYP3A4: A Combined Docking and Pharmacophore Study
on Triazole Fungicide Metabolism.
D. T. Chang1,  C. M. Grulke1,  M. Goldsmith1,  J. F. Kenneke2,  S. Rawat3,
S. A. Marchitti2,  C. S. Mazur2,  K. Holm1,  M. B. Phillips1,  Y. Tan1,  R. Tornero-
Velez1 and C. C. Dary4. 1National Exposure Research Laboratory, US EPA, Research
Triangle Park, NC; 2National Exposure Research Laboratory, US EPA, Athens, GA;
3Student Services Authority, Athens, GA; 4National Exposure Research Laboratory, US
EPA, Las Vegas, NV.
Cytochrome P450 (CYP) 3A4 is one of the major isoforms of enzymes that cat-
alyzes via Phase I oxidation a wide variety of endogenous and exogenous com-
pounds (i.e., broad substrate specificity) including environmental xenobiotics like
chiral pesticides. In particular, several chiral pesticides are well-known to undergo
differential kinetics within the homochiral environment of biological systems. The
current ability to model such metabolic processes within physiologically-based
pharmacokinetic model from an exposure-dose perspective is limited by specific
chiral information coupled together with accurate kinetic data. With available in-
house stereospecific (i.e., individual stereoisomer) in vitro data, we have utilized a
ligand–based approach to develop a prototype CYP3A4 pharmacophore model for
triazole fungicides based on the observed stereoselective CYP3A4 clearance. The
developed model was further used to discriminate between single isomeric configu-
rations thereby enriching the dataset and providing further criteria on putative lig-
and-receptor interactions. We also utilized a combined pharmacophore and dock-
ing approach within the CYP3A4 binding cavity (2V0M PDBID) to provide
estimates on putative ligand stereoselective rate constants for a test set of triazole
compounds. Observations and comparisons between high and low binding affinity
poses as well as homolytic dissociation bond energy estimates at purported sites of
metabolism indicate that this method may be helpful for selecting catalytically
competent ligand substrates for CYP3A4 and thereby reducing the uncertainty
within exposure-based pharmacokinetic models of chiral substrates.
Although this work was reviewed by EPA and approved for publication, it may not
necessarily reflect official Agency policy.
322 Chlorpyrifos Affects Specific Types of Zebrafish Larval
Behavior If Administered during Distinct Developmental
Time Periods.
H. Richendrfer and R. Creton. MCB, Brown University, Providence, RI.
Pesticides are widely used in agriculture and are found ubiquitously in the environ-
ment. While adults have enzymes that are able to break down pesticides, developing
embryos lack the necessary enzymes for toxicant removal.  Low doses of
organophosphate pesticides during early embryonic development in animal models
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and in humans have been documented to affect brain development and behavior. It
is important to determine at which stages of development embryos are most af-
fected by the exposure to organophosphate pesticides. Using zebrafish as a model
system for pesticide exposure is advantageous because embryos can be exposed to
organophosphates immediately after fertilization and large numbers of larvae can
be used for high-throughput behavioral analysis. Behaviors such as swim speed,
preference for edge of a well, and avoidance of a moving stimulus can be quickly
obtained. In the present study, employing a high-throughput assay unique to our
lab, we show that exposure to low doses of a widely used organophosphate, chlor-
pyrifos, affect discrete behaviors if administered during specific developmental time
periods.  The results indicate that even low levels of chlorpyrifos have the potential
to impact behavior when administered during critical periods of development and
these behavioral abnormalities are emerge from pesticide exposure during different
critical points. The results of the present study have the potential to affect food con-
sumption guidelines, especially in pregnant women.  Future studies will include lar-
val zebrafish confocal brain imaging to detect neural patterning changes after chlor-
pyrifos exposure.
323 The AhR Pathway and Aromatic Hydrocarbon-Mediated
Teratogenicity in the Atlantic Killifish.
R. T. Di Giulio1,  C. W. Matson2 and B. W. Clark1. 1Duke University, Durham,
NC; 2Baylor University, Waco, TX.
Exposure of developing fish to polycyclic aromatic hydrocarbons (PAHs) and halo-
genated aromatic hydrocarbons (HAHs) results in a suite of defects including car-
diac malformation, pericardial and yolk sac edema, craniofacial defects and hemor-
rhaging. Several populations of Atlantic killifish (Fundulus heteroclitus) on the
Atlantic coast of the United States are resistant to the developmental toxicity caused
by PAHs and HAHs; this resistant phenotype displays strong down-regulation of
the aryl hydrocarbon receptor (AHR) pathway. The AHR is known to mediate
many toxic responses to PAHs and HAHs in vertebrates. A single AHR has been
identified in mammals, but killifish and other fish species have multiple AHRs and
their roles in contaminant response and development are not clear. In this study,
translation-blocking and splice-junction morpholino gene knockdown was used to
determine the roles of AHR1 and AHR2, as well as CYP1A, in mediating cardiac
teratogenesis induced by β-naphthoflavone (BNF), benzo[k]fluoranthene (BkF),
and 3, 3’, 4, 4’, 5-pentachlorobiphenyl (PCB-126). Here we report that AHR2 and
not AHR1 knockdown resulted in rescue of cardiac teratogenicity induced by BNF,
BkF, and PCB-126 in laboratory-reared offspring of non-adapted of parents from
unpolluted sites. Knockdown of CYP1A enhanced the toxicity of PAHs but not
PCB126. Furthermore, knockdown of AHR2 partially rescued the severe cardiac
teratogenicity caused by extracts of sediments from the Atlantic Wood (AW)
Superfund site (Elizabeth River, VA, USA), a site heavily contaminated with a com-
plex mixture of creosote-derived PAHs (and home to a resistant population of killi-
fish). These data demonstrate that AHR2 is an important mediator of cardiac ter-
atogenesis caused by multiple aryl hydrocarbons in killifish and suggest that
suppression of the AHR pathway through modulation of AHR2 is a plausible
mechanism for PAH resistance in adapted fish. CYP1A, which is recalcitrant to in-
duction in the AHR down-regulated AW population, appears to play a protective
role against PAH developmental toxicity.
324 Characterization of glo1 Gene Expression during
Development and Alterations Induced by Atrazine Exposure
in Zebrafish.
G. Ryan1,  G. J. Weber1,  S. M. Peterson1,  M. S. Sepulveda2 and J. L. Freeman1.
1Health Sciences, Purdue University, West Lafayette, IN; 2Forestry and Natural
Resources, Purdue University, West Lafayette, IN.
Atrazine is a commonly used herbicide that is an endocrine disruptor and a sus-
pected carcinogen. Although atrazine was recently banned by the European Union
for widespread contamination risks in potable water supplies, this herbicide is still
commonly used in the United States with a current maximum contaminant level
(MCL) of 3 ppb. The health risks associated with this MCL are currently being re-
viewed by the Environmental Protection Agency, but the mechanisms of atrazine
toxicity are not well defined. In this study, we are using [1] global gene expression
analysis to identify altered genes, [2] in situ hybridization to qualitatively analyze
spatial gene expression throughout development, and [3] quantitative PCR (qPCR)
to assess gene expression levels of specific targets throughout development in the ze-
brafish model system. In a previous study completed in our laboratory, zebrafish
were exposed to 0.3, 3, or 30 ppb atrazine or a control treatment throughout devel-
opment (1-72 hours post fertilization [hpf ]). This analysis showed that expression
alterations were enriched with genes associated with neuroendocrine development
and function, cell cycle regulation, and carcinogenesis. From this list of genes, gly-
oxylase 1 (GLO1) was targeted for further study. GLO1 is part of the glyoxylase
system which converts methylglyoxal to S-D-lactoylglutathione. Upregulation of
GLO1 is linked to cell proliferation and is associated with various cancers in hu-
mans. To further our understanding of this genetic target, expression was analyzed
at five developmental time points: 24, 36, 48, 60, and 72 hpf. In situ hybridization
and qPCR were coupled to determine spatial and quantitative gene expression of
glo1 throughout development under normal conditions and after atrazine treat-
ment. This data is furthering our understanding of glo1 expression during develop-
ment and alterations induced by atrazine exposure.
325 Developmental Effects of 6-Formylindolo[3, 2-B]Carbazole
in Birds.
M. E. Jönsson1,  S. Shaik1, 2,  A. Rannug2 and B. Brunström1. 1Environmental
Toxicology, Uppsala University, Uppsala, Sweden; 2Institute of Environmental
Medicine, Karolinska Institutet, Stockholm, Sweden.
Birds show a strikingly large species variation in susceptibility to developmental
toxicity of dioxins and coplanar polychlorinated biphenyls (PCBs). The chicken is
the most sensitive to these compounds among avian species, while e.g. the Japanese
quail is much more resistant. Such differences are proposed to depend on binding
affinity of dioxin to the aryl hydrocarbon receptor (AHR), i.e., the degree of sensi-
tivity is linked to variation in a few amino acids in the ligand binding domain of
avian AHRs. The proposed endogenous AHR ligand 6-formylindolo[3,2-b]car-
bazole (FICZ) has high AHR binding affinity and causes strong transient induction
of CYP1 mRNA in human cells and zebrafish embryos. In Xenopus tropicalis tad-
poles FICZ is almost as potent an inducer of CYP1A as in zebrafish embryos.
However, Xenopus tadpoles are much less sensitive to PCB126-induced toxicity
than zebrafish embryos. The goal of the present study was to determine mRNA ex-
pression responses and other effects of FICZ in developing birds. Peanut oil-
lecithin emulsions with or without FICZ were injected into the yolks of day-4
chicken embryos (0, 2, 20, or 200 μg FICZ/kg egg) and day-3 quail embryos (0, 2,
or 200 μg FICZ/kg egg). Twenty four hours post-injection CYP1A4 and CYP1A5
showed dose-dependent induction by FICZ in both chicken and quail, and the de-
gree of induction was similar in the two species. The CYP1B1 level in both species
and the CYP1C1 level in chicken were unaffected by FICZ exposure. In chicken
embryos exposed to 200 μg FICZ/kg the CYP1A levels remained induced in liver
and thymus 13 days post-injection (day 17). Furthermore, liver lesions were ob-
served in 48% of these animals, suggesting that FICZ is toxic at high doses. Our re-
sults suggest that while there is a large species variation in sensitivity to dioxin-like
compounds the strong AHR activation by FICZ is evolutionary conserved, indicat-
ing an important physiological function. Funding: The Swedish Research Council
Formas and Carl Tryggers Stiftelse.
326 Aryl Phosphate Esters within a Major PentaBDE
Replacement Induce Cardiotoxicity in Developing Zebrafish
Embryos: Potential Role of the Aryl Hydrocarbon Receptor.
D. Volz1,  S. McGee1,  A. Konstantinov2 and H. Stapleton3. 1University of South
Carolina, Columbia, SC; 2Wellington Laboratories, Guelph, ON, Canada; 3Duke
University, Durham, NC.
Firemaster 550 (FM550) is an additive flame retardant formulation of brominated
and aryl phosphate ester (APE) components introduced in 2004 as a major replace-
ment for the commercial polybrominated diphenyl ether mixture (known as
PentaBDE) used primarily in polyurethane foam. Due to rapid adoption, certain
FM550 components have been detected at elevated concentrations within indoor
environments. However, little is known about the potential effects of FM550-based
ingredients during early vertebrate development. Therefore, we first screened the
developmental toxicity of each FM550 component using zebrafish as an animal
model. Based on these initial screening assays, we found that exposure to triphenyl
phosphate (TPP) or mono-substituted isopropylated triaryl phosphate (Mono-
ITP) – two APEs comprising almost 50% of FM550 – resulted in targeted effects
on cardiac looping and function during embryogenesis. As these cardiac abnormal-
ities resembled aryl hydrocarbon receptor (AHR) agonist-induced phenotypes, we
then exposed developing embryos to TPP or Mono-ITP in the presence or absence
of a selective AHR antagonist (CH223191) or AHR2-specific morpholino. Based
on these studies, we found that CH223191 blocked the cardiotoxic effects of
Mono-ITP but not TPP, while AHR2 knockdown failed to block the cardiotoxic
effects of both components. Moreover, using a cell-based human AHR reporter
assay, we found that Mono-ITP (but not TPP) exposure resulted in a significant in-
crease in human AHR-driven luciferase activity at similar nominal concentrations
as a potent reference AHR agonist (β-Naphthoflavone). Overall, our findings sug-
gest that two major APE components of FM550 induce severe cardiac abnormali-
ties during early vertebrate development, raising questions about the potential
health risks of these APEs resulting from indoor exposure.
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327 Cytochrome P450 Gene Transcripts in Early Development of
Zebrafish Danio rerio.
J. Stegeman,  A. Kubota,  B. Woodin,  E. Hawley,  Z. Janes,  B. Lemaire and
J. Goldstone. Biology, WHOI, Woods Hole, MA.
Understanding the roles of cytochromes P450 (CYPs) in zebrafish is important to
the use of this non-mammalian model in toxicological, pharmacological and car-
cinogenesis research. In this study, we determined whether maternally derived tran-
scripts for many CYP genes are present in zebrafish oocytes, and how levels change
up to the mid-blastula transition (MBT) (3 hours post fertilization, hpf ), focusing
on genes involved in xenobiotic and endobiotic metabolism. The maternal contri-
bution to transcript abundance in the eggs varied greatly among CYP genes exam-
ined. CYP2V1 showed the highest levels in the oocytes, followed by CYP20 and
CYP1A. The transcript levels of all CYPs examined were similar between unfertil-
ized eggs and fertilized eggs at < 2 cell stage (prior to the first division). Many of
CYPs including CYP1B1, 1C1, 1C2, 2P6, 2R1, 2AA4, 11C1, 17A2, and 26A1
showed significant increases in their transcript levels at 3 hpf (1,000 cells). In con-
trast, CYP1A and the steroidogenic CYPs 11A1, 17A1, and 19A1, showed constant
levels of transcript from egg to 3 hpf. Other CYPs, including CYP2V1, 2AA3, 3C1,
and CYP51 showed an increasing trend at 2 hpf (64 cells), well before the MBT.
We also examined the effect of exposure to an aryl hydrocarbon receptor agonist,
3,3’,4,4’,5-pentachlorobiphenyl (PCB126) on transcript levels of CYP1 and se-
lected other genes in oocytes. Exposure of females to waterborne PCB126 caused
increases in the transcript levels of CYP1A, 2AA3, 3C1, 11A1, and CYP51 genes in
eggs as compared to those from vehicle-exposed females. The results reveal maternal
transcript deposition of a suite of CYP genes in the egg, and also show that tempo-
ral patterns of CYP transcript levels during early development from egg to the
MBT differ substantially among different CYP genes. Maternal exposure to chemi-
cal was shown to cause change in the transcript deposition of some CYPs in the
eggs. [Support: JSPS Postdoctoral Fellowships for Research Abroad no. 820 (A.K.),
and NIH Superfund Research Program grant P42ES00738 (J.S.)]
328 Benzo[a]pyrene Exposure Effects on Reproductive Success,
Development, and Transcriptome in Zebrafish.
K. L. Willett1,  C. Thornton1,  J. Corrales1,  X. Fang1,  M. White1,  K. Mislan1,
L. Ballard2 and B. E. Scheffler2. 1Pharmacology and Environmental Toxicology,
University of Mississippi, University, MS; 2Genomics and Bioinformatics, USDA ARS,
Stoneville, MS.
Benzo[a]pyrene (BaP) is an environmentally relevant carcinogenic and endocrine
disrupting compound that causes multigenerational effects in mammals. We hy-
pothesized that, like in humans, BaP exposure would adversely affect zebrafish gene
expression, reproduction and cause quantifiable pathologies across generations.
Adult zebrafish (2 females x 2 males, N=10 replicate tanks per treatment) were fed
2% body weight/day flake food treated with 0, 11.6, 110, 1086 μg BaP/g flake
(equivalent to 0, 0.23, 2.2, and 22 μg BaP/g fish/day) for 22 days. Parental gonad
pathology and reproductive success, and F1 and F2 survival and morphological ab-
normalities were measured. The total number of eggs produced and fertilization
success was non-significantly reduced in a dose-dependent manner, and parental
ovarian atresia was significantly decreased. Mortality was significantly increased in
F1 larvae whose parents were exposed to 2.2 and 22 μg BaP/g fish by 48 and 56
hours post-fertilization (hpf ), respectively. High dose BaP F1 fish hatched sooner
(48 hpf ) compared to control (56 hpf ). Body and tail shape and swim bladder were
negatively impacted after parental exposure to 2.2 and 22 μg BaP/g fish. Moreover,
differential gene expression by RNA-Seq of embryos and larvae was documented
after a seven day parental embryonic water-borne BaP exposure. As expected, CYP1
genes in 96 hpf BaP-exposed embryos were induced as was vtg7. Based on these re-
sults, BaP negatively impacted zebrafish reproduction and development. Supported
by NIEHS R21ES019940.
329 Molecular Pathway of Neurotoxicity Caused by
Developmental Exposure to Bisphenol A in Embryonic
Zebrafish.
S. R. Das1,  K. S. Saili1,  S. M. Bugel1,  M. M. Corvi1,  S. C. Tilton2,
K. M. Waters2 and R. L. Tanguay1. 1Environmental and Molecular Toxicology,
Oregon State University, Corvallis, OR; 2Computational Biology and Bioinformatics,
Pacific Northwest National Laboratory, Richland, WA.
Bisphenol A (BPA) is an endocrine disrupting compound widely used in consumer
product manufacturing. Developmental exposure to 0.1 μM BPA results in a hy-
peractive phenotype in zebrafish larvae and impairment of learning in adults. The
mode of action underlying these effects presumably involves impacts on nervous
system development through activation of classical estrogen receptors (ERs) or
other receptors such as estrogen related receptor gamma (ERR3) and G-protein
coupled estrogen receptor (GPER). Transient knockdown of ERR3 using an anti-
sense morpholino rescued the hyperactive phenotype in the zebrafish larvae sug-
gesting a role of ERR3 in the developmental toxicity induced by BPA. We further
used global mRNA and miRNA expression analysis to investigate the transcrip-
tional effects of BPA exposure and to identify candidate genes and signaling path-
ways that mediate the observed behavioral response. Zebrafish embryos were ex-
posed to either of 0.1% DMSO, 0.1 μM BPA, 0.1 μM 17β-estradiol, 0.1 μM
GSK4716 (an ERR3 agonist) from 8 hours post fertilization (hpf ) to 24 hpf. At 24
hpf RNA was isolated to identify transcriptional changes that precede behavioral re-
sponse using a 135K NimbleGen microarray platform. Functional analysis of dif-
ferentially expressed genes revealed CREB and prothrombin activation as top
canonical pathways impacted by both BPA and E2 exposure, and suppressed ex-
pression of key genes involved in nervous system development and function. For
miRNA expression analysis, total RNAs isolated at 24 hpf after exposure to either
0.1% DMSO or 0.1 μM BPA were labeled and hybridized onto a Exiqon
miRCURY LNA miRNA array (v. 11). The expression of a number of miRNAs was
altered by BPA exposure. These results provide insight into potential modes of ac-
tion underlying BPA’s neurodevelopmental toxicity in zebrafish. Supported by
NIEHS T32 ES7060, R21 ES018970, P30 ES000210, P42 ES016465.
330 Methylmercury-Induced Notch Signaling Points to a Role for
Muscle Targets in Motor Nerve Development in Drosophila.
C. T. Mahapatra2,  M. D. Rand1,  G. Engel1 and A. Delwig1. 1Environmental
Medicine, University of Rochester, Rochester, NY; 2College of Agriculture, Purdue
University, West Lafayette, IN.
Methylmercury (MeHg) is a ubiquitous environmental toxicant that targets the de-
veloping fetal nervous system. Despite a wide variety of toxic mechanisms ascribed
to MeHg, its specificity for neural targets is not completely understood. Previous
work in mammalian and insect cells has shown that MeHg induces expression of
Notch pathway target genes, notably the Enhancer of split m-delta (E(spl)mδ)
gene. We have shown earlier that MeHg induction of E(spl)mδ can occur inde-
pendent of the Notch receptor and thus may directly influence neural develop-
ment. In this study we examine the effects on MeHg on E(spl) gene expression in
parallel with neural development events in the Drosophila embryo. We now show
that E(spl)mδ is specifically upregulated in MeHg-exposed embryos. We exclude
the possibility that MeHg-induced E(spl)mδ expression is a by-product of a general
stress response or a shift in developmental timing. MeHg phenotypes are apparent
in the outgrowth of the embryonic intersegmental and segmental motor nerves.
Genetic manipulations causing overactivity of the Notch pathway in neurons can
mimic these phenotypes. Unexpectedly, induced expression of E(spl)mδ in neurons
does not cause a failure of motor nerve outgrowth. We now demonstrate that en-
dogenous E(spl)mδ expression localizes to developing muscle and that E(spl)mδ
overexpression in embryonic muscle causes a segmental nerve phenotype similar to
MeHg treatment. Closer examination shows altered patterning in muscle fields
stemming from either MeHg treatment or E(spl)mδ overexpression. In contrast,
targeting expression of the closely related E(spl)mγ to developing muscle shows no
embryonic phenotype, whereas E(spl)mγ targeted to neurons is embryonic lethal.
In summary these data highlight a novel mechanism whereby MeHg can engage the
activity of a Notch pathway target gene to alter coordinated development of mus-
cles and motor neurons.
331 Effects of Benzo[a]pyrene on Early Zebrafish Development.
K. M. Alharthy,  F. T. Booc,  J. Corrales,  C. Thornton and K. L. Willett.
Department of Pharmacology and ETRP, University of Mississippi, Oxford, MS.
Benzo[a]pyrene (BaP) is a ubiquitous environmental contaminant that is an en-
docrine disrupting and carcinogenic high molecular weight polycyclic aromatic hy-
drocarbon. Our previous work found that BaP significantly decreased fish brain
aromatase (CYP19b) expression, a key enzyme in steroidogenesis. We hypothesized
that BaP deregulates the steroid hormone hypothalamus-pituitary-gonad feedback
loop adversely affecting reproductive development and physiology. Zebrafish em-
bryos were exposed to waterborne concentrations of BaP (0, 10, and 50 μg/L) for
96 hours postfertilization (hpf ). Fifty μg/L BaP significantly increased mortality
compared with the control and 10 μg/L groups at 24, 48, 72, and 96 hpf, whereas
mortality was not significantly increased until 96 hpf in the 10 μg/L BaP group. In
order to quantitate effects on larval estrogen and testosterone concentrations, larvae
were collected at 48, 72, 96, 168 and 504 hpf. Histopathological assessment of
gonad maturation was done on paraffin embedded and sectioned fish at 28, 32, 35,
and 52 days post fertilization. In a treatment-blinded morphological assessment of
larvae at 96 hpf, the high BaP dose significantly decreased the body length, optic
vesicle, and swim bladder size while increasing pericardial and abdominal edema
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compared to control and 10 μg/L treatments. Body and tail shape and fin malfor-
mation scoring also indicated a dose-dependent adverse impact of BaP-treatment
on development. Results extend previous studies highlighting the adverse impacts
on early development of BaP-exposure. (Supported by NIEHS R03 ES018962)
332 Drosophila CYP6g1 and Its Human Homolog CYP3A4
Confer Tolerance to Methylmercury during Development.
M. D. Rand1,  J. A. Lowe1 and C. T. Mahapatra2. 1Environmental Medicine,
University of Rochester, Rochester, NY; 2College of Agriculture, Purdue University,
West Lafayette, IN.
The fetal nervous system is a well-known primary target for methylmercury
(MeHg) toxicity. Despite knowledge of numerous cellular processes that are af-
fected by MeHg, the mechanisms that ultimately influence tolerance or susceptibil-
ity to MeHg in the developing fetus are not well understood. Using transcriptomic
analyses of developing brains of MeHg tolerant and susceptible strains of
Drosophila, we previously identified members of the cytochrome p450 (CYP) fam-
ily of monooxygenases/oxidoreductases as candidate MeHg tolerance genes. CYP
genes encode Phase I enzymes best known for xenobiotic metabolism in the liver as
well as synthesis and degradation of essential endobiotics, such as hormones and
fatty acids, that are critical to normal development. We now demonstrate that nat-
ural and induced variation in expression CYP genes can strongly influence MeHg
tolerance in the developing fly. We show that modulating expression of a single
CYP, CYP6g1, specifically in neurons or the fat body (liver equivalent) is sufficient
to rescue Drosophila development in the presence of MeHg in the diet.
Furthermore, we identify CYP3A4 as a human homolog of CYP6g1 and show that
it similarly confers MeHg tolerance when ectopically expressed in flies. Finally,
pharmacological induction of endogenous CYPs with caffeine also results in ele-
vated tolerance to MeHg in developing flies. These findings establish a previously
unidentified role for CYPs in modulating MeHg toxicity and point to a potentially
conserved role of CYP genes to influence susceptibility to MeHg toxicity across
species.
333 Systems Approaches to Define the Developmental Toxicity of
Polybrominated Diphenyl Ethers.
M. T. Simonich,  L. Truong,  S. M. Bugel,  B. C. Goodale,  W. Bisson,
D. C. Koch,  S. K. Kolluri and R. L. Tanguay. Environmental & Molecular
Toxicology, Oregon State University, Corvallis, OR.
Polybrominated diphenyl ethers (PBDEs) are high production volume flame retar-
dants used in a number of consumer products. PBDEs are ubiquitous environmen-
tal pollutants due to their widespread usage, persistence and lipophilicity.
Developmental exposure to PBDEs is associated with a number of neurological and
developmental effects in humans and wildlife. A major complexity in assessing the
hazard and risk posed by PBDEs is the diversity of chemical congeners; chemical
structure-toxicity relationships are not established for these compounds. Our hy-
pothesis was that developmental toxicity of PBDEs is highly structure dependent
and that the molecular targets of these compounds are distinct. We performed
rapid throughput assessment of PBDE developmental and neurotoxicity in ze-
brafish with PBDE congeners 47, 77, 99, 100, 153, 154, and 183. All exposures
were from 6 until 120 hours post fertilization (hpf ) at which time larvae were as-
sessed for photo-induced locomotor activity and changes in a suite of 20 morpho-
logical endpoints. Preliminary global gene expression data suggested that some
PBDE congeners may activate the aryl hydrocarbon receptor (AHR). We used our
AHR PAS domain homology model for molecular docking analysis, which pre-
dicted that PBDE 47, 77, and 99 would bind to the human and zebrafish AHR.
Immunohistochemistry confirmed CYP1A induction for PBDE 77 and PBDE 99.
Mammalian AHR dependent in vitro reporter assays supported these results.
Finally, PBDE exposures in AHR2 null fish confirmed that AHR2 is necessary for
PBDE 77, and 99 neuro and developmental toxicity. Collectively these data indi-
cate that some PBDEs induce toxicity primarily via activation of the AHR, while
others act through uncharacterized AHR-independent pathways, and we are now
positioned to identify these distinct mechanisms of PBDE action. This research is
supported by NIEHS grants P30 ES00210, T32 ES07060 and RC4ES019764.
334 Evaluating Morphological, Neurologoical, and Gene
Expression Changes in Response to Developmental PAH
Exposures.
A. Knecht and R. L. Tanguay. Oregon State University, Corvallis, OR.
Polycyclic aromatic hydrocarbons (PAHs) are ubiquitous environmental contami-
nants present in urban air, dust, and soil resulting from incomplete combustion of
organic materials or fossil fuels. It is widely recognized that PAHs pose risks to
human health, especially for the developing fetus and infant where PAH exposures
have been linked to low birth weight and in-utero mortality and lower intelligence.
Using the embryonic zebrafish model, we evaluated the developmental and neuro-
toxicity after exposure to two PAHs: benzo[a]pyrene (B[a]P) and
dibenzo[a,l]pyrene (DB[a,l]P). Dechorionated embryos were exposed from 6 to
120 hours post fertilization (hpf ) to a broad concentration range of PAHs and as-
sessed for mortality and 20 unique endpoints at 120 hpf. Using the Viewpoint
Zebrabox, we identified that larvae exposed to B[a]P exhibited a hyperactive phe-
notype. To determine if this behavioral defect persists throughout development, a
subset of exposed animals were raised to adulthood and assessed for learning and
memory deficiencies using shuttleboxes. Previously, we have demonstrated that ex-
posure to PAHs resulted in an induction of the oxidative stress genes set. Using the
Seahorse Extracellular Flux Analyzer, we measured oxidative stress in vivo in 24hpf
embryos exposed to PAHs from 6 – 24 hpf. The Seahorse results confirm the pres-
ence of oxidative stress and that exposure to PAHs cause decreased oxygen con-
sumption rates and acidification rates suggesting the presence of mitochondrial
damage. To explore what transcriptional events are occurring prior to the onset of
developmental and neurotoxicity, a global gene expression analysis using RNA-seq
was performed on 48 hpf embryos exposed to 1 and 10ppm B[a]P and 10ppm
DB[a,l]P. Analysis of our collective data will be discussed and provide insight into
potential mechanism of action for some PAHs. This research was supported by the
NIEHS grants P42 ES016465 and P30 ES000210.
335 Defining Pathways of Polycyclic Aromatic Hydrocarbon
Developmental Toxicity in Zebrafish Using Systems-Based
Transcriptional Profiling.
B. C. Goodale1,  S. C. Tilton2,  A. Knecht1,  A. Swanson1,  K. Anderson1,
K. M. Waters2 and R. L. Tanguay1. 1Environmental and Molecular Toxicology,
Oregon State University, Corvallis, OR; 2Computational Biology and Bioinformatics,
Pacific Northwest National Laboratory, Richland, WA.
Polycyclic aromatic hydrocarbons (PAHs) are ubiquitous in the environment as
components of fossil fuels and by-products of combustion. Defining toxicity mech-
anisms for this large family of multi-ring structures and substituted derivatives is a
substantial challenge. In addition to the well-studied carcinogenic properties of sev-
eral PAHs such as benzo(a)pyrene, reports of cardiac and developmental effects
have increased concern about health risks of exposure to PAHs. Some PAHs induce
toxicity via activation of the aryl hydrocarbon receptor (AHR), while others act
through uncharacterized AHR-independent pathways. We employed the zebrafish
model to rapidly assess developmental toxicity, global transcriptional responses and
AHR activation in embryos exposed to parent, oxygenated PAHs (OPAHs) and en-
vironmental mixture samples during development. Using comparative analysis of
mRNA expression profiles from microarrays with embryos exposed to benz(a)an-
thracene (BAA), dibenzothiophene (DBT) and pyrene (PYR), we identified expres-
sion biomarkers and disrupted biological processes that precede developmental ab-
normalities. These transcriptional responses were associated with PAH body
burdens in the embryos detected by GC-MS. We found that uptake data was essen-
tial for discerning molecular pathways from dose-related differences, and identified
two primary toxicity profiles. While BAA disrupted transcripts involved AHR sig-
naling and vasculogenesis, DBT and PYR misregulated ion homeostasis and mus-
cle-related genes. Biomarkers of these toxicity pathways are under investigation
with a diverse group of OPAHs, and comparative analysis of embryos exposed to
OPAHs with different proposed molecular mechanisms using RNA-seq will ex-
pand and refine pathways of PAH-induced developmental toxicity. This research is
supported by NIEHS grants P30ES00210, P42ES016465 and T32ES07060.
336 Ebselen As a Countermeasure for Nitrogen Mustard Vesicant-
Induced Toxicity.
J. D. Laskin1,  Y. Jan1,  D. E. Heck2,  R. P. Casillas3 and D. L. Laskin4.
1Environmental & Occupational Medicine, UMDNJ-RWJMS, Piscataway, NJ;
2Environmental Health Science, New York Medical College, Valhalla, NY;
3MRIGlobal, Kansas City, MO; 4Pharmacology & Toxicology, Rutgers University,
Piscataway, NJ.
Mechlorethamine (HN2), a nitrogen mustard vesicant, is a bifunctional alkylating
agent commonly used as a model to study sulfur mustard-induced lung injury.
Previously, we reported that HN2 selectively targeted antioxidants in lung A549
epithelial cells including the selenoprotein thioredoxin reductase (TrxR) forming
intra- and inter-molecular cross links. This resulted in dimer and oligomer forma-
tion, and enzyme inactivation, a process contributing to oxidative stress and toxic-
ity. In this study, we examined the effects of ebselen, a seleniumn-containing an-
tioxidant, on HN2-induced toxicity. In A549 cells, HN2 was found to be cytotoxic
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(LD50 = 25 μM). Both pre- and post-treatment with ebselen (50 μM) significantly
attenuated HN2-induced toxicity. This was correlated with reduced inhibition of
TrxR enzyme activity and decreased formation of TrxR dimers and oligomers.
Ebselen treatment was found to induce TrxR protein expression in A549 cells, sug-
gesting that inhibition of toxicity was due to both reduced TrxR damage and in-
creased TrxR enzyme activity. Using purified rat liver TrxR, ebselen also protected
against enzyme inactivation by HN2. This was due to a decrease in HN2 binding
to the catalytic residues on TrxR, thus preventing enzyme inactivation. Taken to-
gether, our data suggest that ebselen has the potential to be an effective counter-
measure for HN2-induced lung injury. Support: NIH grants AR055073,
ES004738, CA132624, ES05022 and GM034310.
337 Identification of Thioredoxin As a Molecular Target for
Sulfur Mustard Analog Vesicants.
Y. Jan1,  I. Wohlman2,  D. E. Heck3,  R. P. Casillas4,  D. L. Laskin2 and
J. D. Laskin1. 1Environmental & Occupational Medicine, UMDNJ-RWJMS,
Piscataway, NJ; 2Pharmacology & Toxicology, Rutgers University, Piscataway, NJ;
3Environmental Health Science, New York Medical College, Valhalla, NY;
4MRIGlobal, Kansas City, MO.
The thioredoxin system, composed of thioredoxin reductase, thioredoxin and
NADPH, is a cellular disulfide reduction system important in antioxidant defense
and cell growth control. We reported previously that thioredoxin reductase is a tar-
get of both monofunctional [2-chloroethyl ethyl sulfide (CEES)] and bifunctional
(HN2, nitrogen mustard) vesicating agents. These vesicants were found to cova-
lently bind to selenocysteine/cysteine residues in the redox centers of the enzyme,
leading to its inactivation and toxicity. Thioredoxin contains two catalytic cysteine
and three structural cysteine residues. In these studies, we determined if vesicants
also target thioredoxin. Both CEES and HN2 treatment were found to cause time-
and concentration-dependent inhibition of thioredoxin in A549 cells. Western blot
analysis revealed that a band corresponding to tetramers of thioredoxin was present
in HN2-, but not CEES-treated cells, suggesting that HN2 caused inter-molecular
thioredoxin cross-links. Using recombinant enzyme and mass spectrometry, we
found that both CEES and HN2 alkylated cysteine and lysine residues on thiore-
doxin, including cysteine-32 and cysteine-35 in the redox center of the enzyme. In
addition, several inter-peptide cross links were identified in HN2-treated thiore-
doxin, providing a mechanism for the formation of thioredoxin tetramers in A549
cells. These data demonstrate that thioredoxin is a molecular target of sulfur mus-
tard vesicants. Agents that can reactivate the thioredoxin system may be effective
countermeasures for sulfur mustard-induced tissue injury. Support: NIH grants
AR055073, ES004738, CA132624, ES05022 and GM034310.
338 Novel Therapeutic Compounds YEL001 and YEL002
Mitigate Radiation-Induced Toxicity Authors.
Y. Rivina and R. H. Schiestl. Pathology; Environmental Health Sciences, Radiation
Oncology, University of California Los Angeles, Los Angeles, CA.
The possibility of a radiation disaster from a nuclear detonation or accident has ex-
isted for over 50 years and spawned much of the basic research in radiobiology in
the 1950-60s. The recent Fukushima accident was yet another reminder that there
remains a dire need to develop novel therapies against radiation-induced toxicities.
Here we report on the development of two novel radiation countermeasure thera-
pies: Yel001 and Yel002. These small, biologically active, drug-like molecules were
uncovered in the DEL high throughput assay reducing radiation-induced cyto- and
geno-toxicity in yeast. Radiation-modulating activity was further confirmed in
yeast plate-based DEL Assay: addition of either Yel001 or Yel002 to irradiated cul-
tures reduced cell death and genomic instability. Further, Yel compounds increases
survival to 75% in vivo following an LD100/30 dose of ionizing radiation (IR)
with the first therapeutic injection administered 24 hours post exposure followed
by injections at 48,72,96, and 120 hours. Additionally, treatment with Yel001 and
Yel002 compounds reduces radiation-induced leukemia from 90% to to 50% and
40% respectively. Of note, treatment with either Yel001 or Yel002 reduced sponta-
neous leukemia rate from 10% to 0%. Treatment with Yel002 following IR acceler-
ates the recovery of the hematopoietic cells after sub-lethal exposures. In addition,
treatment with Yel002 reduces EMS, MMS, UV, cigarette smoke extract as well as
nitrogen mustard induced toxicity as well as genotoxicity showing a broad applica-
tion spectrum. Toxicity has not been observed in neither in vitro or in vivo admin-
istrations. Overall, Yel compounds have much potential as stockpile therapies for
radiation-induced lethality and cancer: they are highly effective when administered
up to 24hours post exposure, they reduce radiation-induced sequelae such as
leukemia, and appear to have an acceptable toxicity profile.
339 Show Bispyridinium Nonoximes Direct Interactions with
Muscle-Type Nicotinic Acetylcholine Receptors?
H. Thiermann,  T. Seeger,  F. Worek and K. V. Niessen. Bundeswehr Institute of
Pharmacology and Toxicology, Munich, Germany.
Objective: In poisoning with some organophosphorus nerve agents, e.g. soman,
therapeutic efficacy of oximes is limited. For such cases, a direct intervention at
nicotinic acetylcholine receptors (nAChR) might be an alternative. Studies with the
bispyridinium non-oxime MB327 (1,1’-(propane-1,3-diyl)bis(4-tert-butylpyri-
dinium) di(iodide)) demonstrated a therapeutic effect against soman in vitro and in
vivo. As MB327 was found to interact most probably with muscle-type nAChRs,
improved therapeutic efficacy could possibly be achieved with compounds that
show enhanced activity. To identify potential candidates, homologous series of sub-
stituted and non substituted analogues (linker C1-C10) of MB327 were investi-
gated in binding and functional assays. In addition, their inhibitory activity was as-
sessed with human acetylcholinesterase (AChE).
Experimental procedures: In competition radioligand binding assays, the influence
on [3H]epibatidine binding sites of Torpedo californica nAChR was investigated.
Functional assessments were performed with cell-free electrophysiology based on
solid supported membranes (SSM). AChE inhibitory properties of the compounds
were assayed with a modified Ellmann assay using haemoglobin-free human ery-
throcyte ghosts.
Results: MB327 and several bispyridinium structure analogues exhibit no regular
displacement curves at [3H]epibatidine binding sites. Compounds with unsubsti-
tuted pyridinium ring and long linkers (> C7) show regular competition but no in-
trinsic effect. Inhibition of human AChE (IC50 < 1 μM) for both bispyridinium
compound series (unsubstituted and with p-tert-butyl in both pyridine rings) was
observed with increasing distance between the pyridinium N (> C9 and > C6 re-
spectively).
Conclusion: The interaction with [3H]epibatidine binding sites and functional im-
provement of Torpedo californica nAChRs depend on the substitution and C-
linker between the pyridine N. Further research is necessary for better understand-
ing how these compounds interact with the nAChR.
340 Novel Pyridinium Oximes Offer Neural Protection in the
Central Nervous System against Nerve Agent Surrogates.
R. B. Pringle1,  E. C. Meek1,  H. W. Chambers2,  J. M. Gearhart3 and
J. E. Chambers1. 1College Veterinary Medicine, Mississippi State University,
Mississippi State, MS; 2Biochemistry, Molecular Biology, Entomology and Plant
Pathology, Mississippi State University, Mississippi State, MS; 3AFRL, Wright-
Patterson AFB, Dayton, OH.
Organophosphates (OPs), including nerve agents, target the cholinergic system via
inhibition of acetylcholinesterase (AChE), with subsequent overstimulation result-
ing in neural damage and potential detrimental long-term effects. The efficacy of
novel pyridinium oxime reactivators, created with moieties to increase blood-brain
barrier penetration, was tested using highly relevant sarin and VX surrogates. Glial
fibrillary acidic protein (GFAP; an indicator of neural damage) and monoamines
(dopamine, serotonin (5-HT) and their metabolites) were measured in select brain
regions via immunohistochemistry and HPLC, respectively. Adult male rats were
treated ip with high, sub-lethal doses of surrogates for sarin or VX, nitrophenyl iso-
propyl methylphosphonate (NIMP; 0.325mg/kg) or nitrophenyl ethyl
methylphosphonate (NEMP; 0.4mg/kg), respectively. Surrogate treatment was fol-
lowed after 1 hr by im administration of novel oxime (0.1mmol/kg). Seizure activ-
ity was monitored, and kainic acid (KA; 10mg/kg) served as a positive control.
Administration of KA or surrogate (NIMP or NEMP) significantly (p<0.05) in-
creased GFAP expression compared to control animals. Two different formulations
of oxime (bromide vs. mesylate salt) attenuated seizures and reduced GFAP levels
over NIMP or NEMP treatments alone to levels near those of controls (p<0.05) in
both the piriform cortex and dentate gyrus region of the hippocampus, while 2-
PAM did not provide protection. Serotonergic activity was also altered in several
brain regions, including the piriform cortex (significant increase in both 5-HT and
5-HIAA; p<0.05), one hr after NIMP treatment, with early markers of oxidative
stress (isoprostanes) also being tested. These results indicate the potential therapeu-
tic efficacy of these oximes and suggest this innovative chemistry may protect
against neural damage induced by OPs. Supported by Defense Threat Reduction
Agency: 1.E0056_08_AHB_C
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341 Sulforaphane Induces Antioxidants and Glutathione S-
Transferase A1 and Protects against Vesicant-Induced
Toxicity in Mouse Keratinocytes.
R. G. Udasin1, 4,  M. Shakarjian2, 3,  V. Mishin4,  D. E. Heck3,  R. P. Casillas5,
D. L. Laskin1, 4 and J. D. Laskin1, 6. 1Joint Graduate Program in Toxicology, Rutgers
University/UMDNJ, Piscataway, NJ; 2Department of Medicine, UMDNJ-RWJMS,
Piscataway, NJ; 3Department of Environmental Health Science, New York Medical
College, Valhalla, NY; 4Pharmacology & Toxicology, Rutgers University, Piscataway,
NJ; 5MRI Global, Kansas City, MO; 6Environmental & Occupational Medicine,
UMDNJ-RWJMS, Piscataway, NJ.
Sulfur mustard and the related skin vesicant nitrogen mustard (mechlorethamine
hydrochloride, HN2) are bifunctional alkylating agents known to cause oxidative
stress and persistent tissue damage including blistering. In the present studies we
determined whether HN2-induced oxidative stress and cytotoxicity in mouse ker-
atinocytes could be mitigated by upregulating antioxidant enzymes. Sulforaphane
(SFN), an isothiocyanate found in cruciferous vegetables including broccoli, is a
well characterized inducer of antioxidants and phase II metabolizing enzymes
through a pathway mediated by the transcription factor nuclear factor-erythroid 2-
releated factor 2 (Nrf2). Treatment of PAM212 mouse keratinocytes with HN2 in-
hibited keratinocyte growth (IC50 = 1.0 μM). Pretreatment of the cells with 3 μM
SFN for 3 hours protected against growth inhibition (IC50 = 6.0 μM). SFN also
protected primary mouse epidermal keratinocytes from HN2 (IC50 = 2.0 μM and
30 μM with and without SFN, respectively). SFN also decreased HN2-induced
phosphorylation of histone H2A.X, a marker of DNA damage, in PAM212 cells.
SFN was functionally active causing Nrf2 to translocate from the cytosol to the nu-
cleus. This was associated with a marked increase in expression of the antioxidants
heme oxygenase-1, thioredoxin reductase 1, and NADPH quinone oxidoreductase-
1, as well as the phase II metabolizing enzyme glutathione-S-transferase A1. Taken
together, these data indicate that oxidative stress is important in HN2-induced tox-
icity in mouse keratinocytes and that SFN may be an effective countermeasure
against vesicant-induced toxicity. Supported by NIH grants AR055073,
ES004738, CA132624, GM034310 and ES005022.
342 Effects of Delayed Treatment with a Centrally Active Oxime
on Acetylcholinesterase and Survival following Sarin
Intoxication.
T. Shih,  R. K. Kan,  T. M. Myers and I. Koplovitz. Research Division, US Army
Medical Research Institute of Chemical Defense, Aberdeen Proving Ground, MD.
Organophosphorus (OP) nerve agents (NA), such as sarin, irreversibly inhibit the
enzyme acetylcholinesterase (AChE), which leads to an excess of acetylcholine in
the synapses, causing numerous toxic effects, such as convulsions, respiratory dis-
tress, and death. The current NA treatment regimen includes 2-pralidoxime (2-
PAM) to reactivate NA-inhibited AChE. The quaternary structure of 2-PAM, how-
ever, does not allow it to cross the blood brain barrier to reactivate brain AChE and
to mitigate CNS toxicity. We have shown earlier that the tertiary oxime monoisoni-
trosoacetone (MINA), when given soon after NA exposure, provided some AChE
reactivation in the brain, enhanced survival and mitigated the seizure activity fol-
lowing NA exposure. In this study, we evaluated the efficacy of delayed MINA ther-
apy in reactivating brain AChE and enhancing survival following lethal sarin intox-
ication. For the reactivation study, guinea pigs were treated with MINA (30, 60, or
120 mg/kg, im) 30 min after one LD90 of sarin, and AChE was assessed 60 min
later. MINA was capable of producing a dose-related reactivation of brain (from 5.8
to 27.4% recovery) and peripheral tissue (from 4.1 to 21.0% recovery) AChE ac-
tivity that was inhibited by sarin. In a 24-hour survival study, animals were chal-
lenged with 3 x LD50 of sarin and treated 1 min later with intramuscular atropine
(0.5 mg/kg) and 2-PAM (25 mg/kg), and MINA (56 mg/kg, im) was given as an
adjunct at 1, 3, 5, 15, or 30 min after sarin. Treatment with atropine and 2-PAM at
1 min resulted in 67% mortality, while additional therapy with MINA ensured
100% survival anytime from 3 to 30 min. These findings suggested that delayed
therapy with a centrally active AChE reactivator for up to 30 min following lethal
exposure to sarin is still capable of reactivating NA-inhibited AChE and saving
lives. Thus, inclusion of a CNS penetrating oxime in the therapeutic regimen for
OP NA intoxication is beneficial even when the therapy would be delayed.
343 Novel Oximes That Penetrate the Blood-Brain-Barrier (BBB)
and Reactivate Organophosphate (OP) Inhibited
Acetylcholinesterase (AChE).
E. C. Meek1,  H. W. Chambers2,  R. B. Pringle1,  J. E. Chambers1 and
J. M. Gearhart3. 1College of Veterinary Medicine, Mississippi State University,
Mississippi State, MS; 2Department of Biochemistry, Molecular Biology, Entomology
and Plant Pathology, Mississippi State University, Mississippi State, MS; 3AFRL,
Wright-Patterson AFB, Dayton, OH.
Inhibition of AChE following exposure to toxic OPs (nerve agents and pesticides),
results in the overstimulation of the nervous system. The approved therapies in-
clude an oxime, e.g. 2-PAM, to reactivate OP inhibited AChE; however these
oximes have little, if any ability to cross the BBB. A series of novel pyridinium
oximes has been synthesized that incorporate moieties that increase BBB penetra-
tion and AChE reactivation. Oximes were screened in vitro for their ability to reac-
tivate AChE inhibited by a sarin surrogate, phthalimidyl isopropyl methylphospho-
nate (PIMP), or a VX surrogate, nitrophenyl ethyl methylphosphonate (NEMP),
which phosphorylate AChE with the same moiety as sarin or VX, as well as with
paraoxon, the active metabolite of the insecticide parathion. Rat brain homogenate
was incubated with a concentration of OP that yielded about 80% AChE inhibi-
tion, followed by an oxime (0.1mM) and AChE activity measured. In vitro AChE
reactivation varied among oximes but was similar for each of the nerve agent surro-
gates; PIMP, 14-79%, and NEMP 23-76%, but differed for paraoxon 16-93%.
Oxime lipophilicities ranged from 0.009 to 2.244 (Kow) and were greater than for
2-PAM (0.006). A subset of oximes that demonstrated AChE reactivation ≥40% in
vitro were selected for testing in vivo in rats with the nerve agent surrogates. A high
sublethal dose of a stable sarin surrogate, nitrophenyl isopropyl methylphosphonate
(NIMP) (0.325mg/kg) or NEMP (0.4mg/kg) was administered ip, yielding about
80% brain AChE inhibition, followed by an im injection (0.1mmol/kg) of an
oxime at the time of peak brain AChE inhibition (1hr). Twelve of 25 novel oximes
tested yielded 10-35% brain AChE reactivation and attenuated OP induced
seizures, indicating their ability to cross the BBB, reactivate brain AChE and thus
demonstrating their therapeutic potential. Supported by DTRA:
1.E0056_08_AHB_C
344 Toxicokinetics of ST-246, an Antiviral Product Developed
for the Treatment of Human Pathogenic Orthopoxvirus
Infection, in Cynomolgus Monkeys.
M. Trinh1,  A. Amantana2,  J. M. Leeds2,  Y. Chen2,  K. Honeychurch2,
D. E. Hruby2,  B. M. Saville3,  C. Chang1,  J. F. Marier1 and M. Beliveau1.
1Pharsight Consulting Services, Pharsight Corporation, Montréal, QC, Canada;
2SIGA Technologies, Inc., Corvallis, OR; 3Charles River Laboratories Preclinical
Services, Reno, NV.
Smallpox is still considered a serious bioterror threat even though worldwide sur-
veillance and vaccination eradicated the virus from the natural environment. ST-
246 is an antiviral drug developed for the treatment of pathogenic orthopoxvirus
infections (includes smallpox and monkeypox). Efficacy trials previously demon-
strated that treatment of monkeypox virus-infected monkeys with ST-246 provided
significant survival benefit at doses ≥3 mg/kg. Once daily, 6-h IV infusions of 3, 10
and 30 mg/kg ST-246 were administered for 14 days in a total of 19 male and fe-
male cynomolgus monkeys. Toxicokinetic (TK) parameters of ST-246 were evalu-
ated with non-compartmental analysis methods on Day 1 and 14. Mean AUC0 24
and Cmax increased in a dose-proportional manner on Day 14, with values ranging
from 6839 to 76908 ng.h/mL and 904 to 12827 ng/mL, respectively. The accumu-
lation ratio (AUC0-24 Day 14 vs. Day 1) ranged from 1.00 to 1.54, suggesting min-
imal accumulation after repeated dosing. Mean CL (415 to 766 mL/h/kg) were
consistent with liver blood flow in a typical 5-kg monkey (612 mL/h/kg). Mean Vss
(1200 – 2503 mL/kg) were markedly higher than the total body water in a typical
5-kg monkey (693 mL/kg), suggesting extensive distribution in peripheral tissues.
Steady state concentrations (range: 285 to 3205 ng/mL) were markedly higher than
in vitro inhibitory concentrations associated to 50% of the maximum effect (IC50)
against monkeypox virus and different variola strains (10.8 and 12.3 ng/mL, re-
spectively). Overall, ST-246 displayed favorable TK parameters, such as dose-pro-
portional increase in exposure, limited accumulation following repeated dosing,
and extensive distribution in peripheral tissues.
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345 Prediction of Human Equivalent Dose (HED) of
Levofloxacin (LEVO) in New Zealand White Rabbits (NZW)
to Support Efficacy of Combination Treatment with Novel
Therapeutics against Inhalation Anthrax (IA).
M. Beliveau1,  A. L. Menard1,  J. F. Marier1,  J. T. Troyer2 and E. K. Leffel2.
1Pharsight Consulting Services, Pharsight Corporation, Montréal, QC, Canada;
2PharmAthene, Inc., Annapolis, MD.
Regulatory agencies have suggested that novel therapeutics for treatment of IA do
not diminish the efficacy of the standard-of-care (SOC) antibiotics in combination
therapy, which would be the likely treatment. The NZW is an accepted animal
model for IA where the SOC LEVO is both well tolerated, efficacious and where
benefits of combination therapy would therefore need to be demonstrated.
However, for proper demonstration of the added benefit of the new drug, the ad-
ministered dose of LEVO must not be supra-therapeutic. Therefore, a HED of
LEVO in NZW must be used. The objective of the current analysis was to deter-
mine pharmacokinetic (PK) parameters of LEVO in NZW and to determine the
NZW dose equivalent to the HED of 7.14 mg/kg (500 mg QD) for IA. LEVO was
administered to NZW by either PO or IV bolus administration and blood for PK
analysis was collected at various times up to 48h post dose. Plasma samples were as-
sayed for concentrations of LEVO using a validated LC/MS/MS method.
Following calculation of PK parameters such as clearance (CL) and volume (Vss) by
standard non-compartmental methods, the NZW HED was extrapolated from the
clinical dose using the following equation: Doserabbit(HED) = (HED/CLhuman) x
CLrabbit where the HED = 500 mg and the CLhuman was taken from the literature
(175 mL/min). Following IV dosing, mean CLrabbit and Vss of LEVO were 17.7
mL/min/kg and 1619 mL/kg, respectively. Bioavailability in NZW was dose de-
pendant and ranged from 37.9% to 79.7%. Using CLrabbit, CLhuman and the HED,
the dose of LEVO in NZW corresponding to the HED was 50.5 mg/kg IV. If ad-
ministered PO, the NZW HED would range from 53.8 mg/kg to 63.1 mg/kg. In
conclusion, the above results suggest that LEVO IV dosing of 50.5 mg/kg or PO
dosing of 53.8 to 63.1 mg/kg in NZW in combination with novel anthrax thera-
peutics are expected to allow sufficient demonstration of any added benefit of the
novel drug.
346 The Beneficial Effect of a Treatment with Macrophages on
Sulfur Mustard Cutaneous Burns.
S. Dachir1,  D. Kamus-Elimeleh1,  R. Sahar1,  E. Fishbine1,  R. Gez1,
J. S. Graham2,  A. Eisenkraft3,  V. Horwitz1 and T. Kadar1. 1Pharmacology, Israel
Institute for Biological Research, Ness Ziona, Israel; 2Office of the Commander,
USAMRICD, Aberdeen Proving Ground, MD; 3NBC Protection Division, Ministry
of Defense, Tel Aviv, Israel.
Sulfur mustard (HD) is a potent vesicant that its toxicology has been for many years
a subject for research, yet, the exact mechanism of its toxicity is still elusive and
treatment is only partially effective. Macrophages are known to play an essential
role in almost every stage of wound healing and there is evidence for their beneficial
effects in treating decubital ulcers and deep sterna wound infections in human. 
This study was aimed to investigate the efficacy of a treatment with activated
macrophages in ameliorating acute and long-term HD induced skin injuries in the
hairless guinea pig (HGP) model.
HGP were exposed to HD vapor creating superficial dermal skin lesions. They were
treated with either a single or multiple intra-dermal injections of human activated
macrophages (hAMS) into the wound bed. Clinical and histological evaluations
were conducted up to four weeks post-exposure.
A single intra-dermal injection into the wound bed administered early (15min or
6hr) after exposure inflicted an initial positive effect on the extent of the damage,
demonstrating a temporal decrease in clinical symptoms, reduced number of aci-
dophilic epithelial cells and less micro-vesications compared to untreated control.
Repeated injections with hAMS (15min, 48hr and 7d post-exposure), decreased
significantly the wounds’ area and improved the integrity of the barrier function as
expressed by trans-epidermal water loss measurements up to 10 days. Still, at 21
days there were no differences between the experimental groups.
The results demonstrated a beneficial effect of macrophages on HD induced le-
sions. Further investigation is required to determine whether macrophages are re-
quired during the early phase of wound development or during the late phase of
scar formation and remodeling.
This work was supported by the US Army Medical Research and Material
Command under award #: W81XWH-08-2-0128.
347 Comparative Anticonvulsant Effects of Diazepam in Rats
Exposed to DFP, Paraoxon and the Chemical Warfare Nerve
Agent Soman.
R. K. Kan,  J. A. Leuschner,  T. T. Dao,  S. W. Kaski,  J. F. Irwin,  C. Acon-Chen,
C. R. Braue,  E. A. Johnson,  H. Hoard-Fruchey and T. Shih. Pharmacology,
USAMRICD, Aberdeen Proving Ground, MD.
Diazepam is routinely used to control organophosphate-induced seizures. The pres-
ent study was designed to evaluate the effectiveness of diazepam to control seizures
induced by soman (GD), diisopropylfluorophosphate (DFP) and paraoxon. Prior
to experimentation, animals were instrumented with cortical electrodes for moni-
toring brain activity. Animals exposed to GD (180 ug/kg, sc) were pretreated with
HI-6 (125 mg/kg, ip) 30 min prior to GD challenge and treated with atropine
methylnitrate (2.0 mg/kg, im). Animals exposed to DFP (4.0 mg/kg, sc) were pre-
treated with pyridostigmine (0.026 mg/kg, ip) 30 min prior to DFP challenge and
treated with atropine sulfate (AS; 0.2 mg/kg, im) and 2-PAM (25 mg/kg, im).
Animals exposed to paraoxon (1.05 mg/kg, sc) were treated with AS (2.0 mg/kg,
im) and 2-PAM (25 mg/kg, im). In all cases, diazepam (10 mg/kg, im) was given at
40 min after the onset of seizures. Diazepam was effective in terminating DFP- and
paraoxon-induced seizures, but it was ineffective in terminating GD-induced
seizures. In addition, neuropathology in animals treated with diazepam at 40 min
after DFP or paraoxon-induced seizures was markedly reduced at 24 hr after seizure
onset. In contrast, diazepam treatment at 40 min after the onset of seizures-induced
by GD did not prevent or attenuate brain injury. DFP and paraoxon models were
developed as surrogate animal models for nerve agent (NA) biomedical research for
evaluation of putative therapeutics. The difference in the effectiveness of diazepam
in controlling seizures and reducing neuropathology induced by GD, DFP or
paraoxon indicates that DFP and paraoxon are not suitable simulants for NA bio-
medical research, at least not for screening of potential anticonvulsants to control
on-going seizures. Novel anticonvulsants that are effective in terminating seizures
induced by DFP or paraoxon may not be efficacious against NA-induced seizures.
348 Determination of Cholinesterase Levels in the Blood and
Brain following Galantamine Administration in the Guinea
Pig Model.
C. Wilhelm1,  A. Moulder1,  G. Platoff2,  D. Jett2,  D. Yeung2 and M. C. Babin1.
1Battelle, Columbus, OH; 2CounterACT Program, NIH OD, Bethesda, MD.
The CounterACT Program at the National Institutes of Health is investigating
galantamine hydrobromide (GAL) as a treatment for organophosphorus nerve
agent (NA) intoxication and is establishing a dose response representation to deter-
mine optimal doses for future efficacy studies. GAL is a reversible acetyl-
cholinesterase (AChE) inhibitor that crosses the blood–brain barrier and is
presently approved for the treatment of mild to moderate Alzheimer’s disease. It has
shown some efficacy against NA toxicity in animal studies. Ongoing studies are in-
vestigating the efficacy of GAL when administered either as a pre-treatment or
post-treatment and when used in conjunction with standard NA treatments at-
ropine and 2-PAM (pralidoxime). The objective of this study was to correlate clini-
cal biomarkers and pharmacodynamics with clinical observations after treatment
with GAL. Blood and brain levels of GAL and ChE inhibition were determined at
various time-points along with standardized clinical observations.  Cohort A used
36 animals with six dose levels of 0, 2, 4, 8, 12 and 16 mg/kg and serial blood col-
lections from 5 minutes to 24 hours post treatment. These samples were assayed to
determine the percent AChE activity at seven time-points. Cohort B used 144 male
Hartley guinea pigs with six dose levels of 0, 2, 4, 8, 12 and 16 mg/kg with desig-
nated sacrifice time-points on 4 animals for each dose level at 5, 30, 60 min, 2, 4
and 24 hours post treatment. Clinical observations showed a trend of increasing
severity of clinical observations as the dose level increased. All clinical signs started
at 5 minutes post treatment and all animals were normal by the 24 hour post treat-
ment time-point. Significant observations of toxicity were present at and above the
12 mg/kg dose level, combined with the greatest inhibition of AChE. Inhibition of
AChE was seen at the 5 minute time-point (post treatment) with results showing a
dose dependent inhibition from low to high dose levels.
349 Characterization of Protein Adducts of Nitrogen Mustards As
Potential Exposure Biomarkers.
V. R. Thompson and A. P. DeCaprio. Department of Chemistry & Biochemistry and
International Forensic Research Institute, Florida International University, Miami,
FL.
Protein adducts are useful as longer-term biomarkers of exposure to electrophilic
xenobiotics, including chemical warfare agents (CWA) and their metabolites. The
purpose of this study was to characterize protein adducts of the nitrogen mustards
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HN-2 and HN-3 as potential exposure biomarkers. Limited data exist on HN
adducts to protein thiols but not other nucleophilic sites such as lysine and histi-
dine. Initial in vitro experiments used three model peptides (AcPAAXAA; X = C, K,
or H) incubated with HN-2 and -3 (100-fold molar excess) at pH 7.4, 37°C to
mimic physiological conditions. Adduct formation was monitored by LC-QQQ-
MS/MS analysis at various incubation times. Rapid adduction by both agents oc-
curred at all three nucleophilic sites. Major reaction products included S- and N-(2-
chloroethylaminoethyl) adducts (determined by MS isotopic ratios) and S- and
N-(2-hydroxyethylaminoethyl) hydrolysis products. Adduct stability was assessed
by extended incubation of modified peptides after removal of unreacted agent via
C18 SPE. LC-MS/MS analysis demonstrated that adducts were stable for up to
three weeks. In addition, hemoglobin (Hb) as a model protein was incubated with
HN-2 at a mustard:protein molar ratio of 100:1. LC-QTOF MS demonstrated a
mass shift on each Hb subunit corresponding to up to two modifications. Trypsin
digestion of modified protein followed by LC-MS/MS confirmed adduction at C,
K, and H. Finally, in vitro results were compared to in silico calculations (Gaussian
03W software) to predict relative electrophilic reactivity of HN-2 and -3 with pro-
tein nucleophiles. Calculated parameters showed good concordance to the experi-
mental data with regard to kinetics and comparative adduct formation. Results of
this study confirm that nitrogen mustards can stably adduct nucleophilic protein
sites including lysine and histidine. Current work involves assessing the specificity
of binding in both Hb and serum albumin, with the ultimate goal of developing
adduct-based biomarkers for these important potential CWA.
350 Glucocorticoid Exposure Primes the Neuroinflammatory
Response to the Nerve Agent DFP in a Model of Gulf War
Illness.
K. A. Kelly1,  D. B. Miller1,  S. M. Lasley2 and J. P. O’Callaghan1. 1CDC-NIOSH,
Morgantown, WV; 2University of Illinois College of Medicine, Peoria, IL.
We have shown previously that chronic exposure to the glucocorticoid corticos-
terone, (CORT), at levels associated with high physiological stress, can prime the
CNS proinflammatory response to neurotoxic insults. Persistent sickness behavior,
a prominent component of Gulf War (GW) Illness, is associated with neuroinflam-
mation. Veterans of the 1991 GW were exposed to the stresses of war, prophylactic
treatment with the reversible acetylcholinesterase (AChE) inhibitor, pyridostigmine
bromide (PB), the insect repellent, DEET, and, potentially, acutely to the nerve
agent sarin. Previously, we showed that subchronic CORT pretreatment primed the
CNS to mount a neuroinflammatory response to these GW exposures when pro-
voked 24 h after the termination of CORT treatment. Here, we investigated the
persistence of this priming effect on neuroinflammation and the minimal amount
of CORT required to produce the priming response. Male C57BL/6 mice were pre-
treated with chronic (14 days) PB (2mg/kg/day, s.c.) and DEET (30 mg/kg/day,
s.c.), as well as subchronic CORT (200 μg/ml in drinking water on days 7-14) or
acute CORT (20 mg/kg, s.c., 2 injections, 7 h interval on day 14) exposures. Acute
doses (days 15 or 45) of the sarin surrogate and irreversible AChE inhibitor diiso-
propyl phophorofluoridate (DFP, 4 mg/kg, i.p.) or known inflammogen
lipopolysaccharide (LPS, 2 mg/kg, s.c.) were used to provoke neuroinflammation.
We found that both acute and chronic CORT exposure greatly augmented neu-
roinflammation in response to LPS and DFP. Marked neuroinflammation in re-
sponse to DFP was found even when the exposure was 30 days after the cessation of
the subchronic CORT treatment (a time point equivalent to 6 years in humans).
Our findings are suggestive of a possible critical and yet unrecognized link between
the stressful environs of the 1991 GW theater and agent exposure(s) unique to this
war, exposures in which the CNS is primed to amplify future exposure to
pathogens, injury or toxicity. (Supported by CDMRP W81XWH-09-2-0098)
351 Evaluation of Selected Organoselenium Analogs of Ebselen
As Protective Agents against HN2 Toxicity in A-431 Skin
Cells.
M. A. Pino1, 2,  B. Billack2 and M. Pietka-Ottlik3. 1Basic Sciences, TouroCOM,
New York, NY; 2Pharmaceutical Sciences, St. John’s University, New York, NY;
3Division of Organic and Pharmaceutical Technology, Faculty of Chemistry, Wroclaw
University of Technology, Wroclaw, Poland.
Our lab has previously demonstrated that the organoselenium compound ebselen
(EB-1) possesses the ability to reduce the cytotoxicity of mechlorethamine (HN2),
a sulfur mustard surrogate, in vitro. The main objective of the present study was to
determine the extent to which three structurally related compounds, namely EB-2,
EB-3 and EB-4, could mimic this effect in human epidermoid carcinoma cells (A-
431). Using MTT cell viability analysis, we found that in the absence of any test
analog, a reproducible and robust cell death was observed in the cells following in-
cubation with HN2 (25 μM, 24 h), while cells treated with test analog alone (15,
30 or 60 μM) for a similar period of time were generally unaffected. When incu-
bated in the presence of both HN2 and test analog for 24 h, we observed that all
analogs reduced HN2 toxicity to varying degrees, with the EB-4 analog being the
most effective. An examination of cellular morphology using light microscopy
analysis confirmed cytoprotection among cells treated with organoselenium
analogs. It is noteworthy that all analogs of EB-1, at a test concentration of 60 μM,
were capable of reducing the levels of HN2-induced thiobarbituric acid reactive
substances (TBARS), suggesting an antioxidant activity. Among the EB-1 analogs
tested, EB-4 was found to be the most potent at reducing TBARS while EB-2 was
the least potent in this regard. Taken together, these data identify a cadre of
organoselenium analogs which are active against a mustard gas surrogate in vitro.
Future studies are warranted to determine whether or not said compounds will be
effective at reducing mustard-related injury in vivo.
352 Hydroxamate Inhibition of EMMPRIN, an MMP Inducer,
after Mustard Exposure.
A. S. Rodrigues1,  A. Miller1,  R. A. Hahn1,  M. Patel1,  C. Lacey2,  A. N. Pillai2,
S. Young2,  R. A. Flowers2,  N. Dennisova1,  M. A. Gallo3,  D. R. Gerecke1,
K. K. Svoboda4,  N. D. Heindel2 and M. K. Gordon1. 1Pharmacology and
Toxicology, EMSOP, Rutgers University, Piscataway, NJ; 2Department of Chemistry,
Lehigh University, Bethlehem, PA; 3Environmental and Occupational Health,
UMDNJ, Robert Wood Johnson Medical School, Piscataway, NJ; 4Biomedical
Sciences, Baylor College of Dentistry, Texas A&M University, Dallas, TX.
Mustards are blistering agents injuring the eye, skin and lungs. Corneal mustard in-
jury causes separation at the epithelial-stromal border, resulting in epithelial slough-
ing. ADAM17 is a transmembranous enzyme that cleaves collagen XVII, a trans-
membranous hemidesmosomal component that is part of the anchoring complex
riveting the epithelium to the stroma. ADAM17 is activated in rabbit corneal organ
cultures immediately after nitrogen mustard (NM) exposure, and persists 24 hr
post exposure, correlating with the degree of epithelial-stromal separation. To pro-
mote epithelial-stromal integrity after mustard exposure, two hydroxamates were
tested for their inhibition of ADAM17 to reduce collagen XVII cleavage. The hy-
droxamates olvanil OH (NDH4409) or retro olvanil 8 (NDH4417) were applied 4
times to organ cultures over the course of 22 hrs, beginning 2 hours post NM ex-
posure. Epithelial sloughing at 24 hr was reduced. Surprisingly, only NDH4417
significantly inhibited ADAM17 activity. However, both drugs reduced matrix
metalloproteinase-9 (MMP-9). To further evaluate why corneal epithelial-stromal
integrity was preserved after NM exposure, the effects of each drug on expression of
EMMPRIN was tested. EMMPRIN is an MMP inducer. EMMPRIN was greatly
upregulated after mustard exposure. Both NDH4409 and NDH4417 significantly
reduced EMMPRIN expression. Our data indicate that hydroxamates inactivate
ADAM17 and MMPs, and may also preserve corneal epithelial-stromal integrity by
attenuating the vesicant-induced upregulation of the MMP-inducer EMMPRIN. 
Supported by UMDNJ-Rutgers Counteract Center of Excellence NIAMSD
U54AR055073; NIH NEI EY009056; and NIEHS P30ES005022
353 Sulfur Mustard Induces Cytotoxicity and Apoptosis in
Mouse Skin Hair Follicles.
L. Joseph1,  J. A. Cervelli1,  G. M. Composto1,  M. C. Babin2,  R. P. Casillas3,
P. J. Sinko1,  D. R. Gerecke1,  D. L. Laskin1,  J. D. Laskin4 and D. E. Heck5.
1Rutgers University, Piscataway, NJ; 2Battelle, Columbus, OH; 3MRI Global, Kansas
City, MO; 4UMDNJ-Robert Wood Johnson Medical School, Piscataway, NJ; 5New
York Medical College, Valhalla, NY.
Sulfur mustard (SM), a potent vesicant, damages follicular and interfollicular epi-
dermis. We examined the effects of SM vapor on pilosebaceous units in dorsal skin
of 5 wk old male SKH1-Hr mice. Control skin contains prominent sebaceous
glands, atypical hair shafts, isolated utriculi, and small follicular cysts. Fatty acid
synthase and proliferating cell nuclear antigen (PCNA) were expressed in sebocytes.
PCNA was also expressed in hair root sheaths and dermal papillae. Three to seven
days following SM exposure, alterations in the pilosebaceous unit were evident in-
cluding epithelial cell karyolysis within hair root sheath, infundibulum and isth-
mus, as well as loss of sebocytes. Utriculi, some with connections to the skin sur-
face, and engorged dermal cysts were observed. One day post SM exposure
phoshophorylated H2A.X (γH2A.X), a DNA damage marker, and cleaved caspase-
3, a marker of apoptosis, were expressed in the pilosebaceous unit and epidermis.
Although evident in the pilosebaceous unit, PCNA was not expressed in the inter-
follicular epidermis. Decreased numbers of pilosebaceous units and increased num-
bers of inflammatory cells were observed surrounding utriculi and cysts  3 days post
SM.  Decreased expression of γH2A.X, PCNA, and fatty acid synthase was noted,
whereas cleaved caspase-3 was upregulated in the hyperplastic hair root sheath. By
7 days post SM, there were no hair follicles or sebaceous glands within the wound;
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only remnants, including utriculi and large follicular cysts. By 14 days, follicular
cysts within the hyperplastic epidermis were greatly enlarged. Significant amounts
of PCNA and cleaved caspase-3 were expressed in cells surrounding the follicular
cysts. Taken together, these data indicate that the hair follicle is an important target
contributing to SM-induced skin injury. Support: NIH AR055073, ES004738,
CA132624, GM034310, and ES005022.
354 Acute Respiratory and Neurological Toxicity in Rats
following Inhalational Exposure to Lethal Doses of Soman.
B. Wong,  M. Perkins,  G. Murphy,  D. A. Alves,  A. M. Rodriguez,  J. Devorak,
R. K. Kan,  J. A. Leuschner,  T. Dao and A. M. Sciuto. USAMRICD, Aberdeen
Proving Ground, MD.
Soman (GD) is a potent chemical warfare nerve agent (CWNA). GD irreversibly
inhibits acetylcholinesterase (AChE), resulting in accumulation of the neurotrans-
mitter acetylcholine (ACh). High ACh at synapses results in prolonged stimulation
of muscarinic and nicotinic receptors leading to cholinergic crises. This study de-
veloped a novel head-out inhalation exposure system to serve as a realistic and ap-
plicable model for a mass casualty-type scenario to study the development of acute
respiratory and neurological toxicity. GD vapor (520, 560, 600 and 825
mg×min/m3) was generated in a saturator cell and carried by filtered N2 into a cus-
tomized glass exposure chamber. Male rats (250-300 g) were restrained in head-out
exposure tubes and exposed to GD for 4-10 minutes. The probit analyzed LCt50 of
vaporized GD was 593.1 mg×min/m3. A majority of the animals developed severe
cholinergic responses followed by convulsions and died within 4–8 min post-expo-
sure (PE). Mild to severe convulsions and muscular fasciculations were observed up
to 24 h in animals exposed to 560 and 600 mg×min/m3. GD exposures produced
significant, concentration-dependent inhibition in cardiac blood AChE activity.
AChE activity was inhibited in bronchoalveolar lavage (BAL) fluid, lung and whole
brain tissues. Rats exposed to a 600 mg×min/m3 exhibited severe brain damage in
the piriform cortex, neocortex, dentate hilus, amygdala and thalamus. Analyses of
lung tissue showed morphologic changes in alveolar histiocytosis, hemorrhage and
inflammation consisting of neutrophilic exudate. Respiratory and neurological tox-
icity induced by GD vapor was determined by clinical observations, histopathology
and biochemical analyses of tissues 24 h PE. We integrated novel technologies in
inhalation toxicology and physiology to evaluate CWNA toxicity to develop an im-
proved model suitable for testing medical countermeasures in a mass casualty sce-
nario.
This research was supported by the Defense Threat Reduction Agency project
#3.F0014.
355 Inflammatory Profile and Macrophages Population in Sulfur
Mustard (SM)-Exposed Skin Wound Repair.
Y. Chang1,  M. Soriano1,  J. D. Laskin2,  R. P. Casillas3,  M. K. Gordon1 and
D. R. Gerecke1. 1Pharmacology and Toxicology, EOHSI, Rutgers University,
Piscataway, NJ; 2UMDNJ-RWJMS, Piscataway, NJ; 3MRI Global, Kansas City, MO.
Cutaneous SM induced injury is characterized by a severe inflammatory response
and delayed wound repair. Development of quantifiable inflammatory biomarkers
is needed for screening anti-inflammatory drugs against SM injury. Since most in-
flammatory marker studies with SM exposed skin are only available for early time
points (less than 24h), we extended this study to 7 days to better understand the in-
flammatory profile induced by SM. We examined the macrophage population and
inflammatory profile using the mouse ear vesicant model (MEVM). RT-PCR data
showed neutrophil collagenase/MMP8 was significantly unregulated 6h,12h, and
168h post-SM exposure and macrophage elastase/MMP12 was significantly unreg-
ulated at 24h post SM exposure, increasing as time progressed.
Immunohistochemical studies using a macrophage specific marker, F4/80 identi-
fied increased numbers of macrophages at 72h and 168h post-SM exposure. RT-
PCR data showed early upregulation of IL6, IL1b, CCl3, CCL4, CXCl2, CXCL5,
CXCL7 and CXCR4. Upregulation at 72 h post-SM exposure included: IL1rl1,
IL2rg, IL4ra, IL10ra, CSF2rb2, Tnfrsf1b, and Tnfsf11. Using a mouse
cytokine/chemokine multiplex protein assay, we showed upregulation and persist-
ent expression of IL6 and KC/CXCL1, and downregulation of IL10. CCL2 signif-
icantly increased over time beginning at 24h post -SM exposure. CCl3, GCSF, and
IP10/CXCl10 were significantly increased at 72h and 168h post-SM exposures.
These findings suggest that the cytokine/chemokines pattern we observed may be
related to the persistent macrophage population that is generally seen in SM-ex-
posed skin wounds. In addition, this inflammatory profile may be useful as in vivo
biomarkers for evaluating anti-inflammatory drugs against SM-induced skin injury.
This work is supported by ES005022, EY09056, and AR05507
356 Activation of the Endoplasmic Reticulum Stress and
Unfolded Protein Responses for Protection against Sulfur
Mustard-Induced Skin Injury.
D. R. Gerecke1,  J. D. Wang1,  J. D. Laskin2,  M. K. Gordon1 and Y. Chang1.
1Pharmacology and Tox, EOHSI, Rutgers University, Piscataway, NJ; 2UMDNJ-
RWJMS, Piscataway, NJ.
The endoplasmic reticulum (ER) stress response, a cell survival pathway upregu-
lated when cells are under severe stress, contributes to the pathogenesis of various
diseases. It triggers the unfolded protein response (UPR) which initiates ER-to nu-
cleus signaling pathways to protect against cell death via several types of UPR sen-
sor proteins. One of these, ATF6, is proteolytically cleaved and translocated into
the nucleus to regulate gene expression. Skin exposed to the vesicant sulfur mustard
(SM) results in increased expression of specific chaperone proteins. We performed
time course studies with SM using the mouse ear vesicant model (MEVM) and
showed progressive histopathologic changes including edema, separation of the epi-
dermis from the dermis, prolonged inflammation, and delayed wound repair from
24h to 168h post exposure. This study explored the contribution of UPR and in-
creased ER chaperones in ER stress induced by SM injury. RT-PCR analysis of the
ER stress survival gene GRP78; UPR gene ATF6; and ER stress apoptotic gene
CHOP, demonstrated at least a 2 fold increase as time progressed. Western blot
analysis confirmed upregulation of GRP78 and CHOP as time progressed. Both
the full length cytoplasmic ATF6 and the 50 kDa cleaved nuclear fragment of
ATF6 were increased after 24h post SM. Immunofluorescent data showed cytoplas-
mic staining at 24h post exposure and significant nuclear staining in the proliferat-
ing keratinocytes at 168h post exposure. Double-labeled immunofluorescent stud-
ies of GRP78 and CHOP indicated GRP78 staining in the basal, proliferating
keratinocytes. In contrast, expression of CHOP was greater in the outermost mi-
grating cells. These data suggest the ER stress response and UPR are activated in the
proliferating keratinocytes to protect cells against SM induced skin injury. This
work is supported by ES005022, EY09056, and AR055073.
357 Detection of Sulfur Mustard or Half Mustard-Induced DNA
Adducts in Human Skin Cells.
K. Kehe,  V. Schrettl,  D. Steinritz and H. Thiermann. Bundeswehr Institute of
Pharmacology and Toxicology, München, Germany. Sponsor: A. Bürkle.
Introduction: Sulfur mustard (SM) and 2-chloroethyl ethylsulfide (CEES) are bi-
and monofunctional DNA alkylating agents, respectively. SM is an old chemical
warfare agent causing blisters (vesicant). Both chemicals react with N7 guanine.
SM will form 7-Hydroxyethylthioethylguanine for SM and CEES 7-ethyl
thioethylguanin for CEES. A specific monoclonal antibody (2F8) exists which de-
tects SM and CEES adducts at N7 position.
Aim: The 2F8 antibody was used to develop a slot blot technique for detection of
SM and CEES exposure in human keratinocytes (HaCaT cells).
Methods: HaCaT cells were exposed with different concentrations of SM or CEES
(30 min). After exposure, cells were scraped and DNA was isolated, normalized and
transferred to a Nylon membrane using slot blot technique. After incubation with
2F8 antibody, the DNA adducts were visualized with DAB staining.
Results: DNA adducts were detected after CEES and SM exposure below 30 μM
which is the vesicant threshold.
Conclusion: The presented technique is potentially able to confirm SM or CEES
exposure in blister roofs of exposed patients.
358 Differential Inhibition of Cytoplasmic and Mitochondrial
Thioredoxin and Thioredoxin Reductase by Nitrogen
Mustard in A549 Lung Epithelial Cells.
I. Wohlman1,  Y. Jan2,  D. E. Heck3,  R. P. Casillas4,  D. L. Laskin1 and
J. D. Laskin2. 1Pharmacology & Toxicology, Rutgers University, Piscataway, NJ;
2Environmental & Occupational Medicine, UMDNJ-Robert Wood Johnson Medical
School, Piscataway, NJ; 3Environmental Health Science, New York Medical College,
Valhalla, NY; 4MRIGlobal, Kansas City, MO.
The thioredoxin system, consisting of thioredoxin reductase (TrxR) and thiore-
doxin (Trx), plays an important role in cellular antioxidant defense. Both cytosolic
(TrxR1, Trx1) and mitochondrial (TrxR2, Trx2) forms of the enzymes have been
identified in mammalian cells. Previously, we reported that the bifunctional nitro-
gen mustard vesicant, mechlorethamine (HN2), targeted cytosolic TrxR1 by alky-
lating catalytic residues in the enzyme’s redox centers. In the present studies, we
compared the effects of HN2 on the cytoplasmic and mitochondrial forms of TrxR
and Trx in A549 lung epithelial cells. HN2 treatment was found to cause a concen-
tration- and time-dependent inhibition of the activities of both cytoplasmic and
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mitochondrial forms of TrxR and Trx. HN2 was significantly more efficient in in-
hibiting cytosolic, when compared to mitochondrial forms of the enzymes. For
TrxR1 and TrxR2, the IC50’s for inhibition of enzyme activity were 2.7 μM and
14.3 μM, respectively. Immunoblot analysis of subcellular fractions from control
cells on denaturing SDS-PAGE showed TrxR (57 kDA) and Trx (14 kDa)
monomers. HN2 treatment cross-linked Trx1 and Trx2 forming tetramers, and
TrxR1 and TrxR2 forming dimers and oligomers. These data demonstrate that
HN2 can target the thioredoxin system in cytosolic and mitochondrial fractions of
A549 cells by cross-linking proteins. Disruption of this system in lung cells pro-
vides a mechanism for nitrogen mustard-induced oxidative stress and toxicity.
Support: NIH grants AR055073, ES004738, CA132624, ES005022 and
GM034310.
359 Nitrogen Mustard (NM)-Induced Pulmonary Injury and
Inflammation Are Associated with Alterations in Histone
Methylation and Acetylation.
A. Venosa1,  R. Malaviya1,  J. D. Laskin2 and D. L. Laskin1. 1Pharmacology and
Toxicology, Rutgers University, Piscataway, NJ; 2Environmental & Occupational
Medicine, UMDNJ-Robert Wood Johnson Medical School, Piscataway, NJ.
NM (mechloretamine hydrochloride) is a highly toxic vesicant which acts by alky-
lating DNA and proteins and generating oxidative stress. The lung is known to be a
major target for NM. Exposure to NM results in rapid structural changes including
perivascular edema and thickening of the alveolar wall followed by bronchiolization
of the epithelium which progresses to lung fibrosis. We have previously shown that
inflammatory mediators including reactive nitrogen species and tumor necrosis fac-
tor-alpha contribute to NM-induced lung injury. Expressions of genes for these
mediators, as well as antioxidants, are known to be regulated by methylation and
acetylation of histones. In these studies we determine if NM-induced injury and in-
flammatory/antioxidant protein expression is associated with histone modification.
Lung samples were collected 1 d – 28 d after exposure of male Wistar rats to NM
(0.125 mg/kg, intratracheal) or PBS control. NM intoxication resulted in increased
expression of inducible nitric oxide synthase, cyclooxygenase-2 and heme oxyge-
nase-1 in the lung within 1 d, a response which persisted for 28 d; Mn-superoxide
dismutase was also up regulated beginning at 7 d. Analysis of lung homogenates by
western blotting using specific antibodies revealed that this was correlated with a
time-dependent increase in acetylation on histone 3 lysine 9 (H3K9Ac) which re-
turned to baseline by 28 d. In contrast H3K4 methylation decreased 1 d - 7 d post-
NM; this was followed by an increase at 28 d.  Additionally, whereas H3K36
methylation increased beginning 3 d post-NM and persisted up to 28 d, increases
in H3K27 methylation were only evident 28 d after NM exposure. These data sug-
gest that NM-induced lung injury leads to specific alterations in chromatin struc-
ture which may contribute to pro-inflammatory and antioxidant gene expression.
Supported by NIH Grants AR055073, ES004738, CA132624, GM034310, and
ES005022.
360 Dose Modulation of a Potential Therapeutic for
Neovascularization from Ocular Exposure to Sulfur Mustard.
M. L. Meade1,  J. J. Schlager2 and M. C. Babin3. 1Henry M Jackson Foundation,
Wright-Patterson AFB, OH; 2711th Human Performance Wing, Wright-Patterson
AFB, OH; 3Battelle Biomedical Research Center, Jeffersonville, OH.
Sulfur mustard is a potent alkylating agent affecting the skin, respiratory tract and
eyes. Ocular exposure to HD can result in long term injuries including corneal neo-
vascualrization (NV) and blindness. The immunosuppressant, cyclosporine A, has
shown promise for protecting epithelial cells against apoptosis in in vitro experi-
ments. To investigate the effects of cyclosporine A in vivo, two studies were con-
ducted, an initial long term study for 112 days, and a 28 day study using the white
rabbit ocular model to evaluate the effects of different concentrations of cy-
closporine A. The right cornea was insulted with 0.4 μl (0.51 mg) of neat HD
while using the left as a control. Cyclosporine was administered beginning at five
days post exposure for three weeks decreasing the frequency throughout the regi-
men. Clinical assessments, including stromal damage and corneal thickness were
performed throughout the study. Following the study, corneas were harvested and
shipped to Wright Patterson AFB for quantitative proteomic analysis. In the initial
16 week study, cyclosporine performed significantly better than did no treatment or
other potential therapeutics thought to aid in NV prevention. H&E staining shows
continued inflammation in the stroma in the untreated eyes at 15 weeks post expo-
sure, while the cyclosporine treated eyes appear normal. A follow up study using
differing concentrations of cyclosporine A was also performed. The clinical assess-
ment data acquired during this study showed that all concentrations of cyclosporine
performed well in eliminating stromal opacity at 28 post exposure compared to no
treatment. The 2% cyclosporine group performed better than other concentrations
in preventing NV with only one animal in the group experiencing NV at the con-
clusion of the study. Quantitative proteomics of the epithelium and endothelium of
the corneas also showed protein expression levels consistent with the unexposed
eyes in the 2% cyclosporine group.
361 Development and Optimization of In Vitro Models of
Chemical Ocular Injury for High-Throughput siRNA
Screening.
J. G. Lehman,  S. L. Beach,  R. D. Causey and A. L. Ruff. US Army Medical
Research Institute of Chemical Defense, Aberdeen Proving Ground, MD.
Chemically induced ocular injuries are considered one of the few true ocular emer-
gencies based on their high potential to inflict rapid and significant tissue damage.
Currently there are no specific therapeutics to treat chemically induced corneal in-
jury, and there is a pressing need to rapidly screen therapeutics to discover a treat-
ment. Understanding of the molecular mechanisms of this injury is necessary to aid
in rational therapeutic development. We intend to utilize high throughput small in-
hibitory RNA (siRNA) screening to elucidate the mechanisms of chemical cornea
injury and to identify therapeutic targets. Herein we present the development of
the in vitro models for this screening effort. Two immortalized human corneal ep-
ithelial cell lines will be used for screening: SV40 large T antigen immortalized
corneal epithelial cells (SHECs) and telomerase immortalized corneal epithelial
cells (TCECs). Hydrofluoric acid (HFA) is used for the induction of chemical in-
jury. The major conditions optimized included cell line plating density, exposure
dose, and transfection conditions. Matrices of these conditions were evaluated to
ensure optimal target knockdown without sacrificing cell viability. Transfection
conditions were optimized using siRNA targeting cyclophilin b, and knockdown
was assessed using the QuantiGene Plex assay, a bead based assay using hybridiza-
tion to amplify specific mRNAs allowing for quantification. A dose-response study
of HFA injury was performed, and the HFA-induced production of the cytokines
was evaluated by multiplex bead-based assay for a panel of 30 cytokines. Once op-
timized, these models will be used to screen subgenomic siRNA libraries targeting
HF-induced ocular inflammation.
Disclaimer: The views expressed in this article are those of the author(s) and do not
reflect the official policy of the Department of Army, Department of Defense, or
the U.S. Government. This research was supported by the Defense Threat
Reduction Agency – Joint Science and Technology Office, Medical S&T Division.
362 Multiarray Gene Expression Approach Analyzing Cultured
Primary Human Astrocytes and Neurons following Chemical
Warfare Nerve Agent Exposure.
C. Rothwell,  S. Swayze,  J. F. Dillman and H. Hoard-Fruchey. USAMRICD,
Gunpowder, MD.
Chemical warfare nerve agents (CWNAs) are irreversible organophosphorus
cholinesterase inhibitors that cause seizure. Within 24 h of CWNA exposure, neu-
ronal degeneration, astrocytic activation and cellular death can be observed in vari-
ous brain regions. In this study, we investigated the effects of CWNA exposure on
primary cultures of neurons and astrocytes to determine direct molecular alter-
ations in the absence of CWNA-induced seizure activity. Cultured primary human
astrocytes were exposed to 100 μM of the CWNAs sarin, soman, VX, or VR and
harvested at 24 h. Similarly, cultured primary human neurons were exposed to 100
μM soman or VX and harvested at 24 h. Total RNA was isolated from exposed
cells, processed for microarray analysis, and hybridized to Affymetrix Human
Genome U133 Plus 2.0 arrays. Principal component analysis (PCA) of the astro-
cyte data did not show distinct profile differences based on agent type, indicating
few if any significant differences in transcript expression in response to agent expo-
sure. However, PCA of the neuronal data showed a distinct profile difference based
on agent type. For both cell types, the dataset was filtered by agent type, and an
analysis of variance (ANOVA) was performed using agent as the factor. Using these
combined data, the pathways significantly affected by agent type in cultured
human primary neurons were identified. The genes differentially expressed in re-
sponse to soman exposure mapped to canonical pathways containing inflammatory
molecules. Using the same samples, real-time PCR was utilized to provide quanti-
tative measurements of gene transcription across genes associated with the human
immune response. These data suggest a non-cholinergic effect of soman that in-
duces transcriptional expression of inflammatory molecules as well as components
of the GABA pathway. In addition, these data suggest that an in-depth analysis of
in vivo transcriptomic data focusing on the GABA pathway may reveal new targets
within that pathway for improved medical countermeasures to these toxic agents.
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363 MicroRNA Microarray Analysis of Human-Induced
Pluripotent Stem Cell-Derived Neurons and Cardiomyocytes
following Exposure to the Organophosphate Nerve Agents
Soman and VX.
E. K. Yego,  J. F. Dillman and H. Hoard-Fruchey. Research Division, US Army
Medical Research Institute of Chemical Defense, Aberdeen Proving Ground, MD.
Chemical warfare nerve agents (CWNA) are potent cholinesterase inhibitors that
may also have non-cholinesterase effects. Several in vivo studies have demonstrated
CWNA-induced damage in the brain and heart following CWNA exposure. The
mechanisms of this damage have been a critical area of research for the development
of medical countermeasures. This study utilized microRNA (miRNA) analysis to
evaluate potential direct cellular effects of the nerve agents soman (O-Pinacolyl
methylphosphonofluoridate) or VX (o-ethyl-s-[2 (diisopropylamino) ethyl]) on
human-induced pluripotent stem cell (iPSC)-derived neurons and cardiomyocytes.
This approach was taken since miRNA expression changes are stimulus specific and
no previous studies of miRNA profiles have been conducted for CWNA exposure.
Cells were treated with soman or VX at concentrations of 0 μM, 0.1 μM or 100
μM for either 1 hr or 6 hr. Following treatment, isolated total RNA was processed
for miRNA microarray analysis and analyzed for significant changes. Soman- and
VX-treated samples were analyzed separately. Principal component analysis (PCA)
was used to identify major sources of variability in the dataset. PCA analysis of neu-
rons identified differences in miRNA expression only for cells exposed for 6 hr to
soman. Targets that were significantly altered under these conditions were miR-
2277, miR-1910 and miR-1972. miR-2277 was significantly altered in soman- and
VX-exposed neuron data sets that were analyzed by both time and dose. Minimal
sample variability was observed with cardiomyocytes as determined by PCA analy-
sis. One-way ANOVA with time as the factor identified miR-3178 as the only tar-
get that was altered significantly by both soman and VX in cardiomyocytes. This
miRNA modulates several targets including complexin-1 and splicing factor-1.
This study demonstrates the feasibility of using miRNA microarray analysis for the
study of CWNA cellular effects.
364 Toxidromes—A Decision-Making Tool for Early Response to
Chemical Mass Exposure Incidents.
M. Kirk1,  P. J. Hakkinen2,  J. S. Ignacio3,  O. Kroner4,  A. Maier4 and
J. Patterson4. 1University of Virginia, Charlottesville, VA; 2National Library of
Medicine, Bethesda, MD; 3Department of Homeland Security, Washington DC;
4TERA, Cincinnati, OH.
A common language to describe and recognize clinical manifestations of toxic
chemical exposures is essential for emergency responders and hospital first receivers
to be prepared to provide rapid and appropriate medical care for victims of indus-
trial chemical mass exposures and terrorist attacks. In these situations, when the
identity of the chemical is not known, first responders need a tool to rapidly evalu-
ate victims and identify the best course of treatment. Military and civilian emer-
gency response communities use a “toxic syndrome” (toxidrome) approach to
quickly assess victims and determine the best immediate treatment when informa-
tion on chemical exposures is limited. Toxidromes can be defined by a unique
group of clinical observations, such as vital signs, mental status, pupil size, mucous
membrane irritation, and lung and skin examinations. Data on over 20 toxidrome
systems were evaluated to identify salient features and develop a consistent lexicon
for use by state, local, tribal, territorial, and federal first responders and first re-
ceivers. A workshop of over 40 practitioners and experts in emergency response,
emergency medicine, and medical toxicology developed names and definitions for
12 unique toxidromes that describe and differentiate the clinical signs and symp-
toms from exposures to chemicals. These toxidromes focus on acute signs and
symptoms caused by inhalation and dermal exposures. Each toxidrome is character-
ized by exposure routes and sources, organs/systems affected, initial signs and
symptoms, underlying mode of action, and treatment/antidotes. Toxidrome names
and definitions are designed to be readily understood and remembered by users.
Communication in a crisis requires accurate and succinct terms that can quickly
convey the health conditions of patients. These toxidromes lay the foundation for a
consistent lexicon, that if adopted widely, will improve response to chemical mass
exposure incidents.
365 Activation of DNA Damage Repair Pathways in Response to
Nitrogen Mustard-Induced DNA Damage and Toxicity in
Skin Keratinocytes.
S. Inturi1,  N. Tewari-Singh1,  C. Agarwal1,  C. W. White2 and R. Agarwal1.
1Pharmaceutical Sciences, University of Colorado Denver, Aurora, CO; 2Pediatrics,
University of Colorado Denver, Aurora, CO.
Alkylating agent nitrogen mustard (NM), a structural analog of chemical warfare
agent sulfur mustard (SM), upon exposure to tissues, forms adducts and crosslinks
with DNA, RNA and proteins. The major mechanism of NM-induced toxicity in-
volves DNA interstrand crosslinks (ICL) formation resulting in either induction of
cell cycle arrest to facilitate DNA damage repair or cell death, in the case of inade-
quate repair. Consistently, NM (0.75 μM) exposure in mouse epidermal JB6 cells
decreased cell growth and caused S-phase arrest by 16 h after exposure. Cells were
then released to G2-M phase by 24 h and resumed normal cell cycle progression by
48 h after exposure. Repair of NM-induced DNA ICLs involves formation of DNA
double strand breaks (DSB). Our studies showed an increase in comet tail extent
moment starting between 4 and 8 h of NM exposure, as well as an increase in levels
of DNA DSB repair molecules (phospho H2A.X and p53, rad50 and XRCC1).
The repair of DNA double strand breaks occurs via homologous recombination re-
pair (HRR) or through the non homologous end joining pathway (NHEJ). The ac-
tivation of the HRR pathway was evidenced by formation of Rad51 foci at 4 h after
NM exposure, and activation of NHEJ pathway was indicated by increases in phos-
pho and total DNA-PK levels. To confirm this, NHEJ and HRR pathways were in-
hibited by using DNA-PK inhibitor NU7026 and Rad51 SiRNA, respectively.
Inhibition of NHEJ did not result in a significant decrease in total cell number after
48 h of NM exposure and also did not affect the NM-induced S-phase arrest at 16
h. However, inhibition of the HRR pathway caused a 28% decrease in cell number,
and a lack of NM-induced S-phase arrest, probably leading to an increase in the ob-
served cell death. These studies indicate that HRR may be a key pathway involved
in repair of NM-induced DNA DSBs. These findings may be useful in developing
new therapeutic strategies against NM-induced skin toxicity.
366 Progression of Injury and Toxic Effects following Nitrogen
Mustard Exposure in SKH-1 Hairless and C57BL/6J Mice
Skin: Clinical and Pathological Significance.
N. Tewari-Singh1,  A. K. Jain1,  S. Inturi1,  D. J. Orlicky2,  C. W. White3 and
R. Agarwal1. 1Pharmaceutical Sciences, University of Colorado Denver, Aurora, CO;
2Pathology, University of Colorado Denver, Aurora, CO; 3Pediatrics, University of
Colorado Denver, Aurora, CO.
Lack of availability of relevant skin injury models and clinically applicable bio-
markers are major limitations in developing therapies to rescue skin injury and vesi-
cation by chemical warfare agent sulfur mustard (SM). Consequently, we con-
ducted studies to establish useful clinical and histopathological endpoints with
primary vesicating agent nitrogen mustard (NM). NM possesses strong vesicating
and alkylating properties and causes damage to cellular macromolecules, exerting
severe skin toxicity comparable to SM. Our comprehensive studies employing NM
(3.2 mg) exposure for 12, 24, 72 and 120 h in both SKH-1 and C57BL/6J mice
showed clinical sequelae of toxicity, including visible microblistering (12-24 h),
edema (12-120 h), erythema (12-24 h), and hyper- and hypopigmentation,
wounding, xerosis and scaly dry skin (72-120 h) that were comparable in both the
mouse strains, and similar to those reported with SM in humans. In addition, 40%
mortality was observed by 120 h after NM exposure in C57BL/6J mice. H&E
stained skin sections of both mice showed that NM (12-120 h recovery) caused in-
creased skin bi-fold thickness; histopathological effects such as hyperproliferation,
microvesication, epidermal and dermal necrosis, denuding and scab formation, and
parakeratosis (24-120 h), hypercornification (12-120 h), acanthosis and re-epithe-
lialization (72-120 h); increase in inflammatory cells; and red blood cell extravasa-
tion into the dermis. These histopathological effects with NM were comparable to
those reported in humans and other animal species with SM, and were quantified as
percent of skin sections showing these effects, fold increases in histopathologic ab-
normalities, and prevalence among mice (% that showed these effects). These NM-
induced effects are novel clinically relevant biomarkers to be used in screening and
optimization of rescue therapies for skin injuries due to NM and SM in humans.
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367 Long-Range Assessment and Treatment of Lung and
Systemic Injury in Rats Exposed to Inhaled Sulfur Mustard.
D. S. Olivera,  T. R. Varney,  D. A. Alves,  K. Whitten,  V. I. Morthole,
R. K. Kan,  J. L. Collins,  J. B. Simons,  J. L. Devorak,  A. M. Rodriguez,
C. M. Bowens,  A. M. Witriol,  E. A. Lyman,  R. R. Deckert,  S. L. Russell and
A. M. Sciuto. Analytical Toxicology, USAMRICD, Gunpowder, MD.
Sulfur mustard (HD) causes severe chemical burns to the skin, eyes, and airways.
HD was used as a chemical warfare agent (CWA) in the Iran/Iraq conflict, and
more than half of surviving HD-exposed casualties suffer from permanent lung in-
juries. The mechanisms and timing of the development of these pathologies are
poorly defined, and there is no effective antidote. Rats were intubated and venti-
lated for 10 min with nebulized HD or vehicle to achieve doses of 0, 0.5, 1.75,
2.25, and 3 mg/kg. Pulmonary function was analyzed by whole-body plethysmog-
raphy. Rats were euthanized at various time-points ≤ 6 months post-exposure,
blood chemistry was analyzed, broncho-alveolar lavage fluid was analyzed for cy-
tokines/ redox state, and lungs were subjected to pathologic analysis. The data show
high correlation between blood gas perturbations, upper airway necrosis and pul-
monary function in the 24 h to 48 h after the 3 mg/kg HD exposure. In longer-
ranging animals, the 3 to 7 wks period was a significant challenge because 15% of
the 3 mg/kg group and 10% of the 2.25 mg/kg group died suddenly or required
withdrawal from the study during this time. Alveolar exudates, edema, oxidative
stress, and inflammation peaked at 3 wks and correlated with changes in pul-
monary function and respiratory distress. Therefore, the first day and the second to
third wks post-exposure may be crucial windows in the progression of HD inhala-
tion injury, and treatment at these times may be the best approach. Based on this,
we have evaluated single and multiple infusions of mesenchymal stem cells as a
treatment and have found success in reducing HD-induced edema, necrosis, in-
flammation, and death at 5 wks post-exposure. This study provides the first long-
term examination of HD-induced lung injury and systemic effects, and demon-
strates the feasibility of stem cell therapies for treatment of HD inhalation injury.
368 Therapeutic Efficacy of Serum-Derived Human
Butyrylcholinesterase against Topical Challenges of VX in
the Hartley Guinea Pig.
T. Snider1,  J. D. Johnson1,  K. G. McGarry1,  G. H. Van der Zwaag1,
R. L. Malek2,  B. Peterson2 and A. N. Nunley2. 1Battelle, Columbus, OH;
2Chemical Biological Medical Systems/Medical Identification and Treatment Systems,
Frederick, MD.
The protective efficacy of human serum butyrylcholinesterase (HuBChE) was as-
sessed in the guinea pig against topical challenges of VX. Male Hartley guinea pigs
with jugular catheters were clipped on the left flank and challenged with neat VX at
multiples of the 24-hr median lethal dose (LD50). Two hours after challenge, ani-
mals received either 1.04 mL/kg saline or HuBChE at 26 mg/1.04 mL/kg by intra-
venous (IV) infusion. Blood samples were collected at 5 min before challenge, 5
min before therapy, and 48 and 96 hr after challenge, and assayed for acetyl-
cholinesterase (AChE) and butyrylcholinesterase (BChE) activity. Clinical signs,
recorded for up to 96 hr after challenge, indicated that VX rapidly penetrated skin.
The protective ratio of HuBChE, 2.8, was calculated as the LD50 determined by
probit analysis among IV therapy-receiving guinea pigs (0.39 mg/kg) divided by
the LD50 for unprotected guinea pigs (0.14 mg/kg). VX was lethal to all guinea
pigs challenged at 4x and 8x LD50. AChE activity among survivors, likely through
VX dissociation, rebounded to more than 80% of the baseline value by 96 hr.
BChE activity among survivors increased after therapy and remained at more than
30 times endogenous levels over the 4-day study. In a follow-on study, the thera-
peutic window was characterized by fixing the topical VX challenge dose at the
LD15 (0.34 mg/kg) and changing the time interval to IV therapy. Probit modeling
indicated that 50% lethality would be expected after a 4.3 hr delay post-challenge
of HuBChE therapy. Blood AChE activity profiles declined with delay in therapy
followed by a rebound among survivors. BChE activity increased after therapy and
remained at 30 to 54 times endogenous levels over the 4-day study.
This work was conducted under the CBRNIAC Contract No. SF0 700-00-D-
3180, Delivery Order 0599, Task 789.
369 A Comparative Study of Biomarkers of Nitrogen Mustard-
Induced Skin Injury in Male SKH-1 Hairless and C57BL/6J
Mice.
A. K. Jain1,  N. Tewari-Singh1,  S. Inturi1,  D. J. Orlicky2,  C. W. White3 and
R. Agarwal1. 1Pharmaceutical Sciences, University of Colorado Denver, Aurora, CO;
2Pathology, University of Colorado Denver, Aurora, CO; 3Pediatrics, University of
Colorado Denver, Aurora, CO.
Sulfur mustard (SM) is a primary vesicating warfare agent that upon exposure
causes severe skin injuries. Currently, we lack effective antidote against SM-induced
skin injuries, in part due to lack of appropriate animal model(s) that can be used for
mechanistic and efficacy studies in laboratory settings. Our earlier studies have es-
tablished biomarkers related to inflammation and vesication in SKH-1 hairless
mice using 2-chloroethyl ethyl sulfide (CEES), an SM analog. However, CEES is a
monofunctional alkylating agent that is less toxic than SM. Therefore, to develop a
more relevant skin injury model, we have now used nitrogen mustard (NM); a pri-
mary vesicant and a bifunctional alkylating agent that induces toxic effects compa-
rable to SM. We compared the effect of NM (3.2 mg) exposure for 12, 24, 72 and
120 h in SKH-1 hairless and C57BL/6J mice. NM caused significant increases in
skin microvesication, cell proliferation, apoptotic cell death, inflammatory cells
(neutrophils, macrophages, and mast cells) and MPO activity in both mouse
strains. However, in SKH-1 mice there was a more prominent increase in epidermal
thickness, macrophages and mast cell infiltration, relative to that seen in C57BL/6J
mice. NM also caused collagen degradation at early time points (12-24 h) with a
decrease in collagen trichrome staining and an increase in dermal thickening, due,
at least in part, to edema. However, at later time points (72 and 120 h), dense col-
lagen staining with reduced dermal edema was observed, indicating a healing
process. This study indicates that both mouse strains have comparable susceptibil-
ity to NM injury, as shown by inflammation and vesication. However, some in-
flammatory responses were more pronounced in NM-induced skin injury in SKH-
1 mice. These newly established biomarkers in a more accessible and relevant NM
skin injury model should aid in identifying effective therapies for treatment of skin
injuries due to NM and SM.
370 24 h LD50 for Subcutaneous Exposure to Chemical Warfare
Nerve Agents in Rats: Comparison across Multiple Age
Groups.
L. K. Wright,  R. B. Lee,  S. H. Robertson,  K. M. Licht,  M. F. Stone,
M. C. Moffett and L. A. Lumley. US Army Medical Research Institute of Chemical
Defense, Aberdeen Proving Ground, MD.
In a mass casualty situation involving the release of chemical warfare nerve agents
(CWNA), infants, children and adolescents are likely to be exposed. These sub-
groups of the population may be more susceptible than adults to the toxicological
effects of CWNA exposure because of their closer proximities to a ground source,
smaller body masses, higher respiratory rates, greater skin permeabilities and imma-
ture brains and metabolic systems. Unfortunately, there have only been a handful of
studies on the effects of CWNA in younger animals, and more research is needed to
confirm this hypothesis. Using a stagewise, adaptive dose design, we determined
the 24 h LD50 for subcutaneous (sc) exposure to sarin (GB), as well as VX, in both
male and female Sprague-Dawley rats at five different time points during their de-
velopment (postnatal day [PND] 7, 14, 21, 42 and 70). For males, the 24 h LD50
for both GB and VX increased from PND 7 thru PND 42 and then slightly de-
creased at PND 70. Similar results were observed for females; however, fewer sig-
nificant differences between age groups were observed. Regardless of CWNA, no
significant differences were observed between males and females for any age group.
Thus, younger rats are more susceptible to the lethal effects of subcutaneously ad-
ministered CWNA than older rats. The views expressed in this abstract are those of
the authors and do not reflect the official policy of the Department of Army,
Department of Defense, or the U.S. Government. The experimental protocol was
approved by the Animal Care and Use Committee at the United States Army
Medical Research Institute of Chemical Defense (USAMRICD), and all procedures
were conducted in accordance with the principles stated in the Guide for the Care
and Use of Laboratory Animals and the Animal Welfare Act of 1966 (P.L. 89-544),
as amended. This research was supported by interagency agreement between the
Biomedical Advanced Research and Development Authority and USAMRICD.
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371 Mechanisms of Vesicating Agent Nitrogen Mustard-Induced
Skin Injury in SKH-1 Hairless Mice.
D. Kumar1,  N. Tewari-Singh1,  S. Inturi1,  C. Agarwal1,  A. K. Jain1,  D. Dhar1,
C. W. White2 and R. Agarwal1. 1Pharmaceutical Sciences, University of Colorado
Denver, Aurora, CO; 2Pediatrics, University of Colorado Denver, Aurora, CO.
Lack of a comprehensive understanding of molecular mechanisms and signaling
pathways involved in skin injuries due to chemical warfare agent sulfur mustard
(SM)- is a major limitation in developing mechanism-based therapies for rescue of
skin injuries by vesicating agents. Our recent studies in SKH-1 hairless mice show
that exposure to nitrogen mustard (NM; 3.2 mg) for 12, 24, 72, 120 or 168 h trig-
gers an inflammatory response, vesication, apoptotic cell death, and either initia-
tion of healing or 40% mortality by 168 h of exposure. Both SM and NM vesicant-
induced tissue injury is mainly due to alkylating properties, with DNA damage
resulting from direct toxicity and/or oxidative stress. In this study we extended our
efforts to identify the mechanism/s involved in NM-induced toxic response at 12-
120 h after exposure. In skin tissue of SKH-1 mice, NM exposure caused p53 ser15
phosphorylation and increased p53 accumulation, both indicating DNA damage.
Our results also showed that NM exposure, with recovery for 12-168 h, induced
expression of inflammatory mediators COX-2 and iNOS in mouse skin, and >2-
fold increase in expression of protease MMP-9, that may contribute to NM-in-
duced vesication. NM exposure, with recovery for12-168 h, also was associated
with phosphorylation of mitogen-activated protein kinases (MAPKs; ERK1/2,
JNK, and p38) and increased oxidative stress, as indicated by enhanced 4-HNE
(lipid peroxidation) and DMPO protein adduct formation. Our results thus far in-
dicate that NM induces activation of upstream signaling pathways including
MAPKs and oxidative stress that could, in part, be responsible for DNA damage,
cell death, and expression of inflammatory and proteolytic mediators contributing
to the inflammatory response and vesication. These molecular targets could be use-
ful in developing therapeutic interventions against NM- and SM-related skin in-
juries.
372 Ovarian Hormones Affect the Physiological Response to VX
in Female Rats.
C. Smith,  L. K. Wright,  J. E. Schwartz,  S. H. Robertson,  K. M. Licht and
L. A. Lumley. US Army Medical Research Institute of Chemical Defense, Aberdeen
Proving Ground, MD. Sponsor: J. McDonough.
Chemical warfare nerve agents (CWNAs), such as VX, irreversibly bind to acetyl-
cholinesterase, which induces a “cholinergic crisis” that causes numerous physiolog-
ical events including seizures and death. Females are historically an understudied
subset of the population, largely because of conflicting data related to the effects of
CWNAs both within groups of females and in comparison to males. The profound
impact of circulating ovarian hormones on biological processes is well known, and
parsimony suggests that these hormones contribute to these observed differences.
To date, few studies have investigated the impact of naturally circulating ovarian
hormones in animals exposed to CWNAs. In the current study, we examined the
effects of VX (1.0 x LD50) in female rats that had their ovaries removed (OVEX) or
left intact. The estrous cycles of females left intact were monitored, and they were
further divided by stage of the cycle (estrus or diestrus). Results show that females
in estrus survived for a significantly longer period of time than OVEX rats. Seizure
activity was also significantly different, with 5/8 OVEX, 2/8 diestrous, and 0/8 es-
trous female rats exhibiting seizures. These data suggest that ovarian hormones, in-
cluding estrogen, progesterone, and their metabolites, which rise the evening before
estrus, offer protection against the seizure-inducing and lethal effects of VX.
The views expressed in this abstract are those of the authors and do not reflect the
official policy of the Department of Army, Department of Defense, or the U.S.
Government. The experimental protocol was approved by the Animal Care and Use
Committee at the United States Army Medical Research Institute of Chemical
Defense and all procedures were conducted in accordance with the principles stated
in the Guide for the Care and Use of Laboratory Animals and the Animal Welfare
Act of 1966 (P.L. 89-544), as amended. This research was supported by the U.S.
Army’s In-house Laboratory Independent Research (ILIR) program.
373 Inflammatory Response following Neurogenic Cardiotoxicity
Induced by Exposure to the Chemical Warfare Agent Soman.
H. Hoard-Fruchey,  C. J. Smith,  M. A. Guignet,  J. F. Irwin,  T. L. Dao,
J. A. Leuschner,  E. A. Johnson,  J. F. Dillman and R. K. Kan. US Army Medical
Research Institute of Chemical Defense, Aberdeen Proving Ground, MD.
Chemical warfare nerve agents (CWNAs) are potent inhibitors of cholinesterase ac-
tivity, causing inhibition of acetylcholinesterase and accumulation of acetylcholine
(ACh) at synaptic junctions. Excess ACh causes hyperstimulation of the central and
peripheral cholinergic systems, and seizure activity ensues in susceptible brain re-
gions. Because of the extensive neuronal damage and death caused by the resulting
seizure activity, studies of CWNA-induced injury have focused primarily on the ef-
fects to the central nervous system with few studies focused on other organ systems.
Previous studies have demonstrated cardiac damage following exposure to seizuro-
genic doses of the CWNAs soman and sarin. Following acute exposure to soman,
up to 88% of rats display cardiac lesions in the interventricular septum and left ven-
tricular wall. To initiate molecular characterization of soman-induced cardiotoxic-
ity, we used multiplex immunoassays to determine concentrations of inflammatory
and cardiac markers altered in left ventricle samples from rats exposed to a seizuro-
genic dose of soman. Increased concentrations of cytokines such as IL-1 beta, IL-4,
IL-5, IL-13, and IFN gamma were observed within 24 hours of soman-induced
seizure. Cytokine IL-6 concentrations peaked 3 hr after soman-induced seizure, in-
dicating early involvement of inflammatory response in cardiac tissue. Chemokines
MCP-1 and CXCL1 also increased, indicating that signals for neurophil and
monocyte recruitment to cardiac tissue are present following soman exposure. In
addition, increases in TIMP-1 and VEGF concentrations within 6 hr of soman ex-
posure suggest that cardiac injury occurs within hours of seizure initiation and that
in response, repair mechanisms are activated. These results support development of
anti-inflammatory medical countermeasures to treat the peripheral as well as the
central effects of chemical warfare nerve agents.
374 Development of an Inhalation Exposure System to Control
Concentration and Time Profile of a Test Gas to Evaluate the
Predictivity of “Toxic Load” Models.
B. A. Wong,  R. James,  B. C. Sharits and L. M. Sweeney. Naval Medical Research
Unit - Dayton, Wright Patterson Air Force Base, OH.
For dose calculations of an inhaled toxic material, a time-varying concentration sce-
nario is generally modeled as a constant concentration times a specified duration
(step profile) that yields the same cumulative exposure, such as in the toxic load
model (Cn × T). The adequacy of the toxic load model to predict mortality from a
realistic exposure scenario based on step profile laboratory experiments is under re-
view. An inhalation exposure system was set up to provide separate pulses of a test
atmosphere at different concentrations and time durations as a first approximation
of a time varying exposure.
A test atmosphere was generated by mixing a test gas from a cylinder (hydrogen
cyanide in oxygen and nitrogen) with clean air to a target concentration. A combi-
nation of two generation systems, one at a high target concentration and one at a
low target concentration was used to produce a specified change in concentration.
The two generation systems could be switched on and off to insert a time gap be-
tween the two exposure concentrations, if desired. Precision mass flow controllers
were used to control the flow of test gas and dilution air to achieve the target con-
centrations. Electric solenoid valves were used to change the different gas flows for
precise timing. A Fourier Transform Infrared Spectrometer was used to measure the
test material concentration in the exposure air entering the breathing zone of the
test subject. A 12-port nose-only exposure unit was used to expose animals to the
test atmosphere. Three basic patterns were generated, a single constant concentra-
tion for a defined time duration, a high concentration and low concentration pulse
with no separation, and a high concentration and low concentration with a clean
air gap between pulses. Test generation results showed excellent control of time and
concentration of the exposure atmospheres.
375 A Decade of Nanotoxicology: Where Do We Stand Now?
S. M. Hussain and J. J. Schlager. Air Force Research Laboratory, US Air Force,
Wright-Patterson, Dayton, OH.
The last ten years have seen an explosion in the development and evolution of nan-
otoxicology. This milestone of a decade of research provides a great opportunity to
look back and evaluate both the progress made, as well as identify challenges that
can potentially plague future research. Early studies had few materials to work with.
However, advances in material science have resulted in a large array of nanomateri-
als (NM) with controlled size, shape, and surface functionalities. From early on, it
became apparent that the unique properties associated with NMs, (i.e., primary
size, agglomeration patterns, crystal structure, shape, etc.) can dictate the observed
effects. Systematic evaluation of toxicity mechanisms necessitated development of
novel tools to assess NM physicochemical properties that include: enhanced mi-
croscopy techniques, dynamic and static light scattering, and quantitation of cellu-
lar uptake. However, adaptation of such characterization tools within the nanotox-
icity community has been slow, due to convoluted literature reports of the same
NM property measured with different techniques. Recently, the question of
dosimetry has become a focus of inquiry due to such conflicting reports.
Experiments are being performed to evaluate and compare the effect of dosage by
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mass, surface area, and number of particles. However, the evaluation of aggregation
state has largely ignored the structure of aggregation, which can substantially influ-
ence NM mass exposure and uptake. In addition, another challenge in nanotoxicity
is the lack of strategies to accurately extrapolate in vitro results to predict in vivo re-
sponses. This generates the need for enhanced cell model development and imple-
mentation in nanotoxicity research. The emerging field of nanotoxicology has
made remarkable progress over the past decade and holds immense promise for the
next. The focus of this discussion will be to highlight the current state of nanotoxi-
city and determine key gaps in dosimetry, interpretation of characterization to deci-
pher mechanistic toxicity, and translating data to reliable assessment of human ex-
posure and risk.
376 Predicting Human Thorough QT (TQT) Study Outcomes
with Nonclinical Data—How Good Are We and How Good
Do We Need to Be?
J. Valentin1,  O. Della Pasqua2,  J. Koerner3,  D. Leishman4,  L. Ewart1 and
M. Krucoff5. 1AstraZeneca, Macclesfield, United Kingdom; 2Leiden University,
Leiden, Netherlands; 3US FDA, Silver Spring, MD; 4Lilly, Greenfield, IN; 5Duke
University Medical Center, Durham, NC.
The ability to predict and thus prevent drug-induced ventricular arrhythmia and
Torsades de Pointes (TdP) is a significant public health issue and a primary focus of
regulatory safety pharmacology studies. Data are generated both nonclinically (via
hERG, ECG, APD studies) and clinically primarily via a thorough QT study
(TQT). The speakers in this roundtable session will consider the predictive value of
each of these studies individually and their utility as a panel overall. Specifically,
speakers will discuss concordance between nonclinical and clinical data for safety
pharmacology endpoints; discuss optimization of nonclinical study design and data
collection; identify opportunities for data from additional metrics; and discuss per-
spectives on the collection and use of nonclinical data to inform clinical trials. The
panelists will also be challenged to identify strengths and weaknesses in current test-
ing approaches and propose recommendations to improve or modify these ap-
proaches in the future. Participants will be engaged in these discussions and provide
input in the debate of the predictive value of nonclinical QT studies as well as the
potential for alternative assays or extrapolations to improve our ability to anticipate
clinical outcome.
377 Diesel and Gasoline Exhaust and Cancer.
A. M. van Erp1,  J. D. McDonald3,  R. O. McClellan2 and E. Garshick4. 1Health
Effects Institute, Boston, MA; 2Toxicology and Human Health Risk Analysis,
Albuquerque, NM; 3Lovelace Respiratory Research Institute, Albuquerque, NM;
4Veterans Administration Boston Health Care System, Boston, MA.
In 1989, the International Agency for Research on Cancer (IARC) classified whole
diesel exhaust as a “probable human carcinogen” and whole gasoline engine exhaust
as a “possible human carcinogen.” Since then, stringent regulations on diesel engine
emissions have been introduced, and there have been significant developments in
engine technology and introduction of ultra-low sulfur fuel resulting in marked re-
ductions in the hazardous components in diesel exhaust. These changes are ex-
pected to provide substantial benefits to air quality and human health. The time
course for realizing the benefits will be related to the rate at which old engines are
replaced with new technology. In June 2012, IARC re-evaluated the carcinogenic
hazard of diesel and gasoline exhaust based on new information that has become
available from studies in humans and animals, which has led to the current desig-
nation of diesel exhaust as a “known human carcinogen.” This session provides a
historical overview of diesel engine technology and emissions, and the significant
changes that have occurred over the past decades. We also take a look at what is
known about the health effects of diesel and gasoline exhaust and its public percep-
tion over the years. We provide a detailed characterization of the June 2012 IARC
Working Group re-evaluation of the carcinogenic hazard classification of diesel ex-
haust and gasoline emissions, both regarding the toxicologic and epidemiologic ev-
idence, and discuss potential implications of the new hazard classification for pub-
lic policy. Although the Working Group discussed whether to distinguish between
“traditional diesel exhaust” and “new technology diesel exhaust” in the cancer haz-
ard assessment, they concluded that this was not possible due to a lack of data on
health effects associated with exposure to new technology diesel exhaust.
378 From New Submissions to Competitive Renewals: Different
Phases of Grant Writing.
C. E. Sulentic1 and B. L. Kaplan2. 1Wright State University, Dayton, OH;
2Michigan State University, East Lansing, MI.
Grant writing is a challenging endeavor. One must effectively communicate the sig-
nificance, innovation, and approach of their research project in a clear, but concise
manner with appropriate grammar. While there are some aspects of grant writing
that apply regardless of the grant application phase, such as a clearly stated hypoth-
esis and specific aims, the style, and required elements of the various phases of the
grant writing process can differ significantly. Thus, the goals of this session are to
discuss the various phases of the grant writing process, including preparing a new
application versus a competitive renewal, composing the rebuttal and revised grant
application, how best to create a “new” grant if a grant has not been funded after
two review cycles, and an overview of the review process, and choosing the best sci-
entific review group. Three speakers from NIEHS and a well-funded fourth
speaker, who is also an experienced grant reviewer, will expertly cover these topics
and participate in a panel discussion at the end of the session.
379 Erionite Induces Th-17 Pathway Cytokines In Vitro and In
Vivo.
N. Zebedeo and J. Pfau. Idaho State University, Pocatello, ID.
Erionite is a fibrous zeolite with similar morphological and physical properties to
amphibole asbestos. Erionite can also cause malignant mesothelioma and other dis-
eases similar to what is seen in individuals who have been exposed to asbestos.
There is little known about how erionite affects the immune system or whether it is
associated with systemic autoimmune diseases.
Given these similarities to amphibole asbestos, the hypothesis of this study is that
erionite will evoke autoimmune reactions similar to what has been seen upon as-
bestos exposure. Certain cytokine profiles from macrophages and lymphocytes that
may indicate autoimmunity were examined after exposure to asbestos. The cy-
tokines belonging to the Th17 pathway have been implicated in the development
of pathologies in some autoimmune diseases. 
In vitro exposures were done using bone marrow derived macrophages from a cell
line and macrophages and lymphocytes from spleens of C57BL/6 mice. Mice were
also exposed in vivo through peritoneal injections for 1, 3 and 7 days. Cytokines
from peritoneal fluid and splenocyte cultures were examined using ELISAs. 
Data has shown that erionite causes an increased production of cy-
tokines belonging to the Th17 profile including IL-17, IL-6 and TNF-α. This may
be a marker that indicates autoimmune reactions associated with erionite. There are
populations in the United States that may be at risk to developing diseases due to
erionite exposure. Understanding the mechanism of disease caused by erionite can
provide targets for therapies and help implement regulations on its use.
380 Resistance to Asbestos-Induced Apoptosis with Continuous
Exposure to Crocidolite on a Human T Cell.
T. Otsuki1,  M. Maeda2,  S. Yamamoto1,  N. Kumagai-Takei1,  S. Lee1,
H. Mastuzaki1 and Y. Nishimura1. 1Hygiene, Kawasaki Medical School, Kurashiki,
Japan; 2Biofunctional Chemistry, Graduate School of Natural Science and Technology,
Okayama University, Okayama, Japan.
We have been investigating the immunological effects of asbestos. The establish-
ment of a low-dose and continuously exposed human T cell line, HTLV-1 immor-
talized MT-2, to chrysotile (CB) revealed reduction of CXCR3 chemokine receptor
and production of IFN-γ that caused a decline of tumor immunity. These effects
were coupled with upregulation of IL-10, TGF-β, and BCL-2 in asbestos-exposed
patients. To observe the immunological effects of crocidolite (CR) on human T
cells, a trial to establish a low-dose and continuously exposed model was conducted
and compared with a previously reported CB-exposed model (MT-2CB). Transient
exposure of MT-2 original cells to CB or CR induced a similar level of apoptosis
and growth inhibition. The establishment of a continuously exposed subline to CR
(MT-2CR) revealed resistance against CR-induced apoptosis and upregulation of
the BCL-2/BAX ratio similar to that recorded for MT-2CB. Both sublines showed
reduced production of IFN-γ, TNF-α, and IL-6 with increased IL-10. cDNA mi-
croarray with network/pathway analyses focusing on transcription factors revealed
that many similar factors related to cell proliferation were involved following con-
tinuous exposure to asbestos in both MT-2CB and MT-2CR. These results indicate
that both CB and CR fibers affect human T cells with similar degrees even though
the carcinogenic activity of these substances differs due to their chemical and phys-
ical forms. Trials to identify early detection markers for asbestos exposure or the oc-
currence of asbestos-inducing malignancies using these findings may lead to the de-
velopment of clinical tools for asbestos-related diseases and chemoprevention that
modifies the reduced tumor immunity.
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381 Effect of Asbestos Exposure on Regulatory Role of NK Cells
for Expanded Autologous CD4+ T Cells.
Y. Nishimura,  N. Kumagai-Takei,  H. Matsuzaki,  S. Lee and T. Otsuki. Hygiene,
Kawasaki Medical School, Kurashiki, Japan.
We have studied about effect of asbestos exposure on anti-tumor immunity to date,
which demonstrated altered function of natural killer (NK) cells exposed to as-
bestos, showing decreased cytotoxicity against cancer cells with altered expression of
NK cells receptors. Recently, it has been become known that NK cells show cyto-
toxicity for not only abnormal cells but also healthy autologous cells, by which NK
cells play a regulatory role in immune response. Therefore, the present study exam-
ined effect of asbestos exposure on regulatory role of NK cells for CD4+ or CD8+
T cells. Human peripheral blood mononuclear cells (PBMCs) were cultured in IL-
2-supplemented media with or without chrysotile B asbestos or silica, while CD4+
or CD8+ T cells were freshly sorted from PBMCs magnetically, and cultured upon
stimulation by antibodies to CD3 and CD28. After 7 days, expanded CD4+ or
CD8+ T cells were cultured with CD3-CD56+ NK cells isolated from harvested
PBMCs by flow cytometry for a day. The culture with NK cells caused a decrease in
the percentage of viable CD4+ T cells. However, CD4+ T cells cultured with NK
cells exposed to asbestos, but not with silica-exposed those, showed more decrease
in viable cells, compared with control culture. In addition, the expression levels of
cell surface CD25 and CXCR3, activation and effector markers respectively, de-
creased in those CD4+ cells. In contrast, CD8+ T cells did not show alteration in
percentage of viable cells and expression of FasL and CXCR3 by culture with NK
cells. These results indicate that asbestos-exposed NK cells show enhanced function
to regulate expanded CD4+ T cells, in which effector cells are reduced more. The
enhanced regulatory function might lead to insufficient anti-tumor response.
382 Long-Term Exposure of Asbestos on MT-2 Cell Affects Cell
Cycle Progression and Cell Death.
S. Lee1,  H. Matsuzaki1,  M. Maeda2,  N. Kumagai-Takei1,  Y. Nishimura1 and
T. Otsuki1. 1Hygiene, Kawasaki Medical School, Kurashiki, Japan; 2Laboratory of
Functional Glycobiochemistry, Department of Biofunctional Chemistry, Division of
Agricultural and Life Science, Graduate School of Environmental and Life Science,
Okayama University, Okayama, Japan.
Asbestos is a silicate mineral that causes serious illness such as malignant mesothe-
lioma and lung cancer. Regulatory T cells (Treg), are known as a suppressor of im-
mune activity and cause a less anti tumor immunity. We have hypothesized that as-
bestos causes less immune reaction including tumor immunity through the
enhancement of Treg function. Here we used MT-2 cell line, an HTLV-trans-
formed human FoxP3 positive Treg model cell line, and established 7 sub-cell lines
from original MT-2. They were exposed to 3 kinds of asbestos (Chrysotile A,
Chrysotile B and Crocidolite) at low concentration (10 μg/ml or 25 μg/ml) for
long term (more than 8 months). Microarray analysis revealed that transcriptional
factor FoxO1 was remarkably decreased in these all of sub-cell lines. Since FoxO1
regulates expression of several cell cycle regulatory molecules, in this study we fo-
cused on the cell cycle regulation in these sub-cell lines. Real time PCR analysis
showed cyclin dependent kinase (CDK) inhibitors, p21Cip1, p57Kip2, p18Ink4c,
p19Ink4d were decreased and CyclinD1 was remarkably increased in these sub-cell
lines. Western blot analysis also showed us p21Cip1 was decreased and CyclinD1
was increased in these sub-cell lines. Annexin V/PI staining showed some sub-line
cells contained more living cells than original MT-2. We detected significantly less
Fas-ligand mRNA expression in all sub-cell lines. These results suggested that long-
term exposure of asbestos might accelerate cell cycle progression, and decrease cell
death, and conduct them increase. Abnormal proliferation of Treg may down regu-
late tumor immunity. Further study is required to elucidate whether the down reg-
ulation of FoxO1 is implicated cell cycle progression in these sub-cell lines.
383 Difference in Functional Property of CD8+ Lymphocytes
between Patients with Pleural Plaque and Malignant
Mesothelioma.
N. Kumagai-Takei1,  Y. Nishimura1,  M. Maeda2,  H. Matsuzaki1,  S. Lee1,
T. Kishimoto3,  K. Fukuoka4,  T. Nakano4 and T. Otsuki1. 1Department of Hygiene,
Kawasaki Medical School, Kurashiki, Japan; 2Department of Biofunctional Chemistry,
Graduate School of Natural Science and Technology, Okayama University, Okayama,
Japan; 3Okayama Rosai Hospital, Okayama, Japan; 4Division of Respiratory
Medicine, Department of Internal Medicine, Hyogo College of Medicine,
Nishinomiya, Japan.
[Background and Purpose] We have demonstrated effect of asbestos on in vitro de-
velopment of cytotoxicity in CD8+ lymphocytes, and reported the property of
CD8+ cells in people positive for pleural plaque (PL), a mark of asbestos exposure,
last year. In the present study, CD8+ lymphocytes of malignant mesothelioma
(MM) patients as well as PL-positive people were examined by flow cytometry.
[Materials and Methods] Freshly prepared PBMCs were assayed for cell number of
CD3+CD8+ cells and percentages of granzyme B+, perforin+, and CD45RA- cells in
CD8+ lymphocytes by flow cytometry. PBMCs were stimulated with PMA/iono-
mycin for 4h and assayed for percentages of IFN-γ+, CD107a+, granzyme B+ and
perforin+ cells in CD8+ lymphocytes. [Results] CD3+CD8+ cells in PL and MM
showed lower cell number than those of healthy volunteers (HV). There was no dif-
ference in % CD107a+, showing degranulation, and % IFN-γ+ cells in stimulated
CD8+ lymphocytes among three groups. Although % granzyme B+ cells in fresh
CD8+ lymphocytes of PL and MM were similar to that of HV, % perforin+ cells of
PL and MM was higher than that of HV. However, the stimulated CD8+ lympho-
cytes of MM showed more decrease in % perforin+ cells than those of the other
groups. The CD8+ lymphocytes of PL and MM groups showed higher percentages
of CD45RA- cells than that of HV. [Discussion] These results indicate that PL and
MM groups share increase in CD45RA- and perforin+ CD8+ cells, suggesting effect
of asbestos on tumor immunity. In addition, the results indicate the enhanced de-
crease in perforin+ CD8+ cells of MM after stimulation, implying impairment in
stimulation-induced cytotoxicity.
384 Cadmium Exposure Effects on the Class- Switch
Recombination in Burkett’s Lymphoma Cell Lines.
V. Poltoratsky. Pharmaceutical, St. John’s University, Queens, NY. Sponsor: L.
Trombetta.
Cadmium is an environmental and industrial pollutant, which enhances suscepti-
bility to pathogens and autoimmune disease. It has been demonstrated that expo-
sure to cadmium modulates the human humoral and cell-mediated immunity.
Exposure to cadmium in high doses causes a decrease in B and T cell concentrations
and exposure to low doses causes selective inhibitory effect on immunoglobulin iso-
types. While the effect of the high concentrations of cadmium in induction of the
oxidative stress and apoptosis is well documented, the effect of lower cadmium con-
centrations on modulating humoral immune response has not been fully under-
stood.
It has been previously demonstrated that low concentrations of cadmium specifi-
cally inhibit the miss matched repair pathway, by inhibiting the ATPase activity of
MSH2 and MSH6 proteins (Clark and Kunkel, 2004). On other hand, Msh2 and
Msh6 deficient mice are defective in class switch recombination (Wiesendanger et.
al, 2000). In this study, we suggested that exposure to the low concentrations of the
cadmium is affecting mismatch repair and the class switched recombination in B
lymphocytes, due to its effects on the MSH2 and MSH6 proteins.
Here we tested the effect of low concentrations of cadmium on the miss matched
repair and class switched recombination in human B cells. Cadmium at micromo-
lar concentrations inhibited CSR in Burkett’s lymphoma cells but did not signifi-
cantly affect the mRNA level of the activation induced cytosine deaminase and
MSH2 and MSH6 genes. The study also covered relations between cadmium con-
centrations and mismatch repair activity.
385 Arsenic Species Have Differential Impacts on Pseudomonas
aeruginosa Induced Immune Response in Human Bronchial
Epithelial Cells.
E. Notch,  R. Barnaby,  B. Coutermarsh,  V. Taylor,  B. Jackson,  T. Hampton and
B. Stanton. Geisel School of Medicine at Dartmouth, Hanover, NH.
Arsenic is the number one environmental contaminant of concern with regard to
human health. In animal and epidemiological studies arsenic exposure has been as-
sociated with a variety of deleterious health outcomes. In utero and early life stage
arsenic exposure has been linked to lung disease, including acute and chronic bac-
terial infections, and chronic obstructive pulmonary disease, all of which are associ-
ated with Pseudomonas aeruginosa (Pa) infection. Animal models have also shown
that chronic arsenic exposure decreased immune response to viral challenge.
However, little is known about the mechanisms by which these alterations occur or
the relative contributions of different arsenic species. This study examined the im-
pacts of inorganic sodium arsenite (iAsIII) and two major metabolites, monomethy-
larsonous acid (MMAIII) and dimethylarsenic acid (DMAV), on Pa induced cy-
tokine secretion by primary human bronchial epithelial cells (HBEC, n=4 donors).
HBEC cells did not metabolize iAsIII, MMAIII or DMAV. Exposure of HBEC to
10ppb iAsIII for 6 days did not alter Pa induced cytokine secretion. In contrast,
10ppb DMAV for 6 days significantly decreased IL-8, IL-6, CXCL1 and CXCL2
secretion after Pa stimulation compared to cells exposed to Pa alone. Exposure to
10ppb MMAIII increased Pa induced IL-8, and Gro-b secretion. HBEC exposed to
DMAV also had significantly decreased mRNA levels of IL-8, IL-6, CXCL1 and
CXCL2 after Pa stimulation. These data provide the first evidence of arsenic species
dependent alterations of the immune response of HBEC to infection by Pa. IL-8,
IL-6, CXCL1 and CXCL2 are key proinflammatory cytokines that recruit mono-
cytes, macrophages and neutrophils to clear Pa. Thus, MMAIII and DMAV-induced
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changes in cytokine secretion by HBEC in response to Pa are likely to contribute to
the observation that exposure to arsenic dramatically increases the incidence of
acute and chronic bacterial infections. Supported by Dartmouth Superfund
Program P42 ES07373.
386 Evidence for Low-Dose Suppression of T Cell Proliferation
by Arsenite in Certain Normal HPBMC Donors In Vitro.
F. T. Lauer,  K. Liu,  L. G. Hudson and S. W. Burchiel. College of Pharmacy,
University of New Mexico, Albuquerque, NM.
Arsenic exposures in the United States and elsewhere in the world have been associ-
ated with numerous chronic diseases. People are exposed to arsenic via drinking
water, diet, and air vectors. Arsenic exposure is now considered a top environmen-
tal public health concern worldwide. Several epidemiologic studies have shown that
T cell proliferation is suppressed in individuals exposed to arsenic via drinking
water. Previous studies in our laboratories have shown that sodium arsenite sup-
presses T cell proliferation in HPBMC obtained from normal donors. We have pre-
viously reported that some individuals respond to extremely low concentrations (<1
nm) of sodium arsenite when exposed to T cell mitogens (phytohemagglutin, PHA)
and arsenite in vitro for 72 hrs. We have now extended these studies to additional
individuals and have examined additional assays for assessing T cell proliferation,
including PHA-induced 3H-thymidine incorporation and a flow cytometry-based
CFSE assay. Using the CFSE assay, we are examining differentially affected T cell
subsets. In addition, the work has been extended to the activation of human T cells
using anti-CD3/anti-CD28 beads. We find excellent agreement between the results
obtained using 3H-thymidine incorporation and CFSE. In this poster we will
demonstrate examples of the inter-individual variations in responses to arsenic and
polycyclic aromatic hydrocarbons (PAHs) as well as potential synergistic interac-
tions between these chemical classes of agents. 
This work was supported by NIH 1R01ES019968-01A1.
387 The Aryl Hydrocarbon Receptor and Th17 Polarization:
Relevance of Receptor Affinity.
M. D. Hayes1,  A. Smith2,  I. Kimber1 and R. J. Dearman1. 1Faculty of Life
Sciences, Manchester University, Manchester, United Kingdom; 2MRC Toxicology
Unit, Leicester, United Kingdom.
There are in mice well-characterized strain differences in responsiveness of the aryl
hydrocarbon receptor (AhR) to its archetypal ligand 2,3,7,8-tetrachlorodibenzo-p-
dioxin that result from genetic variants of AhR displaying variable affinities. Thus,
C57BL/6 are categorized as being very responsive, with DBA strain mice being the
least responsive. Importantly, the human AhR is defined as being of low affinity
comparable with the DBA strain receptor. The AhR is expressed relatively ubiqui-
tously but in T cells it is restricted to the T helper (Th) 17 and T regulatory cell
subsets. Furthermore, it has been reported that AhR activation is required for opti-
mal Th17 cell polarization. However, such studies have used exclusively the high
affinity C57BL/6 strain. We have investigated whether the class of AhR affects op-
timal in vitro polarization of Th17 cells using various mouse strains including an
AhR null mouse. Th (CD4+) cells were isolated by negative selection from the pe-
ripheral lymph nodes of naive mice and polarized into Th17 cells with anti-CD3
and anti-CD28 antibodies and cytokines interleukin (IL)-6, IL-1β and TGF-β.
Th17 cell differentiation was assessed as a function of mRNA and protein expres-
sion for key IL-17 cytokines and the frequency of IL-17+ cells by intracellular cy-
tokine staining. Using an AhR antagonist (CH-223191), the majority of Th17 cell
activity was shown to be dependent upon AhR ligation in all wild type mouse
strains (C57B/L6, DBA and BALB/c), regardless of AhR affinity phenotype.
Residual Th17 responses (IL-17A+ cells and IL-17A and IL-17F mRNA and pro-
tein) were detected in all strains and in AhR null mice. These data demonstrate that
natural ligands can stimulate Th17 development through the AhR and that also rel-
ative AhR affinity appears not to influence the impact of natural agonists on Th17
polarization. These data suggest that despite their low affinity receptor, endogenous
AhR ligands could play a major role in driving human Th17 cell differentiation.
388 2, 3, 7, 8-Tetracholordibenzo-p-dioxin (TCDD) Reduces
Leishmania major Burdens in Mice but Not in Macrophages
In Vitro.
R. E. Teagarden,  J. L. Lenberg,  A. R. Dunn and G. K. DeKrey. Biological
Sciences, University Northern Colorado, Greeley, CO.
A previous study by Bowers et al. (Am. J. Trop. Med. Hyg., 75: 749, 2006) reported
significantly lower parasite burdens in L. major–infected C57Bl/6 mice when pre-
treated with TCDD at a dose of 40 μg/Kg or higher. This result was unexpected
given that 1) TCDD suppresses T helper cell responses in mice, and 2) resistance to
L. major infection in mice normally depends upon appropriate T helper cell func-
tion. To explain this, we hypothesized that TCDD reduces L. major burdens in
mice by a mechanism that does not involve T cells. Severe combined immunodefi-
cient (SCID) mice were treated with peanut oil or TCDD (50 or 200 μg/Kg) one
day prior to infection with 104 stationary phase L. major promastigotes. A dose-
and time-dependent reduction of lesion size and lesion parasite numbers was ob-
served with the greatest effect on day 45 in the highest dose group: 12% of control
(p < 0.05) and 2% of control, respectively. These results suggested that T cells are
not required for reduced L. major burdens in TCDD-treated mice. Because
macrophages are the primary host cell for L. major in vivo, we hypothesized that
TCDD reduces L. major burdens in mice by inhibiting macrophage infection.
Using a WST-1 cell viability assay and mouse RAW 264.7 cells, we found that
TCDD exposure (0 or 10-10 to 10-7 M for up to 48 hours) did not significantly
change macrophage viability. Using light microscopy and starch-elicited C57Bl/6
mouse peritoneal macrophages, we found that TCDD exposure (0 or 10-10 to 10-7
M for 48 hours) did not significantly change the number of intracellular parasites
(4.2 L. major/infected macrophage, overall) at 24 hours after infection with station-
ary phase promastigotes. These results suggest a mechanism other than altered par-
asite uptake by macrophages or macrophage cytotoxicity to explain reduced parasite
burdens in TCDD-treated mice.
389 Carbamate Pesticides Induce Apoptosis in Human NK-92CI
Cells.
Q. Li,  M. Kobayashi and T. Kawada. Department of Hygiene and Public Health,
Nippon Medical School, Tokyo, Japan.
Purpose:
Carbamate pesticides are widely used throughout the world in agriculture as fungi-
cides and insecticides. We previously found that ziram, a dithiocarbamate fungi-
cide, significantly inhibited natural killer (NK) activity in a dose-dependent man-
ner (1). To explore the mechanism of carbamate pesticide-induced inhibition of
NK activity, we investigated carbamate pesticide-induced apoptosis and its underly-
ing mechanism in human NK cells.
Methods:
NK-92CI cells, a human NK cell line, were treated with carbaryl (insecticide),
maneb (fungicide), thiram (fungicide), and ziram (fungicide) at different concen-
trations for 2-24 h at 37°C. Apoptosis was determined by FITC-Annexin-V/PI
staining. To explore the mechanism of apoptosis, intracellular levels of active cas-
pases 3 and mitochondrial cytochrome-c release were determined by flow cytome-
try (2-3). 
Results and Conclusions:
Ziram and thiram significantly induced apoptosis in NK-92CI cells in a dose- and
time-dependent manner. Maneb also significantly induced apoptosis in NK-92CI
cells at higher concentrations (more than 20 μM). On the other hand, carbaryl, a
carbamate insecticide, showed a very weak effect on apoptosis in NK-92CI cells
even at 40 μM. Moreover, ziram and thiram significantly increased the intracellular
level of active caspase 3 and Z-VAD-FMK, a caspase inhibitor, partially but signifi-
cantly inhibited the apoptosis, respectively. Ziram and thiram also significantly
caused mitochondrial cytochrome-c release. These findings indicate that carbamate
pesticides can induce apoptosis in NK-92CI cells, and the apoptosis is mediated by
both the caspase-cascade and mitochondrial cytochrome-c pathways. The strength
of the apoptosis-inducing ability differed among these pesticides, and the order was
as follows: thiram, ziram > maneb > carbaryl. 
References:
1. Li et al. Arch Toxicol. 2012;86(3):475-81.
2. Li et al. Arch Toxicol. 2011;85:355-61.
3. Li et al. Arch Toxicol. 2012;86(4):615-23.
Acknowledgements:
This work was supported by a Grant-in-Aid for Scientific Research in Japan.
390 PCB126 Inhalation Reduces the Number and Function of
Lymphocytes in Rats.
A. B. Shimada,  W. S. Cruz,  A. Nakasato and S. H. Farsky. Clinical and
Toxicological Analysis, University of São Paulo, São Paulo, Brazil. Sponsor: S. Moraes
Barros.
Polychlorinated biphenyls (PCBs) are persistent organic pollutants and ubiquitous
environmental contaminants that resist to degradation and accumulate in the food-
chain. PCB126 was widely used in industrial processes and is the most potent aryl
hydrocarbon receptor agonist. Once respiratory tract is an important pathway of
PCB 126 absorption, this work aimed to investigate the effects caused in the im-
mune system by PCB126 inhalation in rats. Male Wistar rats were exposed to
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PCB126 at doses of 0.1; 1 or 10μg/kg of body weight, for 15 days, by nasal instil-
lation. Control animals were exposed to vehicle (saline + 0.5% DMSO). Five hours
following the last exposure, animals were killed and bone marrow and blood leuko-
cytes were evaluated as following: a) total number cells by hemocytometer; b) dif-
ferential bone marrow cells were evaluated by anti-granulocyte, CD3 and CD45R
expression analyzed by flow cytometer and differential leukocyte blood cells were
quantified in stain smear; c) the expression adhesion molecules on circulating lym-
phocytes membranes were evaluated by flow cytometer at basal or in vitro fMLP
stimulation conditions (N-formyl-methionine-leucine-phenylalanine; 10-8M; 1
hour). All the experiments were conducted according to Ethics Committee in
Animal Experiments approved by protocol number CEUA/FCF/315. Exposure to
10μg/kg of PCB126 reduced the number of total circulating leukocytes and bone
marrow cells, which reflected reduced CD45 labeled lymphocytes in the bone mar-
row cells and lymphocytes in the blood. Exposure to 1 or 10μg/kg of PCB126 re-
duced the expression of CD62L on circulating lymphocytes at basal conditions and
in vitro fMLP stimulation impaired CD18 and CD31 expression in these cells. Our
data indicates that PCB126 exposure modify the pattern of adhesion molecules ex-
pression by blood lymphocyte and it may affects the lymphocytes production, mat-
uration or traffic between the body compartments. These effects may affect the host
defense, as lymphocytes are pivotal cells in the immune response. Financial sup-
port: FAPESP and CNPq.
391 Alternariol Induces Differentiation of Macrophages.
A. Solhaug1,  C. Wisbech1,  T. E. Christoffersen2, 3,  L. Olsen2,  T. Lea2,
L. L. Vines4,  J. Pestka4,  J. A. Holme5 and G. S. Eriksen1. 1Norwegian Veterinary
Institute, Oslo, Norway; 2Norwegian University of Life Sciences, Ås, Norway; 3Østfold
University College, Halden, Norway; 4Michigan State University, East Lansing, MI;
5Norwegian Institute of Public Health, Oslo, Norway.
Mycotoxins are often found, as contaminants of food and feed, and may pose a risk
for disease in humans and animals. Mycotoxins sometimes aberrantly affect the im-
mune system and cause immune stimulation as well as immune suppression. The
fungi Fusarium and Alternaria often co-occur in grain, and mixtures of mycotoxins
are often more potent than the level of the pure well known toxins (eg. the tri-
chothecenes from Fusarium) would indicate. The objective of this study was there-
fore to examine the potential immune effects of a frequently co-occurring myco-
toxin, alternariol (AOH; Alternaria toxin). RAW 264.7 mouse macrophages as well
as primary peritoneal mouse macrophages and human primary macrophages were
therefore used as a model system. AOH was found to induce DNA damage, abnor-
mal nuclei and cell cycle arrest in RAW 264.7 cultures. However, only low levels of
cell death were observed. Instead the cells were found to change morphology into
star-shaped cells, with increased expression of several cell surface receptors (CD80,
CD11b, MHCII) increased TNF-alpha secretion as well as increased endolytic ac-
tivity. Interestingly, the cells entered a senescent state after prolonged AOH expo-
sure, possibly as a response to the different stresses induced by this mycotoxin. In
contrast to RAW 264.7, peritoneal mouse macrophages and human primary
macrophages do not proliferate in culture and as a likely consequence, did not ex-
hibit abnormal nuclei upon AOH exposure. Interestingly, AOH was found to
change the morphology and most of the cells got a dramatically elongated or a star-
like shape, with no increase in cell death which is possibly associated with pheno-
typical changes. AOH-induced differentiation of macrophages might contribute in
part to the observed effects of mycotoxins mixtures on the immune system.
392 Analysis of Epigenetic Reprogramming of CD8+ T Cell
Responses by Developmental Aryl Hydrocarbon Receptor
Activation.
B. Winans1,  A. Nagari2,  M. Chae2,  W. Kraus2 and B. Lawrence1. 1University of
Rochester Medical Center, Rochester, NY; 2University of Texas Southwestern Medical
Center, Dallas, TX.
The developing immune system is susceptible to environmental insults, leading to
altered immune function later in life. The aryl hydrocarbon receptor (AhR) is a lig-
and-activated transcription factor that acts as an environmental sensor and binds
many dioxins and polychlorinated biphenyls (PCBs), pollutants to which humans
are constantly exposed. AhR also plays a role in the development and function of
the immune system. Human and animal data demonstrate that early life exposure
to AhR-binding ligands leads to persistent alterations in immune function, sup-
porting the idea that inappropriate AhR activation influences the developing im-
mune system. In order to study the susceptibility of the immune system to pertur-
bation by AhR signaling, our laboratory uses 2,3,7,8-tetrachlorodibenzo-p-dioxin
(TCDD) as a model developmental immunotoxicant and influenza A virus as a
prototypical human pathogen. Mice exposed to TCDD during development have
persistently reduced clonal expansion and differentiation of CD8+ T cells. This
functional alteration is due to direct AhR signaling in the offspring, and results
from a direct effect on hematopoietic cells. Furthermore, this altered function oc-
curs without detectable changes in lymphoid organ cellularity or the distribution of
immune cell subpopulations in naïve animals. These findings suggest the novel idea
that inappropriate activation of AhR influences the epigenetic regulation of the de-
veloping immune system, leading to persistent changes in immune function. To
test this idea directly we have examined genome-wide DNA methylation patterns
in naïve and activated CD8+ T cells isolated from developmentally exposed mice,
and correlated these with changes in gene expression. These novel data provide an
important framework for understanding how changes in epigenetic marks, cued by
developmental exposure, may affect gene expression and T cell function.
393 DES and Methoxychlor Metabolite, HPTE, Induction of Cell
Death and Alteration of Thymocyte Development: Timing of
Induction of Apoptosis.
C. Broussard,  L. Leung Liu,  C. Zambrano,  F. Mourad,  Z. Muscato and
P. Escalante. Biology, University of La Verne, La Verne, CA.
Estrogen and putative endocrine-disrupting chemicals, such as diethylstilbestrol
(DES) and methoxychlor, induce death of thymocytes and alter T cell develop-
ment. Such alterations have the potential to profoundly affect the functioning of
the immune system in the long term, particularly when they occur during gesta-
tion. We have previously shown that exposure of embryonic thymocytes to two
EDCs, DES and hydroxyphenyl-trichloroethane (HPTE; the primary physiological
metabolite of methoxychlor), results in death of the thymocytes and alteration of
the development of T cells. We undertook the current study to elucidate the mech-
anism of action of DES and HPTE. C57BL/6 embryonic thymocytes were cul-
tured in the presence of DES or HPTE in an assay that mimics the in vivo process
of positive selection. Using Annexin V and propidium iodide staining we identified
the time course for induction of cell death in the treated thymocytes. By six hours
of treatment with DES or HPTE, thymocytes began to express markers of apopto-
sis, Annexin V+ and PI-. In addition, we assessed the induction of caspase activity,
a later event in the apoptotic pathway. The induction of caspase activity distin-
guished the cell death we observed from other forms of cell death including necro-
sis and necroptosis. Our results suggest that death induced by DES and HPTE is
rapid (beginning by 6 hours of exposure) and caspase-dependent, hallmarks of sig-
nal-mediated death induction.
^This research is supported by NIEHS ES017345-01. The opinions expressed in
this work are solely the authors’.
*At the time the work was completed, these individuals were undergraduate re-
searchers at the University of La Verne.
394 Genetic Alterations by Prenatal Exposure to Mercury.
K. L. Kracke,  D. L. Shirley and J. F. Nyland. Pathology, Microbiology &
Immunology, University of South Carolina School of Medicine, Columbia, SC.
Background: Mercury (Hg) is an ubiquitous environmental toxicant which bioac-
cumulates and can produce many biological effects, including on the nervous and
immune systems. Because Hg can cross the placenta and concentrates in the fetal
compartment, the developing fetus is particularly vulnerable. We hypothesize that
developmental exposure to Hg will cause immunological changes, leading to an in-
creased susceptibility to, or exacerbation of, immune disorders later in life.
Therefore, we exposed pregnant female mice to low doses of Hg for a short dura-
tion and examined the genetic effects related to immune function in the offspring.
Methods: Pregnant BALB/c mice were exposed to Hg (200 μg/kg HgCl2 in PBS by
subcutaneous injection) or vehicle control every other day from gestation day (GD)
5 to GD15. Female offspring remained with the dam until weaning and were euth-
anized at 8 weeks of age with no further exposures to Hg. Splenic RNA was isolated
using RNeasy (Qiagen), then gene expression changes quantitated by microarray
(Affymetrix). Gene expression data were analyzed with GeneSpring and differences
in expression levels interrogated through Ingenuity Pathway Analysis software.
Results: We found that a number of genes were differentially expressed when mice
were prenatally exposed to Hg. Focusing on cytokines, macrophage activation, and
regulatory T cells, we found that expression of IL-1, CTLA4, CX3CL1 and IGHM
was upregulated at least two fold with prenatal Hg exposure.
Discussion: In this project, we demonstrate that prenatal Hg exposure can produce
lasting programming changes in the immune system. Increased expression of pro-
inflammatory cytokine IL-1 has been associated with autoimmune disorders, while
pro-inflammatory chemokine CX3CL1 has been associated with microglial
(macrophage-lineage cells of the brain) activation. These changes may increase the
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risk of developing autoimmune disorders or the possibility of exacerbating existing
immune disorders later in life. Future studies will include examining sex differences
in the effects of prenatal Hg exposure effects.
395 Cannabinoid Receptors and PPAR-Gamma Interactions in
Endocannabinoid-Modulated Differential CD8+ T Cell
Responses.
S. T. Pike1,  R. B. Crawford1,  B. L. Kaplan1, 2 and N. E. Kaminski1, 2. 1Center for
Integrative Toxicology, Michigan State University, East Lansing, MI; 2Department of
Pharmacology and Toxicology, Michigan State University, East Lansing, MI.
Endogenous cannabinoids (endocannabinoids), eg, anandamide (AEA), bind
cannabinoid receptors, CB1 and CB2, and modulate immune responses. In addi-
tion, PPARγ-dependent but cannabinoid receptor-independent suppression of im-
mune responses has been reported by endocannabinoids; however, the relationship
between cannabinoid receptor-dependent and independent events is poorly charac-
terized. In addition, phytocannabinoids, but not endocannabinoids, have been
shown to both enhance and suppress immune function. Using AEA and an in vitro
model mimicking the CD8+ T cell response to early HIV infection, we are seeking
answers to two questions: 1) Do endocannabinoids differentially modulate CD8+
T cell responses? and 2) What roles do cannabinoid receptor-dependent and inde-
pendent signaling play in these effects? In this model, the percentage of interferon-
gamma (IFNγ) producing CD8+ T cells activated by a HIVgp120-expressing anti-
gen presenting cell line is measured. These studies showed that in the presence of
sub-optimal activation (Vh groups <28% CD8+IFNγ+ cells), AEA significantly
(~10%) enhanced IFNγ production. Under supra-optimal activation conditions
(>68%), the CD8+ T cell response decreased by ~5%. If activation was optimal (be-
tween 28% and 68%), little AEA-effect was observed. In addition, enhanced re-
sponses were AEA concentration-dependent. Using CB1-/-/CB2-/- mice, an in-
creased baseline CD8+ T cell response (~8%) was observed compared to wild type
mice, but an AEA-induced increase above this response was not evident.
Surprisingly, addition of a PPARγ antagonist over a range of activation levels was
additive (~5%) to AEA-induced T cell effects. Overall, our results show endo-
cannabinoids differentially modulate immune responses with cannabinoid recep-
tors involved in the initial activation of CD8+ T cells. In addition, the AEA effects
were PPARγ-dependent. (Supported in part by R01DA020402 & F32DA030167)
396 Perinatal Exposure to Bisphenol A through Maternal Diet
Alters Allergen-Induced Lung Inflammation in Adult
Offspring.
E. O’Brien1,  D. Dolinoy1,  M. Peters-Golden2,  Z. Zaslona2 and P. Mancuso1.
1Environmental Health Sciences, School of Public Health, University of Michigan,
Ann Arbor, MI; 2Internal Medicine, School of Medicine, University of Michigan, Ann
Arbor, MI.
Bisphenol A (BPA), a monomer of polycarbonate plastics and epoxide resin, is a
high production volume chemical that has been implicated in asthma pathogenesis
when exposure occurs to the developing fetus. However, few studies have examined
the effect of in utero and early-life BPA exposure on the pathogenesis of asthma in
adulthood. Using an allergen-induced model of asthma, we examined whether peri-
natal BPA exposure through maternal diet alters lung inflammation in adult off-
spring by measuring cellular recruitment, cytokine production, lipid mediator pro-
duction, and serum IgE levels. Two weeks before mating, BALB/c dams were
randomly assigned to a diet containing low (50 ng BPA/kg diet), medium (50 μg),
or high (50 mg) levels of BPA or a BPA-free control diet. Dams remained on the as-
signed diet throughout gestation and lactation until postnatal day 21 when off-
spring were weaned onto the BPA-free diet. Twelve-week-old offspring were sensi-
tized to ovalbumin with alum by intraperitoneal injection and subsequently
challenged with aerosolized ovalbumin to induce an allergic inflammatory re-
sponse. Offspring exposed to medium or high levels of BPA exhibited increased
serum anti-ovalbumin IgE levels compared to controls, while animals exposed to
the low dose displayed increased lymphocyte recruitment, RANTES production,
and TNF-α and IFN-γ production from splenocytes. Offspring exposed to low or
high doses of BPA exhibited decreased macrophage, neutrophil, and eosinophil re-
cruitment and decreased production of TNF-α, IFN-γ, IL-4, IL-13, cysteinyl
leukotrienes, and prostaglandin D2. Our data show that perinatal BPA exposure
has quantitatively different effects on various measures of allergen-induced inflam-
mation. These data indicate that perinatal BPA exposure does not worsen allergen-
mediated inflammation in the adult lung, but suggests that exposure may increase
inflammation on a systemic level.
397 Direct Evidence of Altered Conformation and Evidence for a
Binding Site on TLR3 for Ethanol at Relevant
Concentrations.
S. B. Pruett2,  V. Le1,  E. Lewis1,  S. Gwaltney1,  B. Manikanthan1 and A. Shack2.
1Chemistry, Mississippi State University, Mississippi State, MS; 2Basic Sciences,
Mississippi State University, Mississippi State, MS.
The mechanism by which ethanol causes a complex array of changes in animal
models and humans has been vigorously debated and investigated for more than 50
years. Some progress has been made on the direct effects of ethanol on conforma-
tion and function of receptors for neurotransmitters, which apparently cause many
of the neurological effects of ethanol. However, there has been no similar investiga-
tion of any component of the immune system. We selected TLR3 for this purpose
because its 3-dimensional structure has been published, it forms dimers in solution
in the presence of ligand which is also the initial event in signaling in vivo, the cy-
tokines and other inflammatory mediators induced by this receptor are inhibited
substantially by ethanol, and TLR3 plays an important role in innate immunity to
viruses. We used molecular docking software (Autodock 4.2) to determine that
there is a highly probable binding site for ethanol in both human and mouse TLR3,
and they are at different locations. They are not within the ligand binding region of
the molecule, so they should not directly affect ligand binding (though indirect ef-
fects are possible). We used circular dichroism to evaluate the dose-response effects
of ethanol on the conformation of human or mouse TLR3 with ligand (poly I:C).
The difference in rotation of light (millidegrees) in control and ethanol treated
samples at 220 nm exhibits a biphasic concentration-response pattern with a peak
at ~40 mM (a concentration which is not uncommon in human binge drinkers)
and the lowest value at ~80-100 mM (a near lethal concentration of ethanol). The
concentration at the peak of the response curve is near the binding constant calcu-
lated by the docking software, suggesting that conformational change may be re-
lated to the ethanol binding site on TLR3. This is the first report that ethanol at rel-
evant concentrations alters the conformation of an immunological receptor.
398 Developmental Aryl Hydrocarbon Receptor (AhR) Activation
Attenuates Hematopoietic Stem Cell (HSC) Capacity to
Undergo Lymphocyte Differentiation.
L. Ahrenhoerster,  P. A. Lakatos and M. D. Laiosa. Zilber School of Public Health,
University of Wisconsin—Milwaukee, Milwaukee, WI.
HSCs are the foundational cells of the blood system, responsible for balancing self-
renewal and differentiation into mature effector cells. Environmental exposures to
the HSCs in utero can profoundly affect future development of immune diseases.
Indeed, transplacental exposure to 2,3,7,8 Tetrachlorodibenzo-p-dioxin (TCDD)
leads to numerous later-life immunological deficits. TCDD mediates this develop-
mental immunotoxicity by binding to and activating the AHR, which is an impor-
tant regulator of immunological development and function. Given the centrality of
hematopoiesis in immune development throughout the life-course, we investigated
the effect AHR activation by TCDD has on murine HSCs. Since it is known that
the AHR maintains HSCs in a state of non-proliferative quiescence, we hypothe-
sized that persistent developmental AHR activation modulates HSC differentiation
capacity and self-renewal ability. To test this hypothesis, pregnant dams were ex-
posed to 3 μg/kg TCDD or vehicle control. On gestational day 14.5, lineage nega-
tive, cKit+, Sca-1+ (LSK) cells were harvested, quantified, and placed into T-lym-
phocyte differentiation cultures using a limiting dilution approach. We found
approximately 2.5 fold more LSKs present in fetuses exposed to TCDD in utero.
Measuring potential, we found approximately 1 in 17 vehicle-exposed LSKs had
the capacity to undergo T-cell differentiation while only 1 in 39 did if developmen-
tally exposed to TCDD. These effects are mediated by the AHR in the individual
fetuses as supported by studies conducted in offspring from AHR+/- crosses.
Specifically, the T-cell differentiation potential of LSKs from TCDD-exposed
AHR-/- fetuses approximates that of vehicle-exposed wild type LSKs. Conversely,
the TCDD-exposed AHR+/- and AHR+/+ siblings produce LSKs with a dimin-
ished T-cell precursor potential. These data suggest that developmental AHR acti-
vation in HSCs reprograms the balance between self-renewal and differentiation,
potentially affecting future immune system development and function.
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399 Immunotoxicity of the Nasal Associated Lymphoid Tissue
Induced by the Black Mold Toxin Satratoxin-G in Rhesus
Monkeys.
S. A. Carey1,  V. M. Takala1,  D. M. Hyde2,  J. Pestka1 and J. Harkema1.
1Michigan State University, East Lansing, MI; 2University of California Davis, Davis,
CA.
Damp Building-Related Illnesses (DBRI) include many respiratory and immuno-
logic symptoms etiologically linked to exposure to Stachybotrys chartarum, a black
mold that grows in water-damaged indoor environments. The mechanisms by
which airborne exposure to S. chartarum causes immune dysfunction remain poorly
understood. Epidemiological evidence suggests that children may be particularly
vulnerable to the harmful effects of airborne toxicants. To assess the potential risk of
nasal injury and immunotoxicity in children, we developed an in vivo model of in-
tranasal mycotoxin exposure in juvenile monkeys, whose nasal airways are morpho-
logically and functionally similar to those of children. We recently reported that in-
tranasal exposure to Satratoxin-G (SG), a trichothecene mycotoxin produced by S.
chartarum, causes apoptosis of olfactory sensory neurons. The present study tests
the hypothesis that intranasal exposure to SG causes apoptosis of the nasal associ-
ated lymphoid tissue (NALT). Juvenile male rhesus macaques received either a sin-
gle intranasal instillation of 20 μg SG (n=3), or daily instillations of 5 μg SG (n=3)
for four consecutive days in the right nasal passage. Saline vehicle was administered
to the left nasal passage. Left and right nasal passages were sectioned and preserved
for light microscopic, immunohistochemical, and morphometric analyses of the
NALT. Both single dose and repeated dose exposure to SG caused atrophy of the
NALT, resulting in a 19% (single) and 70% (repeated) reduction in the area of
NALT along the nasal septum in the SG-exposed nasal passages, compared to the
respective saline-exposed nasal passages. NALT apoptosis was identified morpho-
logically and using immunohistochemistry for caspase-3. SG exposure caused a
2.75-fold increase in caspase-3 immunoreactivity in septal NALT compared to
saline exposure. The results in this model provide new insight into a potential
mechanism of immune dysregulation associated with exposure to damp indoor en-
vironments.
400 Prenatal Exposure to Benzo(a)pyrene Confers an Enhanced
Susceptiblity of Macrophage Membranes to Microbial
Infection.
R. S. Clark1,  A. Ramesh2,  M. Maguire1 and D. B. Hood1. 1Neuroscience and
Pharmacology, Environmental Health Disparities and Medicine, Center for Molecular
and Behavioral Neuroscience, Meharry Medical College, Nashville, TN; 2Biochemistry
and Cancer Biology, Meharry Medical College, Nashville, TN.
The purpose of this study was to elucidate the mechanism of benzo(a)pyrene,
[B(a)P]-induced immune suppression by determining whether exposure suppresses
macrophage function and alters membrane components to increase susceptibility to
infection. C57BL and SCID times pregnant dams were exposed to varying concen-
trations of B(a)P by oral gavage on embryonic days 14-17. An ex vivo macrophage
experimental model system was generated from offspring spleen where monocyte
differentiation, phagocytic activity, ROS production and modulation of lipid raft
cholesterol homeostasis were quantified.  Exposure-induced modulatory effects on
differentiation was quantified by adhesion assays in the presence or absence of GM-
CSF then verified using CD11, F4/80 antibodies and a WST-1 assay. Macrophage
respiratory burst activity detection was performed by incubating PMA-stimulated
macrophages with dihydrorhodamine, an ROS intermediate sensitive probe. ROS
intermediate production was measured by flow cytometry. To determine whether
B(a)P modulates lipid raft homeostatic cholesterol levels, lipid rafts from cultured
macrophages were isolated by discontinuous sucrose gradient centrifugation and
the lipid fractions were verified by CD59 and CD55, two lipid raft proteins. In par-
allel the fractions were analyzed by HPLC for B(a)P metabolites. The preliminary
results demonstrate that in utero B(a)P exposure suppresses macrophage functional
indices and alters macrophage lipid raft cholesterol levels in offspring. Future stud-
ies are directed at establishing whether B(a)P increases macrophage susceptibility to
microbial infection.
401 The CpG Adjuvant Increases Immune Responses to
Ovalbumin (OVA) following Sublingual Immunization in
C57/BL6 Mice.
L. A. Coney3,  A. Parlapiano2,  A. Curran5,  G. Bannish4, 1,  M. Perpetua1,
J. Doughty1,  A. Beavis1 and E. Dadey2. 1Biologics and Biomarker Analysis,
Huntingdon Life Sciences, East Millstone, NJ; 2MonoSol Rx, LLC, Warren, NJ;
3Group Strategic Marketing, Huntingdon Life Sciences, Huntingdon, United
Kingdom; 4Group Strategic Marketing, Huntingdon Life Sciences, East Millstone, NJ;
5Safety Assessment, Huntingdon Life Sciences, East Millstone, NJ.
The sublingual route of administration has been demonstrated to modulate hu-
moral responses. A protease resistant, phosphorothioate CpG oligonucleotide in-
duces TH1 immune responses through a TLR9-mediated activation of B lympho-
cytes and dendritic cells and was used as an adjuvant to evaluate its utility in
sublingual immunizations. Mice were immunized sublingually with either 4.0ug or
175ug ovalbumin in the presence of 0.5ug or 8.8ug CpG adjuvant on up to 4 oc-
casions (Days 1, 8, 22, 29) and terminated on Day 36. As a control, additional co-
horts of animals were treated with vehicle or dosed intraperitoneally (i.p.) with
ovalbumin in incomplete Freund’s adjuvant (IFA), or ovalbumin in CpG adjuvant.
Robust immune responses were observed in the control animals with either IFA or
CpG adjuvant on Days 22 and 36. No antibody responses specific to OVA were ob-
served with sublingual dosing on Day 22 in both groups and on Day 36 with 4.0ug
OVA and 0.5ug CpG. In contrast, detectable specific antibody responses to OVA
were observed on Day 36 with sublingual dosing of 175ug OVA and 8.8ug CpG in
3 of 4 animals. The response was clearly positive but notably lower in magnitude
compared to i.p. immunization. Flow cytometry evaluation of B lymphocyte sub-
sets, NK lymphocytes, and T lymphocyte subsets in the spleen revealed no de-
tectable systemic changes. Finally, ELISpot evaluation of splenic cells stimulated
with an OVA peptide generated detectable responses in 2 of 4 animals in both the
control group using CpG adjuvant and high dose sublingual group. In conclusion,
these results are consistent with the known TH1 effects of the CpG adjuvant in
C57/bl6 mice and demonstrate the ability to generate a humoral response via sub-
lingual immunization under these conditions.
402 Effects of Early Life Farm Exposure on Phenotype and
Functional Properties of Dendritic Cells and Contribution to
the Risk of Disease.
H. Kääriö1,  J. Nieminen2,  K. Huttunen1,  M. Hirvonen1, 3,  J. Pekkanen3,
O. Vaarala2 and M. Roponen1. 1Environmental Science, University of Eastern
Finland, Kuopio, Finland; 2Viral Diseases and Immunology, National Institute for
Health and Welfare, Helsinki, Finland; 3Environmental Health, National Institute for
Health and Welfare, Kuopio, Finland. Sponsor: M. Viluksela.
Dendritic cells (DCs) are the major antigen presenting cells that play a central role
in the induction of the cellular immune response. Exposure to farm-associated mi-
crobes might alter DC numbers or accelerate their maturation, thereby enhancing
the development of healthy immune tolerance that would protect against allergic
sensitization and disease. In early childhood still immature DCs are very susceptible
to environmental exposure. Therefore, the objective of this study was to investigate
if numbers or functional properties of DCs in 4.5 year old Finnish children (a se-
lected part of a European birth cohort study, EFRAIM) are associated with the farm
exposure and/or atopic outcome. Myeloid DC1 (mDC1, CD11c+CD1c+), mDC2
(CD141+), plasmacytoid DC (pDC, CD123+CD303+), monocytes (CD14+), func-
tional markers (CD80, CD86, TLR4) and intracellular cytokines (IL-6, TNF-α)
were analyzed by flow cytometry per se and following 6 hour stimulation with
lipopolysaccharide. The frequency of subpopulation mDC1 was lower in non-asth-
matic children who had lived in farm environment, as compared to non-farmer
children. Also, lower frequency of pDC subpopulation was associated clearly with
food atopy. Consequently, the ratio of pDC/mDC1 was lower in children with
food atopy. Other associations between DC phenotype/function and atopy were
more complicated and dependent on the type of the atopy/sensitisation and the se-
lected IgE cut-off concentration. The main conclusions are that 1) the farm expo-
sure seems to reduce the frequency of circulating mDC1 cells, possibly affecting the
antigen-presenting function of the exposed children, 2) the reduced number of
pDC cells predisposes children to the development of food atopy and 3) the defini-
tion of atopy is crucial when associations between DCs and atopy are studied.
86 SOT 2013 ANNUAL MEETING
403 Role of PKC Beta in Allergen-Induced CD86 Expression and
IL-8 Release in THP-1 Cells.
V. Galbiati,  M. Marinovich,  E. Corsini and C. L. Galli. DiSFeB, Università degli
Studi di Milano, Milan, Italy.
Protein kinase C (PKC) is a family of twelve serine–threonine kinases, involved in
signal transduction of hormones, neurotransmitters, and cytokines. We have found
an age-related alteration in PKC signaling and TNF-α release in epidermal cells ex-
posed to different stimuli, including contact allergen DNCB. We demonstrated an
age-related decrease in the receptor for activated C kinase (RACK-1) expression,
which underlies defective PKC β activation and age-related functional deficit in
Langerhans cells (LC) responsiveness (1). It has been indeed demonstrated that LC
cannot migrate from the epidermis when PKC β is inhibited, indicating that PKC
β transduces the signal for migration of LC from the epidermis (2). 
The purpose of this study was to investigate the role of RACK-1 and PKC β in con-
tact allergen-induced CD86 expression and IL-8 release. The human promyelocytic
cell line THP-1 was used as surrogate of dendritic cells, while dinitrochlorobenzene
(DNCB), p-phenylenediamine (PPD) and diethylmaleate (DEM) were used as ref-
erence allergens. CD86 expression was evaluated by FACS analysis and IL-8 release
by commercially available ELISA. The selective cell-permeable inhibitor of PKC β,
the specific kinase isoform interacting with RACK-1, and the broad PKC inhibitor
GF109203X, completely prevented allergen-induced CD86 expression and signifi-
cantly modulated the release of IL-8 (50% reduction). The use of a RACK-1 pseu-
dosubstrate, which directly activates PKC, resulted in a dose-related increase in
CD86 expression and IL-8 release. These effects were not due to cytotoxicity, as as-
sessed by lactate dehydrogenase leakage, or to endotoxin contamination of RACK-
1 pseudosubstrate, as assessed using polymixin B. Overall, we demonstrate a role of
PKC β and RACK-1 in allergen-induced CD86 expression and IL-8 production,
confirming the pivotal role of PKC in immune cell activation.
Acknowledgement. This project was supported by Ministero dell’Istruzione,
dell’Università e della Ricerca (PRIN2009).
References
(1) Br J Dermatol 160:16-25, 2009
(2) Immunology 79:621-6, 1993
404 Perfluorooctanoic Acid Exposure Suppresses T-Independent
Antibody Responses.
J. DeWitt1,  N. Creech1,  Q. Hu1,  W. Williams2 and R. Luebke1. 1Pharmacology
and Toxicology, East Carolina University, Greenville, NC; 2Cardiopulmonary &
Immunotoxicology Branch, Research Triangle Park, NC.
Exposure to ≥ 3.75 mg/kg of perfluoroocatnoic acid (PFOA) for 15d suppresses T-
dependent antibody responses (TDAR), suggesting that T helper cells and/or B
cells/plasma cells may be impacted. This study evaluated effects of PFOA exposure
on the T cell-independent antibody response (TIAR) to dinitrophenyl-ficoll
(DNP) . Adult female C57BL/6 mice were given 0, 0.94, 1.88, 3.75, or 7.5 mg/kg
of PFOA in drinking water for 15d and immunized with 1 μg of DNP in 0.2 ml of
sterile saline on d11 of dosing. Seven days after immunizations and 3d after dosing
ended, animals were euthanized and bled; sera were evaluated for IgM anti-DNP
titers by ELISA. PFOA exposure did not alter body or lymphoid organ weights.
Mean (log2) IgM serum titers of animals dosed with ≥ 1.88 mg/kg PFOA were sta-
tistically suppressed, on average, by 10% relative to control responses. Splenic B
and T cell subset phenotypes were evaluated in separate groups of animals dosed
with 0, 3.75 or 7.5 mg/kg of PFOA for 10, 13, or 15d. Animals exposed for 13 or
15d were immunized with sheep erythrocytes on d11 of dosing. In animals exposed
for 15d, the mean percentage of B cells was increased by all doses. Within the
CD3+ T cell population, the following changes were observed in the mean percent-
age of cells: CD4+CD8- T cells were increased at doses of 3.75 and 7.5 mg/kg after
10, 13, and 15d of exposure; CD4+CD8+ T cells were increased after 13d of expo-
sure across all doses relative to 10 and 15d of exposure; CD4-CD8+ and CD4-
CD8- T cells had dose and duration interactions, with no clear effect of dose or du-
ration of exposure. Overall, PFOA exposure did not reduce splenic B or T cell
populations. Suppression of TDAR and TIAR, in the absence of obvious lympho-
cyte subpopulation loss, suggests that effects on humoral immunity are likely medi-
ated, at least in part, by disruption of normal B cell/plasma cell function. This ab-
stract does not represent EPA policy.
405 African Dust Fine PM Induce the Expression of GSTp, HO-
1, IL-6 and IL-8 in BEAS-2B.
R. I. Rodríguez1, 2 and B. D. Jiménez-Vélez1, 2. 1Biochemistry, University of Puerto
Rico-Medical Sciences Campus, San Juan, Puerto Rico; 2Center for Environmental
and Toxicological Research, University of Puerto Rico-Medical Sciences Campus, San
Juan, Puerto Rico.
African dust travels seasonally across the Atlantic Ocean and impacts Puerto Rico
increasing the airborne particulate matter (PM) load and the probability of devel-
oping an oxidant atmosphere over the Island. The impact of this global event on the
general health of Puerto Ricans is still uncertain. We evaluated the generation of re-
active oxygen species (ROS) by African dust (ADE) atmospheric load on bronchial
epithelial cells (BEAS-2B). In addition, we also measured antioxidant
[Glutathione-S-Transferase (GSTp); Heme Oxygenase 1, (HO-1)] and pro-inflam-
matory (Interleukins, IL-6 and IL-8) gene expressions in cells exposed to PM or-
ganic extracts. Cells were treated with extracts (50μg/ml) from ADE and Non-
ADE and the contribution of metals determined using 50 μM deferoxamine
mesylate (DF). Cells were co-treated with N-acetyl-L-cysteine (NAC) to evaluate
the extract oxidant capacity. The rate of ROS formation was monitored with 2’7
dichlorofluorescein diacetate for 2 hrs reading fluorescence every 15 min.
Quantitative fluorogenic amplification of cDNA was performed using the TaqMan
Gene Expression Assays. ADE and Non-ADE induce the generation of ROS,
which was significantly reduced with DF. GSTp and HO-1 mRNA expression in-
creased 6 and 8-folds respectively after 4 hrs with ADE extract treatment. The use
of DF or NAC significantly reduced both GSTp and HO-1 expression. ADE ex-
tracts also induced IL-8 mRNA (7 folds) and IL-6 (5 folds) after 8 hrs. DF or NAC
co-treatments similarly reduced cytokine expression confirming the importance of
metals in the extracts. African dust arriving Puerto Rico increases local concentra-
tions of trace elements and other constituents in ambient PM2.5, which generate
ROS and induce the expression of antioxidant and inflammatory gene responses as
demonstrated in vitro by the use of BEAS-2B. Supported by MBRS-RISE Grant
R25GMO61838 and by NCRR 2G12-RR00305 and NCMHD 8G12-
MD007600.
406 Aminoglutethimide-Induced Immune Changes and
Idiosyncratic Drug Reactions.
W. Ng and J. Uetrecht. Faculty of Pharmacy, University of Toronto, Toronto, ON,
Canada.
Aminoglutethimide (AMG) is an aromatic amine aromatase inhibitor associated
with a high incidence of idiosyncratic blood dyscrasias, especially agranulocytosis.
Despite evidence for immune involvement, the mechanisms of idiosyncratic drug
reactions (IDRs) are poorly understood. Animal models of IDRs represent an es-
sential tool to study these reactions; however, like humans, treating animals with
drug alone does not usually induce an IDR. Conversely, studying the lack of re-
sponse may be crucial to understanding why only certain people develop an IDR to
a specific drug. Therefore, the objective of this study was to characterize the im-
mune response of Brown Norway rats treated with 125 mg AMG/kg/day and to de-
termine whether immune suppression may prevent the induction of IDRs. An early
increase in peripheral blood neutrophils in AMG-treated rats corresponded to
changes in the bone marrow that were consistent with an increase in the myeloid
cell population. Expression of CD62L on neutrophils decreased at both 24 and 48
hours after AMG treatment, which suggests neutrophil activation, and this was fol-
lowed by elevated serum levels of Gro/KC and MCP-1. In the spleen, increased
proliferation was observed in the white pulp after 14 days of AMG treatment,
which was attributed to CD4+ T-cells; however, this may be a local response be-
cause it did not extend to the auricular lymph nodes. Furthermore, an early increase
in IL-17-expressing CD4+ T-cells in the spleen of the AMG-treated was followed
by increased expression of IL-10 after 48 hours, which could modulate the immune
response. These results suggest that the major immune response to AMG involves
the innate immune system. Although there is some evidence to suggest activation of
an adaptive immune response, further investigation of how the innate and adaptive
immune interact may provide a better understanding of the mechanisms of IDRs.
This research was funded by grants from the Canadian Institutes of Health
Research.
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407 The Dermal Exposure to Silica Nanoparticles Induces IgE-
Mediated Hypersensitivity.
T. Hirai1,  Y. Yoshioka1,  H. Takahashi1,  K. Ichihashi1,  N. Nishijima1,
T. Yoshida1,  H. Nabeshi2,  T. Yoshikawa1,  S. Tsunoda3, 4,  K. Higashisaka1 and
Y. Tsutsumi1, 3, 4. 1Laboratory of Toxicology and Safety Science, Graduate School of
Pharmaceutical Sciences, Osaka University, Osaka, Japan; 2National Institute of
Health Science, Tokyo, Japan; 3Laboratory of Biopharmaceutical Research, National
Institute of Biomedical Innovation, Osaka, Japan; 4MEI Center, Osaka University,
Osaka, Japan.
To fully utilize the potential benefits of nanomaterials (NMs), it is crucial to evalu-
ate the hazard associated with NMs on human health. Previously, we reported that
amorphous silica nanoparticles (nSPs), one of the most frequently used NMs in
cosmetics, could penetrate the skin barrier and might have potential risk to enhance
allergic responses (Hirai T et al. Part. Fibre Toxicol. 2012). Thus, to ensure the
safety of nSPs, it is needed to investigate the effect of dermal exposure to nSPs on
allergic diseases. Here, we identified hazard of dermal exposure to nSPs using atopic
dermatitis (AD) model mice. The mixture of mite extract antigen (Dp) and nSPs
with diameter of 30 nm (nSP30) were swabbed on upper back and both ears for 4
weeks. To evaluate whether nSP30 affects severity of Dp-induced AD, ear thickness
and Dp-specific immune responses were measured. Dermal exposure to nSP30 did
not affect Dp-induced ear swelling, indicating that nSP30 did not aggravate AD-
like skin lesion. The levels of Dp-specific IgE were also not affected by dermal ex-
posure to nSP30. In contrast, the level of Dp-specific IgG in nSP30 (Dp+) groups
were significantly lower than those in Dp alone. Furthermore, we showed that the
decrease of IgG levels in nSP30 (Dp+) groups induced IgE-mediated hypersensitiv-
ity in Dp-mediated anaphylaxis model. Recent epidemiologic study revealed that
allergen exposure through the epidermis is important factor to initiate not only AD
but also other allergic diseases such as asthma and food allergy. Considering our re-
sults together, it is important to examine the relationship between the dermal expo-
sure to NMs and initiation of allergic diseases more precisely.
408 Effects of Clozapine on the Bone Marrow and Immune Cells
in Rodents and Humans: Implications for Drug-Induced
Agranulocytosis.
A. R. Lobach and J. Uetrecht. Leslie Dan Faculty of Pharmacy, University of
Toronto, Toronto, ON, Canada.
Clozapine is a very effective antipsychotic agent, but its use is limited by the risk of
drug-induced agranulocytosis. At the start of treatment, the majority of clozapine
patients display evidence of an inflammatory response paired with elevated neu-
trophil counts. These immune changes appear to be accompanied by changes in the
bone marrow, specifically a faster release of neutrophils to the blood. To further in-
vestigate these immunomodulatory effects, studies were carried out in rats focused
on the peripheral blood and bone marrow responses.
Methods: Rats were treated with clozapine for up to 10 days and bone marrow was
collected at study endpoint. Flow cytometry was employed to measure changes in
the balance of myeloid, lymphoid, and erythroid compartments in the bone mar-
row. Progenitor cell changes in vivo were assessed by the methylcellulose assay.
Patient studies have been initiated in which the T cell response (ie. Th1/2, Th17,
Treg) at the start of clozapine therapy will be monitored in the blood using flow cy-
tometry.
Results: Clozapine treatment in rats was found to significantly elevate the number
of mature myeloid cells in the bone marrow. This increase was found to be due to
an upstream increase in the number of myeloid progenitor cells. Furthermore, these
progenitor cells were observed to favor the formation of granulocyte (G) colonies
over macrophage (M), or mixed GM colonies.
Conclusions: Clozapine alters the normal production of hematopoietic cells in the
rat bone marrow by promoting the formation of granulocyte colonies. This is re-
flected in the blood as an increase in neutrophil counts, which is also observed in
patients at the start of therapy. The mechanism of clozapine-induced agranulocyto-
sis remains unclear; however, other studies suggest that it may be the result of cloza-
pine-induced neutrophil apoptosis. Clozapine-induced agranulocytosis may occur
in cases where this damage leads to an immune response, which doesn’t resolve with
tolerance. This research was supported by grants from the Canadian Institutes of
Health Research.
409 A Mechanistic Analysis of Silica Nanoparticle-Induced
Immune-Modulating Effect in Murine Dendritic Cells.
H. Takahashi1,  Y. Yoshioka1,  T. Hirai1,  K. Ichihashi1,  N. Nishijima1,
T. Yoshida1,  H. Nabeshi2,  T. Yoshikawa1,  S. Tsunoda3, 4,  K. Higashisaka1 and
Y. Tsutsumi1, 3, 4. 1Graduate School of Pharmaceutical Sciences, Osaka University,
Laboratory of Toxicology and Safety Science, Suita, Japan; 2National Institute of
Health Science, Setagaya, Japan; 3National Institute of Biomedical Innovation,
Laboratory of Biopharmaceutical Research, Ibaraki, Japan; 4Osaka University, MEI
center, Suita, Japan.
Nanomaterials (NMs) exhibit unique physicochemical properties and innovative
functions, and they are increasingly being used in a wide variety of fields. Ensuring
the safety of NMs is now an urgent task. Recently, we reported that amorphous sil-
ica nanoparticles (nSPs), one of the most widely used NMs, induced immune mod-
ulating effect via the cross-presentation (CP) in murine dendritic cells (DCs). Here
we investigated the mechanism of nSP-induced CP in DCs for the development of
safer nSPs. It is known that CP is induced by internalized antigens entered the cy-
tosol via endosomes, and these antigens are then degraded by proteasomes. To ex-
amine whether this pathway is necessary for nSP-induced CP, we investigated the
effect of the potent proteasome inhibitor lactacystin on nSP-induced CP.
Lactacystin treatment strongly inhibited nSP-induced CP. In addition, we analyzed
the effect of cellular uptake of nSPs on the induction of CP. Because some reports
have shown that scavenger receptor (SR) was related to the uptake of nSPs, we ex-
amined nSP-induced CP after treatment with Poly I, which is a SR inhibitor. nSP-
induced CP was inhibited with Poly I treatment. These results suggest nSPs en-
hanced CP in proteasomes- and SR-dependent manner. We believe a detailed
analysis of the mechanisms of nSP-induced CP will be invaluable for the design of
safe nSPs.
410 Programmed Death-1 Receptor Interactions with Its Ligands
May Play a Role in Inhibiting Drug-Induced Liver Injury
Mediated by the Adaptive Immune System.
K. Semple,  P. Ryan,  M. Chakraborty,  W. R. Proctor and L. Pohl. Molecular and
Cellular Toxicology Section, Laboratory of Molecular Immunology, National Heart,
Lung and Blood Institute, Bethesda, MD.
Although clinical evidence suggests that many cases of serious idiosyncratic drug-
induced liver injury (SIDILI) are mediated by hepatic protein adducts of drugs and
the adaptive immune system, detailed experimental proof for this mechanism of
toxicity has remained elusive due to the lack of animal models. We have hypothe-
sized that SIDILI is as rare in animals as it is in humans due at least in part to the
tolerogenic nature of the liver, which consists of multiple negative regulators of the
adaptive immune system. One negative regulatory pathway that may play a role in
modulating the incidence of SIDILI involves the interaction of programmed death-
1 receptor (PD-1) on the surface of activated T and B cells with its ligands (PD-L1
and PD-L2) found on a variety of other cells. This possibility has now been tested
in an established murine model of halothane-induced liver injury. Twenty-four
hours after female Balb/cJ mice were treated with halothane, analysis of the liver re-
vealed perivenous necrosis and an infiltration of CD4+ and CD8+ T cells as well as
neutrophils and eosinophils determined by flow cytometry. Further study revealed
that T cells expressed PD-1 on their surface, while neutrophils and eosinophils too
a lesser extent expressed PD-L1, but not PD-L2 on their surface. These findings
suggest that neutrophils may play a role in directly regulating the adaptive immune
system. This possibility can be tested in vitro and in vivo by modulating the activi-
ties PD-L1 and PD-1 and may have a role in determining susceptibility to SIDILI
that is mediated by cells of the adaptive immune system.
411 In Vitro Characterization of Immunostimulation by siRNA-
Lipid Nanoparticles.
P. Kasperkovitz,  R. Duncan,  B. Bettencourt,  J. Harrop,  G. Warner and
S. Barros. Alnylam, Cambridge, MA.
The treatment of human diseases using RNA interference (RNAi) therapeutics re-
quires efficacious and safe delivery of short interfering RNA (siRNA) to target tis-
sues. A well-established strategy for systemic delivery is formulation of siRNA in
lipid nanoparticles (LNP). Our current multi-component lipid formulation has
been shown to be highly efficient for liver delivery and silencing of therapeutically
relevant gene targets. Similar to liposomal drug products, siRNA-LNP delivery can
also cause minor transient increases in serum cytokines or complement activation
in a small subset of patients. The aim of this study was to systematically assess fac-
tors influencing cytokine responses to siRNA-LNP in vitro to obtain insight into
the mechanistic basis of immunostimulation. We established a consistent healthy
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blood donor pool that gave us the unique opportunity to analyze both population
heterogeneity and response consistency by repeat-characterization of single donors
(41 donors, mean 3.7 visits per donor). Whole blood was incubated in vitro with
siRNA-LNP and plasma levels of 13 cytokines were determined using multiplex
analysis. As anticipated, we observed considerable variability in cytokine responses
between donors. For large-scale analysis of 13-dimensional cytokine data, we ap-
plied Principal Component Analysis (PCA) to reduce redundancy among variables
and to identify data patterns. We found that Principal Components 1 and 2 cap-
tured ~85% of variance in our dataset. Moreover, individual donors could be sub-
classified into three categories (High, Intermediate, Low) based on responsiveness
to siRNA-LNP. Using an algorithm to analyze the reliability of our subclassifica-
tion, we demonstrated that donor sensitivity to in vitro siRNA-LNP immunostim-
ulation was consistent over time. Our data suggest that the observed heterogeneity
in sensitivity to siRNA-LNP immunostimulation is due to stable, intrinsic immune
differences.
412 Characterization of Suppression of the Innate Immune
System by Sodium Methyldithiocarbamate.
W. Tan,  B. Jan,  X. Deng,  M. Gadson and S. B. Pruett. Basic Sciences, Mississippi
State University, Mississippi State, MS.
Sodium methyldithiocarbamate (SMD) is the most widely used soil fumigant in
the US. The parent compound and its major breakdown product – methylisothio-
cyanate (MITC) have been reported to suppress innate immunity in animal mod-
els. Our studies indicated that both SMD and MITC altered pro- and anti-inflam-
matory cytokine and chemokine production in a mouse sepsis model, and increased
mortality in a similar manner at 72 hr. Experiments described here were conducted
to understand the mechanisms by which SMD alters innate immunity. In NF-κB
reporter mice, both SMD and MITC decreased the signal strength of NF-κB,
which clearly suggested that the NF-κB pathway was inhibited by both com-
pounds. Therefore, it is important to determine how SMD alters NF-κB signaling.
Early studies showed that in vivo administration of SMD decreased the concentra-
tion of reduced glutathione in mouse peritoneal macrophages, which indicated that
SMD administration induced oxidative stress. NF-κB signaling is known to be sen-
sitive to oxidative stress. However, our studies showed that neither BSO nor NAC
altered the signal inhibition of NF-κB induced by SMD, which indicated that
other mechanisms are more important. Interestingly, NF-κB p65 was not altered by
SMD. In contrast, NF-κB p50 was downregulated at the level of mRNA expression
in microarray analysis. Meanwhile, microarray analysis indicated that other path-
ways could be potentially involved in the suppression of innate immune responses
induced by SMD, such as hormone pathways, recognition receptors of bacteria and
viruses, and others. Therefore, further studies are necessary to determine the inter-
action of these impaired pathways after methyldithiocarbamate treatment. This
work was supported by grant R01ES013708 from the National Institute of
Environmental Health Sciences.
413 Submicrometer-Sized Iron Oxide Particles and
Inflammation.
A. M. Nilsen and D. Mihaylova. Norwegian University of Science and Technology,
Trondheim, Norway.
Iron-containing nano- and sub-micrometer particles are increasingly used in daily
life products such as clothes and paint as well as in nanomedicine. Thus, it is of im-
portance to find if such particles might cause harmful inflammatory responses.
The aim of the study was to determine if two types of iron oxide particles activate
isolated immune cells and initiate inflammatory responses in blood, and if they dif-
fer in their potential for doing so. 
We compared two super paramagnetic iron oxide particle types (100 nm and 1 μm
diameter) functionalized with carboxyl or glucuronic acid carboxyl and determined
if they activate human monocytes in culture or activate cells and initiate inflamma-
tory responses in human whole blood. Activation of the immune cells were deter-
mined by quantification of secreted cytokines by ELISA and multi-plex, by induced
expression of surface proteins (CD11b) on monocytes and granulocytes in whole
blood using flow cytometry and by determining activation of the complement sys-
tem (TCC) by ELISA. 
The results suggest that the 100 nm beads caused a dose dependent activation of
isolated monocytes as seen by elevated levels of secreted IL-1β and TNF-α 6h after
adding the beads. Multi-plex confirmed the increase in IL-1β and demonstrated in
addition an elevation in IL-2, IL-6, GM-CSF and IFN-γ. The 1 μm beads were
found much less potent in inducing the secretion of these pro-inflammatory cy-
tokines. Priming of the cells using LPS (100 pg/ml for 2h) gave very minor effects
on the cytokine responses to the particles. From the whole blood analysis it was
found that the 100 nm beads at the highest concentration (100 μg/ml) caused an
elevated level of CD11b on both monocytes and granulocytes, activated comple-
ment, and increased the secreted levels of IL-1β, IL-2, IL-6 and TNF-α. The 1 μm
beads gave no cytokine changes compared to the negative control except for an ac-
tivation of the complement system that was similar to the smaller beads.
The functionalized 100 nm iron oxide particles seem to induce a higher inflamma-
tory response in human monocytes and whole blood than the 1 μm beads.
414 A 28-Day Inhalation Immunotoxicity Study of Methyl
Isothiocyanate in Female B6C3F1 Mice.
J. Weinberg1,  D. Kirkpatrick1,  V. Peachee2,  V. Piccirillo3,  A. Jonynas3 and
J. Hauswirth3. 1WIL Research, Ashland, OH; 2ImmunoTox, Inc., Richmond, VA;
3MITC Task Force, Washington DC.
The objective of this study was to evaluate potential immunotoxic effects of methyl
isothiocyanate (MITC) when administered via whole-body inhalation to female
B6C3F1 mice for 28 consecutive days. MITC is the active metabolite of metam
sodium, an organosulfur compound used as a soil fumigant for protection against
soil fungi and nematodes. Groups of 10 female mice were exposed to target vapor
concentrations of 0, 1, 3 and 10 ppm. All animals were immunized with an intra-
venous injection of sheep red blood cells (sRBC) on study day 24. A concurrent
positive control group received once daily intraperitoneal injections of cyclophos-
phamide monohydrate (CPS) at a dosage level of 50 mg/kg/day on study days 24-
27. All animals were observed at the midpoint of exposures for signs of toxicity.
Body weights were recorded twice weekly and food consumption was recorded
weekly. A gross necropsy was conducted on all animals on study day 28. Spleen and
thymus weights were recorded at necropsy. Immunotoxicity assessment was based
on the results of a splenic antibody-forming cell (AFC) assay to assess the T-cell de-
pendent antibody response. There were no MITC-related effects on survival, body
weights, food consumption, macroscopic findings or spleen and thymus weights.
An increase in eye closure was observed in mice at the 3 and 10 ppm exposure lev-
els. Spleen cellularity, specific activity (AFC/106 spleen cells) and total activity
(AFC/spleen) of splenic IgM antibody-forming cells to the T cell-dependent anti-
gen sRBC were unaffected. CPS administration resulted in an expected suppression
of the humoral component of the immune system. There was no suppression of the
humoral component of the immune system when female B6C3F1 mice were ex-
posed to concentrations of 1, 3 and 10 ppm MITC vapor by whole-body inhalation
for 28 consecutive days. In the absence of MITC-related effects on the AFC re-
sponse, the No-Observed-Effect-Concentration (NOEC) on the immune system
was greater than 10 ppm.
415 Activation of the Aryl Hydrocarbon Receptor during
Development Leads to an Altered Cd4+ T Cell Response to
Influenza Virus.
L. Boule1 and B. Lawrence2, 1. 1Immunology, Microbiology, and Virology, University
of Rochester Medical Center, Rochester, NY; 2Environmental Medicine, University of
Rochester Medical Center, Rochester, NY.
Recent reports suggest developmental exposures to certain pollutants lead to lower
antibody responses to childhood immunizations, but the mechanism by which this
occurs is unknown. An intracellular receptor activated by a variety of chemicals is
the transcription factor aryl hydrocarbon receptor (AhR). It is expressed by many
cell types, including immune cells, and can alter their function upon activation.
Previously, we have shown that developmental triggering of the AhR by one of its
most potent ligands, the pollutant 2,3,7,8-tetrochlorodibenzo-p-dioxin (TCDD),
results in a decrease in the class-switched antibody response to influenza virus in-
fection. CD4+ T cells differentiate into various effector subsets dependent on the
environment in which they are activated. CD4+ T cells that secrete IFNγ and ex-
press the transcription factor TBet are defined as Th1 cells, and these Th1 cells are
critical effectors in the class-switched antibody response to influenza virus. We ex-
amined the CD4+ T cell response to influenza virus in developmentally exposed
mice and found that there are fewer activated and virus-specific CD4+ T cells in the
draining lymph nodes of infected adult mice that were developmentally exposed to
TCDD. In addition, there are fewer Th1 cells in the MLN of these mice.
Conversely, the percentage of CD4+CD25+Foxp3+ regulatory T cells (Tregs), re-
sponsible for suppressing immune responses, is increased the MLNs of develop-
mentally exposed mice. This is the first report in the context of an influenza virus
infection that AhR activation during development disrupts the normal function
and differentiation of CD4+ T cells, an effect of which may lead to decreased anti-
body responses to both infections and immunizations.
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416 Exposure to Triclosan Augments the Allergic Response to
Ovalbumin in a Mouse Model of Asthma.
C. M. Long1, 2,  J. Franko3,  M. L. Kashon1,  K. L. Anderson1,  A. F. Hubbs1,
E. Lukomska1,  B. J. Meade1 and S. Anderson1. 1HELD/ACIB, CDC-NIOSH,
Morgantown, WV; 2West Virginia University, Morgantown, WV; 3Bethany College,
Bethany, WV.
During the last decade there has been a remarkable and unexplained increase in the
prevalence of asthma. These studies were conducted to investigate the role of der-
mal exposure to triclosan, an endocrine-disrupting compound, on the hypersensi-
tivity response to ovalbumin (OVA) in a murine model of asthma. Triclosan has
had widespread use in the general population as an antibacterial and antifungal
agent and is commonly found in consumer products such as soaps, deodorants,
toothpastes, shaving creams, mouth washes, and cleaning supplies. For these stud-
ies, BALB/c mice were exposed dermally to concentrations of triclosan ranging
from 0.75-3% (0.375-1.5 mg/mouse/day) for 28 consecutive days. Concordantly,
mice were intraperitoneally injected with OVA (0.9 ug) and aluminum hydroxide
(0.5 mg) on days 1 and 10 and challenged with OVA (125 ug) by pharyngeal aspi-
ration on days 19 and 27. Compared to the animals exposed to OVA alone, in-
creased spleen weights, OVA-specific IgE, Interleukin (IL)-13 cytokine levels, and
lung eosinophils were demonstrated when mice were co-exposed to OVA and tri-
closan. Statistically significant increases in OVA-specific and non-specific airway
hyperreactivity (AHR) were observed for all triclosan co-exposed groups when
compared to the vehicle and OVA controls. In these studies exposure to triclosan
alone was not demonstrated to be allergenic, however co-exposure with a known al-
lergen resulted in enhancement of the hypersensitivity response to that allergen,
suggesting that triclosan exposure may augment the allergic responses to other en-
vironmental allergens.
417 Oral Exposure to Genistin but Not Daidzein Increased
Natutal Killer (NK) Cell Activity in Female B6C3F1 Mice.
T. Guo1,  R. D. Brown2 and J. F. Zheng2. 1University of Georgia, Athens, GA;
2Virginia Commonwealth University, Richmond, VA.
Genistin (GIN), the glycoside form of phytoestrogen genistein (GEN), is the pre-
dominant isoflavone found in soy products. The objective of this study was to de-
termine if exposure to GIN (2, 6 or 20 mg/kg) by daily gavage for 28 days modu-
lated immune responses in female B6C3F1 mice in comparison with daidzein
(DAZ), another soy isoflavone. There were no significant changes in the body
weight and absolute weights of thymus, spleen, lungs, kidneys, or liver in either
GIN or DAZ-treated mice. However, exposure to GIN increased relative kidney
weight (20 mg/kg: 11%). In contrast, exposure to DAZ decreased relative spleen
weight (2 mg/kg: 21%; 6 mg/kg: 24%; 20 mg/kg: 24%), relative kidney weight (6
mg/kg: 15%), relative liver weight (6 mg/kg: 14%; 20 mg/kg: 14%;), and relative
lung weight (20 mg/kg: 24%). In the thymus, GIN exposure increased the percent-
ages of CD4+CD8+ cells (2 mg/kg: 22%; 20 mg/kg: 26%) and CD44-CD25- cells
(20 mg/kg: 5%) but decreased the percentages of CD4+CD8- cells (20 mg/kg:
28%), CD4-CD8- cells (2 mg/kg: 41%; 20 mg/kg: 41%), and CD44-CD25+ cells
(20 mg/kg: 53%). Exposure to DAZ increased the percentages of CD44-CD25-
cells (2 mg/kg: 5%) while decreased that of CD4+CD8- cells (2 mg/kg: 30%),
CD44+CD25+ cells (2 mg/kg: 51%), and CD44-CD25+ cells (2 mg/kg: 71%; 6
mg/kg: 45%; 20 mg/kg: 43%). In the spleen, GIN exposure increased the percent-
ages of NK cells (20 mg/kg: 86%), T cells (20 mg/kg: 74%), and neutrophils (2
mg/kg: 148%) while DAZ exposure increased the percentages of T cells (20 mg/kg:
112%), CD4+ T cells (20 mg/kg: 58%), CD8+ T cells (6 mg/kg: 69%; 20 mg/kg:
133%) but decreased the percentage of neutrophils (20 mg/kg: 48%). In correla-
tion with observed increased %NK cells, exposure to GIN but not DAZ increased
NK cell activity. Taken together, the differential effects of GIN and DAZ suggest
that both the estrogenic and non-estrogenic properties of these compounds con-
tribute to their immunomodulatory roles (Supported in part by NIEHS contract
NO1-ES05454).
418 Neural Autoimmunity and Low-Level Mercury Exposure.
C. Wright,  D. L. Shirley and J. F. Nyland. Pathology, Microbiology & Immunology,
University of South Carolina School of Medicine, Columbia, SC.
Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system
(CNS) involving demyelination; the mechanism of disease pathology involves stim-
ulated auto-reactive T cells that are elicited against myelin proteins and primarily
strikes more women than men. Mercury (Hg), a heavy metal found in many con-
sumer products and as an environmental contaminant, affects the immune system,
although there is little data linking low-level Hg exposure to the development of au-
toimmunity. Contrarily, high-level Hg exposure has proven to be toxic to the
human CNS, specifically on neurons and glial cells. Since glial cells are CNS-resi-
dent immune lineage cells, we hypothesized that low-level Hg pre-exposure will in-
crease neural autoimmunity in the animal model of MS, experimental autoimmune
encephalomyelitis (EAE), induced with myelin oligodendrocyte glycoprotein
(MOG). Adult C57BL/6 male mice were first pre-treated with HgCl2 or PBS every
other day by subcutaneous injection for 2 weeks pre-disease induction, then di-
vided into 3 groups: (1) Hg only, (2) disease (MOG35-55 peptide) only, and (3) Hg+
disease. Clinical scores were recorded daily until day 25 when mice were eutha-
nized. Brain, spinal cord, and spleen tissues were collected and analyzed for 9 cy-
tokines (pro- & anti-inflammatory) using a multiplex assay. Hg alone raised levels
of both pro-inflammatory and anti-inflammatory cytokines in the spinal cord;
however, in diseased animals, Hg did not have the same effects and only increased
IFN-γ in the brain. Low-level Hg alone is insufficient to prompt disease in males
but exposure does upregulate cytokine levels in the CNS (IFN-γ) when disease is
present. These data indicate that low-dose Hg interacts with components of the
CNS milieu, specifically cytokine-producing cells of the immune system. Future
studies will focus on exploring sex-specific effects of disease severity with Hg pre-
treatment in female mice of the same animal model.
419 Modulation of HIVGP120-Specific T Cell Responses by Δ9-
Tetrahydrocannabinol In Vitro and In Vivo.
W. Chen1, 3,  B. L. Kaplan2, 3,  S. T. Pike3 and N. E. Kaminski2, 3. 1Microbiology
and Molecular Genetics, Michigan State University, East Lansing, MI; 2Pharmacology
and Toxicology, Michigan State University, East Lansing, MI; 3Center for Integrative
Toxicology, Michigan State University, East Lansing, MI.
Approximately 25% of HIV patients use marijuana for its putative therapeutic ben-
efit; however, it is unknown how cannabinoids affect the immune status of im-
munocompromised HIV patients. A surrogate in vitro mouse model was estab-
lished to investigate the effects of cannabinoids on the early stages of the anti-HIV
response. Specifically, T cell responses to HIVgp120 were induced using gp120-ex-
pressing antigen presenting cells and target cells. CD8+ T cell proliferation and
gp120-specific IFNγ production were observed, which was suppressed or enhanced
by Δ9-tetrahydrocannabinol (THC), the predominant psychoactive compound in
marijuana, depending on the magnitude of cellular activation. To further determine
the molecular mechanisms by which THC differentially modulates T cell responses,
PMA/ionomycin (Io) or anti-CD3/CD28 were used as stimuli. THC suppressed or
enhanced IFNγ or IL-2 production under optimal or suboptimal activation, respec-
tively, but increased intracellular Ca2+, regardless of the activation levels, suggesting
that appropriate or excessive Ca2+ affected T cell activation differentially. To deter-
mine whether THC has similar effects in vivo, a mouse model to stimulate
HIVgp120-specific response has also been established. Vector plasmid VRC2000 or
gp120-expressing plasmid VRCgp120 was injected intramuscularly into mice. The
gp120-specific IFNγ response was detected by ELISPOT, when splenocytes were
restimulated with the pool of gp120-derived peptides 81-84, which were identified
as the putative immunodominant ones among 211 tested peptides. The THC effect
on the gp120-specific response in vivo will be characterized. Overall, our data will
provide in-depth understanding of cannabinoid effects on HIV antigen-specific T
cell responses in vitro and in vivo. (Supported by NIH DA07908)
420 Cannabinoid Enhancement of Humoral Immunity in
CB1/CB2 Null Mice Is Correlated with Enhanced Splenic
Norepinephrine (NE) Concentration.
T. J. Simkins1, 2, 3,  K. J. Lookingland2, 3 and B. L. Kaplan1, 2, 3. 1Center for
Integrative Toxicology, Michigan State University, East Lansing, MI; 2Pharmacology
and Toxicology, Michigan State University, East Lansing, MI; 3Neuroscience Program,
Michigan State University, East Lansing, MI.
Cannabinoid compounds, such as Δ9-tetrahydrocannabinol (THC), are immune
suppressive as evidenced, in part, by their ability to inhibit T cell-dependent B cell
responses. In response to sheep erythrocytes, THC suppresses immunoglobulin M
(IgM) antibody production in a cannabinoid receptor (CB) 1 and/or CB2-depend-
ent manner. Moreover, previous studies demonstrated that the magnitude of IgM
production in response to sheep erythrocytes was higher in CB1/CB2 null mice as
compared to wild type mice, suggesting endogenous cannabinoid control of hu-
moral immunity. Thus, the focus of the present studies was to determine the mech-
anisms by which cannabinoids regulate humoral immunity. A direct comparison of
female and male wild type and CB1/CB2 null mice demonstrated that CB1/CB2
null mice produce more circulating IgM and IgG, even in the absence of immune
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sensitization. In response to various antigens, including influenza and lipopolysac-
charide (LPS), CB1/CB2 null mice also produced more IgM. It has been demon-
strated that NE engagement of β2 adrenergic receptor (β2AR) on B cells is part of
the normal physiological mechanism that contributes to antibody production, and
in fact, splenic NE concentration and β2AR expression on B cells were higher in
CB1/CB2 null mice as compared to wild type mice. These results provide a correla-
tion between splenic NE concentration and antibody production, suggesting the
possibility that cannabinoid-mediated suppression of NE release from splenic sym-
pathetic neurons contributes to cannabinoid-induced inhibition of antibody re-
sponses. (Supported in part by NIH DA007908).
421 Differential Effects of Delta(9)-Tetrahydrocannabinol on
NFκB Activation in T Cell-Dependent Humoral Immune
Response in Humans.
T. Ngaotepprutaram1, 2,  B. L. Kaplan1, 2 and N. E. Kaminski1, 2. 1Pharmacology
and Toxicology, Michigan State University, East Lansing, MI; 2Center of Integrative
Toxicology, Michigan State University, East Lansing, MI.
Delta(9)-Tetrahydrocannabinol (THC), a major psychoactive constituent found in
marijuana, modulates immune function. Previously, our laboratory demonstrated
that THC inhibits humoral immune responses to T cell-dependent antigens in
mice by suppressing sheep erythrocyte or CD40 ligand (CD40L)-induced im-
munoglobulin M (IgM) secretion and antibody forming cell (AFC) response.
CD40 is constitutively expressed on B cells, whereas CD40L is induced in activated
T cells. Thus, the objective of this study was to investigate the role of the CD40-
CD40L interaction in THC-mediated suppression of the T cell-dependent hu-
moral immune response in humans. These studies show that THC suppressed the
anti-CD3/CD28-induced DNA binding activity of NFAT and NFκB, two tran-
scription factors critical in the upregulation of CD40L in activated human CD4+ T
cells. An assessment of the effect of THC on proximal T cell-receptor signaling in-
duced by anti-CD3/CD28 revealed modest impairment of sustained elevation in
intracellular calcium, but no significant effect on the phosphorylation of Zap70,
PLCγ, Akt, and Gsk3β. Additional findings, using an in vitro T cell-dependent an-
tibody response model, which employs cell surface-expressed CD40L and recombi-
nant cytokines [interleukin (IL)-2, IL-6, and IL-10], to induce B cell responses
demonstrated that THC suppressed STAT3, but not NFκB activation in B cells.
Moreover, THC impaired B cell activation and proliferation, ultimately resulting in
suppression of IgM AFC response. Collectively, these findings suggest that THC
exhibits stimulation- and/or cell type-specific selectivity in NFκB inhibition, and
identifies many aspects of the multi-faceted mechanism by which THC suppresses
T cell-dependent humoral immunity in humans. Supported in part by DA07908
and Royal Thai Government Scholarships.
422 Phenotypic Comparison of Leukocyte Populations between
Wild Type and Aryl Hydrocarbon Receptor (AhR) Null Rat
in the Developing and Mature Spleen and Thymus.
R. B. Crawford1,  N. Joshi1,  R. S. Thomas2 and N. E. Kaminski1. 1Department of
Pharmacology & Toxicology and Center for Integrative Toxicology, Michigan State
University, East Lansing, MI; 2Institute for Chemical Safety Sciences, The Hamner
Institutes for Health Sciences, Research Triangle Park, NC.
The immunotoxic effects produced by dioxin and dioxin-like polyaromatic hydro-
carbons are mediated through the AhR; however, little is known concerning the
role of the AhR in the development or functionality of the immune system. The ob-
jective of the present study was to investigate whether targeted deletion of the AhR
in the Sprague-Dawley rat altered the leukocyte composition within the developing
(3 week) and/or mature (8 week) thymus or spleen of male and female rats. No sig-
nificant differences were observed between AhR null and wild type rats in the
spleen or thymus body to organ weight ratios or cellularity of the thymus or spleen
at 3 or 8 weeks of age. Similarly, leukocyte populations as characterized by compre-
hensive phenotyping using multiple panels of antibodies directed against specific
cell surface proteins (i.e., B cells, T cell subtypes, monocyte-derived lineages, neu-
trophils and NK cells) using flow cytometry showed no significant differences in
the cellular composition of the thymus between the wild type and AhR null rat.
Similar analysis of the spleen showed an increase in the CD8+NK+ (NKT) popula-
tion at week 3 in the AhR null rat. A trend toward an increase in NKT cells was also
present at week 8 but this difference was not statistically significant. These studies
show that target deletion of the AhR in the Sprague-Dawley rat has minimal effects
on the leukocyte composition of the developing and mature rat thymus and spleen.
(Supported in part by the Dow Chemical Company)
423 Differential Expression Kinetics of miRNA Involved in
Allergic Chemical Sensitization following Dermal Exposure
in a Murine Model.
S. Anderson1,  K. Beezhold2,  E. Lukomska1,  J. Richardson1,  C. M. Long1,
K. Anderson1,  J. Franko3,  B. J. Meade1 and D. H. Beezhold1. 1NIOSH,
Morgantown, WV; 2University of Pittsburgh, Pittsburgh, PA; 3Bethany College,
Bethany, WV.
Allergic disease is an important occupational health concern with work related
asthma and allergic contact dermatitis among the most frequently diagnosed occu-
pational illnesses. The development of rapid and sensitive methods for hazard iden-
tification of the responsible agents is critical. MicroRNAs (miRNAs) are small non-
coding RNAs 20-22 nucleotides long whose primary function is to regulate gene
expression by functioning as endogenous inhibitors of protein translation. Allergic
disease is characterized by an imbalance between Th1 and Th2 cytokines; however
the role of posttranscriptional mechanisms like the ones regulated by miRNAs is
just starting to be explored. These studies describe the kinetics of miRNA expres-
sion during the sensitization phase of an allergic response following dermal expo-
sure to prototypical chemical sensitizers in a mouse model. Using microarray and
other data, six miRNAs were identified for further analysis with RT-PCR including
mi-21, 22, 210, 155, 133a, and 27b. These data demonstrate that miRNAs may
have a central role early in the allergic response focused on establishing the fine bal-
ance of Th1 verses Th2 responses to chemical sensitizers. Identification of unique
miRNA expression profiles may help to elicit the mechanisms by which exposure to
sensitizing chemicals induce immune cell activation and can potentially help to
identify biomarkers for new treatments and preventions.
424 Potential for Immune Sensitization following Dermal
Exposure to Indium Tin Oxide.
B. J. Meade1,  E. Lukomska1,  K. Brock2,  C. M. Long1,  K. Anderson1 and
S. Anderson1. 1NIOSH, Morgantown, WV; 2West Virginia University, Morgantown,
WV.
Pulmonary disease including pulmonary fibrosis, emphysema and pulmonary alve-
olar proteinosis has been observed in workers in the indium industry. The mecha-
nisms underlying this disease and its natural history have not been fully elucidated.
Among other findings, following inhalation exposure to Indium-tin Oxide (ITO)
animal studies have revealed hyperplasia of mediastinal lymph nodes and granulo-
mas of mediastinal nodes and bronchus-associated lymphoid tissue. These studies
were undertaken to investigate the potential for ITO to induce immune sensitiza-
tion using the mouse Local Lymph Node Assay. Furthermore studies were con-
ducted following exposure to both intact and abraded skin to begin to evaluate the
potential for dermal penetration of the nanoparticles. BALB/c mice (5 animals/per
group for both intact and abraded skin groups) were exposed to either vehicle (di-
methyl sulfoxide), increasing concentrations 2.5%-10% ITO (90:10 indium
oxide/tin oxide, particle size <50 nm) or positive control (30% alpha-hexylcin-
namaldehyde). A dose response was observed in both groups reaching statistical sig-
nificance and a SI of 4 in the 5% intact dose group (EC3 value of 2.6). Students t-
test showed no statistical differences when responses were compared between intact
and breach skin exposures at the same dose levels. These studies demonstrate the
potential for ITO to induce sensitization following dermal exposure and suggest
that the particles may have similar bioavailability through intact and abraded skin.
425 Rat Bioassay of Diisocyanate Asthma: Comparison of
Thresholds of the Asthmagenic Response and Pulmonary
Irritation.
J. Pauluhn. Toxicology, Bayer Pharma AG, Wuppertal, Germany.
Occupational exposure to polymeric diphenylmethane-diisocyanate (MDI) and the
more volatile toluene-diisocyanate (TDI), known human asthmagens, can be at-
tributed to two potential routes: the skin and the respiratory tract. Both routes were
systematically compared in the Brown Norway (BN) rat MDI asthma model.
Induction utilized either 2 topical exposure sessions or inhalation exposures on 5
consecutive day at concentration x exposure time (C x t) relationships of 1000,
5000, and 10000 mg MDI/m3 x min using exposure dura-tions of either 10- or
360-min. This was followed by four 30-min inhalation challenges to 40 mg
MDI/m3 on every alternate follow-up week. This comparison revealed that a ‘high
dose’ dermal exposure is markedly more efficacious to produce ‘asthmatic rats’ than
a repeated high-dose/high-concentration inhalation protocol. Therefore, further
testing was focusing solely on the topical route for induction. Under otherwise sim-
ilar conditions, rats were challenged to 80 mg TDI/m3. This overcomes the loss of
dose due to the vapor retention in the upper airways of rats and associated drop in
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ventilation. Two independent methods were used to characterize the asthma-like re-
sponse at the last challenge, the analysis of pulmonary inflammatory by bron-
choalveolar lavage (BAL) and physiologic endpoints showing changes in respiration
delayed in onset. The most distinct outcomes characterizing the asthmatic response
in this bioassay were increased neutrophils in BAL and the delayed respiratory re-
sponse. These data demonstrated further that the vigor of asthma-like response
after challenge is clearly dependent on the inhalation elicitation dose (C x t) of pre-
challenged rats to attain the asthmatic state. This relationship of the elicitation re-
sponse served as basis for the dose-response analysis and estimation of the bench-
mark NOAEL. After adjustments accounting for differences exposure durations, in
the rat-to-human pulmonary doses, and the intra-human variability, the resultant
threshold Cxt of asthmatic rats and humans converged into the same threshold
limit value.
426 Identification of Novel Exposure and Lung Cancer Gene
Markers in Carbon Nanotube-Exposed Human Lung
Epithelial Cells.
T. A. Stueckle1,  A. Mishra1,  R. Derk1,  T. Meighan1,  V. Castranova1,
Y. Rojanasakul2 and L. Wang1. 1NIOSH, Morgantown, WV; 2West Viriginia
University, Morgantown, WV.
Concern for increased risk of CNT-induced lung cancer has arisen due to asbestos-
like high aspect ratio, pulmonary persistence and fibrosis. Our previous study
found that chronic in vitro exposure to dispersed single (D-SWCNT) and multi
wall CNT (D-MWCNT) resulted in neoplastic transformation in human small air-
way epithelial cells (SAEC). Genome profiling identified oncogene signaling mech-
anisms in CNT SAECs that were quite different from asbestos-exposed (ASB)
SAEC. Few in vivo studies identified whole lung gene markers associated with
MWCNT exposure, but did not compare CNT vs. asbestos genetic response. Here,
toxicogenomic profiling with correlation feature selection strategies identified par-
ticle-specific, key gene markers from our previous study. D-SWCNT, D-MWCNT,
ASB, ultrafine carbon black (UFCB) and control SAEC genome profiles were sub-
jected to comparative marker and class neighbor analyses followed by multistep
cross validation to identify genes with highly correlated expression for each treat-
ment. Specific treatment markers and genome profiles were subjected to Ingenuity
Pathway and Biomarker Analysis to determine both specific markers performance
and identify disease markers. Gene marker subsets and disease markers were vali-
dated using rtPCR and protein expression. Here, we present robust SWCNT,
MWCNT, ASB and UFCB specific gene marker sets for in vitro chronically ex-
posed SAEC. Matching our original analysis, both D-MWCNT and D-SWCNT
markers were associated with lipid metabolism and cancer while ASB and UFCB
centered on inflammatory response and senescence, respectively. Biomarker
Analysis identified known lung and other cancer markers (MYC, PPARG) in CNT
SAECs which differed from inflammation-associated cancer markers (IL-1B) in
ASB SAECs. In conclusion, toxicogenomic profiling in a chronic in vitro exposure
model identified particle-specific gene markers and known lung cancer markers
which can potentially aid in assessing CNT exposure and detection of early disease
markers.
427 ROS Evaluation for Series of CNTs Using ESR Method and
Its CNT Concentration Effects.
S. Tsuruoka1,  K. Takeuchi2,  K. Koyama2,  F. Tristan-Lopez1,  H. Matsumoto3,
N. Saito4,  Y. Usui4,  M. Endo1,  M. Terrones1,  D. W. Porter5 and V. Castranova5.
1ENCs, Shinshu University, Nagano, Japan; 2Faculty of England, Shinshu University,
Nagano, Japan; 3Department of Organic and Polymeric Materials, Tokyo Institute of
Technology, Meguro, Japan; 4Department of Applied Physical Therapy, Shinshu
University, Nagano, Japan; 5NIOSH, Morgantown, WV.
Carbon nanotubes (CNTs) are becoming important materials in industries. It is a
concern that CNTs may induce carcinogenic responses through pulmonary expo-
sure. It has been recently reported that CNTs scavenge ROS, which is utilized for
toxicological evaluations. Although the electron charge transfer seems the notice-
able phenomena of toxicological chemical reactions, any comprehensive evaluation
of ROS scavenging capabilities using a variety of CNTs has not been demonstrated
well. The present work specifically investigates ROS scavenging capabilities using
the series of CNTs and their derivatives: more than 15 kinds of CNTs. Those ROS
scavenging properties were measured by ESR with DMPO. Highly crystallized,
mechanically chopped, mechanically de-bulked, and metal doped CNTs were eval-
uated (Group A). Furthermore, several of commercially available CNTs (Group B)
were compared with Group A. Interestingly the ROS scavenging rate was not sig-
nificantly influenced by mechanical treatments, but depended on crystallization at
high temperature. Very thin DWCNTs showed elimination of OH radical almost,
implying existence of diameter threshold. The ratio of CNTs to DMPO influenced
the scavenging rate of CNTs buy not titanium dioxide, as a higher concentration of
CNTs showed the lower scavenging rate, this suggests that DMPO is partly ad-
sorbed on the CNT surface and decreases the activity. The results suggest that the
electron transfer on the CNT surface is the fundamental mechanism of ROS scav-
enging. Dangling bonds are not a key factor for scavenging, though. ROS is af-
fected by CNT/DMPO ratio.
428 The Biological Response to Carbon Nanotubes in the BEAS-
2B Cell Line Is Affected by Medium Conditions.
H. Haniu1,  N. Saito2,  Y. Matsuda3,  Y. Usui4,  K. Aoki1,  S. Takanashi1,
S. Kobayashi1,  H. Nomura1,  M. Okamoto1 and H. Kato1. 1Department of
Orthopaedic Surgery, Shinshu University School of Medicine, Matsumoto, Japan;
2Department of Applied Physical Therapy, Shinshu University School of Health
Sciences, Matsumoto, Japan; 3Clinical Pharmacology Educational Center, Nihon
Pharmaceutical University, Ina-machi, Japan; 4Research Center for Exotic
Nanocarbons, Shinshu University, Matsumoto, Japan. Sponsor: T. Kadota.
There are many reports on the use of an SV-40/adenovirus-transformed normal
human bronchial epithelial cell line (BEAS-2B) to evaluate nanomaterials, espe-
cially multi-walled carbon nanotubes (MWCNT). However, the results have been
controversial; one explanation is that while some experimental culture media con-
tained serum, others did not. Here, we clarified the influence of serum on the
BEAS-2B response to MWCNT compared with that on normal human bronchial
epithelial cells (NHBEC; Cell application) and studied its effect on MWCNT en-
docytosis. Cytotoxicity and cytokine secretion profiles of MWCNT on BEAS-2B
cells or NHBEC were examined in media with or without serum (Ham’s F12 con-
taining 10% fetal bovine serum [Ham’s F12] and serum free growth medium
[SFGM]). Cellular uptake of MWCNT was observed by fluorescence microscopy
and analyzed by flow cytometry. We also examined if MWCNT uptake was sup-
pressed by two kinds of endocytosis inhibitors. BEAS-2B cells cultured in Ham’s
F12 and NHBEC cultured in SFGM exhibited similar biological responses to in-
ternalized MWCNT in terms of cell growth inhibition and cytokine secretion.
BEAS-2B cells cultured in SFGM did not internalize MWCNT, and the IC50 value
of this cell line was 10 times higher than that in Ham’s F12. MWCNT uptake was
suppressed both by clathrin- and caveolae-mediated endocytosis inhibitors for
BEAS-2B cells cultured in Ham’s F12 and NHBEC in SFGM. We conclude that
the BEAS-2B cell line in serum-containing medium exhibits clathrin- and caveolae-
mediated endocytosis of MWCNT, and displays the biological responses suitable
for safety assessment of nanomaterials as a model of NHBEC.
429 Evaluation of the Effect of Carbon Nanotubes on the
Expressions of Endothelial Genes Implicated in Different
Pathways of Cellular Death.
O. Janouskova1,  M. Orecna2,  T. Tegegn2,  S. Lacerda2,  K. Holada1 and
J. Simak2. 1First Faculty of Medicine, Charles University, Prague, Czech Republic;
2Division of Hematology, CBER, US FDA, Rockville, MD.
Carbon nanotubes (CNTs) are attractive for various nanomedicine applications in-
cluding their intravascular use. Therefore, the vascular biocompatibility of CNTs is
a critical safety issue. Here we investigate the effect of carboxylated multi-walled
CNTs (M60COOH) and their pristine counterparts (M60) on cultured human
umbilical vein endothelial cells (HUVECs) by evaluating the changes in the expres-
sion of selected genes with known involvement in autophagy, apoptosis or necrosis. 
We have utilized Death PathwayFinder RT2 Profiler PCR Array (Qiagen), to mon-
itor expression of 84 selected genes. HUVECs were treated for 24 h with 100μg/ml
of M60 or M60COOH. Controls included HUVECs with serum starvation, or
treatment with 1μM camptothecin for 24h, or incubation with 1mM H2O2 for 2h.
The cDNA was constructed from isolated RNA and the level of gene expression
was analyzed by real time PCR using the PCR Array Data Analysis software
(Qiagen). 
Out of 84 monitored genes just 40 genes changed the expression significantly
(P<0.05) often only after one or two treatments. The Bonferroni correction re-
duced the number of significantly changed genes to 14. Expression profiles after
treatment with M60 and M60COOH differed (P<0.05). Both nanomaterials up-
regulated different proapoptotic genes. In contrast to M60, only M60COOH up-
regulated autophagy related genes for NFKB1, SQSTM1, and INS. Comparably,
these gene array results complement our previous finding of a significant acumula-
tion of the autophagosome protein marker LC3B in M60COOH but not in M60
treated HUVECs.
Our study suggests that the screening of mRNA levels of cell death pathway genes
may be a valuable complementary tool in the testing of cellular toxicity of nanoma-
terials. However, further gene selection, standardization and validation of assays are
required. 
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This presentation reflects the views of the author and should not be construed to
represent FDA’s views or policies. (1CR grant LH12014)
430 Carboxylated Multiwalled Carbon Nanotubes Induce mTOR
Independent Autophagosome Accumulation in Endothelial
Cells by Blockade of Autophagic Flux.
M. Orecna1,  S. Lacerda1,  O. Janouskova2,  T. Tegegn1,  K. Holada2 and
J. Simak1. 1Division of Hematology, CBER, US FDA, Rockville, MD; 2First Faculty
of Medicine, Charles University, Prague, Czech Republic.
Carbon nanotubes (CNTs) are attractive for various nanomedicine applications in-
cluding their intravascular use. Therefore, the vascular biocompatibility of CNTs is
a critical safety issue.
We have previously shown that in contrast to their pristine counterparts M60, car-
boxylated multiwalled carbon nanotubes M60COOH at 100μg/ml induced in-
crease in the LC3B autophagosome protein marker in cultured human umbilical
vein endothelial cells (HUVECs). Here we investigate a mechanism of this process.
The autophagosome accumulation in M60COOH treated HUVECs was visual-
ized by Laser Scanning Confocal Microscopy (LSCM) using immunodetection of
the LC3B as well as in HUVECs transfected with Premo™ Autophagy Sensor
LC3B-Green Fluorescent Protein using the baculovirus BacMam 2.0 technology.
Moreover, western blotting (WB) analysis confirmed accumulation of LC3B in
M60COOH treated HUVECs. The autophagosome accumulation can be caused
either by induction of autophagy or by blockade of autophagic flux. The WB analy-
sis of p62 (SQSTM1), a protein which is preferentially degraded by autophagy,
showed that the induction of autophagy by serum starvation caused a significant
decrease in p62 protein levels, while no change in p62 was observed in
M60COOH treated HUVECs. The classical pathway of induction of autophagy
involves inhibition of the mTOR kinase. The WB analysis of the mTOR substrate
p-p70S6K showed no changes in levels of phosphorylation of this protein after
M60COOH treatment. In addition, the LSCM kinetic study of HUVECs treated
with Alexa555-conjugated M60COOH indicated the autophagic flux blockade.
Our results showed that the accumulation of autophagosomes in HUVECs in-
duced by M60COOH likely resulted from the blockade of autophagic flux, rather
than induction of autophagy. This presentation reflects the views of the author and
should not be construed to represent FDA’s views or policies. (2CR grant
LH12014)
431 Effects of the Protein Corona on the Interaction of Carbon
Nanotubes with Blood Platelets.
S. Lacerda1,  L. L. Diduch2,  M. Orecna1,  T. Tegegn1,  E. Karnaukhova1 and
J. Simak1. 1US FDA, Bethesda, MD; 2NIST, Gaithersburg, MD.
With the potential uses of carbon nanotubes (CNTs) in medicine and related CNT
toxicity concerns, the importance of CNT–protein interaction studies cannot be
stressed enough. We have shown that CNTs activate store operated calcium entry in
blood platelets (De Paoli Lacerda SH et al, ACS Nano 2011). Here, we investigate
how the PLT-activating effect of multiwalled carboxylated-CNTs (M60COOH) is
influenced by interaction of M60COOH with different human proteins: albumin
(HSA), fibrinogen (FBG), Gamma-globulins (HGG) and histone H1 (H1). Pymol
molecular visualization was used to determine protein dimensions, electrostatic po-
tential surfaces, and the number of aromatic residues available for binding to the
M60COOH. Dissociation constants KD = 0.049, 0.053, 0.079 and 0.165 mg/mL
for H1, FBG, HSA and HGG, respectively, were calculated for binding of these
proteins to M60COOH. Circular dichroism revealed that the secondary structure
of the studied proteins changed upon binding to M60COOH surface. Platelet
(PLT) aggregometry showed that pre-incubation of M60COOH with HSA, HGG,
and FBG reduced PTL-aggregating effect compared to bare M60COOH. In con-
trast, pre-incubation of M60COOH with H1 markedly increased their PLT-aggre-
gating activity which was comparable to the effect of 20μM TRAP. In addition, the
flow cytometry analysis of PTL membrane microparticles (CD41+CD62P+MP)
showed that H1-M60COOH induced marked increase in CD41+CD62P+MP re-
lease compared to bare M60COOH. It is likely that positively charged H1 strongly
interacts with the negatively charged plasma membrane of PTLs enhancing the
nanopenatration of CNTs through the platelet plasma membrane. FBG leads
M60COOH to self-assembly resulting in loss of the CNT surface area for interac-
tion with PTLs which possibly explains the decrease in PLT-aggregating activity of
FBG-treated M60COOH. In conclusion, binding of different proteins to CNTs
greatly modulate their interactions with blood platelets. This presentation reflects
the views of the author and should not be construed to represent FDA’s views or
policies.
432 Genotoxicity of Multiwalled Carbon Nanotubes.
S. H. Reynolds1,  C. Dinu2,  D. T. Lowry1,  M. L. Kashon1,  A. F. Hubbs1,
B. Stanley3,  J. L. Salisbury4,  J. Mastovich5,  B. Kristin5,  J. Sturgeon5,
M. Keane1,  C. Lorenzo1 and L. Sargent1. 1CDC/NIOSH, Morgantown, WV; 2West
Virginia University, Morgantown, WV; 3NSA, Knoxville, TN; 4Mayo Clinic,
Rochester, MN; 5RJ Lee, Monroeville, PA.
Carbon nanotubes have many unique applications in industry and medicine.
Although the low density and small size of carbon nanotubes makes respiratory ex-
posures to workers likely during the production or use of commercial products, the
genotoxicity is not fully investigated. We have previously shown mitotic spindle
aberrations in cultured primary and immortalized human airway epithelial cells ex-
posed to single-walled carbon nanotubes (SWCNT). In order to investigate
whether mitotic spindle damage was unique to SWCNT, we examined mitotic
spindle aberrations following dosing of cells to multi-walled carbon nanotubes
(MWCNT) at concentrations anticipated in the workplace. MWCNT induced a
dose responsive increase in disrupted centrosomes, abnormal mitotic spindles and
aneuploid chromosome number. The data further showed that monopolar mitotic
spindles comprised 95% of the disrupted mitoses. Cell cycle analysis demonstrated
a greater number of cells in G1 and S-phase in MWCNT-treated compared to dilu-
ent control, indicating a G1/S block in the cell cycle. The monopolar phenotype of
the disrupted mitotic spindles and the G1/S block in the cell cycle is in sharp con-
trast to the multi-polar spindle and the G2 block in the cell cycle observed in
SWCNT-induced disruption. Three dimensional reconstructions showed carbon
nanotubes integrated with the microtubules, the DNA and within the centrosome
structure. The lower doses did not cause cytotoxicity or apoptosis 24 hours after ex-
posure; however, after 72 hours, significant cytotoxicity was observed in the
MWCNT-exposed cells. One month following exposure, MWCNT-treated cells
had a dramatic increase in both size and number of colonies. Our results demon-
strate significant disruption of the mitotic spindle by MWCNT at occupationally
relevant doses.
433 Loss of Epithelial Monolayer Integrity following Exposure of
Primary Human Airway Cells to Multiwalled Carbon
Nanotubes.
R. J. Snyder1,  S. Hussain1,  R. Wine2,  J. Roberts2,  J. M. Brown3,  N. J. Walker4
and S. Garantziotis1. Division of Bioinformatics and Biostatistics, National Center
for Toxicological Research, US FDA, Jefferson, AR.
Pulmonary health effects due to inhaled multi-walled carbon nanotubes
(MWCNT) have been a growing concern, as MWCNT become more widely used
due to their unique physical and chemical properties. Studies have implicated
MWCNTs in the pathogenesis of pulmonary fibrosis and inflammation. Airway
epithelia are crucial for the maintenance of airway homeostasis and epithelial injury
leads to airway remodeling and inflammation. We therefore tested the effect of
MWCNT on airway epithelial integrity. In vivo mouse exposure to MWCNTs in-
duced loss of airway columnar and ciliated epithelium within 7 days, and changes
consistent with airway epithelial metaplasia. We then explored the mechanism for
these changes in vitro. Bronchial epithelial cells (BECs) were obtained from healthy
human volunteers via bronchoscopy, grown on E10+ electrode arrays until conflu-
ent, and electrical resistance across monolayers was measured continuously for 7
days after treatment with either dispersion medium, nanographene shape control
(12ug/ml), or MWCNT (3 or 12 ug/ml). MWCNT treatment induced a signifi-
cant reduction in epithelial resistance over time, suggesting breakdown of mono-
layer integrity, as well as alterations in cell morphology, but cytotoxicity was ob-
served only in the higher MWCNT dose. Epithelial-mesenchymal transition was
ruled out by western blotting, RT-PCR and staining for relevant markers.
Microarray analysis revealed that MWCNT induced significant downregulation of
cornulin, cadherins, and keratins, as well as upregulation of genes involved in
retinoid signaling. These results suggest that MWCNT disrupt airway epithelial in-
tegrity through cytotoxicity and metaplasia linked to by retinoid-related dedifferen-
tiation.
434 Human Pleural Mesothelial MeT-5A Cells Are a Limited In
Vitro Model for Detection of Potential Asbestos-Like
Genotoxic Effects of Multiwall Carbon Nanotubes.
C. Ziemann,  S. Reamon-Büttner,  A. Hackbarth,  H. Brockmeyer,  H. Rahmer
and B. Bellmann. Fraunhofer Institute for Toxicology and Experimental Medicine,
Hannover, Germany. Sponsor: C. Dasenbrock.
Multiwall carbon nanotubes (MWCNT) are nanomaterials with important techno-
logical impact. But, depending on diameter and length some MWCNT may in-
duce fiber-like toxicity/genotoxicity, similar to asbestos. Thus, a project funded by
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the German Federal Ministry of Education and Research (contract No. 03X0109A)
focuses on potential adverse biological effects and toxicity determining characteris-
tics of divers MWCNT, both in vivo and in vitro, using long fiber amosite asbestos
(LFA) as positive control. Since mesothelial cells are targets for adverse effects of as-
bestos, notably mesothelioma development, human SV40-transformed, non-malig-
nant pleural mesothelial MeT-5A cells were initially chosen as in vitro model. In
this study part, their usefulness for investigation of potential asbestos-like adverse
effects of MWCNT in vitro was characterized. Proliferation parameters and a
MWCNT-optimized lactate dehydrogenase assay indicated concentration-depend-
ent cytotoxicity of LFA (2, 10 and 20 μg/cm2) in MeT-5A cells. LFA also induced
DNA-strand breaks and oxidative DNA-damage in the hOGG1-modified comet
assay. For determination of MWCNT-related aneugenic effects/spindle fiber dam-
age, basal frequency of micronuclei, chromosome aberrations, and altered meta-,
ana- and telophase morphology was firstly determined. MeT-5A cells exhibited
highly variable chromosome numbers (6.5% cells with normal 46 chromosomes), a
markedly higher spontaneous micronucleus frequency, compared to rodent bone
marrow erythrocytes (∼15-fold) and V79 cells ∼5-fold), and a high frequency of
aberrant mitosis stages (bridges, lagging chromosomes, multipolar divisions). In
conclusion, MeT-5A cells are a limited in vitro model to study potential asbestos-
like effects of MWCNT. Cells are responsive to asbestos, but demonstrate marked
genomic instability and thus limited significance concerning genotoxic effects. LP9
and LP9/TERT-1 cells are thus currently characterized as alternative models.
435 Multidisciplinary Approach to Determination of C60
Fullerene Presence in Lipid Membranes.
K. A. Russ1,  P. T. Williamson3,  P. Elvati2,  A. Dews1,  T. Adzemovic1,  M. Ray1,
A. Violi2,  P. Smith4 and M. A. Philbert1. 1Environmental Health Sciences,
University of Michigan, Ann Arbor, MI; 2Mechanical Engineering, University of
Michigan, Ann Arbor, MI; 3Centre for Biological Sciences, University of Southampton,
Southampton, United Kingdom; 4Institute for Life Sciences, University of
Southampton, Southampton, United Kingdom.
The incorporation of C60 fullerenes into cell membranes was confirmed by compu-
tational modeling, 31P and 2H solid-state NMR, and transmission electron mi-
croscopy. Computational modeling shows that the free energy required for C60s to
exist in or near the lipid bilayer is lowest when the C60 is positioned between the
lipid tails of the membrane. Static 31P and 2H solid-state NMR were used to study
the interaction of the C60 with model lipid bilayers composed of deuterated 1-
palmitoyl-2-oleoylphosphatidylcholine. Temperature- dependent 31P NMR spectra
show that C60s are able to enter the membrane. Reduced magnetic deformation in
the 31P spectra suggests that C60s increase the rigidity of the membrane. Increased
motional averaging in the phosphate groups and reduction in quadrupolar splitting
(resulting in a higher density of motions occurring on the microsecond timescale in
the glycerol backbone) were also seen with increasing concentrations of C60s.
Transmission electron microscopy (TEM) shows C60s are able to enter the cell via
three mechanisms: endocytosis (well-known), diffusion through the membrane,
and an unknown mechanism allowing entry into the nucleus. Freeze fracture TEM
images of RAW 264.7 immortalized cells show decreasing C60 aggregate size with
increasing proximity to the membrane as well as structures within the membrane
space. This multidisciplinary approach clarifies some of the complex questions of
nanomaterial-membrane interaction. Alteration of membrane composition via the
addition of C60s may alter the structure/function of the cell. Further research will
elucidate interactions between C60 and receptors in the membrane that may in turn
alter the normal functions of the cell. Supported by ES 08846, U01 ES020128-01,
NIEHS Training Grant T32-ES007062-26 and NSF-CAREER Award CBET
0644639.
436 Single-Walled Carbon Nanotubes Increase Influenza Virus
Infectivity in Lung Cells.
P. Sanpui1,  J. Loeb1,  J. Lednicky1,  N. B. Saleh2 and T. Sabo-Attwood1.
1Department of Environmental & Global Health, University of Florida, Gainesville,
FL; 2Department of Environmental Engineering, University of South Carolina,
Columbia, SC.
Possibility of engineered nanoparticles to influence the behavior of infectious
agents, such as influenza A viruses (IAV) can have critical consequences. We are
mainly interested in single-walled carbon nanotubes (SWNTs) because of their
ever-increasing use in consumer products and structural resemblance with asbestos
that may be relevant to their long-term health effects. Here, we aim to identify
mechanisms controlling the immune response of lung epithelial cells (LEC) ex-
posed to SWNTs and determine their influence on IAV infection. We concentrate
on the role of toll-like receptors (TLRs) which are activated by pathogens to stimu-
late production of immune proteins. To examine the impact of SWNTs on TLRs
and immune genes, LEC were exposed to SWNTs for 24 hours and expression of
84 genes were quantified using a TLR-selective array. Results revealed an immuno-
suppressive profile with 3 genes (CLEC4E, CD14, CSF3) being significantly
downregulated. Since exposure to IAV results in a robust immune response we in-
vestigated whether SWNTs could enhance IAV infectability. LEC were exposed to
SWNTs for 24 hours followed by co-incubation with H1N1 IAV. After immuno-
fluorescence staining with an H1N1-specific antibody, we observed that LEC pre-
exposed to SWNTs had significantly higher levels of IAV infection (~10%). These
results were consistent with the quantified number of virus particles released into
the cell culture media as determined by a titer assay showing an increase of 5.6
times over cells exposed to IAV only. To investigate the impact of SWNT on im-
mune response, we measured secretion of a panel of cytokines (TNFα, IFNγ, G-
CSF, GM-CSF, IL1α, IL8, IP10, Rantes) in media of exposed cells. The overall
profiles showed that cytokines induced by IAV were repressed or enhanced in pres-
ence of SWNT. Overall results from these studies indicate that SWNTs have the
potential to increase the susceptibility of lung cells to IAV infection and modulate
IAV-associated classical immune response.
437 Accumulation of Lipids and Oxidatively Damaged DNA in
Hepatocytes Exposed to Particles.
P. Moller,  L. K. Vesterdal,  P. H. Danielsen,  J. K. Folkmann,  L. F. Jespersen,
M. Roursgaard and S. Loft. Department of Public Health, University of Copenhagen,
Copenhagen K, Denmark. Sponsor: M. Campen.
Exposure to particles has been suggested to generate hepatosteatosis by oxidative
stress. We investigated lipid accumulation in cultured human hepatocytes (HepG2)
and rat liver after exposure to Printex 90 carbon black (CB) particles. HepG2 cells
were exposed to particles for 3 h and subsequently incubated for another 18 h to
manifest lipid accumulation. There was a concentration-dependent increase after
exposure to CB (50 and 100 μg/ml), which was only observed after co-exposure to
oleic/palmitic acid. Similar results were observed in HepG2 cells that were exposed
to diesel exhaust particles (SRM2975), fullerenes C60 or single-walled carbon nan-
otubes. All four types of particles at a concentration of 25 μg/ml generated oxida-
tively damaged DNA, assessed as formamidopyrimidine (FPG) sensitive sites by the
comet assay, in HepG2 cells after 3 h exposure. We have previously shown that a
single oral exposure to 0.64 mg/kg of CB increased the level of 8-oxo-7,8-dihydro-
2’-deoxyguanosine in the liver of rats (Danielsen et al., Toxicol Sci 118: 574-585,
2012). Recently we have assessed the level of hepatosteatosis by Oil Red staining in
lean and obese Zucker rats that had been exposed to 0.064, 0.64 or 6.4 mg/kg of
CB by a single oral administration (Folkmann et al., Toxicol Sci 129:98-107,
2012). There was slightly increased lipid load in the liver after exposure to 0.64
mg/kg (P=0.077) and statistically significant increased lipid load in lean Zucker rats
that had received 6.4 mg/kg of CB (P<0.05). This was not associated with increased
iNOS staining in the liver, indicating that the oral CB exposure was associated with
hepatic steatosis rather than steatohepatitis. The obese Zucker rats had higher level
of lipid load compared to the lean counterparts, whereas the oral CB exposure did
not affect the lipid load level. In conclusion, our results indicate that exposure to
particles is associated with accumulation of lipids in hepatocytes, concomitantly
with signs of oxidatively damaged DNA.
438 IL-4 and IL-13 Suppress IL-1β Production by Human THP-
1 Macrophages after Exposure to Multiwalled Carbon
Nanotubes.
K. A. Shipkowski,  A. J. Taylor and J. C. Bonner. Toxicology, North Carolina State
University, Raleigh, NC.
Introduction: Multi-walled carbon nanotubes (MWCNT) are prominent in the
field of nanotechnology due to their novel properties, but represent a potential
health hazard for human lung disease as mice exposed to MWCNT develop pul-
monary inflammation and fibrosis. It has also been shown that mice with allergen-
induced lung inflammation, driven largely by the Th2 cytokines interleukin (IL)-4
and IL-13, are susceptible to MWCNT-induced fibrosis. IL-1β is a pro-inflamma-
tory cytokine secreted by MWCNT-activated macrophages via multi-protein scaf-
folds known as inflammasomes. In this study, MWCNT were evaluated as a stimu-
lator of IL-1β expression by human THP-1 macrophages in the presence of IL-4 or
IL-13 to model the microenvironment in allergic asthma. Methods: THP-1 cells, a
human monocytic cell line, were activated with vitamin D3, differentiated with 12-
O-tetradecanoylphorbol 13-acetate (TPA), primed with lipopolysaccharide (LPS),
and dosed with either MWCNT alone (1-100 μg/mL) or MWCNT with IL-4 or
IL-13 (10 ng/mL). IL-1β mRNA and protein levels were measured via TaqMan
quantitative real-time RT-PCR and ELISA, respectively. Protein levels of phospho-
rylated and total STAT-6, an intracellular transducer of IL-4 and IL-13, were meas-
ured by Western blotting. Results: THP-1 cells treated with MWCNT showed a
dose-dependent increase in IL-1β mRNA and protein levels. IL-1β induction was
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significantly greater in differentiated cells, showing that activation of THP-1 cells
increases their response to MWCNT stimulation. Cells co-exposed to IL-4 or IL-
13 showed a significant decrease in MWCNT-induced IL-1β levels. Western blot-
ting showed that IL-13, but not MWCNT, activated STAT-6 in THP-1 cells.
Conclusions: IL-4 and IL-13 suppress MWCNT-induced expression of IL-1β in
macrophages via STAT-6 phosphorylation. Our data suggest that Th2 cytokines
up-regulated in asthma inhibit the innate immune response of macrophages to car-
bon nanotubes. (Funded by NIEHS RC2 ES018772 and R01 ES020897)
439 Zinc Oxide Surface Modification of Multiwalled Carbon
Nanotubes Enhances Chemokine and Growth Factor
Production in Human Monocytes and Lung Fibroblasts In
Vitro.
A. J. Taylor1,  C. K. Devine2,  G. N. Parsons2 and J. C. Bonner1. 1Department of
Environmental and Molecular Toxicology, North Carolina State University, Raleigh,
NC; 2Department of Chemical and Biomolecular Engineering, North Carolina State
University, Raleigh, NC.
Carbon nanotubes, a product of emerging nanotechnologies, are gaining increasing
attention due to possible health risks from occupational and environmental expo-
sures. Previous studies with rodents have shown that MWCNTs stimulate the pro-
duction of pro-fibrogenic growth factors such as transforming growth factor-β1
(TGF-β1) & platelet-derived growth factor (PDGF) in vivo. Thin-film coating of
MWCNT with metal oxides by a process called atomic layer deposition (ALD)
modifies and enhances the functionality of MWCNTs in electronics and engineer-
ing. We hypothesize that metal oxide surface coating of MWCNT with zinc oxide
(ZnO) alters the production of pro-inflammatory cytokines & chemokines as well
as pro-fibrogenic growth factors by human monocytes (THP-1) and human lung
fibroblasts (HLF-16Lu). To test our hypothesis MWCNTs were coated with ZnO
via ALD. THP-1 and HLF-16Lu were exposed to coated or uncoated MWCNT
for 24 hr and then we measured mRNAs levels (via RT-PCR) of the growth factors
PDGF and TGF-β1, the pro-inflammatory cytokine IL-1β, and the mononuclear
cell chemokine CXCL10. THP-1 cells exposed to ZnO-coated MWCNTs showed
a 6-fold increase in IL-1β mRNA expression, and ~2-fold increase in TGF-β1
mRNA and PDGF mRNA levels. In the HLF-16Lu fibroblasts, ZnO-coated
MWCNTs increased the mRNA expression of TGF-β1 3-fold and CXCL10 6-fold
but proved to be cytotoxic at higher doses. Uncoated MWCNTs had no effect on
any of the target mediators in either cell line. Our findings indicate that surface
modification of MWCNTs with ZnO enhances the production of pro-fibrogenic
proteins by macrophages and fibroblasts in vitro. These findings suggest that
MWCNT modified by ALD coating with ZnO could increase the toxicity and
pathogenicity of MWCNT in the lung.
(Funded by: NIEHS Grants R01ES020897 & RC2-ES018772)
440 Metabolomic Analysis of Liver Cells Exposed to Carbon
Nanotubes and Graphene Oxide.
W. M. Henderson1,  D. Bouchard1,  X. Chang2,  I. Chowdhury3,  B. Foster2,
S. Aronson2 and Q. Teng1. 1National Exposure Research Laboratory, Office of
Research and Development, US EPA, Athens, GA; 2Student Service Authority
Contractor to US EPA, Athens, GA; 3Grantee to US EPA via National Research
Council Cooperative Agreement, Athens, GA.
Carbon nanotubes (CNTs) and other graphenic nanomaterials are being used ex-
tensively in industrial, consumer, and mechanical applications based in part on
their unique structural, optical and electronic properties. Due to the widespread use
of these nanoparticles (NPs), human and ecological exposure is probable and in-
evitable. To determine the effects CNTs and graphene oxide (GO) have on bio-
chemical processes, metabolomics-based profiling of human (C3A) and zebrafish
(ZFL) liver cells was utilized. Cell cultures were exposed to 0, 10, or 100 ng/mL of
covalently or non-covalently modified nanomaterial for 24 and 48 hrs while parti-
cle size distribution, charge, and aggregation kinetics were monitored concurrent
with exposure studies. Following NP exposure, metabolites were extracted and de-
rivatized prior to GC/MS analysis or lyophilized and buffered for 1H NMR analy-
sis. Acquired spectra and chromatograms were subjected to multivariate analysis to
determine the consequence of NP exposure on the metabolite profile of C3A and
ZFL cells. The resulting scores plots illustrated temporal and dose dependent re-
sponses to all classes of NPs tested. Loadings plots coupled with univariate analysis
were then used to identify metabolites of interest. Preliminary data suggest that
CNT and GO exposure causes perturbations in processes involved in cellular oxi-
dation as well as fluxes in lipid metabolism and fatty acid synthesis. Dose-response
trajectories are apparent for each nanomaterial tested and spectral components re-
lated to both dose and NP modifications were determined. Correlations of the sig-
nificant changes in metabolites will aid in identifying potential biomarkers associ-
ated with carbonaceous nanoparticle exposure in both humans and ecologically
relevant species.
441 Physical Characterization of Multiwalled Carbon Nanotubes
for Inhalation Studies.
B. T. Chen,  D. Schwegler-Berry,  W. McKinney,  S. Stone,  J. L. Cumpston,
S. Friend,  D. W. Porter,  V. Castranova and D. Frazer. PPRB, NIOSH,
Morgantown, WV.
Animal inhalation studies have reported that adverse pulmonary, cardiovascular,
and immune reactions may result from exposure to multi-walled carbon nanotubes
(MWCNTs). At the present time, however, there is little guidance for adequate
sampling and characterization of MWCNT aerosols for evaluating exposures and
obtaining an applicable dose metric for risk assessment. This is mainly because
MWCNTs tend to agglomerate and form complex structures making them difficult
to characterize. To address this problem, we conducted detailed sampling and char-
acterization studies of MWCNTs that had similar particle morphologies to those
found in the workplace. Representative samples were collected using filters, a cas-
cade impactor, and direct reading instruments, and they were used for microscopic
observation, gravimetric analysis, and real-time monitoring. Particle number distri-
butions on a filter (0.008–0.10 particles/μm2), and mass distributions using an im-
pactor (0.1–0.3 mg on peak stages) were determined. Microscopic analyses indi-
cated that MWCNTs can be classified into three shape categories: irregular,
isometric, and fibrous particle structures. Each particle structure contained a mean
of 18 nanotubes, and 1 μg of MWCNTs contained 2.7 x 106 particle structures
composed of 4.9 x 107 individual nanotubes. Impactor measurements showed that
the mass median aerodynamic diameter of the aerosol was 1.5 μm with a geometric
standard deviation of 1.67. The shape factor of individual fibers was 1.94–2.71,
and the isometric particles had an effective density of 0.71–0.88 g/cm3. Results also
indicated that real-time particle number counts were realistic, but without an index
of agglomeration, they were insufficient for adequate risk assessment. Information
from this study can be used to estimate initial lung burden and to design an im-
proved lung deposition model that considers three individual MWCNT particle
shapes. The described methods can be used as guidance for sampling and character-
izing other engineered nanoparticles.
442 Cellular Responses Induced by Single-Wall Carbon
Nanotubes with Varying Physical Properties in Alveolar
Epithelial Cells.
K. Fujita1, 2,  M. Fukuda2,  S. Endoh2,  H. Kato1, 2,  N. Shinohara1, 2,  R. Nagano2,
M. Horie3,  S. Kinugasa1, 2,  H. Hashimoto1 and A. Kishimoto1, 2. 1AIST, Tsukuba,
Japan; 2TASC, Tsukuba, Japan; 3University Occupational Environmental Health,
Kitakyushu, Japan.
Concern over the influence of carbon nanotubes (CNTs) on human health has
risen due to advances in the development of nanotechnology. Some studies have
shown that unpurified CNTs induced high levels of cellular responses than those of
purified CNTs. They suggest that the residual metals involved in CNTs attribute to
induction of oxidative stress. Here, we examine our hypothesis that the physico-
chemical properties of single-wall carbon nanotubes (SWCNTs) may have impor-
tant implications for biological responses. We have developed novel dispersion pro-
cedure of CNTs with their different physical properties in culture medium. In vitro
cytotoxicity assays were performed on human alveolar epithelial cell lines (A549)
using impurity-free SWCNTs with varying physical properties and commercial
SWCNTs with residual metals as a reference. Cell viability, apoptosis, intracellular
reactive oxygen species (ROS) generation, cell cycle distribution, and cellular up-
take of SWCNTs were investigated. Impurity-free SWCNTs with their different
physical properties (CNT-1, CNT-2) and SWCNTs containing trace amounts of
metals (CNT-3) did not cause significant inhibition of cell proliferation, induction
of apoptosis and arresting cell cycle progression. On the other hand, all samples sig-
nificantly increased level of the intracellular ROS production after 24h incubation.
These results show that residual metals involved in SWCNTs may not be a defini-
tive parameter for induction of oxidative stress. The relatively short line shape of
SWCNTs small bundles were observed in the vacuoles of cells exposed to CNT-1.
The relatively long line shape of SWCNTs large bundles were observed in the cyto-
plasm and vacuoles of cells exposed to CNT-2. A large number of aggregated
SWCNTs with punctate structures were observed in the cytoplasm and vacuoles of
cells exposed to CNT-3. We suggest that the physical properties of SWCNTs are
closely related to the cellular uptake and induction of oxidative stress.
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443 Sonolytic Degradation of Pluronic® Surfactants to Toxic
Byproducts: Implications for Nanotoxicity Testing.
R. K. Draper1, 2,  R. Wang1, 2,  H. Tyler1,  S. Beck1,  S. Vakil1,  S. Li1 and
P. Pantano2. 1Molecular & Cell Biology, University of Texas at Dallas, Richardson,
TX; 2Chemistry, University of Texas at Dallas, Richardson, TX.
Poloxamers (known by the trade name Pluronic®) are triblock copolymer surfac-
tants that contain two polyethylene glycol blocks and one polypropylene glycol
block of various sizes. Poloxamers are widely used as nanoparticle dispersants for
nanotoxicity studies wherein nanoparticles are sonicated with a dispersant to pre-
pare suspensions. It is known that poloxamers can be degraded during sonication
and that reactive oxygen species contribute to the degradation process. However,
the possibility that poloxamer degradation products are toxic to mammalian cells
has not been well studied. We report here that aqueous solutions of poloxamer 188
(Pluronic® F-68) and poloxamer 407 (Pluronic® F-127) sonicated in the presence
or absence of multi-walled carbon nanotubes (MWNTs) can became highly toxic to
cultured cells. Moreover, toxicity correlated with the sonolytic degradation of the
polymers. These findings suggest that caution should be used in interpreting the re-
sults of nanotoxicity studies where the potential sonolytic degradation of disper-
sants was not controlled.
444 Effects of Carbon Black Nanoparticles on Human
Pulmonary Cell Lines and Precision Cut Lung Slices.
T. Hansen1,  J. Kopf1,  O. Danov1,  M. Ströbele3,  A. Braun1,  K. Sewald1,
P. Steinberg4 and H. Fehrenbach2. 1Fraunhofer Institute for Toxicology and
Experimental Medicine, Hannover, Germany; 2Research Center Borstel, Borstel,
Germany; 3Karlsruhe Institute of Technology (KIT), Karlsruhe, Germany; 4University
of Veterinary Medicine Hannover, Hannover, Germany. Sponsor: C. Dasenbrock.
Carbon black nanoparticles (CBNPs) are among the most abundantly used nano-
materials and have been reported to cause adverse health effects after inhalation ex-
posure. The aim of this study was to compare the effects of Printex® 90 and acety-
lene soot particles in human pulmonary cell lines (16HBE14o-, Calu-3, A549) and
precision cut lung slices (PCLS) of mice, rats and humans using a wide concentra-
tion range. Particle size distribution in the cell culture medium was determined by
dynamic light scattering. Viability assays were LIVE/DEAD® staining and WST-1
assay for PCLS and WST-8 and neutral red assay for cell lines. CBNP-induced for-
mation of reactive oxygen species (ROS) was assessed in A549 and 16HBE14o-
cells by flow cytometry using the DCFH-DA assay. Furthermore, the effect of
CBNP exposure on the transepithelial electrical resistance (TEER) was investigated
in Calu-3 cells after 24, 48 and 120h treatment with 10 and 50 μg/ml CBNPs.
With PCLS, the inflammatory response was assessed by measuring pro-inflamma-
tory cytokines (i.e. IL-1α, TNF- α, IL-8). Both CBNPs tested were not toxic in
physiologically relevant concentrations. Significant cytotoxicity was observed in the
WST-8 assay for both CBNPs at 50 μg/ml after 48h, whereas no effects were found
in the neutral red assay. Increased ROS formation was observed with both CBNPs
after 24 and 48 h. Interestingly, acetylene soot particles cause significant TEER re-
duction at both dose levels and all time points tested whereas Printex® 90 reduced
the TEER only after 120h at the high dose. Neither Printex® 90 nor acetylene soot
particles induced the secretion of proinflammatory cytokines in mouse and rat
PCLS. In conclusion, the combination of in vitro and ex vivo models provides a
valuable tool to assess the acute irritation and inflammation effects of CBNPs on
lung tissue.
445 Rho-Kinases Are Involved in Caspase-1-Mediated IL-1β
Secretion following In Vitro Exposure to Multiwalled
Carbon Nanotubes and Asbestos in Human Monocyte.
S. Kanno1,  S. Hirano2,  S. Chiba1,  H. Takeshita1,  T. Nagai1,  M. Takada1 and
T. Mukai1. 1Department of Legal Medicine, St. Marianna University School of
Medicine, Kawasaki, Japan; 2Research Center for Environmental Risk, National
Institute for Environmental Studies, Tsukuba, Japan.
It has been reported that fibrous particles such as asbestos and carbon nanotubes
(CNT) trigger interleukin (IL)-1β release through NLRP3 inflammasome in
phagocytotic cells. GTPase effector Rho-kinases (ROCK1, and 2), are known to be
associated with the organization of the actin cytoskeleton during phagocytosis. In
this study we examined whether ROCKs are involved in asbestos- or multi-walled
CNT (MWCNT)-induced IL-1β release in human monocytic THP-1 cells. THP-
1 were differentiated to macrophages by PMA and were exposed to crocidolite,
MWCNT or lipopolysaccharide (LPS) in the presence or absence of Y27632
(ROCKs inhibitor) or Z-YVAD (caspase-1 inhibitor). Concentrations of IL-1β in
the culture medium were measured using ELISA. Cell-associated MWCNT or as-
bestos were assayed by turbidimetry. Protein levels of ROCK1 and ROCK2 were
analyzed by western blotting. Treatment with PMA increased expression of
ROCK1, whereas that of ROCK2 was not changed in THP-1 cells. Exposure of the
cells to asbestos or MWCNT provoked IL-1β secretion the secretion was sup-
pressed by either Y27632 or Z-YVAD, whereas LPS-induced IL-1β secretion was
inhibited only by Z-YVAD, but not by Y27632. These results indicate that IL-1β
secretion was increased by caspase-1 activation and ROCKs are involved in both as-
bestos- and MWCNT-induced IL-1β secretion. On the contrary, treatment with
Y27632 did not change the amount of those fibrous particles associated with the
cells. To further examine the effect of ROCK1 and ROCK2 on asbestos and CNT-
induced IL-1β secretion, differentiated THP-1 were transfected with siRNA to
knockdown ROCKs. siRNA designed for both ROCK1 and ROCK2 decreased as-
bestos- or MWCNT-induced IL-1β secretion and did not change LPS-induced IL-
1β secretion, indicating that ROCKs are implicated in fiber-induced inflamma-
some responses.
446 Multiwalled Carbon Nanotubes Damage the Mitochondria
to Increase Reactive Oxygen Radical Production, Activate
NF-κB Signaling to Induce Inflammatory Cytokines, and
Stimulate Transforming Growth Factor β1 and Platelet-
Derived Growth Factor Expression to Promote Fibroblast-to-
Myofibroblast Transformation.
X. He1,  S. Young2,  D. Schwegler-Berry2,  W. P. Chishom3,  J. E. Fernback4 and
Q. Ma1. 1Toxicology and Molecular Biology Branch, NIOSH, Centers for Disease
Control and Prevention, Morgantown, WV; 2Pathology and Physiology Research
Branch, NIOSH, Centers for Disease Control and Prevention, Morgantown, WV;
3Exposure Assessment Branch, NIOSH, Centers for Disease Control and Prevention,
Morgantown, WV; 4Chemical Exposure & Measuring Branch, NIOSH, Centers for
Disease Control and Prevention, Cincinnati, OH.
Carbon nanotubes (CNTs) are novel material with unique electronic and mechani-
cal properties. Here, we report that multi-walled carbon nanotubes (MWCNT)
have potent, dose-dependent toxicity on cultured human cells. Molecular charac-
terization revealed that MWCNT induced substantial ROS production and mito-
chondrial inner membrane depolarization at sub-toxic doses. MWCNT stimulated
the secretion of a panel of inflammatory cytokines and chemokines (TNFα, IL-1β,
IL-6, IL-10 and MCP1) from macrophages (Raw264.7) by activating the canonical
NF-κB signaling pathway. Activation of NF-κB signaling involves rapid degrada-
tion of IκBα, nuclear accumulation of NF-κBp65, binding of NF-κB to specific
DNA-binding sequences, and transactivation of target gene promoters. Finally,
MWCNTs induced the production of fibrogenic growth factors TGFβ1 and
PDGF that function as paracrine signals to promote the transformation of lung fi-
broblasts into myofibroblasts, a key molecular step in the development of lung fi-
brosis. These results demonstrated that MWCNT elicit multiple and intertwining
molecular signaling events involving oxidative damage, inflammatory cytokine pro-
duction, and myofibroblast transformation, which potentially underlie the toxicity
and fibrosis in human lungs by MWCNTs.
447 Functionalization-Associated Effects of Carboxylated
Fullerenes on Cellular Aging.
J. Gao and I. Rashi. Bioscience Division, Los Alamos National Laboratory, Los
Alamos, NM.
The systematic evaluation of critical cellular responses such as apoptosis, cellular
proliferation, reproductive clonogenicity and cell cycle responses in lung cells by
distinctly functionalized fullerenes demonstrated that fullerene-mediated responses
are dependent on their ability to perturb cell division that ultimately impact cellu-
lar fate. Moreover, we postulate that the observed cellular responses were charge and
functionalization specific, in that the positively charged fullerenes were cytotoxic as
opposed to the negatively charged fullerene. Interestingly, the negatively charged
fullerenes inhibited cellular apoptosis and necrosis. On further investigation we dis-
covered that, depending on the functionalization, the negatively charged fullerenes
could induce senescence in bronchial epithelial cells, a cellular response that we
have previously reported as a potential toxicological endpoint of fullerenes in der-
mal cells. We demonstrate that the observed non-cytotoxic or cyto-protective effect
of fullerenes may in fact be due to a more novel function of fullerenes to induce pre-
mature senescence in cells. In the present study we utilized immortalized but not
tumorigenic human bronchial epithelial cells (Beas-2b) and normal human-derived
bronchial epithelial cells (NHBE) to perform a systematic evaluation of the effect of
a suite of positively and negatively charged engineered fullerenes on key biological
96 SOT 2013 ANNUAL MEETING
responses. We found that the biological response(s) elicited by fullerenes on inter-
action with lung cells may depend upon their ability to perturb cell cycle check-
points potentially inducing senescence. Further elucidation of the underlying mo-
lecular mechanisms involved in this senescence response indicated the involvement
of GADD45a, p16, p21 and p53a, a response characteristic of cells undergoing
senescence. Finally, we correlated the physicochemical properties of engineered
fullerenes with the observed biological responses to obtain a better understanding
of property-dependent bioactivity of fullerenes.
448 An In Vitro Assay Detects Enhancement of Mouse T Cell
Sensitization to Ovalbumin by Carbon Nanoparticles.
D. E. Lefebvre1,  B. Pearce1,  E. Chomyshyn1,  N. Ross1,  S. Halappanavar2,
A. F. Tayabali2,  I. Curran1 and G. S. Bondy1. 1Bureau of Chemical Safety, Food
Directorate, Health Products and Food Branch, Health Canada, Ottawa, ON,
Canada; 2Environmental Health Science and Research Bureau, Environmental and
Radiation Health Sciences Directorate, Healthy Environments and Consumer Safety
Branch, Health Canada, Ottawa, ON, Canada.
RATIONALE AND SCOPE: Previous studies suggested that some nanomaterials
can promote allergic sensitization. At present there are no in vitro tools to study this
risk. The hypothesis was that an in vitro screening assay could be developed to as-
sess the adjuvanticity of agglomerated carbon black nanoparticles (CBNP). EX-
PERIMENTAL PROCEDURES: DO11.10 transgenic mice have a T cell receptor
which recognizes the ovalbumin (OVA) protein from chicken egg. Splenic leuko-
cytes from these mice were cultured with 0, 0.012, 0.12, 1.2 or 12 ug/mL CBNP,
OVA, or OVA with CBNP. T cell mitosis rate was quantified by flow cytometry on
day 3 post-exposure. T helper (Th1/Th2) cytokine production was measured by
qPCR and ELISA. RESULTS: Printex 90 and Aldrich carbon CBNP products were
characterized. These powders consisted of micron-sized agglomerates made up of
22 nm and 39 nm diameter CBNP base particles, respectively. Following sonication
in saline RP-10 solution, the fraction of agglomerates smaller than 220 nm was pu-
rified by filtration for cell exposure. These particles did not induce T cell mitosis,
and they did not modify this parameter during the response to OVA. These CBNP
alone did not induce Th1/Th2 cytokine expression. However, OVA in combina-
tion with 12 ug/mL of either Printex 90 or Aldrich carbon significantly increased
the allergy-related Th2 cytokines IL-4, IL-10 and IL-13 compared with OVA alone
(p≤0.05; n=3-5/group). This was concurrent with a decrease in the Th1 transcrip-
tion factor Stat4. Lower CBNP doses had no effect. CONCLUSIONS: An in vitro
immunotoxicology tool was developed. At the highest dose, carbon nanoparticles
enhanced allergy pathways in mouse immune cells responding to ovalbumin. This
assay will be used to further characterize nanomaterials for risk assessment pur-
poses.
449 Role of Transforming Growth Factor-β1 Pathway in Carbon
Nanotube Stimulated Collagen Production in Human Lung
Cells.
A. Mishra1, 2,  T. A. Stueckle1,  R. Derk1,  V. Castranova1, 2,  Y. Rojanasakul2,
J. Yuan3 and L. Wang1, 2. 1Pathology and Physiology Research Branch, Health Effects
Laboratory Division, NIOSH, Morgantown, WV; 2School of Pharmacy, West Virginia
University, Morgantown, WV; 3School of Public Health, Hebei United University,
Tangshan, China.
Accumulated studies have shown that carbon nanotubes (CNT) induce rapid and
progressive lung fibrosis in animal models but the mechanisms are not clear.
Following CNT exposure transforming growth factor β (TGF-β), a pro-fibrogenic
mediator, was induced both in vivo and in vitro models and was correlated with in
vivo fibrosis and in vitro collagen induction. To understand the signaling mecha-
nism of this fibrogenic response, we investigated the contribution of TGF-β signal-
ing in CNT-induced collagen production, a hall mark of fibrosis, using cultured
human lung cells and determined the role of TGF-β receptor-Smad (TGF-βR1-
Smad) signaling as a potential mechanism for CNT-induced fibrosis. Human lung
epithelial (BEAS2B) cells and fibroblast (CRL1490) cells were exposed to doses rel-
evant to in vivo exposure (0.02-0.6 μg/cm2 in vitro ~ 10-80 μg/mouse lung) of
well characterized and dispersed multi-walled CNT (MWCNT), single walled
CNT (SWCNT) and ultrafine carbon black (UFCB). Protein expression was meas-
ured by immunofluorescence, western blotting and ELISA. Present results indicate:
1) CNT exposure caused induction of TGF-β1 production in lung epithelial cells;
2) TGF-β, TGF-βR1, p-Smad-2, and collagen type I were overexpressed in CNT-
exposed fibroblast cells; 3) collagen I stimulating effects of MWCNT were partially
blocked in TGF-βR1 and Smad-2 knockdown fibroblast cells. In conclusion, CNT
stimulate lung fibroblasts to induce collagen I in vitro through activation of the
TGF-β R1-Smad Signaling pathway.
450 Factors Associated with the Releasability of Carbon
Nanotubes (CNTs) from Nanocomposites in Potential
Consumer or Industrial Applications.
M. Kovochich,  R. Avanasi and A. K. Madl. ChemRisk, Aliso Viejo, CA.
Engineered nanomaterials offer innovative advancements for a wide range of indus-
trial and consumer product technologies which promise to have global economic
impact. Engineered nanomaterials in composites (nanocomposites) are currently
being used in applications ranging from basic consumer goods to critical national
defense technologies, with carbon nanotubes (CNTs) being popular for nanocom-
posites due to their enhanced mechanical, thermal, and electrical properties. With
comparisons of CNTs to other high aspect ratio fibers, some concerns have been
raised regarding the potential implications for exposure and health risk of
nanocomposites containing CNTs. We hypothesized that the physical and chemical
interactions between CNTs and the composite matrix, as well as settings in which
nanocomposites are handled will influence the release of these nanomaterials. We
analyzed available data on the release of CNTs from different composites as a result
of various stressors. Although no release was detected under UV weathering condi-
tions, CNT surface aggregation was detected in thermoplastic and epoxy compos-
ites compared with cementitious material. Matrix type, nanomaterial dispersion
within the matrix, and chemical bonding were critical determinants for releasabil-
ity. Mechanical stress tests such as cutting, grinding, sanding, and abrasion showed
both positive and negative releasability results. Taken together, data indicate that
physical, chemical, and environmental factors can affect the release of CNTs from
nanocomposites including the location of the CNTs within the matrix, the chemi-
cal and physical bonding between the CNTs and the matrix, as well as the physical
stress applied to the matrix. Analytical methods distinguishing release of CNTs ver-
sus matrix nanoparticles are critical to characterizing nanomaterial exposure.
Understanding the factors that play a role in the release of CNTs will aid in techno-
logical development and safe handling of nanocomposites while minimizing any
potential health risks.
451 In Vitro Endothelial Exposure to Carbon Nanotubes Produce
Reactive Oxygen Species.
Y. Rodriguez Yanez1,  I. Poblete-Naredo1,  B. Chavez-Munguía2,  B. Cisneros3 and
A. Albores1. 1Toxicology, Cinvestav, Mexico City, Mexico; 2Infectomics and Molecular
Pathology, Cinvestav, Mexico City, Mexico; 3Genetic and Molecular Biology,
Cinvestav, Mexico City, Mexico.
Recent studies are focused to carbon nanotubes (CNT) effects on blood coagula-
tion, and have demonstrated that CNT are able to induce platelet aggregation and
vascular thrombosis. However, there is little information on CNT effects on fibri-
nolysis. Therefore, we investigated the role of CNT on fibrinolysis and their contri-
bution to elicit a prothrombotic process in vascular endothelium and the reactive
oxygen species (ROS) participation. In the present study we examined the CNT
oxidative potential by ROS production and the induction of fibrinolysis-related
gene expression in human umbilical vein endothelial cells (HUVEC) isolated from
the vein of the umbilical cord. Primary HUVEC cultures were exposed to single-
walled carbon nanotubes (SWCNT) at 5, 25 and 50 μg/ml during 24 h, and oxi-
dation potential (free-cell dithiotreitol oxidation assay), cytotoxicity (propidium io-
dide stain) and cell morphology (transmition electron microscopy, TEM) were
assessed. SWCNT exposure resulted in concentration-dependent changes: a) oxida-
tion potential increases that suggest a ROS increase and, b) viability decreases.
Additionally, morphological changes in mitochondria, chromatine and nucleus
were observed by TEM. It is expected that the oxidative stress caused by ROS may
affect the transcription of the fibrinolysis related genes, activators: tissue- and
urokinase-activator, tissue kallikrein, [tPA, uPA, KLK1]); and inhibitors: plasmino-
gen activator inhibitor type 1 and kallistatin [serpine1, serpina4]), altering the
physiological fibrinolysis pathway in the vascular endothelium (Supported by
grants SSA/IMSS/ISSSTE/CONACYT grant 162391 and ICyTDF51/2012, YRY
received a Conacyt scholarship 203482).
452 Transport of Inhaled MWCNT to the Pleura, Respiratory
Muscles and Systemic Organs.
R. R. Mercer,  A. F. Hubbs,  J. F. Scabilloni,  L. Wang,  L. A. Battelli,
V. Castranova and D. W. Porter. PPRB, NIOSH, Morgantown, WV.
Inhalation exposure studies of mice were conducted to determine if multi-walled
carbon nanotubes (MWCNT) distribute to the parietal pleura, respiratory muscu-
lature and systemic organs. Male C57BL/6J mice were exposed in a whole-body in-
halation system to a 5 mg/m3 MWCNT aerosol for 5 hours/day for 12 days (4
times/week for 3 weeks). At 1 day and 48 weeks after the 12 day exposure period,
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mice were anesthetized and lungs and systemic tissues were preserved by whole
body vascular perfusion of paraformaldehyde while inflated with air. A separate,
clean-air control group was studied.  Sirius Red stained sections from lung, di-
aphragm, chest wall, heart, kidney and liver were analyzed. Enhanced darkfield mi-
croscopy and morphometric methods were used to detect and count MWCNT in
tissue sections. Counts in tissue sections were expressed as number of MWCNT per
cm2 of tissue (mean±SE, N=8 mice per group).  Although agglomerates account for
approximately 60% of lung burden, only singlet MWCNT were observed in di-
aphragm, chest wall and systemic tissues.  At one day post exposure, the average
length of singlet MWCNT in diaphragm was comparable to that of singlet
MWCNT in the lungs 5.6 ± 0.6 versus 5.1 ± 0.6 um, respectively. There were 26 ±
13 and 134 ± 25 per cm2 in tissue sections of diaphragm at 1 day and 48 weeks post
exposure, respectively.  On average, there were 18 ± 5 and 50 ± 20 per cm2 singlet
MWCNT observed in systemic organ tissue sections at 1 day and 48 weeks, respec-
tively.  The burden of singlet MWCNT in parietal pleura, respiratory musculature
and systemic organs at 48 weeks post exposure was significantly higher than at 1
day post exposure.  Results demonstrate that inhaled MWCNT, which deposit in
the lungs, are transported to the parietal pleura, the respiratory musculature and the
systemic organs in a singlet form and accumulate with time following exposure.
453 Genotoxicity of Long, Tangled Carbon Nanotubes in Mice.
J. Catalán1, 2,  H. Järventaus1,  S. Suhonen1,  K. Siivola1,  C. Moreno2,  E. Rossi1,
J. Koivisto1,  E. Vanhala1,  H. Wolff1,  H. Alenius1,  K. Savolainen1 and
H. Norppa1. 1Nanosafety Research Centre, Finnish Institute of Occupational Health,
Helsinki, Finland; 2University of Zaragoza, Zaragoza, Spain.
Long, needle-like multiwalled carbon nanotubes (MWCNTs) have been described
to induce inflammation, genotoxic effects and mesothelioma in the respiratory sys-
tem of mice, but the mechanisms behind these adverse effects are not well under-
stood. The stiffness of the CNTs has been suggested to play a crucial role in their
clearance from the lungs, affecting their toxicity. We have earlier observed that long,
needle-like MWCNTs increase DNA damage in murine lungs. To find out whether
the shape of the CNTs could affect their genotoxical properties, we examined here
whether also long, but tangled MWCNTs (outer diameter 8-15 nm; Cheaptubes
Inc), administrated either by pharyngeal aspiration or inhalation, could be geno-
toxic in C57BL/6J mice locally in the lungs or systematically in peripheral leuko-
cytes and bone marrow erythrocytes. Cell samples were collected 24-h after a single
pharyngeal aspiration (0.02-4 mg/ml) or a 4-day inhalation exposure (4 h/day; 17.5
mg/m3) to the MWCNTs. DNA damage was assessed by the comet assay in bron-
choalveolar lavage (BAL) cells and lung cells. DNA double strand breaks were as-
sessed by the γ-H2AX assay in peripheral leukocytes and (after pharyngeal aspira-
tion) in lung cells. Micronuclei, a biomarker of chromosome damage, were
analyzed in bone marrow polychromatic erythrocytes sampled 24 h after the end of
the inhalation exposure. No significant dose-dependent increase in DNA damage
(comet assay) was seen in the BAL or lung cells of mice treated by pharyngeal aspi-
ration or by inhalation exposure. The long, tangled MWCNTs neither induced sys-
temic genotoxic effects in peripheral leukocytes or bone marrow. Our findings sug-
gest that the stiffness of long MWCNTs is a central characteristic with respect to
their genotoxicity in vivo, with thinner and flexible tangled MWCNTs, which tend
to form agglomerates, showing no genotoxic effects. (Funded by the Finnish Work
Environment Fund)
454 High-Fat Diet Leads to Increased Lung Inflammation and
Airway Resistance following Multiwalled Carbon Nanotubes
Exposure.
T. A. Brown. Center for Environmental Health Sciences, University of Montana,
Missoula, MT.
Obesity has become a worldwide epidemic responsible in large part for the rising
costs of health care. Obesity leads to systemic low-grade inflammation increasing
risk for the development of diseases such as diabetes, but the link for respiratory
disease is less clear. We investigated the effect of a high fat diet on lung inflamma-
tion and lung physiology when exposed to multi-walled carbon nanotubes
(MWCNT). Nanomaterials, including MWCNT, are used in an increasing num-
ber of consumer products. Given their small dimensions with large surface area and
often very unique properties with high deposition efficiency they can induce signif-
icant immune responses in the lung. In this study, C57Bl/6 mice were kept on a
high fat diet for 6 weeks and then exposed to MWCNT, via oropharyngeal instilla-
tion. Measurements were taken 24 hr later to determine changes in inflammation
and respiratory physiology, specifically lung resistance. Mice given particle on the
high fat diet had significantly increased levels of IL-1β, a pro-inflammatory cy-
tokine produced by the inflammatory complex the inflammasome, as well as in-
creased lung resistance compared to mice on the control diet given particle. In order
to further investigate inflammatory changes due to the high fat diet additional stud-
ies examined the influx of inflammatory cells in response to MWCNT exposure.
Mice on the high fat diet exposed to MWCNT had a greater influx of neutrophils
and eosinophils compared to control diet mice exposed to particle. These results in-
dicate that a high fat diet leads to an increase inflammatory response with measura-
ble physiological alterations in the lungs when exposed to MWCNT. This work was
supported by NIH grants RC2 ES018742 and P20 RR017670.
455 Multiwalled Carbon Nanotubes Cause Mild Inflammation in
the Aorta without Pulmonary Toxicity in a Rapidly Aging
Mouse Model.
K. Luyts,  S. Smulders and P. Hoet. Environment and Health, Kuleuven, Leuven,
Belgium.
Exposure to ambient particulates has been shown to cause co-morbidity in elderly. 
Brain and muscle ARNT-like protein-1 (Bmal1) clock gene–deficient mice, with an
accelerated aging and prothrombotic phenotype, were used to study the pulmonary
and cardiovascular toxicity of multiwalled carbon nanotubes (CNTs). At the age of
8 weeks, wildtype and knockout Bmal1 mice were oropharyngeally aspirated once
weekly during 5 consecutive weeks with 6.4 μg (32 μg in total), 25.6 μg (128 μg in
total) of CNTs or the vehicle as control. 
Cell counts in the bronchoalveolar lavage fluid indicated no inflammatory response
24 hours or 2 months after the last aspiration despite the presence of particle-laden
macrophages. Cytokine measurements in lung homogenates showed trends for IL-
1β, IL-6 and KC increases only in the wildtype mice aspirated with 128 μg CNTs
but this response disappeared after 2 months. 
In wildtype mice, aspiration of 128 μg CNTs caused a non-significant decrease in
platelet and red blood cell counts, no significant differences for the aPTT and PT
clotting tests were found and clotting factor FVIII was (non-significantly) de-
creased 24 hours after the last aspiration and increased 2 months later. In the
BMAL1 knockout mice, FVIII was increased after 24 hours but decreased after 2
months. 
A macrophage staining (MAC-3) on sections of the aorta showed endothelial acti-
vation and vascular inflammation in 60% of the 128 μg dosed knockout animals.
There were no changes observed in the aortas of the wildtype mice.
In this study we showed that multiple dosing (5 weekly doses) of CNTs induced a
mild vascular inflammation in the high dosed Bmal1 knockout mice in the absence
of pulmonary toxicity.
ENPRA Project NMP4-SL-2009-228789
IWT 101061
456 Investigation of the Pulmonary Bioactivity of Double-Walled
Carbon Nanotubes.
T. M. Sager1,  M. Wolfarth1,  D. W. Porter1 and T. Steinbach2. 1NIOSH,
Morgantown, WV; 2Experimental Pathology Laboratories, Sterling, VA.
Nanotechnology is one of the world’s most promising new technologies. In turn,
carbon nanotube production is estimated to reach into the millions of tons within
the decade. Our laboratory has previously established that exposure to multi-walled
carbon nanotubes (MWCNT) causes lung inflammation and fibrosis in mice after
pharyngeal exposure. However, the bioactivity of double-walled carbon nanotubes
(DWCNT) has not been determined. In this study we explored the hypothesis that
DWCNT would promote pulmonary toxicity by analyzing the pulmonary bioac-
tivity of the DWCNT. To test this hypothesis, male mice (C57BL/6J) were given a
single dose of one of the following by pharyngeal aspiration: 1) 0.9% saline with
0.3% (w/v) carboxymethyl cellulose (CMC; vehicle control), or 2) DWCNT (0-40
μg/mouse) suspended in vehicle [0.9% saline with 0.3% (w/v) CMC]. Whole lung
lavage (WLL) was conducted at 1 and 7 days post-exposure. Lungs of non-lavaged
animals were also collected and processed for histopathologic analysis at 7 and 56
days post-exposure. The results show the DWCNT exposure caused a dose-de-
pendent increase in WLL polymorphonuclear leukocytes, indicating that DWCNT
exposure initiates pulmonary inflammation. DWCNT exposure also caused a dose-
dependent increase in LDH activity as well as albumin levels in WLL fluid, indi-
cating that DWCNT exposure promotes cytotoxicity as well as decreases in the in-
tegrity of the blood-gas barrier in the lung. Also, at 56 days post-exposure, the
presence of fibrosis was noted in the highest dose exposure group (40 μg/mouse).
In conclusion, this study provides insight into the previously uninvestigated pul-
monary bioactivity of DWCNT exposure. The results confirm that DWCNT ex-
posure does promote inflammation and fibrosis in the lung. The results also indi-
cate that DWCNT have a similar pulmonary bioactivity as the previously studied
MWCNT.
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457 Multiwalled Carbon Nanotube-Induced Lung Tumors.
L. Sargent1,  D. W. Porter1,  D. T. Lowry1,  L. A. Battelli1,  K. Siegrist1,
M. L. Kashon1,  B. T. Chen1,  D. Frazer1,  L. Staska2,  A. F. Hubbs1,
W. McKinney1,  M. Andrew1,  S. Tsuruoka3,  M. Endo3,  V. Castranova1 and
S. H. Reynolds1. 1CDC/NIOSH, Morgantown, WV; 2Integrated Laboratory Systems,
Durham, NC; 3Shinshu University, Nagano, Japan.
Carbon nanotubes have many promising applications. Although the low density
and small size of carbon nanotubes makes respiratory exposures to workers likely
during the production or use of commercial products, there is limited data on car-
cinogenicity of inhaled multi-walled carbon nanotubes (MWCNTs). We have
therefore utilized a two stage initiation/promotion protocol to determine whether
inhaled MWCNTs act as a complete carcinogen and/or promote the growth of cells
with existing DNA damage. Six week old, male, B6C3F1 mice received a single
dose of either methylcholanthrene (MC, 10 μg/g BW, i.p.) or vehicle (corn oil).
One week after i.p. injections, mice were exposed by inhalation to MWCNTs (5
mg/m3, 5 hours/day, 5 days/week) or filtered air (controls) for a total of 15 days.
The B6C3F1 mouse used in this study has intermediate susceptibility to lung car-
cinogenesis, and data obtained will have relevancy to existing human lung tumor
data because lung tumors in this mouse strain exhibit many molecular and mor-
phological similarities to human pulmonary tumors. At 17 months post-exposure,
mice were euthanized and examined for lung tumor formation. Twenty percent of
the filtered air controls, 33% of the MWCNT-exposed, and 50% of the MC fol-
lowed by air-exposure, had a mean of one tumor per mouse. By contrast, 100% of
the mice which received MC followed by MWCNTs had tumors with an average of
3.6 tumors per mouse. Additionally, mice exposed to MWCNTs or MC followed
by MWCNTs had larger tumor volumes than their corresponding air-exposed con-
trol groups. Our preliminary data suggests that MWCNT exposure promotes the
growth of spontaneously and chemically initiated lung cells, resulting in the devel-
opment of lung tumors. In this study, mouse MWCNT lung burden approximates
feasible human occupational exposures. Therefore, the results of this ongoing study
indicate that caution should be used to limit human exposures to MWCNTs.
458 Toxicological Evaluation of Pulmonary Exposure to
Graphenes of Different Sizes.
J. R. Roberts1, 2,  A. Kenyon1,  S. S. Leonard1, 2,  N. R. Fix1,  D. W. Porter1, 2,
T. M. Sager1, 2,  M. Wolfarth1,  B. M. Yingling2, 1,  I. S. Chaudhuri3,  A. Kyrlidis3,
S. A. Bilgesu1,  R. R. Mercer1, 2,  D. Schwegler-Berry1,  V. Castranova1 and
A. Erdely1, 2. 1NIOSH, Morgantown, WV; 2WVU, Morgantown, WV; 3Cabot
Corporation, Billerica, MA.
Research on the uses and manufacturing of nano graphene has increased dramati-
cally in the past decade. Thus, worker inhalation of graphene nanopowders is likely.
The goal of this study was to evaluate the lung toxicity of three non-oxidized
graphene (Gr) samples of different sizes [20 μm lateral x 7-10 nm thick (Gr20), 5
μm lateral x 7-10 nm thick (Gr5), and <2 μm lateral x 1-2 nm thick (Gr1)]. Gr
samples were diluted in physiological dispersion medium (DM) and characterized
for size, surface reactivity, and free radical generation in vitro. Male C57BL/6J mice
received 4 or 40 μg of Gr1, Gr5, or Gr20, or 40 μg of carbon black (CB; particle
control), or DM (vehicle control) by aspiration. Mice were sacrificed at 4 hr (day
0), 1, 7, and 28 days post-exposure. Lung lavage was performed, the fluid and cells
were retained, and indices of lung injury and inflammation were examined.
Particle/aggregate size ranged from ~ 5-300 μm, 0.5-60 μm, and 0.2-5μm for
Gr20, Gr5, and Gr1, respectively, with CB being similar to Gr1. Electron spin res-
onance (ESR) indicated that all Gr samples and CB had low to no surface reactivity
as compared to a positive control (α-quartz). In vitro, ESR showed all Gr samples
induced free radical production by mouse monocytes with significantly greater re-
sponse in Gr20- and Gr5-treated cells compared to Gr1- and CB-treated cells.
Indices of lung injury in lavage fluid were increased for the 40 μg doses of Gr20 and
Gr5 on days 0, 1, and 7 when compared to control. Gr1 (40 μg) produced an in-
crease only at day 7. Increased lung injury in the CB group was comparable to Gr20
and Gr5 on days 1 and 7. Injury decreased in all groups by day 28. Inflammation
was elevated in the 40 μg Gr20, Gr5, Gr1 and CB groups on day 1, but only in the
40 μg Gr20 and Gr5 groups on days 0 and 7. In summary, the larger Gr particles
appeared to produce more toxicity at the early time points post-exposure when
compared to controls.
459 A 28-Days Repeated Dose of Multiwalled Carbon Nanotubes
(MWCNTs) in Sprague-Dawley Rats.
J. Sung2,  B. Choi2,  K. Song2,  J. Kim2,  K. Ahn3,  G. Lee3,  J. Lee5,  J. Shin5,
J. Lee1,  K. Jeon4, 3 and I. Yu1. 1Institute of Nanoproduct Safety Research, Hoseo
University, Asan, Republic of Korea; 2Bioconvergence Department, KCL, Incheon,
Republic of Korea; 3Mechanical Engineering, Hanyang University, Ansan, Republic of
Korea; 4HCT, Icheon, Republic of Korea; 5Occupational Lung Diseases Institute,
Korea Workers’ Compensation Welfare Service, Icheon, Republic of Korea.
There is a lack of available information on the human health and environmental
hazards of MWCNTs. For this reason, the current study investigated the inhalation
toxicity potential of MWCNTs. Eight-week-old rats were divided into 4 groups (10
rats in each group), including the fresh air control (0 mg/m3), low-concentration
group (0.2 mg/m3), middle concentration group (0.5 mg/m3), and high-concentra-
tion group (1.0 mg/m3), and exposed to MWCNTs for 5 days (6 hrs/day) in nose-
only inhalation exposure system. Then the rats were allowed to recover for 1 and 3
months by ceasing the exposure At the end of the study, the rats were subjected to a
full necropsy. Cellular differential counts and inflammatory measurements, such as
albumin, lactate dehydrogenase (LDH), total protein, and cytokines were also
monitored in the a cellular bronchoalveolar lavage (BAL) fluid of the rats exposed
to the MWCNTS for 28 days. Histopathological, hematological and clinical chem-
istry examinations indicated that there were no significant findings related to
MWCNT exposure after 28 days of MWCNT inhalation exposure.
460 Toxic Effects of MWCNT In Vivo and In Vitro.
A. Schlichting1,  C. Ziemann1,  A. Leonhardt2,  R. Susanne1,  S. Dirk1 and
B. Bernd1. 1Fraunhofer ITEM, Hannover, Germany; 2Leibniz Institute for Solid State
and Materials Research, Dresden, Germany. Sponsor: C. Dasenbrock.
Multiwall carbon nanotubes (MWCNT) are discussed to exhibit a toxic potential
depending on their length and fiber-like shape. For this reason, potential adverse
biological effects in vivo (rat) and in vitro (human peritoneal mesothelial
LP9/TERT-1 cells) of MWCNT are investigated in a project funded by the
German BMBF (contract No. 03X0109A). In this project MWCNT data are com-
pared with long amosite asbestos as a positive control and more particle-like
MWCNT (Baytubes®, milled MWCNT, and Printex 90) as negative controls. For
this study costum made MWCNT with different length and diameter were pro-
duced. To investigate the carcinogenic potential of these MWCNT, they were sus-
pended in artificial lung-like medium using a sonotrode. The separated MWCNT
were applied to the rats by intraperitoneal injection. In addition to the carcino-
genicity study, the proliferation of cells in the diaphragm was investigated as a short
time screening test after 3 month, using a BrdU method. To determine cytotoxicity
in vitro LP9/TERT-1 cells were incubated for 24h with the same MWCNT, sus-
pended in culture medium, and the toxic potential was estimated by cell counting
and subsequent calculation of the relative increase in cell count (RICC).
Suspension, size, and distribution of MWCNT were always monitored by SEM.
CNT3 (length: 8.57 μm; diameter: 0,085 μm) and long amosite (length: 13.95
μm; diameter: 0.39 μm) led to significant thickening of the diaphragm, as com-
pared to the negative control. With CNT2 (length: 10.24 μm; diameter: 0.04) a
high amount of BrdU positive cells were noted. In the in vitro study part both
CNT1 (length: 7.91 μm; diameter: 0.037 μm), CNT2, CNT3 and long amosite
asbestos mediated strong reduction in cell number, compared to the particle con-
trols, indicating a marked cytotoxic potential. In conclusion, some MWCNT me-
diate enhanced proliferation in rat diaphragm which may result in mesothelioma
development and certain MWCNT exhibit a cytotoxic potential in mesothelial
cells in vitro.
461 Carbon Nanotubes Enhance Metastatic Growth of Lung
Carcinoma via Up-Regulation of Myeloid-Derived
Suppressor Cells.
M. Shurin1,  A. V. Tkach2,  E. Kisin2,  T. Khaliullin2,  S. Stanley2,  D. Gutkin1,
A. Star4,  Y. Chen4,  G. Shurin1,  V. Kagan3 and A. A. Shvedova2. 1Department of
Pathology, University of Pittsburgh, Pittsburgh, PA; 2PPRB, HELD, NIOSH,
Morgantown, WV; 3Department of Environmental and Occupational Health,
University of Pittsburgh, Pittsburgh, PA; 4Department of Chemistry, University of
Pittsburgh, Pittsburgh, PA.
Expanding applications of nanomaterials, particularly carbonaceous nanoparticles
(CNP), in new technologies, consumer products and biomedicine, imply their in-
creasing levels of manufacturing. There are numerous attempts to utilize nanoparti-
cles for better delivery of drugs and nucleic acid-based therapeutics to disease sites
in the lung, particularly to the lung epithelium. The inhalation of drug nano-for-
SOT 2013 ANNUAL MEETING 99
mulations propelled the development of new strategies in therapy of several human
lung diseases such as asthma, cystic fibrosis, chronic obstructive pulmonary disease,
lung cancer, tuberculosis, etc. Safety and lack of adverse health effects remain the
major pre-requisites for broader applications of these novel technologies.
Toxicological assessments of nano-particles typically are performed on normal ani-
mals. Thus possible effects of CNP on tumor growth have not yet been considered.
The immune system safeguards the host from infections and malignancies.
Recognition and undesirable interactions of CNP with cells of the immune system
may lead to immunomodulation, hence increasing the host’s susceptibility to infec-
tions and cancer. Here, we show that single wall carbon nanotubes (SWCNT) pro-
mote metastatic establishment and growth of Lewis lung carcinoma in C57BL6/J
mice. The effect was mediated by increased local and systemic accumulation of
myeloid-derived suppressor cells (MDSC), as their depletion abrogated pro-tumor
activity in vivo. These data are important for the design of novel theranostics plat-
forms with modules capable of depleting or functionally suppressing MDSC to en-
sure effective immunosurveillance in the tumor microenvironment.
462 IL-33 Modulates Chronic Airway Resistance Changes
Induced by Multiwalled Carbon Nanotubes.
X. Wang,  J. Shannahan and J. M. Brown. Pharmacology & Toxicology, East
Carolina University, Greenville, NC.
As the field of nanotechnology rapidly grows, the potential health hazards for
human exposure rise. We have previously demonstrated that oropharyngeal instilla-
tion of multi-walled carbon nanotubes (MWCNTs) in C57BL/6 mice leads to in-
creases in total respiratory system resistance (R) and Newtonian resistance (Rn),
which is a measure of central airway resistance. In this study, we hypothesized that
IL-33, a critical immune system alarmin, modulates mechanisms of pulmonary
toxicity following exposure to MWCNTs. We assessed lung histology and pul-
monary function in C57BL/6 and IL-33-/- mice 30 days following oropharyngeal
aspiration of MWCNTs. The total number of bronchoalveolar lavage cells and the
recruitment of neutrophils was increased in C57BL/6 mice following MWCNT ex-
posure. In contrast, IL-33-/- mice exposed to MWCNTs did not demonstrate alter-
ations in bronchoalveolar lavage cell content. Furthermore, C57BL/6 mice dis-
played increased inflammation around the airways demonstrated by histopathology
which was unseen in IL-33-/- mice. To determine if these histopathological changes
impact airway resistance, MWCNT exposed C57BL/6 were challenged with cumu-
lative doses of methacholine (Mch) between 1.5 mg/ml and 24 mg/ml. Aerosolized
Mch increased R and Rn in a dose-dependent manner in all groups with MWCNT
instilled C57BL/6 mice responding with significantly higher R and Rn compared
to control C57BL/6 mice. Importantly, increases in R and Rn induced by
MWCNT were dependent on IL-33, as there was no significant difference between
MWCNT treated and control IL-33-/- mice. In conclusion, these results indicate
IL-33 plays an important role in pulmonary toxicity induced by MWCNT by in-
fluencing airway resistance via an inducible inflammatory response. This work sup-
ported by NIH RO1 ES019311.
463 Pulmonary Toxicity Assessment of Multiwalled Carbon
Nanotubes after Single Intratracheal Instillation in a One-
Year Bioassay of Rats.
M. Naya,  N. Kobayashi,  K. Honda,  M. Ema and J. Nakanishi. National Institute
of Advanced Industrial Science and Technology (AIST), Tsukuba, Japan.
Well-dispersed multi-wall carbon nanotubes (MWCNTs) were instilled intratra-
cheally at dosage of 1.0 or 2.6 mg/kg body weight to male Wistar rats. A negative
(vehicle) control, 0.5 mg/mL Triton X-100 was administered in a similar manner.
After instillation, the bronchoalveolar lavage fluid (BALF) was assessed for the in-
flammatory biomarkers, and the lung, liver, kidney, spleen, and cerebrum were ex-
amined histopathologically at 1-day, 3-day, 1-week, 4-week, 3-month, 6-month,
and 12-month post-exposure. Transient pulmonary inflammatory responses were
observed up to 3-month post-exposure. In the histopathological examination, 1.0
and 2.6 mg/kg of MWCNTs deposited in the lungs were phagocytosed by the alve-
olar macrophages and these macrophages were accumulated in the alveoli up to 12-
month post-exposure. There was no evidence of chronic inflammation, such as an-
giogenesis or fibrosis which induced by MWCNT instillation. These results suggest
that MWCNTs were being processed and cleared by alveolar macrophages.
464 Thirteen-Week Inhalation Toxicity Study with a Multiwall
Carbon Nanotube Test Material in Wistar Rats.
D. Schuler1,  K. L. Reed2,  M. P. DeLorme2,  Y. Okazaki1,  Y. Muro4,
H. J. Chevalier3 and D. B. Warheit2. 1Harlan Laboratories Ltd., Fuellinsdorf,
Switzerland; 2DuPont Haskell Lab, Wilmington, DE; 3Anapath GmbH.,
Oberbuchsiten, Switzerland; 4Showa Denko K.K., Tokyo, Japan.
A subchronic inhalation toxicity study of an inhaled vapor-grown multiwall carbon
nanotube (MWCNT) test substance was conducted in male and female Wistar rats.
The test sample was composed of > 99.5% carbon, containing limited (Fe) catalyst
metals; BET surface area measurements of ~25 m2/g; and average lengths/diame-
ters of 9 μm and 100 nm, respectively. Four groups of rats per sex were exposed
nose-only, 6 h/day, for 5 days/week to aerosol concs. of 0, 0.013 (low), 0.055 (mid)
or 0.53 (high) mg/m3 MWCNT (MMAD ranging from 0.85 – 1.64 μm) over a
91-day period and evaluated 1 day later. Toxicity evaluations included clinical and
histopathology methods, and bronchoalveolar lavage fluid (BALF) analyses.
Additional control and high exposure groups were evaluated at 3 months PE.
Results demonstrated that MWCNT exposures produced no significant adverse ex-
trapulmonary effects. Absolute and relative lung weights were increased in high ex-
posure conc. vs. controls and to a lesser extent after the recovery period. The results
of BALF studies demonstrated increased GGT, LDH and ALK PHOS levels vs.
controls in mid/high exposure groups. In addition, increased numbers of BALF
cells were recovered at 0.53 mg/m3 MWCNT. Principal histopathological findings
consisted of granulomatous lesions in centriacinar regions of male/female rats ex-
posed to 0.53 mg/m3, and in some females at 0.055 mg/m3. The lesion was char-
acterized by aggregation of pulmonary macrophages and focal pulmonary hypertro-
phy/hyperplasia of lung epithelial cells. In the nasal cavities, an increase of
eosinophilic inclusions in the respiratory/olfactory epithelium was noted at 0.53
mg/m3 which was followed by the olfactory epithelial injury in the recovery ani-
mals. Based on the findings in respiratory tract tissues (lungs and nasal cavities), the
overall LOAEL was considered to be 0.055 mg/m3, and the corresponding
NOAEL was determined to be 0.013 mg/m3 under the conditions of this study.
465 Carbon Nanotube Dosimetry: From Workplace Exposure
Assessment to Inhalation Toxicology.
M. Dahm1,  B. T. Chen2,  M. E. Birch1,  D. E. Evans1,  M. K. Schubauer-
Berigan1,  T. Hulderman2,  S. A. Bilgesu2,  H. D. Leonard2,  W. McKinney2,
D. Frazer2,  J. M. Antonini2,  D. W. Porter2,  V. Castranova2,  P. C. Zeidler-
Erdely2 and A. Erdely2. 1NIOSH, Cincinnati, OH; 2NIOSH, Morgantown, WV.
Relevant dosimetry for toxicology studies involving multi-walled carbon nanotubes
(MWCNT) has not been well described due to a lack of detailed occupational ex-
posure assessments. In response, exposure assessment findings from U.S.-based
MWCNT manufacturers and users were extrapolated to results of an inhalation
study in mice. Inhalable and respirable personal breathing zone (PBZ) samples
from 9 facilities were collected for the mass concentration of elemental carbon.
Upon analysis, 95% of the PBZ samples found exposure concentrations to be <10
μg/m3 with an average inhalable concentration of 8.5 μg/m3. At facilities where res-
pirable and inhalable PBZ samples were collected, respirable samples were approxi-
mately 25% of the inhalable size fraction. Using 10 μg/m3, standard worker venti-
latory parameters, and assuming 11% alveolar deposition, alveolar deposition was
calculated to be 10.56 μg/d. Extrapolation to mouse equivalence by surface area
equals 5.2 ng/d. In complement, a 19 d inhalation exposure to MWCNT with
daily alveolar depositions of 1250 ng (=240 d of human exposure at 10 μg/m3), 125
ng (=24 d), and 12.5 ng (=2.4 d) was conducted. Mice were sacrificed at day 0, 3,
28, and 84 post-exposure. Pulmonary cytotoxicity (LDH activity) and polymor-
phonuclear cell (PMN) influx were evident at the high dose through day 84. For
the middle dose, no PMN influx was evident and cytotoxicity was significant only
at day 0. Lung inflammatory gene expression was increased at the high and middle
dose. Alveolar macrophages harvested after exposure and stimulated with LPS
showed enhanced cytokine release at the high dose and day 0 for the middle dose.
No exposure effects were observed at the lowest dose. These results show a no effect
dose lies somewhere in between the middle (=456 d at 10 μg/m3) and low dose
(=45.6 d). The findings stress the importance of exposure assessment when extrap-
olating results of animal MWCNT exposures to potential human outcomes.
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466 Pharmacokinetics and Pharmacodynamics of C60 and
Nanosilver in Nonpregnant, Pregnant, and Lactating Rats.
R. Snyder1,  S. Sumner1,  S. Black1,  A. Lewin1,  R. Tyl1,  M. Levine1,
C. J. Wingard2 and T. Fennell1. 1Discovery Sciences, RTI International, Research
Triangle Park, NC; 2Department of Physiology, East Carolina University, Greenville,
NC.
Pregnancy and lactation represent periods in which the female and her offspring
may be more sensitive to adverse effects from exposure to nanoparticles. The distri-
bution of nanoparticles during pregnancy and lactation has not been comprehen-
sively investigated. We therefore examined the absorption, distribution, and excre-
tion of C60 and two sizes of nanosilver (NS) in nonpregnant, pregnant, and
lactating rats. Rats were dosed via tail vein injection with [14C]C60 solubilized
with polyvinylpyrrolidone (PVP) in saline. [14C]C60 was administered to preg-
nant rats on gestational day (gd) 11, 15, or 18 and lactating rats on postnatal day
(pnd) 8. Nonpregnant and pregnant rats (gd 18) were dosed via tail vein injection
(1 mg/kg) or oral gavage (10 mg/kg) with 20 nm or 110 nm NS stabilized with
PVP in water, equivalent doses of silver acetate, or vehicle. Urine, feces, blood, and
tissues were collected following dosing, and quantitative whole body autoradiogra-
phy of [14C]C60 was conducted. The largest portion of the [14C]C60 derived ra-
dioactivity was detected in the liver (~29%), lung (~31%), and spleen (~ 5%) after
a single iv dose in the pregnant rat, and detected in the liver (~54%), lung (~8%),
and spleen (~ 4%) in the lactating rat.  Radioactivity was above background for
many additional tissues. Less than 1% of the radioactivity recovered was found in
urine and feces at all time points for the pregnant rats. The majority (55%) of the
recovered oral 110 nm NS dose was found in feces after 48 hr. Following iv dosing,
11% of the dose was recovered in feces for the 110 nm NS and 27% for the 20 nm
NS. The highest concentration of nanosilver was found in the spleen for both sizes
of NS. Plasma cytokine and urinary 8-hydroxydeoxyguanosine levels were deter-
mined. This study demonstrated substantial differences in the retention of C60
compared with nanosilver. (Supported by NIEHS U19ES019525)
467 Signal Transducer and Activator of Transcription 1 (STAT-1)
Suppresses Pulmonary Inflammation following Allergen
Sensitization & Exposure to Multiwalled Carbon Nanotubes.
E. E. Anderson Thompson,  A. J. Taylor,  E. E. Glista-Baker,  B. C. Sayers and
J. C. Bonner. Environmental and Molecular Toxicology, North Carolina State
University, Raleigh, NC.
Multi-walled carbon nanotubes (MWCNT) pose a potential risk to human health,
especially in individuals with pre-existing lung diseases such as asthma. A key factor
in asthma is an imbalance of T-helper type 1 (Th1) and type 2 (Th2) cells. STAT-1
is a transcription factor that maintains Th1 development. We postulated that mice
deficient in STAT-1 would be susceptible to ovalbumin (OVA) allergen challenge
and display increased airway disease to MWCNT. STAT-1-/- and wildtype (WT)
mice were sensitized to OVA by i.p. injection on days 0 & 12, followed by OVA in-
tranasal challenge on days 26, 28, & 32. On day 34, mice were exposed to 4 mg/kg
MWCNT or saline/0.1% pluronic surfactant by oropharyngeal aspiration.
Necropsy was performed 1 & 21d post-MWCNT exposure. Lungs were lavaged to
collect inflammatory cells and bronchoalveolar lavage fluid (BALF), right lung was
collected for RNA & protein, and left lung for histopathology. Ashcroft scoring of
H&E-stained lung sections revealed that OVA-sensitized STAT-1-/- mice displayed
significantly greater inflammation compared to vehicle control treated STAT-1-/-
mice at 21 d, and this was not exacerbated by MWCNT. However, BALF differen-
tial cell counts revealed that OVA-sensitized STAT-1-/- mice treated with
MWCNT had significantly increased numbers of neutrophils & eosinophils com-
pared to similarly treated WT mice at 21 d. Quantitative morphometry of Alcian
blue PAS & trichrome stained lung sections revealed that the OVA-sensitized
STAT-/- mice also produced significantly more airway mucus and collagen after ex-
posure to MWCNT. ELISA performed on BALF showed significant increases in
the pro-fibrogenic mediators IL-1β, TGF-β1, and osteopontin in the OVA sensi-
tized STAT-1-/- mice treated with MWCNT at 21d. Taken together, these results
suggest that STAT-1 suppresses the exacerbation of lung disease by MWCNT in in-
dividuals with asthma. (Funded by NIEHS RC2 ES018772 and R01 ES020897)
468 Resolution of Inflammatory and Surfactant Alterations
Mediated by Carbon Black and Silver Nanospheres.
D. Botelho1,  S. Sarker2,  F. Chung3,  A. Porter3,  S. Schwander2 and A. Gow1.
1Toxicology, Rutgers The State University of New Jersey, Piscataway, NJ; 2UMDNJ,
Piscataway, NJ; 3Imperial College London, London, United Kingdom.
Environmental exposure to engineered nanomaterials (ENMs) is on the rise, in par-
ticular inhalation exposure. The consequences of ENM interaction with the lung
are not well understood, including the effects on function and inflammation. We
have examined how carbon and silver nanospheres interact with the lung lining and
alter pulmonary function and inflammation. C57Bl6/J male mice were intratra-
cheally instilled with saline (control), low (0.05 μg/g) or high (0.5 μg/g) doses of ei-
ther silver or carbon black 15nm nanospheres. Lung histology, cytology, surfactant
composition and function, inflammatory gene expression, and pulmonary function
were measured at 1, 3, and 7 days post exposure. One-day post exposure, high dose
carbon black resulted in a classic inflammatory response: increased neutrophilia (19
± 0.002 v. 2.5 ± 0.0004 x103 cells), increased cytokine production (IL-1β 2.6 and
IL-6 1.7 mRNA fold induction vs control), peribronchial infiltration, and in-
creased low-pressure lung elastance. Low dose carbon black did not differ signifi-
cantly from control. Examination of these markers 3 days post exposure shows a
classic injury response with neutrophilia (28.7 ± 6.1 vs 2.7 ± 0.2 x103 cells) and in-
creased macrophage numbers (139 ± 0.006 v. 147 ± 2.6 x103 cells at day 1 v. 3). At
day 7, neutrophilia has resolved, while macrophage numbers remain high (198 ±
5.6 x103 cells). Carbon nanospheres persist within recruited macrophages. Neither
low nor high dose silver particles resulted in inflammation 1 day post exposure.
There was significantly increased tissue stiffness compared to control, which was
paralleled by reduced surfactant function and disrupted surfactant protein expres-
sion. Lung function begins to resolve 3 days post exposure to silver particles; how-
ever, there is a delayed inflammatory response which is resolving by day 7. These
data suggest that silver nanoparticles may have a unique toxicological profile that is
dependent upon disruption of lung function.
469 Biocompatibility of Graphene Nanoplatelets in Terminal
Arterioles.
S. Chowdhury1,  M. Frame1,  A. M. Dewar1,  S. Kanakia1,  J. Touissant1,
W. Moore2 and B. Sitharaman1. 1Biomedical Engineering, Stony Brook University,
Stony Brook, NY; 2Radiology, Stony Brook University, Stony Brook, NY. Sponsor: T.
Nurkiewicz.
Carbon-based nanomaterials are currently being tested for a range of medical uses
from drug delivery vehicles to contrast enhancing agents for magnetic resonance
imaging (MRI). Ensuring biocompatibility is essential for each compound and for-
mulation. Our goal was to evaluate the microvascular effect of graphene nanoparti-
cles known as graphene oxide nanoplatelets (GNPs). The hydrophoblic GNPs (20-
60nm by 15-35nm, 3-4nm thick) were water-solubilized via non-covalent
functionalization with 3.5 mg/ml of the biocompatible natural polymer dextran
(GNP-Dex). Adult male hamsters (N=11) were anesthetized (isofluorane) and pre-
pared for intravital microscopy observation of the cheek pouch tissue terminal arte-
rioles; these arterioles control nutrient flow. GNP-Dex (0-50mg/ml) were mi-
cropipette applied to small terminal arterioles (~10um dia., 30s), where 0 mg/ml
was dextran alone, 2.5mg/ml was the projected therapeutic circulation dose, and
50mg/ml was the highest expected i.v. injection dose when used as a drug delivery
or MRI contrast agent. Based on the pipette delivery conditions, the dose of
50mg/ml would expose that arteriole to 127 pg of GNP-Dex. GNP-Dex induced a
dose dependent dilation (EC50 6.9±0.6mg/ml, maximal dilation 70±2% increase
from baseline). Dextran alone was not vasoactive. We next tested whether acute ex-
posure to 50mg/ml induced endothelial dysfunction, a hallmark sign of cardiovas-
cular inflammation. Comparing before vs. after GNP-Dex exposure, dilator
(acetylcholine, 10-4M) and constrictor (phenylephrine, 10-4M) responses were un-
changed, unlike our prior work with single-walled carbon nanotubes, which in-
duced a profound endothelial dysfunction. Thus, the direct effect of GNP-Dex is
dilation, but there is no residual adverse effect of this formulation on terminal arte-
riole control of tone. (NIH HL55492; AHA 0655908T; Wallace H. Coulter
Foundation)
470 In Vitro Penetration of Amine Terminated Dendrimer
Nanoparticles into Pig and Human Skin.
M. E. Kraeling1,  V. D. Topping1,  X. Gao1,  O. A. Ogunsola1,  K. Schlick2,
E. Simanek2,  S. Man3,  A. K. Patri3,  R. L. Sprando1 and J. J. Yourick1. 1Office of
Applied Research and Safety Assessment, US FDA, Laurel, MD; 2Department of
Chemistry, Texas Christian University, Fort Worth, TX; 3Nanotechnology
Characterization Laboratory, SAIC-Frederick, Frederick National Laboratory for
Cancer Research, Frederick, MD.
Dendrimers are highly branched stable polymeric nanoparticles with terminal func-
tional groups capable of binding other molecules. There is concern about the po-
tential for dendrimers to increase skin absorption of ingredients currently consid-
ered safe in cosmetics. We evaluated the skin penetration of amine-terminated
generation 3 (G3), generation 4 (G4), generation 5 (G5) and generation 6 (G6)
polyamidoamine (PAMAM) dendrimer nanoparticles (positive surface charge).
Alexa Fluor 568 (~1 equivalent per dendrimer) was conjugated to terminal amines
on PAMAM dendrimers via amide bonds for confocal imaging. Free unconjugated
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fluorophore was removed by ultrafiltration followed by gel filtration, and character-
ized. Dendrimers were applied (0.2% concentration) in aqueous solutions or cos-
metic emulsion formulation onto viable pig or human cadaver skin assembled in
diffusion cells. After a 24 hour exposure, the skin surface was washed to remove un-
absorbed dendrimer. The extent of skin penetration was determined by laser scan-
ning confocal microscopy. Most fluorescence from the applied dendrimers ap-
peared on or in the stratum corneum, in hair follicles, or in folds of both pig and
human skin. Fluorescence appeared in the upper regions of the epidermis of pig
skin with the small generation dendrimers using both the solution and emulsion
application. Fluorescence also appeared deeper in the dermal layers of pig skin
when smaller generation dendrimers were applied at a higher dose. In human skin,
small generation dendrimers penetrated skin at the low and high dose application.
Dendrimers applied in emulsions did not penetrate beyond the stratum corneum of
human skin. Further studies will examine dendrimer surface functionalization on
skin penetration.
471 Identifying Data Gaps and Prioritizing Research Areas
Necessary for Risk Assessment of Multiwalled Carbon
Nanotubes.
K. Fedak,  A. Turner,  A. Harris and D. Burch. ICF International, Durham, NC.
The pace of chemical hazard assessment has not maintained pace with the intro-
duction of new chemicals into the market place, with much of the growth in con-
sumer products applications. As a result, scientists must prioritize resources towards
research that fills key data gaps and enables better risk assessment and management.
The application of the first step of an iterative comprehensive environmental as-
sessment (CEA) process is used to describe hazard and identify research priorities as
well as inform risk management decisions for a range of different chemicals, prod-
ucts, and technologies. The CEA framework allows risk assessors to evaluate the
state-of-the-science regarding a new chemical for application in hazard assessment.
A case study on an emerging nano-enabled consumer product—multiwalled car-
bon nanotube flame retardant coatings on upholstery textiles—was conducted
using the CEA framework to identify what is known and not yet know about the
substance. Side-by-side information on decabromodiphenyl ether (decaBDE), a
non-nanoenabled flame retardant that is currently in the process of being phased
out, was presented as a comparison to illustrate the suitability of available
MWCNT data for informed risk assessment and risk management decisions. For
each material, the case study synthesized the available data on primary and second-
ary contaminants, analytical techniques, fate and transport processes, cumulative
and aggregate exposure, and ecological and human health impacts throughout the
life cycle of the product. The case study was subsequently used as an informative
tool in a stakeholder-involved collective judgment process to identify data gaps and
prioritize research areas critical to future risk assessment of MWCNTs and carbon
nanomaterials in general. 
Disclaimer: The views expressed in this abstract are those of the authors and do not
necessarily represent the views or policies of the U.S. Environmental Protection
Agency.
472 Association of Rice and Grain Consumption with Urinary
Concentrations of Total Arsenic and Dimethylarsonic Acid in
US Adults.
Y. Wei1,  J. Zhu2 and A. Nguyen1. 1Department of Community Medicine, Mercer
University School of Medicine, Macon, GA; 2Department of Mathematics and
Computer Science, Fort Valley State University, Fort Valley, GA.
Exposure to inorganic arsenic in the general population occurs mainly from drink-
ing water and food sources. In the United States, levels of exposure are relatively low
and the drinking water might not be the main source of exposure, compared to
those endemic regions where the pump well water has been used as drinking water
supply. To this end, we examined the association between dietary intake and uri-
nary concentrations of arsenic in the U.S. adult population, aged 20-85 years, in
the 2003-2006 National Health and Nutrition Examination Survey. Total arsenic
(tAs) and dimethylarsonic acid (DMA) were detected in urine of 99% and 87% of
the study participants, respectively, and were analyzed in the study. Statistical analy-
ses were performed using SAS 9.3. To control for urine dilution in spot urine sam-
ples, creatinine-adjusted urinary concentrations of tAs and DMA were determined.
Urinary concentrations of tAs and DMA were categorized into low and high expo-
sure groups by a cutoff value of 50th percentiles. A significantly higher percentage
of high exposure to both arsenic species was found in participants who consumed
rice and grain ≥ once per week, compared to the reference group with consumption
< once per week (55.67% vs. 45.33% for tAs; p<0.0001 and 59.61% vs. 43.48%
for DMA; p<0.0001). Logistic regression analysis revealed a statistically significant
association between rice and grain consumption and urinary concentrations of tAs
[adjusted OR=1.39 (1.03, 1.87)] and DMA [adjusted OR=1.97 (1.41, 2.74)] after
adjustment for age, gender, race, family income, education, seafood intake (the
main source of organic arsenic), and source of drinking water. This study demon-
strated that rice and grain consumption contributed to inorganic arsenic exposure
in U.S. adults. Racial groups consuming high amounts of rice and grain showed
significantly higher exposure to arsenic, especially to DMA.
473 Prenatal Exposure to Inorganic Arsenic in Gómez Palacio,
Mexico, Links to Contaminated Drinking Water.
J. E. Laine2,  M. Rubio-Andrade4,  A. F. Olshan2,  M. Styblo3,  G. G. Garcia-
Vargas4 and R. C. Fry1. 1Environmental Sciences and Engineering, University of
North Carolina at Chapel Hill, Chapel Hill, NC; 2Epidemiology, University of North
Carolina at Chapel Hill, Chapel Hill, NC; 3Nutrition, University of North Carolina
at Chapel Hill, Chapel Hill, NC; 4Facultad de Medicina, Universidad Juarez del
Estado de Durango, Gómez Palacio, Mexico.
Exposure to inorganic arsenic (iAs) from drinking water is a global public health
problem, however much is still unknown about the amount of exposure in suscep-
tible populations, such as pregnant women. The aim of this study is to examine ar-
senic (As) exposure levels in a new prospective cohort in Gómez Palacio, Mexico.
IAs and its methylated metabolites (e.g. methylarsonic acid (MMA) and dimethy-
larsinic acid (DMA)) were measured in a cohort of pregnant women in Gómez
Palacio, Mexico. Levels of As in drinking water and urine were measured using hy-
dride generation atomic absorption spectrometry (AAS). In the case of urine analy-
sis, As species were separated by cryotrapping in liquid nitrogen prior to AAS de-
tection. All women had detectable levels of As in their drinking water (n=202). The
mean iAs concentration in drinking water was 24.5 ug/L, with a range of 0.46 ug/L
to 236 ug/L. Over half (n=107) of women’s household samples had values that were
above the WHO’s safe drinking water guidelines of 10 ug/L, and 21 percent were
above the MCL (50 ug/L) for Mexico. There was an association with iAs in drink-
ing water and urine (p<0.01). Most women (n=188) had detectable levels of As in
their urine. Mean concentrations were 46.7 ug/L, 6.8 ug/L, and 35.3 ug/L for total
iAs, total MMA and total DMA, respectively. These data show that pregnant
women are exposed to iAs in their drinking water in Mexico. Findings from this
study support the need for further investigation into the association of health ef-
fects from prenatal exposure to arsenic contaminated drinking water.
474 Is the Relationship Between Prenatal Exposure to
Polychlorinated Biphenyls (PCB) and Birthweight
Attributable to Pharmacokinetics?
M. Verner1, 2,  R. McDougall3,  A. Glynn4,  M. E. Andersen5,  H. J. Clewell5 and
M. P. Longnecker6. 1Channing Laboratory, Brigham and Women’s Hospital, Harvard
Medical School, Boston, MA; 2Institute of Environmental Medicine, Karolinska
Institutet, Stockholm, Sweden; 3Faculty of Engineering and Applied Science,
University of Ontario Institute of Technology, Oshawa, ON, Canada; 4Swedish
National Food Administration, Uppsala, Sweden; 5The Hamner Institutes for Health
Sciences, Research Triangle Park, NC; 6Epidemiology Branch, National Institutes of
Environmental Health Sciences, Research Triangle Park, NC.
Epidemiologic studies have reported an association between exposure to PCBs and
reduced birthweight. However, gestational weight gain is associated negatively with
PCB levels during pregnancy and positively with birthweight, so whether the re-
ported association is mainly driven by noncausal, pharmacokinetic effects is un-
clear. We evaluated the influence of gestational weight gain on the association be-
tween PCB exposure and birthweight using a previously developed physiologically
based pharmacokinetic (PBPK) model that was modified to account for the rela-
tions between maternal weight and fat gain and birthweight. We ran Monte Carlo
simulations to generate realistic profiles of blood PCB-153 levels throughout preg-
nancy. The association between PCB-153 levels and birthweight was evaluated in
the simulated population using linear regression analyses. We observed a small neg-
ative association between maternal blood levels and birthweight. In models that did
not adjust for maternal weight gain, at delivery, a 69 g decrease in birthweight was
observed for each 10-fold increase in blood PCB-153. However, the effect size was
reduced to 8 g when we adjusted for gestational weight gain. Results from this
study suggest that the association between prenatal exposure to PCBs and birth-
weight is strongly confounded by gestational weight gain. Epidemiologic studies on
lipophilic persistent organic pollutants that do not control for gestational weight
gain may strongly overestimate the size of the association.
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475 Association of Serum Levels of PCBs with IL-8 mRNA
Expression in Blood Samples from Asthmatic and
Nonasthmatic Japanese Children.
M. Tsuji1, 2,  T. Kawamoto2,  C. Koriyama3,  S. Akiba3,  C. Vogel1,  Y. Hsu-Sheng2
and F. Matsumura1. 1Department of Environmental Toxicology and the Center for
Health and the Environment, University of California Davis, Davis, CA;
2Department of Environmental Health, University of Occupational and
Environmental Health, Kitakyusyu, Japan; 3Department of Epidemiology and
Preventive Medicine, Kagoshima University Graduate School of Medical and Dental
Sciences, Kagoshima, Japan.
Polychlorinated biphenyls (PCBs) are one of the most commonly found toxins in
the environment. One suggested outcome of PCB exposure during early develop-
mental periods in humans is childhood asthma. The primary objective of the cur-
rent study was to clarify the causal relationship between PCB exposure and devel-
opment of childhood asthma through the development of reliable biomarkers.
Blood samples from fifteen asthmatic children and an equal number of non-asth-
matic children (averaging 2 years of age) were collected and analyzed for select
marker expression using qRT-PCR. At the time of collection, an interview included
questions about the number of siblings, duration of breast feeding, smoking habits
of parents, the parental history of allergic diseases and history of allergies of the
study subjects.
Among biomarkers examined IL-8 expression was significantly correlated to serum
levels of PCB #163+#164 (P=0.022), #170 (P=0.046), #177 (P=0.022), #178
(P=0.022) and #180+#193 (P=0.046) in a dose-dependent manner, which was
found only among asthmatic children. In contrast to IL-8, significant correlations
between COX-2 mRNA levels and individual congener levels were recognized only
among control subjects, and not among asthmatic subjects.
In conclusion, the most important finding from the current study is that there exist
significant correlations between children’s exposure to PCBs and the occurrence of
childhood asthma, which could be recognized by the use of a reliable biomarker
such as IL-8 and selecting certain individual PCB congeners.
476 Pulmonary Function Testing in Emergency Responders.
S. Harbison,  G. Johnson,  J. McCluskey,  P. Xu,  S. Morris,  J. Wolfson and
R. D. Harbison. Environmental and Occupational Health, University of South
Florida, Tampa, FL.
Emergency responders may be exposed to a variety of fumes, gases, and particulates
during the course of their job that may affect pulmonary function (PF) and may re-
quire the use of respiratory protection. This investigation used occupational health
monitoring examination data to characterize PF in a population currently em-
ployed as emergency responders in the state of Florida. PF tests for workers (n=127)
who required health examinations to ensure fitness for continued respirator use
were compared to NHANES III Raw Spirometry subjects (n=9,792) to determine
if decreased PF was associated with employment as an emergency responder. Mean
FVC and FEV1 values were determined and multivariate regression was used to
evaluate the impact of emergency responder status on PF after adjusting for con-
founders. Emergency responders produced a higher mean FVC of 5.11L (95%CI
4.95-5.26) compared to a mean NHANES III subject value of 4.01L (95%CI
3.99-4.03) (p=<0.0001). Emergency responders also produced a higher mean
FEV1 of 4.06L (95%CI 3.92-4.19) compared to a mean NHANES III subject
value of 3.21L (95%CI 3.19-3.23) (p=<0.0001). Stratification by age, sex, height,
and smoking history yielded similar results. Multivariate regression analysis demon-
strated significant predictors of FEV1 included age, height, sex, smoking history,
and emergency responder status (p=<0.0001). Significant predictors of FVC in-
cluded age, height, sex, and emergency responder status (p=<0.0001). The direc-
tion of effect for emergency responder status was beneficial for lung function (para-
meter estimates 0.45L FEV1 and 0.54L FVC). Logistic regression was used to
determine the effect of PF predictors on generating and FEV1/FVC ratio less than
0.8. Emergency worker status was not associated with the production of a
FEV1/FVC ratio less than 0.8. The modest increase in PF observed in emergency
responders in multivariate analysis is likely due to a combination of effective expo-
sure controls in the workplace and the healthy worker effect among aging workers.
477 Association between Copper, Iron, and Zinc Levels in Private
Wells and Birth Defects Prevalence in North Carolina.
A. P. Sanders1,  T. A. Desrosiers1, 2,  A. H. Herring1,  D. Enright2,  A. F. Olshan1,
R. E. Meyer2 and R. C. Fry1. 1University of North Carolina Chapel Hill, Chapel
Hill, NC; 2State Center for Health Statistics, Division of Public Health, Raleigh, NC.
Environmental metals including copper, iron and zinc are typically considered es-
sential metals that are able to cross the placental barrier from mother to fetus. In ex-
cess, however, many essential metals are developmental toxicants. In this popula-
tion-based study, we assessed the association between essential metal concentrations
in private well water and birth defect prevalence in North Carolina. We conducted
an ecologic study including 3,923 infants born between 2003 and 2005 with se-
lected birth defects (cases) identified by the North Carolina Birth Defects
Monitoring Program, and 347,587 non-malformed infants (controls). Residence at
birth as well as over 20,000 measurements of metal concentrations in residential
wells were geocoded. Analyses were conducted at the Census Tract level. Prevalence
ratios (PR) with 95% confidence intervals (CI) were calculated to estimate the as-
sociation between average concentration of each metal within Census Tracts and
the prevalence of birth defects, adjusted for maternal age and race. The highest
quartile of iron exposure was associated with a higher prevalence of conotruncal
heart defects (PR: 2.2; 95%CI: 1.1-4.1) and a decreased prevalence of chromoso-
mal defects (PR: 0.5; 95%CI: 0.3-0.9). In addition, the highest quartile of zinc ex-
posure was associated with a higher prevalence of heart defects (PR: 2.3; 95%CI:
0.7-7.1) and reduction defects of the limbs (PR: 1.7; 95%CI: 0.8-3.5). Sensitivity
analyses revealed similar associations. Our findings suggest evidence of a possible
relationship between levels of environmental metals in drinking water and specific
birth defects. Further research is needed to evaluate the potential associations.
Given the known health effects of in utero metal exposure, these data suggest that it
would be prudent for pregnant women relying on private wells for drinking water
to have their wells tested.
478 Lack of an Association between Cumulative Exposure to
Diacetyl and Changes in Pulmonary Health among Workers
at a Food Flavorings Manufacturer.
C. J. Ronk,  D. M. Hollins,  M. J. Jacobsen,  A. M. Foda,  D. A. Galbraith and
D. J. Paustenbach. ChemRisk, San Francisco, CA.
Declines in metrics of pulmonary health have recently become a topic of interest
for researchers studying the health effects of inhalation exposures to food flavorings
such as diacetyl. To study the effects that occupational exposures to food flavorings
may have on declines in the metrics, forced expiratory volume in one second
(FEV1) and forced vital capacity (FVC), we examined data on a cohort of workers
at a food flavorings manufacturer. Data were extracted from medical records, pul-
monary health records, employment records, and industrial hygiene records to as-
sess and estimate changes in FEV1 and FVC over time in relation to cumulative ex-
posure to diacetyl and time worked in job positions that involve the handling and
use of diacetyl and other food flavorings. Through the use of these data, tenure in
various job tasks was calculated and linked with industrial hygiene data on diacetyl
to form a job-exposure matrix and estimates of cumulative exposure (e.g., dose).
For this analysis, total cumulative exposure for each worker was estimated by sum-
ming area-specific cumulative exposures (i.e., time spent in each work area multi-
plied by the median 8-hour time weighted average of diacetyl measured in those
areas). Generalized estimating equation (GEE) models were used to evaluate the as-
sociations between cumulative dose to diacetyl and declines in FEV1 and FVC.
GEE models were adjusted for obesity status, change in weight, hypertension sta-
tus, age, race/ethnicity, gender, and smoking status. It was found that cumulative
dose did not significantly affect changes in FEV1 (p=0.42) or FVC (p=0.34). The
associations between tenure at the facility and changes in FEV1 and FVC were not
statistically significant (p=0.79 and p=0.40, respectively). Tenure in positions that
handled food flavorings was not associated with changes in FEV1 (p=0.49) or FVC
(p=0.56). In this cohort of food flavoring manufacturing workers, changes in FEV1
and FVC over time were not affected by exposure to diacetyl.
479 DDT/DDE and Breast Cancer: NHANES 1999-2004
Analyses and a Meta-Analysis.
S. Z. Ingber,  F. Scinicariello,  H. R. Pohl,  H. G. Abadin and H. Murray.
DTHHS, ATSDR/CDC, Chamblee, GA. Sponsor: P. Ruiz.
The biological basis for an investigation of dichlorodiphenyltrichloroethane
(DDT) exposure and breast cancer risk stems from research indicating that DDT
has estrogenic effects in both in vitro and animal systems. A meta-analysis report
published in 2004 by Lopez Cervantes et al. found no relationship between DDE
and breast cancer. 
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The objective of this study was: (1) to update the Lopez Cervantes meta-analyses
and, (2) to analyze NHANES 1999-2004 data for any relationship between DDE
exposure and breast cancer prevalence.
Methods Meta-Analyses: PubMed and Web of Science databases were searched for
studies published through June 2012 assessing DDT exposure and breast cancer.
From the 500 studies screened, 40 studies were used for the meta-analyses to quan-
tify the summary Odds Ratios (OR) for breast cancer to DDT exposure in the
highest versus the corresponding lowest exposed group. Both random and fixed ef-
fect models were used. Heterogeneity across studies was calculated using the I2
measure of inconsistency. Heterogeneity was resolved through stratification analy-
ses by study design, tissue sample type, and control population. Publication bias
was assessed by the Begg and Egger tests.
Survey Analyses: Data from NHANES 1999–2004 female participants aged 20
years and older for levels of DDE were analyzed in relation to self-reported breast
cancer (n=51). Logistic regression models were adjusted for age, race/ethnicity, ed-
ucation, alcohol intake, smoking status, body mass index and c-reactive protein. 
Results: Slightly elevated, but not statistically significant summary ORs were found
for the selected studies for DDE (1.05; 95%CI: 0.93 – 1.18) and DDT (1.02;
95%CI: 0.92 -1.13). Logistic regression of NHANES data showed that women in
the higher serum DDE tertile had a not-statistically significant OR (0.89; 95% CI:
0.27 – 2.94; p= 0.75) to have breast cancer compared to those in the lowest serum
DDE tertile.
Conclusion: The existing information does not support the hypothesis that expo-
sure to DDT/DDE increases the risk of breast cancer in humans.
480 Assessing Model Prediction Quality for a Dynamic
Population Simulation Model (DPSM).
J. P. Monteleone1,  R. Gunawan1 and K. Lee2. 1Pharsight Corporation, Cary, NC;
2JT International SA, Geneva, Switzerland.
An increasing amount of tobacco-control literature use DPSMs to predict changes
in tobacco-related excess mortality (EM) and smoking prevalence (SP), typically
using point estimates as model inputs. Point estimate information is often criticized
because estimates are based on limited data and difficult to defend resulting in po-
tentially questionable model predictions. One method for testing prediction quality
is sensitivity analysis (SA), which tests predictions using specific values for point es-
timates. Unfortunately, for complex models, only limited subsets of values are typi-
cally tested. An alternative method uses a prediction interval (PI), which provides
information on the expected distribution of the predictions from numerous ran-
domly generated sets of point estimates. In this study, these methods for assessing
prediction quality were evaluated using a tobacco-related DPSM from the litera-
ture. After reproducing the DPSM, a SA was performed using the author’s simula-
tion scenarios (consisting of a limited selection of point estimate model inputs). A
PI was also constructed by applying a uniform distribution to the minimum and
maximum values for each of the model inputs and randomly drawing samples
(using Monte Carlo simulation) to create 1,000 unique sets of model inputs.
Predictions for EM or SP were simulated annually for the years 2010 to 2050. A
90% PI plot was created by removing the highest and lowest 5% of the predicted
values for each of the 40 years. When the two approaches were compared, most of
predictions from the author’s SA fell within the PI, while the SA results were con-
strained to only a small region of the PI, most likely because only a limited number
of scenarios were tested. Furthermore, the PI demonstrated how variability among
multiple model inputs can interact with each other by illustrating expected variabil-
ity in the EM or SP predictions. A PI approach may therefore prove robust and ef-
ficient, compared to SA, in assessing how well point estimate model inputs predict
outcomes from complex simulation models.
481 Multiple Myeloma Risk and Benzene Exposure among
Pliofilm Workers—A Reanalysis Using an Internal Reference
Group.
S. Lamm1,  J. Britt2 and R. James2. 1Consultants in Epidemiology and Occupational
Health, Washington DC; 2ToxStrategies, Tallahassee, FL.
The Pliofilm worker cohort (Rinsky et al., 2002) is comprised of 1,291 benzene-ex-
posed and 554 unexposed workers with follow-up for leukemia and multiple
myeloma (MM) mortality through 1996. Five of the exposed workers and three of
the unexposed workers died from MM. Prior risk analyses of this benzene cohort
were limited to the exposed cohort using U.S. death rates as the external reference
population. We propose, for this cohort whose unexposed group is 43% the size of
the exposed population (545/1,291 = 43%), that the risk analysis be done by using
the unexposed population as an internal reference group. The crude mortality ratio
(CMR) for MM for the exposed population (5/1,291 = 0.004) is 0.4 % (95% CI,
0.1-0.9), and CMR for the unexposed population (3/554=0.005) is 0.5% (95%
CI, 0.1-1.6). The relative risk is 0.72 (95% CI, 0.17-2.98; Fisher two-tailed p-
value, 0.70). When the analysis is limited to males as all the MM deaths were male,
the relative risk is 0.62 (95% CI, 0.15-2.59, Fisher two-tail p-value = 0.45). The
CMR analysis indicates that the MM risk in benzene-exposed workers is actually
not greater than that of the unexposed. The marginally lower difference seen here is
not significant. These results, like others reported in the literature, reinforce the im-
portance of examining an internal reference group analysis when evaluating the po-
tential risks associated with occupational chemical exposures. Analytic use of an in-
ternal reference population reduces bias from the healthy worker effect or other risk
factors associated with employment.
482 Expression of DNA Repair Genes in Breast Cancer Tumors
from Puerto Rican Women.
J. L. Matta1,  L. Morales1,  A. Cruz2,  M. Bayona3,  J. Dutil4,  A. Gjyshi5,
A. Monteiro5 and E. Suarez6. 1Pharmacology Physiology and Toxicology, Ponce
School of Medicine and Health Sciences, Ponce, Puerto Rico; 2Hematology-Oncology
Fellowship Program, SJCH with VACHS, San Juan, Puerto Rico; 3US FDA, Division
of Epidemiology/OSB/CDRH, Silver Spring, MD; 4Biochemistry, Ponce School of
Medicine and Health Sciences, Ponce, Puerto Rico; 5H. Lee Moffitt Cancer Center,
Tampa, FL; 6Cancer Epidemiology Program, University of Puerto Rico, Ponce, Puerto
Rico.
DNA repair is a critical defense system in the human body aimed at protecting the
integrity and stability of the genome from the harmful effects of cancer-causing
agents. Specific genetic alterations in DNA repair genes have been clinically associ-
ated with risk, survival, aggressiveness, and treatment outcome of breast cancer
(BC). Even though diminished DNA repair capacity is recognized as a risk factor
for BC, no studies to date have identified gene expression profiles in tumors from
Puerto Rican women. Study participants were women with histopathologically
confirmed primary BC (n =35) and normal breast tissue obtained during cosmetic
surgery (n=2). Tumors were snap frozen in liquid nitrogen and RNA was extracted.
Microarrays data were obtained from Affymetrix Plus 2.0 chip to assess whole
genome gene expression. The assessment of differentially expressed genes was per-
formed using Permutation method with 5% false discovery rate. Genome-wide
gene expression levels were initially measured using the Affymetrix Plus 2.0 array,
and DNA repair genes showing significant changes in expression levels were vali-
dated by RT-PCR.  Most of the DNA repair genes were over expressed. Twenty-
three candidate DNA repair genes were found to be differentially expressed (in-
cluding PARP-1, therapeutic target). Of these 21 were overexpressed and 2 were
underexpressed (p<0.001). This is the first report of DNA repair candidate genes in
Puerto Rican women with BC, a population with mixed ancestry. Supported by
grants S06 GM008239-20, 1SCA157250-2 and 5U56CA126379 from the NCI
Center to Reduce Health Disparities and NIH-MBRS Program (NIGMS).
483 Investigation of Route-Dependent Exposure and Metabolism
of Bisphenol A (BPA) in Neonatal Mice following Oral and
Subcutaneous Administration of 3H-BPA.
D. Draganov1,  D. Markam2,  D. Beyer3,  J. Moore1,  T. Riehl1,  J. Waechter2,
S. Dimond4,  R. Shiotsuka5,  K. Ehman6 and S. Hentges7. 1Metabolism, WIL
Research, Ashland, OH; 2The Dow Chemical Co., Midland, MI; 3Bayer Healthcare
AG, Wuppertal, Germany; 4SABIC, Pittsfield, MA; 5Bayer Material Science,
Pittsburgh, PA; 6TRS, Inc., Charlottesville, VA; 7ACC, Washington DC.
Orally administered bisphenol A (BPA) undergoes efficient first-pass metabolism in
the liver to produce inactive metabolites, including BPA-glucuronide (BPA-G) and
BPA-sulfate (BPA-S). The current study was conducted to evaluate the pharmaco-
kinetics of BPA and its conjugated metabolites, specifically BPA-G and BPA-S, in
juvenile mice following a single oral or subcutaneous (SC) administration. This
study had 3 phases: 1) Mass-balance phase in which effective dose delivery proce-
dures for oral or SC administration of 3H-BPA to post natal day (PND) 3 mouse
pups were developed; 2) Pharmacokinetic phase during which systemic exposure to
total 3H-BPA-derived radioactivity in female PND 3 mice was established; and 3)
Metabolite profiling phase in which two groups of 50 female PND 3 mice received
either a single oral or SC dose of 3H-BPA at 400 μg/kg bw with ≈ 4.4 mCi/kg bw
of radioactivity. Blood was collected from 5 pups/route/time point at 5, 10, 20, and
30 minutes, and 1, 2, 3, 4, 6, and 24 hours post-dosing and processed to plasma.
The plasma samples were pooled by group and time point and profiled by HPLC
with fraction collection. Fractions were analyzed for total radioactivity and data
used to generate radiochromatograms and integrate individual peaks. The identity
of the BPA, BPA-G and BPA-S peaks was confirmed using authenticated standards
and LC-MS/MS analysis. Metabolic profiles and key parameter as AUC0-24hr and
Cmax were derived for free-BPA, BPA-G and BPA-S. The result of this study re-
vealed that female PND 3 mice have metabolic capacity to metabolize BPA to BPA-
G, BPA-S and other metabolites after both routes of administration and that sys-
temic exposure to free-BPA is route-dependent as the plasma concentrations were
lower following oral administration compared to SC injection.
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484 Disposition and Kinetics of Tetrabromobisphenol a (TBBPA)
in Female Wistar-Han Rats.
G. A. Knudsen,  J. M. Sanders,  A. M. Sadik and L. S. Birnbaum. Toxicology and
Toxicokinetics, NCI at NIEHS, Research Triangle Park, NC.
Tetrabromobisphenol A (TBBPA) is the brominated flame retardant with the
largest production volume (~150,000 tons/year), representing nearly 60% of all
worldwide demand for brominated flame retardants. TBBPA is used in printed cir-
cuit boards, ABS plastic casings, and laminates. Studies were conducted to charac-
terize the disposition and toxicokinetic profile of TBBPA in female Wistar-Han rats
following single oral bolus (25, 250 or 1,000 mg/kg) or intravenous (25 mg/kg) ad-
ministration. All dosing solutions provided 50 μCi/kg of [14C]-labeled TBBPA. 
Following oral administration of [14C]-TBBPA the primary route of elimination of
radioactivity was in feces; dose recoveries in 72h were 95.7±3.5%, 94.3±3.6% and
98.8±2.2%, respectively. After a single IV administration of 25 mg/kg of [14C]-
TBBPA, ~10% of the administered radioactivity was eliminated in the feces within
6h. Recoveries in urine ranged from 0.2-2% of dose. Less than 0.1% of the admin-
istered [14C]-radioactivity was detected in tissues collected at 72h following oral
doses. Preliminary toxicokinetic profiles were estimated based on total [14C]-ra-
dioactivity detected in whole blood. Oral dosing (250 mg/kg) resulted in a rapid
absorption of compound, with an apparent Cmax occurring at 3h post-dose and
the subsequent distribution phase was consistent with a one-compartment model.
Following IV administration (25 mg/kg), [14C]-radioactivity concentrations in
whole blood decreased rapidly with less than 2% of the administered radioactivity
remaining at 6h post dose. The time-concentration profile for total [14C]-radioac-
tivity following IV administration of [14C]-TBBPA was consistent with a two
compartment model. These early results suggest low systematic bioavailability.
These data indicate that TBBPA has a similar ADME/TK profile in female Wistar-
Han rats as that reported for male Fischer-344 rats. This research was supported in
part by the Intramural Research Program of NIH/NCI; this abstract may not re-
flect official NIH policy.
485 Investigation of BPA-Glucuronide As a Substrate for Human
BCRP, MDR1, MRP2, and MRP3 Transporters.
M. V. Driscoll and A. L. Slitt. Biomedical and Pharmaceutical Sciences, University
of Rhode Island, Kingston, RI.
Bisphenol A (BPA) is a chemical used in plastic manufacturing that is present in
polycarbonate bottles, food containers, and resins that line metal cans. Exposure to
BPA occurs mainly through consumption of food products that are in direct con-
tact with plastics and polycarbonates. Recently, BPA exposure in humans has been
linked to the development of obesity and diabetes, as well as having effects on re-
productive health and cancer. BPA is metabolized to BPA-glucuronide (BPA-gluc)
and BPA-sulfate by Phase II enzymes and is eliminated by ATP-binding cassette
(ABC) transporters. In humans, BPA-gluc is predominantly excreted through
urine, whereas in rodents, it is excreted through bile into feces. One class of ABC
transporters, multidrug resistance-associated proteins (MRPs) is thought to be in-
volved in BPA clearance. There are nine known human MRPs (MRP1-9), and
mouse orthologs exist for all human MRP genes except MRP8. Multidrug resist-
ance protein (MDR1) and breast cancer-resistant protein (BCRP) are also possible
transporters for BPA metabolites. However, despite numerous studies, the mecha-
nism of BPA metabolite clearance remains unclear. In this study we examined
whether BPA-gluc is a substrate for human xenobiotic transporters BCRP, MDR1,
MRP2, or MRP3. Membranes expressing human BCRP, MDR1, MRP2, or MRP3
were used in a colorimetric ATPase assay. The amount of inorganic phosphate (Pi)
released from BPA-gluc-stimulated ATP hydrolysis was measured. Preliminary data
suggest that BPA-gluc is a substrate for MRP3 (Km: 48.2 μM). Furthermore, BPA-
glucuronide is a potential activator of MRP2 at low concentrations, with an ATPase
transporter activation >30% at 0.046 μM, but inhibits transport at higher concen-
trations. Low to negative percent ATPase activation values for MDR1 strongly sug-
gests that MDR1 is inhibited by BPA-glucuronide. As differences exist between ro-
dents and humans, identification of the ABC transporters involved in BPA
clearance will be an important tool in the pharmacokinetic assessment of BPA.
486 A Physiologically-Based Pharmacokinetic Model for
Bisphenol A in Rats at Different Developmental Ages.
X. Yang,  D. R. Doerge and J. W. Fisher. National Center for Toxicological Research,
US FDA, Jefferson, AR.
Bisphenol A (BPA) is an industrial chemical that has been used in the manufacture
of a wide variety of consumer products such as hard plastic products and the lining
of metal food and beverage cans. Widespread exposure to BPA has raised public
health concerns about BPA in food and the environment. A physiologically based
pharmacokinetic model (PBPK) was developed to describe the pharmacokinetic be-
havior of BPA and its metabolites (Phase II conjugates) in adult and neonatal rats.
The model was calibrated using published BPA studies on in vitro hepatic and in-
testinal metabolism, in vivo biliary excretion of BPA metabolites, and in vivo serum
time course data after oral and intravenous administration of BPA. Metabolism of
BPA in the small intestine was predicted to substantially reduce the oral bioavail-
ability of BPA and enterohepatic recirculation of BPA metabolites was predicted to
prolong the systemic levels of BPA and its metabolites. The dosimetry of the agly-
cone BPA was age-dependent, in part, because of immature phase II metabolism in
neonatal rats.
487 Dose-Response Relationship of an Environmental Mixture of
Pyrethroids following an Acute Oral Administration in the
Rat.
M. F. Hughes1,  D. G. Ross1,  J. M. Starr2,  E. J. Scollon1, 3,  M. J. Wolansky4,
K. M. Crofton1 and M. DeVito1, 5. 1ORD/NHEERL, US EPA, Research Triangle
Park, NC; 2ORD/NERL, US EPA, Research Triangle Park, NC; 3OPP/HED, US
EPA, Arlington, VA; 4University of Buenos Aires, Buenos Aires, Argentina;
5NIEHS/NTP, Research Triangle Park, NC.
Human exposure to multiple pyrethroid insecticides may occur because of their
wide use on crops and for residential pest control. To address the potential risk from
exposure to pyrethroids, it is important to understand their toxicity and disposition
in target organs such as the brain and surrogates such as the blood. The objective of
this study was to compare motor activity with pyrethroid concentrations in blood
and brain of rats after oral administration of a pyrethroid mixture. Male Long-
Evans rats were dosed with a mixture of β-cyfluthrin (12.9% of dose), cyperme-
thrin (28.8%), deltamethrin (3.4%), esfenvalerate (2.7%) and cis- (20.9%) and
trans-permethrin (31.3%) in corn oil at one of seven doses (maximum total
pyrethroid dose – 27.4 mg/kg). From 2 to 3 h post-administration, gross motor ac-
tivity was assessed. At 3.5 h, blood and brain were collected and analyzed for parent
pyrethroid using HPLC-tandem mass spectrometry. There was a linear dose-related
increase in concentrations of the pyrethroids in blood and brain. Cypermethrin
(56-62%) and cis-permethrin (57-70%) were the predominant pyrethroids de-
tected in blood and brain, respectively, at all dose levels. The pyrethroids with the
lowest percentage in tissue were trans-permethrin (0.6-2.7%) and β-cyfluthrin
(0.4-1.2%) in blood and deltamethrin (1.1-3.5%) and esfenvalerate (2.4-4.7%) in
brain. The approximate ED30 for decrease in motor activity was 300 ng/ml and
200 ng/g of total pyrethroid in blood and brain, respectively. More research is
needed to understand the dosimetry of pyrethroids in blood and brain of rat and
how this relates to neurotoxic effect. (This abstract does not represent U.S. EPA or
NIEHS/NTP policy).
488 Partition Coefficients of Deltamethrin (DLM) and Cis-
Permetrhrin (CIS) in Male Sprague-Dawley Rats.
M. Amaraneni1,  D. Gullick1,  P. Sethi1,  T. Mortuza1,  T. Osmitz2,  S. S. Anand3,
D. W. Gammon4,  C. A. White1,  J. V. Bruckner1 and B. S. Cummings1.
1University of Georgia, Athens, GA; 2Science Strategies, LLC, Charlottesville, VA;
3DuPont Haskell, Newark, DE; 4FMC, Ewing, NJ.
Pyrethroid insecticides are widely used to control a wide variety of pests in and
around homes, food handling establishments, in mosquito control, and in agricul-
ture. Partition coefficients are essential to the construction of PBPK models, be-
cause of their role in determining systemic distribution. The main aim of this study
was to determine tissue:blood partition coefficients (Kt:p) of two commonly used
pyrethroids, DLM and CIS. In vitro plasma to RBC partition coefficients, as deter-
mined by HPLC analysis, ranged from 0.7 to 1.0 for DLM, and 1.1 to 1.7 for CIS.
The steady state levels of both DLM and CIS were obtained in vivo by constant in-
fusion (0.36 mg/hr) using subcutaneous implantation of Alzet™ pumps, com-
bined with oral loading doses of 34 mg/kg for DLM, or 150 mg/kg for CIS given 4
hr after the implantation of the pump in male rats. The time to reach steady-state
was determined by analyzing blood samples collected by tail vein puncture 24, 48
and 72 hr post loading. Rats were sacrificed at 72 hr and blood and tissues collected
and analyzed for DLM and CIS using a modified GC-MS method. DLM levels in
plasma after 72 hr of constant infusion were 960 ng/mL, compared to 222 ng/mL
in brain, 272 ng/mL in liver, 132 ng/mL in muscle and 1,384 ng/mL in fat. This
corresponded to Kt:p values of 0.23 for brain, 1.45 for fat, 0.28 for liver and 0.14
for muscle. In contrast, the CIS level in plasma was 78 ng/mL, compared to 43
ng/mL in brain, 27 ng/mL in liver, 107 ng/mL in muscle and 1,625 ng/mL in fat.
These corresponded to Kt:p of 0.55 for brain, 20.78 for fat, 0.34 for liver and 1.37
for muscle. These data show that both pyrethroids are sequestered in fat, and that
differences exist in Kt:p for DLM and CIS, as Kt:p values were generally higher for
CIS. Supported by the Council For Advancement of Pyrethroid Human Risk
Assessment.
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489 Preliminary Toxicokinetics of N-Butylbenzenesulfonamide
after a Single Intravenous or Gavage Administration to
Harlan Sprague-Dawley Rats and B6C3F1/NMice.
S. Hong1,  S. Gibbs1,  S. Graves1,  D. Kobs1,  C. Rider2,  A. Martone2 and
S. Waidyanatha2. 1Battelle Memorial, Columbus, OH; 2Division of National
Toxicology Program, NIEHS, Research Triangle Park, NC.
N-butylbenzenesulfonamide (NBBS) is a common plasticizer with limited toxicity
data that has been detected in environmental samples. A preliminary toxicokinetic
study was conducted in Harlan Sprague Dawley rats and B6C3F1/N mice follow-
ing a single intravenous (2 mg/kg) and gavage (2 or 200 mg/kg) administration of
NBBS, and plasma and brain toxicokinetics were evaluated. Intravenous and gavage
TK profiles of NBBS were characterized by a one-compartment kinetic model in
both rats and mice. Following intravenous administration, male and female elimi-
nation (k10) half-life values were 0.300 and 0.387 hours, respectively, in rats, and
0.383 and 0.268 hours, respectively, in mice. Following gavage administration,
male and female elimination half-life values were 0.657 and 1.11 hours (2 mg/kg)
and 4.88 and 3.86 hours (200 mg/kg), respectively, in rats, and 1.21 and 0.494
hours, respectively, in mice. Male and female AUC
∞
values following gavage ad-
ministration were 43.0 and 166 hr*ng/mL (2 mg/kg) and 17,800 and 46,800
hr*ng/mL (200 mg/kg), respectively, in rats indicating saturation of elimination ki-
netics around 200 mg/kg. The absolute bioavailability of NBBS after gavage ad-
ministration at 2 mg/kg was 13% and 39% for male and female rats, respectively.
AUC
∞
values for male and female mice after gavage administration were 20,000
and 15,500 hr*ng/mL, respectively. The absolute bioavailability of NBBS after gav-
age administration to mice at 200 mg/kg was 25% for both sexes. NBBS was ex-
tensively distributed into the brain with concentrations similar to plasma in mice
but greater than plasma in rats. [Supported by NIH, HHSN273201000016C]
490 Gestational and Lactational Physiologically-Based
Pharmacokinetic (PBPK) Models for the Herbicide Atrazine
in Rats: Development and Optimization.
Z. Lin1, 2,  J. W. Fisher3 and N. M. Filipov1, 2. 1Physiology and Pharmacology,
University of Georgia, Athens, GA; 2Interdisciplinary Toxicology Program, University
of Georgia, Athens, GA; 3National Center for Toxicological Research, US FDA,
Jefferson, AR.
Atrazine (ATR) is a widely used chlorotriazine herbicide that is commonly detected
in the environment and in human specimens, including pregnant women’s urine,
umbilical cord blood and breast milk. To help address concerns about reported ad-
verse effects of ATR exposure during development, gestational and lactational
PBPK models for ATR in the rat were developed. The models accounted for poten-
tial differences in the metabolism of ATR in dams, fetuses, and neonates and be-
tween single and repeated daily oral exposures and incorporated binding of ATR
and its major metabolite didealkylatrazine (DACT) with target tissue
(maternal/neonatal brain and fetus), plasma proteins, and red blood cells. Model
predictions correlate well with recently reported measured data on the concentra-
tions of ATR and its metabolites in maternal/neonatal plasma, tissue, fetus, and
milk following repeated daily oral exposure to the dam during gestation, lactation,
or both, including with data from a study (lactational exposure) not used for model
calibration. The model simulations indicate that: (1) the fetus is exposed to ATR
and DACT at levels that are similar to maternal plasma levels, (2) the neonate is ex-
posed mostly to DACT at levels about two-thirds of the maternal plasma DACT
levels and (3) gestational carryover of DACT greatly affects neonatal dosimetry up
until mid-lactation. Hence, excessive exposure to ATR and/or its metabolites dur-
ing pregnancy or early lactation may be of particular concern. These models pro-
vide insights into designing and interpreting early life toxicity and pharmacokinetic
studies with this herbicide and could be used in fetal and neonatal tissue dosimetry
prediction and for improvement of ATR’s exposure assessment.
491 Characterization of the Fate of β-Hexabromocyclododecane
(HBCD) in Mice.
J. M. Sanders,  G. A. Knudsen,  A. M. Sadik and L. S. Birnbaum. NIH/NCI,
Research Triangle Park, NC.
1,2,5,6,9,10-Hexabromocyclododecane (HBCD) is a high production volume cy-
cloaliphatic used primarily as an additive flame retardant in polystyrene foam
building materials. Commercial HBCD mixtures contain three major stereoiso-
mers, alpha (α), beta (β) and gamma (γ), at a typical ratio of 1.2:0.6:8.2. Toxicity
(e.g. developmental neurotoxicity, immune effects, liver hypertrophy, and en-
docrine disruption) in rodents exposed to HBCD mixtures may be affected by dif-
ferential kinetics of the isomers. Previous work from our laboratory demonstrated
that α-HBCD has greater bioavailability and potential for accumulation in mice
than γ-HBCD. The present investigation provides comparative disposition data for
β-HBCD to support toxicological evaluations of HBCD mixtures. In these studies,
a single dose of [14C]-labeled β-HBCD (3 mg/kg), administered orally, was ab-
sorbed rapidly in the female C57BL/6 mouse. The Cmax for β-HBCD-derived ra-
dioactivity in blood and other assayed tissues, except adipose, was observed 3 hours
following gavage. Approximately 90% of the total dose was eliminated in urine and
feces by 24 h postdosing. The extent of dose absorption was ≥ 85% based on HPLC
analysis of feces extracts and comparison of oral and iv excretion data. β-HBCD-
derived metabolites were excreted in urine and feces. Approximately 8% of the total
dose was excreted in feces as γ-HBCD. Oral administration of either 30 or 100
mg/kg of β-HBCD resulted in initial slower rates of [14C] elimination; however,
cumulative excretion data were similar across the dosing range 4 days following gav-
age. Residual concentrations of [14C] in tissues of these mice were highest in adi-
pose and liver. β-HBCD-derived radioactivity accumulated in these tissues follow-
ing four consecutive daily doses of 3 mg/kg by gavage. In conclusion, β-HBCD,
like γ-HBCD, was extensively metabolized, rapidly excreted, and had less potential
for accumulation in tissues over time in female C57BL/6 mice than α-HBCD.
(Research supported in part by Intramural Research Program of NIH/NCI; ab-
stract may not reflect official NIH policy).
492 OATs and OATPs Are Involved in the Disposition of
Perfluoroalkyl Sulfonates in Rats.
W. Zhao1,  J. Zitzow2,  D. J. Ehresman2,  S. Chang2,  J. L. Butenhoff2 and
B. Hagenbuch1. 1Pharmacology, Toxicology and Therapeutics, Kansas University
Medical Center, Kansas City, KS; 2Medical Department, 3M Center, St. Paul, MN.
Perfluoroalkyl sulfonates (PFSAs) are a group of persistent environmental contami-
nants that have been detected in wildlife and human serum. Based on estimations
from retired fluorochemical production workers, the elimination half-lives of cer-
tain PFSAs, such as perfluorohexansulfonat (PFHxS) and perfluorooctanesulfonate
(PFOS), are very long (several years). Pharmacokinetic studies in animal models in-
dicate that the long half-lives of these compounds are due to slow renal clearance
and strong hepatic accumulation. In previous studies we have demonstrated certain
organic anion transporters expressed in the kidney and the liver are involved in the
disposition of another family of perfluoroalkyl substances, perfluoroalkyl carboxy-
lates (PFCAs), in rats. However, so far it is unknown whether PFSAs are also sub-
strates for the same drug transporters. Therefore, we wanted to test whether the or-
ganic anion transporters involved in the disposition of PFCAs are also responsible
for the disposition of PFSAs. We used HEK293 cells overexpressing rat OAT1,
OAT3 and OATP1A1 and measured the uptake of model substrates in the absence
and presence of PFSAs with different carbon chain-lengths, namely perfluorobu-
tanesulfonate (PFBS), PFHxS and PFOS. PFHxS showed the strongest inhibition
for both rat OAT1 and OAT3, while rat OATP1A1 was only inhibited by PFOS.
Direct uptake determination of these PFSAs demonstrated that rat OAT1 and
OAT3 can transport PFBS and PFHxS while rat OAT3 and OATP1A1 might
transport PFOS. In conclusion, these results suggest that the same families of trans-
porters in the rat that are involved in the disposition of PFCAs are also involved in
the disposition of PFBS, PFHxS and PFOS.
493 Toxicokinetics of Inhalation, Metabolism and Elimination of
6: 2 FTOH and 8: 2 FTOH in Rats.
M. W. Himmelstein,  T. L. Serex,  R. C. Buck and M. H. Russell. E.I. DuPont de
Nemours & Co Inc., Wilmington, DE.
This study compares the in vivo metabolism of two fluorotelomer alcohols (6:2
FTOH and 8:2 FTOH). Single 6-h inhalation exposures were conducted in
Crl:CD(SD) rats followed by analysis of per- and poly-fluorinated acid metabolites
in plasma. Both substances were readily absorbed and rapidly eliminated via conju-
gation and oxidative metabolism. Following exposure to either 0.5 or 5.0 ppm 6:2
FTOH, the terminal metabolites included perfluorobutanoic acid (PFBA), perfluo-
rohexanoic acid (PFHxA), perfluoroheptanoic acid (PFHpA) and 5:3 Acid
(C5F11CH2CH2COOH). 5:3 Acid was the dominant acid metabolite in plasma
which, based on toxicokinetic modeling, represented 0.2-3.8 mol% and 1.2-2.8
mol% of the inhaled dose of 6:2 FTOH in male and female rats, respectively.
Corresponding yields of PFHxA were 0.1-2.8 mol% and 0.5-1.7 mol% in male
and female rats, respectively. The sum of all modeled acid analytes ranged between
0.5 and 7.1 mol% with higher yields of all analytes observed at lower inhaled 6:2
FTOH doses. After 6:2 FTOH exposure cessation, the fluorinated acids observed
in plasma were rapidly eliminated with typical elimination half-lives of a few hours.
A single 8:2 FTOH 6-h exposure of rats to 0.16 or 1.6 ppm resulted in dose pro-
portional formation of perfluorooctanoic acid (PFOA) and 7:3 Acid
(C7F15CH2CH2COOH) as the major fluorinated acid metabolites. In male and fe-
male rats, toxicokinetic calculations of 7:3 Acid in plasma resulted in yields of 0.9-
2.1 mol% in male and female rats while PFOA yields ranged between 0.3 and 1.1
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mol%. 7:3 Acid was eliminated with calculated half-lives of 1-7 hrs in male and fe-
male rats while the elimination of PFOA showed distinct gender differences with
half-lives of 6-8 hrs in female rats and no measurable decline in male rats over the
18-h period of depuration. For both fluorotelomer alcohols, the major terminal
acids formed metabolically in rats were 5:3 Acid and PFHxA from 6:2 FTOH and
7:3 Acid and PFOA from 8:2 FTOH. This study demonstrates rapid bioelimina-
tion of inhaled fluorotelomer alcohols from plasma.
494 Absorption, Distribution, Metabolism, and Elimination of
[14C] 6: 2 Fluorotelomer Alcohol in the Rat.
R. T. Mingoia1,  S. C. Carpenter1,  T. L. Whyte1,  M. W. Himmelstein1,
T. A. Snow1,  L. Cox1,  S. A. Gannon1 and R. C. Buck2. 1DuPont Haskell Global
Centers for Health and Environmental Sciences, Newark, DE; 2E. I. duPont de
Nemours and Company, Inc., Chemicals and Fluoroproducts, Wilmington, DE.
Fluorotelomer alcohols (FTOHs; F(CF2)xC2H4OH, x=6, 8, or 10) are used in the
manufacture of specialty fluorinated surfactants and polymers. Fluorotelomer man-
ufacturers are moving away from raw materials that are potential precursors to per-
fluorooctanoic acid (PFOA), such as the higher fluorotelomer alcohol homologues,
to products based on 6:2 FTOH as a raw material. To better understand 6:2 FTOH
biological fate, the absorption, distribution, metabolism, and elimination of [1,2-
14C] 6:2 FTOH was investigated following a single oral dose administration of 5
and 125 mg/kg to male and female rats. The maximum concentration of total ra-
dioactivity in plasma following oral dosing at 5 and 125 mg/kg occurred by 2 h
post dose in both male and female rats. The plasma terminal elimination half-life
values for total radioactivity were approximately 79 h in male rats at both dose lev-
els and 78 and 63 h in female rats following a 5 and 125 mg/kg dose, respectively.
Terminal elimination half-life values in red blood cells were approximately twice
that in plasma, ranging from 121 h to 160 h. The internal dose as measured by area
under the concentration-time curve to infinity (AUCinf ) was similar for both male
and female rats. The increase in AUCinf was slightly less than dose proportional
from 5 mg/kg to 125 mg/kg. Preliminary material balance and tissue distribution
data following an oral 5 mg/kg dose suggests that at 7 days postdose, less than 5%
of the administered radioactivity was present in tissues with the highest concentra-
tions occurring in fat, adrenals, and thyroid. The majority of the [1,2-14C] 6:2
FTOH dose was excreted in feces with 65% and 50% excreted in male and female
rats, respectively. Renal excretion was also a significant elimination pathway with
10% and 18% excreted in urine in male and female rats, respectively.
495 Analysis of tris(2-Chloroisopropyl)phosphate Metabolites in
Rat Plasma for Toxicology Studies.
B. Collins2,  S. Waidyanatha2,  M. Stout2,  A. Gutierrez1,  R. Mathias1,
C. Dillon1,  D. Slade1,  C. Croutch1,  K. Aillon1,  J. Algaier1 and R. Harris1.
1MRIGlobal, Kansas City, MO; 2National Toxicology Program, NIEHS, Research
Triangle Park, NC.
Tris(2-Chloroisopropyl)phosphate, TCPP, is an organophosphate compound used
as a flame retardant and plasticizer especially in polyurethane foam in furniture and
in home insulation. Due to its environmental prevalence and resulting human ex-
posure, TCPP is under study by the NTP.  In support of NTP toxicological studies,
MRIGlobal developed methods to analyze TCPP and two major metabolites,
Mono (MCPP, 2 isomers) and Bis 2-chloroisopropyl phosphate (BCPP, 3 isomers)
in rodent plasma and blood. Because of its similarity to Tris(2-chloroethyl)phos-
phate, BCPP was expected to be the major TCPP metabolite. During the analytical
method development, multiple isomers of MCPP were observed and hence were
included in the method. The 5 isomers of the two metabolites were characterized
using synthetic standards following derivatization with BSTFA/pyridine prior to
analysis by GC/MS without using an internal standard. The ions monitored in the
selected ion monitoring mode were for MCPP, m/z 211, 227, 283 and for BCPP,
m/z 155, 171, 197.
The quantitation of MCPP and BCPP was achieved without derivatization using
LC/MS/MS following extraction of 100 μL of plasma with 200 μL acetonitrile, re-
moving acetonitrile by evaporation, and reconstituting the residue in 100 μL of 2%
MeOH in water containing 50 mM tributylamine, TrBA (pH 5 with formic acid)
with internal standard dibenzylphosphate. The LC/MS analysis used a phenyl-
hexyl column, which resulted in good linearity with a preliminary limit of detection
value of 5 to 10 ng/mL of plasma ranging to over 500 ng/mL. Multiple MCPP and
BCPP isomers were quantified as one MCPP and one BCPP peak.
Plasma samples from rats and mice from single and multiple exposures to TCPP
were analyzed to show the applicability of this method. The data show the presence
of MCPP and BCPP at levels significantly higher than the parent TCPP.
496 In Vitro-In Vivo Extrapolation of 7-Ethoxycoumarin
Metabolism Using 3D-Organotypic Liver Bioreactor.
K. Choi1,  J. Campbell1,  W. P. Pfund2,  J. McKim3,  E. L. LeCluyse1 and
H. J. Clewell1. 1The Hamner Institutes for Health Sciences, Research Triangle Park,
NC; 2RealBio Technology, Inc., Kalamazoo, MI; 3CeeTox Corp., Kalamazoo, MI.
A liver bioreactor system was developed to simulate the metabolism and clearance
of compounds similar to the liver in vivo to provide better prediction of in vivo
clearance and metabolite profiles of compounds from in vitro data. Primary rat and
cryopreserved human hepatocytes were maintained in a RealBio D4™ Culture
System for approximately a month. General metabolic and liver-specific functions
and cellular damage of rat/human hepatocytes inside liver bioreactor were moni-
tored. Stable levels of biomarkers and related functional endpoints were achieved
after a 7-10 day period for both rat and human liver bioreactors, respectively (glu-
cose 64.6 – 86.6/152 – 182 mg/dL; lactate 0.6 – 1.9/0.1 – 3.7 mmol/L; pH 7.4 –
8.0/7.4 – 7.5; albumin 0.8 – 1.0/1.0 – 1.1 mg/mL; total protein 7.5 – 8.8/1.8 – 20
mg/mL; ALT 4.9 – 13.6/6.0 – 9.9 U/L; AST 6.8 – 25.4/18.9 – 53.1 U/L). The ac-
tivities of rat CYP2B, CYP2C11 and CYP3A were monitored by the production of
16β-OH testosterone, 16α-OH testosterone and 6β-OH testosterone, respectively.
Rat hepatocytes at 28 days in a liver bioreactor and treated with 5 μM dexametha-
sone for 24hr showed 3-fold increase in CYP3A activity. Metabolism of 7-ethoxy-
coumarin (7-EC) was characterized in the rat liver bioreactor. 7-Hydroxycoumarin
was the predominant metabolite produced, which was further metabolized to the
glucuronide and sulfate conjugates. The depletion of 7-EC showed mono-exponen-
tial decay with an estimated intrinsic clearance of 113.3 μL/min/106 cells. Scaling
of the in vitro CLint to in vivo CLint yielded in vivo prediction of 135.98
mL/min/rat body weight (250g). In conclusion, hepatocytes maintained in a 3D
organotypic liver bioreactor showed stable liver functional capacity and intrinsic
clearance over an extended period. This system may help resolve current limitations
in assessing the clearance mechanisms and long-term effects of compounds and
their major metabolites on chemical-induced liver toxicity.
497 Enhanced Intranasal Delivery of Gemcitabine to the Central
Nervous System.
M. Krishan1,  G. Gudelsky2,  P. Desai2 and M. Genter1. 1Environmental Health,
University of Cincinnati, Cincinnati, OH; 2College of Pharmacy, University of
Cincinnati, Cincinnati, OH.
Delivery of therapeutics to the brain to treat neurological diseases is a challenge due
to impenetrable nature of the blood brain barrier (BBB). Intranasal (IN) drug ad-
ministration is a non-invasive approach for rapid direct drug delivery from the nose
to the central nervous system (CNS), thereby minimizing systemic exposure. The
current study focuses on a strategy to enhance the delivery of the nucleoside drug
gemcitabine (GEM) to the CNS via IN administration. Our approach takes advan-
tage of the fact that the BBB and olfactory epithelial (OE) tight junctions (TJs)
share many proteins in common. We hypothesized that by transiently increasing
the permeability of nasal epithelial tight junctions using the BBB permeabilizer pa-
paverine (PV), we will increase the concentration of GEM reaching the brain extra-
cellular fluid (BECF) following IN delivery, with the goal of delivering therapeutic
concentrations of nucleoside drugs to the CNS. Experimental methods included
IN administration of fluorescein isothiocyanate-dextran beads (FD4), in-vitro
GEM recovery, in vivo brain microdialysis for BECF collection, HPLC analysis to
measure GEM in BECF, histopathology, and western blot analysis. Distribution
studies with FD4 showed significant deposition in the ethmoid turbinates, suggest-
ing drug uptake through OE. Clinically-relevant doses of PV (up to 1.4% IN) did
not cause histological evidence of cytotoxicity or inflammation in nasal epithelia,
lung, liver, spleen, or kidney. Pharmacokinetics of GEM in BECF showed area
under the curve (AUC) = 5.55±0.84 μg.h/ml for PV (1.4%) + GEM (50mg/kg)
treated animals, compared to 1.5±0.29 μg.h/ml for GEM without PV treatment.
Western blot analysis suggested that IN PV treatment increased permeability
through OE TJs by transiently decreasing the levels of TJ protein occludin. Thus, it
appears that transient permeabilization of nasal epithelial TJs provides a non-inva-
sive means to enhance delivery of nucleoside drugs to the CNS.
498 Altered Irinotecan Pharmacokinetics in Diet-Induced
Obesity.
P. Shah,  A. Gandhi and R. Ghose. Pharmaceutical and Pharmacological Sciences,
University of Houston, Houston, TX. Sponsor: R. Ghose.
Purpose: Irinotecan (CPT-11) is a topoisomerase I inhibitor that has been shown to
be highly effective in treatment of variety of cancers. It has recently been shown that
CPT-11 administration is associated with liver toxicity and this effect is com-
pounded by baseline obesity. It was found that patients with a BMI index of >25
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were twice as much susceptible to developing liver toxicity than patients with BMI
index of <25. CPT-11 metabolizes to SN-38, which then undergoes glucuronida-
tion by uridine glucuronosyl transferase (UGT) 1A1 to form SN-38 glucuronide
(SN-38G). Excess accumulation of the toxic metabolite SN-38 is known to cause
fatal diarrhea in cancer patients. We hypothesize that accumulation of SN-38 is as-
sociated with increased liver toxicity of CPT-11 in obesity. 
Methods: For metabolism studies, liver S9 fractions were prepared from diet-in-
duced obese (DIO, 60% fat) and lean mice (10% fat). UGT1A-mediated metabo-
lism of SN-38 was determined in liver S9 fractions. For pharmacokinetic studies,
mice were injected with a single oral dose of 10 mg/kg CPT-11 and blood and feces
samples were collected from 0-8hr. Samples were analyzed for CPT-11 and SN-38
concentrations using LC-MS/MS. Liver tissues were harvested for real-time PCR
studies. The mRNA and serum TNFα levels were measured in liver and plasma
samples, respectively. 
Results: We found that the rate of formation of SN-38G was 2 fold lower in the
DIO mice compared to the lean controls. This corresponded with reduced expres-
sion of UGT1A1 in DIO mice livers. We did not observe significant changes in the
area under the curve (AUC) or clearance of CPT-11 between the DIO and lean
mice. However, plasma and fecal exposure of SN-38 was increased by 2 folds in the
DIO mice compared to the lean controls. We also observed significantly higher
mRNA and serum levels of TNFα in the DIO mice as compared to the lean mice.
Higher TNFα levels are known to be associated with liver toxicity. 
Conclusion: CPT-11 dosage should be closely monitored for effective and safe
chemotherapy in obese patients who are at a higher risk of developing liver toxicity.
499 Interaction of Immunosuppressants with Human Organic
Anion Transporters 1 and 3 and Multidrug Resistance
Proteins 2 and 4.
R. Greupink1,  A. A. El-Sheikh2,  H. Wortelboer3,  J. J. Van den Heuvel1,
M. Schreurs1,  J. B. Koenderink1,  R. Masereeuw1 and F. G. Russel1. 1Department
of Pharmacology and Toxicology, Radboud University Nijmegen Medical Centre,
Nijmegen, Netherlands; 2Department of Pharmacology, Faculty of Medicine, Minia
University, Minya, Egypt; 3TNO, Zeist, Netherlands.
Renal proximal tubule transporters can play a key role in excretion, pharmacoki-
netic interactions and toxicity of immunosuppressant drugs. Basolateral organic
anion transporters (OATs) and apical multidrug resistance proteins (MRPs) con-
tribute to active tubular uptake and urinary efflux, respectively. Combining im-
munosuppressants during therapy may lead to drug-drug interactions occurring at
the transporter level, resulting in toxicity. We studied the effect of different im-
munosuppressants on OAT1- and OAT3-mediated uptake of [3H]-methotrexate
([3H]MTX) in cells, and on ATP-dependent [3H]MTX transport in membrane
vesicles isolated from HEK293 cells over-expressing human MRP2 and MRP4. For
the uptake transporters, we found that cyclosporine, dexamethasone, azathioprine
and 6-mercaptopurine did not affect either transporter. Cytarabine, vinblastine,
vincristine, hydrocortisone and mitoxantrone significantly inhibited OAT1
(p<0.05 at 10 μM), whereas these compounds did not inhibit OAT3. In contrast to
other compounds, mycophenolic acid (10 μM) inhibited OAT3 more effectively
than OAT1, reducing [3H]MTX uptake by 86 ± 4% and 52 ± 5% of control, for
OAT3 and OAT1 respectively. Subsequent studies showed that the IC50 of my-
cophenolic acid for OAT3 was 4.3 μM (95% CI: 2.7-6.9 μM), which is close to its
reported Cmax, unbound (~ 1 μM). With regard to the apical transporters, cy-
clophosphamide, hydrocortisone, tacrolimus and mycophenolic acid inhibited
both MRP2 and 4. Cyclosporine, vincristine and vinblastine only inhibited MRP2,
while 6-mercaptopurine only inhibited MRP4. In conclusion, immunosuppres-
sants may alter renal transport activity. From a drug safety perspective, the observed
differences in transporter inhibition profiles may provide a selection criterion when
combining immunosuppressive drugs.
500 Accumulation of β-N-methylamino-L-Alanine in Tissues
following Repeat Oral Administration to Harlan Sprague-
Dawley Rats.
C. Garner1,  C. J. Wegerski1,  M. Doyle-Eisele1,  J. Lucak1,  S. Waidyanatha2,
J. D. McDonald1 and J. M. Sanders2. 1Lovelace Respiratory Research Institute,
Albuquerque, NM; 2National Toxicology Program, NIEHS, Research Triangle Park,
NC.
β-N-methylamino-L-alanine (L-BMAA) was nominated to the National
Toxicology Program for toxicological assessment based on widespread environmen-
tal distribution and evidence that the potentially neurotoxic compound may accu-
mulate in CNS tissue. Data describing metabolism and disposition of L-BMAA are
needed to support planned NTP toxicity studies. Male Harlan Sprague-Dawley rats
were dosed by gavage with [1,2-14C]-L-BMAA (1 mg/kg/d) for 1, 5, and 10 con-
secutive days. Excreta and tissues were collected for up to 72 hours after the final
dose. The majority of 14C was recovered as 14CO2 (50-60%) across 10 days of dos-
ing and <10% of dose was excreted in urine. HPLC profiles of urine showed multi-
ple polar metabolites and L-BMAA was not detected. Over 10 days of dosing 14C
continued to accumulate in tissues including the brain. After single and up to 10
day repeat doses the majority of the 14C recovered in tissues was found in liver, adi-
pose, muscle, and skin; < 0.01% dose was recovered in the brain. Accumulation
rate of brain 14C over 10 days exceeded elimination by >3 fold. On days 1,5, and 10
a majority of 14C in brain tissue 24 h following the final dose was recovered in the
protein after exhaustive extraction. The nature of BMAA associated with brain pro-
tein was investigated in vitro. Incubation of [1,2-14C]-L-BMAA in vitro with rat
brain homogenates released 14CO2 and 
14C was incorporated into protein. HPLC
analysis of in vitro protein hydrolysates showed that [14C]-L-BMAA itself and other
14C-equivalents made up the radioactive components. Thus accumulation of L-
BMAA and its equivalents in brain tissue may be due in part to incorporation into
protein. Brain tissue from repeat dose administration in rats is currently being ana-
lyzed to investigate the nature of the radiolabel associated with the protein. This
work was conducted for the NTP under NIEHS Contract N01-ES-75562.
501 Comparative Nonclinical Ocular Tissue Distribution of the
Visual Cycle Modulator (VCM) Emixustat in Rats, Beagle
Dogs, and Cynomolgus Monkeys.
T. Podoll1,  R. J. Eyre1,  S. Al-Fayoumi1,  E. Austin1,  E. Prescott2,  G. Sun2,
M. Orme1 and R. Kubota1. 1Acucela Inc., Seattle, WA; 2Covance, Madison, WI.
Emixustat HCl is a novel, non-retinoid VCM that inhibits a key step in regenera-
tion of 11-cis-retinal by retinyl ester isomerase RPE65. Emixustat is currently in
late Phase 2 clinical development as an orally administered treatment for geo-
graphic atrophy associated with dry age-related macular degeneration (AMD). In
ADME studies, very low plasma concentrations of emixustat are seen as it is exten-
sively metabolized, producing pharmacologically inactive metabolites. Interestingly,
the pharmacological activity of emixustat has been shown to be prolonged beyond
the time at which its plasma concentrations are no longer measurable. Ocular dis-
tribution studies using 14C emixustat were undertaken in rat, dog, and monkey to
better understand the time course of emixustat ocular tissue exposure in relation to
observed pharmacology activity in animal models. 
Pigmented and albino rats received single oral doses of 1 mg/kg, and were prepared
for QWBA, or a repeated oral dose (QD for 7 days) and were prepared for ocular
dissection. Dogs received 0.3 mg/kg as a single or a repeated oral dose (QD for 7
days). Monkeys received 0.9 mg/kg/day as a single or a repeated oral dose (TID for
7 days). Eye levels were observed for up to six weeks postdose.
The mean recovery of radioactivity was >95% in rat and dog, and >90% in mon-
key. The half life of removal of radioactivity from eye tissues was longer in all
species than that observed in plasma. Consistent among the three species, emixus-
tat parent molecule was the major component found in eye tissues. In all three
species, the retina Cmax of emixustat were >50 fold higher than respective plasma
Cmax on a ng•equiv/g basis. Although high levels of the major metabolites were
observed in plasma, they were not observed in eye tissues. Preclinical ocular distri-
bution results indicated emixustat parent is the predominant molecule in the eye re-
sponsible for pharmacological activity.
502 Development of Sustained Release Buprenorphine for Use As
an Improved Analgesic in Toxicology Studies: Assessment of
Formulation Pharmacokinetics.
L. Koetzner1,  W. Stokes2,  W. Lance3,  G. Wnorowski1,  N. South4 and J. Boulet1.
1Product Safety Labs, Dayton, NJ; 2NICEATM, NIEHS, Research Triangle Park,
NC; 3Wildlife Pharmaceuticals, Fort Collins, CO; 4Battelle, Columbus, OH.
Acute toxicology safety testing procedures can involve animal pain and distress.
U.S. regulatory agencies and the OECD recently adopted and updated procedures
that incorporate the routine use of systemic analgesics to avoid or reduce pain and
distress for eye irritation testing procedures. Buprenorphine is recommended as a
useful analgesic for such toxicology studies. However, buprenorphine requires a
minimum of twice-daily dosing at 12 hour intervals to maintain effective analgesia.
A study was therefore conducted to evaluate sustained release formulations to de-
termine their usefulness for once-per-day or less frequent dosing. The pharmacoki-
netics of two sustained release formulations of buprenorphine were compared to
buprenorphine in saline using male 2-2.5 kg New Zealand White rabbits. Sustained
release formulations were prepared using N-methyl-pyrrolidone (NMP) or
Triacetin as the vehicle. Following subcutaneous dosing, blood samples were col-
lected at intervals to four days; plasma buprenorphine was determined using liquid
chromatography with mass spectrometry. Both the NMP and Triacetin formula-
tions produced higher plasma buprenorphine concentrations than the saline for-
mulation at time points from 12 hours on. The Triacetin formulation also resulted
in higher concentrations at earlier time points, as well as concentrations near or
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above 0.1 ng/mL—a concentration previously associated with analgesic activity in
other species—to 96 hours post-dosing. Body weight and food consumption were
recorded, and did not show adverse effects of treatment with sustained release for-
mulations. No abnormal clinical signs or local lesions were observed. These results
suggest that the Triacetin sustained release formulation of buprenorphine can sig-
nificantly reduce the dosing interval required and can be a useful replacement for
twice-daily treatments.
503 Acute Rat Inhalation Pharmacokinetic Study of 10.9 kD
Protein with or without Pegylation.
J. Gould1,  I. Carvajal1,  T. Davidson1,  A. Kozhich1,  J. Laporte2,  J. Li1,
N. Mathias1,  L. Schneeweis1,  S. Thompson-Iritani1,  J. Valentine1,  B. Wang1
and H. H. Haggerty1. 1Bristol-Myers Squibb, New Brunswick, NJ; 2Charles River
Laboratories Preclinical Services Montréal Inc, Senneville, QC, Canada.
Biologics are an evolving protein-based therapeutic approach in the pharmaceutical
industry. As part of assessing hazards, an Occupational Exposure Limit (OEL) is
developed internally for proprietary biologics to support worker safety. Biologics
are considered to be less hazardous than small molecules due to suspected lower sys-
temic bioavailability (BA) from the lung and degradation in the GI tract. To inves-
tigate fate after inhalation (Inh), SD rats were exposed to RGE (10.9 kD protein),
RGE-PEG (40 kD PEG+10.9 kD protein) or saline by nose-only Inh for 1 hr. The
pharmacokinetic (PK) profile was investigated in blood and bronchial alveolar
lavage fluid (BAL). The measured experimental exposures were 42 and 48 mg/m3,
corresponding to a calculated dose of 1.8 and 2.1 mg/kg, and a mean mass aerody-
namic diameter of 1.8 and 1.9 μm for RGE and RGE-PEG, respectively. The sys-
temic PK profile for RGE and RGE-PEG included AUC(INF) of 169 and 357
ng.h/mL; Cmax of 19.8 and 10.1 ng/mL; Tmax of 2 and 9hrs; and t½ of 5.5 and
21 hrs; respectively. When compared to an IV study, systemic BA was 1.4 and
0.05%, respectively. From BAL levels, the left lung lobe contained 4.2 and 3.2% of
the calculated dose at end of exposure and the lung t½ was 4.5 and 7.2 hrs, respec-
tively. These results indicate that after Inh exposure, systemic BA was low, with the
PEG-RGE being markedly less than the unmodified RGE.  However, the overall
AUC(INF) for both proteins was similar. Compared to systemic results, the lung
PK for the two proteins were similar with respect to t½ and reduced percent of dose
delivered to the lung. These PK results suggest that compared to small molecule
drugs, there may be a decreased hazard for proteins, which would be demonstrated
by applying these data-derived PK factors to the OEL calculation. Further studies
on additional biologics would be needed to generalize across proteins.
504 Simulation of Perfluoroacid Accumulation in Humans
Exposed to Perfluorotelomer Alcohol Products.
W. Roth and P. Rice. Office of Food Additive Safety, US FDA, College Park, MD.
Perfluorochemical grease-proofing agents derived from perfluorotelomer alcohols
are commonly used in fast-food packaging, and have been of concern because of the
toxicity and potential for biopersistence of components of these products, such as
the surfactant perfluorooctanoic acid (PFOA) and related perfluoroalkyl carboxylic
acids (PFCAs). Although the predominant products of perfluoroalkyl-ethanol
(PFAE) metabolism are usually conjugates such as PFAE-O-glucuronide or PFAE-
S-glutathiones, studies in the rat indicated that small amounts of PFCAs are also
formed, and might lead to accumulation in other species (especially humans) under
the appropriate kinetic conditions. We have previously conducted pharmacokinetic
modeling of the metabolism of PFOE based on the rat experiments of Fasano et al.
(2006), and were able to explain the metabolic appearance of PFOA with fitted ki-
netic coefficients.  Since that time, additional in vitro data from human, rat, and
mouse hepatocyte incubations has become available (Naab et al., 2007, Fasano et
al., 2009), allowing us to extend our PK model to predict accumulation of PFCAs
derived from PFAE products in the mouse and humans. Although neither the PK
model prediction nor the in vitro data are definitive, this combination of alternative
methods provides insight into PFAE exposures and consequent levels of PFCAs.
505 Uptake and Disposition in Humans of Hydrofluorocarbons
(HFCs) Used As Refrigerants.
L. Ernstgård,  B. Sjögren and G. Johanson. Work Environmental Toxicology,
Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
A variety of hydrofluorocarbons (HFCs) have replaced the ozone-depleting chloro-
fluorocarbons (CFC) and hydrochlorofluorocarbons (HCFC) during the last
decades. There are few data on uptake and disposition of HFCs in humans. In a se-
ries of experiments, we therefore exposed healthy volunteers to vapors of four com-
monly used HFCs, namely difluoroethane (HFC152a; 0, 200 and 1000 ppm), tri-
fluoroethane (HFC143a; 500 ppm), tetrafluoroethane (HFC134a; 500 ppm) and
pentafluoropropane (HFC245fa; 0, 100 and 300 ppm). In parallel, blood:air,
saline:air and olive oil:air partition coefficients (PCs) were determined in vitro. The
inhalation exposures were performed for 2 h during light physical exercise (50 W)
in an exposure chamber. Capillary blood, urine and exhaled air were sampled until
next day and analyzed for the parent substance by head-space gas chromatography.
Fluoride and other potential metabolites were analyzed in urine using an ion selec-
tive electrode and 19F-NMR analysis, respectively. All HFCs had similar toxicoki-
netic profiles in blood with a rapid initial increase of HFC and an apparent steady-
state reached within a few minutes. The area under the concentration-time curves
(AUC) of HFC152a and HFC245fa in blood was proportional to the exposure
level, suggesting first-order kinetics. For all four HFCs, the inhalation uptake was
low (less than 4%) and only minor amounts were excreted unchanged in breath and
urine after exposure. No signs of metabolism were detected except a slightly in-
creased urinary excretion of fluoride after exposure to 1000 ppm HFC152a. No
other urinary metabolites were detected. The observed time courses in blood and
breath could be well described with a physiologically-based pharmacokinetic
(PBPK) model. In conclusion, the uptake and disposition of the four HFCs are
consistent with the PCs determined in vitro and with zero or insignificant biotrans-
formation.
506 Ethanol Toxicokinetics Resulting from Inhalation Exposure
in Human Volunteers and Toxicokinetic Modeling.
J. Dumas-Campagna,  G. Charest-Tardif,  R. Tardif and S. Haddad.
Environmental and Occupational Health, IRSPUM, Université de Montréal,
Montréal, QC, Canada.
There is a lack of information and increased interest on the risks associated with
chronic inhalation exposures to low levels of ethanol (< 1000 ppm). A physiologi-
cally based pharmacokinetic model (PBPK) for inhaled ethanol was previously de-
veloped based on exposed volunteers but only for levels above 5000 ppm.
Uncertainty still remains about the validity of this model to predict the blood levels
of ethanol (BE) for lower level exposures. This project aims to determine the BE re-
sulting from exposure to low concentrations (<1000 ppm) in order to adjust/vali-
date the PBPK model. Ten volunteers (5 men and 5 women) were exposed for 4 h
to vapors of ethanol (125, 250, 500, 750 and 1000 ppm) in resting conditions in
an inhalation chamber. An additional exposure to 750 ppm that included 4 periods
of 12 minutes of exercise at 50W was performed. Blood samples and alveolar air
were collected during and after the exposure. Results show that there is a linear re-
lationship between the ethanol inhaled air concentrations and (i) BE (women: r2 =
0.98/men: r2 = 0.99), as well as (ii) ethanol concentrations in the alveolar air at end
of exposure period (men: r2 = 0.99/women: r2 = 0.99). Furthermore, exercise re-
sulted in a significant increase (2 to 3 times) in BE after each period of 12 min of
exercise. Overall, the model predictions were overestimated at exposure levels <
2616 ppm for men and < 2300 ppm for women. At lower exposure concentrations,
limiting the clearance to the liver compartment was insufficient to account for total
ethanol clearance. Adjusting the model by adding extra-hepatic biotransformation
of high affinity and low capacity associated with the richly perfused tissues allowed
the model to fit adequately the low and high exposure level toxicokinetic data.
These new toxicokinetic data and improved PBPK model for ethanol will facilitate
the refinement of risk assessment for chronic inhalation exposure to low levels of
ethanol. (Project funded by ANSES, France).
507 Physiologically-Based Pharmacokinetic (PBPK) Modeling:
Extrapolation from In Vitro to In Vivo, a Case Study Using a
Novel Dermal Compartment.
M. V. Evans1,  C. A. Wilson2,  L. J. Beesley2,  L. S. Leon2,  R. A. Pegram1,
E. L. Croom1,  C. R. Eklund1 and M. E. Sawyer2. 1PB, US EPA, Research Triangle
Park, NC; 2REU 2012, North Carolina State University, Raleigh, NC.
PBPK models are useful extrapolation tools requiring time course data for calibra-
tion. A unique data set for rodents and humans was used with an existing PBPK
model for species extrapolation. This same data set also enabled an in vitro to in
vivo extrapolation, an emerging application tool for PBPK modeling. By adding a
dermal compartment, a refined rodent PBPK model for orally administered lindane
was developed and optimized using time-course tissue concentration data for
Wistar rats. This refined PBPK model also provided blood and skin partition coef-
ficients (Pblood = 1.72 and Pskin = 26.2); other partition coefficients were ob-
tained from the literature. Next, a human in vivo model was extrapolated from the
rodent model using physiological values from the literature. In addition, a novel in
vitro model of human skin containing a follicular compartment was developed to
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improve the fit to the available in vitro absorption data. In vitro dermal permeabil-
ity coefficients were estimated using two different methods: 1) a permeability coef-
ficient of 0.013 cm/hr was derived with the Potts-Guy equation; simulations gener-
ated with this coefficient matched the upper error results from the in vivo data; and
2) a permeability coefficient of 0.0043 cm/hr resulted from the dermal in vitro
model; simulations generated with this coefficient matched the lower error results
from the same in vivo data. The permeability value obtained using the in vivo
PBPK model was 0.0060 cm/hr, which provided the best fit to the data. This result
is between the in vitro and the Potts-Guy estimates, and PBPK simulations gener-
ated with this in vivo permeability fit through the averaged data points. In sum-
mary, PBPK modeling was found to be a powerful in vitro to in vivo extrapolation
tool, particularly when time course datasets are available. (This abstract does not re-
flect EPA policy).
508 Evaluation of Toxicity Adjustment Factors Used for the Risk
Assessment of Chlorpyrifos Oxon in Drinking Water.
M. Bartels1,  S. Marty2,  J. E. Chambers3,  J. J. Galligan4,  D. W. Lickfeldt5 and
D. R. Juberg5. 1Toxicology, Dow Chemical, Midland, MI; 2Toxicology, Dow
Chemical, Midland, MI; 3College of Veterinary Medicine, Mississippi State University,
Mississippi State, MS; 4Neuroscience Program, Michigan State University, East
Lansing, MI; 5Regulatory Laboratory, Dow AgroSciences LLC, Indianapolis, IN.
In the Preliminary Human Health Risk Assessment for chlorpyrifos (CPF), EPA
has derived toxicity adjustment factors (TAF) for chlorpyrifos oxon (Oxon), for
both acute and chronic dietary scenarios, of 12 and 18, respectively, based on rela-
tive inhibition of RBC acetylcholinesterase (AChE) by Oxon, relative to CPF.
However, a comprehensive evaluation of the biological effects of Oxon, following
oral exposure, has shown that this test material undergoes complete first-pass me-
tabolism, via chemical and/or enzymatic processes in the GI tract, GI tissue, portal
vein blood and liver. As a result, no test material is systemically available at ≤ 10
mg/kg, as shown by non-detectable levels of Oxon in blood and no inhibition of
brain ChE activity at doses up to 10 mg/kg in adult rats. Numerous datasets on tis-
sue sensitivity to Oxon show that effects in brain are predictive and conservative for
ChE inhibition, relative to other target tissues. Minor effects seen in the GI tract, at
dose levels ≥ 5 mg/kg, are limited to the portal of entry (i.e., do not directly affect
other tissues), are not considered to have long-term clinical consequences, and
would not be expected given the predicted, low level exposures to Oxon in drinking
water. As a result of these analyses, it is proposed that the potency of Oxon be based
on a relevant toxicity endpoint (e.g., brain effects seen at > 10 mg/kg) and not on
RBC ChE inhibition, which is an indicator of low levels of Oxon that are not sys-
temically available.
509 Effects of Leucine Administration on Plasma and Brain
Levels of Other Amino Acids.
K. Yu,  L. Narayanan,  J. Gearhart,  J. J. Schlager,  F. Lobo-Menendez,
D. A. Mahle and P. Robinson. AFRL, Wright-Patterson AFB, Dayton, OH.
Leucine (leu), one of the essential branch-chained amino acids (AAs), has been
shown to activate mTOR to increase protein synthesis, and for the brain, may pro-
vide enhanced cognitive memory deposition. However, little is known regarding leu
kinetics. Investigations into the leu kinetics revealed that it was eliminated very fast
from the blood after dosing, and leu levels in brain were higher than blood, indi-
cating active transport of leu across the blood brain barrier (BBB). The objective of
this work was to investigate the effects of leu administration on blood and brain lev-
els of 20 AAs, and the BBB role (if any) to leu kinetics. A rodent model was dosed
leu via iv (5 & 12.9 mg/kg) for dose-response and time-course studies, and orally
(319 mg/kg) for time-course analysis. Tissue leu levels were measured at various
time points (5m– 6h, iv and 30m–4h, orally). Interestingly, more than 65% of all
AAs were increased in brain. At the 5 mg/kg dose, valine, lysine and proline in brain
were increased, while aspartic acid and isoleucine levels decreased. At the 12.9
mg/kg dose, serine, tryptophan, lysine and proline in brain were increased, while
threonine and methionine decreased (all relative to control, p<0.05). With oral dos-
ing, 16 AAs in brain were increased at the 1h time point. Isoleucine (time point 1
& 4h), lysine (0.5 & 1h), histidine (0.5 & 1h) and proline (all time points: 0.5, 1,
2, and 4h) in brain were increased significantly from control at p<0.05 or less.
Brains to plasma AA ratios were increased following dosing for lysine, methionine
and valine at 5 mg/kg, proline at 12.9 mg/kg and isoleucine and proline for oral
dosing groups. Our results indicate that leucine administration initiate complex
time- and dose- dependent responses in both plasma and brain levels of the other
AAs. These preliminary data show that neither the specific BBB transport system
for AAs (most AAs use the L1 large neutral AA transporter for crossing the BBB),
nor obvious general chemical or biological AA properties determine the brain levels
and uptake behavior observed in these studies.
510 Screening for Substrates of the P-Glycoprotein Transporter.
R. A. Pegram1,  E. L. Croom1 and J. A. Campbell2. 1NHEERL/ORD, US EPA,
Research Triangle Park, NC; 2NCBA/SEE Program, Washington DC.
P-glycoprotein (Pgp) is an ATP-dependent efflux transporter of xenobiotic com-
pounds with broad substrate specificity. Pgp is an important component of the
blood-brain barrier and frequently mediates resistance of tumors to chemothera-
peutic agents. Attempts to predict the in vivo toxicity of environmental chemicals
based upon in vitro screening test results can be erroneous if transporter effects are
not considered. In this study, a multi-tiered in silico/in vitro testing approach was
used to predict Pgp substrates within a set of ToxCast chemicals. An in silico analy-
sis using a support vector machine predicted 45 of the 280 chemicals to be Pgp sub-
strates; these predictions matched the results of a separate in silico docking analysis.
Only 5% of the chemicals with MW < 400 (and none with MW < 300) were pre-
dicted as substrates, while 87% with MW > 400 were predicted substrates. In vitro
cell-based assays were used to further screen for Pgp substrates among chemicals
with MW > 300. Dye efflux experiments were conducted with NIH 3T3 MDR1
cells that stably express human Pgp. A number of potential substrates were identi-
fied by this assay (including ivermectin and abamectin), as shown by their capabil-
ity to interfere with efflux of Hoechst 33342 dye from the cells.  A more definitive
assay was used to test chemicals with known cytotoxicity by comparing toxicity in
the MDR1 cells and wild type 3T3 cells. Pgp substrates (i.e., chemicals that were
less toxic to MDR1 cells) included captan, naled, pyriproxyfen, thiophanate,
thiodicarb, abamectin, niclosamide, and rotenone. These results demonstrate that a
systematic approach involving a combination of in silico and cell-based in vitro as-
says can successfully predict Pgp substrates within large chemical test sets. In vitro
toxicants that are identified as Pgp substrates will require additional toxicokinetic
assessment to correctly predict their potential in vivo toxicity. (This abstract does
not reflect EPA policy.)
511 Transport Mediated Mechanism for Nucleoside Penetration
of the Blood-Testis Barrier.
D. M. Klein1,  R. N. Hardwick1,  K. K. Evans2,  W. H. Dantzler2,  S. H. Wright2
and N. J. Cherrington1. 1Pharmacology/Toxicology, University of Arizona, Tucson,
AZ; 2Physiology, University of Arizona, Tucson, AZ.
The blood-testis barrier (BTB) is formed by tight junctions between Sertoli cells
and prevents the entry of many therapeutics into the lumen of the seminiferous
tubules (STs) shielding developing germ cells from chemical exposure. One drug
class of HIV therapeutics, nucleoside reverse transcriptase inhibitors (NRTIs), can
penetrate the BTB and be detected in human seminal plasma at concentrations
higher than that of blood plasma. The purpose of this study is to determine the
mechanisms by which NRTI drugs are transported across the BTB. Transport stud-
ies in isolated rodent seminiferous tubules using H3uridine (Kt 89.72uM) as a
model nucleoside substrate indicate that seminiferous tubules take up nucleosides
almost exclusively via equilibrative nucleoside transporter 1 (ENT1). The IC50 for
NBMPR, an ENT inhibitor, is 12.9 nM. . Trans-epithelial transport of uridine by
primary rat Sertoli cells can also be blocked by ENT1 inhibition. Blocking ENT1
function on the basolateral membrane also prevents uridine uptake into cells. These
data correspond with immunohistochemical staining of rat testes showing ENT1
on the basolateral membrane, whereas ENT2 is on the apical membrane of Sertoli
cells. This localization suggests that ENT1 acts as an uptake transporter and ENT2
may facilitate the efflux of nucleosides and NRTI drugs into the lumen of STs.
Uridine transport can also be inhibited by NRTI drugs. We also demonstrate
transepithelial transport of radiolabeled NRTIs zidovudine (AZT) and didanosine
(ddI) through primary Sertoli cells is partially blocked by ENT1 inhibition (88%
and 67% for AZT and ddI respectively). These data indicate a novel ENT domi-
nant mechanism for the transepithelial transport of nucleosides and NRTI drugs
across the BTB.
512 Pharmacokinetics and Bioavailability Testing of Levofloxacin
in Rats.
K. K. Kabirov,  A. Banerjee,  E. Onua,  M. Hautmann and A. Lyubimov.
Toxicology Research Laboratory/UIC, Chicago, IL.
Drug exposure of the antibiotic levofloxacin was examined in male and female
Sprague Dawley rats following oral and intravenous administration.
Pharmacokinetic modeling and determination of bioavailability were conducted
following single dose treatment and subsequent measurements of levofloxacin levels
in plasma. Dose levels studied were 50 mg/kg oral (PO) and 25 mg/kg intravenous
110 SOT 2013 ANNUAL MEETING
(IV). There were no abnormal clinical signs observed following dosing, which
might have otherwise affected the pharmacokinetic modeling. The systemic
bioavailability of levofloxacin in rats after PO administration ranges between 33.7 –
42.7%, and appears to be lower in males. The volume of distribution (Vz) appeared
to be higher in female than in male rats following IV administration. Other phar-
macokinetic parameters appeared to be similar in both male and female rats for
both routes of administration. Levofloxacin appears to distribute widely in rat tis-
sues and possibly exhibits a large affinity for tissue proteins. The half-life of the
drug is short (4.33 hr and 4.96 hr in males and females, respectively, following PO
administration; 1.38 hr and 1.55 hr in males and females, respectively, following IV
administration), probably due to a high systemic clearance. Levofloxacin single IV
(25 mg/kg) and PO (50 mg/kg) doses were well tolerated by male and female rats.
Mean (±SD) AUC0-inf values following IV administration were 11339.0 ± 572.3
hr*ng/mL and 9422.7 ± 1169.4 hr*ng/mL, in males and females, respectively, and
following PO administration were 8051.4 hr*ng/mL and 10211.6 hr*ng/mL in
males and females, respectively. Based on mean Tmax and terminal elimination
half-life values, levofloxacin is rapidly absorbed and eliminated.
513 Comparative Disposition and Metabolism of 2, 2’-
Dithiobisbenzanilide following Dermal, Oral, and
Intravenous Administration to Harlan Sprague-Dawley Rats
and B6C3F1/N Mice.
J. Lucak1,  C. Garner1,  C. J. Wegerski1,  J. M. Sanders2,  M. Doyle-Eisele1,
J. D. McDonald1 and S. Waidyanatha2. 1Lovelace Respiratory Research Institute,
Albuquerque, NM; 2National Toxicology Program, NIEHS, Research Triangle Park,
NC.
2, 2’-Dithiobisbenzanilide (DTBBA) is used as a peptizing agent in tires and rubber
products and occupational exposure to DTBBA may occur mainly through dermal
contact. Potential systemic exposure via the dermal route was investigated in ro-
dents and compared to intravenous and oral routes. A single dermal doses of
[14C]DTBBA (4 mg/kg, in acetone) were applied (protected from oral grooming)
to male Harlan Sprague-Dawley rats and B6C3F1/N mice and its disposition and
metabolism 72 h after was compared to 4 mg/kg intravenous and gavage doses.
Following a dermal dose of [14C]-DTBBA in rats and mice, 10.9 ± 2.9% and 10.6
± 2.9% of the dose was absorbed, respectively. Excretion of absorbed dose was via
urine (18.4 ± 3.3%; 34.7 ± 7.7%) and feces (32.6 ± 10.7%; 49.5 ± 10.8%) for rats
and mice, respectively. Following gavage administration in both species, the absorp-
tion was complete. Excretion of 14C after rat intravenous doses was mostly via urine
(73.1± 7%). After mouse intravenous, mouse or rat dermal or gavage doses ~30%
to ~40% was recovered in urine and feces. The percent dose in tissues after dermal
dosing was 4.58 ± 1.92% for the rat and 0.98 ± 1.13% for mouse and in both
species non dose site skin had the highest 14C levels. Radioactivity remaining in tis-
sues followed the trend of dermal ≥ intravenous > gavage in rat and intravenous >
gavage ≈ dermal in mouse. DTBBA was not detected in urine. Urine metabolite
profiles were qualitatively similar between species but the levels of some metabolites
varied between dose routes. The structure of the predominant urinary metabolite
was identified as thiobisbenzanilide-S-glucuronide by LC/MS/MS and 1H and 13C-
NMR. This work was conducted for the NTP under NIEHS Contract N01-ES-
75562.
514 Effect of Vehicle on the Dermal Absorption of 2-Hydroxy-4-
Methoxybenzophenone Harlan Sprague-Dawley Rats and
B6C3F1/N Mice.
C. J. Wegerski1,  C. Garner1,  M. Doyle-Eisele1,  J. M. Sanders2,
J. D. McDonald1,  S. S. Auerbach2 and S. Waidyanatha2. 1Lovelace Respiratory
Research Institute, Albuquerque, NM; 2National Toxicology Program, NIEHS,
Research Triangle Park, NC.
2-Hydroxy-4-methoxybenzophenone (HMB) is used as sunscreen agent with sig-
nificant human exposure. To support a vehicle selection for potential dermal stud-
ies in rodents, the effect of different dermal vehicles on absorption and disposition
of 0.1 or 10 mg/kg [14C]HMB was investigated in male and female Harlan Sprague
Dawley Rats and B6C3F1/N Mice 72 h following application. The vehicles inves-
tigated were ethanol, ethanol:coconut oil (1:1), coconut oil, light paraffin oil, or a
lotion (olive oil:emulsifying wax:water,15:15:70). In rats, the greatest absorption
was observed with paraffin oil (79.8 ± 6.9%). Absorption across all vehicles fol-
lowed the trend of paraffin oil > ethanol:coconut oil > ethanol > coconut oil > lo-
tion. Dose did not have an impact on absorption in rats at 10 and 0.1 mg/kg when
paraffin oil was used as the vehicle (79.8 ± 6.9 and 72.5 ± 8.5% dose, respectively
(p > 0.05). Ethanol gave a large difference in absorbed dose between rats (67.8 ±
3.2% dose) and mice (43.7 ± 3.7% dose) (p < 0.001). The absorbed dose was sim-
ilar between rats (34.6 ± 8.5% dose) and mice (36.8 ± 8.2% dose) when using the
lotion vehicle. There was also no significant difference in the absorbed dose be-
tween male and female mice using the lotion (36.8 ± 8.2% and 46.2 ± 7.3% dose,
respectively) (p >0.05). In rats, the percent dose recovered in tissues ranged from
2.8–8.3 for all dosing vehicles, which was higher than the percent recovered in tis-
sues for mice (0.6–1.2). Non-dose site skin was the site of greatest tissue burden in
both species. In conclusion, these studies indicate use of paraffin oil as the vehicle
provides the highest systemic absorption of HMB and there is a difference in ab-
sorption between rats and mice. This work was conducted for the NTP under
NIEHS Contract N01-ES-75562.
515 Lipophilicity and Membrane Affinity of Munitions
Constituents Using Biolipid Beads.
A. B. Goins1,  D. R. Johnson2,  C. Y. Ang1,  A. M. Scott2,  A. J. Bednar2,
T. M. Reese3 and F. C. Hill2. 1Environmental Laboratory, US Army Engineer
Research & Development Center, Vicksburg, MS; 2Badger Technical Services,
Vicksburg, MS; 3Jackson State University, Jackson, MS.
Bioaccumulation of organic molecules into fat can be predicted by chemical
lipophilicity which is measured by the octanol:water partition coefficient (Kow).
Newly developed methods use the liposome:water partition coefficient (Klipw)
with phosphatidylcholine (PC) instead of octanol to more accurately represent the
capacity of membrane lipids to accumulate neutral organic chemicals. In this study,
a new technique for measuring Klipw using solid-supported PC liposomes attached
to silica beads (TRANSIL® Sovicell, Leipzig, Germany) was used to assess the
membrane affinity (i.e., Klipw) of 10 munitions compounds (MCs) and 5 environ-
mental breakdown products (BPs). Nitroaromatic compounds studied were 2,4,6-
trinitrotoluene [TNT], 2,4-dinitrotoluene [2,4-DNT], 2,6-dinitrotoluene [2,6-
DNT], 1,3,5-trinitrobenzene [TNB], 2,4-dinitroanisole [DNAN]; cyclic
nitramine compounds studied were hexahydro-1,3,5-trinitro-1,3,5-triazine [RDX],
octahydro-1,3,5,7-tetranitro-1,3,5,7-tetrazocine [HMX], hexanitrohexaaza-
isowurtzitane [CL-20]; and other nitrogenous compounds studied were 5-nitro-
2,4-dihydro-3H-1,2,4-triazol-3-one [NTO] and 2,2-dinitro-1,1-ethenediamine
[FOX-7]. Results indicate that nitroaromatic and cyclic nitramine compounds have
lipophilicities with log Klipw ranging from 1.55-3.22, with TNT and RDX log
Klipw 2.18 and 2.26, respectively. RDX-like compounds and the TNT BP 4-amin-
odinitrotoluene (4-ADNT) have Klipw >1 log units higher than computational
and literature-based log Kow. NTO and FOX-7 were found to have very low
lipophilicity (log Klipw < 1, below biolipid assay detection limit). In conclusion,
use of Klipw from biolipid beads rather than Kow from literature or computational
sources may allow scientists and risk assessors to avoid underestimating chemical
bioconcentration.
516 Less Is More: Better Toxicity Data from Fewer Rodents Using
Plasma Microsampling.
G. Schmitt,  A. Eichinger-Chapelon,  D. Zaugg and T. Singer. Toxicology, F.
Hoffmann-La Roche, Basel, Switzerland.
The standard design of drug development rodent toxicity studies today involves nu-
merous large volume blood samplings to characterize the toxicokinetics of a drug
candidate. Due to the large volume and generally required anesthesia, standard
practice is to use additional satellite animals. Using the plasma microsampling tech-
nique developed by Ove Jonsson et al. (Bioanalysis (2012), 4(6), 661-674) would
change this. With this technique, satellite animals for kinetic bleedings are no
longer required (3R-Reduce), anesthesia is no longer required for small (i.e., μL)
blood volume sampling from the tail vein (3R-Refine), and lastly less animals
means less test compound is needed. Ultimately, plasma microsampling would be
used for toxicokinetic blood collection in all types of rodent toxicology studies per-
formed at or under sponsorship of F. Hoffmann-La Roche. To reach this goal, a
method validation study has been initiated using acetaminophen and an anti-
CD20 monoclonal antibody as model compounds. These compounds were selected
to investigate the different analytical methods needed for small versus large mole-
cule, i.e., liquid chromatography coupled to mass spectrometry versus an enzyme-
linked immunosorbant assay, respectively. For each compound, one low and one
high dose were selected to check for dose exposure dependence. The validation
study design would use both the microsampling and conventional large volume
sampling in the same animals in an authentic 14-day rat toxicity study and compare
the exposure data obtained from each technique. If successful (i.e, comparable ex-
posure data), the use of the microsampling technique in rodent toxicity studies will
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lead to i) a significant reduction in animal use (e.g., 32 instead of 48 rats in a 14-
day dose-range finding study), ii) the abandonment of anesthesia for toxicokinetic
blood sampling, and iii) better data as effect and exposure are gathered in the same
animal leading to better assessments of drug-related effects.
517 Using PBPK Modeling to Address Diurnal Variation and Age
Differences in Hexavalent Chromium Toxicokinetics in
Humans.
C. R. Kirman1,  C. M. Thompson2,  D. M. Proctor3,  M. Suh3,  L. C. Haws4,
M. A. Harris2 and S. M. Hays5. 1Summit Toxicology LLP, Orange, OH;
2ToxStrategies, Katy, TX; 3ToxStrategies, Rancho Santa Margarita, CA; 4ToxStrategies,
Austin, TX; 5Summit Toxicology LLP, Allenspark, CO.
A physiologically based pharmacokinetic (PBPK) model has been developed to de-
scribe the toxicokinetics of hexavalent chromium [Cr(VI)] in mice, rats, and hu-
mans. The PBPK model was used to support a human health risk assessment
(HHRA) based upon mouse small intestinal (SI) tumors. Key factors contributing
to the delivery of Cr(VI) to the SI were identified by sensitivity analyses, and in-
clude gastric pH, gastric transit time, and gastric reducing equivalents. These fac-
tors affect the rate of Cr(VI) reduction in gastric contents, with a higher delivery of
Cr(VI) resulting from higher pH values (which causes slower rates of Cr(VI) reduc-
tion), shorter stomach transit times, and lower reducing equivalent concentrations.
The PBPK model was used to address 4 important sources of variation. First, the
model was used to account for normal diurnal variation in gastric lumen factors
(e.g., in normal individuals, baseline gastric pH is typically between 1-3 between
meals, but rises rapidly to levels of 5-7 at the start of a meal, then returning to base-
line levels within a 2-3 hours). Second, the model was used to simulate exposures to
different age groups, including infants, children, youths, adults, and elderly, since
some age groups (e.g., infants) normally exhibit higher pH values than adults. Age-
specific differences in the key factors were incorporated in the modeling to estimate
human equivalent lifetime average daily dose corresponding to point of departures
determined for mouse SI lesions. Third, the model was used to assess risk to specific
populations (proton-pump inhibitor users) that may be sensitive to Cr(VI) due to
alterations in gastric pH. Lastly, the model was used to assess the impact of the tim-
ing of Cr(VI) exposure events on delivery of Cr(VI) to the SI with respect to their
occurrence during or between meals. The implications to HHRA are quantified
and discussed.
518 Advantages of Using Quadrupole Time-of-Flight (QTOF) in
the Bioanalysis of Large Therapeutic Peptides.
F. Garofolo. Bioanalytical Services, Algorithme Pharma, Laval, QC, Canada.
Sponsor: K. Draper.
Purpose.
MUC5AC13, hepcidin, and calcitonin were selected as model compounds to
demonstrate the advantages of QTOF in large therapeutic peptides bioanalysis for
toxicokinetic (TK) and pharmacokinetic (PK) studies. 
Methods.
Samples were prepared by spiking MUC5AC13, hepcidin or calcitonin in plasma.
They were extracted using protein precipitation followed by solid phase extraction.
UPLC was used for chromatography. MUC5AC13 and Calcitonin were analyzed
on TripleTOF5600 with DuoSpray. A KinetexC18 column and 0.6mL/min flow
rate in gradient conditions were used. For hepcidin, electrospray Chip emitters
TriVersaNanoMate on TripleTOF5600 with AtlantisT3 column at 0.5mL/min
flow rate in gradient conditions were used. 
Results.
MUC5AC13 showed multiple charge states +2 and +3 as the most abundant ions
in QTOF full scan. Summing +2 and +3 charge states with a 10mDa extraction
window was used for quantification, over 3.5 orders of linear range (0.4-
2000ng/mL), a precision of <9.3% and an accuracy between 86-113% were ob-
tained. In hepcidin quantification, full scan and parent ion quantification showed
interferences even with narrow extraction window (2-5mDa). The interference
peaks might be in source fragments and thus eliminated by the first quadrupole
(Q1). Hence, quantification of hepcidin was performed in QTOF tandem mass
spectrometry and summing +4 charge state isotopomers of parent ion at a 10mDa
extraction window and it showed 3 orders of linear dynamic range (2-2048ng/mL)
a precision of <9% and an accuracy between 80– 112%. Calcitonin quantification
showed +3, +4 and +5 charge states as the most abundant ions. QTOF full scan and
summing +3, +4 and +5 charge states of parent ion at a 10mDa extraction window
were used for quantification. The observed LLOQ was 50pg/mL with 4 orders of
linear dynamic range. The precision was better than 15% and the accuracy between
83-118%. 
Conclusion.
The benefits of QTOF bioanalytical quantification for large therapeutic peptides
(minimum drug optimization; generic method and non-targeted quantification)
were confirmed and it can be used for TK & PK studies.
519 A New Strategy to Effectively Reduce Matrix Effect Caused
by Phospholipids in Plasma Samples under Hydrophilic
Interaction Liquid Chromatography (HILIC).
M. Raigneau and F. Garofolo. Bioanalytical Services, Algorithme Pharma Inc.,
Laval, QC, Canada. Sponsor: K. Draper.
Purpose.
Significant reduction of matrix effect due to phospholipids (PL) in plasma sample
by using aprotic solvent to improve the performance of bioanalytical methods used
for drug quantification in toxicokinetic and pharmacokinetic studies.
Methods.
Rivastigmine was extracted using liquid-liquid extraction and injected using HILIC
column with ammonium acetate / Acetonitrile (ACN) with a flow
rate=0.8mL/min. Analysis was performed on ABSciexAPI3000 with electro-
spray(+). Lower limit of quantification=10pg/mL. PL were monitored at m/z 184.
The PL extractability was evaluated by samples evaporated in polypropylene (PP)
instead of glass tubes and reconstituted with ACN. 
Results.
Extracted plasma samples were reconstituted in mobile phase (MP blank) or in
ACN blank and injected with post-column infusion of rivastigmine. The post-col-
umn infusion of MP and ACN blanks showed no suppression at the drug retention
time. However, the baseline from the post-column infusion of MP blank dropped
by 35% after seven injections. However, ion-suppression was not observed for the
ACN blank. These results suggest that the late eluting suppressors are not reconsti-
tuted in ACN. PL peak was observed after seven MP blank injections suggesting
that the late eluting suppressors in the MP blank are phospholipids. This peak was
not observed in ACN blank. These results suggest that PL are reconstituted in mo-
bile phase and elute as late eluting suppressors under the chromatographic condi-
tions. However, PL are not reconstituted using ACN. The extracted blank plasma
samples were reconstituted in PP tubes with ACN and compared to MP and ACN
blanks reconstituted in glass tubes to determine if the PL are insoluble in ACN or if
adsorption occurred on the glass tube surface. The PP ACN & MP blanks chro-
matograms were identical thus demonstrating that PL are soluble in ACN but were
adsorbed on silica surface. 
Conclusion.
The reconstitution of extracted samples in glass test tube using 100% ACN suc-
cessfully eliminates the matrix effect caused by phospholipids.
520 Impact of Organic Solvent Additive on the Integrity of
Plasma Samples over Time in Bioanalysis by LC-MS/MS.
C. Dicaire and F. Garofolo. Bioanalytical Services, Algorithme Pharma Inc., Laval,
QC, Canada. Sponsor: K. Draper.
Purpose.
Evaluation of plasma integrity over time due to addition of organic solvent in qual-
ity control samples (QCs) for morphine-6-glucuronide (M6G) bioanalytical
method that was validated to be used in pharmacokinetic studies.
Methods.
The samples were extracted using solid phase cartridges. The injection of the sam-
ples was performed on XBridge Phenyl column (2.1X50mm, 5μ) in gradient con-
ditions on Agilent1100 coupled with ABSciex API5000 in electrospray(+). The
QCs were prepared with M6G alone and M6G + naltrexone (Co-Administered
Drug - CAD) at 1.0% organic content vs. 1.5% respectively. M6G and M6G-D3
(IS) were monitored at m/z 462/201 and 465/289 respectively. Full scans and post-
columns infusion were performed to evaluate the presence and determine the im-
pact of interfering compounds. 
Results.
A significant decrease in signal (~35%) was observed for M6G/IS over time for the
QC containing naltrexone. A post-column infusion profile of these QCs showed
the presence of suppressors which co-eluted with M6G/IS. Chromatographic sepa-
ration was achieved between naltrexone and M6G/IS thus eliminating any possible
suppression from naltrexone. Full scan experiments enabled the detection of two
specific masses co-eluting with M6G/IS only in the QCs stored over time and con-
taining naltrexone. QCs containing only the analyte and others containing the an-
alyte with naltrexone were prepared in different plasma matrices. Some blank ma-
trices were tested alongside with blank matrix containing different organic solvent
percentage. The freshly prepared QCs did not show ion suppression; either in the
presence of naltrexone or of the extra organic solvent. The long-term evaluation of
the matrices in the presence of organic solvent (1.5%), showed two unknown com-
pounds to appear over time and elute at the retention time of M6G thus creating a
suppression zone. 
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Conclusion.
The amount of organic solvent added impacted the integrity of the plasma samples
over time. The ion suppression observed in plasma was not due to the addition of
the CAD (naltrexone) but due to the amount of organic.
521 Dried Blood Spots (DBS) On-Card Derivatization: An Easy
& Alternative Form for Sample Handling to Overcome the
Biological Matrix Instability of Thiorphan.
R. Sabelli and F. Garofolo. Bioanalytical Services, Algorithme Pharma Inc., Laval,
QC, Canada. Sponsor: K. Draper.
Purpose.Use of in-house pre-treatment of DBS cards to overcome stability chal-
lenges of thiorphan in toxicokinetic and pharmacokinetic studies.
Methods.
Thiorphan was spiked in whole blood (range of 5-600ng/mL) and 40uL of whole
blood were applied on untreated or in-house pretreated cards with 2-bromo-3’-
methoxyacetophenone FTA DMPK-A, B and C cards. Disks (6mm) were punched
from the blood spots, transferred into tubes and 200uL of internal standard (thior-
phan-D5) in methanol was added. Samples were vortexed and left on bench for one
hour. 100uL of the supernatant was transferred into 96wellplate already containing
100uL of water prior to injection on a Zorbax BonusRP column eluted using a gra-
dient. Analysis was performed on an ABSciex API3000 in electrospray(+).
Results.
The instability of thiorphan in biological matrix was demonstrated and minimized
by derivatization to thiorphan-MP with 2-bromo-3’-methoxyacetophenone
(BMP). In order to simplify sample handling process, on-card derivatization using
DBS was investigated. The instability of thiorphan on-card, without derivatization,
was demonstrated on all DBS cards used. Therefore, on-card derivatization tech-
nique was investigated. BMP could be added directly to the card for at least 2 days
prior to blood spotting without compromising thiorphan derivatization. Although
the on-card derivatization of thiorphan was successful on the A and C cards, the de-
rivatization reaction seemed to be inhibited on the B card. Linearity of a calibration
curve for a range of 5-600ng/mL was demonstrated using A and C cards pretreated
with 0.5M BMP. Precision was 2-8% and the accuracy was 97-104%. Results
showed on-card stability of thiorphan-MP for at least 2 days. 
Conclusion. 
It was clearly demonstrated that DBS on-card derivatization offers a practical alter-
native for the bioanalysis of thiorphan in TK & PK studies since it requires less ma-
nipulation than the regular sample handling process.
522 Superparamagnetic Iron Oxide Loaded Cross-Linked
Nanoassemblies Improve Tumor Accumulation and Magnetic
Resonance Imaging In Vivo.
M. Dan1, 2,  M. T. Dickerson1,  P. A. Hardy3,  Y. Bae1 and R. A. Yokel1, 2.
1Pharmaceutical Sciences, University of Kentucky, Lexington, KY; 2Toxicology,
University of Kentucky, Lexington, KY; 3Anatomy and Neurobiology, University of
Kentucky, Lexington, KY.
Purpose: To improve accumulation and contrast-enhanced magnetic resonance im-
aging of glioma using cross-linked nanoassemblies loaded with superparamagnetic
iron oxide nanoparticles (CNA-IONPs) for potential glioma theranostic applica-
tions. 
Methods: CNA-IONPs were synthesized and characterized. Gd-DTPA was used to
monitor glioma tumor growth as a T1 contrast agent. CNA-IONPs were injected
via the tail veil of a glioma xenograft rat model. T2 weighted MR images were taken
10 min and 2 h after the injection. T2* was used to predict CNA-IONPs concen-
tration increases. Glioma tumor, contralateral brain tissue, blood, and peripheral
organs were collected at 2 or 6 h and iron concentrations analyzed by inductively
coupled plasma mass spectrometry (ICP-MS).
Results: CNA-IONPs had a neutral zeta potential, hydrodynamic size ~ 30 nm, and
were highly stable in medium containing serum at 37 °C over 30 h. CNA-IONPs
showed significant T2 and T2* contrast enhancement 2 h after injection. Gd-
DTPA (0.3 mmol/kg) enhanced the tumor on T1 images acquired immediately
after injection. T1 images acquired 2 h after injection showed Gd-DTPA was al-
most entirely cleared. In certain regions of the tumor, R2* (1/T2*), which is pro-
portional to iron concentration, increased 48% from 10 min to 2 h after CNA-
IONP injection. ICP-MS iron concentration in glioma tissue was 3 to 9 times
higher than in contralateral brain tissue at 2 h. The iron concentrations in blood
and peripheral organs did not significantly change from 2 to 6 h. 
Conclusions: CNA-IONPs had desirable physicochemical properties for in vivo ap-
plication. They preferentially accumulated in glioma and the concentration in-
creased with time consistent with their long blood circulation time. CNA-IONPs
have the potential to improve MRI diagnosis and provide a platform for incorpo-
rating glioma therapeutics.
Support: NCI Cancer Nanotechnology Training Center grant R25CA153954.
523 Age-Dependent Capability of Drug Metabolism in
Commerciall Avairable Human Hepatocytes.
M. Sunouchi1,  K. Nakazawa1,  R. Kikura-Hanajiri2,  K. Kobayashi3,  H. Kojima1
and M. Usami1. 1Pharmacology, National Institute of Health Sciences, Tokyo, Japan;
2Pharmacognosy and Phytochemistry, National Institute of Health Sciences, Tokyo,
Japan; 3Shizuoka Prefectural Agriculture and Forestry College, Iwata, Japan. Sponsor:
H. Kojima.
Primary human hepatocytes have been worldwide used as a good tool to evaluate
the safety of chemicals containing environmental pollutants, pesticides and drugs.
On the other hand, it is known that the drug-metabolizing enzyme activities of he-
patocytes are changing with aging. There, however, are large interindividual varia-
tions in the levels of CYP enzyme activities and the response to inducers among he-
patocyte donors. Therefore, in this study we analyze the relation between the
enzyme activities and the induction levels of the enzymes.
We analyzed the enzyme activities of CYP1A1, CP2B6, CYP3A4 CYP2C8,
CYP2C9, CYP2C19, CYP2D6 and UGT and their responses to CYP inducers by
comparing the data of cryopreserved human hyepatic cell suspension and platable
hepatocytes regarding the enzyme activities and the levels of mRNA’s encoding the
enzymes presented from multiple suppliers. Total samples used in this study were
obtained from more than 100 donors (3 months - 82 years old). 
CYP1A2 activities in hepatocytes from young donors (< 4 years old) tended to be
reduced in cell suspension and were largely inducted both in the activity and the
mRNA levels in platable hepatocytes by beta-naphthoflavone. The enzyme activi-
ties and the mRNA levels of CYP3A4 and CYP2B6 in the young donors were pos-
itively induced by rifampicin. There was large variability in CYP activities and the
abilities of the inducers. The utility of these cryopreserved human hepatocytes as an
evaluation system for the safety of chemicals will be discussed.
524 AhR-Mediated Epigenetic Modulation of CYP19 and BCRP
in Human Breast Adipose Fibroblasts and MCF-7 Cells.
M. B. van Duursen,  S. M. Nijmeijer,  M. de Dreu and M. van den Berg. Institute
for Risk Assessment Sciences, Utrecht University, Utrecht, Netherlands.
The epithelial-stromal microenvironment in breast cancer largely determines
chances of therapeutic success, due to modulation of tumor cell gene expression
and drug resistance. In breast adipose fibroblasts (BAFs) surrounding a tumor, ex-
pression of aromatase (CYP19), the enzyme responsible for local estrogen produc-
tion, is elevated. In breast cancer cells, over-expression of breast cancer resistance
protein (BCRP) is one of the major causes of multi-drug resistance and chemother-
apy failure. Both BCRP and CYP19 over-expression have been related to hy-
pomethylation of the promoter regions by DNA methyltransfereases (DNMTs).
Earlier studies have suggested that the aryl hydrocarbon receptor (AHR) can func-
tion as an epigenetic regulator. Here, the effect of the non-toxic AHR agonist trani-
last on CYP19 and BCRP expression was investigated in BAFs and MCF-7 cells. In
BAFs, tranilast caused a significant 70% reduction of CYP19 expression, which
concurred with a I.3/pII to I.4-promoter switch. In MCF-7 cells, tranilast induced
expression of the AHR-responsive gene CYP1A1 (15-fold) and breast cancer resist-
ance protein (BCRP, 2-fold), but had no effect on the expression of DNMT1, 3a
and 3b. CYP19 expression in MCF-7 cells was too low to be detected. Inhibition of
DNA methylation by 5-aza-2’-deoxycytidine (5-aza-dC, 10 μM) significantly up-
regulated expression of CYP19, BCRP (28-fold) and DNMTs (2 to 5-fold) in vehi-
cle control-treated MCF-7 cells. In combination with tranilast, the induction of
gene expression by 5-aza-dC was attentuated, except for CYP1A1 expression.
Changes in EROD (CYP1A1) and aromatase activity in MCF-7 cells concurred
with the gene expression profiles. These data show that AHR activation by tranilast
leads to epigenetic modulation. This results in downregulation of CYP19 possibly
through alternate promoter use and potential abrogation of multidrug resistance as
result of BCRP overexpression. Our results indicate that the AHR might provide a
multimodal target in the emerging field of epigenetic therapeutics.
525 The Ah Receptor Recruits Protein Kinases to Phosphorylate
Ser10 in Histone H3 of the CYP1A1 Promoter Chromatin.
H. Kurita and A. Puga. Department of Environmental Health, University of
Cincinnati, Cincinnati, OH.
Halogenated aromatic hydrocarbons such as 2,3,7,8-tetrachlorodibenzo-p-dioxin
(TCDD) cause many types of toxicity via the aryl hydrocarbon receptor (AHR).
One of the best known proteins induced by TCDD is the cytochrome P450 1A1
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(CYP1A1). Induction of this enzyme requires AHR ligand-dependent activation
followed by the activated AHR binding to xenobiotic responsive elements (XRE) in
the promoter region of the Cyp1a1 gene. Histone modifications are well-known
epigenetic markers modulating the activity of transcription factors by alteration of
chromatin states. Among histone modifications, phosphorylation of serine-10 in
histone H3 (H3S10ph) by various kinases has been reported to play a role in mito-
sis. Prior work from this lab had shown that the level of H3S10ph in the XRE en-
hancer region of the Cyp1a1 promoter was elevated by AHR activation, which led
us to search for responsible kinases that would be recruited by the ligand-activated
AHR. To search for candidate kinases that phosphorylate H3S10 in an AHR de-
pendent manner, we performed chromatin immunoprecipitation (ChIP) assays for
the enhancer region of Cyp1a1 in TCDD-treated Hepa-1 cells by using antibodies
for AHR, H3S10ph and various kinases previously reported to phosphorylate this
site. We found that binding of a subset of these kinase, including IKKα, MSK1,
MSK2 and SRK, to the Cyp1a1 enhancer region was absent in control cells and sig-
nificantly increased by TCDD treatment. Given the known role of the AHR in cell
cycle and differentiation, these data suggest that H3S10ph might be an activated
AHR-dependent marker that signals cellular proliferation and mitosis. Supported by
NIH grant R01 ES 06273
526 Epigenetics of Arsenic Carcinogenesis and Location of
Methylated DNA Sites Underlying Gene Expression
Changes.
B. A. Merrick1,  E. J. Tokar1,  D. P. Phadke2,  R. R. Shah2,  M. Wang3,
O. Gordon3,  G. M. Wright3,  M. Burke3,  S. A. Baxter3,  K. E. Pelch1,
R. R. Tice1 and M. P. Waalkes1. 1DNTP, NIEHS, Research Triangle Park, NC;
2Bioinformatics, SRA, Durham, NC; 3Genomics, DHMRI, Kannapolis, NC.
Inorganic arsenic (As) is an environmental human carcinogen and the prostate
gland is among its many target organs. CAsE-PE transformed cells, developed after
prolonged As exposure of normal human RWPE-1 prostate cells, have aberrant
methylated DNA (MeDNA) patterns. We hypothesized that MeDNA changes
might influence gene expression in As transformation. MeDNA changes were stud-
ied on a genome-wide level after affinity enrichment followed by bisulfite reduction
and Illumina deep sequencing. Gene expression was determined by RNA-Seq.
Analysis of RNA-Seq data showed 1,068 genes increased and 1,046 decreased at
>2X fold change, p<0.05. Key upregulated genes included vesicular trafficking pro-
tein, Syn3 (594X), the gluconeogenic enzyme FBP1 (321X), the peptidase, GGT5
(414X), and the oncogene, K-Ras (146X); downregulated genes at <100X fold con-
trol included high mobility group HMGA1, fibronectin-1, filamin B and the gly-
colytic enzyme, PKM2. Alignment of bisulfite sequencing data showed 1000’s of
cytosine methylations throughout the genomes of these cells. However, the number
of methylation sites either nearby or within gene coding regions that might influ-
ence expression was a much smaller proportion of total. Several genes had notable
decreases in expression and increased methylation. For example, nestin is an inter-
mediate filament protein and progenitor marker, which was reduced 14X fold in
CAsE-PE transformed cells vs RWPE-1 controls and that had a concurrent average
increase in methylation of cytosines at 27X fold above control within a CpG island
in the 5’ region. Similarly, neurotrimin is an adhesion molecule whose expression in
CAsE-PE cells was reduced by >100 fold vs controls and had a 25X fold increase in
methylation of the promoter region. These data suggest deep sequencing of
meDNA enrichments can provide new insight into effects of environmental car-
cinogens on the epigenetic landscape leading to a malignant phenotype.
527 Age- and Sex-Related Alterations in Renal Global DNA
Methylation during the Life Cycle of Rats.
T. Han,  C. L. Moland,  J. C. Kwekel,  V. Desai and J. C. Fuscoe. Division of
Systems Biology, National Center for Toxicological Research, US FDA, Jefferson, AR.
Epigenetic modifications of DNA, such as methylation of cytosine, are critical to
regulating gene and miRNA expression, cellular differentiation, and X-chromo-
some inactivation, and have been shown to be involved in human diseases includ-
ing cancer. The role of epigenetic changes in renal development and diseases has
been noted. However, comprehensive study is needed to understand the epigenetic
effects on renal disease susceptibility and progression at different life stages and be-
tween the sexes. Recent advances in high throughput technologies such as high
density methylation array and next generation sequencing make it possible to mon-
itor the methylation status at the whole genome level. In this study, kidney tissues
from Fischer 344 rats at 2, 5, 6, 8, 15, 21, 78, and 104wk of age for both sexes were
examined for sex- and age-specific alterations in DNA methylation using Roche
385k rat promoter methylation microarrays, which cover 15,398 CpG island re-
gions. The raw image data were analyzed by DEVA (v1.2.1) to compute the methy-
lation changes in these samples. Biweight mean centering normalization was ap-
plied before downstream analysis. Hierarchical clustering analysis indicated that the
overall methylation patterns are similar between the age groups, but there are dis-
tinct methylation patterns between male and female rats. The results indicate that
there are slightly more methylated sites at 2wk of age compared to later ages. A
higher number of methylated sites were found on the X chromosome in females
than males, suggesting involvement in repression of X-inactivated genes. These re-
sults provide a comprehensive global view of the DNA methylation status in the
kidney over the entire rat life cycle. These age- and sex-related differences in DNA
methylation may provide insights in susceptibility to kidney disease and its progres-
sion.
528 Phylogenetic Identification of Variably Methylated
Transposons As Biomarkers for Early Environmental
Exposures.
C. Faulk,  A. K. Barks and D. Dolinoy. Environmental Health Sciences, University
of Michigan, Ann Arbor, MI.
A small number of retrotransposons in the long terminal repeat (LTR) class are
known to exhibit environmental sensitivity in DNA methylation status, and are
termed “metastable epialleles”. Two of the sequenced examples, the agouti viable
yellow (Avy) and the CDK5 activator-binding protein (CabpIAP) result from a re-
cently inserted LTR, an intracisternal A particle (IAP) element. These insertions are
from the same family, and show high sequence identity (98.5%). Additionally, both
act as biomarkers of early exposure. Until now, neither the full extent of variability
at these metastable epialleles, nor the phylogenetic relationship underlying variable
elements was well understood. Using a computational approach, we identified
10,802 IAP LTRs in mice, and filtered by subtype to yield 1,388 IAP LTRs in the
family that includes Avy and CabpIAP. Phylogenetic analysis revealed duplication
and divergence events subdividing this family into three clades. To characterize vari-
ation across clades, DNA from isogenic mice was subjected to combined bisulfite
and restriction analysis (CoBRA) at 21 LTR transposons (7 per clade). To validate
our candidate IAP LTRs for interindividual variation, we assayed 17 isogenic mice
for shifts in liver DNA methylation patterns. Methylation levels at individual LTRs
varied widely with mean methylation ranging from a low of 59% to a high of 89%.
Among mice, average methylation across all LTRs was not significantly different
(71%-74%, p > 0.99). Finally we determined that the clade with the most con-
served elements had significantly higher average methylation across LTRs than ei-
ther diverged clade. Thus, we increase the number of known epigenetically modifi-
able loci and provide evidence that sequence identity is predictive of methylation
level. Since repetitive elements comprise nearly half of mammalian genomes, they
are likely targets for toxicological disruption, especially during early development.
The characterization of murine metastable epialleles is crucial for the development
of treatments for environmentally-induced disease.
529 Chromatin Context Modulates Genome-Wide p53 Sequence-
Specific Occupancy and Exposure-Induced Gene Expression.
D. A. Bell,  D. Su,  M. R. Campbell and X. Wang. NIEHS, Research Triangle Park,
NC. Sponsor: B. McIntyre.
DNA damaging agents activate p53 to bind to DNA response elements leading to
transactivation of p53 pathway genes and directing cells toward arrest or apoptosis.
To understand the determinants of treatment-specific and tissue-specific responses
to DNA damage we have carried out treatments using ENCODE cells in an expo-
sure model and generated genome-wide data (p53 ChIPseq, H3K4me3 ChIPseq,
sequence specificity, evolutionary conservation and gene expression). Effects of
doxorubicin and nutlin-3 treatments in lymphoid cells have been compared with
other cell types and analyzed in relation to chromatin context based on the EN-
CODE chromatin hidden Markov model (ChromHMM). We identified novel
chromatin interactions that modulate the transcriptional response to p53 activation
following DNA damage. Highly induced p53 genes typically display both low
H3K4me3 marks and low baseline expression. Among the 2568 high confidence
p53-occupied genes detected by p53 ChIP-seq, 45% have active promoter marks
(H3K4me2, H3K4me3, H3k27ac, H3K9ac) prior to treatment. Surprisingly,
based on ChromHMM categorization, ~22% of p53 genes displayed repressive
chromatin states; including many highly-induced p53 response genes. Many p53
peaks were located in genomic regions with preexisting states classified as promot-
ers (16%) or enhancers. However, notably a large percentage (31%) of all p53 bind-
ing peaks were found in repressed or heterochromatin regions far distant from a
transcription start site. Thus p53 binding occurs in regions of both accessible and
inaccessible chromatin although induced expression was most commonly associ-
ated with inaccessible chromatin. We identified p53 DNA binding motifs in 95%
of p53 ChIPseq peaks and used a position weight matrix model (PWM) to score
similarity to the consensus p53 motif. PWM strength and spacer length have dis-
tinctive distribution patterns between different chromatin states. Thus both epige-
netic and sequence-based factors modulate the DNA damage response regulated by
p53.
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530 Mercury Exposure and DNA Methylation among Dental
Professionals.
J. Goodrich,  N. Basu,  A. Franzblau and D. Dolinoy. Environmental Health
Sciences, University of Michigan, Ann Arbor, MI.
Epigenetic alteration may be a key mechanism linking chemical exposures to toxic-
ity and disease. Recent, yet limited, animal and human data suggest that mercury
(Hg) modifies the epigenome, specifically DNA methylation. This study hypothe-
sizes that methylmercury and inorganic Hg exposures from fish consumption and
dental amalgams, respectively, alter DNA methylation patterns at multi-copy re-
peats and candidate genes. Dental professionals were recruited at meetings of both
the Michigan and American Dental Associations (MDA, ADA). Subjects provided
survey data (e.g. exposure sources, demographics) and samples for Hg measurement
and epigenetic analysis. Total Hg was quantified via atomic absorption spectropho-
tometry in hair and urine, indicative of methylmercury and inorganic Hg expo-
sures, respectively. Methylation was assayed globally by pyrosequencing of long in-
terspersed elements (LINE-1) and site-specifically at DNMT1, SEPW1, and SEPP1
in bisulfite converted DNA (isolated from buccal mucosa or saliva in the MDA;
blood leukocytes and saliva in the ADA). In the MDA cohort (n=158), hair Hg
(mean ±SD: 0.55 ±0.54 μg/g) and urine Hg (1.05 ±1.08 μg/L) overlapped with
levels of the general US population. Multivariate linear regression displayed a trend
of hypomethylation at LINE-1 and three candidate genes with increasing hair Hg
levels. Only in males, this trend was significant (p<0.05) in models of mean SEPP1
methylation, methylation of each SEPP1 CpG site, and of one LINE-1 site.
Relationships between urine Hg and DNA methylation were not significant.
Associations between Hg biomarker levels and DNA methylation will be further
explored using samples from the ADA cohort (n>500). This work suggests that
methylmercury modifies DNA methylation at labile regions in males. Epigenetic
modification by Hg should be further investigated to elucidate this pathway as a
mechanism of toxicity.
531 Alteration of Gene Methylation in the Testis of Rats and
Mice Chronically Exposed to Low-Dose Cadmium.
B. Wang1, 2, 3,  L. Yang2,  Y. Tan3 and C. Lu3. 1Department of Pathology, Inner
Mongolia Forestry General Hospital, Hulunbuir, China; 2Department of
Pathophysiology, Jilin University, ChangChun, China; 3Department of Pediatrics,
University of Louisville School of Medicine, Louisville, KY.
Testicular cancer has a unique epigenetic phenotype and Cadmium is known to be
human carcinogens. To further evaluate gene methylation alterations of testis by
Cadmium (Cd) treatment, this study was designed to aim at genome-wide screen-
ing of the altered methylation genes in the testis of rats chronically exposed to low-
dose Cd. First, rats were exposed to Cd at 20 nmol/kg every other day for 4 weeks
and gene methylation was analyzed at the 52nd week with methylated DNA im-
munoprecipitation-CpG island (CGI) microarray. Among the 490 altered genes,
there were 134 genes whose promoter CGIs were all hypermethylated, 346 genes
whose promoter CGIs were hypomethylated, and 10 genes whose promoter CGIs
were some hypermethylated and some hypomethylated. Furthermore, Rassf1 gene
promoter CGI hypermethylation was detected and confirmed in Cd treated mice at
the 60th week by mouse tumor supporessor gene array. In mice model, mice were
given chronic exposure of Cd with and without methylation inhibitor (5-aza-2’-de-
oxyctidene, 5-aza) for 6 weeks and at the 60th week Rassf1 promoter CGI hyper-
methylation was prevented. Results showed that testis of mice previously exposed to
chronic Cd displayed an increased Rassf1 CGI methylation, which was prevented
by 5-aza treatment. These results suggest that DNA methylation of Rassf1 gene
promoter down-regulated its activity, leading to a reduction of testicular apoptosis,
and may be a potential cause of Cd-induced testis cancer.
532 Epigenetic Modifications from Lead Exposure: Influences of
Sex, Exposure Level, and Developmental Timing of Exposure
on DNA Methyltransferases and Methyl Cytosine-Binding
Proteins.
S. Kidd,  D. Anderson and J. Schneider. Thomas Jefferson University, Philadelphia,
PA.
Maintaining normal DNA methylation levels is critical during development and in
adults, DNA methylation may maintain a subtle balance of global gene expression
pattern, crucial for normal neuronal function. DNA methylation is catalyzed by a
family of DNA methyltransferases (Dnmts) that include the maintenance enzyme
Dnmt1 and the de novo methyltransferase Dnmt3a. DNA methyltransferase
(Dnmt) expression is subject to active regulation under both physiologic or patho-
logic conditions and is critical to the regulation of synaptic plasticity in the mature
brain. Dysregulation of Dnmts has been associated with a variety of cognitive dis-
orders. Likewise, methyl cytosine-binding proteins such as MeCP2 and MBD1
play important roles in transcriptional regulation. The present study investigated
the extent to which these enzymes are affected by developmental Pb exposure. Long
Evans dams were fed Pb-containing food (RMH 1000 with or without added Pb
acetate: 0, 150, 375, 750 ppm) prior to breeding and stayed on the same diet
through weaning at postnatal day 25 (perinatal exposure group (Peri)). Other ani-
mals were exposed to the same doses of lead but exposure started on postnatal day 1
and continued through postnatal day 25 (early postnatal exposure group (EPN)). A
third group had Pb exposure from postnatal day 1 through day 45 (long postnatal
exposure (LPE). All animals were euthanized on day 45 and hippocampi were re-
moved, frozen and stored until processed. Analyses showed significant effects on
Dnmt1 and MeCP2 in particular, lesser effects on Dnmt3a and MBD1, with ef-
fects modified by sex, developmental window of exposure and level of Pb exposure.
Interestingly, the degree of modulation appeared to be more related to when the ex-
posure occurred developmentally than to the absolute duration of the exposure.
These data suggest epigenetic effects of developmental Pb exposure on DNA
methylation that depend on sex, level of exposure and developmental period of ex-
posure. Supported by NIH RO1-ES015295.
533 A Clinical Study to Clarify Effect of Blueberry (Vaccinium
spp.) on Oxidative Stress and Global Methylation.
M. Kim and M. Yang. Sookmyung Women’s University, Seoul, Republic of Korea.
Blueberry (Vaccinium spp.) has shown a broad spectrum of biomedical functions
including anti-oxidative and anti-inflammatory effects through in vitro or animal
studies. However, its human studies are relatively few. In addition, food-born epi-
genetic modulators, e.g. folate, genistein, etc., can recover environmental exposure
-related epigenetic alterations. Therefore, epigenetics can be a useful screening
method to find a new functional food. We performed a two weeks- intervention
study to evaluate anti-oxidative and epigenetic effects of blueberry in young women
(N=8, age= 22.6±0.7 yrs, BMI=20.2±1.97 kg/m2). Among the subjects, two per-
sons took vt C (1 g/day) as positive controls and the others took blueberry juice
[240 ml (total polyphenol 300mg, anthocyanin 76mg)/day]. From genomic DNA
of their peripheral blood, we analyzed global methylation-status with
MethylationFlashTMmethylated DNA quantification kit (Epigentek). We also an-
alyzed urinary malondialdehyde (MDA), a biomarker of oxidative stress with
HPLC/UVD. As a result, we found that blueberry did not reduce urinary MDA
levels as much as vt C did. In addition, both blueberry and vt C treatment some-
what increased global DNA methylation. There were no significant differences in
the global DNA methylation between the two treatments (p=0.89). Therefore,
anti-oxidative activity of blueberry was not found in this trial, compared to vt C.
However, its epigenetic effects can be similar to vt C’s. In conclusion, the present
study provides that a medicinal function of blueberry can be induced by global hy-
permethylation rather than anti-oxidative effects.
534 The Role of microRNAs in the Pathogenesis of MMPI-
Induced Skin Fibrodysplasia.
D. P. Tonge1,  J. D. Tugwood2 and T. W. Gant1. 1CRCE, Health Protection Agency,
Oxford, United Kingdom; 2Global Safety Assessment, AstraZeneca, Cheshire, United
Kingdom.
This study sought to investigate the role of microRNAs (miRNAs) in the patho-
genesis of matrix metalloproteinase inhibitor (MMPi) induced skin fibrodysplasia
(FD) in the dog. 
MicroRNAs are short non-protein-coding RNAs that modulate protein translation
from specific mRNAs. Certain miRNAs exhibit tissue specificity, and are dysregu-
lated in response to specific pathologies. MicroRNAs are detectable in biological
fluids, paving the way for their use as biomarkers. Matrix metalloproteinases
(MMPs) are a family of proteolytic enzymes and have been an attractive pharmaco-
logical target for a number of indications. However, development has been ham-
pered by the propensity of these compounds to cause connective tissue pathologies.
The broad-spectrum MMPi AZM551248 has been shown to induce such effects in
the dog, characterised by fibroblast proliferation and collagen deposition in subcu-
taneous tissues.
Thirty 12-month old female beagle dogs were assigned to six groups. Animals were
dosed orally once daily with vehicle, or with vehicle plus 20mg/kg/day
AZM551248 for between 4 and 17 days. miRNA expression profiles in subcuta-
neous skin were determined by high-throughput sequencing (SOLiD 4.0).
Following 4 days MMPi administration, 13 miRNAs were differentially expressed
in the skin compared with vehicle treated animals. Several of these were members of
the miR-200 family and were attenuated in response to MMPi. As the severity of
FD increased at the later time-points, miRNAs associated with TGFβ synthesis
were modulated. Evidence of epithelial to mesenchymal transition was present at all
study time points. Receiver operator curve analysis revealed that miR-21 expression
in the cervical subcutaneous tissue was a sensitive and specific biomarker of FD in-
cidence.
SOT 2013 ANNUAL MEETING 115
We have described a role for miRNAs in processes relevant to the key histopatho-
logical events associated with MMPi-induced FD. Furthermore, we have identified
key miRNAs with the potential to be used as informative biomarkers of FD.
535 Exposure of Pregnant Mice to Chlorpyrifos-Methyl Alters
Embryonic H19 Gene Methylation Patterns.
H. Kang1,  H. Shin1,  J. Seo1,  S. Park1,  Y. Park1,  S. Son1,  S. Jeong3 and J. Kim2.
1Veterinary Toxicology and Chemistry, National Veterinary Research and Quarantine
Service, Anyang, Republic of Korea; 2Toxicology Laboratory, College of Veterinary
Medicine, Konkuk University, Seoul, Republic of Korea; 3GLP Research Center,
College of Natural Science, Hoseo University, Asan, Republic of Korea.
The aim of this study was to identify whether chlorpyrifos methyl (CPM) exposure
during pregnancy leads to changes in the methylation patterns of H19 gene. CPM
4, 20, 100mg/kg bw/day was administered to 4 pregnant mice per group between 7
and 12 days post coitum (d.p.c.). Pregnant mice were killed at 13 d.p.c. and ge-
nomic methylation in primordial germ cells (PGCs) and fetal organs (the liver, in-
testine, and placenta) was examined. Four polymorphism sites in the H19 alleles of
maternal (C57BL/6J) and paternal (CAST/Ei) alleles were identified at nucleotide
position 1407, 1485, 1566 and 1654 and the methylation patterns of 17 CpG sites
were analyzed. The methylation level in male and female PGCs was not altered by
CPM treatment in the maternal allele H19. The methylation level of the paternal
H19 allele was altered in only male PGCs in response to the CPM treatment. The
methylation level at a binding site for the transcriptional regulator CTCF2 was
higher than that at the CTCF1 binding site in all CPM-treated groups. 
In the placenta, the aggregate methylation level of H19 was 56.89% (control) and
ranged from 47.7% to 49.89% after treatment with increasing doses of CPM. H19
gene from theliver and intestine of 13 d.p.c. fetuses treated with CPM was hy-
pomethylated compared with controls, although H19 mRNA expression was unal-
tered. In the placenta, H19 expression was slightly increased in the CPM-treated
group, although not significantly. IGF2 expression levels were not significantly
changed in the placenta. 
In conclusion, CPM exposure during pregnancy alters the methylation status of the
H19 gene in PGCs and embryonic tissues. We infer that these alterations are likely
related to changes in DNA demethylase activity.
536 Autoimmune Disease Triggered by Trichloroethylene Is
Associated with Epigenetic Alterations in Cd4+ T Cells.
K. Gilbert1,  S. Blossom1 and C. Cooney2. 1University of Arkansas for Medical
Sciences/Arkansas Children’s Hospital Research Institute, Little Rock, AR; 2Central
Arkansas Veterans Healthcare System, Little Rock, AR.
Previous studies have shown that chronic (32-week) exposure to occupationally-rel-
evant concentrations of trichloroethylene (TCE) in the drinking water of female
MRL+/+ mice promoted autoimmune hepatitis. This was accompanied by the ex-
pansion of CD4+ T cells that secreted increased levels of IFN-γ and expressed an ac-
tivated (CD44hiCD62Llo) phenotype. The current study was initiated to determine
the mechanism by which TCE altered CD4+ T cell function. The study constituted
a longitudinal evaluation of mouse TCE exposure over 40 weeks. Alterations in
IFN-γ production corresponded to changes in in the expression of markers used to
assess DNA methylation, namely retrotransposons Iap (Intracisternal A Particle)
and Muerv (murine endogenous retrovirus). In addition, global DNA methylation
was significantly altered in CD4+ T cells from TCE-treated mice. Most recently,
bisulfite sequencing revealed that DNA methylation of CpG sites associated with
the Ifng promoter was significantly, and time-dependently altered by TCE expo-
sure. Thus, for the first time, a toxicant known to promote autoimmune disease has
been shown to alter epigenetic processes (DNA methylation) in the cell type that
mediates pathology, namely CD4+ T cells.
537 Is the Current Product Safety Assessment Paradigm
Protective for Transgenerational Epigenetic Effects?
R. A. Alyea1,  M. J. LeBaron1,  R. Sura1,  J. A. Murray1,  I. P. Pogribny2,
J. K. Passage1,  R. G. Ellis-Hutchings1,  N. P. Moore3,  E. W. Carney1,
B. Gollapudi1 and R. J. Rasoulpour1. 1The Dow Chemical Company, Midland, MI;
2Division of Biochemical Toxicology, National Center for Toxicological Research, US
FDA, Jefferson, AR; 3Dow Europe GmbH, Horgen, Switzerland.
Placement of epigenetic effects appropriately into the product safety paradigm is
challenging due to an incomplete understanding of causal associations between epi-
genetics and apical adverse effects. To begin to understand this relationship, groups
of 25 pregnant F0 CD-1 mice were administered ~10 μg/kg/day diethylstilbestrol
(DES) or ~30 μg/kg/day 17β-estradiol (E2) via the diet or by subcutaneous injec-
tion (SC) from gestation day 9 – lactation day 20. F1 offspring were mated for two
additional generations, with F1-F3 offspring evaluated for uterotrophic effects on
postnatal day (PND) 21 and 18 months. F1 generation weanlings in the DES and
E2 diet groups had a 3-4-fold increase in relative uterine weights, which corre-
sponded to hyperplasia and hypertrophy of the endometrial epithelium and hyper-
trophy of the myometrium. Gene array analysis of these groups showed an increase
in cancer and reproductive associated biofunctional and canonical pathways. The
F1 18 month DES SC and diet group had an increase in squamous metaplasia of
the endometrium and squamous cell carcinoma in the DES diet group, but no
histopathological effects in either E2 group at 18 months. When comparing gene
lists in the PND 21 E2 and DES diet groups, ~1500 known genes were unique for
DES, of which 24 remained significantly altered up to 18 months. These gene sets
provided candidates for further epigenetic analysis. The F2 generation DES diet
group had a marginal increase in mean PND 21 uterine weights and a treatment-re-
lated increase in leiomyoma/leiomyosarcoma at 18 months. In the F3 generation,
there was no effect on uterine weight or histopathology at PND 21 or 18 months.
Under the conditions of this study, there were no transgenerational effects associ-
ated with DES or E2, which would suggest that a typical margin of exposure risk
assessment would be protective.
538 Genome-Wide Methylation Profiling in Rat Tissues for
Nongenotoxic Carcinogens Using Medip-Chip.
S. Ozden1,  N. Turgut Kara2,  T. Chen3,  B. Alpertunga1,  K. Chipman4 and
A. Mally5. 1Department of Pharmaceutical Toxicology, Faculty of Pharmacy, Istanbul
University, Istanbul, Turkey; 2Division of Molecular Biology and Genetics, Faculty of
Science, Istanbul University, Istanbul, Turkey; 3School of Public Health, Soochow
University, Suzhou, China; 4School of Biosciences, University of Birmingham,
Birmingham, United Kingdom; 5Department of Toxicology, University of Wüerzburg,
Wüerzburg, Germany.
DNA methylation is an epigenetic mark that has a crucial role in chemical carcino-
genesis. The aim of the study was to perform a genome-wide analysis of DNA
methylation profile of non-genotoxic hepatocarcinogens including tetra-
chlorodibenzo-p-dioxin (TCDD), hexachlorobenzene (HCB), methapyrilene
(MPY) and the male rat kidney carcinogens, d-limonene, p-dichlorobenzene
(DCB), chloroform and ochratoxin A (OTA) in their respective target tissues in rats
dosed under bioassay conditions. Methylated DNA immunoprecipitation
(MeDIP) was used in conjunction with a NimbleGen promoter plus CpG island
array to identify differentially methylated DNA regions (DMRs) on a genome-wide
basis. We first identified a total of 76 candidate DMRs for OTA, 1 DMR for MPY
and 4 DMRs for chloroform by the MeDIP-Chip method. No change was ob-
served in rats treated by TCDD, HCB, DCB and d-limonene. It is expected that
results from this study will contribute to a better understanding of the key molecu-
lar events which occur during early stages of chemical carcinogenesis and aid in
identification of mechanism-based biomarkers for early detection of non-genotoxic
carcinogens.
539 Modulation of DNA (Cytosine-5)- Methylation in the Mouse
Embryonic Stem Es-D3 Cell- and in the Human Intestinal
CaCo2-Cells by Okadaic Acid.
E. E. Creppy,  S. Moukha,  E. Renault and B. Sangare-Tigori. Toxicology,
University Bordeaux Segalen, Bordeaux, France.
Okadaic acid (OA) a polyether fatty acid produced by marine plankton (dinoflagel-
lates) accumulates in the black sponge and in mussels and oysters and causes shell-
fish diarrheic syndrome in consumers. It is also suspected of causing gut tumours in
humans. It is a tumour promoter in mouse skin, inhibitor of protein phosphatase 1
and 2A (IC50=x109M -1) and a potent and specific inhibitor of protein synthesis
in cell-free system (IC50=33.7x1011M-1). The cell death induced by OA occurs by
both apoptosis and necrosis. OA induces hypermethylation and/or hypomethyla-
tion of deosycytidine residues in the DNA concentration-dependently. 
We have investigated the effects of okadaic acid on the methylation of [poly(dIdC-
dIdC)] by DNAMtase of ES-D3 cells in the presence of [3Hmethyl]-SAM, and
3H-labelled OA. The methylation rate was evaluated by the determination of the
total [3H]-label in the thrichloracetate precipitated material after incubation (37°C
for 60 min. in initial velocity conditions) and then by the radioactive counts of the
peak corresponding to the [3H]m5dC by HPLC and Flo-one Packard coupled to
UV detection. m5dC was also quantified by ELISA. In parallel, parameters such as
lipoperoxidation, DNA-oxidized bases related to oxidative stress, ILs production,
NF-kB, 8OH-dG, caspase-3, bax and bcl2 activation were determined. 
The results of three independent experiments showed hypermethylation for low
concentrations of OA (maximum + 90% at 15nM) and hypomethylation for cyto-
toxic concentrations. Altogether these data point at an epigenetic mechanism of ac-
tion of OA in the pathway for its tumour promotion. Since the epigenetic effects
are already induced by low concentration of OA (hypermethylation-mitogenic ac-
tivity) it should be taken into account when assessing the risk for human.
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540 Methylation Profiles of CpG Islands Localized in the
Upstream Regions of the Human Microsomal Epoxide
Hydrolase Gene Promoters.
C. J. Omiecinski,  X. Cai,  S. Su and W. D. Hedrich. Center for Molecular
Toxicology and Carcinogenesis, Pennsylvania State University, University Park, PA.
Previous studies from our laboratory demonstrated that expression of the human
epoxide hydrolyase gene (EPHX1) is driven by a far upstream E1-b promoter in
most human tissues, whereas the proximal E1 promoter selectively drives hepatic
EPHX1 expression. The molecular mechanisms underlying the differential pro-
moter usage are not well elucidated. CpG islands are short stretches of DNA har-
boring relatively higher frequencies of the cytosine/guanine repeat sequence, poten-
tially reflective of higher gene methylation modifications. In-silico analysis of the
human EPXH1 gene indicated that the upstream regions of E1 and E1b promoters
of human EPHX1 gene are both rich in CpG islands. As methylation status of CpG
islands around gene promoter regions is often associated with transcriptional re-
pression of genes, we investigated the methylation status of CpG islands proximal
to the upstream regions of the E1b and E1 promoters in several human cell lines
and in primary human hepatocytes. Our data demonstrate that the methylation
status of all the CpG islands in upstream regions of the E1b promoter from differ-
ent cell lines is essentially the same and only sparsely methylated (<10%). In con-
trast, the CpG islands located at regions close to the E1 promoter are highly methy-
lated (>60%) in cell lines originating from lung and kidney. In contrast, in
hepatocellular carcinoma HepG2/C3A cells, the CpG islands localized at -128bp, -
89bp, -48bp and +8bp of the E1 promoter are 0%, 0%, 0%, 0% and 25% methy-
lated, respectively. Similarly, the CpG islands located at -724bp, -602bp, -128bp, -
89bp, -48bp and +8bp of the E1 promoter in human primary hepatocytes are all
unmethylated. The methylation status of these promoters from human hepatic and
non-hepatic tissues are also consistent with our results from different cell lines and
primary hepatocytes. These findings suggest that differential methylation status de-
termines tissue selective promoter usage for EPHX1 expression in humans.
541 Identification of Arsenic-Responsive microRNAs in Rats by
Genome-Wide High-Throughput Sequencing.
Y. Ge1,  J. R. Olson1,  H. Wu2 and X. Ren1. 1Social and Preventive Medicine &
Pharmacology and Toxicology, The State University of New York at Buffalo, Buffalo,
NY; 2School of Environment and Public Health, Wenzhou Medical College, Wenzhou,
China.
Consumption of drinking water contaminated with arsenic, a naturally occurring
carcinogenic metalloid, constitutes a major public health problem. Although the re-
lationship between exposure and carcinogenesis is well documented, the mecha-
nisms by which arsenic participates in tumorigenesis are not fully elucidated.
Epigenetic modifications are often dysregulated in cancer and occur following ex-
posure to a number of carcinogenic chemicals and are suggested to play a key role
in arsenic-induced carcinogenesis. Beyond DNA methylation, other epigenetic
mechanisms, in particular miRNA expression, that play a critical role in regulation
of gene expression, have yet to be adequately investigated for arsenic. In the current
study, male rats were exposed to sodium arsenite (As(3+)) up to 150ppm in drink-
ing water for 60 days. miRNAs was extracted from rat liver, the primary tissue for
arsenic metabolism and potential target of arsenic carcinogenesis, following As(3+)
treatment. Genome-wide profiling of miRNA in rat livers was generated to identify
As(3+)-responsive miRNAs by next generation high-throughput sequencing tech-
nology. The preliminary results indicate that exposure to environmentally-relevant
levels of As(3+) lead to aberrant expression of multiple miRNAs in rat liver.
Additional analysis will identify miRNAs whose levels are most differentially ex-
pressed in rats due to arsenic treatment, and potentially identify early pre-disease
epigenetic biomarkers of arsenic exposure. The results may also provide insights
into the role of miRNAs in arsenic carcinogenesis (This work was supported by
Zhejiang Natural Science Foundation, China (H.W.); and Startup fund (to X.R.)
provide by SUNY at Buffalo).
542 Benzo(a)pyrene Enhances Line-1 Reactivation in the Absence
of Retinoblastoma Proteins: Implications for Global
Epigenetic Silencing and Heterochromatin Regulation.
D. E. Montoya-Durango and K. S. Ramos. Biochemistry and Molecular Biology,
University of Louisville, Louisville, KY.
Benzo(a)pyrene (BaP) is a ubiquitous environmental pollutant that induces DNA
mutations and disease. At the molecular level, BaP induces the reactivation of
LINE-1 (or L1), a parasitic DNA element that normally remains silent in differen-
tiated cells. L1 epigenetic silencing involves promoter DNA hypermethylation, re-
cruitment of transcriptional repressors such as retinoblastoma (RB), and small
RNAs. Since RB proteins control the cell cycle and help recruit transcriptional
corepressors to chromatin, we hypothesized that i) L1 expression may follow cell
cycle progression, and ii) absence of RB is associated with derepression of L1. In the
present studies, ES-D3 mouse embryonic stem cells were stained live and sorted for
different phases of the cell cycle, followed by measurements of L1 message by quan-
titative PCR. L1 message was most abundant in the G1 phase of the cell cycle, co-
inciding with the stage where RB becomes inactivated by hyperphosphorylation. In
separate experiments, isolates of mouse embryo fibroblast (MEFs) deficient for the
RB family of proteins (TKO MEFs) were exposed to BaP for 12 hours and real time
PCR used to quantify changes in the abundance of L1 transcripts. Compared to
wild type counterparts, RB null cells dramatically overexpressed L1 in the presence
of BaP. Cytochrome P450 genes involved in BaP metabolism also showed an en-
hanced inducibility in mutant cells, suggesting increased chromatin accessibility to
transcription factors. Collectively, these data indicate that L1 is regulated in a cell-
cycle dependent manner and that mutation or loss of RB proteins in humans in the
face of environmental stress may contribute to the deregulation of L1 in somatic
cells. Such deregulation may compromise differentiation programs and induce ac-
quisition of neoplastic phenotypes.
543 DNA Methylation Patterns Represent “Environmental
Footprints” of Transcription Factor Occupancy.
D. Rojas1, 2,  K. Bailey2,  A. Sanders2,  L. Smeester2,  B. Ahir2,  J. E. Rager2,
Z. Drobna3 and R. C. Fry1, 2. 1Curriculum in Toxicology, UNC School of Medicine,
University of North Carolina at Chapel Hill, Chapel Hill, NC; 2Department of
Environmental Sciences and Engineering, UNC Gillings School of Global Public
Health, University of North Carolina at Chapel Hill, Chapel Hill, NC; 3Department
of Nutrition, UNC Gillings School of Global Public Health, University of North
Carolina at Chapel Hill, Chapel Hill, NC.
Previous research has demonstrated that binding of transcription factors (TFs) to
promoters can alter the DNA methylation patterns within these regions. While pre-
vious research was conducted in the context of stem cell differentiation, the impact
of environmental toxicants on TF binding and subsequent effects on DNA methy-
lation has not been examined. Our group recently identified genes in human leuko-
cyte DNA and mouse livers that exhibit differential CpG island methylation fol-
lowing exposure to metals/metalloids including cadmium and arsenic. Among
these genes, we have identified enrichment for transcription factor binding sites
that we postulate represent “environmental footprints” of transcription factor occu-
pancy. For example, we identified enrichment of the Metal-Responsive
Transcription Factor-1 (MTF-1) binding site in the promoter regions of genes in
which DNA methylation status of white blood cells was associated with cadmium
or arsenic exposure in two different human populations. 
Based on these results, we hypothesize that in response to environmental stimuli,
selective occupancy of DNA regions by transcription factors can alter the access of
epigenetic modifiers to DNA, resulting in gene-specific DNA methylation pat-
terns. To support our hypothesis, we utilized in vitro culture of human cells to
study changes in genome-wide promoter DNA methylation patterns associated
with specific changes in transcription factor binding induced by cadmium and ar-
senic. These results provide crucial information relating to the mechanism by which
specific genes display toxicant induced patterns of DNA methylation.
544 Increased Growth Inhibition of Human Breast Cancer Cells
by Co-Treatment with EGCG and 5-aza-2’deoxycytidine Is
Modulated through Epigenetic Mechanisms.
T. Tyagi,  J. Treas and K. P. Singh. Environmental Toxicology, Texas Tech University,
Lubbock, TX.
Breast cancer is the leading cause of cancer deaths in women. Both genetic and epi-
genetic processes are implicated in breast carcinogenesis. Aberrations in DNA
methylation pattern contribute to cancer development. Studies show that half of all
the tumor suppressor genes are inactivated more often by epigenetic, rather than
genetic mechanisms in all types of cancer. As epigenetic changes like DNA methy-
lation are reversible, demethylating drugs, such as, 5-aza -2’ deoxycytidine (5-aza)
are being clinically used as cancer chemotherapeutics. However, there are cytotoxic
effects associated with high doses of these drugs. Alternative dietary compounds
like EGCG, a green tea polyphenol are known to possess anticancer properties with
minimal or no toxic effects on normal cells. EGCG is also reported to have DNA
demethylation and histone modification activity. Therefore, the purpose of this
study was to investigate the efficacy of co-treatment of EGCG and 5-aza, at low
doses in inhibiting growth of MCF-7 breast cancer cells. MCF-7 cells were treated
with either 5-aza, (5μM), EGCG (50μM, 100μM) or their combination. MTT
assay showed that co-treatment significantly decreased cell viability as compared to
SOT 2013 ANNUAL MEETING 117
individual treatment. Both compounds arrest separate phases of cell cycle, but co-
treatment eventually increased the percentage of growth arrested and apoptotic
cells. Increased hypomethylation due to co-treatment was also observed in global
genomic methylation analysis. Downregulation of DNMT1 expression was signifi-
cantly greater in co-treatment than individually treated cells. These data suggest
that co-treatment with EGCG and 5-aza, at low doses can synergistically reverse
hypermethylation induced gene silencing and hence can be used for inhibition of
breast cancer growth while minimizing cytotoxicity on normal cells.
545 Differential Expression of Long Intervening Noncoding
RNAs in the Livers of Female B6C3F1 Mice Exposed to the
Carcinogen Furan.
L. Recio1,  S. Phillips1,  T. Maynor1,  M. D. Waters1,  F. Jackson2, 3 and C. Yauk2.
1ILS, Research Triangle Park, NC; 2Environmental Health Science and Research
Bureau, Healthy Environments and Consumer Safety Branch, Health Canada,
Ottawa, ON, Canada; 3Department of Biology, Carleton University, Ottawa, ON,
Canada.
The mammalian genome is transcribed into mRNAs that code for protein as well as
a broad spectrum of other noncoding (nc) RNA products. Long ncRNAs
(lncRNA), defined as noncoding RNA species > 200 nucleotides long, are emerg-
ing as important epigenetic regulators of gene expression and are involved in a spec-
trum of biological processes of relevance to toxicology. We have conducted a gene
expression profiling study in liver using female B6C3F1 mice exposed to the car-
cinogen furan at 0.0, 1.0, 2.0, 4.0, and 8.0 mg/kg for 3 weeks. LncRNAs showed a
non-linear dose response with no lncRNAs differentially expressed at 1.0 or 2.0
mg/kg and two lncRNAs differentially expressed at 4.0 mg/kg furan. At 8.0 mg/kg
furan, 13.3% (83/632) of the differentially expressed transcriptome was comprised
of lncRNAs. Among the lncRNAs observed, a number showed transcriptional clus-
tering with nearby protein coding genes. For example, in furan-exposed mouse liver
there was increased expression of lncRNA-p21. LncRNA-p21 is an anti-sense tran-
script that is 15 kb downstream from Cdkn1a locus and is known to be induced by
p53 in human cells. LncRNA-p21 appeared to be co-transcribed with the protein
coding gene Cdkn1a in response to 8.0 mg/kg furan. These data suggest that
lncRNAs are transcriptional targets of furan-induced cytotoxicity and cell prolifer-
ation. We hypothesize that lncRNAs have potential as epigenomic biomarkers of
carcinogenic exposures and we are currently examining lncRNA expression in the
liver of mice exposed to a number of other carcinogens.
546 ROS-Generation Leads to 5-Hydroxymethylcytosine
Formation and DNA Demethylation.
J. B. Coulter1, 2,  C. M. O’Driscoll1, 2 and J. P. Bressler1, 2. 1Environmental Health
Sciences, Johns Hopkins University Bloomberg School of Public Health, Baltimore,
MD; 2Neurology, Hugo Moser Research Institute at Kennedy Krieger, Baltimore, MD.
DNA methylation is a chemical modification at the 5’ position on cytosine residues
involved in gene repression. Notably, DNA methylation plays a vital role in stem
cell differentiation. A better understanding of the dynamic processes controlling
methylation and demethylation is critical to identifying chemicals with potential to
disrupt programming of the methylome and may uncover targets in diseases such as
neurodegenerative disease and cancer. While enzymes which methylate cytosines
neighboring guanines (CpG’s) have been identified, no demethylase has been dis-
covered in mammalian cells. Inhibition of DNA methyltransferases leads to
demethylation, though these mechanisms depend on cell division and may not ex-
plain active demethylation in post-mitotic cells such as neurons. Recent work has
uncovered the role of Tet proteins in converting 5-methylcytosine to 5-hydrox-
ymethylcytosine (5-hmC). Subsequent deamination by cytidine deaminases fol-
lowed by base excision repair results in unmethylated cytosine. Here, we show that
sub-lethal exposures of the benzene metabolite hydroquinone (HQ) led to forma-
tion of 5-hmC in HEK293 cells and a human neural progenitor cell line. In
HEK293 cells, HQ exposure led to increases in reactive oxygen species (ROS), re-
activation of a methylation-silenced reporter plasmid, and demethylation of CpG’s
within its promoter. Both 5-hmC formation and plasmid reactivation were inhib-
ited by the antioxidants α-tocopherol and N-acetyl-L-cysteine, indicating ROS for-
mation was involved. Moreover, reactivation of the silenced plasmid by HQ was en-
hanced in cells overexpressing cytidine deaminase APOBEC2. These effects were
observed with no detectable changes in Tet gene expression, though activity may
have changed. Our data indicate toxicant-induced ROS leads to CpG demethyla-
tion in a manner consistent with oxidation-deamination mechanisms catalyzed by
Tet proteins and suggest a link between cellular redox status and maintenance of the
epigenome.
547 A Critical Review of Epigenetic Transgenerational
Inheritance following Environmental Exposures.
J. Heilman,  E. Freeman and B. Polakoff. Exponent, Inc, Washington DC.
Epigenetic transgenerational effects are phenotypic traits passed down from genera-
tion to generation via heritable modifications in the epigenetic landscape. There are
several accounts in the literature investigating the effects of environmental factors
on the transgenerational inheritance of purportedly epigenetic traits. Epigenetic
transgenerational effects have been suggested through animal models to lead to
such conditions as polycystic ovarian disease, prostate disease phenotype, abnormal
sperm parameters, altered discrete brain nuclei, fetal abnormalities, increased tumor
frequency, altered immune function, and indications of kidney disease. Certain
compounds have received particular attention with respect to transgenerational epi-
genetic changes, with some publications claiming to demonstrate transgenerational
epigenetic effects and others refuting the existence of these effects. Recently, in-
creasingly more diverse compounds have been tested for the ability to induce trans-
generational epigenetic changes either alone or in mixtures, including pesticides,
plastics components, and hydrocarbons.  Although many publications claim to
demonstrate clear evidence of transgenerational epigenetic effects, an equally clear
mechanism explaining how the effect is conveyed is often lacking. Additionally, it
remains to be explained how any particular chemical, that is not, for example, a
methyl donor, could impact such a diverse collection of phenotypic outcomes.
While the possibility of epigenetic transgenerational inheritance is not questioned,
it is suggested that a clear or strong mechanistic link has not been established be-
tween many of the compounds purported to effect epigenetic transgenerational in-
heritance, and the subsequently observed phenotypes. A critical analysis of a selec-
tion of the evidence assessing epigenetic transgenerational inheritance following
exposure to environmental agents and chemicals will be presented with particular
focus on mechanisms of epigenetic inheritance, discrepancies in the literature,
study quality, reproducibility and transparency.
548 Effect of Increased Reactive Oxygen Species on microRNA
Expression in First Trimester Placental Trophoblasts.
C. E. Cross,  C. M. Rondelli,  M. Xu and S. Z. Abdel-Rahman. Obstetrics &
Gynecology, UTMB, Galveston, TX.
In early pregnancy, the conceptus is highly sensitive to reactive oxygen species
(ROS). Expression of superoxide dismutase, catalase, glutathione peroxidase and
high levels of glutathione, taurine, and vitamins A and D protect the conceptus by
5 weeks. During implantation, maternal spiral artery remodeling and trophoblast
invasion serves as the beginning of placental development and would result in in-
creased protection of the fetus to normal ROS signaling. However, improper inva-
sion and remodeling can result in disease development. Although debated, the cur-
rent proposed model for preeclampsia, which manifest as abnormally high blood
pressure (>140/80) after 20 weeks gestation in a previously normotensive woman, is
aberrant maternal spinal artery remodeling, subsequent altered angiogenesis and lo-
calized ischemia/reperfusion due to continued muscularization of the spinal arter-
ies. Preeclampsia is associated with low birth weight, preterm labor, small gesta-
tional age, and intrauterine growth restriction as well as altered gene expression in
the placenta as a result of increased ROS production. Epidemiological screening
studies for preeclampsia indicate alterations in placental microRNA (miRNA) ex-
pression as a result of increased trophoblast apoptosis. The goal of this project is to
determine the effect of increased ROS during early placental development on
miRNA expression to better understand the time frame of gene expression alter-
ation. The villous 3A first trimester cell line was exposed to varying concentrations
of H2O2 over 24 hours to determine the amount of intracellular ROS generated
from this model. Using an optimal exposure of 50 μM, we then determined the ef-
fect of increased ROS exposure on the expression of 1008 miRNAs using the
human miRNome PCR array (Qiagen). The miRNAs shown to be altered from in-
creased ROS production are being selected for pathway analysis and further study
using miRNA mimics and inhibitors (Supported by T32-07454; P30-006676).
549 Identification of Mode-of-Action Specific Toxicity Transcript
Profiles In Vitro Using a Connectivity Mapping Approach.
J. M. Naciff1,  N. DeAbrew1,  G. Overmann1,  R. Adams1,  G. Carr1,
R. Settivari2,  J. Tiesman1,  C. Edward2 and G. Daston1. 1Procter & Gamble,
Cincinnati, OH; 2Dow Chemical Company, Midland, MI.
We hypothesize that it is possible to predict toxicity by assessing changes in gene ex-
pression in a small number of cell types enriched in toxicologically relevant path-
ways. We have evaluated the transcriptional profile elicited by 34 chemicals in
HepG2, Ishikawa and MCF7 cells, using microarrays (U219, Affymetrix). These
chemicals act via a number of modes of toxicity and do not involve direct chemical
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reactivity, as this can be adequately detected by a number of simple in vitro meth-
ods. Each of the 34 chemicals was tested at 3 doses and at 3 different time points;
however, data presented here are for only one dose and one time point (6h). The re-
latedness of each transcript profile to each other was analyzed using the cMAP plat-
form (Broad Institute). The results indicate that not all cell lines responded to all
chemicals. For example the response of the Ishikawa cells to methotrexate is mini-
mal (16 genes significantly affected), while the MCF7 and HepG2 cells have a ro-
bust response to this chemical (>3000 genes significantly affected). A comparison
of responses to chemicals that share similar modes of action (MOA) exhibited very
high correlation, even among different cell lines. These correlations held true for
both agonists (cMAP score ≤ 1) and antagonists (score ≤ -1) and extended to
MOAs mediated through receptors (AR, ER, FX, PR, etc.) and enzyme inhibition
(histone deacetylase, DHFR, etc.). For example, using the signature from valproic
acid (VA) treated cells to query the cMAP database yield high positive connectivity
scores for VA in all three cell lines tested, as wells as with other HDAC inhibitors
(vorinastat, trichostatin, bufexama, depudecin and HC toxin), regardless of cell
lines or concentrations. The transcript profile elicited by chemicals with various
MOAs in selected cell types, coupled with a cMAP approach for the analysis of the
response, offers relevant biological data to predict biological activity and MOA, and
thus toxicity, in a defined in vitro system.
550 Analysis of Longitudinal Metabolomic Data from Endocrine
Disruption Studies: The A-SCA Method.
C. Canlet1, 2,  M. Tremblay-Franco1, 2,  N. J. Cabaton1, 2,  R. Gautier1, 2,
L. Debrauwer1, 2,  A. M. Soto3 and D. Zalko1, 2. 1INRA, UMR 1331 TOXALIM
Research Center in Food Toxicology, Toulouse, France; 2Université de Toulouse, INP,
UMR1331, TOXALIM, F-31000, Toulouse, France; 3Department of Anatomy and
Cellular Biology, Tufts University School of Medicine, Boston, MA.
Metabolomics are increasingly being used in the field of toxicology. Experimental
designs involving the study of dynamic changes in the metabolome raise new
methodological challenges in the field of data analysis, regarding long term and
perinatal in vivo studies. Multivariate analysis of variance (MANOVA), often used
to analyze experimental data, is not always appropriate for metabolomics, especially
when sample size is much smaller than the total number of variables, which pre-
vents the testing of underlying hypotheses (normality, homoscedasticity).
Multivariate methods, such as Principal Component Analysis (PCA) or Partial
Least Squares-Discriminant Analysis (PLS-DA), often used to analyze metabolomic
data, do not take into account data’s temporal structure, resulting in a loss of infor-
mation when used alone. In this study, we applied a method combining ANOVA
and PCA: A-SCA (Anova-Simultaneous Component Analysis; SCA is a generaliza-
tion of PCA) taking into account the experimental design, as well as the relation-
ship between variables, to allow data modelisation. Data were first separated into
blocks corresponding to the different sources of variation (experimental design fac-
tors). Then SCA was independently applied on each block, and permutations test
was used to evaluate the significance of model parameters. This method was applied
to the study of the effects of low doses of bisphenol A (BPA) on global metabolism
in SD rats exposed in the perinatal period, (NIEHS project #5RC2ES018822).
Pregnant rats were exposed to DMSO (vehicle-control), 0.25, 2.5, 25 or 250 ng
BPA/kg BW/day. Serum samples of the F1 generation were collected on days 21,
50, 90, 140 and 200 of the experiment, and submitted to 1H NMR spectroscopy.
Using the A-SCA method, time effects were demonstrated.
551 A Systems Chemical Biology Approach to Predict Effects
from Chemical Cocktail Exposure.
K. Kongsbak1, 2,  N. Hadrup1,  A. Vinggaard1 and K. Audouze2. 1National Food
Institute, Technical University of Denmark, Søborg, Denmark; 2Center for Biological
Sequence Analysis, Department of Systems Biology, Technical University of Denmark,
Kgs. Lyngby, Denmark.
Purpose: In its report, Toxicity Testing in the 21st Century, the National Research
Council called for the development of new approaches to human health risk assess-
ment that would rely, in part, on computer-based models rather than animal testing
and epidemiology (National Research Council 2007).
Using a systems chemical biology approach, we have studied the five commonly
used pesticides epoxiconazole, mancozeb, prochloraz, procymidone, and tebucona-
zole that are all known to have effects on male reproductive development. The pur-
pose of this study was to apply a method previously described by Audouze and
Grandjean (Audouze & Grandjean, 2011) to generate hypotheses on the mecha-
nisms linking relevant human outcomes to specific compounds.
Methods: An integrative systems biology approach was adapted to investigate simi-
lar or shared modes of action for the chemicals in the mixture of the five pesticides.
Human chemical-protein/gene associations were collected from the databases
ChemProt, STITCH, and CTD. These associations were then enriched using
known protein-protein interactions (PPIs) to yield associations between the chemi-
cals and PPI networks. Subsequently, data integration was performed using in-
house tools to extrapolate data to human diseases and pathways affected by the se-
lected chemicals.
Results: The applied method on these chemicals is capable of identifying known ef-
fects on male reproductivity and of predicting novel effects on human health.
With the successful identification of known effects, a thorough data analysis is
likely to help the linkage between the investigated compounds and their potential
effects on other aspects of human health.
Perspectives: As the systems chemical biology approach relies on existing data it
serves as an important tool in the efforts to apply alternative methods to animal
testing. Furthermore, the method integrates data from many sources, which allows
for unraveling of previously unidentified pathways of toxicity.
552 Modeling Species-Specific Metabolic Responses to TCDD in
Mice and Rats Using a Reconstructed Metabolic Network.
R. Nault1, 4,  M. Wu3,  C. Chan2, 3, 4 and T. R. Zacharewski1, 4. 1Center for
Integrative Toxicology, MSU, East Lansing, MI; 2Chemical Engineering & Material
Science, MSU, East Lansing, MI; 3Computer Science & Engineering, MSU, East
Lansing, MI; 4Biochemistry & Molecular Biology, Michigan State University, East
Lansing, MI.
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) elicits species-specific transcriptomic
and metabolomics responses. Using a reconstructed metabolic network and pub-
lished microarray datasets, we examined the ability of the network to predict he-
patic metabolomic responses based on TCDD-elicited differential gene expression
profiles. Previously published temporal whole-genome microarray datasets (2-
168h) for TCDD-treated female C57BL/6 mice (30 μg/kg) and female Sprague-
Dawley rats (10 μg/kg) were used. Context-specific metabolic networks were gen-
erated using the Gene Inactivity Moderated by Metabolism and Expression
(GIMME) method by including induced genes (|fold change ≥ 1.5, P1(t) ≥ 0.99)
and reactions necessary to maintain a steady-state flux. The mouse context-specific
metabolic network revealed more reactions involved in fatty acid (FA) activation
and triglyceride synthesis suggesting an increased flux towards lipid synthesis rela-
tive to the rat. Meanwhile, mice had fewer reactions involved in FA oxidation, car-
nitine shuttling, and glycerophospholipid metabolism suggesting FA catabolism is
induced in rats exposed to TCDD. Moreover, the predicted induction of glyc-
erophospholipid metabolism is consistent with reported changes in phospho-
ethanolamine in mice, and phosphocholine and phosphatidylserine in rats. In sum-
mary, we show that context-specific metabolic networks based on transcriptomic
data are consistent with observed species-specific metabolomic changes elicited by
TCDD including hepatic lipid accumulation observed in mice and species-specific
glycerophospholipid metabolism effects. Moreover, the reconstructed metabolic
network facilitated differential gene expression interpretation by providing valuable
insights into the species-specific disruption of metabolic responses. Funded by SRP
P42ES04911.
553 Multiscale Modeling for Individualized Spatiotemporal
Prediction of Drug Effects.
J. G. Diaz Ochoa,  J. Bucher,  J. Niklas and K. Mauch. Insilico Biotechnology AG,
Stuttgart, Germany. Sponsor: C. Yang.
Recently, in silico models for biokinetics have become a relevant way to test the dis-
tribution and metabolism of substances in single cells and in organisms. Its rele-
vance is accentuated by the fact that in the next future an animal free toxicity as-
sessment must be implemented in the European Union. Inside the COSMOS
project (HEALTH-F5-2010-266835), which is funded by the European Union
and a consortium of cosmetic industries (Cosmetics Europe), the central aim is to
develop computational methods and in silico models for the prediction of long
term toxicity upon repeated exposure to compounds. The power of such methods is
(i) to derive quantitative predictions and (ii) to extrapolate results from in vitro
measurements into in vivo predictions.
In this contribution, we present a case study that addresses acetaminophen induced
hepatotoxicity. Based on a metabolic network model assigned to individual cells,
which includes transport, drug metabolism, and intracellular mechanisms leading
to toxicity, we were able to predict the metabolism of acetaminophen and produc-
tion of toxic substances in the liver lobules in different time periods. Depending on
the accumulation of these substances, the cell integrity in the liver was estimated.
Such estimation is relevant not only for the prediction of physical changes in the
organ but also for the prediction of changes in the clearance of the liver under high
or repeated drug dosage. Our model also predicted variations of drug toxicity de-
pending on alterations in metabolic enzyme activities. Variations in enzyme activi-
ties reflect genetic characteristics or diseases of individuals, thus allowing stratified
or even personalized predictions of drug toxicity as well as drug efficacy.
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554 Toxicogenomic Analysis of Environmental PAH Mixtures in
a Model of Transplacental Carcinogenesis.
S. C. Tilton1,  L. K. Siddens2,  A. J. Larkin2,  B. N. Do2,  K. C. Dunn2,
E. P. Madeen2,  S. K. Krueger2,  K. M. Waters1,  W. M. Baird2 and
D. E. Williams2. 1Pacific Northwest National Laboratory, Richland, WA; 2Oregon
State University, Corvallis, OR.
Several polycyclic aromatic hydrocarbons (PAHs) are bioavailable to the fetus in
utero, can generate DNA damage after transplacental exposure and result in in-
creased incidence of carcinogenesis in offspring in an arylhydrocarbon (Ahr)-de-
pendent manner. However, little is known about the effects of environmental PAH
mixtures or mechanisms of carcinogenesis. Therefore, we utilized a mouse model of
transplacental carcinogenesis to investigate the effect of PAH mixtures collected
from environmental samples compared to the known carcinogen,
dibenzo[def,p]chrysene (DBC). Ahrb-1/d (responsive) females were bred with Ahrd/d
(non-responsive) male mice at eight weeks of age. Females were gavaged on gesta-
tion day 17 with DBC, an artificial atmospheric PAH mixture or PAH extract col-
lected from Portland Harbor Superfund Site. Subsamples from each treatment
(n=4) were euthanized 24 hrs post-treatment to collect fetal thymus, lung and liver
for microarrays. At 3-6 months of age, 79% of the offspring from DBC-treated
dams were euthanized due to severe T-cell lymphoma, as expected, which was not
detected in the other treatment groups. Exposure of mice to both DBC and the ar-
tificial atmospheric mixture resulted in significant (p<0.05) increase in the overall
incidence of lung nodules, 100% and 46%, respectively, in offspring at 10 months
of age compared to controls. Global transcriptional analysis of fetal tissues 24 hrs
post-treatment results in treatment-dependent, tissue-dependent and genotype-de-
pendent gene signatures. A pathway-based approach was utilized to identify mech-
anisms of exposure and link gene signatures to tumor outcome. Network and tran-
scription factor analysis of the gene clusters further resulted in identification of
upstream regulators associated with PAH-induced carcinogenesis. These data de-
scribe potential mechanisms for DBC and PAH mixtures in utero that may be
linked to downstream carcinogenesis in offspring. Supported by P42_ES016465.
555 Functional Profiling to Reveal Toxicity Pathways.
C. Vulpe1,  W. Varsally3,  R. Thomas2,  I. Gerlovina2,  B. Gaytan1,  V. De La
Rosa1,  M. North1,  A. E. Hubbard2,  P. Antczak3 and F. Falciani3. 1Nutritional
Science and Toxicology, University of California Berkeley, Berkeley, CA; 2Biostatistics,
School of Public Health, University of California Berkeley, Berkeley, CA; 3University
of Liverpool, Liverpool, United Kingdom.
We contend that functionally conserved toxicity pathways underlie adverse cellular
responses to toxicants. Therefore, we are using functional profiling in Saccharomyces
cerevisiae, to identify the pathways involved in cellular toxicity. In this approach,
the ~4500 viable deletion strains are pooled, grown for multiple generations in the
presence of a toxicant, and sensitivity of each strain is individually quantified. If a
deletion strain is significantly sensitive/resistant, then it provides evidence that the
gene product absent in that strain plays a functional role in toxicity. We utilized this
approach to identify key susceptibility genes to a wide variety of toxicants. We then
applied reverse engineering to infer functional relationships between gene products
and assemble functional networks.  We used the network inference ARACNE algo-
rithm (using a mutual information threshold of 0.35 (equating to a p-value of 10E-
16) to infer a network containing 2604 nodes and 33593 edges representing func-
tional linkage between non-essential genes. We identified key network modules
enriched in different functional properties (e.g. mitochondrial function) that may
represent common toxicity “hubs” and/or endpoints. We evaluated the relationship
between these functional hubs and individual toxicants. We found enrichment of
strains affected by individual toxicants in different hubs, perhaps indicative of the
functional components associated with toxicity for each toxicant. We suggest that
this functional approach in yeast and development of functional networks provides
a unique insight into both the shared and unique molecular responses to toxicant
exposure.
556 Prenatal Exposure to Transition Metals in Ambient PM2.5
Up-Regulates Nitrotyrosine in Human Cord Blood.
C. Barros Veguilla1,  J. Niu2,  B. Yan2,  N. Li2,  Q. Qu1 and L. Chen1. 1Nelson
Institute of Environmental Medicine, New York University School of Medicine,
Tuxedo, NY; 2School of Public Health, Lanzhou University, Lanzhou, China.
Objective: Our previous study indicated that the ambient levels of nickel (Ni), cop-
per (Cu), arsenic (As), and selenium (Se) in Jinchang were 76, 25, 17, and 7 fold
higher than Zhangye, respectively. This pilot study was conducted in both cities to
assess potential adverse effects of prenatal exposures to these high levels of pollu-
tants on the fetus. Methods: A total of 60 healthy nonsmoking pregnant women
were recruited in Jinchang and Zhangye for collection of paired maternal and cord
blood samples. ICP-MS was used to measure the concentrations of Ni, Cu, As, Se,
and Co in blood samples. ELISA kits were used to measure human C-reactive pro-
tein (CRP), interleukin 6 (IL-6), nitrotyrosine, and cotinine. Results: All metals
measured were elevated in both maternal and cord blood collected from Jinchang as
compared to those from Zhangye, while significant differences were only detected
for As, Co, and Se. In addition, Ni and As in cord blood were significantly higher
than those in maternal blood with cord/maternal ratios of 1.56 ± 0.13 and 1.41 ±
0.25, respectively. Surprisingly, the levels of Cu in cord blood were significantly
lower than paired maternal blood (cord/maternal ratios of 0.41 ± 0.04). The cord
blood level of nitrotyrosine in Jinchang was significantly higher than that in
Zhangye (p<0.0001). The other inflammatory biomarkers were not significantly
different between these two groups. In contrast, CRP in maternal blood was 9 fold
higher than cord blood (p<0.0001). The levels of IL-6 and nitrotyrosine were
higher in cord blood compared with maternal blood although the differences were
not statistically significant. Conclusion: The results suggest that the blood-placenta
barrier may effectively prevent transportation of Cu from mother to fetus. On the
other hand, Ni and As may easily penetrate placenta barrier and accumulated in
cord blood, which may be responsible for the up-regulation of nitrotyrosine.
557 A Global Genomic Screening Strategy Reveals Genetic and
Chemical Activators of Peroxisome Proliferator-Activated
Receptor Alpha (PPARalpha).
C. Corton1,  N. Vasani1,  M. B. Rosen1,  B. D. Abbott1,  C. Lau1,  W. Ward1,
R. S. Thomas2,  D. Applegate3 and K. Oshida1. 1US EPA, Research Triangle Park,
NC; 2The Hamner Institutes for Health Sciences, Research Triangle Park, NC;
3Regenemed, San Diego, CA.
A comprehensive survey of chemical, diet and genetic perturbations that activate
PPARalpha in the mouse liver has not been carried out but would be useful to iden-
tify factors that may contribute to PPARalpha-dependent liver tumors. A gene sig-
nature dependent on PPARalpha activation was identified by comparing the tran-
script profiles after exposure to three PPARalpha activators (Wy-14,643,
fenofibrate, perfluorooctanoic acid) in wild-type and PPARalpha-null mice. In in-
dependent experiments using transcript profiles from the livers of chemically-ex-
posed male or female mice, the signature correctly predicted activation by 2 known
PPARalpha activators but not 10 activators of other pathways. Individual genes in
the signature (i.e., Cyp4a10, Pdk4) were used in RT-PCR experiments to show the
specificity of the response to PPARalpha activators compared to chemical-induced
activation of other xenobiotic-activated transcription factors. The signature was
used with standard classification methods to identify perturbations in which
PPARalpha was activated in an Affymetrix compendium of ~750 mouse liver tran-
script comparisons encompassing a broad range of chemical, dietary and genetic
perturbations. We found that PPARalpha is activated by a number of novel chemi-
cals, dietary regimens and genetic mutations. Specific findings include activation by
1) chemicals that cause steatosis (e.g., TCDD, BaP), 2) dietary regimens of triglyc-
erides, “fast food” and “cafeteria” diets, and fish oil, and 3) nullizygous mutations in
a number of genes (Mfp2, Ercc1, Por, Hnf1a, Fah/p21, Udf2, Hif1a, Hif2a) that
could be secondary to steatosis. The findings increase our understanding of the fac-
tors that impact PPARalpha activation and that could contribute to increases in
PPARalpha-dependent liver tumors. (This abstract does not represent EPA policy.)
558 Proteomic Analysis of Biological Responses from Exposures
to Chemical Mixtures.
M. E. Bruno1,  W. Winnik2,  A. Swank2,  K. Wallace1,  S. Leavitt1 and Y. Ge1.
1ISTD, US EPA, Research Triangle Park, NC, NC; 2US EPA, Research Triangle Park,
NC. Sponsor: K. Kitchin.
Nickel (Ni), cadmium (Cd) and chromium (Cr) are human lung carcinogens but
the key events leading to their toxic effects are not fully elucidated. In addition, lit-
tle is known about the molecular basis and the underlying toxic mechanisms of co-
exposure of these carcinogenic metals which are frequently observed in environ-
mental exposures. In this study, we investigated the biological responses and effects
of the exposures of three metals, individually and in combinations, in BEAS-2B
human lung epithelial cells. Utilizing two dimensional gel electrophoresis and mass
spectrometry, we identified 455 differentially expressed proteins in BEAS-2B cells
exposed to the metals and their mixtures at different doses. The identified protein
changes were validated using Western blot and protein functional assays. These al-
tered proteins were mapped to protein interaction networks, toxicity lists, and
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canonical pathways using Ingenuity Pathway Analysis. The number of pathways af-
fected in cells exposed to single metals or metal mixtures were: Ni ( 4 up and 5
down), Cd ( 1 up and 7 down), Cr ( 6 up and 0 down), Cd-Cr binary ( 12 up and
9 down ) and Cd-Cr-Ni ternary ( 11 up and 5 down). The proteins and pathways
that were unique or common to the specific metals and their mixtures were also
identified. For instance, ubiquitin conjugated enzyme E2 protein was present only
in mixtures. At the pathway level, Rho A signaling was changed only in mixtures.
Specific effects of a metal in a binary mixture was also ascertained. Exposure to Cr
(1.8 μm) resulted in upregulation of the protein ubiquitination pathway. In con-
trast, coexposure to a Cd (7.5 μM) and Cr (1.8μm) binary mixture had the oppo-
site effect on this pathway. In summary, this study enabled us to (1) distinguish sin-
gle metals from metal mixtures at both the protein and pathway level and (2)
determine the contribution of a metal in a metal mixture.
This abstract does not necessarily reflect EPA policy
.
559 Environmentally Relevant Concentrations of the Flame
Retardant BDE-209 in Sediment Linked to Potential
Developmental and Neurotoxic Effects on Zebrafish
Embryos.
N. G. Reyero Vinas1,  L. Escalon2,  E. Prats3,  J. Stanley2,  B. Thienpot3,
N. Melby2,  P. Babin4,  E. J. Perkins2 and D. Raldua3. 1Mississippi State University,
Vicksburg, MS; 2US Army, Vicksburg, MS; 3CSIC, Barcelona, Spain; 4University of
Bordeaux, Bordeaux, France.
Decabromodiphenyl ether (BDE-209) is a fully brominated diphenyl ether com-
pound used as a flame retardant in polystyrene applications such as casings for com-
puters, upholstery textile and televisions. It is highly lipophilic and persistent and as
such it is prone to bioaccumulation and biomagnifications in the food chain.
Increasing concentrations of polybrominated diphenyl ethers in wildlife have been
documented since the mid 1990s. BDE-209 is a very large molecule, and the gen-
eral thought was that due to its size it was not bioavailable, and therefore could not
bioaccumulate in wildlife. Several studies now have proven this concept wrong, as
BDE-209 has been found in many aquatic and terrestrial organisms. Exposure to
BDE-209 has been linked to decreased learning and memory in mice, behavioral
changes in mice and inhibition of neural stem cells into neurons in culture. As
many of the toxic effects of BDE-209 have been found on laboratory exposures,
here we analyze the potential effects of an environmentally relevant dose of BDE-
209 on zebrafish (Danio rerio) embryo. Zebrafish embryos were exposed to sedi-
ments that contained 12,500 μg/kg BDE-209 for eight days. We analyzed gene ex-
pression changes, thyroid function, and morphometric parameters. Gene
expression analysis highlighted the potential effects of BDE-209 on development,
neurotoxicity, and liver toxicity. We then analyzed the effects of BDE-209 on ze-
brafish behavior. BDE-209 affected zebrafish response to light as well as movement.
Our results show that environmentally relevant doses of BDE-209 are not only
bioavailable but can have adverse effects on organisms.
560 The Induction of Oxidative Stress by Mixtures of
Dichloroacetate and Trichloroacetate in the Livers of Mice
after Subchronic Exposure.
E. Hassoun and J. Cearfoss. Pharmacology, University of Toledo, Toledo, OH.
Dichloroacetate (DCA) and trichloroacetate (TCA) are drinking water chlorination
byproducts and were previously found to induce oxidative stress (OS) in the hepatic
tissues of B6C3F1 male mice after subacute and subchronic exposures. In order to
determine the effects of mixtures of DCA and TCA on OS induction in the hepatic
tissues, groups of male B6C3F1 mice were treated daily, by gavage, with 3 different
mixtures (Mix I, Mix II and Mix III) of the compounds for 13 weeks. The concen-
trations of the compounds in Mix I, II and III, respectively corresponded to those
producing approximately 15%, 25% and 35% of maximal induction of OS by the
individual compounds in the subchronic studies. The mice were euthanized at the
end of the treatment period and livers were assayed for the biomarkers of OS that
included production of superoxide anion, lipid peroxidation and DNA single
strand breaks. While the effects on all of the biomarkers in response to Mix. I and
II were additive, they were greater than additive in response to Mix III. The induc-
tion of OS in the livers of B6C3F1 mice after long term exposure to DCA and TCA
was previously suggested as an important mechanism in the long term hepatotoxic-
ity/hepatocarcinogenicity of the compounds, hence exposure to mixtures of the two
compounds are expected to significantly increase the risk of exposure to the indi-
vidual compounds. (Supported by NIH/NIEHS grant # R15ES013706-01A2)
561 Ultrafine Particles Are Not Major Carriers of Carcinogenic
PAHs and Their Genotoxicity in Size-Segregated Aerosols.
J. Topinka1,  A. Milcova1,  J. Schmuczerova1,  J. Krouzek2 and J. Hovorka2.
1Genetic Ecotoxicology, Institute of Experimental Medicine AS CR, Prague, Czech
Republic; 2Institute for Environmental Studies, Faculty of Science, Charles University
in Prague, Prague, Czech Republic.
Some studies suggest that genotoxic effects of the combustion related aerosol are in-
duced by carcinogenic polycyclic aromatic hydrocarbons (c-PAHs) and their deriv-
atives forming organic fraction of the ambient air particulate matter (PM). The
proportion of the organic fraction in PM is known to vary with particle size. The
ultrafine fraction is hypothesized to be the most important carrier of c-PAHs, since
it posses the highest specific surface area of PM. To test this hypothesis, the distri-
bution of c-PAHs in the organic extracts (EOMs) was compared from 4 size frac-
tions of ambient-air aerosols: coarse (1<dae<10 μm), upper (0.5< dae<1 μm), and
lower (0.17< dae<0.5 μm) accumulation, and ultrafine (dae<0.17 μm). High-vol-
ume aerosol samples were collected consecutively in 4 localities differing in the ex-
tent of environmental pollution. The genotoxicity of EOMs was measured by the
analysis of DNA adducts induced in the acellular assay consisting of calf thymus
DNA with/without rat liver microsomal S9 fraction coupled with 32P-postlabelling.
The upper accumulation fraction was the major size fraction in all 4 localities form-
ing 37-46 % of the total PM mass. As per m3 of sampled air, this fraction also binds
the highest ammount of c-PAHs. Correspondingly, the upper accumulation frac-
tion induced highest DNA adduct levels. As per PM mass itself, the lower accumu-
lation fraction is seen to be the most efficient at binding DNA-reactive organic
compounds Interestingly, the results suggest that the fraction of ultrafine particles
of various ambient air samples is neither a major carrier of c-PAHs nor a major in-
ducer of their genotoxicity, which is an important finding for the extensively dis-
cussed toxicity and health effects of ultrafine particles.Support: Grant Agency of the
Czech Republic (CZ: P503/12/G147).
562 Acute, Five- and Ten-Day Inhalation Study of
Hydroprocessed Esters and Fatty Acids-Mixed Fats (HEFA-F)
Jet Fuel.
D. R. Mattie1,  A. L. Carter1,  P. Eden1,  J. Z. Hezel1,  T. R. Sterner2,
D. A. Dodd3,  G. A. Wilson4,  K. L. Mumy5 and B. A. Wong5. 1711 HPW/RHDJ,
Wright-Patterson AFB, OH; 2HJF, Wright-Patterson AFB, OH; 3The Hamner
Institutes for Health Sciences, Research Triangle Park, NC; 4EPL, Research Triangle
Park, NC; 5NAMRU-D, Wright-Patterson AFB, OH.
The U.S. Air Force is pursuing development of alternative fuels to augment or re-
place JP-8 jet fuel. Hydroprocessed Esters and Fatty Acids from Mixed Fats (HEFA-
F) jet fuel was administered as an aerosol and vapor mixture to 5 male and 5 female
Fischer-344 rats per group. Inhalation exposures lasted 6 hours per day for 1 day
(with and without an 11-day recovery period), 5 days or 10 days (5 days per week
for 2 weeks). Concentrations for each exposure were 0, 200, 700 and 2000 mg/m3;
mean aerosol percents were 0, 7, 22 and 28%, respectively. There were no signifi-
cant changes in male or female body weights due to HEFA-F exposure at any time
point. Food and water consumption, urinalysis, clinical pathology, lung
cytokine/chemokine and blood cytokines were measured at 10 days. Decreased
mean food consumption in male rats was significant at 2000 mg/m3. A 10% de-
crease in mean water consumption was observed in all HEFA-F exposed female
rats. Urinalysis changes included a slight decrease in pH in all exposed rats, as well
as a small elevation in ketones and the presence of leukocytes and hemoglobin in
the 2000 mg/m3 males. There were no changes in standard clinical chemistry or
hematology parameters. Caudal lung tissue was analyzed for cytokines, chemokines
and receptors using a PCR array for rat inflammatory cytokines and receptors kit;
no significant changes were seen. Proinflammatory blood cytokines showed no sig-
nificant differences, although a trend for increasing MCP-1 with increasing dose
was seen. Male kidney weight increases were likely related to hyaline droplet forma-
tion, relevant only to male rats. Nasal cavity changes included olfactory epithelial
degeneration at 2000 mg/m3. Alveolus inflammation was seen in the 2 higher doses
at 10 days. To examine sensory irritation, male Swiss-Webster mice were exposed
nose-only to 2000 mg/m3 HEFA-F for 30 minutes, resulting in 23% respiratory
depression.
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563 Global Gene Expression Changes Induced by Organic
Extracts of Air Pollutants in Human Lung Cells.
H. Libalova1,  K. Uhlirova1,  J. Klema2,  M. Machala3,  M. Ciganek3,  J. Topinka1
and R. J. Sram1. 1Institute of Experimental Medicine AS CR, Prague, Czech
Republic; 2Czech Technical University, Prague, Czech Republic; 3Veterinary Research
Institute, Brno, Czech Republic.
Many adverse effects of the ambient air pollution have been linked to polycyclic
aromatic hydrocarbons (PAHs) occurring in the complex mixture adsorbed onto
airborne particles. Besides their genotoxic effect, some of them are known to act via
aryl hydrocarbon receptor (AhR)-mediated nongenotoxic and tumor promoting
mechanism. This study employed human lung adenocarcinoma cells (A549) to in-
vestigate the effect of complex mixture of the air pollutants on the global gene ex-
pression changes. We determined whole-genome gene expression profiles (Illumina
platform) of cells treated with organic extracts (EOMs) from particulate matter
(<2.5 μm) collected in four localities in the Czech Republic differing in the level of
the air pollution. Simultaneously, detailed chemical analysis of EOMs from each lo-
cality was performed. Despite various sources, EOMs exhibited equal qualitative
composition although the absolute level of PAHs and other pollutants in the most
polluted locality was much higher comparing to other localities. Gene expression
profiles of cells treated with equal amounts of EOM from each locality showed sim-
ilar patterns. No significant diversity among localities was found. Goeman’s global
test and KEGG pathway database were applied to identify the most deregulated
pathways and contributing genes. We observed significantly deregulated processes
and genes common for all localities including metabolism of amino acids such as
glycine, serine and threonine (SHMT2, PSAT1), xenobiotic metabolism (CYP1B1,
ALDH3A1), vitamine B6 metabolism (PDXK), TGF-beta signaling (SMAD3),
immune system and infectious diseases (IL8, PTGS2) or cell cycle (E2F2,
CCND3). It has been proposed that most of them are modulated by activated Ah-
receptor. Our results suggest the prominent role of activated Ah-receptor and other
events possibly leading to the metabolic reprogramming and tumor promotion in
A549 cells. Support: Grant Agency of the Czech Republic (CZ:P503/11/0142).
564 Evaluation of Additivity of Binary Mixtures of Perfluoroalkyl
Acids (PFAAs) on Peroxisome Proliferator-Activated
Receptor-Alpha (PPARα) Activation In Vitro.
C. J. Wolf1,  C. Rider2,  C. Lau1 and B. D. Abbott1. 1Toxicity Assessment Division,
US EPA, ORD, NHEERL, Research Triangle Park, NC; 2National Toxicology
Program, NIEHS, Research Triangle Park, NC.
Perfluoroalkyl acids (PFAAs) are found globally in the environment and in animal
tissues, and are present as mixtures of PFAA congeners. Mechanistic studies have
found that in vivo effects of PFAAs are mediated by PPARα. Our previous studies
showed that individual PFAAs activate PPARα transfected into COS-1 cells. Here
we evaluated whether binary combinations of perfluorooctanoic acid (PFOA, C8)
and other PFAAs interact in an additive fashion to activate PPARα. COS-1 cells in
96 well plates were transiently transfected with mouse PPARα luciferase reporter
plasmid. After 24 hours, cells were exposed to either vehicle control (0.1 % DMSO
or water), PPARα agonist (WY14643, 10 μM), C8 or perfluorononanoic acid (C9)
at 1 - 128 μM, perfluorohexanoic acid (C6) at 8 – 1024 μM, or perfluorooctane
sulfonate (C8S) at 4 – 384 μM to generate sigmoidal dose-response curves. In ad-
dition, cells in the same plate were exposed to binary combinations of C8 + either
C6, C9, or C8S, in an 8x8 factorial design. After 24 hours of exposure, cells were
lysed and luciferase activity was measured. Data were transformed on a fold-induc-
tion and % maximal response basis. The dose-response data for individual chemi-
cals were fit to sigmoidal curves and analyzed with nonlinear regression to generate
EC50s and Hillslopes, which were used in response-addition and dose-addition
models to calculate predicted responses for mixtures. All PFOA+PFAA combina-
tions produced dose-response curves that were closely aligned with the predicted
curves for both response addition and dose addition. However, at higher concentra-
tions of all chemicals, the observed response curves deviated upward from the pre-
dicted models of additivity, although with more variability. We conclude that at the
lower concentration ranges, binary combinations of PFAAs behave additively in ac-
tivating PPARα in the COS-1 cell system. This abstract does not necessarily reflect
USEPA policy.
565 Reference Dose (RfD)-Based Chronic Human Health Hazard
Ranking System for Complex Mixtures—Assessment of Polar
Nonhydrocarbons in Groundwater at Biodegrading
Petroleum Sites.
A. K. Tiwary1,  R. I. Magaw1,  D. A. Zemo2,  K. T. O’Reilly3,  R. E. Mohler1 and
K. A. Synoweic1. 1CETC, San Ramon, CA; 2Zemo & Associates LLC, Incline Village,
NV; 3Exponent, Inc., Bellevue, WA.
Chronic human health hazard evaluations of chemical mixtures are challenging and
generally rely on similarities in toxicity mechanisms and dose-additivity of chemi-
cals in the mixture. However, such assessments are inadequate for highly complex
mixtures such as those present in groundwater at biodegrading petroleum sites
where thousands of compounds representing many distinct structural classes of
chemicals may be present. A hazard ranking system based on USEPA Reference
Doses (RfDs) was developed to evaluate the potential chronic human health haz-
ards presented by complex mixtures of polar petroleum biodegradation products in
water. Equivalent risk-based drinking water concentrations for the range of identi-
fied RfDs were derived using the USEPA Regional Screening Level (RSL) equation
for Tap Water Screening Levels (SLwater-nc-ing).
Based on the RfDs of representative chemicals for each structural class of potential
biodegradation products, overall summary hazard rankings of “Low”, “Low to
Moderate”, and “Moderate”, were assigned. Classes constituting chemicals with
RfDs ≥ 0.1 mg/kg/day were defined as being of “Low” hazard; “Low to Moderate”
if 0.1>RfD≥ 0.01 mg/kg/day, and “Moderate” if 0.01>RfD≥ 0.001 mg/kg/day.
These three groups included essentially all of the potential polar biodegradation
products for which RfDs were available. This RfD based system is consistent with
similar systems developed by USEPA OPPTS and UN GHS programs and was val-
idated by review of USEPA summary documents. 
The ranking system was applied to groundwater samples collected from biodegrad-
ing petroleum sites and the results show that the vast majority of the polar
biodegradation products are in structural classes that may present “Low” hazard to
humans. Overall, the polar mixtures are unlikely to present a significant risk to
human health if consumed as drinking water.
566 Repeat-Dose and Developmental Toxicity Assessment of
Crude Oil.
R. H. McKee1,  M. J. Nicolich2,  T. Roy3, 4,  R. White5 and W. Daughtrey1.
1Toxicology and Environmental Sciences, ExxonMobil Biomedical Sciences, Inc.,
Annandale, NJ; 2COGIMET, Lambertville, NJ; 3Port Royal Research, Hilton Head,
SC; 4University of South Carolina, Beaufort, SC; 5American Petroleum Institute,
Washington DC.
Abstract
Petroleum (commonly called crude oil), CAS number 8002-05-9, is a complex sub-
stance of variable composition, primarily composed of hydrocarbon constituents.
The principal acute toxicological hazards are those associated with exposure to
volatile hydrocarbon constituents and hydrogen sulfide, and chronic hazards are as-
sociated with exposure to benzene and polycyclic aromatic compounds (PAC). To
further characterize the potential for repeated dose and/or developmental effects
from dermal contact, the PAC content of 46 crude oils was measured using a
method based on DMSO extraction followed by GC separation and quantitation
of the aromatic ring classes (ARC). Statistical models were then used to predict the
potential for target organ and developmental toxicity of the 46 crude oils based on
their ARC profiles. We compared model predictions to empirical data from previ-
ously tested crude oils, showing that one of the previously tested oils approximated
a “worst case” situation. Thus, this modeling exercise demonstrated that data from
previously tested crude oils could be used to form a reasonable basis for characteriz-
ing the repeated dose and developmental toxicological hazards of crude oils in gen-
eral.
567 Insights from Initial Analysis for Harmful and Potentially
Harmful Constituents (HPHC) in Tobacco Products.
M. Oldham,  D. DeSoi,  K. A. Wagner and M. J. Morton. Altria Client Services,
Richmond, VA.
A total of 20 commercial cigarette and 16 commercial smokeless tobacco products
were initially assayed for 96 HPHC (Draft HPHC list, Federal Register, August 12,
2011) prior to draft guidance by FDA (March 30, 2012). The FDA Draft
Guidance specified a reduced list of HPHC with more replicates than initially
tested. Three contract laboratories were used to complete all testing. The same lots
of commercial product were used for all testing. Cigarettes were tested using both
the ISO and Canadian intense smoking regimens. In general, the levels of HPHC
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constituents in the commercial products tested were consistent with levels previ-
ously reported in the literature. Approximately 12% of HPHC measured for ciga-
rettes and smokeless tobacco products were not found or were below the limit of
quantification. Comparison of initial HPHC results with results from additional
replicates demonstrated statistically significant differences for most HPHC (i.e.
temporal variability). Therefore, simple conventional comparisons, such as two-
sample t-tests are inappropriate for comparing products tested at different points in
time from the same laboratory or from different laboratories. Additionally, all of the
HPHC in mainstream cigarette smoke were correlated to tar yield as previously re-
ported in the literature. 
Although each analytical assay was validated within a laboratory, some HPHC re-
sults were quite different between laboratories. These differences demonstrate the
need for standardized methods between laboratories with defined repeatability and
reproducibility determined by inter-laboratory collaborative testing for each
HPHC using certified reference standards. Since no one-to-one relationship of to-
bacco constituent to human disease exists, the biological relevance of these HPHC
results to human disease is unknown.
568 Different Toxicity Outcomes in Rats Correlated with EPR
and NMR Spectra of Crude Oil from Various Sources.
S. A. Meyer1,  S. Jaligama1,  K. A. El Sayed2 and T. R. Dugas3. 1Toxicology,
University LA-Monroe, Monroe, LA; 2Basic Pharmaceutical Sciences, University LA-
Monroe, Monroe, LA; 3Pharmacology, Toxicology & Neurosciences, LSU Health
Sciences Center, Shreveport, LA.
Crude oil varies with source in its relative composition of alkanes, simple and poly-
cyclic aromatics, nitrogen, sulfur, asphaltene and porphyrin nickel and vanadium.
Here, we identify several toxicological effects upon acute exposure of rats to crude
oil from several sources and correlate these with peaks of select constituents from
spectra of the crude oils obtained with EPR and 1H- and 13C-NMR. Sources of oil
were Louisiana sweet crude, Nigerian (Qua Iboe) sweet crude and Iraq high sulfur
(ONTA, Inc., Toronto, Canada). Female Sprague-Dawley rats were given 2 daily
doses of 2.5 and 5 ml/kg of oil or vehicle (0.5% DMSO in corn oil) by oral gavage.
Rats were euthanized after 48 h and blood was taken for hematology, clinical chem-
istry and immunoassay for cytokines and vasoactive agents. Femur bone marrow
cells were assayed for CFU-GM myeloid progenitors. All oils elevated serum alka-
line phosphatase (ALP) with LA oil being least active, in agreement with liver
pathology. Liver weight increased 25-75% and CYP1A1 protein was elevated with
all, Iraqi oil being most effective. Granulocytes increased ~2-fold by high dose of
LA and Iraqi oil. Spleen weights decreased 30% with high dose of Iraqi and
Nigerian oil. CFU-GMs decreased only with high dose of LA oil (40%).
Vasoconstrictor endothelin-1 increased 2-fold in serum from rats treated with Iraqi
and Nigerian oils. 1H- and 13C-NMR spectra gave qualitatively similar alkane peaks
for all oils, but differing aromatic peaks, e.g., benzene (1H-NMR 7.38 ppm) of
Iraqi oil was least intense. EPR spectra of all oils exhibited asphaltene free radical
peak with intensity greatest for Iraqi oil. Vanadium porphyrin was detected in Iraqi
oil only. Summarizing, LA sweet crude oil was uniquely myelosuppressive and with
lesser effect on spleen and liver weights and ALP. Iraqi oil, richest in asphaltene free
radical and vanadium porphyrin and lowest in benzene, most affected liver weight
and CYP1A1 (LA Board of Regents)
569 Complex Mixtures of PaHs Are More Potent Than
Benzo[a]pyrene at Inducing Cellular Inflammatory and
DNA-Damage Response.
K. Dreij1,  I. W. Jarvis1,  C. Bergvall2,  M. Bottai1,  G. A. Umbuzeiro3,
R. Westerholm2 and U. Stenius1. 1Institute Environmental Medicine, Karolinska
Institutet, Stockholm, Sweden; 2Department Analytical Chemistry, Stockholm
University, Stockholm, Sweden; 3Faculty of Technology, State University of Campinas,
Limeira, Brazil. Sponsor: G. Johanson.
Complex mixtures of polycyclic aromatic hydrocarbons (PAHs) are present in air
particulate matter (PM) and have been associated with many adverse health effects
including cancer and cardiovascular disease. We hypothesize that interactions be-
tween different PAHs stand for a major biological effect. We have previously
showed that soil PAH extracts induce persistent DNA damage including prolonged
activation of DNA damage markers H2AX and Chk1. To further study the effects
of mixtures of PAHs biological testing of air PM extracts were performed using
human HepG2 and H1395 cells and sensitive cellular endpoints relevant for car-
cinogenesis (DNA damage response) and cardiovascular pathogenesis (inflamma-
tory signaling). The cellular response was compared to benzo[a]pyrene (BP) and
dibenzo[a,l]pyrene (DBP). The results showed a more than additive response for bi-
nary mixtures of BP and DBP on activation of Chk1. Persistent activation of DNA
damage signaling was observed at significantly lower concentrations of air PM ex-
tracts than BP alone. Activation of DNA damage signaling was more persistent in
air PM fractions containing PAHs with more than four aromatic rings suggesting
larger PAHs contribute more to the genotoxicity of PAHs in air PM. Furthermore,
we observed significant up-regulation of pro-inflammatory stress responsive genes
including several cytokines in response to air PM extracts corresponding to 1 nM
BP. Employing specific inhibitors showed that the activation of inflammatory sig-
naling was mediated through the Ah-receptor and MAPK signaling. Taken to-
gether, our data indicate synergistic effects on important cellular signaling events
due to PAH interactions. This suggests that human health risk assessment based on
additivity such as toxicity equivalency factor scales may significantly underestimate
the risk of exposure to complex mixtures of PAHs.
570 Individual and Cumulative Health Risk Assessment of 17
PFASs in the Swedish Population.
D. Borg1,  B. Lund2,  N. Lindquist2 and H. Håkansson1. 1Institute of
Environmental Medicine (IMM), Karolinska Institutet, Stockholm, Sweden; 2Swedish
Chemicals Agency (KemI), Stockholm, Sweden.
Perfluoroalkylated and polyfluoroalkylated substances (PFASs) are a large class of
chemicals that have emerged as global environmental contaminants. This study,
carried out in accordance with the European chemicals legislation (REACH) guide-
lines for risk assessment, evaluated possible health risks of 17 PFAS congeners in the
Swedish population. The exposure assessment was based on blood and serum levels
from biomonitoring studies in the Swedish population. Population groups consid-
ered were the general population and occupationally exposed professional ski wax-
ers. The hazard assessment primarily considered hepatotoxicity and reproductive
toxicity which were endpoints shared by the selected congeners. Read-across was
performed to the closest most potent congener for 12/17 congeners lacking toxico-
logical data and/or internal dose levels. The result of the risk characterization
showed no cause for concern for hepatotoxicity or reproductive toxicity in the gen-
eral population, except for hepatotoxicity in a subpopulation eating PFOS-contam-
inated fish. However, a cause for concern was identified for the non-conventional
endpoints disrupted mammary gland development and immunotoxicity. For the
occupationally exposed professional ski waxers safe use could not be shown based
on concern for liver toxicity by PFOA and by all congeners in combination, for re-
productive toxicity by all congeners in combination as well as for disrupted mam-
mary gland development and immunotoxicity. This is the first attempt to assess the
health risks to a combination of a large number of PFASs.
571 Mixtures of Benzo(A)Pyrene with Direct or Indirect Acting
Mutagens Have a Nonmonotonic Mutation Profile.
R. David and N. J. Gooderham. Imperial College, London, United Kingdom.
Genotoxic carcinogens are present in the human diet, and Benzo(a)pyrene (BaP),
2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) and acrylamide (AC)
represent three important examples. BaP is a polycyclic aromatic hydrocarbon gen-
erated by incomplete combustion of organic substances such as lipids, thus con-
taminating numerous foodstuffs, PhIP is a heterocyclic amine formed when meat is
cooked, and AC forms when foods, such as potatoes and cereals, are cooked at tem-
peratures exceeding 100°C. Individually these have been shown to be genotoxic but
the biological consequences of exposure to mixtures of these chemicals have not
been systematically examined. 
The aim of the current study was to examine the biological response of MCL-5 cells
(metabolically competent human lymphoblastoid cell line) to mixtures of these
genotoxins at concentrations relevant to human exposure (μM to sub-nM). Cells
were exposed to the chemicals individually or in mixtures for 24h and mutagenicity
was assessed through resistance to trifluorothymidine at the thymidine kinase (TK)
locus and 6-thioguanine at the hypoxanthine-guanine phosphoribosyltransferase
(HPRT) locus. 
At the TK locus the mixtures produced non-monotonic mutation responses;
100nM BaP combined with some low, non-mutagenic concentrations of other mu-
tagens showed synergism, while antagonism was observed for 10μM BaP in mix-
tures with higher concentrations of other genotoxins. Responses differed between
the two loci, with a higher than anticipated mutation frequency (MF) observed for
high concentration combinations at HPRT compared to TK. Combining 10μM
BaP with 100μM PhIP reduced the number of cells in S phase with a correspon-
ding increase in sub-G1 and G1. Moreover, ethoxyresorufin-O-deethylase (EROD;
CYP1A) activity and CYP1A1 mRNA levels significantly correlated with each
other and with the MF at TK emphasising the involvement of the CYP1A family in
this mutation response. This non-monotonic MF is of significance when consider-
ing risk assessment, especially at low concentration combinations where the indi-
vidual chemicals are not measurably mutagenic.
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572 Preliminary Steps in a Whole Mixture Strategy for Risk
Evaluation.
K. Joshi and C. Gennings. Virginia Commonwealth University, Richmond, VA.
When assessing risks posed by environmental chemical mixtures, whole mixture ap-
proaches are preferred to component approaches. When toxicological data on
whole mixtures as they occur in the environment are not available, EPA guidance
states that toxicity data from one or more mixtures considered “sufficiently similar”
to the environmental mixture(s) can serve as surrogates. However, the selection
process of which mixtures to experimentally evaluate is an open line of inquiry. The
objective of our study was to demonstrate a proof-of-concept strategy for the selec-
tion process using a mixture of 17 polychlorinated dibenzo-p-dioxins (PCDDs),
polychlorinated dibenzofurans (PCDFs) and polychlorinated biphenyls (PCBs)
based on (i) human biomonitoring data from the National Health and Nutrition
Examination Survey (NHANES); and (ii) single chemical dose response models
from the literature. Principal component (PC) analysis was conducted to identify
patterns of chemicals present in humans as measured in serum concentrations in
the US population using NHANES data. Five different concentration patterns
were found to represent 82% of the variation in the mixture concentrations for
these 17 chemicals. Population-based median concentration estimates for the
chemicals identified by large absolute values in the PCs were used to define mixing
proportions for the five mixtures. Robust optimal designs, using a maximin opti-
mization criterion which is robust to model misspecification, were determined for
the mixtures using published dose-response models in Crofton et al (2005, EHP).
The approach provides design information for conducting mixtures studies in sup-
port of a whole mixtures risk assessment. Next steps include estimating the dose
values required to approximate the blood concentrations in the mixtures.
Determining how representative these mixtures are to the population concentra-
tions while testing for sufficient similarity is a long-range research goal. (The au-
thors gratefully acknowledge the support from #R01ES015276, #T32 ES007334,
and #UL1TR000058.)
573 Coexposure to Low-Dose Model Testicular Toxicants Induces
Gene Alterations.
N. Catlin,  S. M. Huse and K. Boekelheide. Brown University, Providence, RI.
Testicular effects of chemical mixtures may differ from those of the individual
chemical constituents. This study assesses the co-exposure effects of the model germ
cell- and Sertoli cell-specific toxicants, X-radiation (x-ray) and 2,5-hexanedione
(HD), respectively. X-ray induces germ cell apoptosis and HD has been shown to
attenuate the x-ray effect on germ cells. Adult rats were exposed to different levels of
x-ray (0.5Gy, 1Gy, 2Gy), HD in the drinking water for 18 days (0.33%, 1%), alone
or in combination. Custom PCR arrays were generated based on a panel of genes
identified through microarray studies; hierarchical clustering of these PCR arrays
identified dose-dependent treatment effects on the apoptosis-related genes Fas,
Aen, and Casp3. The 5Gy + 1% HD co-exposure induced Aen and Casp3 expres-
sion, with a maximum fold induction of 3.1 and 2.6, respectively. Also, Fas was sig-
nificantly induced 2.6-fold at this co-exposure dose, despite no induction of Casp3,
Fas, or Aen expression by x-ray or HD alone. In order to assess cell type-specific at-
tenuation of HD effects with x-ray co-exposure, we used laser capture microdissec-
tion (LCM) to examine a panel of apoptosis-related transcripts using PCR arrays.
Several pro-apoptotic genes were identified, which increase with a fold change
greater than 1.4 after 2Gy x-ray exposure, including Traf3, Tnfsf10 and Fas. We
also identified an anti-apoptotic gene, Bcl2a1d, which increases in fold change
across the different exposures (0.33% HD, 1.3 fold; 2Gy x-ray, 1.6 fold; 0.33%
HD + 2Gy, 3.1 fold). Ingenuity Pathway Analysis of the gene expression data pro-
duced two over-represented pathways across all treatment groups examined with
LCM: Induction of Apoptosis by HIV1 and Death Receptor Signaling. We ampli-
fied LCM RNA and examined the same apoptosis transcripts. When compared to
our unamplified RNA, we found a Pearson correlation coefficient of 0.64, indicat-
ing that use of amplified LCM RNA may introduce significant bias. These results
provide insight into environmentally relevant low-dose co-exposures of model tes-
ticular toxicants.
574 Development of a Portable In Vitro System for Lab. and
Field Aerosol Exposure Studies.
J. Zavala,  K. Lichtveld,  S. Ebersviller,  G. W. Walters,  H. E. Jeffries,
K. G. Sexton,  W. Vizuete,  I. Rusyn and I. Jaspers. Environmental Sciences and
Engineering, University of North Carolina at Chapel Hill, Chapel Hill, NC.
There is a growing interest in studying the toxicity of multi-pollutant mixtures
found in ambient air, and the U.S. Environmental Protection Agency (EPA) is
moving towards setting standards for these types of mixtures. Conventional in vitro
exposure methods do not properly emulate human exposures and are not adequate
to meet the EPA’s strategic plan to demonstrate a direct link between air quality and
health effects. Exposure of cells at the air-liquid interface (ALI) is the most realistic
approach to emulate in vivo exposures. A new portable in vitro system that uses
electrostatics to deposit particles onto the cells has been developed and this study
demonstrates the efficacy of this device. The portable system provides a viable envi-
ronment within its electric field for cultured human lung cells grown on permeable
membrane supports. This method provides an efficient and effective way to expose
cells to particles without prior collection and subsequent resuspension in a liquid
medium. Cell viability testing included maintaining normal cell culture conditions
for exposures across the ALI for periods of up to 4 hours outside of a tissue culture
incubator. Results from all cell viability testing with A549 human lung cells show
that no parts, components, materials or operating characteristics of the portable
sampler induce any cytotoxicity, as measured by lactate dehydrogenase (LDH), or
inflammatory response, as measured by interleukin-8 (IL-8). A549 cells were then
exposed to photochemically-aged diesel exhaust (DE) using the UNC rooftop
smog chamber. An exposure dose of 3.6 μg of DE particles in air was delivered to
the cells and a 3-fold increase in LDH and IL-8 was observed when compared to
controls. This new device can serve as a stepping-stone for researchers and engineers
to develop new and improved in vitro exposure technology suitable for field use.
575 Chemical Dispersants Used in the Gulf of Mexico Are
Cytotoxic to Human Lung and Skin Fibroblasts.
J. Wise1, 2,  S. Wise1, 2, 3,  H. Xie1, 2, 3,  J. Griffitt4 and J. Wise1, 2, 3. 1Wise
Laboratory of Environmental and Genetic Toxicology, University of Southern Maine,
Portland, ME; 2Maine Center for Toxicology and Environmental Health, University
of Southern Maine, Portland, ME; 3Department of Applied Medical Science,
University of Southern Maine, Portland, ME; 4Department of Coastal Sciences,
University of Southern Mississippi, Ocean Springs, MS.
Chemical dispersants are chemicals compounds that can be used to aid in the
cleanup of crude oil spills. In 2010, they became a significant public health concern
due to the BP Deepwater Horizon Oil Crisis; when millions of gallons of chemical
dispersants specifically Corexit® 9527 and 9500 were applied via aerial spray and
deepwater injection to break up the crude oil. Toxicity of Corexit® to humans is
unknown, and the primary routes of exposure to these chemical dispersants are in-
halation, direct dermal contact and ingestion. The objective of this study is to de-
termine the cytotoxicity and genotoxicity of these two dispersants in human lung
(WTHBF-6) and skin (BJhTERT) fibroblasts. Cells were treated with and without
S9 fractions with cofactors, because fibroblast cells may not readily express cy-
tochrome P450 enzymes necessary to metabolize chemicals. Corexit® 9500 was cy-
totoxic to lung and skin cells. Specifically in skin, 50, 250, 350 and 500 ppm, it in-
duced 95, 89, 52, and 3 percent relative survival, respectively. S9-mediated
metabolism increased toxicity inducing 78, 84, 39 and 2 percent relative survival,
respectively. Corexit® 9527 was cytotoxic to lung and skin cells. Specifically in
skin, 500, 650, 850 and 1000 ppm, it induced 89, 56, 73, and 24 percent relative
survival, respectively. S9-mediated metabolism increased toxicity inducing 65, 60,
22 and 0 percent relative survival, respectively. Our genotoxicity data is less clear.
Corexit® 9527 induced 8 aberrations per 100 metaphases at 850 ppm, but caused
cell cycle arrest at 875 ppm. Similarly Corexit® 9500 induced 14 aberrations per
100 metaphases at 350 ppm, but caused cell cycle arrest at 425 ppm. Ongoing and
future work will consider the effects of dispersed oil.
576 Micronanoparticle Suspension Formulation Development for
Medical Chemical Countermeasures.
L. Cabell1,  J. McDonough1,  A. Clark1,  T. Belski2 and L. Mobley2. 1SWRI, San
Antonio, TX; 2CBSM /MITS, Frederick, MD. Sponsor: J. Johnson.
Current U.S. medical chemical countermeasures require battlefield stability and an
effective shelf life. One example is bis-pyridinium oximes that are used for the treat-
ment of Organophosphate (OP) intoxication to counter the effects of AChE inhi-
bition. This class of oximes possesses poor thermal stability in an aqueous formula-
tion due to hydrolytic cleavage. CBMS and SwRI have developed non-Newtonian
suspension formulations of oximes in cottonseed oil (CSO) vehicles that impart
oxime solid stability characteristics to oxime/CSO liquid suspension formulations.
MMB4 DMS and HI-6 DMS have shown superior thermal stability in these liquid
suspension formulations compared to aqueous formulations and equal thermal sta-
bility compared to solid formulations. These types of formulations have shown
bioavailability comparable to parent active pharmaceutical ingredients (API) in
aqueous formulations. Cmax and Tmax for these APIs are relatively the same with
absorption and elimination not substantially affected. In principle, these types of
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suspension formulations can be used to stabilize any drug that is prone to hy-
drolytic cleavage. In addition, the nature of these suspensions inhibits drug-drug
interaction in the formulations as well as promotes differential drug controlled re-
lease if designed appropriately. We have designed these suspensions with high zero-
shear viscosity, which allows it to resist sedimentation and non-Newtonian behav-
ior that causes shear thinning, such that the viscosity decreases and the product
flows easily under a shear force, such as injection through a needle. Furthermore,
the viscosity and sedimentation behavior are controlled by formulation parameters
such as particle size and concentration. DISTRIBUTION STATEMENT A.
Approved for public release; distribution is unlimited.
577 Application of Generalized Concentration Addition to
Receptors That Dimerize.
T. Webster. Department Environmental Health, Boston University School of Public
Health, Boston, MA.
Concentration addition is a standard toxicological method for analyzing mixtures
of similarly acting compounds. A significant limitation of concentration addition is
that it cannot be used to describe the effect of mixtures containing partial agonists
at response levels above that for the compound with lowest efficacy. Unfortunately,
partial agonism is a common phenomenon, limiting the application of concentra-
tion addition. We previously proposed generalized concentration addition (GCA)
as a solution to this issue and successfully used this method to describe data from
experiments involving mixtures of full and partial agonists of the AhR receptor.
GCA requires the use of dose-response functions that are invertible over the rele-
vant range. This posed no problem for the AhR-ligand systems described by a Hill
function with a Hill coefficient of one. Receptors that dimerize (or receptors that
bind two ligands) are often modeled using Hill functions with Hill coefficients of
two, but these functions are not appropriately invertible. We used mathematical
models based on equilibrium kinetics and mass balance to describe a simple phar-
macodynamic model of binding of ligands to receptors followed by dimerization:
e.g., A+RAR, AR+ARARRA, where A is a ligand, R is a receptor, AR is a ligand-recep-
tor complex, and ARRA is the dimerized complex. This leads to theoretical dose-re-
sponse functions that are invertible and different from Hill functions but approxi-
mated by them at low doses. Such models may be applicable to examining mixtures
of full and partial agonists of several systems of receptors that dimerize including
the androgen and estrogen receptors.
578 Generalized Concentration Addition Models Some but Not
All Interactions of Mixtures of Androgen- and Estrogen-
Receptor Active Compounds in High-Throughput Screening
Assays.
F. Parham1,  M. DeVito1,  R. Huang2,  M. Xia2,  B. Collins1,  C. Rider1 and
R. R. Tice1. 1NTP, NIEHS, Research Triangle Park, NC; 2NCATS, NIH, Bethesda,
MD.
As part of the U.S. Tox21 collaboration, 69 mixtures of compounds previously
found to be active in estrogen or androgen receptor (ER or AR) reporter assays were
tested in ER and AR high throughput screening assays in agonist and antagonist
mode. ER-active compounds used were acetochlor, alachlor, bisphenol A, butyl
benzyl phthalate, chlordecone, DDT, dicumyl peroxide, ethylenediamine, p,n-
nonylphenol, and zearalenone. AR-active compounds were androstenedione, dex-
amethazone, fluoxymestrone, hydroxyflutamide, medroxyprogesterone acetate, o-
methoxyphenol, oxymetholone, and progesterone. Of the 69 mixtures, 32 were
AR-active compounds only, 23 were ER-active compounds only, and 14 were both
groups of compounds. Mixtures contained between 2 and 18 chemicals and were
equipotent mixtures, mixtures of equal concentration and mixtures that varied po-
tency of the individual chemicals. The 18 compounds were also tested individually.
A generalized concentration addition model for partial agonism and antagonism
was used to model the concentration-response of the mixtures as a function of the
parameters of the response for the mixture components. The parameters were de-
rived using two optimization methods. In the first method, the parameters for the
mixtures components were derived by fitting the model to the single-component
data, and then the model was used to predict the mixture effects. In the second
method, the parameters were obtained by fitting the model to all the data (both sin-
gle-component and mixture) simultaneously. The second method generally accu-
rately models both the single-component and mixture data, although there were
several mixtures that were not accurately represented by the model. The first
method was inaccurate for many more mixtures. The experiment demonstrates that
high-throughput assays can be used to evaluate dose addition theory for large num-
bers of individual chemicals and mixing ratios.
579 Cumulative Risk Assessment of Radon and Confounder
Mixtures.
M. Mumtaz1,  L. Keith1,  D. Wohlers2 and E. Murray1. 1Division of Toxicology and
Human Health Sciences, CDC ATSDR, Atlanta, GA; 2SRC, Inc., North Syracuse,
NY.
Cumulative risk assessment is a challenging proposition because it involves integra-
tion and collective distillation of all available data capturing the essence of the po-
tential risks of multiple stressors, chemical and nonchemical. The conclusions of
such assessments must also integrate the inherent disparities, the constraints of the
data gaps, and address data uncertainties. More recently communities and stake-
holders have also voiced concerns about health effects beyond the single stressor-
specific critical effects and the role of interactions in the overall toxicity of real life
exposures. Most often the focus has been on chemical toxicity; here we present a
case of chemical plus radiological effects. The Agency for Toxic Substances and
Disease Registry (ATSDR) has updated the Toxicological Profile for Radon to com-
prehensively evaluate its systemic toxicity and carcinogenicity. It features informa-
tion from individual and pooled epidemiological studies of miner and residential
cohorts to assess radon carcinogenicity. These studies largely accounted for smoking
and arsenic as confounders. Crystalline silica and diesel exhaust carcinogenicity was
not integrated into the miner assessments. Thus, radon carcinogenicity may have
been overestimated in miners. Residential epidemiological studies of radon have as-
sessed cancer risk addressing smoking as a confounder and suggested that lung can-
cer mortality in radon-exposed populations may be 25 times higher among smok-
ers than never-smokers. It is not possible to avoid exposure to radon and its progeny
since they are ubiquitous. For this reason, to limit potential health effects, EPA rec-
ommends keeping radon air level <4 pCi/L in residential settings. Diesel exhaust
and other indoor chemicals/non-chemical stressors, including biologics, might en-
hance the health effects of residential radon and should be considered as part of any
risk assessment. (The views expressed in this abstract are those of the authors and
do not necessarily represent the views or policies of ATSDR.)
580 90-Day Inhalation Toxicity Study with Hydroprocessed
Esters and Fatty Acids Jet Fuel from Camelina (HEFA-C) in
Rats.
K. L. Mumy1,  W. R. Howard1,  B. A. Wong1 and D. R. Mattie2. 1Naval Medical
Research Unit - Dayton, Wright Patterson Air Force Base, OH; 2711 HPW/RHDJ,
Wright Patterson Air Force Base, OH.
The Department of Defense is actively pursuing the development of alternative
fuels to augment or replace petroleum-based jet fuels. Towards these efforts, nu-
merous synthetic and biologically-based fuels are currently under consideration for
military use. Given the widespread use of fuels within the military, the health effects
associated with occupational exposure to fuels remains a concern. Toxicity studies
are being performed with the fuels in order to assess any possible health effects re-
lated to fuel exposure. Hydroprocessed Esters and Fatty Acids jet fuel (HEFA) is a
type of hydrotreated renewable jet fuel currently under consideration. One specific
type of HEFA is generated from oils extracted from the camelina plant (Camelina
sativa; HEFA-C). In order to evaluate potential toxicity of HEFA-C, an in vivo 90-
day whole body inhalation study was performed with the fuel (concentrations of 0,
200, 700 and 2000 mg/m3 for 6h/day, 5 days/wk) using male and female Fischer
344 rats. Following exposure, a series of toxicity endpoints was evaluated, including
food consumption and body weight, genotoxicity by micronucleus (MN) test, neu-
rotoxicity and histopathology. There was no change in food consumption attrib-
uted to fuel exposure and the average body weight was found to slightly decrease
(not statistically significant) in animals exposed to the high concentration. MN test
was negative for evidence of genotoxicity. No significant effects were observed on
clinical chemistry or hematology evaluations and no significant neurobehavioral ef-
fects were observed based on functional observational battery and motor activity
tests. Minimal effects attributable to exposure to HEFA-C were observed with
histopathology. These effects included goblet cell hyperplasia and olfactory epithe-
lium degeneration at the highest concentration of exposure. These data will help
guide the establishment of an occupational exposure limit for this alternative jet
fuel.
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581 Chemical Characterization of Complex Aromatic Flame
Retardants for Toxicological Studies.
R. Harris1,  M. Kroenke1,  J. Van Scoy1,  Q. Lawrence1,  B. O’Brien1,
A. Ammenhauser1,  L. Siemann1,  K. Aillon1,  J. Algaier1,  B. Collins2 and
S. Waidyanatha2. 1MRIGlobal, Kansas City, MO; 2National Toxicology Program
NIEHS, Research Triangle Park, NC.
Aromatic phosphates (APs), which are replacing polybrominated diphenyl ethers as
flame retardants, contain multiple isomeric forms and are formulated with other
flame retardants in commercial products. Manufacturer and lot-to-lot variation add
to the complex nature of AP products, making toxicity data interpretation difficult
with respect to individual product components. 
Six APs [triphenyl phosphate (TPP), tert-butylphenyl diphenyl phosphate (BPDP),
tricresyl phosphate (TCP), 2-ethylhexyl diphenyl phosphate (EHDP), isodecyl
diphenyl phosphate (IDDP), and phenol, isopropylated phenol phosphate (3:1)
(IPP)] were nominated to the National Toxicology Program (NTP) for toxicity test-
ing. MRIGlobal supported the NTP by performing chemical identity and purity
studies on the selected chemicals.
GC/FID was used to separate components of each AP and GC/MS or NMR was
used to identify components. TPP and EHDP were of low complexity. TPP con-
tained a single component with chromatographic purity of 99.8% and no variation
between 2 lots of a supplier. EHDP from 2 suppliers contained 3 components and
had chromatographic purities of 98.5 and 97.4%. Both lots contained TPP at sim-
ilar concentrations (1.5 vs. 2.5%). BPDP and TCP were considered to be moder-
ately complex. A lot of BPDP contained 6 major components, identified as BPDP
isomers and TPP. A lot of TCP contained 10 major components identified as TCP
isomers and TPP. IDDP and IPP were considered highly complex with over 20
major components. Seven lots of IPP, from 5 vendors, contained TPP and 14 other
major components identified as IPP isomers. Three IDDP lots from 3 vendors con-
tained TPP and more than 30 components, identified as IDDP isomers or struc-
turally similar analogs. Both IPP and IDDP demonstrated a high degree of lot-to-
lot variability and large supplier differences.
582 Preparation of Toxicological Studies: Principal Component
Analysis of Isopropylated Phenol Phosphate.
J. Algaier1,  M. Kroenke1,  L. Lucas1,  K. Bauer1,  K. Aillon1,  L. Siemann1,
R. Harris1,  B. Collins2 and S. Waidyanatha2. 1MRIGlobal, Kansas City, MO;
2National Toxicology Program, NIEHS, Research Triangle Park, NC.
Phenol, Isopropylated Phosphate (3:1), IPP, is one of many multi-component aryl
phosphate flame retardants also used as plasticizers in products such as
polyurethanes, textile coatings, and paints. Due to potential consumer exposure
and the lack of adequate toxicity data, IPP has been selected for evaluation by the
National Toxicology Program (NTP). MRIGlobal supported the NTP by procur-
ing seven different IPP lots from five suppliers and chemically characterizing the
material. IPP characterization will not only inform the NTP of the material’s com-
plexity, but may allow for source identification of IPP used in product mixtures.
Each IPP lot was analyzed and chromatographically fingerprinted following the de-
velopment of a gas chromatographic/flame ionization detection method. Each lot
contained 25 to 30 components pointing towards the existence of mono- bis- or
tris-isopropylated phenyl groups and multiple positional isomers. With this many
component peaks, simple chromatographic overlays do not allow for complex data
evaluation and understanding of the dynamic nature of these lots.
To achieve a better understanding of IPP component complexity Principal
Component Analysis (PCA) was performed. PCA, a common multivariate statisti-
cal technique for finding patterns in data of high dimension, was used to find po-
tential groupings with respect to suppliers in the dataset generated for 11 key IPP
chromatographic components in 48 sample runs of 7 lots from 5 suppliers. Of the
11 possible principal components, the first 2 explained 56% and the first 3 ex-
plained 75% of the total variance in the data. A 3-D plot of the data clearly demon-
strated supplier grouping, enabling identification of specific suppliers. Commercial
products may now be compared to these fingerprints for possible source identifica-
tion.
583 The Effects of Atrazine Exposure on Genome Wide
Expression Levels in Male Drosophila melanogaster.
M. Xie1,  J. Walters2 and A. C. Fiumera1. 1Biological Sciences, Binghamton
University, Binghamton, NY; 2Ecology and Evolutionary Biology, University of
Kansas, Lawrence, KS. Sponsor: A. Fiumera.
Atrazine (2-chloro-4-ethylamino-6-isopropylamino-1,3,5-triazine) is one of the
most commonly applied herbicides in the United States to control broad leaf and
grassy weeds. Although beneficial in agriculture, atrazine can also be a potential en-
vironmental toxicant. It has been detected at low concentrations in surface water,
ground water and precipitation. In addition, many studies demonstrate that
atrazine is a potent endocrine disruptor and affects a variety of reproductive traits in
vertebrates, such as sperm number and motility, as well as, sperm capacitation. We
are studying the effects of atrazine exposure on genome wide expression levels
(RNA-seq) in the model genetic system, Drosophila melanogaster. Male flies were
reared throughout their entire life cycle on either control food or food containing
20 ppm atrazine and flash frozen at 4 to 6 days old. Two biological replicates, each
consisting of a pool of 40 flies, were prepared for each condition and were multi-
plexed in a single lane of an Illumina HiSeq2000, yielding at least 10 million reads
per replicate. We used different combinations of read-counting procedures (HTseq,
RSEM) and testing statistics (DEseq, baySeq) in all 4 possible combinations to de-
termine differentially expressed genes. Twenty six genes that showed consistent ex-
pression differences (i.e. ranked in the top 50 significant genes of the different
analyses) were analyzed using qRT-PCR (20 control and exposed replicates). Eleven
of these 26 genes were significantly changed after 20 ppm atrazine exposure. Most
of these genes are currently uncharacterized and have not been previously shown to
be affected by environmental stressors. Future work will investigate how polymor-
phisms in these genes impact susceptibility.
584 Effects of Atrazine Exposure on Male Reproductive
Performance in Drosophila melanogaster.
A. R. Vogel and A. C. Fiumera. Biological Sciences, Binghamton University, Vestal,
NY. Sponsor: A. Fiumera.
Atrazine is the one of the most commonly applied herbicides in the United States.
In a variety of vertebrate classes, atrazine can feminize males and reduce their re-
productive performance, likely through its effects on aromatase. Much less is
known, however, about the effects of atrazine on invertebrates. In this study, we in-
vestigate the effects of larval atrazine exposure (4 ecologically relevant concentra-
tions and unexposed controls) on reproductive performance of adult male
Drosophila melanogaster. We scored male mating rate when mating to virgins
(mating rate) and previously mated females (remating rate), as well as, a male’s abil-
ity to prevent the female from remating (refractoriness). We also scored measures of
male induced female fertility, including egg laying rate and total progeny produc-
tion. Atrazine exposure significantly negatively affected male mating rate (p =
0.010), male induced egg laying rate (p = 0.001) and total progeny production (p=
0.012). It had no effect on refractoriness . In general, we observed non-monotonic
responses such that the intermediate exposure levels showed the largest reduction in
male reproductive performance. For example, male remating rate was reduced be-
tween the unexposed controls and individuals reared on food with 2 ppM atrazine
(p < 0.05) but not for flies reared on 20 ppM food. Ongoing work is investigating
sperm sperm transfer, storage and utilization rates.
585 Effects of the Herbicide Trifluralin in HepG2 Cell Culture.
M. F. Franco1 and D. J. Dorta2. 1Universidade de São Paulo (USP). Faculdade de
Ciências Farmacêuticas de Ribeirão Preto (FCFRP), Ribeirão Preto, Brazil;
2Departamento de Química, Universidade de São Paulo (USP). Faculdade de
Filosofia, Ciências e Letras de Ribeirão Preto (FFCLRP), Ribeirão Preto, Brazil.
The emerging contaminants are a new category of xenobiotics widely distributed in
the environment. These contaminants include pesticides, within them are the her-
bicides, a heterogeneous category of chemical products, designed to control weeds.
Trifluralin (α,α,α - trifluoro - 2,6 - dinitro - N,N - dipropyl - p - toluidine) is a her-
bicide used on many agronomic crops. The present study aimed to evaluate the cy-
totoxic effects of the Trifluralin in HepG2 cell culture through the assays of cell pro-
liferation, cell viability and mitochondrial membrane potential. It was used
concentrations of 1, 5, 10, 20, 50 and 100μM of trifluralin dissolved in dimethyl-
sulfoxide. The time of exposure was 24, 48 and 72 hours. The assessment of cell
proliferation was performed with the dye sulforhodamine B (SRB Assay), the test of
cell viability was done using the dye bromide 3 - (4,5-dimethylthiazol-2-yl) -2,5
diphenyl tetrazolium (MTT Assay), and for the analysis of the mitochondrial mem-
brane potential, cells were incubated with a solution tetramethylrhodamine methyl
ester. All experiments were performed in triplicate. The ANOVA test was applied
followed by Dunnett. The results of SRB assay at 24, 48 and 72 hours of exposure
showed a significant difference from the control at concentrations of 50 and
100μM of trifluralin. Effects on the MTT assay and mitochondrial membrane po-
tential showed a similar pattern, being significant from the control at the concen-
trations of 50 and 100μM of trifluralin. We can conclude that trifluralin affects the
HepG2 cells by inhibiting cell proliferation and/or inducing cell death and disrupt-
ing mitochondrial membrane potential at concentrations of 50 μM and higher.
Further studies will be performed to better understand the effects of trifluralin on
HepG2 cells.
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586 Effect of p, p’-DDE on Adipogenesis and Macrophage
Activation.
L. Mangum1,  G. E. Howell1, 2,  S. B. Pruett1,  M. K. Ross1 and J. E. Chambers1.
1Center for Environmental Health Sciences, Mississippi State University, Mississippi
State, MS; 2Biological Sciences, Mississippi College, Clinton, MS.
There is evidence that exposure to organochlorine compounds, such as DDE, may
contribute to dyslipidemia, obesity, and insulin resistance, a cluster of signs that
comprise the metabolic syndrome. Obesity results from adipocyte hyperplasia and
hypertrophy which leads to recruitment of immune cells to adipose tissue and even-
tually contributes to localized chronic low-grade inflammation and adipocyte dys-
function. This study investigated a potential COX-2 dependent mechanism by
which DDE could modulate normal physiological function and facilitate an in-
creased risk of developing metabolic syndrome following exposure. Murine
(J774a.1) and human (THP-1) macrophage cell lines and murine preadipocytes
(3T3-L1) were used to investigate the effects of DDE on inflammation and adipo-
genesis. Macrophage cell lines were exposed to DDE or a known COX inhibitor for
18 hr before treatment with an inflammatory challenge of lipopolysaccharide (LPS)
or palmitic acid (PA). Cell culture supernatants were analyzed for the presence of
prostaglandins PGE2, PGD2, PGF2α, arachidonic acid (AA), and thromboxane
(TBX) and for proinflammatory cytokines, including tumor necrosis factor
(TNFα). 3T3 preadipocytes were induced to differentiate to adipocytes using a
sub-optimal differentiation cocktail in the presence of DDE or a COX-2 inhibitor,
with or without TNFα, a known COX inducer and suppressor of adipogenesis.
Mature adipocytes were analyzed for intracellular lipid accumulation by Oil Red O
staining. Both DDE and COX inhibitors increased adipogenesis in a dose-depend-
ent manner in all treatments. In macrophages, DDE exposure followed by LPS or
PA challenge reduced secretion PGE2, PGF2α, and PGD2 and caused a slight in-
crease in secretion of TNFα over vehicle. COX enzymes have a complex role in
both inflammation and adipogenesis, and these results suggest that DDE exposure
may contribute to altered adipogenesis and increased inflammation, potentially
through a COX-2 dependent mechanism.
587 Organophosphorus Pesticides Activate Mast Cells Ex Vivo
and In Vivo.
A. C. Grodzki and P. J. Lein. Molecular Biosciences, University of California Davis,
Davis, CA.
Mast cells are immune cells involved in diverse inflammatory diseases and are best
known for their critical role in allergic reactions and asthma. In asthma, mast cells
are activated by the cross-linking of FcεRI (the high affinity IgE receptor) with
antigen-specific IgE, but these cells can be activated via several additional mecha-
nisms. We hypothesized that organophosphorus pesticides (OPs) can activate mast
cells in an IgE-independent manner. OPs are known to modulate immune function
at levels that do not cause significant inhibition of cholinesterases, and previous
studies of total peritoneal cells exposed to the OP malathion in vivo suggested that
at least this OP modulates primary macrophage functions as an indirect conse-
quence of mast cell degranulation. To determine whether OPs can target mast cells
directly, we evaluated cellular degranulation using morphologic criteria, and release
of β-hexosaminidase, a marker for mast cell degranulation, in percoll gradient-puri-
fied and non-purified rat peritoneal and mesentery mast cells following exposure to
OPs. Preliminary experiments indicated that ex vivo exposure to paraoxon induced
significant mast cell degranulation within 1 h and increased release of β-hex-
osaminidase in a concentration dependent manner. In vivo treatment with
parathion caused mast cell degranulation with increased β-hexosaminidase release
in the peritoneal cavity. Therefore, the data suggests that parathion and paraoxon
affect mast cell stability, provoking degranulation and consequent release of inflam-
matory mediators. Ongoing studies are exploring the action of other OPs, carba-
mates and pyrethrins on mast cells and evaluating the mechanism by which these
pesticides affect mast cell integrity. This work was supported by funding from the
National Institutes of Health (grant R01 ES017592 to PJL) and a postdoctoral fel-
lowship to ACGG (T32 HL007013).
588 Detection of Dichlorvos Targets in Hepatocytes.
T. Bui-Nguyen1,  W. Dennis2,  J. A. Lewis2 and D. A. Jackson2. 1Oak Ridge
Institute for Science and Education (ORISE), Frederick, MD; 2US Army Center for
Environmental Health Research, Frederick, MD.
Toxicity of dichlorvos (DDVP), an organophosphate (OP) pesticide, classically re-
sults from modification of the serine in the active sites of cholinesterases. However,
DDVP also forms adducts on unrelated targets such as transferrin and albumin,
suggesting that DDVP causes cellular perturbation by modifying non-
cholinesterase targets. Here, we identify novel DDVP-modified targets in lysates of
a human hepatocyte-like cell line (HepaRG) in competitive pull-down experiments
using DDVP and a biotin-linked organophosphorus compound (10-fluo-
roethoxyphosphinyl-N-biotinamidopentyldecanamide; FP-biotin), which com-
petes with DDVP for similar binding sites. Using the competition assay and mass
spectrometry, we show that DDVP forms adducts to six new target proteins, in-
cluding Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH). We validated the
results using purified GAPDH incubated with DDVP and found that GAPDH
Tyr-314, a residue in the known active site, is modified by DDVP. GAPDH activ-
ity is inhibited in a concentration dependent manner in DDVP-treated HepaRG
cells, suggesting that the modification directly inhibits the enzyme. These results
may help explain the chronic metabolic effects of DDVP exposure.
Opinions, interpretations, conclusions, and recommendations are those of the au-
thors and are not necessarily endorsed by the U.S. Army. Citations of commercial
organizations or trade names in this report do not constitute an official Department
of the Army endorsement or approval of the products or services of these organiza-
tions. The research described herein was sponsored by the USAMRMC and
Military Operational Medicine Research Program. This research was supported in
part by an appointment to the Postgraduate Research Participation Program at the
U.S. Army Center for Environmental Health Research (USACEHR) administered
by the Oak Ridge Institute for Science and Education through an interagency
agreement between the U.S. Department of Energy and USACEHR.
589 Neonicotinoid Insecticides: Formaldehyde Generation As a
Proposed Mechanism of Mouse-Specific Hepatotoxicity and
Hepatocarcinogenicity of Thiamethoxam.
T. Swenson and J. Casida. Graduate Group in Molecular Toxicology, University of
California Berkeley, Berkeley, CA.
Thiamethoxam (TMX), one of the most important insecticides, is carcinogenic and
hepatotoxic in mice but not in rats. Green et al. (Toxicol. Sci. 86, 36-47, 2005) es-
tablished that TMX is a much better substrate for mouse liver cytochrome P450s
than the corresponding rat or human enzymes in forming desmethyl-TMX (dm-
TMX), which is also hepatotoxic, and clothianidin (CLO), which is not hepato-
toxic or carcinogenic. The present investigation examines the hypothesis that liber-
ation of formaldehyde (HCHO) or an N-methylol intermediate during TMX and
dm-TMX metabolism to CLO and dm-CLO, respectively, provides a molecular ex-
planation for the mouse-specific toxicity. Mouse liver microsomes were compared
to rat and human liver microsomes in the metabolism of the seven commercial
neonicotinoids and dm-TMX in the presence or absence of the cofactor, NADPH.
HCHO production was determined by derivatization with 2,4-dinitrophenylhy-
drazine and monitoring by HPLC while other TMX metabolites (dm-TMX, CLO
and dm-CLO) were quantitated by LC/MS. TMX and dm-TMX yielded more
HCHO than any of the six other commercial neonicotinoids and mouse micro-
somes gave much higher conversion than rat or human microsomes. HCHO or an
N-methylol intermediate in TMX and dm-TMX metabolism is therefore the can-
didate reactive hepatotoxicant. The N-methylol intermediates are difficult to ana-
lyze because of their chemical instability. These results provide HCHO liberation as
an alternative to the earlier explanation of TMX hepatotoxicity in which dm-TMX
is the proposed reactive metabolite and its toxicity is exacerbated by dm-CLO inhi-
bition of inducible nitric oxide synthase (iNOS) (Green et al., 2005). Although the
HCHO generation proposal versus the dm-TMX/ iNOS inhibition hypothesis for
TMX toxicity is not fully resolved, the mouse vs. rat vs. human comparison of
TMX metabolism reconfirms that the rat (showing no carcinogenic effects) is the
best risk assessment model for humans.
590 Chiral Pesticide Pharmacokinetics: A Range of Values.
J. F. Kenneke1,  S. A. Marchitti1,  S. Rawat2,  D. T. Chang3,  C. M. Grulke3,
C. S. Mazur1 and M. R. Goldsmith3. 1US EPA, Athens, GA; 2Student Services
Authority, Athens, GA; 3US EPA, Research Triangle Park, NC.
Approximately 30% of pesticides are chiral and used as mixtures of two or more
stereoisomers. In biological systems, these stereoisomers can exhibit significantly
different pharmacokinetics (absorption, distribution, metabolism, and elimina-
tion). In spite of these differences, these “mixtures” are often treated as a single
compound in exposure and hazard assessment. To evaluate the impact of pharma-
cokinetic differences on internal exposure (dose) estimates, we studied the
stereoisomer-specific metabolism of twenty chiral 1,2,4-triazole fungicides in he-
patic microsomes, hepatocytes, and purified cytochrome P450s (P450).
Additionally, we measured the metabolism of the pure stereoisomers for three of the
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fungicides. Studies indicated that CYP3A4 was a major metabolizing enzyme for a
majority of the fungicides. In general, the stereoisomers of each fungicide (pure and
in the fungicide mixture) exhibited significantly different clearance rates. With
some compounds, one or more stereoisomers inhibited the clearance of the other
stereoisomers. Results were consistent across genders. In an effort to explain the ob-
served stereoisomer clearance rates, we utilized a directed ligand-based pharma-
cophore analysis to identify key ligand features. Triadimefon was the only fungicide
that preferentially underwent stereoselective carbonyl reduction rather than P450-
mediated oxidation. Reduction of the prochiral carbonyl produced four stereoiso-
mers of triadimenol. Relative formation of the triadimenol stereoisomers varied
among 16 vertebrate species; the individual triadimenol stereoisomers differentially
inhibited CYP3A4 metabolism. These results suggest that treating a chiral pesticide
as a single chemical rather than a mixture could introduce errors in risk assessment.
Although this work was reviewed by EPA and approved for publication, it may not
necessarily reflect official Agency policy.
591 Alpha-Cypermethrin Metabolism and Exposure Assessment
in Egyptian Agricultural Workers.
S. T. Singleton1,  J. B. Knaak1,  L. Chi1,  B. P. McGarrigle1,  F. M. Farahat2 and
J. R. Olson1. 1Pharmacology and Toxicology, University at Buffalo, Buffalo, NY;
2Menoufia University, Shibin el Kom, Egypt.
Pyrethroids are neurotoxic insecticides that exert their effects by prolonging the
opening time of sodium channels and increase the duration of neuronal excitation.
Alpha-cypermethrin (aCM) is derived from the 8-stereoisomer containing
pyrethroid cypermethrin, and is one of the most common pyrethroids being used in
agriculture throughout the world. Pyrethroids are extensively metabolized in the
liver by both esterases and oxidative enzymes. In vitro metabolism assays with
human liver microsomes and cytosol demonstrate that aCM undergoes metabolism
to the detoxified metabolites, 3-phenoxybenzoic acid (3-PBA) and cis-3-(2,2-
dichlorovinyl)-2,2-dimethylcyclopropane carboxylic acid (cis-DCCA) in both liver
fractions. Previous studies suggest that 3-PBA may be a general biomarker of
human exposure to pyrethroids, while cis-DCCA is a specific biomarker of aCM. A
sensitive GC-MS NCI method was developed and daily urinary cis-DCCA and 3-
PBA concentrations were quantitated for Egyptian agriculture workers who were
applying alpha-cypermethrin to cotton fields for up to 10 consecutive days. Both
cis-DCCA and 3-PBA were detected in the urine of all workers and ranged from
0.07-17.7 μg/g creatinine and 0.5-19.7 μg/g creatinine, respectively. This study is
the first to use these biomarkers to quantify occupational exposures to alpha-cyper-
methrin. The in vivo biomarker data and in vitro metabolism kinetic data will be
useful in future efforts to model human exposures to alpha-cypermethrin. (This re-
search was supported in part by U.S.EPA STAR grant R833454 and NIEHS R01
ES016308)
592 4’OH-Deltamethrin Metabolit-Induced Changes in
Oxidative Stress Biomarkers in SH-SY5Y Cells and
Alleviation Effect of Melatonin.
M. R. Martinez-Larrañaga,  A. Romero,  E. Ramos,  V. Castellano,
M. A. Martinez,  I. Ares,  M. Martinez and A. Anadon. Toxicology &
Pharmacology, Complutense University, Madrid, Spain.
Oxidative damage has been recognized as one of the primary causes of subcellular
toxicity pesticides. Studies on pyrethroid insecticides have also suggested a putative
role for free radicals in the lipid peroxidation and other oxidative stress-mediated
injuries. Although initially it was thought that metabolites of deltamethrin, a α-
cyano pyrethroid insecticide, should to be less toxic than the parent compound, we
studied the oxidative stress-inducing effect of both the oxidative metabolite 4’-OH-
deltamethrin and the parent compound in SH-SY5Y neuroblastoma cells. Cell line
SH-SY5Y was used by their vulnerability to the oxidative damage. Lipid peroxida-
tion induced by deltamethrin and 4’-OH-deltamethrin with or without melatonin
was evaluated. Intracellular malondialdehyde (MDA) production was quantified
using a thiobarbituric acid reactive substance assay. Changes in nitric oxide (NO)
production were measured indirectly as the accumulation of nitrites (the end-prod-
uct of NO metabolism) in the medium using Griess assay. In the present study, the
levels of both NO and lipid peroxides measured as MDA, which can lead to a loss
of membrane structure and function, were found to be significantly increased in
deltamethrin and 4’-OH-deltamethrin treated cells. Both deltamethrin (10 μM)
and 4’-OH-deltametrhin (10 μM) induced a significant increase in MDA levels (3-
and 3.5-fold above basal, p<0.001 respectively) as well as increased by 3.5- and 5-
fold, p<0.001, NO production. Our results also demonstrated that melatonin
(1μM) significantly reversed the effects of deltamethrin and 4’-OH-deltamethrin.
In the present in vitro study, it is demonstrated that the metabolite 4’-OH-
deltamethrin, is more cytotoxic than the parent compound deltamethrin. This
work was supported by projects Refs. GR35/10-A UCM-BSCH, S2009/AGR-
1469 and Consolider-Ingenio CSD/2007/00063 (FUN-C-FOOD), Madrid,
Spain.
593 Effect of Age on Plasma Protein Binding of Deltamethrin,
Cis-Permethrin, and Trans-Permethrin in Rats.
P. Sethi1,  S. Muralidhara1,  M. Amaraneni1,  T. Mortuza1,  C. Chen1,
B. S. Cummings1,  J. V. Bruckner1,  N. Assaf2,  D. Minnema3 and C. A. White1.
1Department of Pharmaceutical and Biomedical Sciences, University of Georgia,
Athens, GA; 2Valent BioSciences, Libertyville, IL; 3Syngenta Crop Protection,
Greensboro, NC.
Plasma protein binding (PPB) can influence the toxicokinetics of highly-bound
chemicals, by limiting the amount of compound free to reach target organs and
sites of elimination. Because the influence of age on PPB of common pyrethroids is
unclear, this study was undertaken to determine if binding of deltamethrin (DLM),
cis-permethrin (CIS) or trans-permethrin (TRANS) changes during maturation.
The PPB of DLM, CIS and TRANS was studied in plasma of 10-, 15-, 21- and 90-
day-old (adult) rats. A solvent extraction method was developed to quantify the
binding of these highly hydrophobic compounds to rat plasma (RP) proteins and
lipoproteins. A 10-μl aliquot of 14C-DLM, -CIS or TRANS was mixed with 90 μl
of plasma and cold compound yielding concentrations of 250-100,000 nM.
Samples were incubated and shaken at 37oC for 3 hr. The unbound fraction was
extracted with 200 μl of isooctane, the lipoprotein-bound fraction with 200 μl of
octanol, and the albumin-bound fraction with 200 μl of acetonitrile. Samples were
treated with 10 μl of a 0.64 M solution of sodium fluoride to inhibit car-
boxylesterases. The free fractions of DLM, CIS and TRANS were higher in 10-day-
old RP (27.1 ± 6.1 to 29.9 ± 6.4 %) than adult RP (19.2 ± 1.5 to 21.3 ± 2.1 %).
The fractions of DLM, CIS and TRANS bound to lipoproteins were slightly higher
in the pre-weanlings, however the fractions bound to protein were substantially
lower. In 15-day-old rats the free fraction and lipoprotein-bound fraction of DLM,
CIS and TRANS decreased somewhat. At day 21, PPB reached adult levels. The
lower PPB in pre-weanlings is consistent with lower total plasma protein levels.
Their lower albumin levels appear to account for the relatively low protein binding
of DLM, CIS and TRANS. (Supported by the Council for Advancement of
Pyrethroid Human Risk Assessment)
594 Assessment of an In Vitro Human Dermal Absorption
Database for Pesticide Formulations to Establish
Scientifically-Based Default Dermal Absorption Values.
M. Aggarwal1,  A. Hueser2,  C. Strupp3,  C. Wiemann4,  P. Fisher5,  B. Parr-
Dobrzanski6,  M. Soufi7 and R. Billington1. 1Dow AgroSciences, Abingdon, United
Kingdom; 2Dr Knoell Consult GmbH, Leverkusen, Germany; 3Feinchemie Schwebda
GmbH, Kleines Wiesental, Germany; 4BASF Oesterreich GmbH, Vienna, Austria;
5Bayer CropScience, Sophia-Antipolis, France; 6Syngenta, Bracknell, United Kingdom;
7DuPont de Nemours (Deutschland) GmbH, Neu-Isenburg, Germany.
Dermal absorption (DA) values for plant protection products (PPP) are required as
inputs to risk assessment models used in the EU for assessing non-dietary risk for
sprayers, workers, residents and bystanders. DA values are generated using undi-
luted PPP and representative field spray dilutions. The European Food Safety
Authority (EFSA) published guidance on dermal absorption for PPP that includes
highly conservative default DA values of 25% and 75% for undiluted PPP and field
spray dilutions, respectively. Moreover, a default DA value of 75% applies to the
undiluted PPP if it contains ≤5% active substance. To determine the validity of
these default values, data from over 300 in vitro DA studies using human skin have
been collected, collated and evaluated to establish the scientific validity of the de-
faults values and other endpoints. All studies that complied with the principles of
OECD test guideline #428 were chosen for this analysis. These studies were per-
formed on a wide range of formulation types and concentrations. The analysis was
carried out considering two definitions of DA: (i) radioactivity present in receptor
fluid and receptor chamber wash, plus skin minus the first two tape strips (i.e.,
worse-case definition) and (ii) radioactivity present in receptor fluid and receptor
chamber wash plus skin minus stratum corneum (best-case definition). The analy-
sis suggests that the default DA values for concentrate and spray dilution should
not be more than 5% and 40%, respectively, considering the worse-case DA defini-
tion. Preliminary ranking for influence of formulation type on DA for undiluted
PPP is EC = EW > SL = SE = SC > CS = solid formulations = FS. Data will also be
presented on the influence of formulation types on DA for field spray dilutions.
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595 Determination of Pyrethroids in Rat Blood and Tissues
Using Gas Chromatography (GC) Negative Chemical
Ionization Mass Spectrometry.
D. Gullick1,  X. Wang1,  J. V. Bruckner1,  B. S. Cummings1,  D. Minema2,
M. Krolski3 and M. G. Bartlett1. 1PBS, University of Georgia, Athens, GA;
2Syngenta Crop Protection, Greensboro, NC; 3Bayer Crop Science, Research Triangle
Park, NC.
Pyrethroids are the more stable synthetic structural analogues of naturally occurring
pyrethrins, which are potent insecticides that exhibit low mammalian toxicity. A re-
producible and sensitive bioanalytical method was developed to monitor the uptake
and elimination of pyrethroids in plasma and tissues following oral dosing of rats as
part of an approach to assess their risk to human health by physiologically based
pharmacokinetic (PBPTK) models. Blood and tissue homogenates (100 μL) were
spiked with Deltamethrin, cis-or trans-permethrin. 1% phosphoric acid (100 μL)
was added (to reduce binding of pyrethroids to proteins) and mixed. Internal stan-
dard (another pyrethroids)and 400 μL acetonitrile were added and mixed (to pre-
cipitate the proteins and extract the pyrethroids) and centrifuged. Supernatant (500
μL) was evaporated to dryness, reconstituted with toluene (300 μL), filtered (0.2
μm PTFE syringe filter), evaporated, and reconstituted with toluene (50 μL) for
analysis. Samples were injected into an Agilent 6890 gas chromatograph using
pulsed splitless injection onto a Zebron® ZB5-MS capillary column eluting into a
5973 quadrupole mass analyzer in negative chemical ionization mode. Fragment
ions were monitored using selected-ion monitoring for quantitation and verifica-
tion of the analyte. The method was linear from 1 ng/mL to 1 μg/mL from tissues
and blood. The limit of detection was 0.5 ng/mL, the limit of quantitation was 1
ng/mL, and the intraday precision and accuracy of the method were better than
15% across the linear range. Absolute recovery from blood and tissues was greater
than 50%. The method was successfully used to monitor the uptake and elimina-
tion of pyrethroids in blood and tissues following oral dosing of rats. (Supported by
the Council for the Advancement of Pyrethroid Human Risk Assessment).
596 Toxicokinetics of Low Doses of the Pyrethroid, Deltamethrin
(DLM), in Rats.
C. Chen1,  S. Muralidhara1,  D. Gullick1,  T. Mortuza1,  M. Amaraneni1,
P. Sethi1,  D. W. Gammon2,  S. S. Anand3,  T. G. Osimitz4,  C. A. White1,
B. S. Cummings1 and J. V. Bruckner1. 1PBS, University of Georgia, Athens, GA;
2FMC, Ewing, NJ; 3DuPont Haskell, Newark, DE; 4Science Strategies LLC,
Charlottesville, VA.
Pyrethroid insecticides are the widely used to control a wide variety of pests in and
around homes, in food handling establishments, in mosquito control, and in agri-
culture. Pre-weanling and weanling rats are much more sensitive to lethality from a
single high dose of the Type II pyrethroids deltamethrin (DLM) and cypermethrin
than are adult rats. The hypothesis is that this is due to the incomplete development
of the detoxification enzymes in the young rats. No age-related sensitivity to lethal-
ity or acoustic startle response has been noted at low doses of DLM. Our hypothe-
sis is that, despite immature detoxification enzymes, sufficient metabolic capability
is present to readily eliminate low doses. The current work was conducted to gener-
ate low-dose DLM blood and tissue time-course data to test this hypothesis and to
provide input to a physiologically based pharmacokinetic model. Time-courses for
0.1, 1 and 5 mg DLM/kg have been delineated in adult rats dosed orally with DLM
in 1 or 5 ml corn oil/kg or in 1 ml glycerol formal/kg. Serial sacrifices of groups of
3 – 5 rats have been conducted at intervals from 15 min to 96 hr post-dosing to ob-
tain blood, brain, and other tissue samples for GC-MS analysis. Dose-dependent
increases in peak DLM blood and non-adipose tissue levels were manifest from 2 to
6 hr. The larger volume of corn oil resulted in a relatively broad peak or plateau in
blood levels and a more gradual decrease over the monitoring period than with the
low volume. Brain levels at comparable times were significantly lower with the
larger dosing volume. A significant portion of each dose of DLM was sequestered in
fat, with slow release resulting in prolonged elevation of blood levels and thus avail-
ability to other tissues. (Supported by the Council for the Advancement of
Pyrethroid Human Risk Assessment)
597 Dislodgeable Foliar Metabolites of Malathion and
Fenpropathrin May Contribute to Aggregate Harvester
Exposure Estimates Using Urine Biomonitoring.
Y. Liu2,  G. Sankaran1, 2,  L. T. Tang2,  L. Chen2,  A. Krieger2,  J. H. Ross3,
H. Vega2 and R. Krieger1, 2. 1University of California Riverside, Riverside, CA;
2University of California Riverside, Riverside, CA; 3Gem Quality Risk, Inc.,
Carmichael, CA.
Parent insecticide residues dissipate on sprayed leaf surfaces and may yield deriva-
tives used as biomarkers of exposure to the pesticide on foliar surfaces. It is impera-
tive to determine if surface derivatives actually contribute to the apparent aggregate
exposure of harvesters based upon urine biomonitoring. If pesticide derivatives that
are potential urine biomarkers persist longer than the parent insecticide on treated
plants and they are bioavailable, their absorption and excretion may confound har-
vester exposure reconstruction for risk assessment. Strawberry harvester exposures
to malathion and fenpropathrin use were studied during July 2012 at Santa Maria,
CA. Quantitative measurements of parent residues and corresponding biomarker
residues on leaf surfaces determined using nitrile gloves worn by workers and 24 hr
urine samples from harvesters (and matched controls with no occupational expo-
sure) were conducted at specified intervals post malathion and fenpropathrin appli-
cation on strawberry fields. Urine biomonitoring allows reconstruction of absorbed
dose/day from all possible routes of pesticide and biomarker exposure using rapidly
excreted urine biomarkers. Preliminary data show that when foliar malathion
residue transferred to cotton cloths (μg/cm2; 0.238 to 0.027) and harvester gloves
(μg/pair; 13944 to 3435) declined by 90% and 75% respectively in the 3d between
the first picking and the second picking; corresponding malathion transferred foliar
biomarkers dropped only by 16% and 11%, respectively. These data suggest surface
derivatives last longer than parent residues on foliar surfaces. Structurally similar
derivatives are dermally absorbed and this may explain why biomonitoring histori-
cally has indicated exposure to parent long after the parent has dissipated.
598 Soil Concentrations and Human Exposures to Contaminated
Soil in the Remote First Nation Community of Fort Albany,
Ontario, Canada.
E. N. Liberda1,  E. S. Reyes1 and L. J. Tsuji2. 1School of Occupational and Public
Health, Ryerson University, Toronto, ON, Canada; 2Department of Environment and
Resource Studies, University of Waterloo, Waterloo, ON, Canada.
A study was conducted in the James Bay Region of Ontario, Canada to examine the
concentration of dichlorodiphenyltrichloroethane and metabolites (o,p’-DDE,
p,p’-DDE, o,p’-DDD, p,p’-DDD, o,p’-DDT, p,p’-DDT, and ∑DDT) in poten-
tially contaminated soil sites, and to assess the exposure pathways to ∑DDT by
comparing the estimated daily intake (EDI) to acceptable daily intake (ADI) values.
The contaminated soil plots were analyzed by a gas chromatograph equipped with
a 63Ni electron capture detector (GC/ECD) or by gas chromatography with a mass
spectrometer as a detector (GC/MS). The samples were first extracted using a
Soxhlet apparatus with dichloromethane as the solvent and sample cleanup was ap-
plied using a Florisil extraction column. The mean ∑DDT found in the soil plots
were distributed irregularly with values ranging from not detected to 4.19 mg/kg.
From the soil plots analyzed, Plot A had the highest ∑DDT concentration of 1.12
mg/kg, followed by Plot B and Plot C which were 0.09 mg/kg and 0.01 mg/kg, re-
spectively. The exposure analysis showed that the risks to humans was below gov-
ernmental guidelines, even though the DDT concentration in the soil was above
Canada’s soil guidelines of 0.7mg/kg as set by the Canadian Council of Ministers of
the Environment. The DDT concentration in Plot A breached maximum levels,
therefore this land cannot not be used for agricultural as planned nor for recre-
ational purposes. However, both Plots B and C were below maximum threshold
limits, and this land may be used to grow safe food resources.
599 Effect of Soil Fumigation with Methyl Bromide against
Earthworm, Aporrectodea caliginosa.
N. S. Ahmed,  S. S. Desouky,  A. H. Elsebae and S. S. Soliman. Pesticide
Chemistry, Alexandria University, Alexandria, Egypt.
Methyl bromide, MBr, is a soil and food commodity fumigant that is used to con-
trol most kind of pests that born from or affect them, respectively. Earthworms,
Aporrectodea caliginosa, are very important for healthy and productive soil.
Although, MBr has been added to the list of chemicals that deplete the ozone layer
(Montreal Protocol), its use still allowed under several condition worldwide. Effect
of MBr against earthworm was investigated in this study. Worms were exposed to
one fumigation level of 30 gm/m2 where worms were distributed in several depths
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of the used soil. Mortality and some biochemical effects in the exposed worms com-
pared to control were measured at 24, 48, and 72 hours after exposure. MBr at the
tested level caused 100% mortality in worms crawling at 10 and 30 cm depth in all
tested intervals. At the 50 cm depth, mortality rates were 80, 90, and 90 percent at
the 24, 48, and 72 hours after exposure, respectively. 
The effect of MBr against protein content of earthworm crawling at the 50 cm
depth was measured. Results showed that, after 24, 48 hours, the protein content
increased significantly. There was no significant difference after 72 h of exposure in
protein content between exposed worms and the control. Effect of MBr at the
tested level on the activities of earthworms glutathione-S-transferases, GS-T);
acetylcholinesterase, AChE; and cellulase were also determined in worms crawling
at the 50 cm depth. Results showed only slight significant increase in AChE activ-
ity at 24 and 48 hours after exposure relative to control. MBr at the tested level
caused significant increase in GS-T activity of the exposed earthworm at all tested
exposure intervals. On the other hand, there was a significant increase in cellulase
activity after 24 h as compared to control. However, this difference disappeared at
48 and 72 hours following exposure.
These results indicate that MBr is a very potent soil fumigants that also kill the ben-
eficiary earthworms in soil and protection of earthworms must be taken into con-
sideration while searshing for alternative to MBr.
600 Mechanism of Paraquat-Induced Pulmonary Fibrosis and
Intervention of Pyrrolidine Dithiocarbamate.
M. Huang1, 2,  P. Zhang3,  X. Chang2,  Q. Wu2 and Z. Zhou2. 1Occupational
Health Science, Ningxia Medical University, Yinchuan, China; 2Occupational Health
Science and Toxicology, Fudan University, Shanghai, China; 3Occupational Health,
Centers for Disease Control and Prevention of Jiading, Shanghai, China.
The mechanism of Paraquat-induced pulmonary fibrosis and potential therapeutic
effect of pyrrolidine dithiocarbamate (PDTC) were studied. Male SD rats were di-
vided into control group (0.9% NaCl, gavage), PDTC group (100mg/kg, ip), PQ
(80mg/kg, gavage) group and PQ+PDTC (100mg/kg, ip) group. On the1st, 3rd,
7th, 14th, 28th and 56th day after treatment, The expressions of connective tissue
growth factor (CTGF) and α smooth muscle actin (α-SMA) in lung tissues were
measured. The mRNA levels of CTGF, Fn, Col I, Col III and integrin α5 were an-
alyzed with quantitative RT-PCR. Meanwhile, the lung pathological changes were
observed and the content of Hydroxyproline (Hyp) was measured. The expression
of CTGF in PQ group increased gradually compared with control group (P<0.05).
CTGF mRNA level significantly increased from the 1 st to the 14 th day compared
with control group (P<0.05). PQ significantly increased Fn mRNA level on all time
points and intrgrin α5 mRNA level from the 3 rd to 56 th day compared with con-
trol group(P<0.05). Col I mRNA level significantly increased from the 7 th to the
56 th day and Col III mRNA level appears to be decreased from the 14 th to the 56
th day. PDTC treatment significantly deceased the levels of those factors compared
with PQ group in corresponding time points (P<0.05). Noteworthy, PDTC
strongly attenuated histopathological changes and decreased the content of Hyp.
These results suggested that CTGF plays a key role in paraquate-induced pul-
monary fibrosis, which is characterized by increased Fn, integrin α5, Col I and Col
III mRNA levels. PDTC may inhibit NF-κB activity and further significantly de-
crease expressions of CTGF leading to drastically attenuated pulmonary fibrosis.
However, the mechanisms of PDTC intervention still remain to be explored.
601 Testicular Toxicity of Fluorochloridone in Adult Sprague-
Dawley Rats.
L. Xu2, 1,  Z. Zhou2,  Q. Zhao2,  D. Lou2,  X. Chang2,  P. Xiao3,  X. Hong3 and
X. Yu1. 1Department of Environmental Health Science, University of Georgia, Athens,
GA; 2School of Public Health, Fudan University, Shanghai, China; 3Shanghai
Municipal Center for Disease Control & Prevention, Shanghai, China.
Fluorochloridone (FC) a widely used herbicide in Europe and the US, has been rec-
ognized as a potential reproductive and developmental toxicant. However, there is
little data available concerning its male reproductive toxicity. In this study, we ex-
amined the testicular toxicity of FC in SD male rats. Adult rats were treated by gav-
age with FC at doses of 0, 30, 150, 750 mg/kg/d for four weeks. FC exposure re-
sulted in a decrease in the absolute and relative weight of testes and a decrease in the
absolute weight of epididymides as compared with the control. Cauda epididymal
sperm count decreased dramatically in a dose-dependent manner. In addition, his-
tological lesions were also found in the testes of the treated animals. A dose-effect
(response) relationship analysis suggested that changes in cauda epididymal sperm
count and testicular histological structure could be the most sensitive indicators for
FC induced testicular toxicity.
602 Carbofuran Is Not an Endocrine Disruptor—Weight-of-
Evidence of US EPA’s Tier 1 Endocrine Disruptor Screening
Program Assays and Higher Tier Studies.
D. W. Gammon,  B. Sharma,  S. Longacre,  G. Mitchell,  S. Mukhi,  M. Oh and
Z. Liu. APG, FMC Corp, Ewing, NJ.
Carbofuran, the active ingredient in FMC Corporation’s FURADAN®
Insecticide/ Nematicide products, underwent testing in EPA’s Tier I endocrine dis-
ruption screening program (EDSP), as required for all US registered pesticide active
ingredients, to assess whether carbofuran had the potential to interact with en-
docrine systems. Nine of the eleven carbofuran Tier 1 EDSP assays showed no po-
tential to interact with endocrine systems. The slight increase in estradiol in the in
vitro steroidogenesis assay, and the mild to moderate thyroid hypertrophy and mild
thyroid hyperplasia in the amphibian metamorphosis assay observed with relatively
high carbofuran concentrations were not corroborated by any of the other assays.
Only the highest concentration (100 μM) was positive in the steroidogenesis assay,
several orders higher than the concentration required for AChE inhibition.
Previously conducted higher tier in vivo carbofuran developmental, reproductive
and chronic toxicity studies showed no endocrine-mediated effects. The overall lack
of effects in the carbofuran Tier 1 EDSP assays is consistent with the lack of en-
docrine-mediated effects in the previously conducted carbofuran higher tier in vivo
studies. The collective results of the carbofuran Tier 1 EDSP assays and previously
conducted higher tier in vivo studies indicate carbofuran is not an endocrine dis-
ruptor, and that there is no concern for endocrine effects resulting from the use of
FURADAN® products according to label instructions.
603 Reproductive Outcomes in Women Para-Occupationally
Exposed to Pesticides in an Agricultural Community in
Southern Mexico.
G. López-Manzanero1,  N. Pérez-Herrera1,  L. Dzib-Cocom1, 2,  P. García-
Molina1, 2,  M. Vera-Avilés1,  T. Castillo-Burguete3,  L. González-Navarrete1,
J. Alvarado-Mejía1,  B. Jiménez-Delgadillo1,  J. Arias-León1,  V. Suárez-Solís1,
M. Cárdenas-Marrufo1,  I. Vado-Solis1,  C. Pérez-Osorio1,  I. Hernández-Ochoa4
and B. Quintanilla-Vega4. 1Faculty of Medicine, Automous University of Yucatán,
Mérida, Mexico; 2Faculty of Chemistry, Automous University of Yucatán, Mérida,
Mexico; 3Human Ecology Departament, CINVESTAV, Mérida, Mexico; 4Toxicology
Departament, CINVESTAV, Mexico City, Mexico.
Epidemiological studies have shown than farmers are at high risk of developing ad-
verse effects including reproductive problems. However, reproductive outcomes by
para-occupational exposure to pesticides in wives of farmers are poorly docu-
mented. We reported reproductive alterations such as poor semen quality in farm-
ers and spontaneous abortions and preterm birth in wives of agricultural workers
mostly exposed to organophosphate pesticides (OP). Thus we evaluated the scenery
of para-occupational pesticide exposure and its associated reproductive outcomes in
wives of farmers. A transversal study was conducted in Yucatan, Mexico in wives of
farmers exposed to pesticides (n=28) and wives of workers without pesticide expo-
sure (n=45). Women donated a blood sample and responded a questionnaire. The
TORCH profile was determined as potential confounders. General characteristic
and TORCH profile were similar between two groups. Age at menarche was mar-
ginally lower in wives of farmers (11.5±1.06 vs. 12.13±1.56 years, p=0.07).
Difficulty getting pregnant was more prevalent in wives of farmers (63 vs 13%,
p=0.0003), preterm births were marginally more frequent in these women (7 vs
0%, p=0.07), and the birth weight of the first child was slightly lower in couples of
farmers (2.94±0.55 vs 3.16±0.48 Kg, p=0.09). A complex scenery of pesticides ex-
posure was observed, paraquat, glyphosate, 2,4-D amine, methamidophos and
chlorpyrifos were among the most used pesticides. Results show that pesticide para-
occupational exposure in wives of farmers may be involved with reproductive out-
comes. Supported by PROMEP-SEP-México.
604 Extension of a Nasal Dosimetry Model for Acetaldehyde to
Account for Vasodilation.
P. M. Schlosser1,  M. H. Lumpkin2 and J. B. Morris3. 1NCEA, US EPA, Research
Triangle Park, NC; 2ENVIRON International Corporation, Atlanta, GA; 3School of
Pharmacy, University of Connecticut, Storrs, CT.
Acetaldehyde (AAld) is an important industrial chemical, used in manufacturing a
wide range of products, but sources also include volcanoes, forest fires, biological
waste degradation, and respiration by plants. Subchronic inhalation causes olfac-
tory and nasal respiratory tissue degeneration in rats at ≥ 150 ppm and nasal tu-
mors in both regions at ≥ 750 ppm. The toxicity of AAld is likely due to its metab-
olism to acetic acid in nasal tissues. A series of physiologically-based
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pharmacokinetic (PBPK) models have been published which use results from com-
putational fluid dynamics to specify regional airflow and air-phase transport resist-
ance in the nose. Most recently, Teeguarden et al. (Inhal. Toxicol., 20:375-390,
2008) developed a version which included polymorphisms in human high-affinity
acetaldehyde dehydrogenase (ALDH2). However, Stanek et al. (Inhal. Toxicol.,
13:807-822, 2001) showed that AAld causes vasodilation, increasing uptake of ace-
tone with co-exposure of the two. Vasodilation will also increase uptake of AAld. If
this is not included in the model, the extent of metabolism estimated by fitting a
PBPK model to nasal AAld uptake data could be over-predicted at concentrations
where dilation is significant. Therefore we revised the PBPK model of Teeguarden
et al. to include vasodilation (increases in nasal blood flow), with the amount of di-
lation estimated from the data of Stanek et al. using a parallel acetone PBPK model.
An error in model code calculation of tissue phase mass transfer resistance was also
corrected. The net result is an increase in the estimated Vmax for ALDH2 and a
dose-dependent change in total metabolism in rats: increased at lower concentra-
tions where ALDH2 is not saturated, but decreased at 1500 ppm where vasodila-
tion is significant. Quantifying the impact of this revision requires integration of
model results with dose-response (i.e., benchmark dose) modeling. (Views ex-
pressed here are those of the authors and do not necessarily reflect the views or poli-
cies of the U.S. EPA.)
605 An In Silico Model of Spermatogenesis for Use in Predictive
Toxicology.
A. M. Frame,  M. C. Leung,  T. B. Knudsen and R. Judson. US EPA, Research
Triangle Park, NC.
EPA’s toxicity reference database (ToxRefDB), covering 963 compounds tested in
4209 animal studies, indicated testicular atrophy as an adverse outcome for 278
(28.9 %) chemicals and reduced sperm quality or quantity for 72 (9.8 %) chemicals
tested in chronic and subchronic rodent toxicity studies. The sensitivity of the male
reproductive system, coupled with the biological complexity of testicular function
and the large number of untested chemicals, motivates the need for predictive com-
putational models of male reproductive function based on high-throughput screen-
ing (HTS) and in vitro data. Toward this end, we are building a virtual tissue model
of the hypothalamic-pituitary-gonadal system (vHPG) that integrates computa-
tional approaches for kinetic modeling and dynamic simulation. As a proof of con-
cept, we have constructed a multicellular agent-based model of the rat seminiferous
tubule using CompuCell3D. The model integrates cell signaling networks for hor-
monal effects (FSH, testosterone), growth factor and cytokine stimulation (GDNF,
TNFα, TGFβ, IL1α) and transcription factors (e.g. ERM, Rhox5, SOX8, WT1)
responsible for regulating key events in the spermatogenic cycle. It also enables
Sertoli cell interactions including cytoskeletal restructuring and protein secretion.
To test our model, over 1900 chemicals associated with toxic effects on sperm were
characterized for effects on spermatogenesis and mechanisms of action. We then
identified chemicals targeting specific key aspects of spermatogenesis: cellular divi-
sion (bleomycin, cisplatin, doxorubicin), cell/cell adhesion (adjudin, indenopy-
radines, indazole-3-carboxylic acid), and Sertoli cell death (β-benzene hexachlo-
ride), as well as putative endocrine disruptors (e.g. atrazine, bisphenol A,
ketoconazole). Preliminary results indicate that the model responds appropriately,
in terms of sperm production, to the disruption of key signaling events. This ab-
stract does not necessarily reflect Agency policy.
606 Development of PBPK Models for Gasoline in Adult and
Pregnant Rats and Their Fetuses.
S. A. Martin1,  W. M. Oshiro1,  P. A. Evansky1,  J. Ford1,  L. L. Degn1,  H. A. El-
Masri1,  W. R. LeFew1,  E. D. McLanahan2,  D. MacMillan1,  W. K. Boyes1 and
P. J. Bushnell1. 1National Health and Environmental Effects Research Laboratory, US
EPA, Durham, NC; 2National Center for Environmental Assessment, US EPA,
Durham, NC.
Concern for potential developmental effects of exposure to gasoline-ethanol blends
has grown along with their increased use in the US fuel supply. Physiologically-
based pharmacokinetic (PBPK) models for these complex mixtures were developed
to address dosimetric issues related to selection of exposure concentrations for in
vivo toxicity studies. Sub-models for individual hydrocarbon (HC) constituents
were first developed and calibrated with published literature or QSAR-derived data
where available. Successfully calibrated sub-models for individual HCs were com-
bined, assuming competitive metabolic inhibition in the liver, and a priori simula-
tions of mixture interactions were performed. Blood HC concentration data were
collected from exposed adult non-pregnant (NP) rats (9K ppm total HC vapor,
6h/day) to evaluate performance of the NP mixture model. This model was then
converted to a pregnant (PG) rat mixture model using gestational growth equations
that enabled a priori estimation of life-stage specific kinetic differences. To address
the impact of changing relevant physiological parameters from NP to PG, the PG
mixture model was first calibrated using the NP data. The PG mixture model was
then evaluated against data from PG rats that were subsequently exposed (9K
ppm/6.33h gestation days (GD) 9-20). Overall, the mixture models adequately
simulated concentrations of HCs in blood from single (NP) or repeated (PG) ex-
posures (within ~2-3 fold of measured values of most HCs), indicating that the
blood data from PG rats were not highly sensitive to PG-specific physiological pa-
rameters. This PG model will be used to estimate internal HC concentrations in
the total fetus during in utero exposure to HC vapors. This is an abstract of a pro-
posed presentation and does not necessarily reflect EPA policy.
607 Strategy to Support Clearance Model of Inhaled Libby
Amphibole Asbestos Fibers in Rat and Human Respiratory
Tract.
B. Asgharian2,  O. T. Price2,  S. H. Gavett1 and A. M. Jarabek1. 1US EPA, Research
Triangle Park, NC; 2ARA, Inc., Raleigh, NC.
To characterize inhaled Libby amphibole (LA) asbestos fibers as retained dose
(RD), we developed a strategy to integrate experimental data with compartmental
modeling. Compartments extend our model structure for inhalability and deposi-
tion (Asgharian, 2012) to estimate RD in major respiratory tract (RT) regions
(upper respiratory tract, URT; tracheobronchial, TB; and pulmonary, PU), pleural
lining (PL), and lymph nodes (LN). The strategy provides data to derive 3 clearance
mechanisms in the respiratory tract (RT): mucociliary (MC), translocation (TR),
and dissolution (DS). Initial mass in each region is calculated using the deposition
model verified with fiber burden data in the URT, trachea/larynx, 5 lung lobes and
pleural casts in F344 rats from a 6-hr exposure of LA at 0, 3.5, or 25 mg/m3. MC
rates of the URT and TB regions are estimated by refining published rate constants
with fitting mass burdens measured in URT, TB, LN and PL compartments of a 5-
d study in rats at those 3 concentrations with post-exposure time course (0-, 6-, 12-
, and 24-hr). Burden data in rats from a 13-wk study at 0, 3.3, 1, and 10 mg/m3
with post-exposure time course (1-d and 1-, 3- and 18-mo) refine TR rates from
PU to TB, PL and LN compartments and evaluate overload. The initial DS rate is
based on burden data from the URT coupled with in vitro data on DS of LA incu-
bated with synthetic lung lining fluid. Data from in vitro incubation of LA with
acid refine DS rate for TB and PU regions. This integrated strategy is the first to de-
rive characterization of MC, TR and DS rates in the rat RT. For humans, DS rates
were not scaled, published human MC rates are adjusted based on mass conserva-
tion (Asgharian et al., 2001), TR rates to PL and LN compartments are scaled on
MC, and PU TR is scaled from the rat by an approach described for particles
(Jarabek et al., 2005) based on regional surface area. (The views expressed in this
abstract are those of the authors and do not necessarily represent the views or poli-
cies of the U.S. Environmental Protection Agency.)
608 A Modified PBPK Model for RDX (hexahydro-1, 3, 5-
trinitro-1, 3, 5-triazine) to Improve Rat to Human
Toxicokinetic Extrapolation.
A. E. Loccisano1, 3,  R. S. DeWoskin2,  P. M. Schlosser2,  A. F. Sasso3 and
L. J. D’Amico3. 1Oak Ridge Institute for Science & Education, Oak Ridge, TN;
2ORD/NCEA, US EPA, Research Triangle Park, NC; 3ORD/NCEA-IRIS, US EPA,
Washington DC.
RDX is a military explosive that has been detected in air, soil, and ground water at
or near military bases and munitions plants and storage facilities. Studies in rats
provide evidence of mortality, reproductive toxicity, and neurotoxicity associated
with RDX exposure. Physiologically-based pharmacokinetic (PBPK) models can
aid in interpreting toxicological data and extrapolations across dose, species and ex-
posure routes. Presented here is the further development and application of an
RDX PBPK model for rats and humans originally published by Sweeney et al.
(Regul. Toxicol. Pharmacol., 2012 v. 72, p. 107-114). The differences in the GI
tract submodel and absorption parameters for different formulations of RDX in the
Sweeny model are problematic for risk assessment because there is no rationale or
predictability to the changes. Modifications to the model include a consistent sub-
model for the GI tract, a consistent set of absorption parameters to simulate oral ex-
posures to RDX, and oral absorption rate constants keyed to different formulations
of administered RDX per the kinetic data in the literature. Model code was also
added to simulate drinking water and inhalation exposures relevant to human
chronic exposures.  The resulting model simulations are consistent with observed
differences in the time course blood level data from a variety of PK studies, RDX
formulations, and dosing regimens. Blood concentrations of RDX did not differ
considerably when simulating inhalation exposure as compared to oral exposure.
Model fits to rat data resulting from a subchronic drinking water exposure demon-
strated achievement of steady state levels, lack of metabolic induction over time
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from repeated doses, and the utility of the modified RDX model for use in estimat-
ing and extrapolating blood levels following repeated exposure. [The views ex-
pressed are those of the authors and do not necessarily reflect the views or policies
of the U.S. EPA.]
609 Developing New Methods to Measure Reactive Oxygen
Species Related to Aerosol Components.
W. Huynh1,  E. Browne2 and R. E. Peltier1. 1Public Health - Environmental Health
Sciences, University of Massachusetts Amherst, Amherst, MA; 2Veterinary & Animal
Sciences, University of Massachusetts Amherst, Amherst, MA.
Reactive oxygen species (ROS) have been shown to be an important indicator of
adverse toxicological effects and has been widely studied in the context of ambient
air pollution exposure research. ROS is formed in vivo as a result of exposure to am-
bient air pollutants and is thought to be a convenient approach to understanding
responses arising from air pollution exposures. Current methods of measurement
for ROS typically follow a labor-intensive and time-consuming method of collec-
tion and extraction of particles from the field, which are then introduced (often at
very high concentrations) in vitro. The objectives of this research are to streamline
these approaches by developing and characterizing a new instrument capable of au-
tomated, semi continuous quantification of ROS. The work presented here at-
tempts to fill this gap by repeatedly inducing reactive oxygen on plated immortal-
ized pulmonary epithelial cells (BEAS-2B) which have been loaded with
2′,7′-dichlorofluorescein diacetate (DCFH-DA). The data presented here are based
on a method using 96-well plates and standard fluorescent spectrometry methods.
These results are compared with similar approaches using a system of horseradish
peroxidase and DCFH-DA. Tested elements include micromolar concentrations of
hydrogen peroxide, solutions of ammonium sulfate and nitric acid, and quinones.
We show that, with notable limitations, plated cells can respond to repeated dosing
of simulated air pollution, suggesting that this method is suitable for further instru-
ment method development.
610 Designing Quantitative Structure Activity Relationships
(QSAR) to Predict Specific Toxic Endpoints for
Polybrominated Diphenyl Ethers (PBDE) in Mammalian
Cell Culture Systems.
S. Rawat1, 2 and E. D. Bruce2, 3. 1US EPA, Athens, GA; 2Department of
Environmental Science, Baylor University, WACO, TX; 3Department of Civil
Engineering, Texas A&M University, College Station, TX.
Polybrominated diphenyl ethers (PBDEs) are flame retardants that have had vast
industrial application in consumer products, such as plastics, building materials,
electronics and textiles. They are structurally similar to thyroid hormones that are
responsible for regulating metabolism in the body. Therefore, PBDEs compete for
the thyroid hormone binding receptors and this can adversely affect thyroid hor-
mone transport and metabolism. Due to their potential threat to human health,
this study aimed to design Quantitative Structure Activity Relationship (QSAR)
models for predicting specific toxic endpoints, namely, cell viability and apoptosis.
Human hepatocarcinoma (Hep G2) cells were exposed to PBDEs and were used as
a model system to evaluate cell viability using Janus Green dye and apoptosis using
a capsase assay. Data collected from the experiments were used to create QSAR
models using the Genetic Function Approximation (GFA) method of generating
predictive models. Cell viability and apoptosis responses elicited by the PBDEs
were successfully modeled with an r2 of 0.97 and 0.94 respectively. Van der Waal’s
surface area and Gasteiger charges were found to be the important properties that
characterize cell viability. Molar refractivity, Kappa-3, and VSA_PartialCharge fig-
ured as the most appropriate descriptors to characterize apoptosis.
611 A Preliminary Physiologically-Based Pharmacokinetic
(PBPK) Model of Squalene in Vaccines.
M. A. Tegenge and R. J. Mitkus. CBER, US FDA, Rockville, MD.
Adjuvants are often added to vaccine formulations to potentiate the immune re-
sponse to antigen. Aluminum salts are the oldest and most widely used adjuvants;
however, in recent years, oil-in-water emulsion adjuvants have emerged as alterna-
tive adjuvant systems. Two emulsion adjuvants, MF59® and ASO3®, for example,
have been developed commercially using the triterpene oil, squalene. Although
squalene is a natural component of the diet and an endogenous precursor of choles-
terol, its fate following intramuscular (IM) injection as a vaccine adjuvant con-
stituent is not fully understood. In the absence of experimental pharmacokinetic
data in humans, we constructed a whole body physiologically based pharmacoki-
netic (PBPK) model for intramuscularly injected squalene-in-water emulsion in
adults. Based on published information, we assumed a mean diameter of 160 nm
for the emulsion and stabilization by nonionic surfactants. Hence, preferential up-
take into the lymphatics, rather than the blood, would be expected following IM
injection. Tissue-blood partition coefficients for squalene were estimated by an al-
gorithm approach that considered its binding potential to neutral lipids and
lipoproteins. Physiological and biochemical parameters were obtained from stan-
dard sources in the published literature. The results of our modeling indicate that
intramuscular squalene emulsion will transfer from the site of injection into the
lymphatics rapidly and will be essentially cleared from the deltoid muscle in two
days. The major proportion of the injected squalene was predicted to distribute to
the draining lymph nodes and accumulate in distal adipose tissues. Our model in-
dicated slow clearance from the latter compartment most likely because of parti-
tioning into neutral lipids and a low rate of squalene biotransformation there.
However, the predicted contribution of administered squalene was still only ~0.1%
of the endogenous pool of squalene in adipose tissue. In conclusion, our results pro-
vide important pharmacokinetic information that may help to explain the pharma-
codynamic activity of a new class of vaccine adjuvants that contain squalene.
612 A Model for Elucidating the Role of the Aryl Hydrocarbon
Receptor in TCDD-Mediated IgM Suppression in Human B
Cells.
N. Kovalova1, 2,  M. Manzan2,  R. B. Crawford2 and N. E. Kaminski1, 2.
1Pharmacology/Toxicology, Michigan State University, East Lansing, MI; 2Center for
Integrative Toxicology, Michigan State University, East Lansing, MI.
The aryl hydrocarbon receptor (AHR) is a transcription factor mediating toxic ef-
fects of 2,3,7,8 tetrachlorodibenzo-p-dioxin (TCDD). The objective of the present
study was to establish a human B cell model for elucidating the role of the AHR in
TCDD-induced suppression of the IgM production by B cells. The SKW6.4 cell
line used here is an Epstein–Barr virus-transformed, IgM-secreting human B cell
line. Wild-type SKW 6.4 cells are AHR null. We have used a lentiviral transduction
system to establish a SKW 6.4 cell line that stably expresses the human AHR cloned
from hepatoma HepG2 (SKW E8). An expression vector was designed to produce
an AHR-GFP fusion protein under the control of a doxycycline-inducible pro-
moter. SKW E8 and HepG2 cells express similar levels of AHR mRNA, as deter-
mined by qRT-PCR. TCDD treatment significantly induced Cyp1B1 mRNA ex-
pression in SKW E8 but not in SKW 6.4 cells, indicating that the transduced AHR
retained its transactivational activity. To assess the effects of TCDD on IgM secre-
tion, increasing concentrations of TCDD were added to pokeweed mitogen
(PWM) or lipopolysaccharide (LPS) activated SKW cell lines,induced IgM was
measured by ELISA. IgM secretion by PWM- or LPS-stimulated SKW E8 but not
SKW6.4 cells was suppressed by TCDD in a concentration-dependent manner.
Further analysis of the TCDD-induced suppression of the IgM response in SKW
E8 cells revealed that to suppress IgM production, TCDD must be added within
the first 12 h post-LPS activation. A similar window of sensitivity for the TCDD-
induced suppression of the IgM response was previously described in primary
mouse B lymphocytes. We demonstrate that the introduced AHR is functional and
induction of IgM production is suppressed by TCDD-treatment as shown in pri-
mary B cells. These results suggest that human SKW6.4 E8 cells represent a model
for elucidation of the molecular mechanisms involving AHR signaling in IgM sup-
pression.
613 The Impact of Variation in Scaling Factors on the Estimation
of Internal Dose Metrics: A Case Study Using
Bromodichloromethane.
E. M. Kenyon1,  R. A. Pegram1,  C. R. Eklund1 and J. C. Lipscomb2.
1ORD/NHEERL, US EPA, Durham, NC; 2ORD/NCEA, US EPA, Cincinnati, OH.
Physiologically based pharmacokinetic (PBPK) models can include values for meta-
bolic parameters extrapolated from in vitro metabolism studies using scaling factors
such as mg of microsomal protein per gram of liver (MMPGL) and liver weight
(LW). Variation in scaling factor values impacts metabolic rate parameter estimates
(Vmax) and hence estimates of internal dose used in dose response analysis. The
impact of variation in MMPGL and LW on estimates of internal dose was assessed
using a human PBPK model for bromodichloromethane (BDCM). Internal dose
metrics evaluated were area under the curve for blood BDCM (AUC), maximum
concentration of BDCM in blood (Cmax) and amount metabolized in liver per
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hour (AML) - for two exposure scenarios (single 0.25 liter drink of water or 10
minute shower) under typical (10 ppb) and plausible high level (50 ppb) water con-
centrations. MMPGL and LW (as a fraction of body weight) values used in the
analysis reflect the range of values reported for adult humans. For each concentra-
tion, each dose metric was changed less than 5% for the showering scenario (in-
halation and dermal exposure) because Vmax for hepatic metabolism is not a very
influential parameter for dose metrics related to blood concentration following low
level exposures. In contrast, an 8-fold difference in Cmax and AUC was observed
for each oral exposure concentration, but AML was relatively unchanged.
Sensitivity analysis for AUC for the oral exposure scenario revealed that MMPGL
was the most influential parameter, followed closely by LW, with blood flow to the
liver being moderately influential. This analysis demonstrates that variability in the
scaling factors used for in vitro to in vivo extrapolation (IVIVE) of metabolic rate
parameters can have a significant impact on estimates of internal dose metrics
under environmentally relevant exposure scenarios. This indicates the need to eval-
uate both uncertainty and variability for scaling factors used for IVIVE. (This ab-
stract does not necessarily reflect USEPA policy).
614 Kinetic Modeling Reveals the Roles of ROS Scavenging and
DNA-Repair Processes in Shaping the Dose-Response Curve
of KBrO3-Induced-DNA Damage.
D. J. Miller and M. A. Spassova. National Center for Environmental Assessment, US
EPA, Washington DC. Sponsor: S. Vulimiri.
We have used kinetic modeling to investigate how DNA repair processes and scav-
engers of reactive oxygen species (ROS) can affect the dose-response shape of pro-
oxidant induced DNA damage. We used as an example chemical KBrO3, a water
ozonation by-product and environmentally present pro-oxidant with genotoxic and
carcinogenic effects. In our model, KBrO3 is activated via interaction with glu-
tathione and forms reactive intermediates that directly interact with DNA to form
8-hydroxy-2-deoxyguanosine DNA adducts (8-OH-dG) – an effect convincingly
established in literature. The single strand breaks (SSB) that can result from failed
base-excision repair of these adducts were considered in the model as an effect
downstream from 8-OH-dG. We previously demonstrated that in the presence of
effective base-excision repair, 8-OH-dG can exhibit threshold-like dose-response
dependence, while the downstream SSB can still exhibit a linear dose-response. We
now further demonstrate that this result holds for a variety of model variants. In
particular, we investigated how the presence of a scavenger of the bromate reactive
intermediates affects the dose-response shape of 8-OH-dG and SSB. It has been
shown that melatonin, a terminal antioxidant, inhibits KBrO3-caused oxidative
damage. Our modeling revealed that a single pulse exposure to KBrO3 in the pres-
ence of such a terminal scavenger can lead to a sublinear/threshold-like dependence
of the response for both 8-OH-dG and SSB. However, sustained exposure to
KBrO3 can lead to fast scavenger exhaustion, in which case the dose-response
shapes for both endpoints are not substantially affected. The results are important
to consider when forming conclusions on a chemical’s toxicity based on the dose-re-
sponse of early genotoxic events.
615 A Compartmental Pharmacokinetic (PK) Model for Bromate
in F344 Rats.
N. Kolisetty1,  C. A. White1,  R. J. Bull2,  J. A. Cotruvo3,  J. W. Fisher4 and
B. S. Cummings1. 1Pharmaceutical and Biomedical Sciences, University of Georgia,
Athens, GA; 2Mo Bull Consulting, Richland, WA; 3Joseph Cotruvo & Assoc. LLC,
Washington DC; 4National Center for Toxicological Research, US FDA, Jefferson, AR.
Bromate (BrO3
-) is a toxic water disinfection by-product formed during ozonation
of source water containing bromide (Br-). It is a proven animal and probable
human carcinogen (group 2B). However, BrO3
- pharmacokinetics (ADME) at low
doses is not fully understood. To better understand BrO3
- ADME, we developed a
pharmacokinetic (PK) model based on the raw data from our recent publication
(Bull et al. 2012). Based on goodness of fit, and the model diagnostics, a pharma-
cokinetic model fitted with individual animal data and weight-2 (1/Y2) weight
scheme was chosen as a model of choice to describe BrO3
- disposition in female
F344 rats. BrO3
- disposition after IV bolus was best described using a 1-compart-
mental pharmacokinetic model for doses up to 0.5 mg/kg; and by using a 2-com-
partmental pharmacokinetic model for doses of 1-2.5 mg/kg potassium bromate
(KBrO3). BrO3
- disposition was best described using a 1-compartmental model fol-
lowing its oral administration (0.5 to 20 mg/kg KBrO3) in female F344 rats.
Analysis of BrO3
- PK parameters following oral administration, suggested that
BrO3
- absorption occurs in a first order manner with a rate constant (Ka) of ~0.16
min-1. BrO3
- appears to undergo extensive first pass reduction, resulting in
bioavailability of ~19-25%. Approximately 90% of orally administered BrO3
- is re-
duced to Br- in the body, and the remaining BrO3
- appears to be excreted from the
body as BrO3
- in the urine at 0.002 L/min/kg. In conclusion, BrO3
- undergoes ex-
tensive reduction to Br- in liver and blood following its oral administration in fe-
male F344 rats, which limits BrO3
- distribution to the peripheral tissues to exert its
toxic effects.
616 A Strategy for Developing a PBPK Model to Describe the
Kinetics of Silver Nanoparticles.
M. Yoon1,  S. Sumner2,  R. Snyder2,  T. Fennell2 and H. J. Clewell1. 1The Hamner
Institutes for Health Sciences, Research Triangle Park, NC; 2RTI International,
Research Triangle Park, NC.
Our previous model for C60 was proposed as a general platform for PBPK model-
ing of engineered nanoparticles (NPs). Since the structure was based on biological
mechanisms that govern NP disposition, the platform can be applied to other NPs
by changing parameters to account for particle-to-particle variance in biological
processes. In this study, the model was parameterized for silver (Ag) NPs using tis-
sue concentration data collected in adult female SD rats after a single intravenous
(IV) dose (1 mg/kg) of Ag NPs (20 or 110 nm) in water stabilized with polyvinyl
pyrrolidone (PVP) or Ag acetate in PVP. Parameterization was based on size-de-
pendent dissolution potential of Ag NPs under physiological conditions as well as
generally applicable size-dependent endocytosis efficiency for particles. Due to the
dissolution potential, a combination of two kinetic models, one for Ag NPs and the
other for ionic forms of Ag was used. The model successfully simulated observed
concentrations of total Ag in various tissues as well as in urine and feces after a sin-
gle IV dose of Ag NPs. The model was then extrapolated to Ag NPs with other
coating agents. The published data for tissue concentrations of total Ag in adult
male Wistar rats after single or multiple (~ 0.1 mg/kg/day) IV administration of Ag
NPs in phosphate buffer (20 or 110 nm) was simulated. For this evaluation, the im-
pact of different coatings on Ag NPs stability in size, shape and surface properties
was also considered in the parameterization. The current model captured the time
courses of total Ag concentration in blood, liver, lung, spleen, and heart both for
single and multiple exposures from this study. The overall success in extending the
C60 model to Ag NPs demonstrated the applicability of our model structure, as a
general platform, to other NPs when combined with nanoparticle-specific proper-
ties for the given material (This work was supported by NIEHS Award
#U19ES019525, but solely expresses the view of the authors).
617 A Physiologically-Based Pharmacokinetic Model to Describe
the Pharmacokinetic Disposition for Hexamethyldisiloxane,
a Linear Volatile Methyl Siloxane, following Inhalation
Exposures in the Rat.
T. McMullin,  J. Y. Domoradzki,  D. A. McNett,  J. Durham and K. P. Plotzke.
Health and Environmental Sciences, Dow Corning Corporation, Midland, MI.
The purpose of this work was to expand a previously developed physiologically
based pharmacokinetic (PBPK) model for hexamethyldisoloxane (HMDS)
(Dobrev et al., 2003) with additional kinetic data to further examine the processes
regulating the pharmacokinetic disposition of HMDS. Time-course concentrations
of parent HMDS and total metabolites in multiple tissues, blood and exhaled
breath in male and female F344 rats during and following nose only vapor inhala-
tion exposure to 5000ppm 14C-HMDS were used to extend the model. A 15 day
inhalation study was also conducted to understand impacts, if any, following re-
peated exposures. Based on similarities in physicochemical properties, the HMDS
model structure was adapted from another volatile methylsiloxane (VMS) oc-
tamethylcyclotetrasiloxane (D4) model structure (Andersen et al., 2001). This up-
dated model now includes saturable metabolism in the liver, a diffusion-limited up-
take of HMDS in the fat compartment and a blood lipid pool where a fraction of
HMDS is sequestered and unavailable for exchange into blood and exhalation from
the lung. HMDS and its metabolites in blood, liver, lung, fat and exhaled breath
following both single and multiple exposures are well described with this model
using a single set of parameters. Consistent with D4 kinetic behavior, low blood:air
partitioning and extensive metabolism lead to rapid clearance of free HMDS from
the body following both single and repeated exposures. Despite retention of bound
HMDS in tissues at the extended time points following exposure, the extensive and
rapid clearance mechanisms of HMDS lead to tissue and exhaled breath concentra-
tions of HMDS that are similar following both multiple day exposures and single
exposures. This PBPK model is a starting point from which the pharmacokinetic
disposition of HMDS and, upon extension, other linear VMSs, can be evaluated
for risk assessment.
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618 Use of a Physiologically-Based Pharmacokinetic Model to
Simulate the Time Course of 3-Hydroxybenzo(a)Pyrene
Metabolite in Workers Exposed to Polycyclic Aromatic
Hydrocarbons and Predict Most Plausible Exposure
Scenarios.
R. Heredia-Ortiz1,  A. Maître2 and M. Bouchard1. 1Department Environmental
and Occupational Health, University of Montréal, Montréal, QC, Canada; 2CHU de
Grenoble, Université Joseph Fourier, Grenoble, France.
Mathematical modeling has become an important tool to assess xenobiotic expo-
sure in humans. In the present study, we have used a human physiologically-based
pharmacokinetic (PBPK) model to reproduce the time-course of 3-hydroxy-
benzo(a)pyrene (3-OHBaP) in the urine of industrially exposed workers and in
turn predict most plausible exposure scenarios. Urinary voids from a dozen workers
highly exposed to polycyclic aromatic hydrocarbons (PAHs) in the Rhone-Alpes re-
gion in France have been collected during a typical workweek (beginning and end-
of-shift) and subsequent days off; urinary concentrations of 3-OHBaP were then
determined. Based on the information obtained for each worker (airborne BaP con-
centration, daily shift hours, tasks, protective equipment), the time courses of 3-
OHBaP in the urine of the different workers have been simulated using the PBPK
model, considering the various possible exposure routes, oral, dermal and inhala-
tion, as well as combined exposure. The model was constructed from in vivo exper-
imental data in rats and then extrapolated from animals to humans after assessing
and adjusting most sensitive model parameters as well as species specific physiolog-
ical parameters. The model was able to closely reproduce the observed time course
of 3-OHBaP and establish most plausible exposure route depending on the worker.
It appears as a useful tool to better interpret biomonitoring data of PAH exposure
on the basis of 3-OHBaP biomarker levels.
619 Computational Modeling of the Pathway Linking Oxidant
Exposure with a Fluorescent Reporter Protein in Human
Airway Epithelial Cells.
W. Cheng1,  J. M. Samet2 and R. B. Conolly3. 1Environmental Science and
Engineering, University of North Carolina at Chapel Hill, Chapel Hill, NC; 2EPHD,
US EPA, Chapel Hill, NC; 3ISTD, US EPA, Chapel Hill, NC.
Air pollution is one of the most common environmental exposures imposed on hu-
mans in urban areas on a daily basis. Mixtures of gaseous and particle pollutants
contain hundreds of thousands of compounds with the potential for numerous in-
teractions. Many pollutants operate through modes of action involving oxidative
stress. We use the genetically engineered fluorescent reporter roGFP to assess oxida-
tive stress in transformed human airway epithelial cells. The specific goal of current
study was to develop a computational model of the biochemical pathway linking
oxidant exposure with oxidation of roGFP. Models of this type can provide insights
into the structure and kinetics of these pathways that complement the information
obtained directly from the laboratory studies. As our initial effort at model devel-
opment, we used live cell imaging to monitor roGFP oxidation by micromolar
H2O2. roGFP was fully oxidized within 20 min and recovery to its reduced state
took several hours. These kinetics were well described by the model. Furthermore,
the model-based quantitative analysis has shown that the observed response for ox-
idation of roGFP is nonlinear with dose and consistent with Michaelis-Menten ki-
netics. These latter results reflect the underlying sequence of enzymatic reactions,
e.g., glutathione peroxidase, glutaredoxin and glutathione reductase, through
which the oxidizing effect of H2O2 is transmitted to roGFP. These results illustrate
how computational modeling of modes of action of oxidants can provide insights
that complement laboratory observations and that will be needed as we seek to un-
derstand the health risks associated with air pollution exposures. This presentation
reflects the views of the authors and does not necessarily reflect EPA policy.
620 Comparative Toxicokinetic and Toxicodynamic Study of
Trichloroethylene and Tetrachloroethylene in the Mouse.
V. Soldatow1,  H. Yoo1,  B. Wanda1,  L. B. Collins1,  S. Kim2,  K. Xia1,  W. Sun1,
F. Wright1,  W. A. Chiu1,  K. Guyton3 and I. Rusyn3. 1University of North Carolina
at Chapel Hill, Chapel Hill, NC; 2Seoul National University, Seoul, Republic of
Korea; 3NCEA, US EPA, Washington DC.
Trichloroethylene (TCE) and tetrachloroethylene (PCE) are ubiquitous environ-
mental and occupational agents hazardous to human health. Several important gaps
in our understanding of their potential toxicity have been identified: 1) extent of
inter-individual variability in toxicity, 2) complexities associated with linking
metabolites to specific organ toxicity, and 3) comparative analysis of toxicokinetics
(TK) and toxicodynamics (TD) of these closely related agents. This project aimed
to fill these gaps by providing TK and TD data using a panel of mouse strains as a
model for inter-individual variability. We focus on key metabolites of TCE and
PCE: trichloroacetic acid (TCA), dichloroacetic acid (DCA), trichloroethanol
(TCOH), S-(1,2,2-trichlorovinyl)-L-cysteine (TCVC), S-(1,2-dichlorovinyl)-L-
cysteine (DCVC), and S-(1,2,2-trichlorovinyl)glutathione (TCVG), and S-(1,2-
dichlorovinyl)glutathione (DCVG). In the TK and TD studies, a single oral dose of
TCE or PCE (24-800 mg/kg or 30-1,000 mg/kg, respectively, in 5% Alkamuls EL-
620 in saline) was administered to male mice from three strains (C57BL/6J,
NZW/LacJ and B6C3F1/J). Quantification of metabolites (up to 36 hours post
dosing) was performed in serum, liver, kidney, spleen, brain, lung, and bone mar-
row. In addition, RNA Sequencing was used to identify dose-response changes in
gene expression in liver. These data are relevant for human health assessments of
TCE and PCE as they provide data for kinetic modeling, dose-response analysis of
the toxicity mechanisms, and evaluation of inter-individual differences in suscepti-
bility to these chemicals. Funded by P42 ES005948. Disclaimer: The views ex-
pressed here are the authors’ and not necessarily those of the US EPA.
621 A Mechanistic Model of GABAA-Receptor Trafficking during
Status Epilepticus.
E. Merrill1,  J. Gearhart1,  C. Ruark1,  D. A. Mahle2 and P. Robinson1.
1AFRL/RHDJ, Henry M. Jackson Foundation, Wright Patterson Air Force Base, OH;
2Human Performance, AFRL/RHDJ, Wright Patterson Air Force Base, OH.
The efficacy of benzodiazepines (BZ) to abolish seizures diminishes rapidly with
time after onset of status epilepticus (SE). This progressive loss of efficacy is associ-
ated with the rapid internalization of BZ-sensitive GABAA receptors, together with
a slight increase in localization of BZ-insensitive GABAA receptors to the synaptic
membrane. We developed a compartmental model of receptor localization and
movement in the dendritic spine that includes surface receptors within the post-
synaptic density (PSD), including those bound to gephyrin scaffold proteins, and
the extrasynaptic membrane (ESM), as well as internalized receptors. The model
includes movement of receptors between these compartments as well as receptor
synthesis and degradation. The model was used to simulate receptor trafficking
under normal (non-seizure) and status epilepticus conditions.  Data from in vitro
studies using various neuronal cell cultures as well as HEK cells modified to express
GABAA receptors were used to parameterize and validate the model. Increases in
receptor endocytosis rate and lateral movement from PSD to ESM (or a decrease in
gephyrin binding) were found to be sufficient to simulate SE conditions. By inte-
grating the current GABAA receptor trafficking model with a physiologically-based
pharmacokinetic (PBPK) model for diazepam, a time-dependant therapeutic dose
can be predicted. The model suggests that approximately 55% occupancy of the
original receptor number is required to reverse ongoing seizures. This is up from a
reported 37% occupancy required to prevent the initiation of seizures in the rat,
when diazepam is administered as a prophylaxis.
622 Multichemical Bayesian Calibration of a Generic
Physiologically-Based Pharmacokinetic (PBPK) Model to
Calculate Biological Limit Values for Lipophilic Volatile
Organic Compounds.
R. McDougall1,  M. Verner2, 3,  G. Charest-Tardif4,  R. Tardif4 and G. Johanson2.
1Faculty of Engineering and Applied Science, University of Ontario Institute of
Technology, Oshawa, ON, Canada; 2Institute of Environmental Medicine, Karolinska
Institutet, Stockholm, Sweden; 3Channing Laboratory, Brigham and Women’s
Hospital, Harvard Medical School, Boston, MA; 4Département de santé
environnementale et santé au travail, Université de Montréal, Montréal, QC,
Canada.
Biomonitoring provides an integrative measure of internal exposures in workers ex-
posed to contaminants in the occupational setting. PBPK models validated against
empirical data can be used to estimate the variability in biological levels following
specific exposure conditions. Given the large array of contaminants in the work-
place, the calibration of a generic PBPK model could be useful to generate biologi-
cal limit values for chemical with little or no available human data. We aimed to de-
velop a generic PBPK model for lipophilic volatile organic compounds (VOCs) in
end-exhaled air, which can be obtained non-invasively, and to calibrate it using
Markov Chain Monte Carlo (MCMC) techniques and human data from con-
trolled exposures. We built a simple 3-compartment PBPK model (liver, adipose
tissue and rest of the body) that runs on three chemical-specific parameters: intrin-
sic clearance and octanol:water and blood:air partition coefficients. Global sensitiv-
ity analysis was used to identify the most influential parameters on end-exhaled air
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levels. MCMC analysis was employed to infer population and individual distribu-
tions for these significant parameters based on levels measured in 12 individuals ex-
posed to styrene, n-hexane or toluene. The generic VOC PBPK model calibrated by
MCMC analysis was able to predict end-exhaled air levels levels for the 12 individ-
uals and 3 compounds. The chains from the converged MCMC runs will be used
to derive distributions of end-exhaled air for given exposure scenarios. Our next
steps will be to include more individuals, compounds and exposures scenarios with
variable workloads to better describe variability in the population.
623 Development of a New 3D Human Small Intestinal Tissue
Model.
S. Ayehunie,  Z. Stevens,  T. Landry,  P. Hayden and M. Klausner. MatTek
Corporation, Ashland, MA.
The epithelial lining of the gastrointestinal (GI) tract is a gatekeeper for entry of
orally ingested nutrients and xenobiotics including medicaments. The intestinal
lining has a well organized structure containing proliferative cells which migrate
along the crypt-villi axis and differentiate into functional mature epithelial cells.
Currently, the most common in vitro model utilized for study of drug absorption at
the intestinal mucosa is based on a 2-D cell culture model of the colon carcinoma
cell line, Caco-2. These cells differentiate into monolayers of polarized enterocytes
that are connected by tight junctions, but lack mucus-secreting goblet cells and
show inter-passage inconsistency. Others have developed small intestinal organoids
which are not suitable for apical application of test articles. Here, we report the re-
construction of a human organotypic small intestinal tissue (SI) generated from pri-
mary human SI epithelial cells that grow in tissue culture inserts using serum free
medium. Human SI epithelial cells and myofibroblasts were expanded in mono-
layer culture and seeded on a microporous membrane containing a fibroblast-colla-
gen-gel substrate to reconstruct three dimensional organotypic SI tissues. Tissue
morphology and biomarker expression of the SI model were characterized by H&E
staining and immunohistochemistry, respectively. Basal cell proliferation markers,
cytokeratins (CK) and mucin were monitored over an 11-day culture period.
Analysis of the SI tissue model revealed: 1) wall-to-wall growth of the epithelial
layer, 2) columnar epithelial cell morphology similar to that of native SI tissue, 3)
expression of muc-2, CK19, and villin at the surface of the epithelium, and 4)
Lgr5+ (crypt stem cell marker) positive cells. In conclusion, the new human cell
based 3D SI tissue model will likely serve as a valuable tool to evaluate pre-clinical
therapeutic drug candidates intended for oral administration and study microbio-
mes and microbial infection of the GI tract.
624 Evaluating Dose-Response Parameters of an In Vitro DNA-
Chemical Interaction Using a Mechanistic Biological Model.
A. Nong,  K. Lyon,  J. M. Gavina and Y. Feng. Environmental Health Science and
Research Bureau, Health Canada, Ottawa, ON, Canada.
Benchmark dose modeling of genomic data is a trending approach in toxicity test-
ing, and system biology modeling attempts to understand quantitative data in light
of what we expect from more complex biological systems. Biological modeling ap-
proaches can incorporate different forms of kinetic and dynamic data of a chemical
interaction in vitro. The objective of this effort was to interpret a biological model
mechanism and parameters describing a chemical doubled stranded oligonu-
cleotide interaction assay for a series of chemicals (tetrachlorohydroquinone,
styrene-7,8-oxide, methyl methane sulfonate, phenyl glycidyl ether, and
benzo(a)pyrene diolepoxide), with both time series and dose-ranged measurements.
The chemicals have been analyzed with time series, dose-response and inhibition
mixture response analysis. A model using mixed Michaelis-Menten kinetic and
multiple binding was determined to be best suited with the data coherency between
the biological and mathematical expectations. This was based on the results of the
model, as well as the poorer results of other considered models (e.g. constant rate
constants, linear rate constants, multi-step reactions, Hill functions). Correlations
between coefficients and various chemicals, as well as sensitivity analysis, gave evi-
dence of a deeper mechanism underlying nucleotide perturbations (e.g. relations
amongst the half-life, dose and the curvature of the reactions). Two model parame-
ters, molecular binding coefficient (range from 0.1 to 2.6) and nonlinear affinity
rate constant (ranging from 30 to 5300 μM), were dose dependant and specific to
each chemical. These kinetic parameters are suitable candidates for a quantitative
structure-activity analysis with chemical descriptors for nucleotide binding sites
and interaction efficacy as indicators of adduct formation. These biological models
fit the biological expectations for the governing mechanisms, giving further evi-
dence of the effectiveness of statistical and benchmark dose modeling in toxicity
testing.
625 Developing Predictive Approaches to Characterize Adaptive
Responses of the Reproductive Endocrine Axis to Aromatase
Inhibition: Computational Modeling.
M. Breen1, 2,  D. L. Villeneuve3,  G. T. Ankley3,  D. Bencic4,  M. S. Breen5,
K. H. Watanabe6,  A. L. Lloyd2 and R. B. Conolly1. 1ISTD, NHEERL, ORD, US
EPA, Research Triangle Park, NC; 2Biomathematics Program, Department of
Mathematics, NCSU, Raleigh, NC; 3Mid-Continent Ecology Division, US EPA,
Duluth, MN; 4Ecological Exposure Research Division, US EPA, Cincinnati, OH;
5NERL, US EPA, Research Triangle Park, NC; 6Environmental and Biomolecular
Systems, Oregon Health & Science University, Beaverton, OR.
Exposure to endocrine disrupting chemicals can affect reproduction and develop-
ment in both humans and wildlife. We developed a mechanistic mathematical
model of the hypothalamic-pituitary-gonadal (HPG) axis in female fathead min-
nows to predict dose-response and time-course (DRTC) behaviors for endocrine ef-
fects of a well-defined aromatase inhibitor, fadrozole (FAD). The model includes a
regulatory feedback that mediates adaptive responses to endocrine stress by control-
ling the secretion of a generic gonadotropin (LH/FSH) from the hypothalamic-pi-
tuitary complex. Plasma 17β-estradiol (E2) and ovarian cytochrome P450 (CYP)
19A aromatase mRNA data from two time-course experiments, each of which in-
cluded both an exposure and a depuration phase, and plasma E2 data from 4 days
exposure experiment were used to develop and evaluate the model. Model parame-
ters were estimated using E2 concentrations for 0, 0.5, and 3 μg/L FAD concentra-
tions, and good fits to these data were obtained. The model accurately predicted
CYP19A mRNA fold changes for controls and three FAD doses (0, 0.5, or 3 μg/L),
and venous E2 dose-response during FAD exposure on day 4. Comparing the
model-predicted DRTC with experimental data provided insight into how the
feedback control mechanisms embedded in the HPG axis mediate these changes:
adaptive changes in plasma E2 levels occurring during exposure and “overshoot”
occurring post-exposure. This study demonstrates the value of mechanistic compu-
tational modeling to examine and predict the possible dynamic behaviors. This ab-
stract does not necessarily reflect US Environmental Protection Agency policy.
626 Mitochondrial Dysfunction-Induced by Sertraline, an
Antidepressant Agent.
L. Couch1,  Y. Li1,  J. Fang1,  M. Higuchi2 and L. Guo1. 1NCTR, US FDA,
Jefferson, AR; 2Department of Biochemistry and Molecular Biology, University of
Arkansas for Medical Sciences, Little Rock, AR.
Sertraline, a selective serotonin reuptake inhibitor (SSRI), has been used for the
treatment of depression. Although it is generally considered safe, cases of sertraline-
associated liver injury have been documented; however, the possible mechanism of
sertraline-associated hepatotoxicity is entirely unknown. Here we report that mito-
chondrial impairment may play an important role in liver injury induced by sertra-
line. In mitochondria isolated from rat liver, sertraline uncoupled mitochondrial
oxidative phosphorylation and inhibited the activities of oxidative phosphorylation
Complexes I and V. Additionally, sertraline induced Ca2+-mediated mitochondrial
permeability transition (MPT), and the induction was prevented by bongkrekic
acid, a specific MPT inhibitor targeting adenine nucleotide translocator (ANT),
implying that the MPT induction is mediated by ANT. In freshly isolated rat pri-
mary hepatocytes, sertraline rapidly depleted cellular ATP and subsequently in-
duced lactate dehydrogenase (LDH) leakage; both were attenuated by bongkrekic
acid. Our results, including ATP depletion, induction of MPT, inhibition of mito-
chondrial respiration complexes, and uncoupling oxidative phosphorylation, indi-
cate that sertraline-associated liver toxicity is possibly via mitochondrial dysfunc-
tion.
627 Mouse Liver Protein Sulfhydryl Depletion Induced by
Acetaminophen Exposure.
X. Yang1,  J. Greenhaw1,  Q. Shi1 and W. F. Salminen2. 1Division of Systems
Biology, US FDA, National Center for Toxicological Research, Jefferson, AR;
2PAREXEL, Benton, AR.
Since Acetaminophen (APAP) remains the leading cause of acute liver failure in the
western world, a large body of research has been conducted to understand the
mechanisms behind the pathogenesis. The role of protein sulfhydryl depletion in
APAP-induced liver injury was investigated in this study and compared to protein
adducts and classical measures of toxicity. A single oral gavage dose of 150 or 300
mg/kg APAP in B6C3F1 mice produced increased serum alanine aminotransferase
levels, liver necrosis, and glutathione depletion in a dose-dependent manner. The
levels of global free protein sulfhydryls, were significantly decreased at 1 hour and
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remained as such through 24 hours postdose. Histochemical detection of free pro-
tein sulfhydryls showed a zonal pattern of sulfhydryl depletion within the liver lob-
ule. The centrilobular areas exhibited dramatic decreases in protein free sulfhydryls
while the periportal regions were essentially spared. Oxidation of the free protein
sulfhydryls occurred in the same regions of cells that contained APAP-protein
adducts and developed necrotic changes. Interestingly, the majority of free protein
sulfhydryl depletion was due to reversible oxidation since the global and lobule-spe-
cific effects were essentially reversed with TCEP, a sulfhydryl reducing agent, prior
to maleimide labeling. The changes in protein sulfhydryl oxidation may act as the
sensor for oxidants, such as ROS and RNS. Therefore, investigating the protein
sulfhydryl depletion may have important clinical ramifications in understanding
the pathogenesis of APAP-induced hepatocellular injury.
628 Purinergic Receptor Antagonist A438079 Protects against
Acetaminophen-Induced Liver Injury by Inhibiting P450
Isoenzymes Not Inflammasome Activation.
Y. Xie,  C. Williams,  M. R. McGill,  M. Leborfsky,  A. Ramachandran and
H. Jaeschke. Pharmacology, Toxicology & Therapeutics, University of Kansas Medical
Center, Kansas City, KS.
Acetaminophen (APAP) overdose is the most frequent cause of acute liver failure in
the western world. Controversy exists regarding the hypothesis that the hepatocyte
injury is amplified by a sterile inflammatory response, rather than being the result
of intracellular mechanisms alone. A recent study suggested that the purinergic re-
ceptor antagonist A438079 protects against APAP-induced liver injury by prevent-
ing the activation of the Nalp3 inflammasome in Kupffer cells and thereby prevent-
ing inflammatory injury. To test the hypothesis that A438079 actually affects the
intracellular signaling events in hepatocytes, C57Bl/6 mice were treated with APAP
(300 mg/kg) and A438079 (80 mg/kg) or saline and GSH depletion, protein
adduct formation, c-Jun-N-terminal kinase (JNK) activation, oxidant stress and
liver cell necrosis was determined between 0-6h after APAP administration. APAP
caused rapid GSH depletion, extensive protein adduct formation in liver ho-
mogenates and in mitochondria, JNK phosphorylation and mitochondrial translo-
cation of phosphor-JNK within 2h, oxidant stress, and extensive centrilobular
necrosis at 6h. A438079 significantly attenuated GSH depletion, which resulted in
a 50% reduction of total liver and mitochondrial protein adducts and substantial
reduction of JNK activation, mitochondrial P-JNK translocation, oxidant stress
and liver injury. The same results were obtained using primary mouse hepatocytes.
A438079 did not directly affect JNK activation induced by tert-butyl hydroperox-
ide and GSH depletion. However, A438079 dose-dependently inhibited hepatic
P450 enzyme activity. Thus, the protective effect of A438079 against APAP hepa-
totoxicity in vivo can be explained by its effect on metabolic activation and cell
death pathways in hepatocytes without involvement of the Nalp3 inflammasome.
629 The Role of Choline Depletion in Perfluorooctanesulfonate-
Induced Hepatic Steatosis.
P. Krishnan1,  A. D. Patterson1,  D. J. Ehresman2,  P. B. Smith1,  M. K. Scavello1,
S. Chang2,  J. L. Butenhoff2 and J. M. Peters1. 1 Pennsylvania State University,
University Park, PA; 23M Company, St. Paul, MN.
In toxicological studies, perfluorooctanesulfonate (PFOS) exposure has resulted in
hepatic steatosis and hypolipidemia, believed to be the result of decreased produc-
tion and secretion of VLDL and HDL and increased uptake of VLDL-triglyceride.
The hypothesis that PFOS produces hepatic steatosis via ionic sequestration of
available choline necessary for the production of VLDL was examined. Plausibility
was supported by identification of an ion-triad between two molecules of choline
and one molecule of PFOS in vitro. We fed male C57BL/6 mice either a control
diet or a marginal methionine/choline-deficient (mMCD) diet, both with and
without PFOS. After a two-week run-in period on diets without PFOS, control or
mMCD diets containing 0, 30, 60, or 120 mg K+PFOS/kg diet were fed for three
weeks. There was a dose-dependent increase in the relative liver weight in both con-
trol and mMCD fed mice. Dietary PFOS was also associated with dose-dependent
decreases in body weight, increases in hepatic triglyceride concentration, and in-
creases in serum ALT, ALP, and bile acids, all with larger effects observed in mice
fed mMCD compared to those fed the control diet. Serum and liver concentrations
of PFOS were increased in a dose-dependent manner on both diets; however, serum
PFOS concentrations were higher and liver concentrations lower in mMCD-fed
mice compared to corresponding control-fed mice. This is surprising because the
evidence suggested that PFOS-induced hepatotoxicity was exacerbated in the
mMCD diet fed mice. Metabolomic analysis demonstrated that PFOS caused a sig-
nificant decrease in the hepatic concentration of many phosphatidylcholines in the
PFOS-fed mice compared to controls. Further, the average serum concentration of
choline was reduced by dietary PFOS. These studies are the first to provide evi-
dence that PFOS may cause hepatic steatosis through depletion of choline required
for hepatic VLDL production and export.
630 Platelet Depletion Reduces Acetaminophen Hepatotoxicity
in Mice.
K. Miyakawa1, 2,  R. Albee3,  M. Scott1,  P. E. Ganey2, 3,  J. Luyendyk1, 2 and
R. Roth2, 3. 1Department of Pathobiology and Diagnostic Investigation, Michigan
State University, East Lansing, MI; 2Center for Integrative Toxicology, Michigan State
University, East Lansing, MI; 3Department of Pharmacology and Toxicology,
Michigan State University, East Lansing, MI.
Acetaminophen (APAP) overdose is the major cause of acute liver failure in the U.S.
Previous studies identified decreases in blood platelet concentration in patients
with APAP toxicity, but the role of platelets in APAP-induced liver injury is unclear.
We tested the hypothesis that platelets contribute to liver injury in a mouse model
of APAP hepatotoxicity. Blood platelet concentration was reduced 6-36 h after ad-
ministration of APAP (300 mg/kg, ip) to mice, and immunofluorescent labeling
showed increased platelets within livers at 2-6 h. Pretreatment of mice with anti-
CD41 IgG to reduce circulating platelet concentrations to 1/10th of control re-
duced liver injury at 6, 12 and 24 hr after APAP administration, as evaluated by
plasma alanine aminotransferase activity and the area of hepatic necrosis. The ery-
throcyte-to-hepatocyte volume ratio in the livers of APAP-treated mice was also re-
duced by anti-CD41 IgG pretreatment, suggesting a reduction in congestion or
hemorrhage. The early (30 min) APAP-mediated consumption of reduced glu-
tathione (GSH) was unaffected by platelet depletion, suggesting that the reduction
in injury was not a consequence of diminished APAP bioactivation. Activated
platelets provide a thrombogenic surface for amplification of thrombin generation;
indeed, platelet depletion significantly reduced the increase in plasma concentra-
tion of thrombin-antithrombin complexes, a biomarker of thrombin generation, at
3h. Addition of thrombin to cultures of primary hepatocytes in vitro did not affect
APAP-induced cytotoxicity, suggesting that thrombin does not contribute to toxic-
ity through a direct action on hepatocytes. Taken together, the results suggest that
platelets support thrombin generation and contribute to congestion or hemorrhage
and hepatocellular injury after APAP overdose. (Supported by NIH grant R01
DK087886.)
631 Acute Biliary Hyperplasia in F344 Rats Administered the
Indole-3-Carbinol Analog, NSC 743380.
M. Davis1,  S. Eldridge1,  K. Elsass2,  T. Horn3 and J. Morris1. 1DCTD, NCI,
Bethesda, MD; 2Battelle, Columbus, OH; 3IITRI, Chicago, IL.
Biliary hyperplasia discovered in preclinical safety assessment represents a severe
finding due to being unmanageable and non-monitorable in the clinical setting.
NSC-743380 (1-[(3-chlorophenyl) methyl]-1H-indole-3-methanol) is in early
stages of development as an anticancer agent at the NCI. In an exploratory toxicity
study in rats, acute hepatotoxicity, characterized by biliary hyperplasia and inflam-
matory hepatic necrosis, was observed 5 days after dosing orally at 100 mg/kg/day.
The hepatotoxicity noted was also apparent from the clinical chemistry results that
showed marked increases in alkaline phosphatase, alanine aminotransferase and as-
partate aminotransferase levels by day 2 dosing relative to controls. In contrast, IV
dosing with NSC-743380 (6.25 – 25 mg/kg/day,) produced no microscopic lesions
or clinical chemistry changes relative to controls either on day 2 or after day 5 of
dosing. Plasma levels of NSC-743380 and its aldehyde and acid metabolites ob-
tained for IV administration were higher than that achieved from oral administra-
tion; however, liver toxicity, as determined by clinical chemistry and histopathol-
ogy, was observed only after administration of the parent compound and not the
aldehyde or acid metabolite. In addition, the toxicity profiles of a structurally simi-
lar inactive molecule and a structurally diverse molecule (with the same efficacy
profile) were compared to NSC-743380 to explore scaffold versus target-mediated
toxicity. Following 2 days of oral dosing at 100 mg/kg/day, the structurally different
compound produced a similar toxicity profile, although less severe, than NSC-
743380. Taken together, the hepatotoxicity associated with NSC-743380 appears
to be related to the parent molecule rather than its major metabolites and related to
target-modulation representing on-target toxicity. Furthermore, this molecule of-
fers a unique opportunity to explore biomarkers for biliary hyperplasia using a
short-duration toxicology study design. N01CM201100019/N01CM201100027
632 Identifying Proregenerative Signaling after Acetaminophen-
Induced Acute Liver Failure in Mice Using Incremental Dose
Model.
B. Bhushan,  C. Walesky,  P. Borude,  G. Edwards and U. Apte. Department of
Pharmacology, Toxicology, and Therapeutics, University of Kansas Medical Center,
Kansas City, KS.
Overdose of acetaminophen (APAP) is the major cause of acute liver failure (ALF)
in the US with very limited treatment options. Recent studies suggest that liver re-
generation is a critical determinant of overall survival following APAP overdose and
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has highlighted the potential of regenerative therapies for ALF. However, the mech-
anisms of liver regeneration following APAP-induced ALF are not completely clear.
In the present study, we studied the major signaling pathways involved in liver re-
generation following APAP-induced ALF using an incremental APAP dose model.
Two-month-old male C57BL/5 mice were treated with either 300 mg/kg
(APAP300) or 600 mg/kg (APAP600) APAP and liver injury and regeneration was
studied over a time course of 0 to 48 hr. Mice treated with APAP300 developed ex-
tensive liver injury followed by significant liver regeneration resulting in resolution
of APAP-induced injury by 48 hr. In contrast, mice treated with APAP600 exhib-
ited significant injury but substantial decrease in liver regeneration. The inhibition
of liver regeneration in APAP600 group was associated with decreased Cyclin D1
mRNA and protein expression, decreased phosphorylation of Rb protein and sus-
tained expression of p21. Further analysis of several signaling pathways revealed dif-
ferences in pro-mitogenic signaling between APAP300 and APAP600. EGFR, c-
Met, and downstream activation of MAPK pathways were highly activated in
APAP600, where regeneration was inhibited. However, canonical Wnt/β-catenin
pathway and NF-κB signaling were activated in APAP300 where liver regeneration
was stimulated and inhibited in APAP600 group where regeneration was decreased.
Finally, a TaqMan-based PCR array of 15 growth factor genes revealed rapid induc-
tion of several growth factors including HGF, VEGF, Kit-L, and PDGFα specifi-
cally in APAP300 group. Taken together, our study has identified Wnt and NF-κB
signaling as potential pathways that regulate liver regeneration after APAP over-
dose.
633 Potential Hepatoprotective Effects of Licorice Root (Radix
glycyrrhizae) Extract against Carbon Tetrachloride-Induced
Hepatotoxicity in Isolated Rat Hepatocytes.
O. S. El-Tawil1,  A. A. Shalaby2 and E. A. Mohamed3. 1Department of Toxicology
and Forensic Medicine, Faculty of Veterinary Medicine, Cairo University, Cairo,
Egypt; 2Department of Biochemistry, Faculty of Veterinary Medicine, Suez Canal
University, Ismailia, Egypt; 3Department of Pharmacology and Toxicology, Faculty of
Pharmacy, Al-Azhar University, Cairo, Egypt. Sponsor: A. Kadry.
Radix glycyrrhizae is one of the native Mediterranean plants. Licorice root is a pop-
ular soft drink in Egypt. Literatures cited therapeutic effects of licorice. The present
work is to evaluate the potential hepatoprotective effects of aqueous licorice root ex-
tract against the cytotoxic effects and the oxidative stress induced by carbon tetra-
chloride (CCl4) in isolated primary rat hepatocytes
Hepatocytes were isolated by collagenase perfusion technique. Cytotoxicity was de-
termined by assessing cell viability and leakage of cytosolic enzymes, such as lactate
dehydrogenase (LDH), alanine aminotransferase (ALT) and aspartate aminotrans-
ferase (AST). Oxidative stress was assessed by determining reduced glutathione
(GSH) level and lipid peroxidation as indicated by thiobarbituric acid reactive sub-
stances (TBARS) production. Exposure of isolated rat hepatocytes to CCl4 (5mM)
caused cytotoxicity and oxidative injury, manifested by loss of cell viability and sig-
nificant increase in LDH, ALT and AST leakages. As well as, CCl4 caused progres-
sive depletion of intracellular GSH content and significant enhancement of
TBARS accumulation. 
Preincubation of hepatocytes with either licorice (25 μM/ml) or silymarin
(0.5mM) which is a known hepatoprotective agent, ameliorated the hepatotoxicity
and oxidative stress induced by CCl4, as indicated by significant improvement in
cell viability, significant decrease in LDH, ALT and AST leakages, significant pre-
vention of GSH depletion and significant decrease in TBARS formation as com-
pared to CCl4 alone-treated cells. The present results indicate that CCl4 has a po-
tential cytotoxic effect in isolated rat hepatocytes; and licorice extract possess a
highly promising hepatoprotective effects against CCl4 - induced hepatotoxicity
634 Lack of Human Health Relevance of Increased
Hepatocellular Adenoma in Male Cd1 Mouse Treated with
Cyproconazole or Propiconazole.
D. Cowie1,  R. Green1,  E. Barnes1,  R. Currie1 and R. Peffer2. 1Syngenta,
Bracknell, United Kingdom; 2Syngenta, Greensboro, NC.
In 18- to 24-month carcinogenicity studies, treatment with cyproconazole (CCZ)
or propiconazole (PPZ) with high levels (100 to 200ppm and 2500ppm, respec-
tively) in the diet resulted in increased incidences of hepatocellular adenoma in
male CD1 mice. The proposed non-genotoxic mode of action (MOA) for induc-
tion of these tumours involves a number of common key events that define a com-
mon toxicity pathway. The first key event is activation of the constitutive an-
drostane receptor (CAR). This stimulates increased DNA replication and
hepatocellular proliferation along with differential expression of genes that result in
a suppression of apoptosis. Following prolonged exposure, this pro-proliferative mi-
lieu along with suppression of apoptosis promotes the growth and progression of
spontaneously transformed cells eventually producing hepatocellular adenoma.
The ability of CCZ and PPZ to elicit these key events in vivo was confirmed by
measuring Cyp2b and Cyp3a induction as a surrogate for CAR activation and
replicative DNA synthesis to assess hepatocellular proliferation. In addition, the re-
quirement for CAR activation for increased hepatocellular proliferation was
demonstrated for CCZ using CAR knock-out mice. Furthermore, reporter gene as-
says demonstrated that PPZ is a direct activator of both mouse (potent) and human
(weak) CAR. Following experimental demonstration of the proposed MOA for
mice, the lack of human relevance was assessed by comparing the effects of PPZ or
CCZ on primary cultures of mouse and human hepatocytes. Consistent with the in
vivo observations, treatment of mouse hepatocytes with CCZ or PPZ resulted in in-
creases in Cyp2b, Cyp3a and replicative DNA synthesis. In contrast, treatment of
human hepatocytes with these compounds resulted in increased Cyp2b and Cyp3a,
but not replicative DNA synthesis. These data demonstrate a qualitative species dif-
ference in response to CAR activation. The lack of proliferative response in human
hepatocytes means it is reasonable to conclude that neither CCZ nor PPZ are he-
patotumourgenic in humans.
635 In Vivo Lead Hepatotoxicity in Mice Is Reversed by a
Molluscan C-Reactive Protein Purified from Achatina fulica
(Bowdich).
S. Mukherjee,  S. Sarkar,  S. Chatterjee and S. Bhattacharya. Zoology, Visva
Bharati University, Santiniketan, India.
Vertebrate liver is affected by several heavy metals among which lead (Pb) occupies
a significant position. Lead induced prooxidant/ anti-oxidant balance contributes
to tissue injury via oxidative damage to critical biomolecules (lipids, proteins, and
DNA). We have earlier reported amelioration of lead induced toxicity by the appli-
cation of C-reactive protein (CRP) isolated from a mollusc Achatina fulica in rat
hepatocytes in vitro (SOT, 51st Annual Meeting,2012), however, the mechanism of
anti-stress property of ACRP has not been clarified. We evaluated in vivo hepato-
protective role of ACRP against Pb(NO3)2 induced toxicity in mice, where CRP is
not an acute phase protein (Du Clos,2003). Adult male albino mice weighing 20±2
g were segregated in 3 groups of 5 animals each. Group I served as control and re-
ceived intraperitoneal (ip) normal saline. Group II received ip 14.8 mg/kg body
weight Pb(NO3)2 (1/10 LD50) for 7 consecutive days. Group III received ip
Pb(NO3)2 once daily for 7 days and from day 5 onwards ACRP (100 μg/mouse)
was co-administered ip with Pb(NO3)2 until day 7. Generation of superoxides in
liver was routinely assessed by TBARS assay (Buege and Aust, 1978) and the level of
endogenous anti-oxidant GSH was determined (Sedlak and Lindsay,1968).
Administration of Pb(NO3)2 significantly depleted liver glutathione and enhanced
lipid peroxidation by 2 fold against control. Interestingly, ACRP co-treatment sig-
nificantly reversed glutathione level and lipid peroxidation towards control while
enhanced expression of Nrf2 and MAPKs (ERK, JNK and p38) indicated expres-
sion of several antioxidant genes. Protective role of ACRP against lead toxicity is
further evidenced by profound induction of HSP70. It is concluded that ACRP re-
duces metal toxicity by triggering the survival pathway and inducing several anti
oxidant genes in lead treated mice.
636 Eosinophils Not Neutrophils Mediate Halothane-Induced
Liver Injury in Mice.
W. R. Proctor,  M. Chakraborty,  J. C. Morrison,  L. S. Chea,  J. D. Berkson,
K. Semple,  M. Bourdi and L. R. Pohl. Molecular and Cellular Toxicology Section,
Laboratory of Molecular Immunology, National Heart, Lung and Blood Institute,
Bethesda, MD.
Liver eosinophilia has often been associated with drug induced liver injury, though
its role in the etiology of this disease remains unclear. We decided to investigate this
problem in a murine model of halothane-induced liver injury, where neutrophils
have been reported to play a pathogenic role. When female Balb/cJ mice were ad-
ministered halothane, eosinophils were detected by flow cytometry in the liver
within 12 hours and increased thereafter proportionally to liver damage. Infiltrating
neutrophils did not increase significantly until 18 hours after halothane administra-
tion. Chemokines CCL11 and CCL24, which are known to attract eosinophils, in-
creased in response to halothane-treatment. Immunohistochemical staining for the
cytotoxic eosinophil granule protein, major basic protein, revealed that eosinophils
accumulated exclusively around areas of hepatocellular necrosis. The severity of
HILI was decreased significantly when the study was repeated in wild-type mice
partially depleted of eosinophils by pretreatment with Siglec-F antibody, while the
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number of hepatic neutrophils remained unchanged. Conversely, selective deple-
tion of neutrophils by pretreatment with low concentrations of Gr-1 antibody
failed to reduce the extent of HILI when levels of eosinophils remained unchanged.
The pathologic role of eosinophils was confirmed when halothane induced hepato-
toxicity was significantly reduced in the eosinophil lineage ablated ΔdblGata-/-
mice, which are neutrophil competent. Our findings indicate that eosinophils, not
neutrophils, have a pathologic role in HILI in mice and suggest that they may con-
tribute similarly in many clinical cases of DILI.
637 Effect of Ligand Activation of PPARβ/δ in Kupffer Cells.
G. Balandaram1,  J. M. Peters1 and F. J. Gonzalez2. 1Veterinary and Biomedical
Sciences, Pennsylvania State University, University Park, PA; 2Laboratory of
Metabolism, NCI, Bethesda, MD.
Peroxisome proliferator-activated receptor β/δ (PPARβ/δ) can inhibit pro-inflam-
matory activities in the liver. Since activated Kupffer cells can modulate hepatic in-
flammation, the role of PPARβ/δ in modulating Kupffer cell activities was exam-
ined. Kupffer cells were isolated from wild-type, Pparβ/δ-null or Pparβ/δ-null mice
expressing a DNA binding mutant form of PPARβ/δ in the Kupffer cells
(PPARβ/δ DBM). Cultured Kupffer cells from the three genotypes phagocytized
latex beads demonstrating relative purity. Ligand activation of PPARβ/δ in Kupffer
cells increased expression of the PPARβ/δ target gene, adipocyte differentiation-re-
lated protein (Adrp) in wild-type but not in Pparβ/δ-null or PPARβ/δ DBM
Kupffer cells. Ligand activation of PPARβ/δ attenuated lipopolysaccharide (LPS)-
induced expression of the pro-inflammatory gene, tumor necrosis factor-alpha
(Tnfα) mRNA in Kupffer cell cultures from wild-type and PPARβ/δ DBM mice
but not from Pparβ/δ-null mice. Wild-type Kupffer cells treated with LPS to in-
duce an M1 phenotype exhibited increased expression of the pro-inflammatory
macrophage markers Tnfα, interleukin-6 (Il-6), interleukin-1β (Il-1β) and
chemokine ligand- 4 (Ccl4) and ligand activation of PPARβ/δ attenuated these re-
sponses. Wild-type Kupffer cells treated with IL- 4 to induce an M2 phenotype ex-
hibited increased expression of the anti-inflammatory markers arginase type-1
(Arg-1), macrophage galactose N-acetyl-galactosamine specific lectin-1 (Mgl-1), c-
type lectin domain family 7, member A (Clec7A) and interleukin-10 (Il-10), but
ligand activation of PPARβ/δ did not influence these responses. Combined, results
from these studies suggest that PPARβ/δ inhibits hepatic inflammation, at least in
part, via transrepression of pro-inflammatory signaling in Kupffer cells. Since this
effect can be found with a DNA binding mutant form of PPARβ/δ, this suggests
that the attenuation of pro-inflammatory signaling could be due to direct protein-
protein interaction of PPARβ/δ with other inflammatory signaling molecules such
as NF-κB.
638 Hepatocyte Tissue Factor Triggers the Procoagulant
Response Associated with Acetaminophen-Induced Liver
Injury and Hepatocyte Transplantation.
J. Luyendyk1,  A. K. Kopec1,  N. Joshi1,  H. Cline1,  S. Bishop1,  K. M. Kassel1,
C. E. Rockwell2,  N. Mackman3 and B. P. Sullivan1. 1Pathobiology and Diagnostic
Investigation, Michigan State University, East Lansing, MI; 2Pharmacology and
Toxicology, Michigan State University, East Lansing, MI; 3Department of Medicine,
University of North Carolina at Chapel Hill, Chapel Hill, NC.
The localization and regulation of tissue factor (TF) activity in hepatocytes (HPCs)
is poorly understood and a role for HPC TF in vivo has not been established. We
characterized the expression of TF by mouse HPCs and evaluated the role of HPC
TF in mouse models of HPC transplantation and acetaminophen (APAP) over-
dose. TF mRNA, protein, and total procoagulant activity (PCA) were significantly
reduced in isolated HPCs and in liver homogenates from TFflox/flox/albumin-Cre
mice (HPCΔTF mice) compared to TFflox/flox mice (control mice). TF protein on
the surface of intact HPCs had PCA that was reduced by cell-impermeable lysine
conjugating reagents, but was unaffected by an inhibitory TF antibody that com-
petes for factor VII binding. Intact mouse HPCs clotted factor VII-deficient
human plasma and TF-dependent factor Xa generation by HPCs occurred without
exogenous factor VIIa. Thrombin generation in a model of HPC transplantation
was dependent on donor HPC TF expression. Thrombin generation was also dra-
matically reduced in APAP-treated HPCΔTF mice compared to APAP-treated con-
trol mice. The results indicate that TF expressed on the surface of mouse HPCs is
preloaded with VII/VIIa, and that HPC TF is essential for coagulation induced by
hepatocellular injury in vivo. Moreover, the expression of TF by HPCs implies that
most hepatotoxic responses are likely accompanied by activation of the extrinsic
pathway of blood coagulation.
639 Hepatoprotective Effects of Fibrin(ogen) in Chronic
Xenobiotic-Induced Cholestatic Liver Injury: Potential
Involvement of Platelets.
N. Joshi2,  K. M. O’Brien2,  B. L. Copple2,  K. J. Williams1 and J. Luyendyk1.
1Pathobiology and Diagnostic Investigation, Michigan State University, East Lansing,
MI; 2Pharmacology & Toxicology, Michigan State University, East Lansing, MI.
Coagulation cascade activation and hepatic fibrin(ogen) deposition are evident in a
model of chronic alpha-naphthylisothiocyanate (ANIT)-induced cholestatic liver
injury. We have shown previously that complete fibrin(ogen) deficiency increases
liver necrosis in mice fed a diet containing ANIT. The mechanism whereby fib-
rin(ogen) deficiency worsens injury in this model is not known, nor is it clear
whether stabilizing hepatic fibrin would be hepatoprotective. One possibility is that
fibrin(ogen)-dependent platelet activation protects the liver from chronic ANIT
diet-induced injury. We tested the hypothesis that stabilizing hepatic fibrin(ogen)
inhibits ANIT-induced chronic cholestatic liver injury by supporting hepatic
platelet accumulation/activation. Mice fed a diet containing 0.025% ANIT for 2
weeks developed liver injury consisting of multifocal acute hepatocellular necrosis
and inflammation, peribiliary fibrosis, lymphocytic inflammation and bile duct ep-
ithelial hyperplasia. Immunofluorescent CD41 (alphaIIB integrin) staining revealed
a marked increase in platelets in livers of mice fed the ANIT diet compared to mice
fed control diet. Administration of the anti-fibrinolytic drug tranexamic acid (1200
mg/kg, ip, bid) significantly reduced liver injury in mice fed the ANIT diet, but did
not affect platelet accumulation. Administration of the platelet inhibitor clopido-
grel significantly increased serum alanine aminotransferase (ALT) levels and liver
necrosis in mice fed the ANIT diet. Moreover, serum ALT activity was increased in
mice deficient in protease activated receptor-4 (PAR-4), a primary thrombin recep-
tor on mouse platelets. The results indicate that stabilization of hepatic fibrin with
antifibrinolytic therapy significantly reduces liver injury in mice fed ANIT diet.
Moreover, the results suggest that platelets are also hepatoprotective in mice fed the
ANIT diet.
640 Effects of Acetaminophen and Oxidative Stress on Primary
Human Hepatocytes Derived from a Steatotic Liver.
M. J. Liguori,  D. J. Cugier,  R. Ciurlionis,  A. C. Ditewig,  J. Lai-Zhang,
G. D. Gagne and E. A. Blomme. Department of Cellular and Molecular Toxicology,
AbbVie, Abbott Park, IL.
Primary human hepatocytes are a favored in vitro system for characterization of
some types of hepatotoxicity. Donor demographics, disease states, and lifestyles re-
sult in significant donor to donor variability and can have a strong influence on the
sensitivity of primary hepatocytes to hepatotoxicants. Here, we describe a unique
primary human hepatocyte system originating from the liver of a female donor
(SMK) with severe metabolic syndrome and pre-conditioned steatosis. The cells
had a lipid-rich phenotype that was clearly visible both using standard light mi-
croscopy and lipid fluorescent stain, which showed a 400% increase in signal inten-
sity compared to a standard lot of hepatocytes. In general, steatotic cells have en-
hanced sensitivity to the presence of reactive oxidative stress (ROS). To test whether
SMK cells were more susceptible to ROS, SMK and cells from a normal donor were
exposed to acetaminophen, a drug with a well characterized ROS-mediated mecha-
nism of toxicity, at a dose range of 0.5 to 20 mM for 72h using standard culture
conditions. SMK hepatocytes were 2.7-fold more susceptible to APAP induced cy-
totoxicity compared to their normal counterparts. The lipid signal was slightly re-
duced upon high levels of APAP. Total RNA was isolated from SMK both from
naïve and APAP treated cells and subjected to whole genome transcriptomic profil-
ing. When compared to a pool of non-diseased hepatocyte donors, naïve SMK cells
showed extensive gene expression changes that were largely associated with bioener-
getic pathways with marked downregulation of lipid processing control and synthe-
sis genes (e.g. SREBP). Agglomerative hierarchical cluster analysis revealed a clear
distinction between SMK and its normal counterparts of the global expression pro-
files induced after treatment with APAP. In summary, this study demonstrates that
hepatocytes with marked steatosis can serve as interesting molecular models for
ROS-mediated hepatotoxic injury.
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641 Meso-Dihydroguaiaretic Acid Inhibits Alcoholic and
Nonalcoholic Fatty Liver by Antagonizing LXRα Activity.
W. Sim1,  S. Park1,  K. Lee1,  Y. Jye1,  H. Yin1, 4,  Y. Choi1,  S. Sung1,  S. Park2,
H. Park2,  K. Shin3 and B. Lee1. 1College of Pharmacy, Seoul National University,
Seoul, Republic of Korea; 2School of Pharmacy, Sungkyunkwan University, Suwon,
Republic of Korea; 3College of Pharmacy, The Catholic University, Bucheon, Republic
of Korea; 4Molecular Pharmacology and Physiology, University of South Florida
Health Sciences Center, Tampa, FL.
Collaborative regulation of liver X receptor (LXR) and sterol regulatory element
binding protein (SREBP)-1 are main determinants in hepatic steatosis. Recent
studies indicate that selective intervention of overly functional LXRα in the liver
shows promise in treatment of fatty liver. In the present study, we evaluated the ef-
fects of meso-dihydroguaiaretic acid (MDGA) on LXRα activation and its ability
to reverse fatty liver in mice. An LXRα co-activator recruitment assay and molecu-
lar docking analysis were performed to evaluate the binding of MDGA to the lig-
and-binding domain (LBD) of LXRα. The ability of MDGA to inhibit LXRα-de-
pendent steatosis was investigated in an ethanol- or high-fat-diet (HFD)-induced
steatosis model. MDGA inhibited activation of the LXRα-LBD by competitively
binding to the pocket for agonist T0901317 and decreased the luciferase activity in
LXRE-tk-Luc-transfected cells. MDGA attenuated the expression of LXRα and he-
patic neutral lipid accumulation in ethanol- and HFD-induced fatty liver. MDGA
reduced the expression of LXRα co-activator protein RIP140 in HFD-fed mice.
While MDGA decreased the expression of LXRα, SREBP-1, SCD-1, and FAS pro-
teins, genes associated with reverse cholesterol transport such as ABCA1 and
ABCG1 were not affected. These results demonstrate that MDGA has the potential
to reverse alcoholic and nonalcoholic steatosis mediated by selective inhibition of
LXRα in the liver.
642 Toxicity of Diethylnitrosamine (DEN) in the Liver of
Constitutive Andorostane Receptor (CAR)-Knockout (KO)
Mice.
K. Inoue1,  M. Takahashi1,  Y. Sakamoto1,  K. Tamura1,  S. Matsuo1,  Y. Kodama2
and M. Yoshida1. 1Division of Pathology, National Institute of Health Sciences, Tokyo,
Japan; 2Division of Toxicology, National Institute of Health Sciences, Tokyo, Japan.
CARKO mice showed high mortality after injection of DEN. To clarify the cause of
high susceptibility in CARKO mice to the toxicity of DEN, 6-week old male
CARKO and C3H mice were intraperitoneally injected 90 mg/kg body weight of
DEN, and their livers were collected at days 1, 3, 7 and 14 after DEN treatment.
Relative weight, pathological changes, mRNA expression and enzyme activity levels
of CYP2B10 and CYP2E1 in the liver of CARKO mice were compared with con-
trols injected saline or with wild mice. DEN significantly reduced relative liver
weights in both genotypes and the decreased liver weights in CARKO mice were
significantly lower than wild mice at days 7 and 14. Microscopically, pale cytoplasm
of the hepatocytes in the centrilobular area was observed by DEN treatment at day
1, and the area of this change was larger in CARKO than in wild mice. DEN treat-
ment also increased slight to mild single necrosis of hepatocytes and mononuclear
cell infiltration in the centrilobular area from day 1 and from day 3, respectively.
The intensities of single necrosis and mononuclear cell infiltration in CARKO mice
were comparable to wild mice. While the expression level of Cyp2b10 in the liver of
wild mice increased by DEN with or without significance, compared with their
controls, the level in CARKO mice remarkably diminished in both control and
DEN groups at all time points. As for testosterone hydroxylase activity (CYP2B10),
there were no difference between controls and DEN groups or both genotypes at
days 1 and 7. DEN treatment significantly decreased Cyp2e1 and aniline hydroxy-
lase activity (CYP2E1) level in both genotypes at day 1, compared with each con-
trol, and the decreased level of aniline hydroxylase activity was significantly lower in
CARKO than in wild mice. Judging from these results, high susceptibility in
CARKO mice to the toxicity of DEN might be caused by immediate decrease of
CYP2E1 activity after DEN treatment.
643 Leptin Modulates Toxicity Associated Steatohepatitis
through Peroxynitrite in Kupffer Cells.
S. Das1,  A. Kumar2,  D. Ganini2,  E. J. Tokar3,  J. Corbett2,  M. Kadiiska2,
M. P. Waalkes3,  A. Diehl4,  R. P. Mason2 and S. Chatterjee1, 2. 1Environmental
Health Sciences, University of South Carolina, Columbia, SC; 2Laboratory of
Toxicology and Pharmacology, NIEHS, Research Triangle Park, NC; 3Inorganic
Toxicology, NIEHS, Research Triangle Park, NC; 4Gastroenterology, Duke University,
Durham, NC.
Progression from steatosis to toxin-mediated steatohepatitic (TASH) lesions is hy-
pothesized to require a second hit. These lesions have been associated with in-
creased oxidative stress, often ascribed to high levels of leptin and other proinflam-
matory mediators. Here we have examined the role of leptin in inducing oxidative
stress and Kupffer cell activation in toxin-mediated steatohepatitic lesions of obese
mice. Male C57BL/6 mice fed with a high fat diet (60%kcal) at 16 weeks were ad-
ministered CCl4 to induce steatohepatitic lesions. Approaches included use of im-
muno-spin trapping for measuring free radical stress, gene-deficient mice for leptin,
p47 phox, iNOS and adoptive transfer of leptin primed macrophages in vivo. Diet-
induced obese (DIO) mice, treated with CCl4 increased serum leptin levels and
leptin receptor expression. Oxidative stress was significantly elevated in DIO mice
liver but not in OB/OB mice, or in DIO mice treated with leptin antibody. In
OB/OB mice, leptin supplementation restored markers of free radical generation.
Markers of free radical formation were significantly decreased by the peroxynitrite
decomposition catalyst FeTPPS, the iNOS inhibitor 1400W, the NADPH oxidase
inhibitor apocynin, or in iNOS or p47 phox-deficient mice. These results corre-
lated with the decreased expression of TNF-alpha and MCP-1and decreased leptin
receptor expression. Kupffer cell depletion eliminated oxidative stress and inflam-
mation, whereas in macrophage-depleted mice, the adoptive transfer of leptin-
primed macrophages significantly restored inflammation. These results, for the first
time, suggest that leptin action in macrophages of steatotic liver through induction
of iNOS and NADPH oxidase caused peroxynitrite-mediated oxidative stress thus
activating Kupffer cells and modulating leptin receptor expression in the
liver.(NIH-4-R00-ES19875)
644 Occupational Vinyl Chloride Exposures Are Associated with
Significant Changes to the Plasma Metabolome: Implications
for Toxicant Associated Steatohepatitis.
B. Wheeler1,  M. Cave1, 2,  K. Falkner1 and C. McClain1, 2. 1Department of
Medicine/GI, University of Louisville, Louisville, KY; 2Louisville VAMC, Louisville,
KY.
Occupational vinyl chloride (VC) exposure has been associated with steatohepatitis
(TASH) and liver cancer, although the modes of action are unknown.
Metabolomics has recently been utilized for the evaluation of drug-induced liver in-
jury, but has not previously been performed for occupational VC exposures. Plasma
samples from 17 highly-exposed VC workers without liver cancer and 27 unex-
posed healthy volunteers were obtained from a specimen bank. GC/MS (Thermo-
Finnigan Trace DSQ fast-scanning single-quadrupole mass spectrometer) and
LC/MS2 (Waters ACQUITY UPLC, Thermo-Finnigan LTQ mass spectrometer)
were performed. Software was used to match ions to a library of standards for
metabolite identification and quantitation by peak area integration. Statistical sig-
nificance was determined using Welch’s t-tests. 613 unique named metabolites were
identified. Of these, 189 metabolites were significantly increased in the VC expo-
sure group while 94 metabolites were significantly decreased. The most striking dif-
ferences occurred in lipid metabolites. Essential (7 of 7) and long chain free fatty
acids (19 of 19, including arachidonic acid, 6 fold) were significantly increased with
VC exposure. Lipid peroxidation products were likewise increased by VC exposure:
monohydroxy fatty acids (8 of 9, including 13-HODE, 211 fold); fatty acid dicar-
boxylates (8 of 13); oxidized arachidonic acid products (7 of 7, including 5-HETE,
9-HETE, and 15-HETE, up to 616 fold). Other arachidonic acid products includ-
ing leukotriene B4 (52 fold) were also up-regulated with VC exposure.
Abnormalities were also noted in amino acid metabolism, and particularly the
transmethylation and transsulfuration pathways. VC exposure was associated with
increased plasma free fatty acids and lipid peroxidation products. Lipotoxicity, pro-
inflammatory lipid peroxidation products, and impaired
transmethylation/transsulfuration pathways represent novel modes of action for
VC hepatotoxicity.
645 Pregnancy-Related Lactogenic Hormones Alter the
Expression of Uptake and Efflux Transporters in Primary
Human Hepatocytes.
J. E. Moscovitz1,  C. J. Gibson1,  H. J. Chung2,  H. Y. Jeong3 and
L. M. Aleksunes1, 4. 1Department of Pharmacology and Toxicology, Rutgers
University, Piscataway, NJ; 2College of Pharmacy, Gyeongsang National University,
Jinju, Republic of Korea; 3Department of Pharmacy Practice, University of Illinois,
Chicago, IL; 4Environmental and Occupational Health Sciences Institute, Rutgers
University, Piscataway, NJ.
The secretion of lactogenic hormones prolactin (PRL) and placental lactogen (PL)
increases steadily throughout pregnancy and reaches the highest levels just prior to
parturition. The effects of lactogenic hormones on the expression of hepatic trans-
porters critical for the excretion of endogenous chemicals, drugs, and toxicants have
not been characterized. To investigate the regulation of transporters by lactogenic
hormones, sandwich-cultured, freshly isolated human hepatocytes from three adult
female donors were treated for 72 hours with vehicle (carbonate-buffered saline),
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human PRL (150 ng/ml) or human PL (6 μg/ml), and total RNA was isolated.
Gene expression was quantified by microarray analysis and validated with quantita-
tive real-time PCR (qPCR). qPCR analysis shows PRL and PL have differential ef-
fects on the gene expression of hepatic transporters. PRL caused the up-regulation
of mRNA for the uptake transporter OAT2 by 60%, and down-regulation of the
efflux transporters MRP3, MRP6, and BCRP between 15 and 20%. PL decreased
mRNA expression for all uptake transporters tested, significantly for NTCP,
OCT1, OATP1B1, and OATP1B3. In addition, PL increased efflux transporter
gene expression for ABCA1 and BSEP by 100%, but reduced MDR1, MRP2,
MRP3, MRP5, MRP6, and BCRP mRNAs. Taken together, these data suggest
hormones secreted during pregnancy may globally suppress the maternal gene ex-
pression of many uptake and efflux transporters crucial for chemical excretion by
the liver. Supported by ES020522, DK080774, ES007148, ES005022,
HD065532.
646 Acrolein Cytotoxicity in Hepatocytes Involves Endoplasmic
Reticulum Stress, Mitochondrial Dysfunction, and Oxidative
Stress.
M. Mohammad1,  D. Avila1,  J. Zhang1,  S. Barve1,  G. Arteel3,  C. McClain1, 2
and S. Joshi-Barve1. 1Department of Medicine/GI, University of Louisville, Louisville,
KY; 2Louisville VAMC, Louisville, KY; 3Pharmacology and Toxicology, University of
Louisville, Louisville, KY.
Acrolein is a common environmental, food and water pollutant and a major com-
ponent of cigarette smoke. Also, it is produced endogenously via lipid peroxidation
and cellular metabolism of certain amino acids and drugs. Acrolein is cytotoxic to
many cell types including hepatocytes; however the mechanisms are not fully un-
derstood. We examined the molecular mechanisms underlying acrolein hepatotoxi-
city in primary human hepatocytes and hepatoma cells. Acrolein, at pathophysio-
logical concentrations, caused a dose-dependent loss of viability of hepatocytes. The
death was apoptotic at moderate and necrotic at high concentrations of acrolein.
Acrolein exposure rapidly and dramatically decreased intracellular glutathione and
overall antioxidant capacity, and activated the stress-signaling MAP-kinases JNK,
p42/44 and p38. Our data demonstrate for the first time in human hepatocytes,
that acrolein triggered endoplasmic reticulum (ER) stress and activated eIF2α,
ATF-3 and -4, and Gadd153/CHOP, resulting in cell death. Notably, the protec-
tive/adaptive component of ER stress was not activated, and acrolein failed to up-
regulate the protective ER-chaperones, GRP78 and GRP94. Additionally, exposure
to acrolein disrupted mitochondrial integrity/function, and led to the release of
pro-apoptotic proteins and ATP depletion. Acrolein-induced cell death was attenu-
ated by N-acetyl cysteine, phenyl-butyric acid, and caspase and JNK inhibitors.
Our data demonstrate that exposure to acrolein induces a variety of stress responses
in hepatocytes, including GSH depletion, oxidative stress, mitochondrial dysfunc-
tion and ER stress (without ER- protective responses) which together contribute to
acrolein toxicity. Our study defines basic mechanisms underlying liver injury
caused by reactive aldehyde pollutants such as acrolein.
647 Interstrain Differences in Progression from Simple Liver
Steatosis to Fibrosis Are Associated with Altered Hepatic Iron
Metabolism in Mice.
S. Shpyleva1,  L. Muskhelishvili2,  M. Pogribna1,  C. Cozart1,  M. Bryant1,
F. A. Beland1 and I. P. Pogribny1. 1Division of Biochemical Toxicology, NCTR, US
FDA, Jefferson, AR; 2Toxicologic Pathology Associates, NCTR, US FDA, Jefferson, AR.
Nonalcoholic fatty liver disease (NAFLD) is a major health problem and a leading
cause of chronic liver disease in the United States and other developed countries.
The pathogenesis of NAFLD is often conceptualized as a two-step process that con-
sists of hepatic triglyceride accumulation leading to steatosis as a first step, followed
by a second step that includes oxidative stress, inflammation, and fibrogenesis.
However, there is a lack of consensus on the significance of these events and the un-
derlying mechanisms responsible for the disease progression and, more importantly,
for differences in inter-individual disease severity and sensitivity. In a previous study
we demonstrated that the inter-strain variability in severity of NAFLD was associ-
ated with dysregulation of lipid metabolism (first step). Emerging evidence indi-
cates the importance of altered iron metabolism in the mechanism of the second
step leading to progression from simple hepatic steatosis to fibrosis. The goal of this
study was to investigate whether or not inter-individual differences in the intracel-
lular iron metabolism are associated with development and severity of fibrosis in-
duced by methyl-donor-deficiency among individual inbred strains of mice.
Feeding male A/J, 129S1/SvImJ, and WSB/EiJ mice a choline- and folate-deficient
(CFD) diet for 12 weeks caused liver injury similar to NAFLD, with the magnitude
being A/J < 129S1/SvImJ < WSB/EiJ. The inter-strain variability in severity of
NAFLD and its further progression to fibrosis, which was characterized by hepatic
stellate cell activation and up-regulation of fibrosis markers, was associated with the
extent of hepatic iron metabolism deregulation. This was evidenced by strain-de-
pendent alterations in the expression of iron-regulatory genes (Tfrc, Fth1, Slc40a1,
and Hfe2), which was correlated tightly with the degree of hepatic fibrotic changes
in the livers of the mice fed the CFD diet.
648 Dose-Dependent Hepatic Physiological, Histopathological,
and Gene Expression Responses in C57BL/6 Mice following
Repeated TCDD Exposure.
T. R. Zacharewski1, 3,  K. A. Fader1, 3,  J. Harkema2, 3 and R. Nault1, 3.
1Biochemistry & Molecular Biology, Michigan State University, East Lansing, MI;
2Pathobiology and Diagnostic Investigations, Michigan State University, East Lansing,
MI; 3Center for Integrative Toxicology, Michigan State University, East Lansing, MI.
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is a potent aryl hydrocarbon recep-
tor (AhR) agonist. We have previously reported that exposure to a single oral dose
of 1 μg/kg TCDD induces hepatic steatosis in mice. A complementary 28 day re-
peated-dose dose-response study was performed to further investigate the effects of
TCDD on steatosis and its progression to steatohepatitis and cirrhosis. C57BL/6
mice were gavaged every 4 days with sesame oil vehicle control or 0.001 - 30 μg/kg
TCDD. Although repeated dosing did not significantly affect body weight gain,
gonadal white adipose tissue (gWAT) weight was 50% lower at 30 μg/kg while rel-
ative liver weight was increased at 3, 10, and 30 μg/kg TCDD. Histolopathology
revealed dose dependent alterations with minimal centriacinar microvesicular lipid
accumulation (hepatic steatosis) at 3 μg/kg, mild to moderate hepatic lipid accu-
mulation with mild inflammation at 10 μg/kg (steatohepatitis), and widespread
micro- and macro-vesicular lipid accumulation in the centriacinar, mid-zonal, and
periportal regions of the liver, inflammation, and perivenular fibrosis suggesting
early cirrhosis at 30 μg/kg. QRTPCR revealed dose-dependent induction of
Cyp1a1, Cyp1a2, Cyp1b1, Dysf, Gstp2, Notch1, Nqo1, Pla2g12a, Serpinb6a, Srxn1,
Tiparp, and Tnfaip2, as well as down-regulation of Got1 and Pck1. Dose-response
modeling (ToxResponse modeler) revealed similar ED50’s to 24h single dose
TCDD studies. These results suggest that simple steatosis can progress to steato-
hepatitis with fibrosis following repeated TCDD exposure, due to persistent AhR-
mediated differential gene expression associated with lipid transport, processing,
and metabolism. Funded by SRP P42ES04911.
649 Impaired Glycosylation and Membrane Localization of
Uptake and Efflux Transporters in Human Nonalcoholic
Fatty Liver Disease.
J. Clarke1,  P. Novak2,  A. D. Lake1,  R. N. Hardwick1 and N. J. Cherrington1.
1Pharmacology and Toxicology, University of Arizona, Tucson, AZ; 2Biology Centre
ASCR, Institute of Plant Molecular Biology, Ceske Budejovice, Czech Republic.
The prevalence of non-alcoholic fatty liver disease (NAFLD) and the more severe
non-alcoholic steatohepatitis (NASH) is estimated to be 30-40% and 5-17%, re-
spectively. We have previously demonstrated a loss of N-linked glycosylation and
decreased membrane localization of the efflux transporter ABCC2 in rodent and
human NASH resulting in the altered disposition of drugs. N-linked glycosylation
of proteins has been shown to be critical for proper protein folding and trafficking
to the plasma membrane. The purpose of this study was to assess the transcriptomic
expression of genes involved in protein glycosylation and processing through the
endoplasmic reticulum (ER), and to determine the effect of altered glycosylation on
key drug transporters during the progression of human NAFLD. For this study,
human liver samples diagnosed as healthy, steatosis, NASH with fat, and NASH
without fat were analyzed. Using bioinformatics methods we discovered that genes
involved in protein processing in the ER and biosynthesis of N-glycans were signif-
icantly enriched for downregulation in NAFLD progression. Included in the N-
glycan biosynthesis category were genes involved in the oligosaccharyltransferase
complex, N-glycan quality control, N-glycan precursor biosynthesis, N-glycan
trimming to the core, and N-glycan extension from the core. In contrast to down-
regulation of these genes, N-glycan degradation genes were unaltered in the pro-
gression to NASH. Immunoblot analysis of the uptake transporters OATP1B1 and
OATP1B3 and the efflux transporters ABCC2 and BCRP demonstrated a signifi-
cant loss of glycosylation, while immunohistochemical analysis revealed impaired
membrane localization of ABCC2. We propose that the loss of glycosylation and
impaired membrane localization of key uptake and efflux transporters in human
NASH is a potential mechanism for the occurrence of altered drug disposition in
NASH.
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650 High Dietary Fructose Induced Copper Deficiency
Contributes to Alcoholic Liver Disease Progression.
M. Song1,  T. Chen3 and C. McClain1, 2, 3. 1Department of Medicine/GI, University
of Louisville, Louisville, KY; 2Louisville VAMC, Louisville, KY; 3Pharmacology and
Toxicology, University of Louisville, Louisville, KY.
Background/Aims: The increased consumption of fructose parallels the increased
prevalence of obesity and the metabolic syndrome in the United States and world-
wide. Noteworthy is that obesity potentiates the severity of alcohol-induced liver
injury. High fructose feeding impairs intestinal copper absorption and leads to cop-
per deficiency in rodents. Moreover, Copper deficiency is associated with the de-
creased antioxidant defenses and mitochondrial dysfunction. In this study, we in-
vestigated whether high fructose diet induced obesity potentiates chronic alcohol
drinking induced liver injury. 
Methods: Six-week-old male C57BL/6J mice were fed either control diet or high
fructose diet (60%, w/w) for 18 weeks. 20% (w/v) ethanol was given ad libitum
after 8-weeks high fructose feeding until the end of the experiment. Copper status,
hepatic injury and steatosis were assessed. 
Results: High fructose diet feeding led to copper deficiency as indicated by de-
creased plasma ceruloplasmin, Cu, Zinc superoxide dismutase (SOD1) and in-
creased copper chaperone for SOD1 (CCS). Liver injury was significantly induced
in mice fed with high fructose diet followed by chronic alcohol drinking as evi-
denced by robust increased plasma ALT, AST, chemokine (mouse KC) and liver his-
tology. Both liver triglyceride and plasma triglyceride were significantly increased
with chronic alcohol drinking, however, neither additive nor synergistic effects was
observed in mice fed with high fructose diet followed by chronic alcohol. 
Conclusion: Our data suggest that high fructose diet-induced obesity may potenti-
ate chronic alcohol drinking induced liver injury. High fructose feeding induced
copper deficiency might be a priming factor to chronic alcohol drinking induced
liver injury. The potential mechanism might relate to the decreased antioxidant de-
fense caused by copper deficiency.
651 Steroid Sulfatase Enhances Hepatic Estrogen Activity and
Protects Mice from Obesity and Type 2 Diabetes.
W. Xie and M. Jiang. University of Pittsburgh, Pittsburgh, PA.
The enzyme steroid sulfatase (STS) is responsible for the formation of biologically
active estrogens by the hydrolysis of estrogen sulfates and regulates estrogen home-
ostasis. In this report, we showed that hepatic over-expression of STS in female STS
transgenic mice elicited metabolic benefits that protected mice from high fat diet
(HFD) induced obesity and type 2 diabetes. STS transgenic mice subjected to
HFD challenge displayed significant decrease in fat mass and body weight, and in-
creased energy expenditure without alterations in food intake compared with their
wild-type counterparts. Moreover, STS transgenic mice had improved glucose tol-
erance. The metabolic benefic was associated with inhibition of hepatic gluco-
neogenic genes and inflammation related genes. Silencing the transgene expression
through tet-off regulatory system abolished the metabolic benefit, indicating that
the protection is caused by transgene itself rather than non-specific effects from
random transgene insertion sites. The hepatic estrogen signaling was enhanced in
STS transgenic mice, whereas elimination of the primary source of estrogens by
ovariectomy abolished the protective metabolic phenotype, suggesting the meta-
bolic action is mediated by increased estrogenic activity in STS transgenic mice
liver. In summary, our results have revealed an important metabolic function of
STS and may establish it as a novel therapeutic target for the prevention and treat-
ment of obesity and type 2 diabetes.
652 Effect of Diallyl Disulfide on the Cytokines Expression in
Cadmium Chloride-Treated Liver Cells.
S. Smith,  C. Odewumi,  V. Badisa,  A. Abdulla and L. M. Latinwo. Biology,
Florida A&M University, Tallahassee, FL. Sponsor: A. Becker.
Cadmium is one of the most hazardous metals in the environment. Studies have
shown that exposure to cadmium causes damage to many organs that may alter bi-
ological activities of the cells and may lead to cancer in mammalian systems. In the
presence of toxicants, cells produce various cytokines in the body to reduce the
toxic effect of the toxicants. Diallyl disulfide (DADS), an organosulfur compound
in the garlic extract has been used in many countries as a preventive compound for
various diseases. DADS can acts as chelator and/or as an antioxidant. This project
was designed to study the preventive effect of DADS on the cytokines expression in
cadmium chloride (CdCl2) treated normal rat liver CRL1439 cells. For the viability
assay, the cells were treated with CdCl2 alone (0, 50 and 150 μM), DADS alone
(150 and 300 μM) or co-treated with 2 h pre-treatment of DADS (150 and 300
μM) prior to CdCl2 (150 μM) for 24 h and the cells viability was measured by the
crystal violet assay. For the cytokine array analysis, the cells were treated with CdCl2
alone (0, and 150 μM), DADS alone (150 μM) or co-treated with 2 h pre-treat-
ment of DADS (150 μM) prior to CdCl2 (150 μM) for 6 h and the cytokines ex-
pression was measured using the Ray Biotech human cytokine array 7 kit. Viability
results revealed that 150 μM of DADS showed the greatest protection against
CdCl2 toxicity. In the cells treated with CdCl2 alone, 22 cytokines were up- regu-
lated and 2 cytokines were down-regulated. However, in the co-treated cells, the
pattern of cytokines expression observed was reversed, indicating the protective ef-
fect of DADS against CdCl2 toxicity. Cytokines that were up-regulated in CdCl2
alone are involved in the alterations of cell cycle control system and cell mediated
immunity. The present study clearly shows the preventive effect of DADS on the
cytokines expression in the CdCl2 treated liver cells and suggests that DADS can be
used as preventative agent for cadmium toxicity.
653 The Effect of Fenugreek Leaf Extract on Gene Expression
Profile of Cadmium Chloride Treated Normal Rat Liver
Cells.
R. L. Lyles,  C. Odewumi,  V. Badisa and L. M. Latinwo. Biology, Florida A&M
University, Tallahassee, FL. Sponsor: A. Becker.
Rationale and Scope of the Study: Cadmium is a toxic and carcinogenic metal pol-
lutant that has been known to cause DNA damage. It targets many human organs,
mainly lungs, liver, and kidneys.  Many chemo-preventive agents have been used
against the toxic effect of many heavy metals. Fenugreek belongs to the family
Leguminosae and well known for its medicinal value. In our study, the effect of
Fenugreek Leaf Extract (FLE) on the viability and total gene expression profile in
cadmium treated rat liver cells was evaluated. Experimental Procedure: The cells
were treated with CdCl2 (0, 25 μM) alone or pretreated with FLE (0.005μg/ml)
for 4 h followed by CdCl2 (25 μM) for 36 h or 48 h at 37°C in a 5% CO2 incu-
bator. The viability was measured by crystal violet dye staining method. The total
gene profiles were determined using RG230 PM whole genome microarray which
was processed by Affymetrix Gene Atlas system. The Partek Express software ana-
lyzes the genes up or down regulated in the treated samples. The Partek pathway
software identifies the pathways affected by the treatment. Results: In CdCl2 alone
treated cells, the viability was reduced to 37.1%, while in the cells pretreated (4 h)
with FLE followed by CdCl2, the viability was increased to 102% respectively, in
comparison to the control cells (100%). In CdCl2 alone treated cells, out of 31,139
genes on the array 61 were up regulated (>2 fold) and 124 were down regulated (≤-
2 fold) respectively in comparison to control cells. In the cells pretreated with FLE
followed by CdCl2, 181 genes were up regulated (>2 fold) and 161 genes were
down regulated (≤-2 fold). The main pathways affected in above treatment groups
were ribosome, TCA cycle and DNA replication. Conclusion: Our results indicate
that pretreatment with FLE for 4 h affects gene expression profile in the cadmium
treated cells. The alteration in the genes expression in the FLE pretreated cells may
be responsible for the protective effect against cadmium toxicity. Therefore, our
study suggests that fenugreek leaves can be used to reduce cadmium toxicity.
654 Evidence for a Functional Keap1-Nrf2 Cell Defence Pathway
in Human Liver.
I. M. Copple1,  C. Rowe1,  R. P. Jones2, 1,  S. W. Fenwick2,  H. Z. Malik2,
C. Goldring1,  N. R. Kitteringham1 and B. Park1. 1MRC Centre for Drug Safety
Science, University of Liverpool, Liverpool, United Kingdom; 2Department of
Hepatobiliary Surgery, Aintree University Hospital NHS Foundation Trust, Liverpool,
United Kingdom. Sponsor: D. Mendrick.
The transcription factor Nrf2 regulates a battery of cell defence processes that pro-
tect against drug-induced liver injury in rodents, yet very little is known regarding
the role of Nrf2 in regulating resistance to drug-induced stress in man. Utilising he-
patocytes isolated from surgically resected healthy liver tissue (n=6), we provide the
first comprehensive delineation of the Nrf2 pathway in human liver. Hepatocytes
were isolated using a standard collagenase perfusion protocol, seeded onto Type I
collagen-coated culture plates and reverse-transfected with 20 nM of an siRNA du-
plex targeted against Nrf2, Keap1 or a scrambled non-targeting control siRNA du-
plex. siRNA depletion of Nrf2 was associated with a decrease in the mRNA and
protein levels of the established Nrf2 target genes GCLC, NQO1 and SRXN1.
Furthermore, following siRNA depletion of Keap1, the cytosolic repressor of Nrf2,
the total cellular abundance of Nrf2 protein was increased, as was the mRNA and
protein levels of GCLC, NQO1 and SRXN1. The potent Nrf2 activator CDDO-
Me induced a robust stabilisation of Nrf2 in human hepatocytes, and this was asso-
ciated with a time and Nrf2 -dependent increase in the mRNA and protein levels of
GCLC, NQO1 and SRXN1. Under the same conditions, CDDO-Me provoked a
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time and Nrf2 -dependent increase in total glutathione levels. Therefore, the
Keap1-Nrf2 pathway regulates the basal and inducible activity of key cell defence
processes in human hepatocytes, and may therefore be a novel marker of chemical
stress and/or a promising therapeutic target in man. Notably, there was marked (up
to 5-fold) inter-individual variation in the basal and inducible level of Nrf2 protein
across hepatocytes isolated from patients. Such inter-individual variation in the ac-
tivity of Nrf2 may have important consequences for susceptibility to disease and
drug-induced toxicity in man.
655 Dibenzofuran and Mitochondrial Function: Interaction with
Adenine Nucleotide Translocator.
C. M. Palmeira1, 2,  F. V. Duarte1, 2,  A. P. Gomes1, 2,  J. S. Teodoro1, 2,
A. T. Varela1, 2,  A. J. Moreno1 and A. P. Rolo2, 3. 1Department of Life Sciences,
University of Coimbra, Coimbra, Portugal; 2Center for Neurosciences and Cell
Biology, University of Coimbra, Coimbra, Portugal; 3Department of Biology,
University of Aveiro, Aveiro, Portugal.
Dioxins and furans are very toxic and exposure to these environmental pollutants,
such as fuel constituents, is linked to several diseases. Dibenzofuran is listed as a
pollutant of concern due to its persistence in the environment, bioaccumulation
and toxicity to humans and the environment.
Mitochondrial function is very important in cellular homeostasis and keeping a
proper energy supply for eukaryotic cells is essential in the fulfillment of the tissues
energy-demand. The main objectives of this work concerned Dibenzofuran effects
on mitochondrial function. We isolated mitochondria from rat liver and incubated
them with Dibenzofuran to analyze the effects of this pollutant at the level of mito-
chondrial function.
The effects of Dibenzofuran exposure include a markedly increase in the lag phase
that follows depolarization induced by ADP, indicating an effect in the phospho-
rylative system. Experiments performed using carboxyatractyloside (CAT) sug-
gested an interaction of Dibenzofuran with the ANT carrier. Dibenzofuran expo-
sure also produces an inhibition of mitochondrial permeability transition and an
increase in calcium retention capacity, which may also be explained by a putative
interaction of Dibenzofuran with ANT.
Clarifying the role of pollutants in some mechanisms of toxicity, such as unbalance
of bioenergetics status and mitochondrial function, may help to explain the pro-
gressive and chronic evolution of diseases derived from exposure to environmental
pollutants.
Duarte FV (SFRH/BD/38372/2007), Teodoro JS (SFRH/BD/38467/2007),
Gomes AP (SFRH/BD/44674/2008) and Varela AT (SFRH/BD/44796/2008) are
recipients of a Fundação para a Ciência e a Tecnologia (Portugal) scholarship.
656 Trovafloxacin-Induced TNF Expression in Raw Cells Is ATR-
Dependent.
K. L. Poulsen1, 2,  P. E. Ganey1, 2 and R. A. Roth1, 2. 1Pharmacology and Toxicology,
Michigan State University, East Lansing, MI; 2Center for Integrative Toxicology,
Michigan State University, East Lansing, MI.
Trovafloxacin (TVX) is a fluoroquinolone antibiotic associated with idiosyncratic
drug-induced liver injury (IDILI) in humans. The mechanism underlying this tox-
icity remains unknown. An animal model of IDILI in mice revealed that TVX syn-
ergizes with a concurrent inflammatory stress from bacterial lipopolysaccharide
(LPS) to result in liver injury. This hepatotoxic interaction depended upon prolon-
gation of the LPS-induced appearance of tumor necrosis factor-alpha (TNF) in the
plasma of animals coexposed to TVX. We established a model in vitro in RAW
264.7 murine macrophages (RAW cells) in which exposure to TVX alone or in
combination with LPS increases both cellular TNF mRNA and TNF protein re-
leased into the culture medium. TVX is a bacterial topoisomerase inhibitor, and in
a cell-free assay it inhibited mammalian topoisomerase II-alpha as well.
Interestingly, TVX also caused a concentration-dependent increase in DNA dou-
ble-strand breaks (DSBs) in RAW cells. Inasmuch as DSBs can activate kinases such
as ataxia telangiectasia mutated (ATM) and Rad3-related (ATR), kinase inhibitors
were tested for their ability to diminish TVX-induced synthesis and release of TNF
from RAW cells. A selective ATM inhibitor (KU55933) had no effect on TNF
mRNA or TNF release from TVX-exposed RAW cells. In contrast, a novel ATR in-
hibitor (NU6027) significantly attenuated the TVX-induced increase in TNF
mRNA. NU6027 also eliminated the interaction between TVX and LPS, signifi-
cantly decreasing TNF release in cells treated with TVX-LPS to the level induced by
LPS alone. These findings suggest that ATR plays an important role in TNF ex-
pression in response to TVX exposure. (Supported by NIH grant R01 DK061315
and T32 ES007255)
657 3, 3’-Diindolylmethane Attenuates Lipopolysachharide/D-
Galactosamine-Induced Fulminant Hepatic Failure by
Inducing Changes in microRNA Expression in the Liver-
Infiltrating Mononuclear Cells.
S. Tomar,  P. Nagarkatti and M. Nagarkatti. Pathology, Microbiology and
Immunology, School of Medicine, University of South Carolina, Columbia, SC.
Lipopolysachharide/D-Galactosamine (LPS/D-GalN) induced acute liver injury is
a widely used animal model of human fulminant hepatic failure. Our studies
demonstrate that pretreatment with 3,3’ Diindolylmethane (DIM), a plant derived
compound and a ligand for Aryl hydrocarbon receptor (AhR) reduces LPS/D-GalN
induced acute liver injury in BALB/c mice. This was demonstrated by decreased
mortality, serum levels of pro-inflammatory cytokines such as TNFα and IL-6,
serum Alanine Transaminase (ALT) enzyme, liver damage by histology, liver infil-
tration of mononuclear cells and the myeloperoxidase (MPO) activity in the liver
tissues of mice treated with DIM prior to induction of liver injury. DIM treatment
also suppressed Caspase 3 activity, nuclear NF-κB translocation and activation of
ERK MAP kinase in the liver tissues. DIM treatment also causes a reduction in ab-
solute numbers of activated macrophages that infiltrate the liver. In vitro studies
showed that DIM causes suppression in the expression of activation markers,
CD69, CD86 and MHCII, and increased apoptosis of B cells after LPS treatment.
Interestingly, AhR antagonist CH223191 was able to cause a reversal of these DIM-
mediated in vitro effects, indicating that the effects of DIM were mediated through
the AhR. miRNA expression microarray revealed that DIM causes a differential
change in the expression of several miRNAs that regulate multiple pathways of im-
mune cell responses including MAP kinases, STAT proteins, TNFα, IL-6 and NF-
κB signaling within the liver infiltrating mononuclear cells. Our results indicate
that DIM suppresses acute liver injury by regulating miRNA expression within the
liver infiltrating mononuclear cells and that DIM could be a potential therapeutic
strategy for acute liver injury.(Supported in part by NIH grants P01AT003961,
R01AT006888, R01ES019313, R01MH094755, P20RR032684 and VA Merit
Award BX001357).
658 Multiple Mechanisms for the Appearance of Acetaminophen-
Protein Adducts in Plasma: Basic Science and Clinical
Implications.
M. R. McGill,  Y. Xie,  M. Bajt,  M. Yang,  C. Williams and H. Jaeschke.
Pharmacology, Toxicology, and Therapeutics, University of Kansas Medical Center,
Kansas City, KS.
Acetaminophen (APAP) overdose is a major cause of acute liver failure. The drug is
metabolized to an intermediate (NAPQI) which binds to proteins. Protein binding
in the liver initiates a cascade of intracellular signaling events leading to necrosis.
Interestingly, APAP-protein adducts can also be detected in plasma. Initially, this
was thought to be due to release of hepatocyte contents during cell death. However,
it has been shown that plasma adducts can appear without injury. Here, we have
confirmed this by showing that plasma adducts increase before ALT at toxic doses,
are detectable after non-toxic doses, and are detectable in APAP-resistant rats. How
this occurs is not yet known. To explore this further, primary mouse hepatocytes
were treated with APAP in medium with or without serum. In serum-free medium
we could measure extracellular proteins within 3 h (Coomassie), demonstrating ac-
tive protein secretion. Adducts were detected in both regular and serum-free
medium at this time point (0.77±0.08 and 0.31±0.01 nmol/mL, respectively), sug-
gesting that secretion is one mechanism by which extracellular adducts appear. The
difference may be due to diffusion of NAPQI and direct serum-protein binding.
Cell adducts were higher in cultures without serum (0.42±0.02 vs. 0.24±0.02
nmol/mg protein), indicating that serum absence did not reduce metabolism. To
test if necrosis can increase serum adducts, we treated mice with doses of APAP that
did not cause injury and induced necrosis with ischemia-reperfusion. A significant
increase in serum APAP-protein was observed. This could have implications for the
clinical use of this parameter in patients with non-APAP liver injury and incidental
APAP ingestion. Conclusions: Multiple mechanisms are involved in appearance of
serum APAP-protein adducts, including secretion and passive release during necro-
sis. Caution should be used in the clinical interpretation of APAP-protein adducts.
659 Insulin-Mimetic Effects of Arsenic: Modulation of FoxO
Signaling to Affect Selenoprotein P Expression.
I. Hamann and L. Klotz. Faculty of Pharmacy and Pharmaceutical Sciences,
University of Alberta, Edmonton, AB, Canada.
Epidemiological studies have indicated a dose-response relationship between the
prevalence of diabetes mellitus and arsenic exposure from drinking water.
Mechanisms by which arsenic may cause this diabetogenic effect are largely un-
known. Recent studies indicate that arsenic may impair insulin-stimulated glucose
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uptake. The phosphoinositide 3’-kinase (PI3K)/Akt signaling pathway plays an im-
portant role in glucose metabolism, in part by regulating the activity of forkhead
box/class O (FoxO) transcription factors. The present study aimed at investigating
the effect of As3+ (arsenite) on FoxO activity in human hepatoma cells, the role of
PI3K/Akt signaling therein and the modulation of the expression of FoxO target
genes, such as that of selenoprotein P (SelP), a hepatokine causing insulin resist-
ance. We analyzed changes in phosphorylation of Akt and FoxO1a/3a in HepG2
human hepatoma cells in response to As3+ by Western blotting and found a con-
centration-dependent increase in phosphorylation of Akt at S473, with arsenite
being effective already at low micromolar concentrations. Arsenite exposure caused
phosphorylation of FoxO1a and FoxO3a at sites known to be phosphorylated by
Akt, T32 and T24, respectively. Phosphorylation of FoxOs was prevented by wort-
mannin, pointing to the involvement of PI3K. The functional inactivation of
FoxOs by As3+ was observed in an ELISA-based DNA binding assay and at the level
of FoxO target gene expression: SelP and glucose-6-phosphatase mRNA levels were
clearly downregulated after 24h exposure to nanomolar As3+ concentrations, as
demonstrated by real-time RT-PCR. Curiously, As3+ showed a biphasic effect on
SelP protein levels, inducing a small increase in the nanomolar and a distinct de-
crease in the micromolar concentration range. In conclusion, As3+ may perturb cel-
lular signaling pathways involved in fuel metabolism: it stimulates insulin-like sig-
naling in HepG2 cells and affects the expression of FoxO target genes and the
release of the hepatokine SelP, which is known to modulate insulin sensitivity.
660 The Role of Multidrug Resistance Protein 4 (Mrp4, Abcc4)
in Protecting against Acetaminophen (APAP)-Induced
Hepatotoxicity.
A. M. Bataille and J. E. Manautou. Pharmaceutical Sciences, University of
Connecticut, Storrs, CT.
Mrp4 is a member of the ABC family of membrane transport proteins that func-
tions as an efflux transporter for a wide variety of substrates. Previous studies in our
laboratory have shown that Mrp4 is the most significantly induced hepatic trans-
porter by toxic acetaminophen (APAP) treatment. The basal expression of Mrp4 in
normal human and naïve C57BL/6J mouse liver is very low. However, Mrp4 ex-
pression is greatly induced by exposure to hepatotoxicants that cause oxidative
stress, suggesting that this transporter is up-regulated to assist in defending against
cellular stress. Additional studies in our laboratory demonstrated that a low hepato-
toxic dose of APAP protects against subsequent administration of a higher dose of
APAP. This phenomenon is referred to as APAP autoprotection and liver Mrp4 in-
duction is even more pronounced in this mouse model. Despite these findings, the
precise role that enhanced Mrp4 expression plays in protecting against APAP hepa-
totoxicity remains unclear. To study this, we analyzed the responsiveness of Mrp4
heterozygous mice (Mrp4+/-) to APAP hepatotoxicity and the ability of these mice
to exhibit resistance to APAP upon toxicant re-exposure. The results showed that
APAP hepatotoxicity in Mrp4+/- mice is significantly higher than in wild-type
mice. However, the ability of these mice to develop tolerance to APAP liver injury
is unchanged. Analysis of potential differences in gene expression of other hepatic
membrane transporters, oxidative stress-related genes and drug detoxification en-
zymes revealed that there are no significant changes that could account for the dif-
ferential susceptibility of Mrp4+/- mice to APAP toxicity. Based on these results, we
conclude that Mrp4 plays a critical role in preventing APAP-induced hepatotoxic-
ity but that its role in APAP autoprotection may be less substantial.
661 Dual Role of Macrophages in Injury and Repair in
Acetaminophen-Induced Hepatotoxicity.
C. R. Gardner1,  H. M. Choi1,  J. D. Laskin2 and D. L. Laskin1. 1Rutgers
University, Piscataway, NJ; 2UMDNJ-RWJ Medical School, Piscataway, NJ.
Activated macrophages and the mediators that they release play a key role in aceta-
minophen (APAP)-induced hepatotoxicity; however, their role is dependent on
their phenotype and timing of appearance in the liver. Whereas classically activated
M1 macrophages contribute to tissue injury, alternatively activated M2
macrophages are involved in tissue repair. To assess the role of these macrophage
subpopulations in APAP hepatotoxicity, we used gadolinium chloride (GdCl3) and
clodronate liposomes (CL), which block M1 and M2 macrophages, respectively.
Male Long Evans hooded rats were treated with GdCl3 (7 mg/kg, iv) or CL (0.4
ml/100 g body weight), 24 and 48 h prior to APAP (600 mg/kg, ip). Cells were iso-
lated 24 h later. Treatment of rats with APAP resulted in a decrease in CD163+ res-
ident repair macrophages in the liver after 24 h, with no significant effect on infil-
trating CD11b/CD68+ M2 repair macrophages. Pretreatment of rats with GdCl3,
which protects against APAP hepatotoxicity, resulted in a decrease in macrophage
expression of inducible nitric oxide synthase, a prototypical marker of classical acti-
vation. This was associated with an increase in CD163+ resident and
CD11b+/CD68+ infiltrating repair macrophages in the liver. Conversely, CL pre-
treatment, which exacerbates APAP hepatotoxicity, markedly decreased both of
these repair macrophage populations. Expression of markers of alternative M2
macrophage activation including STK, macrophage stimulating protein, and
arginase-1, as well as the anti-inflammatory cytokine IL-10 were also reduced in CL
treated rats. Taken together these data support the concept that macrophages play
distinct role in APAP hepatotoxicity depending on their functional capacity.
Supported by NIH GM034310, ES004738, CA132624, AR055073 and
ES005022.
662 Induction of Hepatic Bcrp Transporter Expression in Mice
Treated with Perfluorooctanoic Acid.
M. Little1, 2,  L. Eldasher2,  X. Wen2,  K. M. Bircsak2,  L. L. Yacovino2 and
L. M. Aleksunes2, 3. 1Department of Chemistry and Biochemistry, Montclair
University, Montclair, NJ; 2Department of Pharmacology and Toxicology, Rutgers
University, Piscataway, NJ; 3Toxicology Division, Environmental and Occupational
Health Sciences Institute, Rutgers University, Piscataway, NJ.
Perfluorooctanoic acid (PFOA) is an industrial chemical that has been associated
with negative health outcomes. The purpose of this study was to determine whether
PFOA alters the expression of the breast cancer resistance protein (BCRP/ABCG2),
an efflux transporter found in hepatocytes and renal proximal tubule cells, in mice
and to determine whether PFOA interferes with BCRP transport in vitro. To test
this, Bcrp mRNA and protein expression were measured in the kidneys and livers of
male C57BL/6 mice treated with PFOA (1 or 3 mg/kg/d po) for 7 days. In addi-
tion, ATPase and membrane vesicle experiments were used to assess whether PFOA
alters human BCRP activity. As expected, PFOA treatment increased liver weights
as well as the mRNA and protein expression of the known target, cytochrome P450
4a14, in the liver and kidneys of mice. Compared to vehicle-treated control mice,
PFOA treatment increased hepatic, but not kidney, Bcrp mRNA and protein be-
tween 2- and 3-fold. Immunofluorescent staining revealed enhanced canalicular
Bcrp staining in liver sections from PFOA-treated mice. In the ATPase assay, PFOA
decreased transporter activity in sulfasalazine-activated BCRP membranes. In addi-
tion, PFOA inhibited BCRP-mediated transport in membrane vesicles between 47
and 69% at high concentrations (>25 μM). In conclusion, PFOA induces hepatic
Bcrp expression in mice and may inhibit human BCRP function at high concentra-
tions. Supported by DK080774, ES020522, ES020721, ES005022 and ASPET
SURF.
663 Xenosensors Mediated Regulation of ATP Binding Cassette
Transporter B6 (ABCB6).
H. D. Chavan and P. Krishnamurthy. Pharmacolgy, Toxicology & Therapeutics,
Kansas University Medical Center, Kansas City, KS.
Cytochromes P450 (P450s) are induced in response to therapeutic drugs and envi-
ronmental contaminants, leading to increased detoxification and elimination of the
xenobiotics. Xenosensors like PXR, CAR and AhR play a major role in drug and
environmental contaminant induced expression of P450s. Each P450 is composed
of an apoprotein moiety and a heme prosthetic group, which is required for P450
activity. Thus, under conditions of P450 induction, there is a coordinate increase in
heme biosynthesis to compensate for the increased expression of P450s. ABCB6, a
mitochondrial ABC transporter, is shown to regulate heme biosynthesis by modu-
lating coproporphyrinogen transport from the cytoplasm into the mitochondria.
However, it is not known if exposure to xenobiotics induces ABCB6 expression, to
assure an adequate and apparently coordinated supply of heme for the functional
P450. In the present study, we evaluated the role of xenosensors PXR, CAR and
AhR in the regulation of Abcb6. Our results demonstrate that AhR and CAR but
not PXR regulate ABCB6 expression. AhR mediated regulation of Abcb6 expres-
sion was observed both in mice and in human cell lines, while CAR mediated reg-
ulation of Abcb6 expression was seen only in mice and not in human cell lines.
Further, promoter activation studies demonstrate that both AhR and CAR induce
Abcb6 expression by interacting with their respective response elements in the 5’
flanking region of the Abcb6. These studies are the first to describe direct transcrip-
tional activation of both mouse and human ABCB6 by xenobiotics similar to those
found in inducible P450s. The results presented in this work have both pharmaco-
logical and toxicological significance. AhR ligands have the ability to precipitate
porphyria and both AhR and CAR ligands have been shown to promote cell growth
and proliferation. We have previously shown that ABCB6 expression promotes cell
growth and proliferation during carcinogenesis. Thus, ABCB6 induction by
xenosensors AhR and CAR could be a potential contributing factor in drug in-
duced porphyria and carcinogenesis.
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664 Hepatic Flavin-Containing Monooxygenase-3 (FMO3)
Protein Is Inducible by Acetaminophen Treatment.
S. Rudraiah and J. E. Manautou. University of Connecticut, Storrs, CT.
Flavin-containing monooxygenase 3 (FMO3) is a drug-metabolizing enzyme with
functions similar to CYP450. Hepatic expression of human FMO3 gene is highly
variable and is important in the detoxification of xenobiotics. Fmo3 was thought to
be non-inducible but recent data showed that activation of the Ah receptor induces
Fmo3 mRNA in mice. Recent microarray work by our group also showed a drastic
induction of liver Fmo3 mRNA expression in a mouse model of resistance to acet-
aminophen (APAP) hepatotoxicity (autoprotection). In addition to APAP, alpha-
naphthyl isothiocyanate treatment and bile duct ligation in mice markedly increase
Fmo3 gene expression. The purpose of this study was to evaluate the Fmo3 gene
regulation and protein expression during APAP hepatotoxicity. Among all Fmo iso-
forms analyzed for mRNA expression, Fmo3 was most significantly induced fol-
lowing a single dose of APAP (400mg/kg). Although Fmo3 mRNA levels increased
significantly by APAP, its protein expression was marginally changed. Consistent
with this, the catalytic activity of Fmo3 measured by oxygenation of methimazole
did not change significantly either. By contrast, both Fmo3 mRNA and protein ex-
pression are significantly higher in mice pretreated and re-exposed to APAP (auto-
protection model). In agreement with greater Fmo3 protein expression in livers of
autoprotected mice, its catalytic activity was also significantly higher. In summary,
the dramatic changes in Fmo3 gene expression produced by a single dose APAP are
not accompanied by concomitant changes in protein and enzyme function, whereas
livers from mice pretreated and re-exposed to APAP exhibit induction of both
Fmo3 protein expression and catalytic function. Additional work is currently un-
derway to determine the functional significance of enhanced Fmo3 protein func-
tion and which factors and signaling pathways mediate Fmo3 gene and protein ex-
pression during APAP toxicity. Taken together, these findings establish for the first
time induction of not only Fmo3 gene expression, but also significant protein lev-
els and function. Supported by NIH DK069557.
665 Vanin-1 Knockout Mice Exhibit Alterations in
Compensatory Immune Infiltration and Hepatocyte
Proliferation following Acetaminophen Toxicity.
D. Ferreira1,  F. Galland2,  P. Naquet2 and J. E. Manautou1. 1Department of
Pharmaceutical Sciences, University of Connecticut, Storrs, CT; 2Centre
d’Immunologie de Marseille-Luminy CNRS-INSERM, Université de la Méditerranée,
Marseille, France.
Previously we have shown that Vanin-1 (Vnn1) knockout mice are more susceptible
to APAP hepatotoxicity (400mg/kg, i.p.) despite no differences in hepatic glu-
tathione (GSH) content or gene expression of APAP metabolizing enzymes or
transporters. Here we show that in vitro, livers from both genotypes showed similar
capacities to bioactivate APAP to its reactive metabolite (~1.8 nmol APAP-
NAC/min/mg protein) and to detoxify the parent compound by glucuronidation
(~1.7 nmol APAP-Gluc/min/mg protein) and sulfation (~15.6 pmol APAP-
Sulf/min/mg protein). Together, these data strongly suggest that the enhanced sus-
ceptibility of Vnn1 knockout mice to APAP toxicity is not due to differences in
APAP metabolism. Immunohistochemistry of formalin-fixed liver sections follow-
ing APAP treatment revealed a lack of PCNA positive hepatocytes and F4/80 posi-
tive macrophages in and around areas of centrilobular necrosis in Vnn1 knockouts
at 48 hours after APAP. qRT-PCR from total RNA isolated from whole livers indi-
cated that inducible nitric oxide synthase (iNos) and interleukin-4 were reduced by
2.9 and 4.3 fold, respectively, in control treated Vnn1 knockout mice relative to
wild-types. Additionally, interferon γ was 2.7 fold lower in Vnn1 knockout mice at
48 hours after APAP treatment in comparison to wild-types. Myeloperoxidase and
iNos exhibited a trend of decreased expression in Vnn1 knockouts at 48 hours, but
these differences were not statistically significant. Together, these results indicate
that a lack of Vnn1 expression may alter the normal compensatory repair and im-
mune responses following toxic APAP exposure although it is unknown to what ex-
tent these mechanisms contribute to the enhanced susceptibility of Vnn1 knockout
mice to APAP hepatotoxicity.
666 Transcription Regulation by Novel Interaction of Kruppel-
Like Factor 6 with Aryl Hydrocarbon Receptor at the NC-
XRE.
A. D. Joshi,  D. P. Jackson,  S. R. Wilson and C. Elferink. Pharmacology and
Toxicology, University of Texas Medical Branch, Galveston, TX.
The Aryl Hydrocarbon Receptor (AhR) is a ubiquitous, ligand mediated basic
helix-loop-helix transcription factor of Per/ARNT/Sim family that regulates adap-
tive and toxic responses to variety of chemical pollutants such as polycyclic aro-
matic hydrocarbons (PAH) and halogenated aromatic hydrocarbons, most notably
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Upon ligand activation, the AhR
translocates into the nucleus and binds to DNA at the XRE along with aryl recep-
tor nuclear translocator (ARNT) and facilitates transcription of cytochrome P450
family members. In addition, AhR-regulated gene expression is known to regulate
G1 phase cell cycle progression. Recent DNA microarray experiments by our group
showed that plasminogen activator inhibitor 1 (PAI-1) is a TCDD responsive gene
lacking the XRE. Subsequent characterization identified a novel non-consensus
XRE (NC-XRE) located within the PAI-1 promoter that supports direct binding of
AhR independent of ARNT. While the XRE and NC-XRE are distinct entities, the
NC-XRE shares marked homology with the DNA binding sequence of the
Kruppel-like Factor (KLF) family of transcription factors. The KLF superfamily of
proteins are related to Sp1 and characterized by three zinc finger domains in their
C-termini that confer binding to a GC-box linked to diverse target genes. Our re-
sults indicate that AhR interacts directly with KLF6 at the NC-XRE in a dioxin-de-
pendent manner. Furthermore, sequential deletion studies demonstrate the impor-
tance of the AhR C-terminal and KLF6 N-terminal domains in this interaction.
Since KLF6 is a liver specific tumor suppressor that has been shown to induce tran-
scription of the G1 cyclin-dependent kinase inhibitor p21Cip1, the potential exists
for overlapping or common roles involving both proteins in cell cycle regulation.
Our further studies will focus on mapping the AhR complex at NC-XRE and un-
derstanding the role of this complex in transcription regulation. This work was sup-
ported by R01ES007800 and P30ES006676.
667 Mild Endoplasmic Reticulum Stress Preconditioning
Attenuates Methylmercury-Induced Cellular Damage by
Inducing Favorable Stress Responses.
F. Usuki1,  M. Fujimura2 and A. Yamashita3. 1Clinical Medicine, National Institute
for Minamata Disease, Minamata, Japan; 2Basic Medical Sciences, National Institute
for Minamata Disease, Minamata, Japan; 3Molecular Biology, Yokohama City
University School of Medicine, Yokohama, Japan. Sponsor: A. Naganuma.
Methylmercury (MeHg) toxicity is a continuous environmental problem to human
health. Failure to protect cells against MeHg-induced early oxidative stress triggers
subsequent endoplasmic reticulum (ER) stress and apoptosis. Here, we demon-
strate the protective effects of mild ER stress preconditioning against MeHg toxic-
ity on a MeHg-susceptible cell line. Cells preconditioned with low concentrations
(0.1-0.3 μg/ml) of an inhibitor of ER Ca2+-ATPase, thapsigargin (TPG), showed
resistance to MeHg cytotoxicity through several favorable stress responses, which
included phosphorylation of eukaryotic initiation factor 2 alpha (Eif2α), accumu-
lation of activating transcription factor 4 (Atf4), and upregulation of stress-related
proteins (glucose regulated protein of 78 kDa (Grp78) and metallothionein 1
(Mt1)). Atf4 accumulation was mediated by translation inhibition of its upstream
open reading frame (uORF) and translation facilitation of its protein-coding ORF
by the phospho-Eif2α. Nonsense-mediated mRNA decay (NMD) activity was sup-
pressed by the combined effects of decreased expression of several NMD compo-
nents besides the phospho-Eif2α-mediated general suppression of translation initi-
ation, resulting in accumulated Atf4 mRNA but not protein. Integrated stress
responses led to a delay of MeHg-induced oxidative stress and the activation of ex-
tracellular signal-regulated kinase pathways to promote cell survival in precondi-
tioned cells exposed to MeHg. Finally knockdown experiments demonstrated that
Grp78 plays a crucial role in protecting preconditioned cells against MeHg cyto-
toxicity. These results suggested that mild ER stress preconditioning is a useful ther-
apeutic intervention against MeHg toxicity, the underlying mechanism being the
induction of integrated stress responses.
668 Differences in Regulation of Gene Expression Profiles of the
Bone Marrow between C57BL/6 and C3H/He Mice after
Benzene Treatment.
Y. Hirabayashi1,  B. Yoon2,  K. Igarashi1,  J. Kanno1 and T. Inoue3, 4. 1Cell &
Molecular Toxicology Division, Biology Safety & Research Center, National Institute
of Health Sciences, Tokyo, Japan; 2Histology & Molecular Pathogenesis Laboratory,
School of Veterinary Medicine, Kangwon National University, Chuncheon, Republic of
Korea; 3Function & Structural Medicine Department, Nihon University School of
Medicine, Tokyo, Japan; 4National Institute of Health Sciences, Tokyo, Japan.
We focused on the differences in the regulation in gene expression profiles of the
bone marrow, which predict benzene-specific early responses related to plausible
leukemogenic changes, between C57BL/6 (B6), a lymphoid-neoplastic-prone
mouse strain, and C3H/He (C3H), a myelogenous-leukemia-prone mouse strain.
Previously, we showed a latent potential of induction of myelogenous leukemias by
benzene in both strains, but with different mechanistic propensities. Consequently,
reciprocal differences between B6 and C3H mice in gene expression profiles related
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to leukemogenesis were found by gene chip analyses 28 days after benzene treat-
ment. Because leukemia did not develop in all mice even under the optimal condi-
tion, we further analyzed the data, focusing on not only strain differences but also
individual differences. Two types of gene expression profile were recognized: one,
corresponding to common gene profiles obtained by one-way analysis of variance
or Welch’s t-test, which were commonly shared by all mice in the same group each;
and the other, corresponding to stochastic gene-expression profiles obtained by
principal component analysis, which were unique genes in each individual mouse.
The results clearly elucidated that the predicted gene expression profiles in the reg-
ulation of transcription factors (TFs) for proliferation were essentially different in
each strain. The selected TFs, i.e., 20 for B6 and 11 for C3H, were less overlapped
among each mouse in the same strain, and their regulation showed the coexistence
of both suppression and activation signals in B6, whereas suppressive signals were
generally predominant in C3H. These differences in regulatory gene-expression
profiles may be essentially related to the strain differences in the incidence and spec-
trum of the leukemogenesis after benzene treatment.
669 Biphasic Influence of Arsenic, Cadmium, Mercury, and
Nickel on Aryl Hydrocarbon Receptor (AhR) Signaling.
A. Rannug1,  A. Mohammadi-Bardbori1,  L. Vikström Bergander1 and
U. Rannug2. 1Institute of Environmental Medicine, Karolinska Institutet, Stockholm,
Sweden; 2Department of Genetics, Microbiology and Toxicology, Stockholm University,
Stockholm, Sweden.
Interaction of oxidants with the metabolic turnover of the endogenous AHR ligand
6-formylindolo[3,2-b]carbazole (FICZ) seems to play critical roles in downstream
AHR-mediated signaling. Production of superoxide leading to increased prolifera-
tion was observed after exposure of immortalized human keratinocytes (HaCaT) to
low levels of As3+, Cd2+, Hg2+ and Ni2+. Higher concentrations lowered the in-
tracellular GSH levels and led to temporal inhibition of FICZ-stimulated cy-
tochrome P4501A1 (CYP1A1) activity and increased adaptive antioxidant re-
sponses as measured by expression of antioxidant genes. After addition of FICZ
(150 pM) together with the metals a temporal inhibition of the metabolic degrada-
tion of FICZ occurred, as determined by HPLC analyses. At these inhibitory con-
centrations, the metals themselves activated CYP1A1 at late time points.
Transcriptional activation of CYP1A1 was estimated with a luciferase reporter assay
in human hepatoma HepG2-XRE-Luc cells and the ability of the metals to activate
the AHR only in the presence of the natural ligand FICZ was established by com-
paring AHR activation in commercial DMEM medium and in DMEM medium
free from background levels of FICZ. NADPH oxidase (NOX) activity was critical
for the stimulation of proliferation by the metals as determined by lack of prolifer-
ative responses in human X-CGD myeloid cells carrying a mutated gp91phox gene.
In addition, influence of NOX on CYP1A1 gene expression was indicated by lower
metal-stimulated luciferase activity in HepG2 cells treated with the NOX inhibitor
diphenyliodonium. Pretreatment with the metals led 24 h later to elevated GSH
levels and increased sensitivity of the AHR to low levels of FICZ (superinduction).
We propose that the AHR/CYP1-dependent auto-regulatory feed-back mecha-
nism, which ensures low steady-state levels of FICZ, works in close concert with the
NADPH oxidase system.
670 Differential Gene Expression Responses by Hepatic Lobe in
Fischer Rats Treated with Carcinogens Phenobarbital and
Diethylnitrosamine.
B. Li1,  M. W. Trimble2,  D. Henderson1,  S. Stepaniants1,  M. L. Parrish1,
B. Kevin2,  A. Sharma2,  G. A. Boorman3 and S. Williams2. 1Covance Genomics
Laboratories, Inc., Seattle, WA; 2Covance Laboratories, Inc., Madison, WI; 3Covance
Laboratories, Inc., Chantilly, VA.
Rodent liver is a primary organ for assessing compound toxicity. Non-genotoxic
carcinogens such as phenobarbital (PB) and genotoxic carcinogens such as diethyl-
nitrosamine (DEN) induce morphological and physiological changes in the liver
that may vary by lobe. For example, DEN induces more tumors in the right liver
lobe than in the left and median lobes. To elucidate the molecular mechanisms un-
derlying the differential compound responses, as well as the differences among the
three liver lobes, groups of male Fischer rats were treated with 0 or 7.5 mg/kg/day
of DEN, or 0 or 65 mg/kg/day of PB, by daily oral gavage for two and four weeks.
Samples of the right lateral (RL), right median (RM), and left lateral (LL) hepatic
lobes were obtained for gene expression analysis and pathological assessment. DEN
induced slight apoptosis/necrosis of individual hepatocytes in all lobes, while ad-
ministration of PB was associated with centrilobular hypertrophy that was much
less prominent in the left lateral lobe compared with the other lobes. Gene expres-
sion profiles were assessed for three animals/group/interval using whole genome
microarrays. The data showed that PB and DEN both induced robust, yet quite
distinct, transcriptional changes in the animals, which could partially explain the
differential morphological/physiological outcomes. In both groups of vehicle-
treated rats, the transcriptional profile of the LL lobe was much different from
those of the RL and RM lobes, whereas the latter two were quite similar to each
other. In animals given DEN or PB, such lobe difference was much reduced,
slightly more so in the rats given DEN than in those given PB. Overall, the gene ex-
pression profile may provide clues to the mechanism of PB- and DEN-induced
liver tumors, and possible molecular biomarkers for predicting liver toxicity.
671 In Vitro Effects of Aldehydes Present in Tobacco Smoke on
Gene Expression in Human Lung Alveolar Epithelial Cells.
N. Cheah1, 2, 4,  J. Pennings2,  J. Vermeulen2,  F. J. van Schooten1 and
A. Opperhuizen1, 3. 1Toxicology, Maastricht University, Maastricht, Netherlands;
2Laboratory for Health Protection Research, National Institute for Public Health and
the Environment, Bilthoven, Netherlands; 3Risk Assessment, Netherlands Food and
Consumer Product Safety Authority, Utrecht, Netherlands; 4Cigarette Testing
Laboratory, Health Sciences Authority, Singapore, Singapore. Sponsor: H. van
Loveren.
Tobacco smoke consists of thousands of harmful components. A major class of
chemicals found in tobacco smoke is formed by aldehydes, in particular formalde-
hyde, acetaldehyde and acrolein. The present study investigates the gene expression
changes in human lung alveolar epithelial cells upon exposure to formaldehyde,
acrolein and acetaldehyde at sub-cytotoxic levels. We exposed A549 cells in vitro to
aldehydes and non-aldehyde chemicals (nicotine, hydroquinone and 2,5-dimethyl-
furan) present in tobacco smoke and used microarrays to obtain a global view of the
transcriptomic responses. We compared responses of aldehydes with that of the
non-aldehydes. Formaldehyde gave the strongest response; a total of 66 genes was
greater than 1.5-fold differentially expressed mostly involved in apoptosis and
DNA damage related processes, followed by acetaldehyde (57 genes), hydro-
quinone (55 genes) and nicotine (8 genes). Acrolein and mixture gave effects to ox-
idative stress genes, no gene expression effect found on the exposure to 2,5-di-
methylfuran. Overall, aldehyde responses are primarily indicative for genotoxicity
and oxidative stress. These two toxicity mechanisms are linked to respiratory dis-
eases such as cancer and COPD, respectively. The present findings could be impor-
tant in providing further understanding of the role of aldehydes emitted from ciga-
rette smoke in the onset of pulmonary diseases.
672 Regulation of the Metabolic Switch between Ductal
Carcinoma In Situ (DCIS) and Invasive Breast Cancer (IBC).
K. C. Scribner1,  Y. Fan2,  M. Ragavan3,  R. Chapkin2,  C. Hilty3,  H. Payne4,
R. Mouneimne4,  F. Behbod5 and W. Porter1. 1Integrative Biosciences, Texas A&M
University, College Station, TX; 2Integrative Nutrition and Complex Diseases, Texas
A&M University, College Station, TX; 3Chemistry, Texas A&M University, College
Station, TX; 4Image Analysis Laboratory, Texas A&M University, College Station, TX;
5Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas
City, KS.
Ductal carcinoma in situ (DCIS) accounts for 15-25% of breast cancers. However,
there is a gap in our understanding of the factors that regulate the progression of
DCIS to invasive breast cancer (IBC). Deregulation of cell metabolism is a defining
feature of tumor cells, which utilize glycolysis instead of oxidative phosphorylation.
Since altered metabolism promotes invasion and metastasis, the mechanisms regu-
lating this switch could be critical in mediating the transition from DCIS to IBC.
Singleminded-2s (Sim2s) is present in early stage DCIS lesions and lost in IBC.
Re-establishment of SIM2s in the MCF10DCIS.com model inhibits tumor
growth, invasion, and metastasis. We hypothesize that SIM2s plays a key role in
mediating the switch between DCIS and IBC.
To determine the effect of SIM2s on metabolism in DCIS progression, we ana-
lyzed SIM2s over and under-expressing MCF10DCIS.com cells for energy depend-
ent differences in growth, autophagy, and metabolism. Live cell imaging and TEM
were used to determine SIM2s’ effect on mitochondria and autophagy. Nuclear
Magnetic Resonance and Seahorse analysis was employed to compare differences in
metabolic signatures and measure oxidative phosphorylation and glycolytic capac-
ity. 
Re-establishment of SIM2s induced oxidative phosphorylation and adaptation to
metabolic stress through increased oxygen consumption, whereas loss of SIM2s
promoted glycolysis by elevating glucose uptake and lactate production. 
These results suggest that SIM2s plays a critical role in DCIS progression and loss
of SIM2s is required for the switch from oxidative phosphorylation to glycolysis.
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673 Hypoxia Perturbs PCB-Induced Aryl Hydrocarbon Receptor
Signaling and CYP1A1 Induction in Human Cells.
S. U. Vorrink and F. E. Domann. Human Toxicology, The University of Iowa, Iowa
City, IA.
The aryl hydrocarbon receptor (AhR) pathway controls cellular responses to expo-
sure of foreign substances by activating genes that aid in xenobiotic metabolism.
The ligand-activated AhR forms a heterodimer with its binding partner aryl hydro-
carbon receptor nuclear translocator (ARNT) and subsequently induces the tran-
scription of genes such as CYP1A1, a member of the cytochrome P450 family and
a phase I detoxifying enzyme. Notably, ARNT proteins also dimerize with hypoxia-
inducible factors (HIFα) which mediate the cellular response to low oxygen (hy-
poxia). During hypoxia, HIFα:ARNT heterodimers form and activate the tran-
scription of genes that promote cell survival in low oxygen environments. Since
HIFα and AhR share a common subunit, ARNT, the possibility for signaling
crosstalk exists at this axis. We hypothesized that hypoxic conditions cause HIFα to
sequester ARNT and thus inhibit the activation of a robust AhR transcriptional re-
sponse in response to a polychlorinated biphenyl (PCB) AhR ligand. To test this
hypothesis we queried several human cell lines for their responses to PCBs. Our re-
sults indicate that CYP1A1 mRNA expression was induced by 3,3’,4,4’,5-pen-
tachlorobiphenyl (PCB 126) in an AhR-specific manner. Exposure of the cells to
hypoxia (1% oxygen for 8 hours) significantly inhibited the induction of CYP1A1
mRNA by up to 74%. EMSA and CYP1A1 promoter:luciferase reporter assays to
measure DNA binding and transcriptional activities of AhR complexes further
showed an inhibitory effect of hypoxia treatment on PCB-induced AhR signaling.
Growth curve and MTT assays demonstrated significant growth inhibition follow-
ing PCB 126 treatment. Taken together, these findings indicate that hypoxia signif-
icantly interferes with AhR-mediated responses to PCBs. Our future studies will in-
vestigate whether the observed effects also occur at the protein level and whether
hypoxia can prevent the growth inhibitory effect of PCB treatment. (Supported by
grant NIEHS P42 ES 013661.)
674 Characterizing Chronic Nicotine Exposure-Induced
Behaviors and Gene Regulations in Caenorhabditis elegans.
J. R. Polli,  F. A. Taki,  M. A. Smith and X. Pan. Biology, East Carolina University,
Greenville, NC. Sponsor: J. DeWitt.
Nicotine is one of the most abused substances. Nicotine binds nicotinic acetyl-
choline receptors (nAChRs), stimulates the mesolimbic dopamine system, and
leads to addiction. With chronic exposures to low concentrations of nicotine are a
common scenario, this study aims to characterize chronic nicotine exposure-in-
duced behaviors and explore affected gene pathways in the model organism,
Caenorhabditis elegans (C. elegans). C. elegans were treated with control, 6.17μM,
and 61.7 μM of nicotine for 24-hour and locomotion behaviors were characterized
using a worm tracking system. Our preliminary data has determined several addic-
tive behavioral patterns following chronic low range micromolar nicotine expo-
sures, including stimulation, withdrawal, and tolerance. Locomotive behaviors
were stimulated in control worms that were exposed to nicotine. Withdrawal be-
haviors were observed as increased locomotion speeds when nicotine dosages were
disrupted in nicotine-dependent worms. We also detected the expressions of 39
functional genes implicated in cholinergic signaling, locomotion, egg-laying, and
stress-response. Findings showed that gene expressions are most active in low but
not in high concentration dosages. The expression profiles of all the tested protein-
coding genes were affected with a range from 12.5 fold down-regulation (old-1) to
138.1 fold up regulation (hlh-14). Nicotine exposure also affected the expression of
microRNAs, an extensive class of a small regulatory RNAs.
675 TNIP1 Regulates the Cell Stress Response through
Repression of Heat Shock Proteins A6 and A1A.
V. P. Ramirez1,  M. Stamatis2,  A. Shmukler2,  C. Zhang3 and B. J. Aneskievich3.
1Pharmacology & Toxicology Program, University of Connecticut, Storrs, CT;
2PharmD Program, University of Connecticut, Storrs, CT; 3Department of
Pharmaceutical Sciences, University of Connecticut, Storrs, CT.
TNIP1 protein represses gene expression otherwise activated by NF-κB, RAR, and
PPAR. Additionally, TNIP1 expression is increased in several cutaneous inflamma-
tory diseases and wound healing. Thus, while some transcription factor targets and
pathologies have been recognized, the spectrum of genes possibly affected by
TNIP1 is unknown. To identify additional gene expression changes due to in-
creased TNIP1 levels, we conducted a microarray analysis from keratinocytes tran-
siently overexpressing TNIP1.
In addition to repression of genes known to be activated by NF-κB, RAR, and
PPAR, a surprising result of decreased HSP gene family expression was observed
(ex. 20x and 3.2x for HSPA6 and A1A, resp.). This reduction was confirmed by
qPCR and western blot. Both HSPA6 and A1A have similar functions in cell pro-
tection where knockdown of either HSP reduced cell viability post-cell stress. Since
HSPA6 basal and induced expression was decreased by TNIP1, it was chosen for
further studies.
To guide analysis of how HSPA6 may be regulated by TNIP1, we isolated and per-
formed in silico analyses on the HSPA6 3-kb promoter. Putative PPAR, RAR and
NF-κB sites were found. PPARα and RAR ligands had no effect, but PPAR β/δ
and γ ligands increased HSPA6 expression ~4x. To search for TNIP1-responsive re-
gion(s), we cloned 5’-HSPA6 promoter deletions into a reporter construct.
Intriguingly, the most repressed region lacks PPREs, RAREs, and NF-κB sites.
These results suggest that although PPAR can regulate HSPA6 and TNIP1 may be
repressing HSPA6 through this transcription factor, there is an additional TNIP1-
sensitive region independent of its previously identified PPAR, RAR and NF-κB
targets. Moreover, our data suggests TNIP1-mediated HSPA6 repression is inde-
pendent of PPAR, RAR or NF-κB, suggesting there may be additional, as yet un-
recognized, targets where interaction with TNIP1 results in reduced transcriptional
activity.
676 Erk1/2 Pathway Inhibition Attenuates BoNT/A-Induced
Neurite Outgrowth in Motor Neurons.
L. Liu and J. A. Coffield. University of Georgia, Athens, GA.
Botulinum neurotoxin A (BoNT/A) is known to be neurotoxic due to its paralytic
effect at cholinergic synapses with extremely high potency. Independent of that,
BoNT/A has been found to stimulate neurite outgrowth of motor neurons both in
vivo and in vitro, which may account at least in part for the initiation of recovery
from botulism. The signaling pathways regulating the BoNT/A-induced neurite
outgrowth process have not been identified. In the current study, we used pharma-
cologic kinase inhibition to investigate the more relevant outgrowth pathways. GFP
positive motor neurons were directly differentiated from HBG3 mouse embryonic
stem cells, and treated with a MEK1/2 inhibitor in the presence of 1nM BoNT/A.
Following 6 and 24h post BoNT/A exposures, single motor neurons were image-
captured. The total neurite length and number of branches of primary and second-
ary neurites were measured and counted. Significant differences were determined
using one-way or two-way ANOVA with post hoc tests. Preliminary results showed
that 10 μM of the MEK1/2 inhibitor specifically blocked BoNT/A’s stimulatory ef-
fect on secondary branching at 6h compared to toxin only treated controls, sug-
gesting an early, transient role in BoNT/A-induced signal transduction. In addi-
tion, there was no effect of MEK1/2 inhibition on the toxin’s enzymatic action to
cleave SNAP-25. Collectively, these data suggest that ERK1/2 pathway may play an
important role in the early phases of BoNT/A-induced neuritogenesis.
677 Inhibition of TGFbeta-Induced Integrin- Growth Receptor
Cooperative Signaling by Cucurbitacin B, Causes Breast
Cancer Growth Suppression.
P. Gupta and S. K. Srivastava. TTUHSC, Amarillo, TX.
Integrins have recently been shown to play an important role in promotion of cell
motility and survival in various cancers through cooperative signaling with EGFRs.
Integrins transmit cell survival signals through ILK-Paxillin complex and further
play role in activating AKT signaling. Curcubitacin B (CuB) is a steroidal class of
chemical present in the plants belonging to cucurbitaceae family. CuB has shown
cytotoxic potential in several cancers by causing G2/M cell cycle arrest and inhibi-
tion of JAK/STAT3 pathway. However, the exact mechanism of CuB and its role in
metastasis and cell survival is not known. Our results show that CuB significantly
suppressed the growth of MDA-MB-231, SKBR3, MCF-7, MDA-MB-231
(HER2) and MCF-7 (HER2), five different breast cancer cells in a concentration
and time-dependent manner. CuB also induced apoptosis and down-regulated
ILK1 expression. In addition, CuB down-regulated ITGB4 and ITGA6 protein ex-
pression and suppressed the phosphorylation of AKT at Ser473, paxillin at Tyr118.
Previous studies have shown that TGFβ mediates physical association of ITGB4
and HER2, through Src kinase to enhance cell survival and motility. Interestingly
we observed significant downregulation of Src, EGFR and HER2 in different breast
cancer cells, suggesting that CuB suppresses cooperative signaling of Integrins and
HER2. We also observed that TGFβ pretreatment imparted protection from CuB’s
cytotoxic effects, indicating that CuB modulates TGFβ mediated Integrin signal-
ing. Taken together our results indicate the anti-cancer effects of CuB in breast can-
cer cells by targeting ITGB4/ITGA6, Src, ILK and TGFβ. Further detailed mecha-
nistic work is in progress. [Supported in part by R01 grants CA106953 and
CA129038 (to S.K.S) awarded by the National Cancer Institute].
Key: ITGB4 – Integrin β4, ITGA6 – Integrin α6, TGFβ – Transforming growth
factor β, ILK- Integrin linked kinase, EGFR – Epidermal growth factor receptor,
CuB – Cucurbitacin B
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678 High Content Live-Cell Imaging of Nrf2 and NF-κB
Signaling Reporters As Predictive Tools to Classify Drug-
Induced Liver Injury Responses.
B. Herpers,  L. Fredriksson,  Z. Di,  H. de Bont and B. van de Water. Toxicology,
Leiden University, Leiden, Netherlands.
Drug-induced liver injury (DILI) is an important clinical problem and predicting
human DILI for novel candidate drugs is difficult. Current models indicate that in
many cases DILI is linked to reactive metabolite formation and involves activation
of innate immune systems. Here we systematically evaluated the combined applica-
tion of high content live cell imaging-based analysis of 1) NRF2 activation as a
measure for reactive metabolite stress, 2) perturbations of the normal NF-κB acti-
vation mediated by TNFα; and 3) synergistic induction of apoptosis by DILI com-
pounds and TNFα. Fifteen drugs associated with DILI were evaluated. Most DILI
compounds induced NRF2 stabilization-dependent activation of the downstream
target SRXN1 (11 out of 15). Various DILI compounds affected the TNFα-in-
duced activation of NF-κB (6 out of 15), which strongly correlated to the strength
of NRF2 activation. In particular for those compounds that show strong NRF2 ac-
tivation and perturbation of NF-κB signaling, a significant drug-cytokine synergy
for apoptosis was observed, which included carbamazepine, diclofenac, ketocona-
zole, clozapine, nefazodone and amiodarone. Together, our data support that mech-
anism-based high content imaging strategies involving combined analyses of cellu-
lar stress responses contribute to DILI hazard identification.
679 Translation Initiation Factor EIF4A1 Determines TNFα-
Mediated Apoptosis in Drug-Induced Liver Injury through
the Stress Protein Chop.
L. Fredriksson,  B. Herpers,  S. Wink,  J. Meerman and B. van de Water.
Toxicology, Leiden University, Leiden, Netherlands.
Drug-induced liver injury (DILI) is an important clinical problem and to minimize
it a more detailed knowledge about the mechanism is essential. Here we used a
functional genomics approach to establish the critical drug-induced toxicity path-
ways that act in synergy with the pro-inflammatory cytokine tumor necrosis factor
α (TNFα) to cause apoptosis of liver HepG2 cells. Transcriptomics-based analysis
of the toxicity response pathways activated by hepatotoxicants diclofenac (DCF)
and carbamazepine (CBZ) revealed significant activation of the nuclear factor-ery-
throid 2 (NF-E2)-related factor 2 (Nrf2) oxidative stress response, and endoplasmic
reticulum (ER) stress/translational initiation signaling. Importantly, significant ac-
tivation of these pathways after drug exposure could be confirmed by transcrip-
tomics of primary hepatocyte cultures as well as in vivo. Systematic siRNA-medi-
ated knockdown of the individual toxicity pathway determinants established the
critical roles of these pathways for the drug/TNFα-induced apoptosis in the
HepG2 cell system. Pre-induction of the cytoprotective Nrf2 pathway by knock-
down of its negative regulator Kelch-like ECH-associated protein 1 (Keap1) sup-
pressed the drug/TNFα synergy. Furthermore, ER stress signaling by selective pro-
tein kinase R-like ER kinase (PERK) activation and subsequent expression of
C/EBP-homologous protein (CHOP) was crucial in the onset of drug/TNFα-in-
duced apoptosis independent of drug-induced oxidative stress. Interestingly, CBZ
and DCF caused an enhanced expression of the translational initiation factor
EIF4A1. Importantly, depletion of EIF4A1 almost completely inhibited CHOP ex-
pression in association with protection against the drug/TNFα-mediated cell
killing. We propose a model in which enhanced drug-induced translation initiates
PERK-mediated CHOP signaling thereby sensitizing towards caspase-8-dependent
TNFα-induced apoptosis.
680 The Effect of Thermal Stress on Drosophila melanogaster
Gene Expression.
K. Silkaitis1, 2,  A. Branco1 and B. Lemos1. 1Molecular and Integrative Physiological
Sciences, Department of Environmental Health, Harvard School of Public Health,
Boston, MA; 2Temple University, Philadelphia, PA. Sponsor: V. Vaidya.
Genetic tools can be used to dissect the biological pathways mediating stress re-
sponse. Studying Drosophila melanogaster responses to environmental stress is in-
formative because prior studies have shown that resistance to one type of environ-
mental stress often confers resistance to additional stresses. In particular,
temperature stress can alter thermal homeostasis, which can affect the biological
dosage of an environmental toxicant. In D. melanogaster, thermal stress has been
shown to affect males differently than females, demonstrated not only by male
sterility but also in autosomal and X-linked gene expression. Gene expression is fur-
ther controlled by the geographic origin of the Y chromosome. We investigated the
effect of cold stress on two genotypes of D. melanogaster that contained a Y chro-
mosome from a natural population in either Massachusetts (Ymass) or Democratic
Republic of the Congo (Ycongo), temperate and tropical climates, respectively.
Newly emerged male flies were collected and reared at 25oC or 16oC. The flies were
then flash frozen, total RNA was extracted and hybridized to a microarray, and dif-
ferential expression (DE) of genes was assessed with Bioconductor/Limma. We
identified more than 1,000 DE genes (p<0.001) in common between the compar-
isons of Ymass 16oC to 25oC and Ycongo 16oC to 25oC. Gene expression in the
testes was most affected by temperature among the 27 tissues examined, while
genes relating to calcium binding, metabolism, and cell proliferation showed high
levels of DE. In tandem, we examined the effects of parental growth temperature
on gene expression in male F1 progeny. We found that maternal exposure to cold
stress differentially affected the expression of genes in progeny involved in cell
death, metabolism, and responses to sodium. Together, these results suggest that re-
sponses to environmental stressors, including toxicants, may depend on both tem-
perature and Y chromosome genotype.
681 Dual Mechanisms for Controlling Chk1 Protein Levels.
F. Zhang,  S. S. Lau and T. J. Monks. Department of Pharmacology and Toxicology,
College of Pharmacy, University of Arizona Health Sciences Center, Tucson, AZ.
2,3,5-tris(glutathion-S-yl)hydroquinone (TGHQ), a metabolite of benzene, cat-
alyzes the generation of reactive oxygen species (ROS), and caspase-dependent
apoptosis in HL-60 cells. We now report that TGHQ induced severe DNA dam-
age, as evidenced by DNA ladder formation and histone H2AX phosphorylation,
and the subsequent engagement of checkpoint response pathways. Thus, TGHQ
induced the activation of both ATR and ATM, which initiate the mammalian
DNA damage response via the phosphorylation of the effecter proteins Chk1 and
Chk2. Perturbation of Chk1 signaling abrogates the TGHQ-induced S-phase ar-
rest, indicating an important role for Chk1 in the S-phase checkpoint following
TGHQ-induced DNA damage. Moreover, Cdc25A, which is required for the
intra-S phase checkpoint, was degraded in HL-60 cells treated with TGHQ.
TGHQ also substantially decreased Chk1 levels, primarily by decreasing the Chk1
gene transcription. Consistent with these findings, MG-132, a proteosome in-
hibitor, failed to restore Chk1 protein levels. Interestingly, MG-132 itself (> 0.1
μM) decreased Chk1 expression, whilst simultaneously inducing Ser-345 Chk1
phosphorylation. RT-PCR data revealed that MG-132 down-regulates Chk1 gene
expression. Finally, following S-phase cell synchronization with aphidicolin,
TGHQ strikingly attenuated the S-phase arrest, which may drive HL-60 cells into
premature mitosis in the presence of un-repaired DNA damage. In summary,
TGHQ-induced DNA damage triggers the ATM/ATR-Chk1/Chk2-Cdc25 path-
way and induces Chk1-dependent S-phase arrest in the p53-deficient HL-60 cells.
The results are consistent with the view that targeting of Chk1 is an effective
chemotherapeutic strategy. However, the data also reveal that in addition to the es-
tablished mechanism of Chk1 protein degradation engaged by the majority of anti-
cancer agents, a novel mechanism to modulate Chk1 protein expression can be en-
gaged at the transcriptional level.
682 Atrazine-Elicited Differential Gene Expression in BLTK1
Leydig Cells.
A. L. Forgacs1, 2 and T. R. Zacharewski1, 2. 1Biochemistry & Molecular Biology,
Michigan State University, East Lansing, MI; 2Center for Integrative Toxicology,
Michigan State University, East Lansing, MI.
Atrazine (ATR) is a widely used triazine herbicide associated with impaired repro-
ductive development and function. We have previously demonstrated that ATR af-
fects basal and recombinant human chorionic gonadotropin (rhCG)-induced
steroidogenic activity in BLTK1 murine Leydig cells as early as 2 hrs. ATR elicited
dose-dependent induction of Star, Hsd3b6 and Hsd17b3 mRNA levels while re-
pressing Hsd3b1, Cyp17a1 and Srd5a1 expression at 24 hrs. The current study
evaluates the temporal gene expression effects (1-48 hrs) of 300 μM ATR on
Agilent 4 X 44K oligonucleotide microarrays using a dye-swap independent refer-
ence design. ATR differentially regulated the expression of 797 unique genes (|fold
change > 1.5, P1(t) > 0.999), with 389 up-regulated and 416 down-regulated at a
minimum of one time point. Most changes were observed at later time points (12-
48 hrs) suggesting early ATR induction of testosterone (T) levels in media are inde-
pendent of gene expression. However, sustained T levels coincide with the induc-
tion of Star mRNA. Database for Annotation, Visualization and Integrated
Discovery (DAVID) and Ingenuity Pathway Analysis (IPA) identified over-repre-
sented gene functions associated with reproductive system development and func-
tion, tissue morphology, and regulation of hormone metabolism, consistent with
ATR effects on BLTK1 cell morphology and steroidogenesis. The IPA transcription
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factor tool predicted the activation of SREBF1 and SREBF2 comprising the induc-
tion of cholesterol uptake (Ldlr), cholesterol biosynthesis (Hmgcr, Hmgcs1, Lss,
Sqle, Cyp51) and cholesterol transporter (Star) gene expression. Additionally, the
predicted activation of CREB1, CREB2, CEBPA and CEBPB suggest increased
cAMP-mediated gene expression such as the induction of Vegfa, Gadd45a, and
Bcat1 involved in cell morphology and growth. Collectively, these results suggest
the later effects of ATR on BLTK1 murine Leydig cell steroidogenesis are mediated
by SREBF- and CREB-mediated changes in gene expression.
683 Hepatic Gene Expression Analysis of 2-Aminoanthracene-
Exposed Fisher-344 Rats Reveal Patterns Indicative of Liver
Carcinoma and Type 2 Diabetes.
W. E. Gato1,  B. D. Hales2 and J. C. Means3. 1Chemistry, Augustana College, Rock
Island, IL; 2Physiology, Southern Illinois University Carbondale, Carbondale, IL;
3Environmental Science & Management, University of California Santa Barbara,
Santa Barbara, CA.
The goal of the present study was to examine hepatic differential gene expression
patterns in Fisher-344 rats in response to dietary 2-aminoanthracene (2AA) inges-
tion for 14 and 28 days. Twenty four post-weaning 3-4 week old F-344 male rats
were exposed to 0 mgkg-1-diet (control), 50 mgkg-1-diet (low dose), 75 mgkg-1-
diet (medium dose) and 100 mgkg-1-diet (high dose) 2AA for 14 and 28 days. This
was followed by analysis of the liver for global gene expression changes. In both
time points, the numbers of genes affected seem to correlate with the dose of 2AA.
Sixteen mRNAs were differentially expressed in all treatment groups for the short-
term exposure group. Similarly, 51 genes were commonly expressed in all 28-day
exposure group. Almost all the genes seem to have higher expression relative to the
controls. In contrast, cytochrome P450 family 4, subfamily a, polypeptide 8
(Cyp4a8), and monocyte to macrophage differentiation-associated (Mmd2) were
down-regulated relative to controls. Differentially expressed mRNAs were further
analyzed for associations via DAVID. GO categories show the effect of 2AA to be
linked with genes responsible for carbohydrate utilization and transport, lipid
metabolic processes, stress responses such as inflammation and apoptosis processes,
immune system response, DNA damage response, cancer processes and circadian
rhythm. The data from the current study identified altered hepatic gene expression
profiles that may be associated with carcinoma, autoimmune response, and/or type
2 diabetes. Possible biomarkers due to 2AA toxicity in the liver for future study in-
clude Abcb1a, Nhej1, Adam8, Cdkn1a, Mgmt, and Nrcam
684 Utilizing RNA Sequencing and the DNA-Damage Response
to Model Chemical Toxicity: How PKC-Activating Tumor
Promoters Create a Path of Their Own.
K. P. Glover1,  L. K. Markell1,  E. Donner1,  Z. Chen2 and X. Han1. 1DuPont
Haskell, Newark, DE; 2DuPont Information & Computing Technologies, Wilmington,
DE.
The DNA damage response (DDR) is an essential cellular pathway for maintaining
genomic integrity and preventing neoplastic transformation. Although tumor pro-
moting compounds do not directly cause fixed mutations, they have been previ-
ously shown to alter many different cellular processes that also impact normal
DDR signaling. Therefore, the purpose of this study was to profile PKC activating
tumor promoting chemicals by their respective alterations to normal DDR signal-
ing induced by short-wavelength ultraviolet light (UVC). Human lymphoblastoid
TK6 cells were exposed to 1 nM 12-O-tetradecanoyl-phorbol-13-acetate (TPA) for
72 hours which caused a reduction in cell growth and changes in cellular morphol-
ogy. Following UVC exposure (10 J/m2), TPA treated cells displayed a synergistic
increase in apoptosis and a significant delay in γH2AX clearance. Other PKC acti-
vating tumor promoters including other phorbol esters, mezerein, sapintoxin D, (-
)-indolactam V, and resiniferonol 9,13,14-ortho-phenylacetate caused similar
changes in cell morphology and a synergistic increase in apoptosis following UVC
exposure. RNA sequencing was used to capture the global transcriptomic profile 8
hours after UVC-induced DNA damage following TPA pretreatment. Principle
component analysis of UVC treated cells revealed a relationship between gene ex-
pression patterns and the concentration of TPA (0.2, 0.5 and 1 nM). These find-
ings indicate a deviation from the normal DDR response. TPA pretreatment at 1
nM caused greater than 300 of the UVC-regulated genes to be downregulated and
greater than 80 UVC-regulated genes to be upregulated compared to the normal
UVC expression profile. These results show that the tumor promoter TPA has a
unique gene expression profile following DNA damage that can be potentially used
to profile this class of chemical.
685 Reactive Nitrogen Species Regulate Autophagy through
ATM-AMPK-TSC2-Mediated Suppression of mTORC1.
D. N. Tripathi1,  R. Chowdhury2,  L. J. Trudel2,  G. N. Wogan2 and
C. L. Walker1. 1Center for Translational Cancer Research, IBT, Texas A&M HSC,
Houston, TX; 2Department of Biological Engineering, Massachusetts Institute of
Technology, Cambridge, MA.
Reactive intermediates such as reactive oxygen species (ROS) and reactive nitrogen
species (RNS) play essential roles in the cell as signaling molecules, but in excess,
constitute a major source of cellular damage in both physiological (i.e. mitochondr-
ial respiration) and pathophysiological (i.e. inflammation) settings. Recently, ROS
were shown to induce autophagy via a novel ATM signaling pathway in the cyto-
plasm. Activation of cytoplasmic ATM by ROS engages LKB1 and AMPK kinases
to activate the TSC2 tumor suppressor, which represses mTORC1 (a negative reg-
ulator of autophagy) to induce autophagy. However, whether RNS engage this or
similar signaling pathway(s) to regulate mTORC1 and induce autophagy is unclear.
We found under conditions of steady-state nitric oxide (NO) exposure, rapid acti-
vation of ATM and downstream signaling by this stress kinase to LKB1-AMPK and
the TSC2 tumor suppressor. As a result, mTORC1 was repressed as evidenced by
decreased phosphorylation of the direct mTORC1 targets S6K, 4EBP1, and ULK-
1, the target for mTORC1 repression of autophagy. Induction of autophagy con-
cordant with decreased ULK-1 phosphorylation by mTORC1 at S757 and in-
creased phosphorylation at S317 by AMPK was demonstrated by increased ratio of
LC3-II/LC3-I, formation of GFP-LC3 puncta, increase in acidic vesicles and de-
creased p62 levels, indicative of increased autophagic flux. While autophagy has
been shown to have pro-death and pro-survival functions, induction of autophagy
by NO caused loss of cell viability, suggesting it functions primarily as a cytotoxic
response to excess nitrosative stress. These data indicate that nitrosative stress, like
oxidative stress, regulates autophagy. As cancer cells are particularly sensitive to ni-
trosative stress, these data open new therapeutic avenues capitalizing on the ability
of NO and RNS to induce autophagic cell death.
686 CYP2S1 Expression Influences Cytotoxicity of the
Anticancer Prodrug, AQ4N, in Human Bronchial Epithelial
Cells.
N. M. Singh and A. M. Rowland. Chemistry and Biochemistry, NMSU, Las Cruces,
NM.
Cytochrome P450 2S1 (CYP2S1) is one of the most upregulated P450s identified
in human cancers and correlates with poor prognosis. The underlying cause of ele-
vated CYP2S1 expression and the consequence of elevated expression is not known.
The only recognized substrate for CYP2S1 is AQ4N (Banaxantrone). AQ4N is a
bioreductive prodrug under clinical investigations for hypoxic tumors. AQ4N is
metabolically reduced in hypoxic environments to the topoisomerase II inhibitor,
AQ4. CYP2S1 is recognized as one of the most efficient enzymes to catalyze this re-
duction. The objective of this study was to determine: i) whether human CYP2S1,
like the mouse CYP2s1, is elevated in response to hypoxia and ii) whether changes
in CYP2S1 expression influence CYP2S1-mediated metabolism of AQ4N. To de-
termine whether CYP2S1 was induced in response to hypoxia we evaluated mRNA
expression in the presence of 1% oxygen as well as the hypoxia mimetics cobalt
chloride and o-phenanthroline. CYP2S1 mRNA was significantly increased by ap-
proximately 8-, 3-, and 50-fold in response to 1% oxygen, cobalt chloride, and o-
phenanthroline. These results suggest that human CYP2S1 mRNA is elevated in re-
sponse to hypoxia. To determine whether changes in CYP2S1 expression influence
AQ4N metabolism we examined the effects of AQ4N and AQ4 on cell viability in
bronchial epithelial cells (BEAS-2B) cells differentially expressing CYP2S1.
Cytotoxicity was estimated using alamar blue reduction in cells expressing high
(CYP2S1-flag), medium (control plasmids: pcDNA3.1 and scrambled shRNA),
and low CYP2S1 expression (CYP2S1 shRNA). Preliminary results demonstrate
that elevated CYP2S1 expression does enhance cytotoxicity under hypoxic condi-
tions (0.2%-1% O2). Interestingly, our results also suggest a protective role for
CYP2S1 in normoxic conditions (21% O2). These data suggest that elevated
CYP2S1 expression may have a dual role in protecting normal cells while promot-
ing AQ4N-mediated cytotoxicity in hypoxic cells.
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687 Transcriptome Analysis Reveals Novel Pathway Regulation in
Response to Differential Expression of CYP2S1 in Human
Lung Cells.
T. W. Madanayake1,  A. M. Rowland1,  N. Devitt2 and I. Lindquist2. 1Chemistry
and Biochemistry, NMSU, Las Cruces, NM; 2National Center for Genomics Research,
Santa Fe, NM.
Cytochrome P450 2S1 (CYP2S1) is considered an orphan P450s with an unknown
biological function. Data from our laboratory and others suggests that CYP2S1
may have an important physiological role in modulating the synthesis and metabo-
lism of of bioactive lipids, including prostaglandins and retinoids, respectively.
CYP2S1 expression is elevated in epithelial-derived cancers. Whether increased
CYP2S1 expression in proliferative disease is protective, detrimental, or fails to im-
pact disease progression remains to be determined. To elucidate its role, we need to
understand the physiological significance of CYP2S1.  We reasoned that transcrip-
tome analysis of human bronchial epithelial cells (BEAS-2B) differentially express-
ing CYP2S1 would reveal metabolic shifts in key regulatory pathways linked to
CYP2S1-mediated metabolism. To test this idea, we established four stable BEAS-
2B cell lines expressing high (CYP2S1-Flag), medium (pcDNA3.1 and scrambled
shRNA), and low (CYP2S1 shRNA) CYP2S1 expression. Expression levels con-
firmed using qRT-PCR and western analysis. Alterations in the transcriptome were
determined using RNA-sequencing (RNA-seq) analysis. RNA was isolated from
three biological replicates from each of the four experimental conditions (CYP2S1-
Flag vs pcDNA3.1 and CYP2S1 shRNA vs SCRAM shRNA). Eight to fourteen
million sequencing reads were generated from each of the 12 samples. Four distinct
population clusters were identified using principal component analysis, represent-
ing each of the transformed cell lines. Approximately 1000 genes were differentially
expressed in response to CYP2S1. Among these were key regulatory enzymes in-
volved in prostaglandin synthesis. RNA-seq also identified novel changes in the
mTOR pathway, which regulates cell size. Significant differences in cell size was in
lung cells differentially expressing CYP2S1, revealing a potentially novel role for
CYP2S1 in cell size regulation.
688 In-Depth Examination of How Exposure to Long-Term Low-
Dose Chromium Alters the Transcriptional Response to BaP.
J. Ovesen,  Y. Fan and A. Puga. University of Cincinnati, Cincinnati, OH.
Complex mixtures and their toxicity are a significant and growing problem that
must be addressed by applied toxicology. Techniques for the assessment of similar
compounds in a mixture based on relative toxicity are inadequate for the assessment
of complex mixtures with different types of components. In complex mixtures,
multiple exposures generate specific changes in gene expression that cannot be at-
tributed to any single mechanism. Data on the responses to these kinds of mixtures
are rare and often contradictory. Our previous work demonstrated that epigenetic
regulation of gene transcription plays an important role in chromium’s toxic re-
sponse, and that Cr is capable of altering the transcriptional regulation of known
BaP responsive genes, like Cyp1a1. Here we use RNA-seq after long-term low-con-
centration exposure to chromium to examine the extent to which chromium expo-
sure can alter BaP induced transcriptional responses throughout the transcriptome.
We find that mouse hepatoma cells exposed to long-term low concentrations of
sodium chromate, in the range of 0.1 – 0.5 μM, accumulate double-strand DNA
breaks, and that the percentage of cells undergoing apoptosis increases concurrently
with either increased concentration or longer period of exposure to Cr. Using
RNA-seq we determined that the transcription of genes critical to several important
processes are regulated differently by BaP if the cells were previously chronically ex-
posed to a low concentration of Cr. In cells grown normally genes related to critical
functions like cell cycle and tissue development are down-regulated but cells treated
with low concentration Cr for a long period of time do not down-regulate these
functions in response to acute BaP treatment. These findings can serve as a guide
for studies to determine what biological functions normally regulated by BaP may
be abnormally regulated when there are previous exposures to chromium.
Supported by NIH grant ES010807.
689 Expression of the Nuclear Receptor Corepressor Tnip1 in
Mouse Tissues.
N. Francis,  C. Zhang and B. J. Aneskievich. University of Connecticut,
Willimantic, CT.
Tnip1 regulates multiple signaling pathways (NF-κB, ERK2, PPAR and RAR) in-
volved in either executing or responding to toxic insults. Altered Tnip1 expression
levels are associated with certain human inflammatory diseases. These cell signaling
and pathology studies revealed some molecular targets and potential organ end-
points. Additionally, body-wide data on expression of Tnip1 is incomplete. To gain
a better understanding of Tnip1’s expression pattern and functional role, we devel-
oped a Tnip1 gene trap knock out (KO) mouse to identify possible new signaling
and organ targets. 
The Tnip1 gene trap KO mouse was created via a β-Geo cassette (β-
galactosidase and neomycin resistance genes) insertion into the Tnip1first intron.
Expression from the cassette allowed for evaluation of Tnip1 promoter activity in
different tissues qualitatively via X-gal staining, immunofluorescent (IF) staining
for β-Galactosidase (β-Gal), and quantitatively via Q-PCR. With WT tissues as a
control, all heterozygote (Tnip1 +/-) tissues turned blue with X-gal staining.
Results of IF β-Gal staining in Tnip1 +/- mouse tissues were similar to that of X-gal
whole organ staining and paralleled the Tnip1 antibody staining. For most organs,
both β-Gal and Tnip1 were homogeneously expressed across the tissue. However,
for kidney, both β-Gal and Tnip1 glomerular staining was significantly reduced
compared to convoluted tubules suggesting distinct expression levels and fidelity of
the β-Gal marker for the endogenous Tnip1 expression. Q-PCR results revealed
that the Tnip1 promoter activity, determined by steady state levels of β-Gal
mRNA, varied among different tissues and mirrored the Tnip1mRNA levels. These
results suggest Tnip1 is expressed at varying levels in different mouse tissues. Recent
studies report a high rate of lethality in Tnip1 KO mouse embryos due to fetal liver
apoptosis (Oshima et al, 2009, Zhou et al, 2011). By contrast, we demonstrate
there are tissues other than liver expressing Tnip1 and that biological function of
these organs may be impacted by changes in levels of Tnip1 protein.
690 Evaluating the Role of Kinase Activation Involved in
Chemical-Dependent p53 Response to DNA Damage.
B. Reidel1,  B. Sun1,  A. Scott2,  Y. Adeleye2,  M. E. Andersen1 and R. A. Clewell1.
1The Hamner Institutes, Durham, NC; 2Unilever, PLC, London, United Kingdom.
Post-translational modifications (PTMs) of p53, individually and in combination,
help determine the function of p53 in DNA damage response, e.g. cell cycle arrest,
apoptosis and DNA repair. The dose-response for p53 activation, cell cycle, apop-
tosis and mutation (micronuclei) were studied for etoposide (ETP), methyl-
methane sulfonate (MMS) and quercetin (QUE). Cellular response was chemical
specific, despite similar induction of DNA damage (double strand breaks) and p53.
Here, we investigated activation of mitogen-activated protein kinases (MAPKs) and
phosphoinositide 3- kinases (PI3Ks) in response to MMS, ETP, and QUE across
doses and time (1 – 24 hrs) in human fibrosarcoma cells (HT1080). The MAPKs
were studied by measuring p-p38, p-ERK1/2, p-JNK1/2, and p-MEK1 using im-
munoblot and Luminex assays, and the PI3Ks: p-ATM, p-ATR, p-DNA-PK and p-
Chk 2 by immunoblot and flow cytometry. MAPKs and ATM were activated by all
three chemicals. Although p-ATM, p-p38, p-ERK and p-JNK increased at 1, 3 and
24 hrs, they showed different patterns of activation that may lead to observed dif-
ferences in cell fate. While ETP and MMS showed maximal p-ERK1/2 and p-ATM
at 24 hr, QUE displayed a much stronger p-ERK and p-ATM response at 1 hr,
which may indicate more efficient repair, and is in agreement with less micronuclei
observed with QUE vs. ETP or MMS. p-p38 - associated with p-p53 (ser46) lead-
ing to apoptosis - was induced quickly with ETP (1 hr), but more slowly with
QUE, an observation consistent with observed apoptosis by ETP, but not QUE in
HT1080 cells. ETP showed a much stronger induction of p-ATM than either
MMS or QUE, and only QUE inhibited p-ATR. Our results indicate that, types
and timings of the activated kinases are chemical specific and likely to determine
the downstream actions of p53. Currently, we are evaluating treatment dependent
PTMs of p53 by proteomics, as well as kinase specific inhibitors to further confirm
the relationship between kinase modification of p53 and cell fate.
691 Global Transcriptional Analysis of Zebrafish Embryos
following Acute Exposure to Cadmium.
M. J. Jenny1,  E. E. Linney2,  B. O’Shields1,  A. Holowiecki1 and A. McArthur1.
1Department of Biological Sciences, University of Alabama, Tuscaloosa, AL;
2Department of Molecular Genetics and Microbiology, Duke University Medical
Center, Durham, NC.
Although cadmium (Cd) exerts its toxic effects through the generation of oxidative
stress, many of the cellular mechanisms involved in Cd toxicity are not fully estab-
lished. Utilizing zebrafish embryos as a model, we undertook a transcriptomic-
based approach to investigate the role of Cd as a developmental toxicant and assist
in the identification of novel mechanisms of cellular dysfunction. Zebrafish em-
bryos (24, 48, 72 and 96 hpf ) were continuously exposed to Cd (25, 50, 100, 150
μM) for 24 hours prior to mortality assessment. No significant mortality was ob-
served prior to 72 hpf. However, at 96 and 120 hpf the 50 μM Cd dose resulted in
20% and 40% mortality, respectively, while the 100 and 150 μM Cd doses resulted
in an average of 75% and >95% mortality, respectively. To investigate global
changes in gene expression, zebrafish embryos (72, 96 and 120 hpf ) were exposed
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to 50 μM Cd for 4 or 8 hours. Global gene expression profiling was performed
using the Agilent 4x44K Zebrafish Oligo Microarray. Overall, 788 probes were sig-
nificantly upregulated, while 679 probes were downregulated in one or more treat-
ments. Principle component analysis was employed to find trends among the vari-
ous treatments. The first principle component separated out the 96 and 120 hpf
Cd-treated embryos, consistent with the mortality curves suggesting that zebrafish
embryos become most sensitive to Cd toxicity around 96 hpf. The majority of
genes altered by Cd exposure resulted in the upregulation of a large subset of genes
responsive to oxidative stress, genes involved in glutathione synthesis and
heme/iron homeostasis, mitochondrial uncoupling proteins, and various solute car-
riers with roles in zinc transport/homeostasis or mitochondrial oxidative phospho-
rylation. The majority of genes downregulated by Cd were involved in cell cycle
control and DNA replication. A thorough analysis of genes differentially regulated
by Cd during zebrafish development will be presented. [R00ES017044]
692 Role of Chromatin Structural Changes in Regulating Human
CYP3A Ontogeny.
N. L. Giebel1,  J. D. Shadley1,  K. Dorko2,  S. C. Strom3,  P. M. Simpson1,
K. Yan1 and R. N. Hines1. 1Pediatrics, Medical College of Wisconsin, Milwaukee,
WI; 2Pharmacology, Toxicology and Therapeutics, University of Kansas Medical
Center, Kansas City, KS; 3Laboratory Medicine, Karolinska University Hospital,
Stockholm, Sweden.
Variability in drug metabolizing enzyme (DME) developmental trajectories con-
tributes to differential susceptibility to chemical toxicity and adverse drug reactions,
particularly in the first years of life. Factors linked to variability are largely un-
known and molecular mechanisms regulating ontogeny are likely involved. To eval-
uate chromatin structure dynamics as a contributing mechanism, age-dependent
changes in histone marks were evaluated within known CYP3A4, CYP3A7, FMO1,
and FMO3 regulatory domains. Chromatin immunoprecipitation with fetal and
adult primary human hepatocyte chromatin pools followed by qPCR was used to
determine relative histone mark occupancy. Histone mark occupancy is consistent
with many regions of bivalent chromatin (i.e., exhibiting histone marks associated
with active and repressive transcription) in adult and fetal hepatocytes with the ex-
ception of the CYP3A7 XREM and C/EBPβ domains in adult hepatocytes. For
CYP3A4, the bivalent regulatory domainains are consistent with a low level of fetal
liver expression. Differential histone mark occupancy indicates adult histone mark
and transcription factor occupancy have a developmental trajectory towards an ac-
tive transcriptional state. In contrast, the bivalent CYP3A7 regions in fetal hepato-
cytes do not correspond with high expression and surprisingly, adult hepatocytes
had less histone mark occupancy, particularly the repressive mark H3K27me3.
These finding for CYP3A7 suggest mechanisms other than chromatin structural
changes involved in regulating ontogeny. Chromatin structural change is an impor-
tant mechanism controlling DME ontogeny, particularly for those whose specific
activity increases substantially after birth. Supported in part by NIH grant
GM081344
693 6-Formylindolo(3, 2-b)carbazole (FICZ) Positively Regulates
the Signalsome Responsible for Retinoic Acid (RA)-Induced
Differentiation of Leukemic Blast Model Hl-60.
R. Bunaciu and A. Yen. Cornell University, Ithaca, NY.
Tryptophan is an essential amino acid that absorbs strongly in UV (extinction coef-
ficient: 5,050 M-1cm-1 for 280 nm). Both in cell free conditions (such as cell cul-
ture media exposed to light) and in the cells (such as skin keratinocytes exposed to
sunlight), tryptophan yields a multitude of photoproducts. One such photoproduct
is 6-Formylindolo(3,2-b)carbazole (FICZ). FICZ has a high affinity for AhR
(Kd=7x10-11 M). It is proposed to be an endogenous AhR agonist and also a cy-
tochrome P450 family 1 substrate. FICZ and a multitude of its metabolites have
been shown to be present in human fluids. Currently all the complete parenteral
nutrition formulations contain tryptophan. The bags for total parenteral nutrition
are made of clear plastic. Since many cancer patients receive both parenteral nutri-
tion and chemotherapy (generally enhancing AhR expression and activity), it is of
significant interest to assess potential effects of FICZ on cell differentiation and in
particular on RA-induced leukemic cell differentiation. HL-60 leukemic cells were
untreated or treated with RA alone or RA in combination with FICZ for 48 h. To
assess the involvement of AhR, other cells were treated either with α-naph-
thoflavone and RA or β-naphthoflavone and RA. Expression of cell surface differ-
entiation markers, cell cycle distribution and respiratory burst response were quan-
tified by flow cytometry. Western blots were performed to assess the proteins
known to be part of the signalsome driving the RA-induced differentiation. FICZ
augments the RA-induced differentiation as evidenced by CD38 and CD11b re-
ceptors, inducible respiratory burst, G0 cell cycle arrest and growth curves.
Signaling molecules previously shown to be upregulated by RA and to drive RA in-
duced differentiation were enhanced by FICZ: MAPK signaling axis, Src family ki-
nases, Cbl, VAV, SLP-76, PI3K, and IRF-1. Moreover, AhR is associated with the c-
CBL adaptor in the signalsome, as shown by IP. In conclusion, FICZ modulates RA
induced differentiation.
694 Nrf2 Gene Regulation during Oxidative Stress in Embryonic
Development.
A. R. Timme-Laragy1, 2,  S. I. Karchner1,  R. C. Harbeitner1,  A. G. MacArthur3
and M. E. Hahn1. 1Biology, Woods Hole Oceanographic Institution, Woods Hole,
MA; 2Public Health, University of Massachusetts, Amherst, MA; 3AGM Consulting,
Hamilton, ON, Canada.
Nrf2 is a transcription factor that regulates antioxidant defenses in response to ox-
idative stress. Embryonic development is highly susceptible to disruption by expo-
sure to chemicals, including those that alter redox balance. The role of Nrf2 in the
oxidative stress response (OSR) during embryonic development remains unclear.
Our previous work identified a novel Nrf2 paralog, nrf2b, in zebrafish (Danio
rerio). This study builds upon that work to elucidate the roles of nrf2a and nrf2b in
regulating the OSR during vertebrate embryonic development. Zebrafish embryos
were micro-injected with antisense morpholino oligonucleotides (MO) to knock
down translation of either nrf2a or nrf2b, or a standard morpholino control (co-
MO). At 48 hours post fertilization, embryos were exposed to the pro-oxidant and
Nrf2 activator, tertbutylhydroquinone (tBHQ) or vehicle (DMSO) for 4 hours,
and preserved for RNA isolation. Microarrays were conducted using Agilent’s V3
44k array, and selected genes validated by QPCR. In response to tBHQ, 71 probes
were up-regulated in the co-MO group, including gstp1, gclc, ferritin, peroxire-
doxin1, hsp70, sod1, and other genes typically found as part of the OSR.
Interestingly, we found that an important and often overlooked part of the OSR is
the down-regulation of genes, including cathepsin, various complement compo-
nents, and apolipoprotein Ea. Knockdown of Nrf2a or Nrf2b blocked some but not
all of the tBHQ-induced changes in OSR gene expression and the effects of Nrf2a-
MO and Nrf2b-MO were distinct. The results show that Nrf2 paralogs primarily
regulate distinct gene sets, with some overlapping targets, in response to oxidative
stress in embryos. This study also highlights the importance of gene down-regula-
tion as a component of the OSR during embryonic development. [F32ES017585,
R01ES016366].
695 On Breast Cancer Treatment, Synergistic Effects of Akt1
shRNA and Paclitaxel-Incorporated Conjugated Linoleic
Acid-Coupled Poloxamer Thermosensitive Hydrogel.
S. Hong1,  C. Cho2 and M. Cho1. 1Laboratory of Toxicology, Seoul National
University, Seoul, Republic of Korea; 2Agricultural Biotechnology, Seoul National
University, Seoul, Republic of Korea.
The phosphoinositide 3-kinase(PI3K)/Akt1 signaling pathway has emerged as a
target for treatment of cancer therapy. In this study, we develop a strategy to en-
hance Akt-targeted therapy. We thought that combination of Akt1-targeted therapy
with conventional chemotherapy using paclitaxel-incorporated conjugated linoleic
acid-coupled poloxamer (CLA-CP) thermosensitive hydrogel may have synergistic
effects in cancer therapeutic efficiency compared with chemotherapy alone. MDA-
MB-231 cell, the human breast cancer cell line, was inoculated into 6-week-old fe-
male BALB/C nu/nu athymic mice. After 2 weeks of inoculation, shAkt1 and
CLA-CP treatments were subcutaneously injected into the tumor. We found that
the combination of shAkt1 with paclitaxel showed synergistic anti-cancer effects,
thus, inhibiting the growth of human breast cancer cells, and breast cancer
xenografts in mice as well. The combination therapy showed enhanced anti-cancer
effects through inhibiting Akt1 signaling, inducing apoptosis. In addition, it sup-
pressed angiogenesis and proliferation, also. It suggests that the presented strategy
of combination of shAkt1 with paclitaxel may have a potential for the treatment of
breast cancer.
Acknowledgements
This work was partly supported by the National Research Foundation (NRF-2011-
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696 TBX5 As Targets for Treatment of Chronic Obstructive
Pulmonary Disease.
J. Lee and G. Acquaah-Mensah. Massachusetts College of Pharmacy Health and
Sciences, Worcester, MA.
Chronic Obstructive Pulmonary Disease (COPD) is a progressive disease of the res-
piratory system which is characterized by destruction of the epithelium cells of
lungs. Current therapies alleviate symptoms of COPD but do not treat the under-
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lying causes. It has been recognized in the literature that the T-box transcriptional
factor TBX5 is suppressed in patients with COPD. The purpose of the study was to
identify regulatory target genes of TBX5 and their significance in future treatment
of COPD. A compendium of lung epithelium microarray datasets was created
using GSE 19027 and GSE 994 from the Gene Expression Omnibus database.
Probe IDs for TBX5 and genes that have known interactions with the TBX5 tran-
scription factor were used to generate an initial network. Bayesian Network
Inference with Java Objects was then used to generate a new regulatory network,
given the gene expression data. Cytoscape was used to visualize the difference be-
tween the initial and predicted networks. In addition, analysis of GSE 1650, which
compared lung tissue from smokers with severe emphysema and smokers with mild
or no emphysema, was done. The resulting network indicates of STAT3 regulates
TBX5, NKX2-5, GATA4, ID2 and TAZ. The regulatory relationships between
STAT3 and TBX5, NKX2-5, GATA4, ID2 have been validated in the published lit-
erature. However, a relationship between STAT3 and TAZ has not been estab-
lished. It is known that TAZ regulates TBX5. This presents with a possible feed-for-
ward relationship among TBX5, STAT3 and TAZ. STAT3 is known to be involved
in cell growth, apoptosis, and regulation of anti-inflammatory response by control-
ling genes involved in the inflammatory response. This result suggests a potential
inhibitory relationship between STAT3 and TBX5 since STAT3 was up-regulated
in smokers with severe emphysema and TBX5 was suppressed in patients with
COPD. The result suggests that future therapies targeting STAT3 or TBX5 can reg-
ulate inflammatory response involved in COPD. Further research is warranted to
investigate how TBX5, STAT3 and TAZ play a role in the inflammatory response
of COPD.
697 Suppressive Effect of HES1 (Drosophila Hairy and Enhancer
of Split-1) on Human Hepatic Multidrug Resistance-
Associated Protein 4 (MRP4) Gene Expression and
Induction of HES1 by Oxidative Stress.
X. Gu and J. E. Manautou. Department of Pharmaceutical Sciences, University of
Connecticut, Storrs, CT.
Previous in silico studies in our laboratory identified a total of 107 canonical
HES1-binding N-boxes (CANNAG) in a 10kb DNA fragment upstream to the
translation start site of the multidrug resistance-associated protein 4
(MRP4/ABCC4). In this study, we investigated the role of HES1 in regulating
MRP4 gene expression. We have identified a 16-bp DNA fragment in the MRP4
promoter-proximal region containing a non-canonical N-box (GGCGTG) for
HES1 that accounts for a profound suppression of MRP4 promoter transcription
activity in HepG2 cells. A point mutation in this cis-element (GGCGTC) resulted
in the loss of this suppressive effect of HES1. Furthermore, suppression of MRP4
reporter genes containing 230 bp, 5 kb or 7 kb of 5’ flanking regulatory sequences
was observed by over-expression of HES1 but not by a dominant negative mutant
form of HES1 which is unable to bind to DNA. From these findings we hypothe-
sized that the MRP4 induction we have previously reported under conditions of ox-
idative stress might be due in part to down-regulation of HES-1 expression. To our
surprise, HES1 mRNA levels are significantly increased in the human liver cell line
HC04 treated with the pro-oxidant chemicals tert-butylhydroperoxide or tert-
butylhydroquinone (100-300μM). We also detected HES1 protein accumulation
in nuclei of HC04 treated with these chemicals in a dose- and time- dependent
manner. Similarly, treatment of mice with toxic doses of APAP increases liver Hes1
mRNA levels. These increases in expression and function of the repressive factor
HES1 by oxidative stress seem inconsistent with the induction of MRP4 that also
occurs under oxidative stress conditions. Studies are currently underway to investi-
gate whether HES1 directly regulates MRP4 gene expression in vivo by oxidative
stress and to determine the interplay of HES1 with other activating and repressive
transcription factors known to regulate MRP4. Supported by NIH Grant
DK069557.
698 Exposure to Metals Mixtures: Genomic Alterations of
Infectious Disease Response Pathways in Children Exposed
to Environmental Metals.
J. Gruber1, 2,  R. D. Patel1,  J. E. Rager1,  A. P. Sanders1,  S. Edwards3,
J. E. Gallagher3 and R. C. Fry1. 1Environmental Sciences and Engineering,
University of North Carolina at Chapel Hill, Chapel Hill, NC; 2Department of
Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC;
3National Health and Environmental Effects Research Laboratory, US EPA, Research
Triangle Park, NC.
Exposure to toxic metals can have harmful health effects, particularly in children.
Although studies have investigated the individual effects toxic metals have on gene
expression and health outcomes, there are no studies assessing the effect of metal
mixtures on gene expression profiles. Here, we assessed the mixture effect of six
toxic metals (arsenic, beryllium, cadmium, chromium, mercury, and lead) on gene
expression profiles in children in Detroit, Michigan. As part of the Mechanistic
Indicators of Childhood Asthma (MICA) cross sectional study, we assessed metal
exposure in 131 children in Detroit using fingernail metals levels. A metals mixture
score was calculated and compared to gene expression profiles across the population
adjusting for age and race. There were 145 unique genes that were significantly dif-
ferentially expressed when comparing children exposed to low and high levels of the
metals mixture. Of the genes differentially expressed, 107 (74%) had increased ex-
pression while 38 (26%) had decreased expression. The main biological function
associated with multiple metals was infectious disease. Within that group, genes
were associated with infection of respiratory tract (P < 10-6) severe acute respiratory
syndrome (P < 10-5), and sepsis (P < 10-3). Taken together, these data demonstrate
that exposure to metals mixtures may activate gene networks related to infectious
disease response. This abstract does not necessarily reflect the views or policies of
the EPA.
699 Transcriptomics Analysis of Lung Tissues of Brown Norway
Rats Exposed to the Sensitizers Trimellitic Anhydride (TMA),
Oxazolone (OXA) or Dinitrochlorobenzene (DNCB).
F. Kuper2,  M. Radonjic2,  J. van Triel1,  Y. Staal1,  R. Woutersen2 and R. Stierum2.
1TNO Triskelion, Zeist, Netherlands; 2The Netherlands Organisation for Applied
Scientific Research, TNO, Zeist, Netherlands.
TMA is a respiratory allergen, OXA is a potent contact allergen in man, but elevates
serum IgE levels and Thelper2 cytokines in test animals, suggesting that it has also
respiratory allergenic potential. DNCB is a contact allergen. Brown Norway rats
(BN) were sensitized by two dermal applications of TMA, OXA or DNCB. The an-
imals were provoked by inhalation on day 21. TMA and OXA both induced eleva-
tion of serum IgE, breathing pattern changes and the same type of allergic laryngeal
inflammation. However, microarray analysis of the lung (sampled 24 hrs after
provocation) indicated that OXA may act through different mechanisms than
TMA, despite a certain overlap in activated genes. TMA upregulated strongly Th2-
associated genes and genes associated with lung remodeling, whereas OXA acti-
vated predominantly Th1-associated genes. The variability in balance between
Th1- and Th2-associated genes may reflect different subtypes of respiratory aller-
gies. DNCB induced a very mild inflammation in the larynx, which resembled
DNCB-induced inflammation in the skin; only a few Th1-associated genes were
differentially expressed in the lung. The transcriptomics analysis supports the idea
that classification of allergens based on single genes is unreliable. Omics data con-
tribute to our understanding of respiratory allergy and may help in the design of a
predictive toxicity test for sensitization.
700 In Vivo Expression of P16INK4a in Response to
Toxicological Exposures.
J. Sorrentino1, 3,  N. Sharpless1, 2, 3 and C. Burd4. 1Toxicology, University of North
Carolina at Chapel Hill, Chapel Hill, NC; 2Departments of Medicine and Genetics,
University of North Carolina at Chapel Hill, Chapel Hill, NC; 3Lineberger
Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel
Hill, NC; 4Molecular Genetics, Ohio State Univerisity, Columbus, OH.
In mammals, expression of p16INK4a is highly regulated. Excess expression can
lead to cellular senescence and aging, while impaired activation is associated with
cancer. The precise mechanism of p16INK4a regulation in vivo is poorly under-
stood. In vitro systems have limited utility since proliferation in culture induces
p16INK4a. Both extrinsic (chemotherapy and ionizing radiation) and intrinsic
(telomere shortening and improper DNA damage repair) stimuli can induce
p16INK4a, but the kinetics of and cellular responses to these genomic insults have
not been examined in vivo. To address this question, we developed a murine strain
with firefly luciferase ‘knocked-in’ to the endogenous p16INK4a locus and under
control of the p16INK4a promoter (p16-LUC). We exposed p16-LUC mice to
50ppm arsenic, 42% fat diet, 350 J/m2 UVB light, or cigarette smoke for a mini-
mum of 6 months. Every other month, p16-LUC mice were imaged to measure lu-
ciferase induction. At 30 weeks of exposure, mice exposed to cigarette smoke dis-
played 2 times higher levels of whole body luciferase activity than no-smoke
controls. Additionally, mice exposed to UVB exhibited 1.5 times higher levels of lu-
ciferase activity by 6 weeks of exposure that reached 8 times over control mice by 24
weeks. In arsenic exposed mice, there was only a slight induction of p16INK4a by
24 weeks (not statistically significant). We observed no differences in p16INK4a
expression in mice on high fat diet (42% fat) compared to normal fat diet (4%)
after 78 weeks. Currently, we are correlating luciferase expression in different or-
gans with tissue damage and mRNA expression of p16INK4a. The data generated
from these experiments will demonstrate how environmental exposures are associ-
ated with expression of p16INK4a, a mediator of tumor suppression and aging.
(Supported by T32 ES07126, HHMI Translational Medicine Program, and UO1-
CA141576)
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701 Reprogramming of the HepG2 Genome by Long
Interspersed Nuclear Element-1: Regulatory Control of
Epithelial to Mesenchymal Transition Is Independent of
Reverse Transcriptase.
P. Bojang1,  M. Anderton2,  R. Roberts2 and K. S. Ramos1, 3. 1Biochemistry and
Molecular Biology, University of Louisville, Louisville, KY; 2General Toxicology
Sciences, AstraZeneca, Manchester, United Kingdom; 3Center for Environmental
Genomics and Integrative Biology, University of Louisville, Louisville, KY.
Long Interspersed Nuclear Element-1 (LINE-1 or L1) is an autonomous, mobile
element within the human genome that transposes via a “copy and paste” mecha-
nism and relies upon L1-encoded endonuclease and reverse transcriptase (RT) ac-
tivities to compromise genome integrity. Because the complexity of L1 biology is
not understood, studies were conducted to evaluate the impact of L1 on epithelial
to mesenchymal transition (EMT) in HepG2 cells. Forced expression of synthetic
wild type or mutant (D702Y) L1 deficient in RT activity was associated with for-
mation of cytoplasmic foci and minor association with the nuclear compartment.
Random de novo L1 retrotransposition was identified in cells expressing wild type
L1, but not the D702Y mutant. Both synthetic wild type and mutant L1 induced
marked reductions in the expression of epithelial markers and overexpression of
mesenchymal markers. These data establish L1 as a key regulator of genome plastic-
ity in HepG2 cells via RT-dependent and RT-independent mechanisms which do
not couple to intrinsic retrotransposition activity.
702 Interoperability Case Study: Connecting Models across
Exposure and Dose-Response Arenas for Characterization of
Vinyl Chloride Hepatotoxicity.
D. S. Womack1,  S. M. Beaulieu1,  A. B. Parks1,  M. Mumtaz2,  P. Ruiz2,
J. Babendreier3 and A. M. Jarabek4. 1RTI, Research Triangle Park, NC; 2ATSDR,
Atlanta, GA; 3US EPA, Athens, GA; 4US EPA, Research Triangle Park, NC.
The 2012 SOT workshop “Building for Better Decisions: Multi-scale Integration of
Human Health and Environmental Data” advanced seamless data and model inte-
gration for support of sustainability and improved risk characterizations. It high-
lighted the need for interoperability of models across the source/exposure/dose-re-
sponse/cost:benefit continuum. We conducted a case study to illustrate
interoperability issues for characterizing aggregate risk of liver cancer or hepatoxic-
ity for inhaled and ingested vinyl chloride (VC).  Exposure models used were the
EPA’s Assessment System for Population Exposure Nationwide (ASPEN) using data
of the National-scale Air Toxics Assessment (NATA) for inhalation, and the Human
and Ecological Exposure and Risk in Multimedia Environmental System
(HE2RMES) domain within the Framework for Risk Analysis in Multimedia
Environmental Systems (FRAMES) with Data for Environmental Modeling
(D4EM) of the Agency’s integrated exposure modeling (iem) technologies. The
dose-response was characterized by data on the Integrated Risk Information System
(IRIS) and the physiologically-based pharmacokinetic (PBPK) model for VC avail-
able in the ATSDR PBPK toolkit. Output from ASPEN and HE2RMES for in-
haled VC exposure illustrates the value to efficient model comparison if plug-and-
play capability is provided by interoperability. Conflicting assumptions regarding
key parameters between exposure and dose-response arenas were highlighted when
computing aggregate risk from oral and inhalation routes; these conflicts must be
rectified prior to proper model integration. This exercise readily shows how the
ability to transparently integrate such models impacts current approaches and en-
hances understanding of each discipline. (The views expressed in this abstract are
those of the authors and do not necessarily represent the views or policies of the
U.S. Environmental Protection Agency or the Agency for Toxic Substances and
Disease Registry.)
703 Modeling Acute Exposure Guideline Levels (AEGLs).
M. T. Chu,  C. M. Nordberg,  R. Manimaran,  Y. Tie and E. Demchuk. ATSDR,
Atlanta, GA.
Acute Exposure Guideline Levels (AEGLs) are comprehensively peer-reviewed
health guidance values for assessing the risk of acute once-in-a-lifetime or rare ex-
posures to hazardous inhalation chemicals. Each AEGL is a concentration designed
to prevent health effects of a certain type (AEGL-1: reversible, AEGL-2: disabling,
AEGL-3: life-threatening) at one of the five exposure durations (1/6, 1/2, 1, 4, 8h).
Currently only 272 compounds have published AEGLs and among them 114 have
unassigned AEGLs-1. The objective of present work was to develop a novel in silico
approach for rapid estimation of provisional AEGL-1 thresholds, specifically at 8h
(AEGL-18h). Correlation and multivariate linear regression analyses were employed
to assess significant predictors for AEGL-1. AEGLs-2 and -3 were identified as per-
spective explanatory variables, controlled for physiochemical properties and chemi-
cal-specific qualitative data used to extrapolate AEGLs (e.g. species, target health
endpoint, uncertainty factors). χ2- and t-tests were used to assess the homogeneity
of covariates in the training and test sets. Variable selection involved multicollinear-
ity, interaction, and confounding assessments. An exhaustive all-possible-subset se-
lection was employed to determine the best information-entropy model. Available
toxicological LOAEL or NOAEL data were used to validate the model. The final
model was developed for AEGL-18h. It relied on AEGL-28h values as the main ex-
planatory variable, controlled for chemical volatility, testing species, and uncer-
tainty factors. For the chemicals without the AEGL-18h assigned, approximately
70% of model-predicted concentration thresholds were within a 10-factor of their
extrapolated LOAEL or NOAEL values. The proposed 1D-QSAR model provides
a meaningful and statistically-valid method to derive provisional AEGL-1 thresh-
olds that is consistent with available toxicological data. Such in silico methods offer
a complementary approach when biological or toxicological evidence is insufficient,
budget is limited, and/or rapid assessment is necessary, as in an emergency re-
sponse.
704 Concentration-Time Relationships for Short-Term
Inhalation Exposures to Hazardous Substances.
R. Manimaran and E. Demchuk. Agency for Toxic Substances and Disease Registry,
Atlanta, GA. Sponsor: P. Ruiz.
Acute Exposure Guideline Levels (AEGLs) are developed by the USEPA AEGL
committee for controlling acute exposures to airborne chemical hazards. AEGLs are
the threshold exposure limits for once-in-a-lifetime or rare chemical exposures at
five exposure durations (1/6, 1/2, 1, 4, 8h). AEGLs are derived from various pub-
lished and unpublished experimental studies described in Technical Support
Documents prepared by the committee. An AEGL concentration (C) for a specific
duration (t) is extrapolated from available experimental data. Extrapolations are
carried out using the exponential function, Cn * t = k, where n, the temporal scal-
ing factor (TSF), is chemical-specific. Preferably, it is derived experimentally, but
thus far experimental TSFs for few chemicals have been derived. For most of 272
chemicals on the AEGL list, TSFs are unknown. For these chemicals, the AEGL
committee has adopted a rule by which n = 1 when extrapolating from short- to
long-term durations, and n = 3, when extrapolating from long- to short-term dura-
tions. However, for many chemicals with unknown TSFs, this rule has been aban-
doned in favor of chemical-specific information deemed appropriate by the com-
mittee. Thus, the AEGL database contains rich expert-validated chemical-specific
information about temporal extrapolation. The objective of the present study was
to extract this information. Using regression analysis for each chemical in the data-
base, a surrogate TSF was derived. In addition to being chemical-specific, TSFs
were found to be health-effects-specific. The relationship between median TSFs for
mild/reversible (n1=2.9, AEGL-1 tier), disabling/irreversible (n2=2.0, AEGL-2),
and life-threatening effects (n3=1.8, AEGL-3) was n1 > n2 > n3. A geometric mean
TSF for the AEGL-3 tier, n3 = 1.88 [95% CI: 1.77, 1.99], was closest to n = 1 in
Haber’s rule, which applies to combat exposures to chemical warfare agents. This
observed agreement indicates that model-derived TSFs may be appropriate for tem-
poral extrapolation of AEGL concentrations to durations of exposure for which ex-
perimental durations are not available.
705 Refined Animal Toxicity Testing Using Unequally Sized Dose
Groups and Benchmark Dose Analysis.
M. Öberg,  J. Ringblom,  F. Kalantari and G. Johanson. Institute of Environmental
Maedicine, Karolinska Institutet, Stockholm, Sweden.
Benchmark dose (BMD) analysis has been recommended as a more robust alterna-
tive to the No Observed Adverse Effect Level (NOAEL) as it makes use of all the
data from the study to derive the point of departure. In this study, we used simula-
tions to examine the possibility to optimize the study design for BMD analysis by
introducing unequally sized dose groups. In addition, this BMD-aligned design of
experiment was evaluated regarding animal distress. Experimental data were gener-
ated by Monte Carlo simulations for fixed doses and equally sized groups. We
started with the OECD standard of 4 dose groups (logarithmic dose spacing: 0-1-
3-10 mg/animal) with 20 animals per group and assumed a sigmoidal dose-effect
curve. The distribution of animals between dose groups was then altered before per-
forming the next set of simulations. The quality of the simulated BMD was evalu-
ated against the “true” dose-effect curve and the standard 4x20 design. The proce-
dure was repeated for scenarios with different effect variability and dose placements
on the dose-effect curve. The designs with more animals in the low dose groups
generally showed significantly better quality than the standard design with equally
sized dose groups. With these designs it was also possible to reduce animal distress
with 45%, under the assumption that the distress is proportional to dose. To reduce
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the number of animals in the high dose group would be an important refinement of
animal testing since the primary parameter for setting the high dose is the tolerabil-
ity determined by clinical signs of moderate severity, e.g. weight loss of up to 20%,
hunched intermittently, intermittent convulsions or transient prostration. In con-
clusion, our simulations suggest that toxicological studies can be improved by un-
equally sized dose groups, which also results in substantially reduced distress. The
study illustrates how regulatory testing may be refined (one of the R:s in 3R –
Reduce, Refine, Replace) by use of BMD-aligned experimental design.
706 A Novel Screening System for Classifying Potential Health
and Environmental Impacts Associated with Hydraulic
Fracturing Fluids.
C. N. McFarland and D. B. Davies. Intrinsik Environmental Inc., Calgary, AB,
Canada.
Public opposition to hydraulic fracturing or “fracking” is being witnessed across
many communities in the U.S.A., Canada and elsewhere. Concerns over this prac-
tice include the potential impacts of fracking on groundwater and surface water
quality, air quality, human health, and terrestrial and aquatic ecosystems. These
concerns have prompted some jurisdictions to place temporary moratoriums on the
practice until a better understanding of these potential impacts is gained.
Numerous initiatives are now underway to heighten this understanding, including
measures aimed at increasing awareness of the chemical additives that are used dur-
ing the process. Many jurisdictions are now mandating public disclosure of these
additives, and chemical registries that list the additives delivered down-hole on a
well-by-well basis have emerged. Although these registries identify the chemicals
used, they provide no indication of the potential health and environmental risks
that the additives could present. To help fill this void, a novel risk-based screening
system was developed to improve the understanding of the potential health and en-
vironmental impacts of the chemical additives used in hydraulic fracturing. The
system relies on the results of toxicity and environmental fate studies for a number
of key endpoints to assess the potential risks involved. The endpoints include acute
and chronic oral toxicity, reproductive and developmental toxicity, mutagenicity,
carcinogenicity, aquatic toxicity, environmental persistence and bioaccumulation
potential. The outcomes of the screening process are used to assign the chemical ad-
ditive products to one of several categories depending upon the potential risks in-
volved. This categorization process allows the product users to take appropriate
steps to manage the potential hazards. The screening system has been used to clas-
sify more than 1,500 products to date, has proven to be reliable and effective, and is
currently being adopted on an industry-wide basis in Canada.
707 Analysis of the Validated Epiderm Skin Corrosion Test
(EpiDerm SCT) and a Prediction Model for Sub-
Categorization According to the UN GHS and EU CLP.
S. Letasiova2,  H. Kandarova2,  T. Milasova2 and M. Klausner1. 1MatTek Corp,
Ashland, MA; 2MatTek IVLSL, Bratislava, Slovakia. Sponsor: P. Hayden.
Skin corrosion refers to the production of irreversible damage to the skin mani-
fested as visible necrosis through the epidermis and into the dermis. In 2004,
OECD adopted two ECVAM-validated reconstructed human skin model assays
(EpiDerm and EPISKIN) for testing skin corrosion (OECD TG 431). However,
OECD TG 431 does not satisfy international labeling guidelines for transport of
dangerous goods since none of the methods were validated for sub-categorization. 
The UN-GHS utilizes 3 corrosion sub-categories (1A-very dangerous, 1B-medium
danger and 1C-minor danger). Labeling a chemical as 1A has important conse-
quences for transport, including very small volume package limits for air transport,
prohibition from passenger aircraft, protective storage conditions, costly containers,
and low market acceptance. Animal tests are still utilized for assessing the packaging
subclasses. An in vitro method that discriminates between the 1A and 1B/1C
classes will therefore have a substantial impact on reducing animal tests for this pur-
pose. 
The current study evaluates whether the EpiDerm SCT can discriminate between
UN-GHS classes 1A, 1B/1C and non-corrosives (NC) based on the MTT viability
assay. Data obtained during the ECVAM validation study (Liebsch et al, 2000) in-
dicated sensitivity of 100% for class 1A. In the current study (> 80 chemicals), sen-
sitivity for class 1A was obtained in a range of 77 – 87% depending on cutoff cho-
sen following a 3 min exposure. None of 1A chemicals was under-predicted as NC.
Specificity for NC chemicals was 80%.  
As demonstrated by results of this study, EpiDerm SCT allows a partial sub-classi-
fication of corrosives into sub-category 1A, 1B/1C, and NC. Adoption of the new
prediction model based on a 3 min endpoint into the validated EpiDerm SCT de-
sign would allow identification of severely corrosive substances and would lead to
significant reduction in animal use for corrosion sub-group package labeling.
708 Physiologically-Based Pharmacokinetic (PBPK) Modeling
for the Development of Provisional Advisory Levels (PALs):
A Case Study with Fentanyl.
H. Shankaran1,  F. Adeshina3 and J. G. Teeguarden2. 1Computational Biology and
Bioinformatics, Pacific Northwest National Laboratory, Richland, WA; 2Systems
Toxicology, Pacific Northwest National Laboratory, Richland, WA; 3National
Homeland Security Research Center, US EPA, Washington DC.
Provisional advisory levels (PALs) are tiered exposure limits for toxic chemicals in
air and drinking water that are developed to assist in emergency responses.
Physiologically-based pharmacokinetic (PBPK) modeling can support this process
by enabling extrapolations across doses, and exposure routes, thereby addressing
gaps in the available toxicity data. Here, we describe the development of a PBPK
model for Fentanyl – a synthetic opioid used clinically for pain management – to
support the establishment of PALs. Starting from an existing model for intravenous
Fentanyl, we first optimized distribution and clearance parameters using several ad-
ditional IV datasets. We then calibrated the model for oral and inhalation exposures
using pharmacokinetic datasets for various Fentanyl formulations. Predictions of
the calibrated model were in good agreement with the >50 datasets considered here.
For aerosolized pulmonary Fentanyl, F=1 and t90<1min indicating complete and
rapid absorption. The F value ranged from 0.35 to 0.74 for oral and various trans-
mucosal routes. Oral Fentanyl was absorbed the slowest (t90 ~ 300mins); the ab-
sorption of intranasal Fentanyl was relatively rapid (t90 ~ 20-40mins); and the var-
ious oral transmucosal routes had intermediate absorption rates (t90 ~
160-300mins). Based on these results, for inhalation exposures, we assumed that all
of the Fentanyl inhaled from the air during each breath directly, and instanta-
neously enters the arterial circulation. We present model predictions of Fentanyl
blood concentrations in oral and inhalation scenarios relevant for PAL develop-
ment, and provide an analytical expression that can be used to extrapolate between
oral and inhalation routes for the derivation of PALs.
709 Pooled Analysis for Chronic Dietary Studies of Di-Isononyl
Phthalate.
C. M. North1,  M. J. Nicolich2,  K. M. Kransler3 and R. A. Barter1. 1ExxonMobil
Biomedical Sciences, Annandale, NJ; 2Cogimet, Lambertville, NJ; 3ExxonMobil
Chemical Company, Houston, TX.
Point of departure selection for risk assessment can be complicated when more than
one study is available for evaluation. Differences in dose spacing and post–mortem
evaluation can result in differing conclusions, leading to uncertainty and additional
conservatism in the overall assessment. Here, several analysis methods were utilized
to estimate the point of departure using the pooled data from two rat chronic toxi-
city studies on di-isononyl phthalate (DINP), a general purpose plasticizer used in
flexible vinyl applications. Two chronic dietary administration studies (two year)
were conducted in DINP-exposed F344 rats. Dietary administration in the two
studies were different, with doses of approximately 0, 15, 152, and 307 (Study I) or
0, 29, 88, 359, and 733 (Study II) mg/kg/day. In addition, the number of liver sec-
tions evaluated between the two studies differed, impacting the overall incidence of
observed liver effects. In both studies, a dose-related increase in the incidence of
spongiosis hepatis was observed in male rats. Separate NOAELs of 15 (Study I) or
88 (Study II) mg/kg/day were determined from the two studies; separate
Benchmark Doses (BMDs) were estimated at 38 and 203 mg/kg/day, respectively.
A pooled data approach, rather than a combining of the NOAEL or BMDs from
the individual studies was utilized to derive a rational, data-based NOAEL or
BMD. A generalized linear model with a logistic link function was used to deter-
mine a NOAEL for the pooled analysis. The NOAEL was the lowest dose group
whose model coefficient was not statistically significantly different from the control
group coefficient at the 5% significance level. The calculated NOAEL using the
pooled data was 152 mg/kg/day. A BMD10 of 72.4 mg/kg/day with a 95%
BMDL10 of 61.0 mg/kg/day were calculated with the pooled data. Pooled analysis,
combined with robust statistical analysis, is a useful and rigorous method for deriv-
ing a point of departure that considers data from multiple, compatible studies.
710 A Systematic Approach for Identifying, Evaluating, and
Presenting Mode-of-Action Evidence in IRIS Toxicological
Reviews.
M. E. Kushman1, 3,  A. D. Kraft2,  K. Guyton2,  B. Sonawane2,  W. A. Chiu2,
S. Makris2 and I. Rusyn3. 1ORISE/US EPA, Washington DC; 2NCEA, US EPA,
Washington DC; 3University of North Carolina at Chapel Hill, Chapel Hill, NC.
Recent National Research Council recommendations on the process of hazard as-
sessment include improving transparency and standardization of evidence collec-
tion, selection, presentation, and evaluation. Per this recommendation, we designed
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a process that was tested using di(2-ethylhexyl)phthalate (DEHP) liver tumorigen-
esis as a case study. We identified relevant modes of action (MOAs) from published
reviews and devised an overall search strategy. Literature search strings containing
relevant synonyms and wildcards for DEHP and its metabolites, MOAs, and
species of interest were tested in PubMed. Specific tiered assessment criteria for ex-
clusion/inclusion into the search were also defined and literature was searched and
screened according to these tiered criteria. For MOAs with large databases, addi-
tional screening criteria were applied through manual curation of the articles. The
evidence gathering process was documented as a literature tree, clearly describing
each step of the search, inclusion/exclusion, and curation. Studies satisfying the as-
sessment criteria were summarized into evidence tables. Narratives for each liver
cancer related MOA were composed. Literature was organized in the EPA’s Health
and Environmental Research Online (HERO) database using tags in accordance
with assessment criteria. This approach streamlines and exemplifies transparent
mechanistic evidence capture and reporting for DEHP liver carcinogenicity. Large
amounts of information are effectively managed and appraised, and enabled for
analysis of concordance across studies and species in MOA determinations for haz-
ard assessment. This research was supported in part by an appointment to the
Research Participation Program for the U.S. EPA, Office of Research and
Development, administered by ORISE through an interagency agreement between
the U.S. Department of Energy and EPA. Disclaimer: The views expressed in this
abstract are those of the authors and do not necessarily represent the views or poli-
cies of the US EPA.
711 A Nonparametric Bayesian Approach for Benchmark Dose
Estimation from Continuous Data.
K. Shao1,  J. S. Gift2,  L. Kopylev3 and W. A. Chiu3. 1NCEA-ORISE, US EPA,
Research Triangle Park, NC; 2NCEA, US EPA, Research Triangle Park, NC; 3NCEA,
US EPA, Washington DC.
The current approach for benchmark dose (BMD) estimation from continuous
data (e.g., body weight, relative liver weight), proposed by Crump (1984) and used
in EPA’s BMD software (BMDS), models the responses at each dose level as a pop-
ulation described by mean and variance. Then, various dose-response models (e.g.
Hill, Exponential, Power and Polynomial) and variance models are fit to the means,
and the model parameters, as well as the variance, are estimated using the maxi-
mum likelihood estimation (MLE) approach for BMD calculation. Due to limited
data, a common situation in risk assessment, the selection of a particular model and
modeling assumptions such as the distribution of the responses (i.e., normal or log-
normal distribution) is usually based on limited biological and toxicological infor-
mation and empirical fit. Consequently, the selection of appropriate BMD and
BMDL estimates from the results of a set of acceptable dose-response models is
often criticized as being somewhat arbitrary. The non-parametric Bayesian (NPB)
approach proposed in the present study models endpoints as a single-point mean
response at each dose level without assuming the format of dose-response models or
the distribution of responses. The NPB is a data-driven approach and the only as-
sumption employed is that the curve is monotonically increasing or decreasing. The
methodology is illustrated through both existing and simulated dose-response
datasets, and compared with prevailing parametric methods available in the stan-
dard BMDS. The results of these analyses suggest that the NPB method can ade-
quately fit the data and provide comparable BMD estimates (to the standardized
models in BMDS). The NPB can provide flexibility in model fitting, and with fur-
ther research, could be refined into a promising supplemental tool for BMD esti-
mation.
712 Material Threat Assessment Chemical and Scenario Selection
Process.
J. Moser1, 2,  D. Howell1, 2 and R. Jablonski1, 3. 1Chemical Security Analysis Center,
Department of Homeland Security, Gunpowder, MD; 2Battelle Memorial Institute,
Columbus, OH; 3Edgewood Chemical Biological Center, Aberdeen Proving Ground,
MD.
The Department of Homeland Security (DHS) Chemical Security Analysis Center
(CSAC) and the Department of Health and Human Services (DHHS) Biomedical
Advanced Research and Development Authority Division of Analytic Decision
Support (BARDA ADS) jointly assess public health hazards and consequences re-
lated to potential chemical agent attacks on the U.S. homeland. To provide a realis-
tic appraisal of the type of threats chemical agents pose to the U.S. populace, the
CSAC and BARDA ADS evaluate a broad range of chemicals to assess an adver-
sary’s potential to cause significant adverse consequences. This is accomplished
through the development of Material Threat Assessments (MTAs), which examine
the potential acquisition of a chemical and whether effective dissemination on a tar-
get can cause significant severe or lethal effects. Each MTA consists of an analysis of
a single chemical or group of chemicals that have a similar mechanism of action,
while modeling these chemicals across a standard set of scenarios to enable compar-
ison among chemicals and scenarios. MTAs include a comparison of public health
consequences of a chemical attack with and without the use of consequence miti-
gating countermeasures. This presentation describes how the Chemical Terrorism
Risk Assessment (CTRA) is used to inform the MTA process and describes the
tools and assumptions employed to select high risk and high consequence chemicals
and scenarios.
713 Use of REACH Registration Data for Improving Thresholds
of Toxicological Concern (TTC).
V. Mostert1,  N. Wieneke1,  C. Wiegand1,  C. Jakupoglu1,  M. Sica1,  G. Werle-
Schneider2 and N. Jägemann2. 1ICB EHS TOX-L, Dr. Knoell Consult GmbH,
Leverkusen, Germany; 2ICB TOX-C, Dr. Knoell Consult GmbH, Mannheim,
Germany.
The Threshold of Toxicological Concern (TTC) concept is utilised to identify
human exposures that are so low that in-depth toxicological investigations are ex-
pendable. This is called “exposure-based waiving”.
Exposure-based waiving serves to focus available resources on substances with rele-
vant human exposure potential.
Important work into establishing TTC values has been published by Munro et al.
(1996). The initial report used a database of 613 organic substances compiled from
publicly available sources. In total, 2941 NOELs were collected in this fashion. The
Munro concept used the Cramer classification to categorise substances according to
their hazard potential.
We broadened the TTC database by including NOAELs published on the EChA
website as per 19 July 2012, containing data for more than 7600 substances. Only
non-gaseous mono-constituent substances with oral NOAELs were included in the
TTC database. Organophosphates and genotoxic substances were excluded from
the database as well as NOAELs obtained for surrogate substances. NOAELs for all
systemic endpoints (general toxicity, developmental toxicity, fertility, neoplasia)
were taken into account. Where appropriate, default assessment factors of up to 6
were used to establish chronic NOAELs for each substance.
For every eligible substance, we collected the published CLP category for acute oral
toxicity as a potential predictor of overall hazard potential. This gives rise to five
categories of acute oral toxicity.
A TTC is calculated from the 5th percentile of NOAELs in each of these categories
using the REACh rules for establishing DNELs for workers and the general popu-
lation.
This poster presents the preliminary results for more than 1500 substances. The re-
sults indicate that the TTC concept becomes more robust when using the very
broad EChA database. It also suggests that acute oral toxicity categories can be used
as a predictor for the overall hazard potential of a substance.
714 Evaluation of the Toxrtool for Assessing Quality of
Toxicological Studies for Risk Assessments.
D. Segal1,  S. Makris1,  D. Bergfelt1,  A. D. Kraft1,  A. Bale1,  K. Raffaele1,
K. Crofton3,  M. E. Gilbert3,  M. Selgrade2,  R. Blain2 and K. Fedak2. 1US EPA,
Washington DC; 2ICF International, Durham, NC; 3US EPA, Research Triangle
Park, NC.
In order to improve transparency and consistency, both the European Union and
National Academy of Sciences have recommended the standardization and docu-
mentation of criteria used to evaluate the quality of studies considered in health risk
assessments of xenobiotics. Although peer reviewed publication is an important cri-
terion for judging scientific data, the quality of studies and reporting of results vary
tremendously. To find a means to efficiently assess the quality of these studies, we
evaluated a publicly available algorithm (Toxicological data Reliability assessment
Tool, ToxRTool) recently developed by the European Commission. The ToxRTool
builds on the Klimisch score, a method for categorizing the reliability of toxicolog-
ical studies, but adds important criteria that should be present in a high-quality
journal article used to support health risk assessments. To evaluate the ToxRTool,
20 peer-reviewed studies on thyroid disrupting chemicals were selected, ranging in
quality from excellent to poor as determined a priori by a thyroid expert on the
team. Eight scientists with various levels of expertise then used the ToxRTool to
evaluate the papers, and the consistency and reliability of scores were compared
across evaluators. Scores were most consistent for previously judged ‘high-quality’
papers with greater variability among scores as the quality of papers diminished.
The basis for inconsistencies appeared to be related to the subjective nature and lack
of clarity for responding to many criteria. In conclusion, by providing more objec-
tive criteria and better instructions for responding, the ToxRTool would likely be
extremely useful for systematic evaluations of peer reviewed studies being consid-
ered for health risk assessments.
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(Disclaimer: The views in this abstract are those of the authors and do not necessar-
ily reflect the views or policies of the EPA.)
715 GO-Quant Systems-Based Quantitative Analysis of Dynamic
Signaling Pathways during Neurodevelopment and
Implication for Risk Assessment.
X. Yu and L. Xu. Environmental Health Science, University of Georgia, Athens, GA.
The most critical biological process during neurodevelopment is the timely con-
trolled signaling pathways. Many reports provided qualitative data demonstrating
the critical role of neuro-developmentally related pathways. However, only few
have provided quantitative evaluation of the dynamic pathways during these
processes. These differences in dynamic signaling pathways are believed to be
tightly associated with the sensitivity of window of exposure to toxicants, but still
have not been clearly examined. Genome-wide scale evaluation of gene expression
has proven to be a powerful tool in understanding molecular mechanism during
neurodevelopment. Thorough analysis of these genomic data during development
will inevitably lead to a greater understanding of how changes in transcriptome re-
late to functional and structural changes in the neurodevelopment. However, the
integration of these gene expression data into a description of dynamic signaling
pathways within specific events of development has proven to be a difficult task.
We constructed and established meta-database for neurodevelopment and applied
systems-based GO-Quant program to quantitatively map the developmental stage-
specific landmark of signaling pathways. Our GO-Quant analysis with rat gene ex-
pression array data demonstrated the dynamic changes of multiple signaling path-
ways during different stages of development. The mapping of the dynamic
pathways greatly improves our understanding of time-dependent role of each sig-
naling pathway during neurodevelopment. The systems-based identification of de-
velopmental stage-specific landmark signaling pathways helps to create sensitive,
breakthrough early biomarkers for neurodevelopmental toxicity.
716 Safety Assessment of a Novel Antibiotic Using a Mouse
Population-Based Approach Predicts Risk of DILI in
Humans Where Classical Models Fail.
M. Mosedale1,  C. Kurtz1,  J. Eaddy1,  K. Adkins2,  H. Wu2,  P. B. Watkins1, 3 and
A. H. Harrill1, 3. 1The Hamner Institutes for Health Sciences, Research Triangle Park,
NC; 2Pfizer, Inc., Groton, CT; 3The University of North Carolina at Chapel Hill,
Chapel Hill, NC.
Development of the macrolide antibiotic PF-04287881 was suspended following
elevations in liver function tests observed in a Phase I clinical trial. The potential for
drug-induced liver injury (DILI) due to this compound was not predicted by stan-
dard nonclinical toxicology studies. We hypothesized that a mouse diversity panel
(MDP), comprised of genetically diverse inbred strains, could predict the DILI po-
tential of PF-04287881. Additionally, using the MDP offers the ability to identify
genetic loci that underlie PF-04287881 DILI susceptibility. In this study, we col-
lected serum and liver tissue from 34 mouse strains treated with PF-04287881 (600
mg/kg, i.g.) or vehicle once daily for 7 days. Significant elevations in serum alanine
aminotransferase (ALT) levels in PF-04287881-treated animals relative to vehicle-
treated controls were observed in 31 of the 34 strains (p<0.05). The average fold
change in ALT varied greatly across strains (from 1.6 - 14.2). Microscopic findings
of single cell necrosis, hepatocellular hypertrophy and Kupffer cell vacuolation were
observed together or individually depending on strain. Genome wide association
analysis conducted using ALT fold change identified 51 significantly associated sin-
gle nucleotide polymorphisms, 12 of which occurred in known genes. These genes
are involved in pathways important for transcriptional regulation, mitochondrial
function, and cell structure and signaling. Taken together, these data support our
hypothesis that the MDP can predict DILI liability for compounds without a clear
hepatotoxicity signal in standard preclinical species. These findings also demon-
strate the potential for this population-based approach to improve human risk as-
sessment in drug-safety testing as well as yield mechanistic insights into the toxicity
mechanisms via pharmacogenetic investigation.
717 An Investigation of Factors Associated with Mortality
Patterns across the Midwestern United States.
M. P. Chan. Environmental Sciences Program, Southern Illinois University
Edwardsville, Edwardsville, IL.
Various studies have indicated that mortality rates are positively correlated with so-
cial inequalities, air pollution, elevated ambient temperature, age, availability of
medical care and other factors. This study develops a model that uses indicators for
multiple factors to predict the mortality rates for selected diseases by county across
the Midwestern United States. A total of 1,055 counties from 12 states in the
Midwestern region were studied. Systematic random sampling was used to select a
subset of counties from the 1,055 counties to validate the model. Appropriate sta-
tistical analyses were used to predict the relationship between environmental pollu-
tants, socio-economic factors, risk factors, social capital, weather, crime, social and
other factors to explain variations in county-specific mortality rates for the leading
causes of death and lifespan in the US. It is anticipated that this study would sug-
gest the complex inter-relationships of multiple factors that influence mortality and
lifespan, and suggests the need for a better understanding of the pathways through
which these factors, mortality, and lifespan are related at the community level, par-
ticularly in urban versus rural settings. The resulting findings might assist policy
makers at local, state, and federal levels in developing effective prevention strategies
in this region.
718 Establishment of the Cumulative Margin of Exposure for a
Group of Polychlorinated Biphenyl (PCB) Congeners.
F. Kalantari1,  C. Bergkvist1,  M. Berglund1,  E. Fattore3,  A. Glynn2,
H. Håkansson1 and S. Sand2. 1Karolinska Institutet, Stockholm, Sweden; 2National
Food Agency, Uppsala, Sweden; 3Institute for Pharmacological Research, Milano, Italy.
Due to the fact that humans are exposed to mixtures of chemicals, the development
of methods that can assess the combined risk resulting from cumulative exposure to
a several chemicals is of high interest. The aims of this study were: (1) to estimate a
cumulative margin of exposure (MOE) for a group of polychlorinated biphenyls
(PCBs) using reduction of hepatic vitamin A as an example endpoint; (2) To com-
pare a relative potency factor (RPF) based approach with a RPF-free approach for
estimating the cumulative MOE.
The MOE was defined as the ratio between a reference dose, derived using the
benchmark dose (BMD) approach (based on experimental dose-response data), and
the estimated human dietary PCB exposure. A distribution for the cumulative
MOE was established, taking into account inter- and intra-individual variability as
well as uncertainty in data measurements. The cumulative MOE reflected mainly
the MOE for PCB 126; other PCB congeners had little contribution to the cumu-
lative exposure and MOE. The median of the 0.1st percentile for the cumulative
MOE was about 20 for women; depending on the percentile, the cumulative MOE
was 2 - 4 times higher for men compared to women. Furthermore, a relative po-
tency factor (RPF) based approach was compared to an RPF-free approach for esti-
mating the cumulative MOE. The RPF-free approach more completely accounts
for variability and uncertainty on the other hand, the RPF-based approach is less
data intensive and can be more easily implemented in practice, allowing for a use of
existing data on RPFs. Consideration of the discussed approaches may contribute
to improving cumulative health risk assessments.
719 A Prototype for Integrating Toxicokinetics into the Human
Health Risk Assessment Process for Agrochemicals:
Sulfoxaflor.
C. Terry1,  M. Aggarwal1,  A. T. McCoy2,  L. G. McFadden2,  R. J. Rasoulpour2,
M. Bartels2 and R. Billington1. 1Human Health, Dow AgroSciences, Oxfordshire,
United Kingdom; 2The Dow Chemical Company, Midland, MI.
Toxicokinetics (TK) has played a central role in the pharmaceutical industry for
decades and this data can provide valuable information for human health risk as-
sessment. However, historically, limited internal dose data have been routinely gen-
erated for agrochemicals. In recent years this trend has begun to change; the main
drivers for this being: ILSI/HESI-ACSA principles, new EU Regulation
(1107/2009 EC) and OECD guidelines.
Integrated TK in toxicity studies is now routine at Dow AgroSciences for all new
active substances. This approach involves no additional animal usage. 
This abstract describes the advantages of integrated TK to each stage of the risk as-
sessment process and specific examples are provided from the toxicology pro-
gramme of the new insecticide, sulfoxaflor, to show that integrated TK allows:
1. Hazard identification: 
a. More relevant routes of administration for toxicity studies – compari-
son of systemic dose across different routes of exposure, for example in rat and rab-
bit developmental toxicity studies.
b. Kinetically-derived maximum dose approach – allowing more appro-
priate dose levels to be selected for the mouse carcinogenicity study, for example.
2. Dose-Response Assessment: 
a. All life-stages of test species to be addressed – application of TK data in
developmental and reproduction studies, for example.
3. Exposure Assessment: 
a. Refinement of default ‘external’ (mg/kg bw/day) exposure assessments –
for example, use of TK data from animals in ‘TK Modeler’, to predict systemic
human exposure.
4. Risk Characterisation: 
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a. Integrated Mode-of-Action (MoA) and human relevance investigations
– for example, anchoring in vitro MoA test concentrations to the in vivo effect lev-
els in animals.
b. Setting of ‘internal’ Reference Doses (RfDs) – for example, proposing
the corresponding blood concentration from critical in vivo studies used to set
RfDs (such as the acceptable daily intake (ADI) or acute reference dose (ARfD), as
an ‘internal’ RfD.
720 Refinement of the Exposure Component of the Human
Health Risk Assessment Process for Agrochemicals:
Development of a Simple Tool.
A. T. McCoy1,  C. Terry2 and G. Drummond2. 1The Dow Chemical Company,
Midland, MI; 2Dow AgroSciences, Milton Park, United Kingdom.
Traditional human health risk assessments include Uncertainty Factors (UFs) to ac-
count for toxicokinetic (TK) and toxicodynamic differences between animals and
humans. Predictions of systemic exposure in humans, based on animal TK data or
measured human biomarker levels, could allow for science-based refinements in the
UFs related to interspecies differences in TK. These refinements could provide
more realistic reference dose values, while predictions of human blood levels could
help to inform calculations of biomonitoring equivalents.  
The aims of this project were two-fold. The first was to develop a user-friendly
modeling method that could accurately predict systemic bioavailability via par-
enteral exposure routes (i.e. dermal) in humans. Ideally, this model could predict
exposure levels in both urine and blood. The second was to utilize animal TK data
(measured or modeled from alternate exposure routes) to predict systemic exposure
in humans from either occupational, bystander or residential exposures, using a
simple TK modeling approach. 
TK Modeler is an Excel-based program developed for prediction of blood levels of
a test material and optimal sampling time selection for TK analysis. This program
was successfully used to predict human blood levels, both, after exposure by par-
enteral routes (dermal), and using data derived only from animals. Three data-rich
Dow AgroSciences molecules were used as case studies: haloxyfop, triclopyr and pi-
cloram. Attempts were made to achieve both of the above aims with each molecule,
though this was not always possible due to limited available data. Overall, accurate
predictions of human blood levels were achieved in most cases where adequate data
were available. The only exceptions were due to large species differences between
animal and human kinetics. A greater understanding of these animal/human sys-
temic exposure comparisons will help to reduce interspecies uncertainty related to
TK that are used in regulatory risk assessments.
721 An Approach for Characterizing Uncertainty in Relative
Potency Factors.
H. Carlson-Lynch1,  J. Stickney1,  A. Bacom1,  G. Diamond1,  B. Thayer1,
P. McClure1,  L. Flowers2,  C. Chen2,  M. Gehlhaus2 and M. Pratt2. 1SRC, Inc.,
East Syracuse, NY; 2US EPA, Washington DC.
Relative potency factors (RPFs) for cancer may be calculated as the ratio of the
slopes of two dose-response curves, each estimated by linear extrapolation from a
benchmark dose (BMD) value. BMD values are subject to uncertainties stemming
from study design features such as dosing interval and numbers of animals tested, as
well as uncertainties pertaining to modeling, such as model choice, goodness-of-fit,
and choice of benchmark response (BMR) relative to the observable data range.
Quantitative characterization of the uncertainty in a RPF estimate is desirable both
for comparing different estimates and for use in characterizing uncertainty in risk
estimates obtained with a RPF. Because it is estimated as a ratio, a RPF poses cer-
tain challenges with respect to statistical approaches to characterizing uncertainty.
Analytic approaches to calculating a confidence interval for a ratio (e.g., Hinkley
1969) were explored as a means of characterizing the uncertainty in a number of
RPF estimates for benzo[b]fluoranthene (relative to benzo[a]pyrene). In addition, a
Monte Carlo simulation method was investigated. For both approaches, the RPF
estimate was simplified as a ratio of BMDs estimated at the same BMR (10% extra
risk), and the standard error of the BMD was approximated using the upper and
lower 90% confidence limits reported by the BMD software.  For the Monte Carlo
method, the benchmark dose was simulated as a lognormal distribution. Each iter-
ation of the Monte Carlo simulation consisted of random samples from the proba-
bility distributions of BMDs for benzo[b]fluoranthene and benzo[a]pyrene, and
calculation of an RPF for each random draw. The Monte Carlo simulation ap-
proach, unlike the analytic approach, provided plausible confidence limits and
therefore, useful quantitative estimates of the uncertainty in the RPFs. (The views
expressed are those of the authors and do not necessarily reflect the views or policies
of the U.S. EPA).
722 The Chemical Terrorism Risk Assessment Medical Mitigation
Model: Approach, Toxicology, and Medical Endpoints.
D. Winkel1,  M. T. Whitmire2,  K. Good1 and J. A. Cox2. 1Battelle Memorial
Institute, Columbus, OH; 2DHS Chemical Security Analysis Center, Gunpowder,
MD. Sponsor: H. Salem.
The Chemical Terrorism Risk Assessment (CTRA) is a probabilistic risk assessment
that considers threat, vulnerability, consequences, and mitigation to yield a com-
prehensive estimate of chemical terrorist risk to the Nation. The Medical
Mitigation (MedMit) model is a key component of the CTRA; it is a stock and
flow model with parameters defined by toxicology and emergency medicine subject
matter experts. The MedMit model estimates the number and type of injured vic-
tims according to dose, and determines the number of victims that may be saved or
benefitted by the public health response. This presentation will discuss the ap-
proach to parameter quantification. It includes the definition of chemical-specific
toxicity values for life-threatening, severe, and mild to moderate injury types, the
desire and benefits of including these different victim types in the Medical
Mitigation model, the segregation of more than 100 chemicals into toxidromes,
and the data collection process. The application of toxicology to the CTRA enables
a more realistic representation of event consequences and the public health re-
sponse. Consequently, the model makes it possible to assess the effectiveness of the
existing public health response system and examine improvement strategies. Such a
capability permits policy makers to make informed decisions regarding resource al-
location, and assists responders’ understanding of chemical terrorist events and
areas of potential improvement.
723 A Decision Tool for Assessing Polymers and Polymeric
Substances with Potential Hazards to Human Health.
B. K. Gadagbui1,  A. Maier1,  P. Nance1,  M. Jayjock2 and C. Franklin2.
1Toxicology Excellence for Risk Assessment, Cincinnati, OH; 2The LifeLine Group,
Annandale, VA.
Polymers display a wide variety of characteristics – e.g., presence of non-bound
residual monomers, polymerization chemicals, degradation products, and additives
– that may pose a potential health hazard. There is a paucity of direct testing data
on many polymers to adequately evaluate their toxicity, but several regulatory agen-
cies have provided guidance for assessing polymer safety. We evaluated each of these
approaches and identified the strengths and weaknesses of each. No single pub-
lished model appears to cover all characteristics of interest. This suggests the need to
develop a comprehensive decision tool to identify polymeric substances that may
pose potential toxicological hazards to human health. We developed a decision tool
that incorporates a weight of evidence approach integrating information for many
individual hazard flags. Hazard flags were placed into four broad categories: (1) em-
pirical hazard information on the polymer or residual monomer; (2) evidence of
toxicity based on structural properties (i.e., based on polymer class, monomer com-
ponents, or reactive functional groups); (3) potential for significant tissue dose (i.e.,
based on molecular weight distribution or systemic bioavailability); and (4) hazard
based on foreseeable special use considerations. Some of these hazard flags have not
been considered previously by the regulatory agencies. We tested this approach for
a number of polymers to demonstrate how the new tool (integrates) incorporates all
available regulatory approaches as well as the new features and provides a compre-
hensive decision framework for evaluating polymer safety.
724 The h-NAG-1 Transgenic Mouse Serves As an Animal Model
for Obesity.
G. J. Moser1,  K. Chrysovergis2,  J. Kosak2,  J. Kim2,  M. Nixon1,  E. Gilas1,
M. Streicker1 and T. Eling2. 1Investigative Toxicology, Integrated Laboratory Systems,
Inc., Durham, NC; 2NIEHS, Research Triangle Park, NC.
NSAIDS-activated gene-1 (h-NAG-1) transgenic mice (C57BL/6-Tg(CAG-
GDF15) over express human NAG-1/ Growth/differentiation factor-15 (GDF15).
Hemizygous h-NAG-1 mice are significantly leaner than their wild-type littermates
and have less abdominal white fat despite comparable food intake. To improve our
understanding of the mechanisms of obesity development, h-NAG-1 mice and WT
were put on a 10 or 60% diet for 12 weeks and blood was collected. Final body and
abdominal white fat weights were increased in WT relative to h-NAG-1 mice. The
h-NAG-1 mice on the high and low fat diet had lower circulating levels of the in-
flammatory adipokine leptin, although the difference on the high fat diet was much
greater (3.5 +/- 1.1; h-NAG-1 and 55.4 +/-8.7 ng/ml; WT) than on the low fat diet
(2.3 +/- 0.7; h-NAG-1 and 15.8 +/-6.8 ng/ml; WT). Similarly, serum insulin levels
were significantly decreased in h-NAG-1 mice on both diets. Because obesity, via
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higher leptin levels, can increase inflammatory responses, hNAG-1 mice and WT
were injected with the inflammatory agent lipopolysaccharide (LPS) and serum in-
flammatory cytokine measured. The levels of KC, IL-6, MCP-1 and TNFα were
lower in the leaner h-NAG-1 transgenic mouse. The data indicate the h-NAG-1
mouse may serve as a model for investigating obesity and how environmental expo-
sures may be altered by obesity.
725 Extended Exenatide Treatment Causes Pancreatic Stress and
Injury in a Rodent Model of Insulin Resistance.
R. L. Rouse,  S. R. Stewart,  B. A. Rosenzweig,  K. L. Thompson,  K. I. Shea,
D. G. Goodwin and J. Zhang. CDER, US FDA, Silver Spring, MD.
A possible association between use of the anti-diabetic drug exenatide and acute
pancreatitis has been suggested by the analysis of post-approval adverse event data
but remains controversial. Studies were undertaken to determine whether an ani-
mal model could be developed to reveal potential safety signals consistent with pan-
creatitis following exposure to drug. Subcutaneous exenatide injection (3, 10, or 30
μg/kg for 6 weeks) of Sprague-Dawley rats, caerulein-treated rats, and Zucker fatty
diabetic rats demonstrated no consistent histopathologic pancreatic injury signal on
standard chow or a high fat, high carbohydrate diet (HFD). However, C57BL6
mice placed on HFD for 6 weeks exhibited a dose and time dependent pancreatic
responses to single daily subcutaneous exenatide injections (3, 10, or 30 μg/kg, for
up to 12 weeks) that were exacerbated by the HFD. Focal areas of acinar cell necro-
sis progressing to edema, inflammation, and general tissue fibrosis and atrophy
were identified in control mice but were much more prevalent in exenatide treated
mice. Other findings included acinar cell hypertrophy and hyperplasia with in-
creased incidence of autophagy and apoptosis in proportion to necrosis and inflam-
mation. Regardless of exenatide exposure, mice on HFD had increased body weight
and significantly elevated blood glucose and serum pro-inflammatory cytokines
compared to mice on standard chow. The type of stress and injury produced in this
study do not approximate the acute necrotizing pancreatitis described in adverse
event reports but represent a reproducible pancreatic signal that might be useful for
the preclinical safety evaluation of pancreatic injury induced by anti-diabetic drugs.
726 Adipose Deficiency of Nrf2 in Ob/Ob Mice Results in Severe
Metabolic Syndrome.
P. Xue,  Y. Hou,  Y. Chen,  B. Yang,  J. Fu,  H. Zheng,  K. M. Yarborough,
C. G. Woods,  Q. Zhang,  M. E. Andersen and J. Pi. The Hamner Institutes for
Health Sciences, Durham, NC.
Nuclear factor E2-related factor 2 (Nrf2) is a transcription factor that functions as a
master regulator of the cellular adaptive response to oxidative stress. Our previous
studies showed that Nrf2 plays a critical role in adipogenesis by regulating expres-
sion of CCAAT/enhancer-binding protein β and peroxisome proliferator-activated
receptor γ. To determine the role of Nrf2 in the development of obesity and associ-
ated metabolic disorders, the incidence of metabolic syndrome was assessed in
whole body or adipocyte-specific Nrf2–knockout mice on a leptin-deficient ob/ob
background, a model with an extremely positive energy balance. On the ob/ob
background, ablation of Nrf2, globally or specifically in adipocytes, led to reduced
white adipose tissue (WAT) mass, but resulted in an even more severe metabolic
syndrome with aggravated insulin resistance, hyperglycemia and hypertriglyc-
eridemia. Compared to wild-type, WAT of ob/ob mice expressed substantially
higher levels of many genes related to antioxidant response, inflammation, adipoge-
nesis, lipogenesis, glucose uptake and lipid transport. Absence of Nrf2 in WAT re-
sulted in reduced expression of most of these factors at mRNA and/or protein lev-
els. Our findings support a novel role for Nrf2 in regulating adipose development
and function, by which Nrf2 controls the capacity of WAT expansion and insulin
sensitivity and maintains glucose and lipid homeostasis.
727 Effect of a Purified Openstandard Diet (OSD) on Body
Weight (BW), Adiposity, and Glucose Tolerance (GT) in
Male C57BL/6 Mice.
M. A. Pellizzon,  M. R. Ricci and E. A. Ulman. Research Diets, Inc., New
Brunswick, NJ. Sponsor: P. Marone.
Purified diets (PDs) offer biologists the ability to have fine control over diet com-
position compared to grain-based chows which often contain phytoestrogens and
toxic heavy metals. However, common PDs such as the AIN-76A (76A) and AIN-
93G (93G) may predispose rodents to moderate elevations in BW, blood and liver
lipids, and reduced GT, vs. chows. The relatively higher levels of sucrose, lower total
fiber (~5% in PDs vs. ~20% in chow) and lack of soluble fiber in PDs (0 vs. ~2%
in chows) may be responsible for these effects. Therefore, we tested two new PDs
for their metabolic effects vs. chow (Purina 5002), 76A and 93G: 1) a PD with no
sucrose and 9% fiber (7% insoluble, 2% soluble fiber; OSD) and 2) OSD with a
fiber level and type similar to chow (18% insoluble, 2% soluble fiber; OSD+F). 75
weanling male C57BL/6N mice (n=15/grp) were fed ad-lib for 88 days. Other than
BW (weekly) and an oral GT test (OGTT; day 83), all other measures (adiposity
index [AI=adipose depot wt*100/carcass wt]), liver triglycerides [TG], 6 hr fasted
serum glucose, insulin and leptin were terminal. Baseline (17±0.4 g) and terminal
BW (31±1 to 37±1) were similar for all groups, but BW gain over time in OSD and
93G was higher (~2.3 g, p<0.05) vs. other groups. AI was similar in all groups but
higher in OSD vs. 93G (13±0.004% vs. 11±0.01%, p<0.05). Serum leptin was
higher in OSD (34±1 ng/ml) and 93G (36±2) vs. chow (22±3) and OSD+F (23±2,
p<0.05). All groups had similar fasting glucose and insulin. Glucose area under the
curve during OGTT was higher (p<0.05) for 76A (38,400±2,500 mg/dl/120 min)
and 93G (36,500±3,000) vs. both chow (27,300±1,400) and OSD
(26,400±1,600), while OSD+F (32,400±1,800) was intermediate and not different
from 76A and 93G or chow and OSD. Liver TG levels were no different between
chow (4.5±0.2 mg/g), OSD+F (8±1) and 76A (6.5±1) but were higher (p<0.001)
for OSD (10±1) and 93G (10±1). These data suggest that PDs with no sucrose and
higher fiber can improve GT over established PDs.
728 Development of an Oral Exposure Model to Predict Drug
Hypersensitivity Using Brown Norway Rat.
A. Tamura,  I. Miyawaki,  T. Yamada,  J. Kimura and H. Funabashi. Safety
Research Laboratories, Dainippon Sumitomo Pharma Co., Ltd., Osaka, Japan.
Background: It is important in new drug development to evaluate the potential of
drug hypersensitivity as well as the other adverse effects in non-clinical study, but
validated methods are not available yet. Brown Norway (BN) rat is a strain that
seems susceptible to substances that induce immune-mediated adverse reaction,
and thus this particular strain has been used in studies on chemical-induced au-
toimmunity and food allergy. In the present study we examined whether it would
be possible to develop a new predictive model of drug hypersensitivity using BN
rat.
Methods: As representative drugs with the potential of drug hypersensitivity in hu-
mans, phenytoin (PHT), carbamazepine (CBZ), amoxicillin (AMX), and sul-
famethoxazole (SMX) were orally administered to BN rats for 28 days to investigate
their effects on these animals. The examinations included observation of clinical
signs, hematology, determination of serum IgE levels, histology, and flow cytomet-
ric analysis of lymphocyte subsets.
Results: Skin rashes similar to what are often seen in humans were not observed in
any animals treated with these drugs. Circulating inflammatory cells and serum IgE
levels increased only in the animals treated with CBZ and SMX. Only germinal
center hyperplasia was commonly noted in spleen and/or mesenteric lymph nodes
in the animals treated with all the drugs. The changes of proportions of lymphocyte
subsets were only noted in spleen of the animals treated with PHT and CBZ for 7
days and not for 28 days.
Conclusion: The potential of drug hypersensitivity was detected in BN rats by per-
forming histological examination of secondary lymphoid organs/tissues. The pres-
ent data suggested that BN rat could provide a useful animal model to evaluate the
potential of drug hypersensitivity. Compared to existing models, the advantages of
using this model are capable to evaluate 1) by oral administration, 2) not using re-
porter antigen, and 3) in easy method (general histological examination).
729 Behavioral, Neurochemical and Histological
Characterization of a Novel MitoPark Mouse Model for
Neurotoxicity and Neuroprotection Studies.
M. R. Langley,  A. Ghosh,  M. Ay,  A. Kanthasamy,  H. Jin,  V. Anantharam and
A. G. Kanthasamy. Biomedical Sciences, Iowa Center for Advanced Neurotoxicology,
Iowa State University, Ames, IA.
Parkinson’s disease is now recognized as a neurodegenerative condition caused by a
complex interplay of genetic and environmental factors. The animal models
presently available, created by neurotoxic insults or genetic defects, do not fully re-
capitulate the chronic and progressive nature of the nigrostriatal dopaminergic neu-
rodegenerative process. Recently, the MitoPark mouse model was created by inacti-
vation of mitochondrial transcription factor Tfam in the nigrostriatal pathway
through the control of a DAT promoter. In this study, we tested the utility of
MitoPark mice for neurotoxicological and neuroprotective studies using behavioral,
neurochemical and histological analyses. Measurement of locomotor activity in
MitoPark mice over 8-25 weeks revealed that motor function started to decline at
12 weeks of age and progressed over time, leading to severe deficits at 17-25 weeks.
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MitoPark mice also showed a dramatic loss of striatal dopamine and its metabolites
compared to wild type C57 mice. In order to determine the gene-environmental in-
teraction, we exposed MitoPark mice to Mn (10 mg/kg, p.o) daily for 30 days.
Motor deficits were significantly exacerbated in Mn-treated Mitopark mice begin-
ning at week 10 compared to vehicle treated MitoPark mice. The depletion of stri-
atal dopamine, DOPAC and HVA content in MitoPark mice was exacerbated in
Mn-treated MitoPark mice. We also evaluated the neuroprotective efficacy of a
novel mitochondrial-targeted antioxidant, mitoapocynin. Oral administration of
mitoapocynin (10 mg/kg, p.o) three times a week to MitoPark mice through 13-24
weeks of age restored behavioral deficits, striatal dopamine depletion and TH neu-
ronal cell loss in MitoPark mice. Our results demonstrate that the MitoPark mouse
is an excellent model to study the gene-environmental interactions associated with
mitochondrial defects in the nigral dopaminergic system as well as to evaluate the
neuroprotective efficacy of novel neuroprotective agents.
730 Continuous Infusion in Genetically-Altered Down Syndrome
Mice.
H. van Wijk. Covance Laboratories Ltd., Harrogate, United Kingdom. Sponsor: S.
Kirk.
Performing femoral vein catheterisation surgery with tail cuff exteriorisation di-
rectly at the performing laboratory offers various advantages. Implanted mice avoid
transport from a third party supplier post-surgery. This reduces the risks associated
with post operative transport (expression of disease), requires a shorter total recov-
ery time, and allows utilisation of unusual strains not surgically available.
In this study we investigated the feasibility of performing femoral vein catheterisa-
tion with tail cuff exteriorisation surgery in-house on B6EiC3Sn a/A-
Ts(1716)65Dn (Ts65DN) Euploid Ts65Dn mice (Jackson Laboratories, Bar
Harbour, Maine, USA) to avoid tube restraint necessary for iv bolus administration
and allow behavioural monitoring.
Ts65Dn is a widely accepted mutant strain model of Down’s syndrome allowing as-
sessment of medicines for potential unwanted side effects in disease patients. The
chromosomal complement of the Ts65Dn mouse is incomplete relative to conven-
tional mice; however the animals do not require special husbandry conditions,
housing or maintenance and are considered to show normal behaviour in most re-
spects. They are not affected by heart abnormalities common in humans affected by
Down’s Syndrome.
The mean bodyweight of the control euploid mice is greater than the Ts65Dn mice
(~ 40g and 30g respectively). The mean body length for Ts65Dn mice is shorter (~
1 cm nose - base of tail; 1.5 cm nose - tip of tail) presenting challenges in surgery
and tail cuff attachment. To ensure tail size was not likely to impede exteriorisation
of the catheter, a range of tail cuff sizes were used.
Of the 16 Ts65Dn and 16 wild type mice that were surgically prepared, only one
Ts65Dn mouse failed to recover and was humanely killed three days post surgery.
No unexpected clinical signs were seen after surgery and infusion and body weights
started to regain six days post surgery, which is quicker than previously described by
Arts et all 2012.
In conclusion, in-house catheterisation of Ts65Dn mice was shown to be more hu-
mane than obtaining and transporting surgically prepared mice from a third party,
reducing the chance of disease expression.
731 Generation and Characterization of a Humanized C. elegans
Transgenic Animal That Results in Early Onset, Age-
Dependent Complete Loss of DA Neurons.
S. Jamadar,  N. VanDuyn and R. M. Nass. Pharmacology and Toxicology, Indiana
University School of Medicine, Indianapolis, IN.
Background: Parkinson’s disease (PD) is a slowly progressive neurodegenerative dis-
ease characterized by the selective loss of dopamine (DA) neurons. Despite over 50
years of intensive research into the disorder, the origin of the pathogenesis and the
molecular determinants involved in PD have not been elucidated. A significant
hindrance in dissecting these molecular components is the lack of facile in vivo ge-
netic models to explore the mechanisms involved in age-dependent cell death.
Aims/Objectives: Our goal in this study was to develop and characterize a viable C.
elegans animal that has early onset, age-dependent complete loss of DA neurons.
Methods: We utilized transgenic C. elegans, reverse genetics, biochemical assays, im-
munofluorescence, mRNA and miRNA arrays, RT-PCR, Western analysis, and
neuronal morphology analysis to characterize expression, localization and the role
of human alpha-synuclein, parkin and mutant genes in DA neuron pathology.
Results: We generated genetic crosses with C. elegans containing human A53T
alpha-synuclein, an endogenous parkin mutation and other genetic modifications.
One product of this study is the generation of a C. elegans transgenic animal that re-
sults in a robust DA neurodegeneration phenotype. Immediately after hatching, the
animals have their full complement of DA neurons as determined by confocal
analysis and DA levels by HPLC, yet animals approximately 8 days old exhibit a
complete loss of DA neurons. Our data suggests that post-translational modifica-
tions play significant roles in DA neuron vulnerability to PD-associated genes and
toxicants. Conclusions: We have generated a novel transgenic, the first animal (ver-
tebrate or invertebrate) that has a complete loss of DA neurons as a function of age.
This animal is proving to be invaluable in determining molecular basis of gene- and
toxicant-associated DA neuron vulnerability. Support: NIEHS ES014459 and
ES003299 to RN, and EPA STAR Graduate Fellowship to NVD.
732 Development of Animal Models of Idiosyncratic Drug-
Induced Liver Injury.
I. G. Metushi and J. Uetrecht. Pharmacology and Toxicology, University of Toronto,
Toronto, ON, Canada.
Background: Idiosyncratic drug-induced liver injury (IDILI) remains a serious
health problem and it also significantly increases the risk of drug development.
Unfortunately, not much is known about the mechanism of IDILI and a main rea-
son is because there are no good animal models. We set out to develop animal mod-
els of IDILI by focusing on two drugs: Isoniazid (INH) and Amodiaquine (AQ),
both of which cause IDILI in humans. Results: INH was found to covalently bind
to mouse and to a lesser extent rat liver macromolecules. Treatment of Balb C,
C57BL/6 mice, Wistar or Brown Norway rats with INH did not result in signifi-
cant liver injury. Treatment of Cbl-b-/-, PD1-/- and NAT 1/2-/- mice resulted in
mild liver injury. One possible reason that these animals did not develop more ex-
tensive liver damage is immune tolerance. Immunization of C57BL/6 mice with
S100 hepatic protein modified with INH produced a greater degree of autoim-
mune hepatitis than S100 alone, but when INH was subsequently given orally this
prevented the autoimmune hepatitis. Treatment of female C57BL/6 mice with AQ
resulted in a mild transaminase (ALT) increase at week 3 and this resolved by week
5. Immunohistochemical staining and flow cytometry showed that AQ-induced
liver injury in C57BL/6 mice was associated with infiltration of immune cells such
as F4/80, CD11b, CD4, CD8 and CD45R in the liver and spleen. Treatment of
Cbl-b-/- and PD1-/- mice with AQ resulted in more severe liver injury, but ALT
still resolved despite continued treatment. Treatment of Cbl-b-/- mice with FICZ
and Anti-CD25 Ab to break immune tolerance was not effective. Treatment of
RAG1-/- mice also resulted in a mild increase in ALT but the ALT did not appear
to resolve as it did in the C57BL/6 mice. Conclusion: These data suggest that the
dominant response to these drugs is immune tolerance. Treatment of female
C57BL/6 mice with AQ results in delayed onset of mild liver injury which resolved
despite continued treatment; this is similar to what happens in humans and this
model is being further characterised. Supported by grants from CIHR.
733 Role of Myeloid-Derived Suppressor Cells in a Murine
Model of Drug-Induced Liver Injury Mediated by the
Adaptive Immune System.
M. Chakraborty,  L. S. Chea,  J. D. Berkson,  W. R. Proctor,  J. C. Morrison,
K. Semple and L. R. Pohl. Molecular and Cellular Toxicology Section, Laboratory of
Molecular Immunology, National Heart, Lung and Blood Institute, Bethesda, MD.
Although clinical evidence suggests that many cases of serious idiosyncratic drug-
induced liver injury (SIDILI) are mediated by hepatic protein adducts of drugs and
the adaptive immune system, detailed experimental proof for this mechanism of
toxicity has remained elusive due to the lack of animal models. We have hypothe-
sized that SIDILI is as rare in animals as it is in humans due at least in part to the
tolerogenic nature of the liver, which consists of multiple negative regulators of the
adaptive immune system. This idea has now been tested in an established murine
model of halothane-induced liver injury where the toxicity is initiated by the me-
tabolism of halothane to form trifluoroacetylated liver proteins and enhanced by
the innate immune system, which are prerequisites for activating the adaptive im-
mune system. Twenty-four hours after female Balb/cJ mice were treated with
halothane, analysis of the liver revealed perivenous necrosis and an infiltration of
CD11b+ Gr-1High neutrophils, as reported by other researchers. Further study re-
vealed that the neutrophils contained a subpopulation of myeloid-derived suppres-
sor cells (MDSC) that inhibited the proliferation of both CD4+ and CD8+ T cells
isolated from naïve mice. When MDSC were depleted from the liver with Gr-1 an-
tibodies prior to two treatments with halothane, enhanced liver injury was observed
nine days after the second exposure of halothane as compared to mice that were
pretreated with isotype control antibodies before halothane treatments. Moreover,
the liver injury was associated with elevated levels of hepatic T cells and serum anti-
bodies that both reacted with trifluoroacetylated liver proteins isolated from
halothane treated mice. Collectively, our data provides a rational approach for de-
veloping animal models of SIDILI mediated by the adaptive immune system and
suggests that deficiencies in liver tolerance may predispose patients to SIDILI.
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734 Defective Platelet Function in a Mouse Model of Progressive
Cholestasis.
Y. Zhang1,  F. Li2,  S. Cheepala1,  Y. Wang1,  F. J. Gonzalez2 and J. D. Schuetz1.
1Pharmaceutical Sciences, St. Jude Children’s Research Hospital, Memphis, TN;
2Laboratory of Metabolism, Center for Cancer Research, NCI, National Institutes of
Health, Bethesda, MD.
We have recently demonstrated that Abcb11-defcient mice recapitulate the human
genetic disease PFIC2 (progressive familial intrahepatic cholestasis type 2) attrib-
uted to loss of function of the ABC transporter, ABCB11 (1). Cholestatic liver dis-
eases lead to coagulopathies, however it is unclear if these are due to defects in the
liver’s production of fibrinogen and procoaguant factors or defects in platelet func-
tion. By metabolomic analysis we demonstrated that lysophosphatidylcholine
(lysoPC) (16:1 and 18:1) concentrations were elevated 2 to 5 times (vs. WT) in the
liver and sera of Abcb11-null mice before evidence of frank liver damage. Because
LysoPC inhibits platelet aggregation (2) we hypothesized that platelets of Abcb11-
null mice might have aggregation defects due to elevated serum lysoPC. Platelet
counts were comparable between the Abcb11-null mice and WT mice and platelet-
rich plasma was used to test platelet aggregation. Agonist-induced aggregation of
Abcb11-null platelets was impaired for agonists: ADP, collagen and thrombin. This
ubiquitous defect is consistent with reduced expression of dense granule marker P-
selectin and platelet receptor protein GPVI. As there are no changes in the down-
stream signaling genes Plcγ1, Syk, and FcRγ1, in platelets of Abcb11-null mice; our
results suggest that defective aggregation of Abcb11-null platelets is the result of
down-regulation of GPVI and P-selectin which may be secondary to lysoPC expo-
sure.  
1. Zhang Y, Li F, Patterson AD, Wang Y, Krausz KW, Neale G, Thomas S,
Nachagari D, Vogel P, Vore M, Gonzalez FJ, and Schuetz JD. (2012) Abcb11
Deficiency Induces. Cholestasis Coupled to Impaired beta-Fatty Acid Oxidation in
Mice. J Biol Chem 287, 24784-94.
2. Yuan Y, Jackson SP, Newnham HH, Mitchell CA, Salem HH. (1995)
An essential role for lysophosphatidylcholine in the inhibition of platelet aggrega-
tion by secretory phospholipase A2. Blood 86, 4166-74.
735 Validation of ROS As a Toxicity Marker in Zebrafish.
W. Seng,  C. Li and P. McGrath. Phylonix, Cambridge, MA.
Oxidative stress, associated with an increased level of reactive oxygen species (ROS),
is a key factor in both drug-induced toxicity and disease pathogenesis. However,
conventional methods for assessing ROS damage are labor intensive and slow ham-
pering widespread use as a toxicity marker. Because of their genetic and physiologi-
cal similarity to humans, zebrafish have shown promise as an efficient and predic-
tive animal model for assessing drug toxicity, safety and efficacy. Similar to effects in
mammals, ROS levels have been shown to increase in zebrafish after drug treatment
and irradiation. In this study, we developed a quantitative whole zebrafish mi-
croplate-based ROS assay format that relies on a commercially available fluorogenic
dye (5-[and-6]-chloromethyl-2,7-dichlorodihydrofluorescein diacetate, acetyl ester,
CM-H2DCFA). We validated the assay using 7 characterized mammalian ROS in-
ducers: TSA [Trichostatin A], PMA [4β-phorbol 12-myristate 13-acetate],
Cisplatin, DCA [Dichloroacetate], Menadione, TBHP [tert-Butyl hydroperoxide]
and Ethanol and 1 negative control compound, NAC [N-Acetyl-L-cysteine]. In
order to optimize the assay, we assessed: ROS level by zebrafish developmental
stage, linear relationship between number of animals per microwell and fluores-
cence intensity, signal to noise (S/N) ratio, effect of carrier DMSO, assay specificity,
and assay reproducibility and robustness,. 
To confirm results using the whole animal microplate format, we also visually as-
sessed site of ROS induction in transparent animals using fluorescent based mor-
phometric image analysis. Using both the microplate format and whole mount
morphometric image analysis, compared to mammals, the overall correct predic-
tion rate in zebrafish was 100%, which according to the European Centre for the
Validation of Alternative Methods (ECVAM), is considered “excellent”. These re-
sults underscore the high conservation of toxicity pathways among species and sup-
port use of the whole zebrafish ROS assay as a rapid, predictive in vivo assay for
compound screening.
736 The Effect of Fluoride on the Bones and Teeth of ICR-
Derived Gromerulonephritis (ICGN) Mice by Subacute
Exposure.
M. Hosokawa1,  C. Sugaya2,  M. Tsunoda2,  K. Itai3,  Y. Kodama4,  Y. Sugita-
Konishi4,  H. Ohta5,  Y. Ito6,  M. Shimahara6,  K. Yokoyama1 and Y. Aizawa7.
1Epidemiology and Environmental Health, Juntendo University, Tokyo, Japan;
2Preventive Medicine, Kitasato University, Sagamihara, Japan; 3Iwate Medical
University, Morioka, Japan; 4National Institute of Health Sciences, Tokyo, Japan;
5Environmental, Occupational Health and Toxicology, School of Allied Health Science,
Kitasato University, Tokyo, Japan; 6Oral surgery, Osaka Medical College, Takatsuki,
Japan; 7Kitasato University, Tokyo, Japan.
Dental fluorosis and osteofluorosis by drinking water contaminated with fluoride
(F) have been reported in China and India. Because fluoride is excreted from the
kidney, the toxic effects of F may be affected more significantly by F in ICR-derived
glomerulonephritis (ICGN) mice that have commonly been used as a model of
renal failure. In this study, we administered F to ICGN and ICR mice to compare
the effects of F on the teeth and bones between mice with and without renal failure.
Both male and female ICGN and ICR mice were administered F at the concentra-
tions of 0, 25, 50, 100, and 150 ppm in the drinking water for 4 weeks. The mice’s
femurs were sampled and photographed with a standard aluminum scale. The pho-
tographs were analyzed by microdensitometry, and the indexes calculated were:
bone mineral content and bone density. The teeth were decalcified in EDTA solu-
tion and stained with HE. All the ICGN mice exposed to 150 ppm died. However,
no ICR mice died. The mean bone density was significantly lower in the female
ICGN mice exposed to 150 ppm compared to the control. The mean mineral con-
tent and bone density of the female 100 ppm ICGN group were significantly lower
than those of the control. There were no significant differences in the bone indexes
among the male ICGN groups. In ICR mice, the mean bone mineral content and
bone density were higher in the 150-ppm group for both male and female. The het-
erogeneity of calcification of in the tooth enamel was observed in the ICGN mice
exposed to 150 ppm. The decrease in bone density in the mice exposed to F may be
due to systemic effects of F. ICR mice exposed to F may be used as a model of oste-
ofluorosis.
737 A Population-Level Mouse Model to Investigate the Genetic
Determinants of Susceptibility to Environmental Toxicants.
M. C. DeSimone1,  S. H. Jennings2,  A. B. Rogers3 and D. Threadgill1. 1Genetics,
North Carolina State University, Raleigh, NC; 2Veterinary Medicine, North Carolina
State University, Raleigh, NC; 3Pathology, University of North Carolina at Chapel
Hill, Chapel Hill, NC.
Carcinogenesis bioassays have lacked the genetic component critical for the evalua-
tion of underlying disease susceptibility genes. Here we used a systems biology ap-
proach to model the genetic heterogeneity of exposed human populations, includ-
ing the inter-individual variation in drug metabolism and transport. We developed
a novel intercross population derived from FVB/NAbcb1a/1b-/-, a multi-drug resistant
p-glycoprotein knockout mouse model, and CAST/EiJ a wild-derived strain that is
genetically distinct from the FVB/N background. Using this intercross to model
human biology, including using a western diet, environmentally-relevant doses of
trichloroethylene (TCE) and inorganic arsenic (iAs), were evaluated for their effects
on toxicity susceptibility. A study cohort of 900 FVB/NAbcb1a/1b-/- x CAST/EiJ F3
mice was divided into nine dose groups, each containing 50 female and 50 males,
and was administered TCE and sodium arsenite via the drinking water and chow,
respectively, at environmentally-relevant concentrations for 56 weeks using a dose-
ratio approach. At harvest, biofluids and tissues were either formalin fixed for
pathology, or flash frozen for molecular analysis. Mice co-exposed to TCE and iAs
developed hepatocellular carcinoma, as well as renal cysts, clear cell foci and dilated
renal tubules consistent with human renal disease pathogenesis. Whole genome ex-
pression analysis of kidney tissues revealed a distinct response signature for the
combinatorial exposures, including overexpression of oncogenes implicated in the
development of human renal cell carcinoma. Genome-wide allelotyping of each
mouse using a 7,851 SNP genotyping array will reveal the genetic variants underly-
ing toxicity response. This experimental paradigm has successfully modeled the
population-level variability in disease response and has the potential to identify in-
dividuals sensitive to toxicity.
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738 Human Antibodies Can Cross Guinea Pig Placenta and Bind
Its Neonatal Fc Receptor: Implications for Evaluating
Immune Therapy during Pregnancy.
L. Ma1,  L. Zhong1,  D. M. Toibero3,  A. Hoglund2,  J. Beren4,  M. G. Norton1,
P. Zhang1 and E. B. Struble1. 1Laboratory of Plasma Derivatives, Division of
Hematology, OBRR, CBER, US FDA, Bethesda, MD; 2Division of Veterinary
Services, CBER, US FDA, Bethesda, MD; 3University of Maryland, College Park,
MD; 4OCTEC, CDER, US FDA, Silver Spring, MD.
Disclaimer: The findings and conclusions in this presentation have not been for-
mally disseminated by the Food and Drug Administration and should not be con-
strued to represent any Agency determination or policy.
Despite increased use of monoclonal and polyclonal antibody therapies, including
during pregnancy, there is little data on appropriate animal models that could hu-
manely be used to understand determinants of protection, and to evaluate safety of
these biologics in the mother and the developing fetus. We have demonstrated that
pregnant guinea pigs can transport human IgG transplacentally at the end of preg-
nancy. Using an intravenous anti-hepatitis B specific immune globulin preparation
as an example, we show that IgG subclasses one, two and three are measurable in
both the sows and their piglets. Given that IgG4 can be transferred transplacentally
in the guinea pig, our observations indicate that all human IgG subclasses can pass
guinea pig placenta during the last third of pregnancy. In addition, we found that
all human IgG subclasses are capable of binding to a soluble form of the guinea pig
neonatal Fc receptor in vitro in a manner similar to that demonstrated for the
human variant. This result suggests that transplacental transport of human IgG
subclasses in guinea pig mirrors the receptor-based mechanism seen in humans.
Together, our studies lay the groundwork in introducing pregnant guinea pigs as an
appropriate model for the evaluation of antibody therapies during pregnancy and
advancing the health of women and neonates.
739 Gender and Perinatal Exposure to Bisphenol A Affect
Markers of Inflammation in the Brain and Spleen of Young
Rats.
J. Rodriguez-Santiago1,  Z. Varguaz-Villarrubia1,  D. R. Mierke3,
R. N. Sadowski2,  L. M. Wise2 and S. N. Lavergne3. 1Aguadilla, University of
Puerto Rico, Aguadilla, Puerto Rico; 2Psychology, University of Illinois, Urbana, IL;
3Comparative Biosciences, University of Illinois, Urbana, IL.
Bisphenol A (BPA) is an environmental estrogen disruptor that has been extensively
studied for its repro-and neurotoxicity. It has also been shown to activate the im-
mune system and to induce inflammation. This study therefore evaluated markers
of inflammation in the brain and spleen of young rats exposed perinatally to BPA.
Pregnant rats were dosed with 400 ug/kg/day of BPA during pregnancy, and rat
pups continued to be dosed during PND1-PND9; they were then weaned, and
eventually humanely euthanized at PND23. The spleens and brains were collected
and snap frozen straight away, and stored at -80’C. MHCII levels in the spleens
were estimated semi-quantitatively using immunohistochemistry. Cytokine levels
were measured in both the spleens and the brains, using a multibead kit. Female
rats had higher MHCII levels in their spleen in the vehicle group; this gender effect
was absent in the BPA exposed animals where both genders showed similarly high
levels. Spleens showed higher levels of IL-1b than brains, but IL-6 and TNFa levels
were similar in both organs. In the spleen, IL-1b and IL-6 were higher in females in
the vehicle group, but they were higher in males in BPA exposed animals; TNFa
levels were higher in females in the control group, but they were similar between
genders in the BPA group. BPA decreased IL-1b, increased TNFa, but did not affect
IL-6 in male brains. Work is underway to investigate the effect of BPA on inflam-
mation status depending on the exposure timing during development.
740 Comparing Minimal Supportive Care Models of
Hematopoietic Acute Radiation Syndrome in Nonhuman
Primates.
R. Guilmette,  M. Doyle-Eisele,  W. Weber and D. Melo. LRRI, Albuquerque,
NM.
Currently male Rhesus Macaques are the standard non-human primate model for
hematopoietic acute radiation syndrome however the availability of these animals
may limit the drug development studies conducted with treatment candidates. As
an alternative, LRRI recently performed a comparison study using male and female
cynomolgus macaques. Animals were irradiated with a 6-MV Varian 600c linear ac-
celerator using a two-dimensional irradiation scheme (bilateral) at a dose of 3.5 Gy.
Blood was collected prior to irradiation (baseline) and at the following time points
post irradiation: 1, 2, 3, 6, 8, 13, 15, and 20 days. Antibiotics, supplemental fluids,
and nutritional support were administered throughout the study. In accordance
with the rhesus macaque published data, an initial spike in neutrophils was fol-
lowed by neutropenia 24 hours following irradiation. By 7 days post irradiation, the
platelet levels dropped. At Day 22, an LD100 for females was established. Males
began recovering and survived to their scheduled necropsy at Day 30. Baseline
measurements for c-reactive protein were consistent with literature values. A bi-
phasic increase occurred between days 1-3 and days 20-27 post irradiation. In addi-
tion to CRP, Flt-2L (a hematopoietic growth factor) was also consistent with the lit-
erature which showed an increase around day 5 and 20-23 post irradiation. Based
on the results, male cynomolgus macaques react similarly to rhesus macaque fol-
lowing external irradiation exposure at this dose level and may be a useful substitute
based on their availability. In addition, these data suggest a sex sensitivity in this
species.
741 Development of a Phosgene-Induced Acute Lung Injury in
the Conscious Pig.
S. Graham1,  A. J. Smith1,  R. L. Perrott1,  S. J. Rutter1,  P. Marshall1,  T. Mann1,
B. J. Jugg1 and A. M. Sciuto2. 1Biomedical Sciences, DSTL, Salisbury, United
Kingdom; 2Medical Toxicology, USAMRICD, Aberdeen Proving Ground, MD.
The toxic industrial chemical (TIC) phosgene (CG) is a reactive intermediate used
in a range of industrial processes. Exposure to high concentrations of CG results in
an asymptomatic period (2-6 h) before pulmonary oedema develops. There are no
specific medical countermeasures for such poisoning, treatment being supportive in
an intensive care setting. Evidence based treatment guidelines are needed for health
care practitioners to guide treatment. Small animal models have been used to screen
candidate therapies, extrapolation of therapeutic benefit to man requires verifica-
tion in a larger animal model e.g. the pig. There is, therefore, a requirement to de-
velop a conscious large animal model of CG-induced lung injury in which to verify
efficacious treatments. If successful, this model will allow assessment of therapeutic
interventions to CG-induced lung injury in a species closer to man.
After a period of socialisation, animals were surgically prepared to allow physiolog-
ical measurements (arterial blood pressures, ECG, temperature and activity via tele-
metric implant) and blood samples (via exteriorised catheters) to be taken. After a 1
week recovery from surgery and baseline measurements (1 week) animals were ex-
posed to either air or phosgene under anaesthesia, then recovered and monitored
for 24 h.
Air-exposed and phosgene-exposed animals were successfully recovered and moni-
tored to 24 h post exposure. The phosgene-exposed animals had a severe but non-
lethal phosgene-induced lung injury at 24 h compared to air-exposed controls,
demonstrated by changes in arterial blood gas measures, gross pathology and
histopathology.
The feasibility of this unique model has been demonstrated. Further refinement of
the telemetry technology may be required to add robustness and improve confi-
dence in extrapolation to man. We intend to use the model to test therapeutic can-
didates proven efficacious in a small animal model.
742 Sex Differences in Inflammatory Response in a DAPM-
Induced Rat Model of Pulmonary Hypertension.
M. A. Carroll Turpin,  V. Y. Hebert,  H. Wensler,  T. Chotibut,  C. Robinson and
T. R. Dugas. Pharmacology, Toxicology and Neuroscience, LSUHSC-Shreveport,
Shreveport, LA.
Pulmonary Arterial Hypertension (PAH) is a cardiovascular disorder characterized
by elevated pulmonary artery pressure as a result of arterial wall thickening. Patients
survive, on average, 2.8 yr after diagnosis and are 3-4 times more likely to be
women than men. There is no cure - the few therapies available can only slow pro-
gression. Our purpose was to develop a relevant animal model of PAH in order to
identify sex differences that contribute to disease progression, and in doing so,
identify potential new treatment strategies. 4,4’-Methylenedianiline (DAPM) is an
aromatic amine used industrially in the synthesis of polyurethanes. Chronic, inter-
mittent treatment of rats with DAPM results in medial hyperplasia of pulmonary
arterioles, exclusively in females, coupled to increases in pulmonary arterial pres-
sures. After 12 wk, significant increases in plasma levels of endothelin-1 (ET-1) and
serotonin (5-HT), but decreases in nitrite (NO2
-), were observed in females (not
males) treated with DAPM. A decrease was observed in the serum ratio of the es-
trogen metabolites 2-hydroxyestradiol (2-OHE)/16α-hydroxyestrogen (16α-
OHE; p = .07). In females, ET-1, NO2
- and 2-OHE/16α-OHE were significantly
correlated with peak pressure gradient, an indirect measure of pulmonary arterial
pressure. In DAPM-treated females, serum IL-10 decreased 37% (p = .0129). INF-
γ increased by 48% and IL-6 increased 3-fold (as determined by Bio-Plex cytokine
assay). These changes were not significant. However, there were significant interac-
tions between sex and treatment. Future studies will address the contributions of
these inflammatory cytokines in PAH initiation and progression in females.
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743 Cynomolgus Macaque (Macaca fascicularis) As a Potential
Animal Model for Studying Bleomycin-Induced Pulmonary
Fibrosis.
M. Doyle-Eisele1,  J. Villlalba1,  Y. Shi1,  J. D. McDonald1 and I. O. Rosas1, 2.
1LRRI, Albuquerque, NM; 2Harvard Brigham and Women’s Hospital, Boston, MA.
Bleomycin Sulfate-Induced Pulmonary Fibrosis has been extensively described in
mice. However, to our knowledge few non-murine animal models have been im-
plemented before. Here we investigated the pathogenic/inflammatory potential of
Bleomycin administration in Cynomolgus Macaques (Macaca fascicularis), a surro-
gate model for human pulmonary fibrosis. Fifteen Cynomolgus Macaques (6 in-
sulin resistant on high fat diet and 9 on standard primate chow) were challenged via
a bolus insufflator with varying doses of Bleomycin Sulfate (0.1-1.9 mg/kg).
Animals were followed during 10 weeks of study by twice daily cage-side clinical
observations. Bronchoalveolar lavage (BAL) and pulmonary function tests (PFTs)
were performed biweekly until necropsy. PFTs were completed for each animal
(previously anesthetized) using a whole body plethysmograph. A subset of inflam-
masome potential markers was further analyzed in BAL cell mRNA. Macroscopic
lung abnormalities were examined at necropsy. Increases in PYCARD and TXNIP
were noted in all animals that received high fat diet compared to those on normal
primate chow irrespective of the bleomycin dose. Interestingly, NLRP3, PYCARD,
PR2X7, TXNIP, and IL-18 mRNA expression showed an inverse relationship with
the bleomycin dose for both feed types. The development of fibrosis in monkeys
mimics more of a chronic process as seen in humans. Though our animals pre-
sented structural/molecular changes, all of them were asymptomatic. Animals fed a
high fat diet have increased inflammasome activation than those fed the standard
diet however there is no significant association with the bleomycin dose and the in-
flammasome activation. These findings suggest that Cynomolgus Macaques may be
a potential animal model for studies of Bleomycin-induced pulmonary fibrosis, and
this might prove to be a prerequisite for translational research.
744 Cue-Induced vs Cocaine+Cue-Induced Reinstatement: Two
Different Animal Models of Relapse.
D. Pushett,  G. Froget,  D. Virley,  V. Castagné and C. Froger-Colleaux. Porsolt
SAS, Le Genest-St-isle, France.
Both environmental factors and abused drugs play a role in drug-seeking. The aim
of this work was to compare two models of cocaine-induced reinstatement (i.e. cue-
and cocaine+cue). Rats were subjected to daily sessions in operant chambers during
which they could receive i.v. infusions of cocaine (0.35 mg/kg/infusion): when rats
pressed the active lever, a cue light and a tone signal were turned on together with
activation of the infusion pump. When cocaine self-administration was acquired,
rats were moved to extinction sessions where active lever-presses no longer pro-
duced cocaine infusion, cue light/tone presentation or noise from the pump. Once
rats had met extinction criteria, they were subjected to a single reinstatement ses-
sion. Rats were pretreated with vehicle or raclopride (0.08 or 0.15 mg/kg s.c., -30
min). The cue-induced reinstatement session began with a tone and cue light. The
remainder of the session was identical to the self-administration session except that
no cocaine was delivered.. For the cocaine+cue-induced reinstatement session, rats
were administered with a non-contingent administration of cocaine (10 mg/kg i.p.)
prior to being placed in the chamber. In rats treated with vehicle, a greater number
of active lever presses were observed during the cocaine+cue-induced reinstatement
session as compared with the cue-induced reinstatement session. A consistent in-
hibitory profile on cocaine-seeking behavior was demonstrated for raclopride at the
higher dose (0.15 mg/kg s.c) in both models. However the suppressing effect of
raclopride at the lower dose (0.08 mg/kg s.c.) was only observed in the cue-induced
reinstatement model. These data demonstrate that the cocaine+cue-induced rein-
statement model induces a higher level of drug-seeking which is more difficult to
reverse than the drug-seeking produced in the cue-induced reinstatement model.
Conversely, the cue-reinstatement model may be more sensitive to detect relapse-fa-
cilitating effects of test substances.
745 Early Juvenile Expposure to High-Dose Acetaminophen
Impacts Adult Murine Social Behavior in a Strain-
Dependent Manner.
G. G. Gould1,  C. Smolik1, 2,  T. Gu1,  M. Vitela1,  M. F. Valdez2,  J. Hensler2,
A. Seillier2,  A. Giuffrida2 and S. T. Schultz3. 1Physiology, UTHSCSA, San Antonio,
TX; 2Pharmacology, UTHSCSA, San Antonio, TX; 3Family and Community
Medicine, UTHSCSA, San Antonio, TX.
Pediatric acetaminophen use has increased since 1980, while baby aspirin use de-
clined after its association with Reye Syndrome. It has been hypothesized that in-
creased exposure of children under 5 years old to acetaminophen may be contribut-
ing to the rise in autism incidence. Cumulative acetaminophen doses < 75
mg/kg/day for 2 days are within recommended guidelines, but may be problematic
for children in whom conjugative disposition pathways are impaired. Alternative
metabolic pathways, either via deacetylation to promote endogenous cannabinoid
neurotransmission or via oxidative pathways, may be harmful at vulnerable stages
of brain development. We sought to model this scenario to clarify possible mecha-
nisms using juvenile mice. We hypothesized that high-dose (>100 mg/kg/day) acet-
aminophen exposure in weanling (PD18-21) mice would produce impairments in
the social behavior of C57BL/6J mice and would worsen them in BTBR mice.
Male pups of each strain were exposed for 4 days to 4x daily injections of acetamin-
ophen (100 mg/kg), WIN 55,212 (0.1 mg/kg) or vehicle (saline + 10% DMSO),
and matured to adulthood (PD 80). Three chamber sociability tests of C57BL/6
mice revealed a significant (p<0.05) reduction in social interaction relative to vehi-
cle controls that was comparable to prenatal treatment with valproic acid. However,
the social behavior of BTBR mice was unaffected. Levels of 2-arachidonoylglycerol
and serotonin transporter binding site density were also reduced in both strains. In
contrast C57BL/6 mice exposed for 4 days to 1.5 mg/ml of acetaminophen were
unaffected. Thus, exposure to supratherapeutic doses of acetaminophen or cannabi-
noid full agonists indicates a possible role for cannabinoid receptors in modulating
social behavior, at least in juvenile mice. This research was supported by US Navy
contracts and a sub-award from UTHSCSA Institute for Integration of Medicine
and Science CTSA grant #UL1RR025767.
746 Interlaboratory Comparison of Clearance Rates of
Xenobiotics by Cryopreserved Trout Hepatocytes for the
Prediction of Bioaccumulation Potential.
K. Fay1,  R. T. Mingoia2,  I. Goeritz3,  D. L. Nabb2,  A. D. Hoffman1,
B. D. Ferrell2,  H. M. Peterson2,  J. W. Nichols1,  H. Segner3 and X. Han2. 1US
EPA, Duluth, MN; 2DuPont Haskell Global Centers for Health & Environmental
Sciences, Newark, DE; 3University of Bern, Bern, Switzerland.
Hepatic biotransformation is an important determinant of chemical bioaccumula-
tion in fish. Consequently, improvements to bioaccumulation models can be made
using estimates of chemical biotransformation rates. Cryopreserved trout hepato-
cytes have previously been used to measure the clearance rates of some compounds.
The use of this information within a regulatory context requires, however, that such
results be reproducible across laboratories. In this study, three independent labora-
tories performed a round-robin study using cryopreserved rainbow trout
(Oncorhynchus mykiss) hepatocytes. Six compounds were selected for testing:
benzo[a]pyrene, 4-nonylphenol, di-tert butyl phenol, fenthion, methoxychlor and
o-terphenyl.  Pre-trial studies were performed to streamline the assay protocol, stan-
dardize hepatocyte counting procedures, and characterize potential sources of vari-
ability.  The results confirmed first-order depletion kinetics for the selected com-
pounds and highlighted the effects of assay temperature as well as lot variability.
Each laboratory then conducted clearance assays for the six compounds using a
substrate depletion approach. The analyses for each substrate were conducted at
one institute to focus the comparison on the assay itself.  Compounds determined
to be poorly (o-terphenyl; <0.05 ml/h/106 cells) or rapidly metabolized
(benzo[a]pyrene; >0.3 ml/h/106 cells) were similarly determined across laborato-
ries. Coefficients of variation across the three laboratories were generally 30% or
better, suggesting this method of determining intrinsic clearance is transferable and
reproducible. This inter-laboratory comparison strongly supports the use of cryop-
reserved trout hepatocytes as a tool for estimating hepatic clearance for bioconcen-
tration factor predictions.
747 Pharmacokinetics of Dichloroacetate in a Canine Model.
H. W. Maisenbacher1,  A. L. Shroads2,  G. Zhong3,  A. D. Daigle1,
M. M. Abdelmalak2,  I. Sosa Samper1,  B. D. Mincey1,  M. O. James3 and
P. W. Stacpoole2. 1Small Animal Clinical Sciences, University of Florida, Gainesville,
FL; 2Medicine, University of Florida, Gainesville, FL; 3Medicinal Chemistry,
University of Florida, Gainesville, FL.
Dichloroacetate (DCA) is an investigational drug for mitochondrial diseases, pul-
monary arterial hypertension (PAH), and cancer in humans. It is metabolized to
glyoxylate by glutathione transferase zeta 1/maleylacetoacetate isomerase
(GSTZ1/MAAI), which also catalyzes the penultimate step in tyrosine catabolism.
DCA is a mechanism-based inhibitor of GSTZ1/MAAI, thereby inhibiting its me-
tabolism and causing accumulation of reactive tyrosine intermediates, such as ma-
leylacetone (MA). Human haplotype variation in GSTZ1 also confers variable rates
of DCA biotransformation that may impact chronic safety. Dogs express
GSTZ1/MAAI and develop PAH and cancer; thus, they may be a valuable model
of human diseases in which DCA is used. Accordingly, we characterized the phar-
macokinetics and dynamics of DCA in a canine model.
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Based on an initial 2 day dose-response study, 3 dogs were orally administered
6.25mg/kg q12h DCA for 4 weeks. Between day 1 and 14, Cmax was significantly
different (p<0.01) and clearance approached significance (p=0.067). The differ-
ences between day 1 and 28 approached significance for t1/2 (p=0.058) and clear-
ance (p=0.065). Urinary levels of DCA (p = 0.074) and MA (p = 0.056) tended to
increase during DCA exposure. There were no differences in packed cell volume,
blood alanine aminotransferase, aspartate aminotransferase or glucose levels, or
nerve conduction velocities between day 0 and 28. Liver biopsies on day 0 and 27
demonstrated complete inhibition of GSTZ1 protein expression and activity
(0.305±0.030 vs. 0.012±0.009nmol glyoxylate formed/min/mg protein, p<0.01).
Dogs demonstrate slower clearance and greater inhibition of DCA metabolism
than rodents and most humans. The plasma kinetics of DCA in dogs is similar to
humans with GSTZ1/MAAI polymorphisms that confer exceptionally slow plasma
clearance. Thus, dogs may be a useful model to further investigate the toxicokinet-
ics of DCA.
748 Determination of Onset of Sexual Maturity in Female
Göttingen Minipigs.
B. Peter1,  H. Lorentsen2,  E. van Duijnhoven1,  M. van Tuyl1,  B. van Rozendaal1
and H. Emmen1. 1Toxicology, WIL Research Europe B.V., ‘s-Hertogenbosch,
Netherlands; 2Ellegaard Göttingen Minipigs A/S, Dalmose, Denmark.
Minipigs are often used in safety assessment studies with pharmaceuticals. Based on
breeding experience, female minipigs are considered to reach sexual maturity at 4-5
months of age. However, more exact scientific data on sexual maturity is lacking.
This information is pivotal for the design and interpretation of toxicity studies dur-
ing drug development.
First, a pilot study was initiated to find useful parameters for the detection of es-
trous cycle in adult female Göttingen minipigs. Three sows at 10-11 months of age
housed adjacent to adult boars were monitored daily for signs of heat (specific be-
havior, changes of the vulva) for 29 days. In addition, rectal body temperature was
recorded, vaginal smears were taken for estrous cycle determination and the repro-
ductive hormones progesterone and 17β-oestradiol were measured in serum.
Progesterone analysis was the most valuable method, showing a cyclic pattern of re-
lease. The outcome of the examination of vulva and vaginal smears was less clear.
Other external signs of heat did not reveal a cyclic pattern.
Subsequently, the approximate age at which female minipigs reach onset of sexual
maturity was determined. For this, two gilts at 2 months of age, housed in the same
room as adult boars, were used. Investigations included progesterone analysis, ob-
servations of the vulva, estrous cycle determination and recording of body weights.
Progesterone levels increased first at approximately 5.5 and 6.5 months of age
(body weight: 12.7 and 17.3 kg), respectively. The hormone release was indicative
for a functional corpus luteum. For one female progesterone analysis was continued
for nearly 3 months. The cycle duration was approximately 3 weeks which is in line
with published data (18-21 days). However, the different stages of the cycle could
not easily be distinguished by evaluation of vaginal smears. This information will be
used in a following study to further investigate onset of sexual maturity in a female
minipig population.
749 Recording of the Full-Field Electroretinogram in the
Göttingen Minipig.
R. Forster1,  A. Augsburger2,  V. Haag1 and J. Legrand1. 1CiToxLAB France,
Evreux, France; 2DMV Clinique Vétérinaire, Bois-Guillaume, France.
The purpose of this work was to evaluate a simple electroretinographic protocol on
a representative sample of Göttingen minipigs. Electroretinogram recordings were
conducted on 162 healthy minipigs (81 males and 81 females) aged 4–6 months.
After a 1.5-h light adaptation period, the animals were placed under general anes-
thesia. First, binocular full-field photopic electroretinogram recordings were con-
ducted under photopic conditions. Subsequently, scotopic electroretinogram
recordings were conducted during dark adaptation every 4 min over a 20-min pe-
riod. At the end of this period, the maximal combined rod-cone response was
recorded by measuring the retinal response to a single high-intensity flash. We used
sclerocorneal clips as active electrodes and needle electrodes for the reference and
ground. The a-wave and b-wave peak times and amplitudes were measured and sta-
tistically analyzed. For each of the statistical comparisons, normality and homo-
geneity of variances were evaluated. No significant gender differences were ob-
served, with the exception of a higher b-wave amplitude for the photopic ERG
recordings in females (48.14 ± 12.91 lV vs. 42.88 ± 10.67 lV; p < 0.005). The
process of dark adaptation was evaluated, and the maximal combined rod-cone re-
sponse was measured (a- and b-wave amplitudes and peak time). In conclusion,
photopic and scotopic electroretinogram recordings were performed in the minipig
using a protocol based on light adaptation followed by dark adaptation.
Sclerocorneal clip electrodes allowed a quick assembly and examination.
750 Normal Physiological Ranges for Hanford Miniature Swine.
J. Liu1,  L. D. Brown1, 2,  T. J. Madsen1,  S. Schlink1,  M. Freeman1,
B. C. Hanks1, 2,  A. Stricker-Krongrad1 and G. F. Bouchard1, 2. 1Sinclair Research
Center, LLC, Columbia, MO; 2Sinclair BioResources LLC, Auxvasse, MO.
The miniature swine have been increasingly recognized as a non-rodent model in
regulatory toxicity. Members of the FDA have even published on the use of minia-
ture swine as an alternative to canine and non-human primates in regulatory toxic-
ity. The similarities between the cardiovascular, renal, and digestive systems make
the miniature swine a suitable animal to model the human counterpart. The minia-
ture swine are also the most recognized species for dermal toxicology. The Hanford
miniature swine (HMS) has other attractive traits that make them a good substitute
to model humans. They are omnivorous, easy to handle, prone to obesity, and will
develop atherosclerosis and dyslipidemia if fed a high fat diet. With the advent of
new techniques, all routes of compound administration can be used with miniature
swine. The HMS should be considered as one of the non-rodent species in toxicity
testing. In an effort to generate a database on baseline information about the nor-
mal physiological status of the Hanford miniature swine, we report expanded and
updated physiological data from normal intact and naïve juvenile and young adult
miniature swine of both genders. The normal physiological data gathered includes
growth parameters, hematology, serum chemistry, coagulation profile, urinalysis,
ECG rhythm and segment intervals, and organ weights.
751 A Six-Month Feeding Study for WistarHannover gpt Delta
Transgenic Rat.
H. Takagi1,  Y. Nozaki1,  A. Kawada1,  M. Yamada2,  K. Masumura2 and
T. Nohmi3. 1Biotechnical Center, Japan SLC, Inc., Hamamatsu, Japan; 2Division of
Genetics and Mutagenesis, National Institute of Health Sciences, Tokyo, Japan;
3Biological Safety Research Center, National Institute of Health Sciences, Tokyo, Japan.
Sponsor: A. Nishikawa.
Transgenic rodent gene mutation assays, recently adopted as OECD test guideline
TG488, are useful methods to evaluate in vivo mutagenicity of chemicals in a target
organ. The multiple copies of genetically neutral transgenes that contain reporter
genes for mutation analysis are integrated in the chromosome of the transgenic ro-
dents. However, biological identities between the transgenic and non-transgenic
animals are not well demonstrated. To evaluate the characteristics of
WistarHannover gpt delta transgenic (Tg) rat in general toxicity study, we investi-
gated the clinical and pathological features of the gpt delta transgenic and non-
transgenic WistarHnnover rats in six months feeding study. The six week-old
Slc:WistarHannover/Rcc (gpt delta) and Slc:WistarHannover/Rcc (40
animals/sex/strain) were employed for this assessment. Twenty animals in each sex
were subjected to necropsy at 13 and 26 weeks after starting, then, clinical and
pathological assessments were conducted. In Slc:WistarHannover/Rcc(gpt delta),
the values of several parameters in hematology, clinical biochemistry and organ
weights were different from those in Slc:WistarHannover/Rcc with statistical signif-
icance. These alterations, however, were within the range of historical control data
of in housed Slc:WistarHannover/Rcc, and thus were considered to be incidental.
In histopathology, spontaneous lesions in WistarHannover such as fibrosis in the
heart, microgranuloma in the liver and so on were observed in both strains. These
results suggested that there were no remarkable differences which indicate pheno-
typic modulation in Tg rats, and supported the conclusion that
Slc:WistarHannover/Rcc(gpt delta) has similar characteristics to WistarHannover.
752 A Medium-Term Animal Model Using gpt Delta Rats for
Predicting Chemical Carcinogenicity and Related
Mechanisms of Action.
K. Matsushita1,  Y. Ishii1,  S. Takasu1,  K. Kuroda1,  A. Kijima1,  T. Nohmi2,
K. Ogawa1,  A. Nishikawa2 and T. Umemura1. 1Division Path., National Institute
Health Science, Tokyo, Japan; 2BSRC, National Institute Health Science, Tokyo,
Japan.
In this study, an animal model (GPG46) capable of rapidly detecting chemical car-
cinogenicity with the underlying mechanisms of action was developed in gpt delta
rats using a reporter gene assay to detect mutations and a medium-term rat liver
bioassay to detect tumor promotion. The standard protocol for the GPG46 model
was developed based on the results of dose-response exposure to diethylnitrosamine
(DEN) and treatment with phenobarbital over time following DEN administra-
tion. Briefly, gpt delta rats were exposed to various chemicals for 4 weeks, followed
by a partial hepatectomy (PH) to collect samples for the in vivo mutation assay. The
mutant frequencies (MFs) of the reporter genes were examined as an indication of
tumor initiation. A single i.p. injection of 10 mg/kg DEN was administered in rats
18 h after the PH to initiate hepatocytes. Tumor promoting activity was evaluated
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based on the development of glutathione S-transferase placental form (GST-P) pos-
itive foci at week 10. The genotoxic carcinogens 2-acetylaminofluorene (2-AAF), 2-
amino-3-methylimidazo[4,5-f ]quinolone (IQ) and safrole (SF), the non-genotoxic
carcinogens piperonyl butoxide (PBO) and phenytoin (PHE), the non-carcinogen
acetaminophen (APAP) and the genotoxic non-hepatocarcinogen aristolochic acid
(AA) were tested to validate the GPG46 model. The MFs of the gpt genes were sig-
nificantly increased in rats treated with 2-AAF, IQ, SF and AA. The number and
area of GST-P positive foci were increased in the livers of rats treated with 2-AAF,
IQ, SF, PBO and PHE. APAP treatment did not elevate the MFs of the gpt genes
and inhibited the development of GST-P positive foci. The validation results indi-
cate that the GPG46 model could be a powerful tool in understanding chemical
carcinogenesis and provide valuable information regarding human risk hazards.
753 Age-Related Changes in Body Composition in Laboratory
Rats: Strain and Gender Comparisons.
R. C. MacPhail,  P. M. Phillips,  C. J. Gordon and K. A. Jarema. NHEERL, US
EPA, Research Triangle Park, NC.
Long Evans (LE), Sprague Dawley (SD), Fischer 344 (F344), and Brown Norway
(BN) rats are all commonly used as laboratory research subjects. These strains have
been studied under many conditions, but few studies have measured changes in
body composition as the animals age. Understanding strain differences with regard
to body composition, age and growth are essential for understanding toxicity mech-
anisms, specifying deprivation regimens for studies on food-rewarded learning and
performance, and developing accurate pharmacokinetic models of toxicity. This
study used a Bruker body composition analyzer to compare the changes in body fat,
lean tissue, and fluid for male (n=12/strain) and female (n=12/strain) LE, SD, F344
and BN rats. We found dramatic differences in body composition between the four
rat strains. In both male and female rats, body weights were similar for the LE and
SD strains, and much lower for the F344 and BN strains. In all cases, body weights
for females were less than males. Lean mass for both genders followed a similar pat-
tern as body weight, with the LE and SD rats differing from the BN and F344 rats,
and males differing from females. Total fat content differed substantially between
strains. The LE rats had the highest fat content, followed by SD, then F344, and fi-
nally BN, which had the lowest fat content. These strain differences were seen with
both males and females. When body fat was calculated as a percentage of total body
weight, the LE rats still had the highest values and the BN rats had the lowest val-
ues.  However, the male SD and F344 rats appeared to be nearly identical in per-
cent fat. Moreover, the female SD and F344 had similar percent fat values early in
development, but these values diverged as they continued to age. These results show
marked differences in body composition between four rat strains commonly used in
toxicology research.
(This is an abstract of a proposed presentation and does not reflect US EPA policy.)
754 Assessment of Cardio-Respiratory Function in Conscious
Rats: Use of Combined Telemetry and Plethysmography.
E. Hayes,  S. Rompion,  E. Gascoin,  M. Maujeul,  M. Lepage and G. Froget.
Porsolt SAS, Le Genest-St-isle, France.
In vivo safety pharmacology assessment of cardiovascular (CV) and respiratory
function is a regulatory requirement during pre-clinical drug development.
Combination of both assessments in a single model could be useful with respect to
reducing animal use. We established a model of combined telemetry and plethys-
mography to evaluate the time-dependent effects of various reference compounds
on CV and respiratory function in conscious rats. Male Sprague Dawley rats (n=5-
6) were implanted with DSI telemetric devices and placed into plethysmographic
chambers (EMKA) with receivers (DSI). Clonidine, verapamil and theophylline
were examined for their effects on heart rate, HR; mean arterial blood pressure,
MAP, minute volume, MV; tidal volume, TV; respiratory rate, ReR and enhanced
pause, Penh before and for 360 min after drug administration. Data were compared
by two-way ANOVA (group, time). In controls, a transient decrease in TV (-22%)
and Penh (-21%) and a transient increase in ReR (+121%) and MV (+69%) were
observed but returned to baseline values within 90 min and remained stable there-
after. No change in MAP or HR occurred in controls. Clonidine (1 mg/kg, i.p.) re-
duced HR (-55%), MV (-39%) and TV (-39%) but increased ReR (+95%) and
Penh (+96%). Verapamil (30 mg/kg, p.o.) reduced MAP (-39%) but had no effect
on ventilation. Theophylline (100 mg/kg, p.o.) exhibited respiratory stimulant and
bronchodilatory properties (MV, +125%; ReR, +313%; TV, -40%; Penh, -28%)
with concomitant tachycardia (HR, +63%). Overall the expected pharmacological
actions of the reference compounds on cardio-respiratory function were adequately
determined using a combined telemetry and plethysmography system in conscious
rats. Combined use of telemetry-plethysmography in the same study may be useful
for the development of new compounds that can be compared to established drugs.
This model also allows for a reduction in animal use requirements for CV and res-
piratory safety pharmacology and fulfills the ethical rule of 3R.
755 Comparison of Ophthalmologic Findings in Young Adult
Crl: CD SD and Wister Han Rats.
H. Kuno1,  S. McPherson2,  Q. Kong2,  S. Mason2 and Q. He2. 1NTO LLC,
Abiko-shi, Japan; 2WuXi AppTec Co. Ltd., Suzhou, China.
With more than one strain of rat now being used in toxicology studies, a study was
instigated to see if there were differences in the incidence and nature of background
lesions between the Crl: CD SD and the Wister Han rat.
The results of pretest ophthalmologic examinations of Wister Han (Charles River
USA) and Crl:CD rats purchased from Charles River USA and BioLASCO Taiwan
Co., LTd respectively were analyzed The percentage incidences (total number of le-
sion(finding)/total number of rats) of the findings were compared for evidence of
any significant differences between the two strains and sexes to see if any particular
finding was unique or predominately expressed in one of the two strains/sexes.
Corneal opacity along with the palpebral fissure is commonly observed in rats.
Wister Han rats showed both a dense and higher incidence of this lesion when
compared with Crl: CD rats. In addition, for Wister Han rats a higher incidence
was observed for females as compared with males. This gender difference was not
apparent for Crl: CD rats. Based on the differences of corneal opacity, the number
eyes of Crl: CD rats that were considered normal was higher than that recorded for
Wister Han rats. In addition, unilateral or bilateral posterior cortical multifocal
pinpoint opacity was observed for Wister Han rats but not Crl: CD rats. In conclu-
sion, there is a clear difference in the incidence of spontaneous ocular findings ob-
served for both Wistar Hans and Crl:CD rats; with Crl:CD rats showing a lower in-
cidence of corneal opacity along with interpalpebral fissure and no posterior
cortical lens opacity.
756 Feasibility of 3-Month Intravenous Bolus Injections via the
Femoral Vein and an External Access Port in Sprague-Dawley
Rats.
J. Perron1,  R. Tavcar1,  L. Armer1 and R. Forster2. 1CiToxLAB North America,
Laval, QC, Canada; 2CiToxLAB France, Evreux, France.
Long term intravenous (IV) dosing continues to be critical in non-clinical develop-
ment of many drugs (e.g., anti-cancer agents, large molecules), or pharmaceuticals
that cannot achieve high systemic exposure by other routes. The IV route is com-
monly used in Sprague-dawley rats and the most common injection site is the tail
vein. Although daily tail vein injection is normally feasible in acute and sub-acute
studies (1, 7 or 14-day duration), sub-chronic and chronic studies (28-days, ≥ 3-
months duration), once, twice and even multiple daily administration may be tech-
nically challenging and require additional animals at each dose level to assure an ad-
equate number of animals to complete the study. Vehicle selection can also
influence the success of long term daily or multiple daily tail vein injections and the
use of the vena cava allows for a greater pool of blood to minimize secondary effects
caused by non-ideal formulations. In alignment with the 3Rs (Reduction, replace-
ment, refinement), our laboratory has demonstrated that daily intravenous injec-
tion via the femoral vein in the rat and external access port was feasible over a pe-
riod of up to 3 months, which helped minimizing the number of animals per dose
level to the minimum required by regulations. A medical grade polyurethane-based
catheter was surgically implanted in the vena cava via the femoral vein and con-
nected to a Quick-connect harness with a Luer Valve. A heparin-based locking so-
lution was used to fill the catheter and the injection cap. Sodium chloride for injec-
tion (0.9% Saline) was injected daily for up to 3 months via the injection cap, at a
dose volume of 5 mL/kg. The experimental procedures were well-tolerated and no
adverse effects were observed in clinical signs, body weight, and clinical pathology.
Histopathological tissue changes were comparable to findings in catheterized ani-
mals. The IV bolus injection via the femoral vein and an external access port was
shown to be a suitable alternative to tail vein injection for rat sub-chronic and
chronic studies.
757 Noninvasive Airway Resistance Measurements in Large
Animals by High-Frequency Airwave Oscillometry.
T. F. Schuessler1,  A. Robichaud1,  R. Forster2,  M. Pouliot2,  A. Ascah2,
E. Troncy3 and S. Authier2, 3. 1SCIREQ Scientific Respiratory Equipments, Montréal,
QC, Canada; 2CIToxLAB North America, Laval, QC, Canada; 3Faculty of
Veterinary Medicine, University of Montréal, St-Hyacinthe, QC, Canada.
Large animals are generally more sensitive than rodents to drug induced respiratory
changes. Methodologies to measure airway resistance in large animals normally re-
quire an esophageal pressure probe placed under anesthesia or a surgically im-
planted pleural pressure catheter. Both approaches could alter experimental end-
points in toxicology studies, which limit their use in drug development. A
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non-invasive methodology to measure airway resistance by high frequency airwave
oscillometry was evaluated in conscious Beagle dogs and cynomolgus monkeys. A
forced oscillation system was used to assess airway resistance and obtain conven-
tional respiratory parameters (tidal volume, respiratory rate) before and after an in-
travenous treatment with a bronchoactive agent. Respiratory mechanics measure-
ments were performed using 16 second long single (19 Hz) or composite (6, 10,
14, 19, 26 and 31 Hz) high frequency waveforms, which were applied at each time
point at the subject’s airway opening via a face mask. During measurements, pres-
sure and flow signals were recorded. After collection of baseline measurements,
methacholine was administered to Beagle dogs (n=4) and cynomolgus monkeys
(n=4) at 8 and 68 mcg/kg, respectively. A peak increase in airway resistance (+64%
in Beagle dogs and +30% in cynomolgus monkeys) was observed after intravenous
methacholine administration in both species with return to baseline comparable
levels within 10 min. Airway resistance data analysis for individual animals revealed
mean percent variations from baseline ranging from 9.5 to 18.6% for dogs and
from 4.4% to 6.9% for cynomolgus monkeys, suggesting stable and reproducible
assessment of lung function. Airwave oscillometry appears to be suitable for non-
invasive respiratory mechanics measurements in large animal toxicology studies.
758 Seizure Liability Models: Seizure Characterization and
Automated Detection in Telemetered Nonhuman Primates.
S. Authier1, 2,  S. Maghezzi1,  M. Pouliot1,  S. Bernasconi3,  T. de Geyer d’Orth3,
P. Zitoun3 and R. Forster1. 1CIToxLAB North America, Laval, QC, Canada;
2Faculty of Veterinary Medicine, University of Montréal, St-Hyacinthe, QC, Canada;
3NOTOCORD, Croissy-sur-Seine, France.
Seizure liability studies in non human primates generally aim to: 1) confirm drug-
induced seizures are self-limiting, 2) determine plasma level at seizure onset 3) iden-
tify prodromal clinical signs which can be monitored in clinical trials 4) confirm
that conventional drugs (e.g. diazepam) can treat drug-induced seizure and 5) con-
firm the no observed adverse effect level (NOAEL) by absence of paroxysmal activ-
ity. To achieve these goals, typical study designs include video-EEG monitoring.
Continuous telemetry monitoring generates a considerable amount of data which
translates into lengthy analysis when solely relying on manual EEG review. A new
application for seizure detection was developed in non-human primates (NHP).
The prototype evaluates temporal and spectral features and compares them to fea-
tures extracted from a sliding reference window. Detected seizures are validated
based on a decision tree and artifact rejection algorithms. The automated prototype
was used to evaluate periods of up to 68h of continuous EEG data and all detec-
tions were subject to a visual review. All animals presented at least one epileptic
event. A detection sensitivity of 86.4% with 2.3 false positives per hour of signal
was achieved using the default parameters of the prototype. Detection sensitivity
increases to 100% when selecting optimal settings for each individual. The process-
ing time was approximately 5 minutes for a 24h EEG telemetry signal. These
promising results reflect progress in an era computerized data analysis. Further im-
provements are investigated to maintain a detection sensitivity of 100% essential
with the model, while keeping the number of false detections low to increase data
analysis efficiency.
759 Comparing Data Obtained by Refined Restraint Methods to
Traditional Methods in Nonhuman Primate Studies.
N. Lalayeva1,  N. Bailey1,  J. Kenfield1,  N. Makori1,  P. Franklin1,  T. Beck1 and
R. Nagata2. 1Safety Assessment, SNBL USA, Ltd., Everett, WA; 2Corporate, Shin
Nippon Biomedical Laboratories, Ltd., Kagoshima, Japan.
As nonhuman primates continue to be an important model in nonclinical toxicol-
ogy/pharmacology studies, improving methods of animal handling during proce-
dures is essential. The aim of this study is to present historical background data col-
lected using a refinement in the restraint technique, the Procedure Cage (PC). Use
of the PC has the potential to contribute to minimizing inter- and intra-animal
data variability when compared to data collected using other restraint methods (e.g.
Restraint Chair [RC]). Historical control pregnancy loss ratio of 16.3% (range
0–31.3%) obtained using the PC is relatively low when compared to published data
(17.8%, Hendrie et al. 1996, Am J Primat 40:41; and 29.6%, Wehner et al. 2009,
BDR [B] 86:144). Restraint-associated stress can also influence values of hemody-
namic and cardiovascular measurements. In a telemetry study comparing cardiovas-
cular parameters for restraint in the Restraint Chair (RC) vs. Procedure Cage (PC),
six telemetry implanted animals were monitored and data analyzed for heart rate
(HR) and mean arterial blood pressure (BP) using a validated Notocord Telemetry
System. In a series of procedures performed, HR for RC animals was on average 1.2
times (range 147-198 bpm) that of PC animals (range 139-167 bpm). BP for RC
animals was on average 1.1 times (range 102-109) that of PC animals (range 90-
96). The RC animals returned to baseline HR and BP levels only 22 and 33% of
the time, beginning at 15 and 30 min post procedure, respectively. In contrast, the
PC animals returned to baseline HR and BP levels 50 and 91% of the time begin-
ning at 5 and 10 min post procedure, respectively. In summary, it is evident that use
of the PC method has potential to contribute to obtaining more robust data and,
thus, could eventually lead to use of fewer animals on study.
760 Comparative Analysis of Noninvasive Blood Pressure Data by
High-Definition Oscillometry (HDO) in Cynomolgus
Monkeys of Mauritian and Asian Origin.
B. Niggemann and U. Zuehlke. Covance Laboratories GmbH, Muenster, Germany.
Sponsor: G. Weinbauer.
Cardiovascular investigations - among other diagnostic parameters – are essential
for the detection and interpretation of untoward findings in preclinical studies. As
cardiovascular toxicity in general and blood pressure determination in particular is
concerned with adverse effects of xenobiotics on the circulatory system, a represen-
tative analysis of non-invasive blood pressure data is mandatory for the right inter-
pretation of apparent circulatory findings.
Cynomolgus monkeys are frequently used in toxicity studies and animals from var-
ious sources such as Mauritius and Asia are available from acknowledged breeders. 
The aim of the present work was to compare non-invasive blood pressure data from
group housed, untreated and unsedated cynomolgus monkeys of Mauritian and
Asian origin.
Individual data from 150 Mauritian and 92/128 Asian male and female animals,
each were analysed for systolic, diastolic and mean arterial blood pressure. 
Blood pressure data of male and female animals of either origin showed slight but
significant differences (P ≤ 0.05 to P ≤ 0.001) and values for males were higher
than for female animals. Comparison of blood pressure data from monkeys of
Mauritian and Asian origin revealed that systolic pressure (+9.0 % M; +10.4% F),
diastolic pressure (+12.0 % M; +14.1 % F) and mean arterial pressure (+10.1 % M;
+11.7 % F) were significantly (P ≤ 0.01 and P ≤ 0.001) elevated in monkeys from
Mauritius when compared to monkeys from Asia.
761 Procedure Refinement and Reduced Restraint Enables
Extended 6-Hour-Daily Inhalation Dosing in Beagle Dogs.
A. Dumais1,  M. Stoute1,  R. Tavcar1 and R. Forster2. 1CiToxLAB North America,
Laval, QC, Canada; 2CiToxLAB France, Evreux, France.
Extended duration of dosing for preclinical assessment of inhaled pharmaceuticals
is considered advantageous when testing products of expected low toxicity.
Technical limitations have often determined the maximum time of exposure in
non-rodents such as Beagle dogs. Increased exposure time can improve the chances
and accuracy of determining the maximum tolerated dose rather than being limited
to a maximum feasible dose. A study was undertaken to confirm whether reduced
restraint (platform) combined with procedural refinements would enable routine 4
hr daily dosing (5 days) and even 6 hr daily dosing (3 days). Prior to delivery from
the supplier, a number of dogs were presented to platform restraint and inhalation
facemask for up to 15 min and those demonstrating acceptance were selected.
Following receipt, the four dogs were gradually acclimated for increasing periods of
time (up to 4 hrs) to the inhalation equipment over 13 consecutive days. During
the acclimation period, the dogs were monitored for behavior changes (excessive
salivation, trembling, vocalization, struggling and increases in respiratory rate).
Reinforcement through positive behavior by voice and minimal animal contact
during the sham dosing where emphasized. Verbal rewards, petting and treats were
provided after completion of each session. All animals underwent the 4 hr daily
sham dosing except one female for which the sham dosing had to be interrupted on
Days 2 to 4. The 6 hr sham dosing was initiated and successfully conducted using
the remaining 3 dogs. There were no changes in clinical signs, body weights or food
consumption throughout the study. In conclusion, extended daily inhalation dos-
ing in Beagle dogs is made possible by combining animal screening at the supplier,
extensive acclimation, positive behavior re-enforcement and reduced restraint. This
enables to more accurately determine the NOEL and improve the determination of
a MTD while improving animal welfare by reducing the level of restraint and stress.
762 Reducing Blood Volume for Hematology and Clinical
Chemistry Analysis in Mice.
A. Prefontaine,  C. Copeman,  L. Huard,  D. Lourdel,  K. Petitclerc and
F. Poitout. Charles River, Montréal, QC, Canada. Sponsor: M. Vézina.
Blood volume limitations are a challenge with mice when used as a preclinical
model. Cohorts of mice are often needed, sampled terminally to meet require-
ments. This is a sub-optimal use of animals and implies more animals, test materi-
als, technical personnel and costs. To permit interim sampling and reduce blood
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volume for hematology and clinical chemistry, we investigated dilution of small
blood volumes collected by jugular venipuncture. Whole blood (300 uL instead of
1.2 mL) collected from 46 mice was split; 150uL for hematology and 150 uL for
clinical chemistry. For hematology, 2 blood and 2 reticulocyte smears were prepared
prior to diluting 100 μL of blood with 200 μL of ADVIA sheath rinse solution®.
The 1:3 dilution was analyzed on the ADVIA 120 hematology analyzer (Siemens).
All flagged values were verified by microscopic blood smear evaluation. Serial blood
dilutions yielded adequate precision up to 1:5 dilution. For clinical chemistry, 40 to
50 uL of serum was diluted 1:3 in saline. Samples were analyzed on the Modular
Analytics biochemistry analyzer (Roche) with exception of electrolytes. Serial dilu-
tions of all chemistry parameters evaluated had previously demonstrated acceptable
precision up to 1:5 dilution in saline. Jugular vein versus abdominal aorta sample
results, were compared using historical ranges. Twelve of 46 (hematology) and 8 of
46 (clinical chemistry) samples were inadequate for analysis, similar incidence to
abdominal aorta sampling. Jugular vein samples had slightly higher RBC and
platelet counts, while clinical chemistry parameters were comparable except for
slight elevations in aspartate aminotransferase. These dilutions necessitated more
technical sample processing, but allowed clinical pathology analysis with only 300
uL of blood (ie. 4X reduction), presenting clear advantages, including interim study
sampling, reduction in animals, combination of endpoints for in a given mouse,
improving correlations and interpretation.
763 Human Health and Environmental Concerns around Natural
Gas Production Using Hydraulic Fracturing.
Z. Naufal. Chevron Energy Technology Company, Houston, TX.
Natural gas production from shale rock formations using hydraulic fracturing has
expanded greatly over the last decade across the United States and other parts of the
world. The expansion came as a result of advances in horizontal drilling technology
which helped unlock large natural gas supplies in shale and other tight rock forma-
tions across the country. Calls to reduce greenhouse gas emissions, the high cost of
energy, and other economic pressures also contributed to the rapid growth of shale
gas drilling using hydraulic fracturing. As a result, natural gas production is the
highest it has been in the United States in decades. However, with the expansion of
hydraulic fracturing into rural communities and areas traditionally not familiar
with oil and gas explorations, questions about public health and environmental im-
pacts have been raised by some residents living in proximity to fracturing opera-
tions. Data gaps may exist since the growth of fracturing operations has outpaced
the research efforts conducted by the broad scientific community around this issue.
In general, recent research activities have focused on understanding the potential
impacts of the chemical components of the fluids used to fracture rock formations.
Other issues raised by the public include the increase in noise, air, and light pollu-
tion in hydraulic fracturing areas and the potential for accidental contamination of
air or groundwater. This session will provide an overview of the current and pro-
jected extent of the use of hydraulic fracturing to meet energy needs, and a discus-
sion of the questions surrounding the public health and environmental impacts of
this technology.
764 Current Status of Tight Oil and Gas Development Using
Hydraulic Fracturing.
J. Imse. ENVIRON International Corporation, Denver, CO. Sponsor: Z. Naufal.
The industry is rapidly evolving - as a result of the variations in world pricing, and
greater public and regulatory scrutiny. The practices of only a few years ago have
been replaced in this changing industry. As a result, there has been increasing
scrutiny into the process of hydraulic fracturing and how current practices may re-
sult in potential exposure pathways that may pose risks to human health. Chemical
additives used in this process – the disclosure of those chemicals is now required in
states representing approximately 90% of the US production – have evolved at a
rapid pace and have evolved from hazardous constituents to food grade substances.
Furthermore, additives once viewed as benign (sand) are now receiving greater
scrutiny when evaluated in a safety context – e.g. silica (sand). Monitoring and ex-
posure evaluations implemented at sites where hydraulic fracturing occurs will need
to evolve rapidly to match the evolving additives in use. Similarly, studies with an
objective of evaluating historical exposures will require a major study component
focused on determining the actual additives used and the concentrations used at
each site.
765 An Assessment of Exposure Pathways and Potential Impacts
to Human Health Associated with Shale Gas Drilling and
Production Operations.
A. Harris. ENVIRON International Corporation, Little Rock, AR.
Shale gas drilling operations continue to expand in the US, leading to increasing
focus on identifying and understanding potential impacts to human health.  The
primary concern is the potential contamination of air and groundwater in commu-
nities located near shale gas drilling sites. Air quality may be affected from drilling
and fracturing activities as well as emissions from vehicles and equipment. Air qual-
ity studies have been conducted both at drilling sites and near community recep-
tors. VOCs, when detected, have been at concentrations below health-based bench-
marks.  Multiple studies have also been conducted to evaluate potential impacts to
groundwater by additives of fracturing fluid, petroleum constituents and methane.
Migration of fracture fluids to groundwater aquifers have been proposed although
there is currently little data indicating that groundwater has been impacted by frac-
ture fluids. Other exposure pathways of concern include leaks or spills of undiluted
additives to surface water and inadequate containment of flowback and produced
wastewater.
766 The Potential Toxicological Impacts of Shale Gas Drilling:
An Overview.
B. Goldstein and J. Kriesky. University of Pittsburgh, Graduate School of Public
Health, Pittsburgh, PA.
The pace of development of hydraulic fracturing technology to extract natural gas
from shale formations has outstripped that of the research necessary to ensure that
we maximize the benefits and minimize the risk of this important activity. Issues of
particular toxicological concern include the potential impact of the evolving list of
chemical and physical agents which are used in hydrofracturing. Concerns also ex-
tend to upstream processes, such as the mining of silica and the delivery of chemi-
cal and physical agents to the site; the on-site drilling, hydrofracturing and long
term extraction processes, including contamination of groundwater, and emissions
and noise from diesel compressors; and downstream activities such as the distribu-
tion of the hydrocarbon products and the safe disposal of the literally millions of
gallons of fluid that comes up from underground containing such agents as brine
components, arsenic and radioactive agents. Of particular toxicological importance
is the potential adverse consequences of the mixtures of hydrofracturing agents, hy-
drocarbons and natural agents brought to the surface. Air pollution also has been
documented and there is concern about the nearby impacts of the release of hy-
drofracturing agents and volatile hydrocarbons, as well as regional ozone issues. The
longer term legacy of site specific pollution is also an issue.
767 Community Exposure and Risk Near Natural Gas
Production Sites: Impacts and Research Needs.
J. Adgate. Colorado School of Public Health, University of Colorado, Aurora, CO.
Sponsor: A. Harris.
The current boom in domestic natural gas production has focused national atten-
tion on the environmental and health impacts of this process. Increased develop-
ment of unconventional natural gas resources (i.e., from shales, coal beds and tight
sands) using hydraulic fracturing (“fracking”) has raised concerns about impacts on
environmental quality and human health, especially as development has moved
into populated areas. While public concerns tend to focus on potential water con-
tamination, the well development process also results in emissions of multiple air
toxics when injected water “flows back” to the surface with the natural gas, accom-
panying petroleum condensate and fracking chemicals. Studies in Colorado and
elsewhere indicate that multiple air toxics and chemicals used in well production
activities are emitted from gas development and production sites. Research on non-
occupational exposure indicates that air pollution is a major concern because
health-based risk estimates for nearby residents are greater than for individuals liv-
ing further from well development sites. Human exposures and risks vary with
proximity to wells, specific activities at well pads, topography/meteorology, and in-
dividual operator practices and controls. This talk explores our current understand-
ing of exposure and health risks around well development sites, identifies major in-
formation gaps and uncertainties, and outlines research that will improve our
understanding of the health risks associated with natural gas development.
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768 Air Quality Impacts of Natural Gas Operations in Texas.
M. Honeycutt,  S. Ethridge and T. Bredfeldt. Texas Commission on Environmental
Quality, Toxicology Division, Austin, TX.
Texas is home to the Barnett Shale, a shale-containing geological formation in a
highly-populated area which is currently being actively drilled using hydraulic frac-
turing. The Texas Commission on Environmental Quality (TCEQ) is charged with
regulating sources of air emissions from natural gas operations and has spent con-
siderable resources examining emissions from these sources. The TCEQ has utilized
flyovers of helicopters outfitted with infra-red (IR) cameras capable of visualizing
volatile organic compound (VOC) emissions, conducted numerous mobile moni-
toring trips, and has installed an extensive ambient air fixed-site monitoring system
in areas with intensive drilling. Between August 1, 2009, and June 30, 2012, the
TCEQ has surveyed 2,307 sites in the Barnett Shale area using hand-held IR cam-
eras, and at 2,263 of these sites, hand-held survey instruments were also used.
These surveys included citizen complaint investigations, compliance investigations,
mobile monitoring trips, and follow-up investigations based on helicopter flyovers.
As a result of observations with the hand-held IR camera and measurements col-
lected using the survey instruments, 1,167 short-term field canister samples have
been collected and analyzed for VOCs. Less than 5% of VOC canister samples
measured short-term levels of concern. Short-term samples have also been collected
and analyzed for carbonyls, NOx, and sulfur compounds and none of the analyses
have measured chemicals at short-term levels of concern. Six stationary VOC mon-
itors were operational in the Barnett Shale area in 2009, thirteen are operational
now. No VOCs have been detected to date at levels of long-term health concern.
769 Role of Metabolic Syndrome and Perivascular Adipose in
Exposure-Induced Vascular Dysfunction.
D. J. Conklin1 and M. J. Campen2. 1Cardiovascular Medicine, University of
Louisville, Louisville, KY; 2Department of Pharmaceutical Sciences, University of New
Mexico, Albuquerque, NM.
Recent epidemiological studies indicate that ambient air pollution enhances the
progression from metabolic syndrome to diabetes but not by increasing obesity.
Because vascular dysfunction and vascular insulin resistance are two early events as-
sociated with metabolic syndrome and air pollution exposure, the mechanisms by
which these alterations occur in the vasculature could be informative of changes in
overall cardiovascular disease risk. Similarly and increasingly, there is a growing
recognition that the perivascular adipose tissue (PVAT) is an important regulator of
vascular tone under normal homeostatic conditions and PVAT is altered during dis-
ease states, including metabolic syndrome and diabetes. The perivascular adipose
tissue structure and function are changed to a proinflammatory state both by dis-
ease, angiotensin II, and by exposure to environmental pollutants, implicating these
alterations in subsequent endothelial and vascular dysfunction. This symposium
will provide both an introduction to the role of perivascular adipose tissue in health
and metabolic disease states and draw on evidence from environmental and experi-
mental model studies to emphasize specific alterations in perivascular adipose tissue
and how these changes contribute to subsequent vascular dysfunction and poten-
tially increase the risk of cardiovascular disease.
770 Turning Vascular Disease Inside Out: Role of Perivascular
Adipose Tissue in Coronary Artery Disease.
N. Weintraub. Division of Cardiovascular Diseases, University of Cincinnati,
Cincinnati, OH. Sponsor: D. Conklin.
Adipose tissue surrounding the great vessels [perivascular (PV) adipose tissue, or
PVAT] expands during obesity and correlates with the extent of visceral fat and in-
sulin resistance in humans. Moreover, both the amount of PVAT and the degree of
PVAT inflammation correlate with the presence of atherosclerotic coronary artery
disease. Studies in isolated perivascular adipocytes indicate that the cells display a
reduced state of adipogenic differentiation, and enhanced pro-inflammatory cy-
tokine expression, as compared with subcutaneous and visceral adipocytes. In re-
sponse to just two weeks of high fat feeding in mice, adipogenic gene expression is
markedly reduced, while pro-inflammatory cytokine expression is up-regulated, in
PVAT. Using a novel model of PVAT transplantation to the mouse carotid artery in
the setting of high fat feeding, we demonstrate that PVAT enhances atherosclerosis
and wire injury-induced neointimal hyperplasia, triggering inflammatory cell infil-
tration and proliferation of vasa vasorum. Our data suggest that PVAT plays a path-
ogenic role in vascular disease, linking metabolic signals to inflammation and an-
giogenesis of the blood vessel wall.
771 Perivascular Adipose and Vascular Dysfunction in Mice after
Combined High-Fat Diet and Concentrated Ambient
Particulate Matter Exposure.
D. J. Conklin and P. Haberzettl. Cardiovascular Medicine, University of Louisville,
Louisville, KY.
Exposure to inhaled fine particulate matter induces endothelial dysfunction and in-
creases the risk of cardiometabolic disease, insulin resistance and the risk of dia-
betes, however, the mechanisms by which PM2.5 enhances this risk are unclear.
Because diabetes and air pollution are worldwide health problems, we examined
whether high fat diet (HFD) enhanced concentrated ambient particulate matter
(CAP)-induced EPC suppression and insulin resistance to ascertain the relationship
between these important changes. Mice (male; C57BL/6) maintained on low fat
(LFD, 10% kcal fat) or high fat (HFD, 60% kcal fat) were exposed to HEPA-fil-
tered air or urban Louisville CAP (80-100 μg/m3) for 9 or 30 consecutive days
(6h/d). CAP exposure or HFD prevented insulin-induced Akt and eNOS phos-
phorylation in isolated aorta, and aortic contractility was progressively dysfunc-
tional under CAP, HFD and combined HFD+CAP treatments. Moreover, only
combined HFD+CAP treatment increased glucose intolerance without increasing
obesity, and thus, worsened the metabolic syndrome and progression toward dia-
betes. These data implicate alterations in vascular structure such as increased pervi-
ascular adipose in the combined effects of HFD+CAP on vascular dysfunction and
insulin resistance.
772 NADPH Oxidase and Perivascular Superoxide Production
with Particulate Matter Exposure.
Q. Sun. Environmental Health Sciences, The Ohio State University, Columbus, OH.
Reactive oxygen species from oxidant-releasing enzymes such as NAD(P)H oxidase
are known to play a causal role in certain disease development, and air pollutants,
such as PM2.5, are known to cause vascular dysfunction in major cardiovascular
diseases. To evaluate the role of exposure to airborne fine particulate matter (diam-
eter, <2.5 μm, PM2.5) pollution on metabolic parameters, inflammation, and adi-
posity, PM2.5 inhalation exposure was performed in C57BL/6 mice and mice defi-
cient in the cytosolic subunit of the nicotinamide adenine dinucleotide phosphate
(NADPH) oxidase p47phox (p47phox-/-) with normal or high fat diet. We found
that PM2.5-exposed C57BL/6 mice exhibited metabolic abnormalities consistent
with insulin resistance. Ex vivo–labeled and infused monocytes demonstrated in-
creased adherence in the microcirculation of normal diet– or high-fat diet–fed
PM2.5-exposed mice. p47phox-/- mice exhibited an improvement in parameters of
insulin resistance, vascular function, and visceral inflammation in response to
PM2.5. We concluded that exposure to high levels of PM2.5 is a risk factor for sub-
sequent development of insulin resistance, adiposity, and inflammation, and reac-
tive oxygen species generation by NADPH oxidase appears to mediate this risk.
Other NAD(P)H oxidase subunits and their roles in PM2.5 exposure-induced car-
diovascular diseases will also be summarized.
773 Role of Perivascular Adipose in Regulation of Vascular
Function by the Aryl Hydrocarbon Receptor.
M. K. Walker. Department of Pharmaceutical Sciences, University of New Mexico,
Albuquerque, NM.
The aryl hydrocarbon receptor (AHR) has been demonstrated to be required for
normal blood pressure regulation as demonstrated by the hypotensive phenotype in
the global AHR knockout mouse. Notably, conditional deletion of the AHR solely
from endothelial cells results in a nearly identical blood pressure phenotype as ob-
served in the global knockout. Thus, we hypothesized that AHR plays a critical role
in the vascular regulation of blood pressure. We generated ECahr−/− mice by cross-
ing AHR floxed mice (ahrfx/fx) to mice expressing Cre recombinase driven by an
EC-specific promoter. BP was assessed by radiotelemetry prior to and following an
acute injection of the potent vasoconstrictor, angiotensin (Ang) II, or chronic treat-
ment with an inhibitor of Ang II formation, Ang converting enzyme inhibitor
(ACEi). ECahr−/− mice exhibited significantly different responses to Ang II and
ACEi. While Ang II increased BP in both genotypes, the increase was sustained in
ECahr+/+, whereas the increase in ECahr−/− mice steadily declined. Area under
the curve (AUC) analysis showed that Ang II-induced increase in diastolic BP
(DBP) over 30 min was significantly lower in ECahr−/− mice (AUC: ECahr+/+
1297±223 mmHg/30 min; ECahr−/− 504±138 mmHg/30 min, p<0.05). In con-
trast, while ACEi decreased BP in both genotypes, the subsequent rise in DBP after
treatment was significantly delayed in the ECahr−/− mice. ECahr−/− mice also ex-
hibited reduced vascular and adipose Ang II type 1 receptor (AT1R) expression,
and reduced aortic Ang II-dependent vasoconstriction in the presence of vascular
166 SOT 2013 ANNUAL MEETING
adipose. Taken together these data suggest that hypotension in ECahr−/− mice re-
sults from reduced vascular responsiveness to Ang II that is influenced by AT1R ex-
pression and perivascular adipose.
774 Role of Perivascular Adipose Tissue in Angiotensin II-
Induced Vascular Diseases.
L. A. Cassis. Graduate Center for Nutritional Sciences, University of Kentucky,
Lexington, KY. Sponsor: D. Conklin.
Adipocytes express all components of the renin-angiotensin system necessary to
synthesize and respond to angiotensin II (AngII). We have previously demonstrated
that infusion of AngII to hyperlipidemic male mice augments atherosclerosis and
causes the formation of abdominal aortic aneurysms (AAAs). Mechanisms for
AngII-induced AAAs include inflammation that extends to perivascular adipose tis-
sue surrounding the abdominal aorta. Inflammation in perivascular adipose tissue
was augmented by genetic or diet-induced obesity, and resulted in marked increases
in susceptibility to AngII-induced AAAs. Moreover, weight loss in previously obese
mice resulted in remodeling of AAAs. Vascular changes in mice experiencing weight
loss included reduced adventitial neovascularization, with alterations in stem cell
populations in perivascular adipose tissue. Current studies are examining effects of
deficiency of components of the renin-angiotensin system in adipocytes on AngII-
induced vascular diseases.
775 Environmental Factors in Neurodegenerative Diseases.
E. Tiffany-Castiglioni1 and A. G. Kanthasamy2. 1Veterinary Integrative Biosciences,
Texas A&M University, College Station, TX; 2Biomedical Sciences, Iowa State
University, Ames, IA.
Exposures to environmental pollutants are implicated in the development of neu-
rodegenerative diseases and protein conformational diseases, including Parkinson’s
Disease (PD) and Alzheimer’s Disease (AD). The purpose of this workshop is to
bring together experts to discuss etiologic factors associated with PD and AD, par-
ticularly environmental pesticides, heavy metals, and other pollutants, and to dis-
cuss new directions for identifying suitable targets for therapeutic strategies. Two
very promising lines of investigation into the mechanisms of dopaminergic cell
death in PD will be discussed, as well as the interaction of senescence-related, ge-
netic, and environmental factors likely contributes to the etiology of late-onset neu-
rodegenerative diseases such as PD and AD. The interactions of heavy metals with
chaperone proteins that regulate protein folding and cell death as related to protein
conformational diseases will also be discussed. The workshop will address six ques-
tions: 1) Despite equivocal results, why are genetic factors still considered the pri-
mary etiological factor in late-onset neurodegenerative disease?; 2) How can exist-
ing models of neuronal cell death in neurodegenerative diseases be integrated?; 3)
How can cell culture models be integrated into a better understanding neurodegen-
erative disease processes?; 4) Are there common pathways or mechanisms that are
relevant to environmental exposures in protein folding diseases, including PD and
AD?; 5) How do chemicals in a similar class of compounds elicit very different ef-
fects on the neurodegenerative processes?; 6) What is the evidence that early expo-
sures to environmental factors predispose to neurodegenerative diseases?
776 ER Chaperone-Metal Interactions: Links to Protein Folding
Disorders.
E. Tiffany-Castiglioni and Y. Qian. Veterinary Integrative Biosciences, Texas A&M
University, College Station, TX.
Chaperones in the endoplasmic reticulum play vital roles in the folding, assembly,
and post-translational modification of secretory proteins and also recycle, refold, or
initiate degradation of misfolded proteins. Chaperone deficiencies are implicated in
protein folding disorders of the CNS. We present evidence that the master chaper-
one 78 kD glucose regulated protein (GRP78) becomes pathologic through delete-
rious interactions with Pb and Cu. The key points of this presentation are that met-
als, including Cu and Pb, are implicated in the etiology of protein folding disorders,
Cu and Pb induce the expression GRP78, Cu and Pb bind to GRP78, and metals
impair GRP78 function when they bind to GRP78. Recent data from our lab
demonstrate that GRP78 is involved in Cu homeostasis in primary astrocyte and
C6 rat glioma cultures. Astrocytes cultured in medium containing 0.3 micromolar
Cu accumulated Cu and expressed increased levels of GRP78 but not metalloth-
ionein (MT1/2). Cu isotope radiography and Cu affinity column analysis with cy-
tosolic fractions of C6 cells showed that GRP78 bound to Cu. However, the level of
GRP78 expression was not proportional to Cu accumulation in astrocytes and C6
cells: astrocytes expressed low protein levels of GRP78 compared to C6 cells but ac-
cumulated significantly more Cu. Furthermore, GRP78 depletion by RNA inter-
ference increased Cu accumulation by C6 cells. Whereas our findings implicated
GRP78 in Cu homeostasis but not storage, we examined the possibility that
GRP78 affected Cu accumulation through its role as a protein chaperone. We
found that antibody to the Cu-extrusion pump Atp7a precipitated GRP78, but an-
tibody to GRP78 did not precipitate Atp7a. We postulate that GRP78 may chaper-
one Atp7a as a client protein in cytosolic trafficking for the removal of Cu from the
cell. Specific questions to be addressed include: Are there common pathways or
mechanisms that are relevant to environmental exposures in protein folding disor-
ders? How can cell culture models be integrated into a better understanding of neu-
rodegenerative disease processes?
777 Novel Oxidative Cell-Death Signaling in Neurotoxicity
Models of Parkinson’s Disease.
A. G. Kanthasamy. Department of Biomedical Sciences, Iowa State University, Ames,
IA.
Although oxidative stress and apoptosis are known to be important in the degener-
ative process in dopaminergic neurons in PD, the apoptotic signaling mechanisms
downstream of caspase-3 that contribute to the degeneration of dopaminergic neu-
rons are poorly understood. We have identified that protein kinase C-delta (PKCδ),
a member of the novel PKC isoform family, is highly expressed in nigral dopamin-
ergic neurons, and that the kinase is persistently activated via a novel mechanism by
which caspase-3 proteolytically cleaves to permanently dissociate the catalytic sub-
unit from the regulatory subunit of PKCδ. We demonstrated that PKCδ prote-
olytic activation contributes to apoptotic cell death of dopaminergic neurons dur-
ing oxidative damage induced by Parkinsonian toxicants such as 6-OHDA, MPTP
and other dopaminergic neurotoxicants. We also unexpectedly identified that pro-
tein kinase D1 (PKD1) is activated by a PKCδ dependent mechanism to protect
dopaminergic neurons from the early stages of neurotoxic insult. The current status
of our systematic characterization of PKCδ-PKD1 oxidative signaling in nigral de-
generative processes using cell culture and animal models of PD as well as human
postmortem PD brains will be presented. Potential therapeutic strategies targeting
the signaling pathway will be discussed. The proposed PKCδ-PKD1 signaling will
provide comprehensive information about signaling pathways associated with pro-
tective responses at the early stages of neurotoxicant-induced oxidative stress, as
well as the cell signaling mechanisms that override them during prolonged oxida-
tive insult in nigral dopaminergic neurons. Specific questions to be addressed will
include: How can existing models of dopaminergic cell death in PD be integrated
in relation to PKCδ-PKD1 signaling? Are there common pathways or mechanisms
that are relevant to environmental exposures in PD and other neurodegenerative
diseases? What are major interplay/interactions between genetic and environmental
risk factors associated with neurodegenerative diseases? (supported by NIH grants
ES10586, NS 074443, ES19267).
778 Industrial Toxicants and Parkinson’s Disease.
G. W. Miller. Environmental Health, Emory University, Atlanta, GA.
The exposure of the human population to environmental contaminants is recog-
nized as a significant contributing factor for the development of Parkinson’s disease
(PD) and other forms of parkinsonism. While pesticides have repeatedly been iden-
tified as risk factors for PD, these compounds represent only a subset of environ-
mental toxicants that we are exposed to on a regular basis. Non-pesticide contami-
nants, such as metals, solvents, and other organohalogen compounds
(polychlorinated biphenyls (PCBs), polybrominated diphenyl ethers, trichloroeth-
ylene), have also been implicated in the clinical and pathological manifestations of
these movement disorders. Here we report a relationship between PCBs and PD
pathology. Post-mortem brain samples from control and PD patients were obtained
from the Emory University Brain Bank and from the Nun Study. Concentrations of
eight prevalent PCB congeners were extracted from post-mortem brain tissue and
analyzed using gas chromatography-mass spectrometry. PCB congeners 153 and
180 were significantly elevated in the brains of Parkinson’s disease patients. When
stratified by sex, the female Parkinson’s disease group demonstrated significantly el-
evated concentrations of total PCBs and specifically congeners 138, 153, and 180
compared to controls, whereas PCB concentrations in males were not significantly
different between control and Parkinson’s disease groups. In a separate population
of women (Nun Study) who had no clinical signs or symptoms of PD, elevated
concentrations total PCB and congeners 138, 153 and 180 were also observed in
post-mortem brain tissue exhibiting moderate nigral depigmentation compared to
subjects with mild or no depigmentation. These quantitative data demonstrate an
association between brain PCB levels and Parkinson’s disease-related pathology.
Recent evidence from cellular and animal studies suggests that PCBs may induce
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pathology by disrupting the normal storage and release of dopamine and related
neurotransmitters. Dr. Miller will also present novel high throughput approaches
that will be used to further study this association. Supported by NIEHS
P01ES016731.
779 Integrating Epidemiological and Basic Research to Assess the
Role of Pesticide Exposure in Neurodegenerative Disease.
J. Richardson. Robert Wood Johnson Medical School, Piscataway, NJ.
Although a significant amount of research effort and resources have been focused
on determining genetic contributors to Parkinson’s disease (PD) and Alzheimer’s
disease (AD), purely genetic contributions account for only a fraction of the cases.
Our laboratory has been specifically interested in the potential role of pesticides in
the etiology and pathogenesis of both PD and AD. Recently, we have found that
serum levels of a long-lasting residue of the organochlorine pesticide hexachlorocy-
clohexane (β-HCH) was significantly higher in the serum of PD patients, while the
DDT metabolite, p,p’DDE, was significantly higher in patients with AD. DDE
levels were 3.8-fold higher in serum of AD patients (2.61 ± 0.35 ng/mg cholesterol;
n = 86) when compared to controls (0.69 ± 0.10 ng/mg cholesterol; n = 79; p <
0.001). After controlling for age, sex, education, race, and sample collection site,
the OR for increased risk of AD in the highest tertile of DDE levels was 4.26 (95%
CI: 3.41-5.32; p < 0.001). To determine whether DDT exposure alters the expres-
sion of AD-related genes in vivo, male C57BL6 mice were dosed with 3 mg/kg
DDT every 3 days for 30 days. DDT significantly increased the mRNA levels of
APP (25%), NEP (77%), and ApoE (150%) in the hippocampus. These data sug-
gest that DDT selectively alters the expression of AD-related genes in a brain-re-
gion specific manner with the hippocampus being more sensitive than the frontal
cortex. Specific Questions to be addressed will include: Despite equivocal results,
why are genetic factors still considered the primary etiological factor in late-onset
neurodegenerative disease? Are there common pathways or mechanisms that are rel-
evant to environmental exposures in both PD and AD? How do chemicals in a sim-
ilar class of compounds elicit very different effects on the neurodegenerative
processes?
780 Life-Course Models for Ensuring Children’s Health
Protection.
S. P. Darney1 and E. M. Faustman2. 1ORD, US EPA, Research Triangle Park, NC;
2Environmental & Occupational Health Sciences, University of Washington, Seattle,
WA.
New knowledge about environmental risks to human reproduction and develop-
ment directly relevant to children’s health protection derives from the fields of de-
velopmental and reproductive toxicology, exposure science, epidemiology, risk as-
sessment, and public health. Together, this information highlights the importance
of the intrauterine environment in setting the stage for lifelong health, along with
the complexities of the physical, chemical, and social factors that operate during
critical windows of development to impact health and wellbeing. For example,
breakthroughs in genetic polymorphisms and epigenetics are extending our under-
standing of inherent and acquired susceptibility to effects of environmental con-
taminants and showing how various intrauterine stressors such as nutrition, toxi-
cants, and social stress may alter developmental programming at the start and
throughout life. These scientific advances point to the need for innovative cumula-
tive risk assessment methods and public health intervention approaches in order to
account for risks that accrue across the developmental continuum from cradle to
cradle. This workshop brings together the interdisciplinary expertise needed to
begin integrating new knowledge into life-course models for children’s health and
wellbeing. Topics include research findings from toxicity testing and epidemiology
studies specific to critical windows of exposure during pre-conception, pregnancy,
and early childhood life stages to stimulate discussion on the broad challenge of op-
timizing testing and risk assessment models and enabling analyses across the whole
life course. The workshop also features an innovative approach for evaluating and
communicating complex scientific information about reproductive risks and inter-
ventions to diverse audiences including health care providers, parents (present and
future), and regulators.
781 Today’s Challenge for Protecting Children’s Environmental
Health for a Lifetime.
E. M. Faustman. University of Washington, Seattle, WA.
Evidence continues to build for the increasing importance of early life experiences
in defining not only childhood development and normal health trajectories but also
the potential for chronic disease risk throughout later life. Thus, a critical need for
protecting children’s health is recognition that our models require a dynamic con-
text, a lifecourse framework in order to address the key differences in developmen-
tal landmarks, functionality and the windows of susceptibility to environmental
impact. Such a framework is also needed to provide the context for incorporation of
the multitude of research findings across lifespan and discipline and to develop ef-
fective public health interventions. To set the stage for the workshop this talk will
identify the emerging issues and most pressing questions for reproductive and de-
velopmental toxicologists, epidemiologists, and risk and health assessors in life-
course study. Research from contemporary science, including community-based
cohort studies, coupled with research to elucidate molecular toxicity pathways and
genetic polymorphisms will be presented to illustrate these important lifestages.
Critical questions and research will be discussed within the framework and will in-
clude: What does this research tell us about critical windows of exposure, suscepti-
bility and impact across lifestage? What sorts of statistical models are needed to ac-
count for multiple stressors over time? How can this new science be used to build a
case for developing a lifecourse approach to risk assessment and children’s health
protection?  How can research in this arena be informed by the parents who live in
communities which are highly impacted by environmental stressors? Research by
developmental and reproductive biologists, toxicologists, epidemiologists and expo-
sure and risk scientists are required and hence determination of how this multidis-
ciplinary science can be integrated within the lifecourse models is essential.
Presentation of both evidence and modeling approaches will be the basis for de-
scribing the lifecourse framework for risk assessment.
782 Periconception Parental Metal Exposures, Couple Fecundity,
and Child Health: Delineating the Chicken and Egg
Question.
G. M. Buck Louis,  R. Sundaram and J. Maisog. Division of Epidemiology,
NICHD, Bethesda, MD. Sponsor: S. Darney.
Growing evidence suggests that human fecundity and fertility may be informative
about the subsequent health and well-being of couples’ offspring. This avenue of
study is in keeping with the early origin for health and disease hypothesis
(DOHaD), and the need for a life course approach for assessing health across the
lifespan. Early evidence suggests that gynecologic and urologic disorders may be as-
sociated with adverse pregnancy outcomes such as genital-urinary malformations or
diabetes in affected children. Similarly, couples experiencing conception delays are
reported to be at higher risk of delivering infants of diminished gestation and birth
size, outcomes associated with developmental disabilities and other childhood mor-
bidities. This evolving body of evidence underscores the importance of exposure as-
sessments in both partners in keeping with the couple-dependent nature of human
reproduction and development. For illustrative purposes, this talk utilizes data from
the recently completed Longitudinal Investigation of Fertility and the Environment
(LIFE) Study to demonstrate the relation between couples’ exposures to persistent
environmental chemicals (i.e., cadmium, lead and mercury) and fecundity as meas-
ured by time-to-pregnancy (in menstrual cycles), and infant health outcomes such
as gestation and birth weight. Blood cadmium concentrations in female partners
(range 0.02-2.87 μg/L) and blood lead in male partners (range 0.34, 6.91 μg/dL)
were significantly associated with a longer time to pregnancy as measured by fecun-
dity odds ratio (FORs) below one (FOR=0.78; 95% CI 0.63, 0.97 and FOR=0.85,
95% CI 0.73, 0.98, respectively). When jointly modeling both partners’ metal ex-
posures as a continuous exposure, female lead and male cadmium exposures were
associated with reductions in gestation and birth weight. Further analysis is under-
way to determine if the reduction in gestation and birth weight is mediated indi-
rectly through reduced couple fecundity or directly on fetal growth and develop-
ment.
783 Prenatal Pesticide Exposures and Children’s
Neurodevelopment across the Life-Course Continuum—
Lessons from the Fields.
B. Eskenazi,  A. Bradman,  K. Harley and N. Holland. Center for Environmental
Research and Children’s Health, University of California Berkeley, Berkeley, CA.
Sponsor: S. Darney.
A growing body of evidence suggests that prenatal pesticide exposure may be related
to adverse effects on neurodevelopment of children. In 2000-2001, we initiated
CHAMACOS (Center for the Health Assessment of Mothers and Children of
Salinas), a longitudinal birth cohort study, with the primary aim to investigate the
association of prenatal and postnatal exposure to agricultural chemicals and health
and development of children. We enrolled 601 pregnant women into this commu-
nity-based participatory research project. The participants were primarily low-in-
come Latinas from the agricultural community in the Salinas Valley, Monterey,
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California. We conducted detailed neurodevelopmental assessment of the
CHAMACOS children at multiple time points and currently the children are
reaching their 12th birthday. During these years, we have monitored their expo-
sures to a number of chemicals including pesticides such as organophosphates,
organochlorines and fungicides. We have also examined potential genetic suscepti-
bility to exposure with analyses of the PON1 polymorphisms and enzyme activity
and we are now beginning analyses of epigenetic endpoints. These studies highlight
the advantages of longitudinal cohort studies for evaluating the long-term impact
of prenatal and early life exposures on children’s health and development. Results of
the CHAMACOS study to date, coupled with those of other longitudinal studies
demonstrate how in utero exposure to certain pesticides can impact neurodevelop-
ment. Furthermore, our results suggest that certain children by virtue of their ge-
netic make-up maybe more susceptible. Lastly, we have identified limitations in as-
sessing exposures to pesticides that challenge our ability to determine “causal”
relationships. Primary funders: Children’s Center grant from NIEHS, NIH and US
EPA
784 New Strategies for Addressing Toxicity Testing across the
Lifespan.
P. M. Foster. National Toxicology Program (NTP), NIEHS, Research Triangle Park,
NC.
A previous NTP workshop evaluating the utility of the cancer bioassay for detect-
ing hormonally-related cancers (particularly breast, prostate, ovary and testis), con-
cluded that the standard approach, commencing exposure as young adults (~ 6
weeks of age) is likely missing important windows during early development that
could be critical for cancer outcomes and therefore assessment of lifetime risk. NTP
used the workshop results to adopt a new default for rat cancer bioassays to incor-
porate early life exposures into the assay. NTP had previously conducted perinatal
bioassays, but required specific justification; now, such studies are conducted rou-
tinely, unless there is a scientific rationale not to do so. This study begins exposure
at implantation and continues until the offspring reach 2 years of age. Embarking
on a cancer study requires preliminary dose setting information. For a cancer bioas-
say, this is normally a 90 d study, but would now require exposure from implanta-
tion thru weaning prior to the 90d component to evaluate target organ toxicity.
Such an approach, would also lend itself easily to evaluations of multiple other end
points from the same exposure paradigm, including developmental neurotoxicity
and immunotoxicity and, if one bred the F1 offspring at adulthood, both fertility/
fecundity and pre-natal developmental toxicity (teratology) - the NTP modified
one-generation study. Each of these end points could be considered interchangeable
“cassettes” depending on the type of toxicity that NTP was required to assess.
Compared to the individual, stand alone studies, this would have considerable sav-
ings in time, cost and animal usage, yet generate high quality developmental and re-
productive toxicity information for risk assessment. This is a similar approach to
the OECD extended one-generation study, but has several major advantages, most
importantly is a significantly improved ability to detect potential effects on fertility
and fecundity in the same animals on which structural changes are evaluated, to-
gether with a pre-breed exposure that is consistent with the length of rat spermato-
genesis.
785 Advancing Risk Communication and Decision Tools for
Children’s Health Protection.
T. J. Woodruff and P. Sutton. Program on Reproductive Health and the
Environment, UCSF, San Francisco, CA. Sponsor: S. Darney.
Parents and physicians who take care of them and their children read and hear a
plethora of information, some contradictory, about environmental and chemical
risks to children’s health. Better tools are needed to evaluate and synthesize this in-
formation and translate it into meaningful prevention strategies for health profes-
sionals, the public and policy-makers. Methods to synthesize the science into evi-
dence-based decisions have been developed and validated in clinical arenas. But
because of differences in approaches, the evidence-base and decision-context of
clinical health sciences methods are not seamlessly applicable to environmental ex-
posures. To meet this need, UCSF’s Program on Reproductive Health and the
Environment undertook an interdisciplinary collaboration to craft a systematic and
transparent methodology to evaluate environmental contaminants and their poten-
tial effects on reproductive and developmental health. The result is the Navigation
Guide, the product of a yearlong collaboration of 22 clinical and environmental
health scientists and/or practitioners, from governmental and non-governmental
organizations in the U.S. and Europe. Government agencies can use the Navigation
Guide methodology to craft evidence-based statements regarding the relationship
between an environmental exposure and health. Government agencies called on to
make risk management decisions can also apply the Navigation Guide to grade the
strength of recommendations for prevention. Professional societies, healthcare or-
ganizations, and other potential guideline developers working with toxicologists
can use the Navigation Guide to craft consistent and timely recommendations to
improve patient, and ultimately population, health outcomes. Development of the
first case studies applying the Navigation Guide methodology is extremely timely as
it coincides with growing recognition of the need for updated methods in risk as-
sessment, and related calls for government agencies such as the U.S. Environmental
Protection Agency to incorporate systematic approaches into decision-making.
786 Nanoinformatics: Computational Challenges for
Nanomaterial Hazard Assessment.
K. M. Waters1 and S. Harper2. 1Systems Toxicology, Pacific Northwest National Lab,
Richland, WA; 2Environmental & Molecular Toxicology, Oregon State University,
Corvallis, OR.
Hazard evaluation of the growing number of nanomaterials can be expedited and
enhanced through the identification of underlying quantitative relationships be-
tween their structural, chemical, and physical properties and responses in key bio-
logical systems. The Toxicity in the 21st century testing paradigm holds particular
promise for nanoparticles because whole animal testing is not economically practi-
cal or feasible for every new material introduced to the marketplace. Important ad-
vancements have been made in this emerging but critical field, yet many challenges
remain. Distillation of the large amount of phenotypic data regarding in vitro cyto-
toxicity and inflammation down to in vivo-relevant adverse events is a daunting
task, given the vast differences in microenvironment, temporal dynamics, and ex-
posure. The use of systems biology approaches will enable the identification of rel-
evant target organs/cell types, the development of mechanism-based assays for haz-
ard assessment and computational modeling for predicting potential toxicity from
human relevant exposures. This session will address computational challenges in
data standards, data integration, and modeling of dose response and structure-ac-
tivity relationships, including talks by experts in the areas of informatics, in vitro
screening, in vivo exposures and PB/PK modeling. Included is an opening by the
co-chair of the US-EU Nanoinformatics Community of Research, which seeks to
facilitate intercommunication between researchers, regulators, and granting agen-
cies on environmental health and safety issues for manufactured nanomaterials.
Speakers will include current experimental and computational approaches as well as
future research needs to identify relevant in vitro assays that are predictive for nano-
material hazard assessment based on in vivo mode of action and realistic human ex-
posures.
787 US-EU Nanotechnology Databases and Ontology
Community of Research.
N. A. Baker1 and H. Rauscher2. 1Pacific Northwest National Laboratory, Richland,
WA; 2DG Joint Research Centre Unit Nanobiosciences/TP 202, European
Commission, Ispra, Italy. Sponsor: K. Waters.
This talk will provide an overview on the work of a new US-EU Nanotechnology
Safety Community of Research (CoR) focused on nanotechnology databases and
ontology with specific examples and highlights from our own research. CoRs are
groups of people who share a significant interest in nano safety, work together to
develop a shared repertoire of resources, and have regular contact to address key
global research challenges. Interconnected information systems are urgently needed
for collating nanoscale material descriptions; their intrinsic and context-dependent
properties and their interactions; and their interactions with biological entities.
One goal of the CoR is to enable the sharing, searching, and analysis of nanoscale
material characterization data across a wide range of experimental sources and guide
the structuring of these data to enable their widest possible use. Achievement of this
goal will deliver important new capabilities to allow integration of risk assessment
data among labs throughout the world, to provide situational awareness of data
coverage across nanomaterial categories, and to enable predictive computational
models for bridging physical properties and biological outcomes with exposure, dis-
persal and fate. In order to realize this goal, the CoR will initially focus on the fol-
lowing three areas of investigation: Identification of the data elements necessary to
establish common data-sharing models for this domain; specification of require-
ments for sharing data between research groups and repositories in human- and
machine-interpretable forms; definition of concepts necessary to support the above
activities and representation of those concepts in an ontological framework. This
will include descriptors for the material itself as well as for its interaction with the
environment and elements to characterize intermediate effects in adverse outcome
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pathways. Through these activities the CoR will provide tools for improving the
overall quality of experimental data being generated in EU and US research com-
munities.
788 High-Throughput Screening of Nanomaterial
Bioactivity/Toxicity: The Computational Side Is Just As
Important As the Testing Assays and Characterization.
A. Wang. US EPA, Research Triangle Park, NC.
High-throughput screening (HTS) of bioactivity/toxicity is currently the only cost-
efficient and rapid tool to screen the numerous nanomaterials (NMs) in use and
under development. In the EPA ToxCast program, diverse classes of NMs and their
micro-particle and ionic salt counterparts are tested in HTS assays to help prioritize
NMs for further targeted testing. While the measured HTS endpoints are the same
as those tested for traditional soluble chemicals, specific challenges arise for NMs
for both experimental procedures and computational analysis. Challenges include
no standard nomenclature, comparison of potency between different classes of
NMs each tested at a different concentration range, linking NM physicochemical
(pchem) characterization data into the analysis, and assay interference by NMs.
With no standard nomenclature, we identified NMs by combining information on
group (nano, micro, ion), chemical composition of the core and coating, primary
particle size, and source. CAS numbers were purposely not used for NMs to avoid
data being aggregated with bulk counterparts. We accounted NM exposure poten-
tial and tested NM at various concentrations, while all soluble chemicals were
tested at the same concentrations in ToxCast and their sigmoidal AC50s were com-
pared. NM bioactivity data is being analyzed using various dose metrics (e.g., either
NM mass or surface area per medium volume or cell surface area) and potency esti-
mates (LEC, sigmoidal AC50, etc.) for NM toxicity ranking. To link NM pchem
properties into the bioactivity data, we choose to build a distinct database of NM
pchem characterization results, instead of modifying the existing ToxCast database
of bioactivity results. While HTS assays we used have successfully screened hun-
dreds of soluble chemicals, inspecting the NM bioactivity results carefully resulted
in discontinuing the use of one of the testing platforms because NMs interfere with
the assay. Future research needs include developing computational models using
NM pchem properties and/or in vitro data to predict in vivo effects.
789 Computational Dosimetry for Nanomaterial Risk Assessment
from Transcriptomic and HTP Data.
J. G. Teeguarden1,  V. Mikheev2,  J. G. Pounds1 and B. D. Thrall1. 1Systems
Toxicology, Pacific Northwest National Lab, Richland, WA; 2Battelle Memorial
Institute, Columbus, OH.
The convergence of evolutionary changes to the field of toxicology and the rapid
emergence of an immense new class of toxicologically untested nanoscale materials
has led to development of new genomic and high-throughput in vitro screening
tools for toxicological assessment of nanomaterials. These advancements and refine-
ments in the measurement and analysis of response have not however, been fol-
lowed by equally important advancements nanoparticle kinetics and in the meas-
urement of cellular or tissue exposure to test materials. The absence of adequate
dosimetry data for nanomaterial toxicity studies is one of the largest sources of un-
certainty in current testing paradigms. We present an integrated computational
dosimetry framework for placing the results of in vitro genomics and high through-
put (HTP) toxicity data in the context of in vivo animal and human exposures and
improving the basis for hazard rankings. The framework is applied in three case
studies to demonstrate the impact of an evolution from “exposure” to target cell
dose based nanotoxicity assessments: 1) the disruption of macrophage pathogen
clearance by macrophages in vitro; 2) in vitro cytotoxicity screening and hazard
ranking of 25 metal oxides; and 3) in vitro screening and hazard ranking of nano-
materials from the U.S. EPA’s ToxCast program.
790 Integrative Nanotoxicology: Linking Rapid Assays and
Informatics to Predict Nanomaterial-Biological Interactions.
S. Harper1, 2. 1Environmental and Molecular Toxicology, Oregon State University,
Corvallis, OR; 2Chemical, Biological and Environmental Engineering, Oregon State
University, Corvallis, OR.
While numerous nanotechnology and nanomaterial-based applications promise
benefit to human health or the environment, the potential health and environmen-
tal risks associated with the unique properties of nanoscale materials are unknown
and may lead to unintended health and safety consequences. The current gap in
nanoparticle toxicological data dictates the need to develop rapid, relevant and effi-
cient testing strategies to assess these emerging materials of concern prior to large-
scale exposures. Among these are informatics approaches to speed the rate at which
we can gain information on the fundamental relationships between specific nano-
material features and their behavior in the environment as well as their interactions
with living systems. Data compiled using a dynamic whole animal (in vivo) assay to
reveal whether a nanomaterial produces adverse responses have been made available
through the Nanomaterial-Biological Interactions (NBI) knowledgebase (nbi.ore-
gonstate.edu). Endpoints such as mortality, development, malformations and be-
havior were assessed in the embryonic zebrafish model. Data compression of the 23
individual endpoints provided the numerical representation of overall mortality
and morbidity elicited by a particular nanomaterial at a given concentration.
Computational analysis performed on 82 nanomaterial datasets has revealed the
importance of surface chemistry as a driver for nanomaterial toxicity across material
classes. Furthermore, data mining techniques to model the biological effects of
nanomaterials were applied to this case study. Results illustrate that individual end-
points have different predictability given the same set of algorithms and cumula-
tively the combined values can provide significant insight into the potential toxicity
associated with nanomaterials for use in hazard ranking.
791 Usefulness of In Vivo Genomics for In Vitro Screening in
Nanotoxicity.
A. Erdely and P. C. Zeidler-Erdely. NIOSH, Morgantown, WV.
Literature-based network analysis of in vivo microarray data, which yields biologi-
cally relevant molecular networks from the dataset, is becoming an increasingly use-
ful tool to identify nanoparticle-induced signaling. This approach can be used to
discover molecules that contribute to endpoint health effects and otherwise un-
known mechanisms of action. While animal inhalation exposures may be the most
relevant for predicting human health effects of nanomaterials, it is not always feasi-
ble because of the vast number of particles being manufactured. Therefore, in vitro
high-throughput screening (HTS) is being used to predict their potential toxicity.
While HTS may be necessary, in vivo genomic studies still provide useful informa-
tion for screening broad classes of nanomaterials. Similar to physiological experi-
ments in which three results are expected—increase, decrease, and no change—the
question of whether network-based genomics from in vivo studies is useful for in
vitro screening can be answered yes, no, and maybe. The output from these studies
provides significant molecular detail of an exposure. Advanced analysis can indicate
specific transcription factors involved in the response, upstream, and downstream
signaling, and also which cell type may be the most affected by a particular nano-
material. However, there are challenges to converting genomic data from in vivo ex-
posures to in vitro screening. These include responsiveness of the cell type in vitro
vs observed in vivo changes, distinguishing temporal effects, and an isolated single
cell response in vitro that lacks regulatory effects occurring in vivo. The in vivo ge-
nomic findings also have limitations including whether altered molecular networks
from studies in rodents are applicable to the human, and therefore applicable to
studies utilizing human cell lines. In addition, experimental design (e.g., dosing rel-
evant to human exposure levels) should be evaluated when interpreting genomic
analysis from in vivo studies. In summary, genomic analysis from in vivo studies, al-
though not without limitations, can offer insight for HTS.
792 Scientific and Regulatory Advances in Genetic Toxicology
Safety Assessment.
M. Aardema1 and B. Mahadevan2. 1Toxicology, BioReliance, Rockville, MD;
2Medical Safety & Surveillance, Abbott Laboratories, Columbus, OH.
Recent reviews of genotoxicity assay performance, the use of these data in the safety
evaluation process, and the development of new assays have led to important ad-
vancements in regulatory and scientific recommendations in the area of genetic tox-
icology. For instance, the International Conference on Harmonization (ICH) has
recently finalized guidelines on genetic toxicology testing for drugs. The OECD is
updating 15 year-old guidelines for genetic toxicology assays. International valida-
tion of new assays like the Comet assay have been completed. Workshops held by
international expert groups on new approaches for genetic toxicology assessments
highlight the importance of incorporating new approaches in drug safety evalua-
tions. In recent years, significant progress has been made in incorporating quantita-
tive approaches to genotoxicity dose response in order to identify a point of depar-
ture for application in risk assessment process. These important initiatives impact
the science and practice of genetic toxicology safety assessments globally and across
all sectors including drugs, chemicals, and consumer products. This workshop
brings together international experts representing key geographies involved in lead-
ing these efforts. In an effort to discuss scientific and regulatory advances in genetic
toxicology safety assessment, the following key aspects will be addressed in this
workshop: (1) US FDA implementation of ICHS2 (R1) guidelines, (2) Latest up-
dates and new approaches in international guidelines for genetic toxicology assays,
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(3) Outcomes on the JACVAM Comet validation and OECD guideline develop-
ment, and (4) New approaches for genotoxicity assessments and guidance on deal-
ing with positive results. In addition, this workshop will provide a forum to discuss
the scientific advances that have led to the latest regulatory guideline changes, and
their implementation.
793 US FDA Implementation of the ICH S2(R1) Guideline.
M. W. Powley. CDER, US FDA, Silver Spring, MD.
The genetic toxicology testing paradigm to support drug development was recently
updated in ICH S2(R1) “Guidance on Genotoxicity Testing and Data
Interpretation for Pharmaceuticals Intended for Human Use”. Although the guide-
line contained a variety of revisions, the most substantial impact was on the selec-
tion and conduct of genetic toxicology assays. Historically, in vitro and in vivo as-
says were performed to detect gene mutations as well as structural and numerical
chromosome damage. While the revised ICH testing battery addresses these same
endpoints, the guideline provides options weighted toward in vitro or in vivo assess-
ments. Another update was the inclusion of the in vitro micronucleus assay and in
vivo comet assay as potential components of the primary evaluation. Additional
changes included a reduced limit dose for in vitro mammalian cell assays (i.e., the
lower of 1 mM or 0.5 mg/mL) and an emphasis on designing studies to evaluate
multiple endpoints. Ultimately, the revisions were intended to improve perform-
ance characteristics of the genetic toxicology testing battery, provide options to
Sponsors of drug development, and maintain patient safety while preventing un-
necessary delays in developing drugs. 
As ICH S2(R1) was adopted in November 2011, regulatory agencies and Sponsors
are just beginning to gain experience with the guideline. This presentation will
briefly review the guideline and discuss implementation by the U.S. Food and
Drug Administration’s Center for Drug Evaluation and Research. Emphasis will be
placed on key factors considered in regulatory decision making and highlighted by
a discussion of case studies where appropriate.
794 New Approaches in International Guidelines for Genetic
Toxicology Assays: Latest Updates on OECD Guidelines.
V. Thybaud1,  J. van Benthem2,  N. Delrue3,  G. Douglas4,  E. Lorge5,
M. M. Moore6,  R. Schoeny7 and T. Singer4. 1Drug Disposition, Preclinical Safety
and Animal Research, Sanofi, Vitry-sur-Seine, France; 2National Institute for Public
Health and the Environment (RIVM), Bilthoven, Netherlands; 3Organization for
Economic Co-operation and Development (OECD), Paris, France; 4Health Canada,
Ottawa, ON, Canada; 5Servier Group, Orleans-Gidy, France; 6National Center for
Toxicological Research, US FDA, Jefferson, AZ; 7Office of Research and Development,
US EPA, Washington DC.
In March 2010, the 22nd meeting of the Working Group of National Coordinators
of the OECD Test Guidelines Programme (WNT) approved a project for updating
the Test Guidelines on genotoxicity, with Canada, the Netherlands, France and the
USA identified as lead countries for this work. An Expert Working Group (EWG)
comprised of international experts was established and has since met twice. The
EWG has recommended the deletion of several Test Guidelines, including the as-
says conducted in yeast and Drosophila. The EWG is currently working on revi-
sions to the in vitro Test Guidelines for the micronucleus test (TG487), chromoso-
mal aberration test (TG473) and gene mutation test (TG476), as well as the in vivo
assays for the mammalian erythrocyte micronucleus test (TG474), the mammalian
bone marrow chromosomal aberration test (TG475), the dominant lethal test
(TG478) and the spermatogonial chromosomal aberration assay (TG483). A new
guideline dedicated to the thymidine kinase locus is also under development. In ad-
dition, an update has been initiated of the Introduction Document to the genetic
toxicology test guidelines, which is intended to provide succinct and useful guid-
ance to guideline users. The purpose of the presentation at the SOT meeting will be
to provide information on the status of the revision process and its main accom-
plishments to date. The opinions in this abstract are those of the authors and do not
represent the policies of the U.S. EPA and FDA.
795 JACVAM Comet Validation and OECD Guideline.
M. Hayashi. Public Interest Incorporated Foundation, BioSafety Research Center,
Shioshinden, Iwata, Japan.
The in vivo rodent alkaline comet assay is used world-wide to detect genotoxicity of
chemicals. The assay, however, has not been formally evaluated for its reliability and
relevance. Thus, the Japanese Center for the Validation of Alternative Methods
(JACVAM) has organized with ECVAM, ICCVAM and NICEATM. This valida-
tion study has been also supported by JEMS/MMS and the consultation team in-
cluding statisticians and specialists for the comet assay. We had the kick-off meeting
for this trial in 2006. We have studied on the protocol optimization, intra- and
inter-laboratory reproducibility before starting the predictive capability as the 4th
phase. In the 4th phase- 1st step validation study, the purpose was to examine the
extent of reproducibility and variability of assay results among labs using coded test
chemicals and the positive control EMS, when experiments were conducted in ac-
cordance with the Comet assay protocol-version 14. In review of the data,
Validation Management Team (VMT) confirmed the reproducibility and variabil-
ity of assay results among laboratories. Thus the VMT decided to move on to the
4th phase- 2nd step validation study with an expanded set of test chemicals in ac-
cordance with the Comet assay protocol-version 14.2. The purpose of the 2nd step
is to investigate the predictive capability of the assay against carcinogenicity of test
chemicals. In the 2nd step, we selected 40 test chemicals, which include different
characteristics in chemical classes including: Genotoxic carcinogen, Genotoxic
non-carcinogen, Non-genotoxic carcinogen, and Non-carcinogen. Each test chem-
ical was examined in one lab, because reproducibility was robustly confirmed in the
1st step validation study. We will disclose all data shortly but up to now VMT sat-
isfied the outcomes. We are finalizing the validation report of our whole trial and
we are also preparing the Comet Assay Atlas to guide how to select nuclei to be an-
alyzed. Now, we are on the line of OECD TG through the peer review of our vali-
dation report and we have started to draft test guideline on in vivo comet assay.
796 New Approaches for Genotoxicity Assessment and Guidance
on Dealing with Positive Results.
B. Gollapudi,  V. Thybaud and J. Kim. ILSI-HESI IVGT Project Committee,
Washington DC.
Exposure to mutagens can lead to adverse health consequences such as cancer and
genetic diseases. A battery of short-term tests has been in use for decades to identify
potential mutagenic agents. However, the relevance of findings from these assays in
predicting human risk continues to be a subject of discussion, centering around
three major topics on how to 1) improve the existing assays, 2) integrate emerging
technologies, and 3) deal with positive findings. An international initiative consist-
ing of experts from academia, industry and the government has been addressing
these issues to enable more accurate assessment of human risk from exposure to
mutgenic agents. In the area of improving the existing in vitro assays, the experts
have been examining the choice of cell lines (e.g., human vs. rodents; p53 deficient
vs. competent) and the metabolic activation systems (human vs. rodent) in order to
make recommendations for future testing protocols. New technologies being con-
sidered as potential replacements and/or complements of the standard testing bat-
tery include the application of stem cells, 3-D skin/ liver tissues, humanized animal
models, high throughput assays (Tox21), incorporation of biomarkers of epigenetic
changes with potential transgenerational significance, and the utilization of non-in-
vasive imaging technologies to probe into time/age-related changes in the same an-
imal with parallel anatomical and functional assessments. Results from the geno-
toxicity assays have traditionally been interpreted in a qualitative manner without
analysis of the dose-response relationships. An expert group examined several quan-
titative approaches to the analysis of the dose-response data to identify a point of
departure (POD) that could be combined with mode of action analysis to deter-
mine whether exposure(s) below a particular level (i.e., POD corrected by safety
and uncertainty factors) constitute a significant risk for humans. These, along with
other ongoing national and international initiatives are paving the way for a para-
digm shift in the field of genetic toxicology.
797 Early Markers for Screening Workers Exposed to
Nephrotoxic Chemicals.
F. M. Metwally and A. ElSafty. Enviromental & Occupational Medicine
Department, National Research Center, Giza, Egypt.
Routine renal function tests are insensitive for detection of subclinical renal impair-
ment. A marker of early renal affection is needed to be used for screening of work-
ers at risk. In this study the activity of the urinary N—acetyl-B-D-glucosaminidase
(NAG) was measured to detect early renal changes in workers exposed to nephro-
toxic chemicals. The efficacy of NAG was also compared with that of urinary B2-
microglobulin. The studied groups included 50 chemical laboratory workers ex-
posed to aliphatic hydrocarbon solvents, 40 car painters exposed to aromatic
hydrocarbon solvents, 36 plumbers exposed mostly to lead fumes and a control
group of 36 clerks, matched the exposed groups in age, sex, smoking habits and so-
cioeconomic status. 
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Approval of the Medical Research Ethics Committee at the National Research
Center and Consent of all participants in the study were obtained. Exposure indices
included lifetime hydrocarbon exposure score (HES), Lead in blood (Ug/dL), and
lifetime exposure score for lead (LES-Pb).
Levels of urinary NAG differed significantly in all groups compared to controls.
Unlike B2-microglobulin, NAG levels also expressed a strong and consistent corre-
lation with cumulative exposure indices (HES&LES-Pb).Furthermore, an expo-
sure-effect relationship existed between NAG and HES in solvent-exposed nor-
motensive subjects. Values of NAG were higher in solvent-exposed hypertensives
than normotensives. These results support the use of urinary NAG in the periodic
screening of workers at risk, especially hypertensives and those with renal disease.
798 Is Indoor Exposure to DEPH a Health Risk?
A. Gotti1,  D. A. Sarigiannis1, 2 and S. P. Karakitsios1, 2. 1Chemical Engineering,
Aristotle University of Thessaloniki, Thessaloniki, Greece; 2Chemical Process and
Energy Resources Institute, Centre for Research and Technology Hellas, Thermi, Greece.
The study describes a mechanistic approach for assessing the timecourse of the
source-to-dose exposure to DEHP. The overall modelling framework was built on
asclxtreme and consists of:
- Multiphase indoor air quality model, for estimating DEHP concentra-
tions in the gas, particle and dust phase starting from gaseous emissions of products
containing DEHP.
- Exposure assessment model that incorporates all possible exposure
pathways and routes (inhalation of DEHP, skin exposure through dust rubbing off,
non-dietary oral exposure through dust ingestion).
- Internal dose model, for the assessment of DEHP and its 3 major
metabolites (MEHP, 5-OH MEHP and 5oxo-MEHP) in human tissues and urine
through a multi-compartmental PBPK model.
- Uncertainty/variability analysis tool across all stages of the assessment.
Under a typical scenario in a common residential dwelling (surface area of 270 m2
and air exchange rate of 0.5hr-1) characterized by DEHP gaseous emissions of 200
μg/h (vinyl flooring and other plastic materials), the concentrations of DEHP in
the gaseous, particles and dust phase are equal to 1.5 μg/m3, 21 μg/m3 and 4400
μg/g settled dust. Overall daily intake varies between 0.2 to 10 μg/kg-bw, depend-
ing on the exposure scenarios considered. The latter are age-dependent: adults are
exposed mostly through inhalation and infants through non-dietary ingestion. For
a common repeated aggregate exposure scenario of 2 μg/kg-bw, the DEHP internal
dose in venous blood and in adipose tissue (where bioaccumulation is clearly ob-
served) reach a quasi-state equilibrium of 0.07 and 0.4 μg/L respectively. The ex-
pected urinary concentrations of MEHP, 5-OH MEHP and 5oxo-MEHP are 3.1,
16 and 8 μg/gCr respectively. These findings are in good accordance to existing bio-
monitoring data from NHANES. They are also one order of magnitude below the
Biomonitoring Equivalent value of 660 μg/gCr for the sum of all DEHP metabo-
lites measured in urine showing that DEHP concentrations in dwellings does not
pose any significant risk.
799 Identifying the Sources of Uncertainty in the Process of
Reconstructing Exposures to Carbaryl Using Exposure-to-
Dose Modeling.
K. Holm1,  R. McDougall2,  M. Yoon3,  B. Young4,  H. J. Clewell3,  R. Tornero-
Velez1,  R. Goldsmith1,  D. T. Chang1,  C. M. Grulke1,  M. B. Phillips1,
C. C. Dary5 and C. Tan1. 1US EPA ORD NERL, Research Triangle Park, NC; 2The
AEgis Technologies Group, Oshawa, ON, Canada; 3The Hamner Institute, Research
Triangle Park, NC; 4Bayer CropScience, Research Triangle Park, NC; 5US EPA ORD
NERL, Las Vegas, NV.
“Exposure reconstruction” is a process for estimating distributions of exposures that
are consistent with observed biomarker levels, and comparable to risk-based guid-
ance values. The research identified uncertainties in reconstructed carbaryl expo-
sure estimates stemming from data gaps. Sources of uncertainty were identified by
evaluating exposure reconstruction results in a simulated population for which we
know the exposure level. The “Cumulative and Aggregate Risk Evaluation System”
(CARES) exposure model was used to generate time-concentration profiles for 500
virtual individuals exposed to carbaryl in food and drinking water for 365 days.
Time-concentrations profiles were the inputs for a human physiologically based
pharmacokinetic (PBPK) model for carbaryl, and biomarker (metabolite 1-naph-
thol) concentrations in spot urine sample were simulated. Three mathematical
techniques (namely, Exposure Conversion Factor, Discretized Bayesian, and
Markov Chain Monte Carlo (MCMC)) were used to reconstruct mean daily car-
baryl intake for the virtual population given the distribution of spot biomarker lev-
els. We found that MCMC was the most precise method.  Using MCMC for expo-
sure reconstruction, we found that MCMC iterations did not converge to an
exposure distribution if either the PBPK parameters or the urine flow rate were var-
ied. Variation in the time between exposure events and spot sampling also con-
tributed to the uncertainty in the reconstructed exposure. We recommend measur-
ing urine flow rate, obtaining accurate estimates of PBPK model parameters, and
monitoring time between exposure events and sample collection for improving re-
constructed exposure estimates for rapidly metabolized compounds such as car-
baryl.
[This abstract has been cleared by the US-EPA but solely expresses the view of the
authors]
800 A Novel Design of Experiments Approach to Assess
Biomarker Usage with Experiments Involving PBPK Models.
J. Ivy,  M. A. Lyons,  A. N. Mayeno and B. Reisfeld. Department of Chemical and
Biological Engineering, Colorado State University, Fort Collins, CO.
In exposure assessment, samples from the environment and population are col-
lected and analyzed to estimate the magnitude, frequency, and duration of exposure
to an agent. In this and other applications, an appropriate design of experiments is
critical to assure the optimal usage of resources and the efficient gathering of data
necessary to answer important public health questions. To aid in such designs,
physiologically based pharmacokinetic (PBPK) models are increasingly used to help
elucidate chemical disposition, identify key biomarkers, and characterize the effects
of uncertainty and variability. Although a number of approaches have been used to
help optimize the design of experiments based on PBPK models, significant gaps
remain in the efficiency and utility of these methods. 
Here we describe a new approach in experimental design that can be used to iden-
tify quantities useful in exposure assessment experiments, such as maximally-in-
formative biomarkers, types of biospecimen, and sampling times. This method in-
volves the integration of an efficient sampling algorithm and metrics to assess
information loss within a Bayesian inference framework containing a PBPK model.
These features expand upon the capabilities of existing tools to include hierarchical
statistical models and design comparison without random error. 
To test the methodology, several models relevant to toxicology were evaluated, in-
cluding those for styrene, methylmercury, dichloromethane, and chlorpyrifos.
Results from these studies showed that the use of information loss as a design met-
ric lead to precise and accurate reconstructions of simulated exposure data. These
results also included a characterization and ranking of various biomarker- and ex-
posure-related quantities in terms of their utility in conducting both forward and
reverse dosimetry.
We expect that the proposed methodology will be useful in the design of exposure
assessment experiments and related studies and will expand the field of Bayesian in-
ference in environmental and human toxicology.
801 Antioxidants and Oxidative Modification of Biomolecules:
Can They Identify a Biomarker of Ozone Oxidative Stress?
M. Kadiiska. NIEHS/NIH, Research Triangle Park, NC.
The effect of ozone exposure on antioxidants and oxidation products of lipids, pro-
teins and DNA in the plasma and urine of rats was studied by the international bio-
marker of oxidative stress study sponsored by NIEHS/NIH. The goal of this multi-
laboratory study was to identify a biomarker of ozone oxidative stress and to assess
whether inconsistent results often found in the field of ozone oxidative stress might
be due to a lack of comparability of the available methods where various oxidative
products are measured as biomarkers. The time and dose-dependent effects of
ozone exposure of rats on plasma and urine lipid hydroperoxides, TBARS, malon-
dialdehyde, isoprostanes, protein carbonyls, methionine sulfoxidation, various tyro-
sine oxidation products, and DNA changes were investigated with different tech-
niques. Effects of ozone on ascorbic acid, tocopherols, coenzyme Q, glutathione
and uric acid were measured to determine if the oxidative effects of ozone would re-
sult in decreases of antioxidants in blood plasma and bronchoalveolar lavage fluid as
expected. Generally, antioxidants were not changed or showed only high-dose
and/or single time point. Ozone exposure did not cause statistically significant dif-
ferences in plasma concentration products of lipid peroxidation or protein and
DNA oxidation in a time- and dose-dependent pattern. However, urinary concen-
trations of isoprostanes measured with an immunoassay were increased by two dif-
ferent doses of ozone 8 h, 56 h and 70 h post-exposure. Since elevation of iso-
prostanes in urine was consistent at three time points studied, it is concluded that it
fulfilled the oxidative stress biomarker criterion of significant effects measured in
biological fluid and seen at both doses at more than one time point. Measurements
of low molecular weight antioxidants in plasma are not sensitive biomarkers for ox-
idative damage induced by the ozone and may not be the tool of choice for the as-
sessment of oxidative damage by ozone in vivo.
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802 Enhancing PM Epidemiological Concentration-Response
Functions by Incorporating Lung Deposition and Oxidative
Potential.
S. P. Karakitsios1,  D. A. Sarigiannis1, 2,  V. Kalaitzis1 and M. Kermenidou1.
1Chemical Engineering, Aristotle University of Thessaloniki, Thessaloniki, Greece;
2Chemical Process and Energy Resources Institute, Centre for Research and Technology
Hellas, Thermi, Greece.
Despite the fact that well documented associations have been established between
urban air PM and mortality/morbidity, incorporating internal exposure and toxic-
ity metrics would be expected to significantly improve risk assessment and manage-
ment.
Thus, existing concentration response functions were modified taking into account
the fraction of particles deposited across the respiratory tract (using the MPPD
lung deposition model) and the relevance to the corresponding health endpoint.
The latter also depends on the actual size distribution for a given PM mass concen-
tration, which is better described by the particle number count (PNC). Finally, the
oxidative potential of particles of different size was also taken into account to derive
revised exposure-response functions.
To investigate the feasibility of using this approach an extensive measurement cam-
paign was carried out in a large Metropolitan area. PM size and number distribu-
tions were recorded in four sites. PM10, PM 2.5 and PM1 samples were analyzed
for oxidative potential by measuring Reactive Oxygen Species (ROS) using the
DTT protocol. The results showed that the fraction of ultra-fine and fine particles
is higher in the city center than in the suburbs. The same is true for oxidative po-
tential especially for the smaller particles. Thus, the actual exposure for endpoints
related to lower respiratory tract deposition and possibly translocation within the
systemic circulation (e.g. cardiovascular disease, adverse pregnancy outcomes)
might rise to up to 4 times higher to the one estimated by the respective differences
in mass concentration. Besides their implications for spatial epidemiology, our re-
sults show that future epidemiological studies would be greatly improved by incor-
porating evidence based on toxicity metrics, resulting in more robust associations
between ambient air PM exposure and ill-health.
803 Continuous, Near Real-Time Toxicological Screening Using
an Autonomously Bioluminescent Human Cell Line: A
Transitory Preclinical Imaging Approach.
D. Close1,  T. Xu2,  J. Webb2,  S. Ripp1 and G. Sayler1. 1490 BioTech Inc.,
Knoxville, TN; 2The University of Tennessee, Knoxville, TN.
Continuous toxicity monitoring using human cell-based bioreporters can report on
the bioavailability and efficacy of toxic substances but is logistically challenging be-
cause of the cells’ relatively high autofluorescent background or the expense and/or
sample destruction required to perform bioluminescent substrate (i.e., luciferin)
addition. To facilitate this process, we have synthetically optimized the bacterial lu-
ciferase gene cassette to function autonomously in human cells without the need
for external substrate addition. A proof-in-principle demonstration using human
kidney cells (HEK293) revealed that bioluminescent output declined in response to
challenge with the DNA damaging antibiotic Zeocin in a dose response fashion.
This response was similar to that displayed using commercially available firefly lu-
ciferase reporter assays, but allowed for repeated monitoring of the same samples,
leading to a lower overall cost and increased data acquisition potential. Similarly,
autobioluminescent reporter cells were designed using a tetracycline activated pro-
moter and were demonstrated to be capable of autonomously initiating a biolumi-
nescent response in reaction to treatment with the antibiotic doxycycline within 2.5
hours at a concentration of 100 ng/ml. The resultant bioluminescent signal was
comparable to existing firefly luciferase-based reporter systems at 1.33 (± 0.1) × 107
photons/second and was significantly greater than uninduced background (p <
0.01). Additionally, we have validated the imaging capabilities of these autobiolu-
minescent cells in a mouse model, demonstrating that the same system can be uti-
lized for both high throughput culture based testing and low throughput animal
studies. This approach therefore provides a route for the direct comparison of re-
sults as toxicological investigations transition across multiple levels of complexity.
804 Provisional Biomonitoring Equivalents for a Screening Level
Evaluation of Urinary 3-Phenoxybenzoic Acid
Concentrations in a Risk Assessment Context.
L. Aylward1,  S. M. Hays2,  K. Irwin3,  A. St-Amand3 and A. Nong3. 1Summit
Toxicology, LLP, Falls Church, VA; 2Summit Toxicology, LLP, Allenspark, CO; 3Health
Canada, Ottawa, ON, Canada.
3-phenoxybenzoic acid (3-PBA) is a common metabolite of a number of com-
monly-used pyrethroid pesticides of differing structures and relative potency and
also exists as a residue in foods resulting from environmental degradation of parent
pyrethroid compounds. Thus, 3-PBA in urine cannot be used as a specific bio-
marker of exposure to specific pyrethroid compounds. However, an approach de-
rived from the use of Biomonitoring Equivalents (BE), which are estimates of
steady-state biomarker concentrations consistent with exposure guidance values,
can be used in an assessment of nine pyrethroid compounds in order to estimate a
conservative initial screening value for a tiered assessment of population data on 3-
PBA in urine.  The most recent USEPA reference doses (RfDs) for these
pyrethroids were identified. An average urinary excretion fraction (FUE) for 3-PBA
was estimated from four pyrethroid compounds with human excretion fraction
data and then applied to all nine parent compounds. Estimated steady-state urinary
3-PBA concentrations associated with the RfD for each of the nine compounds
ranged from 6 ug/L for cyhalothrin to 1,875 ug/L for permethrin. The lower end of
this range can be used as a highly conservative screening value for assessment of
population urinary 3-PBA data through an implicit assumption that all exposures
leading to the observed 3-PBA were to the most potent parent compound and no
direct exposure to 3-PBA has occurred. If population data do not exceed this level,
it is unlikely that cumulative exposures to multiple pyrethroids are exceeding the
RfD equivalent for the mixture. If population data do exceed this level, more de-
tailed assessment and weighting of individual pyrethroid provisional BE values can
be considered.
805 Beyond Biological Equivalents to Biologically Effective Dose.
D. A. Sarigiannis1, 2,  S. P. Karakitsios1, 2 and A. Gotti1. 1Chemical Engineering,
Aristotle University of Thessaloniki, Thessaloniki, Greece; 2Chemical Process and
Energy Resources Institute, Centre for Research and Technology Hellas, Thermi, Greece.
This paper deals with the refinement of the Risk Characterization Ratio (RCR) cal-
culation by employing the enhanced Biomonitoring Equivalences (BEs) –
Biologically Effective Dose (BED) concept, using a generic PBTK model. The over-
all methodology was demonstrated for Bisphenol-A and DEHP.
A generic multi-compartmental two generations (mother-fetus) PBTK model was
developed so that it could be adaptable for humans, mice and rat. The model in-
corporates route and intra-species extrapolations, allowing the direct translation of
animal NOAELs into human BEDs and BEs. The model was parameterized for
BPA and DEHP based on existing human and rodents toxicokinetic data.
To estimate the BEs values, we estimated the BED for rodents corresponding to the
steady-state concentration of orally administered doses as described in the respec-
tive guideline studies (5 mg/kg_bw/day in mice for BPA and 592 mg/kg_bw/day in
Sprague-Dawley Rat for DEHP) from where the respective NOAELs were derived.
The corresponding BED derived for mice (BPA) and rat (DEHP) respectively, were
then translated by reverse modeling into human external exposure doses. Lastly, the
corresponding BEs were derived by running the human parameterized PBTK mod-
els. 
The direct extrapolation of observed NOAELs into human urine BEs through
BEDs, resulted in higher values than the ones derived based on using human equiv-
alent NOAELs and simple pharmacokinetic considerations. This comes as result of
physiology-dependent differences in clearance and entero-hepatic recirculation be-
tween rodents and humans. In addition inter-individual variability is explicitly ad-
dressed via this approach. Thus, translating in vivo testing results into equivalent
human exposure regimes and expected biomonitored values is facilitated; uncer-
tainties are minimized and unnecessary conservatism in population exposure/risk
characterization is avoided.
806 Liver Effects in CD1 Mice Prenatally-Exposed to Low Doses
of Perfluorooctanoic Acid (PFOA): Novel Modes of Action.
S. E. Fenton1,  A. J. Filgo1, 4,  C. A. Cummings5,  M. Hoenerhoff2,  D. Malarkey2
and E. M. Quist1, 2, 3. 1NTP Labs, DNTP, NIEHS, Research Triangle Park, NC;
2Cellular and Molecular Pathology Branch, NIEHS, Research Triangle Park, NC;
3Comparative Biomedical Sciences, College of Veterinary Medicine, North Carolina
State University Raleigh, NC; 4Curriculum in Toxicology, University of North
Carolina at Chapel Hill, Chapel Hill, NC; 5Experimental Pathology Labs, Inc,
Research Triangle Park, NC.
Perfluorooctanoic acid (PFOA) is a perfluoroalkyl acid primarily used as an indus-
trial surfactant. It persists in the environment and has been linked to potentially
toxic and/or carcinogenic effects in animals and people. As a known activator of
peroxisome proliferator-activated receptors (PPAR), PFOA can cause alterations
that lead to defects in fatty acid oxidation, lipid transport, and inflammation. Here,
CD1 mice were orally gavaged with 0, 0.01, 0.1, 0.3 and 1 mg PFOA/kg body
weight from gestation days (GD) 0 through 17. On postnatal day (PND) 21,
histopathologic changes in the liver of offspring included hepatocellular hypertro-
phy and periportal inflammation that increased in severity by PND91 in an appar-
ent dose-dependant response. In an earlier study, similarly exposed wildtype and
PPARα KO SV/129 and CD1 mice also developed significant hepatocellular hy-
pertrophy by 72 weeks (high-dose groups). A significant dose dependent increase in
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bile duct hyperplasia and hepatocellular hypertrophy in the PPARα KO mice sug-
gest a mechanism of hypertrophy independent of that previously reported for
PPARα-induced peroxisome proliferation in the current literature. Transmission
electron microscopy (TEM) of selected liver sections from PND91 mice revealed
PFOA-induced cellular damage and mitochondrial abnormalities with no evidence
of peroxisome proliferation. These mitochondrial changes may represent PFOA-in-
duced alterations in the beta-oxidation pathway regulated by PPARα and/or may
represent an earlier change that proceeds, or is independent of, PPARα-induced
peroxisome proliferation. This abstract does not necessarily reflect NIEHS policy.
807 Dose-Dependent Incidence of Murine Hepatic Tumors
following Perinatal Bisphenol A Exposure.
C. Weinhouse1,  O. S. Anderson1,  I. L. Bergin2 and D. Dolinoy1. 1Environmental
Health Sciences, University of Michigan, Ann Arbor, MI; 2Unit for Laboratory
Animal Medicine, University of Michigan, Ann Arbor, MI.
Epidemiological and animal studies have now critically established that environ-
mental exposures during early embryonic development have the ability to influence
adverse health outcomes in adulthood. This study evaluated adult health outcomes
of perinatal exposure to the endocrine disruptor bisphenol A (BPA) in a mouse
model. Prior studies have linked BPA exposure with precancerous lesions in mam-
mary and prostate glands, and uterus, as well as with hepatic dysfunction. We ex-
posed isogenic mice (n=69) perinatally through the maternal diet to 3 physiologi-
cally relevant doses of BPA (50 ng, 50 μg, or 50 mg of BPA per kg diet) or a control
diet. 23% (16/69) of 10-month offspring presented with hepatic tumors (hepato-
cellular carcinoma or hepatic adenoma), with a risk ratio of 7.15 for the 50 mg
group (p=0.0280) and significant dose-response on Cochran-Armitage test of trend
(p=0.0295). Importantly, observed early disease onset and lack of characteristic sex-
ual dimorphism in tumor incidence support a non-classical etiology. Notably, the
1982 National Toxicology Program chronic feed study finding of multinucleated
hepatocytes (MH) was replicated here. MH were present in 7 animals, exclusively
in low-dose groups (n=4 in 50 ng group, n=3 in 50 μg group); these abnormal cells
may be associated with increased hepatocyte proliferation. The significance of this
study includes: (1) these data represent the first report of frank tumors, in addition
to precancerous lesions, in any organ following perinatal or adult BPA exposure; (2)
these data represent the first report of neoplasms in a non-reproductive estrogen-
target organ; (3) this study underscores the critical importance of exposure timing;
and (4) this study implicates an environmentally ubiquitous chemical in develop-
ment of hepatocellular carcinoma in mice, with potential implications for human
disease. Funding: ES017524 and DK089503.
808 Liver Hypertrophy Is Not a Key Event in Constitutive
Androstane Receptor (CAR)-Mediated Liver Tumor
Development in Mice Treated with Triazoles.
K. Tamura1,  K. Inoue1,  M. Takahashi1,  S. Matsuo1,  K. Irie1,  Y. Kodama2,
S. Ozawa3 and M. Yoshida1. 1Division Pathology, National Institute Health Sciences,
Setagaya-ku, Tokyo, Japan; 2Division Toxicology National Institute Health Sciences,
Setagaya-ku, Tokyo, Japan; 3School Pharmacology, Iwate Medicine University,
Morioka, Iwate, Japan.
Liver hypertrophy is accepted to be a key event in CAR-mediated liver tumor de-
velopment in rodents. Many triazoles (TRIs) have been reported to induce hyper-
trophy and tumors in the livers of rodents. In this study, we clarified the involve-
ment of CAR in TRI-induced liver hypertrophy and tumor development using
CAR knockout mice (CARKO). Seven-week-old male CARKO and wild-type mice
(WT) were treated with cyproconazole (Cypro), tebuconazole (Teb), or fluconazole
(Flu) for 27 weeks at 200, 1500, or 200 ppm, respectively, in the diet. Tumors were
initiated by a single i.p. injection of diethylnitrosamine (DEN) before the treat-
ment. At interim kills at 4 (without DEN) and 13 weeks (with DEN), increases in
liver weight and severe centrilobular/diffuse hepatocellular hypertrophy were de-
tected in WT treated with TRIs. In CARKO, Teb induced severe liver hypertrophy,
whereas Cypro and Flu induced very mild hypertrophy compared to that in corre-
sponding WT. After 27 weeks of treatment, Cypro significantly increased
eosinophilic altered foci/adenomas in WT. In CARKO, both types of lesions were
clearly reduced compared to WT, but the multiplicity of foci was marginally higher
than in the control. Teb increased eosinophilic foci in WT, but significantly de-
pressed formation of these foci in CARKO. Flu and Teb had similar profiles in both
genotypes. Basophilic foci/adenomas were also reduced in CARKO compared to
WT for all TRI groups, but the effects were weak compared to changes in
eosinophilic ones. Our present study indicated that CAR was the major mediator
involved in liver hypertrophy for Cypro and Flu, but another pathway also existed.
In particular, CAR was not involved in Teb-induced hypertrophy. Meanwhile, the
involvement of CAR was crucial for TRI-induced tumors. These results suggested
that liver hypertrophy was not a key event in CAR-mediated liver tumor develop-
ment in mice.
809 Fluopyram: Mechanistic Investigations to Elucidate the MoA
for Liver Tumor Formation in the Rat.
H. Tinwell1,  D. Rouquié1,  O. Blanck1,  P. Maliver1,  F. Schorsch1,  S. Wason1,
D. Geter2 and R. Bars1. 1Bayer CropScience, Sophia Antipolis, France; 2Bayer
CropScience, Research Triangle Park, NC.
Fluopyram, a broad spectrum fungicide, caused hepatomegaly, liver hypertrophy
and resulted in an increased incidence of hepatocellular carcinomas and adenomas
in female Wistar rats following chronic exposure (24 months) at the highest dose
evaluated (1500 ppm equating to 89 mg/kg/d) in the guideline carcinogenicity
study. Mechanistic studies were subsequently conducted in the female rat to iden-
tify the initial key events responsible for the tumor formation and to establish
thresholds for each of the early hepatic changes. Studies showed increased expres-
sion of constitutive androstane receptor (CAR) and pregnane X receptor (PXR) in-
ducible genes from as early as 3 days of treatment. Further confirmation of
CAR/PXR activation was provided by increased activity of specific Phase I enzymes
(PROD and BROD respectively). Increased hepatocellular proliferation (measured
by Ki67) was observed, particularly in the centrilobular region, starting from 3 days
of treatment. Cell proliferation was also increased after 7 and 28 days of treatment
but to a lesser extent than that following a 3 day exposure. In these studies, dose re-
sponses and clear thresholds were established for gene expression, enzyme activity
and cell proliferation. Furthermore, these early hepatic changes were shown to be
reversible following compound withdrawal. Other modes of action (MoAs) for liver
tumor formation such as genotoxicity or peroxisome proliferation were not ob-
served. In conclusion, fluopyram is a threshold carcinogen and the resultant hepa-
tocellular carcinomas in the female rat are due to hepatocellular proliferation medi-
ated by CAR/PXR activation. It is unlikely that fluopyram would induce liver
tumors in humans as the CAR/PXR induced hyperplastic response has been shown
to be absent in human hepatocytes exposed to other known rodent hepatocarcino-
gens with the same MoA.
810 Mechanistic Investigation of Technical Toxaphene (TT)-
Induced Mouse Liver Tumors.
Z. Wang1,  B. H. Neal2,  J. C. Lamb2 and J. E. Klaunig1. 1Indiana University,
Bloomington, IN; 2Exponent Inc, Alexandria, VA.
Chronic exposure to technical toxaphene (TT) resulted in an increase in liver tu-
mors in B6C3F1 mice, with male mice showing higher response. TT appears to act
on the tumor promotion process. The current study was performed to further in-
vestigate the mode of action (MOA) of TT inducing mouse liver tumors. In a pre-
liminary dose range-finding study, mice were given TT (0, 10, 40, 80, 160 and 320
ppm) in diet continuously for two weeks. A decrease in body weight gain compared
to control was observed in mice treated with 320 ppm TT in diet (3.27 g vs. -1.22
g). Body weight gains were also significantly decreased in the 80 ppm and 160 ppm
treatment groups. A significant dose dependent increase in relative liver weight was
observed in mice treated with 0, 40, 80, 160 and 320 ppm TT diet (4.81, 5.32,
6.05, 6.55 and 7.43 g respectively). A similar trend was observed in the liver
weight. A dose dependent increase in liver centrilobular hypertrophy was seen in
mice treated with 80, 160 and 320 ppm TT; this was not observed at the 10 and 40
ppm doses. Similarly, a significant dose dependent increase in hepatocyte DNA
synthesis (BrdU incorporation) was seen in mice treated with 40 ppm, 80 ppm,
160 ppm and 320 ppm, compared with the untreated controls with labeling indices
of 3.28, 6.34, 11.10, and 15.61 respectively, compared with 1.06 in the control
group). The increase in labeling index showed agreement with the absolute and rel-
ative liver weight results. Based on findings of the range-finding study, a second
study using 0, 3, 32 and 320 ppm TT diet was initiated to define the MOA for the
TT mouse liver tumorigenic effects. Using phenobarbital as a positive control, the
well-established hepatic tumor modes of action are being investigated including:
cytotoxicity; receptor activation (PPARα, CAR, estrogen, and AhR) and oxidative
stress in TT treated B6C3F1 mice.
811 In Vitro Cross-Species Comparative Analysis of
Pharmacokinetic and Molecular Responses Mediated by a
Labile AhR Activator.
L. A. Murphy1,  D. L. Rick1,  L. McClymont1,  J. McFadden1,  M. Bartels1,
N. J. Stagg2,  R. Billington2,  R. J. Rasoulpour1 and D. L. Eisenbrandt2. 1The Dow
Chemical Company, Midland, MI; 2Dow AgroSciences, LLC, Indianapolis, IN.
A novel herbicide in development, XDE-729 methyl, induces rodent liver effects
through an aryl hydrocarbon receptor (AhR)–mediated mode-of-action (MoA). To
further characterize species differences in these effects, mouse, rat, and human in
vitro assays were used to elucidate differences in 1) AhR activation, 2) hydrolysis
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rates to non-AhR activator metabolites, and 3) systemic exposure as predicted by a
physiologically based pharmacokinetic (PBPK) model. AhR transactivation and
binding assays indicated that XDE-729 methyl exhibits weak AhR agonism in
mouse cells, no AhR agonism in human cells, and binds weakly to the rat AhR lig-
and binding domain. Fresh hepatocytes from CD-1 mouse, Sprague Dawley rat,
and human (6 donor livers) were used to compare XDE-729 methyl mediated
CYP1A1 induction, a sensitive biomarker for AhR activation. Gene expression
analysis indicated that rats are the most sensitive species with regards to XDE-729
methyl mediated CYP1A1 induction with maximal induction at 100 μM of 147.7-
fold in rat, versus 37.8-fold in mouse, and 2.9, 4.5, 6.2, 8.7, 10.3, and 34-fold in
the six human livers. An in vitro study to determine hydrolysis rates of XDE-729
methyl to the major metabolite, XDE-729 acid, which does not activate AhR, indi-
cated that: 1) the hydrolysis rate in human liver S9 is faster than rodents; 2) hy-
drolysis in human synthetic gastric fluid is faster than rodents 3) hydrolysis of
XDE-729 methyl is slowest in human whole blood versus rat or mouse. A PBPK
model using the in vitro hydrolysis rates predicted similar blood and liver levels of
XDE-729 methyl in rat and human after XDE-729 methyl dietary exposure.
However, the in vitro mechanistic data indicate that humans are less sensitive than
rats based on faster liver hydrolysis rates of XDE-729 methyl and limited AhR acti-
vation; therefore, a margin of exposure risk assessment using the in vivo rat toxicity
studies is protective of human health.
812 Developmental Exposure to 2, 3, 7, 8 Tetrachlordibenzo-p-
dioxin (TCDD) Affects Leukemeogenesis in Adult Tumor
Prone Mice by Interacting with the Thymus Expressed
Notch1.
M. D. Laiosa,  L. Ahrenhoerster,  D. Almagro and P. A. Lakatos. Zilber School of
Public Health, UW-Milwaukee, Milwaukee, WI.
Reprogramming of progenitor cells during development can have profound im-
pacts on later life disease susceptibility and is dependent on the interaction between
genetic susceptibility of the child, the maternal intrauterine environment, and the
timing of exposure to potential insults. In particular, developmental exposure to the
persistent contaminant TCDD, acting through the aryl hydrocarbon receptor
(AHR), is known to cause immunosuppression and is associated with hematologi-
cal malignancies later in life. For example, at least 50% of all T-cell leukemias are as-
sociated with activating mutations in Notch1. Notch1 is a transmembrane receptor
required for T-cell lineage commitment in the thymus. Moreover, preliminary data
suggest a potential interaction between AHR and Notch1 signal transduction. To
test for a possible gene-environment interaction between the AHR and Notch1, we
hypothesized that leukemia prone Notch1 transgenic mice would have a more se-
vere disease if exposed to TCDD during development. To test this hypothesis,
timed pregnant dams were exposed to 0 to 3μg/Kg TCDD throughout pregnancy.
We found that while there was no difference in disease onset, severity or incidence,
there was a significant difference in the cell-type of T-cell thymomas that developed
in these mice and this difference was observed only in males. Specifically, whereas
Notch-TG control mice developed CD4+ tumors, Notch-TG mice exposed to
TCDD in utero developed CD8+ tumors. This lineage switch in disease phenotype
suggests a reprogramming of a hematopoietic precursor or tumor stem cell during
development leading to a reversal in the T-lineage choice in the adult life. These
data suggest that early life AHR activation has a long-term effect on Notch1-medi-
ated thymocyte lineage choice throughout the life-course. These data have implica-
tions for disease susceptibility in vulnerable populations that may possess genetic
instability in the Notch locus and/or have been exposed to AHR agonists develop-
mentally.
813 Critical Evaluation of the Mode of Action of Carcinogenicity
for Acrylonitrile.
J. M. Fritz and A. M. Luke. ORD/NCEA/IRIS, US EPA, Washington DC.
Acrylonitrile (AN) is an aliphatic nitrile used as a reagent in industrial processes,
and is polymerized into injection-molded plastics used to create pipes, automobile
dashboards and children’s building blocks. Annually, over 1.5 million tons are pro-
duced in the U.S. alone, where AN is regulated by EPA as a hazardous air pollutant.
Industrial cohort studies suggest a potential association between AN exposure and
increased risk of cancer mortality and experimental evidence demonstrates that
acrylonitrile induces tumor formation at multiple sites in rodent species following
oral and inhalation exposure. A comprehensive cancer mode of action (MOA)
analysis has been conducted and may inform the correspondence between the
human and animal datasets. The AN literature was reviewed for evidence pertain-
ing to genotoxicity and other potential MOAs; data were sorted by species, end-
point, and study design, and effects were critically evaluated for consistency, mag-
nitude, specificity, plausibility and coherence. Early effects in relevant adverse
outcome pathways were further assessed for causality, to determine if effects could
indicate key events in AN-induced carcinogenesis. Critical analysis of the AN
dataset supports potential contributions from multiple MOAs, including genotoxi-
city. Brain region-specific increases in lipid peroxidation and dose-dependent accu-
mulation of 8-oxodG could support genotoxicity concurrent with oxidative stress
in vivo, while covalent-binding to proteins and nucleic acids, liver DNA alkylation,
leukocyte cell micronuclei formation and dose-dependent induction of forward
mutations all support genotoxicity occurring prior to other cellular effects. While
data-rich in some areas, other endpoints evaluated in the course of this analysis were
data-poor. Some of these data gaps include a comprehensive evaluation of DNA re-
pair and adducts, fixed mutations, and source of AN-induced oxidative species in
rodent cancer target tissues. The views expressed are those of the authors and do not
necessarily reflect the views or policies of the U.S. EPA.
814 Long-Term Inhalation Study with Nanomaterials:
Pulmonary Effects of Nanoscale CeO2 and BaSO4 in a Rat
28-Day Range Finding Study.
J. Keller1,  S. Gröters1,  L. Ma-Hock1,  V. Strauss1,  K. Wiench2,  B. van
Ravenzwaay1 and R. Landsiedel1. 1Experimental Toxicology and Ecology, BASF SE,
Ludwigshafen am Rhein, Germany; 2Product Safety, BASF SE, Ludwigshafen am
Rhein, Germany.
Inhalation exposure has been considered as the major route of concern for nanoma-
terials. Recent published literature reveals a distinct gap of long-term inhalation
studies, especially on industrial relevant poorly soluble bio-persistent particles
(PSP), including their carcinogenic potential. Nanoscale CeO2 and BaSO4 will be
accurately examined in a combined chronic and carcinogenicity inhalation study.
Emphasis is placed on the relationship of inflammatory reactions, particle overload
and lung tumor formation. 
For this purpose, a 28 day range finding study according to the OECD Guideline
412 was performed. Groups of female Wistar rats (5 rats/ group) were whole body
exposed to 0.5, 5, 25 mg/m3 CeO2 and 50 mg/m3 BaSO4 for 28 days. A concur-
rent control group was exposed to clean air. The exposure concentrations for CeO2
were selected to achieve lung burden below and above particle overload. 
Biological effects were examined immediately after last exposure and in a post-ex-
posure period. Examined endpoints considered bronchoalveolar lavage, hematology
and clinical chemistry, gross necropsy, histological examination of the respiratory
tract and cell proliferation of the lung as well as systemic genotoxicity in peripheral
blood cells. 
Increased lung weights in the high dose test group of CeO2 (25 mg/m3) and sig-
nificant changes in lung lavage parameters (cell cytology, protein and enzyme levels)
in the mid (5 mg/m3) and high dose test group of CeO2 are indicative for early
treatment-related findings. Subsequent results of particle related biological effects
associated with an appropriate particle lung burden of the range finding study will
be presented here. The outcome of the 28 day study will serve as basis for concen-
tration selection for the upcoming long-term inhalation study.
815 Pulmonary Responses in Rats after Inhalation Exposure to
Cerium Oxide Nanoparticles Generated by the Harvard
Versatile Engineered Nanomaterial Generating System
(Venges).
V. Castranova1,  M. Barger1,  W. Goldsmith1,  D. Frazer1,  B. Hines1,
W. McKinney1,  G. Pyrgiotakis2,  S. Gass2,  P. Demokritou2 and J. Ma1. 1HELD,
NIOSH, Morgantown, WV; 2Harvard University, Boston, MA.
Recently cerium compounds have been used in a variety of consumer products in-
cluding semiconductors, UV shields and diesel fuel additives to increase fuel com-
bustion efficiency and decrease diesel soot emissions. Our previous studies have
shown that exposure of rats to CeO2 by intratracheal instillation not only induces
sustained pulmonary inflammation, but also lung fibrosis. In the present study, the
aerosols of CeO2 or CeO2 coated with a nanothin layer of amorphous SiO2 (aSiO2-
CeO2) were generated by the Harvard VENGES. The aerosols were diluted with air
and delivered to a whole body exposure chamber. Male Sprague Dawley rats were
exposed to CeO2 or aSiO2-CeO2 at 2.7 mg/m
3, 2h/day for 4 days along with air
controls. Animals were sacrificed at 1or 84 days post exposure. Morphometric
analysis of the CeO2 and aSiO2-CeO2 particle cores showed diameters of 12.8 and
19.2 nm, respectively. Mobility diameter modes of 82 and 96 nm were measured
for the CeO2 and aSiO2-CeO2 aerosols aggregates in the breathing zone of the ani-
mals. Alveolar macrophages (AM) were obtained by bronchoalveolar lavage (BAL),
and acellular BAL fluids (BALF) were saved for further analysis. At 1 day after
CeO2 exposure, but not aSiO2-CeO2, significantly induced PMN infiltration and
lactate dehydrogenase activity in the BALF. CeO2 significantly increased collagen
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degradation enzymes, matrix metalloproteinases (MMPs)-2 and tissue inhibitor of
MMP-1 in the BALF, which may be involved in the modification of extracellular
matrix. At 84 days post exposure, none of the particle treatment groups induced
lung inflammation, cellular injury or alteration of hydroxyproline content in lung
tissues. These results demonstrated that a thin coating of aSiO2 on CeO2 protected
lungs from CeO2-induced acute lung toxicity, suggesting that a thin coating of
aSiO2 may potentially be used to modify other nanoparticle-induced lung toxicity.
816 Gene Expression Profiling of Human Lung Epithelial Cell
Lines Exposed to Manufactured CoO and CeO2
Nanoparticles.
I. Nelissen1,  S. Verstraelen1,  E. Casals2,  S. Remy1,  P. De Boever1,  H. Witters1
and V. Puntes2. 1Flemish Institute for Technological Research (VITO NV), Mol,
Belgium; 2Institut Català de Nanotecnologia (ICN), Barcelona, Spain. Sponsor: P.
Hoet.
Exposure to manufactured nanoparticles (NPs) via inhalation can cause adverse
human health effects. A transcriptomics study was performed to identify molecules
and cellular pathways that are specifically triggered by in vitro exposure of the
human bronchial BEAS-2B and alveolar A549 epithelial cell lines to 7-nm CoO
and 4-nm CeO2 NPs. We aimed to investigate whether 1) the same lung cell type
responds similarly to the NPs, 2) alveolar vs. bronchial epithelial cells respond dif-
ferently to the same NP, and 3) immunological processes are influenced. Non-cyto-
toxic exposure concentrations of monodispersed NPs were used. Statistically signif-
icant changes in gene expression as compared to solvent-treated cells (median
|fold-change|>1.5, p<0.05) were evaluated after 3, 6, 10, and 24 hours. 
The kinetics of the cell responses induced by the 2 NPs were similar within, but dif-
ferent between the 2 cell models. BEAS-2B cells were found to be more sensitive for
NP toxicity, as they showed a higher total number of differentially expressed tran-
scripts (DET) at a 10-fold lower NP-concentration than A549 cells. Hierarchical
biclustering of all DET indicated that the transcriptional responses were quite het-
erogeneous among the 2 cell types and 2 NPs. Between 1% and 14% DET encod-
ing markers involved in immune system processes were observed in the BEAS-2B
and A549 cell lines, resp., with the highest fractions observed in BEAS-2B cells.
Most of these genes, i.e. ITGB2, TLR6, PAG1, HLA-DRB3, TIRAP, and HLA-A,
are involved in immune signalling or yet unassigned pathways. Nanoparticle expo-
sure mainly induced suppression of immune gene transcription, rather than im-
mune stimulation. The AKT1 gene was identified as a possible generic marker of
lung epithelial cell-NP interaction.
Our data suggest that CoO- and CeO2-NP give rise to a distinct immunological re-
sponse in bronchial and alveolar epithelial cells.
817 Mechanistic Insights into the Toxicity of Multiwalled Carbon
Nanotubes and Cerium Dioxide Nanoparticles in Primary
Human Bronchial Epithelial Cells.
S. Hussain1,  R. Snyder1,  S. M. Anderson1,  J. D. Marshburn1,  A. B. Rice1,
N. J. Walker2 and S. Garantziotis1. 1Clinical Research Program, NIEHS
(NIEHS)/National Institute of Health (NIH), Durham, NC; 2DNTP, NIEHS,
Research Triangle Park, NC.
Cerium dioxide nanoparticles (CeO2 NPs) and multi-walled carbon nanotubes
(MWCNT) are priority materials for urgent risk assessment due to wide spread in-
dustrial, consumer product and environmental utilizations. We aimed at decipher-
ing the impact of CeO2 NPs and MWCNTs on primary human bronchial epithe-
lial cells (BEC) following an ex-vivo exposure. CeO2 NPs and MWCNT
suspensions were thoroughly characterized, including using transmission electron
microscopy (TEM), dynamic light scattering (DLS), and zeta potential analysis.
Cells were then exposed to nanomaterials for 18 - 24 hours and mechanisms of cell
injury were studied. TEM revealed that both CeO2 NPs and MWCNTs are inter-
nalized by bronchial epithelial cells and are found either in vesicles or free in the cy-
toplasm. CeO2 NPs fail to elicit a toxic response in BECs at environmentally rele-
vant doses. However, diesel exhaust particles and CeO2 NPs co-exposure leads to
significant increase in cytotoxicity. MWCNT exposure in bronchial epithelial cells
leads to a time-dependent decrease in viability, increased reactive oxygen species
production, NF-κB (p65)/Rel A phosphorylation and nuclear translocation.
Moreover, we observed caspase-1 activation and increased numbers of autophagic
vesicles in MWCNT-treated cells as compared to control cells. An increase in p62
levels indicated a blockage of autophagic turnover rather than autophagy induction
in these cells which was associated with cytoskeletal alterations induced by
MWCNT. In conclusion we demonstrate that nanomaterials exposure leads to
toxic events in primary human bronchial cells. Moreover, we show that doses of
CeO2 NPs and diesel exhaust particles that are innocuous in themselves can result
in toxicity when given as a co-exposure.
818 Inflammatory and Free Radical Generation Characteristics of
Nano-Cerium Dioxide.
V. C. Minarchick1,  D. W. Porter2,  N. R. Fix2,  S. S. Leonard2,  E. M. Sabolsky3
and T. R. Nurkiewicz1. 1Center for Cardiovascular and Respiratory Sciences, West
Virginia University, Morgantown, WV; 2National Institute for Occupational Safety
and Health, Morgantown, WV; 3Mechanical Engineering, West Virginia University,
Morgantown, WV.
Nano-cerium dioxide (CeO2) possesses the potential for use in human health by
protecting against the deleterious effects of ischemia and radiation. However, the
literature is polarized about the effects this compound has in vivo. Our laboratory
has shown that pulmonary nano-CeO2 impairs arteriolar reactivity 24 hrs post-ex-
posure. The mechanisms of this impairment are currently unknown but may be
linked to the free radical scavenging or inflammatory properties of this nanoparti-
cle. The aims of this study were to: 1) thoroughly assess the physical and chemical
characteristics of the nano-CeO2, 2) examine the antioxidant potential of nano-
CeO2 via electron spin resonance (ESR), and 3) assess the pulmonary inflammation
in Sprague-Dawley rats 24 hrs post-intratracheal nano-CeO2 instillation. The pri-
mary particle size of the nano-CeO2 was calculated to ~3 nm (via transmission elec-
tron microscopy and surface area measurements). Dynamic light scattering deter-
mined the agglomerate size (~80 nm) and x-ray photoelectron spectroscopy
determined the valence state of the nano-CeO2. The ESR measurements indicated
that nano-CeO2 alone did not generate free radicals and in the presence of cells
(Raw264.7), nano-CeO2 quenched the free radicals generated by these cells.
Finally, bronchial alveolar lavage from rats instilled with 0, 10, 100 or 400 μg of
nano-CeO2 revealed an increase in polymorphonuclear leukocytes (0.6±0.2,
0.8±0.3, 7.1±0.9, and 10.3±0.9 per 106 cells), and lactate dehydrogenase (90±12,
100±9, 453±33, and 602±32 units/L) but there was no change in albumin. These
findings provide evidence that pulmonary inflammation is present after exposure
but does not damage to the epithelial/endothelial cellular barrier. Additionally,
these nanoparticles are capable of quenching free radicals there by exerting a sys-
temic effect.
NIH-RO1-ES015022 and RC1-ES018274 (TRN), and NSF-1003907 (VCM)
819 Nanoceria Distribution and Biopersistence in Rats Is Not
Consistently Affected by Particle Size, Shape, Dose, or
Dosing Schedule.
R. A. Yokel1, 2,  R. C. MacPhail5,  J. M. Unrine3,  P. Wu4 and E. A. Grulke4.
1Pharmaceutical Sciences, University of Kentucky, Lexington, KY; 2Graduate Center
for Toxicology, University of Kentucky, Lexington, KY; 3Plant and Soil Sciences,
University of Kentucky, Lexington, KY; 4Chemical and Materials Engineering,
University of Kentucky, Lexington, KY; 5Toxicology Assessment Division, US EPA,
Research Triangle Park, NC.
Background: Nanoceria is a diesel fuel additive, an abrasive in integrated circuit
fabrication, and is being developed as an antioxidant therapeutic. Objectives:
Determine the influence of nanoceria size, shape, dose, and dosing schedule on its
distribution and biopersistence. Methods: Aqueous dispersions of citrate-stabilized
cubic or polyhedral ceria and a ceria nanorod (10 x 40 to 600 nm), synthesized and
characterized in-house, were iv infused into rats (single infusion of 5 nm @ 11, 56
or 85 mg/kg, 15 nm @ 70 mg/kg, 30 nm @ 6 or 85 mg/kg, 55 nm @ 50 mg/kg,
nanorod @ 20 or 50 mg/kg; and 5 nm @ 11 mg/kg for 5 consecutive days). They
were terminated 1 h to 90 days later. Controls received vehicle. Multiple organs
were weighed and samples collected from multiple sites and blood for cerium de-
termination. Results: The greatest % of the dose was in the liver, spleen and bone
marrow; these levels decreased over time only in liver for the 30 nm ceria @ 6
mg/kg, and increased in spleen and bone marrow over time in several cases. There
were no consistently significant differences in the % of the dose in the liver or
spleen for the different sizes, shapes, doses, or dosing schedules other than tenden-
cies for more nanorod accumulation in the spleen than the 5 nm polyhedral ceria
and more nanorod accumulation in the bone marrow than the 5 or 30 nm ceria.
Brain nanoceria was low; little to none was in brain parenchyma. Conclusions:
Nanoceria, an insoluble metal oxide, was cleared into mononuclear phagocyte sys-
tem organs in which it persisted for 90 days. Size, shape, dose, and dosing schedule
had little effect on its distribution or persistence, suggesting repeated exposure will
likely produce accumulation, perhaps reaching a level shown to be toxic after single
high-dose administration. Support: US EPA STAR Grant RD-833772.
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820 Metal Oxide Nanoparticles Alter Spontaneous Activity and
Pharmacological Responses in Neuronal Networks Grown on
Microelectrode Arrays.
J. D. Strickland3, 2,  W. R. LeFew1,  K. Dreher2 and T. J. Shafer1. 1IISTD, ORD,
US EPA, Research Triangle Park, NC; 2EPHD, ORD, US EPA, Research Triangle
Park, NC; 3North Carolina State University, Raleigh, NC.
The widespread use of engineered nanoparticles (NP) has increased their exposure
potential and made it necessary to assess potential impacts on human health.
Previous studies indicate that NPs can enter the brain via the olfactory nerve or by
crossing the blood-brain barrier; thus, it is essential that their effects on neuronal
function be examined. In the present study, 5 CeO2 (7 to 1288 nm), and 4 TiO2 (6
to 200 nm) NPs were examined to determine their ability to alter network function
in primary cultures of cortical neurons grown on 12 well microelectrode array
(MEAs) plates. NPs were dispersed in Neurobasal A medium containing 20% FBS
(dispersant). Between days 14 to 21 in vitro, 1 hr of baseline activity was recorded
prior to exposure to NPs. Changes in spontaneous mean firing rate (MFR) relative
to the dispersant control were assessed 1, 24, and 48 hrs after exposure to NPs (3-
50 μg/ml). Following the 48 hr recording, the response to a pharmacological chal-
lenge with the GABAA antagonist bicuculline (BIC; 25 μM) was assessed. In all, 3
of 5 CeO2 and 2 of 4 TiO2 NPs decreased MFR below threshold following 1 hr ex-
posure. All 4 TiO2 NPs altered MFR beyond threshold at 24 hrs. At 48 hr, the
MFR for all 9 NPs deviated from minimum threshold. BIC increased MFR in dis-
persant treated networks; of the 9 NPs tested, 3 TiO2 particles and 1288 nm CeO2
increased the BIC response in MFR, while <7 nm CeO2 suppressed the BIC-in-
duced change in MFR relative to control. Most notably, the results show that
changes in network function occur in the absence of cytotoxicity and were observed
at all time points regardless of particle type. The results indicate that metal oxide
NPs can disrupt both spontaneous and GABAA receptor-mediated neuronal activ-
ity in vitro. Additional studies are necessary to investigate the mechanisms underly-
ing these observations and understand the implications of NP exposure to neuronal
function in vivo. (This abstract does not reflect Agency Policy.)
821 Systems and Computational Biology As Foundations for
Toxicology Research.
L. D. Lehman-McKeeman. Bristol-Myers Squibb Company, Princeton, NJ.
Systems and computational approaches are holistic methods to elucidate and un-
derstand the complex interactions among components of a biologic response net-
work and are central to the comprehensive understanding of all biological
processes. The field requires the integration of concepts from biology and physiol-
ogy, computer science and applied mathematics, as well as physics and engineering.
Toxicology is also a multidisciplinary science and application of systems and com-
putational approaches can aid in unraveling the dynamic and complex nature of
toxic responses. In light of the broad utility of systems biology approaches to toxi-
cology and risk assessment, the goal of this session is to feature eminent scientists
who have made seminal contributions and advances in systems and computational
biology. The broad areas to be addressed include: 
- general concepts of systems biology tools including network mapping
and statistical challenges in assuring the validity of network analyses along with the
newest tools and approaches for gaining insight into the regulation and function of
complex systems;
- applications of systems biology approaches to studying fundamental bi-
ological responses such as cell signaling and kinase networks;
- perspectives on the application of systems networks to biomedical re-
search and particularly for studying disease etiology and prevention;
- computational strategies that inform the prediction of pharmacologic
and toxicologic responses including the prediction of adverse drug reactions; and, 
- novel applications of machine learning and cell imaging to evaluate
subcellular organization and function that inform hypothesis testing and transla-
tional details that may be useful in drug development.
822 Turning Protein Networks into Gene Ontologies.
T. Ideker. Department of Medicine, University of California San Diego, La Jolla, CA.
Sponsor: L. Lehman-McKeeman.
Ontologies have been very useful for capturing knowledge as a hierarchy of con-
cepts and their interrelationships. In biology, a prime challenge has been to develop
ontologies of gene function given only partial biological knowledge and inconsis-
tency in how this knowledge is curated by experts. I will present a method by which
large networks of gene and protein interaction, as are being mapped systematically
for many species, can be transformed to assemble an ontology with equivalent cov-
erage and power to the manually-curated Gene Ontology (GO). The network-ex-
tracted ontology contains 4,123 biological concepts and 5,766 relations, capturing
the majority of known cellular components as well as many additional concepts,
triggering subsequent updates to GO. Using genetic interaction profiling we pro-
vide further support for novel concepts related to protein trafficking, including a
link between Nnf2 and YEL043W. This work enables a shift from using ontologies
to evaluate data to using data to construct and evaluate ontologies.
823 Network2Canvas: Network Visualization on a Canvas with
Enrichment Analysis.
A. Ma’ayan. Department of Pharmacology and Systems Therapeutics, Mount Sinai
School of Medicine, New York, NY. Sponsor: L. Lehman-McKeeman.
Networks are vital to computational systems biology research, but visualizing them
can be a challenge. For networks larger than ~100 nodes and ~200 links, ball-and-
stick diagrams fail to convey much information. To address this, we developed
Network2Canvas (N2C), a web application that provides an alternative way to view
networks. N2C visualizes network nodes by placing them on a square toroidal grid.
These nodes are then clustered together on the grid using simulated annealing to
maximize local connections. For visualizing the canvas, a node’s brightness is made
proportional to its local fitness; the brighter a node is, the stronger its connections
to its neighbors. The grid is interactive, implemented in HTML5 and the Java
Script library D3. We applied N2C to create canvases for 25 gene-gene functional
association networks connecting human and mouse genes, and six drug-drug net-
works connecting FDA approved drugs based on their shared properties. N2C also
has functions to perform enrichment analysis. Given lists of genes or drugs, N2C
highlights enriched terms on the grid as well as computes the degree of clustering
for these enriched nodes. We applied N2C to analyze nine cancer cell lines by com-
paring their enrichment signatures to enrichment signatures of matched normal tis-
sues. Such analysis provides a global visualization of critical differences between
normal tissues and cancer cell lines. In particular, we observed a common pattern of
up regulation of the polycomb group and enrichment for the histone mark
H3K27me3 in many of cancer cell lines. In summary, N2C provides a new flexible
method to visualize large networks and to perform and visualize enrichment analy-
sis on functional drug and gene networks. N2C is freely available at
http://www.maayanlab.net/N2C
824 Computational Approaches to Predicting Adverse Drug
Reactions and Mitigating Off-Target Liabilities in Early-
Stage Drug Discovery.
L. Urban1,  S. Whitebread1,  E. Lounkine1 and P. Müller2. 1Center for Proteomic
Chemistry, Novartis Institutes for Biomedical Research, Cambridge, MA; 2Preclinical
Safety, Novartis Institutes for Biomedical Research, Cambridge, MA.
Identifying unintended off-targets associated with adverse drug reactions (ADRs) is
daunting by empirical methods alone. Many of these are unrelated to the therapeu-
tic target and it would need hundreds of assays to reveal their involvement in clini-
cal side effects. However, latest development in in vitro assay technologies, tools for
pharmacovigilance, and establishment of clinical data warehouses laid the founda-
tion for the development of computational strategies to predict side-effect targets
and even their associations with pathways and complex biological systems.
However, many of the early methods focused on cheminformatic aspects of lead op-
timization with little attention for translational value, not to mention the safety as-
pects of the chemical structures and individual molecules. Introduction of several
theoretical methods to explore drug-target-adverse reactions changed the landscape
of safety assessment and the translational value of these new methods has been in-
creasing significantly. The methods could be characterized as statistical models, ex-
pert or rule-based systems, quantum mechanics calculations, and structure based
approaches. Data used by these models are largely generated in in vitro assays and
obtained from clinical observations. Novartis, in collaboration with UCSF and
SeaChange has conducted a large-scale experimental test of the SEA method to pre-
dict drug activities on targets linked to ADRs, and a guilt-by-association method to
associate that activity with side-effects and provided evidence that a
drug–target–ADR network approach could have wide application to de-risking
toxicological liabilities in drug discovery. In this presentation, we will highlight the
various methods and applications developed for early risk assessment, and provide
insight of their practical applications.
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825 Image-Derived Models of Subcellular Organization and
Perturbation.
R. F. Murphy. Biological Sciences, Carnegie Mellon University, Pittsburgh, PA.
Sponsor: L. Lehman-McKeeman.
Because of their complexity, cutting-edge machine-learning methods will be critical
for building systems models of cell and tissue behavior and for future drug develop-
ment. Such models require accurate information about the subcellular distributions
of proteins, RNAs and other macromolecules in order to be able to capture and
simulate their spatiotemporal dynamics. Unfortunately, information with sufficient
resolution and for different cell and tissue types is currently very limited.
Microscope images provide the best source of this information, and new tools are
being developed to build models of cell organization directly from such images.
The number of possible experiments needed is prohibitive, but active machine
learning methods can be used to help choose which experiments are needed in
order to construct sufficient models of how cell organization changes with cell type
and with disease. In order to use these models for drug development, information
on how thousands of cell components respond to millions of potential therapeutics
is also needed in order to minimize toxicity. Active-learning methods can also guide
experimentation to overcome the dimensionality of this problem.
826 From Inhaled Particles to Cardiovascular Disease and
Toxicity: Evidence from Studies in Volunteers, Experimental
Animals, and Cell-Based Systems.
F. R. Cassee1 and H. Kipen2. 1Centre for Environmental Health Research (MGO),
National Institute for Public Health and the Environment (RIVM), Bilthoven,
Netherlands; 2Environmental & Occupational Medicine, UMDNJ-Robert Wood
Johnson Medical School, Piscataway, NJ.
The adverse effects of air pollution on cardiovascular health have been established
in a series of major observational studies. Even brief exposures to air pollution have
been associated with marked increases in cardiovascular morbidity and deaths from
myocardial ischemia, arrhythmia, and heart failure. The breadth, strength, and con-
sistency of the evidence provide a compelling argument that air pollution, espe-
cially traffic-derived pollution, causes cardiovascular disease. However, these obser-
vational data are limited by imprecision in the measurement of pollution exposure,
and the potential for environmental and social factors to confound these apparent
associations. For a causal association to have scientific credence, a clear mechanism
must be defined. What are the potential pathways through which air pollution me-
diates these adverse cardiovascular effects and diseases? And are the effects caused by
the nano-sized particles? This session will focus on the underlying biological mech-
anisms of complex particle mixtures.
827 Acute Increases in Exhaled Breath Condensate No
Metabolites Suggests Oxidative Stress As a Mechanism for
the Health Effects of Traffic-Related Pollutants.
H. Kipen1,  R. J. Laumbach1 and A. J. Gow2. 1Environmental & Occupational
Medicine, UMDNJ-Robert Wood Johnson Medical School, Piscataway, NJ; 2School of
Pharmacy, Rutgers University, Newarl, NJ.
Explication of a mechanism lends substantial scientific credence to epidemiologic
associations. For example, there are strong epidemiologic associations between in-
creases in air pollution, specifically traffic-related air pollution, and adverse car-
diopulmonary outcomes, but our understanding of explanatory mechanistic path-
ways is incomplete. What are the potential pathways through which air pollution
mediates these adverse cardiopulmonary effects? This presentation will focus on
some of the underlying biological mechanisms. One specifically hypothesized
mechanism is acutely increased oxidative stress/inflammation in the airways, as re-
flected in exhaled breath condensate (EBC) nitrite and nitrate in human subjects.
Nitric oxide (NO) is formed in the lung epithelium from activities of all three NO
synthases, and may then diffuse into the airway lining fluid where it is subject to
oxidation to nitrite and nitrate by multiple pathways. Data showing an increase in
exhaled breath condensate nitrite and nitrate following either controlled diesel ex-
haust inhalation or acute highway traffic exposure will be reviewed. Multiple oxida-
tive pathways for the acute increases in EBC nitrite will be discussed, along with
implications for generation of cardiopulmonary effects.
828 Health Effects from Traffic Particles and Noise in Road
Workers.
M. Riediker1,  R. Meier1,  A. Ghio4,  F. R. Cassee2 and W. Cascio3. 1Department
Workers’ Health, Institute for Occupational Health Sciences, Lausanne, Switzerland;
2Centre for Environmental Health Research (MGO), National Institute for Public
Health and the Environment (RIVM), Bilthoven, Netherlands; 3Environmental
Public Health Division, US EPA, Research Triangle Park, NC; 4Human Studies
Division, US EPA, Research Triangle Park, NC.
Fine particulate matter (PM2.5), gaseous co-pollutant, and noise exposure were as-
sessed in panels of workers that spend most of their professional activities on or
near roads. To quantify workers’ exposure and related short term health effects, up
until now, we observed 13 road maintenance workers, each over 5 non-consecutive
work days. We used a methodology based on personal and work site measurements
to assess the workers’ exposure to particles, noise and co-pollutants. For examina-
tion of personal exposures during and after work, the workers were equipped with a
personal particulate monitor (PM2.5) and a noise dosimeter. Additional exposure
parameters measured at the work site provided a detailed evaluation of exposure
during work. These included ultrafine particle counts, measurement of carbon
monoxide, nitrogen dioxide and ozone as well as PM sampling for compositional
analysis. Cardiovascular health endpoints were assessed before, during and 15 hours
post work shift. These included include a continuous ECG from before until 15
hours post work, measurement of blood pressure and lung function before and 15
hours post work as well as measurement of exhaled nitric oxide and blood markers
15 hours post work shift. Noise levels are generally high with extreme levels during
certain activities. Mean work shift PM2.5 Mass concentrations ranged from 17.0
μg/m3 to 321.0μg/m3 (mean 56.8 μg/m3) and UFP counts were between 15,538
particles/cm3 and 408,518 particles/cm3 (70,721 particles/cm3). Results suggest
that PM2.5 induces cardiovascular effects and inflammation. PM2.5 and noise
were only weakly correlated, allowing further assessment of these associations.
829 Air Pollution Is Associated with Chronic Progression of
Cardiovascular Disease.
A. K. Lund. Lovelace Respiratory Research Institute, Albuquerque, NM.
Traffic-generated pollutant-exposures appear to have a strong correlation to these
adverse vascular outcomes, as shown through roadway proximity studies.
Controlled toxicological studies highlight potential interactions between vehicle-
source emissions and upregulation of signaling molecules associated with progres-
sion of atherosclerosis. Mechanistically, a role for both innate and adaptive immune
responses is emerging, with important recent findings demonstrating that receptors
such as the lectin-like oxidized LDL receptor (LOX)-1 may play a role in commu-
nicating airway exposures to cardiovascular outcomes. Using a mixed vehicle emis-
sion (MVE: gasoline and diesel engine, 100 PM μg/m3) model we show that ather-
osclerotic Apolipoprotein E null (ApoE-/-) exhibit increased oxidized LDL,
associated with proinflammatory responses and lipid accumulation, as well in-
creased vascular LOX-1 expression, when exposed by inhalation 6 h/d for7 days,
compared to filtered air-exposed controls. Furthermore, we observe a significant
upregulation of vascular factors downstream of the LOX-1 receptor that are associ-
ated with atherogenic plaque growth and rupture, including reactive oxygen
species, endothelin (ET)-1 and matrix metalloproteinase (MMP)-9 in MVE-ex-
posed Apo E-/- mice, expression of which are attenuated with anti-LOX-1 antibody
treatment. These data indicate that vascular effects of inhalation exposure to traffic-
generated pollutants, resulting in progression of atherosclerosis and onset of clinical
cardiovascular events, may be mediated through scavenger receptor ligand binding,
internalization, and downstream signaling pathways.
830 Effects on the Vascular System of Source-Specific Particles.
M. E. Gerlofs-Nijland1,  F. R. Cassee1, 2,  M. Steenhof1, 2,  M. Strak1, 2 and
N. A. Janssen1. 1Centre for Environmental Health Research (MGO), National
Institute for Public Health and the Environment (RIVM), Bilthoven, Netherlands;
2Institute for Risk Assessment Sciences (IRAS), Utrecht University, Utrecht,
Netherlands.
Oxidative potential as a metric to predict source specific cardiovascular toxicity?
Presentation Description: Much attention has been paid to the role of tail pipe
emissions on pulmonary and cardiovascular toxicity. Although the focus in the past
few years has been on diesel engine exhaust, PM is emitted from other non-exhaust
sources like brakes as well. Some sources have shown to have a much higher oxida-
tive potential compared to diesel soot. Oxidative stress has been suggested as a key
aspect leading to cardiovascular toxicity and worsening of diseases. It is therefore
very important to measure oxidative stress to check on the health status. A simple
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metric for oxidative stress in vivo could be the oxidative potential of particles indi-
cating the possibility of PM to produce oxygen radicals and cause damage in vivo.
The focus of this presentation will be on the oxidative potential of PM from differ-
ent sources as a measure to predict source specific cardiovascular toxicity in vivo.
Systemic effects in rats exposed for 4-weeks to diesel engine exhaust occurred in-
cluding decreased numbers of white blood cells and reduced von Willebrand factor
protein in the circulation. In addition, lung tissue factor activity is reduced in con-
junction with reduced lung tissue thrombin generation. We have also shown in
studies in which volunteers were exposed to air pollution at various locations dom-
inated by different sources of emission that organic carbon, nitrate and sulfate to be
most consistently linked with different biomarkers (e.g. high-sensitivity C-reactive
protein, fibrinogen, von Willibrand factor and plasminogen activator inhibitor-1)
of acute cardiovascular risk. Associations for PM mass concentrations and OP were
less consistent, while other measured components of the air pollution
831 Diesel Exhaust: The Many Ways That Nanoparticles Can
Impair Cardiovascular Health.
M. Miller,  J. P. Langrish,  N. L. Mills,  K. Donaldson,  P. W. Hadoke and
D. E. Newby. Centre for Cardiovascular Sciences, University of Edinburgh,
Edinburgh, United Kingdom. Sponsor: F. Cassee.
The detrimental effects of air pollution on the cardiovascular system are now well-
established, however, the mechanisms underlying these effects remain to be deter-
mined. Using diesel exhaust as an example of a common air pollutant, rich in com-
bustion-derived nanoparticles, this presentation will give an overview of the
multiple ways urban air pollution can alter cardiovascular function. Studies in both
animals and man have demonstrated that this pollutant impairs vascular function,
promotes thrombosis, exacerbates cardiac ischemia and accelerates the development
of atherosclerosis. The presentation will focus on preclinical experiments with diesel
exhaust particulate (DEP) that provide insight into potential mechanisms for these
effects, including oxidative stress, endothelial dysfunction, inflammation, particle
translocation, as well as considering with constituents of DEP may be responsible
for these harmful effects.
832 The Dynamics of Neuroinflammation and Inflammatory
Cell Responses in Neurologic Disease.
G. J. Harry1 and C. P. Curran2. 1NTP Laboratory, NIEHS, Research Triangle Park,
NC; 2Northern Kentucky University, Highland Heights, KY.
An increasing body of evidence indicates that neuroinflammation and activation of
immune cells within the nervous system are associated with neurodegenerative dis-
ease, neurodevelopmental disorders, and potentially in reaction to environmental
exposures. However, it is also increasingly obvious that these responses may be ben-
eficial or detrimental, and discriminating between these has only recently been ad-
dressed. Understanding the process by which these responses are triggered and the
spatiotemporal dynamics of the response is critical to developing a strategy for
translating neuroinflammatory and immune response to effective prevention or
treatment of neurologic disease/injury. Three well-known neurotoxicants:
trimethyltin, manganese, and mercury will be used as chemical probes to explore
differences in the timing of inflammatory effects and consequences in the brain. We
will conclude by discussing approaches to manipulate the lesion microenvironment
and/or brain macrophage such that inflammation favors tissue repair in the spinal
cord.
833 Microglia Heterogeneity in Neuroinflammation and
Neurotoxicity.
G. J. Harry. NTP Laboratory, NIEHS, Research Triangle Park, NC. Sponsor: C.
Curran.
Microglia cells are the resident immune cells of the brain; however, they are also
critical neural specific cells with multiple roles. The response of microglia has been
associated with environmental exposures and is present in diagnosed neurodegener-
ative disease. In many cases, what is considered a microglia response is often a brain
macrophage response that can be derived from both resident microglia and infil-
trating blood-borne monocytes. In order to better understand the resident mi-
croglia response, data will be presented from a delayed neuronal death model fol-
lowing trimethyltin intoxication. This compound induces death of the dentate
granule neurons across multiple species and is accompanied by a robust microglia
response and elevation in pro-inflammatory cytokines. The process is tightly regu-
lated and with the phagocytic clearance of the neuronal debris, the system actively
undertakes repair. Using this model of resident microglia activation, the dynamic
sequence of events will be described that characterize the microglia response within
areas of neuronal death, synaptic loss, and neuronal activity. Using this model we
are able to identify the various functions of microglia and potentially identify a pro-
file of molecular and morphological responses that will identify the different func-
tions of the microglia. This will serve to identify those processes of microglia that
need to be fostered and those that need to be mitigated by therapeutic intervention.
834 Neuroinflammation and Developmental Vulnerability to
Manganese.
R. B. Tjalkens1, 2. 1Center for Environmental Medicine, Colorado State University,
Fort Collins, CO; 2Toxicology Section, Department of Environmental and
Radiological Health Sciences, Colorado State University, Fort Collins, CO.
There is increasing evidence that activation of microglia and astrocytes during de-
velopment can influence susceptibility to neurodegeneration later in life.
Environmental insults such as infectious agents, pesticides, and heavy metals have
all been implicated in neuronal injury leading to increased activation of glial cells
and development of chronic neuroinflammation. Exposure to elevated levels of the
essential element manganese (Mn) causes a spectrum of neurochemical and neu-
ropathologic changes that can culminate in irreversible neuronal injury in subcorti-
cal and cortical structures. Children are more vulnerable to Mn than adults and re-
cent epidemiological evidence links high Mn in drinking water to cognitive and
behavioral impairment. Mn neurotoxicity is associated with astrogliosis in the basal
ganglia and studies conducted in our laboratory and others suggests that glial-de-
rived inflammatory cytokines and nitric oxide (NO) influence the progression of
neuronal injury. Increased expression of iNOS/NOS2 by activated glial cells in re-
sponse to Mn results in nitrosative stress throughout the basal ganglia and en-
hanced apoptosis within selected populations of neurons in the globus pallidus and
striatum. NOS2 is exclusively expressed in glia and produces high levels of NO,
which forms highly reactive peroxynitrite anion (ONOO-) upon combining with
superoxide, resulting in electrophilic nitration of cellular proteins that damages
neurons. Peroxynitrite-mediated nitrosative stress is also implicated in a number of
neurological disorders, including Alzheimer’s and Parkinson’s diseases.
Inflammatory changes in glial cells may therefore be an important link between
neurotoxic injury and and persistent neurological dysfunction during aging.
835 Spontaneous and Mercury-Induced Antibodies to Brain
Antigens Affect Fetal Brain Development.
D. A. Lawrence1,  Y. Zhang1,  Y. Heo2 and D. Gao1. 1Immunology, Wadsworth
Center, Albany, NY; 2Occupational Health, Catholic University of Daegu, Daegu,
Republic of Korea.
BTBR mice spontaneously develop a high level of serum IgG of which a proportion
are antibodies (Abs) to brain antigens. These Abs enter the brain and are associated
with expression of inflammatory cytokines, which are suggested to be related to
presence of activated microglia and mast cells. The neurodevelopmental effects of
BTBR mice are posited to be autoimmune due to elevated presence of activated
CD4+ T cells driving Ab production, and the offspring have behaviors that resem-
ble autism. IgG from BTBR mice intravenously injected into B6 pregnant dams
caused offspring to have lowered social interactions; likewise, B6 embryos that are
born from BTBR dams have lowered sociability. Changes in mitochondrial func-
tions can alter these behavioral outcomes of BTBR mice, but the mechanisms re-
main unknown. Abs causing behavioral deficits is not a new finding, in that Abs in-
duce neuropsychiatric syndromes in lupus-prone mice. Additionally, certain strains
such as A.SW, which are sensitive to Hg-induced autoimmune responses, generate
autoantibodies to brain antigens upon developmental exposure to HgCl2 and have
behavioral deficits as adults, and inflammatory cytokines in multiple brain regions
are associated with the behavior changes; however, the HgCl2-induced effects are
dependent on the genetics of the strain and sex of the developmentally exposed
mice.
836 Manipulating Microglia and Macrophages to Promote
Repair of Injured Spinal Cord.
P. G. Popovich. Department of Neuroscience, The Ohio State University, Columbus,
OH. Sponsor: C. Curran.
Following traumatic or ischemic/reperfusion injury to spinal cord or brain,
macrophages derived from resident microglia and infiltrating blood monocytes ac-
cumulate in the affected area. Collectively, these cells exert diverse and conflicting
effects on neurons and glia. Indeed, microglia/macrophages can cause neuronal cell
death, axonal injury and demyelination but can also promote neuron survival, axon
regeneration, remyelination and revascularization. Over the past few years, we have
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used a number of strategies to manipulate resident and recruited macrophages in an
effort to understand their seemingly paradoxical functions, specifically in the con-
text of rodent models of traumatic spinal cord injury (SCI). Data will be presented
showing that SCIelicits CNS macrophages with a distinct molecular phenotype,
one that simultaneously favors cell killing and axon growth/regeneration. Newer
data also will be presented to show that it is possible to manipulate the lesion mi-
croenvironment and/or the CNS macrophages such that the natural course of in-
flammation progresses to favor tissue repair without concomitant cell killing. In
this context, preliminary applications of therapeutic gene transfer and bioengineer-
ing will be discussed. Supported by NIH-NINDS and The Craig H. Neilsen
Foundation.
837 Advances in Carcinogenic Risk Assessment of Low-Level
Genotoxic Impurities in Pharmaceuticals.
W. W. Ku1 and D. Jacobson Kram2. 1Nonclinical Drug Safety US, Boehringer
Ingelheim Inc., Ridgefield, CT; 2Center for Drug Evaluation and Research, US FDA,
Silver Spring, MD.
Pharmaceutical syntheses involve the use of reactive starting materials, intermedi-
ates, and reagents, some of which are known or potential genotoxicants and car-
cinogens. Therefore, genotoxic and potentially carcinogenic impurities may appear
in the final drug product. Risk assessment approaches have focused on defining im-
purity limits which pose acceptable risk over a patient’s duration of drug treatment.
Over the past decade, regulatory guidances (EMA, US FDA draft) have been intro-
duced. Drug-associated genotoxic impurities became an ICH guideline topic (M7)
in 2009, and an Expert Working Group is currently developing a harmonized
guideline. The ICH M7 effort presents an opportunity to review existing guide-
lines, evaluate new information and experiences since their introduction, and im-
prove the integration of safety and quality aspects for detection, risk management
and control. This workshop will provide a historical overview and introduce newer
concepts to SOT members for discussion on several approaches being considered in
M7. The workshop will cover the following topics along with case studies: (1) a
brief overview of regulatory risk assessment approaches developed over the past
decade and introduce current M7 concepts being considered; (2) review current in
silico Q(SAR) and genotoxicity testing approaches to predict or identify hazards
and qualify impurity risk; (3) introduce advances in the framework and rationale
for applying less-than-lifetime acceptable risk limits during clinical development
and marketing; (4) highlight differences in chemical space between pharmaceutical
synthetic intermediates or impurities and that used to derive the original lifetime
threshold of toxicological concern (TTC) limit, and its potential implications for
risk characterization; and (5) review approaches for addressing risk of multiple
genotoxic impurities in a drug product.
838 Genotoxic Impurities—Regulatory Advances in Risk
Assessment Approaches.
P. Kasper. Federal Institute for Drugs and Medical Devices, Bonn, Germany. Sponsor:
W. Ku.
The control of impurities in drug substances/products is regulated by internation-
ally harmonized guidelines (ICH Q3A/B). However, these documents lack any spe-
cific instructions on how to treat impurities with a genotoxic potential. This has led
to considerable differences between regulatory authorities on what levels of daily in-
take of genotoxic impurities are acceptable and prompted the European Medicines
Agency (EMA) to release a “Guideline on the Limits of Genotoxic Impurities” in
2007 followed by publication of a draft guidance by CDER/FDA in 2009. Several
basic principles are common to both documents and are currently under discussion
for further development in the ICH process. 
Genotoxic impurities are defined as compounds that are DNA-reactive and have
the potential to directly cause DNA damage when present at low levels leading to
mutations and therefore, potentially causing cancer. Consequently, in silico predic-
tion of DNA reactivity/mutagenicity and Ames mutagenicity testing are basically
the recommended approaches for hazard identification. Since risk assessment based
on such limited set of data is not feasible a generic “Threshold of Toxicological
Concern” (TTC)-value of 1.5 μg/day corresponding to a 10-5 lifetime risk of can-
cer is used as a pragmatic approach for control of impurities that are Ames-positive.
Derived from linear extrapolation of rodent potency data from over 700 carcino-
gens and based on an accumulation of worst-case assumptions the TTC value is a
very conservative and therefore sufficiently safe limit. Possible deviations from the
default TTC approach are currently under discussion and include cases when more
extensive and appropriate data for a proper assessment of potential risks are avail-
able, e.g., data from carcinogenicity studies with the impurity or mechanistic data
providing evidence for a threshold. Also specific clinical aspects may justify an ad-
justment of accepted daily intake levels of mutagenic impurities, such as for in-
stance treatment of life-threatening condition, short life expectancy of patients, or
indications with less-than-lifetime exposure.
839 Advances in Mutagenic Impurity Hazard Assessment: Best
Practices and Current Developments.
K. Dobo. Drug Safety Research and Development, Pfizer Global Research and
Development, Groton, CT. Sponsor: W. Ku.
For many years, pharmaceutical companies have been using in silico methods as a
primary tool for the identification of mutagenic impurities or degradants in drug
substances or products as recommended in the European Medicines Agency (EMA)
guidance, as well as the CDER/FDA draft guidance. Although neither guideline
provides specific recommendations on the conduct of in silico assessments, a re-
cently published survey of industry practice showed that the in silico methods em-
ployed by 8 companies are highly similar. More importantly, the survey showed
that in silico analysis alone or in conjunction with an expert evaluation provides a
high degree of confidence that an impurity that is predicted non-mutagenic will
produce a negative result in the Ames assay. Despite the encouraging survey results,
there remain many specific points of concern which are currently being addressed
by a European pharmaceutical industry (EFPIA) working group in collaboration
with regulators. The working group intends to provide recommendations on the
conduct of (Q)SAR assessments, which, if followed, would be considered suffi-
ciently rigorous methodology. Although many pharmaceutical impurities can be
confidently categorized as mutagenic or non-mutagenic based on in silico method-
ology alone, there are instances in which biological testing is necessary. The Ames
assay is considered to be the most practical and appropriate test for the identifica-
tion of directly DNA reactive substances that warrant TTC control. In most cases
the outcome of this assay is sufficient to define and implement appropriate impu-
rity control measures. However, on occasion (e.g. Ames positive degradant that
can’t be controlled to TTC limits) additional testing is necessary to further address
the biological relevance and risk of Ames positive results.  Case studies will be used
to illustrate potential scenarios warranting additional testing and factors to take
into consideration when deciding what studies to conduct.
840 Less Than Lifetime (LTL) Carcinogenic Risk Limits for
Mutagenic Impurities during Clinical Development and in
Marketed Products.
L. Mueller. Non-Clinical Drug Safety, F. Hoffmann-La Roche Ltd., Basel,
Switzerland.
Mueller et al have provided in 2006 a framework for the application of the thresh-
old of toxicological concern concept to pharmaceuticals with introduction of a
“staged TTC”. In this staged approach, acceptable daily intake levels were defined
for the clinical development phase of pharmaceuticals, i.e. for up to 1 year intake.
In the meantime, this “staged concept” was also introduced into regulatory frame-
work in the existing EU regulatory process on genotoxic impurities. In the ICH
M7 group, the principle has been expanded based on the application of Haber’s
Rule relating concentration (or dose) and duration of exposure. According to a re-
cent review by Felter et al. (2011), the majority of carcinogens are more potent in
rodents if the same cumulative dose is given over a shorter period (e.g. three
months) than a longer one (e.g. two years). Although the number of compounds
tested in such scenarios is low and it is unclear if these data can be extrapolated to
very low exposure scenarios, it was proposed to adjust the acceptable daily exposure
to mutagenic carcinogens for shorter durations with an extra uncertainty factor in
comparison to longer durations of intake. On the other hand, it was recognized
that medication treatment durations are often less than lifetime and depend on
many factors (indication, nature of disease being treated and late onset of disease in
life). Hence, it appeared unreasonable to propose the lifetime TTC or 1.5μg/day
for mutagenic carcinogens in most marketed pharmaceuticals. In adopting this
consideration, it is currently proposed to place clinical trials of longer duration (>1
year) and medical intervention schemes of shorter than 10 years into one category
of “up to 10 years” with the assignment of an adjusted TTC of 10μg/day. The pres-
entation will include examples for such clinical trials and pharmaceuticals in use.
841 Many Potential Mutagens Used in Pharmaceutical Syntheses
Are in Less Potent Classes Than the Carcinogens Used to
Derive the TTC, Justifying Higher Levels without Increasing
Risk.
S. Galloway. Merck Research Laboratories, West Point, PA. Sponsor: W. Ku.
The TTC for mutagenic impurities was derived using several worst-case assump-
tions, and was based on the more potent carcinogens in the public databases. The
TTC is needed only when insufficient information exists to estimate safe levels of a
mutagen.  Most reactive chemicals used in pharmaceutical syntheses are not in the
categories of potent carcinogens on which the TTC was based (Delaney, Reg.Tox.
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Pharm 49, 107-24, 2007), confirmed here by data from 12 companies and 602
“alerting” structures. Thus, for many synthetic intermediates with structural alerts
for mutagenicity, higher daily intakes are appropriate without increased risk.
Especially in early stages of pharmaceutical development the risks from exposure to
potentially mutagenic impurities are negligible without imposing the default TTC
for each. The most common classes are alkylating agents and aromatic amines. For
alkyl halides, the relation between the complexity of the structure and carcinogenic
potency is well established, (Brigo and Muller, in Teasdale, “Genotoxic Impurities”,
Wiley 2010) and justifies an acceptable daily intake for mono-functional alkyl
halides 10 times the default TTC. Aromatic amines have a wide range of carcino-
genic potencies, and we lack sufficient knowledge to define the likely potency of
each new one. However the structural characteristics of the most potent carcino-
gens are well defined, so one can rule out that a new aromatic amine is a highly po-
tent one. The “cohort of concern” (COC) was highlighted as so potent that even
the default TTC did not provide sufficient control of exposure. The COC com-
prises aflatoxins and N-nitroso compounds, not usually relevant to pharmaceuti-
cals, but also azoxy structures.  The known alkyl azoxy compounds are thought to
be mutagenic by forming carbocations and alkylating DNA. In pharmaceutical
syntheses, aromatic azoxy groups are used, which cannot form the alkyl carboca-
tion, so are not in the highly potent class and need not be excluded from the
TTC/ADI approach.
842 Addressing Risks of the Potential Presence of Multiple
Genotoxic/Carcinogenic Impurities in Pharmaceuticals.
J. Bercu. Amgen Inc., Thousand Oaks, CA.
There has been an evolution of risk assessment and regulatory guidance for multi-
ple genotoxic/carcinogenic impurities in pharmaceuticals. While experiences from
other relevant industries have been adapted to pharmaceutical impurities (e.g. food,
environmental), there are also unique aspects applied to pharmaceutical process de-
velopment. Scientific discussions have included application of a probabilistic risk
assessment to low level genotoxic substances, impacts of structurally/mechanistic
similar impurities versus non-similar impurities, and the risk of synergism/potenti-
ation. The science has shaped regulatory guidance to ensure product quality and
patient safety throughout development and in registered use. The European
Medicines Agency (EMA) and US Food and Drug Administration (FDA) have de-
veloped guidances (USFDA is in draft) which include control of multiple geno-
toxic/carcinogenic impurities. The International Conference on Harmonization
(ICH) is developing guidance (i.e., ICH M7) on DNA reactive (mutagenic) impu-
rities. According to the ICH M7 concept paper, one of the issues to resolve is mul-
tiple impurities. Industry is developing strategies to implement these regulatory
guidances. In conclusion, there are many challenges and issues to resolve, but the
advancement of risk assessment for multiple genotoxic/carcinogenic impurities will
best occur through science and regulatory guidance.
843 Health Risks of Sodium (Salt) Intake: Too Much or Too
Little?
M. G. Soni1 and P. M. Bolger2. 1Soni & Associates Inc, Vero Beach, FL; 2Charles
Street, Annapolis, MD.
Public health advocates have been concerned for decades that Americans consume
unhealthy amounts of dietary sodium. Recently, the Institute of Medicine (IOM)
recommended a Tolerable Upper Intake Level of 2,300 mg sodium/day and an
Adequate Intake of just 1,500 mg/day, based on risks of adverse health effects, par-
ticularly hypertension. However, the average sodium intake is estimated to be 3,500
mg/day. The risk for morbidity and mortality due to excessive or insufficient salt in-
take varies because of biochemical individuality. The available evidence from a wide
variety of clinical trials shows a direct relation between salt intake and blood pres-
sure. A recent meta-analysis suggests that salt reduction tended to increase levels of
hormones (renin, aldosterone), cholesterol, and triglycerides, which are all thought
to be risk factors for heart disease. It has been asserted that while the risks of con-
suming too much salt are real, the risks have been exaggerated for the general pop-
ulation, or that the studies done on the consumption of salt can be interpreted in
many different ways. There have also been recent scientific debates upon whether
“excess” sodium in our diet has any adverse effect at all on healthy individuals and
whether the last 50 years of scientific research that strongly correlates salt intake and
hypertension might just be a well intentioned misinterpretation of the scientific
data. In an effort to broaden the understanding of the aforementioned issues per-
taining to salt intake and risk, the following key aspects will be addressed in this ses-
sion: (1) Health risks associated with sodium intake; (2) Should salts’ GRAS status
be modified? (3) Any unintended consequences of salt reduction. (4) Is there a suf-
ficient evidence for salt reduction?
844 Sodium Homeostasis and Cardiovascular Health.
P. M. Bolger. Charles Street, Annapolis, MD.
Under normal circumstances the mammalian physiological system is a highly com-
plex and exceedingly efficient homeostatic system for monitoring and regulating
electrolyte levels throughout the human body. These essential mechanisms include
neurological (e.g., pituitary function) and endocrinological (e.g., adrenal) compo-
nents as well as various organs (e.g., kidneys) and are vital in maintaining a healthy
cardiovascular system. In this regard, it is important to understand various homeo-
static control systems for key electrolytes, with particular attention to the critical
role of sodium in the maintenance of cellular function and cardiovascular health.
The key sodium dependent mechanisms with particular emphasis on those that in-
volve renal function also need attention. An integrative approach will be needed to
demonstrate the multi-factorial and organ system functions that are involved in the
overall systemic homeostatic system to regulate sodium status.
845 Strategies to Reduce Sodium Intake in the United States.
J. Henney. College of Medicine, University of Cincinnati, Cincinnati, OH. Sponsor:
M. Soni.
Reducing sodium intake is a critical public health need for all Americans. In spite of
nearly 40 years of voluntary effort to reduce sodium intake, Americans average
daily intake of more than 3,400 mg. of sodium (approx. 1.5 teaspoons) exceeds the
existing maximum intake level 2,300 mg/d (1 teaspoon of salt) established by the
2005 Dietary Guidelines for Americans. High sodium intake puts the population-
young and old, male and female, and all ethnic groups at risk for hypertension, and
subsequent cardiovascular and/or renal events. The study committee convened by
the Institute of Medicine consulted many sources and was provided additional in-
formation and insight at its public meeting and through the committee’s website.
The committees recommendations were in three categories: Primary; Supporting
and Interim. Primary Recommended Strategy: A coordinated approach to set
mandatory standards for safe levels of sodium in food using existing FDA authori-
ties to modify the Generally Recognized as Safe (GRAS) status of salt and other
sodium containing compounds. Supporting strategies: A nationally organized cam-
paign to educate the public about risks, healthy food choices and support for gov-
ernment, industry and consumer effort; Update nutrition labeling; Training for
restaurant /food service operations; Purchasing specifications by large food pur-
chasers; Enhanced monitoring; Research. Interim strategies; Food manufacturers
and restaurant/food service operations voluntarily accelerate and broaden efforts;
The food industry, government, professional and public health partners should
work together to promote voluntary collaborations to reduce sodium in foods. The
specific recommendations and rationale for each strategy will be discussed along
with the actions taken since the release of the report.
846 The Effects of Sodium Reduction on Blood Pressure,
Hormones, Lipids, and Mortality.
N. Graudal. Department of Internal Medicine/Infectious Medicine/Rheumatology,
Copenhagen University Hospital, Copenhagen, Denmark. Sponsor: M. Soni.
The average normal salt (NaCl) intake in the world is about 9 g per day. The result
of a meta-analysis of 167 intervention studies randomly allocating participants to a
low salt diet or a normal salt diet indicates that the effect of a reduced salt intake of
about 6 g on blood pressure is less than 1 mmHg in people with normal blood pres-
sure and about 3 mmHg in people with hypertension. These effects were contrasted
by significant increases in variables associated with a poor survival prognosis, such
as renin, aldosteron, cholesterol and triglyceride. It is therefore not obvious that
sodium reduction leads to health benefits. In agreement with this, population stud-
ies generally cannot confirm that people on low sodium diets have less morbidity or
mortality than people on normal sodium diets, on the contrary these studies show
a trend towards increased all cause mortality among individuals on low sodium
diet.
847 Unintended Consequences of Salt Reduction.
M. Satin. Science and Research, Salt Institute, Alexandria, VA. Sponsor: M. Soni.
While there is considerable clinical evidence to indicate that substantial reductions
in dietary sodium intake may result in single digit reductions in systolic blood pres-
sure for salt-sensitive individuals, further evidence reveals that these same reduc-
tions may cause a significant increase in morbidity and mortality across a broad
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range of the population. It is generally agreed that most of these negative health
outcomes are a consequence of the increase in renin-angiotensin-aldosterone sys-
tem activity that accompanies reductions in salt consumption. Other negative
health outcomes may result from the changes in nutrient consumption patterns
that accompany recommended salt reductions.  The ideal level of sodium con-
sumption for individuals will result from a rational balance of positive and negative
health outcomes. As new research findings continue to emerge and concern over
potential unintended consequences of restricting sodium intake grows, it is imper-
ative to ensure that nutrition policies reflect the most current, robust and scientifi-
cally sound research.
848 The Importance of Population-Wide Sodium Reduction As a
Means to Prevent Cardiovascular Disease and Stroke.
D. Arnett. Department of Epidemiology, University of Alabama at Birmingham,
Birmingham, AL. Sponsor: M. Soni.
High blood pressure is one of the leading causes of preventable mortality and mor-
bidity, worldwide. National health agencies and professional societies around the
world recommend reduction in dietary sodium as a means to lower blood pressure
and preventing CVD. The American Heart Association (AHA) recommends limit-
ing daily sodium intake to less than 1,500 mg/d for all Americans. For the esti-
mated one in three who will develop high blood pressure in their lifetime, a high-
sodium diet may be to blame. Many consumers do not realize that sodium is
ubiquitous in the environment and found in many unsuspecting foods at levels that
are often unnecessary. Consequently, consumers continue to purchase foods that
are relatively high in sodium and increase their risk of hypertension and related
health risks. There is overwhelming scientific evidence that lowering sodium intake
improves cardiovascular outcomes. Even a modest reduction in sodium intake is
likely to result in substantial health benefits, especially when it is achieved in the
general population. The AHA has undertaken an organizational approach to
sodium reduction in the United States. The health risks associated with consuming
too much sodium in the diet are clear and cannot be ignored.
849 Unique Challenges in Biologic Drug Development:
Separating Mechanism of Action from Mechanism of
Toxicity.
L. Andrews1 and M. Todd2. 1Genzyme, Framingham, MA; 2Pfizer, La Jolla, CA.
A common safety concern of biotherapeutic agents is toxicity associated with mech-
anism of action (MoA). The term MoA refers to the specific biochemical interac-
tion through which a drug substance produces its pharmacological effect. This
workshop will address areas of significant impact to biotherapeutic drug develop-
ment where there is a known disassociation of MoA and MoT in toxicity studies
and/or in translation to the clinic. Most nonclinical toxicity studies are conducted
in healthy animals which may not predict the effects of a biotherapeutic when used
in the patients with specific diseases. The latest paradigms for using animal disease
models, including study conduct and interpretation, will be explored. For many
years, the likelihood of off-target toxicity was considered to be very low for most
biotherapeutics. Data will be presented highlighting that off-target toxicity, partic-
ularly hematotoxicity, can occur and may be more prevalent than previously
thought. Effort has also been put into better understanding the development and
impact of antidrug antibodies (ADA) in nonclinical toxicity studies and their rele-
vance to clinical ADA. In addition to impacting biotherapeutic drug exposure,
ADA may also cause a variety of non-MoA associated toxicities including acute hy-
persensitivity, immune complex disease, and neutralization of the endogenous tar-
get. The incidence of ADA-associated toxicities has been increasing and the current
understanding of these toxicities and their clinical relevance with be discussed.
850 Introduction to the Mechanism of Action/Mechanism of
Toxicity Challenges of Biotherapeutics.
C. Grimaldi. Boehringer Ingelheim, Ridgefield, CT. Sponsor: L. Andrews.
Toxicitites associated with biologics are often attributed to the mode of action
(MoA). Mechanisms of toxicity (MoT) can be caused by “exaggerated pharmacol-
ogy” which can occur as a direct effect of the biotherapeutic on the intended cell
type or biochemical pathway, or as an indirect effect on unintended cell types or
pathways. The extent of the pharmacologic response can be influenced by numer-
ous factors including, but not limited to, biophysical properties of the biotherapeu-
tic agent such as binding potency, effector function and immune stimulatory prop-
erties, drug dose and/or duration, tissue distribution of the target, perturbation of
signaling networks and disease state. Since the expected pharmacologic mode of ac-
tion of biotherapeutics is usually understood, the mechanisms of toxicities may be
predicted using relevant test systems. To this end, specialized pharmacologic end-
points are needed in addition to the conventional nonclinical safety assays for toxi-
city testing in animals. Important considerations to evaluate MoA/MoT include
the use of alternative animal models, safety biomarkers, drug exposure and im-
munogenicity, impact of drug delivery routes and modalities, novel drug formats
and the impact of process changes and engineering on drug safety. Challenges for
nonclinical toxicity testing of biotherapeutics include how and when to incorporate
“fit-for-purpose“ investigational approaches, and importantly how to extrapolate in
vitro and in vivo data to the clinical setting.
851 Use of Animal Models of Disease in Safety Assessments of
Biotherapeutics—Is This the Future?
J. Cavagnaro. Access Bio, Boyce, VA.
A guiding principle in the design of preclinical safety studies is to parallel as closely
as possible the clinical conditions of use and exposure. In accordance with this prin-
ciple, much attention is paid to the dosing regimen with respect to route of admin-
istration, duration of treatment and dosing interval. With respect to mirroring the
characteristics of the patient population to be exposed normal animals appropri-
ately parallel the typical Phase I population in normal subjects (healthy volunteers).
Where toxicologists deviate from the principle of correlation of clinical conditions
of exposure is in the evaluation of potential toxicity in patients in the later safety
and activity/efficacy clinical trials. The deviation from this principle relates prima-
rily to the physiological state of the clinical populations involved as they are no
longer healthy volunteers but rather individuals who either have a specific disease
and/or are very ill. Therefore a relevant question for the toxicologist to ask is
whether toxicology studies in “normal animals” adequately assess the risks in “sick
people”. The answer to this question has even greater significance for biopharma-
ceuticals when first in human (FIH) Phase I trials are conducted in subjects with
disease for ethical and practical reasons. Thus animal models of disease are being
used not only to establish preclinical POC but also to assess exaggerated pharma-
cology and toxicity in an attempt to improve relevance and extrapolation of results
to the intended disease population.
852 Antidrug Antibodies: Interpreting Toxicology Studies and
Translating Nonclinical Findings to the Clinic.
C. Horvath. Genzyme, Framingham, MA.
Animals frequently mount an anti-drug antibody (ADA) response to biological
drugs during toxicology studies. In some cases ADAs have no effect on the prod-
uct’s behavior; while in others they may produce a variety of undesirable effects.
ADAs may affect the pharmacodynamics, pharmacokinetic, bioavailability and effi-
cacy of a test article. For example, enhanced clearance of a test article from the cir-
culation by ADAs will affect exposure in a toxicology study. The production of
ADAs can also result in potentially life-threatening adverse effects. A histamine me-
diated Type I hypersensitivity response can be experienced when dosing large for-
eign proteins into rodents. This response can often be mitigated by co-medicating
with antihistamines, such as diphenhydramine, but can significantly affect the abil-
ity to conduct repeat dosing in rodent models. A Type III hypersensitivity reaction
can lead to tissue injury, such as vasculitis, as a result of the formation of immune
complexes. Additionally, the neutralization of an endogenous protein may occur
when the ADA directed against the drug cross-reacts with an endogenous protein.
The level and resulting toxic effects of an ADA response to a particular product can
be different in various animal species and are not predictive from one species to an-
other. In general, immunogenicity in animals does not predict immunogenicity in
humans, however, caution must be taken when translating the relevancy of any
ADA-mediated toxicity observed in an animal to human safety. It is important to
consider the implications of ADAs when interpreting the results of a toxicity study
and include a comprehensive investigation of potential ADA-mediated lesions to
determine if they are solely related to the presence of ADAs or to the pharmacology
of the target. The ramifications of nonclinical ADA-mediated toxicity on the clinic
can range from additional clinical monitoring to product development termina-
tion.
853 Unexpected Toxicities of Biotherapeutics on Peripheral
Blood Cells.
N. Everds. Amgen, Seattle, WA. Sponsor: L. Andrews.
Monoclonal antibodies and other biotherapeutics are an increasing proportion of
drugs being developed by pharmaceutical companies. Unintended effects of bio-
therapeutics on peripheral blood cells may occur in nonclinical testing or only after
182 SOT 2013 ANNUAL MEETING
clinical trials or product launch. Nonclinical studies generally predict clinical hema-
totoxicity for recombinant cytokines and growth factors, but have not been predic-
tive for the majority of biotherapeutics with clinical hematologic liabilities, espe-
cially those that are immune mediated and/or of low incidence. Hematotoxicities
may be species-specific and affect one or multiple blood cell lineages.
Mechanistically, hematotoxicity caused by monoclonal antibodies or other biother-
apeutics can be directly related to the activity of the test article, or can be indirect
generally due to immune-related events. Direct effects can be due to binding to the
intended target or to an off-target molecule. Recently, several publications have
demonstrated species-specific hematotoxicity due to off-target binding; these ef-
fects have been observed in both rats and NHPs. Indirect hematotoxicity is often
due to autoimmunity, biological cascades, antidrug antibodies, or other immune
system responses. Hematotoxicities due to biological cascades generally involve me-
diators of systemic inflammation, such as cytokines, complement, and immune
complexes, and often are observed as acute post-dosing events. Platelets are particu-
larly susceptible to effects of biotherapeutics, perhaps due to the high expression of
activating FcRs. In vitro assays can be utilized to further investigate and understand
the pathogenesis of unexpected effects of large molecules on blood cells.
Characterizing the hematotoxicity (e.g. primary or secondary, relevance to humans,
underlying mechanism, monitorability, etc) is important for risk assessment.
Despite the potential for unexpected hematologic toxicity, the risk-benefit profile
of most biotherapeutics is favorable; hematologic effects are readily monitorable
and managed by dose modification, drug withdrawal and/or therapeutic interven-
tion.
854 Effectopedia: The Online Encyclopedia and Graphical Editor
for AOPs.
A. Clippinger1,  H. Aladjov2 and G. Veith3. 1People for the Ethical Treatment of
Animals, Norfolk, VA; 2Institute of Biophysics and Biomedical Engineering, Bulgarian
Academy of Sciences, Sofia, Bulgaria; 3International QSAR Foundation, Two Harbors,
MN. Sponsor: K. Sullivan.
The 21st-Century shift to more prospective hazard identification and hypothesis
generation requires greater strategic application of systems biology, QSAR and
archived toxicological data in the form of adverse outcome pathways (AOPs). AOPs
describe the causal linkages among biological responses to chemicals over time. The
complexity of integrating science can be a barrier to progress in terms of the toxic-
ity pathways and networks involved as well as the need to organize knowledge from
many disciplines.
Effectopedia is an open-knowledge aggregation and collaboration tool for delineat-
ing AOPs in an encyclopedic and predictive manner. It includes discrete cause-ef-
fect studies and critical reviews that are relevant to toxicology. To achieve human
and machine interpretability, Effectopedia uses an ontology-enhanced, natural lan-
guage interface that offers clarifying questions and special tags to define the seman-
tic knowledge while preserving the natural language description of the AOP’s ele-
ments. The use of ontologies also allows Effectopedia contributors to publish their
contributions as nanopublications.
Effectopedia serves as a graphical editor to delineate causal linkages at any level of
biological organization and test species. It creates a common organizational space
that (1) helps experts identify gaps in knowledge of causal linkages of biological re-
sponses and (2) acts as a web-based conference room for dialogue and synthesis by
experts with interest in specific AOPs. Effectopedia’s live documents are instantly
open for focused discussions and feedback, whilst giving credit to original authors
and reviewers. New contributions are immediately distributed to interested parties,
keeping all information current and documented. Uncoupling the contribution
and review processes also permits organizations to define their own seals of approval
and associate them with special interest pathways without slowing down the Wiki-
inspired stream of contributions.
855 Exposure Data Curation for Integration into the
Comparative Toxicogenomics Database (CTD).
C. G. Murphy,  C. Mattingly and A. P. Davis. Biology, North Carolina State
University, Raleigh, NC.
Toxicology research is rapidly transitioning from the observational study of adverse
effects of chemical exposures on living organisms to a predictive science based on
mechanistic understanding of chemical actions. Integration of exposure informa-
tion into the network of interactions among chemicals, genes, diseases, and molec-
ular pathways is essential to this transition. Therefore, we initiated a project to cu-
rate exposure data for inclusion into the publicly available Comparative
Toxicogenomics Database (CTD; http://ctdbase.org). CTD is a manually curated
database containing over 16 million toxicogenomic relationships of chemical-gene-
disease interactions and Gene Ontology and pathway annotations that are inte-
grated with analysis tools to promote understanding of the molecular mechanisms
underlying environmental diseases. Building on the community-based develop-
ment of the ExO exposure ontology, (http://ctdbase.org/downloads/#exposures),
biocurators manually curate four types of inter-related exposure data from the sci-
entific literature: Exposure Stressor, Exposure Receptor, Exposure Event, and
Exposure Outcome. Both controlled vocabulary and free text data fields are used to
allow searches among variables, while retaining details specific to the exposure
study. Inclusion of exposure information into CTD will create a centralized expo-
sure data resource that will facilitate the identification of connections between real-
world exposures, chemicals, genes, proteins, diseases, and molecular pathways.
Here we describe our exposure curation paradigm, initial content, and vision for in-
tegration into CTD.
856 Expansion of Toxicity Reference Database (ToxRefDB) Study
Data for In Vivo Phenotypic Modeling.
K. W. McLaurin,  S. Sneed,  I. Thillainadarajah and M. T. Martin. NCCT/ORD,
US EPA, Durham, NC.
The US EPA’s Toxicity Reference Database (ToxRefDB) was originally populated
with pesticide registration toxicity. ToxRefDB now incorporates guideline-like
studies from the pharmaceutical industry, National Toxicology Program (NTP),
and publicly available research literature. ToxRefDB now captures 5000 animal
studies on 1000 chemicals and study data was captured using a standardized, mul-
tilayered effect vocabulary across varied study types and species. Seven predomi-
nant, data rich study type and species combinations were examined in this analysis:
subchronic rat (590), chronic rat (590), chronic mouse (518), chronic dog (325),
developmental rat (663), developmental rabbit (512), and multigenerational repro-
duction rat studies (504). While the majority of chemicals did not have complete
toxicity study coverage, there was substantial overlap with study type and species
combinations. Of 590 chemicals tested in chronic rat studies: 488 have been tested
in chronic mouse studies, 416 in subchronic rat studies, 415 in developmental rat
studies, 372 in developmental rabbit studies, and 373 multigenerational rat studies.
Differences in key study parameters such as dosing duration, species, strain, and
life-stage provided a heterogeneous view of chemical toxicity profiles while helping
to gain evidence as common phenotypic outcomes arise. Across 382 chemicals with
a subchronic and chronic rat study, 42% observed liver pathology in both (correla-
tion = 0.486). The hierarchal effect vocabulary was mapped from study type and
species combination to endpoint supercategory, category, subcategory, class, and
subclass, down to effect type, target and description covering over 27000 effect pos-
sibilities. This multilayered vocabulary allows for comparison of effects occuring
within a biological continuum creating a more effective comparison of hundreds of
chemicals now captured by ToxRefDB.
This abstract does not necessarily reflect US EPA policy.
857 Application of US FDA, Center for Food Safety and Applied
Nutrition’s Knowledge-Base to Two Use Cases for Food
Contact Substances: FCS Inventory Assessment by Read-
Across and Prediction Models.
K. Arvidson1,  J. Aungst1,  S. Boyer2,  C. Hasselgren2,  E. Matthews1,
K. Muldoon-Jacobs1,  A. McCarthy1,  J. Rathman3 and C. Yang3. 1US FDA,
College Park, MD; 2AstraZeneca R&D, Mölndal, Sweden; 3Altamira LLC,
Columbus, OH.
The Chemical Evaluation and Risk Estimation System (CERES) project at FDA
Center for Food Safety and Applied Nutrition delivers a foundation providing
workflows for decision support activities for both pre-market and post-market
safety assessments of food additives, food contact substances, and potential con-
taminants. CERES v1.0 is a data repository and platform for database searching
and computational tools. The content includes chemical structures and properties,
regulatory records, toxicity studies, and other biological screening assays. CERES is
also an institutional knowledgebase where historical regulatory decisions on a given
substance are found. The system also assists new decision-making processes in a sys-
tematic and consistent manner. In cases where no information is available for a par-
ticular substance, CERES provides tools to estimate the toxicity and to assist with
other aspects of safety assessment. Two use cases of the CERES system are described
in this presentation. One is the read-across process within the CERES system to es-
timate a carcinogenicity potential of a compound. The analog searching capability
along with the supporting experimental data as well as genetic toxicity and carcino-
genicity models based on mode-of-actions are employed. Various information types
are combined using a weight-of-evidence (WOE) decision theory method. The sec-
ond use case is a post-market analysis of all historical food-contact substances in the
database of the Office of Food Additives Safety using the MOA (mode-of-action)
QSAR models within CERES, e.g., genetic toxicity endpoints, carcinogenicity, and
reproductive-developmental endpoints. In addition, a plan to connect CERES to
other predictive methods to enhance the system will be discussed.
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858 Flexible and Transparent Computational Workflows for the
Prediction of Target Organ Toxicity.
A. N. Richarz1,  S. J. Enoch1,  M. Hewitt1,  J. C. Madden1,  K. Przybylak1,
C. Yang2,  M. R. Berthold3,  T. Meinl3,  P. Ohl3 and M. T. Cronin1. 1School of
Pharmacy and Chemistry, Liverpool John Moores University, Liverpool, United
Kingdom; 2Altamira LLC, Columbus, OH; 3KNIME.com AG, Zurich, Switzerland.
In silico modeling of target organ toxicity has been held back in part by an inability
to capture all relevant information into a meaningful reductionist approach. It has
also been considered at times too simplistic, using data of often variable quality and
seldom allowing the user to assess the relevance to the intended use. The purpose of
this study was to develop a novel computational toxicology workflow system, to
allow the users greater control and understanding of the target organ toxicity pre-
diction. The workflows were built on the KNIME open-access platform which al-
lows pipelining via a graphical user interface. Various building blocks, known as
nodes, were incorporated, to access chemical inventories and/or databases, to pro-
file structures and calculate properties and to report prediction results. The “basic”
user sees a web-interface, whilst a “trained” user can go behind this to interrogate
the nodes and, if required, link to additional data sources or investigate and update
the models. The workflow was developed to address in particular the prediction of
target organ toxicity of cosmetic ingredients. It comprises an inventory of over
4,400 unique chemical structures (cosmetic ingredients and related substances).
The database contains repeat dose toxicity data for over 1,100 compounds includ-
ing NOEL values. Thus, a user is able to search for similar compounds in the in-
ventory file or database. The compound is then profiled using relevant structural
alerts and chemotypes, currently comprising 108 alerts for protein reactivity, 85 for
DNA binding, 32 for phospholipidosis and 16 for other liver toxicity endpoints.
The workflows are flexible and transparent, they are successful in guiding a user
through the process of making a prediction of target organ toxicity. Supported by
the EU FP7 COSMOS Project.
859 Chemotypes: A New Structure Representation Standard for
Incorporating Atom/Bond Properties into Structural Alerts
for Toxicity Effects and Mechanisms.
C. Yang1,  K. Arvidson2,  A. Detroyer3,  J. Gasteiger4,  J. Marusczyk4,
J. Rathman1,  A. M. Richard5,  S. Ringeissen3,  C. Schwab4,  A. Tarkhov4 and
A. Worth6. 1Altamira, LLC, Columbus, OH; 2US FDA, College Park, MD; 3L’Oréal,
Aulnay S/S, France; 4Molecular Networks, Erlangen, Germany; 5US EPA, RPT, NC;
6JRC, Ispra, Italy.
The representation of structural moieties that carry biological activity information,
historically referred to as structural alerts, has a long association with Structure
Activity Relationships (SAR). Typically, structural knowledge development is per-
formed only by experts and implemented using SMARTS or proprietary formats.
With few exceptions, scientists have generally not been able to query structures
with customized substructure rules. Furthermore, there are needs for standardized
representations and the ability to encode attributes such as atomic and/or bond
properties within structural constructs. Recent efforts to apply cheminformatics to
systems-biology have called for innovation in this SAR area by integrating proper-
ties with structure connectivity. To this end, an XML-based representation of
chemotypes has been developed to define substructures in which each atom and
bond can be annotated with atomic, bond, and/or electronic properties, adhering
to a controlled vocabulary, that go beyond the confines of conventional structural
classes. These chemotypes have been implemented in a publicly free software appli-
cation to enable search and data filtering. This chemotyper has been developed as
part of a project from FDA’s Center for Food Safety and Applied Nutrition to aid in
updating FDA structure categories used by toxicology reviewers and to support the
mode-of-action modeling (MOA) approach adopted in the Chemical Evaluation
and Risk Estimation System. A series of chemotypes have been developed to incor-
porate SAR-informed annotations associated with phenotypic effects in hepatotox-
icity and developmental morphology, as well as skin irritation and sensitization.
These chemotypes enhanced accuracy of categorizations and MOA model predic-
tions. This abstract does not necessarily reflect EPA policies.
860 In Silico Models of Sequence-Specific Mutagenicity:
Exploring Chemical-Mutation Site Associations.
A. Sedykh1,  Y. Low1,  S. Chakravarti2,  R. Saiakhov2 and A. Tropsha1. 1Eshelman
School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC;
2MultiCASE, Beachwood, OH.
The Ames Salmonella test for genotoxicity has undergone several transformations
since its introduction in 1971. The initial strains, histidine-deficient mutants in-
volving different mutation-prone DNA sequences, were designed to detect specific
frameshifts and base substitutions. Later, many strains with the same target se-
quence but improved antibiotic resistance, cellular permeability or impaired repair
mechanisms were introduced as more sensitive alternatives. However, most existing
Quantitative Structure-Activity Relationship (QSAR) models predict either muta-
genicities in major strains or overall mutagenicity. We hypothesized that using ad-
ditional sensitive strains can provide more refined models predicting sequence-spe-
cific mutations. Hence, we curated the Chemical Carcinogenesis Research
Information System (CCRIS) database (n=6,545) and the CASE Ultra data set
(n=5,438) to create a larger database of 6,967 molecules with fewer missing entries
(42% vs 33-39% in original sources). Using mutagenicities reported either in the
presence or absence of metabolizing enzymes, we built QSAR models for five se-
quence-specific mutation sites (hisD3052, hisD3018, hisD6610+hisO1242,
hisG46 and hisC3076). These 10 models were compared with the previous strain-
specific models in CASE Ultra. Sequence-specific models generally exhibited
greater sensitivity (68-88%) and dataset coverage (88-98%) but lower specificity
(51-72%). Conversely, previous strain-specific models, built on unbalanced data
sets, exhibited high specificity (82-99%) but low sensitivity (17-82%). We have
further analyzed the models in terms of statistically significant chemical fragments
that were interpreted as structural alerts, highlighting the susceptibility of targeted
DNA sequences to certain chemical features. For example, fluorenes, due to their
planar structures, are good intercalators often associated with frameshifts in
hisD3052. The curated data, models, and new structural alerts will be included in
future releases of CASE Ultra.
861 ToxML: A Structured and Serialisable Exchange Standard for
Toxicology.
M. A. Ali1,  M. L. Patel1,  P. N. Judson2 and D. R. Benz3. 1Lhasa Limited, Leeds,
United Kingdom; 2Judson Consulting Service, Harrogate, United Kingdom; 3US FDA
Center for Drug Evaluation and Research, Silver Spring, MD.
The amount of toxicity data available for those wishing to share and communicate
knowledge, or to use for data mining and modelling, is continually growing within
the biomedical disciplines. The challenge with this expanding amount of data is
that it exists in a multitude of different formats. ToxML is an open standard based
on Extensible Markup Language (XML) that consists of an XML Schema (XSD)
defining the toxicology schema and lists of controlled vocabulary that ensure con-
sistency of usage. The use of XML means that the data can be created, stored and
transported in a structured format that is not bound to a specific software applica-
tion or programming language. The data file model resulting from this approach is
very versatile and allows for the aggregation of experimental data up to the com-
pound level in the detail needed to support areas such as quantitative structure-ac-
tivity relationship (QSAR) development. ToxML formats have been developed, so
far, for 27 toxicity study types. These cover both in vivo and in vitro, and currently
include the following super toxicity endpoints: genetic toxicity, carcinogenicity,
skin sensitisation, skin penetration, in vivo repeat dose toxicity, in vivo single dose
toxicity and ecotoxicity.
Informatics groups at the FDA CDER-CFSAN use ToxML to populate repositories
with the results of FDA toxicological and clinical data harvesting efforts, and em-
ploy the resulting information to model QSARs. We describe an example of how
ToxML could be used as a practical data exchange standard for genetic toxicology
information. The standard is maintained by a curation team overseen by the
ToxML organisation. The standard is published on a web site (www.toxml.org) to-
gether with tools to view, edit and download it. Contributions from the user com-
munity to the ongoing evolution of the standard are facilitated in an open forum
via a wiki on the web site.
862 ToxCastTM Workflow: High-Throughput Screening Assay
Data Processing, Analysis and Management.
P. G. Kothiya1, 2,  M. T. Martin1,  A. M. Frame1,  A. M. Richard1,  R. Judson1 and
D. Reif1. 1National Center for Computational Toxicology, Office of Research and
Development, US EPA, Research Triangle Park, NC; 2Bioinformatics Program, North
Carolina State University, Raleigh, NC.
USEPA’s National Center for Computational Toxicology (NCCT) is developing
the ToxCast program with the aim of providing high-quality screening data on
thousands of chemicals. The huge library of compounds and wide diversity of high-
throughput assays in ToxCast present daunting practical challenges with respect to
data processing, analysis, and management with the goal of providing transparent
and sustainable data outputs across these massive data sets. To successfully address
these goals, the data analysis workflow was designed with 8 levels of processing
from raw data to finalized hit calls and is distributed within two major portions of
the workflow: “Pipeline” (levels 1-4) and “Curve fit” (levels 5-8). The pipeline por-
tion takes incoming raw data files, performs automated chemical and assay map-
ping, provides plate/batch effect correction, and assay specific data normalization to
supply highly consistent data formats for the curve fitting process. The curve-fitting
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and hit-calling process consists of cytotoxicity-point and outlier detection/masking,
concentration activity estimates using dose response modeling, systematic data con-
founder detection (e.g., fluorescence or non-specific activity). The finalized results
are subsequently uploaded into ToxCastDB for data integration and analysis as well
as to serve as the primary portal for publication and data release. In addition, the
ToxCast workflow has data quality and error identification features quantifying
assay performance and quality. The ToxCast data workflow has been systematically
developed to efficiently address data management challenges, increase curve-fitting
and hit-calling accuracy, and to allow for technology specific customization result-
ing in repeatable and transparent analyses. This work does not necessarily reflect
Agency policy.
863 High-Throughput Electronic Literature Libraries (E-
Libraries) to Support Development of Toxicity Prediction
Models and Adverse Outcome Pathways (AOPs).
N. C. Baker1,  T. B. Knudsen2 and K. M. Crofton2. 1Lockheed Martin/US EPA,
Research Triangle Park, NC; 2NCCT, US EPA, Research Triangle Park, NC.
The elucidation of adverse outcome pathways (AOPs) and mechanistic models of
toxicity depends on a thorough understanding of the relationships among protein
targets, molecular pathways, cellular processes, adverse outcomes, and exogenous
chemicals in a given biological system. Scientists rely on the biomedical literature
for a significant portion of this information; however, common tools and resources
such as PubMed are designed primarily for article retrieval and may fall short in
synthesis of important relationships from the large amounts of available literature.
We developed a series of electronic libraries (e-libraries) to provide investigators a
way to streamline information retrieval from the biomedical literature and focus the
retrieval on key relationships. The foundation for the e-libraries is a broad literature
database in the form of a compilation of the MeSH annotations extracted from
each MEDLINE record. These annotations are processed and organized so that the
relationships among target proteins, biological effects, and chemicals are more eas-
ily extracted. For a particular area of interest (e.g., cleft palate, limb development,
endocrine disruption) or for a particular set of chemicals (e.g., ToxCast) the litera-
ture database is batch-searched for articles containing the corresponding MeSH
terms and the co-annotated terms. To produce the e-library, the terms are organized
and written to Excel spreadsheets. Finding relevant articles is facilitated by allowing
users to use built-in filtering capabilities. A filtering flag for species for instance, will
allow the user to see only the rows about a desired species. The e-libraries have been
constructed around subject areas as diverse as cleft palate, zebrafish, retinal develop-
ment, flame retardants, and endocrine disruption. Access to e-libraries has been
used to assist all kinds of research from basic exploratory research to development of
AOPs and computer simulations. [This abstract does not necessarily reflect EPA
policy.]
864 Interactive Web Application (Dashboards) to Integrate Data
on Chemical Hazard and Exposure.
S. Watford,  M. Martin,  A. M. Frame,  R. Judson,  N. C. Baker,  I. Shah,
J. F. Wambaugh and D. Reif. National Center for Computational Toxicology, Office
of Research and Development, US EPA, Research Triangle Park, NC.
The USEPA has developed web-based interfaces (Dashboards) to synthesize multi-
ple sources of data from Aggregated Computational Toxicology Resource (ACToR)
into customized information displays. Users may select subsets of chemicals and
data types to focus on for the assessment process. The data are organized into cus-
tom classes to present all relevant information for a given task. While not all chem-
icals will have complete information across all classes, each class reports available
data including relevant high-throughput assay results, regulatory information, rele-
vant articles from the biomedical literature, exposure data, and in vivo toxicity data.
Custom widgets display each type of data according to its nature (e.g. dose-response
plots or tables for assay data and summary tables for exposure data). Chemical-spe-
cific summary scores that consider all information in each class are presented in a
dynamic summary table that highlights areas deserving additional attention.
Transparency in decision-making is preserved since Dashboards record and save all
user selections and decisions. Expert judgment can be used to override score criteria
if necessary, again with such events recorded for transparency purposes. The scores
are carried over into a prioritization process where the chemicals are ranked in a
weight-of-evidence scheme to identify candidates for focused assessment. For ex-
ample, the Dashboard created to support analysis of potential endocrine disruptors
contains over 8000 chemicals with the classes Estrogen, Androgen, Thyroid,
Steroidogenesis, Exposure, Occurrence, and Health Effects. The aggregation of rel-
evant data and use of Dashboards to generate custom displays streamlines the toxi-
city assessment process and allows users to zoom from larger chemical subsets down
to very focused chemical-wise views. While the initial Dashboards have been cre-
ated to support EPA programmatic needs, future versions will include a public-fac-
ing web interface. This abstract does not necessarily reflect US EPA policy.
865 Literature Visualization and Navigation to Facilitate
Development and Application of Computational Biological
Models.
N. Pena,  S. R. Crowell,  S. Dowson,  D. McQuerry and J. G. Teeguarden. Systems
Toxicology, Pacific Northwest National Laboratory, Richland, WA.
Physiologically based pharmacokinetic (PBPK) and quantitative structure activity
relationship (QSAR) modeling rely heavily on mining of published literature for
model development and parameterization, a time and resource intensive process.
Because PBPK and QSAR modeling are relatively new disciplines, there is a need
for readily accessible and high quality resources to support the increasing model
use. Resource needs are broad, ranging from parameter values to model archives
and publication archives. A common thread is the need to organize the available
model related literature in a fashion that supports rapid access and organization ac-
cording to data needs and more detailed analysis. We have developed a tree map ap-
plication, a powerful, visually intuitive literature navigation interface, which ex-
ploits the naturally hierarchical nature of information used in biological modeling.
Tree maps organize data thematically, and can be navigated by the user choosing a
theme of interest, and then drilling down through sub-themes to the level of indi-
vidual documents (existing models or relevant publications). Subject matter experts
developed a taxonomy of themes in biological modeling, and relevant documents
were identified in the literature by means of specific search strings. IN-SPIRE
Visual Document Analysis was used to identify linguistically significant themes
within the data, and to develop and test search strings used by the tree map to iden-
tify relevant documents from within the database of biological modeling publica-
tions. Documents were then labeled with their relationships within the class struc-
ture, loaded into a database, and a tree map user interface generated. With
continuing refinement of search strings and development of the tree map applica-
tion, this work has the potential to yield a powerful, evergreen (automatically up-
dating) search tool specifically designed to aid in biological model development and
utilization. An external demo of the tree map can be found at
https://nvacdemo.pnl.gov/srs/dashboard/epa/
866 Database of Chemicals Assayed for Estrogenic Activity in the
US FDA’s Endocrine Disrupting Knowledge Base (EDKB).
J. Shen,  L. Xu,  W. Tong and H. Hong. 1University of Georgia, Athens, GA;
2Jiangnan University, Wuxi, China.
Endocrine disruptors (EDs) are chemicals with ability to disrupt endocrine system.
EDs have sparked intense international scientific discussion and debate and pro-
voked regulatory action. The FDA’s National Center for Toxicological Research
(NCTR) developed a publicly available Endocrine Disrupting Knowledge Base
(EDKB) (http://goo.gl/Qn0nv) 13 years ago. It has been a widely used resource in
the scientific community. Currently, we are expanding the data collection in the
EDKB by including the most up-to-date literatures. Since many EDs display estro-
genic activities and affect the normal estrogen signaling pathway, we first updated
the estrogenic data and developed a database of chemicals assayed for estrogenic ac-
tivity as a component in EDKB. The database contains over 16,500 activity data of
about 7,000 compounds from many public resources. The activity data are catego-
rized based on assay types into binding assay, reporter gene assay and cell prolifera-
tion assay. The database also contains protein subtypes and domains used in the as-
says. Original data were converted into the same units such as logRBA for binding
data (RBA=Relative Binding Affinity). Quality control was performed to ensure the
data quality. The database was implemented using Instant JChem. A user-friendly
interface was designed and developed for rapid navigating and searching the data-
base. Searching multiple fields such as chemical structure, substructure, chemical
name, CAS, assay type, assay species, activity range, and references can be con-
ducted using logical operations. To the best of our knowledge, this database is the
most comprehensive collection of chemicals assayed for estrogenic activity. It pro-
vides the scientific and regulatory communities a free source to search estrogenic ac-
tivity data for chemicals of interest and to develop predictive models for predicting
chemicals for which no assay data are available.
867 The Comparative Toxicogenomics Database.
C. Mattingly1,  C. G. Murphy1,  R. Johnson2,  J. M. Lay2,  K. Lennon-Hopkins2,
C. Saraceni-Richards1,  D. Sciaky2,  B. L. King2,  M. C. Rosenstein2,
T. C. Wiegers1 and A. P. Davis1. 1North Carolina State University, Raleigh, NC;
2MDIBL, Salisbury Cove, ME.
The goal of the Comparative Toxicogenomics Database (CTD; http://ctdbase.org)
initiative is to inform hypothesis development about mechanisms of chemical ac-
tions and the impact of environmental exposures on human health. CTD is a freely
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available tool that provides a foundation of manually curated data describing chem-
ical-gene interactions and chemical-disease and gene-disease relationships. Curated
data are integrated with external data sets (e.g., Gene Ontology and pathway data)
and tools that allow users to navigate and analyze over 16 million biological rela-
tionships relevant to environmental health sciences (EHS). Here we describe CTD
functionality and highlight several new analysis and data visualization features, in-
cluding: a Gene Set Enricher tool that provides deeper insight into the functional
themes and pathways associated with user-defined genes or genes forming the basis
of inferred chemical-disease relationships; filtering options that allow users to better
customize queries and analyses; and a ‘slim’ list for our disease vocabulary that was
implemented with graphical views to provide visual summaries of disease categories
associated with chemicals in CTD. We also present information about emerging
projects, including the use of curated data for developing chemotypes (a chemical
substructure that carries information about biological activity), text-mining work-
flows for identifying chemical-gene-disease data, novel pathway development tools,
and exposure data curation. We continue to expand the depth and functionality of
CTD to meet the evolving needs of the EHS research community.
868 Mode-of-Action Ontology: An Application Ontology for
Risk Assessment Data Mining.
K. L. Painter1 and L. D. Burgoon2. 1Oak Ridge Institute for Science and Education,
Research Triangle Park, NC; 2National Center for Environmental Assessment, US
EPA, Research Triangle Park, NC.
Automated natural language processing (NLP) will make the practice of risk assess-
ment more efficient. In the future, computer algorithms will use NLP to screen the
literature for appropriate studies, identify relevant data, and help synthesize mode
of action (MOA) evidence across several studies. However, before we can utilize the
data from NLP searches, ontologies must be built to facilitate efficient data storage
and sharing using existing standards. We developed the Mode of Action Ontology
(MOAO) to support automated NLP discovery, integration, and management of
mode of action knowledge. MOAO is a semantic model that 1) describes MOA
knowledge, 2) easily combines data from multiple sources, 3) makes MOA knowl-
edge more transparent and easily available to the public via semantic web interfaces,
and 4) will allow computers to discover latent information and relationships via
logical inference. MOAO is the first ontology we are aware of that describes mode
of action information for toxicological purposes. MOAO was conceptualized as an
application ontology, borrowing terms from existing high-quality ontologies pro-
duced for various biological sub-specialties. This allows us to maximize integration
with outside data sources. In this way, MOAO can be a model for how other sub-
domains in toxicology can reap the benefits of ontologies without the overhead of
constructing one completely from scratch. We leverage the work by the Open
Biological and Biomedical Ontologies (OBO) Foundry and the Basic Formal
Ontology (BFO) to facilitate the integration of our ontology with others. The ref-
erence ontologies which MOAO uses include the Gene Ontology (GO), ChEBI
(Chemical Entities of Biological Interest), the Uber Anatomy Ontology
(UBERON), the NCBI Taxonomy, and the NCI Thesaurus. The views expressed in
this abstract are those of the authors and do not necessarily represent the views or
policies of the U.S. Environmental Protection Agency.
869 Development of a COSMOS Database to Support In Silico
Modelling for Cosmetics Ingredients and Related Chemicals.
J. Rathman1, 2,  C. Yang1,  K. Arvidson3,  M. T. Cronin5,  S. Enoch5,
D. Hristozov3,  Y. Lan6,  J. C. Madden5,  D. Neagu6,  A. N. Richarz5,  M. Ridley6,
O. Sacher4,  C. Schwab4 and L. Yang6. 1Altamira, LLC, Columbus, OH; 2The Ohio
State University, Columbus, OH; 3Office of Food Additive Safety, CFSAN US FDA,
College Park, MD; 4Molecular Networks, Erlangen, Germany; 5Liverpool John Moores
University, Liverpool, United Kingdom; 6University of Bradford, Bradford, United
Kingdom.
The Seventh Amendment of the EC’s Cosmetics Directive foresees a deadline in
2013 for the replacement of animal testing of cosmetic products for repeated
dose/reproductive toxicity and toxicokinetics. To this end, the COSMOS project
has been initiated to fill the gap in knowledge and technology via in silico toxicol-
ogy. The management and sharing of chemical, biological and toxicity data play a
central role. The COSMOS database activities cover three main directions: an
overview of toxicity data sources and studies; the design of the data model and the
data entry tool for the database; and the definition of a data curation strategy. The
new COSMOSDB provides a publicly available web-based searching/retrieval sys-
tem and also serves for sharing resources, models and supporting workflow devel-
opments. The database is “compound-centred” and represents both EU COSING
and US PCPC inventories for cosmetics ingredients. For biological data, the data-
base supports repeated dose toxicity, metabolism information and dermal absorp-
tion data. The data have been collected, curated, quality-controlled, stored and
managed in a flexible and sustainable manner to support predictive modelling
tasks. An effective curation strategy for toxicity data has also been reflected in build-
ing the data entry system. Based on the review of existing approaches on good prac-
tice to assess quality entries, the reliability of the toxicity data is supported by all
available data from multiple sources. Additional functionalities for data aggregation
within a data governance framework are described. The COSMOS project is
funded by European Community’s 7th Framework Program (FP7/2007-2013) and
by Cosmetics Europe.
870 The Toxbank Infrastructure Project to Support the
Replacement for Repeated Dose Toxicity.
G. J. Myatt1,  E. Benfenati3,  D. Bower1,  R. Ceder2,  K. P. Cross1,
R. C. Grafström2,  L. Healey4,  C. Helma5,  N. Jeliazkova6,  V. Jeliazkova6,
L. Kidane4,  P. Kohonen2,  S. Maggioni3,  S. Miller1,  M. Rautenberg6,  G. Stacey4,
J. Wiseman8 and B. Hardy7. 1R&D, Leadscope, Columbus, OH; 2Karolinska
Institutet, Stockholm, Sweden; 3Istituto di Ricerche Farmacologiche Mario Negri,
Milan, Italy; 4National Institute for Biological Standards and Control, Potters Bar,
United Kingdom; 5In silico toxicology, Basel, Switzerland; 6Ideaconsult, Sofia,
Bulgaria; 7Douglas Connect, Zeiningen, Switzerland; 8Pharmatrope, Wayne, PA.
Sponsor: R. Benz.
The aim of the €50 million SEURAT-1 (Safety Evaluation Ultimately Replacing
Animal Testing-1) research cluster, sponsored by the European Union and
Cosmetics Europe, is to generate a proof-of-concept replacement for repeated dose
systemic toxicity testing on animals. The SEURAT-1 strategy is to adopt a mode-
of-action framework to describe repeated dose toxicity, combining in vitro and in
silico methods in an intelligent manner to derive predictions of in vivo toxicity re-
sponses. ToxBank is the cross-cluster infrastructure project whose activities include
the development of a data warehouse, the selection of reference compounds for use
across the cluster to support the mode-of-action framework, a physical compounds
repository, and a reference resource for biomaterials. The ToxBank data warehouse
provides a web-accessible shared repository for protocols and experimental results
supporting SEURAT-1 research objectives such as toxicity pathway elucidation and
biomarker discovery. Information in ToxBank is uploaded from the research activi-
ties of the cluster partners and relevant information on the reference compounds
from public databases. In this poster we describe the data warehouse and imple-
mentation based on open standards, the selection of reference compounds, and an
analysis linking the reference compounds to public omics data.
871 Software for Integration of Experimental, Chemical, and
Environmental Data.
E. Peterson1,  K. Hobbie2,  S. C. Tilton1,  R. L. Tanguay2,  K. Anderson2 and
K. M. Waters1. 1PNNL, Richland, WA; 2OSU, Corvallis, OR.
The Oregon State University Superfund Research Program evaluates the potential
health effects of polycyclic aromatic hydrocarbons (PAHs). More than 100 parent
PAH compounds, and an unknown number of PAH derivatives and metabolites
have been identified. PAHs raise concern at over 800 Superfund Sites and serve as
the risk driver for remediation at 20% of all Superfund sediment sites. Assessing the
health effects of PAHs is a major challenge because environmental exposures to
these chemicals are from complex mixtures of PAHs and other toxicants.
Integration of exposure data with biological activity and pharmacokinetics is essen-
tial to evaluate the effects presented by these mixtures on human health.
Increasingly researchers are generating data streams of high content data from ana-
lytical, high-throughput, and ‘omic’ studies, which make direct applications from
these technologies out of reach for clinicians and regulators. However, more accu-
rate and precise thresholds for risk assessments and prediction will ultimately arise
from leveraging the integration of data from across disciplines. Therefore, the prin-
ciple challenge for mixture assessments, epitomized by PAHs, is the efficient inte-
gration of large and diverse data sets. To this end we’ve extended PNNL’s
Experimental Data Management System (EDMS) to create a seamless data work-
flow among researchers and analysts. EDMS has been extended to track and man-
age relationships among any and all data points across a project. This allows us to
integrate chemical and biological data for environmental extracts (LIMS and
EDMS) with analogous data on pure chemical compounds. EDMS provides a
query mechanism that will reach through all the relationships of data from chemi-
cal compounds to the analytics and statistics run on the experimental data. Query
results, visualizations, and data processing results are all also stored together with
and related to the experimental information. This reduces data replication and sup-
ports a streamlining of analysis, collaboration and experimental design allowing re-
searchers to take advantage of all the data generated.
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872 Computational Methods to Reveal Cross-Species, Dose-
Response Patterns in Nonclinical Studies.
S. Nath,  J. Kimball,  S. Madhavan,  V. Krishnan and L. Prabhakar. PointCross Life
Sciences, Foster City, CA. Sponsor: R. Guy.
Drug development scientists and regulatory reviewers alike have a need to under-
stand toxicity patterns of a drug candidate across animal species prior to human tri-
als. Effective exploitation of collected study data has previously been impeded by
differences in mnemonics, terminologies and units across sponsor and CRO data.
Moreover, computational techniques to analyze large volumes of disparate quanti-
tative and qualitative study data, and their respective endpoints, have not been rou-
tinely available for use by practicing toxicologists and reviewers. 
To address these common challenges for the FDA and the Industry, we have devel-
oped new repository techniques to prepare and hold in vivo harmonized datasets
(including standardized formats like SEND, the Standard for Exchange of
Nonclinical Data), and extracted metadata, as a first step towards advanced analyt-
ics and study reviews. Predictive, comparative and cluster analysis techniques have
been performed on large study repository datasets to reveal similarities and differ-
ences in dose-response patterns across species in terms of their magnitude, shape
and trends.  Finally, signal processing techniques such as Z-transform box plots
have been adapted to present trends in ways that scientists and regulatory reviewers
can easily use to interpret potential toxicity patterns and their inter-relationships. 
Collectively, new computational tools are available to better exploit legacy and on-
going data that are already being collected, provide better decision support for
species selection and protocol design, and advance our understanding of how dose-
response patterns translate across species for the same compound and to detect
other compounds that share similar responses.  Implications of applying such com-
putational methods to improve safety prediction across species, and eventually into
humans, will be discussed particularly in light of the FDA’s mandate to require
standardized e-Data submissions, including SEND datasets, as a way to further reg-
ulatory science.
873 ToxCast High-Throughput Screening Assay Annotation
Using Bioassay Ontology and Expanded Assay Target
Information.
J. Phuong1, 2,  K. Houck1 and M. T. Martin1. 1NCCT, US EPA, Research Triangle
Park, NC; 2Environmental Science & Engineering, University of North Carolina at
Chapel Hill, Chapel Hill, NC.
The ToxCast assay library includes 427 high- to Low-throughput screening assays
with a total of 700 assay components. Assessing a battery of cellular, pathway, pro-
tein and gene perturbations, the total number of assay endpoints (assay_compo-
nent_endpoints) generated is 1106. Selecting the appropriate data sets to use for
modeling purposes encounters questions such as suitable cell type, assay design
specifics, protein form, measured target and detection method. To simplify these
concepts, the BioAssay Ontology was applied to annotate 36 descriptors for assay
design and target information and to create a scheme for identifying assay_compo-
nent_endpoints. Assay design information is distinguished by assay design types
(n= 23), detection technology types (n=11), and cell types (n=36), which consists of
14 species and 18 tissues. Assay target information is separated by technological tar-
get mapped to gene(s) (n=381), technological target types (n=15), intended target
genes (n= 362), intended target families (n=145), intended target types (n=14), and
biological process targets (n=11). An example of applying the assay target informa-
tion to identify all applicable assay_component_endpoints is given for the Aryl
Hydrocarbon Receptor (AhR). AhR is assessed by four assay_components
(ATG_Ahr_CIS, Tox21_AhR_BLA_Agonist, CLZD_CYP1A1, and
CLZD_CYP1A2) in eight assay_component_endpoints. The ATG_Ahr_CIS assay
uses an mRNA induction design to target transcription factor activity. The
Tox21_AhR_BLA_Agonist assay uses a beta lactamase reporter gene induction de-
sign to measure receptor activity. Lastly, the CLZD assays measure the mRNA in-
duction of two AhR target genes, CYP1A1 and CYP1A2, at multiple time-points
to measure AhR receptor gene regulation activity. With this approach, the intended
assay targets and the means used to measure their activities can be clearly commu-
nicated in explicit ways to allow for integration into larger systems-models. This ab-
stract does not necessarily reflect U.S. EPA policy.
874 A Novel Hybrid Approach in Combining a QSAR-Based
Expert System and a Quantitative Read Across Methodology
to Achieve Better In Silico Genotoxicity Assessment of
Drugs, Impurities and Metabolites.
S. Chakravarti1,  R. Saiakhov1 and G. Klopman1, 2. 1Multicase Inc., Beachwood,
OH; 2Chemistry, Case Western Reserve University, Cleveland, OH.
Purpose: Purpose of this study is to develop and apply a novel technique of com-
bining the predictions of the CASE Ultra expert system models and a new quanti-
tative read across modeling methodology to obtain better genotoxicity predictions
as opposed to using just one technique. The hybrid methodology successfully pro-
vides the interpretability of toxicity alerts and reduces false positives, false negatives
while increasing the test coverage. This in silico tool can be successfully used for as-
sessment of potential toxicity or beneficial therapeutic effects of new drug candi-
dates, impurities and metabolites.
Method and Data: CASE Ultra is a computer program that automatically extracts
structure-activity knowledge from chemical databases and applies the knowledge
for predicting activity in test chemicals. It also gives a very clear explanation of its
predictions so that they are easily interpretable by chemists and toxicologists.
Recently we have developed a novel read across modeling technique for quantitative
prediction of toxicity that uses the full neighborhood profiles of chemicals. In case
of Salmonella mutagenicity predictions, the read across prediction was applied in a
systematic way on top of the predictions from the CASE Ultra mutagenicity mod-
els, and significant improvements in the sensitivity, specificity and coverage were
achieved. The details of the methodology and results of prediction for a large exter-
nal test set are presented. 
Results of the Study: The improvements in the predictive performance as a result of
the hybrid technique is demonstrated for Salmonella mutagenicity prediction in an
external test set. Improvements in the prediction sensitivity, specificity and coverage
were in the order of 3-5%, 2-5% and 5% respectively.
875 Systematic ‘Omics Analysis Review Tool to Support Risk
Assessment.
E. McConnell1,  S. Bell1,  I. Cote2,  R. Wang3,  E. J. Perkins4,  N. Garcia-Reyero5,
P. Gong4 and L. D. Burgoon6. 1Oak Ridge Institute for Science and Education,
Research Triangle Park, NC; 2NCEA, US EPA, Washington DC; 3NERL, US EPA,
Cincinnati, OH; 4USACE, Vicksburg, MS; 5Mississippi State University, Starkville,
MS; 6NCEA, US EPA, Research Triangle Park, NC.
Incorporating data from molecular and systems biology studies, especially omics
data, presents a major challenge for risk assessors. Omics studies of varying quality
and relevance are currently reported in the literature. Risk assessors need a stan-
dardized, transparent way of screening literature based on study quality prior to
performing in-depth analyses of the data and including the results in human health
risk assessments (HHRA). The Systematic Omics Analysis Review (SOAR) tool is a
spreadsheet of 35 objective questions, currently focused on transcriptomic microar-
ray studies, developed by domain experts. The tool will identify if a study meets
basic published quality criteria, such as those defined by the Minimum Information
About a Microarray Experiment (MIAME) guideline and the Toxicological data
Reliability assessment (ToxR) Tool. Although the tool is currently constructed for
human use in reviewing microarray literature, future work will automate the litera-
ture screening process using natural language processing as a first pass filter, with
fewer subjective questions left for human determination afterward. The questions
cover four sections (Test System, Test Substance, Experimental Design, and
Microarray Data). Seven scientists were recruited to validate the tool by using it to
rate 16 published manuscripts that study chemical exposure with microarrays.
Using their feedback, questions were weighted based on importance of the infor-
mation and a suitability cutoff was set for each of the four question sections. The
SOAR tool was found to be simple, systematic way of performing a first-pass
screening of microarray literature, which will introduce modern research method-
ologies into traditional HHRA procedures. 
The views expressed in this abstract are those of the authors and do not necessarily
represent the views or policies of the U.S. Environmental Protection Agency.
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876 Web-Based Benchmark Dose Modeling Module As a
Prototype Component of an Informatics-Based System for
Human Health Assessments of Chemicals.
A. J. Shapiro1, 4,  N. Cook1,  P. Ross4,  J. Fox2,  V. Cogliano2,  W. A. Chiu2,
N. Wang2,  L. Zeise3,  K. Guyton2 and I. Rusyn1. 1University of North Carolina at
Chapel Hill, Chapel Hill, NC; 2NCEA, US EPA, Washington DC; 3Scientific Affairs
Division, Cal/EPA, San Francisco, CA; 4ICF International, Fairfax, VA.
We propose developing a modular, cloud-ready, informatics-based system to syn-
thesize multiple data sources into overall human health assessments of chemicals.
This system would seamlessly integrate and document the overall workflow from
literature search and review, data extraction, and evidence synthesis, to dose-re-
sponse analysis and uncertainty characterization. Crucial benefits of such a system
include improved data integrity, greater transparency, standardization of data pres-
entation, and increased consistency. By including both a web-based workspace for
assessment teams, and complementary web-based portal for reviewers and stake-
holders, all interested parties would have dynamic access to completed and ongoing
assessments. The modular approach will also facilitate rapid prototyping, testing,
review, and incorporation of methodological improvements. Here we present a pro-
totype module for benchmark dose (BMD) modeling used to develop points-of-de-
parture, from which toxicity values are derived. Previously-developed BMDS
Wizard and DRAGON Excel-based programs were used to develop a web-based
tool where assessment teams can view/upload/enter dose-response data sets into the
module, perform BMD modeling, and export results. Example summary views and
plots are available online, or can be converted to report format. In addition, multi-
ple nested views of the data and analyses enable interested users to rapidly “dive into
the details.” We conclude that given new data streams, diverse user needs, and mul-
tiple stakeholder interests, assuring the utility, integrity, and objectivity of human
health assessments will be greatly facilitated by a modular, upgradeable, informat-
ics-based system for their development, review, and dissemination. Disclaimer: The
views expressed in this abstract are those of the authors and do not necessarily rep-
resent the views or policies of the US or California EPA.
877 An Optimized Cheminformatics Method for Determining
Hazard Communication Information for Research Samples.
N. M. Berdasco,  D. M. Wilson,  P. S. Price,  J. A. Hammond and
C. M. Thornton. TERC, The Dow Chemical Company, Midland, MI.
A Research Sample Safety Data Sheet (RSSDS) is a hazard communication docu-
ment, which describes health and safety properties and characteristics of a chemical
substance, typically for one-time-use only. This document enables research samples
to be safely packaged and shipped worldwide using commercial carriers in compli-
ance with all regulatory requirements. It is the critical vehicle for communicating
relevant toxicity information to workers, shippers and first responders in case of un-
planned release. It can be a time critical service where the client expectation is that
cycle time (CT) will be short, typically 24-48 hrs. Implementation of the Global
Harmonized System (GHS) around the world necessitates the inclusion of GHS
classifications for substances and mixtures. This requirement has greatly increased
the complexity of RSSDS hazard assessment, especially in situations where hazard
profiles must be estimated for novel chemicals where only the structure is known.
This poster describes an optimized method for the delivery of hazard information
as developed by The Dow Chemical Company. The method utilizes cheminformat-
ics tools such as QSAR modeling, read-across and identification of analogs to en-
hance the ability to predict hazards for novel chemicals, enabling clients to comply
with complex international regulations and product stewardship while still meeting
competitive timelines for product development and sampling.
878 California Communities Environmental Health Screening
Tool (CalEnviroScreen).
G. V. Alexeeff1,  J. Faust1,  L. August1,  R. Cendak1,  W. Wieland1,  T. Kadir1,
L. Cushing2,  K. Randles1,  C. Milanes1 and L. Zeise1. 1OEHHA, Cal/EPA,
Oakland and Sacramento, CA; 2Energy and Resources Group, University of California
Berkeley, Berkeley, CA.
Many Californians are burdened by multiple sources of pollution and some people
are more vulnerable to the exposures. We developed a method, called
CalEnvironScreen, which uses existing environmental, health and socioeconomic
data to create a cumulative impacts score for different geographic area across
California. We conducted a preliminary statewide screen at the ZIP code level to
identify communities most burdened by multiple sources of pollution with popula-
tions that may be especially vulnerable to its effects. The method uses a concept of
total pollution burden based on measures of exposure, public health effects and en-
vironmental effects. This is modified by measures of sensitive populations and rele-
vant socio-economic factors. The screen considered data for ambient ozone and
PM2.5 concentrations, traffic density, toxic releases from facilities, pesticide use,
cleanup sites, impaired water bodies, leaking underground storage tanks, solid and
hazard waste facilities, low birth weight infants, asthma, prevalence of children and
elderly, educational attainment, income, poverty and race/ethnicity. The analysis
consisted of a relative comparison of approximately 1800 ZIP codes in California
using a relative risk model structure. The comparisons can viewed by individual in-
dicators, measures of burden or measures of vulnerability. The results are presented
graphically using Geographic Information System tools for each indicator and are
summarized by categories of exposures, environmental effects, public health effects,
sensitive individuals and socioeconomic factors. Sensitivity analyses are used to test
the model structure and the usefulness of each indicator selected.
879 Cellesis: A Novel System Biology Toxicology Tool.
C. F. Biscarrat,  P. Picamal and N. A. Compagnone. Department of Toxicology,
ICDD, Meyreuil, France. Sponsor: Y. Will.
Understanding and predicting adverse drug reactions (ADRs) are crucial goals in
toxicology, since unrecognized toxicity is the most frequent reason for drug with-
drawal. We have developed a novel technology based on dynamical image analysis
of intracellular organelles in live cells. Mitostream®, the dynamic measure of the
mitochondrial behavior, is a system biology experimental technology predictive of
the severity and incidence of ADRs. It is a powerful HCA to help identify drug-in-
duced toxicity, differentiate risk between compounds and evaluate the potential for
rare but severe adverse events. Mitostream® decodes the mitochondrial behavior,
quantifying motility, morphology, permeability and network organization with
multiple endpoints associated to qualitative descriptors to model their interrela-
tionship. We developed the Cellesis algorithm to identify classifiers and predictors
able to fuse the matrix of recorded multi-modal markers into a unique statistical
toxicity index. 
An original set of 27 molecules was studied to classify drugs on a toxicity scale. The
algorithm classified properly 83% of the drugs with 94% specificity and 75% sen-
sitivity. We extended the set to include more non-toxic compounds and com-
pounds with rare but severe toxicity as well as compounds that did not target the
mitochondria. The second training set included 47 compounds and yielded 85%
proper classification, a specificity of 91% and a sensitivity of 92%. Independent in-
dustrial validation was performed through the Consortium for Technology
Evaluation at the DSEC, testing 10 new compounds. Chosen by our industrial
partners these compounds classified properly with similar performances, showing a
good association between Cellesis-predicted ADRs and the lowest tolerable dose
seen in the clinic. A set of NSAID was further studied. Results showed 86 % proper
classification through Cellesis-predicted ADRs. Specificity was 92%, sensitivity was
reduced to 85%, some apparent false positive had a bellow threshold reported clin-
ical ADRs despite having been withdrawn post-marketing due to idiosyncratic he-
patotoxicity.
880 Development of a Systems Computational Model to
Investigate Early Biological Events in Hepatic Activation of
Constitutive Androstane Receptor (CAR) by Phenobarbital.
H. A. El-Masri1,  S. Hester1,  C. E. Wood1,  I. Shah2,  D. C. Wolf1 and
C. Corton1. 1NHEERL, US EPA, Research Triangle Park, NC; 2NCCT, US EPA,
Research Triangle Park, NC.
Activation of the nuclear receptor CAR (constitutive active/androstane receptor) is
implicated in the control several key biological events such as metabolic pathways.
Here, we combined data from literature with information obtained from in vitro
assays in the US EPA ToxCast database, and in vivo outcomes in the US EPA
ToxRef database to link CAR activation to a proposed adverse outcome pathway
(AOP) of hepatic tumors. Key in vivo pathological events for this proposed hepatic
tumor AOP are similar to those of other non-genotoxic receptor-mediated chemi-
cals (i.e., hypertrophy, cellular proliferation, preneoplastic foci, and neoplasia),
highlighting the importance of upstream biological mechanisms mediating the
early proliferative signals of CAR activation. Using phenobarbital (PB), a known
rodent tumor promoter and CAR activator, we developed a computational model
for the early initiating events of CAR activation leading to its nuclear translocation.
Based on literature evidence, the computational model describes the cascade of bi-
ological events leading to CAR nuclear translocation. These events are initiated by
PB activation of Adenylyl Cyclase (AC) leading to an increase in the rate of ATP
transformation to cyclic AMP. In turn, cyclic AMP increases intercellular calcium
levels which inhibit the activity of AC via a negative feedback loop mechanism.
However, the resulting transient increase in cyclic AMP levels activates protein
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phosphatase 2A (PP2A) which inhibits ERK. This inhibition is required for the nu-
clear translocation of CAR and the subsequent binding to a PB-enhancer module
(PBREM) indicated by CYP2B6 gene induction. Future work will bridge these
events with key targets mediating proliferative responses in the proposed AOP for
hepatic nuclear receptor mediated carcinogenesis. Our computational systems
model illustrates the impact of early events for dose-response modeling of receptor-
mediated AOPs. This abstract does not reflect EPA policy.
881 Mechanistic Modeling Illuminates the Most Important
Unknowns in Bile Acid Mediated DILI.
J. L. Woodhead1,  K. Yang2,  K. L. Brouwer2,  P. B. Watkins1,  S. Q. Siler1 and
B. A. Howell1. 1The Hamner-UNC Institute for Drug Safety Sciences, Research
Triangle Park, NC; 2UNC-Eshelman School of Pharmacy, Chapel Hill, NC.
BSEP inhibition and consequent bile acid (BA) buildup has been proposed to be an
important mechanism in drug-induced liver injury (DILI). There are many gaps in
the knowledge of BA homeostasis and its disruption by transporter inhibitors.
Modeling can help us understand which of these knowledge gaps should be filled
first in order to provide maximum understanding. We have constructed a model of
BA homeostasis and toxicity within DILIsymTM, a mechanistic model of DILI that
includes bile acid flux into and out of hepatocytes, the role of the farnesoid X re-
ceptor (FXR) in the regulation of BA transport and synthesis, and gallbladder BA
release and recirculation. We first analyzed our system’s behavior in the presence of
a simulated BSEP inhibitor similar to glibenclamide. We predict a 41% increase in
total hepatocyte content of amide conjugated chenodeoxycholic acid (CDCA).
However, the simulated BSEP inhibition resulted in no change in either unconju-
gated CDCA or the amide-conjugated lithocholic acid (LCA), and the hepatocyte
content of unconjugated LCA decreased by 15%. We next performed a sensitivity
analysis on our system’s response to BSEP inhibition in order to determine which
parameter has the greatest effect on hepatocyte content of BAs and hence BSEP in-
hibitor-induced hepatotoxicity. We found that the most important unknown in the
system is the intrahepatic BA concentration that triggers FXR-mediated regulation
of BA transporters, while other parameters such as the affinity constants for trans-
port of CDCA and LCA and ileal LCA transport efficiency were less important. We
conclude that the highest priorities for wet lab research to inform our model and
enhance our understanding of BSEP inhibitor mediated DILI are: 1) quantifying
the relationship between intrahepatocyte concentrations of individual bile acids
and FXR activation, and 2) quantifying the link between intracellular CDCA
amide conjugates and toxicity.
882 Quantitative Dose-Response in a Virtual Hepatic Lobule.
J. F. Wambaugh1,  J. Jack1,  J. Liu1,  H. A. El-Masri2,  J. Davis1,  W. Setzer1 and
I. Shah1. 1National Center for Computational Toxicology, US EPA, Research Triangle
Park, NC; 2National Health and Environmental Effects Research Laboratory, US
EPA, Research Triangle Park, NC.
The U.S. EPA Virtual Liver (vLiver) is a cellular systems model of hepatic tissue
that provides simulated in vivo context for liver-relevant ToxCast and other in vitro
data. To protect public health it is necessary to quantitatively estimate the risk of
long-term low dose exposure to environmental pollutants. The vLiver model cur-
rently allows testing of early key events in adverse outcome pathways (AOP) by in-
tegrating multiple types of in vitro data in order to predict in vivo (animal) data.
The model was used to simulate hepatocyte proliferation in 28 day repeat dose
studies as an early event in non-genotoxic liver cancer AOPs. In vitro hepatocyte as-
says are often limited in assessing proliferation, in part due to the cells being re-
moved from a tissue context – this context is created via simulation. A hepatic lob-
ule microdosimetry model, developed in conjunction with a high throughput
physiologically-based pharmacokinetic model, links whole-body exposure to cell-
scale concentrations. For seven chemicals (fenarimol, imazalil, azoxystrobin, bife-
nazate, fenamidone, fluoxastrobin, and paclobutrazol) free chemical concentrations
in the liver were predicted as a function of dose and time. A ToxCast assay for up-
regulation of activator protein 1 (AP-1) in HepG2 cells – a transcription factor for
cell-cycle initiation and progression – was used a surrogate for hepatocyte prolifera-
tion. Model simulations predicted the administered dose (mg/kg/day) needed for
excess proliferation in vivo. Five of the seven chemicals displayed non-proliferative
liver lesions in rats (ToxRefDB) at similar doses, while the two without lesions were
among the three chemicals predicted to require the highest dose. This demonstrates
the potential for in silico models to predict the in vivo administered doses that,
based on in vitro data, may lead to in vivo adverse effects.This abstract does not nec-
essarily reflect EPA policy.
883 Quantitative Extrapolation of In Vitro Data to Risk
Management Decisions: Using Hepatic Ah Receptor and Its
Agonists As an Example.
X. Chang1,  M. DeVito1 and M. Easterling2. 1DNTP, NIEHS, Research Triangle
Park, NC; 2SRA International, Research Triangle Park, NC.
A critical question in human risk assessment is how best to incorporate in vitro
data. In a quantitative in vitro to in vivo extrapolation, one assumption is that
media concentration equals blood concentration. Here, we evaluate this assump-
tion by applying physiologically based pharmacokinetic (PBPK) models to predict
cellular responses in primary rat hepatocytes exposed to an aryl hydrocarbon recep-
tor (AhR) agonist. PBPK models for AhR agonists (e.g., TCDD, PeCDF, PCB126)
were developed based on NTP two-year rat carcinogenicity bioassay data. The
model predicts tissue concentrations and CYP1A1 induction well and demon-
strates that ligand binding affinity is an important parameter for AhR-mediated en-
zyme induction and distribution of these chemicals. Using this model, we predicted
the dose response for Cyp1a1 induction in whole rat liver at 48 h after an oral dose
of TCDD. The predicted results were compared to literature data on rat primary
hepatocyte treated with TCDD for 48 hours. The EC50 obtained for Cyp1a1 in-
duction in vitro is about 100 fold less than that predicted in vivo (i.e., the primary
cell culture system is about 100 times more sensitive). To identify which factors
might contribute to this difference, we built a primary hepatocyte culture model,
based on rat primary hepatocyte data from the literature and incorporated the same
parameters used in the in vivo PBPK model of AhR agonists. Based on differences
in parameter values between the two models, we identified critical factors deter-
mining the difference in sensitivity between in vivo and in vitro (e.g., TCDD avail-
ability). The hepatocyte culture model built for TCDD can predict the toxicities or
downstream events for other AhR agonist by changing the parameter associated to
AhR binding affinity only. This evaluation provides a model example of a quantita-
tive in vitro to in vivo extrapolation for nuclear receptors and informs on how to
better use in vitro data for risk assessment. This abstract does not necessarily reflect
the policies or views of NIH.
884 Predicting Plasma Profiles following Oral Dosing for Drug
Liver Transporter Substrates Using Physiologically-Based
Pharmacokinetic Modeling.
H. A. Barton1,  Y. Lai1,  J. R. Gosset2 and H. M. Jones2. 1Pharmacokinetics,
Pharmacodynamics, and Metabolism, Pfizer, Inc., Groton, CT; 2PDM, Pfizer, Inc.,
Cambridge, MA.
A novel prediction approach for OATP substrates was developed using in vitro
sandwich cultured hepatocyte (SCHH) data as input into a physiologically based
pharmacokinetic (PBPK) model and was validated for intravenous (iv) dosing
(Jones et al., 2012). The aim of our work was to extend this to the prediction of oral
profiles. Data for plasma concentrations following oral doses were obtained from
literature. Simple descriptors of oral absorption (fa, ka) were predicted using a
physiologically based gastrointestinal (GI) tract model, which were then used in the
published transporter PBPK model with a single compartment for oral absorption.
The seven literature compounds were bosentan, cerivastatin, fluvastatin, pravas-
tatin, repaglinide, rosuvastatin, and valsartan. In vitro passive permeability and sol-
ubility under fed and fasted conditions were measured as inputs to the GI model.
We tested whether the oral absorption parameters were reasonable by combining
them with the transporter parameters obtained from fitting the iv plasma data.
Characterizing plasma pharmacokinetics using area under the curve to infinity
(AUC(0-inf )), maximum concentrations (Cmax), and time to maximum concen-
tration (Tmax), the fold error for the seven compounds was 1.6, 2.3, and 1.9 re-
spectively, indicating the oral absorption parameters were reasonable. Forward pre-
dictions for the seven compounds based on SCHH data and the oral absorption
parameters provided a test of both aspects of predicting oral plasma time course.
The average fold errors for the seven compounds increased somewhat to 2.5, 3.3,
and 2.4, respectively. This method was then applied to oral plasma data for four in-
house compounds resulting in reasonable predictions for three of the four. An ini-
tial prediction method has been developed using in vitro and in silico inputs to es-
timate plasma profiles and pharmacokinetic parameters for iv and oral dosing of
anionic drugs that are substrates for liver transporters.
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885 A Mechanistic Approach to Understand Idiosyncratic
Toxicity of Perhexiline and Sulindac.
S. Das,  R. Kumar,  N. Rajeswara,  S. Raghavan,  Y. Chandrasekaran,
N. Mandyam,  S. Louha,  A. Khanna,  D. Srivastava,  K. Ra and K. Subramanian.
Strand Life Sciences, Bangalore, India.
Idiosyncratic DILI is one of the most common causes of safety-related post-mar-
keting drug withdrawals. We have developed a dynamic systems based integrative
approach that aids in its understanding by combining a mathematical model along
with a panel of in vitro enzyme and transporter assays.
We tested perhexiline and sulindac in this assay system and fed the assay results into
a mathematical model of liver biology. Our simulations identified the key mecha-
nism behind the steatohepatitis caused by perhexiline. They predict perhexiline in-
duced alterations in mitochondrial function, i.e. inhibition of oxidative phosphory-
lation, generation of oxidative stress along with inhibition of mitochondrial
beta-oxidation leads to steatosis. An interesting insight gained in this process was
the fact that whole cell measurements such as ATP or GSH alone can provide an er-
roneous understanding of the impact of a compound in vivo. On the other hand
measuring various enzymatic functions enabled us to quantify the impact of ROS
in vivo.
In the case of Sulindac, intracellular accumulation of GSH in HepG2 cell line indi-
cated impairment of transport system. Applying this impairment in the model, our
simulations predict bile and bilirubin accumulation indicating the potential for
idiosyncratic cholestasis.
Thus our system enables us to understand mechanistic insights into the effect of
leads and make predictions on their effects in vivo without necessitating the use of
whole animal studies.
886 An Integrated Structure-Based Systems Approach to Predict
Hepatotoxicity.
A. Das,  N. Mandyam,  N. Tiwari and K. Subramanian. Strand Life Sciences,
Bangalore, India.
We have developed a systems biology model for hepatotoxicity prediction. The
input for the model is a set of in vitro assays that capture the effects of a chemical
compound on selected proteins. The model takes these assay results as input, simu-
lates their likely effects on selected pathways in a liver cell and outputs the toxicity
effects in vivo. Though this approach has good predictive value and provides mech-
anistic insights into the toxicity response, the time consuming and expensive assays
are a bottleneck for using the model in a high-throughput manner. 
Using structure based approaches, we have virtualised the assays to use this model
to rapidly evaluate hepatotoxicity of molecules. The binding affinity of a molecule
to each of the proteins is estimated using structure prediction, flexible and induced
docking and pharmacophore approaches and classified as low, intermediate or high.
This forms the input to the systems model which then estimates the integrated im-
pact of these perturbations on various pathways in the liver. We expected that the
model output, though not as precise as with in vitro inputs, can flag likely hepato-
toxicity of a molecule.
As an initial proof of concept, we tested this approach in a set molecules, pioglita-
zone, tolcapone, rofecoxib, quniacrine, propanthaline bromide, benoxinate,
bumetanide, AZ177 and acetaminophen. We found that this method is able to flag
the key toxic mechanisms of each of these molecules and is able to predict synergis-
tic toxic effects. We believe that this approach can be used as screening tool to rap-
idly and accurately assess mechanistic toxic effects and has utility during lead dis-
covery and optimization.
887 Application of an In Silico Approach to Predict Intrinsic In
Vitro Cytotoxicity for Compounds in Primary Human
Hepatocytes during Preclinical Development.
R. Pai,  B. Wei,  P. Chang,  J. Crawford,  W. Young,  D. Ortwine,  D. Misner and
D. Dambach. Genentech Inc., S. San Francisco, CA.
Drug-induced liver injury is a major cause of compound attrition in preclinical and
clinical development and, often, intrinsic hepatotoxicity can be related to chemical
structure. Screening in primary human hepatocytes has been routinely used to as-
sess toxicity in the preclinical setting to allow for assessment of metabolic contribu-
tion. However, the knowledge gained from this screening has not been fully utilized
to drive medicinal chemistry design before compound synthesis. Herein, we present
work in progress in the development of a computational model that is used to pre-
dict the outcome of hepatocyte screening for a set of preclinical compounds with
significant accuracy. Cytotoxicity was determined by treating cryoplateable human
hepatocytes with individual compounds and evaluating cellular ATP levels. In vitro
cytotoxicity was classified based on IC50 values into three buckets: high (<50 μM),
medium (50-100 μM) and low toxicity (>100 μM) groups. Using a machine learn-
ing approach, a large set of structural and non-structural descriptors were evaluated
for their usefulness to classify cytotoxicity on a training set of 72 compounds. Three
calculated physicochemical properties emerged as the most predictive descriptors
(most-basic-pKa, plasma protein binding % and logP), and were used to construct
a decision tree model. Subsequently, predictions were made for 102 compounds
prospectively. The positive predictive values were 77% & 65%, and negative pre-
dictive values were 72% & 85% for high (H) and low (L) toxicity groups, respec-
tively. Interestingly, addition of structural descriptors did not improve the accuracy
of prediction, suggesting that the intrinsic toxicity of those compounds were not
specific to their structures. We show that this model proved useful in reducing com-
pound attrition for an ongoing project. Furthermore, the physicochemical property
space that this work has implicated as being associated with toxicity may also pro-
vide clues toward understanding the underlying mechanism(s).
888 In Vitro In Vivo Correlation: Apparent or Ambiguous?
Analysis of Pfizer Compounds in US EPA’s ToxCast
Chemicals-Assay Space.
F. Shah and N. Greene. Compound Safety Prediction, Worldwide Medicinal
Chemistry, Pfizer Worldwide Research and Development, Groton, CT.
In 2009, Pfizer collaborated with EPA in their ToxCast initiative to identify predic-
tive bioactivity signatures for toxic compounds using ‘dead’ pharmaceuticals. A
total of 52 Pfizer compounds with preclinical data were profiled in multiple assay
platforms measuring bioactivity against diverse assay end-points. The first part of
this work was focused on the analysis of Pfizer compounds in ToxCast chemicals
and pharmacological space. These include a) comparison of bioactivity profile of
Pfizer compounds with other pharma and EPA compounds; b) analysis of com-
pounds sharing similar chemical and pharmacological space as of Pfizer com-
pounds; and c) ability of assay platforms to reproduce the primary mode of action
of Pfizer compounds. Analysis revealed that compound from EPA set seemed to
have different pharmacological and chemistry space than pharma compounds. It
also highlighted assay platforms and sensitive endpoints that are more relevant to
understand the off-target activities of compounds. The second part involves corre-
lation of in vitro ToxCast assay signals with in vivo findings related to liver injury,
observed either in preclinical or clinical studies. The analysis pinpointed diverse cy-
totoxicity endpoints within ToxCast as markers of compound potential to cause
preclinical or clinical liver injury.
889 Improved In Silico Methods to Group Liver Toxicants
Related to Adverse Outcome Pathways.
M. T. Cronin,  S. J. Enoch,  M. Hewitt,  J. C. Madden,  M. Nelms,  K. Przybylak
and A. N. Richarz. School of Pharmacy and Chemistry, Liverpool John Moores
University, Liverpool, United Kingdom. Sponsor: C. Yang.
Prediction of repeat dose toxicity by in silico methods remains an elusive goal.
Current quantitative structure-activity relationship (QSAR) approaches have ac-
knowledged limitations. A more pragmatic approach is to identify relevant molecu-
lar initiating events associated with an adverse effect – integrated into the Adverse
Outcome Pathway (AOP) concept - and attempt to group chemicals accordingly.
Such an approach will have a greater probability of success if targeted at organ level
toxicity. The purpose of this study was to develop novel structural alerts to enable to
the grouping of potential liver toxicants. Specifically, the utility of current ap-
proaches for grouping according to protein reactivity (relating to reactive hepato-
toxicity) was investigated along with novel methods to group chemicals and extract
usable information from the grouping, placing in the context of relevant AOPs.
The objective, therefore, was not to necessarily provide a better predictive model for
liver toxicity, but to improve structural alerts to group compounds to perform read-
across for liver toxicity. Data for over 900 compounds classified as either being toxic
or non-toxic to the liver were assessed in this study. Attempts to group compounds
on the basis of protein reactivity (the OECD Profiler in the OECD QSAR
Toolbox) had poor predictivity, only identifying approximately 34% of liver toxi-
cants, whilst nearly 25% of non-toxicants were found to contain a reactive struc-
tural alert. Therefore, the liver toxicants were grouped according to structural simi-
larity using the ToxMatch software. Over 80 categories were found by this
automated method from which 16 robust categories were manually curated, many
of which were associated to mitochondrial toxicity AOPs. The suite of reactive and
non-reactive MIEs, defined by structural alerts and chemotypes, provides a basis for
grouping potential liver toxicants. Supported by the EU FP7 COSMOS and eTox
Projects.
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890 Construction of a Human Hepatotoxicity Database for
QSAR Modeling.
N. L. Kruhlak and X. Zhu. CDER/OPS/OTR/DDSR, US FDA, Silver Spring, MD.
Sponsor: R. Benz.
Drug-induced liver injury (DILI) represents the second most common reason for
pre-market attrition of drug candidates and post-market withdrawal of approved
products, prompting the need for better tools to predict these serious effects.
Quantitative structure-activity relationship (QSAR) modeling uses computational
algorithms in conjunction with large chemical data sets to identify correlations be-
tween molecular structural features and biological activity, and lends itself well to
the task of improving the prediction of drug safety by exploiting FDA’s vast institu-
tional knowledge of DILI and other adverse event (AE) data. This report describes
the development of a new method for creating a DILI QSAR training set based on
FDA’s Adverse Event Reporting System data. The method utilizes the Multi-item
Gamma Poisson Shrinker (MGPS) algorithm, the gold standard used by FDA
CDER’s Office of Surveillance and Epidemiology for AE signal identification, to
generate Empirical Bayesian Geometric Mean (EGBM) scores for all drugs in the
database binned by MedDRA preferred term. A set of 38 preferred terms (PTs) de-
scribing serious hepatic events, such as hepatic failure, hepatocellular injury, and
hepatic cirrhosis, was selected based on related physiology and their adverse event
counts were pooled to provide a more robust dataset for scoring purposes. An inde-
pendently obtained verification set of 107 known hepatotoxicants with evidence
ranging from clinical manifestations (n=93) to market withdrawals (n=14), was
used as a calibration set to determine whether the standard EGBM cutoff of 2.0 was
appropriate for partitioning the training set. While 92% of the withdrawn drugs
were correctly classified, only 50% of the positives with clinical manifestations were
correctly classified, emphasizing the need for additional parameters and/or PTs to
supplement the AE data used in the training set. This method created a set of over
2000 unique molecular entities that were structurally suitable for QSAR modeling.
891 Virtual Liver: Mapping Pathways to Liver Injury by Linking
In Vitro Assays to In Vivo Outcomes.
I. Shah1,  J. Liu1,  C. Corton2,  S. Hester2,  K. Houck1,  T. B. Knudsen1,
H. A. El-Masri2,  J. Simmons2,  J. F. Wambaugh1 and C. Wood2. 1NCCT, US
EPA, Durham, NC; 2NHEERL, US EPA, Durham, NC.
The EPA ToxCast project uses high-throughput screening (HTS) to evaluate in
vitro bioactivity of chemicals. Here we are attempting to bridge HTS data with
histopathological effects in ToxRefDB using a data-driven computational approach.
Starting with 2,200 guideline studies for 763 chemicals stored in ToxRefDB, we de-
fined 8 broad categories of hepatic histological effects consisting of hypertrophy, cy-
totoxicity, inflammation, regeneration, steatosis, fibrosis, preneoplasia, and neopla-
sia. A subset of 560/763 chemicals were screened in 500 ToxCast assays. Univariate
statistical analysis found 91 assays in which chemicals had a significantly (p<0.05)
greater potency for hepatic effects. We identify mechanistic relationships between
the molecular and cellular targets of these assays from literature and use an infor-
mation-theoretic criterion to calculate the most plausible sequence of key events for
each outcome. The results are summarized as a dependency network including mo-
lecular initiating events (e.g. AhR, PXR, and PPAR), signal transduction
(PI3K/AKT, p53, NfkB, JNK), cellular alterations (oxidative stress, mitochondrial
dysfunction, cytoskeletal changes, cell cycle arrest and apoptosis), and histological
effects. The analysis also suggests markers of hepatic lesion severity: chemicals that
cause hypertrophy without injury have a 3-fold potency (p<0.05) for stress kinase
activation; for hypertrophy and injury a 2-fold greater potency for G2/M arrest and
p53 activation; and for steatosis a 2-fold greater potency for mitochondrial dys-
function. This work should inform current efforts to translate HTS data from a
molecular scale to clinically-relevant health effects.
This work was reviewed by EPA and approved for publication but does not neces-
sarily reflect official agency policy.
892 A Multiscale Dose-Response Model of AhR Toxicity Pathway
Activation in the Human Liver.
S. Bhattacharya,  P. D. McMullen and M. E. Andersen. Institute for Chemical
Safety Sciences, The Hamner Institutes for Health Sciences, Research Triangle Park,
NC.
We have developed a spatial, multicellular agent-based computational model of the
human liver lobule to study the contribution to hepatotoxic injury from multiple
levels of biological organization. This multi-scale “virtual tissue” model combines
molecular circuits in individual hepatocytes with cell-cell interactions and blood-
mediated transport of toxicants through hepatic sinusoids, and dosimetry estimated
by whole-body PBPK models, to enable quantitative, mechanistic prediction of
dose-response. We use the activation of the aryl hydrocarbon receptor (AhR) toxic-
ity pathway in hepatocytes exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin
(TCDD) and other dioxin-like compounds (DLCs) as a case study for data integra-
tion and multi-scale model development for mechanistic dose-response prediction.
By explicitly accounting for basal gradients in AhR expression across the lobule and
stochastic uptake of TCDD molecules by individual hepatocytes, we were able to
reproduce experimentally observed zonal heterogeneity in TCDD accumulation
and cytochrome P450 1A1 expression. A detailed implementation of the AhR sig-
naling and transcriptional cascade in each hepatocyte in this multicellular model
enabled us to characterize differential dose response for various AhR-mediated end-
points at the tissue level, including cytotoxicity and cell proliferation.
893 Evaluation of Perchlorate Intake on Maternal and Fetal
Serum T4 Levels Using a BBDR Model.
A. Lumen1, 3,  D. R. Mattie2 and J. W. Fisher3. 1HJF, Rockville, MD; 2711
HPW/RHDJ, Wright-Patterson AFB, OH; 3US FDA/NCTR, Jefferson, AR.
Perchlorate (ClO4-) is both a naturally occurring and man-made chemical widely
distributed in the environment with low levels detected in food and drinking water.
Disturbances in the maternal hypothalamic-pituitary-thyroid (HPT) axis leading
to hypothyroxinemia and hypothyroidism have been shown to cause negative ef-
fects on the neurodevelopment of the fetus. Downstream perturbations of maternal
and fetal HPT axes following ClO4- competitive inhibition of sodium iodide sym-
porter-mediated thyroidal iodide (I-) uptake have not been evaluated quantita-
tively. In order to quantitate effects of dietary I- intake, ClO4- exposure and their
interactions on maternal and fetal HPT axis, a biologically based dose response
(BBDR) model for HPT axes in the pregnant woman and fetus was developed. The
BBDR model includes sub-models for I-, ClO4-, thyroxine (T4) and triiodothyro-
nine (T3). The model was successfully calibrated for euthyroid, marginal iodide de-
ficiency and ClO4- exposure. Serum thyroid hormone changes were predicted for
dietary I- intake ranging from 75 to 250 μg/day and for ClO4- exposures of 0.01 to
1000 μg/kg/day. Model simulations suggest that ClO4- at environmentally relevant
ranges of exposure (~0.1 μg/kg/day) does not result in significant decreases in ma-
ternal and fetal free serum T4 concentrations for maternal I- intake of 75 to 250
μg/day. For a daily I- intake of 200 μg/day, the daily dose of ClO4- required to re-
duce serum free T4 (fT4) levels from representative euthyroid region to a hypothy-
roxinemic state was estimated to be about 50-fold greater (32 μg/kg/day) than the
current reference dose (RfD, 0.7 μg/kg/day). As I- intakes were lowered (150, 100
and 75 μg/day), ClO4- doses required for similar reductions in fT4 levels were re-
duced to 28, 16, and 4 μg/kg/day, respectively. This BBDR-HPT axis model for
pregnancy provides a novel tool for public health assessments for endocrine active
chemicals found in food and the environment. Funded by the Air Force Center for
Engineering & the Environment through 711 HPW/RHDJ, WPAFB, OH.
894 Cross-Species and Life Stage PBPK Modeling of
Dibenzo[def, p]Chrysene.
S. R. Crowell1,  S. Hanson-Drury1,  J. Soelberg1,  N. Sadler1,  A. Wright1,
A. Sharma2,  E. P. Madeen3,  D. E. Williams3 and R. A. Corley1. 1Pacific
Northwest National Laboratory, Richland, WA; 2Penn State University, Hershey, PA;
3Oregon State University, Corvallis, OR.
Polycyclic aromatic hydrocarbons (PAHs) are ubiquitous, often carcinogenic envi-
ronmental contaminants generated as by-products of combustion processes. PAHs
are found at almost half of Superfund sites, and are drivers for remediation in a sig-
nificant percentage of those sites. Dibenzo[def,p]chrysene (DBC) is a high molecu-
lar weight and highly potent transplacental carcinogenic PAH. We developed the
first species- and life stage-specific physiologically based pharmacokinetic (PBPK)
models for high molecular weight PAHs that can be used to predict target tissue
doses of PAH metabolites important to their carcinogenic mode of action. In ro-
dents, we measured metabolic enzyme activity, rates of metabolism, and pharmaco-
kinetics during vulnerable life stages such as pregnancy and fetal development.
Pregnant animals had elevated tissue concentrations of DBC and its metabolites (2
– 4 fold increase in CMAX), and suppressed rates of clearance compared to naïve
mice. Using activity-based protein profiling (ABPP), a unique proteomic approach
for characterizing functional proteins in complex biological systems, to measure
and compare enzyme activity, we found that multiple enzymes important for PAH
metabolism have significantly altered activity during pregnancy and development
in rodents and humans. Incorporating changes in anatomy and physiology during
pregnancy as well as measured reductions in P450 enzyme activity accounted for
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observed pharmacokinetic differences in mice. We have extrapolated our PBPK
models to describe human dosimetry on the basis of human anatomy and physiol-
ogy, and chemical specific human in vitro metabolic rates. In order to evaluate the
extrapolated human model, a controlled human pharmacokinetic study of DBC at
environmentally relevant exposure levels (30 ng bolus exposure) has been per-
formed by our collaborators. Initial simulations of DBC concentrations in blood
are remarkably similar to those observed in preliminary data from human volun-
teers.
895 Evaluating Early-Life Sensitivity to Pyrethroids by
Physiologically-Based Pharmacokinetic (PBPK) Modeling
Using In Vitro to In Vivo Extrapolation.
H. Wu1,  M. Yoon1,  S. Anand2,  B. G. Lake3,  T. Osimitz4,  N. Assaf5,
A. Efremenko1 and H. J. Clewell1. 1The Hamner Institute for Health Sciences,
Research Triangle Park, NC; 2DuPont Haskell, Newark, DE; 3LFR Molecular
Sciences, Leatherhead, United Kingdom; 4Science Strategies, LLC, Charlottesville, VA;
5Valent BioSciences, Libertyville, IL.
The increased sensitivity of post-natal day (PND) 21 (weanling) rats to acute high-
dose neurotoxicity of deltamethrin (DLM) poses the question of whether children
will be more sensitive than adults both of whom are exposed to a much lower dose
than rats. Age-related pharmacokinetic (PK) differences are hypothesized to be re-
sponsible for the observed differences in rats. We developed a PBPK model for
human children based on rat PK and rat and human in vitro data. Our model in-
corporated species and age-dependent differences in metabolism of DLM as well as
physiological changes during growth. The predicted age-dependent changes in
brain Cmax correlated well with the maturation of metabolic capacity suggesting
the lower metabolic clearance as a mechanism for the increased sensitivity in neona-
tal rats. The predicted Cmax in brain of PND 21 pups after a single oral dose of 4
mg/kg was 50% higher compared to PND 70 rats. The human model was devel-
oped similarly by incorporating maturation physiology and developmental changes
in DLM metabolizing enzymes. Unlike the rat, the predicted brain Cmax of DLM
was comparable between children and adults. After a single oral dose of DLM (0.1
mg/kg), the predicted Cmax was 1.4, 1.7, 2.4, and 2.0 pg/g, respectively, for chil-
dren ages 1, 5, and 10 years old, and adults. The observed species differences in age-
dependent PK seems to be largely attributable to the species differences in enzyme
ontogeny and resulting metabolic clearance rates for DLM as well as differences in
doses. In conjunction with age-specific exposure data, the current model will enable
us to evaluate early life sensitivity in humans under environmentally relevant expo-
sure conditions for this chemical and can be readily applicable to other pyrethroids
with proper parameterization (supported by CAPHRA).
896 Evaluating Age-Related Sensitivity to Carbaryl-Induced
Behavioral Changes by PBPK/PD Modeling.
D. Billings1,  M. Yoon1,  V. C. Moser2,  R. C. MacPhail2 and H. J. Clewell1. 1The
Hamner Institutes for Health Sciences, Research Triangle Park, NC;
2TAD/NHEERL/ORD, US EPA, Research Triangle Park, NC.
Due to its reversible inhibition of cholinesterases (ChEs), acute neurotoxicity is the
primary effect of concern for carbaryl. Sensitivity to acute behavioral neurotoxicity
of carbaryl was observed to be greater in aged rats, which was not fully attributable
to differences in ChE inhibition. We used a PBPK/PD model to evaluate appropri-
ate dose metrics to describe the observed age-related sensitivity to carbaryl in Brown
Norway rats, using the change in horizontal motor activity as a marker of biological
effect. The current model extends our previous PBPK/PD model in adult Sprague-
Dawley rats that describes carbaryl disposition and inhibition of ChE in brain and
blood. Age-appropriate physiological parameters were incorporated in the model in
conjunction with age-specific metabolism parameters determined in primary hepa-
tocytes isolated from young adult and aged rats (4, 12 and 24 month old). The
model-simulated values compared well with the data both for peak and time-de-
pendent changes in carbaryl concentration in the brain, liver and plasma as well as
inhibition of ChE in brain and erythrocytes after a single oral exposure of carbaryl
(3, 7.5, 15, or 22.5 mg/kg). While changes in motor activity were correlated with
the degree of ChE inhibition at the time of peak effect (40 min), the model did not
reproduce the recovery of activity in the older rats up to 240 min. The age-related
difference was not explained by kinetics of reaction with ChE by carbaryl, but sug-
gested differences in recovery dynamics in aged rats. The current study demon-
strated the use of a PBPK/PD model to describe age-dependent acute effects and re-
covery from carbaryl, and provided a novel explanation for prolonged recovery in
old animals. This is an abstract of a proposed presentation and does not reflect EPA
policy (supported by EPA STAR grant R833452 and ACC-LRI).
897 Interpreting Biomonitoring Data for Di-n-Butyl and Di-(2-
Ethylhexyl) Phthalate Metabolites in Urine Using a
Physiologically-Based Pharmacokinetic Model and Reverse
Dosimetry: Estimation of Cumulative In Utero Exposure.
J. Campbell,  R. A. Clewell,  M. E. Andersen and H. J. Clewell. The Hamner
Institutes for Health Sciences, Research Triangle Park, NC.
At high doses, several phthalate esters, including d-n-butyl and di-2-ethylhexyl ph-
thalate (DBP and DEHP respectively), disrupt normal male reproductive develop-
ment in rats. Human biomonitoring data have demonstrated phthalate exposure in
humans of all ages based on serum, urine, cord blood and breast milk measure-
ments. We used PBPK modeling and reverse dosimetry to infer likely environmen-
tal exposures from human biomonitoring data on phthalates in urine. Human
PBPK models for DBP and DEHP and their primary metabolites – mono-n-butyl
and mono-2ethylhexyl phthalate (MBP and MEHP) – during pregnancy were de-
veloped from published rodent PBPK models and human data. To estimate daily
intake of DBP and DEHP consistent with population measures of urinary metabo-
lite levels, Monte Carlo analyses were performed to generate an inverted distribu-
tion between urine concentration and steady state exposure. Based on the
NHANES III biomonitoring data, the predicted distribution of daily intake for
DBP in the U.S. had a median of 0.65 μg/kg/day with a 95th percentile of 5.0
μg/kg/day. For DEHP the estimated daily intakes were higher, with a median of
1.86 μg/kg/day and a 95th percentile of 20.4 μg/kg/day. Applying forward dosime-
try with the pregnancy PBPK model, the 95th percentile exposure concentration
resulted in an average fetal plasma concentration of 6.77 μg/L for MBP and 1.4
μg/L for MEHP. These values can be compared to an average concentration of
1680 μg/L for MBP and 71.2 μg/L for MEHP in rat fetal plasma, simulated with
the rat PBPK models at the NOAELs of 30 and 5 mg/kg, respectively, for develop-
mental effects.
898 Species Extrapolation of Life-Stage PBPK Models to
Investigate Ethanol Developmental Toxicity Using In Vitro
to In Vivo Methods.
E. D. McLanahan1,  S. A. Martin2,  S. Hunter2 and H. A. El-Masri2.
1ORD/NCEA, US EPA, Research Triangle Park, NC; 2ORD/NHEERL, US EPA,
Research Triangle Park, NC.
Ethanol (EtOH), which induces fetal alcohol spectrum disorder-related effects, was
selected to investigate the use of PBPK models in a quantitative in vitro to in vivo
extrapolation (IVIVE) paradigm. Mouse whole embryo culture data on EtOH
time-concentration dependent induction of neural tube defects (NTDs) was used
to assess embryotoxicity. Initially, published rat life-stage PBPK models were ex-
trapolated to adult non-pregnant and pregnant mice and humans using species spe-
cific (SS) growth equations and parameters. Each model was able to predict blood
EtOH concentrations (BEC) following multiple routes of exposure. Once cali-
brated with published data, the mouse and human models produced adequate sim-
ulations (within factor of 2) of time-course BEC data. An IVIVE was performed by
estimating SS BECs in rat and mouse dams using in silico simulations for induction
of NTDs in vitro. Then, a human model IVIVE was performed using rodent in
vitro and pregnant human toxicity and epidemiological reports of EtOH exposure
during windows of gestational susceptibility. As reported in the human literature,
150 mg/dl BEC is associated with developmental neurotoxicity. In human embry-
onic stem cells (hESCs), 145 mg/dl EtOH is associated with apoptosis and altered
neuroprogenitor differentiation and proliferation. The similarity in effective con-
centration illustrates the utility of using BEC in pregnant women as a predictor of
adverse developmental effects. However, since hESCs are more sensitive to EtOH-
induced effects than mouse conceptuses in vitro, a human IVIVE based on mouse
in vitro data exceeds the reported 150 mg/dl BEC. The human model predicted ex-
posure scenarios within a factor of 2 of the observed toxic BECs. This research
demonstrates both the capability of models to extrapolate between in vitro animal
and in vivo human studies and the first pregnancy models for EtOH in mice and
humans. The views expressed in this abstract are those of the authors and do not
necessarily represent the views or policies of the U.S. EPA.
899 A Simple In Vitro Approach for the Rapid Detection of
Neurotoxicity.
Q. Gu,  S. Lantz,  M. G. Paule and L. Schmued. Division of Neurotoxicology, US
FDA National Center for Toxicological Research, Jefferson, AR.
Neurodegeneration is the underlying cause of a vast majority of neurological disor-
ders and often a result of brain trauma, stroke, or neurotoxic insult. A widely used
and reliable method for labeling degenerative neurons in ex vivo brain tissue in-
volves the use of the Fluoro-Jade stains. Recently we described a novel method for
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the labeling of degenerating neurons in unfixed brain tissue samples using Fluoro-
Jade-C (FJC) (Gu et al. Journal of Neuroscience Methods 2012, 28:40-43). This
method is simple, fast, and applicable to unfixed brain tissue sections and works at
neutral pH. Based on these features, we extended our experimentation by examin-
ing the utility of FJC in vitro using cell cultures. Using neural stem cells, for exam-
ple, we report here specific FJC labeling following treatment with neurotoxicants
such as cadmium. The FJC labeling appears to be specific to neural cells, since
other cell types such as cultured kidney epithelial cells did not show similar labeling
even when cells were dying or dead. Further characterization and validation of this
in vitro approach is underway. By employing FJC labeling in multi-well culture
plates and using high-content time-lapsed recordings and additional techniques, a
primary goal will be to achieve high-throughput monitoring and analysis of mor-
phological, biochemical and molecular changes associated with the entire neurode-
generative process in cell culture models after neurotoxicant exposures. This in vitro
approach has the potential to not only reduce animal use and suffering in toxicity
tests but also to facilitate high-throughput screens for potentially neurotoxic com-
pounds.
Supported by NCTR Protocols E07460 and E07477.
900 Evaluation of the Neuroactivity of ToxCast Compounds
Using Multiwell Microelectrode Array Recordings of Primary
Cortical Neurons.
P. Valdivia1, 2,  M. Martin3,  W. LaFew4,  J. Ross2,  K. Houck3 and T. J. Shafer4.
1Duke University, Durham, NC; 2Axion Biosystems, Atlanta, GA; 3NCCT, ORD, US
EPA, Research Triangle Park, NC; 4ISTD, ORD, US EPA, Research Triangle Park,
NC.
Assessment of spontaneous activity in neuronal cultures on microelectrode arrays
(MEA) is a sensitive method to detect responses to drugs, chemicals, and particles.
While single-well MEA systems lack the efficiency to screen large numbers of com-
pounds, recently developed multi-well MEA systems have increased throughput of
MEAs. The present experiments examined the ability of a subset of EPA’s ToxCast
library of compounds to alter neuronal activity using 48 well MEA plates. Sixty-
eight compounds were selected from the ToxCast Phase I and II chemical libraries
based on known neuroactivity or data from 14 ToxCast in vitro assays indicating
that they interacted with ion channels. Two compounds expected not to alter neu-
ronal function, acetaminophen and saccharin, were included as negative controls.
One hr of baseline activity was recorded prior to exposing the cortical networks to
40 uM of each compound for 1 hr and the weighted mean firing rate (wMFR) was
determined in the absence and presence of each chemical. All experiments were
conducted on day in vitro 14 or 15. Based on DMSO-treated wells, chemicals that
increased or decreased activity by >23.6% were considered hits. Of the 68 com-
pounds, 47 altered wMFR by more than the threshold. Saccharin and acetamino-
phen did not change wMFR beyond the threshold. Four of six pyrethroids, and 3/3
conazoles were detected as hits. Interestingly only 1/7 nicotinic agonists (nico-
tine&neonicotinoids) were hits, but were close to the threshold. These data demon-
strate that multiwell MEAs can be used efficiently to screen chemicals for potential
neurotoxicity and that the results are concordant with predictions from 14 ToxCast
ion channel assays. Further, changes in wMFR may not be a sensitive measure to
detect nicotinic effects in this culture model (This abstract was supported by
CRADA #644-11 with Axion Biosystems. This abstract does not reflect Agency
Policy).
901 Development of an In Vitro Multiwell Microelectrode Array
(MEA) Neurotoxicity Assay with Human IPS-Derived
Neurons.
J. Bradley1,  J. Ross2,  M. Brock2,  H. Luithardt1,  J. Gilbert1 and C. Strock1.
1Cyprotex, Watertown, MA; 2Axion Biosystems, Atlanta, GA.
Seizurogenic neurotoxicity produces significant drug attrition during drug discov-
ery.  Current available in vitro assays fail to predict this toxicity due to the failure of
general cytotoxicity assays to predict sublethal target specific electrophysiological li-
abilities. Ion channel and receptor activity assays can be used to predict some
seizure potential, but this only focuses on specifically measured targets for predic-
tion and may miss a response which relies on a combination of endpoints.  Most
evaluation of seizure inducing compounds occurs later in preclinical development
in in vivo studies which have higher costs and could result in species specific results.
Therefore, the development of an in vitro assay to screen compounds for seizuro-
genic potential in a human neural model would give the potential to screen com-
pounds earlier at lower cost and greater reliability. Here we demonstrate the use of
multiwell MEAs to screen for seizurogenic compounds in human IPS derived neu-
rons (hsN). HsNs were seeded in 48 well MEAs and spontaneous activity began at
3 days post plating with greater activity at 7 days when the assay is performed.
Neural action potentials were detected and the results were reported as mean firing
rate (MFR). The seizurogenic compounds tested show dose dependent increase in
MFR with changes in spike train organization, while all of the negative controls
were unaffected.  The seizurogenic compounds tested were Picrotoxin, Gabazine,
L-Glutamate, and pentylenetetrazole (PTZ).  Negative compounds tested were
acetaminophen, naproxen, and DMSO. To further demonstrate the responsiveness
of the cells in the assay, we tested Domoic Acid, a neurotoxin known to cause am-
nesia, and found that it completely blocked network activity while not causing cell
death. These results illustrate the power of the human Neural MEA assay for pre-
dicting compound induced neural toxicity, especially the seizurogenic response.
902 In Vitro Neurotoxicy of Tetrabromobisphenol-A (TBBPA).
R. H. Westerink,  R. G. van Kleef,  M. van den Berg and H. S. Hendriks.
Neurotoxicology Research Group, Institute for Risk Assessment Sciences (IRAS) -
Utrecht University, Utrecht, Netherlands.
Tetrabromobisphenol-A (TBBPA) is a widely used brominated flame retardant.
Studies on the in vitro neurotoxic potential of TBBPA focused on cytotoxicity and
presynaptic effects of neurotransmission, while recent studies indicate that persist-
ent organic pollutants can also affect postsynaptic inhibitory human GABAA and
excitatory α4β2 nicotinic acetylcholine (nACh) receptors. Possible effects of
TBBPA on these neurotransmitter receptors are of considerable interest as these re-
ceptors are critically involved in neurotransmission, synaptic plasticity and brain
development. We therefore investigated the effects of TBBPA on these receptors,
expressed in Xenopus oocytes, using the two-electrode voltage-clamp technique. 
Our results demonstrate that TBBPA acts as full (≥ 10 μM) and partial (≥ 0.1 μM)
agonist on human GABAA receptors, while it acts as antagonist (≥ 10 μM) on
human α4β2 nACh receptors. To further study the effects of TBBPA on calcium-
permeable nACh receptors, effects in B35 cell were examined using single cell fluo-
rescent calcium imaging. TBBPA (≥1 μM) inhibits ACh receptors in B35 cells as
evidenced by a reduction in the ACh-evoked increases in the intracellular calcium
concentration ([Ca2+]i). Additionally, TBBPA (>1 μM) induces a strong and con-
centration-dependent increase in basal [Ca2+]i in B35 cells. In dopaminergic PC12
cells, TBBPA (>1 μM) also increases basal [Ca2+]i. The increase in basal [Ca2+]i is
also evident under calcium-free conditions, indicating it originates from intracellu-
lar calcium stores. Moreover, depolarization-evoked increases in [Ca2+]i are
strongly reduced by TBBPA (≥1 μM), indicating TBBPA-induced inhibition of
voltage-gated calcium channels. Our in vitro studies thus demonstrate that TBBPA
exerts multiple adverse effects on functional endpoints for neurotransmission, justi-
fying the quest for flame retardants with reduced neurotoxic potential.
Funding: EU-FP7 (ENFIRO; grant agreement FP7-ENV-2008-1-226563).
903 Modulation of Nicotinic Acetylcholine Receptor by
Brominated and Alternative Halogen-Free Flame Retardants.
H. S. Hendriks,  R. G. van Kleef and R. H. Westerink. Institute for Risk Assessment
Sciences, Utrecht University, Utrecht, Netherlands.
The large scale use of brominated flame retardants (BFRs) is associated with eco-
logical and toxicological concerns. Previous in vitro research demonstrated that
nicotinic acetylcholine (nACh) receptors are a direct target for e.g., PBDEs and
TBBPA. These (neuro)toxic effects of BFRs argue for replacement by safe(r) and
less persistent alternatives. Since it is essential to assess the (neuro)toxic potential of
proposed halogen-free flame retardants (HFFRs) before they are used on large scale
and in high volume, we measured the effects of three frequently used BFRs and 13
possible halogen-free substitutes on the function of human α4β2 nACh receptors,
expressed in Xenopus oocytes, using the two-electrode voltage-clamp technique.
Our initial rank-order potency based on the in vitro inhibition of nACh receptors
indicates the neurotoxic potential of the HFFR triphenylphosphate (TPP), alu-
minium diethylphosphinate (Alpi), ammonium polyphosphate (APP), and the
nanoclay cloisite 30B (MMT). However, additional studies focusing on expected
concentrations in humans and the environment are required before these com-
pounds can be excluded as viable alternatives. Importantly, five out of the sixteen
tested compounds (brominated polystyrene (BPS), bisphenol-A bis(diphenylphos-
phate) (BDP), resorcinol bis(diphenylphosphate) (RDP), 9,10-dihydro-9-oxa-10-
phosphaphenanthrene-10-oxide (DOPO), and zinc stannate (ZS) are classified as
not potent. Based on this specific neurotoxic endpoint, these five compounds could
therefore be selected for additional testing to further assess the viability of these
HFFRs as alternatives to replace current BFRs.
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Funding: EU-FP7 (ENFIRO; grant agreement FP7-ENV-2008-1-226563.
904 Neurotoxic Effects of Bisphenol AF by the Calcium-Induced
ROS and MAPKs.
S. Kim and S. Lee. Pharmacology, Kyungpook National University Medical School,
Daegu, Republic of Korea.
Bisphenol AF (BPAF), a newly introduced chemical structurally related to bisphe-
nol A (BPA), is used extensively in fluoroelastomers and polyesters, and has been
known to induce estrogen-dependent responses. However, the toxicity of BPAF is
largely unknown except for its endocrine-related effects. In this study, we investi-
gated the neurotoxicity of BPAF and underlying mechanisms of action using hip-
pocampal cell line (HT-22) and mouse primary neuronal cells. We found that
BPAF induced apoptosis in both HT-22 and primary neuronal cells. To clarify the
underlying mechanisms of BPAF-induced apoptosis, various signaling molecules
were evaluated. BPAF increased the level of intracellular calcium, followed by the
generation of reactive oxygen species (ROS). BPAF upregulated the phosphoryla-
tion of mitogen-activated protein kinase (MAPK): extracellular signal-regulated ki-
nase (ERK), p38 and c-Jun N-terminal kinase (JNK), and nuclear translocation of
nuclear factor (NF)-κB. Using specific inhibitors, we confirmed that calcium,
ROS, p38, and JNK mediated the BPAF-induced apoptosis. In addition, BPAF in-
hibited microglial activation in a microglia/neuroblastoma coculture model by the
reduction of nitric oxide production. We found that BPAF interrupted the normal
physiological functions of microglia at non-toxic levels. Taken together, our results
suggest that BPAF, the substitute of BPA, also have neurotoxic properties.
905 Potent Induction of a Series of Endogenous Antioxidative
Enzymes by Triterpenoid CDDO-IM Leads to Neuprotection
Against Oxidative and Electrophilic Injury.
A. Speen,  C. Jones,  R. Patel and Z. Jia. Department of Biology, University of North
Carolina Greensboro, Greensboro, NC.
Evidence suggests oxidative and electrophilic stress as a major factor contributing to
the neuronal cell death in neurodegenerative disorders, especially Parkinson’s dis-
ease (PD). Early depletion in the levels of thiol antioxidant glutathione (GSH),
which may lead to generation of reactive oxygen species, is an important biochemi-
cal feature of PD. However, whether induction of endogenous antioxidative en-
zymes by a novel triterpenoid CDDO-Im (2-cyano-3,12 dioxooleana-1,9 dien-28-
oyl imidazoline) affords protection against oxidative and electrophilic
neurocytotoxicity has not been carefully investigated. Retinoic acid-induced differ-
entiation of human neuroblastoma SH-SY5Y cells are known to possess properties
of mature neurons and thus have been widely used in vitro model for the study of
neurotoxicity and neuroprotection. In this study, we showed that incubation of
retinoic acid-induced differentiation of human neuroblastoma SH-SY5Y cells with
nanomolar concentrations of CDDO-IM (1- 400 nM) for 24 h resulted in signifi-
cant increased in the levels of reduced glutathione (GSH) and NAD(P)H:quinone
oxidoreductase 1 (NQO1), two critical cellular defenses in detoxification of reac-
tive oxygen species and electrophilic quinone molecules. Pretreatment of the cells
with CDDO-IM was found to afford remarkable protection against the neurocyto-
toxicity elicited by acrolein, 4-hydroxynonenal, 3-morpholinosynonimine hy-
drochloride, xanthine oxidase/xanthine, and hydrogen peroxide. Taken together,
this study demonstrates for the first time that CDDO-IM potently induces the cel-
lular GSH system and NQO1 in retinoic acid-induced differentiation of human
neuroblastoma SH-SY5Y cells, which is accompanied by dramatically increased re-
sistance of these cells to the damage induced by various neurotoxicants. The results
of this study may have important implications for the development of novel neuro-
protective strategies.
906 1, 3-Dinitrobenzene Induces Age-Specific Responses in
Primary Neurons.
L. Maurer1,  N. D. Hein2,  J. D. Latham1,  R. Landis3,  I. Speirs1 and
M. A. Philbert1. 1Toxicology Program, University of Michigan, Ann Arbor, MI;
2Neurology, University of Michigan, Ann Arbor, MI; 3Kalamazoo College, Kalamazoo,
MI.
During the normal aging process, the brain successively loses the ability to cope
with pathophysiologic stressors. The accumulation of iron in the aging brain po-
tentially contributes to this by increasing redox activity. Astrocytes participate in
the preservation of neurons during chemically induced stress by releasing adeno-
sine, thereby silencing the electrical (hence energetic and metabolic) requirements
of neurons. 1,3-dinitrobenzene (DNB) stimulates adenosine release from astro-
cytes, and is used as a neural stressor probe in this study. Primary neurons and as-
trocytes were exposed to DNB (0, 100nM, or 100 μM) and 10 μM adenosine with
100nM or 100μM DNB. Neurons were isolated from male F344 rats (1 mo, 3 mo,
& 18 mo), maintained for two weeks and exposed to DNB. Astrocytes were iso-
lated and maintained for five weeks and cocultured with neurons. Adenosine
triphosphate (ATP) was measured in both cell types. Neurons from 3 mo brains ex-
hibited higher ATP than neurons from other age groups. Cocultured astrocytes had
higher ATP levels than neurons at all age groups. Neurons were assayed at a later
timepoint for lactate dehydrogenase (LDH). Neurons from brains of 1 mo and 18
mo rats, but not 3 mo rats, exposed to DNB exhibit statistically significantly higher
LDH than neurons treated with both DNB and adenosine. Immunocytochemistry
for the presence of transferrin (Tf ) and mitochondrial frataxin (mtFr) was per-
formed on neurons. Increases in Tf were observed in older neurons. Colocalization
of Tf and mtFr was observed in the oldest age group. These results suggest that neu-
rons from older animals sequester more mitochondrial iron than younger cohorts,
increasing potential for higher redox activity, rendering them more vulnerable to
chemical insults such as DNB. Future work will elucidate the significance of mito-
chondrial iron in the aging process. 
This work was supported by NIH 2RO1 ES00846 (LM, JDL, ICS, MAP), NIH
2T32 ES007062 (LM), HHMI Award (RL), NIH R01 NS069700 and SPF
N014262 (NDH).
907 Magnetic Resonance Imaging and Spectroscopic Markers of
Kainic Acid-Induced Excitotoxicity in the Rat Brain.
S. Liachenko1,  J. Ramu1,  M. G. Paule1,  L. Schmued1 and J. P. Hanig2.
1Neurotoxicology, NCTR/US FDA, Jefferson, AR; 2Office of Testing & Research,
CDER/US FDA, White Oak, DC.
Neurotoxicity assessment in drug development is typically accomplished using mi-
croscopic analysis, which may be time consuming and not always comprehensive.
In this study we describe changes in brain after acute administration of kainic acid
(KA) using non-invasive magnetic resonance imaging (MRI) and spectroscopy
(MRS) in comparison to histopathology. Adult male Sprague-Dawley rats (N = 24,
361 ± 36 g) were anesthetized with isoflurane and positioned inside a 7 tesla MRI
scanner. T2 relaxation mapping of the whole brain and proton MRS in the left hip-
pocampus were performed. KA (10 mg/kg, ip) was then administered to all animals
after baseline scans and imaging was continued for another 2 hours. One group of
animals (N = 6) was euthanized at this time. The MRI procedure was repeated one
day (N = 6) and 2 days later (N = 12) and these animals were then euthanized. All
rats were perfusion-fixed and their brains underwent histopathological assessment.
KA led to an increase in T2 in the hippocampus as early as 1 hour after administra-
tion. These changes were more pronounced at 2 hours and drastically so at 1 and 2
days after the treatment at which point the findings spread to wider areas of the
brain, including the amygdale, thalamus, and cortex. MRS revealed immediate in-
creases in glutamate and glutamine concentrations right after KA administration
followed by decreases at 1 and 2 days, at which point N-acetyl-aspartate signal was
also decreased. Lactate was not detectable in the normal brain but appeared at 15
min and increased to a maximum at 2 hours after treatment. At 1 and 2 days lactate
was still detectable. The T2 water relaxation correlated with histopathological
changes in the brain at all time points. These data provide the basis for the develop-
ment of imaging biomarkers for the early detection of neurotoxicity, which would
benefit public health by increasing the number of tools available for safety evalua-
tion of new drugs. (Supported by NCTR and CDER, FDA, #E0741801).
908 Effect of Acute Administration of Beta-N-
Methylaminoalanine (L-BMAA) on Rat Hippocampus
Neurochemical Profile Determined with 1H Magnetic
Resonance Spectroscopy (MRS).
J. Ramu1,  J. P. Hanig2,  E. C. Garner3,  M. G. Paule1 and S. Liachenko1.
1Neurotoxicology, NCTR/US FDA, Jefferson, AR; 2Office of Testing & Research,
CDER/US FDA, White Oak, MD; 3Lovelace Respiratory Research Institute,
Albuquerque, NM.
L-BMAA is a non-proteogenic amino acid present in cyanobacteria and in cycad
seed, exposure to which is implicated in western Pacific amyotrophic lateral sclero-
sis and parkinsonism-dementia complex (ALS-PDC). After absorption, L-BMAA is
transported into the brain, metabolized, and L-BMAA and/or its metabolites may
accumulate in brain protein. This bound form may serve as a sink from which L-
BMAA or its metabolites are released, contributing to its neurtotoxic effect. L-
BMAA has been shown to be excitotoxic, acting as a glutamate receptor agonist. In
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this study we used non-invasive 1H-MRS to investigate the changes in the hip-
pocampal neurometabolic profile after single dose of L-BMAA. Nine adult male
Sprague-Dawley rats (390 ± 8 g) were anesthetized with isoflurane and positioned
in 7 tesla MRI scanner. MRS in the left hippocampus (voxel size 4 x 4 x 2 mm) was
performed before and for 1.5 hrs after BMAA administration (100 mg/kg, ip).
Signal intensity of N-acetyl-aspartate, gamma-aminobuteric acid (GABA), creatine,
choline, glutamate, glutamine, myo-inositol, and taurine were measured relative to
water peak in water-unsuppressed reference spectrum. At the end of observation pe-
riod the GABA signal was elevated relative to the baseline (+23%, P = 0.051) and
taurine was decreased (-10%, P = 0.014). Signal intensity of other neurotransmit-
ters did not change. These data may be consistent with L-BMAA mediated gluta-
mate agonist activity Both GABA and taurine are released into extracellular space
after stimulation of NMDA receptors. Increase in GABA may be due to a combi-
nation of uptake and increased synthesis. The lowering of hippocampal taurine may
reflect a reduction in re-uptake after release. These data suggest that L-BMAA has
measurable effect on glutamineric pathways in undisturbed, intact tissues in rats.
909 Pattern of Pathologic Changes Observed in the CNS of
Chronic Toluene Abusers.
D. Pyatt1, 2 and P. Kerzic3. 1Summit Toxicology, Superior, CO; 2Schools of Pharmacy
and Public Health, University of Colorado, Denver, CO; 3Cinpathogen, Los Angles,
CA.
Toluene is a common volatile organic chemical (VOC) found in petroleum-based
products and has wide-spread industrial use as a solvent in paints, lacquers, inks,
adhesives and cleaning agents (degreasing). The toxicity of toluene has been well
described in experimental animals, occupationally exposed humans and healthy
volunteers. Considerable toxicological data has also been obtained from individuals
who purposely expose themselves to high levels of toluene and/or toluene contain-
ing solvents to achieve the narcotic effect common to most organic solvents.
Collectively, this data has demonstrated that high-dose prolonged exposure to
toluene can cause neurological toxicity, ranging from non-specific, reversible symp-
toms to permanent pathological changes in the ‘white matter’ of the brain.
Evaluation of chronic toluene abusers by magnetic resonance imaging (MRI) have
revealed a series of pathologic alterations that appear to be common to most, if not
all, toluene abusers that suffer from permanent neurological alterations. These indi-
viduals almost always provide evidence of direct toxic insult, including diffuse atro-
phy in the brain and/or areas of de-myelination and axonal dying. Other frequently
reported pathological changes include hypo-intensity of the thalamus region and
basal ganglia, high T2 signal intensity in the periventricular white matter and a loss
of grey-white demarcation or differentiation. Most authors report a clear dose-re-
sponse relationship, describing exposures (durations as well as intensities) necessary
to cause these lesions observed in the white matter. While none of the reported al-
terations are dispositive of toluene exposure, the consistent pathological pattern ob-
served in the MRIs of chronic toluene abusers (or those with severe occupational
exposures) has not been previously appreciated or reported. The existing scientific
evidence relevant to this issue, including exposure-response data (where available),
has been comprehensively evaluated and is presented herein.
910 Effects of Short- and Long-Term Exposure to 1-
Bromopropane on Neurogenesis in Adult Rats.
L. Zhang1,  T. Nagai2,  K. Yamada2,  D. Ibi2,  S. Ichihara3,  K. Subramanian1,
Z. Huang1,  S. Sheik Mohideen1,  H. Naito1 and G. Ichihara1. 1Department of
Occupational & Environmental Health, Nagoya University Graduate School of
Medicine, Nagoya, Japan; 2Neuropsychopharmacology, Nagoya University Graduate
School of Medicine, Nagoya, Japan; 3Mie University Graduate School of Regional
Innovation Studies, Tsu, Japan.
Purpose: People with 1-bromopropane (1-BP) intoxication show depression and re-
duction of cognitive function and memory. The present study tested the hypothesis
that 1-BP suppresses neurogenesis in the dentate gyrus which is involved in higher
cerebral function in adult rats.
Methods: Four groups of twelve male Wistar rats were exposed to 1-BP at 0, 400,
800 and 1000 ppm, 8 hrs/day for 7 days. Other four groups of six rats were exposed
to 1-BP at 0, 400, 800 and 1000 ppm for two weeks and 0, 200, 400 and 800 ppm
for another 2 weeks. The other four groups of six rats were exposed to 1-BP at 0,
200, 400 and 800ppm for 4 weeks. Rats were injected with 5-bromo-2’-deoxy-uri-
dine (BrdU) after four-week exposure at 1000/800 ppm to examine neurogenesis in
the dentate gyrus using immunostaining. Factors known to affect neurogenesis, in-
cluding monoamine level in different brain regions, hippocampal brain-derived
neurotrophic factor (BDNF) and glucocorticoid receptor (GR) mRNA expression
levels were measured. 
Results: BrdU positive cells decreased significantly at 800/1000 ppm after 4-week
exposure to 1-BP. 1-week exposure to 1-BP at 800 and 1000 ppm significantly re-
duced noradrenalin level in the striatum. 4-week exposure to 1-BP decreased signif-
icantly noradrenalin level in the hippocampus, prefrontal cortex and striatum at
800 ppm. 1-BP also reduced hippocampal BDNF and GR mRNA levels. 
Conclusion: Long-term exposure to 1-BP decreased neurogenesis in the dentate
gyrus. Downregulation of mRNA expression of BDNF and GR and low hip-
pocampal norepinephrine levels might partly contribute to the reduced neurogene-
sis.
911 Nitrosative Stress in Chemoconvulsant-Induced
Epileptogenesis.
K. Ryan1, 2,  L. Liang1 and M. Patel1. 1Toxicology, Skaggs School of Pharmacy and
Pharmaceutical Sciences; University of Colorado Anschutz Medical Campus, Aurora,
CO; 2NTP, NIEHS, Morrisville, NC.
Reactive oxygen and nitrogen species (ROS/RNS) are mediators of oxidative stress
and are increased in the brain as a result of seizure activity and reactive gliosis; yet
their contributing role in the process by which injury leads to epilepsy (i.e. epilep-
togenesis) is largely unknown. Our previous work in the kainate model of chemo-
convulsant-induced epilepsy has confirmed significant oxidative macromolecular
damage to hippocampal mitochondria (Ryan et al 2012). The primary goals of this
study were to assess the consequences of nitrosative stress in cellular compartments
to gain greater mechanistic insight into mitochondrial dysfunction during epilepto-
genesis.  Rats were exposed to a single high dose of kainate (11mg/kg) or vehicle
and monitored by video and/or EEG for seizure activity 6 wks. Nitrosative stress
was measured in the susceptible hippocampal brain region acutely after kainate ad-
ministration (8hr, 24hr, and 48hr), 1wk after kainate prior to development of
epilepsy (latent period) and during the chronic stages of epilepsy (3wk and 6wk).
Analysis from frozen hippocampal sections indicated global astrogliosis (GFAP)
and microgliosis (Iba-1) after kainate. Hippocampal nitric oxide spiked 2-fold 8hr
after kainate and remained elevated throughout epileptogenesis. Preliminary results
suggest this could be associated with increased iNOS detected by immunohisto-
chemical staining. Furthermore, cellular and mitochondrial 3-nitrotyrosine (3NT)
progressively and significantly increased during epileptogenesis indicating protein
nitration and subsequent immunofluorescent co-labeling showed that 3NT is local-
ized to hippocampal neurons (NeuN). This study demonstrates a probable mecha-
nism for gliosis-mediated nitric oxide production and downstream protein damage
to hippocampal neurons in epileptogenesis. These studies propose a role for target-
ing oxidative and nitrosative species to delay or prevent disease progression by in-
hibiting detrimental protein nitration. NS039587 (M.P.) and NS R21 NS072099
(M.P.)
912 Ozone-Induced Changes in Oxidative Stress Parameters in
Brains of Adult, Middle-Age, and Senescent Brown Norway
Rats.
P. S. Kodavanti,  J. E. Royland,  J. E. Richards,  D. I. Agina-Obu and
R. C. MacPhail. NHEERL, US EPA, Research Triangle Park, NC.
Understanding life-stage susceptibility is a critical part of community based human
health risk assessment following chemical exposure. Recently there is growing con-
cern over a common air pollutant, ozone (O3), and adverse health effects including
dysfunction of the pulmonary, cardiac, and nervous systems. Oxidative stress (OS)
is a known contributor in multiple organ toxicities and plays an important role in
age-related diseases. Growing evidence implicates OS in O3 toxicity. The current
study explored OS as a potential toxicity pathway for O3 exposure and addressed
whether these effects are life stage-dependent. OS-related measures included reac-
tive oxygen species (ROS) production [NADPH Quinone oxidoreductase 1
(NQO1), NADH Ubiquinone reductase (UBIQ)], antioxidant homeostasis [total
antioxidant substances (TA), superoxide dismutase (SOD), γ-glutamylcysteine syn-
thetase (γ-GCS)], and oxidative damage (total aconitase). Male Brown Norway rats
(4, 12, and 24 months) were exposed to O3 (0, 0.25 or 1 ppm) via inhalation for 6
h/day, 2 days per week for 13 weeks. Frontal cortex (FC), cerebellum (CB), stria-
tum (ST), and hippocampus (HP) were dissected 24 hours after last exposure,
quick frozen, and stored at 80°C until analysis. Results indicated life stage-related
increases in ROS production (~ 2x in UBIQ and > 1.5x in NQO1 in striatum),
slight decreases in antioxidant homeostatic mechanisms (TAS, γ-GCS, and SOD),
and a decrease in aconitase activity. The effects of O3 exposure were brain area-spe-
cific, with the striatum being more sensitive than other brain regions. With regard
to life stage, the effects of O3 appeared to be greater in 4 month old than 12 or 24
month old rats. These results indicate OS could be a potential toxicity pathway for
O3, but the complex interactions between age, exposure and brain region require
further investigation. (This abstract does not necessarily reflect USEPA policy).
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913 Protective Role of Carnosine Against Ischemic Brain Damage
through Modulation of Mitochondrial Function and
Autophagy.
O. Bae1,  S. Baek2 and A. Majid3. 1College of Pharmacy, Hanyang University, Ansan,
Republic of Korea; 2College of Pharmacy, Ajou University, Suwon, Republic of Korea;
3Department of Neurology and Manchester Academic Health Sciences Centre, Salford
Royal Hospital, Salford, United Kingdom.
We recently found that carnosine, an endogenous pleiotropic dipeptide, has a neu-
roprotective activity against ischemic stroke. To investigate the mechanism of
carnosine neuroprotection, we examined the effect of carnosine on mitochondrial
dysfunction and autophagic process in ischemic brain. In rat permanent middle
cerebral artery occlusion models, intravenous treatment with carnosine exhibited
robust neuroprotection. Carnosine treatment improved brain mitochondrial func-
tion as found in mitochondrial respiration, and fusion/fission signaling.
Interestingly, autophagic pathways were activated in brain following ischemic in-
sults, such as reduction of phosphorylated mTOR/p70S6K and the conversion of
LC3 I to LC3 II, as found in western blot analysis of isolated brain homogenates.
Treatment of carnosine attenuated the autophagic signaling in ischemic brain,
while the change of ERK phosphorylation was not detected. Taken together, our
data suggest that carnosine neuroprotection is mediated by mitochondrial protec-
tion, inhibiting excessive autophagic processes. We believe that our finding con-
tributes to the development of carnosine as a strong candidate for stroke treatment,
providing a new insight into the role of mitochondrial damage and autophagic
pathways in ischemic brain damage.
914 The Neurotoxic Effects of Tributyltin on Tokai High Avoider
(THA) Rats Evaluated by the Sidman Electric Shock
Avoidance Test.
M. Tsunoda1,  T. Kido2,  M. Hosokawa3,  C. Sugaya1,  H. Endo4,  T. Watanabe4
and Y. Aizawa5. 1Preventive Medicine, Kitasato University School of Medicine,
Sagamihara, Japan; 2Public Health and Environmental Medicine, Jikei University
School of Medicine, Tokyo, Japan; 3Epidemiology and Environmental Health, Faculty
of Medicine, Juntendo University, Tokyo, Japan; 4Basic Clinical Science and Public
Health, Tokai University School of Medicine, Isehara, Japan; 5Kitasato University,
Tokyo, Japan.
Tributyltin (TBT) compounds have been known as environmental pollutants.
Although neurotoxicity is one of the major toxicities of TBT, the effects of TBT on
learning ability have not yet been clearly demonstrated. Wistar-derived Tokai High
Avoider (THA) rats, which were developed at Tokai University, can achieve stable
learning ability in the Sidman electric shock avoidance test because of their innate
high-level avoidance ability and small individual differences. We evaluated the neu-
rotoxicity of TBT in THA rats by Sidman electric shock avoidance test. The male
and female THA rats were administered TBT in their food at 0 and 125 ppm after
weaning (males, n = 5/group; females n = 4/group). From 6 weeks of age, the
Sidman test sessions were performed for 60 min/day for 10 consecutive days. Rats
can avoid electric shocks by pressing a lever. Avoidance rates for shock exposures
were calculated for the first and second halves (30 minutes each) of each session.
The mean values of the avoidance rates were compared between the control and
TBT groups for each sex, and those of the TBT-exposed group were lower than
those of the control for both sexes for all the sessions. Significantly lower mean val-
ues of the avoidance rates compared to the control were observed in the first 30
minutes of the sessions in male rats on days 2 and 5. It is suggested that learning
ability was impaired in the THA rats exposed to TBT at 125 ppm. To detect the
statistically significant differences in future studies, more THA rats should be used.
915 Protein Biomarker Panel of Cisplatin-Induced Neurotoxicity
in a Preclinical Model.
O. Y. Glushakova1,  S. Mondello1,  D. Johnson1,  C. Heldermon2,  J. Streeter1 and
R. L. Hayes1. 1Banyan Biomarkers, Inc., Alachua, FL; 2University of Florida,
Gainesville, FL. Sponsor: C. Markgraf.
Background: Neurotoxic brain damage is a widely recognized adverse effect of
chemotherapy affecting overall outcome and quality of life cancer survivors.
Effective clinical monitoring of neurotoxicity using simple and reliable assays could
provide timely information to clinicians allowing them to adjust treatment and re-
duce neurologic and cognitive side effects of chemotherapy. The goal of this study
was to investigate spatiotemporal distributions in the brain, CSF and serum of glial,
of neuronal and inflammatory biomarkers: ubiquitin C-terminal hydrolase-1
(UCH-L1), glial fibrillary acidic protein (GFAP), αll-spectrin break down products
(SBDPs), microtubule-associated protein 2 (MAP2), myelin basic protein (MBP),
MBP break down products (MBP-BDP), intercellular adhesion molecule (ICAM)
and their relationships to cisplatin-induced neuropathology in rats.
Methods: Neurotoxicity in adult rats was induced by cisplatin (10 mg/kg, i.p.). The
levels and localization of biomarkers in the brain were examined by immunohisto-
chemistry (IHC) and their levels in CSF and serum were evaluated by ELISA.
Results: IHC revealed that cisplatin caused abnormal changes in the brain starting
at 6 h and increasing at 24 and 48 h including gliosis, determined by increased
GFAP level, dendritic damage determined by decreased MAP2 level, neuronal de-
myelination determined by increased level of MBP-BDP, and inflammation deter-
mined by increased level of ICAM. Serum levels of UCHL-1, GFAP and SBDP150
were significantly increased at 24 h after cisplatin administration as compared to
controls. The levels of these biomarkers were correlated with IHC brain pathologies
and survival.
Conclusion: This study demonstrated the potential of using levels of glial and neu-
ronal proteins in blood for assessment of cisplatin induced neurotoxicity. In addi-
tion, assessment of serum levels of biomarkers can provide information on underly-
ing mechanisms of neurotoxicity and facilitate a personalized treatment to
minimize side effects during and after chemotherapy.
916 Effects of a Smokeless Tobacco, Gutkha on Neurotransmitter
Levels and Associated Parameters in the Mouse Brain.
D. E. Lauterstein1,  C. Hoffman1,  M. M. Hossain3,  J. Richardson3,  F. Ganey2
and J. T. Zelikoff1. 1Environmental Medicine, New York University, Tuxedo, NY;
2Memorial Sloan-Kettering Cancer Center, NY, NY; 3Rutgers University, New
Brunswick, NJ.
Many studies have been performed on the relationship between smoked tobacco
and adverse effects on health. However, fewer data are available on the toxicity of
smokeless tobacco. Gutkha, a smokeless tobacco (ST) product manufactured in
India and readily available in the U.S. (used extensively by South Asian communi-
ties), is composed of powdered tobaccos, slake lime, and spices. To assess the effects
of Gutkha usage on the brain, adult male mice (B6C3F1) were exposed daily via
the oral mucosa to water (control), 50 μL of a 21 mg water-soluble Gutkha solu-
tion or of a 8 mg/kg nicotine solution for 3 days and changes in brain levels of
dopamine (DA), serotonin (5-HT), and norepinephrine (NE) were assessed in the
striatum. Monoamine oxidase and tyrosine hydroxylase (enzymes important for
neurotransmitter (NT) breakdown and synthesis, respectively) levels were assessed
in the striatum, frontal cortex, and locus coeruleus. Serum cotinine levels for all the
groups were analyzed upon sacrifice within 1 hr post-exposure; Gutkha- and nico-
tine-exposed mice had comparable cotinine levels ranging between 18-50 ng/mL
and 20-60 ng/mL, respectively. HPLC studies measuring NT levels in the brain
demonstrated that Gutkha-exposed mice had a significant increase in NE com-
pared to those exposed to either nicotine or water. In contrast, Gutkha-exposed
mice had a significant decrease in DA and 5-HT compared to the control and nico-
tine-exposed groups. The results here suggest that: effects of Gutkha on certain
brain parameters may be due to Gutkha-associated toxicants other than nicotine;
Gutkha may provide an additional biological stressor for the brain compared to
nicotine alone; and, Gutkha may be more addictive than nicotine alone based on
the rapid depletion rate of catecholamines in the brain. Studies supported by funds
from the NYU Cancer Center and NYU NIEHS Center.
917 3, 4-Methylenedioxymethamphetamine (Ecstacy)-Mediated
Acute and Long-Term Effects Are Reduced in SERT-
Knockout Rats.
L. E. Lizarraga,  A. B. Cholanians,  J. M. Herndon,  S. S. Lau and T. J. Monks.
Pharmacology and Toxicology, University of Arizona, Tucson, AZ.
3,4-Methylenedioxymethamphetamine (MDMA, Ecstacy) is a ring-substituted
amphetamine derivative structurally related to the psychomotor stimulant amphet-
amines and the hallucinogen mescaline. The neuropharmacological effects of
MDMA are biphasic in nature. MDMA initially causes synaptic monoamine re-
lease, primarily of serotonin (5-HT), producing hyperthermia and hyperactivity (5-
HT syndrome). The long-term effects of MDMA manifest as a prolonged deple-
tion in 5-HT, and structural damage to 5-HT nerve terminals. The effects of
MDMA are in part mediated by an ability to inhibit the presynaptic 5-HT reup-
take transporter (SERT). Using a SERT-knockout (SERT-KO) rat model, we deter-
mined the effects of SERT deficiency on MDMA (10mg/kg, sc, X 4 at 12h inter-
vals) -mediated hyperthermia, locomotor activity, and neurotoxicity in SERT-KO
or Wistar-based wild-type (WT) rats. Open-field activity cages equipped with pho-
tobeam sensor rings revealed that WT rats were 2.4-fold more active (displaying
higher horizontal movement distance and mean velocity) than their SERT deficient
counterparts. Exposure to MDMA stimulated total movement by 4.2-fold in both
WT and SERT-KO rats. Although the peak hyperthermic response in SERT-KO
(38.9C & 38.4C) and WT animals (39.1C & 38.8C) were similar after the first
and third doses of MDMA, the response was delayed and prolonged in WT ani-
mals. Thus the cumulative (temp X time) elevation in temperature was significantly
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(p<0.01) higher in the WT rats. Finally, SERT KO animals were insensitive to
MDMA-mediated long-term (7 days) depletions in 5-HT and its metabolite, 5-hy-
droxyindoleacetic acid (5-HIAA), in both cortex and striatum. In conclusion,
SERT deficiency in KO animals attenuated MDMA-induced hyperthermia and
neurotoxicity but not locomotor activity. The data confirm that SERT is essential
for the manifestation of the acute and long-term effects of MDMA (NIH R01
DA023525, P30ES006694, and T32ES007091).
918 Structurally-Distinct Dopaminergic Neurotoxicants Acutely
Decrease ATP-Dependent Calcium Signaling in Astrocytes
by Inhibiting TRPC3.
K. Streifel,  A. Gonzales,  B. Trout,  B. Mohl,  S. Earley and R. B. Tjalkens.
Environmental and Radiological Health Science, Colorado State University, Fort
Collins, CO.
Dopaminergic nuclei within the basal ganglia are important for control of motor
function but are highly sensitive to damage from oxidative stress, inflammation,
and environmental neurotoxicants. Here we propose that inhibition of transmitter-
evoked calcium (Ca2+) signaling in astrocytes may contribute to this sensitivity be-
cause ATP-dependent Ca2+ waves in these cells modulate diverse trophic functions
in the CNS, including metabolism, synaptic activity, and regional cerebral blood
flow. To examine mechanisms underlying alterations in Ca2+ signaling in astro-
cytes, we postulated that cationic neurotoxicants of the basal midbrain would
acutely inhibit ATP-induced Ca2+ signals in astrocytes through a common chan-
nel. To test this hypothesis, we examined the capacity of MPP+ and 6-
Hydroxydopamine (6-OHDA) to block ATP-dependent Ca2+ waves and tran-
sients in primary striatal astrocytes. Calcium imaging studies revealed a
dose-dependent decrease in ATP-induced intracellular Ca2+ transients and me-
chanically stimulated Ca2+ waves following acute application of both MPP+ and 6-
OHDA. These compounds also acutely inhibited OAG-induced Ca2+ influx, sug-
gesting the transient receptor potential channel, TRPC3, as a probable target.
MPP+ inhibited OAG-induced intracellular Ca2+ transients similarly to the
TRPC3 channel antagonist, pyrazole-3, whereas 6-OHDA only partly suppressed
OAG-induced Ca2+ transients. In whole cell patch clamp experiments conducted
in TRPC3-overexpressing cells, acute application of MPP+ completely blocked
TRPC3-like currents, whereas only partial inhibition was detected in the presence
of 6-OHDA. These findings indicate that dopaminergic neurotoxicants that have
cationic properties differentially inhibit TRPC3 in astrocytes, thereby diminishing
the amplitude of ATP-induced Ca2+ transients. These compounds may therefore
share a common mechanism of neurotoxicity in their capacity to acutely disrupt as-
trocytic trophic functions reliant on this signaling mechanism.
919 Comparative Toxicity of Amphotericin B and Amphotericin
B Methyl Ester in Oligodendrocytes In Vitro and In Vivo.
O. U. Nnodi1,  C. P. Schaffner2 and K. R. Reuhl1. 1Pharmacology & Toxicology,
Rutgers University, Piscataway, NJ; 2Waksman Institute, Rutgers University,
Piscataway, NJ.
Amphotericin B methyl ester (AME) is a polyene macrolide antibiotic highly effec-
tive against systemic fungal infections. Introduced more than 40 years ago, AME is
less toxic than the commonly used Amphotericin B (AMB), which has serious dose-
limiting nephrotoxicity. Nevertheless, reports of neurotoxicity led to cessation of its
clinical use. Research in our lab using pure AME suggest that the reported myelin
toxicity was due to contamination by AMB which injures myelin-producing oligo-
dendrocytes in the CNS. To test this hypothesis, adult female Balb/c mice were ad-
ministered to AMB or AME (5 mg/kg, ip) or vehicle for 28 days and 54 days.
Histopathologic analysis of mice using Fluoromyelin dyes demonstrated white mat-
ter vacuolation and demyelination, with accumulation of myelin debris within
macrophages. AMB also induced apoptosis of glial cells. AME-treated mice were
normal. Quantitative dose-response assessment using an immortalized human
oligodendroglial cell line (MO3.13) exposed to 0.5-30μg/ml AMB or AME
demonstrated that AME was at least 10-fold less toxic than AMB as measured by
dye exclusion. The lowest concentration of AMB to induce cell membrane injury in
MO3.13 cells was 1μg/ml. AMB induced an apoptotic phenotype at concentra-
tions ten times lower than AME as determined by nuclear area factor assessment.
AMB induces the mitochondrial intrinsic apoptotic pathway in the MO3.13 cells.
A direct effect of AMB on the mitochondrial membrane was confirmed by labeling
with JC-1, a fluorescent marker of mitochondrial membrane potential (ΔΨΜ,),
which revealed diminished intensity following AMB treatment at 1μg/ml. Changes
in ΔΨΜ were not rescued by Trolox, a mitochondrial membrane pore inhibitor.
AME concentrations below 10μg/ml did not alter ΔΨΜ. These data suggest that
AMB, but not pure AME, causes potentially lethal injury to oligodendrocytes by
inducing plasma membrane permeability and mitochondrial perturbation, with
consequent apoptosis. (Supported by ES005022 and ES07148).
920 Effects of “Uptake 2” Blockade and/or Risperidone on
Murine 5-HT Uptake, Social and Repetitive Behavior.
C. Smolik1, 2,  M. Javors1,  J. Hensler1,  W. Koek1,  L. C. Daws1 and
G. G. Gould1. 1CBN, UTHSCSA, San Antonio, TX; 2Biology, UTSA, San Antonio,
TX.
Uptake 2 mechanisms in the brain such as organic cation transporters (OCTs) may
play a major role in the modulation of monoamine neurotransmission. OCTs have
affinity for and/or transport many endogenous and xenobiotic compounds. Their
blockade produces similar effects to selective serotonin (5-HT) reuptake inhibitors.
The pseudoisocyanine 1,1’-diethyl-2,2’-cyanine iodide (decynium-22 or D-22)
blocks 5-HT uptake in vivo and produces antidepressant-like effects in mice.
Administration of D-22 (0.01-0.1 mg/kg) or diazepam (1 mg/kg) increased social
approach in BTBR mice 50 min afterward (p<0.05, N=6), in contrast to risperi-
done (0.1 mg/kg). Unlike diazepam or risperidone, D-22 failed to reduce BTBR
marble burying. D-22 (0.01 mg/kg) increased social sniffing of stranger mice by
SERT -/- mice (p<0.05, N=12), with a similar lack of effect on marble burying. We
hypothesized that D-22 produces its effects on social behavior by blocking OCTs or
other uptake-2 sites in the mouse brain. Saturation binding of [3H] D-22 in mouse
hippocampal homogenates revealed a KD of ≈3-4 nM, and a Bmax of 700 ± 167
fmol/mg protein (N=3). Binding of [3H] D-22 is partially blocked by the neuro-
toxin 1-methyl-4-phenylpyridinium (MPP+), a substrate of OCTs. We confirmed
that [3H] MPP+ uptake by hOCT expressing HEK cells was blocked by D-22 with
IC50 values ranging from 3-8 μM (N=5). We also found that D-22 blocks hip-
pocampal 5-HT uptake (IC50=197nM), albeit more weakly than striatal DA up-
take (IC50=35nM), in synaptosomes from mice (N=4-7). Through HPLC meas-
urements D-22 was detectable in the brain when administered by intraperitoneal
(i.p.) injection at 10 mg/kg, but not at lower doses. D-22 has a serum clearance
half-life of 30 min in BTBR mice. OCT3 blockade appears to be a promising ther-
apeutic strategy for social interaction deficiencies. Research was supported by NIH-
NINDS #R25NS080684 START-UP Program, NIH-NIMH #R03MH086708
and DOD AR110109.
921 Social Behaviors, Monoamine Transporter Function, and
Brain Mitochondrial Efficiency in Insulin-Resistant Mice.
R. Lozano1, 2,  W. Q. Zhang1,  C. Smolik1,  P. A. Barba-Escobedo1,  M. Gamez1,
H. Van Remmen3,  L. C. Daws1 and G. G. Gould1. 1Physiology, UTHSCSA, San
Antonio, TX; 2Psychology, Texas A&M University, College Station, TX; 3Barshop
Center, UTHSCSA, San Antonio, TX.
Insulin resistance and elevated blood glucocorticoids are key components of the
metabolic syndrome that often comes before type 2 diabetes. Use of atypical an-
tipsychotics can increase the risk for developing metabolic syndrome, yet the im-
pact of elevated insulin on drug response, monoamine systems and behavior is
poorly understood. In streptozotocin-treated rats and in type 1 diabetes, insulin
production is suppressed and dopamine transporter function is impaired.
Conversely, we hypothesized that high circulating insulin and corticosteroid levels,
as seen in type 2 diabetes, may instead enhance monoamine transporter function
and impair sociability. We tested this hypothesis using BTBR x C57BL/6 (BL6) F1
male mice, which exhibit insulin resistance as adults, and their parent strains.
BTBRxBL6 F1 mice had increased abdominal adiposity, but their serum levels of
corticosterone were intermediate (89 ± 8 ng/ml) to higher BTBR and low BL6 lev-
els (N=5-8). Their social behavior in three chambered tests and marble burying was
similar to that of socially-deficient BTBR mice. Yet BTBRxBL6 F1 were more im-
pulsive than either parent strain in the tube test for social dominance. Brain tissue
from BTBR and BTBRxBL6 F1 mice had lower H2O2 production from mitochon-
drial electron transport than BL6 mice (P<0.05, N=5). Binding of [3H] citalopram
to serotonin transporters in hippocampal synaptosomes was reduced in BTBR and
BTBRxBL6 mice, but [3H] 5-HT uptake was similar to BL6 mice (N=4-6). In con-
trast, [3H] WIN 35,428 binding to dopamine transporters in striatal synaptosomes
was similar among strains, but [3H] dopamine uptake was significantly increased in
BTBR mice (N=4-6). Based on [3H] domperidone binding in cortical synapto-
somes, dopamine receptor density may be increased in BTBR and BTBRxBL6 F1
mice. Hence dopamine transmission could be suppressed in these insulin-resistant
mice, which may alter their responsiveness to antipsychotics.
922 Impact of Pair Housing and Selection of Photobeam-Based
Motor Activity Parameters for Neurobehavioral Evaluation.
P. Mukerji,  S. S. Anand,  L. A. Malley,  N. P. Betts and S. E. Loveless. DuPont
Haskell Global Centers for Health & Environmental Sciences, Newark, DE.
Social housing is widely considered to be beneficial to the welfare of laboratory an-
imals, compared with single housing, and is recommended by the Guide for the
Care and Use of Laboratory Animals. Therefore, the impact of social housing on
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measurable neurobehavioral endpoints was evaluated. Socially defeated or submis-
sive rats exhibit body weight loss and decreased exploratory behavior relative to so-
cially dominant rats. It was hypothesized that any impact of social dominance on a
neurobehavioral endpoint (e.g., motor activity) would correlate with a difference in
bodyweight gain between the two pair-housed rats. However, the control data from
five 90-day studies (N=114) indicated no significant correlation between the differ-
ence in bodyweight gain within each cage and the difference in motor activity, grip
strength, hindlimb splay, or body temperature values within the same cages. Our
second objective was to optimize the use of a photobeam-based system which com-
putes multiple parameters for motor activity assessment and is widely used in the
industry. We evaluated baseline data from eight studies (N=816), to select two rep-
resentative motor activity parameters from a list of multiple options. Duration of
movement and number of ambulatory movements offered the greatest unique value
(lowest correlation coefficients) and were the best predictors (highest R-squared val-
ues) of the remaining motor activity parameters. A positive control study con-
ducted with carbaryl and amphetamine using pair housing conditions demon-
strated neurobehavioral effects that were consistent with previously published
literature. Based on the analysis of data from multiple studies including a positive
control, we concluded that pair housing does not interfere with neurobehavioral
evaluations and that motor activity can be characterized effectively using duration
of movement and number of ambulatory movements in a photobeam-based sys-
tem.
923 Feasibility Study of EEG Measurements in Chair Restrained
Cynomolgus Monkeys.
C. B. Rose,  S. H. Korte and B. Niggemann. Covance Laboratories GmbH,
Muenster, Germany. Sponsor: G. Weinbauer.
Quantitative EEG is one of the most sensitive non-invasive approaches for the de-
tection of drug effects on the brain. Therefore, a validation study was performed
using 4 male and 4 female cynomolgus monkeys. Two electrodes each were placed
on the frontal, central and occipital cortex, with the reference electrode either
placed at CZ (central region) or the mastoid. The electrode positions were calcu-
lated and marked with a tattoo on the head of the sedated animal 1-3 weeks before
start of EEG measurements to guarantee exact electrode placement over the course
of the study. The animals were habituated to the primate chair before start of the
study. At the day of EEG recordings, the animals were habituated to the room ap-
proximately 5-10 minutes prior to EEG recordings. Subcutaneous steel needle elec-
trodes as well as a reference electrode were fixed on the primate head and connected
to the EEG system (EEG Kit for Neuropack S1, MEB-9400, Nihon Kohden). For
determination of artefacts, ECG recordings were simultaneously performed.
Sedating effects were shown using the drug lorazepam. An intermittent slowing of
Delta- and/or Theta- waves was observed for all animals dosed intravenously with
0.2 mg/kg lorazepam, however the expected increase in frontal beta-activity was
only recorded after a lorazepam dose of 0.4 mg/kg. For the 0.4 mg/kg dose level, an
antidot was applied after sedating effects were observed in the EEG. To demon-
strate seizure-inducing effects, female animals of an inhouse project were treated
with pentylenetetrazole (PTZ) under anesthesia until seizures were visible.
Anesthesia was induced with ketamine, the animals were ventilated and anesthesia
was maintained with a mixture of oxygen and nitrous oxide. To avoid muscle arte-
facts in the EEG recordings, rocuronium was used as peripheral muscle relaxant.
Seizures were observed at a single intravenous dose of 20 mg/kg PTZ at a dose vol-
ume of 0.2 mL/kg. In conclusion, this validation study demostrated the feasibility
of EEG recordings in chair-restrained cynomolgus monkeys since sedating as well
as seizure-inducing effects could be demonstrated.
924 Characterization of Urinary microRNA in Cisplatin-Induced
Nephrotoxicity in Rats.
M. Kanki1,  A. Moriguchi1,  D. Sasaki1,  H. Mitori1,  A. Yamada2,  R. Hirota1 and
Y. Miyamae1. 1Astellas Pharma Inc., Osaka, Japan; 2Astellas Research Technologies
Co., Ltd., Osaka, Japan.
Recent studies with urinary microRNA (miRNA) report that some urinary
miRNAs detect renal dysfunction and histopathological damages. The purpose of
this study is to find urinary miRNAs that can detect the drug-induced nephrotoxi-
city in rat as one of novel biomarkers.
Male Sprague-Dawley rats were given a single intraperitoneal injection of saline (10
animals) or cisplatin (6 mg/kg, 20 animals) and the urine was collected from 4 to 5
days (17hr) after administration. To examine the effects of feeding condition, half
of animals in each group were fed and the others were fasted during urine collec-
tion. The kidney and serum were collected at 5 days after administration. Eighteen
protein biomarkers of nephrotoxicity in the urine were also measured. Urinary
miRNAs were individually isolated from 5 animals in each group and miRNA ex-
pression data was obtained by TaqMan® rodent microRNA array cards.
In cisplatin-treated groups, moderate or marked proximal tubular necrosis was ob-
served in the kidney and blood urea nitrogen and creatinine were significantly in-
creased in the serum. Furthermore, most of protein biomarkers were significantly
increased in the urine. There were no noteworthy differences in these items due to
the feeding conditions. Regarding miRNAs, approximately 80 miRNAs showed
statistically significant difference in the expression levels between fed and fasted
condition. These miRNAs might be affected by feeding condition and were ex-
cluded when we explore changed miRNAs in cisplatin-treated groups.
Approximately 30 miRNAs were found to be up- or down-regulated in cisplatin-
treated group regardless of feeding condition during urine collection. Some of up-
regulated urinary miRNAs, such as miR-192, were reported their expression in the
rat kidney, so that these miRNAs might be derived from the injured kidney tissue.
In conclusion, the feeding condition during urine collection affects the urinary
miRNA profiles and we could identify some of urinary miRNAs that can detect the
cisplatin-induced nephrotoxicity in rats.
925 Circulating miR-208a As Potential Cardiac Toxicity
Biomarker.
J. Wang,  L. Ling,  S. Aquirre,  W. W. Collette,  M. Ko,  F. Sace,  Q. Peng,
R. L. Yafawi,  Q. Zong and A. John-Baptiste. Drug Safety Research and
Development, Pfizer, La Jolla, San Diego, CA.
Literature is rife with information about several potential miRNAs that are in-
volved in acute cardiac injury. In this dose finding study, we evaluated miR-1, -
133a, -208a and -499-5p as potential biomarkers for cardiac injury in an oxidative
stress mouse model and compared them alongside Troponin I.
Isoproterenol Hydrochloride (80, 160 or 320 mg/kg) was administered to female
SOD2 +/- mice intraperitoneally once daily for one day to induce cardiac injury.
EDTA plasma samples were collected at 6 and 24 hours for assessing miR-1, -133a,
-208a, and -499-5p by Taqman real time PCR and Troponin I, the current golden
standard for detecting early cardiac injury via MSD® ELISA kit. Cardiac damage
was confirmed microscopically in heart tissues collected at day 10 and by measuring
conventional serum biomarkers ALT, AST, ALP and GLDH at day 10.
Treatment related findings at doses ≥ 80 mg/kg at 6 and 24 h consisted of increased
of cTn I in a dose-response fashion. Levels of cTn I declined after 6 hours.
Concordant with cTn I results, miR-208a was elevated significantly. A similar, yet
smaller, magnitude of response was noted for miR-499-5p while miR-1 and miR-
133a appeared to be the least sensitive. Microscopically, mild myocardial inflamma-
tion and fibrosis at the heart base was observed in some mice given 160 mg/kg
while ALT, AST, ALP and GLDH were not changed. 
In conclusion, the release profile of miR-208a is comparable to cTn I suggests its
utility as a putative cardiac injury biomarker. A dose level of 160 mg/kg caused sig-
nificant elevations in cTn I and miR-208a which correlated with histopathologic
findings in the heart.
926 Evaluation of the Pancreas-Specific microRNAs, miR-216a,
and miR-217 As Biomarkers of Acute Pancreatitis.
D. G. Goodwin,  J. Zhang,  S. R. Stweart,  L. Xu,  B. A. Rosenzweig,
K. L. Thompson and R. L. Rouse. CDER, US FDA, Silver Spring, MD.
Pancreatitis is a serious side effect associated with nearly half of the 100 most pre-
scribed medications that is often under- or misdiagnosed because of its non-specific
symptoms and the relative insensitivity of the clinical biomarkers, serum amylase
and lipase. MicroRNAs (miRs) are short, non-coding RNA sequences involved in
the regulation of gene expression. Serum miR-216a has been reported as a potential
biomarker of acute pancreatitis, and our results suggest that miR-217 may also
serve that purpose. miR-216a and miR-217 are selectively expressed in pancreatic
acinar cells and are present at very low or undetectable levels in serum under nor-
mal conditions. To further evaluate the possible utility of miR-216a and miR-217
as serum biomarkers of pancreatitis, we investigated their performance in models of
acute pancreatitis induced by caerulein, L-arginine, and ductile ligation in both rats
and mice. Liver and acute kidney injury models were used to demonstrate the
specificity of miR-216a and miR-217 for pancreatic injury. Both miR-216a and
miR-217 showed a time and dose dependent correlation with the severity of pan-
creatitis in each of the pancreatic injury models and with amylase and lipase levels.
The preliminary data suggest that miR-216a and miR-217 may be more sensitive
and specific indicators of pancreatic injury than amylase and lipase in mice and rats
and useful in pre-clinical drug development. Given the highly conserved nature of
these microRNAs, a translation to clinical use would be also anticipated.
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927 Multilaboratory Assessment of Best Practices for
Quantification of microRNAs Associated with Isoproterenol-
Induced Myocardial Injury in the Urine and Plasma of Rats.
K. Thompson1,  S. J. Nielsen2,  T. Chen3,  P. Couttet4,  H. Ellinger-Ziegelbauer5,
M. Kanki6,  J. Kelsall7,  E. Boitier8,  R. Nassirpour9,  G. Searfoss10,  C. Spire11,
P. Yuen12 and R. O’Lone13. 1CDER, Silver Spring, MD; 2Exiqon, Vedbæk,
Denmark; 3NCTR, Jefferson, AR; 4Novartis Pharma AG, Basel, Switzerland; 5Bayer
Pharma AG, Wuppertal, Germany; 6Astellas Pharma Inc, Osaka, Japan;
7AstraZeneca, Macclesfield, United Kingdom; 8Sanofi, Vitry-sur-Seine, France; 9Pfizer,
Andover, MA; 10Lilly, Indianapolis, IN; 11Servier, Gidy, France; 12NIDDK, NIH,
Bethesda, MD; 13ILSI Health and Environmental Sciences Institute, Washington DC.
MicroRNAs are promising noninvasive biomarkers of drug-induced toxicities due
to their tissue-selective expression, rapid release post-injury, and stability in bioflu-
ids, but their low levels in biofluids present challenges to their reliable quantifica-
tion. The HESI Genomics committee initiated a collaborative study to assess best
practices for measuring injury-related microRNAs in biofluids. Samples were de-
rived from a model of acute cardiotoxicity in male Wistar rats induced by a single
s.c. injection of 0.5 mg/kg isoproterenol. The heart-enriched microRNAs miR-
208, miR-499, and miR-1 increased by approximately 10-fold in serum and plasma
4 hr after treatment. In a follow-up study using the same model system, urine was
collected overnight and plasma at 24 hr post-injection. Biofluids were pooled from
5 rats per group and aliquots were sent to 10 laboratories for analysis of levels of the
3 heart-enriched microRNAs. At each site, samples were assayed using a standard
protocol and the data normalized to levels of a spiked-in ath-miR159a control.  The
results from this interlaboratory analysis of multiple preanalytical and technical is-
sues provide guidelines for the accurate measurement and reporting of injury-re-
lated microRNAs in biofluids.
928 Circulating mIR-9* and mIR-384-5p As Potential Indicators
for Trimethyltin-Induced Neurotoxicity.
K. Ogata1, 2,  K. Sumida1,  K. Miyata1,  M. Kushida1,  M. Kuwamura2 and
J. Yamate2. 1Environmental Health Science Laboratory, Sumitomo Chemical Co.,
Ltd., Osaka, Japan; 2Laboratory of Veterinary Pathology, Division of Veterinary
Sciences, Graduate School of Life and Environmental Sciences, Osaka Prefecture
University, Izumisano, Japan. Sponsor: T. Yamada.
MicroRNAs (miRNAs) are believed to be promising biomarkers due to their tissue-
specific expression and high stability in blood. Our study was conducted to deter-
mine nervous system-specific miRNAs in blood as potential indicators for neuro-
toxicity. Using trimethyltin (TMT)-induced neurotoxicity model, we analyzed
serum miR-9* and miR-384-5p which were reported to be highly or specifically ex-
pressed in the nervous system, and compared the sensitivity as neurotoxicity pa-
rameters with nervous symptoms and histopathology. 
Seven-week-old SD rats were orally given a single dose of 6, 9 and 12 mg/kg of
TMT. Nervous tissues (brain, spinal cord and sciatic nerve) and blood were col-
lected 1, 4 and 7 days after administration (D1, 4 and 7). Daily observation of
symptoms and histopathology were conducted. Immunohistochemistry (PCNA,
GFAP, Iba1) and TUNEL method were performed on brain. Expressions of miR-9*
and miR-384-5p in serum and hippocampus were analyzed by RT-PCR.
TMT induced tremor, hypersensitivity and decreased auditory response after D2 at
12 mg/kg and after D4 at 9 mg/kg. Neural cell death including apoptosis and glial
reaction in cerebrum (mainly hippocampus) and cerebellum was observed after D1
at 12 mg/kg and after D4 at 6 and 9 mg/kg, and the severities increased in a dose-
and time-dependent manner. 
Expression levels of miR-9* (D4 and 7 at 12 mg/kg and D7 at 6, 9 mg/kg) and
miR-384-5p (D4 at 9 mg/kg, D7 at 12mg/kg) in serum were significantly higher
than the vehicle control, but not changed in hippocampus. Increased serum level of
these miRNAs might be due to leakage from damaged nervous tissue. 
The detection sensitivity of neurotoxicity of serum miR-9* miR-384-5p was simi-
lar to observation of nervous symptoms, therefore they were considered possible
novel indicators of neurotoxicity.
929 Assessment of microRNA 122 As a Preclinical and Clinical
Biomarker of Hepatotoxicity Utilizing Affymetrix
QuantiGene Technology.
S. J. Schomaker1,  D. Burt1,  R. Warner2,  K. Johnson2 and J. Aubrecht1. 1Safety
Sciences, Pfizer Inc, Groton, CT; 2Department of Pathology, University of Michigan
Medical School, Ann Arbor, MI.
Hepatotoxicity is major challenge in drug development. While alanine aminotrans-
ferase (ALT) remains the gold standard biomarker of liver injury, the availability of
alternative biomarkers to better predict the potential for drug induced liver injury is
essential. In this study we evaluated the utility of miRNA122 as a biomarker of liver
injury in both preclinical and clinical serum samples utilizing Affymetrix
QuantiGene Technology. The Affymetrix system is a 96-well plate based assay that
uses a sandwich nucleic acid hybridization platform to detect miRNA directly with-
out a reverse transcription step followed by signal amplification via a branched
DNA amplifier and chemiluminescence signal generation. In this study, male
Sprague-Dawley rats were treated with a single dose of 1400mg/kg acetaminophen
(APAP), 100mg/kg napthylisothiocyanate (ANIT), or 0.2mg/kg microcystin-LR
(MC) to induce hepatocellular necrosis which was confirmed by histopathological
examination. Statistically significant increases (p<0.01 ) in miRNA122 were ob-
served after treatment with all three of the model hepatotoxicants. miRNA122 was
also assessed in cohorts of human subjects including 27 healthy subjects, 31 pa-
tients with a variety of liver impairments, and 7 cases of APAP poisoning collected
from the University of Michigan health care system under an approved IRB. In the
absence of histopathologic evaluation that was not feasible due to ethical and prac-
tical reasons, miRNA122 values were correlated with ALT levels as an indicator of
liver injury. A Spearman’s rank correlation analysis between miRNA122 and ALT
of the 65 human samples yielded a correlation coefficient of rs=0.88. Analysis of
miRNA122 in the APAP poisoned subjects resulted in increases of 13-95 fold when
compared to miRNA122 levels from healthy subjects. This study demonstrates the
utility of miRNA122 as a preclinical and clinical biomarker of liver injury utilizing
Affymetrix QuantiGene Technology.
930 Urinary microRNA Profiles After Glomerular vs Proximal
Tubular Injury.
B. Riefke2,  M. Pavkovic1,  I. Groeticke1,  A. Frisk2,  F. McDonald2 and
H. Ellinger-Ziegelbauer2. 1Bayer Pharma AG, Wuppertal, Germany; 2Bayer Pharma
AG, Berlin, Germany.
MicroRNAs (miRNAs) are small, conserved, non-coding RNAs that modulate
gene expression post-transcriptionally. They are remarkably stable in various body
fluids like urine and thus suggested as new non-invasive biomarkers (BM) of tissue
injury, especially since some miRNAs are produced in cell- or tissue specific man-
ners offering the possibility to identify the site of injury. Furthermore, their tissue
expression profiles may be used for investigation of the mechanistic details of com-
pound-induced toxicities. 
We investigated miRNAs in urine of male Crl:WI (Han) rats rats treated with
nephrotoxicants: Cisplatin (Cp), to specifically elicit proximal tubular injury; and
male Wistar Kyoto rats treated with a nephrotoxic serum (NTS) containing anti-
bodies against the glomerular basement membrane to induce glomerular damage.
The expected tissue injury was confirmed by histopathology. Total RNA including
small RNAs was isolated from urine on day 3, 5, 8, 15 and 26 after a single dose of
Cp (0, 1 and 3 mg/kg) and on day 8 and 14 after NTS injection (0.1, 0.25 and 0.5
mL/100g bw). Urinary miRNA profiles were measured with TaqMan® MicroRNA
Cards (TLDAs). MiRNA levels were normalized to a non-endogenous spiked-in
control miRNA and to urinary creatinine. Comparing Cp-high dose vs. control
samples and NTS-high dose vs. control samples we identified 131 and 68 miRNA,
respectively, with significantly increased urinary levels. About 65 miRNAs were af-
fected by both treatments, whereas app.10 and 35 urinary miRNAs were exclusively
affected by NTS and Cp treatment, respectively. Furthermore, TLDA analysis of
kidneys from NTS-treated rats showed deregulation of many miRNAs upon
glomerular injury.
Our results suggest that urinary miRNAs may be used as promising new and site-
specific BMs for nephrotoxicity and encourage further investigations of their role in
different types of kidney injury.
931 Proposed Workflow for microRNA Analysis in Urine.
H. Ellinger-Ziegelbauer1,  M. Pavkovic1,  B. Riefke2 and R. Khan-Malek3. 1Bayer
Pharma AG, Wuppertal, Germany; 2Bayer Pharma AG, Berlin, Germany; 3Sanofi-
Aventis, Bridgewater, NJ.
MicroRNAs (miRNAs) have emerged as new non-invasive biomarkers (BMs) for
various diseases and tissue injuries due to their release into body fluids upon tissue
damage. At least some of these miRNAs are produced in a cell- or tissue specific
manner.
For evaluation of miRNAs, urine was collected from male Wistar rats treated with
the nephrotoxicant Cisplatin (Cp). Tissue injury was confirmed by histopathology.
Total RNA was isolated from urine on days 3, 5, 8, 15 and 26 after a single dose of
Cp (0, 1 and 3 mg/kg). Using TaqMan® MicroRNA Cards (TLDA) urinary
miRNA profiles were measured. Since currently a commonly accepted endogenous
control miRNA is not available, and since we could not identify invariant miRNAs
in our study, we describe here a normalization procedure based on the spiked-in
control miRNA (ath-miR159a) and urinary creatinine (uCrea). For other urinary
BMs uCrea is commonly used to account for different urine volumes.
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For the TLDA– derived PCR data, a modified ΔΔCt method was applied: delta-Ct
values obtained by subtracting ath-miR-159a Cts from target miRNA Cts were de-
logarithmized and divided by the corresponding uCrea value. This normalization
reduced the variation of the delta-Ct values for miRNAs across samples. Then ra-
tios were calculated between treated and time-matched control groups. With this
method we identified 131 miRNAs with significantly increased urinary levels on
days 3 and 5. Twenty miRNAs with distinct time-dependent profiles were then
measured using TaqMan® MicroRNA Assays. The data were analysed either with
the modified ΔΔCt method, or absolutely quantified using synthetic miRNA stan-
dard curves run in parallel. With both methods we obtained comparable results
with respect to observed direction of changes and time course of affected urinary
miRNAs.
Our results indicate that urinary miRNAs may be used as BMs for nephrotoxicity
in rats.
Furthermore, normalization to uCrea, which is recommended for urinary BMs, ap-
pears feasible for analysis based either on the PCR-generated Ct values only, or in-
cluding absolute quantification.
932 MiR-122 Is a Sensitive Indicator of Stem Cell-Derived
Hepatocyte-Like Cell Maturity with Utility in
Hepatotoxicity Screening.
C. Rowe,  C. Goldring,  L. Kelly,  N. Hanley,  H. Z. Malik,  R. Jones,  D. Tosh,
R. Kia,  N. R. Kitteringham and B. Park. MRC Centre for Drug Safety Science,
University of Liverpool, Liverpool, United Kingdom. Sponsor: D. Mendrick.
Consistent differentiation of embryonic, or induced pluripotent, stem cells into
functional hepatocyte-like cells available on demand for hepatotoxicity screening
would be a valuable resource for drug development programs. Assessments of stem
cell-derived hepatocyte-like cell maturity often lack quantitative comparisons with
primary human hepatocytes and the presumed fetal-like phenotype currently
achieved is concluded from observations of cell morphology and the detection of a
small number of proteins such as albumin, alpha fetoprotein and alpha 1 antit-
rypsin. The identification of a hepatocyte-specific marker that can be quantified ab-
solutely would aid the assessment of cells and be useful for inter-laboratory com-
parisons. miRNA-122 is a micro-RNA species that is very highly enriched in
hepatocytes. We hypothesised that this molecule would be a useful biomarker of
differentiation and could also serve as a more sensitive indicator of hepatocyte-spe-
cific injury. Our study demonstrates that miR-122 is a specific and sensitive marker
of hepatocyte phenotype, present at high levels in primary human hepatocytes and
in fetal liver samples but of low abundance or absent in hepatoma and non-hepatic
human cell lines. Expression of miR-122 was greatly elevated in stem cell-derived
hepatocyte-like cells compared to the undifferentiated stem cell lines. Furthermore
we demonstrate miR-122’s utility as a sensitive marker of hepatotoxicity in primary
hepatocytes and a potential adjunct to screens such as lactate dehydrogenase release
and ATP depletion. We conclude that quantitative measurement of miR-122 may
be used as sensitive and specific marker during the hepatocyte differentiation
process or to confirm the hepatocyte-like status of stem cell-derived material fol-
lowing hepatotoxicity screening assays.
933 Potential Utilization of microRNA As Circulating
Biomarkers in Th2-Mediated Disorders Such As Asthma and
Ulcerative Colitis.
H. Lin1,  M. Kasaian2,  A. Brennan2 and S. Ramaiah1. 1DSRD, Pfizer Inc.,
Andover, MA; 2Immunology & Autoimmunity, Pfizer Inc., Cambridge, MA.
MicroRNAs (miRNAs) are single-stranded RNAs which constitute a class of non-
coding RNAs which have emerged as key regulators of gene expression. They are
generally thought to inhibit translational activities or promote degradation of
mRNA targets. miRNA profiles have been proposed as a diagnostic tool to predict
survival and relapse in lung and colon cancer patients. Moreover, circulating
miRNAs have been proposed as a new class of biomarker of human diseases and
toxicities. IL-4 and IL-13 are central Th2 cytokines in the immune system and po-
tent activators of inflammatory responses during Th2-mediated inflammation. In
particular, an essential role for Th2-mediated immune response has been demon-
strated in animal models of allergic asthma and experimental colitis. We hypothe-
sized that miRNAs may be involved in the homeostatic regulation of IL-4/-13 ex-
pression in disease, or may be modulated during the course of therapeutic
antagonism of IL-4/-13 in order to maintain homeostasis of IL-4/-13 expression.
Using web based databases that provide literature information on the predicted
mRNA targets of miRNAs related to the Th2 immune response, distinct subsets of
miRNAs were selected and used to construct a Taqman miRNA assay panel for
miRNA screening of sera from asthmatic and ulcerative colitis patients. We found
that the profile of circulating miRNAs is capable of distinguishing healthy volun-
teers from patients with asthma or ulcerative colitis. The results described here have
implications for the use of serum or plasma miRNA profiles as biomarkers for Th2-
associated diseases. The overlap with tissue miRNA expression as described in the
literature suggests that circulating miRNA expression may be a sensitive indicator
of disease activity in the target organ.
934 Circulating Nucleic Acids As Lead Exposure Biomarkers in a
Mammalian Model System.
S. Lee and M. E. Gillespie. Pharmaceutical Sciences, St. John’s University, Queens,
NY.
Exposure to lead (Pb) causes numerous deleterious health effects including devel-
opmental and cognitive abnormalities in children. Early detection of lead exposure
is critical to reduce serious health problems arising from chronic lead toxicity.
Circulating nucleic acid based biomarkers are present in various bodily fluids such
as blood, serum, and urine. A number of studies have reported the use of circulat-
ing nucleic acids as biomarkers for pathological conditions and developmental
stages. In this study, a Long Evans rat model system is used to identify lead expo-
sure-induced circulating nucleic acid biological markers in peripheral blood. Two
different groups of animals are used, females and time-pregnant Long Evans rats.
Females are exposed to 112 parts per million (ppm) Pb (lead acetate) via drinking
water ad libitum for 5 days then switched to 19 ppm Pb treatment for an additional
15 days. Dams are exposed to 112 ppm Pb (lead acetate) via drinking water ad libi-
tum from gestation day 16 through 21 then switched to 19 ppm Pb treatment on
postnatal day 1 through 15. Animals are euthanized at the conclusion of treatment
and blood and brain tissue are collected for analysis. Inductively coupled plasma
optical emission spectrometry (ICP-OES) is used to determine blood lead levels of
all samples. A microarray approach was initially used to identify differentially ex-
pressed circulating nucleic acid sequences only present in animals exposed to Pb.
This data highlighted 3 genes of interest: Nt5c3, Skap1, and Coq7. Circulating nu-
cleic acid expression levels in blood samples will be quantified using real-time RT-
PCR analysis. Comparison between lead exposed females and pregnant females will
identify unique genes as biomarkers of lead exposure and confirm the origin of the
circulating nucleic acids.
935 Examination of Oxidative Stress As a Possible Risk Factor for
Colorectal Cancer Susceptibility.
R. Sellamuth,  S. Dickinson,  Z. Wang,  S. Zhou and J. E. Klaunig. Indiana
University, Bloomington, IN.
The present study investigated the role of oxidative stress as a possible risk factor for
colorectal cancer in humans. Blood samples were collected from 232 subjects in-
cluding 102 healthy controls, 90 patients with polyps, 39 patients diagnosed with
colorectal cancer. We measured both direct and oxidative DNA damage in periph-
eral white blood cells (WBCs) using alkaline (direct DNA damage) and formami-
dopyrimidine DNA glycosylase modified (oxidative DNA damage) Comet assay.
Trolax equivalent total antioxidant capacity (TEAC) in plasma was also determined
spectrophotometrically. Results showed that Oxidative Stress induced DNA dam-
age was associated with a significantly higher probability of colorectal cancer in
males (p = 0.008) but not in females (p = 0.675) compared to healthy controls.
Direct DNA damage also showed a marginally significant effect on colorectal can-
cer (p = 0.071). Results from the TEAC assay showed a positive trend on colorectal
cancer, but was not statistically significant (p = 0.230). Oxidative stress induced
DNA damage, TEAC, and direct DNA damage did not show significant relation-
ships with probability of polyps. Females showed significantly higher probability of
developing polyps (p < 0.01); and older patients showed significantly lower proba-
bility of polyps in this study (p < 0.001). Further, these results were not affected by
life-style related oxidative stress such as smoking and alcohol. Selected SNPs for ox-
idative damage, detoxification and DNA repair were examined. Initial results sug-
gested a correlation between SNPs in hOGG and GSTM and colorectal cancer.
The results of this study suggest that high level of oxidative stress induced DNA
damage is associated with increased risk of colorectal cancer in males, not in fe-
males.
936 Circulating mRNA Changes in Rat Serum Associated with
Drug-Induced Vascular Injury.
M. Scicchitano,  D. Dalmas,  K. Roland and H. Thomas. GlaxoSmithKline, King
of Prussia, PA.
Drug–induced vascular injury (DIVI) continues to be an obstacle to early drug-de-
velopment due to the lack of biomarkers and by a limited understanding of the
pathologic mechanism/s. Recently, a novel gene panel has been developed, for use
in rat mesenteric arteries, which can potentially be used to identify and/or predict
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the occurrence of drug-induced medial arterial necrosis (MAN) in rats; however, a
non-invasive method for detecting this type of injury is currently lacking. To deter-
mine whether these genes regulated in mesenteric arteries have the potential to be
utilized as circulating serum genomic biomarkers, the gene panel was assessed in
mRNA isolated from the serum of rats given a vasotoxic dose of Fenoldopam or
Dopamine and compared to mRNA data obtained from serum of rats given
Yohimbine, a vasoactive compound which does not cause histologic evidence of
vascular injury. Out of the 69 potential circulating biomarkers, 10 genes, including
Lrrc59, Tubb6, Kpna2, Abca8a, Pros1, S100a11, IL-8R, CTGF, Nfkbiz, and Daf1,
were observed to be upregulated (5 fold or greater) and correlated with histologic
evidence of MAN following treatment with a vasotoxic dose of Fenoldopam. Six of
the 10 genes including Lrrc59, Abca8a, S100a11, IL-8R, Nfkbiz and Daf1, were
also upregulated (4 fold or greater), in the serum of rats given Dopamine. With ex-
ception of S100a11, these genes were not regulated in the serum of rats given
Yohimbine thereby, providing further evidence of their association with vascular in-
jury, namely mesenteric MAN. Although further studies are required to fully assess
the utility of these serum-derived mRNAs as biomarkers of DIVI, they have the po-
tential to help improve the characterization of DIVI in rats for early safety assess-
ment in drug development.
937 Identification and Quantitative Evaluation of Novel
Circulating Liver-Specific mRNAs in Rats Treated with
Various Hepatotoxic Compounds: Validation for Biomarkers
of Drug-Induced Liver Injury.
S. Okubo1, 2,  M. Miyamoto1, 2,  K. Takami1, 2,  M. Kanki2, 3,  A. Ono2, 4,
N. Nakatsu2,  H. Yamada2,  Y. Ohno4 and T. Urushidani2, 5. 1Drug Safety Research
Laboratories, Takeda Pharmaceutical Company Limited, Kanagawa, Japan;
2Toxicogenomics Informatics Project, National Institute of Biomedical Innovation,
Osaka, Japan; 3Astellas Pharmaceutical Incorporated, Osaka, Japan; 4National
Institute of Health Sciences, Tokyo, Japan; 5Doshisha Women’s College of Liberal Arts,
Kyoto, Japan.
In our previous report, circulating liver-specific albumin (Alb) and α-1 microglob-
ulin/bikunin precursor (Ambp) mRNAs have been shown to be potential biomark-
ers for drug-induced liver injury (DILI). We identified apolipoprotein h (Apoh)
and group specific component (Gc) mRNAs as additional biomarkers, and quanti-
fied total of four mRNAs in plasma from rats treated with wide variety of hepato-
toxicants to validate circulating liver-specific mRNAs as biomarkers for DILI.
Bioinformatic and molecular biological analyses revealed the high liver-specificity
of Apoh and Gc mRNAs, and increased plasma levels of these mRNAs were con-
firmed by real-time quantitative RT-PCR in rats treated with thioacetamide (TAA).
To examine the characters of the four circulating liver-specific mRNAs, seven hepa-
totoxicants were administered to rats. The severities of liver injury were variable
among individuals and compounds. At 24 hr after single dosing, parallel increases
of the four circulating liver-specific mRNAs were noted and the levels correlated
with changes in the ALT values and hepatocellular necrosis scores. In addition, all
the four mRNAs increased with greater magnitude than the ALT values. Time
course analysis within 24 hr after single dosing of TAA showed that the plasma lev-
els of Alb and Gc mRNAs increased remarkably before the ALT elevations and the
timing of the increase was different among mRNA species, indicating that circulat-
ing liver-specific mRNAs may predict the beginning of liver damage and enable us
to know the stages of injury. This validation study clearly demonstrated that the
four circulating liver-specific mRNAs would be reliable and useful biomarkers for
DILI.
938 Metabolomics and Transcriptomics Evaluation of Preclinical
Biomarkers of Hepatotoxicity: An Update.
R. D. Beger1,  L. K. Schnackenberg1,  S. Jinchun1,  L. Pence1,  T. Schmitt1,
Y. Ando2,  X. Yang1,  J. Greenhaw1,  S. Slavov1,  S. Bhattacharyya1, 3,
W. F. Salminen1 and D. L. Mendrick1. 1NCTR, US FDA, Jefferson, AR; 2Daiichi
Sankyo Co. Ltd., Tokyo, Japan; 33Arkansas Children’s Hospital Research Institute,
Little Rock, AR.
Drug-induced hepatotoxicity represents a major reason that drugs are recalled post
market. Furthermore, it has been estimated that 10% of acute liver failure is due to
idiosyncratic events. While there is no standard definition for “idiosyncratic,” the
term is generally applied to compounds that induce a relatively low incidence of he-
patotoxicity in humans and fail to exert liver damage using classical toxicity end-
points in commonly used preclinical testing species such as rats and dogs. The in-
ability to identify such compounds with classical preclinical markers of
hepatotoxicity has necessitated the need to discover new biomarkers. In order to
identify biomarkers of idiosyncratic toxicity, a systems biology study was initiated
to evaluate omics endpoints in urine, blood and liver tissue from rats dosed with
compounds that have been shown to be overt hepatotoxicants, idiosyncratic hepa-
totoxicants, and negative hepatotoxicants. The two overt hepatotoxicants were acet-
aminophen (APAP) and carbon tetrachloride (CCl4). Three additional compounds
have been studied; one is generally classified as idiosyncratic in nature, felbatol
(FEL), while the other two are considered to not cause liver injury, meloxicam
(MEX) and penicillin (PEN). Since idiosyncratic and non-hepatotoxicant drugs do
not cause overt hepatotoxicity, doses were used to induce some adverse effect (e.g.,
a decrease in body weight) to provide a phenotypic anchor. Early results show that
increases in blood levels of multiple acyl carnitines could be an indication of hepatic
mitochondrial injury and altered levels of bile acids may be related to drug-induced
hepatotoxicity, activation of liver transporters or due to effects on gut microflora.
Blood levels of lysoPCs were decreased in the rats treated with a high dose of APAP,
CCl4 and FEB at 6 and/or 24 hr.
939 Whole Transcriptome RNA-Seq of FFPE Liver.
S. S. Auerbach1,  B. A. Merrick1,  R. R. Shah2,  D. Phadk2,  B. Xie3,  J. Shin3,
Y. Gao3 and R. R. Tice1. 1Division of the National Toxicology Program, NIEHS,
Research Triangle Park, NC; 2SRA International, Durham, NC; 3Lieber Institute for
Brain Development, Johns Hopkins University, Baltimore, MD.
Formalin fixed, paraffin embedded (FFPE) pathology specimens represent a poten-
tially rich resource for trancriptomic-based biomarker discovery. While a number of
approaches have been developed that employed targeted, amplification dependent
microarray analysis, no one has employed the agnostic approach of whole transcrip-
tome RNA-seq to the analysis of RNA extracted from FFPE samples. Here, we
compare whole transcriptome using RNA-seq  performed on fresh frozen (FF) and
FFPE RNA samples obtained from Fischer F344 rats exposed to Aflatoxin B1
(AFB1) at 1 ppm in feed for 90d and paired control animals. ~70% of reads gener-
ated from each FFPE sample aligned to Rn4and mapping corresponded well with
defined transcription boundaries for most RefSeq genes. Whole transcriptome PCA
indicated clear distinction between FFPE and FF however robust, parallel differen-
tiation between AFB1 and control samples was obvious in both data sets. A rank
based comparison of global transcript abundance was strongly correlated between
FF and FFPE, suggesting the global liver biology at the transcript level remained in-
tact in the FFPE samples. Differential expression analysis indicated that of the 405
RefSeq genes altered by AFB1 in FF samples, 288 (of 487 showing differential ex-
pression) were also differentially expressed in FFPE samples. Expression of selected
genotoxic carcinogenicity biomarker genes (e.g., Adam8, Mybl2, Cdh13, Ccng1,
Ddit4l, Cdkn1c) were concordantly up-regulated in FF and FFPE by AFB1 treat-
ment. Comparison of the genomic response to AFB1 in FF and FFPE at a pathway
level using GSEA found concordant regulation of cell cycle, autophagy, xenobiotic
metabolism, and p53 signaling and discordant regulation of proteomsome and
NOD-like signaling pathways. We have demonstrated that accurate whole tran-
scriptome profiling is possible with RNA extracted from FFPE samples. The sucess
of this approach opens up new avenues for performing signature-based biomarker
discovery.
940 Hepatic Hemangiosarcoma Due to Occupational Vinyl
Chloride Exposure Generates a Distinct Plasma Metabolite
Profile.
M. Cave1, 2,  B. Wheeler1,  K. Falkner1 and C. McClain1, 2. 1Department of
Medicine/GI, University of Louisville, Louisville, KY; 2Louisville VAMC, Louisville,
KY.
Occupational vinyl chloride (VC) exposure has been associated with the develop-
ment of hepatic hemangiosarcoma (HS), an extremely aggressive and otherwise un-
usual form of liver cancer. Routine liver biochemistries are typically normal even in
advanced hemangiosarcoma. The purpose of this study is to determine if VC-re-
lated hemangiosarcoma alters the plasma metabolome. Plasma samples from 16
highly-exposed VC workers with hemangiosarcoma (VC+/HS+), 17 highly-ex-
posed VC workers without hemangiosarcoma (VC+/HS-), and 27 unexposed
healthy volunteers (VC-/HS-) were obtained from a specimen bank. GC/MS and
LC/MS2 were performed following metabolite extraction. Software was used to
match ions to a library of standards for metabolite identification and quantitation
by peak area integration. Random Forest analysis was performed. Welch’s Two
Sample t-test comparisons were made between the means of each biochemical.
Results of Random Forest analyses of all 613 named and 518 unnamed biochemi-
cals observed in plasma yielded an overall predictive accuracy of 82% for classifying
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samples within each group, strongly indicating that hemangiosarcoma generates a
distinct global metabolic profile in plasma from those that were exposed but failed
to develop the disease. When comparing VC+/HS+ vs. VC+/HS-, 65 named bio-
chemicals were up-regulated while 50 were down-regulated. Likewise, 43 unnamed
biochemicals were up-regulated and 27 were down-regulated. Four key metabolite
subclasses containing named biochemical were identified. Hemangiosarcoma in-
creased metabolite levels in these classes accordingly: Class A (8/10 metabolites, up
to 6 fold increase); Class B (5/7 metabolites, up to 121 fold increase); Class C (3/3
metabolites, up to 84 fold increase); Class D (9/15 metabolites, up to 92 fold in-
crease). In chemical workers with high-level vinyl chloride exposures, hemangiosar-
coma generates a distinct plasma global metabolic profile from those that were ex-
posed but failed to develop the disease.
941 Metabolomic Biomarkers in Long-Term Smokers and Moist
Snuff Consumers.
G. L. Prasad1,  B. A. Jones1,  P. Chen1 and A. D. Kennedy2. 1R & D, RJ Reynolds
Tobacco Co., Winston-Salem, NC; 2Metabolon Inc, Durham, NC. Sponsor: G.
Krautter.
The long-term health effects associated with cigarette smoking have been shown to
be more harmful compared to those associated with the use of non-combustible to-
bacco products, such as moist snuff. To investigate the long-term effects of tobacco
exposure, we evaluated the biochemical profiles of 40 smokers, 40 moist snuff con-
sumers (MSC), and 40 non-tobacco consumers (NTC) using UHPLC-mass-spec-
trometry based global metabolomics. Matching twenty-four-hour urine and plasma
samples were collected from study subjects to generate metabolomic profiles. In this
global profiling study, a total of 511 biochemicals (290 known and 221 unknown
metabolites) were detected in the plasma, whereas 972 biochemicals (396 known
and 596 unknown) were found in urine. The “named” metabolites could be
grouped into diverse physiological pathways such as glucose, lipid, bile acid and
amino acid metabolism. 
Based on the differential levels of metabolites, random forest analyses separated
non-tobacco consumers (NTC), smokers, and MSC with high accuracy (96%)
when all metabolites were included. On the other hand, MSC showed more subtle
changes in metabolomic profiles, and were more difficult to separate from NTC
when nicotine metabolites were excluded from the analyses. The metabolomic
changes suggest that smokers exhibited exacerbated oxidative stress and inflamma-
tory pathways relative to MSC and NTC cohorts. Biochemical changes in glucose,
lipid amino acid and xenobiotic metabolism were also noted in the study cohorts.
These metabolites could be used as potential biomarkers of effect, pending further
validation. In summary, global metabolomic profiles and panels of selected bio-
markers could potentially be used to assess the effects of tobacco use.
942 Effect of Benzo(a)pyrene Exposure Dose on Levels of
Exposure Biomarkers, DNA Adducts, and Gene Expression
in Rats.
M. Moreau1,  P. Ayotte2 and M. Bouchard1. 1Department Environmental and
Occupational Health, University of Montréal, Montréal, QC, Canada; 2Institut
national de santé publique du Québec, Québec, QC, Canada.
The effect of benzo(a)pyrene (BaP) doses on levels of several biomarkers of expo-
sure and early effects was studied in rats intravenously injected with 0.4, 4, 10 and
40 μmol/kg of BaP. Blood, tissues and excreta were collected 8 h and 24 h post-
treatment. BaP and several of its metabolites, 3- and 7-OHBaP, 4,5- and 7,8-
BaPdiols, tetrol, 1,6-, 3,6- and 7,8-BaP-diones, were simultaneously measured in
blood, tissues and excreta by UHPLC/fluorescence. BaPDE-DNA adducts in lungs
were quantified in parallel using an ultrasensitive immunoassay with chemilumi-
nescence detection. Expression of various genes in lungs of treated rats (lung RNA)
compared to control rats was also assessed by qRT-PCR. There was a dose-depend-
ent increase in blood and tissue levels as well as excretion of BaP metabolites. At 8
h and 24 h postinjection, BaP and 3-OHBaP were found in higher concentrations
in blood and tissues compared to the other analytes. However, BaPdiols were ex-
creted in greater amounts in urine and apparently more quickly than hydroxyBaP.
Mean percentages (± SD) of injected dose excreted in urine as 4,5-diol-BaP during
the 0-8 and 0-24-h period post-treatment were 0.16 ± 0.03% and 0.14 ± 0.08%,
respectively. Corresponding values for 3-OHBaP were 0.004 ± 0.001% and 0.026
± 0.014%. Diones were not detectable in blood, tissues and excreta using the de-
veloped method and BaP-7,8-diol and 7-OHBaP were found to be more minor
metabolites. There was also a dose-dependent increase in DNA adduct formation.
Analysis of gene expression further showed a modulation of cyp1a1, cyp1b1, nqo1,
nrf2, fos and Ahr expression at the 10 and 40 μmol/kg doses, but not at the lower
doses. This study confirms the interest of measuring multiple metabolites in com-
bination with DNA adducts and alteration of gene expression for a more compre-
hensive assessment of links between biomarkers of BaP exposure and early effects.
943 Biomarker Discovery for Early Detection of Hepatocellular
Carcinoma (HCC) in Hepatitis C (HCV) Infected Patients.
G. M. Mustafa1,  J. R. Petersen1,  J. Hyunsu1,  L. Cicalese1,  N. Snyder2,
S. J. Haidacher1,  L. Denner1 and C. Elferink1. 1University of Texas Medical
Branch, Galveston, Galveston, TX; 2Kelsey Seybold Clinic, Galveston, TX.
The projected rise in HCC (the most common primary liver cancer) cases in the
US is mainly due to HCV infections with onset of HCC coming several decades
after initial infection. However, additional environmental risk factors including al-
cohol, tobacco and other dietary insults that induce liver injury also increase the in-
cidence of HCC. The poor prognosis for HCC is largely due to late stage diagnosis
making successful intervention difficult. Existing biomarkers for early HCC detec-
tion lack the specificity and sensitivity to be very effective. Our aim is to develop
serum-based biomarkers suitable for early HCC detection that will provide a sensi-
tive yet specific screen. Serum was obtained from individuals positive for HCV who
were clinically diagnosed with liver disease (pre-HCC) or HCC. Serum was pre-
fractionated using an aptamer-based technology and further fractionated using 2D-
Difference In Gel Electrophoresis. Pre-HCC and HCC profiles were compared and
the peptides located in 24 different 2D-DIGE spots exhibiting a statistically signif-
icant ≥1.5-fold change between pre-HCC and HCC samples were identified by
mass spectrometry (MS). Stable isotope O18/O16 labeling was used to verify the
identity of proteins identified by 2D-DIGE and to aid in development of Selected
Reaction Monitoring (SRM) assays. ApoA1 was selected to develop an SRM as
proof of concept in this biomarker discovery protocol. Using a Triple Quadrupole
MS (Agilent), Optimizer (Agilent) and skyline (MacCoss) to assist in the design we
developed an SRM assay to quantify this candidate biomarker using labeled inter-
nal standards (AQUA peptides). The SRM is capable of reliably detecting a >30%
reduction in ApoA1 in HCC serum samples relative to the pre-HCC samples.
Future multiplexing of SRM assays for other candidate biomarkers is envisioned to
develop a biomarker panel for subsequent verification and validation studies.
944 Effects of Acrylamide Exposure on Gene Expression in the
Thyroid of Male and Female Rcchan Wistar Rats.
R. C. Colli-Dula1,  M. A. Friedman2 and N. Denslow1. 1CEHT, University of
Florida, Gainesville, FL; 2TR Services, Oviedo, FL.
Acrylamide is a chemical commonly utilized to make polymers used in industry in-
cluding waste water treatment, mining, among other uses. It became a public
health concern when it was detected in food products. Daily exposure to acry-
lamide has been associated with neurological toxicity in different animal species
and with tumors in the mammary gland, testicular tunica vaginalis, and thyroid. In
relation to its potential for forming tumors, it is important to distinguish its ability
to act as genotoxin from a hormone mimic. The goal of this study was to use mi-
croarray analysis to determine changes in gene expression in the thyroid gland of
male and female RccHan Wistar rats treated at 3 mg/kg in drinking water from ges-
tational day 6 to pnd (post natal day) 30. Thyroid glands were collected from rats at
10 PM to reflect non-quiescent thyroid activity. The transcriptome analysis showed
that acrylamide caused a significant alteration in the expression of genes related to
phase II detoxifying enzymes and oxidative stress, neurotoxicity, apoptosis, and tu-
morigenesis. Results from enrichment and pathway analysis showed that in both
genders, acrylamide caused differential regulation of genes associated with cell
processes of protein folding, microtubule cytoskeleton assembly, DNA replication,
DNA repair and ROS generation. These data suggest a potential involvement of
this chemical in cell processes other than mutagenicity which may be associated
with tumorigenesis. Furthermore, our study, by identifying affected gene ontologies
and pathways, provides insight into a potential mechanism of action and may have
substantial impact on risk assessment.
945 Development of a Quantitative Proteomics Multiplexed
Assay for the Predictive Assessment of Drug-Induced Organ
Toxicity in the Preclinical Setting.
M. Gharib1, 2,  P. Thibault2,  A. Nelson3,  D. Chelsky1,  L. Di Donato1 and
L. McIntosh1. 1Caprion Proteome Inc, Montréal, QC, Canada; 2Université de
Montréal, Montréal, QC, Canada; 3ITR Canada, Baie d’Urfé, QC, Canada.
Sponsor: W. Lee.
Drug-induced organ toxicity is the primary reason for the withdrawal of drugs from
the market and the failure of lead compounds during drug development. Detection
of organ toxicity early in the development pipeline would not only reduce the cost
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of drug development but also prevent injuries to patients in the clinic. Limitations
of traditional approaches highlight the need for more sensitive and specific tools to
predict drug toxicity. With the recent regulatory qualification of seven renal safety
biomarker for use during drug development, biomarkers are increasingly viewed as
potential means for providing toxicity assessments. Here, we have employed a tar-
geted mass spectrometry (MS) approach, known as multiple reaction monitoring
(MRM) to quantitatively measure changes in organ-specific toxicity biomarkers in
rats. A highly multiplexed MRM assay, targeting 192 candidate protein biomarkers
of hepatotoxicity, nephrotoxicity, cardiotoxicity as well as muscle, vascular and neu-
rotoxicity, was developed. Results show that markers for all organs covered in our
toxicity biomarker panel are detectable in serum and urine under normal condi-
tions. Significantly, GGT5 and MDH-1, important liver injury biomarkers cur-
rently under investigation as well as qualified kidney injury biomarkers cystatin-C,
clusterin and β-2-microglobulin and albumin were successfully detected in serum
and urine, respectively. We tested the predictive value of our panel on cyclophos-
phamide treated rat blood samples. In agreement with the literature, we found that
serum biomarkers for the kidney, the vascular system and the liver were markedly
increased following toxicity. The present MRM assay has the potential to become
standard practice for pre-clinical drug safety assessments. Further studies will be
centered on applying this assay to monitor urinary kidney injury biomarkers fol-
lowing cisplatin-induced nephrotoxicity of rats.
946 Development of a LC/MS Serum Bile Acid Profiling Method
for Sensitive Detection of Biliary Injury in Dogs.
J. M. Maher,  T. Sharapova,  R. Yeager,  E. Blomme and S. Cepa. R45M, Abbott
Laboratories, Abbott Park, IL.
Currently there are many non-invasive methods for assessing hepatic toxicity in
large animal species, but biliary injury is often difficult to detect in lieu of
histopathology. Notably hepatobiliary biomarkers such as liver transaminases, alka-
line phosphatase, gamma glutamyl transferase, and total bilirubin suffer from poor
specificity or sensitivity in detection of biliary injury. Quantification of serum bile
acids has been utilized in veterinary medicine in the diagnosis of biliary disease with
success, but the current methods of quantification suffer from technical hurdles and
lack robustness. Thus the purpose of the current study was to develop a method for
detection of serum bile acids in dogs using liquid chromatography-mass spectrom-
etry (LC/MS) for sensitive and rapid detection of hepatobiliary injury by quantify-
ing the individual bile acid species in tandem. Twenty bile acids species were as-
sessed with the current LC/MS method, including primary cholic and
chenodeoxycholic bile acids and secondary bile deoxycholic and lithocholic bile
acids, including the glycine- and taurine-conjugated forms. A diagnostic reference
range was established from more than 50 untreated, fasted beagles of both genders
to assess normal variability with benchmarked clinical pathology. These individual
serum bile acid levels ranged from approximately 900 pmol/ml to levels below the
limits of detection, with all taurine-conjugated species notably detected in serum.
The applications of this method in assessing the sensitivity and specificity of serum
bile acids versus existing methods will be discussed in the early detection of drug-
induced hepatobiliary injury.
947 Lack of Concordance in Microarray Gene Expression
Responses to Phenobarbital in Companion-Aged FFPE and
Frozen Liver Samples.
S. Hester,  G. Carswell,  B. Vallanat,  A. B. DeAngelo and C. E. Wood. US EPA,
Durham, NC.
Despite the immense potential value of public and private biorepositories, direct
utilization of archival tissues for molecular profiling has been limited. A major rea-
son for this limited use is the difficulty in obtaining reliable transcriptomic profiles
from formalin-fixed paraffin-embedded (FFPE) tissue samples with highly frag-
mented nucleic acid. The goal of this study was to evaluate transcriptional re-
sponses in 16 year-old FFPE and companion frozen (FROZ) liver samples from
F344 rats treated for 2 yrs with control water or water with 0.06% Phenobarbital
(PB), a known CAR/PXR inducer and rodent liver mitogen. RNA isolation and
gene expression was performed using the Rat Illumina Bead Array® for 16 samples,
paired FFPE and FROZ. The RNA integrity numbers (RINs) ranged from 2-3 for
FFPE and 3-5 for FROZ, and RNA yield for both FFPE (2 10μm sections) and
FROZ (20 mg) samples was 2-4 micrograms. Nugen Ovation® and Encore®
reagents optimized for FFPE tissues were used to amplify and label the RNA fol-
lowed by hybridization to arrays. We selected 12 of 16 samples based on successful
hybridization performance for analysis. Differential gene expression was assessed
using Rank Products followed by pathway mapping. Results showed only 10 signif-
icantly altered PB-responsive genes in common between paired FFPE (n=1373)
and FROZ (n=721) samples whereas pathway analysis identified only a 10% over-
lap in pathways significantly altered by PB between FFPE and FROZ samples.
Pathway profiles for both FFPE and FROZ samples were unique to their respective
sample type. The lack of concordance in genomic responses to PB suggests that tra-
ditional microarray platforms are inadequate for genomic profiling of aged FFPE
samples, despite improved RNA isolation and labeling methods. Further work will
evaluate more recent next-generation sequencing (NGS) technologies for transcrip-
tomic analysis of archival specimens. This abstract does not reflect EPA policy.
948 Formaldehyde-Induced Changes in microRNA Signaling.
J. E. Rager1,  B. C. Moeller2,  M. Doyle-Eisele3,  J. A. Swenberg1, 2 and R. C. Fry1,
2. 1Environmental Sciences and Engineering, The University of North Carolina at
Chapel Hill, Chapel Hill, NC; 2Curriculum in Toxicology, The University of North
Carolina at Chapel Hill, Chapel Hill, NC; 3Lovelace Respiratory Research Institute,
Albuquerque, NM.
MicroRNAs (miRNAs) are critical regulators of gene expression, yet much remains
unknown regarding miRNA changes resulting from environmental exposures and
whether they influence pathway signaling across various cell types and time. To gain
knowledge on these novel topics, we set out to investigate in vivo miRNA responses
to inhaled formaldehyde, an important air pollutant known to disrupt miRNA ex-
pression profiles. Rats were exposed by inhalation to either 0 or 2 ppm formalde-
hyde (6 hours/day) for 7 days, 28 days, or 28 days followed by a 7 day recovery.
Genome-wide miRNA expression profiles and associated signaling pathways were
assessed within the nasal respiratory mucosa, circulating mononuclear white blood
cells (WBC), and bone marrow (BM). We found that miRNAs were responsive to
formaldehyde exposure in the nose and WBC, but not the BM. A transcriptomics-
based analysis was performed in the nose and WBC of the rats exposed for 28 days.
In the nose, formaldehyde altered the expression of 42 transcripts; of these, 15
(36%) were computationally predicted to be regulated by formaldehyde-responsive
miRNAs. Conversely, in the WBC, formaldehyde altered the expression of 130
transcripts; of these, 18 (14%) were predicted to be regulated by miRNAs. Systems-
level analyses revealed that the transcripts regulated by miRNAs play diverse roles in
cell signaling. Key players include dosage suppressor of mck1 homolog, meiosis-
specific homologous recombination (Dmc1) and secreted frizzled-related protein 4
(Sfrp4) within the nose, involved in cell death signaling. In WBC, key players were
v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma)
(Akt3) and integrin, alpha 2 (Itga2), involved in inflammation signaling. Our study
informs critical knowledge towards the biological consequences of inhaled
formaldehyde exposure.
949 Dermal Sensitization to Toluene Diisocyanate in Mice Is
Manifested by Early Changes in the Proteome of Auricular
Lymph Nodes and Serum.
S. Haenen1, 3,  E. Clynen2,  V. De Vooght1,  L. Schoofs3,  B. Nemery1,  P. Hoet1
and J. Vanoirbeek1. 1Occupational, Environmental and Insurance medicine, KU
Leuven, Leuven, Belgium; 2Biomedical Research Institute, Hasselt University,
Diepenbeek, Belgium; 3Research Group of Functional Genomics and Proteomics, KU
Leuven, Leuven, Belgium.
Introduction.
Diisocyanates are capable of initiating an allergic response, which can lead to occu-
pational asthma after a latency period. Clinical symptoms such as cough, wheezing
and dyspnea occur only late, making it difficult to intervene at an early stage. 
We explored proteome changes, before asthma is apparent, in the local draining
lymph nodes and serum of mice dermally sensitized once or twice with toluene di-
isocyanate (TDI) to explore biomarkers of sensitization. 
Methods.
The proteomes of male BALB/c mice (6 weeks old, 20g), sensitized once (n=12) or
twice (n=12) with 0.3% TDI, were individually compared with control mice
(n=12) using two-dimensional difference gel electrophoresis (2D-DIGE). A level of
p<0.01 (Student’s t-test) was considered significant. 
Western blot or ELISA was used to verify a subset of the differential proteins. A
level of p<0.05 (unpaired t-test) was considered significant.
Results.
In the lymph nodes, we found between TDI-treated and control mice 38 and 58
differential proteins after one and two treatments, respectively. In serum, 7 and 16
differential proteins were detected after one and two treatments, respectively. We
identified 80-85% of these proteins by mass spectrometry. Among them, lympho-
cyte specific protein-1, coronin 1a and hemopexin were verified in an independent
group of mice by Western blot or ELISA.
Conclusion.
Our study revealed, in a mouse model, alterations in the proteome during sensitiza-
tion. If validated in humans, these changes could lead to earlier diagnosis of ex-
posed workers.
All animal experiments were approved by the Local Ethical Committee for animal
experiments of the KU Leuven.
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950 Smoking-Induced microRNA Changes in Human Sperm.
E. L. Marczylo1,  J. Janus3,  A. A. Amoako2,  J. C. Konje2,  T. H. Marczylo1 and
T. W. Gant1. 1CRCE, Health Protection Agency, Didcot, United Kingdom;
2Reproductive Sciences, Leicester Royal Infirmary, Leicester, United Kingdom;
3Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom.
Recent work has suggested that some of the constituents of cigarette smoke, along
with other environmental chemicals, can have adverse effects not just on the ex-
posed individuals, but also on their progeny. Although the mechanisms underlying
multigenerational toxicity are not well understood, a number of studies have impli-
cated heritable microRNA-mediated epigenetic modifications. Using microarray
profiling and pathway analysis, we have shown that cigarette smoke induces specific
differences in the spermatozoa microRNA content of human smokers compared
with non-smokers, and that these altered microRNAs appear to predominantly me-
diate pathways vital for healthy sperm and normal embryo development, particu-
larly cell death and apoptosis. MicroRNA-mediated perturbation of such pathways
may explain how harmful phenotypes can be induced in the progeny of smokers.
Consequently, we have also been developing an in vitro system for investigating the
potential roles of microRNAs in toxicology. By differentiating embryonic stem cells
into embryoid bodies we have been able to generate and subsequently isolate sets of
clonal primordial germ cell lines. These cell lines can be produced in the presence
and absence of environmental chemicals (for example 17β-estradiol and di-butyl-
phthalate), and exhibit chemically-induced differential microRNA expression. This
model (including both the embryoid bodies and the resulting primordial germ cell
lines) shows promise for further investigating the mechanisms of microRNA-medi-
ated toxicity induced by environmental chemicals, including cigarette smoke. 
All work was approved by the Leicestershire, Rutland and Northamptonshire Ethics
(Institutional Ethics) Committee and written informed consent to partake in the
study was obtained from all volunteers.
951 New Data from Old Studies: Development of qRT-PCR
Signature Assays for Assessment of Mode-of-Action from
Formalin Fixed Paraffin Embedded Archival Tissues.
S. Phillips2, 1,  L. Recio1, 2,  T. Maynor1 and M. D. Waters1. 1ILS, Research Triangle
Park, NC; 2ILS Genomics, Morrisville, NC.
Archival formalin fixed paraffin embedded (FFPE) tissue samples collected over
decades from toxicological studies represent a rich source of biological materials
with detailed pathological evaluations from the testing of numerous substances.
Until recently, the application of ‘omics technologies to toxicology studies has been
primarily limited to fresh frozen tissue samples collected at necropsy. Archival FFPE
tissues represent a rich and largely untapped resource of invaluable information.
There is a clear need to develop methods to apply ‘omics based technologies to
FFPE tissue banks. ILS and ILS Genomics have developed a systematic approach
using bioinformatics and laboratory testing for the de novo design of gene specific
qRT-PCR assays for use on FFPE archival tissue samples. For these studies, mouse
liver carcinogen furan was administered by oral gavage at 0.0, 2.0, 4.0 and 8.0
mg/kg with 5 animals per group for three weeks. Animals were necropsied at 4 hrs
after the final administration, liver sections were flash frozen in liquid nitrogen and
stored at -80°C. Other liver sections were fixed in formalin for 18-24 hrs, trans-
ferred to ethanol for 2 days and then processed into FFPE tissue blocks. Total RNA
was extracted from paired frozen and FFPE tissues (10 um sections) for subsequent
qRT-PCR analysis. Custom designed qRT-PCR assays using TaqMan technology
with amplicons of approximately 70 bp were tested to demonstrate equal primer ef-
ficiencies between frozen and FFPE tissue RNA isolations. Using this strategy we
have validated a set of 8 genes and 2 lncRNAs (Chek1, Cyp4a14, Egr1, Ephx2,
Cdkn1a, Xrcc1, Dppa5a, Gsta1 lncRNA-p21 and lncRNA-Chr.9: 78107225-
78118850) and normalization gene Actb to quantify mRNA levels in liver RNA
isolated from FFPE compared to frozen tissues. These studies demonstrate that
quantitative analysis of mRNA levels from FFPE tissue samples can be done using
highly specific mRNA qRT-PCR assays.
952 Identification of Novel Biomarkers for Drug-Induced Renal
Papillary Necrosis in Rats by Toxicoproteomic Techniques.
D. Sasaki1, 2,  M. Kanki1,  K. Nishihara1,  M. Hiramoto1,  M. Yuri1,  H. Umeno1,
A. Moriguchi1,  H. Mitori1,  R. Hirota1,  J. Seki1,  Y. Miyamae1,  G. Hwang2 and
A. Naganuma2. 1Astellas Pharma Inc., Osaka and Tsukuba, Japan; 2Graduate School
of Pharmaceutical Sciences, Tohoku University, Sendai, Japan.
Renal papillary necrosis (RPN) is a type of kidney injury that is often observed in
diabetics and patients taking nonsteroidal anti-inflammatory or anticancer drugs.
However, no prognostic biomarkers (BMs) for RPN in humans have been identi-
fied. Here, we searched for novel BMs suitable for early RPN detection using toxi-
coproteomic techniques. Urine from rats with RPN induced by a single injection of
2-bromoethylamine hydrobromide (BEA; 0, 3, 10, 30, and 100 mg/kg) was pooled
into 4 groups. Urinary proteins in each group were analyzed by 2-dimensional LC-
MS/MS coupled with isobaric tags (iTRAQ) to identify BM candidates. The uri-
nary levels of BM candidates were quantified in individual rats after BEA treatment
to assess the ability of these markers to detect RPN in comparison with FDA-
and/or EMA-approved BMs for assessing preclinical kidney injury. The identified
BM candidates were also measured in the urine of rats with glomerular- or proximal
tubular (PT)-injury induced by puromycin, cisplatin, or gentamicin to verify the
site specificity of the kidney lesions. In BEA-treated rats, 75 proteins with >2-fold
increases in urinary concentrations compared with those in control rats were iden-
tified. Among these proteins, the selectivity and sensitivity of Es2, fetuin-A, and
fibrinogen for RPN were evaluated. Es2 levels in urine were elevated rapidly after
BEA treatment compared to those of serum BUN, creatinine, urinary clusterin,
KIM-1, and RPA-1, and were also increased in glomerular- or PT-injury rats, sug-
gesting that Es2 is a highly sensitive, but nonselective for RPN. In contrast, fetuin-
A and fibrinogen were selective for RPN, as no marked changes in their urinary
concentrations were observed in glomerular or PT-injury rats, but had low sensitiv-
ity for RPN detection. In conclusion, we identified three BM candidates for RPN
with kidney lesion-site specificity and different sensitivities.
953 Determination of Formaldehyde Specific DNA-Protein-
Crosslinks.
B. C. Moeller1,  W. M. Bodnar2 and J. A. Swenberg1, 2. 1Curriculum in Toxicology,
University of North Carolina at Chapel Hill, Chapel Hill, NC; 2Environmental
Sciences and Engineering, University of North Carolina at Chapel Hill, Chapel Hill,
NC.
Formaldehyde (FA) is classified as a known human and animal carcinogen. It is a
ubiquitous environmental pollutant and is used in a number of consumer products
or industrial applications. FA is also endogenously produced as part of normal cel-
lular metabolism. FA is a genotoxic agent, causing a number of effects on cells in-
cluding DNA monoadducts, DNA-DNA crosslinks and DNA-protein-crosslinks
(DPC). DPCs are believed to be one of the critical lesions involved in FA induced
carcinogenesis and is thought to provide a key initiating step in the Mode-of-
Action. Currently, there are no available methods to distinguish between endoge-
nous and exogenous FA induced DPCs. To investigate the possible link between in-
haled FA and the formation of both endogenous and exogenous DPCs, several
analytical techniques are being developed. O6-Alkylguanine-DNA alkytransferase
(AGT) is a DNA repair enzyme that is known to form DPCs with FA and other
crosslinking agents at the active Cys145 residue. Using AGT as a model protein, a
series of experiments were undertaken to understand the formation, stability and
degradation of the DNA-protein-crosslink at the reactive cysteine and the N2 posi-
tion of deoxyguanosine. Digestion conditions for both DNA and protein cleavage
were investigated to determine approaches that would allow for the isolation and
identification of either cysteine-CH2-dG or AGT peptide-CH2-dG crosslinks using
sensitive and selective Liquid Chromatography – Mass Spectrometry. Further ex-
periments investigating the ability to distinguish between crosslinks formed by
both [13CD2]-FA and unlabeled FA were accomplished. Further validation and de-
velopment of these approaches may allow for accurate and quantitative determina-
tion of endogenous and exogenous FA specific DPCs in cell culture and animal
models. This information will be critical in advancing the understanding of the
risks associated with inhaled FA and its role as a human carcinogen.
954 Pulmonary Toxicity and Global Gene Expression Profile in
Response to Crystalline Silica Exposure in Rats.
R. Sellamuthu,  C. Umbright,  J. R. Roberts,  S. Young,  D. Richardson,
W. McKinney,  B. T. Chen,  D. Frazer,  S. Li,  M. L. Kashon and P. Joseph.
National Institute for Occupational Safety and Health (NIOSH), Morgantown, WV.
The ability to detect target organ toxicity as well as to determine the molecular
mechanisms underlying such toxicity by employing surrogate biospecimens that
can be obtained either by a non-invasive or minimally invasive procedure has sig-
nificant advantage in toxicology. Pulmonary toxicity and global gene expression
profiles in the lungs, blood and bronchoalveolar lavage (BAL) cells were determined
in rats 44-weeks following inhalation exposure to crystalline silica (15 mg/m3, 6-
hours/day, 5 days). A significant elevation in lactate dehydrogenase activity and al-
bumin content in the BAL fluid as well as histological alterations, mainly type II
pneumocyte hyperplasia and fibrosis, observed in the lungs suggested silica-induced
pulmonary toxicity in the rats. A significant increase in the number of neutrophils
and elevated monocyte chemotactic protein 1 in the BAL fluid indicated silica-in-
duced pulmonary inflammation in the rats. Determination of global gene expres-
sion profiles in the lungs, BAL cells, and blood of the silica exposed rats identified
175, 273, and 59 significantly differentially expressed genes (SDEGs) (FDR
p<0.05 and >1.5 fold change in expression), respectively, compared with the corre-
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sponding control samples. Bioinformatics analysis of the SDEGs demonstrated a
remarkable similarity in the biological functions, molecular networks and canonical
pathways that were significantly affected by silica exposure in the lungs, BAL cells
and blood of the rats. Induction of inflammation was identified as the major mo-
lecular mechanism underlying the silica-induced pulmonary toxicity. These find-
ings demonstrated the potential application of global gene expression profiling of
blood and BAL cells as a valuable minimally invasive approach to study silica-in-
duced pulmonary toxicity.
955 Comparison of a New Skin Penetration System Containing
an Automated Toxicokinetic Modul with Franz Diffusion
Cells.
A. G. Schepky,  I. Herberz,  M. Akhiani,  S. Müller,  H. Wenck and D. Gerstel.
4218-Research Toxicology, Beiersdorf AG, Hamburg, Germany.
Critical endpoints in in vitro testing of cosmetic ingredients are the determination
of the bioavailability of test substances in different skin layers and the examination
of the toxicokinetic profile. Skin penetration studies are so far performed in Franz
diffusion cells using pig skin. Unfortunately with these cells an automated toxicoki-
netic determination of percutaneously penetrated substance is not receivable.
To perform toxicokinetic studies, we developed a new Vitrocell systems skin pene-
tration system (SPS) with eight parallel running diffusion cells, which is able to take
samples from the receptor fluid automatically. To substitute the Franz diffusion
cells with the SPS it is important to compare both systems in terms of performance
and reproducibility. Therefore we compared the penetration of caffeine through full
thickness pig skin in Franz diffusion cells with manual sampling from the receptor
fluid with the prototype of the SPS that provides automated sampling from the re-
ceptor fluid.
We could show toxicokinetic profiles for manual and automated samples with com-
parable lag times and recovery rates. Furthermore we could even show lower stan-
dard deviations using the SPS.
In conclusion, the new SPS is highly comparable to the Franz diffusion cell with the
additional advantage to allow the automated detection of toxicokinetic profiles
from the receptor fluid.
956 Risk Assessment for Cosmetic Ingredients Using Alternative
Methods—Skin Sensitization.
T. Atobe1,  K. Tsujita1,  S. Oeda1,  M. Hirota1,  T. Ashikaga1,  H. Kouzuki1,
T. Yoshida2 and S. Aiba3. 1Safety Technology Development Group, Shiseido Research
Center, Yokohama, Japan; 2Department of Biochemical Toxicology, Showa University
School of Pharmacy, Tokyo, Japan; 3Department of Dermatology, Tohoku University
Graduate School of Medicine, Sendai, Japan.
Development of non-animal safety evaluation methods for chemicals is necessary
from the viewpoint of animal welfare and to meet the 7th amendment of the
European cosmetics directive. As an in vitro skin sensitization test, we have estab-
lished two methods. One was the human cell line activation test (h-CLAT) detect-
ing augmentation of CD86 and CD54 expression in THP-1 cells exposed by skin
sensitizers. The other was the SH test taking advantage of changing cell-surface thi-
ols on THP-1 cells induced by skin sensitizers. Recently the Antioxidant Response
Element (ARE) assay measuring oxidative stress caused by skin sensitizers have been
attracted attention. However, hazard assessment of skin sensitization has been un-
able to predict by only one test in vitro yet. Furthermore, non-animal methodolo-
gies in risk assessment how much a chemical has skin sensitization potency has just
started in earnest. This study attempted to verify how to combine tests in vitro or in
silico to assess chemical skin sensitizers. EC3 values from LLNA were accumulated
by non-linear analysis using each endpoint from in vitro skin sensitization test and
then some descriptors suggesting correlation to LLNA threshold values were se-
lected. Correlation between the descriptors and EC3 values were analyzed by
Artificial Neural Network (QwikNet Ver. 2.23). Molecular orbital of the three-di-
mensional chemical structures was also used in silico. As a result, the model ob-
tained from tests in vitro or in silico reveals good correlation to in vivo data, thus
the combination of in vitro and in silico method could be a sophisticated non-ani-
mal testing for risk assessment in skin sensitization.
957 Application of a Modified Keratinosens Assay to Predict
Sensitization Hazard for Botanical Extracts.
D. Gan1,  K. Norman2,  N. Barnes2,  H. Raabe2,  C. Gomez1 and J. W. Harbell1.
1Mary Kay Inc., Addison, TX; 2IIVS, Gaithersburg, MD.
An essential step in the safety review of cosmetic/personal care ingredients is hazard
assessment, including dermal sensitization potential. In vitro methods to identify
allergic (haptenic) potential are based on electrophilic interaction with marker pep-
tides or cellular target systems. These assays use a specific molar ratio of the test
chemical to the test system. Botanical extract ingredients, as mixtures, preclude spe-
cific molar ratio determination. Often, the botanical extract portion is a small frac-
tion of the complete ingredient. To assess these mixtures, the KeratinoSens assay
was selected because it operates over a wide dose range and sets cytotoxicity limits
on doses used to measure marker gene expression (Emter et al, 2010). Induction of
a luciferase gene, under the control of the antioxidant response element (ARE), was
measured. Cytotoxicity was assessed by both NRU and MTT assays.
Concentrations up to 1 mg/mL (of complete ingredient) were tested and a test dose
was considered positive if the fold induction of luciferase was 1.5x (EC1.5) and vi-
ability ≥ 70% relative to the solvent controls. The goal of the study was to measure
the activity of 3 known sensitizers (gluteraldehyde (GA) [strong], dimethyl maleate
(DM) [moderate] and cinnamic aldehyde (CA) [moderate] spiked into four differ-
ent botanical ingredients (with different excipient solvent systems). Activity was
measured, relative to the EC1.5 of the neat sensitizer, as a function of sensitizer
concentration and ingredient composition. Three independent trials were per-
formed. No appreciable cytotoxicity was observed. The recovery of the GA spike re-
quired at least a 3-fold increase in concentration relative to the chemical alone and
one extract reduced the activity below detection. The DM and CA showed activity
at about the same effective concentrations as the neat chemicals although the DM
showed reduced activity in one extract as well. These data suggest that the
KeratinoSens assay has the potential to identify electrophile allergens within a
botanical extract ingredient matrix.
958 Development of a Highly Reproducible Three-Dimensional
Chinese Skin Reconstructed Model for Evaluating Drug and
Cosmetic Skin Irritation.
J. Wang1,  Z. Du1,  Z. Wang2 and X. Zhang1. 1Foreland Biopharma Co. Ltd.,
Beijing, China; 2Boston University, Boston, MA. Sponsor: J. Wang.
In vitro models to study irritation, corrosivity and phototoxicity are important
tools for research and development in the pharmaceuticals and cosmetic industries.
Human skin is the best possible model for such in vitro studies. The commercially
reconstructed human epidermis models are similar to the morphology, lipid com-
position and biomarkers of native human tissue and have been approved by
European Centre for the Validation of Alternative Methods (ECVAM) for the vali-
dation of cosmetics. The models are available in many countries but not in China.
Here, we describe the development of a constructed three-dimensional (3D) model
using Chinese human skin, which consists of a “dermis” with fibroblasts embedded
in rat collagen matrix and an “epidermis” comprised of differentiated keratinocytes.
The fibroblasts and keratinocytes were first separated from foreskins of Chinese
adults after incubating in dispase and collagenase solutions. Then, rat type I colla-
gen was constructed onto the polycarbonate membrane of a culture insert. After
gels solidified at room temperature, a collagen matrix with Chinese dermal fibrob-
lasts was constructed above the acellular collagen layer. Keratinocytes were added to
the surface of the contracted collagen gels and allowed to attach to the matrix to
generate a confluent cellular monolayer. The reconstructed tissues were raised to an
air-liquid interface to enable complete stratification and differentiation. After expo-
sure and incubation, MTT assay was performed for cell viability. Nine well-known
irritants or corrosive chemicals caused cell viability rates less than 50%. Cosmetics
both from Western nations and China were also tested in the model. We found the
Western cosmetics did not influence the cell viability compared to some of Chinese
cosmetics which dramatically decreased cell viability 1 hour after exposure. Our
data indicate that the reconstructed 3D Chinese skin model is highly reproducible
and sensitive to assess skin irritation to chemicals and cosmetics.
959 Incorporation of Reconstructed Human Epidermal Tissues
into a Corporate Toxicology Laboratory: Use of In Vitro Test
Data for Diverse Safety and Risk Assessment Applications.
L. M. Milchak,  D. H. Brandwein and J. Zappia. Corporate Medical Department,
3M, St. Paul, MN.
The 3M Strategic Toxicology Laboratory (STL) is an internal corporate resource
providing toxicology support to 3M businesses. An objective in the STL is to rou-
tinely incorporate in vitro test methods, with a recent focus on the use of recon-
structed human epidermis tissues. The first model utilized has been EpiDerm™,
which is currently validated for classification of chemicals for dermal irritation in
OECD 439, and also dermal corrosion in OECD 431. Following the process out-
lined in the standard protocols for demonstration of technical proficiency, both test
methods have been validated and used to assist with classification of chemistries for
consumer and industrial use, utilizing the standardized MTT based cell viability
assay. In addition, custom protocols have been performed using the tissues in time
course irritation studies to evaluate the release of the inflammatory marker cytokine
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IL-1α. This approach has been advantageous for the simultaneous screening of
multiple formulations for irritation potential during research and development for
new products. Other customized studies have evaluated the efficacy of various skin
washing agents at removal of a viscous coating from the skin tissues, in a simulated
washing study to help formulate occupational health recommendations for work-
ers. These studies evaluated irritation potential using MTT, IL-1α and LDH re-
lease, and also analyzed the dermal penetration of an amine component in the coat-
ing.  In summary, incorporation of these test methods has been very useful for the
evaluation of a multitude of dermal exposure scenarios. The tissues have been used
in standardized irritation and corrosion assays, as well as custom protocols utilizing
additional markers of cell damage, and also specialized skin washing and dermal
penetration studies. The results of these studies have provided valuable information
for safety and risk assessment purposes, particularly during the product develop-
ment phases, and have permitted these evaluations without animal use.
960 Intralaboratory Reproducibility of the Direct Peptide
Reactivity Assay (DPRA) to Assess the Robustness of the
Current Prediction Model.
L. Foertsch and F. Gerberick. Central Product Safety, Procter & Gamble Company,
Cincinnati, OH.
One characteristic of a chemical allergen is its ability to react with proteins prior to
the induction of skin sensitization. The majority of chemical allergens is elec-
trophilic and reacts with nucleophilic amino acids such as cysteine or lysine. In the
DPRA, test chemicals are incubated for 24 hours with two synthetic peptides con-
taining a cysteine or lysine residue, and the reactions are analyzed by HPLC to
measure peptide depletion. We have previously demonstrated that reactivity corre-
lates with sensitization potential and have developed a prediction model to assign a
reactivity category for each material tested in the assay (Gerberick et al. Tox Sci
2007; 97:417-427). In order to assess the robustness of this prediction model and
its ability to distinguish reactive skin sensitizers from minimally reactive non-sensi-
tizers, a historical DPRA dataset of 133 chemicals was analyzed retrospectively with
a modified prediction in which the cut-off between minimal and low reactivity was
changed from 6.38% to 8% depletion. Regardless of cut-off, the accuracy of the
prediction model remained at 86% with little to no change in sensitivity, specificity,
and positive and negative productivity.  To further investigate the robustness and re-
producibility of the prediction model, a small intra-laboratory study was con-
ducted. In this study, 9 chemicals were tested blindly in three independent runs.
The depletion data was analyzed using the current prediction model as well as the
described modified prediction model. In both cases, 7 out of 9 chemicals showed
the same reactivity prediction in all 3 runs. Neither the retrospective analysis nor
the intra-laboratory study provided any compelling evidence to adjust this cut-off
value from the current model. Taken together, these studies further display the re-
producibility and robustness of the DPRA and its prediction model.
961 A Novel Animal-Free Approach to Dermal Sensitization
Hazard Identification and Potency Assessment.
J. McCauley. Toxicology Assessment & Compliance Assurance, 3M, St. Paul, MN.
Sponsor: D. Luebker.
International regulatory efforts have played a major role in advocating for the Three
R’s of animals used in safety evaluations for toxicological endpoints. These efforts
support a movement away from the current in vivo-dependent toxicity testing state,
to an animal-free toxicity testing state that includes in vitro human biology and a
computational systems approach. To accomplish this goal, key stakeholders have
proposed an ITS methodology to assess the skin-sensitizing potential of test chem-
icals to facilitate safety evaluation decision-making. The use of this ITS model inte-
grated both novel and literature-reported data on 116 chemicals of known skin-sen-
sitizing potential. Two in vitro assays and one in silico prediction model were used
to cover four key sources of toxicological information: peptide reactivity; induction
of ARE dependent luciferase activity; calculated otanol-water partition coefficient;
and TIMES-SS model in silico prediction. The results from the in vitro assays were
scaled into five classes from 0 to 4 and then compared with the LLNA data, which
were also scaled from 0 to 4. Using an optimized model, an 87.9% overall accuracy
was obtained for predicting sensitizers with a linear relationship between the LLNA
scores and the in vitro scores. The use of clogP to account for potential differences
in the bioavailability of the test chemicals did not reduce the correlation. With the
increasing number of large-scale toxicology risk assessment programs for chemicals
and emerging or expanding areas of chemical use, the development and acceptance
of an ITS model appears to be the solution needed to strike a balance between
safety, speed, cost and animal welfare. Along with ITS data refinements and the in-
clusion of other in vitro assays and in silico models accompanied by larger data sets,
consideration should be given to defining a validation strategy focused on regula-
tory acceptance of an ITS model for skin sensitization.
962 Development of a Compromised Skin Model In Vitro Using
a Tape Stripping Method.
J. Heylings2,  D. Davies2,  M. C. Correa1 and T. J. McCarthy1. 1Johnson &
Johnson, Skillman, NJ; 2Dermal Technology Laboratory Ltd., Keele, United Kingdom.
Dermal absorption of chemicals from topically applied products is studied in a va-
riety of in vitro and in vivo models. Skin barrier function may be impaired due to
intrinsic or extrinsic factors. To our knowledge there is not a standardized model for
evaluation of dermal absorption in compromised skin barrier conditions. Our ob-
jective was to validate an in vitro model of altered barrier function generalizable
across compromised skin states. To investigate the permeability properties of com-
promised skin compared to normal skin, we explored the relationship between non-
invasive (Trans Epidermal Water Loss, TEWL) and invasive (Electrical Resistance,
ER; Tritiated Water Flux, TWF) markers of barrier function in slaughterhouse pig
skin before and after tape stripping. Skin samples were randomly divided into
groups and subjected to a standardized tape stripping procedure. The pre-and post-
values for the 3 measures of skin integrity were recorded for 0, 5, 10, 15 and 20 tape
strips. A full analysis of the distribution of TEWL, ER and TWF for 70 separate
skin samples revealed that only ER was robust enough to discriminate between the
barrier property changes effected by sequential tape stripping. The measurement of
water flux through the skin (TEWL, TWF) required a long period of stabilization
and proved to be unsuitable as a short term test. However, a significant difference
could be observed with ER between control and each group of 5-20 tape strips
(p<0.01, n= 53). Further analysis of the data revealed that removal of 10 tape strips
provided a loss of barrier function approximately equivalent to a 3-4 fold increase
in TEWL, which approximates the altered barrier function clinically observed in
atopic dermatitis, psoriasis, and diaper dermatitis. In conclusion, we have devel-
oped an in vitro model of compromised skin barrier function that is simple and ro-
bust and can be used to study the dermal absorption of chemicals that may come in
contact with skin with impaired barrier properties.
963 A Predictive High-Content Imaging Cell-Based Assay As an
Alternative to the Local Lymph Node Assay for Skin
Sensitization.
R. N. Ghosh,  M. J. Tomaszewski,  M. L. Pietila and J. R. Haskins. ThermoFisher
Scientific, Pittsburgh, PA.
Allergic contact dermatitis (ACD) is a health effect that can develop in those ex-
posed to skin sensitizing chemicals. To decrease the occurrence of this adverse reac-
tion, regulations require that testing be performed to identify which chemicals are
responsible for this effect, and be labeled accordingly. The current standard for
ACD measurement is the Local Lymph Node Assay (LLNA), which is both animal
and labor intensive. The LLNA testing procedure is based upon enumerating the
responding cells in the draining lymph nodes of the mouse after treatment.
Alternatives for this assay have depended on the measurement of phenotypic
changes of a defined cell line, which would be analogous to a prior step in the path-
way of induction of sensitization than that of the LLNA endpoint. To the end of
developing an assay that more comprehensively mimics the role of the immune sys-
tem during ACD in vitro, we describe a phenotypic and functional cell based assay
that can be used to predict the sensitizing potential of compounds. The prediction
method of this assay is based upon the up-regulation of cell surface molecules and
proliferation indicative of the induced maturation of the cell line after compound
treatment, and also a functional response whereby the treated cells are exposed to
chemotaxis inducing reagents and migration measured. These features can easily be
captured and measured via an automated fluorescent imaging and analysis plat-
form. The measurement of these features when combined allow for prediction of
sensitizing potential, but also provide toxicity data which allows for compounds to
be easily re-screened at lower concentrations. Tested compounds (n=24) yielded a
high sensitivity rate (100‰) and a high concordance (82‰) to the LLNA. In sum-
mary, this assay shows promise in its ability to predict in vivo responses and may
offer a viable alternative to traditional animal studies. In addition, it could provide
a valuable first level triage for chemicals entering the consumer and industrial prod-
ucts pipeline.
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964 Performance Standards and Alternative Assays: Practical
Insights from Skin Sensitization.
D. Basketter2,  S. N. Kolle1,  S. Casati3,  W. S. Stokes4,  J. Strickland6,  H. Vohr5,
B. van Ravenzwaay1 and R. Landsiedel1. 1Experimental Toxicology and Ecology,
BASF SE, Ludwigshafen am Rhein, Germany; 2DABMEB Consultancy Ltd.,
Sharnbrook, United Kingdom; 3ECVAM, European Commission, Ispra, Italy;
4Interagency Center for the Evaluation of Alternative Toxicological Methods, National
Toxicology Program, NIEHS, Research Triangle Park, NC; 5Bayer Health Care,
Wuppertal, Germany; 6Integrated Laboratory Systems, Inc, Research Triangle Park,
NC.
To encourage the development and validation of alternative toxicity test methods,
the effort required for validation of test methods proposed for regulatory purposes
should be minimised. Performance standards (PS) facilitate efficient validation by
requiring limited testing. Based on the validated method, PS define accuracy and
reliability values that must be met by the new similar test method. The OECD
adopted internationally harmonized PS for evaluating new endpoint versions of the
local lymph node assay (LLNA). However, in the process of evaluating a lymph
node cell count alternative, the LNCC, simultaneous conduct of the regulatory
LLNA showed that this standard test may not always perform in perfect accord
with its own PS. The LNCC results were similar to the concurrent LLNA; discrep-
ancies between PS, LLNA and LNCC were largely associated with “borderline”
substances and the variability of both endpoints. Two key lessons were learned:
firstly, the understandable focus on substances close to the hazard classification bor-
derline are more likely to emphasise issues of biological variability, which should be
taken into account during the evaluation of results; secondly, variability in the re-
sults for the standard assay should be considered when selecting reference chemicals
for PS.
965 Alternative Method in Practice: Postvalidation Experience of
the Skin Sensitization In Vitro Test Strategy.
S. N. Kolle,  B. van Ravenzwaay and R. Landsiedel. Experimental Toxicology and
Ecology, BASF SE, Ludwigshafen am Rhein, Germany.
Several in vitro methods including dendritic cell line activation (e.g. MUSST and
h-CLAT), keratinocyte activation (e.g. LuSens and KeratinoSens) and in chemico
(e.g. DPRA) assays have been described as promising animal-free tools to qualita-
tively predict skin sensitizing potential. While these methods are currently under-
going evaluations in the different stages of formal validation, testing strategies have
been proposed based on the combination of these assays. Yet to use suggested meth-
ods and prediction models for the diverse industrial sectors, such as the cosmetic,
industrial chemical, pharmaceutical and maybe even the agrochemical sector, the
scope of the substance classes tested as part of the initial validation exercise needs to
be extended. Typically in a first validation phase novel alternative methods are eval-
uated against their gold standard in vivo assays using model substances selected
from literature for their well described toxicological endpoint effects. The sub-
stances tested in the first validation phase, do, however, usually not reflect the typi-
cal test substance portfolio of the different industrial sectors. Therefore in this study
we present the post-validation evaluation of 40 additional substances with available
in vivo skin sensitization data from various substance classes including acrylates,
surfactants, isocyanates, plant extracts, and agrochemical formulations in state of
the art in vitro methods to assess skin sensitization. This additional data provides
valuable information to understand the predictive capacity in terms of the applica-
bility domains and may also help to manage expectations what can be achieved
with those assays.
966 Alternative Methods in Practice: Testing of Acrylate and
Methacrylate Esters with the Skin Sensitization In Vitro Test
Strategy.
K. Wiench2,  S. N. Kolle1,  H. Müllerschön3,  M. Pemberton5,  L. Andrews4 and
R. Landsiedel1. 1Experimental Toxicology and Ecology, BASF SE, Ludwigshafen am
Rhein, Germany; 2Product Safety, BASF SE, Ludwigshafen am Rhein, Germany;
3Chemicals Management, Evonik Industries, Darmstadt, Germany; 4The Dow
Chemical Company, Midland, MI; 5Systox Ltd., Wilmslow, United Kingdom.
Allergic contact dermatitis is a common skin disease and is elicited by repeated skin
contact with an allergen. In the regulatory context, up to now only data from ani-
mal experiments have been accepted to assess the skin sensitizing potential of sub-
stances. Animal welfare concerns and the EU Cosmetic Directive/Regulation call
for the implementation of animal-free alternatives for safety assessments. The
mechanisms that trigger skin sensitization are complex and various steps are in-
volved. Therefore, a single in vitro method may not be able to accurately assess this
endpoint. An in vitro testing battery that addresses different stages of the sensitiza-
tion process was developed based on protein reactivity (direct peptide reactivity
assay, DPRA), activation of the Keap-1/Nrf2 signaling pathway (LuSens and
KeratinoSensTM) and dendritic cell activation assays (MUSST and h-CLAT).
Based on an in-house validation this in vitro test strategy for the identification of
skin sensitizers showed an accuracy comparable to that of the LLNA assay (94%
compared to 89% for the LLNA). In this in-house validation, model substances se-
lected from literature for their well characterized sensitizing potential were selected
but did not necessarily reflect to typical testing portfolio. Therefore in this study,
the in-house validation was extended by acrylates and methacrylate esters with
available in vivo skin sensitization data. Further, the in vitro test battery has been
used as a replacement for more than a dozen acrylates and methacrylate esters.
967 IVSA: In Vitro Sensitization Assay.
M. Troese,  L. F. Pratt,  D. R. Cerven and G. L. DeGeorge. MB Research
Laboratories, Spinnerstown, PA.
Regulatory agencies worldwide are seeking non-animal or in vitro testing methods
that embrace the 3Rs philosophy. Strong support now exists in the consumer prod-
ucts, pharmaceutical and cosmetics industries to develop and validate alternative as-
says for use in preclinical safety testing programs. Our group has adapted the Sens-
it-iv in vitro sensitization NCTC2594 IL-18 response assay of Corsini, et al.
(Toxicol In Vitro 23 (5):789-796, 2009) for use in the MatTek EpiDerm™ model,
measuring IL-18 secretion into the media to identify dermal sensitizers. In intra-lab
validation tests, IL-18 release was measured after a 24-hour topical exposure using
twelve sensitizers and five irritants/non-sensitizers. Either distilled water or EtOH
was used as solvent vehicles. A Stimulation Index (SI) was calculated relative to the
solvent vehicle for each test material. An SI > 1.6 result was considered biologically
significant and best fit the data for identification of a positive sensitizer using a 2x2
contingency table and Cooper statistics. The overall Accuracy of the assay was 94%,
with no false positives. The Sensitivity, Specificity, Positive and Negative
Predictivity were 92%, 100%, 100% and 83%, respectively. The In Vitro
Sensitization Assay (IVSA) produced a dose-dependent release of IL-18 upon treat-
ment with increasing concentrations of 4-nitrobenzyl bromide. In addition, IVSA
correctly identified two photosensitizers (+UVA): chlorpromazine and olaquindox.
Thus, in this initial evaluation, IVSA has proven to be a useful and highly predic-
tive tool for identifying dermal sensitizers without the use of animals.
968 Evaluation of Skin Irritation for Household Products Using
a Reconstructed Human Epidermis Model.
F. Yamaguchi,  N. Takebuchi and J. Sato. Lion Corporation, Odawara-shi, Japan.
Sponsor: H. Kojima.
Classification for irritation using reconstructed epidermis test methods have been
developed. These test methods have been validated with the ability of dividing
chemicals into skin irritants or non-irritants, in accordance with the UN Globally
Harmonized System of Classification and Labeling (GHS). Application of these
models to dermal safety evaluation of household products, which are consisted of
several chemical substances, is of highly importance from the point of view to en-
sure product safety.
The aim of this research is to estimate skin irritation potential of household prod-
ucts comparing cell viability patterns on reconstructed epidermis when household
products are applied. 
We select LabCyte EPI-MODEL24 (Japan Tissue Engineering Co., Ltd) model
with JACVAM validated protocol for GHS classification of chemical substances.
Twenty five commercial household detergents in Japan including laundry deter-
gents, dishwashing detergents, fabric softeners and household cleaners were tested. 
It appeared that the cell viability becomes comparable in some product categories.
The products which contains highly anionic surfactants tends to show low cell via-
bility. Fabric softeners which were based on cationic surfactants showed no cytotox-
icity in this model. Powder laundry detergents tend to show low cytotoxicity.
Liquid laundry detergents, dishwashing detergents and household cleaners shows
various cell viability. It seemed that category and/or its concentrations of contained
surfactants might be affected the results.
These results suggested that reconstructed epidermis test methods useful for the
products safety assessment by performing comparative assessment in each product
category.
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969 Collaborative Project in JCIA for Testing Strategy of Skin
Sensitization Using h-CLAT, DPRA and DEREK.
O. Takenouchi1, 11,  K. Okamoto2, 11,  N. Imai3, 11,  D. Kyotani4, 11,  Y. Kato5, 11,
T. Kasahara6, 11,  A. Toyoda7, 11,  S. Watanabe8, 11,  Y. Seto9, 11,  T. Ashikaga10, 11 and
M. Miyazawa1, 11. 1Kao Co., Tochigi, Japan; 2Kanebo Cosmetics Inc., Kanagawa,
Japan; 3Kose Co., Tokyo, Japan; 4Cosmos Technical Co., Ltd., Tokyo, Japan; 5Nippon
Menard Cosmetic Co., LTD., Aichi, Japan; 6Fujifilm Co., Kanagawa, Japan; 7Pola
Chemical Industries, Inc., Kanagawa, Japan; 8Lion Co., Kanagawa, Japan; 9P&G
Japan K.K., Hyogo, Japan; 10Shiseido Co., LTD., Kanagawa, Japan; 11Working Group
for In Vitro Skin Sensitization Evaluation in Japan Cosmetic Industry Association
(JCIA), Tokyo, Japan. Sponsor: J. Avalos.
For the replacement of the LLNA, the combination of several alternative methods
is necessary. JCIA organized a working group to investigate testing strategies. In this
study, considering the applicable domain, we demonstrated the utility of a testing
strategy using the human Cell Line Activation Test (h-CLAT), Direct Peptide
Reactivity Assay (DPRA) and the in silico system, DEREK. A total of 133 chemi-
cals, some of which exhibt poor water-solubilities, were evaluated. For h-CLAT,
THP-1 cells were exposed to each test chemical for 24 hours. The CD86 and
CD54 expressions were analyzed by flow cytometry. For DPRA, model peptides
were mixed with test chemical for 24 hours. The depletion of peptides was analyzed
by HPLC. For DEREK, the alert of chemical structure was examined. For 133
chemicals, the accuracy of h-CLAT, DPRA and DEREK to predict LLNA results
was 78, 74 and 74%, respectively. Next, we investigated 3 testing strategies: the
Integrated Testing Strategy (A), a tiered approach (B), and a multiple regression
analysis model (C). Each strategy had a high potential prediction (A:84%, B:81%,
C:84%). Regarding false negative chemicals, some chemicals induced no cytotoxic-
ity and other chemicals crystallized or separated in the medium and the buffer. The
logP values of these chemicals were mostly above 3.5. If hydrophobic chemicals
(logP>3.5) were removed from analysis, the accuracy was improved to A:88%,
B:86%, C:87%. The sensitivity was improved to A:96%, B:97%, C:100%. All
strategies provided an accuracy of 73% for the potency prediction. These results
suggested that every strategy has high predictivity for the potential and potency.
970 Refinement of the Prediction Model of the Myeloid U937
Skin Sensitization Test (MUSST).
C. Piroird,  F. Ibanez,  J. Faugere,  C. Gomes,  N. Alépée and S. Martinozzi-
Teissier. L’Oréal Research & Innovation, Aulnay sous Bois, France. Sponsor: E.
Dufour.
Background: In line with the 3Rs concept, in vitro alternatives methods are being
developed based on the early events of the skin sensitization process. One of these is
the capacity of skin dendritic cells to recognize a chemical as a danger. Since the late
nineties, L’Oréal has actively worked on the Myeloid U937 Skin Sensitization Test
(MUSST) which models this early event by measuring the up-regulation of CD86
expression, a co-stimulatory receptor. Year’s in house use of this assay allowed us to
demonstrate its value in combination with other assays (DPRA, Nrf-2 activation)
for the prediction of sensitization hazard (Sensitizer S /NonSensitizer NS) of cos-
metic ingredients. A third class was defined as “Inconclusive (INC)” where the
MUSST is not able to conclude S or NS. The aim of this study was to refine the
predictive model in order to reduce the number of INC, by maintaining the pre-
dictive capacities of the MUSST.
Methods: 208 substances with LLNA data were analyzed. MUSST results on this
set gave 92 S, 56 NS predictions and 60 INC. Statistical methods based on a stack-
ing scoring method were applied on raw data of these 60 INC in order to find ad-
ditional rules to classify these substances into S or NS.
Results: a combination of 6 rules was identified, that allows to classify 44/60 INC
into 23 S and 21 NS with a sensitivity of 95% and a specificity of 91%. The pre-
dictive performances of the MUSST on the 208 substances with the optimized pre-
diction model composed of the original prediction model and the additional 6
rules-based model show 84% concordance, 87% sensitivity and 79% specificity
against LLNA data. No false negative are observed among the extreme and strong
sensitizers.
Conclusion: The optimized MUSST is an efficient assay for the skin sensitization
hazard characterization, promising as a tool to be integrated within a battery of as-
says to perform a skin sensitization risk assessment.
971 In Vitro Phototoxicity Screening Assay for Systemically-
Administered Pharmaceuticals Using a Reconstructed Skin
Model Epiderm.
P. Hayden,  Y. Kaluzhny,  M. W. Kinuthia,  L. d’Argembeau-Thornton,
H. Kandarova and M. Klausner. MatTek Corporation, Ashland, MA.
According to current regulatory guidelines, photosafety testing is required for new
compounds if they absorb light in the range of 290–700 nm or partition into the
skin or eyes. The only approved non-animal in vitro phototoxicity assay, the 3T3
Neutral Red Uptake (3T3 NRU-PT), is overly-sensitive in predicting the in vivo
photosafety hazard to humans and thereby eliminates valuable, new active pharma-
ceutical ingredients (API) from further development, even though they are safe to
humans. 
EpiDerm™, a normal human 3-dimensional (NHu-3D) skin model, is highly re-
producible, contains an in vivo-like barrier, possesses in vivo-like biotransformation
capabilities, and has been pre-validated for determining phototoxicity of topically
applied materials. Here, we utilized EpiDerm to develop an in vitro assay for
screening the phototoxicity of pharmaceuticals following systemic administration
(sPHO). Test articles (n=42) were added into the culture medium and allowed to
partition into the epidermal tissue. Tissues were exposed to solar radiation and pho-
totoxic effects were determined by the comparing the tissue viability of UV irradi-
ated vs. non-irradiated tissue models, using the MTT assay. A prediction model
(PM) was established: a material is phototoxic after systemic administration if one
or more test concentrations in the presence of irradiation (+UVR) decreases tissue
viability by ≥30% when compared to identical concentrations in the absence of ir-
radiation (-UVR); a material is non-phototoxic if the decrease in tissue viability is <
30%. The PM resulted in high sensitivity (91.7%) and specificity (100.0%) for 42
test materials (24 phototoxic/18 non-phototoxic). Results of sPHO assay were
compared to in-house 3T3-NRU-PT assay. 
The current protocol extends phototoxicity testing using EpiDerm for risk assess-
ment to systemically administered chemicals and medications and will provide the
pharmaceutical industry with an in vitro screening method to assess the phototoxic
risk of new API.
972 Validation of In Vitro and Clinical Safety Assessment of
Behentrimonium Chloride-Containing Leave-on Body
Lotions Using Postmarketing Adverse Event Data.
D. Cameron1,  G. Costin2,  L. Kaufman3,  J. Avalos1,  M. Downey1,
W. Billhimer1,  S. Gilpin1,  N. Wilt2 and A. F. Simion1. 1Kao USA, Inc.,
Cincinnati, OH; 2Institute for In Vitro Sciences, Inc. (IIVS), Gaithersburg, MD;
3Scripterra Scientific, Cincinnati, OH.
Behentrimonium chloride (BTC) is a straight-chain alkyltrimonium chloride com-
pound commonly used as an antistatic, hair conditioning, emulsifying-surfactant
or preservative agent in personal care products. Although the European Union re-
stricted the use of alkyltrimonium chlorides and bromides as preservative to ≤0.1%,
these compounds have been safely used at ≤10% in hundreds of cosmetic products
for other uses than as a preservative. In vitro, clinical, and controlled consumer
usage tests in barrier-impaired individuals were conducted to determine if whole
body, leave-on skin care products containing 1-3% BTC cause dermal irritation or
any other skin reaction with use. BTC-containing formulations were predicted to
be non-irritants by the EpiDerm™ skin irritation test and the bovine corneal opac-
ity and permeability (BCOP)/chorioallantoic membrane vascular assay (CAMVA)
ocular irritation test battery. No evidence of allergic contact dermatitis or cumula-
tive dermal irritation was noted under the exaggerated conditions of confirmatory
human occlusive patch tests. No clinically assessed or self-reported adverse reactions
were noted in adults or children with atopic, eczematous, and/or xerotic skin dur-
ing two-week and four-week monitored home usage studies. These results were val-
idated by post-marketing data for five body lotions, which showed only 0.69 unde-
sirable effects (skin irritation) reported per million shipped consumer units during
2006-2011. No serious undesirable effects were reported during in-market use of
the products. Therefore, if formulated in appropriate conditions at 1-3%, BTC will
not likely cause dermal irritation or delayed contact sensitization when used in a
whole-body, leave-on product.
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973 Collaboration Study on Eye Irritation Alternative Method
with Human Corneal Mode; Labcyte Cornea-Model24.
H. Kojima1, 2,  N. Annaka2,  S. Tsuchiya2,  Y. Yoshitake2,  R. Xu2,  M. Suzuki2,
W. Shimatani2,  A. Kajita2,  M. Nakamura2,  M. Watanabe2,  M. Nakajima2,
K. Sakamoto2,  R. Takeda2,  M. Hisama2,  H. Ikeda2,  A. Inagaki2,
Y. Munechika2,  Y. Yamamoto2,  T. Kasahara2,  T. Fukuda2,  S. Nakahara2,
S. Watanabe2,  H. Kurata2,  S. Shinoda2 and M. Katoh3, 2. 1Division of
Pharmacology, National Institute of Health Sciences, Tokyo, Japan; 2Japanese Society
for Alternative to Animal Experiments, Tokyo, Japan; 3Japan Tissue Engineering Co.,
Ltd., Aichi, Japan.
LabCyte CORNEA-MODEL24 is a human corneal model that was developed by
Japan Tissue Engineering Co., Ltd. (J-TEC) as an alternative to animal tests for oc-
ular irritation. It has been reported to provide highly-accurate predictions. A first
step toward the future inclusion of this method in test guidelines is to verify trans-
ferability of the protocol. In collaboration with the Planning Committee of the
Japan Society for Alternative to Animal Testing, a call for collaborating partners was
issued, with respondents participating in a technical training session and a collabo-
ration study to identify potential problems with the protocol. A total of twenty-
four laboratories responded to the call for collaborating partners. These laboratories
were divided into four groups, and four chemicals as well as a positive control were
distributed to each group without coding. These sixteen chemicals and their control
groups were tested using a WST-8 assay to determine cytotoxicity and thereby ver-
ify transferability of the protocol. As a result, we had a good inter- and intra-labo-
ratory reproducibility in this study. On the other hand, a number of problematic
points have already been noted, including several difficult-to-understand parts of
the protocol and an inability to clear standard values for negative controls. The fu-
ture inclusion of this method in established guidelines requires smooth implemen-
tation of a validation process, and a first step in that process is to verify the trans-
ferability of a suitable protocol.
974 Assessing Eye Irritation Potential of Cosmetic Products
Using the STE Test.
T. Abo1,  Y. Nukada1,  K. Ooshima2,  T. Hayashi2,  D. Araki2,  D. Cameron3,
J. Avalos3,  A. F. Simion3,  A. Kirst4,  A. Fuchs4,  R. Fautz4,  H. Sakaguchi1 and
N. Nishiyama1. 1Kao Corporation, Tochigi, Japan; 2Kanebo Cosmetics Inc.,
Kanagawa, Japan; 3Kao USA, Cincinnati, OH; 4Kao Germany, Darmstadt,
Germany.
Various in vitro assays that have been developed as an alternative for the Draize test
are currently used to evaluate the eye irritation potential of cosmetic products and
ingredients. A Short Time Exposure (STE) test, which we developed as a potential
alternative test for eye irritation using rabbit cornea cells (SIRC), is planned for peer
review and expected to be accepted as an OECD test guideline for classifying mate-
rials as Non-irritant/Irritant (NI/I). The test is expected to be able to evaluate cos-
metic products as well as chemicals and cosmetic ingredients. Firstly, we evaluated
the accuracy of the STE test against GHS classification for 20 cosmetic products
(14 rinse-off and 6 leave-on products). Secondly, the results of STE test (including
various rinse-off and leave-on products) were compared with the results of 43 cos-
metic products tested in BCOP (bovine cornea opacity and permeability) test, 20
cosmetic products tested in HET-CAM, and 40 cosmetic products tested in
CAMVA (two hen egg chorioallantoic membrane tests) in order to confirm the ho-
mology of in vitro assays used for evaluating eye irritation of the cosmetic products.
In the first step, the accuracy for STE classifying a product as NI/I, compared to
GHS, was 90% (18/20). Furthermore, STE test is able to provide a rank order
(minimal irritant, moderate irritant and severe irritant) for materials based on the
cell viability. The accuracy which compared GHS classification to a rank order of
STE test was 75% (15/20). In the second step, comparison between STE test and
three in vitro assays demonstrated that the accuracy of STE classifying a product as
NI/I compared to BCOP, HET-CAM, and CAMVA was 79% (34/43), 80%
(16/20), and 90% (36/40), respectively. Our findings show that STE test can be an
alternative for the Draize test as well as for the three in vitro assays used to evaluate
a cosmetic product.
975 The Interlaboratory Reproducibility of the STE Test for
Assessing Eye Irritation of Cosmetic Products.
Y. Nukada1,  T. Abo1,  A. Hilberer2,  A. Heppenheimer3,  M. Watanabe4,
K. Ooshima5,  D. Cameron6,  A. Kirst7,  H. Sakaguchi1 and N. Nishiyama1. 1Kao
Corporation, Tochigi, Japan; 2Institute for In Vitro Sciences, Inc., Gaithersburg, MD;
3Harlan Cytotest Cell Research GmbH, Rossdorf, Germany; 4Food and Drug Safety
Center, Kanagawa, Japan; 5Kanebo Cosmetics, Inc., Kanagawa, Japan; 6Kao USA,
Cincinnati, OH; 7Kao Germany, Darmstadt, Germany.
The Short Time Exposure (STE) test, a potential alternative test for eye irritation
using rabbit cornea cells (SIRC), is planned for peer review and expected to be ac-
cepted as an OECD test guideline for classifying materials as Non-irritant/Irritant
(NI/I). Currently, we evaluated the technical transfer and inter-laboratory repro-
ducibility of the STE test at 3 contract research laboratories and lead laboratory
(Kao Corp). We first assessed the technical transfer at the 3 contract labs by using 5
chemicals (sodium lauryl sulfate, calcium thioglycolate, Tween 80, 1-octanol, and
dodecane). Cell viability, following exposure to a 5% concentration, was used as an
indicator of eye irritation potential, where a material is considered a NI if the via-
bility was more than 70% and an I if the viability was less than 70%. Furthermore,
a rank order (minimal irritant, moderate irritant and severe irritant) was given to
materials based on scores obtained from exposures to 5% and 0.05% concentra-
tion. All 3 contract labs had reproducible and similar results for the 5 chemicals
confirming the technical transfer among the contract labs. The inter-laboratory re-
producibility was confirmed by using 21 cosmetic products (13 rinse-off and 8
leave-on products) and assessed by comparing the accuracy (i.e., ability to classify
same materials as either NI or I, and same rank order) of the results among the 3
contract labs and Kao Corp. The respective accuracy for classifying as either NI/I
for Lab A, B and C were 100, 81 and 95%. The respective accuracy for obtaining
the same rank order for Lab A, B and C were 95, 67 and 76%. Overall, our findings
show that a good inter-laboratory reproducibility was obtained for STE test using
the finished cosmetic products.
976 Choosing the Appropriate Solvent for Solid Materials Tested
in the Bovine Corneal Opacity and Permeability (BCOP) In
Vitro Assay.
G. Costin1,  Y. Jeong2,  D. Anderson2,  J. E. Bader1,  L. Krawiec1,  J. R. Nash1 and
H. Raabe1. 1Institute for In Vitro Sciences, Inc. (IIVS), Gaithersburg, MD; 2The Dow
Chemical Company, Midland, MI.
In compliance with OECD Test Guideline 437 for eye irritation (BCOP assay),
non-surfactant solid materials are typically tested as 20% dilutions prepared in
0.9% sodium chloride solution, distilled water, or other solvent that has been
demonstrated to have no adverse effects on the test system. However, the limited
solubility of some chemicals adds technical challenges in finding a vehicle that
would ensure the material’s availability to the excised corneas and that itself would
not affect the test system. In this study, we evaluated five solvents frequently used in
the BCOP assay: distilled water, mineral oil, corn oil, polyethylene glycol (PEG)-
400, and methocel solution (0.5%). Based on the available classification systems,
our preliminary data showed that water, methocel, mineral oil and corn oil were
predicted as non-irritants, while PEG-400 was predicted as a mild irritant. To
demonstrate the influence of the type of solvent on the outcome/prediction of the
BCOP assay for solid materials, we tested a 20% suspension of benzoic acid (BA)
prepared in these solvents. BA has a non-polar benzoic ring that would preferably
dissolve in non-polar solvents and a polar acidic group with affinity for polar sol-
vents, thus making it a good model for testing its effect on corneas when dissolved
in various solvents. Previous animal tests reported moderate to severe eye irritation
induced by BA. Our results demonstrated that when mixed in water, mineral oil,
corn oil, or methocel, BA was predicted to be a corrosive/severe irritant, while it
was predicted to be a moderate irritant when mixed in PEG-400. These results sup-
port the need for further investigation of the solvent’s influence in the BCOP assay
to allow the correct prediction of the irritation potential of solid materials.
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977 Predicting Eye Irritation of Agrochemical Formulations
According to Different Classification Schemes by In Vitro
Methods.
S. N. Kolle1,  A. Büchse2,  T. Knieriemen3,  M. Rey-Moreno1,  W. Meyer3,  A. van
Cott4,  S. Gröters1,  B. van Ravenzwaay1 and R. Landsiedel1. 1Experimental
Toxicology and Ecology, BASF SE, Ludwigshafen am Rhein, Germany; 2Scientific
Computing, BASF SE, Ludwigshafen am Rhein, Germany; 3Agricultural Products
Formulation Development, BASF SE, Ludwigshafen am Rhein, Germany;
4Agricultural Products - Global Product Safety & Registration, BASF Corporation,
Research Triangle Park, NC.
The bovine corneal opacity and permeability (BCOP) test has been adopted by
OECD for the identification of ocular corrosive and severe irritants (GHS category
1) for single component substances and multi-component formulations. Further,
human reconstructed tissue models have been suggested for incorporation into a
tiered test strategy to ultimately replace the Draize rabbit eye irritation test (OECD
TG 405) and the value of the EpiOcular Eye Irritation Test (EIT) for the prediction
of ocular non irritants (GHS no category) has been shown previously. The purpose
of this study was to evaluate whether the BCOP including corneal histology and
the EIT could be used to predict eye irritancy of agrochemical formulations accord-
ing to different classification schemes including UN GHS, EPA and ANVISA sys-
tems. We have assessed opacity, permeability and histology in the BCOP assay and
relative tissue viability in the EIT for 50 agrochemical formulations with available
in vivo eye irritation data. Using the OECD TG guideline evaluation scheme for
opacity and permeability in the BCOP did not prove predictive with respect to se-
vere eye irritation potential for the 50 agrochemical formulations assessed here,
while corneal histology grades and the EpiOcular tissue viabilities where useful pre-
dictors of eye irritancy potencies. Further we describe here statistical evaluation
based on the experimental in vitro data to predict eye irritancy for the different clas-
sification schemes.
978 A Preliminary Investigation in the Use of Porcine Corneas As
a Substitute for Bovine Corneas in the BCOP Assay.
D. Wolfinger and D. R. Cerven. MB Research Laboratories, Spinnerstown, PA.
Sponsor: G. DeGeorge.
The Bovine Cornea Opacity and Permeability Assay (BCOP) has been used since
1992 to provide estimates of ocular irritation. It has been accepted as an alternative
to the use of rabbit in acute ocular safety testing. However in some areas of the
world, access to bovine eyes is limited, and the Draize eye-scoring test, performed
in rabbits, is still being utilized. In response to this, we have been investigating the
replacement of excised bovine corneas with porcine corneas for evaluation of acute
ocular irritation (PCOP). This preliminary investigation involved the evaluation of
100% ethanol, 0.1% Benzalkonium Chloride (BAK), and four cosmetic products,
all of which had previously been tested in the BCOP as well as the Chorioallantoic
Membrane Vascular Assay (CAMVA). Initially the results from the ethanol and
BAK testing in the porcine corneas showed no correlation to the results from
bovine corneas. These suggested the need for certain modifications to the trimming
and mounting procedures for the porcine corneas, which are smaller than the
bovine corneas. Thus, the trimming process to excise the cornea was modified, and
the same chambers supplied with the opacitometer for use with bovine eyes was also
used for the porcine eyes. After modifying the pre-testing procedures, we proceeded
to test four cosmetic compounds successfully in the BCOP and PCOP. These in-
vestigations indicate that the In Vitro Scores obtained with porcine eyes are similar
to those in bovine eyes. Additional evaluation with a wider range of chemical enti-
ties is underway.
979 In Vitro Ocular Irritation Testing Strategy for Prototype
Cleaning Products.
M. Bauman1,  K. Norman2,  G. Mun2 and H. Raabe2. 1S.C. Johnson & Son, Inc.,
Racine, WI; 2Institute for In Vitro Sciences, Gaithersburg, MD.
The Bovine Corneal Opacity and Permeability (BCOP) assay can be used for pre-
dicting mild, moderate, and severe ocular irritation through quantitative assess-
ment of the changes in opacity and permeability of bovine corneas. In addition, his-
tological evaluation of the corneas may be performed to assess the depth of damage.
The BCOP assay with histology was used to determine the ocular irritation poten-
tial of prototype cleaning products with antimicrobial claims according to the
guideline provided by the EPA-Office of Pesticide Programs (OPP). Several proto-
type cleaners of similar formulation were evaluated along with a reference material.
The results of the BCOP assay showed noticeable differences among the products.
The in vitro score, determined by changes in opacity and permeability of the
corneas, ranged from ~15 to 80. These scores indicate mild, moderate, and severe
irritation according to the guideline provided by the EPA-OPP. In addition, the his-
tological evaluation of the corneas showed differences in the depth of damage to the
stroma between moderate and severe category products, confirming the classifica-
tion of the products by the in vitro score. These results demonstrate the utility of
the BCOP assay with histology as a stand-alone assay for eye irritancy evaluation in
the EPA-OPP program. Furthermore, this testing strategy distinguished the ocular
irritation potential among similar prototypes demonstrating its effectiveness in the
product development process.
980 Development of a Human Corneal Full Thickness Tissue for
Eye Irritation Testing.
L. d’Argembeau-Thornton,  Y. Kaluzhny,  H. Kandarova,  P. Hayden and
M. Klausner. MatTek Corporation, Ashland, MA.
The FDA and other regulatory agencies require ocular irritation testing of ophthal-
mologic pharmaceuticals and consumer products. Human reconstructed tissue
models have been suggested for incorporation into a tiered testing strategy to re-
place the Draize eye irritation test (OECD TG 405) and for use as highly repro-
ducible and cost effective in vitro alternatives.
A newly developed Ocular-Corneal Full Thickness (OCFT) tissue model includes
epithelial, stromal, and endothelial layers. This model has been characterized in
terms of tissue morphology, expression of specific markers for human corneal ep-
ithelium (Cytokeratins 12, 14, and 19, stratifin, tight junction proteins ZO-1, oc-
cluding, and claudin), and NaFl leakage and transepithelial electrical resistance
(TEER) in response to chemical insults. Histological evaluation of the tissues was
used to provide information on the type and depth of the chemical insult. Also, the
OCFT model was used to assess tissue recovery following exposure to increasing
concentrations of surfactants and TA spanning the range of irritancy. Significant re-
covery at 24 and 48 hours was observed for non-irritants (NI) chemicals. The
OCFT tissue was also evaluated in a response to a battery of test articles (TA, n=65)
spanning the range from ocular corrosives and severe irritants (I) to non-irritants
(NI). In vivo irritancy levels were obtained from a published database and in vitro
effects were determined using the MTT tissue viability assay and TEER. Using a
tissue viability cutoff of 50%, the OCFT model was able to detect “I” with
100.0/75.0/and 87.7% specificity/sensitivity/and accuracy. 
The OCFT model will address the needs of ophthalmic and other formulators who
need to screen their products for irritancy and efficacy. Similar to other in vitro as-
says, high levels of reproducibility at a low cost are anticipated. The OCFT model
will facilitate the development and testing of ophthalmologic pharmaceuticals and
allow for basic studies related to corneal physiology, wound repair, and pathologies.
981 Validation of In Vitro Eye and Skin Irritation Assays for
Structurally Complex Pharmaceutical Chemicals.
N. Foglio2,  C. Villano1,  C. Risatti1,  H. Raabe3 and J. Gould1. 1Bristol-Myers
Squibb, New Brunswick, NJ; 2Rutgers University School of Pharmacy, Piscataway,
NJ; 3Institute for In Vitro Sciences, Gaithersburg, MD.
Identification of local ocular and dermal irritation effects is important for occupa-
tional health and hazard communication. OECD has published Test Guidelines
(TG) 439 for In Vitro Skin Irritation (EpiDerm™ System, MatTek) and TG 437
for the Bovine Corneal Opacity and Permeability Test Method (BCOP) to replace
or supplement in vivo tests, but their applicability to complex molecules found in
the pharmaceutical industry has not been fully investigated. A validation study was
conducted to compare in vivo eye (OECD TG 405) and skin irritation (OECD TG
404) to in vitro study data for Bristol-Myers Squibb (BMS) proprietary com-
pounds. The validation set consisted of 15 compounds, which were selected to rep-
resent the BMS chemical space within six chemical classes: αβ unsaturated car-
bonyls, α-halo ketones, aminoalcohols, boronic acids/esters, halogenated
heterocycles, and nitroaromatics. The assay results were interpreted using OECD
and GHS classification schemes and in vitro and in vivo results were compared
using basic statistics. The BCOP assay accurately predicted 12 of 15 compounds
when non- and mildly irritating classifications were grouped together. Both boronic
compounds were under-predicted by BCOP, suggesting the assay may not be ap-
propriate for this chemical class. The in vitro skin assay demonstrated high speci-
ficity by correctly identifying 12 of 13 negative in vivo skin irritants, but, the sensi-
tivity could not be interpreted from the limited number of positive skin irritants in
this study. Additional data are needed to assess the predictivity of positive skin irri-
tants with greater confidence. Overall, the replacement of in vivo studies with these
alternative in vitro irritation methods reduces and refines the tiered testing strategy
for ocular and dermal hazard identification of pharmaceutical chemicals.
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982 Surfactant Responses in the Bovine Corneal Opacity and
Permeability Assay: Points to Consider for In Vitro Eye
Irritation Testing.
J. E. Bader,  G. Costin,  A. Hilberer,  G. Mun,  J. R. Nash,  K. Norman,  N. Wilt
and H. Raabe. Institute for In Vitro Sciences, Gaithersburg, MD.
The Bovine Corneal Opacity and Permeability (BCOP) assay is an ex vivo test used
to evaluate the ocular irritation of a broad range of chemicals. In the regulatory clas-
sification and labeling arena, BCOP can be used to identify severe and corrosive eye
irritants according to the OECD Test Guideline (TG) 437. However, BCOP has
historically under-predicted certain anionic surfactants, when tested according to
the standard liquid protocol. TG 437 specifies that liquid surfactants may be tested
as 10% aqueous dilutions for 10 minutes (although alternate dilutions and expo-
sure times may be conducted with scientific rationale), and the relevant guidance
document (GD) No. 160 suggests that solid and concentrated liquid surfactants
may be diluted to 10% for testing. However, GD No. 160 further directs that sur-
factant-based formulations are usually tested neat, but could be diluted with justifi-
cation, imparting some confusion in identifying the most appropriate test methods.
Since neither the basis for selecting the appropriate surfactant test methods, nor the
justification for modifications are clearly presented in TG 437 or GD No. 160, we
present on the testing of sodium lauryl sulfate (SLS) in the BCOP assay, using stan-
dard and modified dilutions and exposures, to elucidate the impact of these vari-
ables on eye irritation prediction. For example, in vitro scores of 20.7, 28.4, and
28.3 were obtained when testing SLS at concentrations of 50, 20, and 10% for 10
minutes, showing that irritation responses were not fully concentration-dependent,
but demonstrated optimally at intermediate doses. When tested using modified ex-
posure times, SLS showed time-related responses, with improvements in irritation
predictions at the 20 and 30 minute exposures. Histopathology was performed to
assess the surfactant-induced corneal changes. Based upon these results, a frame-
work for testing surfactants, and surfactant-based formulations is proposed.
983 New Detecting Method for Estimating the Eye Irritation
Potential of Chemicals: An Alternative to the Draize Test.
S. Cho,  G. Nam,  J. Kim,  J. Cho and K. Shin. AMOREPACIFIC Corporation
R&D Center, Yongin-si, Republic of Korea.
Determination of eye irritation potential is an essential part of the safety assessment
of chemicals, pharmaceuticals, and cosmetics. For many years, the ocular irritation
potential of chemicals has been mainly evaluated by the Draize rabbit eye irritation
test (OECD Test Guideline 405). Because Draize rabbit eye irritation test is based
on subjective visual scoring evaluation, significant variability has been observed. In
addition, the test causes considerable discomfort and pain to the animal, and it has
also been identified that the eye irritation response of rabbits does not always corre-
spond to those of humans. For scientific reasons, animal welfare issues and the ban
of cosmetics in animal eye irritation tests in the European Union (EU), there are
many efforts to develop alternative methods replacing animal study.
Using a human corneal cell line (HCE-T cells), we developed a new alternative
method to assess the eye irritation potential of chemicals. We exposed HCE-T cells
to 3 fixed concentrations of the 38 chemicals (5%, 0.5%, and 0.05%) for 1 h and
measured the relative cell viability (RCV) at each concentration. Using the RCV
values at 5%, 0.5%, and 0.05%, we developed a new criterion for eye irritation po-
tential (total eye irritation score, TEIS) and estimated the ocular irritancy. We then
assessed the correlation of the results of TEIS with those of the Draize rabbit eye ir-
ritation. TEIS results exhibited good correlations (sensitivity: 80.77%, specificity:
83.33%, and accuracy: 81.58% for TEIS). We conclude that the new in vitro
model using HCE-T cells is a good alternative evaluation model for the prediction
of the eye irritation potential of chemicals.
984 Neonatal Hyperoxia Promotes Lung Fibrosis Independent of
Excessive Leukocyte Recruitment to the Lung following
Influenza A Virus Infection.
B. W. Buczynski1,  M. Yee2,  P. Lawrence1 and M. A. O’Reilly2. 1Environmental
Medicine, The University of Rochester, Rochester, NY; 2Pediatrics, The University of
Rochester, Rochester, NY.
There is a growing appreciation that environmental exposures during critically im-
portant periods of development can influence the onset of many childhood and
adult diseases. For example, preterm infants prematurely exposed to excess levels of
oxygen (hyperoxia) at birth are at increased risk for impaired lung development and
are often more sensitive to respiratory viral infections later in life. Similarly, adult
mice exposed to 100% oxygen during PND 0-4 exhibit persistent lung simplifica-
tion, as well as an increase in inflammation and fibrosis following infection with in-
fluenza virus. Levels of the inflammatory chemokine MCP-1 are selectively in-
creased following infection in these mice. Since increased levels of MCP-1 are often
associated with pulmonary inflammation and fibrosis, we hypothesized that Mcp-
1-/- mice exposed to hyperoxia at birth would have an attenuated inflammatory re-
sponse and reduced fibrotic repair following infection with influenza virus. Prior to
infection, lung simplification was evident and indistinguishable amongst Mcp-1+/+
and Mcp-1-/- mice exposed to hyperoxia at birth. When infected, Mcp-1-/- mice
exposed to hyperoxia had reduced mean body weight loss and leukocyte recruit-
ment to the lung in comparison to Mcp-1+/+ mice exposed to hyperoxia. Although
leukocyte recruitment was not excessive following infection in Mcp-1-/- mice ex-
posed to hyperoxia, they still developed pulmonary fibrosis, which was not ob-
served in infected Mcp-1-/- mice exposed to room air. Thus, the aberrant fibrotic
repair observed following infection in mice exposed to hyperoxia at birth occurs in-
dependently of excessive leukocyte recruitment to the lung. Our findings identify
novel neonatal hyperoxia-mediated pathways disrupted in response to influenza
virus infection, which may provide insight into how early-life exposure to high lev-
els of oxygen leads to childhood and adult diseases later in life.
985 Integrating Genome and Transcriptome Data to Understand
Susceptibility to Postnatal Lung Injury.
J. Nichols1,  A. Burkholder1,  J. Lu1,  Z. McCaw1,  O. Suzuki2,  D. Fargo1,
P. Bushel1,  T. Wiltshire2 and S. R. Kleeberger1. 1NIEHS, Durham, NC; 2Eshelman
School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Late lung development is a critical window of susceptibility as perturbations impair
alveolarization and vascular development. Currently, genetic control of differential
gene expression during lung development and injury is incompletely understood.
We hypothesized that integration of genetics and genomics in expression quantita-
tive trait loci (eQTL) analysis will identify genetic factors contributing to variability
in the neonatal lung and characterize genetic susceptibility. Full term neonates from
30 inbred strains of mice were maintained in room air or exposed to 95% oxygen
for 72hrs beginning on postnatal day 1 (P1). Lungs were collected from 3
neonates/group for each strain on P4. RNA was isolated for transcriptomic analysis
using Illumina WG6v2.0 BeadChips. Transcript intensities were analyzed for dif-
ferential expression, and associations between genetic polymorphisms and tran-
script intensity (eQTLs) were identified by haplotype association mapping with
FastMap. 4513 differentially expressed transcripts were identified on P4, and cis-
eQTL analysis, or associations between a transcript and polymorphism in the same
gene, yielded 29 genes. Biologically interesting candidate genes included Adam17,
Prdx1, Tnfaip2, and Eif2ak2. After hyperoxia exposure, 5386 transcripts were dif-
ferentially expressed. 1230 were specifically hyperoxia-induced and related to devel-
opmental and inflammatory pathways. 23 cis-eQTLs were identified and biologi-
cally interesting candidates included Vcp, Casp9, and Trim30. These analyses
identified significant interstrain variation in transcript levels in the developing lung
that is, in part, due to genetic background. Furthermore, network and pathway
analysis of these candidate genes pointed to a novel role for the integrated stress re-
sponse and proteostasis in neonatal lung development and injury.
986 Analysis of the Developmental Origins of Health and Disease
(DOHaD) Grant Portfolio at the NIEHS.
A. Haugen,  T. T. Schug and J. J. Heindel. Division of Extramural Research and
Training, NIEHS, Research Triangle Park, NC. Sponsor: M. Humble.
Environmental exposures combined with genetics can have a persistent influence
on common chronic health conditions of children and adults. A growing body of
research at the National Institute of Environmental Health Sciences (NIEHS) is fo-
cusing on environmental effects during early-life development and disease occur-
rence over the lifespan—a branch of scientific study referred to as Developmental
Origins of Health and Disease or the “DOHaD paradigm.” This paper describes
the evolution of DOHaD research at NIEHS and how extramural events, including
Requests for Applications (RFA) in the areas of Fetal Basis of Adult Disease
(FeBAD), children’s health, and epigenetics, have stimulated the field of environ-
mental health science as it relates to DOHaD. In order to build and analyze a port-
folio of active NIEHS-funded grants in the area of DOHaD, the electronic
Scientific Portfolio Assistant (eSPA) software application was used. DOHaD port-
folios for the years 1991, 2001, and 2011 were analyzed for exposures,
disease/organ endpoints, windows of exposure, study design, and impact on the
field based on publication data. Priority exposures in the 1991 and 2001 portfolios
comprise of metals (e.g. lead and mercury), PCBs, and air pollutants; but by 2011,
the portfolio has evolved to include or expand the variety of endocrine disruptors
(e.g. BPA, phthalates), pesticides/Persistent Organic Pollutants (POPs) (e.g.
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organophosphates, organochlorines, PBDE, PAH), and metals (e.g. arsenic, man-
ganese). Several disease endpoints related to brain/CNS are apparent across all three
portfolios, whereas reproduction and cancer increase steadily over the same time
period, and new endpoints like obesity are introduced by 2011. The analysis of
NIEHS-funded DOHaD research provides insight into the institute’s impact on
the field, and will help determine how to improve the quality and health impact of
future, funded DOHaD projects.
987 Effects of Gutkha Use during Pregnancy on Hepatic
Parameters Later in Life.
S. P. Doherty-Lyons1,  C. Hoffman1,  J. Odin3,  I. Fiel3,  F. Ganey2,
D. J. Conklin4 and J. T. Zelikoff1. 1Environmental Medicine, New York University
School of Medicine, Tuxedo, NY; 2Memorial Sloan-Kettering Cancer Center, New
York, NY; 3Mount Sinai School of Medicine, New York, NY; 4University of Louisville,
Louisville, KY.
Gutkha, a popular smokeless tobacco (ST) herbal concoction made in India and
sold throughout India and the U.S, is a combination of tobacco, lime, betel and
areca nut, spices, and catechu. Recent evidence demonstrates that consuming
gutkha during pregnancy may be linked to adverse obstetric consequences.
However, whether gutkha exposure during pregnancy increases offspring risk of
chronic disease later on in adulthood, as with combustible tobacco products, re-
mains unknown. For this study, pregnant B6C3F1 mice were exposed daily to 21
mg of a water-soluble gutkha solution beginning on gestational day (GD) 2-4 until
parturition. The main objectives of this study were to evaluate whether prenatal ex-
posure to gutkha altered offspring susceptibility for hepatic disease later in life.
After male pairing, female mice were exposed to a gutkha solution via the oral mu-
cosa. Serum cotinine levels in pregnant mice were measured weekly and ranged
from 24-44 ng/ml. Cotinine levels, also measured in the amniotic fluid and fetal
liver on ~GD 15, averaged 21-22 ng/ml. Beginning at 12-wk-of-age, a sub-group
of male and female offspring were fed a high fat (HF) diet for 14 days. Male off-
spring prenatally exposed to gutkha and fed subsequently a HF diet had increased
hepatic fat mass, fibrosis, and inflammation compared to the other groups.
Additionally, female offspring exposed to gutkha alone had significantly higher
serum levels of the hepatic injury markers, alanine transaminase and aminotrans-
ferase. In conclusion, findings from these studies demonstrate that gutkha usage
during pregnancy may have persistent later life effects that increase the risk of adult
liver disease. As gutkha use by pregnant women in the South Asian communities
are increasing exponentially, such a menacing public health behavior requires im-
mediate attention. Supported by Memorial Sloan Kettering Cancer Institute.
988 Transcriptomic Profiling of Embryos and Adult Female Brain
Tissue Links a Developmental Origin of Atrazine-Induced
Reproductive Alterations in Zebrafish.
G. J. Weber1,  S. M. Peterson1,  S. S. Lewis2,  M. S. Sepulveda2 and
J. L. Freeman1. 1Health Sciences, Purdue University, West Lafayette, IN; 2Forestry
and Natural Resources, Purdue University, West Lafayette, IN.
Atrazine, an herbicide commonly applied to agricultural areas throughout the
Midwest and a common contaminant of potable water supplies, is implicated as an
endocrine disruptor and potential carcinogen. The specific adverse health effects as-
sociated with atrazine exposure and the underlying molecular mechanisms of these
effects are not well defined. In an effort to delineate the mechanisms of atrazine tox-
icity, we exposed zebrafish embryos to environmentally relevant concentrations of
atrazine shortly after fertilization through 72 hours post fertilization (hpf ).
Transcriptomic profiles immediately following the embryonic atrazine exposure
were obtained and subsequent analyses identified an enrichment of genes with al-
tered expression patterns that are involved in neuroendocrine development and
function, cell cycle regulation and carcinogenesis. From these exposures a subset of
individuals was permitted to mature under normal conditions to evaluate later life
effects of the developmental exposure and in unexposed subsequent generations. A
significant difference in the number of pairs that successfully bred in one of the
atrazine treatment groups coupled with distinct altered reproductive histological
and morphological alterations in female adult zebrafish was observed indicating a
later life effect of the developmental atrazine exposure. Furthermore, gene ontology
analysis from microarrays performed on adult female zebrafish brains showed en-
richment for genes involved in neuroendocrine system function and disease. The
reproductive alterations observed in the adult females along with decreased mating
success and altered transcriptomic profiles provide support to the endocrine dis-
rupting effects of this herbicide and warrant further mechanistic investigation.
Current efforts are aimed at assessing transgenerational effects of this developmen-
tal atrazine exposure in subsequent unexposed generations.
989 Bisphenol A and Diethylstilbesterol Treated Mice Respond
Differently to a Very High Fat Diet.
L. Chalifour1, 2,  B. Patel1, 2 and I. A. Sebag1, 2. 1Lady Davis Institute, Montréal,
QC, Canada; 2McGill University, Montréal, QC, Canada.
Rationale: Bisphenol A (BPA) is an estrogenizing endocrine disruptor, and diethys-
tilbestrol (DES) is a non-steroidal estrogen. Some data suggest that BPA is an obe-
sogen. We hypothesized that BPA and/or DES would increase the metabolic impact
of a very high fat diet and that this obesity would reduce heart structure/function. 
Methods: C57bl/6n mice were exposed to Vehicle, oral BPA (5.0μg/kg/da) from
gestation day 11 to weaning and then (0.5μg/kg/da) to 4 months, or diethylstilbe-
strol (DES, 1μg/kg/da) from GD 11-14. Mice were fed control (CD, 10% calories
from fat) or very high fat (HFD, 60% calories from fat) diets from weaning. Body
weight (BW) and body length (BL) were measured monthly. Body mass index
(BMI) and body surface area (BSA) were calculated. Glucose tolerance was tested at
15 weeks. Echocardiography, organ weights and serum for cholesterol, triglycerides
and leptin were collected at 16 weeks. 
Results: All HFD mice had increased BW, BL, BMI and BSA. HFD VEH and BPA
males had similar increases in total fat and total fat indexed to BW or BSA, but
HFD BPA males were smaller in BW, BMI and BSA. HFD VEH and BPA females
had similar total fat and total fat indexed to BW or BSA, BW, BMI and BSA. In
contrast, HFD DES treated males and females had the least fat gain, BW, BMI and
BSA. Cholesterol and triglycerides were increased with HFD in all males and leptin
was increased in BPA and DES males. Cholesterol, triglycerides and leptin were in-
creased with HFD identically in VEH, BPA and DES females. Glucose tolerance
was reduced with HFD equally in all mice. Fractional shortening was unaffected,
but HFD induced eccentric cardiac hypertrophy in VEH and BPA with DES mice
showing the greatest increase. 
Conclusions: Neither BPA nor DES worsened the response to a very HFD. VEH
and BPA mice responded similarly to a very HFD. DES mice had a blunted meta-
bolic response to a very HFD. Cardiac function was unaffected, but cardiac struc-
ture was affected by HFD.
990 Analysis of Transcriptional Profiles and Functional
Clustering of Global Cardiovascular Gene Expression in
Response to In Utero B(a)P Exposure.
G. E. Jules1,  S. Pratap2,  A. Ramesh3 and D. B. Hood1. 1Neuroscience and
Pharmacology, Meharry Medical College, Nashville, TN; 2Microbiology &
Immunology, Microarray/Bioinformatics Core, Meharry Medical College, Nashville,
TN; 3Biochemistry and Cancer Biology, Meharry Medical College, Nashville, TN.
Interest in the correlation between environmental toxicants and cardiovascular dis-
eases has increased considerably over the past few decades. However, little is known
of B(a)P’s effect on the developing heart or the specific biological pathways altered
by B(a)P. Functional comparative genomic analysis of the cellular and developmen-
tal effects of different polycyclic aromatic hydrocarbon (PAH) compounds is con-
sidered a helpful approach to distinguish the complex and specific effects of B(a)P
exposure in utero. Using timed-pregnant Long Evans Hooded rat offspring, we
characterize the genetic modulation in cardiovascular related genes for three con-
centrations of B(a)P (0, 600, and 1,200 μg/kg/BW) at postnatal days 0 and 53 (P-
0 and P-53). In utero exposure to B(a)P at both 600 and 1,200 μg/kg/BW signifi-
cantly modulated the expression of 89 out of 45,000 genes in offspring. The
focused microarray approach identified important subgenomic differences in the
pattern of cardiovascular disease cell-related gene expression in response to in utero
B(a)P exposure. These molecular targets and deduced networks may be employed
as a guide for classifying, monitoring and manipulating the molecular and patho-
logical specificities of different PAHs in key cardiovascular related cell systems and
for potential pharmacological application.
991 Maternal DDT Exposure Increases Risk of Metabolic
Syndrome in Adult Offspring.
M. La Merrill1, 4, 2 and C. Buettner3, 2. 1Environmental Toxicology, University of
California Davis, Davis, CA; 2Metabolism Institute, Mount Sinai School of Medicine,
New York, NY; 3Endocrinology, Diabetes, Bone Disease, Mount Sinai School of
Medicine, New York, NY; 4Preventive Medicine, Mount Sinai School of Medicine,
New York, NY.
DDT is associated with altered carbohydrate and lipid homeostasis in animals that
have been exposed to relatively high doses, and with increased risk of type 2 dia-
betes and hypertension in human studies. We hypothesized that maternal exposure
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to DDT would increase the risk of metabolic syndrome in the adult offspring of
mice. We administered DDT to C57BL/6J mice from gestational day 11.5 to post-
natal day 5, when litters were culled to six pups. We performed comprehensive
metabolic phenotyping in offspring. Maternal DDT exposure increased diastolic-
and systolic- blood pressure in adult offspring. Maternal DDT exposure also caused
a mild obese phenotype in female offspring that was due to impaired thermoregula-
tion (increased cold intolerance) and decreased energy expenditure while food in-
take was not different. When these female offspring were fed a diet high in fat, they
developed elevated fasting insulin and lipids. Thus, the results from the current
study suggest that maternal DDT exposure leads to metabolic syndrome in adult
offspring.
992 Mechanisms Underlying Neurodevelopmental Defects in
Weanling and Adult Rats Associated with Prenatal Exposure
to Methylmercury.
D. De Groot1,  C. De Esch1,  M. de Groot1,  C. Kuper1,  R. Stierum1,
A. Wolterbeek1,  E. De Vries2,  N. Cappaert3,  M. Radonjic1 and R. Woutersen1.
1TNO the Netherlands, Zeist, Netherlands; 2Groningen University Medical Center,
Groningen, Netherlands; 3University of Amsterdam, Amsterdam, Netherlands.
A Developmental Neurotoxicity (DNT) study with MeHg was carried out in
Wistar rats [Guidelines US-EPA OPPTS 870.6300/8600]. To map neurodevelop-
mental defects of MeHg and uncover underlying mechanisms, cerebellum and cere-
brum of female F1-rats, prenatally exposed to MeHg via maternal diet (GD6 -
PD10), were sampled at weaning (PD18-21) and adulthood (PD61-70). Brain tis-
sues were analysed by [18F]FDG PET functional imaging, synaptic excitation
analysis and microarray gene expression profiling.
Brain activity and functionality of neurotransmission assessed by [18F]FDG PET
imaging and synaptic excitation analysis revealed a delay in brain activity and im-
paired neural function. The findings were substantiated by genome-wide transcrip-
tome analysis. The discovered transcriptional patterns revealed that exposure to
MeHg causes (1) a delay in onset of neural development and/or function and (2) al-
terations in pathways related to structural and functional aspects of nervous system
development. The latter includes changes in gene expression of developmental reg-
ulators, developmental-phase associated genes, small GTPase signaling molecules
and representatives of all processes required for synaptic transmission. Marked re-
pression of genes regulating brain development and neural function were observed
particularly at PD70, showing that prenatal exposure to MeHg has long-lasting ef-
fects in adult brain. No effects of MeHg were found in tests proposed in DNT
guidelines.
Summarizing, structural and functional defects associated with MeHg were demon-
strated with [18F]FDG PET functional imaging, synaptic excitation analysis and
microarray gene expression profiling, and molecular mechanisms underlying these
developmental defects identified. The findings are relevant from a health perspec-
tive, but also show that the approaches used are sensitive and superior to conven-
tional tests proposed in current DNT guidelines.
993 Vulnerability Windows of the Developing Rat Brain to
TBTO Demonstrated by Animal-Friendly MRI.
M. Berk1, 2,  S. Folkertsma1,  M. de Groot1, 3,  A. Knaapen1,  I. Waalkens1,
A. Wolterbeek1,  R. Woutersen1,  A. Veltien2,  A. Heerschap2 and D. De Groot1.
1TNO, the Netherlands, Zeist, Netherlands; 2Radboud University Medical Center
Nijmegen, Nijmegen, Netherlands; 3IRAS, Utrecht University, Utrecht, Netherlands.
To design a proper strategy for safety evaluation of drugs for children and adoles-
cents information on the vulnerability of the brain during critical phases of devel-
opment is essential. In this study developmental and juvenile exposure windows
proposed in current guidelines for toxicity testing were studied in a rat model with
tributyltinoxide (TBTO). 
Rats were exposed to 8mg TBTO/kg BW/day during development (TBTOdev:
gestation day (GD)8 to postnatal day (PD)10) or adolescence (TBTOjuv: PD22-
PD62). Brain weight (cerebrum and cerebellum separately) was determined at
weaning (PD22) and young adult age (PD62). Brain (region) volume was esti-
mated from magnetic resonance (MR) images. Brain specific gravity (SG) was cal-
culated from the ratio [weight / volume]. Relative growth for these brain measures
was calculated over time (from PD22 to PD 62) for control and TBTO-exposed
brains.
Effect of TBTOdev included reduced cerebral weight but increased volume at
PD22, whereas at PD62 both weight and volume appeared reduced. Effects of
TBTOjuv implied reduced weight and increased volume at PD62. Effect of
TBTOdev on brain SG was most pronounced on cerebrum at PD22, which was no
more observed at PD62. Effect of TBTOjuv (PD62) was most pronounced on SG
of cerebellum/brainstem. MRI scans demonstrated that effects within cerebrum
were located in particular in anterior regions.
Together, the results demonstrate the relevance of exposure windows relative to the
vulnerability of the developing brain; under the circumstances of this study the
brain appeared more vulnerable when exposed during development with largest ef-
fects on cerebrum at adolescent age (PD22). Effects of juvenile exposure appeared
mild, and seemed to affect both cerebrum and cerebellum/brainstem (PD62). The
results are discussed in light of TBTO-induced delayed development, persistent ef-
fects at adult age and a speculative role of TBTO as obesegon.
994 The Effects of Endocrine Disruption on the Maturation of
the Developing Human Fetal Prostate.
C. Saffarini1,  E. V. McDonnell1,  A. Amin2,  S. J. Hall1 and K. Boekelheide1.
1Pathology and Laboratory Medicine, Brown University, Providence, RI; 2Pathology
and Laboratory Medicine, Rhode Island Hospital, Providence, RI.
The etiology of prostate cancer is unknown, although it has been suggested that
early life exposures to various toxicants, such as estrogenic chemicals, may play an
important role. Previous studies in rat models have demonstrated that early life ex-
posures to estrogens is responsible for causing epithelial and stromal hyperplasia,
inflammation, and prostatic intraepithelial neoplasia (PIN) lesions. We have devel-
oped a xenograft rodent model to characterize the growth and differentiation of
human fetal prostate implants (gestational age 12-24 weeks). This model encom-
passes the effects of both early and later-life exposures to either corn-oil (control) or
250 ug/kg/body weight of 17β-estradiol 3-benzoate post-transplant. To ensure
proper growth of implants, the renal subcapsular space was chosen as the site of im-
plantation to allow for appropriate growth and vascularization of prostate tissue.
This model was characterized based on the expression of key immunohistochemical
markers responsible for epithelial and stromal maturation including p63, cytoker-
atins 18, alpha smooth muscle actin, vimentin, caldesmon, ki-67, prostate specific
antigen, estrogen receptor-α, and androgen receptor. As expected, the human fetal
implants grew and matured as demonstrated by the histopathology seen in 7, 14,
30, 90, 200 and 400 day xenografts. Interestingly, the human prostate xenografts
exhibited marked differences in response to estrogen exposure compared to their
endogenous rodent prostate counterparts. The endogenous rodent prostates exhib-
ited atypical hyperplasia along with the presence of massive cellular debris after es-
trogen exposure, while the human prostates demonstrated basal cell hyperplasia as
indicated by p63 staining. This study of human fetal prostate tissue will allow for
future mechanistic studies investigating the origins of prostate disease.
995 Characterizing Later-Life Spatial Discrimination Deficit
Phenotypes following In Utero Exposure to Benzopyrene.
M. M. McCallister1,  M. Maguire1,  R. Rhoades1,  B. Hudsell2,  A. Ramesh3,
M. Newland2 and D. B. Hood1. 1Neuroscience and Pharmacology, Center for
Molecular and Behavioral Neuroscience, Meharry Medical College, Nashville, TN;
2Department of Psychology, Auburn University, Auburn, AL; 3Department of
Biochemistry and Cancer Biology, Meharry Medical College, Nashville, TN.
To characterize observed behavioral learning deficit phenotypes in offspring adult
rodents arising from in utero exposure to benzo(a)pyrene [B(a)P], timed-pregnant
Long Evans Hooded rats or Cytochrome p450- reductase (Cprlox/lox) mice were
exposed to either B(a)P (0, 150, 300, 600 and 1200μg/kg BW or aerosol
100ug/m3 on embryonic days 14 to 17. In the pre-weaning period, B(a)P metabo-
lites were examined in cerebral cortex. No detectable levels of metabolites were
found in the control offspring during the pre-weaning period but dose-related in-
creases in B(a)P metabolites were seen in cerebral cortex and revealed a time-de-
pendence for elimination during this period.. Reversal learning was evaluated using
a spatial discrimination-reversal procedure in adult offspring. Offspring that were
exposed in utero to 600 and 1200 μg/kg BW or 100ug/m3 required a significantly
higher number of sessions to complete the first reversal than control offspring.
However, with original discrimination and subsequent reversals, exposed offspring
behavioral profiles resembled their respective controls. This effect was seen in errors
of commission, indicative of perseveration or resistance to extinction. Offspring
that were exposed in utero also had shorter choice latencies than controls during the
first session of a reversal. Activity related-cytoskeletal associated protein (Arc), an
experience-dependent cortical protein marker known to be up-regulated in re-
sponse to acquisition of novel behaviors, was also upregulated in B(a)P exposed an-
imals that were trained in the behavioral paradigm. Collectively, the findings sup-
port the hypothesis that in utero exposure to B(a)P during the critical window for
peak neurogenesis produces later-life learning deficit phenotypes in offspring.
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996 Does the Barker Hypothesis Apply to Maternal
Nanomaterial Exposure and Fetal Microvascular Function?
P. G. Stapleton,  V. C. Minarchick,  J. Yi,  C. R. McBride,  K. Engles and
T. R. Nurkiewicz. Physiology and Pharmacology, West Virginia University,
Morgantown, WV.
The continued development of engineered nanomaterials (ENM) has given rise to
concerns over the potential for human health effects. While the lung is the primary
site of exposure, the cardiovascular system is a principal site of impact. One of the
most complex and acutely demanding circulations is the enhanced maternal system
to support fetal development. The “Barker Hypothesis” proposes that metabolic
impairments during gestation predispose future sensitivity. Herein we initiated test-
ing at the microvascular level. 
Pregnant (gestation day 10) Sprague-Dawley rats were exposed to nano-titanium
dioxide aerosols (count mode aerodynamic diameter of 137 nm, 10 mg/m3, 4
hrs/day) for 10 days to evaluate the maternal and fetal consequences of maternal ex-
posure. The calculated daily maternal deposition was 20 μg. 
These exposures lead to fetal irregularities and maternal microvascular dysfunction.
Isolated maternal uterine arteriolar (< 150 μm) reactivity was significantly impaired
overall, consistent with an metabolically impaired profile. This dysfunction pre-
sented as blunted endothelium-dependent reactivity (acetylcholine, Ach, 10-9-10-4
M), reduced adrenergic responsiveness (phenylephrine, 10-9-10-4 M), and im-
paired myogenic responsiveness (transmural pressure, 15-120 mm Hg). 
With respect to the fetal group, maternal exposures lead to a significant decrease in
total fetal weight. Fetal tail arteries (< 150 μm) were isolated to assess microvascular
alterations after maternal exposure. Interestingly, the vessels from the exposed
group also demonstrate significant impairment to increasing concentrations of
ACh (10-9-10-4 M), spermine-NONOate (10-9-10-4 M), and increases in trans-
mural pressure. 
Collectively, impaired uterine microvascular reactivity after ENM exposure during
pregnancy can reduce nutrient exchange, drastically impacting fetal weight and
number. This prenatal exposure may also lead to cardiovascular consequences for
the developing fetus. 
NIH-RO1-ES015022 and RC1-ES018274 (TRN)
NSF-1003907 (VCM)
997 The AhR Contributions to Cardiovascular Development,
Developmental Toxicity, and Adult Disease.
V. S. Carreira1,  Y. Fan1,  J. Rubinstein2,  M. Jiang2 and A. Puga1. 1Environmental
Health, University of Cincinnati, Cincinnati, OH; 2Internal Medicine, University of
Cincinnati, Cincinnati, OH.
Developmental disruption has been increasingly recognized as a key contributor to
adult disease. Exposures to ubiquitous environmental persistent organic pollutants
(POPs), which includes the pervasive organic pollutant 2,3,7,8-
Tetrachlorodibenzo-p-dioxin (TCDD), can result in abnormalities of the cardiovas-
cular system at the structural and functional levels. TCDD is a prototypical aryl-hy-
drocarbon receptor (AHR) ligand but the precise pathogenesis and phenotype of
TCDD developmental toxicity remains poorly characterized. Our work aims at un-
derstanding how developmental perturbations (TCDD-exposure) or absence
(knockout) of the AHR pathway affects the cardiovascular system in the embryo
and adult. To characterize the toxicity phenotype, C57BL/6J pregnant dams were
oral-gavaged with different doses of TCDD (0.1, 0.5, 1, 2.5, 5, and 50 μg/Kg) or
vehicle control at key murine cardiogenesis time points (E7.5, 9.5, and 11.5).
Embryos were harvested at E13.5, 15.5, and 18.5 or carried to term and adulthood.
Additionally, C57BL/6J Ahr-/- mice were included in postnatal functional studies.
At all studied doses, embryos could be carried to term; however, pups died within
24 hours post-partum at the three highest doses. Embryo cardiac toxicity was char-
acterized by dynamic changes in morphometric parameters (right and left ventricu-
lar free wall thickness, cellular density, nuclear size, and extracellular matrix) as well
as the changes in the expression of the Ahr and cellular proliferation proteins. The
postnatal functional studies highlighted LV cavity dilatation in the Ahr-/- mice at
PND60 and 90. These results corroborate the heart as a target of developmental
disruption by in-utero exposure to a POP. Moreover, since all biological effects of
TCDD exposure are believed to be mediated through AHR signaling, these results
underscore the critical role for the AHR pathway in normal cardiovascular develop-
ment. Supported by NIH Grant R01ES06273.
998 Exposure to 2, 3, 7, 8-Tetrachlorodibenzo-p-dioxin (TCDD)
Changes Morphology of Dendritic Spines in the Developing
Anteroventral Periventricular Nucleus (AVPV).
J. Del Pino Sans1, 2 and S. Petersen2. 1Toxicologia y Farmacologia, University
Complutense of Madrid, Madrid, Spain; 2Veterinary and Animal Sciences, University
of Massachusetts, Amherst, MA.
Developmental exposure to TCDD interferes with masculinization of luteinizing
hormone release patterns and sexual behaviors. Consequently, female-typical
luteinizing hormone LH surge release and mating postures can be elicited by ovar-
ian hormones in exposed males. Thus, it is likely that TCDD interferes with
processes important for masculinization the brain. Dendritic spine plasticity plays a
role in sexual differentiation of preoptic areas important for sexual behavior, but no
work has examined whether similar processes regulate differentiation of the an-
teroventral periventricular nucleus (AVPV), the brain region that controls LH surge
release. Likewise, no work has previously investigated the effects of TCDD on
modulation of dendritic spines morphology.  In these studies, we used Golgi stain-
ing to examine sex differences and lasting effects of TCDD exposure on spine den-
sity and shape in the AVPV of rats. We found that compared with female counter-
parts, Postnatal Day 30 (PD30) control males had significantly more dendritic
spines overall. In addition, the shapes of the spines differed between the sexes with
males having more mushroom and stubby spines, but fewer thin dendritic spines
than females. Lactational exposure to TCDD (600 ng p.o. to dams on PND1) did
not change the overall density of dendritic spines in the AVPV. However, exposed
males had more thin dendritic spines and stubby spines, but fewer mushroom
spines than controls. These findings suggest that TCDD interferes with AVPV de-
velopment by both replacing the high surface area mushroom dendritic spines with
thin and stubby spines. Dendritic spines play a major role in neuronal plasticity and
integration of signals, so by altering the number and shape, TCDD exposure dur-
ing development may permanently alter gonadotropin release mechanisms.
999 Breast Cancer 1 (BRCA1)-Deficient Mice Develop Normally
but Are More Susceptible to Ethanol- and
Methamphetamine-Initiated Embryopathies.
A. M. Shapiro1,  L. Miller2 and P. G. Wells1, 2. 1Pharmaceutical Science, University
of Toronto, Toronto, ON, Canada; 2Pharmacology and Toxicology, University of
Toronto, Toronto, ON, Canada.
Brca1 is a DNA repair gene associated with certain familial breast and ovarian can-
cers, and heterozygous (+/-) Brca1-deficient mice develop normally but are more
susceptible to cancer later in life. Little information is available on the developmen-
tal consequences of Brca1 deficiencies, but homozygous (-/-) Brca1 knockout mice
are embryolethal and no confirmed cases of human -/- knockouts exist, even in
families where both parents are carriers. To further investigate the role of Brca1 de-
ficiencies during embryonic development, a conditional Brca1 knockout, driven by
a Sox2 promoter, was implemented in an embryo culture system. Sox2-promoted
Cre-expressing hemizygous males were mated overnight with floxed Brca1 females
(plug designated gestational day (GD) 1). On GD 9, embryos were explanted and
grown in culture for 24 hours. Western blot analysis indicated a 35% reduction of
Brca1 expression in +/- conditional knockout progeny. As previously reported, un-
treated +/- Brca1-deficient embryos developed normally relative to their wild-type
littermates. However, following exposure to the reactive oxygen species (ROS)-ini-
tiating teratogens methamphetamine and ethanol, +/- Brca1-deficient progeny ex-
hibited increased embryopathies at concentrations that were not toxic in their wild-
type Brca1-normal littermates. Preliminary studies suggested an increase in
oxidatively damaged DNA, measured as 8-oxoguanine (8-oxoG), in drug-exposed
embryos, which was further enhanced with Brca1 deficiencies. Ongoing studies are
underway to localize the 8-oxoG lesions and investigate other forms of DNA dam-
age. The protection by Brca1 against embryonic ROS suggests a novel role for
Brca1, and has implications for drug exposure during pregnancy. [Support:
Canadian Institutes of Health Research]
1000 Validation of a ToxCast Predictive Signature for Vascular
Disruption in a Complex Angiogenesis Assay.
N. Kleinstreuer1,  R. Sarkanen2,  T. Heinonen2 and T. B. Knudsen1. 1NCCT, US
EPA, Research Triangle Park, NC; 2FICAM, Tampere, Finland.
Analysis of the ToxCastDB Phase-I dataset revealed a strong in vitro signature for
vascular disruption and developmental toxicity (>90% correlation) based on multi-
ple angiogenic growth factors, chemokines, and receptors. Computer simulation
with a multicellular agent-based model (ABM) predicted phenotypic effects on the
structural integrity and complexity of a developing endothelial network.
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Embryonic vascular development can be disrupted by diverse compounds (thalido-
mide, estrogens, endothelins, dioxin, retinoids, cigarette smoke, metals).
Collaborative studies are underway to test these predictions across an array of assays
(whole embryo culture, aortic explants, endothelial tubulogenesis, transgenic ze-
brafish, etc.). Here, we describe initial results with a complex human-cell based in
vitro angiogenesis assay, on the first 7 of 20 ToxCast Phase I chemicals selected by a
range of predicted activity as vascular disrupters (pVDCs). Degree of endothelial
tubule formation in vitro was scored by AC50 values relative to cytotoxicity. Both
chemicals predicted as non-pVDCs, imazamox and pymetrozine, showed no in-
hibitory activity. The predicted inhibitory potential of 5 pVDCs was confirmed for
4 out of 5 chemicals. Pyridaben, predicted as a strong pVDC, inhibited tubule for-
mation in a concentration-dependent manner in the FICAM assay, first evident at
0.001 μM and complete at 0.01 μM. Other predicted pVDCs with different
ToxCast activity profiles (BPA, oxytetracycline, fluazinam) inhibited endothelial
tubulogenesis at concentrations ranging from 5- to 500 μM. PFOS was the one in-
active pVDC tested; however, the ToxCast prediction was based on inhibition of
Ang1/Tie2 signaling that controls later stages of vessel stabilization – a subtle out-
come in the ABM simulation. Overall, concordance between the tubulogenesis
assay and computer ABM simulation demonstrates the utility of these in vitro and
in silico models for predictive modeling and mechanistic understanding of vascular
disruption in higher-order biological tissues. [This work does not reflect EPA pol-
icy].
1001 A Metabolite-Based Biomarker Approach to Predict
Developmental Toxicity Using Human Embryonic Stem
Cells.
A. M. Smith,  J. A. Palmer,  P. R. West,  K. R. Conard,  L. A. Egnash,  M. E. Ross,
B. R. Fontaine,  P. Bais,  E. L. Donley and R. E. Burrier. Stemina Biomarker
Discovery, Inc., Madison, WI. Sponsor: L. Recio.
Birth defects are the largest cause of infant morbidity and mortality in the United
States. Teratogens, defined as substances that cause fetal abnormalities during de-
velopment, are responsible for 5-10% of all birth defects. The application of more
predictive developmental toxicity screens would reduce the prevalence of birth de-
fects and increase pharmaceutical and chemical safety. Human embryonic stem cell
(hESC) technology provides an innovative and robust alternative in vitro model
system to predict developmental toxicity of chemicals. We have developed a tar-
geted, rapid and highly predictive assay based on specific biomarker metabolites
identified after analysis of metabolomics data obtained from hESCs exposed to 23
known human teratogens and non-teratogens. The new model predicts the concen-
tration at which hESCs respond to treatment indicating the potential teratogenicity
based on treatment dose. We have tested this approach in over 60 compounds with
varying degrees of toxicity in animal tests. hESCs were exposed to a 9-point dose
curve of each compound. Spent media was collected and analyzed by high resolu-
tion LC/MS using a targeted metabolomics approach to determine the relative
abundance of the biomarkers present in the model. We have built a database of the
expected teratogenicity of the tested compounds in in vivo and in vitro tests. The
results show excellent concordance with both human and animal teratogenicity
data and compare well to other commonly used in vitro assays for developmental
toxicity. This new targeted biomarker approach continues to utilize LC/MS analy-
sis while allowing for an 8-fold increase in instrument throughput and simplified
analysis. This biomarker based assay is an attractive new quantitative model provid-
ing faster turn around and lower cost, while retaining high predictivity for early as-
sessment of the developmental toxicity potential across a broad range of chemicals
at multiple treatment levels in an all human derived system.
1002 Metformin-Induced Folate Deficiency-Like Malformations in
Cultured Rat Embryos: Potential for Novel Species
Sensitivity.
C. Zhang1,  J. Panzica-Kelly1,  G. L. Gong2 and K. Augustine1. 1Bristol-Myers
Squibb, Pennington, NJ; 2Bristol-Myers Squibb Co., Princeton, NJ. Sponsor: L.
Lehman-McKeeman.
Metformin has been used alone or in combination with other drugs, including
those recently approved, for patients with Type II diabetes. Even though there has
not been metformin associated teratogenic outcomes, about 7% of patients treated
with metformin present subnormal vitamin B12 levels, suggesting the drug may at-
tenuate folate metabolism. Some reports in rats indicated that metformin may have
weak teratogenic properties resulting in a low incidence (~0.5-1%) of rare neural
tube abnormalities, similar to those caused by folate deficiency. Mouse embryos
cultured with metformin also presented delayed neural tube closure. Our objectives
were to evaluate whether metformin causes adverse effects on neural tube develop-
ment in rats (a standard test species for GLP teratology studies) using whole em-
bryo culture, and metabolomics to determine whether the compound disrupts fo-
late processing. Neurulating rat embryos were exposed to metformin at concentra-
tions observed in rats and humans. Embryos were evaluated for viability, growth,
morphology, and metabolite profiles. Methotrexate was used as a positive control
for adverse morphology and metabolomic profiles induced by disrupted folate sig-
naling. Metformin caused concentration-related neural tube malformations and
embryo lethality occurring at human clinical concentrations. Co-administered
folinic acid with metformin completely rescued the malformations as well as altered
metabolites at rat concentrations and partially rescued the adverse effect at the sub-
lethal human exposure concentration. Together, the studies suggested that rat neu-
rulation may be sensitive to metformin, and the effects were related in part to folate
signaling. Given the severity of neural tube findings at clinical concentrations that
only caused recoverable anomalies in cultured mouse embryos and no reported ef-
fects in human pregnancy, the study suggests that the rat embryo may present novel
species-sensitivity to metformin.
1003 Placental Transfer of 125Iodinated Humanized
Immunoglobulin G2Δa in the Sprague-Dawley Rat.
P. S. Coder1,  J. A. Thomas1,  D. B. Stedman2 and C. J. Bowman2. 1WIL Research,
Ashland, OH; 2Pfizer Inc, Groton, CT.
Biopharmaceuticals are a growing segment of the health care therapeutic arsenal
and indications for these agents are rapidly expanding into patient populations that
include women of child bearing potential. The fetus is typically not a target of these
drug therapies, and thus effects on the developing conceptus are generally undesir-
able. While small molecules generally cross the placenta via passive diffusion
throughout gestation, transfer of large molecules is limited and may be species de-
pendent. Antibody-like biopharmaceuticals (Abs), that contain an Fc region, are
unique and cross the placenta using active transport pathways normally reserved for
maternal immunoglobulin G (IgG). Embryo/fetal, placental and maternal tissue
concentrations of an Ab in Sprague Dawley rats were evaluated by 2 different
biodistribution techniques following maternal injection of 125Iodinated hIgG2Δa
on different gestation days. Blood and tissue samples were collected for gamma
counting or whole maternal carcasses were processed for quantitative whole body
autoradiography. The results indicate the presence of maternally injected IgG in the
conceptus as early as Gestation Day (GD) 11 and a >1000 fold increase in that
amount by GD 21, with the overall tissue concentration generally remaining un-
changed during gestation (within the same order of magnitude). In addition, fetal-
maternal tissue concentration ratios remain stable during organogenesis with only a
slight increase at the end of gestation. These data indicate that Abs with a target
present in the developing conceptus have the potential to elicit an unintended bio-
logical response depending on the Ab affinity and potency. These data also demon-
strate that maternally-administered Abs may be present during organogenesis and
have the potential for adverse developmental outcomes in the rat based on direct
embryo/fetal exposure.
1004 Evidence That Perfluorooctanoic Acid (PFOA) Does Not
Activate Estrogen Receptor (ER) Activities In Vivo or In
Vitro.
P. Yao1,  D. J. Ehresman2,  J. M. Caverly-Rae3,  S. Chang2,  S. R. Frame3,
J. L. Butenhoff2,  G. L. Kennedy3 and J. M. Peters1. 1The Pennsylvania State
University, University Park, PA; 23M Company, St. Paul, MN; 3Haskell Global
Centers for Health and Environmental Sciences, Newark, DE.
We evaluated the potential of perfluorooctanoate to produce estrogenic activity in
both an in vivo uterotrophic assay and an in vitro estrogen receptor (ER) activation
assay. In the in vivo study, pre-pubertal female CD-1 mice born to dams fed an es-
trogen-free diet from PND 14 through weaning on postnatal day (PND 18) were
given daily oral doses of 0, 0.005, 0.01, 0.02, 0.05, 0.1 or 1 mg/kg PFOA on PND
18-20. In addition, a positive control received daily 17β-estradiol (E2, 0.5 mg/kg).
On PND 21, the uterus and vagina were weighed and prepared for histology.
Transcripts concentrations for the ER responsive genes pS2, progesterone receptor
(PR), and trefoil factor (TFF) were quantitated in the uterus (quantitative RT-
PCR). Serum PFOA concentrations were determined by LC-MS/MS. PFOA
caused no changes in body weights, uterine weights, transcripts for ER target genes,
or in squamous hyperplasia and cornification of the vaginal epithelium. E2 admin-
istration produced increased relative uterine weight, increases in transcript concen-
trations for ER-responsive genes, and squamous hyperplasia and cornification of
the vaginal epithelium. Mean serum PFOA ranged from 5 to 1200 ng/mL. In the
in vitro study, PFOA at 0, 0.0005, 0.001, 0.005, 0.01, 0.05, 0.1, 0.5, 1, 5 or 10
μg/ml in media failed to affect estrogen response element activity in a human ovar-
ian carcinoma cell line (BG1-Luc4E2) that carried an estrogen response element
(ERE)-luciferase reporter construct; whereas, E2 exhibited a marked increase.
Collectively, these data do not support an estrogenic effect of PFOA either in vivo
or in vitro.
SOT 2013 ANNUAL MEETING 215
1005 Effects of Di(2-Ethylhexyl)-Phthalate Exposure during the
Peripubertal Period: An Analysis of the Evidence.
A. D. Kraft,  D. Segal and S. Makris. National Center for Environmental
Assessment, US EPA, Washington DC.
Di(2-ethlylhexyl)phthalate (DEHP) is a widely-used plasticizer and ubiquitous en-
vironmental contaminant. DEHP exposure during late gestation in rodents has
been shown to cause a spectrum of adverse effects related to altered androgen func-
tion, collectively termed the “phthalate syndrome”. Thus, many studies on DEHP
have focused on exposures during this critical period of organ development and
outcome measures in male offspring. A more limited database exists for other end-
points or following exposures that do not encompass fetal development. One such
exposure paradigm involves DEHP treatment in young adult animals during the
period of sexual maturation. Several of these peripubertal exposure studies suggest
that the observed responses differ from those manifested following gestational
DEHP exposure. In an effort to evaluate the consistency of these observations, data
were collected from studies analyzing the effects of DEHP on adolescent humans or
animals exposed during the peripubertal period. This evidence was cumulated by
endpoint, the specific timing of DEHP exposure, and the age that the outcome was
assessed. The observations were then compared to evidence from exposures during
fetal development. The human evidence was difficult to interpret, as exposure tim-
ing could not be ascertained. Based on the animal data, several outcomes, including
male reproductive system toxicity, showed evidence of differential effects following
peripubertal exposure. Mechanisms that may explain these differences, such as pro-
posed effects on postnatal androgen biosynthesis, were considered in light of bio-
logical plausibility to inform the interpretation of these data. Overall, our analysis
suggests that the peripubertal period may be a stage of development sensitive to
DEHP exposure; however, more comprehensive studies are needed to determine
the impact of DEHP exposure on sexually immature adolescents. 
Disclaimer: The views expressed are those of the author and they do not represent
U.S. EPA policy or guidance.
1006 Diet Acclimation of NZW Rabbits for Use in Embryo-Fetal
Development Studies.
K. Robinson1,  A. I. Martin1,  M. Freke1,  I. Primakova1,  R. Perras2,  E. Lewis3
and A. M. Hoberman3. 1Reproductive & Juvenile Toxicology, Charles River,
Montréal, QC, Canada; 2Charles River, St. Constant, QC, Canada; 3Charles River,
Horsham, PA.
Poor food intake in pregnant rabbits can lead to adverse outcomes including abor-
tion. Initial validation studies with a line of New Zealand White (NZW) rabbits,
showed a high incidence of inappetence and adverse pregnancy outcomes. Several
studies were conducted to optimize diet acclimation procedures at the breeding fa-
cility to match the certified diet used at the Testing Facility. Once the diet acclima-
tion procedure was optimized, a study was conducted that met the ICH guideline
for evaluation of embryo-fetal development (EFD). Naturally bred adult female
NZW (Crl:KBL[NZW]) rabbits were received from Charles River, Canada on Day
0 or 1 postcoitum (pc). For the premating diet acclimation the does were fed in-
creasing percentages of an irradiated version of PMI 5322 for 10 days before being
given this diet alone at 150 or 180g/day for a further 10 days. The animals were fed
180g/day of PMI 5322 during the study. The does (22/group) were dosed with
standard vehicles from Days 7 to 19 pc by oral gavage, intravenous injection, or in-
halation; in addition there was a room control. Food consumption was measured
daily and body weights were collected twice weekly. Clinical observations and any
signs of abortion or premature delivery were recorded twice daily. Terminal exami-
nations on Day 29 pc included a necropsy, corpora lutea counts and evaluation of
the uterine contents. Live fetuses were weighed and examined for external, visceral
and skeletal abnormalities. The does showed a high pregnancy rate and a low abor-
tion rate. The occurrence of periods of inappetence during gestation was negligible.
Ovarian, uterine and fetal parameters were comparable to other lines of NZW rab-
bits, but with slightly higher litter sizes and consequently slightly lower fetal
weights noted. In conclusion, the diet acclimation procedure decreased the inappe-
tence that was seen in previous rabbit reproductive toxicology studies and this line
of NZW rabbit is considered suitable for use on EFD studies.
1007 Epigenetic and Physiologic Effects of Perinatal Lead
Exposure.
A. K. Barks,  C. Faulk,  J. Goodrich,  O. S. Anderson,  K. E. Peterson and
D. Dolinoy. Environmental Health Sciences, University of Michigan School of Public
Health, Ann Arbor, MI.
Epidemiological and animal data suggest that development of chronic conditions
such as obesity in adulthood is influenced by early life exposures. A proposed mech-
anism for this link is epigenetic modification. This study investigates effects of peri-
natal lead (Pb) exposure on DNA methylation and alterations in physiologic pa-
rameters, including body composition and spontaneous activity. Using the viable
yellow agouti (Avy) mouse, perinatal Pb exposure was modeled by a/a maternal ex-
posure via drinking water supplemented with 0 ppm (control), 3.7 ppm (low), 27
ppm (medium), and 55 ppm (high) Pb two weeks prior to mating with an Avy/a
male. Pb exposure continued through gestation and lactation. Epigenetic effects
were evaluated by scoring coat color of Avy/a offspring (N=172), and physiologic
parameters were evaluated in 3 month old wildtype a/a offspring (N=72) at the
University of Michigan Nutrition and Obesity Research Center (MNORC). A sta-
tistically significant shift towards yellow coat color, indicative of DNA hypomethy-
lation at the Avy allele, was observed in high dose Avy/a offspring, compared to
controls (p=0.01). In a/a offspring, body weight was increased in high dose females,
compared to controls (p=0.04). Females had increased % body fat and decreased %
lean body mass across all exposure groups, compared to controls (p<0.05). Males
showed significant differences in medium (decreased % lean mass) and high (in-
creased % fat mass) Pb doses, compared to controls (p<0.05). Spontaneous activity
was significantly decreased in females, but not males, in medium and high doses,
compared to controls (p<0.05). There were no significant differences in food in-
take. Thus, perinatal Pb exposure resulted in both epigenetic and physiologic re-
sponses. Activity and body weight effects were more pronounced in females. Future
work includes quantitation of methylation at specific target genes and life-course
analysis of physiologic parameters of a/a offspring at 6 and 9 months of age.
Funding: P20 ES018171/RD83480001 and P30 DK08950.
1008 Embryotoxic Potential of Epoxiconazole In Vitro and In
Vivo.
B. Flick1,  F. DiRenzo2,  S. Schneider1,  S. Stinchcombe1,  E. Menegola2 and
B. van Ravenzwaay1. 1Experimental Toxicology and Ecology, BASF SE, Ludwigshafen
am Rhein, Germany; 2Department of Biology, University of Milan, Milan, Italy.
Some triazoles cause CYP26 inhibition of all-trans retinoic acid (RA) metabolism
during organogenesis known to cause cleft palate (CP), via a mode of action (MoA)
where altered tissue RA concentrations disrupt neural crest cell (NCC) migration,
impairing development of the branchial arches (BA). Since very high-dose epoxi-
conazole (EPX) treatment induces clear maternal toxicity, causing CPs, we exam-
ined whether these are also caused by this MoA. 
Both whole embryo culture tests (WEC) and in vivo studies were performed where
the development of the embryos was examined morphologically, NCCs were visu-
alized using whole immunostaining (WIS) for cellular retinoic acid binding pro-
tein, and embryonic tissue levels of EPX were analyzed with UPLC. 
In WEC, embryos were exposed to 0, 1, 3, 10, 20, 30 mg/l for 48 hours starting at
gestation day (GD) 9.5. EPX caused alterations in BA in 30% of the embryos at the
LOAEC (3 mg/l) and dysmophogeneses in 92% of embryos at 30 mg/l (embryonic
tissue conc. = 8 mg/l). Embryos exposed to at least 10 mg/l exhibited an abnormal
NCC distribution in the craniofacial region. 
In the in vivo study, embryos were harvested on GD 11 from dams gavaged since
GD6 with 0, 50, 100, and 180 mg/kg bw/d (the maximal tolerated dose which also
causes CP). EPX caused maternal toxicity at 100 and 180 mg/kg; however, these
embryos (embryonic tissue conc. = 6.4 mg/l) developed similarly to controls. No
treatment-related increase in dysmorphogenesis, no alterations of BA, and no dis-
turbance of NCC distribution were found. 
The observed dysmorphogenesis of BAs and the impaired migration of the NCCs
in the in vitro study supports the thesis that EPX alters CYP26-mediated RA me-
tabolism, causing CP. But, despite comparable embryonic tissue levels in the in vivo
study, neither the morphology nor the NCCs distribution was affected by EPX.
These data do not support the theory that EPX-induced cleft palate in vivo is
caused by alterations in RA metabolism.
1009 Perfluorooctanoic Acid-Induced Cytotoxicity in Primary
Cardiomyocyte Culture.
Q. Jiang and J. DeWitt. Department of Pharmacology and Toxicology, East Carolina
University, Greenville, NC.
Perfluorooctanoic acid (PFOA) is a perfluorinated compound (PFC) that is widely
used as a polymerization aid in the production of fluoropolymers. PFOA is envi-
ronmentally persistent and is now detected ubiquitously in biota. Numerous stud-
ies have shown that PFOA can induce developmental toxicity in laboratory animal
models. Epidemiological studies have demonstrated that PFOA exposure is associ-
ated with increased cholesterol levels and cardiovascular disease risk. We have previ-
ously reported that PFOA induces developmental cardiotoxicity in chicken em-
bryos and hatchlings. To investigate the mechanism, we developed primary
216 SOT 2013 ANNUAL MEETING
cardiomyocyte cultures from D10 chicken embryo hearts and evaluated cell viabil-
ity and reactive oxygen species (ROS) generation after in vitro PFOA exposure.
Primary cardiomyocytes were treated with vehicle (0.1% DMSO in medium) or
0.1, 1, 10, 50, 75 or 100 ug/ml of PFOA for 1h or 36h. No statistical differences
were detected between untreated and vehicle-treated groups. Viability was de-
creased by 74.5% in cells treated with 100 ug/ml of PFOA relative to the vehicle
group (n=4-6, P<0.05) at the 1h time point. At the 36h time point, viability was
statistically decreased at 10, 50, 75 and 100ug/ml concentrations, relative to the ve-
hicle group (18.1%, 18.7%, 34.6% and 70.0%, respectively; n=4-6, P<0.05). At
the 1h time point, an increase in ROS generation was observed at all doses; how-
ever, only 50 ug/ml of PFOA statistically increased ROS generation relative to the
vehicle group (316.8%; n=3, P<0.05). Our results indicate that direct PFOA expo-
sure to primary cardiomyocytes can induce cytotoxicity and ROS generation.
Although additional studies are necessary to verify this effect in vivo, induction of
cell death and generation of ROS may partially contribute to developmental car-
diotoxicity associated with in ovo PFOA exposure in an avian model.
1010 Estradiol Modulates Paraoxonase-2 Expression in Mouse
Brain.
G. Giordano1,  C. E. Furlong2,  T. B. Cole2 and L. G. Costa1, 3. 1Department
Environmental Occupational Health Sciences, University of Washington, Seattle, WA;
2Division of Medical Genetics and Department of Genome Sciences, University of
Washington, Seattle, WA; 3Department of Neuroscience, University of Parma, Parma,
Italy.
Paraoxonase 2 (PON2), a member of the PON gene family, is expressed in mouse
brain; levels are highest in dopaminergic areas (e.g. striatum), and are higher in as-
trocytes than in neurons or microglia. As in other tissues, PON2 exerts a potent an-
tioxidant effect in the CNS, and protects mouse neurons and astrocytes against ox-
idative stress. In all mouse tissues, including the brain, PON2 levels are higher in
female than in male mice. In primary striatal astrocytes and neurons PON2 protein
level in females is 2-3-fold higher than in males. Levels of PON2 mRNA and lac-
tonase activity show similar gender differences. Male astrocytes and neurons are
more sensitive (by 3-4-fold) than female cells to oxidative stress-induced toxicity,
though GSH levels do not differ between cells isolated from the two genders. In
contrast, no significant gender difference in susceptibility is seen in cells from
PON2-/- mice, suggesting that PON2 is a major determinant of gender differences
in susceptibility to oxidative stress-mediated neurotoxicity. Estradiol induces a
time-and concentration-dependent increase in the levels of PON2 protein and
mRNA in male (4.5-fold), and also in female (1.8-fold), astrocytes. Such effect is
due to activation of estrogen receptors alpha. In ovariectomized mice serum estra-
diol levels are decreased to male levels; PON2 protein and mRNA are also de-
creased to male levels in brain areas and in liver. Neuroprotection by estradiol
against oxidative stress-induced neurotoxicity is seen only in astrocytes from wild
type mice, but not in cells from PON2-/- mice, suggesting again that PON2 repre-
sent a major, gender-dependent, factor in protective CNS cells against neurotoxi-
cants. The lower expression of PON2 in males may have broad ramifications with
regard to susceptibility to diseases involving oxidative stress, including neurodegen-
erative diseases (Supp. in part by ES04696).
1011 Suppression of H19 Methylation in Mouse Exposed to
Chlorpyrifos Methyl during Organogenesis Period.
H. Shin1,  J. Seo1,  S. Jeong2,  S. Park1,  Y. Park1,  S. Son1 and H. Kang1.
1Toxicology & Residue Chemistry Division, QIA, Anyang, Republic of Korea; 2GLP
Research Center, Hoseo University, Asan, Republic of Korea.
Chlorpyrifos-methyl (CPM) is widely used organophosphorus insecticide. In
Korea, more than sixty-five tons per year are used in agriculture. In our previous
study, CPM showed anti-androgenic endocrine disruption activity. Lots of EDC
shows the alteration of methylaion in imprinting gene, which inherit to next gener-
ation. This study was performed to examine the effect of CPM on the H19 methy-
lation in mouse. 
After mating CAST/Ei (˛) and B6 (ˇ), CPM was administered at dose of 4
(CPM4), 20 (CPM20) and 100 (CPM100) mg/kg bw/day from embryonic day
(ED) 7 to ED 17. Anogenital distance (AGD) was measured at post natal day
(PND) 21. Clinical signs, body weights, feed and water consumption, organs
weights, serum hormone values and H19 methylaton level of organ and sperm were
measured at PND63.
Body weights were significantly (p value <0.0.1) lower than control until PND 6.
AGD was significantly (p value <0.0.1) decreased at CPM100 group in male and
increased at CPM20 group in female. The weight of thymus and epididymis were
significantly (p value <0.0.1) increased at all of CPM treatment in male. In CPM20
group, liver, kidney, heart, lung, spleen, prostate gland and testes were significantly
increased. Testosterone level in serum was significantly (p value <0.0.1) increased
by CPM treatment in both male and female. H19 methylation level of liver and
thymus showed decreased pattern by dose-dependent manner in male. The levels of
H19 methylation in sperm were 73.76±7.16%(CTL), 57.84±12.94%(CPM4),
64.24±3.79%(CPM20) and 64.24±3.79%(CPM100). 
CPM can disturb the early development of offspring development and disrupt
H19 methylation in organ and sperm. Those altered methylation pattern may pass
down to next generation through sperm.
1012 In Utero Growth Restriction and Dibutyl Phthalate Exposure
May Cooperatively Disrupt Steroidogenesis.
J. Pike1,  E. McDowell2,  A. Kisielewski2 and K. Johnson2. 1Biological Sciences,
University of Delaware, Wilmington, DE; 2AI Dupont Hospital for Children,
Wilmington, DE.
Masculinization of the male reproductive tract occurs in human gestational weeks
10-22, and rat gestational days 16-21. Fetal testes produce a surge of testosterone
causing reproductive masculinization. Disruption leads to reproductive abnormali-
ties including cryptorchidism and hypospadias. In humans, in utero growth restric-
tion (IUGR) is a risk factor for cryptorchidism and hypospadias. Rat work shows
that fetal steroidogenesis is disrupted by exposure to the anti-androgen dibutyl ph-
thalate (DBP). While these fetal circumstances increase the prevalence of the same
birth defects individually, we examined a possible cooperative effect of these treat-
ments on steroidogenesis. A maternal under-nutrition model was examined in the
rat. Pregnant Wistar rats were restricted to 50% (n=9) of the food eaten by ad libi-
tum controls (n=8) beginning on gestational day (GD) 3. Restriction through
GD17 caused a significant decrease in pup weight with no decrease in litter size.
Fetal testes showed decreased testosterone production (40%) by radioimmunoassay.
mRNA levels of steroidogenic genes including Scarb1 and Star were significantly
decreased in the fetal testis after growth restriction. Food restriction (n=11) from
GD3-18 caused no malformations at postnatal days 1, 14, or 28 as compared to
controls (n=10). A coexposure study of IUGR and maternal dosing with the anti-
androgen DBP was performed examining a cooperative effect on steroidogenesis.
Analysis of fetal testes (GD17) following 50% food restriction from GD3-17
(n=11) or exposure to DBP (250mg/kg/day) from GD15-17 (n=7) showed a sig-
nificant decrease in the expression of the steroidogenic genes Cyp11a1, Cyp17a1,
Scarb1, and Star as compared to controls (n=7). When 50% restriction was coupled
with DBP exposure (n=10), further decreased steroidogenic gene expression. While
IUGR and DBP lead to a decrease in steroidogenesis separately, they also appear to
work cooperatively to cause further disruption.
1013 A Comparison of Social Housing Opportunities during
Developmental Toxicity Evaluation in Cynomolgus
Monkeys.
S. M. Henwood1,  C. Luetjens2,  A. Fuchs2 and G. F. Weinbauer2. 1Nonclinical
Safety Assessment, Covance Laboratories Inc., Madison, WI; 2Nonclinical Safety
Assessment, Covance Laboratories GmbH, Munster, Germany.
The demand for developmental toxicity studies in nonhuman primates (NHPs) has
increased, mainly driven by biopharmaceutical drug development. Social housing
of NHPs has become mandatory in many countries and this poses a specific chal-
lenge since NHPs with timed pregnancies cannot be obtained commercially. The
cynomolgus fertility rate in a mating programme is typically 35-45% per mating
cycle and 60% per female animal upon repeated mating trials. Hence, social hous-
ing of pregnant cynomolgus monkeys requires special approaches until a cage is
populated by animals with confirmed pregnancy. Formation of new groups of sex-
ually mature female cynomolgus monkeys has pronounced effects on ovarian
cyclicity to the extent that some animals exhibit transient amenorrhea. Concern has
been raised that social housing of pregnant animals might interfere with mainte-
nance of gestation due to rank order fights, incompatibility, and other group-re-
lated adverse effects. On the other hand, in a social setting, animals experience birth
events and handling of neonates by watching cage mates, and infants have cage
mates of comparable ages to interact with. In the present work, qualitative assess-
ment in more than 200 hundred pregnant control animals under social housing in-
dicated good compatibility with little aggression toward each other. Interestingly, a
reduction of pre- and postnatal loss by 25-30% was encountered under social hous-
ing when compared to single housing. Conceivably, the delivery process and man-
aging the newborn was facilitated by social maternal housing. Moreover, maternal
and infant body weight gains were significantly increased under social housing
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compared to single housing. In conclusion, social housing is feasible for develop-
mental toxicity studies in NHPs and provides distinct advantages over single hous-
ing and is, therefore, recommended for the conduct of NHP developmental toxic-
ity studies and is now the default at Covance Laboratories.
1014 Feasibility of Mouse Continuous Intravenous Infusion for
Fertility and Embryo-Fetal Development Studies.
R. S. Bartlett and H. van Wijk. Covance Laboratories Ltd., Harrogate, United
Kingdom. Sponsor: S. Kirk.
The rat and rabbit are routinely used in pre-clinical reproductive and developmen-
tal toxicity (DART) studies. However, where the rat and/or rabbit are not suitable,
the mouse is an alternative model. 
A model of continuous intravenous infusion using a surgically-implanted femoral
vein catheter with tail cuff exteriorisation has been previously developed in the
mouse. The reliability of this method decreased over time, with a success rate of
only 74% after 28 days because of tail cuff constraints due to animal growth. 
This study aimed to (1) determine whether a larger diameter tail cuff (6 mm) could
extend the continuous infusion duration, and (2) determine the feasibility of evalu-
ating DART parameters in mice using this surgical model in a combined fertility
and embryo-foetal development study. 
33 CD-1 female mice (approximately 7-9 weeks old) were surgically implanted
with a femoral vein catheter exteriorised with a 6 mm tail cuff. After 6 days of re-
covery, they were intravenously administered 0.9% sodium chloride, by continuous
infusion (4 mL/kg/hr) for 2 weeks prior to pairing, during pairing (with un-
catheterised males) and through Gestation Day (GD) 18 (42 days). On GD18, fe-
males were killed and uterine contents examined. 
Technical failure occurred in 9 females; this was attributed to the larger diameter of
the tail cuff, which slipped down and allowed the catheter to be chewed. Of the 24
female mice remaining on study at the end of pairing, 23 (96%) were successfully
mated and 22 (96%) were confirmed pregnant. Catheter failures or poor tail condi-
tions resulted in early removal of 5 additional mice. However, those surviving to
necropsy, uterine and foetal data were within background ranges, indicating no ef-
fects on reproductive or developmental parameters. 
It is concluded that continuous intravenous infusion via this surgical model is a vi-
able method of dosing mice in DART studies. The larger tail cuff did not increase
reliability of the infusion technique for a period greater than 28 days, therefore sep-
arate fertility and embryo foetal development studies are recommended for mice.
1015 Addressing the Mode of Action for Developmental PFOA-
Induced Mammary Gland Delays.
M. B. Macon1, 2 and S. E. Fenton2. 1Curriculum in Toxicology, University of North
Carolina, Durham, NC; 2NTP Labs, NIEHS, NIH, Research Triangle Park, NC.
Perfluorooctanoic acid (PFOA) exposure alters mammary gland (MG) develop-
ment and function in mice. The mode of action (MOA) for these effects has not
been elucidated, although activation of peroxisome proliferator activated receptor
alpha (PPARα) has been implicated. To begin elucidation of a MOA, time preg-
nant CD-1 mice were gavaged with 0.0, 0.01, 0.1, or 1.0 mg PFOA/kg body
weight on gestation days (GD) 10-17. Female offspring MGs were removed and
prepared for RNA on multiple postnatal days (PND). A comparison of MG RNA
from control and 1.0 mg/kg groups with Affymetrix 420.2 microarrays found dif-
ferential regulation of 710 and 41 genes at PND 7 and 14, respectively.
Adiponectin, estrogen receptor alpha, and WNT expression were reduced in
PFOA-treated glands. PPARα expression was not changed. These data were vali-
dated by PCR of MG RNA, using TBP as a reference gene. At PND 7, PFOA in-
duced differential regulation of several genes compared to controls, even at 0.01
mg/kg. When considering developmental scores, glands with higher scores or more
normal growth had increased RNA expression of WIF1, ESR1 and PGR at PND
21 and FABP3 and UCP1 at PND 56. PND 56 MG sections stained for PPARα
protein displayed robust expression in all glands regardless of treatment, yet there
was higher expression in stromal tissues surrounding ducts in PFOA exposed mice
compared to controls. Collectively, these findings suggest that PPAR pathway genes
are altered in conjunction with PFOA-induced MG changes along with other path-
ways. Observed altered genes are involved in signaling of all PPAR isoforms includ-
ing α, β/δ, and γ. Both up and down regulation of these genes were found which
suggests that multiple PPAR isoforms may work together to regulate PFOA-in-
duced MG aberrations. In addition, prenatal PFOA exposure at 0.01 mg/kg leads
to mammary gene changes at human-relevant levels. Future investigations will ex-
amine related gene pathways and protein levels compared to observed morphologi-
cal and hormone outcomes. This abstract does not necessarily reflect NIEHS pol-
icy.
1016 Evaluation of Reproductive and Developmental Toxicity of
Multiwall Carbon Nanotubes in Pregnant Mice After
Intratracheal Instillation.
N. Kobayashi1,  M. Kawabe2,  H. Nakashima2,  T. Numano2, 3,  R. Kubota1,
N. Sugimoto1 and A. Hirose1. 1National Institute of Health Sciences, Setagaya,
Japan; 2DIMS Institute of Medical Science Inc., Ichinomiya, Japan; 3Department of
Molecular Toxicology, Nagoya City University Graduate School of Medical Sciences,
Nagoya, Japan.
Some studies have reported that maternal exposure to nanoparticles may induce
teratogenicity or transfer to their fetuses and affect the development and function
of the central nervous systems. In order to evaluate the reproductive and develop-
mental toxicity of multi-wall carbon nanotubes (MWCNTs) via inhalation expo-
sure, we conducted intratracheal instillation study of MWCNTs dispersed in two
different media (blood serum obtained from female mice and 2% of sodium car-
boxymethyl cellose (CMC-Na) solution) in pregnant mice. MWCNTs (MWNT-7)
dispersions were prepared by ultrasonication using an ultrasonic bath for 30 min.
The above MWCNT dispersions were administered to pregnant Crlj:CD1(ICR)
mice with gestation day 9 at dosage of 0, 3.0, and 5.0 mg/kg bw. Five mice per
group were evaluated. The mice were dissected at 18 days of gestation period.
MWCNT depositions in the tissues and the effect to embryos and fetuses were
evaluated. The MWCNTs were deposited in the lungs as the black spots. No statis-
tically significant difference between the control group and MWCNT-exposed
groups in the number of corpora lutea, implantations, dead fetuses (early or late re-
sorption site), live fetuses, and sex ratio. However, body weight of fetuses and pla-
cental weights were dose-dependently decreased in the both MWCNT-exposed
groups. Furthermore, external malformations (i.e., oligodactyly, extensive contrac-
ture, cleft lip) were observed in the 3 mg/kg of CMC-Na treated MWCNT-ex-
posed group and 5 mg/kg of blood serum treated MWCNT-exposed groups.
Further information is needed to clarify the potential for the reproductive and de-
velopmental toxicity of MWCNTs.
1017 Histology of Selected Organs from the Göttingen Minipig
Fetus from Days 60 (Midterm) and 110 (Term) of Gestation.
M. Perron Lepage,  J. Briffaux,  C. Thuilliez,  E. Marsden and M. Leroy. Ricerca
Biosciences SAS, St. Germain sur l’Arbresle, France.
In a previous study, we demonstrated that chemically induced fetal abnormalities
could be detected in the Göttingen Minipig shortly after mid term. At this time, it
is possible to sex the minipig fetus by observation of the external genital area, al-
though at gross soft tissue examination, the location, size and shape of the male and
female gonads are similar at this stage. The aims of the present study were to com-
pare the histological features of selected organs in the Göttingen Minipig fetus at
GD 60 and GD 110 and to validate histologically the method of sexing the fetuses
by macroscopic observation of the external genital area.
Four 7- to 13-month-old virgin Göttingen Minipig females were mated. Caesarean
sections were performed on two females at mid term (GD 60) and on two others at
term (GD110). The fetuses were weighed, sexed and submitted to standard gross
external and visceral examinations. Selected organs (adrenal glands, heart, kidneys,
liver, lungs, ovaries, thymus, thyroid gland, urinary bladder, uterus, vagina, epi-
didymides and testes) were sampled and fixed in 10% formalin or modified
Davidson’s fluid. Five male and 5 female fetuses obtained at GD 60, and 2 male and
6 female fetuses obtained at GD110 were available for histological examination.
The microscopic appearances and the differences between the two timepoints were
described for each organ.
The histological appearance of the organs at GD110 was similar to that of juvenile
minipigs. At GD 60, however, although all organs were identifiable, maturation
and growth were obviously still incomplete. 
This study reported the histology of selected organs in minipig fetuses at GD 60
and GD 110. At GD 60, there was complete concordance in establishing the sex of
each fetus by microscopic examination and evaluation of the external genitalia.
1018 Mono-Ethylhexyl Phthalate (MEHP) Exposure Reduces
Embryonic Nutrition and Induces Structural Defects in
Mouse Whole Embryo Culture.
K. E. Sant and C. Harris. Environmental Health Sciences, University of Michigan,
Ann Arbor, MI.
Di-2-ethylhexyl phthalate (DEHP) is a highly lipophilic endocrine disruptor and is
the most abundant phthalate plasticizer in the environment. Exposure to DEHP
and its primary active metabolite, mono-ethylhexyl phthalate (MEHP), have been
associated with several adverse health effects, ranging from obesity to reproductive
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dysfunction. The objective of this study was to determine whether MEHP can in-
duce structural defects during embryonic development in vitro in whole embryo
culture (WEC) and to assess whether decreased embryonic nutrition contributes to
these defects. Gestational day (GD) 8 CD-1 mouse conceptuses were explanted
into WEC. MEHP or DEHP at concentrations ranging from 100-1000 μg/ml
were added directly to the culture media and conceptuses were exposed for 26
hours before complete morphological scoring and collection of visceral yolk sac
(VYS) and embryo (EMB) tissues on GD 9. MEHP treatment significantly re-
duced total morphological scores at all doses, reaching a maximal decrease of 67%
(p<0.03), while DEHP failed to produce any significant decreases in total mor-
phology score. Morphological comparison of neural tube-specific endpoints re-
vealed that MEHP produced a significant increase in incomplete neural tube clo-
sure (p<0.001). Clearance of FITC-albumin by the VYS was assessed after 3 h
exposure to 100 or 250 μg/ml MEHP on GD 9 as a measure of histiotrophic nu-
tritional activity. Treatment significantly reduced total clearance in a dose-depend-
ent manner (p<0.008) by 29% and 43% for 100 and 250 μg/ml treatment, respec-
tively. This work demonstrates that MEHP treatment reduces embryonic nutrition,
limiting the substrates essential for normal metabolic activities, and induces struc-
tural defects, especially preventing closure of the neural tube.
1019 Development and Validation of an Analytical Method for
Monobutylphthalate, a Metabolite of Di-n-Butylphthalate,
in Harlan Sprague-Dawley Rat Plasma and Amniotic Fluid
by UPLC-MS/MS.
V. G. Robinson2,  M. A. Silinski1,  T. A. Freed1,  R. A. Fernando1,  C. S. Smith2
and S. Waidyanatha2. 1RTI International, Research Triangle Park, NC; 2Division of
National Toxicology Program, NIEHS, Research Triangle Park, NC. Sponsor: K.
Levine.
Di-n-butyl phthalate (DBP) is a common plasticizer used in a variety of consumer
products. Its major metabolite is its monoester. Exposure to DBP is widespread,
and its potential toxicity has been, and continues to be, investigated. The objective
of this work was to develop, validate, and apply a method to quantitate mono-n-
butyl phthalate (MBP), the major metabolite of DBP, in rat plasma and amniotic
fluid. Samples were extracted by spiking 25 μL of plasma or amniotic fluid with 25
μL of water, 25 μL of internal standard solution (MBP-d4 in water), and 425 μL of
0.1% formic acid in acetonitrile. After centrifugation, 5 μL of supernatant was in-
jected onto an Acquity UPLC HSS T3 column, and separation was performed
using gradient elution. MS/MS analysis was conducted using electrospray ioniza-
tion in negative ion mode and multiple reaction monitoring. The method was suc-
cessfully validated over the range 25-5000 ng/mL in plasma, with cross-validation
for amniotic fluid. Validation parameters included linearity (r >0.99), recovery, se-
lectivity, sensitivity (LOD = 6.9 ng/mL), precision (%rsd <15%), accuracy (%RE
<15%), and stability (% of Day = 100 +/- <20%). It was also demonstrated that
samples as high as 516,000 ng/mL could be accurately and precisely diluted into
the calibration range.
The method is being applied for the analysis of MBP in plasma and amniotic fluid
samples from rats administered 0, 300, 1000, 3000, or 10,000 ppm DBP in feed.
1020 Developmental and Reproductive Studies in Sprague-Dawley
Rats with Gevokizumab, a Novel Monoclonal Antibody
Targeting IL-1 Beta.
C. A. Gasper1,  B. Thorsrud2,  L. Cao1,  J. Chen1,  L. Wong1,  K. Der1,  J. Ma1,
A. Ahene1 and K. Meyer1. 1Nonclinical Safety Evaluation, XOMA (US) LLC,
Berkeley, CA; 2Developmental & Reproductive Toxicology, MPI Research, Mattawan,
MI.
Gevokizumab, also coded XOMA 052 or S78989, is a humanized IgG2 mono-
clonal antibody that binds with high affinity to human interleukin-1 (IL-1) beta.
Gevokizumab inhibits the activation of the IL-1 receptor, thereby modulating the
cellular signaling events producing inflammation. Currently, gevokizumab is in
Phase 3 clinical trials for non-infectious uveitis and Behçet’s uveitis and in Phase 2
proof-of-concept studies for moderate to severe acne and erosive osteoarthritis of
the hand. Developmental and reproductive studies (embryo fetal, fertility, and
pre/postnatal development) in Sprague Dawley rats evaluated the effects of gevok-
izumab when administered subcutaneously once weekly at 3, 30, and 90
mg/kg/dose. The rat (usual rodent model for evaluating developmental and repro-
ductive toxicity) was selected due to similar binding affinity and in vitro functional
activity between human and rat IL-1 beta. Standard ICH S5(R2) study designs
were followed. Observations included clinical signs, body weight, food consump-
tion, drug levels in serum and milk, anti-drug antibodies (ADA), maternal uterine
and ovarian examinations, fetal evaluations, macroscopic pathology, reproductive
performance, parturition, lactation to weaning, and F1 physical growth and devel-
opment. Gevokizumab did not produce any mortality or significant adverse effects.
Measurement of gevokizumab in serum (maternal, fetal, neonate) and maternal
milk confirmed adequate exposure during the dosing periods. ADAs were detected
in a few dams, without neutralizing activities. The NOAEL for maternal and devel-
opmental toxicity including teratogenicity, general reproductive toxicity in male
and female rats, and general toxicity in the dam, including developmental and re-
productive toxicity in the F1 offspring was considered to be at least 90 mg/kg/dose,
the highest dose level tested. No gevokizumab-related findings were observed in any
of the reproductive and developmental studies.
1021 Weight of Evidence Considerations for Developmental
Toxicity Classification of Boric Acid.
W. Ball and M. Harrass. Rio Tinto Minerals, Greenwood Village, CO.
Although reproductive and developmental effects have been demonstrated in labo-
ratory animals exposed to high doses of boric acid (BA), similar effects have not
been observed in highly exposed human populations or workers. Workers in boron
(B) mining/processing industries represent the maximum possible human expo-
sure. A weight of evidence approach was used in evaluating numerous independent
studies on the determination of the hazard of BA to humans. Information that was
considered together included results of in vitro tests, animal data, worker exposure
data, epidemiological studies and mechanistic data. Extensive evaluations of sperm
parameters in highly exposed workers in Turkey and China demonstrated no effects
on male fertility. No evidence of developmental effects in humans attributable to B
has been observed in studies of populations with high exposures to B. Collectively
the epidemiological studies consistently show an absence of effects in highly ex-
posed populations. A comparison of blood, semen and target organ B levels in stud-
ies of lab animals and B workers shows B industry worker exposures are lower than
untreated control rats. Recent studies provide evidence that BA may act by similar
mechanisms in causing developmental effects in mice as sodium salycilate (natural
deacetylated form of aspirin) including effects on Hox gene expression and inhibi-
tion of embryonic histone deacetylases. Although aspirin is known to cause devel-
opmental effects in laboratory animals, similar effects have not been seen in con-
trolled human studies. Similar mechanisms of action of BA and aspirin and the
absence of effects in humans ingesting aspirin suggest that BA related developmen-
tal effects in humans are unlikely. Also, there is evidence that Zinc (Zn) interacts
with B in the body reducing the toxicity of B. Zn levels in soft tissue in humans are
over 2 x greater than in lab animals explaining in part the absence of fertility and
developmental effects in humans. Based on the total weight of evidence, the data
show that it is improbable that BA will cause reproductive or developmental effects
in humans.
1022 Embryonic DNA Repair and Ethanol-Initiated Behavioural
Deficits in Oxoguanine Glycosylase 1 (OGG1) Knockout
Mice: A Role for Oxidatively-Damaged DNA and Protection
by a Free Radical Spin Trapping Agent.
L. Miller1,  D. J. Pinto1 and P. G. Wells1, 2. 1Pharmacology and Toxicology,
University of Toronto, Toronto, ON, Canada; 2Pharmaceutical Sciences, University of
Toronto, Toronto, ON, Canada.
A mother’s consumption of alcohol (ethanol, EtOH) during pregnancy can cause a
spectrum of structural, cognitive and behavioural problems in the developing child
termed Fetal Alcohol Spectrum Disorders (FASD). Reactive oxygen species (ROS)
have been implicated in the mechanism of behavioural teratogenicity, although the
role of embryonic DNA damage and repair are unclear. To determine the latter,
DNA repair-deficient heterozygous (+/-) oxoguanine glycosylase 1 (OGG1) knock-
out mice were mated, and pregnant dams were treated once on gestational day 17
with EtOH (2 g/kg i.p.) or its saline vehicle, with or without pretreatment with the
free radical spin trapping agent alpha-phenyl-N-tert-butylnitrone (PBN) (40
mg/kg i.p.). Saline-exposed progeny exhibited an ogg1 gene dose-dependent learn-
ing deficit in the passive avoidance test compared to wild-type (WT) littermates,
demonstrating for the first time a phenotype in OGG1-deficient mice. EtOH-ex-
posed progeny exhibited an enhanced learning deficit compared to saline controls
at 6 and 9 weeks of age, also in an ogg1 gene dose-dependent fashion. PBN pre-
treatment significantly protected both WT and KO progeny, although this protec-
tion for EtOH was slightly less effective in +/- and -/- KO progeny. These results
provide the first evidence to date that ROS-initiated embryonic DNA oxidation is
involved in EtOH-initiated behavioural deficits, and embryonic DNA repair status
may be a determinant of teratological risk. (Support: Canadian Institutes of Health
Research)
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1023 Hyperactivity of Rat and Mouse Induced by Lactational
Exposure to Hydorxylated PCB (OH-PCB106).
N. Koibuchi,  A. Haijima,  R. Lesmana,  I. Amano,  Y. Takatsuru,  T. Iwasaki and
N. Shimokawa. Department of Integrative Physiology, Gunma University Graduate
School of Medicine, Maebashi, Japan.
Polychlorinated biphenyls (PCBs) are persistent environmental pollutants that may
cause adverse health effects. Previous in vitro studies including ours have shown
that various PCB congeners affect neurodevelopment through different mecha-
nisms. However, behavioral alterations induced by lactational exposure to PCB and
its neurochemical mechanisms have not yet been fully studied. In the present study,
hydroxylated-PCB 106 (OH-PCB 106; 4-hydroxy-2’,3,3’,4’,5’-pentachloro-
biphenyl) was administered to lactating rat and mouse dams via gavage every sec-
ond day from day 3 to 13 after delivery. The exposure did not affect the body
weight of the dams or the physical development of the newborn pups in both sexes.
Male rats and mice exposed to OH-PCB 106 showed hyperactivity that was char-
acterized by increased locomotor activity in open field and circadian period. OH-
PCB 106-exposed rats displayed abnormally high levels of dopamine and D2
dopamine receptor (D2DR), but not D1DR and D5DR, in the striatum, an im-
portant center for the coordination of behavior. These findings indicate that OH-
PCB 106 has a significant neurotoxic effect on rodent behavior, which may be as-
sociated with increased D2DR mediated signals.
1024 Di-isobutyl Phthalate (DIBP) Hazard Identification.
S. Y. Euling1,  K. Hogan1,  G. Cooper1,  C. Cai1,  K. Y. Christensen1,  M. Lorber1,
X. Arzuaga1,  C. Sheth1,  A. F. Sasso1,  M. Pratt1,  A. K. Hotchkiss2 and
J. C. Lambert3. 1NCEA, US EPA, Washington DC; 2NCEA, US EPA, Research
Triangle Park, NC; 3NCEA, US EPA, Cincinnati, OH.
The hazard potential for DIBP is being evaluated as part of EPA’s Integrated Risk
Information System (IRIS) Toxicological Review. DIBP is a plasticizer that confers
flexibility and durability in industrial and consumer products. The epidemiology
and animal toxicology databases are both relatively small. The small DIBP epi-
demiological database includes studies that assessed the relationship between uri-
nary concentrations of the DIBP metabolite mono-isobutyl phthalate (MIBP) and
developmental, neurodevelopmental, immunological or breast cancer outcomes.
There is limited support for associations between MIBP and inflammatory bio-
marker levels, and decreased masculine play behavior. The animal toxicological
database includes studies that assessed male reproductive developmental endpoints
that constitute the phthalate syndrome after in utero DIBP exposure. The largest
developmental study, Saillenfait et al. (2008), reported changes in anogenital dis-
tance, male reproductive organ weights, and litter incidence of phthalate syndrome
endpoints in the lower dose range after early gestational exposure. Other studies ob-
served increased fetal mortality, male postnatal and adult growth decrements, de-
creased fetal testicular testosterone and changes in expression of genes involved in
androgen production pathways. The developmental reproductive effects observed
in animal studies are consistent with the reduced testicular testosterone mode of ac-
tion that is well-characterized for developmentally toxic phthalates. Effects on liver
and kidney weight and function in both male and female adults were also reported.
Research needs include epidemiologic studies that examine DIBP exposure, testos-
terone and related outcomes throughout development as well as multigenerational
reproductive toxicity studies and cancer bioassays. The views expressed are those of
the authors and do not necessarily reflect the views or policies of the US EPA.
1025 Establishment of a Molecular Embryonic Stem Cell
Developmental Toxicity Assay.
J. Panzica-Kelly1,  K. Brannen2,  Y. Ma1,  C. Zhang1,  O. Flint1,  L. D. Lehman-
McKeeman1 and K. Augustine1. 1Discovery Toxicology, Bristol-Myers Squibb,
Princeton, NJ; 2Charles River, Horsham, PA.
Efforts to reduce animal use for embryotoxicity testing of chemicals lead to the de-
velopment of the embryonic stem cell test (EST), a 10-day low-throughput assay.
The objective of this study was to shorten the assay’s duration and increase through-
put by incorporating molecular endpoints to detect aberrant changes in embryonic
stem cell differentiation. Monolayers of mouse D3 embryonic stem (ES) cells were
used to identify IC50 values in a 3-day cytotoxicity assessment. ES D3 cells were
grown for 4 days as embryoid bodies for transcriptional profiling of 12 develop-
mentally regulated genes (nanog, fgf5, gsc, cd34, axin2, apln, chst7, lhx1, fgf8,
sox17, foxa2, and cxcr4). Embryoid bodies were exposed to a single compound
concentration selected from the cytotoxicity assessment (0.1x IC20).  A decision-
tree model to classify compounds for teratogenicity potential was built with IC50
and relative expression values of the target genes after exposure to 65 compounds
(33 teratogens, 32 non-teratogens) of known in vivo teratogenicity. Compounds
with IC50 values <22 μM were classified as teratogens without the use of transcrip-
tional profiling. Compounds with IC50 values between 22 and 200 μM were cate-
gorized as teratogenic if ≥8 genes were deregulated by 10%. Compounds with IC50
values greater than 200 μM were categorized as positive for teratogenic potential if
all 12 genes were deregulated by 10%. For teratogenic predictions of unknowns,
the concordance for teratogens is 76% (22 out of 29), and for non-teratogens is
69% (25 out of 36) with a total concordance of 72% (47 out of 65) with a false
positive error rate of 24%. The model was further tested with 12 additional com-
pounds (5 positive, 7 negative) in which 10 were identified correctly (83% concor-
dance) with a 0% false positive error rate. Increased throughput in combination
with its low false positive error rate makes this assay ideal for first tier hazard iden-
tification screening of pharmaceutical compounds.
1026 A Tiered Screening Platform for Optimizing Predictivity,
Throughput and Cost Effectiveness of In Vitro
Developmental Toxicity Assays.
K. Augustine,  C. X. Zhang and P. Julie. Discovery Toxicology, Bristol-Myers Squibb,
Pennington, NJ. Sponsor: L. Lehman-McKeeman.
In recent years, various laboratories have focused on generation and/or refinement
of in vitro developmental toxicology assays for classification of teratogenic liabili-
tyof small molecules. The impetus for this effort is multifaceted including increas-
ing animal rights pressure, REACH legislation of chemicals and need for proactive
safety optimization of pharmaceutical compounds. In response to these needs, our
laboratory has developed three in vitro developmental toxicology assays: a molecu-
lar embryonic stem cell assay (MESCA), a dechorinated zebrafish embryo culture
(ZEC) assay and a streamlined rat whole embryo culture (rWEC) assay.
Individually, all three assays have demonstrated good utility for screening com-
pounds for teratogenic liability, achieving ~80% overall concordance and relatively
balanced error rates. This study describes the results of evaluating a test set of ~60
compounds across the 3 assays and generation of a tiered testing strategy. The cross-
assay assessment identified the assays’ attributes and deficiencies. For instance, the
MESCA and ZEC assays were found to have 2 limitations: compound solubility
and high misclassification rates of compounds with H1 receptor or GABAergic ac-
tivity. In contrast, solubility limitations were rarely encountered in the streamlined
rWEC assay and it also presented <20% misclassification error rates of compounds
with H1 and GABAergic activity. As such, rWEC assay was found to be a cost ef-
fective stand alone assay for supporting poorly soluble compounds and/or ones
with H1 or GABAergic activity. For all other compounds, using MESCA as a first
tier and the dechorinated ZEC assay as a 2nd tier assay minimizes animal use and
optimizes error rates, throughput and cost. To this end, compounds receive a final
classification if found positive in the MESCA assay, and those that are negative are
followed up in the ZEC assay resulting in overall error rates below 15%.
1027 The Devtox Project: A Comprehensive Source of Information
on Developmental Abnormalities.
J. Buschmann1,  I. Chahoud3,  R. Kellner1 and R. Solecki2. 1Fraunhofer ITEM,
Hannover, Germany; 2Federal Institute for Risk Assessment, Berlin, Germany;
3Institute of Clinical Pharmacology and Toxicology, Berlin, Germany. Sponsor: C.
Dasenbrock.
The potential of a compound to cause adverse effects in the developing embryo or
fetus is an important consideration in human health risk assessment. The terms and
diagnostic criteria used to describe fetal anomalies in animal experiments need to be
consistent from one laboratory to another and must be harmonized between regu-
latory agencies.
Consequently, the DevTox Project (www.devtox.org) has the main objectives to
harmonize the nomenclature used to describe developmental anomalies in labora-
tory animals and to assist in the visual recognition of developmental anomalies with
the aid of photographs.
The use of a harmonized and internationally accepted nomenclature is a basic re-
quirement for the operation of DevTox. A first approach of establishing such a har-
monized terminology was made in 1997 by a publication of the International
Federation of Teratology Societies IFTS (Teratology 55, 249-292, 1997). This ter-
minology has recently been updated (Reproductive Toxicology 28, 371-434, 2009).
In addition, in a series of Berlin Workshops working definitions for the two classi-
fication categories “malformation” and “variation” were agreed.
The results of all these activities were used to establish the DevTox data base. The
easy-to-use Web interface allows different views of the nomenclature, images and
data and a quick navigation throughout the complete site. DevTox currently con-
tains more than 2.500 images, showing examples of external, skeletal, soft tissue
and maternal-fetal anomalies in rats, mice, rabbits, hamsters, primates, Guinea
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pigs, minipigs, dogs and birds. It provides short descriptions of each finding and in
some cases synonyms and further diagnostic notes as well as a hierarchical structure
for the localizations. The system is publicly accessible and allows the electronic
download of the current version of the harmonized terminology.
1028 Reference Images for the Skeletal Examination of
Cynomolgus Monkey Fetuses and Thalidomide-Induced
Malformations.
O. Foulon,  F. Spezia,  C. Dauzat,  M. Da Silva,  P. Barrow,  B. Palate and
R. Forster. CiToxLAB, Evreux, France.
In this poster selected images are presented to illustrate the normal and (drug-in-
duced) abnormal skeletal morphology of the cynomolgus monkey at 100 days post-
coitum. Very little is available in the literature in terms of reference images for the
skeletal examination of cynomolgus monkey (Macaca fascicularis) fetuses in teratol-
ogy studies. This poster will present photographs of the fetal skeleton on day 100
post-coitum. Normal (control) fetuses will be presented and compared with foe-
tuses showing thalidomide-induced malformations. A total of 20 control and 3
thalidomide-treated fetal specimens were photographed. Dams were 3 to 8 years
old at mating and weighed 2.0 to 4.5 kg. Mating was confirmed by the presence of
sperm in a vaginal smear during cohabitation with a male. Pregnancy was con-
firmed 18 or 19 days later by ultrasound examination. The treated dams were given
20 mg/kg/day of thalidomide by oral gavage from days 25 to 30 of gestation. The
control dams received a similar volume of water (10 mL/kg). The fetuses were re-
moved by caesarean section on day 100 of gestation. Fetal and placental weights
were recorded. Morphometric measurements (head circumference and crown
rump-length) were taken. Each fetus was then given a detailed necropsy examina-
tion prior to processing for skeletal examination by the Dawson method: the ossi-
fied skeletal structures were visualised following clearing of the soft tissues in potas-
sium hydroxide and staining with Alizarin Red S. The normal variation in the
degree of skeletal maturity and the corresponding patterns of ossification can be as-
sessed using the control images.
1029 Regulatory Embryofetal Development Studies in Minipigs:
Optimisation of Techniques.
A. Makin,  T. K. Andreassen and J. Løgsted. CiToxLAB, Lille Skensved, Denmark.
Rats and rabbits are traditionally the species of choice for developmental toxicity
(embryofetal development) studies. If for any reason these species are found unsuit-
able (e.g. due to issues of metabolism) a non-rodent alternative choice of species is
the minipig. In our facility we have several years of experience with EFD studies in
the Gottingen minipig. When working with non-standard species for studies of this
nature, a reliable study design producing robust data is imperative. Control data are
presented from 9 preliminary studies and 4 main studies performed over the last 5
years and intended for regulatory submission. On the basis of this experience, study
designs have been reviewed and refined to ensure reliable and consistent results.
Consideration was given to factors such as efficient synchronisation of estrus with
the use of Regumate® (altrenogest) to maximise mating success. Using this ap-
proach a success rate of close to 100% is attained. In this way the required number
of pregnant sows for the study can be accurately provided, allowing precise sched-
uling of the number of sows mated per day according to the facility capacity to per-
form the caesarean sections on the required day of gestation. The data presented
show that our methods give a mating success and an average litter size that are su-
perior to the published literature, thus ensuring that there are sufficient fetuses for
interpretation of findings. Estrus synchronisation is also useful for the provision of
neonatal piglets for juvenile toxicology studies. The present poster presents back-
ground data for all of the fundamental litter-based parameters and demonstrates
the robustness of the methods. Data for Pregnancy rate, Uterus Weight, Litter Size,
Resorptions, Implantations, Corpora Lutea and Pre and Post-implantation Loss are
also presented.
1030 Exploring the Role of the Mediator Gene ‘Med31’ in
Proliferation and Limb Development during Mouse
Embryogenesis.
K. Wolton2,  J. Wright1,  R. Doran1 and K. Henges2. 1Faculty of Life Sciences,
Manchester University, Manchester, United Kingdom; 2Product Safety, Syngenta,
Bracknell, United Kingdom. Sponsor: P. Botham.
Birth defects are recognised as a common global human health concern and they
may arise a a results of a multitude of factors. In terms of ameliorating such anom-
alies, it is important to gain a better understanding of the fundamental mechanisms
controlling embryonic development. A role for the Mediator complex gene Med31
in the developing embryo has been recognised using a random mutagenesis screen
in mice. Developing embryos which lack the Med31 protein are substantially
smaller than their wild type littermates, and show a delay in development. This is
particularly noticeable in the developing limbs, which fail to grow to the same
length as wild type, and demonstrate delays in normal ossification patterns.
Analysis of embryonic fibroblast cultures has revealed a significant defect in cell
proliferation in Med31 mutants, which is recapitulated in the Med31 mutant limb
bud, at embryonic day (E)10.5. 
Med31 forms part of the mediator complex, which acts as a bridge between tran-
scription factors and the RNA Polymerase II to initiate transcription. Mutant em-
bryos lacking Med31 have a reduction in the expression of the cell cycle genes
mTOR and Cyclin B. In situ hybridisation has demonstrated that the mutants do
not express Sox9, a master regulator of chondrogenesis, and this is particularly evi-
dent in the limb bud at E10.5, while genes such as Fgf8, a marker of limb pattern-
ing, retain a normal expression pattern. 
These findings are being further investigated by exploring the genes which are
under the transcriptional regulation of Med31 in limb development. These experi-
ments will provide new insights into the mechanisms by which Mediator complex
proteins regulate developmental processes. 
1) Risley, M.D. Clowes, C. Yu, M. Mitchell, K. Hentges, K.E. (2010)
Developmental Biology. 342. 146-156.
1031 Investigation of Methods for Anesthesitization and
Euthanization of Rat and Rabbit Fetuses in Developmental
Toxicity Studies.
H. Kato,  R. Katagiri,  A. Arima,  Y. Ooshima and R. Nagata. Shin Nippon
Biomedical Laboratories, Ltd., Drug Safety Research Laboratories, Kagoshima, Japan.
Japan Association for Laboratory Animal Medicine recommends humane handling
of laboratory animal fetuses. However, it is a challenge to accept proposed eutha-
nizing methods such as cervical dislocation, decapitation and/or intracardiac injec-
tion of potassium chloride, because these methods would damage fetal specimens
for skeletal and visceral examinations in developmental toxicity studies. The present
study aimed at finding better methodologies for rat and rabbit fetal euthanasia and
anesthesia. We focused on, and evaluated, two parameters: fetal heart rate and re-
sponse to touch stimulus. We were unable to accomplish fetal euthanasia directly in
either species; however, we were able to euthanize fetuses under pain-controlled
anesthesia.
Rat fetuses immersed in physiological saline at 10°C showed complete loss of reac-
tion to touch stimulus within 10 minutes, and a mean heart rate of less than 20
bpm, suggesting that deep anesthesia had been achieved very rapidly. Therefore, it
is recommended that hypothermia by immersion in cold physiological saline is an
appropriate method for anesthetization of rat fetuses. 
Rabbit fetuses intraperitoneally injected with pentobarbital sodium at 3.24
mg/body and retained in filter paper impregnated with physiological saline at 18°C
showed complete loss of reaction to touch stimulus within 30 minutes. Therefore,
it is recommended that intraperitoneal injection of pentobarbital sodium and hy-
pothermia induced by cold physiological saline form an appropriate method for
anesthetization of rabbit fetuses. 
We further recommend that the fetuses should be euthanized promptly upon
reaching anesthesia by exsanguination, removal of vital organs, or immersion in ap-
propriate fixatives.
1032 Acute Intravenous Exposure to Silver Nanoparticles during
Pregnancy Induces Particle Size and Vehicle-Dependent
Changes in Vascular Reactivity.
A. K. Vidanapathirana1,  L. C. Thompson1,  M. Herco1,  J. O. Dawkins1,
S. C. Sumner3,  T. Fennell3,  J. M. Brown2 and C. J. Wingard1. 1Physiology, East
Carolina University, Greenville, NC; 2Pharmacology & Toxicology, East Carolina
University, Greenville, NC; 3RTI International, Research Triangle Park, NC.
With increasing use of engineered silver nanoparticles (NP) in different settings
there are concerns regarding their safety particularly in vulnerable life stages such as
pregnancy. Effects of silver NP on maternal vascular reactivity have not been exten-
sively investigated despite potential occupational, therapeutic and environmental
exposure. Our hypothesis was: the acute intravenous (IV) exposure to silver NP
during late stages of pregnancy increases the vasoconstrictor response in the uterine
artery. Pregnant (17-19 days) Sprague Dawley rats were exposed to a single dose of
20 or 110 nm silver NP (200 μg) suspended in polyvinylpyrorrolidone (PVP) or
citrate solutions. 24 h post-exposure vasomotor responses of segments of the main
uterine artery and thoracic aorta were assessed using wire myography. Cumulative
dose-response curves were constructed for acetylcholine, angiotensin II, endothelin
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1 and Rho kinase inhibitor (HA1077). The response to phenylephrine was studied
in the presence and absence of COX inhibitor, indomethacin. Dose-response
curves, maximum stress and EC50 values were different for silver NP exposed ani-
mals when compared with vehicle controls. Reciprocal changes were seen between
the aortic and uterine vessels: greater vasoconstriction in uterine artery and greater
vasodilation in aorta following 110 nm sliver exposure. Exposure to 20 nm silver
NP increased the HA1077 mediated vasodilatation in aortic segments suggesting a
possible mechanism underlying the changes of agonist mediated vasoconstrictor re-
sponse following NP exposure. NP suspensions in citrate lead to higher stress gen-
eration in both vessels. IV exposure to silver NP during pregnancy induces particle
size and vehicle dependent changes in vascular reactivity which can potentially in-
fluence blood supply to the fetus. This work is supported by NIEHS U19
ES019525.
1033 Gamma Secretase Inhibition: Effects on Fertility and
Embryo-Fetal Development in Rats.
L. Sivaraman1,  K. Thompson1,  G. Pilcher2,  T. Sanderson2 and
M. E. McNerney1. 1Bristol-Myers Squibb Co., New Brunswick, NJ; 2Bristol-Myers
Squibb Co., Mt. Vernon, IN.
BMS-708163 (avagacestat) inhibits γ-secretase (GS), a protease that cleaves amy-
loid precursor protein to produce amyloid β (Aβ) and amyloid plaques that are
prominent lesions in Alzheimer’s disease (AD). As part of the nonclinical reproduc-
tive safety evaluation, studies of embryo-fetal development as well as fertility and
early embryonic development were conducted in female Sprague-Dawley rats. In
the embryo-fetal development study, BMS-708163 was administered (oral gavage)
to pregnant rats at 3, 10 and 30 mg/kg/day from Gestation Day (GD) 6 through
GD 15. Cesarean sections were conducted on GD 21. Assessments of maternal
well-being included clinical observations, body weight, and food consumption;
evaluation of fetal viability, morphology and body weights comprised the assess-
ment of developmental toxicity. BMS-708163 was a selective developmental toxi-
cant at all doses tested, with dose-related increases in the incidence and severity of
fetal malformations and variations in the absence of maternal toxicity.
Malformations and variations included axial and appendicular skeletal anomalies.
In the study of fertility and early embryonic development in female rats, BMS-
708163 was administered for 14 days prior to cohabitation; then throughout co-
habitation and early gestation, until presumed GD 7 at 1, 5, and 15 mg/kg/day.
Mid-gestation cesarean sections were conducted (GD 13-15). Reproductive end
points included estrus cycle length, mating and fertility rates, implantation and
conceptus viability. Dose-dependent reductions in female fecundity at doses ≥ 5
mg/kg/day were attributed to impaired ovarian follicular development; this was re-
flected in dose-dependent reductions in implantation sites, litter size, and gravid
uterine weights. These results occurred at exposures above those which lower brain
Aβ in rats; are consistent with inhibition of GS-mediated Notch processing, a key
signaling pathway in cell-fate determination and embryonic development; and are
considered no risk to the intended AD (> 65 yr) patient population.
1034 Flubendazole Embryotoxicity in Rat Embryos and Fetuses.
P. A. Colombo1,  M. Longo1,  S. Zanoncelli1,  M. Messina1,  R. Schnurbus1,
I. Scandale2 and G. Mazué3. 1Accelera, Nerviano MI, Italy; 2DNDi, Geneve,
Switzerland; 3Consultant, Mantry, France.
Filarial diseases affect millions in poverty-stricken areas. 
DNDi investigated Flubendazole Amorphus Solid Dispersion (ASD) as a possible
drug candidate. Within its preclinical characteristics in particular potential embry-
otoxicity was evaluated. 
With this aim flubendazole ASD was administered orally to Sprague Dawley rats at
0, 2, 3.46, 6.32 and 13 mg/kg/day as flubendazole, during the recognized suscepti-
ble organogenetic period on GD (gestation day) 9.5 and 10.5 as identified in a pre-
vious whole embryo culture study. Fetuses were evaluated on GD 20.
Flubendazole was embryolethal from 6.32 mg/kg/day (Cmax after single adminis-
tration 0.801 ug/mL). In addition Flubendazole was teratogenic at 3.46 mg/kg/day
(Cmax after single administration 0.539 ug/mL). No increase in resorptions was
seen however 80% of fetuses showed malformations namely exencephaly, micro-
/anophthalmia, small/absent kidneys, markedly enlarged renal pelvis/ureters, ab-
sent tail, anal atresia and disruption of skeletal ossification of head, spine and tho-
racic cage.
Flubendazole did not interfere with rat embryonic development, apart from a min-
imal reduction in fetal and placental weights, at 2 mg/kg/day (Cmax after single ad-
ministration 0.389 ug/mL) with treatment restricted to two days during pregnancy
and with a limited number of animals.
In order to evaluate the embryotoxic nature of Flubendazole, embryos of dams
treated as above, were evaluated on GD 11.5 and 12.5, as a window for observing
the origin of alterations detected at term.
Flubendazole confirmed to be embryolethal and teratogenic through its cytostatic
properties. 
At 6.32 mg/kg/day it initially induced a block of embryonic development through
its cytostatic action, followed by cytotoxicity which led to 100% embryolethality
within 48h while at 3.46 mg/kg/day, it markedly reduced embryonic development
through its cytostatic action but did not show cytotoxic effects. Therefore, embryos
still alive markedly retarded with consequent morphological alterations in specific
areas namely brain vesicles, eye, maxillary structures and body axis.
1035 Double-Staining Technique for Minipig Fetal Skeletons at
Gestation Day 60.
S. Baudet,  J. Briffaux,  C. Pique,  P. Quesada and A. Jocteur-Monrozier. Ricerca
Biosciences SAS, St. Germain sur l’Arbresle, France.
In a previous study, we have demonstrated that fetal abnormalities associated with a
known human and swine teratogen (Pyrimethamine) could be detected in the
minipig with fetal examinations performed close to mid-term instead of at term.
The principal objective of the present study was to validate a double staining
method for bone and cartilage of minipig fetuses obtained by caesarean section
close to gestation day (GD) 60 in order to support skeletal examinations.
Two virgin Göttingen Minipig females were mated at the testing facility and subse-
quently submitted to caesarean section close to GD 60. Ten fetuses (5 in each litter)
were available for the trials and the sexes were evenly split. 
The fetuses were used in a number of staining trials based on our own established
methods for other species, including the rat and rabbit. In the first step, the fetuses
were stained, without prior fixing, following evisceration and skinning. Varying
concentrations of ethanol, mixed together with Alizarin red S, Alcian blue and
acetic acid, were tested to obtain the desired results. In order to establish the best
conditions to fix the staining, the fetuses were then transferred to baths containing
different concentrations of ethanol for varying durations. Following fixation, the
specimens were transferred into potassium hydroxide solutions for maceration of
the soft tissue. Finally, the soft tissues were cleared, firstly using Malls solution fol-
lowed by glycerol at increasing concentrations. The fetuses from the successful trial
were then ready for skeletal examination.
The technique is slightly more labour intensive than the single staining technique
using Alizarin red S only. However, the time required to process the specimens for
examination is approximately the same for both methods. Moreover, this new tech-
nique enhances the examination process for mid-term minipig fetal skeletons, at a
time when ossification of the skeleton is obviously less advanced than at term. Our
next step is to generate an atlas of the mid-term minipig fetal skeleton.
1036 Retrospective Review of Skin Irritation and Corrosion
Hazards on the Basis of Existing Human Data.
D. Basketter1,  D. Jirova2 and H. Kandarova3. 1DABMEB Consultancy Ltd.,
Sharnbrook, United Kingdom; 2National Institute of Public Health, Prague, Czech
Republic; 3MatTek IVLSL, Bratislava, Slovakia.
Regulatory classification of skin irritation has historically been based on rabbit data,
however current toxicology processes are transitioning to in vitro alternatives. The
in vitro assays have to provide sufficient level of sensitivity as well as specificity to be
accepted as replacement methods for the existing in vivo assays. This is usually
achieved by comparing the in vitro results to classifications obtained in animals.
Significant drawback of this approach is that neither in vivo nor in vitro methods
are calibrated against human hazard data and results obtained in these assays may
not correspond to situation in human. 
The main objective of this review was to establish an extended database of sub-
stances classified according to their human hazard to serve for further development
of alternative methods relevant to human health as well as resource for improved
regulatory classification.
The literature has been reviewed to assemble all the available information on the
testing of substances in the human 4 h human patch test, which is the only stan-
dardized protocol in humans matching the exposure conditions of the regulatory
accepted in vivo rabbit skin irritation test.
A total of 81 substances tested according to the defined 4 h human patch test pro-
tocol were found and collated into a dataset together with their existing in vivo clas-
sifications published in the literature. While about 50% of the substances in the
database are classified as irritating based on the rabbit skin test, on using the 4 h
HPT test, less than 20% were identified as acutely irritant to human skin.
Based on the presented data, it can be concluded that the rabbit skin irritation test
largely over-predicts human responses for the evaluated chemicals. Correct classifi-
cation of the acute skin irritation hazard will only be possible if newly developed in
vitro toxicology methods will be calibrated to produce results relevant to man.
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1037 Influence of Acidic Extraction Conditions on Formazan
Assay: Assessment of Test Substances Using In Vitro EpiSkin
Skin Irritation Test Method by HPLC and Colorimetry.
M. H. Grandidier,  N. Alépée,  B. Micheau,  S. Grégoire and J. Cotovio. L’Oréal
Research & Innovation, Aulnay sous Bois, France. Sponsor: E. Dufour.
The skin irritation potential of a test substance is typically determined by measur-
ing cell viability in treated tissues by means of the colorimetric MTT reduction
assay after topical application of a test substance. In the EpiSkin validated skin irri-
tation test method, tetrazolium salt-based formazan assay is performed by using
acidific isopropanol extraction conditions (ESAC 2007, OECD TG439 2010).
The current work evaluated the data obtained with the EpiSkin model for the 20
reference chemicals (listed in the OECD TG439) following formazan extraction
with acidified (IPA) or non acidified (IP) isopropanol solutions to evaluate the in-
fluence of acidic extraction conditions. Therefore the objectives of this work was to
establish the use of HPLC measurements as a complementary assay to standard
photometry assay for detection of reduced MTT, a known limitation for test sub-
stances that are highly coloured.
The cell viability in EpiSkin quantitatively measured after acidified (IPA) or non
acidified (IP) isopropanol extractions from tissues were equivalent ranging from 6.4
to 104% by colorimetry (reference method). Following HPLC measurement, for-
mazan quantitative analyses were comprised between 7.9 to 99.2%. The standard
deviation between those 2 conditions was +/- 18%. Therefore, within-laboratory
variability assessed in 3 runs showed similar concordance of classification for each
condition. The sensitivity (based on 10 GHS Cat.2 substances) was 90% and the
specificity (based on 10 No-category substances) was 70%. The HPLC provides
data comparable to those using standard photometry assays for 20 test substances
indicative of the use of HPLC as a complementary assay to photometry in EpiSkin
skin irritation test method. Therefore, those results suggest that acidific isopropanol
extraction conditions did not affect the EpiSkin skin irritation outcomes.
1038 Cytotoxic Effects of Dicyclohexylamine and Three
Metalworking Fluids on Human Epidermal Keratinocytes.
A. D. Linthicum1,  A. O. Inman2,  N. A. Monteiro-Riviere2 and R. E. Baynes1.
1Center for Chemical Toxicology Research and Pharmacokinetics, North Carolina
State University, Raleigh, NC; 2Nanotechnology Innovation Center of Kansas State,
Kansas State University, Manhattan, KS.
Many of the 1.2 million workers in the metal machining industry within the
United States will be exposed to metalworking fluids via the dermal route, making
it a major occupational health and safety concern. Dicyclohexylamine (DCHA), an
anticorrosive agent used in the metalworking industry to prevent corrosion of fab-
ricated materials, is known to permeate the skin and could potentially elicit a toxic
response on human epidermal keratinocytes (HEK). HEK were exposed only to
DCHA or one of the following three generic metalworking fluids: soluble oil, syn-
thetic oil and semi-synthetic oil for 24h. Cells were dosed with solutions ranging
from concentrations of 200-5000μg/ml. The highest concentration of 5000μg/ml
is the relevant occupational exposure dose in the metal machining industry. Cells
exposed to 200-5000μg/ml of DCHA resulted in a 24-91% decrease in cell viabil-
ity in comparison to the media control. The soluble oil and semi-synthetic oil dosed
from 200-5000μg/ml resulted in an 80-83% and 81-85% decrease in cell viability,
respectively, in comparison to the media control. For synthetic oil, there was a 52-
85% decrease in cell viability in comparison to the media control. DCHA and all
metalworking fluid treatments caused a significant (p<0.05) decrease in HEK via-
bility. In conclusion, metalworking fluids and DCHA had a cytotoxic effect to
HEK. This data suggests that the concentration of DCHA in metalworking fluid
formulations should be reduced while safer metalworking fluid formulations are de-
veloped. (Supported by NIOSH R01-01-03669)
1039 Aryl Hydrocarbon Receptor Repressor (AhRR) Function
Revisited: Repression of Cyp1 Activity in Human Skin
Fibroblasts Is Not Related to AhRr Expression.
J. Tigges1,  H. Weithardt1,  G. Christine1,  I. Foerster1,  H. F. Merk2,
T. Haarmann-Stemmann1,  J. Krutmann1 and E. Fritsche1. 1Leibniz Institute for
Environmental Medicine, Duesseldorf, Germany; 2Dermatology and Allergology,
University Clinic RWTH, Aachen, Germany.
The skin reacts to environmental noxae by inducing cytochrome P450 (CYP)-cat-
alyzed reactions via activation of the aryl hydrocarbon receptor (AhR). A drawback
of this response is the generation of oxidative stress, which is especially dangerous
for postreplicative cells such as dermal fibroblasts, in which damage may accumu-
late over time. Accordingly, in dermal fibroblasts, CYP1 expression is repressed and
it has been proposed that this is due to the AhRR, which is supposedly overex-
pressed in fibroblasts as compared with other skin cells. Here, we revisited this
‘‘AhRR hypothesis’’, which has been mainly based on ectopic overexpression studies
and correlation analyses of high AhRR gene expression with CYP1A1 repression in
certain cell types. In primary human skin fibroblasts (NHDFs) of 25 individuals,
we found that (i) the AhRR was expressed only at moderate RNA copy numbers
and that, against the common view, (ii) in some fibroblast strains, CYP1A1 mRNA
expression could be induced by AhR activators. However, even the highest induc-
tion did not translate into measurable CYP1 enzyme activity, and neither basal ex-
pression nor mRNA inducibility correlated with AhRR expression. In addition, en-
hancement of CYP1A1 mRNA expression by trichostatin A, which inhibits AhRR
recruited histone deacetylases at the CYP1A1 promoter, failed to induce measura-
ble CYP1 activity. Finally, AhRR deficient mouse embryonic fibroblasts were not
induced to biologically relevant CYP1 enzyme activity despite impressive mRNA
induction. These data clearly indicate that repressed CYP1 activity in NHDFs is
not causally related to AhRR expression, which may serve a different, yet unknown,
biological function.
1040 Citotoxic Effect of the Temporary Hair Dye Basic Red 51 on
Human Keratinocytes(HaCaT): Development and
Application on a Reconstructed (3D) Artificial Skin.
T. B. Zanoni1,  M. T. dos Santos2,  S. Barro2,  S. Maria-Engler2 and D. de
Oliveira1. 1Enviromental Toxicology, University of São Paulo, Ribeirão Preto, Brazil;
2Laboratory of Pathology and Clinical Cytology, University of São Paulo, São Paulo,
Brazil.
Nowadays, hair dyes are being commonly used for cosmetics purposes. However in
2001, the Scientific Committee on Cosmetic products and Non-Food Products in-
tended for consumers (SCCNFP) of the European Union recommended that hair
dye ingredients should be re-analyzed. Since 2006, 22 hair dyes have been banned
for not being considered safe. On the present work, we evaluated the cytotoxicity of
a temporary hair dye “Basic Red 51” (CAS: 77061-58-6), an azo dye (-N=N-) that
is currently being revised by the EU. We tested the toxicity of the “Basic Red 51” in
immortalized keratinocytes (HaCaT) that are the primary route of exposure.
Moreover, we reconstructed a human (3D) epidermis using HaCaT cells and der-
mal fibroblasts in order to create a new approach that would better represent the
real exposure. For HaCaT cells in monolayer, the Basic Red 51 IC50 was 12.9
μg/mL, determined by Tripan Blue assay. Besides, this concentration of the dye in-
duced cell cycle arrest at G2 phase. Using the clonogenic assay, we observed that 2.
5μg/mL of the dye was sufficient to inhibit completely cell growth after 48 hours of
exposure. In the artificial skin model, we demonstrated that the exposure to Basic
Red 51 at IC50 reduces the skin thickness, decreasing the number of cell layers. We
also observed that the cells appear to be injured and undergoing apoptosis. It is im-
portant to point out that the IC50 used for these experiments (12.9 μg/mL) is
much lower than the commercial concentration (2000μg/mL). We suggest that
similar effects could be induced in humans after the exposure to Basic Red 51,
mainly considering the effects in artificial skin. So, we concluded that the use of
Basic Red 51 for cosmetic proposes should be carefully evaluated.
1041 Skin and Eye Lesions in the Long Evans Rat Produced by
Oral 8-Methoxy-Psoralen (8-MOP) Application and
Subsequent UV-A Irradiation.
M. Sieber1,  C. Simon1,  K. Broich1,  C. Maraschiello1 and K. Weber2. 1Harlan
Laboratories Ltd., Itingen, Switzerland; 2AnaPath GmbH, Oberbuchsiten,
Switzerland. Sponsor: T. Ansai.
For assessment of the dermal and ocular response to the model phototxicant 8-
MOP, 6 female HsdBLu:LE (SPF) Long Evans rats received a single dose of 5.0
mg/kg body weight 8-MOP by oral gavage. 6 control rats were treated with the ve-
hicle only. One pigmented and one unpigmented skin site were clipped free of hair
and irradiated with 15 J/cm2 UV-A (Bio-Spectra irradiation chamber, Vilber
Lourmat Deutschland GmbH). Irradiation was performed 30 min after 8-MOP
application under pentobarbitone anaesthesia. Visual assessment of the skin 4 h
after irradiation showed erythema on the irradiated pigmented and non-pigmented
skin of 8-MOP-treated rats and in control rats which increased in severity in 8-
MOP-treated rats after 20 h and receded in control rats . Injection of Evans Blue
showed moderate vascular leakage 24 h and 48 h after irradiation in all 8-MOP-
treated rats, while only few of the control rats were affected at a lower severity.
Histopathologically, corneal single cell necrosis was recorded in the irradiated eye of
2 of the 8-MOP-treated rats, but not in control rats. Dermal lesions in pigmented
and unpigmented skin of 8-MOP-treated rats consisted of focal/multifocal epider-
mal hyperplasia, focal erosions/scab formation, ulceration, subcutaneous and/or
dermal infiltration, follicular inflammation, focal/multifocal epidermal necrosis
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and subcutaneous and/or dermal inflammation, showing a slightly higher incidence
and severity in non-pigmented than in pigmented skin. An identical experiment
with a higher irradiation dose of 35 J/cm2 UV-A led to erythema and correlating
histopathological findings in the skin of both 8-MOP-treated and control rats;
however, corneal affections consisting of focal or single cell corneal necrosis, corneal
epithelial vacuolation and/or focal corneal keratosis were recorded in 8-MOP-
treated rats only. The results of the experiment confirmed that the test system is ap-
propriate for the assessment of systemic phototoxicity.
1042 13-Week Dermal Toxicity of Triclosan in B6C3F1 Mice.
M. M. Vanlandingham1,  J. Fang1,  F. A. Beland1,  B. E. Juliar1,  G. R. Olson1,
W. A. Harrouk2 and R. E. Patton1. 1National Center for Toxicological Research, US
FDA, Jefferson, AR; 2Center for Drug Evaluation and Research, US FDA, Silver
Spring, MD.
Triclosan [5-chloro-2-(2, 4-dichlorophenoxy)phenol] is widely used as an antimi-
crobial agent, and humans in all age groups have the potential to receive lifelong ex-
posures. We recently demonstrated that the dermal application of triclosan to mice
results in systemic distribution of the compound. The goal of the present study was
to evaluate the toxicities of triclosan administered dermally to B6C3F1 mice for 13
weeks and provide a scientific basis for dose selection for a subsequent chronic der-
mal carcinogenicity study. Groups of 10 male and 10 female mice received dermal
application of 0, 5.8, 12.5, 27, 58, or 125 mg triclosan in ethanol per kg bw daily
seven days per week for a period of 13 weeks. All mice survived the 13-week treat-
ment. Body weights of female mice were not affected, while male mice adminis-
tered 58 and 125 mg/kg weighed 91% and 83% of the control male mice. The
mean weight of livers from females receiving 58 and 125 mg/kg was 11% and 40%
greater than the controls; in males, the highest dose led to a higher mean liver
weight (38% greater than the controls). Skin lesions (epidermal hyperplasia, in-
flammation, necrosis, ulceration, and parakeratosis; dermal fibrosis and inflamma-
tion) were observed in both sexes. The severity of the lesions was minimal at the
12.5 mg/kg dose, and both the severity and incidence of the lesions increased as the
dose was increased. The highest dose of triclosan increased the percentage of reticu-
locytes in both sexes and the percentage of micronucleated normochromatic ery-
throcytes in females; in addition, the 58 mg/kg dose increased the percentage of
reticulocytes in females. A significant dose-dependent decrease in the levels of T4
and cholesterol was observed in both sexes. There were no differences between
treated and control mice in sperm or vaginal cytology measurements. The NOAEL,
under the conditions of this subchronic assay, was 5.8 mg/kg. (Supported by
Interagency Agreement between NCTR/FDA IAG #224-12-0003 and NIH
AES12013.)
1043 Dermal Toxicokinetic Studies of Triclosan in B6C3F1 Mice.
J. Fang1,  M. M. Vanlandingham1,  F. A. Beland1 and W. A. Harrouk2. 1Division
of Biochemical Toxicology, National Center for Toxicological Research, FDA, Jefferson,
AR; 2Center for Drug Evaluation and Research, FDA, Silver Spring, MD.
Triclosan [5-chloro-2-(2, 4-dichlorophenoxy)phenol] is widely used as an antimi-
crobial agent in personal care products, household items, and clinical settings. Due
to its extensive use, there is potential for humans in all age groups to receive lifelong
exposures to triclosan; however, data on the chronic dermal toxicity/carcinogenicity
of triclosan are still lacking. The goal of the present study was to determine the ab-
sorption, distribution, metabolism, and excretion of triclosan following dermal ad-
ministration to B6C3F1 mice. A single dose of [14C(U)]triclosan (10 or 100 mg
per kg bw, 10 μCi per mouse) was administered to mice in two separate experi-
ments: a vehicle selection experiment to compare the bioavailability of triclosan in
male mice using propylene glycol, ethanol, and a generic lotion as vehicles; and a
toxicokinetic experiment to evaluate sex differences in the absorption and deposi-
tion of triclosan and its metabolites. Three mice per sex in each group were killed at
0.5, 1, 2, 4, 6, 8, 12, 24, 48, and 72 h after administration, and excreta and tissues
were collected and analyzed for radioactivity. Ethanol has the best properties of the
vehicles evaluated. Maximum absorption of triclosan (80 ~ 86%) was obtained at
12 h after dermal application. There was some saturation of absorption at the 100
mg/kg. Radioactivity appeared in the excreta and in all tissues examined, with the
highest level in gall bladder and the lowest level in brain. Triclosan was readily me-
tabolized to triclosan sulfate and glucuronide conjugates, 2,4-dichlorophenol, and
hydroxytriclosan. The metabolite profile was tissue-dependent and the predomi-
nant route of excretion was the feces (65 ~ 78%). There were no differences in
bioavaibility between males and females. Slightly lower absorption was observed
with Elizabethan collar, suggesting some oral ingestion due to the normal behavior
grooming. (Supported by Interagency Agreement between NCTR/FDA IAG
#224-12-0003 and NIH AES12013.)
1044 Confocal Raman Microscopy—The Future for Dermal
Absorption Studies.
T. Patel1,  A. Ghaemmaghami1,  P. Williams1,  J. Wright2,  C. Roberts1 and
F. Rose1. 1School of Pharmacy, University of Nottingham, Nottingham, United
Kingdom; 2Syngenta Ltd., Bracknell, United Kingdom. Sponsor: P. Botham.
The activity and absorption of pesticides into the skin of the user is increasingly be-
coming a major problem within the Agrochemical industry. Fewer formulations are
passing the regulatory process of pesticide approval as a result of unknown com-
pound dermal accumulation and toxicity. Currently, 2 gold-standard methods are
used to monitor dermal absorption and determine compound flux (μg/cm2/h)
across the skin but limitations in measuring dermal accumulation most often re-
sults in compound failure. Confocal Raman Microscopy (CRM) is novel label free,
rapid, optical method which allows compounds to be identified within dermal tis-
sue at depths of -300 μm. The aims of the investigations were to develop and es-
tablish CRM methods for in vitro dermal absorption investigations across ex vivo
pig skin. A Lab Ra HR CRM was employed for the analysis of a range of concen-
trations (0.0 - 50.0 mg/mL) of benzoic acid, caffeine (both in 50% (v/v) ethanol
(EtOH)) set at the following: IR laser at 785 nm a filter intensity of 100%, a hole
300 μm with a x50 objective. Depth profiling was also preformed on fresh pig skin
samples from the surface to a maximum depth of -300 μm (-50 μm increments).
CRM spectra for the pig skin investigations demonstrated good reproducibility
with some spectral differences noticed. Intensity of the spectra decreased with in-
creased depth as expected. It was observed that a concentration of 50% (v/v) EtOH
appeared to mask the signal of prominent identifiable peaks for benzoic acid and
caffeine solutions at and below a concentration of 6.25 mg/mL. Compound con-
centrations equal to or higher than 20.0 mg/mL within a 50% (v/v) EtOH solution
could be detected. This data suggests that this masking effect by EtOH requires fur-
ther exploration to better understand the limitations of the technique. The CRM
method has the potential to qualitatively determine dermal compound accumula-
tion within mixed media and solutions ultimately, providing a powerful tool in
identifying toxic compounds early on.
1045 Development of an Alternative Model for Assessing Barrier
Function and Permeability for Infant Skin.
T. J. McCarthy1,  N. K. Tierney1,  S. G. Raney2 and P. A. Lehman2. 1Johnson &
Johnson, Skillman, NJ; 2PRACS Institute, Fargo, ND.
Recent published literature of non-invasive measures of skin barrier function of
full-term human infants indicates a dynamic maturation process over the first year
of life indicative of adaptation from in utero to the external environment. During
this period, infant skin may be more vulnerable to penetration of topically applied
ingredients, however, the magnitude of differences in non-invasive measures may
not correlate to the magnitude of the difference in penetration of topical agents.
While thriving demonstrates that a functional skin barrier exists at birth, differ-
ences in dermal permeability compared to adult skin could have an impact on the
exposure assessment and safety of topically applied ingredients.
The purpose of this study was to compare various indicators of skin barrier func-
tion (electrical impedance, TEWL), and permeability (tritiated water, 14C-octanol,
and 24-hr aqueous caffeine) across skin from donors of different ages. Fresh neona-
tal and pubescent porcine skins (animals culled for other purposes) were collected
from a breeding colony. Cryopreserved ex vivo adult human skins were purchased
from a skin bank. All measures of skin barrier function and permeability were
equally applied to all skin samples. 
The barrier functions in the porcine skin varied, depending upon the measure.
Average impedance indicated parity across age. TEWL and tritiated water flux was
lower through neonatal skin versus either mature species. Neonatal skin octanol
flux showed parity versus pubescent porcine skin while immaturity versus human
cadaver skin. Caffeine absorption ranged from 1.5x to 4.5x higher through neonate
skin than seen in either mature species. These data demonstrate that non-invasive
measures of barrier function may be indicative, but not definitive, for determining
the absorption of topical compounds. The current 10x intra-species safety factor
used in risk assessment adequately captures the difference in neonatal barrier func-
tion.
1046 Modelling Diffusion of Therapeutic Drugs through the Skin
In Vitro Does the Model Need to Be Complicated?
J. Jenner1,  O. Payne1,  C. Dalton1,  S. Graham1,  J. Azeke2,  E. Braue2 and
J. S. Graham2. 1Biomedical Sciences, DSTL, Salisbury, United Kingdom;
2USAMRICD, Edgewood, MD.
A mathematical model accurately simulating diffusion of chemicals though the skin
would be useful for predicting percutaneous absorption and aid understanding
penetration mechanisms. Models of varying complexity have been validated using
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in vivo and in vitro data. In the present study data from the penetration of four
drugs was used to test the output of a simple one compartment model based on
Fick’s 1st law of diffusion.
Methods: Drugs, as off the shelf formulations, were applied to pig skin (500 μm
dermatomed slice) in Franz type diffusion static cells using stirred ethanol:water
(1:1) as a receptor; surface temperature 32°C. Penetration of hydrocortisone, cap-
saicin, clobetasol and diclofenac were measured in the receptor fluid using Ultra
Performance Liquid Chromatography. The experimental permeability constant
(Kp) was estimated from the maximum flux rate (assumed to be steady state; Jss)
and the applied concentration of drug (C0) using the equation:
Kp = Jss / C0
A penetration profile was predicted using a model with the skin as a single com-
partment of a thickness approximating the stratum corneum and using the experi-
mental Kp to calculate flux of drug from vehicle into the barrier layer and from bar-
rier layer into receptor fluid. A best fit (determined by least squares) was then
obtained by adjusting the experimental Kp by a factor which gave an estimate of
the accuracy of the model in predicting the experimental data. 
Results: Model predictions needed to be adjusted by factor of between 1.1 and 1.35
to fit the experimental data as judged by a least squares method and assuming a
membrane thickness of between 0.025 and 0.04 mm. 
Discussion: this work has demonstrated that a very simple model is able to predict
quite closely the penetration of some non-volatile compounds applied to the skin in
a vehicle.
This work is supported by the US Army Medical Research and Materiel Command
under contract W81XWH-08-C-0070.
© Dstl Crown Copyright 2012
1047 Prediction of Skin Disposition After Topical Application of
Drugs—Simcyp Platform As a Tool for Capturing System
Information and Safety Assessment.
S. Polak1, 2,  N. Patel1,  M. Jamei1 and A. Rostami Hodjegan1, 3. 1Simcyp (a Certara
Company), Sheffield, United Kingdom; 2Faculty of Pharmacy, Jagiellonian University
Medical College, Krakow, Poland; 3School of Pharmacy and Pharmaceutical Sciences,
University of Manchester, Manchester, United Kingdom. Sponsor: B. Wetmore.
There are reports where topical application of drugs, which is generally considered
safe, results in health threatening side effects or drug-drug interactions. Simcyp
platform separates the system information from those of drug and uses in vitro in
vivo extrapolation approach to predict disposition of the topically administered
drugs (Polak 2012). Administration of a single 0.4 mg of erythromycin (topical -
2cm2 area of the forearm) with 40 mg simvastatin (oral) is used as a model scenario
to assess anticipated interactions mimicking corresponding clinical study (van
Hoogdalem 1996). Lotion formulation was simulated by modification of perme-
ability/partition parameters (factor of 50 for stratum corneum and viable epider-
mis). Simulated residual amounts of erythromycin collected from the skin surface
at various time and fraction of the dose recovered from stratum corneum after 6
hours were compared with the observed values. The results were consistent with ob-
servations and indicate significant systemic absorption. Subsequently oral simvas-
tatin (40 mg SID) and topical ketoconazole (0.4 mg BID for two weeks, applied on
upper arm) were simulated in 100 healthy individuals and by modification perme-
ability/partition parameters (factor of 5 for stratum corneum) to account for occlu-
sion. The average AUCinh/AUC and Cmaxinh/Cmax ratios were 1.17 and 1.11 re-
spectively, suggesting safe concomitant use. The maximum simulated ratios were
1.51 (AUC) and 1.32 (Cmax) indicating potential risk of significant interaction in
some individuals. This is in agreement with the clinical observations suggesting
general safety with rare occurrence of major side effects (e.g. Lareb Q 2009 report;
myalgia).
References: (1) Polak et al. JPharmSci 2012; 101(7):2584-95. (2) van Hoogdalem
et al. SkinPharmacol 1996;9:104-110.
1048 In Vitro Human Epidermal Penetration of IMX-101
Munitions Chemicals.
W. C. McCain,  L. R. Williams and G. Reddy. Toxicology Portfolio, US Army
Public Health Command, Army Institute of Public Health, Aberdeen Proving Ground,
MD.
Dermal exposure to ammunition chemicals is a major concern of the Army in as-
sessing risk during manufacturing and field operations. The US Army
Environmental Quality Technology (EQT) program is creating new, insensitive
ordnance formulations to replace highly energetic compounds such as RDX and
TNT. There are limited data on dermal absorption of munitions chemicals to sup-
port health risk assessment. We studied in vitro dermal penetration of a newly-de-
veloped munition, IMX-101 (Insensitive Munitions eXplosive) (as a mixture) and
its individual chemicals, 2,4-dinitroanisole (DNAN), 3-nitro-1,2,4-triazol-5-one
(NTO), and nitroguanidine (NQ). Human epidermal membranes were prepared
from frozen cadaver skin according to OECD guidelines and were mounted in
Franz static diffusion receptor cells so that the visceral side was in contact with the
receptor fluid. Neat test chemicals at infinite dose (100 mg powder) were carefully
placed on the mounted skin in the donor chamber and at different times (1, 2, 4, 6
and 8 hrs) 0.1 mL of receptor fluid (buffer) was collected and quantified by HPLC.
The rate of diffusion per cm2 was calculated for each chemical. The analysis of ab-
sorbed chemical in the receptor fluid showed that steady state fluxes of neat NTO,
DNAN and NQ were 332, 1.10 and 31.25 μg/cm2/hr respectively. When com-
plete IMX-101 was tested as 100 mg of mixture, the fluxes for NTO, DNAN and
NQ independently were 135.9, 1.80, and 236 μg/cm 2 /hr, respectively. NTO and
NQ showed about 0.4 and 7 times greater rate of penetration in the combination
mix than as individual compounds These estimated values will be used to deter-
mine occupational exposure levels with dermal exposure.
1049 In Vitro Human Skin Penetration of Acetyl Hexapeptide-8
from a Cosmetic Formulation.
O. A. Ogunsola1,  W. Zhou2,  P. G. Wang2 and M. E. Kraeling1. 1Office of Applied
Research and Safety Assessment, US FDA, Laurel, MD; 2Office of Regulatory Science,
US FDA, College Park, MD.
Peptides are being incorporated into cosmetic creams marketed as anti-aging/anti-
wrinkle products. Acetyl hexapeptide-8 may penetrate into the deep layers of the
skin and potentially stimulate biological activity by interfering with neuromuscular
signaling as its anti-wrinkle effect. The skin penetration of commercially available
acetyl hexapeptide-8 (Ac-EEMQRR-amide) from a cosmetic formulation was de-
termined in human cadaver skin assembled into in vitro diffusion cells. An oil-in-
water emulsion containing 10% Ac-EEMQRR-amide was applied to skin at a dose
of 2 mg/cm2. After a 24 hour exposure, the skin surface was washed to remove un-
absorbed peptide. Skin discs were taped stripped to determine the amount of pep-
tide in the stratum corneum. Removal of the stratum corneum layers was verified
by confocal microscopy. The epidermis was heat separated from the dermis and
each skin fraction was homogenized. Skin penetration of Ac-EEMQRR- was meas-
ured in skin layers by hydrophilic interaction liquid chromatography with tandem
mass spectrometry (HILIC-MS/MS) using electrospray ionization (ESI) in the pos-
itive mode. Stable isotopically labeled hexapeptides were used as internal standards
for the quantitation of native hexapeptides to correct for matrix effects associated
with ESI. Results (% of applied dose) found the majority of the Ac-EEMQRR-
amide was not absorbed and removed by washing (87%). Stratum corneum peptide
levels decreased as each layer was removed by tape stripping. Total Ac-EEMQRR-
amide found in the stratum corneum was 0.22 % and 0.01% in the epidermis. No
peptide was detected in the dermis or receptor fluid. Hairless guinea pig skin pene-
tration of Ac-EEMQRR-amide showed similar results where 0.51% remained in
the stratum corneum and 0.01% penetrated into the viable epidermis. This skin
penetration data will be useful for evaluating the safety of cosmetic products con-
taining short-chain peptides.
1050 Nevirapine-Induced Skin Rash Is Caused by a Reactive
Sulfate Metabolite Formed in the Skin.
A. M. Sharma and J. Uetrecht. Pharmacy, University of Toronto, Toronto, ON,
Canada.
Rationale: Nevirapine (NVP) treatment is associated with significant idiosyncratic
immune-mediated skin rash and hepatotoxicity in humans. NVP causes a very sim-
ilar rash in female Brown Norway rats, and we had previously shown that 12-hy-
droxylation of NVP is required to induce the rash. In this study we studied the fur-
ther metabolism and covalent binding of NVP in the rat model and in human skin.
Immune activation via IL-1β in the skin was also examined. Methods: An anti-
NVP antibody was produced and used in immunoblotting studies to detect cova-
lent binding of NVP, 12-OH-NVP, or NVP-sulfate to skin and liver proteins from
rodents and humans. In vitro incubations of NVP or metabolites with hepatic mi-
crosomes or skin cytosolic fractions from humans, mice, or rats were also per-
formed. The ability of SULT 1A1*1 to metabolize NVP was studied and cutaneous
IL-1β levels were examined by ELISA. Results: Covalent binding was observed in
the epidermis of NVP or 12-OH-NVP-treated rats. Major modified bands ap-
peared between 40K-60K. Depletion of PAPs decreased blood levels of NVP-sul-
fate but did not prevent rash or covalent binding in skin. Topical administration of
1-phenyl-1-hexanol (sulfotransferase inhibitor) prevented rash and covalent bind-
ing where applied, and also prevented covalent binding of 12-OH to cytosolic skin
fractions and SULT 1A1*1 in vitro. IL-1β levels were significantly upregulated in
skin of rats with a rash as well as skin isolates. No skin rash or covalent binding was
observed in the skin of NVP treated mice. Conclusions: In contrast to covalent
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binding in the liver, which involves direct oxidation to a quinone methide, the re-
active metabolite that covalently binds in the skin is a sulfate. The sulfate responsi-
ble for the rash is formed in the skin of rats and in human skin incubations but not
in mice which develop no rash. Further work is being done to confirm the role of
IL-1β in NVP-induced skin rash. Funding: Canadian Institutes of Health
Research.
1051 In Vitro Discrimination of Skin Sensitizing Haptens and
Prohaptens in a Modified Keratinosens Assay with an Added
Metabolic Activation Step.
A. Natsch1,  T. Haupt1 and G. Adamson2. 1Givaudan Schweiz AG, Duebendorf,
Switzerland; 2Givaudan US, East Hanover, NJ.
Prohaptens are chemicals which may cause skin sensitization after being converted
into electrophilic molecules by skin enzymes. In vitro sensitization assays ideally
should detect the potential of molecules to act as prohaptens. The metabolic activa-
tion system most commonly used in in vitro toxicology is Aroclor-induced rat liver
S9 fraction. Even if this system contains higher enzyme activites as compared to
those reported in skin, it may serve as a surrogate system to study the potential of
chemicals to form reactive, skin sensitizing metabolites. To test this concept, the lu-
ciferase induction in KeratinoSens reporter cells treated with chemicals in presence
and absence of S9 fractions was measured. Suspected prohaptens such as
methylisoeugenol, eugenol, trans-anethol or benzo(a)pyrene gave no, or weak, gene
induction in absence of S9 fractions, and a strongly enhanced luciferase induction
in presence of S9 proving their prohapten status. Haptens like DNCB or cinnamic
aldehyde gave a reduced response in presence of S9. We then evaluated whether this
metabolic activation assay might be implemented in a tiered screening strategy to
screen negatives in the classical KeratinoSensTM assay to enhance sensitivity. To
this aim all chemicals classified negative in the classical KeratinoSensTM assay were
retested with this activation step. Among the 77 chemicals found as correct-nega-
tives, 74 were also negative in presence of metabolic activation, thus this counter-
screen does only slightly reduce specificity. However, based on this comprehensive
screening, we found that only a small fraction of the known skin sensitizers need ac-
tivation by the S9/P450 system, and thus the KeratinoSensTM -S9 assay may be
useful for the in vitro evaluation of specific classes of potential prohaptens, rather
than as a general screening approach. These results will be presented along with re-
sults on the predictivity and reproducibility of the KeratinoSensTM assay as accu-
mulated during the prevalidation studies conducted for ECVAM.
1052 Toxicogenomic Characterization of Sensitizer and False-
Positive Responses in the Local Lymph Node Assay (LLNA).
D. Adenuga1,  I. Kimber2,  R. Dearman2,  M. Woolhiser1,  M. Black3,
R. S. Thomas3 and D. R. Boverhof1. 1The Dow Chemical Company, Midland, MI;
2University of Manchester, Manchester, United Kingdom; 3The Hamner Institutes for
Health Sciences, Research Triangle Park, NC.
Recent publications have highlighted chemistries which yield false positive re-
sponses in the LLNA when compared with guinea pig and human data. A toxi-
cogenomic approach was applied to provide insight into the molecular and cellular
mechanisms that may explain these differential responses. Auricular lymph node
gene expression responses were evaluated in female CBA mice exposed to equipo-
tent doses of 9 chemical sensitizers and 7 false positives per the standard LLNA dos-
ing regimen. Lymph nodes were analyzed for 3HTdR incorporation on day 6 and
gene expression responses on study days 4 and 6. Statistical analyses identified 779
and 473 differentially expressed genes (DEGs) between sensitizers and false posi-
tives on days 4 and 6. Class-based comparison of DEGs showed that the most en-
riched functional categories in the sensitizer-specific subsets were consistent with
mechanisms involved in the acquisition of antigen-mediated skin sensitization. Key
immune responses at the 4 day time point were restricted to genes involved in early
T-cell development including pathways involved in Il2 regulation (Il2 and Egr4),
Tbata and the pre T-cell receptor alpha (Ptcra). Day 6 responses were more consis-
tent with a mature T-cell response and included genes involved in the DC/T-cell
maturation process such as Il21, Lag3 and Fxyd4. In contrast, false positives exhib-
ited a strong pro-inflammatory expression profile including markers for activated
macrophages and neutrophils such as Cd5l, Il12b, Mpo, Defa4 and class I stefins.
Expression of these genes in the absence of dermal irritation suggested these re-
sponses were not solely driven by skin irritation. These gene expression profiles sug-
gest a differential cellular recruitment to the lymph nodes following skin exposure
to true sensitizers and false positives and provide a potential new endpoint that
could be applied to address false positives and enhance the predictive value of the
LLNA.
1053 Inductive Effects on Reactivity of the Contact Allergen
Benzoquinone and Its Derivatives to Proteins.
W. Mbiya1,  I. Chipinda2,  P. Seigel2 and R. Simoyi1. 1Chemistry, Portland State
University, Portland, OR; 2Health Effects Laboratory Division, NIOSH,
Morgantown, WV.
Benzoquinone (BQ) and substituted benzoquinones (SB) are used for dye and cos-
metics production. BQ is an electrophile known to covalently modify proteins via
Michael Addition (MA) but the reactivity, reaction mechanistic domains and aller-
genicity of SB are unknown. Electron withdrawing and electron donating sub-
stituents on BQ were assessed for effects on BQ reactivity and allergenicity.
Alternative potential protein binding mechanisms were explored. BQ binding to
Cys34 on human serum albumin (HSA) was studied and for BQ and SB reactivity
studies, nitrobenzenethiol (NBT) was used as a model nucleophile. Hammett and
Taft (HT) constants were used to evaluate the influence of these substituents on
chemical reactivity. Both NBT binding studies and HT values demonstrated chlo-
rine SB to be more reactive than methyl and t-butyl SB. Production of semiquinone
radicals from SB and characterization of SB-NBT adducts demonstrated that hap-
tenation may also occur via free radical mechanism which is pH dependent, and
vinylic substitution mechanisms, in addition to the predominant MA. BQ and SB
dermal allergenicity as evaluated in the murine local lymph node assay (LLNA) was
consistent with that predicted by reactivity and HT data. These results demonstrate
the effect of substituents on BQ reactivity and allergenicity while suggesting poten-
tial utility of chemical reactivity data and HT values for electrophilic allergen iden-
tification and potency ranking.
1054 Interaction of Para-Phenylenediamine with Human N-
Acetyltransferases.
S. Scheitza,  D. Dierolf,  J. Bonifas and B. Blömeke. Department of Environmental
Toxicology, University Trier, Trier, Germany.
The contact allergen para-phenylenediamine (PPD) is known as a good substrate
for N-acetyltransferase 1 (NAT1) but we also found that concentrations above 50
μM are accompanied by inhibition of NAT1 activity in human keratinocytes.
Here, we investigated the substrate and inhibition characteristics of PPD on NAT
enzymes. First we measured whether next to PPD and mono-acetylated PPD
(MAPPD) the PPD oxidation product Bandrowskis Base (BB) can also be acety-
lated. We therefore incubated PPD, MAPPD and BB with human recombinant
NAT1 and NAT2 and found them to be good substrates for both enzymes. 
NAT1 inhibition characteristic of PPD was further studied using the THP-1 cell
line which served as model for antigen-presenting cells. Both PPD and MAPPD are
N-acetylated by THP-1 and the acetylation is accompanied by NAT1 inhibition.
Concentrations above 1 μM PPD clearly reduced enzyme activity already after 8h
while 47% reduction was measured after 24h (200 μM). Independent of the sub-
strate-based enzyme inhibitions, certain compounds are known to oxidize the cat-
alytic cysteine or form adducts with NAT protein. Therefore we studied whether
PPD, MAPPD and/or oxidized PPD including BB also interact with recombinant
NAT protein itself in the absence of acetyl coenzyme A. All but MAPPD interact
with the protein after 2h and the greatest inhibition was found for oxidized PPD
(up to 50%). From these results we can conclude that the observed NAT inhibition
may be caused by both substrate dependent and independent effects. NAT1 activ-
ity in PPD-treated THP-1 cells was completely restored after incubation in fresh
culture medium for 24h, whereas inhibition caused by 24h treatment with
MAPPD could be restored for only 10%.
In sum our data indicate that PPD and its oxidation products can inhibit NAT in
two different ways. In addition we demonstrated that PPD and BB are acetylated
by NAT1 and 2, suggesting that certain amounts of PPD and eventually formed BB
inside the body may be detoxified by NAT1 in skin and additionally by NAT2 ex-
pressing organs.
1055 Pharmacodynamic Profiling of EGFR Inhibitors in HaCaT
Cells.
K. Balavenkatraman,  P. Couttet,  A. Vicart,  B. Bertschi,  M. Marcellin,
N. Rathfelder,  U. Hopfer,  O. Grenet,  R. Funhoff,  S. Chibout,  A. Lambert,
J. Moggs,  F. Pognan and A. Wolf. Discovery and Investigative Safety, Novartis
Institutes for Biomedical Research Basel, Basel, Switzerland.
Skin Rash is a serious adverse effect of EGFR inhibitors observed during anticancer
therapy in the clinic and appears to be linked to inhibition of the target pathway.
The EGFR inhibitors erlotinib and afatinib were investigated at increasing concen-
trations (0, 0.001, 0.01, 0.1, 1 and 10 μM) in the human keratinocyte cell line
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HaCaT at different time points (0, 4, 8, 24 hours). Apoptosis, cytokine gene ex-
pression and protein release, and the EGFR-downstream signaling events Akt and
Erk phosphorylation, were investigated as EGFR pathway pharmacodynamic read-
outs. 
The tested EGFR inhibitors induced dose-dependent pharmacodynamic responses
in HaCaT cells that reflected their differential potencies in recombinant EGFR
protein IC50 assays. Analysis of cytokine modulation (CCL-2, CCL-5 CXCL-10,
IL-8, TGF-alpha) also revealed a very good correlation between the mRNA and
protein levels upon treatment with EGFR inhibitors. 
These results suggest that HaCaT cells might be a useful model for the profiling of
new compounds for potential EGFR pathway inhibitory activities.
1056 Cytokine-Induced Liver Hepatotoxicity of Trovafloxacin in
Co-Culture of Hepatocytes and Kupffer Cells.
E. L. LeCluyse1,  K. Rose1,  K. Freeman2,  S. S. Ferguson2 and R. P. Witek2. 1The
Hamner Institutes for Health Sciences, Research Triangle Park, NC; 2Life Technologies,
Durham, NC.
Immune-mediated chemical-induced hepatotoxicity, i.e. indirect hepatocellular
toxicity resulting from immune cells activating liver inflammatory responses, is
often overlooked as a potential mode of action due to unavailability of appropriate
in vitro models. Kupffer cells are the largest population of resident macrophages in
the liver and thus play a critical role in immune-mediated hepatotoxicity and liver
injury. For this reason, we have established a co-culture system of rat primary hepa-
tocytes and Kupffer cells that can be used to model chemical-induced immune re-
actions resulting in acute hepatotoxicity. Hepatocytes and Kupffer cells were cul-
tured for 24-72 hours with various amounts of lipopolysaccharide (LPS) and
trovafloxacin (TVX), a compound associated with immune-response-mediated he-
patotoxicity in vivo. IL-6 and TNFα levels were assessed by ELISA or Luminex©
bead assays and CYP3A was measured using Luciferin-IPA as a probe substrate to
monitor endotoxin-induced functional changes in metabolic capacity. LPS-treated
co-cultures showed marked down-regulation of CYP3A activity, which correlated
with up-regulation of IL-6 production. This response was blunted in co-cultures
treated with LPS and TVX, showing no changes to CYP3A activity and signifi-
cantly lower production of IL-6. However, TNFα production was unaffected in
TVX/LPS-treated co-cultures and markedly up-regulated in Kupffer cell monocul-
tures. LPS/TVX-treated co-cultures also exhibited increased hepatocellular injury,
represented by decreased ATP content and increased LDH leakage. This data sug-
gests that shifts in cytokine profiles, especially IL6/TNFα ratios may play a role in
immune-mediated chemical-induced hepatotoxicity. Co-culture of hepatocytes and
Kupffer cells may represent a powerful in vitro tool to predict adverse liver effects
resulting from indirect adaptive immune reactions during chemical exposure. 
This project was supported by funding from the Long-Range Research Initiative
(LRI) of the American Chemistry Council (ACC).
1057 Drugs Associated with Idiosyncratic Drug-Induced Liver
Injury Synergize with Inflammatory Mediators to Produce
Cytotoxicity in a Human Hepatoma Cell Line.
A. Maiuri1, 2,  R. Parkins3,  P. E. Ganey1, 2 and R. Roth1, 2. 1Pharmacology and
Toxicology, Michigan State University, East Lansing, MI; 2Center for Integrative
Toxicology, Michigan State University, East Lansing, MI; 3College of Veterinary
Medicine, Michigan State University, East Lansing, MI.
Idiosyncratic drug-induced liver injury (IDILI) typically occurs in a small fraction
of patients and often results in removal of otherwise efficacious drugs from the
pharmaceutical market. The mechanisms of IDILI are unknown, and animal mod-
els of IDILI are few. Several animal models have been developed that suggest that
inflammation plays an important role in IDILI. Moreover, the inflammatory medi-
ators tumor necrosis factor alpha (TNFa), interferon gamma (IFNg), and neu-
trophil-derived elastase (EL) are essential to the pathogenesis of liver injury in these
models. The goal of the present study was to determine if two non-steroidal anti-in-
flammatory drugs associated with IDILI in humans synergize with TNFa, IFNg +/-
TNFa, or EL +/- TNFa in producing hepatocellular toxicity in vitro. HEPG2 cells
were treated with either diclofenac or sulindac sulfide (the active metabolite of
sulindac) and with TNFa, IFNg +/- TNFa, or EL +/- TNFa. Cytotoxicity was sig-
nificantly increased when cells were treated with diclofenac or sulindac in the pres-
ence of TNFa compared to cells treated with drug or TNFa alone. IFNg potentiated
the cytotoxicity caused by either drug in the presence of TNFa. EL increased the cy-
totoxicity caused by diclofenac in the presence of TNFa. These results indicate that
some of the events that occur in drug-inflammatory stress models in vivo can be re-
produced in cultured cells and suggest the possibility of developing in vitro systems
that can predict IDILI liability of drug candidates. (Supported by NIH grant
RO1DK061315 and T32 GM092715-01A1).
1058 Serial Survival Liver Biopsies in Dogs and Monkeys.
V. Dinkel,  M. Taschwer,  J. Nelson,  R. Haas,  A. Wathen,  A. Kamholz,
J. Stuhler,  J. Lindsay and F. Thalacker. Covance Laboratories Inc., Madison, WI.
The liver plays a key role in metabolism and excretion of endogenous compounds
and xenobiotics and is an area of strong experimental focus. The liver may also be a
target for efficacy (e.g. antiviral therapeutics) or toxicity. Animal models are critical
for studying xenobiotic metabolism, biomarkers, and pharmacological/toxicologi-
cal effects on the liver; however the ability to obtain adequate liver tissue samples
for analyses in a survival model has been lacking. A surrogate matrix (e.g. blood,
plasma, bile) is often used as an indirect measure for liver as its location within the
body cavity makes it generally inaccessible for non-terminal sampling. In general,
terminal sampling procedures have been needed when larger samples are required
and survival procedures have typically been limited to a single collection per ani-
mal; the prospect of additional collections being dependent on whether minor (la-
paroscopic) or major techniques were used. The limitation of a single collection per
animal increases the number of animals required to obtain the same data. We have
developed laparoscopic surgical techniques for serial survival liver biopsies of ~100
mg, 18 hours apart in dogs and monkeys. We have also developed techniques, at
least one laparoscopic, for serial survival biopsies of 1+ g in monkeys with samples
taken over a period of weeks. All techniques allow for multiple phases and animal
use has been decreased from 50-88%. In all cases, animals recovered completely fol-
lowing each procedure. They have been BAR (bright, alert, responsive), eating and
mobile on the same day of surgery and display no signs of pain or distress, indicat-
ing exceptional pain management. Also, there have been no significant changes in
body weight or clinical pathology and no surgical complications. Overall this work
has resulted in the ability to obtain serial liver biopsies in multiple species, provid-
ing a significant advantage over current techniques and supporting the 3R philoso-
phy through substantial reductions in animal use without compromising animal
welfare.
1059 Quantitative Relationship Between Intracellular Lithocholic
Acid (LCA) and Toxicity in Rat Sandwich-Cultured
Hepatocytes (SCH): Incorporation into a Mechanistic Model
of Drug-Induced Liver Injury (DILI).
K. Yang1,  J. L. Woodhead2,  R. St. Claire3,  P. B. Watkins2,  S. Q. Siler2,
B. A. Howell2 and K. L. Brouwer1. 1University of North Carolina at Chapel Hill,
Chapel Hill, NC; 2The Hamner-UNC Institute for Drug Safety Sciences, Research
Triangle Park, NC; 3Qualyst Transporter Solutions, Research Triangle Park, NC.
One proposed mechanism of DILI is inhibition of the bile salt export pump result-
ing in cellular accumulation of toxic bile acids (BAs). The purpose of this study was
to establish the quantitative relationship between intracellular LCA concentrations
and toxicity. This information is essential to link BA kinetics to toxicity in a BA
transport inhibition model constructed within DILIsymTM, a mechanistic model of
DILI. Day3 rat SCH in 24-well plate were incubated with LCA (25–200μM) for 6,
12, and 24hr. Cytotoxicity was assessed by LDH release from damaged cells and in-
tracellular ATP levels. Intracellular LCA/metabolites were measured by LC-
MS/MS analysis of lysate after hepatocytes were incubated for 5min with Ca+2-free
HBSS buffer to open tight junctions using B-CLEAR® technology. LCA, and its
taurine (TLCA) and glycine (GLCA) conjugates, accumulated extensively in rat
SCH. Cellular LCA concentrations increased with increasing LCA medium con-
centrations; cellular TLCA and GLCA decreased at LCA doses above 100μM, po-
tentially due to saturation of amidation. LC50 values estimated based on medium
and intracellular LCA concentrations at 12hr were 143 and 1098μM, respectively.
An Emax-type relationship was observed between cellular LCA exposure (AUCLCA)
and toxicity; half maximal toxicity was observed at AUCLCA of 10.4 and
16.3mM*hr for the 12 and 24hr incubations, respectively. Decreased intracellular
ATP concentrations preceded the toxicity measured by LDH. AUCATP,0-24hr was cor-
related with toxicity at 24 hr (r2=0.97) and AUCLCA,0-24hr (r
2=0.95). These results
provide mechanistic insight that increased cellular exposure of unconjugated LCA
leads to ATP depletion and subsequent toxicity. 
Supported by NIH R01 GM41935 and DILI-sim initiative.
1060 Transformation of CO2 Evolution Assays into Multiwell Plate
Format Assays to Assess Effects of Compounds on Substrate
Oxidation in Rat Hepatoma H4IIE Cells.
P. A. Cosgrove and J. W. Lawrence. Comparative Biology and Safety Sciences, Amgen
Inc., Thousand Oaks, CA. Sponsor: S. Sawant.
Perturbations of metabolic processes are involved in several pathologies including
cardiac hypertrophy, hepatic vacuolation, and steatosis. Different substrates can be
used to distinguish between electron transport chain, the citric acid cycle, β-oxida-
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tion, glycolysis, and amino acid metabolism pathway inhibition. The conventional
assay for assessing substrate oxidation is through the use of 14C-labeled substrates
and measuring the formation of 14CO2. Historically, these assays are run with sep-
tum sealed flasks that are awkward to use, prone to sample loss, and have low
throughput. We have adapted the CO2 capture method to a 96-well format by
using a standard 96-well plate for cell incubation with substrate. A neoprene gasket
is used to seal the environment to ensure CO2 is collected on a 96-well capture fil-
ter plate aligned on top. 14C- labeled glucose, pyruvate, glutamine, butyrate, oc-
tanoate, or palmitate were used as substrates and their oxidation was assessed in
H4IIE cells. Etomoxir, an inhibitor of carnitine palmitoyl transferase-1, demon-
strated a concentration dependent decrease in palmitate oxidation, however, glu-
cose oxidation increased after treatment suggesting a fuel switching to compensate
for the defect in fatty acid oxidation. Methylene cyclopropyl acetic acid (MCPA), a
reported inhibitor of medium-chain acyl-CoA dehydrogenase, inhibited both bu-
tyrate and octanoate oxidation and had minimal effects on palmitate oxidation. An
increase in glucose oxidation was observed after MCPA treatment, similar to that
observed with etomoxir suggesting a similar fuel switching. Antimycin A, an elec-
tron transport chain inhibitor, decreased the oxidation of multiple substrates with
similar potencies, suggesting inhibition at a point in the metabolic pathway com-
mon to all substrates. In conclusion, by transforming the classical CO2 evolution
assay into a 96-well format, the effect of various compounds on various substrates
can be assessed in an easier, higher throughput manner.
1061 Effect of Trichloroethylene Exposure on Autoimmune-
Mediated Cholangitis in NOD.c3c4 Mice.
A. K. Kopec,  B. P. Sullivan and J. Luyendyk. Pathobiology and Diagnostic
Investigation, Michigan State University, East Lansing, MI.
Epidemiological studies support the hypothesis that exposure to environmental
chemicals increases the risk of developing autoimmune liver diseases. Despite this
association, the identity of specific chemical perpetrators and the mechanism
whereby environmental chemicals modify liver disease is unclear. Previous studies
have shown that trichloroethylene (TCE) can trigger autoimmunity in susceptible
mice. We investigated whether modulation of hepatic gene expression by TCE ex-
posure modified the pathogenesis of autoimmune cholangitis in mice. NOD.c3c4
mice spontaneously develop autoimmune-mediated liver disease with features in-
cluding biliary cyst formation, portal lymphocytic inflammation, and fibrosis.
Nine-week-old NOD.c3c4 mice were exposed to TCE (0.5 mg/ml) or its vehicle
(1% Cremaphor-EL) via the drinking water for 4 weeks. TCE exposure had little
effect on changes in clinical chemistry, biliary cyst formation, or CD3 T cell accu-
mulation. Rather, global microarray profiling and Ingenuity Pathways (IPA) analy-
sis revealed marked differential expression of PPARα target genes, in agreement
with a computational IPA prediction of PPARα activation. TCE exposure signifi-
cantly down-regulated cholesterol metabolism genes, and resulted in a ~3-fold sup-
pression of early growth response 1 (Egr1). Consistent with a link between Egr1
suppression and liver fibrosis, we found that TCE exposure increased Type 1 colla-
gen mRNA and protein levels in livers of NOD.c3c4 mice. In contrast, TCE expo-
sure did not increase type 1 collagen expression in Nod.ShiltJ mice, which do not
develop liver disease. These results suggest that in the context of concurrent au-
toimmune liver disease with a genetic basis, modification of hepatic gene expression
by TCE may increase profibrogenic signaling in liver. Moreover, these studies fur-
ther highlight the potential use of NOD.c3c4 mice as a model to study gene-envi-
ronment interactions critical for development of autoimmune-mediated liver dis-
ease.
1062 Identification and Categorization of Transcriptional Profiles
and Potential Biomarkers of Liver Injuries Related to a Drug
Pair.
Y. Wang,  W. Ge,  Z. Liu,  M. Lee and W. Tong. Bioinformatics and Biostatistics,
National Center for Toxicological Research, US FDA, Jefferson, AR.
Amiodarone and benziodarone share similar chemical structure and pharmacologi-
cal effects, but induce different types of liver injuries in humans. This aspect of the
difference can not been seen with the current conventional preclinical toxicity as-
sessments. We hypothesize that the difference in liver gene expression profiles be-
tween two drugs correlate with the difference in their injury types. Thus, the aims
of this study are to differentiate the drug-induced liver injury mechanisms between
amiodarone and benziodarone by analyzing liver gene expression profiles in rats ex-
posed to both drugs. Gene expression profiles of rat liver treated with amiodarone
or benziodarone for consecutively 28-days were analyzed and compared to their
concurrently control rats to identify the transcriptional changes. Three doses were
used, where maximum tolerated dose (MTD) determined from dose range finding
studies were considered as the high dose for each molecule while low and middle
doses were calculated from the ratios of the MTD. Several common upstream reg-
ulators such as PPAR-α, pirinixic acid, clofibrate were identified spontaneously in
rat livers treated with two drugs. Sets of genes were detected to show a dose-re-
sponse pattern from liver tissues treated with amiodarone and benziodarone, re-
spectively. We suspected that this alteration of genes may be important in the bio-
logical progress relating to the different liver injuries caused by the drug pair. Using
these differentially expressed genes, biological pathways and networks were devel-
oped to categorize the correlation and interaction of each factor in relating to liver
injuries and in differentiating hepatotoxicity induced by amiodarone and benzio-
darone. The results of this study suggested that genomic profiles can be a good
starting point in developing mechanism-based biomarkers for prediction and dif-
ferentiation of liver injuries related to amiodarone benziodarone in early stage of
drug discovery and development.
1063 In Vitro Assessment of Drug Induced Liver Injury (DILI)
Using a High Content Cellular Imaging System.
M. L. Wolfe1,  S. Einhorn2,  V. Ott2 and H. Ma1. 1Cellular and Molecular Biology,
MPI Research, Mattawan, MI; 2Cellular Dynamics International, Madison, WI.
Sponsor: T. Rogers.
Drug-induced liver injury (DILI) is a leading cause of drugs failing during clinical
trials and being withdrawn from the market. In vivo safety testing in pre-clinical
species ensures that drugs which enter clinical trials do not cause reproducible and
dose-dependent liver injury in man, but is of limited value for exploration of un-
derlying mechanisms and does not assess potential to cause rare idiosyncratic DILI.
Implementation of an in vitro cell-based predictive assay early in the drug discovery
process would help improve early compound attrition and develop safer drug can-
didates. We tested compound-treated human hepatocellular carcinoma Hep G2
cells, human induced pluripotent stem cell (iPSC)-derived hepatocytes (iCell®
Hepatocytes) and primary human hepatocytes using the Thermo Scientific
ToxInsight® IVT platform and DILI Assay Cartridge to determine the hepatotox-
icity risk of a compound through the measurement of multiple toxicity biomarkers
in individual cells. The compounds we investigated include a number of known he-
patotoxic compounds (Ticlopidine, Troglitazone, Naladixic acid, Mefenamic acid,
Phenylbutazone and Aflatoxin B1) and non-hepatotoxic compounds (Aspirin,
Fluoxetine and Melatonin). Each compound was tested at eight concentrations in
triplicate. The DILI Assay Cartridge allows for the high sensitivity and specificity
for predicting hepatotoxicity by simultaneously detecting five multiplexed cellular
targets and properties associated with cell loss, cellular redox stress, and mitochon-
drial stress. The hepatotoxicity prediction using the multiparametric data generated
for the test compounds demonstrates high specificity across the three hepatocyte
models but varying sensitivity for each hepatocyte model system.
1064 Altered-Hepatic Catabolism of Branched Chain Amino Acids
in Progressive Human Nonalcoholic Fatty Liver Disease.
A. D. Lake1,  P. Novak3,  P. Shipkova2,  N. Aranibar2,  D. Robertson2,
M. D. Reily2,  L. D. Lehman-McKeeman2,  R. R. Vaillancourt1 and
N. J. Cherrington1. 1Pharmacology & Toxicology, University of Arizona, Tucson, AZ;
2Bristol-Myers Squibb Co., Princeton, NJ; 3Institute of Plant Molecular Biology, Ceske
Budejovice, Czech Republic.
Branched chain amino acids (BCAAs) and their catabolism have essential roles in
metabolic homeostasis. BCAAs are capable of activating the mammalian target of
rapamycin (mTOR) during states of over-nutrition resulting in an increased risk of
insulin resistance and altered lipid homeostasis. Nonalcoholic fatty liver disease
(NAFLD) is closely associated with features of the metabolic syndrome and over-
nutrition. Approximately 30-40% of the United States population is afflicted with
NAFLD while 5.7-17% is estimated to have severe nonalcoholic steatohepatitis
(NASH). A ‘two-hit’ model has been used to describe the pathological progression
of NAFLD to steatosis and then NASH, although the exact mechanisms for disease
progression are not known. The hypothesis of this study is that these two ‘hits’ drive
alterations in hepatic branched chain amino acid (BCAA) composition and catabo-
lism while enhancing disease progression. Hepatic transcriptomic and metabolomic
data sets representing the entire spectrum of human NAFLD (healthy, steatosis,
NASH Fatty, and NASH Not Fatty livers) were utilized to investigate the role of
BCAAs in the mechanisms of NAFLD pathophysiology. An increase of the BCAAs
leucine (127% of normal), isoleucine (139%) and valine (147%) were observed in
NASH samples. Increased BCAA catabolism through upregulated branched chain
aminotransferase enzyme appears to drive increases of acylcarnitine products that
include butyryl carnitine (353% of normal) and lauryl carnitine (403% of normal).
The hepatic overload of BCAAs also potentiates mTOR signaling thereby increas-
ing metabolic dysregulation. Overall, these findings demonstrate altered catabolism
of BCAAs in NASH with important downstream signaling implications for lipo-
toxicity and insulin resistance in the progression of NAFLD.
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1065 Altered Hepatic and Renal Drug Transporter Expression in
Multiple Rodent Models of Nonalcoholic Steatohepatitis.
M. Canet,  R. N. Hardwick,  A. D. Lake and N. J. Cherrington. Pharmacology
and Toxicology, University of Arizona, Tucson, AZ.
Nonalcoholic fatty liver disease (NAFLD) is the most common form of chronic
liver disease in Western society representing a spectrum of liver damage ranging
from simple steatosis to the more advanced nonalcoholic steatohepatitis (NASH).
Experimental models of NASH include diet-induced models such as the methion-
ine and choline deficient (MCD) diet and genetically obese models such as the lep-
tin-deficient, ob/ob mice. Previous studies have demonstrated alterations in the ex-
pression and activity of multiple drug transporters in human NASH, but little
information is known regarding the most appropriate animal models for predictive
toxicology to extrapolate in vivo hepatic and renal drug disposition data to human
NASH populations. The purpose of the current study was to determine which ex-
perimental NASH model best recapitulates human disease pathology as well as al-
terations in drug transporter expression. Both rat and mouse NASH models were
utilized in this investigation and include; MCD diet, atherogenic diet, ob/ob and
db/db mice, and fa/fa rats. Histologic and pathological evaluations confirmed that
the MCD and atherogenic rats and MCD, ob/ob and db/db mice all developed
NASH. In contrast, the fa/fa rats did not develop pathological NASH. Hepatic
mRNA levels of drug transporters showed that the rat and mouse MCD diet model
and the ob/ob and db/db mice best recapitulate the expression profile seen in
human NASH. In general, the majority of efflux transporters are induced whereas
uptake transporters are decreased. Similar to the liver, efflux transporter expression
in the kidney is also induced at both the mRNA and protein level. However, renal
uptake transporter expression across these models is differentially altered and is
transporter and model-specific. These results suggest that the MCD rat, and the
ob/ob and db/db mouse models may be more useful preclinical models to deter-
mine the effect of NASH on drug disposition as well as determining extra-hepatic
alterations in drug transporter expression.
1066 Regulation of ABCC2 Internalization in Nonalcoholic
Steatohepatitis.
A. L. Dzierlenga,  R. N. Hardwick,  J. Clarke and N. J. Cherrington.
Pharmacology & Toxicology, University of Arizona, Tucson, AZ.
Non-alcoholic fatty liver disease affects 30-40% of the United States population
and can progress to non-alcoholic steatohepatitis (NASH) which is characterized by
an accumulation of fat, oxidative stress, fibrosis and inflammation. It has been pre-
viously shown that NASH can have a significant effect on the disposition of many
drugs and potentially contribute to the occurrence of adverse drug reactions.
NASH-associated altered drug disposition has, in part, been linked to stress-in-
duced alterations of the expression and function of hepatic transporters such as
ABCC2. ABCC2 is located on the canalicular membrane and transports xenobiotic
substrates into the bile for elimination from the body. By mechanisms that are not
entirely understood, ABCC2 has been shown to be internalized in rodent and
human NASH livers, as well as the in vitro conditions of acute oxidative stress and
lipopolysaccharide exposure. Previous reports have suggested that the activation
and cellular localization of radixin, protein phosphatase 1, phosphoinositide 3-ki-
nase, protein kinase A, and protein kinase C (PKC) may be involved in the inter-
nalization of ABCC2. The purpose of this study is to identify potential mechanisms
responsible for ABCC2 internalization in NASH. Sprague-Dawley rats were fed a
control methionine and choline supplemented diet or a methionine choline defi-
cient diet (MCD) to model NASH. It was found that in NASH livers there was an
increase in the membrane association of the PKCε isoform compared to control liv-
ers, but not PKCδ or PKCα, implicating PKCε as a potential regulator of ABCC2
internalization. Additionally, the cellular localization of radixin was not found to
change in NASH livers. Further insight into the mechanisms behind functional
perturbations of hepatic drug transporters such as ABCC2 has implications for im-
proved understanding and identification of targets for alleviating adverse drug reac-
tions in clinical NASH.
1067 A RNA-Interference Screen Identifies Novel Regulators of the
Ubiquitinase A20/TNFAIP3 As Critical Determinants of
Drug-Induced Liver Injury Responses.
B. van de Water,  B. Herpers,  L. Fredriksson,  G. Benedetti and M. de Graauw.
Division of Toxicology, Leiden University, Leiden, Netherlands.
The cytokine tumor necrosis factor alpha (TNFalpha) acts in synergy with different
drugs, including diclofenac, to initiate drug-induced liver injury (DILI). This is di-
rectly related to the inhibition by these drugs of TNFalpha-induced NFkB activa-
tion as demonstrated by an inhibition of the NFkB nuclear oscillatory translocation
response. Here we investigated the underlying mechanism of the drug/TNF syn-
ergy. We used a live-cell imaging-based siRNA screen to identify individual kinases,
(de)ubiquitinases and sumoylases that control the NF-kB oscillatory response. We
applied high content confocal laser scan microscopy in combination with multi-
parametric image analysis to follow the NF-kB oscillation in ~300 individual cells
per condition simultaneously. Out of the ~1500 genes screened, we identified 115
that significantly affected the NF-kB oscillatory response. Using 4 individual
siRNAs, we confirmed the action for 46 genes, which affected: i. the amplitude or
duration of nuclear oscillations; ii. the time between oscillations, leading to an in-
crease or decrease of the number of nuclear translocations; or iii. an inhibition of
the response altogether. In this last category we identified six genes, four novel,
whose reduced expression protected against the diclofenac/TNFalpha-induced
apoptosis. Interestingly, the knockdown of these six genes led to a basic up-regula-
tion of A20 expression. In accordance, A20 knockdown promoted the NF-κB os-
cillation and enhanced apoptosis. Double knockdown experiments indicated a di-
rect relationship between these four genes and A20 in the control of the NF-κB
activation. These findings indicate that the (de)ubiquitinase A20 is a master regula-
tor in the life-death decision upon TNFalpha stimulation in drug-induced hepato-
toxic responses, which, in turn, is kept under control by a network of genes that
control its expression level.
1068 Hepatic Transporters in HepaRG Cells and Sandwich-
Cultured Human Hepatocytes.
C. Guguen-Guillouzo1, 2,  P. Bachour-El Azzi1, 3,  R. Li2,  A. Charanek1,  Z. Abdel-
Razzak3,  A. Guillouzo1 and C. Chesné2. 1INSERM 991, Rennes University, Rennes,
France; 2BIOPREDIC, Rennes, France; 3Lebanese University, Hadath, Lebanon.
Sponsor: M. Robin.
Reestablishment of polarized excretory function and maintenance of expression and
activity of transporters in liver cell models are critical for in vitro analysis of drug
and bile acid excretion as well as toxicity testing. Previous studies have shown that
conventional primary hepatocytes and HepG2 cells do not correctly mimic the in
vivo situation whereas sandwich-cultured hepatocyte conditions do restore cell po-
larity for a few days. In the present work we have analyzed expression, activity and
distribution of several canalicular and basolateral transporters in hepatocytes from
human HepaRG cells compared to sandwich-cultured primary human hepatocytes.
Differentiated HepaRG hepatocytes exhibited high polarity with typical bile canali-
culi structures characterized by F-actin accumulation and restricted by connexin
32-positive tight junctions. In previous reports, most influx and efflux transporters
were found to be expressed in HepaRG cells and adult hepatocytes, at the tran-
scriptional level. Using the immunofluorescence technique and imaging analysis
their specific distribution was investigated. MRP2 was localized in both models, at
the canalicular membrane domain while both MRP3 and MRP4 and the influx
transporter NTCP, were demonstrated at the basolateral plasma membrane do-
mains. Trafficking polarization toward canaliculi structures through MRP2 and
MDR1 was evidenced by using specific substrates coupled with fluorescein and/or
mitotrackers and Ca2+ regulation of canalicular excretion was clearly documented.
In addition, uptake and release of bile acid taurocholate was investigated in
HepaRG cells using H3-taurocholate; both active influx via NTCP activity and
canalicular efflux were evidenced. Moreover, addition of chlorpromazine, a com-
pound known to induce cholestasis in vivo, resulted in bile salt efflux inhibition
mainly at the canalicular pole. Together, these data support the view that HepaRG
hepatocytes represent a suitable in vitro model to investigate human drug and bile
acid excretion.
1069 Deep Sequencing of miRNA in Livers of Rats Exposed to
Hepatotoxicants.
M. Flores Torres1,  J. Wright1,  R. Currie2,  C. Koufaris1 and N. J. Gooderham1.
1Biomolecular Medicine, Imperial College London, London, United Kingdom; 2Safety
Assessment, Syngenta, Jealotts Hill, United Kingdom.
MicroRNAs (miRNAs) are small non-protein coding RNAs. They act as regulators
of gene expression, by inhibiting mRNA translation or promoting mRNA degrada-
tion, and are involved in diverse physiological and pathological events. Recently we
have shown (Koufaris et al. Toxicolog Sci: 128, 532, 2012) that the CAR activator
phenobarbital (PB) induces deregulation of the hepatic miRNAome in the livers of
rats. Next Generation Sequencing (NGS) analysis of small RNAs is a powerful tool
that can be used for miRNA expression profiling, and offers a deeper understanding
of molecular toxicology. Here we explore the liver miRNAome associated with
CAR activation, and to compare this with the effects of the hepatotoxicant di-
methylarsinic acid (DMA), which is known to induce mitochondrial perturbation.
Male rats were dosed with PB (50 or 1000 ppm) or DMA (4 or 40 ppm) in the diet
for 28 days, and sacrificed after 2, 4, 15, and 28. Histopathological evaluation re-
vealed centrilobular hypertrophy at 15 and 28 days after PB treatment and multifo-
cal inflammatory foci with necrosis at 28 days after DMA treatment. Total RNA
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was isolated from frozen samples, and library constructs for NGS were generated
(TrueSeq Small RNA kit, Illumina). Bioinformatics was used to prioritise potential
gene targets of deregulated miRNAs, and qPCR to validate expression of miRNA
families and potential gene targets. Consistent with our previous report, miR200
family was induced by 28 days of treatment with PB at 1000ppm, but not by
50ppm. There was a dose-dependent reduction in the zeb1 and zeb2 transcription
factors, which are known and validated targets of the miR200 family. The zeb1 and
zeb2 transcription factors regulate the epithelial to mesenchymal transition, thus
PB-mediated miR200 family induction appears to be a homeostatic response to
protect the epithelial nature of hepatocytes. NGS permits a more detailed explo-
ration of the response of the miRNAome to hepatotoxicants such as PB, thereby
aiding an understanding of the underlying pathways.
1070 High-Content Imaging of Rat Hepatocytes Long-Term
Cultures to Predict Specific Drug-Induced Liver Toxicity.
D. Germano,  M. Uteng,  P. Couttet,  O. Grenet,  S. Chibout,  F. Pognan and
A. Wolf. Discovery and Investigative Safety, Novartis Institutes for Biomedical
Research Basel, Basel, Switzerland.
Primary rat hepatocytes were investigated for liver-specific functional changes after
repetitive treatments with model liver toxicants at low concentrations for two
weeks. Cells were cultured in the Collagen I/Matrigel™ sandwich configuration.
High content imaging (HCI) was performed by using the Cellomics™
Arrayscan®. The liver-specific pathologies cholestasis/hyper-bilirubinemia, steato-
sis and phospholipidosis were investigated by means of fluorescence dyes. Mrp2-
mediated canalicular transport, intra-cellular accumulation of neutral lipids and
phospholipids were assessed by carboxy-DCFDA, BODIPY or LipidTOX™ Red,
respectively. Unspecific cytotoxicity was measured by ATP contents and LDH re-
leases. Cyclosporin A (CsA), Amiodarone (AMD), Rosiglitazone (RGZ),
Chlorpromazine (CPZ), Troglitazone (TGZ), Metformin (MET), Fenofibrate
(FFB), Ibuprofen (IBU), Acetaminophen (ACT), Valproic Acid (VPA) and
EMD335823 (EMD) were evaluated at four different concentrations and at five
time points (day 1, 3, 7, 10, 14). The results showed that inhibition of canalicular
transport, induction of phospholipidosis and steatosis occurred after multiple treat-
ments at clinical relevant doses in absence of cytotoxicity in the hepatocytes. CsA,
CPZ and TGZ treatment caused time- and concentration-dependent inhibition of
Mrp2-mediated transport, while AMD and CPZ induced dose-dependent accumu-
lation of phospholipids. CsA was also associated with intracellular accumulation of
lipids, whereas VPA did not induce steatosis. Taken together, the current data sug-
gest that the current testing strategy has a high predictive value for compounds in-
ducing hyperbilirubinemia/cholestasis and phopshoplipidosis, but not for drug-in-
duced steatosis. In addition, the present work illustrates that HCI is a sensitive and
reproducible tool for the evaluations of specific cellular functions and that HCI can
be applied in safety profiling of drug candidates. Study is part of the European FP7
PREDICT-IV consortium (grand no 202222).
1071 Gene Expression Profiling Identifies Molecular Mechanisms
of Tamoxifen-Induced Hepatotoxicity in Mice.
V. Tryndyak,  T. Han,  M. Churchwell,  B. Montgomery,  J. C. Fuscoe,
J. R. Latendresse,  F. A. Beland and I. P. Pogribny. US FDA-NCTR, Jefferson, AR.
Tamoxifen is an anti-estrogenic drug widely used for the treatment and prevention
of estrogen-receptor-positive breast cancer. However, despite the indisputable bene-
fits of tamoxifen, its use has been associated with the induction of hepatic steatosis.
The goal of this study was to investigate the underlying molecular mechanisms as-
sociated with tamoxifen-induced hepatotoxicity. Female and male WSB/EiJ mice
were fed a diet containing 420 ppm tamoxifen for 12 weeks. The livers of tamox-
ifen-fed mice exhibited moderate pathomorphological changes, as evidenced by
glycogen depletion, despite having profound genotoxic and non-genotoxic alter-
ations. Specifically, the livers of tamoxifen-fed mice were characterized by extensive
sex-independent accumulation of tamoxifen-DNA adducts and marked changes in
the gene expression. To identify tamoxifen-responsive genes that were differentially
expressed between the control and tamoxifen-exposed mice, a t-test, p < 0.01, cou-
pled with a fold-change cut-off > 1.5 was applied. A total of 1245 and 2100 genes
were found to be differentially expressed in the livers of tamoxifen-exposed female
and male mice, respectively. Interestingly, 361 of the genes were differentially ex-
pressed in both female and male mice treated with tamoxifen. Most of these genes
were associated with altered lipid metabolism, inflammation, cell death and prolif-
eration, and development of liver fibrosis. These results demonstrate the impor-
tance of gene-expression profiling in identify early hepatic molecular events associ-
ated with the chronic administration of tamoxifen.
1072 A 3D Co-Culture Model-Based Assay to Assess Liver
Kupffer-Cell Activation and Functionality.
S. Shetty2,  K. Adkins2,  M. Roy2,  I. Agarkova1,  J. M. Kelm1 and S. Messner1.
1InSphero AG, Zurich, Switzerland; 2Drug-Safety R&D, Investigative Toxicology,
Pfizer, Groton, MA. Sponsor: A. Wolf.
Adverse drug reactions in the liver are one of the major causes of attrition in drug
development with both small and large molecules. Novel therapeutic modalities
such as antibodies and other biologicals can be taken up by non-parenchymal cells,
such as phagocytic cells in the liver (mainly Kupffer cells) and can limit drug expo-
sure and cause liver toxicity. Therefore, evaluating Kupffer-cell uptake can serve as
an indirect screen for liver toxicity. However, due to lack of suitable organotypic in
vitro models, Kupffer cell uptake has been difficult to study. Here, the use of pri-
mary heterotypic 3D rat liver microtissues for assessment of drug-induced Kupffer-
cell activation is demonstrated. Morphological characterization of rat liver microtis-
sues demonstrated the presence of ED1 and ED2-positive Kupffer cells within the
hepatospheres. Electron-microscopy confirmed layering of Kupffer cells between
hepatocytes in the rat liver microtissues. Lipopolysaccharide (LPS) treatment of the
rat liver microtissues resulted in increased uptake of acetylated LDL (ac-LDL),
whereas incorporation of ac-LDL was reduced when the phagocytosis inhibitor
gadolinium chloride was applied, indicating ac-LDL uptake by Kupffer cells is de-
pendent on phagocytosis.  An increase in IL-6 secretion was also observed at 48 and
120 hrs post-treatment with LPS, indicating Kupffer cell activation. Together these
data demonstrate the suitability of heterotypic rat liver microtissues for assessing
Kupffer cell activation and functionality by external stimuli, and highlight the po-
tential of 3D rat liver models for evaluating liver toxicity.
1073 Organic Solute Transporter Ostα-Ostβ As a Potential
Therapeutic Target for the Metabolic Syndrome.
S. Gorman,  C. Hammond,  P. Hinkle and N. Ballatori. Environmental Medicine,
University of Rochester, Rochester, NY.
The metabolic syndrome has increased in occurrence in recent decades, and as a re-
sult has become a major health concern. Environmental contaminants have been
linked to this, as common toxicants have been found to increase susceptibility to
weight gain and/or insulin resistance, key features of the metabolic syndrome. This
has resulted in a need for pharmaceuticals that lower fat accumulation and improve
insulin sensitivity, and this study identifies a novel potential therapeutic target, the
bile acid transporter Ostα-Ostβ. Our laboratory has generated an Ostα-/- mouse in
the C57Bl6 background, a strain susceptible to age-related weight gain.
Interestingly, Ostα-/- mice have a significant reduction in bile acid pool size. The
major purpose of bile acids is to emulsify dietary lipids in the small intestine and fa-
cilitate their absorption, but they have also recently been shown to function as sig-
naling molecules that affect lipid and glucose homeostasis. This study aimed to ex-
plore differences in lipid and glucose homeostasis in Ostα-/- mice. A comparison of
whole body and fat pad weights of Ostα-/- and wild type mice at 5 and 12 months
of age revealed no differences in these parameters at 5 months, but at 12 months,
Ostα-/- mice had accumulated less fat and had lower total body weights. Similarly,
extraction of liver lipids indicated less accumulation of total lipid and cholesterol in
hepatic tissue with age. At both ages, increased fecal lipid excretion and altered ex-
pression of genes involved in bile acid and lipid homeostasis were noted, and glu-
cose and insulin tolerance tests also revealed significant improvement in glucose tol-
erance and insulin sensitivity at both ages. These studies indicate that Ostα-/- mice
excrete more lipids in feces, are resistant to age related weight gain and have im-
proved insulin sensitivity and glucose tolerance, suggesting an inhibitor of Ostα-
Ostβ may be useful in treating the metabolic syndrome. (NIH Grant DK067214,
NIEHS Training Grant ES07026 and Center Grant ES01247)
1074 Predictivity of Drug-Induced Liver Toxicity Using High-
Content Screening in 384-Well Cultures of HepG2 Cells and
Primary Human Hepatocytes.
K. F. Marcoe1,  H. J. Garside2,  J. Chesnut-Speelman1,  A. J. Foster2,  U. Warrior1,
J. Baumgartner1,  D. Muthas3,  J. G. Kenna2 and J. Bowes2. 1Eurofins Panlabs,
Bothell, WA; 2Global Safety Pharmacology, AstraZeneca, Macclesfield, United
Kingdom; 3Global Safety Assessment, AstraZeneca, Molndal, Sweden. Sponsor: J.
Valentin.
Drug-induced liver injury (DILI) is a major cause of failed drug development and
drug withdrawal. Predictive toxicology screening assays are therefore required for
early de-selection of compounds that may cause DILI. Although previous investiga-
tors have reported several potentially promising in vitro approaches, it is unclear
which cell systems and endpoints can provide the greatest predictive power. In this
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study we used multiplexed high content screening, with automated fluorescence
microscopy and image analysis, to assess the in vitro toxicity of 122 drugs associated
with DILI in man and 22 drugs not reported to cause DILI. Studies were under-
taken in HepG2 cells with and without rat S9 fraction and in cryopreserved pri-
mary human hepatocytes. Toxicity was determined at 4, 24 or 48 h. The parameters
assessed were: cell proliferation (nuclear dyes); apoptosis (anti-activated caspase 3);
cell cycle (anti-pHistone H3); stress (anti-HSP70/72); reactive oxygen species gen-
eration (H2DFFDA dye); mitochondrial damage (TMRE dye); phospholipid and
neutral lipid accumulation. All cell systems provided highly specific discrimination
(>90%) between those that caused DILI and non-hepatotoxic drugs. The highest
sensitivity was observed in HepG2 cells without S9, using the apoptosis (29%) and
phospholipidosis (22%) endpoints. Addition of S9 did not increase the sensitivity
of any of the parameters studied. In human hepatocytes, the 24 h H2DFFDA assay
had a sensitivity of 20%, whereas the other endpoints had sensitivities of <11%. We
conclude that toxicity studies in HepG2 cells enabled detection of compounds
which may cause DILI in humans with high specificity but low sensitivity and that
neither the addition of S9 nor the use of human primary hepatocytes provided im-
proved predictivity.
1075 Studying Drug-Induced Cholestasis with a Novel Cellular
Model Coexpressing Major Bile Salt Transporters in the
Liver.
M. S. Warren,  J. X. Zhang,  J. Huang,  P. Druzgala and Y. Huang. Optivia
Biotechnology Inc., Menlo Park, CA.
Drug induced cholestasis and hepatocellular injury are two major manifestations of
drug induced liver disease (DILI). Research has shown such injuries are often at-
tributed to inhibition of bile salt transporters in the liver. NTCP, OATP1B1, BSEP
and MRP2 have been identified as the major transporters modulating hepatic clear-
ance of bile salts and their conjugates.
We recently demonstrated that canalicular excretion and intracellular retention of
bile salts can be studied with a polarized MDCK cell model concomitantly express-
ing three major bile salt transporters in the liver, i.e., OATP1B1, NTCP and BSEP.
To evaluate the utility of this model in studying drug-induced cholestasis, we tested
20 drugs and their major metabolites that have been reported to cause cholestasis in
the human. More than half of the drugs or their metabolites, including traglito-
zone, benzbromarone and bosentan, significantly inhibited B>A transcellular trans-
port (canalicular excretion) of [3H]Taurocholate at clinically relevant concentra-
tions, suggesting that blocking transporter mediated canalicular excretion of bile
salts is a major mechanism of drug induced-cholestasis in vivo. Furthermore, a few
drugs, such as Rifampicin, remarkably elevated intracellular concentration of
Taurocholate (which has been suggested to lead to hepatocellular damage), suggest-
ing that at high concentrations, these drugs are more likely to cause cholestatic hep-
atitis than the others. Other agents, such as estradiol-17-beta-glucuronide, tamox-
ifen and pyrazinamide, did not exhibit significant inhibitory effect on Taurocholate
transport under the test conditions, which suggests there may be other mecha-
nism(s) involved.
In summary, our study demonstrates that the novel OATP1B1/NTCP/BSEP triple
transporter expression model can be a useful economical tool for early-stage screen-
ing and for mechanistic study of compounds with cholestasis liability.
1076 Use of a Multiplexed Endpoint Assay Strategy to Assess
Model Bioactivated Compounds in Sandwich-Cultured
Hepatocytes.
K. Wille1,  A. L. Niles2,  J. J. Cali2 and E. L. LeCluyse1. 1The Hamner Institutes for
Health Sciences, Research Triangle Park, NC; 2Promega Corporation, Madison, WI.
Sandwich-cultured rat hepatocytes (SCRH) represent a metabolically competent in
vitro model for screening and identifying potentially hepatotoxic compounds that
correlates well with in vivo results. In this study, we employ a novel strategy for mul-
tiplexing a broad complement of metabolic platereader assays using SCRH to
measure hepatotoxicity of model bioactivated compounds, such as acetaminophen
(APAP). This approach yields a profile of early toxicity indicators that provides
greater mechanistic insight from fewer experimental replicates. SCRH in 24- or 48-
well plates were exposed to 8 concentrations of APAP in the presence or absence of
the CYP inducer, dexamethasone (DEX); CYP inhibitor, 1-aminobenzotriazole
(ABT); and the glutathione synthesis inhibitor, L-buthionine sulfoximine (BSO).
Toxicity was assessed at 24 and 48 hours for Cyp3A activity (Promega P450-
GloTM), ATP content (Promega CellTiter-Glo® Assay), lactate dehydrogenase leak-
age (Promega CytoTox ONETM Homogenous Membrane Assay), and glutathione
content (Promega Glutathione-GloTM Assay). Resulting ATP, glutathione, and
LDH data showed dose-and time-dependent APAP toxicity which was moderated,
especially at the 24 hour time point, by ABT and exacerbated by DEX. CYP3A ac-
tivity was induced up to 4-fold by DEX and significantly inhibited by ABT (5% of
DMSO controls). BSO nearly eliminated intracellular glutathione levels by 48
hours and increased hepatocyte APAP sensitivity. Collectively, these data demon-
strate the utility of SCRH as a model to assess bioactivated compounds for hepato-
toxicity. The multiparameter assay approach offers greater mechanistic insight into
the nature and timing of the toxicity.
This project was supported by the Long-Range Research Initiative (LRI) of the
American Chemistry Council (ACC) and Promega Corporation, Madison, WI.
1077 Cytotoxic Interaction of Inflammagens with Trovafloxacin in
Spheroid Cultures of Rat Liver Cells.
R. A. Roth1,  P. C. Wilga2, 1,  K. L. Poulsen1,  K. M. Beggs1,  J. Prezenger2,
A. Maiuri1,  P. E. Ganey1 and J. McKim2. 1Pharmacology and Toxicology, Michigan
State University, East Lansing, MI; 2CeeTox, Inc., Kalamazoo, MI.
Idiosyncratic, drug-induced liver injury (IDILI) typically escapes detection in pre-
clinical safety evaluation of drug candidates due to paucity of predictive models.
Recently, models have arisen in which liver injury occurs in rodents treated with
trovafloxacin (TVX) or other IDILI-associated drugs and coexposed to an inflam-
magen such as bacterial lipopolysacharide (LPS). The hepatocellular injury depends
on tumor necrosis factor-alpha (TNF) and possibly other cytokines released by
nonparenchymal cells (NPCs) and therefore cannot be reproduced in monocultures
of hepatic parenchymal cells (HPCs). Accordingly, the cytotoxicity of TVX in the
presence and absence of LPS was evaluated in 3-dimensional (3D) spheroid cul-
tures (InSphero) containing equal numbers of HPCs and NPCs and compared to
data obtained from HPCs in standard sandwich culture. Spheroids or standard
HPC cultures were exposed to various concentrations of TVX (10 -100 μM) alone
or with LPS (10 μg/ml) or TNF (10 ng/ml) for 24 hr. TNF was detected in the cul-
ture medium of spheroids cotreated with LPS and TVX, but not with either agent
alone, and no TNF was detected in HPC cultures treated similarly. Cytotoxicity, as
assessed by decreases in intracellular ATP content, was evident only in spheroids
cotreated with LPS and TVX. In contrast, treatment of either spheroids or HPC
cultures with TNF in the absence or presence of TVX did not result in consistent
cytotoxicity. Levofloxacin (LVX) is in the same pharmacological class as TVX, but
has far less IDILI liability; interestingly, there was no cytotoxic interaction with
LVX and LPS or TNF. These results show that LPS-stimulated inflammatory medi-
ator production and cytotoxicity occurred in 3D spheroid cultures containing
NPCs cotreated with TVX. 2D-sandwich HPC cultures were less sensitive to cyto-
toxicity from the TVX-inflammation interaction, suggesting that spheroids may af-
ford advantages in evaluating interactions between drugs and inflammatory media-
tors.
1078 Trovafloxacin Induces Cell Cycle Arrest and Sensitizes
HepG2 Cells to TNF-Induced Cytotoxicity by an ATR-
Dependent Mechanism.
K. M. Beggs1, 3,  K. Miyakawa2, 3,  M. A. Scott2,  P. E. Ganey1, 3 and R. A. Roth1, 3.
1Pharmacology and Toxicology, Michigan State University, East Lansing, MI;
2Pathobiology and Diagnostic Investigation, Michigan State University, East Lansing,
MI; 3Center for Integrative Toxicology, Michigan State University, East Lansing, MI.
Trovafloxacin (TVX) is an antibiotic associated with idiosyncratic hepatotoxicity in
humans, though the mechanism for this toxicity is unknown. In mice, TVX is not
hepatotoxic by itself but synergizes with tumor necrosis factor-alpha (TNF) to pro-
duce liver injury. Moreover, treatment with combinations of TVX and TNF were
cytotoxic to HepG2 human hepatoma cells, whereas neither TVX nor TNF alone
caused cytotoxicity. It was demonstrated previously that TVX is a weak inhibitor of
eukaryotic topoisomerase-II alpha activity and inhibits HepG2 cell proliferation.
These results led to the hypothesis that signaling mechanisms important in cell
cycle regulation contribute to cytotoxicity from TVX/TNF interaction. In HepG2
cells treated with both TVX and TNF, activities of caspases 9 and 3 were increased
starting 8 hr after treatment, which is a time before the onset of cell death.
Cytologic evaluation revealed that cells treated with TVX or with TVX/TNF were
arrested in the prophase of mitosis compared to vehicle or TNF-treated cells, which
appeared in all stages of the cell cycle. The PI3K-like kinases, ataxia telangiectasia
mutated (ATM), ataxia telangiectasia and Rad3-related (ATR), and DNA protein
kinase (DNAPK), as well as the tumor suppressor protein p53, all play a role in reg-
ulating cell cycle. Pharmacologic inhibitors of ATM, DNAPK, and p53 had no sig-
nificant effect on the cytotoxicity caused by TVX/TNF treatment, whereas an in-
hibitor of ATR attenuated cytotoxicity. Taken together, these data suggest that
increased activity of caspases 9 and 3 is associated with TVX/TNF-induced cyto-
toxicity of HepG2 cells and that ATR plays a role in this cell death response.
(Supported by NIH grant R01DK061315.)
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1079 MicroRNA Regulation of Alcoholic and Nonalcoholic Fatty
Liver Disease.
S. Kondraganti1,  T. K. Varma2,  B. S. Kaphalia1 and G. Ansari1. 1Pathology, The
University of Texas Medical Branch, Galveston, TX; 2Anesthesiology, The University of
Texas Medical Branch, Galveston, TX.
Alcoholic liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD) are
histologically similar diseases as both induce fatty liver (hepatic steatosis) through
mechanisms not yet fully understood. MicroRNAs (miRNAs), small non-coding
RNAs are involved in regulation of various biological process and dysregulated
microRNA expression is observed in various diseases including fatty liver. To un-
derstand the role of miRNAs in inducing hepatic steatosis, miRNAs were analysed
in the livers of both ALD and NAFLD models. Male Fischer-344 rats were fed with
or without 5% alcohol via Lieber-DeCarli diet for one, two or three months or L -
aminoacid rodent diet with or without methionine-choline for one week. We ob-
served differential expression of eleven miRNAs in both treatment models.
Increased expression of miR-122 and miR-34a was observed in ethanol treated rat
livers as time progressed while miR-122 expression decreased and no change in
miR-34a expression was observed in rat livers fed with methionine-choline defi-
cient (MCD) diet. Contrary, expression of miR-451 was increased in both ethanol
fed rats with time as well as MCD diet fed rats. However, the increase in miR-451
expression was more pronounced in MCD diet fed rat livers. miR-122 is known to
be involved in hepatic lipid metabolism and sterol synthesis, miR-34a is involved in
lipid metabolism, cell cycle and apoptosis while miR-451 is involved in regulation
of insulin dependent (gluconeogenesis) pathway. Our miRNA expression data also
supported the differential regulation of genes involved in lipid metabolism such as
sterol regulatory element-binding protein (SREBP), AMP-activated protein kinase
(AMPK), peroxisome proliferator-activated receptor alpha (PPAR-α), sirtuin-1 and
acyl-CoA synthetase long-chain family member 1 (ACSL-1). In conclusion, our
studies show that differential expression of miRNAs results in steatosis in both
models but could be via different mechanisms.
1080 Characterization of HepaRG-EP Cells As a Surrogate for
Primary Human Hepatocytes.
J. J. Cali1,  M. Sobol1,  D. Ma1 and D. Steen2. 1Research, Promega Corporation,
Madison, WI; 2Biopredic International, Overland Park, KS. Sponsor: T. Riss.
HepaRG-EP (EP) cells are a next generation version of HepaRG (HRG), a human
hepatoma cell line with substantial similarity to primary human hepatocytes (HH).
We characterized cryopreserved EP from Biopredic International to evaluate their
suitability as a HH surrogate for in vitro toxicity and ADME studies, and for com-
parison to HRG (Biopredic). The DMSO content of the EP cryopreservation
medium was low enough for compatibility with a no spin thaw/recovery protocol
that yielded about 90% viable cells (HRG required DMSO removal). One cryopre-
served vial of EP provided for two full confluent 96 well plates of cells, which ex-
ceed the yield from typical commercially sourced vials of HH. EP cell viability was
relatively constant over a period of 7 days in culture. Like HRG, EP established an
adherent co-culture of hepatocytes and cholangiocytes but EP had a higher hepato-
cyte/cholangiocyte ratio. Consistent with this hepatocyte enrichment, EP also had
higher activity for CYP1A2, -2D6, -2B6 but similar CYP3A4 activity, and these ac-
tivities were within the range typically observed in HH. The initial EP CYP3A4 ac-
tivity remained elevated for the first 24 hours, but then declined to a lower yet still
robust level that averaged about 25% of the initial activity over the next 6 days. As
a marker of metabolic capacity, the sustained CYP3A4 activity suggests EP will pro-
vide a good model for acute or extended drug metabolism studies. Omeprazole,
phenobarbital and rifampicin respectively caused substantial inductions of
CYP1A2, -2B6 and -3A4 activities with a more pronounced CYP1A2 response in
EP compared to HRG. In common with HH, dose-dependent aflatoxin-B1 toxic-
ity was observed with HRG and EP, indicating their competence for detecting me-
tabolism-based toxicities. In summary, EP provides a convenient model for hepato-
toxicity, metabolism and CYP induction studies with the reproducibility inherent
to a cell line. For the properties tested EP is a reasonable HH surrogate with en-
hanced metabolic capacity and convenience over HRG.
1081 Use of a Multiparametric Assay on Isolated Mouse Liver
Mitochondria to Predict Drug-Induced Liver Injury in
Human.
A. Borgne-Sanchez1,  M. Porceddu1,  N. Buron1,  C. Roussel1 and B. Fromenty2.
1Mitologics Research Laboratory, Mitologics SAS, Paris, France; 2INSERM U991,
Faculté de Pharmacie, Rennes, France. Sponsor: N. Claude.
Drug-induced liver injury (DILI) is difficult to predict using classical in vitro assays
and regulatory animal studies leading to interruption of clinical trials or even to
market withdrawal after commercialisation. Consequently, drug-induced mito-
chondrial dysfunction should be detected early, ideally during pre-clinical screening
of potential drug candidates. This could be done by investigation of drug-induced
mitochondrial dysfunction which appears as a major mechanism of DILI. To
achieve this detection, we have developed a dedicated high-throughput screening
platform using isolated mouse liver mitochondria to measure several parameters re-
lated to mitochondrial function and integrity. Indeed, this multiparametric assay
measures in isolated mouse liver mitochondria: 1) global mitochondrial membrane
permeabilization (swelling), 2) transmembrane potential, 3) outer membrane per-
meabilization (cytochrome c release) and 4) oxygen consumption through respira-
tory chain complex I and complex II. A pool of 124 drugs was tested revealing a
highly significant relationship between drug-induced mitochondrial toxicity and
DILI occurrence in patients (P<0.001) with an excellent sensitivity (94 or 92% de-
pending on cut-off ) and a high positive predictive value (89 or 82%) [1]. Moreover,
our study disclosed for the first time the identification of several drugs triggering
mitochondrial toxicity. Investigation of drug-induced loss of mitochondrial in-
tegrity and function with this assay should be considered for integration into basic
screening processes at early stage to select drug candidates with lower risk of DILI
in human. This multiparametric assay is also a valuable tool for assessing the mito-
chondrial toxicity profile and investigating the mechanism of action of new com-
pounds and marketed drugs.
[1] Porceddu M, Buron N, Roussel C, Labbe G, Fromenty B, Borgne-Sanchez A.
(2012). Toxicol Sci. 129: 332-45.
1082 CAR Activation Increases Bile Flow, Excretion of Major Bile
Acids, and Bile Acid Synthesis, As Well As Transport Genes
in Mice.
A. J. Lickteig,  I. L. Csanaky,  M. Pratt-Hyatt and C. D. Klaassen. Internal
Medicine (Division Gastroenterology), University of Kansas Medical Center, Kansas
City, KS.
Activation of Constitutive Androstane Receptor (CAR) has been shown to protect
against bile acid (BA)-induced liver injury. However, the effect of CAR activation
on bile flow, BA profile, and BA synthesis and transport genes in liver is not well
understood. Therefore, the purpose of the present study was to determine the effect
of CAR activation on BA homeostasis. The CAR ligand 1,4-Bis-[2-(3,5-
dichloropyridyloxy)]benzene (TCPOBOP) was administered intraperitoneally (3
mg/kg) daily to male C57BL6/N wild-type mice for 4 days, followed by collection
of serum, liver, and bile. BAs of serum and bile were quantified by UPLC-MS/MS.
TCPOBOP induced a CAR-dependent increase in bile flow by 67%. TCPOBOP
increased biliary excretion of two of the three quantitatively major bile acids in
mice, TαMCA (3.5-fold) and TβMCA (80%), as well as the quantitatively minor
bile acids TUDCA (38%) and TCDCA (224%). Additionally, TCPOBOP in-
creased biliary excretion of unconjugated bile acids by 74%. These increases in bil-
iary excretion correlated with increased liver mRNA of the two major canalicular
efflux transporters Mrp2 (3.2-fold) and Bsep (2.4-fold). Interestingly, TCPOBOP
induced BA synthesis genes Cyp7a1 (4.3-fold) and Cyp27a1 (110%). Also in livers
of TCPOBOP-treated mice, the sinusoidal efflux transporters Mrp3 (17-fold) and
Mrp4 (14-fold) were markedly increased. Surprisingly, there were no changes in
serum concentrations of total BAs, taurine-conjugated BAs, unconjugated BAs, or
primary BAs, but the serum secondary BAs were decreased 61%. In summary,
while CAR activation has relatively minor effects on serum BA profile, CAR activa-
tion increases bile flow and biliary excretion of TαMCA, TβMCA and total un-
conjugated BAs. (R01ES009649, R01DK081461, F32DK092069)
1083 Role of Aryl Hydrocarbon Receptor (AhR) in Maintaining
Plasma Concentrations and Biliary Excretion of Bile Acids.
I. L. Csanaky,  A. J. Lickteig,  M. Pratt-Hyatt and C. D. Klaassen. Department of
Internal Medicine, University of Kansas Medical Center, Kansas City, KS.
Failure in regulation of bile acid (BA) homeostasis contributes to several liver dis-
eases. It is generally accepted that hepatic FXR-SHP and intestinal Fgf15/19 regu-
late BA homeostasis. However, the contribution of other hepatic transcription fac-
tors to BA homeostasis is not clear. The adaptive role of the aryl hydrocarbon
receptor (AhR) in protecting against BA related liver damage is unknown. The AhR
may be critical for mediating an adaptive response that involves induction of genes
responsible for the metabolism or transport of BAs. To study the role of the AhR in
BA homeostasis, sera, livers, and bile of 12-week-old male wild-type and AhR-null
mice were collected, and BA concentrations in serum and bile, as well as the mRNA
expression of hepatic BA synthesis and transport genes were quantified.
Surprisingly the lack of AhR increased serum total BAs (62-fold), taurine conju-
gated-BAs (52-fold), and unconjugated-BAs (113-fold). Similarly the biliary excre-
tion of total BAs (2.3-fold), taurine conjugated-BAs (2.3-fold), and unconjugated-
BAs (3.8-fold) increased in AhR-null mice compared with controls. In livers of
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AhR-null mice the mRNA expression of Fgfr4 (111%), SHP (83%), Cyp7a1
(170%), Cyp8b1 (70%), BAL (60%), Bsep (50%), and Mrp3 (80%) were in-
creased, whereas Cyp7b1 (-64%) was decreased in comparison to wild-type mice.
In conclusion, lack of the AhR receptor results in an increase in (1) mRNA of the
majority of BA synthesis and transport genes, (2) conjugated and unconjugated
BAs in serum, as well as (3) the biliary excretion of conjugated and unconjugated
BAs. These findings suggest that AhR has a fundamental role in suppressing syn-
thesis, transport, plasma concentrations, and biliary excretion of BAs. (Supported
by NIH grants ES009649, ES013714, DK092069)
1084 Screening of AMPK Activator from Herbal Extract.
S. Lee and M. Dong. School Lifesciences and Biotechnology, Korea University, Seoul,
Republic of Korea. Sponsor: B. Lee.
AMP-activated protein kinase (AMPK) is a key sensor and regulator of glucose,
lipid, and energy metabolism throughout the body. Activation of AMPK improves
metabolic abnormalities associated with metabolic diseases including obesity and
type-2 diabetes. AMPK phosphorylation inhibits sterol regulatory element-binding
protein-1(SREBP-1) activity which plays an important role in lipid metabolism. In
this study, we established in vitro screening methods for potential activators of
AMPK from herbal extracts to develop the inhibitor of hepatic steatosis.  First, the
phosphorylation of AMPK and its substrate ACC-1 were screened by In-cell-west-
ern assay which is an immunocytochemical assay performed in 48 well-microplate
format and then confirmed them using Western blot in HepG2 cells. Oil Red O
staining is performed to observe the accumulation of lipid droplets in cell and then
tested the expression of genes related lipid synthesis and metabolism. When we
screened over 50 herbal extracts, we found three extracts which were significantly
increased the phosphorylation of AMPK and its substrate ACC-1 in a dose-de-
pendent manner. They also reduced the palmitic acid induced lipid droplets accu-
mulation determined by Oil Red O staining. Among them, one extract was selected
and observed SREBP-1 transcriptional activity using a SRE-luc reporter gene assay
and SREBP-1 target genes expression using RT-PCR. In this study, we could iden-
tify the natural extracts for the development of AMPK activator for diabetes and
the metabolic syndrome.
1085 Gender Differences in mRNA and Protein Expression of
Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) and
Nrf2-Dependent Genes.
P. Rohrer and J. E. Manautou. Department of Pharmaceutical Sciences, University of
Connecticut, Storrs, CT.
Nuclear factor erythroid 2-related factor 2 (Nrf2) is a transcription factor that pos-
itively regulates the expression and activity of cytoprotective genes during periods
of oxidative stress. It has previously been shown that some of these cytoprotective
genes are more highly expressed in livers of female than male mice. This could ex-
plain previously reported gender-related differences in susceptibility to acetamino-
phen (APAP) hepatotoxicity in mice. In this study, we examined the presence of
differences in basal mRNA and protein expression for Nrf2 and Nrf2-dependent
genes between naïve fed male and female mice. Hepatic mRNA and protein levels
were measured by quantitative PCR and western blotting, respectively. Basal Nrf2
mRNA expression was significantly lower in livers of female than male mice.
Furthermore, mRNA expression of the Nrf2-regulated genes NAD(P)H quinone
oxidoreductase 1 (Nqo1), heme oxygenase 1 (Ho-1) and multidrug resistance-asso-
ciated protein transporter 4 (Mrp4) was less pronounced in livers of male than fe-
male mice, although these differences were not statistically significant. Conversely,
mRNA levels of glutamate cysteine ligase catalytic subunit (Gclc), glutamate cys-
teine ligase modifier subunit (Gclm), and multidrug resistance-associated protein
transporter 3 (Mrp3) appeared more pronounced in male mice than female mice,
but these difference were not significant either. Protein levels of Nqo1 and Mrp4
were similar between genders, while protein levels of Mrp3 and Gclm were signifi-
cantly lower in livers of female than male mice. In agreement with mRNA levels of
Nrf2, lower protein expression of Nrf2 was seen in female mice, although this dif-
ference was not significant. Collectively, these results indicate that female mice do
not have higher global expression of Nrf2-related genes and that other factors
might be responsible for the lower susceptibility of female mice to APAP hepato-
toxicity. Supported by NIH DK069557.
1086 Metabolomics Evaluating Protective Effects of Green Tea
Extract on Acetaminophen-Induced Hepatotoxicity in Mice.
J. Sun1,  Y. Lu1, 2,  X. Yang1,  J. Greenhaw1,  W. F. Salminen1, 3,  D. L. Mendrick1
and R. D. Beger1. 1NCTR/US FDA, Jefferson, AR; 2Jiangsu Institute for Food and
Drug Control, Jiangsu, China; 3PAREXEL International, Boston, MA.
Green tea has a considerable amount of polyphenolic catechins (potent antioxi-
dants) and it has shown to have protective effects on oxidative stress-related dis-
eases. Acetaminophen (APAP) is a widely used analgesic drug that can cause liver
injury if overdose. The aim of this study was to explore the effects of green tea ex-
tract (GTE) on APAP-induced hepatotoxicity using an LC/MS-based metabolomic
approach. Male B6C3F1 mice were orally administered GTE (500 or 1000 mg/kg)
either 3 h prior to 200 mg APAP/kg oral treatment, or for three consecutive days
(once daily) followed by 300 mg APAP/kg on the fourth day. Blood and liver tissue
samples were collected 24 h after APAP administration for clinical chemistry,
histopathological and metabolomic analysis. LC/MS-based metabolomics profiling
was utilized to examine metabolic changes in liver extracts. The partial least squares
discriminant analysis of the LC/MS data showed that groups dosed with APAP
alone were the most distinct from controls, while animals dosed with 500 mg
GTE/kg followed by APAP treatment were located between these two and those
pre-treated with 1000 mg GTE/kg groups were nearest to control group. These re-
sults were consistent with histopathological data showing that 3h single or 3d con-
secutive dosing with 1000 mg GTE/kg prior to APAP exposure significantly allevi-
ated some of the hepatocyte necrosis. Similar results were observed for ALT and
AST. Dose dependent changes were observed in the energy pathway-related
metabolites, including acylcarnitines (mitochondrial injury biomarker) and
lysophosphatidylcholines, which returned to controls levels after 3h or 3d consecu-
tive dosing GTE prior to APAP treatment compared to APAP treatment alone.
These results indicate that GTE treatments prior to APAP dosing could relieve liver
injury.
1087 Oleanolic Acid Produces Cholestatic Liver Injury in Mice.
J. Liu,  Y. Lu,  Y. Zhang,  K. C. Wu and C. D. Klaassen. Internal Medicine,
University of Kansas Medical Center, Kansas City, KS.
Oleanolic acid (OA) is a triterpenoid that exists widely in fruits and medicinal
herbs. OA is effective in protecting against hepatotoxicants. However, we recently
found that whereas a low dose of OA is hepatoprotective, higher doses and long-
term use of OA produce cholestasis. This study characterized OA-induced cholesta-
tic liver injury. Adult C57BL/6 mice were given OA at doses of 0, 50, 100, 200,
and 300 μmol/kg, sc (suspended in 2% Tween-80 saline) for 5 days, and cholesta-
tic liver injury was observed at doses of 200 μmol/kg and above, as evidenced by in-
creases in serum total bilirubin, serum activities of alanine aminotransferase and al-
kaline phosphatase, as well as by histopathology with feathering-like degeneration
indicative of cholestasis.  Serum bile acid (BA) concentrations were dramatically in-
creased not only for unconjugated bile acids (CA, CDCA, DCA, αMCA and β-
βMCA), but also for taurine conjugated bile acids (TCA, TCDCA, TDCA,
TUDCA, and Tα/βMCA), as determined by UPLC-MS/MS. The mRNAs of he-
patic bile acid uptake transporter for unconjugated BAs Oatp1b2 and conjugated
BAs Ntcp, as well as canalicular efflux transporter Bsep were decreased in a dose-de-
pendent manner. OA decreased OSTα but increased OSTβ. Hepatic uptake trans-
porter Oatp1a1, 1a4, and 2b1 were suppressed, while the efflux transporters Abca1,
Asbt, and Bcrp were increased. OA decreased the mRNA of the nuclear receptors
CAR, FXR, PPARα, but had no effects on AhR and PXR. The mRNA of the BA
biosynthesis limiting enzyme Cyp7a1 was decreased. Taken together, higher doses
of OA produces cholestatic liver injury in mice and this effect appears to be associ-
ated with the alteration of liver transporters resulting in disruption of BA home-
ostasis.
1088 Apoptogenic, Necrogenic, and Unique Patho-Morphological
Changes Induced by Bio-Activation-Dependent
Hepatotoxins.
P. Patel,  M. E. Kiersma and S. D. Ray. Pharmaceutical Sciences, Manchester
University College of Pharmacology, Fort Wayne, IN.
The diagnosis of drug-induced liver disease is an intriguing question often accom-
panied by insufficient clinical data and the difficulty of interpreting histopathology
after exposure to toxins. This study investigated the histopathological changes in-
duced by several different bioactivation-dependent hepatotoxins, such as, aceta-
minophen (an analgesic; 500mg/Kg, ip), carbon tetrachloride (CCl4; a hepato-
toxin), dimethylnitrosamine (DMN; a potent carcinogen), doxorubicin (DOX; an
antineoplastic agent), furosemide (FUR; a loop diuretic) and streptozotocin (STZ;
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an inducer of hyperglycemia) to charaterize most common and most uncommon
pathological traits in order to hypothesize whether a subset of lesions can be used to
diagnose toxicity profile of a particular toxin. Mice were administered CCl4
(1ml/Kg, po), DMN (50 mg/Kg, ip), DOX (60 mg/Kg, ip), Fur (500 mg/Kg, ip)
and STZ (100 mg/Kg, ip 2 consecutive doses) and sacrificed 24-72 hours later.
Blood was collected for serum chemistry and liver sections for histopathology. PAS
or H&E stained liver sections were examined under a brightfield microscope to de-
termine similarities concerning: sinusoidal dilatation, centrilobular necrosis, exces-
sive vacuolization, cells with apoptotic morphology, microvesicular steatosis, bal-
looning degeneration, pericentral or periportal or indiscriminate necrosis, glycogen
depletion trend, inflammation, and formation of ground glass hepatocytes. Results
indicated that all the toxins caused massive liver injury with limited overlapping
profiles. The most common features were indiscriminate glycogen depletion and
ballooning of hepatocytes. Results also indicated various other characteristic mor-
phological changes such as macrovesicular steatosis, bridging necrosis, portal tract
fibrosis and some unique but yet to be reported feature induced by DOX, i.e.,
prominent sinusoidal dilation. Thus, our study made a serious effort in differentiat-
ing and profiling the varied patho-morphological changes induced by diverse hepa-
totoxins. [Suppo. by Dept. of PScs, AMS Coll of Pharm & HScs]
1089 Cholestyramine Liver Effects in Healthy Human Subjects.
R. Singhal1,  A. H. Harrill3,  F. Menguy-Vacheron2,  Z. Jayyosi1,  H. Benzerdjeb2
and P. Watkins3. 1Sanofi, Inc., Framingham, MA; 2Sanofi, Chilly-Mazarin, France;
3The Hamner Institute, Research Triangle Park, NC.
Cholestyramine is an orally administered, an ion exchange non-absorbable resin
with a high affinity for biliary acids used as a cholesterol lowering agent as well as to
accelerate clearance from the body of xenobiotics and to treat itching in patients
with advanced cholestatic liver disease. This treatment has been associated with ele-
vations in serum alanine aminotransferase (ALT), a sensitive biomarker of liver in-
jury, but has never been associated with clinically important liver injury. A recent
clinical trial in healthy adults receiving cholestyramine provided an opportunity to
use current serum biomarkers to investigate mechanisms underlying this phenome-
non. After a double blind, placebo controlled study cholestyramine (8 gm/tid X 11
days) was administered to healthy adult subjects to accelerate clearance of the new
drug candidate given in the active arm. During cholestyramine therapy, eleven sub-
jects previously treated with placebo experienced elevations in serum ALT levels ex-
ceeding three-fold the upper limit of normal (>3x ULN; mean 6.9 fold; range 3-28
fold). Serum samples from those subjects were assayed for additional mechanistic
biomarkers. Compared to predose baseline values, there was a significant (p<0.05)
13-fold mean increase in miR-122 confirming a liver source for the serum ALT.
Mean serum levels of GLDH (8-fold), cytokeratin 18, and HMGB1 (1.7 fold) were
elevated supporting ongoing necrosis. Caspase-cleaved cytokeratin 18 was also in-
creased (1.7 fold) supporting apoptosis. Serum ALT elevations observed during
cholestyramine treatment reflect both hepatocellular necrosis and apoptosis. The
wealth of clinical data available with cholestyramine indicate that this effect on the
liver is self-limited and not a significant safety concern.
1090 Sterile Inflammation and Neutrophil Activation during
Injury Resolution following Acetaminophen Overdose in
Mice and Humans.
C. D. Williams,  M. R. Sharpe,  M. R. McGill,  M. Bajt and H. Jaeschke.
1UAMS, Little Rock, AR; 2Arkansas Children’s Nutrition Center, Little Rock, AR.
Following acetaminophen (APAP)-overdose, there is a robust inflammatory re-
sponse triggered by the release of cellular contents from necrotic hepatocytes into
systemic circulation which recruits neutrophils (PMNs) into the liver. PMNs do
not contribute to APAP-induced injury in mice, but their role, and the role of
NADPH oxidase, in injury resolution is unclear. C57BL/6 mice were treated with
APAP and were euthanized (6h - 72h) for assessment of liver injury and regenera-
tion. Informed and consented human APAP-overdose patients (ALT >800U/L) had
serial blood draws during injury and recovery phases for determination of liver
function tests (LFTs) and flow cytometric analysis. Blood PMNs (mouse, human)
and liver PMNs (mouse) were evaluated by flow cytometry (CD11b, reactive oxy-
gen priming, phagocytosis). To test the importance of phagocyte ROS production,
gp91phox-/- (NADPH oxidase defective) mice were compared to C57BL/6 mice
for hepatocyte proliferation and injury resolution. PMNs in the peripheral blood of
mice showed increasing activation status during and after the peak of injury but re-
turned to baseline levels prior to injury resolution. Hepatic sequestered PMNs
showed an increased and sustained CD11b expression, but no ROS priming was
observed. Confirming that NADPH oxidase is not essential for recovery,
gp91phox-/- mice following APAP-overdose displayed no difference in injury reso-
lution. APAP-overdose patients also showed increased PMN activation status after
the peak of injury, and PMNs remained in an activated state even as LFTs began to
normalize. The time course of PMN activation status in the peripheral blood was
similar in mice and humans, and markers of activation were increased and sustained
well after active liver injury had subsided. The similar findings between surviving
patients and mice indicate PMN activation may be a critical event for injury reso-
lution following APAP-overdose in man, but not a contributing factor to APAP-in-
duced injury.
1091 Ethyl Tertiary -Butyl Ether Induces Oxidative Stress and 8-
OHdG Formation in the Liver of F344 Rats via Activation of
CAR, PXR and PPAR Nuclear Receptors.
A. Kakehashi1,  A. Hagiwara2,  N. Imai2,  Y. Doi2,  K. Nagano3,  M. Banton4,
F. Nishimaki5,  H. Wanibuchi1 and S. Fukushima6. 1Department Pathology, Osaka
City University Graduate School of Medicine, Osaka, Japan; 2DIMS Institute of
Medical Science, Ichinomiya, Japan; 3Nagano Toxicologic-Pathology Consulting,
Kanagawa, Japan; 4Toxicology and Risk Assessment, LyondellBasell Corporate HSE,
Houston, TX; 5Japan Petroleum Energy Center, Tokyo, Japan; 6Japan Bioassay
Research Center, JISHA, Kanagawa, Japan.
To elucidate the mode of action (MOA) of hepatotumorigenicity in rats for non-
genotoxic chemical ethyl tertiary-butyl ether (ETBE), male F344 rats were treated
with ETBE at doses of 300 and 2000 mg/kg/day by gavage and 500 ppm pheno-
barbital (PB) in diet for the comparison analysis for 1 and 2 weeks. Significant in-
creases of hydroxyl radicals and P450 total content levels at weeks 1 and 2 in 300,
2000 mg/kg/day ETBE and PB groups accompanied the accumulation of P450
isoenzymes CYP2B1/2, CYP3A1/2 and CYP2C6 in the cytoplasm of hepatocytes.
Specific up-regulation of CYP2E1 and CYP1A1 was obvious in the high dose
ETBE group. Conspicuous elevation of 8-hydroxydeoxyguanosine (8-OHdG) and
apoptosis in the liver tissue observed in 2000 mg/kg/day ETBE and PB groups was
associated with suppression of Ki-67 positive-cell index, cyclin D1 mRNA expres-
sion and down-regulation of 8-OHdG repair enzyme, DNA glycosylase 1 (Ogg1)
after 2 weeks of application. Results of QSTAR LC/MS/MS and IPA analyses indi-
cated that upstream regulators of gene expression altered by ETBE included CAR,
PXR and PPAR. High dose ETBE induced peroxisome proliferation in hepatocytes
at week 2 detected by TEM. These results indicated that MOA of ETBE hepatotu-
morigenicity in rats is due to induction of oxidative stress and 8-OHdG formation,
subsequent cell cycle arrest and apoptosis, suggesting regenerative cell proliferation,
predominantly induced by activation of CAR and PXR nuclear receptors by a
mechanism similar to that of PB, and furthermore peroxisome proliferation by spe-
cific activation of PPAR. The MOA of ETBE hepatotumorigenicity in rats is indi-
cated to be not relevant to human.
1092 Expression Profiles of Hematopoietic Stem Cell, Endothelial
Cell, and Myeloid Cell Antigens in Spontaneous and
Chemically Induced Hemangiomas and Hemangiosarcomas
in Mice.
S. Kakiuchi-Kiyota1, 2,  C. A. Torrie3,  L. L. Arnold1,  K. L. Pennington1,
J. C. Cook2,  D. Malarkey4 and S. M. Cohen1. 1Pathology and Microbiology,
University of Nebraska Medical Center, Omaha, NE; 2Drug Safety Research &
Development, Pfizer Inc., Groton, CT; 3Experimental Pathology Laboratories,
Research Triangle Park, NC; 4National Toxicology Program, NIEHS, Research
Triangle Park, NC.
It is unclear whether the process of spontaneous and chemically induced heman-
gioma (HA) and hemangiosarcoma (HS) formation in mice involves the transfor-
mation of differentiated endothelial cells (ECs) or recruitment of multipotential
bone marrow-derived hematopoietic stem cells or endothelial progenitor cells
(EPCs) which show some degree of endothelial differentiation. In the present study,
immunohistochemical staining for hematopoietic stem cell markers (CD45 and
CD34), EC markers [VEGFR2, CD31, and Factor VIII-related antigen (FVIII
RAg)], and a myeloid lineage marker (CD14) was used to assess the origin of HA
and HS in mice and compare with results of canine and human EC tumors re-
ported in previous literature. We showed that the staining for CD45, FVIII RAg,
and CD14 was negative in spontaneous and chemically induced HA and HS,
whereas cells stained positive for CD34, VEGFR2, and CD31 in these tumors.
These results indicate that mouse HA and HS are composed of cells derived from
EPCs expressing CD34, VEGFR2, and CD31, but not FVIII RAg. The lack of
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CD45 expression suggests that mouse vascular tumors may arise from EPCs that
are at a stage later than hematopoietic stem cells. Since FVIII RAg expression is
known to occur later than CD31 expression in EPCs, our observations may indi-
cate that these tumor cells are arrested at a stage prior to complete differentiation,
in contrast to vascular tumor cells in humans and canines, which express both
CD31 and FVIII RAg. In addition, unlike human infantile HA or canine HS,
myeloid lineage cells do not appear to contribute to HA and HS formation in mice.
Our results may indicate that mouse HA and HS may arise by a different mecha-
nism than canine or human EC tumors.
1093 Role of the Circadian Clock in the Differential Susceptibility
of Rat Strains to Mammary Carcinogenesis.
M. Fang and H. Zarbl. Environmental Occupational Medicine, University of
Medicine and Dentistry of New Jersey, Piscataway, NJ.
Disruption of circadian rhythm is associated with increased risk of breast cancer in-
cidence and malignancy. DNA damage responsive and repair pathways are con-
trolled by and also modulate the molecular circadian oscillators. In order to investi-
gate the role of the circadian clock on the susceptibility to mammary tumor, we
compared circadian expression patterns of genes involved in circadian rhythm and
DNA damage responsive and repair pathways in mammary glands of susceptible
Fisher 344 (F344) and resistant Copenhagen (COP) rats. The mammary tissue of
susceptible F344 rats showed a 4-hr delay in the rhythmic expression of clock genes
(e.g., Per2 and Bmal1) and much higher amplitude on Rev-ErbAα expression com-
pared to resistant COP rats. In mammary glands of COP rats, 45.1% of DNA re-
sponsive and repair genes (total 82 genes) were up-regulated in a circadian pattern
with peak expression levels over 2 folds at Zeitgeber Time (ZT)12 (lights off ) com-
pared to ZT0 (lights on). By contrast, in the susceptible F344 rats, 30.5% of these
genes showed a circadian pattern of down-regulation, with only one gene being up-
regulated in the active phase. Exposure to a single carcinogenic dose of N-nitroso-
N-methylurea (NMU) disrupted the rhythmic expression of Per2 in mammary
gland of F344 rats after two days and further abolished after 30 days. In contrast,
NMU induced a significant increase in the rhythmic expression of Per2 gene in the
Cop rats in 2 days, and the increase was sustained for at least 30 days post exposure.
Moreover, the ratio of NAD+/NADH and NAD+-dependent Sirt1 activity, were
also significantly increased in NMU-treated COP, but were dramatically decreased
in treated F344 rats. Taken together, we speculate that the genetic block to tumor
progression in COP is, at least in part, due to the ability to maintain or enhance cir-
cadian rhythm, and hence DNA repair upon exposure to carcinogens. (Supported
by NIEHS grants, U19ES011387, P30ES007033, and P30ES005022).
1094 Transcriptomic Profiling of Hepatoblastomas and Associated
Hepatocellular Carcinomas in B6C3F1 Mice.
S. Bhusari1,  A. Pandiri1, 4,  Y. Wang1,  J. Foley1,  H. Hong1,  T. Ton1,
K. R. Shockley2,  S. Peddada2,  K. E. Gerrish3,  D. Malarkey1,  R. Sills1 and
M. Hoenerhoff1. 1Cellular and Molecular Pathology, National Toxicology Program,
NIEHS, Research Triangle Park, NC; 2Biostatistics Branch, NIEHS, Research Triangle
Park, NC; 3Microarray Core, NIEHS, Research Triangle Park, NC; 4Experimental
Pathology Laboratories, Research Triangle Park, NC.
The cell of origin of hepatoblastoma (HB) is unknown; it is thought to be a trans-
formed hepatocyte, an oval cell, or a multipotent hepatic progenitor cell. Many in-
vestigators believe that HBs arise solely within hepatocellular carcinoma (HCC),
and therefore are a more malignant form of HCC. Comparison of differential gene
expression changes in HB to HCC in which they arise may identify alterations spe-
cific to each tumor type, as well as alterations shared by both tumor types. Such
studies may provide information on the possible cell of origin and pathogenesis of
these tumors. In the current study, frozen samples from chemically-induced HB,
associated HCC, tumor-associated normal (AN) liver, and vehicle control normal
(VN) liver from a 2-year National Toxicology Program (NTP) bioassay were laser
capture microdissected from B6C3F1 mouse liver tumor samples. RNA was iso-
lated, amplified, and global gene expression profiling was performed to identify dif-
ferential transcriptomic changes between sample groups. Principal component
analysis of the normalized transcriptomic data showed that the HB samples clus-
tered distinctly from HCC. When compared to AN, there were increased numbers
of differentially expressed genes in HB (10,386 genes) compared to HCC (1,073
genes). Genes involved in Wnt/β-catenin signaling, hepatic embryonic stem cell-
like phenotype and genomic imprinting were significantly altered in HB compared
to HCC, pathways prominent in human HB pathogenesis. Meta-analysis of HB
tumors revealed high concordance with murine embryonic liver E10.5 to 12.5d
gene expression. Understanding the molecular differences between HB and HCC
will provide a more accurate assessment of the pathogenesis of chemically-induced
HB and HCC, and may have an impact on hazard identification of compounds im-
portant in human health risk.
1095 Methionine Sulfoxide Stimulates Hepatocarcinogenesis in
Mouse; Possible Role of Free Radical-Mediated DNA
Methylation.
K. Kawai1,  H. Kasai1, 4,  Y. Li1,  M. Song1,  A. Kakehashi2,  H. Wanibuchi2 and
A. Ootsuyama3. 1Department of Environmental Oncology, University of
Occupational and Environmental Health, Kitakyushu, Japan; 2Department of
Pathology, Osaka City University Medical School, Osaka, Japan; 3Department of
Radiation Biology, University of Occupational and Environmental Health,
Kitakyushu, Japan; 4OHG Institute, Kitakyushu, Japan.
Methylation of the cytosine C-5 position in the promoter region of tumor suppres-
sor genes is an important mechanism of carcinogenesis in addition to gene muta-
tion. However, the actual mechanisms of de novo methylation are not clear. We
have reported the formation of 5-methylcytosine from cytosine in vitro, with
methyl radicals generated from methionine sulfoxide (MetO). To confirm this reac-
tion in vivo, MetO was added to the drinking water and administered to non-alco-
holic steatohepatitis (NASH) mice, which develop hepatitis caused by endogenous
oxidative stress. All of the animal experimental procedures were performed in ac-
cordance with the guidelines for the care and use of laboratory animals at Univ.
Occup. Environ. Health. Histopathological examinations revealed incidences of
hepatocellular carcinoma of 16.7% and 90% in the 0% and 3% MetO groups, re-
spectively. Higher DNA methylation was detected in the promoter region of the
p16 gene isolated from the livers of MetO-treated mice. The higher incidence of
liver tumors may be due to the methyl radical-mediated formation of 5-methylcy-
tosine in DNA, which triggers epigenetic changes.
References: 1) Kawai K, et al. DNA methylation by dimethyl sulfoxide and me-
thionine sulfoxide triggered by hydroxyl radical and implications for epigenetic
modifications. Bioorg Med Chem Lett. 2010; 20: 260-5. 2) Kasai H, et al. DNA
methylation at the C-5 position of cytosine by a methyl radical: a link between en-
vironmental agents and epigenetic change. Genes and Environment. 2011; 33: 61-
5. 3) Kawai K, et al. Methionine sulfoxide stimulates hepatocarcinogenesis in non-
alcoholic steatohepatitis (NASH) mouse: possible role of free radical-mediated
DNA methylation. Genes and Environment. 2012; 34: 123-8.
1096 Differential Activation of Mitogenic Signaling through the
Insulin Receptor or the Insulin-Like Growth Factor 1
Receptor of Various Clinical Relevant Insulin Analogues.
B. ter Braak1,  K. Siezen3,  B. van de Water1 and J. van der Laan2, 3. 1Toxicology,
LACDR, Leiden University, Leiden, Netherlands; 2National Institute of Public Health
and the Environment (RIVM), Bilthoven, Netherlands; 3Medicines Evaluation Board
(MEB), Utrecht, Netherlands.
Several epidemiological studies suggest an association between the use of some in-
sulin analogues and cancer incidence in diabetic patients. Different insulin ana-
logues might affect the affinity and activation of these analogues towards the insulin
receptor (INSR) and the insulin-like growth factor 1 receptor (IGF1R). A switch
towards higher IGF1R affinity is likely to emphasize cellular signalling pathways
that promote mitogenesis rather than glucose metabolism. 
To investigate this hypothesis we have performed in vitro exposure experiments
with several insulin analogues including glargine, AspB10, aspart, glulisine, lispro
and detemir. To separate INSR versus IGF1R activation motilities of these ana-
logues, we used human breast cancer cell lines (MCF7) that either ectopically ex-
press the INSR (A or B isoform) in conjunction with a stable knockdown of the
IGF1R, or the IGF1R in conjunction with a stable knockdown of the INSR. Using
Western blots we measured the activation of INSR and IGF1R as well as down-
stream mitogenic signalling cascades including ERK and Akt. We revealed differ-
ences in activation patterns between the different insulin analogues tested. While
insulin primarily acted through the INSR, the mitogenic signalling activation pat-
tern of the long-acting insulin glargine was highly similar to that of known mito-
genic compounds like insulin AspB10 or insulin like growth factor 1 (IGF1) and
acted mainly via the IGF1R. These findings correlated with the proliferative effect
of insulin glargine: at low insulin glargine concentrations a clear increase in cell pro-
liferation was observed. This occurred despite the fact that the EC50 for the prolif-
erative effect was not much different from regular insulin. Therefore, these data
suggest that insulin glargine is similar in mitogenic potency to AspB10 and IGF1,
at least at low and presumably physiological concentrations.
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1097 Deletion of Hepatocyte Nuclear Factor 4 Alpha Promotes
Diethylnitroasmine-Induced Hepatocellular Carcinoma.
C. Walesky1,  S. Gunewardena2,  G. Edwards1,  P. Borude1 and U. Apte1.
1Pharmacology, Toxicology, and Therapeutics, University of Kansas Medical Center,
Kansas City, KS; 2Kansas Intellectual and Developmental Disabilities Research Center,
University of Kansas Medical Center, Kansas City, KS.
HNF4α is known as the master regulator of hepatocyte differentiation. However,
role of HNF4α in regulation of hepatocyte proliferation is not known. We investi-
gated role of HNF4α in regulation of hepatocyte proliferation using a novel ta-
moxifen-inducible hepatocyte specific HNF4α knockdown mouse model.
Hepatocyte specific deletion of HNF4α in adult mice resulted in increased hepato-
cyte proliferation with a significant increase in liver/body weight ratio. RNA se-
quencing-mediated global gene expression analysis revealed that a significant num-
ber of the 500+ up-regulated genes are associated with cell proliferation and cancer.
Further, a combined bioinformatics analysis of ChIP-sequencing and RNA-se-
quencing data indicated that a substantial number of up regulated genes are puta-
tive HNF4α targets. IPA-mediated functional analysis revealed the most signifi-
cantly activated gene network after HNF4α deletion is regulated by c-Myc. To
determine role of HNF4α in pathogenesis of HCC, we performed the classic initi-
ation-promotion experiment using diethylnitrosamine (DEN). Deletion of
HNF4α resulted extensive promotion of DEN-induced hepatic tumors. HNF4α
deletion resulted in 4-fold higher hepatic tumors, which were highly proliferative
and less differentiated. Further, the HCC observed in HNF4α deleted mice exhib-
ited significant up regulation of c-Myc and its target genes. These data indicate that
HNF4α inhibits hepatocyte proliferation, is a potential tumor suppressor in the
liver and plays a critical role in chemical carcinogenesis.
1098 EGCG Elicits Stage-Specific Sensitivity in a Novel Prostate
Cancer Progression Model.
M. A. Moses1,  W. A. Ricke2 and T. A. Gasiewicz3. 1Department of Pathology,
University of Rochester, Rochester, NY; 2Department of Urology, University of
Wisconsin-Madison, Madison, WI; 3Department of Environmental Medicine,
University of Rochester, Rochester, NY.
Epigallocatechin gallate (EGCG), a major tea catechin, has been shown to have
protective effects in a mouse model of PRCA, however, the relevance to human
PRCA and the mechanism of action are less understood. We made the novel dis-
covery that EGCG is a heat shock protein 90 (hsp90) inhibitor. Therefore, we uti-
lized non-tumorigenic, tumorigenic, and metastatic PRCA cells from a human
PRCA progression model to test the hypothesis that malignant cells are more sensi-
tive to EGCG in a stage-specific manner and that sensitivity is related to the ability
of EGCG to act as a hsp90 inhibitor. Treatment of cells with EGCG (25-50μM) in
vitro decreased the viability and proliferation, and induced apoptosis selectively in
PRCA cells compared to non-tumorigenic cells. EGCG also led to a decrease in the
motility of tumorigenic PRCA cells, as analyzed by scratch assay, at the same con-
centrations tested. Moreover, when tumorigenic or metastatic cells were grown in
vivo, mice supplemented with 0.06% EGCG in drinking water had significantly
smaller tumors than those of the untreated group. To elucidate the mechanism of
EGCG sensitivity, we performed affinity chromatography with EGCG-sepharose.
Binding assays revealed that hsp90 from metastatic cells had a higher affinity for
EGCG than non-tumorigenic cells. Furthermore, EGCG disrupted hsp90 complex
formation, as analyzed by Native PAGE, leading to an accumulation of dimeric
hsp90, and promoted the degradation of hsp90-client proteins such as HER2, p-
Akt, and Raf1 in metastatic cells at concentrations that affected viability. These data
suggest that EGCG may be an efficacious small molecule for the treatment of
PRCA because it selectively targets PRCA cells and inhibits a molecular chaperone
involved in many pro-cancer signaling cascades. Future studies will test if analogs of
EGCG are more stable/bioavailable, and therefore more potent hsp90 inhibitors,
for the treatment of PRCA. Funded by NIH Grant AT006366.
1099 Fluopyram: Mechanistic Investigations to Elucidate the Moa
for Thyroid Tumor Formation in the Mouse.
D. Rouquié1,  O. Blanck1,  H. Tinwell1,  P. Maliver1,  F. Schorsch1,  S. Wason1,
D. Geter2 and R. Bars1. 1Bayer CropScience, Sophia Antipolis, France; 2Bayer
CropScience, Research Triangle Park, NC.
Fluopyram, a broad spectrum fungicide, caused an increased incidence of thyroid
follicular cell (TFC) adenomas in males at the highest dose evaluated (750 ppm
equating to 105 mg/kg/d) in the mouse oncogenicity study. Mechanistic studies
were conducted in the male mouse to characterize the mode of action (MoA) for
the thyroid tumor formation and to determine if thresholds exist for each key
event. The proposed MoA consists of an initial effect on the liver by activating the
constitutive androstane (CAR) and pregnane X (PXR) nuclear receptors causing in-
creased elimination of thyroid hormones followed by an increased secretion of in
thyroid stimulating hormone (TSH). This change in TSH secretion results in an in-
crease of TFC proliferation which leads to hyperplasia and eventually adenomas
after chronic exposure. CAR/PXR nuclear receptors were shown to be activated
from as early as 3 days of treatment as indicated by increased activity of specific
Phase I enzymes (PROD and BROD respectively). Furthermore, evidence of in-
creased T4 metabolism was provided by the induction of phase II enzymes known
to preferentially use T4 as a substrate. Additional support for the proposed MoA
was given by an increase of Tsh transcripts in the pituitary gland. Finally, increased
TFC proliferation (BrdU incorporation) was observed after 28 days of treatment.
In these dose response studies, clear thresholds were established for liver enzyme ac-
tivities, T4 and TSH changes and TFC proliferation. Furthermore, each early
change was shown to be reversible following fluopyram withdrawal. In conclusion,
these studies indicate that fluopyram is a threshold carcinogen and the resultant in-
creased incidence of TFC adenoma in the male mouse is mediated by CAR/PXR
activation, with subsequent TFC proliferation. Since liver mediated thyroid toxicity
has been reported to be rodent specific, it is unlikely that fluopyram would induce
thyroid changes and tumours in humans.
1100 Oncogene PKC Epsilon Inhibits Transcription Factor Nrf2
through Phosphorylation of Its Regulatory Molecule INrf2
(Keap1).
S. K. Niture and A. K. Jaiswal. Pharmacology, University of Maryland, Baltimore,
MD.
Nrf2:INrf2 (Keap1) serve as sensors of chemical and radiation stress and are critical
in protection against oxidative stress and cellular transformation. INrf2 functions as
an adaptor protein for Cul3-Rbx1-mediated ubiquitination and degradation of
Nrf2. Exposure to stressors leads to dissociation of Nrf2 from INrf2, stabilization
and nuclear translocation of Nrf2 and activation of Nrf2 downstream cytoprotec-
tive proteins leading to cellular protection and survival. The molecular signal(s) that
control INrf2 control of Nrf2 remains elusive. In this report, we demonstrate that
oncoprotein protein kinease C epsilon (PKCε) phosphorylates INrf2 at amino acid
positions Ser599 and Ser602 that is essential for INrf2:Nrf2 interaction and ubiq-
uitination/degradation of Nrf2. Therefore, PKCε by regulating INrf2 controls
Nrf2 and expression of downstream cytoprotective proteins and cell survival. PKCε
phosphorylation of INrf2 appears specific for recognizing Nrf2 since it does not af-
fect INrf2 interaction with other proteins including ubiquitin factors Cul3/Rbx1.
Inhibition of PKCε or MEFs lacking PKCε or INrf2S602A mutant all failed to
phosphorylate INrf2 and led to reduced degradation of Nrf2 and enhanced Nrf2
downstream signaling resulting in increased cell survival, proliferation and drug re-
sistance. An analysis of protein microarray data from human lung and liver tumors
showed lower PKCε and higher Nrf2. This inverse relationship between PKCε and
Nrf2 in tumors presumably contributed to cancer cell survival and drug resistance.
In conclusion, this is the first report that demonstrates a role of PKCε in phospho-
rylation of INrf2 and control of Nrf2 with significant implications in survival of
cancer cells that often express lower levels of PKCε.
1101 A Weight-of-Evidence Approach to Determine the Leydig
Cell Tumor Mode-of-Action (MoA) for Pronamide.
R. J. Rasoulpour1,  A. K. Andrus1,  M. J. LeBaron1,  S. Marty1,  L. H. Pottenger1,
S. Papineni2 and D. L. Eisenbrandt2. 1The Dow Chemical Company, Midland, MI;
2Dow AgroSciences, Indianapolis, IN.
Pronamide, a herbicide, caused an increased incidence of Leydig cell tumors (LCT)
in CD rats at 1000 ppm (27% vs. 9% in controls) and liver hypertrophy after two
years of dietary exposure. There was no Leydig cell hyperplasia or tumors at the 12-
month interim necropsy. Dose levels of 40 or 200 ppm had LCT incidences similar
to controls, identifying a clear effect threshold. A series of studies was performed to
elucidate the MoA for rat LCT and its relevance to humans. Pronamide was nega-
tive for mutagenicity/clastogenicity, which is the only known LCT MoA with clear
human relevance. Other LCT MoAs have little to no relevance to humans and all
commonly affect the endocrine system. Pronamide was negative for androgen and
estrogen receptor binding, aromatase inhibition, steroidogenesis alterations, and es-
trogen receptor transactivation. Despite no evidence of direct action upon the en-
docrine system, in vivo MoA studies revealed a slight, but consistent, increase in cir-
culating levels of luteinizing hormone (LH), estradiol, and estrone in rats at ≥ 1000
ppm. It is proposed that the high-dose hormonal alterations are secondary to in-
duction of liver-based testosterone metabolism/inactivation, coincident with liver
hypertrophy and increased cytochrome P450s. Secondary increases in LH are pro-
posed to result in mitogenic stimulation of rat Leydig cells, which are quantitatively
more sensitive than human Leydig cells to LH-driven proliferative response, based
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primarily upon >10-fold more LH receptors per cell in rats vs. humans. This differ-
ence in sensitivity is supported by the >1,000-fold difference between background
incidence of human LCT vs. the rat. Overall, the weight-of-evidence for pron-
amide-induced rat LCT supports a threshold-response (i.e., nonlinear) approach
for risk assessment due to the lack of genotoxicity, absence of direct endocrine ef-
fects, clear NOAEL for the LCT response (200 ppm), and an adequate margin of
exposure for an effect in a uniquely sensitive animal model.
1102 Hepatic Nongenotoxic Carcinoge-Induced Temporal
Changes in the Hepatic miRNAome.
K. Chen1,  W. Jayne2,  R. Currie2,  C. Koufaris1 and N. J. Gooderham1.
1Biomolecular Medicine, Imperial College London, London, United Kingdom; 2Safety
Assessment, Syngenta, Jealotts Hill, United Kingdom.
Non-genotoxic carcinogens are capable of inducing carcinogenesis via means other
than direct modification of DNA structure. While there are many tests readily
available for detecting genotoxic substances, methods for detecting and screening
non-genotoxic chemical carcinogens are limited. Here we explore the potential of
miRNA dysregulation as an indicator of non-genotoxic carcinogens by assessing the
temporal-dependent changes in the miRNAome of Fisher rats. Ten chemical com-
pounds, including: Phenobarbital (PB, 1000ppm), Chlorendic Acid (Chl Ac,
1250ppm), Diethylhexylphthalate (DEHP, 1200ppm), Monuron (Mon,
1500ppm), Methapyrilene Hydrochloride (MP HCl, 250ppm), 2-
Aminoacetylfluorene (genotoxic, 2-AAF, 40ppm), cinnamon anthranilate (CA,
30,000ppm), Diethylhexyadipate (DEHA, 25,000ppm), Benzophenone (BP,
1250ppm) and Diethylthiourea (DETU, 250ppm), were fed in the diet to Fisher
rats for a period of up to three months and liver samples were harvested at 7, 28 and
90 days. The total RNA was purified and analysed with Agilent Rat miRNA
Microarrays Kit (Release 16.0). The expression of multiple hepatic miRNAs was
found to be altered in response to chemical treatment in a temporally-dependent
manner. Chemicals with a similar mode of action (eg: DEHP and DEHA) induced
similar responses on the hepatic miRNAome, confirmed by hierarchical clustering
analysis qPCR. In the case of DEHA and DEHP, miR-101 family and miR-212
were transiently elevated (at least 3 fold) at 7 days of treatment. In contrast MiR-
200 family expression was unaffected at 7 days but was significantly induced at 90
days of treatment. MiR-101 family and miR-212 family are predicted to regulate
MAPK3 pathway and target myc gene in the p53 feedback pathway, whereas the
miR-200 family are involved in regulating the epithelial-mesenchymal transition
and metastasis. These data suggest that miRNAs are potential biomarkers of non-
genotoxic hepatocarcinogens and understanding the consequences of miRNA dys-
regulation aids the understanding of the mechanisms of carcinogens.
1103 Dietary Carcinogen PhIP Induces Early DNA Damage and
p53 Pathway Activation in CYP1A-Humanized Transgenic
Mice.
J. Chen1, 2,  G. Li2,  H. Wang2,  A. Liu2 and C. S. Yang2. 1Joint Graduate Program
in Toxicology, UMDNJ-Rutgers University, Piscataway, NJ; 2Department of Chemical
Biology, Rutgers, The State University of New Jersey, Piscataway, NJ.
2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) is a dietary carcinogen
and the most abundant heterocyclic amine generated from high temperature cook-
ing of meat and fish. PhIP is activated via N2-hydroxylation to a proximate car-
cinogen primarily by cytochrome 1A2. CYP1A-humanized (hCYP1A) mice, which
replaced the murine Cyp1a1 and Cyp1a2 with human CYP1A1 and CYP1A2,
mimic human metabolism of PhIP. Previous study in our lab demonstrated that in
hCYP1A mice, a single oral administration of PhIP induces high-grade prostatic in-
traepithelial neoplasia, mainly in the dorso-lateral glands (DLGs). Because murine
DLGs correspond to the human prostate peripheral zone, the most common site of
prostate cancer, PhIP-induced carcinogenesis in hCYP1A mice is a relevant mouse
model for studying early stage prostate carcinogenesis. Herein, we investigated the
early cellular and molecular events induced by PhIP in the dorso-lateral prostate of
hCYP1A mice. Using immunohistochemistry, we detected strong positive staining
of 8-Oxo-2’-deoxyguanosine as well as γ-H2AX in the DLGs on Days 1 and 3 after
PhIP treatment, suggesting DNA damage and DNA strand breaks. Through gene
expression profiling analysis and RT-qPCR, we found changes in expression of nu-
merous p53-associated genes, including p21 and cyclin D1, indicating p53 activa-
tion and likely cell cycle arrest in PhIP-treated hCYP1A mice. Similar gene alter-
ations were not observed in the PhIP-treated wild-type C57BL/6J mice. Altogether,
these results suggest PhIP-induced DNA damage causing activation of the p53
pathways that may be involved in the early stage of carcinogenesis in the prostate.
(Supported by NIEHS training grant 5T32ES007148-25 and NIH grant
RO1CA133021 as well as shared facilities funded by CA72720 and ES05022).
1104 Reexamination of Initiator Dose in Ultra-Short-Term
Carcinogenicity Study in RASH2 Mice.
H. Tsutsumi1,  K. Urano1,  M. Suguro2,  M. Kawabe2,  T. Numano2, 3 and
F. Furukawa2. 1Testing department, Central Institute for Experimental Animals,
Kawasaki, Japan; 2DIMS Institute of Medical Science, Inc., Ichinomiya, Japan;
3Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
We have established an ultra-short-term carcinogenicity study in which the target
organ was the skin, one of the common targets in rasH2 mice. Although we previ-
ously reported that the suitable dose of 7,12-dimethylbenz[a]anthracene (DMBA)
as an initiator was 50 mg at SOT 2010, several tumors were induced in DMBA
treated groups without promotion, suggesting the dose of DMBA as an initiator
was too high. In this study, we reexamined the suitable dose of DMBA as an initia-
tor. Several compounds were applied to shaved dorsal skin of female rasH2 mice
one week after 12.5 or 25 μg DMBA application: oleic acid diethanolamine con-
densate (OADC, 30 mg/kg, 7 times/week ) or benzethonium chloride (BC, 1.5
mg/kg, 5 times/week), known to have no promoting effect, 99.5 % ethanol (7
times/week) or anhydrous ethanol (5 times/week) as vehicles, or benzoyl peroxide
(BPO, 20 mg/head, 5 times/week) as a positive tumor promoter. Applied skin was
studied histopathologically at eight weeks after DMBA application. Although no
tumors were induced in OADC, BC or vehicle treated groups, skin tumors were in-
duced at five weeks after DMBA application in BPO treated groups, and the inci-
dence of skin tumors reached 100 % by seven weeks after DMBA application. The
number of skin tumors, which were diagnosed as hyperplasia and/or papilloma, at
necropsy were 29.2 and 35.6 in 12.5 μg and 25 μg DMBA treated groups, respec-
tively. Therefore, we concluded that 12.5 μg DMBA was suitable to initiate the
skin of rasH2 mice in an ultra-short-term skin carcinogenicity study.
1105 Modulation of Cocarcinogenic Effect of Aflatoxin B1 and
Fumonisin B1 in a Short-Term Bioassay by Uniform Particle
Size NovaSil Clay.
L. Tang1,  G. Qian1,  S. Lin1,  Z. Yang1,  M. Kang1,  N. J. Mitchell2,  J. Su1,
W. Gelderblom3,  R. Riley4,  T. Phillips2 and J. Wang1. 1University of Georgia,
Athens, GA; 2Texas A&M University, College Station, TX; 3Medical Research Council,
Tygerberg, South Africa; 4USDA ARS, Athens, GA.
Co-contamination ofAFB1 and FB1 in corn-based food and feed is a health con-
cern for their combinative toxic effects as well as potential co-carcinogenic effect.
Uniform particle size NovaSil (UPSN) clay has been used as an enterosorbent to re-
duce AFB1 and FB1 exposure in animals and humans. In this study male F344 rats
(150g) were randomly divided into five groups: negative control group, AFB1+FB1
group, AFB1+ FB1+low UPSN (0.25%) group, AFB1+FB1+high UPSN (0.5%)
group, and positive control group treated with diethylnitrosamine and 2-acety-
laminofluorene. All treated animals were sacrificed after their last exposure. Liver
were dissected and processed with regular H&E staining for examination of histo-
logical alterations. Liver tissue slides were also immunohistochemically stained for
examination of formation of placental form glutathione S transferase positive
(GST-P+) foci. No detectable lesions were found in the negative control group,
while the positive control group showed significant high rates of dysplasia (262 ±
29), prolific foci (53 ±16), and nodules (15 ±10), as well as high rate of GST-P pos-
itive liver foci (58 ± 11), which demonstrates the success of the experiments. Co-ex-
posure to AFB1 and FB1 induced comparable rate of dysplasia (258 ± 40) to the
positive control group and a higher rate of apoptosis (26 ± 8) than the positive con-
trol group (4 ± 4). UPSN in both low and high groups significantly inhibited for-
mation of preneolesion in liver: For dysplasia, reduction of 46% (140 ± 29) and
56.% (113 ± 20); for apoptosis, reduction of 42% (15 ± 4) and 57% (11 ± 4); for
prolific foci, reduction of 74% and 94%; for GST-P positive foci numbers, areas,
and mean areas, the reduction of 77% and 88%; 83% and 94%; and 31% and 53%
were found, respectively. These results demonstrate significant modulation of
UPSN on reducing potential co-carcinogenic effect in this short-term bioassay.
1106 Validation of Cocarcinogenic Effects of Aflatoxin B1 and
Fumonisin B1 in a Short-Term Bioassay.
J. Wang1,  G. Qian1,  S. Lin1,  L. Tang1,  Z. Yang1,  M. Kang1,  N. J. Mitchell2,
J. Su1,  W. Gelderblom3,  R. Riley4 and T. Phillips2. 1University of Georgia, Athens,
GA; 2Texas A&M University, College Station, TX; 3Medical Research Council,
Tygerberg, South Africa; 4USDA ARS, Athens, GA.
A short-term animal assay using Aflatoxin B1 (AFB1) as the initiator and fumon-
isin B1 (FB1) as the promoter demonstrated dramatic increase in formation of pla-
cental form glutathione S transferase positive (GST-P+) foci in rat liver. In this
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study, we validated this short-term bioassay and studied potential interactions be-
tween AFB1 and FB1 on the biochemical and histological changes and the forma-
tion of liver GST-P+ foci through a modified treatment protocol. AFB1 (150 ppb)
containing diet caused dramatic dysplastic hepatocytes, mild bile duct proliferation
and necrosis, and proliferation foci formation. In contrast, FB1 (250 ppm) con-
taining diet induced less dysplastic hepatocytes and more apoptotic bodies while no
proliferation foci were found. Additive effects on increasing serum ALP, ALT and
AST activities were found in co-exposed animals as compared to single AFB1 or
FB1 treated. Sequential co-exposure to AFB1 and FB1 lead to significantly in-
creased numbers of dysplastic hepatocytes, apoptosis and proliferation foci. Co-ex-
posure of AFB1 and FB1 also significantly increased the numbers of liver GTP-P+
foci by approximately 7.2 and 12.2 folds (p<0.01), and increased the mean sizes of
GST-P+ foci by 6.0 and 7.5 folds (p<0.01), as compared to single AFB1 or FB1
treated, suggesting strong synergistic effects in enhancing the preneoplastic lesion
in liver. This study validates co-carcinogenic effects of AFB1 and FB1 in the short-
term bioassay in rat liver and provides evidence for the use of this model in future
intervention studies and mechanistic investigations.
1107 Tumor Promoter Action of Chromium-Containing Stainless
Steel Welding Particulate Matter in the Lungs of A/J Mice.
P. C. Zeidler-Erdely,  T. G. Meighan,  A. Erdely,  L. A. Battelli,  M. L. Kashon,
M. Keane and J. M. Antonini. HELD, NIOSH, Morgantown, WV.
Epidemiology studies show that occupational exposure to metal-rich welding par-
ticulate matter (PM) increases lung cancer risk. However, animal studies are lacking
to conclusively link welding with an increased cancer risk. PM derived from stain-
less steel (SS) welding practices, in particular, contains carcinogenic metals such as
hexavalent chromium and nickel. Previously, we found that PM derived from gas
metal arc (GMA) welding of SS caused a borderline increase in lung tumor inci-
dence and a significant, chronic immune response in the lungs of mice. Thus, we
hypothesized that welding PM may act as a tumor promoter and increase lung
tumor multiplicity. In this study, the capacity of GMA-SS welding PM to promote
lung tumors was evaluated using a 2-stage (initiation-promotion) model in lung
tumor susceptible A/J mice. Age and weight-matched male mice (n=26-29/group)
were treated either with the initiator 3-methylcholanthrene (MCA;10 μg/g;i.p.) or
vehicle (corn oil; CO) followed by 5 weekly pharyngeal aspirations of GMA-SS
(340 or 680 μg) or PBS. Lung tumors were enumerated at 30 weeks following ini-
tiation with MCA. Body weights were recorded at 2 week intervals and no effect of
treatment was found. MCA initiation followed by GMA-SS exposure promoted
lung tumor multiplicity in both the lower dose (12.0 ± 1.5 tumors/mouse;
p=0.0001) and high dose (14.0 ± 1.8 tumors/mouse; p=0.0001) groups signifi-
cantly above that of MCA/PBS (4.77 ± 0.7 tumors/mouse). Not only was this
highly significant for the average total number per mouse, multiplicity was also in-
creased (p<0.004) across all five individual lung regions of GMA-SS-exposed mice.
No treatment effects were found in the corn oil groups at 30 weeks and also, as ex-
pected, tumor incidence was greater than 93% in the MCA treated groups which
verified its carcinogenic potency. In conclusion, GMA-SS welding PM acts as a
lung tumor promoter in vivo. These novel findings implicate that susceptible indi-
viduals may be at greater risk for lung cancer development after exposure to weld-
ing PM.
1108 Induction of 1, 3-Dichloropropene Rat Liver Tumors
through a Nongenotoxic Mode of Action.
S. C. Gehen1,  R. Billington2,  Z. Wang3,  P. J. Klein3 and J. E. Klaunig3. 1Dow
AgroSciences LLC, Indianapolis, IN; 2Dow AgroSciences LLC, Abingdon, United
Kingdom; 3Indiana University, Bloomington, IN.
1,3-Dichloropropene (1,3-D) is a soil fumigant used for control of parasitic nema-
todes. It was previously shown that dietary exposure to 1,3-D was associated with
an increased incidence of benign hepatocellular adenomas in male rats in one of
two rat cancer studies. In in vivo genotoxicity studies, 1,3-D was shown consis-
tently to be non-mutagenic in studies where physiologic levels of glutathione and
glutathione S-transferases were present and genotoxic stabilizers were not present,
thus supporting liver tumorigenesis through a non-genotoxic mode-of-action
(MoA). The present study was undertaken to investigate the hypothesis that 1,3-D
induces rat liver tumors by acting as a tumor promoter in the liver carcinogenesis
process. To assess potential 1,3-D tumor promotion, diethylnitrosamine- initiated
Fischer 344 rats were treated by gavage with 25 mg/kg/day 1,3-D or 80 mg/kg/day
phenobarbital (PB) for either 30 or 60 days, or for 30 days followed by 30 days re-
covery. Staining for the placental form of glutathione S-transferase (GSTP) was
conducted post-exposure as a phenotypic marker of preneoplastic foci. While hav-
ing no effect on GSTP positive foci, 1,3-D significantly enhanced the number and
size of GSTP negative lesions at 30 and 60 days. Importantly, after 30 days recov-
ery, the number and size of GSTP negative lesions in 1,3-D treated animals re-
turned to control levels thus demonstrating 1,3-D promotion of foci and not
tumor initiation. Also supportive of tumor promotion, the hepatocyte labeling
index in GSTP-negative preneoplastic foci was significantly increased in 1,3-D
treated rats at 30 and 60 days and returned to control levels after 30 days recovery.
PB, a well recognized non-genotoxic rodent liver carcinogen, produced an expected
reversible increase in number and size of the GSTP positive lesions. The results pre-
sented are consistent with 1,3-D inducing liver carcinogenesis through a non-geno-
toxic MoA by induction of reversible proliferation of non-GSTP staining focal pop-
ulations of hepatocytes.
1109 Effects of Long-Term Administration of the Tissue-Selective
Estrogen Receptor Modulator Bazedoxifene on Survival and
Tumor Formation in Rats.
D. J. Wright1,  R. Perry1,  C. A. Thompson2,  N. J. Earnhardt3,  S. Bailey1,
B. Komm4,  D. R. Minck5 and M. A. Cukierski1. 1Drug Safety, Pfizer, Groton, CT;
2Abbott Laboratories, Abbott Park, IL; 3Pharmacokinetics, Dynamics, and
Metabolism, Pfizer, La Jolla, CA; 4Medical Affairs, Pfizer, Collegeville, PA; 5Division
of Metabolism and Endocrinology, US FDA, Silver Spring, MD.
Bazedoxifene acetate (BZA) is a selective estrogen receptor modulator that is ap-
proved in a number of countries for the prevention and/or treatment of osteoporo-
sis in postmenopausal women. To assess for carcinogenic potential, BZA was ad-
ministered ad libitum in the diet to male and female rats for 2 years. BZA resulted
in a reduction and a delayed onset in total tumor burden in both male and female
rats. Survival rates were enhanced due to decreased pituitary (males and females)
and mammary tumors (females) and decreased body weight gain in BZA-treated
animals compared to controls. BZA caused an increased incidence of benign ovar-
ian tumors and renal tubular tumors (males). Results from separate studies sug-
gested that BZA caused an increase in LH, which stimulated formation and persist-
ence of ovarian cysts, which eventually progressed into benign ovarian granulosa
cell tumors. The reductions in pituitary and mammary gland tumors were attrib-
uted to BZA-related antagonism of endogenous estrogens at the estrogen receptors.
The greater increase in renal tumor incidence in male rats given BZA was associated
with the increased survival and increased time for development of late onset tu-
mors. These findings are consistent with a non-genotoxic mechanism, unique to
male rats, that involves test article-induced corticomedullary mineralization, renal
tubular injury, and exacerbation of naturally occurring chronic progressive
nephropathy in aged male rats that leads to proliferative changes and tumor forma-
tion. In conclusion, BZA elicited agonistic or antagonistic effects in a tissue-selec-
tive manner which was generally consistent with expression and/or activity of estro-
gen receptors in those tissues.
1110 Resveratrol Exposure Reduces Benzo(a)pyrene-DNA Adduct
Concentrations in ApcMin Mouse Model of Colon Cancer.
A. C. Huderson,  P. V. Rekhadevi,  M. S. Niaz,  S. E. Adunyah and A. Ramesh.
Biochemistry & Cancer Biology, Meharry Medical College, Nashville, TN.
Colon cancer is the third leading cause of cancer cases and related deaths as per the
statistics provided by the American Cancer society. Exposure to toxicants such as
benzo(a)pyrene (BaP) is one of the contributing factors to the development of spo-
radic colon cancer. Our studies have shown a decrease in the size, and number of
adenomas in the colon of mice exposed to BaP and resveratrol (RVT), compared to
BaP exposure alone. We have also shown that RVT exposure caused a decrease in
the expression and activity of CYP1A1/1B1 enzymes and BaP metabolite concen-
trations both in liver and colon. Since DNA damage is one of the key events in car-
cinogenesis, the objective of this study was to investigate whether RVT exposure si-
multaneously or prior to BaP treatment alters BaP-DNA adduct concentrations in
ApcMin mouse. The treatment consisted of BaP only administration (in peanut oil)
at a dose of 100 μg/kg bw via oral gavage over a 60 day period (group I); BaP (100
μg/kg bw) co-administered with RVT (in 10% ethanol + 90% deionized water) at
a dose of 45 μg/kg bw (group II); RVT administered for 1 week prior to BaP dos-
ing (group III). Post exposure, DNA was isolated from colon and liver samples, and
analyzed for BaP- DNA adducts by the 32P-postlabeling method using a four-direc-
tional TLC system. The adduct concentrations showed a trend that mirrored the
concentrations of BaP metabolites in the organs studied with low concentrations in
RVT-treated mice compared to BaP-treated mice. Between the two RVT-treatment
strategies, concurrent administration of RVT appeared to affect the BaP bioactiva-
tion compared to RVT treatment prior to BaP exposure as reflected by the low
adduct concentrations in the former group III compared to groups I & II. Overall,
our results suggest that RVT provides a preventive effect against BaP-induced colon
cancer progression in ApcMin mouse (funded by NIH grants 1F31ES019432-01A1,
5R01CA142845-02, 5T32HL007735-12, and 5R25GM059994-11).
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1111 Triclosan Promotes the Development of Hepatocellular
Carcinoma in Mice.
M. Yueh,  V. Jiang and R. H. Tukey. Laboratory of Environmental Toxicology,
Departments of Chemistry & Biochemistry and Pharmacology, University of
California San Diego, La Jolla, CA.
Triclosan (TCS), a chlorophenol, is used in a large number of personal care prod-
ucts as an antibacterial agent. TCS has endocrine disruption properties, has been
detected in microgram per liter levels in various water ways in the US, and is con-
sidered to be a major environmental contaminant in aquatic ecosystems. Daily ex-
posure to TCS has resulted in its detection in humans with studies showing its pres-
ence in plasma, breast milk, and urine. Studies have increasingly linked TCS to a
range of health and environmental effects; however, there are no mechanism-based
studies that directly address TCS exposure to negative health effects in humans.
Using wild type and Car-/- mice, TCS has been shown to effectively induce hepatic
Cyp2b10 in a CAR-dependent manner. However, transient transfection experi-
ments revealed that TCS is not a direct CAR agonist but behaves as a phenobarbi-
tal-like inducer that indirectly activates CAR and facilitates its translocation to the
nucleus. Using the chemical procarcinogen diethylnitrosamine (DEN) to initiate
tumorigenic episodes in mice, TCS exposure through drinking water promotes the
development of hepatocellular carcinoma (HCC). The development and promo-
tion of HCC by TCC compared to DEN-only treated mice proceeds in a CAR-in-
dependent fashion. This finding stands in contrast to CAR-dependent tumor in-
duction with the liver tumor promoter phenobarbital. HCC tumors produced by
DEN-TCS exposure lead to a number of changes in the liver including histological
alteration in hepatocytes, increases in liver-to-body weights, elevated levels of α-fe-
toprotein, and enhanced levels of tumor-promoting cytokines IL-6 and TNFα. In
addition, tumor-bearing livers significantly alter the expression profile for genes as-
sociated with drug metabolism. The identification of TCS as a liver tumor pro-
moter may be significant because of its abundance and long term use in consumer
products and its propensity for rapid absorption into the systemic circulation.
(Supported by USPHS grant ES010337)
1112 Kupffer Cells Modulate Wyeth-14, 643 and Phenobarbital-
Induced Hepatocyte Proliferation in Naïve and
Diethylnitrosamine (DEN)-Initiated Mice.
T. Peat,  Z. Wang,  S. Zhou and J. E. Klaunig. Indiana University, Bloomington,
IN.
Kupffer cells (KC) play an important role in liver homeostasis. Upon activation,
KC release inflammatory and growth regulatory mediators that have been linked to
acute and chronic liver responses including hepatic cancer. Wyeth 14,643 (WY)
and Phenobarbital (PB) are non DNA reactive hepatic carcinogens in rodents. The
present study was conducted to investigate the role of KC in liver cell proliferation
in naïve and focal lesion containing mice. In our initial study, KCs in male C3H
mice were depleted using liposome encapsulated clodronate (Lip-cld, 0.1 ml/10 g,
iv). LPS, a known KC activator, was used as a positive control (1 mg/kg, ip,
2X/wk). Lip-cld treatment resulted in depletion of 99% of KC as confirmed by
F4/80 positive staining cells.. WY treatment increased the relative liver weight and
DNA synthesis in naive mice after 7 and 21 d treatment. LPS and PB increased he-
patic DNA synthesis (7 and 21 d). Following KC depletion, the induction of DNA
synthesis by LPS and PB were significantly decreased, while WY-induced DNA
synthesis was not altered. In the second study, mice were injected with DEN (50
mg/kg, ip, 1X/wk for 4 wk). Following development of focal lesions, mice were
treated with WY or PB for 28 d. Treatment with PB or WY increased the relative
focal volume and depletion of the KC decreased the relative focal volume. WY and
PB increased DNA synthesis in both basophilic and eosinophilic lesions, similar to
LPS. Upon KC depletion, a decrease in DNA synthesis was seen in PB treated
mice. In the surrounding non-lesion tissue, PB produced a marginal increase in
DNA synthesis (2-fold) and that was decreased following KC depletion compared
to control. In comparison, DNA synthesis increased greatly (10-fold) when treated
with WY. These results show that the KC modulated hepatocyte proliferation both
in naïve mice and in the preneoplastic focal lesions in PB and WY treated mice.
1113 Bioassay-Directed Fractionation of Diesel and Biodiesel
Emissions.
E. Mutlu1, 2,  S. H. Warren1,  C. King1,  W. P. Linak1,  D. G. Nash1, 3,
I. Gilmour1 and D. M. DeMarini1. 1US EPA, Research Triangle Park, Durham,
NC; 2University of North Carolina at Chapel Hill, Chapel Hill, NC; 3ORISE, Oak
Ridge, TN.
Biofuels are being developed as alternatives to petroleum-derived products, but
published research is contradictory regarding the mutagenic activity of such emis-
sions relative to those from petroleum diesel. We performed bioassay-directed frac-
tionation and analyzed the polycyclic aromatic hydrocarbon (PAH) levels of parti-
cles generated using petroleum diesel (B0) and those from soy-based biodiesel
where the soy accounted for 20, 50 or 100% of the fuel (B20, B50, B100) from a
Yanmar L70 diesel engine. We also evaluated a composite sample of diesel-exhaust
particles (C-DEP) generated from petroleum diesel with a 30-kW 4-cylinder Deutz
BF4M1008 diesel engine connected to an air compressor. The biodiesel and C-
DEP particles were extracted with dichloromethane (DCM), and the percentage of
extractable organic material of these complex environmental mixtures were deter-
mined. The extracts were then solvent exchanged into dimethyl sulfoxide and eval-
uated for mutagenicity in various Salmonella strains +/-S9. We calculated the mu-
tagenic emission factors (revertants/megajoule, rev/MJ) from data from strain
TA100 +S9, which responds to PAH-type mutagenicity. These mutagenic emission
factors for the biodiesels were 3X less (B20), 6X less (B50), and 8X less (B100) than
that of petroleum diesel (B0). The whole extract of C-DEP (petroleum diesel) was
sequentially fractionated with solvents of increasing polarity, and >50% of the mass
eluted in fraction 1; this fraction was not mutagenic. The 2nd fraction had 60% of
the TA100+S9 activity, indicative of PAHs; the 3rd fraction contained 60% of the
TA98-S9 activity, indicative of nitroarenes. We conclude that under these experi-
mental conditions, emissions from biodiesel were less mutagenic than those from
petroleum diesel, and based on the fractionation of the C-DEP, most of the activity
is associated with PAHs. [Abstract does not necessarily reflect the views or policies
of the U.S. EPA.]
1114 Phenotypic Characterization of CArG-box Binding Factor-A
(CBF-A) Knock-out Mice.
J. T. Barrett1,  X. Zhang3,  J. Richardson1, 2,  M. Fang1, 2 and H. Zarbl1, 2, 3.
1Environmental and Occupational Medicine, Robert Wood Johnson Medical School,
UMDNJ, Piscataway, NJ; 2Environmental and Occupational Health Sciences
Institiute, Robert Wood Johnson Medical School, Piscataway, NJ; 3Environmental and
Occupational Health Sciences, Robert Wood Johnson Medical School, Seattle, WA.
CArG-box binding factor-A is a member of the heterogeneous nuclear ribonucleo-
protein (hnRNPs) family of RNA-binding proteins involved in a variety of cellular
functions, including transcriptional regulation. We showed that CBF-A (hnRNP
A/B) regulates the expression of the Ha-ras oncogene by binding to enhancer ele-
ments (ets-like) in the promoter region. Deregulated expression of CBF-A isoforms
is associated with mammary carcinogenesis in NMU-treated rats. CBF-A is a regu-
lator of epithelial-mesenchymal transition (EMT), an important process in the can-
cer progression. To evaluate the role of CBF-A, we generated knock-out mice.
Behavioral evaluation in the elevated plus maze showed that CBF-A null mice spent
~300% more time in the open arms of the maze compared to the wild-type, sug-
gesting that loss of CBF-A results in a low-anxiety behavioral phenotype. This be-
havioral abnormality may be related to the role of CBF-A in regulating the expres-
sion of vasopressin in the brain. To further study the role of CBF-A in
tumorigenesis, we exposed wild-type mice, as well as CBF-A null and heterozygous
mice to a single dose of the mutagenic, DNA-alkylating agent ENU (10 mg/mL at
9-10 weeks of age). While administration of ENU decreased the survival rate in all
genotypes compared to vehicle control mice, CBF-A null mice had a decreased sur-
vival rate and tumor-free survival rate compared to the wild-type. Taken in concert,
these data suggest that CBF-A plays an important role in maintaining both normal
growth control and behavior. 
Supported by Grants from the DOD(BC971045), the NIEHS funded
Toxicogenomics Research Consortium (ES011387), NIEHS Center Grants
(ES005022 and ES007033) and CINJ (CA072720).
1115 Inhibition of Hepatocyte Nuclear Factor 1 and 4 Alpha
(HNF1α and HNF4α As a Mechanism of Arsenic
Carcinogenesis.
A. Hernandez1, 2,  A. Pastoret1 and R. Marcos1, 2. 1Genetics and Microbiology,
Autonomous University of Barcelona, Bellaterra, Spain; 2CIBER-ESP, ISCIII,
Madrid, Spain. Sponsor: A. Sampayo-Reyes.
Inorganic arsenic (i-As) is a naturally occurring toxic metalloid affecting millions of
people world-wide. It is known to be carcinogen, liver being a potential target, and
related to the prevalence of diabetes in arseniasis-endemic areas. Hepatocyte nuclear
factor 1 and 4 alpha (HNF1α and HNF4α) are key members of a transcriptional
network essential for normal liver architecture. Changes in HNF1α and HNF4α
expression are clearly associated with the development of liver malignancies and di-
abetes in humans. In this work, hepatic HepG2 cells and Golden Syrian hamsters
were exposed to sub-toxic, environmentally relevant doses of sodium arsenite (SA;
up to 10 μM in vitro, 15 mg/L in vivo) in order to evaluate whether arsenic is able
to compromise the expression of hepatocyte nuclear factors (HNFs). Also, liver
hisopathological examination was carried out and several markers of hepatocyte dif-
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ferentiation and glucose metabolism status were determined as a measure of i-As-
induced effects. Results show a consistent down-regulation of HNF1α and
HNF4α under an scenario of exposure where HepG2 cells (i) gained resistance to
arsenic-induced toxicity/apoptosis, (ii) attained loss of tissue specific features (as
shown by the observed downregulation of ALDOB, PEPCK and CYP1A2, the trig-
gering of the epithelial-to-mesenchymal transition program (EMT) and the hyper-
secretion of matrix metalloproteinase-2 and 9), (iii) failed to maintain balanced the
expression of the “stemness” genes C-MYC, OCT3/4, LIN28 and NOTCH2 and
(iv) showed glucose metabolism impairment. We conclude that the i-As-induced
down-regulation of HNF1α and HNF4α under chronic settings may play a central
role in the features of disease and cancer observed both in vivo and in vitro.
1116 Carcinogenicity of Diesel (DEE) and Gasoline Engine
Exhausts (GEE).
L. Benbrahim-Tallaa,  R. Baan,  Y. Grosse,  B. Secretan-Lauby,  F. El Ghissassi,
V. Bouvard,  N. Guha,  D. Loomis and K. Straif. IARC Monographs, IARC, Lyon,
France.
Recently, an IARC Monographs Working Group (WG) reevaluated the carcino-
genic hazards to humans of DEE and GEE. DEE was classified as “carcinogenic to
humans” (Group 1) and GEE as “possibly carcinogenic to humans” (Group 2B). A
US study in non-metal miners included a cohort analysis and a nested case–control
analysis adjusted for tobacco smoking. Both showed positive trends in lung cancer
risk with increasing exposure, with a 2–3-fold increased risk in the highest cate-
gories of cumulative or average exposure. A 40% increased risk for lung cancer was
observed in U.S. railroad workers exposed to DEE. Indirect adjustment for smok-
ing and a more accurate exposure assessment strengthened the validity of the re-
sults. A large cohort study reported a 15–40% increased lung cancer risk in US
truck drivers and dockworkers with exposure to DEE, with a significant trend of in-
creasing risks with longer duration of employment, adjusted for tobacco smoking.
Findings in other occupational groups and case–control studies including various
occupations with similar exposures supported the WG’s conclusion of “sufficient
evidence” in humans for the carcinogenicity of DEE. The WG concluded that there
was “sufficient evidence” in experimental animals for the carcinogenicity of whole
DEE, DEE particles, and extracts of the particles, which also induced, in vitro and
in vivo, various forms of DNA damage. Positive genotoxicity biomarkers of expo-
sure and effect were also observed in humans exposed to DEE. The WG concluded
that there is “strong evidence” for the ability of whole DEE to induce cancer in hu-
mans through genotoxicity. GEE and cancer risk was investigated in only a few epi-
demiological studies and, because of the difficulty to separate the effect of DEE and
GEE, evidence for carcinogenicity was evaluated as “inadequate”. Organic extracts
of GEE condensate induced a cancer in mice, and in rats, GEE condensate also in-
duced cancer in rats. The WG concluded that there was “sufficient evidence” in ex-
perimental animals for the carcinogenicity of condensates of GEE.
1117 Suicide Inhibition Is Responsible for the Paradoxical
Absence of CYP2B10 Enzyme Activity in Mouse Liver
following Nitrapyrin- or Pronamide-Induced CAR
Activation.
M. J. LeBaron1,  H. L. Kan1,  M. R. Schisler1,  S. Papineni2,  D. L. Eisenbrandt2
and B. Gollapudi1. 1The Dow Chemical Company, Midland, MI; 2Dow
AgroSciences, Indianapolis, IN.
Establishing a mode of action (MoA) for a toxicological finding requires the identi-
fication of key events (both causal and associative) that progress to the apical end
point of interest. In the case of constitutive androstane receptor (CAR)-mediated
rodent hepatocarcinogenesis, the first key event is activation of the CAR signaling
pathway, which is often measured via the empirically observable biomarker of
Cyp2b10 induction (transcript, protein, and/or enzyme activity). The agrochemi-
cals pronamide (herbicide) and nitrapyrin (nitrification inhibitor) induced hepato-
cellular tumors in mice as a result of high-dose, long-term dietary administration.
Subsequent MoA studies for each chemical were consistent with a role for CAR-ac-
tivation in the mouse liver tumorigenesis. With both chemicals significant increases
in Cyp2b10 transcript as well as protein were observed; however, there was no asso-
ciated change in the activity of the enzyme as measured by PROD. To investigate
the role for suicide inhibition in this paradoxical finding, in vitro experiments were
conducted with phenobarbital (PB)-induced microsomes. These microsomes were
treated with PB (negative control), curcumin (positive control), nitrapyrin, or
pronamide. In this system, nitrapyrin and pronamide inhibited PROD activity in a
dose-related manner and up to 97% and 56% at 500 μM, respectively. While PB
had no effect on PROD activity, curcumin had a dose-related inhibition of Cyp2b-
mediated PROD activity of up to 63% at 40 μM. These results indicate that the
two agrochemicals and/or their metabolites irreversibly inhibit Cyp2b10-mediated
PROD activity and elucidate the apparent inconsistency between protein levels and
enzyme activity of treated livers while supporting the CAR-mediated MoA for liver
tumorigenesis. Further, these data indicate that measurement of transcript levels as
biomarkers for CAR activation is more appropriate than traditional enzyme activity
(e.g., PROD) measurements.
1118 Structure-Dependent Effect of Diindolylmethane Derivatives
on Inactivation of the Oncogenic NR4A1/NR4A2 Receptor
in Colon Cancer Cells.
X. Li1,  S. Lee2 and S. H. Safe1, 2, 3. 1College of Medicine, Texas A&M Health Science
Center, College Station, TX; 2Institute of Biosciences & Technology, Texas A&M
Health Science Center, College Station, TX; 3Veterinary Physiology and Pharmacology,
Texas A&M University, College Station, TX.
The nuclear receptor 4A (NR4A) subfamily members TR3 (NR4A1) and Nurr1
(NR4A2) have been investigated in this laboratory as novel drug targets for clinical
treatment of pancreatic cancer. Inactivating of these oncogenic transcription factors
by analogs derived from the chemopreventive phytochemical diindolylmethane
(DIM) exhibit promising in vitro and in vivo chemotherapeutic effects.
Knockdown of NR4A1 and NR4A2 by RNA interference in colon cancer cells de-
creased cell proliferation, induced apoptosis and inhibited colon cancer cell inva-
sion. Using NR4A-responsive promoter elements (monomer-binding NBRE and
dimer-binding NurRE) linked to a luciferase reporter gene, we investigated the
structure-dependent activity of over forty 1,1-bis(3’-indolyl)-1-(substituted
phenyl)methane (DIM-C-Ph) and 1,1-bis(3’-indolyl)-1-(heteroaromatic)methane
(DIM-C-heteroaromatic) analogs as inactivators of NR4A1, NR4A2 or both recep-
tors. In colon cancer cells we identified DIM-C-Ph analogs containing para-hy-
droxy, chloro, methyl, or trifluoromethoxy groups that inactivated NR4A1 and the
3-pyridine analog (DIM-C-Pyr-3) inactivated NR4A2-mediated transactivation. In
contrast, several other p-substituted phenyl analogs containing fluoro, iodo or
cyano groups were potent inactivators of both receptors. The mechanisms of NR4A
inactivation by C-DIMs were investigated and the possible role of site-specific
phosphorylation was determined using several protein kinase inhibitors including
LY294002, PD98059 and SP600125. The results show that in RKO colon cancer
cells transfected with NBRE-luciferase construct and treated with DIM-C-pPhCN,
NR4A inactivation was inhibited by PD98059. These results indicate that the
chemotherapeutic properties of C-DIMs are outcomes of NR4A inactivation and
the NR4A1/NR4A2-dependent pathways and role of kinases are currently being
investigated.
1119 Evaluation of microRNAs in Blood for Detection of
Chemical-Induced Carcinogenesis.
T. Chen1,  F. Meng1,  J. Yan1 and K. L. Thompson2. 1National Center for
Toxicological Research, US FDA, Jefferson, AR; 2Center for Drug Evaluation and
Research, US FDA, Silver Spring, MD.
MicroRNAs (miRNA) are emerging as a valuable tool in toxicological applications
due to their role in regulation of gene expression in different biological pathways.
Multiple studies have revealed that miRNAs are present and relatively stable in clin-
ically accessible biofluids such as blood. miRNAs in biofluids may provide a non-
invasive way of detecting chemical carcinogenicity. In this study, we evaluated
whether microRNA profiling and individual miRNAs in mouse blood can predict
carcinogenesis induced by N-ethyl-N-nitrosourea (ENU). Male B6C3F1 mice were
treated with either a single dose of 140 mg/kg ENU or vehicle alone. Blood was
collected on post-treatment days (PTDs) 1, 2, 3, 7, 14, 28, and 42. Profiling of
total miRNAs in the blood showed that a number of miRNAs associated with car-
cinogenesis were altered by the ENU treatment. The temporal alteration of one of
these miRNAs, miR-34a, a tumor suppressor, by ENU was characterized further.
The level of miR-34a expression was significantly increased by ENU as early as
PTD 1, reached a maximum level of about 10-fold over controls at PTD 7, and
then decreased to control levels at PTD 42. Serum levels of miR-34a were also ex-
amined to assess the contribution of blood cells to miR-34a levels in whole blood.
The results suggest that miRNAs have potential use as early sensitive circulating
biomarkers of carcinogen exposure.
1120 Hemodynamic Changes, Arrhythmias, and Sudden Death in
Dogs following Repeated Dosing of AKT/pp70S6K
Inhibitor.
E. Blasi1,  P. Harris1,  M. Engwall2,  S. Ralston3 and L. Burns Naas4. 1Drug Safety,
Pfizer, San Diego, CA; 2Drug Safety, Amgen, Thousand Oaks, CA; 3Drug Safety,
Abbott, Abbott Park, IL; 4Drug Safety, Gilead, San Francisco, CA.
PF-04176340 (PF) is an inhibitor of AKT & pp70S6K. Target organs in GLP re-
peat dose studies in dogs included eye, GI, liver, testes. In addition, unexplained
deaths were observed. In a 10d dose range-finding study (3, 10, 30 mpk/d), mor-
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tality occurred in 1/4 male dogs at 30 mpk/d on d4 with no preceding signs.
Similar observations were noted on d2 & d4 in a 1mo IND-enabling study in 2/5
male dogs at 20 mpk/d. In a SP study in telemetered male dogs (n=4),10 & 15 mpk
caused a significant increase in BP & dP/dT. Peak effect & duration were not re-
lated to expected exposure profile. An early study was conducted to investigate if
the unexplained deaths were related to CV events as there was no evidence of direct
cardiac toxicity in those animals. Conscious, unrestrained telemetered male dogs
(n=4) were treated with VH or 20 mpk/d PF-04176340 continuously for 5d.
Serum drug concentrations, glucose, insulin, troponin, clin chem, & electrolytes
were measured predose & 5h postdose daily. Clinical signs were assessed by visual
monitoring. PF produced transient cardiac arrhythmias (isolated PVC, polymor-
phic tachyarrhythmias) on d2 (Dog 3) & d3 (Dog 2) approx 6h postdose, and were
associated with significant changes in LVP & dramatic drops in BP, and sponta-
neously resolved. Arrhythmias repeated multiple times on the day they were ob-
served but were not on any other day. Arrhythmias were prolonged in Dog 3.
Arrhythmic events did not appear to be correlated with plasma drug levels. During
arrhythmic events, dogs were observed to be sleeping. Remaining telemetry data
were consistent with the prior SP study. Treatment with PF also produced marked
increases in glucose & insulin. No changes were noted in troponin, clinical chem-
istry, or electrolytes. It was concluded that the cardiovascular events observed in
Dog 3 may explain the mortality in the repeat dose studies since without sponta-
neous resolution, prolonged arrhythmias may instigate a fatal decrease in cardiac
output.
1121 The Role of Endothelial Cell-Specific Nitric Oxide Synthase
in Causing Drug-Induced Vascular Injury.
G. A. Tobin1,  D. G. Goodwin1,  C. González1,  J. Zhang1,  L. Xu1,  S. Stewart1,
A. Knapton1,  M. P. Lawton2,  B. E. Enerson2 and J. L. Weaver1. 1Division of Drug
Safety Research, US FDA, Silver Spring, MD; 2Drug Safety Research and
Development, Pfizer, Inc., Groton, CT.
The finding of drug-induced vascular injury (DIVI) in preclinical toxicology stud-
ies is a major cause of attrition in the development of many classes of drugs. In pre-
vious studies with the phosphodiesterase-4 inhibitor, CI-1044, we found that ele-
vation of serum Nitric Oxide (NO) levels through endothelial cell-specific Nitric
Oxide Synthase (eNOS) was critical for producing mesenteric vascular lesions in a
rat model of DIVI. Furthermore, phosphorylation of key regulatory amino acids in
eNOS such as S615, S1177, and S633 was significantly altered in response to CI-
1044. The aim of the current study was to examine if other classes of drugs would
produce similar lesions and whether these effects are mediated through eNOS ac-
tivity. We examined the effect of a phosphodiesterase-3 inhibitor (SK&F 95654), a
vasopressor (midodrine), and a vasodilator (nicorandil), in causing mesenteric vas-
cular lesions in the rat. We also used SIN-1 or L-NAME to determine if levels of
NO production, as measured by serum nitrate levels, correlated with vascular le-
sions. The combination of SK&F 95654 and SIN-1 led to a ~2-fold increase in
serum nitrate and vascular injury over controls, while SK&F 95654 in combination
with L-NAME caused a complete inhibition of vascular injury, with a three-fold in-
hibition of serum nitrate production, suggesting that this drug acts in a similar way
to CI-1044. Interestingly, phosphorylation at S1177 was increased in response to
SK&F 95654, in contrast to CI-1044. Although SIN-1 caused a ~2-fold increase in
serum nitrate by midodrine, this led to a 4-fold inhibition of DIVI. Nicorandil, an
NO donor, caused a ~300-fold increase in serum nitrate, either alone or in combi-
nation with SIN-1 or L-NAME. Our results illustrate that among the wide variety
of drugs that can cause DIVI, modulation of eNOS activity may be a common fea-
ture of the mechanism leading to vascular injury.
1122 Soluble Components of Ultrafine Particles Induce Cellular
Procoagulant Activity through Oxidant Signaling.
S. J. Snow1,  A. Wolberg2 and M. Carraway3. 1Toxicology, University of North
Carolina at Chapel Hill, Chapel Hill, NC; 2Pathology and Laboratory Medicine,
University of North Carolina at Chapel Hill, Chapel Hill, NC; 3NHEERL, US EPA,
Chapel Hill, NC.
Mechanisms that underlie the strong association between air pollution exposure
and adverse cardiovascular health remain unknown. We hypothesize that soluble
components of ultrafine particles (soluble UF) initiate procoagulant activities in en-
dothelial cells through tissue factor (TF) induction via reactive oxygen species
(ROS) production. Human coronary artery endothelial cells (HCAEC) were ex-
posed to soluble UF and assessed for their ability to trigger procoagulant activity in
platelet free plasma. HCAEC triggered faster thrombin generation and fibrin clot
formation following exposure, which was abolished by an anti-TF antibody, indi-
cating that the effects are TF-dependent. We found that TF mRNA expression was
increased following soluble UF exposure without significant compensatory changes
in mRNA levels of key anti-coagulant proteins, confirming that TF upregulation
plays an important role in this imbalance in the coagulation system. To study early
events that might regulate TF expression, we measured H2O2 production in
HCAEC following exposure to soluble UF. There was an immediate induction of
extra- and intracellular H2O2 production following soluble UF exposure, and pre-
treatment with antioxidants attenuated the UF-induced upregulation of TF, linking
the procoagulant response to ROS formation. Multiple chemical inhibitors indi-
cated NOX as the source of increased TF mRNA, which was confirmed by the
finding that NOX-4 siRNA prevented UF-induced upregulation of TF mRNA.
These data show that exposure to soluble UF induces endothelial procoagulant ac-
tivity, which requires new TF synthesis through ROS production and by NOX-4.
These novel findings provide mechanistic insight into the enhanced thrombosis
and endothelial dysfunction associated with air pollution exposure and increased
risk for CV morbidity and mortality.
1123 Evaluation of Age and Sex Effects on Mitochondria-Related
Gene Expression in Rat Heart.
V. Vijay,  T. Han,  C. Moland,  J. C. Kwekel,  J. C. Fuscoe and V. Desai. Systems
Biology, National Center for Toxicological Research, US FDA, Jefferson, AR.
Age-related susceptibilities and sex-based differences in cardiovascular diseases are
known and the underlying mechanisms need further investigation. Mitochondria
are critical for normal cardiac function so alterations in such at different ages and
sexes may affect the way the heart responds to drugs. To understand the role of mi-
tochondria in age- and sex-related differences in the heart, we investigated the ex-
pression levels of mitochondria-related genes. Gene expression in the heart of male
and female Fischer 344 rats at 8 (young), 21 (adult) and 78 (old) weeks of age was
measured using Agilent whole genome rat arrays. Out of 18,435 unique genes on
the Agilent rat microarray, 869 unique genes were determined to be mitochondria-
related. Age effect was evaluated by using ANOVA coupled with pair-wise t-test
(p<0.05) between each age group, and sex difference was evaluated at each age
using t-test (p<0.05). The expression levels of genes involved in oxidative phospho-
rylation (Ox Phos), membrane transporters, and fatty acid (FA) metabolism were
the highest at 21 wks compared to 8 or 78 wks in both males and females. A signif-
icant age related effect was observed in 21% and 7% of Ox Phos genes and 15%
and 7% of membrane transporter genes in males and females, respectively, at all age
groups. Only male rats showed significant age-related effects on the expression lev-
els of genes (21%) involved in FA metabolism. Significant sex-based differences
were observed in the expression levels of genes involved in Ox Phos at 78 wks
(19%); higher expression levels were noted in female rats compared to males.
Membrane transporters showed significant sex differences at 8 wks (21%), 21 wks
(40%) and 78 wks (13%). Genes involved in FA metabolism also showed sex based
differences at 8 (34%), 21 wks (29%) and 78wks (10%); most of the genes had
higher expression in females than males. These findings may provide important in-
sights into understanding the role of mitochondria in cardiovascular diseases in
terms of sex based differences or altered susceptibility with age.
1124 Assessment of Postmarket Cardiac Adverse Events in Patients
Treated with Antipsychotic Drugs.
D. Bi,  R. Benz,  J. Kerner,  J. Willard and T. Colatsky. Center for Drug Evaluation
and Research, US FDA, Silver Spring, MD.
This study assessed the cardiac adverse events (cAEs) induced by antipsychotic
drugs, and evaluated their relationship to hERG affinities, clinical drug exposure
and the magnitude of clinical QTc prolongation. Data were collected from public
regulatory documents (e.g. Summary Basis for Approvals) and supplemented with
published literature data. The incidence of each cardiac toxicity endpoint was cal-
culated using the total number of all adverse events reported for each drug as a de-
nominator. The incidence of QT prolongation was 5.1, 3.4, 0.5, 1.0, 0.9 and 1.9%
for thioridazine, ziprasidone, quetiapine, risperidone, olanzapine, and haloperidol,
respectively, which were correlated to the magnitude of QTc change from baseline
(dQTc) of 40.7, 26.4, 19.5, 15.8, 12.7 and 11.3 msec, respectively. The incidences
of Torsade de pointes (TdP) were 0.9, 0.7, 0.1, 0.2 and 0.1% for thioridazine,
ziprasidone, quetiapine, risperidone and olanzapine, respectively, which were highly
correlated to the dQTc. Furthermore, the incidence of QT prolongation was corre-
lated to the ratio of total plasma Cmax/hERG IC50 for the same group of drugs.
Pimozide, one of the most potent hERG blockers (hERG IC50 =18 nM), had the
highest incidences in causing QT prolongation (7.2%), TdP (3.4%), long QT syn-
drome (0.7%), syncope (3.4%) and sudden cardiac death (0.3%). The incidences
of ventricular arrhythmia and cardiac arrest were greater than or equal to 5% in pa-
tients receiving diazepam, imipramine, thioridazine, haloperidol, amitriptyline, pi-
mozide, or trazodone. The incidences of sudden death were more than 1% in pa-
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tients treated with desipramine, thioridazine, ziprasidone or pimozide. In conclu-
sion, relatively high incidences of potentially serious cardiac side effects, including
QT prolongation, TdP, and lethal outcomes occurred in patients treated with the
antipsychotics. The hERG affinities combined with the levels of clinical drug expo-
sure may serve as one of the predictors for drug-induced cardiac toxicity by an-
tipsychotics.
1125 Ozone Coexposure Modifies Cardiac Function Responses to
Fine and Ultrafine Particulate Matter in Mice.
R. McIntosh-Kastrinsky1,  H. Tong2,  N. Kurhanewicz1,  L. Walsh2,  A. K. Farraj2
and M. S. Hazari2. 1University of North Carolina at Chapel Hill, Chapel Hill, NC;
2Environmental Public Health Division, US EPA, Research Triangle Park, NC.
There is growing evidence from epidemiological studies that show acute exposure
to particulate matter (PM) increases the risk of cardiovascular morbidity and mor-
tality. Although the data supporting these findings are increasingly more convinc-
ing, the immediate impact of PM inhalation on cardiac function needs to be fur-
ther clarified; this is particularly true of multipollutant exposures. Thus, this study
was designed to evaluate the cardiac effects of concentrated ambient fine (PM2.5)
and ultrafine (UFP) particles with and without ozone (O3) co-exposure. Based on
previous findings, we hypothesized that UFP would cause the greatest decrement in
cardiac function and that O3 co-exposure would worsen the response. Mice were
exposed by whole-body inhalation to either 200 μg/m3 PM2.5 or 100 μg/m3 UFP
with or without 0.3 ppm O3; separate groups were exposed to either filtered air or
O3 only. Twenty-four hours after exposure, cardiac function was assessed using a
Langendorff cardiac perfusion preparation. Coronary flow, left ventricular devel-
oped pressure (LVDP) and contractility were measured before and after cardiac is-
chemia/reperfusion (I/R) injury. PM2.5 or O3 alone, or co-exposure to UFP+O3
caused a significant decrease in baseline LVDP and contractility. Interestingly, UFP
alone or PM2.5+O3 did not cause significant decrements in cardiac function when
compared to controls, nor were there significant differences in recovery LVDP or
contractility between any group after I/R injury. These data suggest that the cardiac
effects of PM inhalation are dependent on particle size and that O3 interacts with
PM2.5 and UFP differently, resulting in varied cardiac impacts. Thus, these find-
ings indicate that the cardiovascular effects of particle and gas co-exposures are not
simply additive or generalizable, which increases the complexity of risk assessment.
(This abstract does not reflect EPA policy)
1126 An Integrative Approach to Identify Functional, Structural
and Pathological Biomarkers of Doxorubicin-Induced
Cardiotoxicity.
H. R. Mellor1,  L. Cove-Smith2,  J. Kirk1,  A. Hargreaves1,  S. Price1,  C. Betts1,
C. Dive2,  P. Hockings1 and N. Woodhouse1. 1Global Safety Assessment/PHB
Imaging Group, AstraZeneca R&D, Macclesfield, United Kingdom; 2The Paterson
Institute For Cancer Research, University of Manchester, Manchester, United
Kingdom. Sponsor: R. Roberts.
Doxorubicin is an anthracycline antibiotic commonly used in treatment regimens
for a wide range of malignancies, including hematological cancers, many types of
carcinoma and soft tissue sarcomas. Cardiotoxicity is a major safety complication
associated with the clinical use of doxorubicin, several other marketed anti-cancer
drugs and with many pre-clinical drug candidates. There is a need for novel, trans-
lational biomarkers to aid cardiac structural and functional monitoring in both pa-
tients at risk of cardiotoxicity and in pre-clinical species administered early drug
candidates. In the present study, a detailed characterization of the effects of chronic
doxorubicin treatment on rat heart structure and function has been performed
using a range of approaches. A rat model of doxorubicin-induced cardiomyopathy
was developed, involving 8 weekly intravenous boluses of doxorubicin hydrochlo-
ride followed by a 4 week ‘washout’ period. A timecourse assessment of cardiac
function using multiple MRI biomarkers was performed under recovery anaesthe-
sia, prior to dosing, on days 1 (baseline), 15, 29, 43, 57 and under terminal anaes-
thesia prior to necropsy on day 78. Reductions in cardiac output and ejection frac-
tion were observed in treated animals from day 15. Peak myocardial enhancement
was observed at day 57 onwards and correlated with serum cardiac troponin I ele-
vations. A detailed immunohistochemical cardiac assessment is currently being per-
formed to provide an understanding of the relationship between the development
of pathological and functional MRI changes, serological biomarker elevations and
cardiac pathological lesions.The ultimate aim is to apply the learning to pre-clinical
drug discovery in order to support safety validation of drug targets, to optimize
chemical design and to ultimately progress the safest molecules into later pre-clini-
cal and clinical testing.
1127 Both Vitamin D Excess and Deficiency Increase Blood
Pressure, but Only Excess Increases Arterial Stiffness.
N. Z. Mirhosseini1,  K. Bohaychuk1,  H. Vatanparast2,  G. George3 and
L. P. Weber1. 1Veterinary Biomedical Sciences, University of Saskatchewan, Saskatoon,
SK, Canada; 2Nutrition and Pharmacy, University of Saskatchewan, Saskatoon, SK,
Canada; 3Geology Department, University of Saskatchewan, Saskatoon, SK, Canada.
Vitamin D deficiency has been linked to an increased risk of hypertension, myocar-
dial infarction and stroke. Recently, the Tolerable Upper Intake Level of 1, 25-di-
hydroxyvitamin D (D3) has been increased to 4000 IU/d, but levels of 10,000
IU/d for treatment of inflammatory conditions and 50,000 IU/week for short-term
supplementation in deficient individuals have been suggested. High doses of D3
may cause arterial calcification and cardionecrosis, but the velocity of the adverse
events related to regular D3 intake in doses higher than 10,000 IU/d, threshold for
these changes and links to arterial calcification or hypertension are unclear. The ob-
jective of this study was to examine the effect of dietary doses of D3 equivalent to
recommended human doses after 1 month in male rats (n = 4/group): 0 IU/d (defi-
ciency), 600 (recommended daily intake; control), 10,000 (upper therapeutic
dose), 30,000 & 150,000 IU/d on cardiovascular function. Blood pressure teleme-
try and carotid artery Doppler ultrasonography were done at the baseline and
weekly during diet testing. After 4 weeks, both systolic and diastolic blood pressure
increased significantly (~15 mmHg; p<0.05, 1-way ANOVA, Duncan’s Post-hoc
test) in both D3 deficiency and groups receiving ≥30,000 IU/d compared to the
10,000 IU/d group. Carotid artery luminal diameter was significantly smaller in 0
and ≥30,000 IU/d D3 compared to control, which could indicate either increased
arterial wall thickness or contractility. Pulse wave velocity and peak acceleration de-
creased over time in control and D3 deficiency, but increased in groups receiving
≥30,000 IU/d D3 indicating increased arterial stiffness. In conclusion, based on in-
creased blood pressure, caution needs to be taken with D3 supplementation
≥30,000 IU/d. Future studies will be directed at confirming the dose threshold and
examining mechanisms for D3-induced arterial stiffness and hypertension.
1128 Fatty Acids Down Regulate and Inhibit Secretion of
Adiponectin in Adipocytes through Oxidative Stress.
S. R. Kotha,  T. O. Gurney,  A. B. Shelton,  S. I. Sherwani,  U. J. Magalang and
N. L. Parinandi. Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine,
The Ohio State University College of Medicine, Columbus, OH.
Adipose tissue is not merely a storage depot for the fat, but has emerged as a vital
organ capable of synthesizing and releasing adipokines which act as regulators of di-
verse physiological functions. Adiponectin (30 kDa) protein, an important member
of the adipokine family is known to regulate insulin action, NADPH oxidase activ-
ity, and lipid mobilization. Adiposity, release of free fatty acids from the adipose fat,
and adiponectin secretion by the adipocyte are interconnected. These phenomena
appear as crucial factors in cardiovascular and sleep disorders. Reports have been
made on decreased circulating adiponectin levels in obese individuals, suggesting a
link between fat load in adipose tissue and decrease in adiponectin release by adi-
pose tissue. However, polyunsaturated fatty acids (PUFA) have been established as
essential dietary fats and recently n-3 fatty acids (Omega-3) have gained impor-
tance in health, nutrition and disease. Having this as the premise, here, we hypoth-
esized that PUFA load would modulate adiponectin secretion by adipocytes. To test
our hypothesis, we loaded the 3T3 differentiated adipocytes with different PUFAs
including linoleic (C18:2), linolenic (C18:3), arachidonic (C20:4), eicosapen-
taenoic (20:5; EPA), and docosahexaenoic (22:6; DHA) acids for 24 h and then an-
alyzed the secreted adiponectin, intracellular adiponectin, fatty acid composition,
triglyceride accumulation, cytotoxicity, and extent of lipid peroxidation (formation
of 4-hydroxy-2-nonenal, 4-HNE) in the cells. Our results revealed that PUFA load-
ing suppressed both adiponectin release by the cells and intracellular adiponectin,
increased cellular PUFA content and triglyceride accumulation, and induced lipid
peroxidation (intracellular formation of 4-HNE). Overall, our results suggested
that the essential PUFAs suppressed secretion and synthesis of adiponectin in
adipocytes through elevated lipid peroxidation and oxidative stress.
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1129 Diesel Exhaust-Induced Cardiac Dysfunction Is Mediated by
Sympathetic Dominance in Heart Failure-Prone Rats.
A. P. Carll1, 2,  M. S. Hazari2,  C. M. Perez3, 2,  Q. Krantz2,  C. King2,
D. W. Winsett2,  D. L. Costa4 and A. K. Farraj2. 1Gillings School of Global Public
Health, University of North CarolinaChapel Hill, Chapel Hill, NC; 2Environmental
Public Health Division, US EPA, Research Triangle Park, NC; 3Curriculum in
Toxicology, University of North Carolina Chapel Hill, Chapel Hill, NC; 4ORD, US
EPA, Research Triangle Park, NC.
Short-term exposure to vehicular emissions is associated with adverse cardiac
events. Diesel exhaust (DE) may provoke cardiac events through defective co-ordi-
nation of the two main autonomic nervous system (ANS) branches. We exposed
heart failure-prone rats once to DE (500 μg/m3 PM2.5, 4 h, whole-body inhalation)
and tested for ANS-mediation of cardiotoxicity by several interventions, including
post-DE sympathetic agonism (dobutamine) before and after parasympathetic ab-
lation (vagotomy) and, separately, sympathetic or parasympathetic inhibition
(atenolol or atropine) during–and treadmill exercise after–DE exposure. Left ven-
tricular pressure (LVP), heart rate (HR), HR variability (HRV), and blood pressure
(BP) were measured to determine cardiac function and autonomic balance. During
exposure hour 2, DE markedly increased HR, BP and contractility in saline-pre-
treated rats, and atenolol entirely inhibited these effects, indicating DE caused mid-
exposure sympathetic excitation. DE increased body temperature regardless of pre-
treatment. Upon exercise recovery at 4 h post-exposure, HRV and HR indicated
that DE increased parasympathetic influence. Conversely, during exercise recovery
at 21 h post-exposure, DE increased sympathetic influence in saline-pretreated rats,
while it impaired contractility and decreased systolic BP in saline- and atropine-pre-
treated rats. Atenolol inhibited all of these effects. LVP at 1 d post-DE indicated
systolic and diastolic dysfunction and changes in diastolic and chronotropic re-
sponses to dobutamine mediated partly through sympathetic dominance. Thus,
DE-induced autonomic dysregulation of the heart involves time-dependent oscilla-
tions between sympathetic and parasympathetic dominance, with the former medi-
ating DE’s cardiotoxic effects. (Does not reflect EPA policy. Funded by EPA/UNC CR-
83515201-0)
1130 Remote Subcutaneous and Intravenous Administration in
Large Animals: Impact on Cardiovascular Safety
Pharmacology Data and Sensitivity.
R. Mikaelian1,  S. Authier1, 2,  A. Ascah1,  M. Pouliot1,  E. Troncy2 and R. Forster1.
1CIToxLAB North America, Laval, QC, Canada; 2Faculty of Veterinary Medicine,
University of Montréal, St-Hyacinthe, QC, Canada.
The regulatory guideline S7A supports the use of unrestrained models for safety
pharmacology assays. Parenteral bolus administrations including the intravenous
(IV) and subcutaneous (SC) routes are associated with CMax achieved immediately
or within minutes of dosing for some compounds. In this context, animal handling
can constitute a major interference to data quality and can obscure pharmacody-
namic responses. The current investigation compared cardiovascular changes after
remote SC and IV delivery in telemetered cynomolgus monkeys and Beagle dogs
with restrained administration in the same species. Remote parenteral administra-
tions were associated with a substantial decrease in data variance and consequently
improved minimum detectable differences. Mean heart rate variations from base-
line in the first 30 min after restrained IV saline dosing reached a maximum of 27%
compared to 9.7% for remote administration. Baseline systolic arterial pressure fol-
lowing remote SC saline dosing in cynomolgus monkeys ranged from 93.7 and
116.4 mmHg while post-dose values in the initial 60 min post-dose ranged from
94.0 and 116.3 mmHg. Recovery of cardiovascular parameters to baseline levels
after animal handling was 25 to 120 minutes in both species which can constitute a
major confounder to evaluation of short half-life drug candidates. Remote dosing
presented optimal results when the animals remained completely undisturbed (i.e.
no staff present in the animal room). Remote IV dosing is generally recognized to
improve telemetry data quality but the current investigation also demonstrate ben-
eficial effects of remote SC injections on sensitivity of cardiovascular investigations
in safety pharmacology studies using telemetry in cynomolgus monkeys and Beagle
dogs.
1131 Acute Silver Nanoparticle Exposure Increases Cardiac
Ischemic/Reperfusion Injury in Sprague-Dawley Rats.
C. J. Wingard1,  R. Urankar1,  J. Shananhann2,  A. K. Vidanapathirana1,
L. C. Thompson1,  S. Sumner3,  T. Fennell3,  J. M. Brown2 and R. M. Lust1.
1Physiology, East Carolina University, Greenville, NC; 2Pharmacology & Toxicology,
East Carolina University, Greenville, NC; 3RTI International, Research Triangle Park,
NC.
The expanding use and production of silver nanoparticles (AgNP) as anti-bacter-
ial/fungal agents is raising concerns regarding their safety to human health. The di-
versity of nanosized silvers (AgNP) and coatings for dispersion may produce com-
binations that minimize potential toxic effects on the cardiovascular system. We
hypothesized that acute intratracheal (IT) exposure to 20 nm (S; small) or 110 nm
(L; Large) AgNP coated with either polyvinylpyrorrolidone (P) or citrate (C) would
increase the susceptibility of cardiac tissue to a regional ischemic reperfusion (I/R)
injury. Young male Sprague Dawley rats were exposed to 200 μg of AgNP. 24 hrs
post-exposure, cardiac ischemia was induced for 20 mins followed by 2 hrs of reper-
fusion in situ. Hearts were sectioned stained with Evans blue to demarcate Area at
Risk (AAR) and counter stained with TTC to determine % of AAR infarcted.
Bronchoalveolar lavage fluid (BALF) and serum was collected post I/R injury to
evaluate pulmonary injury and circulating markers of injury. Neither P (22 ± 2%
Infarct/AAR) nor C (24 ± 1% Infarct/AAR) altered the extent of infarcted cardiac
tissue as compared to naive (22 ± 2% Infarct/AAR). However, the installation of all
forms of AgNP significantly increased the extent of cardiac I/R injury. As a group
the P-coated AgNP developed larger infarcts than C-coated. The 20 nm were more
effective at enhancing I/R Injury (SP 43 ± 2.0 % Infarct/AAR, SC 37 ± 3 %
Infarct/AAR) than the 110 nm size (LP 37 ± 3 % Infarct/AAR, LC 31± 2 %
Infarct/AAR). The opposite pattern was observed in the BALF endpoints with P
and L AgNP having greater effects. Our results suggest IT exposure to AgNP have
differential effects on pulmonary and cardiac tissues following the application of
I/R injury. This work is supported by NIEHS U19 ES019525.
1132 Effect of Pulmonary Exposure to Welding Fumes on
Cardiomyocyte Contractility.
H. Kan1,  J. M. Antonini1,  M. Ye1,  W. Zheng1,  R. Salmen1,  R. Popstojanov2
and V. Castranova1. 1PPRB, NIOSH, Morgantown, WV; 2West Virginia University,
Morgantown, WV.
Studies have found that pulmonary exposure to welding fumes is positively associ-
ated with a higher incidence of cardiovascular events. We reported previously that
pulmonary exposure to welding fumes, manual metal arc-hard surfacing (MMA-
HS), has a negative impact on cardiac function as evidenced by reduced heart con-
tractility. However, the mechanisms underlying MMA-HS-induced depression of
cardiac contractility remain unclear. To study the mechanisms, rats were given an
intratracheal instillation of MMA-HS welding fumes (2 mg/rat) or saline once a
week for seven weeks. Cardiomyocytes were isolated at 1 and 7 days post-exposure.
Cardiomyocyte contractility and intracellular calcium level in response to increas-
ing concentrations of adrenoreceptor agonist isoprenaline and extracellular calcium
were assessed using a Myocyte Calcium Imaging/Cell Length System. Pulmonary
exposure to MMA-HS blunted contractile function in response to both isopre-
naline and calcium at 1 day post-exposure (P < 0.01; P < 0.05, respectively). A
blunted contractile response was also observed with welding fume treated rats at 7
days post-exposure in response to isoprenaline and calcium (P < 0.01). Intracellular
calcium level in response to extracellular calcium stimulation was reduced at 7 days
post-exposure (P < 0.05). These findings suggest that pulmonary exposure to weld-
ing fumes impairs cardiac function by decreasing cardiomyocyte contractility
through a defect in the adrenergic signaling pathway and intracellular calcium han-
dling.
1133 Silver Nanoparticle Exposure Increases Vasoconstrictor
Response in Nonpregnant Female Sprague-Dawley Rats.
J. O. Dawkins1,  A. K. Vidanapathirana1,  L. C. Thompson1,  S. J. Sumner3,
T. Fennell3,  J. M. Brown2 and C. J. Wingard1. 1Physiology, East Carolina
University, Greenville, NC; 2Pharmacology & Toxicology, East Carolina University,
Greenville, NC; 3RTI International, Research Triangle Park, NC.
The use and production of silver nanoparticles (AgNP) is growing rapidly raising
concerns regarding their safety to human health, particularly following transloca-
tion to the circulatory system. Previous findings from our lab have shown intra-
venous (IV) exposure to AgNP changes the vasoconstrictor response in both preg-
nant and male Sprague Dawley (SD) rats. We hypothesized, acute IV exposure to
AgNP in non-pregnant females will increase vascular reactivity of arterial vessels
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from mesenteric and uterine vascular beds and aortas and these changes will be in-
fluenced by NP size and coating. Female, non-pregnant, SD rats were intravenously
exposed to 200 μg of 20 or 110 nm AgNP coated with polyvinylpyrorrolidone
(PVP) or citrate and suspended in water. 24 hrs. post-exposure, wire myography
tested the vasomotor responses in aortic, first order mesenteric and main uterine ar-
tery vessel segments. Cumulative dose response curves were created for phenyle-
phrine (PE), angiotensin II (ANGII), and endothelin 1 (ET1). Segments of uterine
artery and aorta from AgNP exposed animals generated larger stress when com-
pared to vehicle controls. No significant differences were observed in the mesenteric
artery responses. Maximum stress values in the uterine artery were greater (p <
0.05) in response to ET1 and ANGII stimulation following exposure to 110 nm
PVP AgNP (16.4 ± 2.7 and 14.5 ± 2.2 mN/mm2, respectively) as compared to 110
nm citrate AgNP (8.0 ± 1.0 and 6.9 ± 0.8 mN/mm2, respectively). Conversely,
maximum stress in response to PE in aortic segments was greater (p < 0.01) follow-
ing exposure to 20 nm PVP AgNP (1.3 ± 0.2 mN/mm2) as compared to 20 citrate
nm AgNP (2.8 ± 0.3 mN/mm2). Our results suggest IV exposure to AgNP has dif-
ferential effects on increasing the vasoconstrictor responses that are dependent on
the vascular bed, size of the NP and type of coating. This work is supported by
NIEHS U19 ES019525.
1134 Intravenous vs Intratracheal Administration of C60
Differentially Promotes Constriction or Impairs Relaxation
of the Isolated Coronary Artery.
N. A. Holland1,  L. C. Thompson1,  A. K. Vidanapathirana1,  J. O. Dawkins1,
S. J. Sumner3,  A. Lewin3,  T. Fennell3,  J. M. Brown2 and C. J. Wingard1.
1Physiology, East Carolina University, Greenville, NC; 2Pharmacology & Toxicology,
East Carolina University, Greenville, NC; 3RTI International, Research Triangle Park,
NC.
The potential uses of C60 fullerenes have grown to include roles in both commer-
cial industry and medicine, but the impacts on human health are not completely
understood. Data from our lab suggests that C60 may exacerbate cardiac is-
chemia/reperfusion injury. We hypothesized that exposure to C60 would promote
enhanced vasoconstriction and impaired endothelial-dependent relaxation re-
sponses of the coronary artery. Male Sprague-Dawley rats were exposed to a single
93.3 μg/kg dose of intravenous (IV) or intratracheal (IT) C60 or polyvinylpyrroli-
done vehicle. Twenty-four hours following exposures, coronary artery segments
were isolated and evaluated using wire myography. Cumulative dose responses to
serotonin (5-HT), acetylcholine (ACh), or sodium nitroprusside (SNP) were con-
structed. We found that IT exposure to C60 resulted in a leftward shift (P = 0.05)
of the 5-HT EC50 (558.4 ± 104.5 nM) compared to vehicle (870.7 ± 129.7 nM),
but that IV exposure to C60 did not significantly shift the 5-HT EC50 values
(C60: 762 ± 112.3 nM vs. vehicle: 669.3 ± 59.4 nM). Conversely, IV exposure to
C60 led to a rightward shift (P = 0.09) in the EC50 for ACh (232.5 ± 68.9 nM)
compared to vehicle (100.9 ± 48.8 nM), but IT C60 exposure did not produce any
differences in ACh EC50 (C60: 245.7 ± 37.4 nM compared to vehicle: 222.4 ±
31.6 nM). The relaxation responses to SNP were not different between any groups.
The route of exposure to C60 appears to influence an enhancement of smooth
muscle contraction by IT and impaired endothelial relaxation by IV administra-
tion. Based on these data we conclude that C60 exposure could enhance coronary
vascular tone, possibly compromising dilatory flow during reperfusion, and thus
exacerbating myocardial infarction. This work is supported by NIEHS U19
ES019525.
1135 Intratracheal Exposure to Silver Nanoparticles Promotes
Enhanced Coronary Vascular Tone.
L. C. Thompson1,  A. K. Vidanapathirana1,  J. O. Dawkins1,  S. J. Sumner3,
T. Fennell3,  J. M. Brown2 and C. J. Wingard1. 1Physiology, East Carolina
University, Greenville, NC; 2Pharmacology & Toxicology, East Carolina University,
Greenville, NC; 3RTI International, Research Triangle Park, NC.
Silver nanoparticles (AgNP) have physicochemical and antimicrobial properties
that make them useful in both industrial and biomedical applications. In regard to
human exposures, little is known about the way AgNP may impact physiological
systems. We tested the hypothesis that coronary responsiveness to serotonin (5-
HT) and acetylcholine (ACh) would be augmented 24 hrs following exposure to
AgNP, and be dependent on particle sizes and the dispersants used to coat the par-
ticles. We used male Sprague-Dawley rats (10-12 weeks old) and delivered AgNP (1
mg/kg), of either 20 nm (SS) or 110 nm (LS) diameters, and suspended in either
polyvinylpyrorrolidone (PVP) or citrate (Cit), by intratracheal (IT) instillation or
intravenous (IV) injection. After 24 hrs we isolated segments of the left anterior de-
scending coronary artery for wire myography analysis of 5-HT and ACh dose-re-
sponses. Our data indicate no differences in coronary responses from AgNP groups
compared to their vehicle groups. We did observe some unique dispersant- and
AgNP size-dependent comparisons in the coronary responses. Maximal 5-HT
stresses were higher (P < 0.05) in the SSCit-IT group (4.3 ± 0.5 mN/mm2) com-
pared to the SSPVP-IT group (2.9 ± 0.3 mN/mm2) or the LSCit-IT group (3.2 ±
0.4 mN/mm2). ACh responses were impacted in a dispersant-dependent manner,
shifting the EC50 from 106.6 ± 16.6 nM in the LSPVP-IT group to 50.4 ± 19.9
nM in the LSCit-IT group. We found no significant differences between coronary
responses from rats exposed intravenously to AgNP or their vehicles. We conclude
that pulmonary exposure to AgNP activates biological response pathways that are
sensitive both the dispersant and AgNP size. This work is supported by NIH U19
ES019525.
1136 Environmental Predictors of Oxidized Ldl Cholesterol
(oxLDL) in Navajo Populations Exposed to Uranium-
Contaminated Mining Sites.
M. E. Harmon1,  C. Miller2,  M. J. Campen1,  C. Shuey3,  M. Cajero2,
B. Pacheco2,  E. Erdei1,  J. DeGroat2,  G. Stark2,  S. Henio-Adeky3,  S. Ramone3,
T. Nez3 and J. Lewis2. 1College of Pharmacy, University of New Mexico,
Albuquerque, NM; 2Community Environmental Health Program, University of New
Mexico, Albuquerque, NM; 3Southwest Research and Information Center,
Albuquerque, NM.
Numerous abandoned mines within the Navajo Nation contribute uranium, ar-
senic and other heavy metals to the soil and groundwater. Environmental exposure
to heavy metal contaminants may promote or exacerbate cardiovascular disease.
The prevalence of type 2 diabetes, a risk factor for cardiovascular disease, has in-
creased among the Navajo community. Evidence is emerging that pre-existing
metabolic disease may increase an individual’s susceptibility to vascular toxicity of
heavy metal contaminants. To assess the potential impact of these contaminants on
cardiovascular health of exposed individuals, we examined traditional (IL-6, CRP)
and novel (oxLDL, LOX-1 receptor) plasma biomarkers in a large community of
the Navajo Nation. Samples and data were obtained through a culturally appropri-
ate community-based participatory approach, incorporating data collection and
outreach by Navajo community staff. Biomarker data were linked to geospatial data
on contamination sites using traditional linear regression and Bayesian models.
When we used a binary model for uranium and arsenic drinking water levels, we
observed that the estimated annual intake of arsenic was a significant predictor of
oxLDL; age, the occupational exposure score, and the distance-environmental ex-
posure score were also significant predictors. Diabetes, based on glycated hemoglo-
bin, was a significant predictor of oxLDL. No environmental factors were corre-
lated with LOX-1, CRP, or IL6. In summary, oxLDL does not seem to trend with
environmental exposure to abandoned uranium mines or their heavy metal con-
taminants, but oxLDL does seem to trend with arsenic in drinking water. While
still preliminary, these results indicate that arsenic intake may increase markers of
cardiovascular risk.
1137 Pulmonary Nanoparticle Exposure Enhances Cardiac
Parasympathetic Signaling.
T. L. Knuckles,  J. Yi and T. R. Nurkiewicz. Center for Cardiovascular and
Respiratory Sciences, West Virginia University, Morgantown, WV.
Pulmonary nanoparticle exposure has been associated with alterations in auto-
nomic signaling in the peripheral microcirculation. One possible mechanism link-
ing pulmonary nanoparticle exposure to remote effects is modulation of autonomic
influences. Several studies have indicated an increase in parasympathetic signaling
in the heart following particle exposure. We have recently reported that nanoparti-
cle exposure alters microvascular responses to sympathetic nerve stimuli. Thus, we
developed a model of barorereceptor function reflexes to determine the relative au-
tonomic contributions. Rats were exposed to titanium dioxide (nano-TiO2) for 4
hr for 1 day at 9 mg/m3. 24-hours post-exposure, baroreflex sensitivity was deter-
mined by i.v. infusion of sodium nitroprusside (SNP; 5-20 μg/kg) or phenyle-
phrine (PE; 1-16 μg/kg), with or without atropine (1 mg/kg) to diminish parasym-
pathetic signaling. Nano-TiO2 exposure did not alter PE-induced (4 μg/kg)
changes in mean arterial pressure (ΔMAP, 25±5 mm Hg Sham, 26±3 mm Hg
Exposed). However, nano-TiO2 exposure increased the magnitude of Δheart rate in
beats per minute (ΔBPM -20±2 control vs. -26±3 exposed), suggesting an en-
hanced parasympathetic response. When these experiments were repeated in the
presence of atropine, PE-induced ΔBPM was diminished in both groups; however,
atropine significantly altered ΔBPM in nano-TiO2 compared to sham (-18±1
Sham, -12±2 Exposed), suggesting an enhanced sensitivity to muscarinic receptor
blockade. Atropine treatment did not significantly alter ΔMAP in either group.
Nano-TiO2 exposure did not significantly alter SNP-induced changes in ΔMAP (-
36±5 mm Hg control vs. -41±2 mm Hg exposed), or heart rate (ΔBPM 18±7 con-
trol vs. 26±7 exposed). Because parasympathetic projections in cardiovascular sys-
tem are largely confined to the heart, these data suggest that nano-TiO2 exposure
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alters cardiac vagal tone, perhaps as a compensatory mechanism to enhanced sym-
pathetic influence. Future work will focus on mechanisms that precipitate alter-
ations in autonomic function. NIH RO1-ES015022 (TRN)
1138 Cigarette Smoke Induces Ventricular Remodeling through
Activation of the Aryl Hydrocarbon Receptor.
J. Bradley,  M. C. El Hajj and J. D. Gardner. Louisiana State University, Health
Science Center, New Orleans, LA.
Cigarette smoking is the major cause of preventable morbidity and mortality, with
5 million deaths annually worldwide. Cigarette smoke (CS) increases the risk of
cardiovascular disease, including myocardial infarction and coronary artery disease.
Of the 4700 identified components in CS, 60 are known carcinogens with poly-
cyclic aromatic hydrocarbons (PAH) the most abundant carcinogenic agent.
Chronic exposure to PAH can lead to ventricular dilation and dysfunction.
Previously, we found the 5 wks of exposure to diesel exhaust particulates (DEP),
which contain a high level of PAH similar to that in CS, induced ventricular dila-
tion and dysfunction. DEP exposure impaired ventricular remodeling through acti-
vation of the aryl hydrocarbon receptor (AHR). Because of the similarities in chem-
ical composition, we hypothesized that chronic exposure to CS would activate the
AHR pathway inducing ventricular extracellular (ECM) remodeling. Male Sprague
Dawley rats were exposed to six cigarettes per day (Kentucky 2R4F) for 12 wks
using a modified version of the Griffith snout exposure method. CS exposure re-
sulted in increased expression of AHR in the left ventricle. Furthermore, these ani-
mals had increased cardiac expression of cytochrome P450 1A1, an enzyme upreg-
ulated by AHR activation. CS exposure reduced cardiac collagen as assessed
through decreased levels of hydroxyproline. In addition, CS increased the expres-
sion of MMP-9, a key regulator in collagen turnover. These in vivo findings were
confirmed in isolated cardiac fibroblasts, where 10% CS extract reduced the secre-
tion of collagen by cardiac fibroblasts. In all, our findings indicate that CS alters
ventricular ECM remodeling through the reduction of myocardial collagen by an
AHR dependent mechanism.
1139 The Association of Vascular Disease with Exposure to Diesel
Exhaust.
M. Peterson1,  P. Valberg2 and C. Long2. 1Gradient, Seattle, WA; 2Gradient,
Cambridge, MA.
Cardiovascular disease (CVD) includes numerous heart- and circulatory-system re-
lated conditions, many of which are related to the buildup of plaque in the walls of
coronary (heart) arteries, in which case the disease is called coronary artery disease
(CAD). CVD is the leading cause of mortality in the US, with about 25% of all
deaths related to some form of this disease. While the majority of research on the
health effects of exposure to disease exhaust (DE) has focused on pulmonary end-
points, there is a growing body of research on the cardiovascular effects of DE par-
ticulate inhalation. Because DE exposure in the US is widespread, both occupa-
tionally and regionally, possible cardiovascular effects from DE could have
significant public health implications. We performed a weight-of-evidence evalua-
tion of the potential for DE to cause CAD, considering the mechanistic, toxicolog-
ical, and epidemiological aspects of DE. Based on our research and analysis, we find
little evidence to support an association of CAD with DE exposure at low (ambi-
ent) exposure levels. In particular, the occupational epidemiology studies fail to
provide consistent evidence of increased risk. We identified twelve studies of diesel-
exposed worker populations in which cardiovascular health endpoints were studied.
Several of these studies found significantly increased risks of one or two endpoints
(or in one or two subpopulations), while other studies reported significantly de-
creased risks for some endpoints/subpopulations. Overall, there was not a consis-
tent effect observed across the literature. Moreover, because of a lack of dose-re-
sponse between DE particulate levels and CVD mortality, the results of our
evaluation also have implications for assigning cardiovascular mortality risk to am-
bient air PM2.5, as is often done in assessing monetary value of PM2.5 reductions.
1140 FGF21 Expresses in Diabetic Hearts and Protects from
Palmitate- and Diabetes-Induced Cardiac Cell Death In
Vitro and In Vivo via Erk1/2-Dependent p38 MAPK/AMPK
Signaling Pathway.
C. Zhang1, 2,  X. Li2, 1 and L. Cai1, 2. 1University of Louisville, Louisville, KY;
2Wenzhou Medical College, Wenzhou, China.
The present study examined whether fibroblast growth factor (FGF) 21 expresses in
the heart of diabetic mice and also protects from fatty acid (palmitate)- and dia-
betes-induced cardiac apoptosis. Streptozotocin (STZ) induced type 1 diabetes in-
creased FGF21 expression about 40 fold at 2 months and 1.5 fold at 6 months. To
define if the up-regulated cardiac FGF21 expression offers a protective effect on
fatty acid- or diabetes-induced cardiac damage, H9C2 cells were exposed to palmi-
tate at 62.5 μM for 15 h, which significantly increased apoptosis. Pre-incubation of
palmitate-treated cells with FGF21 significantly reduced the apoptosis, examined
by DNA fragmentation and cleaved caspase-3. Mechanistically FGF21 inhibited
palmitate down-regulated phosphorylation levels of Erk1/2, p38 MAPK and
AMPK. Via application of inhibitor of each kinase and Erk1/2 siRNA, FGF21 was
found to prevent palmitate-induced cardiac apoptosis via up-regulating Erk1/2-de-
pendent p38 MAPK/AMPK signaling pathway. To confirm these in vivo, STZ-in-
duced diabetic mice were treated with FGF21 for 10 days, which significantly pre-
vented diabetes-induced cardiac apoptosis along with up-regulation of Erk1/2, p38
MAPK and AMPK phosphorylation. The cardiac protection of FGF21 was com-
pletely blocked by Erk1/2 inhibitor. FGF21also protected cardiac apoptosis in
acute fatty acid-treated mice via the same signaling pathway. More importantly,
compared to wild-type mice, FGF21 gene knock-out mice are highly susceptible to
diabetes-induced cardiac cell death and inhibition of Erk1/2, p38 MAPK and
AMPK phosphorylation, which could be prevented by FGF21 treatment. These re-
sults strongly suggest that the early stage increase in FGF21 mRNA expression may
represent an early protective mechanism; Application of FGF21 to diabetic mice or
acute fatty acid-treated mice can prevent cardiac cell death via ERK1/2-dependent
p38 MAPK and AMPK signaling pathway.
1141 Effects of Nicotine on Cardiovascular Remodeling in a
Mouse Model of Systemic Hypertension.
E. S. Colombo1, 2,  J. Davis1,  M. Makvandi1,  M. Aragon1,  M. Paffett1 and
M. J. Campen1. 1College of Pharmacy & Internal Medicine, University of New
Mexico Health Science Center, Albuquerque, NM; 2Internal Medicine, University of
New Mexico, Albuquerque, NM.
The association of cigarette smoking and hypertension with the development of
heart disease and aortic aneurysms is clear. The use of nicotine-alone formulations,
such as the nicotine patch, gum or ‘smokeless’ electric cigarettes is increasing, as
they are perceived as healthier alternatives to traditional cigarettes. Unfortunately,
there is little data available on the effect of isolated nicotine on myocardial and aor-
tic remodeling in healthy subjects or in the setting of hypertension. We hypothe-
sized that nicotine would exacerbate the effects angiotensin-induced hypertension,
as evidenced by reduced left ventricular wall thickness and aortic wall remodeling.
For this study we utilized subcutaneous osmotic minipumps to administer an-
giotensin II, nicotine, nicotine plus angiotensin II (Ang-II) or saline to C57Bl/6
(n=6) mice for a total of 4 weeks. Ventricular wall thickness, activity of matrix met-
alloprotease 2 and 9 (MMP2/9) and presence of type 1 collagen was assessed as ev-
idence of cardiac remodeling. Heart weights were increased by treatments, with
control<nicotine<ang-II<nicotine+ang-II, but a statistical interaction of nicotine x
ang-II was not noted. Activity levels of MMP-2 mirrored these changes and
demonstrated clear addivitiy between nicotine and ang-II. Additionally,
histopathological analysis of aortas revealed that combined nicotine and ang-II
treatment induced significant hypertrophy compared to all other groups. This pilot
project reveals possible cardiotoxic interactions between nicotine and angiotensin-
II induced hypertension. These data indicate that in the presence of hypertension,
nicotine alone can drive development of cardiovascular, which has important impli-
cations on labeling and marketing of nicotine replacement therapy. These data also
raise the possibility that angiotensin inhibitors may be specifically efficacious in
prevention of cardiovascular disease among hypertensive individuals using nicotine.
1142 Metallothionein Preservation of Akt2 Function by Down-
Regulating TRB3 Restores Diabetic Inhibition of Cardiac
Insulin Signaling.
Y. Tan1, 2,  Y. Wang3, 1,  X. Li2 and L. Cai1, 2, 3. 1Pediatrics, University Louisville,
Louisville, KY; 2CARIDC, Wenzhou Medical College, Wenzhou, China; 3Jilin
University, Changchun, China.
Cardiac insulin resistance is a key pathogenic factor for diabetic cardiomyopathy,
but its mechanism remains largely unclear. Here we demonstrated that strepto-
zocin-induced diabetes significantly inhibited protein kinase B (Akt) Ser473 and
Thr308 phosphorylation from 2 weeks to 2 months. In cardiac-specific metalloth-
ionein-transgenic (MT-TG) diabetic mice, both Akt phosphorylation sites were
preserved normally at all time-points. Analysis of Akt isoforms revealed that Akt2,
but not Akt1, expression and phosphorylation were decreased at all time-points in
wide-type (WT) mice, but not MT-TG mice. Diabetes also increased Akt negative
regulator tribbles (TRB)3 expression only in WT mice, suggesting possible contri-
bution of MT prevention of diabetic up-regulation of Akt negative regulator to
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Akt2 function preservation. For mechanistic study, cardiac H9c2 cells with and
without forced MT overexpression (MT-H9c2) were treated with tert-butyl hy-
droperoxide (tBHP, an organic oxidant). tBHP did not affect basal Akt phosphory-
lation, but significantly inhibited insulin-stimulated total Akt phosphorylation and
increased TRB3 expression only in H9c2 cells. Furthermore, tBHP reduced Akt2
phosphorylation in the basal and insulin-stimulating conditions, which were signif-
icantly, but not completely, attenuated in MT-H9c2 cells. Silencing TRB3 expres-
sion with its SiRNA completely blocked tBHP-induced inhibition of insulin-stim-
ulated Akt2 phosphorylation, while overexpression of TRB3 in MT-H9c2 cells
transfected with recombinant TRB3 plasmid completely abolished MT preserva-
tion of insulin-stimulated Akt2 phosphorylation in response to tBHP. These results
suggest that oxidative stress-attenuated cardiac Akt, especially Akt2, function via
up-regulating Akt negative regulator plays a critical role in diabetic inhibition of in-
sulin signaling in the heart. MT preservation of Akt2 function by inhibition of Akt
negative regulator prevents diabetic inhibition of cardiac insulin signaling.
1143 Development of an Ultrasound Imaging Biomarker of Drug-
Induced Vascular Injury.
T. A. Swanson1,  M. P. Lawton2,  S. Portugal2,  L. Obert2,  J. Kreeger2 and
B. E. Enerson2. 1Comparative Medicine, Pfizer Worldwide Research, Groton, CT;
2Drug Safety Research, Pfizer Worldwide Research, Groton, CT.
Acute drug-induced vascular injury (DIVI) is caused by several classes of drugs, in-
cluding Phosphodiesterase (PDE) inhibitors and dopamine agonists. The finding of
DIVI in preclinical toxicity studies presents a significant challenge for pharmaceu-
tical companies, with many compounds terminated from development because of
the inability to monitor DIVI in the clinic. Ultrasound imaging is a non-invasive
technique that can be used to measure blood flow and vessel diameter in multiple
tissues and across species, and therefore has the potential to be a translatable bio-
marker of DIVI. Our objective was to demonstrate the utility of high-frequency ul-
trasound imaging for measuring hemodynamic changes in mesenteric arteries of
male Sprague Dawley rats treated with fenoldopam and CI-1044 (PDE4 inhibitor).
Blood flow and vessel diameter were measured in the superior mesenteric arteries
and right renal arteries at 4, 8 and 24 hours after dosing and the rats were subse-
quently necropsied at each time point. Microscopic observations consistent with
DIVI were found in animals treated with fenoldopam at 24 hours and included
mild to moderate perivascular accumulations of mononuclear cells, neutrophils in
tunica adventitia and superficial tunica media as well as multifocal hemorrhage and
necrosis in the tunica media.  Animals dosed with both drugs show marked in-
creases in flow and shear stress as early as 4 hours after dosing, with the
fenoldopam-treated rats exhibited the large changes in these parameters. Vessel di-
ameter and blood flow were used to calculate shear stress and regression analysis was
used to model the relationship between the presence of lesions and various hemo-
dynamic parameters and indicated that peak blood flow velocity was the best pre-
dictor of lesion formation. This data suggests that ultrasound imaging may provide
a translatable and non-invasive functional biomarker for localized hemodynamic
changes that may correlate with acute vascular lesion formation in specific target
tissues.
1144 Environmentally-Persistent Free Radicals (EPFRs)
Exacerbate Cardiac Dysfunction during Ischemia-
Reperfusion (I-R) Injury.
B. Burn,  S. Mahne,  V. Subramaniam and K. Varner. Pharmacology, Louisiana
State University Health Sciences Center, New Orleans, LA.
EPFRs have been identified in the particulate matter (PM) milieu at Superfund
sites. These EPFRs, capable of redox cycling and the continual generation of radical
species, form during combustion processes as halogenated hydrocarbons chemisorb
to transition metal-oxide-containing particles. We showed that short-term nose-
only inhalation of EPFRs decreased stroke volume (SV) and cardiac output (CO)
in rats secondary to increased pulmonary resistance and decreased ventricular fill-
ing. EPFRs also increased markers of oxidative stress and inflammation both sys-
temically and in the left ventricle. Epidemiological studies link PM exposure to in-
creased cardiac morbidity and mortality from ischemic events. Therefore, the
current study sought to determine if prior exposure to EPFRs would increase car-
diac vulnerability to I-R injury. The EPFRs (0.2 μm diam) tested were surrogates
consisting of 1,2-dichlorobenzene chemisorbed to a silica/CuO particle at 230°C
(DCB230). Rats were exposed via nose-only inhalation to DCB230 (171 μg), silica
particles or vehicle for 20 min/day for 7 days. Ventricular function was measured in
vivo using pressure-volume catheters. I-R injury was induced by ligating the left an-
terior descending coronary artery for 20 min followed by 60 min of reperfusion.
Compared to controls, baseline CO, stroke work and SV were significantly reduced
by exposure to DCB230. These parameters were further reduced during ischemia
and remained below control throughout reperfusion. Although not significantly
different from controls, end diastolic volume and heart rate trended lower in
DCB230 treated rats throughout, possibly contributing to the reduced ventricular
function. Indices of contractility and diastolic function were not different between
the groups. These data show that EPFRs reduce baseline ventricular function and
exacerbate the decrease in ventricular function elicited during I-R injury. Supported
by NIH P42-ES013648 (subaward 61365).
1145 The Role of Nickel in Systemic Inflammation and Blood
Coagulative Effects Induced by PM2.5.
F. Deng,  P. Xia and X. Guo. Occupational & Environmental Health Sciences,
Peking University School of Public Health, Beijing, China.
Exposure to fine particles (PM2.5) is associated with adverse cardiopulmonary
health effects; however, the causative components in PM2.5 are limited. Nickel is
one of the major elements of ambient particulate matters. This study was designed
to investigate the acute cardiovascular systemic toxicity induced by PM2.5 on
Wistar rats and the role of nickel sulfate in it. Male Wistar rats were exposed by in-
tratracheal instillation to blank membrane (control), fine particles with the doses of
7.5, 15 and 30mg/kg body weight and balanced saline (control), Nickel sulfateat
dosages of 7.5, 75 and 750μg/kg Ni; The rats were sacrificed after 24h, blood sam-
ples were collected and parameters of inflammation, cytokines, coagulative effects
and the nickel levels in serum were measured to estimate the cardiovascular injury.
The results showed that both of PM2.5 and Nickel sulfateinduced a significant in-
creases of serum C-reactive protein, IL-6 and TNF-α, PT levels in the plasma de-
creased significantly in PM2.5-treated rats compared with the control group.
Plasma fibrinogen increased significantly at 15 mg/kg and 30 mg/kg PM2.5
groups. The PT and APTT showed no changes in NiSO4-treated rats, Plasma fib-
rinogen levels increased significantly at 750 μgNi /kg NiSO4-treated rats. The TF
concentrations in plasma increased significantly at 75 μgNi/kg and 750 μgNi/kg
dosage groups (P<0.05), there was a slight increase at low dosage (7.5 μgNi/kg)
group. To be compared with the corresponding concentration of NiSO4, the acute
effects of PM2.5 were more stronger. Our results suggest that water-soluble nickel
in PM2.5 may play an important role in PM2.5 toxic effects on animal cardiovas-
cular system.
Key words: PM2.5; Nickel sulfate ; CardiovascularToxicity
Note: This experiment was carried out in accordance with the Peking University
Society’s criteria for the care and use of animals in research.
1146 Involvement of Shear Stress in Fenoldopam and Dopamine-
Induced Mesenteric Medial Arterial Necrosis.
D. Dalmas,  K. Frazier,  H. Thomas and M. Scicchitano. Safety Assessment,
GlaxoSmithKline, King of Prussia, PA.
Extrapolation and relevance of drug-induced rat vascular injury to humans has
hampered drug development due to lack of understanding of the pathologic mech-
anisms involved. Although vasodilatation and increased shear stress (SS) have been
hypothesized to be involved in the pathogenesis of these lesions, the exact role of SS
on primary target cells, vascular smooth muscle (VSMC) and endothelial cells (EC)
in vivo remain unclear. Dopaminergic DA1 agonists such as Fenoldopam and
Dopamine reproducibly induce mesenteric medial arterial necrosis (MAN) in rats
following single vasotoxic doses. To investigate the involvement of SS in the devel-
opment of MAN, rats were given vehicle, Dopamine or Fenoldopam for 4 days.
Yohimbine, a alpha-2 adrenoreceptor antagonist, also vasoactive but lacking MAN
was given to rats for 4 days for comparison. To evaluate the timecourse of lesion de-
velopment, rats were also given vehicle or a single vasotoxic dose of Fenoldopam
and necropsied 1-, 4-, 6-, 12- or 24 hours postdose. Mesentery from each rat was
collected and frozen in OCT, then EC and VSMC were microdissected from rat
mesenteric arteries, and RNA was amplified and analyzed. Regulations of 37 shear
stress responsive genes were evaluated using TaqMan® gene expression profiling.
Many of the genes evaluated were confirmed to be differentially expressed by
Dopamine and Fenoldopam in EC- and/or SMC-enriched samples as compared to
controls and Yohimbine following 4 daily doses. A number of SS responsive genes
were also shown to be differentially regulated beginning 1- and/or 4-hours post-
Fenoldopam treatment and prior to histological evidence of MAN (which was ini-
tially observed beginning at 12-hours). Evaluation of this panel of genes has pro-
vided evidence of the involvement and regulation of SS responsive genes in both
EC and VSMC during the development of Dopamine and Fenoldopam-induced
vascular injury.
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1147 Direct Interaction between Multiwalled Carbon Nanotubes
and the Coronary Microcirculation.
T. R. Nurkiewicz1,  B. T. Chen2,  D. Frazer2,  R. R. Mercer2,  J. F. Scabilloni2,
V. Castranova2 and P. G. Stapleton1. 1Physiology and Pharmacology, West Virginia
University, Morgantown, WV; 2National Institute for Occupational Safety and
Health, Morgantown, WV.
Recently our collaborative group identified multi-walled carbon nanotube
(MWCNT) translocation from the lung to the heart, liver, and kidneys within 24
hours after pulmonary exposure. From this finding, we continued to examine the
microvascular ramifications associated with this direct interaction. To model drug
delivery platforms, as well as lung migration, MWCNT were injected into the tail
vein of rats (25-900 μg, suspended in 900 μL normosol). 24-hours later, coronary
arterioles (<170 μm in diameter) from the left anterior descending artery distribu-
tion were isolated for reactivity assessments based on responses to transmural pres-
sure (myogenic responsiveness), intraluminal flow (shear stress), phenylephrine
(10-9-10-4 M), acetylcholine (10-9-10-4 M), A23187 (10-9-10-5 M), and
spermineNONOate (10-9-10-4 M). Myogenic responsiveness was not altered after
MWCNT injection. However, MWCNT injection at all concentrations robustly
attenuated reactivity. The coronary microvascular dysfunction associated with
MWCNT injection is significant, impacting endothelium-dependent, -independ-
ent, adrenergic, and flow-mediated dilation pathways. These alterations, in combi-
nation with previous findings, indicate that the microvascular impairments that fol-
low MWCNT injection are more severe than those observed after ingestion or
inhalation exposure. Studies are currently underway to further evaluate mechanistic
differences between these routes of exposure.
NIH-RO1-ES015022 and RC1-ES018274 (TRN)
1148 Phosgene-Induced Lethal Lung Edema Correlate with
Persistent Stimulation of Cardiopulmonary Reflexes.
W. Li1 and J. Pauluhn2. 1Department of Toxicology, Fourth Military Medical
University, Xi’an, China; 2Toxicology, Bayer Pharma AG, Wuppertal, Germany.
Phosgene gas is a lower respiratory tract irritant. As such, it stimulates nociceptive
vagal C-fiber related reflexes in a dose-rate and concentration x exposure duration
(Cxt)-dependent manner. In rats this reflex is characterized by extended apnea time
periods, bradycardia, and hypothermia. While inhalation exposures at non-lethal
Cxt products show rapid reversibility of reflexively induced changes in respiratory
patterns, lethal Cxt products seem to cause their prolonged stimulation after dis-
continued exposure to phosgene. This observation has been taken as indirect evi-
dence that phosgene-induced lethal lung edema is likely to be caused by dysfunc-
tional neurogenic control of cardiopulmonary and microvascular physiology. In
order to verify this hypothesis, data from respiratory function measurements during
and after the inhalation exposure to phosgene gas were compared with time-course
measurements of respiratory and cardiac function over 20 hours post-phosgene ex-
posure. These data were complemented by time-course analyses of nitric oxide
(NOe) and carbon dioxide in exhaled breath, including time-dependent changes of
extravasated protein in bronchoalveolar lavage fluid (BALF) and hemoglobin in
blood. The nitric oxidase synthetase inhibitors L-NAME and L-NIL were used to
further elucidate the role of NOe in this type of acute lung injury and whether its
analysis can serve as an early biomarker of pulmonary injury. Collectively, the se-
quence and time-course of pathological events in phosgene-induced lung edema
appear to suggest that over-stimulated, continued sensorimotor vagal reflexes trig-
ger changes in cardio-pulmonary hemodynamics. In the absence of any successful
intervention, this imbalance progresses eventually to a refractory, self-perpetuating
and self-amplifying acute lung edema within 24 hours post-phosgene exposure.
The continued excessive parasympathetic tone appears to be the major etiopathol-
ogy in this type of high permeability lung edema following acute high-level expo-
sures to phosgene gas.
1149 Role of Nrf2 Antioxidant Defense in Mitigating Cadmium-
Induced Oxidative Stress in the Olfactory System of
Zebrafish.
L. Wang and E. P. Gallagher. Department of Environmental and Occupational
Health Sciences, University of Washington, Seattle, WA.
Exposure to trace metals can disrupt olfactory function in fish leading to a loss of
behaviors critical to survival. Cadmium (Cd) is an olfactory toxicant that elicits cel-
lular oxidative stress as a mechanism of toxicity while also inducing protective cel-
lular antioxidant genes via activation of the nuclear factor (erythroid-derived 2)-like
2 (Nrf2) pathway. However, the molecular mechanisms of Cd-induced olfactory
injury have not been characterized. In the present study, we investigated the role of
the Nrf2-mediated antioxidant defense pathway in protecting against Cd-induced
olfactory injury in zebrafish. A dose-dependent induction of Nrf2-regulated antiox-
idant genes associated with cellular responses to oxidative stress was observed in the
olfactory system of adult zebrafish following 24 h Cd exposure. Zebrafish larvae ex-
posed to Cd for 3 h showed increased glutathione S-transferase pi (gst pi), gluta-
mate-cysteine ligase catalytic subunit (gclc), heme oxygenase 1 (hmox1) and perox-
iredoxin 1 (prdx1) mRNA levels indicative of Nrf2 activation, and which were
blocked by morpholino-mediated Nrf2 knockdown. The inhibition of antioxidant
gene induction in Cd-exposed Nrf2 morphants was associated with disruption of
olfactory driven behaviors, increased cell death and loss of olfactory sensory neu-
rons (OSNs). Nrf2 morphants also exhibited a downregulation of OSN-specific
genes after Cd exposure. Pre-incubation of embryos with sulforaphane (SFN) par-
tially protected against Cd-induced olfactory tissue damage. Collectively, our re-
sults indicate that oxidative stress is an important mechanism of Cd-mediated in-
jury in the zebrafish olfactory system. Moreover, the Nrf2 pathway plays a
protective role against cellular oxidative damage and is important in maintaining
zebrafish olfactory function. This work was supported by the University of
Washington Superfund Research Program (NIEHS P42ES004696).
1150 Cadmium Enhances Instability of Lysyl Oxidase Messenger
RNA.
Y. Zhao,  S. Gao,  P. Toselli and W. Li. Biochemistry, Boston University School of
Medicine, Boston, MA.
Lysyl oxidase (LO), a copper-dependent enzyme, catalyzes crosslinking of collagen
and elastin essential for tissue and organ morphogenesis and repair. Our previous
studies have shown the critical role of downregulation of LO in cadmium (Cd) -in-
duced emphysema pathogenesis in vitro and in vivo. The present studies further in-
vestigate Cd effects on posttranscriptional modification of the LO gene in rat fetal
lung fibroblasts (RFL6). Treatment of cells with Cd (1-5 μM) inhibited levels of
LO steady-state mRNAs in a dose-dependent manner. RFL6 cells displayed a rela-
tively stable LO mRNA stability as assessed by the actinomycin D (an inhibitor of
mRNA synthesis, 5 μg/ml ) chase assay with the t1/2 = 24 h. In contrast, in cells
treated with 5 μM Cd plus actinomycin D, the t1/2 for LO mRNA decay was re-
duced to 0.75-h (45 min). Thus, Cd facilitates the LO mRNA decay. Rat LO
mRNA contains two AU-rich elements (ARE, AUUUA), the stability determinant,
at 174/178 and 200/204 downstream of the translation stop codon in the 3’-UTR.
We cloned the entire LO 3’-UTR (1/229) and the ARE fragment (152/229) into
the pGL3-Promoter vector after the coding region of the SV40 promoter-driven lu-
ciferase gene. The LO 3’-UTR or the ARE fragment strongly stabilized the reporter
mRNAs manifested by increased luciferase activities in transfected cells. Mutation
of two AREs abolished the enhancement of reporter mRNA stabilities by the LO
3’-UTR or the ARE fragment. Notably, luciferase activities driven by the LO 3’-
UTR or ARE in recombinant constructs were significantly inhibited in cells treated
with 5 μM Cd, indicating Cd enhancement of the decay of LO 3’-UTR or ARE-
driven reporter mRNAs. HuR, a major ARE binding protein, enhances the mRNA
stability. RNA immunoprecipitation (RIP) assay indicated that Cd effectively
blocked the binding of HuR into the LO mRNA AREs. Thus, Cd targeting the
HuR may be a critical mechanism for LO mRNA instability by this metal ion (sup-
ported by the grant of NIEHS 011340).
1151 Involvement of Inhibition of UBE2D Family Gene
Expressions on Cadmium-Induced p53 Dependent Apoptosis
in Human Proximal Tubular Cells.
M. Tokumoto1, 2,  J. Lee2,  Y. Fujiwara2 and M. Satoh2. 1Showa Pharmaceutical
University, Machida, Japan; 2School of Pharmacy, Aichi Gakuin University, Nagoya,
Japan.
Cadmium (Cd), known to be a causative agent of Itai-itai disease, produces severe
toxic effects in the kidney, liver, lung and bone. Particularly, chronic exposure to Cd
causes renal dysfunction. Recently, we have found that overaccumulation of p53
may relate to Cd-induced apoptosis and may be due to the suppression of p53
degradation through the inhibition of gene expressions of Ube2d family in rat
proximal tubular cells (NRK-52E cells). In this study, we examined the effects of
Cd on the expressions of UBE2D family, accumulation of p53 and apoptosis in
human proximal tubular cells (HK-2 cells). TUNEL positive cells, indicators of
apoptosis, were increased by treatment with 20 μM Cd for 18 h. Moreover, using
real-time RT-PCR, we demonstrated that Cd caused significant decrease of
UBE2D2 mRNA levels from 6-h treatment, and UBE2D4 mRNA levels from 12-
h treatment. Western blot analysis showed that Cd drastically increased p53 protein
levels in HK-2 cells, even though the mRNA levels of p53 were decreased by Cd.
Additionally, knockdown of UBE2D family genes by siRNA increased cellular pro-
tein levels of p53. These results indicate that Cd induces apoptosis through p53 ac-
cumulated by suppressions of UBE2D family gene expressions, in human proximal
tubular cells as well as in rat proximal tubular cells.
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1152 Serum and Hepatic Alkaline Phosphatase Activity in Rats
Exposed Chronically to Cadmium.
E. Brambila,  S. Treviño-Mora,  A. Andrade-García,  B. León-Chávez and
P. Aguilar-Alonso. Clinical Chemistry Research Laboratory, Facultad de Ciencias
Químicas, Benemérita Universidad Autónoma de Puebla, Puebla, Mexico.
Changes of serum and hepatic alkaline phosphatase activity in rats administered
with 65 ppm of Cd2+ in drinking water were studied during a 3 months period.
After metal administration, Cd2+ in rat livers showed an accumulation of 21 μg/g
tissue. Serum alkaline phosphatase activity decrease in 3 months Cd-exposed rats.
Liver alkaline phosphatase activity increased after 1 month Cd-exposed rats, how-
ever, later enzymatic activity decreased in the rats exposed to the metal by 3
months. In order to determine if Cd accumulated in liver had an inhibitory effect
on enzyme activity, hepatic alkaline phosphatase from non-exposed and 3-month
exposed rats to Cd was isolated and apo-alkaline phosphatase was prepared using
chelex-100. Apo-alkaline phosphatase was reactivated with Zn2+ and Mg2+.
Reactivation assays shown that liver alkaline phosphatase isolated from Cd-exposed
rats had 2-fold more activity as compared with the enzyme isolated from Cd-non-
exposed rats. Protein alkaline phosphatase did not show changes between non –ex-
posed and metal-exposed rats as determined by western-blot and ELISA assays.
Results of this work suggest that chronic Cd-exposure has an inhibitory effect on
serum and hepatic alkaline phosphatase activity, and the mechanism of inhibition
can involve the substitution of native zinc in the enzyme by the Cd progressively ac-
cumulated in the tissue.
1153 The Cadmium-Responsive Genes Numr-1 and Numr-2 Are
Regulated by Multiple Pathways.
Q. Ding and J. H. Freedman. NIEHS, Research Triangle Park, NC.
Exposure to the carcinogenic metal cadmium can activate multiple signaling path-
ways to affect the expression of hundreds of genes. However, the molecular mecha-
nism by which cadmium affects transcription is not completely understood. Whole
genome microarray studies in the nematode C. elegans showed nuclear metal-re-
sponsive gene-1 (numr-1) mRNA levels increased 7-fold following a 24h cadmium
exposure. Subsequent genomic analysis identified a second gene, numr-2, that is
99% identical to numr-1, in both coding and regulatory regions. Both numr’s are
developmentally regulated and expressed in identical cells: constitutively in a subset
of neurons in the head, vulva and tail; and in intestinal and pharyngeal cells follow-
ing metal exposure. Metals and calcium, but not other environmental stressors, in-
duce numr-1/-2 transcription. Bioinformatic analysis identified 25 putative, up-
stream regulatory elements in the numr promoters. The roles of the cognate DNA
binding proteins on numr-1 expression in the absence and presence of cadmium
was examined in loss of function mutants or by RNAi. Among the tested genes,
two alleles of osm-9 (TRPV channel protein), ok1677 and ky10, showed significant
gene-cadmium interactions, suggesting osm-9 regulates cadmium-induced numr-1/-
2 transcription. Three other genes may also be involved in numr-1/-2 transcrip-
tional regulation: ceh-20 (homeodomain protein), unc-86 (POU-type home-
odomain protein) and gem-4 (calcium-dependent phosphatidylserine binding
protein). In addition to osm-9, unc-86 and ceh-20 are expressed in neurons, sug-
gesting a link between neuronal activity and metal-inducible numr-1/-2 transcrip-
tion. The four candidate genes are present in independent signaling pathways,
which suggest that cadmium-induced numr-1/-2 transcription is regulated by mul-
tiple signaling pathways. Further analyses disrupting these signal transduction
pathways will be used to define the role of these genes in cadmium-induced numr-
1/-2 transcription.
1154 SRC Kinase Participation in MT-II Production and
Acetylation STAT3 in Mouse Hepatocytes Exposed to
Cadmium.
K. Martínez1,  V. Souza1,  A. López1,  A. López-Reyes2,  D. Clavijo1,  L. Bucio1,
L. Gómez-Quiroz1 and M. Gutiérrez-Ruiz1. 1Ciencias de la Salud, Universidad
Autónoma Metropolitana, Mexico City, Mexico; 2Dirección de Investigación, Instituto
Nacional de Rehabilitación, Mexico City, Mexico.
Cadmium(Cd),a toxic metal initially accumulated in the liver, forms high affinity
complexes with metallothionein-II (MT-II). This protein requires the activation of
transcription factors such as STAT3. Phosphorylation is crucial to regulate the ac-
tivity of several proteins, as well as acetylation, has been linked in gene expression
processes giving greater affinity for the transcription factors to DNA. This process
has been reported in STAT3 to form more stable dimers. There is evidence that this
modification is carried out by the p300 coactivator protein, which is characteristic
because of its histone acetyltransferase activity and its Stat3 C-terminal affinity.
MT-II production also has been associated with Src; however, molecular mecha-
nisms induced by Cd have not been yet fully understood. The aim was to evaluate
the participation of Src in Stat3 activation and its relation with MT-II production
and acetylation in hepatocytes treated with 5μM CdCl2.Primary mouse hepato-
cytes were treated with different Cd concentrations determining phosphorylation
of STAT3, Src, ERK1/2 and the induction of p300 and MT-II by Western-blot .A
pretreatment for 30 min with Src inhibitor SU6656 was performed to evaluate the
relationship between STAT3 activation and MT-II content; the same approach was
done with the ERK1/2 inhibitor PD98059, used to correlate STAT3 activation and
ERK signaling. We proved that Cd induced STAT3 acetylation.Cd increased acti-
vation of STAT3, Src, ERK1/2, p300, and MT-II.STAT3 phosphorylation and
ERK1/2 were significantly reduced by Src, ERK1/2 inhibitors.MT-II expression di-
minished with Src inhibitor. Our results suggest that Cd induces STAT3 phospho-
rylation by a mechanism dependent of Src and ERK1/2, while STAT3 induces
acetylation by p300 likely to increase production of MT-II as a biological response
to Cd.SEP-CONACYT.CB-2008-106194
1155 Overaccumulation of p53 and Induction of Apoptosis in
Renal Tubules of C57BL/6 Mice Chronically-Exposed to
Cadmium.
J. Lee1,  M. Tokumoto1, 2,  Y. Fujiwara1 and M. Satoh1. 1School of Pharmacy, Aichi
Gakuin University, Nagoya, Japan; 2Showa Pharmaceutical University, Tokyo, Japan.
Long-term exposure to cadmium (Cd) affects adversely to renal tubules. We have
recently demonstrated that Cd induces p53-dependent apoptosis through the inhi-
bition of gene expression of Ube2d family in rat proximal tubule cells (NRK-52E
cells). In this study, we examined the effect of chronic exposure to Cd on the local-
ization of p53-dependent apoptosis in kidney of mice. Five weeks old female
C57BL/6J mice were fed diet containing 300 ppm Cd without restraint for 12
months. After 6- and 12-month feeding, we evaluated renal toxicities, and meas-
ured mRNA levels of Ube2d family and protein levels of p53 in kidney. In order to
examine the localization of p53, we used immunostaining with anti-p53 antibody.
Localization of apoptosis was examined by TUNEL staining. Although exposure of
mice to Cd induced mild renal toxicity, significant decreases of mRNA levels of
Ube2d family and accumulation of p53 were detected in kidney. Interestingly, not
only overaccumulation of p53 proteins but also induction of apoptosis was trig-
gered specifically in renal tubules of mice by Cd exposure. These results indicate
that Cd may induce apoptosis through p53 accumulated by suppressions of Ube2d
family expressions, specifically in renal tubules.
1156 Effects of Cadmium on the Urinary Excretion and
Localization of Cystatin C in Kidney.
W. C. Prozialeck1,  A. Van Dreel1,  S. Zawdzka1,  J. Edwards1,  C. D. Ackerman1
and V. S. Vaidya2. 1Department of Pharmacology, Midwestern University, Downers
Grove, IL; 2Renal Division, Brigham and Woman’s Hospital, Harvard Medical School,
Boston, MA.
Cadmium (Cd) is a nephrotoxic environmental pollutant for which there is an ur-
gent need for improved biomarkers of toxicity. Cystatin C is a low molecular weight
protein that has been shown to be a sensitive biomarker for ischemic, and some
types of toxic, kidney injury. The objective of the present study was to determine if
cystatin C might be a useful early biomarker of Cd nephrotoxicity. Adult male rats
were given subcutaneous injections of Cd (0.6 mg/kg, 5 days per week). At 6, 9 and
12 weeks, urine samples were collected and analyzed for cystatin C, protein, creati-
nine and kidney injury molecule-1 (Kim-1). Serum was analyzed for creatinine and
cystatin C, and kidneys were processed for histopathologic analyses. Cd caused a 1-
2 fold increase in urinary excretion of cystatin C and larger increases in Kim-1 ex-
cretion that were evident at 6, 9 and 12 weeks. No change in urinary protein was
evident until 12 weeks. Cd had no effect on urinary creatinine or serum levels of
creatinine and cystatin C. Histochemical analyses revealed evidence of proximal
tubule injury in the Cd-treated samples, along with alterations in the pattern of cys-
tatin C distribution. Control samples showed a speckled pattern of cystatin C la-
beling beneath the apical surface of the proximal tubule cells, whereas, Cd treated
samples exhibited diffuse labeling in the cytoplasm and on the cell surface. The pat-
tern of cystatin labeling paralleled that of the brush border transport protein mega-
lin, which has been implicated as a mediator of cystatin C uptake in the proximal
tubule. These results indicated that Cd increases the urinary excretion of cystatin C,
and they suggest that this effect may involve disruption of megalin-mediated up-
take of cystatin C by epithelial cells of the proximal tubule.
Supported by Midwestern University and NIH Grant RO1 ES006478 to WCP.
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1157 Cadmium Exposure Affects Insulin Signaling in
Caenorhabditis elegans.
Y. Sun and J. H. Freedman. BSB, DNTP, NIEHS, Research Triangle Park, NC.
Diabetes mellitus (DM) and diabetes-related kidney disease are serious, world-wide
health problems. Although there is no direct evidence linking cadmium (Cd) to
DM, Cd exposure alters blood glucose levels and potentiates diabetic nephropathy.
The insulin/insulin-like growth factor signaling (IIS) pathway regulates multiple
biological functions including glucose metabolism and longevity. The model organ-
ism C. elegans, which has an IIS pathway homologous to that of mammalian
species, was used to investigate mechanistic links among Cd, transcription, and in-
sulin signaling. The focus of this investigation was the C. elegans Cd-responsive
gene cdr-1, whose transcription is up-regulated almost 800-fold exclusively by Cd.
To identify regulatory factors and pathways that control cdr-1 transcription, an in-
tegrated transgenic strain of C. elegans containing GFP under the control of the 5’-
regulatory region of cdr-1 was constructed. Following cadmium exposure (10 μM,
24 h) in the transgenic strain, GFP expression increases in intestinal cells. In a can-
didate screen, genes involved in various stress response pathways were tested for
their potential role in controlling cdr-1 expression. Genes were knocked out either
by genetic crosses to known loss-of-function C. elegans mutants or by RNAi.
Changes of cdr-1 transcription were then determined by measuring GFP expression
or qRT-PCR. The expression of cdr-1, in both the absence and presence of Cd (100
μM, 5 h) was suppressed when genes in the IIS pathway; daf-2, age-1, daf-18, pdk-
1, akt-1, akt-2, sgk-1 and daf-16; were knocked down. Statistically significant in-
teractions between Cd and IIS pathway genes were observed. Furthermore,
knocked down of IIS pathway-related genes; skn-1, hsf-1, pha-4, pop-1, lin-14,
tor-2, ras-1, wnk-1; also inhibited cdr-1 expression in response to Cd. These results
suggest that the IIS pathway mediates Cd-inducible transcription. In addition, they
support a model where Cd exposure could induce elevated blood glucose levels by
directly affecting the IIS pathway. The mechanism by-which Cd activates the IIS
pathway is currently being investigated.
1158 Investigating a Protective Role of the Antioxidant N-
Acetylcysteine against Cadmium-Induced Damage to Bone
Extracellular Matrix.
D. D. Wright,  W. S. Wright and S. J. Heggland. Biology, The College of Idaho,
Caldwell, ID.
Environmental pollution of cadmium, a heavy metal commonly utilized in elec-
tronics, is a global human health concern. Bone is a known target site for cadmium.
One mechanism to protect against cadmium-induced osteotoxicity and bone loss is
by reducing oxidative stress. Our lab previously demonstrated that n-acetylcysteine
(NAC) rescues osteoblasts from cadmium-induced apoptosis. Others have shown
that reactive oxygen species generated through oxidative stress decreases bone min-
eral density, in part, through targeting the collagen component of the extracellular
matrix (ECM). We hypothesize that the antioxidant NAC will protect against cad-
mium-induced damage to ECM produced by osteoblasts. Saos-2 cells were induced
to mineralize and treated with 1mM NAC or 5μM CdCl2 only or in combination
for 6 or more days. Upon termination cell viability, phosphate ECM deposition,
and collagen secretion and distribution in the ECM were evaluated using MTT,
von Kossa, SircolTM collagen assay, and immunofluorescence, respectively.
Treatment with CdCl2 for 6 days resulted in increased phosphate deposition,
which was restored to that of control in the presence of NAC. We also examined
collagen, the main organic component of the ECM. When osteoblasts were in-
duced to form an ECM, treatment with CdCl2 led to significantly less collagen se-
cretion which was reflected in less collagen deposition into the ECM; these effects
were reversed in the presence of NAC. Further, NAC and NAC combined with
CdCl2 significantly increased cell viability compared to control, leading us to also
investigate cell cycle progression. These studies provide further evidence that an-
tioxidants promote bone health by reducing the toxic effects of cadmium. Research
funded by NIH-INBRE P20 RR016454and P20 GM103408 and NIH
R15ES015866 grants.
1159 Cadmium Causes Injury to Pancreatic Islets That Is
Associated with Caspase-3 Labeling.
J. Edwards and Y. Bahrami. Pharmacology, Midwestern University, Downers Grove,
IL.
Diabetes is a growing worldwide epidemic. There is increasing interest in how envi-
ronmental contaminants can contribute to the onset of type II diabetes. Impaired
insulin release is a hallmark of type I diabetes and is key in the progression of type
II diabetes. Multiple epidemiological and experimental studies show that exposure
to the metal cadmium (Cd), is associated with diabetes and reduced serum insulin.
To examine the cytotoxic effects of Cd within pancreatic islets, male Sprague
Dawley rats were injected subcutaneously with either saline (control) or Cd (0.6 mg
Cd/kg/day, 5 days per week). After 6, 9 and 12 weeks of Cd treatment, pancreatic
tissue samples were removed then fixed in formalin. Pancreata were sectioned and
H&E stained to identify islets then examined for changes in islet histology. A
trained veterinary pathologist scored each sample for cytoplasmic vacuolization and
signs of necrosis and apoptosis. All pancreata from Cd treated animals had elevated
scores for signs of vacuolization, apoptosis and necrosis. However, these changes in
cell viability did not appear to change with longer Cd exposure times. In another
study using the same pancreas samples, tissue was labeled for the apoptosis indica-
tor, active caspase 3. In this study, pancreatic samples were counter stained with he-
motoxylin so that immuno-labeled islets could be identified.  This study resulted in
similar findings. Islets from Cd-treated animals had greater caspase-3 labeling and
as before, the intensity of labeling appeared to be time independent. These prelim-
inary results show that Cd acts to injury pancreatic islets which may result in di-
minished insulin release.
1160 Regulation of Glutathione Synthesis in Cadmium-Treated
Cultured Choroid Plexus.
S. Francis Stuart,  R. Young and A. Villalobos. Interdisciplinary Faculty of
Toxicology and Nutrition & Food Science, Texas A&M University, College Station,
TX.
In primary cultures of rat choroid plexus we have shown that exposure to cadmium
(Cd) induces oxidative stress, stimulates apical choline uptake, and alters glu-
tathione (GSH) synthesis. Our aim is to characterize the regulation of GSH avail-
ability and synthesis in response to low dose exposure to Cd and assess the signifi-
cance of GSH in cellular adaptation to Cd. We treated choroid plexus primary
cultures with 0 or 500 nM CdCl2 in serum free medium (SFM) for 12 h and col-
lected samples at 3, 6, 9, and 12 h. Induction of heme oxygenase-1 (HO-1), heat-
shock protein 70 (HSP70), and metallothionein-1 (MT-1) in Cd-treated cells was
compared to time-matched controls by immunoblot and qRT-PCR analyses. HO-
1 protein was induced at 3 h and gradually increased through 12 h. HO-1 gene ex-
pression was maximally induced by 70-fold at 6 h and was sustained through 12 h.
HSP70 protein was maximally induced by 5-fold at 12 h. MT-1 gene expression
was induced by 50-fold at 12 h. Cd induced the catalytic and modifier subunits of
glutamate-cysteine ligase (GCL), the rate-limiting enzyme in GSH synthesis.
GCLC protein levels peaked at 6 h while GCLM peaked at 9 h. Gene expression of
GCLC and GCLM increased by 5-fold and 4-fold at 12 h. To elucidate the effects
of Cd on GSH concentration, cells were pretreated (12 h) without or with buthio-
nine sulfoximine (BSO, 100 μM) then treated with 0 or 250 nM CdCl2 ± BSO in
SFM for 12 h. Intracellular GSH and oxidized glutathione (GSSG) concentrations
were assayed and compared to control. Cd increased GSH by 2-fold and increased
GSSG by 30-fold. In Cd-treated cells, BSO reduced GSH concentrations by 92%
but increased GSSG concentrations by 15-fold above controls. Inhibiting GSH
synthesis with BSO augmented induction of HO-1, HSP70, and MT-1 and en-
hanced stimulation of apical choline uptake in Cd-treated cells. These data indicate
that Cd stimulates GSH synthesis at points of transcription and translation, and
the inhibition of GSH synthesis accentuates cellular stress.
1161 Stable Expression of FRET-Based Cd(2+) Biosensor for
Advanced Research of Cytotoxic Cd(2+).
D. Yang1, 2 and T. Chiu2, 1. 1Department of Medical Research & Education, Taipei
Veterans General Hospital, Taipei, Taiwan; 2Institute of Biophotonics & Biophotonics
and Molecular Imaging Research Center (BMIRC), National Yang-Ming University,
Taipei, Taiwan.
Cadmium ion (Cd2+) causes lots of human tissue damages. Several ion channels
and transporter proteins as the molecular gateway of different ions have been previ-
ously proposed to be the cytotoxic entry mechanism(s) of Cd2+. However, the solid
conclusions have not been made. Here we tried to explore this issue through estab-
lishing human cell line stably expressing the fluorescent resonance energy transfer
(FRET)-based Cd2+ biosensor for monitoring content of intracellular Cd2+. This
newly constructed Cd2+ sensor Met-cad 1.57 contains part of Cd2+-binding pro-
tein CadR originated from bacteria Pseudomonas putida as the Cd2+ sensing key.
Through G418 selection, the HEK293 line stable expressing Met-cad 1.57 HEK-
MCD157 cells have been archived. The spectral patterns and sensing ranges of
Met-cad 1.57 for intracellular Cd2+ sensing were characterized in vivo under 96-
well plate. Under both a fluorescence spectroscopy and a FRET microscopic ratio
imaging, the contents of Cd2+ were than monitored within living HEK-MCD157
cells. The dynamic range of Met-cad 1.57 from 0 to 100 μM of Cd2+ is 2–4.4 (2.2
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fold) with a dissociation constant Kd around 271 nM. The role of voltage-gated
Ca2+ channels as the candidate of Cd2+ entry gateway was further explored with
the HEK-MCD157 cells. In summary, a human embryonic kidney cell line HEK-
MCD157 stably expressed FRET-based Cd2+ biosensor Met-cad 1.57 was con-
structed for both reliable and convenient investigations on content measurement of
Cd2+ within live-cell including the identification of Cd2+ entry pathway and sub-
cellular sequestration.
1162 Blood Cadmium Level of Residents Living near the
Abandoned Metal Mines in Korea.
D. Kim1,  S. Ahn1,  J. Ryu1,  S. Yu1 and D. Park2. 1Environmental Health,
National Institute of Environmental Research, Inchon, Republic of Korea;
2Environmental Health, Korea National Open University, Seoul, Republic of Korea.
Sponsor: J. Park.
Introduction: Preliminary biological exposure monitoring study selected 38 among
906 metal mines abandoned in Korea as the relative high risk areas for national sur-
veillance subjects. They were surveyed from 2008 to 2011 under the environmental
health policy by Ministry of Environment. The purpose of this study is to assess the
blood cadmium levels from people living around a total of 38 abandoned metal
mine areas and to determine if those areas have influenced exposure to cadmium of
residents
Methods: Blood cadmium levels were quantified using graphite furnace atomic ab-
sorption spectrometry (AAS) through appropriate blood collection, storage and
pretreatment procedure. People living less than 3 km from the abandoned mine
area were classified as the exposure group(n=4,687). Control group (n=2,643) was
selected from people living in non-mining areas.
Results: Blood cadmium level from exposure group was found to be 1.59 ug/L as
geometric mean (GM)(95 %CI: 1.56 - 1.62 ug/L) and 1.91 ug/L as arithmetic
mean(AM)(95 % CI = 1.88-1.94 ug/L). Those levels were significantly higher than
those from control group(GM=1.28 ug/L, 95 % CI=1.25-1.31 ug/L, AM= 1.52
ug/L, 95 % CI = 1.49-1.56 ug/L)(p=0.0001). In addition, 79.5% (n=3,728) of ex-
posure group and 69.6% (n=1,840) of control group exceeded the reference value
(1.0 ug/L) derived by German human biomonitoring commission. Multiple regres-
sion model found that exposure group was significantly higher than that of control
group after age, gender and smoking status were all adjusted (adjusted R2= 16.5 %,
p<0.0001)
Conclusions: We found that blood cadmium level of people residing near aban-
doned metal mine area was significantly high, compared with those of control
group. Our findings suggested that the abandoned mine areas may have elevated
blood cadmium level of people in the vicinity of those areas.
1163 One-Week and Four-Week Inhalation Toxicity Studies of
Nickel Sulfate and Nickel Subsulfide in Rats.
D. E. Dodd1,  H. J. Clewell1,  M. A. Sochaski1,  H. G. Wall2,  G. A. Willson2 and
A. R. Oller3. 1The Hamner Institutes for Health Sciences, Research Triangle Park,
NC; 2Experimental Pathology Laboratories, Inc., Research Triangle Park, NC;
3NiPERA, Inc., Durham, NC.
Inhalation toxicity studies of nickel sulfate (NiSO4) and Ni subsulfide (Ni3S2) were
conducted in F344 rats to evaluate cellular pathway responses in lung distal airways
using gene expression analysis. Supportive data included lung histopathology, bron-
choalveolar lavage (BAL) fluid analysis, and total Ni lung burden analysis. Groups
of 5 to 8 male F344 rats were exposed to 0 (control), 0.125, 0.25, 0.5, or 1.0
mg/m3 NiSO4 hexahydrate aerosol (0.8-1.2 μm MMAD) or 0, 0.04, 0.08, 0.15, or
0.6 mg/m3 Ni3S2 aerosol (2.2-3.2 μm MMAD) for one or four weeks duration (6
hr/day, 5 days/week). NiSO4-exposed rats showed the following BAL results at 4
weeks: decrease in macrophage percentage, increases in neutrophil and lymphocyte
percentages (≥0.5 mg/m3); increases in LDH, total protein, and NAG, with a de-
crease in ALP levels (1.0 mg/m3). Minimal to slight/mild bronchial epithelial de-
generation/hyperplasia and slight/mild alveolus inflammation were observed in the
1.0 mg/m3 rats. Total Ni in lungs of exposed rats could not be directly measured
due to interference with RNAlater solution. Ni concentrations were estimated at
0.7 to 1.0 ug Ni per g lung following 0.5 or 1.0 mg/m3 NiSO4. In the Ni3S2 study,
BAL results were similar to those for NiSO4. Macrophage percentage was de-
creased, neutrophil and lymphocyte percentages were increased (≥0.15 mg/m3),
and increases in LDH, total protein, and NAG, with a decrease in ALP were ob-
served. Minimal peribronchiolar/perivascular inflammation and alveolus inflam-
mation were observed in the 0.6 mg/m3 rats following one week exposure. Minimal
to slight/mild alveolus inflammation was observed at 4 weeks (≥0.15 mg/m3).
Quantitative results of total Ni in lung indicated a range of 1.6 to 14.4 μg Ni per g
lung following 4 weeks Ni3S2 exposure (0.04 to 0.6 mg/m
3). These data will be in-
tegrated with results of gene expression analysis to evaluate mode of action path-
ways of Ni toxicity.
1164 Gene Expression Profiles in Peripheral Blood Mononuclear
Cells of Chinese Nickel Refinery Workers with High
Exposures to Nickel and Control Subjects.
A. B. Munoz1,  A. Arita1,  J. Niu1,  Q. Qu1,  N. Zhao2,  Y. Ruan2,  K. Kiok1,
T. Kluz1,  H. Sun1,  Y. Chervona1,  H. A. Clancy1,  M. Shamy3 and M. Costa1.
1Environmental Medicine, New York University Graduate School of Arts and Sciences,
New York, NY; 2Lanzhou University School of Public Health, Lanzhou, China;
3Environmental Sciences, King Abdulaziz University, Jeddah, Saudi Arabia.
Background: Occupational exposure to nickel (Ni) is associated with an increased
risk of lung and nasal cancers. Ni compounds exhibit weak mutagenic activity, alter
the cell’s epigenetic homeostasis, and activate signaling pathways. However, changes
in gene expression associated with Ni exposure have been only investigated in vitro.
This study was conducted in a Chinese population to determine whether occupa-
tional exposure to Ni was associated with differential gene expression profiles in the
peripheral blood mononuclear cells (PBMCs) of Ni-refinery workers when com-
pared to referents.
Methods: Eight Ni-refinery workers and ten referents were selected. PBMC RNA
was extracted and gene expression profiling was performed using Affymetrix exon
arrays. Differentially expressed genes between both groups were identified in a
global analysis and findings were validated using real-time PCR.
Results: A total of 2167 differentially expressed genes displayed a greater than 1.25
fold-change in Ni-refinery workers. DNA repair and epigenetic genes were signifi-
cantly overrepresented (p< 0.0002). Of 31 DNA repair genes, 29 were repressed in
the high exposure group and two were overexpressed while these genes were not re-
pressed in the control group. Of the 16 epigenetic genes 12 were repressed in the
high exposure group and 4 were overexpressed. 
Conclusions: The results of this study indicate that occupational exposure to Ni is
associated with alterations in gene expression profiles in PBMCs of subjects. 
Impact: Gene expression may be useful in identifying patterns of deregulation that
precede clinical identification of Ni-induced cancers.
1165 Differential Severity of Chromium-Induced Hepatotoxicity
in a Day.
N. Miura1,  M. Togawa2 and T. Hasegawa2. 1National Institute of Occupational
Safety and Health (JNIOSH), Kawasaki, Japan; 2Yamanashi Institute Environmental
Science, Yamanashi, Japan.
The diurnal variation of cadmium-induced mortality is our topic (J Toxicol Sci, 37,
191, 2012). We presented further evidences for the Cd-induced diurnal variation
and considered the mechanism of these in SOT 2012 meeting. In this study, we re-
port the diurnal susceptibility of chromium-induced toxicity in mice. Male
C57BL/6J mice adapted for 14 days with assigned to 6 groups of 5 animals were
administrated intraperitoneally (i.p.) with hexavalent chromium (K2Cr2O7, 35
mg/kg) at different hours in the day (10:00, 14:00, 18:00, 22:00, 2:00 and 6:00 h),
describing as zeitgeber time (ZT); ZT2, ZT6, ZT10, ZT14, ZT18 and ZT22. In
case of dark period (ZT14, ZT18 and ZT22), administrations were performed
under red light. The mortality was determined during 14 consecutive days. Mice
were most sensitive to Cr administrated at ZT10, while least sensitive at ZT22. In
contrast, the susceptibility to Cd-induced mortality was higher at ZT6 but lower at
ZT18. Therefore, the daily fluctuation of metal sensitivity differed depending on
metal compounds, probably depending on the valence of metal ion. The GPT
value, an index of hepatotoxicity, also showed higher at ZT10 injection of Cr. The
hepatic levels of Cr determined by ICP-MS were not significantly different between
both time (ZT10 and ZT22), thus Cr accumulation in the liver was not a determi-
nation factor for this diurnal variation. Our results clearly indicate the susceptibil-
ity of metal-induced toxicity is markedly different in a day. We believe this view-
point should be introduced into toxicology as “chronotoxicology” becoming
indispensable in the future toxicology.
1166 Speciation of Chromium Released from Metal-On-Metal Hip
Implants.
K. Thuett1,  B. L. Finley1,  P. K. Scott2 and D. J. Paustenbach1. 1ChemRisk, LLC.,
San Francisco, CA; 2ChemRisk, LLC., Pittsburgh, PA.
Increased blood chromium (Cr) concentrations have been measured in many pa-
tients with hip prosthetic devices containing cobalt-chromium-molybdenum alloy.
To date, no studies have attempted to analytically distinguish between non-toxic
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trivalent Cr, Cr(III), and potentially harmful hexavalent Cr, Cr(VI), in these pa-
tients. However, it is known that Cr(VI) preferentially accumulates in red blood
cells (RBCs), while Cr(III) remains largely confined to the serum compartment of
the blood. Hence, the relative distribution of Cr into RBCs and serum is often used
as an indirect measure of Cr valence. We reviewed 231 blood samples from six dif-
ferent studies involving patients with Cr-containing hip implants. Samples were
generally collected pre-implant and then at three or six month intervals post-im-
plant for up to two years. The ratio of serum to RBC Cr concentrations was highly
consistent. Post-implant serum Cr concentrations (median values of 0.17-2.39
μg/L) typically increased by several fold over pre-implant concentrations (median
value of approximately 0.2 μg/L), but the RBC concentrations did not increase
over time. Specifically, the RBC Cr concentrations did not change pre- vs. post-im-
plant (median values of 0.26 to 2.5 μg/L). These data indicate that the Cr released
from the implants is in the form of Cr(III).
1167 E162 Protects against Chromium (VI)-Induced Cytotoxicity
and Genotoxicity in Human Lung Fibroblast Cells.
M. Braun1, 2,  J. Lechner2 and J. Wise1, 2, 3. 1Wise Laboratory of Environmental and
Genetic Toxicology, University of Southern Maine, Portland, ME; 2Maine Center for
Toxicology and Environmental Health, University of Southern Maine, Portland, ME;
3Department of Applied Medical Science, University of Southern Maine, Portland,
ME.
Hexavalent chromium [Cr(VI)] is a ubiquitous environmental toxicant. Studies
show that Cr(VI) induces many forms of DNA damage that may lead to cancer if
they are not repaired. Nutraceuticals, because of their antioxidant properties, have
the potential to decrease toxicity. The purpose of this study was to assess the pro-
tective effects of E162, a soluble powder made from crushed beets, on Cr(VI)–in-
duced toxicity. We compared the levels of damage generated after co-treatment
with Cr(VI) and E162 in human lung fibroblasts to those after Cr(VI) treatment
alone for both acute and chronic exposures. Sodium chromate was used as a repre-
sentative soluble Cr(VI) compound. After a short-term exposure, there was no pro-
tective effect of E162. After chronic exposure, however, E162 had a noticeable pro-
tective effect on sodium chromate–induced cytotoxicity and genotoxicity. For
example, at 1 uM sodium chromate, only 19 percent of cell colonies survived com-
pared to control, while E162 co-exposure increased that number to 35. 1 uM
sodium chromate generated 23 total chromosomal aberrations, while E162 co-ex-
posure decreased the number of lesions to 6. There were 49 percent of aneuploid
metaphases at 1 uM sodium chromate but only 35 percent after the addition of
E162. Uptake studies were performed, indicating that the protective effect of E162
was not a result of decreasing Cr(VI) uptake. Therefore, E162 may have a direct
protective effect on cells against sodium chromate-induced toxicity. This work was
funded by the NIEHS grant ES016893 (J.P.W.), the Maine Center for Toxicology
and Environmental Health (JPW), and the Maine Space Grant Consortium (MB).
1168 Method: Measuring Protein-Bound and Free Cobalt(II) in
Human Serum—Size Exclusion Liquid Chromatography
with ICP-MS.
B. D. Kerger1,  B. L. Finley2 and D. J. Paustenbach2. 1ChemRisk, LLC., Aliso Viejo,
CA; 2ChemRisk, LLC., San Francisco, CA.
Cobalt (Co) ions are known to have a strong affinity for sulfhydryl proteins and
amino acids in the blood and tissues, and sufficiently high concentrations of free
ionic Co(II) can lead to adverse health effects in humans and animals. We describe
a method using size exclusion liquid chromatography (SEC) to resolve protein-
bound Co fractions from cyanocobalamin and free Co(II) after direct injection of
serum samples stabilized with 0.1M acetic acid. Highly sensitive detection using
ICP-MS was coupled with SEC to provide a method detection limit of 0.12μg/L in
human serum for one higher molecular weight protein-bound Co peak (likely
Co(II) bound to human serum albumin (66 kDa) and other large serum proteins),
as well as for cyanocobalamin (1.3 kDa) and for free Co(II). Validation studies
show that this novel method demonstrates good accuracy with >98% mean recov-
ery and 10.4% relative percent deviation. Good precision was demonstrated for
matrix spikes at 0.5 μg Co/L with 92.7% mean recovery and 4% relative percent
deviation. Other metal cations known to compete with Co(II) for protein binding
sites (Fe(II), Zn(II), Mn(II), Cd(II), Cu(II), Ni(II), Pb(II)) did not significantly
alter Co(II) quantitation in the stabilized acetate solution. The sum of protein-
bound and free ionic Co species provided >90% mass balance when compared to
total Co measurements analyzed by acid digestion and ICP-MS in the same human
serum samples. We conclude that this method complies with the method perform-
ance criteria outlined by the U.S. Depart. of Health and Human Services guidance
for industry bioanalytical method validation. These measurements focusing on
identifying protein-bound and free Co(II) concentrations are likely to be more in-
formative with respect to understanding blood and tissue Co concentrations associ-
ated with adverse health effects in people with workplace Co exposures, dietary Co
supplement users, and patients with elevated Co blood levels due to cobalt-
chromium alloy prosthetic devices.
1169 Chronic Exposure to Particulate Chromate Induces
Persistent DNA Double-Strand Breaks in Human Lung
Cells.
Q. Qin1, 2, 3,  H. Xie1, 2, 3,  A. Holmes1, 2, 3,  S. Wise1, 2, 3 and J. Wise1, 2, 3. 1Wise
Laboratory of Environmental and Genetic Toxicology, University of Southern Maine,
Portland, ME; 2Maine Center for Toxicology and Environmental Health, University
of Southern Maine, Portland, ME; 3Department of Applied Medical Science,
University of Southern Maine, Portland, ME.
DNA double strand breaks (DSB) are one of the most deleterious lesions that are
induced by particulate chromate. If left unrepaired or misrepaired, DSB can cause
mutations or chromosomal aberrations leading to genomic instability. The aim of
this study is to determine the genotoxicity of particulate chromate and investigate
cellular responses of repair proteins after chronic exposure. We found chromate ex-
posure induced concentration-dependent increases in DSB and with longer expo-
sure time, the amount of breaks remained constant. To address whether this re-
flected a cycle of breakage and repair or deficient repair, we developed a human
lung cell line that stably express GFP-53BP1 and generated time-lapse videos of
chromate treated cells. 53BP1 forms discrete nuclear foci at sites of DSB. By mon-
itoring foci kinetics of these cells treated with chromate, we observed residual foci
after 24 h, indicating some breaks persist presumably due to deficient repair.
Therefore, we investigated the repair proteins involved in homologous recombina-
tion (HR) and non-homologous end joining (NHEJ) repair. We found that the nu-
clear fraction of phorphorylated ATM and Rad51 increased in 24 hours indicating
HR is active. However, it largely decreased over time. We also observed concentra-
tion- and time-dependent decrease in Rad51 foci formation, which confirms that
HR was inhibited. In contrast, protein expression of Ku80 and DNA-PKcs in-
creased during chronic exposure to chromate. These results suggest that there is a
signaling switch between HR and NHEJ during chronic exposure to chromate.
Future work will focus on identifying key proteins that regulate the transitions be-
tween two repair pathways. This work was supported by NIEHS grant ES016893
(J.P.W.) and the Maine Center for Toxicology and Environmental.
1170 Repeated Particulate Chromate Exposure Induces
Chromosome Instability, a DNA Double-Strand Break
Repair-Deficient Phenotype, and Neoplastic Transformation
in Human Lung Cells.
S. Wise1, 2, 3,  A. Holmes1, 2, 3,  H. Xie1, 2, 3,  W. Thompson2, 3 and J. Wise1, 2, 3.
1Wise Laboratory of Environmental and Genetic Toxicology, University of Southern
Maine, Portland, ME; 2Maine Center for Toxicology and Environmental Health,
University of Southern Maine, Portland, ME; 3Department of Applied Medical
Science, University of Southern Maine, Portland, ME.
One leading hypothesis for the carcinogenicity of hexavalent chromium (Cr(VI))
posits that Cr(VI) causes a DNA double strand break (DSB) repair deficiency
which leads to chromosome instability and neoplastic transformation. However, no
studies have been done to determine if Cr(VI) can cause DSB deficiency in human
lung cells. To begin to test this possibility, we exposed human lung cells to lead
chromate for three sequential 24 h periods, each separated by about a month. After
each treatment, cells were seeded at colony forming density, cloned, expanded and
retreated. Each generation of clones was tested for chromium sensitivity, chromo-
some complement, DNA repair capacity and ability to grow in soft agar. We found
that after the first treatment, lead chromate-treated cells exhibited a normal chro-
mosome complement though a few clones showed a repair deficient phenotype.
After the second exposure, more than half of the clones acquired an abnormal kary-
otype including numerical and structural alterations and many showed deficient
DNA DSB repair. The third treatment resulted in more abnormal clones, previ-
ously abnormal clones acquiring additional abnormalities, and most clones were re-
pair deficient. Further investigation revealed that some clones were unable to form
Rad51 foci in response to radiation, suggesting a defect in the homologous recom-
bination repair pathway. Finally, clones from the third generation were able to form
colonies in soft agar suggesting that the cells have neoplastically transformed. This
work was supported by NIEHS grant ES016893 (J.P.W.) and the Maine Center for
Toxicology and Environmental Health.
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1171 Fin Whale Cells Are More Resistant to Particulate Chromate
Cytotoxicity Than Human Cells.
C. Wise1, 2,  S. Wise1, 2, 3,  A. Holmes1, 2, 3 and J. Wise1, 2, 3. 1Wise Laboratory of
Environmental and Genetic Toxicology, University of Southern Maine, Portland, ME;
2Maine Center for Toxicology and Environmental Health, University of Southern
Maine, Portland, ME; 3Department of Applied Medical Science, University of
Southern Maine, Portland, ME.
Hexavalent chromium (Cr(VI)) is present in the marine environment and is a
known human carcinogen and skin irritant. Cr(VI) is the form of chromium that is
well absorbed through the cell membrane. It is also the most prevalent form in sea-
water. We compared the cytotoxicity of Cr(VI) in fin whale and human skin cells.
Our data show that particulate chromium is cytotoxic to human and fin whale cells
in a concentration-dependent manner. Specifically, data show that Cr(VI) is less cy-
totoxic to fin whale skin cells than human skin cells. For fin whale cells, we found
that concentrations of 0.1, 1.0, 5, 10 and 20 ug/cm2 lead chromate induced 91,
72, 55, 40 and 38 percent relative survival, respectively. In human cells we found
that concentrations of 0.1, 0.5, 1.0, 5 and 10 ug/cm2 lead chromate induced 64,
28, 10, 0 and 0 percent relative survival, respectively. These data indicate that fin
whale skin cells were 7.2 times more resistant to Cr(VI) than human skin cells.
When corrected for intracellular ion uptake fin whale skin cells remained more re-
sistant. We considered whether this effect was due solely to the chromate ion. Our
data show that soluble chromium was also cytotoxic to human and fin whale cells
in a concentration-dependent manner. They also indicate that fin whale skin cells
were more resistant to soluble Cr(VI) than human skin cells. However, these solu-
ble Cr(VI) differences were accounted for by intracellular ion uptake, which indi-
cates that the difference cytotoxic effects are due to something other than the
chromium ion by itself. Further investigations will look into the genotoxic effects of
hexavalent chromium on these two species. This research is supported by The
Environmental Protection Agency’s Undergraduate Research Opportunities
Fellowship (CFW), NIEHS grant ES016893 (JPW) and the Maine Center for
Toxicology and Environmental Health (JPW).
1172 Cellular Defense against Telomere Dysfunction Induced by
Hexavalent Chromium.
H. C. Pope-Varsalona,  F. Liu and P. L. Opresko. Environmental and Occupational
Health, University of Pittsburgh, Pittsburgh, PA.
Dysfunctional telomeres, the protective caps at chromosome ends, contribute to a
variety of pulmonary diseases. Our previous work established that DNA replication
stress induced by the environmental pollutant hexavalent chromium Cr(VI) causes
telomere loss and aberrations. Chronic inhalation of Cr(VI) leads to a variety of
lung diseases, including fibrosis, and cancers. Cr(VI) forms DNA lesions that im-
pede DNA replication and can cause collapse of the replication fork and chromoso-
mal breakage. Telomeres are fragile DNA sites prone to breakage during replication
stress. Cells have mechanisms for bypassing lesions that block replication forks
called translesion synthesis (TLS). We hypothesize that Cr(VI)-induced DNA
replication stress activates TLS DNA polymerase η (polη) that suppress Cr(VI)-in-
duced mutagenesis and telomere dysfunction. Our research is investigating several
endpoints of telomere dysfunction in human cells proficient and deficient in polη.
We observe that cells deficient in polη are 53 fold more sensitive to low levels of
Cr(VI) compared to isogenic controls. Using a combination of immunofluores-
cence and telomere fluorescence in situ hybridization (IF-teloFISH), quantification
of replication stress at genomic and telomeric DNA show a severely reduced recov-
ery from Cr(VI)-induced replication stress in cells lacking functional polη.
Moreover, we observe that Cr(VI) induces polη mobilization to stalled DNA repli-
cation sites at genomic and telomeric regions in human cells. Post Cr(VI) expo-
sures, we identify telomeric aberrations in senescent cells, a critical endpoint of
telomere dysfunction, by staining metaphase chromosomes with a fluorescent
telomeric probe using teloFISH. Currently, we are assessing cellular senescence
through various biomarkers. Our study attests to one mechanism by which Cr(VI)
directly interacts with the genome, alters telomere integrity, and the cellular path-
ways that protect telomeres in the face of genotoxic replication stress.
1173 Reactive Oxygen Species Regulate PI3K/AKT-Dependent
Activation of GSK-3β/β-Catenin and mTOR signaling in
Cr(VI)-Induced Carcinogenesis.
Y. Son,  J. Lee,  P. Poyil,  L. Wang and X. Shi. Graduate Center for Toxicology,
University of Kentucky, Lexington, KY.
Cr(VI) compounds are known human carcinogens that especially target lungs.
Reactive oxygen species (ROS) are well produced by Cr(VI), however, the relevance
of ROS and the underlying signaling pathways in Cr(VI)-induced carcinogenesis
remain to be elusive. The present study reports that chronic exposure of human
bronchial epithelial cells to Cr(VI) at the low nanomolar range (10 - 100 nM) for 2
months induced cell transformation, as evidenced by anchorage-independent
growth in soft agar and clonogenic assays. Chronic Cr(VI) treatment also increased
the potential of these cells to invade and migrate. Injection of Cr(VI)-stimulated
cells into nude mice resulted in the formation of tumors. In contrast, the Cr(VI)-
mediated increases in colony formation, cell invasion, migration, and xenograft tu-
mors were prevented by transfection with catalase, superoxide dismutase-1
(SOD1), or SOD2. In particular, chronic Cr(VI) exposure led to activation of sig-
naling cascades involving PI3K/ AKT/GSK-3β/β-catenin, and PI3K/ AKT/mTOR
and transfection with each of the above antioxidant enzymes markedly inhibited
Cr(VI)-mediated activation of these signaling proteins. Inhibitors specific for AKT
or β-catenin almost completely suppressed the Cr(VI)-mediated increase in total
and active β-catenin proteins and colony formation. In addition, Cr(VI) inhibited
autophagy under nutrition deprivation condition. Moreover, there was a marked
induction of AKT, GSK-3β, β-catenin, mTOR, and carcinogenic markers in tumor
tissues formed in mice after injection with Cr(VI)-stimulated cells. Collectively, our
findings suggest that ROS is a key mediator of Cr(VI)-induced carcinogenesis, and
it activates PI3K/AKT dependent GSK-3β/β-catenin and inhibits autophagy
through upregulation of mTOR signaling in this process.
1174 Instability of Metallothionein Inhibits Mitochondrial
Activities following Exposure to Silver Nitrate in Human
Bronchial Epithelial Cells.
T. Miyayama1,  Y. Arai2,  N. Suzuki2 and S. Hirano1, 2. 1Risk Center for
Environmental Risk, National Institute for Environmental Studies, Tsukuba, Japan;
2Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan.
Silver (Ag) has been reported to generate reactive oxygen species (ROS) and to bind
sulfhydryl groups in metabolic enzymes and non-enzymatic proteins such as metal-
lothionein (MT). In the present study, we assessed toxicity of AgNO3 in human
bronchial epithelial cells (BEAS-2B) focusing on the intracellular Ag distribution
and ROS production. The cells were exposed to 0 - 100 μmol/l AgNO3 for 0 - 24
h and cytotoxicity was assayed with a modified MTT method. The cell viability was
decreased by AgNO3 in a dose-dependent manner (IC50 = 2.5 μmol/l).
Concentration of Ag in culture media decreased with time and stabilized at 12 h
after exposure. Concentrations of Ag and Ag-bound MT in the soluble fraction of
cells were sharply increased up to 3 h and then decreased, indicating that cytosolic
Ag relocated to the insoluble fraction of cells shortly after Ag exposure. mRNA lev-
els of major human MT isoforms, MT-IA and MT-IIA, paralleled concentrations of
Ag, Cu and Zn-MT. The ROS-derived fluorescence intensity appeared to be ele-
vated at mitochondria after treatment of the cells with Ag. To evaluate effects of Ag
on mitochondrial respiration and activities of electron transport chain complex,
mitochondria were obtained from rat liver tissues. The electron transport activities
of all mitochondrial complexes (I to IV) were inhibited by Ag. We observed that a
concentration of cytosolic H2O2 was increased up to 11.6 pmol per 1.0 x 10
4 cells.
Ag as well as Cu and Zn were released from isolated MT by H2O2 at concentrations
as low as 0.001%. In conclusion, exposure to Ag increased MT synthesis and Ag
was sequestered immediately by MT. 3 h after exposure, MT was decomposed by
cytosolic H2O2. Ag released from MT relocated to insoluble cellular fractions and
inhibited electron chain transfer of mitochondrial complexes, which eventually led
to cell damage.
1175 Development and Optimization of a Procedure for the
Determination of Indium-Tin Oxide Particle Size and
Concentration in Cellular Media.
K. Levine1,  L. Han1,  W. M. Gwinn2,  D. L. Morgan2,  A. S. Essader1,
R. A. Fernando1,  C. S. Smith2 and V. G. Robinson2. 1RTI International, Research
Triangle Park, NC; 2Division of National Toxicology Program, NIEHS, Research
Triangle Park, NC.
Indium-tin oxide (ITO) is a solid mixture often comprised of approximately 90%
indium oxide (In2O3) and 10% tin oxide (SnO2) by weight. ITO is employed as a
transparent conductive coating for flat panel, liquid crystal, and plasma displays
and is typically deposited after sintering as a thin film on the desired substrate
through a variety of technologies. Fatal cases of interstitial pneumonia and alveolar
proteinosis have been reported for workers exposed to ITO particles. In vitro stud-
ies of ITO are planned in order to better understand the toxicity of this compound. 
Comprehensive characterization of ITO test materials is required prior to toxicity
testing. Characterization of ITO particle size under the conditions of laboratory
testing is important because this physicochemical parameter can significantly im-
pact bioavailability and cellular toxicity. 
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In these studies we developed, optimized, and applied a dynamic light scattering
(DLS) sample preparation and measurement protocol for determining hydrody-
namic particle size in a suite of sintered/non-sintered ITO samples. ITO samples
were prepared in cellular growth media at doses ranging from 0.3 – 0.4 mg/mL.
Sonication times of particle suspensions were evaluated from 15 – 90 minutes.
Times ranging from 30 – 60 minutes yielded the most stable suspensions with re-
spect to hydrodynamic particle size over a 24-hour period. Resulting suspensions
from samples with 30 – 60 minute sonication times were stable for 10 – 24 hours
after sonication, with respect to hydrodynamic particle size. Throughout the 24-
hour DLS measurement period, suspensions were analyzed for indium content by
inductively coupled plasma mass spectrometry (ICP-MS) to confirm ITO concen-
trations. The developed protocol enabled investigators to use ITO suspensions of
known particle size and concentration in their in vitro cellular studies.
1176 Tungsten Exposure Increases Lung Metastases in an
Orthotopic Murine Breast Cancer Model.
A. M. Bolt2, 1,  V. Sabourin2, 1,  J. Janiak2, 1,  A. Kelly2, 1,  G. Ursini-Siegel2, 1 and
K. K. Mann2, 1. 1McGill University, Montréal, QC, Canada; 2The Lady Davis
Institute for Medical Research, Montréal, QC, Canada.
Tungsten is a strong, flexible metal that until recently had been thought to be an
“inert” metal. These properties led to its incorporation into the manufacturing of
medical devices. In a recent clinical trial, a tungsten-based shield was used in the
treatment of breast cancer patients undergoing intraoperative radiotherapy.
Following the procedure, the women were left with residual tungsten in their
breasts. Elevated tungsten levels in the blood and urine indicate that tungsten is not
remaining in the breast tissue. Tungsten was detected in the urine of patient even 8
months after mastectomy, indicating another reservoir has been created. Based on
previous data, we hypothesize this reservoir to be the bone. Animal studies suggest
that tungsten may contribute to carcinogenesis and can alter development and in-
crease DNA damage in the immune system. In order to evaluate the effect of tung-
sten on breast cancer, female Balb/C mice were exposed to 15 ppm of sodium
tungstate for 1 month followed by injection of 66cl4 cancer cells into the mam-
mary fat pad. The size of primary tumor, the extent of lung metastases and immune
parameters were evaluated. Tungsten did not alter the growth of the primary tumor.
However, the number and average size of lung metastases was significantly greater
in the tungsten-exposed animals. This model is not known to metastasize to the
bone, but we found that tumor-bearing mice had 3-fold more tungsten in the bone
than non-tumor bearing mice. Tungsten increased the peripheral blood leukocyte
count in non-tumor bearing mice, but decreased the massive granulocytosis associ-
ated with tumor growth. These data suggest that tungsten increases the extent of
breast cancer metastasis to the lung, which could have a significant impact on indi-
viduals who have cancer and are also exposed to tungsten. The levels of tungsten
deposition within the bone and immune cell parameters were also altered, which
could also impact metastasis in this model.
1177 Genetic Variation of Iron Metabolism in Mice.
K. E. Page1,  D. W. Killilea2,  E. Eskin3,  A. J. Lusis3 and C. Vulpe1. 1Nutritional
Sciences and Toxicology, University of Berkeley, Berkeley, CA; 2Children’s Hospital
Oakland Research Institute, Oakland, CA; 3David Geffen School of Medicine,
University of California Los Angeles, Los Angeles, CA.
Iron deficiency is the most common disease in the world with an estimated 4-5 bil-
lion affected persons. Debilitating fatigue, altered immune function, decreased
work capacity and anemia are among the deleterious consequences of this pervasive
disorder. Similarly, liver iron overload is a significant health concern. Multiple ge-
netic disorders of iron metabolism in man, rodents and other vertebrates suggest
multiple loci can contribute to the susceptibility of iron deficiency and severity of
iron overload. Previous studies have shown genetic variation in iron metabolism be-
tween inbred strains of mice. We hypothesize that this genetic variation underlies
the differences seen in iron metabolism between inbred mice. Our aim is to map
the quantitative trait loci responsible for the strain specific differences in iron me-
tabolism. To do this we will use high resolution SNP analysis to “in silico” map the
genetic loci responsible for the divergent iron related phenotypes using the hybrid
mouse diversity panel (HMDP) [1]. Here we show the phenotypic analysis of the
variation in iron metabolism for these mice, and how the overall elemental profiles
change for each strain.
References
1. Bennett BJ, Farber CR, Orozco L, Min Kang H, Ghazalpour A, et al. (2010) A
high-resolution association mapping panel for the dissection of complex traits in
mice. Genome Research 20: 281-290.
1178 ICP-MS Determination of Tissue Iron Levels in the Rat.
J. Bouchard1,  C. Sabadie1,  J. Decorde1,  L. Jaillet1,  P. Elford2 and R. Forster1.
1CiToxLAB, Evreux, France; 2Azad Pharmaceuticals, Bern, Switzerland.
Iron is an essential trace element associated with toxicities when present in excess, as
for example in conditions such as heterochromatosis. We have developed and vali-
dated a reliable and rapid quantitative method for the exploration of endogenous
levels of total iron in rat plasma, heart, liver, spleen, kidney, stomach, lung and
bone marrow. The analysis by ICP-MS (Inductively Coupled Plasma Mass
Spectrometry) was selected among all other techniques, because of its easy handling
of simple or complex matrices requiring very little sample preparation. The method
was evaluated for accuracy, precision, linearity, matrix effect and instability derived
from adsorption on container walls. Precision and accuracy for all matrices ranged
from >4.3% to <7.9% and >1.5% to <12.2% respectively. Matrix effect was negli-
gible and the assays for the evaluation of instability showed no adsorption of iron
on container walls, either in glass, polypropylene or polyethylene. Iron levels were
determined over a 28-day period, on 145 rats aged 7 to 8 weeks at the beginning of
the study. In general a low to moderate inter-animal variability of endogenous iron
levels was observed. The levels of total iron in plasma, heart, liver, stomach and
bone marrow were stable over time with concentrations <5000 ng/mL in plasma
and <18.0 μg/g (heart), <70.0 μg/g (liver), <8.00 μg/g (stomach), <140 μg/g (bone
marrow) respectively. In spleen and kidney, the concentrations increased over time,
from <80.0 μg/g to <400 μg/g in spleen and <15.0 μg/g to <30.0 μg/g in kidney
and this was attributed to the ageing of the animals. A moderate to marked inter-
animal variability was observed in lung, ranging from 5.00 μg/g to 40.0 μg/g. In
conclusion, a reliable and rapid quantitative ICP-MS method was used to deter-
mine endogenous levels of total iron in rat plasma and tissues. This method can
readily be adapted for the study of endogenous iron levels in other laboratory ani-
mal species.
1179 Development of a Transportable Neutron Activation Analysis
System to Quantify Manganese in Bone In Vivo—Feasibility
and Methodology.
Y. Liu1,  D. S. Koltick2,  P. Byrne1, 3,  W. Zheng1 and L. Nie1. 1Health Sciences,
Purdue University, West Lafayette, IN; 2Physics, Purdue University, West Lafayette,
IN; 3Medical Physics Consultants, Indianapolis, IN.
Manganese (Mn) is a vital element in human body for growth and other functions.
However, overdose to Mn compounds can lead to many adverse health effects. An
important issue in assessing Mn exposure is to select a proper biomarker. Over 40%
of Mn in human body is stored in bone and bone Mn represents long term chronic
Mn exposures. Hence it is attractive to develop a technology to quantify the con-
centration of Mn in human bones. In vivo neutron activation analysis (IVNAA) is a
promising non-invasive technique which can determine the concentrations of vari-
ous elements in the human body. In our study, we investigated the possibility and
feasibility of developing a transportable IVNAA system for Mn quantification in
hand bone by Monte Carlo (MC) simulations using a portable deuterium-deu-
terium (DD) neutron generator as neutron source. Experiments were conducted
with a deuterium-tritium (DT) generator available in our lab to validate the MC
simulation results. The count rates calculated from MC simulations were in agree-
ment with those obtained from the experiments for the DT generator system setup.
Different types of moderator and reflector for DD setups were simulated and paraf-
fin was selected as the best material for both of the moderator and reflector. Then
the optimal thicknesses for the reflector and moderator were determined. Assuming
normal concentration of Mn in bone is about 1 μg/g and neutron yield is
4×108/sec, the count rate is 0.324 counts/sec if we use a 4π NaI detector with
100% efficiency. The corresponding dose to the hand for 10 minutes irradiation
time is about 43.704 mSv from MC simulation, which corresponds to about 48.64
μSv total body equivalent dose. In conclusion, it is feasible to develop a trans-
portable NAA system to quantify Mn in bone in vivo with a minimum radiation
dose exposure to the subject.
1180 Relative and Absolute Quantification of Metallothionein
Isoforms in Human Kidney Cells Using Stable Isotope
Labeling of Cysteines and MALDI-TOF/TOF Mass
Spectrometry.
A. Mehus1, 2,  J. B. Shabb2,  W. W. Muhonen2,  S. H. Garrett1,  S. Somji1,
M. Sens1 and D. A. Sens1. 1Pathology, University of North Dakota, Grand Forks,
ND; 2Biochemistry, University of North Dakota, Grand Forks, ND.
Human metallothioneins (MTs) are known to chelate the naturally accumulated
heavy metal pollutant cadmium in the renal cortex and their expression has been
shown to be altered in different types of cancers. The current study was initiated to
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develop analytical means to measure each isoform of this diverse protein family.
The twelve human MT isoforms share 70 to 90% amino acid sequence identity
which hampers antibody-based methods of isoform-specific quantification at the
protein level. Trypsin digestion yields an N-terminal MT peptide that has a unique
mass for each MT isoform. Each of these peptides contains five Cys residues, is N-
terminally acetylated, and once alkylated is relatively hydrophilic.
The human kidney HK-2 epithelial cell line expressing stably transfected MT-3 was
used as a model system. Cytosol was prepared from control cells and cells exposed
to 9 μM cadmium for 3 days. The cytosol was then denatured with urea, reduced
with DTT, and alkylated with either 14N- or 15N- iodoacetamide. For absolute
quantification, ~145 pmols of MT isoform-specific 15N-labeled N-terminal acety-
lated peptides was added to the samples.  The light and heavy-labeled samples were
combined and digested with trypsin. Strong cation exchange (SCX) and C18 re-
verse-phase liquid chromatography (rp-HPLC) successively enriched the N-termi-
nal MT peptides followed by MALDI-TOF/TOF MS and MS/MS. The ratio of
light (control) vs. heavy (induced) MT peak intensities were calculated for each
MT isoform detectable in both the control and Cd-induced samples. Seven MT
isoforms were detected and quantified in the HK-2 MT-3 cells. MT-1F showed the
largest induction (10-fold) from 9 μM Cd treatment. Metallothionein 3 was in-
duced 2-fold.  This study describes an iodoacetamide stable isotope-labeling mass
spectrometry-based method for simultaneous relative and absolute quantification
of human metallothionein isoforms.
1181 Identification of Metallothionein-3 Interacting Proteins in
the Human Proximal Tubule Cells.
A. Slusser1, 2,  C. Bathula1,  J. R. Dunlevy1,  J. B. Shabb2,  D. A. Sens1,  S. Somji1
and S. H. Garrett1. 1Pathology, University of North Dakota, Grand Forks, ND;
2Biochemistry, University of North Dakota, Grand Forks, ND.
Metallothionein 3 (MT-3) is a small, cysteine-rich protein that binds to essential
metal ions required for normal cellular processes, as well as heavy metals that have
the potential to exert toxic effects on cells. MT-3 is expressed by epithelial cells of
the human kidney, including the cells of the proximal tubule. This laboratory has
previously shown that the mortal cultures of human proximal tubule (HPT) cells
express MT-3 and could form domes in the cell monolayer, a morphological feature
indicative of vectorial active transport. However the immortalized proximal tubular
cell line HK-2 lacked the expression of MT-3 and failed to form domes.
Transfection of the HK-2 cells with the MT-3 gene restored dome formation in the
cells suggesting that MT-3 may have a role in vectorial active transport. Recent in
vivo and in vitro studies have reported that MT-3 is interacting with other proteins
and these interactions are thought to be playing an important role in execution of
some of its functions. Thus the goal of this study was to identify the binding part-
ners of MT-3, which would allow us to understand the mechanism through which
MT-3 is regulating vectorial active transport and cell differentiation in HPT cells.
For this purpose cell extracts were prepared using the immortalized human proxi-
mal tubule cell line HK-2. MT-3 pull-down experiments were performed followed
by SDS-PAGE and mass spectrometry analysis. Data analysis revealed an interac-
tion between MT-3 and myosin 9, gelsolin, beta-actin, and tropomyosin 3.
Immunofluorescence studies further confirmed that MT-3 co-localizes with these
proteins. These studies demonstrate that MT-3 is interacting with proteins that are
involved in cytoskeleton reorganization of the cell and thereby regulating vectorial
active transport and cell differentiation.
1182 The Unique N and C-Terminal Domains of Metallothionein-
3 Influence the Growth and Differentiation of MCF-7 Breast
Cancer Cells.
B. Voels,  D. A. Sens,  S. H. Garrett and S. Somji. Pathology, University of North
Dakota, Grand Forks, ND.
Toxic insult from the heavy metal cadmium (Cd2+) is known to induce the expres-
sion metallothioneins (MT) which are heavy metal binding proteins. Previous work
from our laboratory has shown that over-expression of MT-3 in breast cancers is as-
sociated with poor patient outcome. Furthermore, MT-3 has shown to inhibit the
growth of breast cancer and prostate cancer cell lines. Studies have shown that the
MT-3 protein contains 7 additional amino acids that are not present in any other
member of the MT gene family, a 6 amino acid C-terminal sequence and a Thr in
the N-terminal region. The unique N-terminal sequence is responsible for the
growth inhibitory activity of MT-3 in the neuronal system. The goal of this study
was to characterize the function of the N and C-terminal domains of MT-3 in the
breast cancer cell line, MCF-7. For this purpose six different constructs of MTs
were prepared which were as follows: wild type (WT) MT-3, MT-3 N-terminal
deletion (MT-3 NT), MT-3 C-terminal deletion (MT-3 CT), WT MT-1E, and
MT-1E mutated to contain the N -terminal of MT-3 or the C-terminal or both the
N- and the C-terminal of MT-3. Each of these constructs was transfected into
MCF-7 cells and the growth rates and the transepithelial resistance (TER) was
measured. The data obtained suggests that the N-terminal region of MT-3 is in-
volved in growth inhibitory activity whereas the C-terminal region is involved in
vectorial active transport which is indicated by the formation of domes in cell cul-
ture and an increase in TER. In conclusion, this study further characterizes the
unique properties of the N- and the C-terminal domain of MT-3 and the potential
role that it may play in the differentiation of certain breast cancers.
1183 Fluoride, Aluminum, and Mixtures: Histological Changes in
the Liver of Mouse, Mus norvegicus albinus.
A. Vijaya Bhaskara Rao. Ecology and Environmental Sciences, Pondicherry
University, Puducherry, India. Sponsor: I. Rusyn.
Fluoride is one of the chemical contaminants of water causing several health prob-
lems in man and animals. Aluminum is one of the most abundant metals in the en-
vironment. Although aluminum has been historically considered as a non toxic
metal, which is toxic in its trivalent (Al+) form. Earlier studies exhibited fluorosis
and aluminosis when fluoride and aluminum exposed individually. However, it is
important to study two different toxicants in combination to know whether they
can act as synergistic or antagonistic. In this study the toxic effects exerted by the
accumulation of fluoride, aluminum and their mixtures were studied in the liver of
mice. Six different doses were tested for a period of 30 days and 60 days for their
toxic effect in the liver. Microscopic study of liver tissue revealed interesting patho-
logical changes in all the fluoride treated mice. The damage to the tissue was dose-
and time dependent. The aluminum treated mice showed conspicuous histopatho-
logical changes in higher dose, which was more significant with the increase in
period of exposure. Whereas, the histopathological changes, were not much con-
spicuous in lower dose groups, and also decreased with period of exposure. In the
mixture of fluoride and aluminum treated mice, mild to severe changes were ob-
served in the higher dose of fluoride with aluminum, whereas very mild and in-
significant changes were observed in the mice exposed to lower dose of fluoride
with aluminum.
1184 Both the Metal Moiety and the Organic Backbone of
Ethylene Bisdithocarbamate Fungicides Maneb and
Mancozeb Contribute to Toxicity in Human Colon Cells.
L. Hoffman and D. Hardej. Pharmaceutical Sciences, St. John’s University, Queens,
NY.
Ethylene bisdithiocarbamate (EBDC) pesticides are used primarily as broad range
contact fungicides on a wide variety of crops. A subset of the metal containing
EBDC pesticides include Maneb (MB), Mancozeb (MZ), and Zineb (ZB), which
are complexed with the transition metals manganese, zinc, or in the case of MZ,
both manganese and zinc. While these agents are reported to possess low human
toxicity, previous testing in our laboratory has established the toxicity of these com-
pounds to transformed colon cells, HT-29 and Caco2, and to normal colon cells,
CCD-18Co. Significant decreases in viability were observed with MB and MZ in
HT-29 and CCD-18Co (80-260μM), and Caco2 cells (40-180μM). ZB exposure
however, produced no significant decrease in cell viability in all cell types up to
800μM. Therefore, the purpose of this study was to determine if the metal moieties
of MB and MZ contributes to the generation of toxicity. To determine if the man-
ganese and zinc can accumulate within HT-29 and Caco2 cells and initiate toxicity,
inductively coupled plasma-optical emission spectroscopy was performed. MB ex-
posure resulted in a dose dependent increase in intracellular manganese levels
within HT-29 and Caco2 cells (20-200μM). MZ exposure also resulted in a signif-
icant accumulation of zinc within HT-29 and Caco2 cells (40-200μM). To investi-
gate whether manganese and/or zinc was a critical factor in the cytotoxic process,
HT-29, Caco2, and CCD-18Co cells were treated with manganese chloride
(MnCl2) and zinc chloride (ZnCl2). MnCl2 and ZnCl2 exposure produced no sig-
nificant loss of viability in all cell types up to 400μM. The lack of toxicity observed
following treatment with ZB within the same concentration range as MB and MZ
suggests that the manganese portion of these agents may play a key role in generat-
ing the effects seen upon exposure. However, the lack of differences in the cytotox-
icity of MnCl2 and ZnCl2 treated cells indicates that the EBDC backbone may act
in conjunction with the metal moiety to cause toxicity.
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1185 Signalling Pathways and Oxidative Stress Involved in Metal-
Induced Cytokine Responses in Human Epithelial Lung
Cells.
M. Låg,  J. Øvrevik,  E. M. Lilleaas,  A. Thormodsæter,  A. I. Totlandsdal,
J. A. Holme,  P. E. Schwarze and M. A. Refsnes. Department of Air Pollution and
Noise, Norwegian Institute of Public Health, Oslo, Norway. Sponsor: M. Løvik.
Inhalation of metals is associated with development and aggravation of lung and
cardiovascular diseases, and inflammation is considered to be a central pathological
mechanism. In this study we have investigated expression of inflammation-related
genes in human bronchial epithelial cells (BEAS-2B) exposed to cadmium (Cd),
zinc (Zn), arsenic (As), vanadium (V), manganese (Mn) and nickel (Ni), metals
often found in polluted air. As measured by real-time PCR array, Cd, Zn and As in-
duced cytokine expression patterns differing from V, Mn and Ni, with higher levels
of CXCL8, CXCL5, IL-6 and CCL26. Furthermore, Cd, Zn and As, but not V,
Mn and Ni, induced increased levels of 1-heme oxygenase indicative of oxidative
stress. Thus, the mechanisms of Cd-, Zn- and As-induced cytokine responses were
investigated further. In line with the gene-expression data, Cd, Zn and As also in-
duced high levels of CXCL8 and IL-6 protein-release, and addition of antioxidants
reduced the metal-induced cytokine responses. Moreover, the metals activated the
mitogen activated protein kinases (MAPK) p38, JNK and ERK and the p65 sub-
unit of NF-kB, measured as protein-phosphorylation by Western blotting after 2
and 4 hr. Use of MAPK-inhibitors and siRNAs against p65 revealed that these sig-
nalling pathways were involved in the cytokine responses. The p38 pathway seemed
most important for both IL-6 and CXCL8 release induced by all three metals,
whereas JNK seemed to be mainly involved in As-induced CXCL8 and ERK in As-
induced IL-6 and CXCL8 releases. In conclusion, among the tested metals Cd, Zn,
As were potent inducers of inflammatory responses and oxidative stress in epithelial
lung cells. NF-κB and p38 signalling seemed central to metal-induced IL-6 and
CXCL8 responses, whereas the relative involvement of JNK and ERK differed de-
pending on the metal and cytokine.
1186 Development of an Immortalized Urothelial Cell Line to
Study Metal-Induced Bladder Carcinogenesis.
A. Holmes1, 2, 3,  M. Hebert1, 2,  C. Case4 and J. Wise1, 2, 3. 1Wise Laboratory of
Environmental and Genetic Toxicology, University of Southern Maine, Portland, ME;
2Maine Center for Toxicology and Environmental Health, University of Southern
Maine, University of Southern Maine, Portland, ME; 3Department of Applied
Medical Science, University of Southern Maine, University of Southern Maine,
Portland, ME; 4Musculoskeletal Research Unit, University of Bristol, Bristol, United
Kingdom.
Numerous metals are well-known human bladder carcinogens. Despite the signifi-
cant occupational and public health concern of metals and bladder cancer, the car-
cinogenic mechanisms remain largely unknown. In order to fully understand how
metals transform a normal urothelial cell into a cancerous cell, it is important to
study the process in a normal human urothelial cell line. Primary urothelial cells are
insufficient for this purpose because of their very short lifespan, but currently, the
effects of metals in a near-normal urothelial cell line with an extended lifespan are
unknown. The objective of this study was to characterize chromate toxicity in pri-
mary human urothelial cells and to determine if an hTERT-immortalized human
urothelial cell line exhibited a similar response to metals as primary cells.
Hexavalent chromium (Cr(VI)) induced a concentration- and time-dependent in-
crease in chromosome damage with the hTERT-immortalized cells exhibiting more
chromosome damage than the primary cells. Chronic exposure to Cr(VI) also in-
duced a concentration-dependent increase in aneuploid metaphases in both cell
lines which was not observed after a 24 h exposure. Aneuploidy induction was
higher in the hTERT-immortalized cells. When we correct for uptake, Cr(VI) in-
duces a similar amount of chromosome damage and aneuploidy suggesting that the
differences in Cr(VI) sensitivity between the two cells lines was due to differences in
uptake. Therefore, the hTERT-immortalized cell line had a similar response to met-
als and will be a good tool for studying metal-induced bladder carcinogenesis. This
work was supported by NIEHS grant ES016893 (J.P.W.) and the Maine Center for
Toxicology and Environmental Health.
1187 Metallothionein Transcriptional Regulation, Aging, and the
Insulin Signaling Pathway.
J. Hall1,  M. McElwee2 and J. H. Freedman1, 2. 1BSB, DNTP, NIEHS, Research
Triangle Park, NC; 2LTP, NIEHS, Research Triangle Park, NC.
Metallothioneins (MTs) are highly conserved, cysteine-rich metal-binding proteins
that function in metal homeostasis and detoxification, as well as free-radical scav-
enging. To better understand the role of MT in cadmium-associated cellular re-
sponses, regulatory factors and pathways that control the expression of the C. ele-
gans MT gene, mtl-1, were identified through genetic screens. A mutagenesis screen
identified a mutant, JF99 that harbored a mutation affecting atf-7, a negative tran-
scription factor involved in the JNK/p38 pathway. In both JF99 and an atf-7 dele-
tion mutant, steady-state mtl-1 mRNA levels were identical but significantly greater
than levels in wild type nematodes in the absence of cadmium. In addition to atf-7,
mutations in pmk-1 caused a decrease in mtl-1 expression, suggesting that PMK-1
regulated ATF-7 activity. A candidate gene screen identified three insulin signaling
pathway genes (PDK-1 and the AKT-1/AKT-2 complex) that functioned inde-
pendently of this pathway. Further genetic analysis confirmed that these genes act
upstream of PMK-1 and ATF-7 to regulate mtl-1 transcription. Based on our ge-
netic pathway data and previous work, we propose that ATF-7 resides on the pro-
moter region of mtl-1 to inhibit the constitutively active transcription factor ELT-2,
which is important for intestinal cell specific transcription. In the presence of cad-
mium, upstream factors signal PDK-1 and the AKT-1/2 complex to phosphorylate
PMK-1 causing it to translocate to the nucleus and phosphorylate ATF-7, allowing
ELT-2 to initiate transcription. The activation of this pathway results in an increase
in MT, which scavenges cadmium and free radicals. In mammalian cells, knock-
down of PDK1 and ATF7 resulted in changes in MT-1 expression, suggesting that
this pathway was not unique to C. elegans. The insulin signaling pathway affects the
aging process, thus an association between cadmium exposure and the activation of
portions of the insulin signaling pathway provides a mechanistic link between
metal homeostasis, ROS and aging.
1188 Metal-Regulatory Transcription Factor-1 Regulates Metal-
Responsive Transcription of Fosl1.
E. Braithwaite and J. H. Freedman. NIEHS, Research Triangle Park, NC.
The transcription factor fos related antigen-1 (fosl1) is an AP-1 protein whose ex-
pression is often elevated in tumors and transformed cells. Previous studies show
that fosl1 is transcriptionally regulated through the activity of the fos transcription
factor and the MAPK pathway. In addition, fosl1 is induced after exposure to cad-
mium; however, the mechanism by which this induction occurs has not been eluci-
dated. Metals, such as cadmium, are able to induce the expression of a wide variety
of genes though the activation of metal-regulatory transcription factor 1 (MTF-1).
Upon activation, MTF-1 translocates to the nucleus and binds to metal responsive
elements (MREs) in the promoters of metal-inducible genes. To determine if MTF-
1 participates in cadmium-inducible fosl1 regulation, a five kilobase region up-
stream of the transcription start site and the coding region of fosl1 were analyzed
for MRE sequences. Seven MREs were identified and chromatin immunoprecipita-
tion (ChIP) analysis performed to determine if MTF-1 had the ability to bind the
fosl1 promoter after metal exposure. ChIP assays showed that MTF-1 localized to
the fosl1 promoter and bound each MRE sequence to varying degrees. To assess the
biological impact of this binding, MTF-1 null (dko7) cells and dko7 cells trans-
duced with MTF-1 (dko7 + MTF-1) were exposed to cadmium and RNA was iso-
lated at various time periods to evaluate steady state mRNA levels of fosl1 by real-
time PCR (RT-PCR). These studies showed a biphasic increase in fosl1 mRNA in
dko7 + MTF-1 cells up to 12 hours after exposure to 5 μM cadmium after which
the mRNA levels declined to background levels at 24 h. In contrast, dko7 cells
showed a steady increase in fosl1 mRNA accumulation for the duration of the study.
These data suggest that MTF-1 is recruited to the fosl1 promoter and may be a neg-
ative regulator of fosl1 mRNA expression.
1189 Visualization of Reactive Oxygen Species (ROS) Using High-
Content Image Analysis (HCA) in Undifferentiated Human
Embryonic Stem Cells Exposed to Methyl Parathion (MP).
J. S. Madren-Whalley and J. W. Sekowski. ECBC, US Army RDECOM,
Gunpowder, MD.
Organophosphate (OP) pesticides represent a threat to soldiers, first responders and
other civilians since they are highly toxic and widely accessible chemicals used in
crop, industrial, and home applications. However, for many OP pesticides such as
MP, there is incomplete toxicological data in humans. Most of the reports are epi-
demiological studies, adult and juvenile animal studies, or in vitro studies using
transformed cell lines. Since undifferentiated human embryonic stem cells (hESC)
maintain the ability to differentiate into any somatic cell in the body, they offer a
unique vantage point to measure the effect of toxicants on the very early human de-
velopment and cell repair system. 
From our earlier metabolomics work examining the secretome of hESCs following
exposure to MP, we hypothesized that ROS is generated during the toxic response
to MP. In this follow-on work, we chose to visualize and quantitate: 1) the presence
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and location of ROS, and 2) cell and nuclear morphology in MP-exposed WA09
hESC using the Cellomics Oxidative Stress I Assay on a Thermo Scientific
Cellomics® ArrayScan® HCA System.
While low levels of oxidative stress are necessary for normal cell metabolism, high
levels are associated with cellular dysregulation and pathologies such as cancer. As
expected, our imaging data indicated that the cells did not change structurally, nor
did they undergo senescence or apoptosis in response to the MP exposures we ex-
amined. While we were able to measure cellular oxidative stress (fluorescent conver-
sion of dihydroethidium, DHE), the amount measured in the nuclei was much less
than we had predicted. All other DHE was scattered and punctuate throughout the
cell. These data, combined with other studies suggesting that hESC lose their ro-
bust ROS nuclear protection mechanism as they become more differentiated, opens
up a new avenue of investigation to define the point in embryonic differentiation
when cells become more vulnerable to the ROS-induced toxic effects of MP.
1190 Pluripotency Factors Silence Expression of the Aryl
Hydrocarbon Receptor in Embryonic Stem Cells.
C. Ko,  Q. Wang and A. Puga. Environmental Health, University of Cincinnati,
Cincinnati, OH.
OCT4, SOX2, and NANOG are transcription factors that maintain pluripotency
and self-renewal of embryonic stem cells (ESC) in culture: on the one hand, they
activate expression of self-renewal genes, and on the other hand they prevent differ-
entiation by silencing the expression of developmental genes. Unlike DNA methy-
lation, polycomb group (PcG) proteins are chromatin modulators that repress the
expression of developmently important genes, such as those in the Hox family.
PcG-mediated repression represents a plastic and dynamic way to keep genes poised
to be reactivated during development. Promoters of developmental genes in ESC
are often bivalently marked by trimethylation on lysine-4 (H3K4me3) and lysine-
27 (H3K27me3) of histone H3, with PcG-mediated repression allowing these
genes to be ready for reactivation upon differentiation. The aryl hydrocarbon re-
ceptor (AHR) has long been believed to mediate xenobiotic toxicity; increasing ev-
idence suggests that it also plays a role during embryogenesis. To study AHR func-
tions during early development, we have analyzed the regulation of AHR
expression in C57Bl/6 mouse ESC and their in vitro differentiated progeny. In
ESC, Ahr expression is silenced through bivalent marks in its promoter. Specifically,
H3K27 is trimethylated in both distal and proximal promoter regions (dpr and
ppr) and H3K4 is trimethylated in the ppr. We also detect the specific binding of
pluripotency factors and PcG proteins in the dpr. RNA polymerase II appears to be
paused in the ppr, producing short aborted Ahr transcripts. Upon differentiation,
the Ahr promoter resolves into a H3K4me3 monovalent state and recruits Sp fac-
tors, leading to transcription activation. These results define an ESC-specific si-
lencer domain located 2kb upstream of the Ahr gene transcription start site, re-
sponsible for the low, if any, Ahr expression in ES cells. Directed silencing, resulting
from cooperation between pluripotency and PcG-repressive factors suggests that
the Ahr may play a significant role in maintenance of pluripotency. Supported by
NIH Grant 5R01ES06273
1191 Hypersensitivity of Stem Cells and Cancer Stem Cells to
Cadmium Toxicity.
E. J. Tokar,  M. Rogers and M. P. Waalkes. NTP, NIEHS, NIH, Research Triangle
Park, NC.
Stem cells (SCs) generally are resistant to toxicants compared to mature cellular
counterparts. Normal SCs (NSCs) can be malignantly transformed to cancer SCs
(CSCs) which then likely drive the carcinogenic process. Cadmium (Cd), a known
human carcinogen, can also be an effective anti-tumor agent in rodents, selectively
destroying advanced tumors but leaving normal tissue intact, implying cancer cell
sensitivity. CSCs likely are key to cancer maintenance, propagation, metastasis and
repopulation. Thus, to help explain this paradox with Cd, we examined the effects
of Cd on the human prostate NSC line, WPE-stem, and its isogenic mature
parental cell line (PCL), RWPE-1, and a malignant CSC transformant from NSCs,
As-CSC. The untransformed lines had similar LC50 values (NSC = 12.2 μM; PCL
= 13.9 μM). However, the NSCs were much more sensitive to sub-chronic Cd ex-
posure (90% cell loss at 1 week) compared to the mature PCL (15% loss). This is
unusual as SCs are typically toxicant resistant. Various factors involved in Cd toxic-
ity were then assessed. Anti-apoptotic BCL2 decreased in NSCs (50%) but in-
creased in the PCL (225%), and pro-apoptotic BAX increased in the NSCs (216%)
but was unchanged in the PCL suggesting enhanced apoptosis was involved in this
Cd hypersensitivity. The transport protein ZnT1 effluxes zinc, which protects
against Cd toxicity, while ZIP8 aides in zinc and Cd uptake. Cd exposure increased
ZnT1 transcript 650% in NSCs but only 200% in the PCL. ZIP8 levels increased
248% in NSCs but showed no change in the PCL. These data support a biokinetic
basis to higher Cd toxicity in NSCs. To define sensitivity in CSCs, we exposed the
As-CSC and found them even more sensitive to Cd (LC50 = 6.0 μM) than NSCs
(12.2 μM). Similar apoptotic and/or Cd uptake/efflux factors seen in the untrans-
formed cells were involved in CSC hypersensitivity. Thus, Cd sensitivity may be re-
lated to differentiation stage and increased Cd sensitivity in SCs helps explain the
initial loss of SCs during Cd transformation. Further, CSC hypersensitivity to Cd
may be a major factor in Cd’s ability to destroy certain cancers.
1192 Recruitment of Normal Stem Cells into an Oncogenic
Phenotype by Noncontiguous Carcinogen-Transformed
Malignant Epithelia Is Dependent on the Transforming
Carcinogen.
Y. Xu,  E. J. Tokar,  R. J. Person,  R. Orihuela and M. P. Waalkes. NTP, NIEHS,
NIH, Research Triangle Park, NC.
Cancer stem cells (CSCs) are likely key to carcinogenesis. In prior work we found
that arsenic-transformed malignant epithelial cells (MECs) recruit nearby, but non-
contiguous normal stem cells (NSCs) into a CSC-like phenotype. Here, we tested if
this recruiting effect on NSCs occurs with MECs transformed by other carcino-
gens. Normal human prostate epithelial SCs (WPE-stem) were co-cultured via
transwell dishes that separate cells but not secreted factors with isogenic MECs de-
rived from normal human prostate epithelial RWPE-1 cells by cadmium or N-
methyl-N-nitrosourea (MNU) exposure (called Cd-MECs or MNU-MECs, re-
spectively). SCs co-cultured with normal RWPE-1 cells served as control. After 2
weeks of Cd-MEC co-culture, SCs showed high secretion of metalloproteinase-9
(MMP-9, 3.6-fold of control) and MMP-2 (2.2-fold), increased colony formation
(1.8-fold) and invasion (2.5-fold), formation of aggressive ductal structures in
Matrigel and loss of tumor suppressor gene, PTEN, expression (62% of control), all
indicative of caner phenotype. MNU-MEC co-culture had no such effects on SCs.
Epithelial-to-mesenchymal transition occurred in Cd-MEC co-cultured SCs, as
shown by cell morphology and VIMENTIN over-expression, but not in MNU-
MEC co-cultured SCs. During Cd-MEC co-culture, loss and regain of SC-related
gene expression (ABCG-2, OCT-4 and WNT3) occurred, likely as a key to MEC re-
cruitment of NSCs into CSCs. Overall, the data indicate SCs gain a cancer pheno-
type with Cd-MEC co-culture but not with MNU-MECs. Analysis showed Cd-
MECs secreted high levels of the tumor microenvironmental related factor,
TGFβ-1. Direct TGFβ-1 treatment of NSCs duplicated most responses from Cd-
MEC co-culture. Since recruitment of NSCs into CSCs can also occur with ar-
senic-transformed MECs, we conclude that the effects of nearby MECs on NSCs
are not carcinogen specific but apply to some, but not all, carcinogens. This phe-
nomenon may be important in chemically-induced tumor extension and dissemi-
nation.
1193 Aberrant microRNA Expression Correlates with RAS
Activation in Malignant Transformation of Human Prostate
Epithelial and Stem Cells by Arsenic.
N. N. Ngalame,  E. J. Tokar and M. P. Waalkes. NTP, NIEHS, NIH, Research
Triangle Park, NC.
Inorganic arsenic (iAs) is a human carcinogen probably targeting the prostate and
can malignantly transform the human prostate epithelial cell line, RWPE-1 (to
CAsE-PE cells) and a derivative stem cell (SC) line, WPE-stem (to As-CSC cells) by
unclear mechanisms. MicroRNAs (miRNA) are non-coding but exert negative con-
trol on expression by degradation or translational repression of target mRNAs.
Aberrant miRNA expression is likely a key factor in carcinogenesis. By miRNA
array of 84 miRNAs in CAsE-PE and As-CSC cells, for 29 and 13 miRNAs respec-
tively, expression changed by >1.5 fold of control, and 7 were common in both
cells. Target gene expression correlated with miRNA changes (suggested by
TargetScan and microRNA.org) in transformants with shared pathways like onco-
genesis, miRNA biogenesis, SC differentiation, and metastasis and invasion. KRAS
oncogene was induced in CAsE-PE but not by mutation or promoter hypomethy-
lation. Overexpression of KRAS protein was very intense in As-CSC cells. In both
cell types, iAs transformation decreased miRNAs targeting KRAS and RAS super-
family members. Reduced miR-134 (15 fold), miR-373 (11 fold), miR-155 (4
fold), miR-138 (4 fold), miR-205 (4 fold), miR-181d (3 fold), and miR-181c (2
fold) in CAsE-PE cells correlated with increased target RAS oncogenes, RAN,
RAB27A, RAB22A mRNAs and KRAS protein. Reduced miR-143 (5 fold), miR-
34c-5p (3 fold), and miR-205 (2 fold) in As-CSC cells correlated with increased
target RAN mRNA, and KRAS, NRAS, and RRAS proteins. The RAS/ERK signal-
ing pathway helps control cell survival, differentiation, and proliferation, and if
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dysregulated promotes a cancer phenotype. Within the RAS/ERK pathway iAs
transformation increased expression of RAF kinase protein, and ERK kinase
mRNA in CAsE-PE cells, and MEK1/2, ERK and MAP4K4 kinase mRNAs in As-
CSC cells. Thus, dysregulated miRNA expression appears to impact RAS activation
in both iAs transformants, and appears key to iAs-induced acquired cancer pheno-
type in these human prostate cells.
1194 Aryl Hydrocarbon Receptor Contributes to Mouse
Embryonic Stem Cell-Derived Cardiomyocyte
Differentiation.
Q. Wang,  C. Ko,  Y. Fan,  Y. Wang and A. Puga. University of Cincinnati,
Cincinnati, OH.
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) is a ubiquitous toxicant persistent in
the environment. It is a prototypic ligand for the aryl hydrocarbon receptor (AHR),
a ligand-activated transcription factor whose activation upon ligand binding regu-
lates the expression of many xenobiotic detoxification genes. Besides being a critical
mediator of gene-environment interactions, AHR has functions beyond those of a
xenobiotic interacting protein. Studies in Ahr-/- mice have shown that AHR has
physiological roles in hematopoiesis and heart development. To characterize these
roles and the consequences of TCDD exposure in cardiomyocyte specification, we
studied the effects of TCDD exposure during mouse embryonic stem cells
(mESCs) differentiation into cardiomyocytes. mESCs were allowed to sponta-
neously differentiate via embryo-like aggregates (embryoid bodies, EB) into con-
tracting cardiomyocytes. Immunocytochemistry on contracting EBs indicates that
AHR colocalizes with the cardiac markers cardiac troponins T and I and NKX2.5.
ShRNA knockdown of AHR during differentiation or TCDD treatment signifi-
cantly decreased the percentage of contracting EBs. A time series of TCDD treat-
ment revealed that the time between day 0 and day 3 of mESC differentiation was
the most critical window for TCDD toxicity. An ESC clone containing a stably in-
tegrated plasmid bearing a Cyp1a1 promoter-driven puromycin-IRES2-eGFP was
allowed to differentiate in the presence of TCDD followed by puromycin selection.
Real-time PCR analyses of the puromycin resistant selected cells showed that many
mesoderm marker genes were up-regulated while both endoderm and ectoderm
markers were down-regulated, indicating that early AHR activation might be com-
mitted to mesodermal lineages. Our data suggest that AHR is involved in the regu-
lation of cardiomyocyte differentiation during embryonic development and that
TCDD exposure during early differentiation is toxic to cardiomyoctye develop-
ment. Supported by NIH Grant 5R01ES06273.
1195 Exposure to Concentrated Air Particles Depletes Bone
Marrow Hematopoietic Stem Cells.
T. O’Toole,  W. Abplanalp,  J. Lee,  D. J. Conklin and A. Bhatnagar. Diabetes and
Obesity Center, University of Louisville, Louisville, KY.
Results from several epidemiological and laboratory studies suggest that exposure to
airborne particulate matter (PM) is associated with an increase in cardiovascular
disease (CVD) risk. While acute PM exposures have been linked to arrhythmias,
thrombosis, inflammation, endothelial dysfunction, myocardial infarction and
stroke, long term exposures increase the risk of mortality due to heart failure, car-
diac arrest, and ischemic heart disease arrhythmias. Despite these associations how-
ever, relatively little is known about the molecular mechanisms linking exposures to
CVD risk. In previous studies we have shown that circulating endothelial progeni-
tor cells (EPCs) were depleted in humans exposed to natural variations in fine par-
ticulate matter (PM2.5) and in mice exposed to concentrated air particles (CAPS).
However the effects of exposure on other progenitor cell types remains unknown.
Hence, to examine how PM affects other stem cell populations we exposed mice to
CAPS generated from downtown Louisville, Kentucky air using a versatile aerosol
concentration enrichment system (VACES) for 9 days and examined levels of bone
marrow-derived hematopoietic stem cells (HSCs) and mesenchymal stem cells
(MSCs) using colony forming assays. In CAPS-exposed mice we observed an ap-
proximate 35% decrease in CFU-GM (colony forming unit-granulocyte,
macrophage) colonies compared to filtered air-exposed, control mice. However the
absolute number of colonies and the relative decrease versus air controls varied di-
rectly with CAPS levels. Flow cytometry-based phenotypic analysis of these
colonies suggested a uniform decrease of multiple hematopoietic lineages rather
than a decrease in a specific subset. In contrast no change was observed in BFU-E
(burst forming unit-erythroid) colonies between the filtered air and CAPS treat-
ments, or in the number of bone marrow-derived MSCs. These results suggest that
HSC depletion may contribute to the cardiovascular complications resulting from
chronic PM exposure by affecting immune responses to injury and dysfunction.
1196 Cadmium Concurrently Affects Cell Cycle, Total Histone
Protein Production (THP) and H3 Histone Modification
Pathways in Mouse Embryonic Stem Cells.
S. R. Gadhia and F. A. Barile. Pharmaceutical Sciences, St. John’s University College
of Pharmacy and Health Sciences, Queens, NY.
The fetal basis of adult disease (FEBAD) theorizes that embryonic challenges initi-
ate pathologies in adult life through epigenetic modification of gene expression. We
previously reported (2012) that cadmium (Cd) exerts differential toxicity in mouse
embryonic stem cells (mESC) by targeting THP production and H3 (a core histone
protein) early in stem cell development, while H3K27 mono-methylation
(H3K27me1, associated with transcriptional activation) is affected in later stages of
differentiation. Thus, low dose acute Cd exposure selectively disrupts chromatin
structure, an effect not seen in differentially mature cells. In this study we tested the
effects of Cd on cell cycle progression (flow cytometry), chromatin structure and
epigenetic pathways (THP and H3K27me1 analysis, respectively) in undifferenti-
ated mESC after 1-h and 24-h exposures plus recovery. The data suggest that
mESC do not recover from Cd insult at 0.032 mM (IC50 for MTT assay), whereas
cells recovered from 1-h exposure at 0.01 mM (IC25 for MTT assay). This con-
firms our previous results that maximum cytotoxicity is seen during the first few
hours of exposure at low concentrations. Additionally, THP production is sup-
pressed to a greater extent than cell proliferation at 0.01 mM (24-h). Interestingly,
1-h exposure plus recovery resulted in a significant increase in THP production.
Furthermore, 24-h exposure (with recovery) suppressed both cell proliferation and
THP production, indicating that Cd targets THP production at longer exposure
times and disrupts repair mechanisms. Flow cytometry data demonstrates that 0.01
mM Cd, for 24- and 48-h, increases DNA synthesis and percent of cells in G1
phase as well as percent of cells in mitosis; differentiation is affected at 72-h only.
Thus presently we report that low dose acute Cd toxicity is cumulative and disrupts
DNA repair, while concurrently affecting cell cycle progression, repair mechanisms,
chromatin structure and transcriptional state in mES cells.
1197 Cadmium Induces Up-Regulation of Genes Associated with
Early Embryonic Development in Mouse Embryonic Stem
Cells.
A. Aliberti and F. A. Barile. Pharmaceutical Sciences, St. John’s University College of
Pharmacy and Health Sciences, Queens, NY.
Cadmium (Cd) alters gene expression and increases cell proliferation, but the exact
mechanism of its nongenotoxic effect has yet to be elucidated. Previously we re-
ported that exposure to low concentrations of Cd (80 nM to 5 μM) causes a toxi-
cologically relevant increase in cell proliferation, as determined by [3H]-thymidine
incorporation, in undifferentiated pluripotent mouse embryonic stem cells
(mESC). Since epigenetic mechanisms are important during early embryonic de-
velopment, we evaluated the potential of Cd to disrupt normal epigenetic processes
in these cells. Using trypan blue exclusion, exposure of cells to Cd (up to 75 μM for
24 hours) resulted in inhibitory concentrations 50% (IC50) and 25% (IC25) of 40
and 20 μM, respectively. Real-time PCR analysis of genes associated with epige-
netic chromatin modification during early embryonic development indicates that
treatment of cells with IC50 and IC25 concentrations results in a greater than 2-fold
up-regulation of Aurkc, Setd1b, and Smyd1. Aurkc, a member of the Aurora kinase
family, has a significant influence on cell proliferation of the pre-implantation blas-
tocyst. Setd1b is a component of the histone methyltransferase complex that
trimethylates H3K4 (histone 3, a core histone protein, at position lysine 4), result-
ing in downstream expression of Oct-4. Smyd1 is involved early in embryonic de-
velopment of cardiac progenitor cells. The results suggest that Cd up-regulates
genes that are important in early mitosis and blastocyst formation, methyltrans-
ferase activity, and cellular differentiation, the consequences of which implicate the
potential role of the metal to alter the normal processes that are coupled with em-
bryonic development in vivo.
1198 Colony-Forming Cell (CFC) Assays Predict for Increased
Clinical Neutropenia Resulting from Combination
Therapies.
E. Clarke,  A. Mergaert and G. Dos Santos. ReachBio LLC, Seattle, WA.
Combination therapy can be more efficacious than monotherapy in preventing
progression of certain diseases. Unfortunately, this increased therapeutic efficacy
often comes with increased hemotoxicity. In a randomized study of 646 patients
with Multiple Myeloma, Orlowski et al. (2007) saw clinical neutropenia in 20% of
patients receiving Bortezomib alone as compared to 35% of patients receiving
Bortezomib and Doxorubicin. Shah et al. (2007) reported clinical neutropenia in
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25% of patients receiving Imatinib and Hydroxyurea in patients with recurrent ma-
lignant glioma. Some myelotoxic combinations may be unintentional: Hachem et
al. (2003) reported myelosuppression in bone marrow transplant patients treated
with Linezolid that also happened to be on selective serotonin reuptake inhibitors
(SSRIs). To see if in vitro CFC assays could predict the clinical neutropenia ob-
served with these combinations, we tested the compounds alone and in combina-
tion on CFU-GM inhibition. Normal bone marrow cells and single compounds
(range of concentrations) were mixed in methylcellulose-based media (ColonyGel
1102) and plated in 35mm dishes (3 replicates/concentration). CFU-GM were
enumerated on day 14. Compound IC50 values were:
Bortezomib (B) 12μM; Doxorubicin (D) 28 μM; Imatinib (I) 2.6 μM;
Hydroxyurea (H) 31 μM; Linezolid (L) 109 μM; and the SSRI Fluoxitine (F) 27
μM.
Drug pairs (B+D; I+H; and L+F) were then tested using a matrix design. When
compounds were combined at their IC50 equivalent values, there was an additional
inhibition of CFU-GM: 69% with B+D, 84% with I+H and 75% with F+L. These
data suggest that the CFU-GM assay may be a useful tool to evaluate drug combi-
nations and predict for clinical neutropenia in a variety of circumstances: when
concern of increased hemotoxicity with a strategic therapeutic combination exists;
when there is limited information on the drug combinations to be employed; when
a drug is to be used on pre-treated patient populations. CFC assays may also be use-
ful in evaluating compounds with potential myeloprotective effects in combination
with myelotoxic compounds.
1199 The Effect of TCDD on the Development of Human
Hematopoietic Stem Cells to Lineage-Committed B Cells.
J. Li1, 2,  A. Phadnis1, 2,  R. B. Crawford2, 3 and N. E. Kaminski1, 2, 3. 1Genetics
Program, Michigan State University, East Lansing, MI; 2Center for Integrative
Toxicology, Michigan State University, East Lansing, MI; 3Department of
Pharmacology and Toxicology, Michigan State University, East Lansing, MI.
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is an ubiquitous environmental
contaminant that exhibits a broad spectrum of toxicity. Epidemiological studies
have identified an association between exposure to TCDD and B cell disorders,
such as suppression of humoral immunity and increased incidence of B cell
leukemia. Although extensive studies have been dedicated to explicate the mecha-
nism underlying suppression of mature B cell function by TCDD, little is known
whether TCDD will alter the sequential progression of human hematopoietic stem
cells (HSC) to lineage-committed B cells. To address this question, we established a
co-culture system using irradiated human marrow stromal cells as a supportive mi-
croenvironment to drive the differentiation of human cord blood CD34+ HSC in
the presence of cytokines (IL-3, IL-7, SCF and Flt3L). In three weeks of culture, we
observed increased expression of IL-7R, which is a hallmark of lymphopoiesis.
Furthermore, generation of lineage-committed B cells was detected by the co-ex-
pression of B220 and CD19 in 20% of the cell population. To test the effect of
TCDD on B cell development, we treated CD34+ HSC with 1nM, 10nM and
30nM TCDD. Compared to the vehicle control, the cell proliferation was remark-
ably arrested by TCDD in a concentration-dependent manner. We also observed a
significant decrease of IL-7R expression in TCDD-treated cells. These data illus-
trate establishment of an in vitro model system to drive the development of cord
blood HSCs to lineage-committed B cells. Preliminary studies showing downregu-
lation of IL-7R suggest a role by TCDD in altering early B cell development.
1200 New Methodology for the Production of Thin-Layered
Cardiomyocyte Tissue from Human-Induced Pluripotent
Stem Cells (hiPSCs) Derived Cardiomyocytes for Use in
High-Throughput Electrophysiological Platforms and High-
Content Imaging Systems.
S. Yoshida1,  K. Tsuzaki2,  S. Tomizawa2 and Y. Asai1. 1ReproCELL Inc., Kanagawa,
Japan; 2Drug Safety Testing Center Co., Ltd., Saitama, Japan.
We have been developing functional cardiomyocytes derived from human iPS cells
for many years. We have previously reported on cryopreserved cardiomyocytes,
ReproCardio 2, derived from human iPS cells that demonstrate stable cardiac char-
acteristics such as αMHC, cTnT, MLC-2a, MLC-2v, and Cx43. Using
ReproCardio 2 clumps on electrophysiological assay systems, we have further devel-
oped our QTempo® assay (on the MEA platform) to better predict the drug in-
duced QT interval prolongation (DIQTIP). 
The use in cardio-toxicity assays requires the reliable assay platform like tissue. We
have been developing this technology to make functional thin layered cardiac tis-
sue, which has improved beating synchronization and stability, and better reliability
for use in cardio toxicity assays. The thin-layer tissue derived from ReproCardio 2
stained positive for cTnT especially around the synchronized beating cell area. We
have developed a calcium flux assay (inotropic assay) using the thin layered car-
diomyocytes that demonstrate a robust and synchronized calcium flux (Fluo8) and
high content imaging technologies. Furthermore, the thin-layer showed advantages
over monolayers, especially its robust signal with changes in serum concentration,
which is preferable for high through put screening (HTS) platforms. When using
electrophysiology platforms, ReproCardio 2 thin-layer also demonstrated a more
robust electrophysiological output similar to that seen with beating cardiomyocyte
clumps especially the dose response to DIQTIP causing compounds such as E-
4031 and Cisapride. In fact, the results were similar to that obtained in the clinical. 
The thin-layer cardiomyocytes have shown to be the preferred format giving rise to
a robust and sustainable platform for measuring prolonged QT-interval and other
cardiotoxic parameters such as calcium flux, and in turn will produce a more pre-
dictive format for toxicity assays in drug discovery.
1201 Proteomic Analyses of Human Primary Hepatocytes and
Stem Cell-Derived Hepatocytes Identifies Hepatocyte
Maturity Markers and Shows Improved Phenotype
Maintenance in an Air-Liquid Interface Culture Model.
C. Rowe1,  C. Goldring1,  D. Gerrard2,  N. Hanley2,  M. Storm3,  D. Tosh3,
K. Piper Hanley2 and B. Park1. 1MRC Centre for Drug Safety Science, University of
Liverpool, Liverpool, United Kingdom; 2Centre for Endocrinology & Diabetes,
University of Manchester, Manchester, United Kingdom; 3Centre for Regenerative
Medicine, University of Bath, Bath, United Kingdom. Sponsor: D. Mendrick.
Failure to predict hepatotoxic drugs in pre-clinical testing makes it imperative to
develop better liver models with a stable cultured phenotype. Stem cell-derived
models offer promise with hepatocyte-like cells currently considered to be ‘fetal-
like’ in their maturity. This is based on limited biomarkers and lacks the required
proteomic datasets that directly compares fetal and adult hepatocytes. Here, we
quantitatively compare the proteomes of human fetal liver, adult hepatocytes,
HepG2 cells and ES-derived hepatocyte-like cells. In addition, we investigate the
changes in human fetal and adult hepatocytes when cultured in an air-liquid inter-
face format and in extracellular matrix sandwich culture. The proteomes were qual-
itatively similar across all samples but hierarchical clustering showed that each sam-
ple type had a distinct quantitative profile. Hepatocytes cultured at the air-liquid
interface retained a proteome more closely clustered to fresh cells than conventional
culture, which acquired myofibroblast features. Principal component analysis ex-
tended these findings and identified sets of proteins as specialized indicators of he-
patocyte differentiation. Our quantitative datasets are the first that directly com-
pare multiple human liver cells, define a model for enhanced maintenance of
hepatocytes in culture and provide new protein markers for determining human
hepatocyte phenotype and maturity.
1202 Scalable, HTS/HCI-Amenable and NURR1-Expressing
Dopaminergic Progenitor Cells Derived from Human
Embryonic Stem Cells.
J. Chilton1,  B. R. Culp1,  K. L. Galland1,  J. N. Le1,  J. A. McCabe2,  Z. Lin2,
N. M. Filipov2 and S. L. Stice1, 2. 1ArunA Biomedical, Inc., Athens, GA; 2University
of Georgia, Athens, GA.
One of the most common neurodegenerative diseases, Parkinson’s disease (PD) af-
fects approximately 1-2% of the population over age 65. The lack of an appropriate
and scalable cell type hinders progress in PD drug discovery and elucidating disease
mechanisms. Our goal was to generate human dopaminergic progenitor cells, de-
rived from human embryonic stem cells (hESCs), which are homogeneous, ex-
pandable for high throughput screening (HTS) and high content imaging (HCI)
assays and demonstrate a propensity for dopaminergic differentiation. We isolated
cells exhibiting > 95% immunoreactivity for nuclear receptor related 1 protein
(NURR1 or NR4A2), a transcription factor essential for generating midbrain
dopaminergic neurons. We refer to these cells as DopaPro™ cells, which display
normal karyotype, form adherent monolayers and proliferate over multiple pas-
sages. DopaPro™ cells were differentiated with leukemia inhibitory factor (LIF),
brain derived neurotrophic factor (BDNF), glial derived neurotrophic factor
(GDNF), transforming growth factor beta 3 (TGF-β3), forskolin and ascorbic acid
(AA). By 3 weeks, differentiated DopaPro™ cells showed tyrosine hydroxylase
(TH) expression. We asked whether DopaPro™ cells, as putative midbrain pro-
genitor cells, required regionalization signals such as Sonic Hedgehog (SHH) or fi-
broblast growth factor 8 (FGF8), which are normally used in directed differentia-
tion of hESCs to dopaminergic neurons. DopaPro™ cells did not require, nor was
their differentiation to TH positive populations significantly enhanced, when cul-
tures were exposed to SHH and FGF8 for 2 weeks prior to LIF, BDNF, GDNF,
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TGF-β3, forskolin and AA. SHH and FGF8 were also not required for dopamine
production. Here, hESC-derived progenitor cells poised for potential dopaminergic
cell derivation were generated, thus reducing time and need for midbrain induction
factors. Results show DopaPro™ cells are a unique, renewable and scalable cell
source for PD research.
1203 Conditions for Isolation and Maintenance of Rat Hepatic
Stem/Progenitor Cell Colonies.
J. A. Harrill1,  J. Rowlands2,  R. S. Thomas1 and L. M. Reid3. 1ICSS, The Hamner
Institutes for Health Sciences, Research Triangle Park, NC; 2TERC, The Dow
Chemical Company, Midland, MI; 3University of North Carolina at Chapel Hill,
Chapel Hill, NC.
Hepatic stem cells, hepatoblasts, and committed hepatocytic and biliary progeni-
tors constitute a stepwise maturational lineage which produces all mature cells of
the liver. Hepatic stem/progenitors are localized to the Canals of Hering: periportal
ductular structures derived from ductal plates in fetal and neonatal livers. These
periportal stem cell niches are enriched in a variety of extracellular matrix molecules
including certain types of collagens (III, IV and V) and hyaluronans, non-sulfated
polymers of D-gluronic acid + D-N-acetylglucosamine. We have compared the
ability of hyaluronans, as well as type III and type IV collagens, to support the pro-
liferation of hepatic stem/progenitors isolated from neonatal and adult rat livers.
Cells were isolated either by suspension digestion (neonates) or perfusion digestion
with collagenase (adult) and cultured in a serum-free medium (Kubota’s Medium)
designed to culture-select endodermal stem/progenitors. Cells from either age
seeded onto collagen III or IV (5 ug/cm2) yielded hepatic stem/progenitor cell
colonies which expanded for 5-7 days of culture, at which time the mesenchymal
cell components overgrew the plating surface. By contrast, a substratum of hyaluro-
nans (5 – 100 ug/cm2), in combination with Kubota’s Medium, promoted coordi-
nated attachment and growth of discrete hepatic stem/progenitors and their mes-
enchymal cell progenitor partners. Colonies consisted of hepatic stem /progenitors
growing on top of mesenchymal cell progenitors. Neonatal liver-derived colonies
had large expansion potential, increasing in area by more than 100-fold by 10 days
in culture. It is hypothesized that the expansion potential of adult-derived cells was
more limited due to the need for an alternate method of isolation or addition of ex-
ogenous growth factors. This novel culture system provides an opportunity to study
the effects of hepatoxicants on early lineage stages consisting of rat hepatic
stem/progenitor cells.
1204 The In Vitro Human CFU Assay Combined with Automated
Image Analysis of Colony Morphology Markedly Improves
Assessment of Hematopoietic Toxicity of AZT and Other
Nucleoside Inhibitors.
M. Huber1,  D. Raj1,  C. Grande1,  J. Parrott1,  O. Egeler1,  K. Tse1,  C. Farzim1,
A. Eaves1, 2 and J. Damen1. 1STEMCELL Technologies Inc, Vancouver, BC, Canada;
2Terry Fox Laboratory, BC Cancer Agency, Vancouver, BC, Canada.
Antiviral nucleoside analogs target viral polymerases but can also inhibit cellular
polymerases, leading to a decrease in cell proliferation and ultimately suppression of
hematopoiesis, resulting in anemia and neutropenia. For assessment of hematotox-
icity in this compound class, the FDA’s Guidance for Industry: Antiviral Product
Development – Conducting and Submitting Virology Studies to the Agency recom-
mends the use of the colony-forming unit (CFU) assay, which utilizes primary
hematopoietic stem and progenitor cells. In 2003, the European Centre for the
Validation of Alternative Methods (ECVAM) published a standardized CFU assay
methodology that is validated for the prediction of the maximum tolerated dose
(MTD) of myelosuppressive compounds (Pessina et al., Tox Sci. 2003. 75:355-
367). This in vitro assay is a key tool for assessing toxicity prior to initiation of
costly in vivo studies and human clinical trials. Unfortunately, in these standardized
CFU assays, nucleoside inhibitors such as azidothymidine (AZT) do not exhibit
high toxicity (IC50 = 100-200 μM), despite the fact that they are well known to per-
turb hematopoiesis in patients. Although AZT does not strongly reduce the num-
ber of hematopoietic colonies in the CFU assay, it does have a dramatic effect on
their morphology. To quantitate changes in colony morphology, we utilized the
STEMvision™ platform for automated advanced image analysis in conjunction
with the CFU assay. Our results indicate that IC50 values for AZT based on the
quantitation of morphological changes such as colony size were ~20-fold lower (5-
10 μM) than the IC50 based on colony numbers (100-200 μM). These data suggest
that quantitation of colony morphology is a key parameter to predict drug potency
and in vivo toxicity in this drug class.
1205 Investigation of a Redox-Sensitive Predictive Model of Mouse
Embryonic Stem Cell Differentiation via Quantitative
Nuclease Protection Assays and Glutathione Redox Status.
K. J. Chandler1,  J. M. Hansen2,  E. S. Hunter1 and T. B. Knudsen1.
1NHEERL/NCCT, US EPA, Research Triangle Park, NC; 2Department of Pediatrics,
Emory University School of Medicine, Atlanta, GA.
Mouse embryonic stem cells (mESCs) recapitulate developmental signals that occur
in vivo and are amenable to high-throughput profiling of chemical-induced effects.
In silico models of impaired mESC differentiation identified 19 ToxCast™ assays
that distinguished chemical effects on cardiomyocyte differentiation versus cytotox-
icity (Wilcoxon rank sum, p=0.03). Taken together, these assays connect a redox-
sensitive pathway(s) as a likely target of a chemical set that impaired mESC differ-
entiation. To evaluate this predictive model, a custom quantitative nuclease
protection assay (qNPA) array (HTG Molecular Diagnostics) of 41 redox-sensitive
targets and differentiation markers was designed. The concentration-dependent ef-
fects of twelve ToxCast chemicals were evaluated using the qNPA array. The highest
concentration produced AC 20 cytotoxicity in mESCs and the remaining were half
logarithmic decrements. Cells were harvested on days 4 and 9 of culture. The pre-
diction model correctly identified that pyridaben would disrupt redox signaling in
mESCs. Expression of the redox-responsive transcription factors Nrf2, Hif1a and
Mtf2 increased upon exposure. Pyridaben showed significant concentration-de-
pendent effects on markers for endoderm, ectoderm and mesoderm differentiation
on day 4 of culture (decreased Fgf5, Otx2, and Fgf8 expression and increased Tbx3
expression) without producing a 50% decrease in cardiomyogenesis in the standard
assay on day 9. Preliminary data evaluated the redox status (glutathione/glutathione
disulfide ) of mESCs at 3, 6, 9 and 24 hours following chemical exposure and indi-
cated a unique pattern of redox status for predicted redox disrupting chemicals.
These experiments document the importance of using multiple differentiation end-
points and support the linkage of our predictive model to altered differentiation in
chemical profiling. This abstract does not reflect EPA policy.
1206 Arsenic Trioxide Alters Regulation of Differentiation in
Mouse Embryonic Stem Cells.
T. Lee and F. A. Barile. Pharmaceutical Sciences, St. John’s University College of
Pharmacy and Health Sciences, Queens, NY.
Arsenic trioxide (As2O3) is a known human carcinogen yet it is currently approved
by the Food and Drug Administration as a chemotherapeutic agent for the treat-
ment of acute promyelocytic leukemia. As2O3 alters cellular differentiation by
mechanisms of which are yet not clearly understood. Thus, in the current study, we
investigated the influence of As2O3 on differentiation of mouse embryonic stem
cells (mESC). These pluripotent stem cells are derived from the inner cell mass of
the blastocyst, and are capable of continuous proliferation, self-renewal and differ-
entiation into the three germ layers. Undifferentiated cells express early specific
stem cell markers, including Oct-3/4, Nanog, and Sox-2, which have an important
role in developmental regulation and differentiation. In our initial studies, 1.0 μM
to 6 μM As2O3 reduced cell viability over 24-h with increasing concentrations,
whereas significant reductions were observed at or below 1 μM only with 48-h ex-
posures, a concentration which is equivalent to therapeutic administration. End
point PCR analysis revealed that increasing concentrations of As2O3 reduced gene
expression of stem cell markers. This supports the western blot results, protein lev-
els decreased with decreased in gene expression. Western blot analysis for Oct-3/4
and Sox-2 protein expression at the same concentrations indicated that protein lev-
els were decreased by As2O3 in a dose- and time-dependant manner. While Oct-3/4
and Sox-2 protein expression levels are crucial for maintaining mESC in their un-
differentiated state, the reductions in the presence of arsenic imply the loss of
“stemness”. Consequently, it appears that As2O3 exposure reduces the ability of the
stem cells to maintain proper state of differentiation.
1207 Vascular Endothelial Cells Exposed to PCB 153 Show
Increased Expression of Stem Cell Markers.
J. K. Das and Q. H. Felty. Environmental & Occupational Health, Florida
International University, Miami, FL.
The contribution of PCB exposure to the development of vascular disease is an area
of research that has received little attention. The stability of these chemicals has al-
lowed them to persist in the environment and consequently continues to expose the
general population to PCBs. Since PCBs have been reported in human blood; vas-
cular toxicity from PCB exposure is a public health concern. Vascular lesions from
the lung of patients with severe PAH have been characterized with excessive EC
proliferation and markers of angiogenesis. The exact cell type from where vascular
SOT 2013 ANNUAL MEETING 259
lesions originate from is not clear. However, our studies have focused on ECs as the
origin of vascular lesions because EC stem-like cells have been reported to be in-
volved in vascular injury. The theory that malignancies depend on stem-like cells
for proliferation has received much attention, but there have been few studies
which support a pathogenic role for stem cells in vascular disease. Thus, the objec-
tive of this study was to determine whether exposure to the PCB congener 153 can
increase the level of stem cell markers in vascular ECs. ECs overexpressing ID3 were
used to study the effects of PCB153 in 3D spheroid cultures. Co-culture model of
EC with SMCs and fibroblasts was used to study the expression of stem cell mark-
ers in a monolayer by confocal microscopy. The effect that PCB153 had on cell
cycle progression was also determined by flow cytometry. We observed PCB153
significantly increased expression of stem cell markers CD34+, CD133+, VEGFR-
3 in spheroids overexpressing ID3. ECs exposed to PCB153 showed stable sphere
formation in B27 medium at 10 days. ECs exposed to PCB153 in co-cultures
showed increased expression of stem markers CD34+ and Nanog as well as in-
creased angiogenic phenotype. Cell cycle analysis confirmed that more stem like
cells exposed to PCB153 were in G1 phase. Our results show that PCB153 expo-
sure increased expression of stem cell markers and may be related to mechanisms by
which vascular disease depends on stem-like cells for proliferation.
1208 Evaluation of Ionotropic and Chronotrpic Compounds In
Vitro Using Human iPS-Derived Cardiomyocytes and
Impedance-Based Contractility Assay.
X. Zhang,  B. Xi,  X. Wang,  X. Xu and Y. A. Abassi. Acea Biosciences, San Diego,
CA.
The β-adrenergic receptor (βAR) signaling system is one of the most powerful reg-
ulators of cardiac ionotropic and chronotropic function. βAR antagonists, com-
monly known as beta-blockers (β-blockers) have been used for decades to treat hy-
pertension, ischemic heart disease, some arrhythmias, and more recently to treat
congestive heart failure. Up to date, 3 types of β-blocker drugs have been developed
for therapeutic purpose. In order to better understand the cardiac effects of differ-
ent types of β-blockers, we have developed an in vitro assay using human iPS-de-
rived cardiomyocytes in conjunction with impedance measurement. We evaluated
the activities of six β-blocker drugs and compounds including (1) non-selective β-
blockers; (2) cardioselective β-blockers; and (3) nonselective α and β-blockers. The
data as measured by impedance readout revealed that the β-blockers from different
classes displayed subtle but unique profile of acute impedance changes post com-
pound addition. With the exception of atenolol and metoprolol, pindolol, al-
prenolol, propanolol and carvedilol significantly decreased the cell beating rate
(BR) and even temporally led to beating arrest at the highest tested concentration
(3 uM). In addition, the 1 hour pretreatment with all these four compounds at
higher doses abolished the isoproterenol-induced positive chronotropic effects on
BR. Carvedilol was the only drug that appeared to profoundly reduce cell beating
amplitude (CA) in a dose-dependent manner. The in vitro assay used here indicates
that human iPS-dervied cardiomyocytes respond similarly to the β-blockers from
the same group. However, each type of β-blockers generates distinct profiles and do
have different chronotropic and ionotropic effects which we will summarize in the
current poster.
1209 Selection of CYP3A4+ hESC-Derived Hepatocytes for Drug
Metabolism and Toxicity Assays.
K. Bonham1,  R. Rodriguez1,  S. Ogawa2,  C. Blanco1,  H. Xian1,  R. Stull3,
G. Keller2 and R. Snodgrass1. 1VistaGen Therapeutics, Inc., South San Francisco,
CA; 2McEwen Centre for Regenerative Medicine, Toronto, ON, Canada; 3Stem
CentRx, South San Francisco, CA.
The ability to produce human hepatocytes that express adult levels of drug metab-
olizing enzymes including CYP3A4 in a stable and reproducible system will greatly
benefit the drug development process by decreasing costs, reducing animal studies,
and increasing drug safety. Many groups are trying to develop hepatocytes from
human stem cells to address the lack of availability, quality, and reproducibility of
primary hepatocytes, however, most protocols produce immature hepatocytes with
minimal expression of the adult enzymes related to drug metabolism. Since
CYP3A4 is the most abundant P450 expressed in adult liver and metabolizes 50%
of drugs on the market, it is imperative that assay systems express relevant levels of
this enzyme. To this end, we previously reported the generation of a hESC reporter
line (3A4BLA) containing humanized beta-lactamase (hBLA) inserted in frame
with the CYP3A4 gene. Here we show that 3A4BLA-hepatocytes can be used to: 1)
monitor the differentiation of mature hepatocytes; 2) sort for mature hepatocytes;
3) monitor drug induction of CYP3A4; and 4) develop in vitro assays for drug me-
tabolism and toxicity. Using an optimized protocol for hES-hepatocyte differentia-
tion, we demonstrate CYP3A4 in 25-40% of the cells and show that these cells pro-
duce levels of CYP3A4 mRNA approaching primary hepatocytes, express high
levels of ALB, and store glycogen. More importantly, they metabolize testosterone
and midazolam and respond properly to inducers of CYP3A4 like Rifampicin and
Phenobarbital. With this system we can obtain a relative measure of CYP3A4 ex-
pression on a per cell basis in response to compounds and corrolate those data with
cell metabolism, CYP3A4 activity, and secretion of albumin and urea. Taken to-
gether, these data demonstrate development of a robust system with the potential of
purifying human hepatocytes with more mature functions, as well as assaying drug
effects on CYP3A4 expression, activity, and metabolism.
1210 Adapting the MTT Assay for Use with Human Embryonic
Stem Cells (hESC).
R. Z. Behar,  V. Bahl,  Y. Wang,  J. Weng,  S. Lin and P. Talbot. University of
California Riverside, Riverside, CA.
hESC are difficult to adapt to 96-well plate assays because they survive best when
plated as colonies, which are difficult to count and plate accurately. To address this
problem, two protocols were developed to perform the MTT assay using hESC. In
the first protocol, plating was done with Rho-associated kinase inhibitor (ROCKi),
which allows accurate counting and plating of single hESC. The second protocol
involved plating hESC as small colonies without ROCKi but with adaptations to
allow accurate counting and plating of small colonies. In the ROCKi protocol,
5,000 cells/well are counted using a hemocytometer then plated and incubated for
96-hours, while the small colony method calls for 20,000–30,000 cells/well fol-
lowed by 72-hours of incubation. To enable rapid and uniform plating of small
hESC colonies, we developed a spectrophotometric method to accurately deter-
mine hESC concentration. The percent transmittance for multiple readings of the
same sample produced a coefficient of variation (COV) of 1.5%. Next, we deter-
mined the cell concentration needed to carry out an experiment in a 96-well plate
by plating various cell concentrations and determining the optimal concentration
needed for a 72-hour experiment. Finally, to confirm that the correct cell number
was pipetted accurately into each well, control wells were subjected to the MTT
assay and used to calculate the COV, which ranged from 0.7 to 8.5%, showing that
pipetting of small colonies was uniform. The small colony protocol was validated
using the NIH Plate Uniformity and Signal Variability Assessment, which tested for
signal separation, drift and edge effects. When comparing the ROCKi protocol to
the small colony protocol, it was found ROCKi caused a shift in the IC50 from
1.34e-3 to 1.45e-4 M. In addition, hESC morphology was altered with ROCKi
treatment, which appeared to stress the cells, while cells in the small colony proto-
col appeared healthier, tightly packed, and cobblestone-like. Both protocols allow
the MTT assay to be carried out rapidly and accurately with high reproducibility
between replicate experiments using hESC.
1211 Differential Regulation of Pluripotency Maintenance and
Differentiation Genes in Undifferentiated Human
Embryonic Stem Cells (hESC) Exposed to Methyl Parathion
(MP) and Its Active Metabolite Methyl Paraoxon (MPO).
J. W. Sekowski and J. S. Madren-Whalley. ECBC, US Army RDECOM,
Gunpowder, MD.
Given their wide spread use, ease of procurement, and potential for serious health
consequences if deployed by terrorists, toxic industrial chemicals (TICs) represent a
real threat to warfighters and civilians at home and abroad. Unfortunately, for a vast
number of TICs, including the widely-used organophosphate insecticide, MP, there
is incomplete knowledge regarding the basic molecular consequences of exposure in
humans. Although the literature suggests diverse toxicological consequences for
MP exposure during early fetal development, it is primarily based on human epi-
demiological studies, in vivo animal studies, or in vitro studies using immortal,
transformed cell lines. Furthermore, the relative contribution and the molecular
mechanism(s) of action of the parent compound, MP, versus the active metabolite,
MPO, has not yet been elucidated in an early developmental system. In an in vivo
model, the MP is converted by hepatic and extra hepatic phase I and II metabolism
to MPO, and the relative ratios can vary depending on the in vivo system. Given
that undifferentiated hESCs do not produce the enzymes necessary to carry out the
conversion of MP to MPO, they provide a unique opportunity to examine the in-
dividual influence of the parent and active metabolite on molecular pathways influ-
encing very early human development. 
In this study we compared the expression of 84 genes known to be important in the
maintenance of pluripotency and differentiation in hESCs cells following a 24 hour
exposure of cells to either MP or MPO. These RT-PCR data indicate several key
differences in the expression of genes following exposure to MP and MPO. The re-
sults of this study have opened a new avenue toward understanding how MP and its
active metabolite MPO specifically interfere with some of the earliest steps in
human embryonic development.
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1212 IQ-PSLG Nonclinical to Clinical Translational Safety
Database Initiative.
T. Monticello1,  V. Kadambi2,  M. Graziano3,  M. Sommer4,  K. Blanchard5,
Q. Zhu5 and M. Liu6. 1Amgen, Thousand Oaks, CA; 2Millennium: The Takeda
Oncology Company, Cambridge, MA; 3Bristol-Myers Squibb, Princeton, NJ; 4Pfizer,
Groton, CT; 5Boehringer Ingelheim, Ridgefield, CT; 6IQ, Washington DC.
The International Consortium for Innovation and Quality in Pharmaceutical
Development (IQ) is a science-focused organization of pharmaceutical and
biotechnology companies. The mission of the Preclinical Safety Leadership Group
(PSLG) of the IQ is to advance science-based standards for nonclinical develop-
ment of pharmaceutical products and to promote high quality and effective non-
clinical safety testing and human risk assessment. The IQ-PSLG is creating an in-
dustry-wide database to determine accuracy with which the interpretation of
nonclinical safety assessments in animal models correctly predicts human risk in the
early clinical development of biopharmaceuticals. This initiative aligns with the
2011 FDA strategic plan to advance regulatory science and modernize toxicology to
enhance product safety. Eighteen member companies will contribute datasets from
over 150 molecules. Though similar in concept to the initial industry-wide concor-
dance dataset conducted by HESI/ILSI (Olson, et al. 2000 Reg Tox Pharmacol
32:56), the IQ-PSLG database will include both large and small molecules, be con-
temporary (circa 2005-2011) and will proactively track concordance from recently
completed Phase I clinical studies. Database details, preliminary dataset results and
the individual queries to be mined from the dataset will be presented. In summary,
the output from this work will help identify actual human and animal adverse event
data to define both the reliability and potential limitations of nonclinical data and
testing paradigms in predicting human safety in Phase 1 clinical trials.
1213 Target Organ Toxicities in Studies Conducted to Support
First Time in Human Dosing: An Analysis across Species and
Therapy Areas.
R. Roberts,  D. Ryan,  R. Callander,  K. Stamp,  S. Horner and S. Robinson.
Global Safety Assessment, AstraZeneca, Macclesfield, United Kingdom.
Before a new chemical entity can enter human clinical trials, safety and tolerability
must be assessed in non-clinical rodent and non-rodent toxicology studies. We con-
ducted an analysis of target organ toxicities identified for 77 AstraZeneca candidate
drugs (CDs) in these studies across a range of therapy areas and targets. Our analy-
sis showed that in the rodent, the most frequently affected organ was the liver fol-
lowed by the adrenal glands, kidney, spleen, bone marrow and thymus. In the non-
rodent, the liver and thymus were the most frequently affected organs, followed
closely by the testis and GI tract. This pattern was largely similar across intended
therapy areas with the exception of oncology and infection where a larger range of
organs was affected with higher incidences for adrenal glands, femur, spleen and
thymus. Of those CDs for which no target organ toxicity was seen in one or both
pre-clinical species, the majority were from the CNS/pain therapy area. Another
important consideration is the need for a second species in toxicology testing. For
the 75 CDs where both rodent and non-rodent studies were conducted, 1 or more
new target organs were identified in rodents for 52 CDs (69%) and 1 or more new
target organs were identified in non-rodents for 40 CDs (53%). Notably, the
changes seen only in non-rodents included tissues of high relevance for human risk
assessment such as the male reproductive tissues. There was only a single CD in our
data set for which the target organ profile was identical in both preclinical species.
In summary, our data show that liver, thymus, adrenal gland, spleen, kidney, bone
marrow and lymph nodes are the most frequent target organs in preclinical studies.
This profile is largely similar across therapy areas except for oncology and infection
CDs, where a higher incidence of target organ toxicities across a wider range of or-
gans was seen. The data additionally demonstrate the value of a second species in
toxicity testing to support human safety.
1214 Quantitative Protein Expression Profiling of HepG2 Cells
Treated with Compounds Implicated in Drug-Induced Liver
Injury (DILI).
A. Tavendale,  C. Vazquez-Martin,  D. Lamont and P. Ajuh. Dundee Cell Products
Ltd., Dundee, United Kingdom. Sponsor: C. Elcombe.
Drug induced liver injury (DILI) is the single most common reason for removing
approved drugs from the market, or issuing warnings and modifications of use.
However, there is little knowledge of the key cellular mechanisms at the molecular
level that underlie DILI. Insight into these mechanisms and the cellular pathways
involved will enable the design of predictive assays to remove compounds that pose
a toxicity risk early on in the drug discovery and development process. 
In this study, we used a “toxicoproteomics” approach and SILAC (Stable Isotope
Labeling with Amino acids in Cell culture) to study the changes in the proteome of
the human hepatocellular carcinoma cell line HepG2 following treatment with a
set of seven compounds (Labetalol, Nicotinic Acid, Diclofenac, Amoxicillin,
Cefaclor, Rifampin and Tacrine) previously reported to be involved in DILI. 
We identified over 4,000 proteins by high-resolution mass spectrometry with a false
discovery rate of 1%. We used MaxQuant software for protein identification and
the quantitative analysis of data from mass spectrometry and DAVID Bio-infor-
matics - GO (gene ontology) analysis tools to determine protein changes and bio-
logical processes/pathways affected by the treatment of cells with the drugs. 
Our results indicate that the levels of some enzymes with potential effects in drug
toxicity were reduced when treated with the compounds. These include carnitine
O-acyltransferase activity (involved in the metabolism of fatty acids), nucleotide-
excision repair (DNA repair function) and Glutathione S-transferase A1 (detoxifi-
cation of electrophilic compounds). Biological processes generally affected as deter-
mined by the GO analysis include the response to metal ion and nitrogen
compound biosynthetic processes. These results provide further insight into possi-
ble cellular mechanism(s) linked to the toxic activities of the drugs analysed.
Undoubtedly, quantitative proteomics could play a pivotal role in deciphering tox-
icity mechanisms at the molecular level.
1215 Demonstration of a Unique In Vitro to In Vivo to Clinical
Correlation of Drug-Induced Phototoxicity.
T. Su,  P. Stetsko,  J. Gong,  W. Washburn,  S. C. Griffen and T. Reilly. Research &
Development, Bristol-Myers Squibb, New Brunswick, Hopewell, and Lawrenceville,
NJ.
Drug-induced phototoxicity, which occurs when undesirable effects are elicited
after exposure of the skin or eyes to ultraviolet (UV) light, has been an impediment
to therapeutic use of a variety of drugs and can negatively impact pharmaceutical
research and development. Moreover, proposed screening strategies often over pre-
dict in vivo hazards. Herein we report an example where in vitro data not only pre-
dicts in vivo animal effects but these effects are further translated to humans. As
part of the toxicologic evaluation of a drug candidate for obesity, BMS-819881
(‘881) absorbed UV light in the 290-310 nm range and was thus screened in an in
vitro mouse fibroblast 3T3 cell assay. The compound had a photoirritancy factor ≥
18 (>5 indicates phototoxic potential). In a subsequent rat tissue distribution assay,
‘881 and its metabolites were found to distribute to the skin. In a definitive single-
dose study in pigmented Long-Evans rats, ‘881 (given as a prodrug) induced vari-
ous degrees of erythema, edema and/or flaking of the skin in a dose-dependent
fashion after exposing to UV light at ≥ 150 mg/kg [AUC0-24h ≥ 327 μgxh/mL,
Cmax ≥ 21.7 μg/mL; 5x margin to clinical exposures at 600 mg in a multiple as-
cending dose (MAD) study]. To investigate its potential mechanism of phototoxic-
ity, ‘881 was tested for photostability and reactive oxygen species (ROS) produc-
tion, a common causation for photosensitivity. BMS-819881 and its ketone
metabolite were photolabile (≤ 85% degraded) resulting in substantial production
of singlet oxygen after exposure to UV light. Furthermore, in a 4-week MAD trial
with ‘881 (given as a prodrug at ≤ 600 mg) in obese subjects, symptoms consistent
with photosensitivity reactions (eg, sustained redness and itching) were reported in
a dose-dependent manner. These data support a unique nonclinical prediction of
clinical photosensitivity and suggest the potential added utility of photostability
and ROS production assays in phototoxicity testing, at least in some circumstances.
1216 Preclinical Profiling and Computational Differentiation of
Human Vascular Response to 95 Drugs Using Next-Gen
RNAseq Transcriptomics.
R. Figler,  M. J. Lawson,  A. J. Mackey,  E. L. Berzin,  J. C. Anstey,
P. D. Schoppee-Bortz,  R. W. Tilghman,  B. R. Blackman and B. R. Wamhoff.
HemoShear, LLC, Charlottesville, VA. Sponsor: A. Dash.
BACKGROUND: The ability to de-risk and validate preclinical compounds for
on- or off-target vascular response is critical for drug development. Animal models
and static cell culture systems are poor predictors of the human response. METH-
ODS: We have established a human primary vascular endothelial and smooth mus-
cle cell co-culture system which recapitulates hemodynamic forces and restores cell
biology and responsiveness to drugs at physiologically relevant levels. We assayed 95
clinically relevant drugs at concentrations consistent with plasma levels following
therapeutic dosing. Therapeutic areas included: dyslipidemia, inflammation, de-
pression, diabetes, hypertension, thrombosis, and obesity, among others. Using
RNAseq, we profiled the transcriptional responses observed in both cell types,
across 5 biological replicates, to each drug versus its vehicle control. RESULTS:
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Our analysis detected and corrected for small but persistent batch effects related to
sample processing and employed multi-dimensional methods for differential statis-
tics in >1000 samples. Each transcriptomic drug response profile differentiates
drug-specific on- and off-target activities between cell types, within drug classes,
and between drug classes, as well as estimating relative molecular pathway activity
between drugs within a class. For example, preliminary analysis of TZD-class re-
sponses ranked the on-target “insulin receptor signaling pathway” for pioglitazone
at 6th, but rosiglitazone at 159th, and troglitazone at 259th, while off-target “can-
cer” and “cell remodeling” pathways dominated the top 10 signaling pathways for
troglitazone and rosiglitazone, consistent with clinical history of these drugs.
CONCLUSIONS: Methods combining human-relevant systems with mining
drug-specific profiles in conjunction with external drug annotation databases
(FDA’s AERS, Altman’s OFFSIDES, EPA’s ToxCast, Broad’s Connectivity Map)
serves to enhance ability to make broader human vascular drug response predic-
tions.
1217 Towards a Platform of BAC-GFP Transgenomics-Based
Pathway of Toxicity Reporters for Automated High-Content
Imaging-Based Chemical Safety Assessment.
S. Wink,  B. Herpers,  S. Hiemstra and B. van de Water. Toxicology, LACDR,
Leiden, Netherlands.
Adaptive cellular stress responses are paramount in the healthy control of cell and
tissue homeostasis after cell injury during hypoxia, oxidative stress or unanticipated
side-effect of medications and other chemical exposures. Genome-wide transcrip-
tomics analysis has revealed the detailed cellular stress response landscape and
thereby the diversities of organelles and cell functions that are being affected upon
exposure to diverse chemicals. Individual toxicological relevant stress responses
have also been termed pathways of toxicity (PoT). We find that activation of PoT
occur well before the typical ultimate outcome of chemical cell injury: cell death by
necrosis or apoptosis. Understanding the activation of PoT caused by chemicals is
complex because many simultanous biochemical cellular perturbations may occur
thereby affecting different PoT in parallel or a defined order. To increase our under-
standing of chemically-induced PoT activation and its contribution to safety assess-
ment we believe that a time-resolved, sensitive and multiplex readout of chemical-
induced toxicological relevant PoT will be essential.
For that purpose, we are currently developing a automated live-cell high-content
imaging-based platform containing a panel of distinct PoT reporter cell lines. To
conserve the endogenous regulation we tag selected target genes with GFP using
BAC-transgene-omics approaches. So far we have generated 23 different human he-
patoma HepG2 reporter cell lines that define autophagy, mitochondrial organiza-
tion, Golgi structure, nucleosomes, ER morphology and stress, oxidative stress re-
sponse and DNA damage responses.
Here we report the current status of our BAC-GFP PoT reporter platform and
demonstrate that individual reporter cell lines are sensitive to their corresponding
model stress responses. We anticipate that ultimately a phenotypic PoT profiling
platform will allow a high throughput and time-resolved classification of chemical-
induced stress responses in the safety assessment of chemicals.
1218 High-Throughput Respirometric Assay Identifies Predictive
Toxicophore of Mitochondrial Injury.
L. P. Wills2,  G. Beeson1, 2,  R. Trager1,  C. Lindsey1,  Y. Peterson1,  C. Beeson1, 2
and R. G. Schnellmann1. 1Medical University of South Carolina, Charleston, SC;
2MitoHealth, Charleston, SC.
Many environmental chemicals and drugs negatively affect human health through
deleterious effects on mitochondrial function. Currently there is no chemical li-
brary of mitochondrial toxicants, and no reliable methods for predicting mitochon-
drial toxicity. We hypothesized that discrete toxicophores defined by distinct chem-
ical entities can identify previously unknown and future mitochondrial toxicants.
We used a respirometric assay to screen 1760 compounds (5 μM) from the LOPAC
and ChemBridge DIVERSet libraries. Thirty-one of the assayed compounds de-
creased uncoupled respiration, a stress test for mitochondrial dysfunction, prior to
a decrease in cell viability and were toxic to isolated mitochondria. The mitochon-
drial toxicants were grouped by chemical similarity and two clusters containing
four compounds each were identified. Cheminformatic analysis of one of the clus-
ters identified previously uncharacterized mitochondrial toxicants from the
ChemBridge DIVERSet. This approach will enable the identification of mitochon-
drial toxicants and advance the prediction of mitochondrial toxicity for both drug
discovery and risk assessment. This project was funded through grant numbers
GM084147, F32 ES020103-01, and 2R44-ES019378-02.
1219 Nonclinical Toxicology Profiling of the First-In-Class
Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor
Dapagliflozin.
M. Tirmenstein1,  A. Bergholm2,  E. Janovitz1,  D. Hagan1,  J. Whaley1 and
T. Reilly1. 1Bristol-Myers Squibb Research & Development, Princeton, NJ;
2AstraZeneca Research & Development, Mölndal, Sweden.
Dapagliflozin (Dapa) is a novel SGLT2 inhibitor that directly increases urinary glu-
cose excretion as a mechanism for treating diabetes. To support its safe use during
clinical development, Dapa was evaluated in a rigorous battery of in vitro and in
vivo nonclinical safety studies. In vitro screening of >300 diverse targets indicated
no significant off-target activities for Dapa or its primary metabolite. The complete
set of in vivo safety studies included dosing up to 12-months in dogs and a lifetime
(~2 years) in mice and rats. As expected, most of the effects were related to Dapa-
induced pharmacology (i.e. SGLT2 inhibition) such as glucosuria with osmotic di-
uresis and mild loss of electrolytes, and limited body-weight gains despite increased
food consumption. At extremely high doses, Dapa also caused intestinal glucose
malabsorption. This effect only occurred in rats at extremely high doses (> 2000x
clinical exposures) and was related to increased intestinal calcium absorption, a
consequence of exacerbated carbohydrate fermentation in the rodent gut related to
SGLT1 inhibition, which ultimately contributed to thickened trabeculae in long
bones and soft tissue mineralization. Of particular importance, chronic Dapa treat-
ment at >600x clinical exposures did not result in hyperplasia or any adverse effect
on the kidneys or urinary tract nor at > 100x clinical exposures any increases in the
incidence of or shortening in the latency period for tumor development. There was
also no indication that SGLT2-/- mice had adverse urinary tract morphology or
function when compared to their wild type counterparts in a 15-month observa-
tional study. Thus, the pharmacologic activity of Dapa in nonclinical species and
the rigorous attempts to test supra- and off-target pharmacology allowed us to thor-
oughly evaluate its potential toxicity profile, providing us with confidence in its
safety in patients with diabetes.
1220 Bone Assessments in Enhanced Pre-Postnatal Toxicity Study
in Pregnant Cynomolgus Monkeys with up to 6-Months
Postnatal Evaluation.
A. Varela1,  S. Y. Smith1 and G. Chellman2. 1Bone Research, Charles River,
Montréal, QC, Canada; 2Charles River, Reno, NV. Sponsor: M. Vézina.
Assessment of potential test article–related bone liability is becoming increasingly
important, not only in the mature skeleton but also in the developing skeleton.
Skeletal assessments were developed to evaluate potential liability in pregnant mon-
keys and offspring in an enhanced pre postnatal development (ePPND) toxicity
study. Assessment in mothers during gestation and lactation included bone markers
C-telopeptide (CTx), tartrate-resistant acid phosphatase active isoform 5b
(TRAP5b), osteocalcin (OC), and bone specific alkaline phosphatase (bALP). In
infants, assessment included bone markers, radiology, ex vivo bone densitometry
(pQCT) and biomechanical testing.
Control mothers had generally high values of bone markers during early pregnancy
and lactation. At GD20, most had OC levels above the upper limit of quantifica-
tion then decreased at other time points during gestation, and increased during lac-
tation. bALP and CTx increased at the end of the gestation and during lactation.
TRAP-5b increased during pregnancy but decreased during lactation. In control in-
fants, OC, bALP and TRAP-5b were increased up to 2, 4 or 10 fold, respectively,
compared to historical data for 3-4 year-old animals. Radiographs were evaluated
for skeletal abnormalities and bone length: age-related changes in epiphyseal min-
eralization, growth plate morphology, and increases in bone length were noted over
time. Femur and lumbar vertebra geometry (pQCT) changed with increasing age
with lower increases in density. Femur 3-point bending and vertebral compression
showed increases in strength parameters with age (2-fold between BD1 and BD
180).
Skeletal changes were consistent with gestation and lactation in mothers, and with
development and growth in infants. These data support the use of bone markers,
densitometry, radiology, and biomechanical testing in toxicology studies, including
ePPND studies, to provide a comprehensive evaluation of the maternal and devel-
oping skeleton in nonclinical drug development.
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1221 Characterization of Batracylin-Induced Renal and Bladder
Toxicity in Rats.
L. Rausch1,  D. Bunin1,  K. Altera1,  S. Samuelsson1,  R. Kinders2,  M. Davis3 and
T. Parman1. 1SRI International, Menlo Park, CA; 2SAIC-Frederick, Frederick, MD;
3National Cancer Institute, Bethesda, MD.
Batracylin (NSC-320846; BAT) is an investigational anticancer agent that reached
Phase I clinical trials. BAT is a dual inhibitor of DNA topoisomerases I and II and
induces histone gamma-H2AX, a biomarker of DNA damage in vitro.
Hemorrhagic cystitis was one of the dose limiting toxicities observed during clinical
trials, and bladder and kidney were postulated to be responsible for the hematuria
observed in the clinic. We investigated the mechanism of bladder and renal toxicity
in Fisher 344 rats, a physiologically relevant model. The studies were designed to 1)
examine the effect of BAT administration on rat bladder histology, 2) further char-
acterize the previously reported renal toxicity of BAT, and 3) measure DNA damage
in the kidney and bone marrow after BAT administration in rats using gamma-
H2AX immunofluorescence. Once daily oral administration of 16 or 32 mg/kg
BAT to Fisher 344 rats for 4 days caused overt toxicity. Abnormal clinical observa-
tions, adverse effects in clinical pathology, urinalysis, kidney and bladder were seen.
Gamma-H2AX immunofluorescence indicated DNA damage in kidney and bone
marrow. Furthermore, after administration of BAT, defects in the superficial and in-
termediate urothelial layers were observed using scanning electron microscopy. The
maximum tolerated dose is estimated to be <16 mg/kg/day. MesnexTM is known
to reduce the incidence of hemorrhagic cystitis induced by ifosfamide or cyclophos-
phamide, but BAT toxicity in rats was not alleviated by twice daily intraperitoneal
administrations of 80 mg/kg mesna. Thus, the mechanism of BAT-induced bladder
and renal toxicity was not mediated by urotoxic mechanisms similar to those of
ifosfamide or cyclophosphamide. These studies show that BAT causes renal and
urothelial damage in rats that may be related to DNA damage, a previously identi-
fied mechanism of action for BAT. Work supported by NCI Contract N01-CM-
42203 and N0-CM-2011-00028.
1222 NKTR-181, a Novel Opioid Agonist, Demonstrates Mu-
Opioid Agonist Effects and Minimal CNS Side Effects in
Both Rat and Dog.
E. Tonkin,  A. Odinecs and T. D. Sweeney. Nektar Therapeutics, San Francisco,
CA.
NKTR-181 is a novel orally available mu-opioid agonist designed using Nektar’s
advanced polymer conjugate technology to achieve slower kinetics of entry into the
brain relative to other opioids, while still producing analgesic efficacy. Previous
studies of NKTR-181 in rodent models have demonstrated a clear separation of
analgesia from unwanted CNS side effects compared with oxycodone. To assess the
safety of this novel opioid, NKTR-181 was evaluated after daily oral dosing for 2
and 13 weeks in rats and dogs at doses up to 600 and 75 mg/kg/day, respectively.
Clinical observations, body weights, clinical chemistry, and histopathology were
performed and NKTR-181 plasma concentrations were analyzed by LC-MS/MS.
Findings in both species were consistent with the pharmacology of a mu-opioid ag-
onist; no off-target toxicity was observed. In rats, the major clinical sign was foot
sores due to increased paw chewing at 200 to 600 mg/kg/day, a known opioid effect
in rodents. Mild to moderate gait and activity changes were noted at 600
mg/kg/day in a neurobehavioral assessment in the 2-week study. The incidence of
clinical findings diminished with repeated dosing. Decreased mean body weights
relative to controls was observed in males at ≥200 mg/kg/day and in females at 600
mg/kg/day. In dogs, major clinical signs were post-dose emesis at doses ≥15
mg/kg/day and mild, transient hypoactivity at 75 mg/kg/day. Accommodation to
both emesis and hypoactivity was observed. Decreased mean body weights relative
to controls were observed at 75 mg/kg/day in the 13-week study. No adverse clini-
cal pathology or histopathological changes were noted in the rat or the dog. The
NOAEL was determined to be 200 mg/kg in rats and 75 mg/kg in dogs (human
equivalent doses of 32 and 42 mg/kg, respectively). Plasma levels (AUC) at the
NOAEL after 13 weeks of dosing were 170,034 hr*ng/mL in rats and 33,026
hr*ng/mL in dogs. These studies demonstrate that NKTR-181 is well tolerated and
produces minimal CNS side effects in both rat and dog.
1223 Safety Assessment of NU100 in a 6-Month Cynomolgus
Monkey Study.
H. Hu1,  V. Tammara2,  D. Hobson3,  E. Shaw2,  D. Zeng2 and A. M. Brooks1.
1Covance Laboratories Inc., Madison, WI; 2Nuron Biotech Inc., Exton, PA; 3LoneStar
PharTox LLC, Boene, TX.
NU100 is recombinant human interferon beta-1b (IFN beta-1b) being developed
for treating multiple sclerosis. NU100 has a better purity profile (aggregate-free and
HAS free) compared to other marketed products. A GLP monkey study for NU100
safety assessment was conducted which was originally planned as a 6-month subcu-
taneous injection study with a 28-day recovery. Male and female cynomolgus mon-
keys were assigned to 5 groups (4 or 6 animals/sex/group), and were dosed once
daily or every other day with NU100, Betaferon and placebo at dose levels of 0,
0.01, 0.06, or 0.28 mg/kg/dose. Animals were monitored clinically, and blood sam-
ples were collected for evaluation of serum levels of IFN beta-1b, neopterin (a bio-
marker for IFN beta-1b pharmacodynamics), and anti-drug antibodies (ADA). No
NU-100-related adverse clinical findings were noted during the study. IFN-beta-1b
serum concentration peaked in circultaion within 2 to 4 hours after administration
of NU100 on Days 1 and 15 with a higher level on Day 15; however, by Weeks 18
and 22, IFN beta-1b level returned to the baseline levels. Similarly, neopterin con-
centrations increased on Day 1 following administration of NU100 in a dose-de-
pendent manner. Mean predose neopterin concentrations remained slightly ele-
vated on Day 15 compared with Day 1 baseline levels. Nevertheless, no further
induction of neopterin was noted on Day 15. By Weeks 18 and 22, neopterin con-
centrations returned to predose levels. At week 2, 12.5% animals treated with
NU100 and 37.5% treated with Betaferon were confirmed positive for ADA. All
NU100 treated primates were confirmed positive for ADA at weeks 2, 4, 8, 12, and
18 during the study. Due to the loss of IFN-beta-1b activity resulting from the gen-
eration of anti-IFN beta-1b antibodies, the dosing phase of the monkey study was
terminated one month earlier than planned, following discussion with and approval
from the FDA. In conclusion, NU100 was well tolerated by monkeys in this
chronic toxicology study.
1224 BPM31510 Is a Novel Regulator of Mitochondrial Function
That Mitigates/Rescues Drug-Induced Toxicity—Evidence in
Drug-Induced Cardiotoxicity and Cancer Chemotherapy
Using In Vitro and In Vivo Models.
R. Sarangarajan1, 2, 3,  T. Walshe2,  A. Lee2,  R. Ouro-djobo2,  L. M. Mauro4,
V. Vishnudas1, 2,  J. J. Jimenez4 and N. R. Narain1, 2, 3. 1Berg Pharma LLC, Natick,
MA; 2Berg Biosystems, Natick, MA; 3Berg Diagnostics, Natick, MA; 4University of
Miami, Miller School of Medicine, Miami, FL.
In a large cohort of drugs routinely used in clinical practice, disruption of mito-
chondrial function represents a common thread associated with incidence of organ
specific toxicities. An example is the incidence of cardiotoxicity associated with
anti-diabetic drugs, cancer chemotherapeutics and anti-retroviral agents.
Ubidecarenone is a mitochondrial resident molecule with multiple functionalities
including electron transport and generation of ATP. The delivery of ubidecarenone
to the mitochondria is a challenge due to its physiochemical properties. BPM31510
is a nanodisperison formulation containing ubidecarenone incorporated into a
novel lipid mixture with improved ability to deliver ubidecarenone with ability to
influence mitochondrial function. The effect of BPM31510 on the toxicity profiles
of several cancer chemotherapeutic agents was tested in cell cultures and animal
models of cancer and on the cardiotoxicity potential of an anti-diabetic drug in pri-
mary cultures of normal human cardiomyocytes. BPM31510 significantly en-
hanced the efficacy of multiple chemotherapeutic agents used for treatment of can-
cers of the pancreas, prostate, breast and colon in in-vitro and in-vivo models. In
addition, BPM31510 mitigated chemotherapy induced toxicity in primary cultures
of normal human liver, fibroblast and prostate cells. Furthermore, BPM31510 re-
versed mitochondrial dysfunction resulting from exposure to an anti-diabetic drug.
BPM31510 represents a novel technology effectuating a multimodal physiological
response in which it does not interfere with the normal therapeutic mechanism of
action of chemotherapy drugs, yet confers protection to normal tissues. BPM31510
is currently in clinical trial as a mono-therapy for solid-tumors with no reported ad-
verse effects.
1225 Etirinotecan Pegol Nonclinical Toxicology Studies Establish a
Margin of Safety to Support an Every Three-Week Clinical
Dosing Schedule.
T. D. Sweeney,  E. Tonkin,  U. Hoch and C. Ji. Nektar Therapeutics, San Francisco,
CA.
Background: Etirinotecan pegol, formerly NKTR-102, is a unique targeted topoi-
somerase I inhibitor designed for prolonged tumor cell exposure. Etirinotecan
pegol has demonstrated a favorable tolerability profile in nonclinical and clinical
studies with improved safety over irinotecan. Toxicology studies were conducted in
dogs to further evaluate etirinotecan pegol safety and establish dose-related toxici-
ties. Methods: Etirinotecan pegol was administered as an IV infusion to dogs for 3
months using a q14d schedule at doses up to 30 mg/kg (600 mg/m2) irinotecan
equivalents. Direct comparison to irinotecan was evaluated in dogs using a q7dx4
schedule (Persson et al, 2008). Clinical observations, clinical chemistry, and
histopathology were performed and toxicokinetic samples were collected and as-
sayed by LC-MS/MS for etirinotecan pegol, irinotecan, SN38, SN38-Glucuronide,
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and APC. Results: Etirinotecan pegol-treated dogs (25 mg/kg, 500 mg/m2) had re-
duced neutropenia and diarrhea and no mortality compared to irinotecan-treated
animals at the same dose when given q7dx4. When given q14d for 3 months,
etirinotecan pegol-treated dogs (30 mg/kg, 600 mg/m2) had no neutropenia and
minimal diarrhea at SN38 exposure levels up to 5-fold above those in patients given
145 mg/m2 etirinotecan pegol on a q21d schedule. Body weight gain suppression
and decreased food intake were the primary side effects observed at this etirinotecan
pegol dose and schedule. No test-article related alopecia was noted in animals
treated with etirinotecan pegol in any of the toxicology studies in contrast to litera-
ture reports of alopecia in both humans and in animals treated with irinotecan.
Conclusions: Nonclinical toxicology studies show that etirinotecan pegol produces
markedly less neutropenia and diarrhea with no mortality when directly compared
to irinotecan. Etirinotecan pegol is well-tolerated for 3 months at doses that provide
a good safety margin (based on SN38 exposure) to support a clinical regimen of
145 mg/m2 given every 3 weeks.
1226 Transient Thrombocytopenia without Coagulopathy in Rats
following Single IV Bolus of Oxycyte®, a Perfluorocarbon
(Pfc) Based Oxygen Carrier.
S. Anderson1,  L. Bernard2,  J. Szabo2 and T. Bradshaw1. 1Oxygen Biotherapeutics,
Morrisville, NC; 2Ricerca Biosciences, Concord, OH.
Oxycyte®, a 60% w/v perfluoro(t-butylcyclohexane)[FtBu] intravenous emulsion,
is being developed for treatment of traumatic brain injury (TBI). Transient throm-
bocytopenia (TTP), a known class effect of PFCs, may pose a risk for TBI patients.
A rat model of intracranial hemorrhage (ICH) is under development to ascertain
whether TTP subsequent to Oxycyte administration exacerbates ICH and whether
platelet transfusion will ameliorate TTP associated ICH. As part of model develop-
ment, studies were conducted to determine hematology, coagulation, cytokine, and
PK profiles following Oxycyte administration. Male rats received a single IV bolus
of Oxycyte at 3, 6, or 12 mL/kg. Blood was collected via jugular cannula
(n=3/group) at 10 post administration time points and analyzed for FtBu concen-
tration. Additional rats (n=5/group/time point) were sacrificed on Study Days (SD)
2, 3, 4, 5, 7, 10, 14, and 30 for hematology and blood cytokine analyses. Blood
T1/2 following 3, 6, or 12 mL/kg was 4.2, 3.9, and 6.3 hours respectively. AUC
was 12- and 48-fold higher for rats receiving 6 and 12 mL/kg compared to 3
mL/kg. There was a 30-40% decrease in PLT counts on SD3-5 in rats receiving 3
or 6 but not 12 mL/kg suggesting Oxycyte-induced PLT sequestration (TTP)
rather than PLT destruction. Mean platelet volumes were increased in all Oxycyte
groups through SD7 with a decrease in reticulocyte (RTC) counts and elevated fib-
rinogen levels through SD5. Except for elevated fibrinogen concentrations, there
were no significant changes in coagulation parameters. No elevations in IL-6, TNF-
α, and IL-1β levels were detected. Liver and spleen weights were elevated at all time
points. RTC changes were considered a pharmacologic response to Oxycyte with
no concurrent changes in erythrocyte counts. Increased liver and spleen weights
were expected effects due to removal of Oxycyte by the reticuloendothelial system,
the known mechanism for clearing PFC particles.
1227 Immunomodulatory Activity of Orphan Drug Elmiron® in
Female B6C3F1/N Mice.
S. Thakur1,  N. Abraham2,  K. L. White3,  M. J. Smith3,  W. Auttachoat3 and
D. R. Germolec1. 1Division of National Toxicology Program, NIEHS, NIH, Research
Triangle Park, NC; 2Integrated Laboratory Systems, Research Triangle Park, NC;
3Virginia Commonwealth University, Richmond, VA.
Interstitial cystitis/painful bladder syndrome (IC/PBS) is a chronic disorder charac-
terized by bladder discomfort and urinary urgency in absence of identifiable infec-
tion. Elmiron® (EMR; sodium pentosan polysulfate) is the only approved oral
therapy for treatment of IC/PBS. Based on the lack of chronic toxicity data and po-
tential for long term use in the treatment of IC/PBS, NTP conducted 90-day and
2-year toxicity studies for EMR. The results suggested that EMR could potentially
modulate the immune system. Therefore, this study was conducted to evaluate the
immunomodulatory effects of EMR when administered for 28-days via oral gavage
to female B6C3F1/N mice, at doses of 63, 125, 250, 500 or 1000 mg/kg. Mice
treated with EMR had a significant increase in absolute liver weights (500 and
1000 mg/kg). The absolute numbers of splenic macrophages (63, 500 and 1000
mg/kg) and natural killer (NK) cells (250 and 1000 mg/kg) were significantly in-
creased. EMR treatment did not affect the humoral immune response (antigen spe-
cific antibody response to sheep red blood cells [SRBC]) or cell-mediated immu-
nity (mixed leukocyte response). However, innate immune responses such as
phagocytosis of radiolabelled SRBC by liver macrophages (1000 mg/kg) and NK
cell activity were enhanced (500 and 1000 mg/kg). Further analysis using a disease
resistance model showed that EMR-treated mice demonstrated significantly in-
creased anti-tumor activity against B16F10 melanoma cells at the 500 and 1000
mg/kg doses, where the numbers of tumor nodules were decreased by 55% and
68%, respectively. Collectively, we conclude that EMR administration stimulates
the immune system, increasing numbers of specific cell populations and enhancing
phagocytosis and NK cell activity in female B6C3F1/N mice.
1228 Assessment of Long-Term Preclinical Safety of Inhaled
Technosphere® Particles and Afrezza® Inhalation Powder.
S. Greene1,  K. Nikula2,  D. Poulin3,  K. McInally4 and J. Reynolds5. 1MannKind
Corp, Valencia, CA; 2Seventh Wave Laboratories, Chesterfield, MO; 3Charles River
Laboratories, Montréal, QC, Canada; 4ITR Laboratories, Montréal, QC, Canada;
5JA Reynolds & Associates, Madison, CT.
The inhalable insulin, AFREZZA® inhalation powder and novel excipient, FDKP
(fumaryl diketopiperazine which self assembles into Technosphere® Particles),
were evaluated in nonclinical safety studies for the treatment of diabetes. Daily
doses of either Technosphere particles or AFREZZA inhalation powder were ad-
ministered by nose-only route in chronic repeat dose and carcinogencity studies in
rats or oronasal route in dogs. With the exception of transient exaggerated pharma-
cological effects of insulin, inhalation administration for up to 104 weeks in rats
and 39 weeks in dogs was well-tolerated. There were no adverse effects on body
weight, food consumption, ophthalmoscopy, clinical pathology parameters or elec-
trocardiography (dogs). There were no indications of carcinogenic potential or pro-
liferation related to AFREZZA inhalation powder in pulmonary tissues by im-
munostaining using proliferating cell nuclear antigen assay. Non-proliferative
lesions were limited to minimal goblet cell hyperplasia and eosinophilic accumula-
tion in the olfactory/respiratory epithelium in rats; and minimal neutrophil infil-
tration in lung in dogs. Maximum systemic concentrations of insulin and FDKP
were rapidly attained. Terminal half life was approximately 20 and 60 min for in-
sulin and FDKP, respectively. In dogs, systemic exposure of FDKP and insulin was
generally dose proportional with no sex differences or accumulation. In rats, insulin
exposures were generally higher in females compared to males. Exposure to insulin
was inversely related to dose-dependent decreases in serum glucose levels. Based on
the data from these chronic inhalation studies, the no adverse effect level was estab-
lished as the highest studied doses for AFREZZA inhalation powder and
Technosphere particles in both species.
1229 NF-κB Activation in the Hippocampus during Multiple
Subthreshold Exposures to Seizurogenic Compounds.
J. A. Miller1,  K. S. Kirkley1,  Y. H. Raol2,  M. Patel3,  R. A. Bialecki4 and
R. B. Tjalkens1. 1Center for Environmental Medicine, Colorado State University, Fort
Collins, CO; 2Department of Pediatric Neurology, University of Colorado, Denver,
CO; 3Department of Pharmaceutical Sciences, University of Colorado, Denver, CO;
4Safety Assessment, AstraZeneca, Boston, MA.
Drug-induced seizures have been documented for broad classes of pharmaceuticals
including CNS and Non-CNS targeted drugs. A better understanding of the early
molecular signaling events involved in promoting seizures is necessary to identify
potential proconvulsive liability of new pharmacologic agents earlier in the devel-
opment process. The NF-κB pathway is involved in regulating a number of stress
genes and its activation may conceivably be an early indicator of potential seizure li-
ability. Presently, we employed a NF-κB-dependent GFP reporter mouse to investi-
gate the role of NF-κB signaling in rendering hippocampal neurons hyper-ex-
citable. Utilizing EEG recordings and video documentation we established a
sub-threshold dose level of the seizurogenic compound kainic acid (KA).
Transgenic reporter mice were exposed to multiple sub-threshold doses of KA and
regional and cell specific NF-κB activity was assessed after each dose. Under control
levels reporter expression was absent in the hippocampus except for a slight basal
expression in the CA3 pyramidal layer. Upon multiple exposures to KA, a pro-
nounced expression of the GFP reporter was observed in the stratum moleculare,
dentate gyrus molecular layer and in the dentate hilus. Additionally we exposed re-
porter mice to multiple low levels of a different seizurogenic compond,
pentylenetetrazole (PTZ). After multiple doses of PTZ, a global increase in GFP
expression was observed. Comparison of the two compounds suggests a regionally
selective expression consistent with the distinct mechanisms of action for each com-
pound. Utilizing cultured slices from the reporter mice we observed similar selec-
tive GFP expression in response to the two compounds demonstrating the potential
utility of this method for the assessment of proconvulsive properties of new phar-
macologic compounds.
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1230 Starting Dose Selection for First-in-Human Trials Using
Model-Based Approaches.
V. Kadambi,  S. Palani,  A. Lynn,  J. Senn,  S. Ottinger,  J. Mettetal,  S. Chong,
E. Fedyk,  W. Shyu and A. Chakravarty. Millennium: The Takeda Oncology
Company, Cambridge, MA.
Selection of the safe starting dose (SSD) in oncology represents a critical decision
point in the drug development process, as under- or over-prediction of the SSD can
have serious consequences in Phase I, exposing patients to doses that are either sub-
therapeutic or unsafe.
The SSD is commonly estimated by determining if 1/10th the severely toxic dose
in rodents (STD10) is tolerated by non-rodents, and if so, using 1/10th of the ro-
dent STD10 dose as the SSD. In general, the STD10 is estimated from GLP toxi-
cology studies where relatively large numbers of animals are divided into a few dose
groups to increase statistical power within a group. 
Here, we propose an alternative method to estimate the STD10 based on logistic
regression curve-fitting, (a standard technique for modeling binary outcomes in the
clinical setting) with mortality as a binary endpoint. To this end, we simulated mor-
tality data based on 400 different sigmoidal dose-mortality curves with a proba-
bilistic model, and predicted STD10 by logistic regression, comparing this ap-
proach to the traditional dose-picking methodology for the same datasets.
Model–predicted STD10 values outperformed the traditional method, with better
accuracy (absence of downward bias) and precision relative to the true STD10.
Additionally, this approach was resistant to the effect of outliers (unexplained mor-
tality). More importantly, the superior accuracy and precision of the STD10 values
determined by logistic regression could be achieved with fewer animals used in the
conventional approach. A retrospective analysis of an anticancer compound cur-
rently in Phase I clinical trials demonstrated potential to narrow the gap between
the human Maximum Tolerated Dose and SSD from 110-fold to 10-fold. 
By using the information from all animals in a study, logistic regression curve-fit-
ting provides the potential for a more robust and less biased SSD, while at the same
time decreasing the number of animals utilized.
1231 Application of Electroretinography (ERG) in Early Drug
Development for Assessing Ocular Toxicity in Rats.
W. W. Collette,  M. Twamley,  Q. Peng,  S. Aguirre,  W. Huang,  A. Sacaan and
A. John-Baptiste. Worldwide Safety Sciences, Pfizer Inc., La Jolla, CA.
Retinal ocular toxicity is among the leading causes of drug development attrition in
the pharmaceutical industry. Electroretinography (ERG) is a non-invasive func-
tional assay used to assess neuro-retinal physiological integrity by measuring the
electrical responses of various retinal cell types. When applied in the pre-clinical set-
ting, ERG may be utilized to evaluate potential ocular toxicity of drug candidates.
Studies were designed to assess the sensitivity and specificity of ERG to detect ocu-
lar toxicity in Wistar Han rats using several drugs with varied activity in the retina
ranging from no evidence to those with demonstrated microscopic retinal degener-
ation. To directly assess the utility of ERG, these studies were conducted following
a single intravitreal injection (IVT). Doses were selected based on an in-vitro retinal
pigment epithelium (RPE) cytotoxicity assay and compound solubility limit. Serial
collections of ERG assessments were conducted over a two week period. In addi-
tion, EDTA blood samples were obtained for miRNA retinal toxicity biomarker
analysis, in-direct ophthalmic examinations were performed, and eyes were col-
lected at the end of the study for histopathology evaluation. Here we report IVT
administration of AG-012986 resulted in decreases in b-wave amplitude correlating
with increases in plasma levels of retinal toxicity biomarkers (miR-124a and miR-
183) as well as marked retinal degeneration as revealed by microscopic evaluation.
By contrast, administration of vehicle or acetaminophen did not result in any
changes in b-wave amplitude. This work suggests that ERG assessment of retinal
toxicity following a single IVT treatment may be a sensitive and reliable screening
tool in rodents to identify compounds that have a potential risk for ocular toxicity.
1232 Absolute Quantitation of Low-Abundance Protein Adducts
Using a Novel Accelerator Mass Spectrometry Liquid Sample
Interface.
B. Stewart1,  A. T. Thomas2,  T. Ognibene2,  K. W. Turteltaub1 and G. Bench2.
1Biosciences and Biotechnology Division, Lawrence Livermore National Laboratory,
Livermore, CA; 2Center for Accelerator Mass Spectrometry, Lawrence Livermore
National Laboratory, Livermore, CA.
Drug characterization studies including the detection and quantitation of protein
adducts arising from reactive drug metabolites provide important information
about a drug candidate’s potential to cause adverse reactions. Current methods for
characterizing protein adducts are limited by low sensitivity and difficulty identify-
ing modified proteins. We report the use of a novel accelerator mass spectrometry
(AMS) liquid sample interface for absolute quantitation of protein modification by
14C-iodoacetamide and identification of peptide modification patterns.
Competitive binding experiments showed that covalent adducts of cysteine residues
in bovine serum albumin can be quantified at the attomole level in microgram-size
samples of intact protein.  Tryptic digestion and HPLC separation of albumin pep-
tides followed by peptide analysis using the liquid sample interface and electrospray
ionization and tandem mass spectrometry (ESI-MS/MS) showed reproducible pat-
terns of adduct formation, with modifications localized to specific regions of the
protein corresponding to regions predicted by known chemical reactivity.
Measurements of whole protein adducts using the liquid sample interface were
comparable to values measured by standard graphitization with AMS analysis. This
technology presents an important novel method for absolute quantitation of 14C-
labeled proteins and peptides. Potential applications include microdosing studies
using 14C-labeled protein therapeutics and investigation of post-translational and
chemical modifications of proteins.
1233 Evaluation of Respiratory Function in the Conscious,
Nonrestrained Cynomolgus Monkey Using Respiratory
Inductive Plethysmography.
J. Le Bigot,  J. Maucotel,  F. El Amrani,  S. Loriot,  A. El Amrani,  J. Legrand and
R. Forster. CiToxLAB France, Evreux, France.
Evaluation of the potential alteration of respiratory function is mostly performed in
rodents using whole body plethysmography, while cardiovascular telemetry studies
are usually conducted in large animals. The purpose of the present study was to
evaluate the use of respiratory inductive plethysmography (RIP) as a method that
might be suitable for routine evaluation of respiratory function in primates.
Four monkeys were equipped with jacketed external telemetry devices including
abdominal and thoracic belt sets (JET, DSI). Thoracic and abdominal signals were
recorded and analysed using Ponemah software. After an acclimation period, ani-
mals received theophylline (100 mg/kg, p.o), clonidine (100 μg/kg, i.m) and corre-
sponding vehicle (0.5% methylcellulose, p.o or NaCl 0.9%, i.m). Respiratory rate
(RR), tidal volume (TV) and minute volume (MV) were recorded continuously
over 24 hours. 
Theophylline induced increases in TV, MV and RR when compared to vehicle
(Emax: +55%, +118% (p < 0.01) and + 41% (p < 0.01), respectively). Clonidine
produced significant decreases in TV and MV and RR (Emax: -12%, -29 % (p <
0.01) and -27% (p<0.05)). 
The results demonstrate the validity of the RIP method for the assessment of respi-
ratory function in the monkey for a long period (24 hours). These findings support
the use of the RIP method for combined assessment of potential effects of drug can-
didates on cardiovascular and respiratory functions. The methodology could allow
the integration of respiratory investigations into regulatory toxicology studies in
primates. Such an approach is particularly applicable for the safety evaluation of
biotechnology-derived products, for which rodents are often not applicable models.
1234 Impact of Food and Fecal Contamination on Dog Urinalysis
Data.
M. Felx,  V. Allegret,  N. Oleas,  S. Y. Smith and F. Poitout. Charles River,
Montréal, QC, Canada. Sponsor: M. Vézina.
Suspected aberrant urinalysis results were observed in dogs urinating limited urine
volumes, or presenting clinical diarrhea, prompting an investigation to determine
potential causes of contamination. Diet consumed and feces were identified as po-
tential sources. Dietary effects on blood urine contents were determined using two
laboratory diets: Certified Canine Chow No. 5007 and Harlan Teklan Certified
25% Lab Dog Diet (2025). Urine was collected from animals deprived of food and
water, previously fed either diet during a 5 hour period as well as following an
overnight collection period. Each diet was mixed with saline to mimic contamina-
tion. Five hour small urine samples collected from animals fed diet 5007, and 5007
diet-saline suspensions, both tested positive for moderate (3+) to large (4+)
amounts of blood measured semi-quantitatively with urine dipsticks (Multistix
10SG, Siemens). 2025 diet-saline suspensions tested positive for traces of blood.
Larger volumes and more dilute urine collected following overnight collection
tested negative for blood indicating levels were below the detection threshold. The
effect of fecal contamination, in dogs presenting diarrhea, on several markers of
kidney function was also evaluated. Varying amounts of feces, from 1 to 5 grams
were added to approximately 8 mL urine to mimic contamination. Contaminated
and uncontaminated samples were analyzed for N-Acetyl-B-D-glucosaminidase
(NAG), Gamma-glutamyl-transferase (GGT) and protein, with values corrected
for urinary creatinine concentration. Increases in kidney markers were proportional
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to the amount of fecal contamination, with the highest amount of fecal contamina-
tion tested showed NAG/creatinine ratio was increased by 38 fold, GGT/creatinine
ratio by 24 fold and protein/creatinine ratio by 8 fold. In conclusion, the type of
diet and feces were demonstrated as sources that may impact data obtained from
contaminated and/or small urine samples. Optimally, urine should be collected
from dogs deprived of food but with access to water (plus a water catcher), or by
cystocentesis or bladder catheterization to minimize contamination.
1235 High-Resolution Isotope Dilution (HRID) Quantitative
Analysis: Metabolites in Safety Testing (MIST) Application
to Diclofenac.
J. Vrbanac1,  A. Hilgers1,  B. Shilliday1,  T. Dubnicka1,  D. Humphries2 and
R. Hayes2. 1ADME, MPI Research, Mattawan, MI; 2Analytical Sciences, MPI
Research, Mattawan, MI.
During early clinical development it is important to understand the identity and
amount of circulating metabolites in man. Are there human specific metabolites?
Guidelines have been issued by regulatory agencies to address this question
(CDER, 2008). We are interested in applying the metabolism of isotope labeled
drugs [14C alone or both 14C and 13C] and HRID to accurately determine MIST
liability in the clinic in a manner that is both rapid and not excessively expensive
(e.g., involve AMS, de novo synthesis and bioanalytical method development for
relevant drug metabolites). Simplicity and ruggedness are also important aspects of
these efforts. This work investigated diclofenac (D). Diclofenac, [14C]D (62.7
mci/mmole) and [13C6]D were purchased. Human hepatocytes were purchased
from Life Technologies, Grand Island, NY. Incubations were conducted following
Life Technologies procedures. Chromatographic separation was achieved using an
Agilent 1200 HPLC system and detection of radioactivity was by an IN/US β-Ram
Model 3. MS analysis was by Thermo LTQ Orbitrap Discovery MS (+ ESI). No
special tuning was done for D metabolite analysis. Since the specific activity of the
label was known and fixed, the amount of drug metabolite/parent drug in the incu-
bates at 60 minutes were determined using LC-RAM.  Assuming that the amounts
of drug metabolites produced from [13C6]D was similar to the amount produced
for the [14C6]D allowed for the construction of standard curves for all drug-related
material within the limits of detection. This allowed for the quantitative analysis of
drug-related material including, 4-hydroxy-D and D-glucuronide. The method re-
sulted in acceptable linearity, sensitivity and reproducibility for all analytes. A sec-
ond key concept is that using HRMS compared to MS-MS using tandem quadru-
pole affords considerable advantages in simplicity and ruggedness, a key objective.
1236 12-Week Intrathecal Administration Study in Port
Catheterized Juvenile Cynomolgus Monkeys.
S. H. Korte1,  C. B. Rose1,  M. Niehoff1 and M. Butt2. 1Covance Laboratories
GmbH, Muenster, Germany; 2Tox Path Specialists, Frederick, MD. Sponsor: G.
Weinbauer.
The cynomolgus monkey is the predominant NHP species when it comes to pre-
clinical safety evaluation of new medical products. Assessment of juv. toxicity
within this species represents an emerging field, requiring established techniques
for 12 month or younger monkeys. The objective of the study was to determine the
feasibility of bi-weekly bolus delivery in an intrathecally implanted port catheter
system to the juv. monkey for 12 wks and to assess the feasibility of CSF collection.
Vehicle or PBS was administered to 6 implanted (between L2-L5) monkeys (8-13.5
months; ~800 g). Clinical signs, bw, neurological examinations, CSF, and clinical
pathology data were obtained. Perfusion necropsy, spinal cord brain trimming and
pathology were conducted. There were no indications for procedural-related clini-
cal signs, bw development, clinical pathology or neurological findings. Increased
AST was observed on day 2, most likely related to manual restraint of the animals
on day 1. Necropsy confirmed the placement of the catheter tips at T11/12 in 4/6
animals. There were no adverse effects noted at the site of the catheter in the in-
trathecal space and in particular, no evidence of pronounced reactions at the
catheter tips. At the catheter tip, tissue reactions were consistent with those re-
ported to occur with the placement of intrathecal catheters in multiple species (M
Butt, 2011). Changes at the catheter tip included slight to minimal fibrosis, adhe-
sion to the overlying dura, and slight compression of the spinal cord (no cord dam-
age). Overall lumbar CSF sampling through the port was only possible in 1/6 ani-
mals. However, spinal lumbar CSF sampling under sedation using a Pencan Paed®
needle proved to be successful on all occasions. Obtained CSF indicated a low level
of white blood cells after surgery, and minimum of red blood cells contamination.
In conclusion, lumbar intrathecal administration of juvenile cynomolgus monkeys
for up to 12 wks using a surgically implanted port catheter system is considered fea-
sible.
1237 BMS-964210, a Pegylated Bispecific Adnectintargeting
EGFR and IGF-1R, Demonstrates Improved Class-Specific
Toxicity Profile in Cynomolgus Monkeys.
M. Guha1,  R. W. Lange1,  J. Gokemeijer2,  R. White1,  B. Silver2,  N. Marsh2,
K. Manson2,  T. P. Sanderson1 and R. T. Bunch1. 1Drug Safety Evaluation, Bristol-
Myers Squibb, Mount Vernon, IN; 2Early Candidate Assessment, Adnexus, Waltham,
MA.
Simultaneous modulation of epidermal growth factor receptor [EGFR] and insulin
like growth factor receptor 1 [IGF-1R] signaling, as an oncology therapeutic strat-
egy, is based on cross talk between the two signaling pathways to overcome resist-
ance developed if only a single pathway is targeted. However, evidence of class-re-
lated adverse effects of individual anti-EGFR and anti-IGF-1R agents in humans
including diarrhea, acne form skin rash and interstitial pneumonitis (EGFR-spe-
cific) and hyperglycemia, thrombocytopenia and cardiovascular toxicities (IGF-IR-
specific) has emerged in clinical and non-clinical toxicity studies. In contrast to
marketed anti EGFR monoclonal antibodies which bind to domain III of the ex-
tracellular portion of EGFR, BMS 964210 binds with high affinity to domain I
and overlaps the EGF and TGFα binding pocket of both human and cynomolgus
monkey EGFR and IGF 1R. In a 4 week intravenous (2QW) toxicology study with
BMS-964210 in cynomolgus monkeys (6, 12 and 25 mg/kg), pharmacodynamic
elevation of plasma biomarkers of EGFR and IGF 1R blockade (TGFα, amphireg-
ulin, and IGF 1) were observed. Despite the generation of anti BMS 964210 anti-
bodies, systemic exposures following first dose were dose proportional and elimina-
tion was linear. No evidence of rash, pulmonary findings, hyperglycemia or
thrombocytopenia was noted, and there were no drug related deaths or effects on
neurologic, respiratory, or ophthalmologic endpoints. At the highest dose, two fe-
male monkeys suffered body weight loss and dehydration that required fluid ad-
ministration for 3 days. Based on the highest non-severely toxic dose (HNSTD) of
12 mg/kg, there is sufficient safety margin to the proposed clinical starting dose of
0.5 mg/kg (QW). These preliminary data suggests that BMS-964210 may have an
improved tolerability profile compared to marketed anti-EGFR mAb and deserves
further evaluation in clinical studies.
1238 Subcutaneous Injection Sites: Is the Quality of the Diagnosis
Improved When More Than One Tissue Section Is
Examined?
J. Briffaux,  C. Thuilliez,  C. Clément and M. Perron Lepage. Ricerca Biosciences
SAS, St. Germain sur l’Arbresle, France.
At our Laboratory, the microscopic examination of subcutaneous injection sites in-
volves the evaluation of three longitudinal sections per tissue sample. We conducted
a retrospective study to evaluate the relevance of the diagnoses in subcutaneous in-
jection sites if only one section is examined. 
Two rat studies and three primate studies were reviewed. All animals received saline
or test item injected subcutaneously in the dorsum. At necropsy, 3 pieces, each 3
mm wide, were trimmed from each site. Piece 1 was in the middle, piece 2 lateral to
it and piece 3 medial to it. The original study pathologists formulated overall diag-
noses for each site, taken from evaluation of each of the 3 pieces.
One pathologist reviewed the three sections from each site with reference to the
findings recorded by the original study pathologists and attributed each of the orig-
inal diagnoses to the section(s) where it was observed. In each species, animals re-
ceiving saline or test item were evaluated separately. Statistical analysis was per-
formed, comparing section 1 with the other two sections and with the original
overall diagnosis. 
In the rat, section 1 had a statistically significantly higher number of findings when
compared to other sections, in control and treated animals. In the primate, section
1 did not differ from the other sections in control and treated animals. In both
species, however, section 1 had a statistically significantly lower number of findings
when compared with the original overall diagnosis. 
Contrary to the results we obtained in a previous study concerning intramuscular
sites, this retrospective study reveals that examination of three sections of subcuta-
neous injection sites improves the quality of diagnosis. For microscopic changes in-
duced by subcutaneous injections, particularly in primates, one middle piece is not
considered to be sufficiently representative of the whole site.
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1239 Internal Exposure of Common Environmental Pollutants in
a Chinese Population.
S. Chen1,  Y. Lei1,  S. Zhang1,  A. Wang2 and W. Shi1. 1Pharmacology & Toxicology
and Biochemical Pharmaceutics, Zhejiang University, Hangzhou, China; 2Hangzhou
EPIE Bio-detection Technology Limited, Hangzhou, China. Sponsor: D. Thomas.
Studies indicated that exposure to environmental pollutants could increase the po-
tential risk of human’s health. Many efforts have been made to detect the environ-
mental pollutions, but, such data cannot be of concern to ordinary people for no
one knows how many environmental pollutants and at what amounts were exposed
to themselves. In order to provoke the attention of public and point out the indi-
vidual who is at risk mostly, it is necessary to measure the internal exposure of envi-
ronmental pollutants instead of external exposure of environmental pollutants.
These data can directly reflect the exposure of those pollutants to ordinary people.
In present study, we measured the total urinary concentrations of eleven common
pollutants in a Chinese population by GC, GC-MS, HPLC and ELISA. We found
the percentage of people with detectable levels of an individual chemical ranged
from 13% to 100%. Cotinine (COT) was detected in 88% of the persons
(n=2100), dibutyl phthalate (DBP) was detected in 97% of the persons (n=800),
the detection rate of aflatoxin (AFT) and toluene (TOL) were 85% and 13%, re-
spectively (n=600), organophosphorus (Org-p) was detected in 49% (n=400), tar-
trazine (TAR) was detected in 78% (n=351), the detection rate of diethylstilbestrol
(DES), methanoic acid (MA), Styrene (STY), terachlorodibenzo-p-dioxin (TCDD)
and nonyl phenol (NP) were 100%, 100%, 96%, 32% and 21%, respectively
(n=100). The 95th percentiles of COT, DBP, AFT, TOL, Org-p, TAR, DES, MA,
STY, TCDD and NP were 44 ng mL-1, 9 ng mL-1, 0.73 ng mL-1, 39 ng mL-1,
0.28 ng mL-1, 33.92 ng mL-1, 22, 000 ng mL-1, 23, 000 ng mL-1, 930 ng mL-1,
1,600 ng mL-1 and 0.33 ng mL-1, respectively. The present data show that people
in China are widespread exposure to multiple pollutants. Therefore, in order to de-
scribe the real risk of individual, a well designed study is needed to evaluate the as-
sociations between internal exposure of those pollutants and potential adverse
health consequences.
1240 Occurrence of Gaseous Pesticides and Other Hazardous
Volatiles in Sea Containers Arriving in Sweden.
G. Johanson1 and U. Svedberg2. 1Work Environment Toxicology, Karolinska
Institute, Stockholm, Sweden; 2Occupational and Environmental Medicine, Sundsvall
Hospital, Sweden.
Individuals who enter containers for inspection, unloading or cleaning may be ex-
posed to gaseous pesticides (fumigants) and other volatiles. Previous reports from
Hamburg and Rotterdam, as well as a few incidents in Sweden, have raised con-
cerns about the exposure situation in Swedish container terminals. Since systematic
studies in Sweden are missing, we performed a pilot study to investigate the occur-
rence of hazardous volatile chemicals in import containers. Air was sampled from
101 randomly selected containers in the port of Gothenburg. Air samples were
drawn without opening the containers, as they passed and briefly halted at the im-
port inspection station, and analysed by FTIR spectrometry. One container (1%)
contained detectable residues of fumigant (1 ppm carbonyl sulphide), although
none was labeled as fumigant treated. As in the two previous studies, a number of
other volatile chemicals were detected. The most common ones were methanol
(78%) and carbon monoxide (45%), with all readings below the occupational short
term excursion limits (STEL). These substances are likely degradation products
from the plywood flooring as they were also detected in empty containers. Other
frequently detected chemicals include hydrocarbons (unspecified, 47%) and am-
monia (15%), with some readings above or well above the STELs or ceiling limits
(CL). In our judgement, based on the present and two previous studies, the proba-
bility of life-threatening exposure is low. However, violations of STELs and CLs do
occur, thus prolonged or repeat visits in unchecked containers may constitute a sig-
nificant health hazard. In conclusion, extensive and systematic investigations of im-
port and export containers are greatly needed as basis for risk management meas-
ures. Methods for rapid and efficient ventilation should be developed. Prior to
entering it should be ensured, by adequate measurements and/or ventilation, that
the container is safe.
1241 Interactions between Urinary 4-Tert-Octylphenol Levels and
Metabolism Enzyme Gene Variants on Idiopathic Male
Infertility.
Y. Qin1,  M. Chen1,  W. Wu1,  B. Xu1,  G. Du1,  C. Lu1,  J. D. Meeker2,
Z. Zhou1,  Y. Xia1 and X. Wang1. 1Nanjing Medical University, Nanjing, China;
2University of Michigan School of Public Health, Ann Arbor, MI.
Background: Octylphenol (OP) and Trichlorophenol (TCP) are the representative
members of alkylphenols and chlorophenols, which act as endocrine disruptors and
have effects on male reproductive function.
Objectives: We studied the interactions between 4-tert-Octylphenol (4-t-OP), 4-n-
Octylphenol (4-n-OP), 2,3,4-Trichlorophenol (2,3,4-TCP), 2,4,5-Trichlorophenol
(2,4,5-TCP) urinary exposure levels and polymorphisms in selected xenobiotic me-
tabolism enzyme genes among 589 idiopathic infertile male patients and 396 con-
trols in a Han-Chinese population. 
Methods: Ultra high performance liquid chromatography-tandem mass spectrome-
try (UPLC-MS/MS) was used to measure alkylphenols and chlorophenols in urine.
Polymorphisms were genotyped using the SNPstream platform and the Taqman
method. We used likelihood ratio tests (LRT) to explore these gene-environment
interactions in idiopathic male infertility, and used false discovery rate (FDR) to ad-
just for multiple testing.
Results: Among four phenols that were detected, we found that only exposure to 4-
t-OP increased the risk of male infertility (Ptrend=1.70×10-7). The strongest inter-
action was between 4-t-OP and rs4918758 in CYP2C9 (Pinter=6.05×10-7). It pre-
sented a significant monotonic increase in risk estimates for male infertility with
increasing 4-t-OP exposure levels among men with TC/CC genotype (low level
compared with non-exposed, odds ratio (OR) =2.26, 95% confidence intervals
(CI) =1.06, 4.83; high level compared with non-exposed, OR=9.22, 95% CI=2.78,
30.59; but no associations observed among men with TT genotype). We also found
interactions between 4-t-OP and rs4986894 in CYP2C19, and between rs1038943
in CYP1A1, on male infertile risk (Pinter=8.09×10-7, 3.73×10-4, respectively).
Conclusions: We observed notable interactions between 4-t-OP exposure and me-
tabolism enzyme gene polymorphisms on idiopathic infertility in Han-Chinese
men.
1242 Smartphone Technologies Coupled with Environmental
Models Allow for Large Scale Community Outreach and
Risk Assessment.
A. J. Larkin1, 2, 3,  S. K. Krueger3, 4,  D. E. Williams1, 3, 4 and W. M. Baird1, 3.
1Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR;
2Statistics, Oregon State University, Corvallis, OR; 3Superfund Research Center,
Oregon State University, Corvallis, OR; 4Linus Pauling Institute, Oregon State
University, Corvallis, OR.
Chronic exposure to several air pollutants has been identified by the EPA as a major
source of concern for human health. Environmental models have been created to
predict spatial distributions of air pollutants, but are unable to account for daily
travel among the general US population. Several GPS-based methods of tracking a
person’s movement through areas of concern have been developed, but require ex-
pensive or bulky GPS units, have limited ability to provide timely results to partic-
ipants, and are dependent on user compliance. Smartphones are widely popular
across all demographic groups, with more than 100 million US smartphone users.
We developed iphone and android applications with GPS functionality to predict
personal and population-wide exposures to fine particulate matter (PM2.5), coarse
particulate matter (PM10), and ozone. Environmental distribution models were cre-
ated using Kriging algorithms with MODIS satellite imagery and Oregon
Department of Environmental Quality hourly PM2.5, PM10, humidity, ozone, and
temperature measurements. Geographic locations were sampled from four smart-
phone devices at 30 minute intervals (n>10000 sampling events). Locations and
corresponding times were sent to a database running the environmental modeling
software. Predicted exposure levels, times, and locations were returned to corre-
sponding smartphones and were anonymously added to a data set of predicted ex-
posures collected from all participants. Personal exposure levels were presented to
participants as interactive smartphone maps and graphs. Hotspot exposure sites
were predicted by partitioning Oregon into 10 km2 regions and mapping daily
group exposure levels within each region. This project was created with open-source
software and can be scaled to larger groups with minimal cost. This research was
supported by NIH P42 ES014465.
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1243 A High-Throughput Analytical Method for Enhanced
Toxicological Studies.
C. Y. Usenko,  E. M. Robinson,  E. D. Bruce and S. Usenko. Baylor University,
Waco, TX.
Toxicology studies are moving to high-throughput methodologies, however, often
times the chemical concentrations are not analyzed or verified. Historically, analyt-
ical methods capable of measuring organics in aqueous solutions (including fish
water and cell media) often relied on more complicated techniques. The technique
presented here has reduced 99% of the historically used sample preparation.
Thereby reducing the time per sample associated with preparation from ~90 min-
utes to <1 minute. This technique essentially eliminates the chance for target ana-
lyte loss during sample preparation and therefore eliminates the need for surrogate
standards, such as 13C-labeled, which is typically used to correct for analyte loss
during sample preparation.  This method utilizes an innovative liquid-liquid ex-
traction, where ~10-25 μL of cell media or water is transferred to a gas chromatog-
raphy (GC) vial with 1 ml of hexane and 50 mg of sodium sulfate. Target analytes
partition from the water to hexane and the water is captured by the sodium sulfate.
Overall extraction efficiency is ~100%. The utility of the novel method was
demonstrated with a proof of concept experiment that evaluated BDE 47 water
concentrations overtime from glass and plastic (48-well plate) wells. BDE 47 con-
centrations measured in the glass well remained consistent over 24 hrs; however
there was a rapid decrease in BDE 47 water concentrations (~80%) within the first
8 hrs in the plastic well. These results demonstrate that this method is simple and
useful for both water and cell media studies and offers the ability to monitor the
same well over time. Many exposures in toxicology studies start at concentrations
above solubility and are used in plastic plates. While this has been an acceptable
method of rapidly obtaining LC and IC50 values, it may not be an accurate repre-
sentation of the actual water concentration. By accurately analyzing the concentra-
tion and determining the uptake, more accurate results may be obtained and used
for risk assessment and mechanistic determinations, while adding increased study
to study comparability.
1244 Evaluating High-Throughput Exposure Models with
NHANES Data.
W. Setzer and J. F. Wambaugh. National Center for Computational Toxicology, US
EPA, Research Triangle Park, NC.
Prioritizing screening and testing for large sets of chemicals for potential risk re-
quires rapid exposure assessment, ideally based on chemical properties that are eas-
ily measured or computed. There are currently few such approaches, but like any
predictive methodology these need to be evaluated against real exposure data. We
evaluated two models, “Risk Assessment, Identification and Ranking” (RAIDAR;
www.arnotresearch.com/index.html#!/page_RAIDAR_DL) and
USEtox™(www.usetox.org) against the National Health and Nutrition
Examination Study (NHANES) 2005 and 2011 data on urine concentrations of
xenobiotics. Using NHANES to evaluate exposure models requires addressing sev-
eral issues: chemicals measured in urine need to be linked back to potential expo-
sures, and there may be multiple relationships between parent chemicals to which
people are exposed and the product chemicals measured in urine; many chemicals
were below limits of quantitation for a large fraction of the sampled subjects; varia-
tion among chemicals is a function of variation of exposure, pharmacokinetic
(PK)variability, and the distribution of relative times of exposure and sampling.
Steady state PK assumptions and a Bayesian statistical framework were used to infer
parent exposures from NHANES urine products. We further use Bayesian statisti-
cal methods to evaluate the regression of median population exposure to the parent
chemicals on RAIDAR and USEtox predictions, estimated production volume, and
simple indicators of household use. Household use was the single most important
factor. Among those chemicals with a consumer use, median exposure was corre-
lated with production volume, but there was little evidence of a relationship be-
tween estimated exposure and any of the predictors among chemicals with no
household use.  The resulting model can be used for predicting exposure potential
for new chemicals, along with the uncertainty of that prediction. Refining what
constitutes ‘household exposure’, as well as including more exposure datasets,
should reduce the uncertainty of the current model. [This abstract does not neces-
sarily reflect EPA policy.]
1245 Haematology and Erythrocyte Osmotic Fragility Indices in
Domestic Chicken following Exposure to a Polyvalent
Iodophorous Disinfectant in Water Treatment.
O. I. Azeez1,  A. A. Oyagbemi1 and O. T. Iji2. 1Department of Veterinary Physiology,
Biochemistry and Pharmacology, University of Ibadan, Ibadan, Nigeria; 2Federal
College of Animal Health and Production Technology, Moor Plantation, Apata,
Ibadan, Nigeria.
The effect of prolonged use of Iodosteryl, a polyvalent iodophorous compound, as
water disinfectant, on the hematology and erythrocyte osmotic fragility of the do-
mestic chicken was investigated. Twenty-eight adult male domestic chickens of the
Nera black strain were divided into four groups of seven birds per group. Birds in
groups B-D were given potable water containing 1 ml, 2 ml and 4 ml/l Iodosteryl
respectively for six weeks. Group A served as the control. 
Blood samples were collected from each bird after six weeks and analyzed immedi-
ately. No significant changes were observed in the packed cell volume (PCV),
haemoglobin (Hb), mean corpuscular volume (MCV), mean corpuscular haemo-
globin (MCH), mean corpuscular haemoglobin concentration (MCHC), platelet
total and differential leucocytes values. However, red blood cells (RBC) were
slightly lower while erythrocyte osmotic fragility and erythrocyte sedimentation
rate (ESR) was higher in those birds exposed to Iodosteryl compared with control. 
This study confirms that prolonged use of Iodosteryl is stressful and may lead to in-
travascular haemolysis as indicated by the higher erythrocyte fragility and ESR val-
ues, respectively. The damage observed, may be due to peroxidation of erythrocyte
membrane lipids, proteins by generation of free radicals induced by iodine.
1246 How Inaccurate Are Serum-Lipid Unadjusted
Organochlorine Levels?
S. Koifman,  C. Freire,  R. J. Koifman,  A. S. Rosa and P. N. Sarcinelli. National
School Public Health/ FIOCRUZ, Rio de Janeiro, Brazil. Sponsor: E. Silbergeld.
Introduction. Organochlorine pesticides (OCs) have been banned by many coun-
tries, but they are still detected in human and animal tissues worldwide.  An em-
piric assessment comparing serum lipid adjusted and unadjusted OC levels has
been, so far, not reported in the literature. Objective. To estimate how inaccurate
are lipid-unadjusted OCs serum levels compared to adjusted ones. Methods. In a
survey carried out in a rural population in Brazil exposed to OCs since early 1960’s,
blood samples were obtained from 995 residents of both sexes and all ages. Serum
concentrations of 19 OCs were determined by gas chromatography with electron-
capture detection and were further adjusted by triglyceride and cholesterol content.
Pearson correlation coefficients and determination coefficients (R2) of serum lipid-
adjusted and unadjusted concentrations of p,p’-DDE, beta-HCH and aldrin were
calculated. Results. Among male and female adults (> 14 yr.), median (1st and 3rd
quartiles) of serum-lipid adjusted concentrations were, respectively: 8.32 (2.86-
21.9) and 9.64(3.45-28.9) for p,p’-DDE; 6.0 (2.08-15.4) and 6.98 (2.81-17.6) for
beta-HCH; 1.89 (0.73-11.0) and 2.44(0.77-14.1) for aldrin. Determination coef-
ficients of serum lipid-adjusted and unadjusted OCs were R2= 0.91 for p,p’-DDE,
R2= 0.90 for beta-HCH, and R2= 0.93 for aldrin. Correlation between serum
lipid-adjusted and unadjusted concentrations was indeed higher for those OCs
with serum levels < 50 ng/ml. Conclusion. When serum lipid content is unavail-
able, unadjusted OC levels can be reasonably used to estimate internal dose of these
chemicals, particularly when concentrations are < 50 ng/ml.
1247 Revised Methods for Estimating Potential Re-Entry Exposure
Associated with Indoor Crack and Crevice Application.
J. H. Driver1,  J. H. Ross2,  S. Selim3,  J. Sharp4 and M. Pandian5. 1risksciences.net,
LLC, Manassas, VA; 2risksciences.net, LLC, Sacramento, CA; 3Selim & Associates,
Inc., Fresno, CA; 4McLaughlin Gormley King Company, Minneapolis, MN;
5infoscientific.com, Inc., Henderson, NV.
Surface deposition of insecticides applied as indoor residential foggers, baseboard or
perimeter sprays, spot sprays and crack-and-crevice sprays represent pathways of
unintentional, and unavoidable post-application exposure of children and adults.
Estimation of the magnitude of this exposure following an application event is as-
sociated with uncertainty due to many factors including 1) surface residue deposi-
tion and distribution, 2) access to and the nature of contact with treated surfaces
based on time-activity patterns of residents, and 3) the role of residue removal
mechanisms such as cleaning treated surfaces, pesticide degradation or redistribu-
tion, hand washing and bathing following contact. A comparative spatial deposi-
tion study was conducted involving broadcast, perimeter and crack and crevice ap-
plication methods. Residues measured using a spatial grid of deposition dosimeters
on floor surfaces demonstrated significantly lower residue concentrations in readily
268 SOT 2013 ANNUAL MEETING
accessible areas following crack and crevice and perimeter applications, versus
broadcast treatment. Analyses of other monitoring studies support this finding. The
implications of these findings are discussed for both screening-level and higher tier
probabilistic post-application, residential exposure assessment. In addition to sur-
face deposition studies, published biomonitoring data from adults and children
support ≥ 9-fold lower estimates of exposure for perimeter and crack and crevice
applications than EPA’s default of 2-3 fold lower than broadcast. We propose an al-
ternative “random walk” algorithm to provide an alternative to professional judg-
ment when evaluating exposure in rooms where only a fraction of the room has
been treated.
1248 Derivation of Biomonitoring Equivalents for Chlorpyrifos
Using a Pharmacokinetic/Pharmacodynamic Model of Oral
Exposures.
S. M. Arnold1,  A. Morriss2,  J. Velovitch3,  D. R. Juberg3,  P. Price1,  C. Burns1,
M. Bartels1,  A. T. McCoy1,  M. Aggarwal2 and T. Poet4. 1The Dow Chemical
Company, Midland, MI; 2Dow AgroSciences, Milton Park, United Kingdom; 3Dow
AgroSciences, Indianapolis, IN; 4Battelle, Richland, WA.
Blood chlorpyrifos (CPF) and its main urinary metabolite (3,5,6-trichloro-2-
pyridinol, TCPy) are often included in general population-based biomonitoring
data. Methods that put human internal dose measurements in a health-risk context
have been lacking. The concept of Biomonitoring Equivalents (BEs) seeks to ad-
dress this shortfall. BEs incorporate pharmacokinetic models to calculate biomarker
levels consistent with continuous exposure at exposure guidance values (e.g.,
USEPA reference doses). BEs rely upon the underlying toxicological endpoints
used in setting the guidance values and reduced uncertainty factors (UFs). Here, we
calculate BE values for blood CPF and urinary TCPy using a physiologically based
pharmacokinetic/pharmacodynamic (PBPK/PD) model. The model allows the di-
rect determination of CPF blood concentration associated with a 10% inhibition in
red blood cell cholinesterase (RBC ChE), the USEPA regulated endpoint, for oral
exposures. This model also predicts age-specific individual human variability of
blood levels associated with a 10% inhibition in RBC ChE using Monte Carlo
analysis, which allows determination of blood levels protective of sensitive humans.
Thus, no additional UFs are required to derive the BE. The preliminary blood BE
value for CPF in adults is 3.5 μg/L. This level is about 1000 fold higher than the
current reported blood levels in US pregnant women. The preliminary urinary BE
for TCPy is 2,000 μg/L. The 95th percentile urinary TCPy in the general US adult
population was 12.4 μg/L (CDC exposure years 2001-2002). Assuming that 10%
of the reported levels occur from CPF exposure (the remainder is assumed direct ex-
posure to environmental TCPy in non-worker populations), then the BE for TCPy
will also be about 1000 fold larger than current levels. These findings suggest that
current US adult dietary exposures to CPF are well below levels that could cause
10% inhibition of RBC ChE.
1249 Gene Expression of sFLT1 Links Prenatal Arsenic Exposure
to Increased Risk on Small for Gestational Age.
S. Remy1, 3,  E. Govarts1,  B. Wens1, 3,  L. Bruckers2,  M. Paulussen1,  E. Den
Hond1 and G. Schoeters1, 3. 1Flemish Institute for Technological Research (VITO),
Mol, Belgium; 2Hasselt University, Hasselt, Belgium; 3Antwerp University, Antwerp,
Belgium. Sponsor: P. Hoet.
In the Flemish Environment and Health Study (2007-2011) we aimed: 1) to ex-
plore the relationship between prenatal arsenic exposure and the resulting effect on
prenatal growth, and 2) to obtain more insight in the molecular basis of these rela-
tionships. Levels of arsenic were measured in cord blood samples of 255 newborns
and the transcriptome of cord blood mononuclear cells was determined by Agilent
whole human genome microarrays. 
Arsenic levels ranged from 0.01 to 8.20 μg/L. Logistic regression analyses showed
that a higher exposure to arsenic was statistically significantly associated with an in-
creased risk for having a Small for Gestational Age (SGA)-baby, adjusted for a pri-
ori fixed confounders and statistically significant covariates (p < 0.05). The odds of
having an SGA-baby was multiplied with 1.65 (95% CI: 1.15-2.37) for an in-
terquartile range increase of 0.93 μg/L arsenic.
To identify gene transcripts that link prenatal arsenic exposure to increased risk on
SGA, we focused on the subset of most extreme samples (i.e. a group of lowest ar-
senic exposure (n=30) and a group of highest arsenic exposure (n=30)). The list of
transcripts that discriminate both groups was screened for genes involved in embry-
onic growth regulation. As such sFLT1 (soluble fms-like tyrosine kinase-1) was de-
tected, a protein known to inhibit placental angiogenesis. This gene was signifi-
cantly higher (p = 0.004) expressed among high exposed individuals. Moreover,
75% of SGA-babies were found to show expression levels above median.
Our data suggest that disturbed placental angiogenesis, via upregulation of sFLT1,
may link prenatal arsenic exposure to increased risk on SGA. 
The studies of the Flemish Center of Expertise on Environment and Health are
commissioned, financed and steered by the Ministry of the Flemish Community
(Department of Economics, Science and Innovation; Flemish Agency for Care and
Health; and Department of Environment, Nature and Energy).
1250 Plasma Polybrominated Diphenyl Ethers (PBDEs) in
Californian Women at High Risk for Birthing an Autistic
Child.
Y. Lin1,  I. Hertz-Picciotto2,  D. Tancredi2,  I. N. Pessah1 and B. Puschner1.
1Department of Molecular Biosciences, School of Veterinary Medicine, University of
California Davis, Davis, CA; 2Department of Public Health Sciences, School of
Medicine, University of California Davis, Davis, CA.
Exposure to the polybrominated diphenyl ethers flame retardants (PBDEs) is a
major preventable health concern. Little is known about the extent and patterns of
PBDE exposures during pregnancy, especially in populations susceptible to herita-
ble neurodevelopmental disorders. We measured plasma PBDE levels in
Californian women participating MARBLES (Markers of Autism Risk in Babies-
Learning Early Signs) who are at high risk for birthing an autistic child. BDE-28, -
47, -49, -52, -95, -99, -100, -136, -153, and -183 were measured using
GC/MS/MS in plasma samples collected from 79 women at each trimester and at
delivery (215 samples total). PBDEs were normalized to plasma volume (ng/ml)
and total lipids (ng/g). The concentrations of maternal PBDEs in MARBLES were
compared to data from the National Health and Nutritional Examination Survey
(NHANES 2003-2004). All ten congeners were detectable in the maternal samples
from MARBLES, with BDE-100 (0.792 ± 0.540 ng/ml, 163.5 ± 117.5 ng/g) and
BDE-47 (0.661 ± 0.458 ng/ml, 141.1 ± 117.6 ng/g) contributing the highest
abundance. Compared to NHANES, women enrolled in MARBLES had signifi-
cantly higher mean concentrations of BDE-47 (23.9 versus 141.1 ng/g), -99 (5.51
versus 92.3 ng/g), -100 (6.06 versus 163.5 ng/g) and -153 (9.90 versus 28.7 ng/g).
Plasma PBDE (ng/ml) in women 25 to 35 years of age increased during gestation,
but decreased if they were older than 35 years. Because of the increase of total
plasma lipids during gestation, PBDE expressed on an ng/g lipid basis decreased in
all age groups with gestational stage. Fluctuations in maternal plasma PBDE levels
during pregnancy illustrate the importance of gestational age and underscore the
non-linear relationship between volume- and lipid-corrected PBDE concentra-
tions.
1251 Estimation of Dietary Lead Exposure for US Children Using
a New Method: Implications for the Integrated Exposure
Uptake Biokinetic Model for Lead in Children.
M. Follansbee1,  M. Ballew2,  J. Brown2,  M. Burgess2,  M. Stifleman2 and
B. Thayer1. 1SRC, Inc., East Syracuse, NY; 2US EPA, Washington DC. Sponsor: G.
Diamond.
In addition to site-specific inputs, the Integrated Exposure Uptake Biokinetic
Model for Lead in Children (IEUBK model) uses national defaults that are recom-
mended when site-specific information is not available. As part of a periodic evalu-
ation of inputs to the IEUBK model, the methodology underlying the basis for de-
fault calculations of dietary lead intake has been updated. Previously, the food
consumption values in the IEUBK model were based on information reported by
Pennington (1983) and the lead in food values were based on food residue data
from the ongoing FDA Total Diet Study; the latter are updated periodically as new
data become available from FDA.
Recent advances in methods for estimating dietary intake provide a current and sci-
entifically sound basis to develop nationally-representative, age-group specific val-
ues for food consumption. The dietary component of NHANES, called the What
We Eat in America (WWEIA) Dietary Survey, includes two 24-hour dietary recall
interviews during which each respondent reports the amount of all foods they con-
sumed during the prior day. The food consumption values (grams/day) were esti-
mated using a non-linear mixed model developed by the National Cancer Institute
(the NCI method). The NCI method uses information on meal sizes and frequency
(probability) with which specific food items are consumed to estimate daily con-
sumption rates. 
The NCI method produced estimates of dietary lead intake that were 18 to 219%
higher than the previously estimated values, depending on the food item. Further
analysis revealed the increase in the dietary lead intake values was largely due to an
increase in the estimated daily consumption values rather than higher lead concen-
trations in food.
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1252 Using Doubly-Labeled Water Energy Data for Estimating
Ventilation Rates for the Integrated Exposure Uptake
Biokinetic Model for Lead in Children.
B. Thayer1,  M. Follansbee1,  J. Brown2,  M. Burgess2 and M. Stifelman2. 1SRC,
Inc., East Syracuse, NY; 2US EPA, Washington DC. Sponsor: G. Diamond.
The default values in the IEUBK model (Version 1.1, Build 11) are based on values
reported in the Office of Air Quality Planning and Standards report (U.S. EPA,
1989) and the IEUBK Model Technical Support Document (U.S. EPA, 1994).
More recent data provide a more scientifically sound basis to further develop na-
tionally-representative, age-group specific values for ventilation rates in children.
The default values in the IEUBK model were derived based on body size in combi-
nation with smoothed data from Phalen et al. (1985). EPA’s (2008) Child-Specific
Exposure Factors Handbook provides recommendations for long-term (> 30 days)
ventilation rates that are based on the average of several studies (Arcus-Arth and
Blaisdell, 2007; Brochu et al., 2006; Stifelman, 2007).  
Because Arcus-Arth and Blaisdell (2007) used indirect measures of ventilation rates
based on dietary and activity survey responses, it was not considered acceptable for
derivation of default values for the IEUBK model. Brochu et al. (2006) and
Stifelman (2007), however, were based on the doubly-labeled water (DLW) energy
data from the Institute of Medicinr. DLW energy data are recognized as the gold
standard for energy expenditure and an improvement over ventilation estimates
based on dietary recall or activity survey data .
Ventilation rate was calculated from total energy expenditure using Layton’s ap-
proach as described by Stifelman (2007). The analysis was on pooled data for males
and females. More detailed analysis of ventilation rates as a function of age and gen-
der showed the estimated ventilation rates to be parallel and 7% greater in males
than females. The resulting ventilation rate values are between 19-66% higher than
the existing IEUBK model defaults. Because these values are derived from energy
expenditure information, they provide a more scientifically defensible basis for the
default values in the IEUBK model.
1253 Conducting Probabilistic Reverse Dosimetry Calculations to
Estimate Exposure Concentrations from Biomarker Data—
An Example of Perchlorate.
M. B. Phillips1,  C. M. Grulke1,  Y. Yang2,  K. Holm1,  D. T. Chang1,
R. Goldsmith1,  R. Tornero-Velez1,  C. C. Dary3 and C. Tan1. 1US EPA ORD
NERL, Research Triangle Park, NC; 2The Hamner Institutes for Health Sciences,
Research Triangle Park, NC; 3US EPA ORD NERL, Las Vegas, NV.
Given the growing number of population-based biomonitoring surveys, there is an
escalating interest in converting biomarker measurements (chemical/metabolite
concentrations) to exposure concentrations (e.g., daily dose) to help support risk as-
sessment. The conversion involves two steps: (1) formulating a model that describes
the dose-biomarker relationship (forward dosimetry); and (2) solving for the plau-
sible doses that are consistent with observed biomarker concentrations (reverse
dosimetry). The objective of this study is to use probabilistic reverse dosimetry to
estimate the distribution of average daily doses of perchlorate based on the National
Health and Nutrition Examination Survey (NHANES) urinary biomarker data.
Perchlorate was selected for its abundance in both exposure and biomarker data.
First, Monte Carlo simulations of a physiologically based pharmacokinetic (PBPK)
model for perchlorate were performed to account for variability/uncertainty in ex-
posure factors and PK. Next, the simulated exposure-biomarker relationship was
used to convert urinary perchlorate concentrations to a distribution of daily doses.
The conversion was conducted using a web-based tool, Probabilistic Reverse
dOsimetry Estimating Exposure Distribution (PROcEED), with two methods: the
Exposure Conversion Factor and Discretized Bayesian methods. The means of the
estimated dose distributions were comparable to average daily doses estimated
using other methods (point estimates), such as food concentrations multiplied by
consumption rate. Probabilistic reverse dosimetry, however, also provides the distri-
bution of dose estimates to represent the variability/uncertainty in exposure factors
and PK.
[This abstract has been cleared by the EPA but solely expresses the view of the au-
thors]
1254 The Effect of Clothing Care Activities on Textile
Formaldehyde Content.
R. Novick,  M. G. Lew,  M. A. McKinley,  G. L. Anderson and J. J. Keenan.
ChemRisk, San Francisco, CA.
Textiles are commonly treated with formaldehyde-based finishing agents that can
potentially cause allergic contact dermatitis in sensitive individuals. There is limited
data on the current formaldehyde content in textiles and the potential for reduction
through clothing care activities. This study sought to provide information on the
formaldehyde content in clothing specifically focusing on 100% cotton permanent
press shirts and pants, a clothing category that is generally treated with formalde-
hyde-based resins. Textiles were purchased and tested for formaldehyde content
using the Japanese method 112. Several items (~20%) exhibited measurable levels
of formaldehyde (> 20 ppm). Textile samples with the greatest formaldehyde con-
tent were hand or machine washed in hot or cold water, dried on a line or in a
dryer, and ironed. Ironing did not appear to affect the textile formaldehyde con-
tent. The washing and drying procedures reduced formaldehyde content between
28 and 74% compared to the control. Differences in the temperature or type of
washing and drying did not result in a clear trend in the formaldehyde content
data. Understanding the formaldehyde content in commercially available perma-
nent press clothing and the potential reduction through clothing care activities may
be useful for manufacturers and sensitive individuals.
1255 Exposure Associated with Power Stripping of Asbestos
Containing Insulation from Electrical Cable.
C. L. Blake1,  A. Jurkowski1,  G. Johnson2 and R. D. Harbison2. 1Bureau Veritas
North America, Inc., Kennesaw, GA; 2Environmental and Occupational Health,
University of South Florida, Tampa, FL.
Efforts to recycle copper from electrical conductors have lead to the development of
specialized machines which automatically remove insulating covers from wires and
cable products. In the past, certain wire and cable products were insulated using
chrysotile asbestos. This research was undertaken to determine the asbestos fiber ex-
posure risks associated with power stripping machinery to remove asbestos-contain-
ing insulation materials from electrical wire or cable. A Rigby Machinery, Inc.,
Model 4H electric powered wire/cable insulation stripping machine was acquired
along with approximately 42 m of asbestos insulated cable. During two separate,
but nearly identical, test sessions, a laborer used the wire stripper to remove the as-
bestos-containing insulation from the subject cable. This work took place within a
closed metal building with a total interior volume of 2,500 m3. Industrial hygiene
personal and area air samples were collected for airborne fibers throughout all wire
stripping periods. Collected air samples were analyzed using phase contract mi-
croscopy (PCM) and transmission microscopy (TEM). The results of analysis using
PCM for personal samples (n=3) taken during periods of continuous cable strip-
ping activity showed test period airborne fiber exposures ranging from 0.034 to
0.068 (mean 0.056 f/ml). Follow-up analysis of these personal samples using TEM
indicated asbestos adjusted PCM exposures ranging from 0.017 to 0.045 (mean
0.033 f/ml). Area air samples taken at distances ranging from 2 to 9 meters from
the wire stripper (n=16) showed asbestos adjusted PCM concentrations ranging
from less than 0.0001 to 0.041 f/cc (mean 0.007 f/ml). The process of power strip-
ping asbestos-containing insulation from electrical wires and cables can cause expo-
sure to airborne asbestos fibers. However, the levels of such exposure are not ex-
pected to exceed the current day occupational exposure limits for asbestos of 0.1
f/ml as an 8-hr TWA or 1.0 f/ml averaged over a 30-minute exposure period.
1256 N, N’-Di-Tert-Butylacetamidine: Integrated Toxicity Testing
Approach to Establish an Occupational Exposure Guideline.
J. A. Hotchkiss,  R. Sura,  S. M. Krieger,  J. Thomas and L. Andrews. The Dow
Chemical Company, Midland, MI.
N,N’ di-tert-butylacetamidine (AMD; CAS # 54838-72-1) is a raw material and
principal hydrolysis product of a new metalorganic molecule. An integrated testing
strategy involving the assessment of multiple hazard endpoints was used to provide
essential toxicologic data to set an occupational exposure guideline for AMD. The
acute oral LD50 was estimated to be 341.4 mg/kg (95% C.I. = 280-550 mg/kg). In
a 28-day dietary study no target organ toxicity was identified. A no adverse effects
level (NOAEL) of 150 mkd was based on decreased food consumption and body
weight gains at 500 and 1000 mkd. A modified acute inhalation toxicity study with
scheduled necropsies 1- and 14-d post-exposure and analysis of bronchoalveolar
lavage, airway epithelial cell proliferation, and histopathology of the respiratory
tract was conducted to determine the LC50 and to assess airway epithelial injury
and repair. The 4-h LC50 was 388 ppm (506 mg/kg) and 404 ppm (527 mg/kg)
AMD for male and female F344/DuCrl rats, respectively. Histopathologic changes
were concentration-dependent and restricted to the olfactory, respiratory and tran-
sitional epithelium lining the anterior nasal airways. Increased cell proliferation was
evident 1- and 14-d post-exposure. Epithelial regeneration was incomplete 14-d
post-exposure. An RD50 assay was conducted to assess the sensory irritation poten-
tial of inhaled AMD. Based on the concentration-dependent decrease in respiration
rate the RD50 was calculated to be 123.4 ppm (95% C.I. = 59-188). Based on these
data an 8-h time-weighted average (TWA) occupational exposure level of 5 ppm
with a 15 ppm short-term exposure limit (STEL) was established. These exposure
limits are similar to ACGIH threshold limit values of 5-10 ppm for short-chain
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aliphatic amines and suggest that the toxicity of AMD is similar to other alkyl
amines such as dimethyl- and diethyl-amine. The integrated testing strategy used in
this study represents an important approach for reducing animal use and rapidly
adopting exposure guidelines for new materials to assure worker safety.
1257 Lipidomics of Subchronic Low Level Cadmium Exposure in
the Rat.
O. O. Ogunrinola,  O. Ademuyiwa,  A. D. Wusu,  O. K. Afolabi,  E. O. Abam,
D. O. Babayemi,  E. A. Balogun and O. O. Odukoya. Biochemistry, University of
Agriculture, Abeokuta, Nigeria.
Epidemiological studies suggest an association between cadmium in drinking water
and vascular diseases. However, the precise cadmium mechanism of action remains
enigmatic. This study was undertaken to investigate the effect of cadmium on lipid
metabolism of Wister male albino rats by exposing the animals to 100, 200 and 300
ppm cadmium doses for 12 weeks in their drinking water. Control animals received
distilled water for the same period. At the end of 12 weeks, dyslipidemia induced by
the cadmium doses exhibited different patterns. Dose-dependent hypocholes-
terolemia and hypotriacylglyceridemia characterised the effect of cadmium expo-
sure at all doses whereas plasma free fatty acid (29%) was increased by cadmium ex-
posure. Reverse cholesterol transport was inhibited by all the cadmium doses as
evidenced by 65% decreased HDL cholesterol concentrations whereas hepatic cho-
lesterol was decreased by 55%. Renal and brain cholesterol (46%, 65%) and tria-
cylglyceride (62%, 50%) were dose-dependently decreased by cadmium exposure
respectively; on the other hand, exposure to cadmium depleted cardiac cholesterol
by 45%, but enhanced/balanced triacylglyceride content. Cadmium at all doses of
exposure inhibited both hepatic and brain HMG CoA reductase by 49% and 61%
respectively. We observed positive association between tissue cadmium levels and
plasma FFA, and negative associations between tissue cadmium levels and HDL
cholesterol. Our findings indicate that in contrast to strengthening a dose-depend-
ent effect phenomenon as observed with many other compounds, cadmium up- or
down-regulate different pathways in the lipid metabolism spectrum at “low” or
“high” doses and this might be responsible for the insidious vascular effects.
1258 Serum Great Lakes Pollutant Levels in Lake Ontario Fish
and Wildlife Consumers.
F. D. Stephen1,  L. A. Georger1,  M. R. Bonner3,  P. J. Kostyniak2,  J. R. Olson2, 3,
M. S. Bloom4 and J. E. Vena5. 1Math & Natural Sciences, D’Youville College,
Buffalo, NY; 2Pharmacology & Toxicology, SUNY Buffalo, Buffalo, NY; 3Social &
Preventive Medicine, SUNY Buffalo, Buffalo, NY; 4Environmental Health Sciences,
SUNY Albany, Albany, NY; 5Epidemiology and Biostatistics, University of Georgia,
Athens, GA.
Industrialization of the Great Lakes region resulted in the discharge of many halo-
genated aromatic hydrocarbons (HAHs) into the Lake Ontario basin. Due to their
persistence and lipophilicity, HAHs can biomagnify in the food chain and are a po-
tential source of human exposure to polychlorinated biphenyls (PCBs), polychlori-
nated dibenzo-p-dioxins (PCDDs), dibenzofurans (PCDFs) and pesticides.
Consumption of Lake Ontario fish and wildlife is one factor that contributes to
higher serum levels of persistent HAHs and potentially greater risk of adverse
human health effects. The New York State Angler Cohort Study (NYSACS) is a
large prospective cohort of licensed anglers from 16 New York counties in close
proximity to Lake Ontario, 18 to 40 years of age established in 1991. Previously,
394 members of the NYSACS donated blood and were screened for serum PCB
and pesticide levels. For this analysis, participants with the highest serum PCB153
levels (n=27) and with self reported consumption of Lake Ontario fish were chosen,
and matched to subjects having never consumed Lake Ontario fish by age, sex and
geographic area (n=16). We examined serum levels of PCBs, PCDDs, PCDFs and
pesticides by GC/ECD and GC/MS. The consumer group had significant elevated
levels of 20 PCBs, including PCB 126, 153, 138, 180 and 170. The consumer
group also had a 1.6-fold increase in 2,3,7,8-TCDD, a 1.4-fold increase in
1,2,3,7,8-PentaCDD, a 1.54-fold increase in 2,3,4,7,8-PentaCDF, a nine-fold in-
crease in mirex, a 2.5-fold increase in DDE and a two-fold increase in t-nonachlor
relative to the non-consumer group (all values p<0.05). Together, the results indi-
cate that consumption of fish and wildlife from Lake Ontario is a source of expo-
sure to mirex and other HAHs. (Supported in part by ATSDR, Grant H75-ATH
298338)
1259 Exposure to Environmental Tobacco Smoke Causes
Endotoxin Tolerance.
T. Muthumalage2,  K. Hunter3, 2,  D. Redelman4,  K. Pritsos1 and C. A. Pritsos1, 2.
1Agriculture, Nutrition and Veterinary Sciences, University of Nevada, Reno, Reno,
NV; 2Environmental Sciences Program, University of Nevada, Reno, Reno, NV;
3Microbiology and Immunology, University of Nevada, Reno, Reno, NV; 4Physiology
and Cell Biology, University of Nevada, Reno, Reno, NV.
Exposure to cigarette smoke is known to increase susceptibility to and severity of
pulmonary diseases such as bronchitis and emphysema. During tobacco manufac-
turing processes, in which the temperature and humidity are brought to an opti-
mum level for fermentation, tobacco is colonized by fungi and bacteria.
Lipopolysachcharide (LPS), a gram negative bacterial component, has been found
in tobacco smoke. In this study, we wanted to assess whether acute exposure to en-
vironmental tobacco smoke (ETS) could alter the immune response caused by ex-
posure to the bacterial endotoxin, LPS. Using a C57BL/6 mouse model, we com-
pared the inflammatory cytokine levels secreted by LPS stimulated alveolar
macrophages in ETS exposed and unexposed (control) groups. Tumor necrosis fac-
tor-alpha (TNF-a) levels were significantly attenuated in the ETS exposed groups
after ex-vivo exposure to LPS in comparison to the control group. We observed that
whether the ex-vivo LPS exposure was performed immediately after the ETS expo-
sure or a full day post-exposure, the TNF-a cytokine level was decreased by 30-
40%. No significant difference was observed in alveolar macrophage recovery be-
tween groups. Also, no significant difference was found in cell viability between the
two groups. This suggests that TNF-a attenuation in ETS exposed groups resulted
from endotoxin tolerance caused by LPS or LPS-like constituents in ETS. This en-
dotoxin tolerance resulting from acute ETS exposure can suppress the immune
function and subsequently increase susceptibility to bacterial infections. These re-
sults provide insights into the weaker immune defense observed in smokers and sec-
ondhand smokers. This study was supported by the Flight Attendants Medical
Research Institute grant 072083.
1260 Mitochondrial-K+-ATP Channel Activation Rescues of
Phosgene-Induced Toxic Inhalational Lung Injury.
A. Senft1,  J. D. McDonald1,  W. Weber1,  L. Fredenburgh2,  G. Southan3 and
A. P. Salzman3. 1Lovelace Respiratory Research Institute, Albuquerque, NM;
2Harvard Brigham and Womens College, Boston, MA; 3Radikal Therapeutics, Boston,
MA.
To determine whether R-801, a mitochondrial-K+ATP channel activator, is effec-
tive in rescuing acute lung injury (ALI) induced by phosgene (COCl2), C57/BL6
mice were exposed to COCl2 (5 ppm) or filtered air (FA) for 20 min. Animals were
administered intraperitoneal (IP) R-801 (80 mg/kg/dose) or vehicle (hydrox-
ypropyl cyclodextrin, HPCD) at 2 and 6 h after COCl2. Animals were tra-
cheostomized, bronchoalveolar lavage (BAL) performed, and lungs harvested at 24
and 48 h. COCl2-exposed animals developed severe lung injury compared to con-
trols, with interstitial and alveolar edema, hemorrhage, and recruitment of inflam-
matory cells Treatment with R-801 led to significant reduction in histologic lung
injury and near normalization of lung histology Immunostaining for Ly-6G (Gr-1)
at 48 h demonstrated significant neutrophil (PMN) accumulation around bron-
chovascular bundles in COCl2-exposed animals which was profoundly attenuated
in R-801-treated COCl2-exposed animals. Furthermore, levels of the pro-inflam-
matory cytokines and BALF protein were dramatically reduced compared with
controls. Treatment with R-801 restored epithelial barrier integrity after COCl2
with striking attenuation in BALF protein levels 48 h after COCl2. Taken together,
our findings demonstrate that selective mito-K+-ATP channel opening with R-801
is highly effective at rescuing COCl2-induced ALI via attenuation of inflammation,
restoration of epithelial tight junction barrier integrity, and induction of endoge-
nous surfactant protein expression.
1261 Systematic Review of BPA “Low Dose” Literature in the
Context of Human Dosimetry Exposes a Need to Set
Standards for Responsible Communication of Both Toxicity
and Exposure Data.
S. Hanson-Drury and J. G. Teeguarden. Systems Toxicology and Exposure Science,
Pacific Northwest National Laboratory, Richland, WA.
BPA is a weakly estrogenic monomer used for making polycarbonate plastics and
food packaging liners. At sufficient exposures, BPA is toxic in rodent non-human
test systems. Uncritical reference to many toxicity studies as “low dose” has led to
the belief that exposure levels in these studies are similar to human exposure levels,
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implying that BPA is toxic to humans at current exposures. However, a compre-
hensive comparison of exposures in humans and test systems has not been con-
ducted. Applying the fundamental principles of biomonitoring, exposure assess-
ment and dosimetry, we conducted a systematic review of BPA exposure levels in
130 peer-reviewed in vivo and in vitro BPA toxicity studies self-referring as “low-
dose.” Total daily human exposure to BPA is ~ 0.03 μg/kg/day. In contrast, >90%
of “low dose” BPA toxicity studies were conducted at doses exceeding human expo-
sure by 10-1000,000 fold. Human blood concentrations from a single oral bolus
dose of BPA equal to total daily BPA exposure are in the low pM range. In compar-
ison, concentrations used in >90% of in vitro “low dose” studies were 10 to
1000,000 higher. We conclude that the use of the “low dose” descriptor is largely
inconsistent with the state of our knowledge of human exposure. Looking forward,
as human exposure data continue to emerge from large biomonitoring studies, we
believe that there is a need to adopt standards for the conduct and reporting of tox-
icity studies that include objective comparisons to human exposures.
1262 Secondary Particulate Health Effects Research (SPHERES)
Program: Secondary Organic Aerosol Effects on the
Cardiovascular System.
A. Rohr2, 1,  E. Knipping2,  A. K. Lund1,  M. J. Campen3,  M. Doyle-Eisele1 and
J. D. McDonald1. 1LRRI, Albuquerque, NM; 2EPRI, Palo Alto, CA; 3University of
New Mexico, Albuquerque, NM.
The SPHERES research program was created to examine the role of inhaled sec-
ondary organic aerosol (SOA) on cardiovascular outcomes in mice, benchmarking
effects against those observed from motor vehicle emissions (MVE). SOA was gen-
erated in a reaction chamber with either alpha-pinene or toluene, combined with
(1) NOx; (2) NOx + SO2; (3) NOx + NH3; or (4) NOx + NH3 + SO2. To exam-
ine the effects of these mixtures on progression of atherosclerosis, 8 wk old male
Apo E-/- mice, on a high fat diet were exposed for 7 days, and resulting vascular ox-
idative stress and expression of molecular markers were assayed. Exposure to MVE
resulted in enhanced vascular oxidative stess, measured by vascular TBARS and
HO-1 levels. SOA caused a milder response than MVE, and the biological re-
sponses that were observed differed depending on the composition of the mixture.
The only SOA exposure in which a statistical increase in TBARS was measured,
compared to controls, was the “neutral” α-pinene (e.g. α-pinene reacted with
NOx). All other SOA exposure conditions yielded only slight, or no, increase in
TBARS expression, which is consistent with other studies in the literature (Lemos
et al., 2011; rev. in Godleski et al., 2011). Several of the SOA exposure conditions
yielded significant increases in expression of vascular HO-1 transcript. The “acidic”
α-pinene mixture, as well as α-pinene + NH3 (both neutral and acidic) and the
neutral toluene exposure all resulted in statistically significant increases in HO-1
mRNA. Conversely, both the acidic and neutral toluene + NH3 exposures showed
significant decreases in vascular HO-1 expression. In aggregate, the results suggest
that SOA causes mild cardiovascular responses that are dependant on composition.
Research Funded by the Electric Power Research Institute.
1263 Pulmonary Toxicity of Oxygen and Carbon Dioxide
Degraded Amines Used for Carbon Capture and Storage.
D. Kracko1,  C. Wegerski1,  J. D. McDonald1,  M. Doyle-Eisele1,  S. Shaw2,
E. Knipping2 and A. Rohr2. 1Lovelace Respiratory Research Institute, Albuquerque,
NM; 2Electric Power Research Institute, Palo Alto, CA.
Carbon dioxide (CO2) adsorption with aqueous amine solvents is among the lead-
ing candidates for use in carbon capture and sequestion (CCS) techniques aimed at
reducing greenhouse gas emissions from flue gases (coal-fired power plants, refiner-
ies, etc). The environmental consequences from utilizing this technology have been
poorly characterized. A concern is that amines or by-products that may occur due
to interaction with flue gases are emitted creating unintended human exposure.
This study evaluated the inflammatory response associated with inhalation expo-
sure to amines and amine degradation products. Three model amines (monoethy-
lamine (MEA), methyldiethanolamine (MDEA), piperazine (PIP)) and their labo-
ratory-generated degradation products formed via addition of CO2 and O2 were
evaluated. C57bl/6N mice were exposed for three days by whole-body inhalation to
6-25 ppm amine or the equivalent concentration of degraded amines.
Inflammatory response in lungs was assessed by counting inflammatory cells in
bronchoalveolar lavage fluid and measurement of cytokine expression in lung tis-
sue. Inhalation exposure to O2-degraded MEA showed significant increases in total
cells, neutrophils, and lymphocytes compared to control mice. Significant increases
in inflammatory cytokine expression were seen in mice exposed to the O2 degraded
MDEA atmosphere, and minimal inflammation was observed with piperazine or
degraded piperazine. CO2 degraded amines overall showed only mild inflamma-
tory response. Characterization of the degraded amines showed numerous degrada-
tion products including carbonyl compounds, such as formaldehyde, and ni-
trosamines, a class of compound of which some species are carcinogenic. These are
the first known studies to evaluate the potential inhalation hazard of amine degra-
dation products. Research supported by the Electric Power Research Institute.
1264 Volatile Organic Compounds Released from Expanded
Polystyrene.
N. Pajaro-Castro,  J. Perez-Romero and J. Olivero-Verbel. Environmental and
Computational Chemistry Group Pharmaceutical Sciences, University of Cartagena,
Cartagena, Colombia.
The importance of plastic materials for different applications in everyday life has
continuously increased over the years. Manufactured goods made of polymers are
generally complex materials. These are composed of polymers or copolymers them-
selves, together with a variety of additives with different volatilities. Currently, poly-
styrene is among the most widely used plastic in the form of foam containers.
However, under certain conditions polystyrene foam may liberate residual styrene
monomers, and other compounds, with well-known toxic properties. The aim of
this study was to analyze the release of chemicals from expanded polystyrene (EPS)
commercially available in Colombia. Headspace solid-phase micro-extraction with
a 100 μm carboxen-polydimethylsiloxan fiber was utilized to capture organic com-
pounds volatilized by heating EPS at different temperatures (55-85 Celcius).
Volatiles were characterized by GC/MS after thermal desorption. The results
demonstrated that for different EPS products, such as lunch carriers, dishes and
soup containers, there is a temperature-dependent emission of several compounds,
including styrene, benzaldehyde, ethylbenzene, (2-phenylcyclobutyl)benzene and
tetradecane, among others. Data mining suggested these molecules possess a broad
spectrum of toxicities.  Taken together, these findings should encourage citizens to
be careful while using EPS containers as carriers for hot foods or beverages. Vice-
Rectory for Research. UniCartagena. 2011-2012. Colciencias-UniCartagena,
Colombia. Grant 110749326186 (2009).
1265 Assessment of Biomarkers of Benzene Exposure and Effect in
Petrochemical Workers.
S. Inayat-Hussain1, 2,  M. Sabtu2,  F. S. Chin2 and M. K. Chan1. 1Environmental
Health and Industrial Safety Program, Faculty of Health Sciences, Universiti
Kebangsaan Malaysia, Kuala Lumpur, Malaysia; 2UKM Medical Molecular Biology
Institute, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.
This study was conducted to assess biomarkers of benzene exposure and effect, and
the relationship between these parameters in petrochemical plant workers during a
major turnaround. Pre and post shift blood and urine samples were obtained from
35 workers including smokers and non-smokers who were potentially exposed to
low air level of benzene. Air monitoring results showed that the benzene level in air
samples was less than the Permissible Exposure Level (PEL) which is 0.5 ppm.
Interestingly, there was a 2.1 fold increase of the biomarker of exposure namely uri-
nary S-phenylmercapturic acid (SPMA) in workers as assessed by ELISA. There
were 18 out of 35 workers who had levels of post-shift SPMA higher as compared
to the pre shift data. Specifically, 6 workers showed levels of SPMA above the
Biological Exposure Index (25μg/g creatinine). In workers who were smokers, there
was an increase of 2.1 fold in the level of DNA strands breaks as assessed by
Alkaline Comet assay whereas the increase of oxidized base (8-OHdG) was 1.1 fold
as measured using ELISA. However, the non-smokers demonstrated a significant
increase in 8-OHdG level (1.3 fold) but not significant for the DNA strand breaks
(1.2 fold) (p<0.05). Notably, a strong correlation between SPMA and 8-OHdG
(r=0.709) was observed in the post shift data for non-smokers. Taken together,
these results suggest that biomonitoring of workers during exposure to low level of
benzene may be important to protect workers’ health.
1266 Identification of Sulfated Metabolites of 4-Chlorobiphenyl
(PCB3) in the Serum and Urine of Male Rats.
K. Dhakal1, 4,  L. Hans-Joachim1, 4,  L. M. Teesch2,  M. W. Duffel1, 3 and
L. W. Robertson1, 4. 1Interdisciplinary Graduate Program in Human Toxicology, The
University of Iowa, Iowa City, IA; 2High Resolution Mass Spectrometry Facility, The
University of Iowa, Iowa City, IA; 3Department of Pharmaceutical Sciences and
Experimental Therapeutics, The University of Iowa, Iowa City, IA; 4Department of
Occupational and Environmental Health, The University of Iowa, Iowa City, IA.
Polychlorinated biphenyls (PCBs) are legacy pollutants that exert toxicity of various
mechanisms. Lower chlorinated or lighter PCBs (LC-PCBs) are semi-volatile, and
air-borne. In the old public school building in New York City, the EPA in 2012 has
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estimated that students are inhaling six times more PCBs than they are receiving
from dietary sources. However, LC-PCBs or metabolites have been rarely reported
in the serum of population at risk. LC-PCBs are bioactivated to phenols and fur-
ther to quinone electrophiles with genotoxic/carcinogenic potential. We hypothe-
sized that phenolic LC-PCBs are subject to phase II conjugation and excretion via
urine. Our objective was to identify the final metabolites in the urine that could be
potentially employed in the exposure analysis of LC-PCBs. Male Sprague Dawley
rats (150-175 g) were housed in metabolism cages and received a single intraperi-
toneal injection of 600 μmol/kg body weight of PCB3. Control animals received
corn oil only. Urine was collected every four hours, euthanized at 36 h, and serum
was collected. The LC-MS analysis showed that PCB3 sulfates were the major
metabolite in both urine and serum. Approximately 3% of the dose excreted in the
urine as sulfate; with peak excretion occurring at 10-20 h of post-exposure. The
major metabolites were 4’PCB3sulfate, 3’PCB3 sulfate, 2’PCB3 sulfate and pre-
sumably a catechol sulfate. Serum level of 4’PCB3 sulfate was 6.18±2.16 μg/mL
while 4’OH-PCB3 was only 0.095±0.055 μg/mL. This is the first report that sul-
fated metabolites of PCBs are formed in vivo.
1267 Significant Megacluster of Total Cancer Mortality among the
US Non-White Population.
J. Beaubier1 and L. Russell2. 1US EPA, Washington DC; 2US EPA, Washington DC.
Sponsor: J. Murphy.
NCI and EPA collaborated to describe the U.S. population cancer mortality expe-
rience the for the 1950’s, 60’s and 70’s. All mortality data are official statistics in-
cluding 8 million records. For the 30 years, for all anatomic cancer sites, there was
a significant difference in the percentage rate of increase between White and Non-
white U.S. males. The White male increase was 17 %. For the same period, Non-
white males experienced a 46 % increase. For both White and Non-white males
highest rates of increase were in the Southeastern United States. The project also ex-
amined lung cancer. For White male lung cancer mortality, all ~3050 U.S. counties
were ranked by percentile of their absolute rates. The counties were marked as red
(99-98 percentile of absolute rates), orange (97-95 %), yellow (94-90 %), tan (89-
75 %) and blue background (74-1 %). In the 1970s a significant megacluster of
White male lung cancer mortality emerged in the Southeastern U.S. The counties
show up as strings along rivers. But the important unit of analysis is not the rivers,
but U.S. Geological Survey (USGS) hydrologic units. Principal component analy-
sis showed some USGS hydrologic units were more informative: USGS Region 08-
02 St. Francis river valley experienced a 300% increase in White male lung cancer
mortality in the 1970s, or a 10 % increase per year.The heavily forested, rich bot-
tom lands of the river valley were cut down and planted in cotton sprayed with
DDT. DDT induces male rat lung cancers. The strings of high rate White male
lung cancer counties lie predominately in the USGS Coastal Plains physiographic
domain. During late Cenozoic and Tertiary Eras the Coastal Plains filled in with
unconsolidated gravels and sands, porous to pollutants leaching into shallow wells
and aquifers. Relative risk of a red county being within the Coastal Plains was 5.3
times greater than being in another part of the U.S. Color coded counties showed a
“dose-related” effect - the higher the county rate, the more likely it was located in
the Coastal Plains. Authors solely responsible for conclusions herein and do not re-
flect authors’ institutions.
1268 Airborne Diacetyl from Cooking and Consumption of
Microwave Popcorn: Estimation of Consumer Exposure with
a Two-Zone Near-Field/Far-Field Model.
H. M. Bolstad1,  K. M. Unice2,  J. R. Maskrey2,  D. M. Hollins1,  B. D. Kerger3
and D. J. Paustenbach1. 1ChemRisk, San Francisco, CA; 2ChemRisk, Pittsburgh, PA;
3ChemRisk, Orange County, CA.
Diacetyl is a volatile diketone used to impart a butter flavor to foods such as mi-
crowave popcorn. Occupational exposure to airborne diacetyl has been reported to
be associated with obstructive lung disease, and recent concerns have emerged re-
garding exposures to diacetyl by consumers. Given the absence of data on the air-
borne concentrations in the home, we estimated consumer exposure using a two-
zone near-field/far-field model in which the near-field is a hemisphere above the
microwave popcorn bag, and conducted Monte Carlo uncertainty and sensitivity
analyses. A recent study revealed that an average of 778.9±135 μg diacetyl was
emitted during the popping, opening, and 40 minutes following opening. As part
of the input to the model, we estimated that diacetyl is released into the breathing
zone over a 40 minute period (a typical consumption duration) comprised of pop-
ping (2.5 min), opening (15 sec), and consumption (37.25 min). Based on avail-
able information, we estimated that 98.9% of the total diacetyl emitted was re-
leased during opening. The popcorn and the bag were assumed to be an arm length
away from the nose of the consumer and present for the duration of the scenario.
The estimated mean airborne diacetyl concentration in the breathing zone from
one bag of microwave popcorn was 0.0030 ppm, whereas the 5th and 95th per-
centile concentrations were 0.0018 and 0.0048 ppm, respectively. Assuming com-
plete absorption following inhalation and a breathing rate associated with light ac-
tivity (0.6 m3/hr), the estimated mean total intake by inhalation per bag was 5.3
μg. By comparison, the daily intake associated with occupational exposure at the
eight hour TWA and 15 minute STEL Threshold Limit Values set by ACGIH
(0.01 and 0.02 ppm, respectively) are 66 and four-fold greater, respectively.
1269 Examination of Specificity of Retinoid-Like Compounds for
RXRs, RARs and RORs.
P. P. Albrecht1,  K. Toyokawa1,  E. Maddox1,  P. Cramer1,  B. Sherf1 and J. Vanden
Heuvel1, 2. 1Indigo Biosciences, State College, PA; 2Department of Veterinary and
Biomedical Sciences, Pennsylvania State University, University Park, PA.
Vitamin A (retinol) and it’s metabolites play many physiological roles including cell
differentiation, cell proliferation, energy homeostasis, circadian rhythm and im-
mune response. Vitamin A and it’s metabolites are known to act through retinoid
acid receptors (RARs), retinoid-related orphan receptors (RORs) and retinoid x re-
ceptors (RXRs). These receptors are also important drug targets, although the speci-
ficity of many retinoid-like compounds for the retinoid receptors has not been care-
fully explored due to the lack of robust and selective assays. In the present work we
examined the retinoid-like compounds 4-hydroxyphenylretinamide, 4-hydrox-
yretinoic acid, 9-cis retinoic acid (9CRA), 13-cis retinoic acid (13CRA), AC-
55469, Acitretin, Adapalene, AM-580, All-trans retinoic acid (ATRA), BMS961,
Docosahexanoic acid (DHA), EC23, Eicosapentaenoic acid (EPA), ER50891,
HX531, HX630, Methoprene, Methoprene acid, MM11253, Puerarin, RO 41-
5253, SR1001, TO901317, TTNPB, and Ursolic acid for their ability to regulate
RARα, β,γ, RXRα, β,γ, and RORα, β,γ. The compounds were tested for agonistic
as well as antagonistic activities towards these receptors. Additionally cytotoxicity
assays were performed to assess true antagonistic activity. Many of these com-
pounds show a broad range of receptor activity (for example, EC23 shows agonistic
activity for all three RARs) while others were highly selective. The data further il-
lustrate the need to test new retinoic acid like drugs across the panel of RXRs, RARs
and RORs to limit untoward effects.
1270 Oxidative Formation of the High Affinity Endogenous Aryl
Hydrocarbon Receptor Ligand 6-Formylidolo(3, 2-
B)Carbazole (FICZ).
U. Rannug1,  A. Smirnova1,  L. Vikström Bergander2,  E. Wincent2,  T. Alsberg3
and A. Rannug2. 1Department of Genetics, Microbiology & Toxicology, Stockholm
University, Stockholm, Sweden; 2Institute of Environmental Medicine, Karolinska
Institutet, Stockholm, Sweden; 3Department of Applied Environmental Science,
Stockholm University, Stockholm, Sweden.
The endogenous high affinity aryl hydrocarbon receptor agonist FICZ is formed
upon irradiation of tryptophan with UV or visible light. To elucidate the mecha-
nisms in more detail photooxidation products were analyzed by HPLC and
LC/MS. The results revealed that the formation of FICZ was dependent on H2O2
since additions of catalase inhibited the reaction. It was also evident that indole-3-
acetaldehyde (I-3-A) was a precursor that spontaneously generated FICZ.
Monoamine oxidases (MAOs) catalyze the oxidative deamination of monoamines
resulting in the corresponding aldehydes. Human recombinant MAO A and MAO
B were therefore incubated with tryptamine to yield I-3-A. After the reaction and a
post treatment period the amounts of I-3-A and FICZ were measured. Both en-
zymes generated I-3-A, which was then spontaneously converted to FICZ.
Subsequently, tryptophan was incubated with H2O2 at 37 °C in the dark. The
mixture was concentrated on Sep-Pak C18, and HPLC and MS analyses confirmed
the formation of FICZ from tryptophan by H2O2. From these and other experi-
ments it can be concluded that tryptophan can give rise to FICZ in an oxidative en-
vironment, i.e. containing or producing reactive oxygen species. In addition, when-
ever I-3-A is formed there is a possibility for spontaneous formation of FICZ.
Altogether, this implies that there are several different conditions under which the
endogenous Ah receptor ligand FICZ can be formed in the body. Of great interest
in this respect is a recent demonstration of FICZ in the skin of vitiligo patients
characterized by a massive epidermal oxidative stress and high levels of H2O2
(Schallreuter et al., FASEB J, 2012). It therefore seems likely that FICZ is ubiqui-
tous in the human body but expected to be present at low steady state levels under
normal conditions.
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1271 The Aryl Hydrocarbon Receptor Regulates the Expression of
Multiple Growth Factors in Highly Metastatic Head and
Neck Squamous Cell Carcinoma Cell Lines.
K. John1, 2,  J. Hughes1,  T. S. Lahoti1,  K. Wagner1 and G. H. Perdew1. 1Center
for Molecular Toxicology and Carcinogenesis, Pennsylvania State University,
University Park, PA; 2DuPont Haskell Global Centers for Health and Environmental
Sciences, Newark, DE.
The aryl hydrocarbon receptor (AHR) is a ligand activated transcription factor im-
plicated in the regulation of diverse cellular processes. Previous studies in head and
neck squamous cell carcinoma cell lines (HNSCC) have revealed considerable con-
stitutive and ligand inducible AHR transcriptional activity. Antagonism of AHR
activity through AHR antagonist treatment was found to greatly attenuate the
highly metastatic and proliferative phenotype of these cells, suggesting that AHR
plays a significant role in contributing to the ‘aggressive’ phenotype of these cells.
Therefore, this study sought to use expression profiling to identify putative novel
targets of the AHR repressed by AHR antagonist treatment that are associated with
cancer cell survival and tumor invasiveness. Three growth factor targets were con-
sidered; amphiregulin (AREG), epiregulin (EREG) and platelet-derived growth
factor A (PDGFA) identified by expression profiling and from previous studies.
Quantitative PCR analysis revealed an attenuation of basal and/or induced gene ex-
pression levels of these growth factors in two HNSCC lines after AHR antagonist
treatment. ELISA analysis revealed attenuation of both basal and induced protein
levels of the growth factors examined in these cell lines. In addition, siRNA-medi-
ated knock down of AHR exhibited attenuation of growth factor expression. In sil-
ico analysis revealed these growth factors possess dioxin-like response elements.
Additionally, two other AHR ligands, 6-formylindolo[3,2-b]carbazole and
benzo(a)pyrene also exhibited induction of the AHR target genes examined. In
conclusion, AREG, EREG and PDGFA were identified as three key growth factor
targets of the AHR associated with metastatic phenotype of head and neck cancers.
1272 Hepatocarcinogenesis Induced by a Potent, High Affinity
Human PPARα Agonist Is Diminished in PPARα-
Humanized Mice.
J. E. Foreman1,  T. Koga1,  O. Kosyk2,  L. R. Kramer1,  F. J. Gonzalez3,  I. Rusyn2
and J. M. Peters1. 1Pennsylvania State University, University Park, PA; 2University of
North Carolina at Chapel Hill, Chapel Hill, NC; 3National Cancer Institute,
Bethesda, MD.
Pparα-null mice and PPARα-humanized mice are both resistant to hepatocarcino-
genesis induced by a PPARα agonist Wy-14,643, a compound that has higher
affinity towards the mouse PPARα as compared to the human PPARα. While the
studies demonstrating these differences suggest that the mouse PPARα is a key me-
diator in the hepatocarcinogenic effects of PPARα agonists and that species differ-
ences exist, it was noted the duration of the studies was limited to ~1 year, and the
PPARα agonist has higher affinity for the mouse PPARα as compared to the
human PPARα. Thus, the present study examined the effect of a potent, high affin-
ity human PPARα agonist (GW7647) on hepatocarcinogenesis in wild-type,
Pparα-null, or PPARα-humanized mice. Dietary administration of GW7647 for
up to 18 months caused severe hepatomegaly in wild-type mice. This effect was not
found in similarly treated Pparα-null mice and was diminished in humanized-
PPARα mice. Mortality prior to 18 months of treatment was generally found in
greater proportion in wild-type mice fed GW7647 as compared to similarly treated
Pparα-null or PPARα-humanized mice. Administration of GW7647 for up to 18
months caused close to 100% incidence of hepatocarcinogenesis in wild-type mice,
but this effect was largely diminished in Pparα-null mice and PPARα-humanized
mice. Tumors were present in some Pparα-null and PPARα-humanized mice, but
they occurred in both control and treated animals at frequencies well below those
found in wild type mice. Gross examination and results from additional molecular
analysis suggests a difference in mechanism between these tumors and those in-
duced by GW7647 in wild-type mice, but further analysis will be important for de-
termination of mode of action. Results from these studies provide further mecha-
nistic evidence for the species difference in the hepatocarcinogenesis of a high
affinity human PPARα agonist. (Supported by CA124533, CA140369,
FES017568A)
1273 Arsenic Inhibits 3T3-L1 Adipogenesis and Suppresses
Induction of Nuclear Receptors during the Earliest Stages of
Differentiation.
F. Zandbergen1,  A. Adebayo1, 2,  M. M. Vantangoli1, 2,  V. Chatikavanij1 and
J. W. Hamilton1, 2. 1Marine Biological Laboratory, Woods Hole, MA; 2Brown
University, Providence, RI.
Chronic environmental exposure to inorganic arsenic (As) is associated with an in-
creased risk of serious illnesses, including type 2 diabetes and cardiovascular disease
(CVD), which in turn are often associated with aberrant blood lipid levels and ex-
cess adipose tissue. Since we had previously shown that inorganic arsenite (As) can
suppress activation of steroid and other nuclear hormone receptors we hypothesized
that it might also affect adipose lipid metabolism by targeting these or other mem-
bers of the nuclear receptor family. Treatment of mouse 3T3-L1 cells with As dur-
ing their differentiation into adipocytes resulted in reduced lipid content and sup-
pressed induction of the master adipogenic transcription factors PPARγ and
C/EBPα and their target genes. Transient As exposures showed that final lipid con-
tent was reduced most in cultures that had been exposed during the initial induc-
tion phase of adipogenesis. As did not decrease protein and phosphorylation levels
of C/EBPβ - the transcriptional regulator of PPARγ and C/EBPα. C/EBPβ ac-
quires its transactivation activity when growth-arrested 3T3-L1 preadipocytes reen-
ter the cell cycle and undergo a couple of mitoses in response to a combination of
hormones, an event required for their differentiation into adipocytes. Interestingly,
As increased protein expression of the cell cycle inhibitor p27, suggesting it blocks
mitotic clonal expansion, and this may be the proximal event resulting in a cascade
of downstream effects. Interference of As with differentiation of adipocytes and/or
adipocyte-regulated lipid metabolism in vivo might lead to pathophysiological
changes in plasma lipid levels and regulation of lipid storage in adipose tissue and
liver, which in turn may contribute to the known association between As exposure
and increased risk of type 2 diabetes, CVD and other metabolic disorders. (Funded
by NIH-NIEHS SRP (P42 ES007373), and NIH-NRSA (2 T32 ES 7272-21))
1274 Liver X Receptor and Pregnane Xenobiotic Receptor
Crosstalk on Direct Repeat 4 (DR4) Response Elements Is
Sequence Dependent.
K. Falkner1,  B. Wahlang1,  H. Bellis-Jones1,  H. Clair1,  R. Prough3 and M. Cave1,
2. 1Department of Medicine/GI, University of Louisville, Louisville, KY; 2Louisville
VAMC, Louisville, KY; 3Biochemistry, University of Louisville, Louisville, KY.
As both the human Liver X-Receptor α (LXR) and the human Pregnane
Xenobiotic Receptor (PXR) bind to a Direct Repeat 4 (DR4) response elements
(RE), we compared the effects of co-transfection of either LXR, PXR or a combina-
tion of both receptors on their ability to transactivate different DR4 response ele-
ments containing reporter genes. Animal studies suggested that over-expression/ac-
tivation of either of these receptors results in steatosis. Both reporters contained the
same hexa-nucleotide (AGTTCA) core repeat but vary in the sequences in the im-
mediate 5’ and 3’ positions. HepG2 cells were transfected with plasmids expressing
human PXR and human LXR; receptor-responsive reporter plasmid, pGL3-PXRE-
luciferase and tk-LXR-RE-luciferase. Cells were treated with known positive lig-
ands for the respective receptors. The first reporter, optimized for PXR binding, was
activated by co-transfection of PXR treated with 10μM rifampicin and known LXR
ligand T0901317 (100nM), demonstrating that T0901317 is a PXR agonist. This
reporter was also activated by LXR in the presence of T0901317. In combination,
co-transfection resulted in increased fold induction of this reporter with both ri-
fampicin and T0901317. Our LXR selective DR4 reporter was activated by
T0901317 when LXR was co-transfected. The reporter was not activated by PXR
either in the presence of rifampicin or T0901317. In contrast to the PXR optimized
DR4 construct, co-transfection of both receptors resulted in a loss of LXR depend-
ent activation of the reporter by T0901317. These results suggest that both positive
and negative interactions are possible between these receptors and therefore, the re-
sponse of target genes may vary considerably, based in part on minor differences in
the nucleotide sequence of the DR4 response elements. Major crosstalk should be
anticipated between the predominantly endobiotic LXRα and the predominantly
xenobiotic receptor, PXR.
1275 Selective Activation of Human Pregnane X Receptor, Vitamin
D Receptor, and Glucocorticoid Receptor by Flavonols.
A. Lau and T. K. Chang. Faculty of Pharmaceutical Sciences, The University of
British Columbia, Vancouver, BC, Canada.
Pregnane X receptor (PXR), vitamin D receptor (VDR), and glucocorticoid recep-
tor (GR) regulate the expression of many genes, including those involved in the
bioactivation and detoxification of drugs, toxicants, and endogenous chemicals.
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Naturally occurring flavonols have been reported to possess paradoxical biological
activities in vitro and in rodents; e.g. chemoprevention and exacerbation of estro-
gen-induced tumorigenesis. Previously, quercetin, kaempferol, and tamarixetin
were reported to activate human PXR (hPXR). However, it is not known whether
there is a structure activity relationship in the activation of hPXR by flavonols and
whether they activate human VDR (hVDR) and human GR (hGR). In the present
study, we compared the effects of structurally related flavonols (i.e. flavonol, galan-
gin, datiscetin, kaempferol, morin, quercetin, isorhamnetin, tamarixetin,
myricetin, and syringetin) on the activity of hPXR, hVDR, and hGR. Only
flavonol, galangin, isorhamnetin, tamarixetin, and quercetin activated hPXR,
whereas none of them activated hGR or hVDR, as determined in dual-luciferase re-
porter gene assays in transfected HepG2 human hepatoma cells. Dose-response ex-
periments indicated that the minimum effective concentration for hPXR activation
by these flavonols was 10-30 μM. Flavonol and galangin, but not isorhamnetin,
tamarixetin, or quercetin, recruited steroid receptor coactivator-1 (SRC-1), SRC-2,
and SRC-3 to the ligand-binding domain of hPXR, as assessed by mammalian two-
hybrid assays. Flavonol and galangin bound to the ligand-binding domain of hPXR
in a time-resolved fluorescence resonance energy transfer competitive ligand-bind-
ing assay. Overall, flavonols activate hPXR in a receptor-selective and chemical-de-
pendent manner. The addition of OH or OCH3 group at C2’ and C5’ positions in
Ring B of flavonol appears to be unfavorable. Therefore, a minor change in chemi-
cal structure leads to abolishment of hPXR activation, implying that flavonols may
have differential impact on hPXR-mediated effects. [Supported by CIHR and
MSFHR]
1276 A Novel Aryl Hydrocarbon Receptor 1 Sequence from
Rainbow Trout (Oncorhynchus mykiss) Brain.
A. M. Kalinoski,  J. M. Preslar,  M. M. DeRocher,  D. M. Hollis and
E. V. Hestermann. Biology Department, Furman University, Greenville, SC.
The aryl hydrocarbon receptor (AhR) is a cytosolic protein receptor that mediates
the toxic effects of polynuclear aromatic hydrocarbons, polychlorinated biphenyls,
and other halogenated aromatic hydrocarbons. Two isoforms of AhR (AhR2α and
AhR2β) have been described in rainbow trout (Oncorhynchus mykiss). However,
AhR1 (the presumed ortholog of mammalian AhR) has yet to be sequenced. A
novel AhR sequence was obtained through Rapid Amplification of cDNA Ends
(RACE) of O. mykiss whole brain cDNA. Comparison of amino acid sequence in
the conserved bHLH and PAS regions and phylogenetic analysis revealed that the
new sequence is an AhR1. Tissue-specific expression of all three AhR forms was
studied by qRT-PCR. AhR2α and 2β showed similar patterns of expression and
were found in the highest concentration in the heart, gill, and bulbus anteriosus.
AhR1 was found in the highest concentration in the white muscle, heart, and brain.
These results suggest that the newly sequenced AhR1 is functionally distinct from
the previously described AhR2 forms.
1277 Ginsenosides Are Novel AH Receptor Ligands.
Q. Hu1,  G. He2,  J. Zhao2,  A. Soshilov2,  M. S. Denison2,  H. Yin3,  Q. Xie1 and
B. Zhao1. 1State Key Laboratory of Environmental Chemistry and Ecotoxicology,
Research Center for Eco-Environmental Sciences, Beijing, China; 2Department of
Environmental Toxicology, University of California Davis, Davis, CA; 3Xiyuan
Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
The aryl hydrocarbon receptor (AhR) is a ligand-dependent transcription factor
that mediates many of the biological and toxicological actions of structurally di-
verse chemicals. In this study we have examined the ability of a series of ginseno-
sides extracted from ginseng, a traditional Chinese medicine, to bind to and acti-
vate/inhibit the AhR signal pathway. The ability of the ginsenosides to
stimulate/inhibit AhR-dependent luciferase gene expression was examined using a
recombinant guinea pig adenocarcinoma (G16L1.1c8) cell line containing a stably
integrated DRE-driven firefly luciferase reporter plasmid pGudLuc1.1. Our data
show that the ginsenosides Rc and Rh1 are not only relatively weak inducers of
AhR dependent gene expression compared to that of TCDD, but we demonstrated
their ability to compete with [3H]TCDD for binding to and stimulate transforma-
tion and DNA binding of the guinea pig cytosolic AhR in vitro by utilizing a com-
bination of ligand and DNA binding assays. The overall ability of these ginseno-
sides to stimulate AhR signal transduction demonstrates that these ginsengosides
are a new class of naturally occurring AhR agonists. The weaker activity of these
compounds may be due to their relatively large size, which results in steric hin-
drance within the AhR ligand binding pocket, although it remains to be deter-
mined whether the entire compound fits into the binding pocket. Considering the
currently large consumption of ginseng, further studies into the molecular mecha-
nisms of ginsenosides action, including involvement of the AhR pathway, are
needed in order to better understand the diverse effects of these chemicals.
1278 Comparison of Serum Chemistry and Tissue Phenotypes in
Aryl Hydrocarbon Receptor Knockout Rats and Mice.
R. Budinsky2,  J. A. Harrill1,  R. Hukkanen2,  J. Rowlands2 and R. S. Thomas1.
1ICSS, The Hamner Institutes for Health Sciences, Research Triangle Park, NC;
2TERC, The Dow Chemical Company, Midland, MI.
An aryl hydrocarbon receptor knockout (AHR-KO) rat was generated on a
Sprague-Dawley outbred background in order to investigate the mode-of-action of
2,3,7,8-tetrachlorodibenzodixon (TCDD) tumorigenesis. Aside from its role as a
xenobiotic receptor, there is evidence that the aryl hydrocarbon receptor (AHR)
plays a critical role in the development of some tissues. Previous reports describe a
variety of tissue abnormalities in the liver, heart and kidney in AHR-KO mice. We
conducted a comparative study of gross tissue pathology, histology and serum
chemistry in AHR-KO rats and mice, and corresponding wild-types at 1, 6 and 12
weeks of age (n = 5 / sex / genotype / species) in order to evaluate the role of the
AHR in tissue development across species. Adult AHR-KO mice, but not AHR-
KO rats, had alterations in many serum chemistry markers associated with compro-
mised liver function as compared to wild-type. Similarly, in adult AHR-KO mice,
decreased liver-to-body weight and increased kidney- and heart-to-body weight ra-
tios were observed. Similar changes were not observed in AHR-KO rats, save in-
creased kidney-to-body weight ratios in females. Hepatic developmental abnormal-
ities including portal hypercellularity, billiary reduplication, hepatocellular
vessiculation and increased extramedullary hematopoesis were observed in 1 week
old AHR-KO mice and gradually dissipated across 6 and 12 week time points.
Adult AHR-KO mice also had patent ductus venosus. None of these histological or
gross morphological liver phenotypes were observed in AHR-KO rats. In contrast,
AHR-KO rats had severe urinary tract pathology including hydroureter, hy-
dronephrosis with secondary renal pelvic dilation, epithelial hyperplasia and miner-
alization leading to degenerative and inflammatory changes in cortical nephrons.
Renal pathology was not observed in AHR-KO mice. Overall, these data indicate
that the endogenous role of AHR in tissue development differs significantly be-
tween rats and mice.
1279 Selective AhR Modulator-Mediated Suppression of Acute
Joint Edema Associated with Gouty Arthritis.
I. Murray,  T. S. Lahoti,  G. Krishnegowda,  S. G. Amin and G. H. Perdew.
Pennsylvania State University, University Park, PA.
Gouty arthritis is an inflammatory condition associated with the joints of subjects
with high circulating levels of uric acid. Multiple factors promote the deposition of
uric acid salt crystals within the synovium, which initiates an immune response re-
sulting in a proinflammatory cytokine cascade and subsequent acute joint inflam-
mation. Here, we examine the topical efficacy of the selective AHR modulator
(SAhRM) SGA360 as an antiinflammatory therapy to suppress biomarkers associ-
ated with the in vivo monosodium urate (MSU) crystal model of gouty arthritis in
C57BL6/J mice. Intraarticular (i.a.) injection of MSU into the ankle joints of sub-
jects prompted a dose dependent increase in joint edema over sham controls, as de-
termined through micrometry. Peak inflammation was manifest 24-36 h post injec-
tion and resolved over time. Edema was associated with significantly enhanced gene
expression of the inflammatory mediators Il1b, Cxcl1, Saa3, Ptgs2 and Sphk1, as as-
sessed by quantitative PCR. Topical application of SGA360 at 6 h intervals after i.a.
injection of MSU identified an attenuation of joint edema at 24 h when compared
to controls. Ahr null mice revealed no significant difference in the level of MSU-in-
duced edema when compared to wild-type. MSU-dependent edema in Ahr null
mice proved to be refractory to the effects of SGA360 and thus established a re-
quirement for AHR to mediate its antiinflammatory potential. Substitution of
SGA360 with an AHR antagonist failed to inhibit MSU-induced edema in wild-
type mice suggesting the action of SGA360 is independent of competition with en-
dogenous AHR agonists. Analysis of MSU-induced gene expression in the context
of SGA360 revealed a suppression of the mediators Il1b, Cxcl1, Saa3, Ptgs2 and
Sphk1. Furthermore, exposure to SGA360 following the establishment of edema re-
vealed an increased rate of inflammatory resolution when compared to controls.
These studies indicate that SAhRMs such as SGA360 may provide an effective top-
ical therapy against acute inflammation associated with gouty arthritis.
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1280 Aryl Hydrocarbon Receptor (AhR) Regulates Growth Factor
Expression, Proliferation, Protease-Dependent Invasion and
Migration in Primary Fibroblast-Like Synoviocytes from
Rheumatoid Arthritis Patients.
T. S. Lahoti1,  K. John1, 2,  J. M. Hughes1,  B. Zhu1,  I. Murray1,  J. M. Peters1 and
G. H. Perdew1. 1Veterinary Sciences, Pennsylvania State University, University Park,
PA; 2DuPont Haskell Global Centers for Health and Environmental Sciences,
Newark, DE.
Rheumatoid arthritis (RA) is a chronic autoimmune disease. It is characterized pri-
marily by proliferation of cells in the synovial lining such as fibroblast-like synovio-
cytes (FLS). Under non-RA settings, FLS are a highly differentiated unicellular cell
type. However, under inflammatory milieu, they become hyperplastic, invasive and
highly migratory. Epidemiological studies have identified a positive correlation be-
tween cigarette smoking, a source of agonistic AHR ligands, and the progressive
phenotype of RA. Thus, under inflammatory conditions, we hypothesize the AHR
plays an important role in the expression of several growth factors in FLS. Our
AHR gene knockdown data in IL-1B activated primary FLS suggest a positive link
between ablation of AHR protein activity and suppression of inducibility of vascu-
lar endothelial growth factor-A (VEGF-A) and epiregulin (EREG) mRNA levels.
GNF351, a potent AHR antagonist, was also shown to suppress cytokine-mediated
upregulation of VEGF-A, EREG and basic fibroblast growth factor (FGF-2) expres-
sion, further validating the AHR dependency. ELISA was performed on super-
natants collected from FLS-RA cells pre-exposed to GNF351, followed by stimula-
tion with IL-1B, which revealed AHR antagonist-mediated suppression of
VEGF-A activity. Cytokine dependent activation of growth factors has been shown
to enhance FLS cell proliferation, which was attenuated by GNF351 pretreatment.
Upon activation by cytokines, FLS have been shown to become invasive and highly
migratory. Treatment of FLS with GNF351 mitigated cytokine-mediated expres-
sion of matrix metalloproteinases (MMP) -2 and -9 mRNA levels and also dimin-
ished FLS invasive phenotype. Overall, these results suggest that the AHR may be a
viable therapeutic target in amelioration of disease progression in rheumatoid
arthritis.
1281 Pregnane X Receptor and Cytochrome P450 CYP2 and
CYP3 Gene Responses to Potential Agonists for PXR and
AhR2 in Developing Zebrafish.
A. Kubota,  J. Goldstone,  B. Lemaire,  M. Takata,  B. Woodin and J. Stegeman.
Biology Department, Woods Hole Oceanographic Institution, Woods Hole, MA.
We addressed responses of developing zebrafish to potential agonists for the preg-
nane X receptor (PXR; also Steroid Xenobiotic Receptor SXR) and the aryl hydro-
carbon receptor (AHR) to determine involvement and interaction of PXR and
AHR signaling pathways in regulation of genes in cytochrome P450 subfamilies
CYP2 and CYP3. Zebrafish embryos were exposed to 5-pregnen-3β-ol-20-one
(pregnenolone; 1-10 μM) or to carrier (DMSO) for 24 h, starting at 48 hours post-
fertilization (hpf ), and then harvested at day 3. We also exposed one-day-old em-
bryos to 3,3’,4,4’,5-pentachlorobiphenyl (PCB126) or DMSO for 24 h and then
held in clean water until day 4. Expression of PXR and selected CYP genes that are
potential targets in the PXR signaling was assayed. Pregnenolone caused a concen-
tration-dependent increase in mRNA expression of PXR, some CYP2AAs,
CYP3A65 and CYP3C1, all of which peaked at 3 μM and then declined. An AHR
agonist PCB126 also upregulated the transcript levels of those genes in most cases
in a concentration-dependent manner. We next sought to examine the role of the
PXR and AHR in the modified expression of those potential target genes by using
morpholino antisense oligonucleotides (MO or morpholino) to block initiation of
translation of the PXR or AHR. Treatment of embryos with the PXR-MO, but not
the control morpholino, partially inhibited pregnenolone-induced expression of
PXR, CYP2 and CYP3 genes. Similarly, AHR2-MO treatment blocked PCB126-
induced transcript expression of PXR and some CYP2 and CYP3 genes. The pres-
ent study shows that PXR is not only self-upregulated, but also upregulated via ac-
tivation of AHR2 in developing zebrafish. Selected zebrafish CYP2 and CYP3
genes appear to be in part under the regulation of PXR and AHR2. They include
some CYP2AAs that were first identified in zebrafish. [Support: JSPS Postdoctoral
Fellowships for Research Abroad no. 820 (A.K.), and NIH Superfund Research
Program grant P42ES00738 (J.S.)]
1282 Aryl Hydrocarbon Receptor Reduces Cholesterol Absorption
by Regulating NPC1L1 Expression.
R. Tanos,  A. Kusnadi and G. H. Perdew. Pennsylvania State University, University
Park, PA.
Activation of Ah receptor (AHR) by an exogenous ligand such as dioxin is known
to mediate the expression of target genes (e.g. CYP1A1), by binding to dioxin re-
sponse element (DRE) sequences in their promoter region. We have previously
demonstrated the ability of the receptor to attenuate the hepatic expression of cho-
lesterol synthesis genes in a DRE-independent manner in mice and humans with-
out affecting the levels of SREBP2. We opted to look at any changes in the levels of
the NPC1L1 protein, a transcriptional target of SREBP2. NPC1L1 is known to
mediate the intestinal absorption of dietary cholesterol and is clinically targeted by
the drug Zetia, usually used in combination treatment with statins. NPC1L1 is also
expressed in the liver although its exact function in this tissue has not been deter-
mined conclusively. To examine the effect of AHR activation on NPC1L1 expres-
sion, C57BL/6J mice and primary human hepatocytes were exposed to the AHR
agonist B-naphthoflavone or selective ligand SGA 360 and results revealed a dra-
matic repression in the hepatic gene expression of NPC1L1. Attenuation of the ex-
pression levels of this gene was also confirmed in the intestine of C57BL/6J mice
and a human intestinal cell line (Caco-2 cells). Additionally, activation of the re-
ceptor was capable of overcoming the statin-induced increase in NPC1L1 gene ex-
pression. Through mutagenesis experiments targeting the two DRE sequences pres-
ent in the promoter region of the NPC1L1 gene, we established that the repression
does not require functional DRE sequences; while knock-down experiments
demonstrated that this regulation is AHR-specific and independent of the co-factor
p300 and the transcription factor YY1. Finally, cholesterol absorption was shown to
be reduced in human intestinal cells following AHR activation. These observations
clearly establish a role for the AHR as a key regulator of cholesterol absorption and
indicate the potential use of this receptor as a target for the treatment of metabolic
diseases.
1283 Generation and Characterization of a Hairless Mouse Model
to Study the Role of Aryl Hydrocarbon Receptor Activation
in Response to Ultraviolet Light Exposure.
K. J. Smith,  T. S. Lahoti,  J. A. Boyer,  K. Wagner,  I. Murray and G. H. Perdew.
Center for Molecular Toxicology and Carcinogenesis, Pennsylvania State University,
University Park, PA.
The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor
known to be a mediator of biological responses to external stimuli. Reports suggest
that endogenous ligands of the AHR include tryptophan photoproducts generated
upon exposure to ultraviolet (UV) light, such as 6-formylindolo[3,2-b]carbazole
(FICZ), linking the AHR to cellular processes occurring in response to UV light.
Despite advances in treating UV-related pathologies, the prevalence of detrimental
health effects due to UV light indicate that novel therapies are needed. To deter-
mine the in vivo role of the AHR in UV-mediated inflammation, mouse strains ex-
pressing the high affinity ligand binding allele (Ahb) and low affinity ligand binding
allele (Ahd) of the AHR were generated on an SKH1 hairless mouse background.
These strains were characterized using genotyping, AHR proteotyping, and satura-
tion ligand binding assays. The Ahb allele hairless strain was functionally character-
ized by the application of FICZ to the ears and compared to SKH1 mice, which ex-
hibit the Ahd allele, to determine levels of Cyp1a1 induction, an indicator of AHR
transcriptional activity. The Ahb hairless mice showed greater induction of Cyp1a1
when compared to the SKH1 mice upon FICZ treatment. Ahb and Ahd hairless
mouse strains were exposed to UV (360 mJ/cm2), followed by skin treatment with
a selective AHR modulator (SAhRM), to determine the level of induction of in-
flammatory genes, and the role of selective activation of the AHR in decreasing in-
flammatory gene expression. Similar induction of inflammatory genes (e.g.,Ptgs2,
Il6, Il1b) in untreated skin exposed to UV was seen in both mouse strains, but pref-
erential repression of Il1b upon SAhRM treatment was observed only in the Ahb
hairless mice. These strains will be useful in determining how the activity of the
AHR can be pharmacologically modified to reduce inflammation upon UV expo-
sure.
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1284 Inhibition of Heat Shock Protein-90 Prevents the
Transactivation and Translocation of Human Constitutive
Androstane Receptor.
T. Chen,  E. M. Laurenzana,  D. M. Coslo,  F. Chen and C. J. Omiecinski. Center
for Molecular Toxicology and Carcinogenesis, The Pennsylvania State University,
University Park, PA.
17-(Dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG) is cur-
rently in clinical trials for cancer treatment. 17-DMAG is a hydrophilic derivative
of geldanamycin (GA), and its analog, 17-(allylamino)-17-demethoxygel-
danamycin (17-AAG), all inhibitors of the molecular chaperone, heat shock pro-
tein-90 (HSP90). 17-DMAG offers a potential advantage over 17-AAG and GA
due to its increased bioavailability, limited metabolism and reduced in vivo toxicity.
HSP90 inhibition results in defective protein folding, conformation and assembly
of its client proteins, promoting their destabilization and degradation. Client pro-
teins of HSP90 include transmembrane tyrosine kinases (e.g., HER2, EGFR), in-
termediary signaling kinases (e.g., AKT, p53) and nuclear receptor family members
(e.g., AHR, PXR). Previous reports demonstrated that HSP90 is a cytosolic tether-
ing partner of the constitutive androstane receptor (CAR). The present investiga-
tion evaluated the potential effects of 17-DMAG on human CAR transcriptional
activation and nuclear translocation. 17-DMAG treatments repressed CAR-medi-
ated CYP450 induction in cultured human primary hepatocytes. Cell-based gene
reporter assays verified that 17-DMGA inhibited hCAR in a dose-dependent man-
ner. Intracellular localization studies revealed that phenobarbital-stimulated nuclear
translocation of hCAR in hepatocytes was completely blocked by 17-DMAG, as
well as GA. Immunoprecipitation analyses indicated that the suppression of hCAR
activity by 17-DMAG resulted from an enhanced interaction between hCAR and
HSP90. Mammalian two-hybrid assays further demonstrated that 17-DMAG dis-
rupted the interaction of hCAR with the nuclear co-activator, SRC1. Together, the
data indicate that these targeted HSP90 inhibitors markedly disrupt normal hCAR
function, suggesting that their clinical use may potentially impact CAR-mediated
drug metabolism and clearance.
1285 Activation of Transient Receptor Potential Ankyrin-1 by
Wood Smoke Particulate Material.
D. Shapiro,  C. E. Deering-Rice,  E. G. Romero,  G. S. Yost,  J. M. Veranth and
C. A. Reilly. Pharm/Tox, University of Utah, Salt Lake City, UT.
Exposure to wood smoke particulate matter (WSPM) has been linked to exacerba-
tion of asthma, development of causes chronic obstructive pulmonary disease
(COPD), and premature death. Combustion-derived PM (cdPM) such as cigarette
smoke (CS), diesel exhaust (DEP), and WSPM, activate transient receptor poten-
tial ankyrin-1 (TRPA1) which promotes neurogenic inflammation/edema and air-
way irritation/cough. The mechanism of TRPA1 activation by DEP and CS in-
volves the electrophilic/oxidant binding (3CK) and menthol-binding (ST) sites,
and a novel mechanosensitive site. We hypothesized that WSPM would activate
TRPA1 through one or more of these sites similar to other cdPM. Pine and
mesquite PM were generated in the laboratory. Both types of WSPM particles acti-
vated TRPA1 in human TRPA1 over-expressing HEK-293 and primary mouse
trigeminal (TG) neurons. WSPM also activated TRPA1 in A549 cells, a human
alveolar adenocarcinoma cell line, which has recently been shown to express
TRPA1. HC-030031, a TRPA1 specific antagonist, attenuated the calcium flux
due to WSPM treatment in both human A459 cells and mouse primary TG neu-
rons. Several known chemical components of WSPM, including 3,5-ditert-
butylphenol and agathic acid were TRPA1 agonists. Both WSPM and agathic acid
activated TRPA1 primarily via binding the 3CK site, based on inhibition of cal-
cium flux by glutathione and mutation of the 3CK site. Conversely, 3,5-ditert-
butylphenol activated TRPA1 through the ST site. This study established the
mechanism by which WSPM and associated chemical components activated
TRPA1 which may help tailor effective therapeutic treatments for WSPM pneu-
motoxicity. Support: NIEHS ES017431 and the University of Utah Undergraduate
Research Opportunities Program.
1286 Exploratory Phenotype and Molecular Analysis Study in
ROR-Gamma Knockout Mice.
M. J. Horner1,  R. Guzman1,  C. Karbowski1,  J. Schroeder1,  C. DiPalma2,
Y. He2 and C. Afshari1. 1Amgen Inc, Thousand Oaks, CA; 2Amgen Inc., Seattle, WA.
Retinoid-related orphan receptor g (RORg) is an orphan nuclear hormone receptor
that is widely expressed in several tissues including liver and skeletal muscle.
Previous gene expression profiling of liver from RORg knockout (KO) mice sug-
gested a possible role for RORg in metabolism of steroids, bile acids, and xenobi-
otics (Jetten et al. 2007). RORg has also been shown to regulate several metabolism
genes in skeletal muscle cells. The current study was designed to investigate the ef-
fects on pathology and genomics of knocking out the RORg nuclear receptor in
mice with a focus on liver and skeletal muscle tissues. Male and female wild type,
heterozygote, or homozygote RORg KO mice (10/group) were assessed at 10 weeks
of age. Study endpoints included clinical observations, body weights, organ
weights, gross and microscopic examination of tissues, and gene expression evalua-
tion using RNA isolated from liver, skeletal muscle, and spleen. There was no im-
pact with respect to clinical observations, body weight, and pathology on the phe-
notype of the heterozygous animals when compared with controls. Although no
differences in clinical observations or body weights were observed in the homozy-
gous animals, significant microscopic lesions were present in the thymus (thymic
hyperplasia and lymphoma), spleen (increased cellularity), and lymph node (ab-
sent). These findings were not unexpected and are in line with established literature
(Eberl and Littman 2003; Ueda et al. 2002). Pathway analysis of gene expression
changes indicated that a majority of the altered pathways were related to immune
response, an expected outcome. Skeletal muscle gene changes suggested a possible
role for RORγ in energy homeostasis. However, no perturbations in pathways rele-
vant to toxicological consequences were noted. Taken together, the data showed
that knocking out of RORg in mice led to expected changes in immune-associated
pathology and gene expression, but did not reveal any additional phenotypic or
genotypic toxicologically relevant effects.
1287 Estrogen Receptor α and Aryl Hydrocarbon Receptor Are
Not the Sole Determinants of Aminoflavone-Mediated
Growth Inhibition.
A. M. Brinkman1, 2 and W. Xu1, 2. 1Molecular and Environmental Toxicology Center,
University of Wisconsin Madison, Madison, WI; 2Department of Oncology, University
of Wisconsin Madison, Madison, WI.
Numerous studies have suggested that the aryl hydrocarbon receptor (AhR) may be
a potential therapeutic target for several human diseases, including estrogen recep-
tor alpha (ERα) positive breast cancer. Aminoflavone (AF), an activator of AhR sig-
naling that is structurally related to phytochemicals called flavonoids, is currently in
clinical trials for the treatment of solid tumors. It has been hypothesized that ERα
may be a predictor for response to AF-mediated growth inhibition, with ERα-pos-
itive cell lines being sensitive to the drug, and ERα-negative cell lines being resist-
ant. However, the scope of cell lines tested in the literature is limited. Here, we
show that ERα-negative human breast cancer cell lines express greater amounts of
AhR protein compared to ERα-positive human breast cancer cell lines, giving rea-
son to further characterize AF’s efficacy in these models. Using cell counting assays
to measure GI50 values, we show that two ERα-negative breast cancer cell lines,
MDA-MB-468 and Cal51, exhibit sensitivity to AF (GI50 < 1μM), suggesting that
ERα is not the sole predictor of responsiveness to AF. To examine the mechanism of
AF-mediated growth inhibition, a doxycycline-inducible AhR knockdown system
was created in these two cell lines. We show that there is no significant difference in
growth inhibition caused by AF treatment in cells where AhR is knocked down and
cells with endogenous levels of AhR. This suggests that a portion of the mechanism
involved in AF-mediated growth inhibition in MDA-MB-468 and Cal51 cells is
AhR-independent, or that compensatory mechanisms may exist. Overall, this work
suggests that while ERα is not the sole determinant of sensitivity to AF, this com-
pound may also be inhibiting cell growth in an AhR-independent fashion.
Supported by NIEHS Predoctoral Training Grant T32 ES007015.
1288 Understanding the Physiological Role of Aryl Hydrocarbon
Receptor Repressor (AhRR) Using Gene Knock-Down and
Targeted Mutagenesis in Zebrafish.
N. Aluru1,  S. I. Karchner1,  M. J. Jenny1, 2 and M. E. Hahn1. 1Biology, Woods Hole
Oceanographic Institution, Woods Hole, MA; 2Biological Sciences, University of
Alabama, Tuscaloosa, AL.
The aryl hydrocarbon receptor repressor (AHRR) is a transcriptional repressor of
the aryl hydrocarbon receptor (AHR) and is regulated by an AHR-dependent
mechanism. In humans, AHRR has been linked to tumorigenesis and reproductive
defects. Zebrafish have two AHRR genes; AHRRa regulates constitutive AHR sig-
naling during development, while AHRRb regulates polyaromatic hydrocarbon-in-
duced gene expression. The goal of this study was to elucidate the endogenous role
of AHRRs during zebrafish development using two loss-of-function approaches:
morpholino oligonucleotide (MO) knock-down and zinc finger nuclease (ZFN)-
based gene targeting (knock-out). Zebrafish embryos were microinjected with MOs
against AHRRa or AHRRb to knock down the expression of these proteins, fol-
lowed by microarray analysis of gene expression in embryos at 72 hours post-fertil-
ization. In AHRRa-MO injected embryos, 97 genes were upregulated and 182
genes were downregulated. The latter included cone type photoreceptor-specific
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genes, suggesting a role for AHRRa in photoreceptor development. In addition,
AHRRa knock-down caused upregulation of embryonic hemoglobin (hbbe3), sug-
gesting a role in hematopoiesis. Knock-down of AHRRb caused upregulation of 31
genes and downregulation of 85 genes, without enrichment of genes related to any
specific biological process. These results suggest that AHRRa plays an important
endogenous role in development. To understand the role of AHRRa beyond devel-
opment, we targeted ahrra using ZFNs. Microinjection of ZFN mRNA into ze-
brafish embryos caused a 7 base pair frame shift mutation at the ahrra locus. We
screened for germline mutants and identified a founder fish that was outcrossed to
generate heterozygous mutant offspring. Heterozygous mutants were crossed to
generate ahrra mutant homozygotes. Using these homozygotes we are investigating
the role of AHRRa in normal physiology and toxicology. [Supported by NIH
R01ES006272]
1289 Tissue-Specific Expression of Cytokines and Chemokines in
TCDD-Treated B6 and Aryl Hydrocarbon Receptor
Repressor Transgenic Mice.
C. Vogel1, 2,  D. Wu2,  J. Baek2,  S. Kado2,  T. Singh2,  G. Yang3,  P. Leung3,
E. Gershwin3,  T. Herrmann-Stemmann4 and F. Matsumura1, 2. 1Environmental
Toxicology, University of California Davis, Davis, CA; 2Center for Health and the
Environment, University of California Davis, Davis, CA; 3Division of Rheumatology,
Allergy and Clinical Immunology, University of California Davis, Davis, CA;
4Institute for Environmental Research, University of Duesseldorf, Duesseldorf,
Germany.
The aryl hydrocarbon receptor (AhR) has been identified as an important tran-
scription factor regulating the responses of immune cells including T cells and den-
dritic cells but the role of the AhR Repressor (AhRR) is less clear. The AhRR has
been first described to suppress AhR activity as an inducible negative feedback loop,
then again, there are many unanswered questions, as we know now that the basal or
induced cytochrome P450 1A1 (CYP1A1) mRNA level rarely correlates with
AhRR expression. To gain insight into the function of AhRR in vivo we developed
a transgenic AhRR B6 mouse (AhRR Tg). These transgenic mice express signifi-
cantly higher levels of AhRR mRNA in all tissues examined such as liver, lymph-
node, kidney, spleen, and thymus. Treatment of B6 and AhRR Tg mice with
TCDD causes significant induction of AhRR and CYP1A1 in most tissues exam-
ined. However, TCDD-induced expression of CYP1A1 was not significantly sup-
pressed in most of the tissues of AhRR Tg mice. The most consistently observed
trend in AhRR Tg mice was a repressed induction of several inflammatory markers
induced by TCDD as compared to B6 mice. The TCDD-mediated induction in
B6 mice as well as the repression in AhRR Tg mice of markers such as IL-1β, IL-6,
KC, and COX-2 was tissue-specific. Results show that the AhRR may suppress
AhR-mediated induction of inflammatory marker genes and that the AhRR may
control AhR activity in the immune system. The cross-talk of AhR with other tran-
scription factors including NF-κB has been well described. Therefore, this study
suggests that AhRR interacts especially with alternative AhR pathways rather than
simply blocking the classical AhR/ARNT pathway.
1290 Caloric Restriction Induces Nrf2-Dependent Effects on Lipid
Metabolism.
L. Armstrong,  S. R. Kulkarni,  J. Xu and A. L. Slitt. Biomedical and
Pharmaceutical Sciences, URI, Kingston, RI.
Toxcast screening has identified the Nrf2 transcriptional pathway as being highly
correlative to chemical promiscuity. Nrf2 is classically defined to have a role in me-
diating cytoprotection against oxidative stress, but recent work points to a more
fundamental metabolic role in lipid metabolism. Studies have indicated that the
Nrf2-Keap1 pathway is inducible in adipose tissue, and Nrf2 may have a role in
mediating the beneficial effects of caloric restriction (CR). CR promotes the uti-
lization of fat depots and fatty acid mobilization by altering fatty acid synthesis and
β-oxidation through modulating Ppar-α and Ppar-γ signaling. The potential role of
Nrf2 in regulation of lipid metabolism during CR is essential in understanding the
metabolic response of white adipose tissue (WAT) to low nutrient conditions. The
purpose of the study was to determine the role of Nrf2 in the regulation of lipid
metabolism during CR. Adult female lean (C57/BL6) mice and Nrf2KO mice were
fed ad-libitum (AL) or placed on a 25% (kCal) reduced diet for 5-7 weeks. Body
weight and blood glucose concentrations were monitored. Serum, liver, and white
adipose tissues were collected. Hepatic triglycerides, serum free fatty acids, and li-
pogenic mRNA gene expression in WAT were determined. Overall, CR C57BL/6
mice had a greater percent weight loss (21%) and greater decrease in WAT mass
(84%) compared to AL than CR Nrf2KO (11%, 49% respectively). CR C57/Bl-6
had a 4-fold lower liver triglyceride concentration than AL and 2.5-fold lower con-
centration compared to CR Nrf2KO. Further analysis of lipogenic genes in adipose
tissue supported a dysregulation of the lipogenic pathway in Nrf2KO mice that
leads to the resistance of fat utilization during CR. CR increased both Ppar-γ and
–α along with downstream gene expression (Lpl, Cd36, Scd-1, and Acc-1) in WAT
from C57Bl/6 mice compared to Nrf2KO mice. Determining whether Nrf2 has a
role for mediating beneficial effects for lipid oxidation in WAT could have impact
in multiple research areas–including toxicological studies that focus on obesogenic
mechanisms.
1291 Electrophilic Metabolites of Aromatic Hydrocarbons Cause
AhR Activation and Up-Regulation of CYP1A1 in HepG2
Cells: Involvement of S-Arylation of Cellular Proteins.
Y. Abiko1, 2,  A. Puga2 and Y. Kumagai1. 1Environmental Medicine Section,
University of Tsukuba, Tsukuba, Japan; 2Environmental Health, University of
Cincinnati Medical Center, Cincinnati, OH.
It is well established that aromatic hydrocarbons with 1 or 2 benzene rings and
without chlorine substituents are not ligands of the arylhydrocarbon receptor
(AHR), a cytosolic ligand activated transcription factor, the main factor responsible
for the induction of the CYP1A1 gene following nuclear translocation. We have re-
cently found that tert-butyl-1,4-quinone (TBQ) and 1,2-napthoquinone (1,2-
NQ), electrophilic metabolites of tert-butylated hydroxyanisole and naphthalene,
respectively, activate NRF2 through S-arylation of its negative regulator, KEAP1.
To our knowledge there have not been any reports to indicate that electrophiles that
covalently bind to cellular proteins might activate the AHR. In this study, we ad-
dressed this question by exposing cells in culture to several of these agents and using
immunocytochemistry 12 hours later to determine AHR nuclear translocation.
Exposure of HepG2 cells to TBQ, 1,2-NQ, 1,4-NQ or 1,4-benzoquinone, resulted
in AHR translocation and CYP1A1 induction, whereas both measures of AHR ac-
tivation were negative after treatment with BHA, or naphthalene. Similar results
were seen in A459 cells and RAW264.7 cells. TBQ treatment also enhanced the in-
teraction of AHR with ARNT. Interestingly, pretreatment with BSO and NAC to
modulate cellular GSH levels enhanced and suppressed 1,2-NQ-mediated activa-
tion of AHR, respectively, suggesting that covalent modification of these cellular
proteins, possibly through S-arylation of cysteine residues, contributes to the acti-
vation. These results suggest that electrophilic metabolites of aromatic hydrocar-
bons can serve as bifunctional inducers through activation of both AHR and
NRF2.
1292 AhR-Independent Gene Regulation by TCDD in Mouse
Liver and Kidney.
T. M. Seibel1,  C. Lohr1,  K. Andresen2 and D. Schrenk1. 1Food Chemistry and
Toxicology, University of Kaiserslautern, Kaiserslautern, Germany; 2Institute of
Biotechnology and Drug Research, Kaiserslautern, Germany.
Arylhydrocarbon receptor (AhR)-deficient mice have been shown to be resistant to
a variety of adverse effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD).
Furthermore, AhR-deficient mice of various origins exhibit various phenotypes al-
though the physiological function(s) of the AhR still await(s) elucidation. Here, we
investigated the effects of TCDD on liver and kidney gene expression in adult fe-
male wild-type (wt) and AhR-deficient mice (originating from Finish Public Health
Institute, Kuopio, Finnland) from our own breeding five days after treatment with
either TCDD, single dose, 25 μg/kg body weight, or with corn-oil (vehicle) given
by oral gavage. Subsequently, RNA was isolated and Microarray analysis was per-
formed using Agilent Whole Mouse Genome Oligo Microarray 4x44k. In wt mice,
282 genes were more than 2-fold up-regulated by TCDD in the liver including
some of well-known AhR target genes like cytochrome P450 (CYP) 1A1, 1A2 and
1B1; 152 genes were up-regulated in the kidney. In AhR-deficient mice, 242 he-
patic and 90 renal genes showed an increased expression after TCDD treatment.
Among those, 15 hepatic and 13 renal genes were up-regulated in both wt and
AhR-deficient animals. None of the core genes of the ‘AhR gene battery’ except
CYP1B1 was up-regulated in AhR-deficient mice. The AhR-independent, TCDD-
regulated genes comprise genes involved in lipid, carbohydrate, and amino acid me-
tabolism, and in immune regulation. In wt mice, 203 hepatic and 20 renal genes
were more than 2-fold down-regulated. In AhR-deficient mice, 234 hepatic genes
including CYP1A2 and CYP3A44 and 235 renal genes showed a decreased expres-
sion. In addition, 18 hepatic genes were down-regulated in both wt and AhR-defi-
cient animals. Our results demonstrate that TCDD can cause a broad spectrum of
alterations in gene expression in mouse liver and kidney in an AhR-independent
manner.
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1293 Coexposure to Aryl Hydrocarbon Receptor and Thyroid
Receptor Agonists Enhances Induction of Responsive Genes
in Cultured Frog Cells and Prometamorphic Frogs.
J. D. Taft and W. H. Powell. Biology, Kenyon College, Gambier, OH.
Amphibian metamorphosis is a postembryonic developmental process driven by
thyroid hormone (TH) and mediated by the thyroid receptor (TR). 2,3,7,8-tetra-
chlorodibenzo-p-dioxin (TCDD) can disrupt TH function in humans and other
species. Toxicity of dioxin-like compounds is mediated by the aryl hydrocarbon re-
ceptor (AHR). Here we used the African Clawed Frog (Xenopus laevis) as a model to
probe the interaction of TR and AHR signaling. We quantified relative mRNA ex-
pression of both TR and AHR target genes in prometamorphic tadpoles and in
XLK-WG cells following exposure to both TR and AHR agonists. Tadpoles (NF
53-55) were exposed to 5 nM TCDD and/or 10 nM T3 for 18 hours. TR targets
BTEB, TRβa, and TRβb were not strongly induced by TCDD alone, and AHR tar-
get CYP1A6 was not responsive to T3. However, exposure to both compounds re-
sulted in elevated transcriptional responses of both transcript classes. Compared
with T3-exposed animals, BTEB, TRβa, and TRβb mRNAs were 40-70% more
abundant following co-exposure with TCDD. Similarly, CYP1A6 mRNA was
∼50% more abundant in tadpoles following T3 co-treatment than with exposure to
TCDD only. Comparable patterns were observed in XLK-WG cells. The effect of
TCDD on circulating TH varies with species and can differ for T4 and T3. While
the superinduction of TH-responsive frog genes could involve TCDD-related alter-
ation of TH levels, the requirement for co-treatment and the effect in cultured cells
suggest the possibility of a transcriptional mechanism. We examined the promoter
regions of BTEB, TR-βb, and CYP1A6, finding potential cognate binding elements
for each receptor. Overall, our results suggest some degree of co-regulation of the
expression of several genes by both AhR and TR. Frogs display great insensitivity to
TCDD toxicity, and frog AHRs bind TCDD with low affinity. We hypothesize that
the induction of TR-regulated genes by AHR may represent an additional mecha-
nism for protection of metamorphosis from disruption by xenobiotic or endoge-
nous AHR agonists. (NIH: R15 ES011130)
1294 A Global Genomic Screening Strategy Reveals Diverse
Activators of Constitutive Activated Receptor (CAR).
K. Oshida1,  N. Vasani1,  B. Chorley1,  S. Hester1,  W. Ward1,  R. S. Thomas2,
D. Applegate3,  L. M. Aleksunes4,  C. D. Klaassen5 and C. Corton1. 1US EPA,
Research Triangle Park, NC; 2Hamner Institute, Research Triangle Park, NC;
3Regenemed, Inc, San Diego, CA; 4Rutgers University, New Brunswick, NJ; 5KUMC,
Kansas City, KS.
A comprehensive survey of conditions that activate CAR in the mouse liver has not
been carried out but would be useful in understanding their impact on CAR-de-
pendent liver tumor induction. A gene signature dependent on CAR activation was
identified by comparing the transcript profiles after exposure to three CAR activa-
tors (phenobarbital, TCPOBOP, CITCO) in wild-type and CAR-null mice. In in-
dependent experiments using transcript profiles from the livers of chemically-ex-
posed male or female mice, the signature correctly predicted activation of 3 CAR
activators but not 9 activators of other pathways. The signature was used with 5
classification methods (e.g., support vector machines, K-nearest neighbors) to iden-
tify conditions in which CAR was activated in an Affymetrix compendium of ~750
mouse liver transcript comparisons encompassing a broad range of chemical, di-
etary and genetic perturbations. We found that CAR is activated by a large number
of chemicals, dietary regimens and genetic mutations. Specific and novel findings
include activation by 1) two PXR activators in a PXR-dependent manner indicat-
ing crosstalk between CAR and PXR, 2) 12 out of 15 chemical and triglyceride ac-
tivators of PPARalpha to greater levels in PPARalpha-null mice than in wild type
mice indicating that most PPARalpha activators are also CAR activators and there
exists antagonism between CAR and PPARalpha, and 3) null mutations in a num-
ber of transcription factors (AhR, Fxr, Hnf1a, Pxr) that control expression of genes
involved in metabolism of exogenous and endogenous chemicals. The findings in-
crease our understanding of the factors that impact CAR activation and that could
contribute to increases in CAR-dependent liver tumors. This abstract does not rep-
resent EPA policy.
1295 Effects of Munitions Compounds on Xenobiotic-Activated
Nuclear Receptors and Cell Signaling Pathways.
D. R. Johnson1,  C. Y. Ang2,  T. Habib2 and E. J. Perkins1. 1Environmental
Laboratory, US Army Engineer Research & Development Center, Vicksburg, MS;
2Badger Technical Services, Vicksburg, MS.
Exposure to certain munitions compounds is known to alter physiological func-
tions in test organisms, however little is known about their molecular and cellular
effects. The objective of this study to characterize the effects of new and existing
munitions compounds on xenobiotic-activated nuclear receptors and cell signaling
pathways. Munitions compounds (0.01-10 mg/l) (e.g., nitroaromatics, cyclic
nitramines, and new insensitive munitions) were added to wells containing trans-
fected cells containing high constitutive levels of nuclear receptors for 24 h, then
examined for nuclear activation according to in-house and commercially available
kits. In general, nitroaromatic compounds had greater effects on nuclear receptor
activity decreased nuclear receptor activity than other munitions compounds.
Nitroaromatic munitions decreased activation of constitutive androstane receptor
(CAR), peroxisomal proliferator activated receptors (PPAR), liver x receptor (LXR)
at higher concentrations examined, whereas some nitroaromatic compounds acti-
vated the Ah receptor. Effects on 45 cell signaling pathways were examined using
the Signal Finder multi-pathway reporter array kit that reverse-transfected tran-
scription factor-firefly luciferase reporter plasmids into HepaRG liver cells. Cells
were then exposed to munitions compounds for 24 h, then examined for signal
pathway activation. Trinitrotoluene (TNT) and its environmental byproducts dif-
ferentially activated cell signaling pathways, with at least two pathways commonly
shared (AhR and Nrf2/Nrf1). 2,4-Dinitroanisole, a new TNT replacement muni-
tions, activated fewer cell signaling pathways than TNT. These results create a more
comprehensive picture of munitions effects within cells and potential down-stream
effects within organisms. Furthermore, rapid nuclear bioassays, such as the ones de-
scribed above, may help material scientist predict biochemical pathways that may
be impacted by newly developed munitions earlier in the development process.
1296 The Aryl Hydrocarbon Receptor Depletion in Human MDA-
MB-231 Breast Cancer Cell Line Attenuates In Vivo Tumor
Growth and Pulmonary Metastasis in a Nude Mouse Model.
G. Goode and S. E. Eltom. Biochemistry and Cancer Biology, Meharry Medical
College, Nashville, TN.
The aryl hydrocarbon receptor (AhR) is a ligand activated transcription factor that
is best characterized for its role in mediating the toxic responses elicited by environ-
mental poly aromatic hydrocarbons (PAH). However there is compelling evidence
for a PAH-independent role of AhR in breast cancer. AhR is overexpressed and con-
stitutively activated in several human breast carcinoma cell lines and shows strong
correlation with the degree of the tumor malignancy. In the present study we exam-
ine the effect of depleting AhR expression in the highly metastatic MDA-MB-231
human breast cancer cell line on tumor growth and experimental pulmonary
metastasis in a nude mouse model. The AhR was stably knocked down using
shRNA targeting AhR gene. Clonal cell line of MD231 HBC with approximately
80% depletion of AhR and its scramble control cells were transfected to stably and
constitutively express luciferase gene for the purpose of in vivo bioluminescence im-
aging of tumors. Cells were injected either orthotopically in the mammary fat pad
for monitoring the primary tumor growth, or intravenously in the lateral tail vein,
for monitoring pulmonary experimental metastasis. Results showed that knock
down (KD) of AhR expression significantly reduced incidence of mice with tumor
growth, prolonged the latency and reduced tumor size in those mice which devel-
oped tumors compared to controls. Mice with AhR KD in the experimental metas-
tasis group showed a significant reduction in the number of animals with lung
metastasis compared to control, and decreased numbers and sizes of pulmonary
metastasis in those, which manifested metastasis. Global gene expression profiling
identified sets of genes associated with tumor growth and metastasis that have been
altered subsequent to depletion of AhR, and are likely to account for these pheno-
types. Our data provide the first in vivo evidence for the role of AhR in regulating
breast cancer metastasis and identified it as a therapeutic target for metastatic breast
cancer.
1297 Species Specificity of the Peroxisome Proliferator Response
in Primary Hepatocytes.
P. D. McMullen,  S. Bhattacharya,  C. G. Woods,  R. A. Clewell,  E. L. LeCluyse,
K. M. Yarborough,  L. Pluta,  P. Lu,  J. Dong,  J. Pi and M. E. Andersen. 1Clinical
Research Program, NIEHS, Durham, NC; 2Cell Adhesion Group, NIEHS, Durham,
NC; 3Pharmacology and Toxicology, East Carolina University, Greenville, NC;
4National Toxicology Program (NTP), NIEHS, Durham, NC.
Perturbations induced by environmental chemicals often lead to different physio-
logical outcomes in humans and rodents, calling into question the applicability of
animal-based toxicity testing for human risk assessment. For example, peroxisome
proliferators, which include several purported endogenous fatty acids as well as a
number of synthetic ligands, induce lipid metabolism enzymes in humans and have
been used successfully as therapeutic strategies for various dyslipidemias and dia-
betes. For rodents, in addition to their role in regulating fatty acid metabolism, per-
oxisome proliferators also influence peroxisome assembly, inflammatory responses,
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and cellular proliferation. Understanding the basis for differences in clinical reper-
cussions across species is essential to translating information from animal models to
human health.
Here we present a genomic characterization of the response of human and rat pri-
mary hepatocytes to the PPARα-specific agonist GW7647. We used gene expres-
sion microarray experiments to compile a highly resolved time- and dose-response
characterization of the difference of the PPARα-mediated response in these two
species. Consistent with the qualitative differences in the response to peroxisome
proliferators, we identified a substantially larger set of differentially expressed genes
in rat cells compared to human. These additional genes include a suite of develop-
mental processes that may account for the increased toxicity of peroxisome prolifer-
ators in rodents. Surprisingly, in both species, we found that the canonical nuclear
receptor response mechanism accounts for only a small fraction of detected re-
sponse, suggesting a larger role for non-genomic mechanisms than was previously
thought.
1298 Development of a Rapid, Cell-Based Screen for Disruptors of
the Retinol (Vitamin A) Signaling Pathway.
Y. Chen and D. H. Reese. OARSA/CFSAN, US FDA, Laurel, MD. Sponsor: T.
Flynn.
A central goal in the 2007 National Research Council’s vision for Toxicity Testing
in the 21st Century is the development of a comprehensive suite of in vitro tests
covering the major signaling pathways (toxicity pathways) in mammals that can be
used for evaluating chemical toxicity while reducing or eliminating the use of ani-
mals. Our research focuses on the development of in vitro screens for detecting
chemicals in food additives, supplements, and contaminants that can disrupt the
major cellular signaling pathways in mammals. One of these pathways, the retinol
(vitamin A) signaling pathway, is essential for life in all mammals. It is required for
both normal embryonic development and maintenance of cellular phenotype in
adult organisms; chemicals that cause even minor interference with its normal func-
tion and output are potential fetal and adult toxicants. We have developed a rapid
(24 h) screen for detecting chemicals that disrupt this essential signaling pathway. It
uses the mouse pluripotent P19 stem cell line and a medium-throughput 96-well
format gene-expression assay to detect disrupting chemicals. It has detected all
known retinol signaling pathway disruptors and some chemicals that are closely re-
lated, structurally, to known disruptors. Significantly, it also has detected members
of a class of chemicals, the endocrine disruptors, which have not been associated
previously with disruption of this pathway; chemicals that caused disruption in-
cluded xenoestrogens (DES, BPA, 4-n-nonylphenol, and genistein and phthalate
esters (dibutyl phthalate and diphenyl phthalate but not bis(2-ethylhexyl) phtha-
late). The effects of members of this class of chemicals on the pathway suggest the
existence of an additional non-genomic mechanism of action by which some en-
docrine disrupting chemicals cause toxicity.
1299 Asian Ginseng (Panax ginseng) Potentiates Ethanol-Induced
Cardiovascular Dysfunction in Medaka Embryogenesis
(Oryzias latipes).
M. H. Haron2, 1,  L. A. Walker1, 2,  I. A. Khan1 and A. K. Dasmahapatra1, 2.
1National Center for Natural Product Research, University of Mississippi, University,
MS; 2Department of Pharmacology, University of Mississippi, University, MS.
Alcohol is a teratogen, induces fetal alcohol spectrum disorder (FASD) which has
serious central nervous system (CNS), cardiovascular, and craniofacial defects af-
fecting the entire lifetime of an individual. Prevention of FASD, other than women
abstaining from drinking alcohol during pregnancy, is not known. The synthetic
drugs recommended for the treatment of alcoholism cannot be used by women
during pregnancy which led us to investigate on natural products. Due to ethical
constraints FASD studies in humans are very limited and several animal models are
used to understand the molecular mechanisms. We have observed that develop-
mental ethanol exposure of medaka (Oryzias latipes) embryos generates features
which are analogous to human FASD phenotypes. We hypothesize that ethanol
metabolism generates oxidative stress which can disrupt embryonic development of
medaka. In the present experiment, we have used root extracts of Asian ginseng
(Panax ginseng) as a preventive agent of FASD. Fertilized medaka eggs within 4 h
post fertilization (hpf ) were exposed to methanolic extracts (50-100 ug/ml) of gin-
seng root (PG) or ethanol (300 mM) either alone or in combination. After 48 h of
treatment the viable embryos were transferred to clean hatching solution and on 6
dpf the embryos were examined for vessel circulation followed by mRNA analyses
of enzymes related to ethanol metabolism and oxidative stress. It was observed that
ethanol (300 mM) alone was able to disrupt vessel circulation and cotreatment of
PG (50-100 ug/ml) with ethanol was able to enhance the effect; PG (100 μg/ ml)
alone has no effect. mRNA analysis of alcohol metabolizing enzymes or oxidative
stress-related enzymes did not show any significant alterations in any of these treat-
ment conditions. It is therefore concluded that potentiation of ethanol-induced
cardiovascular deformities in medaka by PG may be mediated through a different
mechanism rather than oxidative stress.
1300 Toxicology Profile of Virginia Cedarwood Oil Delivered via
Dermal Application.
I. Surh1,  R. A. Herbert2,  G. S. Travlos2,  M. Vallant3,  L. M. Fomby4,
M. R. Hejtmancik4 and P. Chan1. 1Toxicology Branch, Division of the National
Toxicology Program, NIEHS, Research Triangle Park, NC; 2Cellular and Molecular
Pathology Branch, DNTP, NIEHS, Research Triangle Park, NC; 3Program Operations
Branch, DNTP, NIEHS, Research Triangle Park, NC; 4Battelle, Columbus, OH.
Virginia cedarwood oil (CWO), which is extracted from Juniperus virginiana trees,
is widely used as an insect repellent and a fragrance in cosmetic formulations result-
ing in human exposure. To investigate the toxicological effects of CWO, 90-day
studies in F/344 N rats and B6C3F1/N mice were conducted. CWO was adminis-
tered by dermal application to male and female rats and mice at concentrations of
0, 6.25, 12.5, 25, 50% (v/v) in 95% ethanol or 100% daily (excluding weekends)
for up to 14 weeks with an untreated control included. In rats, there were no effects
on survival or body weights except in the 100% males in which 2 rats were termi-
nated on day 79 due to severe skin lesions and a 13% lower group final mean body
weight than that of the untreated control. All male and female mice in the 100%
group were terminated during week 10 due to the severity of skin lesions. Final
group mean body weights for females given 12.5, 25 or 50% and males given 50%
were less than 90% of the controls. At the site of application, treatment related irri-
tation, thickened skin, and ulcer formation were observed in all treated groups of
rats and mice, except the 6.25% groups in rats. Clinical pathology showed an in-
flammatory leukogram secondary to dermal ulcers/inflammation in both rats and
mice; mice also had a decreased erythron. In rats and mice there were dose-depend-
ent increases in incidences and severity of skin lesions at the site of application, and
bone marrow hyperplasia. In rats, there were dose-dependent increases in inci-
dences and severity of kidney lesions in males. Male mice demonstrated increased
incidences of kidney nephropathy and thymus atrophy.
1301 Novel Antiplatelet Activity of Protocatechuic Acid through
Inhibition of High Shear Stress-Induced Platelet
Aggregation.
K. Kim1,  K. Lim1,  J. Noh1,  S. Kang1,  K. Chung2,  O. Bae3 and J. Chung1.
1College of Pharmacy, Seoul National University, Seoul, Republic of Korea; 2School of
Pharmacy, Sungkyunkwan Universtiy, Suwon, Republic of Korea; 3College of
Pharmacy, Hanyang University, Ansan, Republic of Korea.
Bleeding is the common and serious adverse effect of currently available anti-
platelet drugs. Many efforts are being made to develop novel anti-thrombotic
agents without bleeding risks. Shear stress-induced platelet aggregation (SIPA)
which occurs under abnormally high shear stress plays a crucial role in the develop-
ment of arterial thrombotic diseases. Here we demonstrated that protocatechuic
acid (PCA), a bioactive phytochemical from Lonicera (honeysuckle) flowers, selec-
tively and potently inhibits high shear (>10,000 s-1)-induced platelet aggregation.
In isolated human platelets, PCA decreased SIPA and attenuated accompanying
platelet activation including intracellular calcium mobilization, granule secretion
and adhesion receptor expression. Anti-SIPA effect of PCA was mediated through
blockade of von Willebrand factor (vWF) binding to activated GPIb, a primary and
initial event for the accomplishment of SIPA. Conspicuously, PCA did not inhibit
platelet aggregation induced by other endogenous agonists like collagen, thrombin
or ADP that are important both in pathological thrombosis and normal haemosta-
sis. Anti-thrombotic effects of PCA were confirmed in vivo in rat arterial thrombo-
sis model, where PCA significantly delayed the arterial occlusion induced by FeCl3.
Of a particular note, PCA did not increase bleeding time in rat tail trans-section
model, while conventional anti-platelet drugs, aspirin and clopidogrel substantially
prolonged it. Collectively, these results suggest that PCA may be a novel anti-
platelet agent which can prevent thrombosis without increasing bleeding risks.
1302 The Soy-Associated Phytoestrogen, Genistein, Does Not
Protect Against Alcohol-Induced Osteoporosis in Male Mice.
C. Yang1,  K. Mercer1,  L. Suva1,  T. M. Badger2, 1 and M. Ronis2, 1. The Hamner
Institutes for Health Sciences, Research Triangle Park, NC.
Alcohol abuse acts as a risk factor for osteoporosis by increasing osteoclast activity
and decreasing osteoblast activity in bone. These effects can be reversed by estra-
diol. Soy diets are also suggested to have protective effects on bone loss in men and
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women, as a result of the presence of soy protein-associated phytoestrogens such as
genistein and daidzein. In this study, male mice were pair fed (PF) a control diet, an
EtOH diet or EtOH diet supplemented with genistein (250 mg/kg) for 8 weeks. Ex
vivo microCT analyses of formalin fixed tibias from each group revealed a signifi-
cant decrease in trabecular bone in the EtOH group in comparison with the pair-
fed control in regards to bone volume (BV/TV), trabecular number (Tb.N), and
trabecular separation (Tb.Sp), (p<0.05). No protective effect by genistein was ob-
served in the EtOH+genistein group compared to the EtOH group in BV/TV,
Tb.N, and Tb.Sp. Interestingly, there was an increase in trabecular thickness
(Tb.Th) in the PF+genistein group compared to the PF (P<0.05), suggesting genis-
tein can affect bone remodeling. In ex vivo bone marrow cultures, EtOH exposure
decreased the number -pre-osteoblasts compared to PF controls. In contrast, expo-
sure to EtOH+genistein increased pre-osteoblast numbers compared to the EtOH-
treated group, (p<0.05). These findings suggest that genistein has a partial protec-
tive effect on bone formation. In conclusion, genestein does not protect against
ethanol induced bone loss despite increasing osteoblastogenesis. Supported in part
by R01 AA18282 (M.J.R.) and UAMS INBRE award 8 P20 GM103429-11.
1303 Toxicological Safety Assessment of a Hydroethanolic Extract
of Caralluma fimbriata.
J. R. Endres1,  N. Deshmukh2 and A. G. Schauss1. 1AIBMR Life Sciences, Inc.,
Puyallup, WA; 2INTOX Pvt. Ltd., Pune, India.
A toxicological safety assessment was conducted on a hydroethanolic extract of
Caralluma fimbriata, an ingredient marketed as an appetite suppressant, to predict
safety with oral consumption by humans. Caralluma fimbriata extract (CFE) is
standardized to contain no less than 25% pregnane glycosides and no less than 10%
saponin glycosides. The extract is >98% soluble in water. CFE is currently sold as
the trademarked ingredient Slimaluma™. Two genotoxicity studies were con-
ducted and no evidence of mutagenicity or genotoxicity was observed in the pres-
ence or absence of a rat liver S9 metabolic activation system at concentrations up to
5,000 μg of extract/plate (Ames Bacterial Reverse Mutation Assay) or 5,000 μg of
extract/mL in a chromosomal aberration assay. Studies conducted in Wistar rats in-
cluded a 14-day acute oral toxicity study, and a 90-day repeated oral toxicity study.
A 6-month repeated oral toxicity study was conducted in Sprague-Dawley rats. In
the 14-day study, the NOAEL was determined to be 5 g/kg bw. While a few statis-
tically significant (p<0.05) findings were observed in the 90-day Wistar rat study, it
was considered to be a sound basis for conducting a 6-month study. In the 6-month
Sprague-Dawley rat study, the no observed effect level (NOEL) was concluded as
1,000 mg/kg bw/d, the highest dose group tested. Finally, in a developmental toxi-
city study in Sprague-Dawley rats no fetal abnormalities related to administration
of the test article were observed.
1304 The Antidiabetic Activities of the Soft Drink Leaf Extract of
Phyllanthus amarus (Order Euphorbiales; Family
Euphorbiaceae) in Laboratory Animals.
A. A. Adedapo and S. O. Ofuegbe. Veterinary Physiology, Biochemistry and
Pharmacology, University of Ibadan, Ibadan, Nigeria.
Phyllanthus amarus Schum (Family Euphorbiaceae) is an annual herbal shrub
which has been used in traditional medicine in Nigeria to treat some disease condi-
tions. This study evaluated the soft drink extract (SDE) of the plant for anti-dia-
betic activities in rats.
SDE was prepared by dissolving fresh aerial parts of the plant in 7up soft drink for
48 h, filtered, lyophilized and then used for the pharmacological investigations.
Standard phytochemical methods were used to test for the presence of phytoactive
compounds in the plant. Acute toxicity was carried out in mice to determine safe
doses for this plant extract. The anti-diabetic activities of the SDE of the plant were
assessed using some standard tests as well as histological changes in liver, kidney and
pancreas. Diabetes mellitus was induced in rats using alloxan while glibenclamide
at 0.2mg/kg was the reference drug used in this study.
The SDE at 200 and 400mg/kg body weight caused a significant reduction of fast-
ing blood glucose, significant change in the oral glucose tolerance test, marked ef-
fect in the hypoglycaemic activity test, and pronounced reduction on the glucose,
cholesterol and triglyceride levels of diabetic rats. The haemograms of all treated di-
abetic rats experienced recovery. Histopathologically, the liver of the diabetic non-
treated and glibenclamide-treated groups showed widespread vacuolar change in
the hepatocytes but there was no visible lesion seen in the kidney and pancreas of
extract-treated and glibenclamide-treated groups. No lesion was also seen in the
liver of SDE-treated group.
In conclusion, the results from this study may have validated the traditional basis
for the use of Phyllanthus amarus as antidiabetic agent. The pharmacological activ-
ities noted in this study may be attributed to the presence of flavonoids and other
phenolics contained in this plant. At the doses used, SDE also appeared safer than
glibenclamide even though the latter is more potent.
1305 Protective Effects of Methanolic Root Extract of Balanites
aegyptiaca (L.) Delile on Carbon Tetrachloride (CCl4)-
Induced Hepatotoxicity in Rats.
O. A. Salawu1,  F. Tukur2,  A. Y. Tijani1,  J. Ejiofor2 and S. Ahmed3.
1Pharmacology and Toxicology, National Institute for Pharmaceutical Research and
Development (NIPRD), Abuja, Nigeria; 2Pharmacology and Therapeutics, Ahmadu
Bello University, Zaria, Nigeria; 3Pathology, Ahmadu Bello University Teaching
Hospital, Zaria, Nigeria.
Objective: Balanites aegyptiaca (BA), a widely grown desert tree found in Africa
and Asia is used as a remedy for several ailments including liver and spleen diseases.
This study evaluated the protective activity of the methanol extract of BA root by
direct (curative and prophylactic models) and indirect (barbiturate-induced sleep
model) methods in CCl4 -induced hepatotoxic rats.
Methods: In the curative study, 0.5 ml/kg CCl4 was given intraperitoneally (ip) on
alternate days, for 5 days, followed by 100, 200 and 400mg extract/kg orally daily,
for 7 days. Other groups received the vehicle only, CCl4 and the vehicle, and CCl4
and the standard drug, silymarin (100 mg/kg/day) respectively. In the prophylactic
study,all the rats received the treatment respectively for the first 7days followed by
CCl4 as above. Degree of liver protection was measured in the rats by biochemical
parameters (serum alanine transaminase, aspartate transaminase, alkaline phos-
phatase, albumin, bilirubin, triglycerides and cholesterol levels) monitoring, physi-
cal (weight) and histopathological changes in the liver. The indirect method was
same as in prophylactic study but on the13th day, the rats were given 25mg pento-
barbitone sodium/kg ip and observed for onset and duration of sleep. 
Results: Pre-treatment with the extract significantly (P<0.05) decreased CCl4 - in-
duced elevation of serum levels of the biochemical parameters, better than sily-
marin. In the curative study, its effect was comparable with that of silymarin. It also
significantly decreased pentobarbitone sleeping time. There was improved tissue
histopathology in both studies. 
Conclusion: These results showed that BA root has significant hepatoprotective ac-
tivities and could be useful as ‘lead’ in the development of new hepatoprotective
agent.
1306 The Effects of Citrus Auraptene in Combination with All-
Trans Retinoic Acid on Human Squamous Cell Carcinoma in
a Xenograft Model.
H. E. Kleiner1,  E. R. Lane1,  J. Mathis2,  J. McLarty3,  M. S. Prince1,
S. R. Crooks1,  J. L. Clifford4 and E. A. Orchard1. 1Department of Pharmacology
Toxicology & Neuroscience, Louisiana State University Health Sciences Center,
Shreveport, LA; 2Anatomy and Cellular Biology, Louisiana State University School of
Health, Shreveport, LA; 3Medicine, Louisiana State University Health Sciences Center,
Shreveport, LA; 4Biochemistry & Molecular Biology, Louisiana State University
Health Sciences Center, Shreveport, LA.
Over 2,000,000 new cases of non-melanoma skin cancer (NMSC) are expected in
the United States in 2012. Our group has previously demonstrated that citrus au-
raptene (AUR), combined with all-trans retinoic acid (ATRA), can inhibit the
growth of human skin squamous cell carcinoma (SCC) tumors from the cell line
SRB12-p9 (P9WT) in SCID/bg mice. ATRA is known to inhibit the STAT3 path-
way, whereas AUR suppresses the activation of NF-κB and induces antioxidant en-
zymes such as glutathione S-tranferase (GST). NF-κB and STAT3 are both hyper-
activated in cancer. We hypothesize that suppressing both pathways by these
compounds will produce a greater chemopreventive effect than by using either
agent alone. Groups of 10 each female SCID/bg mice were injected with 1 x 10^6
P9WT cells, s.c. Mice were dosed with AUR (0, 100, 200, 400 mg/kg bw) ± ATRA
(2 mg/kg bw), p.o., beginning 4 days prior to tumor cell injection and 4 days/wk
for the duration of the study (48 days). Tumor volumes were estimated by caliper.
At the end of the tumor study, necropsies were performed, and tissues taken for fur-
ther analyses. Statistical analyses revealed no effect of AUR by itself on tumor vol-
umes. ATRA alone suppressed tumor volume by 16-fold. However, ATRA was so
effective at blocking tumor volume that any additional effects of AUR may have
been masked. ATRA also caused a loss of body weight, but the liver/body weight ra-
tios were not different across groups, and the activity index of the mice was within
range. In conclusion, this study will be repeated using lower doses of ATRA, in
combination with AUR to determine the minimum effective dose of ATRA,
(known to be toxic) while assessing the effect of the AUR. (5R21CA149761-02)
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1307 Toxicological Evaluation of the Aqueous Extract of Morinda
morindoides Root Bark.
M. O. Abatan1, 2,  J. O. Olukunle2,  O. L. Ajayi3,  M. O. Olaniyi3 and
O. T. Adenubi2. 1Veterinary Physiology, Biochemistry and Pharmacology, University
of Ibadan, Ibadan, Nigeria; 2Veterinary Physiology and Pharmacology, University of
Agriculture, Abeokuta, Abeokuta, Nigeria; 3Veterinary Pathology, University of
Agriculture, Abeokuta, Abeokuta, Nigeria.
Toxicological evaluation of Morinda morindoides root bark was carried out using
hematological and serum biochemical changes accompanying prolonged adminis-
tration of the aqueous leaf extract of the plant in Wistar rats. Twenty rats were ran-
domly but equally divided into four groups. Rats in groups I were administered
with 0.9% physiological saline (10ml/kg b.w) as the control animals, while rats in
groups II, III and IV were administered with aqueous extract at 400, 800 and 1600
mg/kg body weight respectively once daily for 28 days according to the acute toxic-
ity study carried out. Parameters evaluated were complete blood count, serum pro-
tein, metabolites and enzymes. Samples from liver, spleen, heart, and kidney were
processed for histopathology. Data were expressed as mean± Standard Error of
Mean and analyzed using one way ANOVA. Difference of means are considered
statistically significant at p<0.05. 
There were no significant changes in the hematological parameters between the
treated groups and the control group. Rats in group IV exhibited significant in-
crease in the serum levels of alkaline phosphatase, aspartate amino transaminase,
alanine amino transferase and creatinine. Histopathology revealed mild diffuse de-
generation of the liver, mild tubular nephrosis and mononuclear cellular infilter-
ation in the heart. It was concluded that ethnomedicinal application of Morinda
morindoides is quite safe at lower doses but it is hepatotoxic, nephrotoxic and car-
diotoxic at higher doses.
1308 Antidiarrheal Evaluation of Aqueous and Ethanolic Leaf
Extracts of Acacia sieberiana DC (Fabaceae) in Albino Rats.
C. J. Dawurung,  I. L. Elisha,  N. V. Offiah,  J. G. Gotep,  O. O. Oladipo,
M. S. Makoshi,  S. Makama and D. Shamaki. Drug Development Unit,
Biochemistry Division, National Veterinary Research Institute (NVRI) Vom, Jos,
Nigeria.
Sequel to reports on the use of Acacia sieberiana leaves in the management of ani-
mal diarrhea in some parts of Plateau State Nigeria,the anti diarrheal activity of
aqueous and ethanolic extracts of the leaves of A. sieberiana were evaluated in al-
bino rats. Studies were carried out on castor oil induced diarrhea and gastrointesti-
nal transit at doses of 300, 600, and 1200 mg/Kg body weight. Both extracts did
not show any significant (P>0.05) inhibitory effect in both assays when compared
to the negative controls. The standard drugs, loperamide (10 mg/Kg) and atropine
sulphate (3 mg/Kg) significantly (P<0.05) inhibited diarrhea and reduced the dis-
tance travelled by the activated charcoal in the intestine respectively. Phytochemical
screenings of the extracts revealed the presence of saponins, cardiac glycosides, and
flavonoids in both extracts, while tannins were present only in the ethanolic extract.
In the toxicity test (limit test), no deaths or any apparent signs of toxicity or side ef-
fects were observed in the animals following the oral administration of both extracts
at 2000 mg/Kg. The traditional use of A. sieberiana leaves in the management of
diarrhea could not be justified by this study. Further work to assess the antibacter-
ial, antiviral, anthelminthic and antiprotozoal activity of the leaves and antidiar-
rheal evaluation of other parts of the plant is necessary to verify the folkloric claims
for its use in diarrheal management.
1309 Protection by Fish Oil against D-Galactosamine-Induced
Hepatic Injury and Biochemical Alterations in the Plasma
and Liver of Rats.
Y. Shen,  M. C. Parikh and C. A. Lau-Cam. Pharmaceutical Sciences, St. John’s
University, Flushing, NY. Sponsor: B. Billack.
The present study has investigated the actions of fish oil (FO) on D-galactosamine
(GalN)-induced changes in plasma glucose (GLC), bilirubin, total proteins (TP)
and enzymatic indices of hepatic damage; and in the levels of plasma and hepatic
triglycerides (TG) and cholesterol (CHOL). Groups of 6 male Sprague-Dawley
rats, 220-50 g in weight, were treated for 3 consecutive days with a 600 mg/kg oral
dose of FO, as an emulsion in 0.9% NaCl-tween 20. On day 4, the rats received a
single intraperitoneal, 400 mg/kg, dose of GalN in 0.9% NaCl. Additional rats re-
ceived only the vehicles of the treatment solutions (control group), only GalN or
only FO. All the rats were sacrificed by decapitation under isoflurane anesthesia 24
hr after receiving GalN, and their blood and livers were collected. The plasma frac-
tion was analyzed for GLC, TG, CHOL, total (TB) and direct (DB) bilirubin, TP,
alanine transaminase (ALT), aspartate transaminase (AST) and alkaline phos-
phatase (ALP). A portion of liver was made into a 1:20 (w/v) homogenate in phos-
phate buffered saline pH 7.5 which was analyzed for its contents in TG and
CHOL. Relative to control values, GalN increased the plasma GLC (41%), ALT
(>290%), AST (>110%), ALP (+ 54%), TB (6.3-fold), DB (46-fold), TG (5.3-
fold) and CHOL (1.6-fold) while decreasing those of TP (by 59%) (all at p≤0.01).
In addition, GalN increased the liver weight to body weight ratio (35%) and the
levels of TG (61%) and CHOL (400%) significantly (p≤0.01 vs. control). A pre-
treatment with FO was able to attenuate the changes in plasma and liver compo-
nents as well as in the liver weight to body weight ratio to a significant extent
(p≤0.05). By itself, FO was found to raise the plasma (98%) and liver TG (23%)
and the liver CHOL (33%) significantly (p≤0.05), but not as much as GalN. In
conclusion, FO is found to protect the liver against GalN-induced hepatic injury,
dysfunction and fat buildup and to attenuate accompanying changes in circulating
GLC, TP, TG and CHOL.
1310 The Phototoxicity of Tagetes Oil and Absolute Evaluated
Utilizing a Human Epidermal Model and Patch Testing.
J. F. Lalko and A. Api. Research Institute for Fragrance Materials Inc., Woodcliff
Lake, NJ.
Tagetes essential oil and absolute (Tagetes minuta L.) are utilized as fragrance ingre-
dients in a variety of consumer and personal care products. Spectral analysis shows
that the materials absorb UV wavelengths in the critical region of 290 – 700nm,
and therefore have the potential to be photoactivated. In order to determine the po-
tential for phototoxic effects, both materials were assessed in a phototoxicity test on
a three dimensional human epidermal model (EST1000). This assay is based upon
a comparison of the cytotoxic effects of the test material following exposure to a
non-toxic dose of UV light. Cytotoxicity is expressed as a reduction in the mito-
chondrial conversion of MTT [(3-4,5-dimethyl thiazole 2-yl) 2,5-diphenyl-tetra-
zoliumbromide] to formazan. A material is considered to have a phototoxic poten-
tial if one or more concentrations +UVA (60 min with 6 J/cm2) results in a decrease
in relative cell viability of ≥ 30%, when compared to the identical concentration
–UVA. Tagetes essential oil and absolute were tested at concentrations ranging from
0.1% to 10% (v/v) in 1:3 ethanol:diethyl phthalate (EtOH:DEP). A confirmatory
phototoxicity patch test was then conducted in a group of human volunteers, at a
concentration identified to be non-phototoxic.  In the EST1000 model, no photo-
toxicity was observed to Tagetes essential oil over the range of concentrations tested.
However, within this same model, phototoxic effects were observed following expo-
sure to Tagetes absolute at concentrations as low as 0.1%. Based on the dose-re-
sponse in these in vitro assays, a concentration of 0.01% was identified as being
non-phototoxic. This concentration (0.01% in 1:3 EtOH:DEP) of Tagetes essen-
tial oil and absolute was confirmed as having no phototoxic effects in humans fol-
lowing the phototoxicity patch test.
1311 Saponins from Platycodon grandiflorum and Its Constituent
Platycodin D Regulates Fatty Acid Metabolism via an AMP-
Activated Protein Kinase Dependent Signaling Pathway.
H. Pil2, 1,  J. Choi1,  H. Kim1,  K. Tilak1,  Y. Chung2 and H. Jeong1. 1Pharmacy,
Chungnam National University, Daejeon, Republic of Korea; 2International
University of Korea, Jinju, Republic of Korea.
The saponins from the roots of Platycodon grandiflorum (CKS) have a variety of
pharmacological properties, including antioxidant and hepatoprotective properties.
This study was conducted to suggest the role of AMP-activated protein kinase
(AMPK) pathway in the anti-obesity effect of CKS. We evaluated body weight,
liver histology, and hepatic triglyceride content in high-fat diet (HFD)-fed mice
treated with CKS. In addition, we characterized the underlying mechanism of
CKS’s effects in HepG2 cells by Western blot and RT-PCR analysis. CKS adminis-
tration attenuated fat accumulation and induction of lipogenic genes such as sterol
regulatory element binding protein-1c (SREBP-1c) and fatty acid synthase in the
liver of HFD-fed mice We also found that CKS suppressed high glucose-induced
lipid accumulation in HepG2 cells. CKS inhibited the high glucose-induced fatty
acid synthase (FAS) and sterol regulatory element binding protein-1c (SREBP-1c)
expression. Blood biochemical analyses and histopathologic examinations showed
that CKS prevented liver injury. Moreover, the using pharmacological AMPK in-
hibitor revealed that AMPK is essential to suppression of SREBP-1c expression in
CKS-treated cells. These results indicate that CKS prevents high glucose-induced
lipogenesis in HepG2 cells by blocking the expression of SREBP-1c, FAS through
AMPK activation, suggesting that CKS is a novel AMPK activator with a potential
role in the prevention and treatment obesity.
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1312 Platycodi radix Attenuates Dimethylnitrosamine-Induced
Liver Fibrosis in Rats.
J. Choi1,  S. Jin1,  Y. Hwang2,  C. Choi3,  Y. Chung2,  Y. Lee4 and H. Jeong1.
1Pharmacy, Chungnam National University, Daejeon, Republic of Korea;
2International University of Korea, Jinju, Republic of Korea; 3Natural Resources
Research Institute, Jangheung-gun, Republic of Korea; 4Jangsaeng Doraji Research
Institute of Biotechnology, Jinju, Republic of Korea.
Liver fibrosis is a wound healing response to a variety of chronic stimuli, including
alcohol intake, viral infection, drugs, and metabolic disease. This study investigated
the anti-fibrotic effects of the aqueous extract of the Platycodi Radix root
(Changkil: CK) on dimethylnitrosamine (DMN)-induced liver fibrosis in rats by
inducing Nrf2-mediated antioxidant enzymes. Repeated DMN exposure causes
chronic liver injury with necrosis, fibrosis, and nodular regeneration through meta-
bolic activation of CYP2E1 in experimental animals. CK inhibited DMN-induced
increases in serum ALT and AST activities, fibrosis score, and hepatic malondialde-
hyde and collagen content. CK also inhibited DMN-induced reductions in rat
body and liver weights. CK inhibited DMN-induced increases in MMP-13,
TIMP-1, and TNF-α mRNA, and collagen type I and α-smooth muscle actin pro-
tein. DMN-induced COX-2 expression and NF-κB activation was reduced by CK
treatment. Furthermore, CK induced activation of Nrf2-mediated antioxidant en-
zymes such as γ-glutamylcysteine synthetase (γ-GCS), heme oxygenase-1 (HO-1),
NAD(P)H quinone oxidoreductase 1 (NQO1), and glutathione-S-transferase
(GST) in HepG2 cells. These results demonstrated that CK attenuates DMN-in-
duced liver fibrosis through the activation of Nrf2-mediated antioxidant enzymes.
1313 Protective Effects of Saponins Isolated from the Root of
Platycodon grandiflorum against Ovalbumin-Induced
Airway Inflammation in a Mouse Allergic Asthma Model.
Y. Chung2,  J. Choi1,  H. Kim1,  Y. Lee3 and H. Jeong1. 1Pharmacy, Chungnam
National University, Daejeon, Republic of Korea; 2International University of Korea,
Jinju, Republic of Korea; 3Jangsaeng Doraji Research Institute of Biotechnology, Jinju,
Republic of Korea.
Bronchial asthma is a chronic airway disorder characterized by airway inflamma-
tion, mucus hypersecretion, and airway hyperresponsiveness. This study investi-
gated the protective effects of saponins isolated from the root of Platycodon grandi-
florum (Changkil saponins: CKS) on airway inflammation induced by allergic
reaction in mice. Mice were sensitized and challenged with ovalbumin (OVA) de-
veloped inflammation and remodeling in airway. CKS inhibited OVA-induced
number of inflammatory cells and levels of TNF-α, INF-γ, IL-4, IL-5, IL-13,
monocyte chemoattractant protein-1 (MCP-1) and OVA-specific IgE in bron-
choalveolar lavage fluid. Also, CKS attenuated OVA-induced mucus hypersecretion
in lung histopathological studies. CKS inhibited OVA-induced mRNA expression
level of MMP-2, MMP-9, and MUC5AC in lung tissues. Furthermore, CKS
blocked NF-κB p65 nuclear translocation in the nuclear extracts from lung tissues
of OVA-challenged mice. These results suggest that CKS ameliorates OVA-induced
inflammation and remodeling in airway.
1314 Topical Application of Cultivated Ginseng Suppresses 2, 4-
Dinitrochlorobenzene-Induced Atopic Dermatitis in
NC/Nga Mice.
J. Choi2,  J. Choi1,  S. Jin1,  Y. Chung2 and H. Jeong1. 1Pharmacy, Chungnam
National University, Daejeon, Republic of Korea; 2International University of Korea,
Jinju, Republic of Korea.
Atopic dermatitis (AD) has been known to be related with local and systemic im-
munologic dysfunction that leads to Th1/Th2 response as well as being related to
environmental factors. This study examined the inhibitory effects of 1-chloro-2,4-
dinitrobenzene (DNCB)-induced AD by cultivated ginseng (CG) (Panax ginseng
C.A. Meyer) in NC/Nga mice. CG, an herb used in Korean herbal medicine, has
been widely used in China and Japan to treat fatigue and to enhance resistance to
many diseases. CG ameliorates DNCB-induced skin dermatitis severity, serum
level of IgE and TARC, and mRNA expression of T helper (Th)1 and Th2 cy-
tokines in mice. In addition, CG reduced thickness of the dermis and dermal infil-
tration of inflammatory cells in histopathological examination. These results indi-
cate that CG inhibits allergic contact dermatitis through the modulating of Th1
and Th2 responses and diminishing the inflammatory cells in the skin lesions in
NC/Nga mice.
1315 Pleurotus eryngii Extracts Inhibits 2, 4-
Dinitrochlorobenzene-Induced Atopic Dermatitis in
NC/Nga Mice by the Regulation of Th1/Th2 Balance.
S. Chun2,  J. Choi1,  S. Jin1,  J. Choi2,  Y. Chung2 and H. Jeong1. 1Pharmacy,
Chungnam National University, Daejeon, Republic of Korea; 2International
University of Korea, Jinju, Republic of Korea.
Atopic dermatitis (AD) is a chronic, relapsing and inflammatory skin disease in hu-
mans and animals, caused by a complex interrelationship among genetic, environ-
mental, pharmacologic, psychological, immunologic and skin barrier dysfunction
factors. This study investigated the inhibitory effect of the Pleurotus eryngii ex-
tracts (PEE) on 2,4-dinitrochlorobenzene (DNCB)-induced atopic dermatitis
(AD)-like skin lesions. Pleurotus eryngii has been used in traditional medicine for
nutritional and medicinal food that enhances the host immune system as a response
to various diseases. This study evaluated skin dermatitis severity, ear thickness,
histopathological examination, and cytokines level in DNCB-applied mice treated
with PEE. Continuous treatment of PEE inhibited the development of the AD-like
skin lesions. PEE attenuates DNCB-induced skin dermatitis severity, serum level of
IgE and TARC, and mRNA expression of TNF-α, INF-γ, IL-4, IL-5, and IL-13 in
mice. Also, PEE reduced thickness of the dermis and dermal infiltration of inflam-
matory cells and mast cells in histopathological examination. These results suggest
that PEE inhibits allergic contact dermatitis through the modulating of T helper
(Th)1 and Th2 responses and diminishing the inflammatory cells and mast cells in-
filtration in the skin lesions in NC/Nga mice.
1316 Chronic Oral Toxicity Study of the Extracts from Herbs in
Phikud Navakot.
K. Kanchana1,  K. Chaimongkolnukul1,  S. Cherdyu1,  S. Ampawong2 and
T. Ketjareon2. 1Academic Services Office, National Laboratory Animal Center,
Mahidol University, Nakorn Pathom, Thailand; 2Veterinary Medical Office, National
Laboratory Animal Center, Mahidol University, Nakorn Pathom, Thailand. Sponsor:
-. NA.
Phikud Navakot is commonly used as Thai traditional medicine for alleviation hy-
perlipidemia, cardiovascular diseases, and cerebrovascular diseases. Chronic toxicity
effects of the extracts from herbs in Phikud Navakot were performed because there
were no 6-month toxicological studies reported in the literature. The repeated dose
as 10, 100, 1,000 mg/kg/day of the extracts were randomly administered to both
male and female Sprague Dawley rats as described in the OECD code 452 guide-
line. 183 rats survived to the end of the study while 20 rats died. The cause of death
was considered to be related to the gavage technical error which positively corre-
lated to high dose concentration. Mean body weights of dosed rats were similar to
those of the control group. No differences in feed consumption, relative organ
weights, and hematology and blood clinical chemistry were noted. Significant pro-
portionally increased incidences of transitional cell hyperplasia of the renal pelvis in
both sexes dosed rats. Therefore our obtained results suggested that Phikud
Navakot is a relatively nontoxic herb for repeated oral administration. However the
contraindication of the usage of Phikud Navakot is related to induce transitional
cell hyperplasia of the renal pelvis after prolong high dose oral administration.
1317 Plum Consumption Modulate Gut Microbiota and Obesity
in Zucker Rats.
G. Noratto1,  J. Garcia-Mazcorro2,  H. Martino3,  D. Byrne4,  M. Markel5,
J. Suchodolski5,  J. Steiner5 and S. U. Mertens-Talcott6. 1School of Food Science,
Washington State University, Pullman, WA; 2Facultad de Medicina Veterinaria y
Zootecnia, Universidad Autónoma de Nuevo León, Monterrey, Mexico; 3Department
of Nutrition and Health, University of Vicosa, Vicosa, Brazil; 4Horticulture, Texas
A&M University, College Station, TX; 5Gastrointestinal Laboratory, Texas A&M
University, College Station, TX; 6Nutrition and Food Science, Texas A&M University,
College Station, TX.
The role of peach and plum polyphenols on the modulation of gut microbiota and
the possible relationship with obesity is unknown. We investigated how peach and
plum consumption can modulate metabolic syndrome and relative proportions of
gut microbiota populations in feces of obese Zucker rats. 
Experimental groups received peach or plum juice ad libitum during 11 weeks, the
control and lean groups received water with same amount of glucose than fruit
juices. At the end of the study blood was analyzed for glucose, insulin triglycerides,
cholesterol and LDL oxidation levels. DNA in feces was analyzed using 454-py-
rosequencing and qPCR. 
Results showed that only plum juice consumption prevented weight gain and mod-
ulated microbiota populations in feces; this was related to the higher content of
polyphenols in plum juice (3X of peach). However, both peach and plum juice ex-
erted similar protective effects on metabolic syndrome and inflammatory markers
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in blood as confirmed by a component score coefficient analysis in which peach and
plum groups were overlapped and located in between the control and lean groups.
Pyrosequencing data from DNA in feces showed that plum group had higher abun-
dance of Bacteroidetes, Ruminococcacea, and Lactobacillus. qPCR data showed
that plum group had higher Faecalibacterium, Lactobacillus, and Turicibacter than
all other groups. The abundance of Bifidobacterium in plum group was similar to
the lean group and higher than peach and control groups (p<0.05). These results
suggest that polyphenols-rich foods can alter the composition of the distal intestinal
microbiota in obese rats and modulate metabolic syndrome and obesity.
1318 Kolaviron, a Biflavonoid of Garcinia kola Seed Offered
Cardioprotection against Ischaemic/Reperfusion Injury by
Up-Regulation of Prosurvival and Down-Regulation of
Apoptotic Signaling Pathways.
A. A. Oyagbemi1, 2, 3,  J. D. Bester2, 3,  A. J. Esterhuyse2, 3 and O. E. Farombi3, 2.
1Veterinary Physiology, Biochemistry and Pharmacology, University of Ibadan, Ibadan,
Nigeria; 2Biochemistry, University of Ibadan, College of Medicine, Ibadan, Nigeria;
3Department of Biomedical Sciences, Faculty of Health and Wellness Sciences, Cape
Peninsula University of Technology, Bellville, Cape Town, South Africa.
Possible cardioprotective effect of Kolaviron (KV) administration and the molecu-
lar mechanism (s) involved in ischaemic/reperfusion injury of isolated rat hearts
were assessed. Twenty  rats were used for this study. They were grouped into ten rats
of group of two. Rats in group I received 2ml/kg of corn oil (vehicle) while animals
in groups II received 200 mg/kg body weight of Kolaviron (KV) for four weeks re-
spectively. Isolated rat hearts were stabilized for 5 minutes on Langendorff, perfused
on working heart model for 10 minutes and subjected to global ischaemia for 15
minutes followed by 25 minutes reperfusion. Antioxidant enzymes, markers of ox-
idative stress and western blot analyses were carried out on snap-frozen heart tis-
sues. There was significant (p<0.05) increase in superoxide dismutase (SOD), cata-
lase (CAT) and glutathione peroxidase (GPx), oxygen radical absorbance capacity
(ORAC) and concomitant significant (p<0.05) decrease in malondialdehyde
(MDA) and intracellular reactive oxygen species (ROS) in isolated rat hearts of an-
imals that received KV compared to the control. Western blot analysis revealed sig-
nificant up-regulation of Akt/PKB, p- Akt/PKB, HSP27, p-HSP27 and down-reg-
ulation of p38 MAPK, Caspase 3, cleaved Caspase 3and cleaved PARP. Taken
together, KV offered cardioprotection by enhancing the expression of pro-survival
signaling pathway and abrogation of apoptotic pathway in isolated rat hearts sub-
jected to ischaemic/reperfusion injury
1319 Antimalarial Activity of Methanolic Fraction of
Clerodendrum violaceumLeaf Extract.
J. O. Adebayo,  A. Zailani and E. A. Balogun. Biochemistry, University of Ilorin,
Ilorin, Nigeria.
Malaria is a parasitic disease with devastating impact in Africa. Decoction of
Clerodendrum violaceum leaf Is indigenously used in Nigeria for the treatment of
the disease. In this study, the methanolic fraction of Clerodendrum violaceum leaf
extract was evaluated in P. berghei- infected mice in a 4-day suppressive test. Also,
its effects on the activities of antioxidant enzymes in the infected mice were also
evaluated. The results revealed that the methanolic fraction of Clerodendrum vio-
laceum leaf extract possesses antimalarial activity, causing 42.69% and 79.42% re-
duction in parasitemia at the doses of 125 and 250 mg/Kg body weight on day 5
post-inoculation. It also caused 61.78% and 87.57% reduction in parasitemia at
the doses of 125 and 250 mg/Kg body weight on day 8 post-inoculation. The ex-
tract fraction however caused a significant increase (P<0.05) in superoxide dismu-
tase and catalase activities and a significant decrease (P<0.05) in glutathione perox-
idase activity in erythrocyte and liver in a dose-dependent manner compared to
controls on day 5 post-inoculation. The results of this study suggest that
Clerodendrum violaceum leaf may be a potential source of cheaper antimalarial
drug.
1320 Effect of Probiotics (Lactobacillus and Bifidobacterium) on
Growth Performance and Haematological Profile of Clarias
gariepinus Juveniles.
S. O. Ayoola1,  E. K. Ajani1, 2 and O. F. Fashae1. 1Marine Sciences, University of
Lagos, Akoka, Lagos, Lagos, Nigeria; 2Aquaculture and Fisheries, University Ibadan,
Oyo State, Ibadan, Nigeria.
This study was carried out to evaluate the use of probiotic (a mixture of
Lactobacillus and bifidobacterium species) on growth performance and haemato-
logical parameters of Clarias gariepinus juveniles. Fifteen tanks were used and 10
Clarias gariepinus juveniles (mean weight (14.9±0.83 g) per tank, each in triplicate.
Five treatment tanks were fed a diet containing 40% crude protein supplemented
with varying inclusion of probiotic comprising about 109 colony-forming units per
gram of diet (the probiotic diet). Diet T0 contain 0g probiotic (control diet) while
the other group contain 0.5 g, 1.0 g 1.5 g and 2.0 g probiotic diet. Results shows
that Fish fed with diet T1 (0.5 g probiotic) had the best growth performance. There
was no significant different (P>0.05) in the Mean Corpuscular Volume, Mean
Corpuscular Haemoglobin and Mean Corpuscular Haemoglobin Concentration,
of fish fed different concentration of probiotic. All blood parameter obtained were
between the range of recommended fish blood. It is concluded that using probiotic
(especially at 0.5 g) as supplementary feed on Clarias gariepinus showed a slight in-
crease in the haematological parameters compare with the control diet but it has no
negative impact on the health status of the species. However, probiotic
(Lactobacillus and bifidobacterium) can be used as a probiotic agent in aquacul-
ture, to enhance fish health, survival and growth performance.
1321 Antifungal and Insecticidal Activities of Five Essential Oils
from Plants of the Colombian Caribbean Coast.
B. E. Jaramillo1,  E. Duarte Restrepo1 and W. Delgado Ávila2. 1Chemistry Program,
University of Cartagena, Cartagena, Colombia; 2Chemistry Program, National
University of Colombia, Bogotá, Colombia. Sponsor: B. Jaramillo.
Plants have developed chemicals mechanisms of self-protection to avoid being at-
tacked by insects fungi, bacteria and viruses. The diseases caused by these pests are
controlled with fumigants, which have a high toxicity, and this necessitates the use
of alternative compounds like essential oils. These are botanical sources of com-
pounds potential alternative fumigants currently used, due to its low mammalian
toxicity, high volatility and toxicity to stored grain pests and microorganisms. 
OBJECTIVE: This study determined the insecticidal, antifungal, activities of es-
sential oils isolated from Chenopodium ambrosioides L., Triphasia trifolia,
Eryngium foetidum, Bursera graveolens, and Swinglea glutinosa collected in
colombian caribbean coast.
METHODS: The essential oils (EO) were obtained from leaves of plants by hy-
drodistillation, The insecticidal activity assay was performed against Sitophilus zea-
mais. EO were also evaluated as fumigants against phytopathogenic fungi Fusarium
oxysporum f. sp. dianthi. 
RESULTS. C. ambrosioides was more active against Fusarium oxysporum than
other EO evaluated, with a percentage of mycelial inhibition of 97.3% at 176.5 μL
EO/L air after 72 h of exposure; followed by Eryngium foetidum (65,4%); Bursera
graveolens (60,0%); Piper marginatum (41,7%) and Swinglea glutinosa (14,7%).
C. ambrosioides and Eryngium foetidum essential oils showed the best fumigant
activity against Sitophilus zeamais (100% at 500 μL/L air after 24 h of exposure);
Piper marginatum oil had weak fumigant toxicity (86,7% μL/L air after 24 h of ex-
posure). 
CONCLUSIONS: This study demonstrated that essential oils exhibit important
fungicidal activity on F. oxysporum and fumigant on S. zeamais, which could be-
come an alternative to synthetic fungicides and insecticides.
1322 Protein Binding Effects the Cellular Uptake of Silver
Nanoparticles in Human Cells.
N. A. Monteiro-Riviere1, 2, 3,  A. O. Inman1, 2,  M. E. Samberg2, 3,  S. Oldenburg4
and J. E. Riviere1, 2. 1Nanotechnology Innovation Center of Kansas State, Kansas
State University, Manhattan, KS; 2Center for Chemical Toxicology Research and
Pharmacokinetics, North Carolina State University, Raleigh, NC; 3Joint Department
of Biomedical Engineering at the University of North Carolina at Chapel Hill and
North Carolina State University, North Carolina State University, Raleigh, NC;
4nanoComposix, Inc, San Diego, CA.
Nanoparticles (NP) absorbed in the body will come in contact with blood proteins
and form NP/protein complexes termed protein coronas, which may modulate NP
cellular uptake. This study quantitated human epidermal keratinocyte (HEK) up-
take of silver (Ag) NP complexed to different human serum proteins. Prior to HEK
dosing, AgNP (20nm and 110nm citrate BioPure™; 40nm and 120nm silica-
coated) were incubated for 2h at 37°C without (control) or with physiological lev-
els of albumin (44mg/ml), IgG (14.5mg/ml) or transferrin (3mg/ml). HEK were
exposed to the protein incubated AgNP for 3h, rinsed with medium and incubated
for 48h, rinsed in buffer and lysed. Ag was assayed by inductively-coupled plasma
optical emission spectrometry. Uptake of Ag in HEK was <4.1% of applied dose
with proteins suppressing citrate, but not silica coated, Ag uptake into HEK two
fold relative to controls. IgG dramatically reduced 110nm citrate AgNP uptake. In
contrast, greatest uptake of 20nm silica AgNP was seen with IgG incubation, while
110nm silica AgNP showing similar uptake profiles across all exposures. Electron
microscopy confirmed cellular uptake of all particles but showed differences in the
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appearance and agglomeration state of the NP within HEK vacuoles. This suggests
that NP association with serum proteins purportedly form different protein coro-
nas that significantly modulates Ag uptake compared to native NP uptake, suggest-
ing caution in extrapolating in vitro uptake data to predict behavior in vivo where
the nature of the protein corona may determine patterns of cellular uptake, biodis-
tribution, biological activity and toxicity.(Supported by NIH RO1 ES016138)
1323 Relationship between Silver Nanoparticle Intracellular
Accumulation and Cytotoxicity in L-929 Fibroblasts.
B. E. Wildt1,  E. I. Maurer2,  G. Kumar1,  H. A. Degheidy1,  S. M. Hussain2 and
P. L. Goering1. 1US FDA, Silver Spring, MD; 2711 HPW/ RHDJ, AFRL, Wright-
Patterson AFB, Dayton, OH.
Medical devices containing silver nanoparticles (AgNPs) may release NPs or leach
silver (Ag) ions, both of which are cytotoxic in vitro at high concentrations. Given
the complexities of NP in vitro dosimetry, proper assessment of AgNP cytotoxicity
requires a better understanding of intracellular Ag concentration and observed bio-
effects. Therefore, the objective of this study was to measure time-dependent AgNP
cell internalization in L-929 fibroblast cells, a cell line that is commonly used for
medical device biocompatibility testing, while simultaneously assessing cell viabil-
ity. These endpoints were assessed following exposure of cells to 50 μg/mL AgNPs
(10, 50, 100 and 200 nm) and to equimolar Ag ions. Intracellular uptake of AgNPs
and Ag concentrations in L-929 cells were assessed using time-lapse confocal mi-
croscopy, flow cytometry and ICP-MS at 4, 16 and 24 hrs after treatment.
Metabolic activity and plasma membrane integrity of the cells were assessed at 4, 16
and 24 hrs after treatment using the MTT assay and ethidium homodimer-1 dead
cell indicator, respectively. A time-dependent, linear increase in intracelluar accu-
mulation of AgNPs and Ag concentrations were observed using confocal mi-
croscopy and ICP-MS. Flow cytometric evidence of AgNP uptake and accumula-
tion in cells was also observed from changes in side scatter characteristics vs.
forward scatter characteristics dot plots. The results of the MTT assay suggest that
Ag ions and 10 nm NPs are highly toxic, compared to 50, 100 and 200 nm NPs.
Membrane integrity analysis of time-lapse images revealed that 10 nm AgNPs are
cytotoxic within 1 hr after dosing and all cells are dead after 10 hrs. In contrast,
equimolar concentrations of Ag ions kill all cells within an hour. This study demon-
strated that the size-dependent in vitro cytotoxicity of AgNPs to L-929 fibroblasts
correlated with intracellular Ag accumulation, and underscores the value of using
multiple analytical methods when determining NP accumulation and cytotoxicity.
1324 Role of Sample Preparation in In Vitro Cytotoxicity
Responses to Silver Nanoparticles.
A. N. Clendaniel2, 1,  G. Kumar1,  H. A. Degheidy1,  B. J. Casey1 and
P. L. Goering1. 1CDRH, US FDA, Silver Spring, MD; 2Richard Stockton College of
New Jersey, Galloway, NJ.
Metallic nanoparticles readily agglomerate in aqueous media and this effect can in-
fluence their physical properties and in vitro biological responses. The goal of this
study was to: 1) compare effects of cell culture medium containing 10% FBS and
DI water as suspension vehicles on AgNP size and agglomeration, and 2) compare
effects of pre-mixing of medium and AgNPs on their biological responses in L-929
fibroblasts compared to direct addition of nanoparticles to the cells. To assess the ef-
fects of premixing on agglomeration, AgNPs were pre-mixed with cell culture
medium or DI water for 1 min, or 1, 5, 24, or 120 hr. Results of dynamic light scat-
tering analysis showed that pre-mixing AgNPs with medium maintained particle
dispersion better than DI water. The hydrodynamic diameter of AgNPs increased
proportionally to the pre-mixing time. AgNP agglomeration was size-dependent;
10 nm AgNPs agglomerated more readily than 100 nm and 200 nm particles. To
assess the effects of premixing on biological responses, AgNPs pre-mixed with cell
culture medium for 1 min, or 1, 5, or 24 hr were added to L-929 fibroblasts, or
were added to the cells without premixing. After 24 hr exposure, cell viability was
assessed by using the standard MTT assay. After 4 and 24 hr exposures, the degree
of cell necrosis (via 7-AAD dye) and apoptosis (via Annexin V dye) was assessed
using flow cytometry. AgNPs produced a mass concentration (μg/ml) dependent
decrease in MTT reduction. Pre-mixing of AgNPs with cell culture medium did
not affect cell viability compared to controls; however, AgNPs added directly to the
media without pre-mixing were cytotoxic. The degree of necrosis and apoptosis of
L-929 cells when exposed to AgNPs depended on mass concentration, exposure
time, and size of AgNPs. Cells treated with 10 nm particles at 50 μg/ml showed 22-
fold and 33-fold increases in the percentage of apoptotic and necrotic cells, respec-
tively, after 24 hr. Thus, the data show that different sample preparation for AgNPs
can affect particle agglomeration and biological responses.
1325 Flow Cytometry Evaluation of Cell Cytotoxicity Induced by
Silver Nanoparticles.
G. Kumar1,  A. N. Clendaniel2, 1,  H. Degheidy1,  B. E. Wildt1 and P. L. Goering1.
1CDRH, US FDA, Silver Spring, MD; 2The Richard Stockton College of New Jersey,
Pomona, NJ.
Particles possess unique properties in the nanoscale, e.g., enhanced catalytic activ-
ity, high surface area and surface energy, and light emission/absorption properties,
which might result in interference with colorimetric in vitro cytotoxicity assays
such as MTT, LDH release, and Neutral Red. Alternatively, assays that do not use
spectrophotometric detection, such as trypan blue exclusion or flow cytometry
(FC) based assays, are less likely to be influenced by nanoparticle interference. The
aim of this study was to evaluate FC assays to assess the cytotoxicity of three differ-
ent sizes (10, 100, or 200 nm) silver nanoparticles (AgNPs) at different mass con-
centrations (1, 25, or 50 ug/ml) in L-929 fibroblast cells. After 4 hrs and 24 hrs ex-
posure, cell necrosis and apoptosis were assessed using 7-AAD and Annexin V dyes,
respectively, with FC. Multiple FC controls (including cells alone, AgNPs alone,
and single fluorophore controls and their combinations) were used to optimize the
experiment and eliminate background autofluorescence and fluorochrome overlap.
The data show that cell necrosis and apoptosis in AgNP-exposed fibroblasts depend
on dose, exposure time, and AgNPs size. Cells treated with 10 nm particles at 50
ug/ml showed 7- to 22-fold increases in percentage of apoptotic cells and 2- to 33-
fold increases in percentage of necrotic cells after 4 hrs and 24 hrs, respectively.
Cells treated with 200 nm particles at 50 ug/ml showed only up to 6 fold increases
in degree of apoptosis after 24 h. The data show that AgNPs produced a dose- and
time-dependent decrease in cell viability; however, 200 nm AgNPs were signifi-
cantly less toxic than smaller sized particles. Thus, standard FC assays can be uti-
lized to assess apoptosis and necrosis in response to nanomaterial exposure.
1326 Incorporation of Silver Nanoparticles into a Degradable
Poly(L-Lactide-Co-Epsilon-Caprolactone) Copolymer
Scaffold for Skin Regeneration.
M. E. Samberg1,  P. Mente1,  T. He2,  M. W. King2 and N. A. Monteiro-Riviere1, 3.
1Joint Department of Biomedical Engineering at the University of North Carolina at
Chapel Hill and North Carolina State University, North Carolina State University,
Raleigh, NC; 2College of Textiles, North Carolina State University, Raleigh, NC;
3Nanotechnology Innovation Center of Kansas State, Kansas State University,
Manhattan, KS.
The development of an antibacterial, degradable scaffold system that utilizes pa-
tient-derived cells would improve upon current skin grafting techniques which
often result in severe scarring, aesthetically undesirable mismatches in skin tones,
and are susceptible to surgical site infection. The objective of this study was to char-
acterize and assess the toxicity of an electrospun scaffold of poly(L-lactide-co-ep-
silon-caprolactone) (PLCL) incorporating antibacterial 20nm silver nanoparticles
(AgNP). The content and distribution of 20nm AgNP incorporated within the
PLCL scaffold was optimized to maximize their biocompatibility and antimicrobial
activity. The toxicity of the scaffold to human epidermal keratinocytes (HEK) was
assessed using Live/Dead and alamarBlue viability assays following 7 days and 14
days. No significant decreases in cell viability were noted at either time point and
cell proliferation increased 120% by 7 days and 200% by 14 days on both control
and AgNP incorporated scaffolds. After 14 days, scanning electron microscopy re-
vealed a confluent layer of HEK on the surface of the scaffolds, and fluorescent mi-
croscopy confirmed cell migration into the scaffold interior. The antibacterial effi-
cacy of the scaffold was evaluated against Escherichia coli and Staphylococcus aureus.
The mechanical properties of the PLCL scaffold were assessed via uniaxial tensile
testing to failure. A slight decrease in the modulus of elasticity was observed follow-
ing AgNP incorporation compared to control, while cellular attachment increased
the modulus of elasticity significantly. (Supported by NIH RO1 ES016138)
1327 Formation of a Protein Corona on Silver Nanoparticles
Mediates Cellular Toxicity via Scavenger Receptors.
J. Shannahan1,  R. Chen2,  T. Fennell3,  C. J. Wingard1,  P. Ke2 and J. M. Brown1.
1East Carolina University, Greenville, NC; 2Clemson University, Clemson, SC; 3RTI
International, Durham, NC.
Addition of a protein corona (PC) on the surface of nanomaterials can modify their
activity, bio-distribution, cellular uptake, clearance and toxicity. As silver nanopar-
ticles (AgNP) are incorporated into many products as anti-bacterial/fungal agents,
the risk of human exposure escalates. We hypothesize that AgNPs will associate
with proteins commonly found in human serum and cell culture media forming
PCs which will impact cell activation and cytotoxicity. Furthermore, we believe that
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activation of scavenger receptor B (SR-B) mediates this toxicity. Citrate- or PVP-
coated AgNPs were incubated with human serum albumin (HSA), bovine serum
albumin (BSA), high-density lipoprotein (HDL), or water (control). AgNPs associ-
ated with each protein (HSA, BSA, HDL) forming PCs by TEM, UV-vis spec-
troscopy and altered Ζ-potential and hydrodynamic size. Rat aortic endothelial
(RAEC) and rat lung epithelial (RLE) cells were exposed to increasing concentra-
tions of AgNPs (0, 6.25, 12.5, 25 or 50μg/ml) with or without PC for 3h or 6h. All
PC-coated AgNPs demonstrated a dose-response relationship in cytotoxicity in
both cell types. To determine the role of SR-B in the observed cytotoxicity, cells
were exposed to AgNPs with or without PCs for 3h in the presence of a SR-B an-
tagonist. Treatment with the SR-B antagonist inhibited cytotoxicity in RAEC but
not RLE. Lastly, cell activation was assessed at 1h by measuring interleukin-6 (IL-6)
mRNA expression. All PC-coated AgNPs induced IL-6 mRNA expression at 1h in
both cell types whereas treatment with the SR-B antagonist was found to inhibit ex-
pression. Differences in the induction of IL-6 were found between PC-coated
AgNPs based upon suspension (citrate or PVP). This study characterizes a PC on
AgNPs using proteins found in human serum and cell culture media. The presence
of these PCs influenced cytotoxicity and cell activation through SR-B leading to al-
tered cell responses. This work was supported by the U19 ES019525 and R01
ES09311.
1328 Importance of p38MAPK and pmk-1 a Caenorhabditis
elegans Homologue, in Silver Nanoparticles-Induced DNA
Damage Response and Apoptosis.
J. Choi,  N. Chatterjee,  H. Eom and J. Ahn. Faculty of Environmental
Engineering, College of Urban Science, Seoul, Republic of Korea. Sponsor: D. Ryu.
Silver nanoparticles (AgNPs) have recently received much attention for their possi-
ble applications in new material design, biotechnology and other commercial pur-
poses. Our previous studies conducted in Jurkat T cells and Caenorhabditis elegans
displayed that AgNP exposure caused dose and time dependent increase in only
p38MAPK and pmk-1 expression among all other stress responsive proteins and
DNA damage in Jurakt T cells. These findings motivated to ask whether and how
p38MAPK and pmk-1 is involved in AgNP induced DNA damage response and
eventually in mode of cell death. Our approach was comparative and we used the
wild type (wt) and p38MAPK knocked down Jurakt T cells (siRNA tranfcetion) as
in vitro model system and wild type (N2) and pmk-1 (KU25) mutant strains of C.
elegans as in vivo model system. The result showed that p38MAPK siRNA kncked
down (KD) Jurkat T cells and pmk-1 mutant worms were more sentisitive to AgNP
and posed higher DNA damage response by activating sensors (hus-1, γH2AX) and
effectors (cep-1 and p53) but preferred necrosis rather than DNA damage mediated
apoptosis which is attested by egl-1 and ced-3 expression in C.elegans and in the
same way, Bax/caspases in KD cells. Moreover, loss of p38MAPK and pmk-1dis-
played impairment with the expression and activation of DNA damage repair sys-
tems (Rad-51, Lig-4). The mode of choosing of cell death pattern ultimately affects
longevity and survival which in turn, support the idea that apoptosis actually play a
defense against AgNP induced toxicity. On the whole, p38MAPK and pmk-1 play
an evolutionarily conserved role in AgNP induced DNA damage response and cell
death.
1329 Cytotoxicity and Genotoxicity of Silver Nanoparticles and
Silver Ions to CHO K1 Cells.
X. Jiang1,  R. Foldbjerg2,  T. Miclaus3,  C. Chen1,  H. Autrup2 and C. Beer2.
1National Center for Nanoscience and Technology, Chinese Academy of Science,
Beijing, China; 2Environmental and Occupational Medicine, Aarhus University,
Aarhus, Denmark; 3Interdisciplinary Nanoscience Center (iNANO), Aarhus
University, Aarhus, Denmark.
Silver nanoparticles (Ag NPs) are used in a variety of commercial products due to
their antimicrobial activity. As both in vitro and in vivo studies have demonstrated
toxic effects of Ag NPs, there is an urgent need to explore the toxicity of Ag NPs.
Here we studied the cytotoxicity and genotoxicity of Ag NPs (BSA coated,
15.9±7.6 nm) and silver ions (Ag+) to Chinese hamster ovary (CHO K1) cells. To
analyse the cytotoxic effects the mitochondrial activity was determined by the
MTT assay, intracellular reactive oxygen species (ROS) and the cell cycle were ana-
lyzed by flow cytometry. Fluorescence microscopy and flow cytometry based mi-
cronucleus assays were applied to qualify and quantify the number of micronuclei
induced by Ag NPs and Ag+. P32 postlabeling was performed to detect DNA
adducts. In addition, inductively-coupled plasma mass spectrometry (ICP-MS) and
transmission electron microscope (TEM) were applied to study the uptake and in-
tracellular distribution of Ag NPs, respectively. 
A time and dose dependent decrease in mitochondrial activity and increase of in-
tracellular ROS level in CHO K1 cells was observed after exposure to Ag NPs and
Ag+ (0-20 μg/ml) for 24h and 48h. Ag NPs and Ag+ induced a cell cycle arrest in
the G2/M phase. Micronucleus assay and P32 postlabeling revealed that both Ag
NPs and Ag+ induced micronuclei and DNA adducts. Using TEM observations Ag
NPs were found to be located in endosomes/ lysosomes suggesting that Ag NPs are
taken up by receptor mediated endocytosis. However, no Ag NPs were found in the
nucleus suggesting that Ag NPs are presumably dissolved into Ag+ in the endo-
somes/ lysosomes and released to the cytoplasma. From here they can enter mito-
chondria and /or the nucleus leading to an increased intracellular ROS level and the
induction of DNA damage.
1330 Chronic Exposure to Realistic Doses of Silver Nanoparticles
Demonstrated Differential Cellular Responses Than Acute
Exposure in Human Keratinocytes.
K. K. Comfort1, 2,  L. Braydich-Stolle1 and S. M. Hussain1. 1Molecular Bioeffects
Branch, Human Performance Wing, Air Force Research Laboratory, Wright-Patterson
AFB, OH; 2Chemical and Materials Engineering, University of Dayton, Dayton, OH.
One obstacle plaguing the field of nanotoxicology is the development of a mecha-
nism to translate acute exposure data to an accurate prediction of real world impli-
cations of nanomaterials (NM). In an effort to enhance the efficacy of information
gathered from an in vitro environment, a chronic NM exposure scenario was de-
signed and implemented in which human keratinocyte cells (HaCaT) were dosed
with 50 nm silver nanoparticles (Ag-NP) 8 h a day, 5 days a week, for 3 months.
Working concentrations were based off the permissible exposure limits set by
OSHA and were 0.4, 4, and 400 pg/ml. The HaCaT stress response of the chroni-
cally treated cells was directly compared to a 24 h acute exposure at a concentration
equal to the cumulative Ag-NP dosage encountered over the 3 months. Cellular
endpoints evaluated include activation of Heat shock protein-27 signal transduc-
tion, ki67 expression, pro-inflammatory cytokine secretion, actin inflammation,
and alterations in gene regulation. Results indicated that the chronically dosed
HaCaT cells were functioning under sustained, augment cellular stress: as seen with
increased reactive oxygen species levels, HSP-27 signaling, cytosolic ki67 expres-
sion, and actin inflammation and disorganization. Furthermore, considerable IL-6
secretion was observed throughout the experiment, indicating a continuous inflam-
matory response. Most notably, these stress indicators were all significantly higher
in chronically dosed cells vs. their acute counterparts, demonstrating a more severe
response. Additionally, chronically dosed cells demonstrated a vastly higher modifi-
cation to gene regulation, again representing the potential for a serious long-term
impact. In conclusion, this study identified a significant variation in the HaCaT
stress response following chronic exposure of Ag-NPs vs. an acute scenario and of-
fers a novel approach to nanotoxicology research.
1331 Evaluation of Uptake and Cytotoxicity of Citrate Stabilised
Gold Nanoparticles in Chinese Hamster Ovary (CHO) Cells
prior to the In Vitro Mammalian Mutation Test.
M. Vetten1, 2 and M. Gulumian1, 2. 1Toxicology and Biochemistry Section, National
Institute for Occupational Health, Johannesburg, South Africa; 2School of Pathology,
University of the Witwatersrand, Johannesburg, South Africa.
The health risk assessment of engineered gold nanoparticles (AuNPs) requires the
generation of hazard identification data. Currently the Organisation for Economic
Co-operation and Development (OECD) has released a guidance manual for the
testing of manufactured nanomaterials. Within this document various established
toxicological endpoints have been proposed for study, including the in vitro mam-
malian cell gene mutation test (OECD TG476) for genotoxicity assessment. Prior
to this mutation study, preliminary experiments were required to assess the cytotox-
icity and uptake of the AuNPs into the cells. Chinese Hamster Ovary (CHO) cells
were treated with 14 nm, 20 nm, and 40 nm citrate stabilised gold nanoparticles.
The Roche xCELLigence RTCA system was used to determine cytotoxicity of the
particles using cell impedance. The nanoparticles were non-toxic for the duration of
the period tested. The use of this technology eliminated any potential interference
of the nanoparticles with the assay. The uptake of the particles into the cells was vi-
sualised using the CytoViva Hyperspectral Imaging system and showed a time-de-
pendent uptake of the particles into the cells. This preliminary data confirms lack
of toxicity of the particles prior to use in the mutation assay, and confirms uptake of
the particles into the cells. Mutagenicity studies using this cell line will be con-
ducted to measure mutation at hypoxanthine-guanine phosphoribosyl transferase
(HPRT). Although gold nanoparticles have been shown in literature to induce
some DNA damage; to our knowledge, the genotoxicity of gold nanoparticles has
not been assessed using the HPRT mutation assay to date.
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1332 Bioavailability of Silver Nanoparticles in Artificial
Physiological Fluids: Coating and pH Impact on Degree of
Ionic Dissociation.
L. Braydich-Stolle,  E. Breitner,  E. I. Maurer,  B. Stacy and S. M. Hussain. 711
HPW/RHDJ, Wright-Patterson AFB, Dayton, OH.
The majority of studies have focused on nanoparticle (NP) fate and their induced
damage with limited information on the physiological environment’s role in alter-
ing NP properties. Artificial fluids (AFs) have been used to test the bioavailability of
metallic compounds (difference between the amount of a substance a person is ex-
posed to and the amount of substance the body receives). Literature has demon-
strated that inhaled NPs accumulated in lungs and clearance was hindered during
chronic exposure indicating the observed effects should become more pronounced
over time due to impeded clearance. Based on these findings, this study examined
the impact of artificial interstitial, alveolar, lysosomal, and gastric fluid on the phys-
ical properties of hydrocarbon coated silver (Ag-HC) and polysaccharide coated sil-
ver (Ag-PS) NPs and the associated changes in toxicity. Since inhalation exposure is
of concern, the toxicity of the Ag-NPs exposed to the AFs was evaluated in alveolar
macrophages and doses represent a week or year of exposure (0.5 ng/ml and 25
ng/ml) based on the concept that this delayed clearance will result in macrophages
continually be recruited to engulf the NPs. For all the AFs, the Ag-HC NPs demon-
strated large agglomeration, limited ionic dissociation, and no changes in cell via-
bility. Ag-PS NPs exposed to alveolar and interstitial fluid demonstrated a similar
trend, in addition to a loss of the PS coating. For the gastric fluid, large agglomer-
ates were observed but these were rare and most likely due to the Ag NPs precipi-
tating out as AgCl. Interestingly, the Ag-PS NPs exposed to lysosomal fluid demon-
strated a loss of coating, less agglomeration, and significant decreases in cell
viability. Since NPs are most likely taken up via endocytosis in cell cultures or by
phagocytic cells in an in vivo system, the interactions of the NP with the lysosomal
environment has critical implications on mediating the NP cellular consequences.
Based on this study, the lysosomal environment has the potential to make a NP
more toxic over time. (88ABW-2012-5185)
1333 Cytotoxic and Inflammatory Responses to Silver
Nanoparticles in Hepatocyte-Kupffer Cell (HC-KC)
Coculture and HepG2 Cells.
M. W. Betz,  B. E. Wildt,  B. J. Casey and P. L. Goering. CDRH, US FDA, Silver
Spring, MD.
Nanoparticles accumulate in several organs following in vivo exposure, notably the
liver. Numerous studies have assessed effects of nanoparticles on liver cells in vitro,
but it is unclear whether it is preferable to conduct these studies using a physiolog-
ically-relevant cell culture model or if using an established liver-derived cell line is
adequate. To address this question, we compared cellular responses to AgNPs in a
primary rat HC-KC coculture with those in HepG2 cells. Metabolic activity (MTT
reduction) was assessed 24 hr after exposure of cells to 10, 50, or 100nm AgNPs ad-
ministered at 1, 10, 25, or 50 μg/mL and 0.25, 0.5, 1, 2, 3, 4 cm2/mL. Calcium
homeostasis and flux were investigated after exposure to AgNPs by mass concentra-
tion. Inflammatory responses were assessed by measuring TNF-α and IL-6 levels in
HC-KCs and monocultures of hepatocytes and Kupffer cells after 6 and 24 hr ex-
posure to 50nm AgNPs ± lipopolysaccharide. Metabolic activity results showed
that HC-KCs are more sensitive to AgNPs than HepG2 cells on the basis of both
mass and surface area. Calcium homeostasis and flux levels also demonstrated that
HC-KCs were more sensitive to AgNPs than HepG2 cells. Using confocal mi-
croscopy, AgNPs appeared to localize in the cytoplasm of both HC-KC cell types;
however, a greater density of particles was observed in Kupffer cells compared to he-
patocytes. Kupffer cells and HC-KCs both produced strong inflammatory re-
sponses (TNF-α and IL-6) to AgNPs by 6 hr, which remained unchanged at 24 hr,
while hepatocytes alone did not produce TNF-α or IL-6. Thus, the data show that
inflammatory responses in HC-KCs are dependent on the presence of Kupffer cells.
Additionally, with increasing AgNP concentrations, TNF-α and IL-6 levels re-
mained constant in HC-KCs but decreased in Kupffer cells suggesting the KCs are
more sensitive in monoculture and protected by hepatocytes in the coculture. This
study demonstrates the value of using a more physiologically-relevant cell culture
system for the in vitro investigation of nanoparticle toxicity on liver.
1334 Evaluation of Genotoxicity of Silver Nanoparticles with In
Vitro and In Vivo Standard Assays.
Y. Li1,  J. Yan1,  N. Mei1,  Y. Chen1,  M. G. Pearce1,  W. Ding1,  C. Candice2,
P. C. Howard2,  P. Rice3,  T. Zhou4,  R. K. Elespuru5,  M. M. Moore1 and
T. Chen1. 1Division of Genetic and Molecular Toxicology, US FDA/National Center
for Toxicological Research, Jefferson, AR; 2Nanotechnology Core Facility, US
FDA/National Center for Toxicological Research, Jefferson, AR; 3Center for Food
Safety and Applied Nutrition, US FDA, College Park, MD; 4Center for Veterinary
Medicine, US FDA, Rockville, MD; 5Center for Devices and Radiology Health, US
FDA, Silver Spring, MD.
Many publications are available on genotoxicity of nanomaterials. However, it is
difficult to compare these results objectively due to conflictive results from different
test methods, most of which were not the standard assays.  In this study, both in
vitro and in vivo standard genotoxicity assays including the Ames test, the in vitro
and in vivo micronucleus assay and the mouse lymphoma gene mutation assay were
applied to assess the genotoxicity of 5 nm uncoated and PVP coated silver nanopar-
ticles (AgNPs). Mutagenic evaluation of uncoated AgNPs with the Ames test
showed negative results possibly due to lack of cell uptake of the nanoparticles and
strong cytotoxicity of AgNPs to bacteria. The AgNPs, however, induced mutations
in a dose-dependent manner in mouse lymphoma cells via an oxidative stress mech-
anism evidenced by the results from loss of heterozygosity analysis of the Tk mu-
tants, oxidative Comet assay and gene expression analysis. Micronuclei in TK6 cells
were also increased by AgNPs in a dose-dependent manner. At a concentration of
30 μg/ml, uncoated AgNPs caused around 50% cytotoxicity (relative population
doubling) and induced a significant, 3.17-fold increase over the vehicle control
while PVP-coated AgNPs induced 50% cytotoxicity and 2.25-fold increase of mi-
cronuclei over the control at only 1.75 μg/ml. Although AgNPs can reach the bone
marrow, they were negative in in vivo micronucleus assay. Our results demonstrate
that the AgNPs are genotoxicity in in vitro mammalian assays, but not in in vivo
mouse micronucleus assay.
1335 DNA-Dependent Protein Kinase Reduces Toxicity of Silver
Nanoparticles in Mammalian Cells through JNK and
Telomerase Pathways.
H. Lim and H. Manoor Prakash. Physiology, Yong Loo Lin School of Medicine,
National University of Singapore, Singapore, Singapore. Sponsor: S. Sawant.
Silver nanoparticles (Ag-np) are distinctively reported to be toxic to mammalian
cells. Less is known about the signalling response triggered in cells to counteract
such toxicity. This study was initiated to enhance our mechanistic insight on corre-
lation between, DNA-dependent protein kinase catalytic subunit (DNA-PKcs) and
toxicity of Ag-np. The toxicity of polyvinyl alcohol (PVA)-coated Ag-np was stud-
ied in normal human lung fibroblast and human breast cancer and brain cancer
cells. DNA-PKcs inhibition was carried out to investigate impact of DNA-PKcs on
influencing toxicity of Ag-np. The toxicity was evaluated using changes in cell sur-
vival, DNA damage and repair and telomeres length. We observed concurrent acti-
vation of DNA-PKcs and JNK pathway in cancer cells upon Ag-np treatment,
which were anticipated as physiologic responses to DNA damage and repair. JNK
pathway was insufficiently activated in DNA-PKcs inhibited cancer cells, abolish-
ing the signalling events required for mediating DNA repair. Further investigation
on genotoxic effect of Ag-np indicated that Ag-np causes telomere attrition and
dysfunction in human cancer cells by disrupting shelterin complex integrity and
telomerase expression. Recruitment of activated DNA-PKcs to damaged telomeres
signifies the importance of DNA repair machinery at damaged telomeres. DNA-
PKcs inhibition potentiates the damaging effect of Ag-np at telomeres in human
cancer cells. Abrogation of JNK mediated DNA repair and substantial damages at
telomeres lead to higher cell death in DNA-PKcs inhibited, Ag-np treated cancer
cells. Altogether, presence of DNA-PKcs effectively reduces the toxic effects of Ag-
np in human cancer cells by triggering the activation of JNK pathway and telom-
eres length maintenance. This study suggests that the potentially detrimental com-
bination of Ag-np with DNA-PKcs inhibition can however be applied as a better
strategy in cancer therapy.
1336 Determination of Nanosilver Dissolution Kinetics and
Toxicity in an Environmentally Relevant Aqueous Medium.
A. Harmon,  A. J. Kennedy,  A. R. Poda,  A. J. Bednar,  M. A. Chappell and
J. A. Steevens. US Army Corps of Engineers, Vicksburg, MS.
The dissolution potential of citrate capped silver nanoparticles (AgNPs) in labora-
tory test media and in the environment is critical for determining toxicity. In the
present study, the ion-release kinetics from citrate capped 20, 50, and 80 nm
SOT 2013 ANNUAL MEETING 287
AgNPs in dilutions of an environmentally relevant freshwater (30μS/cm and
150μS/cm reconstituted water) was examined and related to the associated impact
on an aquatic organism (Daphnia magna). Diluted suspensions of nanoparticles
were placed on a multi-tube vortexer and orbital shaker for 0, 1, 2, 3 and 7 days.
The acute toxicity of the AgNPs suspensions was then assessed with D. magna at 0
and 7 days post interaction between the particles and test media. An increase in hy-
drodynamic diameter measured by dynamic light scattering and field flow fraction-
ation over time was observed at a relatively higher specific conductivity of 150
μS/cm in 20nm particles (3.3 fold increase) and only a small increase in 50 and
80nm particles (1.4 and 1.2 fold increase, respectively). At a lower conductivity of
30 μS/cm a 1.7, 1.0, and 1.2 fold increase was observed in 20, 50 and 80nm, re-
spectively. Results showed that although the total concentration of silver in solution
decreased with time, there was a consistent spike in dissolved concentration after 2-
3 days interaction, followed by a steady decrease in dissolved silver in 150μS/cm
and 30 μS/cm medium. This suggests that the concentration of dissolved silver in
environmentally relevant ionic strength media increases over time after the intro-
duction of citrate capped AgNPs which may have implications on aquatic organ-
isms. When exposed D.magna was exposed to 150μS/cm and 30μS/cm test media,
30μS/cm test media induced more toxicity than 150μS/cm test media. Toxicity in-
creased with longer nAg interaction time with smaller particles inducing more tox-
icity than larger particles.
1337 Silver Nanoparticles Induce Mast Cell Degranulation via
Scavenger Receptors.
A. Aldossari,  J. Shannahan,  S. Hilderbrand and J. M. Brown. Pharmacology and
Toxicology, East Carolina University, Greenville, NC.
Silver nanoparticles (AgNPs) are increasingly incorporated into a variety of con-
sumer and industrial products such as water filters and cosmetics for their antimi-
crobial properties. This has increased human exposures to AgNPs and therefore the
possibility of adverse health effects. Mast cells are well known to orchestrate allergic
immune responses through degranulation and release of pre-formed mediators such
as histamine. Furthermore, mast cells have been shown to mediate pulmonary in-
flammation following exposure to nanoparticles in a murine model. We therefore
examined whether AgNP could induce mast cell degranulation.  Bone marrow de-
rived mast cells (BMMCs) were generated from femoral bone marrow of C57BL/6
mice. BMMCs were exposed to either citrate- or polyvinylpyrrolidone (PVP)-
coated AgNPs (20 nm or 110 nm diameter) at increasing concentrations (6.25,
12.5, 25, or 50 μg/ml) for 3, 6, or 24 h. Exposure to 20 nm AgNPs, but not 110
nm AgNPs, was found to cause concentration-dependent degranulation of
BMMCs at 1 h. TNF-α gene expression was increased in BMMCs following AgNP
exposure while TNF-α protein levels were increased only after exposure to citrate-
coated AgNPs at 50 μg/ml. To determine the mechanism of BMMC degranulation
following exposure to 20 nm AgNPs, we examined scavenger receptors which have
been shown to mediate nanoparticle uptake in macrophages. PCR and flow cytom-
etry demonstrated the presence of scavenger receptor class B1 (SR-B1) on the sur-
face of cultured BMMCs. To determine the role of SR-B1, BMMCs were treated
with two different SR-B1 antagonists (blt-1 or blt-2). Treatment with either SR-B1
antagonist was found to prevent AgNP-induced degranulation of BMMCs. These
in vitro findings suggest that AgNPs may induce an inflammatory response via mast
cell degranulation in vivo, which is dependent upon nanoparticle size and scavenger
receptor activation. Therefore mast cell degranulation may be considered as a indi-
cator of nanomaterial toxicity. This work was funded by NIEHS R01 ES019311
and U19 ES019525.
1338 High-Throughput Methods for Assessing the Molecular
Toxicity of Nanomaterials in Bacteria.
C. Kaweeteerawat1, 2,  A. Ivask2,  C. Low-Kam2, 3,  P. Holden2, 4 and
H. A. Godwin1, 2. 1Molecular Toxicology, University of California Los Angeles, Los
Angeles, CA; 2University of California Center of Environmental Implication of
Nanotechnology, University of California Los Angeles, Los Angeles, CA; 3Department
of Biostatistics, University of California Los Angeles, Los Angeles, CA; 4Donald Bren
School of Environmental Science and Management, University of California Santa
Barbara, Santa Barbara, CA.
Synthesis and use of nanoparticles has skyrocketed during the past decade. To en-
sure that nanotechnology is safely and sustainably developed, rapid, cost-effective
methods are needed to determine the toxicity of nanoparticles. Here, we report the
application of a suite of sub-lethal assay as well as a growth inhibition assay to a se-
ries of silver and metal oxide nanoparticles in bacteria (Escherichia coli). Sub-lethal
effects such as perturbation of membrane integrity (using PI/SYTO) disruption of
membrane potential (using DiBAC) and reduction of respiration rate (using XTT)
were used to identify toxic nanoparticles. To further look into mechanism of toxic-
ity, intracellular Reactive Oxygen Species (ROS) and the intrinsic property of
nanoparticles to oxidize electron (abiotic ROS generation) were measure by using
H2DCFDA and DCFH respectively. These studies revealed that toxicity of the sil-
ver particles studied correlates with size and surface charge, with smaller particles
and particles with a more positive surface charge being more toxic. By contrast, the
toxicity of the metal oxide particles studied correlates most significantly with their
ability to oxidize biomolecules, although dissolution of some of the particles also
plays an important role.
1339 Role of microRNA in Toxicity of Silver Nanoparticles in
Jurkat T Cells.
H. Eom1,  J. Choi1 and J. Lee2. 1Faculty of Environmental Engineering, College of
Urban Science, Seoul, Republic of Korea; 2National Instrumentation Center for
Environmental Management, Seoul, Republic of Korea. Sponsor: D. Ryu.
In this study, in order to identify whether miRNAs are involved in toxicity of silver
nanoparticles (AgNPs), we investigated miRNA expression in AgNPs treated jurkat
T cells using mRNA and miRNA microarrays. Surprisingly small numbers of genes
were affected by both silvers exposure(19 up- and 2 down-regulated mRNA by
AgNPs exposure, and 2 up- and 1 down-regulated mRNA by Ag ion exposure).
More important numbers of differentially expressed (DE) miRNAs than DE
mRNAs were revealed by miRNA microarray, such as, 31 up- and 51 down-regu-
lated miRNAs by AgNPs exposure, whereas 11 up- and 27 down-regulated
miRNAs by Ag ion exposure. The most dramatic alteration was observed in hsa-
miR-1238 (a decrease of 67 folds) by AgNPs exposure. An integrated analysis of
mRNA and miRNA expression was conducted on DE mRNA and DE miRNA by
AgNPs and Ag ion exposure, which revealed that the expression of miRNA, hsa-
miR-219-5p, was negatively correlated with that of mRNA, metallothionein 1F
(MT1F) and tribbles homolog 3 (TRIB3), in the cells exposed to AgNPs; whereas,
the expression of has-miR-654-3p was negatively correlated with the expression of
mRNA, endonuclease G-like 1 (EDGL1) in the cells exposed to Ag ions. However
no mRNA regulated by has-miR-1238 was identified. Individual validation was
followed on these 3 miRNA-mRNA pairs using qPCR. Bioinformatics analysis was
further conducted using Pathway Studio, which suggests hsa-miR-219-5p - MT1F
and -TRIB3 pairs play an important role in AgNPs toxicity in Jutkat T cells by reg-
ulating the genes in important stress response pathways, such as, cell survival, cell
death and oxidative stress. Overall results suggest that compared to serious toxicity,
only limited genes were affected by AgNPs at transcripomic level, whereas more im-
portant number of miRNAs were identified, which suggests fine regulation with
miRNA may play important role in AgNPs toxicity.
1340 Assessing the Influence of Gold and Silver Nanoparticles on
Conventional In Vitro Cytotoxicity Assays.
K. Boodhia1, 3,  L. Koekemoer1, 3,  C. Andros1, 2 and M. Gulumian1, 2. 1Toxicology,
National Institute for Occupational Health, Johannesburg, South Africa; 2Hematology
and Molecular Medicine, University of Witwatersrand, Johannesburg, South Africa;
3Biochemistry, University of Johannesburg, Johannesburg, South Africa.
Gold nanoparticles (AuNPs) and silver nanoparticles (AgNPs), due to their optical
properties are used in optics and biomedical applications. A principal property of
these NPs is their enhanced surface plasmon resonance which enables them to scat-
ter and absorb light with great efficiency. When assessing NP toxicity, there are
many challenges as conventional methods are optically based and make use of ab-
sorbance, luminescence and fluorescence. The objective of this work was to assess if
AuNPs and AgNPs are capable of interfering with currently accepted in vitro cyto-
toxicity assays. Changes in the endpoints of the XTT, ATP, LDH and MitoPT JC-
1 assays was assessed in the absence and presence of cells, after the addition of
AuNPs and AgNPs, to assess interference. Results obtained from XTT, ATP and
LDH assays in the presence of cells showed toxicity. In the absence of cells, the
XTT and ATP assays showed significant changes in their absorbance and lumines-
cence; this could be explained by product adsorption to the NP or interference of
NPs with the readings of the products assessed. On the other hand, the LDH assay
showed little or no change in fluorescence. When using the MitoPT JC-1, evalua-
tion of cell treated with the NPs showed viable mitochondria, however in the ab-
sence of cells there is a decrease in the fluorescence which too can be explained by
product adsorption to the NP. In conclusion, NPs have the ability to interfere in in
vitro toxicity assays, skewing results. For this reason when assessing NP toxicity
using these assay systems, their reliability and sensitivity needs to be determined. To
overcome this interference of the gold and silver NPs a non invasive system such as
the xCELLigence RTCA system, which does not use absorbance luminescence, and
fluorescence, can be used to determine the viability of cells by measuring the cell
index, a dimensionless parameter, which is an expression of cell adherence.
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1341 Realistic Assessment of Nanomaterial Toxicity In Vitro Using
a Nanoaerosol Exposure Chamber.
C. Grabinski1, 2,  M. Sankaran2 and S. M. Hussain1. 1Molecular Bioeffects Branch,
Air Force Research Laboratory, Wright-Patterson AFB, OH; 2Department of Chemical
Engineering, Case Western Reserve University, Cleveland, OH.
Traditional in vitro toxicology methods require dispersion of nanomaterials (NMs)
in biological media for administration to cells, which does not depict realistic in-
halation exposure. The objective of this work is to design and optimize a system to
mimic inhalation exposure by delivering well-characterized NM aerosols to cells
grown at the air-liquid interface. Gold or silver NMs were drawn into the gas phase
from an aqueous dispersion using electrospray. The aerosolized NMs were intro-
duced into a chamber and deposited onto cells using electrostatic deposition. The
deposition of NMs in the chamber was assessed by evenly placing copper grids
throughout the chamber and imaging particle deposition using transmission elec-
tron microscopy (TEM). NM deposition on cells grown in the chamber was quan-
tified by digesting the samples and measuring gold or silver content using induc-
tively coupled plasma – mass spectrometry (ICP-MS). A human nasal epithelial
cell-line was grown in the chamber, and the viability was assessed using the Alamar
Blue assay. Results showed that gold and silver NMs could be deposited uniformly
in the chamber and that the dose could be controlled by varying the electric field
strength and frequency used for electrostatic deposition. Additionally, the dose was
found to be relevant compared to NM deposition in the respiratory tract predicted
by the Multiple Path Particle Dosimetry model. The results of the Alamar Blue
assay showed that the cells could be sustained in the chamber, and the application
of electric fields did not have an affect on cell viability. This study demonstrates a
promising step forward in the development of a standardized realistic exposure
method for assessing NM toxicity in vitro.
1342 Influences of Capping Agent and Cell Type on Cellular
Uptake of Silver Nanoparticles.
F. Zhang,  B. L. Lau and E. D. Bruce. The Institute of Ecological, Earth and
Environmental Sciences, Baylor University, Waco, TX.
The usage of engineered silver nanoparticles (AgNPs) in catalysts, sensors, drug car-
riers, and personal care products is growing because of their unique physicochemi-
cal and biological activities. Consequently both occupational and consumer expo-
sure to these AgNPs is likely to increase in proportion to the production and usage
in the market. Meanwhile, there are increasing concerns that exposure to these NPs
may cause potential adverse effects on humans health as well as the environment.
Capping agents are selected organic or inorganic material applied to the surface of
nanoparticles as stabilizer to prevent aggregation. However, little is known about
the effect of capping agents on the NPs-cell interaction and the mechanisms behind
it. Experiments were carried out to quantitatively and mechanistically investigate
the role of capping agents of AgNPs on cellular uptake by two different cell lines,
human bronchoalveolar carcinoma derived cells (A549) and human colon adeno-
carcinoma derived cells (Caco-2). In vitro studies were used to quantify the uptake
kinetics and the extent of internalized AgNPs and to investigate the uptake mecha-
nism among five capping agents (citrate, polyvinylpyrrolidone (PVP), tannic acid,
silica and penetratin) by two cell lines. Preliminary results on A549 cells showed
that 34% of the penetratin-coated AgNPs were internalized, followed by tannic
acid-coated AgNPs, 25%, while the silica-coated AgNPs showed the least uptake,
only 4% internalized content. Penetratin is a cell-penetration peptide designed to
translocate across the cell membrane, which explains why penetratin-coated AgNPs
were more readily internalized than other capping agents. These results demon-
strated that capping agents play an important role in cellular uptake of AgNPs.
Further experiments on Caco-2 cell line are currently underway and will expand
our knowledge on nanoparticle-cell interactions. The combined results can be ap-
plied to manage the risk associated with occupational and consumer exposure to
AgNPs.
1343 Comparative Cytotoxicity of Silver Nanomaterials in a
Murine Macrophage Cell Line.
T. D. Green1,  A. Badawy2,  T. Tolaymat3 and D. J. Thomas1. 1ISTD, NHEERL,
ORD, US EPA, Research Triangle Park, NC; 2Department Civil & Environmental
Engineering, University of Cincinnati, Cincinnati, OH; 3LRPCD, NRMRL, ORD,
US EPA, Cincinnati, OH.
Manufactured silver nanomaterials (AgNPs) are used as antimicrobials in many
consumer products. Although increased use of AgNPs increases risk of exposure by
inhalation or ingestion, there are few data on human health risks associated with ex-
posure. Here, we evaluated the toxicity of AgNPs in the murine macrophage
J774A.1 cell line. Macrophages play a key role in the inflammatory response by
phagocytosis of pathogens, debris, and particles. Phagocytosis of AgNPs by
macrophages could expose cells to Ag and alter cell structure and function. We used
two in vitro cytotoxicity assays, lactate dehydrogenase (LDH) and reduction of 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), to compare
cytotoxic effects of ionic Ag, polyvinylpyrrolidone PVP coated-AgNPs (MHD=13
nm), hydrogen reduced H2-AgNPs (14 nm), and citrate-AgNPs (12 nm). Cells
were exposed to Ag, PVP-coated AgNPs, H2-AgNPs, or citrate-AgNPs, either in
media alone or media supplemented with 1% fetal bovine serum (FBS) for 1, 4, or
24 hours before assessment. Each AgNP diminished MTT reduction capacity of
J774A.1 cells with 50% reductions in activity in the low parts per million of Ag
concentration range. Compared with AgNPs, Ag was a more potent cytotoxicant.
LDH leakage increased after exposure to Ag and AgNPs indicated that all com-
pounds produced damage to cell membranes. In MTT assays, addition of 1% FBS
to media mitigated cytotoxic effects of all forms of Ag. In LDH assays, addition of
FBS did not affect Ag-dependent membrane damage. These results indicate AgNPs
affect integrity of cell membranes and metabolic competency of cells, although it is
yet unclear whether these effects are mediated by phagocytosis of AgNPs or by ac-
cumulation of Ag solubilized from nanoparticles. Future studies that examine the
disposition, fate, and effects of AgNPs will provide more information for assess-
ment of bioavailability and potential human health risks. (This abstract does not re-
flect U.S. EPA policy.)
1344 Dispersion and Dissolution Behavior of Silver Nanoparticles
in Artificial Biological Fluids.
A. M. Mayo1,  D. R. Johnson2,  A. J. Bednar2 and J. A. Steevens2. 1Badger
Technical Services, Vicksburg, MS; 2Environmental Laboratory, US Army Engineer
Research & Development Center, Vicksburg, MS.
Nano-sized silver (nAg) is the most widely used engineered nanoparticle in con-
sumer products, so much attention is being given to environment, health, and
safety (EHS) risk associated with nAg exposure. The purpose of this study was to
evaluate the agglomeration and dissolution of engineered nAg in artificial biofluids
to better understand nAg stability throughout the body. Twenty-four hour time-
course evaluations of 1 mg/L nAg in artificial biological fluids (alveolar, interstitial,
gastric [pH 1.5], and intestinal fluid) were conducted using field flow fractiona-
tion-inductively coupled plasma-mass spectrometry (FFF-ICP-MS), dynamic light
scattering (DLS), spectrophotometry, and dissolution methods. Silver nitrate
(AgNO3) was used as a positive control. Citrate- and PVP-Ag (20 nm) in alveolar
fluid and intestinal fluid showed similar settling patterns, with absorbance levels de-
creasing only 10% from t=0 to t=24h, likely due to the presence of surfactants. In
contrast, these same particles in interstitial fluid and gastric fluid (pH 1.5) show a
40% decrease in absorbance at 24 h. Rapid agglomeration of coated-nAgs appeared
to be occur, as indicated by the sudden formation of black particulates upon addi-
tion of the coated-nAgs to all artificial biofluids tested. nAg showed marked size in-
creases over 24 h in interstitial, intestinal, and gastric fluids. The decrease in surface
area resulting from this agglomeration may also have an effect on Ag dissolution
rates. Citrate- and PVP-coated nAg dissolution, as well as AgNO3, suggests the loss
of Ag+, when compared with Ag+ concentrations in water. The high concentration
of chloride ions in many artificial biofluids may lead to the rapid formation of AgCl
during nAg dissolution. These studies demonstrate that nAg is likely to undergo
several dissolution and agglomeration changes as the particle moves through differ-
ent organ systems. Furthermore, these data can be used to generate prediction mod-
els of nAg dispersion throughout the body.
1345 Correlating In Vivo Agglomeration State with Oral
Bioavailability of Gold Nanoparticles.
G. K. Hinkley1,  S. M. Roberts1 and K. W. Powers2. 1Center for Environmental
and Human Toxicology, University of Florida, Gainesville, FL; 2Particle Engineering
Research Center, University of Florida, Gainesville, FL.
Particle size is thought to be a critical factor affecting the bioavailability of nanopar-
ticles (NPs) following oral exposure. Nearly all studies of NP bioavailability focus
on characterization of the primary particle size of the material as supplied or as
dosed, and not on the effective particle size within the gastrointestinal tract (GIT),
which is presumably most relevant for absorption. In the study reported here, ag-
glomeration behavior of gold nanospheres was evaluated in vivo throughout the
gastrointestinal tract (GIT) using transmission electron microscopy (TEM).
Agglomeration state within the GIT was then correlated with bioavailability as in-
dicated by tissue levels of Au detected using inductively coupled plasma mass spec-
trometry (ICP-MS). Mice were dosed (10mg/kg) with either 22nm PEG-coated or
uncoated Au NPs. Previous work done by this group using dynamic light scattering
in simulated gastric fluid (SGF) has shown that uncoated Au NPs quickly agglom-
erate in this environment while PEG-coated Au NPs remain well dispersed after 24
hours in SGF. Samples were taken from various regions of the GIT at varying times
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after dosing for TEM analysis. Images from these samples are consistent with pre-
dicted agglomeration behavior in that PEG-coated Au NPs can be observed as pri-
mary (22nm), non-agglomerated NPs in the stomach, small intestine (SI), cecum,
large intestine (LI) and feces of dosed animals. In contrast, uncoated Au NPs were
observed to form agglomerates of several hundred nanometers in the stomach and
remain agglomerated in the SI, cecum, LI and feces. At 12 hours post-gavage there
was significantly more gold detected in the blood and liver (p < 0.05) of animals
dosed with PEG-coated vs. uncoated Au particles. The characterization of these
particles in vivo supports our hypothesis that differences in ICP-MS tissue levels of
Au between animals dosed with PEG-coated vs. uncoated Au NPs is due to the par-
ticle size being presented to absorptive surfaces in the GIT.
1346 Comparison of Acute and Chronic Toxicity and Effects of
Nanoparticles Ceriodaphnia dubia.
A. J. Kennedy1,  A. Harmon1,  J. G. Laird1,  A. J. Bednar1,  C. Detzel2 and
J. A. Steevens1. 1US Army Corps of Engineers, Vicksburg, MS; 2NanoSafe,
Blacksburg, VA.
In recent years, the usage of nanoparticles has grown tremendously, and their po-
tential to exert toxicity in aquatic environments is an increasing concern. This study
evaluated the toxicity of 20 and 100nm nanosilver and nanogold to Ceriodaphnia
dubia in soft reconstituted water. The selected nanoparticles were chosen for
nanosilver ability to dissolve in environmentally relevant solution and nanogold for
its slow dissolution in environmentally relevant solution. Standard toxicity test have
shown that Ceriodaphnia dubia are less sensitive to silver chronically than they are
acutely. This is most likely a result of the addition of food binding to the silver re-
ducing bioavailability. An altered testing procedure adding food after 8 hours from
water renewal alongside standard testing procedures was evaluated acutely and
chronically. This window of time will allow for the uptake of nanoparticles by the
organisms that would otherwise not be available. In acute and chronic test
Ceriodaphnia dubia were less sensitive to nanogold than nanosilver. When compar-
ing acute and chronic 20nm nanogold tests, 100% mortality was shown in the
highest concentration 75 mg/L chronically with 60% survival acutely in the highest
concentration. This would suggest the possibility that toxicity is occurring by dif-
ferent mechanisms. In 20nm nanosilver chronic testing the altered testing proce-
dure showed an increase in mortality and delayed reproduction compared to stan-
dard testing procedures confirming that the addition of food decreases sensitivity to
the organism. Future work will include the testing of 100nm nanosilver and
nanogold. Further studies are needed to indicate that toxicity is occurring by differ-
ent mechanisms when comparing acute-to-chronic ratios and testing of different
aquatic organisms.
1347 Silver Nanoparticles Impair Neuronal Synaptic Function and
Alter Neurotransmitter Content in the Brain.
K. Sriram,  J. R. Roberts,  G. X. Lin,  J. M. Antonini,  A. Kenyon and
A. M. Jefferson. CDC-NIOSH, Morgantown, WV.
Silver nanoparticles (AgNPs) find application in the manufacturing of industrial,
household and diagnostic products, besides its extensive antimicrobial use. While
the economic benefits of manufacturing such materials are highly promising, their
adverse environmental and health effects are yet to be fully realized. The unique
physico-chemical properties of AgNP influence its ability to aerosolize, and thus
occupational or environmental exposure is of major concern. To determine if
AgNPs pose a neurological risk, we evaluated its effects in a rodent model. Well
characterized AgNP (primary particle size = 20-50 nm) suspensions were prepared
in dispersion medium (DM; mean particle aggregate size in DM = 180 nm). Adult
male Sprague-Dawley rats were intra-tracheally instilled with a single dose of either
DM, 37.5, 112.5 or 450 μg AgNP. At 1, 7, 28, or 84d post-exposure, various in-
dices of neural dysfunction were examined in discrete brain areas. By 7d post-expo-
sure, AgNPs caused a partial loss (35-40%) of striatal synaptosomal-associated pro-
tein 25 (Snap25) and syntaxin binding protein 1 (Stxbp1), critical molecular
regulators of synaptic neurotransmission. Levels of Snap25 decreased further
(~85%) by 84d post-exposure. AgNP also decreased (~25%) striatal tyrosine hy-
droxylase (Th) protein content. Further, AgNP caused a time-dependent increase
(16-45%) in striatal norepinephrine, while lowering (25%) serotonin content by
28d post-exposure. However, AgNP did not alter striatal dopamine content, al-
though it reduced striatal Th. Reactive astrogliosis, as evidenced by increased (30%)
expression of glial fibrillary acidic protein (Gfap) was observed in the striatum, 7d
following exposure. The persistent reduction of synaptic proteins 84d following
cessation of exposure suggests that AgNPs can potentially be neurotoxic. Whether
such abnormalities can culminate in neurodegeneration remains to be investigated.
Our findings call for extensive safety evaluation to better understand the risks asso-
ciated with AgNPs and avert any adverse neurological health effects.
1348 A Study of Mice Inhalation Exposures to Silver Nanoparticles
Generated by Nebulization and Electrospray Methods.
A. Lao1,  M. Zhong1,  K. Galdanes1,  D. Chen2,  T. Gordon1 and L. Chen1.
1Environmental Medicine, New York University, Tuxedo, NY; 2Energy,
Environmental and Chemical Engineering, Washington University in St. Louis, St.
Louis, MO.
Many forms of engineered nanomaterials are currently being used in industrial and
medical applications in the advanced field of nanotechnology. One of the major
routes of human exposure to nanomaterials is inhalation. Silver nanoparticles or
nanosilver in particular, are prevalent in consumer products and many other appli-
cations as antibacterial agents, yet there are relatively limited nanosilver toxicity
data in the literature. A series of rodent exposures were conducted to assess the lung
inflammatory response. The nanoparticles were generated via a Collison nebulizer
and an electrospray aerosol generator using suspensions composed of citrate stabi-
lized nanosilver or polyvinylpyrrolidone (PVP) stabilized nanosilver. The primary
size of both nanosilvers was 20 nm in diameter. Particle size distributions of
aerosolized citrate stabilized nanosilver and PVP stabilized nanosilver were also
characterized. Count median diameters (CMD) of citrate nanosilver and PVP
nanosilver were between 50 and 60 nm, while their volume median diameters
(VMD) were between 80 and 100 nm, respectively. The CMD and VMD of citrate
stabilized nanosilver generated by electrospray were found to be about 2-fold and 3-
fold lower, respectively, than that generated by Collison nebulizer. Acute nose-only
exposures were conducted on male BALB/cJ mice using the nebulizer and lung in-
flammatory responses were examined following 4-h exposure to citrate stabilized
nanosilver at a concentration of 1.0 mg/m3. At 24-h and 7-d post exposure, there
were little change in the number of polymorphonuclear neutrophils and protein
concentrations in bronchoalveolar lavage fluid as compared to filtered air control.
Our results showed that citrate and PVP coated nanosilver elicited minimal pul-
monary inflammatory response in mice at the concentration tested in this experi-
ment.
1349 Estimation of Human Equivalent Exposure from Rat
Inhalation Toxicity Study of Silver Nanoparticles Using
Multipath Particle Dosimetry Model.
J. Ji and I. Yu. Institute of Nanoproduct Safety Research, Hoseo University, Asan,
Republic of Korea.
Respiratory tract dosimetry is a useful tool to estimate the exposure concentrations
of an inhaled substance that will produce the same result at a target site of the res-
piratory tract in both rats and humans. Thus, to enable the results of animal in-
halation studies to be extrapolated to human equivalent exposure levels, the MPPD
(multi-path particle dosimetry) model was used to estimate the differences in the
respiratory dosimetry of rats and humans. In our previous study, when animals
were subchronically exposed to silver nanoparticles over a period of 90 days, a no
observable adverse effect level (NOAEL) of 100 μg/m3 was suggested. Therefore,
this study used results from a previous animal study, including the test aerosol in-
formation and estimated clearance rate of silver nanoparticles after a 90-day inhala-
tion toxicity test. As a result, the human equivalent workplace exposure concentra-
tion of silver nanoparticles was estimated as 59 μg/m3 compared to the rat NOAEL
of 100 μg/m3.
1350 Alterations in Lung Host Defense after Pulmonary Exposure
to Silver Nanoparticles in Rats.
B. M. Yingling1, 2,  C. McLoughlin2,  J. M. Antonini2, 1,  R. I. MacCuspie3,
V. A. Hackley3,  B. T. Chen2,  D. Schwegler-Berry2 and J. R. Roberts2, 1. 1WVU,
Morgantown, WV; 2NIOSH, Morgantown, WV; 3NIST, Gaithersburg, MD.
Silver nanoparticles (AgNP) are among the fastest growing categories of manufac-
tured nanomaterials, and there is a need to investigate the risk for potential adverse
effects of respiratory exposure in workers. The goal of the current study was to char-
acterize susceptibility to lung bacterial infection following AgNP exposure in vivo.
AgNP, 20 nm in diameter with a 0.3% wt polyvinylpovidone coating (NanoAmor,
Inc.), were suspended in a physiological dispersion medium (DM) and sonicated.
On day 0, rats were intratracheally (IT) instilled with 37.6 (Ag Low) or 449 (Ag
High) μg of AgNP in DM or DM alone. On day 3, rats were inoculated IT with
5x105 Listeria monocytogenes (LM). Rats were euthanized on day 3 (pre-infection),
and on days 4, 6, 8, and 10. Bronchoalveolar lavage (BAL) was performed on the
right lung. The left lung was cultured to assess LM burden, and the lung-associated
lymph nodes (LALN) were harvested. BAL cells and fluid were retained for analysis
of injury, inflammation and oxidant production, and LALN lymphocytes were
counted to assess immune response. On day 3 pre-infection, increased BAL albu-
min levels (lung injury) neutrophil influx (inflammation), LALN lymphocytes, and
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BAL cell oxidant production were measured in the Ag High group when compared
to the Ag Low and DM groups. Following infection, LM lung burden increased sig-
nificantly in the DM and Ag Low groups as compared to the Ag High group, peak-
ing on day 6, with the highest burden in the DM group. LALN lymphocytes and
BAL neutrophils, lymphocytes, and cellular oxidant production were elevated in
the Ag High group on days 4 and 6 compared to DM and Ag Low groups. By day
8, LM lung burden, and BAL and LALN cell counts were similar for all groups.
Induction of an early inflammatory response and oxidant burst in conjunction with
increased lymphocyte proliferation in the lungs of the high dose AgNP group prior
to infection enhanced the innate immune response and led to an increased clear-
ance rate of bacteria from the lungs.
1351 Exposure to Inhaled Silver-Nanoparticles Results in the
Induction of Gene Expression Alterations in Oxidative Stress
Pathway Components, in a Time-Dependent Manner.
M. A. Popovech,  K. Galdanes,  E. L. Saunders,  M. N. Hernandez,  L. Chen and
T. Gordon. Environmental Medicine, New York University School of Medicine,
Tuxedo, NY.
The use of silver nanoparticles (AgNPs) is ubiquitous, and they are now commonly
employed in pharmaceuticals, medical imaging, medical devices, cosmetics, cloth-
ing, and other consumer products. Due to the commonality of AgNPs, along with
a general lack of toxicity and safety testing, AgNPs have been deemed safe by de-
fault. However, legitimate concerns exist, and a number of recent studies suggest
that AgNPs pose a threat to human health. This study was conducted in order to
examine the hypothesis that inhaled nano-sized Ag particles cause lung and extra-
pulmonary organ dysfunction via oxidative stress pathways. Male and female
FVB/NJ mice were exposed to either 0.5 mg/m3 or 1 mg/m3 of AgNPs generated
from metal rods, using a Palas spark generator, via nose only inhalation for 4 hrs.
An n=5 animals were used in each treatment group, and all treated animals were
compared to air exposed controls. At 2hr, 24hr, 48hr, 72hr, and 7d post-exposure,
animals were euthanized and blood, lavage and tissue were collected. RNA was iso-
lated from lung and liver tissue and mRNA expression levels, of key oxidative stress
genes, were quantified by real-time RT-PCR. A number of significant alterations in
gene expression of key oxidative stress genes were observed in response to AgNP ex-
posure. At 2 hours post exposure, Hmox1 and Keap1 expression increased ~2.75
fold in lung tissue, and modestly decreased to ~ 2.5 fold at 24 hours post exposure.
Whereas in liver tissue, Keap1 expression changed from a 2.5 fold increase to a 3.5
fold increase in liver tissue, at 2 and 24 hours post exposure, respectively. Similarly,
in liver tissue, Txnrd1 expression increased from 0.5 fold to a 2.5 fold increase at 2
and 24 hours post exposure, respectively. These experiments have suggested that ex-
posure to inhaled AgNPs results in the induction of gene expression alterations in
oxidative stress pathway components. Further, these alterations occur in a time-de-
pendent manner.
1352 Genetic Influence of Pulmonary Response to Silver
Nanoparticles Exposure.
M. N. Hernandez,  E. L. Saunders and M. Popovech. Environmental Medicine,
New York University, Tuxedo, NY.
Within the last decade, nanotechnology has seen a boost in commercial, medical
and industrial applications. However, there is great uncertainty in terms of the bio-
molecular activity nanoparticles (NPs) may have on biological systems. In particu-
lar, this study sought out to determine the genetic influence on the pulmonary re-
sponse to silver NPs. Murine models were employed to evaluate the variation of
inter-strain response. Differences were quantitated by measuring inter-strain vari-
ability in terms of polymorphonuclear neutrophil (PMN) infiltration in bron-
choalveolar lavage fluid. Initially, three mouse strains (C57BL/6J, FVB/NJ, and
BALB/cJ) representing resistant, moderate, and sensitive responders, respectively,
were exposed to 0.5 μg/g body weight of 20 and 110 nm citrate or PVP stabilized
silver NPs by oropharyngeal aspiration. Bronchoalveolar lavage was performed 24
hr post exposure to measure PMN number and protein concentration. All three
strains were found to be more sensitive to 20 nm silver citrate (40-85% PMN re-
sponse) and 20 nm silver PVP (15-85% PMN response). We then performed a sim-
ilar exposure in 8 strains of mice (DBA/2J, C57BL/6J, AKR/J, 129SI/SvJ, A/J,
FVB/NJ, C3H/HeJ, Balb/cJ) at a lower dose of 0.25 μg/g body weight of 20 nm
silver citrate. PMN responses between 1.5% and 60% were observed. In addition,
temporal pulmonary response was measured in C57BL/6J, FVB/NJ, and BALB/cJ
mice at 24 hrs and 7days. At 24 hours, PMNs were found to be strain dependent,
between 14-46%, and the response at 7 days was found to be between 0-15% PMN
response. Based upon these initial findings on inter- strain response variation, it can
be concluded that these mouse models show a susceptibility pattern among strains,
and can help to elucidate sensitivity mechanisms in terms of exposure assessment
and innate inter-species responses.
1353 Short- and Long-Term Effects of Commercially Available
Gold Nanoparticles in Rodents.
J. Bahamonde1,  B. Brenseke1 and M. R. Prater1, 2. 1Biomedical Sciences and
Pathobiology, Virginia Tech, Blacksburg, VA; 2Biomedical Sciences, Edward Via
College of Osteopathic Medicine, Blacksburg, VA.
Gold nanoparticles (GNPs) have physical and chemical properties that place them
as top candidates for biomedical uses, including promising alternatives for targeted
drug delivery, cancer therapy, and diagnostic contrast imaging. Their characteristics
and behavior depend largely on their size, shape, and coating, making their unifor-
mity an important aspect to consider, and making comparisons among studies a
great challenge. We acquired 15 nm GNPs commercially available for in vivo con-
trast imaging, characterized them, and exposed female BALB/c mice, female F344
rats, and female and male C57BL/6 mice to either 1g/kg of GNPs, or phosphate
buffered saline (PBS) via tail vein injection. Blood, urine, and feces collection, eu-
thanasia and necropsy were performed at 24 hours, 1, 2, 3, 4, and 18 weeks post ex-
posure. GNPs were found to be polydispersed, polyethylene glycol-coated, and var-
ied in size from about 4 to 30 nm. Three out of the 19 rats exposed to GNPs died
unexpectedly within 24 hours of exposure, with no deaths registered in any other
group. GNPs were detected in urine for up to 1 week post exposure, and in feces for
up to 2 weeks in mice and 4 weeks in rats. On gross inspection, GNPs caused im-
mediate and persistent darkening of all tissues, and stayed in blood for up to 1
week. Histological examination demonstrated accumulation of GNPs in
macrophages and endothelial cells of all tissues examined up to the end of the study,
with increased numbers of activated macrophages in GNPs exposed animals com-
pared to PBS exposed animals. Serum levels of interleukin-18, a pro-inflammatory
cytokine secreted by macrophages, were significantly higher in animals exposed to
GNPs in comparison to those exposed to PBS. Main conclusions of this study are
that commercially available GNPs are not necessarily standardized, may cause acute
death in rats, accumulate in macrophages and endothelial cells, incite granuloma-
tous inflammation, and persist in the body indefinitely.
1354 Assessment of Genotoxicity of Silver Nanoparticles in Myh-
Deficient and Wild Type Mice.
R. Reliene,  P. Kovvuru,  P. E. Mancilla and A. Shirode. University at Albany, State
University of New York, Albany, NY.
Silver nanoparticles (AgNPs) are extensively used in consumer products due to their
antimicrobial properties. AgNPs are released from textile fabrics under regular wash
conditions and were detected in sewage sludge of a municipal wastewater treatment
plant, suggesting a potential for widespread exposures to AgNPs. However, geno-
toxicity and underlying molecular mechanisms of AgNPs are poorly understood.
We studied DNA double strand breaks (DSBs) and chromosomal damage by γ-
H2AX assay and micronucleus assay, respectively, in mice after 5-day treatment
with AgNPs by oral application. AgNPs treatment resulted in a 2-fold induction in
γ-H2AX foci in both bone marrow and peripheral blood. In addition, AgNPs in-
creased the frequency of micronucleated cells in bone marrow erythroblasts and pe-
ripheral blood erythrocytes. Myh is a DNA glycosylase involved in both base exci-
sion repair and mismatch repair. We speculated that Myh is involved in
AgNP-mediated DNA damage, which predisposes Myh deficient mice to DSBs
and/or chromosomal damage. We observed a similar number of γ-H2AX foci and
about 2-fold more micronuclei in AgNP treated Myh deficient compared to wild-
type controls, suggesting a potential role of Myh in the repair of AgNP-mediated
damage. We further investigated the effect of AgNPs on changes in the expression
levels of 84 genes involved in DNA repair using PCR array profiler. In total, 25
genes were downregulated and 12 genes were upregulated as a function of AgNP
treatment (1.5-fold cutoff ). Most downregulated genes play a role in base excision
and nucleotide excision repair, while upregulated genes are part of different DNA
repair pathways. In summary, AgNP exposure by oral ingestion induces DSBs and
chromosomal damage and alters expression of DNA repair genes, suggesting a po-
tential hazard to genetic integrity. Further studies are needed to understand the ef-
fect of AgNP on DNA damage signaling, DNA repair efficiency, genomic instabil-
ity and carcinogenicity.
1355 Comparative Hepatotoxicity Study of Two Different
Diameter Size Silver Nanoparticles in Sprague-Dawley Rats.
A. Patlolla1 and P. Tchounwou2. 1Biology, Jackson State University, Jackson, MS;
2Biology, Jackson State University, Jackson, MS.
The antibacterial effect of silver nanoparticles (Ag-NPs) has resulted in their exten-
sive application in health, electronic, and household products. Due to the intensive
commercial application of Ag-NPs, their health risk assessment is of great impor-
tance. The previous in vitro studies demonstrated that AgNPs caused toxicity in
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various cell-lines. However, the data on the toxicity of Ag-NPs in vivo is largely
lacking. The main objective of this study was to determine the effect of two differ-
ent diameter sizes (6nm, 10nm) silver nanoparticles on certain liver enzymes (ala-
nine ALT, aspartate AST and alkaline phosphatase ALP) in serum and analysis of
liver damage in Sprague-Dawley rats. Four groups of five male rats, each weighing
approximately 80 + 2 g, were administered orally, once a day for five days with
doses of 5, 25, 50, 100, mg/kg body weight (BW) of Ag-NPs. A control group was
also made of five rats. Serum was collected following standard protocols, and the
activity of the liver enzymes (ALT, AST and ALP) was determined by colorimeteric
method. The results demonstrated that Ag-NPs exposure increased the activities of
the liver enzymes (ALT, AST, ALP) and damage in liver tissue in exposed groups
compared to control. The increase in the activity was larger in 6nm size AgNPs
compared to 10nm size. Only the highest two concentrations 50 mg/kg and 100
mg/kg showed statistically significant increases in ALT and ALP in both diameter
size AgNPs compared to control. AST activity showed an increase; however, it was
not statistically significant compared to control. Furthermore, the smallest sized
AgNPs (6nm size) had a greater ability to induce hepatic damage in Sprague-
Dawley rats than the other sized AgNPs (10 nm). These data suggest that the
AgNPs-induced hepatotoxic effects against tissue cells are particle size-dependent,
and thus, the particle size needs careful consideration in the design of the nanopar-
ticles for biomedical uses.
1356 Increased Mucus Production and Histopathological Gill
Alterations after Exposure to Nanosilver and Silver Nitrate.
A. D. Hawkins1,  C. Thornton1,  A. Harmon2,  A. J. Kennedy2,  J. A. Steevens2,
N. G. Reyero Vinas2,  K. Bu3,  J. Cizdziel3 and K. L. Willett1. 1Pharmacology/
Environmental Toxicology Research Program, University of Mississippi, Oxford, MS;
2Environmental Lab, ERDC, Vicksburg, MS; 3Chemistry, University of Mississippi,
University, MS.
Silver nanoparticles are among the most widely used nanomaterials because of their
antibacterial and antifungal properties. Despite their extensive use, information is
now becoming available on the toxicity and fate of nanosilver formulations within
living organisms. Mucus has both increased and decreased the toxicity of different
xenobiotics by either concentrating the xenobiotic on the gills and body or encap-
sulating toxicants to prevent exposure. In order to understand the relationship be-
tween mucus, toxicity and silver exposure, zebrafish (ZF) and fathead minnows
(FHM) were exposed for 36 or 96 hr to nominally 20 nm PVP- or citrate-coated
silver nanoparticles (PVP-AgNPs; citrate-AgNPs) or silver nitrate (AgNO3) at 2
nominal concentrations (20 and 200 μg/L) or (2 and 6 μg/L), respectively. After 4
hr, ZF produced significantly more mucus secretion in every treatment than the
control fish in a dose-dependent manner as measured by a phenol-sulfuric acid
method. FHM gill RNA was extracted for microarray analyses. To quantitate distri-
bution of silver, skin, liver and GI were digested for ICP-MS. FHM gills were also
paraffin embedded, sectioned and examined for histopathological lesions to pheno-
typically anchor the molecular and chemical endpoints. The highest AgNO3 and
both citrate-AgNPs concentrations caused significant atrophy in gill mucus goblet
cells. Every silver treatment also had a significantly higher histopathological alter-
ations index compared to control. Citrate-AgNPs (20 and 200 μg/L) had the high-
est incidence of alterations (3.5 and 3.25 times higher than control, respectively).
The results suggest that mucus production and mucus-related cells are impacted by
silver exposure. This research is supported by US Army ERDC grant: W912HZ-
09-C-0033.
1357 Impact of Silver Nanoparticles (AgNP) on Bacteria Species
Isolated from Gastrointestinal (G.I.) Tract of Sprague-
Dawley (SD) Rats.
M. S. Imam1,  S. Khare2,  A. M. Paredes3 and M. D. Boudreau1. 1Division
Biochemical Toxicology, NCTR, Jefferson, AR; 2Division of Microbiology, NCTR,
Jefferson, AR; 3Office of Scientific Coordination, NCTR, Jefferson, AR.
The food industry is incorporating AgNP into a growing number of products,
which suggests that consumers are being exposed orally to increasing amounts of
these nanoparticles. The absorption of AgNP from the G.I tract has been demon-
strated; however the potential effects from the interactions of AgNP with bacteria
of the G.I. tract are largely unknown. We investigated the bactericidal effects of
AgNP on Lactobacillus sp. (G+) and Bacteroides sp. (G-) isolated from the G.I.
tract of SD rats. Three sizes of AgNP (10, 75, and 110 nm) at (0.1, 0.5, 1, 2, 5, 10
μg/ml) were incubated with cultures of bacteria (in triplicate), and the bactericidal
effects at 60, 120, and 180 min were assessed using colony forming unit (CFU) and
adenosine triphosphate (ATP) release assays. There were no CFUs in cultures of
Lactobacillus sp. or Bacteroides sp. when incubated for 120 min or longer in the
presence of 75 or 100 nm AgNP at concentrations of ≥2 μg/ml or in the presence
of 10 nm AgNP at concentrations of ≥1 μg/ml, suggesting enhanced bactericidal
effects by 10 nm AgNP. Both bacterial species showed a significant decrease in ATP
release when exposed to AgNP (10, 75, or 107 nm) at concentrations > 1 μg/ml. At
equivalent number of cells (10^3 cells/ml), Bacteriodes sp. were more sensitive than
Lactobacillus sp to the bactericidal properties of AgNP (10, 75, or 110 nm), likely
reflecting differences in cell wall composition between species. Scanning electron
microscopy showed that AgNP were attached to bacterial cells at the surface, sug-
gesting that protein binding or cell wall distortion by AgNP might result in cellular
toxicity or death. These results provide new insights into the bactericidal properties
of AgNP and how the consumption of AgNP might disrupt the normal balance of
microorganisms in the healthy G.I. tract. Supported by interagency agreements
224-12-0003 and AES12013 between the NCTR/FDA and NIEHS/NTP
1358 Influence of Dose, Size and Chemical Composition on
Persistence of Silver Nanoparticles in the Rat Lung.
D. S. Anderson,  R. Silva,  D. Lee,  P. C. Edwards,  K. E. Pinkerton and L. S. Van
Winkle. University of California Davis, Davis, CA.
Silver nanoparticles (AgNPs) have antimicrobial activity and unique electrical prop-
erties, resulting in increasing use. While there have been studies of the biological ef-
fects of AgNPs, including persistence and clearance of AgNPs from the lung, an ex-
amination of the effect of AgNP size and surface coating (used to stabilize these
materials when in solution) has not been fully investigated. We investigated lung
deposition, retention and clearance of 20nm and 110nm spherical AgNPs coated
with citrate or polyvinylpyrrolidone (PVP). Rats were instilled intratracheally with
0.1, 0.5 or 1.0 mg/kg of either one of the AgNP solutions or a vehicle control and
were assessed at 1, 7 and 21-days post treatment. Ag was quantified in tissue using
inductively coupled plasma mass spectrometry. At one day postinstillation, lungs
dosed with 1.0 mg/kg AgNPs had 0.25 to 0.51 mg Ag/g dry tissue and these
amounts did not differ by surface coating or particle size. Sham controls had no de-
tectable Ag. Total leukocytes and neutrophils in bronchoalveolar lavage fluid in-
creased in a dose dependent manner 1-day after exposure to all AgNPs with signifi-
cant increases in the 1.0mg/kg dose compared to all other doses for all 4 particle
types. This increase persisted at the 7-day time point in all AgNP groups except for
20nm PVP. Distribution of Ag in the lung was determined using autometallogra-
phy and semiquantitative scoring on paraffin-embedded lung sections to demon-
strate Ag was preferentially localized to the bronchoalveolar duct junction at the 1-
day time point. At 7-days post exposure, Ag was localized to the subepithelial
extracellular matrix of the terminal bronchioles. Uptake of Ag by alveolar
macrophages was also observed. These findings suggest Ag can persist in the lungs
over time and alveolar macrophages have a role in the clearance. Supported by
U01ES02027 and P42ES004699. Nanomaterials supplied by the NIH NCNHIR
consortium.
1359 Subtle Surface Variations Influence Biological Compatibility
of Gold Nanoparticles.
K. Kim1,  T. Zaikova2,  J. E. Hutchison2 and R. L. Tanguay1. 1Environmental and
Molecular Toxicology, Oregon State University, Corvallis, OR; 2Chemistry, University
of Oregon, Eugene, OR.
To better understand the nanoparticle physicochemical properties that influence bi-
ological compatibility, we investigated how subtle ligand variation on the surface of
gold nanoparticles (AuNPs) influences biological responses. The zebrafish embryos
were exposed to four distinct, well-defined ligand-stabilized 1.5 nm spherical
AuNPs. The ligand shells for each AuNPs contain: (1) only anionic 2-mercap-
toethanesulfonic acid (MES), (2) only cationic N,N,N trimethylammoni-
umethanethiol (TMAT), (3) a mixed ligand shell containing MES and a small
amount of triphenylphosphine (TPP), and (4) a mixed ligand shell containing
TMAT and a small amount of TPP. Small-angle X-ray scattering (SAXS) confirmed
the core size of the particles and that there was no agglomeration in the embryonic
test medium. The only difference between partial and full functionalization was the
P/Au ratio as determined by XPS analysis. The MES/TPP coated particles caused
higher mortality and malformation than those fully functionalized with MES, and
in TMAT/TPP coated particles a higher incidence of smaller size and pale gray eyes
was observed. In the gene expression profiles of transcription factors for apoptosis
(p53 and bax), eye development (pax6a, otx2 and rx1) and pigmentation (sox10
and mitfa), the gene expression of embryos were significantly disrupted in both
mixed ligand particles in a concentration-dependent manner, consistently with the
observed developmental toxicity. In addition, laser ablation ICP-MS analysis re-
vealed that biological absorption and distribution of AuNPs in exposed embryos
were closely related to the toxicity phenotype and gene expression caused by differ-
ential surface functionalization. These data provide new insights into the under-
standing of how subtle surface changes impact biological compatibility and further
emphasize the importance of material characterization. This research is supported
by NIEHS P3 ES000210, ES016896 and Air Force Research Laboratory #FA8650-
05-1-5041.
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1360 Gold Nanoparticles in Central Nervous System of Mice:
Localization and Inflammatory Markers.
F. Fallahi1, 2,  S. M. Hussain1, 2,  I. E. Pavel1,  J. P. O’Callaghan3,  M. Sharma1, 2,
R. Saadawi4 and M. Morris1. 1Pharmacology & Toxicology, Wright State University,
Dayton, OH; 2711 HPW/ RHDJ, AFRL, Wright-Patterson AFB, Dayton, OH;
3CDC-NIOSH, Morgantown, WV; 4Chemistry, University of Cincinnati, Cincinnati,
OH.
Gold nanoparticles (GNPs) possess unique physicochemical properties that may fa-
cilitate entry into the central nervous system (CNS) where they may act therapeuti-
cally. There is little information on GNPs biodistribution in specific brain regions
or extent of inflammation induction. Experiments determined the localization and
neuroinflammatory response of spherical GNPs (10 nm) after IV injection in male
C57Bl mice. As a supplement, a known inflammogen, lipopolysaccharide (LPS, 2
mg/kg, sc), was tested. To determine the optimal buffer concentration to maintain
GNP solubility, we measured aggregation of GNPs using various PBS concentra-
tions (10, 1, 0.1, 0.01 X). 0.01X PBS produced the least amount of GNP aggrega-
tion and was used in all studies. The next experiment verified entry of GNPs into
CNS. Mice were IV injected using the tail vein (200 μg/ml 10 nm GNPs in 0.01X
PBS). After 24 hrs mice were perfused transcardially with 2 %
glutaraldehyde/paraformaldehyde and brains were collected. GNPs were measured
using inductively coupled plasma mass spectrometry in whole brain homogenates.
To specifically localize accumulation of GNPs in brain, septum, caudate, hip-
pocampus, hypothalamus, cortex, frontal cortex, and spinal cord were dissected.
Hypothalamus, hippocampus, and septum had the highest levels of GNPs (6.7,
6.2, and 4.6 μg Au/g, respectively). To evaluate brain inflammation, we used q-
PCR analysis of frozen brain regions for study of pro-inflammatory mediators, LIF,
CCL2 and IL1β. GNPs did not affect cytokine/chemokine expression in cortex,
frontal cortex or hippocampus. LPS, as expected, caused a marked (100-fold) in-
crease in the same cytokines. Results show that GNPs enter brain and concentrate
in specific regions without eliciting an inflammatory response. Data raise the possi-
bility of usefulness of GNPs in drug delivery and therapeutic treatment of CNS dis-
eases.
1361 Dissolution Kinetics of Inhaled Metal Nanoparticles in a
Murine Model.
E. L. Saunders,  E. Bartnick,  K. Galdanes,  M. Popovech,  M. N. Hernandez,
L. Chen and T. Gordon. Environmental Medicine, New York University, Tuxedo
Park, NY.
Previous work has established that Ag, Ni, and Ce nanoparticle (NP) inhalation in-
duces a defined dose/inflammatory-response relationship. Adverse responses to
each metal were found to vary by size, shape (TEM analysis) and chemistry (XPS
analysis). This study was conducted to delineate the inflammatory responses gener-
ated by exposure to Ag, Ni, and Ce NP’s in a murine model, as marked by the poly-
morphic neutrophil response (PMN), and examine absorbed kinetics associated
with NP exposure. PMN response for the larger sized particles (100-130nm) did
not exceed 4% across three doses (1mg/m^3, 0.5mg/m^3, and 0.25mg/m^3), and
ranged from 4% to 32% for smaller sized particles (30-45nm) in a concentration
dependant manner. To further investigate the inflammatory response and extrapul-
monary translocation, synthetic body fluids were used to establish dissolution rates;
specifically, synthetic phagolysosomal fluid (PSF, pH 4.6), and synthetic lung sur-
factant (LS, pH 7.5). NP’s were dispersed directly into the fluids using a fritted
bubbler and the dissolved fraction was subsequently separated from the particles
using centrifugation of spin column filters (1-2nm pore size).The metal concentra-
tions were then analyzed using ICP-MS and expressed as percentage of dissolved vs.
total. Surprisingly results of Ag showed similar trends in both fluid types, with
larger particles dissolving more rapidly than smaller particles. The percent differ-
ence between 130nm and 30nm particles in LS was 18% at 15 min, 9% at 30 min,
and 0% at 1 hr. In contrast, percent differences between these two Ag NP’s in PSF
were 42% at 15 min, 26% at 30 min, and 6% at 1 hr. To assess the effect of size on
kinetics, mice were exposed to Ag NP’s of 4 sizes (20, 30, 90, and 130nm) with
liver, kidney, lungs, and brain, digested for ICP-MS analysis. Our results clearly
showed that, for those NPs that dissolve within 48 hrs, the NP’s with the lower dis-
solution rate (e.g., the smaller Ag NPs produce a greater inflammatory response.
1362 Utility of the Greenscreen™ for Nanoscale Hazard
Assessments: Nanosilver Case Study.
N. A. Linde,  T. L. McGrath,  B. J. Lampe and J. C. English. NSF International,
Ann Arbor, MI.
A project employing GreenScreen™ methodology was undertaken to assess the
chemical hazards of selected manufactured nanomaterials. The GreenScreen™
methodology provides a basis for clear and transparent communication of potential
human health and environmental hazards. It is being adopted by businesses, gov-
ernments, and others seeking to identify safer chemical replacements. The purpose
of the present investigation was to evaluate the utility of the GreenScreen™ for as-
sessing the hazards of nanoscale substances and to recommend changes to the
method to accommodate the properties specific to nanomaterials. An independent
Science Advisory Team was assembled and tasked with providing technical guid-
ance from project onset through ongoing implementation, including the selection
of nanomaterials and identification of reliable data. In the initial stage of the proj-
ect, chemical hazard assessments were undertaken for nanoscale silver and a silica-
silver nanocomposite, AGS-20, used to confer antimicrobial properties to textile
fabrics, thereby inhibiting the growth of odor-causing bacteria in the treated textile.
The scope of each assessment was defined with respect to chemical entities, particle
size and shape, use of ligands, stabilizers or capping agents, and potential transfor-
mation products. Modifications to the GreenScreen™ method and template to ac-
commodate nanomaterial applications were developed and incorporated.
Recognizing that the methodology fundamentally assesses only hazard, not risk,
this exercise demonstrated that a GreenScreen™ assessment of nanoscale materials
can reveal hazard characteristics and concern levels that differ among different
nanoscale forms and conventional forms. The availability of data on adequately
characterized materials and the identification and use of relevant analogs to address
data gaps remains a challenge. Potential confounds in the application of the results
for product comparisons are described. Hazard assessments for several additional
nanoscale materials are planned or underway, to further evaluate the utility and
limitations of this approach.
1363 The Role of Macrophage Scavenger Receptor A in the
Disposition of Silver Nanoparticles.
J. N. Smith1,  M. H. Littke1,  J. A. Klein1,  C. W. Frevert2,  B. D. Thrall1 and
J. G. Pounds1. 1Systems Toxicology, Battelle Memorial Institute, Pacific Northwest
Division, Richland, WA; 2University of Washington, Seattle, WA.
The role of macrophage scavenger receptor A (SR-A) in the disposition and biolog-
ical response of silver nanoparticles was investigated using cellular and animal mod-
els. Bone marrow derived macrophages from wild-type C57BL/6J and SR-A defi-
cient mice were exposed to silver nanoparticles (20 and 110 nm, primary size)
coated with citrate and polyvinylpyrrolidone (PVP). Macrophages from wild-type
mice demonstrated higher rates of silver binding/uptake compared those from SR-
A(-/-) mice (0.5 vs. 0.003 hr-1, respectively), which led to increased levels of cell asso-
ciated silver (~10 fold at 24 hr) after exposure to 20 nm silver nanoparticles meas-
ured by inductively coupled plasma mass spectrometry (ICP-MS). In contrast, no
significant differences in total cell binding/uptake or cytotoxicity with 110 nm sil-
ver particles were observed between wild-type and SR-A(-/-) macrophages. After ad-
ministration of 20 nm particles by oropharyngeal aspiration in vivo, wild-type mice
and SR-A(-/-) mice demonstrated similar silver clearance from lungs, bronchoalveo-
lar lavage (BAL) fluid, and BAL cells (half-life: 15.5 vs. 23.8 d, respectively in
lungs) after 28 d measured by ICP-MS. However, wild-type mice had increased lev-
els of silver in liver (area under the curve [AUC]: 0.06 vs. 0.02 g-1×d, respectively)
and spleen (AUC: 0.16 vs.0.03 g-1×d, respectively) driven by higher silver levels in
liver and spleen at day 7, indicating increased uptake of silver by wild-type mice.
After retro-orbital injection, in vivo biokinetics of silver in wild-type and SR-A(-/-)
mice were very similar. Overall, these results support the conclusion that SR-A
plays a significant role in silver nanoparticle uptake at both the cellular and whole
animal levels, but its role may be size-dependent.
1364 Nanosilver-Induced Lung Inflammation Is Mouse Strain
Dependent.
D. Botta1,  S. C. Schmuck1,  D. K. Scoville1,  C. C. White1,  C. M. Carosino1,
C. M. Schaupp1,  W. C. Griffith1,  E. M. Faustman1,  T. Gordon2 and
T. J. Kavanagh1. 1Department of Environmental and Occupational Health Sciences,
University of Washington, Seattle, WA; 2Department of Environmental Medicine,
New York University, New York, NY.
Silver nanoparticles (NanoAg) have found many uses in electronics, medical diag-
nostics and as microbiocides. While ionic silver (Ag+) is acknowledged to have rel-
atively low toxicity toward mammals, the particulate nature of NanoAg has raised
concerns, especially in the context of potential occupational exposures. Because
human genetic variability can influence susceptibility to many toxicants, we used
multiple inbred mouse strains to determine if genetics could influence NanoAg in-
duced lung toxicity and inflammation. We exposed the Collaborative Cross (CC)
parental mouse strains (C57BL/6J, 129S1/SvJ, A/J, NOD/LtJ, and NZO/HlLtJ)
and 3 wild derived strains (CAST/EiJ, PWK/PhJ, and WSB/EiJ) to citrate-stabi-
lized 20 nm NanoAg at a dose of 0.25 μg/gm BW via oropharyngeal aspiration.
Mice were sacrificed either 1 or 21 days after exposure. Lung injury and inflamma-
tion were assessed by examining total protein and lactate dehydrogenase activity,
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and the presence of leukocytes and inflammatory cytokines in bronchoalveolar
lavage fluid (BALF). One day after exposure, none of the strains exhibited differ-
ences in total protein or LDH activity compared to saline vehicle controls.
However, there were marked strain–dependent differences in lung inflammation,
with C57BL/6 mice showing a 3-6 fold lower response compared to other strains.
Evidence to date indicates that neutrophilic inflammation was attenuated by 21
days, suggesting a transient effect for these nanoparticles. Because C57BL/6 mice
were not very responsive, relying on this strain alone to assess NanoAG-induced in-
flammation may not adequately assess their safety.  This work is done in collabora-
tion with the NCNHIR Consortium and supported by NIH/NIEHS grants
U19ES019545, P30ES07033 and T32ES07032.
1365 Characterization and Toxicity of Silver Nanowires.
A. Tagmount1,  B. Gilbert2,  L. Scanlan1,  C. Tran1,  C. Clark1 and C. Vulpe1.
1Nutrition Science and Toxicology, University of California Berkeley, Berkeley, CA;
2Earth Science Division, LBNL, Berkeley, CA.
Metal and semiconductor nanowires (NW) have a diverse range of anticipated ap-
plications in electrical devices, sensors, catalysts and composite materials but there
is very limited information on the fate of NW in the environment or the effect of
NW on organisms. We are studying the environmental fate and biological toxicity
of silver nanowires (Ag NW), a representative metal NW, to (1) Daphnia magna,
an aquatic eco-indicator and (2) cell lines of different species representing potential
target organs, including a cell line from fathead minnow, another eco-indicator
species. LC50 values were determined in D. magna exposed to Ag NW and differ-
ent end-points of cytotoxicity were investigated using cell based imaging assays
(high content screening) and other cell assays. Transcriptomic response to Ag NW
was also studied in Daphnia and in a macrophage cell line using high throughput
RNA sequencing. We characterized the physicochemical properties of Ag NW to
determine how their chemistry relates to cytoxicity. We studied the colloidal stabil-
ity and oxidation rates of Ag NW with two lengths and two coatings in different
aqueous solutions, including conditions relevant to studies of toxicity to D. magna,
and cell media. While poly(vinylpyrrolidone) (PVP) and aluminosilica (SiO2) coat-
ings prevent NW aggregation in ultrapure water, rates of aggregation and settling
were greatly increased in the presence of dissolved inorganic and ionic ions. In
stirred anaerobic solutions, morphological changes, including fusing of multiple
nanowires, was the dominant transformation. In aerobic solutions, Ag oxidation to
release dissolved Ag+ occurred for all coating types. Rates of Ag+ release cannot ex-
plain observed differences in Ag NW toxicity to Daphnia, suggesting that toxicity is
controlled by a complex mixture of colloidal and chemical processes in solution.
Also, in parallel to this physicochemical study, cell internalization, sub-cellular lo-
calization as well as in situ localization of Ag NW in Daphnia were carried out
1366 Examining Mechanisms of Toxicity and Uptake of Gold
Nanoparticles to Caenorhabditis elegans.
O. Tsyusko1,  J. M. Unrine1,  R. M. Nass2 and B. Collin1. 1Plant and Soil Sciences,
University of Kentucky, Lexington, KY; 2Stark Neuroscience Research Institute,
Indiana University, Indianapolis, IN.
Background: Gold nanoparticles (Au-NPs) have been used in previous studies as a
particle-specific probe in nanotoxicity studies due to their resistance to oxidative
dissolution. Objectives: To examine the particle-specific toxicity of Au-NPs to C. el-
egans using a toxicogenomic approach and to explore possible mechanisms of de-
fense against toxicity of Au-NPs using gfp strains, mutants and RNAi. Methods:
The LC10 of 5.9 mg/L Au-NPs was used for 12hr exposure in microarray experi-
ments using Affymetrix whole genome microarrays. qRT-PCR was used to confirm
results for six selected genes. Selected mutant and gfp C. elegans strains were used
for toxicity testing to Au-NPs. Differences in distribution of Au in endocytosis mu-
tants were examined using synchrotron-based X-ray microfluorescence spec-
troscopy. Results: 797 significantly differentially expressed genes identified from
whole genome microarray analyses were linked to seven common biological path-
ways. Significant up-regulation was observed for 26 pqn/abu genes from non-
canonical unfolded protein response (UPR) pathway and molecular chaperones
(hsp-16.1, hsp-70, hsp-3 and hsp-4). There was significant increase in sensitivity to
Au-NPs in non-canonical UPRs (pqn-5 and abu-11) knockouts. Au-NPs induce
gfp expression of the vesicular GABA transporter homologue in GABA neurons.
Significant up-regulation by Au-NPs of FOXO transcription factor daf-16 was con-
firmed by microarrays and through using daf-16::gfp strains. Differences in distri-
bution of Au among endocytosis mutants (chc-1 and rme-2) and wild type nema-
todes were correlated with differences in toxicity. Conclusions: Our results suggest
possible involvement of genes from endocytosis and UPR pathways in uptake and
detoxification mechanisms, respectively. Au-NPs may also induce stress response
through insulin signaling pathway. Support: US NSF EPA CEINT, University of
KY microarray core Pilot grant.
1367 Mouse Neural Progenitor Cells As a Functional Model for
Developmental Neurotoxicity Testing: Intracellular Calcium
Signaling.
M. M. Dingemans,  M. de Groot and R. H. Westerink. Neurotoxicology Research
Group, Toxicology Division, Institute for Risk Assessment Sciences (IRAS), Faculty of
Veterinary Medicine, Utrecht University, Utrecht, Netherlands.
Developmental neurotoxicity (DNT) is often investigated in a traditional manner
(in vivo using large numbers of experimental animals), while development of in
vitro methods for DNT reduces animal use and increases insight into cellular and
molecular mechanisms of DNT. Neural progenitor cells (NPCs) are particularly
suited for the investigation of neurodevelopmental processes as they are pre-pro-
grammed to differentiate into nervous system-specific cell types: neurons and glia.
The intracellular calcium concentration ([Ca2+]i) plays an essential role
in neurotransmission, plasticity and neurodevelopment and can therefore be used
as a functional readout for DNT [1]. We therefore investigated changes in [Ca2+]i
evoked by a set of neurotransmitters in primary mouse NPCs using the Ca2+-re-
sponsive dye Fura-2. Calcium responses were measured at a single-cell resolution at
various differentiation durations. Calcium responses could be evoked by depolar-
ization, acetylcholine, and adenosine triphosphate (ATP), indicating the expression
and functionality of the respective neurotransmitter receptors and related calcium
signaling pathways.
The data demonstrate that this model allows for the investigation of
possible effects of (suspected) developmental neurotoxicants on the development of
neuronal characteristics, such as intracellular signaling in response to neurotrans-
mitters. As investigation of chemical-induced effects on the development of func-
tional neuronal characteristics is underrepresented in DNT testing, we argue that
biochemical and morphological approaches should be complemented with investi-
gations of neuronal (network) functionality, including network formation, inter-
and intracellular signaling and neuronal network function.
Funding: EU (DENAMIC-FP7282957); ZonMW NL (85300003). 
[1] de Groot et al. Toxicol Sci in press [doi: 10.1093/toxsci/kfs269].
1368 Ketamine-Induced Neuronal Damage and Altered N-methyl-
D-aspartate (NMDA) Receptor Function in Rat Primary
Forebrain Culture.
N. Sadovova1,  F. Liu2,  M. G. Paule2,  W. Slikker3 and C. Wang2. 1Toxicologic
Pathology Associates, Jefferson, AR; 2Division of Neurotoxicology, National Center for
Toxicological Research/US FDA, Jefferson, AR; 3Office of Director, National Center
for Toxicological Research/US FDA, Jefferson, AR.
Ketamine, a noncompetitive NMDA receptor antagonist, is used in pediatric gen-
eral anesthesia and causes neuronal cell death during the brain growth spurt. To un-
derstand the underlying mechanisms associated with ketamine-induced neuronal
toxicity and search for approaches or agents to prevent such adverse effects, a pri-
mary cell culture system was utilized. Neurons harvested from the forebrain of new-
born rats were maintained under control conditions or exposed to either ketamine
(10 μM), or ketamine plus L-carnitine (1, 30 and 100 μM) for 24 hours, followed
by a 24-hour withdrawal period. Ketamine exposure resulted in elevated NMDA
receptor (NR1) expression, increased generation of reactive oxygen species (ROS)
as indicated by higher levels of 8-oxoguanine production, and enhanced neuronal
damage. Co-administration of L-carnitine significantly diminished ROS genera-
tion and provided near complete protection of neurons from ketamine-induced cell
death. NMDA receptors regulate channels that are highly permeable to calcium.
Calcium imaging data demonstrated that neurons exposed to ketamine had a sig-
nificantly elevated influx of calcium and higher intracellular free calcium concen-
trations ([Ca2+]i) evoked by NMDA (50 μM), compared to control neurons.
These findings suggest that prolonged ketamine exposure produces an increase in
NMDA receptor expression (compensatory up-regulation) which allows for a
higher/toxic influx of calcium into neurons once ketamine is removed from the sys-
tem, leading to elevated ROS generation and neuronal cell death. L-carnitine ap-
pears to be a promising agent in preventing ketamine toxic effects on neurons at an
early developmental stage.
1369 L-Carnitine Ameliorates Propofol-Induced Toxicity in Rat
Embryonic Neural Stem Cells.
M. G. Paule1,  F. Liu1,  C. M. Fogle1,  N. Sadovova2,  W. Slikker1 and C. Wang1.
1Division Neurotoxicology, National Center Toxicological Research US FDA, Jefferson,
AR; 2Toxicology Pathology Associates, Inc., National Center Toxicological Research US
FDA, Jefferson, AR.
Propofol is a widely used general anesthetic. A growing body of data suggests that
perinatal exposure to general anesthetics can result in long-term deleterious effects
on brain function. In the developing brain there is evidence that general anesthetics
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can cause cell death, synaptic remodeling, and altered brain cell morphology.
Acetyl-L-carnitine (aLc), an anti-oxidant dietary supplement, has been reported to
prevent neuronal damage from a variety of causes. To evaluate the ability of aLc to
protect against propofol-induced neuronal toxicity, neural stem cells were isolated
from gestational day 14 rat fetuses and on the 8th day in culture were exposed for
24 hr to propofol at 10, 50, 100, 300 and 600 μM, with or without aLc (10 μM).
Markers of cellular proliferation (EdU), mitochondrial health (MTT), cell
death/damage (LDH) and oxidative damage (8-oxo-dG) were monitored to deter-
mine: 1) the effects of propofol on neural stem cell proliferation; 2) the nature of
propofol-induced neurotoxicity; 3) the degree of protection afforded by aLc; and 4)
to provide information regarding possible mechanisms underlying protection. After
propofol exposure at a clinically-relevant concentration (50 μM), the number of di-
viding cells was significantly decreased and oxidative DNA damage was increased.
There was also a significant dose-dependent reduction in mitochondrial health as
evidenced by decreases in MTT metabolism. No significant effect on LDH release
was observed at propofol concentrations up to 100 μM. The oxidative damage at
50 μM propofol was blocked by aLc. Thus, clinically-relevant concentrations of
propofol induce dose-dependent adverse effects on rat embryonic neural stem cells
by slowing or stopping cell division/proliferation and causing cellular damage.
Elevated levels of 8-oxo-dG suggest oxidative damage and aLc effectively blocks at
least some of the toxicity of propofol, presumably by scavenging oxidative species
and/or reducing their production.
1370 Determination of Neurotoxicity in the Developing Rat
Induced by Dexmedetomidine.
J. Liu. Anesthesia, Harvard Medical School, Boston, MA.
Anesthetic, sedative and analgesic drugs are used for diagnostic studies and surgery
procedures in infants and children, but little is known about their impact on the de-
veloping nervous system. Dexmedetomidine is a selective a2-adrenergic agonist,
and has been used many clinical applications including the reduction of postopera-
tive delirium and has many protective effects on cell damage in animal models.
However, dexmedetomidine induced human neutrophil apoptosis by activation of
caspases-3, 7, -8 and -9. Based on these, we hypothesize how dexmedetomidine af-
fects neuroapoptosis in the developing rat brain.
Material and Methods: Sprague-Dawley postnatal day 7 (P7) rat pups were used for
this study. Rats were divided into three doses of 10, 25, and 50 ug/kg body weight
of dexmedetomidine and one control group. Each rat pup received 5 intraperi-
toneal doses of either saline, or Dex at 90 minutes intervals over 6 hours. After the
6 hour treatment period, the animals were deeply anesthetized with pentobarbital
(100 mg/kg, IP). Parts of the brain tissues were extracted and flash frozen in liquid
nitrogen for western blotting analysis. The other parts were fixed in 4%
paraformaldehyde for immunohistochemical assay. Apoptosis such as cleaved-cas-
pase-3, TUNEL, and other protein expression such as GSK-3β were determined by
immunohistochemistry and western blotting assays. 
Results and Conclusion: Dexmedetomidine increased neuroapoptosis by increasing
apoptosis and cleaved caspase-3 expression in the rat brain tissues.
Dexmedetomidine also increased the p-GSK-3β / GSK-3β ratio, indicating a re-
duction in GSK-3β activity. These findings suggest that dexmedetomidine may in-
duce neuroapoptosis by regulating GSK-3β in the developing rat brain.
1371 Nicotine-Induced Toxicity in Rat Embryonic Neural Stem
Cells.
F. Liu1,  N. Sadovova2,  C. M. Fogle1,  M. G. Paule1,  W. Slikker1 and C. Wang1.
1Division of Neurotoxicology, National Center for Toxicological Research NCTR/US
FDA, Jefferson, AR; 2Toxicologic Pathology Associates, Jefferson, AR.
Maternal smoking substantially increases the risk of learning disabilities, behavioral
problems, and attention deficit/hyperactivity disorder in offspring. Nicotine is the
main pharmacologically active component of tobacco smoke. Prenatal exposure to
nicotine is capable of causing fetal brain damage. To evaluate nicotine’s effects on
the developing nervous system and explore potential mechanisms underlying such
toxicity, rat embryonic neural stem cells were used.
Brain cortices were collected from fetal rats (gestational day14, GD14) for neural
stem cell isolation and subsequent culture in commercial rat growth medium. On
the 8th day in vitro (DIV), confluent neural stem cells were exposed to nicotine at
concentrations of 0.5, 1.0, 2.0, 5.0 and 10 μM for 24 hours. Neural stem cells were
identified using monoclonal anti-nestin antibody. Markers of cellular proliferation
(EdU), mitochondrial health (MTT), cell death/damage (LDH) and immunohis-
tochemical staining of activated caspase 3 were monitored to determine the nature
of nicotine-induced neurotoxicity.
Nicotine treatment resulted in a substantial dose-dependent reduction in mito-
chondrial function as evidenced by significant decreases in the metabolism of
MTT. No significant effect of nicotine on LDH release was observed. 1 μM nico-
tine significantly increased the expression of activated caspase 3, suggesting that
nicotine induced neural stem cell apoptosis. 
These results suggest that nicotine decreased neural stem cell viability, and nicotine-
induced cell death is probably apoptotic in nature.
1372 Consequences of Nicotine Exposure on Larval Zebrafish
Circadian Rhythms.
M. E. Wolter and K. R. Svoboda. Joseph J. Zilber, School of Public Health, UWM,
Milwaukee, WI.
Cigarette smokers often report having problems associated with disrupted sleep.
One potential mechanism underlying sleep disruption could be related to alter-
ations in an individual’s circadian rhythm. Nicotine from cigarettes can activate
neuronal nicotinic acetylcholine receptors (nAChRs) throughout the nervous sys-
tem including structures important for maintaining the circadian rhythm. We have
utilized oscillations in larval zebrafish locomotor activity as a model to study circa-
dian rhythms. Initially, the circadian rhythm in embryos reared on a 14/10
light/dark (l/d) cycle was evaluated. Of 257 larvae examined, 76.6% exhibited a
typical rhythm where locomotor activity was high in the initial hours of the cycle,
declined to a minimum, and then became elevated again at the end of the cycle. We
then determined the consequences of raising embryos in constant dark or constant
light conditions from 0-127 hours post fertilization (hpf ) as well as being exposed
to nicotine. At 127 hpf, 23.5% of the larvae reared in constant dark exhibited a typ-
ical circadian rhythm and 12.5% of embryos reared in constant light exhibited a
typical circadian rhythm. Moreover, the locomotor activity of larvae reared in con-
stant light was reduced and remained at a constant level for the duration of the
cycle. Since nAChRs are expressed in the zebrafish pineal gland and retina (two
structures that influence circadian rhythms in fish) early in development, we hy-
pothesized that nicotine exposed fish would have a pattern of activity similar to
those reared in constant light. Zebrafish reared in 15 μM nicotine from 36-96 hpf
and then evaluated at 127 hpf indeed lacked the normal circadian rhythm. The lo-
comotor activity pattern of the nicotine-exposed zebrafish was similar to the pat-
tern of zebrafish reared in constant light; the activity was reduced and remained at
constant level for the duration of the cycle. These results indicate that nicotine is ca-
pable of disrupting vertebrate circadian rhythms and could be involved with the
disrupted sleep pattern of smokers.
1373 Ethanol Pretreated Astrocytes Increase Synapses in
Hippocampal Neurons.
P. J. Roque1,  G. Giordano1,  A. Barria2,  M. Guizzetti3 and L. G. Costa1.
1DEOHS, University of Washington, Seattle, WA; 2Physiology & Biophysics,
University of Washington, Seattle, WA; 3Department of Psychiatry, University of
Illinois, Chicago, IL.
In children exposed to alcohol in utero, problems with learning and memory sug-
gest hippocampal involvement and effects on synapse formation and function.
Astrocytes may contribute to synaptogenesis by releasing specific factors. The pres-
ent study investigated how ethanol influences the ability of astrocytes to modulate
synapse formation in vitro. Using immunocytochemical labeling of synaptic pro-
teins, confocal imaging and 3-dimensional object analysis, we found that astrocytes
pre-treated with ethanol (50 mM) and co-cultured with primary hippocampal neu-
rons (14 days in culture) for 24 hours, induce a 4.5-fold increase in synaptic struc-
ture formation. To corroborate that this is reflected in increased functionality, we
used whole cell patch clamp techniques to measure spontaneous miniature excita-
tory post-synaptic currents. In neurons co-cultured with ethanol pre-treated astro-
cytes, we observed a higher frequency of events, relative to neurons co-cultured
with control astrocytes, suggesting more functional synapses in the ethanol group.
However, a second population of neurons in the same treatment group was ob-
served to have a lower frequency than control astrocytes. No amplitude differences
were observed, suggesting no difference in the number of post-synaptic receptors
between groups. Ethanol increases the efflux of cholesterol-containing lipoproteins
(CCL) from astrocytes, and cholesterol appears to play a role in synapse formation.
Direct treatment of hippocampal neurons with high-density lipoproteins induced a
3.2- fold increase in synaptic structures. When cholesterol release from astrocytes
was induced by LXR/RXR agonists, through the over-expression of cholesterol
transporters, this also resulted in an increase in synapses, suggesting a role for astro-
cytic CCLs in the observed synaptic increase after ethanol pre-treatment
(Supported by F31AA019869, AA008154).
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1374 PCB 95 and IFN-gamma Exert Opposing Effects on
Dendritic Growth in Cultured Rat Sympathetic Neurons.
P. E. Goines and P. J. Lein. Molecular Biosciences, University of California Davis
School of Veterinary Medicine, Davis, CA.
There is credible evidence that environmental factors interact with genetic suscepti-
bilities to determine risk for neurodevelopmental disorders such as autism spectrum
disorders (ASD). PCBs and IFNγ are implicated as environmental risk factors for
ASD. Increased levels of both have been documented in ASD, and both interfere
with neuronal connectivity in central neurons via effects on dendritic growth.
Recent reports indicate that PCBs upregulate inflammatory cytokines, but the
combined effects of these factors on neuronal connectivity have not been explored.
Because of emerging awareness of autonomic dysfunction in ASD, which may link
the triad of behavioral deficits, gastrointestinal disturbances, and immune dysfunc-
tion often observed in ASD, we are quantifying independent and combined effects
of PCB95 and IFNγ on dendritic morphology in cultured sympathetic neurons.
Sympathetic neurons were dissociated from superior cervical ganglia of perinatal rat
pups and grown in serum-free defined medium in the absence of glial cells. Under
these conditions, these neurons do not extend dendrites unless treated with BMP7
(10 ng/ml). After 5 d of exposure to BMPs in the absence of presence of PCBs (1
pM-1 μM) and/or IFNγ (30 ng/ml), cultures were fixed and immunostained for
MAP2b to visualize dendrites. PCB 95 increased the number and length of den-
drites in a concentration-dependent manner in the absence or presence of BMP7
and these effects were inhibited by pharmacological block of ryanodine receptor
calcium channels. IFNγ reduced dendritic growth in PCB 95-treated cultures in the
absence or presence of BMP7. These findings illustrate a novel interaction between
PCBs and cytokines in the autonomic nervous system, and suggest that exposure to
these factors during critical windows of neurodevelopment may interfere with nor-
mal patterns of neuronal connectivity in sympathetic neurons and contribute to
neuronal, immune and GI dysfunction in ASD.  Support provided by NIEHS
(R01 ES014901 to PJL) and a Hartwell Biomedical Research Fellowship (to PEG)
1375 PCB 95 Stimulates Synaptogenesis via Ryanodine Receptor-
Mediated miR132 Upregulation.
H. Chen1,  A. Lesiak2,  M. Zhu2,  S. M. Appleyard2,  S. Impey3,  D. Bruun1,
G. A. Wayman2 and P. J. Lein1. 1Department of Molecular Biosciences, University of
California Davis, Davis, CA; 2Program in Neuroscience, Washington State University,
Pullman, WA; 3Vollum Institute, Oregon Health and Sciences University, Oregon
Health and Sciences University, Portland, OR.
Polychlorinated biphenyls (PCBs) are widespread environmental pollutants linked
to developmental neurotoxicity in children. Recent evidence suggests that non-
dioxin-like (NDL) PCBs interfere with neuronal connectivity via interactions with
ryanodine receptors (RyRs) which are calcium release channels broadly expressed in
the nervous system. NDL PCBs stabilize RyRs in the open configuration and this
triggers a calcium-dependent signaling pathway that mediates activity-dependent
dendritic growth via CREB activation. CREB activation is also linked to increased
formation of dendritic spines and synapses via upregulation of miR132, which sup-
presses the translation of p250GAP, a negative regulator of synaptogenesis. This
suggests the possibility that NDL PCBs modulate these signaling events to influ-
ence synaptogenesis. To test this, we quantified dendritic spine and synapse forma-
tion in primary dissociated hippocampal cultures and organotypic hippocampal
slice cultures treated with PCB 95, a NDL congener with potent activity at the
RyR. Nanomolar concentrations of PCB 95 significantly increased spine density
and the frequency of miniature excitatory post-synaptic currents. These effects were
coincident with upregulation of miR132 and were blocked by inhibiting RyR or
CREB, suppressing miR132 or expressing a mutant p250GAP, translation of which
is not suppressed by miR132. These data demonstrate that PCB 95 sensitization of
the RyR modulates synaptogenesis via activation of a CREB-miR132-p250GAP
signaling pathway, and provide further evidence of mechanisms by which NDL
PCBs may interfere with normal patterns of connectivity in the developing brain.
Supported by NIH grants R01 MH086032, R01 ES014901, P42 ES04699, and
the Hope for Depression Research Foundation.
1376 Developmental PCB 95 Exposure Affects Spatial Memory in
Weanling Mice.
C. Barnhart1,  D. Yang1,  H. Chen1,  L. Qi2 and P. J. Lein1. 1Molecular Biosciences,
University of California Davis, Davis, CA; 2Public Health Sciences, University of
California Davis, Davis, CA.
Polychlorinated biphenyls (PCBs) are ubiquitous environmental contaminants that
have been linked to behavioral deficits in children and experimental animals. We
previously reported that developmental exposure to Aroclor 1254 interferes with
spatial memory in weanling rats coincident with decreased experience-dependent
dendritic plasticity. We hypothesize that non-dioxin-like (NDL) PCBs mediate this
phenomenon via interactions with ryanodine receptor (RyR) Ca2+ channels. To test
this hypothesis, we are comparing the effects of developmental exposure to NDL
PCB 95, a potent RyR sensitizer, on spatial memory in wildtype (WT) versus mice
heterozygous (HET) for the human R163C-RyR1 mutation that enhances sensitiv-
ity to halogenated hydrocarbons. RyR1WT dams were exposed to 0, 0.1, 1, or 6 mg
PCB 95/kg/day in the diet for 2 weeks prior to mating with RyR1HET males, and
throughout gestation and lactation. Offspring were weaned at P21 and trained in
the Morris water maze from P24-P29. Preliminary analyses shows that develop-
mental PCB 95 exposure affects latency, percentage of time (PT) and distance (PD)
in the training quadrant, and average distance to the target (ADT) during training
and these effects are both sex- and genotype-dependent. Within dose groups,
RyRHET weanlings have higher PT and PD and lower ADT than RyRWT littermates
during the probe test. There are no treatment, sex or genotype differences in la-
tency, time in walls, or path length during the visual cue test. There are also no dif-
ferences in dam or pup body weight across experimental groups. These experiments
suggest that developmental exposure to a RyR-active NDL PCB congener alters
spatial learning and memory and the magnitude of this effect is influenced by sex
and by expression of the R163C-RyR1 mutation. This work supported by NIH
(grants R01 ES014901, T32 ES007059 and P42 ES04699) and the ARCS
Foundation.
1377 Optimizing Methods to Quantify CYP1A Enzyme Activity in
Mouse Brain following Developmental PCB Exposure.
A. Ashworth and C. P. Curran. Biological Sciences, Northern Kentucky University,
Highland Heights, KY.
Polychlorinated biphenyls (PCBs) are developmental neurotoxicants and endocrine
disrupters that remain widespread in the human food supply. Children exposed
during gestation and lactation are at highest risk of neurotoxicity. Genetic differ-
ences can influence how these chemicals are metabolized, so we use a mouse model
in an effort to identify genes which affect human susceptibility to developmental
PCB exposure. Coplanar PCBs activate the aryl hydrocarbon receptor (AhR) in
high-affinity Ahrb mice and increase cytochrome P450 (CYP1) expression, includ-
ing CYP1A2 protein which can sequester PCBs in the liver. Our work and the work
of others have shown that this sequestration is protective. However, our previous re-
search also found an increase in CYP1A1 mRNA in the brains of our most suscep-
tible mouse line with the AhrbCyp1a2(-/-) genotype at postnatal day 28 when PCB
tissues levels were highest. Other researchers have reported differential expression
and regulation of CYP1A1 and CYP1A2 in the brain. So, we are now assessing
CYP1A protein levels and activity in various brain regions. We used the EROD
assay as a test for CYP1A1 activity and the MROD assay for CYP1A2 activity. Liver
from PCB-treated AhrbCyp1a2(+/+) was used as a positive control whereas
Cyp1a1(-/-) and Cyp1a2 (-/-) knockout mice served as the respective negative con-
trols. We compared traditional methods used for liver tissue (microsome purifica-
tion) and a modified EROD protocol assay developed for smaller tissue volumes
which uses a whole tissue homogenate. Both methods yielded sufficient protein for
enzyme activity assays in all tissues tested: cortex, cerebellum, and hypothalamus.
We found that 100mM potassium phosphate was an optimal buffer to homogenize
the tissue, compared with 50mM Tris buffer. As expected, we also found higher en-
zyme activity in microsomes compared with whole tissue homogenates.
Confirming previous reports, we also detected significant MROD activity in liver
microsomes from Cyp1a2(-/-) mice, indicating this is a non-specific test for
CYP1A2 activity.
1378 Selective Dieldrin Toxicity to Differentiating Dopaminergic
Neurons.
S. Schildknecht,  B. Zimmer and M. Leist. University of Konstanz, Konstanz,
Germany.
Parkinson’s Disease (PD) is characterized by the selective loss of dopaminergic neu-
rons of the Substantia nigra. Epidemiological observations have suggested a
causative role of environmental pollutants such as heavy metals and pesticides in id-
iopathic forms of PD. Dieldrin is an insecticide for which adverse effects on the
dopaminergic system have been reported. However, the underlying selective neuro-
toxicity is not fully characterized yet. In a model of murine embryonic stem cell-de-
rived neurons, we observed a selective degeneration of dopaminergic neurons while
other types such as GABA neurons, were not affected by dieldrin. Based on these
observations with mixed neuronal types, a human dopaminergic cell line
(LUHMES) was used for all further studies. LUHMES cells are conditionally im-
mortalized human fetal mesencephalic cells that acquire a dopaminergic phenotype
following differentiation for 6 days. Exposure to dieldrin during early differentia-
tion (day 0-2) lead to an inhibition of normal differentiation and ultimately cell
death. The same concentrations of dieldrin (0.5-1 μM) did not show any adverse
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effect when added to fully differentiated LUHMES or other, non-neuronal cell
types. By using an alternative differentiation protocol, LUHMES can be differenti-
ated into neurons without tyrosine hydroxylase (TH), the central enzyme in
dopamine synthesis. When exposed during early differentiation (day 0-2), these
TH-negative cells were less sensitive to dieldrin compared with normally differenti-
ated LUHMES, indicating that components of the dopaminergic phenotype are re-
sponsible for the selective degeneration observed.
1379 Differential Gene Expression in the Neonatal Rat Brain
following Combined Maternal Exposure to Chlorpyrifos and
Nicotine.
T. V. Damodaran1, 2,  J. Bradley2 and M. B. Abou-Donia2. 1Biology, NCCU,
Durham, NC; 2Pharmacology and Cancer Biology, DUMC, Durham, NC.
Environmental exposure to toxic chemicals during early fetal development has been
known to manifest long lasting adverse effects for several decades. We hypothesized
that combined exposures to pesticides used in households and to nicotine in ciga-
rettes may have adverse synergistic outcome in both the mother and developing
fetus. We studied the effects of combined exposure to chlorpyrifos (0.2 mg/kg) and
nicotine (1mg / kg) with appropriate controls on the developing rats. Following
parturition from exposed mothers, the brains of the new born litters were dissected
out to isolate different tissues from the brain. Total RNA from the cerebellum was
isolated and global gene expression analysis was done using cell cycle specific super
arrays from Qiagen, employing standard molecular techniques. Some of the major
findings include the following: A) There were a number of cell cycle genes altered in
various treatment groups. B) cdc25b was significantly up-regulated in nicotine
treatment group, but was down-regulated in both chlorpyrifos and combined treat-
ment groups. C) cdk5 was up-regulated in chlorpyrifos alone and combined treat-
ment groups. D) Up-regulation of p27kit1 and p15ink4b were noted in combined
treatment group and not in nicotine or chlorpyrifos alone groups. This data indi-
cates complex pathways of inhibition and acceleration of cell cycle. Further studies
with those genes identified as biomarkers from this study can be useful for develop-
ing molecular tools for diagnostics and therapeutics for toxicities involving chlor-
pyrifos and nicotine
1380 The Effect of Embryonic Exposure to Deltamethrin on the
Dopaminergic System and Swim Activity in the Zebrafish.
T. S. Kung,  J. Richardson,  K. R. Cooper and L. A. White. Rutgers
University/UMDNJ, New Brunswick, NJ.
Pyrethroids are commonly used insecticides that are generally considered to pose
little risk to human and environmental health. However, there is increasing concern
that children are more susceptible to the adverse effects of pesticides. We developed
the zebrafish model to test the hypothesis that developmental exposure to low doses
of pyrethroid pesticide deltamethrin alters dopaminergic gene expression and leads
to persistent behavioral alterations. Zebrafish embryos were treated with
deltamethrin at doses below the LOAEL (0.25-0.5 μg/L), during the embryonic
period (3-72hpf ) using a static non-renewal water exposure. After 72hpf, embryos
were either harvested for RT-qPCR or reared in pesticide free water until adult-
hood. At 72hpf, deltamethrin treated embryos had significant increased expression
of the dopamine transporter (DAT) and dopamine receptors D1 and D2. We quan-
tified the swim activity of 2-week old zebrafish (larvae) and 1-year old zebrafish
(adults) using the Noldus Ethovision system and observed significant increases in
swim activity in both larvae and male adults that had been developmentally ex-
posed to deltamethrin. To determine if the increased swim activity at the 2-week
stage is mediated by deltamethrin’s effect on dopaminergic system, we treated
deltamethrin exposed and control larvae to methylphenidate, a DAT agonist.
Methylphenidate had a significant stimulating effect on control larvae and a signif-
icant suppressive effect on larvae developmentally exposed to deltamethrin. To fur-
ther investigate the role of the DAT, embryos were injected with a DAT mor-
pholino to transiently reduce mature DAT transcript levels during the
developmental period. DAT knockdown alone results in significant increases in
swim activity at 2-weeks of age which is significantly reduced in deltamethrin
treated embryos. Our data suggest that exposure to deltamethrin during the embry-
onic period results in persistent behavioral changes and is likely due to an interac-
tion between deltamethrin and the dopaminergic system. NIEHS R56ES018863,
T32ES007148, R01ES015991
1381 Dysregulation of Redox Homeostasis by Paraquat in Rat
Developing Brain.
M. Rathinam,  L. Chen,  A. Fowler,  A. Riar,  M. Narasimhan,
L. Mahimainathan and G. I. Henderson. Pharmacology and Neuroscience, Texas
Tech University Health Sciences Center, Lubbock, TX.
Immature brain is susceptible to paraquat (PQ) induced oxidative stress resulting in
neuron damage. We hypothesize that dysregulation of glutathione (GSH) home-
ostasis is a key factor in these neurotoxic responses. To test this, postnatal day 4
(PN4) rat pups were chosen as the period between birth and PN10 includes active
brain development equivalent to that in the human 3rd trimester. Initially, LD50
levels on PN4 were evaluated. Sprague Dawley rat pups were grouped as control,
vehicle control, and PQ was administered (I.P) at 10, 25 and 50 mg/kg. At 24h
post-treatment, declines in viability by 45% and 100% were observed in the 25 and
50 mg/kg PQ groups, respectively. During the 24h period, a decline in motor ac-
tivity was also noticed in these two high dose groups. For subsequent studies the 10
mg/kg dose was used for all time points (2-24 hours). Body weight was unchanged
compared to both controls (p<0.05) Brain PQ levels peaked at 4h (140μg/mg pro-
tein) as assessed by HPLC. In brain, a significant (p<0.05) increase in reactive oxy-
gen levels (ROS) was observed by DCF-DA fluorimetry as early as 6h which per-
sisted to 24h. Increased oxidized form of GSH (GSSG) was observed at all time
points (2, 4, 6, 8 and 24h) while decreased reduced glutathione (GSH) was noted
only at 24h. These changes were reflected in decreased GSH/GSSG ratios with an
associated increase in brain PARP-1 levels (50%) at 24h.These results indicate al-
tered redox homeostasis and DNA damage in PQ exposed brain. The studies have
established a role for oxidative stress in PQ induced neurotoxicity in developing
brain and a model for studying PQ neurodevelopmental toxicity.
1382 Neonatal Bisphenol A (BPA) Exposure Alters Sex-Specific
Estrogen Receptor 2 (ERβ) mRNA Expression in the
Postnatal Rat Brain.
J. Cao,  L. Joyner and H. B. Patisaul. Biology, North Carolina State University,
Raleigh, NC.
Perinatal life is a critical window for sexually dimorphic brain organization, which
is profoundly influenced by endogenous steroids, most notably estrogen. Exposure
to endocrine disrupting compounds may disrupt this process, resulting in compro-
mised reproductive physiology and altered sociosexual behavior in adult life. To test
the hypothesis that Bisphenol A (BPA) exposure specifically confined to the neona-
tal critical period impacts ESR expression through weaning, the present study as-
sessed the impact of exposure (on the first three days of life) to 10 μg estradiol ben-
zoate (EB), 50 μg/kg BPA (LBPA) or 50 mg/kg BPA (HBPA) on ESR2 expression
in the bed nucleus of the stria terminalis (BNST), the paraventricular nucleus
(PVN) and the anterior medial amygdala (MeA) in the postnatal rat brain. In un-
exposed animals, ESR2 expression decreased in the BNST and increased in the
PVN from postnatal day (PND) 0 to 19 in both sexes. Sexually dimorphic ESR2
expression was transient in the neonatal BNST and PVN. EB decreased ESR2 ex-
pression in females in the BNST, and in both sexes in the PVN. In the BNST,
ESR2 expression was decreased in males by LBPA and in females by HBPA on
PND 10. LBPA increased ESR2 expression in females but decreased it in males on
PND 10, thus reversing the sexually dimorphic expression pattern observed in the
vehicle controls. In the MeA, BPA mimicked the EB effect and decreased ESR2 ex-
pression levels on PND 4. Collectively, these data demonstrate that the neonatal
period is vulnerable to BPA exposure, and BPA does not simply mirror the impacts
of EB, but rather, disrupted ESR2 expression in a dose, temporal, and region spe-
cific manner. The functional significance of this altered ESR2 expression may un-
derlie reported disruptions of adult reproductive deficiencies and abrogated sex dif-
ferences in sociosexual behavior across the lifespan. Further work will also be
needed to establish if these effects can be induced via exposures which recapitulate
human exposure conditions and doses.
1383 Effects of Different Endocrine Disruptor Mixtures on Gene
Expression in Neonatal Rat Brain Regions: Focus on
Developing Excitatory Synapses.
W. Lichtensteiger1,  C. Bassetti-Gaille1,  O. Faass1,  J. Boberg2,  S. Christiansen2,
U. Hass2,  A. Kortenkamp3 and M. Schlumpf1. 1GREEN Tox and Institute of
Anatomy, University of Zurich, Zurich, Switzerland; 2National Food Institute,
Technical University of Denmark, Søborg, Denmark; 3Institute for the Environment,
Brunel University, Uxbridge, United Kingdom. Sponsor: T. Slotkin.
Brain development is regulated by sex hormones. In mammals, estradiol is thought
to control male sexual brain differentiation, but recent data also indicate a role for
androgen receptor-mediated mechanisms. Female brain development is dependent
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on estrogens. It is not known how these processes are affected by real-world mix-
tures of endocrine disruptors (EDCs). We investigated effects of a mixture of 13
EDCs (T-Mix) and of mixtures of its estrogenic (E-Mix) and anti-androgenic (A-
Mix) components, administered by oral gavage to rat dams from gestational day 7
until weaning. The mixture ratio was chosen to reflect high end human intakes (S.
Christiansen et al., 2012). At postnatal day 6, during the last part of sexual brain
differentiation, exon microarray analyses were performed in medial preoptic area
(MPO) of both sexes in the highest dose group, and real time RT PCR of selected
mRNA species in MPO and ventromedial hypothalamus (VMH) of all dose
groups. Microarray analyses in MPO revealed sex-specific effects on gene expres-
sion patterns that differed between all three EDC mixtures. Real time RT PCR of
individual mRNA species demonstrated treatment- and sex-dependent differences
between MPO and VMH; effects were dose-dependent. Prominent are effects of all
three EDC mixtures on the expression of genes encoding for proteins involved in
excitatory glutamergic synapse formation and function, including a number of
genes identified as risk factors for autism spectrum disorders. Our study demon-
strates differential responses of the developing brain to different types of EDC mix-
tures and points to excitatory synapse development as a new, potentially relevant
focus. Supported by EU FP7 Framework Programme (CONTAMED).
1384 The Effect of Prenatal Exposure to Amorphous Nanosilica
Particles on Neonatal Memory.
Y. Morishita1,  Y. Yoshioka1,  K. Takao2, 3,  Y. Ago4,  H. Satoh1,  N. Nojiri1,
T. Tanaka1,  K. Takuma4,  T. Yoshida1,  H. Nabeshi5,  T. Yoshikawa1,  S. Tsunoda6,
7,  T. Matsuda4,  T. Miyakawa2, 3,  K. Higashisaka1 and Y. Tsutsumi1, 6, 7.
1Laboratory of Toxicology and Safety Science, Graduate School of Pharmaceutical
Sciences, Osaka University, Suita, Japan; 2Division of Systems Medicine, Institute for
Comprehensive Medical Science, Fujita Health University, Toyoake, Japan; 3Section of
Behavior Patterns, Center for Genetic Analysis of Behavior, National Institute for
Physiological Sciences, Okazaki, Japan; 4Laboratory of Medicinal Pharmacology,
Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Japan;
5National Institute of Health Science, Setagaya-ku, Japan; 6Laboratory of
Biopharmaceutical Research, National Institute of Biomedical Innovation, Ibaraki,
Japan; 7MEI Center, Osaka University, Suita, Japan.
Nanomaterials (NMs) are increasingly being used in various fields for their unique
functions. Therefore, it is important to ensure the safety of NMs to take advantage
of their usefulness. Previously we identified the hazard that intravenous injection of
several NMs to pregnant mice might induce intrauterine growth retardation
(IUGR). IUGR children are known to have high risks of contracting some diseases,
such as neurological disorders. Thus, it is important to assess postnatal effects of
prenatal exposure to NMs. In this study, we examined neonatal memory after in
utero exposure to amorphous nanosilica particles (nSP), as one of the typical NMs.
Pregnant mice were intravenously injected nSP. The body weight of pups were
measured weekly. Working memory, reference memory, and context memory of
pups were measured by eight-arm radial maze test, Barnes maze test, and fear con-
ditioning test. Pups of nSP treated mice (nSP pups) had smaller body weight than
control mice from birth to 30 weeks old. On the other hand, no difference was
found on the scores of memory tests between nSP pups and control mice. These re-
sults suggest that in utero exposure to nSP might result in growth disorder of pups
but have little effect on memory of pups.
1385 Sex-Dependent Impairment of Learning due to Exposure to
Concentrated Ambient Particles.
J. L. Allen,  D. Weston,  K. Conrad,  G. Oberdorster and D. A. Cory-Slechta.
Environmental Medicine, University of Rochester Medical School, Rochester, NY.
Multiple studies link air pollution to impaired cognition in humans and experi-
mental animals. Our study sought to determine the effects of ultrafine (<100nm)
concentrated ambient particles (CAPS) on learning in C57BL6 mice exposed to
CAPS or filtered air for 2 weeks during early postnatal life with and without CAPS
re-exposure as adults. Behavioral testing begun at 2-3 mos of age using a repeated
learning and performance paradigm that housed a series of three response levers
(left, center, right) was located on the front wall of the chamber. During the re-
peated learning component of the paradigm, the required sequence changed with
each session, whereas a constant sequence was used in the performance component.
Both male and female mice showed significant sequence-dependent learning im-
pairments, but no alterations in the performance component, consistent with selec-
tive learning deficits. Postnatal female CAPS-exposed mice showed significant
learning impairment in sequences requiring a right-center-left order, whereas male
adult CAPS-exposed mice were impaired on learning sequences requiring a left-
center-right order.  Assessment of brain pathology in non-behaviorally tested litter-
mates showed CAPS-related evidence of sex and brain-region dependent microglial
activation, astrogliosis, and neurochemical changes even several months post termi-
nation of exposure, the importance of which will be determined by histopathologi-
cal examination and neurochemical analysis of the brains from CAPS-exposed mice
that underwent behavioral testing. Collectively, these findings demonstrate long-
lasting brain and behavioral toxicity in response to CAPS exposures, with impair-
ments on the repeated learning and performance paradigm that are sex-, sequence-
, and exposure period-dependent. They support the need for broader assessment of
the role of CAPS exposure in nervous system diseases and disorders. Supported by
T32ES007026, R21ES019105, P30ES01247.
1386 Effects of Maternal Inhalation of Gasoline Evaporative
Condensates on Sensory Function in Rat Offspring.
L. L. Degn1,  D. F. Lyke1,  T. E. Beasley1,  P. A. Evansky2,  S. A. Martin1,
W. K. Boyes1,  P. J. Bushnell1 and D. W. Herr1. 1TAD/NB, US EPA, Durham, NC;
2EPHD, US EPA, Durham, NC.
In order to assess potential health effects resulting from exposure to ethanol-gaso-
line blend vapors, we previously conducted neurophysiological assessment of sen-
sory function following gestational exposure to 100% ethanol vapor (Herr et al.,
Toxicologist, 2012). For comparison purposes, the current study investigated the
same measures after gestational exposure to 100% gasoline evaporative condensates
(GVC). Pregnant Long-Evans rats were exposed to 0, 3K, 6K, or 9K ppm GVC va-
pors for 6.5 h/day over GD9 – GD20. Sensory evaluations of male offspring began
around PND106. Peripheral nerve function (compound action potentials, NCV),
somatosensory (cortical and cerebellar evoked potentials), auditory (brainstem au-
ditory evoked responses), and visual evoked responses were assessed. Visual func-
tion assessment included pattern elicited visual evoked potentials (VEP), VEP con-
trast sensitivity, and electroretinograms (ERG) recorded from dark-adapted
(scotopic) and light-adapted (photopic) flashes, and UV and green flicker.
Although some minor statistical differences were indicated for auditory and so-
matosensory responses, these changes were not consistently dose- or stimulus inten-
sity-related. Scotopic ERGs had a statistically significant dose-related decrease in
the b-wave implicit time. All other parameters of ERGs and VEPs were unaffected
by treatment. All physiological responses showed changes related to stimulus inten-
sity, and provided an estimate of detectable levels of change. The results show that
gestational exposure to GVC vapors did not result in large decrements in peripheral
nerve, somatosensory, auditory, or visual function when the offspring were assessed
as adults. However, the alterations in ERG b-waves may indicate subtle changes in
retinal function. Additional studies are in progress to evaluate the effects of expo-
sure to the evaporative condensate vapors from a blend of ethanol (15%) and gaso-
line (85%). This is an abstract of a proposed presentation and does not necessarily reflect
EPA policy.
1387 Abnormality in Fear-Related Emotional Function in Mice
Perinatally Exposed to a Low Dose of TCDD.
S. Benner1,  A. Haijima1,  Y. Zhang1,  R. Kobayakawa2,  K. Kobayakawa2,
M. Kakeyama1 and C. Tohyama1. 1Laboratory of Environmental Health Sciences,
Center for Disease Biology and Integrative Medicine, Graduate School of Medicine,
University of Tokyo, Tokyo, Japan; 2Osaka Bioscience Institute, Osaka, Japan.
An increasing trend of prevalence of developmental disorders, psychiatric illnesses
and associated pathological behaviors has been suspected of being induced at least
partly by environmental chemical exposure during development. We have previ-
ously reported the lasting consequences of perinatal exposure to a low dose of
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in brain functions, such as cognitive
and social-emotional defects in mice. Nevertheless, the effects on emotional func-
tion have not yet been clearly defined. The current study thus aimed to examine
whether a perinatal TCDD-exposure at an oral dose of 0.6 μg TCDD/ kg on GD
12.5 in C57BL/6 dams affects emotional function in offspring. Eleven brain re-
gions were microdissected by the punch out technique for determination of the
basal monoamine contents using HPLC-ECD. Behavioral responses toward ac-
quired and innate fear were analyzed using fear conditioning and olfactory-based
fear stress tests. A depression-like behavior was assessed using forced swim test. It
was found that the TCDD-exposure enhanced dopamine level in the ventral
tegmental area and ventral hippocampus. These mesolimbic structures are thought
to regulate behavioral responses toward external stimuli by processing internal in-
formation, such as memory and emotion. A mesolimbic dopaminergic balance is
particularly sensitive to aversive stimuli such as fear. Accordingly, the TCDD-ex-
posed mice exhibited abnormal behavioral responses to both acquired and innate
fear. However, no apparent alterations in the basal serotonin levels were found in
the examined regions. In correlation, no abnormalities associated with serotonergic
emotional behavior emerged under the forced swim test. The present results suggest
that a perinatal low-dose TCDD exposure persistently disrupts dopamine balance
in brain regions involved in regulating fear-related emotion.
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1388 Neonatal Exposure to Perfluorohexane Sulfonate (PFHxS) in
Mice Alters Neuroprotein Levels Essential for the Developing
Brain.
I. Lee and H. Viberg. Environmental Toxicology, Uppsala University, Uppsala,
Sweden.
Perfluorohexane sulfonate (PFHxS) is a perfluorinated compound (PFC) used as an
industrial additive. The chemical properties of PFCs make them suitable as surfac-
tants and oil -and water repellents, and they are frequently used in products for
packaging and as protective coatings. However, the same properties account for
their extreme physico-chemical stability, making them practically non-biodegrad-
able, which has generated a worldwide environmental spread and concern. Since we
recently have seen that other PFCs, like perfluorooctane sulfonate (PFOS) and per-
fluorooctanoic acid (PFOA), can induce developmental neurotoxic effects, the pur-
pose of the present study was to explore if neonatal exposure to PFHxS can affect
specific neuroprotein levels e.g. calcium/calmodulin-dependent kinase II
(CaMKII), growth-associated protein-43 (GAP-43), synaptophysin and tau, in the
mouse brain. Male and female NMRI-mice were exposed, on postnatal day 10, to a
single oral dose of 6.1 or 9.2 mg PFHxS/kg bw and control animals received a 20%
fat emulsion vehicle. The animals were euthanized 24h or 4 months after PFHxS
exposure and the neuroprotein levels in hippocampus and cerebral cortex were ana-
lyzed. 24h after exposure there were significant differences seen in the neuroprotein
levels compared with control and the neurotoxic effects differed between hip-
pocampus and cerebral cortex. Increased levels of CaMKII, synaptophysin and tau
in the hippocampus and decreased levels of GAP-43 in the cerebral cortex were
measured for both sexes. The effects on the protein levels in adult animals were less
pronounced than in the neonates. The results from the present study show that a
single oral exposure to PFHxS during a critical period of brain development can
cause developmental neurotoxic effects. The neurotoxic effects are similar to previ-
ous studies done with other PFCs such as PFOS and PFOA. Further investigations
on the developmental neurotoxic effects of PFHxS are needed as there still is very
limited knowledge about the neurotoxicity of PFCs.
1389 Prenatal Exposure to 1-Bromopropane Changes Basic
Excitability of the Hippocampus and Inhibits the Behaviors
Induced by Kainic Acid and Pentylenetetrazole in the Rat
Offspring during Lactation Period.
Y. Fueta1,  S. Ueno1,  T. Ishidao1,  M. Kanemitsu2 and H. Hori1. 1University of
Occupational and Environmental Health, Kitakyushu, Japan; 2Kyushu Institute of
Technology, Kitakyushu, Japan.
1-Bromopropane (1-BP), a substitute for specific chlorofluorocarbons, is mainly
used for degreasing agents and spray adhesives. 1-BP exhibits central neurotoxicity
in adult humans. Animal studies have shown reproductive/developmental toxicity
as well as neurotoxicity. However, developmental neurotoxicity remains unclear.
We aimed to clarify whether prenatal exposure to 1-BP affects development of neu-
ronal excitability and behaviors in the juvenile offspring. 1-BP was inhalationally
exposed to pregnant Wistar rats from day 1 to 20 (6 h/day) with the concentration
of 0, 400, or 700 ppm. On the days of PND 13, 14 and 15, field potentials were
recorded from the CA1 area of hippocampal slices obtained from the control and 1-
BP groups. At PND14, kainic acid (KA, 0, 0.1, 0.5 and 2.0 mg/kg) or pentylenete-
trazole (PTZ, 60 mg/kg) was injected to the control and 1-BP groups.
Stimulation/response curves of field excitatory postsynaptic potential and those of
population spike (PS) enhanced, and the ratios of paired-pulse responses of PS de-
creased in the 1-BP groups at PND14. PTZ or KA injection to the PND14 off-
spring resulted in a significant inhibition of the drug-induced behaviors in the 1-BP
groups. Our results provide the evidence that prenatal exposure to 1-BP/metabo-
lites affects the central nervous system (CNS) of the offspring during lactation pe-
riod, suggesting developmental modification of neuronal networks and changes in
the excitability of the CNS during the lactation period.
1390 Neonatal Exposure to a Single Low Dose of Ionising
Radiation Causes Persistent Disruptions in Cognitive
Abilities and Increased Levels of Tau in Mice.
S. Buratovic1,  B. Stenerlöw2,  S. Sundell-Bergman3,  A. Fredriksson1,  H. Viberg1
and P. Eriksson1. 1Environmental Toxicology, Organismal Biology, Uppsala, Sweden;
2Radiology, Oncology and Radiation Science, Biomedical Radiation Sciences, Uppsala,
Sweden; 3Soil and Environment, Uppsala, Sweden.
Ionising radiation (IR) is extensively used in the medical field for treatment and di-
agnostics. Concern has been raised about possible negative consequences from low
dose exposure to IR during critical phases of perinatal and/or neonatal brain devel-
opment. The brain growth spurt, which is characterized by maturation of axonal
and dendritic outgrowth, establishment of neural connections and acquisition of
new motor and sensory abilities, occurs perinatally in humans and neonatally in
mice. By using the neonatal mouse as an animal model we are able to study the ef-
fect of IR during early periods of brain development and which consequences it has
for the adult animal.
Neonatal NMRI mice were irradiated (0; 0.35 and 0.5 Gy) at one single occasion
on postnatal day 10. At 2- and 4-months of age, spontaneous behaviour was tested
in a novel home environment and parameters observed were locomotion, rearing
and total activity. Analyses of important neuroproteins in cerebral cortex were per-
formed 24h following irradiation (0 and 0.5 Gy) and at 6-months of age. 
Observations of spontaneous behaviour revealed a significantly deranged behaviour
in 2- and 4-month old mice of both sexes irradiated with 0.35 or 0.5 Gy in a dose
response related manner. The observed reduced activity during the beginning of the
test period and increased activity at the end of the test period indicates a lack of ha-
bituation capacity and disrupted cognitive functions. Neuroprotein analyses of
cerebral cortex 24h after irradiation and at 6-months of age showed a significantly
increased level of tau in mice irradiated with 0.5 Gy compared to controls. This
demonstrates that a single dose of IR, given at a defined critical period during brain
development, is sufficient to cause persistently reduced cognitive functions and in-
creased levels of tau in mice.
1391 CYP1A1_CYP1A2(-/-) Double Knockout Mice Exhibit
Impaired Motor Function.
A. Lang,  H. Garber,  C. Strohmaier,  K. Taylor and C. P. Curran. Biological
Sciences, Northern Kentucky University, Highland Heights, KY.
CYP1A1 and CYP1A2, members of the cytochrome P450 superfamily, are key
detoxifying enzymes normally expressed in the liver. Though they are also report-
edly expressed in the cortex and cerebellum of the brain, their physiological func-
tion in the brain remains unknown. Previous work in our lab uncovered motor
deficits in Cyp1a2(-/-) knockout mice. To confirm those findings, we obtained
Cyp1a1_1a2 (-/-) double knockout mice which had the Cyp1a2 gene deleted using
a different genetic strategy. We compared Cyp1a1_1a2 (-/-) double knockout mice
with wild-type Cyp1a1_Cyp1a2 (+/+) mice using a battery of four behavior tests:
The rotarod test primarily identifies deficits in cerebellar function related to balance
and motor coordination. Gait analysis, adhesive removal, and pole climbing tests
primarily identify impairments in the nigrostriatial pathway, which is a major
dopaminergic pathway related to motor function. We found significant impair-
ments in Cyp1a1_1a2 (-/-) double knockout mice in rotarod testing and adhesive
removal. Male knockouts demonstrated the greatest impairment in adhesive re-
moval compared with females. Interestingly, Cyp1a1_1a2 (-/-) double knockout
mice had shorter latencies in the pole-climbing test. This might be explained by a
difference in motivation or anxiety, because the animals climb down a 50cm pole to
return to their home cage. There were no significant differences in the gait test for
stride length, stride width or stride differential. Together, these data suggest a novel
function for CYP1A2 in brain regions important to normal motor function.
1392 Aryl Hydrocarbon Receptor (AhR) Deletion in Cerebellar
Granule Neuron Precursors Impairs Motor Function and
Neurogenesis.
D. P. Dever,  K. Conrad,  D. A. Cory-Slechta and L. Opanashuk. Environmental
Med, University of Rochester, Rochester, NY.
The AhR is a ligand-activated member of the basic-helix-loop-helix (bHLH)/PER-
ARNT-SIM transcription superfamily that regulates the toxicity of 2,3,7,8- tetra-
chlorodibenzo-p-dioxin (TCDD). Increasing evidence suggests that AhR influ-
ences the development of many tissues, including the central nervous system. In
particular, the AhR has been reported to be involved in regulating critical stages of
neurogenesis. Our previous data suggest that inappropriate and/or sustained AhR
activation by TCDD disrupted granule neuron precursor (GNP) development.
Moreover, studies in AhR knockout mice suggested that GNP maturation was ab-
normal. This study tested the hypothesis that the AhR endogenously controls GNP
maturation in the developing cerebellum. We created a GNP-specific AhR knock-
out mouse (AhRfx/fx/Math1CRE/+) utilizing the Cre-LoxP conditional knockout
strategy, then examined motor function and GNP maturation. GNPs in
AhRfx/fx/Math1CRE/+ exclusively expressed Cre recombinase in the developing
mouse cerebellum and the intrachromosomal recombination of AhR alleles by Cre
recombinase resulted in decreased AhR protein expression. Behavioral studies re-
vealed that AhRfx/fx/Math1CRE/+ mice displayed repetitive motor activity and
abnormal rotarod performance. Additionally, DNA content, a surrogate measure of
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cell number, was reduced at PND10, PND21, and PND60 in
AhRfx/fx/Math1CRE/+ mice compared to controls, suggesting that cell numbers
were diminished. Following AhR excision, there were fewer proliferating GNPs in
the external germinal layer of the cerebellum at PND10, which resulted in a reduc-
tion of granule neurons reaching their final destination in the adult cerebellum.
These results suggest that AhR activity plays a role in regulating granule neuron
number, possibly by promoting GNP cell cycle activity, which ultimately impacts
cerebellar function. These studies will provide novel insights for understanding
mechanisms of dioxin-mediated neurotoxicity in the developing cerebellum.
1393 Assessment of Brain Morphometry Data Using Multivariate
Statistical Analysis Methodology.
W. Miner,  T. J. Vidmar and L. Freshwater. BioSTAT Consultants, Portage, MI.
As required by EPA guidelines, brain morphometry is an area of interest in screen-
ing chemicals for developmental neurotoxicity. Brain morphometry data includes
multiple measurements from the same animal such as brain weight, brain width,
and brain length. These measurements are typically resource intensive and costly
and therefore often made on a small subset of animals. Univariate statistical
methodology (eg. ANOVA) treats these measurements as independent of one an-
other and analyzes each separately. By contrast, using multivariate analysis of vari-
ance, the potential error resulting from conducting multiple univariate tests can be
avoided. Multivariate statistical analysis evaluates all measurements simultaneously,
taking advantage of the correlation between those measurements. In this simulated
study, female brain morphometry data were generated in SAS® using the means,
standard deviations, and correlations between measurements observed in an actual
study. Three dose groups (control, low, and high) were created. The simulation was
designed such that individual brain morphometry components suggested the pres-
ence of dose-related increasing trends. A univariate analysis of variance was per-
formed on each of the components: brain weight, brain width, and brain length.
The univariate analysis showed no significance for any of the three brain measure-
ments at the 5% significance level. Performing a multivariate analysis of variance
yielded an overall significant treatment effect (p < .05). Pairwise comparisons pro-
vided evidence that brain morphometry for both the low and high dose groups was
significantly higher when compared to the control group. In the simulated study,
the univariate analysis of variance fails to detect biologically relevant treatment ef-
fects in brain morphometry measurements. The multivariate analysis, which ad-
dresses the measurements concurrently, identifies statistically significant differences
among the dose groups. These results suggest a multivariate analysis should be used
to analyze brain morphometry data.
1394 Mother’s Environmental Tobacco Smoke Exposure during
Pregnancy and Externalizing Behavior Problems in Children.
J. Liu1,  P. Leung2,  L. McCauley3 and J. Pinto-Martin1. 1School of Nursing,
University of Pennsylvania, Philadelphia, PA; 2Chinese University of Hong Kong,
Hong Kong, China; 3Nell Hodgson School of Nursing, Emory University, Atlanta, GA.
Background: While the impact of active maternal smoking during pregnancy on
child health has been well investigated, the association between maternal passive
smoking, or environmental tobacco smoke (ETS), and behavioral development of
offspring is less clear. This study examines the association between maternal ETS
exposure during pregnancy and child behavior problems. 
Methods: As part of the Jintan China Cohort Study, mother-child pairs (n=646)
were included in the analyses. Maternal ETS exposure at home, the workplace, and
other places during pregnancy was retroactively assessed when children were 5-6
years old. Behavior was assessed via the Child Behavior Checklist when children
were 5-6 years old. Logistic regression models were constructed to examine associa-
tions between maternal exposure to ETS during pregnancy and internalizing and
externalizing behavior problems, adjusting for potential cofounders including child
sex and parental characteristics. 
Results: 37% of mothers reported ETS during pregnancy. Children of mothers ex-
posed to ETS during pregnancy had higher scores for externalizing and total behav-
ior problems with 25% of children whose mothers were exposed to ETS, compared
to 16% of children of unexposed mothers. After adjusting for potential con-
founders, ETS exposure was associated with a higher risk of externalizing behavior
problems in offspring of exposed mothers (OR=2.08, 95% confidence interval [CI]
1.27-3.43). Analysis after multiple imputations and sensitivity analysis further ver-
ified the association, but no dose-response relationship was found. ETS exposure,
however, was not associated with internalizing or total behavior problems. 
Conclusion: This study suggests that maternal ETS exposure during pregnancy
may impact child behavioral development, particularly externalizing behaviors.
1395 Patterns of Clinical Bioindicators in Rat Serum following
Acute Exposure to Pesticides of Different Chemical Classes.
D. W. Herr1,  N. A. Stewart2,  D. F. Lyke1,  K. L. McDaniel1 and V. C. Moser1.
1TAD/NB, US EPA, Durham, NC; 2Contractor, Durham, NC.
There is interest in bioindicators of adverse outcomes in safety assessment and
translational research. Chemically-induced neurological effects may be reflected in
specific neuronal changes and/or by general stress-like responses, and such bioindi-
cators may be useful for measuring health impacts. We examined differential pro-
files of clinical bioindicators after acute treatment (po) with different pesticides
(permethrin, deltamethrin, fipronil, imidacloprid, carbaryl, triadimefon). These
same rats were evaluated for EEG changes (Lyke et al., Toxicologist, 2010, 2011,
2012, 2013). Rats were sacrificed after EEG testing. Serum samples were processed
by Myriad RBM using their RodentMAP® and Rat MetabolicMAP® assays.
Depending on the pesticide, 2-18 of 78 analytes were altered, and each pesticide
produced a different pattern of changes. Discriminant analysis indicated that these
alterations differed in a dose-related manner for each chemical. The data show that
acute exposure to different classes of pesticides produced different patterns of
changes in clinical bioindicators, which may be analyzed for linkages to biological
pathways. This is an abstract of a presentation and does not necessarily reflect EPA pol-
icy.
1396 Acute Triadimefon-Induced Changes in the EEG of Long-
Evans Rats.
D. F. Lyke,  K. L. McDaniel,  V. C. Moser and D. W. Herr. TAD/NB, US EPA,
Durham, NC.
We have reported that the non-stimulus driven EEG is altered differently by acute
treatment with deltamethrin, permethrin, fipronil, or imidacloprid (Lyke and Herr,
Lyke et al., Toxicologist, 2010, 2011, 2012) in non-restrained animals. In the cur-
rent study, we examined the ability to detect changes in EEG activity produced by
triadimefon, a triazole pesticide which inhibits sterol synthesis in fungal cell mem-
branes and inhibits dopamine re-uptake in the mammalian nervous system. Adult
male Long-Evans rats were implanted with epidural screw electrodes. After about 1
week recovery, non-restrained animals were gavaged with corn oil (vehicle) and
tested for 2 days for acclimation. On day 3, the rats were dosed with 1 ml/kg corn
oil, 75, or 150 mg/kg triadimefon and tested 1 h later. EEG was recorded as 30 seg-
ments of 2 s durations, transformed using a Fast Fourier Transformation, and the
spectra averaged. These dosages have increased motor activity in Long-Evans rats in
previous studies. Treatment with 150 mg/kg triadimefon increased the amplitude
associated with Theta activity compared to controls (31% increase), and compared
to 75 mg/kg triadimefon (27% increase), when recorded between the visual cortex
and cerebellum. These results were different from the decreased gamma activity re-
sulting from treatment with fipronil, increased gamma activity following treatment
with permethrin, slightly decreased alpha activity with deltamethrin, and lack of
changes after dosing with imidacloprid. The data show that triadimefon can alter
CNS activity as measured by EEG, and the alterations may differ from some other
pesticides. This is an abstract of a proposed presentation and does not necessarily reflect
EPA policy.
1397 In Vitro Assessment of Parkinsonian Neurodegeneration by
Dinitrophenolic Herbicides in PC12 Cells.
H. J. Heusinkveld1,  A. C. van Vliet1,  P. C. Nijssen2 and R. H. Westerink1.
1Neurotoxicology Research Group, Institute for Risk Assessment Sciences, Faculty of
Veterinary Medicine, Utrecht University, Utrecht, Netherlands; 2Department of
Neurology, Elisabeth Hospital, Tilburg, Netherlands.
Parkinson’s disease (PD) is the most prevalent human neurodegenerative disorder
after Alzheimer’s disease affecting 1-2% of the population over 65 years of age. In
several epidemiologic studies, chronic exposure to environmental pollutants, in
particular pesticides, has been linked to neurodegeneration and the development of
PD, though the underlying mechanisms are largely unknown.
Research directed by neurologist Dr Peter Nijssen encountered PD patients clus-
tered in a remote rural area in the Netherlands, both occupationally and non-occu-
pationally involved in agriculture, with relatively high exposure to pesticides.
Among the pesticides, (dinitrophenolic) herbicides, were identified as common de-
nominator. Since this class of herbicides is known as mitochondrial uncouplers, we
assessed the potential role of dinitrophenolic herbicides in dopaminergic neurode-
generation. 
Using a battery of in vitro tests, including measurements of cell viability, oxidative
stress, single-cell fluorescence calcium imaging and protein analysis, the effects of
dinitrophenolic herbicides on different pathways of neurotoxicity were assessed in
PC12 cells as a model for mature dopaminergic neurons. Our results demonstrate
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that dinitrophenolic herbicides induce moderate cytotoxicity via calcium-depend-
ent activation of caspase-mediated apoptosis as well as activation of key proteins
characteristic for Parkinsonian neurodegeneration in surviving dopaminergic cells.
This leads to the hypothesis that human exposure to dinitrophenolic herbicides
may be linked to the pathophysiology of PD.
Funding: EU (ACROPOLIS, KBBE-245163) and the Dutch “International
Parkinson Fonds” (PAGES).
1398 Protein Cysteine Oxidation and Dopaminergic Cell Death
Induced by Pesticides.
J. Navarro-Yepes1, 2,  L. M. Del Razo1,  R. Franco2 and B. Quintanilla-Vega1.
1Toxicology Department, CINVESTAV-IPN, Mexico City, Mexico; 2Redox Biology
Center, University of Nebraska-Lincoln, Lincoln, NE.
Parkinson’s disease (PD) is characterized by the loss of dopaminergic neurons in the
substantia nigra, which is linked to mitochondrial dysfunction, oxidative stress,
protein aggregation and impairment in protein degradation pathways.
Epidemiological studies suggest that chronic exposure to pesticides is associated
with an increased risk of developing PD. However, the underlying mechanisms
have not been precisely elucidated. Oxidative protein modifications can modulate
the activation of cell death pathways. Thus, we explored the role of oxidative cys-
teine modifications in dopaminergic cell death induced by pesticides. Human neu-
roblastoma cells (SK-N-SH and SH-SY5Y) and the fetal human mesencephalic cell
line (LUHMES, Lund human mesencephalic) were exposed to paraquat (PQ),
rotenone and dieldrin. Compared to neuroblastoma cells, LUHMES cells exhibited
greater sensitivity to all pesticides independent from their differentiation state.
Apoptotic cell death induced by pesticides was paralleled to oxidative stress and a
decrease in glutathione content. Cell death was prevented by glutathione ethyl
ester. PQ induced protein alterations in both sulfenic acid (PSOH) and glu-
tathionylation profiles (PSSG). Mass spectrometry of immunoprecipitated
PSOH/PSSG proteins identified several proteins from the ubiquitin/proteosome
degradation system and molecular chaperones as being modified by PSOH and
PSSG in response to PQ, including E3 ubiquitin-protein ligases (SIAH1, TRIM13,
RNF25, RNF139, HERC2, BRE1B), ubiquitin hydrolases (USP47, USP24),
ubiquitin conjugating enzymes (UBE20), and Hsp40 co-chaperones (DNAJB4,
DNAJC11). The expression of the protein DNAJC11 was down-regulated in a
concentration dependent manner by PQ. Results suggest a role for protein cysteine
oxidation (sulfenylation and/or glutathionylation) in the regulation of the ubiqui-
tin/proteosome and chaperone-mediated folding systems in response to pesticide
exposure. Supported by CONACYT-Mexico (Grant #104316).
1399 Aldehyde Dehydrogenase Dysfunction Increases Parkinson’s
Disease Risk via Gene-Environment Interactions.
A. G. Fitzmaurice1, 2,  S. L. Rhodes3,  M. Cockburn4,  B. Ritz3 and
J. M. Bronstein1, 2, 5. 1Neurology, David Geffen School of Medicine at University of
California Los Angeles, Los Angeles, CA; 2Molecular Toxicology, University of
California Los Angeles, Los Angeles, CA; 3Epidemiology, University of California Los
Angeles Fielding School of Public Health, Los Angeles, CA; 4Preventive Medicine, Keck
School of Medicine of University of California Los Angeles, Los Angeles, CA; 5Greater
Los Angeles Veterans Administration Medical Center, Los Angeles, CA.
Parkinson’s disease (PD) is a neurodegenerative disorder characterized by the loss of
dopaminergic neurons in the substantia nigra. We recently reported that exposure
to the fungicide benomyl resulted in dopaminergic neuronal loss, aldehyde dehy-
drogenase (ALDH) inhibition, and an epidemiologic association with increased PD
occurrence. Since the dopamine metabolite 3,4-dihydroxyphenylacetaldehyde (i.e.,
DOPAL) is highly toxic and an ALDH substrate, ALDH inhibition might con-
tribute to the particular vulnerability of dopaminergic neurons. To investigate the
potential relevance of this mechanism, we developed a novel ex vivo neuronal assay
to screen pesticides for ALDH inhibitory activity. All dithiocarbamates tested (e.g.,
mancozeb, maneb, ziram), two dicarboxymides (captan, folpet), and two imida-
zoles (benomyl, triflumizole) inhibited ALDH activity, potentially via metabolic
byproducts (e.g., carbon disulfide, thiophosgene). We developed a geographic in-
formation system method employing state-mandated commercial pesticide use re-
ports to estimate patient exposures to specific pesticides from 1974-1999.
Exposures to ALDH-inhibiting pesticides (i.e., from the screen) were associated
with dose-dependent twofold to fourfold increases in PD risk. Patients were geno-
typed for variation in the mitochondrial ALDH2 gene, and haplotypic analyses of
six single nucleotide polymorphisms revealed that ALDH2 variation potentiated
PD risk for people working where ALDH-inhibiting pesticides were sprayed liber-
ally. This ALDH model for PD etiology might help explain the selective vulnerabil-
ity of dopaminergic neurons in PD and provide a potential new mechanism
through which environmental toxicants contribute to PD pathogenesis.
1400 Pesticide-Linked Parkinson’s Disease: Using Drosophila to
Build a Novel In Vivo Model of Paraquat, Maneb and Ziram
Exposure.
C. A. Martin1,  A. Barajas2 and D. Krantz1, 2. 1Molecular Toxicology, University of
California Los Angeles, Los Angeles, CA; 2Neurobiology, University of California Los
Angeles, Los Angeles, CA.
The vast majority of Parkinson’s disease (PD) cases are sporadic and environmental
exposure to pesticides have long been suspected to contribute to PD development,
though the disease etiology remains poorly understood. Recently, epidemiological
data has supported this and revealed that individual exposures to the pesticides
ziram, maneb, and paraquat increase PD risk. Interestingly, it appears that these
pesticides interact synergistically and exposure to all three pesticides increases PD
risk up to three-fold. We are using the model organism Drosophila melanogaster to
study the connection between pesticide exposures and the neuronal dysfunction
and dopaminergic cell loss characteristic of PD. We find that combined, but not in-
dividual, chronic exposures to maneb and paraquat leads to significant dopaminer-
gic neuron loss. To understand how neuronal dysfunction may contribute to a PD
phenotype, we complement this approach by utilizing the Drosophila neuromuscu-
lar junction. This powerful tool has allowed us to explore the way pesticide expo-
sures may more subtly affect neuronal physiology and behavior in an intact synapse.
We report that ziram exposure significantly alters synaptic vesicle fusion and reup-
take, processes that are essential for proper neuronal signaling. Ziram has been
shown to inhibit the E1 ligase, which is required for targeting proteins to the pro-
teasome for degradation. We find that inhibiting the proteasome increases synaptic
vesicle fusion in a similar manner to ziram, implying a shared mechanism of action.
However, it remains unclear if it is ziram’s inhibition of E1 itself or ziram’s down-
stream effect on the proteasome that is responsible for this synaptic phenotype.
Ongoing investigations are exploring these possible neurotoxic mechanisms of ac-
tion and may help elucidate the interrelationship between ziram, neuronal dysfunc-
tion, and early neurotoxic mechanisms that could initiate a PD phenotype.
1401 High i.p. Doses of Paraquat Do Not Result in a Loss of
Dopaminergic Neurones in the Substantia Nigra of the
Mouse.
M. Butt3,  P. Botham1,  C. Breckenridge2,  L. Smith1,  N. Sturgess1 and J. Wolf4.
1Syngenta, Bracknell, United Kingdom; 2Syngenta, Greensboro, NC; 3Tox Path
Specialists, Frederick, MD; 4EPL, Sterling, VA.
A number of publications have reported that the i.p. administration of paraquat
(PQ) to rodents (normally male C57Bl6J mice; up to 3 x10 mg/kg) results in a loss
of dopaminergic neurones from the substantia nigra pars compacta (SNpc), which
is the primary area of neuropathological damage in Parkinson’s disease (PD). We
have conducted studies in the male C57Bl6J mouse examining the effect of high
i.p. doses (up to the maximum tolerated dose of 3 x 25 mg/kg) of PQ looking not
only for neuronal cell loss, but also for evidence of striatal neurochemical changes
and pathological changes using stains to detect disintegrating neurones and neu-
ronal processes and the expected astrocyte/microglial activation in response to neu-
ronal cell damage. Mice were administered paraquat dichloride on 1, 2 or 3 occa-
sions (separated by one week) at doses of 10, 15 or 25 mg/kg. A relatively low dose
of N-1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP; 10 mg/kg adminis-
tered i.p. 4 times in a single day at 2 hr intervals) was dosed to a separate group as a
positive control. Studies were conducted to GLP and assessment of toxicological
endpoints was by individuals blinded to treatment group. No consistent stereologi-
cal evidence for a loss of tyrosine hydroxylase positive (TH+) dopaminergic neu-
rones in the SNpc was observed in the PQ treated mice. PQ did not alter the con-
centration of striatal dopamine or its metabolites. Over a range of time points
(4-168 hrs post-dose), there was no evidence of PQ-induced neuronal degeneration
in the SNpc, degenerating processes in the striatum or apoptotic cell death; astro-
cytes and microglia were not activated. In the MPTP treated mice the number of
TH+ dopaminergic neurones in the SNpc was reduced, striatal dopamine was re-
duced and significant pathological changes, including necrotic neurones and astro-
cyte/microglial activation in the SNpc, were consistently observed. These results
bring into question the use of PQ mouse studies as a robust model for PD/ parkin-
sonism.
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1402 Repeated Exposure to Paraquat Affects the Neural Behavior
in Male C57BL/6 Mice.
D. Lou1,  Q. Zhao2,  M. Huang3, 1 and Z. Zhou1. 1Department of Occupational
Health Sciences and Toxicology, Fudan University, Shanghai, China; 2Center of
Disease Control in Minhang District, Shanghai, China; 3Department of
Environmental and Occupational Health Sciences, Ningxia Medical University,
Yinchuang, China.
Epidemiological studies have revealed that neural degenerative diseases such as
Parkinson disease are typically influenced by genetic and environmental factors,
while little is known about the environmental factors. The broad application of
paraquat (PQ) has given rise to wide public concern on its potential to damage the
nigrostriatal dopaminergic (DA) system because its chemical structure closely re-
sembles that of the well-known DA neural toxicant MPP+. We used male C57BL/6
mice (aged 8 weeks and weight 20 ± 2g) to examine the effects of PQ oral exposure
on neural behavior. The Society’s criteria for the care and use of laboratory animals
were used for all the experiments in this study. After treated with normal saline (ve-
hicle) and PQ (5mg/kg, 10 mg/kg or 20mg/kg) daily for 30 consecutive days, no
significant differences in the body weight gain as well as the brain coefficient were
observed among different dose groups. The transmission electron microscope
showed that the subcellular structures of DA neurons were impaired when exposed
to the high dose of PQ. The Open Field test revealed reduced locomoter activity
and exploratory drive with the increase of PQ concentrations. Cognitive assess-
ments were conducted in all the groups of mice via Morris Water Maze, no statisti-
cally significant difference among treatment groups was shown in the avoidance la-
tency, although a trend toward less learning can be observed. On probe trial,
PQ-treated mice did show a significant preference for the correct quadrant.
Together, the functional observational battery showed treatment-related, but not
necessarily dose-related changes in the mice’s reactivity and activity. Thus, we pro-
posed that repeated exposure to PQ can induce neurochemical and persistent neu-
robehavioral changes.
(Supported by NSFC81072324)
1403 Protective Effect of Edaravone Pretreatment against
Mancozeb Cytotoxicity in Rat Hippocampal Astrocytes.
L. D. Trombetta and N. Ruparel. Pharmaceutical Sciences, St. John’s University,
Queens, NY.
Mancozeb [manganese-zinc ethylenebis(dithiocarbamate)] is a polymeric dithiocar-
bamate fungicide that has been used commercially for decades. A number of stud-
ies have shown this agent to cause neurotoxicity that is linked to oxidative stress.
The purpose of this experiment was to study the protective effects of edaravone (3-
Methyl-1-phenyl-2-pyrazoline-5-one) on rat hippocampal astrocytes after man-
cozeb insult. Edaravone has been demonstrated to be a free radial scavenger and in-
hibits cerebral edema and infarction after brain ischemia. Rat hippocampal
astrocytes maintained in Dulbecco’s modified Eagle’s medium with 10% FBS were
exposed to a range of concentrations of Mn-Zn dithiocarbamate for one hour at
37°C. Viabilities 23hrs post-treatment with 4uM, 8uM, 16uM, and 24uM doses
were 94%, 82%, 34%, and 20%, respectively. The LC50 was found to be 14.7 uM.
For further experiments, treatment with 12uM mancozeb was chosen. Cells pre-
treated with edaravone (10uM, 80uM, 160 uM, 320uM) for 24 hours, and then
treated with 12uM mancozeb for 1 hour showed significant increases in viability at
all doses of edaravone. The 320uM pretreatment of edaravone increased the viabil-
ity by 63.7% when compared to the group treated with 12μM mancozeb alone.
GSH studies showed that 12uM mancozeb treatment for 1 hr. decreased the
GSH/GSSG ratio by 45.87%, however, when astrocytes were pretreated with
320μM Edaravone the GSH/GSSG ratio was significantly different from the group
with mancozeb alone with a decrease of 36.84%. Edaravone pretreatment was
shown to be protective against mancozeb cytotoxicity and this protection may in-
volve a reduction in oxidative stress.
1404 Role of Alpha-Synuclein and Its Mutants on
Dithiocarbamates Cytotoxicity.
A. Stoll and S. Cheng. Science, John Jay College of Criminal Justice, New York, NY.
Mn-containing dithiocarbamates, such as maneb (MB) and mancozeb (MZ), often
seen in the agricultural industry, have been known to increase the toxicity of neuro-
toxin MPTP on dopaminergic neurons, which can lead to cell death and
Parkinson-like symptoms. Dopamine transporter (DAT) is a key protein in
MPTP’s toxicity by transporting the active metabolite (MPP+) into dopaminergic
neurons; increasing the cell surface expression of DAT raises the uptake of MPTP.
Alpha-synuclein, a protein that interacts with the dopamine transport, can regulate
DAT trafficking and the DAT cell surface expression. Alpha-synuclein (wt) and its
mutants (A30P and A53T) have been associated with Parkinson’s disease. 
The aim of this study is elucidate the role of the alpha-synuclein and its mutants on
dithiocarbamate cytotoxicity. HEK 293 cells transfected with DAT and either
alpha-synuclein or its mutants were treated with dithiocarbamates for 1hour. Cell
lysates from these treated groups and the control group, treated with phosphate
buffered saline (PBS), were used for co-immunoprecipitation using anti-DAT anti-
body. The co-immunoprecipitated proteins were subjected to Western blot analysis,
probed with alpha-synuclein and DAT antibodies. The integrated density values
(IDV) of the alpha-synuclein were normalized to the IDV of the DAT. The PBS
control was taken as 1.
We report roughly a 30% decrease in the DAT/alpha-synuclein interaction in the
presence of the A53T mutant versus wild-type, but not in the presence of the A30P
mutant. With dithiocarbamates, the interaction of DAT and alpha-synuclein (wt)
was enhanced, with increases ranging from 50% to 200%. Cells transfected with
A53T mutants respond to pesticides more dramatically than cells transfected with
A30P mutants in increasing the interaction between the DAT and the alpha-synu-
clein.
1405 The Role of RTP801 in Maneb and Mancozeb-Induced
Cytotoxicity.
S. Cheng,  C. Ta,  A. A. Calderone and S. Oh. Sciecnes, John Jay College of
Criminal Justice, New York, NY.
Environmental factors, such as pesticide exposure, have been implicated in the
pathogenesis of neurodegenerative diseases such as Parkinson’s disease (PD).
Manganese (Mn)-containing ethylene-bis-dithiocarbamate compounds, maneb
(MB) and mancozeb (MZ) have been extensively used for pesticides over the past
50 years. Exposure to MB lowers the threshold for dopaminergic damage triggered
by MPTP, which is a human Parkinson’s disease inducing neurotoxin. Preliminary
data from Cheng’s lab demonstrate that MB and MZ enhance 1-methyl-4-
phenylpyridium (MPP+)-induced cell death in rat pheochromocytoma (PC12)
cells. However, the neurotoxic molecular mechanisms and the signal transduction
pathways involved in the action of these dithiocarbamate toxins in PD are still not
clear. Neuron death, regardless of initiating causes, generally requires proapoptotic
gene activation. Studies showed RTP801 is dramatically increased by oxidative
stresses. A sequential mechanism (induction of RTP801, suppression of mTOR sig-
naling, and then depletion of phosphorylated/activated Akt) has been suggested to
be the mechanism of neurotoxins-induced cell death. In this study we observed no
change in RTP801 protein expression after 4 h diethyldithiocarbamate (DDC) and
MB treatments. But for MZ, RTP801 was twice the PBS control. After 8 h treat-
ment, all chemicals showed significant increase of RTP801 protein expression
(about 3 to 4 fold). This observation proved that the RTP801 protein expression
has been regulated by Manganese (Mn)-containing ethylene-bis-dithiocarbamate
compounds. Then, the transcriptional activation was studied by real time RT-PCR
for 2 h, 4 h, and 8 h treatments. At 2 h, the transcription of RTP801 was increased
for MB and MZ (2 and 3.5 fold), but not very significant for DDC. At 2 h, the
transcription appeared the highest comparing to other time periods, and gradually
decreased at 4 h and 8h. This observation showed that the up-regulation of
RTP801 is due to the increase in RTP801 mRNA transcript. RTP801 shRNA will
be used to further confirm the involvement of RTP801 in MB and MZ induced cy-
totoxicity.
1406 Nrf2 Protects Hippocampus against Oxidative Stress Caused
by Maneb.
D. Kurzatkowski and L. D. Trombetta. Pharmaceutical Sciences, St. John’s
University, Queens, NY.
Maneb is an ethylene(bis)dithiocarbamate fungicide that has been used to treat dis-
eases of vegetables, fruits, and field crops. This study investigated the neurotoxic ef-
fects of maneb on the hippocampus of C57BL/Nrf2 (-/-; knockout) and
C57BL/Nrf2 (+/+; WT) mice. The mechanism by which maneb exerts its neuro-
toxicity is unclear; however, a number of effects have been observed both in vitro
and in vivo, which suggest a link between exposure to maneb and an increase in ox-
idative stress. Genes that are regulated by the ARE help control the redox status of
the cell and protect it against oxidative injury. The Nrf2-ARE pathway can be
found in most tissue types and is responsible for the control of expression of many
genes that are involved in the protection of cells such as γ-GCS light subunit, per-
oxiredoxin, glutathione peroxidase, glutathione reductase, superoxide dismutase,
and heme-oxygenase 1. The activation of Nrf2 has been linked to neural cell pro-
tection against numerous toxicants; therefore, Nrf2-/- mice treated with pro-oxi-
dants such as maneb would be expected to show increased neurologic damage.
Animals were injected I.P., twice a week for 30 days, at 0, 15, 30 and 60 mg of
maneb/kg body weight. Levels of TBARS were not increased in hippocampal tissue
in Nrf2+/+ animals at any dose of maneb but were significantly increased in the
Nrf2-/- animals at the 30 and 60 mg dose. The TUNEL technique demonstrated
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the presence of positive cells in the hippocampus of Nrf2-/- mice treated with 60
mg/kg maneb. Of 84 antioxidant pathway genes included in an oxidative stress and
antioxidant defense array, qPCR demonstrated that the only gene mediated by the
Nrf2 transcription pathway significantly modulated by at least 1.5-fold was glu-
tathione peroxidase 4 (GPX4). This enzyme was significantly upregulated in
Nrf2+/+ mice treated with 30 mg/kg maneb and significantly downregulated in
Nrf2 -/- mice treated with the same concentration. It was concluded that maneb ex-
posure causes oxidative stress mediated by the Nrf2 pathway and that GPX4 plays
an important role in this protection.
1407 Neurotoxicity of the Dithiocarbamate Fungicide Ziram Is
Dependent on Synuclein in Zebrafish: Implications for
Parkinson’s Disease.
A. Lulla1, 2,  L. Barnhill1, 2,  M. Stahl2,  A. G. Fitzmaurice1, 2,  S. Li2 and
J. M. Bronstein2, 1. 1Toxicology, University of California Los Angeles, Los Angeles,
CA; 2Neurology, University of California Los Angeles, Los Angeles, CA.
Parkinson’s disease (PD) is a neurodegenerative disorder characterized by dopamin-
ergic (DA) neuronal death and α-synuclein (α-syn) accumulation. Epidemiological
studies reveal that exposure to the dithiocarbamate fungicide ziram is associated
with increased risk of PD. We have previously found that ziram causes selective tox-
icity to DA neurons, ubiquitin proteasome system (UPS) inhibition, and α-syn ac-
cumulation in primary neuronal cultures. Here, we use developing zebrafish (ZF,
Danio rerio) embryos as an in vivo model to investigate mechanisms of ziram toxi-
city and its dependence on endogenous synuclein.
ZF embryos exposed to environmentally relevant of ziram were deformed, had al-
tered swimming behavior, and premature death with a LD50 of approx. 50 nM at
7 days post fertilization (dpf ). Transgenic ZF expressing green fluorescent protein
(GFP) driven by vesicular monoamine transporter protein (VMAT) were used to
identify aminergic neurons in zf embryos. Ziram exposure (50nM) resulted in a
35% reduction in VMAT-GFP-expressing neurons in anterior DA clusters and
26% reduction in posterior clusters (noradrenergic) but was not toxic to non-DA
sensory neurons. 
ZF express 3 synucleins similar to mammalian β and γ synucleins. Overexpression
of ZF γ1-syn in neurons led to ZF-syn aggregates and neuronal death in a similar
manner as overexpression of human α-syn. ZF embryos exposed to ziram also
showed accumulation and aggregation of endogenous ZF γ1-syn. This accumula-
tion appears to confer some of ziram’s neurotoxicity since knockdown of ZF γ1-syn
expression improved survival. Furthermore, treatment with CLR01, a molecular
tweezer that mitigates α-syn toxicity, also attenuated ziram toxicity. The mecha-
nism/s by which ziram increases ZF γ1-syn appear to involve inhibition of protein
degradation since ziram at concentrations as low as 10 nM inhibited the UPS in ZF
embryos. These studies add further insight into the mechanism of pesticide neuro-
toxicity relevant to the risk of PD.
1408 Linking Developmental Atrazine Exposure in Zebrafish to
Long-Term Neurotransmission Alterations.
C. Xiao,  G. J. Weber,  S. E. Watson,  J. L. Freeman and J. R. Cannon. School of
Health Sciences, Purdue University, West Lafayette, IN.
Atrazine is an agricultural herbicide widely used to prevent pre- and post-emer-
gence of broadleaf and grassy weeds in major crops. It is a major environmental
contaminant, commonly present in potable water supplies. Recent work has sug-
gested that atrazine exposure may affect behavior and neurotransmitter systems in
rodents. However, rodent studies have typically utilized exposures many magni-
tudes above environmentally relevant levels and produced conflicting data. The role
of early-life exposures in the development of late-life neurodegenerative diseases has
recently received much attention. In an effort to assess the immediate and late-life
effects of atrazine on neurological function, zebrafish embryos were exposed to en-
vironmentally relevant doses of atrazine (0, 0.3, 3,30ppb) from 1-72 hours post fer-
tilization. Following the developmental exposure, larvae were changed to atrazine-
free water and allowed to mature under normal conditions to assess lifespan
impacts. Neurotransmitter levels were assessed using HPLC with electrochemical
detection. Adult female zebrafish (9 months) exhibited statistically significant de-
creases in 5-hydroxyindoleacetic acid (5-HIAA), the primary metabolite of sero-
tonin, as well as a reduction in 5-HIAA/serotonin turnover. Interestingly, larvae
evaluated at 7 days post fertilization did not show significant alterations in neuro-
transmitters levels, indicating that deficits arise over time, many months after the
initial exposure. In addition, microarrays performed on adult female brain tissue re-
vealed alterations in genes that are enriched in neurological, psychological and de-
velopmental diseases. Thus, after short-term atrazine exposure during development,
persistent neurotransmitter disruptions are observed, indicating long-term disrup-
tion of brain function. Future experiments are focused on elucidating mechanisms
of neurologic dysfunction and neurodegeneration elicited by toxicant exposure dur-
ing critical development stages.
1409 Effects of the Long-Term Coexposure to the Herbicide
Atrazine and Inorganic Arsenic (IAs) in the Nigrostriatal
Dopaminergic System of the Albine Rat.
U. Bardullas,  M. Giordano and V. Rodríguez. Departamento de Neurobiología
Conductual y Cognitiva, Instituto de Neurobiología, Universidad Nacional Autonoma
de Mexico, Queretaro, Mexico.
The herbicide atrazine (ATR) and the metalloid arsenic (As) are substances widely
distributed in the environment. In recent years interest has growth regarding the
toxicity of these substances on the nigrostriatal dopaminergic system. To date, no
study has evaluated the effects of chronic and simultaneous exposure to ATR and
As, substances that may share the same neuronal target. In order to study the effects
of the coexposure As+ATR, six groups of rats were given atrazine (10 mg ATR/kg),
arsenic (0.5 or 50 mg As/L of drinking water) or their combinations (ATR+0.5 mg
As/L or ATR+50 mg As/L) daily for one year. Behavioral tests showed hypoactivity
in the 50 mg As/L group, and hyperactivity in the ATR group. All treatments de-
creased motor coordination. Striatal DA content was significantly reduced in ATR,
0.5 mg As/L, ATR+0.5 mg As/L and ATR+50 mg As/L groups, compared to con-
trols. The number of mesencephalic TH+ cells was significantly reduced in ATR
and ATR+0.5 mg As/L groups, compared to controls. Furthermore, the assessment
of cell integrity in the substantia nigra showed decreases in cytochrome oxidase re-
activity in all treatment groups, but no changes in malondialdehyde immunoreac-
tivity. In summary, the nigrostriatal dopaminergic system appears to be a target for
the toxic effects of As and ATR. Our results indicate that when combined, ATR +
As act independently, and ATR has more severe effects on dopaminergic neurons.
We appreciate the technical assistance of Biol. Soledad Mendoza. This work was
sponsored by PAPIIT 214608-19 and CONACYT 60662, 103907 and 152842.
1410 Glyphosate Treatment Suggests Offspring and Reproductive
Toxicity in Caenorhabditis elegans.
R. Negga,  M. B. Johnson,  K. A. McVey,  I. B. Snapp and V. A. Fitsanakis.
Biology, King College, Bristol, TN.
Herbicides are widely used in both agricultural and residential areas; therefore, pes-
ticide users, as well as family members, may be routinely exposed to these poten-
tially harmful chemicals. Epidemiological studies have shown pesticide exposure
may lead to decreased fetus viability in exposed versus non-exposed females. A sig-
nificant gap in the literature exists as to whether these observations are applicable to
exposures of glyphosate-containing herbicides. To further examine this question,
we utilized the model organism, Caenorhabditis elegans, to test our hypothesis that
exposure to the glyphosate-containing herbicide, TouchDown (TD), results in de-
creased numbers of offspring in wild-type (N2) worms. Furthermore, this exposure
could render surviving offspring more susceptible to neurodegeneration. Based on
concentrations (LC50 and LC75) from previous data, eggs were removed from
gravid adults and chronically (24 hours) exposed to TD. The numbers of hatched
offspring were counted to determine whether TD adversely affected embryo viabil-
ity. One-way ANOVA indicated a statistically significant decrease (p < 0.05) in the
number of hatched eggs from treated compared to control worms. Our second
study was designed to determine whether eggs exposed to TD would result in gen-
eral neuronal degeneration. Eggs from NW1229 worms (a green fluorescent pro-
tein (GFP)::neuron construct) were treated as described. Data suggested potential
neuronal degeneration in treated worms compared to control (p < 0.05), as deter-
mined by fluorescence photomicrograph analysis. Lastly, we chronically exposed
eggs from strain CL2166 (GFP::glutathione-S-transferase) to varying concentra-
tions of TD. Fluorescence between control and treated groups, however, did not
vary, suggesting that large increases in oxidative stress are not responsible for the ob-
served changes in the nervous system. Taken together, these results suggest that TD
decreases the number of viable offspring in the nematode, and that neurodegenera-
tion may be present in those that survive.
1411 Effects of the Subchronic Exposure to the Herbicide
Glyphosate on Behavior and the Nigrostriatal and
Mesolimbic Dopaminergic Areas of the Albine Rat.
I. Hernandez-Plata1,  M. Diaz-Muñoz2,  M. Giordano1 and V. M. Rodriguez1.
1Neurobiologia Conductual y Cognitiva, Instituto de Neurobiologia, Queretaro,
Mexico; 2Neurobiologia Celular y Molecular, Instituto de Neurobiologia, Queretaro,
Mexico.
Glyphosate (Glyph) is the active ingredient of several herbicide formulations widely
used to eliminate weeds. Although it has been described that the Glyph formula-
tions are slightly toxic for mammals, reports of human exposure and studies using
animal models suggest that Glyph formulations may be neurotoxic. In order to
evaluate the effects of Glyph on the nervous system, male Sprague-Dawley rats re-
ceived six i.p injections of 50, 100 or 150 mg Glyph/kg or saline (n=10) during 2
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weeks (3 injections/week). We recorded locomotor activity 15 min before and 3 h
immediately after each injection. Also, the locomotor activity was recorded during
24 h, 16 days after the last injection. The subchronic exposure to Glyph caused de-
creases in locomotor activity immediately after each injection, as well as 48 h after
the Glyph injection. This hypoactivity was maintained until the 16th day post-
treatment. We did not detect changes neither in monoamine concentrations nor in
the levels of TH in NAcc or STR at 2 and 16 days after the last Glyph injection.
However, specific binding to D1 dopamine receptors in NAcc decreased dose-de-
pendently when measured 48-h after the last Glyph injection. These results indicate
that subchronic exposure to Glyph has acute as well as long-term effects on loco-
motor activity, and that these effects may be related to a decrement in specific bind-
ing to D1 dopamine receptors in NAcc. We thank Soledad Mendoza for her tech-
nical assistance.Supported by CONACYT 60662, 152842 and 103907 and
PAPIIT grants 214608-19 and 211709-21; IHP received a fellowship from
CONACYT 164300.
1412 Relationship between Administered Dose, Target Tissue
Levels and Thermoregulatory Response Alterations after
Acute Oral Exposure to the Potent Tremor-Inducing
Pyrethroid Bifenthrin in Rats.
M. Mosquera-Ortega1,  A. Pato3,  C. Sosa-Holt3,  A. Ridolfi2,  M. J. Wolansky1
and E. Villaamil Lepori2. 1Biological Chemistry, IQUIBICEN (CONICET);
University of Buenos Aires, Buenos Aires, Argentina; 2Toxicology, Pharmacy and
Biochemistry, University of Buenos Aires, Buenos Aires, Argentina; 3Biological
Chemistry, University of Buenos Aires, Buenos Aires, Argentina.
In toxicological studies, potency estimates for pyrethroid insecticides (PYRs) in rats
may depend on the exposure and testing conditions. This experimental factor may
challenge present efforts to reconsider the health risks posed to humans by exposure
to PYRs. We are using exposure-dose-effect studies to explore the influence of the
testing conditions on the qualitative toxicological classification of, and relative po-
tencies for, these insecticides. Four PYRs (tefluthrin, bifenthrin [BIF],
deltamethrin, alpha-cypermethrin) are evaluated in Wistar adult rats. Body temper-
ature is measured using microchip-like transponders implanted in rat backs 5-7
days before testing. Subcutaneous temperature (T-SC) is then monitored by ra-
diotelemetry at 30 min intervals for 5 h after oral dosing of PYRs in corn oil. Basal
T-SC is recorded before the test day, and 30 min before dosing (i.e., physiological
T-SC). The maximal difference in T-SC compared to the pre-dosing baseline (i.e.,
ΔT-max) is here used as a measure of peak response. Soon after the thermoregula-
tion assay, target tissues are dissected out. Blood, liver and brain (striatum, cortex,
cerebellum) are collected at 6 h post-dosing for posterior determination of PYR
residues using a SPE-GC-ECD protocol. Results for BIF are shown in this first
presentation. 0, 0.5, 3, 9 and 12 mg BIF/Kg (N=4-8) produced dosage-related in-
creases in temperature and ΔT. Dose-related increases in both BIF levels in target
tissues and ΔT-max were observed. R-squared values were +0.6 in all pairwise rela-
tionships. These results are mostly consistent with previous BIF studies carried out
using motor activity and rectal temperature as endpoints (Wolansky et al., 2006,
2007), and a toxicokinetic study (Scollon et al., 2011).
1413 Interactions of a Promoter/Potentiator of Neuropathy and
Esterases of Membrane and Soluble Fractions of Brain.
I. Mangas,  J. Estévez and E. Vilanova. Unit of Toxicology and Chemical Safety
Institute of Bioengineering, University Miguel Hernández, Elche, Spain.
Phenylmetyl sulfonyl fluoride (PMSF) is a protease and esterase inhibitor causing
protection or potentiation/promotion of the organophosphorus induced delayed
neuropathy if dosed before or after the organophosphate inducer. The molecular
target/s of potentiation/promotion has not yet been elucidated. The analysis of the
kinetic of inhibition of PMSF on chicken brain esterases (using a kinetic model
which considers the spontaneous hydrolysis of inhibitor) allowed to discriminate
the following esterase components: In soluble fraction, a resistant component Eα
(28%) and two sensitive components, Eβ (61%) and Ey(11%) with I50(20 min) of
70 and 447 μM; in membrane fraction two resistant components EPα and EPδ
(14%) and two sensitive, EPβ (41%) and EPγ(44%) with I50 (20 min) of 138 and
23μM. The enzymatic components discriminated correspond to the previously ob-
served in experiments with mipafox and paraoxon in these fractions. Eα becomes
6-fold more resistant to mipafox after the pre-incubation with 5 μM PMSF and 50-
fold with 4000μM PMSF. Eγ becomes totally resistant after pre-incubation with
10μM PMSF or more and it becomes resistant to PMSF after pre-incubation with
20nM mipafox. However none of the membrane esterases changed their sensitivity.
The data suggest that these effects might be due to an irreversible interaction of
PMSF and mipafox at sites other than the substrate catalytic center. Such interac-
tions should be considered to interpret the potentiation/promotion phenomenon
of PMSF and to understand the effects of multiple exposures to chemicals.
1414 In Vitro Inhibition and Aging of Neuropathy Target Esterase
(NTE) Caused by Fenamiphos and Acephate.
G. L. Emerick,  L. S. Fernandes,  N. G. Santos and A. C. Santos. Departamento de
Análises Clínicas, Toxicológicas e Bromatológicas, Universidade de São Paulo, Ribeirão
Preto, Brazil.
Organophosphorus-induced delayed neuropathy (OPIDN) is a neurodegenerative
disorder characterized by ataxia progressing to paralysis with concomitant central
and peripheral distal axonopathy. Symptoms of OPIDN in people include tingling
of the hands and feet. These symptoms appear about 8–14 days after exposure. One
of the criteria for acceptance of organophosphates pesticides (OPs) in Brazil is if the
compound does not cause OPIDN. Guidelines for evaluating OPIDN require the
observation of dosed animals over several days and the sacrifice of at least 48 hens.
Adhering to these protocols in tests with analytical standards of OPs is difficult be-
cause large quantities of the compound are needed and many animals must be sac-
rificed. Thus, developing an in vitro screening protocol to evaluate if the OP is able
to induce or not delayed neuropathy is important. This study aimed to evaluate in
SH-SY5Y human neuroblastoma cell culture samples the potential of some OPs,
which are widely used in Brazil, in induce delayed neurotoxicity. The relations be-
tween the inhibition and aging of neuropathy target esterase (NTE) by the fe-
namiphos and acephate were evaluated as indicator of the compound ability to in-
duce OPIDN. Mipafox was used as inducer of OPIDN and paraoxon was used as
non-inducer. The compounds were diluted in ethanol and the cells were incubated
with the OPs for 24 hours in a 96-well microplate. Paraoxon exhibited an in-
hibitory concentration of 50% of enzyme activity (IC50) value approximately 47
times greater than that of the mipafox. Fenamiphos and acephate exhibited IC50
values 117 and 124 times, respectively, greater than that of the mipafox in the SH-
SY5Y human neuroblastoma cells. Considering the esterases inhibition and aging
results, fenamiphos and acephate would not be expected to have a great ability to
induce OPIDN in humans compared with the ability of mipafox. Financial sup-
port: Fapesp grant # 2012/00168-6.
1415 Inhibition and Aging of Neuropathy Target Esterase (NTE)
in SH-SY5Y Human Neuroblastoma Cells As Screening for
Inducers of Delayed Neuropathy.
L. S. Fernandes,  G. L. Emerick,  N. G. Santos and A. C. Santos. DACTB,
Universidade de São Paulo, Ribeirão Preto, Brazil.
Organophosphorus-induced delayed neuropathy (OPIDN) is characterized by a
central-peripheral distal axonopathy and Wallerian-type degeneration that develops
8–14 days after poisoning by a neuropathic organophosphate (OP). The current
Organisation for Economic Co-operation and Development (OECD) guidelines
for evaluating organophosphorus-induced delayed neuropathy (OPIDN) require
the observation of dosed animals over several days and the sacrifice of at least 48
hens. Adhering to these protocols in tests with analytical standards of OPs is diffi-
cult because large quantities of the compound are needed and many animals must
be sacrificed. Thus, developing an in vitro screening protocol to evaluate if the OP
is able to induce or not delayed neuropathy is important. This study aimed to eval-
uate in SH-SY5Y human neuroblastoma cell culture samples the potential of some
OPs, which are most utilized in Brazil, in induce delayed neurotoxicity. The rela-
tion between the inhibition and aging of neuropathy target esterase (NTE) by the
trichlorfon was evaluated as a possible indicator of the compound ability to induce
OPIDN. Mipafox was used as inducer of OPIDN and paraoxon was used as non-
inducer. The compounds were diluted in ethanol and the cells were incubated with
the OPs for 24 hours. Paraoxon exhibited an inhibitory concentration of 50% of
enzyme activity (IC50) value approximately 47 times greater than that of the mi-
pafox. Trichlorfon exhibited an IC50 value 48 times greater than that of the mi-
pafox in the SH-SY5Y human neuroblastoma cells. Considering the esterases inhi-
bition and aging results, trichlorfon would not be expected to have a great ability to
induce OPIDN in humans compared with the ability of mipafox.
1416 Use of a Human Haploid Cell-Based Loss of Functional
Genetic Screening Model to Identify Human Susceptibility
Genes for Chlorpyrifos Toxicity.
A. Dubois,  J. R. Olson and X. Ren. Pharmacology & Toxicology, University at
Buffalo, The State University of New York, Buffalo, NY.
Chlorpyrifos (CPF), one of the most widely used organophosphorous pesticides,
has been known to cause neurotoxicity through the inhibition of cholinesterase ac-
tivity. However, other neurobehavioral deficits, unrelated to cholinesterase inhibi-
tion, have been linked to chlorpyrifos exposure. The mechanisms behind these ef-
fects are not fully known or understood. High-throughput loss-of–function genetic
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screening tools in yeast or other non-mammalian model systems have been success-
fully used to study human susceptibility to chemical exposure and decipher chemi-
cal compounds mode of action. We recently obtained a newly developed human
haploid cell based loss of functional genetic screening model and adopted this hap-
loid cell model in our laboratory. We treated the cells with 200 μM CPF, a dose
causing 30% death of haploid cells after 3 days of treatment. After 21-days of treat-
ment, we were able to identify cells carrying genes with deficient functions that play
a role in the resistance to CPF-induced toxicity. We are currently conducting func-
tional tests to validate their association with CPF toxicity. Ultimately, this approach
will help identify novel susceptibility genes and gain insight into potential mecha-
nisms of CPF-induced toxicity. (This work was supported by Startup funds to X.R.
provide by SUNY Buffalo).
1417 Pharmacological Modulation of Endocannabinoid Signaling
Differentially Affects Acute Toxicity of Paraoxon and
Chlorpyrifos Oxon in Rats.
J. Liu and C. Pope. Physiological Sciences, Oklahoma State University, Stillwater,
OK.
Organophophorus anticholinesterases (OPs) elicit acute toxicity by inhibiting
acetylcholinesterase, increasing acetylcholine levels at cholinergic synapses through-
out the nervous system. This leads to excessive/prolonged activation of cholinergic
receptors and resulting signs of toxicity including increased parasympathetically-
mediated secretions (SLUD signs) and involuntary movements (e.g., tremors).
Endocannabinoids (eCBs, e.g., anandamide [AEA] and 2-arachidonoyl glycerol [2-
AG]) are released from membrane lipids upon neuronal activation. AEA, 2-AG and
potentially other putative eCBs can regulate neurotransmission by activating presy-
naptic CB1 receptors to inhibit neurotransmitter release. We hypothesized that
pharmacological modulation of eCB signaling will influence the expression of anti-
cholinesterase toxicity. The comparative effects of WIN 55,212-2 (WIN, a CB1 re-
ceptor agonist, 1.5 or 5 mg/kg), AM251 (a CB1 receptor antagonist, 3 mg/kg),
URB597 (an inhibitor of AEA degradation, 3 mg/kg) and capsazepine (a TRPV1
endovanilloid antagonist, 10 mg/kg) on the toxicity of paraoxon (PO) and chlor-
pyrifos oxon (CPO) were evaluated. Involuntary movements were induced by both
OPs in a dose-related manner (PO: 0.4,0.5,0.6 mg/kg, sc; CPO: 8,10,12 mg/kg,
sc), whereas somewhat less consistent dose-related effects were noted with SLUD
signs. WIN partially reduced signs of toxicity following PO exposure, but had little
effect on toxicity following CPO. The CB1 receptor antagonist AM251 had no ef-
fect on CPO toxicity, but substantially increased lethality following PO exposure
(6/12 vs 1/9). URB597 had no effect on PO toxicity, or on involuntary movements
following CPO, but increased SLUD signs following CPO. Similar to effects of
URB597, capsazepine had little effect on PO toxicity, but increased SLUD signs
following CPO. These results suggest that pharmacological modulation of eCB
and/or endovanilloid signaling may differentially influence selected toxic responses
to anticholinesterases in an OP-related manner. (Supported by NIEHS
R01ES009119).
1418 Hippocampal Changes Induced by Noncholinergic
Diisopropylfluorophosphate (DFP) Exposure in Fischer 344
Rat Brain.
D. A. Mahle1,  A. Soto1,  V. T. Chan1 and N. V. Reo2. 1711 HPW/RHDJ, Wright-
Patterson AFB, OH; 2Wright State University, Fairborn, OH.
The mechanism of organophosphate (OP) induced inhibition of acetyl-
cholinesterase and subsequent excitotoxicity is well described. However, exposure
to OPs at non-cholinergic doses has been reported to cause deficits in cognitive be-
havior and spatial memory, though little is known about the mechanisms of action.
Here an integrated approach using both metabolomic and transcriptomic tech-
niques was used to reveal some of the non-cholinergic effects of DFP in rat hip-
pocampus.  Adult male Fischer 344 rats were administered 1 mg/kg DFP or saline
(control) via subcutaneous injection at 10 mL/kg. Time points for hippocampal
collection were 0.5, 1, 2, 12, 24 and 48 hr post dose. AChE activity reached a min-
imum of 55% at 2 hr post dose.  Total RNA was isolated from hippocampus for
differential gene expression analysis using the Affymetrix 1.0 ST gene array at 1 hr
post dose. Lipid and aqueous extracts were prepared from each hippocampus at 2
hr post dose, and profiles of small molecule metabolites, lipids and phospholipids
were measured using multinuclear NMR spectroscopy. The amino acids valine,
isoleucine and alanine were increased 4-5 fold, while cis-aconitate and fumarate
were increased 2-3 fold after exposure to DFP. Succinate and γ-aminobutyric acid
(GABA) were decreased approximately 57%.  No change was detected in any of the
lipid metabolites measured.  Differential gene expression and pathway analysis re-
vealed that the I-kappaB/NF-kappaB and the Wnt signaling pathways were down-
regulated. By evaluating the impact of low level OP exposure on the metabolic and
transcriptomic profile of the hippocampus, we hope to gain a greater understanding
of the noncholinergic mechanisms of action and sensitive target areas of OPs.
1419 Dose-Dependent Behavioral Deficits in Egyptian
Agricultural Workers with Chronic Organophosphorus
Pesticide (OP) Exposures.
W. K. Anger1,  F. M. Farahat2,  P. J. Lein3,  J. R. Olson4,  M. Lasarev1 and
D. Rohlman1. 1Oregon Health & Science University, Portland, OR; 2Menoufia
University, Shebin Elkom, Egypt; 3University of California Davis, Davis, CA;
4University at Buffalo, Buffalo, NY.
Chronic exposure to OPs is consistently associated with deficits on neurobehavioral
tests in workers using pesticides. While years of work have correlated with degree of
effect in a few studies, a dose-effect relationship has not been identified, leading
some to doubt the association. We identified a population of pesticide application
teams in Egypt primarily exposed to one OP, chlorpyrifos (CPF). Teams include en-
gineers (who do not typically enter the fields during applications), technicians (who
walk side-by-side with the applicators in the fields), and applicators (who are typi-
cally seasonal workers and have the highest exposures). TCPy levels in urine con-
firmed the pattern of lower to higher exposures across these job categories.
Trailmaking, a test of complex visual scanning, motor speed and agility, consists of
two test components, A and B that differ in complexity. The test was administered
to 54 engineers, 59 technicians, 31 applicators, and 150 controls 3 times during the
OP application season and 1.5 months after applications had ended. While time to
complete Trailmaking A and B improved across sessions, a consistent dose-response
relationship was seen in performance speed: Controls had the best (fastest) per-
formance throughout the application season on Trailmaking A (p< 0.04) and B (p<
0.001). Applicators had slower performance than engineers (p=0.015) and techni-
cians (p=0.032) on Trailmaking A. On the more complex Trailmaking B test, appli-
cators and technicians had comparable performance that was significantly slower
(p=0.003 and p=0.012 respectively) than performance of engineers. Test perform-
ance at 1.5 months after applications ended revealed that differences between the
groups were persistent. Ongoing studies are evaluating relationships between neu-
robehavioral performance and genetic polymorphisms of enzymes that metabolize
CPF. (NIH R01 ES016308; MPI: WKA & PJL)
1420 Chlorpyrifos Exposure and Self-Reported Neurological
Symptoms in Adolescent Pesticide Applicators.
D. Rohlman1,  K. Khan1,  A. A. Ismail2,  G. Abdel Rasoul2,  M. R. Bonner3,
M. R. Lasarev1,  A. L. Crane4,  S. T. Singleton4 and J. R. Olson3, 4. 1Occupational
and Environmental Health, University of Iowa, Iowa City, IA; 2Community Medicine
& Public Health, Menoufia University, Shebin El-Kom, Egypt; 3Social & Preventive
Medicine, State University of New York at Buffalo, Buffalo, NY; 4Pharmacology &
Toxicology, State University of New York at Buffalo, Buffalo, NY.
Although studies with adults have demonstrated associations between organophos-
phorus (OP) pesticide exposure and neurological symptoms, the change in symp-
tom reporting across an application season and the relationship between symptoms
and biomarkers of exposure is poorly understood and few studies have examined
adolescents. The prevalence of neurological symptoms across the chlorpyrifos
(CPF)-application season was examined in adolescent pesticide applicators (n=57)
and environmentally exposed adolescents (n=38) in Egypt. Self-reported symptom
data at 32 time points over a 7-month CPF-application season were collected.
Associations of symptoms with the urine CPF biomarker, trichloro-2-pyridinol
(TCPy) and blood cholinesterase inhibition were also investigated. Increased re-
porting of neurological symptoms were observed among both applicators and non-
applicators after several weeks of repeated exposure. Applicators demonstrated a
greater percentage of neurological symptoms relative to baseline than the non-ap-
plicators at all subsequent time intervals. Cumulative TCPy, an estimate of overall
seasonal exposure, was positively associated with average percentage of symptoms
only among the applicators in the adjusted models. No associations were found be-
tween acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibition
and self-reported symptoms after accounting for covariates. Results of the study
demonstrate that adolescent applicators and non-applicators experience a greater
percentage of neurological symptoms due to repeated exposure. Reduction of CPF
exposure among the adolescent applicators should be a public health priority since
neurological symptoms remained elevated even after the cessation of CPF applica-
tion. Supported by NIEHS ES017223.
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1421 Differential Antagonism of Tetramethylenedisulfotetramine-
Induced Seizures by Agents Acting at NMDA and GABAA
Receptors.
M. Shakarjian1, 2,  J. Velíšková3, 4, 6,  P. Stanton3, 6 and L. Velíšek3, 5, 6.
1Environmental Health Science, New York Medical College, Valhalla, NY; 2Medicine,
UMDNJ-RWJMS, Piscataway, NJ; 3Cell Biology & Anatomy, New York Medical
College, Valhalla, NY; 4Obstetrics & Gynecology, New York Medical College, Valhalla,
NY; 5Pediatrics, New York Medical College, Valhalla, NY; 6Neurology, New York
Medical College, Valhalla, NY. Sponsor: D. Heck.
Tetramethylenedisulfotetramine (TMDT) is a highly lethal neuroactive rodenticide
responsible for many accidental and intentional poisonings in mainland China.
Ease of synthesis, water solubility, potency, and difficulty to treat make TMDT a
potential terrorist weapon. We characterized TMDT-induced seizures and mortal-
ity in male C57BL/6 mice. TMDT (ip) produced a syndrome of twitches, clonic,
and tonic-clonic seizures decreasing in onset latency and increasing in severity with
increasing dose; 0.4 mg/kg was 100% lethal. The NMDA antagonist, ketamine
(KET, 35 mg/kg) injected ip after the first TMDT-induced seizure, did not reduce
lethality, but increased the number of clonic seizures. Doubling the KET dose de-
creased tonic-clonic seizures and eliminated lethality through a 60 min observation
period. Treating mice with another NMDA antagonist, MK-801, 0.5 or 1 mg/kg
ip, showed similar effects as low and high doses of KET, respectively, and prevented
lethality, converting continuous (status epilepticus ) EEG activity to isolated inter-
ictal discharges. Treatment with these agents 15 min prior to TMDT administra-
tion did not increase their effectiveness. Post-treatment with diazepam (5 mg/kg;
GABAA allosteric enhancer) reduced seizure manifestations and prevented lethality
60 min post-TMDT, but ictal events were evident in EEG recordings and, hours
post-treatment, mice experienced status epilepticus and died. Thus, TMDT is a
highly potent and lethal convulsant for which single-dose benzodiazepine treat-
ment is inadequate in managing EEG seizures or lethality. Repeated benzodiazepine
dosing or combined application of benzodiazepines and NMDA receptor antago-
nists are more likely to be effective in treating TMDT poisoning. Supported by
NIH NS056093, NS072966, NS044421, DOD PR100634P1 & NYMC
1422 Postexposure Administration of Diazepam Blocks TETS-
Induced Tonic Seizures and Death but Does Not Prevent
Neuroinflammation.
D. Bruun1,  S. Vito2,  B. Inceoglu2,  B. D. Hammock2 and P. J. Lein1. 1VM
Molecular Bioscience, University of California Davis, Davis, CA; 2Entomology,
University of California Davis, Davis, CA.
Tetramethylenedisulfotetramine (TETS) is a potent convulsant rodenticide that is
considered a credible chemical threat agent. There is no approved therapy for TETS
poisoning, although clinical reports suggest that generally-used anticonvulsants, in-
cluding diazepam, keep patients alive when administered soon after exposure. Our
goal was to identify the therapeutic window for diazepam when administered after
TETS exposure, and to determine whether post-exposure administration of di-
azepam would attenuate the delayed neuroinflammation associated with acute
TETS intoxication. In adult male mice administered a lethal dose of TETS (0.15
mg/kg, i.p.), a relatively high dose of diazepam (5 mg/kg, i.p.) blocked tonic
seizures and death when administered3 min after the second clonic seizure (approx-
imately 20 min after TETS injection). Administration of diazepam at later times
did not significantly reduce tonic seizures and death relative to TETS-exposed ani-
mals that did not receive diazepam. However, animals protected by diazepam from
tonic seizures and death still exhibited significant and persistent region- and time-
dependent activation of astrocytes and microglia, as determined by GFAP and Iba-
1 immunoreactivity and microglia morphology. Thus, we next determined whether
combined administration of diazepam with an anti-inflammatory agent would mit-
igate post-TETS neuroinflammatory responses. Inhibition of soluble epoxide hy-
drolase (sEH) has been shown to exert potent anti-inflammatory effects. Combined
administration of diazepam and the sEH inhibitor 1709 (1 mg/kg, i.p. every 24 h
after TETS injection) significantly decreased microglial activation but enhanced as-
trocyte activation. While the functional significance of this combined treatment has
yet to be determined, these data suggest that combinatorial therapy may be neces-
sary to mitigate long-term neurological sequelae of acute TETS intoxication.
Support provided by the NIH NINDS CounterAct Program (R21 NS072094 and
U54 NS079202).
1423 THC-Mediated Immunosuppression Leads to Decreased Th1
Response to Allogeneic Cells by Triggering Induction of
MDSCs.
J. M. Sido,  M. Nagarkatti and P. Nagarkatti. Pathology, Immunology &
Microbiology, University of South Carolina School of Medicine, Columbia, SC.
Host versus graft disease (HvGD) is a model for transplant rejection, wherein the
recipient mounts an immunological response to donor cells causing T-cell driven
destruction of the graft. The host immune response involves activation of T-cells,
up-regulation of Th1 cytokines, and cellular proliferation in lymphoid organs. Δ-9-
Tetrahydrocannabinol (THC) is a cannabinoid (CB) associated with anti-inflam-
matory and immunosuppressive properties, and is a known ligand for CB receptors
1 and 2 (CB1 and CB2). Our lab recently published that administration of THC
recruits myeloid derived suppressor cells (MDSCs) which are innate regulatory
cells, CD11b+Gr1+ in mice, that have been shown to reduce inflammation. To this
end, we used THC (20mg/kg) pretreatment to ameliorate HvGD in C57BL/6
mice administered C3H/HeJ splenocytes (2.2x107 cells). Our studies show that
THC treatment was able to reduce clinical symptoms of HvGD dependent on the
presence of the CB1 receptor. THC-treated mice had significantly reduced lym-
phoid organ proliferation, Th1 cytokine levels, and T-cell activation. Using CB
knockout mice as well as antagonists, we found that THC treatment was unable to
reduce HvGD in the absence of CB1 receptor. Furthermore, THC treatment led to
induction of MDSC resulting in a microenvironment that allowed graft cells to
persist without eliciting graft versus host disease. The mechanism of CB1-depend-
ent THC-mediated reduction in T cell proliferation and in Th1-mediated inflam-
mation by induction of MDSCs, suggests a novel role for THC to induce a state of
homeostasis that results in elevated host immunosuppression and reduced toxicity
associated with transplantation (Support in part by NIH P01AT003961,
R01AT006888, R01ES019313, R01MH094755, P20RR032684 and VA Merit
Award BX001357).
1424 Mechanistic Comparison of Asbestos-Associated
Autoantibodies.
K. Serve,  A. Santin and J. Pfau. Biological Sciences, Idaho State University,
Pocatello, ID.
Chrysotile and amphibole asbestos are structurally distinct silicate fibers that cause
a range of respiratory tract diseases, though Libby amphibole (LA) exposure is asso-
ciated with diffuse pleural fibrosis and chrysotile with localized pleural plaquing.
LA-associated disease seems to progress more rapidly, suggesting additional factors
in disease manifestation. Examination of serum antibodies revealed mesothelial cell
autoantibodies (MCAAs) in both LA and chrysotile exposed subjects. However,
MCAA presence was significantly correlated with pleural disease only in LA ex-
posed subjects, suggesting a role of MCAAs in driving pleural fibrosis on-set and/or
progression. We hypothesized that LA and chrysotile associated MCAAs interact
with mesothelial cells in mechanistically distinct ways, resulting in the different dis-
ease phenotypes observed within each asbestos-exposed cohort. We compared the
ability of LA and chrysotile-associated MCAAs to induce cellular changes indica-
tive of fibrotic disease, including collagen deposition and matrix metalloproteinase
(MMP) expression. Results revealed that both LA and chrysotile MCAAs induce
deposition of insoluble collagen proteins by cultured human pleural mesothelial
cells. However, only LA MCAAs required MMP activity for collagen deposition.
Immunoblot analysis revealed increased levels of MMP-8 in the supernatants of
cells exposed to LA MCAAs whereas chrysotile MCAAs inhibited MMP-8 expres-
sion. These data, coupled with differences in cytokine profiles, indicate mechanisti-
cally distinct routes of MCAA-induced collagen deposition. We additionally deter-
mined that LA MCAAs are predominantly an IgG3 subtype whereas chrysotile
MCAAs are mixed IgG1, 3, and 4 subtypes. This suggests that LA and chrysotile
MCAAs differ in their potential for receptor binding and complement activation,
which may contribute to distinct modes of pathogenicity. The mechanistic dissimi-
larities between LA and chrysotile MCAAs may help explain the disparate disease
phenotypes and fibrosis progression noted in clinical observations of asbestos-ex-
posed subjects.
1425 Cannabidiol-Induced Myeloid-Derived Suppressor Cells
Lead to Amelioration of Experimental Autoimmune
Encephalomyelitis.
D. M. Elliott,  P. Nagarkatti and M. Nagarkatti. Pathology, Microbiology and
Immunology, University of South Carolina School of Medicine, Columbia, SC.
Multiple sclerosis (MS) is an autoimmune disease of the CNS with heterogeneous
symptoms and progression. According to the National Multiple Sclerosis Society,
roughly 400,000 people are affected in the US today and current therapies include
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immunosuppressive agents with harsh side effects. Cannabinoids, which are a
group of compounds derived from the marijuana plant (Cannabis sativa), are
known to mediate their signals through the cannabionoid receptors, CB1 and CB2,
and have been effective as treatment for cancer associated pain, nausea and appetite
loss. Recently, their anti-inflammatory properties have been studied. Moreover, the
use of cannabinoid therapy for MS has also been exploited. However, the proposed
mechanism of action needs to be explored further. We used experimental autoim-
mune encephalomyelitis (EAE), a murine model of MS, to explore the anti-inflam-
matory role of cannabidiol (CBD) and its effects on myeloid-derived suppressor
cells (MDSCs). EAE disease paradigms were consistently reduced with CBD treat-
ment, as a significant reduction in clinical scores of paralysis and decrease in cellu-
lar infiltration, marked improvement of CNS tissue integrity, and reduced demyeli-
nation via histopathological analysis were observed. In addition, CBD treatment
led to a reduction in the percentage and absolute number of T cells particularly the
CD4+ T cells infiltrating the CNS (spinal cord and brain), which were significantly
increased in the untreated EAE mice. However, there was a profound increase in
MDSC induction in the spleens, CNS, and peritoneal wash of CBD treated EAE
mice as compared to the untreated EAE controls. Both granulocytic and monocytic
MDSCs were increased in CBD treated EAE mice. Together, these studies demon-
strate that CBD treatment may ameliorate EAE via the induction of MDSCs which
suppress the aberrant autoimmune response. (Supported by NIH grants R01
AT006888, R01 ES019313, R01 MH094755, P01 AT003961, P20 RR032684
and VA Merit Award BX001357).
1426 Attenuation of Trichloroethene-Mediated Autoimmune
Response in iNOS-null MRL+/+ Mice.
G. Wang1,  M. Wakamiya2,  J. Wang1,  G. Ansari1 and M. Khan1. 1Pathology,
University of Texas Medical Branch, Galveston, TX; 2Institute for Translational
Sciences and Animal Resource Center, University of Texas Medical Branch, Galveston,
TX.
Exposure to trichloroethene (TCE), a ubiquitous environmental contaminant, is
associated with an autoimmune response both in humans and animal models.
However, mechanisms underlying TCE-mediated autoimmunity remain largely
unknown. Previous studies from our laboratory in MRL+/+ mice suggest that reac-
tive oxygen and nitrogen species (RONS) may contribute to TCE-induced autoim-
munity. The current study was undertaken to further assess the role of oxidative and
nitrosative stress in TCE-induced autoimmunity by using iNOS-null MRL+/+
mice. iNOS-null mice were backcrossed to MRL +/+ mice for 10 generations and
then N10 heterozygous mutants were intercrossed to obtain homozygous mutants.
Female MRL+/+ and iNOS-null MRL+/+ mice were given TCE (10 mmol/kg, i.p.,
every 4th day) for 6 weeks; their respective controls received corn oil only. TCE
treatment led to significant induction of anti-malondiadelhyde (MDA)- and anti-
4-hydroxynonenal (HNE)-protein adduct antibodies along with increased iNOS in
sera, and increased nitrotyrosine (NT) in sera, livers and kidneys in MRL+/+ mice,
suggesting an overall increase in oxidative and nitrosative stress. The TCE-induced
oxidative stress was also associated with significant increases in serum anti-nuclear
antibodies (ANA) and anti-double stranded DNA antibodies (anti-dsDNA) levels.
Interestingly, iNOS and NT levels were negligible in both controls and TCE-
treated iNOS-null MRL+/+ mice. However, TCE treatment in iNOS-null mice
still led to significant increases in serum anti-MDA-/HNE-antibodies along with
increases in serum ANA and anti-dsDNA compared to controls. Remarkably, the
increases in serum ANA and anti-dsDNA induced by TCE in the iNOS-null mice
were significantly less pronounced compared to that in MRL+/+ mice. Our results
provide further evidence for a role of oxidative/nitrosative stress in TCE-induced
autoimmune response, and iNOS elimination attenuates this autoimmune re-
sponse. Supported by NIH ES016302.
1427 Mouse Model of Halogenated Platinum Salt
Hypersensitivity.
W. Williams1,  E. H. Boykin1,  C. Copeland1,  L. Copeland1,  S. J. Quell3,
S. H. Gavett1,  M. Selgrade2 and D. M. Lehmann1. 1US EPA, Research Triangle
Park, NC; 2ICF International, Durham, NC; 3Independent, Research Triangle Park,
NC.
Occupational exposure to halogenated platinum salts can trigger the development
of asthma. Concern for increased asthma risk exists for the general population due
to the use of platinum (Pt) in catalytic converters and its emerging use as a diesel
fuel additive. To investigate airway responses to Pt, we developed a mouse model of
Pt hypersensitivity. Previously, we confirmed the dermal sensitizing potency of am-
monium hexachloroplatinate (AHCP) using an ex vivo [3H]methyl thymidine la-
beling version of the local lymph node assay in BALB/c mice. Here, we investigated
the ability of AHCP to induce airway responses in mice sensitized by the dermal
route. Mice were sensitized through application of 100 μL 1% AHCP in DMSO to
the shaved back on days 0, 5 and 19, and 25 μl to each ear on days 10, 11 and 12.
Unsensitized mice received vehicle. On day 24, mice were challenged by oropha-
ryngeal aspiration (OPA) with 0 or 100 μg AHCP in saline.  Before and immedi-
ately after dosing, airway responses were assessed using whole body plethysmogra-
phy (WBP). A dose dependent increase in immediate airway responses (IAR) was
observed in AHCP sensitized and challenged mice. On day 26, changes in ventila-
tory responses to methacholine (Mch) aerosol were assessed by WBP; dose-depend-
ent increases in Mch responsiveness occurred in sensitized mice. Bronchoalveolar
lavage fluid harvested from sensitized mice contained an average of 7.5%
eosinophils compared to less than 0.5% in control mice (p < 0.05); significant in-
creases in total serum IgE was observed for all sensitized mice. This model will be
useful for assessing both relative sensitizing potency and cross-reactivity between
different halogenated Pt salts and for investigating the possible adjuvant effects of
diesel exhaust particles. This abstract does not represent EPA policy.
1428 Effect of Analgesic Administration on the Guinea Pig
Maximization Test.
D. W. Rice,  L. C. Anderson and J. H. Gass. Department of Toxicology, Baxter
Healthcare Corporation, Round Lake, IL.
Guinea pig maximization tests have been associated with inflammation at cuta-
neous induction sites due to the use of 1-chloro-2, 4-dinitrobenzene (DNCB) as a
positive control and Complete Freund’s Adjuvant (CFA). CFA enhances the sensi-
tization potential of the test substances and its use is required by ISO 10993-10. To
alleviate the potential for pain and distress, we evaluated the use of the analgesic,
buprenorphine hydrochloride (HCl). Analgesics can modulate the inflammatory
response and may interfere with the detection of contact sensitization. The purpose
of this study was to determine if the administration of buprenorphine HCl, as a re-
finement to reduce the potential for pain and distress, would affect the results of the
guinea pig maximization test. DNCB and Rubbercare® Gloves were used as the
test articles. The experimental design was consistent with the procedures described
in ISO 10993- 10 and the guinea pig maximization test (Magnusson and
Kligman), with additional parameters evaluated. The experimental design consisted
of 10 groups with each group receiving different concentrations of the test articles
with or without analgesic treatment. Twenty-four to 30 hours after topical induc-
tion, the groups treated with buprenorphine HCl were given 0.006 mg/kg every 12
hours for a total of three doses. Three animals per group were terminated on study
day 10 for hematology, coagulation and histologic evaluation of treatment sites.
The remaining animals were terminated after completion of the sensitization test.
Body weight gain, clinical observations, pain assessment, and sensitization potential
were evaluated. Clinical observations, hematology, coagulation or histopathology of
treatment sites were similar in groups that received analgesics compared to groups
that did not. At least 60% to 100% of animals in each group were sensitized with
no difference between corresponding groups with or without analgesic treatment.
Based upon the results of this study, the use of the analgesic, buprenorphine HCl,
did not interfere with the evaluation of the results of the guinea pig maximization
test.
1429 Chemical Assessment of “In-Use” Allergic Contact
Dermatitis Patch Test Reagents from Dermatology Clinics.
P. D. Siegel1,  J. F. Fowler2,  B. F. Law1,  E. M. Warshaw3 and J. S. Taylor4.
1NIOSH/CDC, Morgantown, WV; 2University of Louisville, Louisville, KY;
3University of Minnesota, Minneapolis, MN; 4Cleveland Clinic, Cleveland, OH.
Epicutaneous patch tests (EPT) are commonly used to identify chemical agents of
allergic contact dermatitis in dermatology patients. Test validity and assessment of
allergic reaction severity are highly dependent on the use of reliable chemical aller-
gen test reagents. The purpose of the present study was to measure the actual con-
centration of nickel sulfate (NiSO4), methyl methacrylate (MM), formaldehyde
(FA) and glutaraldehyde (GA) compared to the labeled concentrations of commer-
cial reagents found in dermatology clinics where patch testing is routinely per-
formed. The commercial reagents, NiSO4, MM and GA are supplied either dis-
solved or suspended in petrolatum (usually in syringe, multiuse containers) while
FA is diluted in water. Participating clinics submitted in-date and out-dated
reagents to the laboratory for analyses. Both NiSO4 and FA levels were at or above
the labeled concentration. NiSO4 particulate was uniformly distributed through-
out the petrolatum. In contrast, MM was low and variable in commercial allergen
reagents. “In-use” MM reagent syringes were all ≤56% of the 2% label concentra-
tion with no observable relationship to expiration date.  One MM syringe pur-
chased directly from the manufactured was 70% of the labeled concentration.
Lower MM levels in syringes were consistently measured at the tip vs. plunger end
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of the syringe suggesting loss due to MM’s volatility. GA patch test reagents con-
centrations ranged from 27 to 45% of the labeled (1% in petrolatum) amount, in-
dependent of expiration date. No GA concentration pattern between tip and
plunger was observed. These data suggest that false negative EPT results may be
due to instability of volatile or self-polymerizing chemical allergens in the test
reagents.
1430 Adjuvant Effect of Dibutyl Phthalate (DBP) in an Animal
Model of Contact Hypersensitivity.
A. S. Lourenço2,  R. M. Zaia2,  A. Prudente2,  M. F. Otuki2 and A. J. Martino-
Andrade1, 2. 1Fisiologia, Universidade Federal do Paraná, Curitiba, Brazil;
2Farmacologia, Universidade Federal do Paraná, Curitiba, Brazil. Sponsor: E.
Silbergeld.
Recent studies have demonstrated that certain phthalates can have adjuvant effects
in contact hypersensitivity models, exacerbating inflammatory responses.
According to human exposure estimates, perfumes containing DBP can result in
topic applications as high as 0.4 mg DBP/day. The aim of the present study was to
investigate the adjuvant effect of DBP in the oxazolone-induced contact hypersen-
sitivity model using human relevant doses. Adult male Balb/c mice were divided
into 5 different groups (n=6/group). These animals received oxazolone (75 μg/ani-
mal) in hairless abdomen (induction). After five days, mice received oxazolone (75
μg/ear; positive control and DBP exposed groups) or vehicle (negative control
group) in the right ear (sensitization). In addition, in the sensitization day and in
the two subsequent days, DBP groups received three different doses (0.04, 0.4 and
4 mg DBP/ear) twice a day, while positive and negative controls received vehicle
(acetone). All exposures were topical. For three subsequent days after sensitization
ear thickness (edema) was measured with the use of a micrometer. After the last
measurement, animals were decapitated and the ears were collected for the determi-
nation of N-acetyl-fl-D-glucosaminidase (NAG) and Myeloperoxidase (MPO) ac-
tivity. The study was in accordance to the ethics committee of the Federal
University of Paraná. Ear thickness was increased in positive control when com-
pared to vehicle only (negative control) group. No difference was seen between pos-
itive control and the lowest DBP dose group. However, oxazolone-induced edema
was increased in the groups treated with 0.4 and 4 mg DBP/ear when compared to
positive control. Similar results were found in MPO and NAG activity. The groups
treated with the two highest DBP doses displayed significantly higher enzymatic ac-
tivity when compared to positive control group. These results indicate that human
relevant doses of DBP can have adjuvant effects in the oxazolone-induced contact
hypersensitivity in mice.
1431 Characterization of the Mouse Allergy Model to Understand
Mechanisms of Drug Allergy.
X. Zhu,  S. Cole,  T. Kawabata and J. Whritenour. Pfizer Inc. Immunotoxicology
CoE, Drug Safety Research and Development, Groton, CT.
Developed as a modification of the Lymph Node Proliferation Assay, the mouse al-
lergy model (MAM) appears to be a promising tool for predicting the potential of
drug development candidates to produce hypersensitivity reactions (HR). In this
model, drugs associated with HR in the clinic produce a marked increase (com-
pared to controls) in the cellularity of the draining lymph nodes (LN).The objec-
tive of this study was to characterize the phenotype of draining LN cells to identify
new parameters that can be used to enhance the sensitivity and specificity of the
MAM and to better understand the mechanism(s) for the response. Drugs that are
associated with HR in the clinic (abacavir and amoxicillin) were selected as positive
controls for this study. Negative control drugs (metformin and cimetidine) were se-
lected based on the low number of reported HR for these compounds. Groups of 5
mice per group were injected subcutaneously with drug (100 mg/kg) or vehicle
once daily for three consecutive days. After a two day rest, cells from the draining
brachial LN were isolated and analyzed by flow cytometry. A significant increase in
total LN cell number (compared to vehicle) was observed for mice treated with the
positive control drugs. Compared to vehicle and negative control animals, an in-
crease in CD4+ and CD8+ T cells and B cells was observed in the draining LN of
abacavir and amoxicillin treated animals. Positive control drugs produced signifi-
cant decreases (~25% compared to control) in the percentage of naïve T cells and
increases (~27% compared to control) in the percentage of L-selectin (CD62L) and
CD44 double-negative T cells. The negative control drugs induced slight, but sta-
tistically insignificant, changes in the expression of these markers. Drugs associated
with HR in the clinic produced changes in draining LN cellularity and phenotype
that are not observed for negative control drugs. Changes observed in adhesion
molecule expression may suggest an effect of positive control drugs on lymphocyte
trafficking.
1432 Characterization and Comparison of Methylene Diphenyl
Diisocyanate Haptenated Human Serum Albumin and
Hemoglobin.
M. Mhike1, 2,  J. M. Hettick1,  I. Chipinda1,  R. H. Simoyi2 and P. D. Siegel1.
1Health Effects Laboratory Division, NIOSH/CDC, Morgantown, WV; 2Department
of Chemistry, Portland State University, Portland, OR.
Methylene diphenyl diisocyanate (MDI) is widely used as a cross-linking agent in
the manufacture of polyurethane products. Exposure to diisocyanates (dNCO),
such as MDI, is known to cause occupational asthma. MDI haptenation of proteins
is central to dNCO immunological sensitization, however, the resultant protein
conjugates are complex and difficult to characterize. The objective of the present
study was to characterize hemoglobin (Hb) and human serum albumin (HSA) fol-
lowing conjugation to different molar concentrations of MDI. MDI-protein conju-
gates were acid digested to obtain free methylene dianiline (MDA). MDA was ex-
tracted, derivatized with fluorescamine and analyzed by HPLC-fluorescence.
MDI-Hb was also digested with trypsin and specific amino acid conjugation sites
determined by ultra-performance liquid chromatography-quadruple-tandem time-
of-flight mass spectrometry. The trinitrobenzene sulfonic acid assay (TNBS) and
denaturing gel electrophoresis were used to determine the extent of cross-linking.
MDI conjugation was observed to be dependent on the MDI: protein ratio and the
concentration of protein. Greater binding to HSA than Hb was observed and MDI
bound to only eight binding sites on Hb compared to twenty for HSA (at 40:1
molar ratio of MDI: protein). Self-polymerization of MDI onto protein was ob-
served on some amino acids at higher MDI concentrations. The TNBS assay was
used to confirm cross linking in MDI-HSA with approximately 60% loss of amine
reactivity at 40:1 MDI: HSA. More cross-linking was observed at 0.5 mg/ml HSA
than at 5mg/ml at 40:1 MDI: HSA It is concluded that MDI has a greater reactiv-
ity toward HSA than Hb with respect to the number of residues haptenated and
amount of MDI bound per mole of protein. 
This work was supported by an Interagency agreement with the NIEHS (Y1-ES-
0001).
1433 Dimethylfumarate: Potency Prediction and Clinical
Experience.
I. R. White2,  D. Basketter1,  F. G. Burleson3,  G. Burleson3 and I. Kimber4.
1DABMEB Consultancy Ltd., Sharnbrook, United Kingdom; 2Department of
Cutaneous Allergy, St. John’s Institute of Dermatology, London, United Kingdom;
3BRT - Burleson Research Technologies, Morrisville, NC; 4Faculty of Life Sciences,
University of Manchester, Manchester, United Kingdom.
Dimethylfumarate (DMF) was the cause of a major outbreak of allergic contact
dermatitis as a consequence of its use as an antifungal agent in leather products,
particularly when used in furniture. This became known, as “toxic sofa dermatitis”.
However, what has not previously been established is why the risks to human health
had not been assessed adequately for this chemical. The purpose of these investiga-
tions was, therefore, to determine whether the frequency and severity of reactions to
DMF arose as a function of its intrinsic skin sensitizing potency and/or the nature
and extent of exposure. The intrinsic sensitizing potency of DMF was measured
using the standard local lymph node assay (LLNA) with determination of an EC3
value; the threshold in the LLNA and which serves as an indicator of relative skin
sensitising potency in humans. The EC3 value for DMF was 0.35% when tested in
dimethylformamide as a vehicle, indicating that this chemical is a strong, but not
an extreme, skin sensitiser in this mouse model. DMF was found therefore to have
a relative sensitising potency that is comparable with formaldehyde, also a strong
human skin sensitiser. The conclusion is drawn that the frequency and intensity of
allergic contact dermatitis reactions to DMF suggest that it was the prolonged, re-
peated and occlusive exposure over large skin areas to this chemical, combined with
strong sensitising potency, that together generated the “perfect storm” conditions
that caused the DMF epidemic.
1434 Characterization of the Allergenic Potential of Proteins: An
Assessment of the Kiwifruit Allergen Actinidin.
L. Beresford1,  S. McClain2,  I. Kimber1 and R. J. Dearman2. 1Faculty of Life
Sciences, Manchester University, Manchester, United Kingdom; 2Syngenta Crop
Protection, Durham, NC.
Assessment of the potential allergenicity (IgE-inducing properties) of novel pro-
teins is an important component of the overall safety assessment of foods.
Resistance to digestion with pepsin is commonly measured to characterize aller-
genicity, although the association is not absolute. We have shown previously that
the measurement of specific IgE antibody production induced by systemic (in-
traperitoneal) exposure of BALB/c strain mice to a range of proteins correlates with
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allergenic potential. The purpose of the present investigations was to explore fur-
ther the utility of these approaches using the kiwifruit allergen, actinidin. During
the past 10 years, kiwifruit has become an important allergenic foodstuff, coinci-
dent with its increased consumption, particularly as a weaning food. The ability of
actinidin to stimulate antibody responses has been compared with the reference al-
lergen ovalbumin, and with the non-allergenic protein bovine hemoglobin.
Hemoglobin was rapidly digested by pepsin whereas actinidin was relatively resist-
ant unless subjected to prior chemical reduction (conditions more closely reflecting
intracellular digestion). Hemoglobin stimulated detectable IgG antibody produc-
tion at relatively high doses (10%), but failed to stimulate IgE. In contrast, actini-
din was both immunogenic and allergenic at relatively low doses (0.25% to 1%).
Vigorous IgG and IgG1 antibody production and relatively high titer IgE antibody
responses were recorded, similar to those provoked by ovalbumin. Thus, actinidin
displays a marked ability to provoke IgE, consistent with allergenic potential. These
data provide further encouragement that in tandem with analysis of pepsin stability,
the assessment of IgE antibody production following systemic (intraperitoneal) ex-
posure of BALB/c strain mice provides an informative approach for the prospective
identification of protein allergens.
1435 Risk of Allergic Reaction to Undeclared Milk Proteins in a
Dietary Supplement.
J. Fleischer and M. H. Whittaker. ToxServices LLC, Washington DC.
In food allergic individuals, the immune system is sensitized to food proteins and
mounts a damaging inflammatory response. As a major food allergen, milk and
milk-derived ingredients must be declared on food labels under the U.S. Food
Allergen Labeling and Consumer Protection Act. Individuals with cow’s milk al-
lergy (CMA) may be at risk from a single exposure to undeclared milk, and may ex-
perience hives, swelling, vomiting, diarrhea, and/or asthma. Life-threatening ana-
phylaxis may occur. 
We assessed the risk of allergic reaction due to consumption of undeclared milk
proteins in a dietary supplement in adults with CMA by calculating acceptable
daily intake (ADI) thresholds for the milk proteins lactoglobulin and casein. ADIs
are the lowest exposures that would elicit only mild symptoms in adults with CMA.
We compared these ADIs with estimated intake (EI) levels for the two proteins,
based on analytical evaluation of the supplement and recommended serving size. 
We conducted benchmark dose (BMD) modeling on data from published double-
or single-blind, placebo-controlled milk challenge studies in individuals with
CMA. Dichotomous modeling (presence/absence of allergic response) was con-
ducted using EPA’s BMD Software 2.1.2. BMDs and BMDLs (lower 95% confi-
dence interval for the BMD) at a benchmark response (BMR) of 10% for allergic
response to milk challenge were modeled. BMDLs were adjusted for milk lac-
toglobulin and casein content (10% and 83% of total milk protein, respectively)
and divided by an UF of 10 (individual variation) to obtain the ADIs. ADIs were
0.3 mg/person for lactoglobulin and 2.1 mg/person for casein, compared to respec-
tive EIs of 0.47 mg/person and 0.02 mg/person. The ADI for lactoglobulin was ex-
ceeded at an EI of 0.47 mg/person, suggesting that levels of undeclared milk pro-
tein in a dietary supplement are sufficient to increase the risk of allergic reaction in
adults with CMA. The potentially severe and life-threatening nature of allergic re-
action suggests the need for immediate risk management action and highlights the
importance of GMPs for dietary supplements.
1436 Allergenic Antibiotics (Blactams and Sulfonamides) Induce
Oxidative Stress in Keratinocytes.
B. E. Lucas1,  A. E. Asangba1,  S. Mohammad1,  M. Gande1,  K. L. Voie2,
K. L. Campbell2 and S. N. Lavergne1. 1Comparative Biosciences, University of
Illinois, Urbana, IL; 2Veterinary Clinical Medicine, University of Illinois, Urbana,
IL.
Drugs can induce hypersensitivity reactions (drug allergies). Delayed drug hyper-
sensitivity occurs after >5 days of drug exposure. Surprisingly, delayed reactions
usually target the skin although most drugs are not administered per-cutaneously.
“Danger” signals such as necrotic cell debris, oxidative stress or inflammation, are
key elements in the events leading to the sensitization of the immune system against
an environmental toxicant or a therapeutic drug. We hypothesized that allergenic
antibiotics would induce oxidative stress in keratinocytes in vitro. We therefore
measured levels of intracellular glutathione (reduced and total GSH) and reactive
oxygen species (ROS) in a canine keratinocyte cell line (CPEK cells) exposed to 2
Blactams (amoxicillin or cephalexin) 2 sulfonamides (sulfamethoxazole and
sulfdimethoxine). Amoxicillin, cephalexin, sulfadimethoxine and sulfamethoxazole
decreased levels of GSH in CPEK cells after 2h compared to the negative control; at
8h, levels were similar to the negative control with the 2 Blactams, but higher with
the 2 sulfonamides; there was no difference between conditions at 24h. These ef-
fects affected total GSH rather than reduced or oxidized GSH. Sulfadimethoxine
was the only antibiotics that increased hydrogen peroxide levels compared to the
media control at 2h/8h/24h. When measuring a larger range of ROS (hydroxyl,
peroxide, superoxide), amoxicillin started to increase ROS levels at 4h; these ROS
levels were further increased by amoxicillin and cephalexin at 24h compared to the
media control. The effects were dose-dependent over a 2-2000uM range. Our data
on these canine keratinocytes confirm results published on sulfonamides and
human keratinocytes; they also expand them to Blactams.
1437 Activities of Xenobiotic Metabolizing Enzymes in Cell Lines
Used for Skin Sensitization Testing In Vitro.
D. Vogel1, 3,  E. Fabian1,  T. Eltze1, 2,  T. Ramirez1,  S. N. Kolle1,  B. van
Ravenzwaay1 and R. Landsiedel1. 1Experimental Toxicology and Ecology, BASF SE,
Ludwigshafen am Rhein, Germany; 2Product Safety Paper Chemicals, BASF SE,
Ludwigshafen am Rhein, Germany; 3Food Chemistry and Toxicology, Technical
University of Kaiserslautern, Kaiserslautern, Germany.
Skin sensitization is caused by repeated contact with an allergen. An early step in
the sensitization process is the interaction of haptens with proteins. In some cases
the hapten is formed from pro-haptens by enzymatic reactions in the skin (1).
Several in vitro methods are currently in the validation process as alternative meth-
ods to test for skin sensitization (2,3). 
The metabolic activities of selected enzymes were assayed in keratinocyte-like cells
Keratinosens® (Givaudan, Switzerland) and LuSens (BASF, Germany) as well as in
the dendritic-like cell U937 (used for the MUSST assay) and THP-1 (used for the
h-CLAT). Protein and cytochrome c reductase contents as well as activities of oxi-
dizing enzymes (CYP, FMO, ADH, AlDH), hydrolysing enzymes (esterase) and
conjugating enzymes (NAT and UGT) weremeasured in subcellular fraction of the
cells by monitoring metabolic transformation of model substrates. CYP,
FMO,UGT and ADH activities were below the detection limit for all investigated
cells. NAT1 and esterase activities were detectable in all cell lines. AlDH activities
were detected in the keratinocyte-like cells Keratinosens® and LuSens but not in
U937 or THP-1 cells. 
These results demonstrate that potential pro-haptens can be metabolically activated
during sensitization testing in vitro. The xenobiotic metabolizing enzymes of the re-
spective cells need, however, to be compared to those of native skin.
1 Jäckh C et al. (2012) Relevance of xenobiotic enzymes in human skin in vitro
models to activate pro-sensitizers. J Immunotoxicol. [Epub ahead of print]
2 Mehling A et al. (2012) Non-animal test methods for predicting skin sensitiza-
tion potentials. Arch Toxicol. 86:1273
3 Bauch C et al. (2012) Putting the parts together: combining in vitro methods to
test for skin sensitizing potentials. Regul Toxicol Pharmacol. 63:489
1438 Interleukin 17 Expression by Chemical Allergen-Activated
Lymph Node Cells: Selectivity for Contact Allergens.
I. Kimber,  A. Metryka,  M. D. Hayes and R. J. Dearman. Faculty of Life Sciences,
Manchester University, Manchester, United Kingdom.
Chemical allergens can cause skin sensitization resulting in allergic contact dermati-
tis, or sensitization of the respiratory tract associated with occupational asthma.
The immunological mechanisms resulting in sensitization, and the contributions
made by the innate immune response are not fully understood. The interleukin
(IL)-17 cytokine family, originally described as Thelper (Th)17 cytokines, are now
known to be expressed by cells of the innate immune system. It has been shown
previously that topical exposure of mice to 2,4-dinitrochlorobenzene (DNCB), a
potent contact allergen, is able to provoke the rapid (within 6-16 hours) production
of IL-17 by components of the innate immune system in regional lymph nodes.
Here we have examined whether this rapid elaboration of IL-17 cytokines is selec-
tive for contact allergens. BALB/c mice were exposed on the dorsum of both ears to
various allergens (DNCB, dinitrofluorobenzene, oxazolone, 2-methyl-4-isothia-
zolin-3-one and 5-chloro-2-methyl-4-isothiazolin-3-one, or α-hexylcinnamalde-
hyde), to the irritants sodium lauryl sulfate and benzalkonium chloride or to the
appropriate vehicle control. At various times thereafter cells from draining lymph
nodes were isolated and cultured, and supernatants analyzed for IL-17A, IL-17F,
IL-17A/F and IL-22 expression. Expression of IL-17 cytokines and IL-22 was selec-
tive for contact allergens with no significant increase in response to skin irritants. A
chemical respiratory allergen (trimellitic anhydride; TMA) also induced IL-17 and
IL-22, but with substantially delayed kinetics compared with contact allergens.
Enhancing the dendritic cell migration kinetics in response to TMA to match those
induced by contact allergens did not impact on the tempo of lymph node IL-17 ex-
pression. Collectively these data suggest that the rapid elicitation of IL-17 cytokines
in draining lymph nodes is a potentially selective biomarker of exposure to contact
allergens, and may provide a platform for the development of a novel approach to
the characterization of skin sensitizing activity.
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1439 Interleukin 17 Responses Induced in Mice by Chemical
Allergens: A Functional Role for Gammadelta T Cells.
R. J. Dearman1,  M. D. Hayes1,  B. Hunt2,  A. Hayday2 and I. Kimber1.
1Manchester University, Manchester, United Kingdom; 2London Research Institute,
London, United Kingdom.
Interleukin (IL)-17 cytokines, expressed by T helper (Th)17 cells, play pivotal roles
in adaptive immune responses. They have been implicated in autoimmune and al-
lergic diseases and have roles in bacterial and fungal clearance. Importantly, IL-17 is
produced not only by adaptive immune cells but also by cells of the innate immune
system including the nonconventional γδ T cell subset. It has been shown recently
that IL-17 expressing γδ T cells are required for the development of adaptive Th17
responses that mediate experimental autoimmune encephalomyelitis, a murine
model of multiple schlerosis. We have examined whether IL-17 influences sensiti-
zation to chemical allergens. BALB/c strain mice were exposed topically to the con-
tact allergen 2,4-dinitrochlorobenzene (DNCB), the respiratory allergen trimellitic
anhydride (TMA), or to vehicle alone. At selected time points single cell suspen-
sions of draining lymph nodes were cultured and analyzed for cytokine secretion or
for mRNA following enrichment/depletion using magnetic beads. A single expo-
sure to either allergen resulted in transient up-regulation of IL-17 from γδ T cells.
Maximal levels of secretion were observed at 6h and 48h following exposure to
DNCB and TMA, respectively. After repeated exposure under conditions where
DNCB and TMA stimulate polarized Th1 and Th2 cytokine phenotypes, respec-
tively, DNCB, but not TMA, was shown to induce the expression of IL-17. IL-17
production by DNCB-activated cells was shown by complement depletion to reside
only in the CD4+ population. In subsequent experiments, responses were explored
in γδ T cell null mice and C57BL6 wild type (WT) controls. A similar pattern of
IL-17 production to that provoked in BALB/c strain mice was seen in the WT mice
following prolonged exposure to DNCB. However, in the γδ T cell null mice the
adaptive Th17 response was completely abrogated. These data suggest strongly that
the lack of IL-17 production by γδT cells during the acute (innate) response affects
the subsequent adaptive Th17 response to contact allergens.
1440 IL-18 Secretion in Human 3D Organotypic Skin Models for
the Identification of Contact Sensitizers.
E. Corsini1,  S. Gibbs2,  V. Galbiati1,  S. Spiekstra2,  H. Kandarova3,  P. Hayden4,
C. Seaman4 and E. L. Roggen5. 1DiSFeB, Università degli Studi di Milano, Milan,
Italy; 2Vrije Universiteit Medical Center, Amsterdam, Netherlands; 3MatTek
Corporation, Ashland, MD; 4GSK, Hertfordshire, United Kingdom; 53Rs
Management and Consultancy, Kongens Lyngby, Denmark.
Over the last decade, several in vitro methods have been proposed to identify po-
tential of contact sensitizers, but no accepted in vitro method yet available.
Keratinocytes play a key role in all phases of skin sensitization. Interleukin-18 (IL-
18) production in keratinocyte was identified as a potentially useful endpoint for
determination of contact sensitizatizers. Limitations of traditional submerged cell
culture include chemical solubility, stability in water and metabolic competence. To
overcome these problems, experiments were performed to test the possibility to use
commercially available 3D organotypic skin models to exploit the possibility to use
the secretion of IL-18 for the identification of contact sensitizers. A protocol was
developed using different 3D skin models, including EpiDerm TM, EST1000TM.
Preliminary experiments were conducted to determine chemical toxicity profiles
using the MTT viability assay. Additional doses were then chosen for IL-18 secre-
tion experiments. Following topical exposure for 24 h to several contact allergens
(including benzocaine, cinnamaldehyde, citral, DNCB, eugenol, isoeugenol, 2-
mercaptobenzothiazole, oxazolone, etc.) and irritants (including chlorobenzene,
lactic acid, octanoic acid, phenol, salicylic acid, SDS, Tween 20, etc.) a robust in-
crease in IL-18 release was observed only after exposure to contact allergens. The
method could be easily trasferred to naïve laboratories. Using a cut-off of 2-fold in-
crease of IL-18 above vehicle control and 40% cell viability, depending from the
laboratory 85-100 % sensitivity and 88-100 % specicificy were obtained. This
model appears to be very promising, additional testing with a larger chemical set is
required to fully evaluate the utility of this assay.
1441 Animal Strains Usable to the LLNA: brdU-ELISA (OECD
442B).
T. Anzai1, 2,  Y. Nozaki3,  M. Kaminishi1, 2,  H. Takagi3,  T. Satoh1,  R. Guest4 and
K. Sato2. 1Harlan Laboratories Co., Ltd., Tokyo, Japan; 2School of Medicine, Showa
University, Tokyo, Japan; 3Japan SLC, Hamamatsu, Japan; 4Harlan Laboratories
(UK), Derby, United Kingdom.
The murine local lymph node assay (LLNA) is a widely accepted alternative test to
assess the skin sensitizing potential of chemical substances. The original LLNA was
designed to quantify lymph cell proliferation in the draining auricular lymph nodes
by incorporation of radiolabeled thymidine analogues. To avoid use of the radioiso-
tope in the tests, some modified LLNA protocols were developed. One of the mod-
ified methods utilizes the nucleus (uridine) analogue of 5-Bromo-2’-deoxiuridine
(BrdU). In this method, the incorporated BrdU is measured by ELISA, using anti
BrdU antibody. This modified LLNA:BrdU-ELISA has been validated and adopted
as OECD test guideline 442B. In this guideline, the CBA/J or CBA JN strains are
recommended, since researchers had used these strains during the validation.
Previously, we noted differences in response in the LLNA with different strains of
mouse. . In this study, we used mice of several CBA strains to compare the reactiv-
ity against several skin sensitizers and a non sensitizer. It is confirmed that the
mouse strains, CBA/CaOlaHsd and CBA/N Slc showed similar but not equal re-
sponse to CBA/JNCrlj, the preferred strain in the LLNA:BrdU-ELISA.
1442 Elucidation of the Reason Underlying the Incorrect
Sensitization Evaluation Results for Methyl Methacrylate,
Methyl Salicylate and 2-Mercaptobenzothiazole by
Nonradioactive Local Lymph Node Assay.
W. Jang1,  K. Jung1,  Y. Lee2,  Y. Yum2,  Y. Heo3 and K. Lim1. 1Amorepacific R&D
Center, Yong-in, Republic of Korea; 2Korea FDA, Cheong-won, Republic of Korea;
3Catholic University of Daegu, Daegu, Republic of Korea.
The non-radioisotopic local lymph node assay (LLNA) using bromodeoxyuri-
dine(BrdU) with flow cytometry (FCM) has been developing as an alternative test
for identifying skin sensitizers. We previously performed pre-validation with rec-
ommended reference substances in the OECD Test Guideline 429 using Balb/c
mice. Our results by non-radioactive LLNA were similar to those of traditional
LLNA. However, a weak sensitizer, methyl methacrylate(MM), a non-sensitizer,
methyl salicylate(MS) and a moderate sensitizer, 2-mercaptobenzothiazole(MBT)
were wrongly identified by non-radioisotopic LLNA:BrdU-FCM as a non-sensi-
tizer, a weak sensitizer and a non-sensitizer, respectively. Therefore, we tried to clar-
ify the reason underlying the wrong prediction by LLNA:BrdU-FCM. First, we
compared strain difference of Balb/c mice from CBA mice that are recommended
strain in the OECD Test Guideline 429 with several test materials including the 3
chemical substances described above. Mice received topical application of the test
material or vehicle on both ears for consecutive 3 days. Mice were sacrificed 24 hr
after intraperitoneal injection of BrdU. Ear thickness and ear weight were measured
for evaluating irritation and auricular lymph nodes were used for determining
BrdU incorporation into lymph node cells. All of test materials including positive
control showed similar stimulation index and ear thickness between two mice
strains suggesting that strain difference may not be the reason for the wrong predic-
tion by LLNA:BrdU-FCM. Interestingly, MBT was correctly identified as a moder-
ate sensitizer when AOO was used as a vehicle while it was a non-sensitizer when
DMF was used as recommended in the OECD guideline suggesting that vehicle se-
lection may profoundly affect the prediction for MBT by LLNA:BrdU-FCM.
1443 Polarized Immune Responses Induced by Chemical Allergens
Display Differential DNA Methylation Patterns.
V. Chapman1,  J. Moggs2,  R. Terranova2,  T. Zollinger2,  I. Kimber1 and
R. J. Dearman1. 1Manchester University, Manchester, United Kingdom; 2Novartis,
Basel, Switzerland.
There is increasing evidence that epigenetic regulation of gene expression plays a
pivotal role in the orchestration of immune responses. It has been demonstrated
previously that chemical allergens can be divided into two categories; contact aller-
gens (such as dinitrochlorobenzene; DNCB), that cause type 1/type 17 polarized
responses and respiratory allergens (such as trimellitic anhydride, TMA) that in-
duce a preferential type 2 response. Such polarization occurs upon repeated (13
day) topical exposure. In order to explore the regulation and maintenance of such
responses at the molecular level, the genome wide pattern of DNA methylation fol-
lowing treatment with the reference allergens DNCB and TMA was characterized.
Mice (n=5 per group) were exposed to DNCB, TMA or vehicle alone for 13 days,
and draining auricular lymph nodes excised. DNA was extracted, sonicated and
processed for methylated DNA immunoprecipitation (MeDIP) followed by hy-
bridization to a high resolution DNA promoter array (Roche) representing 28,000
probe ranges, covering promoter regions and known CpG islands. Changes in
DNA methylation profiles for allergen-activated tissues were compared with the ve-
hicle-treated control samples, with a cut off of p<0.01. More differentially methy-
lated regions (DMR) were recorded for DNCB tissue than for TMA tissue (6319
versus 2178), although approximately half those identified for TMA were in com-
mon with DNCB. Direct comparisons between DNCB and TMA-treated tissue re-
vealed 268 DMR that were differentially regulated between the two different classes
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of allergens. The 15 most significant genes identified were associated with hyper-
methylation and hypomethylation for DNCB and TMA exposure, respectively.
Thus, topical exposure to different classes of chemical allergen under polarizing
conditions results in characteristic patterns of DNA methylation indicative of epi-
genetic regulation of the developing allergic response. Furthermore, DNCB and
TMA are associated with more silencing and activating epigenetic marks, respec-
tively.
1444 Chemicals Acute Toxicity Testing and Evaluation Based on
Nematode Caenorhabditis elegans Model.
Y. Li,  K. Yang,  S. Gao,  H. Jing,  L. Qi,  J. Ning,  Z. Tan,  C. Zhao,  L. Ma and
G. Li. Institute for Toxicology, Beijing Centers for Disease Control and Prevention,
Beijing Research Center for Preventive Medicine, Beijing, China.
The toxicity assessment and risk management of chemicals is highly associated with
the safety of human health. At present, the conventional model of which rodent
tests were greatly characterized, can no longer meet the increasing requirements of
chemical toxicological evaluation. Studies on the non-rodent in vivo assay by using
model organisms are becoming a potential perspective and frontiers in the research
field of chemicals toxicity risk assessment. Nematode Caenorhabditis elegans (C.el-
egans) has great potential value in the chemical rapid toxicity screening and com-
plying with principles of “3R” for its short life cycle, easy operation and low cost.
However, the fact that how the acute toxicity in rodents and even health risks in
human being can be predicted through toxicity in C. elegans, is still a key scientific
problem that remains to be solved. In this pilot study, we assayed 50% lethal con-
centration (LC50) and 50% lethal time (LT50) of 20 selected chemicals using C.
elegans as an in vivo model organism in 96-well plate for 24h, analyzed the correla-
tion between LC50 of C. elegans and LD50 of rat/mouse. The results indicated
that the estimated toleration of chemical pH for C. elegans was greater than 2.75.
There was a positive correlation between LC50 of C. elegans and LD50 of
rat/mouse (R>0.83, P<0.01). LC50 and LT50 of chemicals in C. elegans have pos-
itive correlation as well. Taking together, there is an intrinsic relationship between
LC50 of C. elegans, LD50 of rat/mouse. LC50 and LT50 are recommended as
toxic effect index for further study on acute toxicity test of chemicals using C. ele-
gans. C. elegans will be a potential valuable in vivo pre-screening toxicity model in
the new chemical’s predictive toxicity test and assessment prior to the conventional
rodent model (partly supported by NSFC Grant in China #81273108, Capital
Development Project 2011-1013-03, and Beijing Health Bureau Project-2011.
Corresponding author: Guojun J. Li: guojunli88@yahoo.com).
1445 Predicting Developmental Neurotoxicity in Rodents from
Larval Zebrafish—and Vice Versa.
V. C. Moser,  R. C. MacPhail,  P. M. Phillips,  M. E. Culbreth,  K. L. McDaniel,
K. A. Jarema and S. Padilla. TAD & ISTD, NHEERL, US EPA, Research Triangle
Park, NC.
The complexity of standard mammalian developmental neurotoxicity tests limits
evaluation of large numbers of chemicals. Less complex, more rapid assays using
larval zebrafish are gaining popularity for evaluating the developmental neurotoxic-
ity of chemicals; there remains, however, a pressing need to determine the utility of
the model for predicting adverse neurobehavioral outcomes. We are undertaking
studies to compare the developmental effects of chemicals in both larval zebrafish
and rats. Zebrafish studies show that transitions between light and dark periods can
produce robust changes in activity that may be differentially altered by chemicals;
an analogous behavior pattern is being studied in rats. Developmental heptachlor
in rats increased motor activity in addition to altering righting reflex ontogeny, and
impairing learning and memory in adult offspring. In zebrafish, developmental
heptachlor produced marked increases in dark-induced activity and dysregulation
of the light-dark patterning of activity. Preliminary studies with dimethyl phthalate
(DMP) in zebrafish showed reduced habituation only during the dark period, per-
haps reflecting changes in anxiety or cognitive behaviors. We evaluated develop-
mental effects of DMP in rats using light-dark transition activity measures in addi-
tion to standard neurobehavioral toxicity tests including anxiety. Alterations were
observed on several of these endpoints; however, the results were not always dose-
related and were confounded by maternal toxicity at high doses. While these results
suggest concordance between outcomes of two chemicals from different classes,
considerably more comparisons with positive and negative controls are needed to
understand the predictability of the larval zebrafish assay. Further exploration of
analogous/homologous behavioral tests in both species may be beneficial in evalu-
ating neurotoxic outcomes from developmental exposures, and in assessing the con-
formity of results. 
This is an abstract of a proposed presentation and does not reflect US EPA policy.
1446 Developmental and Reproductive Toxicity of Fusarium
Mycotoxins in the Nematode Caenorhabditis elegans.
Z. Yang2, 1,  L. Tang1,  G. Qian1 and J. Wang1. Toxicology and Environmental
Research & Consulting, The Dow Chemical Company, Midland, MI.
Developmental and reproductive toxic effects of some naturally occurring
Fusarium mycotoxins were shown in certain animal models. In this study we used
the nematode Caenorhabditis elegans (C. elegans), as an alternative model for
mechanistic studies, to investigate the developmental and reproductive toxic effects
of T-2 toxin (T-2), zearalenone (ZEN), and deoxynivalenone (DON). C. elegans
(N2) at1-day or 3-day old were exposed to various concentrations of these toxins
for up to 72 hrs. The development arrested rate (DAR) and the reproduction ar-
rested rate (RAR) were outcomes used to assess the overall effects on the develop-
ment and reproduction of the exposed C. elegans. T-2 has the most potent suppres-
sive effects on the development and growth, concentrations from 0.5- to 8-mg/L
caused averaged DAR from 12.01% to 41.6%; exposure to ZEN from 5- to 80-
mg/L caused averaged DAR from 11.14% to 35.56%; exposure to DON from 50-
to 800-mg/L caused averaged DAR from 12.71% to 32.77%. The concentration
ratio for inducing significant DAR (10%) is approximate to 1:10:100 for T-2,
ZEN, and DON, respectively. T-2 also has the most potent toxic effect on the re-
production, concentrations from 0.5- to 8-mg/L caused averaged RAR from
28.97% to 72.43% with an EC50 at 3.57-mg/L; exposure to ZEN from 5- to 80-
mg/L caused averaged RAR from 26.15% to 90% with an EC50 at 12.02-mg/L;
exposure to DON from 50- to 800-mg/L caused averaged RAR from 23.83 to
52.33% with an EC50 at 585.85-mg/L. The concentration ratio for EC50 is ap-
proximate to1:3.4:164.1 for T-2, ZEN, and DON, respectively. These results sug-
gest that T-2 and ZEN have more significant toxic effects than DON on develop-
ment and reproduction in C. elegans and that C. elegans is an excellent model, due
to its short life cycle and easy genetic manipulation of genes, for studying molecu-
lar mechanisms of developmental and reproductive toxic effects caused by food-
borne mycotoxins.
1447 Zebrafish As a Complementary Model in Toxicology.
A. Menke2,  A. Wolterbeek1,  A. Beker1,  C. Snel2 and D. de Groot1. 1TNO, Zeist,
Netherlands; 2TNO Triskelion BV, Zeist, Netherlands. Sponsor: R. Woutersen.
Growing awareness to apply the principles of Replacement, Refinement and
Reduction (3Rs) of animals in regulatory testing drives the need for alternatives
identifying potential toxic agents with accuracy, speed, reliability and respect for
animal welfare. So far, for complex endpoints like reproduction and developmental
toxicology, animal-free in vitro models are limited and cover only a restricted part
of the reproductive cycle. Various characteristics warrant the Zebrafish (embryos
and/or larvae) as an ideal non-mammalian whole organism model that could bridge
gaps between in vitro cell systems and complex reproduction studies in mammals,
e.g. small size, ease of obtaining high number of progeny, external fertilization,
transparency and rapid development of embryo, and a basic understanding of its
gene function and physiology.
Macroscopical examination of zebrafish embryos/larvae predicted toxicity of chem-
ical and pharmaceutical agents with high certainty and proved to form a reliable
total organism approach to study embryo- and developmental (neuro)toxicity.
More in depth analysis and interpretation of the locomotor data in the developing
zebrafish larvae relative to (nervous system) development increases the use of the ze-
brafish model in developmental neurotoxicity research. A full histopathological sur-
vey of the embryo’s combined with high-end analytical methods appeared to fur-
ther increase the applicability domain of zebrafish into toxicity screening studies.
Further refinement with respect to the physical and chemical properties of test
compounds that determe the body burden and tissue distribution increases the pre-
dictability of the assay. For translation to other toxicity models and man, there is an
urgent need to research on responsible toxicity pathways.
This research is supported by the Dutch Ministry of Health, Welfare and Sport and
the Dutch Ministry of Social Affairs and Employment.
1448 Using Yeast Functional Toxicogenomics to Decipher the
Toxicity of the Dieldrin Organochlorinated Pesticide.
B. Gaytan1,  A. Loguinov1,  S. Lantz1,  N. Denslow2 and C. Vulpe1. 1University of
California, Berkeley Berkeley, CA; 2University of Florida, Gainesville, FL.
Exposure to organochlorinated pesticides (OCPs) has been linked to neurotoxicity,
endocrine disruption, and cancer, but the cellular mechanisms of toxicity remain
largely unknown. It was hypothesized that a chemical genomics approach using a
Saccharomyces cerevisiae gene deletion library could help elucidate the cellular
mechanisms by which various OCPs induce toxicity. In this study, pools of deletion
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strains were exposed in triplicate for five and fifteen generations to the IC20, 50%
IC20, and 25% IC20 dieldrin OCP concentrations. The oligo sequences unique to
each deletion strain were PCR-amplified and hybridized to TAG4 arrays to identify
sensitive, unaffected, and resistant strains. The overrepresented biological terms
within the data assisted in the selection of individual deletion strains for confirma-
tion experiments. Analyses indicate that amino acid sensing and components of the
pyruvate dehydrogenase complex are critical for cell survival under dieldrin expo-
sure. Exogenous amino acids rescue dieldrin toxicity, while lower concentrations of
amino acids in the media exacerbate toxicity. Finally, it was demonstrated that diel-
drin inhibits amino acid uptake in yeast cells. Future investigations will examine
whether amino acid status is tied to dieldrin toxicity in human cell lines.
Additionally, the development of an automated high-throughput system to screen
the yeast deletion library for altered growth in various toxicants may be discussed.
1449 Evaluation of Epigenetic and Developmental Effects in
Danio rerio Zebrafish Embryos following Diethylstilbestrol,
17β-Estradiol And/or 5-Azacytidine Treatment.
R. G. Ellis-Hutchings,  R. A. Alyea,  V. A. Marshall,  M. J. LeBaron,  R. Sura,
N. P. Moore,  B. Gollapudi and R. J. Rasoulpour. Toxicology and Environmental
Research & Consulting, The Dow Chemical Company, Midland, MI.
The fundamental mechanisms that regulate epigenetic modifications as well as em-
bryo development are highly conserved amongst vertebrates. Danio rerio (zebrafish)
potentially may be used to examine epigenetic alterations during stages of early de-
velopment. Zebrafish embryos were treated with estrogenic molecules (17β-estra-
diol (E2) or diethylstilbestrol (DES) (0.001, 0.01, 0.1, 1, 1.5, 2, 2.5, 3, 5, 7, and
10μM) in the presence or absence of a DNA methyltransferase inhibitor 5-azacyti-
dine (5-azaC, 1-100μM) and evaluated daily for lethality. On test day 5, morpho-
logical abnormalities were assessed using a quantitative scoring system: somites, no-
tochord, tail, fins, heart, face, brain, arches and jaw. Treatment with 25μM 5-azaC
prior to the period of DNA re-methylation (2-cell stage) caused >80% lethality
whereas starting treatment shortly after the onset of DNA re-methylation (≥ 16 cell
stage) resulted in <10% lethality. Regardless of developmental stage, treatment with
50 and 100μM 5-azaC caused >90% lethality. Treatment with >2μM DES caused
significant mortality whereas treatment with 1 or 1.5μM increased the incidence of
developmental variations. Treatment with >7μM E2 significantly impacted sur-
vival, while 5μM caused a generalized slight increase in developmental abnormali-
ties; however, 1, 1.5, 2, 2.5 and 3μM E2 caused slight developmental effects on the
heart, face and brain. Overall, E2 had a wide developmental dose response curve
while DES caused significant mortality within a narrow region. Morphological
characterization of embryos and larvae following exposure to these compounds in-
dicated that within the chosen dose response range, clear apical end point no-ob-
served-adverse-effect levels (NO(A)ELs) and lowest-observed-adverse-effect levels
(LO(A)ELs) can be determined thereby providing a useful model to establish asso-
ciations between apical and epigenetic end points.
1450 A High-Throughput Mechanism-Based Toxicity Screen Using
C. elegans.
R. B. Goldsmith2,  J. R. Pirone3,  W. A. Boyd2,  M. V. Smith3 and
J. H. Freedman1. 1NIH, Research Triangle Park, NC; 2NTP, NIEHS, Research
Triangle Park, NC; 3SRA International, Durham, NC.
To quantitatively assess the effects of chemical exposures on transcription, an auto-
mated high-throughput in vivo toxicity assay was developed to measure changes in
the levels and cell-specificity of specific gene expression in C. elegans.
Transcriptional responses were measured in individual strains of transgenic C. ele-
gans that express fluorescent proteins under the control of archetypical stress-in-
ducible genes: ced-3, cyp-35A2, gcs-1, gst-38, gst-4, hsp-16.2, hsp-16.41, hsp-17, hsp-
4, hsp-6, hsp-60, mtl-2, ugt-1 and ugt-13. As part of assay development, transgenic
nematodes with large dynamic ranges (i.e., low constitutive levels of expression)
and sensitivity (high response at low concentrations) were identified following ex-
posure to juglone, an oxidative stressor; N-methyl-N’-nitro-N-nitrosoguanidine, a
DNA damaging agent; cadmium, a heavy metal; chlorpyrifos, an organophosphate
neurotoxin; tunicamycin, an endoplasmic reticulum stressor; and heat shock, a pro-
tein denaturant. Concomitant with chemical exposure, florescence data were meas-
ured from images acquired using a high content imager and subsequently analyzed
using CellProfiler’s WormToolbox, a high-throughput imaging analysis program
designed for use with nematodes. For some of the stress-inducible genes high levels
of constitutive expression limited their dynamic range and utility in this assay. As
expected, not all of the chemicals affected all of the genes; however, the chemicals
generally affected the stress-inducible genes that corresponded to their known
mechanisms of action. For example, nematodes containing the hsp-4 transgene,
which responds to endoplasmic reticulum stress, showed increased fluorescence
after tunicamycin treatment. In addition, strong correlations were observed be-
tween chemical concentration and fluorescent signal. The results obtained using the
transgenic C. elegans were verified by measuring changes in the cognate steady-state
mRNA levels by qRT-PCR. These results show that this assay can be used to assess
the effect of toxicants on gene expression in vivo.
1451 The Effects of Microcystin-LR on the Chemotaxis Indexes
ofCaenorhabditis elegans<i/>
C. Moore and B. Puschner. Molecular Biosciences, University of California Davis
School of Veterinary Medicine, Davis, CA.
The blue green algae toxins microcystins (MCs) are known ubiquitous hepatotox-
ins found in fresh and marine waters. The World Health Organization has estab-
lished a drinking water guideline of 1 μg/L total MCs based on MC-LR liver toxi-
city data after oral exposure. MCs inhibit serine/threonine protein phosphatases
(PP1 and 2A), a mechanism extensively studied in the liver; yet the effects of MCs
on the nervous system are poorly understood. To study MCs’ effects on the nervous
system, a 24-hour exposure assay using the neurotoxicity model Caenorhabditis el-
egans (C. elegans) was established. C. elegans have remarkable genetic and neuro-
biochemical conservation with humans, and with all 302 neurons extensively stud-
ied, key sensory neurons have been linked to specific behaviors. It is well known the
AWA and AWC sensory neurons detect diacetyl and benzaldehyde, respectively, and
sensory neuron function can be quantified using a chemotaxis index (CI). Wildtype
(N2) adult nematodes were exposed for 24 hours to 0, 1, 10, 40, 80, 160 and 320
μg/L MC-LR before determining CIs. No significant changes in CIs for benzalde-
hyde were observed. At MC-LR concentrations of 40 μg/L and above, CIs for di-
acetyl decreased significantly. The unchanged CIs for benzaldehyde suggest that
AWC is not affected. The decreased CIs for diacetyl suggest that AWA is targeted by
MC-LR. PP2A inhibitor okadaic acid and PP1 inhibitor tautomycin were used in
the same 24-hour exposure model to evaluate whether PP1 or PP2A inhibition re-
sult in changes in AWA function. Results of CI indexes suggest that the AWA
chemosensory neuron is affected by MC-LR resulting in neurotoxity.
1452 Quantitative Assessment of Phase II ToxCast™ Chemical
Toxicity in C. elegans.
W. A. Boyd1,  M. V. Smith2,  J. R. Pirone2,  J. R. Rice1 and J. H. Freedman1, 3.
1DNTP, NIEHS, NTP, Research Triangle Park, NC; 2SRA International, Research
Triangle Park, NC; 3LTP, NIEHS, NIH, Research Triangle Park, NC.
The Tox21 community is working to prioritize thousands of chemicals for further
toxicity testing and to develop prediction models for human toxicity. To integrate
the large amounts of high throughput in vitro and in vivo toxicity and develop
these models, better quantitative methods are necessary. To develop quantitative as-
sessments of in vivo toxicity data, the U.S. EPA’s ToxCast Phase II library, which
contains 676 unique chemicals including failed drugs, food additives and industrial
products, was screened using the C. elegans growth assay. This assay uses the
COPAS Biosort to measure size changes in individual nematodes after 48-h expo-
sures. Over the seven concentrations tested (0.5-200 μM), >50% of the chemicals
caused a decrease in growth. To rank their toxicity in C. elegans, a concentration-re-
sponse curve for each chemical was described using isotonic regression and the sta-
tistical significance of the curve assessed. For significant concentration-response
curves, the fitted isotonic regression model calculated three parameters that charac-
terized the efficacy and potency of each chemical: 1) change in response between
control and highest concentration (R); 2) concentration of chemical at which half
of R is reached (ECR50); and 3) slope of the curve at the ECR50. Chemicals were
also ranked by computing a toxicity score, which is a weighted sum of the change in
response at each dose relative to the control. The top 5% most active compounds
included several organic pollutants (e.g., DDT, PFOS), which have been banned
from use due to their toxicity and bioaccumulation. Excellent reproducibility was
observed for eight chemicals replicated in the library: seven were active and one was
inactive for all replicates. The application of this new method for the quantitative
assessment of chemical toxicity in C. elegans could be applied to other in vitro and
in vivo toxicity screens, thus allowing for better comparisons among various assays,
and the development of predictive models of toxicity.
1453 Triazole-Induced Gene Expression Changes in the Zebrafish
Embryo.
S. A. Hermsen1, 2,  T. E. Pronk1,  E. van den Brandhof1,  L. T. van der Ven1 and
A. H. Piersma1, 3. 1Health Protection, RIVM, Bilthoven, Netherlands;
2Toxicogenomics, University, Maastricht, Netherlands; 3IRAS, University, Utrecht,
Netherlands. Sponsor: H. van Loveren.
The zebrafish embryo is a promising alternative test for developmental toxicity. The
classical read-out is via morphological assessment. Microarray analyses may increase
sensitivity and predictability of the test by detecting more subtle and mechanistic
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responses. We have shown earlier that with transcriptomics data we could discrimi-
nate between two chemical classes, glycol ethers and triazoles, in a concentration-
reponse design. It is time-consuming and expensive to perform concentration-re-
sponse analysis for many compounds. Thus, we studied the possibility of relating
gene expression profiles of structurally related chemicals tested in a single concen-
tration, to a complete transcriptomic concentration-response of the triazole anti-
fungal flusilazole (FLU). We tested five other triazoles, hexaconazole (HEX), cypro-
conazole (CYP), triadimefon (TDF), myclobutanil (MYC), and triticonazole
(TTC) at equipotent concentrations based on morphological evaluation. Results
showed that compounds differed in their regulation of major anti-fungal and devel-
opmental toxicity pathways, steroid biosynthesis and retinol metabolism, respec-
tively. Assuming that the ratio between these pathways is relevant for efficacy com-
pared to developmental toxicity, we found TTC was more efficacious and CYP was
more toxic compared to the other triazoles. MYC showed a different response sim-
ilar to the high toxic concentrations of FLU. We here demonstrated that gene ex-
pression data allow more comprehensive assessment of compound effects by dis-
criminating relative potencies using these specific gene sets. The zebrafish embryo
model can therefore provide information on relative pathway sensitivity related to
intended mechanism of action and toxicological activity of compounds.
1454 Early-Life Exposure to Methylmercury and Multiple
Stressors: Daphnia pulex As an Alternative Model System to
Evaluate Long-Term Effects.
D. Doke and J. M. Gohlke. Environmental Health Sciences, University of Alabama
at Birmingham, Birmingham, AL.
While human populations are exposed simultaneously to chemical stressors and
physical factors including temperature and differing nutrition, safe limits of expo-
sure are based primarily on tests using single chemicals. Due to the high cost and
time required to test mixtures in traditional animal models, development of novel
model systems are of critical importance. We are currently evaluating Daphnia
pulex, a standardized USEPA and OECD ecotoxicology model system and an NIH
model organism for biomedical research, as a tool for assessing long-term effects of
early life exposures to multiple stressors. As a case study, we are examining the in-
teraction between MeHg exposure and varying temperature regimes and nutrition.
We hypothesize that: Early life exposures in high temperature or a low food regime
will increase MeHg toxicity as measured by reproduction and lifespan in Daphnia
pulex. D. pulex were exposed to a matrix of three temperature regimes emulating
standard laboratory conditions versus natural environment daily fluctuations, three
feed rates and five concentrations (200ng/l to 1000ng/l) of MeHg as methylmer-
cury (II) chloride. Data evaluating lifespan and fecundity across the temperature
regimes suggest that although there are no significant differences in time to first re-
production, D. pulex lifespan and fecundity were increased in daily fluctuating ver-
sus constant temperature regimes. This indicates that subtle differences in lifespan
can be detected across standard laboratory thermal conditions and those that would
be experienced in a natural environment. Subsequent work will evaluate interac-
tions. Since current alternative model systems are not designed to evaluate long-
term effects of early life exposures, our research is designed to evaluate the utility of
D. pulex as a complementary model system.
1455 A Rapid Chemical Screening Platform in C. elegans for
Assessing Environmental Germline Disruption.
P. Allard1,  N. Kleinstreuer3,  T. B. Knudsen3 and M. Colaiacovo2. 1Environmental
Health Sciences, UCLA, Los Angeles, CA; 2Genetics, Harvard Medical School, Boston,
MA; 3NCCT, US EPA, Research Triangle Park, NC.
Despite the developmental impact of errors in chromosome segregation, we lack
the tools to comprehensively assess environmental effects on meiotic integrity in
animals. Here, we report the development of an assay in C. elegans that fluores-
cently marks aneuploid embryos following chemical exposure. We qualified the
predictivity of the assay against chemotherapeutic agents as reference compounds,
as well as environmental compounds with comprehensive mammalian in vivo end-
point data. The assay was highly predictive of mammalian reproductive toxicities
with a maximum specificity of 78%. Finally, we validated selected compounds from
the screen by analyzing germline maintenance following exposure. With this novel
approach, we provide the first high-throughput screening strategy for the assess-
ment of environmental effects on the germline.
1456 Cytotoxic Effects of Methyl-Mercury in Whole Worms and
Pan-Neuronal GFP-Expressing Embryonic Cultures of
Caenorhabditis elegans.
K. Breithaupt1,  R. K. Hajela1, 2 and W. D. Atchison1, 2. 1Neuroscience Program,
Michigan State University, East Lansing, MI; 2Pharm/Tox, Michigan State University,
East Lansing, MI.
Caenorhabditis elegans (C. elegans) strain KC136 was used to study whole worm
viability in response to methylmercury (MeHg) toxicity in a semifluid gellan gum
medium. Stage L3 KC136 whole worm viability is reduced by exposure to 0.5-25
μM MeHg (p=0.0001) for 24-48 hrs. At the highest [MeHg] tested, cytotoxicity
was 54% and time of exposure (24 and 48 hrs) did not have an effect (p=0.15). C.
elegans strain NW1229, which expresses pan-neuronal Green Fluorescent Protein
(GFP), was used to prepare primary cell cultures from eggs to test the ability of the
nemadipine-A to reduce the cytotoxicity of MeHg in worm neurons. Nemadipine-
A is a novel dihydropyridine (DHP) L-type voltage gated Ca2+ channel antagonist
and we hypothesize it has a similar effect as we have previously reported for the
non-DHP-type antagonist verapamil. At [MeHg] of 0.4-1.2 μM, cytotoxicity in
neurons was both concentration and time dependent as determined by ethidium
homodimer viability assay. Thus the results obtained in whole worms differ some-
what from those of isolated neurons relative to time-dependence of cytotoxicity. As
previously reported, verapamil reduced MeHg-induced cytotoxicity by ~10% at 1
hr of exposure, however, lost its’ protective effect at 3 hrs (p=0.08). Similarly, ne-
madipine-A (0.25-1 μM) protected neurons against MeHg toxicity at 1 hr
(p=0.033), but not 3 hrs of exposure. The reduction of MeHg-induced cytotoxicity
by L-type Ca2+ channel antagonists at early stages of exposure suggests that L-type
Ca2+ channels contribute to MeHg mediated neuronal cell death in C. elegans, just
as they do in mammalian neurons. The lack of correlation between time and expo-
sure to MeHg may result from upregulation of genes for proteins involved in metal
detoxification. Using C. elegans neuronal cultures as a model system for MeHg
neurotoxicity may help uncover why certain neurons are more susceptible to
MeHg-induced cell death furthering our understanding of the underlying mecha-
nisms.
1457 MTBE Disrupts HIF1-Vegf Regulated Angiogenesis in
Zebrafish (Danio rerio).
J. A. Bonventre1, 2,  T. S. Kung2,  L. A. White2 and K. R. Cooper2. 1EMT, Oregon
State University, Corvallis, OR; 2JGPT, Rutgers University, New Brunswick, NJ.
Understanding the sensitivity of developing vascular networks to toxic insult is im-
portant to advancing vascular biology. Methyl tert-butyl ether (MTBE) induces
vascular lesions in the zebrafish embryo, including pooled blood in the common
cardinal vein (CCV), cranial hemorrhages (CH), and abnormal intersegmental ves-
sels (ISV). The transcript levels of two isoforms of vascular endothelial growth fac-
tor, vegfa and vegfc, as well as a primary receptor, vegfr2, are significantly decreased
during the critical period (6-somites to Prim-5). The vascular lesions were hypoth-
esized to be a result of the MTBE-induced down-regulation of vegfa. An over-ex-
pression study was conducted to rescue MTBE-induced vascular lesions. Over-ex-
pression of zebrafish vegfa resulted in 46% fewer animals exhibiting
MTBE-induced CH and 35% fewer embryos exhibiting abnormal ISV, while no
rescue was observed for the CCV lesion. Global gene expression changes during the
critical period, assayed with the Affymetix GeneChip® and analyzed with
Ingenuity Pathway Analysis®, identified the cardiovascular system as a primary
pathway altered by MTBE exposure, as well as other pathways associated with hy-
poxia inducible factors (HIFs). Two further rescue studies were designed to block
HIF1α degradation to test the hypothesis that MTBE toxicity was HIF1α-depend-
ent. Chemical inhibition of HIF1α degradation, by blocking prolyl-4-hydroxylase
activity with N-oxalylglycine, rescued both the CCV lesion (24%) and CH (32%).
Knockdown of a ubiquitin ligase component, von Hippel-Lindau protein, with an
anti-sense morpholino rescued only the CCV lesion (35%). Rescue of MTBE-in-
duced vascular lesions by over-expression of vegfa and inhibition of HIF degrada-
tion demonstrated that MTBE toxicity is mediated by a down-regulation of HIF
driven Vegf at a critical period during the developing cardiovascular system.
Chemicals with anti-angiogenic properties, such as MTBE, can be used to advance
the science of angiogenesis in both a disease state and during development.
Funding: ES07148, ES05022
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1458 An In Vitro Placental Model Using BeWo Cells for the
Prediction of Placental Transfer of Compounds.
H. Li1,  B. van Ravenzwaay1, 2,  I. Rietjens1 and J. Louisse1. 1Division of Toxicology,
Wageningen University, Wageningen, Netherlands; 2Experimental Toxicology and
Ecology, BASF SE, Ludwigshafen, Germany.
The use of reverse dosimetry for in vitro-in vivo extrapolation (IVIVE) enhances
the use of in vitro toxicity data for risk assessment (Louisse et al., 2010). With re-
verse dosimetry, in vitro toxic effect concentrations are translated to in vivo doses
using physiologically based kinetic (PBK) modelling. For the PBK models needed
for reverse dosimetry, parameter values for kinetic processes need to be obtained,
such as for intestinal absorption, metabolism and placental transfer. The present
study aims to assess whether an in vitro model for the placental barrier, consisting
of human placental BeWo cells, could be used to predict the placental transfer ki-
netics of compounds. To this end, BeWo cells were grown on transwell inserts to
form a confluent monolayer, thereby separating an apical maternal compartment
from a basolateral fetal compartment. For a set of 9 compounds the transport ve-
locity from the apical to the basolateral compartment was determined in this
model. Relative transport rates obtained in this model were compared with the rel-
ative transport rates of these compounds calculated from data of ex vivo human pla-
cental perfusion studies reported in the literature (Hewitt et al., 2007). The relative
transport rates in the BeWo model were in good correlation (R2=0.95) with the rel-
ative transport rates calculated for the ex vivo model (Li et al., submitted). This in-
dicates that the BeWo model can be useful in the prediction of the transplacental
transfer of compounds and for obtaining model parameter values for PBK that can
be used for reverse dosimetry.
1459 Controlled Hemodynamics and Transport in Primary
Hepatocytes Shift Induction and Toxic Responses to Drugs
Closer to In Vivo Concentrations.
A. Dash,  T. Deering,  J. Thomas,  B. R. Blackman and B. R. Wamhoff. Liver
Surrogate Systems, Ajit Dash, Charlottesville, VA.
Preclinical in vitro drug screening systems exhibit efficacy and toxicity responses to
concentrations very different from corresponding clinical or in vivo plasma Cmax
levels, contributing to poor in vitro-in vivo correlations. We established a primary
hepatocyte system using controlled hemodynamics and transport that retains polar-
ized morphology and metabolic function more stably than traditional static cul-
tures. We tested the hypothesis that restoring these critical parameters could achieve
in vitro hepatocyte drug response at concentrations closer to in vivo levels. Fresh rat
hepatocytes were cultured under controlled hemodynamics alongside static controls
for 5 days before treating with various concentrations of test drugs (dexamethasone,
acetaminophen, chlorpromazine) for 2 days. Cytotoxic response was evaluated by
MTT and ATP assays and cytochrome p450 activity by standard kits. Under con-
trolled hemodynamics, dexamethasone was significantly more toxic to primary he-
patocytes at concentrations used for induction studies in static cultures
(93.31±5.26% vs. 32.8±9.5% at 50 μM, p <0.01). Induction responses of Cyp3A
activity equivalent to 50μM of dexamethasone in static cultures were seen at 2.5
μM under controlled hemodynamics. Cytotoxic dose response curves of acetamin-
ophen demonstrated a leftward shift with IC50 values at 10 μM in devices com-
pared to 30 μM in static cultures. A similar shift in cytotoxic response was seen
with chlorpromazine with induction of Cyp1A activity in a dose dependent man-
ner at sub lethal concentrations. We demonstrate that control of transport and he-
modynamics in a primary hepatocyte system results in induction and toxicity re-
sponses to drugs at concentrations significantly lower than static systems and closer
to in vivo levels. The retention of in vivo-like hepatocyte phenotype and metabolic
function coupled with drug response at more physiological concentrations empha-
sizes the importance of restoring in vivo physiological transport parameters in vitro.
1460 Validation of In Vitro Systems to Explore Mechanisms of
Striated Muscle Toxicity.
W. Dott1,  J. Wright2,  P. Mistry2 and K. Herbert1. 1Cardiovascular Sciences,
University of Leicester, Leicester, United Kingdom; 2Product Safety, Syngenta,
Bracknell, United Kingdom. Sponsor: P. Botham.
The validation of in vitro cardiac and skeletal muscle models of toxicity may find a
utility in predicting toxicity early within the research and development process. The
primary aim of this project was to investigate the extent of translation from an in
vivo to an in vitro, system, using a toxicogenomics approach. Female Han Wistar
rats were dosed daily via the diet with sulfonyl isoxazoline (SI) chemistries for 4 or
28 days. Histopathological evaluation revealed a dose-dependent myositis and my-
odegeneration in striated muscle. Gene expression profiling of cardiac and skeletal
muscle tissues taken from sub-toxic doses identified a number of perturbed cellular
pathways including; mitochondrial dysfunction, altered energy metabolism, oxida-
tive stress, cell cycle and apoptosis. This data data provided a plausible hypothesis
which suggested mitochondrial toxicity as a principle mechanism of SI-induced
striated muscle toxicity. To investigate the translation of this toxicity to an appro-
priate in vitro system cardiac (H9c2) and skeletal muscle (L6) cell lines were se-
lected. A cell based assay was developed in which the cardiac and skeletal muscle
cells were adapted to use mitochondrial oxidative phosphorylation rather than gly-
colysis. This system identified the SI compounds as mitochondrial toxicants. In ad-
dition there was a significant increases in mitochondrial reactive oxygen species,
which provided further evidence of mitochondrial perturbation. SI treatment also
induced cellular hypertrophy, accompanied by cell cycle arrest, and subsequent cas-
pase-mediated apoptosis. These in vitro results were consistent with the transcrip-
tomics data, providing further validation that the cell systems models may have
utility for predicting striated muscle toxicity. Future work will be aimed at explor-
ing tissue-specific toxicity using higher tier in vitro models (liver, muscle bioreactor
flow through systems) which might better represent the in vivo system.
1461 3D Liver Models for Investigating Drug-Induced
Hepatotoxicity.
E. Jain1,  M. Ehrich2,  T. Murali3 and P. Rajagopalan1. 1Department of Chemical
Engineering, Virginia Tech, Blacksburg, VA; 2Virginia-Maryland Regional College of
Veterinary Medicine, Blacksburg, VA; 3Department of Computer Science, Virginia
Tech, Blacksburg, VA.
Testing the toxic effects of chemicals has traditionally relied on large-scale animal
studies. In addition to being extremely expensive, this strategy has come under
scrutiny for its over-reliance on laboratory animals, and the need to extrapolate re-
sults from animals to humans. In vitro tissue mimics are a promising avenue for
studying the effects of toxicants. Such systems can serve as reliable models of in vivo
structures and can be systematically probed with a wide range of cues. Since they
are engineered, experimentation on these mimics is considerably less complex than
those needed to probe tissues and organisms in vivo. We have designed a novel 3D
organotypic liver model assembled with three cell types (hepatocytes, liver sinu-
soidal endothelial cells and Kupffer cells) and a polyelectrolyte multilayer (PEM)
that mimics the Space of Disse. We have established a dose range (20–40mM) for
acetaminophen in 3D liver models that is non-lethal yet is capable of perturbing
hepatic function. When acetaminophen was administered 4 days after hepatocytes
were obtained from rat livers, conventional monolayer, collagen sandwich and 3D
liver model cultures showed a small decrease in cell viability. When the drug was ad-
ministered at day 12, only the 3D liver models showed a decrease in viability. All
cultures exhibited a decrease in albumin production and urea secretion. The 3D
liver models exhibited better urea secretion than monolayer and collagen sandwich
cultures. Intracellular glutathione levels were measured for all three cultures. 3D
liver models exhibited approximately 40% decrease in glutathione in comparison to
monolayer and collagen sandwich cultures that exhibited greater than 60% de-
crease. These trends suggest that the inclusion of non-parenchymal cells in the 3D
liver model may impart cytoprotective effects and present an in vivo like environ-
ment.
1462 In Vitro Cell Models: Moving from Tumor Cell ‘Monsters’ to
Differentiating Immortalized- or Stem Cells.
D. Gerhold,  D. Kuo,  Z. Tong,  J. Braisted,  M. Xia,  A. Simeonov and
C. P. Austin. Tox21 Consortium, NIH-National Center for Advancing Translational
Sciences (NCATS), Rockville, MD.
The Tox21 Consortium aims to develop in vitro quantitative High Throughput
Screening (qHTS) using human cells and targets to replace animal testing. In
screening for cytotoxicity, primary human cells make useful models, but results
from primary cells are irreproducible and the cells are problematic to obtain. At the
other extreme, transformed cell lines are readily available and reproducible, but are
often poor representations of normal human tissues. Between these extremes, im-
mortalized cells or differentiated stem cells provide reliable phenotypic models for
neurons, kidney proximal tubule epithelial cells or podocytes, cardiomyocytes, vas-
cular endothelial cells, and hepatocytes. We are evaluating cell models for these cell
types by evaluating susceptibilities to toxicants that are organ-selective in vivo.
Efforts are also underway to adapt such cells that require differentiation to qHTS in
1536-well plate format. Gene expression profiling is being leveraged to dissect the
modes of cytotoxicity, and to determine why in vitro models succeed for some com-
pounds and fail for others. We will present the evaluation of several such toxicolog-
ical models vis-à-vis: differentiated phenotypes, cytotoxicity assays, and gene ex-
pression profiling.
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1463 Potential Cholestatic Compounds Assessed by Membrane
Transport Vesicle Assays As Well As Bile Canaliculi
Inhibition in Primary Hepatocytes in Both Human and Rat.
L. Qiu1,  M. Taimi2,  C. Strock2,  J. Gilbert2 and Y. Will1. 1Compound Safety
Prediction, Pfizer Global Research & Development, Groton, CT; 2Apredica,
Watertown, MA.
BSEP (Bile Salt Export Pump) inhibition has been proposed as a mechanism for
drug-induced cholestasis, a subtype of drug induced liver injury (DILI). Screening
systems for BSEP inhibition have been established in membrane vesicles from Sf9
insect cells over-expressing rat or human BSEP transporter. However, as any cell-
free assay, the data from vesicle assays might not reflect true BSEP inhibition profile
due to lack of biotransformation and metabolism. In addition, the contribution of
MRP2 (Multidrug resistance-associated protein 2) to drug induced liver cholestasis
also needs to be considered. 
In this study, we examined 18 potential cholestatic compounds, which were either
known to be BSEP inhibitors, dual inhibitors for BSEP and MPR2 or glutathione
depleters, in both human and rat BSEP and MRP2 vesicle assays. Moreover, a high-
content imaging assay using fluorescent selective substrates for BSEP and MRP-2
transporters including CMFDA and CLF, was used to examine these compounds in
inhibition of bile canaliculi excretion in both human and rat sandwich-cultured he-
patocytes . In addition, CMFDA and CLF were characterized for their ability as
uptake substrates for BSEP and MRP2 transporters. 
We found that both, CMFDA and CLF were not selective for BSEP transport since
they were also potent MRP2 substrates. Vesicle and hepatocyte canaliculi inhibition
data showed no substantial species difference between human and rat, for either
transporter.
Furthermore the vesicle data correlated well with the hepatocyte canaliculi data.
However, for a few compounds the vesicle data did not translate into hepatocyte
canaliculi data probably due to impact of cell-based effects such as metabolism or
permeability. 
In conclusion, to better predict drug-induced cholestasis, a larger set of compounds
with known clinical DILI outcomes need to be tested in both vesicle and hepato-
cyte canaliculi assays in order to elucidate the mechanisms involved in liver toxicity.
1464 Development of Alternative In Vitro Methods to Screen for
Pulmonary Toxicities—Characterization of Epithelial-
Macrophage Coculture and In Vitro Assay Conditions at the
Air-Liquid Interface (ALI).
S. P. Ng and D. B. Warheit. DuPont Haskell Global Centers for Health &
Environmental Sciences, Newark, DE.
The successful development of in vitro assays with cultured pulmonary cells and
aerosols is instrumental for creating toxicity/screening tests for use during product
development. To optimize for future in vitro aerosol exposures using the Nano-
Aerosol Chamber for In Vitro Toxicology system, rat lung epithelial L2 cells and
NR8383 macrophages (MØ) were co-cultured on an ALI system and cell metabo-
lism (XTT), cytotoxicity (LDH), and cytokine (IL-6) release assays were developed
as endpoints to assess cell toxic effects following particle exposures. Co-cultures
were exposed to 0-80 ug/cm2 ZnO fine particles in supplemented growth medium
for 2 hrs followed by 24-hr maintenance of cultures at ALI. Results showed that
both XTT and LDH assays performed with cells co-cultured at the ALI were able
to detect toxicity in a dose-response manner. Cytotoxic effects measured following
20 ug/cm2 ZnO particle exposures (i.e, ~LC40) increased with epithelial cell:MØ
(L2:NR8383) ratios, revealing that the seeding ratio strongly affects the assay sensi-
tivity. In a separate study, optimization for cytokine release assay performed with
different cell seeding densities and L2:NR8383 ratios showed the highest IL-6 re-
lease (~2.5 ng/mL) from cultures seeded at 0.5E5/cm2 in a 2:1 ratio and main-
tained at ALI for 1 day. Maximum stimulation of IL-6 release was detected from
the optimized cultures 4- and 24-hr post-exposure to low dose (2.5 ug/cm2) ZnO
(200-300% of medium-exposed controls); IL-6 release was suppressed to 0-50% of
controls after relatively high-dose ZnO (>10 ug/cm2) exposures. In conclusion,
these studies are useful in characterizing and optimizing the co-culture and in vitro
assay conditions with ALI which could better simulate in vivo exposure of lung cells
to inhaled materials (when compared to a submerged exposure system) and ulti-
mately should facilitate the development of reliable in vitro cell exposure systems
and cell-based lung toxicity/screening tests.
1465 Predicting Heart-Specific Toxicity Using Two Cell Models:
Human iPS-Derived Cardiomyocytes and Human Liver Cells
(HepaRG).
P. C. Wilga,  D. Keller,  B. Franz and J. M. McKim. CeeTox, Inc., Kalamazoo, MI.
A major reason for the failure of new drugs is due to adverse effects in the cardio-
vascular system. An in vitro model capable of identifying heart-specific liabilities
would be of considerable value. To differentiate heart toxicity from liver toxicity, a
dual cell model was developed that utilizes changes in cell health and function fol-
lowing exposure to a test drug. Human cardiomyocytes and normal human liver
cells were used as the test system. Cardiomyocytes were derived from induced
pluripotent stem cells (iPS) obtained from Cellular Dynamics International.
Terminally differentiated bi-potent HepaRG cells were from Life Technologies.
Each cell type was established in a 96-well format and prepared in triplicate wells
for each concentration. Markers of cell health (ATP, LDH leakage, and GSH) were
monitored in both cell types. Additional information was collected for beat rate
(BR) in heart cells and endpoints were monitored over concentration and time. The
concentration-response curves were compared using mean IC50 values. Beat rate
(BR) was measured using the xCelligence RTCA Cardio system (ACEA). To test
the model, hepatotoxic (camptothecin (CAMP), rotenone (ROT)) or cardiotoxic
(doxorubicin (DOX), mitoxantrone (MTX)) compounds were used. These were
added to cells at concentrations of 0, 0.1, 1, 10, and 100 μM and exposed for 24 hr.
In addition, drugs known to produce QT prolongation (Terfenadine (T) and vera-
pamil (V)) were included and the BR determined.  T and V significantly reduced
BR at a concentration of 0.3 μM. To determine heart (H) or liver (L) specificity, av-
erage IC50 values were obtained for each cell type and the H-to-L ratio calculated.
H-to-L ratios were MTX = 0.5, DOX = 2.6, ROT = 0.02 and CAMP undeter-
mined. Ratios < 1.0 indicate cardiotoxicity, those >1.0 but < 3 indicate toxicity in
both models, while ratios >3 indicate hepatotoxicity. BR data was used to improve
these predictions. The combined data provided better resolution and enabled car-
diac toxicity to be determined with greater confidence.
1466 Predicting Respiratory Sensitization Using Activation of
Nrf2/ARE Genes in a Human Reconstructed Airway Model.
J. A. Willoughby,  D. Keller,  P. C. Wilga and J. M. McKim. CeeTox, Inc.,
Kalamazoo, MI.
Current in vitro methods for determining sensitization have focused on skin sensi-
tization and provide data on hazard, but are unable to predict potency. The aim of
this study was to determine if a new method known as SenCeeTox®, originally de-
veloped to detect skin sensitizers, could also identify respiratory sensitizers and pro-
vide potency. The EpiAirway™ model from MatTek Corp. was used as the test sys-
tem. Viability, test article reactivity, and the expression of genes controlled by
Nrf2/ARE (NADPH Quinone oxido reductase (NQO), aldoketoreductase (AKR),
interleukin-8 (IL8), aldehyde dehydrogenase (ADH), heme oxygenase-1
(HMOX1), and glutamate cysteine-ligase catalytic subunit C (GCLC)) were mon-
itored. CYP1A1 was monitored to identify proallergens. Test solutions of p-benzo-
quinone (BQ), benzoic acid (BA), glycerol (Gly), cinnamic aldehyde (CA), tolulene
diisocyanate (TDIC), and oxazolone (OX) were prepared in DMSO. Each test
agent was evaluated in a glutathione depletion assay (GSH) and then applied api-
cally to the tissue at concentrations of 0, 100, 250, 500, and 2500 μM. Following
24 hr incubation, total RNA was isolated and changes in gene expression deter-
mined by qRT-PCR. Tissue viability was monitored by MTT. BQ reduced viability
to 73% at 2500 μM, depleted GSH by 70% and induced NQO, AKR, CYP1A,
ADH, HMOX1 and GCLC. Oxazolone reduced viability to 56% at 2500 μM, de-
pleted GSH by 92% and induced GCLC. TDIC had no effect on viability, de-
pleted GSH by 26% and induced GCLC. CA had no effect on viability, depleted
GSH by 22% and induced GCLC. Glycerol and benzoic acid had no effect on via-
bility or GSH depletion, but did produce a positive response on GCLC. These data
provided a rank order of potency from highest to lowest of BQ > OX > TDIC > CA
>> BA and Glycerol. This ranking is consistent with reported sensitization potency
categories for these chemicals. In conclusion, Nrf2/ARE signaling pathways are in-
tact in the EpiAirway™ tissue and that this model may provide a means of accu-
rately identifying respiratory sensitizers.
1467 Measurement of Phagocytic Activity in Rats with the
Phagotest® Kit.
J. Legrand1,  C. Mimouni1,  M. Valin1,  N. Pearson1,  R. Forster1 and J. Descotes2.
1CiToxLAB, Evreux, France; 2Poison Center, Lyon, France.
Very few tools are available to assess phagocytosis, a major functional component of
the innate immune system, during nonclinical immunotoxicity studies. The objec-
tive of the present study was to evaluate the feasibility of the Phagotest® in rats.
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Phagotest® (Glycotope Biotechnology, Berlin, Germany) is routinely used in clini-
cal immunology laboratories to assess phagocytosis in humans. It allows the quanti-
tative determination of leukocyte phagocytosis by measuring the percentage of
phagocytes that have ingested bacteria and the number of ingested bacteria per cell.
In the present study, 2 ml samples taken from 6 male and 6 female Sprague-Dawley
rats onto heparin lithium tubes were incubated with FITC-labeled E.coli bacteria at
+37°C. Thereafter, phagocytosis was stopped by placing the samples on ice and
adding a quenching solution. After washing and erythrocyte lysis, a DNA staining
solution was added prior to flow cytometry analysis using a XL MCL flow cytome-
ter with the Expo 32 ADC software (Beckman Coulter, France). The percentage of
phagocytizing cells (granulocytes and monocytes, differentiated by side scatter and
forward scatter) and their mean fluorescence intensity (number of ingested bacte-
ria) were determined in four independent runs. The mean ± SD of the percentage
of phagocytizing granulocytes was found to be 84.4 ± 5.0 for males and 86.2 ±
11.02 for females, and the mean ± SD of the percentage of phagocytizing mono-
cytes, 51.6 ± 8.3 for males and 55.5 ± 11.7 for females. Intra-individual precision
(CV%) was between 10.4% and 13.6% for males, and between 18.1% and 24.2%
for females. These results demonstrate that the Phagotest® kit can be used to assess
phagocytosis in rats as it is in humans.
1468 Thirdhand Smoke: Extraction and Cytotoxicity.
V. Bahl1, 2,  P. Jacob3,  C. Havel3,  S. Schick3,  T. Mao3 and P. Talbot1. 1Department
of Cell Biology and Neuroscience, University of California Riverside, Riverside, CA;
2Environmental Toxicology Graduate Program, University of California Riverside,
Riverside, CA; 3University of California San Francisco, San Francisco, CA.
Thirdhand smoke (THS) consists of chemicals that remain in indoor environments
after secondhand smoke has cleared. The purpose of this study was to develop an
extraction protocol for THS and evaluate its cytotoxicity using terrycloth exposed
to cigarette smoke for 110 hours over 334 days and stored at room temperature
(RT). THS was extracted in DMEM culture medium at different temperatures and
for different lengths of time, and concentrations of nicotine, and related chemicals
in the extracts were measured. Highest concentrations of nicotine, cotinine,
nicotilline, anatalline, N-formynornicotine, 2,3’-bipyridine, N’-nitrosonornicotine
(NNN) and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) were present
in the extracts made at RT for 1 hr. However, highest concentrations of 1-(N-
methyl-N-nitrosamino)-1-(3-pyridinyl)-4-butanal) (NNA) and myosmine were in
the 1 hr extract made at 4°C. The 1 hour, RT extract had 144 μg of nicotine per
gram of terrycloth. A terrycloth bathrobe, weighing 450 g and similarly exposed to
smoke, would contain 64 mg of nicotine, which is higher than the LD50 dose for
humans. Cytotoxicity was assayed using mouse neural stem cells. The extract made
at RT for 1 hr was more cytotoxic than that made for 2 hrs. However, when ex-
tracted at 4°C, the 2 hr extract was more cytotoxic. Prolonging the extraction time
to 24 hours at RT caused complete loss of cytotoxicity, whereas extracting for 24
hours at 4°C helped to preserve some activity. Extracts made with lower headspace
volume were more cytotoxic than when the headspace volume was large, presum-
ably due to better preservation of volatile chemicals. In general, the extract made for
1 hr at RT was most cytotoxic, killing cells at the full strength and 30% dose. These
data are consistent with the interpretation that cytotoxicity of THS extracts resides
in the volatile fraction and that extraction conditions are critical when quantifying
chemicals in THS.
1469 Prevalidation of the Ex Vivo Model Precision Cut Lung
Slices (PCLS) for the Prediction of Respiratory Toxicology.
K. Sewald1,  L. Lauenstein1,  S. Vogel2,  A. Hess2,  X. Schneider3,  C. Martin3,
R. Pirow4,  M. Liebsch4,  R. Landsiedel2 and A. Braun1. 1Fraunhofer ITEM,
Hannover, Germany; 2BASF, Ludwigshafen, Germany; 3RWTH, Aachen, Germany;
4BfR ZEBET, Berlin, Germany. Sponsor: C. Dasenbrock.
Introduction: For acute inhalation toxicity studies, animals inhale chemicals. At
the beginning it is difficult to estimate non-toxic doses for in vivo inhalation. In the
context of REACH and the principle of 3Rs, there is a public demand for alterna-
tive methods. The goal of this BMBF-funded project is the pre-validation of PCLS
as a suitable ex vivo alternative model to replace pre-studies of inhalation toxicology.
The project is conducted in three independent laboratories. BfR provides support
in biostatistics.
Methods: In all participating laboratories, PCLS were prepared and exposed to 5
concentrations of industrial chemicals in DMEM under standard culture condi-
tions for 1 hour. After post-incubation, chemical-induced toxicity was assessed by
LDH and WST-1 assay. In addition, PCLS protein content and pro-inflammatory
cytokine IL-1α were measured by BCA assay and ELISA, respectively. For all end-
points a sigmoid dose-response model was fitted to the data and EC50 values were
calculated. Test acceptance criteria were established for each endpoint.
Results:This study shows the results of the first 6 tested substances out of 20. In all
laboratories, concentration dependent toxicity could be shown for aniline, glu-
taraldehyde, triton X-100 and paracetamol, but not for lactose and methyl
methacrylate. EC50-values obtained for the WST-1, LDH and BCA data were very
similar in all participating laboratories. No increase in IL-1α was observed for these
chemicals.
Conclusion: Local respiratory toxicity induced by chemicals could be tested with
comparable results in the PCLS model without in vivo experiments in three inde-
pendent laboratories. The standardization of the PCLS method was successful and
the reproducibility of the results is very promising after testing of the first 6 sub-
stances.
1470 High-Content Analysis of Drug-Specific Neurotoxic Effects
on Rat Dorsal Root Ganglion Cells.
H. P. Behrsing1,  F. M. Cutuli1,  M. Davis2 and R. E. Parchment1. 1Laboratory of
Investigative Toxicology, Applied/Developmental Research Directorate, SAIC-Frederick,
Frederick National Lab.for Cancer Research, Frederick, MD; 2Division of Cancer
Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.
The incidence of chemotherapy-induced peripheral neuropathy (CIPN) is increas-
ing because more neurotoxic drugs are being developed and these are increasingly
administered in combinatorial regimens to longer living cancer patients. To evalu-
ate neurotoxic drugs, a high content analysis (HCA) strategy was developed to as-
sess response differences of exposed rat dorsal root ganglion cells (DRG). DRG mi-
crowell cultures were exposed to CIPN-inducing drugs (up to 1 μM) for 24 hr.
After exposure, treatment medium was removed and cells were fixed, or were given
fresh culture medium and allowed to “recover” for 24 or 72 hr prior to fixation.
DRG were fluorescently stained for nuclei, acetyl-α tubulin, and Nissl bodies. Four
of the six drugs evaluated caused concentration-specific changes in acetyl-α tubulin
staining (AATS) and total neurite area (TNA) after 24 hr exposure. Eribulin and
colchicine were most potent, reducing TNA by 50% at <10 nM, but only
colchicine effects were reversible after drug removal (AATS intensity doubled in
value and TNA increased >5-fold during the 72 hr recovery period). Taxol moder-
ately decreased TNA (~65% of control), but increased AATS intensity to >150% at
1 μM. Initially, bortezomib notably increased AATS intensity but a later effect in-
cluded loss of AATS, TNA, and increased cell loss after drug removal. Evaluation of
Nissl staining areas also showed drug-specific changes in response to exposure and
“recovery”. Cisplatin and thalidomide had no effect on the parameters measured.
Evaluating cellular response is confounded by low level cytotoxicity and loss of via-
bility over time. The use of HCA has identified several morphological endpoints
and biomarkers of rat DRG that may serve as indicators of drug-specific neurotoxic
risk. Funded by NCI Contract No. HHSN261200800001E.
1471 Testing Nanomaterials in Precision-Cut Lung Slices: In
Vitro–In Vivo Comparisons.
S. Vogel1,  A. Aumann1,  W. Wohlleben3, 1,  S. Treumann1,  U. G. Sauer4,
K. Wiench2,  S. Gröters1,  B. van Ravenzwaay1 and R. Landsiedel1. 1Experimental
Toxicology and Ecology, BASF SE, Ludwigshafen am Rhein, Germany; 2Product
Safety, BASF SE, Ludwigshafen am Rhein, Germany; 3Polymer Physics, BASF SE,
Ludwigshafen am Rhein, Germany; 4Scientific Consultancy - Animal Welfare,
Neubiberg, Germany.
The usefulness of precision-cut lung slices (PCLuS) in assessing nanomaterial
(NM) respiratory toxicity was investigated. The data from testing 16 OECD refer-
ence NM (rutile and anatase TiO2, CeO2, SiO2, Ag, coated and uncoated ZnO
NM, and different multi-walled carbon nanotubes) in rat PCLuS were related to
published in vivo acute inhalation toxicity data, and the influence of different test
system parameters on test results was evaluated. 
After 24-hour exposure to the test substances indicators of oxidative stress (glu-
tathione levels), inflammatory reactions (induction of cytokines: CINC-1/IL-8, M-
CSF, OSP, TNF alpha, MCP-1 and intracellular IL-1 alpha), cytotoxicity (mem-
brane integrity by LDH release, mitochondrial activity by WST-1 metabolism),
and apoptosis (caspase 3/7 activity) were measured in the PCLuS. No concentra-
tion-dependent oxidative stress or apoptosis was observed with any NM. Cytokines
were induced by most of the NM, with varying. ZnO and Ag induced severe cyto-
toxicity, whereas the remaining NM induced no or only slight cytotoxicity in the
tested concentrations. Histopathological evaluation of the PCLuS revealed only
particle uptake into macrophages for most of the NM.
The observed effects in PCLuS by most of the NM not always reflected NM size,
NM class, or pulmonary inflammatory reactions in vivo. The relevance of the dif-
ferent effects measured in PCLuS for respiratory toxicity in vivo needs further in-
vestigations.
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1472 A Transcriptomic Comparison between the Neural and
Cardiac Embryonic Stem Cell Tests (ESTn and ESTc).
P. T. Theunissen1, 2,  J. L. Pennings1,  D. A. van Dartel3,  J. F. Robinson1, 2,
J. C. Kleinjans2 and A. H. Piersma1, 4. 1Health Protection, RIVM, Bilthoven,
Netherlands; 2Toxicogenomics, University, Maastricht, Netherlands; 3Human and
Animal Physiology, University, Wageningen, Netherlands; 4IRAS, University, Utrecht,
Netherlands.
In vitro screening assays may increase testing efficiency and reduce animal use in
developmental toxicity testing. The cardiac mouse embryonic stem cell test (ESTc)
is a promising in vitro assay in this field, in which the effect of developmental toxi-
cants on cardiomyocyte differentiation is assessed. To increase prediction of the
EST approach, we developed a neural differentiation variant of the stem cell test
(ESTn). In both ESTn and ESTc, we performed a series of transcriptomic studies
to characterize gene expression changes 1) across time during normal differentia-
tion and 2) in response to a series of developmental toxicants in the ESTn and
ESTc. In the present study, gene expression profiles of ESTn and ESTc over time as
well as model-specific changes induced by seven compounds are compared. Time-
related gene expression profiles showed that specific genes changed over time differ-
ently in each model, related to the two specific lineages of differentiation.
Interestingly, compound-induced gene-expression changes were generally model-
specific, particularly for methylmercury and flusilazole, which were predicted better
in ESTn and in ESTc, respectively. Valproic acid-induced gene expression changes
were most comparable between ESTn and ESTc. Direct transcriptomic compar-
isons between the ESTn and ESTc models indicate that both assays support and
complement each other. Therefore, a combined transcriptomics approach, incorpo-
rating ESTc and ESTn, may result in improved developmental toxicant detection
over individual assays.
1473 In Vitro Proliferation in Human and Rat Urothelial Cells.
E. L. Bowen1,  J. Southgate1,  S. Baker1 and P. Rawlinson2. 1Jack Birch Unit for
Molecular Carcinogenesis, University of York, York, United Kingdom; 2Syngenta,
Bracknell, Berkshire, United Kingdom. Sponsor: R. Peffer.
Despite the regular use of the rat in toxicity studies, which are used for human risk
assessment, the extrapolation from rat to humans is often difficult. This study set
out to explore the utility of cell culture systems to better understand species differ-
ences. As urine is a main route of chemical excretion from the body, the epithelial
barrier lining of the bladder (urothelium) may be exposed to higher concentrations
of xenobiotics, with the potential for adverse findings. Methods have been success-
fully developed to culture normal human urothelial (NHU) cells in vitro, with sub-
sequent differentiation to form a functional barrier. With this in mind, equivalent
normal rat urothelial cell culture systems were grown from Wistar (NRU-W) and
Homozygous Scottish (NRU-HS) rats. They were compared to human cell cultures
by exploring their regulation and capacity for proliferation. 
NHU cells could be propagated beyond passage 6 in serum-free medium, whilst
NRU-W could only be maintained up to passage 1, and NRU-HS cells required
serum to grow to passage 1. By immunofluorescence, NHU cells were shown to ex-
press nuclear Ki67 and cyclin D1, but the same proliferation markers were cyto-
plasmic in NRU cells. In contrast, Ki67 was virtually negative in histological sec-
tions of human and HS rat urothelium, but strongly expressed (nuclear) in Wistar 
The results for human urothelium reflect the fact it is mitotically-quiescent, and has
a low rate of turnover in vivo, but has a large capacity for regeneration, which can
be seen in culture.  It appears that there may be fundamental differences in the way
in which rat urothelium is regulated, with cells maintained in the cell cycle in vivo
and with a less proliferative phenotype observed in vitro. Future work will aim to
further characterise these differences, and to understand the consequence of these
findings for the development of a comparative model.
1474 In Vivo-In Vitro Comparison of Respiratory Tract Toxicity
Using Human 3D Airway Models and Human A549 and
Mouse 3T3 Monolayer Cell Systems.
U. G. Sauer3,  S. Vogel1, 2,  A. Hess1,  S. N. Kolle1,  L. Ma-Hock1,  B. van
Ravenzwaay1 and R. Landsiedel1. 1Experimental Toxicology and Ecology, BASF SE,
Ludwigshafen am Rhein, Germany; 2Performace Chemicals - Master Data, Product
Safety, Product Stewardship, BASF SE, Ludwigshafen am Rhein, Germany; 3Scientific
Cansultancy - Animal Welfare, Neubiberg, Germany.
Four in vitro systems to predict acute inhalation toxicity were evaluated. 19 sub-
stances (lactose, paracetamol, methylmethacrylate, aniline, acetic- and trimellitic
anhydride, N-hexylchloroformate, octanoyl chloride, isophorone and toluene di-
isocyanate, zinc oxide, paraquat, glutar- and formaldehyde, acetone, ethanol, di-
methylformamide, ammonium hexachloroplatinate and sodiumdodecylsulfate)
were tested in 3D human airway epithelial models, EpiAirwayTM and
MucilAirTM, and in A549 and 3T3 monolayer cell cultures. Cytotoxicity was as-
sessed by determining LDH release and MTT or WST reduction. 
IC50 values were compared to literature rat 4-hour LC50 values classified accord-
ing to the US EPA and GHS hazard categories. Best results were achieved with a
prediction model identifying non-toxic substances (determination of LDH release
in 3T3 cells: sensitivity 1.00 and specificity 0.89). 
Further predictions of in vivo hazard categories based on four in vitro hazard cate-
gories resulted in mediocre correlations: 9 of 19 test substances were classified con-
cordantly in the MucilAir™ system determining MTT reduction and 8 of 19 in
A549 cells determining WST reduction. Concordance could be improved by ex-
cluding substances leading to pulmonary edema and emphysema in vivo. 
None of the test systems was outstanding; and there was no evidence that the use of
3D or monolayer systems using respiratory tract cells provide an added value to
simple 3T3 monolayers. However, the test systems only reflected bronchiole ep-
ithelia and alveolar cells and only investigated cytotoxicity so that effects occurring
in other cells by other mechanisms were not recognized.
1475 Neurotoxicity In Vitro: Assessment of the Predictivity of
Neuronal Networks Coped to Microelectrode Arrays for
Identification of Neurotoxicants.
H. Hüner,  T. Ramirez,  T. Weisschu,  N. Stein,  B. van Ravenzwaay and
R. Landsiedel. Experimental Toxicology and Ecology, BASF SE, Ludwigshafen am
Rhein, Germany.
A challenging aspect to assure the safety of a product is the assessment of its neuro-
toxic hazard potential. Currently, only in vivo methods are regulatorily accepted
and so far, no in vitro model has been fully validated. The majority of the test sys-
tems are reduced to the analysis of cytotoxicity in immortalized cell lines, without
including unique characteristics of the nervous system, such as axonal transport,
synaptic transmission or its electrophysiology. Recently, with the advance in tech-
nology and the ability to maintain neuronal models for prolonged periods, a test
system emerged, combining the use of microelectrode arrays (MEAs) and in vitro
culture of 2D neuronal networks (NN). Herein, we report on the in-house valida-
tion of the NN MEA assay using a set of 43 compounds with known neurotoxic
and non-neurotoxic potential with the aim to use it for screening of compounds
under development. The results demonstrate that the methods presents a sensitivity
of 71%, while the specificity is still an aspect for optimization, since in its current
status, it cannot distinguish specific neurotoxicity from unspecific cytotoxicity. In
order to increase the sensitivity and predictivity, we are currently working on the
combination of the electrophysiological assessment with a panel of cytotoxicity as-
says.
1476 A Human 3D Myocardial Microtissue Model for
Cardiotoxicity Testing.
C. Zuppinger1,  I. Agarkova2,  W. Moritz2 and J. M. Kelm2. 1University of Bern,
Bern, Switzerland; 2InSphero, Zürich, Switzerland. Sponsor: A. Wolf.
Cardiomyocytes (CMs) are terminally differentiated cells in the adult organism and
regeneration is limited. This is a worrisome fact, since insults such as ischemia and
cardiotoxic compounds can lead to cell death and irreversible reduction of cardiac
function. As testing platform, isolated organs and primary cells from rodents have
been the standard in research and toxicology so far, but due to a very limited cell
supply there is a strong need for better in vitro models. Hence, an in vitro model
comprising the advantages of 3D cell culture and the availability of induced
pluripotent stem cells (iPSC) from human origin was developed and characterized.
Myocardial microtissues (MTs) were generated by self-assembly in multi-well hang-
ing drop cultures. iPSC-derived CMs were evaluated regarding cardiac features and
toxicological response. Prior use of the iPSC-derived cells, CMs were characterized
after 10 days in standard culture which showed highly differentiated myofibrils pos-
itive for sarcomeric proteins such as myomesin, myosin, cardiac actin and desmin.
The cells showed spontaneous contractile activity and connexin-43 positive gap
junctions. In the hanging drop cultures, iPS-derived CMs formed MT’s within 4
days, contracting up to 3 weeks recorded by optical motion tracking. Excited by
electrical field pacing they complied to the external stimulus up to 2Hz. Effects of a
cardiotoxic cancer therapeutics such doxorubicin on iPSC-derived CMs in 2D- and
3D-culture were further evaluated with respect to caspase activation, LDH release
and cellular ATP levels. Adult human CMs are a very rare and hard to handle cell
source. New concepts have to be developed to create cardiac models systems to be
used for cardiotox testing, ideally in a standard multi-well format. Within this
“proof-of-concept” study a novel 3-diemensional human myocardial MT model
was developed and characterized based on iPSC-derived CMs. Morphological and
functional characterization underline that this model might become a valuable tool
for substance safety testing in the future.
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1477 Use of An In Vitro Flow Cytometric Method As a
Replacement for Live Animal Experimentation.
J. Godin-Ethier1,  S. Thébaud1,  J. Leiva1,  C. Lévesque1,  A. Nelson1 and W. Lee2.
1Immunology, ITR International, Baie d’Urfe, QC, Canada; 2Toxicology, ITR
International, Baie d’Urfe, QC, Canada.
Scope:
Animal welfare guidelines place more and more emphasis on the 3 Rs principle as a
way to achieve excellence in animal care and use. In that objective, we have devel-
oped an in vitro flow cytometry method that allows us to quantify the immune re-
sponse to Il-2 stimulus in a lymphocyte population thus replacing the use of live
monkeys. 
We have evaluated the potency of test items to phosphorylate stat5 in lymphocyte
subsets expressing or not the IL-2 high affinity receptor subunit (CD25). 
Experimental Procedures and Results:
Cynomolgus monkey peripheral blood mononuclear cells (PBMC) were stimulated
with increasing doses of the test items under evaluation. The PBMCs were then
stained using conjugated monoclonal antibodies specific to different lineage mark-
ers such as CD3, CD4, CD8 and CD25 to allow distinction between the different
T lymphocyte subsets. In addition, in order to evaluate the potency of the test items
to differentially stimulate CD25+ and CD25- lymphocytes, we have evaluated the
activation of a downstream mediator of the IL-2 receptor signaling by measuring
the phosphorylation of the Signal Transducer and Activator of Transcription
(Stat5). Intracellular staining using a Phospho-Stat5 (pStat5) specific antibody was
thus performed and data was acquired by flow cytometry. The pStat5 signal fold-in-
crease was plotted against the test items concentration and the half maximal effec-
tive dose (EC50) was determined. The results obtained showed that the calculated
EC50 for the CD4+CD25+ was of approximately 100 to 1000 times lower com-
pared to CD4+CD25- cells and CD8+ cells. In addition, when comparing the po-
tency to the two test articles to stimulate CD4+CD25+ cells, a 2-log difference was
observed between calculated EC50.
Conclusions:
This innovative approach enables us to replace animal experimentation by an in
vitro assay. Our method assesses the potency of test items to signal through the IL-
2 receptor in different lymphocyte subsets.
1478 The Role of Facilitated Transport by Serum Protein in In
Vitro Intrinsic Clearance.
B. J. Blaauboer,  J. Moulin and N. Kramer. Institute for Risk Assessment Sciences,
Utrecht University, Utrecht, Netherlands.
When a chemical is exposed to an in vitro cell assay in culture medium with serum
protein, the effect (e.g. clearance) observed may be lower than when the chemical is
exposed in culture medium without serum protein. This is because the chemical
can bind to serum protein, which reduces the unbound free concentration of the
chemical available for uptake into cells. Therefore, it is better to determine in vitro
intrinsic clearance (CLint) based on unbound fractions of chemicals. However, a
few studies have suggested that serum protein may also facilitate the transport of
chemicals through aqueous media (facilitated transport). Thus the presence of
serum protein may increase the uptake rate of chemicals into cells and solid phase
microextraction (SPME) fibers. If the uptake rate determines clearance, then the
presence of serum protein may increase clearance, thus hampering the extrapolation
of in vitro Clint to in vivo clearance when clearance assays use varying concentra-
tions of serum. Therefore, the uptake rate and clearance of the strongly-albumin
bound, quickly cleared chemical testosterone was measured in HepaRG, HepG2
and H4IIE hepatoma cell lines at varying concentrations of bovine serum albumin
using the substrate depletion approach. To measure the free fraction, mimic uptake
of testosterone in cells, and facilitate the modeling of the transport into cells, a
SPME method was developed for extracting the unbound chemical from the expo-
sure medium. Results indicate that in vitro CLint of testosterone increases with in-
creasing albumin concentration when using the unbound fraction. SPME was suc-
cessfully applied to determine the free concentration and study the uptake rate of
unbound testosterone into cells.
1479 Screening of Cosmetics Ingredients for Phototoxic Potential
Using the In Vitro 3T3 Neutral Red Uptake Phototoxicity
Test.
R. Labib1,  E. Gilberti1,  S. Gettings1 and H. Raabe2. 1Product Safety & Integrity,
Avon Products, Suffern, NY; 2Institute for In Vitro Sciences, Gaithersburg, MD.
Phototoxicity is an acute toxic response after exposure to a phototoxicant and either
UV radiation or visible light (UV/VIS). Phototoxicity from substances applied top-
ically typically occurs at the site of photo-irradiation. Phototoxicity is the result of
direct cellular damage caused by a nonimmunulogical inflammatory response.
Clinically, phototoxicity resembles an exaggerated sunburn (erythema, increased
skin temperature, pruritis and edema). Phototoxicity reactions have been reported
for both synthetic substances and those which occur naturally (eg., botanical ex-
tracts). Although symptoms generally subside quickly, the potential for substances
used in topical products to cause phototoxicity is clearly of concern for manufac-
turers of cosmetics, personal care and other consumer products. Historically, the
potential to cause phototoxicity from substances applied topically was evaluated by
utilizing various animal models; however in 1997 the 3T3 Neutral Red Uptake
Phototoxicity Test (3T3 NRU PT) was validated by ECVAM’s Scientific Advisory
Committee as an in vitro method for evaluating the phototoxic potential of chemi-
cals shown to absorb in the UV/VIS range. To illustrate the utility of the 3T3 NRU
PT as a useful screening tool in the safety evaluation of potential cosmetic ingredi-
ents, the results of the evaluation of 42 botanical extracts and 25 synthetic chemi-
cals found to absorb in the UV/VIS range are reported. Most substances evaluated
were found not to be photoxic in vitro; however, 9 substances were identified as po-
tentially/probably phototoxic in the 3T3 NRU PT and were eliminated from fur-
ther consideration for use as cosmetic ingredients. Several substances found to be
non-phototoxic in the 3T3 NRU PT were formulated with other ingredients in a
prototype cosmetic formulation and subject to clinical testing. No manifestations
of phototoxicity were observed in any of the test subjects in the prototype formula-
tion containing any of the substances identified as non-phototoxic in vitro.
1480 Validation of a Cell Microelectronic Sensing Technique for
Semi-Quantification of Cyanobacterial Toxins (Microcystins)
in Recreational Water.
V. Charoensuk1,  D. Y. Huang1,  W. Zhang2,  S. Gabos3 and D. W. Kinniburgh1.
1Physiology & Pharmacology, Alberta Centre for Toxicology, Calgary, AB, Canada;
2Protection Branch, Family and Population Health, Alberta Health, Edmonton, AB,
Canada; 3Office of the Chief Medical Officer of Health, Alberta Health, Edmonton,
AB, Canada.
Microcystins (MCYSTs) are hepatotoxins produced by cyanobacteria (blue-green
algae) commonly found in fresh water. There are a few semi-quantitative and quan-
titative detection methods available including protein phosphatase inhibition assay
(PPI), enzyme-linked immunosorbent assay (ELISA) and liquid chromatography
tandem mass spectrometry (LC/MS/MS). 
Our laboratory recently developed a novel assay using a cell microelectronic sensing
technology known as RTCA (Real-Time Cell Analyzer, Roche xCELLigence sys-
tem) for detecting MCYSTs cytotoxicity. The assay is based on the fact that
MCYSTs toxicity requires the active uptake of MCYSTs into the cytoplasmic mem-
brane which is mediated by the organic anion transporting polypeptides (OATPs).
By comparing the 48-hour cytotoxic effects of MCYSTs in wild type Chinese ham-
ster ovarian cells (CHO/WT) and in CHO with OATP1B3 expression
(CHO/OATP1B3), we semi-quantified MCYSTs cytotoxicity in recreational water
using standard curves prepared from MCYST-LR, the most common MCYST ana-
logue. MCYSTs levels in water samples were compared with results from PPI,
ELISA and LC/MS/MS. The RTCA directly demonstrated MCYSTs total toxicity
and the semi-quantitative results have high correlation to those from other methods
(p-value < 0.0001), particularly at the Canadian recreational water guideline level
(20 μg/L) or greater.
In summary, we have validated a semi-quantitative assay for cytotoxic testing of
MCYSTs in recreational water by observing real-time toxic response at microgram
per litre concentrations.
1481 Human Intestinal Microflora Reduces Butyl Paraben Toxicity
in HepG2 Cell Cultures.
W. Kang2,  T. Khanal1,  H. Kim1,  T. Jeong2 and H. Jeong1. 1Pharmacy, Chungnam
National University, Daejeon, Republic of Korea; 2Pharmacy, Yeungnam University,
Gyeongsan, Republic of Korea.
Parabens are alkyl esters of p-hydroxybenzoic acid, including methyl paraben, ethyl
paraben, propyl paraben, and butyl paraben. In the present study, possible role of
metabolism by fecalase in BP-induced cytotoxicity was investigated in HepG2 cell
cultures. As an intestinal bacterial metabolic system for butyl paraben, human fecal
preparation containing intestinal microflora (fecalase) was employed. Initially,
among the parabens tested, cytotoxicity of butyl paraben was most severe. When
butyl paraben was incubated with fecalase, it rapidly disappeared, in association
with reduced cytotoxicity in HepG2 cells. In addition, butyl paraben -incubated
with fecalase reduced cytotoxicity of HepG2 cells in a concentration-dependent
manner. Moreover, butyl paraben-incubated with fecalase significantly caused an
increase in Bcl-2 expression together with a decrease in Bax expression and cleaved
Caspase-3. Furthermore, anti-apoptotic effect by the incubation of butyl paraben
318 SOT 2013 ANNUAL MEETING
with fecalase was also confirmed by the terminal deoxynucleotidyltransferase-medi-
ated dUTP-biotin nick-end labeling assay. Taken all together, the findings sug-
gested that metabolism of butyl paraben by human fecalase might have protective
effects against butyl paraben-induced toxicity in HepG2 cells.
1482 Characterization of Cellular and Molecular Markers of
Toxicity in C6-Glioma Cells Exposed to Modern Pyrethroids.
D. M. Romero,  M. J. Wolansky and M. L. Kotler. Biological Chemistry,
IQUIBICEN (CONICET); School of Sciences, University of Buenos Aires, Buenos
Aires, Argentina.
Pyrethroids (PYRs) are insecticides increasingly used in various pest control appli-
cations. Low levels of PYR residues have been detected in diverse environmental
samples, food and human urine. In vitro systems may be useful to characterize the
diversity of primary and secondary toxicogenic pathways that may account for the
pyrethroid-type specific divergence in clinical syndromes observed in small rodents.
We use C6-glioma cell cultures to identify toxicologically relevant PYR exposures
that may require cumulative risk assessment efforts in animals in vivo. Four com-
pounds (bifenthrin, tefluthrin, α-cypermethrin, deltamethrin) were examined after
24 h of PYR exposure. We also evaluated pyrethroid actions in C6 cells treated with
sodium butyrate (NaBu) which induce an astrocyte-like phenotype. Thresold dose
and EC15(24h) estimates were obtained after modeling MTT test data. In order to
study subcellular integrity and signaling pathways with greater specificity and sensi-
tivity, Mitotracker-Red and Neutral Red staining (informing on mitochondrial and
lysosomal status, respectiv.), caspases and p53 (cell deah related markers), AchE (an
insecticide neurotoxicity related target) and GFAP (glia-specific xenobiotic re-
sponse) were then examined. Low μM exposures induced dose-related declines in
cell viability in both cell systems. We further found dose-related increases in frag-
mented mitochondria and mitochondrial membrane potential disruption in C6
cells. Increase in cell death related proteins and drop of GFAP levels were also ob-
served in NaBu-treated cells. In addition, cholinesterase inhibition was not evident
below EC15 levels for general cell viability for any test chemical. These results con-
firm that μM exposures affect cell viability markers unrelated to the proposed pri-
mary mode of action of pyrethroids, and that the classically proposed target cell for
pyrethroids, the neuron, is not the only cell type that may be susceptible of citotox-
icity and severe cell damage in mammals.
1483 DNA Damage-Induced by Goldenseal Constituents.
S. Chen1,  L. Wan1, 2,  H. Lin1,  L. Couch1,  N. Mei1 and L. Guo1. 1NCTR,
Jefferson, AR; 2Shanghai Institute for Food and Drug Control, Shanghai, China.
Goldenseal is used for the treatment of gastrointestinal disturbances, urinary disor-
ders and inflammation. The major alkaloid constituents in goldenseal are berber-
ine, hydrastine, and canadine. Because it is one of the most widely used herbal di-
etary supplements in the United States and the lack of carcinogenicity data,
goldenseal was nominated to the National Toxicology Program (NTP). The NTP
conducted 2 year bioassay on goldenseal and reported that goldenseal increased the
incidence of liver tumors in rodents. However, the mechanisms of goldenseal-asso-
ciated liver carcinogenesis are unclear. In this study, we compared genotoxicity of
five goldenseal constituents and studied the underlying mechanisms.  Five gold-
enseal constituents tested (berberine, palmatine, hydrastine, hydrastinine, and
canadine) did not induce mutagenecity in the salmonella mutation assay. Berberine
and palmatine at high concentrations showed positive results in the mouse lym-
phoma assay. Berberine and palmatine also caused DNA strand breaks in cultured
hepatic cells whereas the rest three did not. The expression of the γ-H2AX, a bio-
marker of double strand breaks, was induced in a dose-dependent manner in re-
sponse to berberine treatment. In addition, berberine and palmatine suppressed
that activities of both topoisomerase I and II, indicating that the inhibitory effect
may contribute to berberine- and goldenseal-induced genotoxicity and tumori-
genicity.
1484 DNA Adduct Formation and Mutation Induction by
Aristolochic Acid in Rat Spleen.
N. Mei,  X. Guo,  P. McDaniel and T. Chen. Division of Genetic and Molecular
Toxicology, National Center for Toxicological Research, Jefferson, AR.
Aristolochic acid (AA) is a potent human nephrotoxin and carcinogen. We previ-
ously reported that AA treatment resulted in DNA damage and mutation in the
kidney and liver of rats. In the present study, we have determined the DNA adducts
and mutations induced by AA in rat spleen. Big Blue transgenic rats were gavaged
with 0, 0.1, 1.0 and 10.0 mg AA/kg body weight 5-times/week for 3 months. Three
DNA adducts, [7-(deoxyadenosin-N6-yl)-aristolactam I, 7-(deoxyadenosin-N6-
yl)-aristolactam II and 7-(deoxyguanosin-N2-yl)-aristolactam I], were identified by
P32-postlabeling. Over the dose range studied, there were strong linear dose-re-
sponses for AA-DNA adduct formation in the treated rat spleens, ranging from 4.6
to 217.6 adducts/10^8 nucleotides. Spleen cII mutant frequencies (MFs) also in-
creased in a dose-dependent manner, ranging from 32.7 to 286.2 x 10^-6 in the
treated animals. Mutants isolated from the different treatment groups were se-
quenced; there were significant differences between the spectra of 1 mg/kg AA-
treated and control groups, and between the 10 mg/kg AA-treated and control
groups. A:T ÇT:A transversion was the major type of mutation in AA-treated rats,
while G:C Ç A:T transition was the main type of mutation in the vehicle controls.
These results indicate that AA is genotoxic in the spleen of rats exposed under con-
ditions that result in DNA adduct formation and mutation induction in kidney
and liver.
1485 In Vitro Genotoxicity of Ginkgo biloba Extract and Two of
Its Major Components, Quercetin and Kaempferol.
H. Lin,  X. Guo,  S. L. Dial,  C. E. Schulte,  M. G. Manjanatha,  M. M. Moore
and N. Mei. DGMT, NCTR/US FDA, Jefferson, AR.
Ginkgo biloba (ginkgo), one of the world’s oldest living tree species, has been used
for many years for a variety of medicinal purposes. The NTP 2-year bioassays on
ginkgo extract found an increased incidence of liver cancer in mice and thyroid
gland cancer in both mice and rats. In this study, the mouse lymphoma assay
(MLA) was used to evaluate the in vitro mutagenicity of ginkgo extract and two of
its major constituents, quercetin and kaempferol. L5178Y/Tk+/—3.7.2C mouse
lymphoma cells were treated with different concentrations of ginkgo extract (0.2-
1.2 mg/ml), quercetin (3-30 μg/ml) and kaemferol (2.7-57.2 μg/ml) in the absence
of metabolic activation. Ginkgo extract, quercetin, and kaemferol significantly in-
creased the mutant frequency in the MLA. Loss of heterozygosity (LOH) analysis
for mutants induced by quercetin and kaempferol were also examined at five mi-
crosatellite loci spanning the entire mouse chromosome 11. The results indicated
that the mutational spectrum from the quercetin and kaempferol treatment were
significantly different from that of the negative control. In addition, the neutral
comet assay conducted in the mouse lymphoma cells with quercetin and
kaempferol also demonstrated a dose-dependent increase in the DNA double-
strand breaks (DSBs). Western blot analysis showed that quercetin increased the
phosphorylation of ATM, and consequently increased expression of γ-H2AX,
phosphorylated Chk1 and Chk2 in the cells; while kaempferol increased expression
of γ-H2AX and phosphorylated Chk1. These results suggest that ginkgo extract
and two of its major constituents, quercetin and kaempferol, are genotoxic in the
mouse lymphoma cells.
1486 Loss of Heterozygosity Analysis of the Tk Mutants Induced
by Cigarette Smoke Condensates in Mouse Lymphoma Cells.
X. Guo,  M. M. Moore and N. Mei. Division of Genetic and Molecular Toxicology,
National Center for Toxicological Research, Jefferson, AR.
Cigarette smoke condensate (CSC) is a set of sticky particles comprised of thou-
sands of chemicals created by burning cigarette. Our previous study on 11 cigarette
smoke condensates (CSCs) using the mouse lymphoma assay (MLA) has demon-
strated that all these CSCs resulted in a dose-dependent increase of both cytotoxic-
ity and mutagenicity in the mouse lymphoma cells. To elucidate the underlying
mutagenic mechanism, we examined the mutational types of CSC-induced Tk mu-
tants by analyzing loss of heterozygosity (LOH) using the allele-specific PCR at five
microsatellite loci (Tk1, D11Mit42, D11Mit36, D11Mit20 and D11Mit74) span-
ning the entire chromosome 11. For each CSC treatment, 48 large and 48 small
mutant colonies were randomly collected from the cultures of the highest accept-
able concentrations. The statistical analysis demonstrated that the mutational spec-
tra of all colonies induced in CSC-treated mouse lymphoma cells were significantly
different from those of the vehicle control, although the most common type of all
the mutations including CSC-treated and control samples was LOH involving the
Tk and D11Mit42 locus. A larger proportion of LOH at Tk and D11Mit 42 loci
was observed in the CSC-induced small colonies, whereas the large colonies showed
different LOH patterns among the 11 CSCs. These results suggest that CSCs are
mutagenic in mouse lymphoma cells with a clastogenic mode-of-action, and the in-
duction of large and small colony mutants may result from different mechanisms.
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1487 Evaluation of Genotoxicity of Cyproterone Acetate in Both
Sexes of Rats.
W. Ding1,  M. E. Bishop1,  M. G. Pearce1,  G. A. White2,  L. Lyn-Cook1 and
M. G. Manjanatha1. 1Division of Genetic and Molecular Toxicology, FDA/NCTR,
Jefferson, AR; 2Toxicology Pathology Associates, FDA/NCTR, Jefferson, AR.
Cyproterone acetate (CPA), a hormone therapy drug with anti-androgenic activity,
is commonly used for androgenisation symptoms in women and treatment of
prostate cancer in men. CPA is known to produce liver tumor in rats, with a higher
incidence in females. In standard genotoxicity assays, such as Ames test, HGPRT
assay, chromosomal aberration assay and in vivo micronucleus assay, negative re-
sponses were observed. However, more recent studies have demonstrated that CPA
induces a sex-specific genotoxicity, forming DNA adducts in female rats but not in
male rats. To investigate the genotoxicity of CPA, and to answer the question if it is
sex-specific, we evaluated the genotoxicity of CPA through in vivo Comet assay in
both sexes of rats. hOGG1- and Endo III-modified in vivo Comet assay were per-
formed to measure CPA induced oxidative DNA damage. Groups of 5 seven-week
old male F344 rats were treated with olive oil or 10, 25, 50 or 100 mg/kg bw CPA
in olive oil at 0, 24, and 45 hr. Animals were sacrificed at 48 hr, 3 hr after the last
treatment. Liver, testis, kidney and blood were collected for Comet assay. CPA
treatment resulted in an increase in DNA strand breaks in the liver of male rats with
significant (p≤0.05) increases detected in rats treated with 50 and 100 mg/kg CPA.
There were near-linear dose responses for EndoIII-sensitive and hOGG1-sensitive
DNA damages in CPA-treated rat livers, both with significant (p≤0.05) increases
detected in all the dose groups, suggesting a possible role of reactive oxygen species
for CPA-induced genotoxicity. To evaluate the genotoxicity of CPA in female rats,
groups of 5 seven-week old female F344 rats will be treated identically with CPA.
Liver, mammary gland, uterus, ovary, kidney and blood will be collected for Comet
assay and the responses will be compared with the males. This study will provide a
further understanding of the cancer mode of action of CPA and if there is any sex-
specific genotoxic response in rats.
1488 Assessment of Dosimetry and Biological Responses In Vitro
Using a Vitrocell® Smoke Exposure System.
D. Thorne1,  J. Kilford2,  B. Payne2,  K. Scott1,  J. Adamson1,  A. Dalrymple1,
C. Meredith1 and D. M. Dillon1. 1Group R&D, British American Tobacco,
Southampton, United Kingdom; 2Covance Laboratories Ltd., Harrogate, United
Kingdom.
Routine toxicological assessment of tobacco smoke commonly uses the particulate
fraction of the smoke aerosol. The particulate phase of cigarette smoke makes up a
small percentage of the total aerosol, approximately 5-9% by weight. The remain-
ing ~91% is associated with the vapour phase of cigarette smoke and is not rou-
tinely evaluated. Whole smoke exposure systems are capable of capturing the full
interactions of both the particulate and vapour phase together and offer unique po-
tential for toxicological assessment. 
In this study we used a Vitrocell® VC10 smoking robot to expose cell cultures at
the air-liquid interface to ISO mainstream 3R4F cigarette smoke. All experiments
were independent and completed a minimum of three times. For biological assess-
ment we developed the Neutral Red Uptake (NRU) assay with a Balb/c cell line,
and the Ames assay using bacterial strain YG1042. We also used a novel quartz crys-
tal microbalance (QCM) tool for real-time in situ deposition analysis. For the Ames
assay we observed a mean fold increase of 5.9 at the highest concentration of smoke
tested (1L/min), which correlated with a 2.29μg/cm2 increase in particulate deposi-
tion. Clear differences were seen at all doses; for example, 12, 8 and 4L/min pro-
duced a 2.1, 2.3, 3.8 and 0.04, 0.09, 0.50 fold increase and deposited mass
(μg/cm2) respectively. The NRU assay showed a complete cytotoxic dose response
(12-1L/min), with a calculated dilution IC50 and deposited mass IC50 of approxi-
mately 6.5 L/min and 1.7μg/cm2 respectively. 
We conclude that the VC10 can be used in conjunction with routine toxicological
assays for the assessment of cigarette smoke toxicity, as demonstrated by consistent
responses in two independent in vitro test systems. Furthermore, QCM measure-
ments in situ of exposure have enabled us to present biological data as a function of
deposited mass. QCMs have also acted a important QC tool for smoke exposure
and provide valuable information on the exposure system itself.
1489 Evaluation of the Results of Several Genotoxicity Tests in
Carvacrol and Thymol.
J. Scognamiglio,  V. T. Politano and A. Api. Research Institute for Fragrance
Materials, Woodcliff Lake, NJ.
Carvacrol (CAS499-75-2) and thymol (89-83-8) are fragrance ingredients that
have been studied in bacterial and mammalian genotoxicity assays in vitro and in
an in vivo chromosome aberration test. These materials have antibacterial and anti-
fungal properties and are cytotoxic. Their cytotoxicity needs to be considered when
evaluating the results of genotoxicity assays using mammalian cell cultures because
cytotoxicity is the most important confounding factor in analyzing these results. To
avoid the occurrence of secondary (indirect) modes of clastogenic activity, the high-
est concentrations tested in these assays should lead to sufficient levels of cytotoxic-
ity within the guidelines, but not cause extreme cytotoxicity. In published litera-
ture, there are inconsistent results of the genotoxicity tests on these two materials,
where positive results correlate with cytotoxicity, indicating that positive results can
be explained by secondary effects. An SOS Chromotest was less prone to false pos-
itives than the Ames test and was negative with both carvacrol and thymol. A posi-
tive chromosomal aberration test in rats on both carvacrol and thymol was further
evaluated to clarify the cause of the chromosomal aberration observed. Thus an in
vitro micronucleus test in human peripheral blood lymphocytes was conducted
with careful selection of doses based on cytotoxicity to determine if these materials
were potential clastogens or a spindle poison. Both assays yielded negative results,
supporting the hypothesis that the previous positive genotoxic outcomes were the
result of high cytotoxic activity in the test system and that carvacrol and thymol are
likely not genotoxic agents.
1490 No Direct Genotoxic Potential of Different Radiofrequency
Electromagnetic Fields in MRC-5 Cells and B6C3F1 Mice.
C. Dasenbrock1,  T. Tillmann1,  A. Oertel1,  H. Brockmeyer1,  M. Murbach2,
M. Capstick2,  N. Kuster2 and C. Ziemann1. 1Fraunhofer ITEM, Hannover,
Germany; 2IT’IS Foundation, Zurich, Switzerland.
Public exposure to electromagnetic fields in the radiofrequency spectrum (RF-
EMF) has increased dramatically, attracting notice to health risk evaluation. RF-
EMF was classified as possibly carcinogenic to humans (Group 2B) by the IARC in
2011. But clear risk assessment is still limited by data gaps and contradictory data,
not only for mobile phones but also for wireless network devices. As there are some
indications for disturbance of DNA-integrity by RF-EMF exposure, we evaluated
the in vitro and in vivo genotoxic potential of different RF-EMF signals by using
well established and standardized genotoxicity. 
In vitro, normal human MRC-5 lung fibroblasts were exposed intermittently (5
min ON, 10 min OFF) in a 1950 MHz exposure system for 1, 4, and 24 h to vari-
ous RF-EMF signals (continous wave (CW), UMTS, WiFi, GSM-basic, RFID) at
specific absorption rates (SAR) up to 4.92 W/kg. DNA-strand break (SB) induc-
tion and oxidative DNA-damage were subsequently evaluated in an enzyme
(hOGG1)-modified comet assay. 
In vivo, male B6C3F1 mice were whole-body exposed to CW, UMTS, WiFi, or
RFID signals at SAR of 1.6, 4.0 and 10 W/kg for 14 d, 20 h/d (5 min ON, 10 min
OFF) using a reverberation chamber. Micronucleus (MN) frequency was deter-
mined in peripheral blood, immature bone marrow erythrocytes and keratinocytes.
Irrespective of signal type, SAR-value, and exposure duration RF-EMF did not me-
diate significant cytotoxicity, induction of DNA-strand breaks, or oxidative DNA-
damage in MRC-5 cells, compared to concurrently sham-exposed cells. In addition,
no increase in MN formation was observed in B6C3F1 mice. In conclusion, none
of the tested signal modulations revealed evidence for a direct DNA-damaging or
cytotoxic potential of RF-EMF. 
This study was part of the SEAWIND project, funded by the European Union’s Seventh
Framework Programme ([FP7/2007-2013)] under grant agreement No. 244149.
1491 In Vitro Evaluation of Cytotoxic and Genotoxic Effects of
Ofloxacin.
V. Sekeroglu1, 2,  Z. Atli Sekeroglu1, 2,  M. Aksoy2 and S. Kontas2. 1Applied
Medical Sciences, University of Southern Maine, Portland, ME; 2Biology, University
of Ordu, Ordu, Turkey. Sponsor: J. Wise Sr.
Ofloxacin (OFX), the second-generation of quinolones, is a broad-spectrum
flouroquinolone antibiotic used in the treatment of various bacterial infections. In
this study, the genotoxic and cytotoxic effects of OFX in cultured human peripheral
blood lymphocytes were investigated by measuring chromosome aberrations (CAs),
sister chromatid exchange (SCE) assay, mitotic index (MI) and proliferation index
(PI). Cultures were treated with three doses of OFX (30, 60 and 120 μg/ml) at 48
h exposure period for all assays. An untreated culture (negative control) and a posi-
tive culture treated with MMC (positive control) were established, as well.
Although the frequency of SCE slightly increased in a concentration-dependent
manner, dose-dependent increases were not observed in the CAs. But, these in-
creases were statistically not significant, compared to negative control (P < 0.05).
With respect to the cytotoxic effects of the test compound on lymphocyte cultures,
as measured by MI and PI, a concentration-dependent reduction in cell prolifera-
tion was also observed. The highest dose of OFX (120 μg/ml) significantly reduced
the MI values compared to negative control (P < 0.05), whereas decreases in PI val-
ues were not found significant compared to negative control.
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The results of this study indicate that OFX can exert a cytotoxic effect especially at
the higher doses because of statistically significant decreases in MI, but has no
genotoxic activity in both CA and SCE assays in human peripheral blood lympho-
cyte cultures.
1492 Genotoxic Effects in Children Environmentally Exposed to
Particulate Matter.
M. Sánchez-Guerra1, 2,  A. Araujo3,  L. Serrano-García3,  L. Hernández-Cadena4,
R. Montero-Montoya1,  I. Alvarado-Cruz1,  A. De Vizcaya-Ruiz1,  L. Rafael-
Vázquez1,  E. Jiménez-Mendoza1, 5,  J. Torres-Arellano1, 5,  V. Mugica6 and
B. Quintanilla-Vega1. 1Toxicology Department, CINVESTAV-IPN, Mexico City,
Mexico; 2Exposure Epidemiology and Risk Program, Harvard School of Public Health,
Boston, MA; 3Instituto de Investigaciones Biomédicas, UNAM, Mexico City, Mexico;
4INSP, Cuernavaca, Mexico; 5FEZ-Iztacala, UNAM, Mexico City, Mexico; 6UAM-
Azcapotzalco, Mexico City, Mexico.
Ecatepec County is considered one of the most contaminated counties in the
Metropolitan Area of Mexico City. There are reports about the high levels of partic-
ulate matter (PM) in this area related to the high traffic and industrial activity. PM
is associated with several health problems including genotoxic effects. Children are
considered one of the most susceptible populations to air pollution. The aim of this
study was to evaluate the DNA damage related to the exposure to PM in the air. We
conducted an air monitoring study and an epidemiological survey in schoolchild-
ren from 6 to 10 years (n=86) of both genders in an area of Ecatepec County and
the following was evaluated: concentrations of PM10 and PM2.5 in the air, as well as
the organic and elemental carbon content (CO and CE, respectively), the presence
of micronucleus (MN), apoptotic cells (AC) and necrotic cells (NC), and the nu-
clear division index (NDI) in peripheral lymphocytes by the cytokinesis-block mi-
cronucleus test in 1000 cells. The geometric average age was 8.4 years; 41% of chil-
dren showed at least 1 MN (range 1-6), 27% showed 1-49 AC and 16% had 1-9
NC, some children showed exceptionally high AC or NC values. We found a sig-
nificant association between CO-PM10 and the presence of MN, AC and NC, and
a decrease in the NDI, while CE-PM10 was associated with MN and NC.
Regarding PM2.5, the CO content was associated only with the presence of MN.
These preliminary data suggest that both the CO and CE contents of PM from
Ecatepec County are involved in the genotoxic effects observed in schoolchildren.
Study supported by CONACYT-México (Grant #106034).
1493 Bariatric Surgery Reduces Intestinal Toxicity in Man.
A. Alkandari,  Q. Wu,  H. Ashrafian and N. J. Gooderham. Surgery and Cancer,
Imperial College London, London, United Kingdom.
Obesity is a global epidemic. Worldwide 500 million people are classified as obese
with a global prevalence that continues to rise. Obesity and its co-morbidities are
amongst the leading causes of global mortality and morbidity and pose substantial
socioeconomic burdens on health services worldwide. Bariatric surgery is a form of
gastrointestinal surgery that leads to sustained weight loss, resolution of type 2 dia-
betes and a decrease in cancer risk. These operations alter gut microbial composi-
tion which is reflected in the bacterial composition of faeces. We hypothesise that
the protective effect of bariatric surgery is due to a decrease in diet-derived intes-
tinal toxic burden. Here, we determined the effect of bariatric surgery on intestinal
cytotoxicity and genotoxicity in man. Aqueous dimethyl sulfoxide faecal extracts
were obtained from preoperative and 2 month postoperative samples from 5 indi-
viduals undergoing Roux-en-Y gastric bypass. Human MCL5 cells, a lymphoblas-
toid cell line expressing CYP1A1, 1A2, 2E1 and 3A4 and epoxide hydrolase, were
used to assess faecal extract toxicity and genotoxicity was determined at the TK and
HPRT loci using benzo(a)pyrene as a positive control. We found a trend of de-
creased cytotoxicity postoperatively, as assessed by relative total growth (20% de-
crease compared to preoperative faecal extracts). Furthermore, the genotoxicity of
the faecal extracts decreased postoperatively at both the TK and HPRT loci (30%
and 70% respectively, whereas the BaP control induced mutation frequency more
than 50 fold). These results support the hypothesis that bariatric surgery leads to a
decrease in diet-derived intestinal toxicity burden, which in turn may contribute to
the health beneficial effects associated with surgery.
1494 The Tobacco-Specific nitrosamine 4-(methylnitrosamino)-1-
(3-pyridyl)-1-butanone (NNK) Induces Mitochondrial and
Nuclear DNA Damage in Caenorhabditis elegans.
R. K. Bodhicharla1,  P. Gaddamanugu2 and J. N. Meyer1. 1Nicholas School of the
Environment, Duke University, Durham, NC; 2R.J. Reynolds Tobacco Company,
Winston-Salem, NC.
The metabolites of the tobacco-specific carcinogen NNK form DNA adducts in
animal models. One report indicates that NNK could cause damage to the mito-
chondrial as well as nuclear genome in rats (Stepanov and Hecht, 2009 Chem. Res.
Toxicol. 22: 406–414). Using a different DNA damage detection technology, we
tested whether this could be repeated in the nematode Caenorhabditis elegans; we
also evaluated whether mitochondrial function would be affected. We treated N2
strain (wild-type) nematodes with NNK in liquid culture. Quantitative PCR was
applied to analyze NNK-induced nuclear and mitochondria DNA damage. This
assay has the advantage of measuring all DNA lesions that inhibit the DNA poly-
merase, and normalizes results to mitochondrial DNA copy number (Hunter et al.,
2010 Methods 51:444-451). Our results confirm that NNK causes both nuclear
and mitochondrial DNA damage, but surprisingly nuclear DNA damage was
greater than mitochondrial DNA damage in C. elegans. To test whether the mito-
chondrial DNA damage was associated with mitochondrial dysfunction, we used a
transgenic nematode strain that permits in vivo measurement of ATP levels and
found lower levels of ATP in NNK-exposed animals when compared to the unex-
posed controls. To test whether the lower levels of ATP were due to the inhibition
of respiratory chain components we investigated oxygen consumption in whole C.
elegans and found reduced oxygen consumption in exposed animals when com-
pared to the unexposed controls. Our data suggest a model in which NNK causes
damage to both nuclear and mitochondrial genomes, and support the hypothesis
that the mitochondrial damage is functionally important. These results also repre-
sent a first step in developing this genetically tractable organism as a model for as-
sessing NNK toxicity.
1495 Meta-Analysis Evaluating the Association between Diseases
Linked to Asbestos and Genetic Polymorphisms.
L. Lievense1,  C. J. Ronk2,  S. A. Gross3 and C. A. Barlow3. 1ChemRisk LLC,
Chicago, IL; 2ChemRisk LLC, San Francisco, CA; 3ChemRisk LLC, Boulder, CO.
Asbestos is a ubiquitous, naturally occurring mineral fiber that has been linked to
the development of malignant and fibrotic lung diseases. Numerous studies have
shown that a polymorphism in the genes involved in xenobiotic and oxidative me-
tabolism or in DNA repair processes may play an important role in the pathogene-
sis of many, if not most, diseases. Unlike some other neoplastic diseases, no associa-
tion with mesothelioma risk has been consistently demonstrated for polymorphic
genes involved with oxidative stress, metabolism, or DNA repair. To evaluate the as-
sociation between diseases linked to asbestos and genetic variability, we performed
a meta-analysis combining the available data on the presence of polymorphisms in
GSTM1, GSTT1, NAT2, mEH, XRCC1, and XRCC3 from Italian (n = 57) and
Finnish (n = 48) populations with pleural mesothelioma in which the relative mag-
nitude of asbestos exposure was classified. Meta-relative risk statistics were esti-
mated through fixed effects modeling using SAS software. Our analysis found that
the GSTM1 null genotype, NAT2 fast acetylator genotype, mEH low activity
genotype, and the T/M variant allele of XRCC3-T241M were significantly associ-
ated with having an increased risk of pleural mesothelioma. When mesothelioma
patients were stratified by asbestos exposure (high vs. low), the association between
mesothelioma and GSTM1, NAT2, and mEH was not statistically significant for
the high exposure group. The association between the T/M variant allele of
XRCC3-T241M and mesothelioma was significantly increased, regardless of as-
bestos exposure. The R/Q variant allele of XRCC1-R399Q appeared to be con-
fined to those mesothelioma patients with a history of high exposure to asbestos, al-
though the confidence interval includes parity. The results from the present analysis
strengthen the hypothesis that intensity of asbestos exposure combined with the
presence of certain genetic polymorphisms may increase individual mesothelioma
risk.
1496 Evaluation of the Mutagenicity of Dyed Fabrics with Direct
Black 38.
G. A. Oliveira1,  D. M. Leme1,  T. C. Santos2,  M. B. Zanoni2 and D. P. Oliveira1.
1Faculty of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo (USP),
Ribeirão Preto, Brazil; 2Institute of Chemistry, University Estadual Paulista
(UNESP), Araraquara, Brazil.
There are several information on toxicity of textile dyes, but data of colored fabrics
are still limited. Although a dye itself may be toxic, its presence in the finished ma-
terial may not be harmful. Direct Black 38 (DB38) is a benzidine-based azo dye,
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commonly used in textile industry. It is known that, under conditions of perspira-
tion, dyes migrate from colored fabrics and penetrate into human skin. Objective:
Evaluate the mutagenicity of DB38 extracted from dyed cotton fibers using artifi-
cial sweat solutions. Methodology: Pieces of cotton fabric were dyed with DB38
and washed with and without rinsing (bath with a colloid dispersant). DB38 was
extracted from the dyed fabric with artificial sweat solutions (pH 5.5, 6.5, 8.0) at
37°C and 42°C for 2, 8 and 12 h. HPLC-DAD analysis was performed to deter-
mine the concentration of dye extracted in each sweat extract. Both original dye
and sweat extracts were evaluated by the Salmonella/microsome assay using the
strains TA98 and TA100 with and without S9 mix in order to compare with the
higher dye concentration extracted with sweat. Results: Original DB38 dye showed
positive mutagenic response for TA98 and TA100 with S9. The migration of DB38
dye into artificial sweat resulted in 5.9 μg/mL (dyeing without rising, pH 8.0,
42°C, 8 h). Sweat extracts with DB38 did not induce mutagenic effects under the
conditions tested. Discussion: Original dye induces mutagenicity by both base-pair
substitution and frameshift mutations in presence of S9. However, these effects
could no longer be observed after its extraction from dyed fabric using artificial
sweat as extracting agent. Our findings showed that DB38 dye can migrate from
colored fabrics to artificial sweat, however the concentration of dye extracted does
not cause mutagenicity. Thus, as important as the toxicological information of tex-
tile dyes, is an investigation of the toxic effects of fabrics which contain these dyes
in order to avoid human health problems.
1497 Characterizing the Genotoxicity of the Trichloroethylene
Metabolite Dichlorovinyl Cysteine.
J. B. Asfaha,  V. De La Rosa and C. Vulpe. University of California Berkeley,
Berkeley, CA.
Trichloroethylene (TCE) is an industrial solvent and common environmental con-
taminant. TCE is metabolized via the glutathione conjugation (GSH) pathway
where the reactive metabolite, dichlorovinyl cysteine (DCVC) is formed. Previous
work in the field has shown DCVC as the penultimate metabolite resulting in renal
toxicity. Our studies using a functional genomics approach in yeast suggest DNA
damage and repair pathways play a role in DCVC toxicity. Specifically, we identi-
fied the error-prone translesion synthesis (TLS) repair pathway and nucleotide ex-
cision repair (NER) as important for response to DCVC exposure. Preliminary
work in human fibroblast cells shows initiation of tranlesion synthesis repair after
DCVC exposure. Studies to identify potential DCVC-DNA lesions were con-
ducted using liquid chromatography mass spectrometry (LCMS) analysis. Results
indicate the potential for DCVC to cause direct DNA damage via DNA adducts
with specific nucleotides. Our data suggests DCVC is genotoxic and has the poten-
tial to lead to cell death.
1498 Coexposure to LA Sweet Crude Oil and Dispersant Alters
Genomic DNA Damage Occurrence in the Gulf Killifish.
K. E. Germ and G. D. Mayer. Environmental Toxicology, The Institute of
Environmental and Human Health, Texas Tech University, Lubbock, TX.
The BP-Deepwater Horizon event in the Gulf of Mexico unleashed an unprece-
dented environmental disaster where more than 650 miles of Gulf coastline was lit-
tered with Louisiana Sweet Crude oil. During this event Corexit 9500, a surfactant
designed to disperse and emulsify crude oil and expedite microbial breakdown, was
used to mitigate damage. However, surfactant additives can increase membrane
permeability and biological uptake of exogenous compounds including compo-
nents of crude oil. Recent studies indicate that although visible traces of weathered
crude oil have long been absent in the estuarine environments, particular toxic mu-
tagens persist in organisms and sediments that were once co-exposed to oil and dis-
persant. This research focuses on the notion that toxic components of crude oil may
persist and adversely affect genomic integrity. We examined genomic DNA coding
sequences, cytochrome c oxidase-subunit1 and cystic fibrosis transmembrane con-
ductance receptor for lesion analysis. Here we show that killifish, Fundulus grandis,
exposed to crude oil and dispersant have increased amounts of genetic damage in
both mitochondrial and nuclear templates, relative to killifish exposed to each indi-
vidual compound. Additionally, DNA lesion formation in the mitochondrial
genome was increased in the co-exposures, compared to singular exposures of con-
taminants.
1499 Absence of Genotoxicity in a Series of 2’-O-Methyl
Phosphorothioate Oligonucleotides.
Y. Ponstein,  C. den Besten and S. de Kimpe. Prosensa, Leiden, Netherlands.
Sponsor: F. van Doesum-Wolters.
PRO044, PRO045 and PRO053 are 2’-O-methyl phosphorothioate RNA anti-
sense oligonucleotides (AON) that are in development for the treatment of
Duchenne Muscular Dystrophy (DMD), a lethal orphan disease for which no dis-
ease modifying therapy exists. The fundamental cause of this disease is mutations in
the dystrophin gene leading to out of frame transcripts for the corresponding mus-
cle protein. AON-induced exon skipping of exon 44, 45 and 53, respectively, in
human dystrophin pre-mRNA results in the restoration of the reading frame and an
internally deleted but functional dystrophin protein. The mutagenic and clasto-
genic potential of PRO044, PRO045 and PRO053 was assessed using in vitro tests
in bacteria and mammalian cells and an in vivo rodent assay. The bacterial reverse
mutation assay (i.e. Ames test using Salmonella typhimurium TA98, TA100,
TA102, TA1535 and TA1537) showed that the mentioned AONs have no muta-
genic activity at concentrations up to 5,000-10,000 μg per plate, in the presence or
absence of an in vitro metabolic activation system (S9-mix). The Chinese hamster
ovary (CHO) chromosomal aberration assay showed that PRO044, PRO045 and
PRO053 did not induce structural aberrations in the presence or absence of S9-
mix, with tested concentration up to 5,000 μg/mL. In addition, PRO044,
PRO045 and PRO053 did not induce any polyploidy or give indications of muta-
genic properties in the presence or absence of S9-mix at 5,000μg/mL. In the in vivo
micronucleus assay, no genotoxic effect was observed in the bone marrow of mice
following repeated subcutaneous administrations of PRO044, PRO045 and
PRO053 at dose levels ranging between 80 and 1,000 mg/kg on days 1, 3, 5, and 8,
resulting in a weekly dose of 320 to 4,000 mg/kg. In conclusion, results from these
experiments demonstrate that PRO044, PRO045 and PRO053 are not mutagenic
nor clastogenic. This is in accordance with the EMA’s reflection paper indicating
that phosphorothioate nucleotides (as potential degradation products/metabolites
of phosphorothioate oligodeoxynucleotides) are unlikely to pose a genotoxic haz-
ard.
1500 Different Extraction Strategies to Evaluate the Genotoxicity
of the Water Soluble Fraction of Air Particulate Matter.
I. C. Palacio2, 1,  R. L. Franklin1,  C. F. Suzuki1,  I. F. de Oliveira1,
D. A. Roubicek1 and S. B. Barros2. 1Departamento de Análises Ambientais,
Companhia de Tecnologia de Saneamento Ambiental, São Paulo, Brazil;
2Departamento de Análises Clínicas e Toxicológicas, Universidade de São Paulo, São
Paulo, Brazil.
Exposure to contaminated airborne particulate matter (PM) as a consequence to
urban air pollution has adverse effects on human health and the ecosystem. In most
air pollution studies, only the genotoxic potential of the organic fraction is evalu-
ated and the toxic effects of the soluble metals are not usually verified.In order to
determine an appropriate extraction method for assessing the mutagenicity of the
water-soluble fraction of PM, we performed microwave assisted (MW) and ultra-
sonic bath (UT) extractions, using water as the only solvent, in 10 different air sam-
ples (Total particulate matter-TPS- and PM10- fraction of particles with diameter
of 10μm or less), from the state of Sao Paulo, Brazil. Mutagenicity and extraction
performances were evaluated using the Salmonella/microsome assay with strains
TA98 and TA100, followed by chemical determination of soluble metals (ICP).
Except for one sample, the mutagenic potential of TPS was significantly higher in
the samples extracted with MW than those with UT. The PM10 samples extracted
with MW showed mutagenic activity only with TA98, with and without metabolic
activation, and in those with UT there was no biological response. Of the metals
analyzed (Ni, Cu, Zn, Cr, Fe, Pb, MN, Co, V and Ti), only vanadium (in the sam-
ples extracted with MW) and copper (in the UT extracted samples) were above de-
tectable levels. Our results demonstrate the importance in determining an efficient
extraction method for evaluating genotoxicity, especially at low concentrations of
water-soluble contaminants in the air particulate matter. The MW represented a
powerful tool to evaluate the genotoxicity of those samples, and additionally has
methodological advantages against UT, allowing more reproducibility of the test
conditions and improving the analysis precision. Suppprted by CAPES Ph.D. fel-
lowship Isabel Palacio
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1501 Time Course Study of Sulphur Mustard-Induced DNA
Damages in Hairless Skh-1 Mice.
M. Batal1, 2,  I. Boudry2,  C. Cléry-Barraud2,  S. Mouret2 and T. Douki1. 1CEA,
Grenoble, France; 2IRBA, La Tronche, France. Sponsor: J. McDonough.
A major target for sulphur mustard (SM) is DNA. DNA alkylation leads to the for-
mation of monoadducts, mainly at the N7 position of guanine (HETE-N7Gua:
N7 hydroxyethylthioethyl-guanine) and in a lesser extent at the N3 position of ade-
nine (HETE-N3Ade: N3 hydroxyethylthioethyl-adenine), and biadducts (N7Gua-
ETE N7Gua: bis[N7guanine–ethyl]sulphide). It is a critical step to explain SM cy-
totoxicity. Therefore, we have developed a high performance liquid
chromatography coupled to tandem mass spectrometry (HPLC-MS/MS) method
to quantify the three main SM-DNA adducts. The assay was applied to SKH-1
mice exposed to liquid SM on the dorsal skin at 2, 6 and 60 mg/kg during 4h and
were sacrificed at 6h, d1 (day 1), d3, d7, d14 and d21 after exposure. SM exposed
skin, skin adjacent to exposed skin and skin being located at 2 cm apart of this lat-
ter were removed. The maximum of DNA lesions in SM exposed skin was obtained
at 6h post-exposure. The contribution of HETE-N3Ade to SM DNA adducts in
skin was much lower than that found in isolated and cellular DNA in previous ex-
periments. Adducts frequencies decreased from d1 likely as the result of DNA re-
pair. Yet a relatively important persistence of SM-DNA adducts was observed since
HETE-N7Gua and N7Gua-ETE N7Gua were still detected at d21 after 60 mg/kg
exposure. For each exposure dose, SM-DNA adducts were also measured, in skin
adjacent to the exposed zone, although in lower amounts. They were quantified
until d14 after 60 mg/kg exposure. For the highest dose, SM-DNA adducts were
detected at 2 cm of the burn but only at d1. These results show a limited radial dif-
fusion of SM in skin but a significant persistence in time. They also demonstrate
the reliability of our method to quantify SM-DNA adducts which could be moni-
tored as part of therapeutic tests.
1502 Acurate Assessment for the In Vitro CB Micronucleus Test by
Comparison of Two Different Protocols Using Human
Lymphocytes.
S. Bohnenberger,  A. Poth and W. Voelkner. Genotoxicity and Alternative
Toxicology, Harlan Cytotest Cell Research, Rossdorf, Germany.
The OECD Guideline 487 for the In Vitro Mammalian Cell Micronucleus Test
(MNvit) became effective in July 2010. The objective of the test is to identify mi-
cronucleus formation via clastogenic and aneugenic mechanisms in cells that have
completed mitosis. This work presents the assessment of various test parameters for
the performance of the assay with human lymphocytes with regard to the above
mentioned Guideline. With respect to the In Vitro Mammalian Cell Micronucleus
Test (MNvit) aneugenic and clastogenic reference chemicals (colcemid/demecolcin,
mitomycin C (MMC) and cyclophosphamide (CPA). were tested for their poten-
tial to induce micronuclei in cultured human peripheral blood lymphocytes. The
protocol given by the current OECD Guideline 487 was compared to a slightly
modified protocol allowing the cells to have a recovery period between end of treat-
ment and addition of the cytokinesis blocker cytochalasin B. Lymphocyte prolifer-
ation was studied in response to stimulation with phytohemagglutinin and the nor-
mal cell cycle time was assessed by bromodeoxyuridine uptake. The presented data
show difficulties in the detection of an aneugenic compounds in binucleate cells
and marked differences in the induction of micronuclei in the micronucleus in
vitro by the two different test protocols employed by using the four different refer-
ence chemicals. Reproducible results were obtained with the clastogenic reference
chemical MMC, regardless of the protocol used. With both aneugenic compounds
robust and adequate results could be obtained by including the evaluation of mi-
cronucleated cells and using the pulse treatment. Robust data were obtained with
CPA when using a time schedule including a recovery period.
1503 Clastogenicity and Mutagenicity Testing of Gaseous
Compounds.
C. S. Farabaugh1,  J. Randazzo2,  M. M. Wells1,  M. L. Moy1 and M. J. Schlosser1.
1WIL Research, Skokie, IL; 2WIL Research, Ashland, OH.
WIL Research evaluated methods for genetic toxicology testing with gaseous com-
pounds in both the In Vitro Chromosome Aberration (CA) assay using human pe-
ripheral blood lymphocytes (HPBL) and the Bacterial Reverse Mutation assay
(Ames assay). In the CA assay, 10 mL HPBL cultures were initiated with S9 (3-
hour exposure) and without S9 (3- and 22-hour exposures) in flasks and were sealed
in airtight Tedlar bags using a heat sealer. The air was evacuated and a mixture of
ambient air, ~5% CO2, and the appropriate concentration of Chloroethane (CE)
up to 30% v/v for the 22-hour exposure or Propylene Oxide (PO) up to 10% v/v
for the 3-hour exposures were added via a septum into the bag. The cultures in the
bags were then incubated at 37°C in a humidified atmosphere with 5% CO2. For
the 3-hour exposure periods, cultures were removed from bags and washed before
being returned to the humidified incubator until a single harvest time of ~22 hours.
Statistically significant, dose related increases in cells with aberrations when com-
pared to the vehicle control cultures were observed with responses of up to 42% of
cells for the 22-hour exposure (at a dose level of 5% v/v), 14.5% for the 3-hour ex-
posure with S9 (2.5% v/v), and 30% for the 3-hour exposure without S9 (2.5 %
v/v).   
In the Ames assay, Salmonella tester strains TA98, TA100, TA1535, and TA1537
and E. coli tester strain WP2uvrA were exposed using the preincubation method to
various concentrations of CE up to 25% v/v and incubated at 37°C for ~30 min-
utes in sealed Tedlar bags. The air was evacuated and a mixture of ambient air and
the appropriate concentration of CE were added via a septum into the bag.
Following exposure, the cultures were removed from the bags, plated, and incu-
bated at 37°C for ~48 hours. Dose related increases in the mean number of rever-
tants when compared to the vehicle control cultures were observed.   
Results indicate that gaseous exposures using Tedlar bags are appropriate for pro-
ducing positive responses with and without S9 with known clastogenic and muta-
genic compounds in the CA and Ames assays.
1504 Quantitative Analysis of Specific DNA Adducts and In Vivo
Mutagenicity following Exposure to the Hepatocarcinogen
Estragole.
Y. Ishii1,  S. Takasu1,  K. Matsushita1,  K. Kuroda1,  T. Nohmi2,  K. Ogawa1,
A. Nishikawa1 and T. Umemura1. 1Pathology, National Institute of Health Sciences,
Tokyo, Japan; 2Research and Development Promotion, National Institute of
Biomedical Innovation, Osaka, Japan.
DNA modifications are considered a trigger for somatic mutations. However, fac-
tors such as DNA repair and cell proliferation are known to contribute to DNA
modification processes, promoting gene mutations. We previously reported that
specific DNA adducts are formed in the livers of rats following treatment with es-
tragole (ES), a heparocarcinogen in rodents. ES caused formation of the DNA
adducts, ES-3’-N2-dG, ES-3’-C8-dG, and ES-3’-N6-dA, in rat livers, as determined
by LC-MS/MS analysis. To clarify associations between the number of modified
bases and the mutant frequencies (MFs) in the same animal and organ, we quanti-
fied ES-specific DNA adducts and performed reporter gene mutation assays in liv-
ers, kidneys, and lungs of 6-week-old F344 gpt delta rats given ES at doses of 0, 3,
30, and 300 mg/kg/day by gavage for 4 weeks. Relative liver and kidney weights
were significantly increased in rats given high-dose ES. Mitosis, single-cell necrosis
in hepatocytes, and oval cell proliferation were seen in high-dose group livers. Three
ES-specific DNA adducts were detected in a dose-dependent manner beginning
with the low-dose group. gpt MF was significantly increased only in the high-dose
group. In lungs and kidneys, DNA adducts were detected only in the high-dose
group, but their frequencies were almost identical to those in the low-dose group
livers. These results suggest that the site specificity observed in ES carcinogenicity
may depend on the number of modified bases. In addition, the fact that ES-specific
DNA adducts were detected to some extent in the livers of rats treated with moder-
ate doses, despite gpt MF being unchanged, suggests involvement of micro-envi-
ronmental factors, such as cell proliferation and DNA repair enzymes, in the pro-
gression from DNA modification to gene mutation. Some of these factors will be
presented, along with results of gpt mutation assays in the lungs and kidneys.
1505 Mutagenic Activity of Allura Red AC and Tartrazine in
Salmonella typhimurium.
R. Naravaneni,  S. Sharma,  S. Visram,  G. Lo and R. D. Mehta. Genetic
Toxicology, PBR Laboratories Inc, Edmonton, AB, Canada.
Allura Red AC (Red 40) and Tartrazine (Acid yellow 23) are two of the most com-
monly used artificial color additives (azo dyes) in food, drug and cosmetic indus-
tries. Allura Red and Tartrazine are nitrous derivatives which are the focus of stud-
ies on mutagenesis and carcinogenesis because of their transformation into
aromatic amines after being metabolized by the gastrointestinal microflora. We in-
vestigated the mutagenic activity of Tartrazine and Allura Red against TA98,
TA100, YG1041 and YG1042 strains of Salmonella Typhimurium using the proto-
col described by Prival and Mitchell (1981). Both YG1041 and YG1042 strains,
derived from TA98 and TA100, respectively carry a plasmid with genes for higher
levels of nitroreductase and O-acetyltranferase involved in the break down of azo
dyes to mutagenic aromatic amines. These strains have been shown to detect muta-
genic activity of azo dyes in the effluents from textile industries, eliciting a higher
mutagenic response compared to TA98 and TA100 (Umbuzeiro et al, 2003). We
used six dose levels (4mM, 2mM, 1mM, 0.5mM, 0.25mM, 0.125mM) of Allura
Red and Tartrazine for testing the mutagenic activity. The assay was performed
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under hamster S9-activated and non-activated conditions. In our study, none of the
four tester strains showed toxicity or an increase in the mutation frequency at the
dose levels tested. Whereas, Tartrazine has been reported to have cytotoxic effect in
mammalian cells (Patterson and Butler, 1982) and Allura Red has been found to
cause DNA damage when tested with the comet assay (Shuji et al, 2001). European
Food Safety Authority (2009) has also reported that Allura Red was negative in in-
vitro genotoxicity as well as long term carcinogenicity studies. Our results demon-
strate that the salmonella strains even with high level of nitroreductase and O-
acetyltranferase activities failed to show mutagenic activity in both, Tartrazine and
Allura Red.
1506 Genotoxicity of 2-Bromo-3’-Chloropropiophenone.
F. Meng1,  J. Yan1,  Y. Li1,  P. Fu2,  L. Fossom3,  R. Sood3,  D. Mans3,  P. Chu3,
M. M. Moore1 and T. Chen1. 1Division of Genetic and Molecular Toxicology,
NCTR/FDA, Jefferson, AR; 2Division of Biochemical Toxicology, NCTR/FDA,
Jefferson, AR; 3CDER, FDA, Silver Spring, MD.
Impurities are generally an integral part of any drug substance or drug product.
They can be either process-related impurities that are not completely removed dur-
ing purification or formed due to the degradation of the drug substance over the
product shelf-life. Unlike the drug, they do not provide health benefits. Therefore,
their amount should be minimized. 2-Bromo-3’-chloropropiophenone (BCP) is an
impurity of bupropion, a second-generation antidepressant and a smoking cessa-
tion aid. The US Pharmacopeia recommends an acceptable level for BCP that is not
more than 0.1% of the maximum dose of bupropion. Recently a qualitative struc-
ture-activity analysis (DEREK for Windows version 13) has shown that BCP is
likely genotoxic. The genotoxicity of BCP, however, has not been tested based on a
search of the available public literature. Because the US FDA limits genotoxic im-
purities to much lower levels than non-genotoxic impurities, it is important to de-
termine whether or not BCP is genotoxic. Therefore, in this study the Ames test
and the in vitro micronucleus assay were conducted to evaluate the genotoxicity of
BCP. BCP was mutagenic with S9 metabolic activation, increasing the mutant fre-
quencies in a concentration-dependent manner, up to 22- and 145-fold induction
over the controls in Salmonella strains TA100 and TA1535, respectively. BCP was
also positive in the in vitro micronucleus assay, resulting in up to 3.3- and 5.1-fold
increase of micronucleus frequency for treatments in the absence and presence of
S9, respectively; and 9.9- and 7.4-fold increase of hypodiploids without and with
S9, respectively. The addition of N-acetyl-l-cysteine, an antioxidant, reduced but
not eliminated the genotoxicity of BCP in both assays. The results suggest that
BCP is mutagenic, clastogenic, and aneugenic, and these activities are possibly me-
diated via generation of reactive metabolites.
1507 Comparison of Mainstream Smoke (Mss) Cytotoxicity and
Clastogenicity from Filtered Cigars with the Corresponding
Data for the Mss from the Ky3r4f Reference Cigarette.
J. H. Lauterbach1,  F. Z. Sheabar2,  D. Muldoon2,  G. Nelluru2,  T. Oshunwusi2
and D. Powell2. 1Lauterbach & Associates, LLC, Macon, GA; 2Arista Laboratories,
Richmond, VA.
Filtered cigars, dimensionally similar to 100s cigarettes, have become popular
smoking articles. Unlike cigarettes, the tobacco column is wrapped with a single ply
of paper-type reconstituted tobacco. The blends in filtered cigars range from light-
air cured tobaccos to tobaccos with more cigar-like character. Since filtered cigars
have been reported to be popular with younger smokers, concern has been raised
about the toxicity of the smoke relative to cigarette smoke. Rickert et al., 2011, re-
ported that on a per unit smoke nicotine basis the toxicity of the mainstream smoke
(MSS) from filtered cigars was no less than that of the MSS from cigarettes.
However, the Rickert work used the Health Canada Intensive (HCI) smoking regi-
men and used king-size like products that are no longer popular or available com-
mercially. In this research, we have used ISO smoking regimen and three contem-
porary 100 mm filtered cigars, one of which (FC1) had a more traditional cigar
blend than did the other two (FC2, FC3). On a unit TPM basis, there was little dif-
ference in the Neutral Red cytotoxicity of the MSS from the three filtered cigars
and the cytotoxicity of the MSS of the KY3R4F reference cigarette. However, when
the results were put on a per unit smoke nicotine basis, the MSS from two of the
three filtered cigars (FC2, FC3), which had low MSS nicotine concentrations, were
more cytotoxic than the MSS from the KY3R4F. On a per unit nicotine basis, the
cytotoxicity of the MSS from FC1 was similar to that of the MSS of the KY3R4F.
Genotoxicity was determined with the in vitro micronucleus assay. On a unit TPM
basis, toxicity rankings (-S9) were FC1≈FC3>FC2>>KY3R4F and (+S9) were
FC3>FC2>FC1>>KY3R4F. On a unit nicotine basis, toxicity rankings (for both
–S9, +S9) were FC3>FC2>FC1>>KY3R4F. Our results were similar to those re-
ported by Rickert et al. and showed that the ISO smoking regimen was better able
to show product differences than was the HCI regimen.
1508 Effects of Obesity on Spontaneous Reporter Gene Mutations
in Gpt Delta Mice Fed a High-Fat Diet.
S. Takasu1,  Y. Ishii1,  K. Matsushita1,  K. Kuroda1,  Y. Kodama2,  K. Ogawa1,
A. Nishikawa3 and T. Umemura1. 1Division of Pathology, National Institute of
Health Sciences, Tokyo, Japan; 2Division of Toxicology, National Institute of Health
Sciences, Tokyo, Japan; 3Biological Safety Research Center, National Institute of Health
Sciences, Tokyo, Japan.
Epidemiologically, obesity has been suggested to be associated with increased risk of
several human cancers, including cancers of the liver, kidneys, and colon. In several
rodent models, genetically induced obesity or high-fat diet (HFD) induced obesity
has been shown to enhance carcinogenesis in the liver and colon after treatment
with a regimen of respective tumor initiators. However, the factors responsible for
the obesity-related progression of carcinogenesis, especially the initiation phase, are
not fully elucidated. To reveal the effects of obesity induced by an HFD on sponta-
neous gene mutations, we performed reporter gene mutation assays in liver, kidney,
and colon tissues from obese mice fed an HFD. Six-week-old male and female
C57BL/6 gpt delta mice were fed either an HFD or a standard diet (STD) for 13 or
26 weeks. At the end of the experimental period, all mice were sacrificed, and re-
porter gene mutation assays were performed. Final body weights of male and female
mice fed an HFD for 13 weeks were significantly increased compared with those
fed an STD. gpt and Spi- mutant frequencies in the liver, kidneys, and colon of male
mice fed an HFD for 13 weeks were not significantly different from those fed an
STD. These results implied that HFD-induced obesity does not influence the
spontaneous frequencies of somatic gene mutations, indicating that obesity may af-
fect the tumor promotion phase rather than the tumor initiation phase to enhance
carcinogenesis. Further data from the organs of mice fed an HFD for 26 weeks will
be presented to evaluate the effects of long-term consumption of an HFD on spon-
taneous mutagenicity in vivo.
1509 Community Lead (Pb) Domains and Exposure Disparities:
Case Study of Pre- and Post-Katrina New Orleans.
H. W. Mielke1, 2,  C. R. Gonzales3,  E. T. Powell3 and P. W. Mielke4.
1Pharmacology, Tulane University School of Medicine, New Orleans, LA; 2Chemistry,
Tulane University, New Orleans, LA; 3Lead Lab, Inc., New Orleans, LA; 4Statistics,
Colorado State University, Fort Collins, CO.
We sought to gain insight into the Pb toxicity characteristics of communities in
New Orleans. Based on previous soil Pb mapping we divided New Orleans census
tracts into two soil Pb domains, high (median ≥100 mg/kg) and low (median <100
mg/kg). Soil samples from four locations represented each of the domains: busy
streets, residential streets, house sides, and open spaces (away from streets and
houses). Blood and soil Pb concentrations within the high and low Pb domains of
New Orleans were analyzed by permutation statistical methods (Multi-Response
Permutation Procedures). The children’s blood Pb prevalence ≥ 5 μg/dL for the
high and low Pb domains were 58.5% and 24.8%, respectively, pre-Katrina vs.
29.6% and 7.5% in post-Katrina New Orleans. In the high Pb domain median soil
Pb was 367, 313, 1228, and 103 mg/kg, respectively, busy streets, residential
streets, house sides, and open space locations; in the low Pb domain median soil Pb
was 64, 46, 32, and 28 mg/kg, respectively (p-Values <10E-16). After Katrina rela-
tively small decreases in soil Pb were observed, and elevated soil Pb permeates the
high Pb domain; children living there generally lack Pb safe areas for outdoor play.
The low Pb domain was safer by factors ranging from 3 to 38 depending on specific
location. Patterns of lead deposition from decades of Pb accumulation have not
been transformed by renovations conducted post-Katrina. We expect that all large
cities will exhibit the same characteristics as observed in New Orleans. Low Pb soils
are available outside of cities to remedy soil Pb contamination. Mapping soil Pb de-
lineates Pb deposition and assists with planning to improve primary prevention of
Pb exposure.
1510 Portable XRF Technology to Quantify Lead and Strontium
in Bone In Vivo—Calibration and Validation.
A. J. Specht1,  M. Weisskopf2 and L. Nie1. 1Health and Human Sciences, Purdue
University, West Lafayette, IN; 2Public Health, Harvard University, Boston, MA.
Concentrations of lead and strontium in bone can serve as a long-term indicator of
exposure levels, and can be more easily correlated to their respective health effects.
Lead adversely affects almost all the systems in the body. High levels of strontium,
on the other hand, have been correlated to skeletal abnormalities in animal and
human populations. We have previously shown the viability of a portable XRF sys-
tem in detection of lead in bone in vivo. This system has since been improved to in-
clude a larger detector with an improved geometry. In this project, the new instru-
ment was calibrated and validated to quantify lead and strontium in bone in vivo.
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The system was effectively calibrated for bone lead quantification with lead doped
bone-equivalent phantoms. However, it is difficult to calibrate the system for bone
strontium quantification using strontium doped phantoms because most of the
bone equivalent materials are severely contaminated with strontium. Therefore, a
new calibration method was developed, which made use of a Monte Carlo (MC)
simulation model developed specifically for this instrument. In this new method,
net strontium signals were obtained for different soft tissue thicknesses using MC
simulations and the signals were plotted against corresponding concentrations of
the strontium. The concentrations of strontium for in vivo measurements can then
be calculated from the calibration lines generated from MC simulation. Three main
results were obtained from this study: a) An agreement between the experimental
and simulated spectra of approximately 13% were shown with the MC simulation
model; b) the detection limit for bone lead and strontium is improved by a factor of
2 with the improved instrument; c) it is valid to calibrate the system with the cali-
bration lines created by MC simulations. In conclusion, the new system with im-
proved detection limit, combined with the use of Monte Carlo simulations for cal-
ibration can be applied to accurately quantify lead and strontium in bone in vivo.
1511 The Effect of Environmental Exposure to Lead on Blood
Pressure in Korean Adults.
J. Park1,  S. Choi1,  S. Eom2,  D. Kim1,  H. Kim2,  B. Choi1,  K. Park3,  H. Pyo3,
Y. Hong4,  S. Sohn5 and H. Kwon6. 1Chung-Ang University, Seoul, Republic of
Korea; 2Chungbuk National University, Cheongju, Republic of Korea; 3Korea Institute
of Science and Technology, Seoul, Republic of Korea; 4Dong-A University, Busan,
Republic of Korea; 5Chonnam National University, Gwangju, Republic of Korea;
6Dankook University, Cheonan, Republic of Korea.
General population is exposed to chronic and low level of lead (Pb). Previous stud-
ies reported that blood Pb is possibly related to the blood pressure. However, the ef-
fect of environmental exposure to Pb on blood pressure is not clear yet. This study
was performed to estimate the representative blood Pb level and to assess whether
blood pressure is affected by chronic and low Pb exposure in Korean adults. The
total study subjects of 2,090 people (male: 908, female: 1,182) were nationwide
sampled by multi-staged, sex- and age- stratified probability method, who had not
been exposed to Pb occupationally. The geometric mean concentration of Pb in
blood was 2.22 ug/dL. The level of blood Pb was significantly higher in males (2.60
ug/dL) than in females (1.97 ug/dL). The level of blood Pb was increased with age-
dependent pattern which was the highest in the group of 50-59 years old. Also,
blood Pb level was affected by individual behavioral patterns such as smoking and
drinking. The mean concentration of blood Pb was higher in rural or urban inhab-
itants than in metropolitan, respectively. The positive relations were observed be-
tween blood Pb concentrations and systolic/diastolic blood pressure in males and in
females, both. However, blood Pb was significantly correlated with systolic and di-
astolic blood pressure after adjustment for covariates in males, but not in females.
In summary, the findings from this study suggest that chronic Pb exposure under
the environment might be increase blood pressure, systolic and diastolic, both, in
males.
1512 Induction of Autophagy and Aberrant MHC Class II Surface
Expression in Lead-Exposed Murine Macrophage Raw 2674
Cells: Dysregulation in Mhc-Ii+ Compartment Exocytosis.
R. M. Gogal1,  R. P. Kerr1,  T. M. Krunkosky1,  D. J. Hurley2,  B. S. Cummings3
and S. D. Holladay1. 1Department of Biosciences and Diagnostic Imaging, University
of Georgia, Athens, GA; 2Department of Population Health, University of Georgia,
Athens, GA; 3Department of Pharmaceutical and Biomedical Sciences, University of
Georgia, Athens, GA.
Aberrant major histocompatibility complex class II (MHC-II) surface expression
on antigen presenting cells (APCs) is associated with dysregulated immune home-
ostasis. Lead (Pb) is known to increase MHC-II surface expression on murine peri-
toneal macrophages ex vivo at concentrations exceeding 25 μM. Little data exist ex-
amining this effect at physiologically relevant concentrations. To address this
deficit, we examined the effects of Pb on MHC-II surface expression, secondary T-
cell activation markers (CD80, CD86, CD40), cell viability, cellular metabolic ac-
tivity, and β-hexosaminidase activity in RAW 267.4 macrophage cell lines, with
changes in cell ultrastructure evaluated by electron and confocal microscopy. Pb in-
duced a bi-phasic, dose dependent increase in MHC-II, CD86, and lysosome-asso-
ciated LAMP-1 and LAMP-2 surface expression during one cell doubling cycle (17
hr), which was mirrored by increased β-hexosaminidase activity. Although cell via-
bility was unaffected, cellular metabolism was inhibited. Electron microscopy re-
vealed evidence of lipid vacuolization, macroautophagy and myelin figure forma-
tion in cells cultured with either Pb or LPS. Confocal microscopy with antibodies
against LC3B showed a punctate pattern consistent with the presence of mature au-
tophagosomes. Collectively, these data suggest that 2.5-5.0 μM Pb increased
MHC-II surface expression by inhibiting metabolic activity, inducing autophagy,
and increasing MHC-II trafficking in a macrophage cell line.
1513 Exposure to Cobalt Causes Changes in Gene Expression and
Protein Abundance in Two Rat Liver-Derived Cell Lines.
M. Permenter2,  W. E. Dennis1,  J. A. Lewis1 and D. A. Jackson1. 1USACEHR,
Fort Detrick, MD; 2Excet, Inc., Fort Detrick, MD.
Cobalt is an essential component of the diet, but in large doses it is acutely toxic,
and chronic exposures can injure multiple organ systems. While the toxic effects of
cobalt have been widely studied, the exact mechanisms of toxicity remain unclear.
In order to further elucidate these mechanisms in liver, we exposed two rat liver-de-
rived cell lines, H4-II-E-C3 and MH1C1, to sublethal concentrations of cobalt
chloride to eliminate cell-line specific effects. We chose the treatment concentra-
tions based on a novel qPCR assay using a panel of genes developed from previous
metal toxicity studies, as opposed to traditional cytotoxicity assays, to more accu-
rately predict gene expression endpoints at sublethal concentrations. We examined
changes in gene expression using DNA microarrays and also examined changes in
secreted and cytoplasmic protein abundance using mass spectrometry. 
We performed both gene-level and functional analyses of the results and observed
changes in pathways that are involved in the Nrf2-mediated response, protein
degradation, glutathione production, Hif-1 signaling, and energy metabolism.
These results are consistent with the known effects of cobalt toxicity, including ox-
idative stress and hypoxic responses. The changes in protein abundance closely re-
semble and validate our conclusions drawn from the microarray analysis. This work
offers key insights into the role specific genes, proteins, and pathways play in cobalt
toxicity mechanisms, and provides leads, which upon validation, may characterize
novel toxic effects.
Opinions, interpretations, conclusions, and recommendations are those of the au-
thors and are not necessarily endorsed by the U.S. Army. The research described
herein was sponsored by the U.S. Army Medical Research and Materiel Command,
Military Operational Medicine Research Program.
1514 Dose-Response Relationships for Blood Cobalt
Concentrations and Associated Health Effects.
A. Monnot,  S. Gaffney,  D. J. Paustenbach and B. L. Finley. ChemRisk, San
Francisco, CA.
Cobalt (Co) is an essential component of vitamin B12. As with all metals, at suffi-
ciently high doses, Co can have detrimental effects on different organ systems, and
adverse responses have been observed in patients on Co therapy, workers handling
Co-containing powders, and other Co-exposed groups. Although blood Co con-
centrations are thought to be the most accurate indicator of ongoing Co exposure,
little is known regarding the dose-response relationships between blood Co concen-
trations and adverse health effects. In this analysis, we reviewed the animal toxicol-
ogy and epidemiology literature to identify blood Co concentrations at which ef-
fects have, and have not, been reported. Where necessary, a biokinetic model was
used to convert oral doses to blood Co concentrations. Our results indicate that
blood Co concentrations in humans of approximately 300 μg/L and higher have
been associated with certain hematological and reversible endocrine responses
(polycythemia and reduced iodide uptake, respectively), while blood Co concentra-
tions of 700-800 μg Co/L and higher have been consistently associated with a risk
of more serious neurological, reproductive, or cardiac effects. Although there are
some anecdotal reports to the contrary, the weight of evidence from the many avail-
able studies suggest that blood Co concentrations of 300 μg/L and less have not
been associated with adverse responses in healthy humans. This suggests that cer-
tain populations known to have blood Co concentrations of < 100 μg/L, such as
some patients with Co-containing hip implants and those who ingest Co vitamin
supplements, are unlikely to be at risk due to Co exposure.
1515 Loss of Hypoxia-Inducible Factor (HIF)-1α, and Not HIF-
2α, in the Lung Alveolar Epithelium of Mice Leads to
Enhanced Eosinophilic Inflammation in Cobalt-Induced
Lung Injury.
S. P. Proper,  K. Greenwood,  J. Harkema and J. J. LaPres. Michigan State
University, East Lansing, MI.
Cobalt is a known hypoxia mimic and stabilizer of hypoxia-inducible factors
(HIFs). HIF-1α contributes to cobalt toxicity in vitro and previous work in our lab
has shown that loss of HIF-1α in the alveolar epithelial cells led to a switch from a
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neutrophilic to eosinophilic response. While HIF-1α and HIF-2α have known
overlapping gene targets, HIF-2α is the predominant HIF isoform in the adult
lung, and little is known about HIF-2α in the context of cobalt-induced lung in-
jury. We therefore hypothesized that HIF-2α could be playing a more active role in
cobalt toxicity. To compare the roles of HIF-1α and HIF-2α in cobalt-induced
lung injury, we used mice deficient in either HIF-1α (HIF-1αΔ/Δ), HIF-2α (HIF-
2αΔ/Δ) or both HIF-1α and HIF-2α (HIF-1/2αΔ/Δ) in alveolar type II epithelial
cells. Mice were exposed to cobalt (60 μg/day) or saline via oropharyngeal aspira-
tion for five consecutive days, and sacrificed on day six. Bronchoalveolar lavage
(BAL) cellularity, qRT-PCR, and histopathologic analyses were performed. Results
confirm previous data showing that loss of HIF-1α leads to enhanced eosinophilic
inflammation, and an enhanced T-helper type 2 (Th2) response. In contrast, in-
flammation in HIF-2α mice resembled that of control mice following cobalt expo-
sure. HIF-1/2αΔ/Δ mice showed similar cobalt-induced eosinophilic inflammation
seen in HIF-1αΔ/Δ mice. Together, data suggest that loss of HIF-1α in lung ep-
ithelium plays the dominant role in determining the response to cobalt-induced
lung injury, and that HIF-2α does not play an active role in cobalt-induced lung
injury. Coupled with other experiments performed in our lab, this indicates that
epithelial HIF-1α in the postnatal developmental period plays a central role in
guiding immune responses in the airway.
1516 Can Zinc Reverse Uranium Toxicity? Potential for a
Community-Based Intervention.
L. G. Hudson,  K. L. Cooper,  R. Tsosie,  D. Begay and J. L. Lewis.
Pharmaceutical Sciences, University of New Mexico, Albuquerque, NM.
Many Navajo people have been, and continue to be, exposed to uranium through
the legacy of uranium mining. 1100 abandoned Cold War uranium waste sites re-
main within Navajo communities and numerous wells exceed maximum contami-
nant levels for uranium and other metals such as arsenic. Certain metals can disrupt
protein function by interacting with zinc finger structures and thus inhibit impor-
tant cellular processes including DNA repair. Based on this mechanism, many met-
als are now viewed as co-carcinogens and amplify the DNA damaging capacity and
tumorigenicity of other carcinogens even at levels where the metals alone are not
carcinogenic. The carcinogenicity of uranium is well established in the literature,
but there is little known regarding uranium interaction with zinc finger protein
structures. Published reports demonstrating that uranium exposure leads to defi-
ciency in DNA repair processes suggest that uranium may interfere with zinc finger
DNA repair proteins. Our work with arsenic demonstrates that very low levels of
arsenic causes zinc depletion from target zinc finger DNA repair proteins leading to
increased DNA damage and mutagenesis that can be reversed by zinc. Based on
these findings, we investigated the effect of uranium on DNA repair and the activ-
ity of a specific zinc finger DNA repair protein target (PARP-1). Uranium in the
form of uranyl acetate (UA) demonstrated little cytotoxicity in an immortalized
human embryonic kidney cell line (HEK293) at concentrations at or below 10 μM.
UA at concentrations of 10 or 100 μM inhibited the DNA repair protein PARP-1
and caused retention of ultraviolet radiation-induced DNA lesions (CPDs and
pH2Ax). The addition of zinc ameliorated PARP-1 inhibition and partially de-
creased the retention of DNA damage. These findings suggest that one mechanism
of uranium toxicity may rely on disruption of zinc finger protein function, so this
work will inform a planned assessment of the potential for zinc to block uranium
toxicity as an additional component of the Navajo Birth Cohort Study.
1517 Toxicological Properties of PM1 from Pellet Combustion—
Role of Zn.
O. Uski1, 2,  P. Jalava2,  M. Happo2,  T. Kaivosoja2,  H. Lamberg2,  J. Leskinen2,
T. Torvela2,  J. Tissari2,  O. Sippula2,  J. Jokiniemi2, 3 and M. Hirvonen2, 1.
1Department of Environmental Health, National Institute for Health and Welfare,
Kuopio, Finland; 2Department of Environmental Science, University of Eastern
Finland, Kuopio, Finland; 3Technical Research Centre of Finland, Espoo, Finland.
Sponsor: M. Viluksela.
Biomass combustion is important source of ambient air fine particulate matter
(PM2.5), which has been associated with a substantial health burden. Thus, it is im-
portant to reveal the effect of used fuel in induced adverse health effects. In search
for causative constituents, we studied the role of Zn on toxicity of combustion
emission PM1.
PM1 samples were produced in complete combustion using a pellet boiler (25 kW).
Untreated reference pellet fuel (including 11 mg/kg Zn) was used as control sam-
ple. The same pellets were doped with Zn in different concentrations; 170, 480 and
2300 mg Zn/kg fuel. PM1 samples were collected on PTFE-filters from diluted flue
gas by using Dekati® gravimetric impactor, and subsquently extracted from filters
by using methanol. Mouse macrophages (RAW264.7) were exposed for 24 h to
four doses (15, 50, 150 and 300 mg/ml) of emission samples. Markers for cytotox-
icity (MTT), inflammation (MIP-2 and TNF-α) and cell cycle analysis (DNA con-
tent analysis) were measured.
All the studied emission samples induced significant dose-dependent decrease in
cell viability when compared to control. However, with the samples where Zn was
added the toxicity was more severe. Moreover, significant increase in S-G2/M-phase
in the cell cycle was detected after exposure to emissions from all Zn doped pellets,
but not with reference pellet. Instead, only minor inflammatory responses were
seen by all the samples.
The present results indicate that in very good combustion conditions, high Zn con-
tent of fuel induces significant changes in the cell cycle and increases cytotoxicity of
PM1. Combustion particles toxicity is affected not only by the appliances design or
the combustion conditions but also of the fuel and fuel quality.
1518 A Preliminary Study on Analytical Methodology for
Determination of Zinc in Liver of Laboratory Rats, by ICP-
QMS.
L. V. Saldivar1,  H. Garcia1,  R. Leon1,  T. Rodríguez Salazar1,  M. G. Espejel1 and
T. I. Fortoul2. 1Analytical Chemistry, UNAM Faculty of Chemistry, Mexico City,
Mexico; 2Cellular and Tisular Biology, UNAM Faculty of Medicine, Deleg Coyoacán,
México City, Mexico. Sponsor: D. Acosta.
Zinc is an essential micronutrient for living organisms. It plays a specific role in the
synthesis and stabilization of proteins. Its deficiency is characterized by growth re-
tardation, and impaired immune function. While the excess of Zn results in fever
and pathological changes in some tissues. Excessive absorption of zinc suppresses
copper and iron absorption. Therefore Zn, Cu and Fe can be utilized as pathologi-
cal indicators. The determination of these elements is of interest in the biomedical
area, where laboratory rats are used as model animals, because of their physiological
similarities to the human body.
The Inductively Coupled Plasma-Quadrupole Mass Spectrometry (ICP-QMS) has
been applied to the analysis of trace elements in biological samples due to its char-
acteristics: low detection limit, multielemental analysis and low sample volume.
In this work, analytical methodology was optimized to determine total Zn concen-
tration in livers of laboratory rats. Samples were dried and homogenized, and di-
gested in a microwave oven using HNO3 and H202 mixture. Analytical quantifi-
cation of the isotopes 66Zn using 74Ge as internal standard, was performed using
an Elan DRC-e spectrometer (Perkin-Elmer). The dynamic reaction cell was not
employed. Results for three replicates of certified reference material (NIST SRM
1577c, National Institute of Standards and Technology) were in good agreement
with certified values: 0.21 % (mean relative error, accuracy), and 0.2 % RSD (pre-
cision). The range of Zn total concentrations found in samples of livers of rats were:
37-163 mg/kg. This study belongs to a research where it is included the determina-
tion of Zn/Cu ratio in several tissues.
The authors thank the financial support of DGAPA-PAPIIT IN229911 and PAL
3400-02.
1519 Effects of Tungsten Chemical Species on Biochemical
Pathways and Mineralization in Bone.
C. Y. Ang1,  D. R. Johnson2,  J. M. Seiter2,  A. R. Osterburg3,  G. F. Babcock3,
P. G. Allison2 and A. J. Kennedy2. 1Badger Technical Services, Vicksburg, MS;
2Environmental Laboratory, US Army Engineer Research & Development Center,
Vicksburg, MS; 3Cincinnati Shriners Hospital for Children and the Unviersity of
Cincinnati, Cincinnati, OH.
Tungsten (W) is a metal that has numerous civil and military applications. When
W enters the environment, it is rapidly oxidizes and speciates based on the environ-
mental matrix it is embedded in. Bone is the long-term storage organ for W—and
presumably W chemical species if present—when taken up by organisms. It is un-
known what long-term effects W has in bone, therefore, we evaluated the effects of
W species on biochemical pathways in hFOB 1.19 osteoblastic cells exposed to
water (control) or W chemical species (sodium tungstate, phosphotungstate [PW],
poly tungstate [polyW], and tungstosilicic acid [TSA]) at 0-10,000 μM for 24 h at
37 degrees C. W species did not affect adenosine triphosphate (ATP) concentra-
tions except at the highest concentration. PW, polyW, and TSA, but not tungstate,
significantly increased protein tyrosine kinase activity at 10,000 μM after 4 h expo-
sure. Tungstate and PT increased cellular cyclic adenosine monophosphate (cAMP)
at ≥ 100 μM, while TSA decreased cellular cAMP at 10,000 μM. Preliminary
analyses also demonstrate an effect on alkaline phosphatase, the enzyme involved in
bone mineralization. Synchrotron analysis of bone from female rats exposed to 200
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mg/kg/d sodium tungstate in drinking water ad libitum for 90 d showed W incor-
poration into bone as calcium poly-tungstate (77% total W in bone) and calcium
tungstate (23%). These data demonstrate that W chemical species generally only af-
fect phosphate-dependent cell signaling and secondary messenger pathways in
hFOB 1.19 cells, and may also affect bone mineralization enzymes, resulting W
species incorporation into bone in animals. Follow-up studies will analyze the ef-
fects on bone mineralization and strength associated with W incorporation due to
chronic exposure.
1520 Accumulation of Manganese (Mn) in Rat Brain Ventricular
Region following In Vivo Subchronic Mn Exposure: Effect
on Copper (Cu) Status.
S. L. O’Neal,  L. Hong and W. Zheng. School of Health Sciences, Purdue University,
West Lafayette, IN.
Welders and smelters occupationally exposed to high levels of Mn have an increased
risk for developing manganism, a disease similar to Parkinson’s. Existing human
and animal studies indicate that Mn accumulates mainly in the striatum, the area
adjacent to the brain ventricular region (BVR) which houses cells implicated in
adult neurogenesis. The neural stem cells in BVR are capable of migrating to stria-
tum and hippocampus en route to the olfactory bulb. This group has previously
shown Mn exposure results in Mn accumulation in the choroid plexus (CP), cere-
brospinal fluid (CSF) and increases intracellular Cu concentration. This study was
undertaken to test the hypothesis that a high Mn level in the CP and CSF may in-
fluence the surrounding ventricular structure and interfere with the homeostasis of
other essential elements. Adult male rats received daily ip injections of MnCl2 at
the doses of 6 and 15 mg Mn/kg as the low and high dose groups, respectively, or
saline as the control, 5 days per week for 4 weeks. Twenty-four hr after the last in-
jection, BVR, femur bone and liver tissues were dissected and quantified by atomic
absorption spectroscopy for concentrations of Mn, Cu, iron (Fe) and zinc (Zn).
Data analysis by Student’s t-test showed that levels of Mn in BVR of the low- and
high-dose groups increased by 94.8% and 218.5%, respectively, as compared to
controls (n=4-6, p <0.01). In femur, Mn concentration increased by 278.2% and
1237.4% in the low- and high-dose groups, respectively (p < 0.01). Interestingly,
Cu concentrations in BVR decreased significantly for low- and high-dose groups
(p<0.05). In contrast, Cu levels in bone increased by 23.2% and 51.2% for low-
and high-dose groups, respectively (p <0.05). Taken together, our data provide the
initial evidence that Mn accumulates in brain ventricular area following in vivo ex-
posure. Mn’s potential impairment of this region in the disease progression of Mn
Parkinsonism deserves further investigation. (Supported in part by NIH RO1
ES008146)
1521 Methylmercury-Induced Dopaminergic Neurotoxicity in
Caenorhabditis elegans.
E. Martinez-Finley and M. Aschner. Vanderbilt University Medical Center,
Nashville, TN.
Mercury is a persistent environmental contaminant that exerts its toxic effects on
the nervous system through molecular mechanisms that remain unknown.
Parkinson’s disease (PD) is a neurodegenerative disorder characterized by the slow
progression and irreversible loss of the dopaminergic (DAergic) neurons. The etiol-
ogy of PD remains elusive, with aging, environmental toxicant exposure and ge-
netic mutations contributing to the disease. Epidemiological studies have pointed
to the contribution of methylmercury (MeHg) to DAergic vulnerability and the
predisposition to PD. We examined the impact of early-life exposure to MeHg on
DAergic neurodegeneration in Caenorhabditis elegans (C. elegans) with emphasis
on gene-environment interactions. SKN-1, orthologue of mammalian Nrf2, is a
major stress-activated cytoprotective transcription factor. We hypothesized that
MeHg’s toxicity is dependent on an intact SKN-1 response and skn-1 knockout
(KO) worms would show heightened toxicity compared to wildtype (N2). We also
tested the effect of MeHg in a pdr-1KO worm, ortholog to the human parkin gene
(mutated form found in juvenile PD), under the premise that these worms would
show heightened sensitivity to MeHg. We identified the impact of early-life MeHg
exposure on MeHg content, stress reactivity and measures of DAergic neurodegen-
eration in N2, skn-1KO and pdr-1KO worms exposed to 0-30μM MeHgCl for 30
minutes following synchronization. Our data suggests that skn-1KO
(LD50=19μM) and pdr-1KO (LD50=17μM) are more sensitive to MeHg than N2
controls (LD50=25μM). MeHg uptake was higher in the pdr-1KO strain com-
pared to the N2 strain. DAergic morphology observed via fluorescent analysis at
adult life-stage revealed presence of puncta at 20μM MeHg in skn-1KOs and loss
of cell body fluorescence in pdr-1KO. Dopamine (DA)-dependent behavioral
analysis revealed alterations in DA following MeHg exposure, corroborated by de-
creased DA levels, measured via HPLC. Taken together this data suggests that ex-
posure to MeHg early in the lifespan can have detrimental effects on DAergic neu-
rons. Supported by R01ES07731 and EST32007028.
1522 Lactational Exposure to Mercury (Hg) and Evidence of
Oxidative Stress.
I. Al-Saleh,  M. Abdel Jabbar,  R. Al-Rouqi,  R. Elkhatib,  A. Alshabbaheen and
N. Shinwari. Environmental Health Section, Biological & Medical Research
Department, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi
Arabia.
The objective of this work was to assess exposure to Hg in mothers and their breast-
fed infants. We also evaluated urinary 8-hydroxy-2-deoxyguanosine (8-OHdG)
and malonaldehyde (MDA) in both the mothers and infants as biomarkers of ox-
idative stress. The mean urinary Hg (UHg) levels in 155 mothers and 102 infants
was 1.47 and 7.9μg/g-Cr, respectively with significant correlation between the two
(r=0.36,P=0). UHg levels>5μg/g-Cr (background level in unexposed population)
found in 3.3% mothers and 50.1% infants. The mean concentration of Hg in
breast milk was 1.19μg/L(range:0.012-6.44μg/L) with only one mother had
Hg>4μg/L, the ATSDR upper limit. This corresponds to approximately a daily in-
take of 1.02μg Hg(0.13-5.47μg). Based on the average infant’s body weight in this
study (7.7Kg) and the EPA reference dose of Hg (0.3 μg/Kg/day), this brings the
highest daily intake to 2.31μg. There were 7 infants exceeded this limit. None of
the mothers had total blood Hg > the EPA reference dose of 5.8μg/L. Probably, this
might be due to the low exposure to organic in comparison to inorganic Hg.
Furthermore, no correlation was noted between UHg in infants and Hg in breast
milk (P>0.05). On the other hand, Hg in breast milk was associated with total Hg
in blood (r=0.53,P=0) suggesting the efficient transfer of organic form of Hg from
blood to milk. Both urinary MDA (r=0.2,P=0.015) and 8-OHdG
(r=0.24,P=0.003) levels increased with the mother’s UHg levels. Infant’s UHg lev-
els in infants were positively associated with urinary levels of MDA
(r=0.31,P=0.003) and 8-OHdG (r=0.43,P=0) in infants. There was also an associa-
tion between Hg in breast milk and increased urinary MDA levels in infants
(r=0.35,P=0). Our results clearly showed the transfer of Hg from the mother to in-
fant through breastfeeding, and its role in inducing oxidative stress, that can be of
potential health risk. Nevertheless, breastfeeding should not be discouraged; and
instead efforts should be made to identify and eliminate the source of Hg exposure
in the present population.
1523 Methylmercury Toxicity in KK-Ay Obese Type 2 Diabetic
Mice.
M. Yamamoto1,  R. Yanagisawa1, 2,  E. Motomura1,  M. Nakamura1,
M. Sakamoto1,  M. Takeya3 and K. Eto4. 1National Institute Minamata Disease,
Minamata, Japan; 2National Institute Environment Studies, Tsukuba, Japan;
3Kumamoto University, Kumamoto, Japan; 4Jushindai, Tamana, Japan.
We examined the toxic effects of methylmercury (MeHg) exposure on the brain,
kidney, pancreas and spleen of KK-Ay type 2 diabetic mice to clarify how the meta-
bolic changes associated with type 2 diabetes mellitus (T2DM) affect MeHg toxic-
ity. MeHg (5 mg Hg/kg/day p.o.) was given to male KK-Ay and C57BL/6J (BL/6)
mice three times per week for 6 weeks beginning at 4 weeks of age. Average of body
weights (BW) of vehicle-treated BL/6 and KK-Ay mice were 16.3 g and 16.4 g on
the first day, and 24.8 g and 42.3 g on the last day of the experiment, respectively.
BW gain in MeHg-treated KK-Ay mice stopped 4 weeks after MeHg-administra-
tion, and these mice began to lose weight around 5 weeks. Six of 7 MeHg-treated
KK-Ay mice showed neurological symptoms such as hind limb crossing in the final
stage of the experiment. Alternatively, no obvious symptoms and decrease in body
weight were observed in vehicle-treated and MeHg-exposed BL/6 mice. The mean
blood mercury level of KK-Ay mice administered MeHg increased constantly
throughout the administration of MeHg and reached a maximum of about 8
μg/ml. On the other hand, the average blood mercury level of BL/6 mice adminis-
tered MeHg was 2.8 μg/ml after 10 days of MeHg administration. The average kid-
ney weights of vehicle-treated and MeHg-exposed KK-Ay mice were 542 mg and
408 mg, and those of BL/6 mice were 357 mg and 413 mg, respectively. The aver-
age spleen weights of vehicle-treated and MeHg-exposed KK-Ay mice were 91 mg
and 135 mg, and those of BL/6 mice were 65 mg and 71 mg, respectively. The av-
erage total mercury concentrations in the cerebrum, kidney, pancreas, spleen and
epididymal fat pad of KK-Ay mice were 27, 51.7, 40.9, 32 and 1.6 μg/g, respec-
tively. The average total mercury concentrations in these organs of BL/6 mice were
7.4, 51.9, 10.4, 6.9 and 0.57 μg/g, respectively. These results indicate that body fat
gain in T2DM and low accumulation of mercury in adipose tissue can increase
organ accumulation of MeHg accompanied by toxicity in KK-Ay mice.
SOT 2013 ANNUAL MEETING 327
1524 The Palmitoylation of Meh1, a Component of EGO
Complex, Has an Important Role in the Reduction of
Methylmercury Toxicity in Budding Yeast.
G. Hwang,  Z. Zhang and A. Naganuma. Graduate School of Pharmaceutical
Sciences, Tohoku University, Sendai, Japan.
Mehthylmercury (MeHg) is an environmental pollutant that causes the severe cen-
tral nervous system disorder. However, the molecular mechanism underlying
MeHg toxicity remains to be clarified. We have found that deletion of the Akr1,
one of palmitoyl transferase, causes hypersensitivity to MeHg in budding yeast.
In this study, we found that yeast cells lacking Meh1, one of substrates for Akr1,
exhibit hypersensitivity to MeHg. Palmitoylation of Meh1 was not detectable by a
deletion of Akr1, suggesting that Akr1 is the main palmitoyl transferase for Meh1.
We also found that the palmitoylation of Meh1 by Akr1 is essential for the protec-
tive effect of Meh1 against MeHg toxicity. Meh1 has been identified as a compo-
nent of the EGO complex that is involved in the regulation of microautophagy. We
found an increased susceptibility to MeHg in yeast cells with deletion of Meh1 or
the other EGO complex components (Gtr2 and Ego3). Moreover, Meh1/Gtr2- or
Meh1/Ego3-double deletion mutants did not exhibit further increase in the suscep-
tibility to MeHg when compared to Meh1 deletion mutant. These results suggest
that Meh1 might reduce MeHg toxicity as a component of the EGO complex. It
has been reported that Meh1 forms an EGO complex by binding with Ego3 on
vacuole membrane. Interestingly, Meh1 with a mutation in the palmitoylation site
was defective in its ability to bind with Ego3. Moreover, normal Meh1-GFP was lo-
calized in the vacuolar membrane, but the mutant Meh1-GFP was widely distrib-
uted in the cytoplasm and not in the vacuolar membrane. These phenomena pro-
posed that the palmitoylation of Meh1 has an important role in its cellular
distribution and formation of the EGO complex. 
As for our result, the palmitoylation of Meh1 by Akr1 is related to the formation of
the EGO complex through its localization into the vacuolar membrane, and this
action is important for the reduction of MeHg toxicity.
1525 Involvement of AAT Transporters in Methylmercury Toxicity
in Caenorhabditis elegans.
S. W. Caito and M. Aschner. Department of Pediatrics/Pediatrics Toxicology,
Vanderbilt University Medical Center, Nashville, TN.
Caenorhabditis elegans (C. elegans) is a powerful genetic model for the investigation
of neurotoxicity of metals, such as methylmercury (MeHg). MeHg has been shown
to accumulate in C. elegans, leading to decreased survival, reproductive and devel-
opmental defects, and neurodegeneration. It is unknown how MeHg is transported
in the worm. In mammals, MeHg complexes with cysteine, which functionally re-
sembles methionine; and the complex is transported into cells via a molecular mim-
icry mechanism involving the large neutral amino acid transporter LAT1. It is un-
known if MeHg can enter cells without being complexed to cysteine or if there are
additional uncharacterized MeHg transport mechanisms. C. elegans can be used to
quickly identify MeHg transport mechanisms due to their ease of genetic manipu-
lability and high degree of homology to mammals. Herein we tested the hypothesis
that LAT1 homologues (AATs) are responsible for MeHg transport in C. elegans.
Worms were pre-treated with 1 mM methionine to assess whether MeHg toxicity
could be attenuated by increasing a competitor for AAT transporters. Treatment
with MeHg resulted in decreased survival of C. elegans (LD50 = 22.91 μM), how-
ever methionine pre-treatment showed significantly less toxicity to MeHg (LD50 =
47.54 μM, p < 0.0001), implicating the AAT amino acid transport systems in
MeHg toxicity. Using RNAi feeding protocols we selectively knocked down expres-
sion of the aat-1, aat-2 and aat-3 genes, and assayed for MeHg induced-lethality.
Knockdown of each gene individually resulted in a significant right hand shift in
the dose-response lethality curve (aat-1: LD50 = 118.1 μM, p < 0.001; aat-2:
LD50 = 102.1 μM, p < 0.001; aat-3: LD50 = 44.65 μM p < 0.001), suggesting
these genes may be involved in MeHg transport. As lethality of MeHg was not
completely blocked by methionine pre-treatment or aat gene knockdown, there is a
possibility that additional MeHg transport mechanisms may be identified in C. ele-
gans.
1526 Effects of Methylmercury on Heart Rate Variability in the
Rat.
M. Sasaki,  M. Yamamoto and M. Fujimura. Department of Basic Medical Sciences,
National Institute for Minamata Disease, Minamata, Japan.
Analysis of heart rate variability (HRV) in humans has revealed that methylmercury
(MeHg) exposure decreases parasympathetic nerve function or increases sympa-
thetic nerve function. However, limited information is available on such effects in
experimental animals. In the present study, 5 rats were treated 2 times per week for
5 weeks with MeHg (4 mg/kg) or vehicle orally. Several weeks before and after
treatment, telemetry recordings of ECG were acquired. HRV and its power spec-
trum parameters were determined from 1-hour segments (approximately 16,000 to
20,000 beats) of ECG data during the day by LabChart and its HRV Module.
With 4 mg/kg MeHg treatment, a decrease in body weights and the hind limb
crossing sign and an increase in the heart rate (HR) were observed from the analy-
sis of the ECG. HRV analyses showed a decrease in the coefficient of HRV (CVRR)
and low frequency (LF) and high frequency (HF) HRV. A slight increase in the
LF/HF ratio was observed due to the decrease in HF. These results suggest that a
decrease in the CVRR, LF, and HF and an increase in the HR indicate the suppres-
sion of parasympathetic nervous system activities after repeat treatments with
MeHg in rats. These findings also suggest similar effects of MeHg on the auto-
nomic nervous system of humans and animals.
1527 Sex Differences in Paraoxonase Activity in Subchronic
Inorganic Mercury Exposure.
A. D. Wusu1,  O. Ademuyiwa1,  O. O. Ogunrinola1,  O. K. Afolabi1,
E. O. Abam1,  D. O. Babayemi1,  E. A. Balogun1 and O. O. Odukoya2.
1Biochemistry, University of Agriculture, Abeokuta, Nigeria; 2Chemistry, University of
Agriculture, Abeokuta, Nigeria.
Epidemiological evidences suggest an increased risk of cardiovascular diseases
(CAD) as a result of inorganic mercury exposure. The underlying mechanisms un-
derpinning this risk, as well as sex differences in response to mercury exposure, are
not yet understood. Paraoxonase (PONase), an enzyme located in the high-den-
sity–lipoprotein (HDL) has been shown to protect against CAD. In order to inves-
tigate the association between inorganic mercury exposure and CAD, male and fe-
male rats were exposed to mercury (0.5, 1.0 and 1.5mg/kg) for 12 weeks. PON
activities towards paraoxon (PONase) and phenylacetate (AREase) in plasma,
lipoproteins, hepatic and brain microsomal fractions were determined using stan-
dard methods. Inhibition of PONase and activation of AREase in plasma and HDL
characterised the effects of inorganic mercury in both sexes. Inorganic mercury ex-
posure inhibited PONase by 63% (plasma) and 67% (HDL) respectively in male
animals, whereas the female enzyme was inhibited by 80 and 47% respectively.
AREase activity was activated by 55 and 53% in male, whereas the activation in fe-
male amounted to 25 and 49% respectively. In the VLDL, inorganic mercury in-
hibited PONase in both sexes whereas AREase was activated in female animals but
inhibited in male. In the hepatic microsomal fractions, only the PONase enzyme
was inhibited in male animals whereas in female, activation was observed in both
enzymes at the highest dose of inorganic mercury. Brain microsomal cholesterol
was increased in male but decreased in female by inorganic mercury resulting in al-
tered cholesterol/phospholipid ratios. Our findings indicate that inorganic mercury
exposure exerts an inhibitory effect on PONase but activated AREase. Modulation
of PON activity may be an early biochemical step in the induction of CAD by mer-
cury. This may also be mediated through changes in membrane fluidity brought
about by changes in the concentration of cholesterol in the microsomes.
1528 Ethylmercury Induces ER Stress and Mitochondria
Dysfunction Mediated Autophagy.
M. Dong and J. Choi. School Lifesciences and Biotechnology, Korea University, Seoul,
Republic of Korea. Sponsor: B. Lee.
Mercury is one of the most important environmental and industrial pollutants
throughout the world. Exposure to mercury causes strong damage to organs in-
cluding the brain, blood, liver, bone and kidneys. Renal proximal tubular cells rep-
resent the primary target site. We previously investigated the cytotoxicity of seven
kinds of mercury compounds in human renal proximal tubule (HK-2) cells.
Ethylmercury chloride (EMC) was shown the strongest cytotoxicity among them
with 2.4 and 0.76 uM of IC50 values exposed for 24 h and 48 h in HK-2 cells, re-
spectively. In this study, we explored the mechanism of EMC induced cytotoxicity
in HK-2 cells. EMC was increased the accumulation of JC-1 monomers in mito-
chondria from 0.5 to 2 μM concentrations in a dose-dependent manner. The ex-
pression of MT-I and Hic-5, which were related to oxidative stress, was also in-
duced by EMC treatment. In addition, calcium is a well-known regulator of many
intracellular processes, including apoptosis and autophagy. Interestingly, EMC was
increased in cytosolic [Ca2+], which was the tendency appears unlikely that the in-
creased after 2μM A23187 treatment. EMC was up-regulated the expression of
UPR target genes and proteins such as transcription factor, CHOP, XBP-1, ERdj4
and GRP 78. After the exposure of EMC to cells, LC3II formation was dose- and
time-dependently increased. When cells were treated with ER inhibitor 4-
Pheylbutyric acid, they blocked the formation of autophagosome compared with
untreated cells. However, cleaved of caspase-9, caspase-12 and PARP were weakly
activated. To test whether ER stress by EMC can occur in vivo, EMC was treated to
328 SOT 2013 ANNUAL MEETING
male C57BL/6 mice with 1, 2, 5 and 10 mg/kg/day. The expression of ER stress re-
lated marker genes were increased by immunoblot analysis. LC3-II was signifi-
cantly increased in the kidneys of EMC treated mice. Together, these results suggest
that EMC induced autophagy via ER stress and mitochondria dysfunction not only
in human renal proximal tubule (HK-2) cells but also in mice kidneys.
1529 Protective Role of Quercetin against Mercury-Induced
Nephrotoxicity in Sprague-Dawley Rats.
J. Kim1,  Y. Kim2,  W. Kim3,  Y. Shin4,  A. Won4,  E. Park4,  E. Lee4,  M. Yoo4,
Z. Lan4,  T. Kim4 and H. Kim4. 1College of Pharmacy, Pusan National University,
Busan, Republic of Korea; 2Gorton School, Farmers Row, Groton, MD; 3The
Hockaday School, Dallas, TX; 4Sehwa High School, Seoul, Republic of Korea.
Mercury chloride (HgCl2) is a well-known nephrotoxicant. HgCl2 preferentially
accumulates in the kidneys and causes nephrotoxicity as a result of oxidative stress.
The aim of this study was to investigate the possible protective role of quercetin
against HgCl2–induced acute renal damage. Quercetin, a naturally occurring phe-
nolic compound found in fruits and vegetables, has gained considerable attention
for its antioxidant properties. In this study, quercetin (250 mg/kg) was adminis-
tered orally to Sprague-Dawley male rats for 3 days prior to HgCl2 (20 mg/kg)
treatment. All animals were sacrificed 24 h after the last treatment and various urine
or blood biomarkers associated with renal damage were measured. Significant in-
creases in urinary volume and decreases in urinary pH were observed in the HgCl2-
treated group. Blood urea nitrogen (BUN) and serum creatinine (sCr) levels were
significantly increased in the HgCl2-treated group when compared to control
group. In the HgCl2-treated group, the urinary excretion of BUN, sCr, lactate de-
hydrogenase (LDH) and total protein were all markedly lower than those of the
control group. These adverse effects were ameliorately by pretreatment with
quercetin. Compared to the HgCl2-treated group, quercetin pretreatment led to a
significant decrease in the amounts of KIM-1, NAGL, HMGB1, and Netrin-1 in
the urine. Furthermore, histopathological examinations indicated that quercetin
had a protective effect against HgCl2-induced proximal tubular damage. These re-
sults suggest that quercetin may be a promising agent to protect against HgCl2-in-
duced acute kidney injury.
1530 Selenium Protects against the Toxic Effects of Methylmercury
in Sperm Whale (Physeter macrocephalus) Skin Cells.
L. C. Savery1, 2, 4,  A. Holmes1, 2, 3,  M. Braun1, 2,  D. Evers5,  I. Kerr2, 4,  R. Payne2,
4,  W. Thompson2, 3,  C. Perkins6,  T. Zheng7,  C. Zhu7 and J. Wise1, 2, 4. 1Wise
Laboratory of Environmental and Genetic Toxicology, University of Southern Maine,
Portland, ME; 2Maine Center for Toxicology and Environmental Health, University
of Southern Maine, Portland, ME; 3Department of Applied Medical Sciences,
University of Southern Maine, Portland, ME; 4Ocean Alliance, Gloucester, MA;
5Biodiversity Research Institute, University of Southern Maine, Portland, ME; 6Center
for Environmental Sciences and Engineering, University of Connecticut, Mansfield,
CT; 7Yale School of Public Health, New Haven, CT.
Mercury (Hg) persists, bioaccumulates and is toxic to the marine environment pos-
ing risks to the marine ecosystem. Selenium (Se), an essential element, antagonizes
Hg toxicity when present in equimolar amounts. The sperm whale, a toothed
whale, is a sentinel of ocean health. We biopsied skin from 343 free-ranging sperm
whales in 17 regions around the globe during the voyage of the Odyssey, between
2000-2005 analyzing them for total Hg and Se levels. Hg was detected in 340 sam-
ples with a global mean of 2.4 ug/g ww ranging from 0.1 to 16 ug/g. Se was de-
tected in all samples with a global mean of 33.0 ug/g ww ranging from 2.5 to 179.0
ug. The global mean Se:Hg molar ratio was 59:1 ranging from 3:1 to 1719:1. This
excess Se may mitigate the toxic effects of Hg. Hg is known to cause cytotoxicity, al-
tered mitotic index and aneuploidy in cells. The aim of this study was to determine
if Se protects sperm whale skin cells from Hg-induced toxicity at similar concentra-
tions found in the skin biopsies. Sperm whale skin cells developed from the biopsies
were cotreated with 72 h exposure to 2, 3, 4 or 5 uM methylmercury (MeHg) and
10 uM sodium selenite, and cytotoxicity, mitotic index and genotoxicity was meas-
ured. Our findings show MeHg induces cytotoxicity, alters mitotic index and
causes aneuploidy in sperm whale skin cells, and Se protects against MeHg induced
toxicity compared to control.
1531 Selenium Compounds Cause Apoptosis and GSH Depletion
in Rat Hippocampal Astrocytes.
S. Roy and D. Hardej. Pharmaceutical Sciences, St. John’s University, Queens, NY.
Selenium (Se) is a required trace element in mammalian systems. While generally
accepted to play a protective role, exposure to high levels of Se have been associated
with neurotoxicity. Previous work in our laboratory has demonstrated toxicity of Te
and Se compounds in rat hippocampal astrocytes. The purpose of this study was to
evaluate the mechanism of cell death of diphenyl diselenide (DPDSe) and selenium
tetrachloride (SeCl4) and to investigate their effects in the functioning of mito-
chondrial complexes III and IV and depletion of the antioxidant GSH. Rat hip-
pocampal astrocytes were used as a model system. The LC50 of both compounds
had been previously found to be 7.8 μM. For the present study, concentrations of
both compounds ranging from1.9-15.625 μM were tested. Phase-contrast mi-
croscopy was used to study the morphological changes in the cells following treat-
ments. Micrographs of cells exposed to high concentrations of either compound
(15.625 and 7.8μM) showed decreases in cell number and increases in rounded
cells with loss of processes. Micrographs of cell exposed to low concentrations (3.9
and 1.9μM) appeared similar to control astrocytes. Inductively Coupled Plasma-
Optical Emission Spectrometry (ICP-OES) demonstrated that treatments with
both compounds resulted in a dose-related increase of Se in the cells that is signifi-
cantly greater than amounts seen in the controls. Caspase 3/7 activities were as-
sessed and significant increases in activity were observed at the 7.8 μM and 15.625
μM concentrations with both Se compounds confirming apoptotic activity. ELISA
assays were used to investigate the activities of complexes III and IV of the mito-
chondrial respiratory chain. There were no significant changes in the activities of
the two enzymes in any treatment group. GSH/GSSG ratios were significantly de-
creased at 7.8 and 15.625 μM of each compound indicating oxidation of sulfhydryl
groups. These results suggest that selenium compounds cause cytotoxicity in rat
hippocampal astrocytes resulting in apoptosis but mitochondrial complexes III and
IV are not involved.
1532 Heavy Metal Hazards of Smokeless Tobacco in Nigeria.
O. Orisakwe2,  Z. N. Igweze1 and K. O. Okoro1. 1Department of Pharmacology
College of Health Sciences, University of Port Harcourt, Rivers State, Nigeria, Nigeria;
2Toxicology Unit, Department of Experimental Pharmacology & Clinical Pharmacy,
University of Port Harcourt, Rivers State, Nigeria, Nigeria.
Smokeless tobacco (ST) or snuff prepared by grinding tobacco leaves into a very
fine powder with addition of salt petre and other ingredients has been in use in
Nigeria for a very long time. STis marketed for oral and nasal use. Recently there
has been an upsurge in the use of ST even amongst the younger generation.
Information on the public health implication and heavy metal hazards of ST in
Nigeria is sparse. This study was carried out to determine the extent of heavy metal
contamination in ST used in Nigeria. Concentration of five heavy metals,
Lead(Pb),Cobalt(Co),Cadmium(Cd), Nickle(Ni), and Chromium(Cr) were deter-
mined in smokeless tobacco by wet digestion usingHNO3 and analysis with AAS
205A Spectrophotometer. Thirty samples of smokeless tobacco sourced from six ge-
ographical regions in Nigeria were used. Our results showed that the level of con-
tamination with all the metals was ≤10μg/g, 11-30μg/g,≤10μg/g,20-70μg/g
and2770-11400μg/g for Pb, Co, Cd, Ni and Cr. These concentrations are higher
than acceptable limits. Health risks associated with ST snuffing have received little
or no attention in Nigeria in spite of wide spread use. This study underscores the
importance of elaborate human risk assessment of ST in Nigeria and indeed Sub
Saharan Africa.
1533 Tobacco Cigarettes: A Source of Metals (Al, Cd, Co, Cr, Mn,
Ni, Pb, Sr) for Humans.
C. Rubio1,  T. Garcia1,  A. Soler1,  D. Glez-Weller1,  A. J. Gutiérrez1,
A. Hardisson1 and A. Anadon2. 1Toxicology, Universidad de La Laguna, La Laguna,
Spain; 2Farmacología y Toxicología, Universidad Complutense de Madrid, Madrid,
Spain.
Every six seconds a smoker dies, the victim of an addiction that causes a high degree
of toxicity.
Al, Cd, Co, Cr, Mn, Ni, Pb and Sr were determined in 33 tobacco samples ran-
domly obtained in Tenerife using Inductively Coupled Plasma Spectrometry by
previously treating the samples according to the standard procedure, that is, by
adding HNO3 at 65% to the sample and burning it in a muffle oven for 50 hours
at 450 degrees Celsius. 
With respect to results, 428 mg Al/kg, 0.810 mg Cd/kg, 0.558 mg Co/kg, 1.442
mg Cr/kg, 112.026 mg Mn/kg, 2.238 mg Ni/kg, 0.602 mg Pb/kg and 82.206 mg
Sr/kg. Al was the metal with the greatest concentration while Co had the lowest.
The tobacco was also classified according to the type of tobacco (Virginia vs Dark),
type of cigarette (Normal vs Light) and manufacturer. The amount of Al in Virginia
tobacco was 423 mg/kg while in Dark this was 478 mg/kg, Cd concentrations were
0.807 mg/kg for Virginia and 0.844 mg/kg for Dark, Co values were 0.56 mg/kg
for Virginia and 0.533 mg/kg for Dark, Cr values were 1.487 mg/kg for Virginia
and 1 mg/kg for Dark, Mn was determined to be 113.362 mg/kg for Virginia and
98.667 mg/kg for Dark, Ni values were 2.242 mg/kg for Virginia and 2.199 mg/kg
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for Dark, Pb afforded 0.607 mg/kg for Virginia and 0.556 mg/kg for Dark, and Sr
gave values of 77.982 mg/kg for Virginia and 124.444 mg/kg for Dark. Regarding
the differences between Light and Normal tobacco, the following values were ob-
tained in Light: 412.4 mg Al/kg, 0.873 mg Cd/kg, 0.553 mg Co/kg, 1.64 mg
Cr/kg, 120.02 mg Mn/kg, 2.4 mg Ni/kg, 0.873 mg Pb/kg and 78.627 mg Sr/kg;
while in Normal tobacco the values determined were 434.783 mg Al/kg, 0.783 mg
Cd/kg, 0.559 mg Co/kg, 1.366 mg Cr/kg, 108.56 mg Mn/kg, 2.168 mg Ni/kg,
0.484 mg Pb/kg and 83.762 mg Sr/kg.
Exposure to metals though the inhalation of cigarette smoke represents a significant
source of metal contamination to smokers, adding to the dietary intake of these
same metals.
1534 Metal Mobilization from Retained Embedded Fragments in a
US Veteran: Biomonitoring Correlates with Fragment
Content.
J. Gaitens1, 2,  K. Squibb1, 2,  J. Centeno3,  M. Condon1 and M. McDiarmid1, 2.
1VA Medical Center, Baltimore, MD; 2School of Medicine, University of Maryland,
Baltimore, MD; 3Joint Pathology Center, Silver Spring, MD.
Recent clinical findings implicate the potential for local and systemic long-term
health effects from embedded metal fragments associated with injuries from impro-
vised explosive devices in soldiers serving in military conflicts. In the past, frag-
ments embedded in muscle tissue were thought to be relatively inert; however, evi-
dence has shown that soldiers with embedded depleted uranium fragments have
elevated urine U levels 20 years after exposure. To understand the potential health
risks associated with embedded fragments from blast injuries, the Department of
Veterans Affairs has established a medical surveillance program which integrates
fragment composition data, surrounding tissue analyses, and urine biomonitoring
results that characterize systemic and local tissue exposure to: Al, As, Cd, Cr, Co,
Cu, Fe, Mn, Ni, Pb, U, W and Zn. These metals were chosen based on available
fragment composition data and known toxicity of individual metals. We present
here results from a Veteran who had 3 fragments removed several years after injury.
Using EDXRF, the removed fragments were determined to be an Al-Cu alloy.
Chemical analysis of adherent tissue showed levels of Al and Cu consistent with
mobilization of these elements from the fragment to the surrounding tissue.
Histology showed focal foreign body-type giant cell reaction and chronic inflam-
matory cell infiltrates, but no evidence of neoplastic changes. Prior to fragment re-
moval, biomonitoring results showed a urine Al level 1.5 fold higher than the refer-
ence range, but below levels associated with adverse health effects. Concentrations
of all other metals were within established reference ranges. These results provide
further evidence that metal fragments in the body are not inert and materials re-
leased from fragments can enter systemic circulation over time, thus warranting
long-term biomonitoring and medical surveillance of Veterans with embedded frag-
ments. Supported by the Department of Veterans Affairs.
1535 Baseline Blood Levels of Manganese (Mn), Lead (Pb),
Cadmium (Cd), Copper (Cu), and Zinc (Zn) in Residents of
Beijing Suburb.
L. Zhang1,  L. Lu1,  Y. Pan2,  C. Ding2,  D. Xu1,  J. Zhao1,  W. Zheng3 and
H. Yan2. 1Occupational Disease Control, Fengtai CDC, Beijing, China; 2Institute of
Occupational Health, China Center for Disease Control and Prevention, Beijing,
China; 3School of Health Science, Purdue University, West Lafayette, IN.
The baseline blood concentrations of heavy metals are important for monitoring
metal exposure in the general population. The data can be used to evaluate the cur-
rent environmental pollution and also serve as the references for exposure assess-
ment in local residents as well as in occupational settings. The purpose of this study
was to determine the blood levels of Mn, Pb, Cd, Cu, and Zn among the residents
(aged 12-60 years old) living in the suburb southwest of Beijing, China. Blood sam-
ples were drawn from a total of 648 subjects from March 2009 to February 2010.
Metal concentrations in the whole blood were measured by ICP-MS. The geomet-
ric means of the blood levels of Mn, Pb, Cd, Cu and Zn were 11.4, 42.6, 0.6, 802.4
and 4,665 ug/L, respectively. Blood Mn level of all participants is similar to the re-
ports by Korean (Lee et al. Int J Hyg Env Health 2012;215:449) and Canadian
(Clark et al. Chemosphere 2007;70:155) studies in literature. Blood Pb level was
higher in Chinese residents than those of Korea’s and Czech’s (Batariova et al. Int J
Hyg Env Health 2006;209:359). Blood Pb levels in the all participants were higher
among Chinese than those of Korean and Czechs; the magnitude of increase be-
came more evident when compared with Korean data. Blood Cd levels in this
Chinese cohort were within the same range as Czech’s, but were significantly higher
than German’s (Heitland & Koster J Trc Elem Med Biol 2006;20:253). Blood Cu
levels were significantly lower in Chinese than those of Germany and Canadian,
while blood Zn levels were significantly lower than those of Czechs. Based on the
data of the 95th percentile, we estimate the normal reference values for the whole
blood Mn to be 21.7 ng/mL, Pb 10.3 ug/dL, Cd 5.3 ng/mL, Cu 1.36 ug/mL, and
Zn 9.03 ug/mL in Chinese resident living in Beijing suburb. These baseline values
will be useful for occupational and environmental exposure assessment.
1536 Effect of Long-Term Exposure of Heavy Metals on the
Expression Profile of Cytoprotective Genes among
Individuals Living in Mining Areas.
I. M. Attafi,  S. A. Albakheet and H. M. Korashy. Pharmacology and Toxicology,
King Saud University, Riyadh, Saudi Arabia.
Environmental exposure to heavy metals is one of the most global concerns, partic-
ularly among whom living around the polluted areas. These heavy metals are
known to generate oxidative stress species, and induce of oxidized DNA adduct for-
mation, and DNA repair genes causing disease induction. The aim of this study is
to evaluate the effects of long-term exposure to environmental heavy metals in the
expression profile of some cytoprotective genes and the level of oxidized DNA
adduct formation among individuals living around mining areas. Sixty healthy vol-
unteers were divided to two groups; exposed group consisted of 40 male residents
in a heavy metal-polluted area, whereas the control group consisted of 20 male res-
idents in a non-polluted area. Whole blood concentrations for heavy metals, partic-
ularly lead, cadmium, and mercury, were determined using ICP-MS. Total RNA
was isolated using PAXgene Blood RNA kits and the mRNA levels of heavy metals
biomarker genes: NQO1, HO-1, and MT-1 and DNA repair genes: OGG1 and
APE1 were determined by RT-PCR. Plasma levels of 8-OHdG were evaluated by
ELISA technique. The results showed a significant increase in blood levels of heavy
metals among exposed group. RT-PCR results revealed significant inhibitions of
NQO1 mRNA level in group which were highly contaminated with lead, whereas
the group of highly contaminated with cadmium showed the highest inhibitory ef-
fect on MT-1 mRNA level and significant induction of OGG1 mRNA level.
Furthermore, mercury contaminated group showed a significant inhibition of
APE1 mRNA level. The level of 8-OHdG was well correlated with the level of
OGG1 mRNA. We conclude that long-term exposure to environmental heavy
metals differentially altered the expression of cytoprotective and DNA repair genes.
Therefore, they may be used as biomarkers for early prediction of disease risk
among individuals living around polluted areas.
1537 Phytotoxicity and Trace Metal Accumulation from Long-
Term Chicken Litter Amendment in Wilkes County, North
Carolina: A Field Study.
A. K. Hastings,  S. Mouro,  M. Brower and S. Tuberty. Biology, Appalachian State
University, Boone, NC. Sponsor: G. LeBlanc.
Arsenic, zinc and copper are commonly integrated in chicken feeds to ensure in-
creased weight gain in chickens and prevent chicken house diseases. These metals
ultimately become part of the litter that is spread by farmers over crop fields as an
alternative to expensive fertilizers. Massive growth in industrial chicken production
across Wilkes County, NC has resulted in increased concentrations of phytotoxic
metals in farmland soils and loss of copper sensitive crops such as peanuts. Using
Zea mays as a representative crop species, our research objective was to evaluate the
long-term sustainability of this practice by measuring adverse effects on corn in
fields that have received a varied number of poultry litter amendments. Three agri-
cultural fields receiving chicken litter amendment ranging from less than 10 yrs to
more than 30 yrs within Wilkes County were selected as sampling areas for trace
metal analysis. Soils were collected prior to and after annual litter application dates
and corn tissue samples were collected in thirty day intervals (30, 60 & 90 days post
planting) from each field. Nearly 400 corn tissue and soil samples were lyophilized
and homogenized; 0.5g samples were nitric acid digested with a microwave reactor
(USEPA Method 3051); and analyzed using ICP- OES to quantify levels of Cu and
Zn. ICP- OES analysis indicated that industrial broiler chicken litter contains con-
siderably elevated Cu (~388 ppm) and Zn (~481 ppm) concentrations. Thirty day
corn seedling Cu and Zn burdens correlate closely with soil metal levels and with
significantly delayed seedling emergence time and reduced growth rates (e.g., mean
leaf height and area). No correlation was observed between soil metal levels and ma-
ture plant burdens. Continued chicken litter application may result in significantly
reduced Zea mays productivity due to elevated Cu and Zn levels and therefore is not
sustainable at the maximum application rates currently practiced in NC.
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1538 Association of 25-Hydroxyvitamin D and 1, 25-
Dihydroxyvitamin D with Metals in a Cohort of Adolescents
in Torreon, Mexico.
R. D. Zamoiski1,  E. Guallar2, 3,  G. G. Garcia-Vargas4,  M. Rubio-Andrade4,
P. J. Parsons5,  A. J. Steuerwald5,  S. J. Rothenberg6,  A. Navas-Acien1, 2,
C. Resnick1,  V. Weaver1 and E. K. Silbergeld1. 1Environmental Health Sciences,
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; 2Epidemiology,
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; 3Cardiovascular
Epidemiology and Population Genetics, National Center for Cardiovascular Research,
Madrid, Spain; 4Facultad de Medicina, Universidad Juárez del Estado de Durango,
Gómez Palacio, Mexico; 5Inorganic and Nuclear Chemistry, Wadsworth Center,
Albany, NY; 6Centro de Investigación en Salud Poblacional, Instituto Nacional de
Salud Publica, Cuernavaca, Mexico.
Background: Data suggest that nephrotoxic metals may disrupt vitamin D metabo-
lism and inhibit production of 1,25(OH)2D, the active vitamin D metabolite,
from 25(OH)D in the kidney. Prior studies support this but are few in number and
limited by small sample sizes. We sought to describe this association in a much
larger sample.
Methods: Cross-sectional study of 512 adolescents in Torreon, a smelter town in
Mexico. BPb was measured using atomic absorption; urine As, Cd, Mo, W, Sb, Tl,
and U using ICP-MS. Vitamin D was measured using radioimmunoassay and
chemiluminescent assay. Multivariate linear models with vitamin D as the outcome
measured effect of metal on vitamin D level, controlling for age, sex, smoking, SES,
and time outdoors. 
Results: 25(OH)D was positively associated with Mo, Tl, and U (β=2.25, 1.46, and
0.89, respectively). 1,25(OH)2D was positively associated with As and U
(β=3.64,2.25), even after controlling for 25(OH)D (β=3.45,1.90).
Conclusions: No evidence that metals are inhibiting production of 1,25(OH)2D.
Exposure to U or As may upregulate 1,25(OH)2D, perhaps in response to proxi-
mal tubule damage. Nephrotoxic metals such as U and As may cause a sub-thresh-
old Fanconi syndrome, wasting phosphorus, and upregulating 1,25(OH)2D to
maintain homeostasis.
1539 Is Genotoxic Metal Exposure Part of the Toxic Legacy of the
Deepwater Horizon Oil Crisis?
J. J. Wise1, 2, 4,  J. Wise1, 2, 4,  W. Thompson2, 3,  C. Perkins5 and J. Wise1, 2, 4. 1Wise
Laboratory of Environmental and Genetic Toxicology, University of Southern Maine,
Portland, ME; 2Maine Center for Toxicology and Environmental Health, University
of Southern Maine, Portland, ME; 3Department of Applied Medical Science,
University of Southern Maine, Portland, ME; 4Ocean Alliance, Gloucester, CT;
5Center for Environmental Sciences and Engineering, University of Connecticut,
Storrs, CT.
In the wake of the Deepwater Horizon oil disaster of 2010, we collected tissue sam-
ples from sperm whales in order to determine the effects of the oil and chemical dis-
persants on their population. We focused on whales because they are at the top of
the food chain and they are biologically similar to humans. Sperm whales live and
feed at the same depth as the Deepwater Horizon well head, placing them at high
risk to this disaster. After it became apparent the spewing oil was going to be the
worst incident in US history, concern largely focused on oil and dispersants while
the potential threat of genotoxic metals in the oil has gone largely overlooked.
Genotoxic metals, such as chromium and nickel, damage DNA and bioaccumulate
in organisms resulting in longer exposures. Analysis of sperm whale skin samples
showed mean levels of Ni and Cr at significantly higher levels than those found in
whales collected around the world prior to the spill. We found Cr and Ni levels
ranged from 0.4-94.63 ppm in tissue collected from Gulf of Mexico whales in the
wake of the crisis, with mean Ni and Cr levels of 14.9 and 12.00 ppm, respectively.
In addition, we found Cr and Ni levels ranged from 0.24-8.46 ppm in crude oil
from the riser, oil slicks from surface waters and tar balls from Gulf beaches. Maps
of where we collected our samples showed the highest metal levels in whales closest
to the epicenter. Given the capacity of these metals to break DNA, their presence in
the oil and their elevated levels in whales, we believe metal exposure is an important
overlooked concern for the Deepwater Horizon oil disaster. Further analysis is un-
derway to determine the impact of this disaster on the genetic health of the whales
and the long term impact in years following.
1540 Broad Spectrum Safety of LOWAT: A Novel Weight
Management Ingredient.
F. Lau1,  Z. M. Saiyed1,  J. Lugo1,  G. Trimurtulu2,  A. V. Krishnaraju2 and
K. Sengupta2. 1R&D, Interhealth Nutraceuticals, Benicia, CA; 2Laila Nutraceuticals,
Vijayawada, India.
LOWAT is a novel formulation consisting of extracts from Piper betle leaves and
Dolichos biflorus seeds. Clinical research demonstrated that LOWAT is effective
and well-tolerated in weight management. The current study evaluated the broad
spectrum safety of LOWAT in a battery of animal and in vitro studies including
acute oral, acute dermal, primary dermal irritation, primary eye irritation, mam-
malian erythrocyte micronucleus and chromosomal aberration tests. A sub-chronic
repeated-dose 28-day toxicity study was conducted to determine the no-observable-
adverse-effect-level (NOAEL) of LOWAT. 
The LD50 levels of LOWAT in Sprague-Dawley (SD) rats, as determined by the
acute oral and acute dermal toxicity studies, were >5,000 and >2,000 mg/kg body
weight, respectively. Primary skin and eye irritation studies done on New Zealand
rabbits classified LOWAT as non-irritating to the skin and as mildly irritating to the
eye. Genotoxicity studies showed that LOWAT was non-mutagenic. 
In a repeated-dose 28-day oral toxicity study, SD rats were administered orally with
LOWAT at 0, 50, 250 or 2,500 mg/kg body weight daily dose. Rats were sacrificed
at 28 days after supplementation. Body weight, food and water consumption, select
organ weights, ocular health, hematology, blood chemistry, clinical chemistry and
histopathology were assessed. No morbidity, mortality, or significant adverse events
were observed at 28 days. Based on these findings, NOAEL of LOWAT was deter-
mined to be at least 2,500 mg/kg body weight in male and female SD rats. 
These results, combined with the tolerability of LOWAT in the human clinical
trial, demonstrate the broad spectrum safety of LOWAT.
1541 Evaluation of Nose-Only Inhalation Exposure to Aerosolized
Linalool in Sprague-Dawley Rats.
J. Randazzo1,  D. Vitale2,  D. Kirkpatrick1,  F. G. Burleson3 and M. Singal2. 1WIL
Research, Ashland, OH; 2Research Institute for Fragrance Materials, Woodcliff Lake,
NJ; 3Burleson Research Technologies, Morrisville, NC.
Linalool is a commonly used fragrance material that has been associated with skin
sensitization. The study objective was to understand the effects of inhalation expo-
sure in Sprague-Dawley (SD) rats when aerosolized linalool when administered to
rats by nose-only inhalation at 0.1, 1, and 10 ppm (0.63, 6.3, 63 mg/m3) for 2
weeks (6 hours/day, 5 days/week). Standard endpoints evaluated included: clinical
observation; body and organ weights; hematology and serum chemistry evaluation;
macroscopic/microscopic examination of selected organs; and bronchoalveolar
lavage fluid (BALF) analysis for cellular markers of inflammation (i.e., cytokines).
As a positive control to validate the utility of cytokine measures as indicators of pul-
monary inflammation, a nose-only inhalation pilot was conducted with 25 mg/m3
amorphous silica (0, 1, 2, 5 or 10 exposures). At all exposure levels, linalool was
well tolerated with test substance-related effects limited to non-adverse microscopic
findings in the nasal cavity. Therefore, the no-observed-adverse-effect level
(NOAEL) was considered to be 10 ppm (equivalent to 63 mg/m3), the highest ex-
posure concentration tested.
1542 Evaluation of Nose-Only Inhalation Exposure to Aerosolized
Cinnamal in Sprague-Dawley Rats.
D. Vitale1,  J. Randazzo2,  D. Kirkpatrick2,  F. G. Burleson3 and M. Singal1.
1Research Institute for Fragrance Materials, Woodcliff Lake, NJ; 2WIL Research,
Ashland, OH; 3Burleson Research Technologies, Morrisville, NC.
Cinnamal is a commonly used fragrance material that has been associated with skin
sensitization. The study objective was to understand the effects of inhalation expo-
sure in Sprague-Dawley (SD) rats when aerosolized cinnamal when administered to
rats by nose-only inhalation at 1, 10, and 100 ppm (5.4, 54.1, 540.5 mg/m3) for 2
weeks (6 hours/day, 5 days/week). Standard endpoints evaluated included: clinical
observation; body and organ weights; hematology and serum chemistry evaluation;
macroscopic/microscopic examination of selected organs; and bronchoalveolar
lavage fluid (BALF) and serum analysis for cellular markers of inflammation (i.e.,
cytokines). As a positive control to validate the utility of cytokine measures as indi-
cators of pulmonary inflammation, a nose-only inhalation pilot was conducted
with 25 mg/m3 amorphous silica (0, 1, 2, 5 or 10 exposures). Exposure to cinnamal
at 100 ppm was not tolerated as evidenced by adverse clinical observations and sub-
stantial body weight loss coupled with histologic changes in the upper and lower
respiratory tract and clinical chemistry alterations suggestive of hepatotoxicity.
Exposures were terminated for the 100 ppm group following the 5th exposure and
the animals were sacrificed on study day 7. Exposures at 1 and 10 ppm (equivalent
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to 5.4 or 54.1 mg/m3, respectively) did not result in any adverse findings and show
a clear threshold of response for lung and liver. Therefore, the no-observed-adverse
effect concentration (NOAEC) was determined to be 10 ppm (equivalent to 54.1
mg/m3).
1543 Evaluation of Nose-Only Inhalation Exposure to Aerosolized
Isoeugenol in Sprague-Dawley Rats.
M. Singal1,  J. Randazzo2,  D. Kirkpatrick2,  F. G. Burleson3 and D. Vitale1.
1Research Institute for Fragrance Materials, Woodcliff Lake, NJ; 2WIL Research,
Ashland, OH; 3Burleson Research Technologies, Morrisville, NC.
Isoeugenol is a commonly used fragrance material that has been associated with
skin sensitization. The study objective was to understand the effects of inhalation
exposure in Sprague-Dawley (SD) rats when aerosolized when administered to rats
by nose-only inhalation at 0.15, 1.5, and 14.9 ppm (1, 10, and 100 mg/m3) for 2
weeks (6 hours/day, 5 days/week). Prior to the main study, a preliminary 3-day ex-
posure (6 hours/day) was run at 89.4 and 44.7 ppm to allow selection of appropri-
ate doses. At both concentrations, the animals were observed to have decreased
body weight over the 3 day exposure period. Therefore, a third of the lowest dose
tested, 14.9 ppm, was chosen as the high exposure level for the main study.
Standard endpoints evaluated included: clinical observation; body and organ
weights; hematology and serum chemistry evaluation; macroscopic/microscopic ex-
amination of selected organs; and bronchoalveolar lavage fluid (BALF) and serum
analysis for cellular markers of inflammation (i.e., cytokines). As a positive control
to validate the utility of cytokine measures as indicators of pulmonary inflamma-
tion, a nose-only inhalation pilot was conducted with 25 mg/m3 amorphous silica
(0, 1, 2, 5 or 10 exposures). Exposure of SD rats to ≥ 0.15 ppm isoeugenol resulted
in adverse histologic changes indicative of dose dependent epithelial irritation.
These were the only findings noted following isoeugenol exposure up to 14.9 ppm.
There were no test substance-related microscopic effects in the lower respiratory
tract tissues (lungs, trachea or larynx), liver, or kidneys. There were no toxicologi-
cally significant effects on BALF or serum cytokine levels. Therefore, neither a no-
observed-adverse-effect level (NOAEC), nor a no observed effect level (NOEC)
could be determined for this study regarding upper airway irritation. For the lower
airway the NOEL was considered to be 14.9 ppm.
1544 Toxicological Evaluation of 4, 4, 5, 5, 6, 6, 7, 7, 8, 8, 8-
Undecafluoro Octanoic Acid (5: 3 Acid).
S. MacKenzie1,  T. L. Serex1,  C. Carpenter1,  D. L. Nabb1,  R. Hoke1,
S. A. Gannon1,  D. Hoban1,  M. Donner1 and R. C. Buck2. 1DuPont Haskell
Global Centers for Health and Environmental Sciences, Newark, DE; 2E.I. du Pont de
Nemours & Company, Inc., Chemicals and Fluoroproducts, Wilmington, DE.
Studies were conducted to evaluate mammalian and aquatic toxicity of
4,4,5,5,6,6,7,7,8,8,8-undecafluoro octanoic acid (5:3 acid) (CAS# 914637-49-3).
5:3 acid is a metabolite of 6:2 fluorotelomer alcohol (6:2 FTOH). 6:2 FTOH is a
raw material for fluorotelomer-based products. Rat oral and dermal LD50 values
were 2950 mg/kg and >5000 mg/kg, respectively. 5:3 acid produced no dermal irri-
tation but irreversible eye irritation in rabbits, while a weak dermal sensitization re-
sponse was observed in mice (LLNA), with an EC3 of 23%. A bacterial reverse mu-
tagenicity assay and an in vivo rat micronucleus assay were negative. A 2-week rat
gavage study identified red blood cells (anemia), liver (hypertrophy, focal necrosis,
and increased beta-oxidation), kidney (tubular vacuolation), stomach (ulceration),
and thyroid (follicular hyperplasia; of questionable relevance to humans) as target
organs. Rats dosed at 600/900 mg/kg/day were euthanized in extremis. The
NOAEL was <30 and 30 mg/kg bw/day in males and females, respectively. In vitro
metabolism was evaluated in male and female rat hepatocytes and predicted half-
life in males and females of 430 and 2573 min., respectively, and identified several
metabolites. Preliminary evaluations (single dose and repeat dose exposures)
demonstrated that 5:3 acid exhibits biphasic pharmacokinetics. Studies demon-
strated low to moderate toxicity in aquatic organisms with the following results: 72-
hour EbC50 in Pseudokirchneriella subcapitata was 22.5 mg/ml; 90-day NOEC in
rainbow trout was 9.14 mg/L; 48-hour EC50 in Daphnia magna was >103 mg/L;
21-day NOEC in Daphnia magna was 1.25 mg/L. The 90-day bioconcentration
factor (BCF) measured in rainbow trout was 2.25-5.85, which supports a lack of
predicted bioaccumulation in fish. 5:3 Acid is not expected to be harmful to human
health or the environment at environmentally relevant concentrations.
1545 A 28-Day Toxicity Study of PSOA by Oral Gavage in Rats
Followed by a 14-Day Recovery Period.
T. O’Brien1,  N. Pechacek1,  W. Aulmann2 and K. Laidlaw3. 1Ecolab, St. Paul,
MN; 2Ecolab, Düsseldorf, Germany; 3Charles River, Edinburgh, United Kingdom.
The objective of this study was to determine the potential repeat dose toxicity and
reversibility of any findings over a 14 day recovery period for a peroxy sulfonated
fatty acid (PSOA). The study design followed OECD Guideline 407. Sprague-
Dawley (Crl:CD(SD)) rats were given PSOA once daily via gavage for 28 days at
doses of 0, 5, 15 and 50 mg/kg/day. The highest PSOA concentration used was
0.5%. On completion of the dosing period, designated recovery animals were re-
tained for a 14 day recovery period. The following parameters and end points were
evaluated in this study: clinical signs, body weights, body weight changes, food
consumption, ophthalmology, functional observations, clinical pathology parame-
ters, gross necropsy findings, organ weights, and histopathology. No early deaths
were observed in the dose groups. At the end of the treatment period, gross and mi-
croscopic findings observed were of the nature and incidence commonly seen in
rats of this age and strain for studies of this type, and/or were of similar incidence in
control and treated animals. Differences in the incidence of dark foci in the lungs,
observed in male rats sacrificed on Day 29, were shown to correlate with alveolar
hemorrhage which showed no biologically significant difference in incidence be-
tween treated animals and controls. The increased incidence of minimal hemor-
rhage in the thymus of treated animals which were sacrificed after the recovery pe-
riod on Day 43 is considered incidental, as this is a common background lesion.
Overall, no test article-related findings were observed for this study. Also no im-
pairment of the mucous membranes of the gastrointestinal tract was observed up to
the highest concentration of 0.5 %, which can be regarded as a No-Observed-
Effect-Concentration (NOEC) in terms of local toxicity after 28 days repeated ex-
posure. In conclusion, administration of PSOA by once daily oral gavage was well
tolerated in rats at levels of 5, 15 and 50 mg/kg/day. Based on these results, the No-
Observed-Effect Level (NOEL) was considered to be 50 mg/kg/day.
1546 Smokeless Tobacco (Gutkha)-Induced Toxicological Effects
in a Mouse Model: A Nicotine Twist.
D. Willis1,  M. A. Popovich1,  F. Gany2,  C. Hoffman1,  J. L. Blum1 and
J. T. Zelikoff1. 1Environmental Medicine, New York University, Tuxedo Park, NY;
2Memorial Sloan Kettering Cancer Center, New York, NY.
The popularity of smokeless tobacco (ST), usually placed within the mouth to be
chewed, sucked, or swallowed, is growing rapidly and its prevalence of use is rising
globally, due (in part) to greater convenience and stricter smoking laws. Gutkha, an
addictive form of ST that contains areca nut, catechu, cardamom, lime, flavored
chewing tobacco, and natural and artificial flavoring materials, is particularly com-
mon amongst Southeast Asian communities throughout the world, including the
US. This study seeks to determine the generalized toxic effects of Gutkha and to de-
termine the role of nicotine in producing Gutkha-associated toxicity. Ten-week-old
B6C3F1 male mice were divided randomly into three groups and treated for 3-wk
(5 d/wk) via the oral mucosa with equal volumes of water (control), a water-soluble
nicotine solution, containing 0.24 mg of nicotine, or a water-soluble, 21 mg
lyophilized Guthka solution. Serum cotinine, used as the exposure metric, was
measured weekly in all three groups and was similar in both the Gutkha- and nico-
tine-treated mice (36 vs. 48 ng/mL, respectively). At sacrifice, liver, heart, spleen,
tongue, kidneys, thymus, and testes were collected, weighed, and evaluated histo-
logically; serum testosterone (T) and hepatic CYP 2A5 (equivalent to human
CYP2A6 in humans and the major nicotine and cotinine oxidase in mouse liver)
was also measured. Heart weight (relative to body weight) was significantly de-
creased following either nicotine or gutkha exposure, while normalized liver/body
weight and serum T levels were significantly decreased in the Gutkha-treated group
only. These findings suggest that repeated Guhtka use adversely impacts body
weight, organ weight, and circulating T levels and that Gutkha toxicity may be
driven by toxic components other than nicotine. As the use of Guthka rapidly in-
creases worldwide, future studies are needed to further delineate its toxicological
implications. MSK Cancer Center and NIEHS Center Grant ES000260.
1547 Safety Assessment of Dicamba Monooxygenase from the
Biotechnology-Derived Soybean MON 87708.
M. Koch,  L. Burzio,  J. Finnessy,  T. Kaempfe,  H. Kang,  A. Silvanovich,
C. Wang and E. Bell. Monsanto Company, St. Louis, MO.
Monsanto has developed a soybean, MON 87708, which is tolerant to dicamba
herbicide. It contains a gene, dmo, that expresses dicamba monooxygenase (MON
87708 DMO). A safety evaluation of the MON 87708 DMO protein was con-
ducted, it examined: 1) the source of the gene; 2) its function and a history of safe
use for structurally similar proteins; 3) its homology to known allergens, toxins, or
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other proteins known to have adverse effects in mammals; 4) its stability to heat
treatment; 5) its digestibility in simulated gastrointestinal fluid; and 6) its potential
toxicity in vivo. The dmo gene was obtained from a strain of Stenotrophomonas mal-
tophilia; a bacterium that is found in a variety of foods (i.e., “ready to eat” salads,
vegetables, frozen fish, milk, and poultry), is widespread in the home environment,
and has not been reported to be allergenic. Accordingly, the gene was considered to
come from a safe source. Structurally, MON 87708 DMO is classified as a Rieske-
type non-heme iron oxygenase (RO), as such it shares structural and functional
similarities with related proteins in plants - including crops like corn, rice, and soy-
bean. Thus, there is a history of safe use of RO proteins that are structural ho-
mologs of MON 87708 DMO. Similarly, protein homology searches conducted
with MON 87708 DMO indicate no biologically relevant sequence similarities to
allergens (including 8 amino acid epitopes), toxins, or other proteins with adverse
biological activities. When subjected to temperatures approximating soybean pro-
cessing, MON 87708 DMO demonstrates a loss of enzymatic activity and a change
in structural stability. The protein also rapidly digests in simulated GI fluids. As
well, field trial data indicates low MON 87708 DMO expression levels in planta.
Taken together, dietary exposure to intact/active MON 87708 DMO is anticipated
to be negligible. MON 87708 DMO was also administered to mice in acute and
28-day toxicity studies, and the protein was not associated with signs of toxicity.
The weight of evidence demonstrates that MON 87708 DMO is safe for food and
feed.
1548 A 14-Day IV Infusion Exploratory Toxicity Study of
Hydroxylamine in Rats.
J. Zhou,  R. Giovanelli,  W. J. Reagan and M. D. Aleo. Drug Safety R&D, Pfizer
Worldwide Research and Development, Groton, CT.
Hydroxylamine (HA) is an important industrial reducing agent with little thera-
peutic value. However, it may be formed as a by-product when drugs containing
hydroxamic acid functional groups are used, and thus exhibit hemotoxicities. As
many of these compounds are developed as intravenously (IV) administered (infu-
sion) drugs, understanding the dose-toxicity relationship of HA by IV infusion be-
comes important in risk mitigation and management. In this study, we investigated
if, at the same daily doses (12, 24 or 36 mg/kg/day), either by continuous infusion
(CI) or by twice daily 1-hour intermittent infusions (II), HA produced the same
level of toxicity. As systemic toxicities of HA are well-known, the focus of this study
was on toleration and hematologic effects. Clinical signs, body weight and quanti-
tative food consumption were assessed. Blood samples were taken at various times
to evaluate methemoglobin (metHb) and total hemoglobin (Hb) levels.
Hematology parameters and morphology were evaluated in blood samples taken on
Days 3, 9 and 15. Dose-dependent increases in the metHb level were observed in
both CI- and II-treated animals, however, a higher level of metHb was generally ob-
served in II animals at the same daily doses. The metHb level increased within the
first 4-6 days of dosing and then declined in the remaining course of study.
Clinically, administration of HA up to 36 mg/kg/day (CI or II) was well-tolerated,
with only pale appearance observed in the high-dose animals (CI and II) during the
second week. No significant effect of HA on the body weight was observed al-
though food consumption at 36 mg/kg (CI and II) was significantly reduced.
Multiple hematology parameters demonstrated HA induced a dose- and time-de-
pendent hemolytic anemia with the formation of Heinz bodies in both CI and II
animals. The reduction of total Hb worsened with daily dosing and appeared to
reach a plateau after 6-9 days of dosing. These data provided useful information on
the choice of infusion regimen and risk management of some hydroxamic acids by
infusion.
1549 Increased Hypothalamic Dopaminergic Neuron Tyrosine
Hydroxylase Expression in Lean Wistar Rats.
S. M. Plummer1,  M. Beltran2,  M. Millar2,  R. Wiegand3 and J. Wright4.
1MicroMatrices Associates Ltd., Dundee, United Kingdom; 2MRC Centre for
Reproductive Health, Edinburgh, United Kingdom; 3MRC Centre for Inflammation
Research, Edinburgh, United Kingdom; 4Syngenta Ltd., Bracknell, United Kingdom.
Calorific restriction in Wistar rats has been reported to show a decrease in mam-
mary and pituitary tumours and an increase in uterine tumours (1, 2) associated
with delayed hypothalamic dopaminergic neuronal senescence (3). This study was
designed to assess the effects of reduced body weight gain on hypothalamic
dopaminergic neurons using FFPE tissue obtained from 100 female Wistar rats (50
controls; 50 with >30% body weight gain reduction) from a 2 year bioassay. A com-
bination of immunostaining (IHC) and RNAscopeTM in situ hybridisation (ISH)
was used to examine expression of tyrosine hydroxylase (TH), a rate limiting en-
zyme for dopamine synthesis. 
TH protein expression was detected in both the paraventricular(PVH)/periventric-
ular (PeVH) nuclei and the median eminence (ME). TH RNA expression was also
detected in these regions, but there was a disparity in the strength and location of
TH RNAscopeTM staining compared to TH protein staining. TH protein staining
was strongest in the ME, whereas TH RNA staining was strongest in the
PVH/PeVH nuclei. To examine the relationship between TH protein vs RNA
staining in more detail dual fluorescence IHC/ISH was performed. This analysis
showed coincident TH protein and RNA staining in some neuronal cell bodies and
axons; however, some neurons displayed TH protein staining in the absence of TH
RNA staining and vice versa. Qualitative assessment indicated that rats with re-
duced bodyweight gain showed an increase in the number and intensity of TH
RNA and TH protein positive neurones in the PVH/PeVH nuclei and the ME, re-
spectively. These results indicate a disparity between the expression of TH RNA
and TH protein in the rat hypothalamus, and suggest that chronic reduction in
bodyweight gain may alter regulation of TH expression at the RNA and protein
levels in hypothalamic nuclei. 
(1) Roe et al 1995; 
(2) Keenan et al 1995;
(3) Harlemann et al 2012
1550 Proposition 65 and Cancer Incidence in California.
L. Haighton,  H. Fikree,  A. Pais,  S. Prasad and J. W. Card. Intertek Cantox,
Mississauga, ON, Canada.
Proposition 65 has been in effect in California (CA) for 25 years. It requires busi-
nesses to notify consumers if products they buy contain chemicals that are known
to the State of CA to cause cancer and birth defects or other reproductive harm.
This study determined the tumor types reported to be associated with the 71 car-
cinogens that were first added to the Proposition 65 list in 1987 and evaluated the
incidence rates for these tumor types in males (M) and females (F) in CA through
to 2009. Corresponding incidence rates in Washington State (WA; geographically
similar) and New York State (NY; as a diverse East coast regional control) were eval-
uated as comparators. Of the 71 chemicals added as carcinogens to the Proposition
65 list in 1987, >10 have each been reported to be associated with urinary bladder
and breast tumors and >20 each with liver and lung tumors. Between 1988 and
2009, there was a modestly decreased trend in bladder cancer incidence in CA [lin-
ear slope = 0.19 (M) and 0.06 (F); R2 = 0.75 (M) and 0.77 (F)]. Less robust de-
creases were observed in WA [slope = 0.05 (M and F); R2 = 0.01 (M) and 0.18 (F)],
while a modestly increased trend was observed in NY. Over the same time period,
there was a modestly increased trend in breast cancer incidence (slope = 0.15 to
0.41; R2 = 0.02 to 0.18) and an approximate doubling of liver cancer incidence in
both sexes in all 3 states (slope = 0.07 to 0.41; R2 = 0.80 to 0.99). A substantial and
comparable decrease in lung cancer incidence was observed in males in all 3 states
(slope = 1.18 to 1.80; R2 = 0.90 to 0.99). For females, lung cancer incidence de-
creased in CA (slope = 0.36; R2 = 0.79) but increased in WA and NY. The results of
this preliminary assessment indicate that since Proposition 65 came into effect 25
years ago, liver cancer incidence in CA has approximately doubled but consistent
and robust decreases in incidence rates have been observed for bladder cancer in
both sexes and for lung cancer in females. The contribution of Proposition 65 to
these observed changes is unclear and warrants further investigation.
1551 Alternatives to Bisphenol A in Thermal Paper: Analysis of
Substitution Options and Trade-Offs.
C. Baier-Anderson1,  J. Rhoades2,  M. Kawa2 and J. Tunkel2. 1US EPA,
Washington DC; 2SRC, Inc, Syracuse, NY.
The U.S. Environmental Protection Agency (US EPA) Design for Environment
(DfE) Program undertook a chemical alternatives assessment for the use of bisphe-
nol A (BPA) in thermal paper, including cash register receipts, as part of the Action
Plan for BPA in March 2010. The purpose of the alternatives assessment is to iden-
tify and compare alternative chemicals to inform decision-making. The alternatives
assessment was conducted via a multi-stakeholder partnership that identified 19
functional alternatives to BPA. The hazard assessment for BPA and the alternatives
used the DfE hazard evaluation criteria to assign hazard designations for human
health toxicity, ecological toxicity and environmental fate endpoints. Some alterna-
tives were well characterized for all endpoints. Other alternatives were poorly char-
acterized, wherein analog data, predictive models, structural alerts and expert judg-
ment were used to make hazard designations for data gaps. Trends for human
health, ecological toxicity and fate characteristics were indicated in a number of the
alternatives due to particular molecular size ranges and/or molecular structures. In
general, all alternatives have important trade-offs although if used with appropriate
control measures, some of the alternatives could provide incremental benefits.
Effective hazard assessment approaches, coupled with decision-making protocols
that are practical tools for businesses to use in materials selections, will lead to more
sustainable product development when human health or ecological toxicity con-
cerns exist. The resulting hazard profiles should be of value to manufacturers mak-
ing substitution decisions and facilitate reductions in environmental releases and
subsequent exposures.
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1552 Body-Residue Based Environmental Safety Assessment of
Personal Care Product Ingredients: A Case Study with
Benzophenone-3.
F. Liu1,  V. Tu1 and N. Y. Wang2. 1Revlon Research Center, Edison, NJ;
2Environmental Assessment Scientist Serving in a Personal Capacity, Cincinnati, OH.
Personal care product (PCP) ingredients are released into aquatic ecosystem via
wastewater discharge and potentially affect environmental health. The environmen-
tal safety assessment (ESA) is an important component of overall ingredient safety
evaluation. We presented here an exploratory effort in applying the body-residue
based approach in ESA of PCP ingredients. The traditional water-concentration
based ESA has been used to evaluate the environmental impact of PCP ingredients.
Compared with the water-based concentration, body residue concentration repre-
sents an internal dose, takes chemical disposition into account and provides an in-
tegrated assessment of the exposure an organism receives over space and time. With
advancement of computational toxicology, critical body residues (CBRs) corre-
sponding to toxicity endpoints and chemical bioaccumulation levels can be mod-
eled as an alternative to animal testing. Organic UV filters are widely used in PCPs
to offer sunscreen benefit. Environmental occurrence of various organic UV filters
has been documented in both abiotic and biotic media. As a lipophilic UV filter,
benzophenone-3 bioaccumulates in fish and concerns have been raised due to its in
vitro antiestrogenic and antiandrogenic activities. The CBR and body residue level
of benzophenone-3 were predicted using QSAR models. Information on environ-
mental occurrence of benzophenone-3 was compiled and analyzed. The modeled
tissue levels were comparable with the measured tissue levels in the environment.
Our ESA analysis indicated that the CBR was significantly higher than the tissue
level of benzophenone-3 in various fish species habituated in different aquatic
ecosystems. The result was in good agreement with water-concentration based ap-
proach obtained by comparing the measured water concentration with the pre-
dicted no effect concentration (PNEC). As a result of this work, an alternative ap-
proach based on available in silico methods was developed for conducting screening
level ESA of PCP ingredients.
1553 Evaluation of the Potential for Establishing a Threshold for
Chemical Ocular Irritation Using a Model of Repeated
Topical Ocular Administration in Albino Rabbits.
K. G. Eckles,  J. Amin,  K. Krenzer and M. E. Richardson. Nonclinical Safety,
Bausch & Lomb, Rochester, NY.
Rationale: The qualification of low levels of impurities in topical ophthalmic prod-
ucts is often hampered by a lack of ocular safety data at levels relevant to the prod-
ucts; establishing a threshold would be valuable in safety assessments. Therefore,
the goal of this study was to explore the possibility of a threshold level for ocular ir-
ritation from repeated topical exposure to agents in solution.
Methods: Ten compounds from 8 chemical families (acids, acrylates, alcohols, alde-
hydes, alkalis, amines, anionic surfactants, and cationic surfactants), were identified
which resulted in severe ocular irritation or corrosive effects when administered as a
single drop on the rabbit eye at high concentrations. Each chemical was prepared in
an appropriate vehicle (saline or sesame seed oil) to give concentrations of 20 and
100 ppm. One eye of albino rabbits (5/dose group) was administered 50 μL of the
test article 4 or 6 times daily (oil- or saline-vehicle, respectively) for 3 days. The
contralateral eye served as a vehicle control. Draize scoring was performed before
the first daily dose and after the final daily dose and biomicroscopy was performed
pre-dose and on Days 2 and 3.
Results: None of the 10 chemicals resulted in notable ocular irritation at either 20
or 100 ppm after repeated ocular administration.
Conclusion: Despite being severe irritants or corrosives when dosed as a single drop
at high concentrations, the favorable ocular irritation results observed with up to
100 ppm concentrations of severe irritants or corrosives suggest that it may be pos-
sible to establish a threshold for ocular irritation.
1554 Human Health Assessment of Scented Candle Emissions.
T. Petry2,  D. Vitale1,  L. Cruse3,  F. J. Joachim4,  R. Mascarenhas5,  S. Schneider6,
B. Smith7 and M. Singal1. 1Research Institute for Fragrance Materials, Woodcliff
Lake, NJ; 2ToxMinds BVBA, Brussels, Belgium; 3Procter & Gamble, Cincinnati, OH;
4SC Johnson & Son, Racine, WI; 5Reckitt-Benckiser, Hull, United Kingdom;
6Firmenich SA, Princeton, NJ; 7Firmenich SA, Geneva, Switzerland.
Airborne compounds in the indoor environment arise from a wide variety of
sources such as environmental tobacco smoke, heating & cooking, dusts, emissions
from furniture and construction materials as well as outdoor sources. One product
category which has received recent attention as a source of indoor airborne sub-
stances is scented candles. The potential impact of airborne candle emissions on the
quality of the indoor air is highly dependent on the type and concentrations of
chemical substances released. To better understand the potential of scented candles
to contribute to the indoor load of airborne substances, a comprehensive candle
emission testing program initiated by the consumer products and fragrance indus-
try was undertaken to investigate the emissions of volatile and semi-volatile organic
compounds (VOC; SVOC) and particulate matter (PM). Associated human expo-
sures scenarios were derived and computer models used to estimate exposure of
these materials to consumers. Measured chamber concentrations of VOC, SVOC
and PM were used to predict their respective, cumulative indoor air concentrations
in a standard EU-based dwelling using 2 models - the well-known and widely ac-
cepted ConsExpo 1-Box inhalation model and the recently developed, refined
RIFM 2-Box indoor air dispersion model. The output from both models has been
used to estimate realistic yet conservative consumer exposure to scented candle
emissions measured under this program. The potential consumer health risks asso-
ciated with the exposure to these materials was compared to existing air quality
guideline values and established safe exposure levels. This investigation concluded
that even under the conservative assumptions, potential human exposures are a
minimum of one order of magnitude below established regulatory indoor air guide-
line values and/or published safe exposure levels.
1555 Cobalt Whole Blood Concentrations in Healthy Adult
Volunteers following Two Weeks of Ingesting a Cobalt
Supplement.
B. L. Finley2,  B. E. Tvermoes1,  K. M. Unice3,  J. M. Otani2,  D. J. Paustenbach2
and D. A. Galbraith2. 1ChemRisk, Boulder, CO; 2ChemRisk, San Francisco, CA;
3ChemRisk, Pittsburgh, PA.
Recently, there has been an increase in the marketing and sales of dietary supple-
ments, energy drinks, muscle builders and other consumer products that may con-
tain relatively high concentrations of essential elements. Cobalt-containing supple-
ments are readily available in the U.S. and have been marketed to consumers as
energy enhancers. However, little information is available regarding cobalt (Co)
body burden and steady-state blood concentrations following the intake of Co di-
etary supplements. We assessed Co whole blood concentrations in four healthy
adult male volunteers who ingested a commercially available Co supplement (0.4
mg Co/day) for 15 or 16 days. Pre-supplementation blood Co concentrations were
less than the reporting limit of 0.5 μg/L, consistent with background concentra-
tions reported to range between 0.2 to 0.4 μg/L. The mean whole blood Co con-
centration in the volunteers after 15 or 16 days of dosing was 3.6 μg Co/L and
ranged from 1.8 to 5.1 μg Co/L. The mean observed concentration in the study
group was approximately 9 to 18 times greater than background concentrations.
Further studies of Co whole blood concentrations following supplementation over
longer time periods with additional monitoring of physiological parameters may
provide useful information for evaluating the health of persons who take various
doses of Co.
1556 Multiparameter In Vitro Toxicity Testing of Crizotinib,
Sunitinib, Erlotinib, and Nilotinib in Human
Cardiomyocytes.
K. Doherty1,  R. L. Wappel1,  D. R. Talbert1,  P. B. Trusk1,  D. M. Moran1,
J. W. Kramer2,  A. M. Brown2,  S. A. Shell1 and S. Bacus1. 1Quintiles, Westmont,
IL; 2ChanTest, Cleveland, OH.
Targeted therapy has greatly improved the treatment and prognosis of multiple
types of cancer. However, unexpected cardiotoxicity has arisen in a subset of pa-
tients for some of the tyrosine kinase inhibitors (TKi). For these TKi, the car-
diotoxicity was not wholly predicted by pre-clinical testing, which centers around
the inhibition of the human Ether-à-go-go-Related Gene (hERG) channel.
Therefore, we sought to determine whether a multi-parameter panel of tests that as-
sesses a drug’s effect on cellular, molecular, and electrophysiological endpoints
would more accurately predict cardiotoxicity. To do so, we examined how 4 FDA-
approved drugs impacted cell viability, apoptosis, reactive oxygen species (ROS)
generation, metabolic status, impedance, and ion channel function in human car-
diomyocytes. The 3 drugs with known associated cardiac adverse events (crizotinib,
sunitinib, and nilotinib) all proved to be cardiotoxic in our series of in vitro tests
while erlotinib, a cardiac-safe drug, did not show any indications of toxicity.
Crizotinib, an ALK/ MET inhibitor, was the most cardiotoxic by our panel, leading
to increased ROS production, caspase activation, cholesterol accumulation, and a
significant disruption in cardiac cell beat rate and blockage of ion channels. The
multi-targeted TKi sunitinib also demonstrated severe cardiotoxicity in our tests,
showing decreased cardiomyocyte viability, inhibition of AMPK, increased lipid
droplet accumulation, disrupted beat pattern, and hERG block. Nilotinib, a second
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generation Bcr-Abl inhibitor, led to increased ROS generation, caspase activation,
hERG block, and an arrhythmic beat pattern. Thus, each drug showed a unique
toxicity profile, demonstrating that a multi-parameter approach allows for a more
complete assessment of the potential for drug-induced cardiotoxicity and may allow
for earlier detection in the drug development process.
1557 Safety Assessment of Chemicals in Toys.
M. Whitehead,  J. Doran,  G. Goodfellow and J. Daniels. Intrinsik Health Sciences
Inc., Mississauga, ON, Canada.
Numerous countries have enacted laws and regulations to protect children from the
potential health hazards associated with exposures to chemicals used in the manu-
facture of toys, including the United States, Canada and the member states of the
European Union. Assessing the risk posed to children from exposure to chemicals
in toys poses a special challenge, due to the particular vulnerability of this popula-
tion to both adverse effects and chemical exposure. Examples of chemical categories
used in toys that may be of concern include metals, boron-containing substances,
pigments and colorants, preservatives, and allergenic fragrances. The aim of this
study was to evaluate the risk of substances flagged as potential chemical hazards
when included as ingredients in child-intended products in various jurisdictions.
Results of toxicological studies indicate that metal-containing pigments, certain azo
dyes, and boric acid and its salts are associated with toxicity concerns such as repro-
ductive, developmental, mutagenic, and carcinogenic effects. Product formulation
data collected in a proprietary database over a two-year period was analyzed in order
to determine the levels and frequency of use of these substances in various cate-
gories of toys. Exposure considerations and scenarios designed to specifically ad-
dress the enhanced risk to children from chemical exposures as a result of the inten-
tional use and reasonably anticipated misuse of different categories of toys were
developed. Using the results of the toxicological studies and exposure scenarios de-
veloped by our group, we analyzed the margin of safety for the use of these chemi-
cals of concern with respect to toxicity effects in toys. The results of our studies sug-
gest that restricted chemicals are still being used to formulate toys at levels that
indicate potential concern for this sensitive population.
1558 Health-Based Framework for Evaluating the Safety of
Hydraulic Fracturing Products.
D. Wikoff1,  L. Fitzgerald1,  L. C. Haws1 and M. Harris2. 1ToxStrategies, Austin,
TX; 2ToxStrategies, Houston, TX.
Hydraulic fracturing has made it possible to extract natural gas from dense shale
rock formations and has become the fastest-growing source of gas in the U.S.
Because the process involves drilling through groundwater formations, there has
been concern that drinking water aquifers could become contaminated – a concern
compounded by a lack of information regarding the composition and safety of the
products used. In an effort to address these concerns, we developed a quantitative
framework to characterize potential safety of hydraulic fracturing products. The
framework consists of four evaluation criteria that are applied to each of the prod-
uct components: composition and use, toxicity, exposure, and risk of release. Each
of the criteria has specific requirements associated with scores ranging from 1-5
(with 1 being the best and 5 being the worst) that are based on USEPA guidelines
and standard risk assessment practices. A final composite product score is calculated
based on scores for each of the criteria for each of the components and this score is
used to place the product into a category of use relating to its safety (not recom-
mended for use, use with caution/specialized conditions, or acceptable for desig-
nated use). Importantly, if any component of the hydraulic fracturing product does
not achieve a score below the STOP point for any of the four criteria (indicative a
minimum level of knowledge or safety), the product is automatically placed into
the not recommended for use category. This framework allows health experts to tai-
lor the evaluation to any type of product used in the fracturing process and can be
consistently conducted by independent parties. Because this process focuses on
human health risk and environmental exposures, it is different than those currently
available in the natural gas industry and is more in line with standard risk assess-
ment practices. Most importantly, this framework allows for transparency in the
evaluation process and provides a quantitative method upon which experts can
make decisions.
1559 Novel Methodology in Hazard Assessment: Chemical
Clustering for Read Across—The Phthalate Alternatives Case
Study.
M. Kawa1,  J. Rhoades1,  C. Baier-Anderson2,  T. Webb1,  K. Mayo-Bean3 and
J. Tunkel1. 1SRC, Inc., East Syracuse, NY; 2US EPA, DFE, Washington DC; 3US
EPA, OPPT, Washington DC.
Phthalates are a class of compounds produced in high volume in the U.S. and are
found in many products, primarily as plasticizers. The U.S. EPA published an ini-
tial Action Plan for eight phthalates in 2010 due to concern about the toxicity of
phthalates and the evidence of pervasive human and environmental exposure. As
indicated in the Action Plan, a Design for the Environment (DfE) alternatives as-
sessment (AA) will be performed for these chemicals. The DfE Program publishes
AAs to help industries identify safer chemicals and provide a comparison of poten-
tial human health and environmental impacts of chemical alternatives. DfE hazard
criteria are used to assign hazard designations for human health toxicity, ecological
toxicity and environmental fate endpoints. Over 70 substances were identified as
potential alternatives to the eight action plan phthalates. Some alternatives are well
characterized for all endpoints, while others are data poor. In the absence of experi-
mental data, DfE assessment methodology designates hazards based on a read
across approach to structurally similar compounds. This poster describes a novel
technique for green chemistry and hazard screening that uses the EPA’s Office of
Pollution Prevention and Toxics ChemACE program to cluster the alternatives
based on common structures, functional groups, and molecular architectures. The
ChemACE program automates chemical clustering based on structural similarities
and generates reliable and organized results. Using this methodology, read across
(analog) data from data-rich chemicals was used to assist in assigning and justifying
hazard designations for data poor chemicals within a cluster. This allows for the de-
termination of hazard designations for as many endpoints as possible including
human health endpoints that often lack experimental data and methods for estima-
tion. The resulting AAs should be of value to manufacturers making substitution
decisions and facilitate reductions in potential human health impacts.
1560 Transdermal Toxicity of the Phorbol Ester Isolated from
Biodiesel Feedstock, Jatropha Curcas.
M. Nakao,  S. Kinoshita and Y. Ishihara. Kurume University, Kurume, Japan.
[Purpose] Jatropha curcas attracts rising attention as a biodiesel feedstock in the
world. However, Jatropha contains various toxic components, generating concerns
about its health effects. One of toxic components is potential tumor promoter,
phorbol esters. Toxicity of Jatropha phorbol esters has not been fully described. In
this study, transdermal toxicity of main component of Jatropha phorbol esters was
assessed in mice.
[Experimental procedures] One of the Jatropha phorbol esters, 12-deoxy-16-hy-
droxyphorbol-4’-[12’,14’-butadienyl]-6’-[16’,18’,20’-nonatrienyl]-bicyclo [3.1.0]
hexane-(13-O)-2’-[carboxylate]-(16-O)-3’-[8’-butenoic-10’] ate (DHPB) (1 – 10
μg), was applied onto skin of mice. As a positive control, 12-O-
Tetradecanoylphorbol 13-acetate (TPA) (1 – 10 μg) a known tumor promoter was
applied. Transformation activity of test compound was assayed using Bhas42 cells.
Autopsy was conducted on the dead mice to observe the lesions. All survived mouse
were sacrificed at 8 weeks from the beginning of the study and hematological tests
and splenic lymphocyte measurement using flow cytometer were carried out.
[Results] 2.5 μg of DHPB led to weight loss and over 5 μg of DHPB caused death
during 3 weeks observation. There were no such symptoms in the mice treated with
the same dose of TPA. Gastrointestinal bleeding and splenic atrophy was observed
in the dead mice. The NOAEL of DHPB was considered to be 2 to 2.5 μg. No pa-
pilloma on the skin was observed in DHPB group in contrast to TPA which devel-
oped papilloma when the dose exceeded 1 μg. There was no significant difference
in splenic lymphocyte composition among DHPB, TPA, and control groups.
Hematological analyses showed that the number of red blood cells, platelet, and
lymphocyte was markedly decreased in DHPB treated mice at 8 weeks.
[Conclusion] DHPB, on the contrary to TPA, showed no tumor promotion in this
experiment but showed acute toxicity which was not seen in the mice treated with
TPA. These results suggest that DHPB has different characteristics in transdermal
toxicity in comparison with those of TPA.
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1561 Identifying No Observed Effect Levels (NOEL) and No
Observed Adverse Effect Levels (NOAEL) through
Metabolomics.
G. Montoya1,  V. Strauss1,  H. G. Kamp1,  W. Mellert1,  T. Walk2,  R. Looser2,
M. Herold2,  G. Krennrich2,  E. Peter2 and B. van Ravenzwaay1. 1Experimental
Toxicology and Ecology, BASF SE, Ludwigshafen am Rhein, Germany; 2metanomics,
Berlin, Germany.
A key quantitative element in toxicity studies is the identification of the NO(A)EL
– no observed (adverse) effect level. With the introduction of omics into toxicology,
questions have been raised concerning the sensitivity of these methods. BASF’s
Experimental Toxicology and Ecology unit and metanomics developed the
MetaMap® Tox database with more than 500 reference compounds obtained from
rat studies (OECD 407 design). Metabolome analysis in plasma was performed
after 7, 14 and 28 days and relative levels of endogenous metabolites in treated rats
versus controls were analyzed. We have obtained metabolome data at toxicological
NO(A)EL doses. 
Recent advances in metabolic profiling technologies together with expert judgment
offer the possibility of identifying whether differences from control values are treat-
ment related and to discriminate between those that are adverse and those that are
not. To obtain a measure of sensitivity of metabolomics vs. classical toxicology, we
have used these data to analyze metabolomics changes at toxicological NO(A)EL
doses. We have done this considering the number of statistically significant metabo-
lite changes (p<0.05), the false-positive rate and the correlation with defined pat-
terns for diverse modes of action (approximately 100 defined in MetaMap®Tox).
Results show that in most cases where there are no toxicological effects (NOEL)
there are also only few metabolomics changes (at/below the level of the false posi-
tive rate and without a match to the predefined MoA patterns). In some cases in
which the study demonstrated a NOAEL (only effect noted being liver weight in-
crease) metabolomics changes are often present and identify the liver as target
organ. Following this analysis, it would seem that metabolomics is generally not
more sensitive than classical toxicology, with respect to the identification of a
NO(A)EL.
1562 Metabolic Profile of Rats in Repeated Dose Toxicological
Studies after Oral and Inhalative Exposure.
E. Fabian1,  N. Bordag2,  M. Herold2,  H. G. Kamp1,  G. Krennrich2,  R. Looser2,
L. Ma-Hock1,  W. Mellert1,  E. Peter2,  A. Prokoudine2,  M. Spitzer2,  V. Strauss1,
T. Walk2,  J. Wiemer2 and B. van Ravenzwaay1. 1Experimental Toxicology and
Ecology, BASF SE, Ludwigshafen am Rhein, Germany; 2Metanomics, Berlin,
Germany.
BASF and metanomics, in a joint effort, developed the MetaMap®-Tox application
containing metabolic profiles attained from administration of over 500 toxicants.
The toxicants were administered to five Wistar rats for each sex and each of the two
dose levels for a total duration of four weeks following a standardized protocol, in
accordance with OECD 407. Metabolome analysis of plasma samples was per-
formed after one, two and four weeks. The ratios of the metabolites from treated
rats versus untreated rats (control) were transferred to MetaMap®-Tox for data as-
sessment.
In this study, metabolic profiles after oral and inhalative exposure were compared
for six selected model compounds: aniline (A), chloroform (CL), ethylbenzene
(EB), 2-methoxyethanol (ME), N,N-dimethylformamide (DMF) and tetrahydro-
furane (THF). The toxicants were dosed inhalatively for six hours/day, five days a
week and orally each day via the feed (DMF) and by gavage (A, CL, EB, ME,
THF). Statistical evaluation (pairwise comparison in MetaMap®-Tox as well as
principle component analyses) showed similar metabolic changes for DMF, EB, CL
and ME, indicating a comparable systemic toxicity after oral and inhalative expo-
sure. In contrast, metabolic profiles of A and THF showed differences between the
tested exposure routes. Metabolic profiles were sufficient for the identification of
test substance related toxicological modes of action using MetaMap®Tox. In con-
clusion, our results indicate the potential of metabolic profiling for generating fin-
gerprints of systemic toxicity following different exposure scenarios.
1563 Percellome Toxicogenomics Application to Sick Building
Syndrome-Level Inhalation Toxicity.
J. Kanno,  K. Aisaki,  K. Igarashi,  Y. Taquahashi and S. Kitajima. Division of
Cellular and Molecular Toxicology, National Institute of Health Sciences, Tokyo,
Japan.
Toxicity of low concentration formaldehyde (FA) corresponding to the level of Sick
House/Building Syndrome (SHS) is difficult to assess by the ordinary inhalation
animal studies; histopathological endpoints are negative for toxicity at such con-
centration. However, transcriptomic responses are captured at this exposure level.
Here we applied our Percellome Toxicogenomics Project. This project has been
launched to develop a comprehensive gene network for the mechanism-based pre-
dictive toxicology. For this purpose, a normalization method designated as
“Percellome” is developed (BMC Genomics 7:64, 2006) to generate mRNA ex-
pression values in “copy numbers per one cell” from microarrays and Q-PCR. The
time- and dose-dependent alteration of gene expression induced by various expo-
sure protocols in mice (4 time points x 4 dose levels, triplicate) are studied on more
than 100 chemicals. Data are expressed in 3-D graphs (time x dose x mean copies
per cell +/- sd); 45,000 surfaces corresponding to the probe sets of the Affymetrix
Mouse Genome 430 2.0 Array. 
FA at concentrations close to the “Indicative indoor exposure value of SHS
(Ministry of Health Labour and Welfare, Japan)” of 0.08 ppm was applied to the
22hr/day x 7 day exposure protocol (0, 0.1, 0.3 and 1.0ppm, 4 time points, tripli-
cate). C57Bl/6J mice were exposed and lung, liver and hippocampus were analyzed.
As a result, strong suppression of gene expression related to neuronal activity in hip-
pocampus, i.e. the immediate early genes including Arc, Nr4a1, Fos, Junb and Egr4
were shown. This study indicated that the comprehensive transcriptomic analysis
will become useful for prediction of the effect on central nervous system of the very
low concentration of toxicants. Our finding may be considered as a first substantial
data that would explain the indefinite or unidentified complaint by this SHS-level
exposure of FA. (Supported by Health Sciences Research Grants from the Ministry
of Health, Labour and Welfare, Japan)
1564 Ten-Year Retrospective Assessment of the Food Contact
Notification Program.
A. P. Neal-Kluever,  J. Cooper,  T. Zebovitz and K. Butts. Division of Food Contact
Notifications, US FDA, College Park, MD.
The Food Contact Notification (FCN) Program is FDA’s premarket review system
for evaluating the safety of packaging and other materials that contact food.
Additionally, FCN notifiers can take advantage of a pre-notification consultation
(PNC) program designed to provide guidance in advance of FCN filing. To assist
program development and improve program transparency we performed a retro-
spective assessment of the FCN program. We analyzed the first 10 years of program
performance, which included 924 FCNs and 980 PNCs. Overall, 76% of FCNs
become effective, 23% were withdrawn, and 1% received not-accepted status.
Some trends were observed which influenced the likelihood of an FCN becoming
effective, such as whether the FCN was a resubmission, received a time extension,
proposed a new use, or proposed the use of a novel or polymeric FCS. Company
size as determined by the Small Business Association influenced whether an FCN
was likely to become effective, with larger companies exhibiting a higher effective
outcome rate. Smaller companies were more likely to withdraw FCNs, but experi-
enced very high effective outcome rates with resubmitted and extended FCNs.
There were some differences between the outcomes of notifiers utilizing and not
utilizing the PNC program. Interestingly, 78% of the PNCs in the study period
were not associated with an FCN.
1565 Development of a Regulatory Value for the Carcinogenic
Potential of Isoprene via Inhalation Exposure.
T. D. Phillips1,  R. L. Sielken2 and C. Valdez-Flores2. 1Toxicology Division, Texas
Commission on Environmental Quality, Austin, TX; 2Sielken & Associates Consulting,
Inc., Bryan, TX.
Isoprene is the 2-methyl analogue of 1,3-butadiene, a known human carcinogen.
While isoprene is synthesized and used in the manufacturing of substances such as
synthetic rubber, it is also produced naturally by plants, animals, and bacteria and is
one of the main endogenous compounds found in human breath. Following the
Texas Commission on Environmental Quality (TCEQ) Guidelines for the develop-
ment of toxicity factors, a preliminary review and characterization of the carcino-
genic potential of isoprene was conducted. Three key studies provided adequate
data for the dose-response assessment of isoprene’s carcinogenic potential. In order
to determine URFs for study endpoints assuming exposure for 24h/d, 7d/wk, for a
lifetime, the dose levels and numbers of animals at risk in the data sets were ad-
justed for differences between the exposure durations and times of response obser-
vation. The doses were adjusted to the constant lifetime environmental dose that is
equivalent to the time-dependent doses in the studies, based on the multistage the-
ory of carcinogenesis using the Armitage and Doll (1954) mathematical description
of carcinogenesis with the number of stages being m = 1, 2, or 3. Similarly, the
number of subjects at risk of developing the specified response by necropsy time in
the study was adjusted to the equivalent number of animals at risk if the time to
necropsy were equal to the nominal animal lifetime. The adjusted parameters were
used to carry out 171 model fits. The EC10 for each endpoint was identified using
the estimated multistage models, and from there a URF for each endpoint was cal-
culated. Based on the TCEQ Guidelines, only malignant endpoints considered rel-
evant to humans and showing a statistical significance were considered for the draft
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URF. The chosen draft URF was 9.1E-04 per ppm for liver carcinoma in a one
stage carcinogenic process (m=1). From the draft URF, a draft air concentration at
the 1E-05 excess cancer risk level is calculated to be 11 ppb.
1566 Evaluation of Selected Nitrosamines As Candidates for
Regulatory Determination Using a Group Approach.
J. Donohue1,  M. Simic1,  Z. Bain1,  A. Gebhart2,  S. Goldhaber2 and R. Howd2.
1Office of Water, US EPA, Washington DC; 2ToxServices, Washington DC.
In May 2011, EPA Administrator, Lisa Jackson announced the Drinking Water
Strategy, a new cost-efficient approach to protecting public health that included
broadening the traditional regulatory framework for chemicals by addressing
groups of contaminants. Common physical and/or toxicological properties are fea-
tures to be considered in determining group composition. The six nitrosamines, re-
cently monitored nationally at public water systems (PWSs) under the Second
Unregulated Contaminant Monitoring Rule (2009—2011), meet the grouping cri-
teria based on a common mutagenic mode of action plus their chemical, and meta-
bolic properties. Their toxicological data and co-occurrence at PWSs have been in-
tegrated to evaluate the practicality of considering a group of toxicologically similar
chemicals in a Regulatory Determination context. The nitrosamines evaluated in-
clude N-Nitrosodi-n-butylamine, N-Nitrosodiethylamine, N-
Nitrosodimethylamine, N-Nitrosodi-n-propylamine, N-Nitrosomethylethylamine,
and N-Nitrosopyrrolidine. [The views expressed in this abstract are those of the au-
thors and do not necessarily reflect the views or policies of the U.S. EPA.]
1567 Key Decisions in Establishing National Ambient Air Quality
Standards.
L. Fraiser1 and L. J. Bradley2. 1Environment, AECOM, Austin, TX; 2Environment,
AECOM, Chelmsford, MA.
This paper provides an evaluation of key decisions made by the US Environmental
Protection Agency (EPA) in establishing more stringent short-term National
Ambient Air Quality Standards (NAAQS) and provides an opinion on whether the
supporting science suggests that their implementation will result in additional pub-
lic health protection. Although EPA states that the NAAQS are based on evaluation
of all relevant scientific evidence, they routinely are not. Despite many epidemiol-
ogy studies that found no association between particulate matter (PM) exposure
and mortality, EPA based the recent 24-hr PM2.5 NAAQS on only two studies re-
porting associations between PM2.5 reductions and health benefits. Only one con-
trolled sulfur dioxide (SO2) study caused a significant response in the range used as
the point of departure in establishing the 1-hr SO2 NAAQS and neither clinical
nor epidemiological studies support clinically-relevant lung decrements at this level.
EPA used a consistent definition for moderate decrements in the lung function of
asthmatics in establishing 1-hr NAAQS for nitrogen dioxide (NO2) and SO2 but
used a slightly different categorization in the latest review of the 8-hour ozone
NAAQS. EPA included human exposures to NO2 by mouthpiece in establishing
the NO2 NAAQS, but excluded mouthpiece exposure studies in developing the 1-
hr SO2 NAAQS because of the potential for increased pollutant delivery and al-
tered distribution/deposition of pollutant that can occur. This evaluation of re-
cently promulgated NAAQS reveals inconsistency in the way that EPA uses health
effects studies to support its decisions, emphasizing the need to define key crite-
ria/concepts, such as “adverse” effect, “sensitive” populations and principles of
cause-effect relationships. It also highlights the need for guidelines on incorporating
negative study results into weight-of-evidence evaluations. When all relevant data
are considered, particularly in the context of other contributing factors, they do not
support that the recent ratcheting down of NAAQS will result in additional health
public protection.
1568 Development of a Proposed 24-Hour Health-Protective Air
Monitoring Comparison Value for Formaldehyde for
Comparison to 24-Hour Monitoring Data in the Barnett
Shale Area.
A. L. Curry,  J. T. Haney and D. McCant. Toxicology Division, Texas Commission
on Environmental Quality (TCEQ), Austin, TX.
The Barnett Shale is a large natural gas reserve encompassing more than 5,000
square miles and covering approximately 26 counties in North Texas. Due to pub-
lic concern that natural gas compressor stations emit high formaldehyde concentra-
tions, formaldehyde has been of increased public and regulatory interest in recent
years. It has also been detected in 24-h carbonyl samples collected by the TCEQ in
the Barnett Shale. However, use of these data for evaluating potential health effects
is typically limited to calculating long-term annual means for comparing to
chronic, health-protective air monitoring comparison values (AMCVs). For evalua-
tion of acute exposures, the agency generally uses 1-h AMCVs, which are not de-
signed to evaluate 24-h results. Thus, the development of a 24-h AMCV would
allow the TCEQ to evaluate 24-h formaldehyde data for possible health concerns.
Critical effect dose-response data for irritation (e.g., eyes, upper respiratory tract)
from acute (~400 ppb) and chronic (~200 ppb) human studies suggest a narrow
range for the lowest reported effect levels, indicating these irritant effects are prima-
rily concentration dependent. The TCEQ conservatively used the same point of de-
parture (POD) that its chronic noncarcinogenic AMCV is based on (NOAEL of 70
ppb) because the exposure duration (8 h/d) is more similar to the 24-h duration of
interest than the 2-4 h exposure durations for the acute studies. Because the 8 h/d
exposure was repeated 5 d/wk for 10 yrs, and irritation appears to be primarily con-
centration dependent, an 8-to-24-h exposure duration adjustment was judged not
to be necessary. Dividing the POD of 70 ppb by an intrahuman uncertainty factor
of 3 results in a proposed 24-h, health-protective AMCV of 23 ppb. The 24-h
AMCV falls between TCEQ’s 1-h (41 ppb) and chronic (8.9 ppb) noncarcinogenic
AMCVs. To date, there has been only 1 exceedance in 1999 of the proposed
formaldehyde 24-h AMCV when compared to Barnett Shale monitored data.
1569 Use of Other Scientifically-Relevant Information to Satisfy
Tier 1 Testing Requirements in US EPA’s Endocrine
Disruptor Screening Program.
P. L. Bishop1 and C. Willett2. 1People for the Ethical Treatment of Animals, Norfolk,
VA; 2The Humane Society of the United States, Washington DC.
The Endocrine Disruptor Screening Program (EDSP) has been designed to deter-
mine whether certain substances may have effects on the estrogen, androgen and
thyroid hormonal systems. EPA is using an initial Tier 1 screening battery consist-
ing of five in vitro and six in vivo assays to evaluate a chemical’s potential to inter-
act with the hormone systems in mammals and other animals. By order of the
Office of Management and Budget, EPA must also consider Other Scientifically
Relevant Information (OSRI) that is directly or functionally equivalent to data
gathered in Tier 1, in lieu of developing new test data. This study characterizes the
types of OSRI submitted by recipients of the first 67 test orders issued by EPA and
reviews EPA’s approach to acceptance of OSRI. It also assesses the impact of OSRI
acceptance on reducing the number of animals used in screening this first round of
chemicals. Companies submitted OSRI in lieu of some or all Tier 1 assays for 47
chemicals and sought waivers for 412 assays. EPA granted only 94 waivers, an over-
all acceptance rate of 23%; of these, 50 were for in vivo tests. For 20 of the 47
chemicals, EPA denied all OSRI and required the entire battery of assays to be per-
formed. In most instances, the OSRI accepted was either identical to data that
would have been generated by the Tier 1 test or indicated a positive response by the
chemical in question. Although identified as potential sources of OSRI in EPA’s
guidance to test order recipients, guideline studies for pesticide registration, such as
the mammalian two-generation reproductive toxicity study and 90-day rodent or
dog studies, were all consistently rejected by EPA as satisfying Tier 1 data require-
ments. The 50 in vivo waivers EPA granted saved about 2,800 animals; however,
nearly 26,000 were killed in the Tier 1 assays EPA required. The study concludes
with a discussion of the implications for future use of OSRI in the EDSP.
1570 A New Approach to Academic and Guideline Research: The
CLARITY-BPA Research Program.
A. F. Johnson2,  J. Aungst4,  J. R. Bucher3,  C. Luisa5,  K. Delclos5,  J. J. Heindel1,
P. C. Howard5,  D. Keefe4,  R. Newbold3,  W. Nigel3 and T. T. Schug1. 1Division
of Extramural Science, NIEHS, Durham, NC; 2Program Evaluation, MDB,
Durham, NC; 3NTP, NIEHS, Durham, NC; 4Office of Food Safety, US FDA,
College Park, MD; 5Division of Biochemical Toxicology, National Center for
Toxicological Research, US FDA, Jefferson, AR.
Recently, medical research has seen a strong push toward translational research, or
“bench to bedside” collaborations, which strive to enhance the utility of laboratory
science for improving medical treatment. The success of that paradigm supports the
potential application of the process to other fields, such as risk assessment. Close
collaboration among academic, government, and industry scientists may facilitate
the application of scientific findings to regulatory decision making. The National
Toxicology Program (NTP), National Institute of Environmental Health Sciences
(NIEHS), and U.S. Food and Drug Administration (FDA) developed a consor-
tium-based research program to more effectively link academic and guideline-com-
pliant research. An initial proof-of-concept collaboration, the Consortium Linking
Academic and Regulatory Insights on BPA Toxicity (CLARITY-BPA), uses bisphe-
nol A (BPA) as a test chemical. The CLARITY-BPA program combines a core peri-
natal guideline-compliant 2-year chronic toxicity study with mechanistic
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studies/endpoints led by academic investigators. Twelve extramural grantees were
selected by NIEHS through an RFA-based initiative to participate in the overall
study design and conduct disease-relevant investigations using tissues and animals
from the core study. While the study is expected to contribute to our understanding
of potential effects of BPA, it also has ramifications beyond this specific
focus.Through CLARITY-BPA, NIEHS has established an unprecedented level of
collaboration among extramural grantees and regulatory researchers. The CLAR-
ITY-BPA represents a potential new model for filling knowledge gaps, informing
chemical risk assessment, and identifying new methods or endpoints for regulatory
hazard assessments.
1571 How Consistent Are the Derived No-Effect Levels (DNELs)
in the European REACH Legislation?
L. Schenk1, 2,  U. Deng1 and G. Johanson1. 1Work Environment Toxicology,
Karolinska Institute, Stockholm, Sweden; 2Division of Philosophy, Royal Institute of
Technology, Stockholm, Sweden.
The new European REACH regulation places more responsibility than hitherto on
manufacturers and importers of chemicals (“industry”) to provide safety informa-
tion. An important part of the development of a REACH Chemical Safety Report
is derivation of Derived No-Effect Levels (DNELs) which represent “the level of ex-
posure above which humans should not be exposed”. In order to study the consis-
tency, we compared DNELs presented by industry at the website of the European
Chemicals Agency (ECHA) with those derived by us in our interpretation of the
REACH guidance (Chapter R.8: Characterisation of dose [concentration]-response
for human health,
http://echa.europa.eu/documents/10162/13632/information_requirements_r8_en
.pdf ). There are various DNELs, e.g. representing short-term, long-term, inhala-
tion and dermal exposure, as well as workers and the whole population. We limited
our study to “worker-DNELs long-term” for inhalation route as they resemble oc-
cupational exposure limits (OELs). We found 24 substances for which (1) such
DNELs were given in the ECHA chemical database
(http://echa.europa.eu/web/guest/information-on-chemicals/registered-substances)
and (2) a scientific basis for OEL had been published by the Swedish Criteria
Group within the last 15 years in the serial Arbete och Hälsa
(https://gupea.ub.gu.se/handle/2077/3194?locale=en). The results were startling, as
the DNELs given by industry were 2.4 to 1,100 times higher than ours for 23 sub-
stances and 260,000 times higher for trimellitic anhydride. Some of the discrep-
ancy is explained by different choice of key studies/points of departure (PODs).
However, the choice of assessment factors (AFs) also differed markedly, as industry’s
total AFs (calculated implicitly from the POD and the DNEL) were 1-230 times
lower than ours. We conclude that although the REACH guidance is relatively de-
tailed, many arbitrary choices remain that will influence the DNEL. A major prob-
lem is that little advice is given on when and how to depart from default AFs.
1572 Animal Use for Testing Involving Unrelieved Pain and
Distress.
M. Paris1,  L. Rinckel1,  W. Casey2 and W. Stokes2. 1ILS, Inc., Research Triangle
Park, NC; 2NTP/NICEATM, NIEHS, Research Triangle Park, NC.
Each facility in the United States that uses live animals for research, tests, experi-
ments, or teaching must submit an annual report to the U.S. Department of
Agriculture (USDA) that includes “the common names and the numbers of ani-
mals upon which experiments, teaching, research, surgery, or tests were conducted
involving accompanying pain or distress to the animals and for which appropriate
anesthetic, analgesic, or tranquilizing drugs were (or were not) used” (9 CFR,
Chapter 1 Part 2, Section 2.36). In accordance with the definitions in §2132 of the
Animal Welfare Act (7 U.S.C. 54), it is not necessary to report birds, rats of the
genus Rattus and mice of the genus Mus bred for use in research, or fish, amphib-
ians and livestock or poultry used in agricultural research. In the 2010 USDA an-
nual report on animal usage, a total of 1,134,693 animals were reported, with
97,123 of those reported as experiencing unrelieved pain and distress. Based on an
analysis of these data by the National Toxicology Program Interagency Center for
the Evaluation of Alternative Toxicological Methods (NICEATM), 95%
(91,997/97,123) of the animals reported to the USDA as experiencing unrelieved
pain and distress were used for testing. Of these animals, 57% (54,889/97,123)
were used for vaccine testing, and 38% (37,108/97,123) were used for toxicity test-
ing. Most of the animals used for toxicity testing were used for safety testing and
drug efficacy testing. NICEATM is currently investigating and promoting alterna-
tive test methods to further reduce the number of animals used in painful proce-
dures. Supported by ILS staff under NIEHS Contract N01-ES-35504.
1573 A Reference Database for the Evaluation of Alternative Tests
for Acute Dermal Systemic Toxicity.
J. Strickland1,  F. Stack1,  M. Paris1,  L. Rinckel1,  W. Casey2 and W. Stokes2. 1ILS,
Inc., Research Triangle Park, NC; 2NTP/NICEATM, NIEHS, Research Triangle
Park, NC.
Alternatives for acute systemic toxicity testing are one of the highest priorities of
ICCVAM and NICEATM. These are the most commonly performed product
safety tests worldwide and are required by multiple U.S. Federal agencies. Acute
toxicity testing can involve large numbers of animals and result in significant unre-
lieved pain and distress to test animals. High quality reference data are needed to
evaluate alternative toxicity tests that may reduce, refine (enhance animal well-
being and lessen or avoid pain and distress), and replace the use of animals for acute
dermal systemic toxicity testing. To identify appropriate reference data for the acute
dermal systemic toxicity test, NICEATM collected and analyzed data for 1897 sub-
stances. Rabbits were used for 28% (526) of the studies, and rats were used for 72%
(1371). Of the 1897 substances, 84% (1598/1897) had data for both male and fe-
male animals, and 98% (1561/1598) of those substances were in the same GHS
dermal hazard category. For the 37 substances that showed a different dermal haz-
ard category between the sexes, female values were more often in a higher hazard
category (21 for females vs. 16 for males). Two hundred forty six studies reported
day of death. Approximately two thirds of the deaths (67% of male deaths
[513/761]; 63% of female deaths [463/733]) occurred by Day 2 after a 24-hour
dermal treatment on Day 0. Eighty-five substances had sufficient data to calculate
dermal dose–mortality slopes. Dose–mortality slopes did not vary by species, sex, or
GHS hazard category. As expected, the dermal dose–mortality slopes were lower
than acute oral dose–mortality slopes. These data were used to design a proposed
sequential test for acute dermal systemic toxicity, the dermal up-and-down proce-
dure, to reduce the number of animals tested for acute dermal hazard classification.
Supported by ILS staff under NIEHS Contract N01-ES-35504.
1574 Regulatory Acceptance of the BG1Luc Estrogen Receptor
Transactivation Test Method.
W. Casey1,  P. Ceger2,  J. Strickland2,  L. Rinckel2,  E. Grignard3,  S. Bremer3,
H. Kojima4,  S. Han5 and W. Stokes1. 1NTP/NICEATM, NIEHS, Research
Triangle Park, NC; 2ILS, Inc., Research Triangle Park, NC; 3EURL ECVAM, Ispra,
Italy; 4JaCVAM, Tokyo, Japan; 5KoCVAM, NIFDS/KFDA, Cheongwon-gun,
Chungcheongbuk-do, Republic of Korea.
NICEATM coordinated an international interlaboratory validation study of the
BG1Luc estrogen receptor transactivation test method (BG1Luc ER TA,
LumiCell®) developed by Xenobiotic Detection Systems, Inc. In 2010, the valida-
tion study completed its goal to evaluate the usefulness and limitations of the
BG1Luc ER TA test method to screen for substances with in vitro ER agonist or
antagonist activity. The international validation study was sponsored by
NICEATM, with participation from the European Centre for the Validation of
Alternative Methods, and the Japanese Center for the Validation of Alternative
Methods. In 2012, NICEATM–ICCVAM released a test method evaluation report
on the usefulness and limitations of the BG1Luc ER TA test method. ICCVAM
recommended the use of the BG1Luc ER TA as a screening test to identify sub-
stances with in vitro ER agonist and antagonist activity and recommended that the
BG1Luc ER TA test method could be considered as an alternative to the existing
ER TA test guideline (EPA OCSPP 890.1300/OECD TG 455). All 15 ICCVAM
member agencies, including the US Environmental Protection Agency, concurred
with the ICCVAM recommendations. NICEATM sponsored the new method for
evaluation by the Organisation for Economic Co-operation and Development
(OECD), which approved the BG1Luc test method and added the BG1 agonist
protocol to the existing Test Guideline 455. The BG1 antagonist method has been
adopted as OECD Test Guideline 457. Acceptance of the BG1Luc ER TA test
method by U.S. and international agencies is an example of increased cooperation
and collaboration to support the international adoption of scientifically valid test
methods that will protect people, animals, and the environment while reducing, re-
fining, and replacing animal use. Supported by ILS staff under NIEHS Contract
N01-ES-35504.
1575 Quantitative Risk Assessment As the Basis for a Proposed
NIOSH Recommended Exposure Limit for Hexavalent
Chromium Compounds.
K. MacMahon,  R. Park,  F. Rice and K. Ashley. NIOSH, Cincinnati, OH.
Sponsor: D. Dankovic.
To update the National Institute for Occupational Safety and Health (NIOSH)
recommendations for protecting workers with occupational exposure to Cr(VI)
compounds, all aspects of occupational exposure to and control of hexavalent
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chromium compounds (Cr(VI); e.g., chromic acid, CAS No. 1333-82-0; sodium
dichromate, CAS No. 7789-12-0) were evaluated including epidemiology, toxicol-
ogy, risk assessment, analytical methods, and industrial hygiene practices.
Derivation of a proposed Recommended Exposure Limit (REL) was one compo-
nent of the updated risk management recommendations. The NIOSH proposed
REL was derived based on the results of a quantitative risk assessment (QRA) of
lung cancer in chromate production workers. The NIOSH REL was previously
based on the quantitative limitation of the 1975 analytical method; at that time
NIOSH recommended that occupational carcinogens be controlled to the lowest
feasible concentration. Data from a cohort of Baltimore chromate production
workers were selected for analysis due to the availability of extensive exposure as-
sessment data, information about smoking histories, strong statistical power, and
relative lack of confounding exposures. Excess lifetime risk at the REL of 1 μg
Cr(VI)/m3 was estimated as 6 (95% confidence limits=3-12) lung cancer deaths
per 1000 workers. Based on these results, NIOSH proposed a REL of 0.2 μg
Cr(VI)/m3 8-hour time-weighted average exposure during a 40-hour workweek.
The proposed REL has an estimated working lifetime (45 years) excess risk of lung
cancer mortality of approximately one in 1000. NIOSH, Occupational Safety and
Health Administration, and international consensus standard analytical methods
can accurately quantify workplace exposures at the proposed REL. Recommending
the control of occupational Cr(VI) exposures to below the proposed REL is in-
tended to reduce the incidence of work-related lung cancer.
1576 The Dermal Up-And-Down Procedure: An Alternative Test
Method for Acute Dermal Systemic Toxicity Testing.
W. Stokes1,  J. Strickland2,  R. Morris3,  L. Ho3,  J. Wilkerson3,  F. Stack2,
M. Paris2,  L. Rinckel2 and W. Casey1. 1NTP/NICEATM, NIEHS, Research
Triangle Park, NC; 2ILS, Inc., Research Triangle Park, NC; 3SRA International,
Research Triangle Park, NC.
Acute dermal systemic toxicity testing is required to identify chemicals and prod-
ucts that have the potential to cause life-threatening or fatal toxicity following skin
exposures. Such testing is one of the five most commonly conducted safety tests and
requires up to 20 or more animals per test. A dermal up-and-down procedure
(UDP) was developed to estimate acute dermal toxicity hazard classification cate-
gories with fewer animals. The UDP incorporates an efficient experimental design
using sequential testing to estimate LD50 rather than the simultaneous testing of
multiple groups of animals at multiple doses, as specified by current regulatory test
guidelines. In the dermal UDP, individual animals are dosed sequentially, and the
response of each animal after 48 hours is used to determine the dose applied to the
next animal. If a dose produces significant toxicity, the next animal is tested at a
lower dose. Conversely, if no significant toxicity is observed, the next animal is
tested at a higher dose, with the highest dose not to exceed a pre-specified limit
dose. Unless there is a basis for a lower starting dose, the initial dermal UDP start-
ing dose is the appropriate limit test dose (2000 or 5000 mg/kg). The default dose-
progression factor for subsequent doses is 4.2. If the expected LD50 is less than the
default starting dose, testing is started at one dose below the closest default dose.
Using a starting dose of 5000 mg/kg, default doses are 5000, 1200, 300, 70, 15,
and 4 mg/kg, while the default doses for a starting dose of 2000 mg/kg are 2000,
500, 100, 25, and 5 mg/kg. The dermal UDP provides LD50 point estimates and
confidence limits for dermal hazard classifications while using up to 85% fewer an-
imals. The proposed dermal UDP can support accurate hazard identification while
significantly reducing animal use. Supported by ILS staff under NIEHS Contract
N01-ES-35504 and SRA staff supported by NIEHS Contract GS-23F-9806H.
1577 Fatal Misuse of Humidifier Disinfectants in Korea:
Importance of Screening Risk Assessment and Implications
for Management of Chemicals in Consumer Products.
J. Lee1,  J. Kwon2 and Y. Kim3. 1Institute of Environmental Safety and Protection,
NeoEnBiz Co., Bucheon, Republic of Korea; 2Department of Environmental
Engineering, Ajou University, Suwon, Republic of Korea; 3Korea Institute of
Toxicology, Dajeon, Republic of Korea. Sponsor: K. Park.
The Korea Centers for Disease Control and Prevention (KCDC) reported on
August 31, 2011 that the unidentified fatal lung disease found in Korea might have
been caused by chemical disinfectants used with household humidifiers. Among
them, four patients passed away because of the rapid development of pulmonary fi-
brosis after long exposure to the disinfectants over several months. A provisional
conclusion by an epidemiological investigation that active ingredients of disinfect-
ing products (polyhexamethyleneguanidine (PHMG) and oligo(2-(2-
ethoxy)ethoxyethyl guanidinium chloride (PGH)) caused this disease was rein-
forced by a subsequent inhalation toxicological study using rats. In Korea,
humidifier disinfectants have been put in the water tanks of humidifiers for the pre-
vention of germs, mold, and/or algae. The disinfectants were manufactured and
sold on the market without any data on inhalation toxicity being submitted and
without risk evaluation on an industrial or government level. We conducted a
screening-level risk assessment for the disinfectants. With these high values of the
risk quotients for PHMG and PGH containing the guanidine moiety, it should
have been possible to screen the chemicals with potential health concerns before
their introduction to the market. Precautionary measures such as “premarket regis-
tration and evaluation” and “significant new use notice and re-evaluation” need to
be complemented by post-market control systems such as product recall and health
surveillance systems to screen the health hazards of chemicals.
1578 Multiple Federal Hazard Assessment Programs—A Relevant
Information or Redundant Efforts?
N. B. Beck1,  B. A. Richard1 and A. Twardowski2. 1American Chemistry Council,
Washington DC; 2Concordia College, Moorehead, MN.
Much interest, at both the Executive and Legislative levels, is currently directed to-
wards evaluating how to reform and streamline government to improve efficiencies
and decrease costs. In Jan. 2010, President Obama, acknowledging challenging eco-
nomic times, began an effort to decrease waste and inefficiencies in the govern-
ment. Similarly, Public Law 111-139 (2010) required the Government
Accountability Office to identify federal programs with duplicative goals and activ-
ities. Regarding the evaluation of hazards associated with environmental contami-
nants, there are at least three Federal programs that have seemingly overlapping, al-
though not perfectly aligned goals. Our question was: Do these government
programs provide novel information or are the efforts redundant? While the EPA
Integrated Risk Information System (IRIS) evaluates risk information for chronic
non-cancer and cancer effects, the Agency for Toxic Substances and Disease
Registry (ATSDR), in its Toxicological Profiles, evaluates non-cancer effects at
acute, sub-chronic and chronic exposures. The National Toxicology Program’s
Report on Carcinogens (RoC) provides cancer descriptors, as does the IRIS
Program, although NTP does not develop quantitative risk values. The IRIS
Reference Values and the ATSDR Chronic Minimal Risk Levels were examined.
Additionally, the IRIS and NTP cancer classifications for substances were also re-
viewed. If the same substance was evaluated by two programs, we also compared the
final Agency recommendations. Significant findings will be presented. For example,
the analyses show that even though the IRIS program has evaluated over 550 chem-
icals there are only 85 chemicals with Reference Concentrations (RfC) and since
1995 EPA releases, on average, 3 new RfCs a year. Similarly, although ATSDR has
evaluated over 170 chemicals, there are only 42 with chronic inhalation values and
approximately half of these chemicals are the same ones EPA evaluated. The full
analysis of results will help the agencies and stakeholders assess the value in sup-
porting three separate programs.
1579 Utilization of Benzene Chromosomal Biomarkers by US
Courts in Adjudicating Causation.
G. E. Marchant. College of Law, Arizona State University, Tempe, AZ.
This study evaluates the utilization of chromosomal biomarkers in court cases that
involved benzene exposure, one of the first major set of cases to rely on biomarker
data. The methodology involved searching the Westlaw database for all toxic tort
cases involving plaintiffs allegedly injured by beneze exposure in which evidence of
chromosomal aberrations was offered. The judicial decisions in these cases were
evaluated to determine whether the judges properly understood and applied the sci-
entific information on biomarkers, and to determine how useful the biomarker data
was to the ultimate outcome of the case. A standardized multi-criteria analysis sheet
was used to evaluate each case. A total of 17 U.S. court cases decided in the period
from 1995 to 2012 that involved benzene chromosomal biomarker evidence were
identified and evaluated in this study. The analysis identifies several problems in
how judges and juries in these cases dealt with biomarker evidence, including: (i)
some courts treat the evidence as deterministic rather than probabilistic, incorrectly
concluding that biomarker evidence alone proves or disproves causation, or in other
cases holding that the biomarker data is completely irrelevant and thus inadmissi-
ble; (ii) different courts treated the same biomarker evidence differently, resulting in
inconsistent decisions; and (iii) individual judges made statements in specific cases
indicating a poor understanding of biomarkers. Notwithstanding these limitations,
the overall results of using chromosomal biomarker evidence in these toxic tort
cases was beneficial, as the evidence was instrumental in helping to prove or dis-
prove causation in appropriate cases. This analysis demonstrates that biomarker
data can provide effective and useful evidence in toxic tort litigation, and are likely
to be used increasingly frequently in such cases. At the same time, the problems
identified in this analysis with handling of biomarker data by some courts provide
important lessons for judges, attorneys, and scientific experts.
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1580 In Vitro Episkin Skin Corrosion As a Reference Test Method
in OECD TG431 for the Assessment of Skin Corrosion in
Subcategories 1A, 1B, and 1C.
N. Alépée,  M. H. Grandidier and J. Cotovio. L’Oréal Research & Innovation,
Aulnay sous Bois, France. Sponsor: E. Dufour.
Skin corrosion or irritation refers to the production of irreversible or reversible
damage to the skin following the application of a test substance, respectively. An ef-
fective way of predicting test substance toxicity is to make use of testing strategies
which incorporate a range of alternative test methods. For the determination of
skin irritation and corrosion, hazard assessments for both endpoints could be con-
ducted using in vitro test methods that have been regulatory accepted (OECD
TG431 & TG439). In the present study, skin irritation and corrosion evaluations
were performed on Reconstructed human Epidermis (RhE) models i.e. EpiSkin
and SkinEthic RHE. In the case of skin corrosion, GHS guidelines differentiate be-
tween non corrosive (NC) to corrosive (C) substances with 3 subcategories: 1A, 1B
and 1C. The current evaluation of the test method was performed on 81 test sub-
stances from a wide range of chemical for each subcategory class (38 NC, 31
Cat1B/1C and 12 Cat1A) enlarging the evidence base associated with this method.
Using the EpiSkin test method, within-laboratory variability (>87%) was assessed
in 3 runs. Therefore a sensitivity of 98% and overall accuracy of 89% (with an ac-
curacy of 1A, 1B/1C, NC of 79%) were obtained. The test method able to dis-
criminate 1A, from 1B and 1C classes with the highest well -prediction rate for sub-
categorize the substances in comparison with the others validated methods, was
submitted to OECD for scientific review and adoption. Adoption of the EpiSkin
seems sufficient to fill the gaps in terms of sub-categorisation predictions leading to
a significant impact on the sub-group transport package labeling.
1581 Application of Systems Biology to Identify Molecular
Mechanisms and Biomarkers of Lead (Pb) Neurotoxicity:
Implications in a Developmental Origin of Alzheimer’s
Disease.
J. L. Freeman. Health Sciences, Purdue University, West Lafayette, IN.
The heavy metal lead (Pb) can induce a wide-range of adverse health effects de-
pending on dose and duration of exposure. During development the nervous sys-
tem is most sensitive to Pb toxicity with epidemiological studies linking neurologi-
cal deficits at and below the previous CDC blood Pb level of concern. Although the
toxicity of Pb is extensively studied, the underlying genetic, epigenetic, and molec-
ular mechanisms of Pb neurotoxicity are not completely understood. Moreover, re-
cent studies link developmental Pb exposure with latent effects that do not appear
until late in life, indicating a developmental origin of adult neurodegenerative dis-
orders. More specifically, the latent overexpression of hallmark genes and proteins
in Alzheimer’s disease (AD) are reported in these studies. This session brings to-
gether a group of investigators that are actively applying systems biology (transcrip-
tomics and epigenomics) and targeted approaches to define the mechanisms and
identify biomarkers of both the developmental and late-life neurological alterations
associated with a developmental Pb exposure in a variety of model systems and in
human populations. Topics cover a study with the zebrafish model on the genetic
mechanisms of developmental Pb neurotoxicity with an emphasis on transcrip-
tomic alterations to a human comparative transcriptomic study in young adults
aiming at establishing biomarkers between early-life Pb exposure and AD. The ses-
sion also addresses the transcriptomic and epigenomic pathways of the develop-
mental origin of Pb-induced neurodegenerative alterations with a specific focus on
AD in rodent and primate models. Furthermore, the mechanism by which Pb in-
creases the formation of amyloid β plaques in a transgenic mouse model is dis-
cussed. Overall, this session highlights the latest findings on the genetic, epigenetic,
and molecular mechanisms of Pb neurotoxicity linking neurodevelopmental and
later life impacts to further deduce the developmental origin of Pb-induced neu-
rodegenerative disease with a specific focus on AD.
1582 Genetic Mechanisms of Developmental Lead Neurotoxicity
and Links to Adult Neurodegenerative Disease Pathogenesis.
J. L. Freeman. Health Sciences, Purdue University, West Lafayette, IN.
It is well established that lead (Pb) exposure is detrimental to neurological develop-
ment, but the underlying mechanisms of Pb developmental neurotoxicity are not
clearly elucidated. Furthermore recent evidence supports the hypothesis that a de-
velopmental Pb exposure results in later lifespan effects including pathological fea-
tures characteristic of Alzheimer’s disease (AD) proposing a developmental origin of
Pb-induced adult neurological disease. The genetic and epigenetic mechanisms un-
derlying and linking the immediate adverse effects of the developmental Pb expo-
sure and the lasting impacts of the developmental exposure throughout the lifespan
are yet to be determined. In this study, global gene expression analysis using the ze-
brafish vertebrate model system demonstrated that developmental Pb exposure re-
sults in immediate altered expression of genes associated with axon guidance, neu-
rogenesis, and neurodegeneration. Furthermore, gene expression alterations were
correlated to functional changes in the form of altered protein levels and a delay in
axonal growth. While being an established developmental model, characterization
of the adult zebrafish is limited and is just beginning to be explored for application
in neurodegenerative disease pathogenesis research. Studies utilizing zebrafish em-
bryos show that many genes with direct roles in AD are highly conserved in terms
of sequence and function supporting the application of the adult zebrafish brain as
a model to investigate the role of a developmental Pb exposure in the pathogenesis
of neurological disease. To further our understanding of these genes, protein se-
quence analysis and gene expression characterization was conducted. This study
demonstrates that a strong degree of conservation occurs in regards to the presence
and orientation of specific functional domains and in expression patterns. This
study provides a framework for assessment of the influence of a developmental Pb
exposure on late life neurological disease pathogenesis.
1583 Prenatal Lead Exposure and Biomarkers for Alzheimer’s
Disease in Humans.
M. Mazumdar1, 2. 1Environmental Health, Harvard School of Public Health, Boston,
MA; 2Neurology, Children’s Hospital Boston, Boston, MA. Sponsor: J. Freeman.
Animal studies suggest that early life lead (Pb) exposure influences gene expression
and production of proteins associated with Alzheimer’s disease (AD). This presen-
tation will discuss recent studies in humans implicating early-life Pb exposure in the
pathogenesis of AD. Aggregation of β-amyloid (Aβ) is a hallmark of AD pathology
and plasma concentrations of Aβ are biomarkers that potentially could predict the
risk of AD prior to the clinical manifestation of dementia. To evaluate the associa-
tion between early-life Pb exposure and AD risk, the mean plasma Aβ concentra-
tion was measured in young adults and compared among those that had high um-
bilical cord blood Pb concentrations and those with lower cord blood Pb
concentrations. Expression of genes whose products affect Aβ production and dep-
osition was evaluated and was inversely correlated with umbilical cord blood Pb
concentrations. Gene network analysis suggested enrichment in gene sets involved
in nerve growth and general cell development. These data suggest that prenatal Pb
exposure may influence Aβ-related biological pathways that are implicated in AD.
Challenges in designing studies that investigate the contribution of early-life envi-
ronmental exposures to adult disease will also be reviewed in this presentation.
1584 Do Epigenetic Pathways Initiate Late Onset Alzheimer’s
Disease (LOAD)?: Towards a New Paradigm.
N. H. Zawia. Biomedical and Pharmaceutical Sciences, University of Rhode Island,
Kingston, RI.
Cognitive decline and many of the hallmark pathological features of Alzheimer’s
disease (AD) such as amyloid plaques and tau tangles are present in normal aging
individuals and pose a challenge for distinguishing AD from normal aging. The
majority of AD cases occur in the elderly; however, it is still unresolved whether AD
is a disease of old age or whether it has earlier beginnings. The development of early
onset AD (EOAD) seems to be largely genetic; however, late-onset AD (LOAD)
may be influenced by epigenetic factors acquired during early developmental stages.
LOAD exhibits numerous non-Mendelian anomalies that suggest an epigenetic
component in disease etiology. The sporadic nature of >90% of AD cases, the dif-
ferential susceptibility and course of illness, as well as the late age onset of the dis-
ease suggest that epigenetic and environmental components play a role in the etiol-
ogy of LOAD. In this presentation, the evidence derived from primates and rodents
(genomic and epigenomic as well as biomarker-specific) that AD has a develop-
mental origin and that early life exposure can reprogram gene expression in old age
through epigenetic pathways rendering the brain more susceptible to neurodegen-
erative diseases will be provided.
1585 CNS Homeostasis of β-Amyloid, Plaque Formation, and
Lead Toxicity.
W. Zheng. Health Sciences, Purdue University, West Lafayette, IN.
The hallmark of Alzheimer’s disease (AD) pathology is aggregation of β-amyloid
(Abeta or Aβ). Previous studies in this laboratory have established that the brain
barrier systems are actively engaged in regulation of the homeostasis of Abeta in
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brain extracellular milieu (Crossgrove et al., Exp Biol Med 2005;230:771) and that
lead (Pb) exposure can alter the property of the Abeta transport protein (LRP1)
leading to abnormal accumulation of Abeta in brain tissues (Behl et al., TAAP
2009;240:245; Neurotox 2010;31:524). In the current study, we used transgenic
PDAPP mice which over-express amyloid precursor protein (APP) and exhibit
amyloid plaques in brain tissues to investigate if in vivo Pb exposure shortened the
onset of amyloid plaque formation and increased the plaque aggregation. Our data
show that in vivo Pb exposure resulted in an increased deposition of amyloid
plaques in these transgenic mouse brains. Mechanistic investigation revealed that
Pb reduced Abeta clearance from the central nervous system by inhibiting LRP1 at
brain barriers. Pb also directly participated in physiochemical reaction with Abeta
molecules in the test tube. Moreover, Pb increased the concentrations of other met-
als (i.e., Fe, Zn) in amyloid plaques in the mouse brain by synchrotron X-ray fluo-
rescent (XRF) quantitation. Within the plaques, Pb concentrations were found to
be significantly correlated with those of Fe and Zn. Our data support a role of Pb in
the formation of amyloid plaques; how these findings may relate to human AD eti-
ology deserves further investigation (Supported in part by NIH/NIEHS ES008146
and ES017055).
1586 Bone As a Target Tissue for Environmental Toxicants.
J. Schlezinger. Environmental Health, Boston University School of Public Health,
Boston, MA.
Bone brings to mind the strong, but light, organ that provides the skeleton for ver-
tebrates. However, bone is more than just inert, osseous tissue. The bone marrow is
a multifunctional organ that supports not only ongoing bone remodeling, but also
provides the microenvironmental niche for hematopoiesis and regulates whole
body energy homeostasis and as such, represents a significant target for environ-
mental toxicants. Critical cell types in the bone marrow include multipotent mes-
enchymal stromal cells (MSCs) and hematopoietic stem cells (HSCs). MSCs are
the source of both adipocytes and osteoblasts. HSCs are the source of all blood cell
lineages and the bone-resorbing osteoclasts. The interaction between osteoblasts
and osteoclasts creates a balance of bone formation and resorption, which is essen-
tial for maintenance of bone quality. There also is essential crosstalk between the
mesenchymal and hematopoietic compartments that supports lifelong blood cell
generation. Lymphocyte development, in particular, requires stromal cell
support/interaction. Understanding how environmental toxicants disturb the inter-
play of bone marrow compartments requires attention given the rapidly aging pop-
ulation who are already at risk for loss of bone quality and immune suppression. We
will explore new data suggesting that bone is responsive to many environmental
toxicants, which may perturb the delicate balance between bone marrow cell types.
A series of presentations will define interactions within both the mesenchymal and
hematopoietic compartments and how exposure to toxicants may impact bone bi-
ology. Presentations will move from a broad, multispecies analysis of the effects of
persistent organic pollutants on bone to more focused analyses of effects of ethanol
and metals (lead, organotins, and tungsten) on bone and the bone marrow mi-
croenvironment.
1587 Bone Tissue As a Target for POPs Acting As EDCs (an
Overview from Wild Animals to Humans).
M. Lind. Occupational and Environmental Medicine, Uppsala University, Uppsala,
Sweden.
Since World War II, there has been an increase in age-standardized incidence rates
of osteoporotic bone fractures in industrialized countries, with the Nordic countries
taking the lead. The reason for this increase is unknown but the idea that exposure
to endocrine-disrupting chemicals (EDCs) could be involved has been put forward.
The consequences of environmental contaminant-induced bone toxicity is evident
across many species. Exposure to persistent organic pollutants (POPs) acting as
EDCs, has been shown to negatively affect the bone tissue (e.g. leads to an osteo-
porotic phenotype) in laboratory models (monkeys, rats, mice, frogs, goat, sheep,
bone cells), as well as wild-life (polar bears, seals, alligators and herring gulls).
Important signaling pathways such as the estrogen receptor and aryl hydrocarbon
receptor pathways have been suggested to contribute to the observed effects.
Importantly, epidemiological studies on humans also support this hypothesis since
they show a relationship between exposure to endocrine disrupting POPs and de-
creased bone mineral density or increased risk of bone fractures. The literature on
this topic is, however, rather small and prospective studies on in utero or early EDC
exposure and future osteoporotic bone fractures do not exist. The mechanisms be-
hind the deleterious effects of EDCs on bone tissue also need to be a focus of study.
1588 Lead Exposure and Skeletal Dysregulation: A Molecular
Mechanism of Toxicity That Contributes to Osteoporosis
and Other Bone Diseases.
J. Puzas and E. Beier. Center for Musculoskeletal Research, University of Rochester,
Rochester, NY.
Rationale and Scope: Lead exposure and osteoporosis represent two of the most
widespread health issues affecting humans. Our recent investigations provide evi-
dence that these entities are linked. We have also identified a molecular mechanism
by which lead can adversely affect bone forming cells.
Experimental Procedures: We used a small animal rodent model as well as isolated
cell experiments to evaluate the effect of lead exposure. The animals were treated
with lead in their drinking water. The cell studies were performed in culture media
with added lead acetate. All treatments achieved lead levels relevant to human ex-
posures. Bone mass parameters were measured with micro CT analysis, histology
and Raman infrared spectrometry. Cell effects and signaling pathways in osteoblasts
were measured with molecular methods for mRNA and protein.
Results: Our findings indicate that lead exposure induces an osteoporotic-like phe-
notype in the animal model. Bone volume, bone formation rates, bone quality and
bone cell number were all significantly depressed in the treated animals. Lead also
induced a strong adipogenic response in the marrow space. Data from exposure of
cells to lead indicate that all parameters of osteoblastic bone formation were also
markedly inhibited. Immunohistochemical assays as well as a molecular analysis of
in vitro cell signaling pathways indicate that the effect of lead is, at least partially,
due to a strong depression of the TGFbeta and Wnt pathways. The mechanism for
this depression appears to be related to an up regulation of the bone formation in-
hibitor, sclerostin.
1589 Role of Nadph Oxidases and Reactive Oxygen Species in
Regulation of Bone Turnover and the Skeletal Toxicity of
Alcohol.
M. Ronis1, 2,  K. Mercer1,  L. Suva2,  T. M. Badger1, 2 and J. Chen1, 2. 1Arkansas
Children’s Nutrition Center, Little Rock, AR; 2University of Arkansas for Medical
Sciences, Little Rock, AR.
Recent studies with genetically modified mice and dietary antioxidants have sug-
gested an important role for superoxide derived from NADPH oxidase (NOX) en-
zymes and other reactive oxygen species (ROS) such as hydrogen peroxide in regu-
lation of normal bone turnover during development and also in the responses of the
skeleton to toxicants such as ethanol (EtOH) which generate excess ROS in bone
tissue. We have shown that EtOH causes bone loss as a result of NOX generated
ROS, reduced bone formation via impaired Wnt-β catenin signaling and increased
RANKL-dependent osteoclastogenesis. Buffering of anti-oxidant capacity though
administration of the glutathione precursor N-acetylcysteine, completely prevented
EtOH-induced loss of bone mineral density, inhibiting both suppression of bone
formation and increases in bone resorption. There was no apparent bone phenotype
associated with genotype at age 3 mo., in mice lacking the NOX co-factor p47phox
and thus with impaired capacity to generate excess superoxide in response to
EtOH. However, these mice were only protected from alcohol-stimulated increases
in bone resorption. This was accompanied by inhibition of EtOH-associated in-
creases in osteoclastogenesis and induction of RANKL. In mice where hydrogen
peroxide concentration in bone is reduced as a result of transgenic expression of
catalase, whereas 6 wk old mice had increased trabecular bone, 3 mo. old mice had
reduced trabecular bone and impaired osteoblastogenesis compared to wild type
mice and were unprotected against ethanol actions. These data suggest that ROS
signaling involving hydrogen peroxide is important in regulation of adult bone for-
mation but that excess production of superoxide via NOX as a result of exposure to
toxicants such as EtOH can stimulate RANKL-dependent increases in bone resorp-
tion. Supported in part by R01 AA018282 (M.J.R.).
1590 Organotins: Unique Modulators of Bone Quality and the
Bone Marrow Microenvironment.
J. Schlezinger1,  A. Baker2 and L. Gerstenfeld3. 1Environmental Health, Boston
University School of Public Health, Boston, MA; 2Medicine, Boston University School
of Medicine, Boston, MA; 3Orthopaedic Surgery, Boston University School of
Medicine, Boston, MA.
Bone marrow multipotent mesenchymal stromal cells (BM-MSC) are critical for
osteogenesis, as well as for creating the supportive niche for lymphopoiesis. PPARγ
is a central mediator of BM-MSC differentiation, traditionally thought to promote
adipogenesis while suppressing osteogenesis. A growing number of environmental
contaminants (e.g. phthalates, organotins) have been shown to activate PPARγ and
increase adipogenesis, and thus recently have been termed environmental obeso-
gens. Organotins are unique in their ability to bind and activate both PPARγ and
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RXR, opening the possibility that they may activate multiple permissive nuclear re-
ceptor pathways. We investigated the hypothesis that tributyltin (TBT) is a potent
modifier of BM-MSC differentiation and thus a negative regulator of bone quality
and lymphopoiesis. In vivo TBT exposure results in decreased cortical bone and in-
creased marrow adiposity without significantly altering bone resorption. B cell pop-
ulations are altered in both the bone marrow and the spleen of TBT-treated mice.
In primary BM-MSC cultures, TBT potently induces adipogenesis and suppresses
osteogenesis. Surprisingly, female-derived BM-MSCs are significantly more sensi-
tive to TBT-mediated suppressive effects than male-derived cells. In addition to ac-
tivating a PPARγ-mediated gene expression pathway (FABP4 and adipsin) and sup-
pressing a Runx2-mediated pathway (osterix and osteocalcin), TBT activates the
LXR in vivo and in vitro, another nuclear receptor that contributes to bone home-
ostasis. Finally, TBT completely suppresses the development of hematopoietic cells
in culture. Given its potency and ubiquitous environmental presence, TBT presents
a risk to bone health and may accelerate the accumulation of adipocytes and loss of
lymphopoiesis that occurs during aging.
1591 Tungsten: Effects on Bone Marrow and Lymphocyte
Development.
K. K. Mann. Oncology, McGill University, Montréal, QC, Canada.
Very little is known about the toxicity of tungsten. Recently, increased environ-
mental tungsten levels were found near sites of pediatric leukemia clusters. These
leukemia cases were predominantly of the preB lymphocyte subtype of acute lym-
phocytic leukemia. While no data link tungsten exposure to leukemogenesis, tung-
sten is known to accumulate within the bone, the site of B cell development. This
important hematopoietic compartment is likely the site where leukemogenic events
occur. We have explored the effects of tungsten exposure on developing B lympho-
cytes using in vitro and in vivo models. In vitro, B lymphocytes are more sensitive to
tungsten-induced DNA damage and growth inhibition than the supporting mes-
enchymal stromal cells. In wild-type mice, we have shown that tungsten concentra-
tions rapidly increase in the bone and reach a plateau after approximately 4 weeks
of exposure. Removal of tungsten results in a slow release of tungsten from the bone
with a much slower “off ” rate. In addition, we see alterations in bone mineral con-
tent and density following tungsten exposure. Tungsten exposure alters B lym-
phopoiesis, increases DNA damage within the bone marrow B cells, and increases
preB-colony forming units. Any of these could provide a leukemogenic hit, and
thus, tungsten could act as a tumor promoter. Although we did not observe devel-
opment of leukemia in wild-type mice, current data in pre-leukemic mouse models,
as well as murine breast cancer models, will be discussed.
1592 Nonmonotonic Dose-Response Curves and Endocrine-
Disrupting Chemicals: Fact or Falderal?
L. E. Gray1 and P. M. Foster2. 1RTB, US EPA, Research Triangle Park, NC; 2NTP,
NIEHS, Research Triangle Park, NC.
“All substances are poisons. It’s the dose that makes the poison,” (Paracelsus,
1493–1541) is a fundamental tenet in toxicology: the severity of a response to a
toxicant increases proportionally to the dose. Furthermore, it is generally assumed
that dose-response curves for noncancer effects display a threshold below which
there is no effect. Currently these assumptions are being challenged by claims that
endocrine-disrupting chemicals (EDCs) often display U-shaped or inverted U-
shaped nonmonotonic dose-response curves (NMDRCs) at low, environmentally-
relevant exposure levels; levels below traditional NOAELS (“Current Chemical
Testing Missing Low-Dosage Effects of Endocrine-Disrupting Chemicals”
Endocrinology Society, 2012). In addition, the US EPAs Endocrine Disruptor
Screening program (EDC program) has been severely criticized, sometimes un-
fairly. This symposium will review the state of the science on EDCs concerning the
shape of the dose-response curve in the low-dose range and the prevalence of
NMDRCs. Talks will initially discuss mechanisms of action, the biologically plausi-
bility for NMDRCs, and then focus on chemicals that disrupt the estrogen and an-
drogen signaling pathways and the prevalence of in vitro and in vivo NMDRCs.
Presentations will also discuss the shape of the dose-response curves from “case
studies” of estrogenic chemicals. These “case studies” are robust, multigenerational
studies conducted in a government laboratory using a protocol that had been “en-
hanced” to include several estrogen-sensitive endpoints in addition to the standard
endpoints. Finally, we will discuss how some governmental agencies are addressing
the NMDRC-low dose issue and views on how this might impact the risk assess-
ment of EDCs and other chemicals. Changing how EDCs are tested to accommo-
date NMDRCs would significantly increase the resources need for testing as it
would require the addition of several “low” dose groups and if NMDRCs are preva-
lent, then this would significantly impact several of the default assumptions used in
risk assessment, including noncancer health effects displaying a threshold, and that
adverse effects do not occur below the NOAELs.
1593 Molecular Pharmacology of Steroid Hormone Action:
Nonmonotonic Dose-Responses.
W. R. Kelce. Nonclinical Development, Novan Therapeutics, Durham, NC.
The basic biology of steroid hormone (SH) synthesis and action is reviewed to pro-
vide a molecular pharmacology basis for typical monotonic and nonmonotonic
dose-response observations. Examples illustrate the molecular pharmacology basis
for observed in vitro and in vivo effects. As the level of biological organization in-
creases (from cell-free binding to transcription to in vivo adverse effects), the op-
portunity for complex nonmonotonic dose-responses emerge. Full strong receptor
agonists and antagonists in vitro provide the highest level of predictability whereas
weak agonists and antagonists are affected by ambient ligand levels. Agonist or an-
tagonist activity can be passive (competition for receptor binding and subsequent
direct receptor activation or inactivation) or active (influenced by co-activator
and/or co-repressor preference and/or availability which can be cell type and tissue
specific). In vitro cytotoxicity, cofactor squelching and substance metabolism can
confound data interpretation. SH ligands can also have rapid nongenomic effects
leading to receptor/co-regulator phosphorylation and nonmonotonic responses.
Similar to SH receptors, inhibition of rate limiting steroidogenic enzymes (delivery
of cholesterol to the inner mitochondrial membrane and P45017α) are more pre-
dictive than enzymes whose activity can be reduced by 95% or more without alter-
ing the rate of SH production. The intact animal leads to an even higher order of
biological complexity where interactions with the hypothalamic-pituitary gonadal
axis can logically lead to nonmonotonic dose responses. Exogenously administered
androgens and the maintenance of spermatogenesis will be used as an example. Low
levels of testosterone have little effect, physiological levels reduce GnRH and LH
production leading to reduced intratesticular levels of testosterone and the conse-
quent inhibition of spermatogenesis and supraphysiological levels restore intrates-
ticular testosterone and maintain spermatogenesis. Discussion of the molecular
pharmacology of SH action will provide the mechanistic basis for examples dis-
cussed by the other speakers.
1594 Mechanistic Requirements for Nonmonotonic Dose-
Response.
R. B. Conolly1,  L. E. Gray1 and G. T. Ankley2. 1US EPA, Research Triangle Park,
NC; 2US EPA, Duluth, MN.
Conolly and Lutz (Toxicol. Sci. 77, 151-157, 2004) noted that “Dose-response
curves for the first interaction of a chemical with a biochemical target molecule are
usually monotonic; i.e., they increase or decrease over the entire dose range.”
Nonmonotonic dose response (NMDR) thus reflects more complex behaviors.
Examples of such complexity include the regulation of cAMP levels in the striatum
of the rat brain by the combined action of adenosine A1 and A2 receptors, dimer-
ization of ligand-bound steroid hormone receptors prior to the promotion of gene
expression, and induction of DNA repair in response to a DNA damaging xenobi-
otic, where the repair activity acts on previously formed endogenous adducts and
on exogenous adducts due to the xenobiotic. Computational models will be used to
illustrate how these relatively simple systems can give rise to NMDR. Interestingly,
for each example, the models show that quantitative adjustments of key parameters
allow for transitions from nonmonotonicity to monotonicity, with an intermediate,
threshold-like behavior. The models that will be described are supported to varying
degrees by relevant data. Full consideration of the ecotoxicological and human
health significance of NMDR will require, among other things, understanding of
the extent to which (1) the frequency with which NMDR occur is a function of the
level of biological organization involved, (2) the nonmonotonic behaviors are
wholly or partially aspects normal homeostatic regulation and, (3) the dose ranges
over which NMDR occur in the laboratory are relevant to actual exposures in the
real world. This work was reviewed by the U.S. EPA and approved for publication
but does not necessarily reflect Agency policy.
1595 Nonmonotonic Dose-Response Curves (NMDRCs) Are
Common after Estrogen or Androgen Signaling Pathway
Disruption—Fact or Falderal?
L. E. Gray. Reproductive Toxicology Branch, NHEERL, US EPA, Research Triangle
Park, NC.
The shape of the dose response curve in the low dose region has been debated since
the 1940s, originally focusing on linear no threshold (LNT) versus threshold re-
sponses for cancer and noncancer effects. Recently, it has been claimed that en-
docrine disrupters (EDCs), which act via high affinity, low capacity receptors, com-
monly induce adverse effects displaying NMDRCs at low doses. Effects that would
be missed in standard EDC screening and multigenerational testing protocols. 
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Case studies of chemicals that disrupt reproductive development and function via
the androgen and estrogen signaling pathways were reviewed, including in vitro
and in vivo multigenerational studies for LNT, threshold and NMDRCs responses.
In vivo studies selected included comprehensive, robust, well designed studies that
administered the chemical via a relevant route of exposure over a broad dose re-
sponse range, including low doses. The chemicals include ethinyl estradiol, estra-
diol, genistein, bisphenol A, trenbolone, finasteride, flutamide, phthalate esters, se-
lective estrogen receptor modulators and inhibitors of aromatase. 
Current conclusions are: 1) EDCs appear to induce some LNT effects. 2)
NMDRCs are biologically plausible and occur frequently in vitro, but the points of
inflection occur at high concentrations that are not relevant in vivo. 3) NMRDCs
appear to be more common a) in short- versus long-term exposures and b) with up-
stream, mechanistic events vs. downstream phenotypic effects. 4) A few adverse ef-
fects of EDCs are non-monotonic, but other effects in these studies displayed mo-
notonic responses at lower dose levels. 5) A number of robust multigenerational
studies of estrogens and antiandrogens showed NMDRCs were uncommon at low
dose levels. 6) Multigenerational Test guidelines can be enhanced on a case-by-case
basis to improve the sensitivity to low dose effects of some EDCs. 7) Additional
data needs to be examined from robust, multigenerational studies using a broad
range of dosage levels for other toxicity pathways. This abstract does not reflect
USEPA policy
1596 Comprehensive Studies Addressing Critical Questions in the
Dose-Response Assessment of Endocrine-Active Compounds.
K. Delclos,  D. R. Doerge,  S. M. Lewis,  M. M. Vanlandingham and
L. Camacho. NCTR, US FDA, Jefferson, AR.
It has been strenuously argued that standard guideline-compliant screening and
testing protocols used to assess reproductive and developmental toxicants are inad-
equate to detect endocrine-active agents due to unique characteristics of the dose
response. In particular, it has been proposed that potentially adverse effects may be
missed by not including low doses that are closer to exposures in the general human
population. Over the past decade, our laboratory has been conducting studies, in-
cluding both multigenerational and chronic exposures, in Sprague Dawley rats that
attempted to address this and other issues (e.g., long term cross generational ef-
fects). Articles tested include the potent estrogen ethinyl estradiol (EE2), the soy
isoflavone genistein, p-nonylphenol, and the weak and ubiquitous estrogen bisphe-
nol A. In addition to covering a range of doses within or close to human exposure
ranges, these studies covered a broad range of endpoints and, importantly, included
measures of internal doses. Knowledge of the serum levels of the test article and its
metabolites allows better understanding of the relationship between the method
and window of exposure and the observed effects. Clear effects on estrogen-sensi-
tive endpoints were observed, but were largely confined to the high end of the dose
range and there was no evidence for unique effects at low doses. Genistein induced
estrogenic effects at an internal dose range achievable in humans. In the case of EE2,
there appeared to be opposite effects on the age of vaginal opening, a marker of pu-
berty, due to low (acceleration) or high (delay) neonatal doses. These studies were
largely focused on endpoints that are typically considered as indicative of adverse ef-
fects for risk assessments. However, questions of whether molecular or other non-
standard endpoints are altered at lower doses or with a different dose response are
also being explored with the goal of evaluating whether such endpoints can enhance
safety assessments of endocrine-active agents. Support: NIEHS/FDA IAG # 224-
12-0003(FDA)/AES12013(NIEHS).
1597 Low Dose and Nonmonotonic Dose-Response Curves for
Endocrine Disruptors.
L. S. Birnbaum. NIEHS, Research Triangle Park, NC.
The incidence of conditions such as diabetes, obesity, asthma, neurodevelopmental,
and reproductive problems has increased substantially in the past 20 years. The
human genome has not changed in that period of time, which leads to the hypoth-
esis that the environment is likely the cause of much of this increase. The endocrine
system is a highly organized system of glands and hormones that regulates vital
functions such as growth, response to stress, sexual development and behavior, pro-
duction and utilization of insulin, metabolism, intelligence and behavior, and the
ability to reproduce. This system can be perturbed by environmental chemicals that
were designed for one effect but have been shown to interfere with endocrine sig-
naling. 
To date, there are over 800 identified endocrine disrupting chemicals
(EDCs) and they are found in many everyday products. Recent evidence shows that
the mechanisms by which EDCs, as well as endogenous hormones, act are much
more intricate than originally recognized. 
One aspect of endocrine disruptors is their ability to cause effects at low
doses. Just as tiny amounts of hormones can have large effects on physiological sys-
tems, tiny amounts of chemicals that mimic hormones can have similar large ef-
fects. A feature related to low dose effects is the non-monotonic dose-response be-
havior of EDCs. In the past, basic toxicology focused on the simple dichotomy of
toxic versus nontoxic, which implies that all substances can be harmful at high
doses while at some lower dose, no harm is done. However, we now know that
EDCs can create physiologically relevant effects at low doses, and these effects can
have a substantial impact on our health. These effects may be beneficial at certain
doses and deleterious at others. This modern understanding of non-monotonic ef-
fects is critical to understanding the behavior of chemical agents and also how re-
sulting health effects may differ based on various exposures.
1598 Understanding Toxicities of Abnormal Lipid Metabolism:
Alcoholic, Nonalcoholic, and Toxicant-Induced Fatty Liver
Disease.
M. S. Mitra1 and M. You2. 1Drug Safety Evaluations, Bristol-Myers Squibb, Mt.
Vernon, IN; 2Department of Molecular Pharmacology and Physiology, University of
South Florida, Tampa, FL.
Accumulation of excess neutral lipids in the liver, referred to as fatty liver disease
(FLD), is a major metabolic disorder and risk factor for development of hepatotox-
icity. It is a progressive disease that initially manifests as reversible fatty liver, which
upon infliction of inflammation advances to a nonreversible steatohepatitis, and fi-
nally leading to hepatic cirrhosis. FLD is generally categorized on the basis of its eti-
ology, the two main types being alcohol-induced steatohepatitis (ASH) and obesity-
induced (nonalcoholic steatohepatitis, NASH). Another class of FLD,
drug/toxicant-induced FLD (TASH), is a major cause of pharmaceutical candidate
attrition. The underlying pathogenic mechanisms of hepatic lipid accumulation
and their implications are not completely understood. In this symposium, recent
advances in the pathogenic role of microRNAs in the development of FLD will be
introduced. The molecular mechanisms by which fatty liver promotes liver injury
will be discussed using examples of drug overdose, hepatic ischemia-reperfusion,
and obstructive cholestasis. Further, the implications of excess hepatic lipid accu-
mulation in regards to altered drug metabolism and cellular uptake will be pre-
sented. The symposium will end with a comparative analysis of novel clinical bio-
markers of ASH, NASH, and TASH. Students, as well as toxicologists working in
academia, federal, and pharmaceutical industries interested in animal models, path-
ogenic mechanisms, biomarkers, and drug metabolism and toxicity of ASH,
NASH, and TASH will benefit from this symposium.
1599 Symposium Introduction—Pathogenesis of Hepatic Fat
Accumulation.
M. S. Mitra. Drug Safety Evaluations, Bristol-Myers Squibb, Mt. Vernon, IN.
The introductory talk will focus on presenting a high level overview of FLD by pro-
viding background information on its pathogenesis. This will include presentation
of epidemiology of FLD and the mechanisms of development of FLD that includes
two stage model of development and progression of fatty liver to steatohepatitis to
cirrhosis. Further, the molecular mechanisms of pathogenesis of FLD in regards to
hepatic lipid uptake and esterification, de novo lipogenesis, fatty acid oxidation,
and export of VLDL-triglyceride will be presented. The presentation will also in-
clude pathology of FLD and review the current scoring systems. The presentation
will also describe the available biomarkers for diagnosis and monitoring FLD.
1600 miR-217-SIRT1 Signaling and Alcoholic Fatty Liver Disease.
M. You. Department of Molecular Pharmacology and Physiology, University of South
Florida, Tampa, FL. Sponsor: M. Mitra.
Alcohol-mediated inhibition of hepatic sirtuin 1 (SIRT1) plays a central role in the
pathogenesis of alcoholic fatty liver disease. Our group has investigated the under-
lying molecular mechanisms of this inhibition by identifying a new hepatic target
of alcohol, microRNA-217 (miR-217). We have found that, in cultured hepato-
cytes and in mouse livers, chronic alcohol administration dramatically and specifi-
cally induced miR-217 levels and caused excess fat accumulation. Our studies have
further revealed that overexpression of miR-217 in hepatocytes promoted ethanol-
mediated impairments of SIRT1 signaling. More importantly, miR-217 impairs
lipin-1, a vital lipid regulator, in hepatocytes. Taken together, our novel findings
suggest that miR-217 is a specific target of alcohol in the liver and may present as a
potential therapeutic target for treating human alcoholic fatty liver disease. This
presentation will discuss the results and implications of these novel findings in the
pathogenesis of alcoholic fatty liver disease.
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1601 Enhanced Susceptibility of Fatty Livers to Drug
Hepatotoxicity and Innate Immune Responses.
H. Jaeschke. Department of Pharmacology, Toxicology & Therapeutics, The
University of Kansas Medical Center, Kansas City, KS.
Steatosis is a risk factor for enhanced liver injury during drug hepatotoxicity and
sterile inflammation. However, the mechanisms of this aggravated liver damage can
vary dependent on the degree of steatosis and the pathophysiology. Steatosis can
trigger microcirculatory disturbances, mitochondrial dysfunction and cause inflam-
mation, which are important contributing factors for the increased susceptibility to
liver cell death. The molecular mechanisms by which fatty liver promotes liver in-
jury in genetic versus diet-induced steatosis models will be discussed in detail using
examples of drug overdose (acetaminophen), hepatic ischemia-reperfusion and ob-
structive cholestasis.
1602 Increased Risk of Drug Toxicity due to Altered
Pharmacokinetics in Nonalcoholic Steatohepatitis.
N. J. Cherrington. Pharmacology and Toxicology, University of Arizona, Tucson, AZ.
Many severe adverse drug reactions occur when a patient is unable to metabolize
and eliminate the standard dose of a drug due to alterations in drug metabolizing
enzymes or transporters. Sources for this inter-individual variability include genetic
polymorphisms or environmental factors such as inflammatory diseases that di-
rectly or indirectly alter the function of the enzymes and transporters that deter-
mine the pharmacokinetics of the drug. This presentation will discuss obesity-re-
lated and other possible sources of inter-individual variation in the transcriptional
regulation, post-translational modification, and sub-cellular localization of specific
drug metabolizing enzymes and transporters, thereby altering the pharmacokinetics
and toxicity of drugs in patients that are at greater risk of adverse drug reactions
1603 Biomarkers and Mechanisms for Steatohepatitis.
C. McClain. Pharmacology and Toxicology, University of Louisville, Louisville, KY.
Steatohepatitis may be caused by toxicants (TASH), obesity (NASH), or alcohol
(ASH) among other causes. Mechanistic similarities and differences appear to exist
between different types of steatohepatitis. We compared serum adipocytokines, cy-
tokeratin 18 (CK18), and antioxidants in human subjects with ASH, NASH, and
TASH. All forms of steatohepatitis were associated with reduced serum antioxi-
dants and insulin resistance (although adipokine levels differed by etiology). ASH
and TASH were characterized by higher levels of pro-inflammatory cytokines.
Likewise, ASH and TASH were associated with increased hepatocellular
necrosis:apoptosis ratios compared with NASH which had a similar ratio to healthy
controls. Lastly, complementary studies in mice showed major interactions between
diet (high fat) and environmental toxins. This presentation will describe these find-
ings and highlight the similarities and differences of novel clinical biomarkers of
TASH, NASH, and ASH.
1604 “Air”-ing on the Side of Caution: Anticipating Impacts of
Emerging Issues in the Health Effects of Air Pollution.
A. K. Farraj. EPHD, NHEERL, US EPA, Durham, NC.
Dramatic reductions in air pollution over the last three decades have largely been
driven by the enactment of federal regulations (e.g., the Clean Air Act in the United
States). Today, policymakers and air quality managers rely on cutting-edge science
to reduce and control air pollution. Toxicology is at the fore-front of this effort pro-
viding critical input on health effects of air pollution including dose-dependence,
the role of constituents and size, mode of action, and relative toxicity of air pollu-
tion sources. Despite these advances, serious adverse health effects including car-
diopulmonary mortality are still measurable at ambient air levels to which millions
of people are currently exposed. Risk assessment of these air sheds is likely to get
further complicated in light of the uncertainty posed by several emerging issues that
intersect air quality and health. Climate change is one such issue that may affect
health via direct effects of weather (i.e., heat and precipitation) and indirectly
through increasing concentrations in ground-level ozone and particulate matter,
two key air pollutants linked to adverse health effects. The burgeoning increase in
obesity and associated metabolic disorders, groups with exaggerated sensitivity to
the adverse effects of air pollution, is likely to aggravate health outcomes. With the
implementation of new fuel standards and increasing popularity of alternative fuels,
it is unclear what impact these changes may have on health effects of traffic-related
emissions. Finally, several methods of power generation, including modern coal
technology, nuclear energy, and hydrofracking have recently captured public inter-
est, yet their impacts on air quality are unknown. This workshop discusses the cur-
rent state of the science including key toxicological findings and recent innovations
as well as challenges in the study of these emerging issues. The workshop concludes
with a prospective look at air pollution research with a discussion session that en-
gages the audience in an effort to define data gaps and potential mitigation strate-
gies.
1605 Health Impacts from Climate Change through Atmospheric
Systems: Recent Findings and Challenges.
M. Bell. Environmental Health, Yale University, New Haven, CT. Sponsor: A.
Farraj.
Climate change is anticipated to exacerbate many existing human health burdens
such as through an increase in the duration and intensity of heat waves and through
accelerated formation of tropospheric ozone. However, many questions on the na-
ture of these impacts remain. This presentation discusses case studies of research on
how atmospheric systems (air pollution, weather) could be impacted by climate
change, thereby affecting human health, and will explore the challenges of this type
of research. The case studies involve linking air quality, meteorological, and climate
modeling to estimate the health consequences from changes in ozone levels in 50
U.S. cities and the mortality impacts from changes in heat waves in Chicago,
Illinois, U.S. Challenges and assumptions of approaches to estimate health impacts
from a changing climate include uncertainty in the various modeling systems (e.g.,
air quality models, climate change models), the use of current day relationships for
weather or pollution and health for future scenarios, the changing distribution of
susceptible subpopulations (e.g., elderly), and adaptive measures (e.g., air condi-
tioning).
1606 Environmental Factors and Cardiometabolic Disease: Signals
in the Air.
S. Rajagopalan. Cardiovascular Medicine, Ohio State University, Columbus, OH.
Sponsor: A. Farraj.
Cardiometabolic diseases represent a pandemic, with the World Health
Organization (WHO) projecting that more than 2.3 billion people will be over-
weight/obese by 2015. Technology innovations, globalization with its free move-
ment of food and services, seismic shifts in agrarian practices coupled with rural-
urban migration, nutritional transition to freely available high-caloric diets have
irrevocably altered energy expenditures during work and leisure. These and other
factors are helping to foster the continued “epidemiological transition” occurring
across the globe. Scientific effort over the last few decades has focused on compo-
nents of urbanization such as inactivity and dietary factors. More recent observa-
tions provide additional links between chronic exposure to environmental factors in
air/water and propensity to diseases. This issue is of importance given the extraor-
dinary confluence of high levels of airborne and water pollutants in urbanized envi-
ronments. Multiple studies in China, India and other rapidly urbanizing economies
demonstrate a steep gradient in urban-rural prevalence. This presentation summa-
rizes recent evidence on how air pollution may represent an under-appreciated yet
critical linkage between urbanization and the emergence of cardiometabolic dis-
eases, with a focus on diabetes mellitus.
1607 Implications of New Fuel Standards and Alternative Fuels on
Traffic Emissions: Insight from the Chemistry and Health
Effects of Soy Biodiesel Emissions.
M. S. Hazari. Environmental Public Health Division, US EPA, Research Triangle
Park, NC.
The environmental impacts of combustion-derived vehicular emissions are well-es-
tablished. In an effort to reduce greenhouse gas (GHG) emissions, improve fuel
economy, and expand the nation’s renewable fuel sector, new standards detailing the
minimum volume of renewable fuel, which includes cellulosic biofuel, biomass-
based diesel, advanced biofuel and total renewable fuel, contained in transportation
fuel sold in the United States were recently proposed. Although it is assumed that
these alternative energy sources will provide a “greener” fuel option, it is still largely
unknown how their combustion emissions will impact human health, particularly
when combined with traditional sources such as gasoline or diesel. Each biofuel has
a unique chemical makeup, which will impact emissions characteristics and poten-
tial toxicity. Thus, this presentation highlights the new 2012 standards for renew-
able fuel, addresses the complexity of emissions arising from the combustion of var-
ious biofuel types, and examines the potential human health implications of
incorporating biofuels into the transportation fuel sold in the U.S. For this last
point, many of the health effects of vehicular air pollution in the last 10 years have
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focused on particulate matter (PM). Recent studies suggest that certain biodiesel
blends contain less PM and may be less toxic. Hence, a recent soy biodiesel study is
discussed with respect to chemical composition and component analysis, and toxi-
cological effects, including cardiovascular, pulmonary and carcinogenic endpoints,
in several rodent models.
1608 Fracking, Coal, and Nuclear Energy: Impacts of
Contemporary Methods of Power Generation on Air Quality
and Remediation Efforts.
J. D. McDonald. Toxicology, Lovelace Respiratory Institute, Albuquerque, NM.
The complexity of the worlds power production needs requires that a number of
approaches be used to generate and distribute power. Natural gas, coal, nuclear, and
other sources are all in play. Each of these energy sources are subject of intense reg-
ulation targeted at mitigating potential air and other contamination, recently in-
cluding mitigation of carbon dioxide. The increase in demand for natural gas has
led to new methods for harvesting and obtaining it, including the controversial
techniques such as fracking. Carbon capture and sequestration offers a number of
engineering challenges, and methods for capturing include potential approaches
that may initiate additional environmental concerns. Of course nuclear energy, es-
pecially considering the recent events in Fukushima, has its own environmental
concerns. This presentation focuses on emerging considerations related to the im-
pact of power generation on air quality. The emphasis will be on coal emissions
(modern vs traditional), carbon capture and sequestration (CCS), and natural gas
(including fracking). Some mention of nuclear concerns will be considered. The
presentation includes recent toxicology data on the health effects of inhaled amines
and their degradation products used in CCS, and data on emissions from coal after
they are atmospherically transformed in the environment and on air contaminants
associated with fracking.
1609 Predicting the Future: Getting Ahead of Problems—A
Presentation and Discussion.
D. L. Costa. Office of Research & Development, US EPA, Research Triangle Park,
NC.
Despite dramatic reductions in air pollution since 1970, the impact of pollutants
on health and the environment remains a concern to both regulators and the gen-
eral public. Studies have not been able to show thresholds of effect for prominent
“criteria” pollutants like particulate matter (PM) and ozone (O3) and much uncer-
tainty remains with air toxic air pollutants that vary across sources. Millions of peo-
ple are exposed to the criteria pollutants, but there are subpopulations which are at
risk due to unusual exposure circumstances or underlying biologic susceptibility or
increasing age. Science continues to chip away at these concerns through human
population studies, and human and animal toxicological studies. But as we look to
the future with increasing national demand for energy and global population and
industrial growth, there is increasing pressure on resources and the atmospheric
reservoir for pollutants. Climate change with its impacts on air pollution chemistry
as well as regional weather is widely thought to be undermining the gains we’ve seen
in reducing the national air pollution burden through challenging environmental
complexities. New technologies, fuels, and ambient pollutant profiles require sys-
tematic assessments and innovative tools if we are to dissect these many interlaced
issues to ensure optimal strategies to protect human and environmental health.
This presentation attempts to draw on what we know and speculate on what we
need to know from our science to forecast both emerging issues and solutions –
preferably preventative – that have been discussed in this workshop. The audience
will be engaged to embellish and enhance this discourse.
1610 Breaking the Routine: Is There Room for Modern
Techniques of Neuropathology Assessment in Routine
Preclinical Safety Studies?
C. D. Toscano1 and J. P. O’Callaghan2. 1FDA/CDER/OND/DNP, Silver Spring,
MD; 2CDC/NIOSH/Neurotoxicology Laboratory, Morgantown, WV.
Neurotoxicity in routine preclinical safety studies is traditionally assessed with three
H&E-stained brain sections; an approach that is not optimal, considering the
brain’s complex neuroanatomy. The need to increase the sensitivity of this approach
is supported by the finding that routine neuropathology assessments would fail to
detect MPTP, ethanol and carbonyl sulfide induced-CNS lesions. Increasing the
number of brain sections sampled and inclusion of additional histology stains have
been recommended but there is no expert consensus on the feasibility of incorpo-
rating modern methods of assessment into routine preclinical safety studies. We
will explore and comment on the adequacy of the traditional approach to neu-
ropathology assessment in routine preclinical safety studies. We will also examine
the current regulatory guidance on neurotoxicity assessment in routine preclinical
safety studies and discuss the feasibility of changing the current approach. Examples
of emerging methods, such as MRI-directed histology and detection of circulating
biomarkers of CNS damage, along with strategies for incorporating these tech-
niques into standard preclinical safety studies will also be discussed. Finally, we will
attempt to build consensus on appropriate approaches for improving the sensitivity
of neurotoxicity assessment in routine preclinical safety studies by fostering a dis-
cussion between the audience and panel members. This discussion will focus on the
feasibility of employing the proposed new markers, endpoints, and approaches and
potential issues with interpretation of results of these studies. In conclusion, we be-
lieve that by examining the adequacy of current approaches of neuropathology as-
sessment, discussing possible improvements to regulatory guidance and presenting
emerging approaches of neurotoxicity assessment that this workshop will allow for
a much needed dialogue on the need and feasibility of improving the current meth-
ods of neuropathology assessment in routine preclinical safety studies.
1611 Routine Neuropathology Analysis for Nonclinical General
Toxicology Studies.
B. Bolon. Veterinary Biosciences, Ohio State University, Columbus, OH.
Microscopic neuropathological evaluation in Good Laboratory Practice (GLP)-type
nonclinical general toxicology studies is one component of a battery of assays per-
formed to assess potential nervous system toxicity of new chemical entities.
Strategies for neuropathological assessment in such studies vary by species and
among different industries and regulatory bodies. A Society of Toxicologic
Pathology (STP) Working Group has recommended the following neuropathologi-
cal strategy as suitable for all GLP-type nonclinical general toxicology studies.
Selected brain areas should be examined routinely: caudate / putamen; cerebellum;
cerebral cortex; hippocampus; hypothalamus; medulla oblongata; midbrain; olfac-
tory bulb (in rodents only); pons; and thalamus. In rodents, these regions can be as-
sessed in 6-7 full coronal sections on 2 standard-size slides; in non-rodents, they
may be evaluated unilaterally in 6-7 standard slides each bearing 1 coronal hemi-
section. Spinal cord (cervical, thoracic, and lumbar regions) and peripheral nerve
(sciatic and/or tibial) should be viewed in longitudinal / oblique and transverse sec-
tions. Current neurohistology practices—immersion fixation in 10% formalin, em-
bedding in paraffin, and initial analysis only of H&E-stained sections—is accept-
able for nonclinical general toxicology studies. These recommendations slightly
expand current practice (i.e., analysis of 3-4 transverse brain sections in rodents) to
improve sampling consistency using available technology. These recommendations
affirm the importance of consistent routine neuropathological evaluation in GLP-
type nonclinical general toxicology studies while acknowledging that histopathol-
ogy is only one component of neural safety testing in such studies. Therefore, insti-
tutions should retain flexibility in devising the neuropathology portion of
GLP-type nonclinical general toxicology studies as long as major nervous system re-
gions are evaluated systematically.
1612 A Regulatory Perspective on the Current State of
Neuropathological Assessments in Drug Development.
R. Mellon. FDA/CDER/OND/DAAAP, Silver Spring, MD. Sponsor: C. Toscano.
Neurotoxicological assessment of drug products is currently accomplished in pre-
clinical studies by evaluation of central nervous system (CNS) safety pharmacology
studies and general toxicology studies, which include simple behavioral observa-
tions and histopathological evaluation of the brain. Histopathological assessments
in routine toxicology studies have identified adverse findings not detected by be-
havioral observation and therefore generate critical safety data. The scientific com-
munity has raised concern that histopathology in routine toxicology studies lacks
adequate granularity for such a complex organ as the brain and therefore may not
be appropriate for initial evaluations nor do they adequately identify when detailed
“second tier” neurotoxicology studies are necessary. For example, the standard sam-
pling and staining approach used in general toxicology studies may not be sufficient
to detect certain CNS lesions (e.g. “Olney” lesions associated with NMDA receptor
antagonists). Adopting an expanded sampling routine, such as the recently pro-
posed Society of Toxicologic Pathology recommendations for the sampling and as-
sessment of the brain in routine safety into Tier 1 testing, would increase the sensi-
tivity of these studies. As there is currently no official CDER guidance on the
assessment of the neurotoxicity of drug candidates, many approaches have been
taken to addressing and reviewing the neurotoxicity of drug candidates; examples of
these approaches and the level of success of such approaches will be provided. A reg-
ulatory perspective of the limitations of the current standard approach and feasibil-
ity of including modern methods of neuropathology assessment will be discussed.
Overall, incorporation of modern methods of neuropathology assessment and im-
proving the documentation of procedures used into the final study reports would
provide greater confidence in the quality of the assessment. Such changes have the
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potential to impact the safety assessment of a drug candidate prior to first-in-
human clinical studies, throughout drug development and as part of post-market-
ing safety assessments.
1613 Utilization of MRI Imaging to Optimize the Selection of
Brain Sections for Assessment by Classical
Neurohistopathology.
J. P. Hanig1,  M. G. Paule2,  J. Ramu2,  L. Schmued2 and S. Liachenko2. 1OTR,
FDA/CDER, Silver Spring, MD; 2Neurotoxicology, NCTR/FDA, Little Rock, AR.
Sampling of 3 coronal brain sections for morphological assessment in routine pre-
clinical toxicology studies is clearly insufficient to reliably characterize all potential
neuropathologies that may be caused by new drug candidates. It has been estimated
that 60 coronal sections would be required to adequately insure that this can be ac-
complished. This is never done in routine safety studies. Using a panel of classical
neurotoxicants, including kainic acid, trimethylin, domoic acid and nitropropri-
onic acid that target different brain areas and structures and that exhibit effects
varying from the massive to the subtle, a method has been developed for using MRI
imaging to complement routine preclinical toxicology studies by allowing for a fo-
cused targeting and selection of candidate sections for histology in the rat. Proof of
concept involves in-vivo MRI scanning to create files that can be compared and
registered with coronal sections of the same brain sample after it has been fixed and
stained appropriately for traditional neuropathology. Validation involves the estab-
lishment of concordance between the loci of pathological manifestation in each of
these imaging approaches. Issues of comparability with respect to sensitivity, tem-
poral equivalence of damage detection and whether MRI signals always predict
morphological damage will be discussed. Successive in vivo MRI scans also allow
subjects to be used as their own controls and for establishing time of onset, devel-
opment and repair of morphologic damage. The MRI information may be used to
optimize time of sacrifice for maximal visualization of traditional neurohistopathol-
ogy. Most importantly, this method, when qualified, could provide guidance on
where in the brain 3 “smart” sections should be taken for classical neuropathology
in support of preclinical drug safety studies. Overall, we show that low resolution
MRI imaging in the intact rat, may represent a powerful biomarker that can inform
classical neurohistopathology assessment, but is not a substitute for it.
1614 Translational Safety Biomarker Assessment of Neurotoxicity.
A. Jeromin. NextGen Sciences DX, Boston, MA. Sponsor: C. Toscano.
Neurotoxic effects of drugs pose a significant hurdle in the drug development
process. Traditionally, neurotoxicity is assessed pre-clinically by classical
histopathology, which has limited translational value for clinical development.
Recent advances in imaging, functional assessment and the identification of fluid-
based biomarkers of neurotoxicity might allow for the nomination of novel transla-
tional safety in neurotoxicity. Ideally, fluid based biomarkers of neurotoxicity de-
tected in either CSF or blood could be combined with histopathology,
high-resolution structural MRI and PET imaging, and other methods to assess neu-
rotoxicity. We have assessed protein-based biomarkers of necrosis and apoptosis in
addition to glial fibrillary acid protein (GFAP), ubiquitin C-terminal hydrolase L1
(UCH-L1), a biomarker of cell body injury and member of the ubiquitin protea-
some system, myelin basic protein (MBP), a demyelination marker, and micro-
tubule-associated protein (MAP-2), a biomarker of dendritic injury, in pilot studies
with known neurotoxicants, including kainate. We developed and employed sensi-
tive and qualified ELISAs to assess this panel of biomarkers. In addition, this data
will be supplemented by existing multiplexed solutions for cytokines to incorporate
inflammatory components in addition to these brain injury biomarkers. Along with
the ELISAs, we have developed and applied multiple-reaction monitoring (MRM)-
based panels of brain biomarkers. These MRM-type assays have shown significant
improvement in sensitivity and allow for the multiplexed assessment of hundreds of
proteins for targeted discovery with a follow-up verification studies on validated as-
says. These multiplexed biomarker panels comprise markers of different pathways,
ranging from inflammation to synaptic changes and have proven to be useful in
identifying neurotoxicity.
1615 Drug Safety Assessment and Regulatory Landscape in
Emerging Markets.
P. Mu1 and G. Krishna2. 1TeamedOn LLC, Rockville, MD; 2Supernus
Pharmaceuticals, Inc., Rockville, MD.
With 85% of world’s population and rapid economic growth, the emerging market
countries are up and coming, and are now actively courted by large global pharma-
ceutical industries. Within the next decade, Asia is expected to overtake Europe in
pharmaceutical sales. For example, China is predicted to be the second largest phar-
maceutical market after the United States by 2015 (Nature Reviews Drug
Discovery, 2010). Many large pharmaceutical companies have increased their pres-
ence in emerging markets for research and discovery, and are seeking to market
their products locally. Due to the short history of innovative pharmaceutical re-
search and development, many of the emerging countries have limited experience
of first hand review of new drugs applications, hence rely mostly on the review de-
cisions taken elsewhere to grant the approval in local markets. However, regulatory
agencies of the emerging countries are working diligently to catch up with the in-
ternational standards and in the process establishing the regulations that address
their country specific needs to promote innovation and bring drugs that are appro-
priately tested to demonstrate safety for their own population. The establishment
and expansion of regulatory agencies functions is creating local job opportunities
for people with specialized skills, to help with the review of various components of
the new drug applications while at the same time presenting challenges never expe-
rienced before due to the nature of innovation. This has sometimes led to regula-
tions that are not well defined and open to interpretation. The drug safety assess-
ment and regulatory landscape in China, India, Korea, and Brazil will be
introduced during the presentations. The similarity and difference of the regulatory
environment in the emerging countries will be compared with the major ICH
guidelines. The challenges and possible solutions for companies seeking regulatory
approval in emerging markets will be discussed. This will also provide an open
forum for regulators from emerging markets to exchange ideas on how to tackle
unique situation they experience.
1616 Framing the Workshop Theme.
S. Goel. Supernus Pharmaceuticals, Inc., Rockville, MD.
Countries in emerging markets are gaining increased focus regarding research and
development activities and regulatory filings to market drugs due to an increase in
consumer demand and rapid growth of their economies. To this end, it is essential
to understand the progress and the intricacies in the regulatory filings among
emerging markets. The speakers of this workshop will address several common
questions on regulatory filing in their respective countries, including 1) The overall
structure of the regulatory agencies and divisions under which various classes of
drugs applications are submitted for reviews, 2) Comparison of various milestones
in regulatory review process, preIND meeting, IND, SPA, end of Phase 2 meeting,
and NDA, 3)Discovery and nonclinical safety studies required to support various
stages of drug development and general comparison with ICH guidelines, 4)
Requirements for country of origin of data, 5) Expertise and composition of non-
clinical reviewers, 6) State of GLP compliance in contract research organizations
within their countries, 7) Language used in regulatory submissions, 8) Regulatory
outcomes and issue resolution.
1617 Current Status of Preclinical Safety Assessment of Drugs in
China.
J. Wang. State FDA (SFDA), Bejing, China. Sponsor: P. Mu.
In China, Ministry of Health had regulated new drug registration and evaluation
from 1949 to 1998. Starting from 1998, State Food and Drug Administration
(SFDA) took over this function. There are three laws in China regulating the drug
evaluation and registration process. In addition, SFDA has published 17 technical
guidance for safety assessment of chemical drugs or biologics and 12 for traditional
Chinese herbal medicines. Currently, in China chemical drugs or biologics are di-
vided into 6 different registration categories. They are (1) investigational drug never
marketed in any country, including synthesis or semi-synthesis; natural sources or
by fermentation; optical isomer; new combination of products, (2) drug with
changed administration route, not marketed both domestically and internationally,
(3) drug marketed outside of China, but not in Chinese market, (4) raw materials
and formulations of drugs with changed acid or alkaline radicals or metallic ele-
ments, but no changes of pharmacology, (5) drug with changed dosing form, but
not administration route, and (6) raw materials and formulations of drugs fitting in
Chinese national standard. Moreover, there are 11 registration categories for tradi-
tional Chinese herbal medicines. Preclinical safety assessments vary according to
the registration categories of new drugs. During early development, investigator de-
velops strategies to determine safety of investigational drug according to the regis-
tration category. In 2003, SFDA officially issued the “Good Laboratory Practice
(GLP) for Non-clinical Laboratory Studies” and required all preclinical safety as-
sessments of drug to be conducted in GLP accredited labs. China has developed its
own unique drug evaluation system, which ensures safe and effective drug products
for patients.
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1618 Regulations and Developments in Safety Assessment of New
Drugs in India.
Y. K. Gupta. All India Institute of Medical Sciences, New Delhi, India. Sponsor: G.
Krishna.
India is emerging as a major center for research and development of new chemical
entities for therapeutic use. The Drug and Cosmetic Rules, 1945 and all its amend-
ments set the foundation for manufacture and sale of drugs. The “Schedule Y” of
the above rule specifies the studies that must be done in animals to establish safety
and efficacy of new drugs prior to trails in humans. However, until recently India
has been a center for manufacture of generic drugs. The Government of India
Ministry of Health and Family Welfare established the Office of Central Drugs
Standard Control Organization (CDSCO) headed by the Drugs Controller
General (India) [DCG(I)] to regulate drug development. The current and up to
date information on CDSCO can be found at http://www.cdsco.nic.in. In March
2011, the DCG(I) formed 12 New Drug Advisory Committee (NDAC) based on
broad categorization of use of drugs on various systems in the body, such as
Reproductive & Urology, Cardiovascular & Renal, Ophthalmology, Vaccines,
Dermatology and Allergy, etc. The NDAC’s consists of expert members to advise
on the matters of review and regulatory approval of clinical trials & new drugs. The
charter for NDACs specifies that the drugs under development should consider rel-
evance to population, innovation, and un-met medical need in India. India is
unique in that it officially recognizes the development and marketing of traditional
medicines (Ayurvedic, Siddha, and Unani drugs) for therapeutic use. India also
prohibits certain drugs for manufacture and sale that it considers detrimental to its
populations health. In India, the regulatory compliance of non-clinical studies is
monitored by National Good Laboratory Practices (GLP) Compliance Monitoring
Authority in Department of Science and Technology of Government of India. The
Indian GLPs are based on the OECD guidelines due to initial close working rela-
tion between OECD countries in audit and GLP certification of Indian CROs.
1619 Safety Assessment and Regulatory Landscape in Korea.
S. Han1 and I. J. Yu2. 1Korea FDA, Osong, Republic of Korea; 2Hoseo University,
Asan, Republic of Korea.
Korea is another major emerging center for research and development of new phar-
maceuticals. The 2011 Pharmaceutical Affairs law had changed the regulations for
manufacture, application, review, and approval of drugs. Korea Food and Drug
Administration (KFDA), similar to US FDA, is a sole regulatory agency governing
manufacture, application, review, approval, and surveillance of drugs. Within
KFDA, the Pharmaceutical Safety Bureau with the Drug Evaluation Department is
responsible for establishment of safety control system for drugs, promotion/support
of the pharmaceutical industry, establishment of standards for the production of
drugs and quality management, approval screening for drugs, and collection and
evaluation of information on the side effects of drugs. Biopharmaceutical & Herbal
Medicine Bureau and Medical Device Safety Bureau have similar roles in the rele-
vant areas. As the research and development institute under KFDA, NIFDS
(National Institute of Food and Drug Safety Evaluation) has played the key role in
comprehensive research that is necessary for food and drugs regulation in Korea. It
has been instrumental in the development and evaluation of toxicological and phar-
maceutical methods. Center for Drug Development Assistance in KFDA supports
for new drug R&D and regulatory affairs. The nonclinical safety studies at various
stages of development are required according to ICH guidelines. Korean GLPs are
based on the OECD GLP principles as a member country of OECD and Korean
CROs have been frequently monitored jointly by three GLP authorities: KFDA,
Rural Development Administration (RDA), and National Institute of
Environmental Research (NIER).
1620 Regulatory Developments in Brazil to Address Market
Needs.
D. Barbano. Brazilian Health Surveillance Agency (ANVISA), Brasília, Brazil.
Sponsor: S. Goel.
In Brazil, for registration purposes, the medicines are classified in different cate-
gories, such as synthetics, biologics, phytotherapeutics. Synthetic medicines are
classified as new, generic and similar. Each category of medicine is regulated by spe-
cific resolution, and its registration is granted for five years. The registration must
be renewed by resubmitted the drug for evaluation at the end of each five year pe-
riod. The registration of biological products is regulated by ANVISA since 2002.
Due to the recent expiration of several patents for innovative biotechnology prod-
ucts, the interest in the production and sale of copies of these products is growing
in Brazil. The regulatory framework for registration of biological products, (includ-
ing new molecules or copies), was established in Brazil in December 2010 with the
publication of RDC No. 55/2010. For development of this technical regulation,
the regulatory frameworks and guidance’s of different agencies in the world were
considered, including Health Canada (Canada), European Medicines Agency
(EMA, Europe), CECMED (Cuba), and WHO Similar Biotherapeutic Products
(SBP) guidelines. New Biological Products must be registered by the classic and
regular manner, with the presentation of complete dossier, containing all the pro-
duction, quality, non-clinical and clinical data. The non-innovative biological prod-
ucts can be registered with reduced information. ANVISA is actively developing
new resolutions to fill old regulatory gaps to support development of biological
products. The regulatory developments at ANVISA in relation to emerging needs
of Brazil will be presented.
1621 Workshop Summarization and Question and Answer
Session.
G. Krishna. Supernus Pharmaceuticals, Inc., Rockville, MD.
Drug safety assessment around the globe is evolving. With the introduction of
International Conference on Harmonization (ICH) guidelines, most emerging re-
gions are trying to learn and adapt to the new expectations and processes. Drug in-
dustry scientists and the regulatory agencies are coming together and working dili-
gently in the hopes of making a difference in the “waiting” patient. To this end, the
workshop on Drug Safety Assessment and Regulatory Landscape in Emerging
Markets is expected to answer multiple questions on the dynamics of evolving sci-
ence, regulations, and processes based on the experiences from the more established
markets/regions verses the individual interpretation and application of guidelines in
the emerging markets. The Question and Answer session would provide an oppor-
tunity to deliberate current thinking on the subject and summarize the thoughts.
1622 Cell-Level Model of Morphogenetic Tissue Fusion for
Computational Toxicology.
M. Hutson1 and T. B. Knudsen2. 1Physics & Astronomy, Vanderbilt University,
Nashville, TN; 2NCCT, EPA, Research Triangle Park, NC.
Vertebrate development is replete with instances of tissue fusion in which two tis-
sues – each with its own complement of mesenchymal and epithelial cells – meet,
adhere and eventually fuse into a seamless mesenchyme and epithelium. Such fu-
sion is critical for proper morphogenesis of multiple organs, with failure implicated
in several developmental defects: cleft lip/palate; closure defects of the neural tube;
omphalocele (body wall); coloboma (optic cup); and hypospadias (urethra). Some
of these defects are context-dependent – e.g., instances of cleft palate caused by fail-
ure of the palatal shelves to elevate, or hypospadias concomitant with impaired
growth of the genital tubercle. Nonetheless, there is mounting evidence for fusion-
specific defects (e.g., Pallister-Killian syndrome and VACTERL association).
Furthermore, a predictive model built from ToxCast Phase-I data and ToxRefDB
mapped cleft palate to Gene Ontology terms for diverse biological processes (bal-
anced accuracies of 0.66-0.76): negative regulation of epithelial cell proliferation;
epithelial-mesenchymal transitions (EMT); TGFβ2 production and type-II TGFβ
receptor binding; and neural crest migration. We have thus constructed a cell-level
computational model of tissue fusion that incorporates cellular adhesion and vis-
coplasticity with paracrine/juxtacrine control of proliferation, apoptosis, EMT and
cell migration. The model includes three growing tissues – only two of which nor-
mally fuse – to explicitly model failures of both fusion competence and specificity.
As a first demonstration, we model secondary palate fusion by tuning the relative
contributions of apoptosis, EMT and cell migration to match dissolution of the
midline epithelial seam. This flexible model is a platform for computational toxi-
cology that can elucidate the varying interplay of such cell behaviors in the normal
course of different tissue fusion events and their role in differential susceptibility to
chemical disruption. [This work does not reflect EPA policy].
1623 Investigating Adverse Outcome Pathway Models for
Mitochondrial Toxicity.
M. L. Patel,  S. Canipa and D. Portinari. Lhasa Limited, Leeds, United Kingdom.
Sponsor: C. Marchant.
Adverse Outcomes Pathways (AOPs) are used to describe the steps of a chemical in-
teracting with a biological system from the subcellular to population level of obser-
vation. We investigated the published literature to develop qualitative AOPs for ox-
idative phosphorylation by mitochondria.
Literature searches were carried out to identify chemicals and potential mechanisms
of inhibition for each of the complexes of the electron transport chain (ETC) and
for ATP synthase. Compounds for which sufficient experimental data could be lo-
cated were then used to build plausible mechanistic pathway maps.
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A dataset of over 200 compounds covering experimental data in a number of rele-
vant screens (measuring individual complex activity, cellular ATP levels, reactive
oxygen species (ROS) generation, oxygen consumption, mitochondrial membrane
potential and cytotoxicity) was constructed. Seven model compounds were identi-
fied as having sufficient data and plausible mechanistic evidence to construct AOPs.
The compounds used were: Rotenone, Thenoyltrifluoroacetone, 3-Nitropropionic
acid, Antimycin A, Myothiazol, and Cyanide for mapping the ETC pathway, and
Oligomycin A for ATP synthase. Using these representative model compounds an
AOP was mapped for each complex from the molecular initiating event (MIE) to
effects at the cellular level. The AOPs for inhibition of complexes of the ETC were
then combined to create a single pathway.
We report the construction of AOPs for oxidative phosphorylation in mitochondria
and their speculative extrapolation to in vivo endpoints such as cardiotoxicity, neu-
rotoxicity and hepatotoxicity. The AOP maps are described in terms of the normal
physiological pathway processes and potential intervention points, with reference
to experimental in vitro assays which were used to support the elucidated steps. Not
all compounds with mitochondrial effects may go on to display in vivo toxicology.
An AOP view of such pathways is an useful construct in providing information in a
form suitable for assessing outcomes relevant to risk assessment.
1624 Interactive Data Mining of Toxicogenomics and In Vivo
Toxicity Databases Using Chemotypes to Improve Chemical-
Disease Prediction Inferences and Mode-of-Action QSAR
Models.
A. Mostrag-Szlichtying1,  C. Yang1,  J. Rathman1, 2,  C. Mattingly3,  A. Davis3,
A. Planchart3 and A. M. Richard4. 1Altamira, LLC, Columbus, OH; 2The Ohio
State University, Columbus, OH; 3North Carolina State University, Raleigh, NC; 4US
EPA, Research Triangle Park, NC.
The Comparative Toxicogenomics Database (CTD, http://ctdbase.org) aims to
shed light on the connection between chemical exposures and human health out-
comes by inferring relationships via integration of curated chemical-gene, gene-dis-
ease and chemical-disease data from the scientific literature. Independent of CTD,
structural knowledge via chemotypes, features linking chemicals to phenotypes, has
been developed based on in vivo studies from toxicity databases, including regula-
tory sources at the US EPA and the US FDA. A chemotype is defined as a chemical
substructure annotated with atom/bond properties that carry biological activity in-
formation. We explored whether the chemical-disease links in CTD could con-
tribute to the further development of chemotypes, and whether mode-of-action
Quantitatve Structure Activity Relationship (QSAR) models for toxicity endpoints
built around chemotypes could be used to validate CTD disease inferences or fur-
ther delineate phenotypic effects. We applied a set of previously developed MOA
models and chemotypes, e.g., for cleft palate, to the data found in CTD. Many of
the same chemotypes (representing attributes of glucocorticoids, retinoids, cona-
zoles, dioxanes, and phthalic esters) were found to be associated with cleft palate in
CTD, either by direct curation or inferred via common interacting genes. The
structural feature space enriched with cleft palate chemotypes was highly populated
by the chemicals deemed associated with this condition in CTD. This work
demonstrated how interactive data mining between CTD and in vivo toxicity data-
bases with chemotype probes can improve the predictive power of gene-disease and
chemical-disease associations, as well as the MOA models; also described is how
these associations can be tested experimentally. This abstract does not reflect EPA
policy.
1625 Cheminformatics Analysis of Compound-Cytochrome P450
Interaction Profiles.
D. Fourches1,  M. Elias2,  E. Muratov1,  L. Sheppard3,  P. Bradley3,  J. Reed3 and
A. Tropsha1. 1University of North Carolina at Chapel Hill, Chapel Hill, NC; 2The
Hebrew University of Jerusalem, Jerusalem, Israel; 3Instem Scientific, Cambridge,
United Kingdom. Sponsor: I. Rusyn.
Only five isoforms (1A2, 2C9, 2C19, 2D6, and 3A4) of Cytochrome P450 (CYP)
enzymes are responsible for the metabolism of the vast majority of drugs. Beyond
knowing what drugs are metabolized by a specific isoform and the subsequent
metabolites, it is of critical importance to evaluate the CYP inhibition potency of a
compound for predicting its most likely CYP-related adverse effects. In this study,
our objective was to integrate, analyze, and model the growing compendium of
publicly-available CYP-related datasets for these five isoforms using cheminformat-
ics approaches: INSTEM (4,676 compounds) was obtained as assertional meta-
data generated from MEDLINE abstracts; SUPERCYP (678 compounds) ex-
tracted from the online webportal; NCGC (16,142 compounds) is a compilation
of qHTS screening results released by the NIH Center for Translational
Technologies. After chemical curation and duplicates’ analysis, we have analyzed
these datasets using cheminformatics approaches and addressed questions pertain-
ing to: (i) the chemical concordance between the different isoforms illustrating the
singularity of 1A2 and the tight 2C9:2C19 coupling, (ii) the identification of com-
pounds being simultaneously potent and selective for a particular CYP isoform;
compounds with selective CYP profiles found in the INSTEM database were ex-
perimentally confirmed in the NCGC screening, and (iii) the detection of erro-
neous database entries by performing neighborhood analysis using chemical simi-
larity calculations. We have aimed to achieve and test robust predictors of CYP
interaction profiles by building Quantitative Structure-Activity Relationships
(QSAR) models for each isoform. To further benchmark our QSAR models (solely
based on two-dimensional structures of chemicals), we docked our integrated CYP
database into the CYP binding pockets using their crystal structures. We show how
QSAR models and docking approaches can be used in synergy to predict CYP in-
teraction profiles of drug candidates.
1626 Mechanistic Analysis of Welding Aerosol Toxicity Using
Ingenuity Pathway Analysis (IPA).
S. Tugendreich1,  N. Ng1,  P. C. Zeidler-Erdely2,  J. M. Antonini2,  M. L. Kashon2
and A. Erdely2. 1Ingenuity Systems, Redwood City, CA; 2NIOSH, Morgantown, WV.
Welding involves occupational exposure to an aerosol containing gases and metal-
rich particulates that induce adverse physiological effects including inflammation,
immunosuppression, and cardiovascular dysfunction. To develop a deeper mecha-
nistic understanding of these adverse effects, mice were exposed by inhalation to gas
metal arc-stainless steel (GMA-SS) welding fume at 40 mg/m3 for 3 hr/d for 5 d a
week for 2 weeks followed by gene expression analysis of whole blood cells, aorta,
and lung at 4 hr and 28 d post-exposure. New features in Ingenuity Pathway
Analysis (IPA) were used to analyze the expression data. The analysis results estab-
lish the importance of interferons and the IRF-family of transcription factors, pre-
dicting that they are activated at 4 hours and maintained through 28 days in both
blood and lung. The IPA Upstream Regulator Analysis also predicted involvement
of several toxicants, such as nickel and ozone, which have been detected in welding
aerosol thereby highlighting the utility of Upstream Regulator Analysis for toxi-
cogenomics applications. In addition, as an important drug discovery tool, IPA pre-
dicted several compounds that might be useful to ameliorate the inflammatory phe-
notype. One such compound was LY294002, a PI3K inhibitor that has already
been shown to be efficacious in a mouse model of asthma. The new Mechanistic
Network Analysis in IPA was used to computationally construct a plausible hy-
pothesis that TRIM24 inactivation may lead to activation of IRF7 and STAT1 and
other upstream regulators to drive the gene expression profile after the first expo-
sure. Finally, Downstream Effects Analysis in IPA predicted large increases in pro-
liferation, chemotaxis, and trafficking of immune cells in the lung after 4 hours. In
summary, IPA has a unique new set of capabilities to enhance the mechanistic un-
derstanding of toxicological datasets and to provide support for new hypotheses
that can be tested in the lab.
1627 Insights into the TBX2 Role in Cellular Senescence in
COPD: A Bayesian Structure Learning Approach.
U. Tran and G. Acquaah-Mensah. Massachusetts College of Pharmacy and Health
Sciences, Worcester, MA.
COPD ranks among the top leading causes of death worldwide. The transcriptional
factor T box 2 (TBX2) plays an important role in the COPD molecular etiology. A
senescence hypothesis for the etiology of COPD has emerged. TBX2 and related
genes have anti-senescence activity. Their expressions are suppressed in COPD, but
elevated in many cancers. The purpose of this study was to identify the directional-
ity of regulatory relationships between TBX2 and other genes involved in cellular
senescence. From a compendium of lung epithelium cell microarrays generated
using the Robust Multi-Array Average procedure, a subset of genes of interest was
used for structure learning. The Bayesian Network Structure Learning approach
was then used to learn the regulatory relationships. The Bayesian Network
Inference with Java Objects toolkit (Banjo) was used, in each instance, to generate
the single best-scoring direct acyclic network, given the gene expression data. In
order to focus the large search space, an initial network of genes that TBX2 interacts
with including ANF, NKX2-5, NDRG1, CDNK1A, PML, E2F, CDKN2A, and
CDKN2B was identified. Simulated Annealing and Greedy Search were the net-
work search algorithms used. The results predicted that TBX2 regulates both
COL4A3 and PML. Reports in the literature confirm that TBX2 interacts with
both COL4A3 and PML. Subsequently, the original known network was updated
with these two interactions, and a new iteration of the learning procedure initiated.
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As part of this new iteration, the compendium subset with expression data of genes
of interest was updated to include senescence related genes. The results identified
new TBX2 interaction partners including WNT3, WNT6, WNT7B, WNT11,
IL12RB1, IL13, IL13RA1, IL27RA, CTNND1, E2F4, and FOXO3.The pub-
lished literature, a functional map scoring relationships based on microarrays from
over 15000 publications (HEFaLMp), as well as entries in a cis-regulatory elements
database (cREMag) were utilized to validate the results. Thus, the results affirm the
importance of TBX2 in the COPD etiology.
1628 Prediction of Metabolites Using Computational Approaches.
M. Kansy1,  L. T. Anger1,  U. Gundert-Remy2 and A. Brigo1. 1Non-Clinical Safety,
F. Hoffmann-La Roche Ltd., Basel, Switzerland; 2Institute of Clinical Pharmacology
and Toxicology, Charité University Medical School Berlin, Berlin, Germany.
An increasing number of computational tools are nowadays available, which are
claimed to predict drug metabolism. Those tools could most probably be used in an
extended way to consider potential drug metabolites earlier in toxicity prediction of
for example.genotoxicity or carcinogenicity. Therefore it’s important to understand
the quality and limitations of metabolism prediction tools if applied in a broader
context. However, to date, the software packages used in metabolism prediction
have only been validated with relative small datasets containing limited number of
compounds. Hence, they require a more comprehensive and explorative evaluation.
Aim: Meteor (Lhasa Ltd., Leeds, UK), an available prediction tool, has been used to
predict the metabolites of 325 drugs in therapeutic use. The results of the predic-
tion were compared to the known human metabolites.
Methods: The WHO ATC index was used to extract drugs for the therapeutic
classes of antiinfectives (A07E, M01A, S01BA, G02CC, M02AA, S01BC), central
nervous system drugs and muscle relaxants (N, M03), cardiovascular drugs (C), on-
cologic substances (L01) and virustatics (J05, D06BB, S01AD). Additional infor-
mation was received by queries in the DrugBank database. PharmaPendium and
DrugBank were the sources to obtain information on the human metabolites of the
therapeutic drugs observed in clinical studies.
Meteor (version 13.0.0, Lhasa Ltd.) is a so called knowledge-based expert system.
As such it uses structured expert knowledge and its output offers the structures of
metabolites with a guess on the probability of the occurrence of the metabolite.
The evaluation shows that the reliability of the prediction of human metabolites is
presently limited. Hence, further development is necessary to improve the predic-
tion potential.
1629 Comparison of Microarray and RNA-Seq for Gene
Expression Analyses of Dose-Response Experiments.
M. B. Black1,  E. Healy1,  B. B. Parks1,  L. Pluta1,  T. Chu2,  R. D. Wolfinger2 and
R. S. Thomas1. 1The Hamner Institutes for Health Sciences, Research Triangle Park,
NC; 2SAS Institute, Cary, NC.
Relative to microarrays, differential gene expression analysis using RNA-Seq data
has been reported to offer higher precision estimates of transcript abundance, a
greater dynamic range of transcript detection, and detection of novel transcripts.
However, appropriate methods of analyzing RNA-Seq data and the number of
reads required to match the sensitivity of microarrays are still a subject of debate.
Moreover, comparisons of the two technologies have not covered dose-response ex-
periments that are relevant to toxicology. Male F344 Rats were exposed for 13
weeks to 5 concentrations of bromobenzene. RNA was extracted from livers of five
animals per dose level and used for measuring gene expression changes using both
Affymetrix HT RG-230 PM microarrays and ABI SOLiD 50bp single read RNA-
Seq. Sequencing produced an average of 9.3M reads per sample mapping to exons.
The sequencing data was normalized using RPKM (Reads Per Kilobase per
Million) and the microarray data was normalized using RMA. A standard one-way
ANOVA was used to analyze the data across doses. Results were compared based on
statistical significance (FDR<0.05) and fold change (FC>±1.5) for 5,906 genes
which had read counts >10 and matched unambiguously to genes on the microar-
ray. The results showed that paired fold-change values were highly correlated be-
tween microarrays and RNA-Seq, while the –log p-values showed little correlation.
Random sampling at different read depths showed that RNA-Seq and microarrays
produced similar numbers of significant genes based on fold-change (FC ±1.5) at
~6-8M mapped reads per sample. However, RNA-Seq produced significantly less
significant genes based on p-value (FDR < 0.05) at even the highest read depth of
9.3M mapped reads per sample. Among the significant genes, ~50% overlapped be-
tween RNA-Seq and microarrays at each dose. The results highlight the need for
additional studies examining the use of RNA-Seq data in toxicology.
1630 The Symbiosis of Mentoring: Getting the Most out of the
Mentor-Mentee Relationship.
B. Hannas1,  N. J. Walker2,  S. H. Safe3,  E. W. Carney4 and O. Olivero5.
1Reproductive Toxicology Branch, US EPA, Research Triangle Park, NC; 2NTP,
NIEHS, Research Triangle Park, NC; 3Molecular & Cellular Medicine, Texas A&M
University, College Station, TX; 4The Dow Chemical Company, Midland, MI;
5Laboratory of Cancer Biology & Genetics, National Cancer Institute, Bethesda, MD.
Mentoring is a critical element in the career development of all toxicologists, both
in terms of making the most of potential mentors and developing effective mentor-
ing skills. Whether through involvement in academia, or helping to develop the ex-
pertise of an early-career scientist, most toxicologists will provide mentoring at
some point in their career. The mentor role serves to transfer knowledge, give ad-
vice and provide support to a trainee or developing scientist, while the mentee is re-
lied upon by the mentor to provide active participation and input into the relation-
ship. According to national polls, as well as SOT-specific surveys, one of the
resounding topics of interest for developing scientists is mentoring from the broad
perspectives of choosing the right mentor, down to developing the skills to become
a sound mentor. Therefore, this session was designed to complement existing men-
tor matching opportunities offered through SOT. Speaker presentations will focus
on: (1) the fundamentals of mentoring, including the different situations and roles
in which the mentee-mentor dynamic may be encountered; (2) an introduction to
the most commonly used mentoring techniques; (3) identifying characteristics of a
strong mentor-mentee relationship; and (4) mentoring towards the future of sci-
ence and the challenge to overcome more complex scientific problems. Speaker per-
spectives will address the mentorship role within academia, government, and in-
dustry. Attendees of this session will learn to identify a healthy mentor-mentee
relationship and understand the benefits to each member of the collaboration.
Mentoring topics discussed in this session will be applicable to scientists at every ca-
reer stage through highlighting the basics behind a strong, mutually-beneficial
mentoring relationship.
1631 Role of Systems Biology in Characterizing Risk of
Developmental Origins of Disease.
D. T. Szabo1 and T. L. Palenski2. 1National Center for Environmental Assessment,
US EPA, Arlington, VA; 2Molecular and Environmental Toxicology, University of
Wisconsin Madison, Madison, WI.
Systems biology is the study of complex interactions of biological components,
such as nucleic acids, proteins, chemical reactions, cells, and whole organisms, at
multiple levels of organization. The National Research Council recommends im-
plementing the use of systems biology approaches in the risk assessment process.
While recent advances have been made to prioritize chemicals for further screening,
to better understand mode of action, strengthen weight-of-evidence, and eventually
replace traditional in vivo animal model data with in vitro and in silico methods,
these data have not been systematically considered in mainstream approaches for
risk assessment which also largely focuses on adult populations. The goal of this
symposium is to consider emerging knowledge and information from systems biol-
ogy to inform risk assessment and decision making in the arena of developmental
origins of disease. Growing evidence suggests that chemical exposures in early life
can have immediate and long-term effects on the structure and function of organ
systems, leading to the development of disease later in life. Systems biology ap-
proaches can aid in understanding molecular, cellular, metabolic, and morphologi-
cal changes resulting from such exposures. These approaches, which include analy-
sis of complex data sets from multiple experimental sources, interdisciplinary
‘omics tools, and computer simulation modeling, are increasingly being applied to
better understand developmental origins of disease. We will present current systems
biology approaches on how to better identify developmental origins of disease and
its implications to the risk assessment process through several case studies.
1632 Predictive Models of Developmental Toxicity.
N. S. Sipes and T. B. Knudsen. National Center for Computational Toxicology, US
EPA, Research Triangle Park, NC.
Environmental chemical exposure during development can lead to birth defects
which can have lasting effects through adulthood. In vivo data from both rodent
and non-rodent species gathered using standardized prenatal guidelines are used in
risk assessments to determine developmental toxicity potential; however these stud-
ies may not indicate the underlying complex mechanisms which lead to develop-
mental toxicity. We used a systems biology approach to develop predictive models
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that link in vivo outcomes (including malformations, fetal weight reductions, and
prenatal loss) with potential mechanisms of toxicity. This approach uses in vivo
data from guideline and literature studies and over 3 million in vitro data points
from high-throughput and high-content screening techniques on chemical-biolog-
ical interactions. Specifically, these assays are obtained from biochemical, cell-free
and cell culture assays, along with embryonic stem cells and zebrafish embryos. The
predictive models developed confirm known pathways, such as retinoic acid recep-
tor and transforming growth factor, and suggest novel pathways such as G-protein-
coupled receptors and inflammatory pathways to be important pathways involved
in developmental toxicity of environmental chemicals. These models have the po-
tential to aid in the prioritization of chemicals for further targeted toxicity testing
and risk assessment, to generate hypotheses about mechanistic pathways leading to
adverse developmental outcomes, and to reduce cost and increase throughput of
chemical testing.
1633 Multiple Organ-Omic Integration for HBCD Developmental
Neurotoxicity Hazard Identification.
D. T. Szabo1 and L. S. Birnbaum2. 1National Center for Environmental Assessment,
US EPA, Arlington, VA; 2NIEHS/NCI, Research Triangle Park, NC.
Exposure to environmental chemicals during critical windows of development has
shown to disrupt adult neurobehavioral function; however, the mode-of-action is
not always well understood. A systems biology approach was taken to identify toxi-
city pathways after exposure to the major brominated flame retardant mixture,
hexabromocyclododecane (HBCD), along with the individual chemicals that make
up the commercial mixture to better characterize developmental neurotoxicity,
strengthen its overall weight-of-evidence, and support its hazard identification for
risk assessment. Short-term disruptions to the developmental profile of genes, pro-
teins, and metabolites in the hippocampus, liver, and systemic circulation were
identified after exposure to the commercial mixture and individual stereoisomers.
Different molecular pathway profiles generated in several organs suggest the neces-
sity to assess the effects from the individual isomers as well as the mixture when
evaluating HBCD and can be used as a model for other environmental mixtures for
chemical risk assessment. This presentation will demonstrate the utility of an omics
and systems biology strategy to capture information on various facets of brain de-
velopment that can be altered after environmental exposures and to provide focus
for further toxicity studies in determining possible modes-of-action including
methods to prioritize individual chemicals in mixtures for chemical risk assess-
ments.
1634 Assessing Antiandrogenic Effects of In Utero Exposure to
Dibutyl Phthalate and Other Xenobiotics.
D. Spade and K. Boekelheide. Department of Pathology and Laboratory Medicine,
Brown University, Providence, RI.
The rates of male reproductive tract malformations such as cryptorchidism and hy-
pospadias have increased in the United States throughout the latter half of the 20th
century. These disruptions in androgen-sensitive development may be influenced
by early life exposures to environmental anti-androgens. However, determining the
impact of exposure on human fetal development is hindered by species differences
and a lack of human data. Using a fetal testis xenograft model, we have shown that
human fetal testis is more resistant than fetal rat testis to the anti-androgenic effects
of dibutyl phthalate (DBP). We are expanding this analysis to determine how envi-
ronmental anti-androgens affect human fetal testis, particularly through alterations
in gene expression and DNA methylation. To provide a baseline for this analysis, 12
unimplanted human fetal testis samples aged 14 to 23 weeks gestation have been
evaluated using Affymetrix Human Gene 1.0 ST gene expression microarrays and
the Illumina Infinium 450k methylation arrays to reveal developmental trends in
fetal testis gene expression and DNA methylation. This will provide a baseline for
ongoing analysis of xenografted tissues after exposure to anti-androgens.  During
this window, global testis DNA methylation increases significantly, although not at
all genes. DNA methylation at imprinted sites consistently increases throughout
this time frame, and there are significant changes in DNA methylation of genes re-
lated to testosterone biosynthesis, cell cycle, and transcriptional control. Therefore,
reprogramming of testis DNA methylation during this developmental time period
aligns with the existing data in mouse, and suggests that this window may be sensi-
tive to disruption by xenobiotics. Assessing the anti-androgenic effect of various en-
vironmental compounds in human systems is essential for determining the risk that
environmental chemicals pose for the in utero development of the male reproduc-
tive system, including understanding the fetal origins of disorders of the male re-
productive tract.
1635 Mechanistic Pathways Underlying Low-Dose PFOA Effects
on Mammary Gland Growth.
M. B. Macon1 and S. E. Fenton2. 1Curriculum in Toxicology, University of North
Carolina at Chapel Hill, Chapel Hill, NC; 2National Toxicology Program, NIEHS,
Research Triangle Park, NC.
Perfluorooctanoic acid (PFOA) is a synthetic surfactant and, in areas of high con-
tamination in the US, has recently been found to have a probable link to several
human diseases. Prenatal exposure to PFOA causes delayed mammary gland
growth in female mice. Exposure to low levels of PFOA throughout gestation re-
sults in persistent mammary gland abnormalities in female offspring that remain
until late in life. Although activation of peroxisome proliferator activated receptor
alpha (PPARα) is thought to mediate PFOA-induced liver toxicity, the role of this
transcription factor in the mammary gland is unclear. Genome-wide microarray
analysis, protein expression approaches, and morphological analysis were used to
identify molecular mechanisms involved in mammary gland delays following pre-
natal PFOA exposure. Our studies followed female mice exposed to environmen-
tally relevant levels of PFOA in utero spanning neonatal time-points to late adoles-
cence. Through analysis of whole mammary tissues and isolated cell types, it was
found that PFOA altered pathways involved in epithelial-stromal interactions, in-
cluding endocrine disruption, leaving the mammary gland more susceptible to the
development of disease. The dosing levels of PFOA used in our studies produce
body burdens in mice that are similar to those found in humans living in highly
contaminated areas, therefore, these finding have implications related to the human
risk assessment of PFOA.
1636 Molecular Mechanisms Linking Maternal Diet-Induced
Obesity to Offspring Metabolic Syndrome.
M. Alfaradhi and S. Ozanne. Metabolic Research Laboratories, University of
Cambridge, Cambridge, United Kingdom. Sponsor: D. Szabo.
Population studies have suggested that the maternal nutritional status during key
stages of development is able to influence offspring risk of metabolic diseases.
Recent focus has been on maternal over-nutrition and obesity in programming
metabolic disorder in offspring. This stems from human data which has correlated
maternal body-mass index (BMI), maternal weight gain during pregnancy, and ges-
tational diabetes to offspring BMI and risk of metabolic disorders such as type 2 di-
abetes. A large number of studies have reported dysregulation of key organs in-
volved in glucose homeostasis and feeding regulation in the offspring of obese
mothers. We have utilized a mouse model in which dams are fed a western-style diet
(highly palatable, high-fat, high-sugar diet) during gestation and lactation and
taken a whole systems approach to establish mechanisms through which metabolic
disease in the offspring arises. Our studies incorporate analysis at the whole body,
tissue and cellular level. Offspring of these dams are hyperphagic from a young age,
leading to increased body weight and the development of type 2 diabetes later in
life. Hyperinsulinaemia is an early observation in these offspring compared to off-
spring in the control group fed regular chow and we have associated this with im-
paired insulin signaling protein expression, especially in adipose tissue. We have
employed both candidate and genome-wide mRNA and microRNA array ap-
proaches to explore the mechanisms by which the programmed changes in insulin
signaling protein expression occurs and to identify novel genes and regulatory ele-
ments that are associated with metabolic disorders in the offspring. These findings
have important implications for the identification of markers of disease risk and
identification of susceptible populations to adverse effects resulting from sub-opti-
mal early life exposures.
1637 Toxicoepigenomics, Disease Susceptibility, and Implications
for Risk Assessment.
K. Kutanzi1 and M. Verma2. 1Biochemical Toxicology, National Center for
Toxicological Research, US FDA, Jefferson, AR; 2Division of Cancer Control and
Population Sciences, National Cancer Institute, NIH, Bethesda, MD.
In the past, classical toxicology has largely focused on the genotoxic effects of envi-
ronmental toxicants and chemicals. Recent studies have clearly indicated that envi-
ronmental chemicals, along with their genotoxic abilities, can cause epigenetic al-
terations that, in concert, may lead to the development of a number of pathological
states. The field of toxicoepigenomics has since emerged from the combination of
epigenetics, which studies the methylation of DNA, histone modifications, and
chromatin condensation, and toxicology. During the last few years, excellent
progress has been made in detecting altered epigenomic profiles in response to var-
ious chemical insults. Future investigations, however, are needed to link chemical
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exposure to epigenetic alterations which develop over time, and, in turn, may in-
crease the risk of disease. Although whole populations may be exposed to toxic sub-
stances, only a few people develop the disease, which may, in part, be due to the dif-
ferent epigenomic backgrounds of individuals. That is why the potential role of
epigenetics in disease susceptibility, along with the potential opportunities for epi-
genetic biomarkers in the assessment of toxicity and carcinogenicity of chemicals
have received a lot of attention recently. Specifically, the following key aspects need
to be addressed: 1) How stable are the epigenetic alterations induced by environ-
mental toxicants?; 2) What periods of development across the lifespan are windows
of vulnerability and/or opportunity for an altered epigenome?; 3) How can expo-
sure to toxicants in utero affect the epigenome and predispose individuals to various
diseases throughout life?; 4) Are there methodological and measurement gaps to be
filled to advance our understanding of toxicoepigenomics?; and 5) How can we de-
velop risk prediction models? Evidence that epigenetic alterations can be potentially
reversed may be helpful in developing treatment and preventative strategies.
1638 Epigenetic Alterations in Response to Exposure to
Environmental Toxicants.
I. Koturbash. Department of Environmental and Occupational Health, College of
Public Health, University of Arkansas for Medical Sciences, Little Rock, AR.
Epigenetics is the study of heritable changes in gene expression that are not associ-
ated with alterations in DNA sequence. Epigenetic mechanisms include DNA
methylation, post-translational histone modifications, and nucleosome positioning
along DNA, and are important for maintenance of normal cellular homeostasis.
Disruption of epigenetic mechanisms may compromise the balance of the cellular
epigenome and lead to development of various pathological states, including can-
cer. Accumulating evidence clearly indicates that various environmental toxicants,
independently of their genotoxic abilities, can cause epigenetic alterations. These
changes in the cellular epigenome are exhibited as decreases in global DNA methy-
lation, aberrant gene-specific DNA methylation, changes in histone modifications,
as well as associated alterations in chromatin status. Importantly, epigenetic alter-
ations can be detected long before the occurrence of genetic changes; and are stable,
persisting after the initial exposure-related DNA damage has been repaired. These
findings highlight the significance of epigenetic alterations in the mechanisms of
toxicity and carcinogenicity.
1639 Application of Cancer Toxicoepigenomics in Identifying
High-Risk Populations.
M. Verma. National Cancer Institute, NIH, Rockville, MD. Sponsor: K. Kutanzi.
The epigenome is dynamic and very susceptible to environmental changes.
Toxicoepigenomic studies are conducted to explain the epigenetic effects of envi-
ronmental exposures. Epigenetic programming occurs during development and re-
flects altered gene expression in disease states. This programming differs from ge-
netic polymorphisms or mutations because genetic changes are reflected in all cells,
whereas epigenetic changes are cell- and tissue-specific. Studies that involve the
measurement of epigenetic changes that occur at the genome-wide level and their
association with disease are called epigenome-wide association studies (EWAS).
Epigenetic alterations respond quickly to environmental changes, and technologies
are available to measure these changes. During the last 5 years, excellent progress
has been made in the field of altered epigenomic profiling in response to toxins and
environmental. It now is possible to use high-throughput technologies to measure
epigenetic patterns that are altered by toxin exposure. Different environmental ex-
posures, including toxins, affect different components of the epigenetic machinery
and alter the methylation and acetylation equilibrium. Epidemiologic studies help
to identify the etiology of a disease, especially factors that contribute to disease de-
velopment. In the case of cancer, such factors include toxic substances, radiation,
infectious agents, specific dietary components, tobacco, alcohol, and environmen-
tal factors. It makes sense to identify epigenetic markers in normal and exposed
populations. The advantages of identifying epigenetic biomarkers of exposure in-
clude improved exposure assessment, documentation of early alterations preceding
cancer development, and identification of high-risk populations. Examples of inter-
action between toxic substances and cancer initiation and progression will be dis-
cussed.
1640 Changes in Histone Tail Modifications and Gene Expression
in PBMC from Subjects Exposed to Nickel and Arsenic.
M. Costa. Environmental Medicine, New York University School of Medicine, Tuxedo
Park, NY.
A major target of Nickel (Ni) ions in cells is the iron- and ascorbic acid-dependent
dioxygenase enzymes. The family of histone H3 demethylases is an example of
these enzymes. Since Fe binding is required for catalytic activity and Ni ions readily
displace the Fe from all of these enzymes, Ni exposure results in inactive enzyme
which increases global levels of the activating mark H3K4 trimethylation
(H3K4me3) and the silencing mark H3K9 dimethylation (H3K9me2). Arsenic
(As) induces oxidative stress in cells and will deplete reduced ascorbate which is re-
quired for the activity of these histone demethylases. In vitro exposure to Ni or As
increases the levels of posttranslational modifications of histone tails. Here we show
changes in global levels of histone modifications in peripheral blood mononuclear
cells (PBMCs) of subjects with occupational exposure to Ni by inhalation in a
Nickel refinery in China and subjects from Bangladesh exposed to As in their
drinking water. Occupational exposure to Ni was associated with an increase in
H3K4me3 and decrease in H3K9me2. A global increase in H3K9me2 and decrease
in H3K9ac was found in subjects exposed to As. Additionally, exposure to As re-
sulted in opposite changes in a number of histone modifications in males compared
to females in the As exposed population. We also analyzed the gene expression
changes in PBMC in a smaller subset of individuals exposed to Ni and As.
Hierarchical clustering revealed that several thousand genes were similarly changed
across subjects highly exposed to Ni, and there was similar clustering with low Ni
exposure and with controls. With As the results were more complex because of the
strong effect of gender. With As there were genes that changed in a gender depend-
ent manner and also with As exposure independent of gender.The results of these
two studies suggest that exposure to Ni or As compounds, and possibly other car-
cinogenic metal compounds, can induce changes in global levels of posttransla-
tional histone modifications and gene expression in PBMC.
1641 Chromatin Remodeling As a Driver and Target for Lung
Cancer.
S. A. Belinsky. Lovelace Respiratory Research Institute, Albuquerque, NM. Sponsor:
K. Kutanzi.
Epigenetic silencing of genes and microRNAs (miRs) via chromatin remodeling
and cytosine methylation has emerged as a major mechanism in lung cancer etiol-
ogy. The reversal of gene and miR silencing using pharmacological agents and po-
tentially dietary supplements (e.g., omega-3 polyunsaturated fatty acids [n-3
PUFA]) by affecting cytosine-DNA methyltransferases (DNMTs), histone methyl-
transferases (HMTs), or histone deacetylases (HDACs) offers new strategies for pre-
vention and intervention for lung cancer. We have developed an in vitro model
using hTERT/cdk4 immortalized human bronchial epithelial cell lines (HBECs)
that identifies molecular changes driving transformation of preneoplastic lung ep-
ithelial cells during exposure to carcinogens found in mainstream and environmen-
tal tobacco smoke. Our studies provided a mechanistic link between increased
DNMT1 protein, de novo methylation of genes, and reduced DNA repair capacity
that together seemed causal for transformation. Our recent studies show that the
exposure of HBECs to carcinogens for 4 wks induces a persistent and irreversible,
multifaceted dedifferentiation program characterized by the epithelial-to-mes-
enchymal transition (EMT). EMT induction was epigenetically driven, initially by
chromatin remodeling involving H3K27me3 enrichment, with ensuing DNA
methylation sustaining the silencing of miR-200b, -200c, and -205 implicated in
this developmental program and persisting in malignant tumors. Overexpression of
these miRs reversed transformation. Genome-wide profiling has identified >300
genes with a promoter CpG island whose expression is reduced after only 4 wks of
treatment. The polycomb repressive complex PRC2 regulated many of these genes.
While ensuing promoter methylation after 8 wks of further exposure to the car-
cinogens is seen in a small subset of these genes, many of these genes show dense
methylation in tumor-derived cell lines and primary tumors. These findings impli-
cate chromatin remodeling mediated by HMTs whose expression increases during
carcinogen exposure and in primary tumors, as important initiators of epigenetic
gene silencing (Supported by R01 ES008801).
1642 Molecular Basis for Dioxin-Induced Cardiovascular Disease.
A. Puga. Environmental Health, University of Cincinnati College of Medicine,
Cincinnati, OH.
Interactions between genetic and environmental factors are responsible for several
forms of human congenital cardiovascular malformations. Of these, valvular steno-
sis and hypoplastic left heart syndrome are the most common forms of birth defects
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in humans, occurring in eight newborns from every 1000 live births and constitut-
ing 25–30% of all cases of human cardiovascular malformation. These two congen-
ital heart defects are the leading cause of neonatal and infant death and, underscor-
ing the fetal origin of adult disease concept, are also a major cause of adult cardiac
insufficiency, linking fetal and adult cardiovascular disease. The main known risk
factors for these abnormalities in cardiac development are genetic inheritance and
maternal exposure to hazardous chemicals, but their precise molecular etiology re-
mains elusive. We have recently found that treatment of differentiating mouse ES
cells with dioxin represses Nkx2.5 gene expression and other cardiac markers as a
consequence of AHR activation. By following the expression trajectories of car-
diomyocyte markers during ES cell differentiation we found that dioxin silenced
the expression of Nkx2.5 and other cardiomyocyte-specific genes, including the
genes coding for cardiac troponin-T and α- and β-myosin heavy chains, and inhib-
ited the formation of beating cardiomyocytes, a characteristic phenotype of differ-
entiating mouse ES cells. The key mediator of these effects was the aryl hydrocar-
bon receptor (AHR), epigenetically silenced in pluripotent ES cells and activated
during differentiation. Our work with ES cells may unravel molecular and epige-
netic mechanisms responsible for human cardiac malformations due to environ-
mental (organochlorinated compounds) or genetic (NKX2.5 mutations) causes.
NKX2.5 repression by dioxin-mediated AHR activation may help us identify the
regulatory loops controlling the NKX2.5 functions that determine embryonic
identity and progression of cardiac tissue differentiation, and how these functions
are silenced by the activated AHR. (Supported by NIH grants 5R01ES006273 and
5P30ES06096).
1643 Dietary Arsenic—Forms, Hazards, and Risks.
P. M. Bolger. Exponent, Annapolis, MD.
Arsenic, particularly inorganic arsenic, is a well known and ubiquitous environ-
mental contaminant, particularly in drinking water, and it originates from both an-
thropogenic and natural sources. It demonstrates a myriad of toxicological effects
across a broad spectrum of organ systems. It has generally been believed that arsenic
in food occurs in organic forms that demonstrate minimal, if any, toxicological ac-
tivity. This is particularly the case with the forms found in seafood (e.g., arsenosug-
ars). However, there has been concern for some time that organic forms may not be
the predominant forms in certain foods, like rice, where concentrations of inor-
ganic forms in certain cultivars may be significant. In addition, other organic
forms, like tri- and penta- mono- and dimethyl forms, may be found, and at levels
that are not insignificant, and could potentially pose a health hazard. These organic
forms may not be as innocuous as the organic forms found in seafood. This session
will explore the current state of knowledge regarding the occurrence of various
forms of arsenic found in foods, as well as their potential exposures, hazards (e.g.,
toxicological, epidemiological) and risks to public health, and what risk manage-
ment options maybe available.
1644 Noncancer Disease Risk Promoted by Low Level Arsenic
Exposures.
A. Barchowsky. Environmental and Occupational Health, University of Pittsburgh,
Pittsburgh, PA.
Exposure to arsenic through drinking water and diet increases risk for a number of
cancers and non-cancer diseases. Cardiovascular diseases contribute to a large por-
tion of non-cancer arsenic-promoted morbidity and mortality, and may occur at
relatively low levels of arsenic exposure that were considered safe based on cancer
risk. While epidemiological studies have established the disease risk to low level ex-
posures, basic studies have lagged in demonstrating mechanism for disease.
However, recent low level exposure studies in mice and cultured human cells sug-
gest novel receptor mediated and reactive oxygen species-dependent modes of ac-
tion for arsenic induced pathogenic vascular and tissue remodeling, as well as meta-
bolic dysfunction. This talk will review the current state of understanding of
arsenic-induced cardiovascular disease risk and potential modes of action.
1645 Exposure Assessment Methods for Dietary Arsenic.
L. Barraj and N. Tran. Exponent, Washington DC.
A brief overview of types of dietary exposure assessments and discusses the associ-
ated data requirements will be presented. Existing food consumption data sources
that can be used for estimating dietary expsoure to arsenic are reviewed and their
strengths and limtations are discussed. Algorithms and models typically used are
presented and their applicability to the various exposure scenarios (e.g., short term
versus long term) are discussed.
1646 Recent Epidemiologic Studies of Arsenic and How They
Apply to the Health Evaluation of Arsenic in Food.
H. J. Gibb. Tetra Tech Sciences, Arlington, VA. Sponsor: P. Bolger.
The association of arsenic in drinking water with an increased risk of skin, lung,
bladder, and kidney cancer has been known for several decades. In addition to the
association of arsenic with increased risks of various forms of cancer, studies have
found an association of arsenic in drinking water with a variety of noncancer effects
including skin lesions, cardiovascular disease, diabetes, liver damage, and kidney
disease. Some of these effects have been reported to occur at drinking water con-
centrations lower than 100 μg As/L. Several studies indicate that exposures at
younger ages have a disproportionately greater effect than exposures at older ages.
Recent reports of arsenic in brown rice syrup and apple juice have raised concern
whether arsenic in food products may also present a health problem, particularly
for infants. The development of an epidemiologic database that focuses primarily
on recent studies and how such studies may affect the risk assessment of arsenic in
food will be presented.
1647 Potential Risks to Human Health from Arsenic in the Diet: A
European Food Safety Authority (EFSA) Perspective.
J. R. Schlatter. Federal Office of Public Health (retired), Zurich, Switzerland.
In 2010, the Panel on Contaminants in the Food Chain (CONTAM Panel) of the
European Food Safety Authority (EFSA) assessed the risks to human health related
to the presence of arsenic in food. More than 100,000 occurrence data on arsenic in
food were considered with approximately 98 % reported as total arsenic. Making a
number of assumptions for the contribution of inorganic arsenic to total arsenic,
the inorganic arsenic exposure from food and water across 19 European countries
was estimated for average consumers, for 95th percentile consumers and for chil-
dren. The CONTAM Panel modeled the dose-response data from key epidemio-
logical studies and selected a benchmark response of 1 % extra risk. A range of
benchmark dose lower confidence limit (BMDL01) was identified for cancers of
the lung, skin and bladder, as well as skin lesions. The estimated dietary exposures
to inorganic arsenic for average and high level consumers in Europe as well as for
children are within the range of the BMDL01 values identified, and therefore there
is little or no margin of exposure and the possibility of a risk to some consumers
cannot be excluded.
1648 Pulmonomics, the Exposome, and Microbiomes in
Immunotoxicology.
M. A. Williams. US EPA, Research Triangle Park, NC.
The exposome has revealed itself to be a powerful approach for assessing environ-
mental exposures and their influences on human diseases. As we explore the origins
of human disease, and the contributions made by environmental pollutants, a com-
prehensive understanding of systems biology is needed. This requires an integrated
understanding of how environmental chemicals and other stressors of gene and
protein expression are not only linked to a toxicological outcome but which may
impact on chronic inflammatory diseases such as allergic asthma, COPD, and even
lung cancer. Perturbations in normal cell cycle kinetics, apoptotic cell-death path-
ways, immune dysfunction, and a recent appreciation of the consequences of inad-
vertent dysregulation of the gut and lung microbiomes collectively distort normal
systems biology homeostasis and the advent of adverse health effects. For the first
time, this symposium presents emerging critical issues and paradigms that discuss
the contributions and interplay of systems biology, the exposome, and microbiomes
as they relate to immunotoxicology, dysregulation of inflammatory pathways, and
chronic diseases. Invited speakers will place in context and share state-of-the-art ap-
proaches for advancing our understanding of the interplay of gene and environ-
ment and of the exposome in initiating and prolonging chronic inflammatory dis-
ease.
1649 Breath Biomarkers from Viable Pulmonary Aerosols:
Discovery of Human Microbiome Contributions.
J. Pleil. Methods Development and Applications Branch, National Exposure Research
Laboratory (NERL), US EPA, Research Triangle Park, NC.
Exhaled breath and exhaled breath condensate (EBC) are two human biological flu-
ids collected non-invasively to assess previous exposures to exogenous compounds
and to evaluate metabolic (or health) effects. Although expression of volatile or-
ganic compounds (VOCs) in exhaled breath is considered a window into the circu-
lating blood representing external exposures and human metabolism, it also repre-
sents contributions from the life cycles of the human microbiome. We have
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developed methodology for distinguishing between human and bacterial contribu-
tions via collection of human generated aerosols in EBC, culturing them in growth
media, and analyzing headspace with gas-chromatography – mass spectrometry. We
have cataloged a series of VOCs from both aerobic and anaerobic conditions to in-
form human biomonitoring efforts for the assessment of in-vitro and in-vivo stud-
ies of the safety of manufactured chemicals.
1650 Experimental Exposure of Mice to House Dust Alters Gut
Microbiome and Attenuates Allergic Pulmonary Responses.
N. Lukacs. Pathology, University of Michigan Medical School, Ann Arbor, MI.
Sponsor: M. Williams.
Atopic asthma is more common in clean Western countries and its prevalence has
increased greatly during the last century, along with improved hygiene and housing
conditions. Exposure to a more diverse microbiome during childhood correlates
with a lower risk of developing asthma during later life. Recent data has suggested
that a diverse microbiome is associated with growing up with older siblings and
pets. Dietary sampling from the environment can directly impact the gut micro-
biome. Interaction between intestinal microbiome and Gut Associated Lymphoid
Tissue (GALT) not only directs local immune responses but also appears to affect
the outcome of antigen-driven responses in the respiratory system. Using 2 differ-
ent mouse models of allergic asthma (using the model-antigen ovalbumin –OVA –
and the clinically relevant cockroach allergen – CRA), we set out to study pul-
monary immune responses after dietary supplementation with household dust col-
lected from homes with or without pets. Daily dosing of sieved dust administered
to 6-8 week old BALBc mice via oral gavage for 2 weeks was used for controlled ex-
posure. Following the dust treatment, mice were sensitized and challenged with
CRA, or alternatively received a transfer of OVA-specific DO11.10 T-cells and a
subsequent OVA challenge. In the dust exposed animals a significant decrease in
Th2 cytokine protein expression and total IgE levels was observed in pet dust-
treated animals exposed to allergen. Moreover, these mice showed reduced mucus
hypersecretion in the lung, as determined by PAS staining and RT-PCR for gob5.
Interestingly, phylochip analysis of the cecal content of these mice revealed that the
pet dust treatment altered the microbiome in favor of Lactobacillus species.
Altogether these data demonstrate that short-term oral sampling of dust from
homes with pets, but not without pets, significantly alters the gut microbiome and
can subsequently attenuate pulmonary allergen-induced immune responses.
1651 Translating the Airway Transcriptome into Biomarkers of
Tobacco-Related Lung Disease.
A. Spira. The Pulmonary Center, Boston University School of Medicine, Boston, MA.
Sponsor: M. Williams.
While cigarette smoke exposure is associated with lung cancer, COPD and a num-
ber of chronic inflammatory diseases of the lungs, only a fraction of smokers de-
velop these diseases and there are currently no effective tools for identifying those
smokers at highest risk for disease. Furthermore, we lack biomarkers for measuring
the host response to inhaled toxins like cigarette smoke. This talk will focus on ap-
plying whole-genome gene-expression studies to airway epithelial cells in order to
gain insights into the physiological responses to tobacco smoke exposure. The goal
of the presentation will be to explore how individual variability in the airway ge-
nomic response to tobacco smoke associates with risk of tobacco-related lung dis-
eases and how this information can be leveraged to serve as clinically-relevant bio-
markers of disease activity in both lung cancer and COPD. This talk will be of
broad interest to the biomedical research community including those with expertise
in genomics, molecular biology, and epidemiology related to tobacco exposure and
pulmonary disease.
1652 Immune-Mediated Adverse Effects of Drugs and
Environmental Agents.
J. Uetrecht. Pharmacy, University of Toronto, Toronto, ON, Canada.
Many adverse effects of drugs and environmental agents are immune-mediated.
Exposure to drugs is easier to determine than most environmental agents, and most
drugs can cause idiosyncratic (i.e. specific to an individual) adverse reactions
(IDRs) such as skin rash, liver injury, bone marrow injury, and autoimmunity, most
of which are immune-mediated. This provides a clear example of how different
people can be affected by agents in different ways. Most drugs associated with a sig-
nificant risk of IDRs form chemically reactive metabolites, which suggests that a
major factor is the ability of the drug to form a hapten. However, this observation
is also consistent with the danger hypothesis because reactive metabolites can also
cause cell injury leading to the release of danger signals that promote an immune
response. There are also environmental agents that form reactive intermediates and
lead to an immune response, e.g. poison ivy and hair dyes can cause contact hyper-
sensitivity. However, not all drugs that cause IDRs form reactive metabolites so
there must be other possible mechanisms. Other apparent mechanisms involve epi-
genetic changes, reactivation of viruses and direct binding to MHC. One example
of an environmental agent that binds to MHC leading to an immune response is
beryllium, which binds to HLA-DPB1 that has a glutamic acid at AA 69, and very
low exposures to beryllium can lead to severe chronic lung disease in patients with
this genotype. Other agents such as vinyl chloride can lead to autoimmunity.
Although IDRs are frequently referred to as dose independent, this is not true;
drugs given at a dose of 10 mg/day are associated with a very low risk of IDRs. This
may reflect a threshold in hapten density required to induce an immune response.
This suggests that most environmental agents are unlikely to cause immune-medi-
ated adverse reactions; however, beryllium is an exception, and this threshold may
be significantly lower for agents that act more directly to modulate immune re-
sponses. Environmental agents such as benzene can also lead to immunosuppres-
sion. Funded by grants from CIHR.
1653 Targeted ‘Omics Research in the Regulatory Environment.
J. Sobus. Exposure Measurements and Analysis Branch, US EPA, Research Triangle
Park, NC.
The US EPA’s Office of Research and Development (ORD) has recently imple-
mented the “Chemical Safety for Sustainability” (CSS) research program. Much of
this program is dedicated to “facilitating faster, more efficient, more certain, and
sustainable chemical assessments and management decisions”. Achieving these
goals will require high-throughput and multi-chemical assessments of environ-
ments, living intact organisms, and surrogate (in vitro) systems. Single chemical as-
sessment strategies alone cannot support these requirements, and will be supple-
mented using ‘omic-based approaches to exposure- and health-based assessments.
This presentation will highlight opportunities to integrate cutting-edge ‘omics ap-
proaches into existing regulatory-based research frameworks. Special attention will
be given to biomarker-based ‘omics tools that can be used to link across environ-
mental, biological (in vivo), and in vitro sample environments.
1654 Standard and Nonstandard Animal Models for Evaluation of
Drug Abuse Potential for Pharmaceutical Compounds with
Novel Mechanisms.
C. G. Markgraf2 and M. Guha1. 1Drug Safety Evaluation, Bristol-Meyers Squibb
Co., Mt Vernon, IN; 2DSS, Merck, Kenilworth, NJ.
Preclinical assessment of abuse liability potential for new drugs with central nervous
system (CNS) activity has been a recent focus of both regulatory and industry in-
terest. The standard animal models used for evaluation of abuse potential for these
pharmaceutical candidates are self-administration and drug discrimination. These
models have been well characterized in both rats and monkeys with known drugs of
abuse. However, unique challenges encountered when evaluating drugs with novel
mechanisms or with difficult pharmaceutical properties raise questions: How can
reinforcing properties be evaluated if there is no acceptable IV formulation? What
comparator drug is appropriate for a candidate compound with a novel CNS-active
mechanism? In these situations, using a nonstandard model may offer an attractive
alternative. The promise of such alternative animal models is balanced by the chal-
lenge in data interpretation and in incorporation of the data into a comprehensive
risk assessment. This workshop will start with a discussion of the regulatory re-
quirements and standard data collected for a preclinical abuse potential assessment,
followed by presentations on conditioned place preference (CPP) and intracranial
self stimulation (ICSS)—both nonstandard animal models of drug abuse potential
in a regulatory setting. The scientific rationale for their use, how each compares to
standard animal models, and the use of their data in risk assessment and in an abuse
potential package for submission to health authorities will be discussed.
1655 Current Challenges in Abuse Liability Assessment of Drugs
with Novel Mechanisms of Action.
K. H. Horn. Drug Safety Evaluation, Bristol-Meyers Squibb, Mt Vernon, IN.
Preclinical data from abuse liability assessments are required to support the registra-
tion and scheduling of new drugs with central nervous system activity. Despite the
availability of a standard set of well characterized animal models (self administra-
tion and drug discrimination), there may be circumstances for compounds with
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novel mechanisms of action where the standard models are not suitable or cannot
be utilized for the lack of suitable comparators for training or due formulation is-
sues. In these cases, investigators may wish to turn to alternative approaches to un-
derstand the abuse liability potential for drugs under development. The purpose of
this presentation is to highlight the complexity and challenges associated with de-
signing an abuse liability package for drugs with novel or unknown mechanisms of
action where the use of standard assays may not be appropriate or when pharma-
ceutical properties prevent the use of standard assays. The first part of the presenta-
tion will focus on the standard pre-clinical models of abuse liability (self-adminis-
tration, drug discrimination, and withdrawal/dependence). Following this
introduction, the presentation will discuss specific circumstances, situations, and
/or challenges that investigators may encounter during drug development which
may require consideration of unconventional approaches.
1656 The Assessment of Abuse Liability: The Regulatory
Perspective.
S. N. Calderon-Gutkind. CDER, FDA, Silver Springs, MD. Sponsor: M. Guha.
The assessment of the abuse liability of a drug is part of the evaluation performed
by FDA, according to the requirements of the Federal Food, Drug and Cosmetic
Act. 
Issues concerned with the assessment of potential for abuse and with scheduling a
drug under the U.S. Controlled Substances Act (CSA) are the responsibilities of the
Office of the Center Director, Controlled Substance Staff. 
When a new drug has structural or pharmacological similarity to a known drug of
abuse, sponsors are required to thoroughly characterize its abuse potential and sub-
mit study results for scientific review. A drug’s abuse potential is determined relative
to a pharmacologically similar or other appropriate comparator drug. The abuse li-
ability assessment is based upon comprehensive evaluation of chemistry, pharma-
cology (preclinical and clinical), pharmacokinetics, and pharmacodynamic profiles
of the drug, and adverse events observed in clinical trials, as well as anticipated pub-
lic health risks that may follow introduction of the drug on the market. 
This presentation will focus on the current guidance for industry on the assessment
of the abuse potential of drugs, and on the particular challenges encountered when
assessing the abuse potential of drugs with novel mechanisms of action or pharma-
cological profiles.
1657 Conditioned Place Preference As a Tool for Assessing Abuse
Liability.
C. L. Cunningham. Behavioral Neuroscience, Oregon Health & Science University,
Portland, OR. Sponsor: C. Markgraf.
The conditioned place preference (CPP) procedure is commonly used to assess the
rewarding and aversive effects of drugs in laboratory animals. This procedure is also
used to study the role of learning in the control of drug seeking and relapse as well
as the brain mechanisms underlying drug-induced learning and reward. However,
the CPP procedure has not been used systematically in the assessment of abuse po-
tential. This presentation will focus on important issues that should be considered
when using the CPP procedure for such assessments. The basic procedure and its
parametric determinants will be briefly described, followed by a review of its advan-
tages and limitations as a tool for assessing abuse potential. This review will focus
on relevant theoretical, methodological, empirical and practical issues that arise
when comparing the CPP procedure to the most commonly used tool for assessing
abuse potential, i.e., drug self-administration. For example, consideration will be
given to the use of these procedures for assessing “reinforcement” vs. “reward” and
to the conceptual issue of whether these procedures simply offer different strategies
for measuring a common biological process. Literature showing similarities and dif-
ferences in drug effects between these procedures will be briefly reviewed along with
examples showing a positive effect of a known abused drug in one procedure but
not in the other. Although a more systematic evaluation of its utility for predicting
drug abuse liability in humans is needed, CPP might have significant value as an
additional tool for assessing abuse potential in laboratory animals.
1658 Use of Intracranial Self-Stimulation for Abuse Liability
Assessment.
T. J. Hudzik. 1Neuroscience Research, Abbott, Ludwigshafen, Germany; 2Institute of
Pharmacology, Pavlov Medical University, St. Petersburg, Russian Federation.
Sponsor: C. Markgraf.
All drugs entering the CNS may initially be viewed as having a potential risk for
abuse. As there is no single test or assessment procedure likely to offer an ultimate
characterization of abuse liability, preclinical abuse liability assessment is based on
using several experimental approaches that focus on establishing pharmacological
equivalency to known drugs of abuse, ability to induce physical dependence, and
reinforcing effects. This report discusses intracranial self-stimulation (ICSS; brain
stimulation reward) as a tool that could complement existing assessment strategies.
Many drugs of abuse facilitate ICSS in laboratory animals prepared with electrodes
implanted into brain “reward” areas. In addition to fairly robust predictive validity,
ICSS has a number of important advantages in studying: i) drug-drug interactions;
ii) quantitative comparisons among drugs; iii) complex drug formulations, espe-
cially those intended to be abuse-resistant; and iv) multiple, repeated drug expo-
sures. This report limits a review of the ICSS literature to that pertinent to its use-
fulness as a procedure predictive of the abuse liability of drugs, and argues for the
standardization of experimental protocols to enable a more final assessment of its
usefulness in this regard.
1659 Impact of Nonstandard Animal Models on Preclinical Study
Design for Meeting Regulatory Requirements.
M. Kallman. Discovery and Translational Services, Covance, Greenfield, IN.
Although most pharmaceutical companies have transitioned to provide non-clinical
data to address regulatory requirements for scheduling decisions on new drugs these
studies have typically been the traditional dependence, drug discrimination, and
self-administration studies. Alternative models of conditioned place preference and
intracranial self-administration have been available as scientific tools for sometime
but they have only rarely been conducted to support the regulatory environment.
The reasons for the emphasis on the traditional models will be considered. In addi-
tion, a discussion of the advantages and potential applications of the non-standard
models for scheduling decision making may provide insight into the utility of these
models. The emphasis of the talk will be what the future environment might be and
how we can develop scientific data packages using these non-standard models to
meet the future decisions for scheduling.
1660 The Placenta in Toxicology: Target or Travel Agent?
C. J. Bowman1 and W. Foster2. 1Developmental & Reproductive Toxicology, Pfizer
Inc., Groton, CT; 2Department of Obstetrics & Gynecology, McMaster University,
Hamilton, ON, Canada.
The placenta is a fascinating organ in its dynamic form and function appearing as a
transient and critical tissue in the reproductive cycle. It is a collaboration of mater-
nal and zygotic cellular layers whose major function is a conduit between mother
and fetus focused on the growth and viability of the next generation whilst preserv-
ing maternal well-being. The unique physiology of biodistribution and metabolism
of the placenta also render it sensitive as a target of toxicity. The human placenta is
a complicated organ and understanding the comparative physiology of nonclinical
species can be a critical component for drug and chemical safety assessment; both as
a potential target of toxicity and as a presumed barrier to undesirable xenobiotics.
As in much of toxicology, it is important to appreciate different perspectives in-
cluding clinical, epidemiological, basic research, industry, and regulatory. It is only
when this information is integrated and applied that we can appreciate the value
and importance of basic research and the views of regulatory and industrial sci-
ences.
1661 How Predictive Are Animal Studies in Detecting Fetal Risks
in Humans?
G. Koren1, 2. 1The Hospital for Sick Children, The University of Toronto, Toronto,
ON, Canada; 2Molecular Toxicology, The University of Western Ontario, Toronto,
ON, Canada. Sponsor: C. Bowman.
Every year scores of new molecules enter the market. Because half of all pregnancies
are unplanned, fetal exposure to these drugs is inevitable. Unfortunately, due to
wide variability and differences between and human placenta in anatomy and phys-
iology, making animal models of placental transfer difficult to interpret. There is an
urgent need for non human models to predict human risk/safety. The placenta is
the only human organ that can be ethically harvested and kept alive ex vivo for 4-6
hr. By cannulating maternal and fetal vessels, the perfusion model can be used to
study rates and extent of drug transfer across the human placenta, as well as placen-
tal functions such as oxygen consumption, hCG secretion etc. Using placental per-
fusion, we have established a model of predicting in vivo drug transfer, correlating it
with results of in vivo fetal and neonatal sampling (Hutson et al, Clin Pharmaco
Ther, 2011). Implementation of this model can revolutionize the prediction of fetal
exposure to drugs in vivo.
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1662 Environmental Factors in Placental Toxicology and Women’s
Health.
M. M. Veras1, 2 and P. Saldiva1, 2. 1Pathology, University of São Paulo, São Paulo,
Brazil; 2National Institute of Integrated Analysis of Environmental Risk, São Paulo,
Brazil. Sponsor: C. Bowman.
Environmental pollution is shown to affect reproductive functions in humans. In
some situations exposures are unavoidable, such as traffic-derived air pollution in
urban areas. The relationship between gestational exposure to air pollution and fetal
outcomes is receiving progressively greater attention. Epidemiological findings cor-
relate low birth weight, higher frequency of preterm birth, neonatal mortality and
compromised specific reproductive endpoints such as infertility with air pollution.
The limitations of epidemiological studies are associated with difficulties of identi-
fying individual exposure levels as well as the presence and management of many
cofounder factors such as nutritional and social status and smoking that challenges
the establishment of causal relationships. To overcome these factors our group con-
ducted experimental studies (murine model) using realistic concentrations of air
pollutants, which “mimic” human exposures. Experimentation using real-world ex-
posures to air pollutants provided corroboration of epidemiologic data and was
used to identify the pathophysiological mechanisms involved. Changes in estrous
ciclicity, fertility, number of ovarian follicles, embryonic implantation index, fetal
development and placentation were some of the outcomes observed. In summary
this session will provide an overview of the effects of environmental air pollution on
reproductive functions; in particular, adverse effects on pregnancy outcome and
placentation.
1663 The Placenta As Therapeutic Border Patrol for Unintended
Populations.
C. J. Bowman. Developmental & Reproductive Toxicology, Pfizer Inc., Groton, CT.
For most bio/pharmaceuticals the placenta and developing conceptus is not the tar-
get of therapy so effects on these tissues would generally be undesirable and should
be addressed in the safety assessment and benefit-risk considerations of the in-
tended therapy. In addition to direct placental toxicity and/or altered placental
function, placental transfer of bio/pharmaceuticals may permit direct effects on the
developing embryo, including teratogenicity. The most important placental trans-
fer mechanism of small molecule pharmaceuticals is simple passive diffusion, but
there are other mechanisms such as facilitated and active transport,
phagocytosis/pinocytosis, membrane discontinuity and electrochemical gradient.
The emerging class of large molecule therapies have brought new attention to the
currently held dogma that all drugs cross the placenta to some extent (some more
than others). These large molecule biopharmaceuticals are generally too big to pas-
sively cross plasma membranes and thus may offer a safety advantage (lower risk of
teratogenicity) due to limited exposure to the unintended embryo. Antibody-like
biopharmaceuticals have a unique placental transfer mechanism that is normally re-
served for transport of maternal antibodies to protect the conceptus before and
after birth. There is limited data regarding this mechanism of transfer and its tim-
ing as it pertains to antibody-like biopharmaceuticals and how it may impact the
interpretation of nonclinical developmental toxicity data for human risk assessment
to minimize the potential for birth defects. Recent data in the rodent indicates that
antibody-like biopharmaceuticals cross the placenta during organogenesis in this
species. This potential for embryo exposure during rat organogenesis, even at low
levels, merit additional attention to placental transfer in nonclinical species and
their concordance to human and how best to use nonclinical data to inform human
developmental toxicity risk assessment.
1664 The Placenta As a Target Organ in Toxicology—A Case
Study.
B. van Ravenzwaay. Experimental Toxicology and Ecology, BASF SE, Ludwigshafen,
Germany.
Triazole fungicides are known to cause changes in the placenta and they are known
to cause late post implantation losses in prenatal studies in rats. Studies were initi-
ated to investigate if there is a connection between these effects and the general
mode of action of triazole fungicides, aromatase inhibition, causing a reduction of
circulating estradiol. In prenatal studies, estradiol was co-administered with the tri-
azole fungicide during rat prenatal development to test whether estrogen could pre-
vent triazole late fetal resporptions. Co-treatment with estradiol reduced post im-
plantation loss to 9%, compared to 48% without estradiol. Placental changes
(labyrinth and tropospongium degeneration) were also less severe with estradiol
treatment, indicating that these changes are secondary to reductions in estradiol.
Thus, placental pathology may be the cause of late fatal resorptions. Expert patho-
logical evaluation indicated that placental pathology could not support late fetal de-
velopment; a quantitative evaluation suggested that degeneration of at least 70% of
the labyrinth correlated well with late fetal resorption. As rat placenta is histologi-
cally and biochemically different from human placenta, while guinea-pig placentas
are quite similar, we studied the effect of the triazole fungicide using guinea-pigs. In
this model, prenatal triazole treatment did not result in an increase in the incidence
of late fetal resorptions, despite a profound reduction in circulating estradiol levels.
Similarly, no placental changes were noted. These differences can be explained by
the fact that the rat placenta is unable to produce estradiol whereas the placenta is
the main source of estradiol maintaining pregnancy following implantation in
guinea-pigs and humans. Despite the triazole fungicide-induced decrease in total
circulating estrogen production, the local concentration of estradiol in the guinea
pig placenta is sufficiently high to support normal maintenance and development
in the fetal compartment. Therefore, the guinea-pig is a better model to assess pre-
natal toxicity of compounds inhibiting aromatase activity.
1665 Regulatory Perspectives on Embryo-Fetal Developmental
Studies: The Placenta in Pharmacological Studies and
Toxicological Assessments.
L. Leshin. US FDA, Silver Spring, VA. Sponsor: C. Bowman.
In the safety assessment of bio/pharmaceuticals, a gross examination of the placenta
is included as part of the in vivo embryo-fetal developmental toxicity study. Data
from this study contribute to the risk assessment of drugs for use by patients of
childbearing potential and during pregnancy. A more thorough evaluation of the
placenta has the potential to contribute mechanistic information that could sub-
stantially inform the interpretation of study outcomes. Our knowledge of placental
transport, metabolism, and immunology has increased dramatically since the devel-
opment of the currently used regulatory practices and requirements. Closer exami-
nation of the placenta using various in vitro and in vivo approaches could provide a
more complete understanding of drug effects on embryo-fetal development. With
the progress made in understanding placental biology this critical multifunctional
tissue can take on a more prominent role for improved pregnancy risk assessment.
1666 K–12 Toxicology Outreach Activities: Regional Chapter
Successes and Resources.
C. E. Sulentic1 and R. Ponce2. 1Pharmacology & Toxicology, Wright State University,
Dayton, OH; 2Amgen Inc, Seattle, WA.
K–12 activities are a vital component in our mission to educate the community re-
garding hazards and hazard communication. Several regional SOT chapters have
very active K–12 community outreach programs and others are interested in estab-
lishing these programs within their communities. Facilitating this type of outreach
across all regional chapters is a tactical goal of the Regional Chapter Collaboration
and Communication Committee (RCCCC) and the Education Committee. This
goal ties directly into the SOT strategic plan of promoting recognition of toxicol-
ogy and communicating the benefit of toxicology to external audiences. The 2011
Education Summit sponsored by SOT underscored the need for enhancing the per-
ception of toxicology as a valuable discipline among scientists and nonscientists
alike, which is vital to maintaining the discipline of toxicology and the pipeline of
future toxicologists. Community outreach at the K–12 level is an important com-
ponent in increasing the visibility and perceived importance of toxicology. Regional
SOT chapters can be and have been a vital resource in facilitating outreach activities
among the membership-at-large. This session will highlight some of the successful
K–12 outreach activities supported by regional chapters and will include hands-on
demonstrations, one organized and implemented by graduate students, as well as an
overview of efforts to update website resources for K–12 activities. This session will
also provide pedagogical insights helpful to those new to educational outreach.
Promoting and facilitating K–12 activities by regional chapters has the added po-
tential of greater graduate student and postdoc engagement and therefore increased
opportunities for skill development and pedagogical background for those trainees
considering academic careers.
1667 Totally Toxic! A K–12 Outreach Program Based on the 5E
Model of Science Education.
C. P. Curran. Biological Sciences, Northern Kentucky University, Highland Heights,
KY.
The Ohio Valley SOT (OVSOT) chapter developed an outreach program called
“Totally Toxic!” to introduce middle and high school students to the fundamentals
of toxicology. The program uses the Biological Sciences Curriculum Study (BSCS)
5E Model to Engage, Explore, Explain, Elaborate and Evaluate student under-
standing. Working in teams, students identify common toxins and toxicants in
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their homes, learn about historic and recent poisonings then solve a toxic mystery.
The “Strange Case of Jennifer Strange” is based on the true story of the water in-
toxication death of a California mother. The activities will be demonstrated, and
the pedagogical advantages of the 5E model for science education will be discussed.
1668 Inspector Tox Outreach Activity.
D. Hardej1 and A. Schatz2. 1Department of Pharmaceutical Sciences, St. John’s
University, Jamaica, NY; 2Merck & Co., Whitehouse Station, NJ.
Inspector Tox was developed by the Mid-Atlantic SOT (MASOT) chapter as a
means of introducing the basic concepts of toxicology to school aged children. This
program includes Inspector Tox an investigator of harmful or toxic events and helps
guide the audience through determining if several “toxic scenes” set in the house,
backyard, and at the beach are relatively safe or dangerous. The various scenes are
devised to introduce a mix of potentially toxic compounds including chemicals
(pesticides), natural toxins (bee sting, poison ivy), UV radiation (sunlight), so-
cial/behavioral toxicants (alcohol, cigarette smoking, and poor diet), and even in-
cludes components that the audience might not initially recognize as toxic, such as
food allergies (peanuts) and dust.
1669 Silly Science and Other Activities for K–12 Outreach.
M. M. Bourgeois. EOH, University of South Florida, COPH, Tampa, FL.
Activities to explore dose, toxicity and therapeutic windows of drugs will be
demonstrated and include describing dosages using familiar measurements (i.e.
tablets, teaspoons, medicine cups, glasses, buckets and kiddie pools) that are toxic
by showing children the different amounts of specific household substances (water,
salt, sugar, baby aspirin, etc.) necessary to do them harm.
1670 Exploring Toxicology: Designing Learning Goals and
Evaluation Strategies for Outreach Activities.
E. Shanle and K. L. Blanke. Molecular and Environmental Toxicology Center,
University of Wisconsin Madison, Madison, WI.
Molecular & Environmental Toxicology Center (METC) graduate students at the
University of Wisconsin-Madison participate in toxicology outreach events to pro-
mote a better understanding of toxicology to the local community. METC cur-
rently has 37 graduate students, and 15 students (41%) have participated in at least
one educational outreach activity over the past year. Two activities graduate stu-
dents use to teach about toxicology are Carnation Intoxication and Tox Land.
Carnation Intoxication uses colored dye added to the water of white carnations to
show that plants can take up toxins from their environment along with water and
nutrients. Learning goals for this activity are age dependent and include a basic un-
derstanding of toxicology and the concepts of bioaccumulation and experimental
design. Tox Land is a game that takes participants on a path through global events
related to toxicology while also highlighting local daily activities that have positive
or negative effects on people, animals, and the environment. The learning goals for
Tox Land are that participants are informed about global/local toxicologically rele-
vant events. Both Carnation Intoxication and Tox Land are evaluated using survey
questions that reflect the learning goals to assess what participants learn.
Evaluations are used to improve activities in order to better inform the public about
toxicology.
1671 Resources for Toxicology K–12 Education Outreach:
Updating the SOT K–12 Website.
M. R. Gwinn. Office of Research & Development, US EPA, Washington DC.
The Society of Toxicology’s Education K-12 Sub-Committee is updating the SOT
website to increase support for K-12 education activities, share resources across the
membership and with the public, and increase effectiveness in interacting with ed-
ucators, parents and students. One main goal is to work with the Society member-
ship to create the most useful resource website to help support excitement for toxi-
cology through K-12 education outreach. Ideally, this website would be accessible
to the public, easily searchable and contain hands-on activities, PowerPoint presen-
tations and recommendations for increasing K-12 education outreach. Many SOT
members are active in toxicology outreach, and many more would like to be but
don’t know where to start. Working with Society members, the K-12 Sub-
Committee will include links to successful activities, including past Annual
Meeting activities and ongoing Regional Chapter outreach activities. This resource
website will serve as a tool for those interested in getting involved in K-12 educa-
tion outreach, as well as for those interested in learning more about what toxicolo-
gists do.
1672 The Regulatory Framework for Cosmetics: Current Status,
Recent Science, and Future Prospects.
P. Wexler. Toxicology and Environmental Health Information Program, National
Library of Medicine, Bethesda, MD.
Cosmetic products represent an immense global industry. It has been estimated that
the $60 billion cosmetics industry uses some 12,500 unique chemical ingredients
in personal care products. These products and their chemical components are sub-
ject to varying degrees of regulation globally. In the US, the US FDA’s regulatory
authority over cosmetics is relatively minimal and different from that of other prod-
ucts regulated by the Agency, such as drugs, biologics, and medical devices.
Although the US FDA can inspect cosmetic manufacturing facilities, respond to
complaints of adverse reactions, and conduct research on cosmetics and their ingre-
dients to address safety concerns, the Food, Drug, and Cosmetic Act does not sub-
ject cosmetics to US FDA premarket approval. The regulation of cosmetics in the
European Union is considerably more stringent. A Safe Cosmetics Act of 2011 was
introduced in the US House of Representatives in June, 2011, with the aim of en-
suring that all personal care products are safe. It would establish labeling require-
ments and a safety standard, and issue guidance prescribing good manufacturing
practices for cosmetics and ingredients. People, largely though not exclusively
women, are exposed to vast quantities of cosmetics over their lifetimes. Compared
with the safety of most other products, cosmetics are commonly believed to present
a minimal, if any, risk, and are overlooked in discussions of hazardous substances.
Are the regulations currently in place adequate? What is the US government’s view-
point? What is the stance of industry and advocacy groups on the cosmetics regula-
tory framework? How does the European Union handle issues involving the safety
of cosmetics? Recent scientific issues surrounding production, safety, and testing of
cosmetics could well influence the regulatory arena in years to come. These include
1) the increasing use of nanomaterials in cosmetic products and 2) computational
and high-throughput alternative test methodologies. Both these topics will offer a
backdrop to current and future regulatory approaches.
1673 Safety Evaluation of Nanoparticles and Skin.
N. A. Monteiro-Riviere. Anatomy and Physiology, Kansas State University,
Manhattan, KS.
This presentation will review the physicochemical properties such as size, shape,
coatings, vehicles and charge on skin penetration of nanoparticles (NP) that may
enhance or prevent toxicity. There are properties of a chemical/ NP that determines
its propensity to cause dermatotoxicity, which is the ability to penetrate skin and
subsequently interact with biological components that could elicit a toxicological
response. Recent advances of NP in consumer products such as cosmetics indicate
safety concerns. Penetration of NP in skin is a controversial subject, partly because
many factors that influence absorption were not studied and opinions of some in-
vestigators were generalized and based on limited studies of a few NP, many on
large particles and not nanosize. Discrepancies may relate to differences in NP com-
position, surface chemistry, vehicles or solvents, techniques and methods of expo-
sure, and analytical analysis, and duration of the experiment. This review will show
how formulation, surface chemical alterations and mechanical stressing of skin and
species can modulate the results.
1674 US EPA Computational Toxicology Predicting Cancer and
Noncancer Outcomes for Cosmetics and Industrial
Chemicals.
N. Kleinstreuer. National Center for Computational Toxicology, US EPA, Research
Triangle Park, NC.
EPA’s Computational Toxicology Research Program (CompTox), part of the
broader Chemical Safety for Sustainability Research Program, is at the forefront of
a major transformation in the field of toxicology in how chemicals are evaluated for
potential effects on human health and the environment. EPA is partnering with the
cosmetics company L’Oréal, pharmaceutical companies, European regulatory au-
thorities, and other U.S. government agencies to research ways CompTox can de-
crease the cost of testing large numbers of chemicals, reduce animal use, identify
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targeted testing strategies, and understand potential mechanisms of toxicity. Broad
compound libraries may be screened and prioritized using rapid, automated high-
throughput screening (HTS) assays with human gene and protein targets. Multiple
HTS assay targets, e.g. chemokine expression in human primary skin cells, are
highly relevant to cosmetics safety assessments. CompTox has already screened
more than 1,000 chemicals in over 650 HTS assays in the ToxCast (“toxicity fore-
caster”) research program, including many key ingredients in personal care prod-
ucts, fragrances, and cosmetics. The L’Oréal partnership provides collaborative re-
search funding and access to existing cosmetics ingredients safety data, which are
compared to the ToxCast results to determine the utility of CompTox tools in the
safety assessment of chemicals in cosmetics. CompTox research has also developed
predictive models for cancer and non-cancer toxicity endpoints, with a focus on the
molecular and cellular pathways that are the targets of chemical interactions. Using
computational approaches, EPA is building decision support tools based on
ToxCast in vitro HTS results to help prioritize cosmetics chemicals for further in-
vestigation, as well as applying and refining predictive models for a number of ad-
verse health outcomes. This abstract does not necessarily represent EPA policy.
1675 Cosmetics—US FDA Regulatory Perspectives.
P. A. Hansen. Office of Cosmetics and Colors, US FDA, College Park, MD. Sponsor:
P. Wexler.
The two most important laws pertaining to cosmetics marketed in the United
States are the Federal Food, Drug, and Cosmetic Act (FD&C Act) and the Fair
Packaging and Labeling Act (FPLA). The presentation will cover the specific legal
authorities granted to FDA under these two laws and the regulatory tools FDA uses
to implement them. These regulatory tools include regulations, guidance, inspec-
tions, import monitoring, and other programs. The presentation will also cover
other activities important to the oversight of cosmetic safety, such as FDA’s
Voluntary Cosmetic Registration Program, the agency’s adverse event monitoring
systems, outreach to consumers and health professionals, and more. The role of
FDA’s research and other scientific efforts will be discussed. Examples of recent ac-
tivities in areas important to cosmetic safety will be highlighted. Additional author-
ities that have been suggested for strengthening FDA’s monitoring of cosmetic
safety and labeling will also be presented.
1676 Assessing the Safety of Cosmetics in the US.
H. Breslawec. Personal Care Products Council, Washington DC. Sponsor: P. Wexler.
Cosmetics in the United States have been regulated under the same legal framework
for almost 75 years. The Cosmetic Safety Amendments Act of 2012 proposes to
modernize the existing regulatory frame-work, and the proposed provisions in that
legislation will be discussed. The responsibility for the pre-market assessment of the
safety of cosmetics prior in the US, as in the EU, rests with the manufacturers. This
presentation compares the US regulatory system with that in the EU and discusses
how the industry assesses the safety of cosmetic ingredients and products. The
Cosmetic Ingredient Review (CIR) Expert Panel, is an independent group of der-
matologists, toxicologists and others scientists who have, for over 35 years, assessed
the safety of cosmetic ingredients in an open and public manner. The CIR is
funded by the industry, but operates independently in a transparent manner.
Current issues of interest in safety evaluation of cosmetic ingredients and products,
will be discussed.
1677 Safety Evaluation of Cosmetics and Their Ingredients in
Europe: New Challenges Ahead.
V. Rogiers. Toxicology, Dermato-Cosmetology and Pharmacognosy, Vrije Universiteit
Brussel, Brussels, Belgium. Sponsor: P. Wexler.
Cosmetic products present on the European market must be safe for the consumer.
In Europe, product safety is based on the safety of the ingredients (chemical struc-
ture, toxicological profile, exposure) and is the responsibility of the manufacturer,
first importer or marketer. In July 2013, the EC Regulation n°1223/2009 will re-
place in all Member States the well-known Cosmetic Directive 76/768/EEC with
its important sixth and seventh amendments. Under this RECAST, a so-called re-
sponsible person gets a key function in the follow-up of the safety of the products
under consideration. This is not an easy task as the safety of cosmetics and their in-
gredients has to be guaranteed by the use of in vitro methods, replacing experimen-
tal animal testing. In the EU, during the last years the 3R principle (Refinement,
Reduction, Replacement) of Russell and Burch has been implemented in the spe-
cific legislation of several types of products, including chemicals, pesticides, phar-
maceuticals, food additives, … but the cosmetics legislation is the only one in the
world allowing only replacement methods, which additionally need to be validated.
Therefore, complete banning of animal testing of cosmetics and their ingredients
has a tremendous impact with far reaching consequences. This presentation will
cover the safety assessment process of cosmetics and their ingredients and the
changes that have been introduced by shifting from legislation to a regulation (in-
cluding special considerations for CMRs, nanomaterials...). Also, the actual status
of validated in vitro methods will be given and the prospective for the near future
will be discussed.
1678 Cosmetics: Health Risks, Choices, and Opportunities for
Change.
S. Lunder. Environmental Working Group, Washington DC. Sponsor: P. Wexler.
The $60 billion cosmetics industry relies on over 8,000 unique ingredients to pro-
duce tens of thousands of products sold in the U.S. Women use an average of 12
products daily, with an average of 167 ingredients, and men use about half that.
Products go on skin, lips, hands and around eyes. Consumers ingest, inhale, and
dermally absorb ingredients, in various amounts. Biomonitoring studies have estab-
lished that cosmetic chemicals are common pollutants in blood and urine. Are these
exposures safe? FDA regulates the cosmetic industry, but lacks the authority to re-
quire premarket testing, review products before they are sold, or recall products
known to pose risks. Lacking a mandatory safety standard for cosmetics, the indus-
try makes its own determinations about what is safe enough for costumers. But re-
cent studies have detected lead, formaldehyde and other hazardous compounds in
some everyday cosmetic products. And many other ingredients are poorly tested, or
show no toxicity information at all in the public scientific literature. With the in-
dustry under growing scrutiny and pressure, change is in progress. Consumer
awareness is on the rise, some companies are removing ingredients of greatest con-
cern, and Congress has introduced legislation to modernize cosmetics safety regula-
tions.
1679 The DNT-EST: A Predictive Embryonic Stem Cell Test for
Developmental Neurotoxicity Testing In Vitro.
A. E. Seiler,  K. Gulich,  K. Hayess,  R. Pirow,  B. Slawik,  M. Steinfath,
C. Riebeling,  A. Visan and A. Luch. ZEBET, Federal Institute for Risk Assessment,
Berlin, Germany. Sponsor: E. Fritsche.
Disturbances and diseases of the brain and nervous system such as attention-deficit
hyperactivity disorder, dyslexia, sensory deficits, mental retardation, autism-like
disorders, learning disabilities, and cerebral palsy has also put the vulnerability of
the developing human brain to environmental chemicals exposure into the focus of
public awareness. Most of the chemicals on the market have not been evaluated for
their toxic potency, an issue now being addressed by the registration, evaluation and
authorization of chemicals (REACH) legislation of the European Union. In order
to answer the increasing need for toxicity testing, the development of reliable meth-
ods ensuring a higher throughput than the currently available test guidelines be-
came a main issue of risk assessment. One of the key aspects in this context is the
application of alternative, non-animal approaches including in vitro test methods.
Recently, we developed a new in vitro assay using mouse embryonic stem cells
(mESC) to predict adverse effects of chemicals and other compounds on neural de-
velopment - the so-called DNT-EST. After treatment of differentiating stem cells
for 48 h or 72 h at two key developmental stages, endpoints for neural differentia-
tion, viability and proliferation were assessed. As a reference we treated undifferen-
tiated stem cells 2 days after plating for 48 h or 72 h in parallel to the differentiat-
ing stem cells, also measuring viability and proliferation.
Here, we show that chemical testing of a training set comprising nine substances
(six substances of known developmental toxicity and three without specific devel-
opmental neurotoxicity) enabled a mathematical prediction model to be formu-
lated that can discriminate positive from negative DNT compounds with an in vivo
– in vitro concordance of 100%. Thus, the mESC model introduced here might
represent a useful tool for predicting adverse health effects of exogenous agents that
affect brain development.
1680 Identification of Pathways of Developmental Neurotoxicity
for High-Throughput Testing by Metabolomics.
H. T. Hogberg1,  M. Bouhifd1,  T. Dao1,  A. Kleensang1,  S. J. Nolan1,  S. Odwin-
DaCosta1,  L. Smirnova1,  E. van Vliet2,  H. Welles1,  L. Zhao1 and H. Thomas1.
1The Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD;
2University of Barcelona, August Pi i Sunyer Biomedical Research Institute, Barcelona,
Spain.
Tox-21c proposed a paradigm shift in the field of toxicology. Instead of relying on
traditional animal experiments, the report proposes the application of the latest ad-
vances in science and technology to develop more relevant test strategies. An area of
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toxicology where Tox-21c could have a significant impact is developmental neuro-
toxicity (DNT). There is concern that exposures to environmental chemicals con-
tribute to the increasing incidence of neurodevelopmental disorders in children.
However, due to lack of DNT studies only very few substances have been identified
as developmental neurotoxicants. 
This study aimed to develop an in vitro approach using metabolomics and gene ex-
pression for DNT assessment. A 3D rat primary neuronal organotypic model was
exposed from day 7 up to 21 to suspected (developmental) neurotoxicants includ-
ing pesticides (carbaryl, chlorpyrifos, lindane maneb), drugs (fluconazole, isotre-
tionin, phenytoin, terbutaline, valproic acid) and metals (CaCl2, PbCl2). Mass
spectrometry based metabolomics measurements and quantitative measurement of
genes expressed in different cell types (neural precursor cells, neurons and glial cells)
were performed. Treatment with the different compounds significantly modified
the expression of selected genes, related to the different stages of neuronal and/or
glial cell development and maturation. Moreover, the mass spectrometry analysis
showed differences in metabolite levels between control and treated cells. Further
analysis of the altered metabolites could give mechanistic insight into the DNT of
these compounds. This study demonstrates that gene expression and metabolomic
analysis can be sensitive endpoints for DNT assessment.
Funded by the Swedish Research Council and the FDA
1681 Reduced Nrf2 Signaling Contributes to Human
Neuroprogenitor Cell (hNPC) Aging.
E. Fritsche,  J. Schuwald,  S. Giersiefer and K. Gassmann. IUF, Duesseldorf,
Germany.
During the normal brain aging process, neural progenitor cells (NPC) lose their ca-
pacities to proliferate and differentiate into neurons, which is associated with age-
related impairment of cognitive functions. Molecular mechanisms causing NPC
aging are unknown and also effects of chemicals, which might induce extrinsic
brain aging are so far enigmatic. One common mechanism, however, well known to
be involved in cellular aging processes, is oxidative stress. As a wide variety of toxi-
cants cause cell damage through their ability to elicit oxidative stress, this study tests
the hypothesis if changes in the oxidative stress response contributes to NPC aging.
Therefore, young (1-2 months in culture (MIC)) and aged (3-9 MIC) human
NPCs, which grow as neurospheres, were studied for their abilities to proliferate
and differentiate into neurons. Moreover, their capabilities to activate the nuclear
factor erythroid 2-related factor2 (Nrf2) pathway and thus respond towards oxida-
tive stress were investigated. Finally, Nrf2 was knocked down via lentiviral trans-
duction.
Our data indicate that aged neurospheres reproduce the aging phenotype observed
in brains in vivo: NPC proliferation and the potential to differentiate into neurons
is decreased. Moreover, ‘old’ NPC accumulate beta-galactosidase, which is an estab-
lished aging marker. With regard to the antioxidant defense, young and old NPCs
express mRNA for the transcription factor (Nrf2). However, Nrf2 protein is not in-
duced in old NPCs challenged with H2O2 or tetrachlorohydrochinone (TCHQ)
like it is in young cells. As a consequence, the Nrf2 downstream targets superoxide
dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPx) are not up-reg-
ulated in aged NPCs either. Knocking down Nrf2 indicates that NPC proliferation
and neuronal differentiation are dependent on sufficient Nrf2 signaling.
1682 Effect of Organophosphorus Flame Retardants on Neuronal
Development In Vitro.
W. Mundy1,  T. Freudenrich1,  K. Wallace1 and M. Behl2. 1ISTD, US EPA,
Research Triangle Park, NC; 2Kelly Government Solutions, NTP/NIEHS, Research
Triangle Park, NC.
The increased use of organophosphorus compounds as alternatives to brominated
flame retardants (BFRs) has led to widespread human exposure. There is, however,
limited information on their potential health effects. This study compared the ef-
fects of nine organophosphorus flame retardants (OPFs) with the BFR tetrabromo-
bisphenol A and the known developmental neurotoxicants Pb and t-retinoic acid
on neuronal proliferation and neurite outgrowth in vitro. Proliferation was assessed
in human stem cell-derived neuroprogenitor (hNP1) cells after a 24 hr exposure by
counting the number of cells incorporating BrdU. Neurite outgrowth was assessed
in human stem cell-derived (hN2) neurons and rat primary cortical neurons after
48 hr of exposure by measuring the length and branching of neurites labeled with
βIII-tubulin antibody. Cytotoxicity was estimated by total cell counts. Cells were
cultured and exposed to chemicals (0.003 to 30 uM) in 96-well plates and end-
points quantified using the Cellomics ArrayScan high content imager. In hNP1
cells, Pb, t-retinoic acid, tetrabromobisphenol A and a majority of the OPFs were
cytotoxic at concentrations > 3 uM; however, tricresyl phosphate and triphenyl
phosphate both decreased proliferation at 30 uM in the absence of cytotoxicity. In
hN2 cells OPFs, tetrabromobisphenol A and t-retinoic acid decreased neurite out-
growth only at cytotoxic concentrations, while Pb decreased neurite outgrowth in
the absence of cytotoxicity. Rat neurons were less sensitive than hN2 cells in that no
chemical was cytotoxic at the concentrations tested; however, tricresyl phosphate, t-
butylphenyl diphenyl phosphate, isodecyl diphenyl phosphate, and isopropylated
phenyl phosphate decreased neurite outgrowth at 30 uM. These data suggest that
some OPFs have the ability to affect neurodevelopmental processes in vitro at mi-
cromolar concentrations, and that human neurons may be more sensitive compared
to rats. This abstract does not necessarily reflect U.S. EPA policy.
1683 PCB 95-Induced Dendritic Growth in Primary Cultures of
Rat Hippocampal Neurons Is Dependent on mTOR
Activation.
G. W. Miller,  H. Chen and P. J. Lein. Molecular Biosciences, University of
California Davis, Davis, CA.
Despite being banned since the late 1970s, polychlorinated biphenyls (PCBs) re-
main persistent environmental toxicants that pose significant risk to the developing
nervous system. We recently demonstrated that the non-dioxin-like PCB 95 alters
neuronal connectivity by promoting dendritic arborization in cultured hippocam-
pal neurons via ryanodine receptor (RyR)-mediated, transcriptionally driven mech-
anisms. PCB 95 sensitizes RyR and this interaction requires FKBP12. Interestingly,
FKBP12 also regulates mammalian target of rapamycin (mTOR), and the mTOR
signaling pathway enhances dendritic growth via increased protein synthesis. Based
on these observations, we hypothesize that mTOR signaling contributes to the den-
drite promoting activity of PCBs. To test this hypothesis, primary cell cultures dis-
sociated from hippocampi of wildtype (Sprague Dawley) postnatal rats were plated
at high density and exposed to PCB 95 (2,2’3,5’6-pentachlorobiphenyl, 20 pM – 2
nM) in the absence or presence of rapamycin. Exposure to PCB 95 from days 7 to
9 in vitro increased dendritic growth in pyramidal hippocampal neurons in a con-
centration-dependent manner. Simultaneous exposure to rapamycin at 20 nM, a
concentration that inhibits mTOR activation, ameliorated the dendrite promoting
activity of PCB 95. Ongoing studies are confirming that PCB 95 activates the
mTOR signaling pathway implicated in dendritic growth, and determining
whether these effects are RyR-dependent. These findings identify a novel mecha-
nism by which low level exposures to non-dioxin-like PCBs cause developmental
neurotoxicity, and perhaps dysfunction of other cell types, such as immune cells,
whose function is heavily dependent on mTOR signaling. Supported by NIH
grants R01 ES014901 and P42 ES04699.
1684 Diazinon and Diazoxon Impair Glial-Neuronal Interactions
and Production of Neuritogenic Proteins in Primary
Astrocytes.
D. M. Pizzurro1,  G. Giordano1 and L. G. Costa1, 2. 1Department of Environmental
and Occupational Health Sciences, University of Washington Seattle, Seattle, WA;
2Department of Neuroscience, University of Parma Medical School, Parma, Italy.
Many organophosphorus insecticides (OPs) are increasingly recognized as develop-
mental neurotoxicants. However, the mechanisms by which they exert their neuro-
toxicity remain unclear. This project focuses on a widely-used OP, diazinon (DZ),
and its active metabolite, diazoxon (DZO), and their potential to impair astrocytes’
ability to foster neuronal development. We have previously shown that astrocytes
play a major role in fostering neurite outgrowth in neurons; in this project, a 50%
decrease in the longest neurite length was observed in primary hippocampal neu-
rons incubated with primary astrocytes previously exposed to 10 μM DZ or DZO.
We have also shown that this effect is largely mediated by increased oxidative stress
in astrocytes that results from exposure to DZ or DZO. To further elucidate how
these compounds adversely affect astrocytes and disrupt normal glial-neuronal in-
teractions, levels of the pro-neuritogenic extracellular matrix proteins fibronectin
and laminin were evaluated by Western blot analysis and confocal microscopy.
Fibronectin and laminin have been extensively shown to play a vital role in a variety
of neurodevelopmental processes, including neurite outgrowth and differentiation.
At the same concentrations that significantly inhibit neurite outgrowth, both DZ
and DZO cause a 30-40 % decrease in fibronectin and laminin protein levels in as-
trocytes. These decreases are prevented by astrocyte pre-treatment with the antioxi-
dants melatonin and N-t-butyl-alpha phenylnitrone (PBN), further supporting the
role of oxidative stress in the mechanism of neurotoxicity. These findings were con-
firmed by confocal microscopy analysis of extracellular fibronectin expression,
which showed a 40% decrease after exposure to DZ or DZO. These results suggest
that DZ and DZO impair neuronal development by adversely affecting astrocyte
production and secretion of important neuritogenic factors.
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1685 Increased Oxidative Stress and Mitochondrial Dysfunction in
a PARK2-Mutant iPSC Model of Environmental Risk in
Parkinson’s Disease.
A. Aboud1,  A. M. Tidball1,  K. K. Kumar1,  B. Han1,  G. G. Li1,  K. M. Erikson2,
P. Hedera1,  M. Neely1,  K. C. Ess1 and A. B. Bowman1. 1Neurology, Vanderbilt
University, Nashville, TN; 2University of North Carolina Greensboro, Greensboro,
NC.
Interactions of environmental and genetic risk factors for Parkinson’s disease (PD)
are believed to modify disease onset and progression in a patient-specific manner.
We sought to examine such interactions by assessing sensitivities of neural progeni-
tor cells (NPCs) differentiated from human induced pluripotent stem cells (iPSCs)
to PD-relevant environmental toxicants. These iPSCs were derived from a patient
(SM) with biallelic PARK2 mutations and preclinical PD as assessed by DaTScan,
and from healthy control subjects (CA and CB). Mn exposure resulted in signifi-
cantly higher ROS generation in SM than CA NPCs, but no difference in cytotox-
icity or mitochondrial fragmentation was observed. Moreover, we found that SM
NPCs accumulate significantly less intracellular Mn than CA NPCs. These results
indicate heightened susceptibility of SM NPCs to Mn given the higher rate of ROS
generation and the comparable cytotoxicity and mitochondrial fragmentation in
the presence of significantly less intracellular Mn. While the accumulation of Cu
was not different between SM and CA NPCs, it induced significantly greater ROS
generation, loss of mitochondrial function and cytotoxicity in SM than CA NPCs.
These differences in Cu exposure-associated phenotypes were not observed in the
primary fibroblasts used to generate the iPSC lines. Given the role of PARK2 in mi-
tochondrial integrity, heightened sensitivity of SM NPCs to manganese and copper
may be due to suboptimal mitochondrial function in cells that lack functional
PARK2. Our results support the hypothesis that genetic alterations may increase
sensitivity to specific toxicants. We demonstrate here that iPSC technology can de-
tect patient-specific and cell type-specific differences in vulnerability to PD envi-
ronmental risk factors. Support: NIH ES016931 and NS078289
1686 Evaluation of the Ames II and 96-Well In Vitro Flow
Micronucleus (MN) Assay Using 25 ToxCast™ Chemicals.
M. Aardema1,  A. D. Kligerman2,  K. Houck1,  R. R. Young3,  L. F. Stankowski3,
K. Pant3 and T. E. Lawlor3. 1Marilyn Aardema Consulting; Chief Scientific Advisor
Toxicology BioReliance by SAFC, Fairfield, OH; 2US EPA Office of Research and
Development, Research Triangle Park, NC; 3BioReliance by SAFC, Rockville, MD.
ToxCast™ is a multi-year effort to develop a cost-effective approach for the US
Environmental Protection Agency to prioritize thousands of chemicals that need
toxicity testing. Initial evaluation of more than 650 high-throughput, robotic, mi-
crowell-based endpoints with little or no metabolic activation showed that most of
these assays lacked specificity and sensitivity for detecting direct-acting genotoxi-
cants. In an attempt to understand how to improve this approach for genotoxicity
testing, we evaluated the specificity and sensitivity of 25 selected Phase I and Phase
II chemicals from the ToxCast™ program using standard genotoxicity endpoints.
These chemicals were chosen because of their known genotoxicity, their responses
in specific ToxCast™ assays, or available data from the literature and databases.
The tests used were the medium throughput Ames II and in vitro flow MN assays
conducted ±S9. Results to date indicate that, as expected, the Ames II assay showed
an excellent correlation with published data and industry submissions. Overall con-
cordance was 89 and 82% (with and without S9, respectively). The MN assay also
had good concordance of 78 and 73% (with and without S9, respectively); how-
ever, the number of conclusive calls was significantly smaller mainly due to concen-
trations limits and cytotoxicity. Chemicals were also tested in a 96-well in vitro sin-
gle cell gel electrophoresis (Comet) assay though there were insufficient data from
the literature to evaluate performance of this assay. Taken together, these studies
offer a promising approach to higher throughput genotoxicity testing. [This is an
abstract of a proposed presentation and does not necessarily reflect US EPA policy.]
1687 The Role of DNA Polymerase Eta in Oxidative Stress
Response and Mutagenesis.
K. N. Herman and S. D. McCulloch. Toxicology, North Carolina State University,
Raleigh, NC.
Oxidative stress is induced by exposure to chemicals and radiation such as heavy
metals, pesticides and ultraviolet exposure from sunlight. Oxidative stress leads to
elevated levels of reactive oxygen species (ROS), which in turn can produce DNA
lesions including 8-oxoguanine (8-oxoG). 8-oxoG has been linked to mutagenesis,
cancer and aging. One way cells respond to this damage is translesion synthesis
(TLS), most often by Y family DNA polymerases. Y-family polymerases have open
active sites, allowing them to copy past DNA adducts that otherwise block replica-
tion. DNA polymerase eta (pol η) is known to bypass cyclobutane pyrimidine
dimers (CPD); more recently, pol η has been shown to bypass 8-oxoG.
Intriguingly, while in vitro bypass of 8-oxoG by pol η appears to occur with nearly
50% error rate, in vivo experiments suggest it acts to suppress mutagenesis, similar
to CPD. This apparent discrepancy has not been fully explained. 
Due to the ability of pol η to bypass 8-oxoG very efficiently but with poor fidelity
in vitro, we investigated pol η response in cells to oxidative-stress-induced DNA
damage. We have demonstrated that pol η acts as a suppressor of oxidative stress-in-
duced mutagenesis, likely due to bypass of 8-oxoG. We examined both pol η-ex-
pressing and -deficient cells and evaluated cell responses to various ROS-inducing
treatments. We evaluated the cytotoxicity of these treatments and found that while
pol η did not greatly alter cell survival, the mutation rate of surviving cells was
markedly decreased when measured using hypoxanthine phosphoribosyl transferase
(HPRT) mutation assay; showing the presence of pol η suppresses mutations com-
pared to deficient cells. The measured mutation rates varied depending on the treat-
ment used, possibly due to variation in the types and levels of different lesions gen-
erated by each. In total, the results demonstrate that pol η acts to suppress oxidative
stress-induced mutations, suggesting that polymerase fidelity in vitro data is only
part of the larger picture of lesion bypass.
1688 Different Micronucleus Induction of Mice Exposed to Ν-
Ethyl-Ν-Nitrosourea at Light and Dark Dosing Times.
K. Ito1, 2,  S. Masumori1,  M. Nakajima1,  M. Hayashi1,  H. Sakakibara3 and
K. Shimoi2, 4. 1Public Interest Incorporated Foundation Biosafety Research Center,
Iwata, Japan; 2Graduate School of Integrated Pharmaceutical and Nutritional
Sciences, University of Shizuoka, Shizuoka, Japan; 3Graduate School of Agriculture,
University of Miyazaki, Miyazaki, Japan; 4Institute for Environmental Sciences,
University of Shizuoka, Shizuoka, Japan.
Mammals, including human beings, have a circadian clock system to regulate be-
havioral and physiological processes. In this study, we investigated the effect of dos-
ing time on micronucleus induction in the bone marrow by evaluating the frequen-
cies of micronucleated peripheral reticulocytes (MNRETs) in mice exposed to
Ν-ethyl-Ν-nitrosourea (ENU) to assess any difference in genotoxic sensitivity to
chemicals between light and dark periods (inactive phase/sleep phase for rodents
and active phase/awake phase for rodents). Nine-week-old male C3H/HeSlc mice
were treated intraperitoneally with ENU (12.5 or 25 mg/kg body weight) at zeitge-
ber time (ZT) 3 in the light period or ZT15 in the dark period, and then the time
courses of the frequencies of the MNRETs were determined. The frequencies of the
MNRETs induced by ENU increased time-dependently and peaked at 48 hr after
treatment for ZT3 and ZT15, and were obviously higher in the ZT15 treatment
group than the ZT3 treatment group. The MNRETs were measured at 48 hr after
treatment with ENU (25 mg/kg body weight) at various dosing times (ZT0, 3, 6,
12, 15 and 18). The frequencies of the MNRETs in mice treated at ZT0, 15 and 18
were significantly higher than those in mice treated at ZT3, 6 and 12. These results
suggest that genotoxic sensitivity to ENU in mouse bone marrow is different be-
tween light and dark periods maybe due to different biological responses (detoxifi-
cation, cell cycle, DNA repair, etc.) related to circadian rhythms. The results in this
study also suggest that varying treatment time points may change the toxicological
activity of chemicals.
1689 The Use of Immunoflourescent Techniques in the CB
Human Lymphocyte Micronucleus Test for Discrimination
of Clastogenic and Aneugenic Compounds.
A. Poth and S. Bohnenberger. Genotoxicity and Alternative Toxicology, Harlan
Cytotest Cell Research, Rossdorf, Germany.
The micronucleus assay in human lymphocytes was developed as a short term
screening test for the detection of both clastogenic and aneugenic chemicals. For
human lymphocytes it is recommended to score micronuclei by the cytokinesis
block (CB) method using cytochalasin B. The original method developed by
Fenech and Morley, 1985, focusses exclusively on binucleated cells. However, re-
cent studies suggest that micronuclei in mononucleated cells could provide com-
plementary information. Results obtained with aneugenic compounds show a dose-
dependent increase of micronuclei in mononucleated cells. At present, the
underlying mechanism has not been clearly indentified. In order to obtain more in-
formation a immunofluorescence technique was employed involving CREST
analysis for detection of kinetochore proteins. As reference positive controls,
Ethylmethanesulfonate (EMS) and Mitomycin C (MMC) were used as clastogenic
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compounds and Colcemide as an aneugenic compound. Both, MMC and EMS
exert a clastogenic activity which lead to a dose-dependent increase in micronu-
cleus-positive binucleates only. In contrast treatment with colcemide resulted in an
increase in micronuclei in both mononucleated and binucleated cells. The high
level of CREST+ micronuclei in mononucleated cells suggest that polyploid cells
which have undergone an incomplete endomitosis might be the case. Our results
suggest that micronuclei in mononucleated cells can be used to investigate the
aneugenic activity of chemicals in a fast and easy way, and can be included in the
CB assay with human lymphocytes.
1690 Induction of Nucleotide Excision Repair Is Diminished in
Heterozygous p53 Knockout Mice following Chronic
Dietary Exposure to Aflatoxin B1
J. E. Mulder1,  R. Mehta2,  G. S. Bondy2 and T. E. Massey1. 1Pharmacology and
Toxicology, Queens University, Kingston, ON, Canada; 2Toxicology Research Division,
Health Canada, Ottawa, ON, Canada.
Aflatoxin B1 (AFB1) is produced by Aspergillus species, moulds that grow on grains,
oilseeds and spices. AFB1 is biotransformed in vivo into a highly reactive metabolite
that binds to DNA, forming DNA adducts that may induce cancer if not repaired.
p53 is a tumour suppressor gene implicated in both AFB1 carcinogenesis and the
regulation of DNA repair. Male heterozygous p53 knockout mice (p53 (+/-);
B6.129-Trp53tm1BrdN5, Taconic) and their wild type controls were exposed to 0, 0.2
or 1.0 ppm AFB1 in AIN 93M semi-purified diet for 26 weeks. Nucleotide excision
repair (NER) activity of lung and liver nuclear protein extracts was assessed with an
in vitro assay, using adducted plasmid DNA as a substrate. In wild type mice, repair
of AFB1-N
7-Gua adducts was 124% and 96% greater than control in lung extracts
from mice exposed to 0.2 ppm or 1.0 ppm AFB1 respectively, and 224% greater
than control in liver extracts from mice exposed to 0.2 ppm AFB1 (p<0.05). In
p53(+/-) mice, repair of AFB1-N
7-Gua was only 45% greater than control in ex-
tracts from lungs of mice exposed to 0.2 ppm AFB1 (p<0.05), and no difference was
observed in extracts from lungs of mice treated with 1.0 ppm AFB1 or extracts from
livers of mice treated with either AFB1 concentration. When comparing AFB1 ef-
fects on NER activity after normalizing to untreated tissue, the induction of NER
activity was significantly attenuated in p53(+/-) mice compared to wild type con-
trols in both lung and liver, and AFB1 dose had a significant effect in p53(+/-) mice.
In conclusion, the increase in NER activity seen in wild type mice following
chronic AFB1 exposure indicates a homeostatic response to DNA damage. This
homeostatic response was diminished or lost in p53(+/-) mice, which is consistent
with p53 having a key role in regulating NER. (Supported by CIHR Grant No.
MOP- 89698 and GRDI)
1691 XPC Haplotypes Alter Nucleotide Excision Repair and Levels
of UV-Induced Genetic Damage.
C. M. Rondelli1, 2,  C. J. Etzel3,  C. E. Cross2,  M. Xu2 and S. Z. Abdel-Rahman2,
1. 1Cell Biology & Environmental Toxicology, University of Texas Medical Branch,
Galveston, TX; 2Obstetrics and Gynecology, University of Texas Medical Branch,
Galveston, TX; 3Epidemiology, MD Anderson Cancer Center, University of Texas,
Houston, TX.
The XPC protein encoded by the polymorphic XPC gene is essential for initiating
global genome nucleotide excision repair (NER). Over 90 single nucleotide poly-
morphisms (SNPs) have been reported in XPC, but only a few were evaluated as
disease risk modifiers with conflicting results. SNPs do not exist as independent
variants in the genome but as combinations forming specific haplotypes due to
linkage disequilibrium (LD) between them. The impact of XPC haplotypes on
DNA repair capacity (DRC) is not known. Using bioinformatics, we recently de-
termined the haplotype structure of XPC and found a correlation between XPC
haplotypes and genetic damage in smokers. In this study we test the hypothesis that
XPC haplotypes influence DNA damage by altering NER capacity through modi-
fying transcription and/or translation. To test this hypothesis, we exposed human
lymphoblastoid cell lines representing different XPC haplotypes to low UV dose to
induce pyrimidine-6-4-pyrimidone photoproducts (6-4PPs) and cyclopyrimidine
dimers (CPDs) formation. Levels of these adducts (reflecting DNA damage) and
their rate of removal over time (representing DRC of the cells) were determined to
evaluate the effect of XPC haplotypes on NER. We found that XPC haplotypes do
not only influence NER, but that the haplotype influence is affected by the adduct
being repaired. To provide a mechanistic explanation to our findings, we deter-
mined XPC mRNA and protein expression levels in different cell lines as a function
of time after exposure. Our data indicate that XPC haplotypes significantly influ-
ence the rate of translation and transcription. Additional in-depth mechanistic
studies examining the effects of haplotypes on XPC transcription, translation, and
function are currently in progress to clarify the role of XPC haplotypes in disease
risk. (Supported by F31-019053; T32-07454; P30-006676; K07-CA093592;
CA123208.)
1692 Evaluation of High-Throughput Mutation Test with
Proprietary Pharmaceutical Candidates.
H. Adachi,  K. Kijima,  T. Yamada,  J. Kimura and H. Funabashi. Dainippon
Sumitomo Pharma Co., Ltd., Osaka, Japan.
[Background] High-Throughput Fluctuation Test (HTFT) is a bacterial gene mu-
tation assay in Salmonella typhimurium with the same endpoint as that of the
Ames assay. HTFT requires only a few mg of a test sample for the assay, which
makes it possible to incorporate the assay into an early drug developmental stage. It
is reported that the results in HTFT have a high concordance with the Ames assay
results for well-known positive and negative control compounds. In the present
study, to assess the availability of the test to early drug screening, we tested our pro-
prietary pharmaceutical candidates in HTFT. 
[Method] HTFT was performed for 47 our proprietary pharmaceutical candidate
compounds in TA100 and TA98 with and without metabolic activation system pre-
pared from rat liver (S9). Most of the compounds tested in this study were pre-
dicted as not having any obvious structural alerts for mutagenicity by a commer-
cially available in silico system, DEREK for Windows. Microplates were used
during the pre-incubation and incubation period, and mutation was detected with
a pH indicator, which reflects the bacterial growth in medium. All the test com-
pounds were also evaluated in the conventional Ames assay using five strains and
the results were compared with HTFT results.
[Results and Discussion] The sensitivity (the proportion of positives in Ames assay
correctly identified by HTFT), specificity (the proportion of negatives in Ames
assay correctly identified by HTFT) and the concordance between the both assay
results for a total of 47 test compounds were 88% (23/26), 86% (18/21) and 87%
(41/47), respectively. In conclusion, the results of the present study indicate that
HTFT is a reliable assay with a high sensitivity and specificity for detecting geno-
toxic compounds even among pharmaceutical candidates without obvious muta-
genic structural alerts as well. Considering the advantages with respect to the
amount of required sample and potential throughput capacity, HTFT is therefore
thought to be a good screening tool for genotoxicity in the earlier drug screening.
1693 Establishment of the Comet Assay and Micronucleus Test
Using Chimeric PXB-Mice® with Humanized Liver.
C. Tateno1, 2,  Y. Ishida1, 2,  M. Kakuni1,  M. Fukumuro3,  J. Tanaka3,
S. Masumori3,  M. Nakajima3 and M. Hayashi3. 1PhoenixBio Co., Ltd.,
Higashihiroshima, Japan; 2Liver Research Project Center, Hiroshima University,
Hiroshima, Japan; 3Public Interest Incorporated Foundation, Biosafety Research
Center, Iwata, Japan.
Genotoxicity studies have been performed as in vitro screening tests to predict car-
cinogenesis and genetic disorders in humans. Notably, the comet assay and mi-
cronucleus test may be used to detect the in vivo genotoxicity of test compounds
and their metabolites in rodents. However, metabolic activities differ between hu-
mans and rodents. Thus, we developed humanized chimeric PXB-mice®—whose
liver retains human-type metabolic activities—by using albumin enhancer/pro-
moter-driven urokinase plasminogen activator transgenic/severe combined immun-
odeficiency disease (uPA/SCID) recipient mice. Using the PXB-mice, we per-
formed a comet assay and micronucleus test of N-ethyl-N-nitrosourea (ENU). At
the SOT 2012 Annual Meeting, we presented that a dose-dependent increase in the
number of positive cells was observed (i) in the comet assay using liver, (ii) in the
micronucleus test using bone marrow, but not (iii) in the micronucleus test using
liver, which is probably because of insufficient mitotic condition in the liver. In the
present study, we established a new type of PXB-mice by using cDNA-uPA/SCID
recipient mice, which would be expected to supply a higher mitotic condition for
human hepatocytes. Cryopreserved human hepatocytes from a 2-year-old Hispanic
were transplanted into cDNA-uPA/SCID mice. The 7- or 9-week-old male new
PXB-mice were orally treated daily with ENU at 25 mg/kg body weight for 2 or 4
weeks. The liver and femur bone marrow were collected from the PXB-mice and
employed in the comet assay and micronucleus test. The number of positive cells
significantly increased (i) in the comet assay using hepatocytes and also in the mi-
cronucleus test using (ii) bone marrow or (iii) hepatocytes from the 7-week-old
male PXB-mice treated orally with ENU for 4 weeks. In conclusion, we established
comet assays and micronucleus tests using a new type of PXB-mice to predict
human genotoxicity in vivo.
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1694 Reconstructed 3D Human Skin Micronucleus Assay:
Preliminary Prevalidation Results.
R. Fautz1,  S. Pfuhler2,  M. Aardema3,  G. Ouédraogo4,  B. Barnett2,  B. Faquet4,
G. Mun5,  N. J. Hewitt6,  S. Hoffmann7,  R. Curren5 and J. Barroso8. 1Kao
Germany GmbH, Darmstadt, Germany; 2Procter & Gamble Company, Cincinnati,
OH; 3Marilyn Aardema Consulting LLC, Fairfield, OH; 4LOreal, Paris, France;
5IIVS Inc., Gaithersburg, MD; 6Hewitt Consutling, Erzhausen, Germany; 7seh
Consutling+Services, Koeln, Germany; 8Cosmetics Europe, Brussels, Belgium.
The skin is the main route of exposure of many chemicals and cosmetic ingredients;
therefore, Cosmetics Europe (formerly COLIPA) has funded projects to establish
and evaluate more realistic models for genotoxicity using 3D reconstructed skin
(RS) tissues. The aim is to use these to follow-up on positive results from the in
vitro genotoxicity battery[1], which has been criticized for its low specificity. The
RS model, EpiDermTM, was combined with the micronucleus (MN) assay and the
resulting “RSMN” assay exhibited good intra- and inter-laboratory reproducibil-
ity[2], and correctly identified 3 coded chemicals as being either positive or nega-
tive[3]. A detailed protocol for the RSMN assay was published, together with a har-
monized scoring atlas for micronuclei[4]. We have extended the number of coded
chemicals to 29 as part of the pre-validation process. Eight of these were true posi-
tives, 11 were false positives and 10 were negatives. There was an excellent speci-
ficity (88%), demonstrating that the RSMN has a good potential to improve the
specificity of in vitro genotoxicity assays as a whole. Of the 8 carcinogens with a
suggested genotoxic mode of action, 5 were correctly predicted. While this indi-
cates that the model shows decent sensitivity, the total number of true positives was
considered too low to draw a final conclusion about the sensitivity of this assay.
Therefore more coded compounds will be tested in a next project phase with a
focus on genotoxic carcinogens. Overall, these data support the use of the 3D skin
EpiDerm™ model for genotoxicity testing of dermally applied chemicals. [1]
Pfuhler et al. 2010, Reg Pharm Tox; [2] Hu et al. Mutat Res. 2009, 673(2):92; [3]
Aardema et al. 2010, Mutat Res. 2010, 701(2):123, [4] Dahl et al. Mutat Res.
2011, 720(1-2):42. Sponsored by CosEur and ECVAM
1695 Reduction of Ataxia telangiectasia Associated Death Rates in
ATM KO Mice with Yel002.
M. J. Davoren and R. H. Schiestl. Environmental Health Science, University of
California Los Angeles, Los Angeles, CA.
Ataxia Telangiectasia is a devastating disease that affects 1 in every 40,000–100,000
individuals worldwide. 1% of Americans carry a copy of a compromised Ataxia
Telangiectasia Mutated (ATM) gene, an important signaling protein involved in
both DNA repair and apoptosis. Having two copies of defective or null alleles leads
to the disease, symptoms including motor defects (ataxia), extreme sensitivity to
ionizing radiation, immunodeficiency, and predisposition to cancer. Lymphoma
rates, in particular, occur at nearly 100 times the normal. Despite all of the defects,
patients with AT are mentally normal, and many promising young high school and
college graduates have their lives cut short by 22, the median age of death. The only
treatments are palliative, focused on treating infections that result due to the com-
promised immune system.
The Schiestl Lab investigates the nature of DNA damage and its repair. During a
yeast based high-throughput screen for agents that mitigate the damaging effects of
radiation, the candidate drug Yel002 was identified. In later trials on healthy mice
subjected to lethal radiation doses, Yel002 was found to significantly increase sur-
vival, even when administered a day after the insult. As radiation induces damage
largely via strand breaks in DNA, it was thought to act by upregulating the DNA
repair process. As AT patients symptoms result from DNA repair deficiency, we de-
cided to treat ATM KO mice with the drug weekly in a long term study to cut
death rates. Previous data on this same mouse strain showed that these mice usually
die of cancer in the sterile facility by 50 weeks on average. Mice treated with a
weekly injection of 75mg/kg Yel002 show far lower death rates – over 80% are still
alive at week 60, and survival looks promising as it continues.
1696 Classification of Genotoxic Mode of Action in TK6 Cells via
a High Content, Flow Cytometric In Vitro Micronucleus
Assay.
S. Bryce,  S. Avlasevich,  J. Weber,  E. Beha and S. Dertinger. Litron Labs,
Rochester, NY.
This laboratory has previously described a high content flow cytometric method for
scoring micronuclei (In Vitro MicroFlow®) in CHO-K1 cells that is capable of dis-
criminating aneugenic from clastogenic modes of action (MoA). It would be useful
to capture MoA information when studying other cell lines, for instance the human
cell line TK6. Previous reports suggested that the proportion of metaphase cells rep-
resents a signature that can effectively discriminate between clastogenic and aneu-
genic MoA. We therefore set out to combine a flow cytometric micronucleus scor-
ing method with a technique for enumerating metaphase cells and evaluate the
multiplexed assay’s ability to differentiate clastogenic and aneugenic responses. In
order to accomplish metaphase scoring, the fluorescent reagent anti-histone H3
(pS28) antibody (anti-H3-P), which recognizes the phosphorylated form of the hi-
stone, was incorporated into the flow cytometric micronucleus assay procedure.
TK6 cells were treated in a continuous exposure design with each of ten reference
clastogens and seven reference aneugens. At the time of harvest (24 to 27 hrs after
treatments were initiated), cells were processed according to In Vitro MicroFlow kit
instructions; with the exception that anti-H3-P was incorporated into the sample
processing. Data acquisition occurred for 4 mins per sample and provided approxi-
mately 2,000 metaphase cells per replicate. Each of the genotoxicants was observed
to cause increased MN frequencies and relative survival values to decrease in a con-
centration-dependant manner. Whereas the proportion of metaphase cells to total
cells (as well as the proportion of metaphase cells to G2/M cells) were decreased by
each of the ten reference clastogens, they were elevated by each of the seven aneu-
gens. These data indicate that automated and multiplexed micronuclei and
metaphase cell-scoring of TK6 cells provide strong aneugenic versus clastogenic
MoA signatures that effectively discriminate between these classes of genotoxic
agents.
1697 Qualification of 96-Well High-Throughput In Vitro
Micronucleus and Comet Assays.
T. E. Lawlor1,  K. Pant1,  M. Aardema2 and L. F. Stankowski1. 1BioReliance by
SAFC, Rockville, MD; 2Marilyn Aardema Consulting, Fairfield, OH.
We recently qualified 96-well high throughput versions of the in vitro micronucleus
(MN) assay in CHO cells, and the Comet assay in TK6 cells. The MN assay evalu-
ated the ten reference compounds in OECD TG 487 using MicroFlowTM kits
(Litron Laboratories; 10 independent trials), while the Comet assay evaluated six
reference compounds using the Japanese Center for Validation of Alternative
Methods (JaCVAM) Comet validation protocol (version 6.2; four independent tri-
als). All trials were performed, using 7-10 concentrations in duplicate cultures with
and/or without exogenous metabolic activation (S9), to assess inter- and intra-ex-
perimental variability, as well as sensitivity and specificity. Using an empirical analy-
sis of the results, it was possible to reduce the criteria for a positive response for mi-
cronuclei and hypodiploidy to 2- and 6-fold concurrent vehicle control values,
respectively, thereby increasing sensitivity without an appreciable loss of specificity.
Mitomycin C and cytosine arabinoside were reproducibly positive without S9, as
were benzo(a)pyrene and cyclophosphamide with S9; all four compounds produced
a clastogenic signature. Colchicine and vinblastine were positive with and/or with-
out S9, and both produced a significant increase in micronuclei and hypodiploid
cells, indicative of an aneugenic mechanism of action. In contrast, di(2-ethyl-
hexyl)phthalate, nalidixic acid, pyrene and sodium chloride were all negative in all
trials and at all dose levels with and without S9 except for one concentration of
pyrene in one trial +S9. Reproducible positive results were observed in the Comet
assay for the genotoxins 2-aminoanthracene +S9, and 9-aminoacridine, ethyl
methanesulfonate and methyl methanesulfonate –S9, while reproducible negative
results were observed for the nongenotoxins cycloheximide and triton-X ±S9.
These results support the utility of these high throughput assays for genotoxicity
screening in general and are being employed in the US EPA ToxCast program.
1698 Integration of Pig-a and Micronucleus Endpoints into a 28-
Day Rodent Toxicity Assay with Urethane.
L. F. Stankowski1,  M. Aardema2,  T. E. Lawlor1,  S. E. Miller1,  S. Roy1,  Y. Xu1
and R. H. Elbekai1. 1BioReliance by SAFC, Rockville, MD; 2Marilyn Aardema
Consulting, Fairfield, OH.
Urethane is a rodent carcinogen (by po, ip, sc and inhalation routes) and is muta-
genic and clastogenic in vivo, but generally considered non-genotoxic in vitro.
Thus, it is an important chemical to evaluate the utility of the Pig-a in vivo gene
mutation assay. As part of the Pig-a international validation trial, we examined the
induction of CD59-negative reticulocytes and total red blood cells (RETCD59- and
RBCCD59-) in the peripheral blood of male Sprague Dawley® rats treated with ure-
thane for 29 consecutive days (25.0, 100 and 250 mg/kg/day, po). Animals also
were evaluated for micronucleated reticulocytes (mnRET) in peripheral blood on
Days 4, 15 and 29. Ethylmethane sulfonate (EMS; 200 mg/kg/day on Days 3, 4,
13, 14, 15, 27, 28 and 29) and sterile saline (daily) were evaluated as positive and
vehicle controls, respectively (all n = 6). All animals survived to Day 29, no animals
exhibited overt signs of toxicity due to urethane, and there were no significant dif-
ferences in body weight gain between urethane and control groups. Significant,
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dose dependent increases (p< 0.05) were observed for urethane, up to 74- and 24-
fold vehicle control values for RETCD59-, up to 4.2- and 8.1-fold for RBCCD59-
(each on Days 15 and 29), and up to 6.6-, 4.0- and 5.3-fold for mnRET (Days 4,
15 and 29). EMS also induced significant 31- and 18-fold increases in RETCD59-,
4.5- and 5.7-fold increases in RBCCD59- (Days 15 and 29), and up to 2.8-, 11- and
16-fold in mnRET (Days 4, 15 and 29). These results compare favorably with ear-
lier in vivo observations, and demonstrate the utility and sensitivity of the Pig-a in
vivo gene mutation assay. Samples also were collected for evaluation of chromo-
some aberrations in peripheral blood lymphocytes; micronucleus induction in bone
marrow; and DNA damage in peripheral blood and various organs using the
Comet assay (the 29th dose being required for the Comet endpoint at terminal sac-
rifice).  However, these latter analyses are ongoing.
1699 Reconstructed Skin Micronucleus (RSMN) Assay in Normal
Human 3-Dimensional (NHu-3D) Skin Model.
M. Klausner,  Y. Kaluzhny,  V. Karetsky and J. DeLuca. MatTek Corporation,
Ashland, MA. Sponsor: P. Hayden.
Safety assessment of new products for human use requires genotoxicity testing.
Current in vitro assays have low specificity resulting in a high rate of false positives
that may be due to use of transformed cell lines, non-physiological exposures, and
lack of normal metabolism. Furthermore, the 7th amendment to the Cosmetics
Directive banned in vivo genotoxicity testing in 2009. 
EpiDerm is a 3D normal human cell-based epidermal model that is highly repro-
ducible, contains a skin-like barrier, and possesses biotransformation capabilities in-
cluding CYP450, GST, and UDP enzymatic activity. The RSMN assay utilizes top-
ical application of test materials in a similar fashion to actual human contact. Test
materials are dosed 2 to 4 times every 24 h in the presence of Cytochalasin-B and
cells are harvested from the EpiDerm tissues 24 hours after the last dose.
Altogether, 50 materials (24 direct genotoxins, 14 non-genotoxins, and 12 geno-
toxins that require metabolic activation) have been analyzed in the RSMN assay.
Analysis of the complete set of chemicals resulted in 93.3% Sensitivity, 100%
Specificity, and 95.5% Accuracy. In addition, a co-culture system that utilized a
lymphoblast cell line TK6 cultured beneath of the EpiDerm tissues was used as a
target to expand the relevance of dermally applied compounds to systemic carcino-
genicity. Micronucleus induction in TK6 cells was assessed after treatment of the
EpiDerm with MitomycinC, β-Propiolactone, and Ethyl Methanesulfonate. The
TK6 cells, as well as the EpiDerm tissue itself, were found to be positive. However,
exposure to the genotoxin, Benzidine, was negative in EpiDerm but positive in
TK6 cells.
In conclusion, the RSMN assay that utilizes the EpiDerm skin model is more spe-
cific in identifying dermal human carcinogens than existing in vitro assays. The ap-
proach of using the human reconstructed skin together with a human lymphocyte
target cell line appears to be a good method of detecting genotoxic effects for hard
to predict chemicals and expanding the relevance of dermally applied compounds
to systemic carcinogenicity.
1700 The Use of 3D Human Dermal Equivalents to Assess
Genotoxicity of Textile Dyes.
D. M. Leme1,  F. L. Primo2,  A. Tedesco2 and D. P. Oliveira1. 1Faculdade de
Ciências Farmacêuticas de Ribeirão Preto (FCFRP/USP), Ribeirão Preto, Brazil;
2Faculdade de Filosofia, Ciências e Letras de Ribeirão Preto (FFCLRP/USP), Ribeirão
Preto, Brazil.
Introduction: The use of 3D-human reconstructed skin seems to be promising for
safety assessment of chemicals. Compared to traditional 2D in vitro systems, which
basically represent one cell type, this model can provide organ-specific toxicity, me-
chanical/biochemical signaling and cell-cell communication. Humans are daily ex-
posed to textile dyes through skin contact with colored garments. Studies have
pointed that some textile dyes can be hazard to human beings. Considering that
dyes, under conditions of perspiration, can migrate from clothes and penetrate into
human skin, identification of safe textile dyes, related to dermal exposure, is rele-
vant to avoid human health problems. Objective: Genotoxicological assessments of
Reactive Green 19 (RG19), Reactive Blue 2 (RB2) and Disperse Red 1 (DR1) using
the Comet assay with in vitro human dermal equivalents. Methodology: The der-
mal equivalent models were constructed in 3D-collagen matrix, using human gin-
gival fibroblasts isolated from adult donors, at a density of 3x105 cell/cm2, into 60
mm cell culture dishes, containing collagen type-I and D-MEM supplemented
with 10% BFS and other nutrients (Primo et al., 2011). The alkaline Comet assay
was carried out according to Tice et al. (2000), with slight modifications. Results:
RB2 and DR1 did not induced DNA damage, whereas RG19 showed weak geno-
toxic response. Discussion: Our data are not in agreement with previous genotoxi-
cological assessments of these dyes using 2D cell cultures. Genotoxicity was re-
ported to DR1 using in vitro hepatocarcinoma cells. However, here this dye showed
to be non-genotoxic. RG19 did not induce DNA damage in in vitro human dermal
fibroblasts, but a weak genotoxicity was here observed. Conclusion: This difference
might be related to the test systems used in each study (2D and 3D cell cultures).
3D-human reconstructed skin affords better cellular environment, which could
provide more reliable data of the genotoxicity of chemical (e.g. textile dyes).
1701 Comparison of Two High-Throughput Methods for In Vitro
Micronucleus Assessment Comparison of Two High-
Throughput Methods for In Vitro Micronucleus Assessment.
B. Goodwin1,  J. Bemis2,  Z. Liu3,  S. Bryce2,  K. Luu3,  K. L. Witt4,
C. P. Austin1,  R. R. Tice4 and M. Xia1. 1NCGC, NCATS, NIH, Rockville, MD;
2Litron Laboratories, Rochester, NY; 3IntelliCyte Corporation, Albuquerque, NM;
4Division of the National Toxicology Program, NIEHS/NIH, Raleigh, NC.
Identification of compounds with the potential to induce DNA damage is an im-
portant component of the chemical safety evaluation process. Micronuclei (MN), a
frequently used endpoint for genotoxicity studies, are formed by clastogens induc-
ing acentric chromosome fragments or aneugens disrupting anaphase during cell
division. The traditional in vitro micronucleus (IVMN) test uses trained individu-
als to manually count MN, which is both labor intensive and time consuming.
Here, we compare the performance of two automated high throughput methods for
MN detection using CHO-k1 cells in 384-well format. Method 1 is a high-content
MN assay using the Thermo Scientific Arrayscan VTi. Method 2 is the IntelliCyt
Corp high capacity flow (HCF)-based High Throughput Flow Cytometry (HTFC)
Screening System® using the In Vitro MicroFlow® kit (Litron Laboratories). For
this comparison, cells were exposed to 10 compounds (20 dilutions, selection based
on solubility, cytotoxicity, dose range finding, or 100 μM limit concentration) for
24h, and processed on both systems, or incubated with cytochalasin B (CB) for an-
other 24h prior to Arrayscan analysis. The compounds used included clastogens
(etoposide, camptothecin, methyl methanesulfonate, bleomycin), aneugens
(colchicine, griseofulvin, vincristine, geldanamycin), and non-genotoxic ones
(nalidixic acid, sodium chloride). Both platforms correctly identified the known
MN-inducing compounds and the 2 non-genotoxic compounds. Scoring of a 384-
well plate required ~3h for the ArrayScan and 30m for the HTFC; the latter plat-
form was also able to distinguish aneugens from clastogens. These data show that
the throughput of the IVMN assay can be increased dramatically to permit screen-
ing large chemical libraries on a robotic platform. Supported by NIEHS
Interagency Agreement Y3-ES-7020-01.
1702 Genome Profiling of Carcinogen Resistance in Budding Yeast
Expressing Human P450 Genes.
M. Fasullo1, 3,  P. Egner2 and T. Begley1, 3. 1Nanobiosciences, College of Nanoscale
Sciences and Engineering, Albany, NY; 2Bloomberg School of Public Health, John
Hopkins University, Baltimore, MD; 3Biomedical Sciences, State University of New
York, Albany, NY.
Human susceptibility to environmental carcinogens is highly variable.
Epidemiological studies have identified genes that confer resistance; however, these
studies are limited due to small sample sizes. We use Saccharomyces cerevisiae
(yeast) to profile eukaryotic genes that confer resistance to environmental carcino-
gens, such as the potent hepatocarcinogen, aflatoxin B1 (AFB1). A yeast collection
is available containing ~5,000 diploid strains homozygous for individual gene
knock-outs. Each gene knock-out is bar-coded and can be identified by high-
throughput DNA sequencing. Since many carcinogens require P450-mediated ac-
tivation, we introduced human CYP1A2, constitutively expressed on a high-copy
expression vector, in the yeast diploid collection. We verified P450 expression in se-
lected mutants by Western blots. To identify which strains are AFB1 sensitive, cells
were inoculated in 96 well plates and growth was measured in a plate reader. To ex-
pedite results, we switched to high-throughput DNA sequencing of bar code se-
quences using an illumina platform. Results indicate the importance of the recom-
binational and excision repair pathways in conferring AFB1 resistance, and the
accumulation of AFB1-N7-guanine DNA adducts in nucleotide excision repair
(NER) mutants. The functional importance of recombination is further indicated
by the presence of carcinogen-associated DNA repair foci that appear in AFB1-ex-
posed cells, and the extreme sensitivity of double mutants lacking both recombina-
tional and nucleotide excision repair. Conclusions: We have modified the yeast
diploid strain collection to profile the genome resistance to P450-activated carcino-
gens, and identified genes in the recombinational and NER pathways that confer
resistance. Further studies will identify orthologous human genes that confer car-
cinogen resistance. The yeast strain collection will be valuable in monitoring resist-
ance to additional P450-activated chemicals and drugs.
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1703 Roles for Telomeric Proteins in Regulating Nucleotide
Excision Repair at Telomeres.
D. Parikh and P. Opresko. University of Pittsburgh, Pittsburgh, PA.
Ultra-violet (UV) irradiation is the most ubiquitous environmental inducer of skin
cancer and melanomas. UV exposure creates DNA photoproducts primarily cy-
clobutane pyrimidine dimers (CPD) and 6-4 photoproducts (6-4 PP). These cause
mutations and block DNA replication, unless repaired by nucleotide excision repair
(NER). Thymine repeats (TT) on G-rich strands of telomeric DNA are hotspots
for CPD formation. Telomeres are DNA-shelterin protein complexes at ends of
chromosomes, reported to lack a defined NER pathway for CPD repair.
Diminished binding or loss of shelterin proteins TRF1 and TRF2 at telomeres
cause telomere deprotection and end-to-end fusions directly leading to genomic in-
stability. Also TRF2 binds to the key NER protein XPF-ERCC1 and recruits it to
telomeres. Our working hypothesis is that telomeric photoproducts are repaired at
slower rates compared to genomic lesions and that this repair inhibition involves in-
teractions between XPF-ERCC1 with TRF2.
We measured photoproduct formation and repair in telomeres purified from
human osteosarcoma(U2OS) cells exposed to UVC via a novel dot blot assay. We
report a method for direct quantification of photoproducts formed in vivo and en-
suing repair based on a standardized qPCR assay for DNA damage. Photoproducts
were detected in genomic and telomeric DNA using specific antibodies following
exposure of cells to 10 J/m2 UVC and after recovery times of 0 to 12 hours. CPDs
decreased in genomic DNA after 12 hours but persisted in telomeric DNA.
Southern blot assays using radio-labeled oligonucleotides that bind to telomeric
DNA confirmed enrichment of telomeres in purified fractions. To investigate pos-
sible mechanisms for repair inhibition, we tested directly effect of TRF2 on NER
protein XPF-ERCC1 via enzyme activity assays. We discovered that nuclease cleav-
age activity of purified XPF-ERCC1 on a stem-loop DNA substrate was completely
abolished by TRF2. Our results provide the first direct biochemical evidence to-
wards quantifying critical UV damage at telomeres and elucidating NER pathway
regulation by shelterin.
1704 Oxidative Stress-Induced PIGO Mutations in DT40 Cells:
Critical Role of NHEJ and TLS Repair Pathways in ROS-
Induced Mutations.
V. Sharma1,  L. B. Collins1,  J. A. Swenberg1, 2 and J. Nakamura1. 1Department of
Environmental Sciences and Engineering, University of North Carolina at Chapel
Hill, Chapel Hill, NC; 2Curriculum in Toxicology, University of North Carolina at
Chapel Hill, Chapel Hill, NC.
A major mechanism resulting in the genetic alterations that can lead to cancer is
through the induction of mutations in genes controlling vital cellular functions.
Genotoxic chemicals cause chemically specific DNA adducts that can result in gene
mutations, whereas non-genotoxic carcinogens can exert their effects through ox-
idative stress. The cells in animals, humans, and cell culture are subjected to con-
tinuous endogenous DNA damage arising mainly from oxidative stress and depuri-
nation. To understand mechanisms by which oxidative stress causes mutations,
hydrogen peroxide (H2O2) was chosen as a model compound. 8-oxo-dG, a major
DNA lesion generated during oxidative DNA damage showed non-linear increases
following H2O2 treatment. Similarly, H2O2 caused a significant increase in PIGO
gene mutations in parental DT40 cells. In addition, to study the critical DNA re-
pair pathways associated with the oxidative stress, DNA damage response analyses
were performed in different repair protein deficient DT40 cells. Hypersensitivity of
RAD18, REV1, Rad54, RAD51c, Fen1, POLκ, POLη, Ku70, Lig4 deficient cells
to H2O2 suggests that homologous recombination (HR), non-homologous end
joining (NHEJ), translesion synthesis (TLS), and base excision repair (BER) are es-
sential for tolerance to oxidative DNA damage. Due to the error prone nature of
NHEJ and TLS repair pathways, we hypothesize that H2O2 induced mutation lev-
els may be decreased in NHEJ and TLS deficient cells. As we expected, Ku70
(NHEJ) and REV1 (TLS) deficient cells revealed a significant decrease in PIGO
mutation frequency which might be due to the lack of these error prone pathways
in the cells. This indicates that NHEJ and TLS pathway may play an important role
in the mutagenesis observed during oxidative stress.
1705 Evaluating the Role of p53 in Cellular Fate and
Micronucleus Induction following Exposure to Etoposide
and Mms.
R. A. Clewell1,  B. Sun1,  S. M. Ross1,  A. Scott2,  Y. Adeleye2 and
M. E. Andersen1. 1The Hamner Institutes, Research Triangle Park, NC; 2Unilever,
Colworth, United Kingdom.
Etoposide (ETP) and methyl methanesulfonate (MMS) represent genotoxic chem-
icals with direct and indirect mechanisms of DNA damage. ETP inhibits binds
topoisomerase II, leading to double strand breaks (DSBs).  MMS is an alkylating
agent that induces single strand breaks and DSBs. To evaluate the role of p53 in
downstream protein response and cell fate with ETP and MMS exposure, we gen-
erated p53 knockdown (KD) HT1080 cells and utilized HCT116 p53 knockout
(KO) cells for comparison with wild-type human HT1080 fibrosarcoma and
HCT116 colon carcinoma cells. In WT cells, MMS and ETP induce DSBs (p-
H2AX), (s15)p-p53, and p53 protein at 100 μM and 0.2 μM, respectively. Despite
similar induction of p53, cellular response was different for the chemicals: ETP in-
duced apoptosis, M-phase arrest, and a large increase in micronuclei (MN), while
MMS induced S-phase arrest and showed little induction of apoptosis or MN. p53
regulated protein MDM2, p21 and Wip1 responses were reduced in KD HT1080s
and completely abolished in KO HCT116s. Apoptosis was also significantly re-
duced in p53 KD/KO cells. Cell cycle arrest, however, was similar in WT and p53
KD/KO cells. Basal MN levels were approximately 1.8-fold higher in p53 KO cells
than WT cells at 27 and 40 hr. However, chemical induction of MN in WT and
p53 KO HCT116 cells showed notable time-dependencies. MN were slower to
form in p53 KO cells; only the 40 hr time point showed a strong increase in MN
induction in KO cells compared to WT cells after ETP or MMS treatment. While
the total frequency of MN 40 hours after treatment was higher in KO cells than
WT. Interestingly, the ratio of MN in p53 KO cells to WT cells remained constant
across doses (KO:WT ~ 2:1) and chemicals. It appears that the efficiency of DSB
break repair is similarly affected by p53 in the naïve and chemical treated cell at the
tested doses (≤ 1 μM ETP, ≤ 200 μM MMS).  Mechanistic studies of the relation-
ship between DSBs, p53 function and MN are important in assessing the value of
MN as functional marker of DNA damage.
1706 AZT-Induced Aneuploidy Is Mediated by Aberrant
Stathmin1 Expression.
A. Rivera-Rodriguez,  M. Poirier,  O. Olivero and V. Sanchez. NCI, NIH,
Bethesda, MD.
Previous studies have shown that the antiretroviral nucleoside reverse transcriptase
inhibitor (NRTI) zidovudine (AZT) causes cell cycle anomalies resulting in aneu-
ploidy. In addition, we demonstrated a decrease in β-tubulin polymerization in
normal human mammary epithelial cells (NHMECs) exposed to 100 μM AZT for
24 hours. Polymerized β-tubulin is a critical component of normal chromosome
segregation, the lack of which causes improper spindle formation and chromosome
misalignment. MicroRNA analysis of AZT-exposed NHMEC’s revealed downregu-
lation of hsa-miR-770-5p, which has multiple cellular targets including Stathmin 1
(STMN1). Active STMN1 (non-phosphorylated) inhibits the polymerization of α-
and β-tubulin required for normal cellular functions. Because hsa-miR-770-5p is
downregulated in AZT-exposed cells, we hypothesized that AZT exposure would
produce upregulation of STMN1, and result in decreased levels of
polymerized/functional tubulins. Here we exposed human breast MCF-10A cells to
100 μM AZT for up to 3 passages (p), and quantified total STMN1 (tSTMN1)
and phosphorylated (inactive) pSTMN1 by Western Blot. At p1 there was an in-
crease in tSMN1 (1.49 + 0.3 fold) and a decrease in pSTMN1 (0.66 + 0.3 fold) in
AZT-exposed cells compared to unexposed cells. At p2 a consistent increase in
tSTMN1 (1.46 + 0.0003 fold), and an increase in pSTMN1 (1.78 + 0.05 fold) was
observed. At p3, no change was detected for tSTMN1 while a decrease was ob-
served in pSTMN1 (0.51 + 0.5 fold). The data are consistent with the conclusion
that AZT induces aneuploidy by inhibition of hsa-miR-770-5p followed by upreg-
ulation of STMN1, decreased polymerization of tubulin, spindle abnormalities,
and missdistribution of chromosomes into daughter cells at replication.
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1707 Dose Response and Temporality of Ethylene Oxide-Induced
Macromolecular Changes and Genotoxicity in Mice.
M. R. Schisler1,  M. J. LeBaron1,  F. Zhang1,  Y. C. Jeong1,  M. Bartels1,  R. Sura1,
J. A. Hotchkiss1,  D. R. Geter1,  B. Gollapudi1 and N. P. Moore2. 1Toxicology &
Environmental Research & Consulting, The Dow Chemical Company, Midland, MI;
2Toxicology & Environmental Research & Consulting, The Dow Chemical Company,
Horgen, Switzerland.
Ethylene oxide (EO), a reactive industrial chemical, induced alveolar/bronchiolar
adenomas and carcinomas in the lungs of B6C3F1 male mice at atmospheric con-
centrations of 50 and 100 ppm. The purpose of the current study was to character-
ize the mode of action (MoA) for lung tumors induced by EO. Male B6C3F1 mice
were exposed by inhalation (6 hours/day, 5 consecutive days/week) to 0, 10, 50,
100, or 200 ppm (4 weeks) or 0, 100, or 200 ppm (8 or 12 weeks) and examined
for incidence of micronuclei in the peripheral blood (MNT), DNA damage
(Comet assay), histopathology of the lung, and characterization of DNA- and glu-
tathione-adducts and lipid peroxidation in the tumor target and non-target tissues.
In general, reactive oxygen species-related adducts (8-OHdG, CrotondG, M1dG)
were only minimally affected, whereas alkylated DNA adducts (O6-HEdG, N1-
HEdA, N6-HEdA, and N7-HEG) were increased more robustly. There was a dose-
dependent increase in glutathione adducts (HESG) in all tissues, although severe
GSH depletion was not noted. There were no treatment-related changes in the
MN-RET (reticulocyte) frequency or %RET. Comet analysis of the lung revealed a
dose-dependent, statistically significant increase in DNA damage at 50 ppm and
above. There was no treatment-related histopathology in the lung, although a slight
decrease in the proportion of Ki-67 positive cells was observed at 4 and 8 weeks in
the terminal bronchioles. In summary, these observations reveal a complex sequela
of biomarkers of exposure and effect following inhalation exposure to EO with a
clear NOEL for all apical endpoints studied.
1708 Cii Mutant Frequencies and Types of Mutations in the Lung
of Big Blue Mice Exposed to Ethylene Oxide for up to 12
Weeks by Inhalation.
M. G. Manjanatha1,  S. D. Shelton1,  Y. Chen1,  B. L. Parsons1,  B. Gollapudi2,
N. P. Moore3,  L. T. Haber4 and M. M. Moore1. 1Genetic and Molecular Toxicology,
FDA/NCTR, Jefferson, AR; 2Toxicology & Environmental Research and Consulting,
Midland, MI; 3Dow Europe GmbH, Horgen, Switzerland; 4TERA, Cincinnati, OH.
Ethylene oxide (EO) is a direct acting mutagen and many in vitro and in vivo data
in rodents support its role as a mutagen and carcinogen, but whether EO is car-
cinogenic through a mutagenic mode of action remains unclear. To investigate this
question, male Big Blue B6C3F1 mice (10 mice/group) were exposed to EO by in-
halation, six hours/day, five days/week for 4 (0, 10, 50, 100, or 200 ppm EO), 8 or
12 weeks (0, 100, or 200 ppm EO). Lung DNAs were analyzed for induction of cII
mutant frequencies (MFs) at 4, 8 and 12 weeks of exposure and 428 mutants de-
rived from 4-12 wk control and 200 ppm EO treatments were analyzed to deter-
mine the mutational spectra. The background cII MFs increased with age from
17.4 ± 2.2 x 10-6 at 4 weeks to 29.6 ± 4.1 x 10-6 at 12 weeks. Although EO-induced
cII MFs were 1.5-2.75-fold higher than the concurrent controls, significant in-
creases in the cII MF were found only after 8 and 12 weeks of exposure to 200 ppm
EO (p ≤ 0.05). DNA sequencing of cII mutants showed a significant shift in the
mutational spectra between control and 200 ppm EO following 8 and 12 wk expo-
sures (p ≤ 0.035), consistent with the significant increases in the EO-induced MFs
at these weeks. The predominant types of EO-induced mutations in lung were
GÇT and AÇT transversions; the role of EO- induced DNA adducts in the etiol-
ogy of these mutations needs further elucidation. These results indicate that EO is
likely to be a weak mutagen at high exposure concentrations in the lung, a tumor
target tissue.
1709 Gain and Loss of K-Ras Mutations in Mouse Lungs
following Inhalation Exposure to Ethylene Oxide.
B. L. Parsons1,  M. G. Manjanatha1,  M. B. Myers1,  K. L. McKim1,  Y. Wang1,
B. Gollapudi2,  N. P. Moore3,  L. T. Haber4 and M. M. Moore1. 1Division of
Genetic and Molecular Toxicology, US FDA-NCTR, Jefferson, AR; 2Toxicology &
Environmental Research and Consulting, The Dow Chemical Company, Midland,
MI; 3Dow Europe GmbH, Horgen, Switzerland; 4TERA, Cincinnati, OH.
K-ras codon 12 GGTÇGAT mutation is the most prevalent K-ras mutation in
spontaneous mouse lung tumors, whereas K-ras codon 12 GGTÇGTT mutation
was detected in 21/23 (91%) of mouse lung tumors induced by ethylene oxide
(EO) [Hong et al. (2007) Toxicologic Pathology 35:81-85]. To investigate whether
EO drives GÇT transversion through a mechanism involving oxidative damage
and induction of 8-oxo-2’-deoxyguaninosine at the second position of K-ras codon
12, allele-specific competitive blocker PCR (ACB-PCR) was used to measure the
levels of three different K-ras codon 12 mutations (codon 12 GGTÇGAT,
GGTÇGTT, and GGTÇTGT) in lung DNAs of male Big Blue B6C3F1 mice ex-
posed to EO. Ten mice per group were exposed to EO by inhalation, six hours/day,
five days/week for 4 (0, 10, 50, 100, or 200 ppm EO), 8 or 12 weeks (0, 100, or
200 ppm EO). Four weeks of exposure to 100 ppm EO caused a significant in-
crease in K-ras codon 12 GGTÇGTT mutant fraction (MF) relative to controls,
and 50, 100, and 200 ppm EO caused significant increases in K-ras codon 12
GGTÇGAT MF. Surprisingly, 8 weeks of exposure to 100 and 200 ppm EO
caused significant decreases in K-ras codon 12 GGTÇGAT and GGTÇGTT MFs
relative to controls. The increases and subsequent decreases in K-ras MF may be in-
terpreted as mutant cell proliferation, followed by selective killing of K-ras mutant
cells, mediated by EO dose-dependent production of reactive oxygen species.
Therefore, the shift in K-ras mutation spectrum observed in EO-induced mouse
lung tumors may be due to effects on intracellular signaling pathways and selection
of preexisting mutant cells, rather than direct mutagenesis of the K-ras gene by EO.
1710 Genotoxic and Epigenetic Effects of Tamoxifen Exposure in
Mouse Liver.
A. de Conti,  V. Tryndyak,  M. Churchwell,  F. A. Beland and I. P. Pogribny.
FDA-NCTR, Jefferson, AR.
Tamoxifen is a widely used non-steroidal anti-estrogenic drug for treatment and
prevention of breast cancer in women; however, there is sufficient evidence that ta-
moxifen is hepatocarcinogenic in rats, but not in mice. Currently, there is insuffi-
cient knowledge to clarify the absence of hepatocarcinogenic effect of tamoxifen in
mice. In light of this, the goal of the present study was to investigate the mechanism
of mouse resistance to tamoxifen-induced liver carcinogenesis. Feeding female
WSB/EiJ mice a 420 p.p.m. tamoxifen-containing diet for 12 weeks resulted in
substantial accumulation of tamoxifen-DNA adducts, e.g., (E)-α-(deoxyguanosin-
N2-yl)-tamoxifen (dG-Tam) and (E)-α-(deoxyguanosin-N2-yl)-N-desmethylta-
moxifen (dG-DesMeTam), in the livers as assessed by electrospray ionization tan-
dem mass spectrometry coupled with high-performance liquid chromatography.
The levels of hepatic dG-Tam and dG-DesMeTam DNA adducts in tamoxifen-
treated mice were 261 adducts/108 nt and 340 adducts/108 nt, respectively. In con-
trast, the degree of global DNA methylation and extent of histone modifications,
including trimethylation of histone H4 lysine 20 and histone H3 lysine 9 and ly-
sine 27 in the livers of tamoxifen-exposed mice did not differ from their values in
control mice. Previously, we demonstrated that hepatocarcinogenic activity of ta-
moxifen in rats is associated with its ability to induce, in addition to genotoxic al-
terations, extensive epigenetic abnormalities. In contrast, in mice tamoxifen-treat-
ment induced only genotoxic alterations without affecting the cellular epigenome.
These results provide additional evidence that carcinogenic process requires geno-
toxic and non-genotoxic alterations and latter are indispensable events in carcino-
genesis.
1711 Acinar Cell Autophagy in Experimental Pancreatic Injury:
Immunolocalization and Response of Relevant Proteins.
L. W. Zhang,  J. Zhang,  K. I. Shea,  G. A. Tobin,  A. Knapton and R. L. Rouse.
CDER, US FDA, Silver Spring, MD.
Drug-induced pancreatitis (DIP) is an under-diagnosed condition that lacks sensi-
tive and specific biomarkers. In vivo and in vitro studies were designed to identify
models and potential biomarkers for DIP. As a part of these studies, experimental
pancreatitis was created in male C57BL/6 mice by intraperitoneal injection of
caerulein (10 or 50 μg/kg) at one hour intervals for a total of seven injections.
Pancreata from caerulein-treated mice exhibited consistent acinar cell autophagy
and apoptosis with sporadic necrosis. Both serum amylase and lipase showed signif-
icant caerulein dose-dependent increases. TUNEL staining detected significant
dose-dependent acinar cell apoptosis. By light microscopy, autophagy was charac-
terized by the formation of autophagosomes and autolysosomes within the cyto-
plasm of acinar cells. Immunohistochemical (IHC) studies with specific antibodies
for proteins related to autophagy and pancreatic stress were used to evaluate the role
of acinar cell autophagy in the response to pancreatic injury. Western blots were
used to confirm IHC results using pancreatic lysates from control and treated ani-
mals. Autophagy was identified as a contributing process in caerulein-induced pan-
creatitis and proteins previously associated with autophagy were impacted by
caerulein treatment. Autophagy identified by autophagosomes and autolysosomes
was found to be a common pathway, in which cathepsins, LAMP2, VAMP1, LC3,
ATG9, Beclin1, and pancreatitis-associated proteins were simultaneously engaged.
Regenerating islet-derived 3 gamma (Reg3γ), a pancreatic acute response protein,
was dose-dependently changed in caerulein-treated mice and co-localized with the
autophagosomal marker, LC3. These data suggest a role for autophagy in DIP and
supports Reg3γ as an IHC marker of pancreatic injury.
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1712 Deciphering the Role of Trail in Altering Spermatogenesis by
Controlling Germ Cell Apoptosis.
Y. Lin and J. Richburg. The University of Texas at Austin, Austin, TX.
TRAIL (TNFSF10/Apo2L) is a member of the tumor necrosis factor (TNF) super-
family of proteins, expressed in human and rodent testis. TRAIL is known to in-
duce apoptosis via binding to its receptors DR4 (TRAIL-R1/TNFRSF10A) and
DR5 (TRAIL-R2/ TNFRSF10B) in humans, and TRAIL-R (MK/mDR5) in mice.
TRAIL is found in Leydig cells and germ cells during development and TRAIL-R is
predominantly expressed in post-meiotic germ cells in the rat. The major role of
TRAIL in male reproduction is still unclear. In this study, we investigated TRAIL-
/- mice and evaluated the possible role of TRAIL in germ cell development by
measuring testis weight, germ cell apoptosis, and spermatid head count in peripu-
bertal (28 day-old) or young adult animals (44 day-old). Our results revealed that
there was a significant difference in testis to body weight ratio between C57 and
TRAIL-/- mice. Also, peripubertal TRAIL-/- mice show a dramatic increase in the
basal germ cell apoptotic index (A.I., 21.54%) as compared to the C57BL/6J wild-
type strain (5.16%). The A.I. in adult C57 mice had dropped to 1.5%, but re-
mained elevated in adult TRAIL-/- mice (20.2%); indicating a sustained high inci-
dence of germ cell apoptosis. Spermatid head counts in adult TRAIL-/- mice were
dramatically reduced compared with C57 (39%), indicating these animals suffer a
marked decline in the production of mature spermatozoa. We hypothesize that
TRAIL is an important factor for maintaining germ cell homeostatsis during germ
cell development via a death receptor-dependent mechanism.
1713 Investigation of Sex-Dependent Toxicity of Cysteinyl
Leukotriene Receptor 1 Antagonist Zafirlukast.
Q. Shi and Z. Weng. Division of Systems Biology, US FDA, NCTR, Jefferson, AR.
Sponsor: X. Yang.
The FDA-approved prescription drug label states zafirlukast, a cysteinyl leukotriene
receptor 1 (CysLT1) antagonist, induces adverse hepatic events “predominantly in
females.” To model this possible sex-dependent toxicity, we examined suspension
cultured hepatocytes from male and female rats. Concentrations ranging from 1-
200 μM were tested at multiple time points (1-4 hr). Three parameters were exam-
ined: cytotoxicity (lactate dehydrogenase (LDH) leakage), energy level (cellular
adenosine triphosphate (ATP)) and cellular respiration (O2 consumption).
Hepatocytes from female rats were more sensitive than male rats in all three param-
eters. Changes in ATP and cellular respiration were seen as early as 1 hr while cyto-
toxicity was not observed until 2 hr. Additional studies are underway and include
two pharmacological counterparts to zafirlukast (montelukast and pranlukast).
With such studies we hope to identify drugs that exert sex-dependent toxicity and
their mechanisms.
1714 1, 3-Dinitropyrene (1, 3-DNP)- and 1, 8-DNP-Induced
DNA Damage and Cell Death: Possible Link to Carcinogenic
Effects.
J. A. Holme1,  H. E. Nyvold1,  V. M. Arlt2,  R. Becher1,  K. B. Gutzkow1,
A. Solhaug3,  L. Ekeren1,  M. Låg1,  P. E. Schwarze1,  M. A. Refsnes1 and
J. Øvrevik1. 1Division of Environmental Medicine, Norwegian Institute of Public
Health, Oslo, Norway; 2King’s College London, London, United Kingdom;
3Norwegian Veterinary Institute, Oslo, Norway. Sponsor: M. Løvik.
Nitro-polycyclic aromatic hydrocarbons (nitro-PAHs) are found on particulate
matter from diesel and gasoline exhaust. Often they are found to have greater mu-
tagenic and carcinogenic potencies when compared with their parent PAHs. In the
present study we have compared the genotoxic and cytotoxic effects of two closely
related carcinogenic dinitropyrenes (DNPs); 1,3-DNP and the more potent 1,8-
DNP. 
In human lung BEAS-2B cells, both compounds induced reactive oxygen species
(H2O2; flow cytometry), oxidative DNA damage (comet assay), and a DNA dam-
age response measured as phosphorylation of p53 (Western blotting) at non-cyto-
toxic concentrations (3-30 μM). In mu-rine hepatoma Hepa1c1c7 cells 1,3-DNP
(>3 μM) induced cell death (a mixture of apoptosis and necrosis), while 1,8-DNP
had no cytotoxic effects. The compounds caused little/ less H2O2, and oxidative
DNA damage than in BEAS-2B. Interestingly, 1,8-DNP was overall more potent
than 1,3-DNP with regard to the induction of single-strand DNA breaks (comet)
and the formation of DNA adducts (32P-postlabelling). Furthermore, 1,8-DNP
gave a stronger DNA damage response (phosphorylation of H2AX and p53) than
1,3-DNP in Hepa1c1c7 cells. Thus, there was no apparent link between the induc-
tion of cell death and early increases in ROS-formation or DNA damage/DNA
damage responses in the two cell lines. 1,3-DNP-induced apoptosis in Hepa1c1c7
cells was specifically associated with mitochondrial damage (increased formation of
superoxide anion; flow cytometry), but was also dependent on the p53-linked tran-
scriptional apoptotic pathway (inhibitors and siRNA). 
We suggest that the stronger carcinogenic potency of 1,8-DNP compared to 1,3-
DNP is due to its greater DNA damage properties, which in combination with its
lower potency to induce cell death increases the probability of causing mutations.
1715 Role of NOX Mediated Autophagy in Reducing Cytotoxic
Effects of Erlotinib in Head and Neck Cancer Cells.
A. Sobhakumari1, 2,  E. V. Fletcher1, 2,  A. Raeburn2,  L. Love-Homan2 and
A. L. Simons2, 1. 1Human Toxicology, University of Iowa, Iowa City, IA; 2Department
of Pathology, University of Iowa, Iowa City, IA.
Most head and neck squamous cell carcinomas (HNSCC) overexpress Epidermal
Growth Factor Receptor (EGFR) which makes it an attractive candidate for molec-
ular targeted therapies. A combination of surgery, radiation and chemotherapeutic
agents like EGFR inhibitors are routinely used in the treatment, however, many
HNSCC tumors become resistant to EGFR inhibitors. The cellular self-degrada-
tion process autophagy is activated by oxidative stress and has recently been re-
ported to reduce the efficacy of chemotherapy. Previous work in our lab has shown
that the EGFR inhibitor Erlotinib induces oxidative stress via NADPH Oxidase 4
(NOX4) in HNSCC cells. The purpose of this study is to determine if Erlotinib in-
duces autophagy in HNSCC cells via NOX4 and if autophagy is a pro-survival or
pro-death mechanism. Erlotinib induced cytotoxicity (as determined by clonogenic
assay) in FaDu and Cal-27 HNSCC cells compared to control treated cells.
Erlotinib induced the expression of the autophagy marker LC3B-II in both cell
lines as determined by western blot and immunofluorescence assays. Knockdown of
autophagy genes Beclin-1 and Atg5 sensitized both cell lines to the cytotoxic effect
of Erlotinib, suggesting that autophagy may be a pro-survival mechanism. Erlotinib
increased NOX4 mRNA and protein levels in FaDu and Cal-27 cells. Treatment
with DPI (diphenyleneiodonium) and a p38 inhibitor in the presence of Erlotinib
suppressed the increase in LC3B-II expression in FaDu and Cal-27 cells. Finally,
knockdown of NOX4 using adenoviral siNOX4, partially suppressed the activation
of LC3B-II in FaDu and Cal-27 cells. These results suggest that Erlotinib may acti-
vate autophagy in HNSCC cells as a pro-survival mechanism, and NOX4 may play
a role in mediating this effect. In conclusion, NOX4-induced autophagy may play
a role in reducing the efficacy of Erlotinib. [Supported by NIH grant K01-
CA134941 and ACS grant IRG-77-004-34].
1716 The Aryl Hydrocarbon Receptor (AhR) Suppresses Apoptosis
in UVB-Irradiated Keratinocytes and May Serve As a New
Target for Chemoprevention.
T. Haarmann-Stemmann1,  K. Frauenstein1,  J. Tigges1,  F. Engel1,  C. Wiek2,
H. Hanenberg2,  E. Fritsche1 and J. Krutmann1. 1Leibniz Research Institute for
Environmental Medicine, Duesseldorf, Germany; 2Otorhinolaryngology, Heinrich
Heine University, Düsseldorf, Germany.
Exposure of keratinocytes to ultraviolet (UV) radiation results in the initiation of
apoptosis, a protective mechanism that eliminates cells harbouring irreparable
DNA damage. Hence, a modulation of this process may significantly influence the
initiation and progression of UV-induced skin cancer. We have found that the aryl
hydrocarbon receptor (AHR), a ligand-activated and UVB-sensitive transcription
factor, serves an anti-apoptotic function in UVB-irradiated human keratinocytes.
Chemical and shRNA-mediated disturbance of AHR signaling significantly en-
hanced UVB-induced apoptosis. This effect was due to a loss of expression of E2F1
and its downstream target checkpoint kinase-1 (CHK1), two factors critical for
cell-cycle control and DNA damage response. Ectopic overexpression of E2F1 in
AHR-knockdown keratinocytes restored CHK1 expression and diminished the ob-
served sensitization to UVB-induced apoptosis. Accordingly, experimental CHK1
recovery alone was also sufficient to attenuate UVB-induced apoptosis in AHR-
knockdown keratinocytes, indicating that that the loss of proper checkpoint con-
trol drives damaged keratinocytes into programmed cell death. Our results demon-
strate for the first time an interplay between AHR, E2F1 and CHK1 and identify
this signaling axis as a novel anti-apoptotic pathway in keratinocytes, which may
represent a putative target for chemoprevention of non-melanoma skin cancer.
1717 Role of Secretory Phospholipase A2 in the Toxicity of Bile
Acids to Prostate Cancer Cells.
S. L. Wilding and B. S. Cummings. University of Georgia, Athens, GA.
Bile acids mediate the digestion and absorption of fats and fat-soluble vitamins;
however, pathological increases are associated with choleostasis and cell death.
Recent studies show that high concentrations of bile acids can induce apoptosis in
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several cells, including cancer cells, by mechanisms that are not fully understood.
The goal of this study was to determine the toxicity of three different bile acids
(chenodeoxycholic acid, deoxycholic acid, and lithocholic acid) in prostate cancer
cell lines (PC-3, LNCaP, and DU-145). Treatment of cells with bile acids induced
time- and concentration-dependent decreases in MTT staining, a marker of cyto-
toxicity, with IC50 values of approximately 100-200 μM after 72 hr. In general,
lithocholic acid was more potent than chenodeoxycholic acid, followed by deoxy-
cholic acid. Further, LNCaP cells tended to be more susceptible to bile acid-in-
duced toxicity, than either DU-145 or PC-3 cells. Based on reports that bile acids
increase the expression of inflammatory enzymes called secretory phospholipase A2
(sPLA2), we tested the hypothesis that these enzymes regulate the mechanisms of
bile acid-induced cell death. Analysis of sPLA2 expression using quantitative PCR
showed that several sPLA2 isoforms were expressed in PC-3, LNCaP and DU-145
cells, including Group IB, IIA, V and X sPLA2. Nevertheless, treatment of cells
with the sPLA2 inhibitor LY311727, prior to exposure to bile acids, did not alter
MTT staining compared to cells exposed to bile acids alone.  Similar results were
seen with the calcium-independent PLA2 (iPLA2) inhibitor bromenol lactone.
Collectively, these data show the novel finding that bile acids can induce toxicity to
prostate cancer cells and suggest the neither sPLA2 nor iPLA2 activity mediate the
mechanisms of cytotoxicity.
1718 Etoposide-Induced Mitochondria-Dependent Apoptosis
through C-Jun N-Terminal Kinases, Extracellular Signal-
Regulated Kinases, and Glycogen Synthesis Kinase-3α/β
Pathway in Pancreatic β-Cells.
K. Lee1,  S. Hsieh1,  C. Su2,  D. Hung3,  K. Chen4,  T. Tseng5,  T. Lu6,  S. Liu7,
Y. Chen6 and C. Huang8. 1Department of Emergency, Buddhist Tzu Chi General
Hospital, Taichung, Taiwan; 2Department of Otorhinolaryngology, Head and Neck
Surgery, Changhua Christian Hospita, Changhua, Taiwan; 3Toxicology Center, China
Medical University Hospital, Taichung, Taiwan; 4Department of Urology, China
Medical University Hospital, Taichung, Taiwan; 5Department of Anatomy, China
Medical University, Taichung, Taiwan; 6Department of Physiology and Graduate
Institute of Basic Medical Science, China Medical University, Taichung, Taiwan;
7Institute of Toxicology, National Taiwan University, Taipei, Taiwan; 8School of
Chinese Medicine, China Medical University, Taichung, Taiwan.
Etoposide, a semisynthetic derivative of podophyllotoxin, is an important
chemotherapeutic agent and widely used to treat human cancers. Etoposide also
can produce the severe side effects and cause cell damages and the physiological
dysfunctions. However, the toxicological effects of etoposide-induced pancreatic β-
cell death remain unclear. Here, we investigate the cytotoxic effect and its possible
mechanisms of etoposide on pancreatic β-cells. Treatment of pancreatic β-cell-de-
rived RIN-m5F cells with etoposide (1-100 M) for 24 h significantly reduced cell
viability and underwent apoptosis, accompanied with mitochondrial dysfunctions.
Moreover, etoposide triggered the protein phosphorylation of glycogen synthesis
kinase (GSK)-3α/β at 8 h treatment and maintained to 24 h, which could be re-
versed by lithium chloride (LiCl, a specific inhibitor of GSK-3α/β). In addition,
etoposide (20 μM) markedly increased the phosphorylation of JNK and ERK1/2,
but not p38. Pharmacological inhibitors SP600125 and PD98059 effectively atten-
uated etoposide-induced caspase-3 activity and JNK and ERK1/2 activation, but
LiCl could not reverse the phosphorylation of JNK and ERK1/2 induced by etopo-
side. In conclusion, these results suggest that etoposide exerts its cytotoxicity on
pancreatic β-cells by inducing the mitochondria-dependent apoptosis through
JNK/ERK activation-regulated GSK-3α/β signaling pathway.
1719 Berberine Induces Human Tongue Squamous Carcinoma
Cell Apoptosis through PI3K-Regulated ER Stress Pathway.
C. Su1,  T. Lu2,  D. Hung3,  K. Chen4,  T. Tseng5,  C. Huang6 and Y. Chen2.
1Department of Otorhinolaryngology, Head and Neck Surgery, Changhua Christian
Hospital, Changhua, Taiwan; 2Department of Physiology and Graduate Institute of
Basic Medical Science, China Medical University, Taichung, Taiwan; 3Division of
Toxicology, Trauma and Emergency Center, China Medical University Hospital,
Taichung, Taiwan; 4Department of Urology, China Medical University Hospital and
China Medical University, Taichung, Taiwan; 5Department of Anatomy, China
Medical University, Taichung, Taiwan; 6School of Chinese Medicine, China Medical
University, Taichung, Taiwan.
Until now, oral cavity squamous cell carcinoma (OSCC) is the most common
head-and-neck cancer, which accounts for approximately 3% of all newly diag-
nosed cancer cases. Despite of recent advances in surgical, radiotherapy, and
chemotherapy treatment protocols, it has been discussed that OSCC could not be
eradicated. Berberine is a natural alkaloid. Recently, berberine has been showed to
inhibit metastasis in lung cancer cells, and cytotoxic in glioma, prostate and na-
sopharyngeal cancer cells. However, the therapeutic effects and the possible mecha-
nisms of berberine in OSCC are still unclear. Results found that berberine signifi-
cantly decreased cell viability in human tongue squamous carcinoma derived SAS
cells line. Besides, berberine increased the ER-stress signals, including Grp94,
CHOP, Xbp-1 mRNAs and proteins. Further, the pro-caspase-12 protein level was
decreased, and the caspase-12 mRNA level was increased. In mitochondrial path-
way, berberine increased Bax, Bak, Bid mRNAs and proteins levels and decreased
Bcl-2 mRNAs and proteins levels. Besides, the pro-caspase-9, pro-caspase-7, and
pro-caspase-3 proteins level was decreased. We also found that phospho-AKT pro-
tein level was decreased after berberine treatment in cells. Besides, LY294002, the
inhibitor of phosphoinositide 3-kinases (PI3Ks), promoted ER-stress and mito-
chondrial related apoptosis signals. Through this study, suggested that berberine
may a useful compound in inhibition of OSCC through PI3K-AKT regulated ER-
stress and mitochondrial pathways.
1720 Amiodarone-Induced Autophagy Protects Lung Epithelial
Cancer Cells from Death.
K. Lee1,  S. Oh1,  S. Oh2,  B. Lee1,  Y. Yang3,  M. Yang3 and K. Lee3. 1College of
Pharmacy and Research Institue of Pharmaceutical Sciences, Seoul National
University, Seoul, Republic of Korea; 2Research Center for Resistant Cells, Chosun
University, Gwangju, Republic of Korea; 3Inhalation Toxicology Center, Korea
Institute of Toxicology, Jeongeup, Republic of Korea.
Amiodarone-induced toxicities in various off-target organs including cornea, liver,
skin, thyroid and lung often limit the use of this drug especially in the case of long-
term treatment. Despite low incidence rate, amiodarone-induced pulmonary toxic-
ity is the one of greatest concern and leading cause for discontinuation. In the pres-
ent study, we investigated the induction of autophagy following amiodarone
treatment in vitro and the relevance of autophagy to the pulmonary toxicity.
Amiodarone treatment caused morphological change in H460 cells. Increased
numbers of cytoplasmic vacuoles as well as round and floating cells were observed.
Amiodarone-induced autophagy was demonstrated by increased LC3-II conver-
sion, upregulation of Atg5 and Atg7 and degradation of p62 protein. Autophagic
flux as determined by lysosomal inhibitor bafilomycin A1 was also increased by
amiodarone. The phosphorylation of AMP-activated protein kinase at Thr172 was
increased and that of Akt at Ser473 was decreased by amiodarone which resulted in
the reduction of mTOR and p70S6 kinase phosphorylation. To determine the role
of autophagy in amiodarone toxicity, amiodarone-induced cell death was evaluated
in the presence of 3-methyladenine or by knocking down autophagy related genes,
Atg5 or Atg7. Inhibition of autophagy decreased the cell viability and increased
apoptosis significantly. In conclusion, amiodarone-induced autophagy functions to
rescue stressed cells from death. The findings have important implications in devel-
oping further strategy to minimize drug-induced toxicity in human.
1721 Paraquat Causes Hepatocytes Death via Oxidative Stress-
Induced JNK/ERK Activation Regulated Mitochondria-
Dependent Apoptosis Pathway.
D. Hung1,  T. Tseng2,  C. Su3,  K. Lee4,  K. Chen5,  S. Hsieh4,  T. Lu6,  L. Tsai6,
S. Liu7,  Y. Chen6 and C. Huang8. 1Division of Toxicology, Trauma & Emergency
Center, China Medical University Hospital, Taichung, Taiwan; 2Department of
Anatomy, China Medical University, Taichung, Taiwan; 3Department of
Otorhinolaryngology, Head and Neck Surgery, Changhua Christian Hospital,
Changhua, Taiwan; 4Department of Emergency, Buddhist Tzu Chi General Hospital,
Taichung, Taiwan; 5Department of Urology, China Medical University Hospital and
China Medical University, Taichung, Taiwan; 6Department of Physiology and
Graduate Institute of Basic Medical Science, China Medical University, Taichung,
Taiwan; 7Institute of Toxicology, National Taiwan University, Taipei, Taiwan; 8School
of Chinese Medicine, China Medical University, Taichung, Taiwan.
Paraquat (1,1’-dimethyl-4,4’-bipyridium dichloride, PQ), a common herbicide
used all over the world, is toxic to human beings and causes severe injuries to mul-
tiple organs, including lung and liver. However, the toxicological effects and molec-
ular mechanisms of PQ-induced on hepatocytes are mostly unclear. In this study,
we found that PQ significantly reduced the cell viability in rat hepatocytic cell line
H4-II-E cells. Treatment of H4-II-E cells with PQ also induced several features of
mitochondria-dependent apoptotic signals, including loss of mitochondrial mem-
brane potential (MMP), increase in cytosolic cytochrome c release, activation of
PARP and caspase-3/-7, and increased oxidative stress injuries such as reactive oxy-
gen species (ROS) generation and glutathione depletion. These PQ-induced apop-
totic-related signals could be effectively reversed by antioxidant NAC. Moreover,
PQ increased the phosphorylation of JNK and ERK1/2, but not p38.
Pharmacological inhibitors SP600125, PD98059, and NAC significantly attenu-
ated PQ-induced cytotoxicity, caspase-3/-7 activation, MMP loss, and inhibited
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the phosphorylation of JNK and ERK1/2. Taken together, these results suggest that
PQ exerts its cytotoxicity on hepatocytes by inducing apoptosis via an oxidative
stress-induced JNK and ERK1/2 activation regulated mitochondria-dependent sig-
naling pathway
1722 Oxidative DNA Damage and Apoptosis Induction after
Enniatin B Exposure in Caco2 Cells.
M. Ruiz,  A. Prosperini,  A. Juan Garcia and G. Font. Preventive Medicine,
University of Valencia, Burjassot Valencia, Spain.
Enniatin (EN) B is a cyclohexadepsipeptidic mycotoxin produced by Fusarium spp.
often found in cereals and cereal-based products. Its cytotoxic potential have been
reported but the mechanisms involved in its toxicity remain to be elucidated. Since
the oxidative pathway could be implicated in mycotoxin’s toxicity, in this study the
generation of reactive oxygen species (ROS) and lipid peroxidation (LPO) have
been investigated in human colorectal adenocarcinoma (Caco-2) cells.
Subsequently the induction of oxidative stress have been assumed to be directly re-
lated to DNA damage and apoptosis. Cells were exposed to EN B at sub-cytotoxic
concentration of 1.5 and 3 μM. A significant increase (p≤0.05) in ROS production
was observed by the fluorescent probe H2-DCFDA after 3 μM exposure in Caco-2
cells from 10 up to 120 min. LPO was determined by thiobarbituric acid reactive
substances (TBARS) after 24 h of exposure. Significant increase of malondialdehide
(MDA) was observed after the highest (3 μM) concentration tested of 48%
(p≤0.05), as compared to control. Genotoxicity was evaluated through the alkaline
Comet assay after 2 and 24 h of exposure. Median tail moment (μM) was signifi-
cantly high respect to the control with a dose-dependent relationship (p≤0.05) after
short and longer exposure. The induction of apoptosis and necrosis was assessed by
flow cytometry. Annexin V coupled to FITC in combination with PI was used to
determine different apoptotic phases after 24 h of exposure to EN B (1.5 and 3
μM). Both concentrations induced apoptosis and necrosis in a dose-dependent
manner. These findings show that 3 μM concentration of EN B caused oxidative
damage, by means of ROS generation that could be responsible of LPO, DNA
damage and triggers apoptosis in Caco2 cells.
Acknowledgements: The Science and Innovation Spanish Ministry (AGL2010-
17024/ALI). A. Prosperini thanks “Santiago Grisolia” fellowship (Conselleria de
Educación, Comunitat Valenciana)
1723 Mevalonate Pathway Plays a Major Role in Adriamaycin
Resistance.
T. Takahashi,  S. Nakashima,  T. Masuda,  S. Yoneda and A. Naganuma. Graduate
School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan.
In a search for novel mechanisms of resistance to adriamycin, an anthracycline anti-
tumor antibiotic used in cancer chemotherapy, we have previously screened a ORF
library derived from budding yeast for genes related to adriamycin resistance and
found that overexpression of the gene for HMG-CoA synthase, an enzyme in
mevalonate pathway, confers resistance to adriamycin in budding yeast. We have
also found that promotion of mevalonate pathway decreased the toxicity of adri-
amycin in yeast cells. 
In this study, we examined the relationships between enzymes involved in meval-
onate pathway and the adriamycin resistance, and found that deletion of the gene
for Ram1, a farnesyltransferase, reduced the degree of adriamycin resistance in-
duced by overexpression of HMG-CoA synthase. These results suggest that overex-
pression of HMG-CoA synthase might decrease the adriamycin toxicity throuth
promotion of farnesylation of proteins. Moreover, overexpression of HMG-CoA
synthase or addition of mevalonate to culture medium decreased the toxicity of
adriamycin in human breast MCF7 cells, suggesting that mevalonate pathway plays
a key role in mechanism of adriamycin resistance not only in yeast cells but also in
human cells.
1724 Carbamazepine Suppresses Ischemia/Reperfusion Injury to
Mouse Livers by Enhancing Autophagic Flux.
J. Kim,  J. Wang and K. E. Behrns. Surgery, University of Florida, Gainesville, FL.
BACKGROUND: Onset of the mitochondrial permeability transition (MPT)
plays a causative role in ischemia/reperfusion (I/R) injury, a pathological event oc-
curring during organ transplantation, cardiac failure and hemorrhagic shock.
Current therapeutic strategies for reducing reperfusion injury remain disappoint-
ing. As autophagy selectively and timely eliminates abnormal or damaged cellular
constituents and organelles such as dysfunctional mitochondria, this lysosome-me-
diated catabolic process confers cytoprotection against I/R injury and various dis-
eases. We have shown that calpain-dependent depletion of autophagy-related pro-
teins (Atg) causes the MPT and hepatocyte death after I/R. Carbamazepine (CBZ),
an FDA approved anticonvulsant drug, has recently been reported to increase au-
tophagy. The AIM of this study was to investigate the effects of CBZ on hepatic I/R
injury. 
METHODS: Hepatocytes and livers from male C57BL/6 mice were subjected to
simulated and in vivo I/R, respectively. Cell death, intracellular calcium, calpain ac-
tivity, changes in Atg, autophagic flux, MPT and mitochondrial membrane poten-
tial after I/R were analyzed in the presence and absence of 20 μM CBZ. 
RESULTS: CBZ significantly increased hepatocyte viability after reperfusion, as
judged by propidium iodide fluorometry. Confocal microscopy of rhod-2, fluo-4,
calcein and tetramethylrhodamine methylester revealed that CBZ prevented reper-
fusion-induced mitochondrial calcium loading, onset of the MPT and mitochon-
drial depolarization. Immunoblotting and fluorometric analysis showed that CBZ
blocked calpain activation, Atg6 depletion, and loss of autophagic flux after reper-
fusion. Intravital multiphoton imaging of anesthetized mice demonstrated that
CBZ substantially reversed autophagic defects and mitochondrial dysfunction after
I/R in vivo. 
CONCLUSION: CBZ protects hepatocytes against I/R injury by preventing a
temporal sequence of calcium overloading, calpain activation, Atg6 depletion, de-
fective autophagy, onset of the MPT, and cell death.
1725 A Multiplexed Assay for Differentially Examining Cytostatic
and Cytotoxic Effects.
A. L. Niles2,  M. Zhou1,  T. L. Riss2 and D. Lazar2. 1Promega Biosciences, San Luis
Obispo, CA; 2Promega, Madison, WI.
We have developed a multiplexed assay which can conveniently differentiate be-
tween cytostatic and cytotoxic effects produced in cell culture under standard com-
pound screening conditions. The assay first employs a pro-fluorescent, cell imper-
meant, DNA probe which changes fluorescent intensity only with changes in
membrane integrity due to cytotoxicity. Second, an ATP detection chemistry is ap-
plied to examine the relative number of viable cells after treatment.  We examined
the utility of this multiplex by dosing a suspension cancer cell line (K562) and at-
tachment-dependent cancer line (HeLa) with serially diluted compounds for a pe-
riod of 72hrs. We chose the antimetabolite compounds, 6-aminomercaptopurine
and methotrexate, because of their anti-neoplastic properties and mechanistic rele-
vance in halting cell growth and division. Here we show that by coupling two con-
venient biomarkers for viability and cytotoxicity, we can define the differences be-
tween anti-proliferative and cytotoxic effects.  The distinction between cytostatic
and cytotoxic effects on particular target cell populations may ultimately help direct
prioritization of oncology drug development efforts or offer insight into rational
combinations during chemosensitivity testing.
1726 Amiodarone-Induced Perturbations in Rat Pleural
Mesotheial Cells.
S. Chappidi and J. M. Cerreta. PHS, St. John’s University, Queens, NY. Sponsor: L.
Trombetta.
Amiodarone (AM) is an anti-arrhythmic drug whose clinical use is often limited
due to its toxic effect on the lungs. AM’s pulmonary toxicity is mediated in part
through apoptosis of the epithelial cells and their replacement with fibrotic tissue.
Our laboratory has previously determined that Caspase 8 and 9 levels are increased
in cells exposed to AM. Such increases suggest that both the extrinsic and intrinsic
pathways have a role in AM induced apoptosis. The current study was carried out
to further examine the pathway of AM induced cell injury and determine cellular
changes caused by such injury in rat pleural mesothelial cells (RPMC’s). RPMC’s
were grown to confluence in Ham’s F-12 medium containing 15% FBS at 37 °C in
a humidified, 5% CO2 environment. Cultures were treated with increasing concen-
trations (12.5, 25, 50, or 100 μg/ml) of AM for 1, 6, 12, or 24 hours. Cytotoxicity
of AM was determined by MTT assay. Cell membrane integrity was observed indi-
rectly by measuring the levels of LDH released into the supernatant after 24hr of
treatment with AM. To examine activation of the apoptotic pathway, translocation
of BAX protein from cytosol to mitochondria was measured by Western Blot analy-
sis following exposure to the 50 μg/ml of AM. Cell extracts of both control and AM
treated (50μg/ml) cultures were examined to determine cellular GSH/GSSG levels.
AM exposed cultures had a time and concentration dependent cytotoxicity at all
points tested. At 24 hrs, cell viability was found to be 96%, 72%, 47% or 13% re-
spectively with increasing concentrations of AM. The LDH levels were found to in-
crease (275%, 550%, 1575%, 2075%) following treatment with increasing con-
centrations of AM. Cultures exposed to 50μg/ml AM had a 330% increase in levels
of BAX present in the mitochondrial fraction. Cells exposed to various concentra-
tions (as above) of AM had a concentration dependent decrease (72%, 85%, 68%
or 26%) in the levels of GSH/GSSG ratio when compared to the control. Such re-
sults suggest that amiodarone is triggering multiple pathways leading to cell death.
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1727 Characterization of Cigarette Smoke and Menthol on
Human Alveolar Adenocarcinomic (A549) Cells.
E. R. Esposito,  B. Greene,  M. L. Coronel and H. Tran. Pharmaceutical Sciences,
Sullivan University College of Pharmacy, Louisville, KY.
Purpose: Menthol provides local anesthesia to nerve endings, allowing smokers to
take deeper, longer inhalations, thus giving longer exposure to carcinogenic ele-
ments found in cigarette smoke. There are few cellular studies addressing evidence
concerning the risk of developing lung cancer between mentholated and non-men-
tholated cigarettes. We would like to determine if an association exists between
mentholated cigarettes and incidence of lung cancer in the smoker population.
Using an in vitro model, we aimed to characterize the effects of cigarette smoke,
with or without menthol, in human alveolar adenocarcinomic (A549) cells and de-
termine if the rate of cell proliferation and cell death is altered.
Methods: Dose response studies were conducted to determine appropriate concen-
trations of cigarette smoke condensate (CSC) and menthol for cell viability assays.
Cells were treated for 24 hours with either: CSC, menthol, or CSC + menthol com-
pared to vehicle controls. Several techniques were applied to measure cell death and
apoptosis. Cell viability was measured using Trypan blue, while intracellular caspase
activation was determined using a fluorescein-conjugated antibody designed for
flow cytometric applications. Early and late indicators of apoptosis were assessed
using Annexin-V and propidium iodide detection assay. 
Results: Data suggest that menthol alone decreased cell viability and increased
Annexin positive cells while co-treatment with CSC + menthol did not affect cell
viability. Pan-caspase activation was not significantly altered for CSC, menthol, or
CSC + menthol treated cells. Interestingly, cells treated with CSC only appeared to
emit a source of auto fluorescence. Future studies are required to address the issue.
Data are the average of three independent experiments +/- standard error of the
mean (S.E.M.) Statistical significance is determined p <0.05.
1728 Induction of Late-Apoptosis on Chinese Hamster Ovary
Cells by Sandalwood (Santalum album) Essential Oil.
C. M. Ortiz-Sanchez,  L. Morales-Torres and J. L. Matta. Physiology, Pharmacology
and Toxicology, Ponce School of Medicine and Health Sciences, Ponce, Puerto Rico.
Essential oils (EOs) are volatile aromatic compounds that can be extracted from any
part of a given medicinal or aromatic plant. EOs have a wide range of applications
in the pharmaceutical, food, and cosmetic industries. Recently, there has been an
increased interest regarding the pharmacological properties of EOs. Among the
large diversity of commercially available EOs, sandalwood essential oil (SEO) is
used in food industry as a flavoring ingredient with a daily consumption of 0.0074
mg/kg. It is also used in perfumery and other cosmetic products. SEO has antiviral
and antimicrobial properties. However, its pharmacological activity on mammalian
cells is largely unknown. The aim of this study was to determine the effect of SEO
on Chinese hamster ovary cell (CHO-K1) proliferation and viability. These cells
were exposed to concentrations of SEO ranging from 1 – 600 μg/mL for 24, 48,
72, and 96 hours. Cell viability was measured by Trypan blue exclusion using the
Cellometer Auto T4, while cell proliferation was determined by the tetrazolium salt
(MTT) assay. Apoptosis detection was performed by flow cytometry using
Annexin-V-PE (a marker for early apoptosis) and 7-AAD (a marker for late apop-
totic/necrotic cells). Among all exposure times studied, the same tendency was seen
at 24, 48, 72, and 96 hours; SEO decreased cell proliferation in a dose-dependent
manner to around 80%. The inhibitory concentration (IC50) was approximately
31 μg/mL. Apoptotic effects were studied in concentrations above and below the
IC50 using three doses: 25, 30 and 35 μg/mL. An increase of 3% and 15% in late
apoptotic cells was detected with increasing SEO concentration at 30 and 35
μg/mL, respectively (p<0.05). In conclusion, SEO has the potential to decrease cell
proliferation by inducing late apoptosis in CHO-K1 cells. However, further analy-
ses are needed to elucidate the pathways involved in this process. Research sup-
ported by the NIGMS-NIH Award # R25GM082406.
1729 Investigating the Role of HO-1/BVR Expression on
Apoptosis Regulation.
C. George and M. J. Jenny. Department of Biological Sciences, University of
Alabama, Tuscaloosa, AL.
Cadmium (Cd)-resistant cells, when exposed to a variety of chemicals capable of in-
ducing oxidative stress, exhibit significantly lower occurrences of apoptosis com-
pared to non-resistant cells, suggesting that Cd-resistance is in part an adaptation to
oxidative stress. Previous studies have attributed this adaptation to increased expres-
sion of metallothionein genes and genes involved in the glutathione synthesis/recy-
cling pathway. However, recent studies over the last several years have demonstrated
novel anti-oxidant and anti-apoptotic properties with members of the heme oxyge-
nase-1 (HO-1)/biliverdin reductase (BVR) pathway. To investigate the role of HO-
1/BVR in resistance to Cd-toxicity we established a Cd-adapted human hepatocel-
lular liver (HepG2) Tet-On cell line by continuously culturing the cells in 5μM Cd
for 16 weeks, with routine media change and cell passage every 3-4 days. After 16
weeks, control and Cd-adapted cells were dosed with additional 0.1, 0.5, 1, 10 and
20uM Cd concentrations and real-time PCR was used to compare gene expression
of HO-1, BVRa, BVRb and glutathione reductase (GSR). Interestingly, basal ex-
pression of GSR was significantly down-regulated while HO-1, BVRa and BVRb
was up-regulated in the Cd-adapted cell line. In addition, there was greater induc-
tion of BVRa and BVRb expression in the Cd-adapted cells after additional Cd
treatment as compared to control cells. Custom PCR arrays (QIAGEN Inc) were
used to analyze expression of genes related to stress and toxicity when control and
Cd-adapted cells were dosed with 10uM Cd. The Cd-adapted cells displayed sig-
nificant alterations in other genes related to oxidative stress, DNA repair and cell
division/apoptosis signaling pathways, including many pathways linked to
BVRa/ERK regulation, such as tumor necrosis factor (TNF), TNF receptor, lym-
photoxin alpha, early growth response 1,insulin-like growth factor 1, interferon
alpha and interferon beta 1. Future studies will investigate the direct role of HO-1
and BVR in regulating the potential anti-apoptotic properties of these Cd-adapted
cells. [Supported by R00ES017044]
1730 Role of BCL-2 Proteins in Heat Shock-Induced Apoptosis.
I. M. Mahajan1, 2,  M. Chen1, 2,  I. Muro2,  C. W. Wright2 and S. B. Bratton1, 2.
1Molecular Carcinogenesis, UT Austin/MD Anderson Cancer Center, Smithville, TX;
2Pharmacology and Toxicology, University of Texas at Austin, Austin, TX.
Apoptosis is a programmed form of cell death executed by caspases (cysteine pro-
teases) that cleave substrates exclusively after aspartic acid residues. In response to
stress, cells often activate the intrinsic apoptotic pathway, wherein mitochondrial
outer membrane permeabilization (MOMP) initiates the release of proapoptogenic
proteins, such as cytochrome c and Smac, into the cytosol. In particular, cy-
tochrome c promotes formation of a caspase-activating complex known as the
Apaf-1-caspase-9 apoptosome. Heat shock (HS) is an ancient stress that activates
both prosurvival (thermotolerance) and prodeath cellular responses, and we have
previously shown that HS induces apoptosis through pathways that involve
MOMP and downstream effector caspase-3 activation, but do not require activa-
tion of the apoptosome. HS-induced MOMP is strictly controlled by BCL-2 fam-
ily members, which include both pro-apoptotic (e.g. Bax, Bim, Bid, etc.) and anti-
apoptotic (e.g. Bcl-2, Mcl-1, etc.) proteins. Other studies suggest that HS initiates
MOMP following cleavage of Bid by caspase-2. However, we observe that mouse
embryonic fibroblasts (MEFs), lacking either caspase-2 or Bid, remain sensitive to
HS. In contrast, we find that bim-/- MEFs are highly resistant to HS-induced
apoptosis and exhibit significantly decreased levels of MOMP. Thus, our findings
indicate that Bim is essential for HS-induced death, while caspase-2 and Bid func-
tion as part of an amplification loop. Interestingly, Bim is known to induce MOMP
through direct activation of Bax and/or Bak, but we find that bax-/-/bak-/- MEFs
are only partially resistant to HS-induced cell death, implying the existence of a
Bim-dependent, Bax/Bak-independent pathway. We speculate that another
proapoptotic Bcl-2 family, namely Bok, may functionally substitute for Bax and
Bak, or alternatively that Bim may directly permeabilize lysosomal membranes, re-
sulting in the release of proapoptotic cathepsins. (These studies were supported by
grants, CA129521 and GM096101, from the NIH.)
1731 SDF-1β Protects High Fat-Induced Cardiac Cell Apoptosis
through Its Receptor CXCR7-Mediated AMPK Activation.
Y. Zhao1, 2,  L. Cai2, 1 and W. Li1. 1Cancer Center, First Bethune Hospital of Jilin
University, Changchun, China; 2KCHRI, University of Louisville, Louisville, KY.
Hyperlipemia often occurs in the patients with obesity and type 2 diabetes, and is
also primary trigger for cardiac remodeling and dysfunction. Stromal cell-derived
factor-1beta (SDF-1β) was cardiac protective, but whether it also protects the car-
diac cells from high fat -induced apoptosis remains unknown. By using H9c2 car-
diac muscle cell line, we observed the effect of SDF-1β on saturated free fatty acid-
induced its apoptotic response. Exposure of H9c2 cells to palmitate at 62.5 nM for
15 h caused a significant apoptotic effect, shown by up-regulation of cleaved-cas-
pase3. Pretreatment with SDF-1β significantly prohibited palmitate-induced apop-
tosis along with significant increases in AMPK-mediated IL-6 production. AMPK
activator (AICAR) significantly prevents palmitate-induced cardiac apoptosis while
AMPK inhibitor (compound C) prohibited SDF-1β’s protective effect. Direct ad-
dition of recombinant human IL-6 to cell cultures prevented palmitate-induced
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apoptosis whereas IL-6 siRNA abolished the protective effect of SDF-1β. CXCR7
siRNA, but not CXCR4 antagonist abolished SDF-1β’s protective effect and above
related signal transduction. These in vitro results suggest that SDF-1β prevents
palmitate-induced cardiac apoptosis via its receptor CXCR7 and further activating
AMPK-mediated IL-6 excretion. In vivo studies, by using type 2 diabetes models,
we confirmed that high fat diet induced cardiac apoptosis, and that SDF-1β pre-
vented high fat diet-induced cardiac apoptosis along with its activation of AMPK.
This important finding opens a new road for the research of SDF-1β’s cardiac pro-
tection that is irrelevant with its well-known function of stem cell mobilization.
1732 Paraoxon Induces Cell Death by the Activation of Caspases
in Cultured Human Pulmonary Cells.
D. J. Angelini1, 2,  R. A. Moyer3,  A. Hajjaj1, 4,  S. Cole1, 2, 3,  K. L. Willis1, 2, 3,
J. Oyler5,  R. M. Dorsey1 and H. Salem1, 6. 1Edgewood Chemical Biological Center,
Aberdeen Proving Ground, MD; 2National Research Council, Washington DC;
3Defense Threat Reduction Agency, Fort Belvoir, VA; 4Science Applications
International Corporation, Abingdon, MD; 5US Army Medical Research Institute of
Chemical Defense, Aberdeen Proving Ground, MD; 6Department of Homeland
Security, Chemical Security Assessment Center, Aberdeen Proving Ground, MD.
INTRODUCTION: Organophosphate chemicals are known to induce pulmonary
toxicity in both humans and experimental animals. To elucidate the mechanism of
organophosphate-induced cytotoxicity, we examined the effects of parathion and
paraoxon on primary cultured normal human bronchial epithelial cells (NHBECs)
as well as small airway cells (SAECs).
METHODS: We evaluated the viability/cytotoxicity of primary NHBECs and
SAECs following exposures to the organophosphate chemicals parathion and
paraoxon. Since caspases have a major role in the regulation of apoptosis and cell
death, we evaluated paraoxon-induced cell death in the presence of the caspase in-
hibitor Z-VAD.
RESULTS: Parathion failed to induce losses in cellular viability at concentrations
known to cause toxicity in vivo following a 24 hour treatment (IC50 >9mM) in ei-
ther NHBECs or SAECs. Its toxic metabolite, paraoxon, produced a dose-depend-
ent decrease in cell viability following a 24 hour treatment period for both pul-
monary cell types (IC50 ~0.5mM). Treatment with paraoxon also induced caspase
activation in these cells. Pharmacological inhibition of caspases with Z-VAD during
paraoxon treatment protected against paraoxon-induced cell death. 
CONCLUSIONS: These combined data suggest that paraoxon induces cell death
in NHBECs and SAECs, at least in part, through the activation of caspases.
1733 BDE-154 Decrease Cell Proliferation, Viability and
Mitochondrial Membrane Potential Leading to HepG2 Cell
Death.
A. O. Souza1,  L. C. Pereira2,  M. Tasso1,  D. P. Oliveira2 and D. J. Dorta1.
1Química, FFCLRP-USP, Ribeirão Preto, Brazil; 2Análises Clínicas, Bromatológicas e
Toxicológicas, FCFRP-USP, Ribeirão Preto, Brazil.
INTRODUCTION: Polybrominated diphenyl ethers (PBDEs) are a class of flame
retardants composed by 209 different congeners with evidences of several toxic po-
tential on the organisms. Toxic damages of lower and higher brominated congeners
have been widely reported but more information about other congeners to clarify of
risk of PBDEs class on the health is still necessary. OBJETIVE: The aim of this
work was to investigate the effects of the BDE-154 on HepG2, because it had
showed growth levels of bioaccumulation on the biotic compartments.
METHODOLOGY: We performed a cell proliferation test using SRB colorimetric
assay in order to evaluate its inhibitory effects on cell proliferation and then we did
a cell viability test by MTT assay, that was performed to investigate relationships
between the inhibitory potential of cell growth with the induction of cell death.
Subsequently, the effect on the mitochondrial membrane potential (MPP) using
TMRM dye was performed to evaluate a possible effect on the cell mitochondria
and finally the exposure of phosphatidylseryne on the outer membrane using
Anexin V and propidium iodeto (PI) staining was evaluated. In all tests, the cells
were exposure at concentrations ranging from 0.1 to 25μM for 24 and 48 hours.
RESULTS: Our results shown that BDE-154 are capable of inhibiting cell prolifer-
ation at doses starting at 10μM (p< 0.05) after 48 hours of exposure, although the
results of MTT assay had shown a significant decrease in cell viability on lower
doses in both times of incubation. Changes on cell proliferation and viability were
followed by decrease of MPP and an increase of phosphatidylseryne exposure at the
cell membrane. CONCLUSIONS: According to our results, BDE-154 presents a
significant potential to interfere with the mitochondrial homeostasis of HepG2
cells which can lead to apoptosis in the concentration of 25 μM .
1734 Computational Dosimetry Driven Hazard Ranking of 25
Metal Oxide Nanomaterials Using Low- and High-
Throughput In Vitro Toxicity Data.
D. Telesca2,  J. G. Teeguarden1,  T. Xia3,  H. Zhang3,  A. Nel3,  J. G. Pounds1 and
B. D. Thrall1. 1Biological Sciences, Pacific Northwest National Laboratory, Richland,
WA; 2Biostatistics, University of California Los Angeles, Los Angeles, CA;
3Nanomedicine, California Nanosystems Institute, University of California Los
Angeles, Los Angeles, CA.
Seeking to integrate broad sets of mechanistic and more traditional dose-response
data across in vitro and in vitro systems, and between species, the nanotoxicology
field faces the challenge of translating these data into knowledge that will impact
public health policy for this emerging class of materials. Using a rich data set on in
vitro toxicity of 25 metal oxides as an example, we present framework for nanoma-
terial risk assessment and hazard ranking based on a paradigm for nanomaterial
dosimetry in vitro and in vivo that is consistent with current practice for chemical
risk assessment. Integrating cytotoxicity and high-throughput data on 25 metal
oxide nanoparticles with cellular dosimetry data derived from in vitro and in vivo
models of nanoparticle dosimetry, we demonstrate the impact of cellular dosimetry
on hazard ranking schemes. Specifically, the dosimetry hazard ranking approach
showed that on a cellular dose and tissue-dose basis, the relative toxicity of the
metal oxides is fundamentally different than those bases solely on exposure meas-
ures (μg/ml). For example, Co3O4 was ranked #10 based on in vitro studies, but
scaled based on tissue doses in exposed humans, Co3O4 was the most hazardous
material. Human exposure equivalents calculated using ISDD and MPPD models
for each nanomaterial ranged from 0.1 to 10,000 mg/m3, indicting some but not
all might pose a hazard for exposed humans. Making dosimetry corrections for iron
oxide particles, we also show good correspondence between in vitro and in vivo in-
flammatory responses. The framework, along with high-throughput in vitro data,
can clearly be used to rank nanomaterial hazards for broad classes of particles,
though it remains an untested hypothesis that such approaches accurately reflect
risk in exposed humans.
1735 Ranking and Profiling Nanomaterial (NM) Bioactivity by
ToxCast High-Throughput Screening (HTS).
A. Wang1,  E. Berg2,  M. A. Polokoff2,  J. Yang2,  A. El-Badawy3,  D. Reif1,
N. Kleinstreuer1,  S. Marinakos4,  A. Badireddy4,  S. H. Gavett1,  D. Rotroff1,
S. Gangwal5,  J. Rabinowitz1,  C. W. Matson6,  T. Tolavmat3,  M. Wiesner4 and
K. Houck1. 1ORD, US EPA, Research Triangle Park, NC; 2BioSeek, LLC, San
Francisco, CA; 3ORD, US EPA, Cincinnati, OH; 4CEINT, Duke University,
Durham, NC; 5Xanofi, Raleigh, NC; 6Environmental Sciences, Baylor University,
Waco, TX.
HTS allows for rapid examination of large numbers of chemicals for biological ef-
fects and the results can be used to prioritize them for further assessment and pro-
vide mechanistic insight. To prioritize NMs for further testing, we screened NMs
(Au, Ag, CeO2, CNT, CuO, TiO2, SiO2, or ZnO core) and their ion and micro
counterparts for cytotoxicity, transcription factor activation, and cellular protein
expression. We ranked samples by promiscuity (the number of assays affected) and
potency. Two ranking methods produced very similar results and high promiscuity
was coupled with high potency. Ag, Cu, and Zn samples were ranked highest prior-
ity for further testing. Sample replicates, screened in different test runs, had the
same rankings, indicating consistency in data among test runs. To research poten-
tial mechanisms of bioactivity, we tested ion contribution to Cu NM bioactivity
and compared CNT to asbestos in 8 BioMAP® human primary cell systems for tis-
sue and inflammatory responses. 3 Cu stocks (micro-CuO, nano-CuO, fungicide A
containing nano-Cu(OH)2) were split and one half was repeatedly washed until the
wash liquid had the same electrical conductivity as pure H2O, indicating very few
released ions. This wash decreased, but did not eliminate, bioactivity, suggesting re-
leased ions contribute to bioactivity. The bioactivity profiles of micro-CuO, nano-
CuO, and washed nano-CuO were more similar to each other than to other Cu
samples, including washed micro-CuO, implying micro- and nano-CuO were af-
fected by the wash differently. The 3 asbestos had similar profiles but only minimal
overlap with CNTs. One CNT had a similar profile with Cu, suggesting Cu was
present in this sample. Thus HTS can be used to prioritize NMs and provide info
on potential mechanism of bioactivity including chemical composition of the sam-
ples.
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1736 Coating Nanoporous Alumina: Cellular Responses to Surface
Layers of Zinc and Titanium Oxides.
P. E. Petrochenko2, 1,  G. Kumar1,  W. Fu3,  S. A. Skoog2, 1,  Q. Zhang1,
J. Zheng1,  C. Liang3,  P. L. Goering1 and R. J. Narayan2. 1CDRH, US FDA,
Silver Spring, MD; 2Joint Department of Biomed Engineering, University of North
Carolina at Chapel Hill, Chapel Hill, NC; 3Chemical Sciences Division, Oak Ridge
National Lab, Oak Ridge, TN.
Nanoporous anodic aluminum oxide (AAO) membranes have applications in skin
wound repair; the surface topography of these materials has been shown to modu-
late wound healing. Previous work by our group has shown that coating titanium
dioxide (TiO2) onto nanoporous AAO does not affect cell viability and that zinc
oxide (ZnO)-coated AAO membranes exhibit antimicrobial activity against several
bacterial strains associated with skin infection. In this study, the nanoporous struc-
ture of 20, 100, or 200 nm pore diameter AAO membrane substrates was main-
tained by depositing nm-thick layers of TiO2 or ZnO using an atomic layer deposi-
tion (ALD) process involving alternative adsorption/hydrolysis of Ti isopropoxide
or diethyl Zn, respectively. X-ray spectroscopy (EDX) confirmed the presence of
ZnO or TiO2 on AAO membranes. Cell viability and inflammatory responses were
evaluated on ZnO- and TiO2-coated AAO membranes. RAW 264.7 macrophages
cultured on ZnO-coated AAO exhibited a significant decrease in metabolic activity
(MTT reduction) after 24 or 48 h exposure; however, no changes were observed in
lactate dehydrogenase (LDH) release or reactive oxygen species (ROS) production.
L929 fibroblasts grown on TiO2-coated AAO had higher viability (MTT assay)
than controls (uncoated AAO) after 48 hrs; no change in viability was observed
using the Neutral Red assay. No significant increase in fibroblast cell proliferation
(DNA assay) was observed. No TNF-α production or decrease in viability was seen
in RAW 264.7 macrophages grown on TiO2-coated membranes. The total ad-
sorbed protein per unit area on uncoated and TiO2-coated AAO was up to 12-times
greater than that on tissue culture polystyrene. The results show that nm-thick
ALD coatings maintain the nanoporous structure of AAO membranes. Further, an-
timicrobial ZnO coatings decrease cell viability and TiO2 coatings appear to be
more biocompatible in vitro.
1737 Potential Phototoxicity of Aged Al(OH)3-Coated TiO2
Nanoparticles in Retinal Pigment Epithelial Cells.
J. N. Ortenzio1,  L. L. Degn2,  R. Zucker2,  J. Virkutyte3,  S. R. Al-Abed4,
H. Ma5,  S. Diamond6,  K. Dreher2 and W. K. Boyes2. 1Contractor, Research
Triangle Park, NC; 2US EPA, Research Triangle Park, NC; 3Contractor, Cincinnati,
OH; 4US EPA, Cincinnati, OH; 5Contractor, Duluth, MN; 6US EPA, Duluth, MN.
Titanium dioxide (TiO2) nanoparticles (NPs) exposed to UVA radiation generate
reactive oxygen species (ROS). As a component of sunscreen formulations, TiO2
NPs may be coated with Al(OH)3 to prevent ROS from causing oxidative damage
to tissues. Simulated swimming pool water (SSPW) degrades the Al(OH)3 coating
which could reduce the coating’s protective function. We examined the potential
phototoxicity of 25 nm, Al(OH)3-TiO2 NPs that had been aged in SSPW for 0
min, 45 min, 1 day, 3 days, 10 days, or 14 days. In two non-cellular assays, meas-
uring methylene blue degredation or thiobarbituric acid reactive species, aged
Al(OH)3-TiO2 showed substantially less photocatalytic activity than the positive
control: uncoated Aeroxide P25, 31 nm. In a cellular assay, a human-derived retinal
pigment epithelium cell line (ARPE-19) was used as a site of photoreactivity. Cells
were split into 24-well culture plates, incubated for 24h, then treated with 0, 3, 10,
30, or 100 ug/ml of each aged NP or 30 ug/ml of positive control. After treatment,
the cells were either exposed to 1.5h UVA radiation or no light. 24h later, cell via-
bility was assessed by live/dead assays (calcein-AM/propidium iodide). Flow cytom-
etry and dark field microscopy verified that the TiO2 NPs entered the cells. Flow
cytometry showed dose-related increased side-scatter signal consistent with uptake
of NPs, and dark field microscopy showed TiO2 accumulation along the nuclear
envelope and near the endoplasmic reticulum of ARPE-19 cells. No difference in
cytotoxicity was observed after UVA irradiance among the SSPW-aged groups. The
positive control yielded 100% cytotoxicity under UVA irradiation. The lack of
phototoxicity observed with SSPW-aged Al(OH)3-TiO2 suggests that degradation
of the particle coating did not increase the risk of phototoxic reactions under the
conditions tested.
This abstract does not reflect EPA policy.
1738 Silica and Gold Nanoparticle Exposure Decreases
Phagocytosis in Mouse Raw 264.7 Cells.
S. Bancos and K. M. Tyner. US FDA, Silver Spring, MD.
Silica (SiO2) and gold (Au) nanoparticles (NPs) have been proposed for various
therapeutic and diagnostic applications. It has been previously shown in vivo that
administration of NPs leads to particle accumulation in macrophages of the reticu-
loendothelial system independent of NP core composition, size, or mode of admin-
istration. There is, however, little to no information on whether NP accumulation
affects macrophage function. Using a panel of in vitro assays, we assessed the prolif-
eration, activation, cytokine production and phagocytosis ability of RAW 264.7
cells in response to non-toxic concentrations of SiO2 NPs (~10 nm) and Au NPs
(~10 nm) during a 6h-48h time course. There was a 50-60% reduction in cell num-
ber in SiO2 NP-treated cells that was associated with an increase in the percentage
of cells arrested in G0/G1 phase and a decrease in the percentage of cells in the S
phase; there were no significant changes in the expression of CD40, CD80 and
CD86 markers. Au NP-treated cells showed a 14- 40% decrease in cell number;
neither the cell cycle status of Au NP-treated cells nor the expression of surface
markers could be assessed due to Au NP interference with the flow cytometry assay.
Among the cytokines analyzed, TNF-α levels increased only in cells treated with
0.01 g/L SiO2 NP, whereas IL-6 and IL-10 levels did not change in SiO2 NP- or Au
NP-treated cells. The ability of SiO2 NP- and Au NP- treated cells to phagocytose
FITC-E. coli bioparticles was evaluated by flow cytometry and confocal mi-
croscopy. The results show that phagocytosis was reduced by ~50% in both SiO2
NP- and Au NP- treated macrophages. Overall, the results indicate that 10 nm
SiO2 NP and Au NP exposure can impact macrophage phagocytosis in vitro, but
does not appear to impact cytokine production or the expression of activation
markers. A decrease in phagocytosis may lead to decreased immunity and dimin-
ished response to bacterial infections.
1739 Comprehensive Assessment of Property-Dependent
Bioimpact of Engineered Nanomaterials Using Novel ‘Bench-
Top’ Human Tissue Screening Platforms.
R. Iyer1,  J. Gao2,  A. Nagy2,  S. Iyer2,  J. Hollingsworth3,  J. Drocco4,  J. Song2,
T. Sanchez2 and H. Wang5. 1Defense Systems and Analysis, Los Alamos National Lab,
Los Alamos, NM; 2Biosciences Division, LANL, Los Alamos, NM; 3MPA-CINT:
Center for Integrated Nanotechnologies, LANL, Los Alamos, NM; 4Theoretical
Division, Los Alamos National Laboratory, Los Alamos, NM; 5Chemistry Division,
LANL, Los Alamos, NM.
The core focus of our effort was to develop human three-dimensional (3-D) in vitro
tissue models to serve as a realistic representation of human exposures and for as-
sessing NM toxicity to decisively rank what physico-chemical parameters can drive
toxicity. Core NM parameters including composition, size, shape, redox activity,
functionalization and charge were all tested by investigating a multitude of NMs.
Kinetics of bioresponses such as necrosis, apoptosis, oxidative stress, cytokine secre-
tion and changes in gene and protein expression were all evaluated in response to
nanomaterial exposure. We also developed novel computational analytics to differ-
entiate bioresponses as a factor of NM property. Network-inference-based meth-
ods, such as context-likelihood of relatedness (CLR), as well as clustering-based
methods, such as principal component analysis (PCA) were used to identify a set of
known regulons as well as other co-regulated transcripts potentially unique to nan-
otoxicity. Further investigation revealed that NM composition, followed closely by
charge, were parameters which significantly influenced NM-driven toxicity.
Moreover, we found significant differences between the molecular mechanisms of
NMs toxicity in monolayer cell culture models versus our complex, more physio-
logically relevant tissue models. As such, we conclude that further development of
human 3-D tissue models is warranted in order to gain accurate information re-
garding the risk and consequences of NM exposure.
1740 Genotoxicity of TiO2 Anatase Nanoparticles in B6C3F1 Male
Mice Pig-A and Flow Cytometric Micronucleus Assays.
J. Yan1,  R. Sadiq2, 1,  J. A. Bhalli1,  R. S. Woodruff3,  M. G. Pearce1,  Y. Li1,
T. Mustafa4,  F. Watanabe4,  L. M. Pack5,  A. S. Biris4,  Q. M. Khan2 and
T. Chen1. 1Division of Genetic and Molecular Toxicology, National Center for
Toxicological Research, US FDA, Jefferson, AR; 2National Institute for Biotechnology
and Genetic Engineering, Faisalabad, Pakistan; 3Division of Microbiology, Arkansas
Regional Laboratory, US FDA, Jefferson, AR; 4Nanotechnology Center, University of
Arkansas at Little Rock, Little Rock, AR; 5Nanotechnology Core Facility, National
Center for Toxicological Research, US FDA, Jefferson, AR.
In vivo micronucleus and Pig-a (phosphatidylinositol glycan, class A gene) mutation
assays were conducted to evaluate the genotoxicity of 10 nm titanium dioxide
anatase nanoparticles (TiO2-NPs) in mice. Groups of five 6- to 7-week-old male
B6C3F1 mice were treated intravenously for three consecutive days with 0.5, 5.0,
and 50 mg/kg TiO2-NPs for the two assays; mouse blood was sampled one day be-
fore the treatment and on Day 4, and Weeks 1, 2, 4, and 6 after the beginning of
the treatment; Pig-a mutant frequencies were determined at Day -1 and Weeks 1, 2,
4 and 6, while percent micronucleated-reticulocyte (%MN-RET) frequencies were
measured on Day 4 only. Additional animals were treated intravenously with three
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daily doses of 50 mg/kg TiO2-NPs for the measurement of titanium levels in bone
marrow after 4, 24, and 48 hrs of the last treatment. The measurement indicated
that the accumulation of the nanoparticles reached the peak in the tissue 4 hrs after
the administration and the levels were maintained for a few days. No increase in ei-
ther Pig-a mutant frequency or the frequency of %MN-RETs was detected, al-
though the %RETs was reduced in the treated animals on Day 4 in a dose-depend-
ent manner indicating cytotoxicity of TiO2-NPs in the bone marrow. These results
suggest that although TiO2-NPs can reach the mouse bone marrow and are capable
of inducing cytotoxicity, the nanoparticles are not genotoxic when assessed with in
vivo micronucleus and Pig-a gene mutation tests.
1741 Comparative Assessment of Nanomaterial Definitions and
Considerations for Implementation.
R. David4,  D. R. Boverhof1,  J. H. Butala2,  S. Clancy3,  M. Lafranconi5 and
J. West6. 1The Dow Chemical Company, Midland, MI; 2Ferro Corp, Cleveland, OH;
3Evonik Degussa, Parsipanny, NJ; 4BASF Corp, Florham Park, NJ; 5Procter &
Gamble, Cincinnati, OH; 6American Chemistry Council, Washington DC.
The use of nanomaterials is bringing promising new advances to science and tech-
nology. In concert have come calls for increased regulatory oversight to ensure their
appropriate identification and control. If nanomaterial-specific regulations are im-
plemented, it will be critical that they are accompanied by definitions that are clear,
consistent and practical to apply. Numerous definitions for nanomaterials have
been proposed by various government, industry, and standards organizations; how-
ever, these definitions differ in their core elements and scope. A comprehensive
comparative assessment was conducted on existing nanomaterial definitions with
the goal of identifying elements essential for a sound regulatory definition.
Common elements across definitions included size and dimensions; however, size
limits were inconsistent and several important elements were not captured consis-
tently including: consideration of agglomerates and aggregates, distributional
thresholds, novel properties and solubility. Other important differences included
number size distributions versus weight distributions and natural versus intention-
ally-manufactured materials.  Accordingly, this analysis was extended to identify the
critical elements to clearly define the materials subject to a nanomaterial regulation.
The analysis also evaluated the extent of characterization required to determine
whether a material falls within current nanomaterial definitions and found that
some are not aligned with currently available analytical capabilities. Overall, this
analysis highlights the similarities and differences in currently proposed nanomate-
rial definitions as well as the technical constraints that will need to be addressed for
the successful implementation of a regulatory nanomaterial definition.
1742 Cytotoxicity and Genotoxicity Studies in A549 Cells
Cultured with Metal Oxide Nanoparticles.
A. Miyajima-Tabata1,  K. Sakai1,  T. Kawakami2,  R. Kato1,  A. Matsuoka1 and
K. Isama2. 1Division of Medical Devices, National Institute of Health Sciences, Tokyo,
Japan; 2Division of Environmental Chemistry, National Institute of Health Sciences,
Tokyo, Japan. Sponsor: A. Hirose.
Nanomaterials are now widely used in various fields of science, technology and
medicine. However, there are many unclear safety issues because they are new ma-
terials. An in vitro cellular toxicological study using well-characterized nanoparticles
is conducted for the evaluation of the biological effects of nanoparticles. In this
study, we compared the sensitivity of human lung-derived epithelioid-like cell line
A549 cells and Chinese hamster lung fibroblast (CHL) cells to nanoparticles. This
study also evaluated the cytotoxicity and the genotoxicity of ten kinds of metal
oxide nanoparticles (MNs; primary diameter: <50 nm) in A549 cells. 
A549 and CHL cells were treated with ZnO or polystyrene as typical nanoparticles
and the cytotoxicity and the genotoxicity were examined. A549 cells were treated
with MNs and the cytotoxicity and the genotoxicity of MNs were evaluated. The
cytotoxicity was evaluated with colony formation and MTT assays, and the geno-
toxicity test was evaluated with an in vitro micronucleus test. The physicochemical
properties, such as the hydrodynamic diameter of secondary MNs, the zeta poten-
tial etc., were determined in both suspension and 10%FBS-MEM. 
No remarkable difference was observed between A549 and CHL cells in the cyto-
toxicity and the genotoxicity when treated with ZnO or polystyrene. The hydrody-
namic diameter of MNs observed in suspension and 10%FBS-MEM were 41.0 to
256.8 nm and 152.9 to 1388.6 nm, respectively. Although the zeta potentials of
MNs measured in suspension were positive (+41.6 to +62.1 mV), except SiO2 and
ZnO (-54.4 and -7.5 mV), all of the zeta potentials of MNs measured in 10%FBS-
MEM were negative (-22.7 to -10.7 mV). Cytotoxicity was observed following
treatment with CuO, NiO, ZnO, ITO, and Y2O3 in the colony formation assay
and with CuO, NiO, and ZnO in the MTT assay. The results of the genotoxicity
study will be discussed.
1743 In Vitro Toxicity Evaluation of Chemical Biological Defense
(CBD) Nanomaterials.
C. J. Cao,  A. O’Neill,  L. C. Crouse and M. S. Johnson. Toxicology Portfolio, US
Army Institute of Public Health, Aberdeen Proving Ground, MD.
Nanomaterials are gaining in commercial and military applications which yield
new capabilities applicable to CBD. US Army Public Health Command (US-
APHC) and Office of the Surgeon General (OTSG) have made efforts in chemical,
biological, radiological and nuclear incident response for protecting the work force,
civilian and military, from the unintended consequences of nanotechnology
processes and materials exposures. The study used the Microtox® Toxicity Test
System and Neutral Red Uptake (NRU) assay to fast evaluate four CBD nanoma-
terials for their aquatic toxicity in marine organisms, Vibrio fischeri, and basal cy-
totoxicity in human liver cells in support of the ongoing USAPHC/OTSG efforts.
Four nanomaterials: RNP-212 and FAST-ACT®, proprietary formulation of
nanocrystaline metal oxides used for neutralizing a wide range of toxic chemicals
and chemical warfare agents; PhotoScrubTM, a fiberglass cloth coated with TiO2
that uses UV light induced catalytic ionization of TiO2 to destroy chemical /bio-
logical warfare agents; Nano SBC, a nanosized sodium bicarbonate being investi-
gated as a replacement fire extinguishing agent in hand held fire extinguishers of
Army Aviation Weapons Systems, were selected for these tests. Microtox toxicity
(EC50 15min; mg/L) shows FAST-ACT (13.78) > RNP-212 (362) > Nano SBC
(1394) > PhotoScrub (>2500). Using US Fish and Wildlife Service aquatic toxicity
criteria, FAST-ACT and RNP-212 are considered “slightly toxic” and “practically
nontoxic”, respectively; both Nano SBC and PhotoScrub are considered “relatively
harmless”. The Microtox study fills the data gap for aquatic toxicity information for
the new nanomaterials. Neither FAST-ACT, RNP-212, PhotoScrub at 1250
μg/mL, nor Nano SBC at 2500 μg/mL were found toxic to human cells with NRU
assay. The human basal cytotoxicity data and predicted LD50 are comparable with
the results from animal studies. Both in vitro and in vivo studies assessed these four
nanomaterials as low hazard.
1744 Inhibition of Adipogenic Differentiation of Human
Mesenchymal Stem Cells by TiO2 Nanoparticles.
Y. Zhang1,  L. Guo2,  L. Yu2,  Y. Gao2,  Y. Jones1,  A. Keasling1,  B. Green2,
D. Hansen2,  A. Inselman2,  L. Shi2,  P. C. Howard1 and B. Ning2. 1NCTR/ORA
Nanotechnology Core Facility, Office of Scientific Coordination, NCTR/FDA,
Jefferson, AR; 2Division of Systems Biology, NCTR/FDA, Jefferson, AR.
Nanotechnology has resulted in the creation of many new materials and devices
with a vast range of applications. TiO2 has historically been used as a pigment with
many applications, and nanoscale TiO2 is additionally appearing in human con-
sumer products, raising safety issues of human health and environmental concerns.
Stem cells are proposed to be attractive tools for toxicity testing because of their
sensitivity to external stimuli during differentiation. The physical and chemical
properties of TiO2 nanoparticles were characterized using transmission electron
microscopy (TEM), nanoparticle tracking analysis, dynamic light scattering,
Brunauer-Emmett-Teller, Raman and X-ray fluorescence spectroscopy. We exam-
ined the impact of TiO2, and other nanomaterials, on cytotoxicity and differentia-
tion of human mesenchymal stem cells (hMSC). TiO2 nanoparticles induced cyto-
toxicity in a concentration-dependent manner in hMSCs. Additionally, the
differentiation of hMSCs to adipocytes, determined using imaging and Oil Red O
staining, was inhibited in a concentration-dependent manner. Moreover, uptake of
the TiO2 nanoparticles by hMSCs was confirmed using TEM, suggesting a possi-
ble endocytosis pathway. The mRNA expression for the adipogenic markers
adiponectin, aP2, and LPL were significantly reduced to 61%, 53%, and 61% of
control levels following exposure to TiO2 nanoparticles. Furthermore, incubation
of the TiO2 with the mesenchymal stem cell lysate resulted in the identification of
208 proteins associated with the nanoparticles using proteomic and mass spectrom-
etry analyses. These results indicate (i) the interaction and impact of nanoparticles
with stems cells is selective (other nanoparticles did not induce this effect), (ii)
TiO2 nanoparticles inhibited differentiation of mesenchymal stem cells, and (iii)
further work is needed to elucidate the mechanism of action of TiO2 in this cell
population.
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1745 Comparison of Toxicity of Bare- and Phospholipid-Coated-
Iron Oxide Nanoparticles in Different Cell Lines.
E. Park1,  D. Choi1,  H. Umh2,  J. Kim1,  D. Kim1,  S. Kim1 and Y. Kim2.
1Department of Molecular Science and Technology, Ajou University, Suwon, Republic
of Korea; 2Department of Chemical Engineering, Kwangwoon University, Seoul,
Republic of Korea. Sponsor: E. Park.
We pursue a better quality of life as well as a rich life through the development of
science and technology. However, the scientific principles and its application
threaten our health sometimes. In this study, we compared the toxicity of phospho-
lipid coated-iron oxide nanoparticles (PLC-FeNPs) and bare-FeNPs in different cell
lines. PLC-FeNPs showed higher negative charge than that of bare-FeNPs in the ve-
hicle, but not in the cell culture media containing fetal bovine serum. In addition,
the trend of uptake in each cell lines was very similar between both types of FeNPs,
despite differences in their diameters. However, cell cycle changes varied according
to the cell line and the type of FeNPs. We performed further study using two
macrophage cell lines. At 1 h after exposure, MH-S cells exposed to both types of
FeNPs showed a strong correlation between gene expression changes despite the up-
take process was different, but RAW264.7 cells exposed to both types of FeNPs
showed a weak correlation between gene expression changes despite the uptake
process was similar. At 24 h after exposure, two macrophage cells exposed to PLC-
FeNPs and RAW264.7 cells exposed to bare-FeNPs induced the increase in the
number of autophagosome-like vacuoles. While, the cytosolic component of MH-
S cells exposed to bare FeNPs completely disappeared, although the membrane re-
mained intact. The predominant gene in MH-S and RAW264.7 cells was also dif-
ferent. Furthermore, when treated with both types of FeNPs, RAW264.7 cells
secreted TNFα only, whereas MH-S cells secreted IL-1β and IL-6 along with
TNFα. Based on these results, choice of cell line is very important to improve the
reliability of in vitro toxicity data. Further, we think that the increase of autophago-
some-like vacuoles may be an important cause of cell death which is caused by
nanoparticles.
1746 Mechanisms of Silica Nanoparticle-Induced Interleukin-8:
Requirement of p38/TACE/TGF-α/EGFR-Cascade-and NF-
κB Signalling in Lung Epithelial Cells.
M. A. Refsnes,  T. Skuland,  J. Øvrevik,  P. E. Schwarze and M. Låg. Depatment of
Air Pollution and Noise, Norwegian Institute of Public Health, Oslo, Norway.
Sponsor: M. Løvik.
Nanoparticles (NPs) of non-crystalline (amorphous) silica particles (SiNPs) are
used in a large range of products. Inhalation of NPs represents a potential health
hazard and may induce inflammation in lung tissues. We have previously shown
that SiNPs induced marked cytokine responses independently of particle uptake in
human bronchial epithelial cells (BEAS-2B). In the present study the mechanisms
involved in SiNP-induced IL-8 responses were further examined. SiNP-exposure
induced an early increase in phosphorylation of p65 (NF-κB) as well as the three
main MAP-kinases ERK1/2, p38 and JNK, concurrent with an early up-regulation
of IL-8 mRNA. SiNP also induced a time-dependent increase in phosphorylation
of the epidermal growth factor receptor (EGFR) and release of the EGFR-ligand
transforming growth factor (TGF)-α. SiNP-induced IL-8 responses were attenu-
ated by the p38-inhibitor SB202190, the NFkB-inhibitor PDT-p65 and siRNA
against p65, as well as the EGFR-inhibitor AG1478, a TGF-α-neutralizing anti-
body and TAPI-1 (inhibitor of the metalloprotease TACE which cleaves pro-TGF-
α to TGF-α). However, inhibitors of ERK and JNK did not exert any effect on
SiNP-induced IL-8. Moreover, SiNP-induced EGFR-phosphorylation was inhib-
ited by AG1478 and TAPI-1, and SB202190 reduced the SiNP-induced TGF-α re-
sponse. The SiNP-induced phosphorylations of p38 and p65 were not affected by
TAPI-1 or AG1478. Thus, SiNP appeared to induce EGFR-phosphorylation
through a p38- and TACE-dependent cleavage/release of TGF-α. Interestingly,
EGF and TGF-α induced little effect on IL-8 release compared to SiNP, suggesting
that EGFR-signalling alone is an insufficient stimuli for IL-8 induction. In conclu-
sion, SiNP-induced IL-8 responses seemed to require activation of
p38/TACE/TGF-α/EGFR-cascade, presumably acting in concert with the classical
NF-κB pathway in BEAS-2B cells.
1747 Role of Tungstate Nanoparticles in the Production of ROS
and Induction of Cellular Damage.
K. M. Dunnick1, 2,  M. A. Badding1,  N. R. Fix1,  J. M. Patete3,  S. S. Wong3, 4,
V. Castranova1 and S. S. Leonard1, 2. 1HELD, National Institute for Occupational
Safety and Health, Morgantown, WV; 2Pharmaceutical and Pharmacological Sciences,
West Virginia University, Morgantown, WV; 3State University of New York at Stony
Brook, Stony Brook, NY; 4Brookhaven National Laboratory, Upton, NY.
Alkaline-earth metal tungstate AWO4 (A= Ca, Ba, Sr ) nanoparticles are currently
being used in a variety of applications including use as components of medical
equipment, optical fibers, gas sensors, and scintillator detectors. Due to tungstate
nanoparticle versatility, their manufacturing is expected to increase within the next
10 years. Our ongoing study is designed to examine the effects of tungstate
nanoparticle exposure in order to develop safe workplace practices to limit expo-
sure. Electron Spin Resonance (ESR) was used to measure hydroxyl radical (.OH)
production of tungstate nanoparticles following incubation with either hydrogen
peroxide (H2O2) or RAW 264.7 cells. Additionally, enhanced dark field microscopy
was used to assess nanoparticle association and engulfment by RAW cells over mul-
tiple time points up to 3 hours. Assays measuring H2O2 production, oxygen con-
sumption, DNA damage and lipid peroxidation were used to assess possible cellular
injury following RAW cell incubation with tungstate nanoparticles. Data showed
that tungstate nanoparticles are capable of producing .OH in the presence of H2O2
and RAW cells. Further, tungstate nanowires produced significantly greater .OH
compared to nanospheres as shown through ESR measurements. Initial dark field
microscopy data showed an increase in association between tungstate nanoparticles
and cells and a decrease in non-specific binding after 3 hours of exposure. Cellular
damage results in conjunction with ESR data will promote an understanding of
tungstate nanoparticle toxicity. It is important to understand the damaging effects
and free radical production produced by tungstate nanoparticle exposure in order
to ensure that accurate toxicity models are developed and to promote proper train-
ing in nanoparticle inhalation prevention.
1748 Comparative In Vitro Toxicity Study of Bismuth and
Bismuth-Derivatives Nanoparticles.
A. De Vizcaya-Ruiz1,  M. Esquivel-Gaón1, 6,  O. C. Barbier1,  M. Uribe-Ramirez1,
J. Narváez-Morales1,  J. Muñoz-Saldaña2,  S. Velumani3,  Y. Matsumoto3,
D. Diaz4,  E. Berea5,  K. A. Dawson6 and S. Anguissola6. 1Toxicology, Cinvestav,
Mexico City, Mexico; 2Unidad Queretaro, Cinvestav, Queretaro, Mexico; 3Electrical
Engineering Department, Cinvestav, Mexico City, Mexico; 4Facultad de Quimica,
UNAM, Mexico City, Mexico; 5Farmaquimia, Mexico City, Mexico; 6CBNI,
University College Dublin, Dublin, Ireland.
Bismuth and bismuth-derived nanoparticles (Bi-NP) were developed for safer con-
sumer applications as bioprobes, photocatalysts, piezoelectrics and contrast agents.
A comparative in vitro study was performed to test the biointeraction and toxicity
of Bi-NP - bismuth trioxide (Bi2O3), bismuth vanadate (BiVO4), bismuth antimo-
nium (Bi-Sb), bismuth-sodium-barium-titanate (BNT-BT), and zero-valent col-
loidal Bi (ZV-Bi). Dispersion and stability in biological fluids and in vitro toxic ef-
fects in target cells (liver-HepG2, kidney-LLCPK1, lung-A549 and
brain-SHSY5Y) were evaluated using a nanometer fractionized suspension (<~200
nm) achieved through sonication, centrifugation, and addition of bovine serum al-
bumin (BSA) to reduce agglomeration. Scanning electron microscopy (SEM) con-
firmed morphological analysis and dispersion of Bi-NP. Cytotoxicity was observed
at high concentrations (100 μg/ml) at 24 to 72 h, using well established LDH and
MTT assays and High Content Analysis. Lung and brain cells were more suscepti-
ble, the main form of cell death was necrosis withoutinvolving reactive oxygen
species (ROS) generation. Cell cycle analysis showed arrest at G0-G1 phase with
BNT-BT and Bi-Sb. With BiVO4 treatment an increase in S-phase and significant
DNA damage assessed with the comet assay, were observed. No relevant acute cyto-
toxicity was observed in the exposed cell systems from the initial screening of Bi-
NP. The severity of biological outcomes of Bi-NP in descending order were
BiVO4>Bi2O3>Bi-Sb>BNT-BT>ZV-Bi. Further work is underway to elucidate the
mechanisms and nuclear effects, and to connect the biological effects with the
physicochemical properties of the Bi-NP. Funding from the European Community
Seven Framework Programme and CONACYT (Grant agreements #263878 and
12514).
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1749 Long-Term Inhalation Study with Nanomaterials:
Characterization of As-Produced Properties and Persistence
Simulation Assays.
W. Wohlleben3, 1,  L. Ma-Hock1,  J. Keller1,  K. Wiench2 and R. Landsiedel1.
1Experimental Toxicology and Ecology, BASF SE, Ludwigshafen am Rhein, Germany;
2Product Safety, BASF SE, Ludwigshafen am Rhein, Germany; 3Polymer Physics,
BASF SE, Ludwigshafen am Rhein, Germany.
The most urgent knowledge gap in nanosafety research concerns the long-term fate
and effects of nanomaterials that may have been released into the air or the envi-
ronment. BASF and the German Ministry for the Environment (BMU) have initi-
ated a chronic inhalation study as part of the EU project NanoREG.Here we report
whether the materials chosen can be regarded as representatives of poorly soluble
biopersistent (PSB) particles.
The original batch of CeO2 distributed as NM212 from the OECD sponsorhip
program and an identical reproduction of the BaSO4 distributed as NM220 were
characterized by 20 physical-chemical endpoints according to the nanospecific
REACH guidance R7.1, benchmarked against TiO2 (NM105) and the non-per-
sistent SiO2 (Aerosil 150). The as-tested solubility was simulated by incubation for
28d in buffer (PBS) or phagolysosomal fluid (PSF), or 1d in stomach (0.1n HCl).
Analysis included released ions by atom spectroscopy, agglomeration by analytical
ultracentrifugation and laser diffraction, morphology by electron microscopy
(TEM, SEM) and selected area electron diffraction (SAD).
The re-characterization of CeO2 NM212 and BaSO4 NM220 confirms their con-
formity with earlier work on the OECD batches by PROSPECT and NanoCare
projects. The solubility of CeO2 NM212 is as low as TiO2 NM105. The positive
control SiO2 dissolves as expected. The solubility of BaSO4 NM212 in all media,
including PSF, is vanishing against the positive control, and noticeable only in 0.1n
HCl. All materials, incl. TiO2, undergo morphological changes by Ostwald ripen-
ing and recrystallization in PSF and HCl, but retain their crystallinity.
Dissolution is 0 to 0.1% per month; extrapolated on the chronic inhalation study,
CeO2 NM212 and BaSO4 NM220 remain 99% persistent.
1750 Intracellular Generation of Reactive Oxygen Species As a
Central Parameter for the Interaction of Manganese Oxide
Nanoparticles with Lung Epithelial Cells.
U. Sydlik1,  C. Bieschke1,  D. Stöckmann1,  M. Gotic2,  S. Music2 and
K. Unfried1. 1IUF, Duesseldorf, Germany; 2Institute Ruder Boskovic, Zagreb, Croatia.
Sponsor: T. Haarmann-Stemmann.
Nanoparticles consisting of manganese oxide have been suggested for several inno-
vative technological approaches, including the use in nanomedicine and diagnos-
tics. Therefore, the interaction of such nanoparticles with human target cells is of
particular interest for the success of nanomedical approaches but also with regard to
unintended side effects. To address this problem, we tested different kinds of man-
ganese nanoparticles (MnNP) in an in vitro system which we earlier evaluated for
proliferative, apoptotic, and pro-inflammatory endpoints induced by poorly solu-
ble nanoparticles. 
MnNP were synthesized and the biological and toxic effects of the generated parti-
cles were studied in comparison to carbon nanoparticles (CNP) in dose response
experiments with rat and human lung epithelial cell lines. After physico-chemical
characterization, a set of three MnNP consisting of Mn3O4 or MnO2 with signif-
icant differences in size and shape were selected. According to the different oxida-
tion stages of manganese, the particles showed significant differences in Fenton re-
activity in the cell free system. These data, however, did not reflect the capacity of
the particles to induce intracellular oxidative stress. However, quantitative differ-
ences in intracellular reactive oxygen species (ROS) correlated with the capacity to
trigger membrane-dependent signaling processes. Furthermore, the metabolic ac-
tivity (WST-Assay) was negatively correlated with intracellular ROS, indicating a
link between mitochondrial activity and ROS generation. None of the particles had
effects on the membrane integrity of the cells. The data clearly demonstrate that the
intracellular generation of ROS by MnNP, probably determined by particle size and
shape, has more relevance for nanoparticle cell interaction that the oxidative capac-
ity of the particles themselves.
1751 The Effects of Ceria Nanoparticles on Primary Human
Monocyte-Derived Macrophages and Bronchial
Macrophages.
J. D. Marshburn1,  A. B. Rice1,  M. D. George1,  S. M. Anderson1,  N. J. Walker2,
S. Garantziotis1 and S. Hussain1. 1Clinical Research Program, NIEHS/National
Institute of Health, Durham, NC; 2National Toxicology Program, NIEHS, Durham,
NC.
Cerium dioxide (CeO2) nanoparticles (NPs) are used in various industrial and con-
sumer product applications and are of significant environmental health interest.
The health effects of CeO2 NPs on primary human cells are poorly understood. We
have previously shown that CeO2 NPs are toxic to primary human peripheral
blood monocytes at relatively low doses, which led to apoptosis and autophagy.
Now we aimed at deciphering the cytotoxic effects of CeO2 NPs in mature
macrophages (human peripheral blood monocyte-derived macrophages) and
bronchial macrophages. CD14+ cells were isolated from peripheral blood samples
of healthy volunteers and matured ex-vivo over a 7 day period to obtain
macrophages. Bronchial macrophages were isolated from sputum inductions of
healthy volunteers. Cells were exposed to 0, 1, 5, 10, or20 μg/mL CeO2 NPs for
over a period of 24 or 48 hours. Transmission electron microscopy analysis revealed
that both, blood and bronchial macrophages were internalizing CeO2 NPs and
were found either in vesicles or free cytoplasm. No significant change was observed
in the viability of both types of cells after exposure to CeO2 NPs. Moreover, we did
not observed any increase in caspase 3/7 activity after exposure to CeO2 NPs.  We
found that this increased resistance to NPs as compared to monocytes was due to
decreased apoptosis and autophagy induction in mature cells. In conclusion we
demonstrate that mature antigen presenting cells are resistant to the cytotoxic ef-
fects of environmentally relevant CeO2 NP exposures.
1752 Structural Basis for the Toxic Potential of Cellulose
Nanocrystals.
F. L. Sinche1,  J. Simonsen3 and S. Harper1, 2. 1Environmental and Molecular
Toxicology, Oregon State University, Corvallis, OR; 2Chemical, Biological and
Environmental Engineering, Oregon State University, Corvallis, OR; 3Wood Science &
Engineering College of Forestry, Oregon State University, Corvallis, OR.
Cellulose nanocrystals (CNCs) are a renewable nanomaterial that holds promise for
an array of nano-related applications such as drug delivery and reinforcing
nanocomposites. Although the core material of CNC is widely believed to be bio-
compatible, some of its intrinsic features such as geometrical ratio (L/d) and its
high strength and stiffness are reminiscent of other fiber-like nanomaterials such
carbon nanotubes and metal oxides crystals, which have been reported to induce
toxicity. Despite these similarities, we still lack knowledge of how those features of
CNC may affect biological responses in vivo. Following acid hydrolysis of cellulose
fibers to obtain CNC, we further used surface modifications and a wide range of
concentrations to study the influence of fibrous and spherical shapes of CNC on
the biological responses using zebrafish embryos as a model organism. We account
for the surface modifications of CNC and differentiate between the responses
elicited by embryos exposed to nanofibrillated cellulose (NFC) synthesized via
TEMPO (T) and mechanical homogenization (H). We found chemical modifica-
tions of CNC yielded homogenous dispersion and the conversion of surface func-
tional groups for charge modifications was high. Using morbidity and mortality
measures in embryonic zebrafish exposed to the CNC formulations, our findings
suggest relatively low toxicity from both CNC and surface-modified CNCs com-
pared to hundreds of other nanomaterials that have been tested in our model sys-
tem (nbi.oregonstate.edu). However, NFC-T and NFC-H influenced the toxicity
in a concentration-dependent manner. Our results give insight into the biological
responses from in vivo exposures using cellulosic nanomaterials with fiber-like and
modified-charge features.
1753 Identification of Metal and Silicate Particles Including
Nanoparticles in Electronic Cigarette Fluid and Aerosol.
M. T. Williams1,  A. Villarreal1,  K. Bozhilov2,  S. Lin1 and P. Talbot1. 1Cell Biology
and Neuroscience, University of California, Riverside, Riverside, CA; 2Central Facility
for Advanced Microscopy, University of California Riverside, Riverside, CA.
Electronic cigarettes (EC) deliver aerosol by heating fluid containing nicotine, fla-
vorings, and a humectant. EC cartomizers combine the fluid chamber and heating
element in a single unit. Because EC do not burn tobacco, they may be safer than
conventional cigarettes. Their use is rapidly increasing worldwide with little prior
testing of their aerosol. We hypothesized that EC aerosol contains metals derived
from the various components. Cartomizer contents and aerosols were analyzed
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using microscopy, cytotoxicity testing, x-ray microanalysis, particle counting, and
inductively coupled plasma optical emission spectrometry. A nickel-chromium fila-
ment was coupled to a thicker silver coated copper wire. The silver coating was
sometimes missing. Four tin solder joints attached the wires to each other and cou-
pled the copper/silver wire to the air tube and mouthpiece. All cartomizers had ev-
idence of use before packaging (burn spots on the fibers and electrophoretic move-
ment of fluid in the fibers). Fibers in two cartomizers had green deposits that
contained copper. Centrifugation of the fibers produced large pellets containing
tin. Tin particles and tin whiskers were identified in cartridge fluid and outer fibers.
Cartomizer fluid with tin particles was cytotoxic in assays using human pulmonary
fibroblasts. The aerosol contained particles >1μm comprised of tin, silver, iron,
nickel, aluminum, and silicate and nanoparticles (< 100 nm) of tin, chromium, and
nickel. Of 22 elements identified, 12 were present in concentrations higher than
the minimum risk level. Many of the elements identified in EC aerosol are known
to cause respiratory distress and disease. The presence of metal and silicate particles
in cartomizer aerosol, often above minimal risk levels, demonstrates the need for
improved quality control in EC design and manufacture and studies on how EC
aerosol impacts the health of users and bystanders.
1754 Does Nanostructured Synthetic Amorphous Silica
Disintegrate after Oral Uptake?
M. Maier1,  F. Babick2,  R. R. Retamal Marin2 and M. Stintz2. 1Evonik Industries
AG, Hanau, Germany; 2Technical University Dresden, Dresden, Germany. Sponsor:
D. Warheit.
The interest in manufactured nanomaterials with potential new properties has led
to increasing concern about their potential systemic uptake and fate as well as the
associated risk to humans. Materials applied in processed food are of special inter-
est. Synthetic amorphous silica (SAS) is a nanostructured material formed by flame
hydrolysis or precipitation that has been used for decades. In commercial products,
basic structural elements are submicron aggregates (fused nanosized primary parti-
cles) that themselves form micrometer (or even larger) agglomerates. SAS is em-
ployed in a variety of products, e.g. as free-flow agent in soup powders. As to risk
evaluation, it is important to understand whether structural changes may occur
during the further processing or after oral uptake.
In a first step, we addressed possible effects of heating in water (modeled processing
of soup powder) and acid environment (pH of gastric juice) on the structure and
size distribution of SAS. Methods for the reproducible dispersion of SAS and the
reliable determination of the volume weighted particle size distribution of SAS sus-
pensions were developed and validated. Two food grade SAS types were studied:
precipitated SAS and pyrogenic (fumed) SAS. SAS was first heated in water (100
°C) and then poured into HCl to reach pH=1.3 (paddle apparatus). During both
steps time dependent changes in the volume weighted size distribution were moni-
tored using laser diffraction (LD).
LD with validation, e.g. by comparison to microsieve analysis, proved as a reliable
technique to characterize the dispersity of SAS suspensions and to evaluate the vol-
ume fraction of fine particles. Heating of SAS in water is only a weak dispersion
leading to size distributions well above 1 μm. In acid environment (2 hours,
pH=1.3) no significant changes in dispersity of SAS – neither agglomeration nor
erosion of agglomerates or aggregates – was observed. In separate animal studies
(rats, oral, repeated dose), no isolated nanosized primary particles of SAS were de-
tected in the blood or organs.
1755 In Situ Characterization of Nanoparticles: Surface Properties
Affecting Agglomeration and Particle’s Corona.
A. Haase1,  M. D. Driessen1,  C. Schulze2,  M. Wiemann3,  H. Galla4,  M. Lehr2,
5,  A. Luch1 and W. Wohlleben6. 1Federal Institute for Risk Assessment (BfR), Berlin,
Germany; 2Saarland University, Saarbrücken, Germany; 3IBE, Münster, Germany;
4University of Münster, Münster, Germany; 5Helmholtz Institute for Pharmaceutical
Research, Saarbrücken, Germany; 6BASF SE, Ludwigshafen, Germany. Sponsor: M.
Pallardy.
In situ characterization of ‘as-tested’ nanoparticles is essential to understand their
toxic effects and to develop Nano-QSARs. The national project nanoGEM corre-
lates as-produced with as-tested and as-released properties, and further to uptake
and effects in-vitro and in-vivo. 
Here we report on lipid and protein interactions of 16 nanoparticles in a) serum
containing cell culture medium, b) pure phospholipids vs. CuroSurf vs. native lung
surfactant.
The surface of suspended nanoparticles with sizes of 10nm (ZrO2), 15nm (SiO2)
and 50nm or 200nm (Ag) was furnished either with acidic, amino-functional,
PEG, acrylic and electro-steric functionalities. Characterization followed the
nanospecific REACH guidance R7.1, benchmarked against OECD reference mate-
rials TiO2, ZnO, BaSO4, AlOOH. We assessed in situ agglomeration by light scat-
tering, nanoparticle tracking and analytical ultracentrifugation; protein corona by
1D/2D gel electrophoresis with mass spectrometry; lipid interaction by secondary
ion mass spectrometry (SIMS), phosphate assays and film balances.
In protein containing media, only nanoparticles with electro-steric functionalities
remained dispersed, partially due to negative charge; all nanoparticles attracted a
corona with BSA as main component that often decreased during 1h to 24h.
Astonishingly, phospholipids had a low affinity to nanoparticles. Only few func-
tionalities attracted lipids and then agglomerated afterwards. The presence of pro-
teins in CuroSurf or native surfactant may induce lipid binding in some cases but
not vice versa.
The surface coating controls the dispersability and the corona of proteins and lipids
by kinetic properties. However, nanoparticles behave completely different in lung
lining fluid compared to serum containing cell culture media. This has implications
for the validity of toxicity testing.
1756 Possible Adjuvant Role of Manufactured Nanoparticles in
Chemical-Induced Sensitization.
B. Baré1,  N. Lambrechts1,  P. Hoet2 and I. Nelissen1. 1Environmental Risk and
Health Unit, Flemish Institute for Technological Research (VITO NV), Mol, Belgium;
2Lung Toxicology Unit, Catholic University Leuven (KULeuven), Leuven, Belgium.
The adjuvant activity of air pollution particles on allergic airway sensitization is
well known, but a similar role of manufactured nanoparticles in allergic sensitiza-
tion following chemical exposure has not been clarified. Such mixed exposure situ-
ations may be relevant to daily life activities.
The goal of our study is to assess the possible adjuvant effect of manufactured
nanoparticles (NPs) on a chemical-induced sensitization response in vitro.
Human cord blood-derived CD34+ progenitor cells that are differentiatied into
immature myeloid dendritic cells (CD34-DC) are used as in vitro antigen-present-
ing cell model. These are exposed to sensitizing model chemicals, such as nickel sul-
phate, and spherical Au-NPs (5, 50 and 250 nm) for 6 and 24 hours, either as sep-
arate inducers or as a mixture. Concentration-response series of the chemicals are
used. Cytotoxic effects of the chemicals and NPs are assessed using flow cytometric
analysis of propidium iodide incorporation. Triggering of antigen-presenting prop-
erties of the exposed CD34-DC is assessed by expression analysis of the VI-
TOSENS® genes CCR2 and CREM (Lambrechts et al., Toxicol. Lett. 2011) on
mRNA samples of lysed cells after 6 hours of exposure using RT-qPCR.
Additionally, maturation of CD34-DC is assessed by quantifying cell surface ex-
pression of HLA-DR and the co-stimulatory molecules CD80, CD86, and CD83
after 24 hours using flow cytometry. 
The results that are obtained in this study, clarify whether gold nanoparticles oper-
ate as adjuvants for allergenic responses and as such enhance our insight in the risks
that nanoparticle exposure may pose to our health.
1757 Zinc Oxide Particles Induced Migration of Monocytes and
Increased Macrophage Cholesterol Uptake.
Y. Suzuki1,  S. Tada-Oikawa1,  G. Ichihara2 and S. Ichihara1. 1Graduate School of
Regional Innovation Studies, Mie University, Tsu, Japan; 2Department of
Occupational & Environmental Health, Nagoya University Graduate School of
Medicine, Nagoya, Japan.
Background: Metal oxide nanoparticles have been widely used in industry, cosmet-
ics, as well as biomedicine. However, the correlation between exposure to metal
oxide nanoparticles and the increased incidence of cardiovascular disease remains
elusive. The present study investigated the migration of monocytes and
macrophage cholesterol uptake that are essential for atherosclerotic progression in-
duced by nano-sized metal oxide particles.
Methods and results: Human umbilical vein endothelial cells (HUVECs) were cul-
tured and exposed to nano-sized TiO2 and ZnO. Exposure to ZnO for 6 hours re-
duced the cellular viability in a dose-dependent manner and increased the produc-
tion of reactive oxygen species (ROS) whereas there were no changes by the
exposure to TiO2. Exposure to ZnO for 21 hours increased the level of monocyte
chemotactic protein-1 (MCP-1) in HUVECs, and cell migration of human mono-
cytic leukemia (THP-1) was observed after incubation with HUVEC supernatants.
We also investigated the effect of nano-sized metal oxide particles on cholesterol
uptake in THP-1 macrophages after stimulation with acetylated-LDL. The expo-
sure to ZnO up-regulated the expression of membrane scavenger receptors of mod-
ified LDL particles and increased cholesterol uptake.
Conclusion: The exposure to ZnO reduced the cellular viability in a dose-depend-
ent manner and increased the production of ROS in HUVECs. The exposure to
ZnO also induced THP-1 cell migration and increased macrophage cholesterol up-
take. The study indicates that nano-sized ZnO particles accelerate foam cell forma-
tion in THP-1 macrophages.
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1758 Comparison of Cellular Uptake of Titanate Nanomaterials
by Human Monocytes.
S. Boonrungsiman,  W. Suchaoin and R. Maniratanachote. National
Nanotechnology Center, National Science and Technology Development Agency,
Pathum Thani, Thailand.
Titanate nanomaterials (TiNMs) have been applied in various industrial products,
including cosmetics, dye sensitized solar cells, and photocatalytic materials. There is
also increasing concern on human health risk due to exposure to these nanomateri-
als during production and application of the products. Therefore, safety assessment
of TiNMs is required. Several studies have been focused on toxicity and biological
interactions of titanate nanoparticles (TiNPs), but less is known for titanate nanofi-
bres (TiNFs). The aim of this study was to investigate the uptake patterns and tox-
icity of two TiNFs with different dimensions (about 50 and 70 nm in diameter and
500 and 1500 nm in length, respectively) compared with a spherical TiNP (about
170 nm in diameter) in human monocytes, THP-1cells. The uptake of TiNMs into
the cells was observed over the time for up to 24 hours using side scatter cytome-
try(SSC), which reflect internal cellular complexity, and electron microscopy. The
results showed that all of TiNMs were immediately absorbed on plasma membrane
when they exposed to the cells as observed by SEM and SSC. Engulfment of both
TiNFs and TiNPs by THP-1 cells occurred within 10 minutes exposure.
Interestingly, SSC profile may suggest the different uptake patterns between TiNFs
and TiNPs. In addition, the results from SSC and SEM suggested that TiNFs were
taken up by the cells which took longer time than that of TiNPs because of their
length. TiNFs with concentrations up to 100 μg/ml did not reduce cell viability,
while TiNPs significantly reduced cell viability at concentration of 100 μg/ml.
None of TiNMs (with concentrations up to 100 μg/ml ) significantly trigger intra-
cellular ROS generation. This information on cellular uptake and response might
be useful for risk assessment of nanomaterials.
1759 Air-Liquid Interface Exposure of Lung Cells to Metal
Nanoparticles Generated by a Spark Discharge System.
J. Kim,  J. Park,  T. M. Peters and P. S. Thorne. Occupational and Environmental
Health, The University of Iowa, Iowa City, IA.
Metal-based nanoparticles (NPs) are generated from a variety of processes including
welding, cutting and brazing. Airborne NPs are of particular concern over human
exposure, as they can readily move in ambient air and enter the body through in-
halation. The objective of this study was to investigate toxic effects on human alve-
olar type-II cells (A549) after air-delivery of various metal NPs. We used a spark
discharge system (SDS) capable of generating and depositing airborne NPs directly
onto cells at an air-liquid interface (ALI). The generated NPs (from various source
materials including Cu, Zn electrodes and welding rods) were characterized by
using a scanning mobility particle sizer, inductively coupled plasma-mass spectro-
scope and electron microscopes (SEM, TEM). To better model in vivo repeated-low
dose protocols we sequentially exposed lung cells to NPs in vitro (4 h exposure-2 h
rest in an incubator-4 h exposure) and cell viability was determined by Alamar Blue
assay at 4 h post-exposure. The SDS produced stable NP aerosols for 4 h (Cu, 8 x
106; Zn, 6 x 106; welding rods, 7 x 106 particles/cm3). Particle size distribution in-
dicated the geometric mean diameter of the generated particles to be average 15
(Cu), 25 (Zn) and 16 nm (welding rods) with a geometric standard deviation of
1.5, 1.7 and 1.4, respectively. SEM and TEM results confirmed the deposition of
nano-sized particles on cell-free transwells. The cellular concentration of Cu NPs
was 5.9 μg Cu/transwell (4.7 cm2) and a substantial amount of Cu was released to
the basolateral medium (0.3 μg) during air-delivery of Cu NPs in 4 h. Viability for
cells exposed to Cu NPs was significantly reduced to 79% (p<0.05) at 4 h post-ex-
posure compared to cells maintained in an incubator. Our results demonstrated
that the SDS can be useful for generating metal NPs and simulating welding fumes
for their toxicity assessment. In addition, integrated ALI exposures of human lung
cells with SDS can provide screening data to aid prediction of toxicity of metal
NPs.
1760 Engineered Nanoparticles Enhanced CD8+ T Cell Cytokine
Production.
B. L. Kaplan1, 4,  W. Chen2, 4,  Q. Zhang3,  G. L. Baker3 and N. E. Kaminski1, 4.
1Pharmacology and Toxicology, Michigan State University, East Lansing, MI;
2Microbiology and Molecular Genetics, Michigan State University, East Lansing, MI;
3Chemistry, Michigan State University, East Lansing, MI; 4Center for Integrative
Toxicology, Michigan State University, East Lansing, MI.
Engineered nanoparticles are being used in various commercial products; however,
a significant concern is the potential of these particles to cause adverse effects on
human health, as evidenced by exacerbation of allergic airway disease. The objective
of this interdisciplinary research is to investigate the putative adjuvant properties of
engineered nanoparticles on biological responses at the animal, cell, and membrane
levels. Silica nanoparticles (SNPs) were modified with alkyne-terminated surfaces
and appended with polyethylene glycol azides via “click” chemistry. At the cell level,
in vitro mouse models were utilized to examine the effect of modified SNPs on den-
dritic cell (DC)-induced T cell effector function. Ovalbumin (OVA)-derived pep-
tides OVA257-264 or OVA323-339 were presented by endogenous antigen presenting
cells in splenocytes or a mouse DC line, DC2.4. IFNγ and IL-2 production by
CD8+or CD4+ T cells in response to OVA peptides was measured by flow cytome-
try. At modest peptide stimulation levels, modified SNPs (up to 10 μg/ml) en-
hanced the proportion of CD8+, but not CD4+, T cells that produced cytokines.
Various functional groups (-COOH, -NH2, -OH) on modified SNPs enhanced cy-
tokine production to different levels, with -COOH SNPs being the most effective.
Furthermore, 50 nm -COOH SNPs exhibited greater enhancement effect on CD8+
T cell response than the other sizes. Importantly, modified SNPs did not aggregate
in in vitro culture media, demonstrating their effect at the true nanoscale.
Collectively, our results demonstrated the potential adjuvant effect of modified
SNPs on CD8+ T cell function and will also complement other studies being con-
ducted by the team at the membrane and the intact animal level. (Supported by
NIH Grant RC2 ES018756)
1761 Biological Impacts of Ferroelectric Nanoparticles:
Comparison between Lead and Bismuth.
M. Esquivel-Gaón1, 3,  M. Uribe-Ramirez1,  E. Herrera-Jimenez2,  J. Muñoz-
Saldaña2,  L. M. Del Razo1,  M. Monopoli3,  K. A. Dawson3,  S. Anguissola3 and
A. De Vizcaya-Ruiz1. 1Toxicology, Cinvestav, Mexico City, Mexico; 2Unidad
Queretaro, Cinvestav, Queretaro, Mexico; 3CBNI, University College Dublin, Dublin,
Ireland.
The risk posed by lead during manufacturing of ferroelectric ceramics has led to ef-
forts to develop lead-free options, bismuth sodium titanate with barium titanate
(BNT-BT) nanoparticles (NP) have become a strong candidate to replace lead zir-
conate titanate (PZT)-based ceramics. In order to evaluate the biological effects
generated by PZT and BNT-BT NP we investigated their interaction with biomol-
ecules adsorbed on the NP surface, which defines the interface with cellular mem-
branes, the uptake and potential toxicity in human cell lines. The NP were dis-
persed, stabilized with bovine serum albumin (BSA) and characterized in complete
cell culture medium showing an average size of 188 nm (BNT-BT) and 168 nm
(PZT), as measured by differential centrifugal sedimentation. The analysis of the
proteins absorbed with high affinity to the NP surface (hard corona) after the incu-
bation with FBS showed prevalently BSA and complex protein profiles dependent
on the concentration of FBS. Uptake studies in cell cultures rely on fluorescently la-
beled NPs; we generated BNT-BT and PZT NP showing fluorescent properties by
labeling BSA used to stabilize the dispersions. The NP were tracked through the en-
dolysosomal pathway using a time lapse live cell imaging approach. For cytotoxicity
assessment, cell membrane damage and mitochondrial activity were measured in
Hep G2, LLC-PK1, A549 and SH-SY5Y cells after exposure to increasing concen-
trations of BNT-BT and PZT NP for 24 or 48 h. The integrity of the cell mem-
brane was not significantly affected; however the mitochondrial activity decreased
after 48 h with 100 μg/ml for both NP being more evident for the PZT NP in neu-
roblastoma cells. Our results suggest that BNT-BT showed lower levels of toxicity
compared to PZT thus it could be a good replacement for PZT-based ceramics.
Funding from the European Community Seven Framework Program and CONA-
CYT (Grant agreements #263878 and 12514) and Epitope Map Program.
1762 Role of Lung Surfactant Lipid and Protein Corona in
Airborne Positively Charged Nanoparticle Exposure.
Y. Xie,  A. Tolic,  W. Chrisler,  C. Mihai,  C. Szymanski,  D. Hu and G. Orr.
Pacific Northwest National Laboratory, Richland, WA.
Airborne nanoparticles (NPs) that reach the alveolar region are likely to be pre-
sented to alveolar epithelial cells coated with a corona of lung surfactant lipids and
proteins. However, the effect of the corona on airborne NP toxicity is still unclear,
mainly because most studies were conducted in cells exposed to NPs in growth
media, limiting the corona to molecules found in the media. Furthermore, accu-
mulating observations support a role for positive surface charge in NP toxicity, but
the impact of the corona, which shifts the NP surface charge to more negative val-
ues, is unclear. To understand the role of coronas in airborne NP exposure, we ex-
posed alveolar epithelial cells at the air-liquid interface (ALI) to aerosolized NPs
that were pre-incubated with a natural surfactant lipid and protein (Infasurf®) or
BSA solution. Bare polystyrene (PS) NPs, showing no toxicity, were compared with
aminated or carboxylated PS NPs, showing high or low level of toxicity, respec-
tively. Cellular response was compared between NPs at the same cellular dose,
measured as μg/cm2 using a quartz crystal microbalance. We found that the lowest
dose required to induce toxicity by aminated NPs with no corona was 3 folds lower
than the dose required to induce toxicity by aminated NPs with a surfactant co-
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rona, and 1.8 folds lower than the dose required by aminated NPs with a BSA co-
rona. In contrast, BSA corona eliminated toxicity of carboxylated NPs at all meas-
ured doses. With no corona, the level of aminated NPs at the cell surface or inside
the cytoplasm was significantly higher than the level of carboxylated NPs. To evalu-
ate the possibility that the observed protective effect of surfactant or BSA coronas
from aminated or carboxylated NP toxicity, respectively, is due in part to a decrease
in NP-cell interaction and internalization, we currently quantify any changes in
these processes that might be induced by the coronas. This work was funded by
NIEHS grant 1RC2ES018786-01 to GO.
1763 Metastatic Capacity Induced by Cells Exposed to Titanium
Dioxide Nanoparticles.
A. Déciga-Alcaraz1,  V. Freyre-Fonseca1, 2,  E. I. Medina-Reyes1,  N. L. Delgado
Buenrostro1 and Y. I. Chirino1. 1Facultad de Estudios Superiores Iztacala,
Universidad Nacional Autonoma de Mexico, Mexico City, Mexico; 2Departamento de
Graduados e Investigación en Alimentos, Escuela Nacional de Ciencias Biológicas,
Instituto Politécnico Nacional, Mexico City, Mexico.
Background. Titanium dioxide nanoparticles (TiO2 NPs) have been classified as a
possibly carcinogenic to humans (Group 2B) by the International Agency for
Research in Cancer. In this regard, its potential carcinogenic effects have been
under research. However, less has been investigated about the effects of cells ex-
posed to TiO2 NPs when they reach bloodstream, especially if TiO2 NPs exposed
cells could proceed from a tumor. 
Aim. We hypothesized that tumor cells exposed to TiO2 NPs could promote a
metastatic events. To test this hypothesis, lung adenocarcinoma cells were exposed
to TiO2 NPs (1, 5 and 10 μg/cm2) for 7 days and 30,000 cells of each concentra-
tion were injected into bloodstream of chicken chorioallantoic membrane (CAM)
of free pathogens fertilized eggs previously incubated during 11 days at 37°C and
80% humidity. Analysis of morphological changes was performed at 16th day.
Results. TiO2 NPs were characterized by transmission electronic microscopy
(TEM) suspended in F12K medium with 10% Serum Fetal Bovine (SFB) and zeta
potential was -20.98±0.75, and TiO2 NPs agglomerate size was 212.3 ±4.417nm,
630.2±20.94 nm and 588.3±43.11 nm for 1, 5 and 10 μg TiO2/mL respectively.
Images showed that there is an increase in distance between blood vessels and a de-
crease in number of nodes in CAM treated with cells exposed to 10 μg/cm2 of
TiO2. In addition, there were observed cell clusters on the CAM treated with cells
exposed to 1 and 5μg/cm2 of TiO2 NPs. 
Conclusion. TiO2 NPs exposure (10 μg/cm2) to lung adenocarcinoma cells in-
duced an increase in blood vessel distance and a decrease the number of nodes,
which seems to be a downregulation effect in angiogenesis. However, pre-exposed
lung adenocarcinoma cells to 1 and 5 μg/cm2 of TiO2 NPs provided a capacity to
form clusters, which could represent a higher metastatic effect.
1764 Phenotypic Polarization and Attenuation of Toll Receptor
Signaling Functions in Macrophages Exposed to Engineered
Nanoparticles.
V. K. Kodali1,  M. H. Littke1,  S. C. Tilton2,  J. G. Teeguarden1,  L. Shi1,
C. W. Frevert3,  W. Wang4,  J. G. Pounds1 and B. D. Thrall1. 1Systems Toxicology,
Pacific Northwest National Laboratory, Richland, WA; 2Computational Sciences
Division, Pacific Northwest National Laboratory, Richland, WA; 3Department of
Comparative Medicine, University of Washington, Seattle, WA; 4Bioscience Division,
Oak Ridge National Laboratory, Oak Ridge, TN.
Although macrophages play a critical role in scavenging engineered nanoparticles
(ENPs) from tissue, relatively little is known about how their normal innate im-
mune function is impacted. We investigated how pretreatment of macrophages
with 33 nm superparamagnetic iron oxide (SPIO) or 50 nm amorphous silica mod-
ulated the transcriptional response of macrophages to the toll 4 receptor (TLR4)
ligand LPS. Affymetrix microarray analysis showed over 5000 mRNA’s were differ-
entially regulated (>1.5 fold, p<0.05) in response to LPS (10 ng/ml, 6 hrs). SPIO
pretreatment (25 μg/ml) alone altered expression of a smaller set of genes (1029
total), but modulated expression of nearly 500 LPS regulated genes in a greater
than additive manner. In contrast to SPIO, relatively few LPS regulated genes were
modulated by silica pretreatment. Pathway analysis showed that pretreatment with
SPIO suppressed LPS activation of several key cellular functions like chemotaxis,
interferon and Jak-Stat inflammation signaling while enhancing cell adhesion and
oxidative/nitrative stress responses. Pretreatment of macrophages with SPIO also
caused a dose dependent decrease in phagocytosis of S.pneumoniae and S.ty-
phimurium, whereas silica pretreatment had no effect. Flow cytometry studies
using fluorescent LPS or antibodies against TLR4 revealed that SPIO exposure
caused dose-dependent down regulation of cell surface TLR4 level while silica had
no effect. Our results demonstrate that macrophages exposed to some ENPs are po-
larized toward an anti-inflammatory phenotype which attenuates pro-inflamma-
tory signaling by TLR4, and suppresses their phagocytic activity against pathogens.
This work was supported by NIEHS Grant U19-ES019544.
1765 Intracellular Trafficking and Accumulation Dynamics of
Zinc Ions in Alveolar Epithelial Cells Exposed to Airborne
ZnO Nanoparticles at the Air-Liquid Interface.
C. Mihai,  W. Chrisler,  Y. Xie,  C. Szymanski,  A. Tolic,  D. Hu,  B. Tarasevich
and G. Orr. Pacific Northwest National Laboratory, Richland, WA.
Airborne nanoparticles (NPs) that enter the respiratory tract are likely to reach the
alveolar region. Accumulating observations support a role for zinc oxide (ZnO) NP
dissolution in toxicity, but the majority of the studies were done in cells exposed to
NPs in growth media, where large doses of dissolved ions are shed into the exposure
solution. To better represent the exposure in the respiratory tract and focus on the
dissolution of airborne NPs in the cellular environment, we exposed alveolar ep-
ithelial cells to aerosolized NPs at the air-liquid interface (ALI). Using a fluorescent
indicator for zinc ions (Zn2+) and organelle-specific fluorescent proteins, we quan-
tified Zn2+ in single cells and organelles over time and correlated these values with
toxicity. We found that intracellular Zn2+ in cells exposed at the ALI peaked 3 h
post exposure and decayed to normal levels by 24 h, which was in contrast to expo-
sures in submersed cultures where intracellular Zn2+ continued to increase over
time. For the lowest toxic dose at 24 h, the peak at the ALI was ~3 folds lower than
the 24 h value in submersed cells, and ~8 folds lower than the 24 h value in sub-
mersed cells exposed to Zn2+ only. At the ALI, 45% of intracellular Zn2+ was
found in endosomes at 1 h post exposure, decreasing to 24% by 3 h. In contrast,
20% of intracellular Zn2+ was found in lysosomes at 1 h, increasing to 42% by 3 h.
Interestingly, exposure of submersed cells to Zn2+ only, led to a minimal accumu-
lation of ions in either the endosomes or lysosomes, with the majority of ions found
in larger vesicles. Our observations indicate that airborne ZnO NPs induce toxicity
at the ALI at intracellular Zn2+ levels that are significantly lower than those de-
tected when toxicity is induced in submersed cultures, and the localized dissolution
and trafficking of Zn2+ in endosomes following with their accumulation in lyso-
somes play critical roles in airborne NP toxicity. This work was funded by NIEHS
grant 1RC2ES018786-01 to GO.
1766 Aggregation Dynamics and Structure Measurements of
Nanomaterials in Biologically Relevant Conditions.
N. B. Saleh1,  S. M. Hussain2 and A. Afrooz1. 1Civil and Environmental
Engineering, University of South Carolina, Columbia, SC; 2Wright-Patterson AFB,
US Air Force, Dayton, OH.
Nanomaterial dosimetry for in vitro studies continued to be debated in nanotoxi-
cology literature, particularly due to the propensity of aggregation of highly diffu-
sive nano-scale materials. In classical nanotoxicology literature, average particle size
and surface charge are the typical measured parameters either initially or at the end
of exposure time period; with no information on the dynamic behavior throughout
the process. Moreover, aggregate structural information is mostly ignored. This
study focuses on monitoring dynamic aggregation behavior of metallic and car-
bonaceous nanoparticles under biological (i.e., in exposure media with added peni-
cillin streptomycin, at 37 °C) exposure conditions. The aggregation dynamics is
monitored by employing state-of-the-art ALV goniometer system. Suspension-
phase fractal dimension was measured with angle-dependent static light scattering
for an angular range of 12°-120°. Aggregation dynamics results indicate that elec-
trostatic interaction serves as the key interfacial force to providing stability to nano-
materials. In addition, continuous measurements of aggregate size in physiological
condition show network formation. Furthermore, time dependent fractal dimen-
sion results indicate that aggregate structure remains unchanged over time; how-
ever, were significantly altered by the background solution chemistry. The key im-
plications of the study include: consideration of intermediate time-endpoint
(instead of 24 hr); aggregation dynamics and network formation can minimize size-
effects on nanotoxicology; aggregation dynamics with aggregate structure informa-
tion can better determine nanomaterial dosimetry.
1767 Targeting Alternatively Activated Rat Macrophages Using
Mannose Functionalized Nanocarriers.
P. Chen1,  X. Zhang1,  A. Venosa2,  Z. Szekely1,  D. L. Laskin2 and P. J. Sinko1.
1Pharmaceutical Science, Rutgers University, Piscataway, NJ; 2Department of
Pharmacology & Toxicology, Rutgers University, Piscataway, NJ.
In response to inflammatory signals generated at sites of injury, macrophages are ac-
tivated into two main phenotypes: classically activated M1 cells and alternatively
activated M2 cells. Whereas M1 macrophages release cytotoxic/proinflammatory
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mediators that contribute to tissue injury, M2 macrophage-derived mediators sup-
press inflammation and initiate wound repair. Mannose receptor (MR) is known to
be expressed at high levels on M2 macrophages. In these studies, a mannose func-
tionalized nanocarrier (NC) was designed and developed with the goal of selectively
targeting M2 macrophages. Mannose functionalized NC (FITC-Gaba-Ser(Man)-
PEG12-Ser(Man)-Gaba-Gaba-Cys) were prepared using solid phase synthesis and
their identity confirmed by MALDI-TOF/MS and HPLC analysis. Rat peritoneal
macrophages (PMs) were incubated for 24-48 h with IFN-γ (20ng/ml) or IL-4/IL-
13 (10ng/ml), to induce M1 or M2 activation, respectively. mRNA levels of the
M1 marker, inducible nitric oxide synthase (iNOS) and the M2 marker, arginase
(Arg)-1 were quantified by RT-PCR, and protein levels by western blotting.
Treatments of PMs with IFN-γ resulted in increased expression of mRNA and pro-
tein for iNOS, whereas IL-4/IL-13 upregulated Arg-1 expression. After incubating
for 60 min, NC binding to macrophages was quantified by confocal microscopy.
Confocal microscopy showed that uptake of mannosylated NC into M2 PMs was
2.4 fold greater than control PMs, and 11.8 fold greater than M1 PMs. M2-
macrophage phenotype-specific uptake was completely abolished by mannan, sug-
gesting MR-mediated targeting. NCs were co-localized with rhodamine-dextran, a
general fluid phase endocytosis marker, indicating that the NCs were internalized
by PMs. The present studies demonstrate that mannosylated NCs are specific for
macrophages expressing mannose receptor. These NC may be useful for delivery of
drugs to sites of injury and infection. 
Support: NIH AI51214, AR055073, CA132624, ES004738, ES005022, and
GM034310
1768 Synthesis, Characterization and Toxicological In Vitro
Activity of Nanomaterials Containing Active Ingredients of
Matricaria chamomilla L.
A. Vera1,  L. A. Flores1,  F. M. Mercado1,  R. Vazquez1,  J. A. Soriano1,
R. L. Ortega1,  A. Jain2,  P. Sengar2,  G. A. Hirata3,  R. E. Cachau4,
R. Hernandez5,  U. Pal6,  Z. N. Juarez1,  M. C. Miranda1 and T. D. Palacios-
Hernandez1. 1Ciencias Biológicas, UPAEP, Puebla, Mexico; 2School of Biosciences and
Technology, VIT, Vellore, India; 3Centro de Nanociencias y Nanotecnologia, UNAM,
Ensenada, Mexico; 4Frederick National Laboratory for Cancer Research, Frederick,
MD; 5Ciencias Quimico-Biologicas, UDLAP, Puebla, Mexico; 6Instituto de Fisica,
BUAP, Puebla, Mexico.
In this contribution, the synthesis, characterization and biological activity of poly-
meric nanocapsules (PNC) and iron oxide nanoparticles (NPs) containing active
ingredients of Matricaria chamomilla L., is being evaluated. M. chamomilla L.
specimens were collected and dried, to obtain the chloroform, hexane and water ex-
tracts. Iron oxide NPs were prepared by a co-precipitation method using FeCl3,
Na2SO3 and NH4OH. PNC were prepared by emulsion method using aqueous
solutions of sodium alginate containing the active principle, calcium chloride and
dioctyl sodium sulfosuccinate. Characterization of all the materials was done by dy-
namic light scattering (DLS), transmission electron microscopy (TEM), phase con-
trast microscopy, RAMAN spectroscopy, X-ray diffraction (XRD) and Fourier
Transformed Infrared spectroscopy (FTIR). Plant extracts are being purified by col-
umn chromatography and were characterized by proton (1H) and carbon (13C)
Nuclear Magnetic Resonance (NMR). TEM analysis confirmed the presence of
nanoparticles in a size range of 6-10 nm, XRD and RAMAN showed the magnetite
phase at SPION and FTIR showed the characteristic vibrations for OH in mag-
netite NPS and organic groups at PNC. A high particle size distribution (93-200
nm) was obtained in polymeric nanocapsules by DLS and confocal microscopy, due
the presence of aggregates. NMR showed in the hexane extract the presence of
flavonoids, sugars and phenols. At this moment we are still working on the purifi-
cation of M. chamomilla L extracts and the evaluation of biological activity upon
bacterial cultures, to determine ecotoxicity of all the materials synthesized.
1769 Comparative In Vitro Cell Uptake of Bismuth and Bismuth-
Derivatives Nanoparticles in Lung Cells.
L. M. Del Razo1,  B. Quintanilla-Vega1,  O. C. Barbier1,  M. Esquivel-Gaón1, 2,
M. Uribe-Ramirez1,  A. Barrera-Hernández1,  L. C. Sanchez-Peña1,
K. A. Dawson2,  S. Anguissola2 and A. De Vizcaya-Ruiz1. 1Toxicology, Cinvestav-
Instituto Politecnico Nacional, Mexico, City; 2CBNI, University College Dublin,
Dublin, Ireland.
Bismuth (Bi) has exceptionally low magnetic susceptibility and very low thermal
conductivity which favors their use as a thermoelectric material. Therefore, low-di-
mensional Bi compounds are good candidates as nanomaterials. In this study, the
physicochemical properties of Bi-derived nanoparticles (Bi-NP) – Bi trioxide
(Bi2O3), Bi vanadate (BiVO4), and zero valent Bi in colloidal form (ZV-Bi) – and
uptake in A549 lung cells were evaluated. The properties include the dispersion and
stability, elemental composition and uptake in lung cell cultures. Testing for bio-
compatible dispersants for biological and toxicological evaluations was performed
using sonication and centrifugation steps, combined with stabilization of the NP
surface with bovine serum albumin (BSA; 10mg/ml) to reduce agglomeration. Its
dispersion properties and elemental composition were confirmed using dynamic
light scattering and energy dispersive X-ray spectroscopy. Average size of Bi2O3,
BiVO4, and ZV-Bi was 9.2 nm (0.34 pdl), 49.9 nm (1 pdl) and 3.3 ±1nm, respec-
tively. Elemental content was in 67.6%-Bi, 32.4%-O in Bi2O3, 55.5%-Bi, 25.9%-
V and 18.6%-O in BiVO4 and 49.9%-Bi, 33.7%-O and 16.4%-Na in ZV-Bi.
From a parallel cytotoxicity study of the exposure to Bi2O3, BiVO4, and ZV-Bi the
50 μg/ml non-cytotoxic level was chosen to assess the cellular uptake of Bi at 6, 24
or 48 h in lung cells by atomic fluorescence spectrophotometry by hydride genera-
tion. A differential uptake of Bi was observed, BiVO4 was internalized in cells in
86.6% while Bi2O3 and ZV-Bi in 27.8 and 26.1%, respectively. Our results suggest
that Bi-NP cellular internalization is dependent of the physicochemical properties,
where a more conductive NP such as BiVO4 was more effectively internalized;
therefore, NP transport and uptake is a relevant process that needs to be thoroughly
investigated. Funding from the European Community Seven Framework
Programme and CONACYT (Grant agreements #263878 & 12514).
1770 Oxidative Stress, Cell Viability and Types of Cell Death
Induced by Transition Metal Oxide Nanoparticles Depend
on Surface Charge, Available Surface Binding Site, and Ion
Dissolution.
Y. Huang1,  C. C. Chusuei2,  C. Wu1,  S. Mallavarapu2,  J. G. Winiarz3 and
R. S. Aronstam1. 1Biological Sciences, Missouri University of Science and Technology,
Rolla, MO; 2Chemistry, Middle Tennessee State University, Murfreesboro, TN;
3Chemistry, Missouri University of Science and Technology, Rolla, MO.
We investigated physicochemical properties of nano-sized oxides of Fourth Period
transition metals that contribute to cytotoxicity. The cytotoxicity (i.e., cell killing)
of nanoparticles (NPs) TiO2, Cr2O3, Mn2O3, Fe2O3, NiO, CuO, and ZnO in-
creases as atomic number increases. This trend is not cell type specific, as it is ob-
served in nontransformed human lung (BEAS-2B) and adenocarcinomic human
alveolar basal (A549) epithelial cell lines. We assessed physiochemical properties of
NPs to discover the determinants of cytotoxicity: 1) the point-of-zero charge (PZC)
(i.e., isoelectric point) describes the surface charge of NPs in cytosolic and lysoso-
mal compartments; 2) the relative number of available binding sites on the NP sur-
face was used to estimate the probability of biomolecular interactions on the parti-
cle surface; 3) band-gap energy predicts electron abstraction from NPs which might
lead to oxidative stress and subsequent cell death; and 4) ion dissolution. Our re-
sults indicate that that cytotoxicity is a function of particle surface charge, relative
number of available surface binding site, and metal dissolution from NPs. These
NPs are capable of inducing oxidative stress that is consistent with the trend of cell
killing; however, H2DCFDA is not a suitable dye to accurately assess oxidative
stress due to quenching effect. Ratio of apoptosis and necrosis also follows the trend
of cell killing. Our findings provide a basis for both risk assessment and the design
of safer nanomaterials.
1771 Cytotoxic and Antitumor Effect of Vitamin E Analogues
Functionalized to Magnetite Nanoparticles.
A. Angulo Molina1, 2, 3,  J. Reyes Leyva3,  J. Hernández1,  T. D. Palacios-
Hernandez2, 4,  M. A. Méndez Rojas2,  M. Cerro López2,  J. Flores3,  F. Ruiz5,
O. Contreras5 and G. A. Hirata5. 1Centro de Investigación en Alimentación y
Desarrollo, CIAD, AC, Hermosillo, Mexico; 2Universidad de las Américas Puebla,
UDLAP, Puebla, Mexico; 3Centro de Investigaciones Biomédicas de Oriente CIBIOR,
IMSS, Metepec, Puebla, Mexico; 4Universidad Popular Autónoma del Estado de
Puebla, UPAEP, Puebla, Mexico; 5Centro de Nanociencias y Nanotecnología, CNYN,
Ensenada, Mexico.
BACKGROUND: Magnetite nanoparticles (Nps) can be used as nanocarriers to
enhance and improve the efficiency of delivery of vitamin E analogues. Herein we
report the citotoxic and antitumor effect of magnetite Nps functionalized with
alpha tocopheryl succinate (α-TOS), the most effective analogue of vitamin E in
inducing death in cancer cells. One problem with α-TOS is its vulnerability to es-
terases, making impossible its oral use or in cancer cells with high levels of esterases.
OBJETIVE: To investigate the cytotoxicity and antitumor effect of magnetite Nps
functionalized with α-TOS (Nps-α-TOS). 
METHODS: Magnetite Nps-α-TOS were functionalized mixing Nps, silane
agents and α-TOS under vigorous stirring (40oC) for 4 h. The Nps-α-TOS were
characterized by FTIR, EDS, TEM, SEM and DLS. Then a human cervix cancer
cell line (SiHa) high in esterases was treated with the various concentrations by 72
h. Its effects on cytotoxicity and antitumor effect were evaluated using confocal mi-
croscopy and MTT assay. 
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RESULTS: Electronic microscopy studies revealed an average Nps size of 130 nm
(σ = ±32.7 nm) and irregular spherical in shape. IR, EDS and DLS results support
the formation of Nps detecting mineral and organics constituents respectively with
high stability. The in vitro tests shows by first time the Nps-α-TOS can be inter-
nalized and are more cytotoxic and effective that α-TOS alone and inhibits the
growth of resistant cervix cancer cell. 
CONCLUSION: In this study we found that magnetite Nps can work as nanocar-
riers of α-TOS. This composite protect the anticancer activity of α-TOS and en-
hances the anti-tumor effect in resistant cancer cells.
1772 Cellular Internalization and Trafficking of Individual
Nanoparticles Investigated with Nanometer Resolution Using
Super Resolution Fluorescence Microscopy.
G. Orr,  D. Hu,  A. Tolic,  Y. Xie,  C. Mihai,  C. Szymanski,  M. Markillie,
L. Cosimbescu and B. Tarasevich. Pacific Northwest National Laboratory, Richland,
WA.
The cellular internalization mechanism of engineered nanoparticles (NPs) and their
intracellular trafficking govern the cellular interactions of the particles, which ulti-
mately determine their impact on the cell. These cellular mechanisms largely de-
pend on the size of the NPs or the aggregates that are often formed. To identify
mechanisms specific to individual NPs or small nano-scale aggregates, we used sto-
chastic optical reconstruction microscopy (STORM) to resolve the intracellular lo-
cation of individual NPs within organelles and in respect to subcellular structures
with 10-20 nanometer resolution. Using FastLime, a photo-switching derivative of
green fluorescent protein, we created fluorescent chimeras for clathrin, caveolin and
actin, and expressed the proteins in alveolar epithelial cells. The transfected cells
were exposed to amorphous silica NPs, tagged with a photo-switching dye, and im-
aged at 2 h and 16 h post exposure. We found NPs within clathrin- and caveolin-
coated vesicles in both time-points, suggesting a preferential binding of the NPs to
molecules found in clathrin-coated pits and caveolae at the cell surface. A signifi-
cant number of NPs were found aligned along actin filaments at 16 h post expo-
sure. The distance between the NPs and the filaments was calculated for more than
1100 NPs, and the distribution of the distances in the range of 0 to 100 nm was sig-
nificantly different from the distribution expected to occur if the NPs were ran-
domly placed in the cytoplasm. Together, our observations suggest a mechanism for
the internalization and trafficking of amorphous silica NPs in alveolar epithelial
cells that occurs through interactions with molecules found in caveolae and
clathrin-coated pits, followed by internalization via vesicles that eventually are shut-
tled along actin filaments within the cytoplasm. This work was funded by NIEHS
grant 1RC2ES018786-01 to GO.
1773 Signaling Pathways and microRNA Changes in Nano-TiO2
Treated Human Lung Epithelial (BEAS-2B) Cells.
S. Thai,  C. P. Jones,  K. Wallace,  H. Ren,  R. Y. Prasad,  W. O. Ward,
M. J. Kohan and C. F. Blackman. US EPA, Research Triangle Park, NC. Sponsor:
C. Corton.
The effect of titanium dioxide nanoparticles (nano-TiO2, Degussa p25, 86%
anatase and 14% rutile) treatment of human lung epithelial cells (BEAS-2B) was
examined by analyzing changes in messenger [mRNA] and microRNA [miRNA].
BEAS-2B cells were treated with 0, 3, 10, 30 or 100 ug/ml nano-TiO2 for 1 day
(for mRNA analysis) or 3 days (for miRNA analysis). Differentially expressed
mRNA and miRNA were analyzed using Affymetrix microarrays (human U133
Plus 2.0) and Affymetrix miRNA microarrays, respectively. Although, the tested
doses were not cytotoxic, there were alterations in both mRNA and miRNA ex-
pression. The expression of mRNA/miRNA changes were examined in MetaCore
(GeneGo) and IPA (Ingenuity Pathway Analysis) to delineate associated signaling
pathways.  Signaling pathways altered by nano-TiO2 treatments included: cell cycle
regulation, apoptosis, calcium signaling, translation, NRF2 –mediated oxidative re-
sponse, IGF1 signaling, RAS signaling, PI3K/AKT signaling, cytoskeleton remod-
eling, cell adhesion, BMP signaling, and inflammatory response. Many of the genes
in these signaling pathways are known to be regulated by the miRNAs that were al-
tered by the nano-TiO2 treatment. The miRNA 17-92 cluster and let-7 miRNA
family that are reportedly involved in lung cancer formation were altered by nano-
TiO2 treatment. The miR-17-92 cluster, an oncogenic microRNA cluster, is in-
duced while the tumor suppressor microRNA, let-7 family, is suppressed. The ob-
served changes in miRNA expression introduces an additional mechanistic
dimension that supports the significance of the observed mRNA expression
changes, and demonstrated that the nano-TiO2 treatment can cause diverse but co-
ordinated pathway alterations associated with changes in in vivo response to tu-
morigenes.  [This abstract does not necessarily reflect the policies of the U.S. EPA.]
1774 In Vitro Co-Culture System to Examine the Effects of
Inhaled Nanoparticles.
K. B. Donohue1,  A. M. Mayo2,  D. R. Johnson1,  R. Nellums3,  S. F. Son3 and
J. A. Steevens1. 1Environmental Laboratory, US Army Engineer Research &
Development Center, Vicksburg, MS; 2Badger Technical Services, Vicksburg, MS;
3Purdue University, West Lafayette, IN.
Engineered nanoparticles (NPs) possess numerous potential benefits to society in
fields as diverse as electronics, textiles, medicine, energy and construction. The res-
piratory system represents a unique target for the potential toxicity of NPs. Due to
their dimensions, inhaled NPs can reasonably be expected to penetrate to the deep-
est part of the lungs, the alveolar sacs. Completed inhalation studies in laboratory
rats have demonstrated that some NPs induce oxidative stress, inflammation and fi-
brosis. In this study, we examine the effects of nanothermite and parent nano-ma-
terials (bismuth oxide [Bi2O3] and copper oxide [CuO] spheres and rods) on an
alveolar co-culture model consisting of human type II pneumocytes and alveolar
macrophages. Co-cultures were set up with a ratio of 3:1 of type II pneumocytes to
each alveolar macrophage 24 h prior to treatment. Media was then removed and co-
cultures were treated with 0.001 100 mg/l NPs for 24 h. Cell viability was only af-
fected by CuO at 100 mg/l; CuO spheres and rods had similar effects. These stud-
ies demonstrate that only high concentrations of raw Bi2O3 and CuO NPs affect
respiratory co-cultures and that CuO NP size does not affect respiratory co-cul-
tures. Additional phagocytosis studies and cytokine analysis studies (intracellular
and secreted concentrations) are being conducted to evaluate inflammatory effects
of these NPs in the respiratory co-culture immune cells.
1775 Metabolomic Studies of the Nanotoxicity of TiO2 and CeO2.
K. T. Kitchin1,  B. Robinette1,  B. Castellon1 and R. Michalek2. 1US EPA,
Durham, NC; 2Metabolon, Durham, NC.
Nanomaterial exposures to humans and wildlife pose unknown degrees of risk to
major organ systems including the liver. TiO2 and CeO2 nanomaterial exposures
(3 or 30 ug/ml for 3 days) were performed in cultures of human liver HepG2 cells.
TiO2 and CeO2 nanomaterial exposures altered the concentrations of biochemi-
cals associated with arginine metabolism, lipids and fatty acids, TCA cycle and glu-
tathione. Some metabolites that were significantly altered in 4 or more of the 8
TiO2 or CeO2 nanomaterial treatments were cysteine, GSH, asymmetric dimeth-
yarginine and gamma-glutamyl amino acids. Asymmetric dimethylarginine (a com-
petitive inhibitor of nitric oxide synthase) was significantly increased by many
nanomaterial exposures, particularly by CeO2 exposures. One CeO2 nanomaterial
with smaller primary particle size caused increases in many lipids, including long
chain fatty acids, lysolipids, membrane sphingolipids, monacylglycerols and diacyl-
glycerols; six other nanomaterial exposures did not. With respect to the TCA cycle,
nanomaterial exposures sometimes decreased the concentrations of gluatamate, glu-
tamine, malate, fumarate and succinate. In 5 nanomaterial treatment groups, hepa-
tocyte glutathione depletion reached 13 to 34% of control levels. Overall, our nan-
otoxicology studies have shown (a) many biochemical effects in HepG2 cells and
(b) major differences in the biochemical and biological responses between different
TiO2 and CeO2 nanomaterials and (c) oxidative stress (major GSH depletion) was
caused by exposure to both TiO2 and CeO2 of different primary particle sizes.
Disclaimer: [This is an abstract or a proposed presentation and does not necessarily
reflect EPA policy. Mention of trade names or commercial products does not con-
stitute endorsement or recommendation for use.]
1776 Neurotoxicity of Au-NPs in an In Vitro Blood Brain Barrier
(BBB) Model.
M. Sharma1, 2,  C. E. Sulentic2,  J. J. Schlager1 and S. M. Hussain1, 2. 1711
HPW/RHDJ, AFRL, Wright-Patterson AFB, Dayton, OH; 2Department of
PharmTox, WSU, Dayton, OH.
Gold nanoparticles (Au-NPs) have demonstrated great potential in the develop-
ment of a variety of tools with applications ranging from biomedical to military
fields. Biodistribution studies indicate differential uptake of NPs depending on
their functionalization, treatment conditions, and location in the body. Unlike
other organ systems, brain vasculature is comprised of endothelial cells that form an
anatomical and physiological barrier that protects neurons from metabolic fluctua-
tions and toxins. The cost and extent of expertise required for in vivo studies, pose
limitations, and therefore, better in vitro models are pursued to study toxico-physi-
ological aspects of the BBB. The main aim of this study is to modify a previously
described static in vitro BBB model by adding a constant flow of media containing
NPs and then studying the NP trafficking across the endothelial cells. Murine brain
endothelial cells (bEnd3) and astrocytes (C8D1A) were cultured on the luminal
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and abluminal sides, respectively, of a transwell membrane. Permeability studies
using Fluorescein isothiocyanate-tagged dextran and polyethylene glycol (PEG)
confirmed a tight layer of bEnd3 cells with transendothelial resistance of 122 + 3
Ωcm2. This culture set up was treated with citrate and PEG-coated Au-NPs (50
μg/ml) for 24 hr to quantify non-specific leakage of substrates across the cell barrier
and to evaluate the association of NPs with astrocytes, with and without flow of
media. Inductively coupled plasma mass spectrometry results show fewer NPs on
the abluminal side confirming a tight cell barrier and transmission electron mi-
croscopy imaging suggest endosomal localization of NPs in bEnd3 cells. Unlike the
static set up, brightfield imaging suggested less aggregation of NPs with flow and
citrate-coated NPs associate more with astrocytes in comparison to PEGylated NPs.
These data demonstrate that surface properties influence passage of NPs across
bEnd3 cells. This multicell model could be applied as a rapid screening technique
to analyze uptake and toxicity of NMs across the BBB.
1777 Effect of Surface Modification of Metal Oxide Nanoparticles
upon Cell Viability and Genotoxicity of Epithelial Breast
Cells.
T. D. Palacios-Hernandez1,  E. Gonzalez2,  M. A. Mendez3,  G. A. Hirata4,
D. Momot5,  E. E. Hernandez5,  A. Marogi5,  M. Poirier5,  O. Olivero5 and
R. E. Cachau6. 1Biological Sciences, UPAEP, Puebla, Mexico; 2Chemistry Center,
ICUAP, Puebla, Mexico; 3Chemical and Biological Sciences, UDLAP, Puebla, Mexico;
4Nanosciences and Nanotechnology Center, UNAM, Ensenada, Mexico; 5National
Cancer Institute, NIH, Bethesda, MD; 6Frederick National Laboratory of Cancer
Research, Frederick, MD.
In this work, the biological activity of different metal oxide nanoparticles (Fe3O4,
Co3O4, CuO) upon epithelial breast cells MCF-10A have been evaluated. The first
step is the fabrication and characterization of the metal-oxide nanoparticles
(MONPs) followed by the functionalization with folic acid, L-arginine and L-cys-
teine which is confirmed by Fourier Transform Infrared Spectroscopy (FTIR) and
Low Voltage Electron Microscopy (LVEM) measurements. In order to determine
real time cell viability, semi-confluent cells were exposed to either 0, or 0.2 mg/mL
of particles with and without functionalization. 2 x103 cells/well were grown in a
gold wired 16-well plate for 15 hours, with readings of impedance collected every
15 minutes to monitor cell proliferation. To determine cell-nanoparticle interac-
tions, cells were grown during 24 hours, exposed to 0.2 mg/mL of particles and al-
lowed to grow for additional 48 hours. After that, cells were fixed and stained with
DAPI to evaluate apoptosis necrosis and characterization of normal nuclear mor-
phology. Additionally a dose-response growth curve using Fe3O4 nanoparticles,
presumably, the less toxic exposure, free and functionalized with folic acid (Fe-AF)
was carried out. Results indicate that the most toxic treatment was Fe3O4 and the
less toxic was Fe3O4 functionalized with folic acid, although all the MONPs eval-
uated didn’t cause a strong toxic response due the values of cell index obtained by
impedance evaluation. However, the presence of particles interacting with the cell
and nucleus showed the possibility of genotoxic effects, and for that reason, in an
attempt to explore this condition, the micronucleus assay employing Cytochalasin
B (Cytome assay) is being conducted as a follow up.
1778 Synthesis, Characterization and Evaluation of Biological In
Vitro Activity of Eu3+ Doped Hydroxyapatite.
J. Delgado-Jimenez1,  T. D. Palacios-Hernandez2,  A. Angulo Molina1,
J. L. Varela3,  R. Agustin3 and E. Rubio-Rosas3. 1Ciencias Quimico-Biologicas,
UDLAP, Puebla, Mexico; 2Ciencias Biológicas, UPAEP, Puebla, Mexico; 3Centro de
Vinculacion Universitaria y Transferencia de Tecnologia, BUAP, Puebla, Mexico.
In this work, the synthesis, characterization and biological in vitro activity of Eu3+
doped hydroxyapatite (Eu-HAp) is being evaluated. Hydroxyapatite synthesis is
being carried out by microwave-hydrothermal techniques, modifying parameters
such as temperature, power, pH and calcium precursors. In a typical process, the
synthesis was carried out by the mixture of CaCl2 or Ca(NO3)2.4H2O and
Eu(NO3)3.5H2O. After that, a solution of (NH4)2HPO4 was added. The full
mixture was alkalinized and transferred into a Milestone START D Microwave
Digestor System. Power and temperature measurements were adjusted regarding
the literature, and after that the product was purified and dried. The products ob-
tained, as powders, were grinded and characterized by X-Ray Diffraction (XRD),
Scanning and Transmission Electron Microscopy (SEM, TEM), Atomic Force
Microscopy (AFM) and Fourier-Transformed Infrared Spectroscopy (FTIR). As
preliminary results, infrared spectroscopy showed the signals corresponding to O-H
stretching at approximately 3500 cm-1. Regarding PO4 vibrations, we found ap-
proximately at 400, 550, a small signal at 600, 1000 and 1100 cm-1 the character-
istic vibration of this group. Regarding XRD, we have obtained nanocrystals at a
size range of 37-50 nm, and the crystalline phase corresponding to hydroxyapatite
was confirmed in the samples obtained by the most alkaline pH ranges (above 10),
while at pH 9 we obtained a mixture between hydroxyapatite and monetite phases.
To evaluate the biological in vitro activity of our materials, MTT assay is being per-
formed upon mouse fibroblasts that are treated with representative samples of Eu-
HAp nanoparticles previously synthesized by our group.
1779 Interactive Toxicity of Usnic Acid and Lipopolysaccharide in
Human Liver HepG2 Cells.
S. C. Sahu,  M. W. O’Donnell and R. L. Sprando. Toxicology, US FDA, Laurel,
MD.
Usnic acid (UA), a natural botanical product, is a constituent of some dietary sup-
plements used for weight loss. It has been associated with clinical hepatotoxicity
leading to liver failure in humans. The present study was undertaken to evaluate the
interactive toxicity, if any, of UA with lipopolysaccharides (LPS), a potential con-
taminant of food, at low nontoxic concentrations. The human hepatoblastoma
HepG2 cells were treated with the vehicle control and test agents, separately and in
combination (UA+LPS) at concentrations of UA 1.0 μM and LPS 1.0 ng/ml, for
24 h at 370 C in 5% CO2. Following the treatment period, the cells were evaluated
by the traditional biochemical endpoints of toxicity in combination with the toxi-
cogenomic endpoints that included cytotoxicity, oxidative stress, mitochondrial in-
jury and changes in pathway-focused gene expression profiles. Compared to the
controls, low nontoxic concentrations of UA and LPS separately showed no effect
on the cells as determined by the biochemical endpoints. However, the simultane-
ous mixed exposure of the cells to their mixture resulted in increased cytotoxicity,
oxidative stress and mitochondrial injury. The pathway-focused gene expression
analysis resulted in the altered expression of several genes out of 84 genes examined.
Most altered gene expressions induced by the mixture of UA and LPS were differ-
ent from those induced by the individual constituents. The genes affected by the
mixture were not modulated by either UA or LPS. The results of this study suggest
that the interactions of low nontoxic concentrations of UA and LPS produce toxic-
ity in HepG2 cells.
1780 Dihydroartemisinin Inhibits PMA-Induced Cyclooxygenase-
2 Expression through Downregulating AKT and MAPK
Signaling Pathways in Murine Macrophages.
E. Han1,  H. Kim1,  J. Choi1,  Y. Hwang2 and H. Jeong1. 1Pharmacy, Chungnam
National University, Daejeon, Republic of Korea; 2Korea International University,
Jinju, Republic of Korea.
Dihydroartemisinin (DHA), a semi-synthetic derivative of artemisinin isolated
from the traditional Chinese herb Artemisia annua L., has recently been shown to
possess antitumor activity in various cancer cells. However, the effect of anti-in-
flammatory potentials of DHA in murine macrophage RAW 264.7 cells has not
been studied. The present study investigated the effect of COX-2 and molecular
mechanisms by DHA in phorbol 12-myristate 13-acetate (PMA)-stimulated RAW
264.7 cells. DHA dose-dependently decreased PMA-induced COX-2 expression
and PGE2 production, as well as COX-2 promoter-driven luciferase activity.
Additionally, DHA decreased luciferase activity of COX-2 regulation-related tran-
scription factors including NF-κB, AP-1, C/EBP and CREB. DHA also remark-
ably reduced PMA-induced p65, C/EBPβ, c-jun and CREB nuclear translocation.
Furthermore, DHA evidently inhibited PMA-induced phosphrylation of AKT and
the MAP Kinases, such as ERK, JNK and p38. These data indicated that DHA ef-
fectively attenuates COX-2 production via down-regulation of AKT and MAPK
pathway, revealing partial molecular basis for the anti-inflammatory properties of
DHA. These findings demonstrate that DHA effectively attenuates COX-2 pro-
duction, and provide further insight into the signal transduction pathways involved
in the anti-inflammatory effects of DHA.
1781 Protective Role of Silymarin against Oxidative Stress Induced
in Human Neuroblastoma Cell Line SH-SY5Y.
A. Anadon,  M. A. Martinez,  E. Ramos,  V. Castellano,  I. Ares,  M. Martinez,
M. R. Martinez-Larrañaga and A. Romero. Toxicology & Pharmacology,
Complutense University, Madrid, Spain.
Silymarin (SM) is a mixture of bioactive flavonolignans isolated from Silybum mar-
ianum (L.) Gaertn., employed usually in the treatment of alcoholic liver disease and
as anti-hepatotoxic agent in humans. The essential activity of SM is an antioxidant
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effect of its flavonolignans. Because of the importance of oxidative stress and mito-
chondrial dysfunction in causing neuronal death, prompted us to investigate the ef-
fects of SM against an in vitro model of reactive oxygen species (ROS) production
in the human neuroblastoma cell line SH-SY5Y. We selected two cytotoxic stimuli,
for one hand, hydrogen peroxide (H2O2)(500 μM), and on the other hand the
combination of 30 μM rotenone plus 10 μM oligomycin-A (R/O) that inhibit mi-
tochondrial respiration complexes I and V, respectively. Cell viability, measured as
MTT reduction, was decreased to 70% in cells treated with H2O2 and to 60% in
cells exposed to R/O. Cell incubation with increasing concentrations of SM (1-
1000 μM) for 24 hr, followed by a 24-hr period with H2O2 (extracellular ROS) or
R/O (intracellular ROS). Maximum protection was achieved with 300 μM SM
(30% protection). Our results showed that R/O and H2O2-induced cytotoxicity in
SH-SY5Y cells was suppressed by treatment with SM. Because, it is recently re-
ported that SM crosses the blood–brain barrier and enters the CNS and it is non-
toxic even at higher doses, this flavonoid may be useful in diseases known to be ag-
gravated by reactive oxygen species and in the development of novel treatments for
neurodegenerative disorders. This work was supported by projects Ref.
BSCHGR58/08(UCM), Ref. No. S2009/AGR-1469(CAM) and Consolider-
Ingenio 2010 No.CSD2007-063(MEC), Spain.
1782 Thymoquinone, a Bioactive Component of Nigella sativa,
Modulates Redox Status and Insulin Secretion from
Pancreatic Beta Cells.
J. P. Gray1, 3,  R. Follmer1,  R. Rebar1,  N. Seeram2 and E. Heart3. 1Science, US
Coast Guard Academy, New London, CT; 2Bioactive Botanical Research Laboratory,
University of Rhode Island, Kingston, RI; 3Cellular Dynamics, Marine Biological
Laboratory, Woods Hole, MA.
Nigella Sativa is a traditional medicine that has been used in the Mediterranean to
treat a variety of disorders, including type 2 diabetes. A primary component of
Nigella sativa extract is thymoquinone which, like Nigella sativa extract, attenuates
diabetes symptoms. The molecular targets and interactions of thymoquinone with
metabolic pathways relevant to glucose-stimulated insulin secretion (GSIS) from
pancreatic β-cells have not yet been identified. Our laboratory previously demon-
strated that low (nM-μM) doses of various quinones such as menadione stimulate
insulin secretion from β-cells, and this action was coupled to the generation of low
levels of H2O2, a putative mediator of GSIS. Here we compared the mechanism of
action of thymoquinone to that of menadione in β-cells. Like menadione, thymo-
quinone induced a dose-dependent increase in the production of H2O2. Unlike
menadione, the redox cycling of thymoquinone was not dependent on the glucose
concentration. Both NADPH and NADH supported the redox cycling of thymo-
quinone in cytosolic and mitochondrial fractions. This was consistent with the abil-
ity of thymoquinone to decrease NADH/NAD+ and NADPH/NADP+ ratios, thus
reducing intracellular redox poise. Thymoquinone-dependent redox cycling activi-
ties were inhibited by diphenylene iodonium, an inhibitor of flavin-containing ox-
idoreductases. Dicoumarol and MAC220, NQO1 inhibitors previously shown to
inhibit menadione-dependent redox cycling, failed to inhibit thymoquinone-de-
pendent redox cycling. Unlike menadione, thymoquinone was found to potentiate
GSIS in a dose-dependent manner at stimulatory glucose (concentrations which
potently stimulate insulin secretion). These data suggest that while the mechanisms
of thymoquinone redox cycling are different than those of menadione, thymo-
quinone retains the ability to regulate both redox status and insulin secretion from
β-cells.
1783 Antioxidant and DPPH-Scavenging Activities of Compounds
and Ethanolic Extract of the Leaf and Twigs of Caesalpinia
bonduc L. Roxb.
O. O. Olubanke1,  O. E. Ogunlana2,  A. T. Lawa1,  J. O. Olagunju3,
A. A. Akindahunsi4 and N. H. Tan5. 1Biological Sciences, Covenant University, Ota,
Nigeria; 2Biological Sciences, Crawford University, Igbesa, Nigeria; 3Medical
Biochemistry, College of Medicine, Lagos State University, Ikeja, Nigeria;
4Biochemistry, Federal University of Technology, Akure, Nigeria; 5State Key Laboratory
of Phytochemistry and Plant Resources, Kunming Institute of Botany, Kunming,
China.
Antioxidant effects of ethanolic extract of Caesalpinia bonduc and its isolated bioac-
tive compounds were evaluated in vitro. The compounds included two new cassane
diterpenes, 1α,7α-diacetoxy-5α,6β-dihydroxyl-cass-14(15)-epoxy-16,12-olide (1)
and 12α-ethoxyl-1α,14β-diacetoxy-2α,5α-dihydroxyl-cass-13(15)-en-16,12-olide
(2); and others, bonducellin (3), 7,4’-dihydroxy-3,11-dehydrohomoisoflavanone
(4), daucosterol (5), luteolin (6), quercetin-3-methyl ether (7) and kaempferol-3-
O-α-L-rhamnopyranosyl-(1Ç2)-β-D-xylopyranoside (8). The antioxidant proper-
ties of the extract and compounds were assessed by the measurement of the total
phenolic content, ascorbic acid content, total antioxidant capacity and 1-1-
diphenyl-2-picryl hydrazyl (DPPH) and hydrogen peroxide radicals scavenging ac-
tivities. Compounds 3, 6, 7 and ethanolic extract had DPPH scavenging activities
with IC50 values of 186, 75, 17 and 102 μg/ml respectively when compared to vita-
min C with 15 μg/ml. On the other hand, no significant results were obtained for
hydrogen peroxide radical. In addition, compound 7 has the highest phenolic con-
tent of 0.81±0.01 mg/ml of gallic acid equivalent while compound 8 showed the
highest total antioxidant capacity with 254.31±3.54 and 199.82±2.78 μg/ml gallic
and ascorbic acid equivalent respectively. Compound 4 and ethanolic extract
showed a high ascorbic acid content of 2.26±0.01 and 6.78±0.03 mg/ml respec-
tively. The results obtained showed the antioxidant activity of the ethanolic extract
of C. bonduc and deduced that this activity was mediated by its isolated bioactive
compounds.
1784 Selective Elimination of Malignant Melanomas through
Autophagic and Mitochondria-Based Mechanisms by the
Antitumor Agent Osw-1.
K. Riaz Ahmed,  C. Garcia-Prieto,  L. Feng and P. Huang. Molecular Pathology,
University of Texas MD Anderson Cancer Center, Houston, TX. Sponsor: M. Smith.
Drug resistance and lack of therapeutic selectivity are two of the biggest challenges
to successful melanoma therapy. Constitutive activation of Extracellular Signal
Regulated Kinase 1/2 (ERK1/2) and subsequent chemoresistance has been reported
in malignant melanomas. ERK1/2 has also been implicated in activation of mito-
chondrial gene expression and regulation of autophagy thus making it an important
therapeutic target.
The natural product, OSW-1, isolated from the bulbs of ivory coast lily, has been
shown to be highly cytotoxic in numerous cancer cell lines with yet undefined
mechanisms of action. Herein, we report our results on the anticancer activity and
selectivity of OSW-1 in malignant melanoma cells and its potential mechanisms of
action.
Our preliminary results demonstrated that OSW-1 was highly effective in killing
tumor cells that are resistant to most of the currently available anticancer drugs,
with IC50 values in sub-nM concentrations. Importantly, OSW-1 preferentially
killed melanoma cells and exerted much lower toxicity to normal melanocytes in
culture. Biochemical analysis revealed that OSW-1 treatment caused damage of the
mitochondrial membrane integrity, leading to a decrease in transmembrane poten-
tial and subsequently initiating cell death, apparently through autophagy. Further
study demonstrated that OSW-1 inhibited ERK1/2 expression in melanoma cells
and caused a significant disturbance of cellular calcium homeostasis, leading to
aberrant calcium-mediated processes including mitochondrial impairment. Based
on these results, we postulate that OSW-1 inhibits ERK1/2 mediated signaling and
triggers mitochondrial damage in cells leading to a significant disturbance of cellu-
lar calcium and cell death through autophagy. This study is of great significance
since ERK1/2 signaling is important to melanoma cell survival and inhibition of
ERK1/2 expression and induction of autophagic cell death by OSW-1 will be criti-
cal to combat therapeutic resistance and enhance drug selectivity.
1785 3-Caffeoyl, 4-Dihydrocaffeoylquinic Acid from Salicornia
herbacea Attenuates High Glucose-Induced Hepatic
Lipogenesis in Human HepG2 Cells.
H. Chun2,  Y. Hwang3, 1,  J. Choi1,  H. Kim1,  Y. Chung3 and H. Jeong1.
1Pharmacy, Chungnam National University, Daejeon, Republic of Korea; 2Korea
Research Institute of Bioscience and Biotechnology, Jeongeup, Republic of Korea;
3International University of Korea, Jinju, Republic of Korea.
3-Caffeoyl, 4-dihydrocaffeoylquinic acid (CDCQ) from Salicornia herbacea has a
variety of pharmacological properties, including antioxidant and anti-inflammatory
and hepatoprotective properties. The aims of our study were to provide new data
on the molecular mechanisms underlying the role of CDCQ in prevention of high
glucose-induced lipid accumulation in human HepG2 cells. We found that CDCQ
suppressed high glucose-induced lipid accumulation in HepG2 cells. CDCQ
strongly inhibited the high glucose-induced FAS expression by modulating
SREBP-1c activation. Moreover, the use of a specific inhibitor or liver kinase B1
(LKB1)-siRNA transfected HepG2 cells showed that CDCQ activated AMP-acti-
vated protein kinase (AMPK) via silent information regulator T1 (SIRT1) or LKB1
in HepG2 cells. These results indicate that CDCQ prevents lipid accumulation by
380 SOT 2013 ANNUAL MEETING
blocking the expression of SREBP-1c and FAS through LKB1/SIRT1 and AMPK
activation in HepG2 cells, suggesting that CDCQ is a novel AMPK activator with
a potential role in the prevention obesity.
1786 Effects of Saponins from the Roots of Platycodon
grandiflorum on TGF-β1-Induced Epithelial-Mesenchymal
Transition in in A549 Cells.
C. Ho1,  H. Kim1,  Y. Hwang2,  Y. Chung2 and H. Jeong1. 1Pharmacy, Chungnam
National University, Daejeon, Republic of Korea; 2International University of Korea,
Jinju, Republic of Korea.
Epithelial to mesenchymal transition (EMT) is a key event in the progression of
cancer. EMT is characterized by the loss of epithelial and the gain of mesenchymal
features. Previous studies have revealed that treatment with CKS, saponins from the
roots of Platycodon grandiflorum, significantly reduces metastasis and tumorigene-
sis, but the underlying mode of action has not been elucidated. In this study, we in-
vestigated the inhibitory effect of CKS on transforming growth factor (TGF)-β1-
induced alterations characteristic of EMT in human lung carcinoma cells. We
found that CKS-treated cells displayed inhibited TGF-β1-mediated E-cadherin
down-regulation and Vimentin up-regulation and also retained epithelial morphol-
ogy. Furthermore, TGF-β1-increased Snail expression was reduced by CKS.
Pretreatment of cells with CKS blocked TGF-β1-induced Smad2/3 phosphoryla-
tion and Smad7 down-regulation. CKS inhibited TGF-β1-induced phosphoryla-
tion of Akt, ERK1/2, and glycogen synthase kinase-3β (GSK-3β). Furthermore,
TGF-β1-increased Snail expression was reduced by pharmacology inhibitors of
Akt, ERK1/2, and GSK-3β. These results indicate that pretreatment with CKS in-
hibits the TGF-β1-induced EMT process and prevents TGF-β1-induced transdif-
ferentiation via activation of Akt and ERK1/2 and inactivation of GSK-3β in A549
cells.
1787 Platycodin D Regulates Hepatic Lipogenesis via an AMP-
Activated Protein Kinase Dependent Signaling Pathway in
Human HepG2 Cells.
H. Lee2,  Y. Hwang3, 1,  J. Choi1,  H. Kim1,  Y. Chung3 and H. Jeong1. 1Pharmacy,
Chungnam National University, Daejeon, Republic of Korea; 2Korea Research
Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea; 3International
University of Korea, Jinju, Republic of Korea.
Platycodin D, the saponins from the roots of Platycodon grandiflorum (CKS), has
a variety of pharmacological properties, including anti-hyperlipidemic, antioxidant
and hepatoprotective properties. This study was conducted to suggest the role of
AMP-activated protein kinase (AMPK) pathway in the anti-obesity effect of platy-
codin D. We characterized the underlying mechanism platycodin D’s effects in
HepG2 cells by Western blot and RT-PCR analysis. Platycodin D increased the
phosphorylation of AMPK and acetyl-CoA carboxylase (ACC) in HepG2 cells. Use
of a specific inhibitor showed that platycodin D activated AMPK via SIRT1/cal-
cium/calmodulin-dependent kinase kinase (CaMKK) in HepG2 cells. Taken to-
gether, these data suggest that platycodin D exert improving effects on high glu-
cose-induced lipogenesis by reducing of SREBP-1c and FAS expression via AMPK
activation.
1788 Rutaecarpine Suppresses LPS-Induced Inflammation in
Mouse Macrophages: A Possible Pathway through the
Induction of Heme Oxygenase-1 Expression.
S. Jin1,  Y. Hwang2,  H. Kim2,  J. Choi1,  H. Kim1,  Y. Chung2 and H. Jeong1.
1Pharmacy, Chungnam National University, Daejeon, Republic of Korea;
2International University of Korea, Jinju, Republic of Korea.
Rutaecarpine, a quinazolinocarboline alkaloidal compound, is a natural product
isolated from Evodia rutaecarpa and has various biological and pharmacological ef-
fects, including anti-inflammatory and anti-oxidative properties. In the present
study, we investigated the effect of rutaecarpine against lipopolysaccharide (LPS)-
induced inflammation in RAW264.7 macrophages. Treatment with rutaecarpine
suppressed inducible nitric oxide synthase expression and nitric oxide (NO) pro-
duction by downregulating NF-κB activity in lipopolysaccharide (LPS)-stimulated
RAW264.7 macrophages. Rutaecarpine acts by inducing the expression of heme
oxygenase-1 (HO-1) in a dose- and time-dependent manner. The signaling path-
way involved in rutaecarpine-mediated HO-1 induction included Ca2+/calmod-
ulin-dependent protein kinase II (CaMKII) and extracellular signal regulated ki-
nase 1/2 (ERK1/2). Furthermore, the CaMKII-ERK1/2 cascade targets the
transcription factor, NF-E2-related factor-2 (Nrf2). Taken together, our results
demonstrate that rutaecarpine-induced expression of HO-1 is mediated by the
Ca2+-CaMKII-Nrf-2-HO-1 pathway and inhibits LPS-induced inflammation in
RAW264.7 macrophages.
1789 Cultivated Ginseng Inhibits Tarc Expression by Suppressing
the Activation of NF-κB and STAT1 in Human Keratinocyte
Cells.
B. Park1,  J. Choi1,  J. Choi2,  Y. Chung2 and H. Jeong1. 1Pharmacy, Chungnam
National University, Daejeon, Republic of Korea; 2International University of Korea,
Jinju, Republic of Korea.
Atopic dermatitis (AD) is associated with the paradigm of an allergic T helper (Th)
2-mediated disease, characterized by abnormal IgE production, peripheral
eosinophilia, mast cell activation, as well as Th2 and Th1 cytokine up-regulation in
chronic skin lesions. This study examined the inhibitory effects of cultivated gin-
seng (CG) (Panax ginseng C.A. Meyer) on atopic dermatitis in HaCaT cells. CG,
an herb used in Korean herbal medicine, has been widely used in China and Japan
to treat fatigue and to enhance resistance to many diseases. CG suppressed TNF-
α/IFN-γ-induced TARC, CTACK, and MDC mRNA expression in HaCaT cells.
Additionally, CG inhibited TNF-α/IFN-γ-induced activation of NF-κB and
STAT1. These results indicate that CG inhibits chemokine expression in ker-
atinocytes by suppressing of NF-κB and STAT1 activation.
1790 Mollugin Inhibits Proliferation and Induces Apoptosis by
Inhibiting HER2 Expression in HER2-Overexpressing Breast
and Ovarian Cancer Cells.
M. Do,  T. Tran,  M. Na and H. Jeong. Pharmacy, Chungnam National University,
Daejeon, Republic of Korea.
Overexpression of the HER2 gene causes many cancer types and has been reported
to enhance cell proliferation, tumor growth, angiogenesis, and metastasis. This
study investigated the molecular mechanisms by which mollugin exerts anti-tumor
effect in HER2-overexpressing breast and ovarian cancer cells. Mollugin exhibited
potent inhibitory effects on cancer cell proliferation, especially in HER2-overex-
pressing SK-BR-3 human breast cancer cells and SK-OV-3 human ovarian cancer
cells in a dose- and time-dependent manner. Additionally, caspase-3 activity and
PARP cleavage were significantly upregulated in HER2-overexpressing SK-BR-3
and SK-OV-3 cells treated with mollugin. Mollugin treatment caused a dose-de-
pendent inhibition of HER2 gene expression at the transcriptional level, potentially
in part through suppression of NF-κB activation. Moreover, mollugin inhibits cy-
clin D1 expression by downregulating HER2 activation and consequently reducing
PI3K/Akt signaling. These results suggest that mollugin is a novel modulator of the
HER2 pathway in HER2-overexpressing cancer cells with a potential role in the
treatment and prevention of human breast and ovarian cancer with HER2 overex-
pression.
1791 Multiple Signaling Pathways Involved in Suppression of
MDR1 by Mollugin from Rubica cordifolia.
T. Tran,  H. Kim,  M. Do,  S. Jin,  E. Shim,  H. Han,  M. Na and H. Jeong.
Pharmacy, Chungnam National University, Daejeon, Republic of Korea.
Multidrug resistance (MDR) is known to be a serious problem in cancer treatment
and has been identifed as a negative prognostic factor in malignancies. This study
investigated mollugin, purified from roots of Rubica cordifolia L., down-regulated
MDR1 expression in MCF-7/adriamycin (MCF-7/adr) cells, human breast mul-
tidrug-resistant cancer cell. Mollugin treatment significantly inhibited MDR1 ex-
pression by blocking MDR1 gene transcription. Mollugin treatment also signifi-
cantly increased intracellular accumulation of the fluorescently-tagged P-gp
substrate, rhodamine-123. The suppression of MDR1 promoter activity and pro-
tein expression was mediated through mollugin-induced activation of AMP-acti-
vated protein kinase (AMPK) and inhibited NF-κB as well as CREB activation.
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These results suggest that mollugin treatment enhanced suppression of P-gp ex-
pression by inhibiting the NF-κB signaling pathway and attenuating CRE tran-
scriptional activity through AMPK activation.
1792 Liver Kinase B1 Is Required for Phillyrin-Induced AMPK
Activation in Human HepG2 Hepatocytes.
H. Han,  M. Do,  H. Kim,  T. Khanal,  T. Tran,  M. Na and H. Jeong. Pharmacy,
Chungnam National University, Daejeon, Republic of Korea.
Phillyrin, an active constituent found in certain functional foods, has anti-obesity
activity in vivo. This study investigated the ability of phillyrin to induce AMP-acti-
vated protein kinase (AMPK) in human HepG2 hepatocytes. Phillyrin strongly ac-
tivated the phosphorylation of AMPKα at Thr172 in HepG2 cells under normal
glucose condition. Additionally, the phosphorylation of AMPKα at Thr172 and
ACC at Ser79 was significantly suppressed in cells treated with high glucose,
phillyrin dose-dependently recovered the phosphorylation of AMPKα at Thr172
and the downstream target acetyl-CoA carboxylase (ACC) phosphorylation at
Ser79 in HepG2 cells pretreated by phillyrin. Moreover, phillyrin significantly
stimulated the phosphorylation of liver kinase B1 (LKB1) at Ser428 in a time-de-
pendent manner, with a time course matching that of AMPKα phosphorylation at
Thr172. In addition, the defeat of phillyrin-stimulated AMPKα activation in HeLa
cells deficient in LKB1 or in siRNA LKB1-transfected HepG2 cells, suggesting that
LKB1 is required for phillyrin-induced AMPK activation. These results indicate
that anti-obesity effects are mediated, at least in part, by the activation of
LKB1/AMPK.
1793 Prevention of Free Fatty Acid-Induced Hepatic Steatosis by
S-Allyl Cysteine through AMPK Pathways.
H. Jeong1,  Y. Hwang2,  H. Kim1,  J. Choi1 and Y. Chung2. 1Pharmacy, Chungnam
National University, Daejeon, Republic of Korea; 2Korea International University,
Jinju, Republic of Korea.
S-allylcysteine (SAC) is the most abundant organosulfur compound in aged garlic
extract (AGE), which has been used to standardize commercial aged extracts. SAC
has been reported to have antioxidant, anti-cancer, anti-hepatotoxic and neu-
rotrophic properties. In this study, we provide evidence that SAC prevented free
fatty acid (FFA)-induced lipid accumulation and lipotoxicity in hepatocytes. SAC
significantly reduced FFA-induced generation of reactive oxygen species, caspase
activation, and subsequent cell death. Also, SAC mitigated total cellular lipid and
TG accumulation in steatotic HepG2 cells. SAC significantly increased the phos-
phorylation of AMP-activated protein kinase (AMPK) and acetyl-CoA carboxylase
(ACC) in HepG2 cells. Additionally, SAC down-regulated the levels of sterol regu-
latory element binding protein-1 (SREBP-1) and its target genes, including ACC
and fatty acid synthase (FAS). Use of a specific inhibitor showed that SAC activated
AMPK via calcium/calmodulin-dependent kinase kinase (CaMKK) and SIRT1.
Our results demonstrate that SAC activates AMPK through CaMKK and inhibits
SREBP-1-mediated hepatic lipogenesis. The results indicate that SAC inhibit lipo-
genesis in cultured human hepatocytes, and further suggest that SAC impair
triglyceride synthesis in part due to decreased de novo fatty acid synthesis resulting
from inhibition on AMPK-dependent FAS and SREBP-1c.
1794 Cyto-/Genotoxic Effect of Extract from Bufo bufo
gargarizans Cantor in Human T Cell Leukemia Cells.
S. Lee,  Y. Lee,  Y. Choi and H. Chung. School of Public Health, Seoul National
University, Seoul, Republic of Korea. Sponsor: J. Chung.
Cinobufacini (Huachansu), an extract from the skins of Bufo bufo gargarizans
Cantor and has been widely used as an oriental medicine for cancer therapy.
Although numerous experimental studies on cinobufacini have been investigated its
anti-cancer properties, there is no information whether cinobufacini has anti-can-
cer effects on human leukemia. The genotoxicity of cinobufacini has not been de-
termined. The aim of the present study was to examine the cyto-/genotoxic effect of
cinobufacini in human T cell leukemia (Jurkat T-cells) and human normal lympho-
cytes.
Jurkat T-cells and normal lymphocytes were treated for 24 or 48 hours with various
concentrations of cinobufacini. Cytotoxicity was evaluated by Trypan blue exclu-
sion assays. Apoptotic cell death was detected by propidium iodide (PI) staining,
and intracellular reactive oxygen species (ROS) was determined by fluorescent dye
5-(and 6)-141 carboxy-2, 7-dichlorodihydrofluorescein diacetate (DCF-DA;
Molecular Probes) using flow cytometry analysis. The genotoxicity of cinobufacini
in Jurkat-T cells was measured by comet assay and cytokinesis-block micronucleus
assay.
Cinobufacini significantly inhibited cell viability in Jurkat-T cells but not in nor-
mal lymphocytes in dose- and time- dependent manner. Jurkat T-cells treated with
cinobufacini induced significantly higher levels of sub-diploid cells compared with
control. The DNA content in the sub-G1 region increased from 3.35 % to 22.2 %
and from 6.13 % to 42.25 %, when Jurkat-T cells treated with cinobufacini for 24
or 48 hours, respectively. Cinobufacini treatment resulted in significantly higher
levels of intracellular ROS. Cinobufacini also induced significant DNA damage de-
termined by comet assay and cytokinesis-block micronucleus assay. In conclusion,
these findings suggest that an extract from Bufo bufo gargarizans Cantor may be ef-
fective for treatment of leukemia.
1795 Potentially Toxic Minerals Used in South African Traditional
Medicine.
R. Street and M. P. Cele. University of KwaZulu-Natal, Durban, South Africa.
Sponsor: A. Ndifor.
The World Health Organization recognizes the incorporation of plant, animal
and/or mineral based products in traditional medicines. Millions of South Africans
rely on traditional medicines for their primary health care needs. Heavy metal toxi-
city related to the use of traditional medicine has been reported worldwide.
Although minerals are widely available at South African traditional medicine mar-
kets, there is insufficient pragmatic information regarding them. Thus the aim of
this study was to identify the commonly used crude metal and crystalline salts in
the South African traditional medicine trade. Premarket surveys indicated com-
monly available minerals. These minerals were then purchased from a rural tradi-
tional medicine market. Information regarding the colloquial name, mode of ad-
ministration as well as the price and weight were recorded. Scanning electron
microscopy-energy dispersive X-ray was used to determine the composition of the
unknown medicinally used powdered products. The elemental spectra was viewed
using a Leo 1450 SEM. Mineral salts identified included ammonium chloride, cal-
cium sulphate and sulphur powder. If not handled correctly, such salts can cause
numerous infirmities including eye irritation and dermal toxicity. Among the avail-
able metal salts were potassium dichromate, a Class 1 carcinogen, which is rou-
tinely taken both orally and as an enema, and potassium permanganate. Also very
concerning was the finding of liquid mercury documented as being ingested for fe-
male reproductive complaints. This study is the first to classify and document the
commonly available minerals used in South African traditional medicine.
Identifying such products has revealed actual and present hazards in the South
African traditional medicine trade. Training programmes are underway to alert tra-
ditional healers to the risks involved in handling and consuming such potentially
harmful substances as well as to provide healthcare workers with algorithms for
metal poisonings.
1796 Safety Assessment of Botanical Extracts in Cosmetics.
J. Song and Y. Yang. L’Oreal R&I, Shanghai, China.
It’s a worldwide trend that customers prefer to use personal care products (PCP)
containing natural and organic ingredients from botanicals. However natural does
not equal safe. In fact, various preparations and complex compositions of plants
have great potential to cause adverse effects such as irritation, sensitization and sys-
temic toxicity. The current dilemma is that there is no official guideline to evaluate
botanicals in PCP and the chemical assessment cannot be easily adapted to the
safety assessment of botanic substances. In line with the guideline issued by
Scientific Committee on Consumer Safety in EU, we proposed a strategy to guide
the safety evaluation of botanical extracts. The first and foremost is a good charac-
terization of the botanicals which include species, geographic origin, growing and
harvesting conditions, manufacturing process, profile of macro and micronutrients,
analytical markers, chromatographic fingerprint, known toxins, etc. Other com-
monly checked points are UV absorptive capability, 26 major allergens, residual sol-
vents, and additives. For botanical ingredients from food or herbal medicines with
a safe history of use, the assessment should be carefully made by taking into consid-
eration of all factors such as parts of plants used, genetic modifications, safety files
for registration, and exposed population etc. The focus is to assure that botanicals
intended to be used as a cosmetic ingredient is similar to its traditional counterpart
used as food and / or herbal drugs in terms of composition, specifications, quality,
and safety. After identifying the potential hazard, the exposure analysis will cover all
relevant toxicological endpoints. Special attention should be paid to the type I al-
lergy and local tolerance i.e., skin/mucous irritation, photoxicity/photoallergy, and
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Type IV sensitization. In risk assessment, besides in vitro, in vivo and clinical tests,
the threshold of toxicological concern (TTC) is a popular and robust tool to sup-
port safety of the concerned or unknown partition in composition.
1797 Effects of Crocetin and Safranal, Constituents of Saffron, in
22Rv1 Prostate Cancer Cells.
F. F. Albaqami and K. L. Willett. Department of Pharmacology and ETRP,
University of Mississippi, University, MS.
Saffron extracts have induced apoptosis, cell cycle arrest, inhibited cellular prolifer-
ation, and tumor progression in various cancer cell lines. We are interested in study-
ing the potential chemopreventative effects of saffron especially as it relates to
prostate cancer. Recognized active constituents of saffron are crocetin and safranal.
Cytotoxicity of safranal was investigated using the androgen responsive 22Rv1
prostate cancer cell line. The cytotoxicity IC50 of safranal at 24 hr was 141 μM
using the tetrazolium dye assay (XTT). The assay was incompatible with crocetin.
Using the Caspase-Glo® 3/7 assay system, it appears that apoptotic mechanisms
were involved in safranal’s cytotoxicity because after 6 hr of exposure, the EC50 of
apoptosis was similar to the cytotoxicity IC50. Safranal’s antioxidant activity as
measured by a 2’,7’-dichlorodihydrofluorescein diacetate assay indicated decreased
reactive oxygen species formation. Ongoing studies are investigating the potential
of saffron to also inhibit prostate cell invasion and migration in vitro. (Supported
by Saudi Arabian Ministry of Higher Education and Salman bin Abdulaziz
University)
1798 Kahweol Induces Apoptosis Trough Inhibition of STAT3
Phosphorylation in Human Lung Adenocarcinoma A549
Cells.
H. Kim1,  J. Choi1,  K. Tilak1,  Y. Hwang1, 2 and H. Jeong1. 1Pharmacy,
Chungnam National University, Daejeon, Republic of Korea; 2International
University of Korea, Jinju, Republic of Korea.
Epidemiological studies have shown that unfiltered coffee consumption is associ-
ated with a low incidence of cancer. Kahweol, the coffee-specific diterpene, has
been reported to have anti-carcinogenic properties. Animal data support such a
chemopreventive effect of coffee. However, the precise underlying protective mech-
anisms are poorly understood. In this study, the apoptotic effect of kahweol in
human lung adenocarcinoma A549 cells was investigated. In cell viability assays
and cell proliferation assays, kahweol exhibited anti-proliferative and pro-apoptotic
effects on A549 cells in a time- and dose-dependent manner. Kahweol considerably
inhibited the expression of Bcl-2 but increased that of Bax; it also stimulated the
cleavage of caspase-3 and poly ADP-ribose polymerase. In addition, kahweol-in-
duced apoptosis was confirmed by TUNEL assays. Furthermore, kahweol inhibited
dose-dependent phosphorylation of signal transducer and activator of transcription
3 (STAT3). An overexpression in STAT3 led to resistance to kahweol-induced
apoptosis, suggesting that STAT3 was a critical target of kahweol. These findings
suggest that kahweol inhibited A549 cell growth and induced apoptosis via down-
regulation of STAT3 signaling pathway. These data may contribute to the explana-
tion of the reported antitumoral effects of kahweol, including the recent epidemio-
logical meta-analysis showing that drinking coffee could decrease the risk of certain
cancers.
1799 In Vitro Antioxidant Activities of Fractions of Clerodendrum
violaceum Leaf Extract.
E. A. Balogun,  A. Zailani and J. O. Adebayo. Biochemistry, University of Ilorin,
Ilorin, Nigeria.
Many diseases are mediated by reactive oxygen species. Clerodendrum violaceum is
a medicinal plant used indigenously in Nigeria for the treatment of some of such
diseases. In this study, the antioxidant activities of the hexane, ethyl acetate and
methanolic fractions of Clerodendrum violaceum leaf extract were evaluated in
vitro using 2,2-diphenyl-1-picryl-hydrazyl-hydrate (DPPH), superoxide anion and
hydrogen peroxide scavenging assays. The antioxidant components of the extract
fractions were also determined. The results showed that the methanolic fraction
had the highest concentrations of vitamin C, vitamin E, selenium, phenols and
flavonoids. Moreover, the methanolic fraction of the extract had the highest free
radical scavenging activities against DPPH, superoxide anion and hydrogen perox-
ide with EC50 values of 0.08, 0.45 and 0.60 mg/ml respectively. It also had the
highest reducing power against ferric ion. The results of the study suggest that the
methanolic fraction of Clerodendrum violaceum leaf extract may be a potent
source of antioxidant compounds which may be useful for the prevention and treat-
ment of reactive oxygen species-mediated diseases.
1800 Comparative Pharmacodynamic Effects of Rituximab-EU
(MabThera®) and Rituximab-Pfizer in Cynomolgus
Monkeys.
A. M. Ryan1,  S. Sokolowski1,  M. Collinge1,  A. Shen1,  J. Arrington2,
T. Cummings1,  S. Ploch2,  S. Stephenson2,  N. Tripathi2,  S. Hurst1,  G. Finch1
and M. Leach1. 1Pfizer WRD, Groton, CT; 2Covance, Madison, WI.
Background: Rituximab-Pfizer is in Phase 1/2 in RA patients as a potential biosim-
ilar. Analytical and functional characterization has demonstrated in vitro similarity
to the licensed rituximab products. Methods: The pharmacodynamic effects of rit-
uximab-Pfizer and rituximab-EU were compared in sexually-mature cynomolgus
monkeys in single-dose PK and repeat-dose toxicity studies; both had a 13-week
postdose observation period to assess B cell repletion. Peripheral blood lymphocytes
were evaluated by flow cytometry, and spleen and axillary and mesenteric lymph
nodes (repeat-dose only) were examined microscopically by CD20+ immunohisto-
chemistry. Results: B cell effects were similar in magnitude and time course be-
tween rituximab-Pfizer and rituximab-EU. Marked to complete depletion of pe-
ripheral blood B cells occurred on Day 4 (the first time point evaluated) in both
studies. In the single-dose study, repletion of B cells began on Day 15 (2 mg/kg)
and Day 29 (10 and 20 mg/kg) and continued through Day 92, with a subset of an-
imals in each group near or above the pre-dose values at the end of the 13-week ob-
servation period. In the repeat-dose study, peripheral B cell depletion persisted
through Day 30 of the dosing phase and was associated with lower splenic weights,
decreased lymphoid follicle cellularity and decreased CD20+ cells in lymphoid tis-
sues. After repeat-dosing, partial repletion of peripheral blood B cells was noted in
recovery animals by Day 92 of the recovery phase. Complete histopathologic recov-
ery occurred in 3 recovery animals (2 rituximab-Pfizer and 1 rituximab-EU).
Lymphoid cellularity and CD20+ cells were increased in the remaining 9 recovery
animals (relative to the dosing phase results), indicating partial recovery.
Conclusion: The magnitude and time course of B cell depletion and repletion were
similar between rituximab-Pfizer and rituximab-EU and were consistent with the
expected pharmacology of anti-CD20 monoclonal antibodies and the reported in-
novator data.
1801 Brain Microhemorrhage Assessment of an Antiamyloid Beta
Peptide (Aβ) Monoclonal Antibody (mAb) Using a
Transgenic Mouse Model of Alzheimer’s Disease (AD).
L. A. Buckley1,  D. Hall1,  J. Douville2,  W. H. Jordan3,  D. Koger1,
W. H. Anderson1,  D. G. Waters1 and R. B. DeMattos1. 1Eli Lilly & Co.,
Indianapolis, IN; 2Charles River Laboratories, Montréal, QC, Canada; 3Vet Path
Services, Inc., Mason, OH.
Solanezumab (SLZ), a humanized mAb against Aβ peptide, is being developed for
the treatment of AD. SLZ recognizes a mid domain epitope of the Aβ peptide with
high affinity and selectivity to soluble monomer. The potential to cause cerebral
amyloid angiopathy (CAA)-associated microhemorrhage (MH) was studied in an
aged transgenic mouse (APPV717F) model of AD using a murine surrogate of
SLZ, m266.2. Critical study design factors included the use of: 1) age-optimized
mice (>21 months) known to have established cerebral amyloid prior to treatment
and thus potentially susceptible to CAA-MH; 2) sufficient numbers (≥25) of
mice/group; 3) a dose projected to achieve a near-maximal pharmacologic response;
4) a positive control mAb against an N-terminal epitope of Aβ peptide (3D6); 5)
meticulous attention to brain collection and processing; 6) expanded brain section-
ing and specialized microscopy; and 7) examinations by primary and peer-review
pathologists experienced in neuropathologic assessments. Groups of mice received
either vehicle control, 50 mg/kg m266.2, or 50 mg/kg 3D6 by weekly ip injection
for 4 months (curtailed from the original 6-month duration due to age-related
mortality). Plasma exposure to m266.2 and 3D6 was demonstrated at the end of
the study. Multiple histologic brain sections stained with Perls’ Prussian Blue/DAB-
enhanced Perls from each animal were evaluated to score siderophages resulting
from hemorrhage, and multiple H&E stained slides were examined with both
brightfield and epifluorescent illumination for the presence of other changes in the
brain. While the positive control 3D6 elicited the expected robust microhemor-
rhage response associated with vascular degeneration, the brains of mice given
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m266.2 were not different from those of vehicle control mice. In conclusion,
m266.2 did not induce CAA-MH or microscopic evidence of any inflammatory or
degenerative changes in the brain.
1802 Safety Assessment of REGN1001 a Monoclonal Antibody
Against Angiopoietin-Like 4 (AngPTL4) in Cynomolgus
Monkey Toxicology Studies Under Normal and High-Fat
Diet Feeding Regimens.
J. Trejos1,  R. Soltys1,  T. Daly1,  T. O’Neill2,  K. Mozzachio2 and
A. Arulanandam1. 1Drug Safety, Regeneron Pharmaceuticals, Tarrytown, NY;
2General Toxicology, WIL Research, Ashland, OH.
REGN1001 is an antibody directed against Angiopoietin-like 4 (AngPTL4) and
blocks its ability to inhibit lipoprotein lipase (LPL), an enzyme that hydrolyzes
triglycerides (TG) and hence leads to a reduction in plasma TG levels. Evidence for
the role of AngPTL4 as a regulator of TG metabolism has been obtained in
AngPTL4 gene knockout studies in which profound decreases in TG levels were
observed. Several studies have also indicated that AngPLT4 ablation in rodents ei-
ther via AngPTL4 gene KO or Ab inhibition during high-fat diet (HFD feeding)
regimens can lead to the prominent appearance of foamy macrophages and severe
inflammatory changes in mesenteric lymph nodes (MLN). To better predict the
safety profile of REGN1001 in hyperlipidemic patients (prone to ingest a high fat
diet), a toxicology program evaluating REGN1001 intravenous dosing under nor-
mal diet and high-fat diet conditions was undertaken in 2 separate 13-week
cynomolgus monkey toxicology studies. The first study utilized a normal (high-
fiber) feeding regimen; the second study used a HFD regimen that closely resem-
bles a western diet. Consistent with the data described in rodents, only the HFD
regimen resulted in foamy macrophages in the MLN in monkeys. After a 15-week
treatment free recovery period, during which half the animals were withdrawn from
HFD, the incidence/severity of foamy macrophages in MLN was decreased relative
to those maintained on the HFD regimen. These studies for the first time demon-
strate in primates that AngPTL4 inhibition under HFD fed conditions can result in
the presence of foamy macrophages in the MLN. In addition, these toxicology
studies demonstrate the importance of incorporating human disease factors in to
animal models for safety testing. Given these data, the likelihood of a similar, clini-
cally-relevant toxicity occurring in hyperlipidemic humans receiving REGN1001
or other ANGPTL4 inhibitors cannot be discounted.
1803 13-Week Toxicity Study of an Anti-Interleukin-6 Antibody
(MEDI5117) by Every Other Week Intravenous or
Subcutaneous Injection to Cynomolgus Monkeys.
T. S. Manetz1,  P. C. Ryan1,  R. Faggioni2,  Z. Yao2,  R. Lee2,  A. Schneider2,
I. Vainshtein2,  C. Nhan2,  K. Mojica2,  C. Chavez2,  K. McKeever1 and R. Dixit1.
1Translational Sciences, MedImmune, LLC, Gaithersburg, MD; 2Translational
Sciences, MedImmune, LLC, Hayward, CA.
MEDI5117 is a human immunoglobulin G1 (IgG1)-YTE (triple mutation) mono-
clonal antibody that binds to interleukin 6 (IL-6) with sub-pM affinity and neu-
tralizes it by preventing binding to the interleukin 6 receptor (IL-6R). The Fc do-
main of MEDI5117 contains the YTE mutation that increases MEDI5117
Fc-binding to the neonatal Fc receptor (FcRn) at pH 6.0 and thus increases the an-
tibody half-life. To support the first in human clinical study, the nonclinical safety
of MEDI5117 was assessed in a GLP repeat IV or SC administration study in
cynomolgus monkeys when given by IV bolus injection (15 or 100 mg/kg) or SC
injection (15 or 50 mg/kg) every other week for 13 consecutive weeks (7 total dose
administrations). Administration of MEDI5117 by SC injection did not result in
adverse findings. Administration of MEDI5117 by IV bolus injection resulted in
the unscheduled euthanasia of one 15 mg/kg animal that had apparent and treat-
able anaphylactic reactions to the two previous MEDI5117 dose administrations.
There were no similar findings for the other 15 mg/kg IV animals or for animals
administered the higher 100 mg/kg IV dose level, and the data demonstrated de-
creased observed pharmacodynamic and toxicokinetic profiles from this animal as
compared to other 15 mg/kg IV animals, as well as the presence of anti-drug anti-
bodies. Since this was most likely related to the formation of anti-drug antibody
that has been recognized by regulatory agencies as not predictive of immunogenic-
ity in humans and there was a lack of any other findings which is consistent with
the toxicology profiles reported for other anti-IL-6 antibodies (Martin et al., 2004
and Femta Pharmaceuticals IND Submission Press Release), this adverse event was
not factored into the NOAEL determination. Therefore, the NOAEL from the
GLP study was 100 mg/kg for animals dosed IV and 50 mg/kg for animals dosed
SC, the highest doses tested.
1804 Mavrilimumab (CAM-3001): A Novel Anti-GMCSF
Receptor Alpha Monoclonal Antibody for the Treatment of
Rheumatoid Arthritis.
P. C. Ryan1,  M. Sleeman2,  M. Rebelatto1,  B. Wang3,  H. Lu3,  X. Chen3,
C. Wu3,  L. Roskos3,  D. Close2,  H. Towers2,  K. McKeever1 and R. Dixit1.
1Biologics Safety Assessment, MedImmune, Gaithersburg, MD; 2Research and
Development, MedImmune, Cambridge, United Kingdom; 3Clinical Pharmacology
and DMPK, MedImmune, Hayward, CA.
Rheumatoid arthritis is a progressive and disabling autoimmune disease character-
ized by inflammation of the joints, with subsequent long term structural damage,
chronic pain, and limited daily activity. Despite the availability of a variety of effec-
tive therapies, a significant portion of patients fail to achieve optimal outcomes in-
cluding clinical remission and ongoing low disease activity. MedImmune is cur-
rently pursuing development of mavrilimumab (CAM-3001), a human
monoclonal antibody (MAb) targeting GM-CSF receptor alpha, as a novel treat-
ment for RA. GM-CSF plays a central role in the pathogenesis of rheumatoid
arthritis (RA) through the activation, differentiation, and survival of macrophages
and neutrophils. The nonclinical safety of mavrilimumab was evaluated in several
studies in cynomolgus monkeys as the pharmacologically relevant species. Overall,
the nonclinical safety results supported the continued clinical development of
mavrilimumab. In clinical studies in RA patients, mavrilimumab has demonstrated
good clinical activity with adequate safety to support further clinical development.
A Phase 2b study of mavrilimumab in subjects with RA is in progress.
1805 Preclinical Safety and Pharmacodynamics of an Anti-GM-
CSF Monoclonal Antibody in Cynomolgus Macaques.
D. Blanset,  E. Musvasva,  A. Avakian,  S. van Tongeren,  J. Phillips,  C. Grimaldi
and S. Cannan. Boehringer-Ingelheim, Ridgefield, CT.
Administration of anti-GM-CSF monoclonal antibodies (mAb) have been pro-
posed as potential therapeutics for inflammatory diseases. In addition to its role in
immunity and inflammation, GM-CSF is required for proper maintenance of sur-
factant catabolism by pulmonary alveolar macrophages (PAM). In humans, loss of
GM-CSF signalling results in deregulated surfactant turnover and can manifest as
pulmonary alveolar proteinosis (PAP). Therefore, specialized assessments were in-
cluded in a toxicology study to assess the potential for an anti-GM-CSF mAb to af-
fect surfactant catabolism. The mAb was given intravenously at 0.25 or 50 mg/kg
once weekly for 4 weeks or subcutaneously at 0.25, 5 or 50 mg/kg for 13 weeks. In
addition to standard toxicity endpoints, bronchoalveolar lavage fluid (BALF) was
assessed for cell differentials, intracellular lipids and surfactant protein-D (SP-D)
levels. Serum SP-D levels were also evaluated. The mAb was well tolerated with no
clinical signs of toxicity. There were no adverse effects on clinical or anatomic
pathology. Non-adverse effects in the lung included a dose related increase in the
percentage of enlarged PAM, increased numbers of lipid containing PAM and in-
creased BALF SP-D levels. These minor changes may be related to changes in sur-
factant catabolism but were not accompanied by clinical or histopathological find-
ings indicative of PAP. Serum SP-D values were comparable across groups,
consistent with absence of PAP as determined by histopathology. In ex vivo assays,
GM-CSF induced CD11b, pStat5 and proliferation of TF-1 cells were inhibited in
a dose related manner consistent with the expected pharmacology. Exposure at 0.25
mg/kg was significantly decreased by the formation of anti-drug antibodies which
correlated with decreased activity in the ex vivo assays. In conclusion, anti-GM-
CSF mAb was well tolerated by cynomolgus monkeys and produced expected phar-
macological effects that were reversible upon treatment cessation.
1806 Nonclinical Safety Evaluation of Anti-PD-L1 (MDPL3280A)
in Mice and Cynomolgus Monkeys.
R. Prell,  R. Fuji,  R. Deng,  R. Pai,  N. Ma and J. McBride. Genentech, S. San
Francisco, CA.
Programmed cell death 1 (PD-1) is a receptor expressed on T cells following activa-
tion and binding to its ligand, PD-L1, down-regulates the quality and magnitude
of T-cell responses. Many neoplastic cells express PD-L1 and evade destruction by
the immune system. MPDL3280A, an effectorless (FcγR-binding deficient) human
IgG1 mAb that blocks PD-1/PD-L1 interactions, is in development as a potential
therapy for solid tumors. The nonclinical safety program included an in vitro cy-
tokine release assay with human PBMCs, a tissue cross reactivity study, an ex-
ploratory 15-day repeat-dose study in C57BL/6 and CD-1 mice, and an 8 week re-
peat dose toxicity study in monkeys. MPDL3280A did not induce cytokine release
from human PBMCs. MPDL3280A-specific staining was detected in the lymph
node of monkey tissues and the placenta, lymph node, tonsil, and thymus of
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human tissues.  In vivo, no adverse drug related changes in immunologic endpoints
were observed in either species. Drug-related findings were consistent with the ex-
pected pharmacology following PD-1/PD-L1 pathway inhibition. In mice, this in-
cluded reversible increases in splenic weights in both strains, attributed to an en-
hanced immune response to a heterologous mAb.  Minimal sciatic neuropathy with
inflammation was observed in C57BL/6 mice only, a strain expressing the MHC
H-2b haplotype that in PD-1-deficient mice, develops spontaneous autoimmune
peripheral neuropathy. In monkeys, arteritis/periarteritis in parenchymal and/or tu-
bular organs was observed, which is a recognized spontaneous inflammatory condi-
tion in this species, and may reflect an MPDL3280A-related enhancement of a pre-
existing condition. A high incidence of anti-therapeutic antibodies (50/56 (89%)),
which had no consistent impact on exposure, and minimal SC injection sites reac-
tions were also attributed to MPDL3280A-enhanced immune responses. These
findings are consistent with PD-1/PD-L1 inhibition and identify heightened im-
mune responses and the potential to increase autoimmune liabilities in predisposed
individuals as possible safety risks in patients.
1807 Investigation of the Potential Role of Immunogenicity in
Abatacept-Related Lymphocytic Inflammation in Adult and
Juvenile Rats.
J. Li1,  J. Mysore1,  D. A. DeVona1,  M. Abbott2,  M. P. Bernard1,  S. Eble1,
W. J. Freebern1 and H. G. Haggerty1. 1Drug Safety Evaluation, Bristol-Myers
Squibb, New Brunswick, NJ; 2Drug Safety Evaluation, Bristol-Myers Squibb,
Syracuse, NY.
Abatacept is a fusion protein of a human IgG1 Fc and the extracellular domain of
human CTLA-4 that inhibits T-cell activation. Species specific lymphocytic inflam-
mation of the thyroid and pancreatic islets was observed in adult and juvenile rats
treated with abatacept subcutaneously (SC) every 3 days for 3 months at pharma-
cologic doses of 65 and 20 mg/kg/day respectively. Studies in adult and juvenile rats
were performed to assess a potential relationship of immunogenicity to lympho-
cytic inflammation observed in juvenile and adult rats. Abatacept was administered
SC at 0 (control) or 0.03 mg/kg (a subpharmacologic dose) to adult rats
(20/sex/group) on Days 1 and 29, or to juvenile rats (20/sex/group) on Days 1
(postnatal day 28), 15, 29, and 43. Anti-drug antibodies (ADA) were measured
pretest, on Days 29, 43, 57, and 85. Additional criteria for evaluation included sur-
vival, toxicokinetics, clinical observations, body weights, food consumption, T cell-
dependent antibody response (TDAR), peripheral blood T-regulatory cell pheno-
typing, selected organ weights, gross and microscopic pathology analyses.
Scheduled necropsies were conducted 3 months following study initiation.
Abatacept was clinically well tolerated in both adult and juvenile rats with no abat-
acept-related toxicologic effects. There were no effects on TDAR or the percentage
of CD4+CD25+Foxp3+ lymphocytes (a T-regulatory cell population) in abatacept-
treated rats consistent with a lack of pharmacologic activity. Robust and persistent
ADA responses were detected in all abatacept-treated rats, with no evidence of lym-
phocytic inflammation of the thyroid or pancreatic islets. Thus, the lymphocytic
inflammation previously observed in abatacept-treated adult and juvenile rats at
pharmacologic doses was most plausibly due to pharmacologic immunosuppression
and not a consequence of immunogenicity.
1808 Assessment of Biocomparability of NU100 and Betaferon in
Cynomolgus Monkeys.
A. M. Brooks1,  V. Tammara2,  D. Hobson3,  E. Shaw2,  D. Zeng2,
F. G. Burleson4 and H. Hu1. 1Toxicology, Covance Laboratories Inc., Madison, WI;
2Nuron Biotech Inc., Exton, PA; 3LoneStar PharmTox LLC, Boerne, TX; 4Burleson
Research Technologies, Morrisville, NC.
Betaferon is a marketed recombinant human interferon beta-1b (IFN beta-1b) for
treatment of relapsing-remitting multiple sclerosis (RRMS). NU100 is an im-
proved recombinant human IFN beta-1b produced using proprietary manufactur-
ing technology. NU100 is aggregate-free and HSA-free in its formulation.
In a GLP monkey study for NU100 safety assessment, male and female cynomol-
gus monkeys were assigned to 2 groups (4 animals/sex/group), and received once
every other day NU100 or Betaferon at a dose level of 0.06 mg/kg/dose for 15 days.
Animals were monitored for safety; blood samples were collected to determine
serum levels of IFN beta-1b, neopterin (a biomarker for IFN-beta-1b pharmacody-
namic profile), and anti drug antibodies (ADA). No NU-100- or Betaferon-related
adverse safety signs occurred within these 15 days.
IFN-beta-1b levels peaked approximately 3 hours postdose; Cmax and AUCall for
NU100 and Betaferon were 23.7 (CV 49.1%) and 14.3 (CV 48.0%) ng/mL and
225 (CV 51.6%) and 157 (CV 40.6%) h*ng/mL at steady state, respectively, and
were not statistically significantly different. Neopterin levels peaked 24 hours post-
dose on Day 1; Emax and EAUCall for NU100 and Betaferon were 5.4 (CV
41.4%) and 6.29 (CV 31.7%) nMol/L and 65.9 (CV 45.2%) and 75.7 (CV
39.5%) h*nMol/L, respectively; whereas Neopterin concentrations reached steady
state on Day 15; Emax and EAUCall for NU100 and Betaferon were 1.71 (CV
78.1%) and 1.03 (CV 107.2%) nMol/L and 21 (CV 77.3%) and 35.6 (CV 7.9%)
h*nMol/L, respectively, and were not statistically significantly different. This re-
duced response on Day 15 to treatment was likely due to the production of anti-
drug antibody (ADA), with 3 of 8 animals in the Betaferon group and 1 of 8 ani-
mals in the NU100 group positive for ADA. In conclusion, NU100 and Betaferon
had comparable safety, toxicokinetic, and pharmacodynamic profiles in cynomol-
gus monkeys.
1809 Preclinical Development and Safety Assessment of the First
Inhaled Nanobody ALX-0171.
S. Jacobs1,  E. Depla1,  S. Rossenu2,  S. Priem1,  E. Vanheule1,  A. Schoolmeester1,
K. Allosery1,  S. De Boever1,  L. Detalle1,  V. H. Chen3 and J. Baumeister1.
1Ablynx NV, Zwijnaarde, Belgium; 2MSD BV, Oss, Netherlands; 3Boehringer
Ingelheim, Ridgefield, CT.
Nanobodies are therapeutic proteins based on the smallest functional fragments of
naturally occurring heavy chain only antibodies. The trivalent Nanobody ALX-
0171 targets the respiratory syncytial virus (RSV) with high specificity and potency.
It has the potential to be effective in prevention and treatment of RSV infection, a
cause of severe upper and lower airway inflammation in susceptible populations.
The medical need is high in young children, with 0.3million patients younger than
5 years hospitalised every year. ALX-0171 is formulated as a nebulizer solution for
pulmonary inhalation as clinical route of administration. Using a vibrating mesh
nebuliser, a droplet size ≤3.4 μm (MMAD) was achieved, while the drug’s stability
was maintained. The preclinical package consisted of 2-week repeated dose toxicity
studies via iv administration or inhalation in adult rats, a respiratory safety pharma-
cology study in rats via single inhaled dose and a cardiovascular safety pharmacol-
ogy study in dogs (iv, single ascending dose). No drug- or immunogenicity-related
safety findings were observed. A standard BCOP assay demonstrated the non-cor-
rosive nature of the compound. In addition, a cotton rat disease model was per-
formed to assess safety, tolerability and efficacy of ALX-0171 (intratracheal deliv-
ered). A dose-dependent reduction of viral transcripts following viral re-challenge
in lung tissue of RSV-infected cotton rats was demonstrated as efficacy marker. A
significant improvement of infection-related events (body weight stagnation, organ
weight, BALF inflammatory cell counts) was demonstrated without signs of im-
mune-induced events upon ALX-0171 administration. Treatment-induced anti-
drug antibodies were measured in BALF and plasma and results indicated a mild
immunogenicity response. It can be concluded that ALX-0171 was well-tolerated
in safety assessments in preclinical species. ALX-0171 successfully completed a
phase I clinical trial.
1810 The Occurrence of Microscopic Vacuoles in Toxicology
Studies with Marketed Pegylated Proteins Is Associated with
High Doses, High Clinical Multiples, and Accumulation.
L. S. Kaufman1,  C. Conover2 and A. Buchbinder2. 1PDS, Mt Arlington, NJ;
2Enzon Pharmaceuticals, Piscataway, NJ.
To obtain a more complete understanding of the clinical significance of micro-
scopic vacuoles observed in toxicology studies with marketed pegylated proteins,
nonclinical programs were reviewed from FOI data (publicly available BLA re-
views) for Omontys, Krystexxa, Cimzia, Mircera, Macugen, Somavert, Pegasys,
Neulasta, PegIntron, and Adagen. Cumulative toxicology doses for conjugate,
PEG, and protein were calculated for each study and compared with cumulative
recommended clinical doses over the same interval. None of the studies included
PEG control groups. Microscopic pathology evaluations across programs were part
of GLP toxicology studies and were performed on formalin/immersion-fixed tis-
sues. There was no indication of whole-body perfusion techniques. Microscopic
vacuoles were noted in toxicology studies with Omontys, Krystexxa, Cimzia,
Macugen (IV but not intravitreal), Somavert, and Neulasta but not for Mircera,
Macugen (intravitreal), Pegasys, PegIntron or PEG12kD. Across programs, their
appearance and reversibility were dose-related and associated with large cumulative
PEG/conjugate doses, short inter-dose intervals, longer study durations, drug accu-
mulation, and large clinical multiples. At high cumulative doses (up to 14,000-fold
the recommended clinical dose based on mg/m2 and PEG doses of 2720 mg/m2),
vacuoles were noted in the macrophage phagocyte system and, in some instances,
choroid plexus, uterus, ovary, pituitary, and adrenal cortex. Nearly all of the high
doses associated with vacuoles exceeded high-dose guidelines per ICH S6
Addendum. In conclusion, the appearance of microscopic vacuoles in toxicology
studies with marketed pegylated proteins appears related to high cumulative doses
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and associated drug accumulation, which is not present at recommended clinical
doses. This review does not address the potential for vacuole formation in pegylated
proteins associated with toxicities in excess of those appropriate for marketed prod-
ucts.
1811 TAS-116, an Orally Highly Potent HSP90α/β Selective
Inhibitor, Leads Minimized Ocular Toxicity in Both Albino
and Pigmented Rats.
H. Hitotsumachi1,  Y. Kodama2,  S. Ohkubo2,  K. Yonekura2,  K. Besshi1,
F. Morita1 and T. Hayashi1. 1Tokushima Research Center, Taiho Pharmaceutical Co.,
LTD., Tokushima, Japan; 2Tsukuba Research Center, Taiho Pharmaceutical Co.,
LTD., Tsukuba, Japan. Sponsor: M. Takahashi.
BACK GROUND: Heat Shock Protein 90 (HSP90) is a key chaperon which has a
critical role for cancer cell growth and survival. Several HSP90 inhibitors have been
developed clinically, however, visual symptoms have limited the ability to maximize
drug exposure in patients. TAS-116 is an orally available HSP90α/β selective in-
hibitor showing high antitumor activity in various human tumor xenograft models.
To evaluate the effect of TAS-116 to the optic organ, we confirmed the safety pro-
files of TAS-116 in both albino and pigmented rat.
RESULTS: When TAS-116 administered orally for 14 days, no dose-related change
was revealed in ophthalmological examination in albino rat. In histopathology, ref-
erence HSP90 inhibitors (AUY922 and 17-DMAG) caused degeneration and/or
disarrangement of photoreceptor cells and increase in TUNEL positive apoptotic
cells in retinal outer nuclear layer (ONL). On the other hand, TAS-116 demon-
strated no histological changes or increase in TUNEL positive cells in ONL in al-
bino rat. When all compound administered intravenously in albino rat, AUY922
and 17-DMAG showed greater exposure in retina compared to plasma, whereas
TAS-116 showed less distribution in retina than in plasma. In addition, oral ad-
ministration of TAS-116 demonstrated less retinal distribution and did not accu-
mulate in retina after 2-week repeated dosing. In contrast, TAS-116 indicated a
much higher distribution in subcutaneously implanted tumor over retina in rat
model. Furthermore, TAS-116 had no melanin affinity because TAS-116 did not
induce the retinal toxicity and also showed less distribution in retina in pigmented
rat.
CONCLUSION: TAS-116 does not induce ocular toxicity in both albino and pig-
mented rat. This is probably due to less distribution in retinal tissue of TAS-116.
These unique profiles of TAS-116 indicate that TAS-116 has a potential to be a
best-in class HSP90 inhibitor with minimized ocular toxicity.
1812 ETEC Vaccines: An 85-Day Intradermal Repeat Dose
Toxicity Study of Three Candidates in Guinea Pigs.
C. S. Godin1,  M. Maciel2 and S. Savarino2. 1AVANZA Laboratories, Gaithersburg,
MD; 2Naval Medical Research Center, Silver Spring, MD.
A vaccine against enterotoxigenic E. coli (ETEC) is being developed to protect trav-
elers and young children that are at risk from this disease. The purpose of this study
was to evaluate the potential toxicity and immunogenicity of three vaccine candi-
dates, proteins 1, 2 and adjuvant, when administered either alone or in combina-
tion to guinea pigs by the intradermal route on Days 1, 22, 43, and 64 at a dose of
100 μg. Animals were dosed with saline, proteins 1, 2, and adjuvant alone, a com-
bination of protein 1 and adjuvant, or a combination of protein 2 and adjuvant.
Evaluations included mortality, physical examinations, body weights, body temper-
atures, dermal Draize scores/induration measurements, gross pathology, organ
weights, and histopathology. On Day 3, punch biopsies were collected from the
first injection site. Punch biopsies of the remaining vaccination sites, from all vacci-
nation sites of the remaining animals, and from a naïve site distant from the sites of
vaccination, were collected at necropsy. Administration of protein 1 alone, protein
2 alone, adjuvant alone, protein 1 with adjuvant, and protein 2 with adjuvant in
guinea pigs was well tolerated as all animals survived to termination with no adverse
clinical signs. There were no test article-related effects upon the following parame-
ters: mortality, physical examinations, body temperature, and body weights.
Dermal erythema and induration were more significant when the vaccines were in
combination with adjuvant than when administered alone or when adjuvant was
administered alone. However, these observations resolved over time. On Days 3
and 63, but not at other intervals, total protein and/or albumin were increased in
some treated groups suggesting immune stimulation correlating with inflammation
at the injection site. Increased incidence and severity of cellular infiltrate, edema,
and hemorrhage in the dermis and subcutis were noted in biopsy sites collected on
Days 3 and 66. Following recovery, all findings had either resolved or would be ex-
pected to resolve.
1813 The Inhibin B Response to a Motilin Receptor Agonist in
Male Rats.
M. K. Ziejewski1,  J. D. Vidal2,  D. J. Stanislaus1,  A. R. Apostoli1,
P. Chowdhury3 and S. B. Laffan1. 1Safety Assessment - Reproductive Toxicology,
GlaxoSmithKline, King of Prussia, PA; 2Safety Assessment - Pathology,
GlaxoSmithKline, King of Prussia, PA; 3Safety Assessment - Toxicology,
GlaxoSmithKline, Ware, United Kingdom.
Background: In a repeat oral dose toxicity study, 16/16 male rats given 100
mg/kg/day GSK1322888 sustained testicular injury after 4 weeks of treatment; the
findings were not reversible after 12 weeks off-dose. A subsequent study was con-
ducted to further characterize testicular toxicity and to explore the possible rela-
tionship between onset of lesions and, changes in circulating hormone levels.
Methods: Male Sprague-Dawley rats (11 weeks old at study start) were orally ad-
ministered 30 or 100 mg/kg/day GSK1322888 for 2 weeks with a 4 week off-dose
period. Blood was collected via tail vein twice during the treatment period (Day 4
and 11) and three times during the off-dose period (Day 28, 36 and 42) for meas-
urement of serum testosterone (T), dihydrotestosterone (DHT), and inhibin B
(InhB), luteinizing hormone (LH), and follicle stimulating hormone (FSH) con-
centrations. A histopathologic examination of testes was performed at the end of
the treatment and off-dose periods. Results: At 100 mg/kg/day, microscopic find-
ings of the testis (degeneration of the germinal epithelium) were evident for 9/10
male rats on Day 14 and 10/10 rats at the end of the 4-week recovery period. There
was no testicular toxicity observed at 30 mg/kg/day. During all stages of evaluation,
there was no apparent difference among control and treated animals in hormone
concentrations. Conclusion: There was poor correlation between changes in serum
levels of InhB and testis histopathology. Based on these observations, the utility of
InhB as a hormonal marker for germ cell toxicity is limited.
1814 Preclinical Safety Evaluation of JNJ-35815208, a Selective
Estrogen-Related Receptor Alpha Modulator.
J. Zhou,  F. Selan,  L. Hall,  R. Mamidi,  M. Duvall and C. Louden. Drug Safety
Sciences, Janssen Research & Development, LLC, Raritan, NJ.
Estrogen-related receptor-α (ERRα) is an orphan nuclear receptor that has
emerged as a novel therapeutic target for the treatment of type II diabetes and can-
cer. Here we describe non-clinical safety evaluation in rats and dogs of a novel and
selective ligand, JNJ-35815208, for ERRα as a potential anti-diabetic agent.
Following single oral administration in rats, mortality was observed at ≥ 1000
mg/kg. Repeated dose for 14 days to rats at 8, 40, and 200 mg/kg/day was well tol-
erated at doses up to 40 mg/kg. At 200 mg/kg/day, microscopic findings were ob-
served in the testes and epididymides, characterized by mild bilateral degenera-
tion/atrophy of the seminiferous tubules, minimal bilateral degeneration of the
germ cells, luminal cellular debris, and oligospermia in the epididymides. In the 4-
week rat study at 1, 6, or 40 mg/kg/day, there were no toxicological findings. In
dogs, following single-dose administration at 50 and 250 mg/kg, as well as during
the 5-day repeat dose at 150 and 250 mg/kg/day, the primary finding was emesis
noted at all dose levels. In the four-week dog study at 2, 16 and 75.5/100
mg/kg/day, microscopic findings were noted in the female reproductive organs and
the mammary glands at all doses. That resulted in reductions in the size of the
ovaries, uterus, and vagina as well as atrophy of the mammary glands. These effects
were associated with a persistent anestrus of the reproductive cycle. In male dogs,
multifocal atrophy of the glandular epithelium of the prostate gland was observed
at the mid- and high doses and small testes accompanied by mild degeneration of
the germinal epithelium and vacuolated Sertoli cells at the high dose. Erythroid
hypocellularity in the bone marrow was noted in males at 16 mg/kg/day and in
both sexes at 75.5/100 mg/kg/day, with corresponding decreases in RBC, hemoglo-
bin, hematocrit and reticulocyte counts at the high dose. Overall, these data suggest
ERRα may play a role in both male and female reproductive organs as well as in the
bone marrow.
1815 Humanized Mice: A New Animal Model for Risk Assessment
of Biologics.
K. E. Howard1,  X. H. Li1,  C. M. Gonzalez1 and J. A. Ragheb2. 1CDER/OTR, US
FDA, Silver Spring, MD; 2CDER/OBP, US FDA, Bethesda, MD. Sponsor: J.
Weaver.
Testing of biological drug products for safety and efficacy in animal models has
been difficult to assess because common models such as rodents, canines and non-
human primates do not necessarily share common biological receptors with hu-
mans. A new animal model, the humanized mouse, has recently emerged in wide-
spread use for infectious disease pathogenesis and vaccine testing research.
Humanized mice are made via ablation of the bone marrow followed by surgical
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implantation of human liver and thymic tissue underneath the kidney capsule and
CD34+ hematopoietic stem cell transplantation. Approximately 12-16 weeks fol-
lowing surgery, the mice have an engrafted functional human immune system,
achieve 20-25% humanization in peripheral blood and are suitable for studies. This
approach potentially offers the ability to test for efficacy and safety of drug products
in an in vivo model of the human immune system. If proven reliable via testing of
commercially available biologics, this animal model could be a powerful tool in
drug testing. 
In order to begin assessing the ability of this model to predict uniquely human im-
mune responses, we tested two forms of interferon-β (IFN-β) currently marketed
in the USA using clinically relevant dosing regimens and routes. Humanized mice
were initially given IFNβ-1a subcutaneously (sc) at doses 0.6 μg, 1.5 μg or 3.0 μg
once weekly or IFNβ-1b sc at doses of 2.5 μg, 12.5 μg or 25 μg three times weekly
for four weeks to determine if acute toxicity would result. A follow-up study using
doses of 0.3 μg of IFNβ-1a or 5 μg of IFNβ-1b for eight weeks assessed serum drug
levels, immunogenicity and immune responses. The results of these studies demon-
strated that (1) standard drug doses used in IFN-β studies in transgenic IFNβ mice
can be toxic to mice with a human immune system, as humanized mice can re-
spond to the drug in a clinically relevant manner; (2) presence of the appropriate
human receptors makes drug level assessment possible in humanized mice; and (3)
humanized mice respond immunologically to IFNβ.
1816 Evaluation of Antisense Oligonucleotides in Human Pbmcs
and Association of Release of IL-6 In Vitro to Constitutional
Symptoms.
H. S. Younis,  T. Machemer,  D. A. Norris and S. P. Henry. Preclinical
Development, ISIS Pharmaceuticals, Carlsbad, CA.
Oligonucleotide based therapeutics produce low-grade non-specific proinflamma-
tory responses that manifest as increased cytokine/chemokine production,
splenomegaly and/or lymphohistiocyte cell infiltrates in multiple tissues in animal
models of toxicity. In humans, antisense oligonucleotides are well tolerated and
may produce constitutional effects such as flu-like symptoms and injection site ery-
thema that are typically self-limiting. The objective of this research was to deter-
mine if in vitro cytokine production from human peripheral blood mononuclear
cells (PBMC) may be used to determine the potential for antisense oligonucleotides
(ASO) to produce constitutional symptoms in humans. Fresh PBMC (n=50
donors) were cultured with a selected list of ASOs (ISIS 104838, ISIS 113715, ISIS
325568 and ISIS 353512; 0-80uM) that have been evaluated in humans and pro-
duced a broad range of constitutional symptoms (none to moderate). By 24 hr of
treatment, the culture supernatant was harvested for measurement of cytokine (IL-
6 and IL-10) release. A sigmoidal Emax model was used to determine the Emax and
EC50 for the IL-6 response of each ASO. Dose-dependent increases in IL-6 were
consistently greater (0.3uM EC50) for ISIS 353512 (the ASO that produced the
most pronounced constitutional symptoms in humans) than for the other evalu-
ated ASOs (1.3-3uMEC50 range). The IL-6 Emax/EC50 ratio was 10-fold greater
for 353512 than the least responding ASO ISIS 104838, and provided the best
term for differentiating ISIS 353512 from the ASOs generating lesser responses.
The release of IL-10 was also greater for ISIS 353512 but was more difficult to
quantify given the lack of a dose response and relative low magnitude of change.
Collectively, the results suggest that human PBMC may be a viable in vitro model
to rank order ASOs for their potential to produce constitutional symptoms in hu-
mans and to investigate the mechanisms of ASO mediated proinflammation.
1817 Mechanistic Basis of the Species-Specific Complement
Activation in Cynomolgus Monkeys with Oligonucleotide
Treatment.
L. Shen1,  A. Frazer-Abel2,  P. C. Giclas2 and S. P. Henry1. 1Isis Pharmaceuticals,
Inc., Carlsbad, CA; 2National Jewish Health, Denver, CO.
Antisense oligonucleotide (ASO)-mediated alternative pathway of complement
(APC) activation is a common class effect in macaque monkeys at high doses.
Activation is due to the interaction between ASO and complement Factor H
(CFH), the inhibitory protein of the APC. Transient reduction of circulating CFH
protein is observed after each dosing in monkeys, and is correlated with peak ASO
plasma concentration. While common across multiple ASO sequences in macaque
monkeys, there is no evidence of APC activation in rodents, dogs, or humans. The
mechanistic basis of the sensitivity for macaque monkeys to ASO-induced APC ac-
tivation was studied using an in vitro model with serum from various species. Dose-
dependent increase in C3a was found in cynomolgus monkey serum after incuba-
tion with ISIS 104838, replicating the phenomena seen in vivo. No evidence of
complement activation was observed in human serum under the same conditions.
Serum collected from the new world monkeys, such as marmoset and squirrel mon-
keys, also showed no ASO-induced APC activation. There is 88% amino acid se-
quence homology found between cynomolgus and human CFH proteins, and
CFH gene single nucleotide polymorphisms (SNP) in human have been associated
with functional change of the protein. Therefore, the relative inhibitory effect of
cynomolgus and human CFH proteins in ASO-induced APC activation was evalu-
ated by supplementing the purified CFH proteins in cynomolgus serum followed
by ASO challenge. Dose-dependent inhibition in C3a formation was observed with
CFH from both species, however, the IC50 for the human CFH protein was about
3-fold lower than the monkey protein, suggesting stronger fluid phase inhibition to
its substrate. Collectively, the results suggest a species and possible strain-specific
complement effect with ASO in cynomolgus monkeys that likely due to the differ-
ence in regulatory function of the CFH protein and the result of interaction with
ASO.
1818 Perturbation of Autophagy by Basic Lipophilic Compounds:
Correlation of LC3 and P62 Abundance Employing U2OS-
GFP Cells.
R. L. Yafawi,  S. Lu,  B. Jessen and A. John-Baptiste. Drug Safety, Pfizer Global
Research and Development, San Diego, CA.
Many psychotropic compounds possess weakly basic lipophilic properties, with
lysosomal trapping being an important mechanism of their distribution. Weakly
basic lipophilic compounds accumulate in acidic intracellular organelles (i.e. lyso-
somes, endosomes, and phagosomes) via pH partitioning which may result in cyto-
toxicity. Multiple mechanisms regulate autophagy, with the lysosome being the
major component of the autophagic pathway. Recognizing the potential toxicity
caused by modulation of autophagy is critical, and understanding possible factors
attributing to its dysfunction is necessary. We hypothesized that psychotropic
agents with lysosomotrophic properties have the potential to disrupt autophagy. We
examined the link between lysosomal accumulation and autophagic dysfunction in
osteosarcoma cells (U2OS), by examining the effects of eleven weakly basic
lipophilic compounds known to accumulate in lysosomes. Their affects on au-
tophagy were determined by using specific autophagy markers (Microtubule
Associated Protein 1 Light Chain 3 (LC3), Sequestosome 1 (p62), and p70S6K).
LC3 and p62 were employed to measure either the induction of autophagy, or the
inhibition/perturbation of autophagolysosomal degradation. To gain greater insight
regarding the pathway regulating autophagy, p70S6K (phosphorylation) a down-
stream marker of the Mammalian Target of Rapamycin (mTOR) activity was ex-
amined. All compound treatments resulted in at least a 3-fold increase in LC3 im-
munofluorescence and p62 abundance relative to controls. Treatment with
compounds did not inhibit phosphorylation of p70S6K as observed via immuno-
fluorescent staining. The data presented indicates lysosomotropic compounds may
contribute to the perturbation of autophagy. However, mTOR activity did not
seem to play a part in altering the autophagic process.
1819 Effects of Tyrosine Kinase 2 Inhibitors on Megakaryocyte
Development.
H. Uppal1,  D. Danilenko1,  E. Harstad1,  J. Tarrant1,  E. Clarke2,  P. Dhawan1,
A. Kauss1,  B. McCray1,  D. Misner1 and J. Singh1. 1Safety Assessment, Genentech
Inc., San Ramon, CA; 2ReachBio LLC, Seattle, WA.
Background: Tyrosine Kinase 2 (Tyk 2) is a member of the Janus Activated Kinase
(Jak) family. Tyk 2 is associated with signaling of pro-inflammatory cytokines, IL-
12 and IL-23. Therefore, inhibition of Tyk 2 may potentially treat inflammatory
diseases such as inflammatory bowel disease (IBD), rheumatoid arthritis, and psori-
asis. Tyk 2 is also activated during thrombopoietin signal transduction, a pathway
necessary for megakaryocyte development and platelet production.  Studies were
conducted in vitro and in vivo with potent Tyk 2 inhibitors with varying levels of
JAK-family and general kinase selectivity to understand potential effects of these
Tyk 2 inhibitors on platelet development.
Methods: Tyk 2 inhibitors were evaluated in vitro in human, mouse and cynomol-
gus monkey megakaryocyte colony forming cell assays. General cytotoxicity was
evaluated by measuring cellular ATP levels. Direct effects of Tyk 2 inhibitors on
platelet function (aggregation), energetics (oxygen consumption), and viability
(ATP levels) were also evaluated in vitro.  The effect of Tyk 2 inhibitors on platelet
number was evaluated in short term (5-10 day) mouse studies. Tyk 2 and Jak
mRNA expression was evaluated in human megakaryocytes by quantitative PCR to
understand target expression.
Results: Tyk 2 inhibitors caused a comparable reduction in the number of colony
forming cells and the viability of megakaryocytes from human, mouse and non-
human primates.  There were no direct effects of Tyk 2 inhibitors on the aggrega-
tion capacity, oxygen consumption, or ATP levels of human platelets in plasma.
Tyk 2 inhibitors caused platelet reduction in mice. Tyk2 and Jak 1, 2, and 3 were
comparably expressed in human megakaryocytes.
Summary: The in vitro and in vivo findings demonstrate that platelet reductions
caused by multiple Tyk 2 inhibitors (with varying selectivity against other Jak fam-
ily kinases) are likely due to effects on megakaryocyte development.
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1820 Application of Canine Kidney Tissue Slices to Detect the
Toxicity of Prototypical Nephrotoxic Agents.
K. Kowalkowski,  M. Klapczynski,  D. J. Cugier,  E. A. Blomme,  W. R. Buck and
M. J. Liguori. Cellular and Molecular Exploratory Toxicology, AbbVie, Abbott Park,
IL.
Precision-cut renal tissue slices retain the multicellular, structural, and functional
features of their original organ and offer a more relevant approach to interrogate
toxicity compared to traditional cell-based in vitro systems. Here, we sought to
evaluate the utility of this system to detect toxicity induced by prototypical kidney
tubular toxicants, including cadmium chloride (CdCl2) and cisplatin. Kidneys
from male beagle dogs were cut into 300 μm slices, and cultured at 37°C in an O2
rich atmosphere for 24 to 48 h. Initial experiments optimized the culture condi-
tions to maintain viability to at least 48 h. The slices were immediately treated after
isolation with multiple doses of CdCl2, cisplatin, or vehicle. Multiple endpoints of
toxicity were evaluated including H&E stained sections, intracellular ATP content,
LDH release, total RNA integrity, and a novel endpoint for this type of system, kid-
ney injury molecule-1 (Kim-1) mRNA levels via in situ hybridization. There was a
significant elevation of LDH leakage at all doses tested for both compounds. The
intracellular level of ATP also declined significantly at 100 μM CdCl2 and 100 μM
cisplatin, indicative of substantial cellular damage. Mild to marked degeneration
and necrosis of renal tubules was evident beginning at 24 h upon microscopic ex-
amination. Kim-1, which has been previously demonstrated as a promising in vivo
kidney injury biomarker and is not normally expressed in normal tissue, was clearly
overexpressed in CdCl2 treated slices, but not vehicle treated slices, especially along
the tubular epithelium. In severely necrotic slices, Kim-1 was undetectable, likely
due to RNA destabilization as later confirmed using integrity assessments. These
data demonstrate that a renal slice in vitro model can be used to detect potent
nephrotoxicants and that Kim-1 should be further explored as a novel in vitro bio-
marker to monitor toxicity in renal slice systems.
1821 Investigation of Protein Kinase C Inhibitor-Induced Steroid
Hormonal Perturbation in Rat.
H. Schadt,  M. Schwald,  D. Ledieu,  U. Junker Walker,  F. Spence,  S. Chibout,
A. Wolf and F. Pognan. Preclinical Safety, Novartis Pharma AG, Basel, Switzerland.
Steroid hormones are crucial endogenous mediators synthesized and secreted into
the bloodstream by endocrine glands, such as the adrenal cortex and gonads. They
mediate a wide variety of physiological functions. Altered steroid hormone status
may affect the progression of various types of cancer. For instance, prepubertal
ovarectomy in BFU/Mna rats accelerated the growth of spontaneous thymoma,
which could be mitigated by intraperitoneal injection of estrogens. In azaserine-
treated rats, the rate of spontaneous pancreatic tumors in males is increased, while
orchidectomy reduced the incidence of such neoplasms compared to intact ani-
mals.
In a 104-week oral carcinogenicity study in rat with a protein kinase C inhibitor, a
treatment related increased incidence of pancreatic acinar adenoma in males and
thymoma in females were observed at dosages  100 mg/kg/day. Since changes in
steroid hormones are considered to potentially affect the development of pancreatic
and thymus neoplasia in rodents, a 2-week oral mechanistic follow-up study was
conducted in rats to investigate this hypothesis. For this purpose, a mass spectrom-
etry method previously developed in our lab for the quantification of steroid hor-
mones in plasma, was further applied to analyze 17 steroids in adrenal, testicular
and ovarian tissues. Aldosterone was increased in plasma and adrenals in treated
males with a concomitant and pronounced decrease of androstenedione and testos-
terone in plasma, adrenals and testes. In female rats, progesterone, together with
corticosterone, showed a trend towards increased concentrations in adrenals and
ovaries after treatment, whereas ovarian androstenedione and estrogen levels tended
to be reduced. This correlated with a circulating luteinizing hormone decrease in
both sexes. In conclusion, the reduction in ovarian estrogen levels might be con-
nected to the thymus neoplasias of the previous study. As androgen levels were
found to be decreased, a direct connection to the previously reported pancreatic tu-
mors is unlikely.
1822 Comparison of In Vivo Central Corneal Thickness (CCT)
Measurements in Dogs, Rabbits, and Nonhuman Primates
Using a Handheld Ultrasound Pachymeter or Specular
Microscope.
M. Vézina1,  S. Wise1,  K. Tenneson1 and M. Bussières2. 1Charles River, Montréal,
QC, Canada; 2V&O Services, St. Lazare, QC, Canada.
The cornea is responsible for 2/3 of light refraction in the eye and thus is a critical
tissue for clear vision. Alterations in corneal thickness have a direct effect on visual
acuity and can be caused by alterations in the function of the corneal endothelium,
aqueous humor composition, drainage or formation rate, or in the glands produc-
ing the tear film.  There has been an increase in the number of topical ocular thera-
peutics as this method is deemed one of the simplest clinically. As the formulations
are in direct contact with the cornea, it can be an intended or unintended target tis-
sue. In non-clinical topical ocular studies, serial in-vivo measurement of corneal
thickness can provide a rapid empirical insight into the health of the cornea during
study conduct and whether or not any changes in corneal thickness are reversible.
There are several ways to obtain central corneal thickness measurements, two of
which are ultrasound pachymetry (UP) that requires contact with the corneal sur-
face and specular microscopy (SM) which is a non-contact procedure. The data pre-
sented represent background thickness measurements and precision between the 2
methods. In most cases, animals required sedation in order to reduce eye move-
ments. CCT measurements by UP and SM were: dogs (n=10) 548.5±33 μm and
583.5±27 μm; rabbits (n=12) 378±27 μm and 394±16 μm; NHPs (n=10) 422±21
μm and 440±19 μm. Direct comparison showed a difference of 6% between the 2
methods for dogs, 4% for rabbits and 4% for NHP, with the SM values consistently
higher. Precision as determined by 2 separate measurement occasions in dogs was
0.6% for SM and 0.1% for UP.  In conclusion, both specular microscopy and ul-
trasound pachymetry provide reproducible, precise CCT data in dogs, rabbits and
non-human primates allowing for repeat measures during the course of a study
when corneal changes are of concern. Care should be taken for interpretation if
data are acquired using both methods considering the 4-6% lower results using UP.
1823 In Vivo Evaluation of the Corneal Endothelial Cell Layer
Using Specular Microscopy.
K. Tenneson and M. Vézina. Ocular and Neuroscience, Charles River, Montréal,
QC, Canada.
The corneal endothelium is a monolayer of specialized cells whose primary physio-
logical function is to maintain the health and transparency of the corneal stroma. In
preclinical ocular and non-ocular studies, pharmacological and/or toxicological ef-
fects of a test compound may produce changes in the structure and function of the
corneal endothelium. Additionally, intraocular surgery (including induced disease
models) or implanted devices can compromise the endothelium and cause corneal
edema. Specular microscopy (SM) enables a rapid, minimally invasive, direct evalu-
ation of the cornea, and can provide supplemental information on corneal en-
dotheliopathies, alone or in combination with direct slit-lamp examination on pre-
clinical toxicology studies. SM provides three primary endpoints: number of
cells/unit area (density), shape of cells (pleomorphism) and size of cells (poly-
megathism). When the endothelium is disrupted, there can be an overall shift in
the number of cells, proportion of cell shapes (pleomorphism) and sizes (poly-
megathism). In order to characterize the endothelial layer in species regularly used
on ocular toxicology studies, dogs, rabbits and non-human primates (NHP) were
subjected to SM. Overall, cell density was similar across species (rabbits: 2769
cells/mm2; dogs: 2635 cells/mm2; NHPs: 3058 cells/mm2). Normal endothelial
cells have a hexagonal shape, and account for the majority of cells (rabbits: 75%;
dogs: 65%, NHPs: 71%). Average cell sizes were 364 um2 for rabbit, 384 um2 for
dog, and 328 um2 for NHP. In conclusion, SM is a sophisticated tool that can
complement the standard endpoints performed on specialized ocular preclinical
studies and the data presented provides background data in rabbits, dogs and NHPs
to facilitate the recognition of compound-related changes.
1824 Therapeutic Effect of MG132 on Diabetic Cardiomyopathy
Is Associated with the Suppression of Proteasome Activities:
Roles of Nrf2 and NF-κB.
W. Sun1,  Y. Fu2 and L. Cai1. 1University of Louisville, Louisville, KY; 2Jilin
University, Changchun, China.
MG132, a proteasome inhibitor, can up-regulate nuclear factor erythroid 2-related
factor 2(Nrf2)-mediated anti-oxidation and down-regulate nuclear factor-(NF-
)κB-mediated inflammation. The present study was to define whether through
above two mechanisms MG132 can provide a therapeutic effect on diabetes-in-
duced cardiomyopathy. To this end, transgenic OVE26 type 1 diabetic mice were
used. OVE26 mice develop hyperglycemia at 2 – 3 weeks after birth and exhibit al-
buminuria and cardiac dysfunction at 3 months of age. Therefore starting at 3
months of age OVE26 diabetic mice were treated intraperitoneally with MG132 at
10 μg/kg body-weight daily for 3 months. At 3 and 6 months of age, cardiac func-
tion was measured with M-mode echocardiography. At 6 months, cardiac tissues
were subjected to pathological and biochemical examination. OVE26 diabetic
mice, but not MG132-treated OVE26 diabetic mice, showed significant cardiac
dysfunction, including increased left ventricular systolic diameter and wall thick-
ness and a decreased left ventricular ejection fraction with an increase of heart
weight/tibia length ratio. Hearts of OVE26 diabetic mice exhibited structural de-
rangement and remodeling (fibrosis and hypertrophy). In OVE26 diabetic mice,
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there was also increased cardiac oxidative damage and inflammation. All of these
pathogenic changes were reversed by MG132 treatment, which is associated with a
significant suppression of diabetic increase in proteasome activity. In addition,
MG132 treatment also significantly up-regulated Nrf2 expression and transcrip-
tion (shown by increased expression of Nrf2 down-stream antioxidant genes) and
down-regulated Iκ-B expression and NF-κB nuclear accumulation. These results
suggest that MG132 provided a therapeutic effect on diabetic cardiomyopathy in
OVE26 diabetic mice possibly via the up-regulation of Nrf2-dependent anti-oxida-
tion and the down-regulation of NF-κB-mediated inflammation.
1825 MG132 Prevents the Progression of Diabetes-Induced
Pathological Damage to Aorta Is Associated with Its Up-
Regulation of Nrf2 and Its Down-Stream Antioxidant
Proteins.
X. Miao1, 2,  G. Su2 and L. Cai1. 1University of Louisville, Louisville, KY; 2Jilin
University, Changchun, China.
Endothelial damage and dysfunction are manifested in diabetic cardiovascular com-
plications. Nuclear factor-erythroid 2-related factor 2 (Nrf2) is one of the most im-
portant cellular defense mechanisms against oxidative stress by up-regulation of
several antioxidants, phase II detoxifying enzymes, and other proteins that detoxify
xenobiotics and neutralize reactive oxygen and/or nitrogen species. Deletion of
Nrf2 gene significantly enhances the susceptibility of cardiomyocytes to high-level
glucose-induced reactive oxygen species generation and cell death. The present
study was to define whether induced Nrf2 by MG132 can provide a therapeutic ef-
fect on diabetes-induced aortic pathogenic changes. To this end, transgenic OVE26
type 1 diabetic mice and age-matched control mice were used. OVE26 mice de-
velop hyperglycemia at 2 – 3 weeks after birth and exhibit renal and cardiac dys-
function at 3 months of age, suggesting the induction of diabetic complications.
Therefore starting at 3 months of age, OVE26 diabetic mice were intraperitoneally
treated with MG132 at 10 μg/kg body weight daily for 3 months. At the end of
MG132 treatment, aortas from these mice were morphologically and immunohis-
tochemically examined. Significant increases in the wall thickness and structural
derangement of aorta were found in OVE26 diabetic mice, which was accompa-
nied by significant increases in aortic oxidative and/or nitrosative damage (4-HNE
as lipid peroxidation and 3-NT as protein nitration), inflammation (TNF-α
andPAI-1), and remodeling (CTGF and TGF-β1). These pathological changes
were not observed in MG132-treated OVE26 diabetic mice, which was also associ-
ated with a significant increase of aortic Nrf2 expression and transcription func-
tion. These results suggest the therapeutic effect of MG132 on diabetes-induced
aortic pathogenic damages and tis association with Nrf2 expression and function.
1826 Characterization of mIR-208a Responses in Isoproterenol-
Induced Cardiac Injury in Sod2+/- and C57BL/6J Mice.
L. Liu. Pfizer, San Diego, CA.
The present investigation aimed to characterize miR-208a as a putative biomarker
for early cardiac injury in isoproterenol (ISO)-induced acute myocardial damage in
mice and to investigate potential strain-dependent effects in response to ISO ad-
ministration. Plasma from age-matched male C57BL/6J and Sod2 +/- mice treated
with a single intraperitoneal (IP) administration of ISO was collected for measuring
cardiac troponin I (cTnI) and miR-208a at 3, 6, and 24 hours post injection.
Administration of ISO led to increases in both cTnI and miR-208a at all time
points tested. However, the magnitude of increase and the temporal release profiles
of these biomarkers were different between the two strains. In C57BL/6J mice,
cTnI and miR-208a tracked with each other in both magnitude and time, the high-
est values were seen at 3 hours. By contrast, in Sod2+/- mice, the magnitude of
miR-208a was much greater than that of cTnI with the highest values of both bio-
markers observed at 6 hours. Similar to C57BL/6J mice, the temporal profile of
miR-208a followed that of cTnI in Sod2+/- mice. Histopathologic examination of
hearts treated with ISO revealed myocardial degeneration at ≥ 3 hours in
C57BL/6J mice and ≥ 6 hours in Sod2+/- mice which correlated with the highest
concentration of the biomarkers in each strain. The higher systemic exposure of
ISO in C57BL/6J mice compared to that in Sod2 +/- mice may have contributed to
the observed earlier response in C57BL/6J mice compared to Sod2 +/- mice.
1827 Polybrominated Diphenyl Ethers Exposure and Intrauterine
Growth Restriction: A Case-Control Study in Chinese
Newborns.
Y. Zhang1,  Y. Zhao1,  H. Ao1 and X. Meng2. 1Fudan University, Shanghai, China;
2Tongji University, Shanghai, China. Sponsor: Z. Liu.
BACKGROUND: Intrauterine growth restriction (IUGR) is associated with peri-
natal morbidity and mortality. It has multifactorial etiology. Along with malnnutri-
tion and psychosocial, environmental pollutants, including polybrominted dipheny
ethers(PBDEs), have aslo been considered to be involved in the etiology of this dis-
ease. 
OBJECTIVES: This case-control study was performed to assess maternal–fetal ex-
posure to PBDEs and investigate whether in utero PBDEs exposure is associated
with IUGR. 
METHODS: A total of 29 newborn-mother pairs residing in Wenzhou were en-
rolled in this study during December 2010 and February 2011. Maternal blood
and umbilical cord blood (UCB) samples were collected and analyzed for PBDEs
by the method of Gas chromatography–mass spectrometry (GC-MS). Conditional
logistic regression and Spearman correlation were used to analyze the association
between PBDEs exposure and IUGR.
RESULTS: All PBDE congeners in serum were detected except for BDE 138, 183,
and 190. BDE 209 was the most abundant congener followed by BDE 207, 208,
and 66, with the detection frequencies of 50%, 83%, 74%, and 74%, respectively.
The concentrations of BDE 66, BDE 209, BDE 183- 209 and 19 PBDEs in UCB
are significantly higher in newborns with IUGR than those in controls. BDE 183-
209 and 19 PBDEs levels in UCB were inversely associated with birth weight and
Quetlet’s index (p=0.008, 0.020 respectively). After controlling for potential con-
founders, dose-response relationships were observed between IUGR and BDE 183-
209 and 19 PBDEs levels in UCB. 
CONCLUSION: Only one UCB sample from the control group did not detect
PBDEs which might indicated that newborns in China were ubiquitously exposed
to PBDEs. Significantly higher PBDEs levels were detected in IUGR cases com-
pared with those in controls. In utero PBDEs (especially high-brominated BDE
congers) exposures were associated with IUGR in a dose-dependent manner.
Prenatal PBDEs exposure may be a risk factor for IUGR.
1828 Maternal and Child Polybrominated Diphenyl Ether (PBDE)
Levels in US National Children’s Study (NCS) Formative
Research.
A. J. Schecter1,  D. Cherry2,  L. S. Hynan3,  D. Cheng1,  N. Imran1,
M. Hommel1,  K. Kannan4,  L. Wang4,  S. H. Yun4,  N. Thiex5,  B. Specter5,
J. Moye6, 7, 8 and L. S. Birnbaum9, 8, 10. 1The University of Texas School of Public
Health, Dallas, TX; 2The University of Texas, Tyler, TX; 3The University of Texas
Southwestern Medical Center, Dallas, TX; 4New York Health Department, Albany,
NY; 5South Dakota State University, Brookings, SD; 6NCS, Bethesda, MD; 7NICHD,
Bethesda, MD; 8NIH, Bethesda, MD; 9NIEHS, Research Triangle Park, NC; 10NCI,
Bethesda, MD.
The NCS is a prospective health study of 100,000 children (birth to 21 years) and
their mothers. We report on a nested, formative study involving measurement of
lipid soluble persistent PBDE flame retardants. PBDEs have been associated with
various health effects. This study involved 20 mother-child pairs; 20 samples each
of maternal third trimester blood, maternal blood at birth, cord blood, and breast
milk were tested individually for nine PBDE congeners. Total PBDE was the sum
of nine PBDE congeners when quantifiable. Some PBDE congeners were detected
in maternal blood samples and breast milk samples at all time points. In infant cord
blood samples, only BDE 47, BDE 100, BDE 99 and BDE 153 were detected in
≥40% of samples. BDE 183 and BDE 209 levels were below detectable levels in all
samples. Lipid normalized PBDE levels were higher in maternal birth serum and
one month postpartum breast milk than in infant cord blood. Across all congeners,
medians for maternal third trimester plasma were highest. Further investigation of
PBDE compartmentalization during the prenatal and postpartum periods is war-
ranted to understand fetal and infant exposure. The views expressed in this abstract
are those of the authors and do not necessarily reflect the views of the National
Institutes of Health or the Department of Health and Human Services. Funded by
the Eunice Kennedy Shriver National Institute of Child Health and Human
Development, contracts number HHSN 275201100004C and
HHSN275200800035C.
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1829 Effect of Body-Weight Loading onto the Articular Cartilage
on the Occurrence of Quinolone-Induced Chondrotoxicity
in Juvenile Rats.
K. Goto,  M. Imaoka,  M. Goto,  I. Kikuchi,  T. Suzuki,  T. Jindo and
W. Takasaki. Medicinal Safety Research Laboratories, DaiichiSankyo Co., Ltd., Tokyo,
Japan.
Quinolone antibacterial agents have been reported to induce chondrotoxicity in ju-
venile animals, and the mechanism has not yet been clarified. We have reported
that gene expression of tumor necrosis factor receptor superfamily, member 12a
(Tnfrsf12a, cell death-related gene), prostaglandin-endoperoxide synthase 2 (Ptgs2,
inflammatory response-related gene), plasminogen activator, urokinase receptor
(Plaur, stress response-related gene), and matrix metalloproteinase 3 (Mmp3, prote-
olysis-related gene) was involved in the induction of cartilage lesions of the distal
femoral articular cartilage in juvenile rats treated orally with ofloxacin (OFLX). In
the present study, the effect of body-weight loading onto the articular cartilage on
the occurrence of the cartilage lesions was investigated in male juvenile Sprague-
Dawley (SD) rats given OFLX orally once at 900 mg/kg. Just after dosing of
OFLX, hindlimb unloading was performed for 0 h, 2 h, 4 h, and 8 h by a tail-sus-
pension method. Animals were sacrificed at 8 h post-dose, and then the distal
femoral articular cartilage was subjected to a histological examination and an inves-
tigation for gene expression of Tnfrsf12a, Ptgs2, Plaur, and Mmp3 by qRT-PCR
analysis. As a result, cartilage lesions and up-regulations of these 4 genes that were
seen in rats without the tail suspension were not observed in rats with the 8-h tail
suspension, and a tendency to decrease in the incidence of the cartilage lesions and
the gene expression was noted in a tail-suspension time dependent manner. Our re-
sults clearly indicate that body-weight loading onto the cartilage is necessary to in-
duce cartilage lesions and gene expression of Tnfrsf12a, Ptgs2, Plaur, and Mmp3 in
juvenile rats treated with OFLX.
1830 Effects of Maternal Exposure to Phthalates and Bisphenol A
on Neonates.
A. M. Vetrano1,  F. E. Archer1,  S. W. Marcella2,  B. Buckley3,  D. Wartenberg1, 3,
M. G. Robson3, 4,  L. Wang5,  D. Q. Rich5 and B. Weinberger1. 1UMDNJ-Robert
Wood Johnson Medicine School, New Brunswick, NJ; 2UMDNJ-School of Public
Health, Piscataway, NJ; 3Environmental and Occupational Health Sciences Institute -
UMDNJ and Rutgers University, Piscataway, NJ; 4School of Biological and
Environmental Sciences - Rutgers University, New Brunswick, NJ; 5Univ. of Rochester,
Rochester, NY.
RATIONALE: Phthalate and bisphenol A (BPA) metabolites may have anti-andro-
genic and pro-inflammatory effects. We hypothesized that maternal exposure to
phthalates and BPA in pregnancy is associated with decreased anogenital index in
infants and shortened gestation. 
METHODS: Urinary concentrations of phthalate and BPA metabolites were meas-
ured from 72 pregnant women enrolled in a high-risk obstetric clinic, at the last
clinic visit prior to delivery, using high-performance liquid chromatography–tan-
dem mass spectrometry.  Anogenital index (AGI) was calculated by normalizing
anogenital distance to weight. Gestational age was determined by either sono-
graphic dating or date of implantation. Using linear regression models, we esti-
mated the change in gestational age and anogenital index associated with each in-
terquartile range (IQR) increase in phthalate and BPA metabolite concentration.
RESULTS: IQR increases in urinary mono(2-ethyl-5-hydroxyhexyl) phthalate
(MEHHP) and total BPA concentrations were associated with 4.2 and 1.1 day de-
creases in gestation, respectively. When stratifying by gender, these alterations were
found only in male infants. Levels of monoethyl phthalate (MEP) were associated
with lower AGI in males, but this difference (0.2 mm) is not likely to be clinically
significant.
CONCLUSIONS: MEHHP and total BPA were associated with small reductions
in gestation, and MEP with a small reduction in AGI, with effects only in males.
Increased sensitivity of males to the effects of phthalates and BPA may be related to
the roles of androgen precursors in both genital differentiation and in the initiation
of labor.  
Supported by NIH P30ES005022, R21HD058019 and NJ Dept. of
Environmental Protection
1831 Intravenous Dose Range-Finding Toxicity of
Allopregnanolone (ALLO) in Neonatal Dogs.
K. L. Steinmetz1,  L. Rausch1,  M. Patrick1,  J. M. Brune1,  S. H. Mellon2 and
P. S. Terse3. 1SRI Intl, Menlo Park, CA; 2Department OB GYN, University of
California San Francisco, San Francisco, CA; 3NCATS, NIH, Bethesda, MD.
Treatment with allopregnanolone (ALLO), a GABA-ergic neurosteroid, may be
useful treating Niemann-Pick Type-C (NP-C) disease. NP-C is a rare autosomal re-
cessive neurodegenerative disease caused by genetic mutations, resulting in lysoso-
mal accumulation of unesterified cholesterol and glycolipids. Treatment of neonatal
NIH NPC1 mice with a single sc dose of ALLO resulted in increased life span,
onset delay of neurological symptoms, survival of cerebellar Purkinje and granule
cell neurons, and reduced cholesterol and ganglioside accumulation. Previous toxi-
city studies with ALLO suggested that the presence of isoflurane anesthesia may
have contributed to a relatively low MTD of <3 mpk bolus intravenous (IV) injec-
tions to unconscious neonatal Beagle dogs. The current study determined the toler-
ability of ALLO administered IV with extended infusion or bolus injections in con-
scious pups. Indwelling IV catheters were placed under isoflurane anesthesia.
Animals were allowed to recover from anesthesia for ALLO/vehicle treatment. Pups
(1-2 per dose, age: postnatal day (PND) 17-PND59) received vehicle 20% hydrox-
ypropyl β-cyclodextrin (HPBCD) up to 10 hr with no notable clinical signs. After
3 days washout between dose administration, pups received up to 20 mpk (7.5, 15,
and 20 mpk) ALLO by IV infusion, which extended up to 4-8 hr. Dose-dependent
sedation was observed at all IV infusion dose levels. After determining that ALLO
was well tolerated by extended infusion, bolus IV doses were escalated up to 50
mpk in 1-2 pups (age range PND27-59) per dose level. Hematology and clinical
chemistry values were within normal ranges. In summary, ALLO can be adminis-
tered as IV bolus or extended infusion (>8hr) to conscious neonatal dogs. Pups tol-
erated ALLO in 20%HBCD vehicle up to the highest doses tested; 20 mpk
(PND17) by infusion and 50 mpk (PND59) by bolus. Conscious neonatal pups
appear to tolerate higher doses of ALLO as compared with ALLO administered
under isoflurane anesthesia suggesting additive and/or synergistic sedative effects.
1832 Oxidative and Genetic Damage in School Children from a
Heavily Polluted City.
I. Alvarado-Cruz1,  M. Sánchez-Guerra1, 2,  L. Hernández-Cadena3,  L. Espinosa-
Juárez1,  N. Pelallo-Martínez1,  L. Rafael-Vázquez1,  R. Angulo-Olais1,
M. J. Solís-Heredia1,  A. De Vizcaya-Ruiz1,  V. Mugica4 and B. Quintanilla-Vega1.
1Toxicology Department, CINVESTAV-IPN, Mexico City, Mexico; 2Public Health
School, Harvard University, Boston, MA; 3INSP, Cuernavaca, Morelos, Mexico;
4UAM-Azcapotzalco, Mexico City, Mexico.
Ecatepec County is one of the most industrialized, populated and polluted counties
in Mexico. Particulate matter (PM10 and PM2.5) concentrations in this area are fre-
quently above the air quality Mexican standards. Other contaminants, such as lead
(Pb) are present. PM and Pb are associated with adverse effects, including oxidative
and genetic damage. A cross-sectional study was conducted in 185 schoolchildren
(7-10 years of both genders) from two regions of Ecatepec; an industrialized area
with heavy traffic (Zone 1; n=94) and a zone with moderate vehicular traffic (Zone
2; n= 91). PM was obtained by air sampling, blood lead (PbB) levels were deter-
mined by atomic absorption spectroscopy, plasma malondialdehyde (MDA) as ox-
idative stress indicator by colorimetry and the DNA damage in mononuclear cells
by the comet assay; parents answered a structure questionnaire. PM10 and PM2.5
levels, as well as the organic and elemental carbon content (CO and CE, respec-
tively) were higher in Zone 1. Children from this zone showed significantly higher
PbB (62% showed >5 μg/dL) and MDA levels, but similar DNA damage compared
to Zone 2 children. We observed positive associations between PM10 and PM2.5 and
OTM values (p<0.05); while a positive association between CO in PM10 and PM2.5
and OTM (p<0.05) was also found. MDA levels were associated with PM10, PM2.5
and PbB levels, as well as with CO and CE content in both particles (p<0.05).
Results suggest that children from Ecatepec are exposed to high PM concentrations
and that CO and CE content in PM as well as Pb are involved in the genetic and
oxidative damages observed in children living in this highly polluted area.
Supported by CONACyT-Mexico (Grant #106034).
1833 Developmental Immunotoxicity Testing for Hazard
Identification.
E. C. Tonk1, 2,  A. Verhoef1,  E. R. Gremmer1,  H. van Loveren1, 2 and
A. H. Piersma1, 3. 1RIVM, Bilthoven, Netherlands; 2Health Protection, RIVM,
Bilthoven, Netherlands; 3Toxicogenomics, University, Maastricht, Netherlands.
The inclusion of parameters to assess developmental immunotoxicity (DIT) is an
important and critical step forward in regulatory toxicity testing of chemicals. We
have performed multiple juvenile and generation studies in rats using various study
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designs and test compounds (methylmercury, di-octyltin dichloride (DOTC), di(2-
ethylhexyl) phthalate, alcohol, nonylphenol) and the results demonstrate the rela-
tively high sensitivity of immune parameters compared to developmental parame-
ters. Specifically, functional immune parameters appeared affected at relatively low
doses. An expanded T cell dependent antibody response (TDAR) parameter set and
evaluation of LPS-stimulated NO and TNF-α production by adherent splenocytes
were identified as sensitive functional immune parameters. For example, in a juve-
nile exposure study DOTC affected KLH-induced lymphocyte proliferation at
BMD 0.29 mg/kg whereas body weight was affected at 57.7 mg/kg. In a generation
study design, alcohol affected splenocyte proliferation at BMD 0.49 % whereas de-
velopmental delay was noted at 1.2 %. These results support the OECD TG 443
extended one-generation reproductive toxicity study (EOGRTS) guideline, includ-
ing its cohort for DIT assessment. It provides substantial insight in the immuno-
toxic potential of chemical. Our research thus identified complementary immune
parameters as potentially useful additions to the EOGRTS guideline which can be
easily added to the study protocol. Furthermore, our research demonstrated the rel-
ative sensitivity of the juvenile immune system (postnatal day 10-50) and the sig-
nificance of the juvenile window in DIT testing. The comparisons of various sce-
narios have provided important lessons about parameter assessment and exposure
protocols, which will feed into the definition of a preferred approach to regulatory
developmental immunotoxicity testing for chemicals.
1834 Feasibility of Continuous Intravenous Infusion in
Postweaning Juvenile Rats.
L. Allais,  J. Briffaux,  C. Gerhardy,  P. Vignand,  S. David and P. Fant. Ricerca
Biosciences SAS, St. Germain sur l’Arbresle, France.
Juvenile animals are increasingly requested in nonclinical safety studies to con-
tribute to the commercialization of pediatric therapeutics. The main objectives
when conducting Pivotal Toxicology studies in juvenile animals are to ensure a
complete evaluation of potential adverse effects of the drug at the relevant target pe-
diatric age and additionally to detect any potential delayed toxicity during animal
development, regardless of the treatment period duration. The rat is still the most
commonly used species in Juvenile Toxicology studies, hence enabling extensive
background data starting from birth.
Various administration routes have been investigated in the juvenile rat and are
mostly technically feasible from the early days after birth. However, increasing chal-
lenging requirements in terms of dosing procedures implies that juvenile study de-
signs need to be adapted taking into account animal welfare recommendations. 
We investigated the suitability of a continuous intravenous infusion method for use
in a juvenile toxicity study in pups surgically implanted on Post-Natal Day (PND)
21. A polyurethane catheter was implanted into the posterior vena cava via the
femoral vein and then tunneled subcutaneously to exit at the nape of the neck. The
pups were continuously infused (24 h/day) with sterile physiological saline for 4
weeks and all possible technical challenges with respect to the growth of the animal
were investigated. We assessed standard toxicology endpoints (including clinical
observations, growth, food intake and clinical pathology) and compared the results
with background data from non infused animals at a similar age.
The results of the present evaluation demonstrated that continuous intravenous in-
fusion using adapted equipment is feasible in young pups and did not interfere with
the animal growth from PND 21 to the age of 7 weeks.
1835 Lung Function in Children Chronically Exposed to Arsenic
in Drinking Water.
R. Recio-Vega1,  E. Olivas-Calderon1,  T. Gonzalez-Cortes1,  C. Gonzalez-De
Alba1,  G. Ocampo-Gomez1,  J. A. Gandolfi2 and R. Lantz3, 4. 1Environmental
Health, University of Coahuila, Torreon, Mexico; 2Pharmacology and Toxicology,
College of Pharmacy, University of Arizona, Tucson, AZ; 3Cell Biology and Anatomy,
University of Arizona, Tucson, AZ; 4Southwest Environmental Health Science Center,
University of Arizona, Tucson, AZ.
Introduction
Arsenic level in drinking water at the Comarca Lagunera in Mexico surpassed (50-
120 μg/l) the permitted levels by the Mexican Official Norms (25μg/l) due to the
intense over-exploitation of the aquifers.
Arsenic exposure through drinking water has been associated with different cancers.
Additionally negative effects over human lung function have been described.
Experimental animal studies have reported pathological changes in pulmonary de-
velopment as well as bronchial hyperresponsiveness and disturbances in pulmonary
tissue repair proteins. Clinical human studies have shown diminishment in spiro-
metric values and higher bronchiectasis and chronic obstructive pulmonary disease
frequencies. These findings have been reported in adults but not in children.
Objective
To evaluate the relationship between lung function and arsenic levels in children
chronically exposed to arsenic.
Results
At present, 390 children have been included. The mean age is 9.0 years and 98%
have lived in the community all their life. 77.6 % of the children were conceived in
their current communities. From the studied population, 6.3% reported chronic
cough for more than 2 years and 2.9% for 7-12 years. In addition, 12.1% have
been treated for bronchiolitis. The mean urinary arsenic level was 155.4 ppb (range
of 14.6-893.8). In all subjects spirometric values of FVC, FEV1 and FEV1/FVC
ratio were lower with respect to reference values.
Conclusion
A high incidence of lung diseases and a reduction in the lung function were
recorded in children chronically exposed to arsenic in drinking water.
1836 Blood and Urine Cadmium Concentrations and
Micronucleus Frequency in Buccal Epithelium from
Children in Three Populations in Yucatan, Mexico.
N. Pérez-Herrera1,  J. Perera-Rios1,  A. Rodriguez-Uc1,  J. Gordillo-Mena1,
J. Uicab-Ventura1,  J. Alvarado-Mejía1,  L. González-Navarrete1,  L. Fargher2,
R. Moo-Puc3,  L. Yañez-Estrada4 and F. Arcega-Cabrera5. 1Faculty of Medicine,
Autonomous University of Yucatán, Mérida, Mexico; 2Human Ecology Departament,
CINVESTAV, Mérida, Mexico; 3Research Unit, Mexican Institute of Social Security,
Mérida, Mexico; 4Faculty of Medicine, Autonomous University of San Luis Potosí, San
Luis Potosí, Mexico; 5Faculty of Chemistry, National Autonomous University of
Mexico, Mérida, Mexico. Sponsor: B. Quintanilla-Vega.
Buccal epithelium represents the first boundary against inhalation or ingestion of
toxicants. Micronucleus (MN) tests of buccal ephitelium have been effectively used
in epidemiological studies in adult populations exposed to genotoxicants; yet, its
use in juvenile populations has been limited. A transversal study was conducted in
children from the cities: Merida, Progreso and Ticul, in the Yucatan Peninsula to
evaluate the MN frequency in exfoliated buccal epithelium and cadmium concen-
trations in blood and urine from children exposed to different scenarios. Ten chil-
dren (6 and 8 years of both genders) were selected from each city (n=30). MN fre-
quency was analyzed by microscopy after a Shift staining and Cd concentrations by
atomic absroption spectroscopy. MN frequency was similar in the three popula-
tions (p=0.7451), Merida 0.33 (0-1.33/1000 cells), Progreso 0.33 (0-1/1000 cells),
and Ticul 0.66 (0-2.33/1000 cells). Cadmium levels in urine were higher (p=0.043)
in children from Merida (State Capital) compared to the other cities (1.30 vs 1.09
and 0.73 ug/l). However, urine Cd concentrations did not correlate with MN fre-
quencies (p=0.505). Blood Cd levels were similar in the three populations
(p=0.6021), and a significant and positive correlation between MN frequency and
blood Cd levels was observed (rs =0.4583, p=0.0484). Our preliminary results em-
phasize the importance of conducting biomonitoring of metals and early detection
of genotoxic effects in children. Supported by CONACYT-México, Grant #
FOSEC-Salud 139738.
1837 Orellanine, a Bipyridyl Mycotoxin, Induces Apoptosis in a
Cell Culture Model of Parkinson’s Disease.
P. Anantharam1,  B. Taiwo1,  J. Luo2,  V. Anantharam2,  A. Kanthasamy2,
A. G. Kanthasamy2,  E. Whitley3 and W. K. Rumbeiha1. 1VDPAM, Iowa State
University, Ames, IA; 2Biomedical Sciences, Iowa State University, Ames, IA;
3Pathology, Iowa State University, Ames, IA.
Parkinson’s disease (PD) affects over one million people in the U.S. alone and more
than 6 million people worldwide. Potential risk factors for PD include aging, ge-
netic alterations, and environmental neurotoxicant exposures. Although incom-
pletely understood, the etiology and pathological mechanism of PD is characterized
by a profound degeneration of dopaminergic neurons in the substantia nigra pars
compacta. The majority of PD patients do not know the specific trigger of their dis-
ease although exposures to environmental factors are believed to contribute to or
influence the development and progression of the disease. We have identified a
novel environmental bipyridyl mycotoxin similar to Paraquat (PQ) and MPTP.
Like PQ and MPTP, orellanine (OR) is a bipyridyl molecule and we hypothesized
that OR will induce apoptosis in N27 cells. Here, we investigated the neurotoxic ef-
fects of OR (3,3’,4,4’-tetrahydroxy-2,2’-bipyridine-1,1’-dioxide) on mesencephalic
dopaminergic neuronal cell line (N27 cells), an in vitro model of PD. Using an
MTT assay, OR induced a dose-dependent decrease in the viability of N27 cells
with an EC50 of 44.9 ± 15.3 μM (six times lower than that of PQ or MPP+), sug-
gesting that OR is more potent than PQ or MPP+ on N27 cells. To explore the
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mechanisms of cell death, we investigated the effect of OR on mitochondrial-de-
pendent apoptotic pathway in N27 cells. The results showed that OR (100 μM) in-
duces mitochondrial cytochrome C release followed by sequential activation of cas-
pase-9 and caspase-3, and subsequently DNA fragmentation in a dose- and
time-dependent fashion, with peak activation occurring 12 h after OR exposure.
Co-treatment with caspase-3 specific inhibitor, Z-DEVD-FMK (50 mM) signifi-
cantly attenuated OR-induced caspase-3 and DNA fragmentation. Together, this
study demonstrates that OR induces cytotoxicity in mesencephalic N27 dopamine-
producing cells via the caspase-3-dependent apoptotic pathway.
1838 Trichostatin A (TSA), a Histone Deactylase Inhibitor,
Mediates Dopaminergic Cell Death via an NF-κB Dependent
Mechanism.
V. Lawana,  N. Singh,  G. Huh,  P. Chandramani-Shivalingappa,  H. Jin,
V. Anantharam,  A. G. Kanthasamy and A. Kanthasamy. Biomedical Science, Iowa
State University, Ames, IA.
Trichostatin A (TSA) is a potent, reversible inhibitor of histone deacetylase
(HDACi) that functions through hyperacetylation of core histones. A previous
study from our lab has linked histone hyperacetylation to dopaminergic neurode-
generation. TSA has been shown to induce profound dopaminergic neuronal cell
death, but the cellular mechanisms underlying HDACi-mediated apoptotic cell
death remains unclear. Herein, we show that TSA treatment induced dose depend-
ent apoptotic cell death in the dopaminergic neuronal cell culture model (N27
cells). In order to better define the apoptotic cell death, we investigated the role of
caspases including caspase-2, caspase-8, caspase-9, and caspase-3. The caspases (2,
8, 9,and 3) activation coincided with ROS generation and proteasomal dysfunction
and was found to occur early and prior to cell death. Additionally, TSA induced
apoptotic cell death was preceded by PKC delta activation, upregulation of p44/42
MAP kinase, nuclear translocation of p-65 and hyperacetylation of histone (H3).
Conversely, downregulation of IkBα and survivin levels was also observed as re-
vealed by Western blot and immunohistochemical analyses. Notably, pharmacolog-
ical inhibition of NF-kB and caspases via SN-50 and ZVAD, respectively, conferred
resistance against TSA induced apoptotic cell death in dopaminergic neuronal cells.
These results suggest that NF-kB mediated and caspase dependent cell death sig-
naling events may be critically linked to TSA induced dopaminergic neuronal de-
generation. Further investigation of the mechanistic link between oxidative stress
and proteasomal dysfunction in TSA-induced dopaminergic neuronal cell death
may enhance our understanding on the influence of histone modifications on the
nigrostriatal dopaminergic degeneration (supported by NIH grants ES10586 and
NS65167).
1839 Chemically-Induced Aging of PC12 Cells to Study In Vitro
Neurodegeneration.
M. de Groot and R. H. Westerink. Neurotoxicolgy Research Group, Institute for Risk
Assessment Sciences, Faculty of Veterinary Medicine, University of Utrecht, Utrecht,
Netherlands.
Neurodegenerative diseases, e.g. Parkinson’s disease, are multifactorial and the
mechanisms underlying these disorders are often unknown. In vitro models can in-
crease insight into the cellular and molecular mechanisms by reducing multifactor-
ial diseases to a more controllable set of parameters. A well-known cell model in in
vitro neurotoxicology is the pheochromocytoma (PC12) cell line. PC12 cells have
been used for decades to study the effects of environmental stressors on important
processes of neuronal development, function and degeneration, including differen-
tiation and neuritogenesis, the synthesis, storage and release of neurotransmitters
and the regulation and function of different ion channels. However, the use of
PC12 cells to investigate neurodegeneration in vitro is debated as this tumor-de-
rived cell line is rather resistant against environmental insults.
In this study we therefore induced different degrees of aging in PC12 cells by alter-
ing their oxidative status to investigate if this would increase the susceptibility to
environmental stressors, such as pesticides. The characteristics of these ‘aged’ PC12
subtypes and their sensitivity to an environmental stressor were investigated using
different (functional) assays, i.e. measurements of cell viability, measurements of
oxidative stress using the ROS-sensitive dye H2-DCFDA, and single cell measure-
ments of [Ca2+]i using the Ca
2+-sensitive dye Fura-2.
Our data demonstrate that the different aged PC12 models show a clearly different
Ca2+-homeostasis as compared to naïve PC12 cells. This altered homeostasis is ac-
companied by a change in ROS production over time and by an increased sensitiv-
ity to an environmental stressor as compared to naïve PC12 cells. As such, these
aged PC12 models with increased vulnerability can be used to gain mechanistic in-
sight in in vitro neurodegeneration studies.
Funding: ZonMW NL (85300003).
1840 Differential Alternate Splicing of L-Type Calcium Channel in
Brain Regions: Implication in Parkinson’s Disease.
A. Verma and V. Ravindranath. Centre for Neuroscience, Indian Institute of Science,
Bangalore, India. Sponsor: B. Moorthy.
Parkinson’s disease (PD) is a movement disorder characterized by resting tremors,
bradykinesia and rigidity caused by death of dopaminergic neurons in substantia
nigra pars compacta (SNpc) of the brain. An intriguing question in the pathogene-
sis of PD is the selective degeneration of SNpc neurons and their terminals in stria-
tum, while the adjacent dopaminergic neurons in ventral tegmental area (VTA) are
affected only in later stages of the disease. Among the several hypotheses that have
been put forth to address cell death, mitochondrial dysfunction, oxidative stress
and accumulation of misfolded proteins in the cytosol (Lewy body) have been stud-
ied extensively. More recently it has been shown that SNpc neurons exhibit L-type
calcium channel, Cav1.3, mediated autonomous pace-making, which could poten-
tially result in increased cytosolic calcium resulting in neurotoxicity. While the VTA
neurons also exhibit pace-making, it is driven by sodium conductances thereby en-
suring that cytosolic calcium levels are not elevated. Thus, Cav1.3 channels could
play a role in the selective susceptibility of SNpc neurons in PD. A short splice vari-
ant of Cav1.3, Cav1.3-42A has been shown to promote calcium influx into the cell
in contrast to the long variant Cav1.3. Thus the presence of greater amounts of
Cav1.3-42A relative to Cav1.3 could lead to increased intracellular calcium. We
measured the relative levels of Cav1.3 and the short splice variant Cav1.3-42A in
brain regions and found that the expression of Cav1.3-42A was 4-fold higher in the
ventral midbrain compared to striatum or cortex. Concomitantly, levels of Cav1.3
were significantly less in ventral midbrain. These results indicate that the presence
of Cav1.3-42A in significantly higher concentration in ventral midbrain, could
contribute not only to amplified pace-making but also result in increased cytosolic
calcium levels in neurons thus contributing to the degeneration of these neurons.
1841 Development of a Cellular Model to Assess Catecholamine
Transport and Toxicity.
K. Stout,  A. I. Bernstein and G. W. Miller. Environmental Health, Emory
University, Atlanta, GA.
Environmental exposure to neurotoxicants can lead to catecholaminergic degenera-
tion and subsequent Parkinson’s disease (PD) development. Historically, dopamine
neurons have been the primary focus of neurotoxicological research in PD though
the importance of noradrenergic degeneration is becoming increasingly evident.
Our laboratory recently developed a cellular model to assess dopaminergic trans-
port and toxicity.  Here we demonstrate the development of a novel noradrenergic
cellular model for assessing catecholamine transport and toxicity. Many neurotoxic
compounds act as inhibitors of the vesicular monoamine transporter 2 (VMAT2)
within monoaminergic neurons. The primary role of VMAT2 is to sequester
monoamines into vesicles, protecting them from cytosolic metabolism, and ready-
ing them for release upon stimulation. Inhibition of vesicular packaging results in
increased metabolism of neurotransmitter. NE metabolites inhibit mitochondrial
complex I, thereby reducing ATP synthesis and likely inducing toxicity. To investi-
gate noradrenergic transport and toxicity we are utilizing a monoamine-like fluo-
rescent substrate (Molecular Devices) to investigate VMAT2 function in HEK cells
stably transfected with the human norepinephrine transporter (NET) and
mCherry-tagged human VMAT2. These cells model physiological NE uptake
within NE neurons. NET localizes to the cell membrane and VMAT2 forms intra-
cellular vesicle-like structures. The fluorescent substrate we are utilizing mimics the
action of NE in these cells. It is transported into the cell via desipramine-sensitive
NET uptake (IC50 = 113.9 nM). Within the cell, the dye is sequestered into vesi-
cles by VMAT2, evidenced by co-localization of fluorescence between the substrate
and mCherry. Tetrabenazine, a VMAT2 inhibitor, inhibits co-localization in a
dose-dependent manner (IC50 = 382.8 nM). Both co-localization and inhibition
are detectable by microscopy and analyzed with IDEV (Cellomics). This cellular
model allows investigation of both normal and altered transporter function in re-
sponse to toxicants in a noradrenergic cellular model.
1842 Alpha-Synuclein Protein Aggregates Activate Microglia and
Contribute to Neurotoxicity in the Nigral Dopaminergic
System through a Fyn Kinase Dependent Mechanism.
N. Panicker1,  K. Kanthasamy2,  D. Harischandra1,  H. Saminathan1,
R. Gordon1,  V. Anantharam1,  A. G. Kanthasamy1 and A. Kanthasamy1.
1Biomedical Sciences, Iowa State University, Ames, IA; 2Biochemistry & Cell Biology,
Rice University, Houston, TX.
Abnormal protein aggregation and chronic neuroinflammation are recognized as
key pathophysiological hallmarks of many neurodegenerative diseases including
Parkinson’s disease (PD). Aggregates of the presynaptic protein α synuclein are the
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major component of Lewy bodies, the histological marker of PD. Aggregated α
synuclein is known to stimulate resident brain microglia, leading to their chronic
activation and subsequent production of neurotoxic factors and proinflammatory
cytokines. Identification of the molecular signaling events perpetuating α-synuclein
mediated microglial activation could unravel glial neuronal crosstalk mechanisms
that lead to persistent gliosis and neurodegeneration in PD. In the present study, we
examined the role that Fyn, a major non-receptor tyrosine kinase, plays in aggre-
gated α synuclein induced microglial activation. Immunocytochemical and
Western blot analyses revealed that Fyn was expressed in primary murine microglia
as well as in BV2 microglial cells. Stimulation of the cells with α synuclein aggre-
gates rapidly activated Fyn within 30 minutes of exposure. The time course activa-
tion of Fyn also paralleled PKCδ Y311 phosphorylation. Interestingly, the α-synu-
clein induced PKCδ Y311 phosphorylation was suppressed in primary microglia
isolated from Fyn knockout (Fyn -/-) mice, implicating Fyn as the kinase that car-
ries out this event. The α-synuclein induced activation of p44/42 (Erk1/2) and p38
map kinases was diminished in both Fyn, as well as PKCδ knockout microglia.
Notably, the Fyn knockout primary microglia showed attenuated release of cy-
tokines TNFα, IL-10 and IL-12 in response to α synuclein aggregate stimulation
when compared to wild type microglia. Collectively, our results demonstrate a non
receptor tyrosine kinase mediated pro-inflammatory signaling pathway that may
mediate neuroinflammation in PD (supported by NIH grants ES19276 and
NS65167).
1843 Loss of NF-κB p50 Enhances LPS-Induced Systemic
Inflammation and Early Microglial Activation.
T. Taetzsch,  S. Levesque,  C. McGraw,  M. Surace and M. L. Block. Anatomy &
Neurobiology, VCU, Richmond, VA.
Inflammation associated with chronically activated microglia has been implicated
in the progressive degeneration of nigral dopaminergic (DA) neurons in Parkinson’s
disease (PD), but the mechanisms are not well understood. NF-kB p50 is an im-
portant regulator of the pro-inflammatory response with both inhibitory and initi-
ating roles in the production of cytokines. Importantly, reduced NF-kB p50 ex-
pression has been observed in the substantia nigra (SN) of patients suffering
dementia with lewy bodies, supporting a potential role for NF-kB p50 in PD- like
neurodegeneration. To examine the consequences of loss of NF-kB p50 function in
microglial activation in vivo, NF-kB p50+/+ and NF-kB p50-/- mice were injected
with 5mg/kg LPS IP and sacrificed after 3 hours. Expression of the pro-inflamma-
tory genes TNFα and IL-1β were significantly higher while iNOS expression was
lower and COX2 expression was unchanged in the midbrain of LPS treated NF-kB
p50-/- mice, as compared to NF-kB p50+/+ mice. Analysis of microglia morphol-
ogy in the SN using unbiased stereology revealed significantly higher numbers of
microglia with activated morphology in LPS treated NF-kB p50-/- mice versus NF-
kB p50+/+ mice. In addition, LPS-treated NF-kB p50-/- mice had significantly el-
evated serum levels of TNFα when compared to LPS-treated NF-kB p50+/+ mice.
In vitro kinetics studies demonstrated that TNFalpha and iNOS expression is sig-
nificantly increased at 6 and 12h, but not 3h post-LPS treatment in NF-kB p50-/-
mixed glia cultures, suggesting a possible role of NF-kB p50 in resolution of the
glial pro-inflammatory response. These studies underscore that loss of NF-kB p50
function amplifies systemic inflammation, increases neuroinflammation, enhances
microglial activation, and may impede glial resolution of the pro-inflammatory re-
sponse.
1844 Fungal Volatile Organic Compound(s): Potential
Environmental Agent(s) for the Pathogenesis of Parkinson’s
Disease?
A. A. Inamdar1,  M. M. Hossain2,  J. Richardson2 and J. Bennett1. 1Plant Bio and
Pathology, Rutgers, The State University of New Jersey, New Brunswick, New Jersey;
2EOHSI, Rutgers, The State University of New Jersey, Piscataway, NJ.
Parkinson’s disease (PD) is the most common movement disorder and possesses
multifactorial etiology. Recently, environmental contaminants including mold ex-
posure are implicated in PD-like movement disorders in epidemiological studies.
Although the exact fungal component responsible to such movement disorder is
under speculation, fungal volatile organic compounds (VOCs), a class of fungal
secondary metabolites has been reported to be associated with the adverse health ef-
fects in the human population. There are few in vitro and human studies demon-
strating the biological activity of these fungal VOCs; however, the plausible studies
elucidating the mechanism of action of these VOCs are lacking. Our lab has pio-
neered invertebrate Drosophila model to study the neurotoxic effects of common
fungal VOCs (Inamdar et al., 2010). We have reported that exposure to chemical
standards of 1-octen-3-ol and other fungal VOCs cause loss of dopaminergic neu-
rons and movement deficits in Drosophila suggesting that these tested fungal
VOCs has potential to induce Parkinson’s disease like symptoms. To determine the
mechanism of toxicity of fungal VOCs, we focused on 1-octen-3-ol. Employing the
available genetic and molecular tools in our Drosophila model, we demonstrate the
modulatory effect of 1-octen-3-ol on dopamine regulatory pathway. We show that
1-octen-3-ol inhibits the vesicular monoamine transporter, VMAT thereby causing
the induction of oxidation of dopamine and loss of dopaminergic neurons.
Furthermore, we show that 1-octen-3-ol alters regulation of JNK and Akt signaling
pathways in flies. In conclusion, our data present strong cues in support of
Parkinson-mimetic activity of 1-octen-3-ol and provide insights into neurological
problems especially movement disorders associated with damp indoor environ-
ments.
1845 Mutations in pink-1 and pdr-1 Result in Reduced
Dopaminergic Neurodegeneration after Chemical Insult in
Caenorhabditis elegans.
C. P. Gonzalez,  R. K. Bodhicharla and J. N. Meyer. Nicholas School of the
Environment, Duke University, Durham, NC.
Mitochondrial dysfunction has been linked to neurodegenerative diseases including
Parkinson’s disease. Neurons are cells with a high energy demand, and as a result are
hypothesized to be particularly vulnerable to disturbances to mitochondrial home-
ostasis. We investigated how knocking out two genes involved in mitochondrial dy-
namics, pink-1 and pdr-1, affected dopaminergic neuron viability after chemical in-
sult in Caenorhabditis elegans. pink-1 and pdr-1 are the nematode homologs of the
human genes PINK1 and PARK2 which when mutated cause familial Parkinson’s
disease. We induced neurodegeneration with 6-hydroxydopamine (6-OHDA) and
assessed damage 48 hours post-exposure using the BY250 (dat-1::GFP) strain in
which the four cephalic dopaminergic neurons are visualized with GFP. We used
the BY250 strain as wild-type for pink-1 and pdr-1. The strain BY250 was gener-
ously provided by Michael Aschner (Vanderbilt University) and the strains pink-1;
dat-1::GFP and pdr-1; dat-1::GFP were kindly provided by Guy Caldwell
(University of Alabama). Each neuron was scored from 0 to 2.5, with zero repre-
senting an intact dendrite and 2.5 representing the highest level of neurodegenera-
tion observed, utilizing fluorescent microscopy. Our preliminary results indicate
that after exposure to 15 mM 6-OHDA, the wild-type worm had a higher level of
neurodegeneration than the pink-1 knockout (p<0.0001) and the pdr-1 knockout
(p=0.0052). These counterintuitive results might be explained by the fact that loss
of pink-1 promotes mitochondrial fusion, which in turn could protect from 6-
OHDA damage through mitochondrial functional complementation. Because 6-
OHDA generates reactive oxygen species within the cell, it may cause lipid peroxi-
dation and mitochondrial DNA damage, possibilities that we are currently testing.
Future studies will explore the effect of these mutations on mitochondrial home-
ostasis and neurodegeneration after exposure to 6-OHDA and other toxicants asso-
ciated with Parkinson’s disease including rotenone and paraquat.
1846 Identification of Novel Genes and Epigenetic Mechanisms in
C. elegans Models of Idiopathic Parkinson’s Disease and
Manganism.
R. M. Nass1,  S. Ghosh2,  K. Shah2,  J. Trinidad3 and N. VanDuyn1.
1Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis,
IN; 2Chemistry, Purdue University, West Lafayette, IN; 3Chemistry, Indiana
University, Bloomington, IN.
Background: Idiopathic Parkinson’s disease (PD) and manganism are oxidative
stress-related disorders that result in abnormal dopamine (DA) signaling and cell
death. Both neurological disorders involve basal ganglia and mitochondrial dys-
function, and suggest overlapping epidemiology, yet the origin of the pathogenesis
and the molecular determinants common to both disorders are ill-defined. Recently
we have shown that the PD-associated transcription factor SKN-1/Nrf2 is ex-
pressed in C. elegans DA neurons and inhibits PD-associated DA neurodegenera-
tion. Aims/Objectives: In this study we asked what are the common genes, molecu-
lar pathways, and mechanism involved in DA neuron vulnerability to
PD-associated toxicants. Methods: We utilized reverse genetics, biochemical assays,
immunofluorescence, transgenic C. elegans, RT-PCR, Western analysis, behavioral
and neuronal morphology analysis to characterize expression, localization and the
role that SKN-1, IDN-1, and post-translational modifications play in 6-OHDA-,
rotenone-, and manganese (Mn)-induced neuronal death. Results: In this study we
demonstrate that IDN-1 mutants render DA neuron up to 15-fold more resistant
to the neurotoxicants relative to WT. We show that IDN-1 is expressed in DA neu-
rons, and IDN-1 overexpression results in a 2-fold increase DA neuron vulnerabil-
ity. We also show that DA neuron vulnerability is affected by transcriptional and
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post-translational modifications of involving these and other proteins identified
using RNAi affects DA neuron vulnerability. Conclusions: This study identifies
novel genes and molecular pathways involved in DA neuron vulnerability in PD
and manganism, and provides the first in vivo evidence that a common epigenetic
mechanism likely plays a significant role in both disorders. Support: NIEHS
ES014459 and ES003299 to RN, and EPA STAR Graduate Fellowship to NVD.
1847 Decreased Mitochondrial Biogenesis and Suppression of
Mitochondrial Gene Expression Induced by Environmental
Toxicants in Caenorhabditis elegans Model of Parkinsonism.
S. Zhou,  Z. Wang and J. E. Klaunig. Indiana University, Bloomington, IN.
Mitochondrial alterations have been documented in the brains of subjects with
Parkinson’s disease (PD), a disorder characterized by the selective loss of dopamine
(DA) neurons. Recent studies demonstrating that PD-associated proteins are either
in the mitochondria or translocated into mitochondria in response to stress.
Pesticides and heavy metals have been suggested to be risk factors for PD. While,
environmental agents can modulate mitochondrial function, the mechanism of this
alteration has not been defined in the context of the development and progression
of PD. The complexity of the mammalian neurological system has made it difficult
to dissect the molecular components involved in the pathogenesis of PD. In the
present study we used C. elegans as the model of neuron degeneration and investi-
gated the effect of Mn2+ and rotenone on mitochondrial biogenesis and gene regu-
lation. Exposure to rotenone (2 or 4 μM) resulted in significant loss of dopamine
(DA) neuron in C. elegans. We then determined if the rotenone-induced neuron
degeneration is accompanied by a change in mitochondria biogenesis. Analysis of
mitochondrial genomic replication showed a dramatic decrease in mitochondrial
DNA (mtDNA) copies in rotenone-treated C. elegans compared to control. This
decreased mitochondrial biogenesis occurred prior to the development of loss of
DA neurons, and was persistent. The inhibition of mtDNA replication was also
found in C. elegans exposed to neuron toxicant Mn2+ at the concentration 50 or
100 mM. We further examined the mitochondrial gene expression and found sig-
nificant lower level of mitochondrial complex IV subunits COI and COII in C. el-
egans exposed to rotenone. These results demonstrated that environmental chemi-
cals cause persistent suppression of mitochondrial biogenesis and mitochondrial
gene expression, and suggest a critical role of modifying mitochondrial biogenesis
in toxicants-induced neuron degeneration in C. elegans model.
1848 A Genome-Wide RNAi-Based Screen for Enhancers and
Suppressors of Manganese Toxicity in Caenorhabditis
elegans.
P. Chen1, 2,  T. T. Nguyen2, 3 and M. Aschner1, 2, 3. 1Pediatric Toxicology, Vanderbilt
University, Nashville, TN; 2Neuroscience, Vanderbilt University, Nashville, TN;
3Pharmacology, Vanderbilt University, Nashville, TN.
Environmental or occupational exposure to manganese (Mn) causes a neuropathy
resembling idiopathic Parkinson’s disease (PD). Exposure to excessive Mn levels has
been linked to mitochondrial dysfunction, oxidative stress, protein aggregation and
disruption of iron homeostasis. However, the mechanisms behind these impair-
ments remain unknown, partially due to limited knowledge about genetic factors
associated with Mn toxicity. The complexity of the vertebrate brain and the diffi-
culties associated with vertebrate models of PD has hindered the understanding of
molecular mechanisms associated with this disorder. The nematode, Caenorhabditis
elegans (C. elegans) and mammals share a highly conserved genetic code, and offers
an innovative and powerful platform to evaluate the genetic factors associated with
Mn-induced toxicity. Taking advantage of the RNA interference (RNAi) technique
and the available RNAi library, we are able to evaluate the impact of ~ 87% of C. el-
egans genes on Mn toxicity, individually. By feeding the worms with a specific strain
of RNAi bacteria, we have successfully knocked down (quantified by qRT-PCR)
three selected genes (smf-2, smf-3 and dpy-7) in C. elegans. In vertebrate, the diva-
lent metal transporter 1 (DMT1) has been shown to regulate Mn transport; its
nematode homologs (smf-1, 2 and 3) have also been proved to involved in Mn in-
duced toxicity. We hypothesized that knocking down smf-1, 2 or 3 would affect
worms’ survival after exposure to Mn. Consistent with our hypothesis, knocking
down of SMF-1 significantly increases the survival rate of C. elegans by 2 fold
(P<0.01) and SMF-3 by 1.5 fold (P<0.05) after Mn treatment at the larval (L4)
stage; smf-2 knockdown did not cause to a significant change in Mn-induced sur-
vival rate. Taken together, our studies establish that a genome-wide RNAi based
screen could be carried out using the survival assay to identify genetic enhancers
and suppressors of Mn induced toxicity in C. elegans.
1849 Loss of Pdr-1/Parkin Alters Manganese Homeostasis in C.
elegans.
S. Chakraborty1, 2 and M. Aschner2, 3. 1Neuroscience Graduate Program, Vanderbilt
University, Nashville, TN; 2Center for Molecular Toxicology, Vanderbilt University,
Nashville, TN; 3Pediatrics, Vanderbilt University, Nashville, TN.
Environmental overexposure to the essential trace element manganese (Mn) can re-
sult in an irreversible, toxic condition known as manganism. This disorder shares
similar neuropathology with Parkinson’s disease (PD), exhibiting overt dopaminer-
gic (DAergic) cell loss associated with the presentation of motor and cognitive
deficits. However, the mechanisms behind the pathophysiology of both disorders
remain unclear. Many PD genes have been identified to explain a subset of cases,
including the parkin/PARK2 gene that encodes for an E3 ubiquitin ligase. Using
Caenorhabditis elegans (C. elegans) as a model that contains the necessary DAergic
machinery, we hypothesize that a loss-of-function mutation in pdr-1, the worm ho-
molog of parkin, would increase vulnerability to Mn toxicity compared to wildtype
(WT) worms by altering proper Mn homeostasis. Synchronous L1 worms from
WT N2 and pdr-1(gk448) mutant strains were acutely exposed to MnCl2 for 30
minutes, followed by lethality scoring of approximately 40-50 worms 24 hours
post-treatment. Here, we show that a loss of pdr-1 increases Mn-induced lethality
compared to WT worms (p=0.0005), as seen with a leftward shift in the dose-re-
sponse curve. Moreover, pdr-1 mutants show higher, dose-dependent Mn accumu-
lation compared to WT worms (p<0.001), suggesting overall impaired Mn home-
ostasis in pdr-1 mutants. Interestingly, pdr-1 mutants show altered mRNA
expression levels of key C. elegans Mn importers, including up-regulation of smf-1
and smf-3, and down-regulation of smf-2. However, pdr-1 mutants do not show any
difference in mRNA levels of ferroportin (fpn-1.1 in worms) at baseline, indicating
a lack of regulation at the export level. Finally, upon exposure, pdr-1 mutants show
altered total glutathione (GSH) levels compared to WT animals (p<0.05). Such
changes indicate a role of pdr-1 in modulating Mn import through altered trans-
porter expression, implicating a novel role of the PD-associated gene in metal
homeostasis and increased oxidative stress.
1850 Manganese Accumulations in Gill Mitochondria of
Crassostrea virginica.
A. Nuhar,  B. Boisette,  M. A. Carroll and E. J. Catapane. Biology, Medgar Evers
College, Brooklyn, NY.
Manganese is a neurotoxin causing Manganism in people chronically exposed to el-
evated levels in their environment. Manganese targets dopamine neurons in basal
ganglia. Oxidative stress has been implicated as a factor of manganese toxicity and
dopamine dysfunction. Mitochondria play a role as cause and target of oxidative
stress damage. The mechanisms of damage is attributed to manganese’s capacity to
produce toxic levels of free radicals and induce mitochondrial dysfunction. Others
report manganese accumulates in mitochondria and represent the primary pool of
manganese in cells. Controversy exists to the extent of manganese accumulation in
mitochondria. Others report manganese accumulates within nuclei and cytoplasm,
but not mitochondria. Our lab is using the oyster, Crassostrea virginica, as a test an-
imal to study manganese neurotoxicty. We found manganese disrupts the
dopamine system as well as mitochondrial respiration. To study if manganese accu-
mulates within mitochondrial of gill cells of C. virginica we used differential cen-
trifugation and atomic absorption spectrometry. Gills were homogenized and cen-
trifuged to isolate nuclear, mitochondrial and post-mitochondrial fractions. Each
fraction was analyzed for manganese. To determine if isolated mitochondria accu-
mulate manganese we prepared treated mitochondrial suspensions with up to 300
mM manganese. Results show a dose dependent accumulation of manganese in mi-
tochondria of up to 5000%. Two day treatments of animals with 500 and 1000 μM
Mn increased manganese (μg/gdw) in gill from a baseline of 5.8 to 41.6 and 133.8,
respectively, and centrifugation revealed Manganese accumulations were primarily
in nuclear and mitochondrial fractions. The study shows mitochondria accumulate
manganese. In vivo treatments reveal accumulations with both the nuclear and mi-
tochondrial fractions.
1851 Manganese Treatments Decreases Immunofluorescence
Emissions of Postsynaptic Dopamine D2 Receptors.
Y. Chekayev,  R. Opoku,  M. A. Carroll and E. J. Catapane. Biology, Medgar Evers
College, Brooklyn, NY.
Manganese a neurotoxin causing Manganism, a Parkinsons-like disease, disrupts
dopamine neurotransmission. Gill lateral cell cilia of Crassostrea virginica are con-
trolled by serotonergic-dopaminergic innervations. Dopamine causes cilio-inhibi-
tion, serotonin cilio-excitation. Our lab showed post-synaptic dopamine receptors
in gill cells are D2 type and manganese blocks cilio-inhibitory effects of dopamine
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by blocking dopamine post-synaptic receptors. Questions exist in the literature if
manganese decreases the number of D2 receptors in brain. To test that we used an-
tibody-antigen histoimmunofluorescence techniques to visualize dopamine D2 re-
ceptors in gill and ganglia of C. virginica. We used a primary antibody against D2
receptors followed by FITC linked secondary antibody. Animals were treated with
500 μM of manganese for 5 days. Gill, cerebral and visceral ganglia were excised
and exposed to primary and secondary antibodies. Paraffin embedded sections were
viewed with a phase contrast Zeiss epilume fluorescence microscope with a ProgRes
C3 Peltier cooled camera. Antibody treated sections showed bright FITC fluores-
cence in lateral ciliated cells and other areas of gill and ganglia. Sections lacking pri-
mary antibody treatment did not display similar fluorescence. We analyzed fluores-
cence intensity of 120 control and 80 gill lateral cells from animals treated with
manganese using ImageJ software. Intensity of manganese treated cells was 70%
less than controls. The study identifies dopamine D2 receptors in gill cells and cere-
bral and visceral ganglia, and shows a negative correlation between fluorescence in-
tensity of dopamine D2 receptors in manganese treated animals and controls. The
question if the decrease in intensity is due to decrease in actual number of receptors
or if manganese alters protein conformation of D2 receptor and D2-ligand binding
sites needs to be further explored.
1852 Chelating Agents Reverse Neurotoxic Effects of Manganese
on Dopaminergic Innervation of Gill of the Bivalve Mollusc
Crassostrea virginica.
C. Ojo,  K. Rogers,  T. Adams,  E. J. Catapane and M. A. Carroll. Biology, Medgar
Evers College, Brooklyn, NY.
Lateral cilia of gill of Crassostrea virginica are controlled by a serotonergic-dopamin-
ergic innervation. Dopamine is an inhibitory transmitter at gill causing cilio-inhi-
bition. Manganese is a neurotoxin causing Manganism in people exposed to high
levels in the atmosphere. Clinical interventions for Manganism have not been suc-
cessful. Recently, p-aminosalicylic acid (PAS) was reported to provide effective
treatment of severe Manganism in humans. PAS is an anti-inflammatory drug
which has been used to treat tuberculosis. It also has chelating properties.
Previously, we showed treatments of C. virginica with Mn disrupts dopaminergic
innervation of gill. Pre- or co-treatments with PAS or calcium disodium EDTA pre-
vented the neurotoxic effects of manganese. We hypothesized chelating agents
would be effective in reversing neurotoxic effects of manganese when applied to
gills after manganese. We used gills of C. virginica to measure lateral cilia beating
rates of preparations treated first with manganese followed by treatments with ei-
ther PAS, calcium disodium EDTA or DMSA (meso-2,3-dimercaptosuccinic acid).
Beating of cilia were measured by stroboscopic microscopy. Dose responses of PAS,
calcium disodium EDTA and DMSA (10-11 - 10-4 M) against beating were con-
ducted after 100 μM of manganese was added to gill. All 3 drugs reversed the neu-
rotoxic effects of manganese in a dose-dependent manner. DMSA was the most po-
tent. The study demonstrates these chelators are effective in reversing acute
neurtoxicity of manganese. This information should be of interest to those design-
ing therapeutic drug treatments for Manganism.
1853 Effects of Antioxidants and Anti-Inflammatory Agents on
Neurotoxic Effects of Manganese on Dopaminergic
Innervation of Gill of the Bivalve Mollusc Crassostrea
virginica.
K. LaFleur,  M. Rotibi,  E. J. Catapane and M. A. Carroll. Biology, Medgar Evers
College, Brooklyn, NY.
Lateral cilia of the gill of Crassostrea virginica are controlled by a serotonergic-
dopaminergic innervation. Dopamine acts as an excitatory neurotransmitter within
the ganglia, but an inhibitory neurotransmitter at gill, causing cilio-inhibition. The
mechanism of action of manganese toxicity is not fully understood, but may be due
to oxidative damage. We found several chelators, including p-aminosalicylic acid
(PAS) prevented neurotoxic effects of manganese in C. virginica. The therapeutic
actions of PAS are thought to be due to chelation, but PAS is also anti-inflamma-
tory. We sought to determine if anti-inflammatory agents and/or antioxidants are
effective in preventing neurotoxic actions of manganese in gill of C. virginica.
Indomethacin, an anti-inflammatory agent with antioxidant abilities, and ascorbic
acid, an antioxidant with possible anti-inflammation abilities were tested. We ex-
amined acute and short term (3 - 5 days) treatment of indomethacin and ascorbic
acid on manganese toxicity on dopaminergic innervation. Beating rates of lateral
cilia in gill epithelial cells were measured by stroboscopic microscopy. Acute or
short-term treatments of indomethacin or ascorboc acid (25 - 100 μM) and had no
effect on the cilio-inhibitory effects of dopamine (10-6 - 10-3 M). When acute or
short-term manganese treated animals (25 - 100 μM) were pretreated with in-
domethacin or ascorbic acid (25 - 100 μM), both drugs effectively prevented the
neurotoxic effects of manganese, with ascorbic acid being more effective than in-
domethacin. The study demonstrates antioxidants and anti-inflammatory agents
can block the neurotoxic actions of manganese and may be possible therapeutic
agents in the treatment of Manganism.
1854 Neurotoxic Effects of Manganese on GABAergic Innervation
in the Bivalve Mollusc Crassostrea virginica.
J. Ogunnoiki,  K. Jackson,  E. J. Catapane and M. A. Carroll. Biology, Medgar
Evers College, Brooklyn, NY.
High levels of airborne manganese cause Manganism, a neurotoxsic, Parkinsons-
like disease in humans by interfering with dopaminergic neurotransmission in
brain. Recent studies are showing GABAergic neurons also are damaged by man-
ganese. C. virginica contains a dopaminergic and serotonergic innvervation of its
gill. It is a simple system to study manganese toxicity. Previously we showed man-
ganese disrupts dopaminergic innervation. We also showed the cerebral ganglia of
C. virginica contains GABA and within the cerebral ganglia GABA inhibits sero-
tonergic innervation of gill lateral cell cilia. Here we studied if ganglia and periph-
eral tissues contain GABA receptors, and if manganese has effects on GABA neu-
rons within cerebral ganglia of C. virginica. We used primary antibodies (GABAA
Ra1-6 ) and secondary antibodies (IgG-FITC) to detect GABA receptors with
paraformaldehye fixed, paraffin embedded tissues using a Zeiss epilume fluores-
cence microscope and ProgRes C3 Peltier cooled camera. We found fluorescence
due to GABA receptors in cerebral ganglia, visceral ganglia, palps and digestive
tract. We also examined effects of manganese treatments on GABAergic inhibition
of serotonin neurons in cerebral ganglia. Beating of lateral cilia in gill cells were
measured by stroboscopic microscopy. Applying serotonin to cerebral ganglia
caused a dose-dependent increase in cilia beating. Applying GABA prior to sero-
tonin prevented the increase. Acute applications of manganese (50 and 500 μM)
prior to GABA prevented GABA from inhibiting serotonin. The study is showing
GABA receptors are present in ganglia and peripheral tissues in C. virginica, and
acute manganese treatments damage GABA neurons. C. virginica preparations are
good, simple test preparation to study the GABAergic system and the mechanism
underlying the neurotoxic effects of manganese.
1855 Optimization of Fluorescence Assay of Cellular Manganese
Status for High-Throughput Screening.
K. K. Kumar1, 3,  A. Aboud1,  D. K. Patel1,  M. Aschner2 and A. B. Bowman1, 2.
1Department of Neurology, Vanderbilt University, Nashville, TN; 2Department of
Pediatrics, Vanderbilt University, Nashville, TN; 3Medical Scientist Training Program,
Vanderbilt University, Nashville, TN.
The advent of high throughput screening (HTS) technology permits identification
of compounds that influence various cellular phenotypes. However, screening for
small molecule chemical modifiers of neurotoxicants has been limited by the scala-
bility of existing phenotyping assays. Furthermore, the adaptation of existing cellu-
lar assays to HTS format requires substantial modification of experimental parame-
ters and analysis methodology to meet the necessary statistical requirements. Here
we describe the successful optimization of the Cellular Fura-2 Manganese
Extraction Assay (CFMEA) for HTS. By optimizing cellular density, manganese
(Mn) exposure conditions, and extraction parameters, the sensitivity and dynamic
range of the fura-2 Mn response was enhanced to permit detection of positive and
negative modulators of cellular manganese status. Finally, we quantify and report
strategies to control sources of intra- and inter-plate variability by batch level and
plate-geometric level analysis. Our goal is to enable HTS with the CFMEA to iden-
tify novel modulators of Mn transport. Support: NIH ES016931and ES010563.
1856 Manganese Exposure Alters Mitochondrial Biogenesis in
Dopaminergic Neuronal Cells.
M. Ay,  A. Kanthasamy,  H. Jin,  D. Kim,  V. Anantharam and
A. G. Kanthasamy. Iowa State University, Ames, IA.
Excessive manganese (Mn) exposure causes a movement disorder commonly re-
ferred to as manganism in humans. Mn mainly accumulates within mitochondria
and adversely affects mitochondrial structure and function both in vivo and in
vitro. Over the past decades, mitochondrial dependent biochemical processes such
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as oxidative stress, Ca2+ dysregulation and apoptotic signaling have been identified
as possible mechanisms of Mn neurotoxicity.  However, mitochondrial dynamics
and the molecular mechanisms that govern the mitochondrial biogenesis during
Mn neurotoxicity are yet to be determined. Since the transcriptional co-activator
peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-
1alpha) is the master regulator of mitochondrial biogenesis, herein, we examined
the effect of Mn on PGC-1alpha dependent mitochondrial biogenesis in dopamin-
ergic neuronal cells. The MN9D dopaminergic neuronal cell model was exposed to
100-500 μM of manganese, and the mRNA expression levels of several mitochon-
drial biogenesis markers, including PGC-1alpha, mitochondrial transcription fac-
tor A (TFAM), and cytochrome B (CytB), were measured using qRT-PCR analysis.
Interestingly, the results revealed a dose-dependent induction of PGC-1alpha,
TFAM, and CytB mRNA levels following 24 h of manganese exposure, whereas
short-time manganese exposure (3-6 h) did not result in any significant induction
of PGC-1alpha mRNA. Since PKD1 serves as a key compensatory anti-apoptotic
kinase, we measured PKD1 phosphorylation, and the kinase phosphorylation was
significantly decreased at 24 h with 500 μM Mn exposure. A decreased level of Bcl-
2 (a pro-survival protein) was also observed at 24 h. Importantly, overexpression of
PGC-1 alpha protein significantly protected the cells against Mn-induced neuro-
toxicity. Taken together, our data indicate that Mn exposure induces mitochondrial
biogenesis through PGC-1 alpha transcription to counter metal induced neuro-
toxic stress (NIH grants ES19267, ES10586, and NS074443).
1857 Manganese Exposure Induces Release of α-Synuclein and
Promotes Exosome Mediated Cell to Cell Transmission of
Synuclein Aggregates in Neurotoxicity Models.
D. Harischandra,  H. Jin,  A. Kanthasamy,  V. Anantharam and
A. G. Kanthasamy. Biomedical Science, Iowa State University, Ames, IA.
Chronic manganese exposure is a well-known occupational and environmental haz-
ard considered to be a potential risk factor for environmentally linked
Parkinsonism. α-Synuclein (α-syn) is a major presynaptic protein in CNS, and ag-
gregation of α- has been implicated in the pathophysiology of Parkinson’s disease.
Previously, we showed that α-syn protects dopaminergic neuronal cells against
metal neurotoxicity during early exposure. In the present study, we further charac-
terized the effect of long-term manganese exposure on α-syn metabolism. A
300μM manganese exposure to human α-syn stably expressing N27 dopaminergic
cells for 24-48 hr induced a time-dependent increase in α-syn immunoreactive ag-
gregates in the cells. Further analysis of the protein aggregation by inclusion body
specific fluorescence probes revealed formation of aggregasomes in a time-depend-
ent manner. We were also able to detect enhanced accumulation of protein
oligomers in manganese treated dopaminergic cells. Studies conducted with
MN9D cells stably expressing human α-syn showed that the α-syn is secreted out
of the cells into extracellular media following manganese exposure, in a time-de-
pendent manner. Further characterization of extracellular media by ultracentrifuga-
tion followed by electron microscopic analyses revealed that manganese treatment
induces exosome vesicle formation in α-syn cells. Interestingly, we also observed
manganese increased the expression of prion in α-syn expressing cells as compared
to vector control cells. Furthermore, manganese treatment increases GRP 78 and
caspase 12 levels, suggesting that manganese induces ER stress in α-syn expressing
cells. Collectively, these results demonstrate that prolonged manganese exposure
promotes α-syn protein aggregation and secretion into extracellular milieu by
forming exosomal vesicles, which may contribute to propagation of protein aggre-
gation by a prion-like mechanism in dopaminergic neuronal cells. (NIH grants
ES19267, ES10586, and NS65167)
1858 Trp73 Gene in Dopaminergic Neurons Is Highly Susceptible
to Manganese Neurotoxicity.
D. Kim,  H. Jin,  V. Anantharam,  R. Gordon,  A. Kanthasamy and
A. G. Kanthasamy. Biomedical Science Department, Iowa State University, Ames, IA.
Chronic exposure to elevated levels of manganese has been linked to a Parkinson’s
disease like movement disorder, resulting from dysfunction of the extrapyramidal
motor system within the basal ganglia. However, the exact cellular and molecular
mechanisms of manganese-induced neurotoxicity remain elusive. Since oxidative
stress and apoptosis are considered to be prime mechanisms of manganese neuro-
toxicity, we sought to identify genes that are susceptible to manganese-induced neu-
rotoxic insult using the Qiagen mouse apoptosis RT2 Profiler™ PCR array system.
C57 black mice were treated with 10 mg/kg manganese via oral gavage for 30 days.
The nigral tissue was collected and RT-PCR based gene expression was performed
for 84 genes associated with apoptotic signaling. Interestingly, we found significant
down-regulation of a tumor repressor gene, namely Trp73, in manganese treated ni-
gral tissue, as compared to control. To further determine the molecular mechanism
of manganese-induced Trp73 down-regulation, we treated N27 dopaminergic cells
with 300 μM manganese and examined the gene expression. Consistent with our
animal study, we found reduced expression of Trp73 at mRNA levels in N27
dopaminergic cells. We further determined the Trp73 protein levels during man-
ganese treatment. Trp73 protein level was also reduced in manganese treated N27
cells as well as in manganese treated nigral lysate. Furthermore, manganese treat-
ment in primary striatal culture down-regulated Trp73 protein level in a dose de-
pendent manner. After confirming Trp73 down-regulation during manganese toxi-
city in three different models, we have begun additional mechanistic studies in cell
culture models of manganese neurotoxicity. Taken together, our results demonstrate
Trp73 is a gene susceptible to manganese neurotoxicity, and further characteriza-
tion of the role of Trp73 in cell survival/cell death will improve our understanding
of the molecular underpinnings of manganese neurotoxicity (supported by NIH
grants ES10586 and ES19267).
1859 Mechanism of Manganese-Induced Inhibition of Glutamate
Transporter GLAST Function.
A. North1,  A. Webb1,  D. Son1,  M. Aschner2 and E. Lee1. 1Physiology, Meharry
Medical College, Nashville, TN; 2Pediatrics, Vanderbilt University Medical Center,
Nashville, TN.
Manganese (Mn) is an essential trace element required for normal growth, develop-
ment and homeostasis; however, chronic overexposure to elevated levels of Mn in-
duces a Parkinson’s disease-like symptoms referred to as manganism. It has been re-
ported that manganism is associated with excitotoxicity, resulting from the
dysfunction of the astrocytic glutamate transporters (GLAST and GLT-1), which
take up ~80% of synaptic glutamate. However, the mechanism by which Mn dis-
rupts glutamate transporter function has yet to be elucidated. Our previous studies
have shown that Mn suppressed transcriptional activity of astrocytic GLAST by de-
creasing its mRNA and protein levels. Accordingly, herein, we seek to understand
the molecular mechanism of Mn-induced GLAST suppression at transcriptional
levels, testing whether Mn induces a modulatory effect on astrocytic GLAST pro-
moter activity. The experiments were conducted by assessing EAAT1 (human form
of GLAST) luciferase activity in astrocytes transiently transfected with EAAT1 vec-
tors. We hypothesized that Ying-Yang 1 (YY1) and NF-κB pathways play a critical
role in repressing the GLAST gene expression, and that Mn modulates the activities
of these transcriptional factors. The results revealed that Mn activates the YY1 pro-
moter (p<0.05), and overexpression of YY1 decreases EAAT1 promoter activity. We
have also found that CBP (CREB binding protein) acts as a co-regulator of YY1 on
the EAAT1 promoter. NF-κB also regulates EAAT1 promoter activity.
Overexpression of NF-κB p65 increases the EAAT1 promoter activity (10 folds,
p<0.001), whereas mutation on NF-κB binding sites at -533 or -163 of EAAT1
promoter represses EAAT1 promoter activity (p<0.001) and reduces p65 effects on
EAAT1 promoter activity (3 folds, p<0.001). Mn activates NF-κB reporter activity
and produces TNF-α which decreases EAAT1 activity via NF-κB activation. Taken
together, our results indicate that the YY1 and NF-κB pathways play critical roles
in Mn-induced repression of EAAT1 promoter activity.
1860 Analysis of Brain Mn Distribution Influenced by Disease
Stage in Mouse Models of Huntington’s Disease.
T. V. Bichell1, 2,  M. Wegrzynowicz1, 2,  M. S. Cardone1,  M. Uhouse1,
M. Aschner1, 2, 3 and A. B. Bowman1, 2, 3. 1Department of Neurology, Vanderbilt
University, Nashville, TN; 2Center for Molecular Toxicology, Vanderbilt University,
Nashville, TN; 3Department of Pediatrics, Vanderbilt University, Nashville, TN.
Huntington’s disease (HD) is a genetic neurodegenerative disorder primarily affect-
ing the striatum. There is considerable variability in age of onset in HD strongly in-
fluenced by environmental factors. We have previously reported a disease-toxicant
interaction between HD and manganese (Mn) exposure, wherein the pathogenic
HD mutation is associated with a striatal specific defect in net Mn uptake. For ex-
ample, there is decreased Mn accumulation in the striatum of FVB-YAC128 mice
at 13 weeks of age after 7 day subcutaneous Mn exposure with 3 total injections at
50mg Mn chloride tetrahydrate/kg. To determine if increased exposure duration in-
fluenced this phenotype we measured striatal Mn after a 9 day exposure with a total
of 5 injections. At this age (13 weeks), prior to the onset of neurodegenerative phe-
notypes, the higher exposure strengthened the difference in striatal Mn accumula-
tion between wildtype and mutant mice. To determine if this Mn phenotype was
progressive over the course of disease, we examined striatal Mn levels at 12 months
of age. Unexpectedly, no difference in striatal Mn accumulation between wildtype
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and HD mice was observed using the 7 day paradigm. This alteration in Mn accu-
mulation may be related to disease processes, or to changes due to normal aging, or
it may be that the Mn transport defect diminishes with disease progression. To ex-
amine this in more detail we will measure and image regional brain Mn accumula-
tion using Inductively Coupled Plasma Mass Spectroscopy (ICPMS), laser ablation
ICPMS and other novel methods in HD mouse models. In addition, we will exam-
ine primary cultured glia and neurons for cell-type differences in the HD-Mn phe-
notype. Our ultimate goal is to determine whether disease progression influences
brain Mn deposition in HD, and if so, what role glia and neurons play in this
process. Supported: NIH ES016931, T32 ES007028
1861 Verification of Manganese-Related Choroid Plexus
Differentially Expressed Proteins In Vitro.
G. J. Li,  Y. Dong,  J. Liu,  Y. Liu,  H. Jing,  C. Zhao and L. Ma. Institute for
Toxicology, Beijing Centers for Disease Control and Prevention, Beijing Research
Center for Preventive Medicine, Beijing, China.
The regulation of brain manganese (Mn) depends largely on the blood-brain bar-
rier and blood-cerebrospinal fluid barrier (BCB). The latter is constituted by
choroid plexus (CP) epithelial cells, which is specialized for cerebrospinal fluid
(CSF) production, has been considered as a primary target in Mn-induced neuro-
toxicity. In our previous study, a total of 32 Mn-related differentially expressed pro-
teins were identified by 2D-PAGE combined with Nano-LC-MS/MS in an in vivo
Mn-toxicity rat model, of which 27 were up-regulated, 5 were down-regulated.
This study aims to further verify the 7 selected proteins (PHB1, VDAC, β-actin,
HSP70, STIP1, TTR, Vimentin) at transcriptional and translational level respec-
tively in immortalized choroidal epithelial Z310 cells in vitro under manganese
chloride (MnCl2) exposure. The expressed level of 7 proteins and their mRNA
were detected by Western Blot and Real Time RT-PCR, following MnCl2 (0, 50,
100, 200μmol/l)) exposure for 24h or 12h in Z310 cells. The results demonstrated
that PHB1, β-actin and STI1 were up-regulated and TTR was down-regulated at
both transcriptional and translational levels as compared to controls, which are in
accordant with results in in vivo study. Whereas VDAC, HSP70 and Vimentin
were down-regulated at both transcriptional and translational levels as compared to
controls, which are opposite to the results in in vivo study. Taking together, this
study validated that Mn toxic effects on PHB1, β-actin, STIP1 and TTR in CP are
accurate and reliable, which provide the valuable clue for elucidating the molecular
mechanism of Mn toxicity on choroid plexus epithelial cells (partly supported by
NSFC Grant in China #81273108, Capital Development Project 2011-1013-03,
and Beijing Health Bureau Project-2011. Corressponding author: Guojun J. Li,
guojunli88@yahoo.com).
1862 Expression and Aggregation of a-Synuclein in the Blood-CSF
Barrier: New Evidence for the Effects of Toxic Intracellular
Manganese and Copper Levels.
C. A. Bates1,  X. Fu1,  D. Ysselstein2,  J. Rochet2,  H. Gu3,  Y. Du3 and
W. Zheng1. 1Health Sciences, Purdue University, West Lafayette, IN; 2Medicinal
Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, IN;
3Neurology, Indiana University School of Medicine, Indianapolis, IN.
The blood-cerebrospinal fluid barrier (BCB) is responsible for maintaining the
homeostasis of a variety of molecules in the brain and cerebrospinal fluid (CSF) in-
cluding alpha-synuclein (a-Syn). a-Syn plays an integral role in the pathoetiology of
Parkinson’s disease. Little is known about the role of the BCB in the transport and
regulation of a-Syn in the brain and CSF. Previous findings in this lab provided ev-
idence that a-Syn was endogenously expressed in our immortalized Z310 choroidal
epithelial cell model, and 100 μM MnCl2 exposure for 24 and 48 hours induced a-
Syn aggregation in these cells. The current studies test the hypothesis that the in-
creased a-Syn aggregation in Z310 cells may result from Mn interacting with a-Syn
expression and/or its aggregation. qPCR was used to quantify a-Syn expression in
Z310 cells after 100 μM MnCl2 incubation for 24 hr. Our data revealed that Mn
treatment did not affect a-Syn mRNA expression in Z310 cells. Using the
Thioflavin T fibril aggregation assay, 70 μM recombinant a-Syn was incubated
with 2 mM MnCl2 and CuCl2 for 7 days in vitro. a-Syn aggregation increased sig-
nificantly (530% and 634%, respectively) as compared to controls (n=3, p<0.05).
Finally, we found that 24 hr incubation with 50 and 100 μM CuCl2 induced a-Syn
aggregation in Z310 cells. These findings support the hypothesis that cellular ag-
gregation of a-Syn in the BCB is facilitated by exposure to heavy metals. More
specifically, Mn exposure induces this effect by two pathways: 1) direct interaction
with cellular a-Syn within the cell and/or 2) increasing intracellular Cu levels,
shown by our data in literature, leading to Cu-accelerated a-Syn aggregation.
(Support by NIH/NIEHS ES08146-S2 Minority Supplemental Award)
1863 Reduced Copper (Cu) Efflux across the Blood-CSF Barrier
(BCB) following Manganese Exposure: Effect on Cu
Transporters ATP7A and ATP7B.
X. Fu,  Y. Zhang,  W. Jiang and W. Zheng. School of Health Sciences, Purdue
University, West Lafayette, IN.
Increased Cu levels in blood, saliva and brain are found in Mn-exposed animals and
humans. However, the underlying mechanism is unknown. ATP7A and ATP7B are
Cu-ATPases that function to maintain intracellular Cu homeostasis by exporting
excess Cu from the cytosol to extracellular space. This study was designed to test the
hypothesis that Mn exposure disrupted the Cu transport across the BCB by inter-
rupting the intracellular trafficking of ATP7A and ATP7B. Rats received ip injec-
tions of 6 mg Mn/kg as MnCl2 or saline, 5 d/wk for 4 wks. Increased Cu and Mn
levels in serum and CSF were observed following Mn exposure. An in situ ven-
triculo-cisternal perfusion by infusing [64Cu] and [14C]-sucrose into brain ventri-
cle was conducted to determine Cu clearance by the BCB. Mn exposure signifi-
cantly increased [64Cu] radioactivity by 2.6 fold in the CSF outflow, as compared
to controls, suggesting a reduced Cu removal by the choroid plexus. Confocal im-
ages exhibited both Cu-ATPases distributed in perinuclear region in normal plexus
tissues and Z310 cells. Incubation of plexus tissues with Mn or Cu caused translo-
cation of ATP7A from the cytosol toward the apical membrane facing the CSF,
whereas ATP7B relocated toward the basal membrane facing the blood. Exposing
Z310 cells to 100 μM MnCl2 for 24 hr led to a significant decrease in ATP7A and
ATP7B fluorescent intensities, which was consistent with their significant mRNA
and protein expression reductions in tissue and Z310 cells. The two-chamber
Transwell transport studies showed a reduced Cu efflux from the CSF to the blood
following Mn exposure or when ATP7A or ATP7B expression were knocked down
by siRNA. Collectively, these data suggest that Mn exposure reduces Cu efflux by
the BCB which appears to be due to the reduction of ATP7A and ATP7B. A de-
creased clearance of Cu by Mn exposure may result in the buildup of Cu in the
brain. Opposite translocation of ATP7A vs. ATP7B is interesting, yet how this may
help interpret a decreased Cu efflux via the BCB remains uncertain. (Supported by
NIH/RO1-ES008146)
1864 Bone Manganese (Mn) Concentrations in Sprague-Dawley
Rats following Subchronic Manganese Exposure.
L. Hong,  S. O. Neal,  L. Nie and W. Zheng. Purdue University, West Lafayette, IN.
Occupational exposure to Mn causes a Parkinson-type disorder called Manganism,
a neurodegenerative disease currently without reliable biomarkers for body burden
estimation and for pre-symptomatic toxicity assessment. Data in literature suggest
that Mn deposited in bone accounts for 43% of total body Mn. The objective of
this study was to determine if bone Mn levels were parallel to Mn concentrations in
brain regions known to be the targets of Mn toxicity. Groups of rats (6-7 each) re-
ceived daily dose of 50 mg Mn/kg as MnCl2 PO for 0, 2, 4, 6, 8 or 10 weeks before
tissue dissection. The metal concentrations of Mn, zinc (Zn), iron (Fe), and copper
(Cu) in bone tissues, body fluids, brain tissues, as well as other organs were analyzed
by atomic absorption spectrophotometry. Following Mn exposure, bone tissues in-
cluding femur, tibia, humerus and skull bones showed a dose-time-dependent in-
crease in Mn concentrations, with 1.0-1.6 μg/g of bone mass at week 10, which
were about 2.3-3.6 fold higher than those in controls (~0.4 μg/g) at day 0 (p<0.01).
A statistically significant relationship exists between bone Mn concentrations and
Mn levels in brain tissues such as striatum (r=0.755, p<0.001), hippocampus
(r=0.782, p<0.001) and choroid plexus (0.652, p<0.001), and in brain fluid such as
cerebrospinal fluid (r=0.720, p<0.001). Interestingly, in vivo exposure to Mn also
led to significantly increased Fe (152-372%) and Zn (194-230%) concentrations in
bone tissues except the skull bones, with no statistically significant effect on bone
Cu (58-95%). These results suggest that bone is a significant storage site for body
Mn; the good correlation between bone Mn and brain Mn alludes to bone Mn
being an internal source of Mn long-term exposure. Further experimentation for
noninvasive quantitation of Mn in bone is well warranted for Mn neurotoxicologi-
cal research. (Supported in part by R21 OH010044, and RO1 ES008146)
Keywords: 
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1865 Effects of Chronic Manganese Exposure on Cognitive
Functioning in Nonhuman Primates.
J. Schneider1,  C. Williams1,  M. Ault1 and T. R. Guilarte2. 1Thomas Jefferson
University, Philadelphia, PA; 2Columbia University, New York, NY.
Exposure to elevated levels of manganese (Mn) can result in neurological dysfunc-
tion in humans including effects on cognitive functioning, particularly those that
depend on the integrity of frontal cortex. Our group is performing longitudinal
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studies assessing cognitive and motor function consequent to Mn exposure along
with measures of in vivo brain chemistry in non-human primates to better define
the neurological consequences and molecular mechanisms of chronic Mn exposure.
Adult cynomolgus monkeys were trained to perform cognitive tasks including tests
of attention (5 choice serial reaction time (5-CRT)), executive functioning (spatial
and non-spatial working memory (self-ordered spatial search (SOSS) and delayed
matching-to-sample (DMTS)), and visuospatial learning (paired associate learning
(PAL)). After these (and other) tasks were learned to criterion (using the monkey
CANTAB test system) and performance was stable, animals received Mn (1.66 -
2.5 mg Mn/kg per injection, 2x/wk) or vehicle (2x/wk) with an intended total ex-
posure period of 1.5 yrs. Through 8 mos. of exposure, the PAL task, a sensitive
index of mild cognitive impairment (MCI) in humans, showed consistent deficits
beginning in the second mo. of Mn exposure. Deficits in SOSS and DMTS per-
formance became obvious at 4 and 6 mos. of Mn exposure and attentional impair-
ments, suggested by increased reaction times in the 5-CRT task, were observed con-
sistently at approx. mo. 5. Over the same period of time, performance of the
control group either did not change significantly or in some instances, improved.
These data show that using a sensitive cognitive assessment battery based on mon-
key versions of human neuropsychological tests, deficits in several cognitive do-
mains are associated with Mn exposure and in particular, Mn disrupts performance
of the PAL task, highly sensitive to detecting early Alzheimer’s disease and MCI,
and in particular, disrupts frontal–related functions. Supported by NIH RO1
ES010975.
1866 Neurochemical Alterations in the Nonhuman Primate Brain
during Chronic Exposure to Manganese: A 1H MRS Study.
S. Dharmadhikari1, 2,  J. L. McGlothan3,  R. Edden4, 5,  P. Barker4, 5,
J. Schneider6,  U. Dydak1, 2 and T. R. Guilarte3. 1School of Health Sciences, Purdue
University, W Lafayette, IN; 2Department of Radiology, Indiana University School of
Medicine, Indianapolis, IN; 3Department of Environmental Health Sciences,
Columbia University Mailman School of Public Health, New York, NY; 4Russell H.
Morgan Department of Radiology and Radiological Science, Johns Hopkins University,
Baltimore, MD; 5F.M. Kirby Center for Functional Brain Imaging, Kennedy Krieger
Institute, Baltimore, MD; 6Department of Pathology, Anatomy and Cell Biology,
Thomas Jefferson University, Philadelphia, PA.
Alterations in brain chemistry upon chronic manganese (Mn) exposure can be
studied non-invasively using 1H Magnetic Resonance Spectroscopy (MRS). In this
longitudinal Mn exposure study, 1H MRS was used for the detection of brain
metabolite changes that are associated with chronic Mn exposure in non-human
primates. A total of 7 adult male cynomolgus monkeys underwent MRS on a 3 T
Philips Achieva MRI scanner before Mn exposure and after 8 months of Mn expo-
sure (n=3, 1.66-2.5 mg Mn/kg per injection, 2x/wk). Short echo-time PRESS sin-
gle voxel MRS data was obtained from frontal cortex (FC), parietal cortex (PC),
thalamus, and putamen, and gamma-aminobutyric acid (GABA)-edited MRS data
was obtained from FC and striatum using MEGA-PRESS. The quantification of
metabolites including N-Acetyl-aspartate (NAA), Glutamate (Glu), Glutamine
(Gln), mI (myo-Inositol), total creatine (tCr), choline (tCho) and GABA was done
using LCModel. A significant decrease in NAA/tCr (p=0.035) and mI/tCr
(p=0.013) and a significant increase in Glu+Gln (p=0.03) from baseline was meas-
ured in the PC. The thalamus showed a significant increase in tCr (p=0.041) and a
significant decrease in mI/H2O (p=0.022). No significant changes were measured
in any metabolites in the FC and in GABA levels in any region. The significant dif-
ferences in major metabolites are quite robust despite the small number of animals
and changes in NAA/tCr in the PC are in agreement with our previously published
results (Guilarte et al., Toxicol Sci 94: 351-358, 2006).(Supported by NIH
ES010975)
1867 What Is the Mechanistic Evidence for Trichloroethylene As a
Cause of Parkinson’s Disease?
D. G. Dodge1 and B. D. Beck2. 1Gradient, Bend, OR; 2Gradient, Cambridge, MA.
Parkinson’s Disease (PD) is a type of movement disorder characterized pathologi-
cally, in part, by the progressive and selective loss of dopaminergic neuron cell bod-
ies within the substantia nigra pars compacta (SNpc) and associated deficiency of
the neurotransmitter dopamine in the striatum. Mitochondrial dysfunction (i.e.,
Complex I inhibition), oxidative stress, and abnormal protein aggregation (with in-
tracellular α-synuclein accumulation) have been strongly implicated in PD pathol-
ogy. A number of recent papers have suggested a causal role for trichloroethylene
(TCE) in PD, either directly or via its role in the endogenous formation of 1-
trichloromethyl-1,2,3,4-tetrahydro-β-carboline (i.e., the TaClo hypothesis). We as-
sess, from a toxicological perspective, the evidence for TCE as a cause or substantial
contributor to PD in humans. With regard to the TaClo hypothesis, in vitro studies
in a number of different cell systems have provided evidence that TaClo causes
changes in mitochondria and dopaminergic neurons but is not preferentially selec-
tive towards dopaminergic cells. In vivo studies in rats have shown that high doses
of TaClo injected directly into the brain cause only modest decreases in dopamine
neurons; intraperitoneal (i.p.) administration of TaClo was not selective towards
dopaminergic neurons; and i.p. and oral exposure of TaClo caused locomotor
changes that were not consistent in direction or with dose. Furthermore, there is no
experimental or credible human evidence that TaClo is formed in vivo after expo-
sure to TCE. In animal studies conducted to evaluate TCE directly as a potential
cause of PD, relatively high i.p. or oral doses have resulted in findings that are both
consistent and inconsistent with mechanistic and motor effects thought to be im-
portant in PD. Compared to other well-developed models of PD, the TCE model
is poorly characterized. Overall, we conclude that TCE as a causal factor in PD has
not been demonstrated and remains speculative.
1868 Neuroprotective Efficacy and Pharmacokinetics of Novel
Para-Phenyl Substituted Diindolylmethanes in a Model of
Parkinson’s Disease.
B. Trout1,  J. A. Miller1,  R. Hansen1,  S. H. Safe2,  D. Gustafson1 and
R. B. Tjalkens1. 1Center of Environmental Medicine, Environmental Radiological
and Health Science, Colorado State University, Fort Collins, CO; 2Center for
Environmental and Genetic Medicine, Institute of Biosciences and Technology, Texas
A&M Health Science Center, Houston, TX.
There are no approved therapeutics that block the chronic inflammatory compo-
nent of neurodegenerative diseases such as Parkinson’s. This is partly because of
poor distribution to the central nervous system for compounds with demonstrated
efficacy in vitro. This study examined selected para-phenyl substituted diindolyl-
methane (C-DIM) compounds, which we previously demonstrated to be effective
at decreasing glial-derived inflammatory gene expression in vitro. We postulated
that the pharmacokinetic properties of C-DIM compounds would positively corre-
late with neuroprotective efficacy in a progressive model of Parkinson’s disease (PD)
in vivo. Pharmacokinetics and metabolism of 1,1-bis(3’-indolyl)-1-(p-
methoxyphenyl)methane (C-DIM5), 1,1-bis(3’-indolyl)-1-(p-
hydroxyphenyl)methane (C-DIM8), and 1,1-bis(3’-indolyl)-1-(p-
chlorophenyl)methane (C-DIM12) were determined in plasma and brain of
C57Bl/6 mice. Intravenous (1 mg/kg) and oral (10 mg/kg) doses were given to de-
termine the optimal route of administration and putative metabolites were meas-
ured in plasma, liver, and urine. Oral dosage of C-DIM compounds displayed
greater AUC, Cmax, and Tmax levels than intravenous administration. C-DIM12
exhibited distinguished pharmacokinetics of the selected C-DIMs, with an oral
bioavailability of 42% in comparison of C-DIM8 (6%). Following pharmacoki-
netic studies, efficacy of C-DIM5, C-DIM8, and C-DIM12 (50 mg/kg, oral gav-
age) was established using a progressive, neuroinflammatory PD model employing
MPTP and probenecid (MPTPp) over a period of 14 days. By first creating a lesion
in the region of the brain affected in PD (substantia nigra) and then treating with
anti-inflammatory C-DIMs, we determined that C-DIM5 and C-DIM12 demon-
strated the greatest efficacy in attenuating the progressive loss of dopamine neurons.
1869 Neurotoxicity Study of Lipopolysaccharide (LPS) Induced
Mouse Model of Parkinson’s Disease.
Z. Nan1,  W. Wang2 and W. Low1. 1Neurosurgery, University of Minnesota,
Minneapolis, MN; 2Global Regulatory, HB Fuller, St. Paul, MN.
Parkinson’s disease (PD) is a debilitating neurodegenerative disease characterized by
gradual and progressive loss of dopaminergic (DA) neurons in substantia nigra pars
compacta (SNc). 95% of PD may be attributed to multi-variant etiology; among
them, inflammation is getting more attention. Current understanding is that in-
flammation in the central nervous system can produce large amount of pro-inflam-
matory factors such as tumor necrosis factor α, interleukin-1β, interleukin-6, pro-
teinases, and glial activation; the subsequent interaction among these factors and
host cells leads to progressive death of dopaminergic neurons in SNc, resulting in
PD. Lipopolysaccharide (LPS) is an endotoxin derived from gram-negative bacteria
and is widely used as an inflammation inducer. In this preliminary study, we
wanted to know what dose level of LPS can effectively induce PD in C57Bl/6 mice
by direct brain injection at the SNc site. Six groups of mice were injected with low
dose LPS (200 microgram/Kg), high dose LPS (400microgram/Kg) and normal
saline as control, respectively, into one side of the SNc site or the target it projects
to (striatum of the same side). The surviving DA neurons in the SNc site were
shown and counted by immunohistochemistry method using rabbit anti-tyrosine
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hydroxylase and visualized by diaminobenzidine staining at 1st and 3rd week after
injection. We compared the number of surviving DA neurons at SNc with DA neu-
rons at SNc on the contralateral side. We found significant loss of DA neurons at
SNc in both injection sites of SNc and striatum in the high dose groups at 1st and
3rd week. No significant loss of DA neurons was observed in the low dose and the
control groups. We concluded that LPS at the dose level of 400microgram/kg can
effectively and rapidly induce PD in C57Bl/6 mice through direct brain injection,
and the pathological change resembles the neurodegenerative characteristics found
in PD. The dose response relationship and the pro-inflammatory characteristics as-
sociated with the DA neuron loss may need further investigation.
1870 Neuroinflammation and Microglial Dysfunction.
M. Entezari1 and M. Javdan2. 1Natural Sciences, LaGuardia Community College,
Long Island City, NY; 2Biological Sciences and Geology, Queensborough Community
College, Bayside, NY.
Neuro-inflammation and accumulation of Aβ-containing amyloid plaques are crit-
ical components in the pathogenesis of Alzheimer’s disease (AD). Microglia are the
brain tissue macrophages that play critical roles in the inflammatory aspects of AD
by releasing proinflammatory cytokines. Activated microglia are also able to mi-
grate to the sites of Aβ deposition and eliminate Aβ by phagocytosis. Thus, the im-
pairment of microglia migration and Aβ phagocytosis appear to be closely involved
in the progression of AD. The underlying molecular mechanisms responsible for
disease progression are still unclear. Previously we have shown that elevated levels of
high-mobility group box 1 (HMGB1), a ubiquitous DNA binding protein that
promotes inflammatory tissue injury impairs the peritoneal macrophages’ func-
tions. Therefore, we hypothesized that HMGB1 contributes to microglial dysfunc-
tion in neuro-inflammation.  In this study we demonstrate that HMGB1 levels
were significantly elevated in the extracellular space of cultured BV2 macroglia cells
24 hours after exposure to 1 μg/ml Lipopolysaccharide (LPS) compare to untreated
control cells. Exposure to 1 μg/ml LPS also resulted in significant suppression of
microglia’s ability to migrate and to phagocytose. Simultaneous treatment of BV2
cells with LPS and anti-HMGB1 antibody significantly improved the migration
and phagocytic ability of these cells. Moreover, treating BV2 cells with recombinant
HMGB1 not only induced impairment in migration and phagocytosis but also ac-
companied by the expression of Toll-like receptor 4 (TLR4) on these cells. These re-
sults suggest that activation of the LPS-induced HMGB1/TLR4 signaling pathway
contributes to the microglia dysfunction. Thus, inhibiting of HMGB1 may provide
a therapeutic target for enhancing of microglia’s ability to migrate and phagocytose
in AD.
1871 Translocator Protein 18 KDA (TSPO) in Sandhoff Disease:
An Update on a Preclinical Biomarker of Neurodegeneration.
M. Loth1,  J. Choi1,  J. L. McGlothan1,  H. Wang2,  M. Pomper2 and
T. R. Guilarte1. 1EHS, Columbia University, NYC, NY; 2Radiology, Johns Hopkins
University, Baltimore, MD.
Translocator protein 18 kDa (TSPO) is extensively used as a biomarker of active
brain disease and neuroinflammation (Chen & Guilarte, Pharm Ther 118: 1-17,
2008).Sandhoff disease, which is clinically similar to Tay-Sach’s disease, is a neu-
rodegenerative condition in which a deficiency in the enzyme lysosomal β-hex-
osaminidase leads to accumulation of gangliosides and glycolipids in the brain, re-
sulting in progressive and widespread neurodegeneration.
We previously reported the longitudinal expression of TSPO in a mouse model of
Sandhoff disease at the later stages of the disease (2 and 3 months). Now we report
TSPO expression at early disease time points (1 and 1.5 months) in order to assess
the temporal expression of TSPO and its relationship to behavioral and neu-
ropathological endpoints. Using TSPO quantitative autoradiography with the
TSPO specific ligands [125I]Iodo-DPA-713 and [3H]-DPA-713, we show that
TSPO levels are increased as early as 1 month in relevant brain regions concurrent
with behavioral expression of disease. We also demonstrate that the temporal in-
crease in TSPO levels is associated with ongoing neurodegenerative changes and ac-
tivation of microglia and astrocytes using silver staining (marker of active degenera-
tion) and immunohistochemistry of Mac-1 (microglia) and GFAP (astrocytes).
Triple labeled immunofluorescent confocal imaging confirmed that TSPO colocal-
ized with microglial markers as well as with the gp91phox subunit of NADPH oxi-
dase at an age when brain tissue is undergoing neurodegeneration. These results
further strengthen the evidence that TSPO can be used as an early and sensitive pre-
clinical biomarker of brain injury and inflammation [Supported by NIEHS grant
ES007062 to TRG].
1872 Characterization of Mice with Overexpression of the
Vesicular Monoamine Transporter 2 (VMAT2; Slc18a2).
K. Lohr1,  A. I. Bernstein1,  T. Guillot1,  K. Stout1,  E. Heath1,  M. Wang1,  Y. Li1,
A. Salahpour2 and G. W. Miller1. 1Environmental Health, Emory University,
Atlanta, GA; 2University of Toronto, Toronto, ON, Canada.
The vesicular monoamine transporter 2 (VMAT2) is responsible for packaging
monoamines for rapid release at neuronal synapses. VMAT2 is also responsible for
sequestering toxicants away from their sites of action in the cell. Despite previous
evidence suggesting that decreased levels of VMAT2 can contribute to cellular dys-
function, it was not known if an increase in VMAT2 protein would result in in-
creased function in vivo. We generated C57BL6 BAC transgenic mice with in-
creased VMAT2 expression to determine the effects of increased vesicular
monoamine filling on associated neurochemical and behavioral outcomes. Our
VMAT2-HI mice show robust VMAT2 overexpression, proper localization of
VMAT2, increased whole brain synaptic vesicle [3H]-dopamine uptake, and a
measurable behavioral phenotype. These data show the effects of elevated VMAT2
levels on neurochemistry and behavior, suggesting that increased vesicular
dopamine storage mediated by increased VMAT2 levels can alter the neurochemi-
cal and behavioral output of the monoaminergic system. Finally, as VMAT2 acts as
a neuroprotective mechanism in monoaminergic neurons, these VMAT2-HI mice
serve as a valuable tool to investigate resistance to toxicant exposure.
1873 Background Survival of Transgenic Mouse Models of
Alzheimer’s Disease in Our Laboratories.
J. Douville and C. Copeman. Charles River, Montréal, QC, Canada. Sponsor: M.
Vézina.
Transgenic mouse models of Alzheimer’s disease are of great value for evaluating ef-
ficacy and/or toxicology of drug therapies. These models typically present hall-
marks of the disease between 12 and 20 months of age; however, age-related attri-
tion represents a challenging issue that may impair the statistical significance of the
data generated. We present survival data of three different transgenic Alzheimer
mouse models when housed under our optimized laboratory conditions. The ho-
mozygous strain of PDAPP mouse (STOCK-TgN(APP)<V717F> (line number
6042M)) showed mortality rates of 13 (males) and 21% (females), between the ages
of 7 to 12 months and of 70 (males) and 60% (females), between the ages of 12 to
21 months. Heterozygous PDAPP mice (STOCK-TgN(APP)<V717F> (line num-
ber 6042T)) showed greater survival with only 6.4 and 16.8% mortality for males
and females, respectively at 14 to 20 months of age and 16% and 42% mortality for
males and females, respectively, between 20 to 26 months of age. Young Tg2576
mice (B6; SJL-Tg (APPSWE) 2576Kha) presented a survival rate comparable to
wild type mice with 100 and 90% survivors between the ages of 9 and 14 weeks.
When survival is calculated for older Tg2576 mice, 79 and 75 % of males and fe-
males, respectively, survive over the age of 13 to 22 months. As the survival rates
vary between the different strains and the age-related attrition is relatively high,
consideration for increased population should be given accordingly in study designs
using these transgenic mouse models.
1874 Oxidative Damage and Age-Related Alterations in Kainic
Acid-Induced Excitotoxicity.
R. C. Gupta1,  S. Zaja-Milatovic2 and D. Milatovic3. 1Toxicology, Murray State
University, Hopkinsville, KY; 2University of Virginia, Charlottesville, VA; 3Vanderbilt
University Medical Center, Nashville, TN.
Recent research findings in brain have highlighted increased excitatory stimulation
as a contributor to aging as well as neuronal damage that accompanies multiple
neurodegenerative diseases. Findings from patients and animal models have widely
supported the hypothesis that neuronal oxidative/nitrosative damage is a major ef-
fector contributing to neurodegeneration. Therefore, the present study investigated
antioxidative and neuroprotective effects of the antioxidant vitamin E (α-toco-
pherol) and the NMDA receptor antagonist memantine in age-related excitotoxic-
ity induced by kainic acid (KA). Mice exposed to KA (1 nmol/5 μl, icv) showed sig-
nificant increases in cerebral oxidative biomarker F2-isoprostanes (F2-IsoPs, 158%)
and nitrosative biomarker citrulline (249%) formation when determined at 30 min
after exposure. At the same time, pyramidal neurons in the hippocampus of young
and old mice showed significant reductions in dendritic length (60%) and spine
density (40%) compared to controls (100%). Pretreatment with vitamin E (100
mg/kg, ip/day for 3 days) and memantine (5 mg/kg, ip, but not 1 mg/kg) attenu-
ated the KA-induced increases in cerebral F2-IsoPs and citrulline and decrease in
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spine density of hippocampal pyramidal neurons in young mice. However, vitamin
E (100 mg/kg, ip/day for 3 days) and memantine (5 mg/kg, ip) were not effective
in suppressing KA-induced oxidative stress and a decrease in the dendritic length of
hippocampal pyramidal neurons in aged mice. These data strongly suggest that dif-
ferent mechanisms are involved in cerebral neuroprotection of aged mice compared
to young mice. Elucidation of these mechanistic changes has important clinical im-
plications for therapeutic strategies in both normal aging and neurodegenerative
disease.
1875 Rapid Immunoassay Development and Evaluation of ICAM-
1 and E-Selectin As Potential Biomarkers of Vascular Injury
in Rats.
M. J. Cameron1,  H. W. Smith2,  J. L. Weaver4,  N. King5,  N. Vansell3 and
B. E. Enerson3. 1Immunology, MPI Research, Mattawan, MI; 2Investigative
Toxicology, Eli Lilly and Company, Indianapolis, IN; 3Drug Safety Research and
Development, Pfizer Inc, Groton, CT; 4DDSR/OTR/OPS/CDER, FDA, Silver Spring,
MD; 5Predictive Safety Testing Consortium, Critical Path Institute, Tucson, AZ.
To qualify biomarkers of vascular injury in support of the Predictive Safety Testing
Consortium’s (PSTC) Vascular Injury Working Group (VIWG) we developed bio-
marker immunoassays on the Gyros platform for rat ICAM-1 and E-Selectin using
a fit-for-purpose approach. ICAM-1(Intercellular Adhesion Molecule 1), also
known as CD54, is a cell surface glycoprotein typically expressed on endothelial
cells. E-Selectin, also known as CD62 and endothelial leukocyte adhesion molecule
1, is typically expressed on activated endothelial cells. The assays were developed
using commercially sourced reagents. Rats (n=5/group) were treated with either 60
mg/kg of CI-1044 (oral gavage) or 100 mg/kg of fenoldopam (subcutaneous). Both
drugs are known to cause vascular injury. Samples were taken at 4, 8, 16, 24, 48, 72
hours and recovery for CI-1044 and at 0.5, 2, 6, 24, 72 hours and recovery for
fenoldopam and serum was evaluated for levels of ICAM-1 and E-Selectin.
Histopathologic examination indicated vascular lesions were present from the CI-
1044 rats starting at 16 hours post dose consisting of perivascular inflammation of
the mesenteric arteries and progressing to fibrinoid necrosis at later time points.
The mesenteric vascular lesions in fenoldopam-treated rats consisted of arterial
necrosis/apoptosis observed at 24 hours post dose, followed by perivascular inflam-
mation and fibrinoid necrosis at later time points.  There was no significant change
noted in the circulating levels of ICAM-1 in CI-1044 or fenoldopam treatment
groups. There was a significant decrease in serum E-Selectin levels in both CI-1044
and fenoldopam treated groups after 48 hours. E-Selectin has the potential to be-
come a valuable biomarker in the evaluation of vascular injury for preclinical drug
safety studies.
1876 Synthesis and Characterization of PEG-Ylated Meso-
Porphyrins for Targeting the Epidermal Growth Factor
Receptor in CRC.
R. J. Ledet1,  K. R. Fontenot2 and G. H. Vicente2. 1Chemistry and Biology,
Southern University and A&M College, Baton Rouge, LA; 2Chemistry, Louisiana
State University and A&M College, Baton Rouge, LA. Sponsor: W. Gray.
This project introduces a novel macrocycle conjugated to polyethylene glycol
linker, which we hypothesize will serve as the template for a selective molecule with
high fluorescence yields that greatly increases earlier detection of CRC by utilizing
the EGFR as a biomarker. Our targeted remedy is a porphyrin that is conjugated to
a peptide with an affinity for the Epidermal Growth Factor Receptor (EGFR).
Porphyrins are characteristically aromatically stable, contain trademark absorption
bands in the visible and near-IR range, and have fluorescence quantum yields much
above the current fluorophores. This makes the macrocycle optimal for confocal
laser endomicroscopy (CLE) agent production. Consequently, we use a polyethyl-
ene glycol linker in order to increase water solubility, retain low toxicity, and to
achieve high fluorescence quantum yields, as well as high conjugation yields. In this
research, we were able to produce both precursors to the porphyrin-peptide conju-
gate, MesoPOR-(mono)-3PEG and MesoPOR-(di)-3PEG. These molecules were
synthesized successfully with the use of peptide conjugation mechanisms.
Molecular weights were confirmed using Matrix Assisted Laser Desorption
Ionization Mass Spectrometry (MALDI-MS). Characterization was performed
using 1H Nuclear Magnetic Resonance (1H-NMR) and Ultraviolet-Visible
Spectroscopy (UV-Vis) of the intended molecules. The synthesized molecules,
MesoPOR-(mono) 3PEG and MesoPOR-(di) 3PEG, will be useful in peptide con-
jugation that targets EGFR. These peptide ligands will increase selectivity and de-
tect CRC via CLE.
1877 Multiplex Analysis of Urinary Protein Biomarkers for the
Detection of Vancomycin Induced Sub-Acute Nephrotoxicity.
W. Zheng1,  T. C. Fuchs2,  I. Yoon1,  D. Droll1,  X. Qiang1 and P. Hewitt2. 1R&D,
EMD Millipore, St. Charles, MO; 2Non-Clinical Safety R&D, Merck Serono,
Darmstadt, Germany.
In pharmaceutical and chemical industries the kidney is routinely assessed during
preclinical safety evaluations. The importance of the kidney as a central detoxifica-
tion organ leads to a high exposure of renal tissue to drugs, reactive metabolites or
environmental compounds. Traditional markers for assessing renal toxicity, such as
blood urea nitrogen (BUN) and serum creatinine (SCr), are insensitive. Although
both are direct measurements of renal function, increases in serum concentrations
of these biomarkers occur only after substantial renal injury. For improved detec-
tion of acute nephrotoxicity a panel of novel urinary kidney biomarkers has been
approved by the FDA, EMA and PMDA. However, limited data regarding the per-
formance of these acute markers after sub-acute or sub-chronic treatment are pub-
licly available. To increase the applicability of these markers, it is important to eval-
uate the ability to detect these markers after 28 days or even longer. 
In this study, Wistar rats were treated with three doses of Vancomycin to induce
renal damage and studied for 28 days. Urine was collected under cooled conditions
on an 18-hour cycle on days 4, 8, 15 and 29. Luminex® xMAP® based MILLI-
PLEX® Rat Kidney Toxicity Magnetic Bead Assays were used to measure 14 candi-
date protein biomarkers simultaneously from the urine samples. Vancomycin treat-
ment resulted in a dose-dependent increase in urinary biomarkers, specific for the
observed areas within the nephron, determined histopathalogically. Several bio-
markers were found promising in this study, which includes NGAL, Cystatin C,
KIM-1, Osteopontin, Clusterin and Albumin. The simultaneous measurement of
these proteins with multiplex technology offered a robust and convenient method
to study these biomarkers. Taken together, our data demonstrate the high accuracy
and predictivity of some of these new markers to detect sub-acute treatment with
one well described nephrotoxin, Vancomycin.
1878 Association of the Cumulative Body Burden of Estrogen-3,
4-Quinone with Body Mass Index and Breast Cancer Risk
Using Albumin Adducts As Biomarkers.
P. Lin1,  D. Chen2,  C. Lin1, 2,  W. Hsieh3,  W. Yu3,  C. Lin1,  M. Go1 and
C. Juan1. 1Environmental Engineering, National Chung Hsing University, Taichung,
Taiwan; 2Comprehensive Breast Cancer Center, Changhua Christian Hospital,
Changhua, Taiwan; 3Department of Laboratory Medicine, Da-Chien General
Hospital, Miaoli, Taiwan.
Both 17β-estradiol-2,3-quinone (E2-2,3-Q) and 17β-estradiol-3,4-quinone (E2-
3,4-Q) are reactive metabolites of estrogen. Elevation of E2-3,4-Q to E2-2,3-Q
ratio is thought to be an important indicator of estrogen-induced carcinogenesis.
Our current study compared the cumulative body burden of these estrogen
quinones in serum samples taken from Taiwanese women with breast cancer
(n=152) vs healthy controls (n=140) by using albumin (Alb) adducts as biomarkers.
Results clearly demonstrated the presence of cysteinyl adducts of E2-2,3-Q-4-S-Alb
and E2-3,4-Q-2-S-Alb in all study population at levels ranging from 61.7-1330
and 66.6-1590 pmol/g, respectively. Correlation coefficient between E2-2,3-Q-4-
S-Alb and E2-3,4-Q-2-S-Alb was 0.610 for controls and 0.767 for breast cancer pa-
tients (p<0.001). We also noticed that in subjects under age 50 with body mass
index (BMI) less than 27, background levels of E2-3,4-Q-2-S-Alb was inversely
proportional to BMI with about 25% increase in E2-3,4-Q-2-S-Alb per 5 kg/m2
decrease in BMI (p<0.001). In addition, we confirmed that mean levels of E2-3,4-
Q-2-S-Alb in breast cancer patients were ~5 fold greater than in those of controls
(p<0.001). Overall, this evidence suggests that disparity in estrogen disposition and
the subsequent elevation of cumulative body burden of E2-3,4-Q may play a role in
the development of breast cancer. (This work was supported by the National
Science Council, Taiwan, through Grants NSC99-2314-B-005-001-MY3)
1879 Biomarker-Based Evaluation of Diesel Exhaust Emissions
from 2007-Compliant Engines in Rats and Mice Exposed for
Defined Time Periods.
L. M. Hallberg1,  J. L. Parks1,  C. M. Norton2,  C. Hernandes1,  J. B. Ward1,
B. T. Ameredes1 and J. K. Wickliffe2. 1University of Texas Medical Branch,
Galveston, TX; 2Tulane University Health Sciences Center, New Orleans, LA.
In 2001 the USEPA adopted new air quality standards for diesel fuels and emis-
sions; the health impact was not established. Diesel exhaust (DE) is associated with
adverse health effects, including cardiovascular, lung cancer, and neurological
400 SOT 2013 ANNUAL MEETING
deficits. Proposed mechanisms include damage to DNA and lipids through expo-
sure to reactive oxygen, toxic DE particulates, and inflammation. Our objective is
to determine if engineering changes in 2007 diesel engines significantly reduces
DNA and lipid damage.
To determine the extent of oxidative and genotoxic damage caused by inhaled DE,
biomarkers of lipid peroxidation (LP) and DNA damage were employed being as-
sessed by the Comet assay (DNA damage), serum levels of 8-OHdG, and LP.
In rats (1 month exposure), no significant differences (NSD) were noted by Comet
assay (exposure level vs air control p<0.53 Low(L), 0.92 Mid(M), 0.77 High(H)
nor were there gender effects in either tail moment (TM) or tail length (TL) (p<
0.59 L,0.90 M,0.42 H,0.16 gender effects). After 3 months exposure, NSD were
noted in TM or TL in rats. NSD in mice (1 month, p<0.56 L,0.0.20 M,0.61
H,0.79 gender effects) in TM or TL (p< 0.60 L,0.21 M,0.63 H, 0.73 gender ef-
fects). After 3 months, NSD in TM or TL (p<0.15, p<0.16) nor gender were ob-
served.
In serum (8-OHdG ELISA) NSD were observed in rats (p<0.86) or mice (p<0.46)
among 1 and 3 month groups. In rodent hippocampus (L P-T-Bars assay), signifi-
cant differences were observed in rats between L and M groups (p<0.02) but NSD
among other groups. NSD were observed among mice (p<0.92) treatment groups.
In mouse, 1 month was significantly higher than 3 months (p<0.01). 
In conclusion, NSD was evident comparing air controls to 3 treatment groups.
Based on the endpoints evaluated, we conclude that 2007-compliant engines did
not produce any significant, persistent, oxidatively-induced DNA damage (lung) or
exposure-dependent lipid peroxidation in (hippocampus) from these exposures.
1880 Investigation of Early Biomarkers of Doxorubicin (DOX)-
Induced Cardiac Tissue Injury in B6C3F1 Mice.
V. Desai1,  E. Herman2,  C. Moland1,  S. Lewis3,  K. Davis4,  N. George5,
S. Kerr6 and J. C. Fuscoe1. 1Division of Systems Biology, NCTR, US FDA, Jefferson,
AR; 2Division of Applied Pharmacology Research, CDER, US FDA, Silver Spring,
MD; 3Division of Scientific Coordination, NCTR, US FDA, Jefferson, AR;
4Toxicologic Pathology Associates, NCTR, US FDA, Jefferson, AR; 5Division of
Bioinformatics and Biostatistics, NCTR, US FDA, Jefferson, AR; 6Arkansas Heart
Hospital, Little Rock, AR.
Cardiac troponins (cTn) are widely used as biomarkers for assessing cardiac injury
in preclinical and clinic testing. Here we report a study that was designed to iden-
tify early biomarkers of cardiac injury in male B6C3F1 mice. Mice were treated
weekly for 2, 3, 4, 6, and 8 weeks with (a) 3 mg/kg DOX given intravenous (i.v.) via
tail vein, resulting in cumulative doses of 6, 9, 12, 18, and 24 mg/kg, respectively,
(b) an equivalent volume of saline (SAL) given i.v. via tail vein, (c-d) 60 mg/kg
dexrazoxane (DXZ), a cardioprotective drug, given intraperitoneal (i.p.) 30 min be-
fore i.v. injection of DOX or SAL, and (e) SAL given i.p. 30 min before i.v. injec-
tion of SAL. At necropsy, which was performed a week after the last dose, blood
samples were collected for measurements of cTnT and hematological parameters.
Also, hearts were collected for evaluations by light and electron microscopy, ge-
nomics, proteomics, and metabolomics. Preliminary results showed a release of
cTnT in plasma in 8% of mice at 6 mg/kg, 17% of mice at 9 and 12 mg/kg, and
92% of mice at 18 and 24 mg/kg cumulative DOX doses, indicating a dose-related
increase in cardiac injury. Plasma cTnT levels were also elevated in 16%, 58%, and
55% of mice treated with DXZ+DOX for 3, 6, and 8 weeks, respectively.
Microscopic examination of hearts revealed the presence of cardiac lesions only in
mice exposed to 24 mg/kg cumulative DOX dose, suggesting that DXZ provided
cardioprotection against irreversible damage. The presence of histological damage
in the heart of only mice exposed to the highest cumulative DOX dose yet some el-
evation in cTnT at lower cumulative DOX doses suggests that our ongoing evalua-
tion of molecular changes may reveal more sensitive biomarkers of cardiac injury.
1881 Investigation on Plasma Bile Acids As Biomarkers of
Cholestasis Induced by Bsep Inhibition in Preclinical
Animals.
M. Miyake1,  T. Shimizu1,  M. Kobayashi1,  M. Yamazaki2,  H. Satou1,
T. Honda1,  T. Tomari1 and N. Masutomi1. 1Safety Research Laboratories, Research
Division, Mitsubishi Tanabe Pharma Corporation, Chiba, Japan; 2Advanced Medical
Research Laboratories, Research Division, Mitsubishi Tanabe Pharma Corporation,
Saitama, Japan. Sponsor: J. Sugimoto.
[Purpose] The bile salt export pump (BSEP) is a bile acid efflux transporter, the in-
hibition of which has been proposed to play a role in drug-induced cholestasis.
However, there are no known biomarkers (BMs) to detect BSEP inhibition. We
previously performed metabolomics analyses on rat plasma treated with cyclosporin
A, a well-known BSEP inhibitor, and found that plasma bile acids (PBA) could be
BMs for BSEP inhibition. To further evaluate the usefulness of PBA, we character-
ized the specificity and time-course changes of PBA in rats and dogs.  [Methods and
Results] PBA were measured by LC/MS in rats dosed rifampicin (a BSEP in-
hibitor), methapyrilene (a hepatocellular toxicant), 2,3,5,6-tetramethyl-1,4-
phenylenediamine (a muscular toxicant) and dexamethasone (a hepatic glyconeoge-
nesis inducer). Increase of cholic acid and taurocholic acid, accompanied by
decrease of glycocholic acid and chenodeoxycholic acid were specific to rifampicin
treatment, confirming the reproducibility of the previous analyses. Next, single dos-
ing studies were conducted in rats and dogs to investigate the time-course changes
of PBA. In rats, PBA were increased maximally at 6~9 hrs after cyclosporin A dos-
ing and tended to return to the normal level at 24 hrs after dosing, which corre-
sponded to the toxicokinetics of cyclosporin A. On the other hand, PBA were de-
tected only after feeding in untreated dogs, and rifampicin intensified the rise in
PBA concentration induced by meal.  [Conclusion] The results show that PBA can
be specific BMs of BSEP inhibition in preclinical animals. Since PBA showed time-
course changes associated with plasma drug concentrations and were also affected
by meal in dogs, plasma sampling time point would be critical to evaluate changes
in PBA induced by BSEP inhibition.
1882 Kidney Injury Biomarkers Lipocalin-2, Clusterin and
Albumin, but Not Kidney Injury Molecule 1, Are More
Sensitive Than Traditional Markers of Gentamicin-Induced
Kidney Injury in Beagles.
M. Wagoner1,  L. Cheatham1,  D. Eisinger2,  F. Sace3,  K. M. Lynch4,
J. McDuffie5,  M. Sonee5,  K. Marshall2,  M. Damour2,  L. Stephen2,
Y. P. Dragan1,  J. Fikes1 and L. B. Kinter1. 1Safety Assessment, AstraZeneca
Pharmaceuticals, Waltham, MA; 2Myriad RBM, Saranac Lake, NY; 3Pfizer, San
Diego, CA; 4GlaxoSmithKline, King of Prussia, PA; 5Janssen Pharmaceuticals, La
Jolla, CA.
A panel of 8 novel urinary protein biomarkers were recently qualified by the FDA
for the detection of acute kidney injury (AKI), significantly improving the sensitiv-
ity and specificity with which renal injury may be detected in rat. However, the
translation of these biomarkers to dogs, one of the most common species used in
preclinical drug development, remains unknown yet must be established prior to
broad implementation in toxicity screens. Here, we monitored AKI biomarkers
kidney injury molecule 1 (Kim-1), lipocalin-2 (NGAL), clusterin and albumin in
urine from male beagles infused once daily for 10 days with the nephrotoxic antibi-
otic gentamicin. Histological examination of the kidneys following treatment re-
vealed severe epithelial degeneration, necrosis and regeneration alongside tubular
dilation in gentamicin-treated dogs only. In gentamicin-treated dogs, significantly
elevated urinary protein levels of albumin, clusterin and NGAL were measurable as
early as 3 days after start of treatment with peak levels >100-fold above background.
Both the speed and magnitude of response detected with these new biomarkers
were superior to traditional AKI biomarkers, blood urea nitrogen (BUN) and
serum creatinine (sCr), which did not increase until day 8. Urinary Kim-1 levels
peaked around 2-fold, an order of magnitude lower than published levels from a
similar 10-day rat study. Further analysis of samples for Kim-1 mRNA and protein
will tell whether the canine Kim-1 response is markedly different from that ob-
served in rats. These data indicate that three of four novel biomarkers qualified in
rat (NGAL, clusterin and albumin) translate to canine and represent a substantial
improvement over traditional AKI biomarkers in preclinical drug development.
1883 Bio-Monitoring of Multimycotoxin Exposure in Human
Urine Samples from Cameroon Using a Multibiomarker
Approach.
W. A. Abia1, 2,  B. Warth2,  M. Sulyok2,  R. Krska2,  A. Tchana1,  P. B. Njobeh3,
P. C. Turner4,  C. Kouanfack5,  M. M. Dutton3 and P. F. Moundipa1.
1Biochemistry, University of Yaounde I, Yaounde, Cameroon; 2Department for
Agrobiotechnology (IFA-Tulln), University of Natural Resources and Life Sciences,
Vienna, Austria; 3Food, Environment and Health Research Group (FEHRG),
University of Johannesburg, Doornfontein, South Africa; 4MIAEH, School of Public
Health, University of Maryland, College Park, MD; 5Day Hospital, Central Hospital,
Yaounde, Cameroon.
Mycotoxins are secondary metabolites of fungi that contaminate food, but bio-
monitoring of human exposure has mostly been limited to a few individually meas-
ured mycotoxin biomarkers, mainly aflatoxin. The aim of this study was to deter-
mine frequency of exposure and level of multi-mycotoxin in urine samples obtained
from Cameroonian adults, mostly from HIV infected individuals. 175 urine sam-
ples (145/175; 83% from HIV positive individuals) as well as food frequency ques-
tionnaire responses were collected from consenting Cameroonians, and analyzed
for 8 parent mycotoxins and 7 key metabolites using liquid chromatography sepa-
ration and tandem mass spectrometry detection. In total, 11 mycotoxin biomarkers
[e.g. aflatoxin M1 (AFM1), fumonisin B1 (FB1), ochratoxin A and total deoxyni-
valenol] and bio-measures [FB2, nivalenol and total zearalenone] were recovered,
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individually or in combinations, in 110/175 (63%) samples; from HIV positive
(64%) and HIV negative (57%), with additional 4 analytes present only in HIV
positive samples. AFM1 (10%; mean 0.5, range <LOQ-1.4μg/L) and FB1 (3%;
mean 0.6, range 0.5-15μg/L) were detected in the HIV subpopulation whilst low
levels (<LOQ) were found in one sample each from HIV negative group. One HIV
positive individuals’ urine contained 6 metabolites. Levels of these metabolites were
generally similar to those reported elsewhere in Africa. For the first time in Africa
and elsewhere, this study has reported on 11 mycotoxin biomarkers/bio-measures
quantified in human urine. Mycotoxin exposures in HIV individuals may require
particular attention. The findings may constitute a major step towards mycotoxin
exposure assessment and national mycotoxin regulations in Cameroon.
1884 Development of a New Oxidative Stress Biomarker
Dityrosine ELISA.
K. Sakai1,  M. Takeuchi1,  T. Ochi1,  R. Rathnam2 and Y. Kato3. 1Japan Institute
for the Control of Aging, Fukuroi, Japan; 2Genox Corporation, Baltimore, MD;
3School of Human Science and Environment, University of Hyogo, Himeji, Japan.
Sponsor: K. Rao.
Accumulating evidence indicates that oxidative stress plays an important role in
various diseases such as cancer, diabetes and hypertension. Recently it is also re-
ported that oxidative stress is involved in toxicity of chemical substances such as ar-
senic, asbestos, diesel exhaust micro particles and antineoplastic drugs, and moni-
toring of oxidative stress inside human body may be informative for toxicological
study. Oxidative stress may cause oxidative damages to biomolecules such as nucleic
acids, lipids, proteins and enzymes, and oxidized products of such biomolecules
have been used for the assessment of oxidative stress in the living bodies. Although
protein is one of the most important biomolecules, only limited number of reports
about the oxidized proteins has been published. Tyrosine is one of the major targets
of protein oxidation, and dityrosine is known to be formed by oxidative stress. In
this presentation, development of a new dityrosine ELISA is reported.
A competitive dityrosine ELISA is established using anti-dityrosine monoclonal an-
tibody (clone 1C3) which was developed by Kato et.al. 50 uL of diluted samples or
standards are poured into micro plate wells which is pre-coated by dityrosine anti-
gen, and incubated at 4 degree C overnight. After washing by PBS-tween buffer,
100 uL of HRP-conjugated anti mouse antibody is poured, and incubated for 1
hour at room temperature. TMB is used for color development.
Assay range of dityrosine ELISA is 0.05 to 12 umol/L, and shows good linearity
and reproducibility. Dityrosine concentration in human urine ranges between 0.12
and 3.95 umol/L (mean 1.44 umol/L), and urinary dityrosine concentration meas-
ured by ELISA significantly correlated with that measured by LC-MS/MS. In con-
clusion, dityrosine ELISA may be useful for the assessment of oxidative stress in the
living bodies.
1885 Method Development of Serum Canine Inhibin B Enzyme-
Linked Immuosorbent Assay (ELISA).
R. Kuk1,  D. Kumar2 and S. B. Laffan1. 1Reproductive Toxicology, Safety Assessment,
GlaxoSmithKline, King of Prussia, PA; 2Assay Development, Bristol-Myers Squibb,
Syracuse, NY.
Inhibin B (INH-B) is a heterodimeric glycoprotein consisting of an alpha and a
beta-B subunit linked by disulphide bridges. INH-B is produced by the testes as
well as the ovaries, and is responsible for the selective negative feedback control of
follicle stimulating hormone. In males, INH-B is synthesized by the sertoli cells in
the testis, and can be used as a marker of sertoli cell function and spermatogenesis
in adult males. Hence, it is being considered a biomarker for detecting testicular
damage. INH-B has been quantified in humans, rats and non-human primates, but
not in canines due to lack of availability of reagents. Here, we report the methods
development of the canine INH-B ELISA from Cusabio Biotech Co. (Wuhan,
China). Assay standard curve is ranged from 4 to 1000 pg/mL with serum require-
ment of 50 μL. Assay optimization included modification of the procedure to in-
clude sample mixing followed by prolonged primary antibody-antigen incubation
time to ensure saturation. Two custom quality controls were prepared at levels that
are on the sensitive part of the standard curve. Qualification criteria included as-
sessment of the standard curve, quantification range, reproducibility (precision)
and dilutional linearity (% recovery). Standard curve was made more robust by
adding more points on the sensitive part of the curve. Lower limit of quantification
was qualified to be statistically above the variance of the blank value.
Reproducibility was good (%CV≤30%) among assays. Linearity was acceptable for
kit standards diluted with castrated dog serum or commercially available serum ma-
trix, also, for intact serum diluted with its respective castrated serum (R2>0.9). This
assay can detect >8 fold INH-B difference between intact and castrated canine
serum samples. Other parameters like frozen storage, freeze/thaw and lot-to-lot sta-
bility are pending. We conclude that this canine INH-B assay can consistently
quantify INH-B levels in canine serum under the modified procedures.
1886 Mitigation of Fumonisin Biomarkers by Green Tea
Polyphenols.
K. Xue1,  L. Tang1,  Q. Cai2,  L. Xu1,  J. Su3 and J. Wang1. 1University of Georgia,
Athens, GA; 2Texas Tech University, Lubbock, TX; 3Guangxi Cancer Institute,
Nanning, China.
Fumonisin B1 (FB1) is a carcinogen and a strong tumor promoter in animal mod-
els. Green tea polyphenols (GTP) are highly effective in inhibition of a variety of
carcinogen-induced tumorigenic effects in many model systems. In this study we
assessed mitigative effects of GTP on FB1-biomarkers in blood and urine samples
collected from a randomized, double blinded, and placebo controlled intervention
trial, which recruited a total of 124 people aged 20-55 who exposed FB1 via their
corn-based diet. These participants were consented, randomly divided into 3
groups, and daily treated with either low-dose (GTP 500 mg, n=42), high-dose
(1,000 mg, n=41) or placebo (n=41) for 3 months. Urinary levels of free FB1 at
baseline were comparable (medium at 560.73, 574.56, and 559.09 pg/mg creati-
nine) for all three groups (p=0.162). Levels at urine samples collected at 1-month of
the intervention was significantly decreased in the high-dose group (medium:
364.94 pg/mg creatinine; p<0.01) as compared with level in the placebo group
(medium: 575.25 pg/mg creatinine). The inhibition rate is 18.95% in low-dose
group and 33.62% in high-dose group. Levels of free FB1 at samples collected at 3-
month of the intervention showed significant decrease in both low-dose (medium:
319.45pg/mg creatinine; p<0.01) and the high-dose (medium: 215.83pg/mg crea-
tinine; p<0.01) groups as compared with the levels of the placebo group as well as
the baseline levels. The inhibition rate is 40.18% in low-dose GTP group and
52.6% in high-dose GTP group. Levels of sphinganine (Sa), sphingosine (So), and
their ratio in urine and serum samples were also evaluated in this study. These re-
sults demonstrate that supplement of GTP effectively mitigates urinary excretion of
free FB1 via to be specified pathways in humans.
1887 Variation of Urinary Creatinine.
H. Na and M. Yang. Sookmyung Women’s University, Seoul, Republic of Korea.
Urinary creatinine has been commonly used for adjusting dilution status of urine
species in biological monitoring. However, it can vary according to sex, age, race,
BMI, meat intake, etc. The purposes of our study are to investigate the intra- and
inter-individual variations of urinary creatinine in a sex, age and race matched sub-
jects, and to study the impact of meat intake on the variations of urinary creatinine.
We designed a diet-controlled study among the subjects who were Korean healthy
females (N=9, age= 20±4 yrs, BMI 19.7±2.4 kg/m2) and measured urinary creati-
nine at 5 intervals during 24 hours with and without meat consumption. As results,
diverse intra-and inter-variations of creatinine levels were shown in the subjects:
When subjects did not take meat, the largest and smallest intra-variations in uri-
nary creatinine ranges were detected in the subject C and G, i.e. 0.34-2.97
(Δ2.63)g/L and 0.93-1.63 (Δ0.7) g/L, respectively. In addition, creatinine levels at
5-intervals were significantly different between the highest and lowest average lev-
els-subjects, i.e. 2.13±0.73 g/L of the subject I and 0.86±0.52 g/L of the subject A
(p<0.05), respectively. With intake of meat (charcoal-grilled Korean beef tender-
loin), the trend of intra-variation of urinary creatinine in each subject was not dif-
ferent (p=1.00 by Fisher exact test). It suggests that meat intake had little influence
on intra- and inter-variation of urinary creatinine. In conclusion, our data re-em-
phasize that urinary creatinine must be measured in each spot urine even among
the subjects who have similar age, sex, race and BMI due to its intra- and inter-vari-
ation. In the near future, the causes of intra- and inter-individual variations of uri-
nary creatinine should be further studied.
1888 Cardiolipin As a Biomarker of Mitochondrial Dysfunction
Associated with Parkinson’s Disease.
Y. Tyurina1, 2,  D. Winnica1, 2,  V. Kapralova1, 2,  V. Tyurin1, 2 and V. Kagan1, 2.
1Department of Environmental and Occupational Health, University of Pittsburgh,
Pittsburgh, PA; 2Center for Free Radical and Antioxidant Health, Pittsburgh, PA.
A commonly used pesticide, rotenone, is a mitochondrial respiratory complex I in-
hibitor capable of selective oxidation of mitochondrial phospholipid, cardiolipin
(CL). Given that rotenone exposure is associated with the development of
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Parkinson disease (PD), we hypothesized that CL peroxidized molecular species ac-
companying mitochondrial dysfunction may represent a new biomarker of PD. In
this study, we used circulating lymphocytes isolated from human blood and found
that rotenone (50-250μM, 12-18h) caused apoptosis (phosphatidylserine external-
ization, caspase 3/7 activation), reactive oxygen species production (superoxide,
H2O2), mitochondrial dysfunction (inactivation of complex I, decrease of mito-
chondria membrane potential, depletion of ATP) and activation of peroxidase ac-
tivity of mitochondria. Using an oxidative lipidomics approach, we found that
treatment of lymphocytes with rotenone resulted in accumulation of monolyso-CL
and oxygenated free fatty acids. In addition we were able to detect oxygenated mo-
lecular species of tetra-linoleyl CL, a major CL molecular species in lymphocytes.
Notably, molecular species of oxygenated CL formed in human lymphocytes were
similar to those formed in cyt c driven reaction in the presence of H2O2 – in line
with the known participation of cytochrome as a catalyst of CL peroxidation dur-
ing apoptosis. Using the combination of lipidomics and oxidative epitope-targeted
enzymatic digestion of oxidized tetralinoleoyl-CL we found that its oxygenated LA
species were represented by hydroxy- and hydroperoxy-derivatives. Thus, we con-
clude that CL and its oxygenation products and metabolites may represent a new
biomarker of rotenone-induced mitochondrial dysfunction associated with PD.
Supported by NIOSH OH008282; NIH ES020693, U19 AI068021, HL70755.
1889 Evaluation of Insulin-Like Growth Factor Acid-Labile
Subunit As a Novel Biomarker of Effect to the Mycotoxin
Deoxynivalenol.
B. Flannery1, 2,  C. J. Amuzie2 and J. Pestka1, 2, 3. 1Food Science and Human
Nutrition, Michigan State University, East Lansing, MI; 2Center for Integrative
Toxicology, Michigan State University, East Lansing, MI; 3Microbiology and
Molecular Genetics, Michigan State University, East Lansing, MI.
Deoxynivalenol (DON) is a trichothecene mycotoxin produced from Fusarium
species frequently found in grain products due to its recurrent contamination and
resistance to food processing treatments. In growing experimental animals, chronic
low-level DON exposure has resulted in anorexia, weight suppression and growth
hormone axis perturbations. As a result, children are thought to be especially sensi-
tive to DON. Though a biomarker of exposure exists to measure DON exposure in
humans, no biomarker of effect is currently available to predict the adverse negative
weight effects of DON, thereby hindering complete risk assessment of this myco-
toxin. Two studies were conducted to assess the potential of plasma insulin-like
growth factor acid-labile subunit (IGFALS) to be used as an effect biomarker for
DON. In the first study, a 9 wk dietary DON exposure was employed in mice to
test the hypothesis that depression in plasma IGFALS occurs at toxicologically rele-
vant doses prior to significant weight suppression. Results showed that the 1)
NOAEL for depressed plasma IGFALS and weight was 2.5 ppm DON and 2) de-
creased plasma IGFALS was detectable before significant weight suppression was
evident. In the second study, the specificity of reduced plasma IGFALS to DON,
rather than DON-induced anorexia, was assessed using a dietary restriction study.
Mice were fed ad-lib control diet, restricted control diet or identical amounts of re-
stricted 15 ppm DON diet. Mice fed restricted DON diet exhibited significantly
less plasma IGFALS than the restricted control indicating the specificity of plasma
IGFALS reductions to DON. Thus, plasma IGFALS might be one suitable bio-
marker for predicting DON’s adverse growth effects in animals and humans.
1890 Validation of a Meso Scale Discovery Immunoassay for KIM-
1 Renal Biomarker in Cynomologus Monkey (Macaca
fascicularis) Urine.
D. Fix and W. J. Reagan. Drug Safety, Pfizer, Groton, CT. Sponsor: J. Aubrecht.
The purpose of this study was to validate an immunoassay for detection of Kidney
Injury Molecule 1 (KIM-1) in the urine of cynomologus monkeys (NHP).
Monkeys were treated with escalating doses of a compound that induced tubular
degeneration/regeneration as determined by histopathology. Urine was collected
pre-dose, 16 days post dose and 21 days post dose and urine with low, medium and
high values of KIM-1 were used to validate the Meso Scale Discovery (MSD)
Human KIM-1/TIM-1 (single-plex) immunoassay kit as this kit cross reacts with
NHP KIM-1. Additional urine from older colony monkeys as well as normal
younger NHPs were also used to establish a preliminary observed range
(<0.01ng/mL). We determined intra-assay (7.7% CV) and inter-assay precision
(24.5% CV), limit of blank (0.000331ng/mL), limits of quantitation (0.01ng/mL
to 10ng/mL), dilutional linearity (not linear when diluted), recovery (84.8% -
122.8%), preliminary quality control range evaluation (0.438ng/mL/ CV 18.7%;
0.615ng/mL/ CV 16.8%), freeze/thaw (F/T) stability out to 4 F/T cycles (95.5% -
112.5%), and sample storage stability out to 10 weeks. There was also a good bio-
logic correlation with time and dose-dependent increases in KIM-1 for the toxicity
study samples. All parameters measured showed acceptable immunoassay assay per-
formance except dilutional linearity. Based on this assay performance and the other
results obtained, the validated method is robust and can be performed under good
laboratory practice conditions to support nonclinical studies to assess for renal tox-
icity.
1891 Evaluation of a Three-Dimensional Oral Cell Model for the
Assessment of Tobacco Products.
W. Fields,  K. Fowler and B. R. Bombick. R. J. Reynolds Tobacco, Company,
Winston-Salem, NC. Sponsor: S. Theophilus.
Oral disease is frequently associated with viral and environmental exposures as well
as oral hygiene. The goals of this study were to evaluate the impact of smokeless to-
bacco extracts (STE) and cigarette total particulate matter (TPM) on cell survival,
oxidative stress, inflammatory response and tissue integrity using three-dimensional
cultures of human buccal (EpiOral™) cells.
EpiOral™ cells were treated with extracts of 1S2 (reference dry snuff ), 2S3 (refer-
ence moist snuff ) and a smokeless tobacco blend prepared in complete artificial
saliva (CAS) as well as with TPM from Kentucky Reference 3R4F cigarette
(DMSO-based) for time points through 24 hours. Toxicity was assessed with the
lactate dehydrogenase (LDH) assay. Glutathione (GSH) measurement and histo-
logical analyses were used to assess oxidative stress and changes in tissue integrity,
respectively. Gene expression analyses were also conducted via QRT/PCR and mul-
tiplex cytokine testing.
Dose- and time-dependent release of LDH was observed for all test articles. The
optimal exposure time appears to be 12 hours where 3R4F TPM elicited up to a 3-
fold increase in LDH release; the 1S2 and 2S3 extracts yielded a 2-fold increase
while no increase was observed for the smokeless tobacco blend. Tissue integrity
was slightly disrupted by TPM exposure, while no impact was observed for the
STEs.
Oxidative stress as measured by GSH analysis was not apparent for any of the test
articles; however, altered inflammatory response was observed by changes in IL-1α
and G-CSF cytokine release and modulations in at least one of the following genes,
IL-1α,TNFα or COX-2. The test articles also induced increases in cellular stress
and xenobiotic metabolism as determined by changes in HO-1, HSP-70, CYP1A1
and CYP1B1.
Collectively, the data suggest that the EpiOral™ three-dimensional human cell cul-
ture model may be useful in evaluating tobacco extracts.
1892 Assessment of Cardiac Biomarkers in Cynomolgus
Macaques.
T. Parman,  N. Chini,  D. Vuong,  M. Patrick,  B. Schneider,  K. Tinajero,
L. Tang,  D. Fairchild,  K. Lopez and J. C. Mirsalis. SRI International, Menlo Park,
CA.
A number of new cardiac biomarkers have recently been developed for use in ro-
dents; however, there are no validated cardiac biomarkers suitable for use in nonhu-
man primate (NHP) studies. We previously reported results of cardiac markers in
African green monkeys (AGM) and Rhesus macaques (RM). In the current study
we have extended these evaluations to Cynomolgus macaques (CM), the most
widely used NHP species for toxicity studies. Two CM/sex were given a single sub-
cutaneous (sc) injection of isoproterenol (IPT; 4 mg/kg); 1 CM/sex received sc
saline. Cardiac effects of IPT were observed within 1 hr postdose and included hy-
potension, ventricular premature complexes, ventricular bigeminy, atrial premature
complexes, with or without aberrant conduction and ST segment elevation. Blood
samples were collected prestudy and at 1, 4, 24, 48 and 72 hr postdose, and evalu-
ated with MSD MIP-1 muscle injury kits (rat: cTnI, cTnT, FABP3, Myl3, sTnI;
human: TNI). IPT produced significant increases in the level of most cardiac bio-
markers: cTnT, FABP3, Myl3, sTnI and human cTnI were increased over predose
levels by 4.2-, 2.5-, 25-, 28- and 23-fold, respectively, with peak times ranging from
4 to 48 hours. Similar results were seen in females, though rat cTnI was not in-
creased in males, but a 4.9-fold increase was seen in females. At 72 hr postdose,
there were still elevations in Myl3 and sTnI. IPT plasma levels at 1 hr postdose were
higher in males (708 ng/ml) than in females (324 ng/ml) and fell to 324 and 102
ng/ml at 4 hr in males and females, respectively. Heart histopathology 3 days post-
dose revealed minimal to moderate cardiac myofiber degeneration, myofiber kary-
omegaly and leukocyte infiltration in all treated animals. These results indicate that
the MSD rat and human muscle injury panel provides excellent sensitivity for as-
sessing cardiac effects in CMs, and these data are consistent with the utility of these
kits previously reported in RM and AGM. Work supported by NIAID Contract
N01-AI-70043.
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1893 A Comparative Study on Renal Toxicity of Industrial
Chelates Using Novel Urinary Protein Biomarkers As Early
Predictors of Nephrotoxicity.
R. Krishnaraj1,  E. C. Bisinger1,  N. Edgerton2,  D. E. Dodd2 and J. Mapes3.
1AkzoNobel Services, Inc., Chicago, IL; 2The Hamner Institutes for Health Sciences,
Research Triangle Park, NC; 3Myriad RBM, Inc., Austin, TX.
Toxicogenomic approaches have identified protein biomarkers of renal cell in-
jury/repair as early predictors of renal toxicity prior to changes in renal histopathol-
ogy. We used these novel biomarkers to determine if rats orally dosed with indus-
trial chelates exhibited altered urinary biomarker levels that preceded
histopathologic changes in kidney. The nephrotoxicant/renal carcinogen, nitrilotri-
acetic acid (NTA), is known to cause rat proximal tubule cell injury/repair (3–7
weeks) followed by renal tumors (2 years) after oral dosing. A new, readily
biodegradable chelate, L-glutamic acid diacetic acid (GLDA), previously which
showed no significant microscopic renal changes (90-day, oral), and EDTA, known
non-carcinogen (oral bioassay) were also included in our study. Male Wistar rats
were gavaged daily (oral, 28 days, 1000 mg/kg/day; n=10/group) with Na+ salts of
these chelates. As expected, mean urinary levels of Na+ & Zn2+ were elevated in all
chelate-treated groups. Two rats in NTA group were euthanized as moribund on
Day 13. The surviving NTA group showed decreases in mean body weights, food
and water consumption, and urine Mg2+, and increases in the mean levels of urine
Ca2+, total protein, lactate dehydrogenase, kidney injury molecule-1 (Kim-1),
Clusterin (CLU) and increased proximal tubule cell proliferation (BrdU). No such
changes were seen with GLDA. Kim-1 and CLU are inducible kidney proteins and
are approved by FDA as predictive, early and noninvasive urinary biomarkers of
kidney cell injury/repair. At necropsy, bilateral kidney enlargement (mean relative
kidney weights) was noted with NTA, but not GLDA. In conclusion, our study
showed that NTA, but not GLDA or EDTA, caused significant early renal cell tox-
icity when evaluated with urinary protein biomarkers as early predictors of nephro-
toxicity.
1894 Identifying Biomarkers of Kidney and Liver Toxicity by
Integrating Toxicogenomics Datasets with Biological
Networks.
P. Hewitt1,  T. C. Fuchs1,  R. B. Russell2,  D. Mitic2 and G. Apic2. 1Merck KGaA,
Darmstadt, Germany; 2Cambridge Cell Networks Ltd., Cambridge, United Kingdom.
The aim of this study was to identify candidate biomarkers of kidney toxicity by in-
terrogating transciptome profiles from hundreds of publicly available toxicoge-
nomics datasets and to test the findings with additional in vivo studies. We manu-
ally annotated 34,837 toxicogenomics observations from over 345 articles.
Additionally, raw transcriptomics datasets from the EU PredTox and Japanese TG-
GATEs projects were assessed. We ranked biomarkers by a combination of scores:
1) presence of the datasets where biomarkers were sought (e.g. nephrotoxicity); 2)
absence in control datasets (e.g. other toxicities); 3) network centrality within the
dataset (by exploiting, curated dataset of interactions between protein, gene and
chemicals, which considers the nature of the interaction and its confidence; 4) pre-
viously observed presence of the protein coded by the gene in urine or blood sam-
ples. Application of these approaches to the three datasets identifies 43 significant
candidates (of 1273 genes identified at least once in a kidney array) including
NGAL, HAVCR1 (Kim-1) and clusterin and several new candidates. These find-
ings correspond to tests performed on model nephrotoxic compounds (cisplatin
(0.3 and 0.6 mg/kg), vancomycin (50 and 300 mg/kg) and puromycin (10 and 30
mg/kg)) using whole genome expression profile experiments [Illumina RefSeq]
both in vivo (Rat; 3, 7, 14 and 28 days) and in vitro (rat NRK cells; 24 and 72h),
and a battery of biomarker detection assays in urine. Four of the six best kidney tox-
icity biomarker candidates identified by these experiments were among the 43 can-
didates above. Overall, the results demonstrate that our in silico approach can
greatly enrich candidates for those likely to be true biomarkers when given large
datasets of dysregulated genes. 
This project was funded by the German Federal Ministry of Education and
Research (BMBF) under the BioRhine-Neckar Spitzencluster (BioRN-BMC-
TP08).
1895 Evaluation of Novel Biomarkers of Nephrotoxicity in
Monkeys Treated with Gentamicin.
J. Gautier1,  X. Zhou2,  Y. Yang3,  T. Gury1,  Z. Qu2,  J. Léonard1,  J. Wang2,
P. Detilleux1 and B. Li2. 1Preclinical Safety, Sanofi, Vitry-sur-Seine, France;
2National Center for Safety Evaluation of Drugs, Beijing, China; 3Preclinical Safety,
Sanofi, Shanghai, China.
Most studies to evaluate renal safety biomarkers have been performed in rats. This
preliminary study was conducted in cynomolgus monkeys to define the optimal
conditions to evaluate the potential usefulness of novel biomarkers of nephrotoxic-
ity in this species. Groups of 3 males were given daily intramuscular injections of
10, 25, 50 mg/kg/day gentamicin, a known nephrotoxic agent, for 10 days and 75
mg/kg/day for 9 days and were sacrificed on Day 10 or 11. Blood samples and 16-
hour urine samples were collected on Days -7, -3, 2, 4, 7 and at the end of the dos-
ing period. In parallel to conventional parameters, the novel urinary renal biomark-
ers evaluated (after normalization to urinary creatinine) included
α1-microglobulin, microalbumin, clusterin and calbindin. Kidney microscopic
findings consisted in dose dependent increase in tubular cell degeneration/necrosis
from minimal to mild at 10 mg/kg/day, moderate at 25 mg/kg/day, to severe at 50
and 75 mg/kg/day gentamicin. Serum creatinine was slightly increased at 10
mg/kg/day on Day 11 (less than 25% increase as compared to pre-test values in
each individual animals), moderately increased (2-fold) at 25 mg/kg/day on Day
11, and markedly increased (more than 2-fold) at 50 and 75 mg/kg/day from Day
7. Parallel increases were observed with BUN. Urinary α1-microglobulin was in-
creased by 4.5-fold and microalbumin, clusterin, calbindin were increased by more
than 20-fold as compared to pre-test values in each individual animals at 10
mg/kg/day on Day 11. Marked increases in these urinary biomarkers were also ob-
served at higher doses of gentamicin from Day 7. These first results indicate that
the urinary biomarkers α1-microglobulin, microalbumin, clusterin and calbindin
may be useful sensitive biomarkers of nephrotoxicity in monkeys and potentially in
humans.
1896 Restricted Diet Prevents Negative Effects of OVX on Soft
Tissue Composition.
R. Samadfam and S. Y. Smith. Bone Research, Charles River, Montréal, QC,
Canada. Sponsor: M. Vézina.
Ovariectomy (OVX) in rats is associated with weight gain and loss of bone mass.
The increased body weight is in part attributed to increases in growth, consistent
with OVX-induced hyperphagia.  The objective of this study was to determine the
effects of OVX on body composition in aged rats (over 6 months of age) with or
without food restriction. PMI Nutrition International diet was used for all animals
with animals assigned to the restricted diet groups receiving 21 g/day. Body com-
position was evaluated at baseline and at 4, 8, 12 and 19/20 weeks post surgery
using DXA (Dual Energy X-ray Absorptiometry) and/or pQCT (Peripheral
Quantitative Computed Tomography).  DXA evaluation showed increases in whole
body area and BMC for OVX rats on both restricted and unrestricted diet com-
pared to their corresponding sham controls, with greater increases for animals fed
ad libitum. Overall, BMD for OVX groups were comparable to baseline values
whereas increases up to 2 and 6% were noted for sham controls respectively on the
restricted and fed ad libitum. Significant increases were noted over the study period
in muscle mass for rats on restricted diet, with trends for increases in fat mass. For
ad libitum fed rats, although an increase in muscle mass was noted 4 weeks follow-
ing surgery compared to sham controls, muscle mass gradually declined over the re-
maining study period with lower values 20 weeks post surgery. Fat mass increased
for this group. When muscle mass and fat mass values were adjusted for body
weight, no significant differences were noted between OVX and sham controls for
animals on the restricted diet, indicating that the increased body weight is the result
of proportional increases in muscle and fat mass, likely related to the effect of OVX
on skeletal growth. For animals fed ad libitum, significant decreases in lean mass
with significant increases in fat mass were noted when adjusted for body weight,
compared to sham controls, indicating negative effects on soft tissue composition.
Data from the restricted diet group suggest that calorie restriction prevents OVX-
induced muscle loss and fat gain.
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1897 3, 3’, 4, 4’, 5-Pentachlorobiphenyl (PCB 126) Decreased the
Ratios of Epoxide Metabolites to Their Corresponding Diols
in Male Rodents.
X. Wu1,  J. Yang2,  C. Morisseau2,  L. W. Robertson1,  B. D. Hammock2 and
H. Lehmler1. 1Department of Occupational and Environmental Health, University of
Iowa, Iowa City, IA; 2Department of Entomology, University of California Davis,
Davis, CA.
Oxylipins are oxygenated metabolites of certain fatty acid species. Changes in the
homeostasis of these regulatory lipid mediators are of interest as markers of expo-
sure to certain toxicants, including the aryl hydrocarbon receptor agonist
3,3’,4,4’,5-pentachlorobiphenyl (PCB 126). Here we test the hypothesis that
chronic exposure to PCB 126 alters the levels of regulatory lipid mediators (oxylip-
ins) in rats. Male Sprague-Dawley rats (5 weeks old) were treated biweekly with in-
jections of PCB 126 in corn oil over a period of 3 months, representing cumulative
PCB doses of 0, 0.06, 0.3, and 1.2 μg/kg body weight. PCB 126 treatment caused
a dose-dependent reduction in growth and relative thymus weight, while relative
liver weight was increased with PCB dose. PCB 126 levels in the liver increased in a
dose-dependent manner, while PCB 126 levels in plasma were below the detection
limit. The ratios of epoxide/diol metabolites displayed a dose-dependent decrease in
plasma for oxylipins derived from arachidonic acid (ARA), eicosapentaenoic acid
(EPA), docosahexaenoic acid (DHA) and linoleic acid (LA), as determined by
metabolomics profiling of oxylipins with liquid chromatography-tandem mass
spectrometry. Similarly, the epoxide/diol ratios for ARA and DHA derived oxylip-
ins decreased in a dose-dependent manner in the liver. The effects of PCB treat-
ment on epoxide/diol ratios were associated with significantly increased activities of
soluble epoxide hydrolase (sEH) in cytosol and peroxisomes in the liver at the high-
est PCB 126 dose. Since increased sEH activity and decreased epoxide/diol metabo-
lites ratios have been linked to cardiovascular disease and inflammation, our results
suggest that changes in oxylipin plasma levels may be useful biomarkers of human
exposure to PCB 126 and other dioxin-like compounds [supported by NIH grants
ES04699 and ES013661].
1898 Identification of Neural Biomarkers of Altered Sexual
Differentiation following Gestational Exposure.
G. W. Louis1, 2,  D. R. Hallinger1 and T. E. Stoker1. 1Endocrine Toxicology Branch,
Toxicity Assessment Division, US EPA, Research Triangle Park, NC; 2ORISE
Program, Department of Energy, Oak Ridge, TN.
Sexual differentiation of the brain occurs during late gestation through the early
postnatal period. The development of the phenotypical male brain is dependent on
the aromatization of circulating testosterone to estradiol. Exposure to endocrine
disrupting chemicals (EDCs) during early-life alters sexual maturation of the rat
hypothalamic-pituitary-gonadal axis and subsequently, the timing of puberty and
adult reproductive behavior. We set out to identify predictive neuronal biomarkers
for use in evaluating the effect of EDCs on sexual differentiation in the male and fe-
male. We examined changes in gene expression in the rat hypothalamus [(specifi-
cally, in the anteroventral periventricular nucleus (AVPV) and arcuate nucleus
(ARC)] after in utero exposure to the aromatase inhibitor, letrozole. Pregnant dams
were gavaged with vehicle or letrozole (0.1mg/kg) on gestational days 20 and 21.
The AVPV and ARC were microdissected from male and female offspring on sev-
eral pre-, peri-, and post-pubertal postnatal days (PND) and were evaluated for
changes in expression of a number of neuropeptides that have sex specific patterns
during development. These genes include those that encode for kisspeptin (Kp) and
tachykinin-2 (Tac2). We identified an increase with age in the expression of Kp in
the AVPV of the genetic female, but not the genetic male. Kp expression in the
AVPV of the letrozole-exposed genetic male was increased to the same level ob-
served in the genetic female on PND 14, 25 and 49. However, Kp expression in the
male ARC was not altered by letrozole. ARC Tac2 expression in the male was also
not changed by letrozole. This work will provide optimal time points for these
measures, but additional studies are needed to determine whether these, and other
CNS biomarkers, are predictive of altered puberty and/or sexual behavior due to
early-life EDC exposure. This abstract does not necessarily reflect EPA policy.
1899 Biomarkers of Exposure and Effect in Long-Term Smokers
and Moist Snuff Consumers.
B. A. Jones1,  G. L. Prasad1,  P. Chen1 and D. W. Graff2. 1R & D, RJ Reynolds
Tobacco Co., Winston-Salem, NC; 2Celerion, Lincoln, NE. Sponsor: G. Krautter.
To assess the effects of chronic exposure to combustible and non-combustible to-
bacco product use, a single site, cross-sectional clinical study was conducted. Three
cohorts of healthy males (40/cohort, 35-60 years) were enrolled: long-term smokers
and moist snuff consumers (MSC), and non-tobacco consumers (NTC). Select
biomarkers of exposure (BioExp) and potential biomarkers of effect (BioEff ) indi-
cating oxidative stress, inflammation and metabolomic changes, among others,
were investigated. Blood biomarkers were measured in subjects abstaining
overnight from both food and tobacco, and urinary biomarkers were measured in
ambulatory collections of 24h urine samples. Nicotine (and its metabolites) and
total tobacco specific nitrosamines (TSNAs) were higher in MSC followed by
smokers and NTC. Tobacco combustion-related BioExp (polycyclic aromatic hy-
drocarbons, aromatic amines and mercapturic acid metabolites) were significantly
higher in smokers, with no difference observed between MSC and NTC cohorts.  
Compared to NTC and MSC, smokers exhibited significantly elevated levels of
biomarkers associated with oxidative stress, inflammation, and platelet activation.
Smokers also exhibited significantly higher levels of apolipoprotein B100 and oxi-
dized low-density lipoprotein relative to NTC and MSC. Thus, alterations in
BioEff suggesting inflammation, oxidative stress and altered lipid metabolism were
detected in smokers compared to the non-smoking cohorts. In summary, our find-
ings are in agreement with existing epidemiological data which show the reduced
harm from smokeless tobacco consumption compared to smoking, with no-to-
bacco-use being the least risky. The BioExp and BioEff evaluated in this study are
likely to be useful in future assessments of the health effects of new tobacco prod-
ucts.
1900 Mechanistic Biomarkers Provide Early Detection of
Acetaminophen-Induced Acute Liver Injury at First
Presentation.
D. Antoine1,  C. Goldring1,  P. Starkey-Lewis1,  J. Dear2,  J. Moggs3,  V. Platt1 and
B. Park1. 1MRC Centre for Drug Safety Science, University of Liverpool, Liverpool,
United Kingdom; 2NPIS Edinburgh, University of Edinburgh, Edinburgh, United
Kingdom; 3Preclinical Safety, Novartis Institutes for Biomedical Research (NIBR),
Basel, Switzerland. Sponsor: D. Mendrick.
We investigated the potential of a panel of novel biomarkers - which demonstrate
either enhanced liver expression or are linked to the mechanisms of toxicity - to
identify patients with paracetamol (acetaminophen)-induced acute liver injury at
first presentation to hospital when current liver injury markers are normal. In
plasma samples from patients (n=129), at first presentation to hospital following
paracetamol overdose, we measured microRNA-122 (miR-122; high liver speci-
ficity), High Mobility Group Box-1 (HMGB1; marker of necrosis), full length and
caspase-cleaved Keratin-18 (K18; markers of necrosis and apoptosis, respectively)
and glutamate dehydrogenase (GLDH; marker of mitochondrial dysfunction). In
all patients, the biomarkers at first presentation significantly correlated with peak
ALT/INR (International Normalized Ratio). In patients with normal ALT/INR at
presentation, miR-122, HMGB1 and necrosis K18 identified the development of
liver injury (n=15) or not (n=84) with a high degree of accuracy, and significantly
outperformed ALT activity, INR and plasma paracetamol concentration for the
prediction of subsequently liver injury (n=11) compared with no injury (n=52) in
those patients presenting within 8 hours of overdose. Elevations in plasma miR-
122, HMGB1, and necrosis keratin-18 identify subsequent development of acute
liver injury in patients on admission to hospital, soon after paracetamol overdose,
and in patients with ALTs in the normal range. The clinical development of such a
biomarker panel could improve the speed of clinical decision making, both in the
treatment of acute liver injury and in the design/execution of new treatment strate-
gies that aim to refine the management of this common poisoning.
1901 Lead Concentrations Correlation between Fingernails and
Whole Blood.
K. P. Olympio1,  C. A. Cardoso2,  M. C. Rodrigues2,  I. Ramires2,  M. S. Luz3,
L. G. Albuquerque3,  F. Barbosa4,  M. A. Cardoso1,  P. V. Oliveira3,
W. R. Günther1 and M. A. Buzalaf2. 1Faculdade de Saúde Pública - USP, São Paulo,
Brazil; 2Faculdade de Odontologia de Bauru - USP, Bauru, Brazil; 3Instituto de
Química - USP, São Paulo, Brazil; 4Faculdade de Ciências Farmacêuticas - USP,
Ribeirão Preto, Brazil.
Whole blood has been the biological fluid of choice to assess lead exposure. Other
biomarkers need to be studied deeply, and the analysis of trace metals concentra-
tions in nails is a non-invasive and simple collection procedure. The aim of this
study was to investigate possible correlations between blood lead levels (BLL) and
washed and non-washed fingernails lead levels (FLL) in 55 adults living in a lead
contaminated area. Venous blood and fingernails (thumbs and forefingers) samples
were collected. The nails of the left hand were washed with acetone and HCl 0.1
mo L-1 and the nails from right hand were not submitted to any pre-analytical pro-
cedure. Samples were analyzed by GF AAS and pairwise correlations were used to
correlate lead concentrations between: BLL and FLL; nails from fingers from the
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same hand and between washed and non-washed fingernails. It was found a non-
significant correlation between BLL and washed forefinger nails lead (r=0.219,
p=0.112) and between BLL and thumb nails lead (r=0.182, p=0.191). Comparing
fingernails from the same hand (thumb and forefinger), lead concentrations of non-
washed nails varied largely, even when transversal fragments from the same nail
were analyzed. Lead concentrations in non-washed forefingers nails were not found
to be correlated with non-washed thumb nails (r=0.169, p=0.219). On the other
hand, for washed nails, thumb and forefinger nails were found to be correlated
(r=0.39, p=0.003). In conclusion, the results showed that non-washed nails are not
a reliable biomarker for lead exposure. However, although washing up the nails may
diminish the lead external contamination, the correlation between fingers is still
weak to consider fingernail as a biomarker to lead exposure. In addition, even the
washed nails were not found to be significantly correlated to BLL.
1902 Detecting and Quantifying Endogenous and Exogenous
Formaldehyde Adducted Hemoglobin Utilizing Selected
Reaction Monitoring.
G. L. Andrews Kingon1,  B. C. Moeller1 and J. A. Swenberg1, 2. 1Curriculum in
Toxicology, University of North Carolina at Chapel Hill, Chapel Hill, NC;
2Environmental Sciences and Engineering, University of North Carolina at Chapel
Hill, Chapel Hill, NC.
Widely recognized as a highly toxic compound, formaldehyde (FA) is considered to
be a known animal and human carcinogen. It is ubiquitously present through nor-
mal cellular metabolism as well as from environmental pollutants. This compound
is highly reactive towards macromolecules, forming diverse protein adducts and
DNA damage that can be employed as biomarkers of chemical exposures. In partic-
ular, hemoglobin and red blood cells (RBCs) exposed to FA have been shown in
laboratory studies to form an imidazolidone-type structure on the N-terminal pep-
tides of hemoglobin alpha and beta chains. This data and the long lifetime of he-
moglobin in RBCs (63 days in rats and 120 days in humans) afford investigation of
the formation of endogenous and exogenous FA-hemoglobin adducts and the accu-
mulation and loss of adducts. Monitoring this biomarker may reveal if inhaled FA
enters the systemic circulation and reaches distant sites. In order to differentiate the
origin of FA (endogenous versus exogenous), 10 ppm [13CD2]-FA rat inhalation ex-
posures of 6 hours/day for 1 or 5 days were performed and globin was isolated from
the washed RBCs. Stable isotope labeled peptides for the alpha and beta chains of
hemoglobin were synthesized and purified then reacted with FA to achieve the im-
idazolidone modification. These internal standards were then spiked into the glo-
bin samples prior to trypsinization and off-line fractionation. Utilizing protein
cleavage isotope dilution mass spectrometry and selected reaction monitoring,
methods were developed for quantification of the N-terminal valine FA hemoglo-
bin adduct peptides. In vitro reactions of RBCs and FA are ongoing to determine
penetration of the chemical into the RBCs and biomarker stability following expo-
sure. Additional globin samples from exposed and control rats and nonhuman pri-
mates have been collected and analyses are in progress.
1903 Assessment of the Relative Performance of Ten Urinary
Biomarkers for Renal Safety across Twenty-Two Rat
Toxicology Studies.
Z. Erdos,  K. Vlasakova,  H. Jin,  K. McNulty,  L. Phadtare,  V. Chapeau,
N. Mokrzycki,  S. P. Troth,  N. Muniappa,  E. Wang,  D. Holder,  W. J. Bailey,
F. D. Sistare,  W. E. Glaab and Y. Gu. Safety Assessment and Laboratory Animal
Resources, Merck Research Laboratories, West Point, PA.
Novel kidney injury markers have been recently identified which may outperform
or add value to the conventional kidney injury biomarkers blood urea nitrogen
(BUN) and serum creatinine. To assess the relative performance of the growing list
of these novel biomarkers, a comprehensive evaluation was conducted for 10 uri-
nary biomarkers in 22 rat studies including both kidney toxicants and compounds
with toxicities observed only in other organs. Furthermore, these kidney toxicity
studies included proximal tubule toxicants as well as glomerular toxicants. The ten
urinary biomarkers evaluated included Kim-1, Clusterin, Osteopontin,
Osteoactivin, Albumin, Lipocalin-2, GST-alpha, β2-Microglobulin, Cystatin C,
and Retinol Binding Protein 4 using novel immuno-based assays developed on the
MesoScale platform. Receiver operator characteristic (ROC) curves were employed
as the main criteria to compare the performance of this panel of biomarkers in in-
dividual study animals against the microscopic histomorphologic changes observed.
Of the kidney toxicity studies analyzed, Kim-1, Clusterin, and Albumin showed
the highest overall sensitivity for detecting tubular injury, while Albumin exceeded
all other markers in detecting glomerular injury. The data presented here represents
a comprehensive parallel analysis of the performance of leading renal biomarker
candidates, and further demonstrates that this multiplexed approach enhances the
ability to monitor drug-induced renal injuries as well as provide insight to linkages
between individual biomarkers and specific histopathologic processes.
1904 Drug-Induced Kidney Injury Urinary Biomarker Response
in Rats after Treatment with Nonnephrotoxicants.
L. Besenhofer,  M. Wagoner,  L. Cheatham,  F. McGrath,  P. Bentley,  J. Fikes and
L. B. Kinter. Safety Assessment US, AstraZeneca, Waltham, MA.
Drug induced kidney injury (DIKI) biomarkers are important tools with which to
monitor and diagnose acute and chronic kidney injury. Qualification of the bio-
markers for use in nonclinical studies requires an understanding of the DIKI bio-
marker profile after treatment with nephrotoxicants and non-nephrotoxicants to
fully understand the potential for false positives in future studies. Renally-acting
pharmacotherapies were used in this study to investigate the renal biomarker profile
of non-nephrotoxicant drugs. Diuretic drugs were chosen to target specific nephron
segments including furosemide (Loop of Henle), hydrochlorothiazide (distal
tubule), spironolactone (collecting duct), and erythritol (pan-nephron). Male and
female Han-Wistar rats (n=10) were treated orally for 14 days and biomarker excre-
tion was measured on days 1, 8, 15 and 22 (recovery groups, n=5). Data were nor-
malized to urine creatinine and then to control levels. There were no significant dif-
ferences between controls and treated rats in excretion of any of the eight
biomarkers assessed including: alpha-glutathione-s-transferase (αGST), mu-GST,
renal papillary antigen-1 (RPA-1), clusterin, albumin, lipocalin-2, osteopontin and
kidney injury molecule-1 (KIM-1). Osteopontin excretion in female rats and clus-
terin excretion in male rats were the most variable with up to 19.1 and 9.9 fold dif-
ferences from controls, respectively, despite mean values being roughly equivalent
to vehicle controls. The results from this study indicate that diuretic treatment af-
fecting different portions of the nephron does not result in increased biomarker sig-
nal. As such, the likelihood of obtaining false positive results due to physiological
differences in animals in nonclinical safety screening studies is minimal.
1905 Urinary Biomarker Response to Hepsera-Induced Kidney
Toxicity in Rats.
Y. Yang,  S. Morgan,  C. Thompson,  D. Desmond,  D. Zhao,  R. Yeager and
E. Blomme. Abbott Laboratories, Abbott Park, IL.
Hepsera (adefovir dipivoxil) is an acyclic nucleoside phosphonate analog approved
for treatment of hepatis B infection. It is associated with renal tubular toxicity in
rats and monkey, and has dose-limiting nephrotoxicity in the clinic. The purpose of
this study was to evaluate urinary biomarker response for Hepsera-induced kidney
toxicity in rats. Male Sprague-Dawley rats were first administered Hepsera at 20, 40
and 60 mg/kg/day orally for 14 days. Minimal to mild tubular degeneration was
observed at 20 mg/kg/day with increased severity at 40 and 60 mg/kg/day. There
were no changes in BUN or serum creatinine. In contrast, urinary biomarkers
(KIM1, albumin, NAGL, and osteopontin) were dose-dependently elevated. To
further investigate the time-course of the biomarker changes, male and female rats
were treated with 20 mg/kg/day Hepsera for 1, 2, 4 weeks with 4 weeks of recovery.
Tubular degeneration was observed with males more affected than females, This
was first observed on Day 8 (minimal) and increased in incidence and severity with
longer duration of dosing. Renal histopathology was still present at the end of re-
covery in males. There were no changes in BUN, while serum creatinine was
slightly increased in males on Days 16 and 29. In males, urinary KIM1, beta2-mi-
croglobulin (B2M), albumin, and NGAL were increased (2.5-37 fold) on Days 16
and 29. NGAL and B2M levels were still elevated after 29 days of recovery in con-
trast to KIM1 and albumin levels. Similar changes were observed in females on Day
29, but not on Days 8, 16 or recovery Day 29. These results indicate that urinary
biomarkers can be more sensitive for Hepsera-induced kidney toxicity than BUN
and serum creatinine.
1906 Novel Noninvasive Biomarker of Irradiation-Induced Gastro-
Intestinal Injury.
A. Banerjee1,  N. Sieracki2,  A. Zakharov1,  M. Bonini2 and A. Lyubimov1.
1Toxicology Research Laboratory, UIC, Chicago, IL; 2Pharmacology, UIC, Chicago,
IL.
A non-invasive early marker of radiation induced gastro-intestinal (GI) injury con-
tinues to be in high demand. Hence, our aim was to establish a novel fecal bio-
marker of GI damage in mouse models which can be further extrapolated for use in
non-human primates as well as in humans. A Reactive Nitrogen Species (RNS)-de-
tector compound NMAA-1 was established as a novel GI irritation/oxidative stress
biomarker in an irradiated mouse model. NMAA-1 is a small molecule, which
upon reaction with peroxynitrite (ONOO-) produces cleaved NMAA-1. The abil-
ity of NMAA-1 to detect ONOO- selectively and in a concentration-dependent
manner in aqueous solution and in living cells is known. We exploited this selectiv-
ity in the quantification of NMAA-1 and cleaved NMAA-1 in feces of mice with ir-
radiation-induced GI damage. C57Bl/6 mice were irradiated at a high lethal dose of
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13Gy or at a LD70/30 of 8.1Gy in two independent experiments using a Cs
137
source. NMAA-1 was administered at 40-60 μM per animal via oral gavage with-
out any signs of toxicity. Fecal samples were collected from the irradiated and non-
irradiated control mice at different time points (pre-dose, 4, 6 and 8 hr post dose)
prior to irradiation and also on days 1, 5 and 7 post irradiation from all animals.
NMAA-1 and cleaved NMAA-1 levels were measured in the feces using LC-
MS/MS method. Up to a three-fold increase in the level of the marker was noted in
the fecal samples collected between days 5 to 7 in mice irradiated at 13Gy as com-
pared to the control levels with Cmax at about 6 hrs post dose. In case of 8.1Gy irra-
diation, two-fold or more increase in NMAA-1 and % cleaved NMAA-1 levels was
seen in the feces until day 7. It was also observed that post irradiation the appear-
ance of the fecal marker was moved to later time points probably due to decreased
GI motility. NMAA-1 has proven to be very distinctive in its role as an indicative
marker of GI damage due to radiation-induced toxicity. This promises to be an ex-
tremely important diagnostic tool for such condition and further optimization is
ongoing.
1907 Exploring Challenges in Reconstructing Doses or Estimating
Blood Concentrations from Urinary Biomarker Data Using a
Pharmacokinetic Model for Perchlorate.
C. Tan,  M. B. Phillips and J. Sobus. US EPA ORD NERL, Research Triangle Park,
NC.
Many human biomarkers of current-use environmental chemicals are measured in
urine. While urinary biomarkers are easier to collect than others (e.g., blood mark-
ers), reconstructing doses from urinary biomarkers is challenging. In many cases
there exists a complicated relationship between dose and biomarker, for example,
when a common biomarker for several chemicals exists and the concentration/rela-
tive proportion of the exposures from the environment are unknown. Even when
there is a simple dose-biomarker relationship, many factors can impact the inter-
pretability of urinary biomarker data, including urine volume, time between voids,
and time between dose(s) and sample collection. In this study, a physiologically
based pharmacokinetic (PBPK) model of perchlorate was used to examine how
these various factors impact our ability to reconstruct doses from urinary biomark-
ers. The selection of perchlorate was based on its simple dose-biomarker relation-
ship: 100% oral bioavailability and 100% excretion of the parent compound in
urine. First, synthetic exposure profiles (varying daily intake doses, time of expo-
sure, etc.) were generated and used as inputs to the PBPK model for simulating
three biomarker sampling protocols: random spot voids, first voids, and 24 h cu-
mulative voids. Correlations between simulated urinary concentrations and intake
doses were calculated at both the individual- and population-level to determine
which sampling protocol provides a more accurate and precise intake estimate. The
strongest correlations were observed between the 24 h cumulative concentrations
and average daily intake. Additional considerations for the impacts of changing
urine volume, time between voids, and time between exposure and sample collec-
tion showed that random spot urine samples were highly sensitive to all three fac-
tors whereas 24 h cumulative samples were less sensitive.
[This abstract has been cleared by the EPA but solely expresses the view of the au-
thors]
1908 Fecal and Blood Biomarkers for Gastrointestinal Injury and
Subsequent Recovery.
A. Lyubimov1,  Y. Chen2,  J. Anwer2,  A. Zakharov1 and A. Banerjee1. 1Toxicology
Research Laboratory, UIC, Chicago, IL; 2Center for Biomedical Testing, Chicago, IL.
The search for reliable, non-invasive biomarkers of gastro-intestinal (GI) injury/re-
covery is ongoing but so far no biomarkers as reliable as histopathology have been
identified in animal models. Our aim was to establish such biomarkers in non-
human primates (NHPs). Previously we established ELISA and MSD methods for
lactoferrin and calprotectin measurements in NHPs feces. These methods are cur-
rently being improved by multiplexing on one MSD platform. Two new markers
including intestinal and liver fatty acid binding protein (I-FABP) and L-FABP were
established as markers of intestinal epithelial integrity. These are released rapidly
from GI enterocytes into the blood after cellular damage. I-FABP was assayed on a
MSD standard plate with a specific antibody (LLOD=5.95 pg/mL), whereas L-
FABP was analyzed using ELISA (LLOD=102 pg/mL). Our MSD method for I-
FABP has about 10 times lower LLOQ (9.7 pg/mL) as compared to its ELISA
method (94 pg/mL). Normal ranges in NHPs plasma were established and found to
be above the LLOD for both methods. These biomarkers proved to be helpful for
assessment of drug therapeutic effect and potentially survival prognosis after irradi-
ation GI damage. Additionally an LC-MS/MS method was established to estimate
the systemic citrulline levels as a marker of GI injury. Cirtulline is an amino acid re-
leased in circulation predominantly by the intestine enterocytes and is considered a
marker of intestinal integrity. The LC-MS/MS method works in the dynamic range
of 125-125000 ng/mL (~0.7-700 μM) of citrulline concentration in plasma. The
L-FABP and I-FABP changes correlated well with the citrulline levels as well as
histopathology findings based on the analysis of the samples obtained from a NHP
irradiation study. Further optimization of the MSD, ELISA and LC-MS/MS meth-
ods are being undertaken to provide more sensitive assays from smaller sample vol-
ume (including dried blood spot measurements) for these fecal and/or circulating
biomarkers of gastro-intestinal inflammation, injury, and recovery.
1909 Clearance Rates of Organophosphate Metabolites in an
Occupationally-Exposed Cohort of Farmworkers.
W. C. Griffith1,  Z. N. Guerrette1,  B. Thompson2,  G. D. Coronado2,
D. B. Barr3,  E. M. Vigoren1 and E. M. Faustman1. 1Institute for Risk Analysis and
Risk Communication, University of Washington, Seattle, WA; 2Fred Hutchinson
Cancer Research Center, Seattle, WA; 3Rollins School of Public Health, Emory
University, Atlanta, GA.
Our studies in the Yakima valley of Washington state follow a cohort of 99 farm-
workers (orchard workers) and 95 non-farmworkers to investigate potential expo-
sures to organophosphate pesticides (OPs) by assaying urine samples for the 6 di-
akyl non-specific metabolites of OPs. Urine samples were collected April-June 2005
on three dates spaced two days apart when OP pesticides were being applied and
workers were in the orchards. The most commonly used OP in this time period was
azinphos-methyl and one of its metabolites, DMTP, had the highest concentration
in urine compared to other metabolites of OPs for both farmworkers and non-
farmworkers. We used a Bayesian Markov chain Monte Carlo method to estimate
the joint distribution of the metabolites and clearance rates in a mixed effects
model. The farmworker levels of DMTP were 19 times non-farmworkers. The
clearance half-life of DMTP had a geometric mean (95% confidence interval) of
3.6 (2.5,6.0) days across all of the farmworkers (fixed effects), whereas non-farm-
workers showed no clearance. The half-lives for individual farmworkers (random
effects) varied between 1.5 days and no clearance . The shorter half-lives occurred
in farmworkers who had higher first day concentrations of DMTP and farmwork-
ers with no clearance with those who had lower first day concentrations. These re-
sults are consistent with a continuing variable level of occupational exposure of the
farmworkers but some of the farmworkers having a higher exposure before our col-
lection of urine. The pattern in the non-farmworkers is consistent with exposures to
metabolites of OPs through diet and other routes of non-occupational exposure.
Similar results were also found for DMP. (Supported by grants P01 ES009601, P30
ES007033 from NIEHS and RD-834514, RD-831709, RD-832733 from US
EPA. Contents are authors’ responsibility.)
1910 Assessment of MMP-3 and MMP-9 As Preclinical
Biomarkers of Drug-Induced Vascular Injury.
R. J. Gonzalez,  B. Bednar,  S. Lin,  B. Connolly,  S. Patel,  G. Mesfin,
T. Johnson,  H. Miyazaki,  W. E. Glaab and F. D. Sistare. Merck & Co., West Point,
PA.
Drug-induced vascular injury (DIVI) continues to be a major obstacle in drug de-
velopment. Attempts to correlate this observation in preclinical toxicity studies
with hemodynamic changes are not always successful. Additionally, no accessible
and specific biomarkers of DIVI exist, making risk assessment and monitoring in
humans a challenge during drug development and regulatory approval. It has been
previously reported that circulating levels of matrix metalloproteinases (MMPs),
specifically MMP-3 and MMP-9, were able to distinguish between patients with
active antineutrophilic cytoplasmic antibody (ANCA)-associated vasculitis (AAV)
and remission. In order to determine whether MMPs are involved in the arterial
pathology associated with DIVI observed in animal toxicology studies, a fluores-
cent imaging probe, MMPSenseTM, was used to measure activity of MMPs along
with a fluorescent blood pooling agent, AngioSenseTM, ex-vivo in the mesenteric
arteries of rats following administration of fenoldopam. Increased fluorescence in
the mesenteric arteries from both imaging probes correlated well with vascular in-
jury, as determined histologically, and was in agreement with increases in both
MMP-3 and -9 expression in the affected arteries using immunohistochemical
staining. To assess whether changes to circulating levels of MMP-3 and -9 respond
to incidence and severity of DIVI, we compared their levels in plasma from several
models of DIVI in rat, dog and monkey. Circulating levels of MMP-3 appear to
correlate well with DIVI and the response is conserved across our pre-clinical
species. In summary, MMPs appear to have a role in the arterial pathology associ-
ated with DIVI seen in animal toxicology studies, which is reflected in circulating
levels of MMP-3 in pre-clinical species, and provide a potential accessible bio-
marker to monitor for DIVI in animals and in the clinic.
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1911 Molecular, Cellular, and Histological Changes in Mice
Living on Sand Contaminated with Coal Dust under
Laboratory Conditions.
K. Caballero-Gallardo,  L. Carranza-Lopez and J. Olivero-Verbel. Environmental
and Computational Chemistry Group Pharmaceutical Sciences, University of
Cartagena, Cartagena, Colombia.
Coal mining is one of the most important economical activities in Colombia.
However, few data have been gathered concerning the impact of these activities on
human and ecosystem health. During coal mining and transport, different types of
dust material are formed. The aim of this work was to evaluate the toxic effects as-
sociated with the exposure to total suspended particle matter fraction of coal dust
(<38 μm), from a sample collected in the Loma mine, Cesar, Colombia. Washed
and sterilized sand was contaminated with coal dust to obtain concentrations rang-
ing from zero (control) to 4%.  Six different mice per group were allowed to live in
boxes with this bed for eight weeks with ab libitum water and food. At the end of
the experiment, animals were euthanized and blood and tissues collected. Mice in
contact with coal dust did not evidence significant weight or hepatosomatic
changes compared to control. However, animals in the 4% coal dust group grew
faster. Real Time PCR analysis revealed an increase in Cyp1A1 mRNA for animals
living on sand with concentrations greater than 2% coal dust. Unexpectedly, for
mice on polluted sand, SOD and MT1 hepatic mRNA were donwregulated, and
no changes were observed on Myc expression. The results of comet assay in periph-
eral blood cells, and the micronucleus test in blood smears revealed significant po-
tential genotoxic damage at the greatest tested coal dust level. Histopathologycal
analysis showed a dose-response relationship for the presence of hepatic necrosis,
steatosis, vacuolization and nuclei enlargements in exposed animals. These results
suggest that soil contaminated with coal dust induces several molecular, cellular and
histopathological changes in mice. Accordingly, it is necessary to revise the current
legislation on mining practices in Colombia in order to prevent health problems
derived from these particles. Vice-Rectory for Research. UniCartagena. 2011-2012.
Colciencias-UniCartagena, Colombia. Grant 110749326186 (2009).
1912 Advancing Adoption of Novel Safety Biomarkers into Drug
Development through Voluntary Submission of Data at US
FDA, EMA, and PMDA.
E. G. Walker,  M. Brumfield and E. H. Dennis. Critical Path Institute, Tucson, AZ.
Regulatory science, the science of developing new tools, standards, and approaches
to assess the safety, efficacy, quality, and performance of regulated medical products,
has advanced over time due to a number of factors. However, many safety biomark-
ers used in nonclinical and clinical safety assessment in drug development have not
changed in decades. Recently established channels for FDA, EMA, and PMDA to
receive and evaluate scientific data supporting novel tools for use in drug develop-
ment are now better defined in guidances, e.g. FDA’s Draft Guidance for Industry
“Drug Development Tool Qualification” and EMA’s “Evaluation of novel method-
ologies for use in drug development.” The outcome of a qualification submission to
one of these regulatory agencies is a formal opinion regarding the utility of a novel
drug development tool (DDT) for a particular and well-circumscribed application
in the drug development process, defined within a “context of use.” While recog-
nizing that other mechanisms exist within the research community for driving sci-
entific consensus on novel biomarkers, this study focuses on the formal regulatory
qualification process. This study compares the procedure, volume and types of sub-
missions, and proposes a framework for assessing success at FDA, EMA, and
PMDA. Safety biomarkers comprise over half of the sixteen unique biomarkers
qualified thus far, and are highlighted. Qualification of new safety biomarkers by
regulatory agencies and subsequent adoption by drug developers is anticipated to
speed therapeutic development for patients in need, build scientific consensus as to
the usefulness and readiness of novel tools for understanding disease and therapeu-
tic development, and decrease uncertainty between the regulators and sponsors re-
garding their appropriate application.
1913 Growth Hormone and IGF-1 Measurements in Beagle Dogs
by ELISA: Assay Implementation and Variations in Baseline
Levels.
C. Gauthier,  J. Leiva,  G. Gonzalez and A. Nelson. Immunology, ITR
International, Baie d’Urfe, QC, Canada. Sponsor: W. Ruddick.
Scope :
Measurements of GH and IGF-1 in Beagle dogs are complicated by several techni-
cal and biological issues. In this poster, we present data from ELISA methods that
were specially adapted and qualified at our facility for the quantification of GH &
IGF-1 in canine serum. During assay implementation and routine use, several ob-
servations have been made with these hormone baseline levels and some biological
& technical parameters.
Experimental Procedures & Results :
Beagle dog serum was obtained from males and females, originating from two dif-
ferent breeders; Marshall and Covance. Samples were tested from dogs housed at
three different preclinical testing facilities; ITR Laboratories Canada Inc. (“ITR”)
and two other undisclosed facilities (“Lab B” & “Lab C”). A commercial GH
ELISA kit designed for rat/mouse GH and another commercial human IGF-1 kit
were adapted for use with dog serum samples. Typical basal GH levels in Beagle
dogs vary from < 6.25 to 40 ng/mL. No significant differences were observed in the
GH basal level between different genders, breeding source or test facility. However,
GH levels generally increased with higher body weight and age. GH varied between
individuals of the same study. Typical basal IGF-1 levels in Beagle dogs varied
greatly, from < 42 to 150 ng/mL (ex. from Mashall-bred dogs housed at ITR),
while the normal range increase to 150-500 ng/mL with Covance-bred dogs
housed at “Lab C”. Age and body weight only had minor impact on the IGF-1
basal levels, while a gender difference was only seen within the Covance-bred dogs
housed at “Lab C”.
Conclusions :
The GH/IGF-1 data gathered internally from several preclinical studies with Beagle
dogs of various origins have shown that basal IGF-1 levels can vary significantly de-
pending on the dog breeding source and housing facility, in addition to age and
body weight. It was also found that due to the natural cyclic activity of GH, multi-
ple pre-dose samplings are useful, with the last pre-dose sample being ideally taken
as close as possible to dosing with the test item.
1914 Evaluation of Iodide Deficiency in the Lactating Rat and
Pup Using a Biologically-Based Dose Response (BBDR)
Model.
J. W. Fisher1,  S. Li2,  K. Crofton3,  R. Zoeller4,  E. D. McLanahan3,  A. Lumen1
and M. E. Gilbert3. 1FDA/NCTR, Jefferson, AR; 2Georgia Health Sciences University,
Augusta, GA; 3EPA/ORD, Research Triangle Park, NC; 4University of Massachusetts,
Amherst, MA.
A biologically-based dose response (BBDR) model for the hypothalamic-pituitary
thyroid (HPT) axis in the lactating rat and nursing pup was developed to describe
the perturbations caused by iodide deficiency on the HPT axis. Model calibrations,
carried out by adjusting key model parameters, were used as a technique to evaluate
HPT axis adaptations to dietary iodide intake in euthyroid (4.1 -39 μg iodide/d)
and iodide deficient (0.31 and 1.2 μg iodide /d) conditions. Iodide deficient condi-
tions in both the dam and pup were described with increased blood flow to the thy-
roid gland, TSH-mediated increase in thyroidal uptake of iodide and binding of io-
dide in the thyroid gland (organification), and in general, reduced thyroid hormone
production and metabolism. Alterations in thyroxine (T4) homeostasis were more
apparent than for triodothyronine (T3). Model predicted average daily area-under-
the-serum- concentration-curve (AUC, nM*day) values for T4 at steady-state in
the dam and pup decreased by 14-15% for the 1.2 μg iodide /d iodide deficient
diet and 42 to 52% for the 0.31 μg iodide /d iodide deficient diet. In rat pups that
were iodide deficient during gestation and lactation, these decreases in serum T4
levels were associated with synaptic response suppression in the hippocampal region
of the brain, while other measures of neurotoxicity were unaltered.
1915 An Animal Model of Marginal Iodine Deficiency during
Development: The Thyroid Axis and Neurodevelopmental
Outcome.
M. E. Gilbert1,  J. M. Hedge1,  L. Valentin-Blasini2,  B. C. Blount2,  K. Kannan3,
J. Tietge4,  R. Zoeller5,  K. Crofton1,  J. Jarrett2 and J. W. Fisher6. 1US EPA,
Research Triangle Park, NC; 2CDC, Atlanta, GA; 3SUNY, Albany, NY; 4US EPA,
Duluth, MN; 5University of Massachusetts, Amherst, MA; 6FDA, Jefferson, AR.
Thyroid hormones (TH) are essential for brain development and iodine is required
for TH synthesis. Environmental chemicals that perturb the thyroid axis result in
modest reductions in TH, yet there is a paucity of data on the neurological impair-
ments associated with low level TH disruption. This study examined the dose-re-
sponse characteristics of marginal iodine deficiency (ID) on parameters of thyroid
function and neurodevelopment. ID diets were prepared by adding varying con-
centrations of iodine to a casein-based diet producing 5 nominal iodine levels rang-
ing from ample (1000 μg iodine/kg chow) to deficient (25 μg iodine/kg chow).
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Female Long Evans rats were maintained on these diets beginning 7 wk prior to
breeding until the end of lactation. Dams were sacrificed on gestational days16 and
20, or when pups were weaned on postnatal day (PN)21. Fetal tissue was harvested
with sacrifice of the dams, pups were sacrificed on PN14 and PN21. Blood, thyroid
gland, and brain were analyzed for iodine, TH, TH precursors and metabolites.
Serum and thyroid gland iodine and TH were reduced in the two most deficient
diets. T4 was reduced in the fetal brain but was not altered in the neonate.
Cognitive function, assessed by acoustic startle, water maze learning and fear con-
ditioning, was unchanged in adult offspring, but excitatory synaptic transmission
was impaired in the dentate gyrus by the two most deficient diets. A 15% reduction
in cortical T4 in the fetal brain was sufficient to induce permanent reductions in
synaptic function in the adult. These findings have implications for regulation of
TH-disrupting chemicals, and suggest that standard behavioral assays do not read-
ily detect neurotoxicity induced by modest developmental TH disruption. (Does
not reflect EPA or CDC policy).
1916 Association of Paraoxonase-1 Activity and Gene
Polymorphisms with Type 2 Diabetes Mellitus.
P. Eden1, 2,  E. Olsen3,  J. Watt3 and J. E. Chambers2. 1711th Human Performance
Wing, Wright-Patterson AFB, OH; 2Mississippi State University, Starkville, MS; 381st
Medical Group, Keesler AFB, MS.
Paraoxonase-1 (PON-1) is an HDL-associated lactonase that hydrolyses
organophosphates such as paraoxon and diazoxon, the active metabolites of the in-
secticides parathion and diazinon, as well as affords protection against LDL oxida-
tion. There is evidence that Type 2 diabetes mellitus (T2DM) patients display lower
PON-1 activity. This study examined plasma from 150 T2DM and 150 non-dia-
betic subjects to evaluate PON-1 activity and relevant genetic variations associated
with changes in PON-1 activity. PON-1 activity was measured spectrophotometri-
cally using the substrates paraoxon, diazoxon, and phenyl acetate. Two significant
genetic polymorphisms (PON-1192 and PON-155) were also determined using
real-time polymerase chain reaction melting curve analysis. The PON-1192 geno-
type displayed an average melting curve peak at 61.1°C ± 1.1 (SD) for the (R) ho-
mozygous allele while the (Q) homozygous allele showed a peak of 66.3°C ± 0.6.
The PON-155 genotype had an average melting curve peak at 61.9°C ± 0.9 for the
(L) homozygous allele and 66.3°C ± 0.9 for the (M) homozygous allele. A preva-
lence of the PON-1192RR polymorphism was found between T2DM subjects and
non-diabetics (odds ratio = 2.3; 95% confidence interval = 1.25- 4.21, p = 0.01).
The substrate diazoxon demonstrated lower plasma PON-1 activity in T2DM sub-
jects (7469 ± 140 U/L) compared to non-diabetics (8287 ± 151 U/L), p = 0.02. In
addition, African-Americans in this study demonstrated a higher association with
the PON-1192RR genotype (51.5%) than did Caucasians (9.1%) (p<0.001, odds
ratio = 10.66). The genetic and plasma PON-1 activity results suggest that the
PON-1192RR polymorphism is less protective against development of T2DM and
that decreased PON-1 activity is associated with increased development of T2DM.
1917 Effect of Dioxin on the Nursing Behavior of Dams and the
Growth of Pups: A Study for the Mechanism Focusing on
Damage to Maternal Prolactin and Fetus/Infant Growth
Hormone.
M. Fujii1,  T. Takeda1,  J. Taura1,  Y. Hattori1,  Y. Ishii1,  H. Uchi2,  K. Tsukimori3,
M. Furue2 and H. Yamada1. 1Graduate School of Pharmaceutical Sciences, Kyushu
University, Fukuoka, Japan; 2Kyushu University Hospital, Fukuoka, Japan; 3Fukuoka
Children’s Hospital, Fukuoka, Japan. Sponsor: Y. Kumagai.
Maternal exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) causes a num-
ber of developmental disorders including growth retardation in the pups. Although
our previous studies have demonstrated that TCDD imprints defects in gender-
specific phenotypes through a reduction in gonadotropin production in perinatal
pups (1,2), the mechanism for growth retardation by TCDD remains unknown. In
this study, we investigated a hypothesis that maternal exposure to TCDD damages
to maternal prolactin, a regulator of milk secretion and maternal care to the pups,
and growth hormone (GH) in the pups to disturb the growth of offsprings. As has
been reported so far, oral administration of TCDD (1 μg/kg) to pregnant Wistar
rats at gestational day 15 attenuated the body weight and height of infants and their
short-term memory examined 5 weeks after birth. In addition, we observed that
TCDD reduced the number of pups after birth, whereas the same was not seen at
fetal stages. In relation to this finding, TCDD reduced not only maternal expres-
sion of prolactin in a nursing period-specific manner, but also the frequency of lick-
ing, one of the maternal nursing behaviors. Furthermore, maternal exposure to
TCDD attenuated the serum concentration of GH in perinatal pups. Such attenu-
ation may be an outcome due to the reduced expression of a receptor for GH-re-
leasing hormone (GHRH), a regulator of GH biosynthesis, because a lowered ex-
pression of GHRH receptor cause by TCDD also appeared during the same period.
Taken together, it is suggested that maternal exposure to TCDD produces its devel-
opmental toxicity on pups by a combination of a reduction in the expression of ma-
ternal prolactin and pup GH.
References: 1) Takeda, T., et al., J. Pharmacol. Exp. Ther., 329, 1091 (2009); 2)
Takeda, T., et al., J. Biol. Chem., 287, 18440 (2012).
1918 Effects of Perfluorooctane Sulfonate (PFOS) on the
Hypothalamic-Pituitary-Testicular Axis Activity in Adult
Male Rat.
M. A. Lafuente and N. Pereiro. Laboratory of Toxicology, University of Vigo, Orense,
Spain.
Perfluorooctane sulfonate (PFOS) is considered such as an endocrine disruptor.
This study was designed to evaluate the possible alterations induced by PFOS on
the hypothalamic-pituitary-testicular axis activity. For this purpose, male Sprague-
Dawley rats were orally treated for 28 days with PFOS, at the doses of 0.5, 1.0, 3.0
and 6.0 mg/kg/day. Control rats received 0.5% Tween-20 vehicle. Twenty four
hours after the last dose of PFOS, rats were killed by decapitation and the hypo-
thalamus was removed in order to determine in this brain region both neuropeptide
Y (NPY) and gonadotropin-releasing hormone (GnRH) concentration by specific
enzyme-linked immunoabsorbent (ELISA) assays. Serum luteinizing hormone
(LH), follicle stimulating hormone (FSH) and testosterone levels were measured by
specific commercial kits. In addition, the relative gene expression of NPY and
GnRH in hypothalamus, of GnRH receptor in pituitary and of LH receptor and
FSH receptor in testis was determined by quantitative real time PCR. Serum LH
and testosterone levels and relative gene expression of GnRH and of FSH receptor
were decreased in rats treated with PFOS. Serum FSH concentration and relative
gene expression of LH receptor in testis were increased in these same animals.
Hypothalamic concentration of NPY and GnRH was decreased with the doses of
1.0 and 3.0 mg/Kg/day, but GnRH levels were increased with the dose of
6.0mg/Kg/day. Relative gene expression of NPY was diminished with the dose of
0.5mg/Kg/day, but it was increased with the dose of 6.0mg/Kg/day. Finally, relative
gene expression of GnRH receptor was not modified in pituitary by PFOS. The ob-
tained results suggest that PFOS exposure can modify the hypothalamic-pituitary-
testicular axis activity at several levels, and these alterations seem to be dependent of
the administered dose. This work was supported by a grant from the Ministry of
Education and Science, Spain (AGL2009-09061).
1919 Conditional Knockout of the Aryl Hydrocarbon Receptor in
the Liver Alters Mouse Phenotype As Well As Glucose and
Lipid Homeostasis.
D. Carter and C. Elferink. Pharmacology and Toxicology, UTMB, Galveston, TX.
The aryl hydrocarbon receptor (AhR) is a ligand activated transcription factor his-
torically known for its role in the adaptive metabolism of xenobiotics. However,
generation of the AhR knockout mouse (AhR-KO) has provided evidence of phys-
iological roles for the AhR. To study the physiological role of AhR in the liver, AhR
conditional knockout (AhR-CKO) mice were utilized by crossing AhR fx/fx (con-
trol) mice with mice that express Cre recombinase under the control of the albumin
promoter, resulting in loss of AhR expression specifically in the liver parenchyma.
Our experiments indicate a novel sex dependent phenotype wherein, AhR-CKO fe-
males exhibited reduction in body weight, loss of adipose tissue and increased basal
glucose levels (218 ± 19.73 mg/dl). Therefore, our goal is to characterize the AhR-
CKO mouse phenotype and identify potential AhR-dependent mechanisms re-
sponsible for lipodystrophy and abnormal glucose homeostasis. AhR-CKO and
control mice were subjected to glucose and insulin tolerance tests. Our data sug-
gests decreased glucose tolerance and increased insulin sensitivity in AhR-CKO fe-
males compared to their controls. Plasma analyses also suggest alterations in leptin
(control 3.227 ± 0.27 vs CKO 1.028 ± 0.129), FFA (control 0.3630 ± 0.026 vs
CKO 0.594 ± 0.02) and insulin levels (control 0.495 ± 0.008 vs CKO 0.253 ±
0.004). Immuno-Histochemical staining for insulin revealed reduced insulin con-
tent and smaller pancreatic islets in AhR-CKO mice. We also conducted
histopathological analysis using Oil red O staining, which revealed decreased lipid
content in AhR-CKO mice livers compared to controls. Our experiments strongly
suggest that AhR activity in the liver communicates with extra-hepatic tissues and
alters their function. AhR-CKO mice may offer an elegant model to study the link
between endogenous AhR activity in the liver and clinically relevant metabolic dis-
orders such as diabetes, lipodystrophy and obesity.
SOT 2013 ANNUAL MEETING 409
1920 Endocrine Modulatory Effects of Cadmium and Activation
of MAPK Signaling.
I. Ali1,  P. Damdimopoulou2,  S. I. Mäkelä3,  M. Berglund1,  U. Stenius1,
A. Adamsson4,  A. Åkesson1,  H. Håkansson1 and K. Halldin1. 1Institute of
Environmental Medicine, Karolinska Institute, Stockholm, Sweden; 2Department of
Biosciences and Nutrition, Karolinska Institute, Huddinge, Sweden; 3Department of
Cell Biology and Anatomy and Turku Center for Disease Modeling, Institute of
Biomedicine, University of Turku, Turku, Finland; 4Department of Physiology,
Institute of Biomedicine, University of Turku, Turku, Finland.
Research on endocrine modulatory effects of Cadmium (Cd) started over a decade
ago, when this metalloestrogen was found to interact with the estrogen signaling
pathway. Since then, several independent in vitro as well as in vivo reports have
emerged on this topic. Our objective has been to characterize the details of molecu-
lar mechanisms of action for the endocrine modulatory effects of Cd. We applied a
combined in vivo and in vitro approach by using transgenic ERE-luc reporter mice
model as well as hepG2, MCF-7 and ECC-1 cell lines. After 3-days s.c. exposure to
CdCl2, we did not detect reporter gene activation in the dose ranges 5-500 μg/kg
bw and 0.5-500 μg/kg bw in female and male mice respectively. Nevertheless, we
observed significant thickening of the uterine epithelium in the absence of uterine
weight increase in females, and detected activation of Raf, Erk1/2 MAPK in the
liver of both genders in low dose groups. Further, in our in vitro settings, low doses
of CdCl2 (1nM-100nM) also activated Raf, Erk1/2 MAPK and this effect disap-
peared with the inhibition of GPR30 and EGFR receptors. Our data shows that the
molecular markers that are modulated by Cd differ depending on the exposure
level; i.e. low doses relevant to human exposure via diet stimulate cytoplasmic ki-
nases, while higher doses induce cellular stress responses. We conclude that CdCl2
affects cellular signaling pathways that can produce physiological effects reminis-
cent of bonafide estrogen stimulation. However, CdCl2 does not activate canonical
estrogen signaling.
1921 Bisphenol A (BPA) Levels Were Associated with Increased
Estrogen.
M. Lind1,  T. Naessen2,  J. Bergquist3,  M. M. Kushnir3, 4 and L. Lind5.
1Occupational and Environmental Medicine, Uppsala University, Uppsala, Sweden;
2Department of Women’s and Children’s Health, Section for Obstetrics and Gynecology,
Uppsala University, Uppsala, Sweden; 3Analytical Chemistry/Department of Physical
and Analytical Chemistry, Uppsala University, Uppsala, Sweden; 4ARUP Institute for
Clinical and Experimental Pathology, Salt Lake City, UT; 5Department of Medical
Sciences, Acute and Internal Medicine, Uppsala University, Uppsala, Sweden.
BACKGROUND: The plastic associated compound bisphenol A (BPA) is a known
estrogen-receptor agonist. Since background exposure to BPA could be detected in
most individuals, we explored the relationships between BPA levels in serum and
levels of endogenous sex hormones and their precursors in a population-based sam-
ple. 
METHODS: 1,016 subjects all aged 70 years were investigated in the Prospective
Investigation of the Vasculature in Uppsala Seniors (PIVUS) study. BPA was meas-
ured in serum at ALS Canada using an API 4000 liquid chromatograph/ tandem
mass spectrometer, and sex hormones were measured at ARUP Institute for Clinical
and Experimental Pathology, Salt Lake City, by high-specificity liquid chromatog-
raphy-tandem mass spectrometry.
RESULTS: In men, BPA levels were related to estone (E1, p<0.00001) and estra-
diol (E2, p=0.02) levels. BPA levels were also related to levels of the precursors preg-
nenolone and 17-OH-pregnenolone (p<0.05) and estimated aromatase activity
(p<0.05), indicating an increased formation of estrogens from androgen precursors.
In women, only weaker relationship compared with E1 was found (p<0.05).
IN CONLUSION: increased levels of BPA were associated with increased estrogen
levels in elderly males, indicating endocrine disrupting activity in the elderly.
1922 A Comparison of RIA and LC-MS/MS Methods to Quantify
Steroids in Rat Serum and Urine following Exposure to an
Endocrine Disrupting Chemical.
B. W. Riffle1, 2,  S. C. Laws1 and W. M. Henderson3. 1ETB, TAD, NHEERL,
ORD, US EPA, Research Triangle Park, NC; 2ORISE, US Department of Energy,
Oak Ridge, TN; 3ERD, NERL, ORD, US EPA, Athens, GA.
Commercially available radioimmunoassays (RIA) are frequently used in toxicolog-
ical studies to evaluate effects of endocrine disrupting chemicals (EDCs) on
steroidogenesis in rats. Currently there are limited data comparing steroid concen-
trations in rats as measured by RIAs to those obtained using liquid chromatography
coupled with tandem mass spectrometry (LC-MS/MS). This study evaluates the
concordance of serum and urine steroid concentrations as quantified by both RIA
and LC-MS/MS following exposure to a known EDC, atrazine (ATR). Adult male
rats were dosed with ATR (200 mg/kg/d) or methylcellulose (solvent control) by
oral gavage for 5 days. Animals were decapitated 2 hours after the final dose. Serum
was collected and seperated into 2 aliquots for analysis. Serum was assayed by RIA
for androstenedione (A), corticosterone (CORT), estradiol (E2), estrone (E1),
progesterone (P4), and testosterone (T). Serum was extracted via solid phase ex-
traction prior to LC-MS/MS analysis with positive electrospray ionization in mul-
tiple-reaction monitoring mode for A, CORT, P4, and T. E1 and E2 serum con-
centrations were quantified similarly by LC-MS/MS, following derivatization with
dansyl chloride. To compare CORT values from urine, pregnant adult rats were
dosed with either ATR (100 mg/kg/d) or methylcellulose by oral gavage for 5 days
(i.e., gestational days 14-18). Urine samples were collected daily for 2 consecutive 6
hour intervals following dosing and assayed for CORT by RIA and LC-MS/MS as
described above. Data analyses demonstrated a high degree of correlation between
the two detection methods (R2 = 0.88 – 0.92). No statistically significant differ-
ences were observed between RIA and LC-MS/MS means for any of the steroids as-
sayed. These findings indicate that steroids may be reliably measured in rat biolog-
ical media using RIAs or LC-MS/MS in toxicological studies.   
This abstract does not reflect U.S. EPA policy.
1923 Exposure of Pregnant Fischer 344 Rats to Low Levels of
Dietary Zeranol Induces Precocious Puberty and Decreased
Mammary Tumor Latency in F1 and F2 Progeny.
C. Lewis1,  J. T. Barrett1,  M. A. Gallo1, 2 and H. Zarbl1, 2. 1Environmental and
Occupational Medicine, Robert Wood Johnson Medical School, UMDNJ, Piscataway,
NJ; 2Environmental and Occupational Health Sciences Institute, Robert Wood
Johnson Medical School, Piscataway, NJ.
Zeranol (Zer) is a synthetic derivative of zearalenone (Zea), a potent myco-estrogen
produced by several species Fusarium that contaminate grain. Zer has estrogenic ac-
tivity comparable to that of DES and is ~1000 times more estrogenic than
Bisphenol A. After its growth promoting effects on livestock were noted in the early
1970’s, Zer replaced diethylstilbestrol (DES) in implants to enhance meat produc-
tion and quality. Accidental and occupational exposures were associated with pre-
cocious puberty and gynecomastia. Banned in Europe and Asia, Zer is introduced
into livestock in the Americas, can be detected in the finished product, andis stable
at cooking temperatures. Our recent studies in prepubescent girls indicate that
human exposure is primarily via the consumption of beef and corn, and urinary
levels of unconjugated Zer were associated with differences in the onset of puberty,
height and weight (Bandera et al., Science of the Total Environment 409(24):5221-
5227, 2011). Our studies in rats indicated that exposure to non-toxic doses of Zer
in utero (between prenatal day 7 to term) via the mother’s diet (0.1μg/day in saf-
flower oil), results in precocious puberty in females F1 progeny, defined by a three
day decrease in age at vaginal opening. F1 male progeny showed feminization as as-
sessed by a decreased ano-genital distance. F1 female treated with a single carcino-
genic dose of N-Nitroso-N-methylurea (NMU) showed a decrease in latency and
an increase in the incidence of mammary tumors. Similar effects on puberty and
carcinogenesis were also observed in the F2 progeny, but only if both the dam and
the sire were exposed to Zer in utero. Together these studies suggest that in utero
exposure to the Zer may produce transgenerational effects on sexual maturation
and carcinogenesis. 
Supported by grants from The NJCCR and the NIEHS (ES005022).
1924 P-p-DDE Levels Are Associated with Reduced Testosterone
Levels in Elderly Males.
L. Lind1,  T. Neassen2,  J. Bergquist2,  M. M. Kushnir3 and M. Lind2.
1Department of Medicine, Uppsala, Sweden; 2Uppsala University, Uppsala, Sweden;
3ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT.
Background: The DDT metabolite p-p-DDE is a known androgen-receptor ago-
nist. Since background exposure to p-p-DDE still could be detected in most indi-
viduals, we explored the relationships between p-p-DDE levels in serum and levels
of endogenous sex hormones and their precursors in a population-based sample.
Methods: 1,016 subjects all aged 70 years were investigated in the Prospective
Investigation of the Vasculature in Uppsala Seniors (PIVUS) study. p-p-DDE was
measured in plasma by a high-resolution chromatography coupled to high resolu-
tion mass spectrometry (HRGC/HRMS), and sex hormones by high-specificity liq-
uid chromatography-tandem mass spectrometry.
Results: In men, p-p-DDE levels were related to both reduced testosterone
(p=0.006) and SHBG levels (p=0.008). Furthermore, also reduced levels of the pre-
cursors pregnenolone and 17-OH-pregnenolone were related to high p-p-DDE lev-
els (p<0.05), indicating a general reduction in endogenous sex hormone synthesis
in subjects with high p-p-DDE levels. Similar tendencies, but less pronounced,
were seen in women.
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In conclusion, increased levels of p-p-DDE levels were associated with both re-
duced testosterone and SHBG levels in elderly males, indicating endocrine disrupt-
ing activity by DDT in the elderly.
1925 In Utero Bisphenol A (BPA) Exposure, the Developing
Immune System and Memory.
J. N. Franklin,  Q. Hu and J. DeWitt. Pharmacology and Toxicology, East Carolina
University, Greenville, NC.
Exposure to exogenous agents during susceptible stages of neurodevelopment may
be associated with the onset of neurological disorders. The emerging contaminant
bisphenol A (BPA) is a widely used ingredient in the production of plastics and
resins utilized in food and beverage packaging. Our hypothesis is that developmen-
tal exposure to BPA induces neural and behavioral alterations and that these alter-
ations will be associated with developmental immunotoxicity. C57BL/6 female
mice were given 0, 25, 50, or 100 mg/kg of BPA in a corn oil vehicle by gavage, be-
ginning at pairing with males and ending at weaning of pups. Littermates were as-
sessed on a Barnes maze at postnatal day 21 (PND21), PND42, and PND60.
Splenic lymphocytes, including B cells, natural killer cells (NK cells) and T cells
(CD3, CD4, CD8, and CD25 subclasses), were immunofluorescently labeled to
determine the immunophenotype of offspring from each treatment group. The
Barnes maze is a reliable indicator of hippocampal-dependent learning and mem-
ory that has been used to link immune dysfunction with altered neurodevelopment.
On the Barnes maze, the time to initially reach the escape hole did not significantly
differ among treatment groups. A significant interaction between sex and dose was
detected in offspring immunophenotype, indicating that immune cell subpopula-
tions responded differently between sexes by dose. Liver weights increased in adult
offspring by dose, though this trend was not statistically significant. Our data indi-
cate that developmental exposure to BPA does not alter aspects of learning and
memory as evaluated by the Barnes maze, but may induce differences in im-
munophenotype between sexes that may confound behavioral responses.
Additional work is ongoing to evaluate changes to hippocampal neurons induced
by developmental BPA exposure.
1926 Low-Dose Evaluation of the Antiandrogen Flutamide in a
28-Day Toxicity Study in the Rat.
A. Sarrabay1,  H. Tinwell1,  O. Blanck1,  F. Schorsch1,  M. Pallardy2,  R. Bars1 and
D. Rouquié1. 1Bayer CropScience, Sophia Antipolis, France; 2Faculty of Pharmacy,
University Paris-Sud, INSERM UMR 996, Chatenay-Malabry, France.
The dose-response characterization of endocrine mediated toxicity is an on-going
debate which is controversial when exploring the nature of the dose-response curve
and the effect at the low end of the curve. Therefore, to contribute to this debate we
have assessed the effects of a wide range of dose levels of the antiandrogen flutamide
(FM) on male rats using omic and traditional tools. Flutamide was administered to
Wistar rats at the doses of 0, 0.001, 0.01, 0.1, 1 and 10 mg/kg/day for 28 days. The
highest dose level corresponds to a therapeutic dose in humans and it is also known
to induce changes in male reproductive tissues in rodents. At necropsy, blood sam-
ples were collected for testosterone measurements. Male reproductive tissues were
weighed. The testes were collected for histopathological assessment in addition to
the evaluation of gene expression changes. Results showed that testicular lesions
(Leydig cell hyperplasia) were detected from 1 mg/kg/day whereas the testosterone
levels were only increased at 10 mg/kg/day. A preliminary molecular investigation
of targeted genes by qPCR shows changes at 1 and 10 mg/kg/day. Based on the
available results, only monotonic responses were observed based on gravimetry, mi-
croscopic examination, hormonal analyses and gene expression using qPCR analy-
ses. Full genome gene expression evaluation using DNA microarrays is on-going to
evaluate the shape of the global gene expression dose response curves.
1927 Investigation of Vinclozolin at Environmentally-Relevant
Concentrations.
S. Gröters1,  S. Schneider1,  K. C. Fussel1,  V. Strauss1,  M. Frericks2,  S. Melching-
Kolmuss2,  B. Siddeek3,  M. Benahmed3 and B. van Ravenzwaay1. 1Experimental
Toxicology and Ecology, BASF SE, Ludwigshafen am Rhein, Germany; 2Product
Safety, BASF SE, Ludwigshafen am Rhein, Germany; 3U895, équipe 5, Bâtiment
Universitaire Archimed, Centre Méditerranéen de Médecine Moléculaire (C3M),
Inserm, Nice, France.
Endocrine disruption has become an important topic of public concern. Despite an
increasing amount of attention, little is understood about if environmentally rele-
vant doses of endocrine disrupting chemicals (EDCs) affect homeostasis.
Furthermore, there are often knowledge gaps in the studies used to assess EDCs. To
address these concerns, we performed a pre-/post-natal reproductive toxicity study
of vinclozolin as part of a larger BASF and CEFIC funded project to measure the
developmental toxicity of low single- and mixture-doses of anti-androgens. The
tested doses were selected to mimic a low-effect level, the no observed adverse effect
level (NOAEL) for endocrine effects, and the acceptable daily intake (ADI). 
At the LOAEL dose, female offspring developed normally, while the male offspring
showed effects known for anti-androgens. No effects at all were noted at the lowest
two doses, the NOAEL and the ADI. At the top dose, an increase was noted in nip-
ples and/or areolas in male animals on PND 12. This effect was transient, as all had
regressed by PND 21. In both of these dose groups, male offspring which were
reared to young adulthood displayed additional anti-androgen effects including,
delayed sexual maturation and reduced male sex organ sizes and weights. However,
no significant decrease in ano-genital distance on PND 1 was noted in the animals
of this dose group. Similarly, assessment of sexual steroid hormones and their pre-
cursors revealed no effects at any of the dose levels. Taken together, the weight of ev-
idence of the clinical and pathological findings suggests a lack of a non-monotonic
dose-response curve.
1928 Investigation of Flutamide at Environmentally-Relevant
Concentrations.
S. Melching-Kolmuss2,  S. Schneider1,  K. C. Fussel1,  S. Gröters1,  V. Strauss1,
B. Siddeek3,  M. Benahmed3,  M. Frericks2 and B. van Ravenzwaay1.
1Experimental Toxicology and Ecology, BASF SE, Ludwigshafen am Rhein, Germany;
2Product Safety, BASF SE, Ludwigshafen am Rhein, Germany; 3U895, équipe 5,
Bâtiment Universitaire Archimed, Centre Méditerranéen de Médecine Moléculaire
(C3M), Inserm, Nice, France.
Endocrine disruption has become an important topic of public concern. Despite an
increasing amount of attention, little is understood about if environmentally rele-
vant doses of endocrine disrupting chemicals (EDCs) affect homeostasis.
Furthermore, there are often knowledge gaps in the studies used to assess EDCs. To
address these concerns, we performed a pre-/post-natal reproductive toxicity study
of flutamide as part of a larger BASF and CEFIC funded project to measure the de-
velopmental toxicity of low single- and mixture-doses of anti-androgens. The tested
doses were selected to mimic a low-effect level, the no observed adverse effect level
(NOAEL) for endocrine effects, and the acceptable daily intake (ADI). 
While female offspring developed normally, the male offspring showed effects
known for anti-androgens. No effects were noted at the lowest dose, the ADI.
Significant decreases in ano-genital distance on PND 1 were noted in animals ex-
posed to the top dose. An increase in nipples and/or areolas in male animals on
PND 12 was noted at the top two doses. This effect was partially transient, as all
had regressed by PND 21, except at the flutamide top dose. In both of these dose
groups, male offspring which were reared to young adulthood displayed additional
anti-androgen effects including, delayed sexual maturation and reduced male sex
organ sizes and weights; however, offspring from the top dose group also had an in-
creased incidence of developmental sexual defects including hypospadias, short
penis, and cryptorchidism. Assessment of sexual steroid hormones and their pre-
cursors revealed no effects at any dose level. Taken together, the weight of evidence
of the clinical and pathological findings suggests a lack of a non-monotonic dose-
response curve.
1929 The Effects of 2, 3, 7, 8-Tetrachlorodibenzo-p-dioxin
(TCDD) on Hypothalamus-Pituitary-Gonadal (HPG) Axis
in Female Rat Primary Cultures.
K. Solak,  F. Wijnolts,  B. J. Blaauboer,  M. van den Berg and M. B. van Duursen.
Institute for Risk Assessment Sciences, Utrecht University, Utrecht, Netherlands.
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) belongs to a group of structurally
persistent, highly lipophilic compounds, that exerts a variety of adverse effects on
the development and physiology of the reproductive system. TCDD and other
dioxin-like PCBs act as endocrine disruptive compounds (EDCs) on the hypothal-
amus-pituitary-gonad (HPG) reproductive axis, mainly through the activation of
aryl hydrocarbon receptor (AHR) signaling. Females are believed to display higher
sensitivity to TCDD mainly due to the sex differences in adipose tissue percentage
and thus higher accumulation of TCDD in female tissues, including ovaries. The
present study was designed to explore the mechanisms of endocrine disrupting
properties of TCDD on female adult rat hypothalamus–pituitary-gonadal axis
(HPG axis) in vitro by employing primary hypothalamus, pituitary and ovaria cul-
tures. In all HPG axis compartments, TCDD elevated its sensitive markers CYP1a1
and AhRR after 24hours. No changes in gonadotropin-releasing hormone (GnRH)
and gonadotropins mRNA and protein levels were observed after 10nM TCDD
treatment. TCDD exerted its anti-estrogenic effects by alteration of the crucial en-
zymes in ovarian steroidogenesis. Significant down-regulation of CYP17 and
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CYP19 mRNA levels were observed with a slight decrease of estradiol levels after 24
hours. Furthermore, the FSH receptor was significantly down-regulated by TCDD,
indicating that TCDD may disturb the HPG axis via this receptor by modulation
of ovarian response to gonadotropins. This process may which further lead to ovar-
ian desensitization. To investigate the AhR involvement in these enzyme and recep-
tor mRNA observed changes, siRNA against AhR was applied. The results suggest
a key role of the AhR in CYP19 gene regulation in the regulation of female repro-
ductive tract.
1930 BPA and TBBPA Target ATP Binding Cassette Transporters
in the Blood-Testis Barrier and Impair Leydig Cell
Steroidogenesis.
M. J. Roelofs1,  A. C. Dankers2,  A. H. Piersma1, 3,  F. G. Russel2,  R. Masereeuw2
and M. B. van Duursen1. 1Institute for Risk Assessment Sciences, Utrecht University,
Utrecht, Netherlands; 2Department of Pharmacology and Toxicology, Radboud
University Nijmegen Medical Centre (RUNMC), Nijmegen, Netherlands; 3Center for
Health Protection, National Institute for Public Health and the Environment
(RIVM), Bilthoven, Netherlands.
Disturbances of androgen production in Leydig cells and/or androgen function in
Sertoli cells in the (fetal) testis have been shown to cause a wide variety of male re-
productive abnormalities in experimental animals. Drug transporters in the blood-
testis barrier (BTB) prevent entry and accumulation of xenobiotics in the testis, but
are also involved in local transport of steroid hormones. Among these are the ATP-
binding cassette (ABC) transporters, P-glycoprotein (P-gp/ABCB1), breast cancer
resistance protein (BCRP/ABCG2), multidrug resistance protein 1
(MRP1/ABCC1) and 4 (MRP4/ABCC4). We studied the interaction of Bisphenol
A (BPA) and Tetrabromobisphenol A (TBBPA) with human P-gp, BCRP, MRP1
and MRP4-mediated transport using membrane vesicles of human embryonic kid-
ney (HEK293) cells overexpressing these transporters. Also, the effects of these
compounds on testosterone production and expression of steroidogenic genes (Star,
Cyp11A1, 3β-HSD, 17β-HSD, Insl3, Cyp17A, Cyp19, LH receptor, Srd5a1) in
mouse Leydig MA-10 cells were determined. BPA and TBBPA concentration-de-
pendently induced testosterone secretion by MA-10 cells and expression of testis-
specific mRNAs of 17β-HSD and Srd5a1 (5α-reductase 1) were upregulated. BPA
and TBBPA differentially inhibited P-gp, BCRP, MRP1 and/or MRP4 activity.
Blocking P-gp using PSC833, increased testosterone secrection upon BPA and
TBBPA exposure. The MRP inhibitor MK571 completely blocked testosterone se-
cretion elicited by BPA and TBBPA. Our data suggest that EDCs might disrupt
local androgen production and androgen transport from the Leydig into Sertoli
cells thus affecting normal germ cell development.
1931 Effects of GPER Activation on (Xeno) Estrogen-Induced
Cellular Responses.
L. C. Smith1,  K. Ralston-Hooper2,  P. Ferguson2 and T. Sabo-Attwood1.
1Department of Physiological Sciences, Environmental & Global Health and Center
for Environmental and Human Toxicology, University of Florida, University of
Florida, Gainesville, FL; 2Department of Civil and Environmental Engineering and
Nicholas School of the Environment, Duke University, Durham, NC.
Estrogen can exert cellular effects through both nuclear (ESR1 and ESR2) and
membrane-bound receptors (GPER). It is unclear if these receptors act independ-
ently or engage in crosstalk to influence hormonal responses. To investigate each re-
ceptor’s role in proliferation, activation of reporter genes and protein phosphoryla-
tion in breast cancer cells (MCF-7), we employed ESR1 (PPT), ESR2 (DPN) and
GPER (G1) selective agonists. As anticipated, 17β-estradiol (E2), PPT and DPN,
enhanced cell proliferation, whereas G1 had no impact. However, E2, PPT- and
DPN-induced proliferation was repressed when cells were co-exposed with G1.
Similar results were observed for activation of an estrogen response element (ERE)-
driven luciferase reporter gene where G1 elicited a dose-dependent decrease in E2-,
PPT- and DPN induced activity. As membrane receptors typically initiate a series of
phosphorylation events, we performed global cytosolic phosphoproteome analysis
by HPLC-MS/MS on cells exposed to E2 or G1. Of the 238 phosphorylated pro-
teins identified only 10 sites were shared between E2 and G1 whereas 31 and 13
events were specific for each ligand, respectively. Using pathway analysis we devel-
oped a putative network of proteins that are influenced by GPER activation and
have identified ‘central nodes’ (i.e. NDRG2) which highlights a possible role for
these proteins as targets of GPER activity. As xenoestrogens, such as bisphenol-A
and genistein, bind to ESRs and GPER we are currently investigating the impact
these compounds have on nuclear and membrane estrogen receptor signaling net-
works. Overall, our proteomic and mechanistic approaches will lead to the identifi-
cation and sorting of GPER networks and the potential interplay with ESRs that
will illuminate the role of these receptors in cellular responses to E2 and xenoestro-
gens.
1932 Antiproliferative, Antiandrogenic, and Cytotoxic Effects of
Novel Synthetic Derivatives of Caffeic Acid in LNCaP
Human Androgen-Dependent Prostate Cancer Cells.
T. Sanderson1,  H. Clabault1,  C. Patton1,  L. M. LeBlanc2,  M. Hébert2 and
M. Touaibia2. 1INRS-Institut Armand-Frappier, Laval, QC, Canada; 2Département
de Chimie et Biochimie, Université de Moncton, Moncton, NB, Canada.
Caffeic acid and its naturally occurring derivative caffeic acid phenethyl ester
(CAPE) have antiproliferative and cytotoxic properties in a variety of cancer cell
lines, but little is known about their effects on prostate cancer cells. We evaluated
the effects of caffeic acid, CAPE and 18 novel synthetic derivatives on cell prolifer-
ation, subcellular localisation and expression of androgen receptor (AR) and secre-
tion of prostate-specific antigen (PSA) in LNCaP human hormone-dependent
prostate cancer cells. LNCaP cells cultured in steroid-free medium were exposed to
0.1 nM dihydrotestosterone (DHT) in combination with various concentrations of
caffeic acid derivatives (0.3-100 μM) for 24-72 h during which cell proliferation
was followed using an xCELLigence cell monitoring system (Roche).Cytoplasmic
and nuclear levels of AR were determined by immunoblotting and PSA secretion
using a commercial ELISA. Cytotoxicity was measured by assessing mitochondrial
function using a WST-1 assay. Seven synthetic derivatives of CAPE were strong,
concentration-dependent inhibitors of androgen-stimulated LNCaP cell prolifera-
tion with up to 3-fold greater potencies (IC50=8-24 μM) than CAPE
(IC50=28.9±4.5μM); caffeic acid had no effect. Concomitant with inhibition of
cell proliferation, DHT-stimulated PSA secretion was reduced by CAPE and the 7
derivatives. The most potent derivative MT-30 (IC50=7.9 ± 2.4 μM) inhibited
DHT-stimulated cell proliferation and PSA secretion significantly at 0.3 μM.
Exposure to 10 nM DHT increased cytoplasmic and nuclear AR levels and co-
treatment with increasing concentrations of MT-30 and CAPE, interestingly, fur-
ther increased these levels. In conclusion, a number of synthetic derivatives of caf-
feic acid are potent inhibitors of androgen-dependent prostate cancer cell growth,
acting via an antiandrogenic mechanism that involves increased nuclear accumula-
tion of (possibly inactive) AR.
1933 Cadmium Content in Human Pancreatic Insulin Producing
Beta Cells.
M. El Muayed1,  K. W. MacRenaris2 and W. L. Lowe1. 1Division of Endocrinology,
Northwestern University Medical School, Chicago, IL; 2The Chemistry of Life
Processes Institute, Northwestern University, Chicago, IL. Sponsor: J. Bolton.
Evidence suggests that chronic low level cadmium exposure impairs the function of
insulin producing beta cells and may be associated with type 2 diabetes mellitus.
We previously reported that insulin producing beta cells accumulate Cd avidly and
gradually in a dose and time dependent manner over prolonged time periods, lead-
ing to impaired beta cell function at environmental Cd exposure concentrations.
This is likely due to the high beta cell Zn turnover and the significant overlap be-
tween Zn and Cd transport and buffering mechanisms. In the present study we
compared the content of cadmium (Cd) and Mercury (Hg) between native human
islets with that of liver samples (10 human subjects living in the USA). The content
of Cd and Hg in these tissues lysates was measured by ICP-MS. All studies were ap-
proved by our institutional review board. The cadmium (Cd) content in islets from
10 human non-diabetic subjects ranged from 7.4 to 71.92 nM/g protein (average
28.80 ± 6.73 nM/g protein). The concentration of mercury (Hg) was significantly
lower ranging from undetectable (detection threshold 4 nM/g protein) to 5.05
nM/g protein. In comparison, human liver lysates contained significantly less Cd
(9.04 ±1.99 nM/g protein). No Hg was detected in any of the liver samples (detec-
tion threshold 4 nM/g protein). We conclude that human islets accumulate mea-
sureable, and likely relevant quantities of Cd that are higher than these of Hg under
normal environmental exposure conditions. In comparison, the Cd concentration
in Liver samples was significantly lower, likely due to the significantly lower Zn
turnover rate in liver cells compared to that in beta cells.
1934 Formulation Development and Analysis Methods for
Bisphenol AF in 5K96 Verified Casein Feed.
K. Aillon1,  V. Ault1,  A. Sullivan1,  R. Mathias1,  J. Algaier1,  R. Harris1,
B. Collins2 and S. Waidyanatha2. 1MRIGlobal, Kansas City, MO; 2National
Toxicology Program, NIEHS, Research Triangle Park, NC.
Bisphenol AF (BPAF), a perfluorinated BPA homologue, is a cross linking agent in
fluoroelastomers used in food and pharmaceutical processing equipment. Due to
inadequate toxicity data, occupational and potential consumer exposure, and struc-
tural similarity to bisphenol A, BPAF was selected for evaluation by the National
Toxicology Program (NTP). MRIGlobal supported the NTP by formulating BPAF
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into a phytoestrogen-free rodent diet, LabDiet 5K96 Verified Casein diet, develop-
ing the associated formulation analysis methods, and evaluating homogeneity and
storage stability in the formulated diet. 
The analysis method involved the extraction of BPAF from feed using acetoni-
trile/acetic acid (99/1 v/v). The method covered a formulation range of ~200 to
~10,000 μg/g with dilution into the curve up to 15,000 μg/g. The method was lin-
ear, accurate, and precise with BPAF recoveries ≥ 99%. 
Homogeneity evaluation of 937.5 and 15,000 μg/g formulations showed recoveries
≥ 99% with RSD values ≤ 0.9%. Long-term BPAF stability for the 937.5 μg/g for-
mulation showed the formulation was stable for 42 days (recovery ≥ 94.5%) when
stored under refrigerated or freezer conditions. 
When the 937.5-μg/g formulation was stored under simulated dosing conditions,
in the presence of rat urine and feces, the ACN/acetic acid extraction resulted in an
68% BPAF recovery after 7 days, indicating possible BPAF instability or extensive
binding to feed under these conditions. To investigate this, several solvents with dif-
ferent polarity and pH were tested. ACN/acetic acid 99/1 extraction resulted in
79% BPAF recovery after 8 days storage in the presence of rat urine and feces.
Adding an additional acid-digestion and extraction step, in which the formulation
was digested with 8.3N HCl at ~ 75C and extracted with ethyl ether:petroleum
ether (1:1), BPAF recovery increased to 90% in Day 7 samples. This suggests that
BPAF is stable but exhibits non-covalent binding to feed components.
1935 Silencing of Testisin through CpG Methylation from
Exposure to Phthalates in Ntera-2 Cells.
J. Gomes,  J. Kapongo,  B. Nguyen and D. Krewski. University of Ottawa,
Ottawa, ON, Canada.
Di (2-ethylhexyl) phthalate (DEHP) is one of the most highly produced and fre-
quently studied phthalates. Its metabolite, monoester mono (2-ethylhexyl) phtha-
late (MEHP) is reported to be a testicular toxicant. Following toxicity pathway
analyses we identified Testisin, GSTP1 and MGMT genes to study their expression
in testicular germ cells (Ntera-2). Testisin present in normal tissue but absent in
neoplastic tissue and regulates proteolytic reactions in testicular germ cells; GSTP1
inactivates carcinogens and is a member of glutathione-S-transferase; and
Methylguanine DNA methyltransferase (MGMT) provides defense against neo-
plasm. Testicular cells under laboratory conditions were exposed to MEHP in a
dose- and time-dependent manner at concentrations of 1μM, 10μM, and 100μM
at 24, 48, 72 and 96hr time points. The control was made by exposure of MEHP to
5’aza (demethylating agent) for hypermethylation. After exposure, those genes were
analyzed by Quantitative Real Time PCR (qRT-PCR). The results revealed an over-
all down regulation for each gene as the concentration and/or time increased. The
expression of Testisin, GSTP1 and MGMT was downregulated but not signifi-
cantly in the last two cases. Following exposure to 5-aza treatment and coexposure,
there was a significant up-regulation and restoration of the expression of the
Testisin gene. This suggests that MEHP may down-regulate Testisin gene expres-
sion by DNA methylation. These findings provide evidence that MEHP can alter
the expression of Testisin, GSTP1 and MGMT, genes. Testisin which is associated
with testicular germ cell tumors and its downregulation and subsequent restoration
may be caused by DNA methylation following exposure to MEHP. The expression
of GSTP1 which is a xenobiotic metabolizing enzyme gene and the DNA repair en-
zyme gene suggests that the toxicant if fairly active in these cells exposed to MEHP.
The investigation of DNA methylation at the CpG islands of the promoter region
of Testisin is described.
1936 An Examination of the Effects of Methyltriclosan on Early-
Emrbyonic Development in the South African Clawed Frog
(Xenopus laevis).
M. Cromie1,  M. Wages2,  B. Perafan1,  E. Smith2 and J. Carr1. 1Biological Sciences,
Texas Tech University, Lubbock, TX; 2The Institute of Environmental and Human
Health, Texas Tech University, Lubbock, TX. Sponsor: W. Gao.
Triclosan (5-chloro-2-(2,4-dichlorophenoxy)phenol) is a commonly used bacteri-
cide present in many personal care products such as detergents, liquid hand soaps,
deodorants, cosmetics, lotions, mouthwash, and toothpaste, and it can be inte-
grated with fabrics, plastics, carpets, and toys. Methyltriclosan is a derivative that is
formed from triclosan via biological methylation at an unknown interval during
waste water treatment. Methyltriclosan is more abundant in the environment, more
lipophilic than triclosan, and has a greater potential to accumulate in fatty tissues.
The global decline of amphibian populations has raised awareness surrounding the
possible effects of poor water quality on the health of habitats. Since metamorpho-
sis and reproductive development in amphibians is highly regulated by thyroid hor-
mone (TH), and the structure of triclosan is similar to that of TH, there is the pos-
sibility that triclosan and methyltriclosan may act on TH receptors to alter
metamorphosis and reproductive development. Standard 96-hour Frog Embryo
Teratogenic Assay-Xenopus protocols were followed using South African Clawed
Frog (Xenopus laevis) embryos. After measuring the larvae the data revealed that
early embryonic exposure to environmentally relevant concentrations of methyltri-
closan resulted in statistically significant alterations in total body length, snout-to-
vent length and crown width. Furthermore, molecular studies were performed to
identify the effects of methyltriclosan exposure on the TH-responsive gene,
TH/bZIP. The results of the quantitative real-time polymerase chain reaction did
not support the induction of TH/bZIP gene expression after exposure to environ-
mentally relevant concentrations of methyltriclosan. However, the expression of
other TH-responsive genes may be altered upon exposure. Collectively, these data
are the first to report on the responsiveness of vertebrate embryos to methyltri-
closan exposure.
1937 No Evidence of Endocrine Disruption by Glyphosate in Male
and Female Pubertal Assays.
J. Bailey1, 2,  J. Hauswirth2 and D. Stump3. 1Dow AgroSciences, LLC, Indianapolis,
IN; 2Joint Glyphosate Task Force, Raleigh, NC; 3WIL Research Laboratories, LLC,
Ashland, OH.
The Food Quality Protection Act and Safe Drinking Water Act amendments
(1996) required the USEPA to develop the Endocrine Disruptor Screening
Program (EDSP), which currently consists of 11 Tier 1 screening assays to evaluate
the potential for a chemical to interact with the endocrine system. Glyphosate was
included in the first list of 67 compounds subject to the EDSP, which were selected
for screening based on their potential for exposure rather than suspected interfer-
ence with the endocrine system.
The potential for glyphosate (G) to induce endocrine disruption has now been eval-
uated in the male and female Pubertal assays, the two most apical mammalian
EDSP Tier 1 assays.
The female pubertal assay evaluates potential effects on pubertal development and
thyroid function in the juvenile female. Four groups of fifteen juvenile female rats
were dosed with the following: 0, 100, 300 and 1000 mg/kg/d G once daily via oral
gavage from postnatal day (PND) 22 to 42. There was no evidence of any direct test
substance-related estrogenic or anti-estrogenic effects, nor was there any evidence of
direct test substance-related effects on pubertal development or thyroid function in
the juvenile female rat following oral administration of glyphosate at any dosage
level tested.
The male pubertal assay evaluates potential effects on pubertal development and
thyroid function in the juvenile males. Four groups of fifteen juvenile male rats
were dosed with the following: 0, 100, 300 and 1000 mg/kg/d G once daily via oral
gavage from PND 23 to 53. There was no evidence of any direct test substance-re-
lated androgenic or anti-androgenic effects, nor was there any evidence of direct
test substance-related effects on pubertal development or thyroid function in the
juvenile male rat at any dosage level tested..
Based on these results, glyphosate does not exhibit endocrine disruption in the male
and female pubertal assays.
1938 Exposure to G-1, a Selective Agonist for G Protein-Coupled
Estrogen Receptor 1 (GPER), Results in Elevated Levels of
Vitelloginin in Adult Fathead Minnows (Pimephales
promelas).
S. Jayasinghe1,  K. Kroll1,  N. Denslow1 and T. Sabo-Attwood2. 1Department of
Physiological Sciences, Center for Environmental and Human Toxicology, University
of Florida, Gainesville, FL; 2Department of Environmental and Global Health,
Center for Environmental and Human Toxicology, University of Florida, Gainesville,
FL.
Several research groups have shown that G protein-coupled estrogen receptor-1
(GPER) mediates 17β-estradiol (E2) activation through non-genomic membrane
initiated pathways. Estrogens play critical roles in a variety of biological processes,
including reproduction and development in vertebrates. In fish, hepatic synthesis of
vitellogenin (VTG), a precursor egg yolk protein that is vital to successful repro-
duction, is controlled by E2 via nuclear estrogen receptors (ESR). However, the in-
volvement of GPER in vitellogenesis has not been investigated. As the GPER is not
a well characterized in fish the aims of our study are to; (1) assess the tissue-specific
expression of GPER in adult fathead minnows (FHM) and (2) determine the effect
of GPER activation on VTG synthesis in FHM males and females using a selective
GPER agonist (G-1) and antagonist (G-15). Using qRT-PCR we show that GPER
mRNA is detectable in numerous organs, and is most highly expressed in the brain
followed by gall bladder, trunk kidney, intestine, liver, heart, ovary and muscles.
Aqueous exposure to G-1 (5, 30 and 100 ng/L) for 48 hours resulted in a dose de-
pendent increase of hepatic VTG expression compared to vehicle control in both
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males and females. In efforts to block GPER-mediated induction of VTG expres-
sion, we co-exposed male fish to G-1 and the GPER antagonist G-15. Preliminary
results were surprising as the combination of G-1/G-15 enhanced VTG expression
compared to each agent singly. Overall, these data suggest that control of VTG syn-
thesis likely involves both nuclear and membrane receptors that are sensitive to E2
activation. We are currently investigating the impact of xenoestrogens on GPER ac-
tivation in control of VTG synthesis.
1939 Study on the Subchronic Oral Toxicity of the Circuit Board
Powder in Rats.
N. Wu. Institute of Hygiene, Zhejiang Academy of Medical Sciences, Hangzhou,
Zhejiang, China.
Objective To investigate the subchronic oral toxicity of the circuit board powder in
SD rats. Methods Male and female SD rats were randomly divided into four groups
named A, B, C and D, A and D group had 16 rats, B and C group had 14 rats, A
and D group retained 4 rats for a 45d recovery experiment after the 90d subchronic
experiment. A group was given normal diet as control, B, C and D groups were
given mixed feed which was made from adding the circuit board powder 10, 20,
50g per kg to the normal diet. All of the groups were ate and drank freely under
natural light. After 90 days’ feeding, each group calculated the major organ coeffi-
cient, measured the blood biochemical parameters, and determined the content of
serum triiodothyronine (T3), thyroxine (T4) and testosterone (T) after 45d, 90d
and 45d recover. Results Compared with the control group, each dose group of the
circuit board powder have no significant difference in body weight. There were sig-
nificant differences between the high-dose group and control group of female rats
in some blood biochemical parameters. The organ coefficient of liver in the
medium- and high-dose groups of female rats was also significant increase. The
content of serum T3, T4 and T in each dose group were significantly higher than
that of the control group after 45d and 90d, each index had the most obviously in-
crease in the low-dose group. There was no significant difference between the high-
dose group and control group in serum T3, T4 and T after 45d recovery.
Conclusion subchronic oral exposure to the circuit board powder can cause liver
damage in rats, and elevated the content of serum T3, T4 and T.
1940 Activation of the Hypothalamic-Pituitary-Adrenal (HPA)
Axis following Extended Exposure to Atrazine (ATR).
S. C. Laws1,  R. Cooper1 and B. W. Riffle1, 2. 1ETB, TAD, NHEERL, ORD, US
EPA, Research Triangle Park, NC; 2ORISE, US Department of Energy, Oak Ridge,
TN.
While it is known that adrenal steroids impact reproduction and a variety of other
physiological and behavioral functions, disruption of the HPA-axis is not typically
considered in toxicological studies. Here we characterize changes in basal corticos-
terone (CORT) and progesterone (P4) over a 21- day exposure to the chlorotriazine
herbicide, ATR. Adult Wistar male rats were dosed by oral gavage with 0, 5, 25, 75,
or 200 mg/kg/d given either as a single dose or multiple daily doses (7, 14, or 21
doses) at 0900 hrs (nadir of circadian CORT rhythm) and were decapitated 30
minutes after the last dose (n=10/group).  Necropsy body weight was significantly
lower than controls (p < 0.05) only in the 200 mg/kg group dosed for 21 days.
Adrenal weights were unaffected by ATR at any time point. Serum CORT was ele-
vated in response to a single dose of ATR (LOEL=5mg/kg). Serum CORT was also
increased following 7 (LOEL=75mg/kg), 14 (LOEL=25mg/kg), and 21
(LOEL=75mg/kg) daily doses.  A similar profile was observed for serum P4 follow-
ing a single dose (LOEL=25 mg/kg), or 7 (LOEL=75 mg/kg), 14 (LOEL=75
mg/kg), and 21 (LOEL=200 mg/kg) doses of ATR. Urinary CORT (ratio of
CORT/urinary creatinine), measured over a 6 hr period after dosing, was signifi-
cantly increased in the ATR groups (e.g., LOEL for one dose =75 mg/kg, LOEL for
21 doses =75 mg/kg). These data demonstrate a HPA response after daily doses of
ATR (e.g., 75 and 200 mg/kg) for up to 21 days. Further work is needed to evalu-
ate the effects of ATR on the circadian CORT rhythm and to discern any impact
on reproductive function.  This abstract does not reflect U.S. EPA policy.
1941 2-Isopropylthioxantone (ITX) Induces Endocrine Disrupting
Effects and Increases Liver Weight during Puberty in Male
Wistar Rats.
P. Hendriksen,  E. Kramer,  M. Groot,  J. C. Rijk,  R. L. Hoogenboom and
A. A. Peijnenburg. Toxicology, RIKILT Institute of Food Safety, WUR, Wageningen,
Netherlands. Sponsor: S. Rangarajan.
2-isopropylthioxantone (ITX) is a photo-initiator used in the printing process of
many materials. ITX has been detected as contaminant in food such as milk and
fruit beverages. Previous in vitro studies revealed ITX acting agonistic on the aryl
hydrocarbon receptor (AhR) and antagonistic on both the androgen receptor and
estrogen receptor. In addition, ITX increases aromatase activity in vitro. To validate
these findings in vivo, male rats were treated daily with 50, 150 or 500 mg/kg/day
ITX during their puberty period from PND 23 to 53. For comparison, rats were
treated with 50 ng/kg/day TCDD (AhR agonist), 30 mg/kg/day Casodex (AR an-
tagonist) or 50 mg/kg/day flutamide (both AhR agonist and AR antagonist).
ITX, from the lowest dose onwards, exerted a decrease in weight of the ventral
prostate, and the highest dose of ITX decreased the weight of the seminal vesicles
and coagulating gland, and reduced the number of spermatozoa in the cauda. The
same effects, but more severe, were induced by flutamide and Casodex. Epididymal
weight, caput sperm counts and preputial separation were negatively affected by
Casodex and flutamide and not by ITX. ITX reduced testosterone and increased es-
trogen levels confirming the in vitro finding on increased aromatase activity. 
500 mg/kg/day ITX-500 reduced the body weight, while it increased liver weight
with 20% and relative liver weight with 38%. Whole genome mRNA expression
profiling of the liver revealed a striking similarity of genes affected by ITX and flu-
tamide. Furthermore, many TCDD-affected genes, including many known AhR
target genes, were regulated by ITX as well. Taken together, these results convinc-
ingly demonstrates ITX to be an endocrine disruptor that exerts AhR agonistic and
AR antagonistic activities both in vitro and in vivo.
1942 In Vivo Human Pharmacokinetics of Dibenzo[DEF,
P]Chrysene (DBC) following Microdosing—Bridging the
Gap between High-Dose Animal Data and Environmentally-
Relevant Human Exposures.
E. P. Madeen1, 4,  R. Corley3,  K. W. Turteltaub2,  T. Ognibene2,  M. Malfatti2,
M. Garrard1, 4,  K. Sudakin1, 4,  T. Mcquistan1, 4 and D. E. Williams1, 4. 1Oregon
State University, Corvallis, OR; 2Lawrence Livermore National Lab, Livermore, CA;
3Pacific Northwest National Lab, Richland, WA; 4Linus Pauling Institute, Corvallis,
OR.
Polycyclic Aromatic Hydrocarbons (PAHs) comprise environmental mixtures of
toxicants resulting from the combustion of carbonaceous material, of which some
high molecular weight constituents are carcinogens in animal models. There is little
data currently available on the pharmacokinetics or pharmacodynamics of any
PAHs, especially the higher molecular weight, carcinogenic PAHs, in humans.
Utilizing the sensitivity of accelerator mass spectroscopy (AMS), 14C- labeled
PAHs can be studied at environmentally relevant concentrations, below the average
daily exposure and at levels regulatory agencies have determined from animal stud-
ies to be safe daily exposures over a lifetime. The 30 ng DBC dose utilized in this
study has an EPA estimated B(a)Peq of 300-900 ng, falling within the U.S. daily di-
etary estimate of an average B(a)P exposure of 40-2800 ng/person . Over 90% of
exposure to carcinogenic PAHs is through the diet. 14C-DBC was detected in
blood and urine post ingestion of a 5 nCi (30ng) 14C- DBC dose given by capsule
to healthy male and healthy, infertile female volunteers (n=9). Blood was collected
at 15 time points over 72 hours with 11 collections during the first 8 hours post-
dosing. Urine was collected in 5 pools over 72 hours with 3 pools in the first 24
hours. Plasma concentrations of 14C reached maximal concentrations of 11 to 68
fg DBC eq./ml within 1.5-4 hr after consumption with an alpha phase half-life for
14C clearance that averaged 3.5 ± 2.3 hr across all volunteers.  A more prolonged
beta-elimination phase was also observed. These results are the first available
human pharmacokinetic data from a high molecular weight, probable human
(IARC class 2A) carcinogenic, PAH. This unique dataset can be used to enhance
the confidence of human health risk assessments to PAH exposures.
1943 Evaluation of Tumor Pathology Concordance between
Epidemiological and Rodent Studies.
J. Wan1,  J. W. Card1,  H. Fikree1,  L. Haighton1,  V. Lee-Brotherton1 and
B. Sangster2. 1Intertek Cantox, Mississauga, ON, Canada; 2ASAT Foundation,
Leidschendam, Netherlands.
To assist with evaluating human cancer risk from chemical exposures, an investiga-
tion was conducted to assess concordance at the tissue level between tumors re-
ported in epidemiological investigations and rodent bioassays for a selected group
of chemicals. This investigation focused on chemicals that were considered to be
probable human carcinogens (Group 2A) by IARC or “Reasonably Anticipated”
carcinogens by the US NTP, and for which there was evidence of tumor concor-
dance at the organ level. The 7 chemicals identified for this evaluation, and the
organ-level tumor concordances for each, were as follows: 1-amino-2,4-dibromoan-
thraquinone (lung), tetrachloroethylene (liver, kidney), trichloroethylene (liver,
kidney), inorganic lead compounds (lung, kidney, brain), 2,4,6-trichlorophenol
(lymphoma), polychlorinated biphenyls (liver, gastrointestinal), and benzyl chlo-
ride (lung). Based on pathology, concordance between rodent and human tumors
for at least 1 tumor type was identified for 4 of the 7 compounds (tetrachloroethyl-
ene, trichloroethylene, inorganic lead compounds, and polychlorinated biphenyls);
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however, the strength of the concordance was considered weak in all cases. For the
same 4 compounds, there were a large number of tumors which lacked concor-
dance between animal and epidemiological studies. Of the remaining compounds,
insufficient data were available for an evaluation of tumor pathology (1-amino-2-4-
dibromoanthraquinone and 2,4,6-trichlorophenol) or there was an absence of con-
cordance at the tissue level (benzyl chloride). In conclusion, this investigation of
concordance between animal and human tumors reported to be caused by specific
compounds shows that, even when chemically-induced tumors are identified to be
occurring in the same organ in both rodents and humans, there is no strong evi-
dence of concordance of these tumors at the level of the affected tissue.
1944 Benchmark Dose Models for Benzene Genotoxicity Using
the Diversity Outbred Mouse.
K. L. Witt1,  G. E. Kissling1,  D. L. Morgan1,  K. R. Shockley1,  D. M. Gatti2,
G. A. Churchill2 and J. E. French1. 1DNTP, NIEHS, Research Triangle Park, NC;
2Center for Genome Dynamics, The Jackson Laboratory, Bar Harbor, ME.
The genetic basis for inter-individual variation in response to toxicant exposure is
poorly understood. The Diversity Outbred (DO) mouse is a new model that can be
used to explore population based response variation. DO mice were derived from a
set of eight inbred founders and are maintained by random breeding as an het-
erozygous population containing over 38 million SNPs and 5 million indels
(CNV). The genetic diversity and a fine recombination haplotype structure allow
high mapping resolution. In experiments reported here, J:DO male mice were ex-
posed to benzene (0, 1, 10, 100 ppm; 75 mice/group) by inhalation, 6 hr/day, 5
days/wk for 28 days in two independent cohorts (300 mice each). Samples of pre-
and post-exposure peripheral blood (PB) or post-exposure for bone marrow (BM)
were evaluated for frequency of micronucleated reticulocytes (MN-RET) using
flow cytometry. MN-RET showed significant increasing trends in response to ben-
zene exposure (p<0.0001) in both cohorts and were significantly higher than con-
trols in both the 10 ppm (p=0.013) and the 100 ppm (p < 0.0001) groups.
Genotoxicity was highly variable within the 100 ppm groups. Linkage analysis
identified quantitative trait loci (QTL) on chromosome 10 (Chr10) between
megabase 26 and 35 (LOD=14.6). We identified benzene resistant and susceptible
Chr10 QTL genotypes from the lowest and highest quartiles of the BM MN-RET
response in the 100 ppm group. Animals in the 0, 1, and 10 ppm groups having
these genotypes were placed into the resistant or susceptible groups for modeling.
The benchmark concentration (BMC) and its 95% lower confidence limit
(BMCL) were estimated from the best-fit model for the most resistant (BMCL =
5.9 ppm) and most susceptible (BMCL = 0.01 ppm) animals, a 590-fold difference
between subpopulations. These data suggest that an uncertainty factor of 100 for
interspecies and intraspecies variation may not be sufficient for calculation of a
human benzene reference concentration based on benzene genotoxicity.
1945 Is There a Subset of Susceptible Individuals in Controlled
Air Pollution Studies?
M. Seeley and J. E. Goodman. Gradient, Cambridge, MA.
To establish primary National Ambient Air Quality Standards for criteria air pollu-
tants such as nitrogen dioxide (NO2), ozone (O3) and sulfur dioxide, US EPA eval-
uates results from epidemiology, controlled human exposure, and animal studies.
For the controlled human exposure studies, which focus on individuals with
asthma, there is concern that there may be a subset of susceptible individuals who
respond to lower concentrations than the average individual with asthma, but
whose response is obscured by evaluating group-level data. To address this, we iden-
tified controlled human exposure studies with more than one exposure concentra-
tion that provided individual-level data for airway hyper-responsiveness. We identi-
fied three studies involving exposure to NO2 (including data for 38 subjects), and
one study each for ozone (O3) and sulfuric acid (each including data for 10 sub-
jects). For each study, we compared individual data across exposures to determine
whether there were individuals who were consistently more or less responsive, de-
fined by having a response that differed by more than two standard deviations from
the group mean response. To determine whether evaluating group-level responses
might obscure responses for potentially susceptible individuals, we compared the
concentration-response function (CRF) for all subjects to the CRF for a subset that
excluded less responsive subjects and the CRF for only more responsive subjects.
Among the five studies, we identified only one subject, in one study, who was con-
siderably more responsive at both exposure levels in the study. The shapes of the
CRFs, however, were similar for the group as a whole and the more responsive sub-
ject. We also identified one subject, in one study, who was less responsive at all ex-
posure levels in the study. Exclusion of data for this subject did not qualitatively
change the shape of the CRF. Our analysis of these five studies indicates that evalu-
ating group-level responses to air pollutants does not obscure CRFs for potentially
susceptible individuals.
1946 Concordance of Transcriptional and Apical Benchmark Dose
Levels for Conazole-Induced Liver Effects in Mice.
V. S. Bhat1,  S. Hester2,  S. Nesnow2 and D. A. Eastmond1. 1Environmental
Toxicology, University of California Riverside, Riverside, CA; 2NHEERL, US EPA,
Research Triangle Park, NC.
The ability to anchor chemical class-based gene expression changes to phenotypic
lesions and to describe these changes as a function of dose and time can inform
mode of action and improve quantitative risk assessment. Previous research identi-
fied a 330-gene cluster commonly responsive to three hepatotumorigenic conazoles
(cypro-, epoxi- and propiconazole) at 30 days. Extended to two more conazoles (tri-
adimefon and myclobutanil), the present assessment encompasses four tumorigenic
and one non-tumorigenic conazole. Transcriptional benchmark dose levels
(BMDLT) were estimated for a subset (~50 genes) of the gene cluster that had a ≥5-
fold change in signal intensity at the tumorigenic dose and demonstrated dose-re-
sponsive behavior. The modeled genes primarily encompassed pathways involved in
Phase I/II or lipid metabolism, oxidative stress, MAP kinase signaling, and/or apop-
tosis (such as Cyp2b10, Lcn13, Abcc4, Akr1b7, Gadd45b). The median BMDLT
estimates from the gene subset were concordant (within a factor of 0.8 to 1.2) with
the apical benchmark dose (BMDLA) for increased liver weight at 30 days for the
four tumorigenic conazoles. The 30-day median BMDLT estimates were within
one-half order of magnitude (generally more sensitive) of the chronic BMDLA for
liver tumors. Discordant 30-day BMDLT and BMDLA values were obtained for the
non-tumorigenic conazole (myclobutanil). Potency differences seen in the dose-re-
sponsive transcription of some of these biomarker genes, particularly those involved
in Phase II metabolism and bile acid transport (such as Gstm3, Gstt3, Abcc4,
Akr1b7), mirrored each conazole’s tumorigenic potency. The 30-day BMDLT and
BMDLA estimates corresponded to tumorigenic potency on a mg/kg-day basis with
cyproconazole > epoxiconazole > propiconazole > triadimefon > myclobutanil
(non-tumorigenic). These initial results support the utility of measuring short-term
gene expression changes to inform quantitative risk assessments from long-term ex-
posures. This abstract does not reflect EPA policy.
1947 Assessment Factors for Susceptible Populations—Analysis of
Airway Response during Short-Term Exposure to Volatile
Chemicals.
M. Johansson,  G. Johanson and M. Öberg. Institute of Environmental Medicine,
Stockholm, Sweden.
Health-based guidance values for short-term exposure to airborne hazardous chem-
icals are developed to support the protection of the general population, including
susceptible sub-groups such as asthmatics, in the case of sudden release of chemi-
cals. The Acute Exposure Guideline Level (AEGL) program is one of the most well-
known set of short-term values. Our analysis of AEGL documents reveals that only
8% include data on asthmatics. A comparison of documents in nine additional sets
of short-term values shows that data on asthmatics are frequently disregarded. The
aim of the present study was to investigate the experimental support of a general
difference in airway response between healthy and asthmatic individuals during
short-term exposure. We performed a review of experimental data from 108 studies
including both asthmatic and healthy subjects exposed to airborne chemicals dur-
ing identical experimental conditions. In total, experimental data for 19 chemicals
and 9 mixtures were identified. Thresholds for airway response and the difference
between asthmatic and healthy subjects were calculated in each study. The differ-
ence between subgroups was compared to the general assessment factors applied for
susceptible populations in the derivation of guidance values. In addition, dose-re-
sponse relationships of four high volume chemicals were calculated for healthy and
asthmatic individuals, separately, to identify threshold concentrations for effects on
lung function. Our results show that asthmatic individuals generally are more sus-
ceptible than healthy individuals. An inter-individual assessment factor of three
may not be sufficiently protective for all chemicals.
1948 Thermal Constraints and Chemical Exposure in the
Workplace: Prioritization of Occupations for Better
Prevention.
A. Adam-Poupart1,  G. Truchon2,  M. Lévesque1,  M. Busque2,  P. Duguay2,
R. Bourbonnais3 and J. Zayed1, 2. 1Environmental and Occupational Health,
Université de Montréal, Montréal, QC, Canada; 2Institut de recherche Robert-Sauvé
en santé et sécurité du travail (IRSST), Montréal, QC, Canada; 3ROH Consultant,
Laval, QC, Canada.
Chemicals and heat exposure are common hazards found in the workplace and
their coexposure may lead to increased health risk due to potential interactions:
some chemicals can affect the thermoregulatory mechanisms and reduce the
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worker’s capacity to adapt to heat, while heat exposure can modify physiological pa-
rameters and increase the absorption of some chemicals. Therefore, the aim of this
research was to identify the occupations at risk of concomitant exposure to heat and
chemicals in Quebec (Canada). To achieve this goal, a list of occupations from all
industry sectors of Quebec was built from national employment data, and occupa-
tions at risk of heat stress were determined with a risk rating matrix based on the
probability of occurrence and the severity of health effect. For occupations judged
as having significant and critical heat stress risk, the presence of chemicals that may
be found at work was documented (solvents, dust, pesticides, polycyclic aromatic
hydrocarbons, toxic gases, heavy metals, asbestos/silica and reagents/other chemi-
cals) and a list of occupations with high potential of simultaneous exposure to heat
and chemicals was produced and submitted to a panel of experts for prioritization.
From an initial set of 1010 occupations, 257 were judged as having significant and
critical heat stress risk and 136 of these were included in the list of occupations with
high potentially simultaneous exposure. Experts identified 22 priority occupations
grouped in metal manufacturing, non-metallic mineral product, construction and
public administration sectors. This innovative approach, based on a matrix analysis
and judgment of experts, served as a useful tool to identify sectors/occupations
where health risk assessments, preventive interventions and regulatory practices
should be conducted or developed.
1949 Acute and Chronic Noncancer Inhalation Toxicity Factors for
Acrylonitrile.
J. Lee,  R. L. Grant and S. Shirley. Toxicology, TCEQ, Austin, TX.
Acrylonitrile (AN) is used extensively in the production of plastics, synthetic rub-
ber, nitrile elastomers, resins, and acrylic fibers. The USEPA indicates that Texas
contributes 11% of the nations reported ambient AN emissions annually.
Inhalation of AN vapors can cause respiratory irritation, and at higher levels, neu-
rological symptoms including dizziness, weakness, headache, and impaired judg-
ment. To ensure that the general public in Texas is protected against potential in-
halation effects from AN exposure, the Texas Commission on Environmental
Quality (TCEQ) has developed acute and chronic reference values (ReVs). An
acute ReV (1-hr exposure duration) of 1100 μg/m3 was derived based on no signs
or symptoms observed in human volunteers exposed to AN for up to 8 hours. A
chronic ReV of 2.2 μg/m3 was derived based on benchmark dose modeling for in-
creased nasal lesions observed in female rats. The chronic ReV is comparable to the
California EPA reference exposure level of 5 μg/m3. Effects Screening Levels
(ESLs) were calculated from ReVs by applying a target hazard quotient of 0.3, to
account for possible cumulative exposure. ESLs are used to evaluate modeled
ground level concentrations due to emissions from facilities during air permit re-
views. The corresponding acute and chronic ESLs were 330 and 0.7 μg/m3, respec-
tively. Reproductive/developmental animal and epidemiological data were not used
to derive ReVs since AN is not expected to be a developmental or reproductive tox-
icant in the absence of significant maternal toxicity. Furthermore, the overall car-
cinogenic weight-of-evidence shows that while AN is capable of causing tumors in
rats and mice at high doses, AN does not appear to contribute to the development
of cancerous tumors in humans. Thus, no inhalation unit risk factor was derived.
The derived chronic ESL, however, is within the range of the concentrations at 1 x
10-5 cancer risk estimated by USEPA and thus, is expected to be protective against
potential cancer risk.
1950 Hexavalent Chromium Carcinogenicity: Use of a Nonlinear-
Threshold Assessment to Develop a Cancer-Based Chronic
Inhalation Reference Value.
N. Erraguntla1,  J. T. Haney1,  R. L. Sielken2 and C. Valdez-Flores2. 1Toxicology
Division, Texas Commission on Environmental Quality, Austin, TX; 2Sielken &
Associates Consulting, Bryan, TX.
It is important to conduct up-to-date chemical assessments for known human lung
carcinogens such as hexavalent chromium (CrVI). An updated carcinogenic assess-
ment has been conducted for CrVI, which has been the subject of recent scientific
debate. In addition to default linear low-dose extrapolation methods used to calcu-
late an inhalation unit risk factor (URF), the study authors believe epidemiological
data supported by data relevant to the mode of action (MOA) are sufficient to jus-
tify considering the results of a nonlinear-threshold carcinogenic assessment for
comparison to URF-based de minimis excess risk (e.g., 1 in 100,000) air concen-
trations. The intent of the current study is not to perform an exhaustive weight of
evidence evaluation of all data potentially relevant to the MOA (or MOAs), but
rather to present available summary MOA information and statistical evidence in-
terpreted as supporting a potential practical threshold for CrVI-induced carcino-
genicity and the results of the consequential nonlinear-threshold inhalation car-
cinogenic assessment. Relevant epidemiological studies available in the scientific
literature were reviewed and additional statistical dose-response analyses conducted
to identify potential carcinogenic thresholds and points of departure (PODs).
Occupational-to-environmental dosimetric adjustment of the “sub-threshold” cu-
mulative exposure POD selected (0.195 mg CrVI/m3-yr) resulted in a PODHEC of
0.0071 mg CrVI/m3. Uncertainty factors (total UF of 30) were then applied to de-
rive a cancer-based chronic inhalation reference value (ReV) of 0.24 μg CrVI/m3.
The margin of exposure is ≈16,000-475,000 based on the ratio of the “sub-thresh-
old” cumulative exposure POD to cumulative exposures estimated based on annual
average CrVI ambient air concentrations measured at various sites in Texas (5.9E-
06 to 1.7E-04 μg CrVI/m3), which are ≈1,400-41,000 times lower than the calcu-
lated cancer-based chronic ReV.
1951 Hypothesis-Based Weight-of-Evidence Evaluation of the
Human Carcinogenicity of Toluene Diisocyanate.
R. L. Prueitt1,  J. E. Goodman2 and L. R. Rhomberg2. 1Gradient, Seattle, WA;
2Gradient, Cambridge, MA.
Humans are exposed to toluene diisocyanate (TDI) primarily through inhalation in
workplaces where it is produced or used. It is classified as a possible human car-
cinogen, based primarily on increased tumor incidences in rodents treated with
TDI by oral gavage. We used the hypothesis-based weight-of-evidence (HBWoE)
method to conduct a novel evaluation of all the evidence regarding the hypothesis
that TDI is a human carcinogen. We weighed the available data from epidemiology,
animal toxicity, and mechanistic studies in terms of quality and relevance to hu-
mans, allowing each data set to inform one another. We then evaluated all of the
data together to determine whether TDI carcinogenicity is plausible in humans.
Our analysis determined that the epidemiology data are not sufficiently robust to
support TDI as a human carcinogen; the few positive associations are more likely
attributable to alternative explanations than causation. The experimental animal
studies indicate that inhalation exposure to TDI does not induce tumors in rats or
mice. Tumors observed after oral gavage exposure are most likely due to the conver-
sion of a small amount of the administered TDI to toluene diamine (TDA), which
also causes tumors in rats and mice when administered through this aphysiological
exposure route. Further, TDA is formed in in vitro TDI genotoxicity assays. While
TDI is genotoxic in these assays, it is not genotoxic in rodents or humans in vivo
after inhalation exposure (during which TDA is not formed). Our HBWoE analy-
sis indicates that the conversion of TDI to TDA is necessary for carcinogenesis to
occur, but it does not occur in mammalian species under physiological exposure
conditions. Thus, our analysis demonstrates that a causal association between TDI
exposure and carcinogenic effects is not plausible in humans. This analysis not only
provides insight about TDI carcinogenicity, but it addresses the larger issue of com-
bining human, animal, and mechanistic data for risk assessment.
1952 Evaluation of Toxic Effects of 3-MCPD and Associated Esters
in Rats.
S. Onami1,  Y. Cho1,  T. Toyoda1,  Y. Ishii1,  T. Umemura1,  M. Yoshida1,
K. Horibata2,  M. Honma2,  T. Nohmi3,  A. Nishikawa3 and K. Ogawa1.
1Pathology, NIHS, Tokyo, Japan; 2Genetics and Mutagenesis, NIHS, Tokyo, Japan;
3Biological Safety Research Center, NIHS, Tokyo, Japan.
3-Monochloropropane-1,2-diol (3-MCPD) is regarded as a rodent renal and
Leydig cell carcinogen. Furthermore, 3-MCPD esters may be generated in various
foods and food ingredients as a result of food processing. Since there are limited re-
ports about toxicity of these compounds, we conducted the following two studies.
1) In vivo genotoxicity study (Pig-A and gpt gene mutation assays in the kidneys
and testes, micronucleus assay) with male F344 gpt delta transgenic rats carrying re-
porter genes for mutations, treated by gavage with a carcinogenic dose of 3-MCPD
(3.6×10-4 mol/kg body weight) or its esters, i.e., 3-MCPD palmitate diester (PD),
3-MCPD palmitate monoester (PM) and 3-MCPD oleate diester (OD) at the
molar equivalents for 4 weeks. 2) 13-Week subchronic toxicity study of these com-
pounds with F344 rats at three doses where the highest was the same as that in the
genotoxicity study. In the first study, no clear in vivo genotoxicity of 3-MCPD or its
esters was observed in the three assays. In the 13-week study, the absolute and rela-
tive kidney weights were significantly increased in rats treated with 3-MCPD at a
carcinogenic dose and the esters at high and medium doses. Relative liver weights
were significantly increased in the 3-MCPD-treated rats and the high dose ester-
treated rats, except for female rats treated with PM. By 4 weeks, 1 male and 5 fe-
males of 3MCPD group died from the renal tubular necrosis. On histopathological
analysis, a significantly increased incidence of renal mineralization in all high dose
ester-treated females and of apoptotic epithelial cells in the epididymis of 3-MCPD
and high dose ester-treated male were observed as compared to vehicle control. The
results suggest 3-MCPD fatty acid esters may be non-genotoxic but have potential
toxicity for kidneys and epididymes of rats. NOAELs of PD, PM and OD were
suggested to be 14, 8 and 15 mg/kg/day, respectively.
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1953 A Simulation Study Investigating the Risk of Obtaining
BMDs Which Are Higher Than the “True” BMD.
J. Ringblom,  G. Johanson and M. Öberg. Karolinska Institutet, Institute of
Environmental Medicine, Stockholm, Sweden.
A central aspect of quantitative health risk assessment of chemicals is the derivation
of the point of departure (POD). Historically, calculating NOAELs has been the
most common way to obtain the POD. However, Benchmark Dose (BMD) analy-
sis has been recommended as a more robust alternative, as it uses data from all dose
groups in the study to derive the POD. An important step in the BMD approach is
the identification of the BMDL, i.e. the lower limit of the confidence interval for
the BMD. The aim of this study was to investigate how often the estimated BMDL
corresponds to an effect greater than the critical effect, thereby underestimating the
risk in the derivation of guidance values.
In this simulation study we assume a known sigmoidal dose-effect curve (and hence
a known BMD) and examine how often the BMDL is higher than the “true” BMD.
Effects were generated by Monte Carlo simulations using 5 different dose place-
ment scenarios. All scenarios used 4 dose groups (control, low, medium and high
dose) and logarithmic dose spacing. Each scenario was simulated using 5, 10, 20 or
50 animals per group, assuming dose-effect curves typically seen in continuous data
from experimental studies. The BMD and the BMDL values were calculated using
a set of 5 nested exponential models implemented in available BMD-softwares
(BMDS and PROAST). 
The results suggest that the risk of obtaining a BMDL which is higher than the true
BMD can be considerably larger than normally expected. In one scenario the
BMDL was higher than the true BMD in 74% of the simulations. This occurs be-
cause the second model in the nested set of models lacks the ability to level off at
higher doses. 
It is therefore suggested that the second model in the nested set (y=a*ebx) should be
used with caution. It is also important to visually inspect the dose effect curve and
the individual data points.
1954 Characterizing the Impacts of Uncertainty and Scientific
Judgment in Exposure Limit Development.
A. Maier1,  R. Sussman2,  B. Naumann3 and R. Roy4. 1Toxicology Excellence for
Risk Assessment, Cincinnati, OH; 2SafeBridge Consultants, Inc., New York, NY;
3Merck and Co., Whitehouse Station, NJ; 4Corporate Toxicology, 3M, St. Paul, MN.
There is a misperception by some that exposure limits are precise estimates. In the
eyes of risk managers, one discrete value is often considered to be “correct” and all
others considered “incorrect.” Exposure limits should be evaluated based on
whether the value is derived in a manner “consistent with current principles” or
“not consistent.” An analysis of current risk assessment methods was conducted to
identify the bases for variability in exposure limits for individual chemicals. The
role of scientific judgments, risk policy perspectives, and evolving science methods
were evaluated in the context of exposure limit setting methods. A systematic meth-
ods analysis shows that important drivers to be considered in evaluating acceptabil-
ity of an exposure limit include: thoroughness of the review of available data, inter-
pretation of results according to current scientific principles under the regulatory
framework being used, and consideration of sufficient sources of variability and un-
certainty. Sources of variability that may be encountered in risk assessments per-
formed by different industrial hygienists or toxicology professionals using identical
data sets include: selection of the point of departure, uncertainty factors used for
data extrapolation, and use of adjustments for toxicokinetics, among others. These
and related considerations form the basis of a “quality evaluation” process proposed
for assessing the robustness of an exposure limit. Transparency in methods to assure
robustness is a core principle embedded in risk assessment methods harmonization.
Application of a systematic quality evaluation process provides for more informed
use of exposure limits for risk management. A clear understanding of the basis for
disparate values can provide useful information regarding the current level of un-
certainty in the science and the level of confidence appropriate in using different ex-
posure limits to characterize risk.
1955 Chemical-Induced Methemoglobin Formation and
Exploration on Its Biological Threshold.
Z. Yan1 and Q. Zhao2. 1ORISE, Cincinnati, OH; 2NCEA, US EPA, Cincinnati,
OH.
Methemoglobin (metHb) is hemoglobin with the iron oxidized from Fe2+ to the
Fe3+ state. An accumulation of metHb in the blood (methemoglobinemia) is often
observed in response to exposure to many chemical agents, such as aniline and ani-
line derivatives like dapsone, and is often used as the basis for the derivation of non-
cancer risk values. Therefore, an understanding of the relative sensitivity of com-
mon laboratory animals compared to humans to these metHb-forming agents is
important. In this research, we compared the relative sensitivities to dapsone, a
metHb-forming agent in rats, mice, and humans based on the data from in vitro
and in vivo studies. In vivo data indicate that humans are more sensitive to dapsone
than rats, followed by mice. However, in vitro results are inconsistent in terms of
metHb formation. The inconsistency can be explained by differences in liver me-
tabolism among species. In vitro comparisons between the parent compound (dap-
sone) and its metabolite (hydroxylamine) also suggest that the metabolite is more
potent than the parent compound to induce metHb. Due to a higher sensitivity in
vivo, the rat might be a more suitable animal model than the mouse for predicting
metHb-forming effects in humans. In addition to the relative sensitivities, we fur-
ther examined the background levels of metHb to explore the potential for identi-
fying the biologically significant threshold of metHb formation after exposure to
metHb-forming agents. F344 rats were used as an example. We identified a 100%
increase above the control mean as a benchmark response (BMR) based on the col-
lected metHb background levels. A comparison of the identified BMR and one
standard deviation from the control mean, as commonly used in benchmark dose
modeling, suggests that the new BMR generates lower or comparable benchmark
dose lower confidence limits (BMDLs). Therefore, a 100% increase above the con-
trol mean could be another way to establish a BMR for methemoglobinemia in
F344 rats. The views expressed in this abstract are those of the authors and do not
necessarily reflect the views or policies of the U.S. EPA.
1956 Analysis of Possible Changes to the Levels of Concern for
Polycyclic Aromatic Hydrocarbons in Seafood.
R. E. Weil,  L. D. Stuchal,  A. S. Kane and S. M. Roberts. University of Florida,
Gainesville, FL.
Anthropogenic contamination of coastal regions with oils from drilling operations,
spills and tanker leaks has impacted coastal communities and seafood safety for
decades, and will likely continue based on our oil-based economy. Federal and state
agencies suspend commercial and recreational harvests in oil-affected regions based
on testing for petrogenic toxicants, including polycyclic aromatic hydrocarbons
(PAHs). Criteria for re-opening affected fisheries are dependent on human health
risk-based levels of concern (LOCs) developed by the US Food and Drug
Administration (FDA) for specific petroleum-related contaminants in seafood, in-
cluding seven carcinogenic PAHs. As with the Deepwater Horizon oil spill and
other oil spill events, FDA cancer-based risk assessment for seafood consumption
applies the US Environmental Protection Agency (EPA) cancer slope factor for
benzo[a]pyrene (BaP), and relative potency factors (RPFs) for the remaining six
PAHs relative to BaP. Use of LOCs in risk assessment is based on numerous as-
sumptions. Here we examine how LOCs for PAHs change with modifications
based on: (1) variable seafood consumption rates using data reflective of high-end
seafood consumers in affected regions, (2) an expanded list of carcinogenic PAHs
and changes in relative potency factors as described in the EPA draft document
“Development of a Relative Potency Factor Approach for Polycyclic Aromatic
Hydrocarbon Mixtures,” 3) the proposed change in the EPA cancer slope factor for
BaP (the index carcinogenic PAH), and (4) exposure assumptions relevant to chil-
dren, including incorporation of an age-dependent adjustment factor for PAH car-
cinogenicity. Analyses provide an indication of both direction and magnitude of
changes in LOCs associated with each possible modification. This study suggests
that LOCs for PAHs in seafood from the Gulf of Mexico may be more numerous
and markedly lower than the suite currently applied relative to the Deepwater
Horizon oil spill.
1957 The Use of Genetically Modified Mice in Cancer Risk
Assessment: Challenges and Limitations.
S. V. Vulimiri1,  D. A. Eastmond2,  J. E. French3 and B. Sonawane1. 1National
Center for Environmental Assessment, US EPA, Washington DC; 2Cell Biology &
Neuroscience, University of California Riverside, Riverside, CA; 3NIEHS, Research
Triangle Park, NC.
The use of genetically modified (GM) mice to assess carcinogenicity is playing an
increasingly important role in the safety evaluation of chemicals. While progress has
been made in developing and evaluating models such as the Trp53+/-, the Tg.AC
and the rasH2 models, the suitability of these models as replacements for the con-
ventional rodent cancer bioassay and for assessing human health risks remains un-
certain. The objective of this research was to evaluate the prospective use of GM
mice and the recently developed accelerated cancer bioassays in evaluating the po-
tential health risks associated with exposure to carcinogenic agents. We compared
the published results from the GM bioassays with those obtained using the
National Toxicology Program’s conventional chronic mouse bioassay for their po-
tential use in risk assessment. To date, the GM models have shown moderate suc-
cess in distinguishing carcinogens from non-carcinogens. Analysis of information
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from different studies indicates that the GM models are less efficient in detecting
carcinogenic agents but more consistent in identifying non-carcinogenic agents. We
identified several issues of concern related to the assay design of GM models (e.g.,
sample size, study duration, genetic stability, and reproducibility) as well as path-
way-dependent effects, and different carcinogenic mechanisms operable in GM and
non-GM animals. The use of the GM models for dose-response assessment is par-
ticularly problematic as these models are, at times, much more or less sensitive than
the conventional cancer bioassays. Thus, the existing GM mouse models may be
useful for hazard identification, but will be of limited use for dose-response assess-
ment. Hence, caution should be exercised when using GM mouse models to assess
the carcinogenic risks of chemicals.
Disclaimer: The views expressed in this abstract are those of the authors and do not
necessarily reflect the views or policies of the USEPA or the NIEHS.
1958 Integrating Local Communities in the Health Risk
Assessment Process following the Deepwater Horizon Oil
Spill—A Focus on Vietnamese-Americans.
M. J. Wilson1,  S. Frickel4,  D. Nguyen5,  J. Howard1,  B. R. Simon3 and
J. Wickliffe1, 2. 1Pharmacology and Toxicology, Rutgers University, Piscataway, NJ;
2Environmental and Occupational Medicine, UMDNJ-Robert Wood Johnson Medical
School, Piscataway, NJ.
Vietnamese-American populations in southeast Louisiana consist largely of com-
mercial and subsistence fisherfolk and represent one of the highest seafood con-
suming groups in the Gulf South. We collected targeted survey data from a
Vietnamese-American fishing community in Orleans Parish Louisiana, to deter-
mine shrimp consumption rates, body weights, ages, and genders in order to con-
duct deterministic and probabilistic health risk assessments tailored to this unique
population. Cancer risk estimates and levels of concern (LOCs) for several poly-
cyclic aromatic hydrocarbons were determined using GC/MS in SIM mode on a
sample of white shrimp collected from the Gulf with shrimpers from this commu-
nity. Our approach also developed health risk assessments using LOCs, oral slope
factors, and risk levels used by the Food and Drug Administration and the Natural
Resources Defense Council. Our results demonstrate the need to include key pop-
ulations in the risk assessment process and measure risk model parameters in such
populations rather than rely solely on generic exposure assumptions.
1959 Challenges in Safety Assessment of Botanicals in Cosmetics:
A Possible Risk Assessment Strategy.
B. Mukerji,  P. Hepburn,  E. Antignac,  T. Ashikaga,  D. Chavez,  K. Khoo,
P. Sinhaseni and A. Khaiat. Safety and Toxicology, Asean Cosmetic Association,
Singapore, Singapore.
There is a growing trend of using botanical raw materials in personal care products,
such as those used in traditional medicine or those from the many exotic plants
which may be part of local folklore or food use. These materials present a challenge
to both the Product Developer and Regulator alike, in assuring the development of
safe cosmetic products, from the complex composition of the materials through to
the lack of documented data on history of use and safety. 
This paper presents a strategy for the safety assessment of these botanicals used in
cosmteics, based on various risk assessment concepts. A critical first step in the risk
assessment is the characterisation of the botanical raw material, with key measure-
ments being identified. A complete understanding of “what is known?” about the
material should then be developed from both literature sources as well as traditional
knowledge. It may then be possible to determine whether a history of safe use
(HOSU) can be established and if the material can be considered safe at that stage
for particular cosmetic applications. If not then further risk assessment approaches
(ie comparative approach, threshold of toxicological concern (TTC)) are proposed.
Finally, in order to complete the risk assessment there may be a need to fill gaps in
the hazard profile and/or potential consumer exposure scenarios, by conducting
some further testing.
1960 Simulation of Acute Reference Dose (ARfD) Setting for
Pesticides in Japan.
M. Yoshida1,  D. Suzuki1,  K. Matsumoto2,  K. Inoue1,  M. Takahashi1,
T. Morita3,  M. Shirota4 and A. Ono5. 1Department of Pathology, National Institute
of Health Sciences, Tokyo, Japan; 2Research Center for Human and Environmental
Sciences, Shinshu University, Nagano, Japan; 3Division of Safety Information on
Drug, Food and Chemicals, National Institute of Health Sciences, Tokyo, Japan;
4Laboratory of Comparative Toxicology, School of Veterinary Medicine, Azabu
University, Kanagawa, Japan; 5Division of Risk Assessment, National Institute of
Health Sciences, Tokyo, Japan.
We conducted simulations of Acute Reference Dose (ARfD) setting, based on re-
view documents of 208 pesticides published by Food Safety Commission (FSC) in
Japan. These pesticides were evaluated in FSC during last 8 years. We applied the
conceptual framework of Solecki, et al.(2005) to create and implement a concep-
tual framework adapted to current assessment needs in Japan. Through this process,
we were able to set the ARfDs for over 90% of those 208 pesticides. The studies
that provided the rationale for ARfD setting were primarily reproductive and devel-
opmental toxicity studies, acute neurotoxicity studies, and pharmacology studies. It
was not necessary to establish ARfDs for approximately 30% of the pesticides sim-
ulated in the present study. Some of the simulated ARfDs might be conservative,
and some endpoints for ARfD setting might not be proper,because the published
data obtained in the present study were written for acceptable daily intake (ADI)
setting. We were unable to set an ARfD for 14 pesticides because of insufficient
data on acute toxicities. This could be improved by more complete record-keeping
(for example, the type of changes observed immediately after administration, and
the duration of the observation period). Furthermore, we categorized the 208 pesti-
cides by mechanism of action or chemical structure. In comparison of absolute
ARfDs or relative ARfDs to ADI among the categories, considerable number of
pesticides with similar mechanisms of action or similar chemical structure also
showed similar ARfDs.
1961 Tumour and In-Life Data from CD-1 Mouse Dietary and
Oral Gavage Tumorigenicity Studies, Completed over the
Period of 1995 to 2011.
W. N. Hooks1 and I. Taylor2. 1Safety Assessment, Huntingdon Life Sciences,
Huntingdon, United Kingdom; 2Pathology, Huntingdon Life Sciences, Huntingdon,
United Kingdom. Sponsor: D. Mitchell.
A previous review (1) of Crl:CD-1 ® (ICR) BR mouse tumorigenicity studies indi-
cated terminal (Week 104) mortality values of 53±10.2% for males and 57±7.7%
for females, with no major differences between the dietary and oral gavage routes of
administration. Expanding on this, the aim of this review was to establish if the in-
life data and tumour profile had changed over time and if there were any differences
between the routes of administration. Data was analysed from over 60 mouse stud-
ies terminated at or about 2 years and completed over the period of 1995 to 2011.
Analysis of bodyweight gain and food consumption over the first year revealed
lower values for oral gavage studies (both sexes) when compared with dietary stud-
ies. The analyses over time (Period 1, 1995-2001 against Period 2, 2002-2011),
performed for oral gavage studies only, did not show any remarkable differences.
The most prevalent tumours were hepatocellular adenoma/carcinoma and adrenal
adenoma (males), bronchioalveolar adenoma/carcinoma, Harderian gland ade-
noma and haemopoietic tumours (males and females), and uterine polyps (fe-
males). Generally, excluding the latter, these tumours were also the major patholog-
ical factors contributory to death (FCTD). Other major FCTD included urinary
tract lesions (males) and ovarian haemorrhagic cysts (females). The most prominent
difference between dietary and oral gavage studies was a lower incidence of hepato-
cellular tumours (males) in the latter. Analyses over time (for oral gavage studies
only), indicated a lower incidence of hepatocellular tumours (males) and Harderian
gland adenoma (both sexes) in Period 2. In conclusion, although there were some
differences in the mortality patterns, in-life parameters, tumour profile and FCTD
between the alternative oral routes and between the time periods, the CD-1 mouse
has a well-defined tumour profile and continues to be suitable strain for use in tu-
morigenicity bioassays.
(1) W. Hooks, Abstract 2301, The Toxicologist CD, Vol. 126, Issue 1, March 2012.
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1962 Factors Influencing the Outcome of Developmental
Neurotoxicity Studies of Bisphenol A—Implications for
Regulatory Testing and Risk Assessment.
A. Beronius1,  N. Johansson1,  C. Rudén2 and A. Hanberg1. 1Institute of
Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; 2Department of
Applied Environmental Science, Stockholm University, Stockholm, Sweden. Sponsor:
G. Johanson.
Developmental neurotoxicity (DNT) of bisphenol A (BPA) has been investigated
in a large number of studies. However, there are discrepancies in the results re-
ported between these studies. This investigation aims to identify and analyze factors
that have contributed to these differences and to assess whether there are sex-differ-
ences in the sensitivity of certain endpoints or tests used in DNT-studies. 
Forty-four DNT studies of BPA were identified in the open literature. Details
about study design and results from each study, as well as the criteria for DNT test-
ing according to the standardized OECD test guideline (TG) 426, were collected in
a data base. This enabled systematic and detailed comparisons between studies as
well as to the TG criteria. Multivariate analyses of the compiled data were applied
in order to investigate how different factors of the study design contribute to differ-
ences in outcomes between studies.
The results from this investigation indicate that the choice of behavioral endpoints
and the behavioral test methods used seem to have the largest impact on study out-
come. In general, the most sensitive endpoints were the ones not required according
to the standard OECD TG 426. Interestingly, non-standard endpoints seem to be
especially important to detect effects in females. 
One main conclusion from this investigation is that non-standardized studies seem
to provide information that could be pivotal for the risk assessment of BPA, espe-
cially in the identification of effects in females. There is a need to develop tools that
improve the usability of non-standardized studies in risk assessment of chemicals,
particularly with regard to endocrine disrupting compounds, and that can facilitate
the evaluation of data obtained from such studies.
1963 Development of Human Health Benchmarks for Pesticides.
S. Ramasamy1,  E. Doyle1,  B. Behl1,  B. May2,  M. Goodis2 and S. Knizner3.
1Office of Water, US EPA, Washington DC; 2Office of Pesticide Programs, US EPA,
Arlington, VA; 3Office of Environmental Information, US EPA, Washington DC.
On March 22, 2010, EPA Administrator, Lisa P. Jackson announced a new drink-
ing water strategy that outlines four principles to expand public health protection.
One of these principles is to use the authority of multiple laws to more effectively
protect drinking water, by sharing data collected under different statutes. Under
this principle, the Office of Water (OW) and the Office of Pesticide Programs
(OPP) collaborated to develop the human health benchmarks for approximately
350 pesticides (HHBPs) that are currently registered to be used on food crops.
These HHBPs are levels of certain pesticides in water at or below which adverse
health effects are not anticipated from one-day or lifetime exposures. EPA derived
the HHBPs using toxicity studies conducted on laboratory animals submitted to
EPA under the Federal Insecticide, Fungicide and Rodenticide Act (FIFRA) the
Federal Food Drug and Cosmetics Act (FFDCA) as amended by the Food Quality
Protection Act (FQPA), with the typical methods used for developing drinking
water health advisories under the Safe Drinking Water Act (SDWA). Specifically,
EPA used the acute or chronic reference doses established for human dietary assess-
ment for the most sensitive population and applied standard exposure assumptions
used in calculating drinking water health advisories based on gender, age, body-
weight, and water consumption of target populations. For the acute benchmark,
the entire exposure is assumed to occur from drinking water (100 percent). For the
chronic benchmark, EPA applied a default relative drinking water source contribu-
tion (20 percent), assuming additional exposure may arise from other sources. The
HHBPs are not enforceable. EPA is providing the benchmarks for informational
purposes for use by states, water systems and the public to help understand moni-
toring data for pesticides that have no drinking water standards or health advisories.
The HHBPs can be found on EPA’s website at:
http://www.epa.gov/pesticides/hhbp
1964 Differences between US EPA Iris Inhalation Reference
Concentrations (RfCs) and European Chemicals Agency
(ECHA) Long-Term Inhalation Derived No Effect Levels
(DNELs) for the General Population.
M. Jackson1,  R. Lemus-Olalde2,  C. Inhof2,  Z. Yin2,  B. Locey1,  B. H. Magee3
and K. T. Connor3. 1ARCADIS, Brighton, MI; 2ARCADIS, Cincinnati, OH;
3ARCADIS, Chelmsford, MA.
ECHA previously released manufacturer/importer REACH (Registration,
Evaluation, Authorization and Restriction of Chemicals) chemical registration files,
making available the Derived No Effect Levels (DNELs) for hundreds of sub-
stances. The DNEL is defined as “the level of exposure above which humans should
not be exposed” and needs to reflect the likely route(s), duration and frequency of
exposure. Typically, DNELs are developed by Industry using ECHA’s guidance; the
registrant has the final decision on the selection of the key studies, endpoints of
concern, and the assessment factors to account for sources of uncertainty, instead of
a regulatory agency such as the U.S. EPA for the IRIS program. Considering this
major difference, we have conducted a comparison analysis between REACH’s
long-term inhalation DNEL for non-carcinogenic effects for the general population
and IRIS’ chronic RfC, which is defined as “an estimate (with uncertainty spanning
perhaps an order of magnitude) of a continuous inhalation exposure to the human
population (including sensitive subgroups) that is likely to be without an apprecia-
ble risk of deleterious effects during a lifetime.” Overall, despite being defined sim-
ilarly, many of the current U.S. EPA IRIS inhalation RfCs for which long-term in-
halation DNELs were available are lower by a factor of at least 10. The differences
between these RfCs and DNELs may be a result of differences in the processes by
which they are derived, including differences in the availability of toxicity data, as
unpublished data or ECHA-required data may be used in the REACH assessments
[ECHA requires the registrant to conduct toxicity testing (when data for a required
endpoint are not available)], the entity (industry versus regulatory agency) respon-
sible for generating the reference values, the methodologies and selection of default
values used in the derivation, and the process by which the final values are accepted.
1965 Assessment Factors in Human Health Risk Assessment and
Their Associated Level of Safety.
S. Escher2,  S. Hoffmann-Doerr1,  M. Batke2 and I. Mangelsdorf2. 1BASF Personal
Care and Nutrition GmbH, Duesseldorf, Germany; 2Fraunhofer Institute for
Toxicology and Experimental Medicine - ITEM, Hannover, Germany. Sponsor: K.
Wiench.
Human health risk assessment requires solid information on adverse effects after
long-term exposure. Because of ethical considerations, human data or long-term
studies with animals are in general scarce. Consequently, reliable assessment factors
(AF) are needed in risk assessment to overcome differences between short-term an-
imal studies and the human situation. 
In human health risk assessment, traditional AF are established, e.g. a factor of 100
(10 x 10) for interspecies/intraspecies extrapolation. Some of these AF were sub-
stantiated by either deterministic or probabilistic approaches, whereas other factors
lack a scientific rationale. Furthermore, the level of safety achieved with the appli-
cation of more than one AF has remained an open question so far. Our analyses
aimed therefore at the derivation of AF and their corresponding level of safety when
applied solely or in combination in human health risk assessment.
The toxicological database RepDose(TM) (containing appr. 2500 repeated dose
studies on appr. 700 chemicals) served as the basis for the derivation of AF. Pairs of
NOEL ratios - e.g. obtained from two studies with the same chemical and species,
but different application durations if time AF were analyzed - were plotted in a dis-
tribution curve. Distribution curves for interspecies and time extrapolation were
evaluated. All distribution functions were best described by lognormal curves.
Furthermore, the combinations of these distributions were analyzed in probabilistic
approaches by means of Monte Carlo simulations. On the basis of the resulting dis-
tribution curves, overall AF were determined, for which the corresponding per-
centile indicates the associated level of safety. Our results demonstrate that the
probabilistic approach is well suited to derive AF, provided that the database is com-
prehensive and contains studies of good quality. 
RepDose: Trademark of the Fraunhofer Gesellschaft zur Foerderung der ange-
wandten Forschung e.V., 80686 München, DE
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1966 Associations between Carcinogenic and Immune Suppression
Activities of PaHs: Insights into Improving Cancer Risk
Assessment for PAH Mixtures.
K. Zaccaria and P. McClure. SRC, Inc., Syracuse, NY.
Multiple studies have noted that many carcinogenic polycyclic aromatic hydrocar-
bons (PAHs) also demonstrate immunosuppressive effects. Here, we have tested the
strength of this association by deriving both cancer and immunotoxic relative po-
tency factors (RPFs) for multiple PAHs, using the well-studied carcinogenic and
immunotoxic compound benzo(a)pyrene (BaP) as the index PAH. Our quantita-
tive analysis demonstrated a correlation between the immunosuppressive and car-
cinogenic potential of PAHs. As evasion of immune destruction has been identified
as an “emerging hallmark of cancer” (Hanahan and Weinberg, 2011 Cell 144: 646-
674), we propose that this association between carcinogenic and immune suppres-
sion activities of PAHs offers an opportunity to improve cancer risk assessment for
PAH mixtures. While current assessments of cancer risks from PAH-containing
fractions of environmental mixtures rely on a component-based RPF approach, we
hypothesize that a more scientifically defensible whole mixtures approach would be
advanced not only by a battery of inexpensive, short-term tests of different modes
of carcinogenic action (e.g., genotoxic and non-genotoxic), but also a battery of
tests for immunosuppressive activity. The addition of immunotoxicity tests may
improve the ability to discern the similarity of an untested environmental mixture
with reference mixtures that have cancer slope factors. Therefore, we performed a
comprehensive review of the immunotoxic effects of BaP, and developed an inte-
grated knowledge map illustrating immunosuppressive effects of BaP and, when
known, tissue-specific mechanistic information. Our analysis revealed that research
to date has not yet identified a transcriptional signature(s) for immune suppression
to aide in the development of a specific battery of short-term in vitro test for im-
munotoxicity. Thus, future directed research to develop and validate a battery of
tests for immunotoxicity is warranted and could find widespread use in assessing
cancer risk from environmental PAH-containing mixtures.
1967 Potential Involvement of Oxidative Stress and Iron
Disturbance in the Development of Oral Cavity Tumors in
Rats Exposed to Hexavalent Chromium.
M. Suh1,  C. T. Thompson1,  G. Hixon1,  M. A. Harris1,  C. R. Kirman2,
S. M. Hays2,  L. C. Haws1 and D. M. Proctor1. 1ToxStrategies, Katy, TX; 2Summit
Toxicology, Allenspark, CO.
In the NTP 2-year Cr(VI) drinking water study, the incidence of oral cavity tumors
was significantly increased in male and female rats of the highest dose group (516
mg/L sodium dichromate dihydrate [SDD]). We investigated the potential involve-
ment of iron (Fe) disturbance and oxidative stress in rat oral cavity tumor formation
because Cr(VI) has been shown to compete with Fe uptake and causes microcytic
anemia at high doses. Also, Fe deficiency can cause oxidative stress. We measured
the GSH/GSSG ratios in rat oral mucosa and plasma following 90-days of treat-
ment, and observed a significantly decreased ratio in oral mucosa at exposures ≥60
mg SDD/L, and in plasma at ≥170 mg SDD/L. We also found that Fe levels were
significantly decreased in rat liver at ≥60 mg SDD/L, in bone marrow at ≥170 mg
SDD/L, and in the duodenum at 520 mg SDD/L. A statistical mediation analysis
using the NTP data on rat oral cavity tumor incidence and that for chronic liver in-
flammation, bone marrow hyperplasia, and salivary gland atrophy—all of which
may be caused by Fe disturbance—was conducted to assess the association between
Fe disturbance and oral cavity tumors in treated rats. The link from Cr(VI) expo-
sure to these three endpoints combined was significant, as well as the link from
these endpoints combined to oral tumors, t(498)=3.985, p<1x10-4. When each
endpoint was analyzed separately, only the link from Cr(VI) exposure to salivary
gland atrophy, and that from salivary gland atrophy to tumors were significant,
t(498)=4.282, p<1x10-4. Taken together, these findings suggest that Fe metabolic
disruption, oxidative stress and salivary gland atrophy may contribute to tumor for-
mation in Cr(VI)-exposed rats. Further, these cancers may be species-specific as rats
are generally more susceptible to oral cancers than mice, oral tumors were not ob-
served in the NTP Cr(VI) treated mice, and no increase in oral cavity tumors have
been reported in Cr(VI)-exposed workers.
1968 Estimating the Relative Bioavailability of Polycyclic Aromatic
Hydrocarbons (PAHs) from Soil at Environmentally-
Relevant Concentrations.
J. W. Munson1,  Y. W. Lowney2, 1,  M. V. Ruby3 and S. M. Roberts1. 1CEHT,
University of Florida, Gainesville, FL; 2Exponent, Boulder, CO; 3Integral Consulting,
Louisville, CO.
Polycyclic aromatic hydrocarbons (PAHs) are common soil contaminants at a vari-
ety of sites, including industrial facilities, military bases, and former skeet ranges.
The risk from exposure to PAHs in soil is driven primarily from incidental inges-
tion of carcinogenic PAHs, and as with many other soil contaminants, is dependent
in part upon their oral bioavailability. Most previous studies attempting to under-
stand PAH bioavailability from soil have used PAH concentrations well above the
range of greatest environmental interest. We report here a method by which the rel-
ative oral bioavailability (RBA) of 3H-benzo[a]pyrene (BaP) in vivo in constructed,
weathered soils and PAH source materials can be measured at BaP concentrations
in the ppb range. A suite of these materials is being used to examine the BaP-soil in-
teractions that may control in vivo RBA, as well as for the development of in vitro
PAH RBA estimation methods. Soil was spiked with 3H-BaP in varying concentra-
tions and allowed to weather for up to two months. No loss of BaP or 3H label was
observed as a result of weathering. Rats were administered a single dose of soil or
PAH source material by gavage, and blood samples were taken via jugular cannula
for up to six days after the dose. For comparison, in order to estimate RBA, other
rats were given a comparable gavage dose of 3H-BaP added to food. The area under
the curve (AUC) for total radioactivity in blood was used to indicate absorbed BaP
dose for each animal, and the ratio AUCs for soil versus food doses was used to es-
timate RBA for the soil or PAH source material. AUCs could be measured without
difficulty for soil/food BaP concentrations as low as 200 ppb, facilitating study of
critical factors controlling bioavailability at environmentally relevant concentra-
tions. Supported in part by a grant from the Strategic Environmental Research and
Development Program (SERDP).
1969 Mode-of-Action Evaluation for Lung Tumors in Mice
Exposed to Ethylene Oxide via Inhalation.
L. T. Haber1,  B. L. Parsons2,  N. P. Moore3,  B. Gollapudi4,  M. G. Manjanatha2,
M. J. LeBaron4 and M. M. Moore2. 1Toxicology Excellence for Risk Assessment
(TERA), Cincinnati, OH; 2Division of Genetic and Molecular Toxicology, National
Center for Toxicological Research, US FDA, Jefferson, AR; 3Dow Europe GmbH,
Horgen, Switzerland; 4Toxicology & Environmental Research and Consulting, Dow
Chemical Company, Midland, MI.
Ethylene oxide (EO) is a direct acting mutagen and a rodent carcinogen, but it is
uncertain whether EO is carcinogenic through a mutagenic mode of action
(MOA). To address the MOA for mouse lung tumors, an integrated study was con-
ducted evaluating a variety of biomarkers related to oxidative stress, DNA reactiv-
ity/ breakage, mutations in a reporter (cII) and endogenous (K-ras) gene, and cell
proliferation as putative key events, in the target tissue. The dose response and tem-
porality for these key events was assessed in male B6C3F1 mice exposed to 0, 10,
50, 100, or 200 ppm EO (4 weeks) or 0, 100, or 200 ppm EO (8 or 12 weeks) by
inhalation (6 hours/day, 5 consecutive days/week). Results indicate that: (1) EO
does not appear to cause the lung tumors primarily via its DNA reactivity, since a
sustained increase in cII MF was not seen at 100 ppm (which produced substantial
increases in lung tumors in the mouse NTP study), and the increase at 200 ppm
was only weak. (2) Oxidative stress is likely to play a multifaceted role in the tu-
morigenic process, in light of the absence of an effect on 8-OHdG adducts, and the
observed mutation spectra of K-ras codon 12 and cII. The role of EO-induced
DNA adducts in the etiology of the observed mutations needs further elucidation.
(3) The available data on cell proliferation and K-ras mutations support a MOA
that includes effects on intracellular signaling pathways and selection of preexisting
K-ras mutant cells, as well as an interplay between oxidative stress and RAS activa-
tion. These results suggest a complex multi-faceted MOA, potentially involving EO
action at multiple steps along the pathway to tumor development.
1970 Challenges in Estimating Safe Levels of Nanomaterials for
Humans from Animal Toxicology Experiments.
A. Bacom1,  M. Odin1,  P. McClure1,  K. Salinas1,  P. Wood2,  D. Bottimore2 and
T. Thomas3. 1SRC, Inc., East Syracuse, NY; 2Versar, Inc., Springfield, VA; 3US
Consumer Product Safety Commission, Bethesda, MD. Sponsor: G. Diamond.
The use of nanosized particles in commercial products is increasing, leading to
greater exposure of people to these materials. Exposure is most likely to occur
through inhalation and dermal routes, but oral exposure may also occur. We evalu-
ated published toxicity data for 3 different nanomaterials: nanosilver (nAg), nanoti-
tanium dioxide (nTiO2), and carbon nanotubes (CNT), as a preliminary step for
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deriving safe exposure levels for these materials. Each of these materials comes in a
multitude of forms, varying in size, shape, structure, purity, and surface coating,
which affect chemical properties, such as solubility, reactivity, and propensity for
agglomeration. All 3 nanomaterials have multiple repeated exposure inhalation
studies available, suitable for use in dose-response assessment, but only nAg has re-
peated dose oral studies, and none of the materials has a suitable dermal study. The
lung was the critical target in the inhalation studies of all 3 materials, with pul-
monary inflammation being the most sensitive endpoint. For nAg, the liver was
also identified as a target by both inhalation and oral exposure (bile duct hyperpla-
sia). Using these data, it is possible to derive safe exposure levels for long-term ex-
posure to the specific forms of nAg, nTiO2, and CNT tested in these studies. It is,
however, unclear to what extent these levels may apply to other forms of nAg,
nTiO2, and CNT. Mechanistic data for all 3 nanomaterials show that the specific
physical and chemical characteristics of the particles can influence toxicity in de-
fined ways. However, the relationships are complex, and as yet, only partially un-
derstood, making the task of estimating safe levels of a particular nanomaterial chal-
lenging. Toxicity assessments for nanomaterials must take these additional
uncertainties into account. (The views expressed in this abstract are those of the au-
thors only and do not necessarily reflect the views or policies of the U.S. CPSC).
1971 Quality Assurance and Quality Control for an xCelligence
High-Throughput Risk Assessment Assay.
M. Stampfl1,  F. Ackah2,  V. Charoensuk3,  T. Pan4,  C. Jin1,  Y. A. Abassi1,
X. Xu1,  X. Wang1,  B. Huang4,  D. Kinniburgh3,  W. Zhang2 and S. Gabos2.
1Acea Biosciences, Inc, San Diego, CA; 2Alberta Health and Wellness, Edmont, AB,
Canada; 3Alberta Centre for Toxicology, University of Calgary, Calgary, AB, Canada;
4University of Alberta, Edmont, AB, Canada.
Taking advantage of impedance based non-invasive, real time cell analysis (RTCA)
technology, and human cell lines with different organ origins, a High Throughput
Risk Assessment (HTRA) assay is under development to meet 21st century toxicity
testing requirement for hazard identification, chemical mode of action understand-
ing, and eventually human health risk assessment. The HTRA assay is run on an
fully automated system, composed of 4 xCELLigence RTCA HT stations running
384 well EPlates, liquid handler, and compound/cell culture hotels. Impedance sig-
nal derived from adherent cells in the EPlate 384 are continuously monitored for
100 hours to reflect cell growth and responses to testing chemicals. To assess and
validate the usefulness of this new in vitro screening system for identifying general
toxicity of environmental hazards, 14 chemicals with known in vivo LD50 values
were tested with 11 different concentrations in duplicate or quadruplicate, and re-
peated in 2 separate experiments. The quality assurance program includes the gen-
eration of SOPs for experiments and data analysis. Specifically, experimental plate
layout to reduce false responses is discussed. The quality control system includes
variability and reproducibility analysis. Coefficient of variation, signal to noise ratio
and Z factor were calculated to evaluate variability. The analysis excluded one cell
line from the cell panel. Intra-plate reproducibility of impedance signals was within
acceptable range. Intra-plate reproducibility based on LC50 values from different
cell lines, was acceptable. Inter-laboratory validation is in progress. In summary, re-
sults from HTRA assay system showed good screening quality and reproducibility.
Together with its higher throughput, rich real-time information, HTRA assay sys-
tem could effectively provide biologically relevant cytotoxicity information for
human health risk assessment.
1972 Advancing Human Health Risk Assessment: Charting a
Course through Committee Recommendations.
M. Dourson1,  R. Becker2,  L. T. Haber1,  L. H. Pottenger3,  T. Bredfeldt4 and
P. Fenner-Crisp5. 1Toxicology Excellence for Risk Assessment, Cincinnati, OH;
2American Chemistry Council, Washington DC; 3The Dow Chemical Company,
Midland, MI; 4Texas Commission on Environmental Quality, Austin, TX;
5Independent Consultant, North Garden, VA.
Over the last dozen years, many national and international expert groups have
weighed in on specific improvements to risk assessment. Many of their stated rec-
ommendations are mutually supportive, but others appear conflicting, at least in an
initial assessment. This effort synthesizes these opinions, identifies areas of consen-
sus and sources of differences, and recommends a biological-centric, practical
course forward for risk assessment, which includes: (1) Incorporating a clear prob-
lem formulation process at the outset of the assessment to ensure the level of com-
plexity in design of the risk assessment is appropriate for informing the relevant risk
management decision; (2) Use of mode of action (MOA) information and an un-
derstanding of the relevant biology as the key, central organizing principle for dose-
response assessment; (3) Integrating MOA information into dose-response assess-
ments using existing guidelines for noncancer and cancer assessments, and applying
this knowledge with toxicokinetics to enable interpretation of human biomonitor-
ing data in a risk context; (4) Using the tiered, iterative approach developed by the
World Health Organization International Programme on Chemical Safety as a sci-
entifically robust, fit-for-purpose approach for risk assessment of combined expo-
sures (chemical mixtures). While scientifically-based defaults will remain important
and useful when data on MOA or other data to refine an assessment are absent or
insufficient, assessments should always strive to achieve the ultimate goal—to use
21st century knowledge of biological processes, dose-response, and chemical inter-
actions at the molecular, cellular, organ and organism levels to minimize the need
for extrapolation and reliance on default approaches.
1973 Assessment on Health Risk and Risk Factors Related to Lead
Exposure by Ingestion of Aquatic Animals from the Overflow
Marsh.
S. Chaiklieng1 and S. Kiatsayomphu2. 1Environmental Health Science, Faculty of
Public Health, Khon Kaen University, Muang, Thailand; 2Central Laboratory,
Faculty of Public Health, Khon Kaen University, Muang, Thailand.
The previous study identified that aquatic animals in Loeng Puay marsh were lead
polluted. The lead concentrations in River snails were exceeded the food standard.
This survey research aimed to determine health risk on ingestion of lead-contami-
nated aquatic animals from Loeng Puay marsh and the adverse health effects. The
interviews of 75 residents at Loeng Puay on the consumptions of the aquatic ani-
mals and adverse health effects related to lead toxicity were conducted. The lead
concentrations in aquatics animals (n=100) i.e. Nile tilapia, Common silver barb,
River snail and Golden apple snail were analyzed by using Atomic Absorption
Spectrophotometry. Health risk assessment was performed according to the
US.EPA guideline (2004). The correlated factors with the adverse health effects
were identified by the univariate analysis. 
The highest lead concentration in all kind of aquatic animals was found
in River snail and was used as represent concentration for health risk assessment on
the acute effect. By considering the total intake rate of all aquatic animal consump-
tion in the day, the maximum dose of lead exposure was 26.46 g/kg/day which was
higher than the provisional tolerable weekly intake (PTWI=25 g/kg). The adverse
health effects related to lead toxicity were reported from 46.67% of residents. Most
of symptoms were disorders of joints and skeleton, numbness, and acroanesthesia,
respectively. The univariate analysis identified that the fishermen had the higher
risk on lead exposure (justified by adverse health effect) when compared to other
occupations (OR=7.07, 95% CI: 2.20-23.81, p<0.001).
The findings indicated the health risk from high dose ingestion of lead-contami-
nated aquatic animals. However, the potential health risk depends on amount of
food ingestion and personal factors. There should be continuously environmental
monitoring of the lead accumulation in this overflow marsh for the safety of food
chain and the health surveillance program.
1974 Integrating Hazard Characterization Approaches for
Evaluating the Potential of Consumer Products to Cause
Asthma.
J. Patterson,  A. Maier,  M. J. Vincent and B. K. Gadagbui. TERA, Cincinnati,
OH.
Concerns have been raised regarding the potential for consumer products, includ-
ing cleaning products to cause or exacerbate asthma or asthma-like responses.
Although many forms of asthma are inflammation-based, some low-molecular-
weight chemicals have been shown to trigger immunoglobin E (IgE) independent
occupational asthma. Single exposures to high concentrations of chemical irritants
are also known to elicit an asthma-like response: reactive airways dysfunction syn-
drome (RADS). RADS can occur within hours of the initial exposure and may con-
tinue, as non-specific bronchial hyper-responsiveness, for extended durations.
Exposure to irritants may be a trigger for respiratory symptoms in individuals with
pre-existing asthma. Current methods cannot adequately assess the potential for
consumer product ingredients to trigger asthma or asthma-like responses; epidemi-
ological studies can only measure possible effects associated with a multitude of
chemicals and products, and no single animal model can reliably replicate the com-
plexity of an asthma-like response in humans. In order to characterize asthma and
respiratory related hazards associated with consumer products, a decision system is
needed that incorporates existing guidance, frameworks, and models. To develop
such a tool, we compiled and evaluated in vivo, in vitro, and in silico methods that
may provide data, or insight, to predict potential asthma or asthma-like responses
(e.g., respiratory sensitization) and noted strengths and weaknesses associated with
each method. We collaborated with asthma research experts to refine our findings
and approach. Despite the wealth of information on asthma, current guidelines,
bioassays, and computer models cannot definitively identify whether a particular
ingredient, or chemical, causes or exacerbates asthma or asthma-like responses.
However, possible predictors of allergy-induced asthma, such as respiratory sensiti-
zation, are useful to assess the likelihood that a particular chemical, ingredient, or
product may be associated with asthma induction.
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1975 Assessment of the Impacts of Changes in Regulatory
Toxicology of Polycyclic Aromatic Hydrocarbons on Site
Assessments.
J. H. Salatas1,  M. R. Garry1 and Y. W. Lowney2. 1Exponent, Bellevue, WA;
2Exponent, Boulder, CO.
Polycyclic aromatic hydrocarbons (PAHs) are common soil contaminants at many
industrial facilities, military bases, and other sites. For PAH mixtures, the U.S.
Environmental Protection Agency (EPA) and other regulatory agencies use relative
potency factors (RPFs) to assess the potential toxicity of individual PAHs. EPA cur-
rently provides RPF values for cancer risks for seven individual PAHs, but is con-
sidering RPFs for 25 individual PAHs, spanning values of potency relative to
benzo[a]pyrene (BaP) from 0.009 to 60. As part of a larger study aimed at tying to-
gether research on soil PAH chemistry with in vivo measures of bioavailability
across diverse soil types and contaminant sources for the purpose of improving re-
medial decisions for soil PAHs at U.S. Department of Defense (DOD) sites, we in-
vestigated the potential impacts of proposed changes in regulatory toxicology of
PAHs on regulatory decision-making. Specifically, we investigated the degree to
which changes in PAH RPFs could alter conclusions about health-based screening
at DOD sites. Using EPA’s Records of Decision database for Superfund sites, we
identified 11 DOD sites with 22 exposure units in which PAHs were identified as
chemicals of concern in surface or subsurface soil. Site data were evaluated for ex-
ceedances of heath-based soil screening levels using current and proposed RPFs.
Results indicate that the percentage of sites exceeding a screening level would in-
crease; up to twice as many sites for some individual PAHs (e.g., chrysene). In ad-
dition, the magnitude of exceedance would increase for all sites. The results suggest
that both the number of sites and the areal extent of individual sites requiring re-
mediation could increase with the proposed changes in RPFs. Additional issues in-
clude lack of background data for PAHs newly added to the risk assessment para-
digm and methods for assessing undetected PAHs. This work was supported in part
by a grant from the Strategic Environmental Research and Development Program.
1976 Rapid Risk-Based Response to a Crude Oil Spill.
K. Phillipps and D. B. Davies. Intrinsik Environmental Sciences Inc., Calgary, AB,
Canada.
Issues surrounding pipeline safety and the potential health and environmental im-
pacts that can result from pipeline accidents and malfunctions have led to consider-
able debate lately across North America. A number of recent high-profile oil spills
in areas that are populated highlight the need for risk assessment to be completed
rapidly to inform risk-based decision making. An example of such an assessment
was completed in response to a break at an underwater pipeline crossing in which a
sweet crude oil was released in a watercourse, upstream of several residences, active
livestock farming operations, recreational properties and a municipal drinking
water intake. Within 24-hours, a clean-up and contaminant sampling strategy was
developed and implemented, and continued over several weeks. Preliminary evalu-
ation and interpretation of the contaminant data was completed to aid in commu-
nity consultation, to identify the need for further monitoring, and to provide risk-
based decision making strategies to local authorities managing drinking water and
recreational use access.  The conclusions of an initial risk assessment completed two
weeks after the spill served to provide reassurance to regulators and the general pub-
lic regarding the safety of drinking water for residents and livestock, resulting in the
re-opening of some drinking water intakes in the impacted area. The assessment
considered the nature and levels of the contaminants that were determined to be
present in the water column and sediments, the results of toxicity studies for the
various contaminants, and the opportunity for exposure of people and animals to
the contaminants.  Following the analysis of additional sampling results, a more
comprehensive risk assessment was completed. The final results of the assessment
revealed that the clean-up efforts had successfully mitigated risk to human health
and the local ecosystem.
1977 Validation Oral Slope Factors for Benzo(a)pyrene Using
Whole Mixture Results.
K. T. Connor and B. H. Magee. Risk Assessment, ARCADIS, Chelmsford, MA.
EPA’s draft Integrated Risk Information System Assessment of Benzo(a)pyrene
(BaP) is due to be released for public review in 2013. The document will present an
Oral Slope Factor (OSF) that will replace the current value of 7.3 (mg/kg-day)-1.
The OSF will be coupled with new Relative Potency Factors (RPFs) when EPA fi-
nalizes the PAH Mixtures guidance document. A literature search identified the
available studies that meet EPA’s study quality criteria and OSFs were derived using
EPA’s benchmark dose model software (BDMS) in accordance with standard EPA
policy and guidance. The OSFs and the proposed RPFs have been validated against
the results of rodent mixture studies to determine if the BaP OSF in conjunction
with EPA’s proposed RPFs properly estimate PAH mixture effects. Benchmark dose
modeling Culp et al. (1998) data results in two BaP OSFs with reasonable model
fits: forestomach – 1.23 (mg/kg-day)-1 and esophagus – 0.19 (mg/kg-day)-1.  Culp
et al. (1998) also tested two coal tar samples in the same study. BaP-Toxic
Equivalents were calculated for the coal tar mixtures using the EPA proposed RPFs.
A nominal concentration of 100 ppm was assumed for unusual PAHs for which
concentrations were unknown. When compared to the whole mixture OSFs for
two separate coal tar mixtures, the current BaP OSF overestimates carcinogenic risk
by 20 to 31-fold. The BaP OSF based on forestomach tumors in Culp et al. (1998)
overestimates risk by 3 to 5-fold, whereas the BaP OSF based on esophagus tumors
in the same study gives no overestimation. If the unusual PAHs with new RPFs are
present in coal tar at concentrations significantly higher than the assumed 100
ppm, then the BaP OSF based on esophagus tumors will overestimate the coal tar
tumorigenic risks observed in the whole mixture studies. This validation exercise
demonstrates that the EPA proposed RPFs have to be implemented side-by-side
with an OSF for BaP that is less than 1 (mg/kg-day)- 1 to ensure that risks from real
world PAH mixtures are not overestimated by the RPF risk assessment approach.
1978 Cytotoxicity Test for Hazardous Substances by Using the
RTCATM High-Throughput Assay.
Y. Li1,  D. Y. Huang1,  W. Zhang2,  S. Gabos3 and D. Kinniburgh1. 1Alberta
Centre for Toxicology, University of Calgary, Calgary, AB, Canada; 2Health Protection
Branch, Family and Population Health, Alberta Health, Edmonton, AB, Canada;
3Canadian Institute of Public Health Inspectors - Alberta Branch, Edmonton, AB,
Canada.
Most current toxicity tests require the use of laboratory animals and involve expo-
sure by various routes and monitoring whether animals die or exhibit any clinical
signs of toxicity. Increasing societal concerns about animal use have led to the de-
velopment of alternative in vivo test methods that can significantly reduce and re-
fine the use of mammalians for this purpose. The emerging in vitro cell based assays
endeavor to provide information about the mode or mechanism of action that
causes cytotoxicity and use such information to develop cell-based in vitro tests that
can adequately model and predict in vivo toxicity. A non-invasive biophysical ap-
proach for the detection of cellular changes, the RTCATM instrument was devel-
oped for screening hazardous substances. In the present study, 6 chemicals (sodium
arsenate, cadmium chloride, colchicine, verapamil, propranolol and mercury chlo-
ride) were applied to human renal adenocarcinoma cell line (ACHN) at 11 serial
diluting working concentrations, respectively. The net cellular responses (the Cell
Index) were recorded for 72 hours after adding chemicals. The real-time and
unique time-concentration-dependent response curves (TCRC) were obtained.
The experimental design composed two stages: initial screening test (range finder
test) and definitive test (more defined test concentrations). The better TCRC pat-
terns were observed in the latter. The patterns were associated with some toxicity
pathways or mode of action for these chemicals. The lethal concentrations could be
calculated, which could be used to predict the starting lethal doses in vivo test.
Based on these preliminary findings, other 8 substances in other 6 cell lines will be
tested in the future. This work will facilitate cellomic based test development and
achieve the replacement of animals in acute oral toxicity testing.
1979 Advancements in Arsenic Research Suggest a Dose-
Dependent Transition Concentration for Cancer Endpoints.
R. Gentry1,  H. J. Clewell2,  P. Balbuena2,  A. Efremenko2,  M. B. Black2 and
J. W. Yager3. 1ENVIRON International Corporation, West Monroe, LA; 2The
Hamner Institutes for Health Sciences, Research Triangle Park, NC; 3University of
New Mexico, Albuquerque, NM.
Recent in vitro studies have been conducted in both animal and human primary
bladder cells to investigate the potential mode of action for bladder cancer follow-
ing exposure to arsenic compounds. Results from 24 hour in vitro gene expression
studies with human uroepithelial cells treated in culture with mixtures of inorganic
arsenic and its pentavalent or trivalent metabolites provide evidence of a common
suite of gene changes consistently identified for a number of key signaling path-
ways: oxidative stress, protein folding, growth regulation, metallothionine regula-
tion, DNA damage sensing, thioredoxin regulation, and immune response. Lowest
observed effect levels (LOELs) ranged from 0.6 – 6.0 μM total arsenic and no ob-
served effect levels (NOELs) ranged from 0.18 – 1.8 μM total arsenic. Benchmark
dose modeling of the responses indicated lower confidence limits (BMDLs) ranging
from 0.09 – 0.58 μM total arsenic for the eight genes most commonly significantly
expressed across individual samples for the trivalent arsenical mixture, and from
0.35– 1.7 μM for total arsenic in the pentavalent arsenical mixture. These studies
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provide the first evidence of no effect levels for arsenical-induced cell signaling per-
turbations in normal human cells exposed to biologically plausible concentrations
of arsenic.  Results from longer term exposures, again in primary human cells, pro-
vide consistent results that also suggest a dose-dependent transition for arsenic.
Results of these in vitro studies, in combination with evidence from epidemiologi-
cal studies, provide the basis for a shift in the approach for conducting a cancer risk
assessment for arsenic. It also provides support for a concentration demonstrating a
dose-dependent transition in responses from those representing adaptive change to
those that may be key events in the development of cancer endpoints.
1980 Refining the Application of a Database Uncertainty Factor in
Human Health Risk Assessment.
C. Fleming1,  Z. Yan1,  J. Lambert2 and Q. Zhao2. 1ORISE, Cincinnati, OH; 2US
EPA, Cincinnati, OH.
In human health risk assessment (HHRA), lack of information on a chemical is
typically accounted for by the use of uncertainty factors (UFs). Typically, UFs are
applied to account for five major areas of uncertainty: interspecies variation, in-
traspecies variation, extrapolation from subchronic to chronic exposure duration,
extrapolation from a LOAEL to a NOAEL, and an incomplete database. To reduce
uncertainty inherent in HHRA, methods are needed to replace or better assign val-
ues to these UFs. In this preliminary analysis, we analyzed all chemicals from the
USEPA’s Toxicity Reference Database (ToxRefDB) with complete databases (i.e.,
general toxicity studies in two species, developmental toxicity studies in two
species, and a multigeneration reproductive study) to assess whether a database UF
(UFD) of 3 or 10 is sufficient to account for missing data. A subtractive approach
was employed in which the points of departure (PODs) based on reported LOAELs
and NOAELs in the ToxRefDB were compared for the complete database and fol-
lowing removal of selected studies. Removal of developmental toxicity studies from
the database increased the POD by >3-fold in 12/186 (6.5%) chemicals and by
>10-fold in only 1 chemical. Removal of multigeneration reproductive toxicity
studies from the database increased the POD by >3-fold in 18/186 (9.7%) chemi-
cals and by >10-fold in 4/186 (2.2%) chemicals. Removal of general toxicity stud-
ies from the database increased the POD by >3-fold in 59/186 (31.7%) chemicals
and by >10-fold in 27/186 (14.5%) chemicals. This analysis will need to be supple-
mented with studies from a broader spectrum of chemical types (ToxRefDB is com-
posed almost entirely of pesticides). When completed, this analysis could provide a
method to systematically and empirically select the UFD in cases where chemical-
specific information to inform selection of the UFD is lacking. The views expressed
in this abstract are those of the authors and do not necessarily reflect the views or
policies of the U.S. EPA.
1981 Short-Term Exposure to Perfluoroalkyl Acids Causes Increase
of Hepatic Lipid and Triglyceride in Conjunction with Liver
Hypertrophy.
K. P. Das1,  C. R. Wood1,  M. B. Rosen2,  C. Lau1 and B. D. Abbott1. 1Toxicity
Assessment Division, ORD, NHEERL, US EPA, Research Triangle Park, NC;
2Integrated Systems Toxicology Division, ORD, NHEERL, US EPA, Research Triangle
Park, NC.
Persistent presence of perfluoroalkyl acids (PFAAs) in the environment is due to ex-
tensive use of industrial and consumer products. These chemicals activate peroxi-
some proliferator-activated receptor-alpha (PPARα) in liver and alter lipid metabo-
lism. The current study was designed to evaluate liver toxicity of perfluorooctanoic
acid (PFOA), perfluorononanoic acid (PFNA), perfluorohexane sulfonate
(PFHxS), and perfluorophosphonoic acid (PFPA), with emphasis on hepatocellular
hypertrophy and steatosis. SV129 wild-type (WT) and PPARα-null (Null) adult
male mice were dosed for 7 days with vehicle, PFOA, PFNA, PFHxS (10 mg/kg),
and PFPA (20 mg/kg); and WY14643 (50 mg/kg) was a positive control. Mice were
killed 24 h after the last treatment. Liver samples were collected for biochemical
analysis of triglyceride (TG) and DNA content. Frozen 6 μm sections of liver were
stained with Oil Red O for lipid and used for morphometric analysis. Liver weights
were elevated in both WT and Null mice in all of the treatment groups, except in
Null mice of the PFPA and WY groups. Morphometric analysis revealed an increase
in cell size in WT and Null livers exposed to PFOA, PFNA, PFHxS or PFPA, ex-
cept for the PFPA and WY groups in Null mice. This pattern of change is consis-
tent with the reduced DNA content per mg liver. In the Oil Red O stained sections,
WT liver showed increased lipid accumulation in all treatment groups; whereas in
Null livers, this was seen only after PFNA and PFHxS treatment. Similarly, elevated
TG level was found in PFAA-exposed WT but not in WY-exposed mice, and in-
creased TG was seen in Null mice only after PFNA treatment. Null livers had more
lipid and TG than WT livers, both in control and treated mice. These results indi-
cate that PFAAs induce liver hypertrophy and steatosis in WT; and the involvement
of PPARα is suggested by observations in Null mice. (This abstract does not neces-
sarily reflect US EPA policy.)
1982 Structure-Activity Relationships for Perfluoroalkane-Induced
Interference with Rat Liver Mitochondrial Respiration.
K. B. Wallace1,  G. E. Kissling2,  R. Melnick3, 4 and C. R. Blystone3. 1Biochemistry
& Molecular Biology, University of Minnesota Medical School, Duluth, MN;
2Biostatistics Branch, NIEHS, Research Triangle Park, NC; 3National Toxicology
Program, NIEHS, Research Triangle Park, NC; 4Ron Melnick Consulting, LLC,
Chapel Hill, NC.
Perfluorinated alkanes (PFAAs) represent a broad class of commercial products de-
signed primarily for the coatings industry. Unfortunately, residues have been de-
tected in a variety of species world-wide prompting aggressive toxicity testing.
Although some effects of PFAA exposures are linked to activation of the PPARα
nuclear receptor, interference with mitochondrial bioenergetics has been implicated
as an alternate and possibly important mechanism of cytotoxicity. The current in-
vestigation was designed to explore structure-activity relationships for the various
modalities by which PFAAs interfere with mitochondrial respiration. Freshly iso-
lated rat liver mitochondrial were incubated with one of 16 different PFAAs. The
effects of each PFAA on mitochondrial respiration was measured at five different
concentrations and dose-response curves generated. All PFAAs tested inhibited mi-
tochondrial respiratory control, mostly by stimulating state 4 and inhibiting state 3
respiration with the EC20 ranging from 1 μM to 413 μM. The perfluoroalkyl sul-
fonamides were most potent with an EC20 between 1 and 11 μM. The results are
consistent with evidence that the perfluorinated carboxylic acids stimulate the mi-
tochondrial permeability transition whereas the sulfonamides act as protonophoric
uncouplers of oxidative phosphorylation. In all cases, there was a pronounced in-
crease in potency with increasing carbon number, with a prominent inflection in
potency between the six and eight carbon congeners. The results provide a founda-
tion for classifying PFAAs according to specific modes of mitochondrial toxicity
and establishing structure-activity evidence-based initial estimates of safety for
PFAA congeners for which minimal in vivo toxicity testing currently exists. (This
work was funded by NIEHS NTP contract 273200620005C).
1983 Determination of Polychlorinated Biphenyls (PCBs) and
Hydroxylated Metabolites (OH-PCBs) in Human Blood
Serum from Two Populations in East Chicago, IN and
Columbus Junction, IA.
W. Koh1,  R. Marek2,  J. DeWall3,  P. S. Thorne1, 3 and K. C. Hornbuckle1, 2.
1Interdisciplinary Graduate Program in Human Toxicology, The University of Iowa,
Iowa City, IA; 2Department of Civil and Environmental Engineering, The University
of Iowa, Iowa City, IA; 3Department of Occupational and Environmental Health, The
University of Iowa, Iowa City, IA. Sponsor: L. Robertson.
PCBs are persistent and bioaccumulating toxic pollutants which pose health risk to
humans and organisms. Although commercial production of these compounds was
reduced and then banned in the 1970s, they are still present in our environment
and found in human blood serum. In this study, we determined PCBs and their
metabolites in human blood serum in these two populations. Human blood serum
samples were collected as part of the Airborne Exposure to Semi-Volatile Organic
Pollutants (AESOP) study from East Chicago, an industrialized area with known
high PCBs exposure in the past, and Columbus Junction, a rural area with no rec-
ognized historical PCB contamination. Our methods, which emphasize rigorous
quality assurance and control (QA/QC), enabled us to evaluate all 209 PCB con-
geners and a sub-set of OH-PCBs congeners. After a series of extraction and clean-
up procedures, samples were analyzed using gas chromatography with tandem mass
spectrometry (GC-MS/MS) for PCBs and gas chromatography with electron cap-
ture detection (ECD) for OH-PCBs. Our results show that the sum of PCB con-
geners ranged from non-detect to 658 ng/g l.w. (median = 33.5 ng/g l.w.) and the
sum of the four major OH-PCB congeners ranged from non-detect to 1.2 ng/g f.w.
(median = 0.07 ng/g f.w.). We conclude that PCBs and OH-PCBs are detected in
human blood serum from populations living in East Chicago, IN and Columbus
Junctions, IA.
1984 Associations among Polychlorinated Biphenyls (PCBs) and
Chlorinated Pesticides and Serum Lipids in Residents of
Anniston, Alabama.
M. Pavuk1,  Z. Aminov2,  R. Haase2,  D. O. Carpenter3, 2 and W. E. Turner4.
1ATSDR/CDC, Atlanta, GA; 2School of Public Health, University at Albany,
Rensselaer, NY; 3Institute for Health and the Environment, University at Albany,
Rensselaer, NY; 4NCEH/CDC, Atlanta, GA. Sponsor: N. Karch.
Associations among total cholesterol, triglycerides, and high density lipoprotein
cholesterol (HDL) and serum polychlorinated biphenyls (PCBs) and chlorinated
pesticides concentrations were examined in a sample of residents of Anniston,
Alabama, participants of the Anniston Community Health Survey (ACHS).
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For this analysis, nine PCBs with different number of chlorines (in brackets) and
toxicological characteristics were selected: PCBs 74 (4), PCB 99 (5), PCB 118 (5),
153 (6), 170 (7), 187 (7), 196-203 (8), 206 (9), and 209 (10) were included. Four
chlorinated pesticides were also included in the analyses: β-HCCH, Oxychlordane,
trans-Nonachlor, and p,p’-DDE. 
Study includes 765 subjects with PCBs and lipid measurements. We wanted to
minimize the effect of altered lipid levels due to presence or progression of dis-
ease(s) in studying the associations. Persons on lipid lowering medications, with
dyslipidemia, diabetes, and coronary heart disease were excluded from the statistical
analyses. Multiple linear regression models adjusted for age, race, gender, and BMI
were used to analyze the data. Other major CHD risk factors such as smoking, ex-
ercise, and family history of heart disease were also examined.
Only higher chlorinated PCBs 206 and 209 were related to total cholesterol. Seven
out of 9 PCBs were related to triglycerides; PCBs 99, 118 were not associated with
triglycerides. Oxychlordane and pp’-DDE were related to both total cholesterol and
triglycerides; trans-Nonachlor was associated with triglycerides only. No association
with PCBs or pesticides was found for HDL.
Interpretations of these results are limited. In particular, potential sequence of
events relating lipid levels and PCB exposure is complex and uncertain and can
only be elucidated with longitudinal study design.
1985 Persistent Organic Pollutants and Transthyretin-Bound
Thyroxin in Plasma of Inuit Women of Childbearing Age.
Y. Audet-Delage1,  R. Dallaire1,  N. Ouellet1, 2,  <\!s>Dewailly1 and P. Ayotte1, 2.
1Axe en Santé des Populations et Environnementale, Centre de Recherche du CHUQ,
Québec, QC, Canada; 2Laboratoire de Toxicologie, Institut National de Santé
Publique du Québec, Québec, QC, Canada.
The Inuit population of Nunavik (Northern Quebec, Canada) is highly exposed to
persistent organic pollutants (POPs) through their traditional diet which comprises
fatty tissues from marine mammals. Some POPs – i.e. hydroxylated metabolites of
polychlorinated biphenyls (HO-PCBs), pentachlorophenol (PCP) and perfluo-
rooctane sulfonate (PFOS) – are known to compete with thyroxin (T4) for binding
sites on transthyretin (TTR), a T4 transport protein located in plasma and cere-
brospinal fluid. Displacement of T4 from TTR could result in decreased T4 deliv-
ery to the developing fetus and in turn delayed growth and impaired neurodevelop-
ment in infants. We set out to test the hypothesis that POPs or their metabolites
decrease circulating concentrations of T4 bound to TTR (T4-TTR) in Inuit
women of reproductive age. We measured T4-TTR concentrations in archived
plasma samples obtained from 120 Inuit women (18-39 year old) by combining
native polyacrylamide gel electrophoresis and liquid chromatography-tandem mass
spectrometry (LC-MS/MS) techniques. Total T4 concentration was measured by
LC-MS/MS, while those of TTR and thyroxin binding globulin (TBG) were deter-
mined by gel densitometry and an ELISA assay, respectively. POPs levels had been
previously determined in those samples. The mean T4-TTR concentration was 8.4
nmol/L (SD = 2.4) with values ranging from 2.9 to 14.4 nmol/L, representing on
average 6% of total T4 circulating concentration. Plasma levels of HO-PCBs, PCP
or PFOS were not correlated to T4-TTR concentrations. Linear regression analysis
revealed that TTR, TBG and total T4 concentrations were significant predictors
(p<0.001) of T4-TTR levels (adjusted R-square=0.26, p<0.001), but not POPs lev-
els. Our results suggest that actual circulating levels of POPs in Inuit women of
childbearing age are not high enough to affect TTR-mediated thyroid hormone
transport.
1986 Effect of TCDD on Peripheral Hormones Regulating Feed
Intake and Energy Balance in Rats.
R. Pohjanvirta1,  S. Lensu2 and J. Lindén1. 1Department of Food Hygiene and
Environmental Health, University of Helsinki, Helsinki, Finland; 2Department of
Biology of Physical Activity, University of Jyvaskyla, Jyvaskyla, Finland. Sponsor: M.
Viluksela.
A lethal dose of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) brings about a dras-
tic body weight loss dubbed the wasting syndrome in rats. The decline of body
weight primarily results from severe hypophagia but at present next to nothing is
known about the factors underlying the reduced feed intake. The most important
peripheral hunger signal in the body is ghrelin, mainly secreted into blood by stom-
ach cells, whereas the principal satiety hormone is leptin produced by the white adi-
pose tissue. Practically no data exist on the impact of TCDD on these hormones. In
the present study, we exposed TCDD-sensitive Long-Evans (Turku/AB; L-E) and
TCDD-resistant Han/Wistar (Kuopio; H/W) rats to 100 μg/kg TCDD ig. and eu-
thanized the rats at days 1, 4 or 10. The dose selected is lethal to all L-E rats but
sublethal to H/W rats. A feed-restricted control (FRC) group of L-E rats was in-
cluded in the study to help distinguish between primary and secondary effects. In
addition to leptin and ghrelin, also glucagon was determined in serum samples with
the Bio-Plex Suspension Array System. By 10 days, body weight dropped by about
30% in TCDD-treated and FRC L-E rats but only by some 5% in TCDD-treated
H/W rats. Concurrently, serum leptin decreased to non-detectable levels in FRC. It
diminished also in TCDD-treated L-E and H/W rats but less prominently. Serum
ghrelin was elevated by TCDD in L-E rats at all time-points, and in H/W rats on
day 10; in FRC, the increase was lesser on day 4 and comparable on day 10.
Glucagon took an upward course in TCDD-treated L-E rats alone reaching a nine-
fold increase vs. control on day 10. These data reveal that the major peripheral sig-
nals of energy balance remain intact and change appropriately in lethally TCDD-
treated L-E rats. However, they do not lead to the normal behavioural response (i.e.
feeding) to rectify the tilted energy status.
1987 Effects of Developmental PCB Exposure on Energy
Metabolism in Adult and Aged Mice.
A. Brown,  A. Ashworth,  K. Smith and C. P. Curran. Biological Sciences, Northern
Kentucky University, Highland Heights, KY.
Polychlorinated biphenyls (PCBs) are known to cause learning, memory, and be-
havioral deficits in the developing human brain. Our previous work showed that al-
lelic differences at the Ahr and Cyp1a2 loci alter susceptibility to developmental
PCB neurotoxicity. While exploring behavioral differences in aged animals, we dis-
covered a significant divergence in weights dependent on sex, genotype and treat-
ment. The experiments described here were designed to see if gestational and lacta-
tional PCB exposure could alter energy metabolism in adult and aged mice. We
compared blood glucose, triglycerides and cholesterol in PCB-treated and corn oil-
treated control mice with the following genotypes: AhrbCyp1a2(+/+),
AhrbCyp1a2(-/-) and AhrdCyp1a2(-/-). The knockout lines were both back-
crossed onto a C57BL/6J background which was our wild type control. Pregnant
dams were exposed to an environmentally relevant PCB mixture during gestation
and lactation. One male and one female per litter were tested at 6 months and 13
months of age. There was a significant effect of genotype and a significant gene x
treatment x sex interaction for fasting blood glucose levels. For glucose tolerance
testing, mice were fasted overnight, then injected with 2 mg/kg glucose and blood
collected over two hours. There was a significant main effect of sex and genotype in
glucose tolerance at 6 months. We observed a significant main effect of genotype
and sex for plasma cholesterol and a significant genotype x sex interaction for
triglycerides. At 13 months, there was a significant genotype x treatment interac-
tion for triglycerides, but only a main effect of sex for cholesterol with male mice
having significantly higher levels. We replicated our prior weight trends with PCB-
treated male AhrbCyp1a2(-/-) mice weighing significantly less than their corn oil-
treated controls. These mice also had significantly lower triglyceride levels com-
pared with the corn oil-treated controls. Our results indicate that the metabolic
effects of developmental PCB exposure are persistent, but vary depending on both
sex and genotype.
1988 Parent PBDEs and the Hydroxylated Congeners Alter
Normal Thyroid Activity.
E. D. Bruce and C. Y. Usenko. Biology, Baylor University, Waco, TX.
Polybrominated diphenyl ethers (PBDEs) are brominated flame retardants that
have been used for over 30 years. In recent years, the different technical mixtures
have been banned or phased out, however there are still significant environmental
concentrations. Due to the similarity in chemical structure between PBDEs and
thyroid hormones, it has been postulated that PBDEs act through an endocrine dis-
ruption pathway by mimicking thyroid hormone. In this study, embryonic ze-
brafish are used to investigate the interaction of PBDEs on thyroid hormone home-
ostasis. Thyroid hormone levels were increased following exposure to BDEs 47, 99,
and 100. Furthermore, co-exposure with propylthiouracil, a thyroid hormone in-
hibitor, exacerbated the effects of BDE 47 exposure on spontaneous movement.
Additionally, alterations in gene transcription of thyroid-related genes to several dif-
ferent PBDE congeners (BDE 28, BDE 47, BDE 99, and BDE 100) were com-
pared. There was limited alteration in gene expression for most of the genes exam-
ined. Deiodinase 1 and the sodium-iodide symporter (SLC5r) were upregulated
following exposure to all congeners. Additionally, a hydroxylated PBDE was also
investigated for disruption of thyroid-related gene expression. Thyroid transcrip-
tion factor (NKX2.1) was downregulated by exposure to BDEs 28, 99, and 100;
however it was significantly increased following exposure to 6-OH-BDE 47.
Exposure to 6-OH-BDE 47 induced the greatest amount of induction, even at con-
centrations 4-fold below the parent PBDE exposure concentrations. Hydroxylated
PBDEs have an even greater similarity to thyroid hormone structure and may be
primarily responsible for the adverse effects of PBDE exposure. These results
demonstrate that PBDEs do affect thyroid homeostasis; however hydroxylated
PBDEs may pose the greatest risk of exposure.
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1989 Search for the Basis of PCB126-Triggered Disruption of
Hepatic Metal Homeostasis in Rodents.
W. D. Klaren1, 2,  I. K. Lai1, 2 and L. W. Robertson1, 2. 1Interdisciplinary Graduate
Program in Human Toxicology, University of Iowa, Iowa City, IA; 2Occupational and
Environmental Health, College of Public Health, University of Iowa, Iowa City, IA.
PCBs, industrial chemicals and persistent environmental pollutants, are found in
many rural and urban settings. Previous studies have shown that the treatment of
rats with PCB126 causes a significant disruption of hepatic metal homeostasis that
could potentially alter antioxidant defenses. The current study is focused on this
metal disruption, in particular on Cu, Zn and Se. Two copper-containing proteins
were investigated, tyrosinase (TYR) and cytochrome c oxidase (COX), along with
metal chaperones ceruloplasmin (CP), selenoprotein p (SelP) and metallothionein
(MT). These proteins cover a wide range of functions from intra-and extracellular
metal trafficking (MT, SelP and CP), pigment production (TYR) and electron
transport (COX). An animal study was conducted where 56 rats were fed one of
three AIN diets containing levels of copper (2, 6 & 10 ppm). After three weeks, an-
imals were given a single IP injection of PCB126 (1 umol/kg or 5 umol/kg in corn
oil) and euthanized two weeks later. The expression levels of these proteins were in-
vestigated by qRT-PCR, ELISA, and western blot. Metals analysis showed a de-
crease of Zn and Se, but an increase of Cu in the liver. Serum CP concentration and
hepatic mRNA levels were increased with dietary copper and PCB treatment (al-
though the latter not significantly). TYR was expressed in the liver both transcrip-
tionally and translationally a new finding. COX was decreased with PCB126 expo-
sure and had no statistical association with dietary copper. SelP was unchanged
either by PCB126 or dietary copper, not reflecting the decrease of hepatic Se. MT
was highly increased by PCB126 at the 1 umol/kg dose. The increase of metalloth-
ionein seen along with the higher binding affinity of Cu potentially explains the
changes seen with Zn. Although metallothionein may contribute to the disruption
of hepatic metal homeostasis, it fails to fully explain the Se and Cu changes. (P42
ES 013661)
1990 Aroclor 1254-Induced Modulation of Osteoblast
Differentiation Is Predominantly AhR-Dependent.
M. Herlin1,  M. Korkalainen2,  J. Ringblom1,  M. Öberg1,  M. Viluksela2 and
H. Håkansson1. 1Institute of Environmental Medicine, Karolinska Institutet,
Stockholm, Sweden; 2National Institute of Health and Welfare, Kuopio, Finland.
Exposure to food-derived mixtures of persistent organic pollutants modulates de-
veloping bone tissue properties. To further clarify details in the mode-of-action in-
volved in the in vivo findings, this study used a comparative approach to elucidate
qualitative and quantitative details in the modulations of osteoblast differentiation
in vitro. MC3T3-E1 cells were exposed to Aroclor 1254 (A1254) or 2,3,7,8-tetra-
chlorodibenzo-p-dioxin (TCDD), the model compound for high affinity ligands of
the aryl hydrocarbon receptor (AhR). Following A1254 exposure, the expression of
the matrix maturation and mineralization marker genes ALP and OCN, were de-
creased, while no effects were seen on the proliferation marker gene RUNX2. These
results suggest that the late phases of osteoblast differentiation were affected, which
is in accordance with observations following TCDD exposure. However, higher
doses of A1254, as compared to TCDD, were required to achieve significant effects
and the maximal effects were lower. The AhR-dependent genes, CYP1A1 and
AhRR, were induced by A1254 and TCDD at doses comparable to those where the
differentiation markers were affected. Taken together, these results show that
A1254, which is a technical mixture of dioxin-like and NDL-PCB congeners pre-
dominantly, exhibits dioxin-like modulations on osteoblast differentiation, suggest-
ing that, in accordance with the in vivo findings, the A1254 induced effects are
mainly AhR-dependent. We further evaluated the relative potency (REP) of A1254
as compared to TCDD. The REP values for OCN, CYP1A1 and AhRR expression
were a magnitude higher as compared to the estimated toxic equivalent dose based
on the chemical composition of A1254, while the REP value for ALP expression
was at the same level as the estimated equivalent chemical dose. Therefore, on a
quantitative basis the higher than expected REP values in this study might indicate
a contribution also of NDL-PCB congeners to the observed in vitro responses.
1991 Adduction of Cytochrome C by Quinoid Metabolites of
Polychlorinated Biphenyls (PCBs).
M. Li1,  L. Teesch3,  D. Murry1, 4,  L. W. Robertson1, 2 and G. Ludewig1, 2.
1Interdisciplinary Graduate Program in Human Toxicology, University of Iowa, Iowa
City, IA; 2Department of Occupational and Environmental Health, University of
Iowa, Iowa City, IA; 3High Resolution Mass Spectrometry Facility, University of Iowa,
Iowa City, IA; 4College of Pharmacy, University of Iowa, Iowa City, IA.
PCBs, a group of 209 individual congeners, were widely used as industrial chemi-
cals and are ubiquitous and persistent human and environmental contaminants.
Even though PCBs are carcinogens in rodents, they are still in use in closed appli-
cations. Lower chlorinated biphenyls can be metabolized to dihydroxy metabolites
and further oxidized to quinoid metabolites both in vitro and in vivo . Quinoid
metabolites may form adducts at nucleophilic sites of proteins like cytochrome c,
an essential component in the mitochondrial electron transport chain. We hypoth-
esized that the PCB-quinones covalently bind to cytochrome c thereby causing de-
fects in mitochondrial function. LC-MS was used to detect adducts of cytochrome
c with selected PCB-quinones in vitro. SDS PAGE gel electrophoresis followed by
NBT staining was employed to separate the adducted proteins. Trypsin digestion
and LC-tandem MS were applied to identify the amino acid binding sites on cy-
tochrome c. SYBYL-X was employed to simulate the conformation change of cy-
tochrome c after binding with PCB3-para-Q. We found that more than one mole-
cule of PCB-quinone can bind to one molecule of cytochrome c. In addition,
cross-linking of cytochrome c was observed on the SDS PAGE gel.  Different con-
ditions, such as PH, incubation time and concentrations of PCB quinones, influ-
ence the formation of cross links. Lysine (K27, K39, K54/56, K73/74) and glu-
tamic acid (E61, E62) were identified as binding sites by LC-tandem MS. Software
simulation showed conformation changes of adducted cytochrome c. These prelim-
inary data provide evidence that covalent binding of PCB quinone metabolites to
cytochrome c, may be included among the toxic effects of PCBs. (Supported by
NIEHS Superfund Program P42 ES013661.)
1992 Alterations in Xenobiotic Metabolizing Enzyme and Immune
Relevant Genes following Administration of Brominated and
Chlorinated Dioxins and Furans in Female B6C3F1 Mice.
R. Frawley1,  M. Smith2,  K. White Jr2,  N. J. Walker1,  L. S. Birnbaum1, 3,
T. Maynor4,  M. DeVito1 and D. R. Germolec1. 1DNTP, NIEHS, Research
Triangle Park, NC; 2VCU, Richmond, VA; 3NCI, Research Triangle Park, NC; 4ILS,
Inc, Research Triangle Park, NC.
Increased use of brominated flame-retardants and incineration of bromine-contain-
ing materials has lead to an increase in the presence of polybrominated dibenzo-p-
dioxins and dibenzofurans (PBDD/Fs) in the environment. Measurable amounts of
PBDD/Fs have been detected in sediment, seafood, and human serum. Previous
studies indicated that an acute single exposure to 2,3,7,8-tetrachlorodibenzo-p-
dioxin (TCDD), 2,3,7,8-tetrabromodibenzofuran (TBDF), 2,3,7,8-tetra-
chlorodibenzofuran (TCDF), 1,2,3,7,8-pentabromodibenzofuran (1PeBDF),
1,2,3,7,8-pentachlorodibenzofuran (1PeCDF), 2,3,4,7,8-pentabromodibenzofu-
ran (4PeBDF), 2,3,4,7,8-pentachlorodibenzofuran (4PeCDF), and 2,3-dibromo-
7,8-dichlorodibenzo-p-dioxin (DBDCDD) suppressed antigen-specific antibody
forming cell (AFC) responses in B6C3F1/N mice, and that the brominated com-
pounds were more potent than their chlorinated analogs. In addition, we evaluated
expression of xenobiotic metabolizing enzyme (XME) and immune-relevant genes
in the livers from these mice. Gene expression was measured using qRT-PCR.
TCDD, TBDF, TCDF, 1PeBDF, 1PeCDF, 4PeBDF, 4PeCDF, and DBDCDD up-
regulated the phase I XME genes Cyp1a1 and Cyp1a2. Based on estimated ED50,
the rank order of potency for Cyp1a1 was
TCDD>TBDF>4PeBDF>1PeBDF>TCDF>4PeCDF>1PeCDF, and for Cyp1a2
was TCDD>TBDF>1PeBDF>4PeCDF>4PeBDF>TCDF>1PeCDF. TCDD,
4PeBDF, TBDF, TCDF, and DBDCDD altered expression of phase II XME, phase
III XME, and the thyroid transport protein transthyretin (Ttr) genes. 4PeCDF and
1PeBDF altered a phase II XME and Ttr genes. Additionally, 4PeBDF, TBDF,
TCDF, and DBDCDD downregulated several genes that have been associated with
antibody production and/or inflammation. Collectively these changes in gene ex-
pression are consistent with previously reported suppression of the AFC response
and induction of aryl hydrocarbon-mediated and thyroid hormone responses. This
abstract does not necessarily reflect the policies or views of NIH.
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1993 PBDE-100 Induces Mitochondrial and HepG2 Impairment.
L. C. Pereira1,  A. O. Souza2,  M. J. Tasso2 and D. J. Dorta2. 1FCFRP, Faculdade de
Ciências Farmacêuticas de Ribeirão Preto, Ribeirão Preto, Brazil; 2FFCLRP,
Faculdade de Filosofia, Ciências e Letras de Ribeirão Preto, Ribeirão Preto, Brazil.
INTRODUCTION: Polybrominated diphenyl ethers (PBDEs) have been used in
diverse products and are ubiquitous contaminants in sediments, in biota and are
also found in human tissues, raising concerns about its toxicity. Many studies have
reported liver toxicity and induction of apoptosis by mitochondrial dysfunction.
OBJECTIVE: The aim of this work was to investigate the mechanisms of toxicity
using HepG2 cells and isolated rat liver mitochondria. METHODS: Briefly, the ef-
fects of BDE-100 (0,1-50 μmol/L) was assessed on the mitochondrial respiration;
Mitochondrial Membrane Potential (Δψ); mitochondrial swelling; interaction with
membrane using 1-anilino-8-naphthalene sulfonate (ANS) and 1,6-diphenyl-
1,3,5-hexatriene (DPH); Ca+2 release and mitochondrial ATP levels with the lu-
ciferin-luciferase system using isolated rat liver mitochondria. Furthermore, cyto-
toxic effect was investigated by testing cell viability with (4,5 dimetilthiazol-2-il) -
2,5 diphenyltetrazolium bromide dye (MTT) assay and cell proliferation with
Sulphorhodamine B. RESULTS: In higher concentrations BDE-100 was able to in-
duce mitochondrial alterations, and interact with the mitochondrial membrane, in-
hibiting the phospholilation; leading to dissipation of the Δψ, deregulation of cal-
cium homeostasis and mitochondrial swelling add a reduction in mitochondrial
ATP content. In addition, it was observed inhibition the proliferation and reduce
viability of the cells showing its cytotoxic action. CONCLUSIONS: These results
suggest the formation of pores in the mitochondrial membrane and alteration in
mitochondrial structure and function, leading to cell death due to cytotoxic effects
in HepG2, perhaps through mitochondrial pathway. Word Keys: Mitochondria;
HepG2; BDE-100 Supported by: FAPESP
1994 Genomic Plasticity and Polychlorinated Biphenyls:
Telomerase Reactivation and AhR Desensitization in Human
Keratinocytes after Long-Term Exposure to PCB126.
S. Pk,  L. W. Robertson and G. Ludewig. Human Toxicology, The University of
Iowa, Iowa City, IA.
Polychlorinated biphenyls (PCBs) are environmental pollutants and dioxin-like
PCB126 (3,3’,4,4’,5-pentachlorobiphenyl) is classified by IARC as a human car-
cinogen. Chromosome ends have ‘telomeres’ which shorten with age in somatic
cells. Lengthening of telomeres and high telomerase activity, the telomere main-
taining enzyme, are key steps in carcinogenesis. To examine if PCB126 carcino-
genicity is mediated through this mechanism, we exposed immortalized human
skin keratinocytes (HaCaT) for 90 days to 5 μM PCB126. Every sixth day cells
were re-seeded and telomerase activity, telomere length, cMyc, hTERT and hTR
(telomerase components), TRF1 and TRF2 (reduce telomerase access to telomeres)
mRNA, CYP1A1 mRNA and activity, superoxide and H2O2 levels were deter-
mined. PCB126 caused an increase in CYP1A1 mRNA and activity, TRF1/2
mRNA, and superoxide and H2O2 and a reduction of telomerase activity (50%),
hTERT and hTR mRNA (10%), telomere length (40%), and cell growth from
Days 6 to 48. From Day 54 on, an increase in cell growth, cMyc, hTERT, and hTR
mRNA levels (to 130%), reactivation of telomerase activity (to 100%), elongation
of telomere length (to 90%), and a decrease in TRF1 and TRF2 mRNA were ob-
served. In addition, from Day 78 PCB126 no longer activated the AhR response
(CYP enzymes) and no mutation were found on the AhR ligand binding region.
Microarray results confirmed an increase in expression of cell growth genes on Day
54 and desensitization of AhR-response on Day 78. This study shows for the first
time a telomerase reactivation, telomere lengthening, and increased cell growth
after telomeres were significantly shortened by PCB-exposure in human cells.
Possible mechanisms include de novo cMyc amplification (telomerase) and/or se-
lection of a small subpopulation of cells. Either way, this work adds a new toxicity
pathway for PCBs and a possible mechanism of carcinogenesis for this and related
contaminants to be considered in their safety evaluation and risk assessment.
1995 Exposure to PCB 126 Triggers Antioxidant Defense through
Cross-Talk of Caveolae and Nrf2 Signaling.
M. C. Petriello,  B. Hennig and S. Han. Toxicology, University of Kentucky,
Lexington, KY.
Environmental toxicants such as polychlorinated biphenyls have been implicated in
the promotion of multiple inflammatory diseases including cardiovascular disease,
but information regarding mechanisms of toxicity and cross-talk between relevant
signaling pathways is lacking. We have reported that coplanar PCBs promote en-
dothelial cell activation through the lipid microdomain caveolae, and the loss of
caveolin-1 (Cav-1) ameliorates these detrimental effects. We have also shown that
PCB 126 can activate the antioxidant transcription factor Nrf2 resulting in upreg-
ulation of antioxidant genes and downregulation of inflammatory markers.
Normally, Nrf2 is sequestered in the cytoplasm and degraded through inhibitory
action of Keap1, but upon activation via toxicants such as PCBs, can enter the nu-
cleus and activate the transcription of a battery of protective genes. Our previous
data suggests downregulation of Cav-1 and upregulation of Nrf2 protects against
PCB-induced cellular dysfunction, but here we show for the first time an intimate
example of cross-talk between these two cellular signaling pathways. To examine
the cross-talk between Cav-1 and Nrf2 pathways in PCB-induced inflammation we
silenced cav-1 in vascular cells. Importantly, Cav-1silenced cells treated with
PCB126 resulted in increased levels of Nrf2-ARE binding determined by EMSA.
Also, in cells treated with PCB 126, silencing of Cav-1 resulted in decreased protein
levels of both inhibitory Keap1 and Fyn kinase, which both have been shown pre-
viously to be implicated in Nrf2 deactivation. We also show that Keap1 levels were
significantly decreased in livers from Cav-1 KO mice when compared to control
C57Bl6 mice. Finally, Cav-1 silencing allowed for a more effective antioxidant re-
sponse, as observed by higher levels of the antioxidant genes glutathione s-trans-
ferase (GST) and NADPH dehydrogenase quinone 1 (NQO1) in cells exposed to
PCB 126. Ultimately, these data introduce novel cross-talk between Cav-1 and
Nrf2 and implicates the ablation of Cav-1 as a protective mechanism of PCB-in-
duced cellular dysfunction and inflammation.
1996 Fibroblast Growth Factor 21 (FGF21) Is a Target Gene of the
Aryl Hydrocarbon Receptor (AhR).
X. Cheng1, 2 and C. D. Klaassen2. 1Pharmaceutical Sciences, St. John’s University,
Queens, NY; 2Internal Medicine, KU Medical Center, Kansas City, KS.
Dioxins, such as 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD), are environmen-
tal pollutants. The toxic effects of TCDD are well documented mainly through ac-
tivating the aryl hydrocarbon receptor (AhR). However, the underlying mecha-
nisms for TCDD’s adverse effects, such as the wasting syndrome, are not well
understood. Fibroblast growth factor (Fgf ) 21 plays critical roles in metabolic adap-
tation to fasting by increasing lipid oxidation and ketogenesis in the liver. The pres-
ent study was performed to determine whether activation of the aryl hydrocarbon
receptor (AhR) induces Fgf21 expression. In mouse liver, TCDD increased Fgf21
mRNA in both a dose- and time-dependent manner. Moreover, TCDD increased
Fgf21 mRNA levels in livers of wild-type mice, but not of AhR-null mice.
Chromatin immunoprecipitation assays indicate that TCDD increased AhR pro-
tein binding to the Fgf21 promoter (-105/+1 base pair). Diethylhexylphthalate
(DEHP) decreased Fgf21 mRNA expression and DEHP pretreatment attenuated
TCDD-induced Fgf21 expression, which may explain a previous report that
DEHP pretreatment decreases TCDD-induced toxicities. In mouse liver, TCDD
increased the mRNA of fatty acid uptake protein CD36 but decreased mRNA of de
novo fatty acid biosynthesis enzyme fatty acid synthase (FAS). In addition to these
findings in liver, TCDD induced Fgf21 mRNA in mouse white adipose tissue. In
conclusion, TCDD induces Fgf21 expression via activation of the AhR-signaling
pathway. Pharmacological manipulation of Fgf21 expression by AhR activators
may provide an effective strategy for treating obesity, diabetes, and the metabolic
syndrome. (Supported by NIH grants DK-081461, ES-09649, ES-019487, and
RR-021940.)
1997 Human Transcription Factor Activation by Polychlorinated
Biphenyls and Organochlorine Pesticides.
B. Wahlang1,  L. Al-Eryani1,  K. Falkner1,  H. Bellis-Jones1,  H. Clair1,
R. Prough3 and M. Cave1, 2. 1Department of Medicine/GI, University of Louisville,
Louisville, KY; 2Louisville VAMC, Louisville, KY; 3Biochemistry, University of
Louisville, Louisville, KY.
Introduction: Polychlorinated Biphenyls (PCBs) are persistent environmental tox-
ins, present in 100% of the US adult population and theoretically predicted to act
as ligands for transcription factors involved in xenobiotic/endobiotic detoxification,
obesity and steatosis. These human receptors include pregnane xenobiotic receptor
(PXR), arylhydrocarbon receptor (AhR) and possibly the liver-X-receptor-α (LXR).
This study evaluates a PCB mixture, Aroclor 1260, and selected individual PCB
congeners, as potential ligands for these receptors. Additionally, we also look at
PXR activation by selected organochlorine pesticides. Methods: MTT assay was
performed to determine acutely toxic concentrations for Aroclor 1260. HepG2
cells were transfected with plasmids expressing human LXR or human PXR; and re-
ceptor-responsive plasmids including tk-LXR-RE-luciferase, pGL3-PXR-RE-lu-
ciferase or pGL3-AhR-RE-luciferase. Transfected cells were treated with ligands for
LXR (T0901317:100nM), PXR (Rifampicin:10μM) and AhR
426 SOT 2013 ANNUAL MEETING
(Benzanthracene:50μM); varying concentrations of Aroclor 1260 or individual
congeners and organochlorine pesticides. Results: The toxicity threshold of Aroclor
1260 in HepG2 cells was 26.0±3.7μg/mL. Aroclor 1260 did not activate the
LXR/LXR-RE system and had no effect on LXR-dependent induction by
T0901317. Aroclor 1260 induced the PXR reporter system in a simple monotonic
fashion with significant inductions being observed at concentrations of 10μg/mL
or greater. Amongst congeners tested, 126 and 196 activated PXR. Aroclor 1260
did not activate AhR but as expected, individual congeners 126 and 118 were po-
tent inducers of AhR. Organochlorine pesticides including dieldrin and chlordane
activated PXR. Conclusion: Aroclor 1260 is a direct agonist of human PXR but not
LXR. This mixture did not significantly activate AhR. PCB 126 activated both
PXR and AhR and 196 activated PXR only.
1998 Validation of QuEChERS-Based Extraction for the
Determination of Organochlorine Pesticides in Liver and
Serum Using GC-MS/MS.
M. Bokhart1,  A. Lehner2,  M. Johnson2 and J. P. Buchweitz2, 3. 1Chemistry,
Michigan State University, East Lansing, MI; 2Diagnostic Center for Population and
Animal Health, Michigan State University, East Lansing, MI; 3Pathobiology and
Diagnostic Investigation, Michigan State University, East Lansing, MI.
Organochlorine (OC) pesticides are chemically stable, have low volatility, and low
rates of degradation which lead to their persistence in the environment and classifi-
cation as persistent organic pollutants (POP). OC pesticides bioaccumulate and
biomagnify to greater extents in animals at higher trophic levels due to their high
lipid solubility. These compounds generally affect the nervous system of the target
organism. The mechanism of action involves the disruption of chemical ion move-
ment in neurons but the major pathologic changes are observed in the liver and re-
productive systems. Michigan State University Diagnostic Center for Population &
Animal Health (MSU DCPAH) has developed and validated a quantitative
QuEChERS approach for 24 organochlorine analytes in liver and blood serum.
Identification and quantitation of the extracted compounds is by capillary gas chro-
matography interfaced to a tandem quadrupole mass spectrometer (GC-MS/MS).
The QuEChERS approach utilizes an acetonitrile extraction, partitioning facili-
tated by the addition of salts and a dispersive solid phase extraction cleanup.
Depending on compound and matrix, the limits of detection (LOD) vary from
0.002-2.4 ppb and limits of quantification (LOQ) vary from 0.01-7.4 ppb.
Compared to other multiresidue methods for trace pesticide detection, the
QuEChERS extraction method has many advantages including less sample size re-
quired, faster throughput time of samples, and less solvent used per sample leading
to a reduction in overall cost, a lower carbon footprint and improved lab safety.
1999 Development of Weighted Distributions of Relative Potency
Estimates for Dioxin-Like Compounds.
L. C. Haws1,  G. Hixon1,  M. DeVito2,  N. J. Walker2,  L. Kuriakose3,
L. S. Birnbaum4,  M. Harris3 and D. Wikoff1. 1ToxStrategies, Austin, TX; 2NIEHS,
Research Triangle Park, NC; 3ToxStrategies, Houston, TX; 4NCI, Research Triangle
Park, NC.
Potential human health risks associated with exposure to dioxin-like compounds
(DLCs) are evaluated using toxic equivalency factors (TEFs). TEFs are single point
estimates even though they are based on relative estimates of potency (REPs) that
often span several orders of magnitude. One potential improvement to the TEF
methodology would be to use the full distributions of REP values for each con-
gener. WHO recognized the value of such an approach during their most recent re-
view of the TEF methodology but expressed concern that all REP values are not of
equivalent quality or relevance. As such, we previously established a consensus-
based framework that weights REPs based on REP quality and relevance and to de-
velop a numerical approach for quantitatively weighting each REP using machine
learning. Since that time, we have applied the quantitative weighting framework to
the REP database to develop a numerical weight for each REP value, which in turn
has been used to develop a weighted distribution of REPs for each congener, and
have also developed 95% confidence intervals (CIs) around the percentile associ-
ated with the TEF values using the R statistical programming environment. The
weighted distributions were generally tighter than were the unweighted distribu-
tions. Additionally, when examining where the current WHO TEFs fell on the
weighted distributions for each congener, we found a lack of consistency across
congeners, with values percentiles ranging from the 1st–99th percentiles. The CIs
for many of the congeners were also quite broad. For example, the TEF for 12378
PeCDF fell on the 47th percentile of the weighted distribution, but the CI ranged
from the 29th to the 68th percentile. These calculations improve characterization
of the variability and uncertainty inherent in the health risk estimates for this class
of compounds, demonstrating that reliance on the point estimate TEFs could sig-
nificantly under- or over-estimate risk. (This abstract does not reflect the policies or
views of NIEHS or NCI).
2000 Uptake and Systemic Relative Effect Potencies of 4-PECDF,
PCB-126, PCB-118 and PCB-156 in Female Mice after
Acute Exposure.
K. I. van Ede1,  P. Andersson2,  K. P. Gaisch1,  M. van den Berg1 and M. B. van
Duursen1. 1Institute for Risk Assessment Sciences, Utrecht University, Utrecht,
Netherlands; 2Faculty of Science and Technology, Umeå University, Umeå, Sweden.
Risk assessment of mixtures of chlorinated dioxins (PCDDs), furans (PCDFs) and
biphenyls (PCBs) is performed using Toxic Equivalency Factors (TEFs) that are de-
rived from multiple relative effect potencies (REPs) linking administered dose levels
to toxic/biologic effects. Increasing evidence suggests that using administered dose
levels instead of systemic levels (e.g. liver or plasma concentrations), may lead to
misinterpretation of risk. In this study, REPs of 4-PeCDF, PCB-126, PCB-118 and
PCB-156 were determined in female mice three days after a single oral dose. REPs
were calculated relatively to TCDD, based on cytochrome P450 1A1 (EROD) ac-
tivity in liver and gene expression of CYP1A1, 1A2 and 1B1 in liver and peripheral
blood lymphocytes (PBL) using administered dose, liver levels and plasma levels.
Using the administered dose, REPs for the various endpoints ranged between 0.01
– 0.2 for 4-PeCDF (WHO-TEF 0.3), 0.005 – 0.04 for PCB-126 (WHO-TEF
0.1), 0.000005 – 0.00003 for PCB-118 (WHO-TEF 0.00003) and 0.00001 –
0.00003 for PCB-156 (WHO-TEF 0.00003). Recalculating the REPs using
plasma levels increased REPs 4- to 9-fold for 4-PeCDF and 2-fold for PCB-126. In
contrast, plasma-based REPs for PCB-118 and PCB-156 where slightly lower than
the REPs based on administered dose. Recalculating the REPs using liver levels re-
sulted in a decrease in REPs for 4-PeCDF and PCB-126 and an increase for PCB-
118 and PCB-156. In general, deviation in REPs using either administered or sys-
temic levels were seen for all tested congeners. However, most administered and
systemic REPs were within or below one order magnitude uncertainty of WHO-
TEFs. Only liver REPs for PCB-118 and PCB-156 based on liver concentration
were higher. Even though, tissue specific REPs might give a more accurate value of
the potency of a single compound. Additional rat and human in vitro data will be
used to further confirm and/or explore these findings.
2001 Phenylethyl Isothiocyanate and Dithiocarbamate Restore
Proangiogenic Properties of Cyp1b1-Deficient Vascular Cells
through Decreased NF-κB Activity and Oxidative Stress.
T. L. Palenski1,  C. M. Sorenson2 and N. Sheibani1. 1Ophthalmology & Visual
Sciences, University Wisconsin-Madison, Madison, WI; 2Pediatrics, University
Wisconsin-Madison, Madison, WI.
Purpose: Cytochrome P450 1B1 (Cyp1B1) is expressed in the vasculature and loss
of its expression/activity is associated with increased oxidative stress, increased
thrombospondin-2, and NF-κB activation. This is concomitant with attenuation
of angiogenesis in vivo and in vitro. Both phenylethyl isothiocyanate (PEITC),
found in cruciferous vegetables, and pyrrolidine dithiocarbamate (PDTC) inhibit
NF-κB activity. The objective of this study was to determine if inhibition of NF-κB
by PEITC or PDTC restores the reductive and proangiogenic properties of
Cyp1B1-deficient vascular cells.
Methods: Primary cultures of retinal endothelial (EC) and pericytes (PC) were pre-
pared from Cyp1B1+/+ and Cyp1B1-/- mice. Cyp1B1-/- retinal vascular cells were
incubated with either 1 μM PEITC or 10 nM PDTC for 24 h, unless indicated
otherwise. NF-κB expression and activity were determined by Western blot analysis
and luciferase reporter activity. Immunofluorescence staining was performed to vi-
sualize p65 localization. Oxidative stress was measured using dihydroethidium
staining. The ability of Cyp1B1+/+ and Cyp1B1-/- vascular cells to undergo capil-
lary morphogenesis in Matrigel was also determined after 8 h incubation with
PDTC or PEITC. Rates of cell migration were compared using a transwell assay.
Results: PEITC and PDTC both inhibited NF-κB p65 expression and activity. NF-
κB inhibition decreased p65 staining and nuclear localization in Cyp1B1-/- retinal
vascular cells. Inhibition of NF-κB restored capillary morphogenesis and migration
of retinal vascular cells. Oxidative stress in Cyp1B1-/- retinal vascular cells was re-
lieved with incubation with PEITC and PDTC. 
Conclusion: Cyp1B1 expression/activity is essential for maintaining the normal
proliferative, migratory, and reductive state of the vascular cells, and its alteration
has significant impact on vascular development and angiogenesis.
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2002 Cyp1b1-Deficiency Alters Structure and Function of
Trabecular Meshwork via Increased Oxidative Stress.
Y. Zhao1,  S. Wang1,  C. M. Sorenson2,  D. M. Peters1, 3,  L. Teixeira5,
R. R. Dubielzig5 and N. Sheibani1, 4. 1Departments of Ophthalmology and Visual
Sciences, University of Wisconsin-Madison, Madison, WI; 2Pediatrics, UW-Madison,
Madison, WI; 3Pathology, UW-Madison, Madison, WI; 4Pharmacology, UW-
Madison, Madison, WI; 5Comparative Ocular Pathology Laboratory of Wisconsin,
UW-Madison, Madison, WI.
Cytochrome P450 1b1 (Cyp1b1) is a member of the cytochrome P450 super fam-
ily of proteins with mono-oxygenase activity. Although mutations in Cyp1b1 gene
have been reported in patients with congenital glaucoma, the role Cyp1b1 plays in
the development and function of trabecular meshwork (TM) remains unknown.
Here we determined the impact of Cyp1b1 deficiency on the development and
function of TM tissue in C57Bl/6 mice. The intraocular pressures (IOPs) of
Cyp1b1+/+ and Cyp1b1-/- mice were measured non-invasively with a commer-
cially available tonometer. The integrity of TM tissues of 1-week to 8-month-old
Cyp1b1+/+ and Cyp1b1-/- mice were assessed by electron microscopy (EM).
Oxidative stress in the TM tissues was evaluated by immunostaining for 4-hy-
droxyl-2-noneal (HNE). N-Acetylcysteine (NAC; 1.5 mg/g body weight, once
every three days for three weeks, IP) was administrated in 3-day-old Cyp1b1-/-
mice and the morphology of TM was assessed by EM. Our results showed a mod-
est but significant increase in diurnal IOP of Cyp1b1-/- mice at 6-12 weeks of age.
The 2-week-old Cyp1b1-/- mice presented ultra structural irregular collagen distri-
bution in the TM tissue, which became more severe as mice aged. Increased HNE
staining was observed in TM tissue of Cyp1b1-/- mice in vivo. Administration of
NAC prevented the postnatal formation of lesions in Cyp1b1-/- TM. These results
were consistent with our previous in vitro findings that TM cells prepared from
Cyp1b1-/- mice exhibit increased oxidative stress and cellular defects, which are re-
versed when incubated with NAC. Thus, the metabolic activity of Cyp1b1 con-
tributes to oxidative homeostasis and integrity of ultra-structure and function of
TM.
2003 Macrophage Toxicity in Response to Particles Collected from
Indium-Tin Oxide Production.
M. A. Badding1,  N. R. Fix1,  K. M. Dunnick1,  K. J. Cummings2,  V. Castranova1
and S. S. Leonard1. 1Health Effects Laboratory Division, National Institute for
Occupational Safety and Health, Morgantown, WV; 2Division of Respiratory Disease
Studies, National Institute for Occupational Safety and Health, Morgantown, WV.
Occupational exposure to indium compounds has recently been associated with
lung disease among workers in the indium-tin oxide (ITO) industry. Previous stud-
ies have suggested that autoantibodies and reactive oxygen species (ROS) may play
a role in the development of pulmonary lesions following indium compound expo-
sures. However, the molecular mechanisms behind indium compounds’ toxicity re-
main largely unknown. Thus, we aim to uncover how compounds encountered in
the ITO production process affect cultured macrophages and ultimately, contribute
to the pathogenesis of indium lung disease. The indium compounds used in this
study were collected from different process stages at an ITO production facility.
Darkfield microscopy has revealed that various indium compounds interact with
the cells as early as 5 minutes post-exposure, suggesting that cellular reactions to the
ITO compounds may be occurring very rapidly. Indeed, using electron spin reso-
nance (ESR) to measure ROS generation, we found that various collected indium
compounds produce free radicals in the presence and absence of RAW 264.7 mouse
macrophages within 5 minutes. We also hypothesize that indium compound parti-
cle uptake by macrophages leads to subsequent cellular damage, which could be
contributing to lung pathology. Therefore, various imaging techniques are being
used to observe particle association with and uptake by macrophages over a time
course. Current studies are underway to evaluate the effects of the collected indium
compounds on intracellular ROS production, lipid peroxidation, DNA damage,
and cell proliferation over the same time course. These findings will provide a foun-
dation for the molecular basis behind an emerging occupational health issue and as-
sist in the prevention indium lung disease.
2004 Role of Cytochrome P450 (CYP)1A Enzymes in Sex-Specific
Differences in Hyperoxic Lung Injury.
K. Lingappan,  W. Jiang,  L. Wang,  X. Couroucli and B. Moorthy. Pediatrics,
Baylor College of Medicine, Houston, TX.
Preterm male infants have a higher incidence of chronic lung disease (CLD) com-
pared to females and hyperoxia contributes to its pathogenesis. Cytochrome
P450(CYP)1A enzymes attenuate hyperoxic lung injury. The mechanisms responsi-
ble for sex differences in hyperoxic lung injury and the role of CYP1A enzymes re-
main largely unknown. We tested the hypothesis that mice will display sex-specific
differences in hyperoxic lung injury and that this phenomenon will be altered in
mice lacking the genes for CYP1A1 or 1A2. Male (M) and Female (F) (8-10 wk)
wild type (WT) (C57BL/6J), Cyp1a1-null, and Cyp1a2-null mice were exposed to
hyperoxia (FiO2>0.95). Lung injury was estimated by lung-weight/body-weight
(LW/BW) ratios, histopathology and immunohistochemistry for quantitation of
neutrophil infiltration. Levels of 8-iso PGF2α (lung) were determined by LC-
MS/MS and apoptosis was assessed by TUNEL (terminal deoxynucleotidyl trans-
ferase-mediated dUTP nick end-labeling) staining. Measurement of cytokine pro-
tein expression levels in lung homogenates was done using suspension bead array.
CYP1A1 and A2 expression was quantified in the lungs and liver at the enzyme,
protein and mRNA level. Upon exposure to hyperoxia, WT males showed a greater
increase in LW/BW ratios, displayed greater perivascular and alveolar injury, neu-
trophil infiltrates and TUNEL+ cells than females. The suspension bead array assay
revealed increases in mouse lung tissue homogenate levels of IL-6 (F>M) and
VEGF (M>F). WT females showed higher hepatic and pulmonary CYP1A level
and activity compared to males. Strikingly, the sex-based differences were lost in
mice lacking Cyp1a1 or 1a2. The increased susceptibility of WT males to hyperoxic
lung injury suggests modulation by sex-specific factors like reactive oxygen species,
inflammatory cytokines, and factors that regulate apoptosis. Further studies to elu-
cidate the mechanistic role of CYP1A in the sex specific modulation of hyperoxic
injury could lead to the development of strategies to prevent or treat CLD in the
premature infant.
2005 Towards Elucidating the Pathophysiological Role of Reactive
γ-Ketoaldehydes Formed through the Isoprostane Pathway of
Lipid Peroxidation.
T. T. Nguyen1, 2,  P. Chen2, 3,  M. Aschner1, 2, 3 and L. Roberts1, 4. 1Pharmacology,
Vanderbilt University Medical Center, Nashville, TN; 2Pediatrics, Vanderbilt
University Medical Center, Nashville, TN; 3Neuroscience, Vanderbilt University
Medical Center, Nashville, TN; 4Medicine, Vanderbilt University Medical Center,
Nashville, TN.
Numerous environmental toxins cause oxidative damage to lipids, proteins, and
DNA. Lipid peroxidation leads to the formation of reactive aldehydes amongst
which the γ-ketoaldehydes formed via the isoprostane pathway of lipid peroxida-
tion, termed isoketals (IsoKs), are the most reactive and injurious. Selective scav-
engers of IsoKs have been developed which have shown remarkable protection
against oxidative damage in animal models of oxidative stress. However, the precise
molecular processes preserved due to scavenging IsoKs have not been defined. This
can, however, be elucidated studying the highly tractable organism, Caenorhabditis
elegans (C. elegans). Accordingly, to identify the pathophysiological roles of IsoKs in
oxidative injury, C. elegans are exposed to oxidative insult in the absence and pres-
ence of salicylamine. A fluorescent C. elegans strain containing a GFP transcrip-
tional reporter for the SKN-1 target gene gst-4 (Pgst-4::GFP) was utilized for detec-
tion of altered gene expression in order to determine processes protected by reactive
γ-ketoaldehyde scavengers. Late-stage L4 worms were dosed with a submaximal
dose of a SKN-1 activating xenobiotic, juglone, for one hour and plated for recov-
ery for one hour. Current studies show a nearly 4-fold increase in fluorescent inten-
sity after a submaximal (LD20) dose of juglone (p-value = 0.02). These results
demonstrate that a brief exposure to the xenobiotic juglone is sufficient in activat-
ing SKN-1 in C. elegans, and can be used in oxidative and xenobiotic stress studies.
(Supported by T32ES007028-38 [T.T.N.]).
2006 High-Content Imaging Assay to Detect Drug-Induced
Reactive Oxygen Species Generation.
Y. Will,  R. Swiss and S. Nadanaciva. Pfizer Inc, Groton, CT.
The disruption of cellular redox circuits can lead to an increase in reactive oxygen
species (ROS) within cells, causing oxidative stress and eventually cell damage.
Mitochondria are the main producers of ROS in the form of superoxide anion. Two
of the electron transport chain complexes, Complex I and Complex III, are thought
to be responsible for most of the ROS generated in mitochondria.
Several drugs associated with oxidative stress have been shown to contribute to tox-
icity in the liver, heart, kidney and central nervous system. Thus, it is important to
be able to screen new chemical entities that may cause an increase in ROS produc-
tion in order to reduce compound attrition at the early drug discovery stage. 
Hence, we developed a 384-well format high content imaging assay that measures
superoxide production. The effect of 60 compounds including thiazolidinediones,
antipsychotics, antidepressants and anticancer agents was measured in this assay in
transformed human liver epithelial cells (THLE) using the fluorescent dyes,
Dihydroethidium (for superoxide levels) and Hoechst (for cell number). In a sepa-
rate 384-well format high content imaging assay, we tested the effect of the com-
pounds on the mitochondrial membrane potential (MMP) of the cells using the
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fluorescence dye, TMRM. Quantitative image analysis showed that the compounds
could be grouped into four categories: (a) those that caused superoxide formation
and a loss in MMP at similar concentration ranges (for example, astemizole, so-
rafenib), (b) those that caused superoxide production but had no effect on MMP
(dasatinib), (c) those that caused a loss in MMP but had no effect on superoxide
formation (tamoxifen, sertraline), and (d) those that had no effect either on super-
oxide formation or on the MMP over 24 hours (pioglitazone, risperidone). Both
high content imaging assays were robust and rapid and can be implemented within
a screening paradigm to identify compounds that modulate oxidative stress and mi-
tochondrial membrane potential.
2007 The Antioxidant Lipoic Acid Exacerbates Paraquat-Induced
Cytotoxicity.
Z. Suntres1, 2,  R. Pycko2 and J. Coccimiglio2. 1Northern Ontario School of
Medicine, Thunder Bay, ON, Canada; 2Biology, Lakehead University, Thunder Bay,
ON, Canada.
In several countries the use of herbicides has become important in the preservation
of sustainable agriculture. A widely used herbicide for broadleaf weed control is
paraquat (PQ) known to be toxic to humans and animals. The treatment against
PQ poisoning remains supportive with no antidotes or specific treatments available.
Recognizing that PQ induces its toxicity primarily via oxidative stress-mediated
mechanisms, modulating the levels of cellular antioxidants seems to serve as a po-
tential treatment strategy. We studied the in vitro effects of the thiol-containing an-
tioxidant lipoic acid (LA) in a human lung adenocarcinoma epithelial cell line.
Incubation of control A549 cells with PQ resulted in time- and concentration-de-
pendent increases in intracellular PQ levels with concomitant decreases in cell via-
bility and mitochondrial membrane permeability (MMP) and increases in intracel-
lular calcium concentrations [Ca+2]i.  Challenge of cells with LA alone did not
cause any changes in any of the biochemical parameters measured with the excep-
tion of the MMP being significantly decreased. Co-treatment of A549 cells with
LA and PQ potentiated the PQ-induced cytotoxicity as evidenced by the further
exacerbation of PQ-induced decreases in MPP and increases in DNA fragmenta-
tion and [Ca+2]i. Chromatographic analysis (GC/MS/MS) showed that LA was
primarily associated with cell membranes. These data suggest that LA does not offer
any protective effects against PQ-induced toxicity. The mechanism(s) for its ability
to modulate cell survival/death by modulating the cellular redox-regulated signal
transduction in PQ-challenged cells is under investigation. This research project
was supported by Natural Sciences and Engineering Research Council of Canada
(NSERC).
2008 Lipid Droplets with Oxygenated Fatty Acids and
Triglycerides in Dendritic Cells: Possible Role in Antigen
Presentation in Cancer.
V. Tyurin1, 2,  W. Cao3,  J. Loomen3,  V. Kagan1, 2 and D. Gabrilovich3.
1Department of Environmental and Occupational Health, University of Pittsburgh,
Pittsburgh, PA; 2Center for Free Radical and Antioxidant Health, University of
Pittsburgh, Pittsburgh, PA; 3Department of Immunology, H. Lee Moffitt Cancer
Center, Tampa, FL.
Immuno-surveillance plays a critical role in control of tumor progression whereby
dendritic cells (DC) are the most potent antigen presenting cells responsible for the
development of immune responses. Our previous work has identified lipid droplets
as potent regulators of DC’s immune functions. Notably, DCs isolated from
tumor-bearing mice or treated with tumor explant supernatants (TES) accumu-
lated lipid droplets containing considerable amounts of PUFA (C18:2, C18:3,
C20:4 and C22:6). Among those, the amounts of C18:2 were significantly higher
compared to other PUFA species. Since accumulation of lipid droplets in DCs in
cancer was mediated via Msr1 receptor, which is primarily responsible for the up-
take of oxidatively modified lipids, we performed analysis of oxidized lipids in DCs
using LC-ESI-MS. To investigate possible role of oxidized fatty acid in antigen
presentation we used a model system were DCs from naïve mice were grown in the
presence of C18:2. Treatment of DCs with C18:2 in combination with a hy-
drophobic free radical generator, an azo-intiator AMVN, - but not with C18:2
alone - resulted in accumulation of oxygenated lipid droplets and caused significant
decrease in antigen presentation. Oxygenated FFA containing one, two and three
oxygens as well as oxygenated triacylglycerols, TAGs, including truncated TAGs
with m/z 766 [M+NH4]+, containing acyl corresponding to 9-oxo-nonanoic acid,
were observed in DC grown in the presence of TES and DC treated with C18:2
and AMVN. Given that lipid droplets can directly co-localize with cellular com-
partments involved in antigen processing and formation of pMHC complexes, it is
likely that accumulation of oxygenated FFAs and TAGs in DC may be responsible
for the loss of their immune-regulatory functions in cancer. Supported by grant
with CA165065, NIOSH OH008282, NIH U19 AI068021, HL70755.
2009 Mitochondrial Cardiolipin As a Substrate for Cytochrome C-
Catalyzed Production of Oxygenated Lipid Mediators.
V. Kagan1,  V. Tyurin1,  S. Poloyac2,  M. Epperly3,  J. Greenberger3,  H. Bayir4 and
Y. Tyurina1. 1Department of EOH, University of Pittsburgh, Pittsburgh, PA;
2Pharmaceutical Science, University of Pittsburgh, Pittsburgh, PA; 3Radiation
Oncology, University of Pittsburgh, Pittsburgh, PA; 4Critical Care Medicine,
University of Pittsburgh, Pittsburgh, PA.
Lipid mediators – central to the normal homeostasis and responses to stress and dis-
ease - are generated through oxygenation of polyunsaturated fatty acids (PUFA),
such as linoleic acid (LA), arachidonic acid (AA) and docosahexaenoic acid. Their
regulatory effects are believed to depend on a fine balance between PUFA esterifi-
cation/reacylation of phospholipids and on their hydrolysis by phospholipases A
(PLA). We suggested that mitochondrial cardiolipins (CLs) can be a source of
bioactive lipid mediators generated with the catalytic participation of cytochrome c
(cyt c). In this study we employed models of rat traumatic brain injury (TBI) and
mousetotal body irradiation (TIR). Using oxidative lipidomics approach and
MS/MS analysis, we found that TBI resulted in oxidation of polyunsaturated mo-
lecular species of CL and accumulation of its hydrolysis products such as oxy-
genated LA, AA and monolyso-CL. Similar, a significant increase of oxidized CLs
in small intestine of TIR mice (9.5 Gy) was accompanied by accumulation of CL
hydrolysis products. To generate oxygenated CL in vitro we utilized brain CL, with
its highly diversified polyunsaturated molecular species, and cyt c. We found that
incubation of brain CL with cyt c in the presence of H2O2 yields a rich assortment
of oxygenated CL species, hydrolysis of which by PLA1 and A2 generated multiple
oxygenated fatty acids similar to those that were formed in vivo in brain after TBI
and small intestine after TIR. An oxidation-specific lipoprotein lipase A2, was able
to utilize peroxidized tetralinoleoy-CL to yield different oxygenated species of
linoleic acid and lyso-CLs. Thus, mitochondrial CL/cyt c represents a novel mech-
anisms involved in lipid mediators-generating pathways.  Supported by NIH
ES020693, ES021068, U19 AI068021, HL70755; NIOSH OH008282,
NS076511, NS061817.
2010 Development of a Mitochondria-Targeted Nano-Complex of
Imidazole-Substituted Oleic Acid As a Radiomitigator.
A. Star1, 3,  A. Kapralov2, 3,  A. Amoscato2, 3,  V. Tyurin2, 3,  W. Seo1, 3,
M. Epperly4, 3,  J. Greenberger4, 3,  Y. Tyurina2, 3 and V. Kagan2, 3. 1Department of
Chemistry, University of Pittsburgh, Pittsburgh, PA; 2Department of Environmental
and Occupational Health, University of Pittsburgh, Pittsburgh, PA; 3Center for
Medical Countermeasures against Radiation, University of Pittsburgh, Pittsburgh, PA;
4Radiation Oncology, University of Pittsburgh, Pittsburgh, PA.
Increasing likelihood of intended or accidental exposure to ionizing radiation dic-
tatesthe necessity to develop effective medical countermeasures of radiation injury
as has been recognized as a high priority both in the US and worldwide. No effec-
tive medical radiation countermeasures of acute and delayed radiation injuries are
currently known. Based on newly discovered mechanisms of radiation damage –
oxidation of cardiolipin by cytochrome c in mitochondria as a required stage in ra-
diation-induced apoptosis - we designed and synthesized mitochondria-targeted
triphenylphosphonium-conjugated imidazole-substituted oleic (TPP-OA) which
prevented/mitigated cell death induced by irradiation and protected C57BL6 mice
against total body irradiation. To improve therapeutic efficiency of TPP-IOA we
chose to employ branched polyethylene glycol (PEG) functionalized single walled
carbon nanotubes (SWCNT) and use it as a carrier to deliver mitochondria-tar-
geted TPP-IOA to tissues. We found that loading of PEG-SWCNT with TPP-IOA
caused a marked extension of the life-span of TPP-IOA in circulation. Moreover we
showed that TPP-IOA-nano-complex was more effective as radiomitigator than
free TPP-IOA. While the dose of TPP-IOA in TPP-IOA-nano-complexes was two
times lower compared with free TPP-IOA the mitigating effect of TPP-IOA-nano-
complexes was higher than that of TPP-IOA alone. Importantly, we were able to
detect TPP-IOA nano-complexes in radiosensitive tissue such as small intestine.
These data warrant further studies aimed at the development of radioprotectors/ra-
diomitigators with broad spectrum of applications in biomedicine and biodefense.
Supported by NIOSH OH008282; NIH U19 AI068021, HL70755, ES019304.
2011 XBP1, SYVN1 and Nrf2: At the Crossroads of ER Stress and
Oxidative Stress.
T. Wu and D. D. Zhang. College of Pharmacy, University of Arizona, Tucson, AZ.
Transcription Factor Nrf2 has long time been revealed as the master regulator of in-
tracellular redox homeostasis. As an adaptive response to oxidative stress, Nrf2 ac-
tives transcription of a battery of genes encoding antioxidant protein, detoxification
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enzymes and xenobiotic transporters by binding to the cis-antioxidant response el-
ements in the promoter region of these genes. Previous works by our lab and others
demonstrated that Nrf2 is subject to poly-ubiquitin-mediated proteasomal degra-
dation in a Keap1-dependent manner. Here we report that active form of XBP1,
XBP1s suppresses Nrf2 and its downstream signal under ER stress condition,
through activation transcription of synovial apoptosis inhibitor 1 (SYVN1).
SYVN1, also known as Hrd1, is an ER-associated degradation (ERAD) ubiquitin
ligase. We have determined that SYVN1 directly interacts with the Neh4 and Neh5
domain within Nrf2. Overexpression of SYVN1 attenuates Nrf2 signaling, whereas
knockdown of SYVN1 enhances expression of Nrf2 and its downstream genes.
Furthermore, SYVN1 accelerates the clearance of Nrf2 protein through promoting
ubiquitination of Nrf2. These findings demonstrate that XBP1 and SYVN1 are in-
volved in regulating the Nrf2 pathway in a new Keap1-independent mechanism.
Moreover, our data revealed a possible crosstalk between ER stress pathway and ox-
idative responses via UPR and Nrf2 signaling pathway in order to protect cells
against environmental stress.
2012 Sulforaphane Stimulates Basal but Inhibits Glucose-
Stimulated Insulin Secretion in Beta-Cells: Role of Reactive
Oxygen Species and Induction of Endogenous Antioxidants.
J. Fu1,  Q. Zhang1,  C. G. Woods1,  H. Zheng1,  B. Yang1, 2,  M. E. Andersen1 and
J. Pi1. 1Institute for Chemical Safety Sciences, The Hamner Institutes for Health
Sciences, Durham, NC; 2College of Basic Medical Science, China Medical University,
Shenyang, China.
Excessive oxidative damage by reactive oxygen species (ROS) is a major contributor
to pancreatic β-cells dysfunction. Interestingly, ROS are also involved as a second
messenger in glucose-stimulated insulin secretion (GSIS) in β-cells. This paradox
obscures the regulatory role of antioxidants in insulin secretion. In the present
study, we used an integrated mathematical modeling and in vitro approach to un-
derstand the effects of antioxidant sulforaphane (SFN) on insulin secretion.
Experiments with INS-1(832/13) cells and isolated mouse islets showed that 30-
min SFN treatment stimulated basal insulin secretion in a concentration-depend-
ent manner at low glucose conditions (3 mM). This acute stimulatory effect re-
sulted from an initial SFN-elicited increase of ROS, and when suppressed with
cell-permeable ROS scavenger N-acetylcysteine or glutathione ethyl ester, SFN-
stimulated insulin secretion was diminished. Due to the negative feedback and in-
coherent feedforward loops comprising the redox homeostatic control circuit, cells
can adapt to prolonged SFN treatment and settle to a steady state exhibiting strong
induction of antioxidants but only marginally increased ROS levels. This adapted
state slightly increased basal insulin secretion in INS-1(832/13) cells. More impor-
tantly, the model predicted that the elevated antioxidant capacity at the adapted
state attenuates glucose-stimulated ROS signal and GSIS. This effect was validated
in INS-1(832/13) cells exposed to low, non-cytotoxic concentrations of SFN.
Despite suppressing GSIS, prolonged exposure to SFN protected INS-1(832/13)
cells from cytotoxicity induced by exogenous H2O2. Taken together, our studies
demonstrated that SFN has divergent effects on basal and glucose-stimulated in-
sulin secretion in β-cells. Although the adaptive induction of endogenous antioxi-
dants by SFN enhances β-cell survival, it suppresses GSIS.
2013 Generation of Reactive Oxygen Species by Process Materials
from Indium-Tin Oxide Production.
N. R. Fix1,  K. M. Dunnick1,  M. A. Badding1,  A. B. Stefaniak2,
K. J. Cummings2,  V. Castranova1 and S. S. Leonard1. 1Health Effects Laboratory
Division, National Institute of Occupational Safety and Health (NIOSH)/CDC,
Morgantown, WV; 2Division of Respiratory Disease Studies, National Institute of
Occupational Safety and Health (NIOSH)/CDC, Morgantown, WV.
The transition metal indium has been used for decades for various applications in-
cluding electronics, fusible alloys, and solar cells. Indium compounds usage has in-
creased dramatically based on the rise in demand of touch screens and flat panel
displays (LCD’s). With this growth of industry, there is potential for increase of in-
dium lung disease among workers who produce, use, or reclaim indium-tin oxide
(ITO). Inhalation exposure of indium samples can occur during various times of
manufacturing. Materials from different process stages were collected from an ITO
production facility. While the pathogenesis of indium lung disease is unknown,
previous work has suggested a role for reactive oxygen species (ROS). Chemical
characteristics of the process materials will aid in determination of reactivity differ-
ences between compounds. Electron spin resonance (ESR), a common tool used for
measuring ROS, was used in both acellular and cellular exposures. Acellular sam-
ples were evalyated by combining 10 mg/mL process material, phosphate buffered
saline (PBS), 10mM hydrogen peroxide (H2O2), and 100mM DMPO (spin trap).
RAW 264.7 mouse monocyte macrophages, DMPO, and the same concentration
of composite were used in the cellular samples conducted in ESR. Scavengers and
chelators were used to define radical mechanisms. Results indicated that ventilation
dust (VD), tin-oxide (SnOX), and unsintered ITO (UITO) cause a greater increase
in ROS production than the other process material. H2O2 and O2 consumption
measurements were used to determine the source of the ROS. ESR studies com-
bined with investigation of ROS production will help to determine the mechanisms
behind indium lung disease. Data from this study will be used to determine possi-
ble hazards in occupational exposure of indium process material while increasing
the understanding of indium lung disease.
2014 Lower Expression of Nrf2 Promotes Proliferation, Migration
and Invasion of Prostate Cancer Cells.
R. Khatri and A. K. Jaiswal. Pharmacology and Experimental Therapeutics,
University of Maryland Baltimore, Baltimore, MD.
The nuclear factor Nrf2 is known to play a critical role in cellular protection against
oxidative stress and cellular transformation. However, unabated nuclear accumula-
tion of Nrf2 is also known to reduce apoptosis, promote cancer cell survival and
drug resistance. Mutations in INrf2 and Nrf2 leading to nuclear accumulation of
Nrf2 in many cancers including prostate and breast cancer are known. These also
raise interesting questions regarding the role of Nrf2 in cancer metastasis and/or
metastasis progression that remains elusive. In this study we have investigated the
hypothesis that loss of Nrf2 is associated with metastasis/metastasis progression. We
used less metastatic LNCaP and highly metastatic LNCaP derived C4-B2 prostate
cancer cell lines to test our hypothesis. The analysis revealed that highly metastatic
C4-B2 cells expressed higher INrf2 and lower Nrf2 levels as compared to less
metastatic LNCaP cells. We used control, INrf2 and Nrf2 shRNA to generate C4-
B2 and LNCaP derived cells with altered levels of INrf2 and Nrf2 to determine the
role of Nrf2 in metastasis and metastasis progression in Soft agar colony formation
and X-CELLigence proliferation, migration and invasion assays. C4-B2-
INrf2shRNA cells expressing inhibited levels of INrf2 and higher levels of Nrf2
showed fewer colonies in soft agar and proliferated faster but did not migrate as
compared to C4-B2-Control shRNA cells. Similarly, LNCaP-Nrf2shRNA cells ex-
pressing inhibited levels of Nrf2 in less metastatic LNCaP cells demonstrated sig-
nificantly higher number of colonies in soft agar, proliferated faster and showed
greater migration and invasion as compared to LNCaP-Control shRNA cells. These
results together suggest that lower Nrf2 levels are associated with higher prolifera-
tion, migration and invasion or metastatic progression. Currently, we are investigat-
ing the mechanism of the role of Nrf2 in metastasis progression and plan in vivo ex-
periments to test our hypothesis of the association of lower Nrf2 with metastasis
progression in mice.
2015 Mechanisms of Oxidative Stress Promoted by 1, 4-Diamino-
2-Butanone in Trypanosoma cruzi and Mammalian Cells.
E. J. Bechara1, 2,  C. O. Soares2,  W. Colli2 and M. M. Alves2. 1Ciências Exatas e da
Terra, Universidade Federal de São Paulo, Diadema, Brazil; 2Bioquímica,
Universidade de São Paulo, São Paulo, Brazil.
The putrescine analogue 1,4-diamino-2-butanone (DAB) is highly toxic to patho-
genic microorganisms, including various fungi and Trypanosoma cruzi. Similar to
other α-aminocarbonyl metabolites such as aminoacetone and 5-aminolevulinic
acid, DAB exhibits pro-oxidant properties. DAB reportedly undergoes metal-cat-
alyzed oxidation in aerobic medium yielding H2O2, NH4+ ion, and 4-amino-2-
oxobutanal, a highly toxic α-oxoaldehyde. Administered to mammaliian cell cul-
tures, DAB decreases the cell viability which was shown to be associated with
changes in redox balance. Thus, treatment of RKO cells derived from human colon
carcinoma or cultured LL-MK2 Rhesus epithelial cells with millimolar DAB caused
significant decline in cell viability, which was inhibited by pre-addition of catalase,
aminoguanidine (an α-oxoaldehyde trap), N-acetyl cysteine or reduced glu-
tathione. Now we explore the mechanisms by which DAB exhibits pro-oxidant ef-
fects on trypomastigotes and on intracellular T. cruzi amastigotes. DAB (0.05-5.0
mM) exposure in trypomastigotes, the infective stage of T. cruzi, leads to a decline
in parasite viability (IC50 c.a. 0.2 mM DAB; 4 h incubation), changes in morphol-
ogy, thiol redox imbalance, and increased TcSOD activity. Medium supplementa-
tion with catalase (2.5 μM) protects trypomastigotes against DAB toxicity, while
host cell invasion by trypomastigotes is hampered by DAB. Additionally, intracellu-
lar amastigotes are susceptible to DAB toxicity. Furthermore, pre-treatment with
100-500 μM buthionine sulfoximine (BSO) of LLC-MK2 potentiates DAB cyto-
toxicity, whereas 5 mM N-acetyl-cysteine (NAC) protects cells from oxidative
stress. Together, these data support the hypothesis that redox imbalance, not only
the long reported DAB-promoted inhibition of polyamine metabolism, contributes
to its cytotoxicity in both T. cruzi and mammalian host cells.
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2016 Receptor-Mediated Reactive Oxygen Species Contribute to
Impaired Coronary Vasodilation following Acute Ozone
Exposure in Rat.
M. Paffett1,  S. Robertson1,  S. Lucas1,  T. Anderson2,  M. Nysus2,  J. Norenberg2
and M. J. Campen1. 1Pharmaceutical Sciences, University of New Mexico,
Albuquerque, NM; 2Radiopharmaceutical Sciences, University of New Mexico,
Albuquerque, NM.
Ozone (O3) exposure in both humans and rodents leads to elevations in alveolar
and peripheral inflammation, believed to promote endothelial dysfunction.
Although pulmonary inflammation is a well-defined response to inhaled O3, little
is known regarding acute effects of O3 exposure on the mechanisms responsible for
impaired coronary vasodilation. We hypothesized that a single, whole-body O3 ex-
posure will induce pulmonary inflammation and the transference of pulmonary in-
flammatory elements will contribute to reactive oxygen species (ROS)-induced en-
dothelial dysfunction. We tested this hypothesis by assessing pulmonary immune
infiltrates from bronchial alveolar fluid lavage (BALF), circulating WBCs and coro-
nary artery endothelial function 24 hrs following O3 exposure (4h at 1ppm) or fil-
tered air (FA). BALF total protein, cell number, macrophage/neutrophil counts and
circulating WBC differentials were assessed. Furthermore, experiments assessing
the effects of O3 on the endothelial-dependent vasodilator, acetylcholine (ACh), in
coronary arteries pre-constricted (~50%) with a thromboxane mimetic (U46619)
in the presence or absence of luminal administration of the superoxide dismutase
mimetic (PEG-SOD). Parallel experiments were performed where rodents were in-
jected (i.p.) with inhibitory antibodies directed against lectin-like oxidized low den-
sity lipoprotein receptor-1 (LOX-1). Our results demonstrate significant increases
in BALF total protein and cell number were evident in O3 exposed rats, specifically
neutrophils, compared to FA controls. Systemic increases in circulating neutrophils
were also evident following O3 exposure. Moreover, ACh-mediated vasodilation
was restored in vessels loaded with PEG-SOD and partially restored in rodents pre-
treated with the LOX-1 inhibitor. Our data suggest that that O3-induced pul-
monary inflammation contributes to increased ROS-mediated endothelial dysfunc-
tion downstream of LOX-1.
2017 In Vitro Modification of Plasminogen by Methylglyoxal
Disrupts Normal Zymogen Activation.
O. R. Kinsky,  M. J. Kimzey,  T. J. Monks and S. S. Lau. Southwest
Environmental Health Sciences Center, Department of Pharm/Tox, College of
Pharmacy, University of Arizona, Tucson, AZ.
Reactive dicarbonyls such as methylglyoxal (MG) are present in blood and react
with arginines (R) of target proteins, leading to diabetic micro- and macrovascular
complications. Normal MG plasma concentrations are estimated to reach 4.5 μM,
with these values tripling as diabetic complications progress. Dicarbonyls irre-
versibly modify R residues, resulting in a net loss of positive charge via hydroimida-
zolone formation. Previous shotgun LC/LC-MS/MS proteomics analysis of human
serum reacted with MG (18 hrs at 37°C) indicated that plasminogen (PLG) was
readily modified at multiple sites. Subsequent studies in our laboratory determined
that modification at R561 of PLG resulted in drastic energy-of-interaction changes
between PLG and tissue plasminogen activator (tPA). The model revealed that a
MG-adduct formed at R561 decreased the interaction energy by up to 410.4
kcal/mol, 164-fold higher than the minimum energy change necessary for an al-
tered interaction. Modified R561 in PLG is of particular biological interest because
of its role in the thrombolytic cascade, R561 being the site of cleavage from PLG to
plasmin. In an effort to determine functional consequences of this adduction, MG-
modified PLG and its activation by both exogenous and endogenous activators was
studied. The activation of MG-modified PLG by streptokinase (STK) was altered
in both a time (0-60 min) and concentration (1-500 μM MG) dependent manner.
Unmodified PLG (90-100 kDa) was cleaved by STK, with the concurrent forma-
tion of angiostatin (ANG; 38 kDa) and plasmin light chain (PLC; 25 kDa). In con-
trast, such effects were diminished in MG-modified PLG, with reduced accumula-
tion of ANG and PLC, and reduction in the disappearance of PLG. Similar studies
are underway with tPA and urokinase. The findings indicate that MG-modification
of PLG may disrupt the thrombolytic cascade thereby contributing to vascular
complications associated with diabetes. (R24DK083948, ABRC, ES016652,
T32ES007091, P30ES006694).
2018 Oxidative Stress-Dependent Destruction of Cdc25C As a
Novel Chemotherapeutic Strategy for the Targeted Induction
of Cell Cycle Arrest.
S. Qiao1, 2 and G. T. Wondrak1, 2. 1Pharmacology and Toxicology, University of
Arizona, Tucson, AZ; 2Arizona Cancer Center, University of Arizona, Tucson, AZ.
Sponsor: W. Klimecki.
Cellular oxidative stress is an established causative factor in carcinogenesis. Recent
research suggests that elevated oxidative stress in cancer cells represents a pheno-
typic vulnerability that can be targeted by redox intervention. Multiple myeloma is
a redox sensitive hematological malignancy characterized by dysregulation of cell
cycle progression and checkpoint control. Guided by a phenotypic drug screen for
novel leads that display antiproliferative activity through induction of oxidative
stress, we have identified the FDA-approved antimicrobial thiostrepton (T) as mul-
tiple myeloma-directed experimental chemotherapeutic. In RPMI-8226 multiple
myeloma cells, major hallmarks of hyperproliferation including hyperphosphoryla-
tion of retinoblastoma (pRb; Ser 780, Ser807/811) and overexpression of c-myc
and cyclin D1 were fully suppressed at both mRNA and protein levels at submicro-
molar concentrations of T. Moreover, T-induced G2/M cell cycle arrest was charac-
terized by inhibitory phosphorylation of cyclin-dependent kinase 1 (CDK1;
Tyr15), dephosphorylation of histone H3 (Ser10), and cyclin B1 accumulation as
revealed by immunodetection. Flow cytometric analysis indicated rapid induction
of cytotoxic oxidative stress followed by destruction of the redox-sensitive onco-
genic phosphatase cdc25C (cell division cycle 25C), known to abrogate the G2/M
checkpoint by activational dephosphorylation of cyclin B-CDK1 (Tyr15).
Strikingly, hydrogen peroxide treatment mimicked T-induced destruction of
cdc25C. Vice versa, antioxidant pretreatment (N-acetyl-L-cysteine) prevented
cdc25C depletion, inhibitory phosphorylation of CDK1, and enrichment of the
G2/M fraction, further substantiating the causative role of ROS in T-induced cell
cycle arrest. Taken together, these data suggest feasibility of T-based prooxidant in-
tervention targeting the oncogenic redox-sensitive G2/M regulator cdc25C and its
downstream effectors for experimental chemotherapy of multiple myeloma.
2019 Selective Detoxification of Hypothiocyanite by Mammalian
Thioredoxin Reductase, the Missing Link in Lung Innate
Immunity and Antioxidant Defense.
J. D. Chandler1, 2,  R. J. Hondal3 and B. J. Day1, 2. 1Pharmaceutical Sciences,
University of Colorado Denver, Denver, CO; 2Medicine, National Jewish Health,
Denver, CO; 3Biochemistry, University of Vermont, Burlington, VT.
Haloperoxidases metabolize thiocyanate (SCN) in the presence of hydrogen perox-
ide (H2O2) producing the thiol-selective oxidant hypothiocyanite (OSCN).
OSCN has been implicated in innate immunity through its ability to inhibit the
growth of multiple pathogens. Paradoxically, SCN has been shown to protect cells
from promiscuous oxidizing species such as hypochlorite (OCl) by a direct reaction
forming OSCN, suggesting its selective detoxification by mammalian cells.
Mammalian thioredoxin reductase (TR) is distinguished from lower order TRs by
its C-terminal selenocysteine (Sec) redox couple and broader substrate specificity.
Recombinant rat TR1, recombinant mouse TR2 and purified rat TR metabolized
OSCN with high affinity but do not metabolize OCl. Mutant forms of mouse TR2
lacking Sec had significantly higher Km for OSCN. Recombinant E. coli TR did
not metabolize OSCN or OCl. Lysates from human lung epithelial cells (16HBE)
readily metabolized OSCN but lysates from E. coli and P. aeruginosa were inactive.
Auranofin, a TR inhibitor, decreased OSCN metabolism in 16HBE lysates.
16HBE cells and P. aeruginosa were exposed to an oxidase-peroxidase coupled sys-
tem that generated a 100 μM steady state exposure of OSCN or OCl for 2 hours.
OCl was highly toxic to both 16HBE and P. aeruginosa, but OSCN was only toxic
to P. aeruginosa. Inhibition of mammalian TR with auranofin increased OSCN
toxicity in 16HBE cells. These findings implicate mammalian TR as the major
detoxification pathway for OSCN and suggest a novel mechanism of innate immu-
nity and antioxidant defense in mammals wherein OSCN formation simultane-
ously results in pathogen inhibition while preventing damage to host tissue. This
study was funded by NIH Grant HL084469 and a Cystic Fibrosis Foundation
Research Grant.
2020 GRP78 Contributes to the Selective Cytoprotection Afforded
by All-Trans-Retinoic Acid against Renal Injury.
J. Sapiro,  A. C. Gallegos,  I. Y. Rojas,  A. B. Romans,  R. D. Canatsey,
T. J. Monks and S. S. Lau. SWEHSC, Pharm/Toxicol, University of Arizona, Tucson,
AZ.
Chemical-induced nephrotoxicity is a major cause of acute kidney injury.
Pretreatment of LLC-PK1 cells with all-trans-retinoic acid (ATRA) affords cytopro-
tection against chemical nephrotoxicants. ATRA pretreatment (25 μM, 24 hrs)
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protected against p-aminophenol (PAP, 150 μM, 3 hr), iodoacetamide (25 μM, 2
hr), and H2O2 (250 μM, 3 hr)-induced cytotoxicity as assessed by the MTS assay.
Moreover, ATRA suppressed tumor necrosis factor-alpha (TNF-α, 30 ng/mL, 2
hr)-induced caspase-3 cleavage by 4-fold, indicative of a reduction in apoptosis. In
contrast, pretreatment of cells with ATRA had no effect on cisplatin (25 μM, 24
hr)-induced caspase-3 cleavage. The data reveal that ATRA selectively protects
against toxicants that induce necrotic and death receptor-mediated (extrinsic)
apoptotic cell death but not against mitochondrial-mediated (intrinsic) apoptotic
cell death. Although the molecular mechanism(s) underlying the cytoprotective ef-
fects of ATRA remain unclear, the endoplasmic reticulum (ER) molecular chaper-
one Grp78 is a pivotal contributor to the cytoprotective/adaptive response to cell
stress. Therefore, we subsequently used Grp78 non-inducible cells to explore the re-
lationship between the ER stress response and ATRA signaling. LLC-PK1 cells, in
which the induction of grp78 expression was disrupted via stable expression of an
antisense grp78 RNA (pKASgrp78), were more sensitive to the cytotoxic effects of
PAP relative to control cells transfected with an empty vector (PKNEO).
Furthermore, although ATRA itself induced Grp78 in naïve LLC-PK1 and
PKNEO cells, it was unable to do so in the pKASgrp78 cells. Thus, Grp78 may
contribute to ATRA-mediated cytoprotection and ATRA may provide an effective
therapeutic intervention for chemical-induced renal injury or other pathological
conditions. (ES006694, ES016578).
2021 Sulfur Dioxide Modulates Oxidative Stress Responses in IL-
10-Deficient Mice with Airway Inflammation.
A. L. Reno1,  L. M. Hallberg2,  W. C. Spear1,  J. L. Parks1,  A. P. Chaparro3,
E. G. Brooks3 and B. T. Ameredes1. 1Internal Medicine, University of Texas Medical
Branch, Galveston, TX; 2Preventive Medicine and Community Health, University of
Texas Medical Branch, Galveston, TX; 3Pediatrics, University of Texas Health Science
Center, San Antonio, TX.
RATIONALE: Inhaled sulfur dioxide (SO2) at low concentrations (1-5 ppm) can
produce bronchospasm in asthmatics, linked to increased oxidative stress and air-
way inflammation (AI), potentially due to a deficiency in IL-10 production. We
tested this hypothesis in IL-10-sufficient C57Bl6 (C57), and IL-10 knockout (-/-)
mice, with experimentally-induced AI.
METHODS: AI was induced by sensitization and challenge with ovalbumin
(OVA, O/O), with and without inhaled SO2 (1 ppm for 6 hr/day over 10 days).
Bronchoalveolar lavage fluid (BALF) was analyzed for leukocyte counts; a pro-oxi-
dant/anti-oxidant balance (PAB) assay provided an index of oxidative stress, and in-
terleukin-4 (IL-4) levels in lung homogenates were measured by ELISA, as an indi-
cator of AI. Nitrite levels were measured in BALF by Griess assay, as an index of
iNOS activity.
RESULTS: Respective mean eosinophil counts (x 10^3/g mouse) for C57 and IL-
10-/- mice (P<0.05) were: O/O-SO2 (3.1 vs. 1.4; n.s.), and O/O+SO2 (3.0 vs. 4.3;
n.s.), indicating eosinophilia in mice with mild AI alone, and those that inhaled
SO2, as compared to saline-challenged controls having no eosinophils. SO2 shifted
the PAB toward pro-oxidative in C57 mice with AI, whereas the opposite was
found for their IL-10-/- counterparts (P<0.05). IL-4 levels in the O/O+SO2 C57
mice were significantly increased compared to their IL-10-/- counterparts. BALF
nitrite levels (μM/kg body weight) were decreased in the C57 O/O+SO2 group
(61±5; n.s.) as compared to O/O-SO2 (86±15). A similar trend was seen for the
IL-10-/- mice (62±7 vs. 80±10; n.s.).
CONCLUSIONS: The results indicate there is a robust inflammatory response in
the lungs of mice exposed to OVA allergen attenuated by SO2 inhalation, perhaps
via an anti-oxidant promotion mechanism.
2022 Statin-Induced Cytotoxicity in C2C12 Myoblasts Is
Accompanied by Mitochondrial Dysfunction and Excessive
ROS Production.
T. Schirris1, 3,  J. J. Nabers1, 3,  J. D. Beyrath2, 3,  J. A. Smeitink2, 3 and
F. G. Russel1, 3. 1Pharmacology and Toxicology, Radboud University Nijmegen
Medical Centre, Nijmegen, Netherlands; 2Pediatrics, Radboud University Nijmegen
Medical Centre, Nijmegen, Netherlands; 3Centre for Systems Biology and
Bioenergetics, Nijmegen, Netherlands.
Statins are widely used cholesterol-lowering drugs that are generally well-tolerated.
The most important adverse effects are muscle pain and inflammation of muscle
cells. The mechanism is not fully understood, although for some statins a direct ef-
fect on mitochondrial function has been found. Here, we systematically studied the
effect of a series of sixteen different statin drugs on mitochondrial function and cy-
totoxicity in a mouse myoblast cell line (C2C12). A high-content method was de-
veloped to measure the viability and ROS production of C2C12 cells using a 384-
well microscopy assay. Furthermore, mitochondrial function was assessed using
high-resolution oxygen consumption measurements in comparison with maximal
ATP production rates. Nine of the sixteen statins studied induced cell death after
24h, including cerivastatin, simvastatin, atorvastatin and rosuvastatin, which are
most frequently associated with clinical cases of myopathy. Of these nine statins, ro-
suvastatin lactone had the highest potency (IC50 22±10 μM) and atorvastatin the
lowest (IC50 182±36μM). After 8h treatment at IC50 concentrations, all nine
statins showed increased ROS levels; itavastatin lactone gave the largest increase of
4300±36AU compared to control (585±99AU, P< 0.001). Moreover, these nine
statins reduced the ATP production, most potently by cerivastatin lactone (16±8%
of control, P<0.05). These results were further confirmed by a reduced malate-, glu-
tamate-, and succinate-driven oxygen consumption by all nine statins. In conclu-
sion, a series of clinically relevant statins affected mitochondrial function and via-
bility of C2C12 myoblasts with different potencies. Further research is needed to
investigate the link between the observed mitochondrial dysfunction and the in-
flammatory and the apoptotic hallmarks of statin-induced myopathies.
2023 Screening and Characterization of Aldehydes on the Basis of
Protein Carbonylation.
H. Dhot1, 2 and P. J. O’Brien2. 1Institute of Environmental Medicine, Karolinska
Institutet, Stockholm, Sweden; 2Faculty of Pharmacy, University of Toronto, Toronto,
ON, Canada.
Proteins are easily susceptible to Post Translational Modifications (PMT) where
protein carbonylation is the most common type that plays a pivotal role in etiology
and/or progression of lethal diseases like neurodegenerative diseases, cancers, aging,
diabetes and sepsis. Since, ROS and secondary by products of oxidative stress can
induce the protein carbonylation and this type of protein oxidation is regarded as a
well-known biomarker of oxidative stress with different susceptibility for different
amino acids. In this study, we studied the protein carbonylation caused by different
aliphatic (formaldehyde to decanal i.e. aldehydes from carbon 1 to carbon 10) and
aromatic (benzaldehyde and its derivatives) aldehydes by applying BSA Protein car-
bonylation assay. Taking into account the ED 50 values of the aliphatic aldehydes,
2mM and 4mM concentrations of aldehydes were used. Among aliphatic aldehy-
des, only first two aldehydes (HCHO and CH3CHO) showed the highest protein
carbonylation in a dose dependent manner. On the other hand, aromatic aldehydes
showed the following trend: 4Chlorobenzaldehydes (max at 120 mins) >
Cinnamaldehyde (max at 120 mins) >benzaldehyde (max at 120 mins) >p-
Tolualdehyde (max at 60 mins) >m-Tolualdehyde (max at 40 mins). GSH was
found effective against protein carbonylation. Protein carbonylation increased with
increase in dose except in case of cinnamaldehyde and benzaldehyde where high
dose decreased the carbonylation. So, our result suggests that aliphatic aldehydes
can be characterized as less reactive towards protein carbonylation reaction than
aromatic aldehydes. Among aromatic aldehydes, cinnamaldehyde and 4-chloroben-
zaldehyde can be regarded as fast reacting aldehydes, m-tol and p-tol as slowly re-
acting with or without lag phase respectively, ortho substituted aldehydes as causing
no protein carbonylation.
2024 Autophagy Is Protective against CYP2E1-Dependent
Arachidonic Acid, Buthionine-Sulfoximine, and Carbon
Tetrachloride Cytotoxicity in E47 HepG2 Cells through
Preventing Mitochondrial Dysfunction.
D. Wu and A. I. Cederbaum. Pharmacology & Systems Therapeutics, Mount Sinai
School of Medicine, New York, NY. Sponsor: Y. Lu.
The goal of this study was to evaluate if autophagy promotes or is protective against
CYP2E1 toxicity. E47 HepG2 cells express CYP2E1 and control C34 cells which
do not express CYP2E1 were treated with arachidonic acid (AA), or buthionine-
sulfoximine (BSO), or carbon tetrachloride (CCl4), in the presence or absence of 3-
methyladenine (3MA) or rapamycin. All three compounds reduced cell viability in
E47 cells but not in C34 cells. 3MA further reduced cell viability while rapamycin
increased it. These results suggested that autophagy prevented against AA, BSO and
CCl4 cytotoxicity in E47 cells. These compounds induced oxidative stress in E47
cells as TBARS increased and GSH decreased. 3MA enhanced TBARS and de-
creased GSH while rapamycin prevented these changes. Flow cytometry suggested
that these compounds mainly induced necrosis and 3MA enhanced necrosis but
not apoptosis; rapamycin prevented the necrosis. These compounds induced mito-
chondrial membrane swelling, cytochrome c release, reducing mitochondrial ATP
production, 3MA enhanced but rapamycin prevented these changes.
Mitochondrial ROS protection was enhanced by rapamycin but decreased by 3MA.
E47 cells were transfected with Atg7 siRNA which enhanced AA cytotoxicity, in-
creased oxidative stress. The decline in viability was restored and oxidative stress
was blocked in the presence of rapamycin. The antioxidant N-acetyl-L-cysteine pre-
vented the AA or Atg 7 siRNA-induced oxidant stress and loss of E47 cell viability
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and the potentiation of these effects by 3MA.  Treating the E47 cells with AA in-
duced p38 MAPK, 3MA enhanced the activation and rapamycin inhibited it. This
study shows that autophagy is protective against AA, BSO and CCl4 induced
CYP2E1 dependent cytotoxicity. This protection may be due at least in part
through prevention of mitochondrial dysfunction to maintain cell survival.
2025 Absence of Upstream Consensus Regulatory Element
Sequences for Nrf2 in Human Glutathione S-Transferase
Genes.
C. M. Schaupp1,  T. K. Bammler2,  R. P. Byer2,  T. J. Kavanagh1, 2 and
D. L. Eaton1, 2. 1Environmental and Occupational Health Sciences, University of
Washington, Seattle, WA; 2Center for Ecogenetics & Environmental Health, University
of Washington, Seattle, WA.
Nuclear factor erythroid-derived 2-like 2 (NFE2L2, or NRF2) is involved in an-
tioxidant response to cellular stress. In response to oxidative or electrophilic stimuli,
NRF2 binds its target genes containing an antioxidant response element (ARE),
upregulating expression of detoxifying/antioxidant enzymes. Numerous studies
have demonstrated that some rodent liver GSTs are highly inducible via activation
of the Keap1/Nrf2/ARE antioxidant response pathway by prototypical Nrf2 activa-
tors such as BHA, sulforaphane and oltipraz. Thus, these chemicals may have ther-
apeutic value based on their putative ability to activate NRF2-mediated antioxidant
pathways. However, human studies in vitro and in vivo have not generally seen a
robust induction of GSTs following administration of Nrf2 activators, suggesting
that human liver GSTs are less responsive to ARE-mediated induction. To identify
the potential basis for a possible inter-species difference in GST inducibility, we
used the web-based oPOSSUM software to identify ARE sequences up to 10,000
base pairs upstream of the transcriptional start sites of antioxidant enzymes puta-
tively regulated by NRF2 in murine and human genomes. Only three out of 19
human GST genes (GSTM2, GSTO2, and GSTZ1) contained an ARE consensus
sequence within 10kb of the transcriptional start site, whereas ARE sequences were
present in 11 of 17 murine GSTs analyzed. Notably, none of the common, highly
expressed human alpha or mu class GSTs contained consensus NRF2 elements,
whereas 2 of 4 alpha class, and 5 of 7 mu class, mouse GSTs contained one or more
Nrf2 response elements. Our data suggest that inter-species differences in GST in-
ducibility may result from differences in the presence and location of ARE consen-
sus sequences upstream of murine and human GST genes—a conclusion which
may have major implications in the clinical setting.
2026 Pharmacological Inhibition of Thioredoxin Reductase I
Attenuates Hyperoxic Lung Injury by Augmenting
Glutathione Synthesis.
L. K. Rogers1, 3,  R. D. Britt1,  T. E. Tipple1, 3 and M. Velten1, 2. 1Center for
Perinatal Research, The Research Institute at Nationwide Children’s Hospital,
Columbus, OH; 2Anesthesiology and Intensive Care, Rheinische Friedrich-Wilhlems
University, Bonn, Germany; 3Pediatrics, The Ohio State University, Columbus, OH.
Inflammation and oxygen toxicity increase free radical production and contribute
to the development of acute respiratory distress syndrome (ARDS). We have previ-
ously shown increased glutathione (GSH) levels in lung epithelial cells in vitro and
attenuated adult murine hyperoxic lung injury in vivo following thioredoxin reduc-
tase-1 (TrxR1) inhibition with auranofin and aurothioglucose (ATG), respectively.
The present studies tested the hypothesis that ATG treatment increases pulmonary
GSH levels, decreases lung injury, and improves survival. Adult male mice were
given a single IT dose of 0 or 0.375 μg/g E. coli LPS. After12 h, an injection of 0
or 25 mg/kg ATG or a combination of ATG and 800 mg/kg buthionine sulfox-
imine (BSO) were administered, i.p. Mice were then exposed to room air (RA) or
>95% hyperoxia (O2). After 3 d exposure, bronchoalveolar lavage (BAL) and lung
tissues were collected. BAL protein concentrations were significantly greater in
LPS/O2-exposed mice when compared to PBS/RA controls. In LPS/O2-exposed
mice, ATG treatment significantly decreased BAL protein concentrations, increased
lung GCLM expression, GSH levels, and GSH/GSSG ratios, and improved sur-
vival compared to PBS-treated LPS/O2-exposed mice. BSO treatment dramatically
decreased the survival of ATG-treated LPS/O2-exposed mice. In summary, ATG
enhances GSH levels, decreases lung injury, and improves survival in a GSH-de-
pendent manner in a murine model of ARDS. If enhancement of pulmonary GSH
levels can be accomplished via drug-mediated TrxR1 inhibition, which seems to be
without detrimental effects, this approach could constitute a novel strategy to im-
prove outcomes in patients with oxidant-mediated lung injury. This work was sup-
ported by the National Institutes of Health (RDB F31HL097619, TET
K08HL093365, and LKR R01AT006880).
2027 Aniline Up-Regulates Cyclins via Induction of Oxidative
Stress in Rat Spleen.
J. Wang,  G. Wang,  H. Ma and M. Khan. University of Texas Medical Branch,
Galveston, TX.
Aniline exposure is associated with toxicity to the spleen leading to splenomegaly,
fibrosis and a variety of sarcomas of the spleen. In earlier studies, we have shown
that aniline exposure leads to iron overload, oxidative and nitrosative stress and ac-
tivation of redox-sensitive transcription factors, which could regulate various genes
leading to a tumorigenic response in the spleen. However, molecular mechanisms
leading to aniline-induced cellular proliferation in the spleen remain largely un-
known. This study was undertaken to further assess the role of oxidative and ni-
trosative stress in the regulation of cell cycle proteins (cyclins) following aniline ex-
posure. Groups of male SD rats were treated with aniline (1 mmol/kg/day by
gavage), aniline plus N-acetylcysteine (NAC, an antioxidant, 300 mg/kg/day, i.p.),
aniline plus aminoguanidine (AG, an iNOS inhibitor, 200 mg/kg/day, i.p.) or ani-
line plus zinc protoporphyrin (ZP, a heme oxygenase inhibitor, 50 μmol/kg/day,
i.p.) for 7 days (controls received drinking water only), and mRNA expression of
cyclins A, B, D3 and E were measured in spleen. Aniline treatment resulted in sig-
nificant increases in the expression of cyclin A (7.9-fold), cyclin B (7.3-fold), cyclin
D3 (3.7-fold) and cyclin E (5.4-fold) as compared to the controls. Interestingly, all
of the three inhibitors significantly reduced the aniline-induced overexpression of
cyclins. Specifically, NAC reduced the expression of cyclins A, B, D3 and E by
61%, 48%, 38%, and 41%, AG reduced cyclins A, B, D3 and E by 60%, 63.0%,
51%, and 37%, whereas ZP reduced cyclins A, B, D3 and E by 30%, 61%, 62%,
and 44%, compared to aniline only treated rats, respectively. Our data suggest that
oxidative and nitrosative stress play a role in aniline-induced overexpression of cy-
clins which could be critical in cell proliferation, and may contribute to aniline-in-
duced tumorigenic response in the spleen. Supported by NIH ES06476.
2028 Understanding the Role of UCP2 in Fatty Acid Beta-
Oxidation and Drug-Induced Liver Injury.
J. E. Montanez1,  P. B. Smith2 and A. D. Patterson1, 2. 1Veterinary and Biomedical
Science, The Pennsylvania State University, University Park, PA; 2Center for
Molecular Toxicology and Carcinogenesis, The Pennsylvania State University,
University Park, PA.
UCP2, originally described as a mitochondrial uncoupling protein, has been re-
ported to serve many other functions including regulation of glucose and lipid me-
tabolism as well as regulation of ROS in cancerous cells. We recently reported that
under hepatotoxic conditions such as that induced by acetaminophen, UCP2 ex-
pression was found to protect against liver damage in a PPARα-dependent fashion.
Interestingly, polymorphisms in the coding sequence of the UCP2 gene have been
found to be associated with obese and/or diabetic individuals further implicating
UCP2 in the fatty acid beta-oxidation pathway. However, the precise mechanism
by which UCP2 exerts these salubrious effects is unknown. In this study, the meta-
bolic functions of UCP2 and UCP2 (A55V) variant were compared using a gas
chromatography coupled with mass spectrometry-based metabolomics approach.
COS-7 cells were transfected with myc/flag-tagged UCP2 and UCP2 (A55V).
After confirming expression of the constructs via Western blotting (no difference
was observed between UCP2 and UCP2 (A55V)), the cells were extracted, metabo-
lites derivatized using methoxamine and MSTFA, and the samples ran on an
Agilent 5975C Series GC/MSD. Principal component analysis of the data show
distinct separation of the UCP2 transfected cells from the control and UCP2
(A55V) transfected cells. Among others, palmitic acid was found to be dramatically
decreased (~ 2.3 fold) in the UCP2-transfected cells compared to control and
UCP2 (A55V) transfected cells. Further, palmitic acid is thought to induce UCP2
expression through PPARα activation. This study illustrates the utility of the
metabolomics approach for elucidating and/or clarifying the metabolic function of
UCP2.
2029 Real-Time Monitoring of Xenobiotic-Induced Intracellular
Redox Changes Using Ozone As a Model Oxidant.
E. A. Gibbs-Flournoy1,  S. O. Simmons2,  P. A. Bromberg3 and J. M. Samet4.
1Curriculum in Toxicology, University of North Carolina at Chapel Hill, Chapel Hill,
NC; 2ISTD/NHEERL, US EPA, Research Triangle Park, NC; 3Center for
Environmental Medicine, Asthma, and Lung Biology, University of North Carolina at
Chapel Hill, Chapel Hill, NC; 4EPHD/NHEERL, US EPA, Chapel Hill, NC.
Oxidative injury is often cited as a key feature in the toxic action of many xenobi-
otics; however, unambiguous indices of xenobiotic-induced oxidative stress have
proven elusive. A new generation of sensors capable of reporting intracellular redox
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status has shown much promise. However, their use in toxicological assessments in-
volving strong electrophiles remains to be validated. Exposure to ozone (O3), a
highly reactive oxidant gas, induces pulmonary function decrements and inflam-
matory responses in the airways through oxidative mechanisms. An important un-
resolved toxicological question concerns the effect of O3 exposure on intracellular
redox status. Using live-cell microscopy, we addressed this issue directly with the
novel application of roGFP2, a genetically-encoded fluorescent reporter of the in-
tracellular glutathione redox potential, EGSH. BEAS-2B human bronchial epithelial
cells transduced to stably express cytosolic roGFP2 were exposed to concentrations
of O3 ranging from 0.15 - 1.0 ppm. Cells were imaged in real-time during O3 ex-
posure in a custom-built stage-top exposure chamber. O3 exposure induced a dose-
and time- dependent increase of the cytosolic EGSH. Modulation of glutathione sys-
tem components confirmed that roGFP2 is not directly oxidized but properly equi-
librates with the oxidation status of the glutathione pool. Exposure to O3 induces a
substantial increase in EGSH in BEAS-2B cells that is indicative of an oxidant-de-
pendent impairment of redox homeostasis. Moreover, this study demonstrates the
utility of using redox reporters in making reliable assessments of cells undergoing
exposure to xenobiotics with potent oxidizing properties. THIS ABSTRACT OF A
PROPOSED PRESENTATION DOES NOT NECESSARILY REFLECT EPA
POLICY.
2030 Formation 4-Hydroxynonenal, an Electrophilic Lipid
Peroxidation End Product, in Rabbit Corneal Organ
Cultures Treated with Nitrogen Mustard.
A. T. Black1,  R. Zheng1,  I. Po1,  D. E. Heck2,  D. L. Laskin1,  D. R. Gerecke1,
M. K. Gordon1 and J. D. Laskin3. 1Pharmacology & Toxicology, Rutgers University,
Piscataway, NJ; 2Environmental Science, New York Medical College, Valhalla, NY;
3Environmental & Occupational Medicine, UMDNJ-Robert Wood Johnson Medical
School, Piscataway, NJ.
Sulfur mustard (SM, bis (2-chloroethyl) sulfide) and nitrogen mustard (NM,
mechlorethamine) are cytotoxic vesicants that can cause ocular injury. The cornea is
particularly sensitive, developing opacity and ulcerations following SM exposure.
In these studies we used an air–liquid interface (air lifted) organ culture model in
which vesicants are applied directly to the central cornea to assess mustard-induced
oxidative stress. Three and six hr post treatment (100 nmol NM in 10 μl PBS), the
corneal epithelial layer was found to express proteins containing the lipid peroxida-
tion product 4-hydroxynonenal (4-HNE). This was associated with expression of
the antioxidant hemeoxygenase-1 (HO-1). To assess molecular mechanisms under-
lying this response, we analyzed the effects of 4-HNE on human corneal epithelial
cells (HCEC) in culture. 4-HNE (0.03 mM) was found to cause a time-dependent
induction of HO-1 mRNA and protein; optimal expression of the enzyme was evi-
dent after 10 hr. HO-1 is known to be regulated by both MAP kinases and phos-
phatidylinositol (PI)-3 kinase (PI3K)/Akt signaling. Treatment of corneal cells with
a p38 MAP kinase inhibitor (SB203580, 10 μM) blocked upregulation of HO-1
protein by 4-HNE. Inhibitors of the MAP kinases Erk1/2 (PD98059, 10μM) and
JNK (SP600125, 20μM), and PI-3K (Wortmannin, 100 nM), partially suppressed
HO-1 expression. These data indicate that NM is an effective inducer of oxidative
stress in corneal epithelial cells, as measured by the formation of 4-HNE protein
adducts. Moreover, induction of HO-1 is regulated by 4-HNE in a process de-
pendent on MAP kinase and PI3K/Akt signaling. Countermeasures that target ox-
idative stress may be effective countermeasures for SM-induced corneal injury.
Supported by NIH grant U54AR055073.
2031 Isoniazid-Induced Cellular Challenge in HL-60 Cells: An In-
Depth Proteomic Perspective.
M. R. Khan1,  A. Baghdasarian1,  R. P. Fahlman2 and A. Siraki1. 1Pharmacy &
Pharmaceutical Sciences, University of Alberta, Edmonton, AB, Canada;
2Biochemistry, University of Alberta, Edmonton, AB, Canada.
INTRODUCTION: Isoniazid (INH) is the first line therapy to combat tuberculo-
sis. However, its use is associated with potent clinical toxicity, particularly liver
damage. However, the rare but important side-effect of INH-induced agranulocy-
tosis is an idiosyncratic drug reaction for which the toxicity mechanism is unclear.
Since INH forms various reactive metabolites, we hypothesized that intracellular
protein modification by INH could reveal a possible mechanism of INH-induced
agranulocytosis. METHODS: HL-60 (promyelocytic leukemia) cells were used for
these studies. Trypan Blue exclusion was performed for cytotoxicity. Immunoblot
assays were conducted by using anti-INH and anti-DMPO antibodies to identify
INH-covalently bound proteins and INH-induced protein radicals, respectively.
Later, these modifications were confirmed by MALDI-TOF MS. For quantitative
proteomics, we performed SILAC (stable isotope labelling by amino acids in cell
culture). RESULTS: 5 mM INH had no significant cytotoxicity after 48 hrs. Anti-
DMPO (protein radicals) showed a prominent protein radical at 50 kDa, however,
multiple INH covalent protein adducts were found by anti-INH immunoblotting.
In SILAC experiments, we found changes in 101 proteins (very high confidence
limits) of which 38 were upregulated and 63 were downregulated. We observed a
significant down regulation of ribosomal proteins, transcriptional factors and splic-
ing factors. But at the same time, factors associated with protein stability were up-
regulated. Pro-apoptotic signals were counterbalanced by anti-apoptotic signals,
and cell growth factors were upregulated. CONCLUSION: Our result showed that
INH is acutely non-toxic to HL-60 cells, and is unlikely to possess direct toxicity to
neutrophils or bone marrow precursors. INH treatment appeared to induce cellular
energy conservation through downregulation of protein synthesis and enhanced
protein stability. Further pathways will be elucidated once INH-induced protein
radicals and covalent adducts are identified.
2032 Attenuation of Experimental Retinopathy of Prematurity by
Vitamin A in the Newborn Rat.
X. Couroucli1,  Y. Liang1,  G. Zhou2,  W. Jiang1 and B. Moorthy1. 1Pediatrics,
Baylor College of Medicine, Houston, TX; 2Institute of Biosciences and Technology,
Texas A&M University Health Science Center, Houston, TX.
Supplemental oxygen administration is frequently encountered in the treatment of
premature infants suffering from respiratory distress. However, hyperoxia con-
tributes to the development of chronic lung disease [bronchopulmonary disease
(BPD)] and retinopathy of prematurity (ROP). In this investigation, we tested the
hypothesis that exposure of newborn rats to vitamin A and hyperoxia would atten-
uate retinopathy and abnormal neovascularization compared to those exposed to
hyperoxia alone. Newborn Fisher 344 rats were maintained in room air or exposed
to hyperoxia ([gt] than 95% O2) for 7 days. Some animals were treated i.p. with vi-
tamin A [2 mg/kg], once daily for the first 5 days of hyperoxic exposures. Animals
were sacrificed at selected time points after termination of hyperoxia. Retinal vascu-
lar densities of flat mounted retinas were assessed. Protein expression of HIF-1α
was determined by Western blotting. Oxidative DNA damage in retinal tissue was
determined by 32P-postlabeling. Immediately after 7 days of exposure to hyperoxia
alone, we observed constricted retinal vessels, compared to those given vitamin A +
hyperoxia. Seven to thirty days after termination of hyperoxia alone, the animals
displayed formation of abnormal retinal vessels and capillaries, compared to the vi-
tamin A + hyperoxia group.  At the 7 day time point, the HIF-1α protein expres-
sion in the hyperoxia + vitamin A group was much higher than the hyperoxia alone
group. On the other hand, at later time points, the HIF-1α protein levels were
higher in the hyperoxia group.  Interestingly, oxidative DNA adducts were signifi-
cantly decreased in the retinas of animals given vitamin A + hyperoxia. Our study
supports the hypothesis that vitamin A protects retina from oxygen-induced abnor-
mal neovascularization, and this is the first report that shows oxidative DNA dam-
age to contribute to experimental ROP.
2033 Systemic Nerve Growth Factor Modulates the Transcription
of Amino Acid Transporters and Glutathione (GSH)
Synthesis in Mice Striatum.
C. Valdovinos-Flores and M. E. Gonsebatt. Universidad Nacional Autonoma de
Mexico, Mexico City, Mexico.
Nerve growth factor (NGF) is a member of structurally related proteins, named
neurotrophins (NTs), that regulate neuronal survival, development, function, and
plasticity. Moreover, NGF is an important activator of antioxidant mechanisms.
These functions of NGF are mediated by the tropomyosin-related kinase receptor
A (TrkA). There is evidence that NTs and their receptors are expressed also in vis-
ceral tissues. Physical exercise and stress increase levels of NGF in plasma. Using a
murine model we have shown that systemic inhibition of GSH synthesis with L-
buthionine-S-R-sulfoximine (BSO) increased brain GSH content and induced the
transcription of ngfb in liver. Murine striatum cholinergic neurons express TrkA re-
ceptors thus, we investigated if an i.p. injection of BSO or of sodium arsenite (iAs)
modulate the transcription of ngfb and trka as well TrkA phosphorilation in mice
striatum. Both agents induced the activation of the NGF/TrkA pathway which cor-
related with an increased transcription of xCT, LAT1, EAAC1 amino acid trans-
porters system genes that provide L-cys / L-cys2 to central nervous system and of
GCLm which participates in the de novo synthesis of GSH. The inhibition of TrkA
phosphorylation by K252a or anti-NGF neutralizing antibody abrogated the BSO
and iAs induced transcription of xCT, LAT1, EAAC1 and GCLm suggesting the
participation of this pathway in the in vivo antioxidant response at least in striatum.
Furthermore, since anti-NGF neutralizing antibodies would not cross the blood-
brain barrier, our results suggest that NGF functions as a systemic redox-sensor in
both CNS and peripheral tissues and that the NGF/TrkA pathway plays a critical
role in the antioxidant response in the striatum in our murine model. 
Supported by CONACYT 102287
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2034 HMGB1 Mediates Hyperoxia-Induced Impairment of
Pseudomonas aeruginosa Clearance and Inflammatory Lung
Injury in Mice.
V. S. Patel1,  R. Sitapara1,  A. Gore1,  B. Phan1,  L. Sharma1,  V. Sampat1,  J. Li2,
H. Yang2,  S. Chavan2,  H. Wang2,  K. Tracey2 and L. Mantell1, 2, 3.
1Pharmaceutical Sciences, Saint John’s University, Fresh Meadows, NY; 2Center for
Inflammation and Immunology, The Feinstein Institute for Medical Research, North
Shore-LIJ Health Science, Manhasset, NY; 3Center for Heart and Lung Research, The
Feinstein Institute for Medical Research, North Shore-LIJ Health Science, Manhasset,
NY.
Mechanical ventilation with supraphysiological concentrations of oxygen (hyper-
oxia) is routinely used to treat patients with respiratory distress. However, a signifi-
cant number of patients on ventilators have enhanced susceptibility to infections
and develop ventilator-associated pneumonia (VAP). Pseudomonas aeruginosa (PA)
are one of the most common bacteria found in these patients. Previously, we
demonstrated that prolonged exposure to hyperoxia can compromise the ability of
alveolar macrophages (AM), an essential part of the innate immunity, to phagocy-
tose PA. The objective of this study was to investigate potential molecular mecha-
nisms underlying hyperoxia-compromised innate immunity against bacterial infec-
tion in a mouse model of PA pneumonia. Here, we show that exposure to hyperoxia
(≥99% O2) led to a significant elevation in levels of airway HMGB1 and an in-
creased mortality in C57BL/6 mice infected with PA. Treatment of these mice with
neutralizing anti-HMGB1 monoclonal antibody (mAb) resulted in a reduction in
bacterial counts, injury, and number of neutrophils in the lung and an increase in
leukocyte phagocytic activity compared to mice receiving control mAb. This im-
proved phagocyte function was associated with reduced levels of airway HMGB1.
The correlation between phagocytic activity and levels of extracellular HMGB1 was
also observed in cultured macrophages. These results indicate a pathogenic role for
HMGB1 in hyperoxia-induced impairment in host ability to clear bacteria and in-
flammatory lung injury. Thus, HMGB1 may provide a novel molecular target for
improving hyperoxia-compromised innate immunity in patients with VAP.
2035 Exposure to Perfluorooctanoic Acid (PFOA) Causes
Oxidative Stress in the Mouse Pancreas.
Q. Wu,  A. A. Bond,  L. M. Kamendulis and B. A. Hocevar. Environmental
Health, Indiana University School of Public Health, Bloomington, IN.
Perfluorooctanoic acid (PFOA), a perfluoroalkyl compound used in the manufac-
ture of many industrial and commercial products, does not readily decompose in
the environment, and is biologically persistent in fish, animals and humans.
Human exposure to PFOA occurs through both environmental and occupational
exposures. Due to the long half-life of PFOA in humans (3.8 yrs), the potential ex-
ists for PFOA exposure to participate in chronic diseases. Chronic PFOA exposure
in rodents induces pancreatic acinar cell tumors (PACTs), and human epidemio-
logic studies also suggest that PFOA exposure may have adverse effects on the pan-
creas. While multiple animal studies have examined PFOA-mediated liver toxicity,
very little is known about the effects of PFOA on pancreatic function. To assess the
role of PFOA on the pancreas, we treated C57Bl/6 mice with vehicle, or PFOA at
doses of 0.5, 2.5 or 5.0 mg/kg BW/day for 28 days. In addition, mice were treated
with cerulein, which induces mild pancreatitis and produces an oxidative stress in
the pancreas. We found significant accumulation of PFOA in the serum, liver and
pancreas of PFOA treated animals, which was associated with induction of oxida-
tive stress, as measured by the lipid peroxidation products malondialdehyde and
F2α-isoprostanes, as well as the oxidatively modified DNA base, 8OHdG. The
serum, liver and pancreatic ratio of reduced to oxidized glutathione decreased with
increased PFOA dose, again indicating the stimulation of oxidative stress in the
liver and pancreas. For both of these responses, the pancreas was more severely af-
fected in comparison to the liver. As a further response to oxidative stress, induction
of anti-oxidant genes was also evaluated. While mitochondrial superoxide dismu-
tase mRNA levels were induced to comparable levels in both liver and pancreas, the
pancreas failed to upregulate either glutathione peroxidase or catalase genes. These
results suggest that the pancreas may be highly susceptible to oxidative damage
elicited by exposure to perfluoroalkyl compounds.
2036 Chronic Over-Expression of Receptor Tyrosine Kinase ErbB2
in the Heart Alters Redox-Sensitive Molecules in the
Mitochondria.
F. Belmonte1, 2,  S. Das3,  V. Sivakumaran3,  P. Sysa Shah2,  C. Steenbergen3 and
K. Gabrielson2. 1Environmental Health Sciences-Molecular and Translational
Toxicology, Johns Hopkins University, Baltimore, MD; 2Molecular and Comparative
Pathology, Johns Hopkins University, Baltimore, MD; 3School of Medicine, Johns
Hopkins University, Baltimore, MD.
Previous studies on cardiac-specific over-expression of epidermal growth factor re-
ceptor 2 (ErbB2) demonstrated that ErbB2 activates protective signaling pathways
(pro-survival) and induces a hypertrophic phenotype that does not progress to heart
failure. To explore this interesting phenomenon, we used the ErbB2 transgenic
murine model to determine whether the observed phenotypes are due to redox-sen-
sitive molecules in the mitochondria that alter mitochondrial function by regulat-
ing reactive oxygen species (ROS) formation. Microarray data that compare the
transgenic mice to wild type mice suggest that ErbB2 alters various oxidative stress
genes. We found that ErbB2 over-expression in the heart upregulates glutathione
reductase (Gsr), glutathione peroxidase 1 (Gpx1), and peroxiredoxin 5 (Prdx5) pro-
teins. We measured ROS production and found that the transgenic mitochondria
produce less ROS than the wild type mitochondria. Total glutathione (GSH) levels
and glutathione peroxidase activity are higher in the transgenic mice compared to
the wild type group. We measured the mitochondrial Ca2+ retention capacity and
found that the transgenic group has less Ca2+ uptake than the wild type group. The
mitochondrial membrane potential (ΔΨ) was measured with the fluorescent dye
tetramethylrhodamine ethyl ester (TMRE) and we found that the transgenic group
has a higher baseline ΔΨ than the wild type group. Our data suggest that ErbB2
over-expression alters redox-sensitive genes that regulate ROS production through
pro-survival and mitochondrial pathways to ultimately prevent heart failure.
2037 The Role of NO and the Glutathione Pathway in
Menadione-Induced Oxidative Stress.
P. Venkatakrishnan,  B. Masters and L. J. Roman. Biochemistry, UTHSCSA, San
Antonio, TX.
Skeletal muscle cells undergo frequent oxidative challenges due to rapid changes in
energy demand, high metabolic activity, and high levels of heme-proteins. The in-
duction of oxidative stress and resulting protective responses involves many path-
ways. Among them are the products of oxygen metabolism by flavoproteins, hemo-
proteins, Fe-S-center-containing proteins and other oxidation-reduction centers.
Nitric oxide synthases (NOSs) reduce redox-cycling compounds such as menadione
(MD), forming superoxides, which in the presence of nitric oxide (NO) reacts to
form peroxynitrite, both of which cause oxidative injury. Therefore, we examined
the mechanistic role of NO for cell survival during MD-induced oxidative stress
under NOS inhibition using a NOS inhibitor, L-NAME. Dose viability studies
performed with various amounts of MD +/- L-NAME for 24 hrs allowed us to
choose 10 μM MD for further studies and also showed that NOS inhibition did
not significantly affect the cell viability at any concentration. Increased nNOS pro-
tein expression and increased 3- nitrotyrosine formation, a biomarker for peroxyni-
trite formation was observed with MD and MD + L-NAME over the controls alone
by both Western blotting and Immunocytochemistry, suggesting that the cells com-
pensate for decreased bioavailable NO by increasing nNOS.  We examined the
major antioxidant involved in cellular protection mechanism at 24 hours.
Glutathione peroxidase1 protein levels was decreased with MD+L-NAME treat-
ment which was reversed in the presence of NO donor deta-NONOate with
MD+L-NAME. On the other hand, SOD1 and PRDX6 levels remain unchanged.
Interestingly, at 24 hrs, GSH assays and stable isotope labeling of amino acids with
cell culture along with LC-MS analysis also reveal that proteins in glutathione
homeostasis are modulated by NO under oxidative stress as a mechanism of cell
survival. Current studies are aimed to dissect the relationship between NO and glu-
tathione under MD-induced oxidative stress.
2038 Synthesis and Crystal Structure of N-Acetyl-5-Chloro-3-
Nitro-L-Tyrosine Ethyl Ester.
T. T. Mutahi1,  B. J. Edagwa2,  F. R. Fronczek2 and R. M. Uppu1. 1Environmental
Toxicology, Southern University and A&M College, Baton Rouge, LA; 2Chemistry,
Louisiana State University, Baton Rouge, LA.
3-Nitro-L-tyrosine and 3-chloro-L-tyrosine are widely regarded as markers of per-
oxynitrite (PN) and HOCl formation (respectively) in vivo. A question that follows
naturally but never addressed in detail is what happens when PN and HOCl that
are co-produced at the inflammatory sites react simultaneously with tyrosine
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residues in proteins. The significance of these combined oxidations on the issue of
biomarker validation could be overwhelming given the report by Whiteman and
Halliwell (Biochem. Biophys. Res. Commun. 258,168–172,1999) wherein it was
shown that the 3-nitro-L-tyrosine was lost to some unknown product(s) following
oxidation with HOCl. Another important consequence could be that we need ad-
ditional biomarkers and their validation. Herein, we report the synthesis and char-
acterization of the oxidation product of HOCl reaction with N-acetyl-3-nitro-L-ty-
rosine ethyl ester (NANTEE), a model for protein-bound 3-nitro-L-tyrosine.
When HOCl was a limiting reagent ( HOCl < NANTEE), the major product at
pH 7.2 was found to be N-acetyl-5-chloro-3-nitro-L-tyrosine ethyl ester (NACN-
TEE). Following purification (reversed phase HPLC) and characterization (1H-
NMR; 400 MHz, CD3OD: δ 1.23 (t, J = 7.1 Hz, 3H), 1.92 (s, 3H), 2.92 (dd, J =
14.1, 8.7 Hz, 1H), 3.12 (dd, J = 14.1, 5.8 Hz, 1H), 4.16 (q, J = 7.0 Hz, 2H), 4.63
(dd, J = 8.6, 5.8 Hz, 1H), 7.60 (d, J = 2.1 Hz, 1H), 7.86 (d, J = 2.1 Hz, 1H), 8.43
(s, 1H)), single crystals of NACNTEE obtained in methanol were used for the de-
termination of crystal structure using KappaCCD (charge-coupled device) diffrac-
tometer. It was found that the OH group forms an intramolecular O—H....O hy-
drogen bond to the nitro group and the N—H group forms an intermolecular
N—H...O hydrogen bonds to an amide O atom, linking the molecules into chains
along [1 0 0]. The crystal studied was a non-merohedral twin, with a 0.907
(4):0.093 (4) domain ratio. [Support from NSF (HRD-1043316) and the US
DoED (PO31B040030) is acknowledged. Corresponding author’s email:
rao_uppu@subr.edu].
2039 Oxidative Stress Mediates Chlorpromazine-Induced
Cholestasis in Human HepaRG Cells.
A. Guillouzo1,  S. Antherieu1,  P. Bachour-El Azzi1, 2,  J. Dumont1,  Z. Abdel-
Razzak2,  C. Guguen-Guillouzo1,  B. Fromenty1 and M. Robin1. 1Inserm 991,
University of Rennes, Rennes, France; 2Lebanese University, EDST-PRASE and
EDST-AZM Center-LBA3B, Hadath, Lebanon.
Intra-hepatic cholestasis represents a frequent manifestation of drug-induced liver
injury in humans. However, the mechanisms involved are diverse and remain
poorly understood. Early hepatic effects of chlorpromazine (CPZ), known for years
to induce intra-hepatic cholestasis, have been analyzed using differentiated human
HepaRG cells. Bile acids (BA) efflux was found to be inhibited as early as after
30min-CPZ treatment as shown by [H3]-taurocholic acid (TA) intracellular accu-
mulation. This accumulation seemed to be mediated by reactive oxygen species
generated by CPZ since it was mostly prevented by N-acetyl cysteine co-treatment.
In addition, CPZ-induced ROS generation was accompanied by a disruption of the
pericanalicular distribution of F-actin as well as an alteration of the inner mito-
chondrial membrane potential.  Following 24 hour-treatment, CPZ inhibited the
expression of the two main canalicular bile transporters BSEP and MDR3.
Moreover, NTCP mRNA and activity as well as CYP8B1 mRNA were inhibited,
while MRP4 was overexpressed. These alterations indicate that BA uptake and syn-
thesis were decreased, whereas basolateral transport was enhanced. These alterations
likely represent hepatoprotective mechanisms against BA toxicity. These data sup-
port the conclusion that among other mechanisms, oxidative stress plays a major
role as both a primary causal and an aggravating factor in early CPZ-induced intra-
hepatic cholestasis in human hepatocytes (This work was supported by the
European Community, Contracts LIINTOP-STREP-037499 and Predict-IV-
202222).
2040 Evaluation of Thiotaurine for Effects against Ethanol-
Induced Oxidative Stress in the Presence and Absence of
Inhibitors of Ethanol Metabolism in the Rat.
M. C. Parikh,  Y. Shen and C. A. Lau-Cam. Pharmaceutical Sciences, St. John’s
University, Jamaica, NY. Sponsor: B. Blase.
The present study was undertaken to verify the in vivo effects of thiotaurine
(TTAU), a sulfane compound reported to exhibit antiradical activity in vitro,
against ethanol (EtOH)-induced oxidative stress. For this purpose, TTAU was
given to male Sprague-Dawley rats (200-250 g) as a single, 2.4 mmol/kg, intraperi-
toneal (i.p.) dose 30 min before an oral, 4 g/kg, dose of EtOH (40% w/v). The
same experiments were carried out with rats treated with the alcohol dehydrogenase
inhibitor 4-methylpyrazole (4MP, 75 mg/kg, i.p.) and the aldehyde dehydrogenase
inhibitor cyanamide (CYN, 60 mg/kg, i.p.), administered 30 min and 60 min, re-
spectively, before EtOH. Control animals received only physiological saline. All the
rats were sacrificed by decapitation at 1 hr after EtOH administration, and their
blood and livers were collected for the assay of plasma and hepatic levels of malon-
dialdehyde (MDA) and reduced (GSH) and oxidized (GGSG) glutathione and of
corresponding activities of the antioxidant enzymes catalase (CAT), glutathione
peroxidase (GPx) and superoxide dismutase (SOD). EtOH elevated the plasma
(+34%) and liver (+ 32%) GSH, lowered the plasma (-65%) and liver (-63%)
GSH/GSSG ratio, and lowered the corresponding activities of CAT (-86% and -
77%, respectively), GPx   (-91% and -70%, respectively) and SOD (-45% and -
54%, respectively). Both CYN and 4MP attenuated the alterations caused by
EtOH, with the latter compound appearing more potent than the former. In con-
trast, the GSH/GSSG ratio seen with ethanol was lowered further by CYN but
raised by 4MP. TTAU was not only more protective than 4MP against EtOH-in-
duced alterations in the liver and plasma but in its presence the protective actions of
CYN and 4MP became enhanced. The present results indicate that EtOH metabo-
lism to acetaldehyde and beyond influences oxidative stress by EtOH to a greater
extent than EtOH itself, and that such an event can be effectively counteracted by
TTAU.
2041 Skeptically Examining the Limits of Toxicology Evidence in
the Courtroom.
G. B. Corcoran1,  J. Norman2,  M. J. Saks3,  S. Bobst4 and R. T. Kennedy5.
1Pharmaceutical Sciences, Wayne State University, Detroit, MI; 2ExxonMobil
Biomedical Sciences, Annandale, NJ; 3Sandra Day O’Connor College of Law, Arizona
State University, Tempe, AZ; 4Nexeo Solutions, The Woodlands, TX; 5New Mexico
Court of Appeals, Albuquerque, NM.
The opposing orientation of toxicology experts and select evidence can skew the ac-
curacy and value of testimony in court. Lawyers and judges are acquiring increasing
skills to evaluate technical and scientific assertions with skepticism. Scholarly scien-
tific approaches are required to establish whether techniques and methods asserted
to be scientifically sound are valid and support justice. An introduction briefly cov-
ers topics helpful to understanding what happens to experts in litigation. This in-
cludes the law’s theory of expert evidence, rules of evidence and procedure relating
to expert testimony, alternative admissibility rules (Frye v Daubert trilogy), the
NRC report and Canadian parallels, a law-science syllogism, the adversary process
in theory and practice, ethical principles, clashes of ethics, data (especially quantita-
tive), disclosure of evidence helpful to the other side, and for whom the litigation
expert works. The toxicology expert must address relevant science in a fair, repre-
sentative manner and communicate effectively. The use of Bradford-Hill Criteria
(1964) has been promoted to address general causation in toxic torts. While com-
prehensive, it poses challenges including jargon and communication. Recently, a
five question approach was introduced to address specific causation. Explanations
and examples of causation will be reviewed. Finally, the 2009 National Academies
report recommends that forensic sciences look to academic scientific models for re-
liable practice and technique validation to support court testimony. Lawyers and
courts have become more skeptical of unsupported opinions and increasingly aware
of how to combat them. Academic toxicology can offer much to advance the legiti-
macy of admitted evidence, including in the area of forensics. A discussion will in-
clude foibles and solutions.
2042 Harnessing Electronic Standards and Informatics to
Transform the Use of Regulatory Toxicological Data.
L. P. Myers1,  L. Burns Naas2,  T. Kropp1,  A. Nanzer3 and T. Smyrnios4. 1Center
for Drug Evaluation and Research, US FDA, Silver Spring, MD; 2Gilead Sciences,
Inc., Foster City, CA; 3F. Hoffmann-La Roche Ltd., Basel, Switzerland; 4MPI
Research, Inc., Mattawan, MI.
One of the major efforts in nonclinical regulatory informatics has centered on the
development and testing of the electronic data submission standard, also called
SEND (Standard for Exchange of Nonclinical Data). This standard was developed
by the Clinical Data Interchange Standards Consortium’s (CDISC) SEND Team
for nonclinical data collected from animal toxicology studies and allows for the
electronic submission of tabulated toxicology data in an electronic format. The ini-
tial pilot project began in 2003 and was followed by a second pilot in 2007 focused
on CDER-regulated projects. The production of the SEND 3.0 Implementation
Guide in 2011 was a major step forward for the electronic submission and exchange
of standardized data and enablement of data warehousing efforts that better sup-
port scientific review and regulatory science initiatives. However, it is recognized
that data standards are simply enablers to support the broader goals of better ex-
ploring and exploiting diverse study data and metadata in order to answer impor-
tant scientific review and regulatory science questions. The range of needs and chal-
lenges in the regulatory pharmacology and toxicology field can be daunting but
many of the challenges are shared among key stakeholders (e.g., the US FDA, spon-
sors, and CROs). These challenges, which range from warehousing to analysis to
QA/GLP ramifications, are laying the foundation for a compliant exchange of data
and opportunities for collaboration through public/private partnerships. This ses-
sion will discuss the current computational science initiatives at the US FDA and in
industry, existing partnerships, challenges and successes, as well as the transforma-
tive effect on the CRO model.
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2043 Regulatory Science and Risk Assessment: Lessons for Early-
Career Scientists on What to Expect and How to Pursue This
Career Path.
B. J. Lew1,  J. A. Torres2,  D. L. Bjerke1,  J. C. Lipscomb3,  A. Maier4 and
D. Jacobson Kram5. 1PS&RA, Procter & Gamble Company, Cincinnati, OH;
2Environmental Toxicology, Texas Southern University, Houston, TX; 3NCEA, US
EPA, Cincinnati, OH; 4Toxicology Excellence for Risk Assessment (TERA),
Cincinnati, OH; 5CDER, US FDA, Silver Spring, MD.
During academic training, postdoctoral and graduate students generally are not
provided with opportunities for interacting with toxicologists who are involved in
risk assessment and regulatory affairs. The educational training mainly focuses on
basic sciences or solving mechanistic problems and thus lacks the practical aspects
of risk assessment and regulatory preparation. This concern was discussed at the
Education Summit in October 2011, which was organized by the Education
Committee of the SOT. Dr. John Doull’s comment that, “toxicology is what we do,
but risk assessment is why we do it,” shows the importance for trainees to become
aware of both. Unfortunately, when it is time for the trainee to make the decision
on what will be the next step in their careers, they are well prepared on what we do,
but fall short on why we do it. The objectives of this session are to provide postdoc-
toral and graduate students with basic understanding of approaches in risk assess-
ment and regulatory affairs in some of the sectors and to educate them about nec-
essary preparative steps in this field. In this 80-minute Education-Career
Development Session, trainees will become more familiar with the routine job of
toxicologists outside of the academic setting. Further, there will be a panel discus-
sion on steps that can be taken during graduate school and postdoctoral training to
improve the preparation for a career in risk assessment and regulatory fields. Thus,
the participants are expected to gain a basic knowledge of risk assessment and regu-
latory preparation in the life of a toxicologist and how to pursue this field.
2044 Surgical Alternatives for Multiple CSF Sampling in
Conscious Cynomolgus Monkeys: A Novel Approach.
J. Sternberg,  S. H. Korte and C. B. Rose. Covance Laboratories GmbH, Muenster,
Germany. Sponsor: G. Weinbauer.
Intrathecal infusion via the lumbar route represents an accepted while specialized
clinical route for drug delivery in humans. Since primates are often required as rel-
evant species for pre-clinical safety assessment, this dose route is well established in
cynomolgus monkeys. However, for the majority of these studies, CSF (cere-
brospinal fluid) for bioanalysis, clinical chemistry as well as cell counts needs to be
collected at multiple time points within few days. Sampling using spinal needle
(Pencan Paed®: 25G, 50 or 25 mm, B. Braun Melsungen AG, Melsungen,
Germany) on sedated animals (Ketamin and Domitor; Antisedan as antidote) is
limited to three occasions within the first 24 hours, hence limiting the ability for a
detailed evaluation. In this study, three female cynomolgus monkeys (~3.5 kg)
where implanted (L2-L3) using MID-LOVOL port (Solomon Scientific, USA),
connected to a 3FR intrathecal PU catheter. To compare our established technique
of s.c. port placement under the shoulder blade, the MID-LOVOL port was im-
planted in the established way (animal A), in the thoraco-lumbar region (animal B)
and in the region of the sacrum (animal C). To ensure the patency of the system it
was flushed every three days with 0.5 ml artificial CSF beginning on the day of sur-
gery. On day 14, 17, 20 and 23 after surgery a Huber needle was used for CSF col-
lection, while the animals were placed in a restrain chair. There were no adverse
clinical signs, body weight changes, clinical pathology or neurological findings di-
rectly after surgery in all three animals. Successful CSF collection could only be per-
formed in animal C. The port position of this animal proved to be an advantage for
needle insertion/fixation hence CSF collection in the restrain chair. In conclusion,
port implantation under the shoulder blade, in the thoraco-lumbar region as well as
in the region of the sacrum is possible.
2045 Hydration with Saline Decreases Toxicity of Calcitriol-
Injected Mice in Preclinical Studies.
A. Azari,  M. Kanavi,  S. Darjatmoko,  V. Lee,  H. Potter,  L. Teixeira and
D. Albert. Ophthalmology, University of Wisconsin Madison, Madison, WI.
Purpose: To study the effectiveness of saline injection in reducing the toxicity pro-
file of calcitriol when coadministered in mice. 
Design: Meta-analysis of published mice studies with calcitriol. 
Methods: A comprehensive PubMed and ISI web of knowledge search was per-
formed to identify all published case control articles of calcitriol injection in mice,
and relevant articles were selected. Using mortality as an end point to study the
toxic effects of calcitriol, the relative risk of mortality in mice given saline injections
was evaluated for different calcitriol dosages, as well as mouse and tumor types. 
Results: Coadministration with 0.25 ml of normal saline solution injected in-
traperitoneally is associated with a lower mortality rate than calcitriol given alone.
The calculated relative risk of mortality was 0.1419 (95% CI 0.0093-2.2133, z-sta-
tistic 1.393, p-value = 0.1636) when saline is administered with calcitriol compared
to calcitriol alone.
Conclusions: Hydration with saline is a common practice in patients receiving cal-
citriol, which appears to be pertinent in experimental studies of mice receiving cal-
citriol. It is important to note that results of preclinical studies form the basis for
decisions in drug use in patient trials. Decreasing mortality in animal experiments
will prove to be a meaningful contribution to the field of research. To avoid some
mortality due to toxicity, a common practice for investigators was administering
less than the target doses or even skipping doses in order to decrease calcitriol in-
duced mortality in mice. Combination of high mortality in mice and administra-
tion of suboptimal dose in certain situations may impede evaluation of the poten-
tial therapeutic effects of calcitriol. The same problem is likely to exist with other
drugs as well (e.g., chemotherapeutic agents). This preliminary data indicates that
supplemental hydration should be kept in mind in evaluating drug toxicology.
2046 Identification of Behaviorally Active Doses of Morphine and
Evaluation of Its Analgesic Effects in the Rhesus Monkey.
T. Wolinsky1,  C. Cruz2,  I. Hubert2,  G. Froget1, 2,  M. Lemaire1 and D. Virley1, 2.
1Porsolt SAS, Le Genest-St-isle, France; 2Porsolt Inc. USA, San Antonio, TX.
Pain affects millions of people worldwide and is commonly treated with opioid
analgesics, despite considerable safety/risk management concerns. The purpose of
this study was two-fold: First, to establish a therapeutic index for morphine by de-
termining the behaviorally active range in an operant responding procedure and
second, to work within this dose range to evaluate the analgesic effects of morphine
in the rhesus monkey (Macaca mulatta) in a thermal pain tail withdrawal proce-
dure.
For the operant responding procedure, 2 monkeys were trained to lever-press for
food on a fixed-ratio (FR30) schedule. The sessions lasted 120 minutes (8 cycles of
15 minutes) during which the rate of responding was recorded. Acute doses of mor-
phine sulfate (0.3 – 3 mg/kg s.c.) were administered at the beginning of the session.
For the tail withdrawal procedure, 4 monkeys were seated in restraint chairs and the
lower section of the shaved tail was immersed into water at 40, 50, and 55 C.
Sessions began with a control tail withdrawal latency determination at each tem-
perature followed by an acute dose of morphine sulfate (0.3 – 3 mg/kg s.c.).
Temperatures were presented to the animals in a randomized order at 15, 30, 60, 90
and 120 minutes post-dose.
Morphine markedly decreased the rate of operant responding at 1 mg/kg and elim-
inated lever-pressing at 3 mg/kg. Analgesic effects of morphine in the tail-with-
drawal assay were observed at all doses tested: The onset and duration of action
were dose-dependent. The minimum effective dose was found to be 0.3 mg/kg,
while 3 mg/kg produced the maximal effect in all 4 animals tested.
These results suggest that acute morphine has a narrow therapeutic index in the
rhesus monkey. The selected behavioral test procedures could therefore provide ap-
propriate efficacy and safety measures for assessing novel opioid and non-opioid
based analgesics with high translational validity and relevance.
2047 Pharmacodynamic Glycemia Effects from Rapid and Long-
Acting Insulins Administered at Mealtime to Alloxan-
Induced Diabetic Miniature Yucatan Swine.
L. D. Brown1, 2,  T. J. Madsen1,  E. C. Blair1,  B. C. Hanks1, 2,  K. P. Horlen1,
J. Hiemstra2,  A. Stricker-Krongrad1,  J. Liu1 and G. F. Bouchard1, 2. 1Sinclair
Research Center, LLC, Columbia, MO; 2Sinclair BioResources LLC, Auxvasse, MO.
Pharmacodynamic effects from various insulins with known properties in humans
were studied in the Yucatan miniature swine for comparative purposes. Yucatan
miniature swine (Sus scrofa, at least 3 months, 20-60 kg) were made diabetic with
intravenous alloxan and regulated on insulin. Animals were considered diabetic if
they became hyperglycemic (≥150 mg/dL) within 2-5 days following induction. All
procedures were on overnight fasted animals (no feed or insulin for 18 hrs). Our di-
abetic miniswine average baseline bG of 429 ± 84.5 (SD) mg/dL (N=148 measure-
ments) while non-diabetics average 58.7 ± 8.2 (SD) mg/dL (N=238 measure-
ments). For this study, well-known prototypical marketed insulins (Apidra™,
Humalog™, Lantus™; 0.25 or 0.45 U/kg s.c.) were administered at mealtime,
then blood glucose profiles recorded using handheld glucometer devices (One
Touch Ultra®, Lifescan) over the next 8 hrs (rapid-acting) or 24 hrs (long-acting).
Venous blood samples were collected from vascular access ports for bG readings.
Blood glucose profile data in the diabetic Yucatan generally compared well to pub-
lished human glucodynamic data for glycemia effects following insulin. These data
suggest the Yucatan diabetic model has similar pharmacodynamic responses to the
presentation of exogenous insulins for onset and peak effects but not duration for
the rapid-acting insulins. The long-acting insulin (Lantus™) peaked in swine
SOT 2013 ANNUAL MEETING 437
where no peak (same action throughout day) is normally reported in humans.
These differences could be due to either the duration of the fasting, the relative
high doses of insulin or the use of a small number of animals in this study.
2048 Toxicity Mechanisms of Anti-Inflammatory Kinase
Inhibitors.
E. Berg,  M. A. Polokoff,  A. O’Mahony,  J. Melrose and D. Nguyen. BioSeek
LLC, South San Francisco, CA. Sponsor: K. Houck.
Improving the safety of drug candidates that enter clinical development requires as-
says that are more predictive of human outcomes. The BioMAP® platform uses
human primary cells to model complex aspects of disease and tissue biology and
can be applied to better understand biological mechanisms that underlie drug ad-
verse effects.  Here we present the analysis of several anti-inflammatory kinase in-
hibitors, including inhibitors of p38 MAPK, Jak kinase (tofacitinib) and Syk kinase
(fostamatinib) tested in a panel of 12 BioMAP® systems covering a broad range of
human biology. Specific effects of these compounds in BioMAP® assays modeling
aspects of wound healing and vascular biology appear to correlate with certain side
effects of these drugs in patients, including skin rash (p38 MAPK), gastrointestinal
perforations (Jak), and hypertension (syk).  These in vitro effects may be useful in
screening lead candidates prior to testing in animals or humans.
2049 Evaluation of PBPK Models for Medical Decision Making
upon Acute Chemical Exposure: Dichloromethane (DCM)
As an Example.
R. Z. Boerleider1, 2,  C. C. Hunault1,  J. C. van Eijkeren3,  I. de Vries1,
J. G. Bessems3 and J. Meulenbelt1, 2. 1National Poisons Information Center,
University Medical Center Utrecht, Utrecht, Netherlands; 2IRAS, Utrecht University,
Utrecht, Netherlands; 3RIVM, National Institute for Public Health, Bilthoven,
Netherlands.
Rationale: Assessing the risks of exposure to hazardous chemicals in emergency sit-
uations and decision-making on individual medical treatment is not straightfor-
ward. We therefore evaluated the use of physiologically based pharmacokinetic
(PBPK) models in this context, taking DCM as an example. DCM is toxic by in-
halation and can cause mild to serious health effects.
Methods: In a clinical trial approved by the Hospital Medical Ethical Board, six
healthy volunteers were individually exposed to DCM for 1 hour. The volunteers
had to apply a paint stripper to a surface without air mask, in a closed room.
Eighteen blood samples were drawn (t = - 1h to 48h post-dose). Whole blood
DCM concentrations and percentages of carboxyhemoglobin (% HbCO) were
measured using GC. The DCM air concentration in the room was continuously
monitored by a Miran 1B2 infrared spectrophotometer. Experimental blood DCM
concentrations and % HbCO were subsequently compared to the predictions of a
previously published PBPK DCM model.
Results: The DCM external dose (area under the exposure-time curves) ranged be-
tween 175 and 390 ppm*h (equal to 608 - 1354 mg*h /m3). DCM blood concen-
trations reached maximum levels at the end of the exposure (t = 1h) and ranged be-
tween 0.25 and 5.1 mg/L. Increase in % HbCO was delayed (maxima reached
between 2 and 6 h) and ranged between 0.4 and 2.3 %. The predicted DCM blood
concentration ranged between 1.55 and 4.20 mg/L at t = 1 h and the predicted %
HbCO ranged between 3.1 and 4.1 % at t > 1.5 h. The general form of the con-
centration-time profiles was well predicted, especially in the elimination phase of
DCM from blood.
Conclusion: The model was found to fit experimental DCM blood concentrations
reasonably well but should be refined for % HbCO. Such a PBPK model might be
helpful in case many individuals are acutely exposed to DCM and for whom
HbCO monitoring is not available.
2050 Specificity Protein (Sp) 1 Transcription Factor Modulates
Long Noncoding RNA Expression in Liver Cancer Cells.
S. Gandhy1, 2 and S. H. Safe2, 3. 1College of Medicine, Texas A&M College of
Medicine Health Sciences Center, Houston, TX; 2Institute of Biosciences and
Technology, Texas A&M College of Medicine Health Sciences Center, Houston, TX;
3Department of Veterinary Physiology and Pharmacology, Texas A&M College of
Medicine Health Sciences Center, Houston, TX.
Hepatocellular carcinoma is one of the most prevalent forms of cancer worldwide
and it exhibits highly invasive and metastatic properties. Recent studies have shown
that of the small proportion of the genome that is transcribed only about 1.4% en-
codes for protein-coding genes. Of the remaining vast majority of transcripts that
do not encode protein, long noncoding RNAs (lncRNAs) have recently gained at-
tention because of their pivotal role in disease. LncRNAs are a class of transcripts
longer than 200 nucleotides and have been characterized as having both tumor sup-
pression and oncogenic functions in many types of cancers. Although their mecha-
nisms of action remain largely unknown, many lncRNAs are regulated by tran-
scription factors in a tissue-specific manner. Specificity protein (Sp) transcription
factors Sp1, Sp3, and Sp4 are overexpressed in many tumors, and regulate expres-
sion of genes required for cancer cell and tumor growth, survival, angiogenesis, and
inflammation. Sp proteins are the targets of many conventional and alternative
chemotherapeutic drugs, and therefore further study of their functions is of great
interest. In this study, we examined the role of Sp transcription factors in regulating
lncRNAs in liver cancer cells. Using HepG2 and Huh-7 cells as models, we investi-
gated the effects of Sp downregulation on the expression of several lncRNAs as well
as cell growth and survival. Downregulation of Sp transcription factors by RNA in-
terference or by drugs that target these proteins identified a set of lncRNAs in liver
cancer cells that are modulated by Sp transcription factors. Further studies are un-
derway to examine the specific functions of these lncRNAs in liver cancer growth
and metastasis as well as their utility as diagnostic biomarkers.
2051 The Third Trimester: The Critical Phase of the Deleterious
Effects of Cadmium in Pregnancy.
J. I. Anetor,  P. Tawari-Eebi,  M. Charles-Davies and A. Arowojolu. Chemical
Pathology, College of Medicine, University of Ibadan, Ibadan, Nigeria.
Environmental cadmium (Cd) is rising globally particularly in the developing
countries. Reports indicate that the deleterious effects of Cd may occur at lower lev-
els than hitherto thought. The effects of Cd on female reproduction particularly in
pregnancy has received only measured attention and these reports did not delineate
the phases of pregnancy at which adverse effects may be critical. One hundred and
sixty subjects (125 pregnant; 35 non-pregnant), were studied. Pregnant subjects
were classified into three trimesters:1st (35), 2nd (35) & 3rd (55). Cadmium, Cu,
Zn, Fe, Se, Serum proteins were determined in all subjects. Third trimester subjects
were followed until delivery. Cadmium levels were similar in the 1st & 2nd
trimesters but significantly increased in the 3rd trimester compared to controls and
1st & 2nd trimesters. Zinc level was significantly decreased in the 3rd trimester
compared with the 1st & 2nd trimesters. Importantly, Cd was inversely related to
Zn. Thirty-two (58%) subjects delivered normal weight babies, 19 (35%) delivered
babies with low birth weight (LBW). Four (7%) delivered babies with high birth
weight. Women with LBW babies had significantly higher Cd and lower Zn levels
as well as low BMI . Cadmium, Zn, Se all correlated inversely with neonatal birth
weight (NBW). Cadmium and Se strongly correlated inversely with NBW (r-0.7, p
= 0.000; r- 0.31, p = 0.02) respectively. Zinc also correlated directly with NBW.
These data suggest that the third trimester with the lowest Zn level also had the
highest Cd level (Cd is a metabolic antagonist of Zn). It appears the critical phase
that Cd may elicit its toxic effect in pregnancy is the 3rd trimester and low Zn level
may be the driving factor. The third trimester is therefore the phase to target in risk
assessment, communication and management.
2052 Ethanol Is a Significant Cofactor in HAART-Induced
Hepatotoxicity.
H. Donde1,  S. Ghare1,  J. Zhang1,  I. Kirpich1,  S. Joshi-Barve1,  C. McClain1, 2
and S. Barve1. 1Department of Medicine/GI, University of Louisville, Louisville, KY;
2Louisville VAMC, Louisville, KY.
Highly Active Antiretroviral Therapy (HAART) has led to a significant increase in
the life expectancy of HIV patients; however, there are significant side effects in-
cluding lipodystrophy and hepatotoxicity. Alcohol abuse is highly prevalent in HIV
infected individuals and hence may be a significant negative cofactor in HAART
induced hepatotoxicity. 
The present study examines the mechanisms underlying HAART and alcohol in-
duced hepatotoxicity. The effects of HAART drugs (azidothymidine, and Indinavir
sulphate) in combination with alcohol were examined both in vitro (H4IIEC3- a
rat hepatoma cell line) and in vivo. Individual treatments of H4IIEC3 cells with al-
cohol and AZT showed a certain level of hepatotoxicity which was significantly in-
creased in combinatorial treatment of alcohol and AZT. These data indicate that al-
cohol can induce and further enhance HAART-induced cytotoxicity. 
Alcohol and HAART drug interactions and hepatotoxicity were also assessed in-
vivo using an animal model of chronic alcohol feeding. Mice were pair-fed liquid
diets (Lieber DeCarli) containing 35% of calories as alcohol (alcohol-fed, AF) or as
isocaloric maltose-dextrin (pair-fed, PF). HAART treatment groups received AZT
(30mg/kg BW) and IDV (50mg/kg BW) by oral gavage for 5 weeks. Animals ex-
posed to both alcohol and HAART developed increased visceral adiposity com-
pared to pair-fed animals, suggesting disturbances in lipid metabolism in these
mice. Lipodystrophy was also evidenced by macro and microvesicular steatosis in
the livers; elevated liver triglycerides and free fatty acids. Additionally, animals re-
ceiving combinations of alcohol and HAART exhibited increased inflammation
and greater hepatic neutrophil infiltration. 
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Overall, our data demonstrate that alcohol exacerbates HAART hepatotoxicity, and
is a significant cofactor in the development of hepatic steatosis and liver injury.
2053 Acute Exposure to Acrolein, a Ubiquitous Environmental
Pollutant, and Anti-HIV HAART Medication Leads to
Hepatotoxicity.
S. Ghare1,  H. Donde1,  S. Joshi-Barve1,  C. McClain1, 2 and S. Barve1.
1Department of Medicine/GI, University of Louisville, Louisville, KY; 2Louisville
VAMC, Louisville, KY.
Highly Active Antiretroviral Therapy (HAART) is the current treatment for HIV
infection. Although HAART leads to a significant increase in the life expectancy of
patients with HIV; the prolonged use of HAART causes hepatotoxicity. This has
become a significant clinical problem which leads to discontinuation of therapy in
turn causing HIV virus reactivation and the development of AIDS. Additionally,
environmental pollutants are known to significantly impact general health as well as
therapeutic outcome; however their contribution to HAART therapy-induced liver
toxicity is unknown. Acrolein is a common environmental, food and water pollu-
tant and a major component of cigarette smoke. It is also produced endogenously
via lipid peroxidation and cellular metabolism. The present study examines the po-
tential impact of acute acrolein exposure on the hepatotoxic effects associated with
HIV medication. A well characterized human hepatoma cell line (HepG2) model
system was used to investigate the combined cytotoxic effects of acrolein along with
HAART drug, azidothymidine (AZT). HepG2 cells were treated with various con-
centrations of acrolein and HAART drugs either individually or in combination.
Our results showed that acute exposure to either acrolein or HAART drugs had
minimal to no effect on hepatocyte survival. However acrolein exposure enhanced
the AZT- induced apoptotic death in HepG2 cells. Acrolein also sensitized hepato-
cytes to AZT- induced mitochondrial dysfunction, as shown by mitochondrial
membrane depolarization and ATP depletion. Notably, acrolein and AZT respon-
sive epigenetic modifications at the FasL promoter were observed, leading to a
marked enhancement in FasL gene expression, a known death ligand for hepatocyte
and liver damage. Overall, the data suggest that exposure to environmental pollu-
tant acrolein has the potential to exacerbate AZT- induced hepatotoxicity, and in-
crease the severity of drug induced liver injury. This work was supported by NIH
grants.
2054 Solubility Enhancement Studies for a Potential Cyanide
Antidote.
M. Negrito,  K. Kovacs,  M. Ancha,  M. Jane,  S. Lee,  S. Angalakurthi,
S. Rasheed and I. Petrikovics. Chemistry, Sam Houston State University, Huntsville,
TX.
Present studies focused on the solubility enhancement for the sulfur donor methyl
propyl trisulfide (MPTS) to develop an intramuscular formulation for treating
cyanide (CN) intoxication. Various FDA approved co-solvents (ethanol, polyethyl-
ene glycols (PEG 200, PEG 300, PEG 400) and propylene glycol (PG)), and sur-
factants (Cremophor EL, Cremophor RH40, polysorbate 80, sodium cholate and
sodium deoxycholate) and their combinations were applied to enhance the solubil-
ity of the lipophilic MPTS. For solubility determination GC-MS methods were de-
veloped. The maximum solubility of MPTS was found at 90% ethanol of over 170
mg/ml. The maximum solubility of over 40 mg/ml was achieved with 20 %
Cremophor EL. The combination of the surfactant 20% Cremophor EL and the
co-solvent 75% ethanol lead to a synergistic solubilizing effect with the solubility
reaching over 400 mg/ml of MPTS. 
The in vitro efficacy studies for the MPTS vs. thiosulfate (TS), determined by
measuring the thiocyanate formation spectrophotometrically, showed that MPTS is
a significantly superior sulfur donor than TS. Similarly, the preliminary in vivo effi-
cacy studies, determined on a therapeutic mice model and expressed as Antidotal
Potency Ratios (APR), the ratio of CN LD50 with and without the test antidote(s),
showed that MPTS is superior to TS. The combination of MPTS + TS showed a
synergistic effect (APR= 3.6).
2055 Chemical Hazards Emergency Medical Management
(CHEMM): Chemical Specific Acute Patient Care Guidelines
for Prehospital and Emergency Department/Hospital
Management.
P. J. Hakkinen1,  D. Siegel2,  A. Maier3,  F. Chang1,  A. Wullenweber3,
J. Strawson3,  A. Willis3,  P. Nance3,  O. Kroner3 and R. Sandhu3. 1National
Library of Medicine (NLM)/National Institutes of Health (NIH), Bethesda, MD;
2National Institute of Health (NIH)/National Institute of Child Health and Human
Development, Bethesda, MD; 3Toxicology Excellence for Risk Assessment, Cincinnati,
OH.
Chemical Hazards Emergency Medical Management (CHEMM) is an online and
downloadable interactive tool. It is designed to enable first responders, first re-
ceivers, other healthcare providers, and planners to plan for, respond to, recover
from, and mitigate the effects of mass-casualty incidents involving chemicals.
Content has been developed via NLM staff, CHEMM contractors, and Federal
government and non-Federal government subject matter experts (SMEs).
CHEMM includes chemical-specific, acute patient care guidelines for pre-hospital
and emergency department/hospital management for exposures to selected groups
of chemicals. The information is divided into sections for response in the Hot
Zone, Decontamination Zone, and Support Zone/Treatment Area, and each chem-
ical page includes chemical specific information on substance identification, rescuer
protection, triage, pediatric/geriatric/obstetric vulnerabilities, clinical symptoms,
antidotes, and more. The first version of CHEMM was released in mid-2011, with
recent efforts including the addition of over 50 new chemicals with the types of in-
formation noted above.
2056 Manganese Accumulation in the Brain of Asymptomatic
Welders and Its Functional Consequences.
E. Lee1,  M. R. Flynn2,  G. Du1,  M. Lewis1 and X. Huang1. 1Neurology,
Pennsylvania State University, Hershey, PA; 2Environmental Sciences and Engineering,
University of North Carolina at Chapel Hill, Chapel Hill, NC.
Manganese, a neurotoxicant that is concentrated in welding fumes, may play a role
in neurodegenerative processes such as Parkinsonism.
In the present study, we examined possible brain biomarkers of manganese expo-
sure in asymptomatic welders using state-of-the-art MRI techniques and correlated
imaging findings with functional measures (neuropsychological tests). Sixteen
welders and 16 age- and education-matched controls comprised the current sample. 
For welders, increased welding hours were associated with higher T1 relaxation
rates in amygdala, caudate nucleus, hippocampus, putamen, and orbitofrontal
white matter in addition to traditionally reported globus pallidus, reflecting in-
creased accumulation of manganese. The higher hours in welding were also associ-
ated with greater T1-weighted intensity values in caudate nucleus and hippocam-
pus for welders. Subgroup analysis of welders who were highly exposed to welding
compared to controls with no lifetime exposure to welding indicated that welders
had higher T1 relaxation rates in globus pallidus and putamen consistent with cur-
rent literature. 
Correlation analyses of MRI results and neuropsychological tests revealed that per-
formance on set shifting tasks (stroop and visual-verbal tests) were negatively corre-
lated with T1-weighted intensity values in orbitofrontal white and grey matter for
all subjects. In addition, executive function (the D-KEFS tower test) also was corre-
lated negatively with T1-weighted intensity values in amygdala, caudate nucleus,
hippocampus, putamen, and globus pallidus. Moreover, welders with high welding
exposure showed decreased working memory performance and associated increased
T1-weighted intensity values.
These results suggest that brain regions other than the globus pallidus, e.g., the cau-
date nucleus and/or hippocampus, also may reflect sensitively manganese exposure.
In addition, there may be some cognitive decline associated with manganese depo-
sition in brain.
2057 Ethanol-Induced Reductions of Antimicrobial Peptide LL-37
in THP-1 Cells and Bal Fluid of Ethanol Fed Mice.
M. McCaskill,  H. Hottor,  M. Sapkota and T. Wyatt. Department of
Environmental, Agricultural, Occupational Health, University of Nebraska Medical
Center, Omaha, NE.
The most common infections plaguing the pulmonary system outside of common
viral infections such as Rhinovirus and Influenza are Haemophilus influenzae,
Klebsiella pneumonia, Burkhoderia repacia, Bordetella pertussis, and
Mycobacterium tuberculosis. Respiratory infection incidence has been directly cor-
related to circulating levels of vitamin D. Vitamin D is required for antimicrobial
peptide LL-37 production and function in the lung. As a result, antimicrobial LL-
37 production is correlated with respiratory function and health. C57Bl6 mice
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were exposed to ethyl-alcohol via the Meadows-Cook model for 6 weeks. Mice were
also fed Diallyl Disulfide (DADS) at 1uM/gram of feed, and 4000IU of cholecal-
ciferol in their daily diet. THP-1 human acute monocytic cell line were pre-treated
with 80mM alcohol for 24 hours, and treated with 1uM of DADS, and 100nM of
1,25 dihydroxy vitamin D for 6, 12, 24 hours. Eighty mM alcohol exposed THP-1
cells displayed a 53% reduction in the cellular supernatant of LL-37. The 6 hour
exposure of DADS attenuated the alcohol induced reduction of cellular super-
natant LL-37. The 6 hour treatment of 1,25 dihydroxyvitamin D also attenuated
the reduction LL-37 in the supernatant of THP-1 cells. In the BALF of the 6 week
alcohol fed mice, 1,25 dihydroxyvitamin D was reduced by 70%. In the in-vivo
model DADS exposure completely abrogated the alcohol induced reduction of
BALF LL-37. This data displays the propensity of alcohol to affect the ability of
THP-1’s (pre-monocyte cell model) to produce an antimicrobial peptide LL-37.
This may be related to the disturbances in 1,25 dihydroxy vitamin D in the pul-
monary epithelium as reflected by reductions of BALF of alcohol fed mice. The
ability of DADS and vitamin D to attenuate this alcohol induced reduction of LL-
37 in the THP-1 cells, and BALF of chronically alcohol fed mice may assist with
novel treatment options for human chronic alcohol related respiratory infection
severity and rates.
2058 Utility of Intranasal Fentanyl Powder Formulation:
Pharmacokinetics-Pharmacodynamics Relationship in
Rhesus Monkeys.
K. Yunomae,  N. Yanagida,  M. Nishizono,  T. Kamenosono,  S. Haruta,
Y. Ooshima,  H. Sameshima,  K. Fukuzaki and R. Nagata. Shin Nippon
Biomedical Laboratories (SNBL), Ltd., Kagoshima, Japan.
The recent survey conducted by the American Pain Foundation revealed that break-
through pain posed the greatest challenge to the quality of life (QOL) of cancer pa-
tients. The fentanyl buccal tablet, a self-administration formulation, is used at pres-
ent to relieve breakthrough pain rapidly. However, a new formulation that possesses
much quicker pain relief is required to improve the QOL. SNBL has developed an
intranasal fentanyl powder formulation (TRF) with the applied “μco System”, an
intranasal drug delivery system technology. The purpose of this study was to inves-
tigate the utility of TRF by comparing the absorption properties and time of onset
of action after administration of TRF with those of the commercial buccal tablet.
[Methods] Six male rhesus monkeys with body weights 5.4-8.0 kg were used. The
plasma fentanyl levels were analyzed by LC/MS/MS. The tail withdrawal latency
(TWL) procedure using 50°C water was conducted to evaluate antinociception of
fentanyl following administration (8 μg/kg) of fentanyl in 3 forms: TRF (in-
tranasal), intravenously injectable formulation, and buccal tablet. [Results] Tmax
and Cmax after administration of TRF were 12.8 min and 2.6 ng/mL, respectively,
and were much quicker and higher than the corresponding values for the buccal
tablet (50.8 min and 1.1 ng/mL). TRF prolonged the TWL. The effect continued
for 25 min from just after nasal administration, similar to that of the intravenously
injectable formulation. The effect of the buccal tablet on TWL was noted only at
45 min after buccal administration, suggesting a slow onset of action. [Conclusion]
TRF showed a quicker inociceptive effect due to a more rapid nasal absorption of
fentanyl in comparison with the buccal tablet. These results indicated that TRF
would be a useful formulation for rapidly relieving breakthrough pain in cancer pa-
tients with self-administration.
2059 Better Prediction of Immunogenicity of Biopharmaceuticals,
Is It Possible?
G. M. van Mierlo3,  F. J. Tielen2,  R. Klein Entink1,  A. Penninks3,
M. Sauerborn3,  S. Folkertsma1,  E. Reefman2 and B. Fabriek1. 1Quality and Safety,
TNO, Zeist, Netherlands; 2Metabolic Health Resarch, TNO, Leiden, Netherlands;
3Toxicology Applied Pharmacology, TNO Triskelion, Zeist, Netherlands. Sponsor: R.
Woutersen.
A major drawback of biologicals is the possible induction of immunogenicity upon
clinical use, that may result in a safety issue and/or a reduction of drug efficacy.
Anti-drug antibodies (ADA) are determined as a measure of immunogenicity.
Current preclinical models have proven lack of predictivity for clinical immuno-
genicity. Therefore, there is a need for better methods to predict which drugs are
likely to induce immunogenicity in clinical trials. 
Based on historical data of immunogenicity, information on structurally, therapeu-
tically and/or ‘mode-of-action’ similar compounds can be obtained to establish the
translational aspects these models. We selected interferon alfa, beta and TNF-in-
hibitors as model compounds (13 in total) for which the public domain (FDA re-
views, BLA, NDA, EMEA, pubmed) was scavenged for immunogenicity related in-
formation. The Information consisted of physical chemical properties, formulation
aspects (including stability data), preclinical animal toxicity data, clinical data
(study specifics and ADA occurrences and effect). 
Due to the lack of information on in vitro immunogenicity in literature, we de-
cided to generate these data for the 13 selected compounds. We performed autolo-
gous ex vivo human T-DC co-cultures and established T cell proliferation and DC
maturation as response markers.
A logistic regression model has been developed relating physical chemical, animal
and in vitro information to immunogenicity, where immunogenicity has been de-
fined as two dimensional: the prevalence in the general population and the potency
of the substance (dose-response sensitivity). In a statistical analysis of the model, to-
gether with expert information, important predicitive factors for immunogenicity
were successfully identified. 
In conclusion, retrospective analysis of various characteristics and preclinical data
from on-market biological can provide us with insight in the mechanism of im-
munogenicity.
2060 Improved Efficacy of Delivery of Antigen Using a Novel
Injection Device in the Rabbit.
N. Hebert1,  S. Gariepy1,  I. Brochu1,  A. Caron-Laramée2,  M. Brouillette2 and
C. Hébert2. 1Charles River, Sherbrooke, QC, Canada; 2University of Sherbrooke,
Sherbrooke, QC, Canada. Sponsor: M. Vézina.
Needle-free injector devices show a novel, improved and safer alternative to more
classical intramuscular injection immunization protocols. 
Two routes of administration [intramuscular (IM) versus intradermal (ID) injec-
tion; with a gene-gun type needle-free injector device] were compared in rabbits
and the immunogenicity response, together with any potential toxicity were evalu-
ated following immunization with a plasmid coding for the Hepatitis B surface pro-
tein (HbSAg) when administered up to three times (Days 1 and 29 [and Day 43;
intradermal only]). 
Overall, there were no differences between routes of administration when body
temperature, body weight, food consumption, selected coagulation and clinical
chemistry parameters, and C-Reactive proteins were compared over a period of 43
days. At necropsy, there were no organ weight changes or any adverse macroscopic
observations. Based on the magnitude of antibody response and the number of an-
imals mounting a response, a more robust immune response was observed in ani-
mals immunized with the injector delivery method (ID). Only 17% of animals re-
ceiving the IM injection showed detectable levels of anti-HBsAg antibodies,
compared to 50% of animals receiving the ID injection. Furthermore, anti-HBsAg
levels in animals administered ID were generally higher than the IM responder. In
conclusion, these results suggest that a needle-free injector device shows a safe alter-
native to intramuscular injection with an increased efficacy when using in immu-
nization regimens.
2061 Development of a Protocol to Determine the T Cell
Dependent Antibody Response (TDAR) to Klh in the
Mouse—A Comparison between the CD-1 and C57BL/6N
Strains.
S. Kirk,  A. Lucock and K. Troth. Covance Laboratories Ltd., Harrogate, United
Kingdom.
Pre-clinical safety assessment of biopharmaceuticals may require testing in a specific
strain of mouse, when this is the only species where the test material is pharmaco-
logically active. This can present challenges when evaluating immunotoxicity due
to known differences in immune responses that exist between different strains. In
this study we developed a robust TDAR protocol in the CD-1 mouse then at-
tempted to transfer a similar protocol for use in the C57BL/6N strain.
Initially CD-1 mice were immunised twice intravenously, 1 week apart, at KLH
dose levels of 0.3 or 80 mg/kg/challenge. Cyclosporin was also tested at 20 and 100
mg/kg/day in order to establish a positive control. KLH and cyclosporin dose levels
of 80 mg/kg and 100 mg/kg respectively, were not tolerated resulting in several pre-
mature decedents. A strong IgM and IgG response was observed at the 0.3 mg/kg
dose level. Cyclosporin administration at 20 mg/kg/day was sufficient to suppress
this response in females only. Cyclosporin administration was tested at 60
mg/kg/day, which proved adequate to suppress the immune response to KLH in
both sexes. This protocol was tested in C57BL/6N mice, but failed to produce a ro-
bust antibody response. Based on a protocol provided by another lab, C57BL/6N
mice were challenged subcutaneously with KLH at 0.1 mg/kg in alum on Day 1
then challenged with KLH only at 0.05mg/kg on Day 7. Control group mice were
tested in parallel, without the use of alum. A strong IgM and IgG anti-KLH re-
sponse was noted in both sexes, most notably in females. In the control group, only
the females produced a robust anti-KLH response.
In conclusion, we have established a robust immunisation protocol to measure the
TDAR response in CD-1 mice and a suitable positive control to suppress the re-
sponse. An immunisation protocol in the C57BL/6N mouse was also established
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however the use of an adjuvant was required to produce a strong anti-KLH re-
sponse. Further work to establish a suitable dose level of cyclosporin in C57BL/6N
mice is still required.
2062 T Cell Dependent Antibody Responses in the Rat: Forms and
Sources of Keyhole Limpet Hemocyanin Matter.
H. Lebrec1,  M. B. Hock2,  J. Sundsmo3,  D. Mytych2,  H. Chow3,  L. Carlock1,
M. K. Joubert2 and J. L. Bussiere2. 1Amgen, Seattle, WA; 2Amgen, Thousand Oaks,
CA; 3Stellar Biotechnologies, Port Hueneme, CA.
The T-cell dependent antibody response (TDAR) is a functional assay used in im-
munopharmacology and immunotoxicology to assess the ability to mount an anti-
body (IgM and/or IgG) response to immunization. Keyhole limpet hemocyanin
(KLH) is extensively used as immunogen of choice both in nonclinical and clinical
settings. Native KLH is comprised of high molecular weight (HMW) assemblies
(>600-800 kDa) of KLH subunit dimers. It is not known how the different forms
(HMW vs. subunit) and manufacturing processes (commercial sources) may im-
pact the nature of anti-KLH immune responses (e.g., magnitude and inter-animal
variability). Anti-KLH IgM and IgG responses were studied in female Sprague-
Dawley rats immunized on days 1 and 22 with 100 ug of HMW KLH from two
different sources or subunit KLHs from three different sources without co-injection
with any adjuvant. Dose analysis and biophysical characterization of KLH formula-
tions were conducted. Anti-KLH IgM and IgG responses were measured on days 1,
8, 15, 22, 29, 36, and 43 using a proprietary indirect electrochemiluminescence
immunoassay. The two HMW KLH preparations showed a greater number of sub-
visible particles (2-150 μm size range) than the three subunit KLHs. All HMW
KLHs and all subunit KLHs were equivalent on SEC (hydrodynamic volume),
PAGE (size and charge) and SDS-PAGE (molecular radius). Robust primary and
secondary anti-KLH IgG and IgM responses were detected for both sources of
HMW KLH. The subunit KLH immunizations resulted in lower IgG and IgM re-
sponses, with the exception of Stellar Biotechnologies subunit KLH which pro-
duced a robust secondary response. Inter-animal variability for IgM and IgG re-
sponses was lower with HMW KLH than with subunit KLHs. In conclusion,
different forms and sources of KLH are associated with different magnitudes and
inter-animal variabilities in IgM and IgG responses, a critical finding to take into
consideration when designing TDAR studies for proper immunotoxicology or im-
munopharmacology testing.
2063 Use of the T Cell-Dependent Antibody Response to Evaluate
Immunostimulation.
M. S. Piché1,  J. Shenton2,  C. Dumont1,  R. Bourgeois1,  I. Brochu1,
A. J. Grenier1,  E. Marcotte1,  L. Durette1,  M. Poirier1,  L. de Haan2 and
L. LeSauteur1. 1Immunology, Charles River, Montréal, QC, Canada; 2Medimmune,
Cambridge, United Kingdom.
Purpose: The T-cell-dependent antibody response (TDAR) has traditionally been
used to evaluate immunosuppression. The purpose of this study was to evaluate
whether the TDAR following immunization with the T-dependent antigen (TDA)
KLH, has utility for evaluating pharmacologically-mediated immunostimulation in
cynomolgus monkeys. Recent advances in the development of immunostimulatory
therapeutics, primarily T-cell stimulating biologics with cross-reactivity limited to
the cynomolgus monkey, have presented a need for pharmacodynamic assays capa-
ble of measuring increased T-cell activation in monkeys.
Methods: Instead of immunizing the monkeys with 10 mg of KLH, an immuniza-
tion dose used for evaluating immunosuppression, monkey were immunized twice
(1 month apart) with either 0.1 mg or 1.0 mg of KLH in the presence or absence of
adjuvants as model immunostimulants. The subsequent antibody response to KLH
was measured in the serum following both immunizations, while the cellular re-
sponse was measured by ELISpot following the second immunization after ex vivo
challenge of peripheral blood cells with KLH.
Results: Immunostimulation by the adjuvant, defined as an increased magnitude of
the TDAR, was more clearly demonstrated in monkeys dosed with 0.1 mg of KLH
as compared to monkeys dosed with 1 mg of KLH. In addition, a strong KLH-in-
duced IFN-γ response and a mild IL-5 response were elicited following KLH im-
munization in the presence of the model immunostimulants; however, the cytokine
responses were not consistently observed across all animals.
Conclusion: Although further validation using known immunostimulatory thera-
peutics (as opposed to adjuvants) is required, it is clear that monitoring enhanced
antibody responses and possible ex vivo cytokine responses following low dose im-
munization with KLH may present an opportunity to evaluate pharmacologically-
mediated immunostimulation in cynomolgus monkeys.
2064 Assessment of Hepatitis B Surface Antigen and Tetanus
Toxoid-Specific T Cell-Dependent Antibody Responses in
Cynomolgus Monkeys.
B. Wang1,  D. A. DeVona1,  M. P. Bernard1,  Q. Wang2,  C. Gleason3,
H. G. Haggerty1 and W. J. Freebern1. 1Immunotoxicology, Bristol-Myers Squibb,
New Brunswick, NJ; 2Rutgers University, New Brunswick, NJ; 3Global Biometric
Sciences, Bristol-Myers Squibb, Syracuse, NY.
Assessment of T-cell-dependent antibody responses (TDAR) is implemented in
nonclinical safety testing to evaluate test article effect on immune function. Robust
ELISA-based assays to analyze hepatitis B surface antigen (HBsAg)- and tetanus
toxoid (TT)-specific antibodies in serum from cynomolgus monkeys immunized
with HBsAg and TT were developed. Assay optimization included evaluation of
vaccination doses (Engerix B [HBsAg] at 10 and 20 μg, human pediatric and adult
doses; TT Adsorbed at 5 flocculation units) and dosing regimen, post-immuniza-
tion blood collection times, capture reagents and concentrations thereof, initial test
serum dilutions, detection antibody dilutions, and incubation times. HBsAg- and
TT-specific IgG and IgM endpoint titers (EPT) were analyzed pretest and weekly
up to 6 weeks post-immunization to evaluate antibody response kinetics to these
antigens. In brief, HBsAg or TT (0.2 or 0.03 μg/well, respectively) is adsorbed
overnight onto a 96-well microtiter plate followed by incubation with an initial test
serum dilution of 1:5 or 1:50 and titrated 3x to final dilutions of 1:295245 or
1:2952450 for HBsAg or TT-specific antibody analyses, respectively. Bound
HBsAg or TT specific-antibodies are detected using a 1:500 or 1:1000 dilution of
alkaline phosphatase-conjugated goat anti-human Ig (total, IgM or IgG). After sub-
strate addition and colorimetric analysis, an EPT is calculated. Following primary
immunization, peak HBsAg IgM- and IgG-specific responses were observed 22 and
28 to 35 days post immunization, respectively. HBsAg-specific IgG EPT did not
generally increase from primary peak response after a second challenge. Since the
study monkeys were immunized with TT prior to purchase, a TT IgM-specific re-
sponse was not detected. TT-specific IgG responses peaked 15 days post on-study
immunization.
2065 Development of a Delayed Type Hypersensitivity (DTH)
Model in Cynomolgus Monkeys.
G. Bannish1, 5,  H. Babbe2,  A. Curran6,  L. A. Coney5,  L. Hall3,  J. Zhou3,
J. Ma4,  M. Perpetua1,  J. Doughty1,  A. Beavis1 and M. Scully2. 1Biologics and
Biomarker Analysis, Huntingdon Life Sciences, East Millstone, NJ; 2Janssen R&D,
LLC, Radnor, PA; 3Janssen R&D, LLC, Raritan, NJ; 4Janssen R&D, LLC, La Jolla,
CA; 5Group Strategic Marketing, Huntingdon Life Sciences, Huntingdon, United
Kingdom; 6Safety Assessment, Huntingdon Life Sciences, East Millstone, NJ. Sponsor:
C. Auletta.
We have developed an improved delayed type hypersensitivity (DTH) model to as-
sess the cellular immune response. Animals were sensitized with three antigens, key-
hole limpet hemocyanin (KLH), Candida Albicans (CA), and Tetanus Toxoid (TT)
emulsified in incomplete Freund’s adjuvant (IFA). These antigens were adminis-
tered subcutaneously on 3 to 5 occasions over 1 to 2 weeks, followed by a resting
period of 1 month. Antigenic challenge was administered intra-dermally with re-
duced amounts of antigen and in the absence of IFA adjuvant, and at multiple sites
with individual antigens or a combined cocktail. Specific IgG responses to each of
the antigens were detected. Slight erythema and induration were observed at some
sites and some animals, most prominent at 48 hours and with KLH or cocktail.
Histological evaluations detected a more intense cellular response with KLH and
the combination than TT or CA at both 48 and 72 hours post challenge.
Mononuclear cell infiltration (CD3 labeled lymphocytes and CD68 labeled
macrophages) was observed in biopsies from CA (3 of 4 animals), TT (3 of 4 ani-
mals), KLH (all animals) and the cocktail (all animals), with maximal responses oc-
curring at the 48 and 72 hour time points. Flow cytometry was performed on sam-
ples from blood, bone marrow, spleen, and lymph nodes to assess regular and
activated immune cell subsets, including evaluation of naïve T lymphocytes
(CD95-CD28+) and central memory T lymphocytes (CD95+CD28+) throughout
the course of the study. In summary, these findings are consistent with infiltration
of cytotoxic T lymphocytes into the challenge site, which is a hallmark of a classical
DTH response.
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2066 Validation of a 7-Color Flow Cytometry Panel for
Lymphocyte Phenotyping in Peripheral Blood from
Cynomolgus Monkeys.
S. Eble1,  B. Wang1,  D. A. DeVona1,  C. Thompson1,  C. Gleason2,
H. G. Haggerty1,  W. J. Freebern1 and M. P. Bernard1. 1Bristol-Myers Squibb, New
Brunswick, NJ; 2Global Biometric Sciences, Bristol-Myers Squibb, Syracuse, NY.
Standard peripheral blood immunophenotyping is often implemented in nonclini-
cal safety testing to evaluate potential test article effects on specific lymphocyte
population cell counts. The purpose of this study was to validate a robust, resource
efficient, high throughput 7-color flow cytometry panel for the identification of T,
B, and NK cells in cynomolgus monkey blood. In brief, whole blood was aliquoted
into wells (2.2 mL capacity) of a 96-deep well block, washed with PBS, and incu-
bated with fluorophore-conjugated, cell-marker specific antibodies. Following red
blood cell lysis, subsequent paraformaldehyde fixation of leukocytes and addition
of counting beads, detection of immunostaining was performed using a BD
FACSCanto II flow cytometer. Total lymphocytes were identified by side light scat-
ter and CD45 immunostaining and the CD45+ lymphocyte subpopulations were
characterized as follows: total T cells (CD16-CD3+), helper T cells (CD16-
CD3+CD4+CD8-), cytotoxic T cells (CD16-CD3+CD8+CD4-), double positive
T cells (CD16-CD3+CD8+CD4+), double negative T cells (CD16-CD3+CD8-
CD4-), B cells (CD16-CD20+), and NK cells (CD3-CD16+CD159a-, CD3-
CD16-CD159a+, and CD3-CD16+CD159a+). The inter-assay, intra-assay, and
inter-analyst precision estimates based on absolute numbers of lymphocyte subpop-
ulations (calculated using counting beads) were all within 20% (%CV; coefficient
of variation). Validation testing demonstrated antibody specificity and minimal flu-
orescence carryover between samples. Whole blood stability (ie prior to immunos-
taining) was demonstrated for up to 24 hours at ambient temperature and the fixed
samples were determined to be stable for up to 24 hours at 5 ± 4°C prior to flow cy-
tometric analysis. Based on the results from this validation study, it was determined
that the 7-color flow cytometry panel described herein reliably and precisely identi-
fies T, B, and NK cells in cynomolgus monkey whole blood.
2067 Testing the Use of CD107a and IFN-γ As Markers of
Cynomolgus Cytotoxic T Lymphocyte Activation.
L. Anest,  A. Guerrero,  M. Fort and P. Narayanan. Discovery Toxicology, Amgen,
Seattle, WA.
Cytotoxic T lymphocytes (CTLs) are key effector cells, in the immune system, that
play an important role in anti-viral host defense and cancer immune-surveillance.
Non-human primates, especially cynomolgus macaques, are the closest surrogates
for detecting immunosuppressive properties of targeted anti-inflammatory thera-
peutics in human. While qualified methods exist to measure CTL function in hu-
mans and rodents, there are few assays currently available for detection of changes
in CTL function in response to drug exposure in cynomolgus macaques. Herein,
we present an adaptation of a flow cytometry-based human CTL degranulation
assay for characterization of cynomolgus macaque CTL function. This is based on
detection of lysosomal-associated membrane protein 1 (CD107a) on the surface of
degranulated CTL in conjunction with the secretion of IFN-γ which allows for the
identification of fully activated CTL. Briefly, whole blood samples from cynomol-
gus macaques were stimulated in vitro with staphylococcal enterotoxin B (SEB) for
six hours, then stained for the detection of intracellular IFNγ and surface expression
of CD3, CD4, CD8 and CD107a prior to analysis on a flow cytometer. Whole
blood samples from naïve cynomolgous macaques (n = 11) were tested to establish
a range of dual positive CD107a+IFNγ+ CTL (0.04-1.58% of CD3+CD4-CD8+
T cells) in response to SEB stimulation. Next, a longitudinal study was completed
to determine the intra-animal variation of CD107a+IFNγ+ CTL responses in 4
cynomolgus macaques by collecting samples at 2-3 week intervals over a two month
period. CTL activation in response to SEB stimulation demonstrated a %CV of
31-57% over the course of the study. The direct addition of an immunosuppressive
compound, cyclosporine A, to WB suppressed IFN-γ secretion but not degranula-
tion of CTL in response to SEB in a concentration-dependent manner. The ability
to quantify the CTL functional responses in cynomolgous macaques may be a use-
ful tool for determining any immunomodulatory effects of drug candidates in pre-
clinical safety studies on this important lymphocyte subset.
2068 Validation of Assays for Phagocytic Function of
Polymorphonuclear Neutrophils and Monocytes in Whole
Blood from Cynomolgus Macaque.
M. Perpetua1 and G. Bannish2, 1. 1Biologics and Biomarker Analysis, Huntingdon
Life Sciences, East Millstone, NJ; 2Group Strategic Marketing, Huntingdon Life
Sciences, East Millstone, NJ.
Phagocytosis constitutes an essential arm of host defense against bacterial and fun-
gal infections. The process can be subdivided into phagocyte chemotaxis to sites of
inflammation, binding to foreign agents, ingestion of opsonized bacteria, and intra-
cellular killing by oxygen-dependent and oxygen-independent mechanisms. We
have assessed several of these functions in whole blood from cynomolgus macaque
using commercially available kits designed for human use. Tests included intra-
assay precision, inter-assay precision, processed stability, sample stability, and inter-
analyst variability. The percent coefficient of variation was lower for granulocytes
than monocytes, typically 1% versus 10% or less in the ingestion assay. Respiratory
burst following stimulation with phorbol 12-myristate 13-acetate (PMA), op-
sonized bacteria, or the chemotactic peptide N-formyl-Met-Leu-Phe (fMLP) was
within ranges established for human whole blood. The PMA stimulant was high
and consistently > 95% above unstimulated negative control values, the fMLP was
low (< 5%), and opsonized bacteria induced a high percentage of stimulated granu-
locytes (>95%) but lesser stimulated monocytes (~60%). The highest CV values oc-
curred in tests of oxidizing monocytes for inter-assay (19%), processed stability
(19%), and sample stability (15%), but were otherwise typically below 5%. Overall
these results determine the ability to use these assays for analysis of phagocytic func-
tion in cynomolgus macaque under GLP conditions.
2069 Flow Cytometry Immunophenotyping of Lymphocyte
Subsets in a Large Cohort of Beagle Dogs.
J. Descotes2,  C. Mimouni1,  J. Legrand1 and R. Forster1. 1Marketing, CiToxLAB,
Evreux, France; 2Poison Center, Lyon, France.
Since the dog is a major non-rodent species used in regulatory drug safety studies,
there is a growing need to generate historical immunological background data to
interpret the results of nonclinical immunotoxicity studies in dogs. We have initi-
ated the compilation of data on peripheral blood lymphocyte subsets in a large co-
hort of male and female naïve Beagle dogs of at least 6 months of age. Venous blood
samples of approximately 0.5 ml were collected from fasted animals in the morn-
ing. Immunophenotyping analysis of B lymphocytes, total T lymphocytes, T
CD4+ and CD8+ lymphocytes with commercial BD Pharmingen fluorescent anti-
body reagents (BD Biosciences, France) is performed using a Navios 10-color flow
cytometer with the Navios v1 software (Beckman Coulter, France). Flow count®
fluorospheres are added to each sample prior to flow cytometry analysis for direct
determination of lymphocyte subset absolute counts. At writing, validated results
are available on 40 males and 50 females. Results obtained in males and females, re-
spectively, are presented as percentage of gated cells and mean (± standard devia-
tion) of absolute count of each lymphocyte subset/μl: B lymphocyte percentage
(21.3% & 18.5%) and absolute count (604.4±185.5 & 495.5±171.5); total T lym-
phocyte percentage (60.8% & 64.1%) and absolute count (1719.6±599.4 &
1728.5±334.9); T CD4+ lymphocyte percentage (41.0% & 43.6%) and absolute
count (1180.4±399.7 & 1159.3±228.1); T CD8+ lymphocyte percentage (12.7%
& 12.2%) and absolute count (360.2±136.6 & 324.6±106.9). Stored samples from
additional animals (total of 100 animals from each sex) are being processed, which
will very shortly constitute the largest cohort of data on peripheral blood lympho-
cyte subsets in the naïve Beagle dog.
2070 Development of Molecular Classifiers for Distinguishing
between True Sensitizers and False Positives in the Local
Lymph Node Assay.
D. R. Boverhof1,  D. Adenuga1,  M. Woolhiser1,  I. Kimber2,  R. Dearman2,
M. Black3 and R. S. Thomas3. 1The Dow Chemical Company, Midland, MI;
2University of Manchester, Manchester, United Kingdom; 3The Hamner Institutes for
Health Sciences, Research Triangle Park, NC.
Recent publications have highlighted certain chemistries which yield false positive
responses in the LLNA when compared with guinea pig and human data.
Toxicogenomics was applied to provide molecular characterization of the LLNA re-
sponses with the goal of developing classifiers for predicting true skin sensitizers.
Auricular lymph node gene expression responses were evaluated in female CBA
mice exposed to equipotent doses of 9 known chemical sensitizers and 7 false posi-
tives per the standard LLNA dosing regimen. Lymph nodes were analyzed for
3HTdR incorporation on study day 6 and gene expression responses on study days
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4 and 6. Subsequent to data filtering, a comprehensive cross-validation model com-
parison using 84 different statistical classification methods was performed to iden-
tify expression-based classifiers for each chemical class (sensitizers and false posi-
tives) and time point. The predictive performance of the models was evaluated
using five-fold cross-validation. The gene lists from the top performing model for
each chemical class and time point were subsequently confirmed and refined using
quantitative RT-PCR. The top performing day 4 classifiers had AUC values of
0.904 and 0.926 for sensitizers and false positives, respectively, while the day 6 clas-
sifiers showed higher AUC values of 0.962 and 1.00 for sensitizers and false posi-
tives, respectively. The optimal day 6 classifier gene list included 44 and 30 genes
for sensitizers and false positives, respectively, with 19 overlapping genes. The 55
total genes displayed functional relevance to sensitization and irritation responses
and both classifiers are now being evaluated against a series of new chemistries to
independently assess model performance. Overall these data highlight the potential
utility of molecular classifiers for distinguishing between sensitizers and false posi-
tives.
2071 Development of an Ex Vivo BrdU-Labeling Procedure for the
Murine Llna.
D. M. Lehmann1,  C. Copeland1,  E. H. Boykin1,  S. J. Quell2,  L. Copeland1 and
W. C. Williams1. 1NHEERL, US EPA, Research Triangle Park, NC; 2Independent,
Research Triangle Park, NC.
The murine local lymph node assay (LLNA) is widely used to identify chemicals
that may cause allergic contact dermatitis. Exposure to a dermal sensitizer results in
proliferation of local lymph node T cells, which has traditionally been measured by
in vivo incorporation of [3H]methyl thymidine (3HTdR). A more recent non-iso-
topic variation of the assay utilizes bromodeoxyuridine (BrdU) incorporation in
vivo. To eliminate the need for animal injections, we developed an ex vivo labeling
procedure. BALB/c mice were dosed topically on the dorsum of both ears for 3 con-
secutive days with vehicle or one of 3 concentrations of eugenol (EUG), cin-
namaldehyde (CA), hexyl cinnaminic aldehyde (HCA), nickel sulfate (NiS), iso-
propanol (IP) or lactic acid (LA).  On day 5, lymph nodes were harvested, and
single-cell suspensions were labeled ex vivo with 3HTdR or BrdU. Lymphocyte
proliferation was determined by scintillation counting or BrdU ELISA, respectively.
Concentration-dependent increases in ear thickness and lymphocyte proliferation
were observed for EUG, CA and HCA, but none of the doses tested resulted in ex-
cessive skin irritation. The results of both the ex vivo 3HTdR and ex vivo BrdU as-
says correctly identified EUG, CA and HCA as dermal sensitizers according to the
criteria outlined in the Globally Harmonized System for Classification and
Labeling of Chemicals. As anticipated, non-sensitizers IP and LA did not induce a
positive threshold response in either assay.  Furthermore, a positive threshold re-
sponse was not obtained for the false negative chemical NiS in either assay. The re-
sults of both ex vivo assays are in close agreement with those of the in vivo BrdU la-
beling procedure. We conclude that the ex vivo BrdU labeling method offers
predictive capacity comparable to the other previously established LLNA protocols
while eliminating animal injections and the use of radioisotope. This abstract does
not represent EPA policy.
2072 A Proteomics Approach to Elucidate the Role of Nrf2 in
Primary Bone-Marrow-Derived Dendritic Cells of Mice
upon Activation by Contact Allergens.
A. Haase1,  F. Mussotter1,  Z. El Ali2,  S. Kerdine- Römer2,  J. Tomm3,
M. Pallardy2,  M. von Bergen3 and A. Luch1. 1Federal Institute for Risk Assessment
(BfR), Berlin, Germany; 2University of Paris- Sud, INSERM UMR-996, Paris,
France; 3Department of Proteomics and Metabolomics, Helmholtz Centre for
Environmental Research (UFZ), Leipzig, Germany.
Contact sensitizers are low molecular weight compounds, which can prompt den-
dritic cells in the skin to subsequently activate naïve T-cells in draining lymph
nodes. Often these compounds are electrophilic and lead to activation of the
Keap1/Nrf2 pathway. We aimed to further elucidate the underlying molecular
mechanisms of skin sensitization and to identify putative biomarkers.
We used bone marrow-derived dendritic cells (BMDC) from CD34+ progenitor
cells from wild-type or Nrf2 -/- mice. Cells were treated for 8 h with different con-
tact allergens: cinnamaldehyde (CA), 1-chloro-2,4-dinitrobenzene (DNCB), nickel
sulfate (NiSO4) or with SDS as an irritant control. Analysis was done using 2D gels
and ESI-MS/MS. Protein spots were considered as differentially expressed if they
changed at least 1.5-fold (p < 0.05).
While treatment with 250 and 400 μM nickel and 100 μM SDS hardly had any ef-
fects, CA and DNCB led to significant changes in protein expression. We found 9
and 27 spots upregulated with 50 and 100 μM CA, respectively. For 5 and 10 μM
DNCB 14 and 35 spots were upregulated, respectively. Some of those were not de-
tected in Nrf2 -/- cells, indicating a Nrf2-dependent regulation. More than 90% of
the proteins could be identified. Some of those have been already characterized as
Nrf2-dependent such as glutathione S-transferases, glutamate cysteine ligase, or
catalase. We also identified other proteins involved in oxidative stress, signal trans-
duction pathways, basic cellular pathways and also heat shock proteins. Some of
them were not inducible in Nrf2 -/- cells and were not previously described as
Nrf2-dependent. 
We could confirm Nrf2 activation in the response of mouse BMDC upon exposure
to contact sensitizers. We could identify interesting potential biomarkers, some of
which should be studied in more detail in the future.
2073 Nrf2-Dependent and -Independent Effects of tBHQ on Early
T Cell Activation.
C. E. Rockwell1,  P. E. Fields3,  C. D. Klaassen2,  J. W. Zagorski1,  A. E. Turley1
and H. Dover1. 1Pharmacology & Toxicology, Michigan State University, East
Lansing, MI; 2Pharmacology, Toxicology & Therapeutics, University of Kansas
Medical Center, Kansas City, KS; 3Pathology & Laboratory Medicine, University of
Kansas Medical Center, Kansas City, KS.
Nrf2 is a transcription factor that is activated by cellular stress from various sources,
including oxidative stress and electrophiles. In response to cell stress, Nrf2 upregu-
lates a battery of cytoprotective genes. In addition to this role, Nrf2 has also been
shown to have immunomodulatory effects, including anti-inflammatory effects in
innate immune cells and effects on T cell differentiation. The purpose of the pres-
ent studies was to determine the role of Nrf2 in cytokine production and other
events associated with early T cell activation. The present studies demonstrate that
the Nrf2 activator, tBHQ, causes a significant decrease in the early production of
IFNγ and IL-2 in anti-CD3/anti-CD28-activated splenocytes from both wild-type
and Nrf2-null mice. Interestingly, splenocytes from Nrf2-null mice produced in-
creased levels of IFNγ, but decreased levels of IL-2, as compared to those from wild-
type mice. In addition to IL-2 and IFNγ, the effects of tBHQ on other genes that
are upregulated after T cell activation were investigated. In contrast to IL-2 and
IFNγ, tBHQ caused only modest effects on the upregulation of CD25 and CD69,
which are also induced during early T cell activation. Treatment of activated spleno-
cytes with tBHQ also inhibited calcium influx. Collectively, the current studies
suggest that tBHQ inhibits early production of IFNγ and IL-2 and that this effect
is at least partially Nrf2-independent. These studies also suggest that Nrf2 pro-
motes IL-2, but inhibits IFNγ, at early time points after T cell activation. (This
work was funded by NIH grant: ES018885.)
2074 Activation of Nrf2 by TBHQ Inhibits IL2 Production, but
Not CD69 Expression, in Human Jurkat T Cells.
J. W. Zagorski1, 2,  A. E. Turley2,  K. R. Vandenberg2,  J. Compton2,  H. E. Dover2
and C. E. Rockwell2, 1. 1Cellular and Molecular Biology, Michigan State University,
East Lansing, MI; 2Pharmacology and Toxicology, Michigan State University, East
Lansing, MI.
Nuclear factor erythroid 2-related factor 2 (Nrf2) is a transcription factor that is ac-
tivated by cell stress, such as electrophilic and oxidative stimuli. Once activated,
Nrf2 translocates to the nucleus and induces the transcription of its target genes,
including HMOX and NQO1. Previously, it has been shown that Nrf2 skews
CD4+ T cell differentiation in primary murine T cells, however the role of Nrf2 in
human T cells is largely uncharacterized.  Therefore, the purpose of the present
studies was to determine the effects of Nrf2 activation upon early events of CD4+
T cell activation, in human Jurkat T cells. Treatment of Jurkat cells with the Nrf2
activator, tBHQ (5 μM), significantly decreased both transcript and protein pro-
duction of IL-2. Similarly, a modest reduction of CD25 induction by tBHQ was
observed, but CD69 expression remained unaffected.  Nuclear translocation of c-
fos and c-jun (transcription factors that regulate IL-2) was not affected by tBHQ
treatment. In contrast, cells pretreated with 1 μM and 5 μM tBHQ showed both a
delay of and decrease in Ca2+ influx stimulated by anti-CD3/anti-CD28.
Collectively, the current studies suggest a differential effect of tBHQ on early events
of CD4+ T cell activation, and these effects are at least partially due to inhibition of
Ca2+ influx into the cell. (This work is supported by NIH grant: ES018885)
2075 Inhibition of Early Cytokine Production by the Nrf2
Activator, tBHQ, in Human Primary Blood Mononuclear
Cells.
A. E. Turley1, 2,  J. W. Zargorski1 and C. E. Rockwell1, 2. 1Pharmacology and
Toxicology, Michigan State University, East Lansing, MI; 2Center for Integrative
Toxicology, Michigan State University, East Lansing, MI.
tBHQ (tert-butylhydroquinone) is a common food preservative and a known Nrf2
(nuclear factor erythroid 2-related factor 2) activator. Nrf2 is a ubiquitously ex-
pressed transcription factor responsive to cell stress that regulates many cytoprotec-
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tive and detoxification genes. In addition, Nrf2 has been shown to have anti-in-
flammatory properties and to modulate the activity of numerous immune cell
types, including T cells. The purpose of the present studies was to characterize the
role of Nrf2 during T cell activation in primary blood mononuclear cells isolated
from human whole blood. The induction of several genes associated with early T
cell activation, including IL-2, IFN-γ, CD25 and CD69, was investigated in
PBMCs treated with tBHQ prior to T cell activation. Treatment with tBHQ inhib-
ited production of the early cytokines IL-2 and IFN-γ, in a dose-dependent man-
ner. Compared to the cytokines, induction of the cell surface markers CD25 and
CD69 was less sensitive to tBHQ, with expression inhibited only at the highest
concentration of tBHQ. The effects of tBHQ on protein expression of IL-2, IFN-
γ, CD25, and CD69 correlated with the mRNA expression of these genes.
Consistent with Nrf2 activation, tBHQ treatment also caused induction of the
Nrf2 target genes Hmox-1, Nqo1, and Gclc. Collectively, these studies demon-
strate that tBHQ inhibits early cytokine production by anti-CD3/anti-CD28acti-
vated PBMCs while only modestly decreasing CD25 and CD69 induction.
Overall, these data suggest that Nrf2 may differentially modulate the early events of
T cell activation in primary human T cells. (This work is supported by NIH grant
ES018885)
2076 Diethylstilbestrol (DES)-Regulated microRNA-30a May
Induce Autophagy by Regulating Beclin1 in Thymic Cells of
Neonatal Mice.
N. P. Singh,  U. P. Singh,  I. K. Abbas,  P. Nagarkatti and M. Nagarkatti.
Pathology, Microbiology, and Immunology, University of South Carolina School of
Medicine, Columbia, SC.
Prenatal exposure to DES is known to cause changes in immune functions thereby
increasing susceptibility to autoimmune diseases in humans. Experimental studies
have also indicated that prenatal exposure to DES affects thymic T cells. Our labo-
ratory has been investigating DES-regulated miR profile in fetal thymocytes fol-
lowing prenatal exposure. Of the 608 miRs examined by performing high-through-
put miR arrays with thymocytes on gestational day 18 (GD18) of C57BL/6 mice
exposed to DES, we observed more than 60 miRs that were up- or down-regulated
(>1.5-fold) when compared to vehicle treated group. Upon further analyses, we ob-
served significant downregulation (>2.0 fold) of miR-30a in fetal thymocytes post
DES exposure. miR-30a has been shown to regulate Beclin 1 (BECN1) expression
affecting autophagic activity. In the current study, therefore, we examined whether
miR-30a that was down regulated in fetal thymocytes post DES exposure plays a
role in autophagy vis a vis immune dysfunction in neonatal mice. Recent studies
have suggested that autophagy in the thymic epithelium is dispensable for negative
selection of autoreactive T cells. Upon analysis of miR-30a by Real-Time PCR, we
observed significant (more than 2-fold) downregulated expression of miR-30a in
fetal thymocytes but upregulated expression of BECN1. We further characterized
miR-30a for its binding affinity with BECN1 3’UTR region. Our studies demon-
strated significant blocking of BECN1 expression in the presence of miR-30a and
the effect of mir-30a was reversed in the presence of DES. Together, these data
demonstrate that prenatal exposure to DES can cause alterations in thymocyte dif-
ferentiation through dysregulation in miR-30a leading to altered BECN1 expres-
sion that in turn may influence the mechanisms of autophagy in fetal thymocytes.
(Supported in part by NIH grants P01AT003961, R01AT006888, R01ES019313,
R01MH094755, P20RR032684 and VA Merit Award BX001357).
2077 Δ9Tetrahydrocannabinol (THC) Rescues Mice from
Staphylococcal Enterotoxin B (SEB)-Induced Acute Lung
Injury (ALI) and Subsequent Mortality by the Induction of
Regulatory T Cells and the Down-Regulation of microRNA-
182.
R. Rao,  P. Nagarkatti and M. Nagarkatti. University of South Carolina, Columbia,
SC.
Acute Lung Injury (ALI) is characterized by infiltration of lymphocytes in the lung,
edema, Acute Respiratory Distress Syndrome (ARDS), and death. In this study,
Staphylococcal Enterotoxin B (SEB) was used to induce ALI in mice. SEB is a su-
perantigen that activates T cells expressing Vβ8, which leads to activation of ~20%
of T-cells and massive release of pro-inflammatory cytokines leading to the induc-
tion of ALI/ARDS. We tested the hypothesis that Δ9Tetrahydrocannabinol (THC),
a cannabinoid known for its anti-inflammatory properties can rescue mice from
SEB induced mortality. Intranasal followed by intraperitoneal administration of
SEB resulted in death of mice, while THC treatment rescued them from mortality.
SEB exposure induced vascular leak in the lung, which was reduced by THC treat-
ment. SEB administration resulted in the infiltration of lymphocytes (CD3+, VB8+,
NK, NKT, MDSC and macrophages) in the lung and THC treatment led to the
decrease in their absolute cell numbers. Interestingly, THC treatment caused an in-
duction of CD4+Foxp3+ T-cells in the lung, indicating a role for regulatory T-cells
in the amelioration of SEB induced inflammation. Additionally, SEB exposure led
to the induction of miR-182 that caused a downregulation in Foxo1 expression
leading to clonal expansion of T-cells. THC treatment however, decreased miR-182
expression indicating that THC might mediate its effects in part through the down-
regulation of miR-182. Cytokine analysis showed that while SEB exposure led to
the increase of IL-2 and MCP-1 in the serum and IFN-γ and IL-6 in the
Broncheoalveolar lavage fluid (BALF), THC treatment resulted in a decrease in
these cytokines. Together, our data demonstrates that THC can rescue mice from
SEB induced ALI and death. (Supported in part by NIH grants P01AT003961,
R01AT006888, R01ES019313, R01MH094755, P20 RR032684 and VA Merit
Award BX001357)
2078 Identification of microRNA That Affect Multiple Pathways
of TCDD-Induced T Cell Dysregulation.
P. Mehrpouya,  P. Nagarkatti and M. Nagarkatti. Department of Pathology,
Microbiology and Immunology, University of South Carolina School of Medicine,
Columbia, SC.
2, 3, 7, 8-Tetrachlorodibenzo-p-dioxin (TCDD), an environmental contaminant,
is well known for inducing severe toxicity including immunosuppression. We ex-
amined the mechanisms by which TCDD affects the T cell response to
Staphylococcal enterotoxin B (SEB). SEB, a superantigen, activates ~20% of T cells
via Vb8 T cell receptor, causes a robust release of pro-inflammatory cytokines. We
injected C57BL/6 mice with SEB in footpads and treated i.p with vehicle or
TCDD. Our studies showed that TCDD treatment of SEB-activated lymphocyte
led to a decrease in Vβ8+ T cells in compare to vehicle and causes an increased in-
duction of apoptosis in SEB-activated T cells. TCDD led to induction of FoxP3+ T
regulatory cells (Tregs) and suppression of pro-inflammatory cytokines, IFN-γ,
TNF-α and IL-6 while increasing the expression of the anti-inflammatory cy-
tokine, IL-10. Showing the role of microRNA (miR) in TCDD-induced immune
dysregulation, we performed high throughput miR analysis. Following TCDD ad-
ministration, 36 miRs were up-regulated while 50 were down-regulated. In silico
analysis demonstrated that several pathways were affected including induction of
apoptosis, cytochrome P450 expression and Treg differentiation. We validated the
role of selected miR following vehicle or TCDD treatment of SEB-activated LN
cells. miR-31, complementary to the 3’-UTR of the target gene Foxp3, was down
regulated in the TCDD treated group which is validated by RT-PCR. miR-351 di-
rected against the target gene CYP1A1, was down-regulated in the TCDD treated
group which suggests that TCDD acts as an AhR ligand causing increased CYP1A1
expression as well as Tregs induction. miR-21 targets the pro-apoptotic targets, Fas
and FasL was down-regulated, which results in TCDD-mediated toxicity. Our
studies demonstrated that TCDD affects miR expression that acts through several
mechanisms to cause immune dysregulation. (Supported by NIH grants
P01AT003961, P20 RR032684, R01AT006888, R01ES019313, R01MH094755
and VA Merit Award BX001357)
2079 Quantitative Phosphoproteomic Analysis of the Dynamic
Signaling Network Mediating Proinflammatory Response in
the Spleen of Mice under Deoxynivalenol-Induced Ribotoxic
Stress.
X. Pan1, 2,  D. Whitten3,  C. Wilkerson1, 3 and J. Pestka2, 4. 1Department of
Biochemistry and Molecular Biology, Michigan State University, East Lansing, MI;
2Center for Integrative Toxicology, Michigan State University, East Lansing, MI;
3Proteomics Core Facility, Michigan State University, East Lansing, MI; 4Department
of Food Science and Human Nutrition, Michigan State University, East Lansing, MI.
The trichothecene mycotoxin deoxynivalenol (DON) is a widely-studied model ri-
botoxin that targets the innate immune system and has public health significance
due to its common contamination of human and animal food. Induction of proin-
flammatory genes in the spleen by DON is known to involve activation of tran-
scription factors medicated by rapid phosphorylation of mitogen-activated protein
kinases (MAPKs). To further understand how phosphorylation of proteins leads to
the onset of proinflammatory response, stable isotope dimethyl labeling-based pro-
teomics was applied to quantitatively profile the immediate (≤30 min) phospho-
proteome changes in the spleen of mice orally exposed to a toxicologically relevant
dose of DON. A total of 90 phosphoproteins indicative of novel phosphorylation
events were significantly modulated by DON. In addition to critical branches and
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scaffolds of MAPK signaling being affected, DON exposure altered phosphoryla-
tion of proteins that mediate PI3K/AKT, B cell receptor and T cell receptor-linked
pathways and DNA methylation. Gene ontology analysis indicated that DON ex-
posure affected biological processes such as cytoskeleton organization, regulation of
apoptosis and immune system development, which could modulate cell adhesion
and lymphocyte function, setting the stage for the proinflammatory response.
Fuzzy c-means clustering analysis further revealed that DON evoked several dis-
tinctive temporal profiles of the regulated phosphopeptides. These results should
shed light on mechanisms of the immunotoxicity of ribotoxins and could ulti-
mately lead to novel strategies for countering the adverse actions of such agents.
2080 Targeted Proteomic Analysis of Phospho-Lyn in Hg
Intoxicated B Cells.
J. A. Caruso1,  P. M. Stemmer1,  M. J. McCabe2 and A. J. Rosenspire3. 1Institute of
Environmental Health Sciences, Wayne State University, Detroit, MI; 2Environmental
Medicine, University of Rochester, Rochester, NY; 3Immunology and Microbiology,
Wayne State University, Detroit, MI.
Network and key node analysis of proteins undergoing Hg(2+)-induced phospho-
rylation and dephosphorylation in Hg intoxicated mouse WEHI 231 B cells iden-
tified Lyn as the top scoring node. Lyn is a Src family protein tyrosine kinase known
to be intimately involved in the B Cell Receptor (BCR) signaling pathway. Under
normal signaling conditions the tyrosine kinase activity of (mouse) Lyn is con-
trolled by phosphorylation, primarily of two well known canonical regulatory tyro-
sine sites, Y397 and Y508. However Lyn has multiple tyrosines, threonines and ser-
ines, which have not so far been determined to play a major role under normal
signaling conditions, but are potentially important targets for phosphorylation fol-
lowing Hg(2+) exposure. In order to determine how Hg(2+) intoxication modu-
lates the phosphorylation of additional residues in Lyn, a targeted MS assay was de-
veloped. Initial mass spectrometric surveys of purified Lyn identified seven
phosphorylated amino acid residues (6 tyrosines and 1 serine). A targeted quantita-
tive assay was then developed from these results using the multiple reaction moni-
toring (MRM) strategy. WEHI 231 cells were treated with Hg, pervanadate, or
anti-mu antibody (to stimulate the BCR), and cell stimulation confirmed by anti-
phosphotyrosine western blots. Whole cell lysates from these same samples were
then separated by 1D SDS-PAGE and the regions containing Lyn were selected for
analysis. In gel digestion produced tryptic peptides that were analyzed on a TSQ
Vantage MS system using a Lyn-specific MRM method that targeted 11 peptides
and 6 phosphopeptides. Data indicate that several Lyn sites are subject to Hg(2+)-
induced phosphorylation. However Y117 and Y194 were especially susceptible,
suggesting that their phosphorylations may be important mediators of Hg im-
munotoxicity. Supported by NIEHS: R21ES019228
2081 Penicillium Mycotoxins Alter the Expression of Genes
Coding Enzymes That Regulate Epigenetic Programming in
Bovine Macrophages.
S. Oh1,  R. Cliff1,  C. G. Balch1,  B. S. Sharma1,  H. J. Boermans2,  S. Haladi3 and
N. A. Karrow1. 1Animal & Poultry Science, University of Guelph, Guelph, ON,
Canada; 2Biomedical Sciences, University of Guelph, Guelph, ON, Canada; 3Alltech
Inc., Guelph, ON, Canada.
Penicillium mycotoxins (PM) are natural immunomodulatory contaminants that
accumulate in grains, crops, fruits, and fermented products, especially during post
harvest periods, due to improper storage and harvesting methods. In this study, the
expression of genes coding key enzymes involved in epigenetic regulation was as-
sessed using a bovine macrophage cell line (BoMac). BoMac were activated with
bacterial lipopolysaccharide (LPS) and exposed for 6 hr to the following PM: cit-
rinin (CIT), ochratoxin A (OTA), patulin (PAT), mycophenolic acid (MPA), peni-
cillic acid (PA), or a combination of one of the above with OTA at the concentra-
tion that inhibits BOMAC cell proliferation by 25% (IC25). Messenger RNA was
isolated and real-time PCR analysis was performed to assess mycotoxin-induced
changes in the expression of DNA methyltransferases (DNMTs), histone demethy-
lases (JMJD3 and UTX), histone acetylases (CBP/p300), histone deacetylases
(HDACs), and histone ubiquitin ligase (BMI1). LPS-induced expression of
DNMT3a was augmented by OTA+PA, while DNMT3b expression was reduced
by PA, OTA+PA and CIT+OTA. JMJD3 expression was induced by PA but down-
regulated by OTA+PA. CBP/p300 expression was reduced by all individual myco-
toxins as well as OTA+MPA and OTA+PA, and BMI1 expression was reduced by
MPA, OTA+MPA and OTA+PA. The expression of HDAC1 was reduced by CIT,
MPA and PA, while HDAC2 expression was induced by CIT+OTA and
OTA+PAT. Lastly, HDAC3 expression was reduced by MPA, PA, CIT+OTA,
OTA+PAT, OTA+MPA and OTA+PA. These findings propose a potential novel
regulatory mechanism by which PM can modulate bovine macrophage gene ex-
pression and function.
2082 Genipin-Induces Cyclooxygenase-2 Expression through
Upregulating NF-κB, C/EBP and AP-1 Signaling Pathways
in Murine Macrophages.
T. Khanal,  H. Kim,  J. Choi and H. Jeong. Pharmacy, Chungnam National
University, Daejeon, Republic of Korea.
Genipin, the aglycone of geniposide, exhibits anti-inflammatory and anti-angio-
genic activities. Cyclooxygenase-2 (COX-2) acts as a link between inflammation
and carcinogenesis through its involvement in tumor promotion. In the present
study, we examined the effect of genipin on COX-2 gene expression and analyzed
the molecular mechanism of its activity in murine RAW 264.7 macrophages.
Furthermore, genipin dose-dependently increased the levels of COX-2 protein and
mRNA. These results demonstrate that genipin induced COX-2 expression via NF-
kB and AP-1 activation. Moreover, genipin increased the luciferase reporter gene
activity in cells transfected with a COX-2 promoter. Transient transfections utiliz-
ing COX-2 promoter deletion constructs and COX-2 promoter constructs, in
which specific enhancer elements were mutagenized, revealed that the NF-κB,
C/EBP and AP-1, were predominant contributors to the effects of genipin.
Together, these results suggest that genipin induces the expression of COX-2 in
Raw 264.7 macrophages, and the induction is related with activation of NF-kB and
AP-1 signaling pathway. Taken together, these findings suggest that genipin is re-
lated biological activities and induced inflammation.
2083 The Role of Transcription Factor FoxO1 in Asbestos-Induced
Apoptosis of MT-2 Cells.
H. Matsuzaki1,  S. Lee1,  M. Maeda2,  N. Kumagai-Takei1,  Y. Nishimura1 and
T. Otsuki1. 1Department of Hygiene, Kawasaki Medical School, Kurashiki, Japan;
2Laboratory of Functional Glycobiochemistry, Department of Biofunctional Chemistry,
Division of Agricultural and Life Science, Graduate School of Environmental and Life
Science, Okayama University, Okayama, Japan.
Asbestos is known to cause mesothelioma and lung cancer. We previously reported
that asbestos affects not only mesothelial and lung epitheial cells, but also anti-
tumor immune system. Regulatory T cells, Treg, produce inhibitory cytokines to
suppress anti-tumor immune system. MT-2 cells were cultured with asbestos for 8
months and employed as Treg model exposed to asbestos. MT-2 cells exposed to as-
bestos showed higher viability after treatment with high concentration of asbestos
than original MT-2 cells, and was designated as MT-2Rst. Total RNA were pre-
pared from MT-2Rst and original MT-2 cells, respectively, and mRNA expressed in
these cells were analyzed by using a micro array containing 41,000 human genes.
FoxO1, forkhead transcription factor, was found to decrease in MT-2Rst cells. We
generate FoxO1 knock-down MT-2 cells with shRNA. FoxO1 shRNA reduced
population of apoptotic cells after treatment with asbestos, whereas did not alter
basal apoptotic ratio. These results suggest that FoxO1 play a role in regulation of
asbestos-induced apoptosis, and down-regulation of FoxO1 in MT-2Rst is involved
in its resistance to asbestos.
2084 BCL-6 and SHP-1: Putative Regulators of TCDD-Mediated
Impaired Human B Cell Activation.
A. Phadnis1, 2,  R. B. Crawford2, 3,  R. S. Thomas4 and N. E. Kaminski2, 3.
1Genetics, Michigan State University, East Lansing, MI; 2Center for Integrative
Toxicology, Michigan State University, East Lansing, MI; 3Department of
Pharmacology and Toxicology, Michigan State University, East Lansing, MI; 4Hamner
Institute for Health Sciences, Research Triangle Park, NC.
The environmental contaminant 2,3,7,8-Tetrachlorodibenzo-p-dioxin(TCDD) is
known to cause suppression of humoral immune responses. Evidence from epi-
demiological studies performed in dioxin-contaminated areas suggest associations
between exposure to dioxin-like compounds and increased incidence of non-
Hodgkin’s lymphoma (NHL) in human subjects. We have observed that TCDD-
treatment of CD40L and cytokine- activated human peripheral blood B cells leads
to suppression of B cell activation. Hence, in order to elucidate the molecular
mechanisms underlying impaired B cell activation by TCDD, we focused on two
candidate genes – SHP-1, a protein tyrosine phosphatase that inhibits signaling in
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activated B cells and BCL-6, a transcriptional repressor of B cell activation and dif-
ferentiation also mutated in NHL. SHP-1 was identified through a genomic analy-
sis of AHR binding in TCDD-treated mouse B cells. To evaluate the potential in-
volvement of SHP-1 in this process, time-course measurements were performed
and SHP-1 mRNA and protein levels were induced at day 3 in presence of TCDD.
In several donors, we also observed a TCDD concentration-dependent increase in
protein levels of SHP-1. With respect to BCL-6, we observed decreased downregu-
lation of protein levels compared to control cells. When BCL-6 and SHP-1 levels
were measured simultaneously in human B cells, an increase in the double positive
(SHP-1hi BCL-6hi) population was seen in the presence of TCDD. This increase
in SHP-1 and BCL-6 levels was observed in several TCDD-sensitive human donors
and the changes were concentration-dependent. Collectively, these results suggest
that the regulators, BCL-6 and SHP-1 may be involved in the TCDD-mediated
suppression of human primary B cell activation. (Supported in part by NIH R01
ES002520 and P42 ES004911)
2085 Paradox of Epithelial Early Growth Response 1 in Epithelial
Inflammatory Signaling under Ribosomal Insults.
K. Do,  H. Choi,  J. Kim,  S. Park,  C. Oh and Y. Moon. Lab.of Mucosal Exposome
and Biomodulation, Department Microbiology and Immunology, Pusan National
University School of Medicine and Medical Research Institute, Yangsan, Republic of
Korea.
Regulation of gut epithelial NF-κB expression and activity are crucial for prevent-
ing overstimulation of pro-inflammatory response following exposure to commen-
sal bacteria. To determine whether the EGR-1 modulates epithelial NF-κB signal-
ing, we investigated the effects of epithelial EGR-1 on responses to bacterial
NF-κB-activating lipopolysaccharide (LPS) in intestinal epithelial cells under ribo-
somal stress. Although nuclear translocation of NF-κB was observed in the cells ex-
posed to LPS, chemokine expression was slightly affected. In contrast, simultaneous
exposure to LPS and ribosomal insults decreased epithelial NF-κB activities, but
chemokine expression was super-induced. Similar to our previous study, ribosomal
insults-induced EGR-1 mediated induction of pro-inflammatory chemokines in
the intestinal epithelial cells. Mechanistically, mucosal ribosomal insult-triggered
EGR-1 mediated PPARγ induction, which blocked NF-κB activation by LPS.
Taken together, EGR-1 regulates pro-inflammatory NF-κB activation by LPS via
EGR-1-induced PPARγ although EGR-1 is a positive mediator of chemokine in-
duction by mucosal ribosomal insult in gut epithelial cells (This study was carried
out with the support of National Joint Agricultural Research Project of RDA (pro-
ject number PJ008405032012) RDA, Republic of Korea).
2086 TCDD-Induced Modulation of Ig Expression in a Human B
Lymphocyte Cell Line.
B. Johnson,  J. Liu and C. E. Sulentic. Pharmacology & Toxicology, Wright State
University, Dayton, OH.
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) is a potent environmental toxin
known to inhibit immunoglobulin (Ig) gene expression in various animal studies.
We have identified the mouse 3’Igh regulatory region (3’IghRR) as a sensitive tran-
scriptional target of TCDD that may mediate inhibition of Ig expression.
Interestingly, the hs1,2 enhancer of the human 3’IghRR is polymorphic and has
been associated with a number of autoimmune diseases. In contrast to the in-
hibitory effects of TCDD on the mouse hs1,2, the human hs1,2 is activated by
TCDD. Whether this species difference in hs1,2 modulation translates to the
3’IghRR and Ig expression is unknown. The sensitivity of the antibody response to
TCDD-induced suppression in animal models suggests that human B-cells could
be a sensitive target of TCDD; however, very few studies have evaluated the effect
of TCDD on human B-cell function and Ig expression and none have evaluated the
human 3’IghRR. The objective of this study was to characterize the CL-01 human
B lymphocyte cell line as a potential human cellular model to determine the rela-
tionship between the AhR, 3’IghRR, Ig expression and class switch recombination.
Our results support expression of a functional AhR in the CL-01 cells. TCDD
treatment also induced transcriptional activity of luciferase reporters regulated by
each allele of the polymorphic human hs1,2 enhancer. Additionally, the CL-01 cells
can be activated to express Ig by ligands for the Toll-like receptor 9 (TLR9) and this
activation appears to be sensitive to TCDD-induced modulation. Future studies
will evaluate the role of the hs1,2 polymorphism in 3’IghRR activation, Ig expres-
sion and CSR and in the effects of TCDD on these processes. Since TCDD repre-
sents a large class of chemicals found in the environment, diet, and pharmaceuti-
cals, understanding chemical-induced modulation of the human 3’IghRR and
hs1,2 enhancer may provide a clue to the etiology of autoimmune diseases associ-
ated with the hs1,2 polymorphism. (Supported by NIEHS R01ES014676)
2087 Comparison of the Effects of Deoxynivalenol and Tributyltin
Oxide to That of Model Compounds Inducing Endoplasmic
Reticulum Stress, Ribotoxic Stress and T Cell Activation.
P. C. Schmeits1,  M. R. Katika1,  A. A. Peijnenburg1,  H. van Loveren2 and
P. Hendriksen1. 1Toxicology and Effect Monitoring, RIKILT Institute of Food Safety,
Wageningen, Netherlands; 2Laboratory for Health Protection Research, National
Institute of Public Health and the Environment, Bilthoven, Netherlands.
Two common immunotoxicants, the mycotoxin deoxynivalenol (DON) and the
organotin compound tributyltin oxide (TBTO), were previously studied for their
effects on the human Jurkat transcriptome. DON induces ribotoxic stress and both
DON and TBTO induces ER stress, oxidative stress, calcium mediated signalling,
NFAT and NFκB pathways, T cell activation and apoptosis. The present study
aimed to confirm this finding by comparing the effects of DON and TBTO on
mRNA expression in Jurkat cells to that of positive controls inducing ribotoxic
stress (anisomycin), ER stress (thapsigargin) and T cell activation (PHA and iono-
mycin).
Jurkat cells were exposed for 6 hours to subcytotoxic concentrations of DON,
TBTO, anisomycin, thapsigargin, ionomycin and PHA. RNA was isolated and hy-
bridised on Affymetrix U133 Plus 2.0 Arrays. Effects on mRNA expression were
analysed on the level of individual genes or on the level of pathways.
The gene expression profiles of anisomycin and DON were almost identical con-
firming that DON and anisomycin both induce ribotoxic stress and act via the
same mechanism. Anisomycin and DON upregulated the processes of ribosomal
function, RNA biosynthesis, T cell activation and apoptosis. Genes were similarly
affected by thapsigargin and TBTO confirming that both compounds induce ER
stress. Both TBTO and thapsigargin upregulated genes involved in RNA biosyn-
thesis, ER stress, T cell activation and oxidative stress, and downregulated riboso-
mal function. Another group of genes were upregulated by TBTO and not affected
by the other compounds and are involved in DNA packaging and nucleosome as-
sembly. As expected, ionomycin induced genes involved in T cell activation. In con-
trast, PHA did not affect any pathway. In conclusion we showed that DON induces
ribotoxic stress and TBTO induces an endoplasmic reticulum stress response.
2088 Bidirectional Impact of Atrazine-Induced Elevations in
Progesterone (P4) on the LH Surge in the Ovariectomized
(OVX), Estradiol (E2)-Primed Rat.
J. M. Goldman1,  L. K. Davis2,  A. S. Murr1 and R. L. Cooper1. 1Endocrine
Toxicology Branch, Toxicology Assessment Division, NHEERL, ORD, US EPA,
Research Triangle Park, NC; 2Impact Pharmaceutical Services, Research Triangle Park,
NC.
Multiple daily exposures to the herbicide atrazine (ATRZ) have been reported to
suppress the luteinizing hormone surge (LHS) in female rats. Exposure has also
been found to elevate P4 concentrations, and an increase in P4 is known to have a
different directional effect on LH depending on its temporal association to the
surge. Consequently, the present study focused on the effects of ATRZ dose and ex-
posure duration on the LHS in OVX, E2-primed Long-Evans rats. ATRZ was ad-
ministered by gavage (1300h), and serial tail blood samples were taken at 1400,
1600, 1800 & 2000h following 1, 2 & 4 days of exposure. An initial study with 0
& 100 mg/kg (previously demonstrated to suppress the LHS after multiple treat-
ments) significantly enhanced the afternoon LH surge peak & area under the curve
(AUC) in response to a 1-day exposure, an effect consistent with kisspeptin genetic
expression in the brain anteroventral periventricular region. In contrast, 4 daily
treatments caused a significant suppression in both measures, whereas no effects
were present following 2 days of dosing. After a 1-day treatment, prompt & marked
elevations in serum P4 concentrations, attributable to adrenal secretion, were pres-
ent at both 30 minutes & 1 hour, but by the 4th day a marked decline was present
at 1 hour. A dose-response assessment was subsequently conducted with 0, 10, 30
& 100 mg/kg ATRZ for 1 & 4 days. At 1 day, 100 mg/kg caused similar elevations
in circulating P4, the LH peak & AUC, whereas 4 daily exposures resulted in a shift
to a reduced AUC. No effects on the surge were observed with 10 or 30 mg/kg at 1
or 4 days. This influence on the LHS indicates that the effectiveness of ATRZ in in-
ducing P4-associated bidirectional shifts in LH depends on both the dosage admin-
istered and importantly on the temporal association of exposure to the appearance
of the surge. (This abstract does not represent EPA policy.)
2089 Chloroethylaziridine: An Ovotoxic Metabolite of
Cyclophosphamide?
J. A. Madden and A. F. Keating. Iowa State University, Ames, IA.
Phosphoramide mustard (PM) has been implicated as the ultimate ovotoxic
metabolite of the chemotherapeutic agent cyclophosphoramide, however, studies
suggest that in extra-ovarian tissues PM can spontaneously metabolize to a volatile
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cytotoxic compound, chloroethylaziridine (CEZ). To our knowledge, CEZ toxicity
has not been characterized directly in the ovary. Postnatal day 4 (PND4) Fisher 344
(F344) rat ovaries were cultured in media containing vehicle control (1% DMSO;
CT) in the absence or presence of PM (60 μM) or CEZ. CEZ-treated ovaries were
those that were present in the same incubator as PM-treated (60 μM) ovaries, thus
receiving exposure to the volatile metabolite.  Additionally, the requirement of
ovarian tissue for CEZ formation was evaluated by adding PM (60 μM) to wells
that did not contain an ovary to determine any ovotoxic impact on ovaries that
were in control media in the same incubator.  Following 6 days of culture, follicle
types were classified and counted in all treatments. Relative to control, PM and
CEZ caused primordial follicle loss (P < 0.05), with PM being more ovotoxic (P <
0.05) than CEZ (CT – 426.7 ± 28.88; PM – 86.33 ± 9.9; CEZ – 260 ± 30.0).
Small primary follicle depletion only occurred following PM exposure (P < 0.05),
not CEZ, relative to CT (CT – 103.3 ± 16.95; PM – 3.67 ± 1.45; CEZ – 83.67 ±
7.8). In the absence of ovarian tissue, CEZ spontaneously arose from PM, and de-
pleted (P < 0.05) both primordial (CT – 377.5 ± 53.24; CEZ – 82.75 ± 29.93) and
small primary follicles (CT – 85.0 ± 21.91; CEZ – 24.5 ± 6.4), relative to control.
Thus, ovarian tissue is not a requirement for CEZ generation from PM.  This study
supports that CEZ is a novel ovotoxicant that warrants further characterization in
the ovary to understand its contributions to the detrimental effects of chemother-
apy on female fertility. The volatility and toxicity of CEZ is particularly concerning
for chemotherapy patients and their families as well as the medical professionals
caring for these patients (Supported by ES016818).
2090 Role of Connexin Proteins during the Ovarian Response to
7, 12-Dimethylbenz[A]Anthracene Exposure in Rat Ovaries.
S. Ganesan and A. F. Keating. Animal Science, Iowa State University, Ames, IA.
7,12-dimethylbenz[a]anthracene (DMBA) is an ovotoxic polycyclic aromatic hy-
drocarbon liberated through burning of organic matter. Connexin (CX) 43 and 37
are gap junction proteins providing granulosa:granulosa and granulosa:oocyte com-
munication, respectively, and are essential for follicle survival. CX43 can inhibit
chemical-induced apoptosis and low CX43 expression correlates with increased
granulosa cell apoptosis. An acute single DMBA exposure to cultured postnatal day
4 (PND4) F344 rat ovaries caused loss of both large primary and secondary follicles
at a concentration of 12.5 nM DMBA, while a higher concentration, 75 nM, re-
sulted in only large primary follicle loss 8 days after exposure. This study investi-
gated CX protein involvement during the ovarian response to DMBA exposure.
PND4 F344 rat ovaries were cultured for 4 days followed by single exposures of ve-
hicle control (1% DMSO) or DMBA (12.5 nM or 75 nM) and the culture was
maintained for 4 or 8 days for Cx43 and Cx37 mRNA or protein quantification (n
= 3; 6-10 ovaries/pool) and localization (n = 3). After 4 days, Cx37 mRNA was in-
creased (P < 0.05) by 12.5 nM (3.5-fold) and 75 nM (1.5-fold) DMBA exposures,
while, conversely, Cx43 was decreased (12.5 nM - 0.94-fold; 75 nM - 0.70-fold; P
< 0.05). After 8 days, Cx37 and Cx43 mRNA decreased (12.5 nM - 0.99 and 0.95-
fold; 75 nM - 0.85 and 0.95-fold; P < 0.05), regardless of DMBA concentration,
compared to control. CX43 protein was located between the granulosa cells of all
follicle stages, while CX37 was present in the oolemma. After 8 days, decreased (P
< 0.05) CX37 (12.5 nM - 13%) and CX43 (12.5 nM - 8%; 75 nM - 23%) proteins
were observed. These data support an initial increase in Cx37 and Cx43 mRNA as
part of the ovarian protective response to DMBA exposure, while the decrease after
8 days of DMBA exposure is likely a reflection of the loss of follicular viability in-
duced by DMBA. (Supported by ES016818 to AFK and AAUW fellowship to SG).
2091 Endocrine Modulation Potential of Steroids for Possible
Applications in Contraception.
K. Kim,  A. Wang and K. L. Steinmetz. SRI International, Menlo Park, CA.
The objective of this study was to evaluate novel steroids for selective endocrine
modulation potential using high-throughput in vitro screening cell-based and re-
ceptor binding systems. Steroids were tested for their potential to bind and modu-
late activity of the androgen receptor (AR), estrogen receptor (ER), progesterone re-
ceptor (PR), and glucocorticoid receptor (GR). For cell-based assays, a reporter
gene construct of each hormone response element upstream of the luciferase re-
porter gene promoter was stably or transiently transfected into mammalian cells
and luciferin used for light generation. Relative hormone-responsive activity was
quantified by measuring light produced. In the cell-based system, the orally active
androgens dimethandrolone (DMA, CDB-1321) and 11β-methyl-19-nortestos-
terone (CDB-4746) showed androgenic, progestational, anti-estrogenic, and anti-
glucocorticoid activities. Their esterified prodrugs, DMAU (DMA-17β -unde-
canoate, CDB-4521) and 11β-methyl-19-nortestosterone 17β-dodecylcarbonate
(CDB-4754) were less progestational and anti-estrogenic than DMA and CDB-
4746, respectively. In contrast, testosterone (CDB-0111) and testosterone 17β-un-
decanoate (CDB-3122) only showed androgenic activities. The AR binding system
showed that the prodrugs have almost no receptor binding capacity compared with
the parent drugs. Levonorgestrel (CDB-0107), a progestational compound used in
emergency contraceptive pill, and its esterified prodrug, levonorgestrel-17β-bu-
tanoate (LB, CDB-1830) showed androgenic, strong progestational and anti-estro-
genic, and weak anti-glucocorticoid activities. In conclusion, we have screened
steroids for endocrine modulating activity. For esterified prodrugs, liberation of the
parent drug by ester cleavage appears essential for biological activity.
This work is supported by NICHD Contract N01-HD-9-0014.
2092 Dioxin-Produced Imprinting of Sexual Immaturity through
Fixing the Status of a Reduction in the Hypothalamic
Expression of Gonadotropin-Releasing Hormone.
T. Takeda1,  M. Fujii1,  J. Taura1,  M. Yamamoto2,  M. Himeno2,  Y. Ishii1 and
H. Yamada1. 1Graduate School of Pharmaceutical Sciences, Kyushu University,
Fukuoka, Japan; 2Faculty of Pharmaceutical Sciences, Nagasaki International
University, Sasebo, Japan. Sponsor: Y. Kumagai.
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) causes a number of disorders in re-
production and development. Our previous studies have revealed that single treat-
ment of pregnant Wistar rat with TCDD (1 μg/kg, orally) reduces the pituitary
synthesis of gonadotropin in perinatal pups, leading to not only a reduction in go-
nadal steroidogenesis but also the imprinting of sexual immaturity such as defects
in sexual behaviors after growing up. However, the reason why the attenuation of
pituitary gonadotropin imprints sexual immaturity remains largely unknown. To
address this issue, we performed a DNA microarray analysis to identify target gene
the altered expression of which is linked to dioxin-induced sexual immaturity, using
the hypothalami of 70 days-old male pups. The result showed that TCDD causes
alterations in the expression of many genes in the hypothalamus (up: 332, down:
283). Among them, we focused on a reduction in gonadotropin-releasing hormone
(GnRH) gene, because this hormone plays a pivotal role in the regulation of sexual
behaviors. Further analysis indicated that a reduction in GnRH mRNA emerges
from postnatal day 4 which is involved in the critical period for the brain organiza-
tion/differentiation stimulated by sex-steroids. The cerebral level of GnRH protein
in the pups was also reduced by maternal exposure to TCDD, although the hypo-
thalamic content remained unchanged. Intracerebroventricular infusion of GnRH
into the TCDD-exposed pups after their growing up restored many defects in sex-
ual behaviors. These results together with our previous findings suggest that mater-
nal exposure to TCDD impairs the maturation of GnRH neurons in the offspring
by reducing steroidogenesis at fetal and neonatal stage, and this is the origin for im-
printed defects in sexual behaviors at adulthood owing to a permanent reduction in
GnRH expression.
2093 Bisphenol A Down-Regulates Cytochrome P45011a1 prior
to Inhibiting Steroidogenesis in Mouse Antral Follicles.
J. Peretz and J. A. Flaws. Comparative Biosciences, University of Illinois, Urbana, IL.
Bisphenol A (BPA) is an endocrine disrupting chemical used in polycarbonate plas-
tic products and the epoxy resin lining of food and beverage cans. Once released
from these products, BPA readily enters the body and affects physiological processes
such as steroidogenesis. Previous studies in our lab have shown that exposure to
BPA decreases sex steroid hormone levels in mouse antral follicles. The current
study was designed to expand these findings by testing the hypothesis that BPA first
decreases the mRNA expression levels of cytochrome P45011a1 (side chain cleave;
Scc), which then leads to decreased sex steroid hormone production. To test this hy-
pothesis, antral follicles were mechanically isolated from adult cycling mice, indi-
vidually cultured in supplemented α-minimum essential medium, and treated with
either vehicle control (DMSO) or various concentrations of BPA (1, 10, or
100μg/mL). Follicles and media were collected at various time-points between 6h
and 96h. Exposure to BPA10μg/mL and 100μg/mL significantly decreased proges-
terone levels beginning at 24h and continuing throughout culture compared to
DMSO (24h:DMSO:4.86±2.25; BPA10:1.62±0.82; BPA100:0.95±0.06
ng/mL;n=5-6;p≤0.05). Exposure to BPA10μg/mL and 100μg/mL significantly de-
creased androstenedione, testosterone, and estradiol levels at 72h and 96h com-
pared to DMSO. Further, exposure to BPA10μg/mL and 100μg/mL decreased ex-
pression of Scc beginning at 18h and continuing throughout culture compared to
DMSO. These data suggest that BPA decreases expression of Scc as early as 18h and
that this reduction in Scc leads to a decrease in progesterone production by 24h, fol-
lowed by a decrease in androstenedione, testosterone, and estradiol production at
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later time points. Therefore, BPA exposure targets Scc and thus, inhibits the con-
version of cholesterol to pregnenolone, resulting in the decreased sex steroid hor-
mone levels of BPA-exposed antral follicles.
Supported by National Institute of Health R01 ES019178 and P20 ES 018163
2094 Di(2-Ethylhexyl) Phthalate Alters the Expression of
Phosphatidylinositol 3-Kinase Signaling Proteins Involved in
Early Ovarian Folliculogenesis In Vivo.
P. R. Hannon and J. A. Flaws. Department of Comparative Biosciences, University of
Illinois, Urbana, IL.
Di(2-ethylhexyl) phthalate (DEHP) is a common plasticizer in consumer, building,
and medical products containing polyvinyl chloride. Widespread production and
use in everyday items represent a public health concern as humans are exposed to
DEHP via ingestion, inhalation, and dermal contact. Large doses of DEHP harm
ovarian function; however, the effects of DEHP on the ovary at environmentally
relevant doses are unknown. Our group has shown that 30 day exposure to rela-
tively low doses of DEHP accelerates recruitment of primordial follicles to the pri-
mary stage of development. Immature follicles at this stage rely on intrinsic ovarian
factors and proper regulation of the phosphatidylinositol 3-kinase (PI3K) signaling
pathway for primordial follicle survival, quiescence, and activation of folliculogene-
sis. Since DEHP accelerates primordial follicle activation, we tested the hypothesis
that 30 day treatment with DEHP alters the expression of intrinsic ovarian factors,
specifically those involved in the PI3K signaling pathway. To test this hypothesis,
CD-1 mice (post-natal day 39) were orally dosed with tocopherol stripped corn oil
(vehicle control) or DEHP (20 μg/kg/day, 200 μg/kg/day, 20 mg/kg/day, and 200
mg/kg/day) daily for 30 days. Whole ovaries and ovarian tissue with antral follicles
removed were subjected to gene expression analysis by qPCR (n=4/group). In the
whole ovary, DEHP increased the mRNA expression of Kit at the 20 μg/kg dose,
and decreased the mRNA expression of Pten and Foxl2 at the 20 mg/kg dose and
Kit, Pten, Rps6, and Tsc1 at the 200 mg/kg dose (e.g. Tsc1 vehicle: 1.05±0.19; 200
mg/kg: 0.5±0.02; p≤0.05). In ovarian tissue with antral follicles removed, DEHP
decreased the mRNA expression of Mtorc1 at the 200 μg/kg and 20 mg/kg doses.
These data suggest that DEHP alters the expression of factors involved in early fol-
liculogenesis, specifically in PI3K signaling. Furthermore, the dysregulation of
PI3K signaling could lead to adverse acceleration of early folliculogenesis.
Supported by R01 ES019178.
2095 Humoral Immunity in Infant Cynomolgus Monkeys:
Control Background Data.
S. Oneda1,  N. Lalayeva1,  R. Watson1,  N. Makori1,  P. Franklin1,  T. Beck1,
K. Fukuzaki1 and R. Nagata2. 1SNBL USA, Ltd., Everett, WA; 2Shin Nippon
Biomedical Laboratories, Ltd., Tokyo, Japan.
Background: Developmental immunotoxicity (DIT) evaluations are performed to
determine if the test article has an immunotoxic effect on the developing immune
system. T-cell dependent antibody response (TDAR) to keyhole limpet hemo-
cyanin (KLH) is one of the methods to assess DIT in the nonhuman primate.
Differences in KLH-specific IgM and IgG responses within animal age and animal
origin were evaluated in infant cynomolgus monkeys (Macaca fascicularis, hereafter
Cynos).
Methods: KLH was administered by intramuscular injection to infant Cynos twice.
The initial KLH injection (1st dose) occurred postnatal days (PND) 90, 120, 180,
or 270. The second KLH injection (boost, 2nd dose) occurred 2 to 3 months after
the 1st dose (PND180, 180, 240, and 330, respectively). The origins of the Cynos
were Indonesian (Island, IL) and Cambodian (Mainland, ML). Serum samples
were obtained prior to each KLH injection and once weekly for 4 weeks following
each KLH injections. KLH-specific serum IgM and IgG levels were measured using
ELISA methods. 
Results: IgM elevated rapidly after the 1st and 2nd doses. The highest IgM in IL
(69.2 and 73.6 μg/mL after the 1st and 2nd doses, respectively) was 24-27% lower
than ML (95.2 and 96.4 μg/mL). IgG elevated gradually after the 1st dose but rap-
idly after the 2nd dose. The highest IgG after the 1st dose in IL (34.5 μg/mL) was
24% lower than ML (45.2 μg/mL). After the 2nd dose, the highest IgG in IL
(1339.7 μg/mL) was 39% higher than ML (941.7 μg/mL). The profiles (patterns)
of IgM and IgG were similar between IL and ML. IgM was clearly low on
PND90/180 group when compared with PND120/180 while IgG was compara-
ble. There were no notable differences in IgM and IgG between PND120/180 and
PND180/240 groups. Both IgM and IgG were highest in PND270/DB330 group
at most time points.
Conclusion: There were no remarkable differences in TDAR results between ani-
mal origins. It is recommended that TDAR assessment be conducted in 4 month or
older infants.
2096 Bisphenol A Treatment of Cultured Mouse Ovarian Antral
Follicles May Affect the Aryl Hydrocarbon Receptor
Signaling Pathway.
A. Ziv-Gal,  Z. R. Craig,  W. Wang and J. A. Flaws. Comparative Biosciences,
University of Illinois, Urbana, IL.
Bisphenol A (BPA) is a commonly used plasticizer in the manufacture of polycar-
bonate plastics. Previous studies indicate that BPA exposure has toxic effects on the
female reproductive system. For example, BPA (50-100 μg/ml) inhibits growth and
steroidogenesis in cultured adult mouse antral follicles. Nevertheless, not much is
known about the underlying mechanism. The aryl hydrocarbon receptor (AHR) is
a ligand activated transcription factor that regulates cellular processes in the ovary
including transcriptional activation of cytochrome P450, family 1, subfamily B,
polypeptide 1 (Cyp1b1). Interestingly, previous studies have shown that in-utero
BPA treatment alters expression levels of AHR signaling pathway related genes in
mouse embryonic ovaries. Hence, our current study was designed to examine
whether the toxic effects of BPA observed in adult mouse antral follicles are medi-
ated by the AHR signaling pathway. We hypothesized that BPA treatment of cul-
tured adult mouse antral follicles alters expression levels of Ahr, aryl hydrocarbon
receptor nuclear translocator (Arnt), aryl hydrocarbon receptor repressor (Ahrr),
and Cyp1b1. To test this hypothesis, we mechanically isolated antral follicles from
mouse ovaries (C57BL/6) and cultured them in vehicle control or BPA (0.001-50
μg/mL) for 24 and 96 hours. At the end of the cultures, follicles were further
processed for gene expression analyses. Our results indicate that at 24 hours, BPA
50 μg/mL treatment significantly decreased Ahrr and Cyp1b1 expression levels
compared to the control group (p≤0.05). At 96 hours, BPA treatment (0.001-10
μg/mL) did not alter expression levels of any of the examined genes compared to
the control group. These data suggest that relatively low doses of BPA do not affect
the expression levels of selected AHR related genes. A high dose of BPA (50 μg/mL)
may affect the expression of selected genes in the AHR signaling pathway as early as
24 hours. Supported by: NIH ES019178 (JAF), NIH K99ES021467 (ZRC), the
Environmental Toxicology Scholar Program (WW, AZG).
2097 Oral Two-Generation Reproduction Toxicity Study with
Synthetic Amorphous Silica, NM200 in Wistar Rats.
A. Wolterbeek1,  S. Schneider2,  R. Landsiedel2,  D. de Groot1,  I. Waalkens1,
M. Wouters3,  R. van Ee3 and H. van de Sandt1. 1TNO, Zeist, Netherlands; 2BASF,
Ludwigshafen, Germany; 3TNO, Eindhoven, Netherlands. Sponsor: R. Woutersen.
Safety assessments must complement the technological progress in engineering of
new nanomaterials.
Although the current test guidelines on developmental and reproductive toxicity
are generally able to determine hazards, their specific application to nanomaterials
needs to be evaluated. The results of a two-generation reproduction toxicity study
(OECD 416) with NM200 are presented here. 
Male and female Wistar Han rats (28 per group) were treated by oral gavage with
NM-200 (supplied by Joint Research Centre, Italy) at dose levels of 0, 100, 300 and
1000 mg/kg body weight/day for two consecutive generations (premating 10
weeks, mating 2 weeks, gestation and lactation 3 weeks each). The nanostructured
material was tested ‘as delivered’ and aggregates were not artificially broken down.
The nanomaterial particle size distribution was characterized. Body weight and
food consumption were measured regularly. Reproductive (including estrus cycle
evaluation and sperm analysis) and developmental (including sexual maturation)
parameters were measured and at sacrifice (reproductive) organs and tissues were
sampled for histopathological analysis. 
Oral administration of synthetic amorphous silica, NM-200 up to 1000 mg/kg
bw/day had no adverse effects on the reproductive performance of rats or on the
growth and development of the offspring into adulthood for two consecutive gen-
erations.
The systemic distribution of the silica particles will be studied in various target or-
gans of F1-generation animals, both by chemical analysis and by electron mi-
croscopy. Measurement of uptake and organ burdens could be valuable additions to
OECD standard test guidelines when applied to the hazard assessment of nanoma-
terials.
This study was sponsored by CEFIC (LRI-N3 project) and monitored by Monika
Maier, Evonik Industries AG, Hanau, Germany on behalf of ASASP a CEFIC
Sector group.
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2098 Toxicological Profile and Tolerability of Pixantrone (Pixuvri)
in Newborn Mice Comparative Study with Doxorubicin
(DOX).
A. M. Giusti1,  P. A. Colombo1,  M. Longo1,  P. Della Torre1,  A. Morisetti2,
C. Allievi2 and J. Singer3. 1Accelera, Nerviano Milano, Italy; 2CTI Advisor, Milano,
Italy; 3Cell Therapeutics, Seattle, WA.
Pixuvri at the doses of 15 and 27 mg/kg/day was given intraperitoneally to juvenile
mice on Post Natal Days 10, 13, 17, 20, 35, 39 and 42 to assess its toxicological
profile. Particularly, heart, bone marrow, liver and kidneys toxicity was evaluated
for early and late onset. 
DOX at 3 mg/kg/day was given as a comparator. Animals were sacrificed at the end
of treatment and after 4- or 8-week of observation (DOX terminated after 4-week).
Pixuvri up to 27 mg/kg/day was better tolerated than DOX at a dosage nine times
lower (3 mg/kg/day) DOX induced a marked reduction in bodyweight gain and a
cumulative mortality higher than 50% in pups, survivors being however sacrificed
pre-term due to severe decay of their health conditions. Bone marrow toxicity was
comparable between Pixuvri at low dose and DOX, whereas more pronounced ef-
fects were observed with Pixuvri 27 mg/kg/day, but recoverable after 4 or 8 weeks
off-dose. Pixuvri was measurable in plasma up to 2 and occasionally to 6 h. after ad-
ministration. After repeated treatments Cmax and AUC increased proportionally
with the dose and no accumulation was seen. No significant gender difference was
observed. Toxicity to thymus and reproductive organs was observed with both test
items while no nephro- or hepatotoxicity was detected. Cardiotoxicity was negligi-
ble up to 27 mg/kg/day of Pixuvri in females, and quoted as minimal in high dose
males at 4- and 8-week of recovery. The cardiotoxicity of DOX, assessed at the end
of treatment and 4-week after, was lower than that of Pixuvri, although a significant
reduction in heart weight was observed at the end of treatment sacrifice. Notably,
for DOX it was not possible to assess the onset and severity of cardiotoxicity at the
last timepoint of 8-week, that is definitely the most indicative of late cardiotoxicity.
In conclusion, Pixuvri was better tolerated than DOX in newborn and young ani-
mals, all reaching adulthood, suggesting Pixuvri as a possible alternative to DOX
for pediatric use.
2099 Murine Uterine Receptivity Markers Are Affected by
Particulate Air Pollution in a Dose Response Manner.
K. R. Castro1,  G. Ribeiro Jr1,  M. Peres1,  P. Saldiva1,  M. Matsuda2 and
M. M. Veras1. 1Pathology - LIM05, University of São Paulo, São Paulo, Brazil;
2Oftalmology - LIM33, University of São Paulo, São Paulo, Brazil. Sponsor: S.
Barros.
It is of concern that exposure to air pollutants (AP) negatively affects reproductive
function. Recently, we observed that AP is associated with increased rates of im-
plantation failures (IF) in mice. The uterus requires a subtle collaboration of a vari-
ety of factors including: cytokines (LIF), adhesion and antiadhesion (MUC-1) mol-
ecules and hormonal induced morphological changes (e.g. decidualization,
epithelial changes) to become receptive. The aim of this study was to investigate if
increased IF due to chronic exposure to PM2.5 could be related to changes in uter-
ine receptivity. To test this, female mice (n=10/group) were continuously exposed
(45 days) to either filtered air (AF) or 2 different daily exposure doses of concen-
trated ambient particles (600 and 1200 μg/m3 of PM2.5). Estrous ciclicity was
evaluated 2 weeks before mating and at 4.5 dpc females were euthanized and the
following outcomes were evaluated: ovarian and uterine weight, number of corpora
lutea, uterine histopathology and LIF and MUC-1 expression by qPCR and im-
munohistochemistry. We observed that the effects are dose dependent, being more
pronounced in the higher dose. Results have shown that estrous cyclicity is affected
by a reduction in the duration of the cycle accompanied by an extended diestrus.
Ovarian weights are increased but there was no significant change in the number of
CL. The histopathological evaluation of the uterus indicated a decrease in the vol-
ume and thickness of the endometrium. In both exposed groups, increased diame-
ter and thickness of the glandular and luminal epithelium were seen. No significant
alteration was observed in the expression of MUC-1 but there was significant sup-
pression of LIF during the implantation window. In conclusion, exposure to
PM2.5 could have significant negative effects on endometrial receptivity by affect-
ing the fine regulation of proliferation and differentiation (decidualization) of uter-
ine cells mediated by LIF expression.
2100 Functional Assessment of Sexual Maturity in Female
Cynomolgus Monkey (Macaca fascicularis).
C. Luetjens and G. F. Weinbauer. Covance Laboratories GmbH, Muenster,
Germany.
Selection of suitable criteria for assessing sexual maturity in the female long-tailed
macaque (Macaca fascicularis) has yielded conflicting results. The present retro-
spective work investigates whether the presence of two consecutive menstrual
bleedings hallmarks complete sexual maturation. Daily vaginal swabs were collected
from 1175 Asian and 660 Mauritian origin animals and the records were used to as-
sess the ovarian cycle pattern and seasonality. Animals were housed socially. The
swabs were rated from no to heavy menstruation. Menstrual cycle length was cate-
gorized (C1, C2, and C3) depending on the cycle length difference between con-
secutive cycles to distinguish normal cycling females from females with prolonged
cycle length. Data from 12446 cycles, comprising 1-38 cycles/animal were corre-
lated with animal age and body weight. Mean cycle duration was 32.4 days. No sea-
sonal differences were detected. The bleeding length for Mauritian animals (median
2.9 days) was significantly longer than for the Asian animals (median 2.6 days) and
the bleeding severity differed also significantly (Mauritian animals: median 3.0;
Asian animals: median 2.5). Among the 1835 females under study, 784 had single
prolonged cycles and were in the category C2 or C3 whereby the Asian animals had
three times more prolonged cycles. At arrival at our facility the average Mauritian
origin animals were significantly heavier (3.75 ± 0.62 kg) than the Asian females
(n=3.25 ± 058 kg) although the Asian animals were significantly older (4.74 ± 1.18
years) compared to Mauritian animals (4.01 ± 0.58 years). This investigation indi-
cates that the onset of sexual maturity is different depending on female cynomolgus
monkey origin. However, cycle lengths of the majority of cynomolgus monkeys ap-
peared rather consistent and the cycle category was predictable. This information
has to be taken into consideration in the planning phase of studies under the ICH
guideline S6(R1) (ICH, 2011) in which the use of sexually mature animals have be-
come part of toxicity studies.
2101 Air Pollution Accelerate Atherosclerosis Progression on
Predisposed Mice.
M. Peres1,  K. R. Castro1,  N. Costa1,  G. Ribeiro Jr1,  F. César2,  M. Cavalcante2,
D. Abdalla2,  P. Saldiva1 and M. M. Veras1. 1Pathology, University of São Paulo, São
Paulo, Brazil; 2Toxicology, University of São Paulo, São Paulo, Brazil. Sponsor: S.
Barros.
Exposure to urban particulate air pollution is linked to cardiovascular diseases in-
cluding atherosclerosis. In this study we investigated if gestational (G) and/or post-
natal (P) exposure to PM2.5 is associated with aortic plaque formation in suscepti-
ble individual. LDLr-/- mice were exposed during pregnancy to either filter or
polluted air (daily exposure dose=600 μg/m3 of PM2.5) using a Harvard Particle
Concentrator. After weaning, male pups were subdivided and 4 groups were
formed according to the exposure period (G or PN). No hypercholesterolemic diet
was given to the animals. After 20 weeks of exposure, we assessed non-invasively the
size of atherosclerotic plaque (AP) in the aortic arch by ultrasound biomicroscopy.
Then, aortic roots were collected and the expression of genes involved in plaque
formation and progression was assessed by qPCR (VCAM, ICAM, PCAM, IL-1β,
IL-6, IL-10, INFγ, MCP-1, CD36, MMP-1, MMP-9, TIMP-1 and TIMP-2).
Birth weight was reduced in animals exposed to PM.5 during G period (less 11%).
Groups exposed to PM2.5 presented greater AP areas and there was an interaction
effect (p<0.001) between G and P exposures and the size the plaque (r=-0.43,
p<0.01). Expression of IL-1β and IL-6 (proatherogenic cytokines) were higher in
exposed groups and IL-10 expression (antiatherogenic cytokines) was reduced.
Expression of adhesion molecules and genes involved in plaque destabilization were
reduced (VCAM, MMP2, TIMP1 and 2). In most of the cases differences in genes
expression were associated with G exposure to PM2.5 but there were also interac-
tion effects with P exposure. For other genes no differences were observed. Results
demonstrate how environmental pollution can negatively influence intrauterine en-
vironment, impair fetal development and along with postnatal chronic exposure
predispose susceptible individuals to atherosclerotic plaque formation later in life.
Imbalance between pro- and anti-inflammatory cytokines might account for the
progression of atherosclerosis due to PM2.5 exposure.
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2102 Brominated Diphenyl Ether-47 Induces Oxidative Stress-
Stimulated Pro-Inflammatory Pathways in Human
Extravillous Trophoblasts.
H. Park and R. Loch-Caruso. Environmental Health Sciences, University of
Michigan, Ann Arbor, MI.
Preterm birth is associated with significant infant morbidity and mortality.
Although the etiology of preterm birth is not fully determined, critical roles of ox-
idative stress and inflammation are implicated. Polybrominated diphenyl ethers
(PBDEs) are widely used flame retardant compounds. Brominated diphenyl ether
(BDE)-47 is one of the most prevalent PBDE congeners found in human breast
milk, serum and placenta. Despite the presence of PBDEs in human placenta, the
effects of PBDEs on pregnancy are poorly understood. The present study investi-
gated BDE-47-induced oxidative stress and the roll of oxidative stress on BDE-47-
stimulated pro-inflammatory responses in a human extravillous trophoblast cell
line, HTR-8/SVneo. HTR-8/SVneo cells were exposed to 5, 10, 15 and 20 μM
BDE-47 for 4 h and reactive oxygen species (ROS) generation was measured using
the dichlorofluorescein (DCF) assay. Inhibition of ROS formation was measured
after pre-treatment for 1 h with deferoximine (DFO), an iron-chelating antioxi-
dant. To determine oxidative stress-mediated activation of inflammatory pathways
by BDE-47, HTR-8/SVneo cells were pretreated with 1 mM DFO for 1 h prior to
BDE-47 treatment for 24 h, or co-treated with 100 μM (±)-α-tocopherol for 24 h.
Cytokine release was analyzed by enzyme-linked immunosorbent assay. Treatment
of HTR-8/SVneo cells with 15 and 20 μM BDE-47 increased DCF fluorescence
compared with solvent controls, indicating increased ROS formation. When cells
were pretreated with DFO, BDE-47-stimulated DCF fluorescence was decreased.
Pre- or co-treatment with DFO and (±)-α-tocopherol prevented BDE-47-induced
interleukin-6 release. These data indicate that BDE-47-induced cytokine release in
HTR-8/SVneo cells depended on ROS formation. Because inflammation occur-
ring at gestational tissues during pregnancy has been associated with preterm birth,
further research is needed to ascertain potential relevance of these findings to preg-
nancy and preterm labor.
2103 One-Generation Reproduction Study of Isobornyl Acetate in
Rats, with an Evaluation through Sexual Maturity in the F1
Generation.
V. T. Politano1,  E. M. Lewis2,  A. M. Hoberman2,  R. M. Diener3 and A. Api1.
1Research Institute for Fragrance Materials, Inc., Woodcliff Lake, NJ; 2Charles River
Laboratories, Horsham, PA; 3Argus International, Inc., Horsham, PA.
Isobornyl acetate, a widely used fragrance ingredient, was administered to male and
female rats (25 rats/sex/dose) at dosages of 0, 30, 100, and 300 mg/kg/day.
Administration via gavage of the test material or the vehicle, corn oil, began before
the cohabitation period (83 days for males; 14 days for females), through cohabita-
tion (maximum 14 days), until the day before sacrifice (males) or day 25 of pre-
sumed gestation (females that do not deliver) or day 22 of lactation. F1 generation
rats selected for continued evaluation were sacrificed on day 60 (+/- 3) postpartum.
There were no treatment-related deaths at any dosage level tested. Excess salivation
was observed in P generation male rats at 300 mg/kg/d and P generation females at
100 and 300 mg/kg/d. Mean body weights, body weight gains and feed consump-
tion values were comparable among the dosage groups. There were 23, 22, 24, and
22 pregnant rats in the four dosage groups; all pregnant rats delivered litters. All
natural delivery and litter observations were comparable. There were no treatment-
related clinical signs, gross lesions or changes in body weight, body weight gains,
feed consumption, or organ weights in the male and female F1 generation rats at
any dosage level tested. Sexual maturation was unaffected in the F1 generation.
Based on the results of this study, the no-observable-adverse-effect-level (NOAEL)
for toxicity of isobornyl acetate is 300 mg/kg/day. The reproductive NOAEL in the
P generation rats and the NOAEL for viability and growth of the F1 generation off-
spring is greater than or equal to 300 mg/kg/day. This dose is 2000 times greater
than the conservatively calculated exposure (assuming 100% dermal absorption) to
isobornyl acetate from fragrance use.
2104 Di (2-Ethylhexyl) Phthalate Is Not Genotoxic to Oocytes,
but May Induce Apoptosis in Two-Cell Zygotes.
S. Vargas-Marín,  L. Vega,  M. Solís-Heredia,  B. Ramos-Robles,  B. Quintanilla-
Vega and I. Hernández-Ochoa. Department of Toxicology, Cinvestav-IPN, Mexico
City, Mexico.
Di (2-ethylhexyl) phthalate (DEHP) is a phthalate found in food packaging, toys,
medical equipment, among others. DEHP decreases the fertile capacity of the
oocyte by interfering with its progression through meiosis and impairing embryo
development. Since DEHP is genotoxic to different cell types, we suggest that the
decrease in the fertile capacity of the oocyte is also attributed to the genotoxic effect
of DEHP. This study evaluated whether in vivo exposure to DEHP causes DNA
damage in oocytes, and if this damage persists in the zygote. Female CD1 mice (n =
6 per group) were exposed orally to DEHP (20, 200 and 2000 mg/kg/d) or vehicle
(corn oil tocopherol-stripped) every 24 h for 3 estrous cycles. The minimal dose of
DEHP was based on the reference dose established by the Environmental
Protection Agency (EPA). 5-fluorouracil (1 μM) was used as positive control.
Following treatments, mice on estrus received equine chorionic gonadotropin hor-
mone (eCG; 5 IU) ip, 48 h later mice received hormone human chorionic go-
nadotropin (hCG; 5 IU) and 16 h post-hCG mice were either euthanized to collect
eggs or bred with a fertile proved male mouse to collect zygotes. Oocytes were in-
cubated with hyaluronidase to remove cumulus cells and then with Tyrode solution
to remove the zona pellucida. Denuded oocytes were used to evaluate viability by
staining with propidium iodide/Hoecht 33342 and DNA damage by comet assay.
Viability was expressed as percentage live cells and DNA damage was assessed as the
Olive Tail Moment (OTM). No significant differences in viability or OTM were
observed among groups. Two-cell zygotes from mice exposed to 2000 mg/kg/d
DEHP were used to assess the induction of micronuclei (MN) by staining with
Hoechst 33342. DEHP did not induce MN in the zygote, however, intra-cytoplas-
mic prolongations resembling cell death by apoptosis were observed. These data
suggest that DEHP is not genotoxic to oocytes, but it could elicit apoptosis in two-
cell zygotes and thus contribute to reduced fertility. Conacyt-Mexico CB-167678.
2105 Inhaled Ambient Particulate Matter Induces Preterm Birth
and Low-Birth Weight in a Mouse Model of Pregnancy.
J. L. Blum,  L. Chen and J. T. Zelikoff. Environmental Medicine, New York
University School of Medicine, Tuxedo, NY.
Recent epidemiologic evidence has linked exposure to elevated levels of particulate
matter (PM) in air pollution to preterm birth (PTB), low birth weight (LBW), and
small for gestational age babies. However, several questions remain unanswered in-
cluding mechanisms of action (MOA), gestational windows of vulnerability, and
most active PM size and composition. To begin to better understand how PM ex-
posure impacts fetal development, timed-pregnant B6C3F1 mice were exposed
whole body from gestational day (GD) 0.5 (morning of confirmed breeding)
through GD17.5 to concentrated PM2.5 (CAPs, at 15-times of ambient concentra-
tion) at our site in Tuxedo, NY or to filtered air (FA) for 6hr/day, 7days/wk. The
daily average CAPs concentration throughout exposure was 163.8 ± 99.6 μg
PM/m3. Based on EPA standards for PM2.5 of 35 μg/m3/24 hr, our 24 hr time-
weighted average (i.e., 6.8 μg/m3) is relevant for many U.S. urban centers.
Exposure to CAPs in this study reduced the duration of gestation by 0.5 days (com-
pared to FA controls), which is comparable to a 1 wk decrease in human pregnancy
bringing birth close to the PT category (i.e., <37 wk). Concomitant with the ob-
served PTB were both an 11.4% decrease in birth weight and 2.5% decrease in
crown-to-rump length (CRL) at birth and at postnatal day 1. Neonates born to
CAPs-exposed dams remained lighter than their filtered-air counterparts through
the 21 days of nursing, though daily rates of weight gain were equal to that of FA
controls. Exposure to airborne PM had no effect on conception rate, maternal
weight gain during pregnancy, offspring anogenital distance, or sex ratio compared
to FA control. These studies are the first to provide biological plausibility for the
epidemiologic evidence demonstrating an association between PM exposure and
PTB/LBW. The same recently-developed mouse model will be used in future stud-
ies to determine MOA and PM sensitive gestational “windows” of vulnerability.
Supported by March of Dimes and NIEHS NYU Center ES000260.
2106 In Utero Exposure to Bisphenol A Increases Germ Cell
Apoptosis in the Neonatal Mouse Ovary.
W. Wang,  Z. R. Craig,  J. Peretz and J. A. Flaws. Comparative Bioscience,
University of Illinois, Urbana, Urbana, IL.
Bisphenol A (BPA) is a known endocrine disruptor that is widely used as a synthetic
plasticizer to harden polycarbonate plastics and epoxy resin. However, BPA can
leach from plastic products into the food and water of consumers, leading to
human exposure to BPA on a daily basis. The objective of this study was to exam-
ine the effects of prenatal BPA exposure on early ovarian development in mice.
Pregnant dams (6 per treatment group) were orally dosed with tocopherol stripped
corn oil (vehicle control) or BPA (0.5 and 50 μg/kg/day) daily starting on gestation
day 11 and continuing throughout pregnancy. After birth, neonatal ovaries were
collected and subjected to histological evaluations and gene expression analyses.
Our results show that the selected doses of BPA affected ovarian development dif-
ferently. Specifically, compared to vehicle controls, BPA 0.5 μg/kg/day treatment
increased the number of healthy germ cells present in germ cell nests and increased
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the number of primordial follicles, suggesting that BPA at this dose prevents apop-
tosis of germ cells, which is critical for the formation of the primordial pool. In con-
trast, BPA 50 μg/kg/day significantly increased the numbers of apoptotic germ
cells, indicating BPA at this dose might accelerate germ cell apoptosis. To explore
why the selected doses of BPA affect early ovarian development differently, we com-
pared the expression of various apoptotic factors in the treatment groups. BPA 0.5
μg/kg/day increased the expression of the pro-apoptotic factor Bad and selected
anti-apoptotic factors (Mcl-1, Bcl2l1), and the ratio of Bcl2/Bax, but decreased the
expression of the pro-apoptotic factor Bik. In contrast, BPA 50 μg/kg/day signifi-
cantly increased the expression of the pro-apoptotic factor Bak1. Collectively, these
data suggest that in utero exposure to BPA affects early ovarian development, but
that selected doses of BPA affect ovarian development differently. Supported by:
NIH T32ES007326 (WW), NIH P20ES018193 (JAF), NIH K99ES021467
(ZRC).
2107 Enhanced Pre-Postnatal Toxicity Study of AMG 162
Administered by SC Injection to Pregnant Cynomolgus
Monkeys with up to 6-Months Postnatal Evaluation.
J. L. Bussiere1,  R. Boyce1,  I. Pyrah1,  D. Branstetter2,  M. Loomis1,  C. Farmin3,
L. Chouinard4,  G. Elliott5,  A. Varela4 and G. Chellman5. 1Amgen Inc., Thousand
Oaks, CA; 2Amgen Inc., Seattle, WA; 3Genentech Inc, S. San Francisco, CA; 4Charles
River -PCS, Montréal, QC, Canada; 5Charles River -PCS, Reno, NV.
AMG 162 is a fully human IgG2 monoclonal antibody that inhibits bone resorp-
tion by targeting RANKL, an essential mediator of osteoclast formation, function,
and survival. Monthly SC injection of pregnant cynomolgus monkeys with 0 or 50
mg/kg AMG 162 from ~GD20 until parturition resulted in test article-related ef-
fects on the pregnant females and their offspring. In the pregnant females, there
were reductions in biomarkers of bone turnover, increased stillbirths, one instance
of dystocia, and one stillbirth following maternal signs of hypocalcemia. Lactation,
mammary gland histomorphology, and fetal growth were comparable in controls
and the AMG 162 group. In infants exposed in utero, there was increased postnatal
mortality, decreased body weight gain, decreased growth/development, and de-
creased biomarkers of bone turnover from birth to 10 weeks of age. AMG 162-re-
lated effects in infants were present in bones (osteoclast hypoplasia, nonproliferative
hyperostosis, physeal hypertrophy, and decreased marrow space), normally erupted
teeth (dysplasia and malalignment), lymph nodes (most absent), and in multiple
tissues (extramedullary hematopoiesis). Signs of infection in multiple tissues were
detected in 3 infants that underwent unscheduled necropsy. In infants necropsied
at 6 months of age, there was full recovery from all bone-related changes observed
earlier postpartum with some AMG 162-related effects persisting (absent/decreased
size of lymph nodes, extramedullary hematopoiesis, dental dysplasia). One AMG
162-exposed infant, in which there had been recovery from pharmacological ef-
fects, had minimal to moderate mineralization of multiple tissues. In general, the
effects observed in mothers and infants were consistent with the pharmacological
action of AMG 162.
2108 Impact of Feed Choice When Performing Generational
Reproduction Studies.
A. Milius,  R. Read,  J. Waldschmidt and D. Dandekar. Toxicology, Xenometrics,
Stilwell, KS.
The selection of an appropriate lab diet is extremely important for reproduction
(repro) studies. In our lab, Purina Mills (PM) Rodent Diet 5002 has been the stan-
dard feed for all rodent repro studies for over 22 years. Our lab has not veered from
this diet as a strong historical control exists with its’ utilization. A new diet, Harlan
Teklad® (HT) Global 16% Protein Rodent Meal 2016CM, was recently intro-
duced for use in an extended one-generation study. This feed was recommended by
the supplier based on its use in other labs for repro studies and it meets the qualifi-
cations stated in guidelines of the Endocrine Disruptor Screening Program. Per
guidelines, the Genistein-equivalent content of genistein plus daidzein (aglycone
forms) of each batch of feed must be ≤ 300 μg/g vs. ~300 – 550 μg/g in the stan-
dard diet used in the past studies. During the delivery phase of the study, an in-
creased incidence of pup mortality was noted in all groups including the control
group. An increased incidence of pups with no milk in their stomach was also noted
in all groups. Upon further evaluation, it was discovered that the feed was occlud-
ing the nostrils of many of the pups, thereby interfering with the suckling process.
The general physical appearance of the HT feed was very similar to the PM, so
feed-related differences due too physical form were not anticipated. However, after
discovering the cause of mortalities relating to the feed, it was then noted that the
texture of this feed was much finer (similar to talcum powder). Therefore, while a
specific feed may be suitable for many repro & developmental study types, the same
feed may not be suitable for those study types where offspring are reared. While the
HT may be an excellent feed source for many repro & developmental study types,
we did not consider this feed type to be suitable for our one-generation study.
Although, our findings are based on one experience in our lab, our findings demon-
strate that a cautious approach should be taken when making changes in study de-
sign as any changes can be crucial to study outcome and interpretation of results.
2109 In Vitro Exposure to Di-n-Butyl Phthalate (DBP) Decreases
the Expression of Cell Proliferation Transcripts in Cultured
Mouse Ovarian Antral Follicles.
Z. R. Craig,  T. DelValle,  W. Wang and J. A. Flaws. Comparative Biosciences,
University of Illinois, Urbana, IL.
Di-n-butyl phthalate (DBP) is commonly found in consumer products such as
plastics, cosmetics, insecticides and oral medications. We have shown previously
that DBP (1000 μg/mL) inhibits growth and causes death of mouse antral follicles
treated in vitro. Furthermore, we have shown that DBP may do so by altering the
expression of important cell cycle regulators and causing an imbalance in the ex-
pression of key members of the Bcl2 family, markers for the intrinsic apoptotic
pathway. However, no studies have evaluated the effects of DBP on other cell pro-
liferation markers or the extrinsic apoptotic pathway. The purpose of this study was
to further investigate the mechanisms by which DBP inhibits follicle growth and
causes antral follicle death. We hypothesized that DBP decreases the expression of
cell proliferation genes such as Mki67, Pcna, and Igf1, and also increases the ex-
pression of Fasl, a marker for the extrinsic apoptotic pathway. To test our hypothe-
sis, antral follicles were isolated from adult CD-1 mice (32-37 days old) and indi-
vidually exposed (n= 8-12/culture) to DBP (1-1000 μg/mL) or vehicle
(dimethylsulfoxide, DMSO) for 24 h. Following culture, follicles were subjected to
qPCR analysis for the expression of Mki67, Pcna, Igf1, and Fasl. DBP treatment
(100 and 1000 μg/mL) decreased the expression of Mki67 and Igf1 compared to
control follicles (p≤0.05). DBP treatment did not alter the levels of Pcna transcript
when compared to control follicles, while Fasl mRNA was undetectable in all treat-
ment groups. Decreased expression of the cell proliferation genes Mki67 and Igf1
further supports that DBP-induced inhibition of antral follicle growth involves a
defect in follicular cell proliferation. Also, undetectable Fasl suggests that the ex-
trinsic apoptotic pathway may not be involved under these conditions. Supported
by NIH grants K99ES021467 (ZRC), R01ES019178 (JAF), T32ES007326
(WW) and the Billie Field Fellowship in Reproductive Biology (WW).
2110 Evaluating Benzo[a]pyrene Effects on Steroidogenesis and
Reproduction.
F. T. Booc1,  C. Thornton1,  X. Fang1,  A. Lister2,  D. MacLatchy2 and
K. L. Willett1. 1Pharmacology, University of Mississippi, University, MS; 2Biology,
Wilfrid Laurier University, Waterloo, ON, Canada.
Benzo[a]pyrene (BaP) is a polycyclic aromatic hydrocarbon (PAH) that has been
implicated in modulating aromatase enzyme function. This effect has potential to
interrupt normal reproductive function by causing imbalances in homeostatic an-
drogen and estrogen levels. The aim of this study was to use a fish model, Fundulus
heteroclitus, in order to assess whether BaP caused a significant change in steroid
concentrations that could negatively alter additional reproductive biomarkers.
Adult fish were exposed to waterborne BaP concentrations of (0, 1 or 10 μg/L) for
28 days. Males and females were combined for the second half of the exposure (days
14-28) in order to quantitate egg production and fertilization rates. BaP exposure
did significantly reduce male gonad somatic index (GSI) and egg fertilization at 10
μg/L. Testosterone concentrations in males were significantly reduced at the high
BaP dose averaging only 355 pg/mL plasma versus 2510 pg/mL in the controls.
Also, estradiol concentrations in the females were significantly reduced at 1 and 10
μg/L BaP averaging 4070 and 3350 pg/mL plasma respectively compared to 7540
pg/mL plasma in the controls. Sperm concentrations, egg production, male liver so-
matic index (LSI), and female GSI and LSI were not altered. BaP exposure at these
environmentally relevant concentrations caused negative alterations to both molec-
ular and phenotypic biomarkers associated with reproduction. Our next goal is to
assess if these parental effects will cause permanent changes in subsequent genera-
tions of progeny. (Supported by NIEHS R03 ES018962)
2111 Comparison of Estrogen Mixtures In Vitro vs In Vivo.
B. Hannas,  J. R. Furr,  L. E. Gray and V. S. Wilson. RTB, US EPA, Research
Triangle Park, NC.
Numerous sources contribute to widespread contamination of drinking water
sources with both natural and synthetic estrogens, which is a concern for potential
ecological and human health effects. In vitro screening assays are valuable tools for
identifying mechanisms of toxicity but in vitro results cannot be directly extrapo-
lated to in vivo exposures since most in vitro assays do not account for metabolism,
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distribution and excretion or other systemic toxicities.  In this study, we highlight
some of the limitations associated with using in vitro estrogen transcriptional acti-
vation assays for predicting in vivo action of xenoestrogens.  In particular, we com-
pared the ability to predict the uterine growth response (uterotrophic assay, UA) to
estrogens, administered to the rat orally either individually or as mixtures,, using an
in vitro estrogen transcriptional activation (TA) assay (T47D-kbluc cell line). We
demonstrated that a binary mixture of bisphenol-AF (BPAF) + Methoxychlor in
the UA conforms to dose additive (DA) estrogenicity, whereas the degree of estro-
genicity of this mixture is underestimated by the TA assay. In contrast, the TA assay
responded to a binary mixture of benzylbutyl phthalate (BBP) + BPAF in a DA
manner, whereas, the UA displayed no estrogenic response to this mixture. These
data illustrate the limitations associated with making in vivo predictions based on
in vitro assay data for compounds that are metabolically inactivated in vivo in the
liver, gut or other tissues or activated by the liver in vivo. Ongoing efforts related to
this study include characterizing individual dose response curves and mixture estro-
genicity for additional estrogens in vitro and in vivo. These data will be used to
make predictions from the in vitro assay to the in vivo response to exposure to the
compounds. This information is critical for valid interpretation of in vitro screen-
ing assay results. Disclaimer: Abstract does not necessarily reflect U.S.EPA policy.
2112 Bisphenol A May Affect the Fertilizing Ability of Mouse
Oocytes via Mechanisms Involving Events from Sperm
Penetration into the Oocyte to Formation of 1-Cell Zygote.
B. Ramos-Robles1,  M. Sánchez-Gutiérrez2,  S. Vargas-Marín1,  D. Acuña-
Hernández1,  B. Piña-Guzmán3 and I. Hernández-Ochoa1. 1Department of
Toxicology, Cinvestav-IPN, Mexico City, Mexico; 2Instituto de Ciencias de la Salud,
UAEH, Pachuca, Mexico; 3Departamento de Bioprocesos, UPIBI-IPN, Mexico City,
Mexico.
The cumulus cells surrounding the oocyte expand before ovulation to allow oocyte
maturation, and to facilitate sperm cell to penetrate the oocyte. It has been demon-
strated that bisphenol A (BPA), a plasticizer that leaches from plastics into food and
water, alters the expansion of cumulus cells. Since we have shown that BPA de-
creases the ability of oocytes, surrounded by cumulus cells, to be fertilized by sperm
cells, this study examined whether BPA affects the fertilizing ability of oocytes
through effects on cumulus cells, oocyte penetrability by sperm cells or zygote de-
velopment to 8-cell stage. Female C57BL/6J mice (n = 6-8 per group) were exposed
orally to BPA (50 μg/kg/d), diethylstilbestrol (10 μg/kg/d, positive control) or corn
oil during 3 estrous cycles every 24 h. Following treatments, mice on estrus received
equine chorionic gonadotropin hormone (5 IU) ip, 48 h later mice received hor-
mone human chorionic gonadotropin (hCG; 5 IU) and 16 h post-hCG mice were
either euthanized to collect oocytes and perform in vitro fertilization or bred with a
fertility proven male mouse to collect zygotes. Percentage of fertilized oocytes de-
creased in BPA-treated mice compared to control regardless of the presence or ab-
sence of cumulus cells surrounding the oocyte. Percentage of penetrated oocytes by
sperm cells decreased in BPA-treated mice compared to control, but additional in-
dependent experiments are needed to validate these last data. The numbers of 2-, 4-
and 8-cell zygotes were similar in BPA-treated mice and control. Our data confirm
the detrimental effect of BPA on the reproductive capacity of oocytes, and further
suggest that BPA alters the fertilizing ability of oocytes via decreasing the oocyte
penetrability and/or via mechanisms that involve events from sperm penetration
into the oocyte to the formation of 1-cell zygote. Conacyt-Mexico CB-167678.
2113 Amphoteric Fluorotelomer-Based Surfactant: 28-Day
Subchronic and One-Generation Reproduction Toxicity in
Rats.
J. OConnor1,  T. L. Serex1 and R. C. Buck2. 1Haskell, DuPont, Newark, DE;
2Chemicals & Fluoroproducts, DuPont, Wilmington, DE.
An amphoteric fluorotelomer-based surfactant in glycol solvent mixture and water
was evaluated in a 28-day oral gavage study (OECD 407) with a 28-day recovery
subset and a one-generation reproduction study subset (OECD 422). Groups of 20
Crl:CD(SD) rats were dosed with vehicle (deionized water) containing 0, 10, 50, or
200 mg/kg/day test substance. Dams were allowed to deliver and rear their off-
spring until postnatal day (PND) 4. Litter examinations were determined at birth
and on PND 4. For the subchronic and recovery evaluations, gross postmortem ex-
aminations were performed on selected rats and selected organs were weighed
and/or retained for histopathological examination. There were no test substance re-
lated deaths or clinical observations, no effects on body weight or nutritional pa-
rameters, no effects on neurobehavioral endpoints, clinical pathology, reproductive
performance, or on offspring at any dose. Test substance-related changes occurred
at ≥ 50 mg/kg/day in the kidneys of male rats and in the nose of male and female
rats. Increased hyaline droplets consistent with alpha2u globulin were noted at ≥ 50
mg/kg/day in the cortical tubules of males after 28 days of administration, and were
also observed in the P1 males after 45 days of test substance administration.
Increased hyaline droplet accumulation was not present in the recovery males. Low
incidences of nasal olfactory epithelium degeneration/atrophy were present in the
28-day and/or P1 rats at 200 mg/kg/day in males, and at ≥ 50 mg/kg/day in fe-
males. Olfactory lesions were reversible; the human relevance of this effect is un-
known. No test substance-related changes were present in the nose of the 200
mg/kg/day recovery groups. Under these study conditions, the systemic toxicity
NOAEL was 10 mg/kg/day based on histopathologic effects observed in the noses
and kidneys of male rats at 200 mg/kg/day and in the noses of female rats at ≥ 50
mg/kg/day. The NOAEL for reproductive toxicity and effects on offspring was 200
mg/kg/day, the highest dose tested.
2114 Effects of Zearalenone with or without Proprietary Binders
on Vaginal Morphology of Prepubertal Gilts.
D. Bradley,  T. J. Evans,  D. Ledoux and G. Rottinghaus. University of Missouri,
Columbia, MO.
The xenoestrogenic mycotoxin, zearalenone (ZEA), can cause hyperestrogenism in
prepubertal gilts, resulting in changes in the size, structure, and, potentially, func-
tion of the female reproductive tract. Objectives of the present study were to: 1)
evaluate ZEA-induced changes in the vaginal epithelium using morphologic pa-
rameters and 2) determine whether proprietary binders can ameliorated the xenoe-
strogenic effects of ZEA. Thirty prepubertal gilts were assigned to five treatment
groups. The gilts were housed individually and fed either a control diet, the same
control diet with an added 1.5 mg of ZEA per kg of feed, or the ZEA-contaminated
diet with Binder A, B, or C added. Animals were humanely sacrificed on Day 21
and portions of the reproductive tracts were removed and fixed in formalin. Image
analysis software was used to measure total vaginal lumen circumference, as well as
the total length of vaginal epithelium exhibiting hyperplasia and/or squamous
metaplasia. The mean vaginal luminal circumference of the cross sections was
greater in ZEA-treated groups and the controls, with or without binder. Likewise,
the mean percentage of hyperplastic vaginal epithelium was also higher in the ZEA-
treated groups, regardless of the presence of binder. There was a tendency for two of
the binders to have ameliorative effects on the percentage of vaginal epithelium un-
dergoing ZEA-induced squamous metaplasia. It is clear that treatment with ZEA
affected the morphometric parameters evaluated. While none of the binders ap-
peared to ameliorate the ER-α estrogen receptor-mediated effects of ZEA, those ef-
fects of ZEA and its metabolites involving ER-β estrogen receptors, such as squa-
mous metaplasia, were reduced by two of the binders. The results of this
experiment demonstrated how morphometric parameters can be used to assess the
effects of xenoestrogens, such as ZEA, and the potentially receptor-dependent ame-
liorative effects of proprietary binders.
2115 Effect of Bisphenol A (BPA) and Ethinyl Estradiol (EE2) in
the Gene Expression of Estrogen Receptors (ER) and ER-
Related Receptors in the Rat Prostate and Mammary Gland.
L. Camacho,  M. Basavarajappa,  R. Prabhu,  S. M. Lewis,
M. M. Vanlandingham and K. Delclos. NCTR, US FDA, Jefferson, AR.
Tissue and temporal expression of receptors involved in estrogen signaling and their
modulation by hormonally active agents are hypothesized to influence the long
term effects of such agents; however, these expressions are poorly defined. NCTR
Sprague-Dawley rats were dosed from gestation day 6 until parturition by oral gav-
age and their pups were directly dosed by the same route from postnatal (PND) 1
to 90. Dose groups included naïve and vehicle controls, BPA (2.5 μg-300 mg/kg
body weight (bw)/day), and EE2 (0.5 and 5.0 μg/kg bw/day). The expression level
of genes coding for nuclear ERs (Esr1 and 2), ER-related receptors (Erra, b, and g),
and G-protein-coupled ER (Gper) was analyzed in the whole prostate and female
mammary gland at PND 4 and 90. Quantitative real-time RT-PCR was used and
data was expressed as % Gapdh expression level. The most highly expressed recep-
tor in PND 4 prostate was Esrra and its expression was also high in adult prostate
(3 and 30% Gapdh, respectively). The expression of Esr2, which encodes ERβ, was
only 0.1% Gapdh in PND 4 prostate, but increased to 40% Gapdh at PND 90.
The expression of the other receptor genes was 1% Gapdh or less and was not af-
fected by age (Esr1 > Esrrg > Gper > Esrrb). Neither BPA nor EE2 affected the ex-
pression of the receptor genes analyzed in the prostate under our conditions. In the
mammary gland, the most expressed gene analyzed was ERα-coding gene Esr1 (6%
Gapdh), while the least expressed gene was Esr2 (0.05% Gapdh), at both PND 4
and 90. At PND 4, Esrrg was slightly (<2x) induced by the low EE2 dose, relative
to vehicle control. In the PND 90 mammary gland, both EE2 doses induced ~ 3x
the expression of Esr2, while the expression of Esrrb was induced ~3.5x by the low,
but not high, EE2 dose. BPA did not alter the expression of the genes analyzed in
the mammary gland. Our data suggest that the expression of these receptors is tis-
sue-specific and that BPA and EE2 differentially modulate their expression. IAG
FDA 224-12-0003/NIH ES12013.
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2116 A Combined Repeated Dose and
Reproductive/Developmental Toxicity Screening Study of
Perfluoroundecanoic Acid in Rats.
A. Ono1,  M. Ikeya2,  T. Suzuki3,  T. Nishimura4,  T. Kawamura1,  M. Takahashi1,
M. Matsumoto1,  H. Kato1,  M. Hirata-Koizumi1 and A. Hirose1. 1Division of
Risk Assessment, National Institute of Health Sciences, Tokyo, Japan; 2Bozo Research
Center Inc., Tokyo, Japan; 3Tokyo Metropolitan Institute of Public Health, Tokyo,
Japan; 4Teikyo Heisei University, Chiba, Japan.
Perfluoroalkyl carboxylic acids are one of environmental contaminants which have
received attention because of their possible effects on wild life and human health in
recent years. In order to obtain the initial risk information on the toxicity of perflu-
oroundecanoic acid [PFUnA (C11)], we conducted the repeated dose and repro-
ductive/developmental toxicity screening test. PFUnA was administered by gavage
to rats at 0 (vehicle: corn oil), 0.1, 0.3 or 1.0 mg/kg/day. Males were dosed for 42
days beginning 14 days before mating and females were dosed from 14 days before
mating to day 4 of lactation. During the dosing period, body weight gain was in-
hibited in both sexes at 1.0 mg/kg/day. In this group, there was a decrease in fib-
rinogen in both sexes and shortening of activated partial thromboplastin time in
males. Blood biochemical examination revealed an increase in BUN and decrease in
total protein in both sexes and increases in ALP and ALT and decrease in albumin
in males at 1.0 mg/kg/day. The relative liver weight was increased in males at 0.3
mg/kg/day and above and in females at 1.0 mg/kg/day, and histopathologically,
centrilobular hypertrophy of hepatocytes was observed in both sexes at 0.3
mg/kg/day and above. Focal necrosis and diffuse vacuolation of hepatocytes were
also found in the 1.0 mg/kg/day group. Regarding the reproductive/developmental
toxicity, the body weight of pups at birth was lowered and body weight gain for 4
days after birth was inhibited at 1.0 mg/kg/day while no dose-related changes were
found in the other reproductive/developmental parameters. Based on these find-
ings, the NOAELs for the repeated dose and reproductive/developmental toxicity
are considered to be 0.1 mg/kg/day and 0.3 mg/kg/day, respectively.
2117 The Detrimental Effect of Bisphenol A on Mouse Two-Cell
Zygote May Depend on the Dose.
T. Moore-Ambriz1,  D. Acuña-Hernández1,  B. Ramos-Robles1,  S. Vargas-Marín1,
M. Sánchez-Gutiérrez2 and I. Hernández-Ochoa1. 1Department of Toxicology,
Cinvestav-IPN, Mexico City, Mexico; 2Instituto de Ciencias de la Salud, Universidad
Autonoma del Estado de Hidalgo, Pachuca, Mexico.
Early development of the zygote begins with the first cleavage that forms diploid
cells and it depends on the contribution of paternal gametes. Bisphenol A (BPA) is
an environmental compound that may leach from plastics into food or water. Some
studies have shown that BPA alters embryonic development but they mostly focus
on effects at later stages of development. This study evaluated the effect of an in
vivo exposure to different doses of BPA on the formation of two-cell zygotes.
Female mice C57BL/6J (39 days old) (n = 6-16 per group) were orally exposed to
BPA (0.05, 0.5 and 50 mg/kg/d) or corn oil (tocopherol-stripped, negative control)
for 3 estrous cycles every 24 h. Following treatments, mice on estrus received
equine chorionic gonadotropin hormone (5 IU) ip, 48 h later mice received hor-
mone human chorionic gonadotropin (hCG; 5 IU) and 16 h post-hCG mice were
bred with a fertility proven male mouse to collect two-cell zygotes. Zygotes were
stained with Hoechst 33342 and classified for abnormalities such as cell lysing and
cytoplasmic prolongations. Mice treated with all doses of BPA had lower percent of
fertilized oocytes compared to control, but zygote abnormalities were observed
from the dose of 0.5 mg/kg/d BPA. Specifically, two-cell zygotes from mice exposed
to 0.5 mg/kg/d BPA had higher percent of cell lysing or cytoplasmic prolongations
compared to control, and two-cell zygotes from mice exposed to 50 mg/kg/d BPA
had higher cytoplasmic prolongations compared to control. Our data suggest that
BPA alters the formation of 2-cell zygote causing abnormalities depending on the
dose. Conacyt-Mexico CB-167678.
2118 Body Burden and Preliminary Effects in Rats following Low-
Dose Drinking Water Exposure to a VOC Mixture during
Pregnancy and Adolescence.
A. J. Filgo1, 3,  D. M. Chambers2,  E. M. Quist1, 4,  B. C. Blount2 and
S. E. Fenton1. 1NTP Laboratory, DNTP, NIEHS, NIH, DHHS, Research Triangle
Park, NC; 2National Center for Environmental Health, Centers for Disease Control
and Prevention, Atlanta, GA; 3Curriculum in Toxicology, University of North
Carolina at Chapel Hill, Chapel Hill, NC; 4Comparative Biomedical Sciences,
College of Veterinary Medicine, NC State University, Raleigh, NC.
Volatile organic compounds (VOCs) such as benzene, trichloroethylene, trans-1,2,
dichloroethylene, tetrachloroethylene, and vinyl chloride are common industrial
solvents used in a number of cleaning agents and solvents. Ingestion or inhalation
are the most common routes of reported environmental or occupational exposures
to VOCs. In the US, spikes in birth defects, infant mortality, reproductive cancers
and leukemia have occurred in areas where high levels of VOCs were detected in
drinking water supplies. Here, time-pregnant Harlan Sprague Dawley rats and their
offspring were given access to water containing mixtures of these 5 VOCs at con-
centrations 5, 10 and 50 times those detected in contaminated US drinking water
(Sonnenfeld et al., 2001). Dams and pups were exposed from gestation day (GD)
10 until sacrifice. Blood was collected under hermetic conditions to determine
VOC body burden in both dams (GD13, 15, 20 and postnatal day (PND)15, 21)
and pups (PND15, 21, 28, 48). In exposed dams, low levels of VOCs were detected
in the blood during pregnancy and increased during lactation. Dose dependent
changes among each compound was also evident. Blood levels did not plateau, and
differences in VOC body burden were attributed to the varying amounts of water
consumed. Pup VOC levels also varied with changing body weight, milk and water
consumption. At necropsy, pup body, liver and spleen weights were recorded and
various tissues were collected for further analysis. VOC-exposure had no effect on
selected organ weights or body/organ weight ratios. Morphological changes in the
mammary gland were detected and were most prominent in male mammary tissue.
Disclaimer: This abstract does not necessarily reflect NIEHS and CDC policy.
2119 The Inhibin B (InhB) Response to the Testicular Toxicants
Mono-2-Ethylhexyl Phthalate (MEHP), 1, 3 Dinitrobenzene
(DNB) or Carbendazim (CBZ) following Short-Term Repeat
Dosing in the Male Rat.
W. Breslin1,  A. Paulman2,  D. Sun-Lin1,  K. M. Goldstein1 and A. Derr2. 1Eli
Lilly and Company, Indianapolis, IN; 2Covance Laboratories Inc., Greenfield, IN.
The objectives of this study were to evaluate the utility of plasma InhB as a bio-
marker of testicular injury in adult rats using the known Sertoli cell toxicants
MEHP, DNB or (CBZ). The studies were run under conditions of short-term re-
peat dosing similar to that which would be used in early stage drug development to
screen and prioritize drug candidates. The short-term high-dose exposure paradigm
also allowed for assessment of changes in InhB as an early indicator of testicular in-
jury. Following oral gavage administration of the compounds for 2 or 7 days, the
rats were evaluated for clinical signs, body weight, food consumption, organ
weights, plasma hormone levels, and gross and microscopic pathology of selected
organs. MEHP, DNB, and CBZ produced a range of testicular toxicity character-
ized by minimal exfoliation of germ cells as demonstrated by increased cellular de-
bris in the epididymis (MEHP) to more severe and dose/duration responsive Sertoli
cell vacuolation, germ cell degeneration, and multinucleated giant cells of germ cell
origin (DNB and CBZ). The slight to moderate Sertoli and germinal cell injuries
did not correlate with significant changes in plasma InhB levels following 2 or 7
days of exposure. However, moderate to severe injury to germinal epithelium fol-
lowing up to 7 days of exposure, but not after a 2 day exposure, correlated with de-
creased in plasma InhB levels and less consistently with increases in plasma follicle
stimulating hormone (FSH). In conclusion, under the conditions of these studies,
changes in InhB were not an effective early onset marker of testicular toxicity or an
effective marker for slight to moderate levels of acute injury and only reflected more
severe disruption of spermatogenesis. Changes in plasma InhB and FSH were
poorly correlated except in some instances of moderate to marked testicular toxic-
ity.
2120 Poor Correlation between Rat Testis Histology and Serum
Inhibin B after Treatment with Two Drug Candidates.
W. J. Reagan1,  R. E. Chapin1,  J. A. Alvey1,  R. A. Goldstein1,
M. G. Dokmanovich1,  K. Johnson2 and F. J. Geoly1. 1Drug Safety R&D, Pfizer,
Inc, Groton, CT; 2Arbor Analytics, Ann Arbor, MI.
Serum Inhibin B was measured in two studies of known-testis-toxic drug candi-
dates. Study 1 was for a Hepatitis C candidate, and utilized a 10 week dosing pe-
riod, followed by mating and necropsy of half of each group, and then a 12 week re-
covery period for the remaining 15 rats/group. At the end-of-dosing post-mating
necropsy, 6 of 15 high-dose males had testis lesions (germ cell loss, degeneration);
Inhibin B was significantly reduced in all animals in that group. The mid-dose
group had no testis lesions but significantly reduced mean serum Inhibin B. After
the 12 week recovery, 9/15 high-dose males showed damage in testes, and no mid-
dose animals had testis lesions. Mean serum Inhibin B in all treated groups at re-
covery was not different from controls. Inhibin B appeared to both over-report and
under-report testis damage in Study 1.  Study 2 was an acute pathogenesis study for
an antibacterial compound, using control and two dose levels and multiple time-
points (days 5, 8, 15, 22, and then untreated until day 71). At each timepoint
blood was sampled from all remaining rats and 5/group were killed for histologic
evaluation. The low-dose group developed minimal to moderate lesions, while
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serum Inhibin B was never changed. The high-dose animals progressed quickly
from minimal lesions to being broadly and moderately affected (germ cell death,
cell absence, disorganization); serum Inhibin B levels were reduced at days 8 and 15
only. In this study, Inhibin B appeared less sensitive than histology, except with
marked testis damage, when Inhibin B was routinely low. Serum Inhibin B both
over-reported damage (being reduced in the absence of lesions) and under-reported
testis damage (being normal in the presence of testis lesions) in these two studies.
We conclude that across both of these studies, there was a poor correlation between
changes in serum levels of Inhibin B and testis histopathology.
2121 Assessment of Inhibin B As a Biomarker of Testicular Injury
following Administration of Carbendazim, Cetrorelix, or 1,
2-Dibromo-3-Chloropropane in Wistar Han Rats.
L. S. Her,  A. M. Mineo,  J. A. Phillips,  M. S. Thibodeu and J. S. Moffit.
Nonclinical Drug Safety US, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield,
CT.
Although histopathology is considered the gold standard for assessing testicular tox-
icity in the nonclinical setting, identification of non-invasive biomarkers for testic-
ular injury are necessary to improve safety monitoring capabilities for clinical trials.
Inhibin B has been investigated as a potential noninvasive biomarker for testicular
toxicity. The present study investigates the correlation of Inhibin B serum levels in
Wistar Han rats with the onset and reversibility of testicular histopathology from
classical testicular toxicants, carbendazim (CBZ), cetrorelix acetate (CTX), and
1,2-dibromo-3-chloropropane (DBCP). The dosing paradigm was selected with
Interim (Day 8), Drug (Day 29), and non-dosing Recovery (Day 58) Phases.
Monitoring of serum Inhibin B was not effective at predicting the onset of CBZ- or
CTX-mediated testicular pathology in rats. Inhibin B level was reduced by DBCP
administration at the end of the Drug Phase only, acting as a leading indicator of
the onset of testicular toxicity, prior to the onset of germ cell depletion. However,
since Inhibin B was decreased at the end of the Dosing Phase and the onset of tes-
ticular pathology occurred without any additional dosing in the Recovery Phase, it
is unclear if monitoring Inhibin B would provide sufficient advanced warning of
the onset of testicular pathology. Furthermore, FSH was decreased and the ratio of
Inhibin B/FSH was increased with DBCP administration in the Interim Phase, but
not in the Drug or Recovery Phases. Although the Inhibin B/FSH ratio was a lead-
ing indicator of testicular pathology, the effective window for monitoring may be
narrow. Conclusion: Inhibin B has limited predictive capacity as a leading testicular
biomarker in rats.
2122 The Inhibin B Response in Male Rats Treated with a GnRH
Agonist and an Endothelin Receptor Antagonist.
T. Mitchard,  M. Coulson,  S. Bickerton,  J. Harris,  C. Betts and J. Stewart.
Safety Assessment, AstraZeneca R&D, Macclesfield, United Kingdom. Sponsor: R.
Roberts.
The testis shows a moderate frequency as a preclinical toxicity target organ. This is
primarily detected by histopathology and there is a need to identify circulating bio-
markers to enable longitudinal monitoring and facilitate safe progression of com-
pounds into the clinic. Inhibin B is primarily synthesized by the Sertoli cells and
regulates pituitary FSH release through a negative feedback loop. This study was
part of a HESI-sponsored initiative to evaluate inhibin B as a marker of spermato-
genic dysfunction in the rat. 
Inhibin B was measured in male Han Wistar rats (10 weeks old) administered vehi-
cle or an endothelin receptor antagonist (ET-An) orally for 28 days or a GnRH ag-
onist (GnRH-A) as a subcutaneous implant on Day 1. Ten animals/group/time
point were killed on Days 4, 8, 15 and 29 (controls on Days 15 and 29), for testes
weights and histopathology. In-life blood samples were taken on Days 4, 8, 15 and
29 to measure inhibin B, FSH and LH, and at necropsy for the same hormones
plus testosterone. 
Plasma inhibin B showed a wide concentration range in control animals (group
means 76.4 to 184.2 pg/mL; individual animals 17.8 to 381 pg/mL). GnRH-A
caused decreased testes weights plus degenerative testicular pathology from Day 4
with partial recovery by Day 29. Statistically significant reductions in inhibin B
were observed at all time points and appeared to track the development and partial
recovery of the pathology (generally <50 pg/mL on Days 4 to 15; group mean 92
pg/mL on Day 29). ET-An produced an increase in testes weights and a non de-
generative lesion of minimal tubular dilatation. There was a trend for lower inhibin
B values (30 to 50%) at all time points, including on Day 4 when tubular dilatation
was not yet evident. Overall, we conclude that following GnRH-A administration,
inhibin B showed a good correlation with testicular pathology for GnRH-A, and
following ET-An administration appeared to give a signal that might reflect changes
in tubular function in the absence of degenerative pathology.
2123 Inhibin B As a Marker of Sertoli Cell Damage and
Spermatogenic Disturbance in the Rat.
T. Pfaff2,  G. F. Weinbauer1,  J. Rhodes3 and M. Bergmann4. 1Covance Laboratories
GmbH, Muenster, Germany; 2AiCuris GmbH & Co. KG, Wuppertal, Germany;
3Covance Ltd., Harrogate, United Kingdom; 4Department for Anatomy, Giessen,
Germany.
This study was designed to determine the effects of Compound A on the fertility
and early embryonic development in the male rat over a 15-19 weeks treatment and
a 19 weeks treatment free period in control and 30, 60 and 180 mg/kg dose groups
(n =22/group). Compound A in a dose-dependent manner induced various degrees
of spermatogenic alterations compatible with Sertoli cells being the primary target,
e.g. inter- and intracellular Sertoli cell vacuolization and altered cellular morphol-
ogy followed by germ cell degeneration and marked reduction of epididymidal
sperm numbers. Blood-testis barrier remained intact (electron microscopy and hy-
perosmotic fixation test) until germ cells disappeared. Mating behaviour and
weights of androgen-dependent prostate and seminal vesicles remained unaffected.
Inhibin B levels correlated only with moderate to severe spermatogenic alterations.
Ten animals with inhibin B levels below detection limit were encountered and five
of these animals were fertile in week 19 but following another 15 weeks without
treatment, animals were rendered infertile and inhibin B levels remained unde-
tectable. In the rat, inhibin B only reflects major spermatogenic alterations and
markedly reduced inhibin B levels might indicate irreversibility of these alterations
and even infertility.
2124 The Inhibin B Response to Testicular Toxicants Ethylene
Glycol Monomethyl Ether or Dibromoacetic Acid in Male
Rats.
B. Enright1,  B. Tornesi1,  H. Lorenz2 and K. Whitney1. 1Abbott Laboratories,
Abbott Park, IL; 2Abbott GmbH &Co. KG, Ludwigshafen, Germany. Sponsor: R.
Yeager.
This study was conducted as part of an ILSI-HESI consortium effort to assess the
utility of circulating inhibin B as an early biomarker of testicular toxicity in rats.
Two known testicular toxicants were selected for use in this study: ethylene glycol
monomethyl ether (EGME) and dibromoacetic acid (DBAA). EGME (200
mg/kg/day), DBAA (250 mg/kg/day) or vehicle control (0.2% hydroxypropyl
methylcellulose [HPMC]) were administered orally to male rats for 3, 6, or 14 con-
secutive days. On study days 4, 7, and 15, serum was collected for evaluation of in-
hibin B levels from all surviving animals and a subset of animals was necropsied
from each of the control, EGME, and DBAA groups. Administration of EGME re-
sulted in spermatocyte degeneration in late stage tubules and spermatocyte deple-
tion to stage III on day 4, progressing to loss of spermatocytes and round sper-
matids to stage VI by day 7 and continued germ cell loss and degeneration of
elongating spermatids by day 15. Inhibin B levels among EGME-treated animals
progressively decreased relative to their respective controls at all time points.
Administration of DBAA was associated with spermatid retention at all three time
points and abnormal residual bodies at days 7 and 15. Inhibin B levels among
DBAA-treated animals decreased progressively relative to their respective controls
on days 7 and 15. The results of this study indicated that serum inhibin B levels in
rats provided a signal of testicular toxicity for each of these known testicular toxi-
cants administered at high levels; however, histopathology provided the earliest evi-
dence of toxic effects.
2125 The Inhibin B Response to the Testicular Toxicant, 1, 3
Dinitrobenzene in Rats and the Analytical Evaluation of
Inhibin B ELISA Kit.
N. Bogdan1,  M. Sonee1,  M. Singer1,  L. Hall1,  S. Bryant1 and P. Vinken2. 1Drug
Safety Sciences, Janssen Research and Development, LLC, Raritan, NJ; 2Drug Safety
Sciences, Janssen Research and Development, LLC, Beerse, Belgium.
Background: This work is part of an ILSI-HESI consortium effort to evaluate the
analytical performance of a second generation ELISA kit and also to assess the util-
ity of circulating inhibin B (InhB) as an early biomarker of testicular toxicity in rats.
Methods: A commercially available InhB ELISA was used to assess for dilution lin-
earity, frozen stability and serum/plasma comparison. Reference ranges were gener-
ated for male Sprague Dawley rats. To evaluate the biological utility of InhB, 1, 3-
dinitrobenzene (DNB), a Sertoli cell toxicant, was orally administered to male rats
for 2 or 5 consecutive days at 2 or 6 mg/kg/day. On Days 1 and 2, serum was col-
lected for evaluation of InhB and follicle stimulating hormone (FSH) from all rats
treated for 2 days, and on Days 1, 3 and 5 from all rats treated for 5 days. At the
end of treatment, testes were weighed and examined histologically.  Results: There
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was no difference between serum or plasma InhB values and they were stable out to
12 weeks when stored at -20oC and -80oC. Dilution linearity was acceptable up to
32-fold. An age-related decline of InhB levels was seen between 6 and 9 weeks of
age after which levels were stable up to 20 weeks. DNB caused a time-dependent
increase in incidence and severity of testicular findings characterized by degenera-
tion of the germinal epithelium, loss of pachytene spermatocytes and vacuolization
of the Sertoli cells. InhB levels decreased only with the high dose treatment on Day
5 and without any associated changes in FSH. Conclusions: Overall, the InhB assay
performed well under our conditions; however it is important to be aware of the bi-
ological variability and low control values observed by some other laboratories. In
our study, a change in serum InhB levels was detected only in association with
moderate/severe testicular toxicity, and is therefore considered of limited value as an
early biomarker for Sertoli cell toxicity.
2126 The Inhibin B (InhB) Response to the Testicular Toxicants
Hexachlorophene, Ethane Dimethane Sulfonate (EDS),
Dibutylphthalate (DBP), Nitrofurazone, Dl-Ethionine, 17-
Alpha Ethinylestradiol, 2, 5-Hexanedione, or Carbendazim
(CBZ) following Short-Term Dosing in the Male Rat.
L. P. Saldutti1,  Z. Erdos1,  K. Pearson1,  M. Goedken2,  K. Menzel1,  K. Turner3
and W. E. Glaab1. 1Merck Pharmaceuticals, West Point, PA; 2Merck Pharmaceuticals,
Kenilworth, NJ; 3Research Triangle Institute, Research Triangle Park, NC.
Background: Inhibin B is a hetero-dimer glycoprotein that down regulates follicle
stimulating hormone and is produced predominantly by the Sertoli cells. The po-
tential correlation between changes in plasma Inhibin B and Sertoli cell toxicity was
evaluated in male rats administered various testicular toxicants in 8 separate studies.
Inhibin B fluctuations over 24 hours were also measured. Methods: For the testicu-
lar toxicity studies, five to eight Sprague-Dawley, Wistar, or Wistar-Han rats rang-
ing from 8 to 13 weeks of age were administered 1 of 8 testicular toxicants for 1 to
29 days (depending on the compound). The 8 testicular toxicants were DL-
Ethionine, dibutyl phthalate, nitrofurazone, 2,5-hexanedione, 17-alpha
ethinylestradiol, ethane dimethane sulfonate, hexachlorophene, and carbendazim.
For the 24-hour time period, plasma was collected by an automatic blood sampler.
Results: Histomorphologic testicular findings were seminiferous tubule degenera-
tion (STD), aspermatogenesis, and interstitial cell degeneration. Across the 8 testic-
ular toxicants tested there were varying degrees of correlation between decreases in
Inhibin B and STD and aspermatogenesis. In an ROC exclusion model analysis,
where treated samples without histopathology were excluded, performed on all
studies except EDS (Leydig cell toxicant), Inhibin B showed a sensitivity of 72% at
90% specificity, demonstrating the potential value of Inhibin B as a biomarker of
testicular toxicity. Conclusion: Decreases in Inhibin B showed a good correlation
with Sertoli cell toxicity. As anticipated, there was no correlation between decreases
in Inhibin B and Leydig cell toxicity (interstitial cell degeneration). A pattern of
Inhibin B secretion could not be identified over a 24 hour time period.
2127 Simvastatin and Dipentyl Phthalate Lower Testosterone
Production and Exhibit Dose Additive Effects on the Fetal
Testis via Distinct Mechanistic Pathways.
B. Beverly1,  C. Lambright1,  J. R. Furr1,  H. Sampson1,  B. McIntyre2,
P. M. Foster2,  G. S. Travlos2,  V. S. Wilson1 and L. E. Gray1. 1US EPA, ORD,
NHEERL, TAD, Research Triangle Park, NC; 2NIH, NIEHS, NTP, Research
Triangle Park, NC.
Sex differentiation of the mammalian reproductive tract is a highly regulated
process that is driven, in part, by fetal testosterone (T) production. In utero expo-
sure to phthalate esters (PE) during sex differentiation can result in reproductive
tract malformations in rats. PE alter the expression of genes associated with steroid
synthesis/transport and cholesterol biosynthesis. Simvastatin (SMV) is a choles-
terol-lowering drug that interferes with cholesterol biosynthesis. As cholesterol is a
precursor for steroid biosynthesis, we proposed that like PE, maternal exposure to
SMV during the critical period of sex differentiation would lower fetal T produc-
tion and result in corresponding alterations in cholesterol- and androgen-mediated
gene expression. Timed pregnant Sprague Dawley rats were dosed orally with 15.6,
31.25, or 62.5 mg/kg/d SMV from GD14-GD18. Testicular T production on
GD18 was measured by RIA and changes in gene expression in fetal testes and liv-
ers were assessed by quantitative rt-PCR. Circulating lipid concentrations were also
measured in dams and fetuses. SMV lowered fetal testicular T production and al-
tered several genes involved in cholesterol biosynthesis in the fetal liver.
Triglycerides, LDL, HDL, and total cholesterol were also lowered significantly in
the fetal circulation, while lipids in the dam were not. Unlike PE, SMV did not
alter genes associated with sexual differentiation or development. In a second ex-
periment, dams were dosed with 62.5 mg/kg/d SMV, 50 mg/kg/d dipentyl phtha-
late (DPeP, a PE), or a mixture of both. SMV and DPeP reduced fetal T production
to 38.6 and 42.3% of the control values, respectively, but the SMV/DPeP mixture
reduced T production to 20.9% of control. These studies suggest that although
SMV and DPP affect two different pathways, they exhibit dose additive effects
within the fetal testis.
Abstract does not reflect the views of the EPA. Support provided by USEPA/NTP
IA# RW-75-92285501
2128 Postnatal Effects of Dipentyl Phthalate on Male Rat
Reproductive Development.
J. R. Furr and L. E. Gray. NHEERL, Toxicity Assessment Division, Reproductive
Toxicology Branch, United States EPA, Research Triangle Park, NC.
We conducted several in utero, ex vivo and in vitro studies to characterize the rela-
tive potencies of a series of phthalates on fetal rat testis testosterone production and
gene expression. Dipentyl phthalate (DPeP) was the most potent of the active
chemicals in its effect on fetal testis endocrine function. Although these studies
have pointed to the overall potency of DPeP, little literature exists defining its dose-
response curve in vivo. The objective of this study was to determine if the potency
of DPeP on fetal testis endocrine function was predictive of the ability of the chem-
ical to induce reproductive tract malformations in male rats. We treated timed-
pregnant Sprague-Dawley rats 0, 11, 33, 100 or 300 mg DPeP/kg/d, from GD 8-
18 and examined the postnatal development of the male offspring. Male offspring
of treated dams displayed decreased AGD, increased nipple retention, incomplete
preputial separation, decreased sperm production, hypospadias, undescended
testes, malformations of the testes, ventral prostate, and seminal vesicles, reduced
body weight (300 mg/kg/day) and reduced postnatal survival. Phthalate syndrome
(PS) malformations were seen in about 9%, 44% and 100% of the F1 male off-
spring at 33, 100 and 300 mg/kg/d, dosage levels that reduced fetal T production
by 35%, 77% and 93% respectively. Also of note were skull malformations in high-
est treatment group in the form of malocclusions and incomplete zygomatic ossifi-
cation. These results indicate the DPeP is about 3.5 fold more potent in inducing
the PS in F1 male rats than is DEHP and demonstrate that the relative potencies
for disrupting fetal testis endocrine function can be used to predict some the post-
natal reproductive effects of this class of endocrine disruptors. Disclaimer: This ab-
stract doesn’t necessarily reflect USEPA policy. Supported in part by NTP/NIEHS
IA# RW-75-92285501.
2129 Changes of Expression Levels of Oxidative Stress-Related
Genes in Mouse Epididymides by Neonatal Exposure to
Low-Dose Decabromodiphenyl Ether.
M. Nakamoto1,  H. Miyaso1,  M. Komiyama1,  Y. Matusno1, 2 and C. Mori1, 2.
1Department of Bioenvironmental Medicine, Graduate School of Medicine, Chiba
University, Chiba-shi, Japan; 2Center for Preventive Medical Science, Chiba
University, Chiba-shi, Japan.
Decabromodiphenyl ether (decaBDE), one of polybrominated diphenyl ethers
(PBDEs), is the most famous flame retardant and is used in worldwide. In a previ-
ous study, we identified adverse effects of neonatal decaBDE exposure on mouse
epididymides, for example decrease of epididymal weight. On the other hand,
neonatal exposure to diethylstilbestrol (DES), artificial estrogenic compounds, also
causes several adverse effects on epididymides. DES exposure causes the decrease of
epididymal weight, morphological abnormality, and the lasting change of expres-
sion levels of several genes. Molecular mechanisms for induction of harmful effects
by decaBDE exposure remain unclear. Since many studies have reported that
PBDEs have estrogenic activity, this activity may contribute to induction of adverse
effects of decaBDE exposure. This study was carried out to examine how effects are
caused in epididymides by neonatal decaBDE exposure, and elucidate molecular
mechanisms of adverse effects by decaBDE exposure. Administration of decaBDE
was performed subcutaneously at 0.25 mg/kg body weight/day, on postnatal days 1
to 5. At 12 weeks of age, epididymides were histologically examined and gene ex-
pression was analyzed using DNA microarray and real-time PCR. Our data showed
that 1) no histological change was observed on epididymal tissues by neonatal
decaBDE exposure, differently from that of DES, 2) decaBDE exposure could not
induce the change of expression levels of genes which were affected by DES, but
caused changes of expression levels of some oxidative stress related genes in mouse
epididymides, 3) the expression level of Ubiquitin C (Ubc) increased in decaBDE-
exposed mouse epididymides. Our presented data suggest the possibility that in-
crease of oxidative stress is related to elicitation of harmful effects in decaBDE-ex-
posed mouse epididymides.
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2130 Structural Changes in Various Organs of Male Rats Caused
by Long-Term Oral Administration of Chlorpyrifos.
S. Tripathi and A. K. Srivastav. Department of Zoology, DDU Gorakhpur University,
Gorakhpur, India.
- Wistar rats (male) were divided into two groups — group A (GA) served as con-
trol and group B (GB) were daily administered orally chlorpyrifos (Anu Products
Ltd., India) at a dose of 5 mg/kg b wt. Rats were sacrificed on 1st, 2nd, 4th, 6th,
and 8th week after initiation of the experiment. Left testis and duodenum were ex-
tirpated and fixed in aqueous Bouin’s solution. The tissues thus fixed were routinely
processed for histological studies. Chlorpyrifos treatment caused degeneration in
seminiferous tubules and thus inhibit the spermatogenesis in rats. Few seminiferous
tubules lack the germinal epithelium. After exposure to chlorpyrifos the morpho-
logical observations of duodenum showed an increased mucous cell activity, disrup-
tion and sloughing of duodenal villar cells, lymphocytic infiltration and degenera-
tion of cells. In conclusion the findings of the present study indicate that the
organophosphate – chlorpyrifos can inhibit spermatogenesis and provoke degener-
ative features in the duodenum of rats and thus severely affect these organs.
2131 Assessment of Phthalate-Induced Changes in Fetal Rat Testis
Gene Expression Using a rt-PCR Array.
C. Lambright1,  H. Sampson2,  J. R. Furr1,  B. Hannas1,  N. Evans1,  L. E. Gray1
and V. S. Wilson1. 1ORD/RTD, US EPA, Research Triangle Park, NC; 2ORISE/US
EPA Fellow, Research Triangle Park, NC.
Phthalate esters (PE) such as diethyl hexyl phthalate (DEHP) produce reproductive
malformations in male rodents by reduction of testosterone (T) production and
gene expression after dams are exposed during the critical period of sexual differen-
tiation. We investigated the effects of seven PE known to reduce fetal T production
and further evaluated gene expression using novel SABiosciences PCR arrays. Each
array tests for 84 genes either involved in phase one drug or lipoprotein transport
and cholesterol metabolism/synthesis.  Timed pregnant Sprague-Dawley rats were
orally dosed with individual phthalates from gestational day (GD) 14-18. On GD
18, testes were collected from 3 fetuses per dam and cultured for 3 hours. Medium
was collected and T values measured by RIA. Remaining testes were pooled by lit-
ter, RNA extracted, cleaned, quantified, and evaluated for gene expression using
PCR arrays. PE were DiHP (750 mg/kg), Dihexyl (750 mg/kg), DPP (100 mg/kg),
DiBP (900 mg/kg), DiNP (1500 mg/kg), DCHP (0, 100, 300, 600, or 900
mg/kg), and DEHP (750 mg/kg). Of the 84 genes on the Drug Metabolism arrays,
four were significantly reduced: Cyp11b1, Cyp11a1, Cyp17a1, and ALDH2.
Cyp11a1 and Cyp17a1 are involved in T synthesis, while Cyp11b1 aids in the pro-
duction of cortisol and corticosterone. Using the lipoprotein/cholesterol arrays, we
identified 10 genes that were significantly altered that are involved in cholesterol
biosynthesis (such as APOc3, Dhcr24/7, EBP, MVK, Tm7sf2). These data support
that PE effects in the fetal testis are not limited to alterations in androgen synthesis
and include genes for other hormones (Insl3), growth factors, steroid transport pro-
teins, and multiple genes involved in cholesterol synthesis. Disclaimer: This ab-
stract doesn’t necessarily reflect USEPA policy. Supported in part by NTP/NIEHS
IA# RW-75-92285501-1 and fellowship administered jointly between EPA/DOE
and the Oak Ridge Institute for Science and Education.
2132 Modulation by Antioxidants of Chemotherapeutic Drugs-
Induced Alterations in Steroidogenic Enzyme Activities in
the Testis.
N. Kilarkaje1 and M. Al-Bader2. 1Department Anatomy, Faculty of Medicine,
Kuwait University, Safat, Kuwait; 2Physiology, Faculty of Medicine, Kuwait
University, Safat, Kuwait.
Combined treatment of bleomycin, etoposide and cisplain (BEP) is a ‘gold stan-
dard’ therapy for several types of cancers. These drugs impair testicular functions,
although the effects on Leydig cell steroidogenic enzymes are not known. We inves-
tigated the effects of the drugs on the enzymes and putative modulation by antiox-
idants of the drug effects. Male Wistar rats (13-15 week-old; N=5/group) were
treated with either water (G1), or an antioxidant cocktail (AO; G2: α-tocopherol
[100 mg/kg], L-ascorbic acid [50 mg/kg], Zn [40 mg/L] and Se [100 μg/L, po]), or
three cycles of 21 days each of BEP (G3; 1.5 mg/kg, 15 mg/kg and 3 mg/kg; ip), or
BEP+AO (G4). In G3 and G4, E and P were given from day 1-5 and B on days 2,
9 and 16 of each cycle. The rats were anesthetized with ether and sacrificed by CO2
asphyxiation the next day. The gene expressions were quantified by ReT-PCR by
using specific primers. The expression of the proteins was evaluated by Western
blotting and confocal microscopy. Data were compared by one way ANOVA and
LSD test and p<0.05 was considered significant. The gene expressions of Cyp17a1,
P450scc, StAR and Scarb1 were up-regulated and that of Cyp19a1, 3β-hsd and
17β-hsd were down-regulated in G3 and G4. In G2, Cyp19a1,3β-hsd, 17β-hsd
and StAR expressions were down-regulated (p<0.05). The protein levels of LHR
and 3β-HSD were unaffected, whereas that of StAR were up-regulated, and that of
P450scc, 17β-HSD, Cyp17a, and Cyp19a were down-regulated in G2-G4 com-
pared to G1 (p<0.05). No significant protective effects of the AO were observed,
except on Cyp17a and Cyp19a. All proteins were localized in the cytoplasm. In
conclusion, the drugs affect both gene and protein expressions of steroidogenic en-
zymes in Leydig cells and the antioxidants have limited protective effects
(Supported by Kuwait University Grant # MA02/08, GM01/01 and GM01/05).
2133 Comparison of Fetal Testosterone Production in Various
Tissues of the Male Sprague-Dawley Rat Dosed In Utero
with Dipentyl Phthalate during the Critical Window of
Sexual Differentiation.
K. R. Tatum-Gibbs1,  J. R. Furr2,  C. Lambright2,  N. Evans2,  B. Hannas2,
B. W. Riffle1,  H. Sampson1,  A. K. Hotchkiss3,  V. S. Wilson2 and L. E. Gray2.
1ORISE, US DOE, Oak Ridge, TN; 2Reproductive Toxicology, US EPA, Research
Triangle Park, NC; 3NCEA, US EPA, Research Triangle Park, NC.
Phthalate esters are high-production volume chemicals used in the manufacture of
numerous plastics and consumer products, which generates major concern for po-
tential human exposure and environmental contamination. Several studies have
demonstrated adverse effects associated with phthalate exposure administered dur-
ing the critical window of sexual differentiation on the development of the male re-
productive system, many of which can be attributed to a decrease in fetal testos-
terone (T) production. However, there is very little information regarding
reduction in fetal T in tissues other than the testes and the “Point of Departure” as
it relates to the relationship between reductions in fetal T levels and resultant post-
natal male reproductive malformations. Therefore, the objective of the current
study was to assess fetal T production in various tissues following in utero exposure
to dipentyl phthalate (DPeP) to determine the relationship between reductions in
fetal T with the postnatal reproductive male malformations. DPeP was given to
timed pregnant Sprague-Dawley rats via oral gavage on gestation days (GDs) 14-18
at doses of 11, 33, 100, or 300 mg/kg/d (n=3); controls received the vehicle corn
oil. At GD 18 dams were necropsied and fetal specimens (plasma, testes, reproduc-
tive tract, and whole body) were recovered for extraction of T using Solid Phase
Extraction (SPE). We found the dose response curves for T production (media ex-
traction) were very similar to the extracted T levels in the testes and serum.
However, preliminary results suggest the dose response curves for the reproductive
tract and whole body may be quite different from those of testes and serum T lev-
els. This abstract does not reflect U.S. EPA policy. Supported by EPA/NTP IA #
RW-75-922-85501
2134 Cumulative Effects of a 9 Phthalate Mixture on Charles
River-Sprague-Dawley (CR-SD) Fetal Rat Testis Testosterone
(T) Production and Gene Expression.
V. S. Wilson,  J. R. Furr,  C. Lambright,  B. Hannas and L. E. Gray. Reproductive
Toxicology Branch, US EPA, ORD, NHEERL, TAD, Research Triangle Park, NC.
In utero exposure to mixtures of 2 to 5 phthalate esters (PE) with similar modes of
action have been shown to inhibit male reproductive development in a dose-addi-
tive fashion. Further when PE were administered to pregnant dams during the pe-
riod of sexual differentiation, when reproductive malformations were observed in
male offspring they correlated to significant reductions in fetal T levels. We have
observed that a mixture of 9 PE administered on gestation day (GD) 14-18 to
Harlan SD rats (dilutions of a fixed ratio mixture; top dose of 80 mg DEHP, DiHP,
DiBP, DBP, BBP, DCHP, D(hexyl)P, D(heptyl)P, and 10 mg DPeP/kg/d) reduced
fetal T production in a dose additive manner (Hannas et al, 2011). The current
study compared the sensitivity of the fetal testis of CR-SD to the Harlan SD rat for
disruption of testis T production and gene expression of the 9 PE mixture. A pilot
postnatal study with Harlan SD rats (administered at the top dose and 67, 33, 17,
and 8% of the top dose) the high dose group produced a high incidence of phtha-
late syndrome malformations accurately predicted by dose addition modeling, but
far in excess of that predicted by response addition. The CR-SD rat (ED50 = 38%
of top dose) was slightly less sensitive to disruption than the Harlan SD rat (ED50
= 26%) for fetal T production.  Results demonstrate that mixtures of 9 PE behave
in a manner accurately predicted by dose addition modeling. Thus considering PE
hazard identification on an individual basis, without inclusion of other PE, could
underestimate the risk posed by a mixture of PEs. Future postnatal 9 PE studies are
planned in the CR-SD rats to determine the point of departure correlation between
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reduced fetal T levels and the resultant postnatal male reproductive malformations.
Disclaimer: This abstract does not necessarily reflect USEPA policy. Supported in
part by NTP/NIEHS Interagency Agreement # RW-75-92285501.
2135 Impact of Clinically Relevant Cisplatin Treatment on the
Undifferentiated Spermatogonia Population and Niche.
J. Harman and J. Richburg. University of Texas at Austin, Austin, TX.
A typical clinical cisplatin (CDDP) regimen consists of repeated cycles of 5-7 daily
low dose injections followed 1-2 week recovery period; and while effective, often re-
sults in prolonged, sometimes permanent, infertility. Theoretically, undifferentiated
spermatogonia (undiff-Sp), including spermatogonial stem cells (SSCs), should re-
populate the testis after exposure has ceased. We hypothesize that SSC mitotic ac-
tivity increases following the initial exposure to CDDP, rendering SSCs increasingly
susceptible to CDDP-induced injury during subsequent cycles. We examined
changes in the adult C57 undiff-Sp population and niche at days 1, 8 and 16 of the
recovery period following a clinically-relevant course of 1 cycle (2.5 or 5.0
mg/kg/d) and 2 cycles (2.5 mg/kg/d) of intraperitoneal CDDP. Histological exam-
ination of the testis epithelium showed an increase in damage correlating with ex-
posure dose and cycle number. Apoptosis was measured via TUNEL and found to
increase during the recovery period following 1 cycle of 2.5mg/kg and 5.0mg/kg
(300%), as well as 2 cycles of 2.5mg/kg (400%) CDDP compared to controls.
Immunohistochemistry (IHC) was performed using antibodies specific for FOXO1
(undiff-Sp marker) and GDNF (critical SSC niche protein secreted by Sertoli cells).
Analysis of FOXO1 showed a reduction in undiff-Sp during the recovery period
following 1 cycle of 2.5 (50%) and 5.0mg/kg CDDP (66%), as well as 2 cycles of
2.5mg/kg CDDP compared with controls (50%); followed by a return to numbers
equal with or surpassing controls at 16d recovery. IHC analysis of GDNF revealed
a general increase in expression, prominently along the basal membrane, during the
recovery period in all treatment groups. These data suggest that a greater dose of
CDDP in a single cycle of exposure causes a greater impact on the functional stem
cell pool and its niche and multiple cycles of exposure result in a still greater impact
than an equivalent cumulative dose. Future experiments focus on whether CDDP
exposure targets the SSCs, the Sertoli cells, or both.
2136 Using a Rat Primary Epididymal Cell Model to Evaluate
Drug-Induced Inflammation and Granulomas.
K. Stachelek2,  W. Nowland1,  T. Winton1,  S. Kumpf1,  S. N. Campion1,
R. E. Chapin1 and M. E. Hurtt1. 1Drug Safety Research and Development, Pfizer
Inc., Groton, CT; 2College of Pharmacy, University of Rhode Island, Kingston, RI.
Epididymal inflammation and sperm granuloma formation have been detected in
vivo in Sprague Dawley (SD) rats following various treatments. The objective of
this in vitro primary rat cell model is to identify compounds that cause epididymal
inflammation and granulomas using minimal compound and fewer animals. We
had previously found that more potent granulomagens produced larger increases in
transcript levels for the IL6 and GRO cytokines (3 to10-fold increases), while less
potent and negative compounds produced smaller (less than or equal to 2X) or no
increases. We evaluated the marketed phosphodiesterase type 4 inhibitors, ibudilast
(I), roflumilast (R), and the active metabolite roflumilast N-oxide (RNO), which
are known to cause sperm granulomas in rats. Primary cultures of mixed epididy-
mal epithelial cells were isolated and plated on Matrigel 24-well plates and exposed
to increasing concentrations of test compounds. 24 hours post dosing, we measured
mitochondrial metabolic activity using the MTS assay and cell lysates were evalu-
ated for IL6, GRO, and IL10 gene expression by qRT-PCR at the IC20 (80% MTS
activity). R and RNO were poorly soluble, which limited the in vitro exposure lev-
els. Perhaps for this reason, modest increases in IL-6 and GRO were seen with R
and RNO treatment (1.2- and 1-fold for R, 1.6- and 1.9-fold for RNO) while
MTS activity was not reduced. However, treatment with ibudilast resulted in larger
increases in IL-6 and GRO, 2.7- and 2.9-fold respectively at the IC20, consistent
with its in vivo activity. The results of this study demonstrate that this primary epi-
didymal culture model detects inflammatory signals that reflect the in vivo activity
of at least one of these compounds in rats.
2137 Evaluation of an In Vitro Model of Spermatogenesis for
Predicting Testicular Toxicity.
K. M. Goldstein1,  M. Perrard2,  P. Durand2,  T. K. Baker1 and D. E. Seyler1.
1Investigative Toxicology, Eli Lilly & Co., Indianapolis, IN; 2Kallistem, Lyon, France.
Sponsor: C. Thomas.
Due to the complex physiology of the testes, in vitro models have been largely un-
successful at predicting testicular toxicity in vivo. These models often bear limited
resemblance to in vivo cellular organization. We evaluated an in vitro model (Hue et
al 1998) that forms tight junctions similar to the blood-testis-barrier (BTB), and
supports spermatogenesis through meiosis II (secondary spermatocytes) and the
formation of round spermatids. We used this in vitro model to evaluate the toxicity
of four known testicular toxicants: Bisphenol A (BPA), 2-Methoxyacetic acid
(MAA) 1,3-Dinitrobenzene (DNB), and Lindane in pre-pubertal rat seminiferous
tubule cultures treated with compound for 28 days. Formation of the BTB (tight
junctions) was measured by transepithelial electrical resistance (TEER) every 2
days. Cells were collected weekly for flow cytometric analysis to measure total via-
bility and cell counts for each stage of spermatogenesis. Concentrations for each
chemical were selected to approximate those shown to produce in vivo testicular ef-
fects. BPA and DNB decreased dramatically the TEER in a dose and time-depend-
ent manner, whereas the effects of MAA and Lindane were less marked and transi-
tory, even at the higher concentrations tested. Cell viability was slightly, if any,
modified by the compounds; this was due most likely to the phagocytic activity of
the Sertoli cells. All compounds induced dramatic dose- dependent diminutions of
the populations of spermatocytes I and II, and round spermatids. It is important to
note that the well-known specific toxic effects of MAA and DNB on pachytene
spermatocytes were easily reproduced by this in vitro model. Combined, these as-
says not only predicted testicular toxicity in vivo, but also identified whether the
compound directly targets the Sertoli cells or germ cells. With further validation,
this cell model may be applicable as a screen to minimize running long-term live-
phase studies.
2138 Vinclozolin Alters the Testosterone Homeostasis by
Regulating the Rat Liver Cytochrome P450.
D. C. Escobar-Wilches,  C. L. Zazueta-Beltran,  M. L. Lopez-Gonzalez and
A. Sierra-Santoyo. Toxicology, CINVESTAV-IPN, Mexico City, Mexico.
The Vinclozolin (V) is a well-characterized anti-androgenic fungicide in several
species. The V is able to produce a complex pattern of induction, suppression and
inhibition of cytochrome P450 (CYP) isoforms in mammals. The alteration of liver
CYP expression can modify the testosterone biotransformation pattern. The objec-
tive of this work was to assess the effect of V on liver CYP expression and its reper-
cussion on serum and urine levels of testosterone and its metabolites. Male Wistar
adults rats were orally administered 100 mg/kg/d V for 7 d suspended in corn oil.
After last dose the urine of 24 h was collected and animals were sacrificed and the
blood was obtained by cardiac punction. The liver was processed to obtain micro-
somes for enzyme assays and protein content analysis of different CYP isoforms.
The testosterone and its metabolites were extracted from plasma and urine was
processed by enzymatic hydrolysis using β-glucuronidase/sulphatase and analyzed
by HPLC. V exposure increased 25% the liver relative weight and was accompanied
by an increase of 40.3% of total CYP content. The liver immunoreactive protein
content of CYP1A1, 1A2, 2A, 2B1 and 3A2 increased 6.5-, 16.4-, 2.3-, 6.5- and
1.5-fold, respect to the non-treated group. The protein content of CYP2E1 was not
affected by V. Enzyme activities of EROD, MROD, PROD and PNPH signifi-
cantly increased 3.0-, 6.4-, 64.3- and 1.6-fold, respectively. In V-treated animals
testosterone levels increased 80-fold in serum and 150-fold in urine. V affected the
testosterone biotransformation pattern, androstenedione levels increased in serum
and urine 54- and 3.6-fold, respectively; 6-DHT increased 112-fold in urine.
Other testosterone metabolites were not affected. These results indicate that V reg-
ulates liver CYP expression and alters the testosterone biotransformation pattern.
In addition, they also suggest an alteration on testosterone homeostasis which may
represent another mechanism of action for V. These results will provide further in-
sight into the relationship between toxicity and V exposure.
2139 Sperm mRNAs Are Molecular Markers of Testicular Injury in
Rats.
L. Anderson1,  E. Dere2 and K. Boekelheide1. 1Department of Pathology and
Laboratory Medicine, Brown University, Providence, RI; 2Department of Urology,
Rhode Island Hospital, Providence, RI.
Traditional endpoints used to measure male reproductive toxicity in humans, in-
cluding semen and hormone analysis, are insensitive and unreliable; those used to
monitor toxicity in animal studies, while sensitive, are not easily translatable to hu-
mans. It is therefore necessary to develop sensitive and reliable molecular biomark-
ers of testicular injury that can be used to both monitor human reproductive func-
tion and compare animal studies with human exposures.
Objective: This sub-chronic dose response study aimed to build on existing data
that identified 12 mRNA transcripts that were altered in the sperm following expo-
sure to single doses of the Sertoli cell toxicants 2,5-hexanedione (2,5-HD) or car-
bendazim (CBZ).
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Methods: Adult male Fisher 344 rats were either exposed to 0, 0.14%, 0.21%, or
0.33% 2,5-HD in the drinking water for three months, or exposed by daily oral
gavage to 0, 30, 50, or 70 mg/kg CBZ in corn oil for three months. Body and organ
weights were obtained, and quantifiable histopathological parameters (homoge-
nization resistant spermatid head counts and retained spermatid head counts) were
measured. Sperm mRNAs were measured by qRT-PCR arrays.
Results: At doses that produced no-to-low levels of testicular injury, as assessed by
organ weights and histopathology, a total of eight mRNA transcripts were altered in
the cauda epididymal sperm. Four of the transcripts were significantly increased at
the highest dose of HD, with clusterin increased in a dose responsive manner at all
doses of HD. Six of the transcripts were significantly altered after exposure to CBZ,
with clusterin also increased in a dose responsive manner at all doses of CBZ.
Conclusions: Our data indicate that sperm mRNA transcripts are sensitive markers
of testicular toxicity. The clusterin transcript in particular may be a more sensitive
indicator of Sertoli cell injury than the most sensitive histopathological endpoint.
2140 Effect of Neonatal Exposure to Decabromodiphenyl Ether on
Transcript Levels of Splicing Factors in Mouse Testes.
H. Miyaso1,  N. Nakamura2,  Y. Matsuno3, 1,  M. Komiyama1 and C. Mori1, 3.
1Department of Bioenvironmental Medicine, Graduate School of Medicine, Chiba
University, Chiba, Japan; 2Department of Pharmacology, Physiology and Toxicology,
Marshall University, Huntington, WV; 3Center for Preventive Medical Science, Chiba
University, Chiba, Japan.
Decabrominated diphenyl ether (decaBDE) is one of flame retardants and is used
in worldwide. Our previous study found postnatal exposure to decaBDE had ad-
verse effect to male reproduction in mice. Mice were injected subcutaneously
0.025, 0.25, and 2.5 mg/kg decaBDE during postnatal day 1-5 and evaluated at 12
weeks of age. In 0.025, and 0.25 mg/kg dose groups, the number of Sertoli cells was
reduced significantly. Thyroid hormones (THs) are key players for Sertoli cells de-
velopment. We identified that the transcript levels of TH receptor α (Thra) de-
creased significantly in testes of 0.025 mg/kg decaBDE dose group, while no
change of TH levels was observed between control and all dose groups. Moreover,
we found the ratio of Thra1/Thra2 level decreased in 0.025 and 0.25 mg/kg dose
groups compared to control group. The ratio of Thra1/Thra2 level is known to be
varied by the change physiologically, and the ratio of heterogeneous ribonucleopro-
tein (hnRNP) A1 (hnrnpa1): serine/arginine-rich splicing factor 1 (Srsf1) is related
to Thra1/Thra2 level. However, no change was observed in hnrnpa1: Srsf1 level be-
tween control and dose groups. Therefore, we hypothesized other splicing factors
may be involved in decrease of Thra1/Thra2 level. In this study, the transcript lev-
els of hnRNP F (hnrnpf ) and hnRNP H1 (hnrnph1) were examined by real-time
PCR. Mice were dosed by above described method, and testes were collected at 12
weeks of age. Our data showed the decrease in transcript level of hnrnpf in 0.025
mg/kg dose group, and decrease of hnrnph1 level in 0.25 and 2.5 mg/kg dose
groups compared to the control group. Our study suggests that hnrnpf and hn-
rnph1 are also involved in the decrease of Thra1/Thra2 ratio by neonatal decaBDE
exposure.
2141 RSPOs Counteract TCDD Inhibition of Canonical Wnt
Signaling during Fetal Mouse Prostate Development.
A. Branam1, 2,  N. M. Davis1, 2,  R. W. Moore1, 2,  A. J. Schneider1, 2,
C. M. Vezina1, 3 and R. E. Peterson1, 2. 1University Wisconsin-Madison, Madison,
WI; 2Pharmacy, UW-Madison, Madison, WI; 3Comparative Biosciences, UW-
Madison, Madison, WI.
Prostatic buds are derived from the urogenital sinus (UGS) and later form into the
prostate ductal network in adult mammals. In utero TCDD exposure causes mis-
positioning and reductions in dorsal and lateral prostatic bud numbers and pre-
vents formation of ventral buds leading to ventral prostate agenesis. Here we exam-
ined canonical Wnt signaling following TCDD exposure in vitro. We found
multiple components of the pathway (Lef1, Tcf1, Wif1, Lgr5) to be downregulated
by TCDD. R-spondins (RSPOs) are promoters of canonical Wnt signaling but
their mechanism for activating the canonical Wnt pathway is not fully understood.
Previously, we demonstrated RSPO2 and RSPO3 promote prostatic bud develop-
ment and addition of these proteins can rescue the effects of TCDD on prostatic
bud growth. We now further examined the mechanism of RSPO activation of the
Wnt pathway in the UGS by studying the extracellular Wnt antagonists, DKKs,
and determining their effects on budding in vitro and examining LGRs, which are
putative RSPO receptors, by studying mRNA expression between vehicle and
TCDD treated UGSs. Both mechanisms of Wnt activation by RSPOs have been
demonstrated in other systems; however, it remains unclear if RSPOs preferentially
act through one mechanism over the other. Our results showed little effect on
prostate bud number following treatment with DKK1 and DKK2. We found both
Lgr4 and Lgr5 mRNA expression in the basal epithelium (BE) where prostatic buds
form and additionally we found a decrease by TCDD in Lgr5 mRNA levels in
vitro. These results suggest that RSPOs bind to LGRs located in the BE of the UGS
to initiate prostate bud formation. Together, these data illustrate that TCDD in-
hibits multiple components of the Wnt signaling pathway and that the combined
inhibition of these components significantly contributes to the inhibitory budding
phenotype caused by TCDD. (Grant support: NIH ES01332, T32 ES007015)
2142 Sensitivity of Toxicological Endpoints to Detect Alterations
in the Male Reproductive System of Nonhuman Primates.
G. D. Cappon1,  D. Potter1,  M. E. Hurtt1,  G. F. Weinbauer2 and
C. J. Bowman1. 1Pfizer Worldwide Research & Development, Groton, CT; 2Covance
Laboratories GmbH, Muenster, Germany.
The assessment of the potential for a compound to cause toxicity to male reproduc-
tive processes relies heavily on histopathology and organ weights of the reproduc-
tive tissues. This is even more so with biologics where non-human primates (NHP)
is the only relevant species and evaluation of functional fertility is impractical. To
address this shortcoming ICH S6(R1) included a trigger for the addition of non-
routine endpoints to NHP studies in cases where there is reproductive cause for
concern. To determine the sensitivity of these endpoints to perturbation we per-
formed a power analysis of routine and triggered endpoints. The analysis was done
on control data from sexually mature Asian and Mauritian sourced NHP used in
toxicity studies at Covance Laboratories GmbH. The power calculations were per-
formed with a 2 sample two-sided T-test (a=0.05) assuming 3 NHP/group and the
number of observations ranged from 98 to 472 per endpoint. For reproductive
organ weights the power to detect a 50% change from control was 30%, 35%, 18%
and 13% for testes, epididymides, prostate, and seminal vesicle, respectively. For
testicular volume the power to detect a 50% change was ~ 30%, with slight differ-
ences depending on the method (caliper or ultrasound). For seminal analysis the
power to detect a 50% change was 6%, 6%, 66% and 41% for ejaculate weight,
sperm count, sperm motility, and sperm morphology (percent normal), respec-
tively. For male hormone data the power to detect a 50% change was 10%, 30%,
7% and 78% for testosterone, inhibin B, luteinizing hormone, and follicle stimu-
lating hormone, respectively. Given samples sizes of 3 per treatment group, and the
magnitude of biological variability observed for these endpoints, the ability to draw
conclusions about potential toxicity will be limited for most endpoints.
Consequently, great care should be taken in the choice of endpoints added to gen-
eral toxicity studies to assess the male reproductive system.
2143 Contribution of PI3K/Akt/DAF-16 Activity in C. elegans to
Gene-Environment Interactions following MeHg Exposure.
S. J. Fretham and M. Aschner. Pediatric Toxicology, Vanderbilt University Medical
Center, Nashville, TN.
Neither genetic nor environmental factors completely explain the etiology and pro-
gression of dopaminergic (DAergic) neurodegeneration in Parkinson’s disease (PD).
This study examines PI3K/Akt signaling as a mechanistic link between environ-
mental and genetic factors known to contribute to PD. Specifically the interaction
between methylmercury (MeHg) exposure, a ubiquitous neurotoxin, and
PARK7(DJ-1), an autosomal recessive PD gene. PI3K/Akt signaling is highly con-
served and regulates many aspects of neuronal survival and function. MeHg expo-
sure has been shown to activate PI3K/Akt signaling and DJ-1 modifies PTEN ac-
tivity, an upstream regulator of PI3K/Akt. Mutant and transgenic Caenorhabditis
elegans (C. elegans) strains were used to determine if PI3K/Akt responsiveness and
loss of DJ-1 increases MeHg vulnerability. Strains used include: wild type (WT)
Bristol N2; strains null for daf-16, age-1, daf-18, djr-1.1, and djr-1.2; and a strain
overexpressing DAF16::GFP. Synchronous L1 populations were treated with 0-
40uM MeHg for 30 minutes followed by assessment of survival and basal slowing
(a dopamine-dependent feeding behavior). Compared to WT worms, increased
PI3K/Akt activity resulting from genetic loss of daf-18 (PTEN homolog) and daf-
16 (FOXO homolog) led to increased death and lower lethal dose (LD50) values
following MeHg treatment while decreased PI3K/Akt activity through loss of age-1
(PI3K homolog) and overexpression of DAF-16::GFP increased survival. Loss of
djr-1.1 or djr-1.2 (PARK7 homologs) did not affect survival. Basal slowing was sig-
nificantly reduced in WT worms following 20μM but not 10μM MeHg treatment
(p<0.01). Basal slowing in worms lacking djr-1.1 but not djr-1.2, was decreased by
10μM and 20μM MeHg, suggesting that loss of djr-1.1 increases DAergic sensitiv-
ity to MeHg. Collectively, these findings demonstrate that MeHg-induced
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PI3K/Akt activation contributes to toxicity and that MeHg impairs DAergic be-
havior, an effect that is enhanced by loss of djr-1.1. (Work supported by NIEHS
R01-07331 and NIEHS T32-ES007028).
2144 Low-Dose Postnatal MeHg Exposure Alters mRNA Levels of
Rat Brainstem Glutamate Receptors and Voltage Gated
Calcium Channels.
A. Colón-Rodríguez,  R. K. Hajela,  S. Escudero,  Y. Yuan and W. D. Atchison.
Pharm/Tox, Michigan State University, East Lansing, MI.
Methylmercury (MeHg) hastens the onset of motor paralysis in SOD-1 G93A
mice, a genetic model of Amyotrophic Lateral Sclerosis (ALS), suggesting a gene-
environment interaction in a genetically susceptible animal model. Associated with
this are alterations in [Ca2+]i and glutamate receptor (GluR) function, both of
which are suggested targets for MeHg toxicity. The goal of this study was to deter-
mine if MeHg alters mRNA levels of voltage gated Ca2+ channels (VGCCs),
NMDA, or AMPA receptors. We measured mRNA levels of the pore forming α1
subunit of L, N, P/Q and R type VGCCs, NR1 and NR2A subunits of NMDA re-
ceptors and GluR2 and GluR3 subunits of AMPA receptors. Determining if MeHg
alters levels of these ion channels could contribute to understanding of MeHg-in-
duced alteration in [Ca2+]i in motor neurons. Postnatal day 5 rats were treated sc
with 0.75 or 1.5 mg/kg/day MeHg for 15 or 30 days (d), then stopped for a clear-
ing period of 30 d. Quantitative real time PCR was performed on reverse transcript
of RNA isolated from 10 mg of brainstem tissue, a region rich in motor neurons.
MeHg treated animals had higher levels of GluR2, GluR3 and NR2A at 15 d in
both 0.75 and 1.5 mg/kg/day exposure. MeHg induced an increase in the levels of
all GluR subunits studied. It was highest at 30 d, and more pronounced in the 0.75
mg/kg/day exposure. GluR2 was the most affected subunit. At 60 d, levels of all
GluR subunits were increased but at levels similar to those seen at 15 d of exposure.
With the exception of α1A, levels of all VGCC α1 subunits were higher at 0.75
mg/kg/day MeHg exposure on 15 and 30 d and lower at 60 d. At 15 d 1.5
mg/kg/day MeHg increased levels of all VGCC α1 subunits except α1E. At 30 d the
level was even higher for all of the α1 subunits, but returned to levels similar to
those at 15 d after the clearing period. The increase in the level of GluR subunits
and most of the VGCCs could contribute to the alteration in Ca2+ homeostasis in-
duced by MeHg on motor neurons. Supported by NIH grants R01ES03299 and
R25NS065777.
2145 Effects of Chronic Postnatal Methylmercury Exposure on
mRNA Expression of Calcium Regulatory Proteins in Adult
Mouse Brain Stem.
J. A. Musser1, 2,  A. Colón-Rodríguez1 and W. D. Atchison1, 2. 1Department
Pharmacology/Toxicology, Michigan State University, East Lansing, MI; 2College of
Veterinary Medicine, Michigan State University, East Lansing, MI.
Methylmercury (MeHg) causes marked alterations in neuronal [Ca2+]i homeostasis
through its interaction with membrane ion channels such as voltage-gated Ca2+
channels (VGCC’s), and Ca2+ permeable ligand-gated channels-NMDA
(NMDAR) and AMPA receptors (AMPAR). Chronic postnatal exposure to MeHg
hastens the onset of Amyotrophic Lateral Sclerosis-like phenotype in the
SOD1G93-A genetically susceptible mouse model via glutamate-mediated excito-
toxicity. The underlying mechanism of MeHg effects on brainstem motor neurons
remains unclear. In this study we focused on examining the effects of chronic
MeHg exposure on mRNA expression of the pore-forming α1 subunits of the L
(α1C), N (α1B), P/Q (α1A) and R-type (α1E) VGCC’s, NR1 and NR2 subunits of
the NMDAR, GluR2 and GluR3 subunits of the AMPAR, Ca2+ binding proteins
calbindin D28K and parvalbumin, and glutamate transporter EAAT2, all of which
can modulate [Ca2+]i homeostasis. Eleven week old male ICR mice were exposed to
0, 0.5 or 5 ppm MeHg in drinking water ad libitum for 6 mos. Total RNA was ex-
tracted from 10 mg of brainstem and reverse transcription PCR performed.
Quantitative real time PCR was performed on reverse transcript (cDNA) to meas-
ure expression of the target genes. Exposure to 0.5 ppm MeHg induced a decrease
in the expression of the AMPAR subunits, Ca2+ binding proteins and the α1 sub-
unit of the N- and P/Q-type VGCCs. NMDAR expression at 0.5 ppm MeHg ex-
posure was not altered for the NR1 subunit but was increased for NR2. At 5 ppm
MeHg decreased expression of GluR2, EAAT2, calbindin D28K, parvalbumin, and
all of the VGCC subunits. Expression of AMPAR subunit GluR3 was increased at
5ppm exposure. These results support the idea that MeHg-induced increase in
[Ca2+]i on brainstem motor neurons is due to the glutamate receptors (greater
GluR2 expression, and NR2 expression), or inefficient Ca2+ buffering (decrease in
the Ca2+ binding proteins and EAAT2 transporter). VGCC’s may not contribute to
the alteration in [Ca2+] induced by MeHg because their expression was decreased.
Supported by NIH grants R01ES03299 and R25NS065777.
2146 Perinatal Exposure to Low-Dose Methylmercury Induces
Dysfunction of Motor Coordination with Decreases in
Synaptophysin Expression in the Cerebellar Granule Cells of
Rats.
M. Fujimura. Basic Medical Sciences, National Institute for Minamata Disease,
Minamata, Japan. Sponsor: A. Naganuma.
Methylmercury (MeHg) is an environmental pollutant that is toxic to the develop-
ing central nervous system (CNS) in children, even at low exposure levels. Perinatal
exposure to MeHg is known to induce neurological symptoms with neuropatho-
logical changes in the CNS. However, the relationship between the neurological
symptoms and neuropathological changes induced in offspring as a result of expo-
sure to low-dose MeHg is not well defined. In the present study, neurobehavioral
analyses revealed that exposure to a low level of MeHg (5 ppm in drinking water)
during developmental caused a significant deficit in the motor coordination of rats
in the rotating rod test. In contrast, general neuropathological findings, including
neuronal cell death and the subsequent nerve inflammation, were not observed in
the region of the cerebellum responsible for regulating motor coordination.
Surprisingly, the expression of synaptophysin (SPP), a marker protein for synaptic
formation, significantly decreased in cerebellar granule cells. These results showed
that perinatal exposure to low-dose MeHg causes neurobehavioral impairment
without general neuropathological changes in rats. We demonstrated for the first
time that exposure to low-dose MeHg during development induces the dysfunction
of motor coordination due to changes of synaptic homeostasis in cerebellar granule
cells.
2147 Striatal Synaptosome Mitochondrial Function Is Not Altered
following a 6mo MeHg Treatment in Male BALB/c Mice.
S. M. Fox1, 2 and W. D. Atchison1, 2. 1Pharmacology and Toxicology, Michigan State
University, East Lansing, MI; 2Center for Integrative Toxicology, Michigan State
University, East Lansing, MI.
Methylmercury (MeHg) is a potent environmental neurotoxicant that causes cell-
type specific damage in the cerebellum in a calcium (Ca2+) dependent manner. The
developmental effects of MeHg have been widely explored. However, the effects of
chronic exposure in adults have not been characterized. The ability of MeHg to
cause cell-type specific damage due to alterations in Ca2+ regulation raises the possi-
bility that other subsets of neurons with vulnerability that depends on Ca2+ regula-
tion could be sensitive to MeHg. This study focused on investigating the effects of
chronic MeHg treatment on the mitochondrial function of nigrostriatal dopamine
(NSDA) neurons. These neurons exhibit a unique physiological phenotype; they
autonomously generate action potentials in the absence of synaptic input. The
spontaneous action potentials rely on the influx of Ca2+ through Cav1.3, L-type
Ca2+ channels. We also investigated whether co-treatment with isradipine, a Ca2+
channel antagonist, would protect against MeHg-mediated damage. Beginning at
3mo, male BALB/c mice were given 5ppm Hg as MeHg in their drinking water
alone or were co-treated with 2ppm isradipine in their food for 6mo. Following the
6mo treatment period mouse weight gain was normal and there were no pheno-
typic changes. Mitochondrial function was measured in synaptosome preparations
from NSDA neurons using the Extracellular Flux Analyzer (Seahorse Biosciences).
Mitochondrial basal respiration, ATP production rate, maximal respiration, and
spare capacity were examined. No alterations were seen in any measure of mito-
chondrial function in animals treated with MeHg alone or in animals co-treated
with isradipine (n≥4, p values=0.8494, 0.1019, 0.9178, 0.8227 respectively). These
studies have demonstrated that mitochondrial function of striatal synaptosomes is
unchanged following a 6mo MeHg treatment. The effects of a 12mo MeHg treat-
ment are currently being pursued. This work was supported by a ViCTER supple-
ment to R01ES03299.
2148 Identification and Characterization of Plasma Membrane
and Intracellular Transporters Involved in MeHg-Induced
Whole Animal and DA Neuron Pathology.
N. VanDuyn and R. M. Nass. Pharmacology and Toxicology, Indiana University
School of Medicine, Indianapolis, IN.
Background: Methylmercury (MeHg) exposure from occupational, environmental,
and food sources is a significant threat to public health. Recent epidemiological and
vertebrate studies suggest that MeHg exposure may contribute to the propensity to
develop Parkinson’s disease (PD). We have developed a novel C. elegans model of
MeHg toxicity and have shown that low, chronic exposure confers dopamine (DA)
neuron degeneration, and that the toxicity is partially dependent on the phase II
antioxidant transcription factor SKN-1/Nrf2. Aims/Objectives: In this study we
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asked what genes are involved in MeHg-induced animal and DA neuron pathology.
Methods: We utilized a reverse genetic screen, immunofluorescence, transgenic C.
elegans, RT-PCR, ICP-MS, Western analysis, and neuronal morphology analysis to
characterize expression, localization and the role that SKN-1, MPT-1, and MIT-1
play in MeHg-induced whole animal and DA neuronal death. Results: Over
17,000 genes were screened for whole animal sensitivity to MeHg, and 92 genes
were identified (90% have strong human homologues ) that affect whole whole an-
imal and/or DA neuron pathology. Here we report detailed analysis of several trans-
porters. Specifically, genetic knockdown of MPT-1 results in 40% of animals show-
ing DA neurodegeneration relative to 0% in WT animals following 500 nM MeHg
exposure for 4 days. Genetic knockdown of transporters MPT-1 and MIT-1 fol-
lowing high levels of MeHg exposure (10uM) results in 0% and 2% viability, re-
spectively, compared to 100% in WT animals. Inductively Coupled Plasma Mass
Spectrometry (ICP-MS) studies show that MPT-1 knockdown results in 2-fold
higher Hg levels relative to WT, while MIT-1 contain 60% less than WT. We also
provide evidence for differential cellular localization. Conclusions: This study de-
scribes a novel whole genome reverse genetic screen that has identified a number of
molecular transporters and proteins involved in MeHg resistance. Support: NIEHS
ES014459 and ES003299 to RN, and EPA STAR Graduate Fellowship to NVD.
2149 Biochemical Alterations of Rat Brain Mitochondrial
Enzymes Induced by Aluminium Chloride.
R. Venugopal1,  K. Arumugam1,  V. Dhasal1,  P. Subbarayalu2 and
S. Viswanadhapalli3. 1Zoology, K.M.Centre for Post Graduate Studies, Puducherry,
India; 2Greehey Children’s Cancer Research Institute, University of Texas Health
Science Center at San Antonio, San Antonio, TX; 3Medicine, University of Texas
Health Science Center at San Antonio, San Antonio, TX.
Aim: The present study was planned to investigate the effect of aluminium chloride
(AlCl3) on enzyme activities in the mitochondrial fractions of the brain of male al-
bino rats. Methods: Adult male albino rats were administered AlCl3 at two differ-
ent doses, 50 mg and 100 mg/kg body weight, orally, daily for 45 days. At the end
of the experimental period the animals were sacrificed, the brain was removed and
mitochondrial fractions were isolated. Antioxidant enzymes like catalase, superox-
ide dismutase, glutathione peroxidase, glutathione reductase and glutathione-s-
transferase were estimated in the brain extract. Other biochemical markers were
also studied. Results: AlCl3 administration had no effect on the body weight and
brain weight. Almost all the antioxidant enzymes studied were markedly dimin-
ished in the brain of AlCl3 treated animals. The lipid peroxidation and hydrogen
peroxide were significantly increased. The activities of acid phosphatase and alka-
line phosphatase were significantly increased. The activities of Ca++ ATPase, Mg++
ATPase and Na+ K+ ATPases were decreased by the AlCl3 treatment in the brain.
However, the influence was found to be more in 100 mg treated when compared to
50 mg AlCl3 treated rats. The activity of acetylcholinesterase was diminished while
the lactate dehydrogenase activity increased after aluminium treatment.
Conclusion: The present study suggests the toxicity of aluminium by inducing the
oxidative stress and adverse alterations in the brain metabolism and possible inter-
ference in brain coordination processes.
2150 Effects of Mercuric Chloride on Cell Surface Expression of
Dopamine Transporter in PC12 Cells.
C. Hui,  A. Carpi and S. Cheng. Sciecnes, John Jay College of Criminal Justice, New
York, NY.
Mercury compounds are known to have a ubiquitous nature due to their ability to
move through the biogeochemical cycle and food web. Organic and inorganic
forms of mercury generally target different organ systems of the body while bio-
transformation after exposure can result in the bioaccumulation of various species
of the element. Divalent mercury (Hg2+) can be found within the brain following
exposure to the mercury vapor of dental amalgams and after extended exposure to
methyl mercury. Dopamine transporter protein (DAT) has been implicated as a
link between neurotoxicity following exposure to 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP). Increases in DAT expression on the cell membrane
have been shown to result in amplified sensitivity to MPTP. The in vitro effect of
mercuric chloride (HgCl2) on the cell surface expression of DAT in stably trans-
fected DAT expressing PC12 cells was studied. Cell viability (MTT assay) follow-
ing treatment with 0.5ppm HgCl2 and 1-methyl-4-phenylpyridinium (MPP+) the
active metabolite of MPTP, was observed to result in an additive increase in toxicity
compared with treatment with MPP+ alone. Using immunocytochemistry and
Western blot, DAT surface expression was seen to increase following HgCl2 (0.2-
2.0ppm) exposure which exhibited a biphasic pattern with the maximum expres-
sion observed at 0.5 ppm when compared to the control. With null function DAT
mutant, cell viability following exposure to HgCl¬22 and MPP+ showed an ab-
sence of the increase in toxicity observed at 0.5ppm originally observed in the wild
type control cells. The results show that HgCl¬2 is able to increase DAT surface ex-
pression in a concentration dependent manner and as a result, exposure could trig-
ger subsequent increased susceptibility to pesticides such as MPTP that use the
DAT system as pathway of toxicity.
2151 Changes in Gene Induction Associated with Lead Acetate
Mediated Oxidative Stress and Mitochondrial Dysfunction in
Neuronal PC12 Cells.
H. Kim1,  Z. Paras1,  G. Tsai1,  M. J. Kim1,  M. Shakarjian1, 2, 3 and D. E. Heck1.
1New York Medical College, Valhalla, NY; 2Medicine, UMDNJ-Robert Wood Johnson
Medical School, Piscataway, NJ; 3Environmental and Occupational Medicine,
UMDNJ-Robert Wood Johnson Medical School, Piscataway, NJ.
Lead is a major environmental heavy metal toxin that affects brain development
and impairs cognition in children and adults. Despite extensive research, molecular
mechanisms underlying neurotoxicity mediated by lead are not well understood.
Previous studies have shown that ROS production caused by lead exposure de-
creases cellular antioxidant defense networks in the brain. In the present studies, we
evaluated lead-mediated alterations in oxidative stress pathways in PC12 cells.
Using H2DCFDA in conjunction with flow cytometry, we found that lead expo-
sure increased ROS production up to 2.7- fold (3 hr, 1 nM to 10 μM); this effect
was associated with mitochondrial membrane potential changes which were 60%
lower after 24 hour treatment with 1 μM PbAc2. Using QPCR, we observed that
exposure to lead resulted in the induction of anti-oxidant genes including MnSOD,
catalase, NQO1, HO-1 and GST-M1). QPCR analysis also revealed induction of
genes that are indicators of Ca+2 flux (TRPV1), inflammation (COX-2, IL-1 β,
TNFα), and apoptosis (bcl-2, bax, caspase-3). Relative mRNA for signaling kinases
ERK(p42/p44), SAPK/JNK and PKC-δ were increased while that for p38MAPK
was decreased. Taken together our results suggest that lead treatment of PC12 cells
enhances cellular ROS levels, negatively impacts the anti-oxidant gene profile and
the mitochondrial membrane potential of PC12 cells, upregulates expression of
genes critical for inflammation and apoptosis and alters expression of critical cellu-
lar signaling kinases. We speculate that changes in the expression of antioxidant en-
zymes and signaling kinases are important in lead-mediated neurotoxicity.
(Supported by AR055073)
2152 Effects of Pb2+ in the Neural Differentiation of Mouse
Embryonic Stem Cells.
F. J. Sanchez-Martin and A. Puga. Department of Environmental Health, University
of Cincinnati, Cincinnati, OH.
Exposure to environmental agents during embryonic life is suspected to modify the
epigenetic mechanisms that regulate the gene expression patterns that control de-
velopment. The resulting changes in gene expression may affect lineage differentia-
tion and extend into adulthood, well beyond the time when the organism was ex-
posed to the agents. This paradigm provides a testable molecular basis for the
Barker hypothesis, which proposes that there is a fetal origin of adult disease. Lead
(Pb) is a ubiquitous environmental toxicant whose possible effects, especially at
early ages of development, include reduction of cognitive functions and IQ, behav-
ioral effects, attention deficit and hyperactivity disorder. We are using neural differ-
entiation of mouse embryonic stem cell (mESC) to determine the molecular
changes taking place during embryogenesis and neurodevelopment as a conse-
quence of long-term exposure to Pb2+. We find that after differentiation of mESC
into neuronal cells, cultures express many neuronal markers, including Tubb3, Syp,
Gap43 and Hud, and do not express the glial marker Gafp. Furthermore, the cells
express Vglut1, a marker of glutamatergic neurons. Incubation with Pb2+ during
differentiation reduces the expression of the calcium-dependent exon IV of Bdnf
and alters the expression pattern of other neural genes but does not alter the mor-
phology of the neuron and the expression of Tubb3. Thus, we conclude that after
differentiation of mESC in vitro, we can obtain pure cultures of glutamatergic neu-
rons whose gene expression patterns are changed by Pb2+ exposure. These cells
should provide an useful substrate to analyze the mechanisms of toxicity of envi-
ronmental neurotoxicants. Supported by NIH grant R21 ES020048.
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2153 Developmental Lead (Pb2+) Exposure and Mutant DISC1
Interact to Produce Schizophrenia-Like Neurobehavioral
Abnormalities and Brain Volume Changes in Mice: A Gene-
Environment Interaction Study.
T. R. Guilarte1, 3,  J. L. McGlothan1,  B. Abazyan2,  C. Yang2,  K. Hua3,  S. Mori3
and M. Pletnikov3. 1Environmental Health Sciences, Columbia University Mailman
School of Public Health, New York, NY; 2Psychiatry, Johns Hopkins School of
Medicine, Baltimore, MD; 3Radiology, Johns Hopkins School of Medicine, Baltimore,
MD.
The glutamatergic hypothesis of schizophrenia suggests that hypoactivity of the
NMDA receptor (NMDAR) is an important factor in the pathophysiology of
schizophrenia and related mental disorders. The environmental developmental
neurotoxicant lead (Pb2+) is a potent and selective antagonist of the NMDAR and
two recent human studies have suggested an association between prenatal Pb2+ ex-
posure and the increased likelihood of expressing a schizophrenic phenotype later in
life. Schizophrenia and other major mental disorders likely result from interactions
between genetic risk factors and adverse environmental insults. We evaluated the
neurobehavioral consequences of Pb2+ exposure in mice with inducible expression
of mutant Disrupted-in-Schizophrenia-1 (DISC1), a candidate gene for major psy-
chiatric diseases. We hypothesize that mutant DISC1 and Pb2+ exposure synergisti-
cally interact to produce an exaggerated phenotype in mutant mice. Mutant DISC1
and control mice born by the same dams were raised and maintained on normal or
Pb2+ diet. We tested animals in a series of behaviors associated with schizophrenia
and performed volumetric MRI measurements of the brain. We found that the in-
teraction between developmental Pb2+ exposure and mutant DISC1 produced a
significantly greater increase in locomotor activity, impaired pre-pulse inhibition of
the acoustic startle that was abrogated by D-serine and exacerbated responses to
MK-801, an NMDAR antagonist. Compared to control unexposed mice, mutant
exposed animals had significantly larger lateral ventricles. Our data suggest that in-
teractions between Pb2+ and mutant DISC1 may synergistically produce schizo-
phrenia-like behavioral alterations and brain volume changes in mice. [Supported
by grant # ES06189-18S1 to TRG]
2154 Reduced Parvalbumin Expression in the Striatum, Frontal
Cortex, and Hippocampus after Developmental Pb2+
Exposure: Examining Early Life Pb2+ Exposure As a Risk
Factor for Schizophrenia.
K. Stansfield1,  K. Ruby2,  J. L. McGlothan1 and T. R. Guilarte1. 1EHS, Columbia
University, NYC, NY; 2Lake Erie College of Osteopathic Medicine, Erie, PA.
The calcium-binding protein, parvalbumin (PV), is expressed in GABAergic in-
terneurons and is implicated in working memory and associative learning.
Decreased PV expression is observed in schizophrenia patients and also in animal
models of schizophrenia. N-methyl-D-aspartate receptor (NMDAR) antagonists
are used to model certain aspects of schizophrenia in animal models and NMDAR
antagonists decrease PV levels and the number of PV-positive interneurons, sug-
gesting that NMDAR function plays a role in the expression of PV interneurons
and in schizophrenia. Lead (Pb2+) is a potent NMDAR antagonist that has been
implicated in the etiology of schizophrenia, therefore we examined the effect of de-
velopmental Pb2+ exposure on PV cell density in the striatum and PV protein ex-
pression in the striatum, hippocampus and frontal cortex of rats developmentally
exposed to Pb2+. A trend of decreased PV positive cell density was observed at all
levels of the striatum, however a statistically significant decrease (t11=2.2; p =
0.005) in cell density was found in the caudal striatum of Pb2+ -treated rats relative
to controls. Additionally, PV protein expression measured by western blot was sig-
nificantly reduced in the striatum (t22=3.3; p = 0.003), frontal cortex (t7 = 2.25, p
= 0.05) and hippocampus (t10 = 2.31, p = 0.04) of rats developmentally exposed to
Pb2+. Overall, these findings indicate that early life Pb2+ exposure decreases the
number of PV positive neurons in the striatum, and reduces the expression of PV in
the striatum, frontal cortex and hippocampus. The data suggests a relationship be-
tween Pb2+ induced NMDAR hypoactivity and PV expression, implicating a po-
tential association between developmental Pb2+ exposure and the expression of a
schizophrenia phenotype later in life. [This work was supported by NIEHS grant #
ES006189 to TRG]
2155 Effects of Developmental Lead Exposure on Associative
Learning and Memory Are Modified by Sex, Developmental
Window of Exposure, and Level of Exposure.
D. Anderson,  W. Mettil,  S. Kidd and J. Schneider. Thomas Jefferson University,
Philadelphia, PA.
Trace fear conditioning is a variant of fear conditioning in which a neutral condi-
tioned stimulus (CS) is paired with an aversive unconditioned stimulus (UCS).
Trace conditioning includes a “trace” interval of several seconds separating the CS
and UCS. Learning the CS–UCS association across this interval and the consolida-
tion of the memory requires participation of both the hippocampus and medial
prefrontal cortex (mPFC). Long-term storage of information associating tempo-
rally disconnected events occurs in the mPFC in parallel with memory storage in
the hippocampus. The current research investigated the extent to which these
processes are affected by developmental Pb exposure. Long Evans dams were fed
Pb-containing food (RMH 1000 with or without added Pb acetate: 0, 150, 375,
750 ppm) prior to breeding and stayed on the same diet through weaning at post-
natal day 25 (perinatal exposure group (Peri)). Other animals were exposed to the
same doses of lead but exposure started on postnatal day 1 and continued through
postnatal day 25 (early postnatal exposure group (EPN)). Beginning at postnatal
day 45, animals were placed in the trace fear conditioning apparatus. Conditioning
trials (CS tone-UCS shock pairings) were repeated six times during an 18 min
training period. Freezing behavior was measured during the trace period. Retention
testing occurred 24/48 hrs and 10 days later to assess memory consolidation and
long-term memory. At the lowest level of exposure, EPN-exposed females were
more impaired at short and long-term retention than were Peri-exposed females;
the opposite effect was observed in males. In females, the lowest level of exposure
had the greatest disruptive effect on retention. In males, the highest level of expo-
sure had the greatest disruptive effects on retention. These data suggest complex re-
sponses of the brain to developmental Pb exposure with likely different molecular
effects in hippocampus and PFC that vary with sex and timing and level of expo-
sure. Supported by NIH RO1-ES015295.
2156 Sex- and Hemisphere-Dependent Neurochemical Changes
Produced by Lead, Prenatal Stress, and the Combination.
D. A. Cory-Slechta,  D. Weston,  S. Liu and J. L. Allen. Environmental Medicine,
University of Rochester Medical School, Rochester, NY.
Brain lateralization, important to mediation of cognition and ‘multi-tasking’, is dis-
rupted in attention deficit disorder and schizophrenia. Altered brain lateralization
could play a role in the corresponding cognitive and attention deficits associated
with both low level lead (Pb) exposure and prenatal stress (PS). This study exam-
ined laterality of mesocorticolimbic (frontal cortex, nucleus accumbens, striatum,
midbrain) monoamines and amino acids (frontal cortex only) that mediate such be-
havioral functions, both under normal (control) conditions, and in response to life-
time Pb (0 or 50 ppm), PS (restraint stress on gestational days 16-17) or Pb+PS in
rats. Sex-dependent differences in brain laterality were seen even in control rats, as
noted in frontal cortex, striatum and midbrain monoamines and frontal cortex
amino acids. Hemispheric differences in Pb ± PS effects were most notable in
males, as seen in frontal cortex and striatum, but particularly in midbrain, where
Pb+PS, but neither alone, significantly reduced right hemispheric levels of ho-
movanillic acid and norepinephrine, with similar trends in serotonin. In contrast,
no Pb+PS effects were found in left hemisphere. Pb+PS, but neither alone, reduced
frontal cortex dopamine and increased dopamine turnover in left hemisphere of
males, whereas in the right hemisphere, Pb, PS and Pb+PS reduced frontal cortex
dopamine and Pb alone increased dopamine turnover. The only suggestive Pb+PS
hemispheric difference in females was increased right but not left hemisphere
frontal cortex GABA. Thus Pb, PS and Pb+PS can differentially influence mesocor-
ticolimbic neurotransmitter function both by hemisphere and sex. Such differences
are likely to contribute to associated sex-related alterations in behavioral outcomes,
such as our previously reported contrasting effects on learning accuracy produced
by Pb+PS in males vs. females. The findings also underscore the significance of
defining the hemisphere used for assay in experimental studies for evaluation of
CNS mechanisms of behavior.
2157 Sex-Dependent Changes in the Effects of Lead and Prenatal
Stress on Impulsivity and Neurochemical Substrate.
H. Weston,  D. Weston,  S. Liu,  J. L. Allen and D. A. Cory-Slechta.
Environmental Medicine, University of Rochester Medical School, Rochester, NY.
Both lead (Pb) exposure and prenatal stress (PS) adversely affect cognition and at-
tention.. Impulsivity is one diagnostic component of attention deficit, and en-
hanced impulsivity has been related to multiple neuropsychiatric disorders. This
SOT 2013 ANNUAL MEETING 461
study examined whether combined Pb+PS would enhance impulsivity compared to
either alone, as well as potential associated mechanisms using rats exposed to 0 or
50 ppm Pb from 2 mos prior to breeding through lactation with/without PS on
gestational days 16-17. Impulsivity was assessed in a delay of reward paradigm that
provides a choice between an immediate but small reward or a larger but delayed re-
ward, with delay time increased across test sessions. Choice of the long delay typi-
cally declines with increasing delay time. In males, PS, particularly with Pb, delayed
this transition, consistent with impulsivity of choice. A trend towards increased
omission of trial initiation responding was also noted in males. Females showed no
changes. Adverse effects in males may be related to reduced nucleus accumbens
dopamine (DA) function and reduced frontal cortex, nucleus accumbens and stri-
atal serotonergic (5HT) function, as found in 2 mos old male littermates of behav-
iorally-tested rats; effects less evident in females. The transitory nature of the be-
havioral changes in males may arise from the ‘enriching’ effects of behavioral
testing: post-testing, Pb ± PS increased levels of striatal DA and 5HT and metabo-
lites, and of nucleus accumbens DOPAC, norepinephrine and 5HT in males, con-
sistent with a reversal of pre-testing neurochemical changes. These findings demon-
strate a preferential vulnerability of males to PS-induced impulsive choice that is
enhanced by concurrent Pb exposure and which may arise from early reductions in
mesocorticolimbic DA and 5HT function. As impulsivity is considered to play a
central role in attention deficit, gambling, substance abuse and personality disorder,
the findings have significant public health implications. Supported by EPA Grant
RD 83457801.
2158 Investigation of the Combined Neurotoxicity of
Developmental Iron Deficiency and Lead Exposure.
A. Greminger1,  D. A. Cory-Slechta1 and M. Mayer-Proschel2. 1Environmental
Medicine, University of Rochester, Rochester, NY; 2Biomedical Genetics, University of
Rochester, Rochester, NY.
Iron deficiency (ID) and Lead (Pb) exposure are widespread public health problems
that continue to affect women and children with similar risk factors, as well as pro-
duce similar neurotoxic effects on the developing CNS. Although studies of these
insults singularly suggest a potential for enhanced neurotoxicity in their combina-
tion, previous work has failed to address this in relevant animal models, and consis-
tent data from human cohorts are lacking. We utilized a maternal iron-deficient di-
etary model in the presence or absence of Pb-exposure to examine the possible
synergism of ID and Pb during offspring neurodevelopment. Offspring of each ex-
posure were assessed using hematologic parameters, as well as tissue Pb levels. Our
data show that maternal Pb-only exposure did not cause anemia in either the dam
or the offspring throughout development. In combination with ID, Pb did not de-
crease hematocrit levels in offspring beyond those of ID-only, arguing against the
notion that Pb causes or worsens ID. However, the presence of ID significantly in-
creased blood and tissue Pb levels by more than 50% in the dams and offspring
compared to animals exposed to the same Pb levels in the absence of ID. Our data
suggest that maternal non-anemic ID strongly increases absorption of Pb into the
CNS of offspring underscoring the importance of non-anemic ID as a susceptibil-
ity factor to environmental Pb toxicity. To determine the functional impact of ID +
Pb we measured overall brain maturation using the auditory brain stem response.
We found significant decreases in neuronal conduction velocity in all three expo-
sure groups (Pb-only, ID-only and ID + Pb) compared to control offspring at
PND40. However, the combination of ID + Pb did not result in synergistic in-
creases over either insult alone at this age or decibel level (70dB). Additional analy-
sis at different ages and stimulation levels is required to determine if this lack of
synergy may be due to compensatory mechanisms or is restricted to later in devel-
opment.
2159 Bcl-xL-Mediated Remodeling of Rod and Cone
Photoreceptor (PR) Synaptic Mitochondria (mt) After
Postnatal Lead Exposure (PLE): Structure and Function.
D. A. Fox1,  G. A. Perkins2,  M. H. Ellisman2 and J. E. Johnson3. 1Univ. Houston,
Houston, TX; 2Univ. California: San Diego, La Jolla, CA; 3Univ. Houston-
Downtown, Houston, TX.
PLE produces rod-selective apoptosis (blocked by Bcl-xL) and persistent scotopic-
mesopic ERG and vision deficits in man and animals. Rod, but not cone, inner seg-
ment mt were considered the target: albeit PR synaptic mt were not examined.
Thus, we determined the effects of PLE on these mt and if Bcl-xL provided protec-
tion. C57BL/6 mice pups had PLE during lactation by dams drinking Pb water.
[BPb] was 10-20 μg/dL and at control level by 60 doa. EM, 3-D electron tomogra-
phy, and oxygen consumption (QO2) studies were done at 70 doa: control, trans-
genics overexpressing Bcl-xL in PRs, PLE and Bcl-xL/PLE groups. In PLE, rod
spherule and cone pedicle mt were swollen, cristae structure changed, and the no.
of segments/crista and fraction of cristae with multiple segments (branching) in-
creased. In PLE, mt cristae surface area and volume (abundance) decreased in
spherules and increased in pedicles. PLE remodeling of spherule mt produced
smaller cristae with more branching, whereas pedicle mt had larger cristae with
more branching and increased cristae junction diameter. PLE decreased dark-
adapted PR and PR synaptic terminal QO2. In Bcl-xL/PLE, spherules still had de-
creased abundance; pedicles still had increased branching, crista segments/volume
and crista junction diameter; and PR and synaptic QO2 only partially recovered.
These findings reveal cellular and compartmental differences in the structure, vul-
nerability and remodeling of rod and cone inner segment and synaptic mt to PLE:
consistent with findings that synaptic mt are more sensitive to calcium overload,
oxidative stress and ATP loss than non-synaptic mt. These PLE alterations likely
underlie the persistent scotopic-mesopic deficits, and stress the importance of ex-
amining synaptic dysfunction after developmental insults and preventing synaptic
degeneration even if apoptosis is blocked.
Supported by NIH grants RO1 ES012482, T32 EY07024, P30 EY07551, P42
ES010337, RO1 DK54441, P41 RR004050 and P41 GM103412.
2160 Alpha-Synuclein-Mediated Activation of c-Abl and
Dopamine Depletion in Dopaminergic Neuronal Cells
Treated with Iron-Oxide Nanoparticles or
Methamphetamine.
S. Lantz1,  Z. K. Binienda1,  L. Mohammed Saeed1, 2,  B. Robinson1,
M. G. Paule1,  A. S. Burris2,  S. F. Ali1 and S. Z. Imam1. 1FDA/NCTR, Jefferson,
AR; 2Nanotechnology Center, University of Arkansas, Little Rock, AR.
Mutations in the alpha-synuclein gene have been associated with autosomal domi-
nant forms of Parkinson’s disease (PD). Transgenic mice that over-express the
human alpha-synuclein gene (primarily the point mutations A53T and A30P), de-
velop neurological impairments similar to those of PD. Previous studies in our lab-
oratory have shown that oxidative-stress-mediated activation of the tyrosine kinase,
c-Abl, results in an increase in the phosphorylation of parkin, an important E3
ubiquitin ligase that assists in the clearance of proteins destined for proteasomal
degradation. Here, we show that treatment with iron-oxide nanoparticles or
methamphetamine results in activation of c-Abl, observed via the measurement of
phospho-Abl. Additionally, an over-expression of alpha-synuclein protein in SHSY-
5Y neuroblastoma cells was observed after these treatments. A 45% increase in the
expression of alpha-synuclein was observed in SHSY-5Y cells treated with iron
oxide nanoparticles (10 and 30 nanometers) at a concentration of 10 μg/ml.
Similarly, a 55% increase in the expression of alpha-synuclein protein was observed
24 h after exposure to 500 uM methamphetamine. In addition, a significant deple-
tion in dopamine was observed after treatment with either iron oxide nanoparticles
or methamphetamine (55% and 65%, respectively), suggesting that both the over-
expression of alpha-synuclein and excess dopamine might generate oxidative stress,
which is one of the major pathways of c-Abl activation. These results suggest that
the over-expression of alpha-synuclein and dopamine depletion after exposure to
iron oxide nanoparticles or methamphetamine contribute to oxidative-stress medi-
ated activation of c-Abl, thus initiating events that may lead to dopaminergic neu-
ronal cell death.
2161 Identification of Iron Regulatory Proteins Differentially
Expressed in Brains with Alzheimer Disease by Quantitative
Proteomics.
B. D. Minjarez1,  L. Valero2,  A. D. Rios-Perez4,  M. Sanchez del Pino2,  R. Mena3
and J. P. Luna-Arias1. 1Biologia Celular, CINVESTAV, Mexico City, Mexico;
2Proteomica, Centro de Investigación Príncipe Felipe, Valencia, Spain; 3Fisiología,
Biofísica y Neurociencias, CINVESTAV, Mexico City, Mexico; 4Toxicologia,
CINVESTAV, Mexico City, Mexico.
Alzheimers disease (AD) is the most common form of dementia affecting around
24.3 million people worldwide. As a consequence of the rapid demographic ageing,
AD has become one of the most severe progressive socio-economical and medical
burdens facing countries all over the world. AD brains are characterized by the pres-
ence of extracellular deposits of amyloid-β-containing plaques and intracellular
neurofibrillary tangles (NFTs) composed of paired helical filaments of hyperphos-
phorylated Tau. AD is considered to be the result of complex events involving both
genetic and environmental factors. Among them, two remarkable factors are oxida-
tive stress and mitochondrial damage. Postmortem examinations of human brain
tissue have demonstrated that iron concentrations are increased in the brains of AD
patients compared to controls. The main goal of this study was the identification of
proteins showing different expression levels in AD, using iTRAQ-protein labeling
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and, identification and quantitation of peptides by tandem mass spectrometry. We
identified more than 721 polypeptides, where some iron regulatory proteins were
found up-regulated such as Ferritin light chain, Ferritin heavy chain and
Melanotransferrin. In addition, several proteins involved in redox regulation also
found such as Peroxiredoxin, Superoxide dismutase, Oxidation resistance protein 1,
were up-regulated in AD brains in comparison to a normal brain. This approach
will give us landscape of the proteome of AD brains that could be useful for the po-
tential identification of AD biomarkers that may be involved in oxidative damage.
2162 Prediction of Drug-Induced Liver Injury Using High-
Content Screening Assay of Rat Hepatocytes.
M. Chen1,  T. Chun-Wei1,  Q. Shi1,  L. Guo1,  H. Fang2,  L. Shi1 and W. Tong1.
1US FDA, NCTR, Jefferson, AR; 2ICF International at NCTR, US FDA, Jefferson,
AR.
Drug induced liver injury (DILI) is a leading cause for drug failures in clinical trials
and for post-approval drug withdrawals. This fact implies that the current animal-
based approaches do not provide a sufficiently reliable assessment of DILI; there-
fore, there is an increased interest to develop new approaches for identifying hepa-
totoxicity, especially those that can be applied in the early drug discovery. In this
study, we assessed the feasibility of using high content screening (HCS) assays of rat
primary hepatocytes to predict the human specific hepatotoxicity of pharmaceuti-
cals. We developed a predictive model using a commercial HCS assay on 8 cellular
parameters that were relevant to hepatotoxicity mechanisms including cell loss, nu-
clear size, DNA damage, apoptosis, lysosomal mass, DNA fragmentation, mito-
chondrial potential, and steatosis. The model’s performance was assessed both by
internal cross-validations using a library of 108 drugs with human-specific hepato-
toxicity annotations and by further external validation using an additional sixteen
drugs. In the leave-one-drug-out cross-validation, the HCS assay-based predictive
model yielded accuracy of 68% with sensitivity of 77% and specificity of 50%,
which is significantly higher than that by chance and better than the quantitative
structure–activity relationship (QSAR) model developed using the same set of
drugs in accuracy. The results from the external validation showed that eight out of
nine of the most-DILI-concern drugs (with 89% sensitivity) and four out of seven
no-DILI-concern drugs (with 57% specificity) were correctly predicted. Our find-
ings suggest that the HCS assay of rat hepatocytes can potentially approach useful
for hepatotoxicity screening for drug discovery.
2163 Oral Toxicity Study of the Novel Optimized HCV Protease
Inhibitor in Rats and Monkeys.
Z. J. Zhan1,  H. Yan1,  S. McPherson2,  S. Neu3 and Q. He2. 1AB Pharma Ltd.,
Shanghai, China; 2WuXi AppTec Co. Ltd., Suzhou, China; 3Vet Path Services, Inc.,
Mason, OH.
ZN2007, a novel highly potent HCV-NS3 protease inhibitor with excellent PK
and stability properties, was orally administered as sodium salt (ZN2007Na) to
cynomolgus monkeys at 25, 500, or 1000 mg/kg/day for 14 days followed by a 7-
day recovery period; and rats at 50, 500, or 1000 mg/kg/day for 28 days followed
by a 14-day recovery period.
The monkeys were treated with ZN2007Na formulated in 20% (w/v) sul-
fobutylether-B-cyclodextrin (SBECD) at 25, 500, and 1000 mg/kg/day for 14
days. No death occurred in 14-day study, and only some soft and/or watery stools
were observed in all monkeys including both control and test article-treated groups
through the dosing phase. This was considered to be related to the vehicle as it was
seen in controls and has been reported in scientific publications (Stella and He,
2008). Abnormal stools were resolved from Day 16 through the recovery period. In
rats, no death occurred in 28-day GLP study, and some mild to moderate salivation
was the only test article-related finding in males at ≥500 mg/kg/day, and females at
≥50mg/kg/day, respectively. There were no any test article-related changes in mor-
tality, body weight, food consumption, ophthalmic examinations, clinical pathol-
ogy parameters, electrocardiography (ECG), hematology, coagulation, serum
chemistry, and also no any test article-related effects observed on both macroscopic
and microscopic examinations for all tested animals at any dose levels (25, 50, 500,
or 1000mg/kg/day)in rats and monkeys, respectively. Moreover, there were no any
side effects determined with other protease such as hERG, Cytochrome P450, etc. 
Based on the above findings, it is concluded that the NOAEL was 1000 mg/kg/day
in rats. At NOAEL, the mean values of Cmax and AUC0-24h were 24350 ng/mL
and 71400 h*ng/mL in rats. So far, a number of toxicity studies were conducted at
WuXi AppTec, and the preclinical safety data of inhibitor ZN2007Na in both rats
and monkeys strongly support the safe use conditions for AB Pharma team to file
IND for clinical trials in USA by the end of 2012.
2164 Physicochemical Properties and Compound Accumulation in
Lysosomes and Mitochondria.
S. Lu1,  A. Sistla2,  P. Hoerter2,  B. Jessen1 and Y. Will3. 1Drug Safety Research &
Development, Pfizer Inc, San Diego, CA; 2Pharmaceutical Sciences, Pfizer Inc, San
Diego, CA; 3Compound Safety Prediction, Pfizer Inc, Groton, CT.
Eukaryotic cells are highly compartmentalized composing various functionally dis-
tinct, membrane-enclosed subcellular organelles such as lysosomes and mitochon-
dria. Unwanted accumulation in nontarget sites can interact with organelle compo-
nents, resulting in structural and functional changes, potentially leading to toxicity.
Physicochemical properties have been shown to be a contributing mechanism for
compound accumulation in cells and even organelles. In this study, we examined
the relationship between physicochemical properties such as partition coefficient
(clogP) and acid dissociation constant (pKa) and lysosomal compound accumula-
tion. Our data demonstrate a clear association of basic (basic pKa> 6) and lipophili-
cicty (clogP >2) with lysosomal compound accumulation. We also showed this ac-
cumulation was derived by the low pH in the lysosomes. In addition our data
revealed membrane perturbation by the compounds with similar physicochemical
properties. In an effort to understand how physicochemical properties can con-
tribute to mitochondrial compound accumulation we selected a set of basic com-
pounds and measured their logD (partition coefficient) at neutral (7.4) and acidic
(4.7) pH. The majority of basic compounds with acidic logD (at pH 4.7) > 0.3 in-
duced more toxicity in HepG2 cells cultured in galactose than in cells cultured in
high glucose-containing media, indicating mitochondrial liability associated with
these compounds. This data supports the hypothesis that compounds with rela-
tively pH-insensitive permeability selectively accumulate into mitochondria.
Interestingly, certain compounds such as nefazodone and nicardipine were shown
to carry both, lysosomal and mitochondria liabilities. In summary, our data indi-
cate that physicochemical properties alone can contribute to both, lysosomal and
mitochondrial compound accumulation. How this contributes to in vivo organ
toxicity needs to be further elucidated.
2165 Lack of Retinal Pathology in a BACE1 Knockout Mouse or
in Rats after Intravitreal Injections of BACE1 Inhibitors.
C. Somps,  C. Houle,  T. Brown,  J. Harney,  J. Brady and D. Karanian. Drug
Safety, Pfizer Global R&D, Groton, CT.
The β-site amyloid precursor protein (APP)-cleaving enzyme 1 (BACE1) is a target
of tremendous focus and development interest for the treatment of Alzheimer’s dis-
ease. While initial characterization reports of BACE1 knockout (KO) mice suggest
that BACE1 is a safe target for modulation (Roberds et al., 2001; Lou et al., 2001),
more recent studies present evidence of retinal pathology (Cai, et al., 2012).
Additionally, oral administration of a selective BACE1 inhibitor to rats has been as-
sociated with retinal changes after chronic dosing, including accumulation of auto-
fluorescent material in the retinal pigment epithelium (RPE) and degeneration of
photoreceptors in associated retina (May, et al., 2011). To address these concerns
we evaluated the retinas in BACE1 homozygous KO mice from an in-house colony.
With the goal of enabling a shorter duration screening paradigm for ocular toxicity,
we also evaluated the retinas from rats after a single intravitreal injection of BACE1
inhibitors or non specific protease inhibitor at high (~10 μM) intraocular concen-
trations. We found that 3-month old BACE1 KO mice are viable and without
organ or clinical pathology distinctions from wild-type (wt) littermates. Ocular
evaluation by H&E staining indicated that the retinas of the BACE1 KOs were un-
remarkable when compared to wt mice. Ophthalmic examinations, as well as light
and fluorescent microscopy following intravitreal injections of BACE1 inhibitors,
revealed no significant differences in the retinas or RPE between control and
treated rats 1-8 days post-injection. In summary, our results support those of others
indicating retinal pathologies reported with BACE1 inhibitors are not related to
downregulation of BACE1 activity. Additionally, short duration intravitreal expo-
sure to high concentrations of selective BACE1 inhibitors or nonspecific protease
inhibition was not associated with detectable retinal pathology, and thus may not
be a reliable model for predicting retinal toxicity of BACE1 inhibitors.
2166 Peptide Analysis Using Dry Blood Spot Technology
Combined with Mass Spectrometry for Toxicology Studies: A
Practical Approach for Minimizing Animal Use.
W. Ruddock,  P. Aughton,  J. Chapdelaine and G. Bain. ITR Laboratories Canada,
Baie-D’Urfe, QC, Canada.
Scope: The amount of preclinical research based on peptides is constantly growing,
however the difficulties of reliably analyzing this type of molecule leads to a major
challenge in obtaining reliable toxicokinetic data. Combining the latest technology
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related to dried blood spots and mass spectrometry provides many advantages even
though the initial method development is more arduous than for typical small mol-
ecules of less than 1000 daltons. 
Experimental Procedures: The peptide calcitonin-salmon was chosen based on it
being readily available from Sigma Aldrich and that its molecular weight is higher
than normally monitored by mass spectrometry since it consists of thirty-two
amino acid linear polypeptide. The compound is dosed by oral gavage at 10 mg/kg
to CD-1 mice, and 8 mcL of blood collected by tail clipping every two minutes.
The blood is immediately transferred to Whatman 903 filter paper and allowed to
dry before placing with desiccant and refrigerating. The dry blood samples are then
punched out, and calcitonin-salmon is extracted from the spots and injected. The
chromatographic conditions were developed using reverse phase chromatography
and detection using a triple quadrupole API 4000 mass spectrometer with electro-
spray ionization to monitor the parent and fragment ions of both calcitonin-salmon
and its analog internal standard. 
Conclusions: Results show that this approach provides a toxicokinetic profile with
timepoints every two minutes whilst allowing a considerable reduction in mice re-
quired for a study and giving a full profile for each individual animal. This work
shows that preliminary TK data may be obtained based on 3R principles even for
peptide analysis, an area that still has room for much improvement using dry blood
spot sample analysis.
2167 Early and Progressive Changes in the Urinary Biomarker
Profile of Cisplatin-Induced Kidney Injury in Cynomolgus
Macaques.
Y. Chen1,  W. Luo2,  H. Yu4,  Q. Qin4,  J. Qiao4,  F. Chang1,  D. Thurman1,
M. Pinches3,  S. Gales3,  N. Barrass3,  J. Valentin3,  L. B. Kinter1 and
R. A. Bialecki1. 1AstraZeneca R&D, Waltham, MA; 2Discovery Statistics, Waltham,
MA; 3AstraZeneca R&D, Alderley Park, United Kingdom; 4Shanghai Institute of
Materia Medica, Shanghai, China.
Cisplatin-induced nephrotoxicity has been characterized in animals and humans.
New urinary biomarkers may enable early or parallel detection of drug-induced
kidney injury (DIKI) in non-rodent models. Our aims were to: 1) determine if a
human renal biomarker panel can detect early DIKI when compared with tradi-
tional biochemical and histological indices; 2) monitor progressive cisplatin-medi-
ated changes in DIKI biomarkers over 20 days in cynomolgus macaques. Animals
(3M/3F per group) were treated with a single dose of cisplatin (2.5 mg/kg i.v. infu-
sion; groups 1/2/4/5) or saline (groups 3/6) on day 1. Toxicokinetic profile was de-
termined on day 1. Blood and urine samples were collected predose and postdose
(days 1, 4, 9, 15, 20) for comparing changes in plasma chemistry, urinalysis and
urinary DIKI biomarkers. Renal tissue was examined microscopically at different
intervals. Results indicated cisplatin produced progressive renal histologic changes
from subtle findings on day 2 to maximum effects on day 21. Traditional renal
markers significantly increased in plasma creatinine (8-fold), BUN (3-fold), urinary
glucose (5-fold), protein (3-fold) and enzymes (GGT, NAG) between day 4-9 but
resolved by day 15 when renal pathology appeared more severe. Four new biomark-
ers (clusterin, calbindin, lipocalin, Tamm-Horsfall protein) changed progressively
and significantly from 4 to 20 days to parallel development of renal histologic in-
jury. Importantly, β-2 microglobulin was significantly increased before subtle renal
damage observed on day 2 and increased progressively over 20 days to parallel his-
tologic changes, suggesting this is the most sensitive biomarker for detection of
onset and potentially prodromal cisplatin-induced kidney injury in cynomolgus
macaques.
2168 A Case Study for Exploring Rodent Models to Assess Risk of
Hypotension.
M. Pannirselvam,  D. Hodges,  J. Jones,  J. Prezioso,  K. Tanner,  H. Gao,
E. Inett,  F. Berlioz-Seux,  C. Barnes,  G. Smith,  M. Sanders,  U. Germann and
D. Brewster. Vertex Pharmaceuticals, Cambridge, MA.
A cardiovascular (CV) safety pharmacology study in telemetered conscious dogs
evaluating Compound-A (CPD-A), an anti-cancer agent, demonstrated a dose- and
time-dependent decrease in mean arterial blood pressure (MAP), most likely attrib-
utable to off-target PDE3 inhibition. At 20 mg/kg p.o. CPD-A, MAP was reduced
by ~30% from the baseline within 1-hour of dosing and this effect persisted ~12
hours. The objective of this study was to identify a rodent model that would best
mimic the dog CV response to CPD-A. We investigated CPD-A (at doses up to
120 mg/kg, p.o.) in conscious, telemetered rats and detected no meaningful acute
effects on MAP, although a moderate tachycardia was observed. Upon repeated
daily dosing of 120 mg/kg QD to rats, CPD-A led to a mild decrease in MAP on
Day 3 when compared to pre-dose baseline and time-matched vehicle controls. As
in the acute study, a moderate tachycardia was observed. To maximize exposure, a
single intravenous bolus administration of 20 mg/kg CPD-A was investigated. This
resulted in a significant MAP drop and a moderate reflex tachycardia. Based on
these data, we hypothesized that a difference in sympathetic tone and baroreflex
sensitivity between dog and rat may underlie the species difference in cardiovascu-
lar response observed after single oral administration of CPD-A. To explore this
possibility, we also assessed CPD-A in isoflurane-anesthetized rat model to decrease
sympathetic tone and baroreflex response.  Continuous infusion of CPD-A at 10
and 20 mg/kg/hr led to a gradual decrease in MAP of up to 15 and 45%, respec-
tively, and a mild bradycardia at the highest dose. As an alternative to the rat, we
also evaluated a urethane-anesthetized guinea pig model. Infusion of 10 mg/kg
CPD-A over 10 min resulted in a gradual drop in MAP accompanied by reflex
tachycardia. These studies suggest the anesthetized rat or guinea pig offered good in
vivo screening alternatives for this compound class.
2169 MDR1, MRP2 and BCRP Transporter Gene Knockout in
CACO-2 Cells.
K. E. Sampson,  J. Blasberg,  A. Brinker,  J. Pratt,  N. Venkatraman,  Y. Xiao,
M. Bourner and D. C. Thompson. Sigma-Aldrich, St. Louis, MO.
Purpose: Membrane transporters P-glycoprotein (P-gp, MDR1), MRP2, and
BCRP play a role in drug disposition and can mediate drug-drug interactions lead-
ing to safety/toxicity concerns. The goal of this study was to selectively knock out
these drug transporter genes in a subclone of Caco-2 cells (C2BBe1) using zinc fin-
ger nuclease (ZFN) technology.
Methods: ZFN pairs targeting specific transporter genes were nucleofected into
C2BBe1 cells. Stable clones were isolated and sequenced at gene target sites.
Transport function in wild type (WT) and knockout (KO) cell lines was tested in
bidirectional assays using probe substrates at 5 μM for 2 hr at 37C. Contents of
both wells were analyzed for drug content using LC/MS-MS, and permeability was
calculated for both directions. Lucifer yellow permeability was measured to verify
monolayer integrity.
Results: ZFN-transfected clones were sequenced and the genotype was confirmed
for disruptions in each allele. In bidirectional transport assays to confirm loss of
transporter function, the efflux ratios (ER) for digoxin and erythromycin were re-
duced from 17.7 and 16.8 in the WT cells to 1.4 and 1.0 in the MDR1 KO cells,
respectively. The ER for estrone 3-sulfate and nitrofurantoin were reduced from
22.7 and 13.2 in the WT to 1.8 and 1.7 in the BCRP KO cells, respectively. The
ER for 5(6)-carboxy-2’,7’-dichlorofluorescein was reduced to 2.0 in the MRP2 KO
from 32.0 in the WT cells. Double knockout cell lines (MDR1/BCRP KO,
MDR1/MRP2 KO, and MRP2/BCRP KO) were used to identify substrates of
multiple transporters. Cimetidine was confirmed as a substrate of both P-gp and
BCRP using the MDR1/BCRP KO cell line. Fexofenadine transport required P-gp
and a basolateral MRP transporter such as MRP3, but not MRP2.
Conclusions: Stable single and double KO cell lines of human efflux transporters
were successfully generated and characterized for loss of function using model sub-
strates. These cell lines may be useful in clarifying complex drug-transporter inter-
actions without reliance on the selectivity of chemical inhibitors.
2170 Target Promiscuity and Physiochemical Properties
Contribute to Pharmacologically-Induced ER-Stress.
E. Koslov-Davino,  X. Wang and T. Schroeter. Pfizer, Groton, CT. Sponsor: N.
Greene.
In vivo toxicity of drug candidates remains a major problem in the pharmaceutical
industry, and is a significant cause of late stage attrition.  As a consequence predic-
tive in vitro assays are developed and put in place early in the discovery pipeline to
aid compound selection. Endoplasmic reticulum stress (ER-stress) has been impli-
cated in many disease states, as well as compound-induced organ toxicities.  We ex-
plored the role of ER-stress as a general mechanism of toxicity by utilizing a high-
throughput in vitro assay to screen 318 chemically diverse Pfizer proprietary
compounds with known in vivo toxicity outcome for nuclear accumulation of
spliced X-Box Binding Protein 1 (XBP1s), a key transcription factor of the
Unfolded Protein Response (UPR). We examined the correlation between physico-
chemical properties, such as molecular weight, pKA, lipophilicity, topological polar
surface area, and passive permeability, as well as target promiscuity, between XBP1s
hits and non-hits and found that lipophilicity, target promiscuity and low passive
permeability significantly contributed to ER-stress. In addition, we have shown
that compounds which cause ER-stress in the form of XBP1s activation at concen-
trations below 40μM have a more than four times greater chance of causing in vivo
toxicity at 10μM plasma exposure.
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2171 Enhancing the Safety of Antiviral Compounds by Assessing
Mitochondrial and Nuclear Transcriptional Regulation Using
a Multiplex Branched DNA Screen.
M. Crosby and Y. P. Dragan. Global Safety Assessment, AstraZeneca Pharmaceuticals
LP, Waltham, MA.
The development of antiviral therapeutics can be hindered by the fact that they can
lead to liver, renal, and cardiac injury. One antiviral strategy focuses on inhibiting
the transcription of viral nucleic acids via nucleoside analog reverse-transcriptase in-
hibitors (NRTIs). NRTIs may cause toxicity due to mitochondrial DNA incorpo-
ration (mtDNA) and/or inhibition of DNA polymerase γ (Nature Rev Drug Disc
2003, 2: 812-22; Expert Opin Drug Metab Toxicol 2010, 6:1493-604).
Functionally, such types of therapeutics may affect mtDNA transcription and repli-
cation, resulting in downstream defects in oxidative phosphorylation and mito-
chondrial biogenesis, which can lead to compromised organ function. 
The strategies for ensuring mitochondrial safety include examining changes in mi-
tochondrial biogenesis, metabolism, toxicity, and assaying for specific enzymatic ac-
tivities in the electron transport chain. While these assays answer important func-
tional questions, they may not necessarily pick up subtle changes with respect to
DNA transcription and replication, which can lead to the downstream functional
changes. The development of a multiplex, branched DNA (bDNA) assay to assess
gene transcription in the mitochondria, as well as in the nucleus has the advantage
of detecting a total of eight transcripts in a single lysate. This significantly reduces
the cost, time, and consumables that would be needed for traditional qRT-PCR.
Studies using human liver epithelial cells treated with a selected group of nucleoside
reverse transcriptase inhibitors, including 2’,3’-dideoxyinosine, 2’,3’-dideoxy-3’-
thiacytidine, and 3’-azido-3’-deoxythymidine indicate that this technology may be
applied to support the selection of compounds in pharmaceutical programs inter-
ested in pursuing nucleoside reverse transcriptase inhibitors as a part of their antivi-
ral strategy.
2172 Comparison of In Vitro Models for Prediction of
Hepatotoxicity of Pharmaceutical Drug Candidates.
C. McGinnis1,  T. Sachnik1, 2,  X. Ang1, 3,  J. Johnson4,  E. Viturro2 and
A. Odermatt3. 1Non-Clinical Safety, Hoffmann-La Roche, Basel, Switzerland;
2Technische Universität München, Munich, Germany; 3Division of Molecular and
Systems Toxicology, University of Basel, Basel, Switzerland; 4Hepregen Corporation,
Medford, MA.
Liver toxicity is one of the foremost reasons for failure of a drug candidate to reach
the clinic. It is also a leading cause for market withdrawals, FDA warnings and
modifications of use for current medications. As a result, In vitro hepatocyte-spe-
cific studies using cells from preclinical species and also human donors are being in-
vestigated to allow for prediction of DILI during the early phase of drug discovery.
During this project several novel in vitro models were studied for their potential to
detect livertoxic compounds. A high-throughput, 384-well based assay with two-
dimensional monocultures of rat or human primary hepatocytes was validated and
implemented with ATP depletion as a cellular endpoint. Data obtained from more
than 30 commercial and proprietary compounds were compared to results obtained
from 3T3 mouse fibroblasts as a non-metabolically competent model. Species-re-
lated, and cell type -dependent differences were determined and overall predictabil-
ity compared to more advanced cell culture models such as a micropatterned hepa-
tocyte co-culture model called HepatoPacTM, as well as a 3D hepatocyte spheroid
culture using a Roche developed Hanging Droplet Culture Plate. In depth analysis
of the species-, cell- and culture-dependent in vitro results were put into context
with underlying mode of actions and dose-effect relationships. This work formed
part of a B.Sc. project work carried out by Thomas Sachnik, and M.Sc. project
work carried out by Xiaoman Ang.
2173 Bioassays to Explore Mitochondrial Functions and
Anticipate Drug Toxicity.
E. Robert,  P. Picamal and N. A. Compagnone. Department of Toxicology, ICDD,
Meyreuil, France. Sponsor: Y. Will.
The mitochondria have been identified as one of the major players in previously
unrecognized drug-induced hepatic injuries. Hepatotoxicity is the main reason for
drug withdrawal in clinical phases and post-marketing. Identifying early mitochon-
drial toxicities is thus essential to increase the chances of success in drug develop-
ment. We have developed a panel of integrated functional bioassays aiming at meas-
uring the different functions of the mitochondrial possibly associated with
mitochondrial toxicity in a high throughput and robust manner. Three major axes
were explored using cell-based bioassays: the bioenergetics, the redox status and the
mitochondrial DNA depletion. First, measurements of the dioxygen consumption,
cellular ATP level, extracellular lactate release with regard to cell viability, were mul-
tiplexed using fluorescence and luminescence methods. The identification of mito-
chondrial liabilities associated to hepatotoxicity was largely improved compared to
the literature. Secondly, considering that the redox status is associated to drug toxi-
city, we measured the modulation of the mitochondrial ROS production and an-
tioxidant defenses in response to drugs. Finally, due to its proximity to the electron
transport chain and its lack of histones, mitochondrial DNA constitutes a potential
target for drug-induced damages. The mitochondrial DNA content was quantified
using high content analysis. We performed all the bioassays on HepG2 cells. We
tested a panel of drugs that have been marketed, known to be responsible or not for
mitochondrial liabilities associated or not to liver and/or cardiac injuries. The tested
compounds were classified according to mechanisms of toxicity we detected and
compared to the literature. Mitochondrial liabilities can be identified with a predic-
tivity of 84%. Coupling early indicators of mitochondrial dysfunction to late pre-
dictors of cytotoxicity provides more relevant and complete information on drug-
induced mitochondrial injuries capable of reducing the large space of false negative
left by existing methodologies.
2174 Glucose-Induced Gene Expression Changes Influence Barrier
Function in Human Retinal Pigment Epithelial (RPE) Cells.
G. L. Gong,  L. Lecureux and L. D. Lehman-McKeeman. BMS, Princeton, NJ.
The RPE forms a blood-retinal barrier in the back of the eye, and alterations in this
barrier can adversely affect vision. In the present work, ARPE-19 cells were cultured
in physiologically-relevant glucose levels (5 mM) and high glucose conditions (25
mM) for a period up to 3 weeks. Permeability, assessed by apical-basolateral flux of
FITC-labeled dextran, was 10 ± 1 ng/ml/min in normal glucose and 6 ± 0.3
ng/ml/min in high glucose, suggesting an increase in barrier function. High glucose
also increased mRNA levels of pigment-epithelial-derived factor (PEDF) about 5-
fold, while decreasing VEGF-A mRNA levels about 2-fold; these changes correlated
with secreted levels of these growth factors, which increased 2.3-fold and decreased
2.8-fold, respectively, in culture medium. High glucose levels increased expression
of sphingosine-1-phosphate receptor 1 (S1P1) in ARPE-19 cells more than 3-fold
within 1 week of treatment, a change that was maintained during 3 weeks of expo-
sure, whereas expression of S1P3 decreased in a time-dependent manner to nearly
7-fold lower levels after 3 weeks. mRNA levels of tight junction proteins zonula oc-
cludens-1 and claudin-1 were unchanged after 1 week of high glucose conditions,
but decreased at 3 weeks by 2- and 8-fold respectively.  The results of the present
study indicate that, in ARPE-19 cells, high glucose conditions affect transcellular
permeability and alter expression of proteins involved in tight junction regulation.
Moreover, S1P1 and S1P3 genes, which are known to play critical roles in regulat-
ing the integrity of endothelial cell barrier function, may also contribute to the reg-
ulation of retinal barrier function in RPE cells.
2175 Towards an Integrated Risk Assessment of Hepatotoxic
Drugs via Covalent Binding and Cellular Stress in Primary
Hepatocytes.
M. Teppner1,  F. Boess1,  B. Ernst2 and A. Paehler1. 1Non Clinical Safety,
Hoffmann-La Roche Ltd., Basel, Switzerland; 2Institute of Molecular Pharmacy,
University of Basel, Basel, Switzerland.
Introduction
Idiosyncratic DILI is of concern to drug development as it occurs rarely but with
severe outcome. Early biomarkers for DILI besides covalent binding (CVB) are
warranted to classify problematic drugs in vitro. Here we present on complemen-
tary endpoints in primary hepatocytes that may early identify cellular damage.
Methods
Primary hepatocytes were treated with DILI drugs under attenuated oxidative stress
via enzymatic in situ generation of H2O2 up to 24 h. CVB was determined by 14C
binding, prostaglandins via quantification by LC-MS/MS in addition to ATP and
LDH release. Expression profiles of Nrf2 regulated genes were created by qPCR
analysis 
Preliminary Reults
In hepatocytes generating H2O2, CVB was significantly exaggerated (13-fold for
troglitazone; 20-fold for diclofenac) as compared to controls indicating further per-
oxidase activation of initially formed reactive metabolites. Significant increase of
prostaglandin isomers was observed at lower drug concentrations and at earlier time
points than changes in ATP and LDH. In rat hepatocytes prostaglandins E2 /
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15(R) D2 increased by 3.3 / 2.3-fold for FeNTA and 3.0 / 2.0-fold for troglitazone
at 6 h. In human hepatocytes, this increase was 3.6 and 3.8-fold respectively for
troglitazone with no effect on LDH or ATP. 
mRNA levels indicate the activation of several keap/Nrf2 regulated genes such as
NAD(P)H dehydrogenase (7.7-fold) and GSH-S-transferase α2 (6.1-fold) after 24
h for troglitazone. Heme oxygenase 1 (64.1-fold) as well as GSH-S-transferase π1
(12.3-fold) showed a transient induction after treatment with FeNTA.  
Conclusions
The presented methods are useful for an early identification of DILI liabilities.
Besides CVB, cellular stress in hepatocytes may contribute to development of DILI;
here prostaglandins are sensitive biomarkers.mRNA levels give insight into the
mechanism of toxicity. The in situ generation of H2O2 provides a supportive tool
by attenuating response that is specific to drug treatment.
2176 Aneugenicity Associated with Aurora Kinase Inhibition in a
Novel Series of JAK1-Selective Kinase Inhibitors.
E. Harstad,  K. Ford,  M. Zak,  R. Mendonca,  S. Ubhayakar,  G. Deshmukh,
J. Kenny,  W. Blair and D. Diaz. Genentech, South San Francisco, CA.
JAK1 inhibition imparts therapeutic benefit in inflammatory diseases, in particular
rheumatoid arthritis. A novel series of JAK1-selective molecules was discovered
eliminating anemia associated with JAK2 inhibition. In preclinical lead optimiza-
tion screening, a metabolism-independent aneugenic micronucleus (MN) signal
was discovered using a high-content micronucleus test (HC-MNT) in CHO cells.
The objectives of this study were to: 1) determine the predictivity of the HC-MNT
vs the manual MN assay in normal human mononuclear cells, 2) elucidate the
mechanism of aneugenicity, and 3) develop an in silico toxicophore screen to elim-
inate MN formation. Over 80 JAK1 inhibitors were tested in the HC-MNT, and
20 were tested in the manual MN assay, with 89% positive predictive value in this
series of molecules. Results from the HC-MNT indicated an aneugenic signature
(based on cytotoxicity indices) that was confirmed via standard centromeric FISH
staining in the manual assay. Bone marrow MN evaluations rats confirmed the in
vivo relevance of the in vitro MN finding. Selected molecules tested also confirmed
the lack of clastogenicity in vitro and in vivo. Aurora kinase inhibition was evalu-
ated as a known microtubule-dysfunction mechanism leading to aneugenicity. In
functional cellular assays, Aurora A inhibition was confirmed at high concentra-
tions. Aurora A cellular IC50s were consistent with concentrations producing aneu-
genicity in vitro and in vivo, suggesting a relationship between Aurora A inhibition
and aneugenicity exhibited by these compounds. In silico docking identified key
interacting residues important for Aurora A binding, allowing Aurora A potency to
be screened out prior to chemical synthesis. In summary, these experiments demon-
strate the fidelity of the HC-MNT assay with the in vitro and in vivo MN assays for
aneugenicity in this chemical series and enabled development of a toxicophore
model to eliminate Aurora A liabilities.
2177 Evaluation of High Content Mechanism Screening As a
Prediction Tool for Organ Toxicity.
W. Pennie2,  S. Lu1,  C. Strock3,  J. Gilbert3 and Y. Will2. 1Drug Safety research
and Development, Pfizer Inc, San Diego, CA; 2Compound Safety Prediction, Pfizer
Inc, Groton, CT; 3Apredica, Watertown, MA.
Attrition due to drug safety remains a serious problem for the pharmaceutical in-
dustry. Extensive efforts are made to develop early predictive in vitro screens to as-
sist in selecting compounds with a more desirable safety profile. Since cardiac and
hepatic toxicity remain the top causes of compound attrition, much focus has been
on building predictive assays for such toxicities. One platform is high content
screening performed in an organ relevant cell line to assess of a variety of mechanis-
tic toxicity parameters. We have recently shown that general cytotoxicity screening
such as ATP measurement in organ specific cell lines can not accurately predict spe-
cific organ toxicity. Here we wanted to understand if by choosing more mechanis-
tic parameters we could differentiate compounds with different organ toxicities. In
the current study we selected >50 compounds with known human hepatic or car-
diac toxicity. These were tested in both H9C2 cells (cardiac panel) and primary rat
hepatocytes (hepatic panel) using high content mechanism screening. We found
that the majority of compounds, regardless of their designated organ toxicities, dis-
played similar effects on the two panels tested. Only a small number of compounds
demonstrated differential activity in the two panels (eg. nimesulide was only toxic
in the hepatic panel). Our results indicate that sophisticated high content mecha-
nism screening in itself is still a poor predictor for differentiating cardiac and he-
patic toxicity. More organ relevant endpoints, such as BSEP/MRP assessment for
hepatotoxicity and ion channel pharmacology and beating changes for cardiac in-
jury, might increase this prediction. Whether 3-dimensional tissues or stem cell ap-
proaches will provide more realistic cell models also remains to be seen. At this
point our high content screening approach can detect potential liabilities, identify
mechanism of injury, and at the most provide a Therapeutic Index projection if ex-
posure data are accurately projected.
2178 Consequences of Mrp2 Deficiency for Diclofenac-Induced
Toxicity in Rat Intestine In Vitro.
X. Niu,  D. van de Vegte,  M. Langelaar,  I. de Graff and G. Groothuis. Pharmacy,
Groningen Research Institute of Pharmacy, Groningen, Netherlands.
Diclofenac (DCF), a widely used non-steroidal anti-inflammatory drug (NSAID),
is associated with high prevalence of severe intestinal side-effects. The reactive
metabolite diclofenac acylglucuronide (DAG) formed in the liver, and transported
by bile into the intestine was reported to be involved in the intestinal injury, based
on the observation that Mrp2 deficient (TR-) rat intestine was less sensitive to DCF
toxicity due to the reduced biliary transport and intestinal exposure to DAG.
However, it is not clear what are the direct consequences of Mrp2 deficiency in the
intestine itself. Previously we reported that DCF was toxic in the rat intestine in
vitro without the presence of liver metabolites. Therefore, using precision cut intes-
tinal slices (PCIS), we compared wild type (WT) and Mrp2 deficient (TR-) rat in-
testine in vitro, by studying direct toxicity, DCF disposition and intracellular glu-
tathione concentration.
PCIS from WT and TR- rats were incubated with a concentration range of DCF.
DCF induced similar dose-dependent toxicity and 200 μM DCF caused a signifi-
cant decrease of ATP in both strains of rats indicating that the intestine from TR-
rat is not intrinsically less sensitive to DCF toxicity. 
As glutathione is a substrate of Mrp2, Mrp2 deficiency may influence its accumula-
tion and thereby the DCF induced toxicity. Intestinal GSH level in the TR-rats was
significantly lower than in WT rats but did not make the TR- rat intestine more
vulnerable.
In both strains, hydroxyl DCF as well as DAG were detected as the main intestinal
metabolites after 5 hours incubation, less amount was excreted into the medium by
PCLS of the TR- rats. The study of DCF disposition is ongoing with ussing cham-
ber. 
In conclusion, the TR- rat intestine is not intrinsically less sensitive to DCF toxic-
ity and the lower GSH level does not make it more vulnerable. Less intestinal
metabolites are excreted by the PCLS of TR- rats, but whether this is due to lower
production or lower excretion ability needs to be further validated.
2179 Effects of Nicotinamide Phosphoribosyltransferase
(NAMPT) Inhibitors on Platelet Development.
J. Singh1,  T. Zabka1,  H. Uppal1,  D. Diaz1,  J. Tarrant1,  E. Clarke2,  T. Lin1,
N. La1,  B. McCray1,  T. Nguyen1,  P. Dhawan1,  E. Doudement1,  A. Kauss1,
D. Dambach1 and D. Misner1. 1Safety Assessment, Genentech, South San Francisco,
CA; 2ReachBio, Seattle, WA.
BACKGROUND: Nicotinamide adenine dinucleotide (NAD) is an essential co-
factor in glycolysis. Cancer cells have increased energy demands due to prolifera-
tion. Nicotinamide phosphoribosyltransferase (NAMPT) catalyzes the rate-limit-
ing step of NAD synthesis, and is up-regulated in many cancer types. Thus,
NAMPT inhibitors (NAMPTi) have the potential to treat cancer. Clinical trials
with NAMPTi APO866 and GMX1778 failed to reach projected efficacious doses
due to thrombocytopenia. We assessed the effects of NAMPTi on megakaryocyte
development in vitro and evaluated hematopoietic effects including platelet pro-
duction in rats. We also tested the hypothesis that nicotinic acid (NA), which re-
plenishes NAD via a NAMPT-independent pathway, mitigates the hematopoietic
effects of NAMPTi.  
METHODS: Human megakaryocyte lineage cells were cultured from mononu-
clear cells (containing CD34+ progenitor cells) in vitro for 14 days in the presence
of NAMPTi alone or with NA co-treatment. The differentiation, proliferation and
survival of megakaryocytes were evaluated functionally (by colony formation) and
cell viability was determined biochemically (by ATP levels). Rats were dosed for 4-
14 days with NAMPTi alone or co-treated with NA. Bone marrow effects were
evaluated by complete blood count with white cell differential and histopathology
of hematopoietic tissues. 
RESULTS: NAMPTi reduced the functional (colony forming) and biochemical
(ATP) viability of megakaryocytes in vitro. This effect tracked with NAMPTi po-
tency and was mitigated by NA co-treatment. NAMPTi caused cellular depletion
of hematopoietic tissues and decreases in circulating reticulocytes, red blood cells
and lymphocytes in rats. There was no significant reduction in circulating platelets.
Hematopoietic effects in rats were partially mitigated by NA co-treatment. Thus,
NA may mitigate NAMPTi-mediated thrombocytopenia in the clinic.
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2180 Structural Optimization of the Rac GTPase Inhibitor EHop-
016.
E. Velez,  E. Hernandez and C. Vlaar. University of Puerto Rico Medical Science
Campus, San Juan, Puerto Rico.
The Rho GTPase Rac family are intracellular signaling proteins that control gene
expression and various cellular functions including invasion and metastasis, cell
cycle progression and apoptosis. Furthermore, they have been reported to be impli-
cated in cancer initiation and progression. Rac1 is a member of the Rho family
GTPases associated with lamellipodia or invadopodia causing invading cells to mi-
grate, and is activated via association with Guanine Exchange Factors (GEFs),
among which Vav2. Increase Rac1 activation has been associated with increased
breast and brain cancer cell proliferation and invasion. Therefore, one main goal is
to focus on the design of novel Rac inhibitors for the development of anticancer
drugs. Previously, our laboratory synthesized EHop-016, which was demonstrated
to be the first known inhibitor of Vav2-Rac1 interaction in MDA-MB-435
metastatic cancer cells at low micromolar concentrations. In order to reduce the
toxicity and increase the potency, we utilized molecular docking to design novel
EHop-016 derivatives. The carbazole group of EHop-016 appeared to be required
for inhibitory activity, and thus was maintained as a core fragment in further
desing. It appeared from the docking experiments that replacement of the central
pyrimidine ring with other building blocks that orient the potential inhibitors into
a U-shaped conformation, provided the best docking results. Novel molecules, that
according to docking results bind much better to Rac1 than EHop-016 will be pre-
sented, and the specific interactions leading to increased binding will be discussed.
As the compounds were designed to be easily accessable via laboratory synthesis,
these proposed improved inhibitors of Rac activity could lead to novel antimetasta-
tic cancer therapies.
2181 Role of Renal Cytochrome P450 Isozymes in the
Bioactivation of 3, 5-Dichloroaniline In Vitro.
C. Racine,  T. Ferguson,  S. Baksi,  D. Preston,  D. Anestis and G. Rankin.
Pharmacology, Physiology and Toxicology, Marshall University, Huntington, WV.
Chlorinated anilines are common intermediates in the production of agricultural
chemicals, dyes, industrial compounds, and pharmaceuticals. Some chloroanilines
can induce nephrotoxicity in vivo and in vitro. Previous studies have shown 3,5-
dichloroaniline (3,5-DCA, 1.0 mM) induced nephrotoxicity in isolated renal corti-
cal cells (IRCC) following 90 min exposure. Studies from our lab have also shown
IRCC pretreated with non-selective cytochrome P450 (CYP) inhibitors [piperonyl
butoxide (1.0 mM) and metyrapone (1.0 mM)] partially attenuated 3,5-DCA tox-
icity, suggesting that CYPs may play a role in 3,5-DCA bioactivation. The purpose
of the present study was to further explore the role of CYP mediated 3,5-DCA
bioactivation using an in vitro rat model. IRCC were obtained from male Fischer
344 rats. IRCC (4 x106 cells/ml; 3mL) were incubated with shaking for 90 min
with either dimethyl sulfoxide (DMSO) or 3,5-DCA (1.0mM). IRCC were pre-
treated with various CYP inhibitors [isoniazid (1.0 mM), ketoconazole (0.1 mM),
omeprazole (0.01 mM), diethyldithiocarbamate (DEDTCA; 0.1 mM), olean-
domycin triacetate (0.5 mM), or sulfaphenazole (0.1 mM)] and cytotoxity was de-
termined by measuring lactate dehydrogenase (LDH) release. Pretreatment with
DEDTCA, omeprazole, and sulfaphenazole partially attenuated 3,5-DCA induced
nephrotoxicity, while ketoconazole, isoniazid, oleandomycin triacetate did not alter
3,5-DCA induced nephrotoxicity. Studies in rats have shown that DEDTCA,
omeprazole, and sulfaphenazole are effective inhibitors of the CYP2C family
isozymes. These results suggest that 3,5-DCA is bioactivated via multiple pathways,
one of which involves the CYP2C family. (Supported in part by NIH Grant
8P20GM103434 to the West Virginia IDeA Network for Biomedical Research
Excellence)
2182 Studying Drug Effects on Renal Tubular Secretion of
Creatinine with a Novel Cellular Model Coexpressing Major
Creatinine Transporters OAT2, OCT2, OCT3 and MATE1.
J. X. Zhang,  M. S. Warren,  J. Huang and Y. Huang. Optivia Biotechnology Inc.,
Menlo Park, CA.
Serum creatinine level is a commonly used surrogate measure for glomerule damage
and kidney function evaluation. It is well known that creatinine clearance in the
kidney is through free glomerular filtration and transporter mediated excretion in
proximal tubule. Inhibiting these transporters can result in transient increase in
plasma creatinine level, which can lead to false interpretation of glomerular dam-
age.
Recently, we have identified that, in addition to OCT2 and MATE1, OAT2 and
OCT3 can play major role on creatinine secretion. This finding led to development
of a novel cellular model co-expressing all four transporters, for modeling active cre-
atinine secretion in the kidney. 
Using the model, we tested drugs with reported incidence of increasing serum crea-
tinine. Most of these drugs inhibited B>A transcellular transport of
[C14]Creatinine to different extent, suggesting they are able to block active tubular
secretion of creatinine in vivo. It is noteworthy that Cimetidine, which has been
previously demonstrated by us as a pan-inhibitor of all four transporters, was able
to completely abolish creatinine transport; whereas trimethoprim, which is not an
OAT2 inhibitor, only resulted in partial inhibition. These results are in good accor-
dance with clinical studies that higher dosage of Cimetidine can completely block
active creatinine secretion in proximal tubule whereas there is no statistically differ-
ence in serum creatinine level in patients under moderate- and high-dose of
trimethoprim. Furthermore, salicylic acid, which was tested at clinically relevant
concentrations, also exhibited a dose-dependent and substantial inhibitory effect
on creatinine transport, which suggested that in addition to potentially causing
damage to renal tubules, partial blockage of active creatinine secretion could also
contribute to serum creatinine level increase caused by salicylic acid, possibly
through inhibiting OAT2 and/or MATEs transporters.
2183 Proximal Tubular Transport of Mercuric Species following
Compensatory Tubular Hypertrophy.
C. Bridges1,  D. W. Barfuss2,  L. Joshee1 and R. K. Zalups1. 1Division of Basic
Medical Sciences, Mercer University, Macon, GA; 2Department of Biology, Georgia
State University, Atlanta, GA.
Chronic kidney disease (CKD) is characterized by a progressive and permanent loss
of functioning nephrons. As nephrons are lost, vascular, glomerular and tubular
changes occur in remaining nephrons in an attempt to compensate for this loss.
These changes lead to glomerular and tubular hypertrophy, hyperperfusion and hy-
perfiltration. We have hypothesized that tubular hypertrophy and hemodynamic
changes resulting from CKD may increase the exposure of individual nephrons to
nephrotoxicants, such as mercury, and thus may increase the susceptibility of these
nephrons to toxic compounds. To test this hypothesis we compared the transport of
mercuric species in individually perfused proximal tubules isolated from normal
(Sham) or uninephrectomized (NPX) rabbits. Kidneys of NPX rabbits undergo sig-
nificant hypertrophy in the two weeks following surgery. Tubules isolated from
NPX rabbits were larger in diameter than those from Sham rabbits. When the per-
fusion rate was increased in normal tubules, as a way in which to mimic hyperper-
fusion, we observed an increase in tubular accumulation of mercury. When tubules
from Sham and NPX rabbits were perfused with cysteine-S-conjugates of mercury,
we found that tubular accumulation of mercury was greater in tubules from NPX
animals. Similarly, luminal disappearance flux (JD) of mercury was greater in
tubules from NPX animals. Taken together, our data suggest that hypertrophic
changes in proximal tubules may lead to an increased ability and/or tendency of
proximal tubules to take up and accumulate nephrotoxicants such as mercury.
2184 Suramin Attenuates Hyperglycemia-Induced Renal Oxidative
Stress, Inflammation and Fibrosis in Rats.
M. Korrapati1,  B. E. Shaner1,  B. A. Neely2,  J. L. Alge2,  J. M. Arthur2, 3 and
R. G. Schnellmann1, 3. 1Drug Discovery and Biomedical Sciences, MUSC,
Charleston, SC; 2Medicine, Division of Nephrology, MUSC, Charleston, SC;
3Veterans Administration Medical Center, Charleston, SC.
Hyperglycemia-induced oxidative stress, inflammation and fibrosis increase suscep-
tibility of diabetic kidneys to nephrotoxic agents. Because development of novel
agents that act early to prevent progression of hyperglycemia-induced changes is
important, we examined the efficacy and mechanism(s) of suramin in hyper-
glycemia-induced renal injury before manifestation of overt histological damage.
Two groups of male Sprague Dawley rats received streptozotocin (STZ) and one
group, saline. Three weeks later one STZ group received suramin (10 mg/kg). All
animals were euthanized one week later (4 weeks). While there was a decrease in
creatinine clearance between controls and STZ ± suramin rats, there was no differ-
ence in creatinine clearance between STZ rats ± suramin intervention. LC-
MS/MS-based analysis revealed increases in urinary proteins that are early indica-
tors of diabetic nephropathy (DN) (e.g. cystatin C, clusterin, cathepsin B, and
retinol binding protein 4 and peroxiredoxin-1) in the STZ group and were blocked
by suramin. Endothelial intracellular adhesion molecule-1 (ICAM-1) activation,
leukocyte infiltration and inflammation; transforming growth factor-β1 (TGF-β1)
signaling; TGF-β1/SMAD-3-activated fibrogenic markers fibronectin-1, alpha-
smooth muscle actin and collagen 1A2; activation of pro-inflammatory and pro-fi-
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brotic transcription factors nuclear factor κB (NF-κB) and signal transducer and
activator of transcription factor-3 (STAT-3), respectively, were all increased in STZ
rats and suramin blocked these changes. Therefore, delayed administration of
suramin attenuated urinary markers of DN, inflammation by blocking NF-κB ac-
tivation/ICAM-1-mediated leukocyte infiltration and fibrosis by blocking STAT-3
-TGF-β1/Smad-3 signaling, supporting the potential use of suramin in develop-
ment of diabetes-induced kidney injury.
2185 Resveratrol Alters Subcellular Changes in Oxidative Stress
Mediated by Cisplatin in Rat Renal Tissue.
M. Valentovic1,  J. G. Ball1,  J. Wolfe1,  S. Van Meter1,  M. Wright1,
B. Lamyaithong2 and B. Brown1. 1Pharmacology, Physiology and Toxicology,
Marshall University School of Medicine, Huntington, WV; 2Wheeling Jesuit
University, Wheeling, WV.
The cancer chemotherapeutic agent cisplatin is associated with a 33% incidence of
diminished renal function. Interventions to reduce renal toxicity are important in
improving patient outcome. Resveratrol (RES) is a phytochemical found in grapes,
cranberries and nuts. RES has been recognized as a natural agent possessing anti-
cancer and antioxidant properties. This study investigated RES attenuation of cis-
platin renal in vitro toxicity and focused on differences between cytosolic and mito-
chondrial oxidative stress mediated by cisplatin. Male Fischer 344 rats (200-250 g)
were anesthetized, with isoflurane and the kidneys were isolated. Renal cortical
slices were prepared and pre-incubated with 30 ul ethanol (VEH) or 30 ug/ml
resveratrol (RES, final concentration) for 30 min at 37oC. Tissue were subse-
quently  incubated for a maximum of 120 min with 0, 75, or 150 ug/mL cisplatin.
Loss of membrane integrity was evaluated as leakage of lactate dehydrogenase
(LDH). Oxidative stress and nitrosative stress was assessed in kidney homogenate as
well as in subcellular fractions of mitochondria and cytosol. Oxidative stress was
measured by protein carbonyl formation using an Oxyblot. Nitrosative alterations
were assessed using 3-nitrotyrosine formation by western blot. LDH leakage re-
quired a 120 min exposure to cisplatin. An increase in protein carbonyls as detected
by Oxyblot, was increased by cisplatin and totally prevented by RES. RES also de-
creased protein carbonyls in tissue not exposed to cisplatin. Our findings showed
that a 30 min RES pre-incubation diminished cisplatin renal toxicity and that pro-
tein carbonyl and 3-nitrotyrosine and early changes in oxidative stress prior to the
onset of loss of membrane integrity. (Supported by NIH Grants INBRE
3P20RR016477-09S4; 5P20RR016477 and 8P20GM103434 to the West
Virginia IDeA Network for Biomedical Research Excellence).
2186 Diglycolic Acid Induces Cytotoxicity in Human Proximal
Tubule Cells via Preferential Inhibition Ofsuccinate
Dehydrogenase and Oxidative Phosphorylation.
G. M. Landry,  C. L. Dunning,  T. V. Dupree,  M. J. Hitt and K. McMartin.
Pharmacology, Toxicology & Neuroscience, LSU Health Sciences Center, Shreveport,
LA.
Diethylene glycol (DEG) is an organic solvent used in common consumer prod-
ucts, thus allowing for increased risk for exposure. DEG metabolism produces two
primary metabolites, 2-hydroxyethoxyacetic acid (2-HEAA) and diglycolic acid
(DGA). DGA, not DEG or 2-HEAA, produces proximal tubule cell necrosis lead-
ing to acute renal failure, the hallmark of DEG poisoning. Studies were designed to
assess whether the mechanism for DGA-induced cytotoxicity involves disruption of
cellular metabolic processes resulting in mitochondrial dysfunction. DGA induces
severe ATP depletion in human proximal tubule (HPT) cells that occurs prior to
significant cell death. HPT cells pretreated with increasing DGA concentrations
showed significant decreases in oxygen consumption suggesting that DGA acts as
an oxidative phosphorylation inhibitor, rather than a mitochondrial electron trans-
port chain uncoupler. Co-incubation of DGA with the antioxidant, α-tocopherol
significantly reduced DGA-induced reactive oxygen species (ROS) formation, but
did not reduce ethidium homodimer uptake or lactate dehydrogenase release, two
measures of necrotic cell death, suggesting that ROS production is not a cause, but
a consequence of DGA-induced cell death. DGA treatment also significantly and
preferentially inhibits succinate dehydrogenase activity, but has no effect on other
citric acid cycle enzyme activities. Intracellular transport studies utilizing DGA in
competition with 14C-succinate determined an approximate IC50 value of 175
mmol/L. This value suggests that DGA-induced cytotoxicity is not due to substrate
starvation of cells, but rather inhibition of metabolic processes, which occur at
much lower DGA concentrations. These results indicate that DGA produces prox-
imal tubule cell death by specific inhibition of mitochondrial-mediated processes
resulting in decreased energy production and oxygen utilization.
2187 Chronic Ethanol Ingestion in Mice Induces Renal
Inflammation and Injury through the Platelet-Activating
Factor Receptor.
C. Latchoumycandane1,  J. Liu1,  L. E. Nagy2 and T. M. McIntyre1. 1Department
of Cellular and Molecular Medicine, Lerner Research Institute, Cleveland Clinic,
Cleveland, OH; 2Department of Pathobiology, Lerner Research Institute, Cleveland
Clinic, Cleveland, OH.
Ethanol exposure increases circulating oxidized phospholipids in rats and in alco-
holic steatohepatitis patients, although the biological role of circulating oxidized
phospholipids remains unclear. Platelet-activating factor (PAF), and some oxidized
phospholipids, activate the Platelet-activating factor receptor (PAFR). We hypothe-
sized that PAFR contributes to renal inflammation and injury after ethanol inges-
tion. In this study we find that mice fed a Lieber-DeCarli ethanol diet had in-
creased levels of circulating PAF, and the pro-apoptotic oxidatively truncated
phospholipid azelaoyl-PC. Most strikingly, PAFR-null mice had less infiltrating
neutrophils, oxidized phospholipids and TUNEL positive cells in kidney as com-
pared to wild-type (wt) mice fed with ethanol diet. Blood urea nitrogen and serum
creatinine, renal functional markers, increased after ethanol exposure in wt mice
but not in PAFR-null mice. The renal fibrosis marker, α- smooth muscle actin was
increased in ethanol-fed wt mice, but not in PAFR-null mice. Kidney injury mole-
cule-1 (KIM-1), a marker for proximal tubular injury, is increased during acute
renal injury, and we find higher expression of KIM-1 in the proximal tubules of
ethanol fed wt mice as compared to PAFR-null mice. These results suggest that PAF
and bioactive PAF-like oxidized phospholipids promote renal inflammation, acute
injury, and renal fibrosis. These events completely depend on a functional PAFR.
This demonstrates a novel mechanism of PAFR in alcoholic renal injury.
2188 Nephrotoxicity of Epigenetic Inhibitors Used for the
Treatment of Cancer.
N. E. Scholpa,  M. Moore and B. S. Cummings. Pharmaceutical and Biomedical
Sciences, University of Georgia, Athens, GA.
Several studies exist investigating the anti-neoplastic activity of epigenetic in-
hibitors. In contrast, fewer studies have investigated the toxicity of epigenetic in-
hibitors in non-target organs, such as the kidney. Even fewer have investigated both
the anti-neoplastic activity and toxicity of epigenetic inhibitors under similar con-
ditions. This study determined the anti-neoplastic activity and nephrotoxicity of
epigenetic inhibitors In Vitro. The therapeutic efficacy of epigenetic inhibitors was
first determined in human prostate cancer cells (PC-3 and LNCaP) using the DNA
methyltransferase inhibitor 5-azacytidine (5-Aza) and the histone deacetylase in-
hibitor trichostatin A (TSA). Cells were also treated with carbamazepine (CBZ), an
anti-convulsant with histone deacetylase inhibitor-like properties. 5-Aza, TSA, or
CBZ alone (0-100 μM) did not induce decreases in MTT staining in PC-3 or
LNCaP cells after 48 hr. In contrast, docetaxel, a frontline chemotherapeutic, did
induce concentration-dependent decreases in MTT staining after just 24 hr.
Treatment of prostate cancer cells with CBZ prior to docetaxel exposure decreased
MTT staining in LNCaP cells, but neither TSA nor 5-Aza altered MTT staining
compared to cells exposed to docetaxel alone. Treatment of normal rat kidney
(NRK) and human embryonic kidney 293 (HEK293) cells with the same concen-
tration of epigenetic inhibitors used in prostate cancer cells significantly decreased
MTT staining after 48 hr. The epigenetic inhibitors were generally more toxic than
the nephrotoxicant bromate (0-400 ppm), and TSA and 5-Aza pretreatment in-
creased the cytotoxicity of BrO3- in NRK cells. Increased cytotoxicity in NRK cells
correlated to alterations in epigenetic markers such as histone phosphorylation and
to alterations in the methylation of the cyclin-dependent-kinase inhibitor protein
p21. Collectively, these data suggest that epigenetic inhibitors can induce nephro-
toxicity at doses that are therapeutically relevant in prostate cancer cells In Vitro.
2189 hTERT-Immortalized Renal Proximal Tubule Epithelial
Cells: A Model for Testing Cadmium’s Role in the
Development of Renal Cancer.
B. R. Simon. Global Environmental Health Sciences, Tulane University, New
Orleans, LA. Sponsor: J. Wickliffe.
The incidence of renal cell carcinoma (RCC) has steadily increased in the United
States over the past three decades. Therefore, it is critical that scientists are better
able to understand contributing factors. Cadmium (Cd) is a recognized carcinogen
and widespread environmental contaminant. The kidney is a known target organ of
Cd toxicity, however the mechanistic role(s) that Cd plays in the development of
RCC has not been described. Renal proximal tubule epithelial cells (RPTECs) are
specifically affected by Cd because of their propensity to reabsorb Cd from filtrate
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leading to bioaccumulation. In order to elucidate the mechanisms by which Cd
acts, we aim characterize a newly developed cell line derived from renal proximal
tubule epithelial cells of a healthy human male donor (RPTEC/TERT1). Our goal
is to establish this new in vitro system for future toxicological and cancer research
by characterizing the RPTEC/TERT1 cell line and utilizing them to conduct bio-
logically relevant exposure studies. We will explore these goals through exposure ex-
periments to binary mixtures of two common environmental contaminants, Cd
and benzo(a)pyrene (B[a]P). Our preliminary results demonstrate that these cells
are sensitive to both compounds separately over a wide range of exposure levels.
Additionally, the characteristic Cd-interacting protein, metallothionein I/II, ex-
hibits a Cd-specific protein response, which supports its ability to function as ex-
pected, based on in vivo evidence. The RPTEC/TERT1 cell line expresses meta-
bolic biotransformation enzymes necessary for processing polycyclic aromatic
hydrocarbons (PAHs) which is exemplified by their sensitivity to the representative
PAH, B[a]P. Future experiments will further characterize DNA repair capacity of
the RPTEC/TERT1 cell line and the development of mutagenic lesions when ex-
posed to binary mixtures of sub-cytotoxic doses of Cd and B[a]P. This work will
provide mechanistic support and augment current scientific knowledge regarding
the development of RCC and exposure to xenobiotic mutagens and carcinogens.
2190 BUN and Serum CRE Alterations in Higa and BALB/c Mice
after Subacute Administration of Fluoride via Drinking
Water.
T. Kido1, 2,  M. Tsunoda2,  C. Sugaya2,  H. Yanagisawa1 and Y. Aizawa3. 1Public
Health and Environmental Medicine, The Jikei University School of Medicine, Tokyo,
Japan; 2Preventive Medicine, Kitasato University School of Medicine, Sagamihara,
Japan; 3Kitasato University, Tokyo, Japan.
Fluoride (F) is known as an environmental pollutant. Because F is filtered by the
kidney, mice with impaired renal function may be affected more significantly by F.
IgA nephritis is the most common chronic glomerulonephritis. High IgA (HIGA)
mice have been used as a model of IgA nephritis. The effects of fluoride on BUN
and serum creatinine (CRE) of HIGA and BALB/c mice after subacute administra-
tion via drinking water were examined in this study to get basic information of the
toxic effects of F on the mice with IgA nephritis. F was administered to HIGA and
BALB/c mice, aged 11-12 weeks at 0, 50, 100, and 150 ppm in their drinking
water for 4 weeks. The blood was sampled from the tail artery once a week. The
BUN and CRE in the serum was determined by the kits. For the BUN levels in the
HIGA mice, after one week from the beginning of the exposures, the mean BUN in
the 50-ppm group was significantly higher than those in the 100- and 150-ppm
groups. At 2 weeks, the mean value of BUN in the 100-ppm group was signifi-
cantly higher than those in the 0- and 50-ppm groups. For the BALB/c mice, there
were no significant differences among the groups. For the CRE in the serum of
HIGA mice, after 1 week, the mean CRE in the 50-ppm group was significantly
higher than those in the 100- and 150-ppm groups. For the BALB/c mice, after 3
weeks, the mean CRE in the 50-ppm group was significantly higher than those in
the 0- and 100-ppm groups. The alterations in the BUN and CRE in the serum ob-
served in the HIGA and BALB/c mice may indicate the toxic effects of F on the
kidney. However, the alterations were not dose-dependent, and the effects of F on
the kidney of HIGA mice were not as significant as those on kidney of the BALB/c
mice. The toxic effects of F on the kidney were not enhanced in the HIGA mice at
11 to 12 weeks of age.
2191 Performance Evaluation of Urinary Complement Biomarker
for the Immune-Mediated Glomerular Injury.
M. Ko1,  E. Nagiec2,  D. Fix3,  B. L. Homer2 and A. John-Baptiste1. 1Drug Safety,
Research & Development, Pfizer, San Diego, CA; 2Drug Safety, Research &
Development, Pfizer, Cambridge, MA; 3Drug Safety, Research & Development, Pfizer,
Groton, CT. Sponsor: W. Huang.
With the increased focus on protein biotherapeutic development in recent years,
glomerular injury has become a significant risk factor. In order to monitor this risk
in preclinical and clinical drug development reliable, sensitive and specific bio-
markers are greatly needed. Currently urinary albumin and total protein are the
most commonly used diagnostic biomarkers for monitoring both tubular and
glomerular injury. Rat passive Heymann nephritis (PHN) is a model of glomerular
injury characterized by subepithelial immune complex deposits, along with deposi-
tion of C5b-9 and ensuing proteinuria (Pippin et al., 2009). Schulze et al. estab-
lished that elevated urinary C5b-9 was associated with glomerular immune deposit
formation in this model (1989, Kidney International, 35, 60-68). Consequently,
we evaluated the performance of commercially available Quidel human and USCN
rat C5b-9 ELISA kits on urine samples. Zymosan-activated plasma or serum sam-
ples from non-human primate (NHP) and rat, respectively, were used as positive
controls. The linear detection range of the standard curve, dilution effect, matrix ef-
fect, albumin interference, and inter-assay variability were assessed as performance
parameters for the kits. In addition, a rat PHN study was conducted, and the urine
samples were analyzed with USCN C5b-9 ELISA kits. The results showed poor
performance of the kits, demonstrated by greater than ±30% analytical recovery for
dilution effects, urine matrix effects, albumin interference, and greater than 25%
coefficient of variation for inter-assay variability. Moreover, using Urinary
Stabilizing Buffer (Argutus Medical Ltd, Dublin, Ireland) did not improve the per-
formance. Therefore, we could not demonstrate an association between the C5b-9
positively-stained glomeruli and urinary C5b-9 level in the rat PHN study. We con-
cluded that Quidel and USCN kits performed poorly for the detection of urinary
C5b-9 in rat and NHP urine.
2192 Miniaturized Multiplex Protein Nanoarray Assays for Early
Detection of Drug-Induced Nephrotoxicity in Mice and
Rats.
A. W. Kherzai,  R. G. Sanedrin,  P. Han,  N. A. Amro,  R. Helfrich,  S. Aziz,
N. Patel,  D. Mikos and H. Jamil. Nano BioDiscovery, Nanoink INC, Skokie, IL.
Sponsor: S. Devi.
Drug-induced toxicity is the major cause of kidney damage. The previous methods
for measuring drug induced injury, namely serum creatinine and blood urea nitro-
gen, have been found inadequate. Recently the FDA and EMEA have qualified a
panel of biomarkers that is highly useful in the early identification and characteri-
zation of kidney injury. 
Here we report the development of highly sensitive and small sample volume
NanoArray multiplex assays for early detection of drug-induced nephrotoxicity in
mouse and rat in-vivo models based on dip-pen nanolithography (DPN™) using a
NanoArrayer 3000TM. This instrument enables the production of highly repro-
ducible micro- to nano-scale arrays of proteins which occupy an area approximately
100 times smaller than conventional microarrays. The reduced array area results in
reduced reagent and sample requirement and increased sensitivity due to reduced
analyte depletion. For a multiplexed sandwich ELISA, arrays of specific capture an-
tibodies are printed on activated glass slides. Samples of as little as 2-4 μl can be in-
cubated over the arrays in 48 and 98 well format. The slides are then incubated
with specific biotinylated detection antibodies followed by fluorescently labeled
Streptavidin. The fluorescence is measured with a high resolution fluorescence
scanner. 
The multiplex assays were developed and validated for mouse (Albumin, Clusterin,
Cystatin C, KIM-1, and EGF) and rat biomarkers panels (Albumin, Clusterin,
Cystatin C, KIM-1, B2MG and TFF3) and showed high sensitivity and specificity.
The assay was used to detect and quantify renal injury biomarkers in urine samples
obtained from normal and drug compromised rats. The low volume sample re-
quirements in conjunction with the extremely high sensitivity, selectivity, and re-
producibility help enable longitudinal studies on individual rodents thus saving sig-
nificant study costs and providing better toxicity data than other conventional
methods used for preclinical and clinical safety and toxicity studies.
2193 Magnetic Resonance Imaging (MRI) Assessment of Renal
Glomerular Filtration Rate (GFR).
M. Uteng1,  A. Mahl1,  A. Piaia1,  J. Cunliffe1,  E. Persohn1,  E. Tritto1,
D. Ledieu1,  P. Moulin1,  N. Shangari1,  S. Chibout1,  A. Wolf1,  L. Li1,
F. Pognan1 and N. Beckmann2. 1Novartis Institutes for BioMedical Research,
Novartis, Basel, Switzerland; 2Global Imaging Group, Novartis, Basel, Switzerland.
MRI of kidneys after administration of the contrast agent, gadolinium-tetra-azacy-
clo-dodecanetetra-acetic acid (Gd-DOTA), has been reported as a promising
method for assessment of GFR. However, there is little literature on the sensitivity
of this method compared to standard assessments in non-clinical trials of drug de-
velopment. To this end, we have conducted a study with the aim to determine the
sensitivity of MRI as a method for detection of GFR in rodents.
Sprague-Dawley rats were treated with Adefovir as positive control, and
Telbivudine and Entecavir as negative controls for nephrotoxicity. The rats were
treated daily by oral gavage for 4 weeks with 10X and 25X human equivalent expo-
sure doses (HED) of compounds. After 3, 10 and 28 days treatment, GFR was as-
sessed by MRI and creatinine clearance rate, while renal toxicity was assessed by uri-
nary kidney biomarkers, clinical biochemistry parameters in blood and urine,
histopathology, electron microscopy and gene expression profiling.
Impairment of GFR was detected by MRI showing delayed time-to-peak signal of
Gd-DOTA clearance in the renal cortex of animals treated with 25X HED Adefovir
on day 28. These results correlated with histopathological observations of cortical
tubular degeneration. Moreover, renal toxicity was also confirmed by urinary kid-
ney biomarkers (e.g Kim1), and by down-modulation of renal tubular associated
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genes. On the other hand, the creatinine filtration rate did not reveal any significant
changes. Animals treated with Telbivudine and Entecavir showed neither renal im-
pairment nor toxicity for the entire study duration. 
In conclusion, these results demonstrated that MRI is a sensitive method for non-
invasive detection of GFR changes and that this technique may be a good alterna-
tive to the standard measurements of creatinine filtration in non-clinical investiga-
tive studies.
2194 Identification of 3-Indoxyl Sulfate As an Early Biomarker for
Nephrotoxicant-Induced Acute Kidney Injury.
A. Won1,  T. Kim1,  Y. Shin1,  B. Lee2,  S. Kim3 and H. Kim1. 1College of
Pharmacy, Pusan National University, PUSAN, Republic of Korea; 2College of
Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea; 3Department of
Chemistry and Chemistry Institute for Functional Materials, Pusan National
University, Busan, Republic of Korea.
The identification of new biomarkers of acute kidney injury (AKI) is important for
the detection of drug-induced kidney damage. Various serum or urinary biomark-
ers have been used to detect AKI, but these biomarkers have shown poor sensitivity
and specificity. In this study, we compared the sensitivity of a new metabolomic
biomarker, 3-indoxyl sulfate (3-IS), with traditional biomarkers for the diagnosis of
AKI using the area under the receiver operating characteristic (ROC) curve.
Sprague-Dawley male rats were allocated to several groups. Each group was admin-
istered either a single dose of cisplatin (20 mg/kg, i.p.), continuous injection of cy-
closporin A (10 mg/kg, i.p.), mercury chloride (1.5 mg/kg, i.p., and 7.5 mg/kg,
i.p.), or gentamicin (60 mg/kg, s.c.). Urine and plasma samples were collected 1, 3,
and 7 days after last injection of nephrotoxicants. Urine and blood biochemical pa-
rameters involved in kidney toxicity were measured. We also measured 3-IS levels in
the serum, urine, and kidney¬¬ using HPLC. In the nephrotoxicants-treated rats,
blood urea nitrogen (BUN) and serum creatinine (sCr) levels were slightly in-
creased. The 3-IS levels were significantly reduced in the urine of rats treated with
cisplatin and other nephrotoxicants. In contrast, 3-IS levels were significantly ele-
vated in the serum and kidneys of nephrotoxicants-treated rats. The 3-IS is pro-
duced by bacterial metabolism of tryptophan in the intestine, followed by oxida-
tion and sulfation in the liver. The 3-IS is mainly excreted via active secretion by the
organic anion transporter (OAT) in the proximal tubule. Thus, reduced urinary 3-
IS levels can reflect proximal tubule injury. These results suggest that urinary 3-IS
may be used as an alternative to traditional biomarkers to predict AKI.
2195 A Quantitative High-Throughput Screening Platform for
Predictive Kidney Toxicity.
M. Adler1,  E. Gottwald1,  B. Goodwin2,  M. Xia2 and V. S. Vaidya1. 1Renal
Division, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical
School, Boston, MA; 2National Center for Advancing Translational Sciences, National
Institutes of Health, Bethesda, MD.
Drug and environmental chemical-induced kidney toxicity plays an important role
in the high incidence and prevalence of kidney injury in both hospitalized and non-
hospitalized patients, which in many circumstances can be prevented or at least
minimized by predictive toxicity screening. The goal of this study was to develop a
cell-based quantitative high throughput screening (qHTS) platform with two aims:
1) to identify a more biologically relevant in vitro system for prediction of human
kidney toxicity than currently used immortalized cells and 2) to identify a sensitive,
specific, robust and translatable biomarker of kidney toxicity since in vivo biomark-
ers such as kidney injury molecule-1 do not respond in vitro. We used primary
human proximal tubular epithelial cells (HPTEC) and observed that these cells in a
monolayer possess human tubular epithelial characteristics like 1) formation of
domes; 2) expression of zonula occludens-1, cytokeratin 18 by immunostaining; 3)
a wide range of efflux and influx transporters including aquaporin 1, megalin, or-
ganic cation transporter 2, multidrug resistance protein 2, P-glycoprotein by semi-
quantitative PCR and 4) activity of brush-border enzymes like alkaline phos-
phatase, and γ-glutamyl-transferase. We found that hemeoxygenase-1 (HO-1)
mRNA and protein levels significantly increased in a concentration-dependent
manner (tested over 6-point concentration curve) following exposure to struc-
turally and mechanistically diverse kidney toxicants such as cisplatin, gentamicin,
cyclosporin A and cadmium chloride and correlated well with cytotoxicity. HO-1
expression remained unchanged following treatment of HPTEC with non-kidney
toxic compounds (e.g. carboplatin), demonstrating its specificity. Our results
demonstrate the relevance and potential use of HPTEC in a qHTS platform using
HO-1 as a biomarker for predictive safety assessment of drugs and environmental
chemicals.
2196 Systems Biology Approach Identifies Transcriptional
Regulator of Kidney Injury Molecule-1.
A. K. Ajay1, 3,  T. Kim2, 3,  P. J. Park2, 3,  V. Ramirez1, 3 and V. S. Vaidya1, 3. 1Renal
Dision, Brigham and Women’s Hospital, Boston, MA; 2Centre for Biomedical
Informatics, Harvard Medical School, Boston, MA; 3Department of Medicine,
Harvard Medical School, Boston, MA.
Kidney injury molecule-1 (KIM-1) is the highest upregulated gene following kid-
ney ischemic or toxic insult and functions as a phosphatidylserine receptor to inter-
nalize apoptotic cells. Owing to lack of information about regulation of KIM-1, we
used genome-wide expression data following kidney ischemia reperfusion injury
(IRI) in rats and utilizing ChIP enrichment analysis and kinase enrichment analysis
we identified STAT3 and checkpoint kinase 1 (Chk1) as a potential transcription
factor and kinase regulating KIM-1. Then we performed an extensive biological
validation of the bioinformatics predictions and report that reactive oxygen species
generation following IRI upregulates Chk1 that binds to STAT3 phosphorylating it
at Ser727, which further binds to KIM-1 promoter for its transcription. 
We observed temporal association among pSTAT3, pChk1 and KIM-1 using im-
munoblotting and immunostaining in rat kidneys following IRI and in human kid-
neys from patients with kidney injury. To prove transcriptional regulation of KIM-
1 by STAT3 we used i) primary human proximal tubular epithelial cells (HPTEC)
and showed a significant increase (1.5 fold) in KIM-1 mRNA and protein follow-
ing STAT3 activation. Conversely we used human renal carcinoma cell line (769 P)
expressing high pSTAT3/KIM-1 and found 2-fold decrease in KIM-1 following
STAT3 siRNA transfection. Furthermore, we confirmed that STAT3 binds on
KIM-1 promoter in i) rat kidneys (10 fold by ChIP assay) following IRI; ii)
HPTEC’s transfected with KIM-1-luciferase plasmid (3-fold by STAT3 activation)
and iii) 769 P cells transfected with STAT3 siRNA (2-fold decrease). The binding
of Chk1 to STAT3 was observed using immunoprecipation in HPTEC by hydrox-
yurea (Chk-1 activator). These results reveal Chk1-STAT3 as one of the key path-
ways regulating KIM-1 transcription.
2197 Kidney miRNAs Show Age and Sex Differences in Expression
during the Rat Life Cycle.
J. C. Kwekel,  V. Desai,  T. Han,  C. L. Moland and J. C. Fuscoe. Personalized
Medicine Branch, US FDA, National Center for Toxicological Research, Jefferson, AR.
Increasing evidence for epigenetic mechanisms of gene regulation has fueled inter-
est in the role of miRNAs in toxicogenomics for biomarker discovery. While rela-
tively immature in comparison to other genomic resources, the growing knowledge
base of individual miRNAs and their putative gene targets allows for large scale in-
quiry into more comprehensive, genome-wide analysis of miRNA expression.
Kidney tissues in the F-344 rat model system were examined over the life cycle for
the purpose of evaluating miRNAs with putative roles in drug metabolism and kid-
ney disease. miRNA expression was characterized at 2, 5, 6, 8, 15, 21, 78, and 104
weeks of age in both sexes using Agilent 8x15k rat miRNA microarrays containing
multiple probes for 677 unique miRNAs. Five animals per sex and age were used
for a total of 80 samples. Agilent’s Feature Extraction software was used for initial
analysis and processing of the raw data and 224 miRNAs were found to be ex-
pressed in the kidney in at least one age and sex. Combined filtering criteria of 1.5
fold change and p < 0.05 (2-way ANOVA) revealed 105 miRNAs (47%) exhibiting
differential expression by age or sex. Principal component analysis (PCA) showed
PC1 accounted for 21% of the variability among the 105 differentially expressed
miRNAs in a pattern consistent with age-specific effects. 12 miRNAs showed in-
creased expression at 78 and 104 weeks, consistent with an aging-related effect (e.g.
miR-142-3p, miR-223). Although no large scale, sex-related patterns were evident
from the PCA, some miRNAs showed sex-specific patterns of expression (e.g. miR-
204, miR-499, miR-183). miR-499 has been implicated in regulation of mito-
chondrial dynamics through direct targeting of calcineurin. Collectively, these re-
sults comprise one of the first large-scale characterizations of global miRNAs in the
kidney over the entire rat life cycle and show age- and sex-related differences that
may impact susceptibility to adverse effects in the kidney.
2198 Mice Deficient in microRNA-155 Have Greater
Susceptibility to Cisplatin-Induced Kidney Toxicity.
K. L. Pellegrini,  V. Bijol and V. S. Vaidya. Renal Division, Department of Medicine,
Brigham and Women’s Hospital, Harvard Medical School, Boston, MA.
Although originally identified as an oncogenic factor, microRNA-155 (miR-155)
has also been found to be upregulated in macrophages and dendritic cells in re-
sponse to a range of inflammatory stimuli and required for the activation of Th17
cells. We have previously shown miR-155 to be significantly upregulated following
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ischemic or toxic insult to the kidney and the objective of this study was to further
investigate the role of miR-155 in regulating kidney injury. Male miR-155-/- (KO)
and wild type C57BL/6J (WT) mice were injected intraperitoneally with 20 mg/kg
of cisplatin and sacrificed at 0, 24, 48, 72, 96 and 120 h (n = 5/timepoint) for the
collection of blood and kidneys. Blood urea nitrogen (BUN) and serum creatinine
(SCr) were measured to determine kidney function, and kidney injury molecule
(KIM-1) mRNA, histopathology (necrosis) and TUNEL staining (apoptosis) were
measured to determine the extent of proximal tubular injury.
The miR-155-/- mice had significantly higher kidney dysfunction as evidenced by
more than 2-fold higher levels of BUN and SCr in the KO mice as compared to
WT by 48 h. The KO mice also had significantly higher KIM-1 mRNA levels (3-
fold) than the WT that remained higher than WT through to 120 h. Necrosis and
apoptosis were significantly increased in the kidneys of KO mice as compared to
WT mice throughout the time course, and mortality of approximately 60% was
observed for the miR-155-/- mice as compared to 20% for the WT mice by 120 h.
These results demonstrate that miR-155-/- mice are highly susceptible to cisplatin-
induced kidney toxicity. Tumor protein 53 induced nuclear protein 1 (TP53INP1),
which phosphorylates p53 to induce apoptosis, has previously been identified as a
direct target of miR-155. We hypothesize that miR-155 is repressing the levels of
TP53INP1 (and in turn, the induction of apoptosis) in the kidneys of C57BL/6J
mice treated with cisplatin, and that the dysregulation of TP53INP1 in miR-155-/-
mice promotes the induction of apoptosis, resulting in higher levels of kidney in-
jury.
2199 Urinary microRNAs As Translational Biomarkers to Detect
Acute Kidney Injury.
K. Ramachandran,  J. Saikumar,  S. S. Waikar and V. S. Vaidya. Renal Division,
Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School,
Boston, MA.
MicroRNAs (miRNAs) are a family of short, single stranded, non coding RNA
molecules that direct the expression of nearly 60% of all protein coding genes.
Extracellular miRNAs, identified in 14 different body fluids, have been proposed as
biomarkers of disease and organ damage due to their stability, sensitivity, specificity
and ease of detection. Previously, we identified 3 miRNAs (miR-21, -155 and -18a)
that were upregulated following ischemic injury and gentamicin induced nephro-
toxicity in rats. Human urinary levels of miR-21 and -155 were able to distinguish
patients with and without acute kidney injury (AKI). The aim of our current study
was to profile the human miRNome in the urine of patients with or without AKI to
identify a panel of urinary miRNAs that can serve as sensitive and specific indica-
tors for kidney injury. To estimate the fraction of miRNAs present in the urine, we
used the Human miRNome miScript miRNA PCR Array from Qiagen (miRBase
version 18 containing ~1900 miRNAs) on urines pooled from 6 patients with AKI
and 6 healthy controls. Samples were collected from patients admitted in the
Intensive Care Unit (ICU) with a rise in serum creatinine of 100% over baseline.
Using a cycle threshold (Ct) range of 19-30, miRNAs that were expressed in both,
or in either one of the diseased or healthy pools were selected. All miRNAs that had
Ct values >30 in both the sample sets were considered as ‘Not Expressed’ and elim-
inated. Thus, we designed a customized array of the 378 detected miRNAs and an-
alyzed the 12 urine samples (6 AKI and 6 healthy) individually. We found 52
miRNAs that were upregulated >5-fold in the AKI patients as compared to the con-
trols and 33 candidate miRNAs (out of 52) were selected using a standard deviation
cut-off of 1.5. Further evaluation of these candidate miRNAs for sensitivity, speci-
ficity, stability, reproducibility and robustness in an expanded cohort of patients
with or without kidney damage will help in establishing the value of urinary
miRNAs as non-invasive biomarkers for kidney injury.
2200 Genetic Reduction in Fibrinogen Protects from Progression
of Acute Kidney Injury to Chronic Kidney Disease.
F. Craciun,  A. K. Ajay and V. S. Vaidya. Department of Medicine, Renal Division,
Brigham and Women’s Hospital, Harvard Medical School, Boston, MA.
The incidence of acute kidney injury (AKI) is increasing and recent studies empha-
size the significantly higher risk of developing chronic (CKD) and end-stage kidney
disease for AKI survivors. We have shown that mRNA and protein expression in
the kidney as well as urinary fibrinogen (Fg) is significantly increased following
AKI in mice, rats and humans. Furthermore, we have demonstrated that Fg het-
erozygosity in mice reduces plasma Fg to 75% of the normal circulating levels, pro-
tecting from AKI and promoting faster resolution of kidney damage. Therefore, we
hypothesized that Fg heterozygosity would protect from AKI to CKD progression.
To test this we used a Folic acid (250 mg/kg, single sq injection) induced AKI to
CKD progression model in wildtype (Fg+/+), heterozygous (Fg+/-) and Fg defi-
cient (Fg-/-) mice on Balb/c background and the mice were sacrificed at days 1 and
14 following administration (n=4-6/time point/group). At day 1 there was signifi-
cant kidney dysfunction as assessed by blood urea nitrogen (112, 73 and 65 mg/dL
for Fg+/+, Fg+/- and Fg-/- respectively) and serum creatinine (0.7, 0.6, 0.3 mg/dL
for Fg+/+, Fg+/- and Fg-/- respectively), indicating protection in Fg+/- and Fg-/-.
Kidney mRNA levels of Kidney injury molecule-1 (marker of proximal tubular in-
jury) were significantly higher for Fg+/+ (80 fold) than Fg+/- (46 fold) and Fg-/-
(55 fold) as compared to uninjured mice. By day 14 these markers of acute injury
reverted to normal but there was increased kidney mRNA expression of fibrosis
markers fibronectin (9, 4 and 8 fold in Fg+/+, Fg+/- and Fg-/- respectively) and col-
lagen (8, 3 and 9 fold in Fg+/+, Fg+/- and Fg-/- respectively) when compared to
uninjured mice, with only Fg+/- showing protection. This was confirmed histolog-
ically by Masson’s trichrome staining. We conclude that a lowered but not com-
pletely abolished level of Fg protects from AKI to CKD progression, providing a
therapeutic target that could benefit AKI survivors.
2201 Urinary Levels of N-Acetyl-β-D-Glucosaminidase (NAG),
Glutathione-S-Transferase (GST), Blood Lead and Plasma
Creatinine As Early Indicators of Lead Nephropathy in
Occupationally Exposed Subjects.
I. O. Omotosho1 and G. O. Ademowo2. 1Chemical Pathology, College of Medicine,
University of Ibadan, Ibadan, Nigeria; 2Institute of Advanced Medical Research,
College of Medicine, University of Ibadan, Ibadan, Nigeria.
Lead (Pb) toxicity remains a public health problem. Although early diagnosis is
paramount for meaningful intervention particularly in occupationally exposed sub-
jects, the diagnosis of Pb poisoning at early stage remains a problem even in devel-
oped economies. This work addressed this issue by expressing urinary levels of
NAG and GST as exponents of concentrations of conventional renal function
markers (creatinine, urea and uric acid) and blood Pb. The result of exponential ex-
pression of these results showed a definite pattern particularly in occupationally ex-
posed subjects relative to confirmed chronic renal failure subjects and control.
When these figures were compared logarithmically, definite hyperboles for the con-
trol, the occupationally exposed and the CRF were observed; the importance of this
in early diagnosis of lead nephropathy is to be discussed. Based on these, we pro-
pose hypothesis that can be used in the early identification of renal tubular damage
especially in subjects occupationally exposed to lead using this logarithmic model.
2202 Early Postnatal Gentamicin Treatment Reduces Glomerular
Number in Extra Uterine Growth Restricted Wistar Rats.
R. R. Bueters,  A. Klaasen,  L. P. van den Heuvel and M. F. Schreuder. Pediatric
Nephrology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands.
Sponsor: F. Russel.
Introduction: Nephrogenesis is the process that leads to the formation of nephrons
and ceases around the 36th week of gestation in man, without the possibility of ad-
ditional formation later in life. A lower number of nephrons have been associated
with an increased chance at chronic kidney disease development. In the
Netherlands alone, almost 8% of all children are born preterm, and many are
treated with drugs or suffer from extra uterine growth restriction (EUGR) that may
potentially reduce nephron formation. In this study we investigated the impact of
gentamicin and ceftazidime on kidney development w/wo EUGR.
Methods: Wistar rats were allocated to either normal size litters (12 pups) or in-
creased size litters (20 pups), the last resulting in EUGR. Both cohorts were divided
in control and intervention groups where animals were administered 0.9% NaCl, 4
mg/kg gentamicin or 5 mg/kg ceftazidime via intraperitoneal route from post natal
day 2-8. At day 8 and 35, animals were sacrificed and the kidneys were collected.
Day 8 kidneys were examined for mRNA expression in a selection of targets, prolif-
eration, apoptosis and general histopathology. Total glomerular count (estimated
using stereology) and glomerular generation count were performed in kidneys col-
lected at day 35. 
Results: Gentamicin treatment in combination with EUGR resulted in 20% less
glomeruli compared to sham treatment. EUGR animals had less body weight, but
showed parallel growth compared to non-growth restricted animals, indicating a
successful working model. No clear distinctions were noted in mRNA expression
levels, glomerular generation count or general histopathology. The
proliferation/apoptosis balance is currently under investigation.
Conclusion: Early postnatal gentamicin treatment in combination with EUGR
tends to decrease the total glomerular number in Wistar rats, of which the pathways
were not clarified yet. The long term clinical sequelae are still unclear.
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2203 Resistance to Dioxin-Induced Hydronephrosis in a Mouse
Strain Having Unresponsive Microsomal Prostaglandin E
Synthase-1.
K. Aida-Yasuoka,  W. Yoshioka,  T. Kawaguchi,  S. Ohsako and C. Tohyama.
University of Tokyo, Tokyo, Japan.
Background: The majority of dioxin toxicity is governed by aryl hydrocarbon re-
ceptor (AhR), and the degree of toxicity is affected by its allele type. It is known
that AhRb1 and AhRb2 are responsible for marked manifestation of dioxin toxicity,
but that AhRd is not. Our previous works1, 2) showed that COX-2 and microso-
mal prostaglandin E synthase-1 (mPGES-1), an inducible form of PGE2 synthase,
are critical factors in the pathogenesis of hydronephrosis (HN), and suggested the
presence of the possible strain difference in the development of HN between
C57BL/6J and BALB/c. Thus, we here examined the incidence of dioxin-induced
hydronephrosis (HN) in mouse pups of these strains to clarify causative factors that
bring out a strain difference in dioxin-induced HN.
Methods: Two strains of mice, C57BL/6J and BALB/c, harboring b1 and b2 alleles,
respectively, were administered 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), at
an oral dose of 15 μg/kg, 1 day after birth, to expose pups with TCDD via lacta-
tion. Kidneys were collected on postnatal day 7 for histology and gene expression
analysis by quantitative RT-PCR.
Results: Incidence of HN was approx. 60% in C57BL/6J and 0% in BALB/c de-
spite the comparable induction levels of CYP1A1 in the both strains. There was no
strain difference in COX-2 mRNA abundance. A strain difference in mPGES-1
mRNA abundance was found comparable to the HN incidence. Gene expression of
early growth response 1 (Egr-1), that activates mPGES-1 transcription, was in-
creased in C57BL/6J, but not in BALB/c. In addition, mRNA of aquaporin 2, a
water channel, that absorbs water at the collecting duct, was decreased in C57BL/6J
and increased in BALB/c. 
Conclusions: Although both C57BL/6 and BALB/c have dioxin-sensitive receptors,
this study demonstrates that strain difference in the incidence of TCDD-induced
HN in mouse pups can be partly explained by distinct expression differences in
mPGES-1. It is also suggested that Egr-1 may modulate the induction of mPGES-
1. 
References: 1) Nishimura et al, 2008; 2) Yoshioka et al, 2012.
2204 Escape from Toxic Island: Learning Toxicology Concepts
through Informational Posters and a Board Game.
D. Hardej1, 2,  L. Hoffman1, 2 and A. R. Schatz1. 1Mid-Atlantic Society of Toxicology
(MASOT), Bordentown, NJ; 2Pharmaceutical Sciences, St. John’s University, Queens,
NY.
Escape from Toxic Island is a program that was developed by the MASOT
Education and Outreach Committee to teach toxicology concepts to school aged
children.The program is composed of informational posters containing basic toxi-
cology concepts followed by a board game with toxicology questions. Answers to
many of the questions were contained in the posters and children were encouraged
to use them to obtain correct answers as they moved along the game board. One of
the informational posters contained basic definitions and toxicology concepts such
as routes of exposure, signal words used in the labeling of toxic substances and gov-
ernment agencies that regulate toxicity.The second poster explored toxicity in and
around the home and included information about cleaning products, pesticides,
and car care products.The program was developed by the Chair of the MASOT
Education and Outreach Committee.Review of the informational posters and game
board was accomplished by Education and Outreach Committee members who
represent academia, industry and government experts in toxicology to ensure rele-
vancy and accuracy of information. In step with the success of the Inspector Tox
program developed 2 years ago by this committee, island themed costumes and
props were utilized. Toxic Island’s resident pirate, Captain Tox, assisted with in-
struction and game play. Incorrect answers were cheerfully corrected after “walking
the plank”.The audience for the program resulted from a joint effort of St. John’s
University and the Afterschool All Stars Program. The Afterschool All Stars pro-
vides free programs to roughly 80,000 children in need in 13 different cities in the
continental U.S. and Hawaii.Volunteers were recruited from MASOT, St. John’s
faculty, and graduate and undergraduate toxicology students. Learning outcomes
for the program are based on responses made to questions posed on the game
board. Respondents who answered incorrectly to game board questions were en-
couraged to explore the informational posters for correct answers.
2205 A C. elegans Dose-Response Protocol and Inquiry Lab in an
Undergraduate Toxicology Course.
M. J. Pomeroy-Black. Biology, LaGrange College, LaGrange, GA.
In order to prepare students for a multi-week research project, it is essential to allow
them to practice the protocols that will be used in the project. Using C. elegans,
students initially observed normal behavior and identified the developmental stages
of the organisms. Students then practiced transferring C. elegans between plates
and explored various endpoints that could be used in their research project, includ-
ing avoidance, locomotion and feeding. During the next lab session pairs of stu-
dents were given protocols for a dose-response lab activity in which they were as-
signed a compound, performed a dilution series, and used the dry drop test as a
measure of avoidance. Data were compiled and statistically analyzed after the lab.
After establishing this basis of knowledge the students designed and conducted
their own experiment for the remainder of the semester. Student pairs wrote a re-
search proposal based on a literature search, gathered preliminary data in the lab
and embarked on several replications of their experiment. Students analyzed their
data using an ANOVA and presented their research as a poster session to the
broader community.
2206 The Best of the Worst: A Novel Approach to Teaching
Environmental Toxicology.
C. P. Curran. Biological Sciences, Northern Kentucky University, Highland Heights,
KY.
Curriculum development for undergraduate toxicology courses taught is challeng-
ing, because of the varied preparation and background of students enrolled.
Students are typically majoring in environmental science, chemistry, or biology,
and each discipline has unique program requirements. Environmental toxicology
courses present even greater challenges for students without a solid grounding in
ecology or biochemistry. A novel course was developed at Northern Kentucky
University, focused on problem-based learning and team-based learning to engage
students in identifying and understanding environmental toxicology issues in their
local communities and in a variety of ecosystems (polar, temperate and tropical).
Sample activities such as “What is the Worst Environmental Problem in the
World?” will be explained along with the pedagogical underpinnings of the curricu-
lum design. Student satisfaction with the course was extremely high (4.8 on a 5.0
scale), indicating this course could be a model for other undergraduate educators.
2207 Risk Assessment Capstone Project for Seniors in an
Undergraduate Toxicology Program.
S. M. Ford. College of Pharmacy & Allied Health Professions, St. Johns University,
Jamaica, NY.
Capstone projects are intensive, active learning exercises for seniors to apply their
knowledge and skills to a complex problem in their discipline. The projects vary in
form and function. They may be done in teams or by individual students; the tasks
may be self-selected or assigned. Planning and implementation are student-directed
under supervision of faculty. Outcome of the work may be a written document
and/or an oral presentation. The scope should be substantial, utilize critical think-
ing, and draw upon the learning objectives of the major. In our BS Toxicology pro-
gram, seniors are assigned a risk assessment in the course Regulatory Toxicology
and Risk Assessment. They are given a hypothetical disaster, involving a population
exposed to a chemical through air, water, food, soil, or medication. Ideally the
chemical chosen is one for which the toxicological data is sparse, so that students
must evaluate the agent based on its properties and chemical class. The scenario in-
cludes the amount released, the exposed population, and the media of exposure.
The result of the project is a written risk analysis, a website, and presentation of
their findings to the College. The capstone project requires the students to utilize
the facts and concepts of toxicology in an analytical manner, and apply the skills of
writing, oral communication, and teamwork to a realistic situation. The public
presentation informs the larger university community on the process of toxic risk
assessment.
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2208 Development of a Summer Undergraduate Research Program
in Toxicology and Environmental Health Sciences.
L. M. Aleksunes1, 3,  L. Liang2, 3,  E. Caswell2 and D. L. Laskin1, 3. 1Department of
Pharmacology and Toxicology, Rutgers University, Piscataway, NJ; 2Department of
Health Systems and Policy, University of Medicine and Dentistry of New Jersey-School
of Public Health, Piscataway, NJ; 3NIEHS Center for Environmental Exposures and
Disease, Piscataway, NJ.
Exposure to research opportunities in toxicology and environmental sciences is key
to the development of the next generation of scientists. The Community Outreach
and Engagement Core of the NIEHS Center for Environmental Exposures and
Disease at the University of Medicine and Dentistry of New Jersey-Robert Wood
Johnson Medical School and Rutgers University has developed a summer research
fellowship program to promote toxicology and environmental sciences as careers in
biomedical research. The program consists of 10-week basic science and transla-
tional research experiences for undergraduates and was also designed to include
weekly events including laboratory safety and responsible conduct of research train-
ing, a field trip to a pharmaceutical company, career development and research
seminars and student presentations. Participants of the 2012 summer research pro-
gram ranked the field trip as the most valuable weekly activity followed by presen-
tations from toxicologists and environmental health scientists. Based on pre- and
post-survey results, over 60% of respondents reported that a career as a scientific re-
searcher was most appealing based upon satisfaction from doing research, the per-
ceived benefit of scientific knowledge to the community, and an overall interest in
science. In addition, 87.5% of respondents will continue to pursue research after
completion of the summer research program. This includes five students pursuing
Ph.D. degrees beginning in 2012 or 2013. A summer research program engages un-
dergraduate students in full-time research experiences and provides unique oppor-
tunities to promote toxicology and environmental sciences as research areas for the
next generation of scientists and enhances career development skills. Supported by
ES020721, ES005022, and ASPET SURF.
2209 Incorporation of Toxicology and Risk Assessment Principles
into an Environmental Health Course.
R. N. Phalen. Health Science, CSUSB, San Bernardino, CA. Sponsor: T. Dodd-
Butera.
Environmental health deals with a multitude of public health issues ranging from
sanitation to hazardous materials to air and water quality. Practitioners are largely
involved in the regulatory side of protecting public health, which requires an inti-
mate understanding of toxicology and risk assessment. However, many of the iden-
tified deficiencies with risk assessment are perpetuated by the educational curricula.
For example, chemical hazards are introduced to students and evaluated by regula-
tors on a case-by-case basis, often based on one toxicological endpoint alone. Strong
emphasis is placed on making comparisons of reference doses to exposure estimates
without regard to the effect of uncertainties associated with inadequate data. High
uncertainty alone could result in selection of a more toxic substance over one less
studied. A unique class project was created to give environmental health students,
our future regulators, an improved perspective on how toxicological information
can be used to make informed decisions that best protect human health and well-
being. The multi-step exercise focuses on a decision made by the World Health
Organization to bring DDT back into use to fight malaria. Students work in
groups to collect chemical, toxicological, efficacy, and economic aspects of a com-
mon pesticide used for mosquito control. The class then comes together to compare
and discuss the group results and select the best pesticide option for the impacted
region. A semi-quantitative risk management tool is also used for a more objective
determination. Lastly, a surprise change in one circumstance causes perspectives to
change and the outcome is a completely different conclusion. The end result is a so-
phisticated interaction of ideas and concepts, which motivates students to start
thinking about how there is more to toxicology than lethal doses and dose-response
curves, and that there is more to risk assessment than hazard quotients. A detailed
description of the project and handouts will be provided.
2210 Poisoning Principles: Clinical Toxicology and Undergraduate
Nursing Education.
T. Dodd-Butera1 and M. Broderick Pritty2. 1Nursing, CSU San Bernardino, College
of Natural Sciences, San Bernardino, CA; 2California Poison Control System, San
Diego, CA.
According to the American Association of Poison Control Center’s (AAPCC) an-
nual report (2010), 601,197 human exposures to toxicants resulted in management
in a health care facility. Therefore, education concerning clinical toxicology and
poisonings is essential in preparation of future healthcare professionals. This ab-
stract describes an educational program for undergraduate nurses delivered through
a collaboration with a regional Poison Control Center (PCC) and a local university.
Undergraduate nursing students were assigned to a clinical toxicology rotation and
were required to participate in didactic educational modules addressing principles
of toxicokinetics, such as the ADME (absorption, distribution, metabolism, and
exposure) model, prior to the PCC rotation. During the rotation, clinical toxicol-
ogy approaches to the poisoned patient were reviewed. Attendance at a journal club
at the poison center was included, covering topics such as: environmental expo-
sures, chemicals, drug overdoses, and unintentional poisonings. A lecture on lead
toxicity was then given to the entire class, including those undergraduate students
in other rotations. The program culminated with all students participating in a
poster session addressing clinical toxicology and other environmental health experi-
ences. Students were required to evaluate the entire course, including the PCC ro-
tation. Students reported an increase in knowledge and awareness about the role of
toxicology and environmental health in their professional development. In addi-
tion, the knowledge gained could be applied to bedside nursing to evaluate the role
of poisoning and antidote use, along with toxicology principles, for treatment and
care of patients utilizing healthcare facilities. Recommendations for future pro-
grams include integrating toxicology into didactic and clinical experiences of un-
dergraduate nursing students within all rotations, and across healthcare and scien-
tific disciplines.
2211 Coal Ash Material Safety—A Health Risk-Based Evaluation
of USGS Coal Ash Data from Five US Power Plants.
L. J. Bradley. AECOM, Chelmsford, MA.
Over 42% of the estimated 130 million tons of coal ash produced annually in the
US is put into beneficial use, and is material that is not placed in disposal facilities.
However, these uses are threatened by USEPA’s potential regulation of coal ash as a
hazardous waste, and by constant references to “toxic coal ash” by the press in re-
sponse to environmental groups’ writings. Therefore, a detailed health-risk based
evaluation was conducted of coal ash data released in a report by the US Geological
Survey. Eight robust coal ash data sets were selected as representing material that
could be put into beneficial use from five US power plants each utilizing a different
source of coal. The evaluation was conducted by comparing constituent concentra-
tions in coal ash to risk-based screening levels developed by the USEPA that are
protective of a child’s direct exposure to residential soils (including ingestion, der-
mal contact and inhalation routes of exposure). These screening levels are consid-
ered by the Agency to be protective for daily exposure by humans (including sensi-
tive groups) over a lifetime. Coal ash percentiles (10th-90th) were compared
directly to the screening levels, and in a more detailed evaluation, upper-bound ex-
posure point concentrations were used in a cumulative risk screening process.
Constituent concentrations in coal ash were also compared to USGS background
concentrations in soils in the US. The results indicate that with few exceptions con-
stituent concentrations in coal ash are below screening levels for residential soils,
and are similar in concentration to background US soils. Because exposure to con-
stituents in coal ash used in beneficial applications, such as concrete, road base, or
structural fill would be much lower than assumed for a residential soil scenario,
these uses should also not pose a direct contact risk to human health.
2212 Provisional Advisory Levels (PALs) for Chloroethanol
(Ethylene Chlorohydrin).
S. Milanez1,  P. M. McGinnis2,  L. Koller3 and F. Adeshina4. 1Oak Ridge National
Laboratory, Oak Ridge, TN; 2RG York and Associates, Syracuse, NY; 3Environmental
Health & Toxicology, Corvallis, OR; 4US EPA, Washington DC.
PAL values developed for hazardous materials by the US EPA represent general
public emergency exposure limits for oral and inhalation exposures corresponding
to three different severity levels (1, 2, and 3) for 24-hour, 30-day, 90-day, and 2-
year durations. PAL 1 represents the threshold for mild effects; PAL 2 represents the
threshold for serious, irreversible or escape-impairing effects; PAL 3 represents the
threshold for lethal effects. PALs have not been promulgated nor have they been
formally issued as regulatory guidance, but are intended for use at the discretion of
risk managers in emergency situations when site-specific risk assessments are not
available. The PAL document for chloroethanol was developed based on the SOP
and QAPP requirements. 
Chloroethanol (2-chloroethanol; ethylene chlorohydrin), is a colorless, combustible
liquid with a faint ether-like odor, and is soluble in water and organic solvents. It is
a high production volume chemical that is used as an industrial solvent and a chem-
ical manufacturing intermediate. It is formed when ethylene oxide is used to steril-
ize polyvinyl chloride plastics and to fumigate foods. Humans and animals exposed
by inhalation or orally exhibited CNS, GI, and respiratory symptoms, and had
post-mortem lesions in numerous internal organs. All PALs were derived using rat
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data because the human data were not adequate; the animal data were generally
consistent among species and with the limited human data. Developed PAL values
for oral exposure are 35 mg/L as the PAL 1 for 24 hours; 110 mg/mL as the PAL 2
for 24 hours, and 30 and 90 days; 230 mg/L as the PAL 3 for 24 hours; and 160
mg/L as the PAL 3 for 30 and 90 days. PALs derived for inhalation exposure are
0.26 ppm and 0.78 ppm as the 24-hour PAL 2 and PAL 3, respectively. For 30 and
90 days, the inhalation PAL 1 is 0.0015 ppm and the PAL 2 is 0.015 ppm. Other
oral and inhalation PAL values were not developed due to insufficient data.
2213 Provisional Advisory Level (PAL) Development for Lewisite
and Sulfur Mustard.
C. Bast1,  R. Young2,  P. M. McGinnis3,  C. Baird4 and F. Adeshina5. 1Oak Ridge
National Laboratory (ORNL), Oak Ridge, TN; 2ORNL, Oak Ridge, TN; 3RG York
& Associates, Syracuse, NY; 4US Army Public Health Command, Aberdeen, MD; 5US
EPA, Washington DC.
PAL values developed for hazardous materials by the US EPA represent general
public emergency exposure limits for oral and inhalation exposures corresponding
to three different severity levels (1, 2, and 3) for 24-hr, 30-d, 90-d, and 2-yr dura-
tions. PAL 1 represents the threshold for mild effects; PAL 2 represents the thresh-
old for serious, irreversible or escape-impairing effects; PAL 3 represents the thresh-
old for lethal effects. PALs have not been promulgated nor have they been formally
issued as regulatory guidance. They are intended to be used at the discretion of risk
managers in emergency situations when site specific risk assessments are not avail-
able. Application of PAL protocols has been performed for lewisite and sulfur mus-
tard to estimate inhalation exposure limits; oral PAL values are not recommended
(NR) due to insufficient data. PAL values for the vesicants, lewisite and sulfur mus-
tard, are based on ocular effects in humans and animals or lethality thresholds in ro-
dents.
Lewisite inhalation PAL 1, 2, and 3 values are NR, 0.01, and 0.037 mg/m3, re-
spectively, for 24-hr; and NR for 30-/90-d and 2-yr. 
Sulfur mustard inhalation PAL 1 values are 0.00083 mg/m3 for 24-h and 0.00010
mg/m3 for 30-d/90-d and 2-yr. PAL 2 values are 0.0042 mg/m3 for 24-h, 0.0029
mg/m3 for 30-d, and 0.00097 mg/m3 for 90-d and 2-yr. PAL 3 values are 0.088
mg/m3 for 24-h and NR for 30-d/90-d and 2-yr.
2214 Provisional Advisory Level (PAL) Development for Fentanyl.
C. S. Wood1,  C. Baird2,  L. Koller3 and F. Adeshina4. 1Oak Ridge National
Laboratory, Oak Ridge, TN; 2US Army Public Health Command, Aberdeen, MD;
3Environmental Health and Toxicology, Corvallis, OR; 4US EPA, Washington DC.
PAL values developed for hazardous materials by the US EPA represent general
public emergency exposure limits for oral and inhalation exposures corresponding
to three different severity levels (1, 2, and 3) for 24-hr, 30-d, 90-d, and 2-yr dura-
tions. PAL 1 represents the threshold for mild effects; PAL 2 represents the thresh-
old for serious, irreversible or escape-impairing effects; PAL 3 represents the thresh-
old for lethal effects. Minimum data requirements must be met or a value may be
considered NR (not recommended). PALs have not been promulgated nor have
they been formally issued as regulatory guidance. They are intended to be used at
the discretion of risk managers in emergency situations when site specific risk as-
sessments are not available. Application of PAL protocols has been performed for
fentanyl to estimate oral and inhalation exposure limits.
Fentanyl is a highly potent, synthetic opioid used clinically as an analgesic and anes-
thetic. Dose-response information from humans showed that effects were similar
between children and adults. The magnitudes of sedation and analgesia were posi-
tively correlated with dose. Side-effects included pruritus, nausea, vomiting,
headache, bradycardia, vertigo and respiratory depression leading to decreased oxy-
gen saturation at higher doses. Oral PALs were based on adverse side-effects in hu-
mans. Oral PAL 1 and 2 values are 0.03 and 0.23 mg/L respectively, for 24-hr/30-
d/90-d; oral PAL 3 and all 2-yr values are NR. Inhalation exposure resulted in
sedation and respiratory depression. Inhalation PAL 1, 2, and 3 values are NR,
0.0037, and 0.11 mg/m3 respectively, for 24-h. The 30-d/90-d/2-yr inhalation
PALs are NR.
2215 Development of a Chronic Reference Concentration for
Decalin.
L. D. Stuchal,  R. E. Weil and S. M. Roberts. Center for Environmental and
Human Toxicology, University of Florida, Gainesville, FL.
Decalin is a naturally occurring dicycloalkane present in crude oil and produced as
a product of combustion. Its ability to solubilize oils and fats makes it useful in
paints, cleaning fluids, gasoline, and varnishes. Because of its widespread use in
many types of commercial products, decalin is ubiquitous in the environment and
exposure by the general public is of concern. Neither oral nor inhalation toxicity
values are currently available for decalin in published sources despite recurring
point and non-point source releases. To derive a reference concentration (RfC) for
decalin, inhalation toxicity studies were reviewed using a weight-of-evidence ap-
proach. A two-year mouse inhalation study conducted by the National Toxicology
Program was chosen as the critical study for the derivation of the chronic RfC. In
this study, a significant increase in the occurrence of hepatotoxicity was detected at
the highest concentration tested (400 ppm) in male mice. Benchmark dose model-
ing was utilized to derive a point of departure for hepatic necrosis, syncytial alter-
ation, and erythrophagocytosis.  For data not amenable to modeling, a point of de-
parture was derived using the no observable adverse effect level (NOAEL). The
most sensitive adverse effect, syncytial alteration resulted in a BMDL10 of 7.8 ppm
using the Log-logistic model. A chronic RfC for decalin of 0.08 mg/m3 was calcu-
lated by conversion of the BMDL10 to a human equivalent continuous inhalation
concentration of 1.4 ppm (7.9 mg/m3) using a dosimetric adjustment factor of 1
and application of a total uncertainty factor of 100. The chronic decalin RfC was
derived despite several toxicity database limitations, including a small number of
chronic inhalation studies and uncertainty regarding reproductive effects. Future
research on decalin toxicity is needed to better characterize the adverse effects asso-
ciated with its chronic inhalation.
2216 Weight-of-Evidence Evaluation of Methyl Methacrylate
Olfactory Effects in Humans and Derivation of an
Occupational Exposure Level.
M. Pemberton1,  L. A. Bailey2 and L. R. Rhomberg2. 1Systox, Cheshire, United
Kingdom; 2Gradient, Cambridge, MA.
Methyl methacrylate (MMA) causes olfactory effects in rodents that are considered
relevant to humans. Recent scientific studies have focused on understanding the ap-
parent lack of species concordance between the rodent and occupational studies.
We have applied the hypothesis-based weight-of-evidence (HBWoE) approach to
evaluate the concordance of the available data and the hypothesis that the observed
difference in sensitivity between rats and humans may be the result of physiological
and biochemical differences. Our WoE analysis integrated several lines of evidence
[animal, human, mode of action (MoA), and toxicokinetics data] and found: 1)
acute and chronic rat and mouse MMA inhalation studies consistently indicate de-
generative lesions of the main olfactory region as the most sensitive endpoint; 2)
numerous studies support an MoA for MMA involving high concentrations of car-
boxylesterase activity in nasal epithelial tissue that metabolizes MMA to methyl
acrylic acid (MAA), an organic acid with irritative and corrosive properties; 3) car-
boxylesterases are a group of non-specific enzymes that are widely distributed
throughout the body in animals and humans; 4) toxicokinetic studies and a physi-
ologically based pharmacokinetic (PBPK) model describing inhalation dosimetry
of MMA in the upper respiratory tract (URT) of rats and humans point to differ-
ences in nasal morphology and biochemistry that help reconcile these differences as
species-specific manifestations of a common toxicological process, and predict a rat-
to-human dosimetry adjustment factor (DAF) of 3 to 8, consistent with observed
lower sensitivity in humans compared to rats; and 5) worker studies, although
somewhat limited, consistently suggest a no observed adverse effect level (NOAEL)
for URT irritation, including olfactory dysfunction, of 50 ppm. We derived MMA
occupational exposure levels (OELs) from animal data (ranging from 28-118 ppm)
and human data. Overall, our WoE analysis supports use of the human data for der-
ivation of an MMA OEL of 50 ppm.
2217 An Updated Dose-Response Evaluation of Aldrin and
Dieldrin.
E. Hooker,  H. J. Gibb and K. G. Fulcher. Tetra Tech Sciences, Arlington, VA.
The United States Environmental Protection Agency (USEPA) reviewed the cancer
and non-cancer effects of the organochlorine insecticides, aldrin and dieldrin, in
the late 1980’s. The results of those assessments are reported by USEPA’s Integrated
Risk Information System (IRIS). These assessments include reference dose (RfD)
values of 0.00003 and 0.00005 mg/kg-day and cancer slope factor values of 17 and
16 (mg/kg-day)-1 for aldrin and dieldrin, respectively. The USEPA methods for
dose-response analysis have changed in the decades since these evaluations were
done. The dose-response analyses of cancer and non-cancer health effects of aldrin
and dieldrin were re-evaluated using current methodology, including benchmark
dose (BMD) analysis (BMDS Version 2.2 software) and current body weight scal-
ing. A literature review was updated to determine the most appropriate adverse ef-
fect endpoints. Using current methodology and information, the cancer slope fac-
tors for aldrin and dieldrin were estimated to be 3.4 and 7.0 (mg/kg-day)-1,
respectively (i.e., about 5 and 2.3 fold lower risk than previous assessments). The
current analyses estimated RfD values of 0.0001 and 0.00008 mg/kg-day for aldrin
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and dieldrin, respectively (both higher than previous assessments). Because aldrin
and dieldrin are no longer used as pesticides in the United States, they are a low pri-
ority for additional review by the USEPA. However, because they are persistent and
still detected in environmental samples, quantitative risk assessments based on the
best available methods are required. Several national and international health as-
sessment organizations (e.g., WHO) do not consider aldrin and dieldrin to be
human carcinogens. Recent epidemiologic studies do not demonstrate a causal as-
sociation between aldrin and dieldrin and human cancer risk. These re-evaluations,
based on current methodologies and available data, suggest that these two com-
pounds pose a lower human health risk than currently reported by USEPA.
2218 Benzene: Development of a 24-Hour, Health-Protective
Comparison Value.
J. T. Haney. Toxicology Division, Texas Commission on Environmental Quality,
Austin, TX.
Texas has the most extensive volatile organic compound (VOC) ambient air moni-
toring network in the nation. As part of that network, the TCEQ collects every
sixth-day, 24-hour canister VOC data. These data are used to calculate annual aver-
ages for comparison to chronic, health-protective Air Monitoring Comparison
Values (AMCVs) (i.e., RfC-like values for noncarcinogenic effects, 1E-05 excess
risk levels for cancer effects). In regard to acute exposure durations, however, the
TCEQ typically has only 1-hour AMCVs, which while conservative are not de-
signed to evaluate 24-hour sample results. Thus, the development of 24-hour,
health-protective AMCVs would allow the TCEQ to more fully utilize 24-hour
VOC data for the evaluation of potential public health concerns. The TCEQ has
developed a proposed 24-hour AMCV for benzene since it is a ubiquitous VOC of
both agency and public interest. Critical effect dose-response data for hematotoxic-
ity from mouse studies indicate an effect level range of 10-100 ppm for subacute ex-
posure (e.g., 6-8 hours per day, 5-10 days). A point of departure (POD) from these
studies was used to develop the 24-hour value. The total number of exposure hours
exceeds 24 hours for all these subacute studies and available toxicokinetic informa-
tion indicates the time between the intermittent daily exposures would not allow
for clearance of benzene’s hematotoxicity-implicated metabolites (e.g., hydro-
quinone, hydroquinone glucuronide, catechol) from the bone marrow as evidence
suggests they are not readily excreted. Using the same POD (LOAEL of 10.2 ppm)
and uncertainty factors (total UF of 100) as the TCEQ used to derive its 1-hour
AMCV (180 ppb) but without duration adjustment (based on toxicokinetic con-
siderations) results in a conservative 24-hour, health-protective AMCV of 100 ppb.
This value is well below even chronic human hematotoxicity observed adverse ef-
fect levels (e.g., 7.2-13.6 ppm). The proposed 24-hour AMCV is considered suffi-
ciently conservative for the adequate protection of public health and would signifi-
cantly complement TCEQ health effect evaluations of ambient air data.
2219 Derivation of a Guidance Limit for Cadmium in Children’s
Jewelery: Health Canada’s Perspective.
G. Barrett1,  P. Chantal2,  S. Wright3,  P. Chowhan4,  P. Pelletier1,  H. Ryan1, 2 and
J. Field1. 1Toxicology and Flammability Risk Assessment Unit, Consumer Product
Safety Directorate, Health Canada, Ottawa, ON, Canada; 2Product Safety
Laboratory, Consumer Product Safety Directorate, Health Canada, Ottawa, ON,
Canada; 3Compliance and Enforcement Division, Consumer Product Safety
Directorate, Health Canada, Ottawa, ON, Canada; 4Risk Management Strategies
Division, Consumer Product Safety Directorate, Health Canada, Ottawa, ON,
Canada. Sponsor: G. Chen.
It has been demonstrated that swallowed jewellery items may become lodged in the
stomach, and morbidity and mortality have been associated with jewellery contain-
ing lead. Due to its inherent toxicity, the use of cadmium to make costume jew-
ellery may pose an analogous threat. In the absence of reliable human toxicity data,
the results from animal studies were used to derive an oral acute provisional mini-
mal risk level (pMRL) of 0.0732 mg/kg bw for cadmium. Health Canada analyzed
approximately 200 children’s jewellery samples that were judged small enough to fit
into a child’s mouth for cadmium content. A subset of these samples were also sub-
jected to migration testing, which revealed no consistency between the total
amount of cadmium in a sample, and the amount that might be released in the sim-
ulated physiological environment of the stomach over an extended period (such as
in the case of a piece of jewellery lodged in the stomach over several days). Since
standardized migration testing cannot accurately predict the amount of cadmium
that might leach out of a sample under such circumstances, the use of total cad-
mium content to derive a guideline is considered the most health-protective ap-
proach. Limiting total cadmium content to 130 ppm removes variables that inter-
fere with migratable cadmium quantification (such as the thickness and
composition of the surface plating, and elemental composition of the amalgam)
and is protective of the scenario of an ingested piece of jewellery lodged in the
stomach for an extended period of time.
2220 Assessment of Risks to the US Population Posed by Exposure
to Gold and Ceramic Dental Restorations.
R. E. Peters1,  M. Richardson2,  S. Clemow3,  K. James1 and S. D. Siciliano1.
1University of Saskatchewan, Saskatoon, SK, Canada; 2Stantec Consulting Ltd.,
Ottawa, ON, Canada; 3SNC-Lavalin Environment, Ottawa, ON, Canada. Sponsor:
L. Weber.
There is significant mercury exposure from dental amalgam used in restorative
practice. However, little is known about the chemical exposures and risks of alter-
native dental restorative materials. Thus, it is difficult for clinicians to weigh the
performance, risks, and benefits of dental amalgam to alternate restorative materi-
als. Here we provide the first population-level risk assessment for gold alloy and ce-
ramic restorative materials. Employing the US National Health and Nutrition
Examination Survey (NHANES) data from 2001 to 2004, we assessed the exposure
of adults to the components of gold alloy and ceramic dental restorations in the US
general population. Three specific exposure scenarios were considered: 1) all
restorations were either gold alloy or ceramic; 2) all crowns were gold alloy or ce-
ramic; and 3) 11% of fillings were either gold alloy or ceramic, in 30% of the pop-
ulation. Silver appears to be the most problematic component of gold alloy restora-
tions, due to a combination of relatively high toxicity and high proportional
composition. Based on the toxicity of silver and its proportional content in gold
dental alloys, it was estimated that adults could possess an average of 4 tooth sur-
faces restored with gold before exceeding the Reference Exposure Level (REL) for
silver. Lithium appears to be the most problematic component of dental ceramics.
All other ceramic components considered resulted in estimated daily doses well
below their respective RELs. Based on the toxicity of lithium and its proportional
content in dental ceramics, it was estimated that adults could possess an average of
16 tooth surfaces restored with ceramics before exceeding the REL for lithium.
Relative to dental amalgam and gold alloys, ceramics present the fewest and lowest
chemical exposures and risks.
2221 Development of an Oral Cancer Slope Factor for Acrylamide
Based on Tumors Relevant to Humans.
J. D. Urban1,  C. M. Thompson2,  R. Deskin3,  M. Waite3 and L. C. Haws1.
1ToxStrategies, Inc., Austin, TX; 2ToxStrategies, Inc., Houston, TX; 3Cytec Industries,
Inc., Woodland Park, NJ.
Acrylamide is an industrial chemical used mainly in the production of polyacry-
lamides. Acrylamide and polyacrylamides have many uses, including uses as floccu-
lants and flow control agent for enhancing oil production from wells, in the pro-
duction of dyes, organic chemicals, contact lenses, cosmetics and toiletries, in sugar
refining, and as a chemical grouting agent and soil stabilizer. Acrylamide is also
commonly present in fried foods and the primary route of human exposure in the
general population is diet. In their most recent risk assessment for acrylamide,
USEPA developed an oral cancer slope factor (OSF) of 0.5 (mg/kg-day)-1 based on
a 2-year drinking water study that reported increased incidences of thyroid tumors
and tunica vaginalis mesotheliomas (TVMs) in male F344 rats. However, there is
considerable evidence that F344 rats are particularly susceptible to TVMs, and
therefore TVMs may not be relevant to humans. As such, our objective was to eval-
uate the overall weight of the evidence regarding each tumor type and to derive an
OSF for acrylamide based on those tumors relevant to humans. Among the tumors
induced by acrylamide (thyroid tumors, TVMs, mammary gland tumors, CNS tu-
mors), thyroid and mammary gland tumors were considered most relevant to hu-
mans. Using the rat OSF for the combined increased incidences of thyroid and
mammary gland tumors observed in female F344 rats, we derived a human OSF
using a rat-to-human dose metric conversion factor based on serum levels of the
primary acrylamide metabolite, glycidamide (widely considered to be the putative
proximal carcinogen). The final human OSF for combined thyroid and mammary
gland tumors was determined to be 0.09 (mg/kg-day)-1. This OSF suggests a lower
cancer potency for acrylamide based on target tissues more relevant to humans. It
should be noted however, the FDA and NTP just completed a 2-year, multi-species
drinking bioassay and the results of this study may impact future OSF estimates for
acrylamide.
2222 An Evaluation of the Human Carcinogenic Potency of
Methyl Tert-Butyl Ether (MTBE): Considering New Data
and Mode of Action.
P. Sheehan and K. Bogen. Exponent, Oakland, CA.
The carcinogenic potency of MTBE was initially evaluated by State of California
scientists in 1999 based on a gavage study with rats (Belpoggi et al. 1995, 1997,
1998) and inhalation studies with rats and mice (Bird et al. 1997). Potency was es-
timated at that time using a linearized multistage model. Since then, an additional
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rodent cancer bioassay of MTBE in drinking water (Dodd et al. 2011), several
genotoxicity and mutagenicity studies, evaluations of MTBE metabolites formalde-
hyde and tert-butyl alcohol (TBA), as well as other studies providing information
on MTBE’s mode of action have been reported. In addition, the U.S.
Environmental Protection Agency (EPA) declared the data on lymphomas and
leukemias from Belpoggi et al. (Ramazinni Institute) as unreliable for risk assess-
ment raising additional uncertainty about California’s potency estimate. The new
data and remaining reliable historic rodent bioassay data were used to re-evaluate
the cancer potency or slope factor (CSF) of MTBE considering mode of action
(MOA). The overwhelming majority of studies indicate that neither MTBE nor
TBA is genotoxic. In stark contrast, formaldehyde is clearly genotoxic, but when
generated by MTBE metabolism is efficiently detoxified to preclude elevating back-
ground levels and associated genotoxic damage. Based on genotoxicity and MOA
analyses, the most likely CSF for MTBE is zero, unless chronic exposures induce
target-tissue toxicity including in sensitive individuals. A corresponding expected
CSF value for MTBE conditional on a linear MOA was estimated to be 0.000018
per mg MTBE per kg body weight per day for a chronically exposed adult. If
MTBE is carcinogenic to humans, then it is extremely weak relative to other chem-
ical carcinogens evaluated by EPA.
2223 Development of a 24-Hour Air Monitoring Comparison
Value (AMCV) for 1, 3-Butadiene and Comparison of 1-
Hour, 24-Hour, and Chronic AMCVs to Observed Adverse
Effect Levels.
R. L. Grant and R. E. Jones. Toxicology Division, Texas Commission on
Environmental Quality (TCEQ), Austin, TX.
The TCEQ develops AMCVs, which are considered safe concentrations of chemi-
cals in air, to determine whether 1-hour (hr) or annual average chemical concentra-
tions in ambient air exceed levels of potential concern for adverse health effects.
Previously for 1,3-butadiene (BD), a 1-hr AMCV of 1,700 ppb was derived based
on a mouse developmental study (6 hr/day exposures, gestational days 6-15). A
chronic AMCV of 9.1 ppb was derived based on a 1 in 100,000 excess risk for
leukemia mortality from an epidemiological study in styrene-butadiene workers. To
calculate annual ambient air concentrations, the TCEQ collects a significant
amount of 24-hr monitoring data that are not directly comparable to the 1-hr or
chronic AMCV. Therefore, the TCEQ has developed a 24-hr AMCV for BD to
evaluate the potential for health effects from 24-hr exposure. The same mouse
study used for the 1-hr AMCV was judged to be the critical study for the 24-hr
AMCV based on mode-of-action and toxicokinetic data. The 6-hr human equiva-
lent point of departure (POD-HEC) of 51,300 ppb was duration adjusted (Haber’s
rule with n = 1) to calculate the 24-hr POD-HEC of 12,800 ppb. The proposed
24-hr AMCV is 430 ppb after application of total uncertainty factors of 30. The
TCEQ has developed guidelines to derive observed adverse effects levels (OAELs)
based on available dose response data to better communicate to risk managers and
the public the margin of safety between OAELs and AMCVs. For the 6- and 24-hr
AMCVs, the acute OAEL is 66,000 ppb (the central estimate POD-HEC for 5%
decrease in fetal weight loss). The 1-hr AMCV of 1700 ppb is 39 times lower than
the acute OAEL and the 24-hr AMCV of 430 ppb is 150 times lower. The long-
term OAEL is 10,000 ppb (the lowest average occupational exposure concentration
where the likelihood ratio test that slope = 0 was statistically significant for different
maximum levels of cumulative BD ppm-years for leukemia deaths). The chronic
AMCV of 9.1 ppb is 1,100 times lower than the chronic OAEL.
2224 Health-Based 24-Hour Air Monitoring Comparison Value
(AMCV) for Acrolein in Ambient Air: Comparison to Air
Monitoring Data Collected in Texas.
A. Jenkins. Toxicology Division, Texas Commission on Environmental Quality,
Austin, TX.
Acrolein is of national and state interest because it is ubiquitous, is difficult to ana-
lyze in ambient air, and concentrations causing eye and respiratory irritation are
low. In 2011, a follow-up special monitoring project for acrolein was conducted by
the USEPA at a school near a building products manufacturing facility in Texas.
Ten 24-hour (hr) ambient air samples were collected in canisters downwind of a fa-
cility known to emit acrolein and analyzed using an improved method. The follow-
up project was done in response to finding that acrolein canister results can be af-
fected by the canister cleaning method and calibration gas standards. The TCEQ
has previously derived 1-hr and chronic health-protective AMCVs for acrolein in
order to evaluate air monitoring data. In order to evaluate the 24-hr data collected
at the school and at two other permanent monitoring sites in Texas, the TCEQ has
developed a proposed 24-hr AMCV to better evaluate the potential for adverse
health effects. Acrolein’s toxicity is mainly concentration dependent and levels caus-
ing adverse effects are similar in humans and animals. The same rat study used to
develop the chronic AMCV was selected as the critical study for derivation of the
24-hr AMCV since interim histopathology was performed after various exposure
durations (e.g., 6 hr/day for 4, 14, 30, and 65 days) which encompassed the 24-hr
duration of interest. A no-observed-adverse-effect level of 200 ppb was identified
from the key study for all exposure durations based on the absence of nasal epithe-
lial hyperplasia. Based on a mode-of-action analysis, no duration adjustment was
necessary. After correcting for animal-to-human dosimetric differences, the 24-hr
human equivalent point of departure was 37.4 ppb. Total uncertainty factors of 30
were applied to calculate the 24-hr AMCV of 1.2 ppb. In comparison, the 1-hr
AMCV for acrolein is 4.8 ppb and its chronic AMCV is 0.22 ppb. No concentra-
tions exceeding the 24-hr AMCV using the improved canister method have been
reported at monitoring sites in Texas.
2225 Protection against Toxic Effects of Arsenic by Vitamin E:
Characterization of Transplacental Arsenic Species and
Effects.
A. Sampayo-Reyes1,  R. Marcos2 and A. Hernandez2. 1Departamento de
Toxicogenética, Centro de Investigación Biomédicas del Noreste, Monterrey, Mexico;
2Departament de Genètica i de Microbiologia, Universitat Autònoma de Barcelona,
Bellaterra, Spain.
Millions of people world-wide are exposed to arsenic (As) via drinking water. As is
biotransformed for excretion, and the CH3 groups necessaries for such metabolism
are also essential to DNA methylation. Pregnant women methylate As more effi-
ciently to protect the fetus from immediate toxicity, but at the risk of latter epige-
netic deregulation. Thus, preventing early-life As exposure may be critical for the
health of future generations. In order to evaluate early-life exposure to arsenic, preg-
nant hamsters were exposed to 50 and 100 ppm of arsenite via drinking water at the
0th and 8-9th day of gestation. Co-treatment with 8.5 mg/Kg/day of selenite or 6
mg/Kg/day of vit E was also carried out to assess whether those compounds exert
any As-transplacentary protective role. To characterize arsenic speciation during
pregnancy, fetus development, unweaning and adulthood, As species were meas-
ured in the urine and/ or organs by HPLC-ICP/MS. Teratogenic effects of transpla-
centary arsenic were analyzed observing both reabsortions and embryo anomalies,
and in utero As-exposed litters were followed-up to evaluate tumor incidence at the
adult stage. Characterization of arsenic species indicates that fetuses and unweaned
offspring are As-exposed through placenta and milk, showing a speciation profile
similar to that in mothers. Results demonstrate a teratogenic As effect in a dose and
time-of-gestation dependent manner, and a noticeable protective effect of both se-
lenite and vit E.
2226 Approaches for Deriving an OEL for Peracetic Acid and
Occupational Risk Management Considerations.
N. Pechacek1,  A. Maier2 and L. T. Haber2. 1Ecolab, St. Paul, MN; 2Toxicology
Excellence for Risk Assessment, Cincinnati, OH.
To provide perspective on current and proposed occupational exposure limits
(OELs) for peracetic acid (PAA; CAS 79-21-0) we evaluated PAA toxicity with the
aim of understanding uncertainties and their implications for the resulting OEL.
The database for PAA is limited and no single study is definitive. Two unpublished
reports on human exposures to PAA provide some concentration-response data, in-
dicating that a sensitive acute effect of PAA exposure is eye and respiratory tract ir-
ritation, but the studies differ quantitatively. These differences are not surprising, in
light of the differences in exposures (apparently pure PAA vapor vs. an aerosol of a
mixture), the subjective nature of the reporting, and the likely small sample sizes.
The studies are also limited by the lack of clear concentration-duration-response
data. Nonetheless, the studies provide a reasonable estimate of the threshold for the
onset of irritation in humans in the range of 0.53 mg/m3 for up to 3 hours and 1.56
mg/m3 for up to 45 minutes. RD50 (concentration estimated to cause a 50% de-
pression in respiratory rate) data in mice and rats provide additional information on
the irritant potency of PAA. The RD50 in mice was 17 mg/m3 for pure PAA vapor
and 12 mg/m3 for a commercial mixture. The rat RD50 was 21.5 to 24.1 mg/m3.
Based on the array of human data and the RD50 values in rodents, we calculated
potential TWA OELs ranging from 0.26 to 1.56 mg/m3. A similar range of 0.62 –
2 mg/m3 is found among the published OELs, and any of these values could be jus-
tified as protective of worker health given the uncertainties in the data and the pre-
cision of the OEL methodology. More definitive sensory irritation studies would
further clarify selection of a value in this range. Given the extant data, the ultimate
OEL choice within a range of reasonable values is a policy-based risk management
decision, not a scientific one. The optimal time averaging approach is also not
clearly established by the data; however, a combination of a TWA with a STEL is
the recommended risk management option.
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2227 An Inhalation Risk Assessment for Measured Ambient Air
Concentrations of 6: 2 Fluorotelomer Alcohol.
T. L. Serex,  M. W. Himmelstein,  R. C. Buck and M. H. Russell. E.I. duPont de
Nemours & Co. Inc., Wilmington, DE.
6:2 Fluorotelomer Alcohol (CAS# 647-42-7, 1-Octanol-3,3,4,4,5,5,6,6,7,7,8,8,8
tridecafluoro-, 6:2 FTOH) is a raw material used for manufacturing surfactant and
polymeric products. 6:2 FTOH vapor phase inhalation is a potential exposure
route. The aim of the current investigation was to 1) compare the oral and inhala-
tion repeated-exposure toxicity data to confirm systemic toxicity, target organs, and
lack of an exposure route effect, 2) confirm similar metabolic and toxicokinetic pro-
files via both exposure routes, and 3) conduct an inhalation risk assessment for re-
ported ambient air concentrations. In an inhalation range-finder (5-days) and a 28-
day inhalation toxicity study, the profile of 6:2 FTOH and its metabolites in plasma
under controlled inhalation exposure was investigated as well as the systemic toxic-
ity and target organs. These studies provided a basis for toxicity comparison, plasma
metabolites, and dosimetry between inhalation and oral dosing. Similar toxicity,
metabolic and toxicokinetic profiles via both exposure routes was confirmed.
Benchmark Dose Analysis (BMD) was conducted on the subchronic toxicity end-
points to determine the most sensitive effect and the corresponding BMD associ-
ated with this effect. Based on this analysis, the corresponding human equivalent
dose (HED) was calculated to be 1.4 mg/kg bw/day. An additional assessment fac-
tor of 2 was applied to extrapolate from the subchronic exposure to a chronic expo-
sure and resulted in a final HED of 0.7 mg/kg bw/day. An equivalent air concen-
tration was determined using an allometric scaling factor to arrive at a human
equivalent concentration (HEC) of 2.5 mg/m3. This HEC was then divided by the
reported indoor and outdoor air concentrations to arrive at a margin of exposure
(MOE). MOEs calculated for inhalation exposure to indoor or outdoor air ranged
from 1.1E+05 to 2.5E+07. This assessment indicates there is no human health risk
expected even at the highest ambient air concentrations of 6:2 FTOH reported.
2228 Derivation of an Occupational Exposure Limit for Inorganic
Borates Using a Weight of Evidence Approach.
M. J. Vincent1,  A. Maier1,  E. Hack2,  P. Nance1 and W. Ball3. 1TERA,
Cincinnati, OH; 2The Henry Jackson Foundation, Bethesda, MD; 3Rio Tinto
Minerals, Greenwood Village, CO.
Inorganic borates are encountered in many settings worldwide, spurring interna-
tional efforts to develop exposure guidance (U.S. EPA 2004; WHO 2009; ATSDR
2010) and occupational exposure limits (OEL) (ACGIH 2005, MAK 2011). We
derived an updated OEL to reflect new data and current international risk assess-
ment frameworks. We assessed toxicity and epidemiology data on inorganic borates
to identify relevant adverse effects. International risk assessment frameworks (IPCS
2005; IPCS 2007) were used to evaluate endpoint candidates: reproductive toxicity,
developmental toxicity, and sensory irritation. For each endpoint, a preliminary
OEL was derived and adjusted based on consideration of toxicokinetics, toxicody-
namics, and other uncertainties. Dose-response modeling supported selection of
the point of departure for each endpoint. Developmental toxicity was the most sen-
sitive systemic effect. An OEL of 1.6 mg B/m3 was estimated for this effect based
on a point of departure (POD) of 63 mg B/m3 with an uncertainty factor (UF) of
40. Sensory irritation was considered to be the most sensitive effect for the portal of
entry. An OEL of 1.4 mg B/m3 was estimated for this effect based on the identified
POD and an UF of 1. Reproductive effects are not the most sensitive basis for OEL
derivation. An OEL of 1.4 mg B/m3 was derived as an 8-hour TWA based on sen-
sory irritation potential. The OEL is expected to protect from systemic toxicity
endpoints.
2229 US EPA Decabromodiphenyl Ether Alternatives Hazard
Assessment Results.
J. Rhoades1,  M. Kawa1,  E. Lavoie2,  C. Baier-Anderson2 and J. Tunkel1. 1SRC,
Inc., East Syracuse, NY; 2US EPA, OPPT, DfE, Washington DC.
The U.S. Environmental Protection Agency (US EPA) Design for Environment
(DfE) Program undertook a chemical alternatives assessment for decabro-
modiphenyl ether (decaBDE) as part of the Action Plan for Polybrominated
Diphenyl Ethers (PBDEs) published in December 2009. DfE convened a multi-
stakeholder partnership to explore the human health and environmental profiles of
functional and viable alternatives to decabromodiphenyl ether (decaBDE). The
partnership identified ~ 30 functional alternatives to decaBDE. The hazard assess-
ment for decaBDE and the alternatives used DfE hazard evaluation criteria to as-
sign hazard designations for human health toxicity, ecological toxicity and environ-
mental fate endpoints. The alternatives included a range of flame retardant
chemistries including both halogenated and non-halogen organic substances, inor-
ganic materials, polymeric and non-polymeric substances and novel, new to market
substances. Some alternatives were well characterized for all endpoints, while others
were lacking data. Analog data, predictive models, structural alerts and expert judg-
ment were used to make hazard designations for endpoints with data gaps. Trends
for human health, ecological toxicity and fate characteristics were indicated in a
number of the alternatives and are described in the poster. In general, molecular size
ranges, molecular structures, and/or functional groups were found to be most influ-
ential on the hazard designations. A novel component of this assessment was the
evaluation of higher molecular weight polymers for their human health and ecolog-
ical toxicity based on their low potential for bioavailability and variability in low
molecular weight components. Effective hazard assessment approaches of hazard
criteria coupled with decision-making protocols are practical tools for businesses to
use early in materials selection processes and will contribute to more sustainable
product development. The resulting hazard profiles should be of value to manufac-
turers making substitution decisions in preparation for the upcoming decaBDE
phase out.
2230 Predicting Bioavailability of Arsenic in Mining Soils.
V. L. Mitchell1,  N. T. Basta2,  S. W. Casteel3,  S. Whitacre2,  L. E. Naught3 and
P. A. Myers1. 1Toxic Substances Control, Cal EPA, Sacramento, CA; 2Ohio State
University, Columbus, OH; 3University of Missouri, Columbia, MO.
Arsenic (As) is a naturally occurring element in soil and a key chemical of concern
at former mine sites in California. Risk assessment calculations typically utilize de-
fault oral toxicity values, which are based on ingestion of readily soluble forms of As
such as sodium arsenate (NaAs). However, mining soils in California are relatively
high in iron hydroxide phases that bind As strongly, resulting in reduced solubil-
ity/bioavailability. The juvenile swine model is an approved, but often cost prohib-
itive, method for determining the relative bioavailability (RBA) of As in soils com-
pared to that of NaAs. RBAs can be used to adjust toxicity criteria, resulting in a
more accurate site-specific risk assessment. In vitro methodologies have proven to
be useful surrogates for in vivo feeding studies in predicting bioavailability for other
metals but lack precision for arsenic, particularly in high iron content soils. Six soil
samples collected from Empire Mine State Historic Park (total As 302-12,041
mg/kg) were analyzed in the juvenile swine model. RBA’s ranged from 4 to 20%.
Gastrointestinal modeling correlated but underestimated RBA (1-9%). Sequential
chemical extraction procedures (SEP) were applied to fractionate the As in soils
into (F1) non-specifically sorbed; (F2) specifically sorbed; (F3) amorphous and
poorly-crystalline oxides of Fe and Al; (F4) well-crystallized oxides of Fe and Al and
residual As phases. The results of these extractions demonstrated that the sum of
non-specifically sorbed and specifically sorbed arsenic (F1+F2) was similar to the
predicted in vitro bioaccessibility while F1+F2+F3 is a conservative estimate of the
in vivo RBA (10-50%). SEP could prove to be a cost-effective and valuable screen-
ing tool for estimating in vivo RBA. In summary, the assumption of 100% bioavail-
ability of As in mining soils grossly overestimates exposure and risk to human
health. Adjustments for As bioavailability in these materials and similar mining
wastes provides a more accurate assessment of human exposure.
2231 A Quantitative Risk Assessment of 1-Bromopropane, Based
on Tumor Data.
D. A. Dankovic1 and G. Dotson2. 1Risk Evaluation Branch, CDC/NIOSH,
Cincinnati, OH; 2Document Development Branch, CDC/NIOSH, Cincinnati, OH.
The “green” movement has resulted in the introduction of several new “environ-
mentally-friendly” substitutes into commerce, including 1-bromopropane (1-BP;
CAS no. 106–94–5). Although use of 1-BP is intended to minimize ozone deple-
tion, occupational exposure is of concern. Case studies, occupational exposure as-
sessments, and epidemiological investigations have suggested that workplace expo-
sure to 1-BP may be associated with neurological, reproductive, and hematological
effects. Previous quantitative risk assessments of 1-BP have been based on toxico-
logical studies of these and other non-cancer endpoints. This poster presents a
quantitative risk assessment based on a NTP chronic bioassay, in which rats and
mice were exposed to 125-500 or 62.5-250 ppm 1-BP, respectively, for up to 2
years. Inhalation of 1-BP produced alveolar/bronchiolar adenomas and carcinomas
in female mice, adenomas of the large intestine in female rats, and keratoacan-
thoma/squamous cell carcinoma of the skin in male rats. Benchmark concentra-
tions (BMC) and lower 95% confidence limits (BMCL) estimates at the 1 in 1000
response level (0.1%) were based on a previously published model average proce-
dure. The BMC (BMCL) estimates were 0.85 (0.41) ppm for alveolar/bronchiolar
adenoma + carcinoma; 13.5 (2.76) ppm for large intestine adenomas; and 3.73
(1.44) ppm for keratoacanthoma +squamous cell carcinoma of the skin. The BMC
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(BMCL) estimates were extrapolated to humans on a (body weight)0.75 basis, as-
suming a 45-year occupational exposure. Human-equivalent concentrations for a 1
in a 1000 lifetime added risk at the various tumor sites are 0.39 (0.19) ppm, for
lung tumors; 6.17 (1.26) ppm for intestinal tumors; and 1.75 (0.68) ppm for skin
tumors. These results suggest that even sub-ppm occupational exposures to 1-BP
may pose an increased risk of cancer.
The findings and conclusions in this report are those of the authors and do not necessar-
ily represent the views of the National Institute for Occupational Safety and Health.
2232 Human Health Risk Assessment of Inhaled Acudyne™ Shine
Polymer in Hair Care Products.
S. M. Krieger,  W. Shade,  R. Sura,  J. A. Hotchkiss and G. A. Hazelton. The Dow
Chemical Company, Midland, MI.
ACUDYNE™ Shine is one of a family of acrylic polymers used in hair care prod-
uct applications such as gels/mousses, and pump or aerosol sprays at concentrations
up to 7 wt% to enhance the properties of the product. The pattern of use provides
a potential for inhalation exposure to both consumers and salon workers. Sprague
Dawley rats were exposed 6 h/day, 5 d/wk, for two- or 13-wks to ACUDYNE™
polymer concentrations of 0, 2, 11, and 100 mg/m3 or 0, 1, 8, and 82 mg/m3, re-
spectively, to provide toxicologic data for human risk assessment. A simulated con-
sumer/occupational exposure monitoring study was conducted to determine typical
breathing zone aerosol concentrations during product use. In the 13-wk study, no
treatment-related changes in daily clinical observations, functional tests, ophthal-
mology, urinalysis, hematology, clinical chemistry, or coagulation parameters were
observed. Males and females exposed to 82 mg/m3 ACUDYNE™ had increased
mediastinal and tracheobronchial lymph nodes, higher absolute and relative lung
weights, and chronic-active bronchiolar-alveolar inflammation after 13-wks of ex-
posure. Females also had decreased feed consumption and body weight gains. The
No Adverse Effect Concentration was 8 mg/m3 for males and females. Assuming
100% deposition, the inhaled dose of ACUDYNE™ polymer at an aerosol con-
centration of 8 mg/m3 was estimated to be 0.47 mg/gm lung/day in rats. Based on
a rat-to-human inhalation dosimetry factor of 24-32, the human equivalent inhaled
dose at the same aerosol concentration was estimated to be 11.3 to 15.1 mg/gm
lung/day. Results of the exposure monitoring study indicated breathing zone con-
centrations of respirable aerosol particles of 0.38 and 0.11 mg/m3 and daily poly-
mer lung deposition of ≤ 0.19 and ≤ 0.44 μg/gm lung for consumer and occupa-
tional exposure senerios, respectively. Based on the calculated human equivalent
margin of exposure of > 25,000 to 150,000 for all exposure scenarios, repeated
daily inhalation exposure to ACUDYNE™ Shine polymer in hairspray formula-
tions poses no significant human health risk.
2233 Derivation of Acceptable Drinking Water Levels for Bromine
and Bromide-Releasing Antimicrobial Agents.
J. C. English,  V. S. Bhat and C. J. McLellan. NSF International, Ann Arbor, MI.
Elemental bromine is the active ingredient in brominating cartridges, and is regis-
tered for disinfection of drinking water aboard ships and oil drilling platforms.
Since bromine disproportionates in water to bromide (stable) and hypobromite
(unstable) ions, this assessment applies specifically to inorganic bromide, whereas
health-based guideline values for bromate and organic bromine compounds have
been developed elsewhere. Repeated oral exposure in various mammalian species is
associated with central nervous system effects expressed as behavioral and EEG
changes. Repeated oral dosing also causes a hypothyroid effect that is specific to rats
and not observed clinically. In a rat three-generation study with NaBr administered
via the diet, the NOAELs for reproductive and parental effects were 48 and 12 mg
Br/kg-day, respectively. In oral developmental toxicity studies, the NOAELs for
both parental and developmental effects were 77 and 196 mg Br/kg-day, in rats and
rabbits, respectively. Chronic administration of KBr or methyl bromide via the diet
of rats did not result in treatment-related adverse findings. There is extensive clini-
cal experience with various bromide salts based on their historical use as sedative-
hypnotics and in treatment of seizure disorders. When male and female volunteers
were administered NaBr capsules for 12 weeks, there was a small effect on EEGs
that was reproducible but within normal limits. Serum T4, T3, and related hor-
mone levels remained within normal limits. The most sensitive effect was gastric ir-
ritation expressed as nausea that occurred shortly after the ingestion of the capsules,
but no longer occurred when the capsules were taken with a meal. Based on the ab-
sence of sedation and EEG changes within normal limits, the human systemic
NOAEL was 7 mg Br/kg-day. Using a 10x uncertainty factor to account for in-
traspecies variability, an RfD of 0.7 mg/kg-day was determined for bromide, which
corresponds to a Total Allowable Concentration of 12 mg/L in drinking water and
accounts for exposure of the general population to bromide from the diet.
2234 Low-Level Arsenic in Drinking Water and Bladder Cancer
Risk: Meta-Analysis Update and Risk Assessment
Implications.
J. S. Tsuji1,  D. D. Alexander2 and V. Perez3. 1Exponent, Bellevue, WA; 2Exponent,
Boulder, CO; 3Exponent, Chicago, IL.
A published meta-analysis of relevant case-control and cohort studies was updated
with two recent studies to further examine the association between low-level arsenic
exposure and bladder cancer risk, and whether meta relative risks (mRR) differed
significantly from bladder cancer risks predicted in a 2001 report by the National
Research Council (NRC). Cancer risk estimates from NRC (2001), which are
based on data from southwestern Taiwan, form the basis of the U.S. Environmental
Protection Agency’s 2010 proposed cancer slope factor for assessing arsenic cancer
risks. Our updated meta-analysis of nine studies improved the precision of the pre-
vious estimate (mRR = 1.11; 95% CI: 0.95–1.30), with no significant association
observed between low-level arsenic exposure and bladder cancer (1.07; 0.95–1.26;
p-heterogeneity = 0.54). RRs for never-smokers in the individual studies and the
mRR were consistently below 1.0 (0.83; 0.65–1.06; p-heterogeneity = 0.89). Thus,
exposure misclassification/regression to the null cannot explain the lack of a signif-
icant positive relationship for never-smokers. The mRR was modestly elevated for
ever-smokers, but not significantly, with heterogeneity among studies (1.19;
0.95–1.45; p-heterogeneity = 0.04). To evaluate the independent effect of arsenic in
comparison to NRC (2001) risk estimates for the U.S., the mRR for bladder cancer
in never-smokers was compared to RRs predicted by NRC (2001) at various water
concentrations within the low-level studies and for less than lifetime exposures. The
collapsed category mRR for never smokers was 0.82 (0.62-1.10) (using cut-points
in individual studies near 50 ppb) and was compared to RRs calculated for non-
smokers in the U.S. based on NRC (2001). The 95% CI did not include NRC pre-
dicted RRs at 20 or 50 ppb, even for half lifetime exposures (RRs of 1.14 and 1.31,
respectively). Results of low-level studies differed significantly from, and were in-
consistent with, risks predicted by NRC (2001) for non-smokers including those
with less than lifetime exposure.
2235 A Chronic Oral Reference Dose for Hexavalent Chromium.
C. M. Thompson1,  C. R. Kirman2,  D. M. Proctor3,  M. Suh3,  S. M. Hays4,
L. C. Haws5 and M. A. Harris1. 1ToxStrategies, Katy, TX; 2Summit Toxicology,
Orange Village, OH; 3ToxStrategies, Rancho Santa Margarita, CA; 4Summit
Toxicology, Allenspark, CO; 5ToxStrategies, Austin, TX.
Intestinal tumors have been observed in mice (but not rats) following chronic ex-
posure to high concentrations of hexavalent chromium [Cr(VI)] in drinking water.
Mice (but not rats) also exhibit histological lesions consistent with intestinal
wounding, specifically villous blunting and crypt hyperplasia—collectively termed
diffuse hyperplasia. Recent mode of action studies support that these tumors were
indeed the result of chronic wounding and regenerative hyperplasia to repair the in-
testinal mucosa. Herein, we develop an oral reference dose (RfD) that is protective
of the tumor precursor lesion (diffuse hyperplasia), and therefore is protective of in-
testinal cancer. A rodent physiologically based pharmacokinetic (PBPK) model was
used to predict internal dose measures for chromium in the duodenum, jejunum,
and ileum of mice under the conditions of the 2-year bioassay. These internal dose
metrics together with corresponding incidences for diffuse hyperplasia in each in-
testinal segment were used to characterize the dose-response relationship for the
small intestine in a single plot containing a robust dataset with as many as 24 data
points. Points of departures (PODs) were derived using benchmark dose modeling
and global nonlinear regression, with models providing acceptable fits differing <3-
fold. Human equivalent lifetime average dose values were estimated for each POD
using two different methods of extrapolation with the human PBPK model for
chromium. Dividing the PODs by uncertainty factors (UFs) of 10-30 yields a
range of 8 RfD values (2 modeling approaches × 2 human equivalent dose methods
× 2 UF values). The resulting RfD range is protective against diffuse hyperplasia,
and is therefore protective of both noncancer and cancer effects in the small intes-
tine. This range of RfD values leads to acceptable Cr(VI) concentrations in drink-
ing water that are greater than those typically found in drinking water sources (≤5
μg/L).
2236 Mode-of-Action Evaluation for Hexavalent Chromium-
Induced Lung Cancer.
D. M. Proctor1,  M. Suh1,  C. M. Thompson2 and M. A. Harris2. 1ToxStrategies,
Rancho Santa Margarita, CA; 2ToxStrategies, Katy, TX.
Inhalation of hexavalent chromium [Cr(VI)] has been associated with increased
lung cancer risk among workers of certain industries, but no well recognized or
published mode of action (MOA) exists. Although it has been suggested that
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Cr(VI) acts by a mutagenic MOA because it damages DNA in vitro and in some in
vivo tests, several recent reviews have concluded that Cr(VI) is only weakly muta-
genic and that genetic/epigenetic changes resulting in genomic and/or microsatel-
lite instability, inflammation, oxidative stress and deregulation of repair mecha-
nisms play a role in carcinogenicity. Further, recent data for mouse small intestinal
cancers caused by Cr(VI) in drinking water support a cytotoxic MOA involving
chronic intestinal wound and healing. Using the modified Hill Criteria, we have re-
viewed kinetic, human, animal, and mechanistic data to develop a lung cancer
MOA; evaluated plausibility, dose-response, and temporal concordance; and con-
sidered alternative MOAs. Among workers with an observed increase in lung can-
cer, respiratory tissue irritation and inflammation were common clinical findings,
and in animal studies irritation and inflammation precede tumor formation in dose
(≥50 μg/m3) and time (within 30 days), suggesting that cytotoxicity and inflam-
mation are early key events. The overall evidence supports that Cr(VI) induces lung
cancer by a non-mutagenic MOA involving oxidative stress, cytotoxicity, and in-
flammation, causing oxidative DNA damage, epigenetic DNA modifications and
genomic instability, occurring at the high exposure concentrations. Further, extra-
cellular Cr(VI) reduction in the lung limits absorption and may introduce non-lin-
earity in the extrapolation of tissue dose from high to low exposures. Based on these
findings, the risk assessment for inhalation exposure to Cr(VI) should consider in-
tensity-based dose metrics and non-linear low dose extrapolation approaches.
2237 A Screening Level Assessment of the Health and
Environmental Hazards of Organohalogen Flame Retardants.
D. A. Eastmond,  V. S. Bhat and K. Capsel. Environmental Toxicology Graduate
Program, University of California, Riverside, CA.
Organohalogen flame retardants are extensively used in both industrial and con-
sumer products. However, relatively little is known about the potential of many of
these chemicals to cause adverse health and environmental effects. To address this,
we conducted a health and environmental hazard screening of almost 100 bromi-
nated or chlorinated flame retardants based on the GreenScreen® or Quick
Chemical Assessment Tool (QCAT®) methodologies. Priority consideration was
given to human health hazards such as carcinogenicity (including mutagenicity and
genetic toxicity), reproductive or developmental toxicity, endocrine disruption, and
acute mammalian toxicity. Environmental hazards given priority consideration in-
cluded acute aquatic toxicity, persistence, and bioaccumulation. Using publicly
available information, each hazard category was assigned a concern level (low, mod-
erate, high, or very high) based on pre-defined numerical ranges, such as no-ob-
served adverse effect levels, and hazard classification schemes from authoritative
sources, when available. Less than 10% of the screened chemicals had empirical
data to assess each priority hazard category. Where empirical data were not identi-
fied, structure activity relationship (SAR) models were relied upon to predict haz-
ard potential. After assigning concern levels for each priority health effect, each
chemical received a score, similar to a report card (A, B, C, D, or F). The majority
of the screened chemicals received either a D or F grade due to empirical data sug-
gesting high hazard, SAR model predictions, and/or excessive data gaps.
Carcinogenicity was the most prominent potential health hazard identified based
on empirical data. The most prevalent data gap was endocrine disruption due to the
lack of identified empirical data or computer models able to predict this hazard.
This study highlights the limited toxicity information available for these widely
used chemicals, and indicates that more testing and oversight is critically needed to
identify safer alternatives for fire prevention.
2238 Air Quality and Human Health Risks Along the Texas Gulf
Coast.
T. Bredfeldt and D. McCant. Toxicology, Texas Commission On Environmental
Quality, Austin, TX.
There are several urban and industrial regions along the Texas Gulf Coast that
house some of the largest ports in the US, numerous refineries, thousands of chem-
ical/petrochemical facilities and manufacturing plants. Given its dense population
and industrial activity, monitoring and regulation of air quality in these regions is
critical for protection of human health. The TCEQ has developed the largest ambi-
ent air monitoring network in the US to measure cumulative emissions in the area.
In the coastal regions alone, there are more than 47 fixed-site air monitors (17
AutoGCs and 30 canisters), some of which have been operational for 20 years.
Acrolein, benzene, 1,3-butadiene, and formaldehyde are considered air toxics of
greatest concern. To evaluate risks associated with these air toxics, we collected site-
specific concentrations of these four chemicals and evaluated them from both an
acute and chronic health perspective by comparing them to TCEQ health-protec-
tive values called ambient air monitoring comparison values (AMCVs). We calcu-
lated average annual concentrations measured by1-h AutoGC or 24-h canister and
found that concentrations of these air toxics have steadily declined. Using long-
term average concentrations of these air toxics, we calculated long-term risks to be
within our acceptable risk goal (< 1 E-5) or a hazard quotient (<1) for the majority
of monitoring sites. The long-term average benzene concentration at Lynchburg
Ferry and Huisache monitors reached concentrations that resulted in risk (1.8 and
1.1 E-5, respectively) slightly above our risk goal. To better understand dynamics of
air toxics at sites with a history of exceeding the long-term AMCV, we used 1-h
AutoGC data to characterize ambient conditions contributing to exceedances. We
found exceedances of the respective acute AMCVs to be rare. Instead, a few (<30%)
hourly concentrations influenced the average concentration thereby causing long-
term exceedances. The decline in air toxics concentrations due to improved moni-
toring and regulations has now resulted in air toxics at acceptable levels at all mon-
itors in the coastal region.
2239 Assessment of Potential Perchlorate Exposures from the Use
of Household Chlorine Bleach.
T. Lewandowski1, 2. 1Gradient, Seattle, WA; 2Health and Nutrition Sciences,
Brooklyn College/City University of New York, Brooklyn, NY.
US Government surveys have indicated that perchlorate (ClO4) occurs at low lev-
els (generally below 4 μg/L) in many U.S. public water supplies systems.  Although
small amounts of perchlorate in water may be due to natural processes, the higher
concentrations of perchlorate found in some drinking water supplies (up to 100
μg/L) are believed to be the result of past use of ClO4 in aeronautics, explosives
and/or fireworks, which subsequently affected nearby water bodies or watersheds.
The potential health consequences of exposure to low concentrations of ClO4 in
drinking water remain controversial, with disputed epidemiology findings and
questions about the relevance of animal study data to humans. Because a small
amount of ClO4 is produced by the normal decomposition of chlorate in house-
hold chlorine bleach, we examined whether the use of bleach under various scenar-
ios could lead to exposures associated with possible health effects. We considered
bleach of different ages and different label strengths and used a temperature- and
time-sensitive model to estimate the decomposition of chlorate to ClO4. Predicted
ClO4 concentrations in bleach ranged from 1 to 34 mg/L. The exposure scenarios
considered addressed the use of bleach for household laundry, emergency water de-
contamination, “shock treatment” of private drinking water wells, and regular treat-
ment of water in private swimming pools. In each case, our analysis indicated that
potential exposures to ClO4 from the use of chlorine bleach would be well below
levels associated with potential health effects. For example, the maximum ClO4 ex-
posure of a pregnant woman drinking water sanitized with chlorine bleach in an
emergency decontamination situation was estimated at 0.2 μg/kg-day, 35 times less
than the dose associated with minimal effects on iodide uptake in humans. Thus
the presence of ClO4 as a decomposition product in household bleach does not
pose an adverse health risk for consumers.
2240 Derivation of a Reference Dose for Resorcinol.
B. H. Magee. Risk Assessment, ARCADIS, Chelmsford, MA.
Resorcinol is a common chemical used in industry. US EPA has no final or provi-
sional toxicological criteria for resorcinol. In 2004, a critical analysis of the toxico-
logical database was performed with the purpose of deriving a scientifically reason-
able Reference Dose (RfD).  Key studies, critical effect(s) and associated doses (No
Observed Adverse Effect Levels (NOAELs) and/or Lowest Observed Adverse Effect
Levels (LOAELs) are identified and adjusted using uncertainty factors (UFs) to de-
termine an oral RfD. 
The analysis of available information from epidemiological studies and animal
studies at the time established the one-generational dose range finding study con-
ducted by WIL Research Laboratories (WIL, 2003) and sponsored by the
Resorcinol Task Force (RTF) as the definitive study from which to derive the RfD.
It identified thyroid toxicity as the critical effect of resorcinol exposure and 61
mg/kg-day as the NOAEL. The derived RfD was 2 mg/kg-day. The RfD was en-
dorsed and approved by a Toxicology Excellence for Risk Assessment (TERA)
Independent Peer Review Panel and approved by the Pennsylvania Department of
Environmental Protection’s (PaDEP’s) Cleanup Standards Science Advisory Board
(“CSSAB”) in 2004. 
Soon after that time, a full two-generational reproductive toxicity study was com-
pleted (WIL, 2005) and published (Welsch et al., 2008). The NOAEL from this
definitive study for the same critical effect was 375 mg/kg-day, and the correspon-
ding RfD is 13 mg/kg-day using the WIL (2005) results, thus indicating that the
RfD of 2 mg/kg-day endorsed by the TERA Panel and approved by PaDEP in 2004
was health-protective. 
Meanwhile, other regulatory regimes, such as REACH have focused on a more lim-
ited list of critical effects in order to derive the relevant Derived No Effect Levels
(DNELs) for the development of Chemical Safety Assessments. This can lead to
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outcomes which differ from those outlined above and are often even more conser-
vative. This paper explores the background to these divergences and highlights that
the context under which an RfD or DNEL is developed has a significant bearing on
the final determination made.
2241 Risk Estimates for Dioxins, Furans, and PCBs in Edible Fish
and Shellfish at the San Jacinto River Waste Pits, Texas, USA.
E. S. Williams,  S. Usenko and B. W. Brooks. Environmental Science, Baylor
University, Waco, TX.
From the 1960s to the early 1980s, paper process wastes were disposed of at a pits
site on the San Jacinto River. Eventually the pits subsided into the river, spreading
polychlorinated dioxins, furans, and biphenyls into the adjacent aquatic ecosystem.
Consumption advisories have been in place for local fish and shellfish since 1990.
The San Jacinto River Waste Pits site was identified during a Total Maximum Daily
Loads process, and was added to the National Priorities List in 2008. Previous ef-
forts to characterize bioaccumulation of chlorinated compounds on the site in-
cluded sampling of sediment and thirteen species of fish and shellfish. During the
sampling period, numerous persons were observed fishing on or near the site.
Important fish and shellfish consumed from the area appear to be clams
(Mercenaria spp.), blue crabs (Callinectes sapidus), and black drum (Pogonias
cromis). Mean TCDD concentrations in clams, crabs, and fish from the site were
28, 3.6, and 2.25 pg/g wet weight, respectively. TCDF was the only other
dioxin/furan congener detected, but ten dioxin-like PCBs were observed in these
samples. Excess lifetime cancer risk estimates posed by consumption of contami-
nated fish and shellfish were calculated using default exposure parameters; risk esti-
mates for reasonable maximum exposures ranged from 1.2 * 10-5 to 1.51 * 10-4.
Risks in excess of 10-4 under these parameters are associated only with consump-
tion of clams from the site, and lower exposure frequency would be expected.
Considerations of spatial sampling sufficiency, multiple exposure scenarios, associ-
ated risk estimates, and analysis of uncertainty will be presented.
2242 Evaluation of the Glyphosate Developmental Toxicity
Database: Absence of Potential for Cardiovascular
Malformations.
A. Williams,  G. Kimmel,  C. Kimmel and J. DeSesso. Exponent, Alexandria, VA.
The herbicide glyphosate has undergone multiple safety tests for developmental
toxicity in rats and rabbits. The European Commission’s 2002 review of available
glyphosate data (European Commission, 2002; BBA, 1998-2000) discusses, in par-
ticular, specific heart defects observed in individual rabbit developmental toxicity
studies, but describes the evidence for a potential causal relationship as equivocal.
The present assessment was undertaken to analyze the body of information gener-
ated from the seven unpublished rabbit studies submitted to European regulatory
agencies in order to determine if glyphosate poses a risk for cardiovascular malfor-
mations. In addition, the results of six unpublished developmental toxicity studies
in rats were considered. Five of the seven rabbit studies (dose range: 10-500
mg/kg/day) were GLP- and testing guideline-compliant for the era in which the
studies were performed; a sixth study predated testing and GLP guidelines, but
generally adhered to these principles. The seventh study was judged inadequate. In
each of the adequate studies, offspring effects occurred at or above doses that caused
maternal toxicity. An integrated evaluation of the six adequate studies, using con-
servative assumptions, demonstrated that neither the overall malformation rate nor
the incidence of cardiovascular malformations increased with dose up to the point
where severe maternal toxicity was observed (generally ≥150 mg/kg/day). Random
occurrences of cardiovascular malformations were observed across all dose groups
(including controls) and did not exhibit a dose-response relationship. In the six rat
studies (GLP and testing guideline compliant; dose range: 30-3500 mg/kg/day), a
low incidence of sporadic cardiovascular malformations was reported that was
clearly not related to treatment. In summary, assessment of the entire body of the
developmental toxicity data reviewed fails to support a potential risk for increased
cardiovascular defects as a result of glyphosate exposure during pregnancy.
2243 Oral Risk Assessment for Isooctane—A Class-Based
Approach Using the Surrogate n-Hexane.
B. Wang1,  P. Undesser2 and M. Whittaker1. 1ToxServices LLC, Washington DC;
2Water Quality Association, Lisle, IL.
Isooctane is a volatile liquid commonly found in gasoline. It is principally released
into the environment via the manufacture, use and disposal of products associated
with the petroleum industry. Although the most likely route of human exposure to
this chemical is through inhalation, products such as polyethylene pipes used for
distribution of drinking water can release it in water, and it has high oral absorp-
tion. NSF/ANSI 61 Annex A (2012) risk assessment guideline was used to deter-
mine an acceptable level of isooctane in drinking water. Weight of evidence indi-
cates that isooctane is not mutagenic or carcinogenic. All the available repeated
dose oral studies are short term in nature and the majority was designed to address
the α2u-globulin-associated renal toxicity, which is specific to male rats and not rel-
evant to humans. Thus, insufficient data are available to establish an oral reference
dose (RfD) for isooctane. Since isooctane is categorized into the aliphatic EC5
(equivalent carbon) to EC8 fraction of petroleum hydrocarbons, a class based ap-
proach was taken. Most of the limited oral studies available for the chemicals in this
fraction were performed on n-hexane. Relevant critical health effects with n-hexane
exposure are peripheral neuropathy, reduced body weight and testicular atrophy.
Many groups and agencies used n-hexane as a representative of this fraction, which
is known to significantly overestimate the toxicity of these chemicals, and different
RfD values were derived for n-hexane using different approaches. After comparing
these assessments, we chose to use the most conservative, duration-adjusted lowest
observed adverse effect level of 407 mg/kg/day established from a subchronic gav-
age study in rats, and a composite uncertainty factor of 3000 to calculate the RfD
of 0.12 mg/kg/day for isooctane. Based on this value, a total allowable concentra-
tion of 840 μg/L was derived. This drinking water action level is protective of pub-
lic health since it used the more toxic n-hexane to fill the data gap, and it has a mar-
gin of exposure of over 15,000.
2244 Deriving Dermal Safe Harbor Levels for DEHP Relevant to
Consumer Products for Adults.
T. Jonaitis,  J. W. Card and L. Haighton. Intertek Cantox, Mississauga, ON,
Canada.
Di(2-ethylhexyl)phthalate (DEHP), a plasticizer in various consumer products, is
listed as a chemical known to the State of California to cause cancer and reproduc-
tive toxicity. The Proposition 65 Safe Harbor Levels (SHL) for DEHP include a
Maximum Allowable Dose Level (MADL) for DEHP, specific to the oral route, of
410 μg/day for adults (58 μg/day for infant boys; 20 μg/day for neonatal boys).
The No Significant Risk Level (NSRL) for cancer of 310 μg/day, while not route-
specific, was based on an oral study. While DEHP in children’s toys is of concern
due to mouthing behavior, most 60-day notices of violation for DEHP are related
to consumer products intended for adults. Thus, there is a need for realistic, der-
mal-specific SHLs and accurate calculations of exposure. From studies on dermal
absorption of DEHP from plastic film (present at 25.5 mg/cm2 of film, or 40.37%
w/w) applied to the skin of rats (used as a conservative estimate of migration of
DEHP from a product into the human body since rats have a higher dermal ab-
sorption than humans), a maximum dermal absorption of 0.1% was determined.
Comparatively, the reported oral bioavailability of DEHP is 25%. Using these val-
ues, the dermal MADL would correspond to 102,500 μg/day for adults (410
μg/day x 0.25 oral absorption fraction/0.001 dermal absorption) and the dermal
NSRL would be 77,500 μg/day. From the same study, a dermal absorption rate of
DEHP from the plastic was calculated to be approximately 0.24 μg/cm2/hour for
the rat which corresponds to 0.016 μg/cm2/hour for humans, given observed
species differences. This value can be used to calculate dermal exposures with cor-
rection for differing concentrations. Also, a migration rate of 1.4 μg/cm2/hour can
be used to determine the DEHP skin loading for estimating transfer of DEHP
from a consumer product onto the hands, and then directly and indirectly to the
mouth for comparison to the oral SHLs. In summary, route-specific SHLs are con-
sidered useful for realistically estimating risks associated with exposure of adults to
DEHP from consumer products.
2245 Microfluidic Steroidogenesis Assays for In Vitro Toxicant
Screening.
A. B. Theberge1, 2, 3,  E. Berthier4,  C. J. Hedman5,  B. P. Casavant2,  N. P. Keller1,
4,  W. A. Bushman1, 3 and D. J. Beebe1, 2. 1Molecular and Environmental Toxicology,
University of Wisconsin-Madison, Madison, WI; 2Biomedical Engineering, University
of Wisconsin-Madison, Madison, WI; 3Urology, University of Wisconsin-Madison,
Madison, WI; 4Medical Microbiology and Immunology, University of Wisconsin-
Madison, Madison, WI; 5Institute for Clinical and Translational Research, University
of Wisconsin-Madison, Madison, WI. Sponsor: C. Bradfield.
Many endocrine disrupting compounds act by interrupting steroidogenesis, thus
disrupting subsequent processes that rely on steroids for signaling such as hormone-
mediated pathways crucial for development. High-throughput in vitro assays are re-
quired to identify such compounds efficiently. Liquid chromatography-mass spec-
trometry (LC-MS) is a gold standard technique for steroid characterization and
quantification, but traditional methods for steroid extraction with organic solvents,
typically used to remove matrix components prior to LC-MS, require many manual
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steps, thus presenting a bottleneck for steroid analysis. To expedite steroid extrac-
tion, we developed an integrated microfluidic device consisting of a bottom chan-
nel for cell culture and a top channel in which steroids are extracted directly from
culture media into organic solvent. The top channel is accessible with a pipette or
robot liquid handler, which can be used to transfer the sample to an LC-MS au-
tosampler for analysis. We extracted cortisol solutions of known concentration to
demonstrate consistent extraction over a range of biologically relevant concentra-
tions spanning two orders of magnitude. We validated this microfluidic system
with the human adrenocortical cell line H295A, demonstrating that these cells pro-
duce steroids in microculture and respond to cAMP, a known stimulant of steroido-
genesis. Microfluidic extraction was used to isolate a panel of steroids including
cortisol, cortisone, 11-deoxycortisol, and testosterone, which were quantified using
LC-MS. In addition to high-throughput toxicant screening, the microfluidic plat-
form holds great potential for steroidogenesis assays with limited samples, such as
primary cells. Funded by NIH T32ES007015.
2246 An Improved In Vitro Method for Determining Chemical
Effects on Steroidogenesis Using LC/MS/MS to Monitor
Multiple Steroid Hormones Combined with Gene
Expression.
C. M. Toole1,  H. Wagner1,  K. Lewis2 and J. M. McKim1. 1CeeTox, Inc.,
Kalamazoo, MI; 2OpAns, LLC, Durham, NC.
Steroid hormones play vital roles in development. Environmental compounds can
impact the steroidogenic pathway producing a wide range of effects. Quantifying
multiple steroids from a single biological sample, coupled with gene expression of
the enzymes that form them, allows for a better evaluation of these effects. The
human adrenal H295R cell line is currently used by the Environmental Protection
Agency (EPA) to screen for chemical effects on steroidogenesis by evaluating pro-
duction of Estradiol (E2) and Testosterone. Following EPA guidelines, 22(R)-hy-
droxycholesterol (22RHC) can be added (20-40 μM) to the culture medium to in-
crease basal production of E2. Addition of 22RHC to the H295R culture medium
bypasses steroidogenic acute regulatory protein (StAR). To evaluate the induction
mechanism of 22RHC, H295R exposures were conducted using both 22RHC and
forskolin, a known inducer of steroidogenesis. 22RHC and forskolin were adminis-
tered to cells at 0.4, 1, 4, 10, 20 and 40 μM and 0.03, 0.2, 0.3, 1, 3 and 10 μM, re-
spectively for 48 hr. RT-PCR was used to quantitate the expression of 9 steroido-
genic genes and LC/MS/MS was used to measure hormone levels of 12 steroids.
Forskolin was found to upregulate mRNA of CYP11B2, HSD3B2, CYP21A2,
CYP17A1, CYP19A1 in a dose-dependent manner. StAR mRNA was also in-
creased at the highest exposure concentration. No significant upregulation of
mRNA was observed in the 22RHC-exposed cells within the solubility limit.
Steroid levels from LC/MS/MS displayed first and zero order enzyme kinetics.
LC/MS/MS results showed that 22RHC exposures significantly increased early
event markers (e.g., progesterone, pregnenolone, DOC, and 11 DOC), whereas
forskolin exposures resulted in higher levels of most steroids. These results demon-
strate that steroid genes are not regulated by a positive feedback loop in 22RHC ex-
posed cells. This study shows that evaluation of multiple steroid levels combined
with gene expression provides a more complete picture of steroidogenesis.
2247 Mapping Pathways of Endocrine Disruption in MCF-7 Cells:
2D and 3D Culture Systems.
M. M. Vantangoli,  S. Hall and K. Boekelheide. Brown University, Providence, RI.
It is becoming increasingly important to identify endocrine-active compounds early
in toxicity testing, placing weight on the use of in-vitro screening. Currently, the
pathways of endocrine disruption are being mapped in response to estrogenic com-
pounds. In this study, human breast adenocarcinoma MCF-7 cells are being uti-
lized to map pathways of endocrine disruption following exposure to estrogenic en-
docrine-active compounds. Our study utilizes two models, a 2-dimensional system
representative of classical in-vitro studies, and a scaffold-free 3D culture system.
Both systems follow a protocol that includes 72 hours of growth in media contain-
ing 10% FBS for 72 hours, followed by 48 hours in media containing 5% stripped
serum. Treatments with compounds of interest begin following the 48 hours.
Preliminary data shows that our 2D system is responsive to estrogenic compounds
including estradiol, DES and BPA across several endpoints, including cell prolifer-
ation and protein expression. Over a range of concentrations of estradiol
(0.01nmM-100nM) and times (1, 3, 6, and 12 hours) analysis of gene expression
showed increases in classical estrogen responsive genes including progesterone re-
ceptor (1.5-3.5 fold), cathepsin D (1.5-2 fold), estrogen-inducible pS2 (1.5-4 fold)
and GREB1 (4-14 fold) at concentrations as low as 0.01nM estradiol. These results
were also shown by Western blotting, with time-dependent increases in pS2 and
GPR30 following estradiol stimulation. Our 3D system exhibits cell-contacts and
morphology that may play an important role in evaluating toxicities of estrogenic
endocrine-active compounds. Here, we show the potential use of both 2D and 3D
culture of MCF-7 cells to assess the estrogenic activities of suspected endocrine-ac-
tive compounds.
2248 Cell-Specific Control of Estrogen Response Mechanisms in
HeLa-9903 and T47D-KBluc Cell Lines.
D. Blakeman,  B. Meyer,  A. Hulett,  J. M. McKim and C. M. Toole. CeeTox, Inc.,
Kalamazoo, MI.
Estrogen signaling can be adversely affected by endocrine disrupting chemicals via
agonism or antagonism. Cell lines capable of detecting agonism and antagonism are
useful screening tools for determining estrogenic activity of chemicals.
Transcriptional effects of the Estrogen Receptor (ER) are modulated by interactions
with coregulatory proteins that function as either coactivators (agonism) or core-
pressors (antagonism). Selective ER modulators (SERMs), such as tamoxifen, favor
recruitment of corepressors that inhibit transcriptional activity. In different tissues,
tamoxifen can have partial-agonist-antagonist activities which may be related in
part to the milieu of ER coactivators and corepressors in these tissues. To further
elucidate effects of SERMs on transcriptional activity, agonism and antagonism was
evaluated using reporter gene assays in two cell types, hERα-HeLa-9903, derived
from a human cervical tumor, and T47D-KBluc, stably transfected breast cancer
cells. Cells were acclimated in 96-well plates and exposed for 24 hr to tamoxifen
(TAM), 4-OH tamoxifen (4HTAM), raloxifen (RALOX), estradiol (E2), dihy-
drotestosterone (DHT), corticosterone (CORT), or 17-methyltestosterone (MT).
Cytotoxicity, luminescence, and solubility were measured. An agonist response was
demonstrated for TAM, RALOX and 4HTAM in hERα-HeLa-9903 cells, but not
T47D-KBluc. Antagonism also showed distinct results for the two cell types where
T47D-KBluc cells demonstrated a potential additive effect with 4-HTAM and the
maximal response was 4-fold higher than E2. RALOX and TAM also demonstrated
enhanced responses in hERα-HeLa-9903 cells. Because T47D-KBluc cells have en-
dogenous ERα and ERβ, and hERα-HeLa-9903 cells have exogenous ERα, cou-
pled with the fact that corepressors and activators may be different in breast and
cervical tissues, the resulting mechanisms controlling agonism and antagonism may
be regulated, at least partially, by separate and distinct gene signaling mechanisms.
These findings show that measuring estrogenic activity in two cell lines may pro-
vide a more accurate assessment of estrogen response.
2249 Profiling of ERα-Coregulator Binding As a Means for
Functional Classification of Unknown Endocrine Disruptors.
R. Houtman1,  S. Wang2, 3,  J. M. Aarts2, 3,  W. Westerink4,  B. J. Blaauboer5,
T. Bovee2 and R. van Beuningen1. 1PamGene International BV, Den Bosch,
Netherlands; 2RIKILT-Institute of Food Safety, Wageningen UR, Wageningen,
Netherlands; 3Division of Toxicology, Wageningen UR, Wageningen, Netherlands;
4Wil Research, Den Bosch, Netherlands; 5Division of Toxicology, Institute for Risk
Assessment Sciences, Utrecht, Netherlands.
Testing chemicals for their endocrine-disrupting potential, e.g. interference with es-
trogen receptor alpha (ERα) signaling, is an important aspect of chemical safety
profiling. Due to drawbacks of in vivo testing, the development of in vitro alterna-
tives has a high priority. In a previous study, we have demonstrated an in vitro assay
which profiles binding of (un)liganded nuclear receptors to a microarray of coregu-
lator-derived peptides, as a good candidate. Here, a set of 13 model compounds,
US-EPA recommended for ERα gene reporter assay proficiency testing, was used to
assess reproducibility, robustness and added value of our assay. ERα-coregulator
binding profiles in the presence of a concentration series of each compound were
generated. With a median coefficient of variation of 5% and excellent correlation
(R2=0.99) between duplicate measurements, the uncertainty level of the peptide
microarray was well within the range observed for other commonly used in vitro
ER functional assays. Per compound, a dose-response curve for each ERα-coregula-
tor interaction was constructed. Our results show correct prediction of estrogenic-
ity for 12 out of 13 tested compounds. The potency ranking for 9 out of the 10 ER-
agonists exactly matched that for transcriptional activation as reported by
ICCVAM and US-NIEHS with excellent correlation (R2=0.98). Moreover, unsu-
pervised classification (Hierarchical clustering, Euclidean distance, average linkage)
with the compound-characteristic ERα-coregulator binding profiles results in
structurally related compounds to cluster together, whereas the steroid test com-
pounds having an aromatic A-ring were separated from those with a cyclohexene A-
ring. This latter feature should be exploited to build a prediction model to enable
classification of unknown toxicants by comparison with pre-profiled references.
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2250 Validation of the Yeast Estrogen and Yeast Androgen Screens
for Endocrine Active Substances: Interlaboratory Ring Trial.
C. Woitkowiak1,  T. Ramirez1,  H. Hüner1,  C. Schönlau2,  H. Hollert2,
S. Broschk3,  O. Zierau3,  G. Vollmer3,  M. Jäger4,  A. Poth4,  E. Higley5,
M. Hecker5,  B. van Ravenzwaay1 and R. Landsiedel1. 1Experimental Toxicology
and Ecology, BASF SE, Ludwigshafen am Rhein, Germany; 2RWTH, University of
Aachen, Aachen, Germany; 3Technical University Dresden, Dresden, Germany;
4Harlan Cytotest Cell Research GmbH, Roβdorf, Germany; 5University of
Saskatchewan, Saskatoon, SK, Canada.
Endocrine disruptor compounds (EDCs) are a group of natural or synthetic com-
pounds that have the capacity to interact with the endocrine system of living or-
ganisms and consequently causes adverse health effects in an intact organism, or its
progeny, or (sub)populations. Due to the impact that this interaction could have on
human health, there is an increasing interest in assessing the risk of the exposure to
EDCs. Currently, several in vitro and in vivo assays have been developed and few of
them validated and regulatory accepted. For instance, the US EPA developed the
Endocrine Disruptor Screening Program, which has been recently implemented.
For the program a large number of experimental animals will be still use used even
for testing some of the in vitro assays. Herein, we performed the inter-laboratory
validation of two robust models that addresses agonistic and antagonist effect at the
human hormone receptor, the YES (Yeast Estrogen Screen) and the YAS (Yeast
Androgen Screen). Both assays are non-animal alternatives to the estrogen and an-
drogen receptor binding assays proposed in the EDSP and OECD Conceptual
Framework. The ring trial is the final experimental part of the validation process at
the European Center for Validation of Alternative Methods (ECVAM). A set of 24
blinded compounds (7 estrogens and 6 androgens of diverse potency, 3 anti-estro-
gens, 3 anti-androgene and 5 negative compounds) have been tested in five differ-
ent laboratories. The analysis of the first phase of this ring-trial already demon-
strates a high reproducibility for both methods among the different participating
laboratories.
2251 Comparison of the Manual and Quantitative High-
Throughput Versions of the BG1Luc Estrogen Receptor
Transactivation Test Method.
P. Ceger1,  W. Casey2,  J. Strickland1,  L. Rinckel1 and W. Stokes2. 1ILS, Inc.,
Research Triangle Park, NC; 2NTP/NICEATM, NIEHS, Research Triangle Park,
NC.
NICEATM conducted an international validation study of the BG1Luc estrogen
receptor (ER) transactivation (TA) test method. The test method evaluation report
was reviewed and the method accepted by U.S. regulatory agencies and the
Organisation for Economic Co-operation and Development. In 2011, NICEATM
nominated the BG1Luc ER TA to Tox21 to be evaluated for adaptation into a
quantitative high throughput screening (qHTS) assay. The Tox21 collaboration, an
effort by the National Toxicology Program, NIH Chemical Genomics Center,
Environmental Protection Agency, and Food and Drug Administration, was
formed to advance toxicity testing by shifting from traditional in vivo tests to in
vitro methods. A major goal of Tox21 is to prioritize chemicals for in-depth toxicity
testing. One method for prioritization is the use of qHTS assays using cell- and bio-
chemical-based assays to construct concentration–response curves for thousands of
chemicals. The Tox21 consortium adapted the BG1Luc ER TA manual method to
a qHTS format, making it the first assay validated for regulatory use to be adapted
to Tox21. Data from qHTS assays have been generated for approximately 10,000
chemicals in both the agonist and antagonist versions of the qHTS assay. Seventy-
six chemicals had been tested in both the manual and qHTS methods. Data from
both methods were used to evaluate the degree to which classifications of test chem-
icals in the BG1 manual and qHTS methods matched reference classifications (ac-
curacy) and the degree to which chemical classifications were identical between the
two methods (concordance). Except for a few discrepancies attributable to different
test concentrations used in the two methods, the BG1Luc ER TA manual and
qHTS methods produced almost identical results in terms of accuracy, with a high
degree of concordance. Supported by ILS staff under NIEHS contract N01-ES-
35504.
2252 Reconstructed Vaginal-Eectocervical and Endocervical Tissue
Models for HSV-2, Chlamydia, and Gonorrhea Infections.
T. Landry1,  K. LaRosa1,  J. Pudney2,  R. Ingalls2,  D. Anderson2,  P. Hayden1,
M. Klausner1 and S. Ayehunie1. 1MatTek Corporation, Ashland, MA; 2Boston
Medical School, Boston, MA.
Despite extensive efforts, limited success has been achieved in developing tissue
models for sexually transmitted infections (STIs) such as herpes simplex virus 2
(HSV-2), Chlamydia trachomatis (Ct), and Neisseria gonorrhea (Ng). We devel-
oped highly differentiated, normal human 3-dimensional (NHu-3D) vaginal-ecto-
cervical (EpiVaginal™) and endocervical tissues models for STI infections.
Immunohistochemistry and quantitative real time PCR were used to characterize
the ectocervical tissues to monitor HSV-2 infection. Infection of the endocervical
tissue model by the infectious elementary body (EB) of Ct was assessed by quanti-
tative cultures. ELISA assays were used to quantify TNF-α release in response to
Ng and Toll-Like Receptor (TLR) ligands. Results showed that the EpiVaginal tis-
sue expresses nectin-1, a receptor for HSV-2, and infection experiments showed
that the tissue model was infectable with HSV-2 . Similar to the in vivo situation,
infection of the vaginal-ectocervical tissue model with HSV-2 caused a separation
of the epithelium from the lamina propria layer (“blister formation”). The results
were confirmed by DNA PCR.  The data from Ct infected endocervical tissues
showed a cyclic level of EBs which were. 1) present at 12 hrs, representing bacteria
that failed to be taken up by the cells, 2) not detectable at 24 hrs, all intracellular
EBs might have been converted to the replicative reticular bodies (RB) and are
therefore are not cultivatable, and 3) present at 40 hr, RBs have been converted
back to EBs completing the first cycle. Furthermore, the reconstructed endocervical
tissues respond to Ng infection and TLR ligands by secreting TNF-α into the cul-
ture medium. In conclusion, new in vitro reconstructed ectocervical and endocervi-
cal tissue models have been developed for HSV-2, Ct, and Ng infections. The mod-
els can be used to study the safety and efficacy of candidate therapeutics aimed at
preventing or neutralizing HSV-2, Chlamydia, or gonorrheal infections.
2253 Combining Pathway-Based In Vitro Assays to Prioritize 1848
Environmental Chemicals for Estrogenic Potential.
D. Rotroff1, 2,  D. Reif1,  N. S. Sipes1,  T. B. Knudsen1,  P. Kothia1,  M. Martin1,
K. Houck1 and R. Judson1. 1NCCT, EPA, Research Triangle Park, NC;
2Environmental Sciences and Engineering, University of North Carolina at Chapel
Hill, Chapel Hill, NC.
There are thousands of environmental chemicals subject to regulatory decisions for
endocrine disrupting potential. Due to the resources required to perform tradi-
tional toxicity tests, high-throughput screening (HTS) assays have emerged as a vi-
able tool for chemical prioritization. The ToxCast and Tox21 programs have tested
1848 chemicals in a broad screening panel of 19 assays for estrogen receptor (ER)
agonist and antagonist activity. These assays screen for ER activity by profiling ef-
fects on ligand binding or cellular changes across a diverse array of assay types (e.g.
receptor binding, protein complementation, transcriptional activation, and cell
growth) and cell types (T47D, BG1, HEK293T, CHO-K1, HeLa). The protein
complementation assays were run with and without S9 to determine metabolic po-
tential. Assays were assigned to assay-groups to distinguish ER mechanisms (i.e. ag-
onism, antagonism, metabolic activation/deactivation, ERα/ERβ activation).
Concentration response data for each chemical was normalized to 17β-estradiol,
scaled for differences in assay sensitivity, and fit to a Hill model. A composite con-
centration response curve for each chemical-group combination was created from
curve fitting parameters to develop a weight-of-evidence metric for estrogenicity.
Composite curve efficacy, potency, and “goodness of fit” were used to rank chemi-
cals and distinguish putative partial agonists from discordant assay results. In a sep-
arate analysis, uterotrophic assay results (39 chemicals) were used to characterize
composite curve predictivity using logistic regression. Overall, of the original 1848
chemicals 22 were active in at least 13 HTS ER agonist assays, including known ER
agonists, 4-nonylphenol, and DES. 347 chemicals were active in at least 3 HTS ER
agonist assays, indicating the need for assays measuring multiple biologically plau-
sible ER mechanisms in order to confidently prioritize chemicals for estrogenicity.
This abstract does not necessarily reflect Agency policy.
2254 Identification of Compounds That Activate Aryl
Hydrocarbon Receptor Using a qHTS Platform.
N. R. Miller1,  R. Huang1,  K. Houck2,  M. S. Denison3 and M. Xia1. 1NCGC,
NIH, Rockville, MD; 2EPA, Research Triangle Park, NC; 3Environmental Toxicology,
University of California, Davis, Davis, CA.
The basic helix-loop-helix perARNT-SIM (bHLH-PAS) superfamily of transcrip-
tion factors plays an important role in mediating the biological response to endoge-
nous and xenobiotic small molecules. The Aryl hydrocarbon receptor (AhR) is a
prominent member of the bHLH-PAS, and is crucial to adaptive responses to envi-
ronmental changes. AhR mediates cellular responses to environmental pollutants
such as aromatic hydrocarbons through induction of phase I and II enzymes but
also crosstalks with other nuclear receptor signaling pathways. To identify potential
AhR ligands as part of theTox21 collaboration, we have optimized and miniatur-
ized a cell-based AhR luciferase reporter gene assay in the recombinant human
HepG2 cell line HG2L7.5c1 into a 1536-well plate format. We have validated this
assay by screening a library of 1280 pharmacologically active compounds (LOPAC)
plus 88 Tox21 chemicals in triplicate using a quantitative HTS (qHTS) platform.
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From the primary screen, we have identified a group of relatively potent com-
pounds including known AhR agonist indirubin-3’-oxime; CGS-15943, an adeno-
sine receptor antagonist; the cyclin-dependent kinase inhibitor kenpaullone; the
amiloride analogue phenamil; and the gastric proton pump inhibitor omeprazole.
Validation of the cell-based assay on our integrated robotics system gave a signal to
background ratio of 5 and average Z’ factors of 0.4, that indicates this assay is suit-
able for qHTS of the Tox21 10K library. These findings support the utility of a cell-
based AhR luciferase assay system for the high-throughput detection of compounds
activating the AhR signal transduction pathway. Supported by EPA Interagency
Agreement Y3-HG-7026-03.
2255 Comet and Nucleotide Postlabeling Results in the Chicken
Egg Genotoxicity Assay.
A. M. Jeffrey1,  U. Deschl2,  J. Duan1,  K. D. Brunnemann1,  E. Vock2,
M. J. Iatropoulos1 and G. M. Williams1. 1Department of Pathology, New York
Medical College, Valhalla, NY; 2Boehringer Ingelheim Pharma GmbH & Co. KG,
Biberach, Germany.
For the chicken egg genotoxicity assay, an in vitro alternative model for assessing
genotoxicity, we used white leghorn chicken (Gallus gallus) egg fetal livers before
full development of the nervous system. Injections were made on days 9, 10 and 11,
the last 3 hours before termination. Livers were harvested for the COMET assay for
DNA strand breaks and nucleotide postlabeling for DNA adducts. To deliver test
substances, a variety of vehicles were evaluated, covering the range (from hy-
drophilic to hydrophobic) of solubility, using the endpoint of viability of the em-
bryo-fetus. The following suitable vehicles were selected, i.e., 50 μl of deionized
water, 50 μl of 0.5% aqueous methylcellulose, and 50 μl 20% Solutol HS15 for hy-
drophilic, amphiphilic, and hydrophobic substances, respectively. Test substances
were injected with a 1 ml plastic BD syringe using a 0.4 mm x 13 mm needle.
Following the injection into the air sac, the eggs were sealed with paper tape. Test
compounds included diethylnitrosamine (hydrophylic) and 2-acetylaminofluorene
(hydrophobic). The eggs were incubated and maintained at 37° ± 0.5° C and 60%
± 5% relative humidity. On day 11, the shells of viable eggs were opened at the
blunt end, and the allantochorionic membrane was retracted to allow access to the
entire anterior (visceral) aspect of the chicken fetus via the yolk sac.  Fetal weights,
were recorded after removal of the surrounding excess yolk. The abdominal cavity
was opened and the entire liver was removed and weighed. Diethynitrosamine
(0.25 - 4.0 mg cumulative dose per egg) and 2-acetylaminofluorene (0.1-0.6 mg)
were tested over a dose range and subsequent alkaline COMET assays were con-
ducted on isolated liver cells. Both compounds gave a positive dose response with
plateaus occurring at the higher doses. In addition, 2-acetylaminofluorene was pos-
itive in the nucleotide postlabeling assay and showed patterns of DNA adducts sim-
ilar to those previously observed in turkey eggs and rats.
2256 Development of Hazard Evaluation Support System (HESS)
and the Attached Database (HESS DB) for Repeated-Dose
Toxicity of Chemical Substances.
T. Yamada1,  T. Abe1,  R. Hasegawa1,  Y. Sakuratani1,  J. Yamada1,  T. Yamashita2,
Y. Yamazoe3,  O. Mekenyan4,  A. Hirose5 and M. Hayashi6. 1Chemical
Management Center, National Institute of Technology and Evaluation, Tokyo, Japan;
2BioIT Business Development Office, Fujitsu Limited, Chiba, Japan; 3Graduate
School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan; 4Laboratory of
Mathematical Chemistry, University “Prof. Assen Zlatarov” Bourgas, Bourgas,
Bulgaria; 5Biological Safety Research Center, National Institute of Health Sciences,
Tokyo, Japan; 6BioSafety Research Center, Iwata, Japan.
Repeated-dose toxicity (RDT) is one of the key regulatory endpoints in the hazard
assessment of chemical substances. The data is nationally and internationally uti-
lized for the chemical management. On the other hand, reduced animal testing is
desired for economic and animal welfare reasons. Herein, we developed Hazard
Evaluation Support System database (HESS DB). HESS DB is a new toxicity data-
base of RDT studies for about 500 chemicals, most of which have been conducted
in accordance with Good Laboratory Practice Principles under Japanese Chemical
Substance Control Law. Moreover, the DB includes available reference information
on Absorption, Distribution, Metabolism, and Excretion (ADME) and toxicologi-
cal mechanism for some of those chemicals. It is useful for checking the availability
of toxicity test data and for setting the animal test conditions with related informa-
tion of structural analogs. Additionally, chemicals showing similar histopathologi-
cal changes can be efficiently searched with the DB. The DB is linked to simulta-
neously developed Hazard Evaluation Support System (HESS), which is
compatible with OECD QSAR Toolbox and has a supportive function to group
structural analogs with toxicity data. Combination use of HESS and HESS DB
supports to perform category approach to predicting the primary toxicity of
untested chemicals in a transparent and interpretable manner. HESS and HESS
DB are freely provided in the website of NITE (http://www.safe.nite.go.jp/eng-
lish/kasinn/qsar/hess-e.html).
2257 Mitochondrial Bioenergetics and Drug-Induced Toxicity in a
Panel of Mouse Embryonic Fibroblasts with Mitochondrial
DNA Single Nucleotide Polymorphisms.
C. V. Pereira1,  P. J. Oliveira1,  Y. Will2 and S. Nadanaciva2. 1CNC- Center for
Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal; 2Pfizer Inc,
Groton, CT.
Mitochondrial DNA (mtDNA) variations including single nucleotide polymor-
phisms (SNPs) have been proposed to be involved in idiosyncratic drug reactions.
However, current in vitro and in vivo models lack the genetic diversity seen in the
human population. Our hypothesis is that different cell strains with distinct
mtDNA SNPs may have different mitochondrial bioenergetic profiles and may
therefore vary in their response to drug-induced toxicity. Therefore, we used an in
vitro system composed of four strains of mouse embryonic fibroblasts (MEFs) with
mtDNA polymorphisms. We sequenced mtDNA from embryonic fibroblasts iso-
lated from four mouse strains, C57BL/6J, MOLF/EiJ, CZECHII/EiJ and
PERA/EiJ, with the latter two being sequenced for the first time. The bioenergetic
profile of the four strains of MEFs was investigated at both passage 3 and 10. Our
results showed that there were clear differences among the four strains of MEFs at
both passages, with CZECHII/EiJ having a lower mitochondrial robustness when
compared to C57BL/6J, followed by MOLF/EiJ and PERA/EiJ. Seven drugs (nefa-
zodone, ketoconazole, tolcapone, flutamide, tamoxifen, imipramine and troglita-
zone) known to impair mitochondrial function were tested for their effect on the
ATP content of the four strains of MEFs in both glucose- and galactose-containing
media. Our results showed that there were strain-dependent differences in the re-
sponse to some of the drugs. We propose that this model is a useful starting point
to study compounds that may cause mitochondrial off-target toxicity in early stages
of drug development, thus decreasing the number of experimental animals used.
2258 Assessment of Drug-Induced Inhibition of Fatty Acid
Oxidation in Intact Cells.
S. Nadanaciva,  L. Qiu and Y. Will. Pfizer Inc, Groton, CT.
Fatty acid oxidation in mitochondria is an important metabolic pathway for energy
generation in the heart and in organs such as the liver and muscle during fasting.
Drug-induced inhibition of fatty acid oxidation in the liver can lead to microvesic-
ular steatosis or macrovesicular steatosis and eventually to liver failure. Moreover,
since the liver is the supplier of energy in the form of glucose (via gluconeogenesis)
and ketone bodies to other organs, inhibition of fatty acid oxidation in the liver can
lead to a deficiency in the energy supply for extra-hepatic tissues.
Fatty acid oxidation in intact cells has traditionally been assayed by measuring the
production of tritiated water from labeled fatty acids such as tritiated palmitate. In
order to circumvent the use of radio-labeled material, we assessed fatty acid oxida-
tion in intact cells by measuring the effect of palmitate, a long-chain fatty acid, on
cellular oxygen consumption in an XF96 extracellular flux analyzer. We observed an
increase in the oxygen consumption of cells such as c2c12 mouse myoblasts,
HepG2 cells (a liver-derived carcinoma cell line) and hepatocytes upon palmitate
addition. Etomoxir, an inhibitor of carnitine palmitoyltransferase-1 (an enzyme
catalyzing the rate-limiting step of long-chain fatty acid entry into mitochondria)
inhibited respiration. In a proof-of-concept study, we assessed the effect of drugs
(amiodarone, tamoxifen, tianeptine and perhexiline) that are known to inhibit mi-
tochondrial fatty acid oxidation. Our results showed that the measurement of drug-
induced changes in cellular oxygen consumption in the presence of palmitate is a
convenient method by which to assess inhibition of fatty acid oxidation in cells.
2259 Cytotoxicity and Genotoxicity of 2, 6-dichloro-3-methyl-1,
4-benzoquinone (DCMBQ) Involves Reactive Oxygen
Species Production In Vitro.
C. F. McGuigan,  X. Li and X. Le. Division of Analytical & Environmental
Toxicology, University of Alberta, Edmonton, AB, Canada.
Halobenzoquinones (HBQs) were recently identified as drinking water disinfection
byproducts. Computational toxicity predictions have identified the HBQ 2,6-
dichloro-3-methyl-1,4-benzoquinone (DCMBQ) as a potential carcinogen; how-
ever, little toxicity information is available. The normal BJ human fibroblast cell
line (CRL-2522) was utilized to perform in vitro assays to examine the cytotoxicity,
genotoxicity, and reactive oxygen species production capability of DCMBQ. Real-
time cell electronic sensing (RT-CES) showed a concentration-dependent decrease
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in cell index, indicative of cytotoxicity, after exposure to 12.5-50μM DCMBQ over
a 72-hour period. Using the alkaline comet assay, a significant genotoxic effect
(one-way ANOVA, p<0.05), indicated by increased tail moment, was observed in
cells exposed to ≥20μM DCMBQ for 24 hours. To further determine the mecha-
nism of toxicity, reactive oxygen species (ROS) production was measured using the
fluorophore DCFDA (2’,7’–dichlorofluorescein diacetate) in cells exposed to
DCMBQ (5-50μM) for 2-72 hours. Significant time and concentration-dependent
increases in ROS were observed (two-way ANOVA, p<0.05) for ≥15μM DCMBQ
at 24 hours of exposure but as early as 4 hours of exposure for 50μM DCMBQ.
This effect was significantly reduced by the addition of N-acetylcysteine (NAC), a
ROS scavenger. Likewise, simultaneous addition of NAC to cells treated with
highly genotoxic concentrations of DCMBQ in the alkaline comet assay reduced
tail moment values to those comparable with untreated control groups. Based on
these results, we conclude that DCMBQ is cytotoxic and genotoxic under these ex-
perimental conditions, and these effects are due at least in part to ROS production.
As DCMBQ has been detected in finished drinking water samples, additional test-
ing is urgently required to determine potential effects on human health.
2260 Intra- and Interlaboratory Validation Studies on Reactive
Oxygen Species Assay for Photosafety Evaluation of
Pharmaceuticals.
T. Toda1,  S. Onoue2,  Y. Seto2,  H. Takagi3,  N. Osaki3,  S. Kawakami4,
Y. Matsumoto5,  Y. Iwase6,  T. Yamamoto6,  S. Wakuri7,  K. Hosoi8,
K. Nakamura1 and H. Kojima9. 1Shionogi & Co., Ltd., Osaka/Tokyo, Japan;
2University of Shizuoka, Shizuoka, Japan; 3Taisho Pharmaceutical Co., Ltd., Saitama,
Japan; 4Asahi Kasei Pharma Corporation, Shizuoka, Japan; 5Aska Pharmaceutical
Co., Ltd., Kanagawa, Japan; 6Mitsubishi Tanabe Pharma Corporation,
Saitama/Chiba, Japan; 7Hatano Research Institute, Food and Drug Safety Center,
Kanagawa, Japan; 8Santen Pharmaceutical Co., Ltd., Nara, Japan; 9National
Institute of Health Sciences, Tokyo, Japan.
A reactive oxygen species (ROS) assay was previously developed for photosafety
evaluation of pharmaceuticals. Although outcomes from the previous multicenter
validation study were indicative of satisfactory transferability, reproducibility, and
predictive capacity of the ROS assay using Atlas Suntest CPS/CPS plus solar simu-
lators, the feasibility of different solar simulators for the ROS assay has never been
elucidated. Herein, in 4 participating laboratories, 2 standards and 42 coded chem-
icals, including 23 phototoxins and 19 non-phototoxic drugs/chemicals, were as-
sessed by the ROS assay using Seric SXL-2500V2 solar simulators with the aim of
evaluating the compatibility of different solar simulators for the ROS assay. In the
ROS assay on quinine (200 μM), a typical phototoxic drug, the intra- and inter-
day precisions (coefficient of variation; CV) were found to be 1.7–9.4% and
2.7–6.9%, respectively. The inter-laboratory CV for quinine averaged 13.2% for
singlet oxygen and 7.1% for superoxide. The ROS assay on 42 coded chemicals
(200 μM) provided no false negative predictions as compared to the in vitro/in vivo
phototoxicity, although several false positives appeared. These results were regarded
a convincing demonstration that the ROS assay is compatible with, and can be
adapted to, other available suitable solar simulators without losing performance.
2261 Investigating the Role of Mitochondrial Dysfunction in
Zoniporide Toxicity.
P. Rana,  S. Rachel and Y. Will. Compound Safety Prediction, Pfizer Global Research
& Development, Groton, CT.
Zoniporide, an inhibitor of the Na+-H+ exchanger-,1 was developed for the reduc-
tion of myocardial ischemic injury in acute coronary syndromes, in the high-risk
surgical setting, and secondary for prevention in patients with ischemic diseases. A
28-days intravenous infusion rat study revealed target organ toxicity of the sciatic
nerve, spinal cord, and stomach injury (Pettersen et al., 2008). Due to insufficient
efficacy, zoniporide was discontinued after the phase 2 clinical trial. We have previ-
ously reported that zoniporide seems to affect mitochondrial function (Rana et al.,
2011) here, we expand on our studies by investigating further mechanisms that
could lead to this mitochondrial disturbance. 
We tested zoniporide in rat liver mitochondria for its inhibition of mitochondrial
respiration and conducted mitochondrial swelling experiments to study possible
mitochondrial permeability transition pore (MPT) effects of zoniporide. We fur-
ther tested this compound in H9c2 cells growing in glucose and galactose media
and measured ATP depletion and Caspase 3/7 levels. Finally, we tested zoniporide
on the flux analyzer and measured immediate effect on mitochondrial respiration
and glycolytic rates. In the cell based assays, we tested zoniporide alone and in the
presence of Cyclosporine A (CSA), which has been known to close the MPT.
We observed that zoniporide did not inhibit mitochondrial respiration in rat liver
isolated mitochondria. However, at 24 h, there was more than a 3-fold difference
between glucose/galactose IC50, suggesting an effect on a mitochondrial target.
This was further confirmed using a flux analyzer, where there was decrease in oxy-
gen consumption rate (OCR) which was accompanied by increase in extra cellular
acidification rate (ECAR) suggesting that cell injury is primarily mitochondria tar-
geted as cells switches respiration from mitochondrial OXPHOS to glycolysis. Co-
incubation with CSA had a rescue effect on Caspase3/7 levels in galactose growing
cells. In summary, we believe that zoniporide induced cell injury includes primarily
mitochondria by causing MPT.
2262 Validation of an HTS-Amenable Assay to Detect Drug-
Induced Mitochondrial Toxicity.
R. Swiss1,  A. L. Niles2,  J. J. Cali2 and Y. Will1. 1Compound Safety Prediction,
Pfizer Global Research & Development, Groton, CT; 2Promega, Madison, WI.
Drug-induced mitochondrial dysfunction has been shown to contribute to organ
toxicity and late stage attrition. Therefore, testing for drug-induced mitochondrial
dysfunction pre-clinically is vitally important and has the ability to greatly impact
the success of a potential drug candidate. Several assays have been developed but are
hampered for high-throughput screening because they either require special
reagents, isolated mitochondria or specialized equipment. 
Here we validate in 384-well format, a dual parameter assay that measures both cy-
totoxicity and mitochondrial toxicity simultaneously during very short exposure
durations using standard detection methods. In this assay, cytotoxicity is measured
by evaluating cell membrane integrity via the presence or absence of a distinct pro-
tease activity associated with necrosis. 
For our initial evaluation, K562 cells were grown in both glucose-supplemented
media and galactose-supplemented media and were tested in parallel. The objective
was to see how many mitochondrial toxicants this cell-based assay would be able to
detect.
We validated the assay using the classical mitochondrial toxicants antimycin A,
CCCP and, oligomycin, as well as two drugs known to have mitochondrial liabili-
ties (nefazodone, and flutamide) as well as the non-specific detergent digitonin, in
a 384-well plate format with a 2 hour exposure. 
We determined the assay to have excellent reproducibility with less than 3 fold dif-
ferences between IC50 values form day to day. Once the assay was validated, we
screened a set of 75 commercial compounds that included compounds known to
cause different organ toxicities and with known or unknown mitochondrial liabili-
ties. Our screening data identified that compounds could be sorted into 7 different
categories based on the calculated IC50s of each condition, the cytotoxicity meas-
urement in both glucose and galactose-grown cells and the ATP measurement in
both media conditions. Our results are currently evaluated for their sensitivity and
specificity in comparison to other existing assays.
2263 Establishing a Link between Redox Cycling and Cell Death
for Quinone and Flavin Chemotypes.
L. Jones,  P. Rana,  R. Swiss,  R. Naven and Y. Will. Compound Safety Prediction,
Pfizer Global Research & Development, Groton, CT.
Oxidative stress is one of the major mechanisms of drug induced toxicity. One elec-
tron reduction of oxidants generates reactive oxygen species (ROS) via redox cy-
cling. In biological systems, the flavo enzymes mediate the transfer of electrons to
the quinone by reducing it to the semiquinone. Recently, we evaluated flavin ana-
logues for their ability to redox cycle and tried to establish their association to toxi-
city. We investigated menadione (a quinone analogue) and toxoflavin (a flavin ana-
logue) for its attribution to its redox cycling activity that leads to oxidative stress
which eventually leads to cell death. 
In our proof of concept study, we investigated the redox cycling capability of mena-
dione and toxoflavin by utilizing a biochemical assay that measures the H2O2 pro-
duced through redox cycling of compounds. Next, we tested these compounds in
THLE cells using high content imaging to assess the production of ROS using di-
hydro ethidium (DHE). In addition, we measured glutathione and ATP levels in
THLE cells. Next, we wanted to know if we could rescue the detrimental effects of
redox cycling on cell health, by incubation with two different antioxidants. One of
them was catalase, which effectively dismantle hydrogen peroxide with water as a
byproduct, the other was N-acetyl-cysteine (NAC), which minimizes oxidative
stress. 
Here, we report that both, menadione and toxoflavin redox cycle and produce hy-
drogen peroxide (ROS), both in the biochemical assay as well as in the cell based
assay. Glutathione levels were also depleted with both of these compounds.
Furthermore, the ROS formation and glutathione depletion lead to cell injury that
is measured by ATP depletion. Catalase was able to dismantle H2O2 in the bio-
chemical assay. In the cell based assay, ROS, glutathione and ATP effects were re-
covered in the presence of NAC. In summary, we established the involvement of
redox cycling of quinones and flavin chemotypes to toxicity in THLE cells
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2264 Identification and Characterization of Potential
Mitochondrial Liabilities Using a Multitiered In Vitro Rat
Primary Hepatocyte Screening Paradigm.
D. D. Baker,  B. D. Jeffy and M. A. Breider. Exploratory Toxicology, Celgene, Inc.,
San Diego, CA.
A tier I rat primary hepatocyte multi-endpoint cytotoxicity assay (MECA) system is
an effective tool to assess and rank order compounds on predicted potential to in-
duce toxicity in repeat-dose in vivo rat toxicology studies. Our MECA system uti-
lizes three primary biochemical endpoint assays: an ATP assay for cell viability, a
lactate dehydrogenase (LDH) assay for membrane integrity and a WST-1 assay for
mitochondrial function. A positive signal in the WST-1 assay should be further
characterized with a Tier II specific assessment of sub-mitochondrial toxicity. To de-
termine potential mitochondrial liabilities, our Tier II mechanistic assessment in-
cludes a JC-1 assay for Mitochondrial Pore Transition (MPT) status, a 2’,7’ -dichlo-
rofluorescein diacetate (DCFDA) assay for reactive oxygen species (ROS)
production, a Caspase 3/7 assay for apoptosis, and a Seahorse XF24™ assay system
to determine functional oxidative phosphorylation (mitochondrial respiration).
HMG-CoA reductase inhibitors (statins) are compounds that lower cholesterol and
reduce cardiovascular disease. There has been increasing evidence that some statins
may affect mitochondrial function, leading to adverse effects such as myopathy or
rhabdomyolysis. We investigated the effects of multiple statins, including simvas-
tatin, on various mitochondrial functional endpoints. Tier I screening of the statins
in primary rat hepatocytes identified a general mitochondrial liability with a 50%
decrease in WST-1 throughout the concentration range.  In Tier II assays demon-
strated that simvastatin treatment induced hepatocellular apoptosis at high concen-
trations and lowered both basal mitochondrial respiration and maximal respiration
compared to control at non-cytotoxic concentrations. These data corroborate the
decreased WST-1 reading and suggesting impaired electron transport chain func-
tion. A multi-tiered approach is essential to fully characterize potential mitochon-
drial dysfunction and add predictive value to in vitro toxicology screens in early
phases of drug discovery.
2265 Impact of Exposure Profile on Toxic Response Using
Hepatocytes (HepaRG) Cocultured with Intestinal Cells
(Caco-2).
K. Yuki,  N. Ikeda,  T. Kasamatsu and N. Nishiyama. Kao Corporation, Haga-gun
Tochigi, Japan. Sponsor: J. Avalos.
[Background, Purpose] To develop an alternative method to in vivo toxicity studies,
a general approach would be to extrapolate key markers identified in the early stage
of the in vivo toxic response into an in vitro system. Under in vivo conditions, a test
substance is absorbed, distributed, and/or metabolized before reaching target cells,
whereas in an in vitro system, compounds are directly exposed to target cells and
metabolic activation might or might not be involved. To address the impact of the
significant difference of chemical exposure profiles between in vivo and in vitro sys-
tems, we have developed a co-culture system consisting of HepaRG cells and Caco-
2 cells as a model for hepatocytes, where the system simulates intestinal absorption
and liver metabolism processes.
[Methods] The toxic responses of the co-culture system toward four chemicals (ace-
toaminophen, carbon tetrachloride, amiodatron, and EGCg) reported to have a he-
patotoxic effect were compared to the single culture HepaRG system.
[Results] Co-culturing with Caco-2 cells increased ALB and CYP expression in
HepaRG cells. Although treatment with each test chemical changed LDH and
GSH activity in both culture systems, dosages of EGCg were very different for sim-
ilar toxic effects. Monitoring of EGCg concentration and GSH activity revealed a
two-fold lower EGCg Cmax, a 10-fold higher AUC (0-24), and reduction of GSH
activity after 12 hr for the co-culture system.
[Discussion, Conclusion] This study demonstrated that the exposure profile of test
substances may affect the toxic response of cultured cells. It is important to develop
in vitro models that reflect the in vivo exposure conditions.
2266 Combinatorial High-Throughput Gene Transfection on a
Chip for Metabolism-Induced Toxicity Screening.
M. Lee4,  S. Kwon1,  D. Lee2,  D. Shah1,  B. Ku2,  D. S. Clark3 and J. S. Dordick1.
1Department of Chemical and Biological Engineering, Rensselaer Polytechnic Institute,
Troy, NY; 2Central R & D Institute, Samsung Electro-Mechanics Co., Suwon,
Republic of Korea; 3Department of Chemical and Biomolecular Engineering,
University of California Berkeley, Berkeley, CA; 4Solidus Biosciences, Inc., San
Francisco, CA.
Variation in metabolic enzyme expression among segments of the human popula-
tion may cause deviations from the expected pharmacokinetic profile of a drug, re-
sulting in idiosyncratic toxicity or a lack of efficacy. Cell lines that stably express
metabolic enzymes are emerging tools for prediction of these rare clinical events;
however, it is difficult to create and maintain a library of stable cell lines that mim-
ics the diversity of metabolic profiles. To address this need, we have developed a
“Transfected Enzyme and Metabolism Chip” (or TeamChip) for high-throughput
analysis of systematic drug metabolism and toxicology. The TeamChip is prepared
by infecting an array of miniaturized 3-D cell cultures on a micropillar chip with
varying concentrations of recombinant adenoviruses carrying genes for different
metabolic enzymes in a microwell chip, which generates an array of cell cultures
with differentiated metabolizing capabilities. As a proof of concept, we have
demonstrated the controlled expression of individual drug-metabolizing enzymes
(CYP3A4, 2D6, 2C9, 1A2, 2E1, and UGT1A4) in THLE-2 human liver cell line
on the chip by altering the multiplicity of infection of the various recombinant ade-
noviruses. The expression levels of the metabolizing enzymes on the chip were de-
termined by in-cell immunofluorescence assays and the activity of the expressed en-
zymes in THLE-2 cells were tested with fluorogenic dyes. By printing the 6
recombinant adenoviruses into the microwell chip in a combinatorial way, we were
able to achieve 144 combinations of multiple metabolic enzymes expressed in
THLE-2 cells on a single TeamChip. Finally, 6 model compounds that were shown
to be hepatotoxic, in some cases idiosyncratically and withdrawn from the market,
were tested to simulate enzyme-specific hepatotoxicity.
2267 Validation of High-Throughput and High-Content (HT/HC)
Assays to Support 21st Century Toxicity Evaluations.
R. Becker1,  G. Patlewicz2,  T. Simon3,  K. Goyak4,  R. Phillips4,  J. Rowlands5
and S. Seidel6. 1American Chemistry Council, Washington DC; 2DuPont Haskell
Global Centers for Health and Environmental Sciences, Newark, DE; 3Ted Simon
LLC, Winston, GA; 4ExxonMobil Biomedical Sciences Inc., Annandale, NJ; 5The
Dow Chemical Company, Midland, MI; 6Dow Corning Corporation, Midland, MI.
Advances in high throughput and high content (HT/HC) methods have the poten-
tial to improve the efficiency and the effectiveness of toxicity evaluations and risk
assessments. However, scientific confidence in these methods and their prediction
models must be formally established before use in regulatory decision making.
Traditional validation approaches that define relevance, reliability, sensitivity and
specificity may not be readily applied since a number of these methods are propri-
etary; HT/HC methods may use one of a kind robotics; although run individually,
these assays are likely to be used as a group or battery for decision making and,
HT/HC methods are not exact replacements for in vivo testing. Building on the
frameworks developed in the 2010 Institute of Medicine Report on Biomarkers and
the OECD 2007 Report on (Q)SAR Validation, we present frameorks that can be
adapted to address the validation challenges of HT/HC methods. These require ex-
plicit specification of context and purpose of use such that scientific confidence can
be defined to meet different applications (e.g., a lesser degree of confidence may be
acceptable for priority setting compared to that required to support hazard charac-
terization, or classification/labeling).We recommend that a specific validation strat-
egy be developed and implemented for HT/HC assays and their prediction models,
focused on the specific biological response of interest. We discuss how anchoring
the assays and their prediction models to Adverse Outcome Pathways should facili-
tate the interpretation of results and support scientifically defensible fit-for-purpose
applications. To build scientific confidence, data should be publicly disseminated
and assay results and prediction models should be subjected to independent scien-
tific peer review.
2268 Performance Evaluation of Publicly Available QSAR
Software Platforms for Toxicology Endpoints: Case Study
Involving VEGA, OPENTOX, and OECD QSAR Toolbox.
S. Bobst1 and M. Vracko2. 1Product Safety, Nexeo Solutions LLC, The Woodlands,
TX; 2Laboratory of Chemometrics, National Institute of Chemistry, Ljubljana,
Slovenia.
Several Quantitative Structure Activity Relationship (QSAR) software methods are
available for public use. QSAR methods are gaining greater acceptance as an alter-
native to animal testing, to fill data gaps for hazard communications (e.g. the U.N.
Globally Harmonized System for chemical labeling) and data submissions for regu-
latory requirements (e.g. the European chemical regulation known as REACH).
QSAR software models are constructed using data systems involving molecular de-
scriptors, specific to toxic endpoints, and reference databases comparing known
data references, with unknown data points. VEGA, OPENTOX, and OECD
QSAR Toolbox are three software platforms widely known and publicly available.
The analysis displays the performance of the software programs with a poly aro-
matic hydrocarbon (PAH) test data set. Variation in software performance, includ-
ing specificity (false negatives), sensitivity (false positives), and strength of predic-
tion (regression) is evaluated against the test case data. The comparative analysis
provides insight into the criteria and requirements for determining which software
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platform maybe most appropriate for specific endpoints for unique chemical cate-
gories. Such analysis assists industry stakeholders in planning the use of QSAR
models for hazard communication, regulatory compliance, and sustainable life
cycle management.
2269 Use of a Cell-Based Assay to Monitor the Stability of the
Tox21 10K Compound Library.
R. Huang1,  J. Zhao1,  M. Xia1,  K. L. Witt2,  K. Houck3,  R. R. Tice2,  D. Dix3
and C. P. Austin1. 1NCATS/NIH, Rockville, MD; 2NTP, NIEHS/NIH, Research
Triangle Park, NC; 3NCCT, EPA, Research Triangle Park, NC.
In Tox21 Phase II, a collection of ~10K compounds
(http://www.epa.gov/ncct/dsstox/sdf_tox21s.html) is being screened against a bat-
tery of nuclear receptor and stress response pathway assays. Knowing the identity
and purity of each substance and its stability in dimethylsulfoxide (DMSO), the
solvent of choice, is critical to the interpretation of assay results. In the screening
protocol, a copy of the 10K library, maintained in the Tox21 robotics facility at
room temperature (RT), is used in multiple assays over a 4-month period. In addi-
tion to an ongoing analytical analysis on the library at time 0 and 4 months, the
complete results of which will not be available until mid 2013, we evaluated com-
pound stability using the p53-beta lactamase reporter gene (p53-BLA) assay to
monitor biological activity. This assay was selected because it is a highly repro-
ducible (>95%) cell-based assay with a relatively high hit rate (16%). The library
was tested 1 day, 2 weeks, 2, 4, and 6 months after being placed on the robot. The
number of compounds that showed a significant change in activity (loss or gain) as
an indication of compound degradation at each time point compared to the freshly
thawed library (day one) reached a plateau of 1.7% of the 10K library at approxi-
mately 4 months. Most of the change in activity appeared to occur within the first
2 weeks and included compounds such as dinoterb, bithionol and captafol. Results
show that the majority of compounds are relatively stable at RT for up to 6 months,
with the caveat that the compounds inactive against p53 (i.e., the majority of the li-
brary) were not captured by this method. This study is the first attempt to use a
cell-based assay to systematically monitor the stability of a large-scale, environmen-
tally focused compound library. The results can be used to determine when to re-
place the library plates, and they also serve to validate the quality of the Tox21 pro-
duction screen process – from compound storage and handling to robotic
operations and assay performance.
2270 Application of Metabolomics In Vitro for Identification of
Toxicological Modes of Action.
T. Ramirez1,  N. Bordag2,  W. Mellert1,  H. G. Kamp1,  T. Walk2,  R. Looser2 and
B. van Ravenzwaay1. 1Experimental Toxicology and Ecology, BASF SE, Ludwigshafen
am Rhein, Germany; 2metanomics, berlin, Germany.
The demand for the use of alternatives to animal testing has increased in the last
years, not only due to new regulations, such as REACH or the 7th Amendment of
the cosmetic directive, but also because they can be used for toxicological screening
during compound development. The use of state-of –the-art technologies com-
bined with cellular in vitro models represents a new opportunity to obtain compre-
hensive information about the toxicological mode of action of compounds being in
commerce and most importantly for compounds under development.
Metabolomics is a versatile technology with multiple potential applications in
safety profiling and has been considered as the alternative to elucidate the molecu-
lar basis of toxicity. Moreover, the combination of in vitro systems coped to this
technology may on one hand enable the acquisition of quantitative information
about the multi-parametric metabolic response of the cellular systems in normal
and patho-physiological conditions and on the other hand, it represents a major
steps towards non-animal alternatives in toxicology. Herein, we report on the extra-
cellular metabolic profile (secretome) of HepG2 cells after the exposure to chemi-
cals compounds with well-known toxic profile and differ modes of action. The ob-
tained metabolic fingerprint allowed for a clear distinction between the tested
toxicological modes of action. These results may majorly contribute to the future
elucidation of the biochemical events underlining the toxic modes of actions of
chemical compounds without animal testing.
2271 Functional Genomics Approach in Yeast and the DT40 Avian
Cell Line Identify Conserved Mechanisms of
Trichloroethylene Toxicty.
V. De La Rosa and C. Vulpe. University of California, Berkeley, Berkeley, CA.
Trichloroethylene (TCE) is an industrial solvent and a common drinking water
contaminate. Previous studies have identified the TCE metabolite DCVC as re-
sponsible for increased kidney toxicity and renal cancer, yet the molecular events
mediating renal toxicity an cancer remain controversial. Our studies in yeast pro-
vide a foundation for identifying potential mechanisms of TCE renal toxicity and
to establish an alternative model for identifying mechanisms of toxicity in humans.
A functional genomics approach in yeast identified DNA damage and repair path-
ways important in response to DCVC exposure. Specifically, mutagenic translesion
synthesis (TLS) and nucleotide excision repair (NER) pathways were found to play
important roles in DCVC toxicity. This data suggests DCVC may cause direct
DNA damage that elicits a mutagenic repair response. Follow-up studies were con-
ducted in the DT40 avian cell to assess if the mutagenic DNA repair response is
conserved in higher eukaryotes. The viability of DNA repair mutants was signifi-
cantly decreased particularly for TLS and NER mutants. Furthermore, western blot
analysis showed initiation of TLS repair after DCVC exposure. These results sup-
port a conserved DNA damage and mutagenic repair mechanism mediating
DCVC renal toxicity. Additionally the results support a functional genomics ap-
proach in yeast as a viable model for identifying mechanisms of toxicity in higher
organisms, including humans.
2272 The Value of Pharmacological Data to Support Systemic
Acute Toxicity Evaluation of Compounds: A Profile Analysis.
R. R. Note,  H. Noçairi,  L. Bourouf,  G. Ouédraogo and J. Cotovio. Department
for The Development of Predictive Models and Methods, L’Oréal, Aulnay sous Bois,
France. Sponsor: E. Dufour.
Developing alternatives in the area of acute systemic toxicity implies combination
of multiple parameters. We showed that integration of cell-death data, pharmaco-
logical profiles and physico-chemical properties resulted in a significant improve-
ment of the LD50 prediction model originally developed by CeeTox. In order to re-
duce the false negative rate, correcting factors were applied to the model; this
included considerations of a clear dose-response effect, the magnitude of the re-
sponse and the number of receptors responding. A decrease of the LD50 parameter
was expected the cited criteria were met. At a LD50 threshold of 500 mg/kg, the
predictive performances of the so called V1 model were extremely encouraging with
an overall concordance of 88%*.
The purpose of the study is to get a better understanding of the data generated on
the selection of 13 CNS and Heart receptors potentially playing a causative role in
the toxic effect. The analysis of the profiles observed with the set of 73 public do-
main chemicals was completed as follows:
-Comparison of the LD50 values estimated via the different models (V0, V1, ex-
perimental)
-Toxicological categorization based upon the LD50 threshold of 500 mg/kg
-Identification of the receptors most responding and understanding of their biolog-
ical relevance
No variation of the LD50 values was observed for 43 chemicals while an increase or
a decrease was assigned to 10 and 20 chemicals respectively. As expected, the de-
crease in the LD50 value made the model more predictive for 16 out of the 20 com-
pounds. With regards to the toxic compounds, the receptors most responding were
a subset of 5 CNS and heart receptors (M2, alpha2, beta1, GABA, N neuronal).
Next step will consist of checking the relevance of such receptors for a set of propri-
etary chemicals. As such, we could envisage the development of a more economical
and pragmatic model that would be useful for early screening purposes.
*SOT 2010, SOT 2011, SOT 2012
2273 Development of In Vitro Organotypic 3D Epithelial Models
for High-Throughput Screening of Toxicological,
Immunological and Developmental Signaling Pathways.
C. Mankus,  G. Jackson,  J. Bolmarcich,  P. Hayden and M. Klausner. Mattek
Corporation, Ashland, MA.
Currently, there is a growing need for moderate to high-throughput toxicological
assays that provide mechanistic information regarding cellular targets and signaling
pathways. Here, we describe the development of in vitro organotypic 3D skin
(EpiDerm™) and airway (EpiAirway™) models with the added feature of lu-
ciferase based transcription factor (TF) reporter functions. To produce the models,
early passage normal human epidermal keratinocytes and tracheal epithelial cells
were transduced with lentiviral vectors containing the TF response elements linked
to luciferase. Stably transduced cells were selected by puromycin resistance, ex-
panded several passages and cyropreserved to produce large pools of cells for organ-
otypic model production. To date, reporters for 6 stress response pathways, includ-
ing oxidative stress, DNA damage, metal stress, MAPK/inflammation, NFκB and
xenobiotic stress have been developed in both the EpiDerm™ and EpiAirway™
models. Each model has demonstrated a dose response to positive control test arti-
cles including, TBHQ, Nutlin-3, ZnCl2, PMA, TNFα and TCDD, respectively,
with an average induction of 3-15 fold over vehicle when luciferase activity in tissue
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extracts was quantified using a microplate luminometer. TF reporters can be assem-
bled in custom 96-well arrays for screening of unknown test compounds and mon-
itoring of cell signaling pathway activity. Using this format, 3 test articles and a neg-
ative control (N=3) can be tested against 8 stress pathways in a single assay resulting
in a heat map-like profile of pathway activation. The ultimate goal of the project is
to develop a panel of 14 TF reporter models for both skin and airway models that
can be assembled into custom 96-well high-throughput arrays as well as additional
individual tissue formats. Results from these initial 6 models indicate that
EpiDerm™ and EpiAirway™ reporter models will provide novel tools for con-
ducting mechanistic human toxicological studies.
2274 In Vitro Predictive Toxicology for Breast Cancer.
R. Rudel1,  J. Ackerman1 and C. Vulpe2. 1Silent Spring Institute, Newton, MA;
2University of California, Berkeley, CA.
Identifying chemicals that increase breast cancer (BC) risk could help prevent BC,
but rodent bioassays are expensive. In vitro and computational methods are being
developed to predict adverse effects with limited in vivo testing. The present work
aims to develop in vitro methods to predict chemicals that can increase BC risk.
Animal and human studies suggest that that both genotoxic carcinogens and cer-
tain hormone exposures increase BC risk. Our initial goal is to identify in vitro tests
that predict mammary gland carcinogens (MCs) in rodent bioassays, since few
breast carcinogens have been studied in humans. We have previously identified 208
chemicals causing mammary tumors in rodents in at least one study. We used the
Chemical Carcinogenesis Research Information System (CCRIS) to compare geno-
toxicity profiles for MCs with 27 ‘non-carcinogens’ (nonCs) that did not show in-
creased tumors at any site in National Toxicology Program bioassays. We included
five assay types: bacterial mutagenicity, and in vitro and in vivo micronuclei and
chromosomal aberration. Data from at least one of these were available for 158
MCs and 22 nonCs. We found that most MCs are genotoxic: 87% were positive in
>15% of CCRIS entries within any assay type, with or without metabolic activa-
tion (MA), while 10% were consistently negative (i.e., no study was positive). In
comparison, 59% of nonCs were consistently negative. Since many in vitro predic-
tive toxicity programs do not include MA, we also evaluated whether MA was
needed for genotoxicity. Without MA, the MCs that were consistently negative for
genotoxicity increased from 10% to 24%, and the number consistently positive
(i.e., positive in >15% of entries in every assay type) dropped from 66% to 48%. In
conclusion, a high percentage of MCs are consistently genotoxic but 10% are neg-
ative in all tests. Without activation almost 25% of the MCs would be consistently
negative. The relationship between genotoxicity and cancer has been extensively
discussed, but to our knowledge this is the first focus on breast cancer. Future work
will extend to other in vitro endpoints.
2275 In Vitro to In Vivo Extrapolation Using Data from ToxCast.
M. DeVito1,  S. S. Auerbach1,  A. Merrick1,  K. L. Witt1,  K. Janardhan3,
D. Malarkey1,  H. Nagai4,  I. Shah2,  C. Corton2 and R. Judson2. 1NTP, NIEHS,
Research Triangle Park, NC; 2ORD, US EPA, Research Triangle Park, NC; 3ILS,
Research Triangle Park, NC; 4Nihon Nohayaku Co. Ltd., Tokyo, Japan.
Using data from the USEPA ToxCast Phase I, a model was developed to predict
non-genotoxic rat liver carcinogens. The model predicts that chemicals that activate
PPARα, increases in oxidative stress as measured by H2AX phosphorylation, de-
creases in MCP-1 or are anti-androgens in vitro are likely to induce rat liver tumors
through non-genotoxic mechanisms. The present study evaluated the concordance
of these in vitro responses to in vivo effects. The studied chemicals were either pos-
itive in the predictive model and were rat liver carcinogens (acetochlor, carbaryl,
perfluorooctanoic acid (PFOA), 2,5-Pyridinedicarboxylic acid dipropyl ester (2,5-
PCDA), simazine); positive in the model but were negative in a rat bioassay
(bisphenol A, flusilazole) or were negative in the model and in vivo (triclosan).
Using the highest dose from the cancer bioassay, male Sprague-Dawley rats were ex-
posed by gavage to chemicals for 4d and euthanized 4h after the last dose. Livers
were removed for gene array analysis. Serum MCP-1 levels were determined. In
vitro and in vivo, PPARα was activated by PFOA and acetachlor. Triclosan was pos-
itive in vivo, but not in vitro. None of the chemicals altered serum MCP-1 in vivo
(2,5-PCDA and simazine, were positive in vitro). Carbaryl and bisphenol A in-
duced H2AX phosphorylation in vitro but were not positive in vivo. Bisphenol A,
acetochlor and flusilazole showed anti-androgen activity in vitro and in vivo. While
negative in vitro, 2,5-PCDA, PFOA, carbaryl and triclosan altered androgen re-
sponsive genes in vivo. Carbaryl and acetochlor induced oxidative stress in vitro but
not in vivo. In contrast, triclosan induced oxidative stress responsive genes in vivo
but not in vitro. PPARα pathway activation has a good concordance in vitro and in
vivo. Results for anti-androgenicity, MCP-1 and oxidative stress were much less
concordant between in vitro and in vivo. This abstract does not necessarily reflect
the policies or views of NIH or the USEPA.
2276 The In Vitro 3T3 Neutral Red Uptake Phototoxicity Test:
What to Do with UVB Absorbers?
D. B. Learn,  M. D. Schwartz,  M. E. Dougherty and A. M. Hoberman. Center
for Photobiology, Charles River Laboratories Preclinical Services, Horsham, PA.
The literature suggests and conventional wisdom holds that Ultraviolet B (UVB) is
highly cytotoxic to the Balb C 3T3 fibroblast cell line used in the OECD 432 3T3
NRU Phototoxicity Test and thus the assay is not appropriate for test materials that
absorb primarily in the UVB portion of the spectrum. The choice of an appropriate
light source and filtering is always a critical factor in this or any assay, and, while
this Guidance recommends an Ultraviolet A (UVA) dose of 5 J/cm2, the UVB dose
(if any) or limit of exposure is not addressed. To define the sensitivity of the cells to
UVB and evaluate if indeed their sensitivity precluded the use of UVB, we evalu-
ated the Guidance-required cell viability, OD540 absorption, and other endpoints
with increased UVB (290 – 300 nm) exposure by removing the tissue culture plate
lid during exposure using a xenon arc solar simulator. This direct (uncovered) expo-
sure increased the UVB irradiance from approximately 19 mJ/cm2 to approxi-
mately 32 mJ/cm2, concomitant with the recommended 5 J/cm2 UVA dose. While
cell survival was modestly reduced, the resulting IC50, OD540 absorption, PIF, and
MPE endpoints from this enhanced UVB exposure alone and response to
Chlorpromazine indicate no adverse effect on the validity of the assay and accept-
able Guidance-defined results under these exposure conditions. This additional
ability to test UVB absorbers provides all the advantages of the assay to this subset
of test materials, enhances this step in the preclinical process of drug discovery and
further establishes the robustness of the assay as a valid step in preclinical drug de-
velopment.
2277 Comparison of Multiple Assay Formats to Measure Kinase
Inhibitor Activity.
K. Leach and D. Puppala. Compound Safety Prediction, Pfizer, Groton, CT.
Protein phosphorylation is a key mechanism for controlling cellular functions, and
protein kinase inhibitors show good efficacy as oncology therapeutics. Currently
there are 15 marketed kinase inhibitors, with many more in clinical trials. A key
component of drug discovery efforts for these inhibitors is the optimization of ki-
nase selectivity, since a greater degree of promiscuity is associated with a greater risk
of safety concerns. A wide variety of biochemical and cellular kinase assays which
utilize multiple technologies are available for testing compounds and determining
kinase activity, and an important consideration is the translation across these assays.
A set of 14 Pfizer kinase inhibitors with different primary kinase targets were pro-
filed across three different types of assays: biochemical kinase assays measuring pep-
tide substrate phosphorylation; ActivX technology, which measures specific bind-
ing to kinases within a cell lysate; and cell-based kinase assays, measuring
endogenous substrate phosphorylation. The biochemical assays were conducted at
Km levels of ATP, with nonphysiological peptide substrates, while the cellular assays
utilized intact cells and cellular levels of ATP. A comparison of results across these
platforms against three different kinases, aurora, abl or glycogen synthase kinase
beta, was carried out and the results demonstrate a high degree of congruency with
the cellular kinase activity and the Activ X technology. For this set of compounds,
there was less agreement between the biochemical versus cellular kinase assays.
These results suggest that utilization of high throughput biochemical assays can be
used to provide an initial determination of kinase activity, but that followup testing
under more physiological conditions using the ActivX technology, or cellular as-
says, is required to fully assess kinase inhibitor activity.
2278 Mouse Cecal Microbiota Converts Monomethylarsonic Acid
(MMA) to an Array of Oxy- and Thio-Arsenical Metabolites.
M. J. Kohan2,  D. J. Thomas2,  T. Pinyavev1,  M. Mantha1,  K. M. Herbin-Davis2
and J. T. Creed1. 1MCEARD, NERL, US EPA, Cincinnati, OH; 2ISTD, NHEERL,
US EPA, Research Triangle Park, NC.
The metabolism of arsenicals markedly affects their tissue distribution and reten-
tion as well as the toxic and carcinogenic effects of this metalloid. Metabolism of ar-
senicals by the microbiota of the gastrointestinal tract has been shown to convert
inorganic and dimethylated arsenicals to various methylated species. Here, anaero-
bic microbiota from ceca of adult female C57BL/6 mice was incubated with 20,
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200, 1000, or 2000 parts per billion (ppb) MMA for up to 48 hours at 370C.
Samples of supernates from reaction mixtures were taken for arsenic speciation by
HPLC-ICP-MS. MMA was converted to monomethylated mono- (MMMTA), di-
(MMDTA), and tri (MMTTA) thiolated species.  In addition, MMA was also con-
verted to dimethylated mono- (DMMTA) and di- (DMDTA) thiolated species.
After 48 hours, DMDTA was the predominant metabolite in reaction mixtures
containing 20, 200, or 1000 ppb MMA. In reaction mixtures containing 2000 ppb
MMA, MMDTA was the predominant metabolite of MMA. These results show
that anaerobic microbiota from mouse cecum includes organisms that efficiently
methylate MMA and can convert oxyarsenicals into homologous thioarsenicals.
The presumptive source of sulfur used for conversion of oxyarsenicals into
thioarsenicals is hydrogen sulfide produced by the microbiota through dissimila-
tory sulfate reduction. Conversion of methylated oxyarsenicals into methylated
thioarsenical during preabsorptive metabolism may influence the transport of in-
gested arsenic across the gastrointestinal barrier thereby affecting the systemic dis-
tribution, fate, and effects of arsenic. (This abstract does not reflect U.S. EPA pol-
icy).
2279 Paraoxonase Activity in Subchronic Low-Level Inorganic
Arsenic Exposure.
O. Ademuyiwa1,  O. K. Afolabi1,  A. D. Wusu1,  O. O. Ogunrinola1,
E. O. Abam1,  D. O. Babayemi1,  E. A. Balogun1 and O. O. Odukoya2.
1Biochemistry, Federal University of Agriculture, Abeokuta, Nigeria; 2Chemistry,
Federal University of Agriculture, Abeokuta, Nigeria.
Epidemiological evidences indicate close association between inorganic arsenic ex-
posure via drinking water and cardiovascular diseases. While the exact mechanism
of this arsenic-mediated increase in cardiovascular risk factors remains enigmatic,
studies indicate a role for paraoxonase (PON) in cardiovascular diseases. To study
the association between inorganic arsenic exposure and cardiovascular diseases, rats
were exposed to sodium arsenite (50, 100 and 150ppm) and sodium arsenate (100,
150 and 200ppm) in their drinking water for 12 weeks. PON activities towards
paraoxon (PONase) and phenylacetate (AREase) in plasma, lipoproteins, liver and
brain microsomal fractions were determined. Inhibition of PONase and AREase in
plasma and HDL characterised the effects of the two arsenicals. While arsenite in-
hibited PONase by 33% (plasma) and 46% (HDL) respectively, arsenate inhibited
the enzyme by 41 and 34% respectively. AREase activity was inhibited by 52 and
48% by arsenite; the inhibition amounted to 72 and 67% respectively by arsenate.
The pattern of inhibition in plasma and HDL indicates that arsenite induced a
dose-dependent inhibition of PONase whereas arsenate induced a dose-dependent
inhibition of AREase. In the VLDL, arsenate inhibited PONase and AREase while
arsenite inhibited PONase. In the hepatic and brain microsomal fractions, only the
PONase enzyme was inhibited by the two arsenicals. The inhibition was more pro-
nounced in the hepatic microsomes where a 70% inhibition was observed at the
highest dose of arsenate. Microsomal cholesterol was increased by the two arsenicals
resulting in increased cholesterol/phospholipid ratios. Our findings indicate that
decreased PON activity observed in arsenic exposure may be an incipient biochem-
ical event in the cardiovascular effects of arsenic. Modulation of PON activity by
arsenic may also be mediated through changes in membrane fluidity brought about
by changes in the concentration of cholesterol in the microsomes.
2280 Comparative Early Oncogenic Effects of Cadmium and
Arsenic in Human Lung Epithelial Cells.
R. J. Person,  E. J. Tokar and M. P. Waalkes. NTP, NIEHS, NIH, Research Triangle
Park, NC.
Cadmium (Cd) and inorganic arsenic (iAs) are known human lung carcinogens.  In
this study, we compare development of in vitro cellular models of human lung can-
cer induced by Cd or iAs. We have shown chronic, low-level (5 μM) Cd (as CdCl2)
induces an acquired cancer phenotype in human lung epithelial cells (HPL-1D)
after 20 weeks of continuous exposure. Here we compare an iAs model in develop-
ment to this previously developed Cd model. The HPL-1D cells that were used are
an immortalized, non-tumorigenic human peripheral epithelial cell and were used
with both agents. HPL-1D cells were chronically exposed to non-toxic levels of Cd
(5 μM) or iAs (2 μM) and over 20-26 weeks of chronic exposure signs of oncogenic
transformation were asssessed. Matrix metalloproteinase-2 (MMP-2) activity,
colony formation in soft agar, invasion and expression of cancer relevant genes were
used to assess oncogenic phenotype in these cell models. By 26 weeks of continous
iAs exposure, secreted MMP-2 significantly increased to 147% of control, near lev-
els typical of a cancer phenotype. In comparison, after only 20 weeks of Cd expo-
sure, MMP-2 levels increased to 358% of control and cell invasion and colony for-
mation increased by more than 3-fold compared to control cells, all indicating an
oncogenic phenotype. Following iAs exposure (26 weeks) increases were seen in
MT-1A (768% of control) and MT-2A (614% of control) expression, similar to that
seen with Cd transformation. Expression of epithelial-to-mesenchymal transition
marker VIMENTIN increased to 323% of control with chronic iAs exposure. High
VEGF oncogene expression is often seen in lung adenocarcinomas and after 26
weeks of chronic iAs treatment expression increased to 4.3-fold above control. The
SLC39A8 (ZIP 8) transporter, which is known to influx Cd, though increased by
Cd transformation was unchanged in chronic iAs exposure. Thus, it appears that
both Cd and iAs can induce early signs of transformation in human lung epithelial
cells, although some gene expression is inorganic specific.
2281 Metallothionein Blocks Arsenic-Induced Oxidative DNA
Damage.
W. Qu and M. P. Waalkes. NTP, NIEHS, NIH, Research Triangle Park, NC.
Metallothionein (MT) plays an important role in detoxication of inorganics.
Inorganic arsenic is a toxic metalloid and a human carcinogen that may act, in part,
by causing oxidative DNA damage (ODD). MT can limit ODD induced by other
inorganic carcinogens, like cadmium. Although MT can mitigate arsenic toxicity in
vivo, how MT impacts arsenic-induced ODD has not been defined. Here, we stud-
ied ODD induced by acute arsenic treatment in vitro and the effects of cellular MT
using cells that poorly express MT (MT-I/II double knockout; called MT-null cells)
compared to parental wild-type (WT) MT competent cells. MT-null and WT cell
lines were first exposed to arsenite (NaAsO2) for 24 h to assess cytolethality.
Arsenic was much less cytotoxic in WT cells (LC50 = 11.0 ± 1.3 μM, mean ± SEM)
than MT-null cells (LC50 = 5.6 ± 1.2 μM). Arsenic-induced ODD was measured by
the immuno-spin trapping method which measures DNA radicals after conversion
to stable DNA nitrones in situ. Arsenic treatment (1 or 5 μM; 24 h) induced much
less ODD in WT cells (121% and 141% of control, respectively) than in MT-null
cells (202% and 260%). In WT cells arsenic caused concentration-related increases
in MT expression (transcript and protein), and in metal-activated transcription fac-
tor 1 (MTF1), a requirement for induced MT gene expression by arsenic. In con-
trast, in MT-null cells, the basal levels of MT were very low and were not increased
by arsenic. Transfection of MT-I into MT-null cells markedly reduced arsenic-in-
duced ODD. Two important transport genes, Mrp1 and Mrp2, showed increased
expression in WT cells but not MT-null cells. Arsenic caused concentration-related
increases in the oxidant defense genes, HO-1 and GSTa2 in both WT and MT-null
cells, but to much higher levels in WT cells. Thus, MT protects against arsenic-in-
duced ODD in MT competent cells potentially by multiple mechanisms including
direct sequestration and scavenging oxidant radicals. MT-competent cells are more
adept at activating metal transport systems and oxidant response genes, although
the role of MT in these responses is unclear.
2282 Increase Blood Pressure, Changes of Left Ventricular
Geometry, and Function in Children Environmentally
Exposed to Inorganic Arsenic.
C. Osorio-Yañez1,  J. Ayllon-Vergara2,  L. Arreola-Mendoza3,  G. Aguilar-
Madrid4,  E. Hernández-Castellanos1,  A. Barrera-Hernández1,  L. C. Sanchez-
Peña1 and L. M. Del Razo1. 1Toxicology, Cinvestav-IPN, D.F., Mexico; 2Español
Hospital, D.F., Mexico; 3CIIEMAD-IPN, D.F., Mexico; 4Health and Work, IMSS,
D.F., Mexico.
Hypertension is a known cardiovascular risk factor to develop final cardiac events
and epidemiologic studies in adults have been related hypertension with inorganic
arsenic (iAs) exposure. Left ventricular mass (LVM) increase is a potent predictor of
cardiovascular morbidity and mortality and it is stimulated by higher blood pres-
sure as well as impaired myocardial contractile performance. Ejection fraction (EF)
has been employed as a good index of global systolic function. The aim of this study
was evaluate the association between iAs exposure, blood pressure, and echocardio-
graphic parameters in children.In this cross-sectional study 170 children (3-14
years old) chronically exposed to iAs through drinking water were recruited in iAs-
endemic area of central part of México. LVM and EF were derived from echocar-
diography and blood pressure was measured by standard protocols. Total arsenic in
urine (UtAs) was significant associated with systolic (β=2.65; p=0.056) and dias-
tolic (β=0.012; p=0.019) blood pressure in multivariate regression models adjusted
by age, gender and body mass index. Indeed, diastolic blood pressure was associated
with cumulative arsenic exposure (ΣAsE; ppb*year) thought drinking water
(β=0.003; p=0.002). Notably, LVM (g) was significant associated with ΣAsE
(β=15.43; p=0.002) in adjusted multivariate model. Diastolic prehypertension was
present in 48%, concentric remodeling was presented in 60% [normal LVM and
relative wall thickness (RWT) ≥0.43] and LVM concentric hypertrophy defined as
LVM >88.9 g/m2 and RWT≥0.43 were presented in 7% (11 children). Moreover,
EF was inversely associated with UtAs> 35ng/ml (β=-3.21; p=0.036) in adjusted
multivariate analyses. In conclusion, iAs exposure would be able to cause diastolic
prehypertension, increase of LVM and decrease of EF in children, given evidence of
possible cardiovascular disease in early-life exposure.
488 SOT 2013 ANNUAL MEETING
2283 Reduction of Dimethylarsenate to the Supertoxic
Dimethylarsenite by Rats and Rat Liver Cytosol.
Z. Gregus and B. Németi. University of Pécs, Pécs, Hungary.
Dimethylarsinic acid (DMAsV) is the major urinary metabolite of inorganic arsenic
in humans and most animals. DMAsV is weakly cytotoxic, however, it is reduced to
dimethylarsinous acid (DMAsIII) which is over 100 times more toxic. Although
glutathione S-transferase omega 1 (GSTO1) catalyzes the reduction of DMAsV, its
role in DMAsV reduction in vivo or in cell extracts is uncertain. We studied the re-
duction of DMAsV to DMAsIII in rats and in rat liver cytosol to better understand
its mechanism. To assess DMAsV reduction in rats, we devised a novel procedure.
This is based on following the time course of the accumulation in the blood of the
RBC-bound dimethylarsenic (DMAs), which represents DMAsIII. Therefore, we
serially measured the RBC-bound DMAs in the blood of DMAsV-injected anes-
thetized rats with ligated renal pedicles. These studies indicated that reduction of
DMAsV to DMAsIII was rapid, as in 90 min 31% of the injected 50 μmol/kg
DMAsV dose was converted to DMAsIII that was sequestered by the circulating
erythrocytes. Pretreatment of rats with glutathione (GSH) depletors (phorone or
BSO) delayed the elimination of DMAsV and the accumulation of RBC-bound
DMAs, whereas the methyltransferase inhibitor PAD was without effect.
Reduction of DMAsV by rat liver cytosol was assayed by extraction of DMAsIII
from the incubations of cytosol with DMAsV and quantification by HPLC-HG-
AFS. We found that reduction of DMAsV required cytosolic protein and GSH and
was inhibited by thiol reagents, GSSG and dehydroascorbate. Although thiore-
doxin reductase (TrxR) inhibitors (aurothioglucose and trivalent antimony) inhib-
ited cytosolic DMAsV reduction, TrxR plus NADPH alone or when added to the
cytosol failed to support DMAsV reduction. On ultrafiltration of the cytosol
through a 3 kDa filter, the reducing activity in the retentate was lost but was largely
restored by NADPH. Such experiments also indicated that the reducing enzyme
was larger than 100 kDa, and was not GSTO1. In summary, reduction of DMAsV
to the supertoxic DMAsIII in rats and rat liver cytosol is rapid and GSH depend-
ent, yet its mechanism is still elusive.
2284 Fibronectin Expression in Human Bladder Cells (UROtsa)
Exposed to or Malignantly Transformed by Arsenic or
Cadmium.
A. R. Klinger1,  M. E. Jeno1,  K. J. Wilt1,  H. M. Hewitt1,  X. Zhou2,  S. Somji2,
S. H. Garrett2,  D. A. Sens2 and J. R. Dunlevy1. 1Anatomy, University of North
Dakota, Grand Forks, ND; 2Pathology, University of North Dakota, Grand Forks,
ND.
Fibronectin is an extracellular matrix glycoprotein that is present in nearly all con-
nective tissues as well as a soluble protein within the blood. The main functions of
fibronectin relate to cellular adhesion, cell migration, and cell signaling. In the
bladder, fibronectin is found within the lamina propria, blood vessels, nerves, and
smooth muscle basement membrane. Fibronectin is present at very low levels in the
normal bladder epithelium but in bladder carcinomas it has been found to be sub-
stantially increased in expression and/or present in oncofetal alternatively spliced
forms. This has led to several studies of fibronectin as a potential prognostic marker
in bladder cancer. The purpose of the current study is to validate initial microarray
studies that indicated strong differential expression of fibronectin in UROtsa blad-
der cells transformed with cadmium compared to non-malignant UROtsa cells.
Fibronectin mRNA and protein were found to be increased in 6 of 7 cadmium
transformed cell lines as well as in 5 of 6 arsenic transformed cell lines compared to
the non-transformed parent cells. The ability of fibronectin expression to be altered
epigenetically by histone acetylation or DNA methylation or directly by exposure
to arsenic or cadmium was also examined. Fibronectin mRNA and protein was
found to consistently decrease during 24-72 hours exposure to arsenic but was not
consistently changed by short term exposure to cadmium. The results of this study
show that alternations in fibronectin expression may correlate with transformation
of bladder cells exposed to heavy metals.
2285 Gene Expression Changes Induced by Various Arsenicals In
Vitro.
P. R. Dodmane,  L. L. Arnold,  K. L. Pennington and S. M. Cohen. Pathology and
Microbiology, University of Nebraska Medical Center, Omaha, NE.
Inorganic arsenic (IA) is a human urinary bladder, skin and lung carcinogen. The
mechanism by which IA induces tumors is unknown. IA is metabolized to methy-
lated arsenicals and excreted in urine. In vitro trivalent arsenicals are more cytotoxic
than pentavalent forms. Multiple studies have documented a range of arsenic-in-
duced gene changes in vivo and in vitro, but the dose response is unclear. In this
study, the dose response for IA and effects of various arsenicals for gene expression
changes was evaluated in human bronchial epithelial cells (HBEC). Primary HBEC
were exposed to 0.1, 1, 5 or 10 μM of AsIII, 1 μM MMAIII and 1.4 μM DMAIII
for 24 h and 5.8 μM AsIII for 72 h. Increasing concentration of AsIII showed in-
creasing number of differentially expressed genes (DEG) correlating with increasing
cytotoxicity. The lowest AsIII used, 0.1 μM, did not induce any DEG, whereas
there were 7, 101 and 1735 DEG at 1, 5 and 10 μM AsIII, respectively. Pathway
analysis showed only IFN signaling and pattern recognition receptor pathways
(PRRP) being altered with 1 μM AsIII. IFN signaling was also altered with 5 μM
AsIII in addition to NRF2-mediated oxidative stress response (NOSR) and IL-17A
signaling. Ten μM AsIII altered NOSR in addition to glutamate metabolism, cell
cycle:G1/S check point regulation, p53 signaling and AhR signaling. DMAIII in-
duced 2 DEG and MMAIII induced 268 DEG. DMAIII induced lesser cytotoxic-
ity compared to MMAIII. MMAIII induced canonical pathways of hepatic stellate
cell activation, LXR/RXR activation, atherosclerosis signaling, PRRP and IFN sig-
naling pathways. AsIII for 72 h induced 71 DEG that represented similar signaling
pathways as observed at 24 h. These data suggest that arsenic at lower concentra-
tions induces inflammatory and oxidative stress responses whereas at higher con-
centrations it altered multiple cellular pathways that control cell cycle and cell pro-
liferation. NOAEL for AsIII appears to be between 0.1 to 1 μM. All arsenicals
tested altered similar signaling pathways in HBEC and were similar to urothelial
cells and keratinocytes.
2286 Effects of Treatment with Dimethylarsinous Acid (DMAIII)
on the Urinary Bladder Epithelium of Female Arsenic
Methyltransferase (As3mt) Knockout Mice and C57Bl/6
Mice.
L. L. Arnold,  P. R. Dodmane,  K. L. Pennington and S. M. Cohen. Pathology and
Microbiology, University of Nebraska Medical Center, Omaha, NE.
Chronic exposure to inorganic arsenic (InAs) is carcinogenic to the human urinary
bladder. It produces urothelial cytotoxicity and proliferation in rats and mice.
DMAV, a major methylated urinary metabolite of InAs, is a rat bladder carcinogen.
DMAIII was shown to be the likely urinary metabolite of DMAV- inducing urothe-
lial changes and is postulated be one of the active metabolites of InAs. To evaluate
potential DMAIII-induced urothelial effects, it was administered to As3mt knock-
out mice which cannot methylate arsenicals. Female C57Bl/6 wild type and As3mt
knockout mice (10/group) were administered DMAIII, 77.3 ppm in water for four
weeks. Urothelial effects were evaluated by light and scanning electron microscopy
(SEM) and immunohistochemical detection of bromodeoxyuridine (BrdU).
DMAIII significantly increased the BrdU labeling index in the knockout group
compared to control and to the treated wild type group. DMAIII induced a greater
increase in the incidence of simple hyperplasia in knockout mice (4/10) compared
to wild type mice (2/10). All treated knockout mice had more and larger intracyto-
plasmic granules, compared to the treated wild type mice. Changes in SEM classifi-
cation were not significant. In conclusion, DMAIII induces urothelial toxicity and
regenerative hyperplasia in mice and most likely plays a role in inorganic arsenic-in-
duced urothelial changes. However, in mice, DMAV does not induce hyperplasia,
suggesting that urinary concentrations of DMAIII do not reach cytotoxic levels in
DMAV-treated mice.
2287 Arsenite Inhibits DNA Repair through S-Nitrosation of Poly
(ADP-Ribose) Polymerase 1.
X. Zhou,  K. L. Cooper,  L. G. Hudson and K. Liu. College of Pharmacy,
University of New Mexico, Albuquerque, NM.
Arsenic, a widely distributed carcinogen, is known to significantly amplify the im-
pact of other carcinogens such as ultraviolet radiation and benzo(a)pyrene at low,
non-cytotoxic concentrations. Evidence from our lab and others suggests inhibition
of DNA repair could be an important mechanism of arsenic co-carcinogenesis. We
recently demonstrated that reactive nitrogen species (RNS) induced by arsenic may
play an important role in inhibition of PARP-1 activity, but the role of RNS in the
mechanism of arsenic inhibition is not clear. In this work, we show that As(III)-in-
duced RNS caused S-nitrosative modification on cysteine residuals of Poly(ADP-ri-
bose) polymerase (PARP)-1, a key DNA repair protein in base excision repair. We
found that similar to the effect of a NO donor, As(III) treatment in HaCat cells in-
duced S-nitrosation on PARP-1 protein. This S-nitrosaton of PARP-1 could be re-
duced by L-NAME (nitric oxide synthase inhibitor), c-PTIO (nitric oxide scav-
enger) or ascorbic acid. In addition, As(III) treatment lead to zinc loss and activity
inhibition of PARP-1 protein isolated from cells. Importantly, we confirmed that S-
nitrosation happened on zinc finger DNA binding domain of PARP-1 protein
using biotin-switch assay. Taken together, these results show that arsenite induces S-
nitrosation on zinc finger DNA binding domain of PARP-1 via generation of NO,
leading to zinc loss and activity inhibition of PARP-1. These findings provide novel
insight into the molecular mechanism of As inhibition of PARP-1.
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2288 Paradoxical Effects of Ongoing Arsenic Exposure on an
Arsenic-Transformed Bladder Cancer Model.
F. Zhao,  S. Pacheco,  A. Gandolfi and W. T. Klimecki. Pharmacology and
Toxicology, University of Arizona, Tucson, AZ.
Epidemiology studies have shown a strong link between chronic arsenic exposure
and bladder cancer. An immortalized human urothelial cell line, UROtsa has been
widely used as a model of arsenic-induced bladder toxicity. Chronic exposure to
1uM sodium arsenite transforms UROtsa to a cancerous cell line, URO-ASSC.
This phenotype is stable with no further arsenite selection, and URO-ASSC is typ-
ically assayed for malignancy without arsenite exposure. In the absence of arsenite,
we found that both UROtsa and URO-ASSC demonstrate constitutive autophagy.
Recent evidence suggests that autophagy is a survival mechanism for cancer. This
led us to hypothesize that disrupting autophagy could reduce malignant potential
in URO-ASSC. We found that URO-ASSC accumulates LC3II protein levels 3.4
fold faster compared to UROtsa when autophagic flux was blocked with
bafilomycin A1 in a 2-hour time course, suggesting a higher rate of autophagic
turnover in URO-ASSC. Impairing autophagy in URO-ASSC by siRNA against
ATG7 resulted in 65% reduction of anchorage-independent growth, a key pheno-
type of arsenic-induced malignant transformation. Surprisingly, when we reintro-
duced URO-ASSC cells to 1uM of arsenite exposure, LC3-II levels and autophagic
flux were reduced by 50%, suggesting that ongoing exposure to arsenite impairs au-
tophagy. This autophagy impairment was also associated with a 55% reduction in
soft agar growth in the presence of 1uM arsenite. These in vitro experiments pro-
vide insight into the complex effect of arsenic exposure on the process of autophagy
and its relationship to arsenite-induced malignancy. Furthermore, these studies
raise the possibility that ongoing arsenic exposure may suppress malignant growth
concurrently with establishing the malignant phenotype, perhaps in part through
modulating the autophagic pathway. The translational impact of this finding could
have bearing on human populations such as those in Chile, that transition from pe-
riods of sustained arsenic exposure to periods in which arsenic exposure has been
mitigated.
2289 Effects of Arsenic on Expressions of Ube2d Family and
Accumulation of p53 in Renal Tubular Cells and Vascular
Endothelial Cells.
M. Satoh1,  J. Lee1,  M. Tokumoto1, 2,  Y. Fujiwara1 and C. Watanabe3. 1School of
Pharmacy, Aichi Gakuin University, Nagoya, Japan; 2Showa Pharmaceutical
University, Tokyo, Japan; 3Graduate School of Medicine, University of Tokyo, Tokyo,
Japan.
Arsenic is an environmental pollutant that induces apoptosis in various tissues.
However, underlying molecular mechanisms of arsenic-induced apoptosis are not
clear. Recently, we have found that apoptosis through the overaccumulation of p53
is involved in cadmium toxicity in rat proximal tubular cells (NRK-52E cells).
Moreover, gene expressions of Ube2d family, which conjugate ubiquitin to p53 and
drive p53 to be degraded, are suppressed by cadmium in NRK-52E cells. In this
study, we examined the involvement of gene expressions of Ube2d family (Ube2d1,
Ube2d2, Ube2d3 and Ube2d4) and accumulation of p53 in arsenic toxicity, using
model cells of vascular endothelia and renal tubules. In NRK-52E cells, NaAsO2
(As[III]) decreased mRNA levels of Ube2d family except Ube2d3 and increased
protein levels of p53. Interestingly, although protein levels of p53 were markedly
increased by As[III], mRNA levels of UBE2D family were not decreased by this
metalloid in human brain microvascular endothelial cells (HBMECs). In human
proximal tubular cells (HK-2 cells), As[III] slightly increased protein levels of p53
with low-dose treatment. However, mRNA levels of UBE2D family were not de-
creased by As[III] in HK-2 cells. Moreover, mRNA levels of p53 were decreased by
As[III] in HBMECs and HK-2 cells. Our findings suggest that As[III] increases cel-
lular protein levels of p53, mediating tissue- or cell-specific pathways for p53 sta-
bility.
2290 A Common Arsenic (+3 Oxidation State) Methyltransferase
(AS3MT) Polymorphism Affects Urinary Metabolite Profiles
of Arsenic in a US Population.
D. J. Thomas4,  Z. Drobna1,  M. Styblo1,  R. L. Calderon2,  X. Lu3,  X. Le3 and
E. E. Hudgens2. 1Nutrition, University of North Carolina at Chapel Hill, Chapel
Hill, NC; 2EPHD, NHEERL, US EPA, Research Triangle Park, NC;
3Environmental Health Sciences, University of Alberta, Edmonton, AB, Canada;
4ISTD, NHEERL, US EPA, Research Triangle Park, NC.
AS3MT catalyzes methylation of inorganic arsenic (iAs) forming mono- (MAs) and
di- (DMAs) methylated products that mediate some of the toxic and carcinogenic
effects associated with chronic iAs exposure. Therefore, the catalytic efficiency of
AS3MT may be an important determinant of risk associated with chronic iAs ex-
posure. Concentrations of iAs, MAs, and DMAs in urines from residents of
Churchill County, Nevada, were used to calculate primary (MAs/iAs) and second-
ary (DMAs/MAs) methylation indices (MI). AS3MT genotypes were determined
for 198 individuals selected on the basis of lowest and highest secondary MIs. The
incidence of an AS3MT polymorphism (rs11191439) that replaces a methionyl
residue in position 287 with a threonyl residue (M287T) affected the secondary
MI. For the M287T polymorphism, median values for secondary MIs were 6.5 in
150 individuals homozygous for wild-type AS3MT, 2.8 in 43 individuals heterozy-
gous for wild-type and mutant alleles, and 2.4 in 5 individuals homozygous for the
M287T polymorphism. In contrast, median values for primary MIs were unaf-
fected by this polymorphism. Two intronic variants (T35587C and G35991A) re-
ported to alter the levels of MAs and DMAs in other studies did not alter primary
and secondary MIs in this population. These results indicate that the common
M287T polymorphism of AS3MT is associated with altered profiles of methylated
arsenicals in urine from individuals chronically ingesting iAs in drinking water.
Linkages among AS3MT genotype-dependent alterations in urinary arsenical pro-
files, the catalytic properties of AS3MT variants, and disease susceptibility require
further examination. (This abstract does not reflect U.S. EPA policy).
2291 Arsenic Increases Atherosclerosis by LXRα-Dependent and
LXRα-Independent Mechanisms.
M. Lemaire1,  C. A. Lemarié2,  M. Flores Molina1 and K. K. Mann1. 1Oncology,
Lady Davis Institute for Medical Research, McGill University, Montréal, QC,
Canada; 2Medicine, Lady Davis Institute for Medical Research, McGill University,
Montréal, QC, Canada.
Arsenic exposure has been linked to atherosclerosis; however, molecular mecha-
nisms involved in arsenic-enhanced atherosclerosis are unknown. Previously, we
have shown in vitro and in vivo that arsenic inhibits transcriptional activation of the
liver X nuclear receptors (LXR), key regulators of macrophage lipid homeostasis.
Here, we evaluated the role of LXRα in arsenic-induced atherosclerosis using the
ApoE-/- mouse model. In ApoE-/- mice, 200 ppb arsenic increased atherosclerosis
plaque size after 13 weeks. In contrast, LXRα-/-ApoE-/- mice do not show increased
plaque size following arsenic exposure, indicating that arsenic may enhance athero-
sclerosis in an LXRα-dependent manner. In the ApoE-/- mice, we saw significant
changes in plaque composition, and thus in LXRα-/-ApoE-/-, we assessed plaque
staining of: 1) lipid deposition and macrophage content and 2) collagen composi-
tion and smooth muscle cell content. Interestingly, arsenic decreases macrophages
in LXRα-/-ApoE-/-, where no change was observed in ApoE-/- exposed mice.
However, arsenic increased lipids in both genotypes, suggesting impaired
macrophage cholesterol efflux capacity and subsequent lipid accumulation.
Secondly, we observed that arsenic decreased collagen content in LXRα-/-ApoE-/-
and ApoE-/- to the same extent, but arsenic increased smooth muscle cells, a major
collagen producing cell type, in the in LXRα-/-ApoE-/-, while they were decreased in
ApoE-/-. This indicates that LXRα may be involved in maintaining matrix integrity.
In fact, arsenic-exposed LXRα-/-ApoE-/- plaques had increased matrix metallopro-
teinase (MMPs) activity compared to both control LXRα-/-ApoE-/- and ApoE-/-,
which could be responsible for both the decrease in plaque collagen and the smooth
muscle cells invasion. Our observations suggest that arsenic maybe increasing ath-
erosclerosis formation through LXR inhibition, but it may alter plaque composi-
tion in a LXR independent manner.
2292 Induction of Cytochrome P450 1A1 (CYP1A1) by
Pentavalent Methylated Arsenicals in Human Hepatoma
HepG2 Cells.
A. Anwar-Mohamed,  O. Elshenawy and A. O. El-Kadi. University of Alberta,
Edmonton, AB, Canada.
Arsenic (As(III)) is a worldwide environmental pollutant and a human carcinogen.
It is well recognized that the carcinogenicity of As(III) is largely dependent on the
methylation levels (monomethyl, dimethyl, and trimethyl) that are present during
the process of metabolism in mammals. Oxidative methylation, is based on the
findings that As(III) is sequentially converted to monomethylarsonic acid
(MMA(V)), dimethylarsinic acid (DMA(V)), and trimethylarsine oxide (TMA(V))
in both humans and in laboratory animals such as mice and rats. Activation of the
aryl hydrocarbon receptor (AhR) ultimately leads to the induction of the carcino-
gen activating enzyme cytochrome P450 1A1 (CYP1A1). Therefore, in this study
we examined the effects of co-exposure to MMA(V), DMA(V), or TMA(V) in the
absence and presence of the AhR ligand, 2,3,7,8-tetrachlorodibenzo-p-dioxin
(TCDD), on the expression of CYP1A1 in HepG2 cells. Our results showed that
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treatment of HepG2 cells with MMA(V), DMA(V), or TMA(V) alone signifi-
cantly induces CYP1A1 mRNA, protein, and catalytic activity levels. Furthermore,
when the cells were co-exposed to MMA(V), DMA(V), or TMA(V) in the presence
of TCDD, there was further potentiation of the TCDD-mediated induction of
CYP1A1 mRNA, protein, and catalytic activity levels. In addition, MMA(V),
DMA(V), and TMA(V) in the absence and presence of TCDD induced the AhR-
dependent XRE-driven luciferase reporter activity, suggesting an AhR-dependent
mechanism. In conclusion, this is the first demonstration that As(III) metabolites,
MMA(V), DMA(V), and TMA(V) induce CYP1A1 mRNA, protein, and catalytic
activity levels in an AhR-dependent mechanism and represents a novel mechanism
by which As(III) causes carcinogenicity. Supported by NSERC Discovery Grant
RGPIN 250139-12.
2293 Comparative Oxidation State Specific Analysis of Arsenic by
High-Performance Liquid Chromatography-Inductively
Coupled Plasma-Mass Spectrometry and Hydride
Generation-Cryotrapping-Atomic Absorption Spectrometry.
J. Currier1,  R. Saunders2,  L. Ding2,  W. M. Bodnar3,  P. Cable3,  T. Matoušek4,
J. Creed5 and M. Styblo2. 1Curriculum in Toxicology, University of North Carolina
at Chapel Hill, Chapel Hill, NC; 2Department of Nutrition, University of North
Carolina at Chapel Hill, Chapel Hill, NC; 3Department of Environmental Sciences
and Engineering, University of North Carolina at Chapel Hill, Chapel Hill, NC;
4Institute of Analytical Chemistry of the ASCR, Brno, Czech Republic;
5Microbiological and Chemical Exposure Assessment Research Division, NERL, US
EPA, Cincinnati, OH.
Several methods are used for quantifying the toxic inorganic arsenic (iAs) metabo-
lites, methylarsonous acid (MAsIII) and dimethylarsinous acid (DMAsIII), including
reversed-phase high-performance liquid chromatography-inductively coupled
plasma-mass spectrometry (HPLC-ICP-MS) and hydride generation-cryotrapping-
atomic absorption spectrometry (HG-CT-AAS). While HG-CT-AAS has consis-
tently detected these arsenicals in biological samples, HPLC-ICP-MS has provided
contradictory results. Here, we compare the capacities of both methods to detect
and quantify MAsIII and DMAsIIIin an in vitro methylation system containing re-
combinant human arsenic (+3 oxidation state) methyltransferase (AS3MT), S-
adenosyl methionine, a non-thiol reductant tris(2-carboxyethyl)phosphine, and ar-
senite (iAsIII) or MAsIII as substrates. HPLC separation of the in vitro methylation
mixture resulted in significant loses of MAsIII and DMAsIII with total arsenic recov-
eries below 25%. Ultrafiltration showed that both MAsIII and DMAsIII are bound
to AS3MT. Oxidation of the mixture with H2O2 prior to HPLC separation in-
creased arsenic recoveries to ~95% but oxidized MAsIII and DMAsIII, thus prevent-
ing quantification of these metabolites. In contrast, direct HG-CT-AAS analysis re-
vealed large quantities of MAsIII and DMAsIII and high total arsenic recoveries
(>72%) after cysteine treatment. These data suggest that HPLC-ICP-MS can pro-
vide false-negative results when used for analysis of MAsIII or DMAsIII in biological
samples containing protein at concentrations as low as those commonly found in
human urine.
2294 The Retention of Trivalent Arsenic Metabolites in Urothelial
Cells Is Associated with Markers of As Exposure and
Diabetes.
M. Styblo5,  J. Currier1,  C. González-Horta2,  L. M. Del Razo3,  B. Sánchez-
Ramírez2,  L. Ballinas-Casarrubias2,  G. G. Garcia-Vargas4,  M. C. Ishida2,
R. Saunders5,  Z. Drobna5 and D. Loomis6. 1Curriculum in Toxicology, University
of North Carolina at Chapel Hill, Chapel Hill, NC; 2Universidad Autónoma de
Chihuahua, Chihuahua, Mexico; 3CINVESTAV-IPN, Mexico City, Mexico;
4Universidad Juárez del Estado de Durango, Durango, Mexico; 5University of
Nebraska Medical Center, Omaha, NE; 6Department of Nutrition, University of
North Carolina at Chapel Hill, Chapel Hill, NC.
Chronic exposure to inorganic arsenic (iAs) in drinking water has been linked to an
increased prevalence of diabetes. Laboratory evidence suggests that methylarsonous
acid (MAsIII) and dimethylarsinous acid (DMAsIII) that are formed in the course
of iAs metabolism contribute to the diabetogenic effects of iAs exposure. However,
no data are available on tissue concentrations of these toxic metabolites in humans.
Here, we used a newly developed hydride generation(HG)-cryotrapping(CT)-in-
ductively coupled plasma-mass spectrometry method with limits of detection of
0.04-2 pg As to examine the retention of tri- and pentavalent metabolites of iAs in
urinary bladder exfoliated cells (BECs) isolated from urine of 343 residents of
Chihuahua, Mexico who ingest drinking water contaminated with up to 400 ppb
As. The urinary metabolites of iAs were measured by HG-CT-atomic absorption
spectrometry. The sum of As species in BECs ranged from 0.8 to 3,137 pg
As/10,000 cells. Notably, iAs was the major species retained in BECs (~66% of
total As). MAsIII and DMAsIII accounted for 8 and 2% of total As. We found pos-
itive statistically significant correlations between the concentrations of As species in
in BECs and in urine (r = 0.12–0.55, p<0.001). When adjusted for age, sex, and
BMI, trivalent arsenicals retained in BECs were significantly correlated with mark-
ers of diabetes, fasting plasma glucose (FPG) and 2-hour plasma glucose (2HPG) (r
= 0.13-0.20, p <0.001). Urinary iAs, MAs, and DMAs also correlated with FPG
and 2HPG (r = 0.15-0.21, p<0.001). Thus, both urinary metabolites of iAs and the
metabolites retained in BEC can be used as biomarkers of the diabetogenic effects
of iAs exposure.
2295 Oxidation State Specific Analysis of Arsenic Species in
Tissues of Wildtype and Arsenic (+3 Oxidation State)
Methyltransferase (As3mt) Knockout Mice.
C. Douillet2,  J. Currier1,  R. Saunders2,  Z. Drobna2 and M. Styblo2. 1Curriculum
in Toxicology, University of North Carolina at Chapel Hill, Chapel Hill, NC;
2Department of Nutrition, University of North Carolina at Chapel Hill, Chapel Hill,
NC.
As3mt catalyzes the conversion of inorganic arsenic (iAs) to methylated metabo-
lites, including methylarsonite (MAsIII) and dimethylarsinite (DMAsIII). While
this enzyme is critical for the detoxification of ingested iAs, MAsIII and DMAsIII
are more toxic than iAs. The As3mt-KO mice can thus be used to explore the role of
MAsIII and DMAsIII in the adverse effects of iAs exposure. Wild-type (WT)
C57BL/6 mice exposed to 50 ppm As as arsenite (iAsIII) in drinking water devel-
oped diabetes characterized by impaired glucose tolerance without insulin resist-
ance. Methylated arsenicals were detected in tissues maintaining glucose homeosta-
sis, but the oxidation state of As was not determined. Our recently developed
HG-CT-AAS method for the oxidation state specific speciation of As in complex
biological matrices was used to compare retention of tri- and pentavalent As species
in tissues of WT and As3mt-KO mice drinking water with iAs. As3mt-KO mice
were exposed to 0, 15, 20, 25 or 30 ppm and WT mice to 50 ppm As as iAsIII for
4 weeks. As3mt-KO mice retained almost exclusively iAs; iAsIII was the most preva-
lent species in liver, pancreas, adipose, lung, heart, and kidney, ranging from 53 to
74% of total As. Methylated arsenicals did not exceed 10% of total As in any tissue.
Tissues of WT mice retained iAs and methylated arsenicals; iAsIII, MAsIII and
DMAsIII represented 55-68% of the total As in the liver, pancreas, and brain. High
levels of MAsIII were found in the intestine and intestinal content of WT, but not
As3mt-KO mice, suggesting that intestinal bacteria are not a major source of
methylated As species. Our results indicate that internal total As doses in tissues
critical to glucose homeostasis (liver, pancreas, skeletal muscle, adipose) equivalent
to WT mice can be achieved in As3mt-KO mice after exposure to 25 and 30 ppm
As. Future studies will compare the diabetogenic effects of iAs exposure in WT and
As3mt-KO mice.
2296 Photo-Activatable GFP-Labeled Rat Glucocorticoid Receptor
(paGFP-rGR) As Model to Study Effects of Arsenic on
Endocrine Receptor Activation and Cellular Localization.
S. K. Schmaling1, 3,  F. Zandbergen1,  A. Adebayo1, 2,  C. M. Connolly1, 4,
V. Chatikavanij1,  J. E. Bodwell5 and J. W. Hamilton1, 2. 1Marine Biological
Laboratory, Woods Hole, MA; 2Brown University, Providence, RI; 3Bridgewater State
University, Bridgewater, MA; 4Valdosta State University, Valdosta, RI; 5Dartmouth
Medical School, Lebanon, NH.
Exposure to arsenic (As) is associated with an increased risk of many serious ill-
nesses including several types of cancer, type 2 diabetes, cardiovascular disease, and
reproductive and developmental problems. Previous research showed that As can
act as an endocrine disruptor, altering the regulation of gene expression by numer-
ous nuclear hormone receptors, including the Glucocorticoid Receptor (GR). At
very low doses (0.05-1 μM) As enhanced hormone-mediated, GR-regulated gene
expression by 2- to 3-fold. Conversely, at intermediate non-cytotoxic concentra-
tions (1-5 μM) As inhibits receptor-mediated gene expression. We have hypothe-
sized that these differential effects reflect separate mechanisms with different targets
and that the inhibited activation could be caused by 1) altered rate of hormone re-
ceptor translocation to the nucleus, 2) altered number of receptors that translocate,
3) altered steady-state nuclear levels of receptor (e.g., by decreases in nuclear ex-
port), 4) altered efficiency of receptor function, or some combination of these. To
test this, we used HEK293 cells to generate a cell line stably expressing rat GR fused
to photo-activatable Green Fluorescent Protein (HEK293-paGFP-rGR), allowing
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for intracellular tracking of GR using microscopy. The paGFP-rGR behaves bio-
chemically in a similar manner as native GR. PaGFP-rGR mediates hormone-in-
duced gene expression and microscopy showed that the rate and extent of nuclear
translocation of paGFP-rGR increase in a concentration dependent manner in re-
sponse to synthetic glucocorticoid. We found that intermediate As concentrations
reduce this translocation. (Funded by NIH-NIEHS SRP (P42 ES007373), NSF
REU (0115378), and NIH-NRSA (2 T32 ES 7272-21))
2297 In Utero Arsenic Exposure and Epigenetic Changes in the
Mouse Liver: Comparisons with Transcriptional Modulation.
K. Bailey1,  D. Rojas2,  Z. Drobna3 and R. C. Fry1, 2. 1Environmental Sciences and
Engineering, University of North Carolina at Chapel Hill, Chapel Hill, NC;
2Curriculum in Toxicology, University of North Carolina at Chapel Hill, Chapel Hill,
NC; 3Department of Nutrition, University of North Carolina at Chapel Hill, Chapel
Hill, NC.
Chronic exposure to high levels of iAs in drinking water is associated with cancers
of the skin, urinary bladder, lung, liver, and prostate in humans. Exposure to iAs
during fetal development has been of particular concern as this developmental time
point is often particularly sensitive to the effects of environmental toxicants. In
C3H and CD1 mice, iAs acts as a complete transplacental carcinogen in which
male offspring born to pregnant CH3 and CD1 females exposed to 85 ppm iAs in
drinking water during the latter part of gestation [gestational day (GD) 8-18] have
an increased incidence of hepatocellular carcinomas (HCCs) in adulthood, a major
form of cancer associated with chronic iAs exposure in humans. Analyses of nor-
mal-appearing liver tissue from transplacentally-exposed newborns and adults with
liver tumors have previously reported perturbations in gene expression and/or
global DNA methylation levels and suggested these alterations may contribute to
iAs-associated liver carcinogenesis. Here, we examined the gene expression profiles
of >35,000 transcripts and the DNA methylation levels of >15,000 CpG islands as-
sociated with gene promoters of fetal male CD1 mice (GD 18) transplacentally ex-
posed to a hepatocarcinogenic dose (85 ppm) of iAs (GD 8-18). Compared to ve-
hicle-exposed mice, we observed statistically significant changes in the
transcriptome (308 transcripts) and DNA methylome (191 gene promoters) in ges-
tationally-exposed fetal males (p<0.05, 1.3-fold change vs. controls). Surprisingly,
when using these same criteria for the identification of changes in DNA methyla-
tion and transcript levels, there were no common genes. These results suggest alter-
ations in the DNA methylome may not necessarily be predictive of changes in gene
expression and the relevance of these alterations in disease development warrant
further study.
2298 Arsenic Compromises Airway Epithelial Barrier Properties in
Primary Mouse and Immortalized Human Cell Cultures.
C. L. Sherwood1, 4, 5,  A. Liguori1, 4, 5,  C. Olsen1, 4,  C. Lantz2, 4, 5,  J. L. Burgess4, 6
and S. Boitano1, 3, 4. 1Arizona Respiratory Center, AZ Health Sciences Ctr, Tucson,
AZ; 2Cell and Molecular Mediicine, AZ Health Sciences Ctr, Tucson, AZ; 3Physiology,
AZ Health Sciences Ctr, Tucson, AZ; 4Southwest Environmental Health Sciences Ctr,
University of Arizona, Tucson, AZ; 5Bio5 Institute, University of Arizona, Tucson,
AZ; 6Mel & Enid Zuckerman College of Public Health, University of Arizona, Tucson,
AZ.
Arsenic is a lung toxicant that can lead to respiratory illness through inhalation and
ingestion. Lung effects from arsenic exposure include lung cancer and obstructive
lung disease, as well as reductions in lung function and immune response. As a key
player in innate immune defense, airway epithelial cells provide a barrier that pro-
tects underlying tissue from inhaled particulates, pathogens, and toxicants. In ani-
mal and human studies, arsenic ingestion can lead to altered lung function sugges-
tive of epithelial barrier dysfunction. In this report, we evaluated the effects of a
five-day exposure to environmentally relevant levels of arsenic (i.e., < 4 μM as Na-
arsenite; equivalent to ~300 ppb) on airway epithelial barrier properties. In a pri-
mary mouse tracheal epithelial (MTE) cell model we found that both micromolar
(3.9 μM) and sub-micromolar (0.8 μM) arsenic concentrations reduced transep-
ithelial resistance, a measure of barrier function. Immunofluorescent staining of ar-
senic-treated MTE cells showed altered localization patterns of barrier proteins
claudin-1 and occludin at cell-cell contacts. In order to better quantify arsenic-in-
duced changes in barrier molecular components we used the same arsenic exposure
on an immortalized human bronchial epithelial cell line (16HBE14o-). We found
that arsenic increased the protein expression of claudins -4, -5, and -7 as well as the
mRNA levels of claudin-7 in 16HBE14o- cells. Additionally, micromolar levels of
arsenic resulted in altered phosphorylation of occludin. In summary, exposure to
environmentally relevant levels of arsenic can alter both the structure and function
of airway epithelial barrier constituents and, consequently, basic innate immune de-
fense in the airway.
2299 Associations of Single Nucleotide Polymorphisms and
Haplotypes in Arsenic [+3 Oxidation State] Methyltransferase
(AS3MT)) with Arsenic Metabolism: A Case Study in Arsenic
Contaminated Areas from Vietnam.
T. Agusa1,  T. Kunito2,  N. M. Tue1,  V. M. Lan3,  T. B. Minh4, 5,  P. K. Trang3,
J. Fujihara6,  H. Takeshita6,  S. Takahashi1,  P. H. Viet3,  S. Tanabe1 and H. Iwata1.
1Center for Marine Environmental Studies (CMES), Ehime University, Matsuyama,
Japan; 2Shinshu University, Matsumoto, Japan; 3Center for Environmental Technology
and Sustainable Development (CETASD), Vietnam National University, Hanoi,
Vietnam; 4Faculty of Chemistry, Vietnam National University, Hanoi, Vietnam;
5United Nations Industrial Development Organization (UNIDO), Hanoi, Vietnam;
6Shimane University Faculty of Medicine, Izumo, Japan.
To understand associations of single nucleotides polymorphisms (SNPs) and haplo-
types in arsenic [+3 oxidation state] methyltransferase (AS3MT) with arsenic me-
tabolism, we investigated local residents from arsenic-contaminated areas of
Vietnam. Analysis of 18 SNPs revealed that there were four haplotype (HT) groups
(HT1; AS3MT 03963 – 06144 – 12390 – 14215 – 35587 – 37950, HT2; AS3MT
04602 – 35991, HT3; AS3MT 05913 – 09749 – 27215, HT4; AS3MT 358903 –
37853) in this population. Urinary monomethylarsonic acid (MMA)/inornanic As
(IA) and MMA/dimethylarsinic acid (DMA) ratios were used as indicators of ar-
senic metabolism. AS3MT 12590 genotype and HT2 and 4 groups were signifi-
cantly associated with MMA/IA. On the other hand, MMA/DMA was explained
by AS3MT 07395, 08979, 12590, and 14458 genotypes. Because association of
AS3MT 14458 with arsenic metabolism observed in this study was consistent with
other populations in other previous studies, this SNP may significantly affect the
metabolism regardless ethnicity.
2300 Mechanism of Arsenic Carcinogenesis in Normal Human
Lung Cells.
H. Xie1, 2, 3,  J. Wise1, 2, 3,  S. Martin1 and S. Huang1. 1Wise Laboratory of
Environmental and Genetic Toxicology, University of Southern Maine, Portland, ME;
2Maine Center for Toxicology and Environmental Health, University of Southern
Maine, Portland, ME; 3Applied Medical Sciences, University of Southern Maine,
Portland, ME.
Arsenic originates from both geochemical and numerous anthropogenic activities
including mining, combustion of fossil fuels, wood preservation, agriculture and
metallurgy. Exposure of the general public to significant levels of arsenic is wide-
spread. Arsenic is a well-documented human carcinogen. Long-term exposure to
low levels of arsenic in drinking water have been linked to bladder, lung, kidney,
liver, prostate, and skin cancer. Among them, lung cancer is of great public concern.
However, little is known about how arsenic causes lung cancer and few studies have
considered effects in normal human lung cells. The purpose of this study was to de-
termine the cytotoxicity and genotoxicity of arsenic in human primary bronchial fi-
broblast (NHBF) and epithelial cells (NHBE). Our data show that arsenic induces
a concentration-dependent increase in cell death after short (24 h) or longer (120
h) exposures. Arsenic induces concentration-dependent but not time-dependent in-
crease in chromosome damage in fibroblasts. No chromosome damage is induced
after either 24 h or 120 h arsenic exposure in epithelial cells. Using comet assay and
gamma-H2A.X foci forming assay, we found that 24 h or 120 h exposure to arsenic
induces increases in DNA double strand breaks in both cell lines. These data indi-
cate that arsenic is cytotoxic and genotoxic to human lung primary cells. However,
the mechanism of arsenic-induced genotoxicity could be different in bronchial ep-
ithelial cells than that in fibroblasts. This work is supported by NIEHS grant
R15ES021587 (H.X.) and by NIEHS grant ES016893 (J.P.W.). The content is
solely the responsibility of the authors and does not necessarily represent the official
views of the National Institutes of Health.
2301 Gene Expression Alterations among Adults with Chronic
Arsenic Exposure in Bangladesh.
Y. Chervona1,  A. Muñoz1,  T. Kluz1,  M. V. Gamble2 and M. Costa1.
1Environmental Medicine, New York Univesity School of Medicine, New York, NY;
2Environmental Health Sciences, Mailman School of Public Health, Columbia
University, New York, NY.
Background: Exposure to arsenic (As) is associated with an increased risk of several
cancers, as well as, cardiovascular disease, and childhood neuro-developmental
deficits. Arsenic compounds are weakly mutagenic, but can alter DNA methylation
and post-translational histone modifications (PTHMs) levels, as well, gene expres-
sion.
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Methods: Water and urinary arsenic, as well as, gene expression profiles were ana-
lyzed in peripheral blood mononuclear cells (PBMCs) from a subset of participants
(N=20) of a folate clinical trial in Bangladesh (FACT study). Gene expression pro-
filing was performed using Affymetrix exon ST 1.0 arrays. Differentially expressed
genes were identified in a global analysis and real-time PCR was used to validate the
expression findings.
Results: Expression analysis revealed that a total of 561 and 1198 genes had a
change in expression (p=0.05) with increasing arsenic exposure, in males and fe-
males respectively. When examined together (N=20), 177 genes had a > 1.25 fold
change in expression. The analysis revealed that some genes appear to be gender
specific (i.e. adenosylhomocysteinase (AHCY), oxoglutarate (alpha-ketoglutarate)
dehydrogenase (lipoamide) (OGDH), lysine (K)-specific demethylase 5C/D
(JARID1C/D), and SET domain containing (lysine methyltransferase) 7, while
others changed in the same direction among both males and females (i.e. potassium
voltage-gated channel, Isk-related family, member 3 (KCNE3), elongation factor,
RNA polymerase II, 2 (ELL2), NADH dehydrogenase (ubiquinone) 1 beta sub-
complex, 8 (NDUFB8), lactate dehydrogenase D (LDHD). Moreover, both males
and females exhibited a decrease in the expression of DNA repair genes with in-
creasing arsenic exposure.
Conclusion: Chronic exposure to As is associated with gender specific alterations in
gene expression profiles of Bangladeshi adults.
2302 Changes in Regulation of Lipid Metabolism from Low-Dose
Arsenic Exposure.
A. Adebayo1, 2,  F. Zandbergen2 and J. W. Hamilton1, 2. 1Brown University,
Providence, RI; 2Marine Biological Laboratory, Woods Hole, MA.
Arsenic (As) is naturally present in the environment, and it can be found at various
levels in drinking water resulting from contamination of groundwater. Exposure to
As is a major health concern because it is associated with an increased risk of vari-
ous diseases such as type II diabetes, cardiovascular disease (CVD), several types of
cancer, and reproductive and developmental problems. Type II diabetes and CVD
are in turn associated with altered blood lipid levels and obesity. Indeed, excess adi-
pose tissue and altered blood lipid levels have been shown to be strong predictors
for development of type II diabetes and CVD. Previous cell culture studies have
shown that arsenic affects adipogenesis, and a recent in vivo study found that ar-
senic exposed dams displayed alterations in overall lipid metabolism and triglyc-
eride levels. In the current study, we developed a model to investigate changes in
transcription factors involved in regulating lipid metabolism. We exposed adult
male C57BL6/J mice to 0, 10, or 100 ppb As in drinking water for 6 weeks, and
then isolated various tissues from these mice in the fed or fasted state. We analyzed
expression of genes and proteins involved in lipid metabolism and regulation in adi-
pose tissue and liver using quantitative PCR and western blotting. Our results show
alterations in expression of transcription factor SREBP-1c and its target genes, in-
cluding diglyceride acyltransferase (DGAT2) and fatty acid synthase (FAS). These
results indicate that arsenic can alter the expression of genes and proteins involved
in fatty acid synthesis and triglyceride production, which may contribute to how ar-
senic exposure may cause metabolic imbalances in exposed individuals.
(Funded by NIH-NIEHS Superfund Research Program (P42 ES007373), and
NIH-NRSA Training Grant (2 T32 ES 7272-21))
2303 Survey of Arsenic in Drinking Water in the Southern Gobi
Region of Mongolia.
P. B. Olkhanud1 and E. K. Silbergeld2. 1Department of Environmental Health
Sciences, HSUM, Ulaanbaatar, Mongolia; 2Department of Environmental Health
Sciences, JHSPH, Baltimore, MD.
Arsenic (As) is a naturally occurring toxicant of global concern. The extent of As
content in ground water, however, has not been fully assessed in Mongolia, where
all drinking water is sourced from groundwater. Mongolia is currently experiencing
rapid mining development, especially in the southern region, which is triggering
population growth that will drive increasing water demand for safe drinking water.
Moreover, the high prevalence of As exposure and As related diseases just across the
border in northern China further highlights the necessity for relevant studies in
Mongolia. Thus, this study attempts to determine As concentrations in water
sources near the Oyu Tolgoi mine in the Southern Gobi region of Mongolia and in-
vestigate its relationship with area, type and depth of the well, and develop a geo-
statistical map describing the spatial pattern of As concentration in the drinking
water sources. The results of our study show that the current and the potential fu-
ture exposure to As in the Southern Gobi region of Mongolia is significant. In
terms of current exposures, almost half of the Herder’s wells that are currently in use
and 16.4% of the Monitoring boreholes contain As levels above the World Health
Organization’s recommended level. The results also indicate different levels of As
concentrations in the water from different types of tube-wells even in the same area
and a decreasing tendency of As concentration with increasing well depth suggest-
ing different aquifers in that region. Overall, As in the drinking water sources in the
Southern Gobi region of Mongolia is a critical public health issue, especially given
the current mining boom in this region.
2304 The Role of miRNA-29B in Dysregulation of Mesenchymal
Stem Cell Differentiation to Adipocytes by Low-Dose
Arsenic Exposure.
K. Beezhold,  L. R. Klei,  Y. Garciafigueroa and A. Barchowsky. Environmental
and Occupational Health, University of Pittsburgh, Pittsburgh, PA.
Human exposure to environmental toxicants is a well-known cause of disease and
low chronic exposure may contribute significantly to longitudinal risk of chronic
diseases. Pathogenic mechanisms for many environmental toxicants remain poorly
defined, which limits development of effective interventions to protect against en-
vironmentally-derived chronic diseases. Low dose exposure to trivalent arsenic
(AsIII) in drinking water is a major public health concern that contributes to a
number of diseases and pathologies, including cardiovascular and metabolic dis-
eases. While progress has been made in the understanding of the pathogenic signal-
ing events contributing to arsenic-induced disease, many responsible mechanisms
have not been elucidated. Control of miRNA expression and action presents a
promising new means for understanding downstream effects of arsenic exposure;
however, there are few reports of how arsenic regulates expression of miRNA and
impacts their function. Our preliminary data indicated induction of miR-29 in
white and brown adipose tissue isolated from arsenic exposed (100 μg/L in drink-
ing water for 2 wk) mice and in human adipose-derived mesenchymal stem cells
(hMSC) as arsenic inhibited adipocyte differentiaton. Further analysis via real-time
PCR revealed a 2-3 fold induction of miR-29b following arsenic exposure in
hMSCs. The miR-29 family has been indicated by multiple studies to be involved
in cardiovascular and metabolic diseases, with reduced stem or progenitor cell dif-
ferentiation capacity believed to be a fundamental means for disease progression.
Analysis of downstream proteins by western blot indicates that C/EBP-zeta, an in-
hibitor of adipogenesis, is upregulated in arsenic treated cells and this upregulation
is diminished in cells stably expressing an inhibitor of miR-29b. These data show
that exposure to low-dose arsenic effects expression of miRNA in hMSCs, nega-
tively affecting their ability to properly differentiate into adipocytes. Supported by
NIEHS grant R01ES013781.
2305 Human Exposure to Arsenic in Drinking Water Is Associated
with Increased Protein Halogenation in Blood and Sputum.
R. Zangar1,  R. Lantz2,  R. B. Harris2,  J. L. Burgess2,  M. K. O’Rourke2,
M. M. Montenegro3,  M. M. Matzke1,  B. Webb-Robertson1 and J. G. Pounds1.
1PNNL, Richland, WA; 2University of Arizona, Tucson, AZ; 3Instituto Tecnológico de
Sonora, Tucson, Mexico.
Chronic arsenic exposure to environmentally high levels (> 200 ppb) in geologically
contaminated drinking water has been correlated with increased incidence of
chronic lung disease, including cough, bronchitis, shortness of breath and obstruc-
tive or restrictive lung disease. However, the effects of chronic arsenic exposures at
lower levels (e.g., < 100 ppb), which are prevalent in the United States and near the
current EPA MCL of 10 ppb, have not been well studied. Eosinophils and neu-
trophils are associated with lung disease, and these granulocytes selectively secrete
peroxidases that halogenate protein tyrosines. A custom ELISA microarray plat-
form was used to measure the halogenation of 24 individual proteins in paired spu-
tum and serum samples from 55 subjects in 4 Mexican cities with differing arsenic
levels. Eighteen halogenated proteins were significantly correlated (Spearman’s rank
correlation, p<0.05) between the two fluids (highest r value ~0.58). Halogenated
protein results were compared to total arsenic levels in urine using multiple linear
regression, accounting for the study participants’ age, BMI and resident city. The
total urine arsenic was significantly associated (P ≤ 0.05) with the halogenation of 7
proteins in both plasma and serum (MMP1, 2 and 9, EGFR, VEGF, HBEGF,
TGFα) and 11 additional sputum-only proteins (PDGF, E-selectin, EGF, SP-A,
leptin, HGF, CD14, IGF1, RANTES, TNF, ceruloplasmin) proteins. These results
support the conclusion that environmental arsenic exposure is associated with ele-
vated markers of pulmonary granulocyte activity. Replication in an independent
study population is warranted to confirm our results. Supported by P42 ES4940,
P30 ES006694, P50 CA095060, and U54 ES016015.
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2306 Evaluating Arsenic Speciation in Fish, Shellfish, and Seaweed
Using LC-ICPMS.
B. D. Laird and L. Chan. Department of Biology, University of Ottawa, Ottawa,
ON, Canada.
Rationale & Objectives: Risk due to dietary arsenic (As) exposure is speciation de-
pendent. For example, although elevated As concentrations are commonly observed
in fish, shellfish, and seaweed, the health risks are generally assumed to be low due
to the predominance of organoarsenicals (e.g. arsenobetaine). However, little speci-
ation data is available to support this assumption for many types of seafood. The
objective of the research described in this poster is to fill this data gap by quantify-
ing the relative contribution of various As species for a variety of store-bought
seafood samples.
Methodology: Seafood samples were purchased from several supermarkets for As
speciation analysis using Liquid Chromatography Inductively Coupled Plasma
Mass Spectrometry (LC-ICP-MS). The samples included cherry stone clams, oyster
shell clams, tiger prawn, halibut, mackerel, ling cod, marlin, snapper, yellow
grouper, and Porphyra seaweeds. Extraction of As species was performed with a
methanol-ammonium carbonate solution using a DigiPREP block digestion sys-
tem. Quantified As species included As(III), As(V), arsenobetaine, arsenocholine,
dimethylarsinic acid, and monomethylarsonic acid. 
Results: Total As concentrations ranged between 6 (king mackerel) and 135 (ling
cod) μg g-1 (d.w.). The main contributor to As concentrations tended to be ar-
senobetaine, which ranged between 35% (yellow grouper) and 100% (king mack-
erel). As(V) was not a significant contributor (<1%) to total As concentrations in
any of the samples. 
Conclusions: Arsenobetaine was the major As species in most of the seafood sam-
ples tested. Future work will be done to assess whether As speciation in foods is
modified when digested in simulated gastrointestinal fluids.
2307 Reduction of Arsenite-Enhanced Ultraviolet Radiation DNA
Damage by Supplemental Zinc.
K. L. Cooper,  B. S. King,  M. M. Sandoval,  K. Liu and L. G. Hudson.
Pharmaceutical Sciences, University of New Mexico, Albuquerque, NM.
Arsenic is a recognized human carcinogen and there is evidence that arsenic aug-
ments the carcinogenicity of DNA damaging agents such as ultraviolet radiation
(UVR) thereby acting as a co-carcinogen. Inhibition of DNA repair is one proposed
mechanism to account for the co-carcinogenic actions of arsenic. We and others
find that arsenic interferes with the function of certain zinc finger DNA repair pro-
teins. Furthermore, we reported that zinc reverses the effects of arsenic in cultured
cells and a DNA repair target protein, poly (ADP-ribose) polymerase-1. The study
objective was to determine whether zinc ameliorates the effects of arsenite on UVR-
induced DNA damage in human keratinocytes and in an in vivo model. In order to
investigate the potential zinc effects, normal human epidermal keratinocytes
(HEKn) and SKH-1 hairless mice were exposed to arsenite, zinc or both before
solar-simulated (ss) UVR exposure. Poly (ADP-ribose) polymerase activity and
DNA damage in each treatment group were measured in normal human ker-
atinocytes by immunocytochemistry and mutation frequencies at the hprt locus
were measured. DNA damage was assessed by immunohistochemical staining of
skin sections isolated from SKH-1 hairless mice. Cell-based findings demonstrate
that ssUVR-induced DNA damage and mutagenesis are enhanced by arsenite, and
supplemental zinc partially reverses the arsenite effect. In vivo studies confirm that
zinc supplementation decreases arsenite-enhanced DNA damage in response to
ssUVR exposure. From this data we can conclude that zinc offsets the impact of ar-
senic on ssUVR-stimulated DNA damage in cells and in vivo. This suggests that
zinc supplementation may provide a strategy to improve DNA repair capacity in ar-
senic exposed human populations.
2308 Arsenic-Stimulated Adipose Fat Metabolism Is Mediated by
G-Protein Coupled Receptors.
Y. Garciafigueroa,  L. R. Klei and A. Barchowsky. Environmental and
Occupational Health, University of Pittsburgh, Pittsburgh, PA.
Consumption of low to moderate levels of arsenic (As(III)) promotes a number of
diseases that may stem from dysfunctional adipose tissue and glucose metabolism.
As(III) inhibits adipocyte differentiation and insulin-stimulated glucose uptake.
However, little is known of the impacts of As(III) on adipose lipid storage and lipol-
ysis, as well as mechanisms through which As(III) affects lipolysis. We recently
demonstrated that As(III)-inhibited human mesenchymal stem cell (hMSC) differ-
entiation to adipocytes was mediated by G-protein coupled endothelin-1 receptors
and hypothesized that a similar mechanism signals for As(III)-stimulated fat mobi-
lization and utilization in mature adipocytes. To test this hypothesis, adipocytes
(identified by perilipin-coated, Nile red positive lipid droplets) derived from pri-
mary hMSC were exposed to 1 μM As(III) for 24 to 72 h. As(III) stimulated lipol-
ysis within 24 h relative to untreated adipocytes and caused a progressive loss of
perilipin and lipid droplets over 72 h. As(III)-stimulated lipolysis was not associ-
ated with an increase in cAMP. However, pre-incubation of the adipocytes with the
Gi-inhibitor, Pertussis toxin (Ptx), attenuated As(III)-stimulated lipolysis and lipid
droplet loss. Selective inhibition of Gi-coupled endothelin -1 type A and B recep-
tors (EDNRA/EDNRB) also attenuated the effects of As(III), but inhibition of
other adipose Gi-coupled receptors involved in fat metabolism was ineffective. The
endothelin receptors have different roles in the As(III) responses, since EDNRA in-
hibition was more effective in preserving lipid droplets and perilipin expression
while blocking either endothelin receptor attenuated As(III)-stimulated lipolysis.
These findings provide additional evidence that As(III) effects on adipogenesis, adi-
pose cell function, and lipid metabolism are mediated through stimulation of spe-
cific G-protein coupled receptors. Supported by NIEHS grant R01ES013781 and
R01ES013781-S1.
2309 Autophagy Is a Cell Self-Protective Mechanism against
Arsenic-Induced Cell Transformation.
G. Chen,  T. Zhang and Y. Qi. University of Kentucky, Lexington, KY.
Subchronic exposure to arsenic increases the incidence of human cancers, such as
skin, lung, colon and rectal cancer. The mechanism for arsenic-induced tumorigen-
esis is still not clear. It is generally believed that DNA damage and genomic insta-
bility, generated by arsenic-promoted oxidative stress, account largely for this
process. The major sources of reactive oxygen species (ROS) are arsenic-damaged
mitochondria. Autophagy is a catabolic process functioning in turnover of long-
lived proteins and dysfunctional organelles such as mitochondria. Defects of au-
tophagy under stress conditions promote genomic instability and increase the risk
of tumorigenesis. In the present study using a human bronchial epithelial cell line,
BEAS-2B cells, we investigated the role of autophagy in arsenic-induced cell trans-
formation, an important step in arsenic tumorigenesis. Our results show that sub-
chronic arsenic exposure induces BEAS-2B cell transformation accompanied with
increased ROS generation and autophagy activation. However, the patterns for
ROS and autophagy alteration are different. Arsenic exposure generated a pro-
longed and steady increase of ROS levels, while the activation of autophagy, after an
initial boost by arsenic administration, decreases in response to subchronic arsenic
exposure, although the activity is still higher than a non-treated control. Further
stimulation of autophagy increases mitochondria turnover and decreases ROS gen-
eration as well as arsenic-induced cell transformation. Contrarily, inhibition of au-
tophagy activity decreases mitochondria turnover and enhances arsenic-induced
ROS generation and cell transformation. In addition, the mTOR signaling path-
way is involved in arsenic-mediated autophagy activation. Our results suggest that
autophagy is a cell self-protective mechanism against arsenic-induced cell transfor-
mation.
2310 In Utero Low-Level Arsenite Exposure Alters Blood
Biochemistry in Adult Mice Predisposing for Liver Steatosis.
P. Sanchez Soria1,  S. Quach1,  R. N. Hardwick1 and T. D. Camenisch1, 2, 3.
1College of Pharmacy, University of Arizona, Tucson, AZ; 2Steele Children’s Research
Center, University of Arizona, Tucson, AZ; 3Southwest Environmental Health Sciences
Center, University of Arizona, Tucson, AZ.
Chronic exposure to low levels of arsenic in drinking water has been strongly corre-
lated to higher incidence of hypertension as well as other cardiovascular diseases.
Additionally, recent animal studies have shown that chronic exposure to 100 parts
per billion (ppb) sodium arsenite resulted in a significant increase in systolic blood
pressure, and a similar increase was observed in diastolic blood pressure.
Additionally, mice exposed to arsenic developed concentric left ventricular hyper-
trophy. In order to explore the mechanisms of arsenic-related adult disease, we
wanted to evaluate how in-utero exposure contributes to the development of dis-
ease, later in adulthood. Mice were exposed to either 100 ppb in-utero, or sodium
chloride (control) and were maintained for 34 weeks through adulthood. Blood
biochemistry analysis was done, and organs were harvested for histological assess-
ment, as well as protein and RNA studies. Results show that mice exposed to ar-
senic in-utero had significantly elevated blood glucose levels, as well as significantly
higher cholesterol, LDL and HDL levels with no significant change in weight,
when compared to control mice. Furthermore, liver enzymes alkaline phosphatase
(ALP), alanine transaminase (ALT), and aspartate transaminase (AST) were ele-
vated in the in-utero exposed mice, when compared to controls. Consistent with
these results, oil red-o stain of liver sections show moderate steatosis and higher
lipid content in the arsenic treated animals. Taken together, these results show that
exposure to arsenic early in life may predispose for the development of metabolic
diseases as well as cardiovascular ones.
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2311 Arsenic Impairs Adult Muscle Stem Cells and Skeletal Muscle
Integrity.
A. Roperti1,  D. Stoltz2,  B. Goodpaster3,  E. Brown4,  G. Distefano4,
A. Barchowsky5 and F. Ambrosio4. 1Bioengineering, University of Pittsburgh,
Pittsburgh, PA; 2Cell Biology and Physiology, University of Pittsburgh, Pittsburgh, PA;
3Medicine, University of Pittsburgh, Pittsburgh, PA; 4Physical Medicine and
Rehabilitation, University of Pittsburgh, Pittsburgh, PA; 5Environmental and
Occupational Health, University of Pittsburgh, Pittsburgh, PA.
Arsenic (As(III))-contaminated drinking water is a global health concern as chronic
As(III) exposure increases risk for a number of cancers, diseases, and disabilities.
As(III) exposure is associated with skeletal muscle weakness, impaired gait, and fa-
tigue. While As(III) and other metals impact embryonic stem cells and develop-
ment, it is not clear how As(III)impairs adult stem cell functions in tissue mainte-
nance and regeneration. We hypothesized that As(III) exposure affects adult skeletal
muscle stem cell (MuSC) metabolism and function to disrupt muscle maintenance
and repair capacity. To investigate this hypothesis, we examined muscle integrity,
MuSC metabolism, and phenotype in hind limb muscles isolated from mice ex-
posed to 0 or 100 μg/L As(III) for 5 weeks. Histological analysis demonstrated dis-
rupted muscle bundles with perivascular fatty inclusions and ultrastructural analy-
sis revealed large, fused muscle cell mitochondria in As(III) exposed mice relative to
control. MuSC isolated from the As(III) mice and cultured without As(III) for
multiple doublings retained a phenotype with mitochondrial myopathy, autophagy,
uncoupled oxidative phosphorylation, and impaired differentiation. This pheno-
type was a maladaptation to stress, as As(III) altered growth kinetics and resistance
to oxidative stress. The phenotype and altered growth kinetics were reproduced in
primary human MuSCs. These findings suggest that direct effects on MuSC mito-
chondrial phenotype, metabolism, and differentiation underlies muscle impair-
ment observed following As(III) exposures. Supported by NIEHS grant R01
ES0136781, NIH K12 for Physical and Occupational Therapists (K12
HD055931) and NIA grant K01 1K01AG039477.
2312 Arsenic Induces Premature Senescence and Vascular
Calcification In Vivo and In Vitro.
V. Sorribas,  C. Sosa and A. Martin-Pardillos. Laboratory of Molecular Toxicology,
University of Zaragoza, Zaragoza, Spain. Sponsor: A. Anadon.
Arsenic is a natural vasculotoxic agent with ubiquitous exposure to both, human
and animals. Several mechanisms have been proposed to explain the vascular toxic-
ity of arsenic. This work describes new mechanisms that affect the vascular smooth
muscle cells (VSMC): stress-induced premature senescence (SIPS), dedifferentia-
tion, and medial vascular calcification. 
Rat aortic VSMC were treated with 1-100 μM of sodium arsenate (AsV), arsenite
(AsIII), monomethylarsonic acid, or dimethylarsinic acid. None of the treatments
induced VSMC calcification in the presence of 1 mM inorganic phosphate (Pi),
but 1 μM AsIII increased calcification when induced with 2.5 mM Pi.
Cytotoxicities of the four arsenic species were assayed with an LDH assay and acri-
dine orange/ethidium bromide staining. Results revealed that the calcification in-
crease with AsIII was accompanied by a rise in cytotoxicity due to simultaneous in-
cubation with 2.5 mM Pi. This calcification increase was also observed in the aortas
of an established vascular calcification model: 5/6 nephrectomized rats fed with a
high Pi diet and treated with vitamin D3. Several known mechanisms that might
explain arsenic toxicity in our experimental model were discarded: apoptosis, oxida-
tive stress, and inflammasome activation. Nevertheless, both senescence-associated
β-galactosidase (SA β-gal) activity and p21 expression were increased by AsIII,
which reveals the induction of SIPS. AsIII also caused dedifferentiation of VSMC,
as shown by the reduced expression of the VSMC markers SM22α and calponin.
Senescence and similar patterns of gene expression were also observed in the aortas
of healthy rats treated with 50 ppm AsV in drinking water for one month. 
In conclusion, both the premature senescence in aortic VSMC with phenotypic
dedifferentiation and the increase of Pi-induced calcification are novel mechanisms
of arsenic vasculotoxicity observed in vitro and in vivo.
2313 Prolonged iAs Exposure Leads to Aberrant Insulin Signaling
in L6 Myocytes.
I. L. Druwe,  J. J. Sollome,  J. Gonzales and R. R. Vaillancourt. Department of
Pharmacology & Toxicology, The University of Arizona, Tucson, AZ.
Diabetes mellitus is a metabolic syndrome characterized by inappropriate produc-
tion of insulin or the inability of cells to respond to insulin. It is estimated that by
the year 2050, 1 in 3 U.S. adults will have diabetes mellitus. Insulin is the principal
hormone involved in lowering blood glucose and functions by suppressing liver
gluconeogenesis and glycogenolysis and by stimulating the glucose uptake in skele-
tal muscle and adipocytes. Recent epidemiological studies both in the USA and
abroad have linked chronic ingestion of low levels of inorganic arsenic (iAs), an en-
vironmental toxicant, to the onset of diabetes mellitus. Although these observations
have been met with some skepticism, there are few mechanistic studies to elucidate
the mechanisms by which iAs perturbs insulin signaling. The few studies that have
been performed have focused namely on adipocyte in-vitro models. Here we show
that L6 myocytes, an insulin responsive cell line, exposed to low doses of iAs (0.25
to 2 μM) for 4 or 7 days showed a decreased insulin stimulated glucose uptake but
no decrease in phospho-AKT or phospho-AS160. In addition, we found that phos-
pho-ERK signaling decreased, while phospho-p38 MAPK signaling increased in re-
sponse to prolonged iAs treatment. Interestingly enough increased p38 MAPK ac-
tivity has been associated with insulin resistance. These data support the
epidemiological evidence that chronic exposure to low, physiologically relevant lev-
els of arsenite can contribute to insulin resistance and type 2 diabetes, and that the
mechanisms involved are different than those produced by iAs in adipocyte cell
models. And while the etiology of type 2 diabetes has yet to be elucidated these data
show that in addition to pharmacological treatment and lifestyle modifications, en-
vironmental exposures should also be considered when evaluating the etiology of
type 2 diabetes.
2314 Gene Expression Changes Associated with Chronic Low-
Level Monomethylarsonous Acid Exposure in Human
Urothelial Cells.
M. Medeiros1,  T. Minh le1,  D. J. Troup1,  P. Novak2 and A. Gandolfi1.
1Pharmacology and Toxicology, University of Arizona, Tucson, AZ; 2Biology Centre
ASCR, Institute of Plant Molecular Biology, Ceske Budejovice, Czech Republic.
Bladder cancer has been associated with chronic arsenic exposure.
Monomethylarsonous acid [MMA(III)] is a metabolite of inorganic arsenic and has
been shown to transform a human urothelial cell line (UROtsa). It was used as a
model arsenical to examine the mechanisms of arsenical-induced malignant trans-
formation of urothelium. A microarray analysis was performed to assess the tran-
scriptional changes in UROtsa from chronic 50 nM MMA(III) exposure that leads
to transformation at three months. The analysis revealed only minor changes in
gene expression at one and two months of exposure, contrasting with substantial
changes observed at three months of exposure. To assess the changes occurring be-
tween 2 and 3 months of exposure, incremental analysis was performed for 29
genes, covering 7 distinct pathways (mitogenic, PI3K/AKT, apoptosis, JAK/STAT,
oxidative stress, DNA repair, and inflammation), that were found changed at 3
months of exposure based on the gene array analysis. Between 2 and 3 months of
exposure, progressive alterations in the expression of several genes (i.e., PDGFRA,
COX2, XAF1) were observed. These alterations are being correlated with expected
phenotypic changes (i.e., hyper-proliferation, colony formation in soft agar) in the
transforming cells.  Since short-term exposure (up to two months) has not been
shown to induce transformation, the gene expression changes observed for cultures
treated up to 3 months and beyond suggest that a stress-threshold exists.  This study
was supported by the Superfund Basic Research Program Grant (NIH grant
ES04940) from National Institute of Environmental Health Sciences, and the
Trainee in Toxicology and Toxicogenomics (NIEHS grant ES007091).  Additional
support from NIH grant CA23074, and NIEHS grant ES06694.
2315 Multidrug Resistance Protein 1 Confers Resistance to
Organic Arsenic Compound in HL-60 Cells.
H. Narenmandula,  S. Xu and Y. Zhang. Department of Pharmacology, Toxicology,
and Biochemical Pharmaceutics, Zhejiang University, Hangzhou, China. Sponsor: D.
Thomas.
Arsenic trioxide is established as one of most effective drugs for treatment of pa-
tients with acute promyelocytic leukemia (APL). However, non-promylocytic
leukaemia HL-60 cells is exhibit resistant to As2O3, and little is known about the
underlying resistance mechanism for As2O3 and its biomethylation products,
namely, monomethylarsonous acid (MMAIII) on the treatment of tumors. In the
present study, we investigated the molecular mechanisms underlying iAsIII and its
intermediate metabolite MMAIII-induced anticancer effects in the HL-60 cells.
Here, we show that the HL-60 cells exhibit resistance to inorganic iAsIII (IC50=10
μM), but are relatively sensitive to its intermediate MMAIII (IC50=3.5 μM).
Moreover, we found that the multidrug resistance protein 1 (MRP1), but not
MRP2, are expressed in HL-60 cells, which reduced the intracellular arsenic accu-
mulation, and conferred resistance to inorganic iAsIII and MMAIII. Pretreatment
of HL-60 with MK571, an inhibitor of MRP1, significantly increased iAsIII and
MMAIII-induced cytotoxicity and arsenic accumulations, suggesting that the ex-
pression of MRP1/4 may lead to HL-60 cells resistance to trivalent arsenic com-
pounds.
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2316 Integrative Toxicopathological Evaluation of Aflatoxin B1
Exposure in F344 Rats.
G. Qian1,  F. Wang1,  L. Tang1,  M. E. Massey1,  N. J. Mitchell2,  J. Su1,
J. H. Williams3,  T. D. Phillips2 and J. Wang1. 1Environmental Health Science,
University of Georgia, Athens, GA; 2Veterinary Integrative Biosciences, Texas A&M
University, College Station, TX; 3Peanut Collaborative Research Support Program,
University of Georgia, Griffin, GA.
An integrative evaluation of the toxicopathological effects of aflatoxin B1 (AFB1)
was conducted in this study. Briefly, male F344 rats were orally exposed to a single-
dose of AFB1 at 0, 50, 250 or 1000 μg/kg body weight (BW) or repeated-dose of
AFB1 at 0, 5, 10, 25 or 75 μg/kg BW for up to 5 weeks. Biochemical and histolog-
ical changes were assessed together with the formation of AFB1-lysine adduct
(AFB-Lys) in serum and liver foci positive for placental form glutathione S trans-
ferase (GST-P+). In single-dose protocol, serum AST, ALT and ALP were dose-de-
pendently elevated with maximal changes (> 100 folds) appeared at 3-day after
treatment. Animal that received 250 μg/kg AFB1 showed concurrent bile duct pro-
liferation, necrosis and appearance of GST-P+ hepatocytes at 3-day while the pre-
neoplastic GST-P+ foci appeared after 1-week. Neither liver GST-P+ hepatocytes
nor foci were induced by 50 μg/kg AFB1 treatment. In repeated-dose protocol, bile
duct proliferation and liver GST-P+ foci co-occurred after 3-week, followed by pro-
liferation foci formation after 4-week and dramatic ALT, AST and CK elevations
after 5-week exposure in animals received 75 μg/kg AFB1. Liver GST-P+ hepato-
cytes and foci appeared in a dose- and time-dependent manner, low dose of AFB1
(5 μg/kg) did not induce liver GST-P+ foci formation throughout the experiment.
Serum AFB-Lys increased temporally at low doses (5-25 μg/kg) and reached a max-
imum after 2-week exposure at 75 μg/kg group, consistent with liver histological
changes that may affect the adduct formation. This integrative study demonstrates
that liver GST-P+ cells and foci are sensitive biomarkers for AFB1 toxic effect and
correlated with bile duct proliferation and biochemical alterations in F344 rats,
which hold promise as potential target for future intervention strategies.
2317 Ethoxyquin Protective Effect against Aflatoxins Chronic
Intoxication in Laying Hens.
A. G. Valdivia1,  M. C. De Luna1,  R. Ortiz1,  A. Martinez de Anda1,
T. Quezada1,  F. Jaramillo2 and J. Reyes3. 1Agricultural Sciences Centre,
Aguascalientes Autonomous University, Aguascalientes, Mexico; 2Physiology and
Toxicology, Basic Sciences Centre of UAA, Aguascalientes, Mexico; 3Cellular
Physiology, Research and Advanced Studies Centre of IPN, Mexico City, Mexico.
Ethoxyquin (EQ) is a synthetic compound used to prevent lipid oxidation and pre-
serve the nutritional quality of feed. EQ can increase the expression of some en-
zymes detoxification system. Aflatoxins (AFs) are toxicogenic and carcinogenic
common food contaminants that affect human health and productivity in poultry.
The aim was to evaluate the EQ ability to decrease the toxic effect of AFs chronic
dietary intake in laying hens. At 14 weeks age, 360 Leghorn Hy-Line hens were
subjected to experimental chronic intoxication (0.00, 0.50, 1.00 and 1.50 mg
AFs/kg BW) for 72 weeks, with and without EQ (500 mg/kg feed). The EQ feed
was well accepted by hens and alone did not alter egg production, feed daily intake
and feed efficiency index. Dietary AFs consumption decreased of performance of
hens and produced pathological and biochemical alterations. However, EQ dimin-
ished the AFs induced changes in macro and microscopic architecture of liver and
kidneys, plasma total protein, hepatic/renal reduced glutathione, specific enzyme
activity of glutathione, gammaglutamyl, alanine and aspartate transferases, which
suggests the presence a EQ chemopreventive effect against AFs toxic effects in lay-
ing hens.
2318 Aflatoxin Exposure in Human Populations of Uganda.
M. Kang1,  P. Nkurunziza2,  R. Muwanika3,  G. Qian1,  L. Tang1,  J. Seeley2,
J. Williams1 and J. Wang1. 1University of Georgia, Athens, GA; 2British Medical
Research Council Uganda Unit, Entebbe, Uganda; 3Raikai Health Science Program,
Entebbe, Uganda.
Aflatoxins (AF) exposure and aflatoxicosis as well as chronic hepatocarcinogenic ef-
fects in human populations are serious global public health threats, especially for
the developing world. In this study human serum samples (n=1931) from two ex-
isting cohort studies conducted in Uganda were measured for AFB1-lysine adduct.
In samples (n=725) from the General Population Cohort (GPC), 90% (651/725)
had detectable AFB1-lysine adduct with a median of 1.61 pg/mg albumin, ranged
from 0.40 to 253.11 pg/mg albumin. In samples (n=1,206) from Rakai
Community Cohort (RCC), 85% (1025/1206) had detectable AFB1-lysine adduct
with a median of 3.19 pg/mg albumin, ranged from 0.41 to 167.04 pg/mg albu-
min. Levels of AFB1-lysine adduct in the RCC samples are significantly higher
than those in the GPC samples (p < 0.05). Temporal patterns of AFB1-lysine
adduct in these two distinct human populations were further evaluated in samples
collected at 3-year interval since the initiation of the cohorts. Detection rates of
AFB1-lysine adduct in GPC varied over time: 94% in 1989, 100% in 1992, 84%
in 1995, 80% in 1998, 72% in 2001, 93% in 2004, 97% in 2007, and 94% in
2010 with median (range) of 1.77 (0.43-22.46), 2.44 (1.02-5.06), 0.83 (0.41-
18.60), 0.89 (0.41-6.02), 1.15 (0.41-11.55), 1.77 (0.41-14.80), 1.92 (0.40-30.89),
and 2.29 (0.47-253.11) pg/mg albumin, respectively. Detection rates of AFB1-ly-
sine adduct in RCC also varied: 71% in 1994, 96% in 1996, 91% in 1999, 50% in
2002, 92% in 2005, 89% in 2008, and 90% in 2011 with median (range) of 2.44
(0.41-94.79), 1.16 (0.41-555.33), 1.19 (0.45-122.51), 5.08 (0.51-30.92), 3.58
(0.41-67.56), 3.22 (0.45-117.96), and 2.60 (0.43-167.04) pg/mg albumin, respec-
tively. Levels of AFB1-lysine adduct in samples from these two cohort studies were
further assessed with various demographic parameters. These results demonstrated
the temporal patterns of AF exposure in rural human populations of Uganda.
2319 Immunological and Pathomorphological Study of Combined
Effects of Fumonisin B1 and Ochratoxin A on Piglets.
M. Mwanza1, 2,  M. M. Dutton2 and S. D. Stoev3. 1Animal Health, North West
University, Mmabatho, South Africa; 2Food, Environment and Health Research
Group, Faculty of Health Science, University of Johannesburg, Johannesburg, South
Africa; 3Department of General and Clinical Pathology, Faculty of Veterinary
Medicine, Trakia University, Trakia, Bulgaria.
In this study, two experiments (in vivo and in vitro) were carried out to study the ef-
fects on OTA and FB1 on pigs mononuclear cells as well as on live pigs to assess the
effects of these mycotoxins on their health with particular reference to the immune
system and pathomorphological changes. The in vitro study showed a time vs co-
nentration decrease of pigs mononuclear cells were used the MTT assay and ex-
posed to 5 and 40 ng/ml for ochratoxin A and 5 and 40 μg/ml of FB1 at 12, 24 and
48 hrs. While the in vivo study showed the ochratoxin A induced highest cell via-
bility decrease as compared to FB1 when exposed singularly, whereas exposure to
both mycotoxins simultaneously showed further reduction of cell viability. In the in
vivo study was done with mycotoxic nephropathy induced in eighteen young pigs
with mouldy diets containing 0.5 ppm ochratoxin A (OTA) and/or 10 ppm fu-
monisin B1 (FB1) for three months. The most obvious damage provoked by OTA
was seen in the kidneys, as expressed by the strong degenerative changes in proxi-
mal tubules and fibrosis in kidneys, FB1 was found to induce an increase in perme-
ability of vessels mainly in lung, brain, cerebellum or kidneys and slight to moder-
ate degenerative changes in kidneys. The exposure to both mycotoxins
simultaneously revealed synergistic pathomorphological changes characterized by
the combination of the main lesions provoked by each mycotoxin alone, being
stronger in their expression when administered together. In addition, Exposure to
both mycotoxins and their combination showed induced humoral immune re-
sponse in all experimental pigs shown by decrease in antibody titers.
2320 Deoxynivalenol (DON)-Induced Secretion of the Gut Satiety
Hormone Cholecystokinin (CCK) in the STC-1
Enteroendocrine Cell Model Is Mediated by the Calcium
Sensing Receptor (CaSR) and Transient Receptor Potential
Ankyrin-1 (TRPA1).
H. Zhou1 and J. Pestka1, 2, 3. 1Food Science and Human Nutrition, Michigan State
University, East Lansing, MI; 2Center for Integrative Toxicology, Michigan State
University, East Lansing, MI; 3Department of Microbiology and Molecular Genetics,
Michigan State University, East Lansing, MI.
The trichothecene mycotoxin deoxynivalenol (DON, vomitoxin) causes anorexia
and emesis in part by inducing gut satiety hormone secretion by enteroendocrine
cells of the gastrointestinal tract. To elucidate mechanisms for these effects, we em-
ployed the STC-1 enteroendocrine cell model, which can be induced by DON to
secrete the gut satiety peptide cholecystokinin (CCK). We initially found that in-
tracellular calcium mobilization was evoked in STC-1 cells by DON in a concen-
tration- and time-dependent manner, generating sustained sinusoidal oscillations
that preceded CCK secretion. Pretreatment with EGTA, a chelator of Ca2+, was
found to block CCK secretion. Pretreatments with the CaSR (calcium sensing re-
ceptor) antagonists, NPS 2143 or Calhex 231 or TRPA1 (transient receptor poten-
tial ankyrin-1) antagonist HC 030031 were found to suppress DON-induced
Ca2+ mobilization and CCK release. Both sets of these inhibitors worked in an ad-
ditive fashion. Furthermore, preincubation with 1) phospholipase C inhibitor,
U73122, 2) inositol 1,4,5 triphosphate receptor (IP3R) blocker, 2-aminoethyl
diphenylborinate, 3) the transient receptor potential melastatin-5 (TRPM5) in-
hibitor, triphenylphosphine oxide (TPPO), or 4) the L-type voltage-sensitive Ca2+
channel (L-type VSCCs) blocker, nitrendipine could also significantly attenuate
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DON-induced CCK release in STC-1 cells. The results suggest that DON might
induce CCK release in enteroendocrine cells by increasing CaSR sensitivity to ex-
tracellular [Ca2+]0 which mediates increased [Ca2+]i influx via L-type-VSCCs
Ca2+ and TRPA1 cation channels. DON-induced calcium and hormonal re-
sponses demonstrated herein might ultimately contribute to anorexia and emesis
potentially as a protective mechanism following ingestion of the toxin.
2321 Red Clover Exhibits Multifaceted Activity on Breast Cancer
Cells.
B. M. Dietz,  J. Eskra,  M. Darji,  S. Chen,  G. F. Pauli and J. L. Bolton.
Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago, Chicago,
IL.
An increased breast cancer risk for postmenopausal women taking hormone ther-
apy has been demonstrated by the Women’s Health Initiative. Botanical dietary
supplements, including red clover products, are commonly used to alleviate
menopausal symptoms but still lack efficacy and safety studies. Red clover
isoflavones, such as biochanin A and genistein, have been promoted for their cancer
preventive activity, in part due to genistein’s ERβ selective activity. Other studies
suggested possible side effects in estrogen sensitive tissue due to genistein’s ERα me-
diated estrogenicity. This study examines these controversial claims by performing
several estrogenic assays with a well-characterized clinical red clover extract and
pure isoflavones. Proliferation experiments in ER+ breast cancer cells (MCF-7)
showed that the effect of the red clover extract on cell proliferation is highly con-
centration dependent and has a bell-shaped curve: Low- and high concentrations
(30 - 100 ng/mL and > 5 μg/mL, respectively) reduced cell proliferation, whereas
intermediate amounts (300 ng/mL - 1 μg/mL) increased it. The pure isoflavones,
genistein and biochanin A, exhibited similar bell-shaped dose dependencies. Low-
(10 nM) and high isoflavone concentrations (> 10 μM) decreased cell proliferation,
whereas cell survival increased at 300 nM - 1 μM. These findings are in agreement
with prior reports of genistein preferentially binding to ERβ at 6 - 20 nM and to
ERα at ~300 nM, which may explain the dose-dependent effects of the isoflavones
and the extract. Supporting the proliferation results, ERE-luciferase and gene in-
duction assays showed that red clover extract at 300 ng/mL - 1 μg/mL mimics
estradiol and might, therefore, have similar adverse effects if consumed in higher
quantities. These findings highlight the importance of correct dosing for
isoflavone-containing products and the relevance of dose considerations to ensure
safety of botanical dietary supplements.
2322 Occurrence of T-2 Toxin, HT-2 Toxin and Zearalenone in
Retail Foods in Japan.
T. Yoshinari1,  K. Aoyama2,  M. Nakajima3,  M. Taniguchi3,  H. Takeuchi4,
S. Hashiguchi5,  S. Kai6,  S. Tabata7,  T. Tanaka8 and Y. Sugita-Konishi1. 1National
Institute of Health Sciences, Tokyo, Japan; 2Food and Agricultural Materials Inspection
Center, Sendai, Japan; 3Nagoya City Public Health Research Institute, Nagoya, Japan;
4Mie Prefecture Health and Environment Research Institute, Mie, Japan; 5Kawasaki
City Institute for Public Health, Kawasaki, Japan; 6Kanagawa Prefectural Institute of
Public Health, Kanagawa, Japan; 7Tokyo Metropolitan Institute of Public Health,
Tokyo, Japan; 8Kobe Institute of Health, Kobe, Japan.
Fusarium toxins are a group of mycotoxins produced by many kinds of Fusarium
species, and frequently detected in field crops such as wheat, barley, maize and corn.
They cause mycotoxicosis, a serious health hazard to humans and domestic ani-
mals. Therefore, collecting the information about fusarium toxin contamination in
daily foods is crucial. Occurrence data of deoxynivalenol, a major fusarium toxin,
have been collected in worldwide, but that of other toxins is limited. In this study,
we examined foods from Japanese retail shops for contamination with three kinds
of fusarium toxins, T-2 toxin, HT-2 toxin and zearalenone.
Food samples were extracted with methanol-water (75 : 25). After filtration, the ex-
tract was diluted five times with phosphate buffered saline, and subjected to a DZT
MS-PREP Immunoaffinity column. The toxins were quantified by LC-MS/MS.
In 2011, a total of 196 samples of 12 different products were examined. In corn
grits (20 samples) and tear grass (20 samples), more than 1 ng/g of T-2 toxin on av-
erage was detected. In barley, breakfast cereal, cookie, corn grits, tear grass and
wheat, more than 1 ng/g of HT-2 toxin on average was detected (The sample sizes
were 10, 10, 10, 20, 20 and 40, respectively). The maximum concentration of the
sum of T-2 and HT-2 toxin was 48.9 ng/g in corn grits. In corn grits, red bean (10
samples) and tear grass, more than 5 ng/g of zearalenone on average was detected.
These results showed that the highly toxic trichothecene mycotoxins, T-2 and HT-
2 toxin were contaminated in retail foods in Japan. Especially contributors of these
toxins are breakfast cereal, tear grass and wheat.
2323 In Vitro Metabolism and Interaction of Zearalenone and Its
Metabolites in Mammalian Cells.
G. Font1,  E. Tatay2,  G. Meca3 and M. Ruiz4. 1Preventive Medicine, University of
Valencia, Burjassot, Spain; 2Preventive Medicine, University of Valencia, Burjassot,
Spain; 3Preventive Medicine, University of Valencia, Burjassot, Spain; 4Preventive
Medicine, University of Valencia, Burjassot, Spain.
Zearalenone (ZEA) is a non-steroidal estrogenic mycotoxin produced by Fusarium
sp. fungi. ZEA is rapidly absorbed and metabolized to α-Zearalenol (α-ZOL) and
β-Zearalenol (β-ZOL) in the liver; therefore mixtures of these mycotoxins may be
simultaneously in biological systems and cause human health risk. The objectives of
this study were: a) to compare the cytotoxicity of ZEA, α-ZOL and β-ZOL alone
or in combination in hamster ovary (CHO-K1) and human hepatoma (HepG2)
cells using the MTT assay after 24, 48 and 72h of exposure, b) to evaluate the in-
teractions of mycotoxins mixtures in both cell lines by the isobologram analysis
and, c) to study the in vitro metabolism of ZEA in both types of cells using liquid
chromatography coupled to the mass spectrometry detector-linear ion trap (LC-
MS-LIT). The IC50 values obtained for individual mycotoxins range from 59.4 to
>100.0 μM, from 30.0 to 33.0 μM and from 55.0 to >75.00 μM in CHO-K1 cells
and from 70.0 to >100.0 μM, from 20.6 to 26.0 μM and from 38.4 to >100.0 μM
in HepG2 cells for ZEA, α-ZOL and β-ZOL, respectively. Isobologram analysis
provides a combination index (CI) value to determine the type of interaction that
occurs. The interactions of ZEA and its metabolites became slightly synergism at
low levels (CI from 0.34 ± 0.10 to 0.81 ± 0.33) followed by additive effect (CI
from 0.80 ± 0.18 to 8.54 ± 7.76) and turned into antagonism (CI from 1.41 ± 0.16
to 26.17 ± 20.72). The metabolism assays demonstrated that no conversion of ZEA
in α-ZOL and β-ZOL was detected. However, other metabolites products of ZEA,
α-ZOL and β-ZOL were generated in both cell lines.
Acknowledgement: The Science and Innovation Spanish Ministry (AGL2010-
17024/ALI).
2324 Role of Peptide YY3-36 (PYY) and 5-Hydroxytryptamine (5-
HT) in Emesis Induction by Deoxynivalenol (Vomitoxin).
M. Bates1,  W. Wu1, 5,  S. Bursian3, 2,  B. Flannery1,  H. Zhou1,  J. Link3,
H. Zhang5 and J. Pestka1, 2, 4. 1Food Science and Human Nutrition, Michigan State
University, East Lansing, MI; 2Center for Integrative Toxicology, Michigan State
University, East Lansing, MI; 3Animal Science, Michigan State University, East
Lansing, MI; 4Microbiology and Molecular Genetics, Michigan State University, East
Lansing, MI; 5College of Veterinary Medicine, Nanjing Agricultural University,
Nanjing, China.
Deoxynivalenol (DON, vomitoxin), a trichothecene mycotoxin produced by
Fusarium, frequently contaminates cereal grains causing reported outbreaks of
human and animal food poisoning making it a relevant public health concern.
Although these outbreaks have the rapid onset of emesis as a common hallmark, the
mechanisms for this adverse effect are not fully understood. Recently, our labora-
tory has demonstrated that the mink (Neovison vison) is a suitable small animal
model for investigating trichothecene-induced emesis. We employed the mink to
determine the role of gut satiety hormone peptide YY3-36 (PYY3-36) and neuro-
transmitter 5-hydroxytryptamine (5-HT) in DON-induced vomiting. Emesis in-
duction following intraperitoneal exposure to DON at 100 and 250 ug/kg bw ini-
tiated within 15 to 30 min which persisted for up to 120 min. Measurement of
DON in plasma by ELISA revealed that the emetic period correlated with distribu-
tion and clearance of the toxin. Significant elevations in both PYY3-36 (30 to 60
min) and 5-HT (60 min) were observed during emesis. Pretreatment with the Y2
receptor antagonist JNJ-31020028 attenuated PYY- and DON-induced emesis.
The 5-HT3 receptor antagonist granisetron was found to completely suppress in-
duction of vomiting by cisplatin, a known 5-HT inducer, as well as DON.
Interestingly, granisetron pretreatment could partially block PYY3-36-induced
emesis. Taken together, the results presented here suggest that both PYY3-36 and 5-
HT play contributory roles in DON-induced emesis.
2325 Dietary Inclusion of Montmorillonite Clay Mitigates
Bioavailability of Aflatoxin, Fumonisin and
Aflatoxin/Fumonisin Mixtures in Fischer 344 Rats.
N. J. Mitchell1,  K. Xue2,  A. Marroquin-Cardona1,  K. A. Brown1,  S. E. Elmore1,
S. Lin2,  L. Tang2,  J. Wang2 and T. D. Phillips1. 1College of Veterinary Medicine,
Texas A&M University, College Station, TX; 2Department of Environmental Health
Sciences, University of Georgia, Athens, GA.
Aflatoxins (AFs) have been linked to hepatocellular carcinoma and mortality in hu-
mans and animals. Chronic AF exposure, particularly in developing countries, is a
significant problem that continues to contribute to public health issues in commu-
nities burdened by poor economic status and food scarcity. One possible strategy to
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improve food safety is to reduce exposures to AF using montmorillonite clay which
binds AFs in the GI tract, and decreases bioavailability of these toxins. Our recent
work in Ghana has shown that communities at risk for AF exposure are also at high
risk for fumonisin (FB) exposure. In this study, montmorillonite clay was tested for
FB1 binding capacity in combination with AFB1 in a rodent model. Fisher-344 rats
were gavaged once with 0.125 mg AFB1/kg b.w. and/or 25 mg FB1/kg b.w. follow-
ing an acclimation period with feed containing clay additive. Urine samples were
collected at 12 hr time intervals for 72 hr following gavage and were analyzed for
AF and FB biomarkers. Lower AFM1 and FB1 levels in the urine were indicative of
reduced absorption of the parent compounds through the GI tract and into the cir-
culation. AFM1 and FB1 excretion peaked between 12-24 hr and quickly declined
by 36 hr. Addition of clay at 0.25%, 0.5% and 2% w/w feed decreased AFM1 ex-
cretion by 88-97% at the 12 hr time point, indicating highly effective binding.
Clay treated animals also had a reduction in FB1 excretion, but to a lesser extent
than the AFM1 biomarker (i.e. 41-80%). When in combination both AFM1 and
FB1 binding occurred, but capacity was decreased by almost half, suggesting that
AFB1 and FB1 are competing for similar binding sites on the clay. This study indi-
cates that inclusion of montmorillonite clay in contaminated diets can reduce
bioavailability of both AFs and FBs in populations at high risk for mycotoxin expo-
sure. (Supported by NIH/NCMHD RO1-MD00519-01.)
2326 Development and Validation of an Analytical Method for
Vomitoxin in Gavage Dose Formulations Used in Rodent
Toxicology Studies.
J. C. Blake1,  D. P. Coleman1,  J. Gilliam1,  M. A. Silinski1,  R. A. Fernando1,
C. S. Smith2,  B. Collins2 and V. G. Robinson2. 1RTI International, Research
Triangle Park, NC; 2Division of National Toxicology Program, NIEHS, Research
Triangle Park, NC. Sponsor: K. Levine.
Vomitoxin, also known as deoxynivalenol (DON), is a trichothecene mycotoxin
produced by certain types of Fusarium fungi. It occurs predominantly in grains
such as corn, wheat, barley, and rice, and has been shown to have great stability dur-
ing storage, processing, and cooking of food. Because of the potential for wide-
spread contamination of food and exposure to farmers through inhalation, the
National Toxicology Program is investigating the toxicity of vomitoxin. 
Thus, the current study was undertaken to develop and validate a formulation
analysis method for vomitoxin in deionized water as a gavage vehicle for use in tox-
icology studies. Important objectives of an analytical method for supporting a toxi-
cological study are to insure that the correct test article is being administered at the
specified dose concentrations and that the dose formulations are stable. To achieve
these objectives, an Ultra Performance Liquid Chromatography (UPLC) method
was developed and validated for analysis of vomitoxin in deionized water. Sample
preparation involves a simple dilution with water and addition of an internal stan-
dard solution (2,6-dimethylphenol in acetonitrile). The method was successfully
validated over the range 1.5 to 720 μg/mL. The limit of detection was estimated as
0.2 μg/mL and the limit of quantitation was estimated as 0.8 μg/mL.  Assessment
of formulation stability, at ambient and refrigerated storage conditions, over a 42-
day period was evaluated.  Dose simulation stability testing was also conducted to
evaluate the formulations stability for at least three hours under simulated dosing
conditions. In addition, analysis period stability of the analytical preparations was
assessed. This method will be used to support toxicology studies of vomitoxin con-
ducted by the National Toxicology Program.
2327 Comparative Hepatic Glutathione S-Transferase Mediated
Detoxification of Aflatoxin B1 in Chickens.
B. R. Bunderson1,  C. Rowe1,  S. J. Lamont2 and R. A. Coulombe1. 1Toxicology
Graduate Program, Utah State University, Logan, UT; 2Department of Animal
Science, Iowa State University, Ames, IA.
Efficiency of hepatic glutathione S-transferase (GST)-mediated conjugation of
bioactivated aflatoxin B1 (AFB1) is critical to species resistance to this toxic and
carcinogenic mycotoxin. Poultry are among the most susceptible animals, and do-
mestic turkeys are especially susceptible, a condition we have shown to be associ-
ated with a deficiency of AFB1-detoxifying GSTs. Chickens are more resistant than
domestic turkeys, yet little is known about their hepatic GST detoxification capa-
bilities. In this study, we compared hepatic GST-mediated detoxification of proto-
type substrates 1-chloro-2,4-dinitrobenzene (CDNB), 1,2-dichloro-4-nitrobenzene
(DCNB), ethacrynic acid (ECA), and cumene hydroperoxide (CHP) and toward
the exo-AFB1-8,9-epoxide (AFBO) in livers of Broiler, Fayoumi, and Leghorn
chickens. All breeds had equivalent GST activities, except Fayoumi, which was sig-
nificantly lower toward CDNB. Broiler, Fayoumi, and Leghorn had similar GST-
mediated conjugation activities toward AFBO (6.5 ± 0.2, 6.1 ± 0.6, 6.4 ± 0.2
pmol/min/mg, respectively). This level of hepatic AFB1 detoxification is substan-
tially more than that in livers of domestic turkeys, which are more susceptible than
chickens to AFB1. These data support previous findings that in vitro conjugation of
AFB1 by GST is an accurate predictive marker species resistance to this mycotoxin.
Supported in part by NRI Competitive grant 2007-35205-17880 from the USDA-
NRI Animal Genome Project.
2328 Bisphenol A (BPA) Levels in Liquid Supernatants of Canned
Foods Determined by Highly Sensitive BPA ELISA.
H. Kim1, 2,  A. Joiakim1,  D. Kaplan1,  K. Friedrick1 and D. Putt1. 1Detroit R&D,
Inc., Detroit, MI; 2Institute of Environmental Health Sciences, Wayne State
University, Detroit, MI.
BPA [2,2-(4,4’-dihydroxydiphenyl)propane], an endocrine disruptor, mimics the
action of 17beta-estradiol (E2) in mammals, increasing the risk of hormone-related
health problems such as early puberty, infertility, breast, ovarian and prostate can-
cers and insulin resistance. Fetuses and newborns are most vulnerable to the BPA
toxicity. Recently, BPA levels of canned soup solids were measured by LC/MS/MS
(detection limit, 2 ng/g) and it was found that the soup solids contained 10 to 80
ng/g BPA. A subsequent study revealed that the group that consumed a 12-ounce
serving/day, for 5 days of canned soups, excreted 19-fold higher BPA in urine
(mean, 21 ng/ml) compared with the control group that consumed same amounts
of fresh soups (mean, 1.1 ng/ml). BPA in liquid supernatants of canned foods con-
tain ~10-fold lower levels of BPA compared to the solids. To screen BPA in super-
natants, a highly sensitive and facile BPA ELISA has been developed after produc-
tion of BPA polyclonal antibodies by immunization of a goat with
carboxylalkyl-derivatized BPA conjugated to KLH. The detection limit of the BPA
ELISA was 1 pg. Whereas anti-BPA slightly cross-reacted with BPB, it did not
cross-react with BPS, BPF or resveratrol, which are structurally similar to BPA. Ten-
fold diluted supernatants of canned soups were applied to BPA ELISA.
Supernatants obtained from 3 kinds of soups (3 cans/each kind of soup, 9 data
points) produced by first company contained 9.56 ± 0.96 ng/ml, 9.07 ± 0.38
ng/ml and 10.38 ± 0.83 ng/ml of BPA, similar to ~8.70 ng/ml of BPA levels in su-
pernatants from second company. A negative control, supernatants of canned veg-
etables from third company, contained extremely low levels of BPA (0.05 ± 0.02
ng/ml), suggesting use of BPA-free can linings. These results demonstrate that the
competitive BPA ELISA is suitable for measurements of BPA leaching from the
epoxy film-coated cans using liquid supernatants from canned foods.
2329 Perinatal BPA Exposure at Low Doses Impairs Oral
Tolerance and Immunization to Ovalbumin in Offspring
Rats at Adulthood.
S. Ménard,  V. Braniste,  M. Leveque,  C. Lencina,  M. Naturel,  L. Moussa,
S. Sekkal,  C. Harkat,  E. Gaultier,  V. Theodorou and E. Houdeau. INRA,
Toulouse, France. Sponsor: D. Zalko.
Aims: Bisphenol A (BPA) used in food packaging impacts gut epithelial barrier after
perinatal exposure. Because antigen sampling by gut epithelium drives mucosal im-
mune response, our aim was to address the consequences of perinatal BPA exposure
at low doses on oral tolerance and immunization at adulthood. Methods: Dams
were treated per os from gestation day 15 to pup weaning with BPA [0.5, 5 or
50μg/kg/d] or vehicle (corn oil). Female offsprings (day 45) were used to assess
para- and transcellular jejunal permeability by Ussing chambers, and immune re-
sponse to ovalbumin (OVA) after either oral tolerance, immunization or oral chal-
lenge. Results: Perinatal BPA exposure decreased jejunal paracellular permeability
by 2-fold at 0.5 and 50μg/kg/d, and by 3-fold at all doses for transcellular perme-
ability (p<0.05). BPA exposure at 5 and 50μg/kg/d increased anti-OVA IgG titers
after an oral tolerance protocol (116±62x103 and 86±29x103 respectively vs
7.2±2.2 x103 in controls; p<0.04). Anti-OVA IgG titers were only increased at
5μg/kg/d after OVA immunization. Enhanced humoral response in rats exposed to
5μg/kg/d was associated with higher IFNγ secretion by spleen in OVA-sensitized
(2-fold) and MLN of OVA-tolerized (20-fold) rats (p<0.05). Finally, oral OVA
challenge in BPA group increased MPO activity (316±34 vs 184±22 U/g protein in
controls; p<0.05), IFNγ concentration (2-fold, p<0.05), and decreased TGFβ con-
centration (3-fold, p<0.05) in the colon, indicating inflammation. Conclusion:
Perinatal exposure to low doses of BPA decreased jejunal paracellular and transcel-
lular permeability, and impaired oral tolerance and immunization to dietary anti-
gens at adulthood. BPA treatment during perinatal period affects intestinal home-
ostasis in a nonlinear dose-response relationship. These results suggest that perinatal
period is a critical window for BPA exposure that may trigger food intolerance in
later life.
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2330 Perinatal BPA Exposure at Low Doses Impairs Immune
Homeostasis and Promotes Intestinal Parasite Infection in
Young Rats.
V. Theodorou,  S. Ménard,  C. Lencina,  M. Leveque,  M. Olier,  V. Braniste,
M. Naturel,  S. Sekkal,  C. Harkat and E. Houdeau. INRA, Toulouse, France.
Sponsor: D. Zalko.
Aims: Perinatal exposure to 5μg/kg/day of the food contaminant bisphenol A
(BPA) impaired oral tolerance in adult rats (see Ménard et al, abstract 1). Herein,
we aimed to address the consequences of BPA perinatal exposure on immune
homeostasis in young rats at weaning, i.e. oral tolerance, systemic immunization
with ovalbumin (OVA) and parasitic infection. Methods: Dams were given per os
from gestational day 15 to pup weaning BPA [5μg/kg/d] or vehicle (corn oil).
Weaned female offspring (day 25) were used to assess para- and trans-cellular jeju-
nal permeability by Ussing chambers, and immune responses following oral toler-
ance or immunization to OVA, or after infection with a gut nematode
Nippostrongylus brasiliensis (N bras). Results: Perinatal treatment with BPA did
not affect intestinal permeability or humoral response (anti-OVA IgG titers) fol-
lowing either oral tolerance or immunization in D25 rats. However, a decrease of
OVA-induced IFNγ secretion was observed in spleen of OVA-sensitized rats
(53±15 vs 317±162 pg/ml; p<0.05) and in mesenteric lymph nodes of OVA-toler-
ized rats (3.9±2.3 vs 19±14 pg/ml; p<0.05). The lack of cellular response to food
antigens questioned the ability of BPA-exposed rats to clear intestinal infections. A
3-fold increase in N bras living larvae was observed in the intestine of BPA-exposed
rats compared to controls (2817±689 vs 757±291 larvae/g of faeces, respectively;
p<0.05), but no significant change in myeloperoxidase activity into jejunal tissues.
Conclusion: Perinatal exposure to low dose of BPA did not affect humoral response
to the food antigen OVA in juvenile rats. However, a decrease of OVA-induced
IFNγ secretion in BPA-exposed rats emphasized a lack of specific cellular response
to food antigens. Finally, perinatal BPA treatment evoked an increased risk to intes-
tinal parasitic infection without triggering an inflammatory response, demonstrat-
ing impaired immune defence in early life stages.
2331 Perinatal Peripubertal Exposure to Bisphenol-A Increases
Hepatic Steatosis in Immature and Adult Mice.
P. Shimpi1,  A. Donepudi1,  V. More1,  M. Paranjpe2,  S. DaFonte2,  B. Rubin2
and A. L. Slitt1. 1Biomedical and Pharmaceutical Sciences, University of Rhode
Island, Kingston, RI; 2Sackler School of Graduate Biomedical Sciences, Tufts
University, Boston, MA.
While diet and physical activity remain the predominant reason for development of
obesity and obesity-related disease, there is some concern that environmental expo-
sure to chemicals may be a predisposing factor. Bisphenol A (BPA), a component
used in the manufacturing of certain plastics and plastic resins, can leach into food
and/or drink from food and beverage containers. High urinary BPA levels have
been positively associated with general and abdominal obesity in human popula-
tions. In rodents, developmental BPA exposure increases body weight and fatty
liver (steatosis). The purpose of this study was to uncover potential mechanisms by
which perinatal-peripubertal (PNPP) exposure to BPA increases liver steatosis.
Pregnant CD-1 mice were administered 25 or 250 μg BPA/kg/day (BPA25,
BPA250, respectively) via osmotic pump, and then after weaning on PND 20, the
resulting daughters were exposed to BPA via drinking water up through PND 35.
Tissues were collected at PND32 and at 39 weeks of age. Livers were analyzed for
triglyceride content, stained with Oil Red O and relative mRNA expression was
quantified by qPCR. At PND32, BPA25 and 250 increased liver Oil Red O stain-
ing compared to controls. BPA25, but not BPA250, increased protein expression
for lipogenic enzymes, (Acc-1 and Fas) but did not significantly increase lipogenic
gene expression. In adult mice, BPA25, but not BPA250, increased Oil Red O
staining. BPA25 increased Acc-1 expression, whereas BPA250 increased Srebp1-c,
Acc-1, and Fas. Protein expression was not changed. In conclusion, PNPP exposure
to BPA had some effect in promoting steatosis and pro-steatotic gene expression in
immature and adult female mice, but the exact mechanism by which BPA promotes
steatosis remains unclear.
2332 Leaching of Chemicals with Estrogenic Activity from BPA-
Free Materials after Common Use Stresses.
G. D. Bittner2, 1, 3,  C. Z. Yang2,  M. Stoner2 and D. Klein1. 1PlastiPure, Inc.,
Austin, TX; 2CertiChem, Inc., Austin, TX; 3University of Texas, Austin, TX.
Since 2007, many consumer products are no longer made from polycarbonate (PC)
plastics because of widespread concern about the estrogenic activity (EA) of bisphe-
nol-A (BPA). However, BPA-Free plastics have not been thoroughly vetted by most
product manufacturers to ensure that they do not release other chemicals that have
EA. We have used, robotized MCF-7 and BG1Luc assays currently undergoing val-
idation by ICCVAM/NICEATM to quantify the total EA in chemicals leaching
from a various widely-available plastic resins used to make consumer products and
packaging. This study expands the prior work of Yang et al, 2011(EHP 119:989-
998). We assayed the total EA in chemical mixtures leaching from unstressed and
stressed polycarbonate (PC), polypropylene (PP), polyethylene, (PE), cyclic olefin
copolymer(COC), and polyethylene terephthalate glycol-modified (PETG -
Tritan™) plastic resins. Plastic resins were subjected to simulated common-use
stresses of dishwashing, microwaving, and sunlight, and then extracted for ~ 72
hours at 37 degrees Celsius by saline (hydrophilic) or ethanol (hydrophobic) sol-
vents. The total EA in these leachates were then quantified and EA-specific re-
sponses were validated by conducting confirmation assays. EA positive determina-
tions were made on samples with values 3 standard deviations or more higher than
vehicle controls. Using these criteria, Tritan PETG and PC resins were consistently
significantly positive for EA. PE and PP samples often tested positive for EA, but
some consistently had no detectable EA. Most COC resins consistently had no de-
tectable EA. Our data show that BPA-Free often does not mean EA-Free, i.e., that
leaching of chemicals having EA from the plastic resins is often not addressed by
simply choosing BPA-Free materials.
2333 Microsomal Metabolism of Asarone Isomers.
A. T. Cartus and D. Schrenk. Food Chemistry and Toxicology, University of
Kaiserslautern, Kaiserslautern, Germany.
The alkenylbenzenes alpha-asarone (aA; CAS 2883-98-9), beta-asarone (bA; CAS
5273-86-9), and gamma-asarone (gA; CAS 5353-15-1) are constituents of various
plants, e.g. Acorus calamus (Sweet Flag) and some peppers. Both, aA and bA are
carcinogenic to rodents and exhibit genotoxic effects in vitro. Neither genotoxicity
nor carcinogenicity of gA have been evaluated so far. Several allylic alkenylbenzenes
such as safrole, estragole and methyleugenol are well known genotoxic carcinogens,
whereas their propenylic analogues are not. This suggests that an allylic side chain,
and therefore the capability for the formation of an 1’OH metabolite, may be a
basic prerequisite for the carcinogenicity of those compounds. However, the
propenylic compounds aA and bA are an exception of that “allylic rule”. We suggest
the ortho-methoxy groups of aA and bA to be a key structural element for the mode
of action of their carcinogenicity. 
We investigated the metabolism of aA, bA and gA using liver microsomes from dif-
ferent species (including human). Identity of metabolites was confirmed by LC-
MS/MS and 1H-NMR spectroscopy in comparison with synthesized reference
standards.
Our results show that the side chain hydroxylation of aA and gA was the predomi-
nating metabolic step leading to E-3’OHA (from aA) and 1’OHA (from gA), re-
spectively, together with the formation of side-chain dihydrodiols, for which the
epoxides may be the precursors. To a smaller extent, we found enzymatically
formed secondary metabolites derived from the alcohols like 3’oxoA and 1’oxoA,
but no corresponding carboxylic acids. Furthermore, we found the corresponding
mono-demethylated phenolic metabolites. These results are comparable to our
prior results on phase I metabolism of methylisoeugenol and methyleugenol. In
contrast, bA showed a more complex pattern of metabolites: in addition to Z-
3’OHA, the unexpected direct formation of 1’OHA was proven. This metabolic
step, possibly facilitated by steric attraction of the Z-configurated bA side chain and
the ortho-methoxy substituent, may explain the carcinogenicity of bA, but not of
aA, where no 1’OH metabolite was found.
2334 Histamine in Scombrotoxin Fish Poisoning: Toxicology,
Epidemiology and Dose-Response Analysis.
Y. Zang and P. M. Bolger. US FDA, College Park, MD.
Histamine plays important physiological functions such as immune responses and
gastric acid secretion. However, ingestion of fish containing large amounts of
spoilage-originated histamine can result in scombrotoxin fish poisoning (SFP), a
common chemical-originated food poisoning that affects cardiovascular, gastroin-
testinal and neurological systems. Fish importing countries have established various
regulations and limits for histamine in fish and fishery products to protect con-
sumers. However, many limits were established in a pre-quantitative risk assessment
era. An assessment of toxicological and epidemiological data indicates that though
other biogenic amines might also play a role in the etiology of SFP, histamine is the
most significant causative agent. Due to limitations of the disease-reporting system,
the epidemiology-based dose-response approach is not suitable in developing a
safety limit of histamine in fish. Instead, a dose-response analysis was conducted
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based on human oral challenge studies selected. Both the NOAEL and BMD as-
sessments identified 50 mg of histamine per meal as the dose where either adverse
effects were not noted or the estimate of additional risk (lower confidence level) was
low. At this level healthy adults would not be expected to exhibit any of the symp-
toms associated with SFP. This dosage level will not apply to children and individ-
uals with a specific sensitivity to histamine. In addition, this level was derived from
data on small number of subjects. While the variation of response appears to be re-
flected in the study results, further studies would be most helpful in refining this
threshold value. Using a conservative serving size of 250 g fish meat/meal, the max-
imum concentration of histamine in fish that should not cause an adverse effect was
calculated as 200 ppm. Compliance sampling plan can be derived based on this
threshold level to ensure a desirable level of protection of the public health.
2335 Carrageenan-Induced Disruption of Mucosal Barrier via
Regulation of Proinflammatory NF-κB and Early Growth
Response Gene 1: A Mechanistic Implication of Food-Borne
Inflammatory Bowel Disease.
J. Kim,  H. Choi,  K. Do,  S. Park and Y. Moon. Laboratory of Mucosal Exposome
and Biomodulation, Department of Microbiology and Immunology, Pusan National
University School of Medicine and Medical Research Institute, Yangsan, Republic of
Korea.
The widely used food additive carrageenan (CGN) has been shown to induce intes-
tinal inflammation, ulcerative colitis-like symptoms, or neoplasm in the gut epithe-
lia in animal models, which are also clinical features of human inflammatory bowel
disease. In this study, the effects of CGN on pro-inflammatory transcription factors
NF-κB and early growth response gene 1 product (EGR-1) were evaluated in terms
of human intestinal epithelial barrier integrity. Both pro-inflammatory transcrip-
tion factors were elevated by CGN and only NF-κB activation was shown to be in-
volved in the induction of pro-inflammatory cytokine interleukin-8. Moreover, the
integrity of the in vitro epithelial monolayer under the CGN insult was maintained
by both activated pro-inflammatory transcription factors NF-κB and EGR-1.
Suppression of NF-κB or EGR-1 aggravated barrier disruption by CGN, which
was associated with the reduced gene expression of tight junction component
zonula occludens 1 and its irregular localization in the epithelial monolayer (This
work was supported by the Basic Science Research Program through the National
Research Foundation of Korea, funded by Ministry of Education, Science, and
Technology Grant 2012R1A1A2005837)
2336 Comparison of the Estrogenic Activity of Licorice Species
with Hops in Botanical Dietary Supplement Formulations
for Women’s Health.
A. Hajirahimkhan,  C. Simmler,  Y. Yuan,  D. Nikolic,  S. Chen,  B. M. Dietz,
G. F. Pauli,  R. B. van Breemen and J. L. Bolton. Medicinal Chemistry and
Pharmacognosy, University of Illinois at Chicago, Chicago, IL.
The Women’s Health Initiative showed an increased risk of breast cancer for
menopausal women taking hormone therapy. As a result, many women have turned
to botanical supplements to manage menopausal symptoms, although there is lim-
ited data about their efficacy and safety. Our previous studies demonstrated estro-
genic and chemopreventive properties for hops (Humulus lupulus). The goal of the
current study was to compare the estrogenic effects of three common licorice
species (Glycyrrhiza glabra, Glycyrrhiza uralensis, Glycyrrhiza inflata) with those of
hops. Methanol extracts of the licorice species showed a dose-dependent induction
of an estrogen responsive alkaline phosphatase in endometrial cancer cells with
Glycyrrhiza uralensis being the most potent. Compared to hops, the activity of the
licorice species was significant but less pronounced. Similar results were obtained in
an estrogen response element (ERE)-luciferase reporter assay in breast cancer cells.
The licorice constituent, liquiritigenin, was the major ligand of estrogen receptor
(ER) in pulsed ultrafiltration mass spectrometry of the licorice extracts.
Competitive binding assay using purified human ERs showed liquiritigenin as a se-
lective ligand of ERβ. In comparison to 8-prenylnaringenin (8-PN), the major es-
trogenic principle of hops, liquiritigenin had lower affinity to both ERs.
Liquiritigenin was less active than 8-PN in the induction of alkaline phosphatase
and ERE-luciferase. Isoliquiritigenin, the precursor chalcone of liquiritigenin,
demonstrated significant activity in these estrogenic assays, while xanthohumol, the
precursor of 8-PN, did not exhibit estrogenic effects. The estrogenic activity of
isoliquiritigenin was partially associated with its cyclization to liquiritigenin. These
data suggest that licorice species are moderately estrogenic and are worthwhile fur-
ther exploration as effective and safe dietary supplements to alleviate menopausal
symptoms.
2337 Acrylamide and Acrolein: Heat-Induced Contaminants in
Food.
G. Eisenbrand1,  N. Watzek1,  D. Scherbl1,  M. Baum1,  F. Berger1,  U. Fuhr2,
O. Doroshyenko2,  D. Tomalik-Scharte2 and E. Richling1. 1Chemistry, Division of
Food Chemistry and Toxicology, Kaiserslautern, Germany; 2Pharmacology, University
Hospital of Cologne, Cologne, Germany.
The genotoxic carcinogen (IARC class 2A) acrylamide (AA) is a food contaminant
formed by thermal treatment of food. This applies as well to acrolein (AC) an α,β-
unsaturated aldehyde grouped into IARC group 3B. Whereas human dietary expo-
sure levels to AA are well established and range between about 0.5-5 μg/kg bw/d,
exposure to AC is much less investigated. After uptake, AA is partly metabolised
into the genotoxic glycidamide (GA). GA forms DNA adducts, primarily at N7 of
guanine (N7-GA-Gua). AA, GA and AC are conjugated to glutathione (GSH) and
excreted via urine as mercapturic acids (MA).
AA was given by gavage in single doses of 0.1-10,000 μg/kg bw to female rats.
Formation of urinary MAs and of N7-GA-Gua DNA adducts in liver, kidney and
lung was measured 16 h after application using HPLC-MS/MS. At the lowest
dosage (0.1 μg AA/kg bw), N7-GA-Gua adducts were below the limit of detection
in any organ tested. At 1 μg/kg bw, enhanced adduct levels were found in kidney
(~1 adduct/108 nucleotides) and lung (< 1 adduct/108 nucleotides), but not in liver.
At 10 and 100 μg/kg bw, adducts were found in all three organs not significantly
different to those found at 1 μg AA/kg bw (about 1-2 adducts/108 nucleotides). 
In two pilot intervention studies, MAs of AA and AC were monitored after inges-
tion of test meals of 150 g self-made potato chips (1 mg AA, 13 volunteers, study 1)
and of 175 g commercially available potato chips (44 μg AA and 5 μg AC, 5 vol-
unteers, study 2). Urinary MA contents were determined by HPLC-MS/MS for up
to 72 h (study 1), respectively 24 h (study 2). Total excretion of AC-related MA ex-
ceeded that of AA-related MA by factors of about 12 (study 1) to 4 (study 2). These
results suggest markedly higher exposure to AC than to AA from heat treated po-
tato based foods representing a major source of dietary exposure to AA. They man-
date further research to broaden the database on dietary AA and AC.
2338 Sex Hormone Modulation of Long-Term Induction and
Short-Term Inhibition of CYP1A1/2 by Genistein in
HepG2/C3A Cells.
Y. Liu1, 3,  T. Flynn1,  M. Ferguson2 and M. Garcia1. 1Division of Toxicology, Center
for Food Safety and Applied Nutrition, US FDA, Laurel, MD; 2Division of Public
Health and Biostatistics, Center for Food Safety and Applied Nutrition, US FDA,
College Park, MD; 3Oak Ridge Institute for Science and Education, Oak Ridge, TN.
Genistein is widely consumed in soy products and dietary supplements for its re-
ported beneficial health effects including cancer prevention. However, there have
been conflicting data suggesting that genistein ingestion has both anticancer and
cancer promoting activities. Cytochromes P4501As (CYP1A) play key roles in the
metabolic activation of many carcinogens. Since genistein has both anti-estrogenic
and estrogenic activities, sex-specific factors could also contribute to its biological
activities. In the current study, human hepatoma HepG2/C3A cells were cultured
in media with defined human sex hormone profiles to investigate CYP1As inhibi-
tion and induction by genistein. In male hormone supplemented cells, CYP1A1
and CYP1A2 gene expression and activities were induced to higher extent com-
pared with female hormone supplemented cells after either β-naphthoflavone or
genistein treatment. However, basal gene expression of CYP1A1 and CYP1A2 were
higher in female- than in male-hormone supplemented cells. In the inhibition stud-
ies, CYP1A activities were significantly lower in the male-specific medium than in
female specific medium. The results showed that genistein could exert both long-
term (3-day) induction and short-term (1-hr) inhibition effects on CYP1A activi-
ties in vitro which could explain the inconsistent cancer-related reports.
Furthermore, there were significant differences in both the inductive and inhibitory
effects of genistein between the male- and female-specific media suggesting that sex
hormones, in physiological concentrations and ratios, can modulate the effects of
genistein on CYP1A gene expression and activities in a human liver cell line.
2339 Safety Evaluation of Optimash BG from T. Reesei for Use in
Grain, Brewing, and Carbohydrate Processing.
N. K. Muntean,  V. Sewalt and Q. Bui. DuPont Industrial Biosciences, Palo Alto,
CA.
Optimash BG is a cellulase enzyme used in grain processing (for the production of
potable alcohol and brewing) and glucose production from starch. The enzyme, en-
doglucanase 2, is produced from a recombinant modified strain of Trichoderma
reesei. A battery of toxicology studies was conducted to investigate its potential to
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cause adverse effects in humans using methods complying with OECD guidelines.
All studies were conducted according to OECD Principles of Good Laboratory
Practice. Acutely, Optimash BG is not an eye irritant, a very mild skin irritant, and
not toxic by ingestion with an oral LD50 greater than 2000 mg/kg bw. Optimash
BG is not a mutagen, a clastogen, or an aneugen. In the in vitro cytogenetic test
using cultured human lymphocytes cells, Optimash BG did not induce chromoso-
mal aberrations (both structural and numerical) in the presence and absence of
metabolic activation (S-9 mix) up to the highest concentration (5000 ug TP/ml).
No mutagenic activity was noted in the Ames assay in the presence and absence of
S-9 mix up to 5000 ug TP/plate. In a repeated 90 days oral (gavage) in Wistar rats,
no biological or statistical differences were observed. Also, no treatment-related
changes in the hematology and clinical chemistry were noted at study termination.
The NOAEL was established at 80 mg total protein/kg bw/day (97.6 mg TOS/kg
bw/day). Under the worst-case scenario that Optimash BG is applied at the maxi-
mum rate and the enzyme is neither destroyed nor removed during processing, the
use of the enzyme in grain processing, carbohydrate processing and brewing is not
expected to result in adverse effects to humans. With a margin of safety of 258 and
a pADI of 39%, the use of Optimash BG is not of toxicological concern.
2340 A 13-Week Subchronic Toxicity Study of Glycidol Fatty Acid
Esters in F344 Rats.
T. Toyoda1,  Y. Cho1,  S. Onami1,  J. Akagi1,  A. Nishikawa2 and K. Ogawa1.
1Division of Pathology, National Institute of Health Sciences, Tokyo, Japan; 2Biological
Safety Research Center, National Institute of Health Sciences, Tokyo, Japan.
Glycidol fatty acid esters (GEs) have been recently identified as food process con-
taminants in refined edible oils. Although there is toxicological concern arising
from potential release of glycidol from parent esters during digestion in the gas-
trointestinal tract, little is known about in vivo toxicity of GEs. In the present study,
subchronic toxicity of two types of GEs, oleate and linoleate esters, was investigated
with administration at concentrations of 0, 225, 900 and 3600 ppm (equivalent
molar concentration to 800 ppm glycidol) in drinking water for 13 weeks to male
and female F344 rats. For comparison, treatment with 200 and 800 ppm of glyci-
dol was also performed. Body weight gain of both sexes was markedly reduced with
800 ppm glycidol compared to the controls, and the cause was considered at least
partly related to decreased water consumption. Hematological data showed signifi-
cant increase of MCV in 800 ppm glycidol females and decrease of WBC in 3600
ppm oleate ester females. In serum biochemistry, increase of total cholesterol and
potassium and decrease of ALT were detected in 800 ppm glycidol males, 3600
ppm linoleate ester males, and 800 ppm glycidol females, respectively. Serum crea-
tinine levels in both sexes were decreased in the 800 ppm glycidol group. Relative
weights of kidney and spleen were significantly increased in 200 and 800 ppm gly-
cidol males and 800 ppm females. In addition, increase of relative kidney weights
was also found in 3600 ppm oleate ester males. On histopathological assessment,
increased cell debris was observed in the epididymal ducts of 800 ppm glycidol
males, but not in ester groups. Although more detailed analysis will be needed to
clarify any testicular toxicity of glycidol and in vivo genotoxicity of GEs, our results
suggest that oleate and linoleate esters might be less toxic to F344 rats than glycidol
itself.
2341 Modes of Action Underlying Citirinin-Induced Renal
Carcinogenesis.
K. Kuroda1,  M. Watanabe2,  Y. Ishii1,  S. Takasu1,  K. Matsushita1,  A. Kijima1,
K. Ogawa1,  T. Nomi3,  A. Nishikawa3,  Y. Sugita-Konishi2 and T. Umemura1.
1Division of Pathology, National Institute of Health Sciences, Tokyo, Japan; 2Division
of Microbiology, National Institute of Health Sciences, Tokyo, Japan; 3Biological Safety
Research Center, National Institute of Health Sciences, Tokyo, Japan.
Citrinin (CTN), a mycotoxin produced by Penicillium and Aspergillus, is known to
induce renal tumors in rats; however, the involvement of genotoxic mechanisms re-
mains unclear. To evaluate the genotoxic potential of CTN, reporter gene muta-
tion, comet, and micronucleus assays were performed. For the reporter gene muta-
tion assay, groups of 5 male gpt delta rats were given CTN at doses of 20 and 40
mg/kg by gavage for 28 days to extirpate the kidneys 3 days after the last dosing.
For the comet and micronucleus assays, groups of 5 male F344 rats were treated
with CTN at the same doses by gavage for 2 days to extirpate the kidneys or bone
marrow, respectively. In the reporter gene mutation assay, the high dose (40 mg/kg)
was decreased to 30 mg/kg on day 4 because of severe weight loss. The results of the
reporter gene mutation and comet assays suggested that CTN did not induce DNA
damage and subsequent gene mutations. Positive result was obtained only in the
micronucleus assay, which might result from numerical chromosomal aberrations
due to microtubule dysfunction by CTN. Therefore, it seems likely that non-geno-
toxic mechanisms are involved in CTN-induced carcinogenesis. In kidney samples
from gpt delta rats, increases in the labeling indices of proliferating cell nuclear anti-
gen (PCNA)-positive cells and mRNA expression levels of cell cycle-related genes
(i.e., cyclin E1, cyclin A2, cyclin B1, and E2F1) were observed at all doses, despite
the fact that the low dose showed no toxicological effects. Accordingly, the promo-
tion of cell cycle progression observed in the kidneys of CTN-treated rats may have
resulted from a direct mitogenic function of CTN. Increased phospho-ERK levels
observed at all doses indicated that CTN is a promising candidate trigger for in-
duction of the cell cycle; however, further investigation of the detailed pathway ap-
pears warranted.
2342 The Dynamics of a Harmful Algal Bloom and Paralytic
Shellfish Toxins in Juneau, Alaska.
D. W. Chamberlin1,  G. L. Eckert2 and S. L. Tamone3. 1Department of Biology,
Appalachian State University, Boone, NC; 2School of Fisheries and Ocean Sciences,
University of Alaska Fairbanks, Juneau, AK; 3Department of Natural Sciences,
University of Alaska Southeast, Juneau, AK. Sponsor: G. LeBlanc.
Paralytic shellfish poisoning (PSP) is a deadly neurological syndrome resulting from
the ingestion of shellfish containing high levels of paralytic shellfish toxins (PSTs),
and approximately seven cases of PSP are reported in Alaska annually. The main
component of PSTs is the neurotoxin saxitoxin, which is produced by the dinofla-
gellate Alexandrium sp . In June and July 2012 during this summer undergraduate
project at the University of Alaska Southeast, plankton tows, seawater samples, and
bivalve samples revealed a significant bloom of Alexandrium and subsequent toxin
event in seawater and bivalves. Saxitoxin was extracted from the water column by
filtering 1L of seawater and sonicating the filter for one hour in diH2O. The con-
centration of saxitoxin in seawater, measured using ELISA, ranged from 26 ug/L to
230 ug/L during the bloom. Nine species of bivalves, Saxidomus giganteus, Mytilus
trossulus, Clinocardium nuttalli, Protothaca staminea, Mya truncata, Mya arenaria,
Tresus capax, Mactromeris polynyma, and Hiatella artica, were sampled for saxitoxins
using ELISA following soft tissue homogenization and extraction. Two species,
Mytilus trossulus and Saxidomus giganteus, exceeded the regulatory limit for saxi-
toxin, 80 ug/100g wet wt . Mytilus trossulus saxitoxin concentrations ranged from
67 to 215 ug/100g, while S. giganteus ranged from 143 to 279 ug/100g. After the
bloom, concentration of saxitoxin in the seawater and M. trossulus decreased, at a
rate of 5.7ug/day, but remained elevated in S. giganteus. The concentration of saxi-
toxin in M. trossulus was below the FDA regulatory limit of 80ug/100g wet wt. 26
days after the bloom of Alexandrium was detected. Recreational harvest of bivalves
in Alaska is not regulated for PSP; however, these results suggest that PSP risk is
very high, particularly for S. giganteus.
2343 Acute and 28-Day Oral Toxicity Evaluation of siRNAs and
Longer Double-Stranded RNAs in Mice.
J. S. Petrick1,  B. S. Wahle2,  W. M. Moore1,  R. Shah1,  D. Eveleigh3,
J. H. Sherman1,  W. F. Heydens1 and S. L. Lemke1. 1Monsanto Company, St. Louis,
MO; 2Xenometrics, LLC, Stilwell, KS; 3Asuragen, Inc, Austin, TX.
RNA interference is being used in agricultural biotechnology as a selective tool for
developing crop traits. There are numerous biological barriers to uptake and activ-
ity of ingested nucleic acids that are ubiquitous components of animal diets. To
evaluate the potential for adverse effects of dietary double stranded RNAs
(dsRNAs), we conducted oral toxicity studies in mice with a pool of four 21-mer
small interfering RNAs (siRNAs) and a 218 base pair dsRNA targeting the mouse
ortholog of vacuolar ATPase (vATPAse). When dsRNA targeting the insect or-
tholog of vATPase is expressed in corn plants, they are insecticidal against corn
rootworm. Test materials were administered to CD-1 mice by oral gavage in a sin-
gle dose acute toxicity study at 2000 mg/kg and in a 28 day repeat dose oral toxic-
ity study at 1, 10, and 100 mg/kg. Torula yeast RNA was included as a control in
both studies. There was no impact of treatment on body weight, food consump-
tion, clinical observations, or gross pathology in the acute toxicity study. The acute
NOAELs for both the siRNAs and dsRNA were 2000 mg/kg, the highest doses
tested. In the 28-day study, there were no treatment-related adverse effects on body
weight, food consumption, clinical observations, clinical chemistry, hematology,
gross pathology, or micropathology. The NOAELs in the 28 day study for both the
siRNAs and dsRNA were 100 mg/kg, the highest doses tested. In summary,
siRNAs and longer dsRNAs with 100% sequence identity to mouse vATPase do
not result in adverse effects when administered orally to mice in a large dose. These
results are consistent with the current body of knowledge that exogenous dsRNA
molecules in food, even those with sequences identical to human and/or animal
genes, are safely consumed.
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2344 The Global Burden of Disease Caused by Arsenic in Food.
S. Oberoi,  A. Barchowsky and F. Wu. Environmental and Occupational Health,
University of Pittsburgh, Pittsburgh, PA.
Arsenic is a ubiquitous, naturally occurring metalloid that poses a significant
human cancer risk. While water consumption provides the majority of human ex-
posure to arsenic, naturally occurring levels of arsenic in grains, vegetables, meats
and fish, as well as through food processed with water containing arsenic (e.g. cook-
ing rice) present a significant exposure to millions of individuals worldwide. To es-
timate the global burden of diseases attributable to toxic inorganic arsenic in food,
we first evaluated the weight of evidence that supports a causal role for arsenic in a
number of cancers and non-cancer disease endpoints. We determined that there
was substantial evidence from large epidemiological studies that arsenic causes skin,
lung, and bladder cancer in humans. The body burden of toxic arsenicals from
foods is difficult to estimate and highly variable due to the natural distribution of
arsenic in soils and water and the complication posed by multiple toxic inorganic
and organic arsenicals, as well as non-toxic organic arsenicals contributing to total
arsenic levels. Therefore we used GEMS/FAO-STAT estimates of food consump-
tion in thirteen global clusters and JECFA reported measurements of total and in-
organic arsenic in different foods to determine the upper and lower boundaries of
foodborne inorganic arsenic exposures. We converted previously reported slope fac-
tors for arsenic related bladder, lung, and skin cancers that were based on water ex-
posure to calculate the annual risk of the cancer incidence in males and females
within each GEMS cluster. These cluster incidence estimates were summed to gen-
erate global estimates of 9,129 to 119,176 additional cases of bladder cancer,
11,844 to 121,442 of lung cancer, and 17,882 to 183,358 of skin cancer worldwide
that are attributable to inorganic arsenic in food. These estimates indicate that
foodborne arsenic contributes to a significant, but low level of global disease bur-
den. Supported by the WHO Foodborne Disease Burden Epidemiology Reference
Group, Chemical Toxicology Task Force.
2345 Hydrogen Peroxide Levels in Freshly Brewed Coffee and
Effects on Storage.
S. N. Uppu2,  B. London1,  S. N. Murthy1 and R. M. Uppu1. 1Environmental
Toxicology, Southern University and A&M College, Baton Rouge, LA; 2Science,
Dutchtown High School, Geismer, LA.
Coffee originating in the 15th century from Ethiopia is one of the heavily consumed
beverages. Although there are studies on caffeine and other components of coffee
such as cafestol, the presence of hydrogen peroxide (H2O2) in coffee was not known
till recently as it was confined to scientific community and some informed public.
It is a general belief that H2O2 is formed only after long periods of storage or with
certain roasting practices. The present study focused on dispelling the myths of
H2O2 in coffee. We first measured H2O2 in freshly brewed coffee from different
companies by ferrous oxidation-xylenol orange binding (FOX) method. Following
this, we examined the time dependent accumulation of H2O2 and its changes with
temperature. Further, H2O2 was estimated in coffee obtained from several local
vendors. Contrary to the general belief that the accumulation of H2O2 is an aging
phenomenon of coffee, we found this toxicant even in freshly brewed coffee. This
was true for all brands tested, and H2O2 content increased upon storage. The high-
est increase was seen in coffee stored on the hot plate compared to the ones kept at
room temperature/in cold.  The H2O2 content of coffee from different vendors
ranged between 0.29 and 0.82 mM, which is 5- to 20-fold higher than the typical
H2O2 concentrations at which significant cytotoxic effects have been reported for
assay systems using neuroblastoma and other cell types. Our findings shed new
light on the probable toxic effects of a commonly consumed beverage like coffee,
and the time and temperature dependent variations of keeping. While there are
documented benefits of consumption of coffee, the H2O2 medicated toxic effects
are critical and have also to be borne in mind. Future studies are warranted to de-
lineate the contribution of H2O2 in the healthy well being of individuals who con-
sume coffee extensively [Funding support from NSF (grant HRD-1043316) and
the US Department of Education (grant PO31B040030) is acknowledged.
Corresponding author’s email: rao_uppu@subr.edu].
2346 Toxicologic Evaluation of the Calcium Binding Protein
Apoaequorin.
P. Marone1,  M. R. Bauter1,  H. Hofman-Huther2 and D. Moran3. 1Toxicology,
Eurofins Product Safety Laboratories, Dayton, NJ; 2BSL Bioservice Scientific
Laboratories GmbH, Planegg, Germany; 3Quincy Bioscience, Madison, WI.
The present study evaluated the mutagenic and toxicologic potential of a propri-
etary calcium binding jellyfish protein, Apoequorin. The test article was investi-
gated for its potential to induce gene mutations according to a plate incorporation
and pre-incubation test by Salmonella typhimurium strains TA98, 100, 1535, and
1537 and E.coli WP2uvrA at concentrations of 31.6, 100, 316, 1000, 2500, and
5000 μg/plate with and without metabolic activation. No toxic effects, precipita-
tion or biologically relevant increases in revertant colony numbers of the test item
were noted in any of the five tester strains used up to the highest dose group evalu-
ated with and without metabolic activation in experiments I and II. Therefore,
Apoaequorin did not cause gene mutation by base pair changes or frameshifts in the
genome of the strains used and was considered to be non-mutagenic in the bacter-
ial reverse mutation assay. In a 90-day oral gavage study including dose levels of 0,
92.6, 462.9, and 926.0 mg/kg/day in Sprague-Dawley rats, there were no adverse
clinical, body weight, body weight gain, food consumption, food efficiency, or clin-
ical- or histo-pathology changes associated with the administration of
Apoaequorin. Therefore, the no-adverse-effect level (NOAEL) for Apoaequorin ad-
ministered orally over 90 days was 926.0 mg/kg/day (666.7 mg/kg/day, based on an
concentration of 722mg/g or 72% active ingredient) the highest dose tested, for
male and female Sprague-Dawley rats.
2347 Toxicological Evaluation of a High-Purity Transresveratrol
from an Alternative Synthetic Route.
J. A. Edwards,  M. Beck and P. Beilstein. Product Safety, DSM Nutritional Products,
Kaiseraugst, Switzerland. Sponsor: A. Davidovich.
trans-Resveratrol is a naturally-occurring, polyphenolic compound found predom-
inantly in grapes. resVida (≥ 99.0% trans-resveratrol manufactured by DSM) has
previously been assessed for safety based on toxicity studies (Williams et al, 2009)
and obtained self-GRAS status in 2008. An alternative manufacturing process is
now available in which trans-resveratrol is obtained with the same high purity of ≥
99.0% but with different trace components to those in the original manufacturing
process. Several of these new resveratrol-related by-products are found in nature
(for example trans-pterostilbene). A safety assessment of the new process trans-
resveratrol and its by-products was undertaken. The assessment process comprised: 
- Identification of the new by-products
- Literature review for information on new by-products
- In silico analysis (DEREK) for toxic alerts of new by-products 
- Structural analogue comparisons where appropriate
- In silico analysis (METEOR) for likely metabolism of newly identified by-prod-
ucts
- Ames tests (Salmonella Typhimurium Reverse Mutation Assays) with representa-
tive and spiked batches (to maximal specification level) of the new process material 
- Definition of a new upper limit specification for newly identified by-products 
Information presented from this process includes summarized data from the Ames
test, which showed no mutagenic potential, with or without S9. From the assess-
ment of all this information it was concluded that ≥ 99.0% trans-resveratrol pro-
duced from the alternative route is safe and suitable for use within the marketing
limits defined in the GRAS evaluation of the original process material. 
Williams LD, Burdock GA, Edwards JA, Beck M, Bausch J (2009) Safety studies
conducted on high-purity trans-resveratrol in experimental animals, Food Chem
Toxicol 47(9):2170-2182.
2348 A 28-Day Gavage Study of 2-Methylfuran in Male Fischer
344 Rats.
S. S. Gill1,  M. Kavanagh1,  W. Cherry1,  M. Barker1,  M. Weld2 and
G. M. Cooke1. 1TRD, Health Canada, Ottawa, ON, Canada; 2Chemical Health
Hazard Assessment Division, Health Canada, Ottawa, ON, Canada. Sponsor: R.
Mehta.
In thermally treated products, a series of alkylated furan derivatives have been
found, in particular 2-substituted alkylfurans such as 2-methylfuran. These methyl
analogues are metabolically activated in a similar fashion as the parent furan, yield-
ing highly reactive unsaturated dialdehydes. There is limited toxicological data
available for 2-methyl furan which makes conducting a risk assessment difficult.
This pilot study was designed to determine the dose range of 2-methylfuran for fu-
ture subchronic studies needed to determine a NOAEL. Male Fischer 344 rats 5-6
weeks of age were administered 2-methlyfuran by gavage to final concentrations of
0, 0.4, 1.5, 3, 6, 12, or 25mg/kg bw/day. The animals were weighed daily prior to
gavage. Food consumption was measured on a weekly basis. The liver was the pri-
mary target organ which developed dose-dependent toxicity. Relative liver weights
were increased by 42% at 25 mg/kg bw/day. Histological changes in the liver were
observed at 0.4, 1.5, 3, 6, 12 and 25 mg/kg bw/day. These changes were not ac-
companied by clinical changes in serum liver enzyme markers such as ALT, ALP
and AST. Clinical biochemistry markers for kidney were altered but these were not
accompanied by histological changes. At 25 mg/kg bw/day, spleen weights were in-
creased and the prostate was significantly increased in size. Some hematological pa-
rameters were also altered. In this pilot study, the liver was the major target organ
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for 2-methylfuran as indicated by changes in gross, histological and clinical param-
eters. Although there were changes in the weights of other organs including
prostate, kidneys and spleen, these were not accompanied by histological changes.
The results of this study will be used to conduct a future subchronic study to estab-
lish a NOAEL for risk assessment purposes.
2349 Characterization of Bacterial Mutagenicity QSAR
Predictions of Food Additives to Support Safety Assessments
in a Regulatory Setting.
K. P. Cross1,  G. J. Myatt1,  K. Arvidson2 and K. Muldoon-Jacobs2. 1Leadscope,
Inc., Columbus, OH; 2Center for Food Safety and Applied Nutrition, US FDA,
College Park, MD.
Assessment of food additive safety at the U.S. FDA has utilized quantitative SAR
(QSAR) analysis models for endpoints ranging from genetic toxicity, reproductive
and developmental toxicity to rodent carcinogenicity. However, many of the QSAR
models in routine use were originally developed for drug and industrial chemical as-
sessments. Consequentially a performance assessment on their use for compounds
of interest to FDA CFSAN was undertaken. A set of approximately 4000 com-
pounds of interest to CFSAN was assembled and used to characterize the perform-
ance of a QSAR model developed for predicting overall Salmonella mutagenicity.
The test set was used to assess the suitability of the chemical space of the model for
predicting food additive compounds. Overall performance statistics for accuracy,
sensitivity, specificity and domain of applicability were measured. Structural classes
were identified through compound clustering based on structural fingerprints that
were well-predicted, poorly predicted, and not able to be predicted. Additionally, a
set of public structural alerts that represent different mutagenic toxicophores was
assembled and used to help more precisely quantify performance. Variation in per-
formance was observed across different toxicophores, providing a detailed picture of
the model’s strengths and weaknesses from a structural perspective in assessing food
additives.
2350 The Role of Palmitoylation in Chemical and Microbial
Toxicity: Signal Pathways, Protein Binding and Trafficking.
I. A. Ross and C. S. Kim. Toxicology, US FDA, Laurel, MD. Sponsor: T. Flynn.
Multicellular organisms use chemical messengers to transmit signals among or-
ganelles and to other cells. Relatively small hydrophobic molecules such as lipids are
excellent candidates for this signaling purpose. In most proteins, palmitic acid and
other saturated and some unsaturated fatty acids are esterified to the free thiol of
cysteines and to the N-amide terminal. This process enhances the surface hy-
drophobicity and membrane affinity of protein substrates and play important roles
in modulating protein trafficking, stability, and sorting. Protein palmitoylation has
been involved in numerous cellular processes, including signaling, apoptosis, and
neuronal transmission. The palmitoylation process is involved in diseases such as
Huntington’s disease, various cardiovascular and T-cell mediated immune disorders,
and cancer. Our study on lipopolysaccharide and deoxynivalenol treatment to rats
provides insights on the role of protein palmitoylation in chemical and microbial
toxicity. In the liver of animals treated with 10 mg/kg DON, palmitic acid de-
creased by 22% between 3 and 24 hr and increased 24% between 24 and 72 hr as
compared to the controls. LPS at 83 μg/kg caused 54% decrease in elaidic acid be-
tween 3 and 24 hr, and 7% between 24 hr and 72 hr while stearic acid decreased
33% between 3 and 24 hr and 60% between 24 and 72 hr as compared to the con-
trols. Palmitate is a component of the LPS of Gram-negative bacteria. The bacterial
outer membrane enzyme lipid A palmitoyltransferase PagP confers resistance to
host immune defenses by transferring a palmitate chain from a phospholipid to the
lipid A component of LPS. PagP is sensitive to cationic antimicrobial peptides
(CAMP) which are included among the products of the Toll-like receptor 4 (TLR4)
signal transduction pathway. This modification of lipid A with a palmitate appears
to both protect the pathogenic bacteria from host immune defenses and attenuate
the activation of those same defenses through the TLR4 signal transduction path-
way.
2351 Compartment-Regulated Expression of Macrophage-
Inhibitory Cytokine 1 under Mucosal ER Stress.
S. Park,  H. Choi,  K. Do,  J. Kim and Y. Moon. Lab. of Mucosal Exposome and
Biomodulation, Department Microbiology and Immunology, Pusan National
University School of Medicine and Medical Research Institute, Yangsan, Republic of
Korea.
Endoplasmic reticulum (ER) stress causes global translational arrest during protein
biosynthesis. In spite of global translational arrest, the critical stress responsive
genes, including macrophage inhibitory cytokine 1 (MIC-1), are particularly
turned on. Functionally, MIC-1 played pivotal roles in ER stress-linked apoptotic
death, which was also influenced by C/EBP homologous protein, a well known
apoptotic mediator of ER stress. ER stress enhanced MIC-1 mRNA stability in-
stead of transcriptional activation, and there were two mechanistic translocations
critical for mRNA stabilization. First, C/EBP homologous protein triggered pro-
tein kinase C-linked cytosolic translocation of the HuR/ELAVL1 (Elav-like RNA-
binding protein 1) RNA-binding protein, which bound to and stabilized MIC-1
transcript. As the second critical compartment-regulated modulation, ER stress-ac-
tivated ERK1/2 signals contributed to enhanced stabilization of MIC-1 transcript
by controlling the extended holding of the nucleated mRNA in the stress granules
fusing with the mRNA-decaying processing body. Taken together, these two se-
quential compartment-associate modulation can account for stabilized transcrip-
tion and subsequent re-initiation of translation of pro-apoptotic MIC-1 gene under
mucosal ER stress (This study was carried out with the support of National Joint
Agricultural Research Project of RDA (project number PJ008405032012) RDA,
Republic of Korea).
2352 Azathioprine-Induced Hepatotoxicity in an In Vitro
Inflammation-Immune Model.
A. Maruf1 and P. J. O’Brien1, 2. 1Pharmacology & Toxicology, University of Toronto,
Toronto, ON, Canada; 2Faculty of Pharmacy, University of Toronto, Toronto, ON,
Canada.
Azathioprine (AZP) is widely used in clinical practice for preventing graft rejection
in organ transplantations, various autoimmune and dermatological diseases with
documented unpredictable hepatotoxicity. Several experimental models suggested
that an episode of inflammation during drug treatment predisposes animals to tis-
sue injury. Inflammation caused by infections or endotoxins markedly activates
NADPH oxidase. In the phagosome, superoxide radicals spontaneously form hy-
drogen peroxide (H2O2) and other reactive oxygen species. The effect of inflam-
mation on AZP using “Accelerated Cytotoxicity Mechanism Screening” technique
was investigated in this study. The concentration of AZP required to cause 50% cy-
totoxicity in 2 hr towards isolated rat hepatocytes was found to be 400 μM. AZP
(400 μM) significantly increased cytotoxicity compared to control hepatocytes.
When a non-toxic H2O2 generating system (glucose/glucose oxidase) was added to
the hepatocytes prior to the addition of AZP, an increase in AZP cytotoxicity was
observed. Because neutrophils or Kupffer cells release myeloperoxidase on activa-
tion, the effect of adding peroxidase to the hepatocytes exposed to H2O2 on AZP
was also investigated. AZP showed a significant increase in cytotoxicity compared
to drug-control in presence of glucose/glucose oxidase with or without horseradish
peroxidase. A significant increase was also observed with glutathione depleted and
catalase inhibited hepatocytes. Furthermore, AZP increased reactive oxygen species
(ROS) formation, lipid peroxidation and decreased %mitochondrial membrane
potential with our inflammation-immune model indicating the involvement of ox-
idative stress by glutathione oxidation, lipid peroxidation and mitochondrial toxic-
ity. Protection was achieved by a ROS scavenger, 4-hydroxy-2,2,6,6-tetram-
ethylpiperidene-1-oxyl (200 μM) and an antioxidant
N,N’-diphenyl-p-phenylenediamine (2 μM). These results raise the possibility that
the presence or absence of inflammation may be another susceptibility factor for
azathioprine-induced hepatotoxicity.
2353 Indole-3-Carbinol and 3, 3’-Diindolylmethane Decrease
Histone Deacetylase 3 Which Plays an Important Role in the
Promotion of Stapylococcal Entertoxin B-Induced Immune
Cell Activation.
P. B. Busbee,  M. Nagarkatti and P. Nagarkatti. USC School of Medicine, Columbia,
SC.
Staphylococcal enterotoxin B (SEB) is an exotoxin produced by the Staphylococcus
aureus bacterium. This toxin is classified as a “superantigen” because of its ability to
directly bind T cell receptors with MHC II class receptors of antigen presenting
cells, which activates a large proportion of T cells. SEB is commonly associated with
classic food poisoning, and more recently gained attention as a potential biological
warfare agent since it is easily aerosolized. We have shown that indole-3-carbinol
(I3C) and one of its byproducts, 3,3’-diindolylmethane (DIM), which are found in
cruciferous vegetables, is able to reduce the number of SEB-activated T cells both in
vitro and in vivo. These compounds were also able to reduce immune cell activa-
tion, induce apoptosis, and decrease proinflammatory cytokine release. In the cur-
rent study, we assessed the role histone deacetylases (HDACs) played in SEB-
treated cells, as well as what effect I3C/DIM had on them. Using inhibitors specific
for Class I or Class II HDACs, we showed that inhibition of Class I HDACs leads
to decreased immune cell activation, increased apoptosis, and reduction in proin-
flammatory cytokine release in SEB-activated cells. However, inhibition of Class II
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HDACs had opposite effects, suggesting a dual role of these HDAC classes in SEB
stimulation, where Class I HDACs were important in SEB-mediated immune cell
activation. Screening HDAC expression with western blots, we were able to deter-
mine that HDAC3 was the main HDAC upregulated after SEB stimulation, and
I3C and DIM treatment was able to decrease this expression level. This research es-
tablishes for the first time the important role Class I HDACs, particularly HDAC3,
play in SEB-induced stimulation. We were also able to provide more evidence for
the effectiveness of I3C/DIM treatment in SEB through the downregulation of
HDAC3. (Supported in part by NIH grants P01AT003961, R01AT006888,
R01ES019313, R01MH094755, P20RR032684 and VA Merit Award
BX001357).
2354 Quantification of Cytokines: Enzyme-Linked
Immunosorbent Assay versus Cytometric Bead Array.
M. van Tuyl,  M. Stitzinger,  M. Vloet,  Y. Klijn-Pijnenborg and H. Emmen.
Toxicology, WIL Research Europe B.V., ‘s-Hertogenbosch, Netherlands.
Cytokines are important inflammatory mediators. Disturbance of the balance of
pro- and anti-inflammatory cytokines may result in multiple organ toxicity. In this
study, we compared two commonly used immunoassays for the detection of cy-
tokines, i.e. Enzyme-Linked ImmunoSorbent Assay (ELISA) and Cytometric Bead
Array (CBA). 
BD OptEIA ELISA kits and BD CBA Flex Sets were used to determine interleukin
4 (IL-4), interleukin 10 (IL-10) and interferon gamma (IFN-γ) levels in serum of
untreated rats and in assay diluent. The intra-assay variation was determined after
spiking with the individual recombinant standard of an ELISA kit at concentra-
tions within the ELISA standard range or spiking with the combined recombinant
standards of the CBA sets at concentrations within the CBA standard range. In ad-
dition, inter-assay variation was determined by spiking at two concentrations
within the range of both ELISA and CBA standards and by analyzing these spiked
samples using both methods on the same day. 
Both ELISA and CBA methods showed similar coefficients of variation for all cy-
tokines, i.e. less than 15% for the majority of measurements. The accuracy of assay
diluent spiked with one or more cytokines was within 75-125% for most measure-
ments using both methods. Spiking of serum samples showed clearly that serum
contains factors that interfered with the quantification of IL-4, IL-10 and IFN-γ
using the selected ELISA kits and CBA sets. For example, quantification of IL-10 in
spiked serum showed an accuracy of approximately 30% using both methods and
IFN-γ analysis resulted in an accuracy of <30% using ELISA and an accuracy of 70-
80% using CBA. The absolute values of cytokines in spiked serum samples may dif-
fer between both methods, like for IFN-γ, but relative levels of cytokines always
correlated with the spiked concentrations using either one of these methods. 
In conclusion, both ELISA and CBA showed similar precision and consistency in
relative cytokine levels.
2355 Aryl Hydrocarbon Receptor-Dependent Retention of Nuclear
HuR Suppresses Cyclooxygenase-2 Expression Independent
of DNA-Binding.
M. Zago1,  J. Sheridan1,  P. Nair2,  A. Rico de Souza1,  I. E. Gallouzi1,
S. Rousseau1,  S. Di Marco1,  Q. Hamid1,  D. H. Eidelman1 and C. J. Baglole1.
1McGill University, Montréal, QC, Canada; 2McMaster University, Hamilton, ON,
Canada.
Rationale: The aryl hydrocarbon receptor (AhR) has emerged an endogenous sup-
pressor of cyclooxygenase-2 (Cox-2). Cox-2 is an immediate-early gene that is ro-
bustly increased by cigarette smoke exposure. We have published that the AhR sup-
presses cigarette smoke-induced Cox-2 protein but not mRNA, suggesting
post-transcriptional regulation as a mechanism. The AhR may destabilize Cox-2
mRNA by retaining the RNA-binding protein (RBP) HuR in the nucleus. There is
no known association between the AhR and HuR. Therefore, we investigated
whether AhR-dependent retention of nuclear HuR is responsible for Cox-2 mRNA
destabilization.
Methods: AhR-/-, AhR+/+, AhRDBD/DBD (harboring a mutant AhR unable to
bind DNA) and AhRDBD/B6 mouse lung fibroblasts were exposed to cigarette
smoke extract (CSE) for 3 h followed by Actinomycin D (ActD) for 30 minutes, 1
or 3 h. Cox-2 protein and mRNA were analyzed by western blot and qRT-PCR, re-
spectively. HuR expression was assessed by western blot and immunofluorescence.
AhR-/- cells were transfected with HuR siRNA and exposed to 1% CSE for 3 h
with or without ActD for an additional 3 h. Cox-2 mRNA was then assessed by
qPCR.
Results: Steady-state Cox-2 mRNA levels significantly declined upon ActD treat-
ment in AhR+/+ cells, AhRDBD/DBD and AhRDBD/B6 cells, suggesting that the
AhR destabilizes Cox-2 mRNA by a DRE-independent mechanism. Cox-2 mRNA
instability was due to the nuclear retention of HuR. CSE did not alter HuR expres-
sion, but induced cytoplasmic HuR shuttling only in AhR-/- cells. Knockdown
HuR in AhR-/- cells significantly decreased Cox-2 mRNA expression after exposure
to ActD.
Conclusions: AhR-dependent retention of nuclear HuR suppresses cigarette
smoke-induced Cox-2 protein by a mechanism that is independent of DNA-bind-
ing activity. These important findings open the possibility that a DRE-independent
AhR pathway may be exploited therapeutically as an anti-inflammatory target.
2356 Ultraviolet Radiation (UVB)-Induced Migration of Skin
Dendritic Cell Subsets Is Mediated through Transforming
Growth Factor Beta Signaling.
A. Ravindran1,  J. Mohammed1,  A. J. Gunderson1,  M. C. Udey2 and
A. B. Glick1. 1Center for Molecular Toxicology and Carcinogenesis, The Pennsylvania
State University, State College, PA; 2Dermatology Branch, National Cancer Institute,
National Institutes of Health, Bethesda, MD.
Ultraviolet radiation(UVB) is the leading cause of skin cancer worldwide. UVB also
modulates certain inflammation driven cutaneous pathologies such as contact hy-
persensitivity through actions on skin resident dendritic cell(DC) subsets.
Transforming Growth Factor-β1(TGF-β1) is a potent immunoregulatory cytokine
in the skin microenvironment. Here, we show that TGF-β1 is required for UVB in-
duced activation and migration of dendritic cells to the skin draining lymph nodes.
We irradiated skin of Skin Hairless(SKH1) mice with UVB in the presence or ab-
sence of SB431542, a small molecule inhibitor of the TGF-β type I receptor and
measured lymph node migration of skin dendritic cell subsets at acute time points.
Topical inhibition of TGF-β1 pathway with SB431542 suppressed the migration of
skin dendritic cell subsets, primarily CD103+ CD207+ and CD207- DC popula-
tions to the lymph nodes in response to UVB irradiation. In addition, in an ex vivo,
skin explant assay for the migration of dendritic cells, UVB induced DC migration
into culture media was suppressed with topical inhibition with SB431542. In mice
expressing a dominant negative receptor for TGF-β in CD11c+ dendritic
cells(CD11c-TβRII DNR), UVB induced migration of the DC subsets was sup-
pressed directly linking TGF-β signaling in DCs to UVB induced migration of
DCs. Treatment with SB431542 also suppressed UVB-induced Interferon γ (IFNγ)
secretion as well as the effector differentiation of T lymphocytes within the lymph
nodes. Consistent with decreased activation within the lymph nodes, SB431542
decreased UVB activation of the skin infiltrating CD4 and CD8 lymphocytes after
acute treatments and in UVB-induced skin tumors. Together, these data show that
the TGF-β1 signaling pathway is important for the initiation of the inflammatory
response to UVB irradiation of the skin, mediated primarily through the dendritic
cells.
2357 Alterations in the Hepatic Transcriptome during Live
Citrobacter Rodentium Infection.
M. D. Merrell and E. T. Morgan. Pharmacology, Emory University, Atlanta, GA.
Infection and inflammatory signaling can significantly alter drug metabolism en-
zyme expression (DME), thereby impacting the capacity of the liver to clear toxi-
cants from the body. Previous work in our laboratory has detailed the modulation
of gene expression of several hepatic DMEs during colonic infection with live
Citrobacter rodentium (C. rodentium). These alterations included particularly strong
downregulation of Fmo3 and Cyp4a family members, and appear to be largely in-
dependent of LPS-TLR4 signaling. In order to elucidate potential signaling net-
works and pathways involved in this downregulation, we examined the impact of
C. rodentium infection on the hepatic transcriptome using the Illumina MouseRef-
8 v2 expression BeadChip. HeJ mice (n=4) lacking toll-like receptor 4 (TLR4),
along with appropriate wild type animals (HeOUJ), were orally inoculated with live
C. rodentium in a sucrose solution or received sterile sucrose. After 7 days, animals
were sacrificed, livers were harvested, and RNA was prepared and submitted for
analysis. Genes showing differential expression during infection were identified and
pathway analysis using gene-set enrichment was performed. Increased numbers of
genes with altered expression were found in HeJ mice as compared to HeOUJ con-
trols. Several DME genes not previously reported as being altered in C. rodentium
infection were identified, comprising P450s, UGTs and GSTs. Ontology
terms/pathways with high enrichment included Drug Metabolism, Mitochondrion,
Oxidation Reduction, and Inflammatory Response. Other terms/pathways of interest
include Apoptosis, Glutathione Transferase Activity, and Lipid Metabolism. An analy-
sis of the potential transcription control pathways upstream of these observed gene
expression changes was also performed. Potential upstream factors include Ahr-
ARNT, Ekl-1, and Hnf-3beta, among others. Taken together, these results demon-
strate that drug metabolizing enzymes as a gene class are particularly sensitive to in-
fection, and indicate several potential pathways that may be responsible for these
effects. Supported by grant R01072372 from the NIH.
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2358 Silencing of Keap1 in Macrophages Boosts
Lipopolysaccharide-Induced Transcription of Interleukin 6
via IKKβ Activation.
P. Lu,  P. Xue,  J. Dong,  C. G. Woods,  Q. Zhang,  M. E. Andersen and J. Pi. The
Institute for Chemical Safety Sciences, The Hamner Institutes for Health Sciences,
Research Triangle Park, NC.
Interleukin-6 (IL6) is a multifunctional cytokine that regulates immune and in-
flammatory responses. Multiple transcription factors, including NF-κB and nuclear
factor E2-related factor 2 (Nrf2), are implicated in the transcriptional regulation of
Il6. Kelch-like ECH-associated protein 1 (Keap1) is a substrate adaptor protein for
a Cullin 3-dependent E3 ubiquitin ligase complex, which regulates the degradation
of various vital proteins, including Nrf2 and Ikkβ. In agreement with previous
studies, stable knockdown of Nrf2 in RAW 264.7 mouse macrophages led to sig-
nificantly attenuated antioxidant response and decreased expression of Il6 under
basal and lipopolysaccharides (LPS)-treated conditions. However, Nrf2 activation
alone (e.g. under tert-butylhydroquinone exposure) did not increase the expression
of Il6, suggesting that Nrf2 is a necessary, but not sufficient, factor in regulating
LPS-induced transactivation of Il6. In contrast, silencing of Keap1 in RAW cells
and human monocyte THP1 cells markedly augmented the expression of Il6 under
non-stressed and LPS-challenged conditions. The enhanced expression of Il6 in
Keap1-knockdown (Keap1-KD) cells was significantly attenuated by silencing of
Ikkβ, but not Nrf2, suggesting that stabilized Ikkβ resulting from Keap1 silencing
is the major downstream event responsible for the transactivation of Il6. This find-
ing was further confirmed by the enhanced protein levels of Ikkβ and subsequent
increased expression and phosphorylation of NF-κB p65 in the Keap1-KD cells.
Together, the present studies demonstrated that silencing of Keap1 in macrophages
boosts LPS-induced transcription of Il6 via IKKβ activation. Given the importance
of IL6 in inflammatory response, targeting Keap1 could be a novel approach in the
treatment and prevention of inflammation and associated disorders.
2359 Potent Protection against PM2.5 Diesel Exhaust Particle-
Caused ROS Generation and Vasculature Permeable through
Regulation of Nrf2-Induced Pathways by Triterpenoids.
C. Tseng1, 2,  C. Lin1,  M. K. Gordon3 and M. Chao1. 1Bioscience Technology,
Chung Yuan Christian University, Chung-Li, Taiwan; 2Biomedical Engineering,
Chung Yuan Christian University, Chung-Li, Taiwan; 3Joint Program of Toxicology,
Rutgers University, Piscataway, NJ.
Epidemiologies suggest that an increase of PM2.5 diesel exhaust particles (DEP) in
ambient air corresponds to an increase in myocardial infarctions within 48 hours.
To cause such disorder, the close association of capillaries and alveoli should allow
inhaled DEP to get in close proximity to capillary endothelial tubes. However, the
mechanism of how DEP travel from the alveolar space into bloodstream remains
unclear. Our group has suggested that DEP might upregulate Nrf2 pathway and in-
duce vascular permeability factor VEGF-A secretion. Once VEGF-A goes up, DEP
may cause cell-cell adherent junction disruption and transmigrate into the circula-
tion. In order to minimize the level that DEP traveling in the bloodstream, two
triterpenoids (oleanic acid, ursolic acid) were used as antioxidant. After DEP ±
triterpenoids treatment, MTT was used to examine cell viability of 3D capillary-
like endothelial cultures, Cm-H2DCFDA assays were used to determine the extent
of ROS production in the model, and confocal microscopy was used to evaluate the
endothelial junctional proteins in the cell-cell borders and localization of Nrf2 as
well. At high dose DEP, 80% of the tube cells die within 24 hours. Cells treated
with 25 μg/ml DEP plus triterpenoids not only the translocation of Nrf2 and
downstream HO-1 mRNA expression was reduced, but also ROS generation was
inhibited. Additionally, Z-stacks images revealed that DEP not only accumulated
on the surface of capillary tubes, but also penetrated into the lumen. VE-cadherin
was observed to redistribute in response to DEP. Once combine with triterpenoids,
endothelial tube cells were slightly affected only at high dose DEP, injures caused by
DEP-induced ROS were blocked. Our results suggest that triterpenoids might pre-
vent DEP transmigration into bloodstream by inhibiting oxidative stress produc-
tion and endothelial adherent junctions alternation.
2360 Differential Responses upon Inhalation Exposure to
Biodiesel versus Diesel Exhaust on Oxidative Stress,
Inflammatory, and Immune Outcomes.
A. A. Shvedova1, 2,  N. V. Yanamala1,  A. V. Tkach1,  E. R. Kisin1,  A. R. Murray1,
T. Khaliullin1,  M. Hatfield1,  S. H. Gavett3 and I. Gilmour3. 1PPRB, HELD,
NIOSH, Morgantown, WV; 2Department of Physiology and Pharmacology, School of
Medicine, WVU, Morgantown, WV; 3Cardiopulmonary and Immunotoxicology
Branch, US EPA, Research Triangle Park, NC.
Biodiesel (BD) exhaust may have reduced adverse health effects due to lower mass
emissions and reduced production of hazardous compounds compared to diesel ex-
haust. To investigate this possibility, we compared adverse effects in lungs and liver
of BALB/cJ mice after inhalation exposure (0, 50, 150 and 500 ug/m3; 4 hr/day, 5
d/wk, for 4 wk) to combustion exhaust from 100% biodiesel (B100) and diesel
(D100). Compared to D100, B100 exhaust caused a significant accumulation of
oxidatively modified proteins (carbonyls), increase in 4-hydroxynonenal (4-HNE),
reduction of protein thiols, depletion of antioxidant - gluthatione (GSH), a dose-
dependent increase in the levels of biomarkers of tissue damage (LDH) in lungs,
and inflammation (myeloperoxidase, MPO) in both lungs and liver. B100 exposure
also significantly enhanced expression of cytokines IL-6, and IL-12p70 (in a dose-
dependent manner), along with IL-10, TNF-a and MCP-1 (increased compared to
control) in both lung and liver tissues. Overall, the cytokine profiles in the lung and
liver suggest that B100 and D100 exhaust elicit similar innate immune responses,
predominantly involving T-cell independent pathways; however, the magnitude of
inflammation was greater following B100 exhaust exposure. Interestingly, exposure
to D100, but not B100 exhaust, induced a significant increase in the levels of IFN-
g in the lungs, suggesting a broader engagement of Th1 component by D100 ex-
haust. Based on this, we hypothesize that the distinctive organic compounds and/or
oxidative products formed as a result of increased oxidative stress upon B100 expo-
sure, are capable of targeting biological/molecular pathways that are distinct from
D100 exposure. (This abstract does not represent US EPA policy).
2361 THP-1 and HMC-1 Cell Interaction with Epithelial Cells in
a 3D Tetraculture System of the Alveolar Barrier Modulates
the Response to Oxidative Stress.
S. G. Klein1, 2,  S. Tommaso1,  L. Hoffmann1,  B. Blömeke2 and A. Gutleb1. 1EVA,
CRP - Gabriel Lippmann, Belvaux, Luxembourg; 2Department of Environmental
Toxicology, University of Trier, Trier, Germany.
Exposure to fine and ultra-fine ambient particles is still a problem of concern in
many industrialised parts of the world and the intensified use of nanotechnology
may further increase exposure to small particles. Among the various mechanisms,
the production of oxidative stress is considered to be one of the key mechanisms
how particles affect tissues. Complex in vitro coculture systems may be valuable
tools to study related processes and to further evaluate the effects of particles on the
lung (Klein et al., 2011). Therefore, a system consisting of four different human cell
lines that should mimic the cell response of the alveolar surface in vitro was devel-
oped in order to be used with a native aerosol exposure system (Vitrocell™ cham-
ber). It is composed of an alveolar type-II cell line (A549), differentiated
macrophage-like cells (THP-1), mast cells (HMC-1) and endothelial cells (EA.hy
926), seeded in a 3D orientation on microporous membranes. 
Oxidative stress was induced by incubating the cells with 2,2’-azobis-2-methyl-
propanimidamide, dihydrochloride (AAPH; 20 mM), and quantified as the oxi-
dization of dichlorofluorescein diacetate (DCFH-DA) by measuring fluorescence.
Results are reported as fold increase in ROS production relatively compared to un-
treated cells.
Single cell cultures of EA.hy 926 (11.8 +/- 1.4), THP-1 (11.5 +/- 1.3) and HMC-1
(14.7 +/- 2.9) showed significantly higher oxidative stress than the tetraculture (6.6
2 +/- 0.75). A549 cells alone show the lowest amount of oxidative stress (3.4 +/-
0.18) compared to other cultures. The interplay of model cell for the immune sys-
tem (THP-1 and HMC-1) with A549 epithelial cells strongly influences the behav-
iour of our system, resulting in an alleviative effect for oxidative stress compared to
the monocultures. The use of the tetraculture system may lead to a more realistic
judgement about the hazard of new compounds in the future.
2362 ADME Studies on Nanoparticles Are So Far of Limited Use
for PBPK Modeling.
U. Carlander and G. Johanson. Institute of Environmental Medicine, Work
Environment Toxicology, Karolinska Institutet, Solna, Sweden.
The health hazards with nanoparticles (NP) are largely unknown, and human data
are unlikely to be generated to any great extent. Previous experience with xenobi-
otics shows that combined use of animal ADME studies and PBPK modeling is
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useful in human health risk assessment and this approach should be useful also for
NP. However, it requires that animal experiments are carried out and reported in an
appropriate way. The aim of this study was to review published data on the biodis-
tribution of intravenously injected NP. By this approach the additional complexity
of absorption is avoided. Data were mainly retrieved for gold, silver, titanium diox-
ide, silica and polymeric NP. Very few of the 66 reviewed articles, covering 244 NP
varieties, seem useful for PBPK modeling. The following major limitations were
identified: (1) incomplete NP and dose characterization, (2) short follow-up post-
dosing, (3) few samples per tissue, (4) few tissues/organs studied, and (5) failure to
account for the mass balance, and (6) lack of confirmation of NP integrity in the
tissues. These shortcomings make time course descriptions, half time calculations,
estimates of bioaccumulation uncertain. Most studies present data for blood, liver
and spleen, many also for lungs and kidneys. A few studies suggest that NP deposits
in muscle, bone and carcass should not be neglected. Overall, our review indicates
that it is difficult to draw general conclusions about NP biodistribution. With the
limited data at hand, it seems that no individual factor such as size, coating, shape,
charge, chemical composition or agglomerations status can explain the biodistribu-
tion. In conclusion, the ADME of NP is complex and additional studies are
needed. To be useful in PBPK modeling, these studies should include more com-
plete NP characterization, cover more organs and time points, have longer follow-
ups, and account for the mass balance. It would be valuable to develop a standard
protocol for ADME studies of NP. This study was financed by a grant from the
Swedish Council for Working Life and Social Research.
2363 Copper Oxide Nanoparticle-Induced Acute Pulmonary
Inflammation: Role of Dose Rate and Dissolution Rate.
B. L. Baisch,  N. Corson,  R. Gelein,  P. Wade-Mercer,  A. Walker,
G. Oberdorster and A. Elder. Environmental Medicine, University of Rochester
Medical Center, Rochester, NY.
Numerous studies in rodents use high doses and bolus delivery of nanoparticles
(NPs) to the respiratory tract (RT) in order to identify potential hazards. Past data
suggests differences in inflammatory responses following intratracheal instillation as
compared to whole body inhalation exposure, indicating that bolus delivery may
overestimate NP hazard. However, deposited doses to the lower RT are not always
consistent in these studies and the impact of ions from soluble metal oxide NPs in-
teracting with extracellular fluids and within cells is uncertain. We hypothesize that
the delivered dose rate and dissolution rate are key determinants of the inflamma-
tory response in the RT when the deposited dose is constant. F-344 rats (175-270g)
were exposed to the same deposited dose (3μg) of CuO NPs (30-50nm; 13m2/g) by
high dose rate (bolus) intratracheal instillation and low dose rate (aerosol) whole
body inhalation (1mg/m3 for 4h). Particle size distributions showed agglomerated
structures for both intratracheal instillation (280-420nm, hydrodynamic diameter)
and whole body inhalation (990nm, aerodynamic diameter) exposures. Dynamic
dissolution of the NPs in simulated lung lining fluid (pH 7.4) showed substantial
Cu2+ release over 30h (67%). There were statistically significant increases in bron-
choalveolar lavage fluid (BALF) neutrophils 8 and 24h after bolus delivery of CuO
(4.43 ± 1.25 x 105; 84.18 ± 18.53 x 105) compared to saline controls (1.44 ± 0.41
x 105) and 24h after aerosol exposure (48.34 ± 5.45 x 105) compared to air controls
(0.62 ± 0.14 x 105). Within 7 days BALF neutrophils returned to control levels.
The similar clearance pattern from the lower RT by both methods indicates that
clearance was not affected by delivered dose rate. We conclude that both dose rate
and dissolution rate should be considered when identifying NP hazard. This re-
search was funded by NIH R01CA134218, P30ES01247, RC2ES018741,
T32ES07026 and T32HL066988.
2364 Association between Neutrophilia and Inflammatory
Responses for Ensuring Safety of Nanomaterials.
K. Higashisaka1,  Y. Yoshioka1,  T. Nagano1,  A. Kunieda1,  Y. Iwahara1,
K. Tanaka1,  K. Hata1,  S. Tsunoda2, 3,  H. Nabeshi4,  T. Yoshikawa1 and
Y. Tsutsumi1, 2, 3. 1Laboratory of Toxicology and Safety Science, Graduate School of
Pharmaceutical Sciences, Osaka University, Osaka, Japan; 2Laboratory of
Biopharmaceutical Research, National Institute of Biomedical Innovation, Osaka,
Japan; 3MEI center, Osaka University, Osaka, Japan; 4National Institute of Health
Science, Tokyo, Japan.
Recently, the development of nanomaterials is promoted extensively. These nano-
materials have been already used in various applications. Under this circumstance,
the debate on safety of nanomaterials has expanded worldwide, because they have
unique physicochemical properties and exert innovative functions. Therefore, it is
urgent need to obtain more information to ensure the safety of nanomaterials.
Previously, we demonstrated that some silica nanoparticles (nSP) might induce sys-
temic inflammatory effects, whereas appropriate surface modification suppressed
these effects. However, association with neutrophil that are known to play an im-
portant role in inflammatory responses is hardly understood. Here, for clarifying
the mechanism of inflammatory effects of nSP, we analyzed the changes of neu-
trophil proportion in mice. Initially, to evaluate systemic inflammation induced by
nSP, we analyzed the changes of neutrophil proportion in mice after intravenous in-
jection of nSP with diameters of 70 nm (nSP70) via tail vein. Flow cytometry
analysis showed that the neutrophil proportion was elevated in peripheral blood of
nSP70-treated mice. Furthermore, the plasma level of G-CSF was significantly ele-
vated in nSP70-treated mice compared to that of control mice and anti-G-CSF an-
tibody-treated mice exhibited a decrease in neutrophil proportion. These results
suggested that the nSP70-induced increasing neutrophil proportion was dependent
on G-CSF production. We are now trying to examine the association between neu-
trophilia and inflammatory responses. We believe that our findings provide useful
information for ensuring the safety of nanomaterials.
2365 Differential Response of Brain and Liver Free Fatty Acids
following Administration of Iron Nanoparticles in Rats.
Z. K. Binienda1,  I. A. Ross2,  B. Gough1,  S. F. Ali1,  S. Z. Imam1 and C. S. Kim2.
1Neurotoxicology, NCTR/FDA, Jefferson, AR; 2Toxicology, CFSAN/FDA, Laurel,
MD.
Intranasal treatment with ferric oxide nanoparticles (α-Fe2O3 and γ- Fe2O3 NPs),
in rats caused microglial proliferation and activation in olfactory bulbs, hippocam-
pus and striatum. Our in vitro studies with SHSY-5Y neuroblastoma cells exposed
to 10 and 30 nm ferric oxide NPs showed over expression of alpha-synuclein pro-
tein, depletion of dopamine, and conditions for oxidative stress. Here, we examined
the response of brain and liver free fatty acids (FFAs) in adult male Sprague-Dawley
rats treated intraperitoneally (i.p.) either with saline (control) or ferric oxide
(Fe2O3) – NPs at 25, 50 and 100 mg/kg. Rats were sacrificed 72 hrs after injection
to harvest caudate nucleus and liver. Long chain FFAs were extracted with chloro-
form and methanol (4, 8 v/w) from tissue homogenates and the extracts were
shaken, followed by centrifugation. The supernatants were reconstituted with
Hepes, chloroform and methanol (3.2, 4, 8 v/w). The chloroform was then evapo-
rated under nitrogen. The residue was reconstituted with ether- hexane (50:50, v/v)
and eluted by column chromatography on acid-washed Florisil. FFAs were deriva-
tized with BF3/methanol and fatty acid methyl esters were quantitated using gas
chromatography. Concentrations of saturated FFAs (palmitic, stearic) in the liver
and brain did not change following injection of the iron NPs. However, unsatu-
rated brain FFAs (oleic, linoleic) were decreasing in a dose-related fashion in the
CN (p<0.05). In the liver, the concentration of the unsaturated FFA’s increased sig-
nificantly at 25 and 50 mg/kg (p<0.05) but was no different from control at 100
mg/kg. These data indicate a differential response of liver and brain unsaturated
fatty acids to iron nanoparticle exposure, suggesting different mechanisms in the
liver and brain in response to oxidative stress.
2366 Effects of Cerium Oxide Nanoparticles on Fibroblast
Function in Relation to Lung Fibrosis.
J. Y. Ma,  B. Hines,  M. Barger,  R. R. Mercer and V. Castranova. PPRB/HELD,
NIOSH, Morgantown, WV.
The emission of cerium oxide nanoparticles (CeO2 ) in the diesel exhaust, when
cerium compounds were used as a diesel engine catalyst to lower the diesel exhaust
particles, is a health concern. Our previous studies have shown that CeO2 induced
pulmonary inflammation and lung fibrosis. The objective of the present study is to
investigate the modification of fibroblast function by CeO2 in relation to fibrosis.
Male Sprague Dawley rats were exposed to CeO2 (0.15 to 7 mg/kg) by a single in-
tratracheal instillation and sacrificed at various times post exposure. Alveolar
macrophages (AM) were isolated by bronchoalveolar lavage (BAL), and lung fi-
broblasts were isolated from the lung tissues. The first BAL fluid and AM culture
medium obtained after a 24 h incubation time were saved for further analysis. The
results show that at 28 days after CeO2 (3.5 mg/kg) exposure, lung fibrosis was ev-
ident by increased hydroxyproline content in lung tissues and enhanced Sirius Red
staining collagen fibers in the lung. In addition, the presence of stress actin, ex-
pressed as α-smooth muscle actin (SMA), in fibroblasts was also significantly in-
creased when compared to the control. Lung fibroblasts isolated from CeO2-ex-
posed rats at 28 days post-exposure showed a dose-dependent decrease in
proliferation rate using the MTT assay. Treating primary fibroblasts with CeO2 in
vitro, did not significantly affect cell proliferation rate; however, when treated with
the first BAL fluid collected at 3- or 10-days after CeO2 exposure, significantly in-
creased cell proliferation when compared to the control. In vitro treatment of fi-
broblasts with TGF-β1 significantly increased α-SMA expression. These results
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demonstrate that CeO2 induces a dirverse network of mediators that affects fibrob-
last proliferation and functional changes that may play a role in lung fibrosis. These
findings suggest potential health effects of CeO2 exposure.
2367 Toxicity of Nanoparticles Embedded in Paints Compared to
Pristine Nanoparticles.
S. Smulders,  K. Luyts,  J. Vanoirbeek and P. Hoet. Experimental Unit for
Toxicology, KU Leuven, Leuven, Belgium.
Nanomaterials are increasingly being used in the paint industry due to their unique
physical and chemical properties. Nanoparticles often used in paints and coatings
are TiO2 (anti-UV, self-cleaning, air purification), Ag (anti-microbial) and SiO2
(fire retardant, anti-scratch).
In this study, the toxic effects of 3 pristine nanoparticles (TiO2, Ag and SiO2), 3
aged paints containing nanoparticles (TiO2, Ag and SiO2) and control paints with-
out nanoparticles were compared.
BALB/c mice were weekly oropharyngeally aspirated with nanoparticles or paint
particles (20 μg/aspiration) for 5 weeks. Mice were sacrified 2 or 28 days after the
last aspiration. The local (lung/bronchoalveolar lavage fluid) and systemic (blood)
toxicity was evaluated (cell counts, inflammatory cytokines, blood clotting parame-
ters). 
The pristine nanoparticles showed no effects in the blood and a subtle toxic effect
in the lungs, which was most pronounced in the case of Ag nanoparticles (increase
in neutrophils (7.8x10^3), 2-fold increase in pro-inflammatory cytokines KC and
IL-1β). The paints containing nanoparticles did not show significant toxicity.
In conclusion, we demonstrated that although pristine particles show some toxic ef-
fects, no significant toxicological changes were observed when they were embedded
in a complex paint matrix.
2368 A 15-Day Oral Exposure to Dispersed TiO2 P25 Particles
Induces Epithelial Barrier Dysfunction and Bacterial
Translocation in the Rat Intestine.
E. Houdeau1,  E. Gaultier1,  M. Nabila1,  N. Naud1,  A. Ait-Belgnaoui1,
N. Thieriet2,  M. Carrière3,  J. Cravedi1,  V. Theodorou1 and F. Pierre1. 1INRA
Toxalim, Toulouse, France; 2ANSES, Maisons-Alfort, France; 3CEA-LAN, Grenoble,
France. Sponsor: D. ZALKO.
Aim: Titanium dioxyde (TiO2) has a long-standing use as food additive and is
promised to broad use in food packaging as antimicrobial in biosourced films.
Possible hazards of ingested TiO2 particles for human digestive tract are under dis-
cussion. We addressed consequences for gut barrier function in rats orally exposed
to TiO2 P25 (85% anatase/15% rutile) at human level exposure. Methods: Male
rats were orally given either vehicle (Ve) or TiO2 P25 (provided by European
Commission-Joint Research Center in the OECD sponsorship program) at 100, 1,
0.01μg/kg BW/d in agregated forms or ultrasonicated to obtain a stable dispersed
submicron-sized TiO2 commonly found in food. Particle size was measured by dy-
namic light scaterring. Duodenal to colonic paracellular (4kD dextran) epithelial
permeability was studied by Ussing chamber. Lipid peroxidation was assessed by
Thiobarbituric Acid Reactive Substances (TBARs) assay, and inflammation
through neutrophilar myeloperoxidase activity (MPO). Bacterial translocation
(BT) was assessed in mesenteric lymph nodes (MLN), liver and spleen. Results:
Oral treatment with dispersed TiO2 P25 particles (mean hydrodynamic diameter
630nm) at 100 or 1μg/kg/d increased epithelial permeability (p<0.01) in the je-
junum (+70±16% vs Ve) and colon (+57±19% vs Ve), and only in the jejunum at
10ng/kg/d (85%: 0.19±0.07 vs 0.10±0.03 nmol dextran.cm2.h-1 in Ve; p<0.05).
At all doses, dispersed P25 did not affect TBARs and MPO levels across the gut,
whereas rats dosed with 100μg/kg/d showed enhanced BT to MLN (14 rats/16 vs
4/16 in Ve; p=0.001) (10±0.2 vs 9.3±0.3 log10cfu/g of tissue, respectively), but not
to liver and spleen. Neither gut permeability nor BT was affected in rats exposed to
non-dispersed P25. Conclusion: Chronic oral exposure of rats with dispersed TiO2
at human relevant dietary exposure alters intestinal barrier, with features of bacter-
ial translocation suggesting enhanced risk of pathogen uptake.
2369 The Effect of Nanoparticles from Secondhand Cigarette
Smoke on the Mouse Lung.
Z. Wu1,  M. McCawley2,  E. Kimani2 and R. D. Dey1. 1Neurobiology and
Anatomy, West Virginia University, Morgantown, WV; 2Community Medicine, West
Virginia University, Morgantown, WV. Sponsor: T. Nurkiewicz.
Second hand cigarette smoke (also named Environmental tobacco smoke (ETS)) is
an environmental trigger factor that leads to airway inflammation and airway hy-
perresponsiveness (AHR) in susceptible individuals and animals. The constituents
of ETS exist in the gas-phase and the aerosol particles which consist predominantly
nanoparticles (two dimensions less than 100 nanometres). The purpose of this
study is to characterize the role of nanoparticles on ETS-induced airway responses.
The mice were exposed to side-steam tobacco smoke (SS), a surrogate to ETS, or 50
nm nanoparticles, or 80 nm nanoparticles, or gas-phase or filtered air (FA) for 3hrs.
Lung function and inflammation in bronchoalveolar lavage (BAL) were measured
following exposure. Methacholine (MCh) dose response for lung resistance (RL)
was significantly elevated, and dynamic pulmonary compliance (Cdyn), was signif-
icantly decreased, in the SS, nanoparticles exposure groups compared with the FA
and groups gas-phase exposure. At the same time, the total cells and neutrophils
were significantly elevated in both SS and nanoparticles exposed mice. However,
MCh dose-response curves for RL and Cdyn, inflammation were not significantly
changed in the 50 nm nanoparticles and 80 nm nanoparticles exposure group.
These results suggest that nanoparticles from second hand cigarette smoke play an
important role in smoking-induced lung injury.
2370 The Comparative Immunotoxicity of Mesoporous Silica
Nanoparticles and Colloidal Silica Nanoparticles in Mice.
S. Lee1,  H. Yun2 and S. Kim1. 1Pharmacology, School of Medicine, Kyungpook
National University, Daegu, Republic of Korea; 2Engineering Ceramics, Powder &
Ceramics Division, Korea Institute of Materials Science, Changwon, Republic of
Korea.
Mesoporous silica (MPS) nanoparticles (NPs), which have unique pore structure,
extremely high surface area and pore volume, have attracted attention for their po-
tential biomedical applications, such as carriers for controlled drug delivery and
matrix for tissue regeneration. To use MPS NPs for biomedical devices, their bio-
compatibility both in vitro and in vivo should be confirmed because the surface
area of NPs is one of the important determinants of toxicity such as cellular uptake
and immune response. We previously first reported that MPS NPs exhibited less cy-
totoxicity and inflammation potential than general amorphous colloidal silica (Col)
NPs on macrophages. However, the low cytotoxicity does not guarantee high bio-
compatibility in vivo. In this study, we compared in vivo immunotoxicity of MPS
and Col NPs in mouse model to define the influence of pore structural conditions
of silica NPs. Both MPS and Col NPs (2, 20, 50 mg/kg/day) were intraperitoneally
administered in female BALB/c mice for 4 weeks. There was no overt sign of clini-
cal toxicity in both MPS and Col treated mice. Interestingly, the in vivo test showed
opposite results from in vitro. MPS NPs significantly increased weight of liver and
spleen, and proliferation of splenocytes. MPS NPs treated mice showed the altered
lymphocyte population (CD3+, CD45+, CD4+ and CD8+) of spleen, increased
serum IgG and IgM levels, and histological changes. In spite of the slight changes in
lymphocytes population of spleen, Col NPs did not alter other immunological fac-
tors. Our results showed that in vivo exposure of MPS NPs causes more damages in
systemic immunity than Col NPs by the immunoenhancement of spleen. The in
vivo data showed opposite results from in vitro showing less cytotoxicity of MPS
NPs. Our results suggest the importance of confirmation of biocompatibility both
in vitro and in vivo during the design of new nanomaterials. These findings may
provide useful information for the bioapplication of silica NPs.
2371 Evaluation of Intestinal Absorption of Amorphous Silica
Nanoparticles.
K. Misato1,  Y. Yoshioka1,  M. Uji1,  A. Udaka1,  T. Mori1,  M. Yamaguchi1,
T. Hirai1,  T. Yoshida1,  H. Nabeshi2,  T. Yoshikawa1,  S. Tsunoda3, 4,
K. Higashisaka1 and Y. Tsutsumi1, 3, 4. 1Laboratory of Toxicology and Safety Science,
Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Suita, Japan;
2National Institute of Health Science, Tokyo, Setagaya, Japan; 3Laboratory of
Biopharmaceutical Research, National Institute of Biomedical Innovation, Osaka,
Ibaraki, Japan; 4MEI center, Osaka University, Osaka, Suita, Japan.
With the recent development of nanotechnology, amorphous silica nanoparticles
(nSP) with particle size below 100 nm have already been used in various foods as
anticaking agents. Therefore, to ensure the safety of nSP, it is an urgent need to ob-
tain safety information of nSP. However, there is little information about biodistri-
bution of nSP after oral administration. In this study, we examined the biodistribu-
tion and absorption of nSP via oral route in vivo and in vitro. BALB/c mice were
orally exposed to nSP with diameter of 70 nm (nSP70) or 1000 nm (mSP1000) at
2.5 mg/body for 28 days. After the last administration, we observed the localization
of silica particles in tissues by transmission electron microscope. Both silica particles
were observed in some tissues such as spleen and liver, although these results were
qualitative analysis. Next, we evaluated the absorption of silica particles through in-
testine quantitatively by everted sac method. Although about 0.3% of mSP1000 in
mucosal side was absorbed into serosal side, the level of absorbed nSP70 was about
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1.7% in mucosal side. These results indicated that the particle size would be the
major factor in permeability of intestine. Currently, we are trying to evaluate the re-
lationship between physicochemical properties of nanomaterials and biodistribu-
tion, precisely. We believe that our study will contribute to create safer forms of
nanomaterials.
2372 Indomethacin/Indomethacin Ester-Loaded Nanocapsules
Reduce Brain Tumor in C57bL/6 Mice with No Observable
Local Toxic Effect.
S. F. Rodrigues1,  L. Fiel2,  N. Pereira1,  I. Machado1,  K. Elache1,  S. S. Guterres2,
A. R. Pohlmann2 and S. H. Farsky1. 1Clinical and Toxicological Analysis, University
of São Paulo, São Paulo, Brazil; 2Organic Chemistry, UFRGS, Porto alegre, Brazil.
Sponsor: S. Barros.
Introduction: Potentiation of the indomethacin (IndOH) cytotoxicity was demon-
strated in vitro when IndOH was loaded combined with its ester (IndOEt) in
poly(ε-caprolactone) nanocapsules (NC). Objective: To determine whether the an-
titumor activity of IndOH is kept in vivo when it is combined with IndOEt in NC
and the capacity of those NC to cross the blood brain barrier (BBB). Methodology:
Intravital microscopy was used in oral-, intraperitoneally- (i.p.) or intravenously-
(i.v) treated female C57Bl/6 mice to visualize: 1) The intensity of red fluorescence
within and outside cerebral (pial) venules after rhodamine-labeled NC treatment;
2) The interaction of leukocytes-rhodamine-labeled and platelets-FITC-labeled
with the endothelial cells of pial venules. The BBB permeability was measured by
the Evans blue extravasation assay. Effect of two week-IndOH/IndOEt-NC treat-
ment on the volume of a brain tumor (induced by direct injection of glioblastoma
cell line [GL261] into the brain) was measured. Ethical Committee number:
CEUA/FCF/349. Results: The intensity of fluorescence outside the vessels dramat-
ically increased 30 minutes following i.v. NC injection compared to 10 minutes
time (P<0.05), and was maintained constant up to 2 hours. Higher intensity of flu-
orescence in the parenchyma was also observed 20 minutes, 1 and 2 hours (P<0.05)
after i.p. injection, and 1, 2 and 4 hours after oral intake (P<0.05). No increase in
leukocyte or platelet adhesion to endothelial cells, and Evans blue extravasation
were noticed. IndOH/IndOEt-NC profoundly reduced the brain tumor.
Conclusion: Antitumor activity of IndOH in brain is kept when it is combined to
its ester into NC and may be due to a local effect once they cross the BBB.
Supported by: FAPESP, CNPq.
2373 Isoprostanes As a Biomarker of Nanoparticle-Induced
Toxicity In Vivo.
L. Manzo1, 2,  T. Coccini1, 2,  E. Roda1 and C. Signorini3. 1University of Pavia,
Pavia, Italy; 2Maugeri Foundation IRCCS, Pavia, Italy; 3University of Siena, Siena,
Italy.
Oxidative stress was indicated as one of the main mechanisms associated with
nanoparticle (NP)-induced toxicity. In this study, the validity of plasma F2-iso-
prostanes (F2-IsoPs), a proposed oxidative stress marker (Halliwell & Lee, Antioxid
Redox Signal, 2010), was examined in rats treated intratracheally with a single dose
of cadmium-doped silica nanoparticle (SiNP-Cd), a model nanoparticle previously
shown to induce oxidative stress in vivo (Coccini et al, J Nanopart Res, 2012). The
response to SiNP-Cd (1 mg/rat) was evaluated 24 hr, 7 and 30 days post-instilla-
tion by immunocytochemistry analysis of superoxide dismutase (SOD1), inducible
nitric oxide synthase (iNOS) and cyclooxygenase type 2 (COX-2) expression in
pulmonary tissue. Lung and plasma levels of F2-IsoPs were measured in parallel by
GC/NICI-MS/MS analysis. Furthermore, the effects of SiNP-Cd were evaluated in
comparison with those caused by equivalent amounts of CdCl2 or SiNP. 
In the animals exposed to SiNP-Cd, pulmonary SOD1, iNOS, and COX-2 im-
munoreactivity was enhanced in a time-dependent manner (7 <30 days).
Pulmonary total F2-IsoPs were also increased significantly on thirty days post-ex-
posure (46.7±11 ng/g in SiNP-Cd vs 32.8±7.8 ng/g in control). Pronounced eleva-
tion of free F2-IsoPs similarly occurred in plasma (54.6±2 pg/ml in the SiNP-Cd
group compared to 28±8 pg/ml in controls). The increase in plasma F2-IsoPs was
already detectable at day 7 and lasted until day 30 post-exposure. In the animals
treated with silica nanoparticles no changes were observed regarding the immuno-
chemical and biochemical parameters tested. The pulmonary response to CdCl2
was less pronounced than that found with SiNP-Cd.
These results indicate (i) the potential of SiNP-Cd to cause long-lasting oxidative
tissue injury following pulmonary exposure in rat and (ii) a promising role for
plasma F2-IsoPs as indicator of nanoparticle-induced oxidative insult (Grants:
Italian Ministries of Health & University, and CARIPLO Foundation Rif. 2011 –
2096).
2374 Biokinetics of Nanoscaled Europium Oxide Particles
following an Acute Inhalation in Rats.
O. H. Creutzenberg,  H. Kock and D. Schaudien. Inhalation Toxicology,
Fraunhofer Institute of Toxicology and Experimental Medicine, Hannover, Germany.
Sponsor: C. Dasenbrock.
Nanoscaled europium oxide (Eu2O3) particles were selected to investigate the bio-
kinetics following inhalation. The rare earth Eu allowed a very high accuracy in
analysis of potential translocation from lungs to remote organs. An aqueous disper-
sion of commercially available Eu2O3 particles (0.1 w-%) was prepared in phos-
phate buffer (0.15 w-%) incl. bovine serum albumin (0.25 w-%). A suspension
partially consisting of nanoscaled particles could be realized by mechanical homog-
enization and ultrasonic treatment and was aerosolized with pressurized air. Rats in-
haled the dry aerosol for 6 hours in a single inhalation. Phosphate facilitated the
disintegration of the Eu2O3 particles in lung ambience after deposition. The poten-
tial translocation of Eu2O3 particles was followed by chemical Eu analysis and
transmission electron microscopy (TEM). Using chemical analysis, 36.8 μg/lung
Eu2O3 were detected 1 hour after inhalation in lungs. The amount declined slightly
to 34.5 μg after 1 day and 35.0 μg after 5 days. The liver showed an increase of
Eu2O3 from 32.3 ng 1 hour up to 294 ng 5 days after inhalation. Additionally,
lung-associated lymph nodes, thymus, kidneys, heart, and testes exhibited an in-
crease of Eu2O3 over the time period investigated. In the blood, the highest amount
of Eu2O3 was found after 1 hour whereas feces, urine and mesenteric lymph nodes
revealed the highest amount after 1 day. In the other organs such as brain, spleen,
adrenals and epididymides no changes of the Eu amount were detected. By TEM
analysis, Eu2O3 particles could be detected only in lungs, in liver, however, with one
of the highest chemical Eu concentrations, no particles were detectable. In conclu-
sion, mixed type metal oxide/phosphate particles are a suitable tool for biokinetic
investigations after inhalative uptake. The use of Eu2O3 combined with chemical
and TEM analysis was a very suitable model to examine the translocation potential.
Bioavailability was limited to soluble Eu2O3, a translocation of Eu2O3 particles was
not evident.
2375 NanoMiner—Resource for Human Transcriptomics Data in
Nanoparticle Research.
B. Fadeel1,  L. Kong2, 3,  S. Tuomela3,  L. Hahne2, 3,  H. Ahlfors3,  O. Yli-Harja2,
R. Lahesmaa3 and R. Autio2, 3. 1Institute of Environmental Medicine, Karolinska
Institutet, Stockholm, Sweden; 2Department of Signal Processing, Tampere University
of Technology, Tampere, Finland; 3Turku Centre for Biotechnology, University of
Turku and Åbo Akademi University, Turku, Finland.
The potential impact of nanoparticles on the environment and on human health
has attracted considerable attention in recent years. Transcriptomics data generated
from tissues or cells exposed to nanoparticles are being gathered at ever-increasing
rates. In addition to the importance of the original findings, such data can have
value if interpreted in a broader context and combined with other published results.
To encourage the efficient use of the data, we have developed NanoMiner
(http://nanominer.cs.tut.fi/), an integrative transcriptomics data resource for
nanoparticle research. The data in NanoMiner is collected from public repositories,
and the database currently contains 404 human transcriptomics samples of cells ex-
posed to various types of nanoparticles. All samples in NanoMiner have been anno-
tated, preprocessed and normalized using standard methods to ensure the quality of
the data analyses and to enable systematic use of the database across different exper-
imental setups and platforms. With NanoMiner, it is possible to: 1) search and plot
the expression profiles of one or several genes of interest, 2) cluster the samples
within the datasets, 3) find differentially expressed genes in various nanoparticle
studies, 4) detect the nanoparticles causing differential expression of selected genes,
5) analyze enriched Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways
and Gene Ontology (GO) terms for the detected genes, and 6) search the expres-
sion values and differential expressions of the genes belonging to a specific KEGG
pathway or Gene Ontology. The NanoMiner database is thus a valuable collection
of microarray data and can also be used as a data repository for future analyses.
2376 Nano-Silica Aspiration Exposure Induces Endothelial
Dysfunction in Diabetic Mice.
S. A. Brenner3,  M. Frame1,  A. M. Dewar1 and J. E. Vigilance2. 1Biomedical
Engineering, Stony Brook University, Stony Brook, NY; 2Faculty of Medical Sciences,
The University of The West Indies, Cave Hill, Barbados; 3Nanobioscience, University
of Albany College of Nanoscale Science and Engineering, Albany, NY. Sponsor: T.
Nurkiewicz.
Silica (SiO2) nanoparticles are widely used in many diverse industries, such as pol-
ishing agents in semiconductor fabrication, as potential biomedical drug delivery
agents, and in fabrics to make them wrinkle free. Our goal was to evaluate the ef-
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fects of nano-silica (SiO2, longest dimension 51.9 ± 16.2 nm, aspect ratio 1.1 ±
0.1) on small arterioles in situ. First, a suspension of SiO2 (in 1gm/ml albumin,
saline) was directly applied to arterioles (micropipette, 137 pg total dose), using a
hamster cheek pouch intravital microscopy model (isoflurane, N=6). Endothelial
dysfunction (loss of dilation to acetylcholine, ACH 10-4M) was evident within
minutes (dilation of 78±14% to constriction -3±5%*, p<0.05), while dilation to
adenosine was unaffected. Constrictor responses to phenylephrine were diminished
by SiO2 exposure (from -61±4% to -1±2%*); importantly, the baseline diameters
were not altered by direct exposure to SiO2, and the vessels retained some re-
sponses. Next, mice were exposed to 20ug of SiO2 via aspiration, and 24 hours
later the cremaster m. model was examined (isoflurane). Db/db controls (N=6)
have mild endothelial dysfunction seen as a diminished dilation to ACH (10-4M,
dilation of 43±14% to 10±6%*). Exposure to SiO2 (40gm wt, N=4) induced a
profound endothelial dysfunction seen as constriction to ACH (-13±2%*).
Dilation to adenosine was unaffected. In C57BL/6, exposure to SiO2 (25gm wt,
N=2) did not significantly alter dilation to ACH or adenosine compared to controls
(N=6). Further, in the aspiration model, constrictor responses to phenylephrine
were not affected in either strain. Thus, direct exposure to 137 pg SiO2 induced en-
dothelial dysfunction immediately in healthy hamsters. Aspiration of 20ug induced
a profound endothelial dysfunction in diabetics but not in the genetic background
controls. (NIH DK68401, HL55492)
2377 Copper Nanoparticles or Ionic Copper (II) Causes
Neurotoxicity and Cardiotoxicity in Zebrafish Embryos.
W. Trickler1, 2,  S. F. Ali1,  M. G. Paule1 and J. Kanungo1. 1Division of
Neurotoxicology, National Center for Toxicological Research, US FDA, Jefferson, AR;
2Toxicologic Pathology Associates Inc., Jefferson, AR.
Copper oxide nanoparticles (Cu-NPs) are frequently used in medical devices,
paints, fabrics or as antimicrobials. Their industrial applications may lead to the
contamination of aquatic ecosystems. The toxicological and human health risks of
NPs in the environment are hard to evaluate due to a lack of knowledge about the
mechanisms by which NPs interact with biological systems. In this study, we inves-
tigated the toxicity of Cu-NPs and the ionic copper(II) form in wild-type (WT) ze-
brafish (Danio rerio, AB-strain) embryos and hb9-GFP transgenic zebrafish (Danio
rerio, AB-strain) embryos by comparing bare Cu-NPs to the mass equivalent ionic
from of copper(II) (CuCl2) at various concentrations (1.25-to-20 ug/ml). The tox-
icity was determined by phenotypic changes in the zebrafish embryos including
survival, heart rate, motor neuron development and absorptive permeability. Both
Cu-NPs and CuCl2 were lethal to zebrafish embryos at 20 ug/ml (within 24-hrs)
and 10 ug/ml (within 48-hrs), with CuCl2 being more toxic at equivalent mass
concentrations. Similarly, the heart rate was significantly reduced following expo-
sure to either Cu-NPs or CuCl2 in a concentration-time dependent manner.
Additionally, the embryo permeability studies showed that exposure to either Cu-
NPs or CuCl2 (5 ug/ml) for 24-hrs significantly increased the topical absorption of
the fluorescent tracer 6-coumarin (6CM). Furthermore, embryos treated with ei-
ther Cu-NPs or CuCl2 (2.5 ug/ml for 48-hrs) showed a significant reduction
(nearly 2-fold) of spinal motor neurons.  These results indicate that both CuCl2
and Cu-NPs can be toxic to zebrafish embryos causing significant neurotoxicity and
cardiotoxicity at exposure levels that do not cause lethality.
2378 Nickel Oxide Nanoparticles Provoke Intrinsic Apoptotic
Pathway in HepG2 Cells, Male Wistar Rats and Tomato
Seedling Roots.
Q. Saquib1,  J. Musarrat1,  A. A. Al-Khedhairy1,  M. A. Siddiqui1,  S. M. Attia3,
M. Faisal2,  J. A. Siddiqui1,  S. Dwivedi1 and S. T. Khan1. 1Department of Zoology,
King Saud University, Riyadh, Saudi Arabia; 2Department of Botany, King Saud
University, Riyadh, Saudi Arabia; 3Department of Pharmacology, King Saud
University, Riyadh, Saudi Arabia. Sponsor: M. Verma.
Many features of programmed cell death in plants resemble with those observed in
human and animals. Therefore, this study has been done with a rationale to provide
first evidence on the molecular toxicity of nickel oxide nanoparticles (NiO-NPs,
<50 nm) in human hepatocellular carcinoma (HepG2) cells, male Wistar rats and
tomato seedling roots. The cytotoxicity studies with NRU and MTT assays in
HepG2 cells reveled 20.6 % and 18.4 % decline in the cell survival at the highest
concentration of 100 μg/ml. Treated cells showed an increase in intracellular ROS
generation and 30.5 % increase in flow cytometric sub-G1 apoptotic peak at 100
μg/ml NiO-NPs. Quantitative real-time PCR analysis of apoptotic pathway genes
(P53, caspases 3 and 9) showed 2.0, 1.2 and 1.1-fold higher expression in HepG2
cells. Furthermore, western blot experiments also showed the greater activity of P53
and caspase 3 genes in cells exposed to 100 μg/ml NiO-NPs. Oral exposure of male
Wistar rats with 1, 2 and 4 mg/k.g b.w of NiO-NPs for 48h and 14 days showed in-
creased intracellular ROS generation, DNA damage, micronuclei formation and
apoptosis in bone marrow cells. Tomato seeds exposed to NiO-NPs for 4 h, exhib-
ited repression of root length, higher activities of antioxidant enzymes, and in-
creased frequency of apoptotic and necrotic cells in comet assay. Flow cytometric
analysis of 2 mg/ml treatment group revealed 122% higher ROS generation with
alteration of mitochondrial membrane. Cell cycle data showed a shift of 65.5%
cells towards apoptotic subG1 phase vis-à-vis control showed 16.5% cell in subG1.
An increase in caspase-3 like protease activity validates the involvement of mito-
chondrial dependent intrinsic apoptotic pathway. Thus, this study has provided a
new insight into the fundamental mechanism of NiO-NPs induced toxicity and
signify its potential to induce cell death in animal and plant cells.
2379 Quantifying Quantum Dots in Frozen Tissue Sections Using
Autometallography.
C. White1,  C. M. Schaupp1,  J. Herron1,  D. K. Scoville1,  L. A. McConnachie1,
D. Botta1,  J. Yu1,  X. Yu1,  X. Hu2,  X. Gao2,  J. Wilkerson1 and T. J. Kavanagh1.
1Environmental & Occupational Health Sciences, University of Washington, Seattle,
WA; 2Bioengineering, University of Washington, Seattle, WA.
Quantum dots (QDs) are engineered nanoparticles frequently composed of a CdSe
core, ZnS shell, and an assortment of polymer coatings specific to their application.
QDs are used in electronic systems because of their semiconductor properties and
in biomedical research and medicine as imaging tools because of their unique fluo-
rescent properties. Their widespread use and heavy metal core composition have
raised concerns about their safety. An important consideration in evaluating QD
toxicity is the accurate quantification of these nanoparticles within tissues. The cur-
rent measurement methods favored include inductively coupled plasma mass spec-
trometry (ICP-MS) for the metal components of QDs, and QD fluorescence di-
rectly in tissue sections using microscopy. However, ICP-MS is expensive and
cannot distinguish between metals present in QDs or free ions, and fluorescence
microscopy is often difficult because of interfering tissue autofluorescence. We
adapted a silver-enhanced autometallography technique for detecting QDs in
frozen tissue sections. This technique is efficient and inexpensive, and quantifica-
tion using digital imaging and densitometry correlates well with direct QD fluores-
cence measurements. The ability to efficiently measure QDs in tissues will provide
important dose information that can be useful for evaluating the adverse health ef-
fects of QD exposures.
2380 Influence of Primary Particle Size and Agglomeration State
of Inhaled Nano-TiO2 on Rat’s Pulmonary Response.
A. Noel1,  M. Charbonneau2,  Y. Cloutier3,  R. Tardif1 and G. Truchon3.
1Environmental and Occupational Health, University of Montréal, Montréal, QC,
Canada; 2INRS-Institut Armand-Frappier, Université du Québec, Laval, QC,
Canada; 3Institut de Recherche Robert-Sauvé en Santé et en Sécurité du Travail,
Montréal, QC, Canada.
The physico-chemical properties of nanoparticles (NP) and their agglomeration
state influence their toxicokinetics, reinforcing the importance of the characteriza-
tion of the exposure dose. The objective of this study was to evaluate the influence
of initial particle size and agglomeration state of inhaled 20 mg/m3 TiO2 aerosols
on rat’s pulmonary response. Groups of rats (n=6) were exposed for 6 hr to aerosols
composed of either 5; 10-30 or 50 nm TiO2. Two distinct agglomeration states
were obtained. Aerosols were composed majorly of either large (LA) (>100 nm) or
small agglomerates (SA) (<100 nm). A control group was exposed to compressed
air. Exposures were characterized using weight measurement for mass concentra-
tion, an electrical low pressure impactor (Dekati) for size distribution and electron
microscopy for agglomerates observation. Pulmonary response was analyzed 16 hr
after the end of exposure through bronchoalveolar lavage fluids and lung histology.
Total cell count, number of macrophages and neutrophils were increased statisti-
cally (p < 0.05) compared to control for the 10-30 and 50 nm LA aerosols, while
increases were significant only for total cell count and number of macrophages for
the 5 and 10-30 nm SA aerosols. For each initial particle size, percentages of parti-
cle laden macrophages in LA aerosols were higher and statistically different from
the SA ones. Morphological assessments of lung tissue showed that cellular infil-
trates were more important in exposed groups compared to controls, with exemp-
tion of the 50 nm SA group. Our results indicate that higher increases in neu-
trophils number are related to LA aerosols, as for initial particle size, 10-30 nm
TiO2 NP seemed to induce more pronounced effects. Overall, this suggests that
initial particle size and agglomeration state play a key role in the toxicity of TiO2
aerosols.
SOT 2013 ANNUAL MEETING 509
2381 Silica Nanoparticles Induce Acute Pulmonary Toxicity in
Mice.
T. Lu1,  D. Hung2,  C. Su3,  T. Tseng4,  K. Chen5,  C. Huang6,  S. Liu7 and
Y. Chen1. 1Department of Physiology and Graduate Institute of Basic Medical Science,
China Medical University, Taichung, Taiwan; 2Division of Toxicology, Trauma &
Emergency Center, China Medical University Hospital, Taichung, Taiwan;
3Department of Otorhinolaryngology, Head and Neck Surgery, Changhua Christian
Hospital, Changhua, Taiwan; 4Department of Anatomy, China Medical University,
Taichung, Taiwan; 5Department of Urology, China Medical University Hospital and
China Medical University, Taichung, Taiwan; 6School of Chinese Medicine, China
Medical University, Taichung, Taiwan; 7Institute of Toxicology, National Taiwan
University, Taipei, Taiwan.
Silica nanoparticles (SiO2-NPs) are the one of most widely used and important
nanomaterials in nanotechnology. Lung tissue is one of the main routes of entry
nanoparticles, which may cause severe pulmonary toxicity. However, the toxicolog-
ical effects and the precise mechanisms of SiO2-NPs on lung are still unclear. Here,
we attempted to investigate the toxic injuries and the definite mechanism of SiO2-
NPs on the acute pulmonary toxicity. The adult male ICR mice were exposed to in-
tratracheal signal dose of 50 mg/kg SiO2-NPs and lung tissue were collected after 7
days. Our results found that SiO2-NPs increased 40% mortality rate and signifi-
cantly induced pulmonary morphological and histological changes with neu-
trophils, macrophage and fibroblast cells from the terminal bronchial. The lung tis-
sue weight/body weight ratio (LW/BW) increased 2-fold suggested that SiO2-NPs
may trigger pulmonary edema. Meanwhile, the malondialdehyde (MDA) levels in
the treated lung tissue were increased.Moreover, SiO2-NPs caused apoptosis-related
signals, including up-regulation of Bax and down-regulation of Bcl-2 and activa-
tions of caspase cascades mRNA expression, which accompanied with triggered the
endoplasmic reticulum (ER) stress identified through several key molecules, such as
activating the CHOP, XBP-1, caspase-12, and increasing the GRP-78/-94 mRNA
expression. These results suggest that SiO2-NPs induced an oxidative stress, and
cause acute pulmonary toxicity through mitochondria and endoplasmic reticulum
pathways.
2382 Biodistribution and Toxicity Profiling of Nanosilica in Rats
after Subchronic Oral Exposure.
M. van der Zande1,  R. J. Vandebriel2,  M. Groot1,  E. Kramer1,  K. Rasmussen3,
P. Hendriksen1 and H. Bouwmeester1. 1RIKILT - Wageningen University &
Research Centre, Wageningen, Netherlands; 2The National Institute for Public Health
and the Environment, Bilthoven, Netherlands; 3Joint Research Centre, Ispra, Italy.
Sponsor: S. Rangarajan.
Synthetic amorphous silica (SAS) is a conventional food additive. In earlier publi-
cations, we have shown that up to 43% of SAS in food products can be nanosized.
Yet, the behavior and biological effects of ingested nanosized silicas are still largely
unknown. We evaluated the biodistribution, accumulation, and toxicity of two
nanostructured silicas: NM-202 from the OECD testing program, and a food
grade SAS.
To this end, rats (n=5) were fed daily 0, 100, 500 or 1000 mg/kg bw NM-202, or
100, 1000 or 2500 mg/kg bw SAS during 28 days. Additional rats received 0 or
1000 mg/kg bw NM-202, or 2500 mg/kg bw SAS during 84 days. Using hydrody-
namic chromatography ICP-MS, high fractions of nanosized silica (up to 100% of
the total silica content) were detected in the gut contents of silica exposed rats.
Nevertheless, ICP-MS data at day 29/85 show low, dose-independent distribution
of both materials to the liver, kidney, spleen, brain, and testis, without organ speci-
ficity or accumulation. Analysis of blood biochemical markers and antibodies, NK-
cell activity, and lymphocyte proliferation, did not indicate (immuno)toxicity.
Contrarily, histopathology showed a significantly increased number of mononu-
clear cells per mm2 up to 500% at day 29, and 200% at day 85, and an increase in
apoptosis (cells/mm2) up to 200% at day 29 in livers of silica exposed rats vs. the
controls. Also, the jejunal villus:crypt ratio of NM-202 exposed rats decreased sig-
nificantly to ~90% vs. the controls after 29 days. However, whole genome liver and
jejunal mRNA expression analysis did not indicate toxicity due to silica exposure.
In conclusion, both silicas are non-accumulating and absorption is low. They ap-
pear to be generally non-toxic, but histopathological data suggest adverse effects on
liver and gut tissue, which should be addressed in future research and considered in
risk assessment of nanosilica.
2383 Oral Prenatal Developmental Toxicity Study with Synthetic
Amorphous Silica NM-200 in Wistar Rats.
S. Schneider1,  W. Wohlleben2, 1,  R. Landsiedel1,  A. Wolterbeek3,  I. Waalkens-
Berendsen3 and H. van de Sandt4. 1Experimental Toxicology and Ecology, BASF SE,
Ludwigshafen am Rhein, Germany; 2Polymer Physics, BASF SE, Ludwigshafen am
Rhein, Germany; 3Triskelion, Zeist, Netherlands; 4Quality of Life, TNO, Zeist,
Netherlands.
The engineering of new nanomaterials offers extraordinary opportunities in various
technological fields, but safety assessments must complement the technological
progress. Specifically, application of current developmental and reproductive toxic-
ity test guidelines for hazard testing of nanomaterials must be evaluated. The results
of the prenatal developmental toxicity study (OECD 414) are presented here.
Female Wistar rats received synthetic amorphous silica (NM-200, European Joint
Research Centre, Ispra, Italy) by oral gavage at dose levels of 0, 100, 300 and 1000
mg/kg body weight/day from gestation day (GD) 6 through GD 19. The NM was
dispersed in 10% fetal bovine serum in water and the particle size distribution was
characterized. On GD 20, all females were assessed by gross pathology, including
weight determinations of the uterus and the placentas. The corpora lutea were
counted and the number and distribution of implants (resorptions, live and dead
fetuses) were determined. The fetuses were removed from the uterus, sexed,
weighed and investigated for external findings. Half of the fetuses of each litter were
examined for soft tissue findings and the remaining fetuses for skeletal (and carti-
lage) findings. 
No differences between the treatment groups and controls for clinical observations,
body weights and food consumption of the dams were observed. No effects were
observed on number of corpora lutea, implants, pre- and post-implantation losses
as well as number and viability of offsprings. External, soft tissue and skeletal ex-
amination revealed no test-substance-related abnormalities.
This study was sponsored by CEFIC (LRI-N3 project) and is monitored by
Monika Maier, Evonik Degussa GmbH, Hanau, Germany on behalf of CEFIC
Sector group on Synthetic Amorphous Silica (ASASP).
2384 The T-Box Transcription Factor TBX21 (T-BET) Inhibits
Airway Goblet Cell Hyperplasia Induced by Nickel
Nanoparticles in Mice.
E. E. Glista-Baker,  B. C. Sayers,  A. J. Taylor,  E. A. Thompson and J. C. Bonner.
Environmental and Molecular Toxicology, North Carolina State University, Raleigh,
NC.
Engineered nanomaterials (ENMs), including metal nanoparticles, are increasingly
used in many industrial applications, including electronics and engineering.
Additionally, the human health risks that ENMs pose are of growing concern, espe-
cially in susceptible populations such as asthmatics. The T-box transcription factor
TBX21 (T-bet) maintains Th1 cell development in the lung and loss of T-bet has
been associated with the development of allergic airway inflammation characterized
by Th2 cells. The purpose of this study was to determine if mice deficient in T-bet
are susceptible to goblet cell hyperplasia caused by nickel nanoparticles (NiNP).
Wild type (WT) and T-bet-/- mice were exposed to a NiNP (4 mg/kg) and lung tis-
sues were collected at 1 or 21 days. The mucin-positive staining area (goblet cell hy-
perplasia) was quantified by morphometry using Alcian blue/PAS-stained lung sec-
tions. Whole lung mRNA levels for mucin genes (MUC5AC and MUC5B) were
measured by Taqman real-time RT-PCR. Bronchoalveolar lavage fluid (BALF) was
collected for differential cell counts and for measuring levels of secreted cytokines
known to regulate goblet cell hyperplasia, namely IL-13 and CCL2. NiNP expo-
sure caused a marginal increase in goblet cell hyperplasia in WT mice at 1 or 21 day
post-exposure. However, NiNP caused a significant (p<0.001) increase in goblet
cell hyperplasia in T-bet-/- mice and a significant (p<0.05) increase in MUC5AC
and MUC5B mRNA levels at 21 days. Furthermore, IL-13 protein levels and
eosinophilic infiltration were elevated (p<0.001) after 1 day in the BALF while
CCL2 mRNA and protein levels were significantly increased at 1 and 21 days.
These findings identify T-bet as a potentially important genetic susceptibility factor
for NiNP exposure and suggest that individuals with pre-existing allergic airway
disease are at a higher risk for environmental and occupational exposures to nano-
materials. (Funded by NIEHS RC2 ES018772 and R01 ES020897)
510 SOT 2013 ANNUAL MEETING
2385 Acute Toxicity Study of Nanoparticles of Bismuth Trioxide
by Inhalation Exposure in Male Rats.
O. C. Barbier1,  B. Quintanilla-Vega1,  L. M. Del Razo1,  M. Cortés-Torres1,
R. Angulo-Olais1,  M. Uribe-Ramirez1,  M. J. Solís-Heredia1,  G. Martínez-
Aguilar1,  A. Barrera-Hernández1,  L. C. Sanchez-Peña1,  E. Berea2 and A. De
Vizcaya-Ruiz1. 1Toxicology Department, CINVESTAV-IPN, Mexico City, Mexico;
2Farmaquimia, Mexico City, Mexico.
Bismuth (Bi) compounds are widely used in several products, including metallurgi-
cal alloys and medical devices; Mexico is among the largest Bi producers. Bi toxicity
is poorly studied, at micro scale it alters the kidney, nervous and reproductive sys-
tems, but little is known about the cytotoxicity of Bi nanoparticles (Bi-NP).
Nanotoxicology has gained attention in the last decade due to the dramatically in-
crease of nanomaterials in new appliances and their release to the environment. We
conducted an in vivo study to evaluate the toxicity of Bi-NP by inhalation expo-
sure. We exposed adult male Wistar rats (n=7) to an acute inhalatory dose (140
mg/kg, b.w, dispersed in 10 mg/ml BSA) of Bi2O3 nanoparticles during 5 h using
the InExpose SCIREQ® inhalation system by nebulization of 1.05 mL Bi2O3 sus-
pension/min. The control group (n=7) received nebulized phosphate buffer in BSA.
Physiological parameters such as body weight and relative organ weights, and
histopathology were determined. In addition, complete blood count (CBC) and
blood chemistry were evaluated. Bronchoalveolar lavage (BAL) was performed to
evaluate pulmonary inflammation by differential cell count. Relative weights of
spleen, liver, kidney and testes were significantly higher (12-23% increase) in the
exposed group, while the histopathology reveled alterations in lungs, liver, brain
and spleen, and damage in the epithelium seminiferous. CBC, blood chemistry and
BAL parameters were not affected by the acute inhalation exposure to Bi-NP. In our
experimental conditions, Bi2O3 nanoparticles showed moderate toxicity by inhala-
tion exposure. Further studies are needed to evidence adverse effects due to the ex-
posure to these NP; a subchronic study is underway to reach this objective.
Funding from the European Community Seven Framework Program and CONA-
CYT (Grant agreements #263878 and 12514).
2386 Pharmacokinetics and Biodistribution of Iron Oxide
Nanoparticles Using Accelerator Mass Spectrometry.
H. Enright1, 3,  P. D. Nallathamby2, 3,  V. Mikheev3,  B. Forsythe3,  W. Wang2, 3,
E. Kuhn1, 3,  S. T. Retterer2, 3,  K. W. Turteltaub1, 3 and M. Malfatti1, 3. 1Lawrence
Livermore National Laboratory, Livermore, CA; 2Oak Ridge National Laboratory,
Oak Ridge, TN; 3Battelle Center for Fundamental and Applied Systems Toxicology (B-
FAST), Battelle Memorial Institute, Columbus, OH.
Nanoparticles (NP) and their use as diagnostic and therapeutic agents in the bio-
medical field are becoming increasingly more popular. However, to date, the toxic-
ity and biological fate have not been thoroughly investigated. Iron oxide nanoparti-
cles are utilized for many bio-applications, which include: imaging, as drug delivery
vehicles and for cell tracking. In this work, Accelerator Mass Spectrometry (AMS),
an ultrasensitive technique for quantifying rare isotopes, is used to quantify the
biodistribution and pharmacokinetic properties of 14C-labeled iron oxide NP in
vivo. 
14C-labeled carboxylated iron oxide NP (~10nm core size) were administered by
nose only inhalation (0.175mg) or by a bolus intravenously (IV) (0.15mg) to male
mice. For inhalation delivery, over 7 d, NP were observed to clear primarily from
the lungs through the gastrointestinal system for excretion in the feces (t1/2 = 1.42
d). Detectable levels were also observed in plasma and phagocytic organs such as the
liver and spleen. Furthermore, accumulation in the olfactory bulb was also observed
(1.05 ng/mg at 7d). After intravenous delivery, NP were observed to accumulate
primarily in the liver, spleen and lungs over a 24 h period; the half-life in plasma
was t1/2 = 6.4 h. Taken together, these data indicate that once administered, car-
boxylated iron oxide NP are absorbed and distributed to major organs and are re-
tained in tissue through 24 h for IV and through 7 d for inhalation. These observa-
tions may provide insight for assessment of potential toxicity upon exposure to iron
oxide nanoparticles. 
This work performed under the auspices of the U.S. Department of Energy by
Lawrence Livermore National Laboratory under Contract DE-AC52-07NA27344
and supported by LLNL CRADA No. PNNL/284. 
LLNL-ABS-586092
2387 Zebrafish Xenograft Model of Glioblastoma to Identify
Metal Oxide Nanoparticles with Anticancer Properties.
L. Wehmas1, 2,  L. Truong1, 2,  J. A. Greenwood3,  A. Punnoose4 and
R. L. Tanguay1, 2. 1Environmental and Molecular Toxicology, Sinnhuber Aquatic
Research Laboratory and Environmental Health Sciences Center, Oregon State
University, Corvallis, OR; 2Safer Nanomaterials and Nanomanufacturing Initiative
and Oregon Nanoscience and Microtechnologies Institute, Corvallis, OR;
3Biochemistry and Biophysics, Oregon State University, Corvallis, OR; 4Physics, Boise
State University, Boise, ID.
Zinc oxide nanoparticles (ZnO-NPs) demonstrate selective cytotoxicity toward
cancer cells in culture, and this effect may extend to other metal oxide nanoparticles
(MO-NPs). Therefore, MO-NPs may possess unique qualities applicable to
nanomedicine. To realize their potential as anticancer agents, we must identify safe
and effective MO-NPs. We developed a screening approach that first utilizes cell
culture assays to identify MO-NPs that preferentially inhibit cancer proliferation
and determine the mechanism of selective toxicity. Then we assess the toxicity of
the MO-NPs utilizing the embryonic zebrafish assay, an efficacious model for
nano-safety assessment because of its high homology with humans and use of min-
imal test material. We prioritize MO-NPs that demonstrate relatively low toxicity
to the zebrafish yet maintain preferential toxicity toward cancer cells in culture for
assessment in a zebrafish xenograft model of glioblastoma. By xenotransplanting
human glioblastoma cells into the cranium of zebrafish, we have developed an assay
to identify MO-NPs that selectively inhibit cancer cell proliferation in vivo. We are
testing four MO-NPs: zinc oxide, titanium dioxide, cerium dioxide, and tin diox-
ide. Preliminary results demonstrate that ZnO-NPs inhibit glioblastoma cell prolif-
eration at 0.1 mM. Our screening paradigm holds promise for identifying physico-
chemical traits which enhance the anti-cancer properties of MO-NPs while
supporting safe NP design. Research support: NSF 134468, NIEHS P30
ES000210, ES 016896, T32 ES07060, and Air Force Research Laboratory
#FA8650-05-1-5041.
2388 Toxicity of Zinc Oxide Nanoparticles: Role of Particle
Dissolution and Photocatalytic ROS Production.
H. Ma,  L. Wallis,  S. Li and S. Diamond. Mid-Continent Ecology Division, United
States EPA, Duluth, MN.
Dissolution of zinc oxide nanoparticles (ZnO NPs) to ionic zinc has been recog-
nized as an important mode of toxic action (MOA) due to their high solubility and
high potency of ionic zinc to aquatic organisms. However, toxicity of ZnO NPs as-
sociated with their photocatalytic properties (generation of ROS under UV radia-
tion) has been rarely reported. To understand the relative importance of these two
MOAs, the current study investigated ZnO NP (30-50 nm) toxicity to Daphnia
magna under simulated solar radiation (SSR) versus ambient laboratory light. D.
magna immobilization, intracellular ROS production, and oxidative stress (lipid
peroxidation) were used as toxicity endpoints. Particle dissolution was measured in
a time-course manner using ICP-MS. Photocatalytic ROS production was meas-
ured by a fluorescent-based ROS assay and methylene blue photodegradation. Bulk
ZnO (> 1μm) and ZnCl2 were tested as reference toxicants. Concentration-de-
pendent ROS production was detected for ZnO NPs under SSR, but not under
laboratory light. Particle dissolution showed no significant differences between irra-
diation conditions, and both had a maximum dissolution rate of 20% within 24-h
period. 48-h EC50s for D. magna immobilization under SSR and laboratory light
were 0.069 mg/l (95% CI: 0.043, 0.109) and 0.109 mg/l (0.072, 0.171), respec-
tively. Intracellular ROS production and lipid peroxidation in daphnids exposed
under SSR were significantly greater than those under laboratory light, suggesting
photo-induced toxicity associated with photocatalytic ROS production might have
occurred. ZnCl2 had EC50s of 1.2 mg/l under SSR and 1.1 mg/l under laboratory
light. Bulk ZnO showed slightly lower toxicity than ZnO NPs. Our results suggest
that photo-induced toxicity of ZnO NPs related to their photocatalytic properties
should not be neglected when evaluating potential environmental hazards of these
nanomaterials, and the relative importance of this MOA under different exposure
scenarios and towards different environmental species warrants further investiga-
tion.
2389 Luminescent Lanthanide-Doped Metal Oxide Nanoparticles
for Study of Deposition and Clearance in the Respiratory
Tract.
G. K. Das,  D. S. Anderson,  C. D. Wallis,  A. D. Abid,  L. S. Van Winkle and
I. M. Kennedy. University of California Davis, Davis, CA.
Epidemiological studies have reported increased morbidity and mortality from res-
piratory and cardiovascular diseases which have close associations with exposure to
airborne particulate matter (PM). Of the PM in the ambient air, ultrafine particles
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have been well-demonstrated to be one of the key pathogenic factors for cardiores-
piratory disorders. Previous studies investigating deposition and clearance have
used mostly radiolabeled-PM, fluorescent labeling or specially engineered nanopar-
ticles (NPs) with physical and chemical properties that are atypical of ambient PM.
A low cost and high throughput alternative is needed that will permit direct meas-
urement of PM deposition and clearance. Here, we have used luminescent trivalent
europium ion-doped gadolinium oxide (Gd2O3:Eu3+) PM synthesized by a low
cost spray flame synthesis to study the deposition and clearance of PM in rats. As
rare earth elements, the lanthanides (i.e. Gd and Eu) exhibit very low natural abun-
dance, and provide extremely good detection sensitivity in different organs with the
use of inductively coupled plasma mass spectroscopy (ICP-MS). Moreover, the
strong optical emission that arises from the intra-4f transition of the europium ions
adds a powerful tool to detect the deposition site via fluorescence microscopy. ICP-
MS data from the instillation study showed that 59% of the particles remained in
the lung while a significant amount was detected in the feces (20.4%) after 24 hrs,
suggesting a fast clearance mechanism. Dissolution of the NPs was investigated in
vitro by monitoring the photoluminescence at physiological pH (7.0) and at a lyso-
somal pH (5.0) at 37°C up to 30 days; results confirmed that the lanthanides were
transported as particles and not as soluble ions. The result with the instillation stud-
ies demonstrated the excellent sensitivity of this method. We have adapted our PM
generator to a nose-only inhalation system for exposures of rodents. This work sup-
ported by NIEHS P42ES004699. We acknowledge the W. M. Keck Foundation
for a research grant.
2390 Angiogenesis Alterations Caused by TiO2 Nanoparticles.
V. Freyre-Fonseca1, 2,  A. Déciga-Alcaraz1,  E. M. Flores-Jiménez1,  N. L. Delgado
Buenrostro1,  G. F. Gutiérrez-López2 and Y. I. Chirino1. 1Facultad de Estudios
Superiores Iztacala, Universidad Nacional Autonoma de Mexico, Mexico City,
Mexico; 2Departamento de Graduados e Investigación en Alimentos, Escuela Nacional
de Ciencias Biológicas, Instituto Politécnico Nacional., Mexico City, Mexico.
Angiogenesis is a process by which the preexisting vascular tree of a tissue causes
growing of new blood vessels. It plays a key role in tumor development and it has
been demonstrated that titanium dioxide nanoparticles (TiO2 NPs) exposure in-
creases hypoxia and growth factors levels and these events are related to angiogene-
sis. However, the TiO2 NPs effect in this process has been poorly explored. In this
regard, chronic exposure to TiO2 NPs could develop disorders in angiogenesis. The
aim of this work was to study angiogenesis alterations caused by TiO2 NPs expo-
sure. Characterization of TiO2 NPs was done using dynamic light scattering to
measure nanoparticles size distribution and zeta potential. Chicken chorioallantoic
membrane (CAM) model was used as following: fertilized eggs were incubated dur-
ing 7 days at 37°C and 80% humidity and then exposed to 0, 5 and 10 μg of TiO2
NPs previously suspended in MCDB-131 cell culture media and injected in blood
vessels incubating for 7 days more. On 14th day, eggs were opened and digital
analysis of images was done. Umbilical vein endothelial cells were obtained from
embryos to measure VEGF expression by flow cytometry. Results showed that sus-
pension of 5 and 10 μg of TiO2 NPs had an agglomerated size of 535.2±9.35 nm
and 503.1±1.069 nm, respectively. Zeta potential of agglomerates suspended in
MCDB-131 was -17.36 ±1.18. Images of CAM showed structural differences be-
tween vessels of treated and untreated TiO2 NPs eggs. An increase of 0.5 cm and of
1 cm between blood vessels was found in CAM of 5 μg and 10 μg TiO2 NPs
treated eggs, respectively. In addition, an increase in VEGF expression was observed
in endothelial cells from TiO2 NPs treated eggs. In conclusion, TiO2 NPs exposure
in CAM model induced and increase in the distance between blood vessels and in
the VEGF expression in endothelial cells.
2391 Radiolabeled, Superparamagnetic, Nanoparticles for Bio-
Distribution Studies in Life Sciences.
P. D. Nallathamby1, 2,  H. Enright1, 3,  M. Malfatti3,  S. T. Retterer2 and
W. Wang2. 1Health & Life Sciences, B-FAST, Battelle Memorial Institute, Columbus,
OH; 2BESD, Oak Ridge National Lab, Oak Ridge, TN; 3Biosciences and
Biotechnology Division, Lawrence Livermore National Lab, Livermore, CA.
Nanoscale drug delivery systems have generated considerable interest because they
allow for the addition of cell specific targeting molecules and/or multiple therapeu-
tic agents, while their bio-distribution in vivo displays molecular level kinetics. Iron
based nanomaterials, with their inherent magnetic properties and an easily tailored
surface chemistry, are of particular interest because of their simultaneous diagnostic
and therapeutic potential. To determine how bio-distribution affects the biological
efficacy of an iron based nano-carrier system, hydrophillic iron oxide nanoparticles
(~10 nm) were synthesized, with either a carboxylic acid (-COOH) or an amine (-
NH3) functional group. 
14C labels (t1/2=5730 years) were incorporated into the or-
ganic functional groups on the surface of the nanoparticles. The radiolabeled, su-
perparamagnetic, nanoparticles were then delivered intra-venously to mice and the
pharmacokinetic distribution in vivo was determined by Accelerator Mass
Spectrometry (AMS); an ultrasensitive (10-18 moles) quantitative spectrometric
technique with small sample requirements. The radiolabeled nanoparticles were
well distributed in plasma and also detected in different organs like the lungs, liver
and spleen. The radiolabeling approach used in this study provides comparable bio-
distribution data as the radio-labeled probes have the same chemical properties as
the non-labeled probes. The synthesis approach described here is broadly applicable
to the synthesis of nanoscale materials with multiple core and surface functionali-
ties. The pharmacokinetic data, suggest that functionalized iron nanoparticles may
have broad use as therapeutic, diagnostic or even theranostic agents in biological
systems.
2392 Susceptibility to Quantum Dot-Induced Lung Inflammation
Is Mouse Strain Dependent.
D. K. Scoville1,  C. C. White1,  D. Botta1,  L. A. McConnachie1,
M. E. Zadworny1,  X. Hu2,  X. Gao2,  J. Yu1,  R. Dills1,  R. C. Zanger3,
J. G. Pounds3 and T. J. Kavanagh1. 1Environmental and Occupational Health
Sciences, University of Washington, Seattle, WA; 2Bioengineering, University of
Washington, Seattle, WA; 3Systems Toxicology Group - Division of Biological Sciences,
Pacific Northwest National Laboratory, Richland, WA.
Quantum dots (QDs) are nanoparticles typically composed of a CdSe core, a ZnS
shell, and an assortment of polymer coatings specific to the application. Unique flu-
orescent and excellent semiconductor properties make QDs useful in biomedical
imaging and electronics. However, due to their small size, large surface area, and
heavy metal composition, there is concern over the safety of QDs. Using 8 geneti-
cally inbred mouse strains we have investigated susceptibility to QD induced lung
inflammation using % neutrophils, total protein, and levels of inflammatory cy-
tokines in bronchoalveolar lavage fluid (BALF) as biomarkers. Cadmium was meas-
ured as a marker of exposure and total glutathione (GSH) levels in frozen lung tis-
sue were also measured. Significant treatment group and strain specific differences
in the % neutrophils in BALF indicate that susceptibility to QD induced lung in-
flammation is mouse strain dependent. We also observed that the % neutrophils in
BALF is correlated with lung Cd and GSH levels, as well as BALF cytokines. It is
clear that strong relationships exist in some mouse strains and not in others. For ex-
ample, the % neutrophils in BALF is highly correlated with macrophage inflamma-
tory protein 1a (MIP1a) in A/J, C57BL/6J, WSB/EiJ, NZO/HlLtJ mice. However,
CAST/EiJ, NOD/ShiLtJ, PWK/PhJ, and 129S1/SvImJ mice do not show as strong
a relationship. In future studies, recombinant inbred mouse strains will be used to
map expression quantitative trait loci (eQTLs) associated with QD-induced lung
inflammation. Analysis of such eQTLs could lead to insights regarding the molecu-
lar mechanisms responsible for QD toxicity and ultimately provide guidance on
how to produce safer QDs. Supported by NIH grants R01ES016189,
U19ES019545 and P30ES07033.
2393 Nrf2 Is a Positive Regulator of Cytokine Expression in Lung
of Titanium Dioxide Nanoparticles Exposed Mice.
N. L. Delgado Buenrostro1,  E. I. Medina-Reyes1,  A. Cuadrado Pastor2,
I. Lastres2,  J. Pedraza3,  R. Hernández4 and Y. I. Chirino1. 1Investigación y
Posgrado UBIMED, Fesiztacala, UNAM, Mexico City, Mexico; 2Investigación y
Posgrado, Instituto Alberto Sols, Madrid, Spain; 3Posgrado, Facultad de Ciencias
UNAM, Mexico City, Mexico; 4Ïnvestigación, Instituto de Nutrición, Mexico City,
Mexico.
Background. Titanium dioxide nanoparticles (TiO2 NPs) increase the generation
of reactive oxygen species and the inflammatory response in lung tissue of exposed
animals. As a result, the expression of Nrf2 acts a defense mechanism against ROS
generation; however its role in inflammation remains unclear. 
Aim. The goal of this work was to evaluate role of Nrf2 in inflammatory process in-
duced by TiO2 NPs in lung from exposed mice. 
Methods. Male wild type mice (WT) and Nrf2 knockout mice (KO) were divided
in the following groups: a) control-WT, b) TiO2-WT, c) control-KO and d) TiO2-
KO. TiO2 NPs were suspended in 50μl of SSI and received 5 mg/kg by oropha-
ryngeal via twice a week/4 weeks. Then, mice were perfused with p-formaldehyde
and lung tissue was obtained for histological and immunohistochemical analysis. 
Results. Bronchioles, venules and interstitial space of TiO2-KO group showed
higher inflammation and oxidative stress damage, than TiO2-WT group. On the
other hand, Nrf2 was a positive mediator in the expression of IL-10, Interferon-
gamma, TNF-alpha, and TGF-beta, and acts as a negative mediator of IL-4 expres-
sion in bronchial epithelium and alveolar space. 
Conclusion. This work suggests that Nrf2 has a central role in up-regulation of cy-
tokines released during inflammation induced by TiO2 NPs in lung tissue.
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2394 Distinct Expression Profiles of Stress Defense and DNA
Repair Genes in Daphnia pulex Exposed to Cadmium, Zinc
and Quantum Dots.
S. Tang1,  Y. Wu2,  C. N. Ryan1,  S. Yu1,  D. Edwards1 and G. D. Mayer1.
1Environmental Toxicology, Texas Tech University, Lubbock, TX; 2Biological Sciences,
Texas Tech University, Lubbock, TX.
Use of nanocrystaline semiconductors (Quantum dots; QDs) is growing as new ap-
plications, especially in biomedical research, adopt this technology. More impor-
tantly, industrial and other mainstream uses of QDs seem likely to increase since
QDs can theoretically more than double the efficiency of semiconductors in cur-
rent photovoltaics. Often, with increased use comes increased appearance in the en-
vironment and, given the heavy metal composition of QDs, there exists a concern
regarding the potential toxicity of these nanoparticulates on aquatic organisms. The
freshwater invertebrate Daphnia is a ubiquitous dweller of ponds and lakes
throughout North America, a keystone species in aquatic food chains, and an indi-
cator species for environmental contaminants. In this study, we aimed to compare
transcriptional responses of several key stress-mediated and DNA repair genes in D.
pulex following exposure to QDs and the individual metallic components of which
they are comprised. Exposure to both Cd and QDs led to induction of mortality
and Cd accumulation, which was biologically supported by the increased expres-
sion of the heavy metal responsive gene, metallothionein (MT). Our study also re-
vealed that Cd, Zn and CdSe/ZnS QDs induced a different pattern of gene expres-
sions regarding stress defense and DNA repair, which furthered our knowledge
regarding the different mechanisms of toxicity that are elicited by the nanoparticu-
late form of metals versus the ionic form.
2395 A Delphi Pilot Study in Brazilian Stakeholders About
Nanotechnology, Nanomaterial, and Their Toxicological and
Regulatory Implications.
W. Waissmann1,  R. S. Barros1,  M. Moura1,  E. Wilson2,  A. S. Arcuri3,
V. S. Pinto3,  A. B. Veggi4,  T. P. Silva4 and L. Brickus1. 1School of Public Health,
Oswaldo Cruz Foundation, Rio de Janeiro, Brazil; 2Law, Unisinos, Sao Leopoldo,
Brazil; 3Centro Nacional, Fundacao Jorge Duprat de Figueiredo, São Paulo, Brazil;
4Nutricao, Universidade Gama Filho, Rio de Janeiro, Brazil.
Abstract:
We conducted an email study using Delphi method. In the first phase, 108 ques-
tionnaires (5 questions) were sent, 12 for each of the following groups: Researchers;
Regulators, Personal from Funding Institutions (PFI), Public
Health/Environmentalists, Producers, Workers/Unions Representatives,
Consumers, Legislators, NGOs. Only two rounds were need. At the first, 43 (40%)
questionnaires were completed. From the 43 sent, 33 (77%) were completed at the
second round. We have no answers from legislators and NGOs. Only two answers
have been changed, and this not modified the general results, which show: 60% of
respondents considered the benefits equal or outweigh the risks, but recognize that
population must better understand risks. More than 20% believe all research and
production in nanotech should be suspended until the increase of nanorisk knowl-
edge. Around 60% of the respondents believed Brazil is in a disadvantageous posi-
tion in nanotech market products comparing to other developing countries, even
though who agree that research is at a good level in the country. 80% consider in-
adequate and insufficient the legislation that deal with risks of nanotech, almost
100% understand consumers have insufficient information and more than 80%
understand that even workers who deal with nanotechnology have little informa-
tion on legislation and potential risks. It was used regular ways to send emails, sim-
ilar for all categories. For next researches, the approach to NGOs and legislators
should be modified.
2396 In Vitro/In Vivo Assessment of Engineered Nanomaterials
Using a High-Content Analysis Platform.
S. Anguissola1,  L. Cooke1,  D. Garry1,  M. Esquivel-Gaón2,  A. De Vyzcaia Ruiz2,
M. Monopoli1 and K. A. Dawson1. 1Centre for Bionano Interactions, School of
Chemistry and Chemical Biology, University College Dublin, Dublin, Ireland;
2Department of Toxicology, Cinvestav, Mexico City, Mexico.
With increasing numbers of nanomaterials introduced on the market in consumer
products, bio-medical and environmental applications it is of primary importance
to assess, understand and manage their potential toxicity. To effectively assess and
understand the mechanisms of toxicity induced by nanoparticles (NPs) we imple-
mented a platform that correlates physico-chemical properties of nanomaterials
with their biological effects in vitro on human cell lines and in vivo on zebrafish as
a model of toxicity to aquatic species. Nanomaterials’ physico-chemical characteris-
tics were evaluated in the relevant exposure media for in vitro and in vivo exposure
and High Content Analysis (HCA) was employed to quantify several parameters of
toxicity on exposed human cell lines and anatomical defects observed on exposed
zebrafish larvae. To demonstrate the power of the platform the toxicological out-
comes of surface-functionalized model nanoparticles (i.e. polystyrene Nanoparticles
with carboxyl and amine surface modifications) are described along with Bismuth
(Bi)-derived Nanoparticles designed for industrial applications developed within
the EU/Mexico collaborative project Bisnano. The model NPs were well dispersed
in either complete cell culture medium or zebrafish embryo medium; for Bi-derived
NPs it was necessary to develop a dispersion protocol in order to isolate particles in
the nanometer range from a heterogeneous powder which were subsequently stabi-
lized with bovine serum albumin. The HCA approach was able to differentiate be-
tween apoptosis and necrosis induced in different cell models by amine-modified
polystyrene (PS-NH2) NPs and highlighted lysosomal damage as the triggering
mechanism of toxicity for both the PS-NH2 NPs and the Bi-derived NPs. HCA
analysis of zebrafish larvae quantified changes of anatomical features such as
head/torso ratio, spine length and body curvature. The project was funded by
QNano and Bisnano.
2397 Biomarkers of Disease and Toxicity: Exploiting the
Interconnections.
D. L. Mendrick1 and W. B. Mattes2. 1Division of Systems Biology, NCTR, US FDA,
Jefferson, AR; 2Toxicology, PharmPoint Consulting, Poolesville, MD.
With the recent focus on (a) cellular pathways involved in toxicity sequelae and (b)
translational biomarkers that may link animal and in vitro model observations with
clinical reality, there is a need to broaden the understanding of how experimental
models may replicate human toxicity and disease processes. Multicellular organisms
may have large numbers of genes and proteins, but a relatively limited repertoire in
terms of pathophysiology in response to disease or toxicant exposure. This fact al-
lows research to improve and protect human health to be founded on the use of
model systems that allow for tractable experimentation. Animal models and, more
recently, in vitro systems have served as a means of both exploring mechanisms and
identifying hazards in terms of disease and adverse events. However, the intercon-
nections between disease and toxicity are rarely explored leaving the information in
silos. This symposium will examine organ-based toxicity and disease processes, and
compare lessons learned in biomarker identification and use across toxicity, disease,
and species.
2398 Introduction.
D. L. Mendrick. US FDA, Jefferson, AR.
Biomarkers are needed that increase translation between in vitro/in vivo environ-
ments and across species. For clinical situations particularly, biomarkers that could
distinguish a reaction to a toxin from a disease process would be valuable. However,
since biomarkers arise due to perturbations of normal metabolic pathways, toxicity-
specific biomarkers are scarce. The good news is that it means that research into
toxicity or disease can yield biomarkers of interest in both fields. It is important that
toxicologists and clinicians work together to select appropriate models to advance
our understanding of biological processes.
2399 Use of Biomarkers in Hepatology, Liver Disease, and Liver
Toxicity.
A. Regev. Global Patient Safety, Eli Lilly & Company, Indianapolis, IN. Sponsor: D.
Mendrick.
Biomarkers in use today do not distinguish drug-induced liver injury (DILI) from
other causes of hepatic damage such as viral hepatitis, alcoholic liver disease, and
metabolic liver injury. Such specific biomarkers would be valuable to better manage
patients. Currently available biomarkers fail to differentiate, during the early stages
of live injury, between mild self-limiting hepatic abnormality and one that will
progress to severe liver injury, liver failure and death. There is a clear need for new
translational biomarkers to detect liver injury in animals and humans and to iden-
tify significant injury with more specificity than ALT. To enable the identification
and qualification of translational biomarkers, better communication is needed be-
tween those that focus on preclinical safety testing and clinicians.
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2400 Fibrinogen: A New Kid on the Block of Translational
Biomarkers for Kidney Damage.
V. S. Vaidya. Harvard Medical School, Boston, MA.
Environmental contaminants and therapeutic substances contribute significantly to
the high incidence and prevalence of acute kidney injury (AKI). Preclinical obser-
vations of kidney toxicity stops many compounds from entering later development
due to the lack of early biomarkers of injury. In the clinic, morbidity and mortality
with AKI remains unacceptably high. Our recent work has shown urinary as well as
tissue fibrinogen levels increase significantly in mice, rats and humans following
kidney injury/toxicity. We provide evidence that fibrinogen may function as a key
molecular link between tubulo-vascular damage and regeneration in the kidney and
provides new opportunities for its use in the diagnosis and prevention of kidney
disease and enablement of the clinician to institute therapeutic interventions.
2401 Cardiac Disease, Cardiotoxicity, and Translational
Biomarkers.
J. R. Turk. CBSS, Amgen Inc, Thousand Oaks, CA.
Heart disease is the leading cause of death in the United States. Cardiovascular
health is a prime concern for both toxicologists and physicians. Interactions among
genes and environmental factors including lifestyle and drugs, may negatively affect
the cardiovascular system. Myocardial damage from ischemia, infectious and meta-
bolic diseases, or cardiotoxic drugs may be followed with biomarkers such as the
troponins, natriuretic peptides, and their combination in panels with multiple
evolving biomarkers. These tools facilitate an understanding of the parallels be-
tween toxicity and background disease in animal models and human heart disease.
2402 Links between Neurological Disease and Toxicity.
D. L. Gerhold and C. P. Austin. Division of Preclinical Innovation, National Center
for Advancing Translational Sciences, NIH, Rockville, MD. Sponsor: D. Mendrick.
It is well known that environmental agents, including self-administered drugs, are
capable of causing neurological damage. Such agents may be used to create animal
models of human disease, which may be useful in identifying drug targets, thera-
peutic strategies, and biomarkers. A well-known example is MPTP, a chemical con-
taminant in the illicit manufacture of a synthetic opioid which produced an acute
Parkinsonian syndrome in users. MPTP has been extensively used in Parkinson’s
disease research as an investigative agent in both cultured cells and animals. A chal-
lenge remains that few good biomarkers exist for early neurological damage and
thus there is an intensive focus on better predictive and diagnostic biomarkers. The
combined use of models of neurological damage caused by drugs, toxicants, and
disease may move the field forward faster in the identification and use of transla-
tional biomarkers.
2403 Mechanistic Role(s) of Cytochrome(s) P450 in Oxidative
Stress and Inflammation: New Opportunities for Drug
Discovery.
J. E. Manautou2 and B. Moorthy1. 1Pediatrics, Baylor College of Medicine, Houston,
TX; 2Pharmaceutical Sciences, University of Connecticut, Storrs, CT.
The major goal of this symposium is to discuss the molecular and cellular mecha-
nisms by which cytochromes P450 (CYP) contribute to oxidative stress, which
could in turn lead to inflammatory processes, ultimately leading to many human
diseases including cancer, neurodegenerative diseases, bronchopulmonary dysplasia
(BPD), acute respiratory distress syndrome (ARDS), and drug-induced hepatotox-
icity. Although much is known about the functional role of CYPs in drug metabo-
lism, their role in endobiotic metabolism, in relation to oxidative stress and inflam-
mation, is understudied. The recent findings of the novel role of CYPs in oxidative
stress and inflammation in the manifestation of multiple human diseases warrant
the need for a symposium to discuss the latest mechanistic research in this area and
its impact on human health. Specifically, the symposium will discuss: i) the role of
CYP4f in neuroinflammation, which in turn contributes to neurodegenerative dis-
eases such as Parkinson’s and Alzheimer’s diseases; ii) the role of the Ah receptor, ox-
idative stress, and inflammation in 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCCD)-
induced hepatotoxicity; iii) the functions of CYP1A1, 1A2, and 1B1 in the
metabolism of eicosanoids, which in turn play mechanistic roles in TCDD toxicity;
iv) the contribution of CYP4As in eicasanoid metabolism and the mechanism of
down-regulation of CYPs during infection; and v) the novel protective role of
CYP1A1 and 1A2, and the pro-oxidant role of CYP1B1 in hyperoxic lung injury,
in relation to BPD and ARDS. The symposium will also discuss new opportunities
for drug discovery and their potential translatability in clinical settings.
2404 Cytochromes P4504f, a Potential Therapeutic Target for
Neuroinflammation.
V. Ravindranath. Center for Neuroscience, Indian Institute of Science, Bangaloore,
India. Sponsor: B. Moorthy.
Inflammatory processes are involved in pathogenesis and progression of CNS disor-
ders, such as infection, traumatic brain injury, and neurodegenerative diseases.
Eicosanoids including leukotrienes, particularly leukotriene B4 (LTB4) mediate in-
flammatory response by initiating and amplifying generation of cytokines and
chemokines. Cytochrome P450 (Cyp), a family of heme proteins mediate metabo-
lism of xenobiotics and endogenous compounds, such as eicosanoids. We demon-
strate that mouse brain Cyp4fs are expressed ubiquitously in several cell types in the
brain including neurons and microglia, and modulate inflammatory response trig-
gered by lipopolysaccharide (LPS), in vivo and in microglial cells, in vitro through
metabolism of LTB4 to the inactive 20-hydroxy LTB4. Chemical inhibitor or
shRNA to Cyp4fs enhance the inflammatory response, while the PPARα agonist,
fenofibrate induces Cyp4fs and attenuates it. Fenofibrate also confers neuroprotec-
tion against Japanese encephalitis (JE), in vivo, in a mouse model of JE viral infec-
tion through up-regulation of Cyp4fs, and could potentially be used for prophy-
laxis during JE epidemics to reduce mortality and morbidity. Thus, catalytic
activity of Cyp4fs is a novel target for modulating neuroinflammation.
2405 Metabolomics Identifies an Oxidative Stress-Mediated Signal
Transduction Cascade Involved in Dioxin-Induced
Hepatotoxicity.
F. J. Gonzalez,  T. Matsubara,  N. Tanaka,  K. W. Krausz,  A. D. Patterson and
Y. M. Shah. Laboratory of Metabolism, National Cancer Institute, Bethesda, MD.
A number of chemical contaminants that are highly prevalent in the environment,
elicit some or all of their toxicity through the arylhydrocarbon receptor (AhR), a
ligand-activated transcription factor. Activated AhR forms a heterodimer together
with the AhR nuclear translocator (ARNT), and binds to xenobiotic response ele-
ments in the promoter regions of target genes resulting in induction or inhibition
of expression. Among the AhR target genes are the cytochromes P450 CYP1A1,
CYP1A2 and CYP1B1. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is among
the most potent environmentally toxic compounds. TCDD exposure alters serum
metabolite profiles as a result of attenuating hepatic carboxylesterase 3, CES3 (also
known as triglyceride hydrolase), expression in an AhR-dependent manner. Serum
metabolomics identified azelaic acid-mono esters as significantly increased metabo-
lites after TCDD exposure. The decreased CES3 expression was accomplished by
TCDD-stimulated TGFβ-SMAD3 and IL6-STAT3 signaling, but not by direct
TCDD-activated AhR induction of target genes. Proinflammatory cytokine activa-
tion was achieved by TCDD-mediated oxidative stress in the liver through TCDD-
induction of xanthine dehydrogenase and NADPH oxidase expression in an AhR-
dependent manner. Methionine- and choline-deficient diet-treated mice also
showed enhanced serum azelaic acid ester levels following attenuation of hepatic
CES3 expression, while genetically obese db/db mice did not, suggesting an associ-
ation with steatohepatitis. These results support the view that azelaic acid-mono
ester is an indicator of dioxin exposure and a possible diagnostic biomarker of
steatohepatitis and indicate oxidative stress in the mechanisms of hepatotoxicity by
TCDD.
2406 Lipidomic Analysis Demonstrates That 2, 3, 7, 8-
Tetrachlorodibenzo-p-dioxin Increases the Levels of Multiple
Pro- and Anti-Inflammatory Cytochrome P450 Metabolites
of Polyunsaturated Fatty Acids in Several Organs of the
Mouse.
O. Hankinson1, 2. 1Pathology, UCLA, Los Angeles, CA; 2Molecular Toxicology
Program, UCLA, Los Angeles, CA.
2,3,7,8- Tetrachlorodibenzo-p-dioxin (TCDD) adversely affects the immune sys-
tem and many organs and tissues. These effects are mediated by the aryl hydrocar-
bon receptor (AHR). CYP1A1, CYP1A2 and CYP1B1 are upregulated by the lig-
anded AHR. These cytochromes P450 are known to metabolize arachidonic acid
and certain ω-3 polyunsaturated fatty acids in vitro. Towards investigating a poten-
tial role of metabolism of these fatty acids in TCDD toxicity in vivo, we determined
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the levels of 81 metabolites in several mouse organs/tissues of mice treated with
TCDD. TCDD increased the levels of many hydroxides, epoxides and diols of
arachidonic acid in the liver, lung, spleen and serum, but not the heart. That such
increases occurred in serum, suggests that increases in these metabolites may be
transferred from one organ to another via the blood. The changes in the levels of
the metabolites correlated with changes in levels of CYP1A1, CYP1A2 and
CYP1B1 in some organs but not others, suggesting that other enzymes may also be
involved. TCDD increased the levels of the esterified forms of the eicosanoids in
the liver in parallel with the corresponding free forms. The phospholipids so
formed therefore represent a reservoir for these metabolites. Analysis of Ahr-/- null
mice demonstrated that the changes in eicosanoid levels elicited by TCDD depend
upon AHR. Many epoxides and diols of three ω-3 unsaturated fatty acids, eicos-
apentaenoic acid {20:5(n-3}, docosahexaenoic acid {22:6(n-3)}, and α-linolenic
acid {18:3(n-3)}, were also markedly increased in the liver, lung, but not the heart
of mice treated with TCDD. Since many of the oxlipin metabolites that were in-
creased by TCDD treatment exhibit potent biological activities, including both
pro- and anti-inflammatory effects, these studies lay the foundation for future ex-
periments addressing their potential role in mediating the toxic and other effects of
TCDD and other ligands of the AHR.
2407 Regulation and Functions of Cytochromes P450 during
Infection.
E. T. Morgan and B. A. Nyagode. Pharmacology, Emory University, Atlanta, GA.
Sponsor: B. Moorthy.
Activation of the innate immune system, whether by infection or aseptic stimuli,
causes significant changes in hepatic cytochrome P450 (P450) enzyme expression,
drug metabolism and clearance. This regulation has important consequences for
drug administration and responses in disease states. Its reversal by therapeutic pro-
teins targeting proinflammatory cytokines gives rise to a newly recognized drug-
drug interaction mechanism. Understanding the regulatory pathways for the differ-
ent enzymes is pivotal to predicting the clinical consequences of such regulation
during disease and therapy. We have studied the regulation of hepatic P450 expres-
sion in various disease models in mice, including injection of bacterial lipopolysac-
charide and infection with the colonic pathogen Citrobacter rodentium. The en-
zymes affected are dependent on the disease model, so that different drugs are likely
to be affected in different human disease states. In the C. rodentium model, studies
in cytokine or cytokine receptor-null mice indicate roles for interleukin-6 and
tumor necrosis factor-α in the regulation of a small subset of P450 transcripts, in-
cluding some members of the Cyp3a subfamily. Studies in SCID mice suggest that
T cells or T-cell-derived cytokines might also be important in this model. However,
the absence of cytokine signals fails to alter the down-regulation of the most pro-
foundly suppressed liver enzymes i.e. Cyp4a10, Cyp4a14 and flavin monooxygenase
3 (Fmo3), suggesting a different mechanism of regulation for these genes. To ad-
dress whether or not Cyp4a enzymes play a role in the host-pathogen interaction,
we infected Cyp4a14-/- and Cyp4a10-/- mice with C.rodentium, and compared their
responses to those of wild-type mice. Results from these ongoing studies will be
presented. Supported by National Institutes of Health grant R01DK072372.
2408 Mechanistic Role(s) of Cytochrome P4501A and 1B1
Enzymes in Hyperoxic Lung Injury: Implications for
Bronchopulmonary Dysplasia (BPD) in Premature Infants
and ARDS in Adults.
B. Moorthy. Pediatrics, Baylor College of Medicine, Houston, TX.
Hyperoxia is routinely used in the treatment of pulmonary insufficiency and respi-
ratory distress in preterm and term infants and in adults with acute respiratory dis-
ease (ARDS). However, in premature infants, hyperoxia contributes to the develop-
ment of chronic lung disease (CLD), which is termed bronchopulmonary dysplasia
(BPD). The molecular mechanisms of oxygen-mediated lung injury are not under-
stood, but reactive oxygen species (ROS) are the most likely candidates. ROS-me-
diated reactions with biological macromolecules such a DNA, proteins, and lipids
are also responsible for many other lung diseases such as acute respiratory distress
syndrome (ARDS), asthma, emphysema, chronic obstructive pulmonary disease
(COPD), and lung cancer induced by environmental pollutants. Results from our
laboratory demonstrate a novel role for cytochrome P450 (CYP)1A enzymes in the
detoxification of ROS-mediated lipid peroxidation products, e.g., F2-isoprostanes.
Our major observations are that mice lacking the genes for CYP1A1 or 1A2 are
more susceptible to hyperoxic lung injury than wild type mice, with Cyp1a2-null
mice being the most sensitive. On the other hand, mice lacking the gene for
CYP1B1, are less susceptible to lung injury, suggesting a pro-oxidant role for
CYP1B1. Mice pre-treated with the CYP1A inducer β-napthoflavone (BNF), fol-
lowed by exposure to hyperoxia leads to protection against lung injury. We also
found formation of bulky oxidative lesions (oxidative DNA adducts) in tracheal as-
pirates of premature infants and adults who received supplemental oxygen, and this
was associated with BPD and ARDS, thereby suggesting that these adducts could
serve as novel biomarkers of these diseases. Future studies could lead to the devel-
opment of rational strategies for the prevention/treatment of lung diseases associ-
ated with hyperoxia.
2409 Molecular Basis of Age-Related Susceptibility to Chemicals
and Environmental Hazards: From Model Systems to
Humans.
J. S. Lee1 and J. C. Fuscoe2. 1US EPA, Durham, NC; 2US FDA, Jefferson, AR.
The susceptibility of individuals to chemicals and environmental hazards at the ex-
tremes of the population age-distribution (the very young and the very old) is often
not adequately assessed. By understanding genes expressed at the various life stages,
the assessment of health risk versus benefit can be more rationally determined.
Children are more susceptible to exposures to environmental toxicants compared to
adults because intakes are increased, biologically-effective doses may differ, and
early lifestage exposure may lead to adverse health effects that are chronic in nature.
Older adults are more susceptible to environmental toxicants because of pharmaco-
kinetic and pharmacodynamic changes associated with aging. Altered absorption,
distribution, metabolism, and excretion (ADME), along with decreased blood flow
to the liver, decreased liver mass, and decreased content of specific cytochrome
P450s (CYPs) could result in decreased clearance of chemicals in older adults. In
addition to these factors, genetic and epigenetic changes that occur with age and
chemical exposure may also increase susceptibility to environmental hazards. Our
panel will examine genomic and epigenomic changes that occur with age using an-
imal and human data. Rat liver and kidney data will be used to discuss age-related
target organ vulnerabilities. Human relevance will be addressed using a longitudinal
birth cohort study in Mexican-American children, two mother-child cohort studies
in Mexico and the United States, and a cohort study of older men from the
Normative Aging Study. Ultimately, understanding the implications of genetic and
epigenetic changes related to age on the effects of chemical exposure will help to
protect the health of children and older adults. Disclaimer: The views expressed are
those of the authors and do not necessarily represent the views or policies of the US
EPA or US FDA.
2410 Functional Genomic and Epigenomic Changes in the Liver
and Kidney during the Rat Life Cycle.
J. C. Fuscoe,  T. Han,  V. Vijay,  V. Desai and J. C. Kwekel. Division of Systems
Biology, NCTR, US FDA, Jefferson, AR.
The susceptibility of individuals at the extremes of the population age-distribution
(the very young and the very old) and differences between sexes are often not ade-
quately assessed. By understanding the genes expressed in each sex at the various life
stages, the assessment of health risk versus benefit can be more rationally deter-
mined. Comprehensive analysis of the transcriptome, including miRNA, and the
epigenome in the liver and kidney of Fisher 344 rats from 2 weeks to 2 years of age
reveals substantial differences at various life-stages and between the sexes. In the
liver and kidney, the expression of nearly 4000 genes was found to significantly vary
with age and/or sex. Many of these genes are involved in xenobiotic metabolism
and transport, processes that impact drug efficacy and safety. The expression of
genes that code for some of the kidney injury protein biomarkers recently qualified
by the FDA were found to vary substantially with age and sex, in some cases up to
100-fold. Such dramatic differences may impact the interpretation of biomarker re-
sults. Examination of miRNA expression in the liver showed nearly 200 miRNAs
varied with age and/or sex. Notably, a group of 42 miRNAs was expressed at a rela-
tively high level at 2 weeks of age in both sexes followed by low or no detectable ex-
pression at older ages. However, this 2 week-specific miRNA expression was not ev-
ident in the kidney. Analysis of potential target mRNAs for liver miRNAs suggests
roles in disease susceptibility involving fibrosis as well as regulation of xenobiotic
metabolism related genes. A similar number of kidney miRNAs also displayed sex
and age-related changes which may be linked to gene regulation. These differences
may be related to age- and sex-specific susceptibilities to adverse drug reactions or
disease states. Understanding these differences should improve personalized medi-
cine both in terms of disease prevention and management, and safer use of drugs.
2411 A Case-by-Case Approach to Pediatric Drug Safety Involving
Multiage Juvenile Rat Models That Target Developmental
Issues and Address Regulatory Concerns.
P. Espandiari,  W. Rodriguez and J. P. Hanig. CDER, US FDA, Silver Spring, MD.
The toxicity of drugs in pediatric populations may vary considerably from that seen
in adults. Capacity to generate or inactivate the toxic moiety, issues of drug half-life,
volume of distribution or specific target organ toxicity as well as hypersensitivity are
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all critical factors. Vital organ systems mature at different times and present many
challenges for selecting an appropriate model that captures the vulnerability neces-
sary to characterize safety issues. One example of a multi-age pediatric model uti-
lizes rats 10, 25, 40 and 80 days old roughly corresponding to human infants, tod-
dlers, teenagers and young adults exposed to either the nephrotoxins gentamicin, or
cisplatin or the hepatotoxin valproic acid. The differential effects across the various
age groups were assessed by organometrics, histopathology, hematology, clinical
chemistry, liver and kidney biomarkers, and metabonomics technologies to estab-
lish specific age-related target organ vulnerabilities. Each age group was shown,
using principal component analysis, to be a distinctly separate entity in terms of
treatment responses. This published model, representing a single possible approach,
has potential for significant utility as a tool for pediatric safety evaluation, in com-
parison to dosing throughout the complete maturation process. The FDA
Guidance for Nonclinical Safety Evaluation of Pediatric Drug Products (Feb.,
2006) presents a wide variety of parameters involving juvenile/adult differences.
These constitute many possible choices that may be incorporated into a pediatric
preclinical model appropriate to address preclinical safety. The age of intended ex-
posure, route, frequency and length of exposure are critical and will be discussed. In
general the preclinical safety evaluation of new and approved drugs for pediatric use
is handled on a case by case basis. This is reflected in some of the more recent EMA
and ICH documents (2008, 2009) that allow for a multitude of choices based on
the ultimate requirements of subsequent clinical trials.
2412 Genetic and Epigenetic Mechanisms of Susceptibility to
Environmental Exposures in Children.
N. Holland,  P. Yousefi,  K. Huen,  K. Harley,  V. Volberg,  L. Barcellos,
H. Quach,  A. Bradman and B. Eskenazi. SPH, CERCH, University of California
Berkeley, Berkeley, CA. Sponsor: J. Lee.
Children are more susceptible to exposures to environmental toxicants than adults,
and in utero exposures may result in developmental problems and chronic diseases.
Some children can be particularly vulnerable due to their genetic makeup and age-
related differences in protective enzyme levels such as paraoxonase (PON1). Results
from the Center for the Health Assessment of Mothers and Children of Salinas
(CHAMACOS) birth cohort study will be presented to illustrate complex relation-
ships of the effects of prenatal exposure to pesticides, PON functional genomics
and genome-wide DNA methylation in Mexican-American children. We deter-
mined PON1 genotypes and three PON1 enzyme activities in 450 mothers and
their children. Although it was previously thought that children’s PON1 levels
reach adult ones by age 2, we found that PON1 levels and activities were the lowest
in newborns and steadily increased with age. However, they remained below adult
levels up to 7 years. Infants and young children, particularly those with PON1
genotypes encoding for lower PON1 levels and activities, have up to 65-fold lower
levels of the protective PON1 enzyme than adults and may be especially susceptible
to OP exposures. To assess DNA methylation in cord blood and peripheral blood
(clots) of 9 year old CHAMACOS children we interrogated 485,577 CpG sites
from >24,000 genes using the Illumina BeadChip platform. We found that ~
15.5% of all CpG sites were differentially methylated between children at birth and
9 years of age. More than 2% of CpG sites investigated, in >1,900 genes, showed
significant differences in methylation by sex, including 731 CpG sites located in
autosomes. Candidate genes and pathways involved in response to environmental
exposures during pregnancy have been identified.  Unlike genetics, epigenetic
mechanisms could be reversible and an enhanced understanding of their role may
lead to better protection of pregnant women and children, and improved public
health.
2413 Prenatal Metal Exposure and Health Effects.
R. C. Fry. Environmental Sciences and Engineering, University of North Carolina at
Chapel Hill, Chapel Hill, NC.
We will present data that we are collecting from two mother-child cohorts, one in
Gómez Palacio, Mexico and one in North Carolina, USA. Both of the newborn co-
horts are at risk for metal exposure. The research focuses on an arsenic endemic area
of Mexico, Gómez Palacio, the study site for our newly established birth cohort. In
this region we are assessing exposure to inorganic arsenic in pregnant women. Our
results suggest that pregnant women in this region are at risk for high level exposure
to arsenic, a finding that has implications both for the health of the women and also
their children. In related research we show that exposure to inorganic arsenic is as-
sociated with changes in DNA methylation patterns. We are also examining
changes in DNA methylation patterns in fetal DNA collected from the NC cohort
which is at risk for prenatal exposure to cadmium. We demonstrate using genome-
wide gene-specific DNA methylation analysis that there are significant differences
in levels of promoter methylation in fetal or maternal samples. In addition, we
highlight that prenatal exposure to cadmium is associated with altered patterns of
methylation of genes that play varied roles in the cell. Results from these cohort
studies underscore the potential health effects of early life exposure to inorganic ar-
senic and cadmium, the potential for epigenetic alterations, short term health con-
sequences, and potential relationships to detrimental health outcomes later in life.
2414 Particulate Pollution, Susceptibility, and Epigenetic
Pathways in an Elderly Cohort.
J. Madrigano1, 2,  A. Baccarelli2,  M. A. Mittleman2, 3,  R. O. Wright2,
D. Sparrow4,  P. S. Vokonas4,  L. Tarantini5 and J. Schwartz2. 1Mailman School of
Public Health, Columbia University, New York, NY; 2Harvard School of Public
Health, Boston, MA; 3Beth Israel Deaconess Medical Center, Boston, MA; 4Veterans
Administration Boston Healthcare System and Department of Medicine, Boston
University, Boston, MA; 5Environmental and Occupational Health, University of
Milan, Milan, Italy. Sponsor: J. Lee.
DNA methylation is a potential pathway linking environmental exposures to dis-
ease, and lower blood DNA methylation has been found in processes related to car-
diovascular morbidity. Genetic and other host characteristics, such as psychological
functioning, have been found to modify the association between air pollution and
morbidity. In our study, DNA methylation of repetitive elements, as well as specific
genes, was measured in 1406 blood samples from 706 elderly participants in the
Normative Aging Study (NAS). We will discuss the changes in repetitive element
DNA methylation, as well as two specific genes (the inducible nitric oxide synthase
gene, iNOS, and the glucocorticoid receptor gene, GCR) associated with ambient
particles (PM2.5) and black carbon (BC), estimated with mixed models. We will
also discuss genotype and phenotype characteristic that may modify this associa-
tion.
2415 Challenging the Limits of Nonclinical Safety Assessment of
Pediatric Medicines.
J. S. Moffit1,  T. Ernest2,  A. Mauz3,  M. G. Paule4,  J. Stewart5 and P. Ji6.
1Nonclinical Drug Safety US, Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield,
CT; 2Product Development, GlaxoSmithKline, Harlow, United Kingdom;
3Nonclinical Drug Safety GER, Boehringer Ingelheim Pharma GmbH & Co. KG,
Biberach an der Riβ, Germany; 4Division of Neurotoxicology, US FDA-National
Center for Toxicological Research, Little Rock, AR; 5Reproductive Toxicology Safety
Assessment, AstraZeneca, Macclesfield, United Kingdom; 6Division of Clinical
Pharmacology II, US FDA-Office of Clinical Pharmacology, Silver Spring, MD.
Pediatric safety assessments are a fundamental and integral part of drug develop-
ment programs. Introduction of regulatory guidance in the last decade has formal-
ized the inclusion of safety evaluations in juvenile animals, leading to a better un-
derstanding of potential drug effects on developmental processes and risks specific
to pediatric age groups. Toxicology studies in juvenile animals have evolved to ad-
dress inherent differences in susceptibility between mature and immature systems.
Pediatric safety assessments are challenged by practical and interpretive complexi-
ties of conducting toxicity studies in immature animals against a background of in-
creasingly diverse disease indications. This symposium will review a number of in-
novative approaches that challenge the current limits of the nonclinical safety
assessment of new pharmaceuticals. Our panel of experts will discuss unique ap-
proaches and case studies dealing with the challenges of supporting pediatric for-
mulations, nontraditional routes of administration, and the complexities of devel-
opmental neurotoxicity assessments. Furthermore, our experts will discuss how
information from various sources such as in vitro experiments using neonatal tissue,
pharmacokinetics, and clinical pharmacology work may be brought together to
build a risk assessment specific for a young infant and pediatric dosing. These inno-
vative approaches from industry and government challenge the limits of nonclinical
safety assessment and provide reassurances of safety for pediatric medicines.
2416 Safe and Effective Use of Established and Novel Excipients in
the Development of Children’s Medicines.
S. R. Maguire. Product Development, GlaxoSmithKline R&D, Harlow, United
Kingdom. Sponsor: J. Moffit.
Developing medicines for children is in some respects even more challenging than
developing medicines for adults yet the range of excipients available for use in the
development of children’s medicines is likely to be significantly reduced without ap-
propriate evidence of safe, tolerated excipient limits across the whole paediatric age
range. Industry, with the support of academia, have the opportunity to work with
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national regulatory agencies to raise awareness of the need to build a risk/benefit
approach focused on the use of excipients in paediatric drug products; in particular
the use of novel excipients in this population. Identification of key data should be
determined together with an appropriate mechanism for this data to be shared to
enhance access to medicines for children.
2417 Technical Challenges and Data Interpretation Evaluating an
Inhaled Long Acting β2-Agonist in Juvenile Dogs.
A. Mauz. Nonclinical Drug Safety Germany, Boehringer Ingelheim Pharma GmbH &
Co. KG, Biberach an der Riβ, Germany.
Numerous inhaled medications are marketed to pediatric populations, but most of
these products were registered prior to the regulated integration of juvenile toxicity
studies in nonclinical safety programs. In order to initiate clinical trials in pediatric
populations, safety assessments are conducted in juvenile animals to assess any po-
tential toxicity effects during postnatal development, particularly with regard to
lung development. This presentation will detail a case study for an inhaled, long
acting β2-agonist in juvenile dogs. Discussion will include insight into the pediatric
safety strategy, technical challenges involved in dosing an inhaled medication to ju-
venile dogs, and data interpretation.
2418 Modeling Pediatric Exposures to Neuroactive Agents:
Developmental Neurotoxicology.
M. G. Paule. Division of Neurotoxicology, National Center for Toxicological Research,
US FDA, Jefferson, AR.
Given the obvious limitations, it is difficult to thoroughly explore the effects of pe-
diatric neuroactive agents on neurons in human infants or children. Due to the
complexity of the primate brain, the monkey is often the animal model of choice
for developmental neurotoxicology experiments. Case studies will be presented on
nonhuman primate models of pediatric exposures to general anesthetics and other
neuroactive compounds. These examples will focus on translational endpoints in-
volving cognitive functions such as learning and memory and in vivo imaging using
PET.  Strategies for neuroprotection will also be discussed.
2419 Technical and Scientific Challenges in Risk Assessments for
Neonates and Infants.
T. Mitchard and J. Stewart. Reproductive Toxicology, AstraZeneca, Macclesfield,
United Kingdom. Sponsor: J. Moffit.
Progression into clinical trials in neonates and infants often involves a risk assess-
ment specific for that age group. The risk assessment is likely to include informa-
tion from technically challenging bespoke studies in very young animals. However,
these studies may not be limited to just repeat dose toxicity studies in young ani-
mals but may also include in vitro experiments using neonatal tissue (exploring
pharmacodynamic endpoints), safety pharmacology and ADME work. This pres-
entation will illustrate with case examples how information from various sources
may be brought together to build a risk assessment specific for the young infant.
2420 Pediatric Dosing Regimen Determination during Drug
Development.
P. Ji. Division of Clinical Pharmacology II, US FDA, Office of Clinical
Pharmacology, Silver Spring, MD. Sponsor: J. Moffit.
In the past 10 to 15 years, the medical treatment options for Juvenile Idiopathic
Arthritis (JIA) have greatly evolved and expanded due to a better understanding of
the disease and the application of biologic agents. Regulations pertinent to pedi-
atric clinical research have also helped provide a legal basis for investigating the ef-
fects of drugs and biologics in pediatric populations and facilitate pediatric drug de-
velopment. The evaluation of clinical pharmacology, efficacy, and safety data has
provided valuable labeling information for pediatric use. This presentation will dis-
cuss the application of clinical pharmacology, safety, and efficacy assessments in de-
termining JIA pediatric dosing regimens.
2421 Nanotoxicology: Computational Strategies, Advances, and
Challenges.
S. M. Hussain and J. J. Schlager. Air Force Research Laboratory, US Air Force,
Wright-Patterson AFB, OH.
Engineered Nanomaterials (ENM), in the range of 1–100 nm, have been found to
exhibit fascinating physicochemical properties making them suitable for numerous
applications, extending into numerous military, industrial, medical, and scientific
specialties. However, massive quantities of ENM would need to be produced for
these applications to be realized, thereby increasing the potential risk of human ex-
posure and raising additional concern about their short and long-term toxicological
effects. Nanotoxicology has recently emerged as a new branch of toxicology which
deals with toxicological ramifications of these ENMs based on their physicochemi-
cal properties, such as size, shape, surface coating, and charge. Conducting toxico-
logical studies considering massive quantities of ENM already in the market would
be time consuming and resource intensive. Therefore, there is a great need to de-
velop computational models to predict toxicity and human health effects of ENMs.
A recent report (Nature Nanotechnology Vol 6, 2011 P138) has demonstrated a
computational model to predict the cytotoxicity of various metal-based nanoparti-
cles. The main objective of this workshop is to discuss modeling techniques based
on the electronic and structural complexity of ENMs to predict their biological ef-
fects.
2422 Quantitative Nanostructure-Activity Relationships Modeling.
A. Tropsha. Eshelman School of Pharmacy, University of North Carolina at Chapel
Hill, Chapel Hill, NC. Sponsor: S. Hussain.
Evaluation of biological effects of Manufactured NanoParticles (MNPs) (including
toxicity and environmental fate) is of critical importance for the future of nan-
otechnology. Our group was among the first to assess the potential of modern
cheminformatics methods such as Quantitative Structure – Activity Relationship
modeling to develop statistically significant and externally predictive models that
can accurately forecast biological effects of MNPs from the knowledge of their
physical, chemical, and geometrical properties; we termed this approach
Quantitative Nanostructure Activity Relationship (QNAR) modelling. We devel-
oped QNAR models for two different categories of MNP datasets: (i) those com-
prising MNPs with diverse metal cores and organic surface modifiers, in which ex-
perimentally measured properties were used as particle’s descriptors, and (ii) those
involving MNPs possessing the same core, but different surface-modifying organic
molecules, for which descriptors can be calculated for a single representative of the
surface-modifying molecule. In the former case, binary QNAR models with exter-
nal predictive accuracy as high as 73% were developed for 44 MNPs tested for cel-
lular bioactivty and characterized by experimental descriptors such as size, relaxivi-
ties, and zeta potential. For the latter case, we developed QNAR models for a
library of 109 MNPs with CLIO-NH2 core decorated with different synthetic
small molecules that were tested for uptake in PaCa2 pancreatic cancer cells; mod-
els’ external prediction power was shown to have an R2 of 0.72 with a mean ab-
solute error of 0.18 under 5-fold external validation procedure. Similar results were
obtained for another dataset of 84 surface-modified Carbon Nanotube MNPs
tested for protein binding and acute cellular toxicity; these models were used to de-
sign novel MNPs that were tested experimentally with the success rate of 80%. Our
studies show that QNAR modelling can be used successfully for (i) predicting ac-
tivity profiles of novel MNPs solely from their representative descriptors and (ii) de-
signing and manufacturing safer nanomaterials with the desired properties.
2423 Toxicity of Nanomaterials—Major Challenges for Theoretical
Predictions.
J. Leszczynski. Department of Chemistry, Jackson State University, Jackson, MS.
Sponsor: S. Hussain.
Nanotechnology is expanding rapidly, but development of novel materials synthe-
sized at the ‘nano’ scale should be always accompanied by a comprehensive assess-
ment of risk to human health and to environmental ecosystems. It is vital to be able
to predict possible environmental impact of new nanomaterials before their mass
production and application. Computational Chemistry provides various tools to
evaluate interaction of nanomaterials with biomolecules, shed a light on mecha-
nisms of such phenomena, and predict toxicity of nano sized species. We believe
that there is a strong need to develop “nano descriptors” i.e. novel and reproducible
ways of representing the structures and/or physical properties of nanoparticles that
are suitable for distinctive grouping these types of chemicals. This will facilitate de-
velopment of QSARs that could reliably predict their characteristics and activities.
A conceptual framework for grouping NPs should be considered as a first step in
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identifying QSARs that are applicable within each group. Due to high variability in
the molecular structure and different mechanisms of action, individual groups of
nanoparticles should be modeled separately. In each case, according to the general
QSAR rules, the applicability domain of the models should be carefully validated.
Our recent ab initio study revealed details of interactions of gold clusters, carbon
nanotubes and fullerenes with DNA bases and base pairs. Direct prediction of tox-
icity of unknown nanomaterials was done using QSAR models developed for a test
set of compounds characterized experimentally. Based on experimental testing, we
developed and tested novel interpretative nano-QSAR model describing cytotoxic-
ity of 17 nano-sized metal oxides to bacteria Escherichia coli. The proposed model
allowed us to formulate a hypothesis that mechanistically explained differences in
toxicity between the individual oxides.
2424 Biological Surface Adsorption Index (BSAI): A Molecular
Signature for Nanomaterial Interactions.
J. E. Riviere. Institute of Computational and Comparative Medicine, Kansas State
University, Manhattan, KS.
Most characterization techniques available today for nanomaterials are based on
hard physical-chemical properties of size, shape, and surface properties, often deter-
mined under very non-biological conditions. However, a major factor that deter-
mines biological interactions of nanomaterials in vivo are their surface properties re-
lated to forming interactions with molecules in the biological environment. We
have developed the BSAI metric, which develops a signature of nanomaterial sur-
face properties specifically related to biomolecular interactions. These properties are
developed based on how a nanomaterial interacts with a series of probe compounds
using a QSAR approach to generate five molecular descriptors that could be de-
scribed as a multidimensional partition coefficient. This presentation will introduce
the index and illustrate how it can be used to improve modeling of biological inter-
actions.
2425 Predictive Modeling on Nanoparticle-Biomolecular
Interactions.
R. Pandey. Department of Physics, Michigan Technological University, Houghton, MI.
Sponsor: S. Hussain.
Nano-scale materials, such as semiconductor and metal quantum dots, carbon nan-
otubes, and graphene, exhibit novel optical, electrical, and magnetic properties that
can be exploited for new generations of electronics and sensors. Nanoscale materi-
als also exhibit unique affinity with biological molecules, such as nucleic acids and
proteins, which can be utilized for a wide variety of biological diagnostics and sens-
ing applications. In order to develop such application concepts, however, a funda-
mental understanding of the interactions between various nano and biological sys-
tems is critically important. This talk will present a brief overview of recent
developments in the assembly and structure-property characterizations of hybrid
nano-bio materials with a focus on the physical and chemical properties of their in-
terface. Results obtained from recent theoretical and experimental investigations on
optical protein-QD and nucleic acid base-nanotube (C, BN) interactions will be
presented.
2426 Toxicogenomics in Risk and Safety Assessment: Recent
Advances and Continuing Challenges.
C. Thompson1 and M. D. Waters2. 1ToxStrategies, Inc., Katy, TX; 2Integrated
Laboratory Systems, Inc., Research Triangle Park, NC.
Toxicogenomic studies can provide a vast amount of data with regard to the
changes a chemical can have on a cell, tissue, or organism, and technological
achievements continue to make it easier and cheaper to generate such data.
However, the application of toxicogenomic data to environmental risk assessments
and pharmaceutical safety assessments has progressed more slowly and, despite re-
cent advances, challenges remain as to how best to harness and interpret these large
and complex datasets to facilitate their practical application. This session will de-
scribe recent applications of toxicogenomics in environmental risk assessment with
focus on assessing and predicting genotoxic modes of action and utilizing transcrip-
tome changes from multidose and multi-endpoint animal bioassays in quantitative
risk assessment. In addition, recent advances in the usage of toxicogenomics in pre-
clinical pharmaceutical safety, clinical trial placement, and individualized medicine
will be described.
2427 Characterizing and Predicting Modes of Action of
Carcinogenicity Based on Conventional and Toxicogenomics
Methods.
M. D. Waters. Integrated Laboratory Systems, Inc., Research Triangle Park, NC.
Predictive toxicogenomics uses global molecular expression data resulting from ge-
nomic perturbation (e.g., transcript profiles) to predict a toxicological outcome,
such as carcinogenicity. In the context of risk assessment, the classification of car-
cinogens as genotoxic or nongenotoxic has become an essential and debatable issue
because of the default assumption that drives regulatory decision-making regarding
the presumed linearity of the dose-response curve for genotoxic carcinogens. In
fact, the great majority of known human carcinogens are easily detected in conven-
tional short-term tests for genotoxicity and induce tumors at multiple sites in ro-
dents, thus provoking challenges as to the human relevance of nongenotoxic rodent
carcinogens. Toxicogenomics studies appear quite useful in resolving this di-
chotomy and in pursuing mechanisms of action. In toxicogenomics studies, a
strong DNA damage response at the gene expression level suggests direct DNA
modification whereas increased expression of genes involved in cell cycle progres-
sion is more characteristic of the indirect-acting agents such as those that induce ox-
idative stress. Gene expression profiles have been demonstrated that discriminate
nongenotoxic modes of action (e.g., cytotoxicity and regenerative proliferation,
xenobiotic receptor agonists, peroxisome proliferator-activated receptors, or hor-
monal-mediated processes) and other profiles appear to delineate various paths to
the formation of conventional cytogenetic alterations. The evidence accumulated to
date suggests that toxicogenomics approaches will be useful in conjunction with
conventional test methods in the dose and phenotype anchored assessment of
chemical carcinogenicity. Case studies will be used to illustrate these points.
2428 Case Studies of Dose-Response Genotoxicity and
Toxicogenomic Studies Designed to Replace Default
Assumptions Used in Carcinogenic Risk Assessments.
L. Recio. Integrated Laboratory Systems, Inc., Research Triangle Park, NC.
Characterizing dose-response is a fundamental aspect of toxicology and can be used
determine and predict the potential adverse effects of chemicals to humans. Only
recent genetic toxicology and toxicogenomic studies have adequately characterized
dose–response over a range of exposures and have used these data for point-of-de-
parture (POD) calculations needed in risk assessment, such as benchmark dose 10
(BMD10). Genotoxicity and toxicogenomic endpoints can be considered as bio-
markers of ‘key events’ or adaptive responses that with robust experimental designs
can provide the needed qualitative and quantitative dose-response information to
establish chemical-specific modes-of-action that can be integrated into weight-of-
evidence-based approaches for risk assessments. More recently genomic signatures
for mode-of-action (MOA) (e.g., genotoxic vs nongenotoxic MOA) in target or-
gans are emerging as mRNA biomarkers of effects. Low dose studies designed to
identify exposure levels that do not cause alterations in basal genotoxicity or gene
expression can be used to identify exposure levels (or dose) that represent the tran-
sition between the NOEL concentrations and other PODs such as BMD. Recent
studies conducted at ILS with collaborators, represent case studies aimed at identi-
fying the NOEL concentrations and other PODs using the in vitro micronucleus
and mutagenicity studies in human cells for acetaldehyde, dose-response and im-
pact of liver GSH detoxication on naphthalene genotoxicity, expression profiling
studies to asses genotoxic vs nongenotoxic MOA in human TK6 cells, and an in
vivo dose-response study conducted with the mouse liver carcinogen furan examin-
ing impact on the mouse genome and epigenome.
2429 Application of Transcriptomic Data for Quantitative
Chemical Risk Assessment.
R. S. Thomas. The Hamner Institutes for Health Sciences, Research Triangle Park,
NC.
Current challenges facing chemical risk assessment are the time and resources re-
quired to meet the data standards necessary for a published assessment and the in-
corporation of modern molecular biology information. The integration of tran-
scriptomic data into the risk assessment paradigm may address both challenges by
providing an efficient means to quantitatively and comprehensively evaluating the
molecular changes resulting from chemical exposure. To assess the value of applying
transcriptomics in quantitative chemical risk assessment, a series of studies was per-
formed. In the first study, mice were exposed for 13 weeks to multiple concentra-
tions of five chemicals that were positive in a two-year cancer bioassay. In a second
study, rats were exposed in a time course to multiple concentrations of six chemicals
with published risk assessments. In both studies, histological changes were evalu-
ated and transcriptional microarray analysis was performed on the target tissues.
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The histological and the tumor responses were analyzed using standard benchmark
dose (BMD) methods to identify noncancer and cancer points-of-departure. The
dose-related changes in gene expression were also analyzed using a BMD approach
and grouped based on signaling pathways. The transcriptional BMD values showed
a high degree of correlation with apical responses for specific pathways and many of
the correlated pathways have been implicated in relevant disease pathogenesis.
Importantly, transcriptional points-of-departure for even the most sensitive path-
way were on average less than three-fold different than traditional apical points-of-
departure for both cancer and non-cancer endpoints suggesting that transcriptomic
changes in signaling pathways can be used to estimate noncancer and cancer points-
of-departure for use in quantitative risk assessments.
2430 Challenges and Opportunities of Toxicogenomics Analyses in
Safety Assessment during Preclinical Safety Studies.
C. Karbowski. Discovery Toxicology, Amgen, Thousand Oaks, CA.
Microarray analysis is a key tool utilized in the biotechnology/pharmaceutical in-
dustry as part of a holistic approach to predicting and understanding mechanisms
of toxicity of molecules in development. Historically, researchers have faced signifi-
cant challenges in analyzing and interpreting these large datasets such as under-
standing the translation of molecular changes to phenotypic changes in an organ-
ism and the relevance of observed alterations to other species. However, progress in
overcoming these challenges continues to be made.  For example, contextualization
of gene expression changes utilizing historical and publically available reference tox-
icant datasets coupled with recent advances in Systems Biology such as more com-
prehensive and toxicologically relevant content along with the incorporation of
transcription factor analyses and gene directionality provides opportunities to un-
derstand the genesis and cross-species relevance of pre-clinical phenotypic changes.
This presentation will provide an historical view of the utility of microarray analy-
sis in preclinical safety assessment and then illustrate, through case examples, the
added value provided when current state of the art tools are applied to help dissect
molecular changes underlying phenotypic alterations.
2431 Role of Causal Reasoning in Patient Stratification from
Efficacy and Safety Perspectives.
A. Enayetallah. Drug Safety Research & Development, Pfizer, Inc., Groton, CT.
Advances in genomic technologies have led to the ability to rapidly generate ex-
traordinary amounts of data. However, a lack of efficient tools to manage and in-
terrogate such large amounts of data has limited the application of genomics in the
pharmaceutical industry. Recently, we developed a computational platform we call
the Causal Reasoning Engine (CRE) that is a powerful tool fortranscriptomic data
analysis. The CRE provides explanation of the observed transcriptomic changes in
the context of prior biological knowledge, captured in a knowledge base of com-
putable biological assertions. The platform was initially applied to investigative tox-
icology to provide mechanistic understanding of organ toxicities, including drug-
induced liver injury (DILI) and drug-induced cardiac injury. More recent
developments of the CRE platform indicate potential predictive power for evaluat-
ing compound responses and safety liabilities at the individual patient level, which
would enable the stratification of patients in clinical trials. In the context of efficacy
we will show a use case for patients with diseases known for their heterogeneity,
such as systemic lupus erythematosus and inflammatory bowel disease. In this case
individualized analysis using CRE clearly classifies patients based on their underly-
ing disease mechanisms, and we will discuss the potential impact on patient and
treatment selection in clinical trials. Finally, the results from the individualized
analysis approach in patients with immune-mediated DILI will also be presented.
Based on the examples presented here, we believe that the CRE approach shows
great promise in being able to stratify patients to support the development of more
effective and safer medicines.
2432 Assessment of Environmental, Dietary, and Biological Risk
Factors Impacting Liver Cancer Incidence in Texas.
E. D. Bruce1, 2 and A. Romoser3. 1Institute of Biomedical Sciences, Baylor University,
Waco, TX; 2Institute of Ecological, Earth, and Environmental Science, Baylor
University, Waco, TX; 3Toxicology, Texas A&M University, College Station, TX.
The increasing incidence of primary liver cancer in Texas is a result of multiple risk
factors, including environmental and dietary exposures to carcinogens, as well as bi-
ological factors, such as hepatitis C infection. Texas has the highest liver cancer
mortality rate in the United States, affecting the Hispanic portion of the population
most acutely. It is speculated that the increased incidence of primary liver cancer
observed in these Hispanic communities is due to occupational exposures to pesti-
cides, polycyclic aromatic hydrocarbons (PAHs), and dietary risk factors from con-
taminated maize. Current research and risk assessment in this field is focused on
cancer epidemiology within these populations to determine those risk factors that
are most hazardous to the community health of south Texas. Many pesticides used
in farming and households are labeled as probable carcinogens and can cause many
other negative health effects in people chronically exposed. Research and educa-
tional programs in Texas are striving to increase awareness of health effects from ex-
posure and pesticide safety. PAHs are also known hepatic carcinogens, forming
DNA adducts within the liver. Health effects observed in Texas from chronic PAH
exposure through foods and poor air quality are being assessed. Additionally, myco-
toxin occurrence is heightened in the southern portion of the state where drought
conditions and excessive heat contribute to fungal growth on staple crops (i.e.,
maize). Specifically, aflatoxin and fumonisin exposures have been observed in vari-
ous communities in San Antonio and along the Texas-Mexico border. These myco-
toxins are known to both initiate and promote hepatocellular carcinoma.
Understanding the risk factors for primary liver cancer in Texas is essential to devel-
oping future remediation, prevention, and treatment strategies, as well as identify-
ing and establishing necessary changes in state regulations.
2433 Liver Cancer Incidence Trends in Texas 1995–2009.
J. F. Villanacci,  C. Bowcock and A. Hackenwerth. Texas Department of State
Health Services, Austin, TX. Sponsor: E. Bruce.
Liver cancer is the 12th most commonly diagnosed cancer in the US and the 6th
most common cause of cancer deaths. Liver cancer incidence has been increasing in
both Texas and the US. Although liver cancer only accounts for 1.3% of new can-
cer cases, it accounts for 2.6% of cancer deaths. Survival rates are poor with a five-
year survival of 13 to 15 percent. In 2012, approximately 2,197 Texans are expected
to be diagnosed with liver cancer and 1,768 are expected to die from the disease. 
Liver cancer incidence trends for Texas and the US were determined using data
from the Department of State Health Services, Texas Cancer Registry and National
Cancer Institute, Surveillance Epidemiology & End Results. For a 15-year period
(1995 to 2009) age-adjusted incidence rates were computed by gender and
race/ethnicity.
Texans experience higher liver cancer incidence rates than the US and the rates are
increasing faster. From 1995 to 2009 Texas rates increased by an average annual rate
of 5.7% compared to 3.9% for the US. The 15-year percent changes in incidence
for Texas and the US were 126% and 77%, respectively.
In Texas, liver cancer incidence has been increasing in both men and women but
faster in men. From 1995 to 2009 age-adjusted rates for men increased by 130%,
while rates for women increased by 96%. In both Texas and the US, men of all
race/ethnic groups are diagnosed two to four times as often as women. In Texas,
Hispanics (any race) and Asian/Pacific Islanders have the highest rates but Blacks
had the highest rate of change from 1995 forward with an annual percent increase
of almost 7% and a 15-year increase of 141%. Texas Hispanics and Blacks have sig-
nificantly higher liver cancer incidence rates than US Hispanics and Blacks.
Hispanic men living in the 38 South Texas counties have the highest age-adjusted
rate (25.7). Hispanic and Black men living in the remaining Texas counties have the
next highest rates (19.4 and 19.1). From 1995 to 2005 there has been a downward
shift in the age of diagnosis of liver cancer for both men and women of all race/eth-
nic groups.
2434 A Lay Health Worker-Based Intervention for Reducing
Families’ Environmental Exposures.
L. Cizmas1,  J. Ross1,  R. Rincon2,  H. Tamez2,  A. Ginez2,  R. Perales2,  C. Miller2
and T. McDonald1. 1Texas A&M Health Science Center School of Rural Public
Health, Texas A&M University, College Station, TX; 2South Texas Environmental
Education and Research Program, University of Texas Health Science Center, San
Antonio, San Antonio, TX.
In economically disadvantaged areas of San Antonio and Laredo, TX, poor living
conditions and a hot climate increase the likelihood of pest infestations, leading to
increased pesticide use. Promotoras (lay health workers) were employed to deliver a
pesticide health education module to families with children between 6 months to 5
years of age. Assessments of attitudes and behaviors relating to pesticide use were
given prior to and 6 months after module delivery. In Laredo, participants reported
statistically significant changes in behavior and attitudes six months after the mod-
ule. For example, the percent of participants reporting that they always had emer-
gency numbers by the phone was 35% before the training and 86% six months
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after the training, and the percentage reporting that they always used gloves when
applying pesticides was 35% before the training and 84% six months after the
training. Promotora-driven health education with local collaboration may improve
family attitudes and practices relating to pesticide use, and may be explored as an
option for addressing other environmental exposures as well.
2435 Early Obesity and Risk of Hepatocellular Carcinoma in USA.
M. Hassan1,  D. Li1,  A. Kaseb1,  J. L. Abbruzzese1,  H. M. Hassabo1,  M. Khalil1,
I. Sahin1,  J. Morris1,  E. Hawk1 and M. R. Spitz2. 1The University of Texas MD
Anderson Cancer Center, Houston, TX; 2Baylor College of Medicine, Houston, TX.
Sponsor: E. Bruce.
Despite the public health problem of obesity and increasing incidence of hepatocel-
lular carcinoma (HCC) in the United States (US), the relationship between obesity
and HCC has never been examined extensively in US population. At the University
of Texas MD Anderson Cancer Center we conducted a case-control study aimed at
examining HCC risk factors in the US. Cases were patients with pathologically
confirmed diagnosis of HCC and US residency. The healthy control subjects were
spouses of patients at MD Anderson who had cancers other than liver, gastroin-
testinal, lung, or head/neck cancer. Self-reported weight and body size (Stunkard
pictograms) at ages 20, 30, 40, 50, 60, 70 was obtained from participants by per-
sonal interview. Between 2005 and 2011 we enrolled 403 cases and 661 controls.
Body mass index (BMI) was classified as “underweight” (BMI < 18.5), “normal”
(BMI range, 18.5-24.9), “overweight” (BMI range, 25- 29.9), and “obese” (BMI ≥
30.0). We found that individuals who were obese from the ages of 30 to 49 had a
significant increased risk of HCC, independent of HCC established risk factors.
The estimated odds ratio (OR) and 95% confidence interval (CI) was 4.1(1.6-
10.5). The association was observed in men and women; the ORs (95% CIs) were
2.3(1.1-4.9) and 2.9(1.2-8.9) respectively. Moreover, individuals who were over-
weight or obese from the ages of 30 to 49 years had an earlier onset of HCC by 3 to
6 years (median age of onset was 65 years for patients with normal weight, 62 years
for overweight patients [P=.02], and 59 years for obese patients (P <.001).
Underlying evidence of cirrhosis was significantly observed in HCC patients with
early obesity. We concluded that obesity is a significant risk factor for HCC in US
where underlying cirrhosis can be a significant burden in disease management.
Integration of obesity with other HCC risk factors into a risk model may lead to
the development of a new scoring system to identify high-risk individuals who may
benefit from HCC screening and prevention.
2436 Biomarkers of Hepatocellular Cancer Risk and Diagnosis.
R. M. Santella. NIEHS Center for Environmental Health, Columbia University
Mailman School of Public Health, New York, NY.
Hepatocellular carcinoma (HCC) incidence is increasing in the US and HCC has
one of the fastest growing death rates of any cancer. There is wide geographic varia-
tion in HCC incidence around the world likely due to geographic differences in the
prevalence of various etiological factors. In Asia and Africa hepatitis B virus is the
primary etiologic agent while in the US, hepatitis C virus is more common.
Identified environmental/lifestyle risk factors include aflatoxin B1 (AFB1), a di-
etary mold contaminant, alcohol drinking, and cigarette smoking. We have used
biomarkers in a prospective study in Taiwan to demonstrate that elevated baseline
levels of AFB1 urinary metabolites, AFB1-albumin adducts, polycyclic aromatic
hydrocarbon (PAH)-albumin adducts and urinary isoprostanes, a biomarker of ox-
idative stress, are associated with later development of HCC. We have also found
AFB1- and PAH-DNA adducts in liver tissues of US HCC cases. Using a candidate
gene approach, studies of liver tumor tissues have identified genes that are hyper-
methylated in tumors compared to adjacent tissues and found that this methylation
was associated with elevated levels of AFB1-DNA adducts in the tissues. DNA iso-
lated from plasma collected at the time of diagnosis contains these same methylated
markers. More importantly, methylated DNA released from the tumor can be fre-
quently found in plasma collected many years before clinical diagnosis suggesting
their potential utility in screening high populations such as those with viral infec-
tion. More recently, we have used Illumina Infinium arrays that interrogate methy-
lation of 27k or 450k CpG sites to more comprehensively identify regions with al-
tered DNA methylation. These studies have found large numbers of hyper or
hypomethylated regions in tumors compared to adjacent tissues and identified
methylation markers that should enhance early diagnosis. Biomarkers of environ-
mental exposure in combination with viral infection markers can identify popula-
tions at increased risk while methylation and microRNA markers may potentially
be used for the early diagnosis of HCC.
2437 Mitigation of Aflatoxin Exposures Using a Clay-Based
Enterosorbent.
T. D. Phillips. Veterinary Integrative Biosciences, Texas A&M University, College
Station, TX.
Concerns about the quality and safety of foods destined for human and animal con-
sumption have evoked a growing awareness of the significant hazards associated
with chemicals known as aflatoxins. The aflatoxin problem in foods is longstand-
ing, unavoidable and seemingly inextricable. Aflatoxin exposure is often considered
a risk factor for disease in countries where there is a lack of infrastructure for food
safety regulation. However, aflatoxin exposure has been observed and is a cause for
concern in underprivileged communities in Texas and the Southwest U.S. as well.
Aflatoxin B1 (AFB1) is a direct acting mutagen and has been shown to disrupt
genes involved in carcinogenesis and tumor suppression. Recent research with my-
cotoxin enterosorbent, NovaSil (NS), in an African population has shown the prod-
uct to be safe and efficacious in reducing biomarkers of exposure to aflatoxin. Blood
and urine samples were taken at Baseline, 1 Month, 3 Months and 4 Months. NS
clay significantly reduced biomarkers for aflatoxin exposure in urine and blood and
the treatment was well tolerated by participants. In a recent San Antonio study fo-
cusing on a population with a significantly elevated incidence of liver cancer, it was
determined that biomarkers for aflatoxin correlated with ingestion of foods known
to contain relatively higher levels of aflatoxin. Phase II of this study is underway to
determine NS efficacy in reducing exposures to this toxin in Texas. Mitigating
AFB1 exposure using NS represents an innovative, practical, sustainable and envi-
ronmentally benign approach that will benefit more than 4.5 billion people living
in climates conducive to the growth of fungi and production of mycotoxins in sta-
ple foods.
2438 Risk Factors Influencing the Incidence of Liver Cancer in
San Antonio.
F. A. Guerra. Department of Pediatrics, University of Texas Health Science Center
San Antonio, San Antonio, TX. Sponsor: E. Bruce.
The incidence of hepatocellular carcinoma (HCC) is significantly elevated in
Hispanic communities in Bexar County, Texas. Multiple factors including diet, en-
vironment, occupation, lifestyle, health status, and gender play a role in the etiol-
ogy of HCC. Previous research with Texas A&M University has focused on defin-
ing the risk factors that may influence the high incidence of liver disease observed
in San Antonio. Epidemiological and clinical intervention studies are ongoing in
Bexar County, and have been successful in raising awareness in the community re-
garding environmental, dietary, and biological risk factors for disease. Ongoing
studies with The University of Texas Health Science Center-San Antonio and Texas
A&M University will investigate the impact of an intervention trial designed to de-
crease biomarkers of mycotoxin exposure and enhance public health in communi-
ties at high risk for HCC.
2439 A Novel Single Cell-Based High-Throughput Toxicity Study
of Drugs.
L. Ma,  Y. Qiao and M. Su. NanoScience Technology Center, University of Central
Florida, Orlando, FL. Sponsor: T. Lam.
Many anticancer drugs are genotoxic. The ability of tumor cells to repair drug in-
duced DNA damage is indicative of therapeutic outcomes. But, tumors are hetero-
geneous in their ability to repair damaged DNA, and evaluation population re-
sponse only gives a statistical average. Thus selection of drugs without knowing
tumor response at single cell level can cause side effects due to toxicity of drugs.
There is a need to screen drugs reliably and rapidly for individual patients. This
paper describes a new single cell based HaloChip assay that can be used to detect
and quantify DNA damage and repair capacity after exposing to genotoxic drugs,
and examine drug response without population interference. 
After forming cell array, cells are embedded in agarose that provides an intercon-
nected network for DNA diffusion, followed by exposure to NaOH and stained
with ethidium bromide. Dimensions of halo and nucleus are derived from collected
fluorescent image. In the case of repair, cells are washed after exposing to drug and
incubated for different time before HaloChip assay. The level of DNA damage is
quantified using relative nuclear diffusion factor (rNDF) derived from surface areas
of halo and nucleus. The rNDFs increase from 0 to 6 as drug concentration in-
crease from 0 to 50 μM, and reach plateau when drug concentration is over 10 μM.
At same dosage, VP-16 induces more DNA damage in HeLa cells than that of other
two drugs; CPT-11 induces more DNA damage in LNCaP cells than that of other
two drugs. The bimodal repair curves are attributed to diversity of DNA lesions in-
duced by drugs. The repair data are regressively fitted using first order exponential
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equation. Longer repair time significantly reduces rNDF values. CPT-11 shows a
slower reduction than the other two drugs for LNCaP cells. The time required to
repair 50% DNA damage (t50) is derived within 0-24 hr repair time. 
In summary, HaloChip assay can be used to measure genotoxic drug induced DNA
damage and its repair capacity. It is expected that the method will be useful in clin-
ical, epidemiological, and experimental settings.
2440 New High-Throughput Version of the DEL Assay Detects
Nonmutagenic Carcinogens.
R. H. Schiestl,  L. Parfenova,  Y. Rivina,  V. Kutepova and D. Nguaen. Pathology;
Environmental Health Sciences, Radiation Oncology, University of California Los
Angeles, Los Angeles, CA.
Genetic instability is a hallmark of carcinogenesis. Furthermore, cells from patients
carrying mutations conferring cancer prone phenotypes show a higher level of ge-
netic instability, including DNA deletions. In fact, the original yeast-based DEL
(deletion) Assay with 100 chemicals shows an accuracy of 92% to detect carcino-
gens as compared to 62% detected with the Ames Assay. DEL events in all three
formats are inducible by a wide variety of carcinogens including carcinogens that
are negative in many other short-term tests. The DEL assay results also highly cor-
relate with the clastogenicity of chemicals. Here we introduce the next generation
DEL assay: a novel dual-read out Saccharomyces cerevisiae screen DEL-XG. DEL-
XG simultaneously assesses the compound’s genotoxicity and cytotoxicity proper-
ties. During an exposure to a genotoxic event the sequence is excised and the lacZ
gene recombines to a functional beta-galactosidase genotype that with an addition
of the X-Gal substrate produces a strongly positive indole (blue) product. The most
important advance is that we can determine the effect of target gene expression on
genotoxicity. Surprisingly and most importantly we found that the Ames negative
carcinogens that were weakly positive in our standard His reversion assay, are 10
fold more potent in expressed DNA. This makes the new version of the DEL assay
even more useful and makes sure that the Ames negative carcinogens will be posi-
tive even in the high throughput version. DEL-XG is a rapid and economical way
to screen large chemical libraries for toxicity and potential carcinogenicity proper-
ties.
2441 In Vitro Genotoxicity Assays (Comet and Micronucleus)
Using Engineered Skin.
G. Ouédraogo1,  F. Nesslany2,  S. Simar2,  S. Talahari2,  D. Lagache2,
E. Vercauteren2,  L. Nakab2,  A. Mayoux2,  N. Flamand1,  G. Massin2 and
J. Cotovio1. 1Predictive Model and Method Development, L’Oréal R&I, Aulnay sous
bois, France; 2Laboratoire de Toxicologie, Institut Pasteur de LiIle, Lille, France.
Sponsor: E. Dufour.
An in vitro micronucleus assay using human engineered skin and target cells grown
beneath the tissues was developed. The purpose was to bring some information on
exposure in in vitro genotoxicity assays for dermally applied compounds. Previous
results have shown that this method was reproducible and could be transferred to
other laboratories. The system has now evolved to combine both the comet assay
and the micronucleus assay.
The approach is based on performing the comet assay in cells dissociated from the
tissues, while the micronucleus assay was performed using the cells cultured be-
neath the reconstructed tissues. Four different time schedules were considered for
this project: a 4 h treatment and a 27 h treatment period with or with an extra 27 h
recovery period.
A set of 13 chemicals were tested with this approach. The results obtained show
that the best prediction model was the long treatment period (27 h) without recov-
ery for both the comet assay and the micronucleus assay.
Most of the “irrelevant positives” yielded negative in vitro results using this system.
2442 Development and Validation of a Toxicogenomics Signature
to Differentiate Genotoxins vs Nongenotoxins.
S. Beedanagari,  S. Nicotra and L. Custer. Bristol-Myers Squibb, East Brunswick,
NJ.
Genotoxicity testing has long been used to assess a compound’s potential to induce
genetic damage and hence it’s carcinogenic potential. The standard genotoxicity
testing battery was designed to have high sensitivity but low specificity for detecting
carcinogens that act by damaging DNA. As a consequence, positive genotoxicity
test results require follow-up in vitro and/or in vivo testing to determine the biolog-
ical relevance of the in vitro genotoxicity potential. Recent literature suggests that
Toxicogenomic approaches could serve as a useful tool to identify different mecha-
nisms through which compounds/ chemicals exerts their genotoxic effects.
Although multiple research groups to date have published papers listing several
gene expression based molecular signatures in vitro using human and rodent cell
lines, and in vivo using rodent models, there exists no consensus largely due to
species differences and diverse “omics” technologies used. The broad objective of
this study is to extend the work conducted by the ILSI-HESI technical committee
on differentiating genotoxic and non-genotoxic carcinogens using real-time PCR
(qPCR) based toxicogenomic approaches. In this study using a human lymphoblast
TK6 cell line, we evaluated the utility of a qPCR technique to identify a molecular
signature by studying gene expression profiles of twenty five genes. In our initial
screening study we identified six genes that differentiated genotoxins vs non-geno-
toxins. However, in our validation study using ten model compounds per each
group of aneugens, clastogens and non-genotoxins, we suceeded in reducing six
gene signature to three gene signature. The proposed three genes that could effec-
tively differentiate clastogens and aneugens from non-genotoxins with high speci-
ficity and sensitivity are Cyclin-dependent kinase inhibitor 1A (CDKN1A),
Growth differentiation factor 15 (GDF15) and Tumor protein p53 inducible pro-
tein 3 (TP53I3).
2443 Characterization of Threshold Dose Response of
Genotoxicity from Chemicals with Diverse Mechanisms of
Damage.
B. Sun1,  S. M. Ross1,  A. Scott2,  Y. Adeleye2,  M. E. Andersen1 and
R. A. Clewell1. 1The Hamner Institute, Durham, NC; 2SEAC, Unilever PLC,
Bedfordshire, United Kingdom.
There is much debate regarding the existence of threshold dose-response for geno-
toxity with DNA reactive chemicals. This study used in vitro high content imaging
and flow cytometry assays together with Lutz threshold model (Lutz et al, 2009) to
identify the threshold of dose-response for induction of double strand breaks
(DSBs) and micronuclei (MN) in human p53-competent fibrosarcoma cells
(HT1080). We evaluated 9 prototype chemicals: neocarzinostatin (NCS; direct
DSB induction, mimics γ-irradiation), etoposide (ETP; topoisomerase II in-
hibitor), mitomycin C (MMC; DNA crosslinker), methyl methanesulfonate and
ethyl nitrosourea (MMS, ENU; alkylating agents), hydrogen peroxide and tert-
butylhydroquinone (H2O2, TBHQ; oxidative damage), quercetin and curcumin
(QUE, CUR; oxidative polyphenols). All the oxidative agents H2O2, TBHQ, QUE
and CUR induced a significant threshold response in both DSBs and MN, while
the topo II inhibitor (ETP) and DNA crosslinker (MMC) induced non-threshold
DSBs and MN response.  The two alkylating agents showed different dose response
trends: MMS exhibited threshold behavior of MN and DSBs, while ENU did not
at the doses examined. Interestingly, NCS, a direct genotoxin and potent inducer of
DSBs, induced a linear-like DSB response, but a threshold increase in MN, indi-
cating that the DNA repair response prevents conversion of DSB to MN at low
doses. We also assessed p-p53 (ser15) and total p53 induction by these chemicals.
The shapes of the p-p53 curves are generally comparable to p-H2AX, demonstrat-
ing that dose-response relationship of p53 activation follows similar pattern as
DSBs. Our results indicate that dose-response relationship for DNA damage and
MN formation may exibit threshold or non-threshold depending on the chemical.
Whole genome transcriptomics and repair enzyme proteins induction are currently
being measured to evaluate the role of chemical specific activation/inhibition of
DNA repair in the determination of linear vs. nonlinear dose-dependency of geno-
toxic response.
2444 Concurrent Evaluation of General, Immune, and Genetic
Toxicity Endpoints As Part of an Integrated Testing Strategy
Approach.
L. Sosinski,  L. A. Murphy,  M. R. Schisler,  N. Visconti,  R. Sura,  M. J. LeBaron
and D. R. Boverhof. The Dow Chemical Company, Midland, MI.
Integrated testing strategies involve the assessment of multiple endpoints within a
single toxicity study and represent an important approach for reducing animal use
and streamlining testing. The present study evaluated the ability to combine gen-
eral, immune, and genetic toxicity endpoints into a single study. Specifically, this
study evaluated the impact of sheep red blood cell (SRBC) immunization, as part of
the T-cell dependent antibody response (TDAR) assay, on organ weights, RBC mi-
cronuclei formation, Comet response, and spleen T-cell immunophenotyping.
Groups of female F344/DuCrl rats were dosed with cyclophosphamide (CP) by i.p.
injection for five consecutive days at 0, 1, 3, and 10 mg/kg bw/day. Six rats from
each dose group were injected i.v. with SRBCs on the initial day of dosing, as per
the TDAR assay, while an additional 6 rats per group did not receive SRBCs.  A
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sham control group was included to account for animal handling and an additional
group was dosed with ethyl methanesulfonate by oral gavage as a positive control
for the comet assay. For the TDAR assay, treatment with CP resulted in a dose-de-
pendent decrease in the antibody response with a suppression of greater than 95%
at the high dose. Injection with SRBC had no impact on evaluated organ weights.
Analysis of micronuclei formation revealed a dose-dependent increase in response
to CP treatment, with an induction of greater than 10-fold at the mid and high
doses. Injection with SRBC had no impact on the level of micronuclei in control
animals and did not alter the dose response to CP. There was no increase in liver
DNA damage in response to CP as measured by the comet assay and injection with
SRBCs did not alter this endpoint. Similarly, injection with SRBC did not alter the
spleen T-cell profile in response to CP. Overall these data provide strong support for
the concurrent assessment of general, immune, and genetic toxicology endpoints
within a single study as part of an integrated testing strategy approach.
2445 Evaluation of Repeated Dose Liver Micronucleus Assay in
Rats: Summary of Collaborative Study by CSGMT/JEMS-
MMS.
R. Takashima1,  S. Hamada1,  K. Shimada2,  K. Matsumoto3,  S. Kawakami4,
J. Tanaka5,  H. Matsumoto6,  T. Nakai7,  T. Imamura8,  S. Matsumura9,
H. Sanada10,  Y. Terashima11,  K. Inoue12,  S. Mutou13,  S. Hagio14,  A. Hayashi15,
T. Takayanagi16,  Y. Ogiwara17,  A. Maeda18,  K. Narumi19,  Y. Wako1,
T. Morita20,  H. Kojima20,  M. Hayashi20 and M. Honma20. 1Mitsubishi Chemical
Medience, Ibaraki, Japan; 2Astellas Pharma, Osaka, Japan; 3Astellas Research
Technologies, Osaka, Japan; 4Asahi Kasei Pharma, Shizuoka, Japan; 5Biosafety
Research Center, Shizuoka, Japan; 6Food and Drug Safety Center, Kanagawa, Japan;
7Hokko Chemical Industry, Kanagawa, Japan; 8Ina Research, Nagano, Japan; 9Kao
Corporation, Tochigi, Japan; 10Kaken Pharmaceutical, Shizuoka, Japan; 11Kissei
Pharmaceutical, Nagano, Japan; 12Maruho, Kyoto, Japan; 13Mitsubishi Tanabe
Pharma, Chiba, Japan; 14Nissan Chemical Industries, Saitama, Japan; 15Shin Nippon
Biomedical Laboratories, Kagoshima, Japan; 16Suntory Business Expert, Kyoto, Japan;
17Taisho Pharmaceutical, Saitama, Japan; 18Toray Industries, Kanagawa, Japan;
19Yakult Honsha, Tokyo, Japan; 20National Institute of Health Sciences, Tokyo, Japan.
The repeated dose liver micronucleus (RDLMN) assay has a potential to detect
genotoxic hepatocarcinogens that can be integrated into a general toxicological
study. We have conducted a joint research in the Collaborative Study Group for the
Micronucleus Test (CSGMT) to investigate the inter-laboratory variability and sta-
ble data acquisition in the RDLMN assay, which is supported by 19 Japanese facil-
ities.  In order to evaluate the performance of the assay, 28 chemicals including he-
patocarcinogens were tested in 14- or 28-day RDLMN assays. As a result, the
RDLMN assay detected the 9 chemicals positive out of 10 hepatocarcinogens,
which were positive in the in vitro study while negative in the established bone-
marrow micronucleus test. Also, the RDLMN assay detected the 2 hepatocarcino-
gens positive, which were positive in the short-term bone-marrow micronucleus
test while negative in the 14- and 28-day repeated dose bone-marrow micronucleus
tests. Accordingly, the RDLMN assay is not only useful in detecting genotoxic he-
patocarcinogens but also appropriate for evaluation using a repeated low-dose regi-
men, and thus is considered ideal for integration into the general toxicity study.
2446 Acquisition of In Vivo Mutation and Cytogenetic Damage
Information to Support Cancer Risk Assessment.
S. Dertinger1,  S. Phonethepswath1,  J. Mereness1,  S. Avlasevich1,  D. Torous1,
J. Bemis1 and J. T. MacGregor2. 1Litron Laboratories, Rochester, NY; 2Toxicology
Consulting Services, Arnold, MD.
Assessing the mode of action of carcinogenic chemicals is a critical component of
cancer risk assessment. The US EPA’s Cancer Risk Assessment Guidelines stress the
importance of determining whether or not a chemical causes tumors through a di-
rect DNA-reactive mechanism, particularly in respect to the choice of an appropri-
ate quantitative model for the extrapolation of cancer risk to low doses. Weight of
evidence (WoE) approaches that rely heavily on data from in vitro hazard identifi-
cation assays are commonly used to address carcinogenic mode of action. In vivo
data needed to improve the WoE include both concordance analysis of temporal
mutation induction and dose-response concordance of mutation with tumor inci-
dence (e.g., Moore et al., Reg Toxicol Pharmacol 51:151-61, 2008). We used flow
cytometric methods to acquire such data and thereby to test and extend this hy-
pothesis. For example, male Sprague Dawley rats were treated for 28-consecutive
days with the genotoxic carcinogen melphalan at 0, 0.031, 0.094, 0.28 and 0.75
mg/kg/day, which included dose levels corresponding to 0.33x, 1x, and 3x the tu-
morigenic dose rate 50 (TD50). We assessed two endpoints of genotoxicity via low
volume blood draws in order to efficiently obtain temporal data within the tumori-
genic dosage range: MN-RET at days 4 and 29, and Pig-a gene mutation at days
15, 29, and 56. The earliest time points evaluated showed dose-related increases for
both endpoints, long before tumors or pre-neoplastic lesions would be expected.
These data illustrate the potential of these blood-based analyses to provide dose-re-
sponse and temporality information that relates genetic damage to cancer induc-
tion. Continuing studies will include additional genotoxic and non-genotoxic car-
cinogens and non-carcinogens to provide a deeper understanding of the
relationships between genetic damage and cancer induction.
2447 Axonal Degeneration of Chronic Organophosphate Ester-
Induced Delayed Neurotoxicity (OPIDN) Has Different
Features in Central and Peripheral Levels of the Nervous
System.
B. S. Jortner. Laboratory for Neurotoxicity Studies, Virginia PolyTech Inst State
University, Blacksburg, VA.
OPIDN is considered one of the toxicant-induced central-peripheral distal ax-
onopathies. The latter are characterized by degeneration of distal fibers in both the
central and peripheral regions of the nervous systems. This has been noted in a rat
model of long-term exposure to tri-ortho-tolyl phosphate (TOTP). In the present
report we explore a difference in the nature of the axonopathy in the peripheral and
central extensions of somatosensory fibers arising from neurons of dorsal root gan-
glia as seen in the sural nerve and spinal-medullary levels of the gracile fasciculus.
As reported earlier (Jortner et al., Toxicol. Pathol. 33:378) young adult male Long-
Evans rats were administered 14 TOTP gavage doses at 75, 150 or 300 mg/kg, over
a 63-day period. Sacrifice was on days 63 and 90 (after a 27 day recovery period).
OPIDN was manifest by TOTP dose-related diminished activity of brain neuro-
toxic esterase on day 63, and distal gracile fasciculus and peripheral nerve (includ-
ing sural nerve) myelinated fiber degeneration. In the present report we draw atten-
tion to a qualitative difference between lesions of central somatosensory myelinated
fibers in the distal levels of the gracile fasciculus and those in peripherally directed
sural nerve fibers. Axonopathy progressing to myelinated fiber degeneration was
seen in both regions, and was more florid in the gracile tract. In addition, promi-
nent dystrophic axons (Jellinger, Progr. Neuropathol.1973) were seen in the central
region, and were absent peripherally. Axon dystrophy is considered to reflect termi-
nal degeneration with retrograde progression, possibly due to aberrant regenera-
tion, synaptic dysplasia, failing terminal catabolism or transport. This varying
pathological response of myelinated fibers from the same neuronal population is
considered an effect of the differing (central vs. peripheral nervous system) environ-
ments on the evolution of axonal lesions in this chronic neurotoxic condition.
Supported by USAMRMC DAMD17-99-1-9489.
2448 Maternal Paraoxonase (PON1) Status Modulates Fetal
Effects Associated with Gestational Exposure of Mice to
Chlorpyrifos Oxon.
T. B. Cole1,  W. Li1,  A. Co1,  J. Marsillach1,  A. Hay1,  R. Richter1,
M. J. MacCoss1,  L. G. Costa1, 2 and C. E. Furlong1. 1Departments of Medicine,
Environmental and Occupational Health Sciences, Genome Sciences, and Center on
Human Development and Disability, University of Washington, Seattle, WA;
2Department of Neuroscience, University of Parma, Parma, Italy.
Paraoxonase-1 (PON1) status (PON1 level and presence of the Q192R polymor-
phism) is an important determinant of toxicity for chlorpyrifos (CPF) and its
metabolite, CPF-oxon (CPO). We examined whether maternal PON1 status influ-
ences fetal toxicity associated with gestational CPO exposure by comparing CPO
toxicity among PON1-/-, wild type (WT), and humanized transgenic mice ex-
pressing tgHuPON1R192 or tgHuPON1Q192.. Pregnant mice were exposed der-
mally to 0, 0.50, 0.75 or 0.85 mg/kg/d CPO from gestational days 6-17, and sacri-
ficed on day 18 to measure enzyme inhibition in maternal and fetal tissues and gene
expression in the GD18 fetal brain using Affymetrix microarrays. Fetal body
weights from the PON1-/- dams exposed to 0.75 mg/kg/d CPO were significantly
lower compared to vehicle controls. Pregnancy rate, number of resorptions and
presence of fetal abnormalities were not significantly different among treatment
groups in all genotypes. In the dams, repeated CPO exposure was associated with
inhibition of RBC acylpeptide hydrolase (APH), plasma carboxylesterase (CES),
plasma butyrylcholinesterase (BChE), and brain acetylcholinesterase (AChE).
Maternal tgHuPON1 had protective effects on inhibition of fetal brain AChE and
plasma CES, which were both inhibited only in PON1-/- fetuses. In fetal plasma,
BChE was inhibited in PON1-/- and tgHuPON1Q192, but not WT or
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tgHuPON1R192 mice, supporting the hypothesis that the R allele is more protec-
tive. The relatively high sensitivity of BChE to CPO inhibition is relevant for
human exposures. Using a mass spectrometric (MS)-based approach to identify
OP-adducted active-site serines in plasma BChE, we identified a monoethyl phos-
phoserine aged adduct in the plasma of exposed agricultural workers that is consis-
tent with CPF exposure. Supported by NIEHS ES04696, ES09883, ES07033,
ES09601/EPA-R826886.
2449 Comparative Effects of Parathion and Chlorpyrifos on
Extracellular Endocannabinoids: Influence on Cholinergic
Toxicity.
C. Pope1,  L. Parsons2 and J. Liu1. 1Physiological Sciences, Oklahoma State
University, Stillwater, OK; 2Committee on the Neurobiology of Addictive Disorders,
Scripps Research Institute, La Jolla, CA.
Parathion (PS) and chlorpyrifos (CPF) are organophosphorus insecticides (OPs).
Acute subcutaneous exposure to either can elicit extensive acetylcholinesterase inhi-
bition but cholinergic signs are relatively minimal following CPF compared to PS.
Endocannabinoids (eCBs, e.g., anandamide [AEA] and 2-arachidonoyl glycerol [2-
AG]) inhibit neurotransmitter release via presynaptic cannabinoid CB1 receptors.
Paraoxon and chlorpyrifos oxon, active metabolites of PS and CPF, can block CB1
receptor binding and inhibit eCB-degrading enzymes. We hypothesized that differ-
ential effects on eCB signaling play a role in selective toxicity. Male rats were treated
with vehicle, PS (27 mg/kg, sc) or CPF (280 mg/kg, sc) and toxicity evaluated 2
and 4 d later, just prior to insertion of hippocampal microdialysis probes and
dialysate collection. eCBs were evaluated by LC-MS/MS. PS-treated rats showed
extensive toxicity while CPF elicited few signs. AEA levels were elevated 2 and 4 d
following either CPF (≈ 4-fold) or PS (2-3 fold), while 2-AG levels were unaffected.
If eCB-mediated inhibition of neurotransmitter release influences OP toxicity,
blockade of CB1 receptors should alter functional responses. The CB1 antagonist
AM251 (3 mg/kg, ip, 1 or 3 daily doses) had no effect on CPF toxicity. In contrast,
a single dose of AM251 reduced PS-induced signs, and 3 daily doses further re-
duced toxicity. Although both CPF and PS can increase extracellular AEA levels,
eCB signaling only appears to influence the expression of PS toxicity. This interpre-
tation assumes an essential role for the CB1 receptor, whereas a number of recent
studies suggest non-classical cannabinoid receptors mediate some eCB actions.
CPF may potentially influence eCB signaling through a CB1-independent path-
way. Together, these results suggest that targeting the eCB signaling pathway may
have selective actions in the treatment of acute poisoning by different organophos-
phorus toxicants.
(Supported by NIEHS R01 ES009119)
2450 Developmental Exposure to Chlorpyrifos Increases
Accumulation of the Endocannabinoid Anandamide in the
Brain in the Absence of Cholinesterase Inhibition.
R. L. Carr,  C. A. Nail,  L. C. Mangum and M. K. Ross. Center for Environmental
Health Sciences, Mississippi State University, Mississippi State, MS.
Traditionally, chlorpyrifos (CPS) mediates its toxicity through inhibition of
cholinesterase (ChE). However, in recent years, the toxicological effects of develop-
mental CPS exposure have been attributed to an unknown non-cholinergic mecha-
nism of action. We hypothesize that the endocannabinoid system may be an im-
portant target because of its vital role in nervous system development. We have
previously reported that repeated exposure to CPS results in greater inhibition of
the fatty acid amide hydrolase (FAAH), the enzyme that metabolizes the endo-
cannabinoid anandamide (AEA), than inhibition of either ChE or monoacylglyc-
erol lipase (MAGL), the enzyme that metabolizes the endocannabinoid 2-arachi-
donylglycerol (2-AG). This exposure resulted in the accumulation of AEA in the
forebrain of juvenile rats, but even at the lowest dosage level used (1.0 mg/kg) ChE
inhibition was still present. Thus, it was not clear if FAAH activity will be inhibited
as dosage levels that do not inhibit ChE. To determine this, 10 day old rat pups
were exposed daily for 7 days to either corn oil or 0.5 mg/kg CPS by oral gavage. At
12 hrs post-exposure, the activities of ChE, MAGL, and FAAH were determined in
the forebrain, as well as the levels of the endocannabinoids AEA and 2-AG. There
was no significant inhibition of the activities of ChE or MAGL and no significant
change in the amount of 2-AG. In contrast, FAAH activity was significantly inhib-
ited resulting in a marked accumulation of AEA in the forebrain. Although it has
not been determined whether this alteration of endocannabinoid signaling can im-
pact brain maturation, it does suggest a potential candidate for the non-cholinergic
mechanism of action of CPS.
2451 Prenatal Dexamethasone Augments Neurobehavioral
Teratology of Chlorpyrifos.
E. D. Levin,  M. Cauley,  J. E. Johnson,  H. Sexton,  K. Gordon,  F. J. Seidler and
T. A. Slotkin. Psychiatry, Duke University Medical Center, Durham, NC.
Interactive effects of environmental toxicants and therapeutic drugs have received
little attention despite the fact that there is often simultaneous or sequential expo-
sure to these compounds. We evaluated whether dexamethasone, which is widely
used in preterm labor, augments the subsequent developmental neurotoxicity of the
organophosphate insecticide, chlorpyrifos. Pregnant rats were administered dexam-
ethasone on gestational days 17-19 at a dose (0.2 mg/kg) mimicking that used in
preterm labor; after birth the pups were given 1 mg/kg chlorpyrifos on postnatal
days 1-4, a regimen just above the threshold for barely-detectable cholinesterase in-
hibition. Dexamethasone and chlorpyrifos each caused significant locomotor hy-
peractivity in the figure-8 apparatus in male but not female offspring, assessed dur-
ing adolescence at 5 weeks of age. However, the group that received the combined
exposure showed greater hyperactivity than with either agent alone. In controls, fe-
males showed greater activity than males, and consequently, the elevation in males
with the combined exposure abolished the normal sex difference in locomotor ac-
tivity. Both dexamethasone and the combined treatment reduced habituation to
approximately the same degree. The combined exposure also had a greater effect on
novelty-suppressed feeding behavior, pointing to a greater level of anxiety. Our re-
sults indicate that prenatal exposure to glucocorticoids used in preterm labor could
create a subpopulation with enhanced vulnerability to developmental neurotoxi-
cants. (Support: USPHS ES010356)
2452 Oxidative Stress: A Mechanism-Based Biomarker of
Organophosphorus Pesticide (OP)-Induced Neurotoxicity?
S. N. Levoe1,  D. Bruun1,  S. Y. Gyu1,  E. Napoli1,  D. Milatovic2,  C. Giulivi1,
M. Aschner2,  K. M. Lattal3 and P. J. Lein1. 1Molecular Biosciences, University of
California Davis, Davis, CA; 2Pediatric Toxicology, Vanderbilt University, Nashville,
TN; 3Behavioral Neuroscience, Oregon Health & Science University, Portland, OR.
OPs are widely used in agriculture and industry, and their prevalence has prompted
concern for public and worker safety. However, predicting individuals at risk is
challenging because standard biomarkers of exposure (cholinesterase inhibition and
urinary metabolites) do not correlate well with neurotoxicity following chronic
low-level OP exposures. This may reflect the fact that mechanisms by which such
exposures cause neurotoxicity are independent of or in addition to cholinesterase
inhibition. We are testing the hypothesis that oxidative stress contributes to learn-
ing and memory deficits reported in individuals exposed occupationally to OPs. To
test this hypothesis, we are determining whether biomarkers of oxidative stress cor-
relate with learning and memory deficits caused by chronic exposure to the OP
chlorpyrifos (CPF) and whether treatment with antioxidants protects against
chronic CPF neurotoxicity. We are using a rat model based on exposure data col-
lected from 255 Egyptian agricultural workers responsible for applying CPF to cot-
ton fields. Our preliminary data indicate that exposure to CPF (10 mg/kg/d, s.c.)
for 21 d causes deficits in performance in contextual fear conditioning. This expo-
sure paradigm also causes decreased mitochondrial ATPase activity and increased
expression of PGE2 in the brain of CPF animals that precede the onset of behav-
ioral deficits. Preliminary studies also suggest that administration of the antioxidant
2-acetylcyclopentanone (2-ACP) attenuated oxidative stress; ongoing studies are in-
vestigating whether 2-ACP protects against the behavioral deficits caused by
chronic CPF exposure. If successful, these studies will not only identify a novel bio-
marker of effect for chronic OP neurotoxicity but also suggest novel approaches for
protecting workers occupationally exposed to OPs. Supported by NIH R01
ES016308.
2453 Interactions between Paraoxon and Polyhydroxyfullerenes
Chemically Defined.
G. Magnin-Bissel1,  Z. Zhou2 and M. Ehrich1. 1Virginia Tech, Blacksburg, VA;
2Luna NanoWorks, Danville, VA.
Polyhydroxyfullerenes decrease organophosphate (OP)-induced inhibition of
acetylcholinesterase (AChE) in vitro and moderate OP toxicity in vivo (Toxicol in
Vitro 25, 301, 2011; SOT abstract 2576, 2011; SOT abstract 942, 2012).
Mechanisms contributing to the interaction of OP compounds such as paraoxon
(PON) and fullerenes were evaluated. Formation of a covalent bond was ruled out
by monitoring the release of p-nitrophenol and the decrease in concentration of
PON by HPLC. Nuclear Magnetic Resonance (NMR) was used because hydroxy-
lated fullerenes are known to make aggregates in aqueous media and PON could be
trapped in these aggregates by non-covalent bonding resulting in host-guest inter-
actions. Complexation of PON with two hydroxylated fullerenes was examined
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after 15 min incubation with the C80 derivative containing gadolinium
(GdTMSOH) and a C70 derivative (C70-OH) without any metal. Proton-decou-
pled phosphorus (31P) NMR spectra were recorded on a Bruker Advance III 600
NMR instrument. The experiments with PON and the fullerenes were run in deu-
terium oxide with phosphoric acid 0.04% as an internal reference. Results for
GdTMSOH demonstrated a small upfield change in the chemical shift as the con-
centration of fullerene increased. However, due to strong interferences from the
metal, further studies were done with the C70-OH fullerene. Plotting the variation
its chemical shift versus the concentration of fullerene resulted in a binding
isotherm curve that reached a plateau at 0.03 mole/l. The binding constant (Kb)
calculated by dividing the intercept by the slope from the double reciprocal plot
was determined to be 19 (mole/l)-1. The results suggest that the fullerenes act in a
manner much like cyclodextrins, which have previously been shown to chemically
interact with OP compounds, decreasing their capability to inhibit AChE
(Carbohydrate Res. 345, 141, 2010; Euro J Med Chem. 40, 615, 2005; Toxicology
265, 96, 2010). Supported by the CounterACT Program, NIH OD and NINDS,
grant NS063723.
2454 Conditional Toxicity Value (CTV) Predictor for Generating
Toxicity Values for Data Sparse Chemicals.
J. Wignall1,  E. Muratov1,  D. Fourches1,  A. Tropsha1,  T. J. Woodruff2,
L. Zeise3,  N. Wang4,  D. Reif5,  V. Cogliano4,  W. A. Chiu4,  K. Guyton4 and
I. Rusyn1. 1University of North Carolina at Chapel Hill, Chapel Hill, NC;
2University of California San Francisco, San Francisco, CA; 3California EPA,
Oakland, CA; 4National Center for Environmental Assessment, US EPA, Washington
DC; 5National Center for Computational Toxicology, US EPA, Durham, NC.
Chemical hazard assessments necessarily vary based on data availability and the type
of risk management decision they support. While much recent attention has been
on use of high-throughput toxicological data for screening and prioritization, as-
sessments that support toxicity guidance values or standards still rely on epidemio-
logical and in vivo experimental data. Such assessments, including Integrated
Science Assessments and Integrated Risk Information System Toxicological
Reviews, are highly data-, time-, and resource-intensive, and cannot be realistically
expected for most environmental chemicals. Thus various stakeholders and expert
groups, including the National Research Council in Science and Decisions, call for
“default approaches to support risk estimation for chemicals lacking chemical-spe-
cific information.” This project aims to address this challenge through the
Conditional Toxicity Value (CTV) Predictor. This tool uses chemical properties
and limited experimental data to predict toxicity values, such as the reference dose
(RfD) and concentration (RfC), oral slope factor (OSF), inhalation unit risk
(IUR), or cancer potency value (CPV). CTV predictions combine QSAR, regres-
sion, and hybrid modeling, rely on a new comprehensive database of existing guid-
ance values and experimental data, and incorporate OECD principles for model
building and external cross-validation. QSAR models for predicting existing RfD
values (which span 7 orders of magnitude) had an R2 up to 0.46±0.07 and Mean
Absolute Error of 0.67±0.03 (Log10 mg/kg/day). A tool that can predict a toxicity
value within an order of magnitude fills a critical gap in the current risk assessment
/risk management paradigm. 
Disclaimer: The views expressed here are the authors’ and not necessarily those of
the US or California EPA.
2455 Application of the Threshold of Toxicological Concern
(TTC) Decision Support Approach to Antimicrobial
Pesticides.
R. Canady2,  T. McMahon1,  M. Cheeseman7,  C. Yang5,  S. Felter6,  A. Boobis4,
M. Martin3,  V. Dellarco1,  P. Price8,  M. Laufersweiler6 and K. Jacobs9. 1US EPA,
Washington DC; 2ILSI RF, Washington DC; 3US EPA, Research Triangle Park, NC;
4Imperial College London, London, United Kingdom; 5Altamira llc, Columbus, OH; 6
Procter & Gamble Company, Cincinnati, OH; 7Steptoe and Johnson, Washington
DC; 8Dow Chemical Company, Midland, MI; 9CFSAN, US FDA, College Park,
MD.
A tiered decision support approach has been developed to apply existing knowledge
of antimicrobial pesticides (AMs) to new AMs being considered for use. The ap-
proach is intended to inform product development and regulatory review processes
so that antimicrobial pesticides and pesticide products can be targeted early in de-
velopment and so that animal testing can be focused on those chemicals that need
the most attention.  Expert groups were convened comprised of scientists from
non-government organizations, industry, academia, and government. The experts
have 1) collected high quality data from studies submitted to EPA’s Office of
Chemical Safety and Pollution Prevention and the U.S. Food and Drug
Administration’s regulatory review files and entered the data into a publicly accessi-
ble data set using the structure and approach of EPA’s ToxRef Database; 2) devel-
oped a tiered decision framework for estimating systemic dose from dermal expo-
sures so that comparisons could be made to the oral toxicity data available; 3)
applied chemoinformatics techniques to evaluate whether and how to bridge the
AM data set to the 3 non-cancer TTC values of Munro et al (1996); 4) also used
chemoinformatics techniques to define classes of AMs within a TTC decision
framework, and 5) developed a decision tree to guide consideration of new AMs
with respect to likely toxicity for anticipated systemic dose of a given formulation
and the chemoinformatics class into which it falls. We will present the method for
data curation, chemoinformatics, rationale for the decision approach, and case ex-
amples of the use of the approach. This work will advance the science and practical
use of computational toxicology in support of risk management decision making.
2456 The Navigation Guide As an Evidence-Based Medicine
Methodology to Evaluate Human Health Effects of
Environmental Chemicals: Perfluorooctanoic Acid (PFOA)
and Fetal Growth.
E. Koustas1,  J. Lam1,  P. Sutton2,  P. Johnson2,  D. Atchley2,  S. Sen3,
K. Robinson4,  D. Axelrad1 and T. J. Woodruff2. 1Office of Policy, US EPA,
Washington DC; 2Program on Reproductive Health and the Environment, University
of California San Francisco, Oakland, CA; 3Epidemiology and Biostatistics,
University of California San Francisco, San Francisco, CA; 4Medicine, Epidemiology,
and Health Policy & Management, Johns Hopkins University, Baltimore, MD.
Rationale: Evaluating environmental health literature and determining the weight
of evidence are critical for informing policy and health recommendations. The
National Academy of Sciences has called for an enhanced systematic and transpar-
ent approach to risk assessment and scientific decision-making. The Navigation
Guide was developed through a collaboration of 22 scientists to improve methods
of research synthesis in environmental health. The methodology is based on best
practices in evidence-based medicine and environmental health sciences and aims
to systematically and transparently synthesize the evidence from toxicology and ob-
servational epidemiology studies. 
Approach: To establish proof of concept, we applied the Navigation Guide to the
question of the impact of exposure to perfluorooctanoic acid (PFOA) on fetal
growth. Steps include: (1) Specify the study question; (2) Select the evidence; (3)
Rate the quality and strength of the evidence. 
Findings: We identified 24 human observational and 21 animal toxicological stud-
ies relevant to the study question. Study quality was assessed using a modified ver-
sion of the Cochrane Collaboration’s Risk of Bias tool. Preliminary meta-analysis of
combinable studies suggests there may be small reductions in birth weight with in-
creased PFOA exposure in animals and humans. 
Implication: The case study illustrates that the Navigation Guide can be used to
apply the rigor of systematic review methodology to questions in environmental
health. As has been demonstrated in the clinical field, the adoption of a systematic
and transparent method to synthesize the scientific evidence in the environmental
health field would speed incorporation of research into decision-making.
2457 Incorporating Population Variability and Susceptible
Subpopulations into Dosimetry for High-Throughput
Toxicity Testing.
B. A. Wetmore1,  J. F. Wambaugh2,  H. J. Clewell1 and R. S. Thomas1. 1The
Hamner Institutes for Health Sciences, Research Triangle Park, NC; 2National Center
for Computational Toxicology, US EPA, Research Triangle Park, NC.
Xenobiotic clearance can vary widely across age-based or ethnic subpopulations due
to differences in metabolic enzyme abundances and activities. A strategy to measure
population-specific hepatic clearance values across a wide range of chemicals would
allow pharmacokinetic variability due to age, ethnicity, and other factors to be in-
corporated into in vitro toxicity screening data. Metabolic clearance of ToxCast
chemicals selected based on LC-MS method compatibility and exposure estimate
availability were measured in vitro using 13 cytochrome P450 (CYP) and 5 UDP-
glucuronosyltransferase (UGT) recombinantly expressed isoforms. Together with
plasma protein binding, these isoform-specific clearance rates were then incorpo-
rated into an in vitro-to-in vivo extrapolation (IVIVE) modeling tool, Simcyp. The
modeling tool accounts for known differences in isoform abundances among vari-
ous age- or ethnic-based subpopulations to estimate the daily oral dose for each
subpopulation, called the oral equivalent dose, necessary to produce steady-state in
vivo blood concentrations equivalent to in vitro AC50 values across the ~600
524 SOT 2013 ANNUAL MEETING
ToxCast endpoints. CYPs 3A4, 3A5, 2C9, and 2C19 were the most active enzymes,
contributing to the clearance of all of the chemicals tested. The subpopulation-spe-
cific oral equivalent dose values spanned ranges of 1.2 to 6.7-fold for the chemicals
assessed. For most chemicals, the oral equivalent dose values for pediatric subpopu-
lations fell closer to the estimated exposures than those derived for an adult popula-
tion. Generation of these age-specific oral equivalents also affords direct compari-
son to age-specific exposure estimates in USEPA regulatory documents. This study
demonstrates the feasibility and value of using isozyme-specific clearance data to
tailor dosimetric values for a wide range of subpopulations. This abstract does not
necessarily reflect EPA policy.
2458 Extrapolating In Vitro Embryotoxicity Data Toward In Vivo
Exposure Levels Using a Combined In Vitro-Physiologically-
Based Kinetic Modeling Approach.
M. Strikwold1, 2,  R. Woutersen1, 3,  B. Spenkelink1,  I. Rietjens1 and A. Punt1.
1Division of Toxicology, Wageningen University, Wageningen, Netherlands; 2Van Hall
Larenstein, University of Applied Sciences, Leeuwarden, Netherlands; 3TNO
Innovation for Life, Zeist, Netherlands.
In vitro assays play an important role in screening chemicals for their toxic potency
and prioritizing them for further toxicity testing. Most of these in vitro assays are
not suitable for a quantitative risk characterization as they lack in vivo kinetic
processes. To overcome this limitation, the present research aimed at combining in
vitro toxicity data with physiological based kinetic (PBK) modeling to predict in
vivo exposure levels. In order to contribute to the 3Rs principle for the replacement,
reduction and refinement of animal testing in the most optimal way the required
PBK models were developed on the basis of only in vitro and in silico data and data
available from literature. Phenol was selected as the model compound and the end-
point of interest concerns embryotoxicity. At first, the embryotoxicity of phenol
was evaluated in vitro using the embryonic stem cell test (EST), revealing a concen-
tration dependent inhibition of differentiation into beating cardiomyocytes. In a
second step, PBK models were developed for rat and human using in vitro derived
kinetic constants, in silico derived physico-chemical parameters and literature de-
rived physiological data. After evaluating the performance of the PBK models, the
in vitro concentration-response information from the EST served as an input in the
PBK model, thereby generating an in vivo dose-response curve from which a Point
of Departure for risk assessment could be derived. Finally, in vivo embryotoxic ef-
fect levels available from literature were used to evaluate this combined in vitro-
PBK approach. In summary, this study shows how combining different alternatives
to animal testing like in vitro toxicity testing and PBK modeling will enlarge their
application from screening and prioritizing of chemicals toward deriving safe expo-
sure levels for the risk assessment of chemicals.
2459 A Genomics-Based Determination of Relative Potencies of
Dioxin-Like Compounds in Primary Human Hepatocytes.
J. Rowlands1,  R. Budinsky1,  M. B. Black2,  R. D. Wolfinger3,  D. Cukovic4,
S. Salagrama4,  A. Dombkowski4 and R. S. Thomas2. 1The Dow Chemical
Company, Midland, MI; 2The Hamner Institutes for Health Sciences, Research
Triangle Park, NC; 3SAS Institute Inc., Cary, NC; 4Institute of Environmental Health
Sciences, Wayne State University, Detroit, MI.
Toxic equivalency factors (TEFs) for dioxin-like compounds are predominantly de-
rived from relative potency (REP) determinations of endpoints such as enzyme ac-
tivity from animal studies and in vitro studies in immortalized animal cells.
Currently, REPs based on gene expression changes have not been considered when
deriving TEF values. Moreover, data from humans and human cells are not in-
cluded in the REP database for deriving TEF values. In this study, primary human
hepatocytes were treated for 24 hours with 11 concentrations of 2,3,7,8-tetra-
chlorodibenzo-p-dioxin, 2,3,4,7,8-pentachlorodibenzofuran, or 2,3,7,8-tetra-
chlorodibenzofuran ranging from 0.00001-100 nM. Gene expression changes were
analyzed using ANOVA to assess the relative contributions of concentration, con-
gener, and the interaction between concentration and congener. A total of 1,443
genes showed significant changes with concentration (FDR < 0.05 and fold-change
+ 1.5 in at least one concentration for one congener).  Of these, 399 were signifi-
cant for both concentration and congener effects indicating parallel concentration
response curves with differences in potency. Pathway enrichment analysis was per-
formed on the 1,443 genes differentially expressed by concentration. The top 10
most enriched pathways included several nuclear receptors, immune response, and
cell adhesion pathways. A focused assessment of the benchmark dose values for sig-
naling pathways in the modes of action for DLC-induced effects can be used to de-
termine more relevant REPs used by the World Health Organization (WHO) to
derive TEF values. The addition of human cells to the WHO database could pro-
vide meaningful measures of relative potency and provide quantitative data to re-
duce TEF uncertainty in human health risk assessments.
2460 Aryl Hydrocarbon Receptor Mode-of-Action and Human
Relevance Framework for XDE-729 Methyl-Induced Rodent
Liver Effects.
D. L. Eisenbrandt2,  L. A. Murphy1,  N. J. Stagg2,  M. J. LeBaron1,
V. A. Marshall1,  A. T. McCoy1,  L. Kan1,  D. R. Boverhof1,  M. Bartels1,
R. Billington2 and R. J. Rasoulpour1. 1The Dow Chemical Company, Midland, MI;
2Dow AgroSciences LLC, Indianapolis, IN.
XDE-729 methyl, a novel herbicide in development, induces rodent liver enlarge-
ment, hypertrophy, and hyperplasia via an aryl hydrocarbon receptor (AhR) medi-
ated mode-of-action (MoA) with the following key events: 1) presystemic liver ex-
posure to XDE-729 methyl, 2) AhR activation with associated liver hypertrophy,
leading to 3) hepatocellular proliferation. For key event 1, low levels of XDE-729
methyl are present in the liver after dietary exposure; however, XDE-729 methyl is
rapidly metabolized in the liver to primarily XDE-729 acid, which is not an AhR
activator, and excreted in the urine. For key event 2, AhR activation, measured by
Cyp1a1 transcript induction occurred at dose levels of ≥ 50 mg/kg/day XDE-729
methyl and correlated with liver hypertrophy. For key event 3, hepatocellular pro-
liferation was observed with exposure to 261 mg/kg/day XDE-729 methyl. A
threshold for AhR activation and liver effects occurs at 10 mg/kg/day XDE-729
methyl, the no-observed-adverse-effect level (NOAEL) from the rat 90-day toxicity
study. Collectively, the data provides a high level of confidence that XDE-729
methyl induces rodent liver effects through an AhR-mediated MoA at doses ≥10
mg/kg/day XDE-729 methyl. The AhR pathway is conserved across species and
prototypical AhR ligands are activators of both human and rodent AhR; however,
human AhR binding affinity for prototypical AhR ligands is quantitatively lower
than rodent AhR. XDE-729 methyl is rapidly metabolized to XDE-729 acid,
which does not activate AhR, and does not bioaccumulate in the rat liver. XDE-729
methyl exposure does not result in sustained activation of the AhR pathway and he-
patic effects are transient and reversible. Based on the above, a margin of exposure
risk assessment using the 10 mg/kg/day NOAEL from the rat 90-day toxicity study
to derive the chronic reference dose/acceptable daily intake (cRfD/ADI) for XDE-
729 methyl is protective of human health.
2461 Estimation of Cumulative Risk from Exposure to Phthalates
Using NHANES Exposure Data and an In Vitro Potency
Assay.
P. Balbuena,  J. Campbell,  H. J. Clewell and R. A. Clewell. The Hamner Institutes
for Health Sciences, Research Triangle Park, NC.
Endocrine active phthalates reduce testosterone synthesis in fetal rat testes, interfer-
ing with male sexual development at high doses. As they share the same mode of ac-
tion, it is logical that a phthalate risk assessment should account for cumulative ex-
posure. Lack of potency data in vivo limits the derivation of a cumulative risk
estimate. We illustrate an approach using in vitro pharmacodynamic data together
with NHANES exposure estimates to predict human risk from multiple phthalates.
First, we developed a rat Leydig tumor cell line (R2C) in vitro assay to assess testos-
terone inhibition with several environmentally relevant phthalate metabolites:
monobutyl (MBP), monoethylhexyl (MEHP), monoethyl MEP), monomethyl
(MMP), monooctyl (MOP), monobenzyl phthalate (MBzP) and two oxidative
metabolites of MEHP (5-Ox-MEHP, 5-OH-MEHP). Effects of these chemicals on
steroidogenesis in vitro were highly consistent with in vivo studies. In vitro IC50
values were used to derive relative potency factors (RPFs) in relation to MBP. These
RPFs were used with the 2005 NHANES urine data to calculate relative risk esti-
mates for each phthalate at the 50th or 95th percentile (exposure). Estimates for in-
dividual phthalates were then combined to obtain a dibutyl phthalate (DBP) equiv-
alent risk estimate (mg DBP/kg/day). This in vitro predicted cumulative risk
estimate was then compared to the USEPA in vivo derived reference dose (RfD) for
DBP. At the 50th percentile DBP accounted for 8% of total exposure but repre-
sented 70% of the total risk of all phthalates. At the 95% however, the other ph-
thalates contributed more to the cumulative risk. Cumulative potency weighted ex-
posure for all phthalates was markedly lower than the USEPA RfD for DBP (0.1
mg/Kg BW/day), whether calculated for exposure at the 50th (0.0007 mg/kg/day)
or 95th (0.004 mg/kg/day). Margin of exposure was 148.5 and 27.4 for the 50th
and 95th percentile respectively. The analyses indicate the risk from exposure to ph-
thalates is below current RfDs, even considering multiple phthalates.
SOT 2013 ANNUAL MEETING 525
2462 Nonhuman Primate Sexual Maturity: What Is the Capacity
to Endure Uncertainty?
D. Blanset1,  D. M. Creasy2,  G. F. Weinbauer3,  J. L. Bussiere4,  K. P. Hatfield5
and J. S. Moffit1. 1Nonclinical Drug Safety US, Boehringer Ingelheim
Pharmaceuticals Inc, Ridgefield, CT; 2Huntingdon Life Sciences, East Millstone, NJ;
3Covance Inc, Muenster, Germany; 4Amgen Inc, Thousand Oaks, CA; 5US FDA-
CDER, Silver Spring, MD.
Evaluation of reproductive toxicity in regulatory studies relies on the use of sexually
mature animals. This often involves the use of nonhuman primates (NHP) when
lower order species are pharmacologically irrelevant. However, the decision on
whether to utilize mature NHP and the criteria used to establish sexual maturity is
anything but standardized. Several factors contribute to these differing opinions.
Sexual maturity can occur over a wide range of ages and body weights and histori-
cal methods of predicting sexual maturity have not always correlated with the
histopathological appearance of the gonads at necropsy. Evaluation of toxicity in
the reproductive organs of pre/peripubertal animals is often difficult, given that the
histology of the maturing reproductive organs may resemble the degenerative
changes induced by reproductive toxicants in the sexually mature adult. Finally,
there is a lack of consensus on the toxicological relevance and interpretation of the
various possible reproductive endpoints. All of these factors result in a complicated
balancing act: Ethically weighing the limited availability, high costs, and relevance
of incorporating sexually mature NHP in toxicology studies against effective and
meaningful evaluation of reproductive risks. This roundtable will discuss the chal-
lenges of assessing toxicity in immature vs. peripubertal vs. mature NHP, screening
methods for identifying sexually mature NHP, factors that influence sexual matu-
rity, and case studies where sexual maturity impacted the study interpretation.
Overall, this session seeks to provide an opportunity for stakeholders to review the
current state of the art and exchange views on appropriate paths forward to encour-
age ethical use of animals, while preserving appropriate risk assessments.
2463 Exposure Science in the 21st Century: Perspectives from the
NAS and What It Means for Toxicology.
L. S. Birnbaum1 and J. Orme-Zavaleta2. 1NIEHS, Research Triangle Park, NC; 2US
EPA, Research Triangle Park, NC.
In 2010, US EPA with additional support from NIEHS, requested the National
Academy of Sciences (NAS) to develop a long-range vision for exposure science in
the 21st century and a strategy for implementing this vision over the next twenty
years. Exposure science is the bridge between the sources of chemical, physical and
biological agents and ecological and human health. Exposure science is critical for
predicting, preventing, and reducing human health and ecosystem risks. The re-
port, Exposure Science in the 21st Century: A Vision and a Strategy, was released
September 7 by the NAS National Research Council. This report along with three
other NAS reports, Toxicity Testing in the 21st Century, Science and Decisions:
Advancing Risk Assessment and Sustainability and the US EPA, chart the future di-
rections for using innovative technology and scientific advances to better under-
stand environmental impacts on human and ecological health. The report outlines
a framework for advancing exposure science to study how humans and ecosystems
interact with chemical, biological, and physical agents in their environments. Key
visions in the report in are to develop a universal exposure-tracking framework with
a focus on preventing and mitigating adverse exposures. This will include the appli-
cation of systems science to understand and characterize exposures across time,
space, and biological scale.
2464 Regulatory-Based Nanotoxicology: Evolving National
Strategies, and Research to Address Engineered Nanomaterial
Health Risk Assessments.
W. K. Boyes1,  S. Nadadur2,  P. Sayre3,  V. Castranova4,  K. Dreher1,
P. C. Howard5 and D. B. Warheit6. 1ORD, US EPA, Research Triangle Park, NC;
2NIEHS, NIH, Research Triangle Park, NC; 3ORD, US EPA, Washington DC;
4NIOSH, CDC, Morgantown, WV; 5NCTR, US FDA, Jefferson, AR; 6Haskell
Global Centers, DuPont, Wilmington, DE.
Engineered nanomaterials are increasingly being developed and incorporated into a
variety of products and applications. However, the full development of nanotech-
nology is hampered by an uncertainty regarding their environmental, health and
safety implications, and how these issues will be addressed by responsible regulatory
agencies at the federal and state levels. Novel nanoscale materials present a number
of scientific and technical challenges for assessing their potential health implica-
tions including: exposure and material characterization; adequacy of conventional
toxicity testing methods/guidelines; dose metric(s) across the exposure-dose-effects
paradigm; and the role of alternative testing approaches to assess their toxicity. This
session will bring together scientists from scientific advisory bodies, regulatory
agencies and the private sector to present/discuss research needs, strategies, ap-
proaches and findings regarding the health effects testing of engineered nanomate-
rials and nano-enabled products as it relates to regulatory mission(s). Key topics in-
clude: assessing nanomaterial toxicity for regulatory and risk assessment
applications; the status or role of alternative test methods to screen or prioritize
nanomaterials for in vivo toxicity testing, and the extent to which harmonized test-
ing can be achieved for these novel materials. Each speaker will have 10-12 minutes
to highlight agency/institutional approaches and regulatory actions regarding the
potential for health effects from engineered nanomaterials. The session will con-
clude with a 15 minute general discussion period.  The overall goal is to provide
participants with a view of the status of the development of nanomaterial toxico-
logical assessments that would be sufficient to evaluate health and safety for regula-
tory agencies.
2465 Toxicological Writing for Industrial and Regulatory
Audiences.
C. J. Amuzie1, 2 and M. La Merrill3. 1Department of Pathology, MPI Research,
Mattawan, MI; 2Department of Pathobiology and Diagnostic Investigations,
Michigan State University, East Lansing, MI; 3Department of Preventive Medicine,
Mount Sinai School of Medicine, New York, NY.
Excellence in scientific and technical writing leading to high-quality publications, a
skill set developed and refined from graduate training through early career in toxi-
cology, is one key trait that can lead to a successful career as a toxicologist. Some ac-
ademic institutions have programs that support scientific and technical writing for
their staff. However, the majority of toxicologists (80%) are employed outside aca-
demia, predominately within biopharmaceutical and chemical industries, govern-
ment, and contract research organizations. Graduates from academic programs that
train in writing might acquire skills related to preparation of dissertations, grant
proposals, and manuscripts for scientific peer-reviewed journals. The skills acquired
from this training, when existent, does not necessitate a smooth transition to a suc-
cessful career outside academia. Thus early-career toxicologists are sometimes un-
aware of, or otherwise unprepared for, technical writing assignments that occur in
industrial and regulatory toxicology. In addition, different writing skills are re-
quired for clear and concise communication of toxicological results to nontoxicolo-
gist stakeholders. Therefore, an interactive workshop that evaluates the challenges
presented by, and the skills required for, toxicological writing outside academia will
be of great use to the majority of graduate students, postdoctoral trainees, and
early-career toxicologists. Four speakers from the pharmaceutical industry, the
chemical industry, a government regulatory agency, and a contract research organi-
zation will review the type(s) of technical writing required within their setting.
Notably, they will extensively highlight common mistakes and discuss valuable
strategies and tools to avoid these mistakes through interactive exercises using pro-
vided writing examples.
2466 From Immunotoxicity to Nanotherapy: The Effects of
Nanomaterials on the Immune System.
M. J. Smith1, 2,  D. R. Germolec3 and N. J. Walker3. 1Pharmacology and Toxicology,
Virginia Commonwealth University, Richmond, VA; 2ImmunoTox, Inc, Richmond,
VA; 3National Toxicology Program, Research Triangle Park, NC.
The potential for human exposure to the diverse and ever-changing world of nano-
materials has raised concerns about the ability of these materials to influence health
and disease. The small size of nanomaterials makes them a prime target for interac-
tion with the cells of the immune system. Exposure to nanomaterials (inhalation,
dermal, oral, parenteral) can affect multiple components of the immune system.
For example, a single respiratory exposure to titanium dioxide nanoparticles can
significantly increase the antibody-forming cell response to sheep erythrocytes, sug-
gesting the possibility of nanomaterial interactions with lymphocytes and/or anti-
gen-presenting cells. Furthermore, the cells of the innate immune system, including
mast cells and the cells of the mononuclear phagocytic system, are also potential
targets following nanomaterial exposure. A varied spectrum of effects, including in-
flammation, hypersensitivity, and immunomodulation, may then occur, via mech-
anisms which have yet to be elucidated. While incidental exposure may be undesir-
able, nanomaterials and nanomedicines engineered for various clinical applications
provide opportunities to develop therapies that may or may not intentionally target
the immune system. The interplay between nanomaterials and the immune system
and the pharmacokinetic and phenotypic responses that result from these interac-
tions are therefore critical factors that dictate the balance between toxicity and clin-
ical efficacy of nanomedicines.
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2467 Overview of Concepts and Strategies Needed for Assessing
the Safety of Nanoscale Materials.
N. J. Walker. National Toxicology Program, NIEHS/NIH, Research Triangle Park,
NC.
In recent years there has been considerable research examining the potential utility
of nanoscale materials and nanostructures in commercial and biomedical applica-
tions. Nanoscale materials (nanomaterials, nanoparticles), are a broadly defined set
of substances that have at least one critical dimension less than 100 nanometers.
The same novel chemical and physical properties that make nanomaterials useful
also make their interactions with biological systems difficult to predict and evaluate
in traditional toxicity models. The diversity in composition, size, surface coatings,
and physico-chemical properties even within classes of “similar” nanomaterials can
make translation of findings from one nanomaterial to another problematic. On
the other hand though, testing of each nanomaterial individually and what change
in a physicochemical property constitutes creation of a “new “ material, remains
uncertain. Over the past years there has been considerable effort looking at devel-
oping guidance for assessing safety of nanomaterials. Some of the key considera-
tions include; effective characterization of physicochemical properties of nanomate-
rials not only in the bulk phase but also within the toxicological test system; use of
in vitro biological responses and shorter term in vivo studies of panels of nanoma-
terials to develop structure activity relationships for predicting hazard and guide
prioritizing further targeted in depth testing; development of best practices to re-
duce potential interference of a nanomaterial with the test systems.
2468 Molecular Dynamics Simulations with Advanced Sampling
Techniques to Study Nanoparticle-Membrane Interactions.
M. A. Philbert2,  P. Elvati1,  K. A. Russ2 and A. Violi1. 1Mechanical Engineering,
University of Michigan, Ann Arbor, MI; 2Toxicology Program, University of
Michigan, Ann Arbor, MI.
Classical toxicology assessments consider bulk transport of particulate matter into
discrete organelles of living cells as the primary means of nanoparticle (NP) toxic-
ity. However, little is known about the potential of low-level exposure to alter bio-
physical functions (membrane form/function). Atomistic simulations, such as mo-
lecular dynamics (MD), can provide mechanistic information that is hard to
measure experimentally. They may be used to validate theories derived from indi-
rect experimental analysis, but the results of MD simulations are meaningful only if
the run is long enough to visit all energetically relevant configurations. Well-tem-
pered metadynamics can accelerate system dynamics allowing the analysis of
processes that can take several seconds or hours to occur in real systems. Classically
biased MD simulations were used to reconstruct the free energy landscapes of the
mechanisms of NP entry into biological cells, thus accelerating the sampling of rare
events and allowing exploration of potentially new biologically relevant reaction
pathways. Results show that pristine C60 resides preferentially in the aliphatic re-
gion of the lipid bilayers composed of POPC and cholesterol. With increasing cho-
lesterol concentration, the minimum of the free energy profile moves towards the
interface with water, showing a tendency of C60 to move away from the membrane
center. C60 motility inside the hydrophobic region is not limited by any relevant
thermodynamic barriers at body temperature, but the energetic cost to leave the
membrane is system-dependent and varies from 10 to 20 kβT. Charges (C602-) or
hydroxyl groups (C60(OH)24) make the region where the lipid heads are solvated by
water the most favorable position for these species. These studies make plausible the
potential for intramembranous mechanisms of NP toxicity in immune and other
mammalian cells. Supported by ES08846, NIEHS NCNHIR U01 (MAP), CBET
0644639 (AV), 1 U02 ES020128-01 (KR), T32-ES007062-26 (KR).
2469 Evaluating the Local and Systemic Immunomodulatory
Effects of Nanomaterials.
M. J. Smith1, 2,  D. R. Germolec3,  C. E. McLoughlin1, 4,  W. Auttachoat1 and
K. L. White1, 2. 1Pharmacology and Toxicology, Virginia Commonwealth University,
Richmond, VA; 2ImmunoTox, Inc, Richmond, VA; 3National Toxicology Program,
Research Triangle Park, NC; 4Biomedical Engineering, Virginia Commonwealth
University, Richmond, VA.
The small size of nanomaterials (NM) makes them a prime target for interaction
with the immune system following their uptake, processing, and presentation to
lymphocytes by antigen-presenting cells. Traditional in vivo testing strategies have
been used to evaluate NM-mediated immunotoxicity. The varied routes of expo-
sure to NM (dermal, oral, inhalation, parenteral), as well as particle size, can pro-
duce differing immune effects, including contact hypersensitivity as well as local or
systemic effects. For example, a single pharyngeal aspiration of anatase TiO2
nanoparticles (< 25 nm) produced an enhanced antibody-forming cell response to
sheep erythrocytes, while TiO2 microparticles (< 45 μm) produced no such effect.
Subcutaneous, but not dermal, exposure to anatase nano-TiO2 for 3 days increased
cell proliferation in the draining lymph nodes, while oral exposure for 28 days was
non-immunotoxic. Inhalation of 1.0 and 0.05 μm C60 fullerene for 13 weeks did
not affect the systemic immune response, although inflammatory cytokines (MCP-
1, MIP-1α) in the bronchoalveolar lavage fluid were increased for the 1.0 μm C60
only. Subcutaneous implantation of sub-micron electrospun biodegradable poly-
caprolactone materials in the ventral quadrant for 28 days had minimal effects on
the immune system, suggesting that this material may have the potential for use in
a variety of clinical applications. Nanomedicines intended for clinical applications
unrelated to the immune system must be examined for the possibility that they
might produce unintentional or unanticipated immune effects. However, depend-
ing upon the application (e.g. local anti-inflammatory drug delivery), effects on the
immune system may be desirable.
2470 Mast Cell Directed Nanomaterial Toxicity.
J. M. Brown1,  X. Wang1,  R. Urankar2,  C. J. Wingard2 and P. Katwa1.
1Pharmacology & Toxicology, East Carolina University, Greenville, NC; 2Physiology,
East Carolina University, Greenville, NC.
Concern about the use of engineered nanomaterials (ENMs) has increased signifi-
cantly in recent years due to potentially hazardous impacts on human health. Mast
cells are critical for innate and adaptive immune responses, often modulating aller-
gic and pathogenic conditions. Mast cells are well known to act in response to dan-
ger signals through a variety of receptors and pathways including IL-33 and the IL-
1 like receptor ST2. We have examined the involvement of mast cells and the
IL-33/ST2 axis in pulmonary and cardiovascular responses to ENMs including
multi-walled carbon nanotubes (MWCNT) and silver nanoparticles (AgNP). We
have utilized C57BL/6 mice, mast cell deficient mice (KitW-sh), KitW-sh mice re-
constituted with wild-type or ST2-/- mast cells and ST2-/- mice to assess systemic
and pulmonary inflammatory responses as well as cardiac ischemia-reperfusion (IR)
injury responses following ENM exposure. In addition, we have used an in vitro
mast cell model to screen for the ability of ENMs to directly induce mast cell de-
granulation. We have found that mice with normal mast cell populations
(C57BL/6 and mast cell reconstituted KitW-sh), exhibit significant ENM directed
systemic and pulmonary inflammation, fibrosis, altered lung function and exacer-
bated IR injury. In contrast, these toxicological effects of ENMs were not observed
in mice deficient in mast cells (KitW-sh) or mice with mast cells unable to respond
to IL-33 (ST2-/- mast cell reconstituted KitW-sh mice). Lastly, we have established
that certain ENMs are capable of inducing mast cell activation in vitro. Our find-
ings establish for the first time that mast cells and the IL-33/ST2 axis orchestrate
adverse immune effects to ENMs giving insight into a previously unknown mecha-
nism of toxicity and providing a realistic therapeutic target. The use of mast cells
and the IL-33/ST2 axis as a screening tool for ENM toxicity and in the preclinical
development of nanomedicines will be discussed.
2471 Phenotypically Profiling the Factors Affecting the
Pharmacokinetics and Pharmacodynamics of Nanoparticle
Agents in Preclinical Models and in Patients.
W. Zamboni,  W. Caron,  G. Song,  P. Kumar,  J. Lay and P. Gehrig. Eshelman
School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Sponsor: M. Smith.
Carrier-mediated agents consist of nanoparticles, nanosomes (nanoparticle sized li-
posomes) and conjugates. The theoretical advantages for using carrier-mediated
drugs, including increased drug solubility, prolonged duration of exposure, selective
delivery of entrapped drug to the site of action, and improved therapeutic index.
Pegylated nanosomal formulations contain lipid conjugated to polyethylene glycol.
The disposition of encapsulated drug is dictated by the composition of the carrier,
thus altering the pharmacokinetic (PK) profile of the drug. A proposed clearance
pathway of carrier agents is the monocytes and macrophages of the mononuclear
phagocyte system (MPS). Our studies suggest there is a bi-directional interaction
between nanosomal agents and the MPS. However, potential factors associated
with clearance of carrier agents in patients and preclinical animal models have not
been extensively evaluated. Standard allometric scaling approaches for nanosomal
agents did not scale across all species. In addition, preliminary studies suggest that
there is high variability in the function of the MPS in animal models and in pa-
tients. Thus, new methods for allometric scaling and measures of MPS function
need to be developed for carrier-mediated agents. In addition, the most appropriate
animal models for toxicology and pharmacology of carrier agents needs to be iden-
tified. Novel methods for phenotypically profiling the factors affecting the pharma-
cokinetics and pharmacodynamics of nanoparticle agents in preclinical models and
in patients will be presented.
SOT 2013 ANNUAL MEETING 527
2472 Modeling Human Genetic Variability and Susceptibility in
the Laboratory.
R. Woychik1 and D. Threadgill2. 1NIEHS, Research Triangle Park, NC; 2North
Carolina State University, Raleigh, NC.
Within a population of genetically heterogeneous individuals, a range of responses
is observed for environmental exposures. The observed variability in response is at-
tributable to extrinsic and intrinsic factors, including individual differences in ex-
posure to environmental stressors and genetic/epigenetic heterogeneity, respec-
tively. Current risk assessment practice is to account for interindividual variability
with default uncertainty factors (e.g., a ten-fold decrease in allowable exposure to
protect the most sensitive subpopulations), even though these defaults are seldom
supported by scientific evidence. Advances in exposure science and molecular ge-
netics are greatly increasing our ability to characterize intrinsic differences among
individuals in their exposure and response to toxicants. This symposium highlights
several novel and exciting approaches in safety evaluation that utilize recent ad-
vances in genetics. First, recent collaborative efforts in the complex traits commu-
nity have led to the development of several new, powerful mouse resources that
greatly facilitate the identification of allelic variants of genes associated with differ-
ential response to toxic exposure through genotype-phenotype associations.
Second, several laboratories, including the National Toxicology Program, have
begun applying these new mouse models of human population diversity to studies
on the molecular mechanisms of interindividual variability in chemical metabolism
and toxicity. Third, the ability to generate induced pluripotent stem (iPS) cells from
population-derived human cell resources, as well as the availability of embryonic
stem (ES) and iPS cells from mouse strains, makes it possible to conduct in vitro
studies to investigate interindividual differences in resistance and susceptibility to
xenobiotic exposures. Ultimately, these new approaches should greatly enhance our
ability to characterize variability in response to toxicants and to identify those genes
and pathways that contribute significantly to the observed differential responses to
environmental exposures in humans.
2473 Modeling Genetic Heterogeneity to Understand
Susceptibility to Chemical Combinations: A Mouse
Population-Based Study Using Trichloroethylene (TCE) and
Inorganic Arsenic (iAS).
D. Threadgill. North Carolina State University, Raleigh, NC.
Using the results of a recent mouse population-based study that investigated via
dose response curves the differential toxicity to TCE and iAS singly and in combi-
nation, this presentation illustrates how genetic heterogeneity can be modeled to
understand individual susceptibility to combinations of chemicals. The results
demonstrate that these chemicals can elicit additive and synergistic toxicities in sus-
ceptible individuals. Furthermore, the target organs in the genetically heteroge-
neous mouse populations are similar to those in humans, indicating that suscepti-
bility alleles in the mouse population model will inform on human susceptibility.
2474 The Use of Population-Based Inbred Panels and Diversity
Outbred Mouse Models to Explore Individual Variability and
Toxicity to Benzene.
J. E. French. Division of the National Toxicology Program, NIEHS, Research Triangle
Park, NC.
Benzene is hematotoxic, genotoxic, and tumorigenic to the lymphohematopoietic
systems in both laboratory animals and humans. Results from NTP population-
based mouse model studies show significant individual variability in benzene
ADME/TK and levels of DNA damage at human relevant exposures. The results of
these studies illustrate how individual variability in genetically defined populations
may be used to identify genetic variants associated with differences in toxicokinet-
ics, resistance or susceptibility to a toxicant, and to identify causally related mecha-
nisms of toxicity. Benchmark dose models can be used on quantitative data to de-
termine a reference dose that will aid in the quantification of uncertainty factors
and, possibly, eliminate default assumptions in risk assessment. In additions, by
identifying multiple genetic variants through genotype-phenotype associations
with significant size effects, networks and pathways may be predicted that are sta-
tistically anchored to toxicity phenotypes and functionally-validated through the
use of recombinant inbred mice (Collaborative Cross) cell-based assays, in vivo tar-
geted testing, and molecular biology using reverse genetics. Across species extrapo-
lation is enhanced by identifying variants that are orthologous between mouse and
human and if there are associated in orthologous networks or pathways. In combi-
nation with high-throughput and high content assays validated by in vivo targeted
testing, these new tools will provide a new paradigm for toxicology and exposure re-
lated diseases.
2475 Modeling Genetic Variability in Response to Environmental
Toxicants Using Mouse ES Cells In Vitro.
T. Choi. Predictive Biology, Inc., Carlsbad, CA.
A genetically diverse panel of ES cell lines have been produced from inbred, F1, and
outbred mice, and this panel has been used to investigate the role of strain back-
ground on variable response to environmental toxicants. An example of such a
study is an investigation of how genetic background and environmental factors in-
teract in the onset or severity of arrhythmia, and how these interactions may be in-
volved in the cardiotoxicity of environmental toxicants. The ultimate goal is to dis-
cover novel mechanisms, targets, and chemical structures underlying variability in
cardiotoxic response. The approach is to conduct large scale, high throughput in
vitro screens using cardiomyocytes derived from genetically diverse ES or iPS cells
to interrogate gene x toxicant interactions in vitro. Toward this end, a large panel of
genetically diverse mouse ES lines as well as an automated beating assay performed
in 384 well plate format for time domain analysis of arrhythmia have been devel-
oped. Data based on testing reference compounds of known arrhythmogenic po-
tential in ES derived cardiomyocytes support the validity of this approach.
2476 The 1, 000 Genomes In Vitro Toxicology Project:
Quantitative High-Throughput Screening for Chemical
Toxicity in a Population-Based In Vitro Model.
I. Rusyn. University of North Carolina at Chapel Hill, Chapel Hill, NC.
A series of collaborative studies between the Tox21 consortium and the University
of North Carolina have been conducted in which inter-individual variability in ex-
posure response is being assessed in a population-wide human in vitro model. These
experiments have generated quantitative high-throughput cytotoxicity data on
about 200 chemicals in over 1000 cell lines representing 9 populations from 5 con-
tinents and all major racial groups. This rather simple toxicity phenotype of cyto-
toxicity can be leveraged with other molecular data (genotyping and transcript pro-
filing) available on the same cell lines through the HapMap and 1000 Genomes
consortia and applied to human health assessments.
2477 Opportunities and Challenges to Incorporating Genetic
Variability Data in Risk Assessment.
W. A. Chiu. US EPA, Washington DC. Sponsor: R. Tice.
This presentation discusses how the new approaches and data sources on genetic
variability described by the previous speakers will fit into a changing risk assessment
landscape in the 21st Century. Key opportunities include the direct estimation how
genetic variability contributes to susceptibility to toxicants and the identification of
key biological pathways that confer differential susceptibility. However, some im-
portant challenges remain, such as inter-species and in vivo-in vitro extrapolation
and, especially, the integration of genetic variability with other sources of human
variability. [Disclaimer: The views in this presentation are those of the author, and
do not necessarily reflect the views or policies of the U.S. Environmental Protection
Agency.]
2478 Role of Air Pollution As a Risk Factor for Central Nervous
System Diseases and Disorders.
D. A. Cory-Slechta. Environmental Medicine, University of Rochester Medical
School, Rochester, NY.
Increasing evidence suggests that many of the adverse consequences of air pollu-
tants extend beyond the lungs and indeed can target the brain where they produce
many of the same types of inflammatory and other adverse consequences as docu-
mented in the lungs. Such findings have been variously described in experimental
models for exposures such as the metal constituents of the ultrafine particulate mat-
ter of air pollution, for diesel exhaust and for ozone. Both direct effects via con-
stituents of air contaminants translocated to the CNS and indirect effects via in-
duction of systemic acute phase responses have to be considered. In addition,
epidemiological studies have now begun to report associations of traffic- and com-
bustion-related air pollutants with cognitive deficits in children. While our under-
standing of the extent of such impacts is still quite limited, these highly provocative
findings could suggest that air pollution has been a greatly underappreciated risk
factor for neurodevelopmental or neurodegenerative diseases. This symposium will
present findings from experimental models describing the CNS toxicity of concen-
trated ultrafine particles in adults and in postnatally-exposed rodent models in rela-
tion to neurodevelopmental and neurodegenerative consequences, and of ozone in
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the context of Parkinson’s disease. In addition, recent epidemiological findings link-
ing residential proximity to freeway with autism will be presented. The intent of the
symposium is to stimulate discussion especially in the context of future research
needs in this rapidly emerging area of neurotoxicology which requires a multidisci-
plinary approach involving expertise in the toxicology of the CNS, air pollution,
mixtures, and nanoparticles in order to conduct appropriate risk assessment.
2479 CNS Consequences of Postnatal Exposure to UFP.
D. A. Cory-Slechta and J. L. Allen. Environmental Medicine, University of
Rochester Medical School, Rochester, NY.
Accumulating evidence suggests that air pollutants can induce inflammation and
oxidative stress in the brain and that early development may be a period of particu-
lar vulnerability to such exposures.  Epidemiological studies report associations be-
tween air pollutant exposure and impaired cognitive function in children and
adults and attention deficit in children. Our studies seek to determine the effects of
developmental and/or adult concentrated ambient particulate matter (CAPS) expo-
sure on cognitive behaviors and their potential CNS mechanisms. C57Bl6 mice
were exposed to AIR or CAPS during early postnatal life with or without adult
challenge, yielding 4 groups: Air/Air, Air/CAPS, CAPS/Air and CAPS/CAPS.
Behavioral measures included repeated learning, a fixed ratio wait for reward para-
digm related to impulsivity (males only), Fixed Interval schedule-controlled behav-
ior and locomotor behavior. Learning accuracy was significantly impaired after
CAPS/Air and CAPS/CAPS exposures, particularly in females, even though ability
to perform already-learned responses remained intact. In the fixed ratio wait for re-
ward paradigm, CAPS/AIR and CAPS/CAPS decreased the time animals would
wait for free reward deliveries, and thereby resulted in emission of a greater number
of responses for reach reward earned. Response rates on the fixed interval schedule
were reduced in CAPS/AIR males but increased in Air/CAPS females. Notably, as
measured at the termination of behavioral testing, i.e., almost a full year after the
adult exposures, histopathological hallmarks of CNS perturbation, namely as-
trogliosis and increased microglial presence, were seen in multiple brain regions, in-
cluding dentate gyrus and ventral midbrain and increased glutamate and GABA
was prevalent in frontal cortex of both sexes. Current efforts focus on understand-
ing the relationships between inflammatory and neurotransmitter changes and be-
havioral outcomes. Exposure to CAPS appears to have long-term consequences for
the CNS. As such, air pollutants may represent an underappreciated contribution
to CNS disease and disorders.
2480 Microglia and the Peripheral Immune Response in Diesel
Exhaust-Induced Neuropathology.
M. L. Block. Anatomy & Neurobiology, VCU, Richmond, VA.
Air pollution has been linked to central nervous system (CNS) disease, but the
mechanisms driving this response and the type of exposures responsible are largely
unknown. To discern the early CNS response to diesel exhaust (DE), adult male
rats were exposed to DE (2.0, 0.5, and 0 mg PM/m3) for one month by inhalation.
DE exposure elevated markers of neuroinflammation (nitrotyrosine, IL-6, TNFα,
and MIP-1α) in the midbrain, cortex, and olfactory bulbs, in addition to activation
of microglia, as determined by morphology. The highest levels of neuroinflamma-
tion occurred in the midbrain, which also contained the highest level of the IBA-1
microglial marker. Neurotoxicity and early markers of neurodegenerative disease
were unaffected. One month exposure to biodiesel exhaust revealed only changes in
microglia morphology without any elevation of pro-inflammatory factors, demon-
strating that neuroinflammation may be exposure specific. To reveal how DE might
be causing neuroinflammation, rats were administered an IT bolus of DE particles
(DEP, 20 mg/kg) where DEP exposure elevated serum and brain TNFα, suggesting
a potential role for the particles in initiating peripheral inflammation capable of
transferring to the brain. Microglia cultures treated with DEP (50μg/ml) failed to
produce TNFα, indicating that brain TNFα production may not be due to the di-
rect interaction of microglia with the particles. To explore the role of long-term ex-
posure, we tested the effect of subchronic (6 month) DE (992, 311, 100, 35 and 0
μg PM/m3) inhalation in rats and found elevated levels of the neurotoxic cytokine
TNFα at lower exposures (DE, 100 μg PM/m3) and early protein markers of neu-
rodegenerative diseases (Aβ42, α synuclein and phosphorylated tau) at higher lev-
els (DE 992 μg PM/m3), suggesting that subchronic DE exposure may impinge on
common neurodegenerative disease pathways. Together, these findings demonstrate
that the brain’s immune system can detect and respond to DE and support that cir-
culating cytokines (or another peripheral signal) may play a role in how neuroin-
flammation transfers to the brain.
2481 Particle Translocation As an Explanation for the Adverse
Effects of Inhaled Particulates in the CNS.
A. Elder. Environmental Medicine, University of Rochester, Rochester, NY.
The hypothesis that air pollution can adversely impact the central nervous system
(CNS) is supported by the demonstration of gene-environment interactions for
neurodegenerative disorders, such as Alzheimer’s and Parkinson’s diseases. The
mechanisms by which this might occur are not fully understood, but may include
transport of particulates into the brain, thus resulting in direct delivery of toxicants
to the target tissue. Transport via the olfactory route, for example, has been demon-
strated for poorly-soluble ultrafine or nanosized particles (<100 nm in diameter in
at least one dimension) and for some soluble compounds following inhalation ex-
posures. However, other pathways have been identified and the contribution of
these to the overall accumulation in the CNS is unclear. Likewise, the contributions
of particle physicochemistry and blood-brain barrier integrity are important to ad-
dress in order to understand the long-term consequences to CNS health. Such con-
sequences have been explored in recent research. Using a mouse model of
Alzheimer’s disease, we found that a 12-day inhalation exposure to poorly-soluble
manganese oxide nanoparticle aerosols resulted in the activation of hippocampal
microglia and astrocytes, suggesting activation of an innate immune response in the
brain. Interestingly, this activation persisted for two months post-exposure.
Increased immunostaining for amyloid beta and a loss of synaptophysin staining
were also found. These data contribute to the growing evidence for an association
between environmental exposures and neurodegenerative disease progression.
2482 Does Air Pollution Exposure Increase Risk for Autism?
I. Hertz-Picciotto1,  H. E. Volk2 and R. S. McConnell2. 1MIND Institute & Center
for Children’s Environmental Health, University of California Davis, Davis, CA;
2Center for Children’s Environmental Health, University of Southern California, Los
Angeles, CA. Sponsor: D. Cory-Slechta.
Windham et al. (2006) reported that children with autism were more likely to live
in census tracts with higher ambient levels of diesel, certain metals, and solvents.
Traffic is a major source of air pollution, including particulates, polycyclic aromatic
hydrocarbons, metals, sulfur dioxide and nitrogen oxides. Proximity to freeways
and major roadways is highly correlated with ambient levels of such traffic-related
air pollution. Using data from the CHARGE (CHildhood Autism Risk from Genes
and Environment) Study, we examined the association between autism and prox-
imity of residence to freeways and major roadways during pregnancy and near the
time of delivery, (Volk et al 2011). Using data from 304 autism cases and 259 typi-
cally developing controls, the mother’s address recorded on the birth certificate and
trimester-specific addresses obtained by questionnaire were geocoded, and measures
of distance to freeways and major roads calculated with ArcGIS software. After ad-
justment for sociodemographic factors and maternal smoking, mothers of cases
were more likely, at the time of delivery, to live within a quarter mile of a freeway as
compared with mothers of controls: odds ratio (OR) = 1.86. At greater distances,
risk was not elevated. Autism was also associated with residential proximity to a
freeway during the third trimester (OR = 2.22). For each address, exposures to spe-
cific air pollutants from traffic and stationary sources were estimated with U.S.
EPA’s Air Quality System (Volk et al, in press). Exposures to nitrogen dioxide
(NO2) and particulate matter less than 2.5 and 10 μ in diameter (PM2.5 and
PM10) in the first year of life were associated with about a two-fold increased risk
for autism (NO2 OR=2.06; PM2.5 OR=2.12; PM10 OR=2.14), with similar find-
ings for gestational exposures. Given that many constituents in air pollution induce
neurodevelopmental deficits in experimental rodent studies, a contribution from
air pollution to autism susceptibility is plausible.
2483 Ozone Pollution, Oxidative Stress, and Dysregulation of
Inflammatory Responses in Rat Hippocampus.
S. Rivas-Arancibia. Fisiología, Facultad de Medicina, Universidad Nacional
Autónoma de México, México City, Mexico. Sponsor: D. Cory-Slechta.
The oxidizing compounds contained in the air that we breathe in the large cities, is
related to a large number of chronic degenerative diseases. To study the effects of
ozone pollution on the brain, we developed a model consisting in a chronic expo-
sure of rat to ozone doses, similar to total levels that occur in a day of high pollution
in Mexico City. For this purpose, 84 male Wistar rats (250 to 300 gr) were ran-
domly divided into 7 groups, each group received one of the following treatments:
1) control, 2) exposed to ozone free air for 30 days, 3) exposed to ozone for 7 days,
4) exposed to ozone for 15 days, 5) exposed to ozone for 30 days, 6) exposed to
ozone for 60 days, and 7) exposed to ozone for 90 days. (0.25 ppm /4 hours daily).
Two hours after the last exposure to ozone, each group was randomly divided into
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two subgroups, hippocampus were dissected and afterward processed for immuno-
histochemistry. The second subgroup was used for western blot and spectrophoto-
metric techniques (to determine lipid peroxidation, oxidized proteins, superoxide
dismutase and glutathione). The results indicate that ozone, causes an increase in
lipids and proteins oxidation after 15 days of exposure. After 30 days we found in
the hippocampus damage and decrease of the neuroblasts, and neurons number,
glial activation, increased of proinflammatory markers, together with changes in
levels of antioxidant defenses and loss of its enzymatic activity. Results also showed
accumulation of deposits of amyloid beta (Aβ) 1-42 at 90 days exposure. In con-
clusions: ozone lead to oxidative stress causing a neurodegenerative process in hip-
pocampus, together with, dysregulation of immune responses, and loss of brain to
capacity repair, and Aβ 1-42 plaques formation at 90day of ozone exposure. These
experiments showed that chronic exposure to ozone at low doses, per se, is able to
cause an oxidative stress state, which produces progressive cellular damage and cell
death that resembling the damage described in the physiopathology of neurodegen-
erative diseases. 
Grant DGAPA IN 219511
2484 Translational Methods to Assess the Safety of Natural Health
Products, Including Traditional Medicines and Dietary
Supplements.
J. C. Griffiths1 and S. A. Jordan2. 1Doc Standards, US Pharmacopeia, Rockville,
MD; 2Marketed Health Products, Health Canada, Ottawa, ON, Canada.
Globally, ~80% of the world’s population relies upon traditional medicines as part
of standard healthcare; ~100 million Americans spend ~$28 billion annually to
consume herbals, vitamins, minerals, amino acids, and other naturally occurring
products in the form of dietary supplements, botanical drugs, and natural health
products. The complexity of mixtures with variance in composition and quality
presents a challenge for risk practitioners. To address these issues, new methodolo-
gies and predictive technologies are being developed, tested and validated to miti-
gate risk of human toxicity and effectively increase the quality of information useful
for application in safety assessments. Many of these methods are already reflected in
multiagency government initiatives. Such methods are referred to as “translational”
for making use of and extrapolating data from scientifically defensible approaches
towards establishing human safety and use of viable products. In this symposium,
various in vitro, in vivo, state-of-the-art in silico (computational), and ‘omic
methodologies will be presented. Discussion will cover case studies and regulatory
science activities at US FDA/CDER and NCTR including conventional toxicolog-
ical and computational assessments of individual chemical constituents and mix-
tures. Computational tools to deconvolute complexities and predict molecular tar-
gets for constituent phytochemicals will also be highlighted. Speakers will also
address how the United States Pharmacopeia (USP) conducts evidence-based re-
views on the safety of dietary supplements and how to couple data from in silico
structure-based methods to compliment and strengthen evidence and support com-
mittee-based human expert decision making regarding the suitability of dietary
supplements for monograph development on product quality. Collectively, these
presentations will provide a global picture of the state and utility of modern meth-
ods for assessing toxicity and safety of these products.
2485 Session Overview: The Promise of Translational and
Integrative Safety Assessments of Dietary Supplements,
Traditional Medicines, and Herbal Drugs.
S. A. Jordan. Marketed Health Products, Health Canada, Ottawa, ON, Canada.
For thousands of years, herbs and other natural substances have been used in health
care. Some traditional healing paradigms include knowledge of potential toxicity,
and ways of preventing adverse effects. However, with modern use, a much larger
and varied population now uses these products. In addition, commercial products
may not be true to traditional use, indication, or form. A rise in use of these prod-
ucts with pharmaceutical drugs, resulting in possible herb-drug interactions, also
has become an issue of concern. Potential safety concerns may also arise from qual-
ity issues. Regulators are often faced with a lack of quality information when mak-
ing risk-based decisions on the safety of dietary supplements or traditional medi-
cines, and an increase in these data allows for improved decision making. The
development of translational methods, including omics, and computational mod-
els, has presented an opportunity to increase the amount of information, and to in-
tegrate novel data with traditional methods of assessing toxicity. The integration of
all available data, including those derived from translational studies, can reduce un-
certainty in decision making related to the potential hazard and risk associated with
the use of these product types. Overall, this will benefit the public, the industry,
and the regulatory community which is charged with licensing and monitoring the
safety of dietary supplements and traditional medicines.
2486 In Silico Methods As Translational Tools for Supporting the
Safety Assessment of Natural Health Products.
L. G. Valerio. CDER/Office of Pharmaceutical Science, US Food & Drug
Administration, White Oak, MD. Sponsor: J. Griffiths.
In silico methods including computational toxicology can serve to help address data
gaps during safety evaluations for regulatory and industrial product safety. Natural
health products including dietary supplements, botanicals, herbals, and related sub-
stances can benefit from the wide spectrum of scientific evidence produced by in
silico toxicology analyses. Discussion will cover case studies and regulatory science
activities in the application of structure-based computational assessments of indi-
vidual chemical constituents derived from natural products and mixtures modeling.
Translation of these data to support human safety and risk assessment processes will
be presented. The in silico approach as a translational tool with emerging evidence-
based predictive technologies and the use of these methods in applied safety science
is of extraordinary heightened interest with the goal of meeting today’s needs for
protecting public health.
2487 In Vitro and In Vivo Approaches for Assessing the Safety of
Natural Health Products.
W. F. Salminen. NCTR-Center for Hepatotoxicology, US Food & Drug
Administration, Benton, AR.
Dietary supplement use continues to increase as many people see these “natural”
products as inherently safe alternatives to drugs. However, in the US and many
other parts of the world, dietary supplements require none to minimal safety data
before they are marketed. Many dietary supplements are complex mixtures of a
wide variety of chemical compounds and the composition can vary greatly from
manufacturer to manufacturer and even batch to batch making safety assessments
very difficult. Various in vitro and in vivo approaches for assessing the safety of di-
etary supplements from classical toxicology studies to state-of-the-art toxicoge-
nomics assessments will be reviewed. An overview of the US National Toxicology
Program’s (NTP) testing of dietary supplements will be presented and examples of
potential drug-dietary supplement interactions will be discussed since these are
likely to increase as people use dietary supplements in combination with approved
drugs.
2488 Computational Methods Linking Traditional Chinese
Medicine (TCM) and Western Therapeutics.
D. E. Johnson. Molecular Toxicology, University of California Berkeley, Berkeley, CA.
Herbal remedies are widely used throughout the world with approximately 80% of
the global population relying on traditional medicines as part of standard health-
care. In the US, an estimated 1 in 5 adults regularly consume herbal products and
most of these are not included in patient records as “other medications”, thereby
limiting the understanding of potential herb-drug interactions to both the patient
and health care professional. We have been using computational tools to deconvo-
lute complex recipes and predict molecular targets for constituent phytochemicals
with the goal of forming a comprehensive tool to help predict herb-drug interac-
tions. This work will be illustrated using both open-source tools and commercial
biological pathway mapping and predictive algorithms. Translational methodology
will be introduced that proposes a chemical-disease category linkage between TCM
and Western medicine for a rational integrative medicine approach.
2489 Herbogenomics As a Translational Method for the Safety
Assessment of the Complex Mixtures in Traditional Chinese
Medicines.
Y. Kang. Department of Pharmacology and Toxicology, University of Louisville School
of Medicine, Louisville, KY.
Natural health products, including traditional Chinese medicines (TCMs) are
often complex mixtures. Assessing the safety of individual components of such
products is problematic. The use of TCM has raised concerns of heavy metal con-
tamination and toxicity. However, it has been known that metals and metalloids are
essential components in some TCM preparations. For instance, mercury in
cinnabar is irreplaceable for its therapeutic effect. Another scenario is that the TCM
formulation is toxic to healthy population, but becomes remedy to seriously sick
people. In this context, the dose regiment of arsenic trioxide used to treat acute
promyelocytic leukemia (APL) is extremely toxic to general population, but is of
high therapeutic efficacy for APL patients. It is difficult, if not impossible, to dis-
tinguish metal composition from metal contamination in TCM and their associ-
ated therapeutic or toxic effects. A novel approach of herbogenomics can provide
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alternate perspectives on the active ingredients and toxic contaminations of TCM.
The overall effects of TCM on target organs can be elucidated by functional ge-
nomics and proteomics, thus the addition or subtraction of heavy metals from
TCM preparations would affect the outcome, which can be reflected by the ge-
nomic profile alterations. The information about metal composition and contami-
nation is critical for general population considering the use of TCM as an alterna-
tive remedy.
2490 Evidence-Based Reviews As a Method for Assessing the Safety
of Dietary Supplements.
M. L. Hardy. Center for Integrative Medicine, University of California Los Angeles,
Los Angeles, CA. Sponsor: J. Griffiths.
Dietary supplement safety is one of the main regulatory concerns in the United
States. Adverse events occur for a variety of reasons including contamination,
misidentification or adulteration of plant based dietary supplements. However,
even when a product is correctly made, adverse events in human subjects have been
reported. Systematic review and meta-analysis of published clinical trials and ad-
verse event case reports allow aggregation of disparate reports in order to improve
the analytic strength of evaluations of potential harms. When adverse events are re-
ported in properly randomized clinical trials, causality of the reported adverse event
can be assumed. Clinical trials are almost always of insufficient power to detect any
but the most common adverse events. Rare or serious adverse events are usually re-
ported in as case reports or small case series. Attribution of risk in this case is lim-
ited by a number of factors including timing and duration of exposure to suspected
offending substance as well as the clinical circumstances of the user. Although
causality can rarely be attributed based on case reports, systematic review of aggre-
gated cases can identify a suspicious signal. Additional limitations of all sources of
adverse event reports are the result of incomplete information including very often
poor characterization of the potential offending material. The application of these
principles will be illustrated using an analysis of adverse events related to ephedra.
2491 Are We Like Rodents, Rabbits, or Something Else?
Mechanisms of Developmental and Reproductive Toxicity
across Species.
R. J. Rasoulpour1,  K. Johnson3,  S. N. Campion2,  C. Timchalk4 and
J. E. Goodman5. 1The Dow Chemical Company, Midland, MI; 2Pfizer Global,
Groton, CT; 3Alfred I duPont Hospital for Children, Wilmington, DE; 4Pacific
Northwest National Laboratory, Richland, WA; 5Gradient, Cambridge, MA.
Given the inherent complexity of embryo/fetal development and reproductive biol-
ogy, developmental and reproductive toxicity (DART) hazard identification and re-
search still heavily relies on animal models. Typically, this type of research is con-
ducted in rodents (e.g., mouse and rat) as well as nonrodent species (e.g., rabbit and
nonhuman primate), which, in the face of toxicity findings, raises the question of
relevance to humans. Are we more like mice, rats, or other model organisms? Not
surprisingly, answering this question is a challenge, and the scientific approach may
be quite different depending upon the biological system and the level of mechanis-
tic information available. However, within this challenge is an opportunity to un-
derstand the toxicokinetic and toxicodynamic differences between the species and
provide the appropriate context for developmental and reproductive findings.
Providing this context can directly impact the risk assessment and regulatory deci-
sion-making process. This workshop will highlight several different approaches to
relate animal reproductive and developmental toxicity findings to human health.
Speakers in fields of basic research, product safety testing, epidemiology, and phys-
iologically-based pharmacokinetic modeling will address the central theme of the
workshop, which is applying different experimental strategies to analyze cross-
species toxicity. Within each presentation, potential regulatory implications and
feedback from agencies, when available, will be addressed. The expected outcomes
of the workshop are an increased understanding of the different approaches to dis-
sect complex toxicity mechanisms and to take the next step towards cross-species
comparisons that impact human relevance and regulatory decisions.
2492 Challenges in Elucidating Developmental Toxicity
Mechanisms in the Context of Guideline Safety Assessment
Studies.
R. J. Rasoulpour. Developmental and Reproductive Toxicology, The Dow Chemical
Company, Midland, MI.
This presentation will provide a case study on unique challenges often posed by elu-
cidating developmental toxicity mechanisms identified within guideline toxicity
studies. The case study will focus on a recently identified novel mechanism of rat-
specific developmental toxicity induced by a developmental molecule, sulfoxaflor.
At high doses, neonatal death and limb flexure effects occurred in rats, but not rab-
bits. The proposed mode-of-action was that these effects had a single mechanism
mediated via the rat fetal isoform of the muscle nicotinic acetylcholine receptor.
The studies included a combination of novel in vivo and in vitro mechanistic stud-
ies, which were integrated to identify agonism on this receptor as a critical event.
Moreover, species comparison studies revealed that that this initial event was iso-
lated to sustained agonism on the rat fetal isoform of the nicotinic acetylcholine
muscle receptor and did not occur in humans. Feedback on this project from global
regulatory agencies will be presented and discussed. This stage-setting talk provides
a clear example of how human relevance can be understood if the toxicity is medi-
ated by a relatively simple mechanism (e.g., agonism at a single receptor).
2493 Endocrine Disruption Mediated Developmental Toxicity in
Mice versus Rats: Implications for Humans.
K. Johnson. Alfred I duPont Hospital for Children, Wilmington, DE.
This presentation will examine the mechanisms behind phthalate-induced fetal
testis endocrine disruption in mouse and rats and extrapolation of these rodent data
to humans. It will analyze the species-sensitivity of phthalate endocrine disruption
and compare these responses to those observed after phthalate exposure of human
biological samples. In rats, gestational phthalate exposure produces male reproduc-
tive tract malformations (including hypospadias and cryptorchidism) via a phtha-
late-induced reduction of fetal testis insulin-like 3 and testosterone production.
Although the phthalate molecular target is unknown, extensive molecular mecha-
nistic studies in the rat have established reduced Leydig cell steroidogenic gene ex-
pression as causal for the inhibition of testosterone production. In contrast to the
rat, available data for mouse gestational phthalate exposure indicate this species is
resistant to inhibition of fetal testis hormone production. Despite mouse gesta-
tional phthalate exposure extensively altering the fetal testis gene expression profile
and inducing fetal testis histopathology, no reductions in mouse fetal Leydig cell
steroidogenic gene expression are evident. Because in vitro models do not recapitu-
late the fetal testis/Leydig cell endocrine disruption phenotype, the question of
human susceptibility has been addressed with experiments using human fetal testis
explants xenografted into rodent hosts. In these experiments, phthalate exposure of
host animals harboring rodent fetal testis explants recapitulates the rodent in vivo
phenotypes, and human fetal testis xenografts respond similarly to mouse fetal testis
xenografts. While histopathology is observed in the human fetal testis xenografts,
reductions in fetal testis testosterone production or steroidogenic gene expression
are not seen. These xenografts data have important implications for current and fu-
ture regulatory decisions but are not without caveats. The potential regulatory im-
pact and caveats of these experiments will be presented.
2494 Case Studies on Testis Toxicity in Rodent Models and Risk
Management Strategies.
S. N. Campion. Pfizer Global, Groton, CT.
This presentation will provide case examples of testis toxicity findings in regulatory
studies for pharmaceutical development. For some of these examples, strategies
used to elucidate the mechanisms of toxicity in order to put these findings into per-
spective for human risk assessment will be described. One of these case studies will
focus on mechanistic work performed to determine that the adverse findings noted
in rats were the result of a species specific mechanism that is not relevant in hu-
mans. A second case study will discuss work performed to elucidate the binding tar-
gets of a compound that elicits testis toxicity in rodents. While there are some ex-
amples of mechanistic work to de-risk testis issues with pharmaceuticals,
mechanistic work is not commonly performed since the toxicity is often due to off-
target effects of small molecules. In addition, the impact of the time required to
perform mechanistic work to a program’s timeline often makes this work unfeasi-
ble. Alternative approaches to understanding the impact of the toxicity in order to
develop human health risk management strategies will be discussed, including eval-
uating the safety margin as well as the intended use of the drug (e.g., indication, pa-
tient population, duration of treatment). Marketed drugs with testicular toxicity
findings in nonclinical studies will be discussed to provide a perspective of the tol-
erance of regulatory agencies to such findings. In general, there is a higher tolerance
for male reproductive toxicity findings with pharmaceuticals relative to environ-
mental chemicals because the benefit of the pharmaceutical exposure is considered
relative to the risk when determining the impact of findings in preclinical studies.
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2495 Physiologically-Based Pharmacokinetic/Pharmacodynamic
Modeling of Developmental Toxicity.
C. Timchalk. Pacific Northwest National Laboratory, Richland, WA.
The developing brain is vulnerable to insults and evidence implicates low-level
chemical exposures as potential developmental neurotoxins. Organophosphorus
(OP) insecticides, like chlorpyrifos (CPF), inhibit cholinesterase (ChE) and are
neurotoxic. PBPK/PD models have been exploited to enable cross-species extrapo-
lation of CPF brain dosimetry and ChE inhibition and when linked with a dietary
exposure model can predict response across populations. However, recent epidemi-
ology studies suggest that OP neurotoxicity occurs at low-doses, even in the absence
of significant brain ChE inhibition. The lack of quantitative cross-species brain
dosimetry data associated with epidemiology results hampers any mechanistic
based risk assessments. The implication of localized heterogeneous CYP450 brain
metabolism has historically not been extensively investigated, but recent research
suggests it is of key importance. To address these limitations, we are testing the hy-
pothesis that low-dose exposures of preweanling rats to OP insecticides will result
in differential brain region dosimetry, enhanced by localized brain bioactivation,
potentially resulting in subtle changes in brain chemistry. Comparative in vitro me-
tabolism studies in rats indicate that the overall brain microsomal metabolism was a
fraction (~3%) of the liver. Following in vivo oral administration (1 and 5
mg/kg/day) of CPF to post-natal day-10 pups, CPF and its major metabolite were
quantified in the brain with evidence of regional deposition and localized metabo-
lism. The importance of localized brain metabolism is highly relevant for lipophilic
pesticides that sequester in the lipid rich regions of the brain and can undergo lo-
calized metabolic activation to produce neurotoxic effects. This is particularly im-
portant in juvenile animals, and children, where there may be a disproportionate
deposition of the parent pesticide in the brain. In this regard, these PBPK/PD mod-
eling strategy have significant regulatory implications for assessing developmental
neurotoxicity.
2496 Using Epidemiology to Analyze Neurodevelopmental
Toxicity across Species.
J. E. Goodman. Gradient, Cambridge, MA.
The final presentation of the session will tackle cross-species analysis from a differ-
ent angle by utilizing epidemiology data. This presentation will explore how epi-
demiology studies can address toxicity across species by estimating human expo-
sures and/or outcomes with biomarkers and putting these into context with the
animal model results. It will focus on how the effect of timing, selection choice, and
measurement of biomarkers, as well as the results of toxicology studies, can influ-
ence the interpretation of results. Chlorpyrifos and neurodevelopmental effects will
be used as a case study. US EPA assessed whether epidemiology data suggest that
fetal or early-life chlorpyrifos exposure causes neurodevelopmental effects and, if so,
whether they occur at exposures below those causing 10% inhibition of blood
acetylcholinesterase (AChE), which is currently considered the most sensitive end-
point. We conducted a hypothesis-based weight-of-evidence analysis and found
that a proposed causal association between chlorpyrifos exposure and neurodevel-
opmental effects in the absence of AChE inhibition does not have a substantial
basis in existing animal or in vitro studies, and there is no plausible basis for invok-
ing such effects in humans at their far lower exposure level. The epidemiology stud-
ies fail to show consistent patterns; the few associations are likely attributable to al-
ternative explanations. The human data are inappropriate for a dose-response
assessment because biomarkers were only measured at one time point, may reflect
exposure to other pesticides, and many values are at or below limits of quantifica-
tion. When considered with pharmacokinetic data, however, these biomarkers pro-
vide information on exposure levels relative to those in experimental studies and in-
dicate a margin of exposure of at least 1,000. Because animal data take into account
the most sensitive lifestages, the use of AChE inhibition as a regulatory endpoint is
protective of adverse effects in sensitive populations.
2497 Cumulative Risk: Toxicity and Interactions of Physical and
Chemical Stressors.
J. Simmons1 and C. Rider2. 1NHEERL, US EPA, Research Triangle Park, NC;
2NTP, NIEHS, Research Triangle Park, NC.
Recent efforts to update cumulative risk assessment procedures and develop com-
munity-based risk assessment methods reflect increased interest in incorporating
the totality of variables affecting human health into the risk assessment process.
One key roadblock in advancement is uncertainty as to how nonchemical stressors
behave in relationship to chemical stressors. An assumption that simplifies incorpo-
ration of nonchemical stressors into current risk assessment paradigms is that non-
chemical stressors act in the same manner as chemicals. However, evidence is re-
quired to support this assumption. The term nonchemical stressors encompasses a
diverse set of variables including physical stressors, such as noise, temperature, dis-
ease, and radiation, as well as psychosocial stressors, which involve perception of
circumstances. Physical stressors offer a reasonable starting place for measuring the
effects of nonchemical stressors and their modulation of chemical effects (and vice
versa), as they clearly differ from chemical stressors, present many diverse and
highly-relevant stressors, and “doses” of many physical stressors are easily quantifi-
able. There is a commonly held belief that virtually nothing is known about the im-
pact of nonchemical stressors on chemical-mediated toxicity or the joint impact of
coexposure to chemical and nonchemical stressors. While generally true, there are
several instances where a substantial body of evidence exists. The objective is to pro-
vide expert overviews, for those chemical and physical stressors that have been suf-
ficiently studied to gain at least a limited understanding of their joint impact. In ad-
dition to providing the current state of knowledge, data gaps will be identified that
should be addressed to facilitate inclusion of nonchemical stressors in risk assess-
ment. (This abstract does not reflect US EPA or NIEHS policy.)
2498 Cumulative Risk: Chemicals and Infectious Disease.
M. Selgrade. ICF International, Durham, NC.
At least 4 types of mechanisms underlie potential interactions between toxic chem-
icals and infectious disease. 1) The best understood is suppression of immune re-
sponses, resulting in increased incidence/severity of infectious disease. For example,
decreased alveolar macrophage function following exposure to several air pollutants
enhances the risk of certain bacterial infections. Research on this model provides
both qualitative and quantitative approaches to describe this risk. 2) Certain im-
mune/inflammatory mediators that are activated during infection affect metabolic
enzymes and transporters and have the potential to alter chemical toxicity as illus-
trated by the effects of murine cytomegalovirus on parathion poisoning, sodium
pentobarbital induced sleeping time, and cyt P450. Infection and inflammation
have also been shown clinically to affect the metabolism, distribution, and elimina-
tion of certain drugs. 3) Chemical exposure may enhance inflammation and im-
mune pathology associated with an infection. This is best illustrated by effects of
ozone, ultraviolet radiation, and TCDD on influenza infection. In all cases mortal-
ity is enhanced in the absence of increased virus titers in the lung or viral dissemi-
nation. Deaths appear to be due to increased inflammatory responses. Similarities
exist between receptors and subsequently triggered signaling pathways for pathogen
associated molecular patterns (PAMPs) and damage associated molecular patterns
(DAMPS), which trigger inflammatory responses. A systems approach that exam-
ines the integration of these pathways is needed to better describe this phenome-
non. 4) Infection enhances chemical induced lesions, e.g., p53 mutations, inflam-
mation, cell proliferation. Such mechanisms might explain the interaction between
hepatitis B virus infection and aflatoxin in the induction of liver cancer. These
mechanisms are not necessarily comprehensive, distinct, or mutually exclusive and
are imperfectly understood. However, they provide a useful framework to further
explore the interactions between infectious disease and exposure to toxic chemicals
with the ultimate goal of improving our understanding of cumulative risk.
2499 Enhancement of Noise-Induced Hearing Loss by Chemicals.
T. C. Morata. Division of Applied Research & Technology, NIOSH, Cincinnati, OH.
Sponsor: J. Simmons.
The auditory effects of chemical toxicants have been investigated in the past two
decades, in animal and human field and clinical studies. A number of studies
demonstrated that some solvents, metals, asphyxiants, pesticides not only affect the
sensory organ of the auditory system, as noise does, but also affect central auditory
structures. Ototoxicity induces outer hair cell dysfunction in the cochlea (similar to
the effects of noise), whereas neurotoxicity induces central auditory dysfunction.
Audiological signs of neurotoxicity may or may not include poorer hearing thresh-
olds, in addition to difficulties discriminating sounds such as speech, particularly in
adverse listening conditions. The existing evidence prompted the proposal of new
guidelines and standards on hearing loss prevention. In the U.S., the National
Institute for Occupational Safety and Health has discussed specific research needs
regarding the ototoxicity of chemicals used at work. The American Conference of
Governmental Industrial Hygienists and the U.S. Army have proposed preliminary
practical steps that employers and occupational health professionals can take to im-
prove hearing loss prevention. Australia and New Zealand have developed stan-
dards recommending hearing tests for workers exposed to ototoxic agents. In the
legislative arena, the European Parliament published a new noise directive
(2003/10/EC), that requires employers to give attention to any effects on workers’
health and safety resulting from interactions between noise and work-related oto-
toxic substances, when performing risk assessment of workplaces. Legislation re-
garding compensation has also changed in Australia and Brazil . In this presentation
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the auditory effects of chemical alone or in combination with noise will be re-
viewed, and the recent guidelines, legislative developments and alternative strategies
for the prevention of auditory effects resulting from exposure to chemicals in the
workplace will be presented.
2500 Exacerbation of Toxicity of Air Pollutants and Pesticides by
Thermal Stress.
C. J. Gordon,  C. Aydin and A. F. Johnstone. Toxicity Assessment Division, US
EPA, Research Triangle Park, NC.
Considering the likelihood of global warming in the near future, it is important to
understand how heat stress will alter the health effects of toxicants. The toxicity of
pesticides and airborne toxicants is generally exacerbated in a warm environment.
As air temperature increases, the pulmonary intake of air pollutants and absorption
of pesticides applied to the skin is generally accelerated. Cellular toxicity is typically
exacerbated when body temperature is elevated. This is primarily a result of a Q10
effect, meaning that the rate of a biochemical reaction doubles with a 10 °C increas
in tissue temperature. The generation of reactive oxygen species is also exacerbated
with warmer temperatures. 
Since warmer temperatures worsen chemical toxicity, a thermoregulatory response
to lower body temperature can be protective. Hyperthermia is most likely going to
be detrimental in the recovery from toxicant exposure. Rodents and other small
mammals have relatively large surface area:volume ratio. Following exposure to pes-
ticides and air pollutants, metabolism is reduced and a rapid reduction in body
temperature ensues. If given the opportunity to thermoregulate behaviorally, ro-
dents seek colder temperatures, allowing body temperature to decrease quickly.
Thus, the hypothermic response is a regulated response. This is thought to be an
adaptive response because the hypothermic response is protective. Large mammals,
including humans, have a greater thermal inertia and are unable to mount a hy-
pothermic response as is seen in rodents. A warmer environmental temperature will
thus impede the hypothermic response to toxicant exposure in rodents and will also
be stressful to large mammals that are unable to undergo a significant cooling re-
sponse. With the potential impact of global climate change on increased incident of
heat stress in urban areas that are also rife with pollution, the topic of the ther-
moregulatory responses to environmental toxicants is timely. This is an abstract of a
proposed presentation and does not reflect US EPA policy.
2501 Modulation of X-Ray Mediated Testicular Toxicity by
Chemical Exposure.
K. Boekelheide. Brown University, Providence, RI.
High density microarrays and a detailed bioinformatics analytical approach were
used to demonstrate that an initial chemical exposure to 2,5-hexanedione (HD) al-
tered the rat testis to ameliorate the response to a subsequent exposure to x-irradia-
tion. Adult male rats were exposed to HD (0.33% or 1%) in the drinking water for
18 days followed by x-ray (2Gy or 5Gy), resulting in a total of 9 treatment groups.
Testis samples were collected after 3 hr and gene array analysis was performed.
Using a novel bioinformatic approach to summarize the effect of HD across all
treatment groups, we focused on the modification of x-ray-induced gene alterations
by HD co-exposure. Enrichment analysis was used to identify biological pathways
where HD modification of gene expression was the greatest. HD exerted a signifi-
cant influence on genes involved in Cell Cycle and DNA Replication,
Recombination, and Repair. HD also had an antagonistic effect on x-ray-induced
alterations of several apoptotic genes (Fas, BBC3, AEN). To further investigate the
specific cell populations and stages in which these critical gene alterations occur,
laser capture microdissection (LCM) samples were collected from the basal com-
partment of the seminiferous epithelium, enriching for those germ cells most sus-
ceptible to x-ray-induced apoptosis. Quantitative RT-PCR of the LCM samples
confirmed the suppression of apoptotic genes by HD co-exposure. The co-exposure
attenuation of germ cell apoptosis is the result of an adaptive response to the chem-
ical exposure, causing altered paracrine signalling of the supportive cells in the sem-
iniferous epithelium. These results suggest that toxicity pathway responses deter-
mine the outcome of co-exposures, whether chemical or physical in nature, and
that complex paracrine interactions between cells modulate the extent of injury.
2502 Sunlight Enhancement of the Toxicity of Air Pollutant
Mixtures.
K. G. Sexton1,  J. Zavala1,  B. O’Brien1,  W. Vizuete1,  R. C. Fry1,  I. Jaspers1, 2
and I. Rusyn1. 1Environmental Sciences & Engineering, University of North Carolina
at Chapel Hill, Chapel Hill, NC; 2Center for Environmental Medicine and Lung
Biology, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Sunlight can significantly drive photochemical reactions of mixtures of air pollu-
tants commonly observed in the atmosphere, producing many well known toxic
compounds such as formaldehyde and other carbonyl containing products. These
reactions also contribute to the formation of secondary organic aerosols as well as
modifying the composition of existing aerosols or particulate matter (PM). Smog
chambers can be used to prepare repeatable, controlled mixtures of simple to in-
creasing complexity and be used to study photochemical atmospheric transforma-
tion with natural sunlight or simulated sunlight. Smog chambers can be interfaced
with direct exposure to in vitro or in vivo models for toxicity studies including di-
rect air-liquid-interface in vitro or in vivo inhalation exposures. Photochemical ex-
periments have been conducted in smog chambers with industrial mixtures and
complex mixtures of motor vehicle exhaust in urban atmospheres, often demon-
strating enhanced toxicity as measured by markers of inflammation and other bio-
logical endpoints such as cytotoxicity. Modifications of experiments, exposure con-
ditions and additional toxicological analyses can provide mechanistic and mode of
action understanding. Novel genomic analyses of cells exposed to an urban-like
mixtures showed transcriptional changes on a subset of genes, increasing the num-
ber of genes with altered expressions from 19 for the un-irradiated mixture, to 709
genes after a one-day sunlight irradiation. The implication is that toxicologists and
those dependent on their findings, should consider studies that include mixtures re-
sulting from natural atmospheric photochemical reactivity, transformation of air
components, and the resulting enhancement of toxic effects of air pollutants and
their products. Not considering such effects, could result in misinterpreting the
mode of action and underestimating the potential risk of exposure to air pollution
mixtures or its sources.
2503 Mechanistic, Occupational, and Clinical Aspects of Lead
Exposure.
A. Vale. School of Biosciences, University of Birmingham, Birmingham, United
Kingdom.
The mechanisms of lead toxicity are increasingly being explained by the ubiquitous
reactivity of the bivalent lead cation and its ability to substitute for essential cations,
notably calcium and zinc. By these means, lead complexes with important func-
tional groups including thiol and carboxyl groups, and damages many fundamental
cell processes and structures including enzyme pathways, phospholipid integrity,
ion channel specificity and control, and intrinsic protective systems including free
radical scavengers and cellular repair mechanisms. Owing to the large sample sizes
involved and its nationally-representative nature, NHANES has been the subject of
a number of epidemiological analyses relating blood lead concentrations to a range
of adverse outcomes such as blood pressure, renal function, auditory thresholds,
and a host of other cardiovascular, neurobehavioral, and other developmental or
adult outcomes. Some practitioners are now proposing that, as the NHANES data
suggest that lead concentrations even less than 5 μg/dL (0.24 μmol/L) can have
some health consequences, chelation should be performed at even very low lead
concentrations. Is this an appropriate interpretation of these data? There is concern
that the occupational intervention concentrations worldwide are not only unsup-
ported scientifically and clinically but also have been set at concentrations that per-
mit unsafe practices to continue. A group of experts has proposed that workers
should be removed from occupational exposure if a single blood lead concentration
exceeds 30 μg/dL (1.45 μmol/L), or if two successive blood lead concentrations
measured over a four-week interval equal or exceed 20 μg/dL (0.97 μmol/L). Will
these recommendations prevent clinically significant occupational lead exposure?
Due to the paucity of clinical data, there is controversy about the lead concentra-
tion at which chelation therapy should be instituted in adults when exposure pre-
vention has failed, the antidote to be used, and the most effective regimen to be em-
ployed.
2504 Novel Mechanisms of Toxicity.
R. Lantz. Cellular and Molecular Medicine, University of Arizona, Tuscon, AZ.
The broad spectrum of lead toxicity with adverse manifestations in developmental
and functional aspects of many if not all organ systems are increasingly being ex-
plained by the ubiquitous reactivity of the bivalent lead cation and its ability to sub-
stitute for essential cations, notably calcium and zinc. By these means lead com-
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plexes with important functional groups including thiol and carboxyl groups and
damages many fundamental cell processes and structures including enzyme path-
ways, phospholipid integrity, ion channel specificity and control and intrinsic pro-
tective systems including free radical scavengers and cellular repair mechanisms. 
The ability for lead to substitute for calcium causes erroneous activation of calcium-
dependent proteins and modulation of calcium-sensitive receptors. At its extreme,
impaired regulation of calcium transport results in intracellular calcium accumula-
tion which triggers apoptosis. Lead can activate protein kinase C to disrupt intra-
cellular regulatory processes causing incorrect gene expression resulting in disor-
dered cell proliferation and differentiation. Lead-mediated malfunction of the
calcium sensitive N-methyl-D-aspartate (NMDA) receptor is recognized as one of,
if not the most, important mechanism of lead-induced damage to neuronal devel-
opment, learning and memory. 
As the details of the molecular mechanisms of lead toxicity are unravelled, it is be-
coming clear that their complexity is increased by the fact that lead, like many tox-
ins, acts not in isolation but as part of a multifactorial armoury of adverse influ-
ences including environmental factors, which together dictate the development,
manifestations and progress of disease.
2505 Threshold Toxic Dose: What Can We Learn from the
NHANES Studies?
H. Hu. Dalla Lana School of Public Health, University of Toronto, Toronto, ON,
Canada.
The National Health and Nutrition Examination Survey (NHANES) are cross-sec-
tional surveys of the civilian noninstitutionalized population of the United States
that have been administered by the National Center for Health Statistics and on-
going for decades. Subjects are selected based on a stratified multistage probability
sampling of counties, blocks, households, and persons within households, with
oversampling of some population subgroups (such as Mexican Americans, non-
Hispanic blacks, and adults 60 years or older). Evaluations included the adminis-
tration of extensive questionnaires, physical examination, and collection of urine
and venous blood for a wide range of laboratory analyses. Lead levels have been
measured in samples of venous blood since the 1970’s. Owing to the large sample
sizes involved (typically >10,000 individuals) and its nationally-representative na-
ture, NHANES has been the subject of a number of epidemiologic analyses relating
blood lead levels to a range of outcomes such as blood pressure, renal function, au-
ditory thresholds, and a host of other cardiovascular, neurobehavioral and other de-
velopmental or adult outcomes. This presentation will provide an overview of these
studies from the perspective of understanding dose-response relationships; it will
also compare them with the parallel body of recent epidemiologic studies using
other biomarkers of lead exposure (e.g., KXRF-measured bone lead levels as a
marker of cumulative exposure) and/or other study designs (e.g., prospective or
case-control studies).
2506 Occupational Exposure Limits: Do They Protect Workers?
M. Kosnett. Division of Clinical Pharmacology and Toxicology, University of
Colorado Denver, Denver, CO.
Research findings have heightened public health concerns regarding the hazards of
low dose lead exposure to adults and children. In adults, studies have established
the potential for hypertension, effects on renal function, cognitive dysfunction and
adverse female reproductive outcome in adults with whole blood lead concentra-
tions less than 40 μg/dL (1.93 μmol/L). However, in most nations worldwide, reg-
ulatory occupational exposure limits permit workers to maintain blood lead con-
centrations in excess of 40 μg/dL for a working lifetime. A group of experts has
recently recommended that workers undergo removal from occupational lead expo-
sure if a single blood lead concentration exceeds 30 μg/dL (1.45 μmol/L), or if two
successive blood lead concentrations measured over a four week interval equal or
exceed 20 μg/dL (0.97 μmol/L). Removal from lead exposure should be considered
to avoid long-term risk to health if exposure control measures over an extended pe-
riod do not decrease blood lead concentrations below 10 μg/dL (0.48 μmol/L), or
if selected medical conditions exist that would increase the risk of continued expo-
sure. In order to assure reductions in permissible blood lead concentrations, med-
ical surveillance for lead exposed workers is recommended to include quarterly
blood lead measurements for individuals with blood lead concentrations between
10 to 19 μg/dL (0.48 – 0.92 μmol/L), and semi-annual blood lead measurements
when sustained blood lead concentrations are less than 10 μg/dL (0.48 μmol/L).
2507 Chelation Therapy for Lead Poisoning: Unanswered
Questions and Controversies.
S. M. Bradberry. West Midlands Poisons Unit, City Hospital, Birmingham, United
Kingdom.
Intravenous edetate calcium disodium and oral succimer (dimercaptosuccinic acid;
DMSA) are potent chelators of lead approved in many countries for the clinical
management of lead poisoning. Both agents reduce the body burden of lead by the
renal elimination of a lead-chelating agent complex but there remain unanswered
questions regarding their precise pharmacokinetic and pharmacodynamic proper-
ties. These include the specific effects of each agent on tissue lead distribution and
mobilization and how these parameters are affected by dose and duration of both
lead poisoning and chelation. Edetate calcium disodium chelates by exchanging its
central calcium ion for lead but the exact chemical nature of the succimer-lead
chelate in man remains ill-defined. While assessment of efficacy of both agents is
hampered by limited data, the inadequacy of blood lead as a marker of toxicity,
variations in study design, species differences and, for clinical studies, the subjective
nature of reporting changes in symptoms, available data overall suggest both drugs
offer similar efficacy with regard to enhancing lead elimination, though this re-
mains controversial.  In addition, the indications for chelation in man remain ill-
defined. The adequacy of treatment remains contentious both because of the
paucity of efficacy data and because of increasing evidence that toxic effects of lead
sustained during early development cannot be reversed by chelation. Moreover,
even though most clinical toxicologists agree that where exposure prevention has
failed, chelation should be considered in adults whose blood lead concentrations ≥
50 μg/dL (2.4 μmol/L), the most effective regimen to employ in these circum-
stances is still controversial.
2508 Ocular Medical Devices and Ocular Drug Delivery Systems:
Challenges and Opportunities.
J. A. Render. Toxicology, NAMSA, Northwood, OH.
The eye is a unique organ composed of many different structures working together
to facilitate vision. The maintenance of clear vision during aging is threatened by
various physiological changes (e.g., presbyopia) or diseases (e.g., age-related macu-
lar degeneration). The need for treatments is of increasing importance as the size of
the aging population grows. The National Eye Institute predicts that by 2020, more
than 50 million Americans will be impacted by age-related eye disease. Some of
these conditions have been overcome through the use of medical devices. Ocular
medical devices consist of instruments, apparatuses, appliances, and materials.
Some devices are purely structural; whereas, other medical devices are a part of a de-
livery system that releases a drug. The five presentations in this program are de-
signed to educate the audience on the therapeutic, safety, and regulatory challenges
of developing ocular medical devices and drug delivery systems. The first presenta-
tion will cover the special requirements for developing contact lenses and contact
lens solutions. The second presentation will describe the challenges associated with
accommodative intraocular lenses (IOLs). The third presentation will discuss the
ocular barriers (e.g., blood-eye-barrier) and how ocular medical devices and sus-
tained release drug formulations have been designed to address these barriers with
respect to developing protein therapeutics. Development of and regulatory chal-
lenges associated with a unique biodegradable small molecule ocular drug/injection
applicator delivery system will be discussed in the fourth presentation. The sympo-
sium will conclude with a presentation that discusses the safety and regulatory re-
quirements and complexities pertaining to ocular medical devices and ocular drug
delivery systems.
2509 Assessment of the Ocular Safety of Contact Lenses and Lens
Solutions.
M. E. Richardson. Nonclinical Safety, Bausch & Lomb, Rochester, NY.
Contact lenses and lens care solutions are typically categorized as medical devices
and therefore require biocompatibility testing per ISO standards and regional regu-
latory guidance documents. Recently evolving Regulatory Body expectations have
significantly impacted the number and design of the biocompatibility studies re-
quired to clear an ocular medical device for marketing. The current 10993-1 (4th
Edition) ISO guideline requires that medical device manufacturers utilize a risk
management process as part of the design and implementation of a biological eval-
uation program for medical devices. ISO 10993-1 also requires that the choice of
biocompatibility tests be based on, among other things, the end-use application,
and take into account the chemical composition of the device, the conditions of ex-
posure as well as the nature, degree, frequency and cumulative duration of expo-
sure. These ISO requirements, along with those of the regional regulatory expecta-
tions, create a significant amount of complexity when designing the
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biocompatibility testing strategies for contact lenses and solutions. For example, de-
pending on the type of assay, the tested material may need to be the formulation it-
self, a lens extract or a lens/formulation combination. Further, it has been demon-
strated that the selection of assays and individual study designs can influence the
outcome of the study, which could potentially impact product registration. Testing
protocols therefore need to be designed to account for the unique chemical and
physical properties of the ocular medical device being tested in order to avoid po-
tentially false positive outcomes. Consequently, a rational science-based approach
should be used to develop and justify the biocompatibility testing strategy and
study designs to ensure that the biological evaluation conducted is appropriate, ro-
bust and Regulatory-acceptable. This presentation will highlight some of the key
challenges and case studies when conducting biocompatibility evaluations on con-
tact lenses and solutions.
2510 Accommodative Intraocular Lenses: A New Class of IOLs
with a New Class of Challenges.
A. Glasser. College of Optometry, University of Houston, Houston, TX. Sponsor: J.
Render.
A new class of intraocular lenses (IOLs) is being developed with the goal of restor-
ing the focusing ability of the eye (accommodation) for treating presbyopia (the
age-related loss of near focusing ability). Although cataract surgery may be among
the safest and most common of surgical procedures, these so called accommodative
IOLs (A-IOLs) present new challenges as well as offer new opportunities. A-IOLs
differ considerably from standard IOLs in that they are biomechanical devices de-
signed to move or change shape in response to ciliary muscle contraction. A-IOLs
are bulkier, made from different materials, may be implanted in different locations
in the eye and have mechanisms of action that differ fundamentally from standard
IOLs. The surgical procedures required to implant these devices are also more chal-
lenging, as they require new surgical devices. In addition, the safety considerations
for A-IOLs are different. Pre-clinical animal testing that can be done is limited,
complications that can arise are unique, and regulatory hurdles for demonstrating
safety and effectiveness are higher. The ultimate success of A-IOLs will rely on solv-
ing significant biological challenges that still remain, such as resolving the post-op-
erative healing response of the eye including prevention of post-operative lens ep-
ithelial cell proliferation and fibrosis of the lens capsule. This presentation will
describe the challenges associated with the development A-IOLs. It will also intro-
duce some future potential applications such as, the possibility of delivering drugs
from A-IOLs to solve these biological challenges, as well as other unique surgical
and pharmacological interventions aimed at resolving the problem of presbyopia.
2511 Safety Assessment Strategies and Challenges for Developing
Intravitreally Administered Biologics.
E. A. Thackaberry. Safety Assessment, Genentech, Inc, San Francisco, CA.
The development of intraocular drugs to treat posterior segment disease, such as
age-related macular degeneration, presents both advantages and challenges due to
the unique aspects of ocular anatomy and physiology. While drug administration
within the eye affords the promise of direct and local delivery, the reduction of sys-
temic exposure and toxicity, and the availability of non-invasive tools allowing for
real-time monitoring of the eye, there is an unmet need to reduce intravitreal injec-
tion frequency and treatment burden through sustained delivery formulations and
devices. Adding to these complexities, developing antibody-based therapeutics
presents additional challenges due to their inherent specificity (often limited to pri-
mates), which may limit the animal models available for assessing safety. Case stud-
ies on the safety assessment strategies and challenges encountered in developing
protein therapeutics to the posterior segment of eye will be presented.
2512 Development and Regulatory Considerations for an Ocular
Drug Release System for Ocular Disease.
A. Wiese. Nonclinical Safety, Allergan, Irvine, CA.
Delivering drugs to various compartments of the eye presents unique scientific and
regulatory challenges. This presentation describes these challenges in the context of
the development of Ozurdex®, a bioerodable drug delivery system containing dex-
amethasone delivered to the posterior segment of the eye. Key to the development
of this drug was understanding the drug distribution and its effects in the eye, drug
release characteristics and erosion profile of the implant, and evaluation of the tox-
icological profile of both drug and implant. Additionally, and in parallel, develop-
ment and testing of the applicator and consideration of drug interactions was on-
going. Regional differences in regulatory agency expectations will be presented.
Finally, general learnings and applicability of those learnings to the development of
drug delivery systems to various compartments of the eye will be discussed.
2513 Regulatory Considerations in Ocular Medical Device and
Drug Delivery Systems Development.
C. Ghosh. Center for Drug Evaluation Research, US FDA, Silver Springs, MD.
Ocular medical devices and drug delivery systems encompass a wide variety of
products including solid devices (such as intraocular lenses, surgical instruments
and contact lenses) and devices that are liquid-based (such as viscoelastics and con-
tact lens solutions). This presentation will present the classification and regulatory
requirements for major categories of ocular medical devices and drug delivery sys-
tems and discuss the regulatory decision making and implications pertaining to
preclinical and clinical evaluations.
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Palacio, I C  ������������������������������������������  1500*
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Tsuji, H  �����������������������������������������������������  217
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Twamley, M  �������������������������������������������  1231
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Uhlirova, K  ���������������������������������������������  563
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Unice, K M  ���������������������������������  1268, 1555
Unrine, J  ������������������������������������������������  1366
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Valdivia, P  ���������������������������������������������  900*
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van den Berg, M  �������  524, 902, 1929, 2000
van den Brandhof, E  ����������������������������  1453
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Van der Zwaag, G H  ������������������������������  368
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van Kleef, R G  ��������������������������������  902, 903
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1596, 2115
Vanoirbeek, J  �������������������������������� 949, 2367
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Varma, T K  ��������������������������������������������  1079
Varner, K  �����������������������������������������������  1144
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Vera, A  �������������������������������������������������  1768*
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Vignand, P  ��������������������������������������������  1834
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Vilanova, E  ��������������������������������������������  1413
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Visram, S  �����������������������������������������������  1505
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veterinary toxicology  ��������������������������� 1436
Vinclozolin ������������������������� 298, 1927, 2138
Vinyl Chloride  �������������������������������  644, 940
virtual liver ���������������������������������������������� 882
Visual Cycle Modulator  ������������������������ 501
Vitamin A  ��������������������������������������������� 2032
vitamin D  ������������������������� 1127, 1538, 2057
Vitamin D Receptor  ���������������������������� 1275
Vitamin E  �����������������������������������  1771, 2225
vitellogenesis ����������������������������������������� 1938
vitellogenin  ��������������������������������������������� 101
vitrocell �������������������������������������������������� 2361
VOCs  ����������������������������������������������������� 2118
volatile methyl siloxanes  ����������������������� 617
Volatile organic compounds  ��������������� 1844
vomitoxin  ���������������������������������������������� 2326
vulnerable populations  �������������������������� 878
VX  ���������������������������������������������������  368, 372
Warburg Effect  ��������������������������������������� 672
Water  ������������������������������������������������������� 281
water pollution  ��������������������������������������� 280
weather  �������������������������������������������������� 1605
Web Application  ������������������������������������ 864
Weight of evidence  ��������������������  112, 1021, 
1951, 2456
weighting ����������������������������������������������� 1999
welders ��������������������������������������������������� 1107
welding  �����������������������������������������  211, 2056
Welding fumes  ������������������������������������� 1132
well water  ������������������������������������������������ 477
whale cells  ��������������������������������������������� 1171
Whole Blood  ����������������������������������������� 1555
Wild yam  ������������������������������������������������� 147
Wistar Han rat  �����������������������������  178, 2121
Wnt  �������������������������������������������������������� 1588
Wnt signaling  ����������������������������������������� 632
Wood Smoke  ���������������������������������������� 1285
Workers  ������������������������������������������������� 1948
workers’ exposure  ���������������������������������� 828
XBP1  �������������������������������������������  2011, 2170
xenobiotic metabolizing enzymes  ����� 1437
Xenoestrogen  ���������������������������������������� 2114
xenoestrogens  ��������������������������������������� 1938
Xenograft  ��������������������������� 994, 1306, 2387
Xenopus laevis  ���������������������������  1293, 1936
XPC - NER �������������������������������������������� 1691
XRF  �������������������������������������������������������� 1510
yeast  ��������������������������������������������  1448, 1524
zafirlukast ���������������������������������������������� 1713
Zea mays  ����������������������������������������������� 1537
Zearalenone  ��������������������� 2114, 2322, 2323
zebrafish  ����������������������������������  52, 273, 324, 
326, 328, 331, 333, 335, 559, 735, 988, 
1281, 1288, 1359, 1372, 1380, 1407, 
1449, 1582, 1752, 2377, 2387
zebrafish assay  �������������������������������������� 1453
zebrafish development  �����������������  322, 329
zebrafish embryo toxicity  ��������  1447, 2396
zebrafish larvae  ������������������������������������ 1445
ZFN  �������������������������������������������������������� 2169
zinc  ���������������������������  270, 1517, 1518, 2307
zinc finger nucleases  ���������������������������� 1288
zinc finger protein  ������������������������������� 1516
zinc oxide  ���������������������������������������������� 1757
Ziram  ����������������������������������������������������� 1407
ZnO nanoparticles  ������������������������������� 2388
zoniperide  ��������������������������������������������� 2261
zygote  ������������������������������������������  2104, 2117
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